Nonylphenol	O
diethoxylate	O
inhibits	O
apoptosis	B-T038
induced	O
in	O
PC12	B-T017
cells	I-T017

Nonylphenol	O
and	O
short	O
-	O
chain	O
nonylphenol	O
ethoxylates	O
such	O
as	O
NP2	O
EO	O
are	O
present	B-T033
in	O
aquatic	O
environment	O
as	O
wastewater	O
contaminants	O
,	O
and	O
their	O
toxic	B-T037
effects	I-T037
on	O
aquatic	O
species	O
have	O
been	O
reported	O
.	O

Apoptosis	B-T038
has	O
been	O
shown	O
to	O
be	O
induced	O
by	O
serum	B-T031
deprivation	O
or	O
copper	B-T103
treatment	O
.	O

To	O
understand	O
the	O
toxicity	O
of	O
nonylphenol	O
diethoxylate	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
NP2	O
EO	O
on	O
apoptosis	B-T038
induced	O
by	O
serum	B-T031
deprivation	O
and	O
copper	B-T103
by	O
using	O
PC12	B-T017
cell	I-T017
system	I-T017
.	O

Nonylphenol	O
diethoxylate	O
itself	O
showed	O
no	O
toxicity	O
and	O
recovered	O
cell	B-T038
viability	I-T038
from	O
apoptosis	B-T038
.	O

In	O
addition	O
,	O
nonylphenol	O
diethoxylate	O
decreased	O
DNA	B-T038
fragmentation	I-T038
caused	O
by	O
apoptosis	B-T038
in	O
PC12	B-T017
cells	I-T017
.	O

This	O
phenomenon	O
was	O
confirmed	O
after	O
treating	O
apoptotic	O
PC12	B-T017
cells	I-T017
with	O
nonylphenol	O
diethoxylate	O
,	O
whereas	O
the	O
cytochrome	B-T103
c	I-T103
release	O
into	O
the	O
cytosol	B-T017
decreased	O
as	O
compared	O
to	O
that	O
in	O
apoptotic	B-T017
cells	I-T017
not	O
treated	O
with	O
nonylphenol	O
diethoxylate	O
s	O
.	O

Furthermore	O
,	O
Bax	B-T103
contents	O
in	O
apoptotic	B-T017
cells	I-T017
were	O
reduced	O
after	O
exposure	O
to	O
nonylphenol	O
diethoxylate	O
.	O

Thus	O
,	O
nonylphenol	O
diethoxylate	O
has	O
the	O
opposite	O
effect	O
on	O
apoptosis	B-T038
in	O
PC12	B-T017
cells	I-T017
compared	O
to	O
nonylphenol	O
,	O
which	O
enhances	O
apoptosis	B-T038
induced	O
by	O
serum	B-T031
deprivation	O
.	O

The	O
difference	O
in	O
structure	B-T082
of	O
the	O
two	O
compounds	B-T103
is	O
hypothesized	O
to	O
be	O
responsible	O
for	O
this	O
phenomenon	O
.	O

These	O
results	B-T033
indicated	O
that	O
nonylphenol	O
diethoxylate	O
has	O
capability	O
to	O
affect	O
cell	B-T038
differentiation	I-T038
and	O
development	B-T038
and	O
has	O
potentially	O
harmful	B-T037
effect	I-T037
on	O
organisms	O
because	O
of	O
its	O
unexpected	O
impact	O
on	O
apoptosis	B-T038
.	O

©	O
2015	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Environ	O
Toxicol	O
31	O
:	O
1389	O
-	O
1398	O
,	O
2016	O
.	O

EZH2	B-T017
and	O
ZFX	B-T017
oncogenes	B-T017
in	O
malignant	O
behaviour	O
of	O
parathyroid	B-T038
neoplasms	I-T038

Several	O
studies	B-T062
reported	O
somatic	B-T038
mutations	I-T038
of	O
many	O
genes	B-T017
(	O
MEN1	B-T017
,	O
CTNNB1	B-T017
,	O
CDKIs	B-T017
and	O
others	O
)	O
in	O
parathyroid	B-T038
adenoma	I-T038
,	O
although	O
with	O
different	O
prevalence	O
.	O

Recently	O
,	O
activating	O
mutations	B-T038
of	O
the	O
EZH2	B-T017
and	O
ZFX	B-T017
oncogenes	B-T017
were	O
identified	O
in	O
benign	O
parathyroid	B-T038
adenoma	I-T038
by	O
whole	B-T062
exome	I-T062
sequencing	I-T062
.	O

The	O
same	O
mutations	B-T038
had	O
been	O
found	O
in	O
blood	B-T031
and	O
ovary	B-T017
malignant	B-T038
tumours	I-T038
.	O

On	O
one	O
hand	O
,	O
this	O
result	O
raised	O
the	O
hypothesis	O
that	O
these	O
oncogenes	B-T017
may	O
play	O
a	O
role	O
in	O
the	O
onset	O
of	O
parathyroid	B-T038
tumour	I-T038
,	O
but	O
it	O
would	O
also	O
suggest	O
they	O
may	O
be	O
involved	O
in	O
malignant	O
,	O
rather	O
benign	O
,	O
parathyroid	B-T038
neoplasm	I-T038
.	O

Our	O
aim	O
was	O
to	O
verify	O
the	O
occurrence	O
of	O
selected	O
mutations	B-T038
of	O
the	O
EZH2	B-T017
and	O
ZFX	B-T017
genes	I-T017
in	O
an	O
Italian	B-T098
cohort	B-T098
of	O
23	O
sporadic	O
parathyroid	B-T038
carcinomas	I-T038
,	O
12	O
atypical	O
and	O
45	O
typical	O
adenomas	B-T038
.	O

DNA	B-T103
was	O
extracted	B-T058
from	O
paraffin	B-T017
-	I-T017
embedded	I-T017
tissues	I-T017
,	O
PCR	B-T062
amplified	O
and	O
directly	O
sequenced	O
.	O

No	B-T033
mutations	B-T038
were	O
detected	B-T033
in	O
the	O
coding	B-T103
sequence	I-T103
and	O
boundaries	B-T103
of	O
both	O
genes	B-T017
in	O
any	O
of	O
the	O
samples	O
.	O

Two	O
polymorphisms	O
of	O
the	O
EZH2	B-T017
gene	I-T017
were	O
identified	O
with	O
different	O
prevalence	O
:	O
the	O
rs2072407	B-T017
variant	I-T017
was	O
present	B-T033
in	O
the	O
30	O
%	O
of	O
the	O
samples	O
,	O
in	O
keeping	O
with	O
the	O
overall	O
frequency	O
in	O
larger	O
populations	O
,	O
while	O
the	O
rs78589034	B-T017
variant	I-T017
,	O
located	O
close	O
to	O
the	O
5	O
'	O
end	O
of	O
the	O
exon	B-T103
16	I-T103
,	O
was	O
detected	B-T033
in	O
only	O
one	O
proband	O
with	O
familial	O
isolated	O
hyperparathyroidism	B-T038
;	O
we	O
investigated	O
the	O
possible	O
outcome	O
on	O
the	O
splicing	B-T038
process	I-T038
.	O

EZH2	B-T017
and	O
ZFX	B-T017
genes	I-T017
do	O
not	O
seem	O
to	O
have	O
an	O
impact	O
on	O
the	O
onset	O
of	O
most	O
parathyroid	B-T038
tumours	I-T038
,	O
both	O
benign	O
and	O
malignant	O
,	O
though	O
further	O
studies	O
on	O
larger	O
cohorts	B-T098
of	O
different	O
ethnicity	O
are	O
needed	O
.	O

Patient	O
-	O
Physician	B-T097
Discordance	O
in	O
Global	O
Assessment	O
in	O
Rheumatoid	B-T038
Arthritis	I-T038
:	O
A	O
Systematic	O
Literature	B-T170
Review	I-T170
With	O
Meta	B-T062
-	I-T062
Analysis	I-T062

The	O
integration	O
of	O
the	O
patient	O
in	O
therapeutic	O
decision	B-T038
-	I-T038
making	I-T038
is	O
important	O
in	O
the	O
management	B-T058
of	O
rheumatoid	B-T038
arthritis	I-T038
(	O
RA	B-T038
)	O
,	O
but	O
the	O
patient	O
opinion	O
regarding	O
disease	B-T038
status	O
may	O
differ	O
from	O
the	O
physician	B-T097
'	I-T097
s	I-T097
opinion	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
assess	O
in	O
the	O
published	B-T170
literature	I-T170
the	O
frequency	O
and	O
drivers	O
of	O
patient	O
-	O
physician	B-T097
discordance	O
in	O
global	O
assessment	O
in	O
RA	B-T038
.	O

A	O
systematic	O
literature	B-T170
review	I-T170
of	O
all	O
articles	B-T170
published	O
up	O
to	O
January	O
2015	O
in	O
Medline	B-T170
or	O
Embase	B-T170
,	O
reporting	O
discordance	O
in	O
RA	B-T038
,	O
was	O
conducted	O
by	O
2	O
investigators	B-T097
.	O

Discordance	O
was	O
defined	O
based	O
on	O
the	O
absolute	O
difference	O
of	O
patient	B-T170
global	I-T170
(	O
PGA	B-T170
)	O
and	O
physician	O
global	O
assessments	O
(	O
PhGA	O
)	O
on	O
0	O
-	O
10	O
-	O
cm	O
scales	O
.	O

The	O
frequency	O
of	O
discordance	O
and	O
its	O
predictors	B-T033
were	O
collected	O
in	O
each	O
study	B-T062
.	O

Frequencies	O
of	O
discordance	O
were	O
pooled	O
by	O
meta	B-T062
-	I-T062
analysis	I-T062
using	O
random	O
effect	O
.	O

In	O
all	O
,	O
12	O
studies	B-T062
were	O
selected	O
(	O
i	O
.	O
e	O
.	O
,	O
11	O
,	O
879	O
patients	O
)	O
:	O
weighted	O
mean	O
±	O
SD	O
age	O
was	O
55	O
.	O
1	O
±	O
13	O
.	O
9	O
years	O
,	O
weighted	O
mean	O
±	O
SD	O
disease	O
duration	O
was	O
10	O
.	O
4	O
±	O
9	O
.	O
3	O
years	O
,	O
and	O
80	O
.	O
7	O
%	O
were	O
women	B-T098
.	O

The	O
value	O
of	O
the	O
difference	O
|	O
PGA	B-T170
-	O
PhGA	O
|	O
defining	O
discordance	O
varied	O
between	O
≥0	O
.	O
5	O
cm	O
(	O
n	O
=	O
2	O
studies	O
)	O
to	O
≥3	O
cm	O
(	O
n	O
=	O
5	O
studies	O
)	O
;	O
the	O
weighted	O
mean	O
value	O
was	O
2	O
.	O
7	O
cm	O
.	O

The	O
pooled	O
percentage	O
of	O
patients	O
with	O
discordance	O
was	O
43	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
36	O
%	O
-	O
51	O
%	O
;	O
range	O
25	O
%	O
-	O
76	O
%	O
)	O
.	O

PGA	B-T170
was	O
usually	O
higher	O
than	O
PhGA	O
.	O

The	O
drivers	O
of	O
PGA	B-T170
were	O
pain	B-T033
and	O
functional	O
incapacity	O
,	O
whereas	O
drivers	O
of	O
PhGA	O
were	O
joint	B-T170
counts	I-T170
and	O
acute	B-T103
-	I-T103
phase	I-T103
reactants	I-T103
.	O

Discordance	O
in	O
global	O
assessment	O
was	O
most	O
frequently	O
defined	O
as	O
a	O
difference	O
of	O
3	O
points	O
or	O
more	O
;	O
even	O
with	O
such	O
a	O
stringent	O
definition	O
,	O
up	O
to	O
half	O
the	O
patients	O
were	O
found	O
to	O
be	O
discordant	O
.	O

The	O
long	O
-	O
term	O
consequences	O
of	O
this	O
discordance	O
remain	O
to	O
be	O
determined	O
.	O

A	O
Randomized	B-T062
Controlled	I-T062
Noninferiority	I-T062
Trial	I-T062
of	O
Single	O
Dose	O
of	O
Oral	O
Dexamethasone	O
Versus	O
5	O
Days	O
of	O
Oral	O
Prednisone	O
in	O
Acute	O
Adult	O
Asthma	B-T038

Oral	O
dexamethasone	O
demonstrates	O
bioavailability	O
similar	O
to	O
that	O
of	O
oral	O
prednisone	O
but	O
has	O
a	O
longer	O
half	O
-	O
life	O
.	O

We	O
evaluate	O
whether	O
a	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
plus	O
4	O
days	O
of	O
placebo	B-T103
is	O
not	O
inferior	B-T082
to	O
5	O
days	O
of	O
oral	O
prednisone	O
in	O
treatment	O
of	O
adults	O
with	O
mild	B-T033
to	O
moderate	B-T033
asthma	B-T033
exacerbations	I-T033
to	O
prevent	O
relapse	O
defined	O
as	O
an	O
unscheduled	O
return	O
visit	O
for	O
additional	B-T033
treatment	I-T033
for	O
persistent	B-T038
or	O
worsening	O
asthma	B-T038
within	O
14	O
days	O
.	O

Adult	O
emergency	O
department	O
patients	O
(	O
aged	O
18	O
to	O
55	O
years	O
)	O
were	O
randomized	B-T062
to	O
receive	O
either	O
a	O
single	O
dose	O
of	O
12	O
mg	O
of	O
oral	O
dexamethasone	O
with	O
4	O
days	O
of	O
placebo	B-T103
or	O
a	O
5	O
-	O
day	O
course	O
of	O
oral	O
prednisone	O
60	O
mg	O
a	O
day	O
.	O

Outcomes	O
including	O
relapse	O
were	O
assessed	O
by	O
a	O
follow	B-T058
-	I-T058
up	I-T058
telephone	I-T058
interview	I-T058
at	O
2	O
weeks	O
.	O

One	O
hundred	O
seventy	O
-	O
three	O
dexamethasone	B-T103
and	O
203	O
prednisone	B-T103
subjects	O
completed	O
the	O
study	O
regimen	O
and	O
telephone	B-T058
follow	I-T058
-	I-T058
up	I-T058
.	O

The	O
dexamethasone	B-T103
group	O
by	O
a	O
small	O
margin	O
surpassed	O
the	O
preset	O
8	O
%	O
difference	O
between	O
groups	O
for	O
noninferiority	O
in	O
relapse	O
rates	O
within	O
14	O
days	O
(	O
12	O
.	O
1	O
%	O
versus	O
9	O
.	O
8	O
%	O
;	O
difference	O
2	O
.	O
3	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4	O
.	O
1	O
%	O
to	O
8	O
.	O
6	O
%	O
)	O
.	O

Subjects	O
in	O
the	O
2	O
groups	O
had	O
similar	O
rates	O
of	O
hospitalization	B-T058
for	O
their	O
relapse	O
visit	B-T058
(	O
dexamethasone	B-T103
3	O
.	O
4	O
%	O
versus	O
prednisone	B-T103
2	O
.	O
9	O
%	O
;	O
difference	O
0	O
.	O
5	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
-	O
4	O
.	O
1	O
%	O
to	O
3	O
.	O
1	O
%	O
)	O
.	O

Adverse	O
effect	O
rates	O
were	O
generally	O
the	O
same	O
in	O
the	O
2	O
groups	O
.	O

A	O
single	O
dose	O
of	O
oral	O
dexamethasone	O
did	O
not	O
demonstrate	O
noninferiority	O
to	O
prednisone	B-T103
for	O
5	O
days	O
by	O
a	O
very	O
small	O
margin	O
for	O
treatment	O
of	O
adults	O
with	O
mild	B-T033
to	O
moderate	B-T033
asthma	B-T033
exacerbations	I-T033
.	O

Enhanced	O
compliance	B-T033
and	O
convenience	O
may	O
support	O
the	O
use	O
of	O
dexamethasone	B-T103
regardless	O
.	O

Malignancy	B-T038
is	O
associated	O
with	O
microcalcification	B-T038
and	O
higher	O
AP	O
/	O
T	O
ratio	O
in	O
ultrasonography	B-T058
,	O
but	O
not	O
with	O
Hashimoto	B-T038
'	I-T038
s	I-T038
thyroiditis	I-T038
in	O
histopathology	B-T058
in	O
patients	O
with	O
thyroid	B-T038
nodules	I-T038
evaluated	O
as	O
Bethesda	B-T038
Category	I-T038
III	I-T038
(	O
AUS	B-T038
/	O
FLUS	B-T033
)	O
in	O
cytology	B-T058

The	O
predictors	B-T170
of	O
malignancy	B-T038
are	O
important	O
for	O
the	O
decision	O
of	O
appropriate	O
management	B-T058
in	O
nodules	B-T038
with	O
atypia	B-T038
of	I-T038
undetermined	I-T038
significance	I-T038
/	O
follicular	B-T033
lesion	I-T033
of	I-T033
undetermined	I-T033
significance	I-T033
(	O
AUS	B-T038
/	O
FLUS	B-T033
)	O
.	O

Our	O
aim	O
was	O
to	O
determine	O
the	O
ultrasonographical	B-T170
,	O
clinical	B-T170
,	O
and	O
biochemical	B-T170
predictors	I-T170
of	O
malignancy	B-T038
in	O
these	O
patients	O
.	O

A	O
total	O
of	O
427	O
patients	O
with	O
cytologically	B-T038
Bethesda	I-T038
Category	I-T038
III	I-T038
(	O
AUS	B-T038
/	O
FLUS	B-T033
)	O
thyroid	B-T038
nodules	I-T038
were	O
included	O
in	O
this	O
retrospective	B-T062
study	I-T062
.	O

We	O
divided	O
the	O
nodules	B-T038
into	O
two	O
subgroups	B-T098
according	O
to	O
the	O
histopathology	B-T058
as	O
benign	O
and	O
malignant	O
,	O
and	O
compared	O
the	O
preoperative	O
ultrasonographical	B-T201
,	O
clinical	B-T201
,	O
and	O
biochemical	B-T033
findings	I-T033
.	O

In	O
overall	O
,	O
427	O
patients	O
with	O
449	O
AUS	B-T038
/	O
FLUS	B-T033
nodules	B-T038
who	O
had	O
undergone	O
surgery	B-T058
,	O
the	O
rate	O
of	O
malignancy	B-T038
was	O
23	O
.	O
4	O
%	O
(	O
105	O
/	O
449	O
)	O
.	O

When	O
evaluated	O
separately	O
,	O
the	O
rate	O
of	O
malignancy	B-T038
was	O
25	O
.	O
8	O
%	O
in	O
nodules	B-T038
with	O
AUS	B-T038
(	O
82	O
/	O
318	O
)	O
and	O
17	O
.	O
6	O
%	O
in	O
nodules	B-T038
with	O
FLUS	B-T033
(	O
23	O
/	O
131	O
)	O
(	O
p	O
=	O
0	O
.	O
061	O
)	O
.	O

The	O
vast	O
majority	O
of	O
malignant	O
specimens	O
in	O
histopathology	B-T058
consisted	O
of	O
papillary	B-T038
thyroid	I-T038
carcinoma	I-T038
(	O
PTC	B-T038
)	O
(	O
n	O
=	O
91	O
,	O
86	O
.	O
7	O
%	O
)	O
.	O

Preoperative	O
ultrasonographic	B-T201
features	I-T201
of	O
105	O
malignant	B-T038
nodules	I-T038
in	O
histopathology	B-T058
were	O
compared	O
with	O
the	O
344	O
benign	B-T038
nodules	I-T038
in	O
histopathology	B-T058
.	O

Anteroposterior	O
/	O
Transverse	O
(	O
AP	O
/	O
T	O
)	O
ratio	O
was	O
significantly	O
higher	O
in	O
malignant	B-T098
group	I-T098
compared	O
to	O
benign	B-T098
group	I-T098
(	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O

In	O
multiple	B-T062
logistic	I-T062
analysis	I-T062
,	O
we	O
found	O
that	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	B-T038
were	O
independently	O
associated	O
with	O
malignancy	B-T038
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
malignancy	B-T038
-	O
associated	O
cut	O
-	O
off	O
value	O
of	O
AP	O
/	O
T	O
ratio	O
at	O
maximum	O
sensitivity	O
and	O
specificity	O
was	O
≥0	O
.	O
81	O
.	O

We	O
did	O
not	O
find	O
any	O
correlation	O
between	O
malignancy	B-T038
and	O
Hashimoto	B-T038
'	I-T038
s	I-T038
thyroiditis	I-T038
in	O
histopathology	B-T058
in	O
multivariate	O
analysis	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

In	O
Bethesda	B-T038
Category	I-T038
III	I-T038
nodules	I-T038
with	O
higher	O
AP	O
/	O
T	O
ratio	O
and	O
microcalcification	B-T038
,	O
surgery	B-T058
might	O
be	O
considered	O
as	O
a	O
first	O
therapeutic	O
option	O
instead	O
of	O
repeat	O
fine	B-T058
-	I-T058
needle	I-T058
aspiration	I-T058
biopsy	I-T058
or	O
observation	B-T062
.	O

Impact	O
of	O
cofactor	B-T103
-	O
binding	B-T082
loop	I-T082
mutations	B-T038
on	O
thermotolerance	B-T038
and	O
activity	B-T038
of	O
E	B-T007
.	I-T007
coli	I-T007
transketolase	B-T103

Improvement	O
of	O
thermostability	O
in	O
engineered	B-T103
enzymes	I-T103
can	O
allow	O
biocatalysis	O
on	O
substrates	O
with	O
poor	O
aqueous	O
solubility	O
.	O

Denaturation	B-T038
of	O
the	O
cofactor	B-T103
-	O
binding	B-T082
loops	I-T082
of	O
Escherichia	B-T007
coli	I-T007
transketolase	B-T103
(	O
TK	B-T103
)	O
was	O
previously	O
linked	O
to	O
the	O
loss	O
of	O
enzyme	B-T038
activity	I-T038
under	O
conditions	O
of	O
high	O
pH	O
or	O
urea	B-T103
.	O

Incubation	B-T058
at	O
temperatures	O
just	O
below	O
the	O
thermal	O
melting	O
transition	O
,	O
above	O
which	O
the	O
protein	B-T103
aggregates	O
,	O
was	O
also	O
found	O
to	O
anneal	O
the	O
enzyme	B-T103
to	O
give	O
an	O
increased	O
specific	O
activity	B-T038
.	O

The	O
potential	O
role	O
of	O
cofactor	B-T103
-	O
binding	B-T082
loop	I-T082
instability	B-T033
in	O
this	O
process	O
remained	O
unclear	O
.	O

In	O
this	O
work	O
,	O
the	O
two	O
cofactor	B-T103
-	O
binding	B-T082
loops	I-T082
(	O
residues	B-T082
185	I-T082
-	I-T082
192	I-T082
and	O
382	B-T082
-	I-T082
392	I-T082
)	O
were	O
progressively	O
mutated	O
towards	O
the	O
equivalent	O
sequence	B-T082
from	O
the	O
thermostable	O
Thermus	B-T007
thermophilus	I-T007
TK	B-T103
and	O
variants	B-T017
assessed	O
for	O
their	O
impact	O
on	O
both	O
thermostability	O
and	O
activity	O
.	O

Cofactor	B-T082
-	I-T082
binding	I-T082
loop	I-T082
2	I-T082
variants	B-T017
had	O
detrimental	O
effects	O
on	O
specific	O
activity	O
at	O
elevated	O
temperatures	O
,	O
whereas	O
the	O
H192P	B-T038
mutation	I-T038
in	O
cofactor	B-T082
-	I-T082
binding	I-T082
loop	I-T082
1	I-T082
resulted	O
in	O
a	O
two	O
-	O
fold	O
improved	O
stability	O
to	O
inactivation	O
at	O
elevated	O
temperatures	O
,	O
and	O
increased	O
the	O
critical	O
onset	O
temperature	O
for	O
aggregation	O
.	O

The	O
specific	O
activity	O
of	O
H192P	B-T038
was	O
3	O
-	O
fold	O
and	O
19	O
-	O
fold	O
higher	O
than	O
that	O
for	O
wild	B-T017
-	I-T017
type	I-T017
at	O
60°C	O
and	O
65°C	O
respectively	O
,	O
and	O
also	O
remained	O
2	O
.	O
7	O
-	O
4	O
fold	O
higher	O
after	O
re	O
-	O
cooling	O
from	O
pre	B-T058
-	I-T058
incubations	I-T058
at	O
either	O
55°C	O
or	O
60°C	O
for	O
1h	O
.	O

Interestingly	O
,	O
H192P	B-T038
was	O
also	O
2	O
-	O
times	O
more	O
active	O
than	O
wild	B-T017
-	I-T017
type	I-T017
TK	B-T103
at	O
25°C	O
.	O

Optimal	O
activity	O
was	O
achieved	O
at	O
60°C	O
for	O
H192P	B-T038
compared	O
to	O
55°C	O
for	O
wild	B-T017
type	I-T017
.	O

These	O
results	O
show	O
that	O
cofactor	B-T082
-	I-T082
binding	I-T082
loop	I-T082
1	I-T082
,	O
plays	O
a	O
pivotal	O
role	O
in	O
partial	O
denaturation	B-T038
and	O
aggregation	O
at	O
elevated	O
temperatures	O
.	O

Furthermore	O
,	O
a	O
single	B-T038
rigidifying	I-T038
mutation	I-T038
within	O
this	O
loop	B-T082
can	O
significantly	O
improve	O
the	O
enzyme	B-T038
specific	I-T038
activity	I-T038
,	O
as	O
well	O
as	O
the	O
stability	O
to	O
thermal	O
denaturation	B-T038
and	O
aggregation	O
,	O
to	O
give	O
an	O
increased	O
temperature	O
optimum	O
for	O
activity	B-T038
.	O

Safety	B-T062
of	O
transradial	O
diagnostic	O
cardiac	O
catheterization	O
in	O
patients	O
under	O
oral	B-T082
anticoagulant	B-T058
therapy	I-T058

Cardiac	B-T058
catheterization	I-T058
in	O
anticoagulated	O
patients	O
is	O
usually	O
performed	O
after	O
the	O
anticoagulation	B-T058
has	O
been	O
withdrawn	B-T058
,	O
at	O
least	O
in	O
the	O
previous	O
48h	O
,	O
and	O
sometimes	O
bridging	B-T058
therapy	I-T058
with	I-T058
heparin	I-T058
is	O
used	O
.	O

A	O
prospective	O
observational	B-T062
study	I-T062
including	O
489	O
patients	O
undergoing	O
transradial	B-T058
catheterization	I-T058
was	O
conducted	O
.	O

A	O
total	O
of	O
140	O
patients	O
were	O
under	O
acenocoumarol	B-T103
(	O
group	B-T170
A	I-T170
)	O
and	O
they	O
were	O
compared	O
with	O
the	O
remainder	O
(	O
group	B-T170
B	I-T170
)	O
for	O
complications	B-T038
after	O
the	O
procedure	B-T058
(	O
bleeding	B-T038
and	O
vascular	B-T038
access	I-T038
complications	I-T038
)	O
.	O

Patients	O
in	O
group	B-T170
A	I-T170
were	O
older	B-T098
(	O
74±12	O
years	O
vs	O
.	O

68±17	O
years	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
the	O
main	O
indication	O
for	O
anticoagulation	B-T058
was	O
atrial	B-T038
fibrillation	I-T038
(	O
58	O
.	O
6	O
%	O
)	O
.	O

No	B-T033
complications	B-T038
occurred	O
during	O
the	O
procedures	B-T058
.	O

There	O
were	O
no	B-T033
acute	B-T038
bleedings	I-T038
just	O
after	O
the	O
bandage	B-T074
removal	O
.	O

During	O
the	O
first	O
24h	O
,	O
only	O
3	O
(	O
2	O
.	O
1	O
%	O
)	O
radial	B-T038
occlusions	I-T038
in	O
group	B-T170
A	I-T170
and	O
2	O
(	O
0	O
.	O
6	O
%	O
)	O
in	O
group	B-T170
B	I-T170
(	O
p	O
=	O
0	O
.	O
14	O
)	O
were	O
recorded	O
.	O

Hematomas	B-T038
between	O
5	O
and	O
10cm	O
appeared	O
in	O
5	O
%	O
of	O
the	O
group	B-T170
A	I-T170
vs	O
.	O

4	O
.	O
6	O
%	O
in	O
group	B-T170
B	I-T170
.	O

During	O
the	O
1	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
period	O
,	O
one	O
more	O
radial	B-T038
occlusion	I-T038
in	O
each	O
group	O
was	O
recorded	O
and	O
there	O
were	O
4	O
(	O
1	O
.	O
1	O
%	O
)	O
additional	O
mild	O
hematomas	B-T038
in	O
group	B-T170
B	I-T170
and	O
none	O
in	O
group	B-T170
A	I-T170
(	O
p	O
=	O
0	O
.	O
48	O
)	O
.	O

Performing	O
a	O
transradial	O
diagnostic	O
cardiac	O
catheterization	O
without	O
removal	O
of	O
the	O
oral	B-T082
chronic	O
anticoagulation	O
appears	O
safe	B-T033
in	O
patients	O
under	O
acenocumarol	B-T103
therapy	B-T058
.	O

Does	O
infrared	O
visualization	O
improve	O
selection	O
of	O
venipuncture	B-T058
sites	B-T082
for	O
indwelling	O
needle	B-T074
at	O
the	O
forearm	B-T017
in	O
second	O
-	O
year	O
nursing	B-T097
students	I-T097
?	O

To	O
evaluate	O
the	O
effectiveness	O
of	O
a	O
vein	B-T074
visualization	I-T074
display	I-T074
system	I-T074
using	O
near	O
-	O
infrared	O
light	O
(	O
"	O
Vein	B-T074
Display	I-T074
"	O
)	O
for	O
the	O
safe	O
and	O
proper	O
selection	O
of	O
venipuncture	B-T058
sites	B-T082
for	O
indwelling	O
needle	B-T074
placement	O
in	O
the	O
forearm	B-T017
.	O

Ten	O
second	O
year	O
nursing	B-T097
students	I-T097
were	O
recruited	O
to	O
apply	O
an	O
indwelling	O
needle	B-T074
line	O
with	O
and	O
without	O
Vein	B-T017
Display	O
.	O

Another	O
ten	O
participants	B-T098
were	O
recruited	O
from	O
various	O
faculty	B-T097
to	O
serve	O
as	O
patients	O
.	O

The	O
quality	O
of	O
the	O
venipuncture	B-T058
procedure	I-T058
at	O
various	O
selected	O
sites	B-T082
was	O
evaluated	O
according	O
to	O
a	O
scale	B-T170
developed	O
by	O
the	O
authors	B-T097
.	O

Time	O
,	O
scores	O
and	O
patterns	O
of	O
puncture	B-T058
-	O
site	B-T082
selection	O
were	O
compared	O
with	O
respect	O
to	O
three	O
different	O
methods	O
:	O
[	O
1	O
]	O
attempt	O
1	O
(	O
tourniquet	B-T074
only	O
)	O
,	O
[	O
2	O
]	O
attempt	O
2	O
(	O
Vein	B-T074
Display	I-T074
only	O
)	O
and	O
[	O
3	O
]	O
attempt	O
3	O
(	O
both	O
)	O
.	O

To	O
validate	O
the	O
effectiveness	O
of	O
Vein	B-T017
Display	O
,	O
52	O
trials	O
were	O
conducted	O
in	O
total	O
.	O

We	O
found	O
that	O
venipuncture	B-T058
site	B-T082
selection	O
time	O
was	O
significantly	O
improved	O
with	O
the	O
Vein	B-T074
Display	I-T074
,	O
particularly	O
in	O
the	O
case	O
of	O
difficult	O
to	O
administer	O
venipuncture	B-T058
sites	B-T082
.	O

Overall	O
,	O
we	O
found	O
no	O
significant	O
difference	O
with	O
respect	O
to	O
venipuncture	B-T058
quality	O
,	O
as	O
determined	O
by	O
our	O
scale	B-T170
.	O

These	O
results	O
suggest	O
that	O
equipment	O
such	O
as	O
the	O
Vein	B-T074
Display	I-T074
can	O
contribute	O
immensely	O
to	O
the	O
improvement	O
of	O
practical	O
skills	O
,	O
such	O
as	O
venipuncture	B-T058
,	O
especially	O
in	O
the	O
context	O
of	O
elderly	B-T098
patients	O
.	O

Elective	B-T058
Nephron	B-T058
Sparing	I-T058
Surgery	I-T058
Decreases	O
Other	B-T033
Cause	I-T033
Mortality	I-T033
Relative	O
to	O
Radical	B-T058
Nephrectomy	I-T058
Only	O
in	O
Specific	O
Subgroups	B-T170
of	O
Patients	O
with	O
Renal	B-T038
Cell	I-T038
Carcinoma	I-T038

There	O
is	O
no	O
consensus	O
regarding	O
a	O
protective	O
effect	O
on	O
mortality	O
due	O
to	O
a	O
cause	O
other	O
than	O
cancer	B-T038
in	O
patients	O
treated	B-T058
with	I-T058
elective	B-T058
nephron	B-T058
sparing	I-T058
surgery	I-T058
relative	O
to	O
their	O
radical	B-T058
nephrectomy	I-T058
counterparts	O
.	O

We	O
test	O
whether	O
the	O
protective	O
effect	O
of	O
nephron	B-T058
sparing	I-T058
surgery	I-T058
relative	O
to	O
radical	B-T058
nephrectomy	I-T058
is	O
universal	O
or	O
present	O
in	O
specific	O
subgroups	B-T170
of	O
patients	O
.	O

A	O
collaborative	O
database	B-T170
of	O
5	O
institutions	O
was	O
queried	B-T170
to	O
evaluate	B-T058
1	O
,	O
783	O
patients	O
without	O
chronic	B-T038
kidney	I-T038
disease	I-T038
diagnosed	B-T033
with	O
a	O
clinical	O
T1	O
renal	O
mass	O
that	O
was	O
treated	B-T058
with	I-T058
nephron	B-T058
sparing	I-T058
surgery	I-T058
or	O
radical	B-T058
nephrectomy	I-T058
.	O

Multivariable	B-T170
Cox	I-T170
regression	I-T170
analysis	I-T170
was	O
done	O
to	O
assess	O
the	O
impact	O
of	O
surgery	B-T058
type	O
(	O
nephron	B-T058
sparing	I-T058
surgery	I-T058
vs	O
radical	B-T058
nephrectomy	I-T058
)	O
on	O
other	B-T033
cause	I-T033
mortality	I-T033
after	O
adjustment	O
for	O
patient	O
and	O
cancer	B-T038
characteristics	O
.	O

Interaction	O
terms	O
were	O
used	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
impact	O
of	O
surgery	B-T058
type	O
varies	O
according	O
to	O
specific	O
subcohorts	B-T098
of	O
patients	O
.	O

Ten	O
-	O
year	O
other	B-T033
cause	I-T033
mortality	I-T033
-	O
free	O
survival	O
rates	O
were	O
90	O
%	O
and	O
88	O
%	O
after	O
nephron	B-T058
sparing	I-T058
surgery	I-T058
and	O
radical	B-T058
nephrectomy	I-T058
,	O
respectively	O
.	O

In	O
the	O
overall	O
population	B-T098
radical	B-T058
nephrectomy	I-T058
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
other	B-T033
cause	I-T033
mortality	I-T033
on	O
multivariable	O
analysis	O
compared	O
to	O
nephron	B-T058
sparing	I-T058
surgery	I-T058
(	O
HR	O
0	O
.	O
91	O
,	O
95	O
%	O
CI	O
0	O
.	O
6	O
-	O
1	O
.	O
38	O
,	O
p	O
=	O
0	O
.	O
6	O
)	O
.	O

However	O
,	O
radical	B-T058
nephrectomy	I-T058
increased	O
the	O
risk	O
of	O
other	B-T033
cause	I-T033
mortality	I-T033
according	O
to	O
the	O
increasing	O
baseline	O
Charlson	B-T170
comorbidity	I-T170
index	I-T170
(	O
interaction	O
test	O
p	O
=	O
0	O
.	O
0008	O
)	O
.	O

For	O
example	O
,	O
in	O
a	O
patient	O
with	O
a	O
Charlson	B-T170
comorbidity	I-T170
index	I-T170
of	O
4	O
the	O
probability	O
of	O
10	O
-	O
year	O
other	B-T033
cause	I-T033
mortality	I-T033
-	O
free	O
survival	O
was	O
86	O
%	O
after	O
nephron	B-T058
sparing	I-T058
surgery	I-T058
and	O
60	O
%	O
after	O
radical	B-T058
nephrectomy	I-T058
.	O

Elective	B-T058
nephron	B-T058
sparing	I-T058
surgery	I-T058
does	O
not	O
improve	B-T033
other	O
cause	O
survival	O
relative	O
to	O
radical	B-T058
nephrectomy	I-T058
consistently	O
in	O
all	O
patients	O
with	O
kidney	B-T038
cancer	I-T038
.	O

Patients	O
who	O
are	O
more	O
ill	B-T033
with	O
relevant	O
comorbidities	O
are	O
those	O
who	O
benefit	O
the	O
most	O
from	O
nephron	B-T058
sparing	I-T058
surgery	I-T058
in	O
terms	O
of	O
other	B-T033
cause	I-T033
mortality	I-T033
.	O

Prospective	O
study	O
of	O
dietary	B-T168
Non	B-T058
Enzymatic	I-T058
Antioxidant	I-T058
Capacity	I-T058
on	O
the	O
risk	O
of	O
hip	B-T037
fracture	I-T037
in	O
the	O
elderly	B-T098

Dietary	B-T168
antioxidants	I-T168
may	O
play	O
an	O
important	O
role	O
in	O
the	O
prevention	O
of	O
bone	B-T038
loss	I-T038
and	O
associated	O
fractures	B-T037
by	O
reducing	O
levels	O
of	O
oxidative	B-T038
stress	I-T038
.	O

We	O
prospectively	O
investigated	O
the	O
association	O
between	O
dietary	B-T168
Non	B-T058
Enzymatic	I-T058
Antioxidant	I-T058
Capacity	I-T058
(	O
NEAC	B-T058
)	O
and	O
the	O
risk	O
of	O
hip	B-T037
fracture	I-T037
and	O
whether	O
this	O
effect	O
was	O
modified	O
by	O
smoking	O
.	O

In	O
the	O
Swedish	B-T098
National	I-T098
March	I-T098
Cohort	I-T098
13	O
,	O
409	O
men	B-T098
and	O
women	B-T098
over	O
the	O
age	O
of	O
55	O
who	O
had	O
not	O
experienced	O
cancer	B-T038
,	O
cardiovascular	B-T038
disease	I-T038
or	O
hip	B-T037
fracture	I-T037
,	O
were	O
followed	O
through	O
record	B-T062
-	I-T062
linkages	I-T062
from	O
1997	O
through	O
2010	O
.	O

NEAC	B-T058
was	O
assessed	O
by	O
a	O
validated	O
food	B-T170
frequency	I-T170
questionnaire	I-T170
collected	O
at	O
baseline	O
.	O

We	O
categorized	O
the	O
distribution	O
of	O
NEAC	B-T058
into	O
sex	O
-	O
specific	O
quartiles	O
and	O
used	O
multivariable	B-T170
adjusted	I-T170
Cox	I-T170
proportional	I-T170
hazards	I-T170
regression	I-T170
models	I-T170
to	O
estimate	O
hazard	O
ratios	O
(	O
HRs	O
)	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
95	O
%	O
CI	O
)	O
.	O

During	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
time	O
of	O
12	O
.	O
4years	O
,	O
we	O
identified	O
491	O
incident	O
cases	O
of	O
first	O
hip	B-T037
fracture	I-T037
.	O

Subjects	O
in	O
the	O
highest	O
quartile	O
of	O
dietary	B-T168
NEAC	B-T058
had	O
a	O
39	O
%	O
lower	O
risk	O
of	O
incident	O
hip	B-T037
fracture	I-T037
compared	O
to	O
those	O
in	O
the	O
lowest	O
quartile	O
(	O
HR	O
:	O
0	O
.	O
61	O
;	O
95	O
%	O
CI	O
:	O
0	O
.	O
44	O
-	O
0	O
.	O
85	O
)	O
.	O

The	O
association	O
was	O
non	O
-	O
linear	O
(	O
p	O
for	O
non	O
-	O
linearity	O
:	O
0	O
.	O
004	O
)	O
with	O
a	O
potential	O
threshold	O
between	O
the	O
first	O
and	O
the	O
second	O
quartile	O
and	O
no	O
further	O
risk	O
reduction	O
at	O
higher	O
levels	O
of	O
dietary	B-T168
NEAC	B-T058
.	O

Due	O
to	O
a	O
low	O
smoking	O
prevalence	O
in	O
our	O
study	O
population	O
,	O
we	O
had	O
limited	O
power	O
to	O
detect	O
effect	O
modification	O
between	O
dietary	B-T168
NEAC	B-T058
and	O
smoking	O
on	O
a	O
multiplicative	O
or	O
additive	O
scale	O
.	O

Higher	O
dietary	O
NEAC	B-T058
intake	O
is	O
associated	O
with	O
lower	O
risk	O
of	O
hip	B-T037
fracture	I-T037
in	O
the	O
elderly	O
.	O

Function	B-T038
and	O
clinical	O
meaningfulness	O
of	O
treatments	B-T058
for	O
mild	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038

Effectiveness	O
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
treatments	B-T058
is	O
commonly	O
evaluated	O
with	O
coprimary	O
outcomes	O
;	O
cognition	B-T038
with	O
function	B-T038
to	O
ensure	O
clinical	O
meaningfulness	O
of	O
a	O
cognitive	B-T038
effect	O
.	O

We	O
reviewed	O
the	O
literature	B-T170
for	O
functional	B-T038
outcomes	O
in	O
mild	O
AD	B-T038
or	O
mild	B-T038
cognitive	I-T038
impairment	I-T038
(	O
MCI	B-T038
)	O
patients	O
(	O
distinct	O
from	O
combined	O
mild	O
-	O
moderate	O
/	O
severe	O
AD	B-T038
)	O
treated	B-T058
with	I-T058
approved	O
AD	B-T038
drugs	B-T103
.	O

Cognitive	B-T058
and	O
functional	B-T038
treatment	B-T058
differences	O
in	O
mild	O
AD	B-T038
patients	O
in	O
solanezumab	B-T103
EXPEDITION	O
/	O
EXPEDITION2	O
studies	B-T062
were	O
compared	O
across	O
time	O
.	O

Seven	O
publications	B-T170
provided	O
MCI	B-T038
/	O
mild	O
AD	B-T038
functional	B-T038
outcomes	O
,	O
one	O
of	O
which	O
reported	O
a	O
significant	O
functional	B-T038
treatment	B-T033
effect	I-T033
.	O

Secondary	O
analyses	O
of	O
EXPEDITION	O
studies	B-T062
suggested	O
a	O
smaller	O
functional	B-T038
effect	O
of	O
solanezumab	B-T103
relative	O
to	O
cognition	B-T038
.	O

An	O
increasing	O
effect	O
of	O
solanezumab	B-T103
over	O
18	O
months	O
was	O
shown	O
for	O
cognition	B-T038
and	O
function	B-T038
.	O

Function	B-T038
as	O
the	O
sole	O
measure	O
to	O
demonstrate	O
clinical	O
meaningfulness	O
of	O
cognitive	B-T038
effects	O
in	O
mild	O
AD	B-T038
may	O
have	O
limitations	O
.	O

For	O
disease	B-T038
-	O
modifying	O
treatments	B-T058
,	O
point	O
differences	O
on	O
cognitive	B-T038
and	O
functional	B-T038
scales	B-T170
should	O
be	O
qualified	O
with	O
duration	O
of	O
treatment	O
.	O

In	O
Search	O
of	O
the	O
E	B-T007
.	I-T007
coli	I-T007
Compounds	B-T103
that	O
Change	O
the	O
Antibiotic	B-T103
Production	O
Pattern	O
of	O
Streptomyces	B-T007
coelicolor	I-T007
During	O
Inter	O
-	O
species	O
Interaction	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
interaction	O
between	O
E	B-T007
.	I-T007
coli	I-T007
and	O
Streptomyces	B-T007
coelicolor	I-T007
A3	I-T007
(	I-T007
2	I-T007
)	I-T007
for	O
the	O
increased	O
production	O
of	O
undecylprodigiosin	B-T103
and	O
identify	O
the	O
E	B-T007
.	I-T007

coli	I-T007
actives	O
mediating	O
this	O
inter	O
-	O
species	O
interaction	O
.	O

The	O
antibiotics	B-T103
of	O
interest	O
were	O
the	O
red	B-T103
-	I-T103
pigmented	I-T103
undecylprodigiosin	I-T103
and	O
blue	O
-	O
pigmented	O
actinorhodin	B-T103
.	O

Pure	O
cultures	B-T058
of	O
S	B-T007
.	I-T007

coelicolor	I-T007
in	O
a	O
defined	O
medium	B-T103
produced	O
higher	O
concentrations	O
of	O
actinorhodin	B-T103
compared	O
to	O
those	O
of	O
undecylprodigiosin	B-T103
.	O

The	O
latter	O
however	O
,	O
is	O
more	O
important	O
due	O
to	O
its	O
immunosuppressive	B-T038
and	O
antitumor	B-T038
properties	I-T038
.	O

As	O
a	O
strategy	O
to	O
increase	O
undecylprodigiosin	B-T103
production	O
,	O
we	O
added	O
separately	O
,	O
live	O
cells	O
and	O
heat	O
-	O
killed	O
cells	B-T017
of	O
E	B-T007
.	I-T007

coli	I-T007
C600	I-T007
,	O
and	O
the	O
cell	B-T031
-	I-T031
free	I-T031
supernatant	I-T031
of	O
E	B-T007
.	I-T007

coli	I-T007
culture	B-T058
to	O
S	B-T007
.	I-T007

coelicolor	I-T007
cultures	B-T058
in	I-T058
shake	I-T058
flasks	I-T058
.	O

The	O
interaction	O
with	O
live	O
cells	O
of	O
E	B-T007
.	I-T007

coli	I-T007
altered	O
the	O
antibiotic	B-T103
production	O
pattern	O
and	O
undecylprodigiosin	B-T103
production	O
was	O
enhanced	O
by	O
3	O
.	O
5	O
-	O
fold	O
compared	O
to	O
the	O
pure	B-T058
cultures	I-T058
of	O
S	B-T007
.	I-T007

coelicolor	I-T007
and	O
actinorhodin	B-T103
decreased	O
by	O
15	O
-	O
fold	O
.	O

The	O
heat	O
-	O
killed	O
cells	B-T017
of	O
E	B-T007
.	I-T007

coli	I-T007
however	O
,	O
had	O
no	O
effect	O
on	O
antibiotic	B-T103
production	O
.	O

In	O
all	O
cases	O
,	O
growth	O
and	O
glucose	B-T033
consumption	I-T033
of	O
S	B-T007
.	I-T007

coelicolor	I-T007
remained	O
almost	O
the	O
same	O
as	O
those	O
observed	O
in	O
the	O
pure	B-T058
culture	I-T058
indicating	O
that	O
the	O
changes	O
in	O
antibiotic	B-T103
production	O
were	O
not	O
due	O
to	O
nutritional	B-T038
stress	B-T033
.	O

Results	O
with	O
cell	B-T031
-	I-T031
free	I-T031
supernatant	I-T031
of	O
E	B-T007
.	I-T007

coli	I-T007
culture	B-T058
indicated	O
that	O
the	O
interaction	O
between	O
S	B-T007
.	I-T007

coelicolor	I-T007
and	O
E	B-T007
.	I-T007

coli	I-T007
was	O
mediated	O
via	O
diffusible	B-T103
molecule	I-T103
(	I-T103
s	I-T103
)	I-T103
.	O

Using	O
a	O
set	O
of	O
extraction	B-T058
procedures	I-T058
and	O
agar	B-T058
-	I-T058
well	I-T058
diffusion	I-T058
bioassays	I-T058
,	O
we	O
isolated	O
and	O
preliminarily	O
identified	O
a	O
class	B-T103
of	I-T103
compounds	I-T103
.	O

For	O
the	O
preliminary	O
verification	O
,	O
we	O
added	O
the	O
compound	B-T103
which	O
was	O
the	O
common	O
chemical	O
structural	O
moiety	O
in	O
this	O
class	B-T103
of	I-T103
compounds	I-T103
to	O
the	O
pure	O
S	B-T007
.	I-T007

coelicolor	I-T007
cultures	O
.	O

We	O
observed	O
similar	O
effects	O
on	O
antibiotic	B-T103
production	O
as	O
with	O
the	O
live	O
E	B-T007
.	I-T007

coli	I-T007
cells	B-T017
and	O
their	O
supernatant	B-T031
indicating	O
that	O
this	O
class	B-T103
of	I-T103
compounds	I-T103
secreted	B-T038
by	O
E	B-T007
.	I-T007

coli	I-T007
indeed	O
could	O
act	O
as	O
actives	O
during	O
interspecies	O
interaction	O
and	O
increase	O
the	O
production	O
of	O
undecylprodigiosin	B-T103
.	O

Group	B-T017
III	I-T017
/	I-T017
IV	I-T017
muscle	I-T017
afferents	B-T017
limit	O
the	O
intramuscular	B-T082
metabolic	O
perturbation	O
during	O
whole	B-T017
body	I-T017
exercise	O
in	O
humans	B-T204

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
determine	B-T058
the	O
role	O
of	O
group	B-T017
III	I-T017
/	I-T017
IV	I-T017
muscle	I-T017
afferents	B-T017
in	O
limiting	O
the	O
endurance	B-T033
exercise	O
-	O
induced	O
metabolic	O
perturbation	O
assayed	B-T058
in	O
muscle	B-T017
biopsy	B-T017
samples	I-T017
taken	O
from	O
locomotor	B-T038
muscle	B-T017
.	O

Lumbar	B-T082
intrathecal	B-T082
fentanyl	B-T103
was	O
used	O
to	O
attenuate	O
the	O
central	B-T082
projection	B-T082
of	O
μ	B-T103
-	I-T103
opioid	I-T103
receptor	I-T103
-	O
sensitive	O
locomotor	B-T038
muscle	B-T017
afferents	B-T017
during	O
a	O
5	O
km	O
cycling	O
time	O
trial	B-T062
.	O

The	O
findings	B-T033
suggest	O
that	O
the	O
central	B-T082
projection	B-T082
of	O
group	B-T017
III	I-T017
/	I-T017
IV	I-T017
muscle	I-T017
afferent	B-T017
feedback	B-T038
constrains	O
voluntary	O
neural	O
'	O
drive	B-T038
'	O
to	O
working	O
locomotor	B-T038
muscle	B-T017
and	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	B-T082
metabolic	O
perturbation	O
.	O

Therefore	O
,	O
the	O
CNS	B-T022
might	O
regulate	B-T038
the	O
degree	O
of	O
metabolic	O
perturbation	O
within	O
locomotor	B-T038
muscle	B-T017
and	O
thereby	O
limit	O
peripheral	B-T082
fatigue	B-T033
.	O

It	O
appears	O
that	O
the	O
group	B-T017
III	I-T017
/	I-T017
IV	I-T017
muscle	I-T017
afferents	B-T017
are	O
an	O
important	O
neural	O
link	O
in	O
this	O
regulatory	B-T038
mechanism	O
,	O
which	O
probably	O
serves	O
to	O
protect	O
locomotor	B-T038
muscle	B-T017
from	O
the	O
potentially	O
severe	O
functional	O
impairment	O
as	O
a	O
consequence	O
of	O
severe	O
intramuscular	B-T082
metabolic	O
disturbance	O
.	O

To	O
investigate	O
the	O
role	O
of	O
metabo	B-T038
-	O
and	O
mechanosensitive	O
group	B-T017
III	I-T017
/	I-T017
IV	I-T017
muscle	I-T017
afferents	B-T017
in	O
limiting	O
the	O
intramuscular	B-T082
metabolic	O
perturbation	O
during	O
whole	B-T017
body	I-T017
endurance	B-T033
exercise	O
,	O
eight	O
subjects	O
performed	O
5	O
km	O
cycling	O
time	O
trials	B-T062
under	B-T033
control	I-T033
conditions	I-T033
(	O
CTRL	B-T033
)	O
and	O
with	O
lumbar	B-T082
intrathecal	B-T082
fentanyl	B-T103
impairing	O
lower	B-T017
limb	I-T017
muscle	B-T017
afferent	B-T017
feedback	B-T038
(	O
FENT	B-T038
)	O
.	O

Vastus	B-T017
lateralis	I-T017
muscle	B-T017
biopsies	B-T017
were	O
obtained	O
before	O
and	O
immediately	O
after	O
exercise	O
.	O

Motoneuronal	B-T017
output	B-T058
was	I-T058
estimated	I-T058
through	O
vastus	B-T017
lateralis	I-T017
surface	I-T017
electromyography	B-T058
(	O
EMG	B-T058
)	O
.	O

Exercise	O
-	O
induced	O
changes	O
in	O
intramuscular	B-T082
metabolites	B-T103
were	O
determine	B-T058
d	O
using	O
liquid	O
and	O
gas	B-T058
chromatography	I-T058
-	I-T058
mass	I-T058
spectrometry	I-T058
.	O

Quadriceps	B-T017
fatigue	B-T033
was	O
quantified	O
by	O
pre	O
-	O
to	O
post	O
-	O
exercise	O
changes	O
in	O
potentiated	O
quadriceps	O
twitch	O
torque	O
(	O
ΔQTsingle	O
)	O
evoked	O
by	O
electrical	O
femoral	B-T017
nerve	I-T017
stimulation	B-T058
.	O

Although	O
motoneuronal	B-T017
output	O
was	O
21	O
±	O
12	O
%	O
higher	O
during	O
FENT	B-T038
compared	O
to	O
CTRL	B-T033
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
time	O
to	O
complete	O
the	O
time	O
trial	B-T062
was	O
similar	O
(	O
∼8	O
.	O
8	O
min	O
)	O
.	O

Compared	O
to	O
CTRL	B-T033
,	O
power	O
output	O
during	O
FENT	B-T038
was	O
10	O
±	O
4	O
%	O
higher	O
in	O
the	O
first	O
half	O
of	O
the	O
time	O
trial	B-T062
,	O
but	O
11	O
±	O
5	O
%	O
lower	O
in	O
the	O
second	O
half	O
(	O
both	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
exercise	O
-	O
induced	O
increase	O
in	O
intramuscular	B-T082
inorganic	B-T103
phosphate	I-T103
,	O
H	B-T103
(	I-T103
+	I-T103
)	I-T103
,	O
adenosine	B-T103
diphosphate	I-T103
,	O
lactate	B-T103
and	O
phosphocreatine	B-T103
depletion	O
was	O
55	O
±	O
30	O
,	O
62	O
±	O
18	O
,	O
129	O
±	O
63	O
,	O
47	O
±	O
14	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
27	O
±	O
14	O
%	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
greater	O
in	O
FENT	B-T038
than	O
CTRL	B-T033
.	O

ΔQTsingle	O
was	O
greater	O
following	O
FENT	B-T038
than	O
CTRL	B-T033
(	O
-	O
52	O
±	O
2	O
vs	O
-	O
31	O
±	O
1	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
this	O
difference	O
was	O
positively	B-T033
correlated	O
with	O
the	O
difference	O
in	O
inorganic	B-T103
phosphate	I-T103
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
79	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
H	O
(	O
+	O
)	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
92	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
conclusion	O
,	O
during	O
whole	B-T017
body	I-T017
exercise	O
,	O
group	B-T017
III	I-T017
/	I-T017
IV	I-T017
muscle	I-T017
afferents	B-T017
provide	O
feedback	B-T038
to	O
the	O
CNS	B-T022
which	O
,	O
in	O
turn	O
,	O
constrains	O
motoneuronal	B-T017
output	O
to	O
the	O
active	O
skeletal	B-T017
muscle	I-T017
.	O

This	O
regulatory	B-T038
mechanism	O
limits	O
the	O
exercise	O
-	O
induced	O
intramuscular	B-T082
metabolic	O
perturbation	O
,	O
preventing	O
an	O
abnormal	B-T033
homeostatic	I-T033
challenge	B-T058
and	O
excessive	O
peripheral	B-T082
fatigue	B-T033
.	O

Mitochondrial	B-T017
Ultrastructure	O
and	O
Glucose	B-T038
Signaling	I-T038
Pathways	I-T038
Attributed	O
to	O
the	O
Kv1	B-T103
.	I-T103
3	I-T103
Ion	I-T103
Channel	I-T103

Gene	B-T062
-	I-T062
targeted	I-T062
deletion	B-T038
of	O
the	O
potassium	B-T103
channel	I-T103
Kv1	I-T103
.	I-T103
3	I-T103
(	O
Kv1	B-T033
.	I-T033
3	I-T033
(	I-T033
-	I-T033
∕	I-T033
-	I-T033
)	I-T033
)	I-T033
results	I-T033
i	I-T033
n	O
"	O
S	O
uper	B-T204
-	I-T204
smeller	I-T204
"	I-T204
mice	I-T204
with	O
a	O
se	O
nsory	O
p	O
h	O
enotype	O
t	O
hat	O
includes	O
an	O
increased	O
olfactory	B-T038
ability	O
linked	O
to	O
changes	O
in	O
olfactory	B-T038
circuitry	O
,	O
increased	O
abundance	O
of	O
olfactory	B-T017
cilia	I-T017
,	O
and	O
increased	O
expression	O
of	O
odorant	B-T103
receptors	I-T103
and	O
the	O
G	B-T103
-	I-T103
protein	I-T103
,	I-T103
Golf	I-T103
.	O

Kv1	B-T204
.	I-T204
3	I-T204
(	I-T204
-	I-T204
∕	I-T204
-	I-T204
)	I-T204
mice	I-T204
a	I-T204
lso	O
have	O
a	O
metabolic	O
p	O
h	O
enotype	O
i	O
ncluding	O
lo	O
wer	O
b	O
o	O
dy	O
weight	O
a	O
nd	O
de	O
creased	O
a	O
d	O
iposity	O
,	O
in	O
creased	B-T033
total	I-T033
energy	I-T033
expenditure	I-T033
(	O
TEE	B-T033
)	O
,	O
increased	O
locomotor	B-T038
activity	I-T038
,	O
and	O
resistance	B-T038
to	O
both	O
diet	B-T168
-	O
and	O
genetic	B-T038
-	I-T038
induced	I-T038
obesity	B-T038
.	O

We	O
explored	O
two	O
cellular	O
aspects	O
to	O
elucidate	O
the	O
mechanism	O
by	O
which	O
loss	O
of	O
Kv1	B-T103
.	I-T103
3	I-T103
channel	I-T103
in	O
the	O
olfactory	B-T017
bulb	I-T017
(	O
OB	B-T017
)	O
may	O
enhance	O
glucose	B-T038
utilization	I-T038
and	O
metabolic	O
rate	O
.	O

First	O
,	O
using	O
in	B-T062
situ	I-T062
hybridization	I-T062
we	O
find	O
that	O
Kv1	B-T103
.	I-T103
3	I-T103
and	O
the	O
insulin	B-T103
-	O
dependent	O
glucose	B-T103
transporter	I-T103
type	I-T103
4	I-T103
(	O
GLUT4	B-T103
)	O
are	O
co	O
-	O
localized	O
to	O
the	O
mitral	B-T017
cell	B-T017
layer	I-T017
of	O
the	O
OB	B-T017
.	O

Disruption	O
of	O
Kv1	B-T103
.	I-T103
3	I-T103
conduction	O
via	O
construction	O
of	O
a	O
pore	B-T038
mutation	I-T038
(	O
W386F	B-T038
Kv1	I-T038
.	I-T038
3	I-T038
)	O
was	O
sufficient	O
to	O
independently	O
translocate	B-T038
GLUT4	B-T103
to	O
the	O
plasma	B-T017
membrane	I-T017
in	O
HEK	B-T017
293	I-T017
cells	I-T017
.	O

Because	O
olfactory	B-T038
sensory	I-T038
perception	I-T038
and	O
the	O
maintenance	O
of	O
action	B-T038
potential	I-T038
(	I-T038
AP	I-T038
)	I-T038
firing	O
frequency	O
by	O
mitral	B-T017
cells	B-T017
of	O
the	O
OB	B-T017
is	O
highly	O
energy	O
demanding	O
and	O
Kv1	B-T103
.	I-T103
3	I-T103
is	O
also	O
expressed	O
in	O
mitochondria	B-T017
,	O
we	O
next	O
explored	O
the	O
structure	O
of	O
this	O
organelle	B-T017
in	O
mitral	B-T017
cells	B-T017
.	O

We	O
challenged	O
wildtype	B-T204
(	O
WT	B-T204
)	O
and	O
Kv1	B-T204
.	I-T204
3	I-T204
(	I-T204
-	I-T204
∕	I-T204
-	I-T204
)	I-T204
male	I-T204
mice	I-T204
with	O
a	O
m	O
oderately	B-T058
high	I-T058
-	I-T058
fat	I-T058
diet	I-T058
(	I-T058
M	O
HF	B-T058
,	I-T058
31	O
.	O
8	O
%	O
kcal	O
fat	O
)	O
for	O
4	O
months	O
and	O
then	O
examined	O
OB	B-T017
ultrastructure	O
using	O
transmission	B-T058
electron	I-T058
microscopy	I-T058
.	O

In	O
WT	B-T204
mice	I-T204
,	O
mitochondria	B-T017
were	O
significantly	O
enlarged	O
following	O
diet	B-T038
-	I-T038
induced	I-T038
obesity	I-T038
(	O
DIO	B-T038
)	O
and	O
there	O
were	O
fewer	O
mitochondria	B-T017
,	O
likely	O
due	O
to	O
mitophagy	B-T038
.	O

Interestingly	O
,	O
mitochondria	B-T017
were	O
significantly	O
smaller	O
in	O
Kv1	B-T204
.	I-T204
3	I-T204
(	I-T204
-	I-T204
∕	I-T204
-	I-T204
)	I-T204
mice	I-T204
c	I-T204
ompared	O
with	O
that	O
of	O
W	O
T	B-T204
mice	I-T204
.	I-T204

Similar	O
to	O
their	O
m	O
etabolic	O
r	O
esistance	O
to	O
D	O
IO	B-T038
,	I-T038
the	O
K	O
v1	B-T204
.	I-T204
3	I-T204
(	I-T204
-	I-T204
∕	I-T204
-	I-T204
)	I-T204
mice	I-T204
ha	I-T204
d	O
unchanged	O
mit	O
ochondria	B-T017
in	I-T017
terms	O
of	O
cros	O
s	B-T082
sectional	I-T082
area	B-T082
and	O
abundance	O
following	O
a	O
challenge	O
with	O
modified	B-T058
diet	I-T058
.	O

We	O
are	O
very	O
interested	O
to	O
understand	O
how	O
targeted	O
disruption	O
of	O
the	O
Kv1	B-T103
.	I-T103
3	I-T103
channel	I-T103
in	O
the	O
OB	B-T017
can	O
modify	O
TEE	B-T033
.	O

Our	O
study	O
demonstrates	O
that	O
Kv1	B-T103
.	I-T103
3	I-T103
regulates	O
mitochondrial	B-T017
structure	I-T017
and	O
alters	O
glucose	B-T038
utilization	I-T038
;	O
two	O
important	O
metabolic	O
changes	O
that	O
could	O
drive	O
whole	O
system	O
changes	O
in	O
metabolism	B-T038
initiated	O
at	O
the	O
OB	B-T017
.	O

The	O
effects	O
of	O
paternal	O
high	B-T168
-	I-T168
fat	I-T168
diet	I-T168
exposure	O
on	O
offspring	O
metabolism	B-T038
with	O
epigenetic	B-T038
changes	I-T038
in	O
the	O
mouse	O
adiponectin	B-T017
and	O
leptin	B-T017
gene	B-T017
promoters	I-T017

Recent	O
studies	B-T062
have	O
demonstrated	O
that	O
epigenetic	B-T038
changes	I-T038
resulting	O
from	O
malnutrition	B-T038
might	O
play	O
important	O
roles	O
in	O
transgenerational	O
links	O
with	O
metabolic	B-T038
diseases	I-T038
.	O

Previously	O
,	O
we	O
observed	O
that	O
exposure	O
to	O
a	O
high	B-T168
-	I-T168
fat	I-T168
diet	I-T168
(	O
HFD	B-T168
)	O
in	O
utero	O
caused	O
a	O
metabolic	O
syndrome	B-T038
-	O
like	O
phenomenon	O
through	O
epigenetic	B-T038
modifications	I-T038
of	O
the	O
adiponectin	B-T017
and	O
leptin	B-T017
genes	I-T017
that	O
persisted	O
for	O
multiple	O
generations	O
.	O

Recent	O
etiological	O
studies	B-T062
indicated	B-T033
that	O
paternal	O
BMI	B-T201
had	O
effects	O
on	O
offspring	O
BMI	B-T201
that	O
were	O
independent	O
of	O
but	O
additive	O
to	O
maternal	B-T033
BMI	B-T201
effects	O
.	O

Thus	O
,	O
we	O
examined	O
whether	O
paternal	O
HFD	B-T168
-	O
induced	O
obesity	B-T038
affected	O
the	O
metabolic	O
status	O
of	O
offspring	O
through	O
epigenetic	B-T038
changes	I-T038
in	O
the	O
adiponectin	B-T017
and	O
leptin	B-T017
genes	I-T017
.	O

Additionally	O
,	O
we	O
investigated	O
whether	O
a	O
normal	O
diet	O
during	O
subsequent	O
generations	O
abolished	O
the	O
epigenetic	B-T038
changes	I-T038
associated	O
with	O
paternal	O
HFD	B-T168
exposure	O
before	O
conception	B-T038
.	O

We	O
observed	O
the	O
effects	O
of	O
paternal	O
HFD	B-T168
exposure	O
before	O
conception	B-T038
over	O
multiple	O
generations	O
on	O
offspring	O
metabolic	O
traits	O
,	O
including	O
weight	B-T033
and	O
fat	B-T103
gain	O
,	O
glucose	B-T038
intolerance	I-T038
,	O
hypertriglyceridemia	B-T038
,	O
abnormal	B-T103
adipocytokine	I-T103
levels	O
,	O
hypertension	B-T038
,	O
and	O
adiponectin	B-T017
and	O
leptin	B-T017
gene	I-T017
expression	B-T038
and	O
epigenetic	B-T038
changes	I-T038
.	O

Normal	O
diet	O
consumption	O
by	O
male	O
offspring	O
during	O
the	O
subsequent	O
generation	O
following	O
paternal	O
HFD	B-T168
exposure	O
diminished	O
whereas	O
consumption	O
for	O
two	O
generations	O
completely	O
abolished	O
the	O
effect	O
of	O
paternal	O
HFD	B-T168
exposure	O
on	O
metabolic	O
traits	O
and	O
adipocytokine	B-T103
promoter	O
epigenetic	B-T038
changes	I-T038
in	O
the	O
offspring	O
.	O

The	O
effects	O
of	O
paternal	O
HFD	B-T168
exposure	O
on	O
offspring	O
were	O
relatively	O
weaker	O
than	O
those	O
following	O
HFD	B-T168
exposure	O
in	O
utero	O
.	O

However	O
,	O
paternal	O
HFD	B-T168
exposure	O
had	O
an	O
additive	O
metabolic	O
effect	O
for	O
two	O
generations	O
,	O
suggesting	O
that	O
both	O
paternal	O
and	O
maternal	B-T033
nutrition	B-T038
might	O
affect	O
offspring	O
metabolism	B-T038
through	O
epigenetic	B-T038
modifications	I-T038
of	O
adipocytokine	B-T017
genes	I-T017
for	O
multiple	O
generations	O
.	O

Study	B-T058
of	O
the	O
Microfocus	B-T082
X	B-T074
-	I-T074
Ray	I-T074
Tube	I-T074
Based	O
on	O
a	O
Point	O
-	O
Like	O
Target	O
Used	O
for	O
Micro	B-T058
-	I-T058
Computed	I-T058
Tomography	I-T058

For	O
a	O
micro	B-T058
-	I-T058
Computed	I-T058
Tomography	I-T058
(	I-T058
Micro	I-T058
-	I-T058
CT	I-T058
)	I-T058
system	I-T058
,	O
the	O
microfocus	B-T082
X	B-T074
-	I-T074
ray	I-T074
tube	I-T074
is	O
an	O
essential	O
component	O
because	O
the	O
spatial	O
resolution	O
of	O
CT	B-T058
images	B-T170
,	O
in	O
theory	O
,	O
is	O
mainly	O
determined	O
by	O
the	O
size	B-T082
and	O
stability	O
of	O
the	O
X	B-T058
-	I-T058
ray	I-T058
focal	B-T082
spot	I-T082
of	O
the	O
microfocus	B-T082
X	B-T074
-	I-T074
ray	I-T074
tube	I-T074
.	O

However	O
,	O
many	O
factors	O
,	O
including	O
voltage	O
fluctuations	O
,	O
mechanical	O
vibrations	O
,	O
and	O
temperature	O
changes	O
,	O
can	O
cause	O
the	O
size	B-T082
and	O
the	O
stability	O
of	O
the	O
X	B-T058
-	I-T058
ray	I-T058
focal	B-T082
spot	I-T082
to	O
degrade	O
.	O

A	O
new	O
microfocus	B-T082
X	B-T074
-	I-T074
ray	I-T074
tube	I-T074
based	O
on	O
a	O
point	O
-	O
like	O
micro	O
-	O
target	O
in	O
which	O
the	O
X	B-T058
-	I-T058
ray	I-T058
target	O
is	O
irradiated	O
with	O
an	O
unfocused	O
electron	O
beam	O
was	O
investigated	O
.	O

EGS4	O
Monte	O
Carlo	O
simulation	O
code	O
was	O
employed	O
for	O
the	O
calculation	O
of	O
the	O
X	B-T058
-	I-T058
ray	I-T058
intensity	O
produced	O
from	O
the	O
point	O
-	O
like	O
micro	O
-	O
target	O
and	O
the	O
substrate	O
.	O

The	O
effects	O
of	O
several	O
arrangements	O
of	O
the	O
target	O
material	O
,	O
target	O
and	O
beam	O
size	B-T082
were	O
studied	B-T058
.	O

The	O
simulation	B-T062
results	O
demonstrated	O
that	O
if	O
the	O
intensity	O
of	O
X	B-T058
-	I-T058
rays	I-T058
generated	O
at	O
the	O
point	O
-	O
like	O
target	O
is	O
greater	O
than	O
half	O
of	O
the	O
X	B-T058
-	I-T058
ray	I-T058
intensity	O
produced	O
on	O
the	O
substrate	O
,	O
the	O
X	B-T058
-	I-T058
ray	I-T058
focal	B-T082
spot	I-T082
is	O
determined	O
in	O
part	O
by	O
the	O
point	O
-	O
like	O
target	O
rather	O
than	O
by	O
the	O
electron	O
beam	O
in	O
the	O
conventional	O
X	B-T074
-	I-T074
ray	I-T074
tube	I-T074
.	O

In	O
theory	O
,	O
since	O
it	O
is	O
able	O
to	O
reduce	O
those	O
unfavorable	O
effects	O
such	O
as	O
the	O
electron	B-T033
beam	I-T033
trajectory	I-T033
swinging	I-T033
and	O
the	O
beam	O
size	B-T082
changing	O
for	O
the	O
microfocus	B-T082
X	B-T074
-	I-T074
ray	I-T074
tube	I-T074
,	O
it	O
could	O
alleviate	O
CT	B-T058
image	B-T170
artifacts	O
caused	O
by	O
the	O
X	B-T058
-	I-T058
ray	I-T058
focal	B-T082
spot	I-T082
shift	O
and	O
size	O
change	O
.	O

Early	O
assessment	B-T058
of	O
bilateral	B-T058
inguinal	I-T058
hernia	I-T058
repair	I-T058
:	O
A	O
comparison	O
between	O
the	O
laparoscopic	B-T058
total	I-T058
extraperitoneal	I-T058
and	O
Stoppa	B-T058
approaches	I-T058

The	O
present	O
clinical	B-T062
trial	I-T062
was	O
designed	O
to	O
compare	O
the	O
results	O
of	O
bilateral	B-T058
inguinal	I-T058
hernia	I-T058
repair	I-T058
between	O
patients	O
who	O
underwent	O
the	O
conventional	O
Stoppa	B-T058
technique	I-T058
and	O
laparoscopic	B-T058
total	I-T058
extraperitoneal	I-T058
repair	I-T058
(	O
LTE	B-T058
)	O
with	O
a	O
single	O
mesh	B-T074
and	O
without	O
staple	B-T058
fixation	I-T058
.	O

This	O
controlled	O
,	O
randomised	B-T062
clinical	B-T062
trial	I-T062
was	O
conducted	O
at	O
General	B-T092
Surgery	I-T092
and	I-T092
Trauma	I-T092
of	I-T092
the	I-T092
Clinics	I-T092
Hospital	I-T092
,	O
Medical	B-T092
School	I-T092
,	O
the	O
University	B-T092
of	I-T092
Sγo	I-T092
Paulo	I-T092
between	O
September	O
2010	O
and	O
February	O
2011	O
.	O

Totally	O
,	O
50	O
male	O
patients	O
,	O
with	O
a	O
bilateral	B-T017
inguinal	I-T017
hernia	I-T017
,	O
older	O
than	O
25	O
years	O
were	O
considered	O
eligible	O
for	O
the	O
study	B-T062
.	O

The	O
following	O
parameters	O
were	O
analysed	B-T062
during	O
the	O
early	O
post	O
-	O
operative	O
period	O
:	O
(	O
1	O
)	O
The	O
intensity	O
of	O
surgical	O
trauma	O
,	O
operation	O
time	O
,	O
C	B-T103
-	I-T103
reactive	I-T103
protein	I-T103
(	O
CRP	B-T103
)	O
levels	O
,	O
white	B-T058
blood	I-T058
cell	I-T058
count	I-T058
,	O
bleeding	B-T038
and	O
pain	B-T201
intensity	I-T201
;	O
(	O
2	O
)	O
quality	O
of	O
life	O
assessment	B-T058
;	O
and	O
(	O
3	O
)	O
post	B-T038
-	I-T038
operative	I-T038
complications	I-T038
.	O

LTE	B-T058
procedure	I-T058
was	O
longer	O
than	O
the	O
Stoppa	B-T058
procedure	I-T058
(	O
134	O
.	O
6	O
min	O
΁	O
38	O
.	O
3	O
vs	O
.	O

90	O
.	O
6	O
min	O
΁	O
41	O
.	O
3	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
levels	O
of	O
CRP	B-T103
were	O
higher	O
in	O
the	O
Stoppa	B-T058
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
but	O
the	O
number	O
of	O
leucocytes	B-T017
,	O
haematocrit	B-T033
,	O
and	O
haemoglobin	B-T103
were	O
similar	O
between	O
the	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
no	O
difference	O
in	O
pain	B-T033
during	O
the	O
1	O
st	O
and	O
7	O
th	O
post	B-T033
-	I-T033
operative	I-T033
,	O
physical	B-T033
functioning	I-T033
,	O
physical	O
limitation	O
,	O
the	O
impact	O
of	O
pain	B-T033
on	O
daily	O
activities	O
,	O
and	O
the	O
Carolinas	B-T170
Comfort	I-T170
Scale	I-T170
during	O
the	O
7	O
th	O
and	O
15	O
th	O
post	B-T033
-	I-T033
operative	I-T033
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

Complications	B-T038
occurred	O
in	O
88	O
%	O
of	O
Stoppa	B-T058
group	O
(	O
22	O
patients	O
)	O
and	O
64	O
%	O
in	O
LTE	B-T058
group	O
(	O
16	O
patients	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
comparative	B-T062
study	I-T062
between	O
the	O
Stoppa	B-T058
and	O
LTE	B-T058
approaches	O
for	O
the	O
bilateral	B-T058
inguinal	I-T058
hernia	I-T058
repair	I-T058
demonstrated	O
that	O
:	O
(	O
1	O
)	O
The	O
LTE	B-T058
approach	O
showed	O
less	O
surgical	O
trauma	O
despite	O
the	O
longer	O
operation	O
time	O
;	O
(	O
2	O
)	O
Quality	O
of	O
life	O
during	O
the	O
early	O
post	O
-	O
operative	O
period	O
were	O
similar	O
;	O
and	O
(	O
3	O
)	O
Complication	B-T038
rates	O
were	O
higher	O
in	O
the	O
Stoppa	B-T058
group	O
.	O

Morphological	B-T082
characteristics	O
regulating	O
phallic	B-T017
glans	I-T017
engorgement	B-T038
in	O
the	O
American	B-T204
alligator	I-T204

The	O
distal	B-T082
part	I-T082
of	O
the	O
crocodilian	B-T204
phallus	B-T017
consists	O
of	O
a	O
bulbous	B-T017
glans	I-T017
containing	O
well	O
-	O
developed	O
vascular	B-T017
tissues	I-T017
that	O
can	O
inflate	O
before	O
or	O
during	O
sexual	O
activity	O
,	O
enlarging	O
and	O
elaborating	O
the	O
glans	O
into	O
a	O
complex	O
,	O
though	O
still	O
functionally	O
undefined	O
,	O
copulatory	O
structure	O
.	O

An	O
enlarged	O
glans	O
putatively	O
interacts	O
with	O
the	O
female	O
cloaca	B-T017
and	O
may	O
change	O
the	O
shape	B-T082
of	O
her	B-T022
reproductive	I-T022
tract	I-T022
to	O
facilitate	O
insemination	B-T038
and	O
increase	O
the	O
probability	O
of	O
fertilization	B-T038
.	O

Here	O
,	O
we	O
investigated	O
the	O
cellular	B-T038
-	I-T038
level	I-T038
properties	I-T038
of	O
the	O
glans	O
and	O
other	O
inflatable	B-T017
phallic	I-T017
tissues	I-T017
associated	O
with	O
the	O
sperm	B-T017
-	O
conducting	O
sulcus	B-T082
spermaticus	B-T017
in	O
the	O
American	B-T204
alligator	I-T204
(	O
Alligator	B-T204
mississippiensis	I-T204
)	O
.	O

Using	O
histochemical	B-T058
staining	I-T058
,	O
we	O
visualized	O
and	O
defined	O
collagen	B-T103
and	O
elastin	B-T017
fiber	I-T017
densities	O
and	O
orientations	B-T082
in	O
these	O
tissues	B-T017
.	O

Extracellular	B-T017
matrix	I-T017
architectures	O
provided	O
insights	O
about	O
phallic	B-T017
glans	I-T017
material	O
properties	O
and	O
how	O
they	O
may	O
affect	O
tissue	B-T017
strength	O
and	O
flexibility	O
during	O
inflation	O
and	O
in	O
response	O
to	O
copulatory	O
forces	O
.	O

We	O
also	O
investigated	O
the	O
potential	O
sources	O
of	O
fluids	O
that	O
induce	O
inflation	O
in	O
alligator	B-T204
phalli	B-T017
.	O

Combining	O
serial	B-T058
sectioning	I-T058
and	O
three	B-T058
-	I-T058
dimensional	I-T058
reconstruction	I-T058
,	O
we	O
identified	O
a	O
pair	O
of	O
supracrucal	B-T017
plexus	I-T017
vascular	I-T017
bodies	B-T017
at	O
the	O
proximal	O
end	O
of	O
the	O
alligator	B-T204
phallus	B-T017
that	O
extend	O
distally	O
adjacent	O
to	O
ventro	B-T017
-	I-T017
medial	I-T017
sulcus	I-T017
tissues	I-T017
.	O

Together	O
,	O
our	O
gross	O
and	O
histological	B-T033
examination	I-T033
of	O
the	O
American	B-T204
alligator	I-T204
phallic	B-T017
glans	I-T017
suggests	O
that	O
its	O
tissues	B-T017
are	O
arranged	O
in	O
a	O
manner	O
that	O
would	O
allow	O
vascular	B-T017
inflation	O
to	O
expand	O
the	O
glans	O
to	O
a	O
specific	O
and	O
repeatable	O
shape	B-T082
,	O
and	O
potentially	O
release	O
secretory	B-T017
products	I-T017
into	O
the	O
female	B-T022
reproductive	I-T022
tract	I-T022
.	O

Both	O
elements	O
could	O
play	O
roles	O
in	O
postcopulatory	O
sexual	O
selection	O
,	O
by	O
mechanically	O
and	O
/	O
or	O
chemically	O
affecting	B-T038
female	I-T038
reproductive	I-T038
physiology	I-T038
.	O

A	O
novel	O
role	O
for	O
poly	B-T103
(	I-T103
C	I-T103
)	I-T103
binding	I-T103
proteins	I-T103
in	O
programmed	B-T038
ribosomal	I-T038
frameshifting	I-T038

Translational	B-T038
control	O
through	O
programmed	B-T038
ribosomal	I-T038
frameshifting	I-T038
(	O
PRF	B-T038
)	O
is	O
exploited	O
widely	O
by	O
viruses	B-T005
and	O
increasingly	O
documented	O
in	O
cellular	B-T017
genes	B-T017
.	O

Frameshifting	B-T038
is	O
induced	O
by	O
mRNA	B-T103
secondary	I-T103
structures	I-T103
that	O
compromise	O
ribosome	B-T017
fidelity	B-T038
during	O
decoding	O
of	O
a	O
heptanucleotide	B-T082
'	I-T082
slippery	I-T082
'	I-T082
sequence	I-T082
.	O

The	O
nsp2	B-T103
PRF	B-T038
signal	B-T038
of	O
porcine	B-T005
reproductive	I-T005
and	I-T005
respiratory	I-T005
syndrome	I-T005
virus	I-T005
is	O
distinctive	O
in	O
directing	O
both	O
-	B-T038
2	I-T038
and	O
-	B-T038
1	I-T038
PRF	I-T038
and	O
in	O
its	O
requirement	O
for	O
a	O
trans	B-T103
-	I-T103
acting	I-T103
protein	I-T103
factor	I-T103
,	O
the	O
viral	B-T005
replicase	B-T103
subunit	I-T103
nsp1β	I-T103
.	O

Here	O
we	O
show	O
that	O
the	O
the	O
trans	B-T038
-	I-T038
activation	I-T038
of	O
frameshifting	B-T038
is	O
carried	O
out	O
by	O
a	O
protein	B-T103
complex	I-T103
composed	O
of	O
nsp1β	B-T103
and	O
a	O
cellular	B-T017
poly	B-T103
(	I-T103
C	I-T103
)	I-T103
binding	I-T103
protein	I-T103
(	O
PCBP	B-T103
)	O
.	O

From	O
the	O
results	O
of	O
in	O
vitro	O
translation	B-T038
and	O
electrophoretic	B-T058
mobility	I-T058
shift	I-T058
assays	I-T058
,	O
we	O
demonstrate	O
that	O
a	O
PCBP	B-T103
/	O
nsp1β	B-T103
complex	B-T103
binds	O
to	O
a	O
C	B-T082
-	I-T082
rich	I-T082
sequence	I-T082
downstream	B-T082
of	O
the	O
slippery	B-T082
sequence	I-T082
and	O
here	O
mimics	O
the	O
activity	O
of	O
a	O
structured	O
mRNA	B-T103
stimulator	B-T103
of	O
PRF	B-T038
.	O

This	O
is	O
the	O
first	O
description	O
of	O
a	O
role	O
for	O
a	O
trans	B-T103
-	I-T103
acting	I-T103
cellular	I-T103
protein	I-T103
in	O
PRF	B-T038
.	O

The	O
discovery	O
broadens	O
the	O
repertoire	O
of	O
activities	O
associated	O
with	O
poly	B-T103
(	I-T103
C	I-T103
)	I-T103
binding	I-T103
proteins	I-T103
and	O
prototypes	O
a	O
new	O
class	O
of	O
virus	B-T005
-	O
host	O
interactions	O
.	O

Production	O
of	O
bioactive	O
conjugated	B-T103
linoleic	I-T103
acid	I-T103
by	O
the	O
multifunctional	B-T103
enolase	B-T103
from	O
Lactobacillus	B-T007
plantarum	I-T007

Lactobacillus	B-T007
plantarum	I-T007
α	B-T103
-	I-T103
enolase	I-T103
,	O
a	O
multifunctional	B-T103
-	O
anchorless	O
-	O
surface	B-T103
protein	I-T103
belonging	O
to	O
the	O
conserved	O
family	O
of	O
enolases	B-T103
with	O
a	O
central	O
role	O
in	O
glycolytic	B-T038
metabolism	B-T038
,	O
was	O
characterized	O
to	O
have	O
a	O
side	O
role	O
in	O
the	O
intricate	B-T038
metabolism	I-T038
of	O
biohydrogenation	O
of	O
linoleic	B-T103
acid	I-T103
,	O
catalyzing	O
the	O
formation	O
of	O
bioactive	O
9	B-T103
-	I-T103
cis	I-T103
-	I-T103
11	I-T103
-	I-T103
trans	I-T103
-	I-T103
CLA	I-T103
through	O
dehydration	O
and	O
isomerization	O
of	O
10	B-T103
-	I-T103
hydroxy	I-T103
-	I-T103
12	I-T103
-	I-T103
cis	I-T103
-	I-T103
octadecenoic	I-T103
acid	I-T103
.	O

The	O
identity	O
of	O
the	O
enolase	B-T103
was	O
confirmed	O
through	O
mass	B-T058
spectrometric	I-T058
analysis	I-T058
that	O
showed	O
the	O
characteristic	O
442	O
amino	B-T082
acid	I-T082
sequence	I-T082
with	O
a	O
molecular	O
mass	O
of	O
48	O
.	O
03	O
kDa	O
.	O

The	O
enolase	B-T103
was	O
not	O
capable	O
of	O
using	O
linoleic	B-T103
acid	I-T103
directly	O
as	O
a	O
substrate	O
but	O
instead	O
uses	O
its	O
hydroxyl	B-T103
derivative	O
10	B-T103
-	I-T103
hydroxi	I-T103
-	I-T103
12	I-T103
-	I-T103
cis	I-T103
-	I-T103
octadecenoic	I-T103
acid	I-T103
to	O
finally	O
form	O
bioactive	O
conjugated	B-T103
linoleic	I-T103
acid	I-T103
.	O

Biochemical	O
optimization	O
studies	B-T062
were	O
carried	O
out	O
to	O
elucidate	O
the	O
conditions	O
for	O
maximum	O
production	O
of	O
9	B-T103
-	I-T103
cis	I-T103
-	I-T103
11	I-T103
-	I-T103
trans	I-T103
-	I-T103
CLA	I-T103
and	O
maximum	O
stability	B-T038
of	O
α	B-T103
-	I-T103
enolase	I-T103
when	O
catalyzing	O
this	O
reaction	O
.	O

Furthermore	O
,	O
through	O
structural	B-T058
analysis	I-T058
of	O
the	O
protein	B-T103
,	O
we	O
propose	O
the	O
binding	B-T103
sites	I-T103
of	O
substrate	O
and	O
product	O
molecules	O
that	O
were	O
characterized	O
as	O
two	O
hydrophobic	O
superficial	O
pockets	O
located	O
at	O
opposite	O
ends	O
of	O
the	O
enolase	B-T103
connected	O
through	O
a	O
channel	B-T103
where	O
the	O
catalysis	O
of	O
dehydration	O
and	O
isomerization	O
might	O
occur	O
.	O

These	O
results	O
prove	O
that	O
multifunctional	B-T103
α	B-T103
-	I-T103
enolase	I-T103
also	O
plays	O
a	O
role	O
in	O
cell	B-T038
detoxification	I-T038
from	O
polyunsaturated	B-T103
fatty	I-T103
acids	I-T103
such	O
as	O
linoleic	B-T103
acid	I-T103
,	O
along	O
with	O
the	O
linoleate	B-T103
isomerase	I-T103
complex	B-T103
.	O

Associations	O
of	O
Body	B-T201
Mass	I-T201
Index	I-T201
and	O
Physical	O
Activity	O
With	O
Sexual	B-T038
Dysfunction	I-T038
in	O
Breast	B-T038
Cancer	I-T038
Survivors	O

Sexual	B-T038
dysfunction	I-T038
is	O
a	O
common	O
and	O
distressing	B-T033
consequence	O
of	O
breast	B-T038
cancer	I-T038
(	O
BC	B-T038
)	O
treatment	B-T058
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
investigated	O
the	O
sexual	B-T038
functioning	I-T038
of	O
BC	B-T038
patients	O
and	O
its	O
association	B-T038
with	O
women	B-T098
'	I-T098
s	I-T098
personal	O
characteristics	O
and	O
cancer	B-T058
treatments	I-T058
.	O

In	O
this	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
,	O
sexual	B-T038
function	I-T038
was	O
assessed	O
using	O
the	O
Female	B-T170
Sexual	I-T170
Function	I-T170
Index	I-T170
(	O
FSFI	B-T170
)	O
.	O

The	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQOL	O
)	O
was	O
measured	O
using	O
the	O
European	B-T092
Organization	I-T092
for	I-T092
Research	I-T092
and	I-T092
Treatment	I-T092
of	I-T092
Cancer	I-T092
(	O
EORTC	B-T092
)	O
QLQ	B-T170
-	I-T170
C30	I-T170
and	O
its	O
breast	B-T170
module	I-T170
BR	I-T170
-	I-T170
23	I-T170
.	O

Of	O
the	O
235	O
participants	B-T098
approached	O
,	O
216	O
participants	B-T098
were	O
included	O
in	O
the	O
study	O
.	O

Of	O
these	O
,	O
63	O
patients	O
reported	O
no	O
sexual	O
activity	O
in	O
the	O
last	O
month	O
and	O
thus	O
were	O
analyzed	O
only	O
in	O
relation	O
to	O
the	O
sexual	B-T038
desire	I-T038
domain	O
of	O
FSFI	B-T170
.	O

A	O
total	O
of	O
154	O
(	O
71	O
.	O
3	O
%	O
)	O
patients	O
were	O
classified	O
with	O
hypoactive	B-T038
sexual	I-T038
desire	I-T038
disorder	I-T038
(	O
HSDD	B-T038
)	O
.	O

From	O
those	O
patients	O
reporting	O
sexual	O
activity	O
in	O
the	O
last	O
month	O
,	O
63	O
.	O
3	O
%	O
(	O
97	O
out	O
of	O
153	O
)	O
were	O
classified	O
with	O
sexual	B-T038
dysfunction	I-T038
.	O

Using	O
hierarchical	B-T062
logistic	I-T062
regression	I-T062
,	O
the	O
variance	O
explained	O
(	O
change	O
in	O
R	O
(	O
2	O
)	O
)	O
by	O
the	O
addition	O
of	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
and	O
mild	O
to	O
moderate	O
physical	O
activity	O
in	O
the	O
prediction	O
models	B-T170
of	O
sexual	B-T038
dysfunction	I-T038
and	O
HSDD	B-T038
were	O
6	O
.	O
8	O
and	O
7	O
.	O
2	O
%	O
,	O
respectively	O
.	O

Age	O
,	O
BMI	B-T201
,	O
and	O
physical	O
activity	O
were	O
independently	O
associated	O
with	O
sexual	B-T038
dysfunction	I-T038
and	O
HSDD	B-T038
.	O

Additionally	O
,	O
BC	B-T038
patients	O
with	O
sexual	B-T038
dysfunction	I-T038
reported	O
lower	O
scores	O
on	O
global	O
HRQOL	O
,	O
role	O
functioning	O
,	O
and	O
fatigue	B-T033
.	O

Based	O
on	O
our	O
findings	B-T033
,	O
BC	B-T038
survivors	O
should	O
be	O
encouraged	O
to	O
practice	B-T038
regular	O
physical	O
activity	O
and	O
to	O
lose	O
weight	O
in	O
order	O
to	O
avoid	O
sexual	B-T038
dysfunction	I-T038
.	O

However	O
,	O
future	O
clinical	B-T062
trials	I-T062
are	O
needed	O
to	O
confirm	O
these	O
findings	B-T033
.	O

Combination	B-T103
of	O
telmisartan	B-T103
with	O
sildenafil	B-T103
ameliorate	O
progression	B-T038
of	O
diabetic	B-T038
nephropathy	I-T038
in	O
streptozotocin	B-T103
-	O
induced	O
diabetic	B-T033
model	O

Diabetic	B-T038
nephropathy	I-T038
(	O
DN	B-T038
)	O
is	O
a	O
leading	O
cause	O
of	O
end	B-T038
-	I-T038
stage	I-T038
renal	I-T038
disease	I-T038
in	O
the	O
world	O
.	O

Several	O
signaling	B-T038
pathways	I-T038
are	O
involved	O
in	O
the	O
pathogenesis	B-T038
of	O
DN	B-T038
including	O
elevation	B-T082
in	O
level	O
of	O
angiotensin	B-T103
II	I-T103
,	O
formation	O
of	O
advanced	B-T103
glycation	I-T103
end	I-T103
products	I-T103
(	O
AGE	B-T103
)	O
,	O
activation	B-T038
of	O
protein	B-T103
kinase	I-T103
c	I-T103
(	O
PKC	B-T103
)	O
,	O
and	O
lipid	B-T033
accumulation	I-T033
.	O

These	O
pathways	B-T038
activate	O
one	O
another	O
mutually	O
leading	O
to	O
oxidative	B-T038
stress	I-T038
,	O
increasing	O
expression	B-T038
of	O
transforming	B-T103
growth	I-T103
factor	I-T103
beta	I-T103
-	I-T103
1	I-T103
(	O
TGF	B-T103
-	I-T103
β	I-T103
1	I-T103
)	O
and	O
release	O
of	O
interleukins	B-T103
and	O
adhesion	B-T103
molecules	I-T103
,	O
so	O
the	O
aim	O
of	O
this	O
study	O
is	O
to	O
interrupt	O
more	O
than	O
pathogenic	B-T033
pathway	O
to	O
ameliorate	O
the	O
progression	B-T038
of	O
DN	B-T038
.	O

In	O
the	O
present	O
study	B-T062
,	O
white	O
male	O
rats	O
(	O
N	O
=	O
48	O
)	O
were	O
divided	O
into	O
six	O
groups	O
(	O
8	O
rats	O
each	O
)	O
,	O
the	O
first	O
two	O
groups	O
served	O
as	O
normal	O
control	O
and	O
a	O
control	O
vehicle	O
group	O
while	O
the	O
remaining	O
four	O
groups	O
were	O
rendered	O
diabetic	B-T033
by	O
a	O
single	O
intraperitoneal	B-T058
injection	I-T058
of	O
Streptozotocin	B-T103
(	O
STZ	B-T103
)	O
and	O
being	O
left	O
for	O
4	O
weeks	O
to	O
develop	O
DN	B-T038
.	O

Thereafter	O
,	O
the	O
rats	O
were	O
divided	O
into	O
DN	B-T038
group	O
,	O
DN	B-T038
group	O
receiving	O
Telmisartan	B-T103
or	O
Sildenafil	B-T103
or	O
Telmisartan	B-T103
Sildenafil	B-T103
combination	B-T103
.	O

After	O
the	O
specified	O
treatment	O
period	O
,	O
urine	B-T031
samples	I-T031
were	O
collected	O
(	O
using	O
metabolic	O
cages	O
)	O
to	O
measure	O
proteinuria	B-T033
,	O
animals	B-T204
were	O
then	O
euthanized	O
,	O
blood	B-T031
and	O
tissue	B-T017
samples	I-T017
were	O
collected	O
for	O
measurement	B-T058
of	I-T058
Blood	I-T058
glucose	I-T058
,	O
BUN	B-T058
,	O
S	B-T058
.	I-T058
Cr	I-T058
,	O
LDL	B-T058
,	O
NO	B-T058
,	O
TGF	B-T058
-	I-T058
β1	I-T058
,	O
IL	B-T058
-	I-T058
1β	I-T058
,	O
AGEPs	B-T058
,	O
and	O
SOD	B-T058
.	O

The	O
combination	B-T058
therapy	I-T058
showed	O
significant	O
decrease	O
in	O
BUN	B-T103
,	O
S	B-T103
.	I-T103
Cr	I-T103
,	O
LDL	B-T103
,	O
TGF	B-T103
-	I-T103
β1	I-T103
,	O
IL	B-T103
-	I-T103
1β	I-T103
,	O
Proteinuria	B-T033
and	O
AGEPs	B-T103
and	O
significant	O
increase	O
in	O
SOD	B-T103
and	O
NO	B-T103
.	O

The	O
findings	O
showed	O
that	O
combination	B-T058
therapy	I-T058
was	O
able	O
to	O
ameliorate	O
DN	B-T038
and	O
that	O
the	O
effects	O
were	O
superior	O
to	O
the	O
single	O
drugs	B-T103
alone	O
.	O

Analysis	B-T062
of	O
Low	O
-	O
Biomass	O
Microbial	O
Communities	O
in	O
the	O
Deep	O
Biosphere	O

Over	O
the	O
past	O
few	O
decades	O
,	O
the	O
subseafloor	O
biosphere	O
has	O
been	O
explored	O
by	O
scientific	O
ocean	O
drilling	O
to	O
depths	B-T082
of	O
about	O
2	O
.	O
5km	O
below	O
the	O
seafloor	O
.	O

Although	O
organic	B-T082
-	I-T082
rich	I-T082
anaerobic	I-T082
sedimentary	I-T082
habitats	I-T082
in	O
the	O
ocean	O
margins	O
harbor	O
large	O
numbers	O
of	O
microbial	O
cells	O
,	O
microbial	O
populations	O
in	O
ultraoligotrophic	B-T082
aerobic	I-T082
sedimentary	I-T082
habitats	I-T082
in	O
the	O
open	O
ocean	O
gyres	O
are	O
several	O
orders	O
of	O
magnitude	O
less	O
abundant	O
.	O

Despite	O
advances	O
in	O
cultivation	O
-	O
independent	O
molecular	O
ecological	O
techniques	O
,	O
exploring	O
the	O
low	O
-	O
biomass	O
environment	B-T082
remains	O
technologically	O
challenging	O
,	O
especially	O
in	O
the	O
deep	O
subseafloor	O
biosphere	O
.	O

Reviewing	O
the	O
historical	B-T170
background	I-T170
of	O
deep	O
-	O
biosphere	O
analytical	O
methods	O
,	O
the	O
importance	O
of	O
obtaining	O
clean	O
samples	O
and	O
tracing	B-T033
contamination	O
,	O
as	O
well	O
as	O
methods	B-T170
for	O
detecting	B-T033
microbial	O
life	O
,	O
technological	O
aspects	O
of	O
molecular	B-T091
microbiology	I-T091
,	O
and	O
detecting	B-T033
subseafloor	O
metabolic	B-T038
activity	I-T038
will	O
be	O
discussed	O
.	O

The	O
sensitivity	O
and	O
specifity	O
of	O
DR	B-T103
-	I-T103
70	I-T103
immunoassay	B-T058
as	O
a	O
tumor	B-T103
marker	I-T103
for	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038

Lung	B-T038
cancer	I-T038
is	O
the	O
most	O
important	O
causes	O
of	O
the	O
cancer	O
related	O
mortality	O
.	O

Patients	O
with	O
lung	B-T038
cancer	I-T038
are	O
usually	O
diagnosed	B-T058
at	O
advanced	B-T082
or	O
locally	B-T082
advanced	I-T082
stage	I-T082
,	O
for	O
this	O
reason	O
early	B-T058
diagnosis	I-T058
of	O
lung	B-T038
cancer	I-T038
is	O
very	O
important	O
.	O

For	O
early	B-T058
detection	I-T058
of	O
lung	B-T038
cancer	I-T038
some	O
methods	O
are	O
emphasized	O
such	O
as	O
low	B-T058
-	I-T058
dose	I-T058
computed	I-T058
tomography	I-T058
or	O
tumor	B-T103
biomarkers	I-T103
.	O

In	O
this	O
study	O
we	O
aimed	O
to	O
evaluate	B-T058
DR	B-T103
-	I-T103
70	I-T103
sensitivity	O
and	O
specificity	O
as	O
a	O
tumor	B-T103
marker	I-T103
in	O
detection	B-T058
of	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancers	I-T038
.	O

Between	O
May	O
2013	O
and	O
April	O
2014	O
,	O
the	O
serum	B-T031
samples	I-T031
from	O
88	O
non	B-T038
lung	I-T038
cancer	I-T038
patients	O
,	O
86	O
patients	O
with	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disesase	I-T038
were	O
obtained	O
.	O

Blood	B-T031
samples	I-T031
from	O
each	O
participant	B-T098
were	O
analyzed	B-T062
for	O
DR	B-T103
-	I-T103
70	I-T103
level	O
.	O

Totally	O
174	O
patients	O
were	O
enrolled	O
to	O
the	O
study	B-T062
(	O
152	O
male	B-T098
,	O
22	O
female	B-T098
)	O
.	O

Histopathologically	O
47	O
(	O
53	O
.	O
4	O
%	O
)	O
patients	O
were	O
diagnosed	B-T058
with	O
squamous	B-T038
cell	I-T038
lung	I-T038
cancer	I-T038
,	O
34	O
(	O
38	O
.	O
6	O
%	O
)	O
with	O
adenocarcinoma	B-T038
,	O
and	O
7	O
(	O
8	O
%	O
)	O
with	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
.	O

The	O
mean	B-T103
serum	I-T103
DR	I-T103
-	I-T103
70	I-T103
levels	O
in	O
lung	B-T038
cancer	I-T038
patients	O
(	O
2	O
.	O
43	O
±	O
1	O
.	O
82	O
µg	O
/	O
mL	O
)	O
was	O
significantly	B-T033
higher	I-T033
compared	O
to	O
the	O
86	O
non	B-T033
-	I-T033
cancerous	I-T033
subjects	B-T098
(	O
1	O
.	O
15	O
±	O
0	O
.	O
70	O
µg	O
/	O
mL	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

DR	B-T103
-	I-T103
70	I-T103
exhibited	O
clinical	O
sensitivity	O
and	O
specificity	O
of	O
54	O
.	O
5	O
and	O
83	O
.	O
7	O
%	O
,	O
respectively	O
,	O
at	O
an	O
optimal	O
cut	O
off	O
at	O
1	O
.	O
98	O
µg	O
/	O
mL	O
.	O

It	O
could	O
be	O
said	O
that	O
the	O
risk	O
of	O
the	O
presence	O
of	O
the	O
disease	B-T038
is	O
6	O
.	O
171	O
times	O
higher	O
in	O
the	O
cases	O
where	O
DR	B-T103
-	I-T103
70	I-T103
level	O
is	O
1	O
.	O
98	O
µg	O
/	O
mL	O
and	O
higher	O
.	O

DR	B-T103
-	I-T103
70	I-T103
,	O
a	O
marker	B-T103
used	O
to	O
measure	O
fibrin	B-T103
degradation	I-T103
products	I-T103
,	O
generated	O
by	O
all	O
major	O
cancers	B-T038
,	O
may	O
helps	O
to	O
find	O
high	B-T033
risk	I-T033
lung	B-T038
cancer	I-T038
patients	O
.	O

Catastrophic	O
expenditure	O
and	O
impoverishment	O
of	O
patients	O
affected	O
by	O
7	O
rare	B-T038
diseases	I-T038
in	O
China	B-T082

China	B-T082
is	O
actively	O
promoting	O
regulation	O
of	O
rare	B-T038
diseases	I-T038
,	O
rare	B-T038
disease	I-T038
and	O
orphan	B-T103
drugs	I-T103
have	O
been	O
formally	O
incorporated	O
into	O
the	O
national	O
planning	O
.	O

However	O
,	O
few	O
studies	B-T062
have	O
been	O
done	O
to	O
evaluate	O
the	O
affordability	O
of	O
rare	B-T038
disease	I-T038
patients	O
in	O
China	B-T082
.	O

This	O
study	O
aims	O
to	O
provide	O
policy	B-T170
recommendations	O
for	O
the	O
establishment	O
of	O
social	B-T170
security	I-T170
mechanism	I-T170
for	O
rare	B-T038
diseases	I-T038
in	O
China	B-T082
,	O
so	O
as	O
to	O
address	O
the	O
problem	O
of	O
poverty	O
caused	O
by	O
these	O
diseases	B-T038
.	O

A	O
total	O
of	O
7	O
rare	B-T038
diseases	I-T038
were	O
selected	O
by	O
Delphi	B-T062
method	I-T062
.	O

Affordability	O
of	O
treatment	B-T058
for	O
the	O
7	O
rare	B-T038
diseases	I-T038
was	O
assessed	O
through	O
annual	O
per	O
capital	O
income	O
,	O
catastrophic	O
expenditure	O
and	O
impoverishment	O
expenditure	O
among	O
urban	B-T098
and	O
rural	B-T098
residents	I-T098
in	O
China	B-T082
.	O

Assessed	O
through	O
annual	O
per	O
capital	O
income	O
,	O
health	O
expenditure	O
for	O
the	O
7	O
rare	B-T038
diseases	I-T038
are	O
all	O
rather	O
high	O
.	O

The	O
highest	O
health	O
expenditure	O
is	O
equivalent	O
to	O
income	O
of	O
69	O
.	O
34	O
years	O
of	O
one	O
urban	B-T098
resident	I-T098
,	O
and	O
the	O
burden	O
is	O
heavier	O
for	O
rural	B-T098
residents	I-T098
.	O

Through	O
catastrophic	O
expenditure	O
assessment	O
,	O
proportions	O
of	O
the	O
population	B-T098
experiencing	O
catastrophic	O
expenditure	O
caused	O
by	O
the	O
7	O
rare	B-T038
diseases	I-T038
are	O
all	O
under	O
0	O
.	O
167	O
‰	O
.	O

However	O
,	O
once	O
one	O
is	O
ill	B-T033
and	O
taking	O
medications	B-T170
,	O
he	O
will	O
suffer	O
from	O
catastrophic	O
health	O
expenditure	O
.	O

Through	O
impoverishment	O
expenditure	O
assessment	O
,	O
the	O
proportions	O
of	O
impoverishment	O
payment	O
are	O
low	O
among	O
both	O
urban	B-T098
and	O
rural	B-T098
residents	I-T098
,	O
but	O
the	O
7	O
rare	B-T038
diseases	I-T038
could	O
lead	O
nearly	O
4	O
.	O
6	O
million	O
people	B-T098
into	O
poverty	O
on	O
a	O
national	O
scale	O
.	O

The	O
affordability	O
of	O
treatment	B-T058
for	O
rare	B-T038
disease	I-T038
as	O
well	O
as	O
orphan	B-T103
drugs	I-T103
is	O
rather	O
poor	O
.	O

Residents	B-T098
of	O
different	O
income	O
levels	O
all	O
have	O
difficulties	O
to	O
afford	O
the	O
treatment	B-T058
for	O
rare	B-T038
diseases	I-T038
,	O
so	O
poverty	O
caused	O
by	O
rare	B-T038
diseases	I-T038
is	O
quite	O
widespread	B-T082
.	O

Therefore	O
,	O
social	B-T170
security	I-T170
mechanism	I-T170
for	O
rare	B-T038
disease	I-T038
patients	O
should	O
be	O
established	O
and	O
specific	O
payment	O
pattern	O
for	O
orphan	B-T103
drugs	I-T103
should	O
be	O
set	O
up	O
.	O

Experimental	B-T062
study	I-T062
in	O
pulmonary	B-T017
artery	I-T017
sealing	B-T058
with	O
a	O
vessel	B-T074
-	I-T074
sealing	I-T074
device	I-T074

The	O
development	O
of	O
vessel	B-T074
-	I-T074
sealing	I-T074
devices	I-T074
will	O
facilitate	O
safety	O
in	O
video	B-T058
-	I-T058
assisted	I-T058
thoracoscopic	I-T058
surgery	I-T058
.	O

Our	O
objective	O
was	O
to	O
evaluate	O
the	O
feasibility	O
and	O
safety	O
of	O
sealing	B-T058
pulmonary	B-T017
arteries	I-T017
with	O
the	O
Enseal	B-T074
tissue	I-T074
-	I-T074
sealing	I-T074
device	I-T074
.	O

Pulmonary	B-T017
arteries	I-T017
from	O
beagle	B-T204
dogs	I-T204
(	O
mean	O
body	O
weight	O
13	O
.	O
1	O
kg	O
,	O
range	O
10	O
.	O
5	O
-	O
15	O
.	O
4	O
kg	O
)	O
were	O
divided	O
into	O
3	O
groups	O
according	O
to	O
the	O
in	B-T082
-	I-T082
vivo	I-T082
sealing	B-T170
method	I-T170
used	O
(	O
Enseal	B-T074
,	O
ligation	B-T058
,	O
and	O
proximal	B-T082
ligation	B-T058
plus	O
distal	B-T082
Enseal	B-T074
)	O
and	O
extracted	O
to	O
evaluate	O
the	O
pressure	O
tolerance	O
up	O
to	O
75	O
mm	O
Hg	O
at	O
the	O
sealed	O
end	B-T082
.	O

A	O
left	O
lower	O
lobectomy	B-T058
was	O
performed	O
to	O
evaluate	O
chronic	O
-	O
phase	O
durability	O
of	O
the	O
sealed	B-T074
stumps	I-T074
in	O
a	O
survival	B-T204
model	I-T204
.	O

Two	O
or	O
three	O
branches	O
of	O
the	O
pulmonary	B-T017
arteries	I-T017
in	O
each	O
dog	B-T204
were	O
allocated	O
to	O
each	O
of	O
the	O
3	O
groups	O
.	O

After	O
the	O
scheduled	O
survival	O
period	O
,	O
the	O
pulmonary	B-T017
arteries	I-T017
were	O
sampled	O
.	O

Pressure	O
tolerance	O
at	O
the	O
sealed	O
end	B-T082
was	O
evaluated	O
in	O
91	O
pulmonary	B-T017
artery	I-T017
sections	O
.	O

All	O
sealed	O
ends	B-T082
showed	O
pressure	O
tolerance	O
>	O
75	O
mm	O
Hg	O
.	O

A	O
left	O
lower	O
lobectomy	B-T058
was	O
performed	O
in	O
13	O
dogs	B-T204
in	O
which	O
35	O
pulmonary	B-T017
artery	I-T017
sections	O
had	O
been	O
allocated	O
into	O
the	O
3	O
groups	O
.	O

No	B-T033
sealing	B-T058
failure	O
was	O
found	O
,	O
and	O
pathological	O
findings	B-T033
showed	O
healing	B-T038
and	O
persistent	O
hemostasis	B-T038
at	O
all	O
sealed	O
ends	B-T082
of	O
the	O
pulmonary	B-T017
arteries	I-T017
after	O
2	O
and	O
4	O
weeks	O
of	O
the	O
survival	O
period	O
.	O

Pulmonary	B-T017
arteries	I-T017
sealed	O
in	B-T082
vivo	I-T082
with	O
the	O
Enseal	B-T074
device	I-T074
showed	O
pressure	O
tolerance	O
>	O
75	O
mm	O
Hg	O
in	O
the	O
acute	O
phase	O
,	O
and	O
persistent	O
hemostasis	B-T038
after	O
2	O
or	O
4	O
weeks	O
.	O

Pulmonary	B-T017
artery	I-T017
sealing	B-T058
with	O
the	O
Enseal	B-T074
device	I-T074
is	O
feasible	O
and	O
safe	O
in	O
thoracic	B-T058
surgery	I-T058
settings	O
.	O

Pathophysiology	O
,	O
treatment	B-T058
and	O
prevention	B-T058
of	O
ovarian	B-T038
hyperstimulation	I-T038
syndrome	I-T038

Severe	O
ovarian	B-T038
hyperstimulation	I-T038
syndrome	I-T038
(	O
OHSS	B-T038
)	O
is	O
an	O
iatrogenic	O
condition	O
that	O
affects	O
1	O
%	O
of	O
women	B-T098
that	O
undergo	O
treatment	B-T058
with	O
assisted	B-T058
reproductive	I-T058
technology	I-T058
.	O

The	O
review	B-T170
aims	O
to	O
summarize	B-T170
recent	O
evidence	O
on	O
pathophysiology	O
,	O
treatment	B-T058
,	O
and	O
prevention	B-T058
of	O
OHSS	B-T038
.	O

The	O
pathophysiology	O
is	O
still	O
not	O
completely	O
understood	B-T038
;	O
however	O
,	O
vascular	B-T103
endothelial	I-T103
growth	I-T103
factor	I-T103
is	O
likely	O
to	O
be	O
an	O
important	O
mediator	O
.	O

Human	B-T103
chorionic	I-T103
gonadotropin	I-T103
was	O
previously	O
thought	B-T038
to	O
be	O
necessary	O
for	O
OHSS	B-T038
to	O
occur	O
;	O
however	O
,	O
recent	B-T170
case	I-T170
reports	I-T170
have	O
proven	O
otherwise	O
.	O

The	O
contribution	O
of	O
an	O
attenuated	O
anti	B-T103
-	I-T103
Mullerian	I-T103
hormone	I-T103
signalling	B-T038
pathway	I-T038
and	O
CD11c	B-T103
+	O
HLA	B-T103
-	I-T103
DR	I-T103
+	O
dendritic	B-T017
cells	I-T017
and	O
associated	O
interleukins	B-T103
has	O
been	O
explored	O
recently	O
as	O
contributors	O
to	O
pathogenesis	B-T038
.	O

Treatment	B-T058
is	O
largely	O
supportive	B-T058
and	O
is	O
based	O
mainly	O
on	O
consensus	O
statements	O
rather	O
than	O
evidence	O
.	O

Therefore	O
,	O
it	O
is	O
important	O
to	O
prevent	O
this	O
condition	O
by	O
identifying	B-T058
women	B-T098
at	O
risk	O
,	O
allowing	O
the	O
clinician	B-T097
to	O
implement	O
preventive	O
strategies	O
,	O
including	O
the	O
use	O
of	O
GnRH	B-T103
antagonist	I-T103
cycles	O
with	O
agonist	B-T103
triggers	O
.	O

More	O
research	B-T062
is	O
required	O
to	O
elucidate	O
the	O
pathophysiology	O
behind	O
the	O
condition	O
.	O

Clinicians	B-T097
should	O
employ	O
strategies	O
to	O
prevent	O
OHSS	B-T038
.	O

Eosinophilic	B-T038
Gastroenteritis	I-T038
as	O
a	O
Rare	O
Cause	O
of	O
Recurrent	O
Epigastric	O
Pain	O

Eosinophilic	B-T038
gastroenteritis	I-T038
(	O
EGE	B-T038
)	O
is	O
a	O
rare	O
inflammatory	B-T038
disorder	I-T038
of	O
gastrointestinal	B-T022
tract	I-T022
characterized	O
by	O
eosinophilic	B-T038
infiltration	I-T038
of	O
the	O
bowel	B-T017
wall	I-T017
.	O

It	O
can	O
mimic	O
many	O
gastrointestinal	B-T038
disorders	I-T038
due	O
to	O
its	O
wide	B-T033
spectrum	I-T033
of	I-T033
presentations	I-T033
.	O

Diagnose	B-T033
is	O
mostly	O
based	O
on	O
excluding	O
other	O
disorders	B-T038
and	O
a	O
high	O
suspicion	B-T038
.	O

Here	O
we	O
report	B-T170
a	I-T170
case	I-T170
of	O
26	O
year	O
old	O
man	B-T098
with	O
a	O
history	B-T033
of	O
sever	B-T033
epigastric	I-T033
pain	I-T033
followed	O
by	O
nausea	B-T033
,	O
vomiting	B-T033
since	O
a	O
few	O
days	O
before	O
admission	B-T058
with	O
final	O
diagnosis	B-T033
of	O
EGE	B-T038
.	O

Comparison	O
of	O
sonoelastography	B-T058
with	O
sonourethrography	B-T058
and	O
retrograde	O
urethrography	O
in	O
the	O
evaluation	B-T058
of	O
male	O
anterior	B-T017
urethral	I-T017
strictures	I-T017

Retrograde	O
urethrography	O
(	O
RUG	O
)	O
is	O
the	O
most	O
common	O
and	O
preferred	O
imaging	O
modality	O
for	O
imaging	B-T058
of	O
the	O
anterior	B-T017
urethral	I-T017
strictures	I-T017
despite	O
its	O
well	O
-	O
known	O
limitations	O
and	O
disadvantages	O
.	O

Sonourethrography	B-T058
(	O
SUG	B-T058
)	O
was	O
introduced	O
in	O
1988	O
to	O
overcome	O
the	O
limitations	O
of	O
RUG	O
and	O
to	O
provide	O
more	O
accurate	O
results	O
.	O

As	O
proper	O
selection	O
of	O
imaging	O
modality	O
is	O
very	O
important	O
for	O
planning	B-T170
the	I-T170
treatment	I-T170
,	O
various	O
advances	O
in	O
this	O
area	O
are	O
required	O
.	O

One	O
of	O
the	O
major	O
factors	O
for	O
recurrence	O
of	O
stricture	B-T038
disease	I-T038
is	O
spongiofibrosis	B-T038
.	O

Sonoelastography	B-T058
(	O
SE	B-T058
)	O
is	O
a	O
newer	B-T062
technique	I-T062
,	O
tried	O
in	O
various	O
other	O
pathologies	B-T091
.	O

In	O
this	O
study	O
,	O
we	O
have	O
used	O
this	O
technique	O
for	O
the	O
first	O
time	O
to	O
assess	O
its	O
efficacy	O
in	O
the	O
evaluation	O
of	O
anterior	B-T017
urethral	I-T017
stricture	I-T017
disease	I-T017
by	O
comparison	O
with	O
RUG	O
and	O
SUG	B-T058
.	O

Between	O
August	O
2014	O
and	O
May	O
2015	O
,	O
77	O
patients	O
with	O
clinical	O
features	O
of	O
anterior	B-T017
urethral	I-T017
stricture	I-T017
disease	I-T017
were	O
included	O
in	O
the	O
study	O
and	O
evaluated	O
by	O
RUG	O
followed	O
by	O
SUG	B-T058
and	O
SE	B-T058
for	O
stricture	O
location	B-T082
,	O
length	O
,	O
depth	B-T201
of	O
spongiofibrosis	B-T038
and	O
periurethral	B-T082
pathologies	B-T091
.	O

The	O
results	O
were	O
then	O
correlated	O
with	O
operative	O
and	O
histopathological	O
findings	O
.	O

Overall	O
diagnostic	O
accuracy	O
of	O
SE	B-T058
,	O
SUG	B-T058
,	O
and	O
RGU	O
for	O
the	O
estimation	O
of	O
stricture	O
location	B-T082
,	O
and	O
length	O
were	O
estimated	O
92	O
.	O
68	O
%	O
vs	O
.	O

91	O
.	O
54	O
%	O
,	O
79	O
%	O
vs	O
.	O

78	O
.	O
87	O
%	O
and	O
80	O
.	O
48	O
%	O
vs	O
.	O

43	O
.	O
66	O
%	O
,	O
respectively	O
,	O
while	O
for	O
depth	B-T201
of	O
spongiofibrosis	B-T038
SE	B-T058
,	O
and	O
SUG	B-T058
had	O
accuracy	O
rates	O
of	O
87	O
.	O
3	O
%	O
,	O
48	O
%	O
,	O
respectively	O
.	O

The	O
mean	O
length	O
measured	O
on	O
SE	B-T058
was	O
nearest	O
to	O
the	O
mean	O
intra	O
-	O
operative	O
stricture	O
length	O
(	O
21	O
.	O
34	O
+	O
11	O
.	O
8	O
mm	O
)	O
.	O

SE	B-T058
findings	O
significantly	O
correlated	O
with	O
the	O
colour	B-T033
of	I-T033
bladder	I-T033
mucosa	I-T033
on	O
cystoscopic	B-T058
examination	I-T058
(	O
p	O
=	O
0	O
.	O
003	O
)	O
whereas	O
the	O
association	O
was	O
non	O
-	O
significant	O
(	O
p	O
=	O
0	O
.	O
127	O
)	O
for	O
difficulty	O
in	O
incision	B-T058
.	O

While	O
a	O
nonsignificant	O
correlation	O
existed	O
between	O
SUG	B-T058
findings	O
related	O
both	O
to	O
the	O
colour	B-T033
of	I-T033
the	I-T033
bladder	I-T033
mucosa	I-T033
and	O
difficulty	O
in	O
incision	B-T058
on	O
cystoscopy	B-T058
,	O
SE	B-T058
findings	O
had	O
a	O
significant	O
association	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
with	O
histopathology	O
findings	O
for	O
severe	O
degree	B-T058
of	I-T058
fibrosis	I-T058
.	O

Sonoelastography	B-T058
estimates	O
stricture	O
site	O
and	O
length	O
better	O
in	O
comparison	O
with	O
RUG	O
and	O
SUG	B-T058
.	O

It	O
estimates	O
degree	O
of	O
spongiofibrosis	B-T038
which	O
serves	O
as	O
an	O
important	O
prognostic	B-T201
factor	I-T201
for	O
stricture	O
recurrence	O
more	O
accurately	O
than	O
SUG	B-T058
.	O

Changes	O
in	O
risk	B-T033
factors	I-T033
for	O
young	O
male	O
suicide	B-T033
in	O
Newcastle	B-T082
upon	I-T082
Tyne	I-T082
,	O
1961	O
-	O
2009	O

Aims	O
and	O
method	B-T170
To	O
ascertain	O
differences	O
in	O
patterns	B-T033
of	I-T033
suicide	I-T033
in	O
young	O
men	B-T098
over	O
three	O
decades	O
(	O
1960s	O
,	O
1990s	O
and	O
2000s	O
)	O
and	O
discuss	O
implications	O
for	O
suicide	B-T033
prevention	O
.	O

Data	O
on	O
suicides	B-T033
and	O
open	O
verdicts	O
in	O
men	B-T098
aged	O
15	O
-	O
34	O
were	O
obtained	O
from	O
coroner	B-T170
'	I-T170
s	I-T170
records	I-T170
in	O
Newcastle	B-T082
upon	I-T082
Tyne	I-T082
and	O
analysed	B-T062
using	O
SPSS	B-T170
software	I-T170
.	O

Results	O
An	O
increase	O
in	O
suicide	O
rates	O
from	O
the	O
first	O
to	O
the	O
second	O
decade	O
was	O
followed	O
by	O
a	O
fall	O
in	O
the	O
third	O
decade	O
.	O

This	O
was	O
associated	O
with	O
an	O
increasing	O
proportion	O
of	O
single	O
men	B-T098
,	O
those	O
living	B-T033
alone	I-T033
,	O
unemployment	B-T033
,	O
consumption	O
of	O
alcohol	O
,	O
use	O
of	O
hanging	B-T037
,	O
previous	O
suicide	B-T033
attempt	I-T033
and	O
history	O
of	O
treatment	O
for	O
mental	B-T038
illness	I-T038
.	O

Clinical	O
implications	O
This	O
study	B-T062
highlights	O
the	O
need	O
for	O
more	O
interventions	B-T058
and	O
focus	B-T038
to	O
be	O
given	O
to	O
young	O
males	O
in	O
the	O
suicide	B-T033
prevention	O
area	O
and	O
is	O
of	O
high	O
importance	O
in	O
the	O
field	B-T170
of	I-T170
public	I-T170
health	I-T170
.	O

Areas	O
that	O
could	O
be	O
tackled	O
include	O
reducing	O
access	B-T082
to	O
means	O
of	O
suicide	B-T033
,	O
reducing	O
alcohol	O
use	O
,	O
support	O
for	O
relationship	O
difficulties	O
,	O
engagement	B-T058
with	O
mental	B-T058
health	I-T058
services	I-T058
and	O
management	B-T058
of	O
chronic	B-T038
illness	I-T038
.	O

Social	O
cognition	O
in	O
schizophrenia	B-T038
:	O
Factor	O
structure	O
of	O
emotion	B-T038
processing	B-T038
and	O
theory	O
of	O
mind	O

Factor	O
analytic	O
studies	O
examining	O
social	O
cognition	O
in	O
schizophrenia	B-T038
have	O
yielded	O
inconsistent	O
results	O
most	O
likely	O
due	O
to	O
the	O
varying	O
number	O
and	O
quality	O
of	O
measures	O
.	O

With	O
the	O
recent	O
conclusion	O
of	O
Phase	O
3	O
of	O
the	O
Social	O
Cognition	O
Psychometric	B-T058
Evaluation	I-T058
(	I-T058
SCOPE	I-T058
)	I-T058
Study	I-T058
,	O
the	O
most	O
psychometrically	B-T058
sound	B-T058
measures	I-T058
of	O
social	O
cognition	O
have	O
been	O
identified	O
.	O

Therefore	O
,	O
the	O
aims	O
of	O
the	O
present	O
study	B-T062
were	O
to	O
:	O
1	O
)	O
examine	B-T033
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	B-T038
through	O
the	O
utilization	O
of	O
psychometrically	B-T058
sound	B-T058
measures	I-T058
,	O
2	O
)	O
examine	B-T033
the	O
stability	O
of	O
the	O
factor	O
structure	O
across	O
two	O
study	B-T062
visits	O
,	O
3	O
)	O
compare	O
the	O
factor	O
structure	O
of	O
social	O
cognition	O
in	O
schizophrenia	B-T038
to	O
that	O
in	O
healthy	O
controls	O
,	O
and	O
4	O
)	O
examine	B-T033
the	O
relationship	O
between	O
the	O
factors	O
and	O
relevant	O
outcome	O
measures	O
including	O
social	O
functioning	O
and	O
symptoms	B-T033
.	O

Results	O
supported	O
a	O
one	B-T170
-	I-T170
factor	I-T170
model	I-T170
for	O
the	O
patient	O
and	O
healthy	O
control	O
samples	O
at	O
both	O
visits	B-T058
.	O

This	O
single	O
factor	O
was	O
significantly	O
associated	O
with	O
negative	B-T033
symptoms	I-T033
in	O
the	O
schizophrenia	B-T038
sample	O
and	O
with	O
social	O
functioning	O
in	O
both	O
groups	B-T098
at	O
both	O
study	B-T062
visits	B-T058
.	O

Assessment	B-T058
of	O
Residual	B-T038
Disease	I-T038
With	O
Molecular	B-T058
Breast	I-T058
Imaging	I-T058
in	O
Patients	O
Undergoing	O
Neoadjuvant	B-T058
Therapy	I-T058
:	O
Association	O
With	O
Molecular	O
Subtypes	B-T170

Assessment	B-T058
of	O
residual	B-T038
disease	I-T038
after	O
neoadjuvant	B-T058
therapy	I-T058
for	O
breast	B-T038
cancer	I-T038
is	O
an	O
ongoing	O
challenge	O
of	O
breast	B-T017
imaging	B-T058
.	O

This	O
study	B-T062
evaluates	B-T058
the	O
accuracy	O
of	O
a	O
novel	O
dedicated	O
system	O
for	O
molecular	B-T058
breast	I-T058
imaging	I-T058
(	O
MBI	B-T058
)	O
composed	O
of	O
the	O
new	O
generation	O
of	O
cadmium	B-T103
zinc	I-T103
telluride	I-T103
detectors	O
in	O
assessing	O
residual	B-T038
disease	I-T038
after	O
neoadjuvant	B-T058
therapy	I-T058
in	O
patients	O
with	O
breast	B-T038
cancer	I-T038
.	O

Clinical	B-T170
data	I-T170
,	O
imaging	B-T058
,	O
surgical	O
,	O
and	O
pathological	O
findings	B-T033
of	O
51	O
women	B-T098
with	O
breast	B-T038
cancer	I-T038
undergoing	O
neoadjuvant	B-T058
therapy	I-T058
were	O
recorded	O
.	O

MBI	B-T058
findings	B-T033
were	O
correlated	O
with	O
surgical	B-T170
pathology	I-T170
results	I-T170
.	O

Accuracy	O
of	O
MBI	B-T058
in	O
predicting	O
complete	B-T033
pathological	I-T033
response	I-T033
and	O
size	B-T082
of	O
residual	B-T038
disease	I-T038
was	O
assessed	O
according	O
to	O
molecular	O
subtypes	B-T170
.	O

The	O
size	B-T082
of	O
the	O
largest	O
focus	O
of	O
uptake	O
on	O
MBI	B-T058
correlated	O
with	O
the	O
largest	O
dimension	O
measured	O
on	O
pathology	O
(	O
r	O
=	O
0	O
.	O
55	O
;	O
P	O
<	O
.	O
001	O
)	O
.	O

This	O
correlation	O
was	O
stronger	O
for	O
triple	B-T038
negative	I-T038
and	O
HER2	B-T201
/	I-T201
neu	I-T201
positive	I-T201
subtypes	B-T170
(	O
r	O
=	O
0	O
.	O
92	O
and	O
0	O
.	O
62	O
,	O
respectively	O
)	O
.	O

Sixteen	O
patients	O
(	O
31	O
%	O
)	O
had	O
complete	B-T033
pathological	I-T033
response	I-T033
.	O

The	O
sensitivity	O
and	O
specificity	O
of	O
MBI	B-T058
for	O
detecting	O
residual	B-T038
disease	I-T038
were	O
83	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
66	O
-	O
93	O
)	O
and	O
69	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
-	O
88	O
)	O
,	O
respectively	O
.	O

For	O
triple	B-T038
negative	I-T038
or	O
HER2	B-T201
/	I-T201
neu	I-T201
positive	I-T201
disease	O
the	O
sensitivity	O
and	O
specificity	O
were	O
88	O
%	O
(	O
95	O
%	O
CI	O
,	O
62	O
-	O
98	O
)	O
and	O
75	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
93	O
)	O
,	O
respectively	O
.	O

The	O
accuracy	O
of	O
MBI	B-T058
in	O
assessing	O
residual	B-T038
disease	I-T038
after	O
neoadjuvant	B-T058
treatment	I-T058
might	O
be	O
related	O
to	O
the	O
molecular	O
subtype	B-T170
.	O

Accuracy	O
is	O
highest	O
in	O
the	O
triple	B-T038
negative	I-T038
and	O
HER2	B-T201
/	I-T201
neu	I-T201
positive	I-T201
subtypes	B-T170
.	O

The	O
relationship	O
between	O
histological	O
prostatitis	B-T038
and	O
lower	B-T033
urinary	I-T033
tract	I-T033
symptoms	I-T033
and	O
sexual	B-T038
function	I-T038

This	O
prospective	B-T062
analysis	I-T062
assessed	O
the	O
effect	O
of	O
histological	O
prostatitis	B-T038
on	O
lower	B-T022
urinary	I-T022
tract	I-T022
functions	O
and	O
sexual	B-T038
function	I-T038
.	O

The	O
patients	O
were	O
separated	O
into	O
two	O
groups	O
as	O
histologically	O
observed	O
prostatitis	B-T038
(	O
Group	O
A	O
)	O
and	O
no	B-T033
prostatitis	I-T033
(	O
Group	O
B	O
)	O
according	O
to	O
the	O
biopsy	B-T058
outcomes	O
.	O

International	B-T170
prostate	I-T170
symptom	I-T170
score	I-T170
,	O
international	B-T201
index	I-T201
of	I-T201
erectile	I-T201
function	I-T201
-	I-T201
5	I-T201
scores	I-T201
,	O
maximal	B-T033
and	O
average	B-T033
flow	I-T033
rate	I-T033
,	O
and	O
residual	B-T033
urine	I-T033
volumes	I-T033
were	O
compared	O
statistically	O
between	O
groups	O
.	O

There	O
was	O
no	O
significant	O
difference	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
in	O
baseline	O
age	O
(	O
t	O
=	O
0	O
.	O
64	O
)	O
,	O
body	B-T201
mass	I-T201
index	I-T201
value	I-T201
(	O
t	O
=	O
0	O
.	O
51	O
)	O
,	O
prostate	O
volume	O
(	O
t	O
=	O
0	O
.	O
87	O
)	O
,	O
prostate	B-T058
-	I-T058
specific	I-T058
antigen	I-T058
levels	I-T058
(	O
t	O
=	O
0	O
.	O
43	O
)	O
,	O
maximal	B-T033
(	O
t	O
=	O
0	O
.	O
84	O
)	O
and	O
average	B-T033
flow	I-T033
rate	I-T033
(	O
t	O
=	O
0	O
.	O
59	O
)	O
,	O
and	O
post	O
-	O
void	O
residual	B-T033
urine	I-T033
volume	I-T033
(	O
t	O
=	O
0	O
.	O
71	O
)	O
.	O

Mean	O
international	B-T170
prostate	I-T170
symptom	I-T170
score	I-T170
in	O
patients	O
with	O
prostatitis	B-T038
was	O
numerically	O
but	O
not	O
significantly	O
higher	O
than	O
that	O
in	O
those	O
without	O
prostatitis	B-T038
(	O
t	O
=	O
0	O
.	O
794	O
,	O
P	O
=	O
0	O
.	O
066	O
)	O
.	O

Mean	O
international	B-T201
index	I-T201
of	I-T201
erectile	I-T201
function	I-T201
-	I-T201
5	I-T201
score	I-T201
in	O
the	O
prostatitis	B-T038
group	O
was	O
significantly	O
lower	O
than	O
that	O
in	O
those	O
without	O
prostatitis	B-T038
(	O
t	O
=	O
1	O
.	O
854	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Histological	O
prostatitis	B-T038
notably	O
affected	O
sexual	B-T038
function	I-T038
of	O
patients	O
and	O
may	O
serve	O
as	O
a	O
major	O
risk	B-T033
factor	I-T033
for	O
sexual	B-T038
dysfunction	I-T038
while	O
having	O
little	O
effect	O
on	O
lower	B-T033
urinary	I-T033
tract	I-T033
symptoms	I-T033
.	O

Beyond	O
"	O
Median	O
Waiting	O
Time	O
"	O
:	O
Development	O
and	O
Validation	B-T062
of	O
a	O
Competing	O
Risk	O
Model	O
to	O
Predict	O
Outcomes	O
on	O
the	O
Kidney	B-T017
Transplant	B-T170
Waiting	I-T170
List	I-T170

Median	O
historical	O
time	O
to	O
kidney	B-T058
transplant	I-T058
is	O
misleading	O
because	O
it	O
does	O
not	O
convey	O
the	O
competing	O
risks	O
of	O
death	B-T038
or	O
removal	B-T033
from	I-T033
the	I-T033
waiting	I-T033
list	I-T033
.	O

We	O
developed	O
and	O
validated	O
a	O
competing	O
risk	O
model	O
to	O
calculate	O
likelihood	O
of	O
outcomes	O
for	O
kidney	B-T058
transplant	I-T058
candidates	B-T098
and	O
demonstrate	O
how	O
this	O
information	O
differs	O
from	O
median	O
time	O
to	O
transplant	B-T058
.	O

Data	O
were	O
obtained	O
from	O
the	O
US	B-T170
Scientific	I-T170
Registry	I-T170
of	O
Transplant	O
Recipients	O
.	O

The	O
retrospective	B-T062
cohort	I-T062
included	O
163	O
636	O
adults	O
listed	O
for	O
kidney	B-T058
transplant	I-T058
before	O
December	O
31	O
,	O
2011	O
.	O

Predictors	B-T033
were	O
age	O
,	O
sex	O
,	O
blood	B-T201
type	I-T201
,	O
calculated	B-T058
panel	B-T058
-	I-T058
reactive	I-T058
antibodies	I-T058
,	O
donation	B-T058
service	B-T082
area	I-T082
,	O
dialysis	B-T058
duration	O
,	O
comorbid	B-T033
conditions	I-T033
,	O
and	O
body	B-T201
mass	I-T201
index	I-T201
.	O

Outcomes	O
were	O
deceased	O
or	O
living	B-T098
donor	I-T098
transplant	B-T058
,	O
death	B-T038
or	O
removal	B-T033
from	I-T033
the	I-T033
list	I-T033
due	O
to	O
deteriorating	O
medical	O
condition	O
,	O
or	O
removal	B-T033
due	O
to	O
other	O
reasons	O
.	O

We	O
calculated	O
hazards	O
for	O
the	O
possible	B-T033
outcomes	O
,	O
then	O
the	O
cumulative	O
incidence	O
function	B-T038
for	O
a	O
given	O
candidate	B-T098
using	O
competing	O
risk	O
methodology	O
.	O

Discrimination	B-T038
and	O
calibration	O
were	O
assessed	O
through	O
C	O
statistics	O
and	O
calibration	O
plots	O
for	O
each	O
cause	O
-	O
specific	O
Cox	B-T170
proportional	I-T170
hazard	I-T170
model	I-T170
.	O

C	O
statistics	O
ranged	O
from	O
0	O
.	O
64	O
to	O
0	O
.	O
73	O
.	O

Calibration	O
plots	O
showed	O
good	O
calibration	O
.	O

The	O
competing	O
risk	O
model	O
shows	O
probability	O
of	O
all	O
possible	B-T033
outcomes	O
for	O
up	O
to	O
12	O
years	O
given	O
a	O
candidate	B-T098
'	I-T098
s	I-T098
characteristics	O
,	O
contrasted	O
with	O
the	O
median	O
waiting	O
time	O
for	O
that	O
candidate	B-T098
'	I-T098
s	I-T098
donation	B-T058
service	B-T082
area	I-T082
.	O

A	O
competing	O
risk	O
model	O
conveys	O
more	O
relevant	O
information	O
than	O
the	O
median	O
waiting	O
time	O
for	O
a	O
given	O
transplant	B-T092
center	I-T092
.	O

This	O
model	O
will	O
be	O
updated	O
to	O
create	O
a	O
calculator	O
reflecting	O
the	O
most	O
recent	O
outcomes	O
and	O
changes	O
in	O
allocation	O
policy	B-T170
.	O

It	O
illustrates	O
the	O
conversations	O
that	O
should	O
be	O
initiated	O
with	O
transplant	B-T058
candidates	B-T098
.	O

Tead1	B-T017
regulates	O
the	O
expression	B-T038
of	O
Peripheral	B-T017
Myelin	I-T017
Protein	I-T017
22	I-T017
during	O
Schwann	B-T038
cell	I-T038
development	I-T038

Schwann	B-T017
cells	I-T017
are	O
myelinating	B-T017
glia	I-T017
in	O
the	O
peripheral	B-T022
nervous	I-T022
system	I-T022
that	O
form	O
the	O
myelin	B-T017
sheath	I-T017
.	O

A	O
major	O
cause	O
of	O
peripheral	B-T038
neuropathy	I-T038
is	O
a	O
copy	B-T082
number	I-T082
variant	I-T082
involving	O
the	O
Peripheral	B-T017
Myelin	I-T017
Protein	I-T017
22	I-T017
(	I-T017
PMP22	I-T017
)	I-T017
gene	I-T017
,	O
which	O
is	O
located	O
within	O
a	O
1	O
.	O
4	O
-	O
Mb	O
duplication	B-T038
on	O
chromosome	B-T017
17	I-T017
associated	O
with	O
the	O
most	O
common	O
form	O
of	O
Charcot	B-T038
-	I-T038
Marie	I-T038
-	I-T038
Tooth	I-T038
Disease	I-T038
(	O
CMT1A	B-T038
)	O
.	O

Rodent	B-T038
models	I-T038
of	O
CMT1A	B-T038
have	O
been	O
used	O
to	O
show	O
that	O
reducing	O
Pmp22	B-T017
overexpression	B-T038
mitigates	O
several	O
aspects	O
of	O
a	O
CMT1A	B-T038
-	O
related	O
phenotype	O
.	O

Mechanistic	O
studies	B-T062
of	O
Pmp22	B-T017
regulation	B-T038
identified	O
enhancers	B-T103
regulated	O
by	O
the	O
Sox10	B-T103
(	O
SRY	B-T103
sex	I-T103
determining	I-T103
region	I-T103
Y	I-T103
-	I-T103
box	I-T103
10	I-T103
)	O
and	O
Egr2	B-T103
/	O
Krox20	B-T103
(	O
Early	B-T103
growth	I-T103
response	I-T103
protein	I-T103
2	I-T103
)	O
transcription	B-T103
factors	I-T103
in	O
myelinated	B-T017
nerves	I-T017
.	O

However	O
,	O
relatively	O
little	O
is	O
known	O
regarding	O
how	O
other	O
transcription	B-T103
factors	I-T103
induce	O
Pmp22	B-T017
expression	B-T038
during	O
Schwann	B-T038
cell	I-T038
development	I-T038
and	O
myelination	B-T038
.	O

Here	O
,	O
we	O
examined	O
Pmp22	B-T017
enhancers	B-T103
as	O
a	O
function	O
of	O
cell	B-T038
type	I-T038
-	I-T038
specificity	I-T038
,	O
nerve	B-T037
injury	I-T037
and	O
development	O
.	O

While	O
Pmp22	B-T017
enhancers	B-T103
marked	O
by	O
active	O
histone	B-T038
modifications	I-T038
were	O
lost	O
or	O
remodeled	O
after	O
injury	B-T037
,	O
we	O
found	O
that	O
these	O
enhancers	B-T103
were	O
permissive	O
in	O
early	O
development	O
prior	O
to	O
Pmp22	B-T017
upregulation	B-T038
.	O

Pmp22	B-T017
enhancers	B-T103
contain	O
binding	B-T103
motifs	I-T103
for	O
TEA	B-T103
domain	I-T103
(	O
Tead	B-T103
)	O
transcription	B-T103
factors	I-T103
of	O
the	O
Hippo	B-T038
signaling	I-T038
pathway	I-T038
.	O

We	O
discovered	O
that	O
Tead1	B-T017
and	O
co	O
-	O
activators	O
Yap	B-T017
and	O
Taz	B-T017
are	O
required	O
for	O
Pmp22	B-T017
expression	B-T038
,	O
as	O
well	O
as	O
for	O
the	O
expression	B-T038
of	O
Egr2	B-T017
Tead1	B-T017
directly	O
binds	O
Pmp22	B-T017
and	O
Egr2	B-T017
enhancers	B-T103
early	O
in	O
development	O
and	O
Tead1	B-T017
binding	B-T038
is	O
induced	O
during	O
myelination	B-T038
,	O
correlating	O
with	O
Pmp22	B-T017
expression	B-T038
.	O

The	O
data	O
identify	O
Tead1	B-T017
as	O
a	O
novel	O
regulator	B-T017
of	O
Pmp22	B-T017
expression	B-T038
during	O
development	O
in	O
concert	O
with	O
Sox10	B-T017
and	O
Egr2	B-T017
.	O

Neutrophil	B-T103
gelatinase	I-T103
-	I-T103
associated	I-T103
lipocalin	I-T103
in	O
a	O
triphasic	O
rat	B-T204
model	I-T204
of	O
adenine	B-T103
-	O
induced	O
kidney	B-T037
injury	I-T037

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
whether	O
NGAL	B-T103
,	O
given	O
its	O
advantages	O
over	O
traditional	O
biomarkers	B-T201
,	O
can	O
be	O
used	O
to	O
describe	O
the	O
dynamic	O
characteristics	O
of	O
the	O
renal	B-T038
tubulointerstitial	I-T038
insult	I-T038
caused	O
by	O
adenine	B-T103
.	O

Subsequently	O
,	O
it	O
will	O
be	O
possible	O
to	O
assess	O
NGAL	B-T103
as	O
a	O
biomarker	B-T201
of	O
any	O
acute	B-T037
kidney	I-T037
injury	I-T037
,	O
on	O
top	O
of	O
chronic	B-T038
interstitial	I-T038
disease	I-T038
,	O
if	O
NGAL	B-T103
levels	O
are	O
stable	O
through	O
the	O
chronic	O
phase	O
of	O
our	O
adenine	B-T204
model	I-T204
.	O

Study	B-T098
group	I-T098
rats	B-T204
were	O
fed	O
an	O
adenine	B-T103
diet	B-T168
,	O
and	O
control	O
group	O
rats	B-T204
were	O
fed	O
a	O
regular	O
diet	O
only	O
.	O

Blood	B-T031
and	O
urine	B-T031
samples	I-T031
for	O
urea	B-T103
,	O
creatinine	B-T103
and	O
NGAL	B-T103
were	O
drawn	O
from	O
each	O
rat	B-T204
at	O
the	O
beginning	O
of	O
the	O
study	B-T062
and	O
after	O
1	O
,	O
3	O
,	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
and	O
8	O
weeks	O
.	O

Kidney	B-T017
slices	O
from	O
these	O
rats	B-T204
were	O
stained	B-T058
with	O
Hematoxylin	B-T058
-	I-T058
eosin	I-T058
(	O
HE	B-T058
)	O
and	O
β	B-T103
-	I-T103
actin	I-T103
stainings	B-T058
.	O

Serum	B-T033
urea	I-T033
,	O
creatinine	B-T058
and	O
NGAL	B-T103
levels	O
and	O
urinary	O
NGAL	O
/	O
creatinine	O
ratio	O
in	O
the	O
study	O
group	O
were	O
higher	O
than	O
baseline	O
and	O
than	O
in	O
the	O
control	O
group	O
;	O
these	O
differences	O
were	O
statistically	O
significant	O
in	O
some	O
of	O
the	O
intervals	O
.	O

Tubulointerstitial	B-T038
changes	O
and	O
adenine	B-T103
crystals	O
were	O
evident	O
in	O
the	O
study	O
group	O
rats	B-T204
.	O

In	O
the	O
rats	B-T204
fed	O
adenine	B-T103
,	O
serum	B-T033
urea	I-T033
,	O
creatinine	B-T058
and	O
NGAL	B-T103
levels	O
and	O
urinary	O
NGAL	O
/	O
creatinine	O
ratio	O
followed	O
a	O
triphasic	B-T033
pattern	I-T033
of	O
kidney	B-T037
injury	I-T037
:	O
an	O
acute	O
phase	O
while	O
on	O
the	O
adenine	B-T103
diet	B-T168
,	O
a	O
partial	O
recovery	B-T038
phase	O
after	O
switching	O
to	O
the	O
regular	O
diet	O
and	O
a	O
chronic	B-T038
kidney	I-T038
disease	I-T038
phase	O
after	O
stabilization	O
of	O
renal	B-T038
function	I-T038
.	O

NGAL	B-T103
can	O
serve	O
a	O
biomarker	B-T201
for	O
acute	B-T037
kidney	I-T037
injury	I-T037
and	O
possibly	O
for	O
chronic	B-T038
kidney	I-T038
disease	I-T038
in	O
the	O
tubulointerstitial	B-T038
rat	B-T204
model	I-T204
.	O

Talking	O
or	O
Keeping	O
Silent	O
About	O
Parental	O
Mental	B-T033
Health	I-T033
Problems	I-T033
-	O
A	O
Grounded	B-T170
Theory	I-T170
of	O
Parents	O
'	O
Decision	B-T038
Making	I-T038
and	O
Experiences	B-T038
with	O
Their	O
Children	O

This	O
grounded	B-T170
theory	I-T170
study	B-T062
explored	O
parents	O
'	O
experiences	B-T038
of	O
responding	O
to	O
their	O
children	O
'	O
s	O
need	O
for	O
understanding	O
parental	O
mental	B-T038
health	I-T038
concerns	O
.	O

Fifteen	O
parents	O
with	O
severe	O
and	O
enduring	O
mental	B-T033
health	I-T033
difficulties	I-T033
participated	O
in	O
the	O
study	B-T062
.	O

The	O
findings	B-T033
suggest	O
four	O
main	O
social	O
processes	O
that	O
influence	O
parents	O
'	O
talk	O
with	O
their	O
children	O
about	O
parental	O
mental	B-T033
health	I-T033
issues	I-T033
,	O
namely	O
"	O
Protecting	B-T038
and	O
being	B-T038
protected	I-T038
,	O
"	O
"	O
Responding	O
to	O
children	O
'	O
s	O
search	O
for	O
understanding	B-T038
,	O
"	O
"	O
Prioritizing	O
family	O
life	O
,	O
"	O
and	O
"	O
Relating	O
to	O
others	O
.	O
"	O
Implications	O
of	O
the	O
findings	B-T033
for	O
clinical	O
practice	O
and	O
future	O
research	B-T062
are	O
considered	O
.	O

In	O
particular	O
,	O
the	O
need	O
for	O
more	O
family	O
-	O
orientated	O
services	O
where	O
parents	O
experience	B-T038
parental	O
mental	B-T033
health	I-T033
problems	I-T033
is	O
highlighted	O
.	O

A	O
case	O
of	O
bilateral	B-T082
pneumothoraces	B-T038
resulting	O
from	O
tracheostomy	B-T058
for	O
advanced	O
laryngeal	B-T038
cancer	I-T038

Pneumothorax	B-T038
is	O
a	O
possible	O
complication	B-T038
of	O
tracheostomy	B-T058
.	O

We	O
report	B-T058
a	O
rare	O
case	O
of	O
bilateral	B-T082
pneumothoraces	B-T038
resulting	O
from	O
tracheostomy	B-T058
in	O
an	O
advanced	O
laryngeal	B-T038
cancer	I-T038
patient	O
.	O

A	O
59	O
-	O
year	O
-	O
old	O
man	O
was	O
referred	O
to	O
our	O
clinic	B-T092
for	O
evaluation	B-T058
and	O
treatment	B-T058
of	O
laryngeal	B-T038
tumor	I-T038
.	O

Laryngeal	B-T058
endoscopy	I-T058
showed	O
limited	B-T033
movement	I-T033
of	O
bilateral	B-T017
vocal	I-T017
cords	I-T017
,	O
and	O
computed	B-T058
tomography	I-T058
revealed	O
a	O
tumor	B-T038
lesion	B-T033
extending	O
from	O
the	O
vocal	B-T017
cords	I-T017
to	O
the	O
subglottic	B-T017
area	I-T017
.	O

Three	O
days	O
after	O
the	O
first	B-T033
visit	I-T033
,	O
the	O
patient	O
developed	O
respiratory	B-T033
difficulty	I-T033
,	O
and	O
we	O
elected	O
to	O
perform	O
emergency	B-T058
tracheostomy	I-T058
for	O
airway	B-T058
management	I-T058
.	O

Immediately	O
after	O
the	O
start	O
of	O
the	O
procedure	B-T058
,	O
he	O
began	O
hyperventilating	B-T033
,	O
and	O
complained	O
of	O
respiratory	O
discomfort	O
and	O
chest	B-T033
pain	I-T033
.	O

We	O
then	O
recognized	O
a	O
mediastinal	B-T082
air	B-T038
leak	I-T038
,	O
and	O
we	O
suspected	O
pneumothorax	B-T038
resulting	O
from	O
the	O
tracheostomy	B-T058
.	O

Chest	B-T058
X	I-T058
-	I-T058
ray	I-T058
showed	O
bilateral	B-T082
pneumothoraces	B-T038
;	O
therefore	O
,	O
we	O
inserted	B-T058
bilateral	B-T082
chest	B-T082
drainage	B-T074
tubes	I-T074
,	O
which	O
stabilized	B-T033
his	O
respiratory	O
condition	O
.	O

We	O
speculated	O
that	O
the	O
pathogenesis	B-T038
of	O
the	O
bilateral	B-T082
pneumothoraces	B-T038
was	O
weakened	O
alveolar	B-T017
walls	I-T017
secondary	O
to	O
long	O
-	O
term	O
smoking	O
,	O
and	O
a	O
significant	O
rise	O
in	O
airway	B-T201
pressure	I-T201
because	O
of	O
airway	B-T033
constriction	I-T033
by	O
the	O
neck	B-T082
-	I-T082
extended	I-T082
position	I-T082
and	O
hyperventilation	B-T033
,	O
during	O
tracheostomy	B-T058
.	O

Arsenic	O
Triglutathione	O
[	O
As	O
(	O
GS	O
)	O
3	O
]	O
Transport	B-T038
by	O
Multidrug	B-T103
Resistance	I-T103
Protein	I-T103
1	I-T103
(	O
MRP1	B-T103
/	O
ABCC1	B-T103
)	O
Is	O
Selectively	O
Modified	O
by	O
Phosphorylation	B-T038
of	O
Tyr920	B-T082
/	I-T082
Ser921	I-T082
and	O
Glycosylation	B-T038
of	O
Asn19	B-T082
/	I-T082
Asn23	I-T082

The	O
ATP	B-T103
-	I-T103
binding	I-T103
cassette	I-T103
(	I-T103
ABC	I-T103
)	I-T103
transporter	I-T103
multidrug	B-T103
resistance	I-T103
protein	I-T103
1	I-T103
(	O
MRP1	B-T103
/	O
ABCC1	B-T103
)	O
is	O
responsible	O
for	O
the	O
cellular	B-T017
export	O
of	O
a	O
chemically	O
diverse	O
array	B-T082
of	O
xenobiotics	B-T103
and	O
endogenous	O
compounds	O
.	O

Arsenic	B-T103
,	O
a	O
human	B-T204
carcinogen	B-T103
,	O
is	O
a	O
high	O
-	O
affinity	O
MRP1	B-T103
substrate	O
as	O
arsenic	O
triglutathione	O
[	O
As	O
(	O
GS	O
)	O
3	O
]	O
.	O

In	O
this	O
study	O
,	O
marked	O
differences	O
in	O
As	O
(	O
GS	O
)	O
3	O
transport	B-T038
kinetics	O
were	O
observed	O
between	O
MRP1	B-T103
-	O
enriched	O
membrane	B-T017
vesicles	B-T017
prepared	O
from	O
human	B-T204
embryonic	B-T017
kidney	B-T017
293	B-T017
(	I-T017
HEK	I-T017
)	I-T017
(	O
Km	O
3	O
.	O
8	O
µM	O
and	O
Vmax	O
307	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
and	O
HeLa	B-T017
(	O
Km	O
0	O
.	O
32	O
µM	O
and	O
Vmax	O
42	O
pmol	O
/	O
mg	O
per	O
minute	O
)	O
cells	B-T017
.	O

Mutant	B-T103
MRP1	B-T103
lacking	O
N	O
-	O
linked	O
glycosylation	B-T038
[	O
Asn19	B-T082
/	I-T082
23	I-T082
/	I-T082
1006Gln	I-T082
;	O
sugar	O
-	O
free	O
(	B-T103
SF	I-T103
)	I-T103
-	I-T103
MRP1	I-T103
]	O
expressed	B-T038
in	O
either	O
HEK293	B-T017
or	O
HeLa	B-T017
cells	I-T017
had	O
low	O
Km	O
and	O
Vmax	O
values	O
for	O
As	O
(	O
GS	O
)	O
3	O
,	O
similar	O
to	O
HeLa	B-T017
wild	I-T017
-	I-T017
type	I-T017
(	O
WT	O
)	O
MRP1	B-T103
.	O

When	O
prepared	O
in	O
the	O
presence	B-T033
of	O
phosphatase	B-T103
inhibitors	I-T103
,	O
both	O
WT	B-T103
-	I-T103
and	O
SF	B-T103
-	I-T103
MRP1	I-T103
-	O
enriched	O
membrane	B-T017
vesicles	B-T017
had	O
a	O
high	O
Km	O
value	O
for	O
As	O
(	O
GS	O
)	O
3	O
(	O
3	O
-	O
6	O
µM	O
)	O
,	O
regardless	O
of	O
the	O
cell	B-T017
line	I-T017
.	O

Kinetic	B-T033
parameters	I-T033
of	O
As	O
(	O
GS	O
)	O
3	O
for	O
HEK	B-T017
-	O
Asn19	B-T103
/	I-T103
23Gln	I-T103
-	I-T103
MRP1	I-T103
were	O
similar	O
to	O
those	O
of	O
HeLa	B-T017
/	O
HEK	B-T017
-	O
SF	B-T103
-	I-T103
MRP1	I-T103
and	O
HeLa	B-T017
-	I-T017
WT	I-T017
-	O
MRP1	B-T103
,	O
whereas	O
those	O
of	O
single	O
glycosylation	B-T038
mutants	B-T103
were	O
like	O
those	O
of	O
HEK	B-T017
-	I-T017
WT	I-T017
-	O
MRP1	O
.	O

Mutation	B-T038
of	O
19	O
potential	O
MRP1	O
phosphorylation	B-T038
sites	B-T082
revealed	O
that	O
HEK	B-T017
-	O
Tyr920Phe	B-T103
/	I-T103
Ser921Ala	I-T103
-	I-T103
MRP1	I-T103
transported	B-T038
As	O
(	O
GS	O
)	O
3	O
like	O
HeLa	B-T017
-	I-T017
WT	I-T017
-	O
MRP1	B-T103
,	O
whereas	O
individual	O
HEK	B-T017
-	O
Tyr920Phe	B-T103
-	I-T103
and	O
-	O
Ser921Ala	B-T103
-	I-T103
MRP1	I-T103
mutants	B-T103
were	O
similar	O
to	O
HEK	B-T017
-	I-T017
WT	I-T017
-	O
MRP1	B-T103
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
Asn19	B-T082
/	I-T082
Asn23	I-T082
glycosylation	B-T038
and	O
Tyr920	B-T082
/	I-T082
Ser921	I-T082
phosphorylation	B-T038
are	O
responsible	O
for	O
altering	O
the	O
kinetics	O
of	O
MRP1	B-T103
-	O
mediated	O
As	O
(	O
GS	O
)	O
3	O
transport	B-T038
.	O

The	O
kinetics	O
of	O
As	O
(	O
GS	O
)	O
3	O
transport	B-T038
by	O
HEK	B-T017
-	O
Asn19	B-T082
/	I-T082
23Gln	I-T082
/	I-T082
Tyr920Glu	I-T082
/	I-T082
Ser921Glu	I-T082
were	O
similar	O
to	O
HEK	B-T017
-	I-T017
WT	I-T017
-	O
MRP1	B-T103
,	O
indicating	O
that	O
the	O
phosphorylation	B-T038
-	O
mimicking	O
substitutions	O
abrogated	O
the	O
influence	O
of	O
Asn19	B-T082
/	I-T082
23Gln	I-T082
glycosylation	B-T038
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
cross	O
-	O
talk	O
between	O
MRP1	B-T103
glycosylation	B-T038
and	O
phosphorylation	B-T038
occurs	O
and	O
that	O
phosphorylation	B-T038
of	O
Tyr920	B-T082
and	O
Ser921	B-T082
can	O
switch	O
MRP1	B-T103
to	O
a	O
lower	O
-	O
affinity	O
,	O
higher	O
-	O
capacity	O
As	O
(	O
GS	O
)	O
3	O
transporter	B-T103
,	O
allowing	O
arsenic	B-T103
detoxification	B-T038
over	O
a	O
broad	B-T082
concentration	O
range	O
.	O

Naphthohydroquinones	B-T103
,	O
naphthoquinones	B-T103
,	O
anthraquinones	B-T103
,	O
and	O
a	O
naphthohydroquinone	B-T103
dimer	O
isolated	O
from	O
the	O
aerial	B-T204
parts	I-T204
of	O
Morinda	B-T204
parvifolia	I-T204
and	O
their	O
cytotoxic	B-T038
effects	I-T038
through	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
p53	B-T017

Five	O
unknown	O
compounds	B-T103
,	O
morindaparvins	B-T103
C	I-T103
-	I-T103
G	I-T103
,	O
consisting	O
of	O
naphthohydroquinones	B-T103
,	O
a	O
naphthoquinone	B-T103
,	O
an	O
anthraquinone	B-T103
,	O
and	O
a	O
naphthohydroquinone	B-T103
dimer	O
,	O
together	O
with	O
three	O
known	O
quinones	B-T103
and	O
seven	O
other	O
known	O
compounds	B-T103
,	O
were	O
isolated	O
from	O
the	O
aerial	B-T204
parts	I-T204
of	O
Morinda	B-T204
parvifolia	I-T204
.	O

The	O
structures	O
of	O
morindaparvins	B-T103
C	I-T103
,	O
D	B-T103
,	O
E	B-T103
,	O
F	B-T103
,	O
and	O
G	B-T103
were	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	B-T058
or	O
X	O
-	O
ray	O
diffraction	O
analysis	O
as	O
methyl	B-T103
4	I-T103
-	I-T103
hydroxy	I-T103
-	I-T103
1	I-T103
,	I-T103
6	I-T103
-	I-T103
dimethoxy	I-T103
-	I-T103
naphthalene	I-T103
-	I-T103
2	I-T103
-	I-T103
carboxylate	I-T103
,	O
methyl	B-T103
4	I-T103
,	I-T103
8	I-T103
-	I-T103
dihydroxy	I-T103
-	I-T103
1	I-T103
-	I-T103
methoxy	I-T103
-	I-T103
naphthalene	I-T103
-	I-T103
2	I-T103
-	I-T103
carboxylate	I-T103
,	O
3	B-T103
-	I-T103
amino	I-T103
-	I-T103
6	I-T103
-	I-T103
methoxy	I-T103
-	I-T103
2	I-T103
-	I-T103
methoxycarbonyl	I-T103
-	I-T103
1	I-T103
,	I-T103
4	I-T103
-	I-T103
naphthoquinone	I-T103
,	O
1	B-T103
,	I-T103
4	I-T103
-	I-T103
dihydroxy	I-T103
-	I-T103
7	I-T103
-	I-T103
hydroxymethyl	I-T103
-	I-T103
anthraquinone	I-T103
,	O
and	O
dimethyl	B-T103
1	I-T103
,	I-T103
1	I-T103
'	I-T103
-	I-T103
dihydroxy	I-T103
-	I-T103
4	I-T103
,	I-T103
4	I-T103
'	I-T103
,	I-T103
7	I-T103
,	I-T103
7	I-T103
'	I-T103
-	I-T103
tetramethoxy	I-T103
-	I-T103
2	I-T103
,	I-T103
2	I-T103
'	I-T103
-	I-T103
binaphthalene	I-T103
-	I-T103
3	I-T103
,	I-T103
3	I-T103
'	I-T103
-	I-T103
dicarboxylate	I-T103
,	O
respectively	O
.	O

Naphthoquinones	B-T103
and	O
naphthohydroquinone	B-T103
dimers	O
were	O
previously	O
unknown	O
in	O
the	O
genus	B-T170
Morinda	B-T204
.	O

In	O
addition	O
,	O
the	O
compounds	B-T103
were	O
tested	O
for	O
cytotoxicity	B-T038
against	O
four	O
human	B-T204
cancer	B-T017
cell	I-T017
lines	I-T017
HeLa	B-T017
,	O
A2780	B-T017
,	O
Ketr3	B-T017
and	O
MCF	B-T017
-	I-T017
7	I-T017
and	O
their	O
effects	O
on	O
p53	B-T017
-	O
activated	O
transcription	B-T038
.	O

Three	O
naphthoquinones	B-T103
had	O
moderate	O
cytotoxic	B-T038
effects	I-T038
with	O
IC50	O
values	O
ranging	O
from	O
1	O
.	O
51	O
to	O
9	O
.	O
56	O
μM	O
,	O
through	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
p53	B-T017
transcriptional	B-T038
activity	I-T038
.	O

Identification	B-T038
and	O
SAR	O
Evaluation	B-T058
of	O
Hemozoin	B-T103
-	O
Inhibiting	O
Benzamides	B-T103
Active	O
against	O
Plasmodium	B-T204
falciparum	I-T204

Quinoline	B-T103
antimalarials	B-T103
target	O
hemozoin	B-T103
formation	O
causing	O
a	O
cytotoxic	O
accumulation	B-T033
of	O
ferriprotoporphyrin	B-T103
IX	I-T103
(	O
Fe	B-T103
(	I-T103
III	I-T103
)	I-T103
PPIX	I-T103
)	O
.	O

Well	O
-	O
developed	O
SAR	O
models	B-T170
exist	O
for	O
β	B-T103
-	I-T103
hematin	I-T103
inhibition	O
,	O
parasite	B-T204
activity	O
,	O
and	O
cellular	B-T038
mechanisms	I-T038
for	O
this	O
compound	B-T170
class	I-T170
,	O
but	O
no	O
comparably	O
detailed	O
investigations	B-T033
exist	O
for	O
other	O
hemozoin	B-T103
inhibiting	O
chemotypes	B-T103
.	O

Here	O
,	O
benzamide	B-T103
analogues	B-T103
based	O
on	O
previous	O
HTS	B-T058
hits	O
have	O
been	O
purchased	O
or	O
synthesized	O
.	O

Only	O
derivatives	B-T103
containing	I-T103
an	I-T103
electron	I-T103
deficient	I-T103
aromatic	I-T103
ring	I-T103
and	O
capable	O
of	O
adopting	O
flat	B-T082
conformations	I-T082
,	O
optimal	O
for	O
π	O
-	O
π	O
interactions	O
with	O
Fe	B-T103
(	I-T103
III	I-T103
)	I-T103
PPIX	I-T103
,	O
inhibited	O
β	B-T103
-	I-T103
hematin	I-T103
formation	O
.	O

The	O
two	O
most	O
potent	O
analogues	B-T103
showed	O
nanomolar	O
parasite	B-T204
activity	O
,	O
with	O
little	O
CQ	B-T103
cross	B-T038
-	I-T038
resistance	I-T038
,	O
low	O
cytotoxicity	B-T038
,	O
and	O
high	O
in	O
vitro	O
microsomal	O
stability	O
.	O

Selected	O
analogues	B-T103
inhibited	O
hemozoin	B-T103
formation	O
in	O
Plasmodium	B-T204
falciparum	I-T204
causing	O
high	O
levels	O
of	O
free	O
heme	B-T103
.	O

In	O
contrast	O
to	O
quinolines	B-T103
,	O
introduction	O
of	O
amine	O
side	O
chains	O
did	O
not	O
lead	O
to	O
benzamide	B-T103
accumulation	B-T033
in	O
the	O
parasite	B-T204
.	O

These	O
data	O
reveal	O
complex	O
relationships	O
between	O
heme	B-T038
binding	I-T038
,	O
free	O
heme	B-T103
levels	O
,	O
cellular	B-T038
accumulation	I-T038
,	O
and	O
in	O
vitro	O
activity	O
of	O
potential	O
novel	O
antimalarials	B-T103
.	O

Shear	O
modulus	O
of	O
structured	B-T082
electrorheological	O
fluid	O
mixtures	O

Some	O
immiscible	O
blends	O
under	O
a	O
strong	O
electric	O
field	O
often	O
exhibit	O
periodic	O
structures	B-T082
,	O
bridging	O
the	O
gap	O
between	O
two	O
electrodes	B-T074
.	O

Upon	O
shear	O
,	O
the	O
structures	B-T082
tilt	O
,	O
and	O
exhibit	O
an	O
elastic	O
response	O
which	O
is	O
mostly	O
governed	O
by	O
the	O
electric	O
energy	O
.	O

Assuming	O
a	O
two	O
-	O
dimensional	O
stripe	B-T082
structure	I-T082
,	O
we	O
calculate	O
the	O
Maxwell	O
stress	O
,	O
and	O
derive	O
an	O
expression	O
for	O
the	O
shear	O
modulus	O
,	O
demonstrating	O
how	O
it	O
depends	O
on	O
the	O
external	O
electric	O
field	O
,	O
the	O
composition	O
,	O
and	O
the	O
dielectric	O
properties	O
of	O
the	O
blend	O
.	O

We	O
also	O
suggest	O
the	O
notion	O
of	O
effective	O
interfacial	O
tension	O
,	O
which	O
renormalizes	O
the	O
effect	O
of	O
the	O
electric	O
field	O
.	O

This	O
leads	O
to	O
a	O
simple	O
derivation	O
of	O
the	O
scaling	B-T170
law	I-T170
for	O
the	O
selection	O
of	O
the	O
wavelength	O
of	O
the	O
structure	B-T082
formed	O
under	O
an	O
electric	O
field	O
.	O

Sequence	B-T038
-	I-T038
specific	I-T038
DNA	I-T038
binding	I-T038
by	O
long	O
hairpin	O
pyrrole	B-T103
-	I-T103
imidazole	I-T103
polyamides	I-T103
containing	O
an	O
8	B-T103
-	I-T103
amino	I-T103
-	I-T103
3	I-T103
,	I-T103
6	I-T103
-	I-T103
dioxaoctanoic	I-T103
acid	I-T103
unit	O

With	O
the	O
aim	O
of	O
improving	O
aqueous	O
solubility	O
,	O
we	O
designed	O
and	O
synthesized	O
five	O
N	B-T103
-	I-T103
methylpyrrole	I-T103
(	I-T103
Py	I-T103
)	I-T103
-	I-T103
N	I-T103
-	I-T103
methylimidazole	I-T103
(	I-T103
Im	I-T103
)	I-T103
polyamides	I-T103
capable	O
of	O
recognizing	O
9	B-T082
-	I-T082
bp	I-T082
sequences	I-T082
.	O

Their	O
DNA	B-T038
-	I-T038
binding	I-T038
affinities	O
and	O
sequence	B-T082
specificities	O
were	O
evaluated	O
by	O
SPR	B-T062
and	O
Bind	B-T062
-	I-T062
n	I-T062
-	I-T062
Seq	I-T062
analyses	I-T062
.	O

The	O
design	O
of	O
polyamide	B-T103
1	I-T103
was	O
based	O
on	O
a	O
conventional	O
model	B-T170
,	O
with	O
three	O
consecutive	O
Py	B-T103
or	O
Im	B-T103
rings	O
separated	O
by	O
a	O
β	B-T103
-	I-T103
alanine	I-T103
to	O
match	O
the	O
curvature	O
and	O
twist	B-T082
of	O
long	O
DNA	B-T103
helices	O
.	O

Polyamides	B-T103
2	I-T103
and	I-T103
3	I-T103
contained	O
an	O
8	B-T103
-	I-T103
amino	I-T103
-	I-T103
3	I-T103
,	I-T103
6	I-T103
-	I-T103
dioxaoctanoic	I-T103
acid	I-T103
(	O
AO	B-T103
)	O
unit	O
,	O
which	O
has	O
previously	O
only	O
been	O
used	O
as	O
a	O
linker	B-T103
within	O
linear	O
Py	B-T103
-	I-T103
Im	I-T103
polyamides	I-T103
or	O
between	O
Py	B-T103
-	O
Im	B-T103
hairpin	O
motifs	O
for	O
tandem	O
hairpin	O
.	O

It	O
is	O
demonstrated	O
herein	O
that	O
AO	B-T103
also	O
functions	O
as	O
a	O
linker	B-T103
element	I-T103
that	O
can	O
extend	O
to	O
2	B-T082
-	I-T082
bp	I-T082
in	O
hairpin	O
motifs	O
.	O

Notably	O
,	O
although	O
the	O
AO	B-T103
-	O
containing	O
unit	O
can	O
fail	O
to	O
bind	O
the	O
expected	O
sequence	B-T082
,	O
polyamide	B-T103
4	I-T103
,	O
which	O
has	O
two	O
AO	B-T103
units	O
facing	O
each	O
other	O
in	O
a	O
hairpin	O
form	O
,	O
successfully	O
showed	O
the	O
expected	O
motif	O
and	O
a	O
KD	O
value	O
of	O
16nM	O
was	O
recorded	O
.	O

Polyamide	B-T103
5	I-T103
,	O
containing	O
a	O
β	B-T103
-	I-T103
alanine	I-T103
-	I-T103
β	I-T103
-	I-T103
alanine	I-T103
unit	O
instead	O
of	O
the	O
AO	B-T103
of	O
polyamide	B-T103
2	I-T103
,	O
was	O
synthesized	O
for	O
comparison	O
.	O

The	O
aqueous	O
solubilities	O
and	O
nuclear	B-T038
localization	I-T038
of	O
three	O
of	O
the	O
polyamides	B-T103
were	O
also	O
examined	O
.	O

The	O
results	O
suggest	O
the	O
possibility	O
of	O
applying	O
the	O
AO	B-T103
unit	O
in	O
the	O
core	B-T082
of	O
Py	B-T103
-	I-T103
Im	I-T103
polyamide	I-T103
compounds	I-T103
.	O

Causes	B-T033
of	I-T033
Death	I-T033
among	O
Children	O
Aged	O
5	O
to	O
14	O
Years	O
Old	O
from	O
2008	O
to	O
2013	O
in	O
Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
,	O
Ethiopia	B-T082

The	O
global	O
burden	O
of	O
mortality	O
among	O
children	O
is	O
still	O
very	O
huge	O
though	O
its	O
trend	O
has	O
started	O
declining	O
following	O
the	O
improvements	O
in	O
the	O
living	O
standard	O
.	O

It	O
presents	O
serious	O
challenges	B-T058
to	O
the	O
well	O
-	O
being	O
of	O
children	O
in	O
many	O
African	B-T082
countries	I-T082
.	O

Today	O
,	O
Sub	B-T082
-	I-T082
Saharan	I-T082
Africa	I-T082
alone	O
accounts	O
for	O
about	O
50	O
%	O
of	O
global	O
child	O
mortality	O
.	O

The	O
overall	O
objective	B-T170
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
magnitude	O
and	O
distribution	O
of	O
causes	B-T033
of	I-T033
death	I-T033
among	O
children	O
aged	O
5	O
to	O
14	O
year	O
olds	O
in	O
the	O
population	B-T098
of	O
Kersa	O
HDSS	O
using	O
verbal	O
autopsy	B-T058
method	O
for	O
the	O
period	O
2008	O
to	O
2013	O
.	O

Kersa	O
Health	O
and	O
Demographic	O
Surveillance	O
System	O
(	O
Kersa	O
HDSS	O
)	O
was	O
established	O
in	O
September	O
2007	O
.	O

The	O
center	O
consists	O
of	O
10	O
rural	O
and	O
2	O
urban	O
kebeles	B-T098
which	O
were	O
selected	O
randomly	O
from	O
38	O
kebeles	B-T098
in	O
the	O
district	B-T082
.	O

Thus	O
this	O
study	O
was	O
conducted	O
in	O
Kersa	O
HDSS	O
and	O
data	O
was	O
taken	O
from	O
Kersa	B-T170
HDSS	I-T170
database	I-T170
.	O

The	O
study	B-T062
population	B-T098
included	O
all	O
children	O
aged	O
5	O
to	O
14	O
years	O
registered	O
during	O
the	O
period	O
of	O
2008	O
to	O
2013	O
in	O
Kersa	O
HDSS	O
using	O
age	O
specific	O
VA	O
questionnaires	B-T170
.	O

Data	O
were	O
extracted	O
from	O
SPSS	B-T170
database	I-T170
and	O
analyzed	O
using	O
STATA	B-T170
.	O

A	O
total	O
of	O
229	O
deaths	B-T033
were	O
recorded	O
over	O
the	O
period	O
of	O
six	O
years	O
with	O
a	O
crude	O
death	O
rate	O
of	O
219	O
.	O
6	O
per	O
100	O
,	O
000	O
population	B-T098
of	O
this	O
age	O
group	O
over	O
the	O
study	B-T062
period	O
.	O

This	O
death	O
rate	O
was	O
217	O
.	O
5	O
and	O
221	O
.	O
5	O
per	O
100	O
,	O
000	O
populations	B-T098
for	O
females	O
and	O
males	O
,	O
respectively	O
.	O

75	O
%	O
of	O
deaths	B-T033
took	O
place	O
at	O
home	O
.	O

The	O
study	B-T062
identified	O
severe	O
malnutrition	B-T038
(	O
33	O
.	O
9	O
%	O
)	O
,	O
intestinal	B-T038
infectious	I-T038
diseases	I-T038
(	O
13	O
.	O
8	O
%	O
)	O
and	O
acute	B-T038
lower	I-T038
respiratory	I-T038
infections	I-T038
(	O
9	O
.	O
2	O
%	O
)	O
to	O
be	O
the	O
three	O
most	O
leading	O
causes	B-T033
of	I-T033
death	I-T033
.	O

In	O
broad	O
causes	B-T033
of	I-T033
death	I-T033
classification	B-T170
,	O
injuries	B-T037
have	O
been	O
found	O
to	O
be	O
the	O
second	O
most	O
cause	B-T033
of	I-T033
death	I-T033
next	O
to	O
communicable	B-T038
diseases	I-T038
(	O
56	O
.	O
3	O
%	O
)	O
attributing	O
to	O
13	O
.	O
1	O
%	O
of	O
the	O
total	O
deaths	B-T033
.	O

In	O
specific	O
causes	B-T033
of	I-T033
death	I-T033
classification	B-T170
severe	O
malnutrition	B-T038
,	O
intestinal	B-T038
infectious	I-T038
diseases	I-T038
and	O
acute	B-T038
lower	I-T038
respiratory	I-T038
infections	I-T038
were	O
the	O
three	O
leading	O
causes	B-T033
of	I-T033
death	I-T033
where	O
,	O
in	O
broad	O
causes	B-T033
of	I-T033
death	I-T033
communicable	B-T038
diseases	I-T038
and	O
injuries	B-T037
were	O
among	O
the	O
leading	O
causes	B-T033
of	I-T033
death	I-T033
.	O

Hence	O
,	O
concerned	O
bodies	O
should	O
take	O
measures	O
to	O
avert	O
the	O
situation	O
of	O
mortality	O
from	O
these	O
causes	B-T033
of	I-T033
death	I-T033
and	O
further	O
inferential	B-T062
analysis	I-T062
into	O
the	O
prevention	B-T058
and	O
management	B-T058
of	O
infectious	B-T038
diseases	I-T038
should	O
also	O
be	O
taken	O
.	O

Naïve	B-T017
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
derived	O
tumor	B-T038
-	O
specific	O
cytotoxic	B-T017
effectors	I-T017
as	O
a	O
potential	O
remedy	O
for	O
overcoming	O
TGF	B-T103
-	I-T103
β	I-T103
immunosuppression	B-T038
in	O
the	O
tumor	O
microenvironment	O

Despite	O
of	O
the	O
potential	O
implications	O
for	O
cancer	B-T058
immunotherapy	I-T058
,	O
conventional	O
approaches	O
using	O
in	O
vitro	O
expanded	B-T082
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
have	O
suboptimal	O
outcomes	O
,	O
mostly	O
due	O
to	O
loss	O
of	O
functionality	O
from	O
cellular	B-T017
exhaustion	O
.	O

We	O
therefore	O
investigated	O
the	O
phenotypic	O
and	O
functional	O
differences	O
among	O
in	O
vitro	O
activated	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
of	O
three	O
different	O
sources	B-T033
,	O
namely	O
naïve	B-T017
(	O
NTeff	B-T017
)	O
,	O
memory	B-T017
(	O
MTeff	B-T017
)	O
and	O
tumor	B-T017
-	I-T017
infiltrating	I-T017
lymphocytes	I-T017
(	O
TILeff	B-T017
)	O
from	O
human	B-T204
and	O
mice	B-T204
,	O
to	O
better	O
understand	O
mechanisms	O
behind	O
potent	O
effector	B-T017
functions	O
and	O
potential	O
for	O
overcoming	O
current	O
limitations	O
.	O

In	O
line	O
with	O
the	O
greater	O
proliferation	B-T038
activity	O
and	O
longer	O
telomere	B-T017
lengths	O
of	O
NTeff	B-T017
populations	I-T017
,	O
cells	B-T017
of	O
naïve	O
origin	O
exhibited	O
significantly	O
less	O
amounts	O
of	O
T	B-T017
cell	I-T017
exhaustion	O
markers	B-T201
than	O
those	O
of	O
MTeff	B-T017
and	O
TILeff	B-T017
,	O
and	O
moreover	O
,	O
acquired	O
distinct	O
expression	B-T038
patterns	I-T038
of	O
memory	B-T103
-	I-T103
promoting	I-T103
transcription	I-T103
factors	I-T103
,	O
T	B-T103
-	I-T103
bet	I-T103
and	O
Eomes	B-T103
,	O
induced	O
in	O
a	O
rapid	O
and	O
sustainable	O
manner	O
.	O

NTeff	B-T017
cells	I-T017
appeared	O
to	O
have	O
lower	O
expression	B-T038
of	O
Foxp1	B-T103
and	O
were	O
refractory	O
to	O
apoptosis	B-T038
upon	O
TGF	B-T103
-	I-T103
β	I-T103
conditioning	O
,	O
implying	O
better	O
survival	B-T038
potential	O
and	O
resistance	O
to	O
tumor	B-T038
-	O
induced	O
immune	B-T038
suppression	I-T038
.	O

Of	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
pools	O
activated	O
to	O
tumor	B-T038
-	O
specific	O
CTLs	B-T017
,	O
naïve	B-T017
cell	I-T017
generated	O
effectors	B-T017
possessed	O
the	O
most	O
potent	O
cytotoxic	B-T033
activity	I-T033
,	O
validating	O
implications	O
for	O
use	O
in	O
rational	O
design	O
of	O
adoptive	B-T058
immunotherapy	I-T058
.	O

Antiadipogenic	B-T033
Activity	I-T033
of	O
γ	B-T103
-	I-T103
Oryzanol	I-T103
and	O
Its	O
Stability	O
in	O
Pigmented	O
Rice	B-T168

γ	B-T103
-	I-T103
Oryzanol	I-T103
,	O
a	O
prevalent	O
compound	O
in	O
pigmented	O
rice	B-T168
varieties	O
,	O
has	O
been	O
reported	O
to	O
ameliorate	O
obesity	B-T038
-	I-T038
associated	I-T038
metabolic	I-T038
disorders	I-T038
.	O

Antiadipogenic	B-T033
activities	I-T033
of	O
γ	B-T103
-	I-T103
oryzanol	I-T103
were	O
determined	O
in	O
human	B-T204
adipose	B-T017
-	O
derived	O
mesenchymal	B-T017
stem	I-T017
cells	I-T017
and	O
mouse	B-T204
-	O
derived	O
3T3	B-T017
-	I-T017
L1	I-T017
cells	I-T017
.	O

γ	B-T103
-	I-T103
Oryzanol	I-T103
significantly	O
decreased	O
lipid	B-T033
accumulation	I-T033
and	O
reduced	O
glycerol	B-T038
-	I-T038
3	I-T038
-	I-T038
phosphate	I-T038
dehydrogenase	I-T038
activities	I-T038
in	O
both	O
adipocytes	B-T017
.	O

In	O
addition	O
,	O
γ	B-T103
-	I-T103
oryzanol	I-T103
in	O
four	O
pigmented	O
rice	B-T168
varieties	O
(	O
black	B-T168
with	I-T168
giant	I-T168
embryo	I-T168
,	O
brown	B-T168
,	O
sugary	B-T168
brown	I-T168
,	O
and	O
red	B-T168
)	O
was	O
stable	O
when	O
stored	O
at	O
4°C	O
and	O
also	O
at	O
room	O
temperature	O
for	O
22	O
weeks	O
,	O
whereas	O
other	O
bioactives	O
such	O
as	O
lutein	B-T103
and	O
β	B-T103
-	I-T103
carotene	I-T103
were	O
stable	O
only	O
at	O
-	O
80°C	O
.	O

Furthermore	O
,	O
the	O
yield	O
of	O
γ	B-T103
-	I-T103
oryzanol	I-T103
from	O
these	O
rice	B-T168
varieties	O
was	O
significantly	O
increased	O
through	O
steaming	O
and	O
roasting	O
processes	O
.	O

Therefore	O
,	O
γ	B-T103
-	I-T103
oryzanol	I-T103
exerts	O
antiadipogenic	B-T033
activity	I-T033
by	O
suppressing	O
adipocyte	B-T038
differentiations	I-T038
and	O
is	O
stable	O
in	O
pigmented	O
rice	B-T168
for	O
an	O
extended	O
period	O
of	O
time	O
during	O
storage	O
and	O
after	O
cooking	O
.	O

Thus	O
,	O
the	O
intake	O
of	O
pigmented	O
rice	B-T168
may	O
be	O
a	O
useful	O
strategy	O
for	O
preventing	O
obesity	B-T038
.	O

Impact	O
of	O
Chemotherapy	B-T058
on	O
Diet	B-T168
and	O
Nutritional	B-T033
Status	I-T033
of	O
Women	B-T098
with	O
Breast	B-T038
Cancer	I-T038
:	O
A	O
Prospective	B-T062
Study	I-T062

Certain	O
food	B-T168
groups	I-T168
are	O
often	O
rejected	O
during	O
chemotherapy	B-T058
(	O
CT	B-T058
)	O
due	O
to	O
the	O
side	B-T038
effects	I-T038
of	I-T038
treatment	I-T038
,	O
which	O
may	O
interfere	O
with	O
adequate	O
diet	O
and	O
nutritional	B-T033
status	I-T033
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
treatment	O
impact	O
on	O
the	O
diet	B-T168
and	O
nutritional	B-T033
status	I-T033
of	O
women	B-T098
with	O
breast	B-T038
cancer	I-T038
(	O
BC	B-T038
)	O
.	O

In	O
this	O
prospective	B-T062
longitudinal	I-T062
study	I-T062
,	O
conducted	O
in	O
2014	O
-	O
2015	O
,	O
55	O
women	B-T098
diagnosed	O
with	O
BC	B-T038
,	O
with	O
a	O
mean	O
age	O
51	O
.	O
5±10	O
.	O
1	O
years	O
,	O
were	O
followed	O
and	O
data	O
were	O
collected	O
at	O
three	O
different	O
times	O
.	O

Anthropometric	O
and	O
dietary	B-T058
assessments	I-T058
were	O
performed	O
,	O
the	O
latter	O
by	O
applying	O
nine	O
24h	O
dietary	B-T058
recall	I-T058
s	O
,	O
by	O
using	O
the	O
Brazilian	B-T170
Healthy	I-T170
Eating	I-T170
Index	I-T170
Revised	I-T170
(	O
BHEI	B-T170
-	I-T170
R	I-T170
)	O
,	O
and	O
calculating	O
the	O
prevalence	O
of	O
inadequacy	O
by	O
the	O
EAR	B-T170
cut	I-T170
-	I-T170
off	I-T170
point	I-T170
method	I-T170
.	O

Regarding	O
the	O
BHEI	B-T170
-	I-T170
R	I-T170
analysis	B-T062
,	O
the	O
majority	O
of	O
women	B-T098
had	O
a	O
"	O
diet	B-T168
requires	O
modification	B-T033
'	O
,	O
both	O
at	O
the	O
beginning	O
(	O
T0	O
,	O
58	O
.	O
2	O
%	O
,	O
n	O
=	O
32	O
)	O
and	O
during	O
treatment	O
(	O
T1	O
,	O
54	O
.	O
5	O
%	O
,	O
n	O
=	O
30	O
)	O
.	O

However	O
,	O
after	O
the	O
end	O
of	O
the	O
CT	B-T058
,	O
the	O
greater	O
percentage	O
of	O
patients	O
(	O
T2	O
,	O
49	O
.	O
1	O
%	O
,	O
n	O
=	O
27	O
)	O
were	O
classified	O
as	O
having	O
an	O
"	O
inadequate	B-T033
diet	I-T033
"	O
,	O
since	O
the	O
Total	O
Fruit	B-T168
consumption	O
as	O
well	O
as	O
the	O
Dark	B-T168
Green	I-T168
and	O
Orange	B-T168
Vegetable	I-T168
and	O
Legume	B-T204
consumption	O
decreased	O
significantly	O
during	O
treatment	O
(	O
p	O
=	O
0	O
.	O
043	O
and	O
p	O
=	O
0	O
.	O
026	O
,	O
respectively	O
)	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
the	O
intake	O
of	O
macro	O
and	O
micronutrients	B-T103
,	O
with	O
a	O
high	O
prevalence	O
of	O
inadequacy	O
,	O
of	O
up	O
to	O
100	O
%	O
,	O
for	O
calcium	B-T103
,	O
iron	B-T103
,	O
phosphorus	B-T103
,	O
magnesium	B-T103
,	O
niacin	B-T103
,	O
riboflavin	B-T103
,	O
thiamin	B-T103
,	O
vitamin	B-T103
B6	I-T103
,	O
vitamin	B-T103
C	I-T103
and	O
zinc	B-T103
.	O

Assessment	B-T058
of	O
the	O
nutritional	B-T033
status	I-T033
indicated	O
that	O
56	O
%	O
(	O
n	O
=	O
31	O
)	O
of	O
patients	O
were	O
overweight	B-T033
at	O
these	O
three	O
different	O
times	O
.	O

Weight	O
,	O
BMI	B-T201
and	O
Waist	B-T201
Circumference	I-T201
increased	O
significantly	O
,	O
indicating	O
a	O
worse	B-T033
nutritional	B-T033
status	I-T033
,	O
and	O
there	O
was	O
a	O
correlation	O
between	O
poor	O
diet	O
quality	O
and	O
higher	O
values	O
for	O
BMI	B-T201
,	O
Waist	O
-	O
Hip	O
Ratio	O
and	O
Waist	B-T033
-	I-T033
to	I-T033
-	I-T033
Height	I-T033
Ratio	I-T033
.	O

Chemotherapy	B-T058
interferes	O
in	O
the	O
patients	O
'	O
diet	B-T168
generating	O
a	O
negative	O
impact	O
on	O
the	O
quality	O
and	O
intake	O
of	O
micro	B-T103
and	O
macronutrients	O
,	O
as	O
well	O
as	O
an	O
impact	O
on	O
their	O
nutritional	B-T033
status	I-T033
,	O
with	O
an	O
increase	O
in	O
anthropometric	O
measurements	O
.	O

Benefit	O
and	O
risk	B-T058
in	O
short	O
term	O
after	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
by	O
direct	B-T082
anterior	I-T082
approach	I-T082
combined	O
with	O
dual	B-T074
mobility	I-T074
cup	I-T074

No	O
previous	O
reports	O
have	O
described	O
the	O
benefits	O
and	O
risks	B-T058
associated	O
with	O
the	O
dual	B-T074
mobility	I-T074
cup	I-T074
(	O
DMC	B-T074
)	O
in	O
primary	O
THA	B-T058
via	O
direct	B-T082
anterior	I-T082
approach	I-T082
(	O
DAA	B-T082
)	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	O
the	O
safety	B-T062
and	O
rate	O
of	O
early	O
postoperative	B-T038
complication	I-T038
of	O
the	O
DAA	B-T082
with	O
the	O
DMC	B-T074
for	O
THA	B-T058
with	O
those	O
of	O
the	O
DAA	B-T082
with	O
a	O
single	B-T074
standard	I-T074
cup	I-T074
,	O
and	O
to	O
investigate	O
the	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-T074
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O

We	O
retrospectively	O
investigated	O
60	O
hips	B-T017
treated	B-T058
in	O
the	O
single	O
-	O
DAA	B-T082
group	O
and	O
60	O
hips	B-T017
treated	B-T058
in	O
the	O
dual	O
-	O
DAA	B-T082
group	O
.	O

A	O
primary	O
/	O
secondary	O
outcome	O
variable	O
was	O
the	O
presence	O
of	O
any	O
intra	B-T038
-	O
or	O
perioperative	O
complication	B-T038
within	O
the	O
first	O
6	O
months	O
/	O
the	O
operative	O
time	O
and	O
hip	O
function	O
at	O
6	O
months	O
postoperatively	O
.	O

We	O
also	O
analyzed	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-T074
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O

No	B-T033
intraoperative	B-T038
complications	I-T038
were	O
observed	O
in	O
either	O
group	O
.	O

One	O
anterior	B-T037
dislocation	I-T037
and	O
one	O
periprosthetic	B-T037
hip	I-T037
fracture	I-T037
were	O
occurred	O
in	O
the	O
single	O
-	O
DAA	B-T082
group	O
.	O

The	O
surgical	O
times	O
in	O
the	O
single	O
-	O
DAA	B-T082
and	O
dual	O
-	O
DAA	B-T082
groups	O
were	O
112	O
.	O
0	O
±	O
20	O
.	O
9	O
and	O
121	O
.	O
0	O
±	O
26	O
.	O
9	O
min	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
6	O
-	O
month	O
postoperative	O
hip	O
function	O
scores	O
between	O
the	O
two	O
groups	O
.	O

There	O
was	O
no	O
influence	O
of	O
the	O
learning	O
curve	O
of	O
the	O
use	O
of	O
DMC	B-T074
on	O
intra	O
-	O
and	O
perioperative	O
outcomes	O
.	O

We	O
have	O
demonstrated	O
the	O
short	O
-	O
term	O
safety	B-T062
and	O
lack	O
of	O
inferiority	O
of	O
using	O
the	O
DMC	B-T074
in	O
the	O
DAA	B-T082
compared	O
with	O
the	O
standard	B-T074
single	I-T074
mobility	I-T074
cup	I-T074
.	O

Diffuse	B-T037
traumatic	I-T037
brain	I-T037
injury	I-T037
affects	O
chronic	O
corticosterone	B-T103
function	O
in	O
the	O
rat	B-T204

As	O
many	O
as	O
20	O
-	O
55	O
%	O
of	O
patients	O
with	O
a	O
history	B-T033
of	O
traumatic	B-T037
brain	I-T037
injury	I-T037
(	O
TBI	B-T037
)	O
experience	O
chronic	O
endocrine	O
dysfunction	O
,	O
leading	O
to	O
impaired	O
quality	O
of	O
life	O
,	O
impaired	O
rehabilitation	O
efforts	O
and	O
lowered	B-T033
life	I-T033
expectancy	I-T033
.	O

Endocrine	O
dysfunction	O
after	O
TBI	B-T037
is	O
thought	O
to	O
result	O
from	O
acceleration	O
-	O
deceleration	O
forces	O
to	O
the	O
brain	B-T017
within	O
the	O
skull	B-T017
,	O
creating	O
enduring	O
hypothalamic	B-T017
and	O
pituitary	B-T017
neuropathology	B-T038
,	O
and	O
subsequent	O
hypothalamic	B-T022
-	I-T022
pituitary	I-T022
endocrine	I-T022
(	O
HPE	B-T022
)	O
dysfunction	B-T038
.	O

These	O
experiments	B-T062
were	O
designed	O
to	O
test	O
the	O
hypothesis	O
that	O
a	O
single	O
diffuse	B-T037
TBI	I-T037
results	O
in	O
chronic	O
dysfunction	B-T038
of	O
corticosterone	B-T103
(	O
CORT	B-T103
)	O
,	O
a	O
glucocorticoid	B-T103
released	O
in	O
response	O
to	O
stress	B-T038
and	O
testosterone	B-T103
.	O

We	O
used	O
a	O
rodent	B-T038
model	I-T038
of	O
diffuse	B-T037
TBI	I-T037
induced	O
by	O
midline	B-T037
fluid	I-T037
percussion	I-T037
injury	I-T037
(	O
mFPI	B-T037
)	O
.	O

At	O
2	O
months	O
postinjury	O
compared	O
with	O
uninjured	B-T204
control	I-T204
animals	I-T204
,	O
circulating	O
levels	O
of	O
CORT	B-T103
were	O
evaluated	O
at	O
rest	O
,	O
under	O
restraint	B-T038
stress	I-T038
and	O
in	O
response	O
to	O
dexamethasone	B-T103
,	O
a	O
synthetic	B-T103
glucocorticoid	I-T103
commonly	O
used	O
to	O
test	O
HPE	B-T022
axis	B-T082
regulation	B-T038
.	O

Testosterone	B-T103
was	O
evaluated	O
at	O
rest	O
.	O

Further	O
,	O
we	O
assessed	O
changes	O
in	O
injury	B-T037
-	O
induced	O
neuron	B-T017
morphology	O
(	O
Golgi	B-T058
stain	I-T058
)	O
,	O
neuropathology	B-T038
(	O
silver	B-T058
stain	I-T058
)	O
and	O
activated	B-T038
astrocytes	B-T017
(	O
GFAP	B-T058
)	O
in	O
the	O
paraventricular	B-T017
nucleus	I-T017
(	O
PVN	B-T017
)	O
of	O
the	O
hypothalamus	B-T017
.	O

Resting	O
plasma	B-T031
CORT	B-T103
levels	O
were	O
decreased	O
at	O
2	O
months	O
postinjury	O
and	O
there	O
was	O
a	O
blunted	O
CORT	B-T103
increase	O
in	O
response	O
to	O
restraint	B-T038
induced	I-T038
stress	I-T038
.	O

No	B-T033
changes	I-T033
in	O
testosterone	B-T103
were	O
measured	O
.	O

These	O
changes	O
in	O
CORT	B-T103
were	O
observed	O
concomitantly	O
with	O
altered	O
complexity	O
of	O
neuron	B-T017
processes	B-T038
in	O
the	O
PVN	B-T017
over	O
time	O
,	O
devoid	O
of	O
neuropathology	B-T038
or	O
astrocytosis	B-T038
.	O

Results	O
provide	O
evidence	O
that	O
a	O
single	O
moderate	O
diffuse	B-T037
TBI	I-T037
leads	O
to	O
changes	O
in	O
CORT	B-T103
function	O
,	O
which	O
can	O
contribute	O
to	O
the	O
persistence	O
of	O
symptoms	O
related	O
to	O
endocrine	O
dysfunction	O
.	O

Future	O
experiments	B-T062
aim	O
to	O
evaluate	O
additional	O
HP	B-T103
-	I-T103
related	I-T103
hormones	I-T103
and	O
endocrine	B-T022
circuit	O
pathology	O
following	O
diffuse	B-T037
TBI	I-T037
.	O

Methamphetamine	B-T103
,	O
3	B-T103
,	I-T103
4	I-T103
-	I-T103
methylenedioxymethamphetamine	I-T103
(	O
MDMA	B-T103
)	O
and	O
3	B-T103
,	I-T103
4	I-T103
-	I-T103
methylenedioxypyrovalerone	I-T103
(	O
MDPV	B-T103
)	O
induce	O
differential	O
cytotoxic	B-T038
effects	I-T038
in	O
bovine	B-T204
brain	B-T017
microvessel	B-T017
endothelial	B-T017
cells	I-T017

Designer	B-T103
drugs	I-T103
such	O
as	O
synthetic	B-T103
psychostimulants	I-T103
are	O
indicative	O
of	O
a	O
worldwide	O
problem	B-T033
of	O
drug	B-T038
abuse	I-T038
and	O
addiction	B-T038
.	O

In	O
addition	O
to	O
methamphetamine	B-T103
(	O
METH	B-T103
)	O
,	O
these	O
drugs	B-T103
include	O
3	B-T103
,	I-T103
4	I-T103
-	I-T103
methylenedioxy	I-T103
-	I-T103
methamphetamine	I-T103
(	O
MDMA	B-T103
)	O
and	O
commercial	B-T170
preparations	O
of	O
synthetic	B-T103
cathinones	I-T103
including	O
3	B-T103
,	I-T103
4	I-T103
-	I-T103
methylenedioxypyrovalerone	I-T103
(	O
MDPV	B-T103
)	O
,	O
typically	O
referred	O
to	O
as	O
"	O
bath	B-T103
salts	I-T103
.	O
"	O
These	O
psychostimulants	B-T103
exert	O
neurotoxic	B-T037
effects	I-T037
by	O
altering	O
monoamine	O
systems	O
in	O
the	O
brain	B-T017
.	O

Additionally	O
,	O
METH	B-T103
and	O
MDMA	B-T103
adversely	B-T038
affect	I-T038
the	O
integrity	O
of	O
the	O
blood	B-T017
-	I-T017
brain	I-T017
barrier	I-T017
(	O
BBB	B-T017
)	O
:	O
there	O
are	O
no	O
current	O
reports	B-T170
on	O
the	O
effects	O
of	O
MDPV	B-T103
on	O
the	O
BBB	B-T017
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	O
the	O
effects	O
of	O
METH	B-T103
,	O
MDMA	B-T103
and	O
MDPV	B-T103
on	O
bovine	B-T204
brain	B-T017
microvessel	B-T017
endothelial	B-T017
cells	I-T017
(	O
bBMVECs	B-T017
)	O
,	O
an	O
accepted	O
in	B-T062
vitro	I-T062
model	I-T062
of	O
the	O
BBB	B-T017
.	O

Confluent	O
bBMVEC	B-T017
monolayers	B-T017
were	O
treated	O
with	O
METH	B-T103
,	O
MDMA	B-T103
and	O
MDPV	B-T103
(	O
0	O
.	O
5mM	O
-	O
2	O
.	O
5mM	O
)	O
for	O
24h	O
.	O

METH	B-T103
and	O
MDMA	B-T103
increased	O
lactate	B-T103
dehydrogenase	I-T103
release	O
only	O
at	O
the	O
highest	O
concentration	O
(	O
2	O
.	O
5mM	O
)	O
,	O
whereas	O
MDPV	B-T103
induced	O
cytotoxicity	B-T038
at	O
all	O
concentration	O
s	O
.	O

MDMA	B-T103
and	O
METH	B-T103
decreased	O
cellular	B-T038
proliferation	I-T038
only	O
at	O
2	O
.	O
5mM	O
,	O
with	O
similar	O
effects	O
observed	O
after	O
MDPV	B-T103
exposures	O
starting	O
at	O
1mM	O
.	O

Only	O
MDPV	B-T103
increased	O
reactive	B-T103
oxygen	I-T103
species	I-T103
production	O
at	O
all	O
concentrations	O
tested	O
whereas	O
all	O
3	O
drugs	B-T103
increased	O
nitric	B-T103
oxide	I-T103
production	O
.	O

Morphological	B-T062
analysis	I-T062
revealed	O
different	O
patterns	O
of	O
compound	B-T103
-	O
induced	O
cell	O
damage	O
.	O

METH	B-T103
induced	O
vacuole	B-T017
formatio	O
n	O
at	O
1mM	O
and	O
disruption	O
of	O
the	O
monolayer	B-T017
at	O
2	O
.	O
5mM	O
.	O

MDMA	B-T103
induced	O
disruption	O
of	O
the	O
endothelial	B-T017
monolayer	B-T017
from	O
1mM	O
without	O
vacuolization	B-T033
.	O

On	O
the	O
other	O
hand	O
,	O
MDPV	B-T103
induced	O
monolayer	B-T017
disruption	O
at	O
doses	O
≥0	O
.	O
5mM	O
without	O
vacuole	B-T017
formation	O
;	O
at	O
2	O
.	O
5mM	O
,	O
the	O
few	O
remaining	O
cells	B-T017
lacked	O
endothelial	O
morphology	O
.	O

These	O
data	O
suggest	O
that	O
even	O
though	O
these	O
synthetic	B-T103
psychostimulants	I-T103
alter	O
monoaminergic	O
systems	O
,	O
they	O
each	O
induce	O
BBB	B-T017
toxicity	B-T037
by	O
different	O
mechanisms	O
with	O
MDPV	B-T103
being	O
the	O
most	O
toxic	O
.	O

Alleviation	O
of	O
hepatic	B-T082
fat	B-T033
accumulation	I-T033
by	O
betaine	B-T103
involves	O
reduction	O
of	O
homocysteine	B-T103
via	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
betaine	B-T103
-	I-T103
homocysteine	I-T103
methyltransferase	I-T103
(	O
BHMT	B-T103
)	O

We	O
investigated	O
the	O
anti	O
-	O
lipogenic	O
effect	O
of	O
betaine	B-T103
in	O
rats	B-T204
fed	O
methionine	B-T103
and	O
choline	B-T103
-	O
deficient	O
diet	B-T168
(	O
MCD	B-T168
)	O
.	O

Intake	O
of	O
MCD	B-T168
for	O
3	O
wk	O
resulted	O
in	O
a	O
significant	O
accumulation	B-T033
of	O
hepatic	B-T082
lipids	B-T103
,	O
which	O
was	O
prevented	O
by	O
betaine	B-T103
supplementation	B-T058
in	O
drinking	O
water	O
(	O
1	O
%	O
)	O
.	O

Phosphorylation	B-T038
of	O
AMP	B-T103
-	I-T103
activated	I-T103
protein	I-T103
kinase	I-T103
(	O
AMPK	B-T103
)	O
,	O
acetyl	B-T103
-	I-T103
CoA	I-T103
carboxylase	I-T103
(	O
ACC	B-T103
)	O
,	O
sterol	B-T103
regulatory	I-T103
element	I-T103
-	I-T103
binding	I-T103
protein	I-T103
1c	I-T103
(	O
SREBP	B-T103
-	I-T103
1c	I-T103
)	O
,	O
and	O
liver	B-T103
kinase	I-T103
B1	I-T103
(	O
LKB1	B-T103
)	O
was	O
inhibited	O
by	O
MCD	B-T168
intake	O
,	O
and	O
these	O
changes	O
were	O
all	O
inhibited	O
by	O
betaine	B-T103
feeding	B-T058
.	O

Meanwhile	O
,	O
betaine	B-T103
supplementation	B-T058
reversed	O
the	O
reduction	O
of	O
methionine	B-T038
and	I-T038
S	I-T038
-	I-T038
adenosylmethionine	I-T038
(	O
SAM	B-T038
)	O
,	O
and	O
the	O
elevation	O
of	O
homocysteine	B-T058
levels	I-T058
in	O
the	O
liver	B-T017
,	I-T017
which	O
could	O
be	O
attributable	O
to	O
the	O
induction	B-T038
of	O
betaine	B-T103
-	I-T103
homocysteine	I-T103
methyltransfease	I-T103
(	O
BHMT	B-T103
)	O
and	O
methionine	B-T103
adenosyltransferase	I-T103
(	O
MAT	B-T103
)	O
.	O

Different	O
cell	B-T017
lines	I-T017
were	O
used	O
to	O
clarify	O
the	O
role	O
of	O
homocysteine	B-T103
on	O
activation	B-T038
of	O
the	O
AMPK	B-T103
pathway	O
.	O

Homocysteine	B-T103
treatment	O
decreased	O
pAMPK	B-T103
,	O
pACC	B-T103
,	O
pSREBP	B-T103
-	I-T103
1c	I-T103
and	O
pLKB1	B-T103
in	O
HepG2	B-T017
cells	I-T017
.	O

Metformin	B-T103
-	O
induced	O
activation	B-T038
of	O
AMPK	B-T103
was	O
also	O
inhibited	O
by	O
homocysteine	B-T103
.	O

Treatment	O
with	O
hydroxylamine	B-T103
,	O
a	O
cystathionine	B-T103
β	I-T103
-	I-T103
synthase	I-T103
inhibitor	B-T103
,	O
resulted	O
in	O
a	O
reduction	O
of	O
pAMPK	B-T103
,	O
pACC	B-T103
and	O
pSREBP	B-T103
-	I-T103
1c	I-T103
,	O
accompanied	O
by	O
an	O
elevation	O
of	O
intracellular	B-T082
homocysteine	B-T103
.	O

Betaine	B-T103
treatment	B-T058
prevented	O
the	O
homocysteine	B-T103
-	O
induced	O
reduction	O
of	O
pAMPK	B-T103
,	O
pACC	B-T103
,	O
pSREBP	B-T103
-	I-T103
1c	I-T103
and	O
pLKB1	B-T103
in	O
H4IIE	B-T017
cells	I-T017
,	O
but	O
not	O
in	O
HepG2	B-T017
cells	I-T017
.	O

Also	O
the	O
elevation	O
of	O
cellular	O
homocysteine	B-T103
and	O
inhibition	O
of	O
protein	B-T038
expression	I-T038
of	O
BHMT	B-T103
were	O
prevented	O
by	O
betaine	B-T103
only	O
in	O
H4IIE	B-T017
cells	I-T017
which	O
express	B-T038
BHMT	B-T103
.	O

The	O
results	O
suggest	O
that	O
the	O
beneficial	O
effect	O
of	O
betaine	B-T103
against	O
hepatic	B-T082
lipid	B-T103
accumulation	B-T033
may	O
be	O
attributed	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
the	O
depletion	O
of	O
homocysteine	B-T103
via	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
BHMT	B-T103
in	O
hepatocytes	B-T017
.	O

Dual	B-T058
-	I-T058
color	I-T058
STED	I-T058
microscopy	I-T058
reveals	O
a	O
sandwich	B-T082
structure	I-T082
of	O
Bassoon	B-T103
and	O
Piccolo	B-T103
in	O
active	B-T017
zones	I-T017
of	O
adult	O
and	O
aged	O
mice	B-T204

Presynaptic	B-T017
active	I-T017
zones	I-T017
play	O
a	O
pivotal	O
role	O
as	O
synaptic	B-T017
vesicle	I-T017
release	B-T082
sites	I-T082
for	O
synaptic	B-T038
transmission	I-T038
,	O
but	O
the	O
molecular	O
architecture	O
of	O
active	B-T017
zones	I-T017
in	O
mammalian	B-T204
neuromuscular	B-T017
junctions	I-T017
(	O
NMJs	B-T017
)	O
at	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
remains	O
unknown	O
.	O

Bassoon	B-T103
and	O
Piccolo	B-T103
are	O
active	B-T017
zone	I-T017
specific	O
cytosolic	B-T017
proteins	B-T103
essential	O
for	O
active	B-T038
zone	I-T038
assembly	I-T038
in	O
NMJs	B-T017
,	O
ribbon	B-T082
synapses	I-T082
,	O
and	O
brain	B-T017
synapses	B-T082
.	O

These	O
proteins	B-T103
are	O
thought	O
to	O
colocalize	B-T082
and	O
share	O
some	O
functions	O
at	O
active	B-T017
zones	I-T017
.	O

Here	O
,	O
we	O
report	O
an	O
unexpected	O
finding	O
of	O
non	B-T038
-	I-T038
overlapping	I-T038
localization	I-T038
of	O
these	O
two	O
proteins	B-T103
in	O
mouse	B-T204
NMJs	B-T017
revealed	O
using	O
dual	O
-	O
color	O
stimulated	O
emission	O
depletion	O
(	O
STED	O
)	O
super	B-T058
resolution	I-T058
microscopy	I-T058
.	O

Piccolo	B-T103
puncta	B-T033
sandwiched	O
Bassoon	B-T103
puncta	B-T033
and	O
aligned	O
in	O
a	O
Piccolo	B-T103
-	O
Bassoon	B-T103
-	O
Piccolo	B-T103
structure	B-T082
in	O
adult	O
NMJs	B-T017
.	O

P	O
/	O
Q	O
-	O
type	O
voltage	O
-	O
gated	O
calcium	O
channel	O
(	O
VGCC	O
)	O
puncta	B-T033
colocalized	B-T082
with	O
Bassoon	B-T103
puncta	B-T033
.	O

The	O
P	O
/	O
Q	O
-	O
type	O
VGCC	O
and	O
Bassoon	B-T103
protein	B-T033
levels	I-T033
decreased	O
significantly	O
in	O
NMJs	B-T017
from	O
aged	O
mouse	B-T204
.	O

In	O
contrast	O
,	O
the	O
Piccolo	B-T103
levels	B-T033
in	O
NMJs	B-T017
from	O
aged	O
mice	B-T204
were	O
comparable	O
to	O
levels	B-T033
in	O
adult	O
mice	B-T204
.	O

This	O
study	O
revealed	O
the	O
molecular	O
architecture	O
of	O
active	B-T017
zones	I-T017
in	O
mouse	B-T204
NMJs	B-T017
at	O
sub	O
-	O
diffraction	O
limited	O
resolution	O
,	O
and	O
described	O
the	O
selective	B-T038
degeneration	I-T038
mechanism	I-T038
of	O
active	B-T017
zone	I-T017
proteins	B-T103
in	O
NMJs	B-T017
from	O
aged	O
mice	B-T204
.	O

Interestingly	O
,	O
the	O
localization	B-T038
pattern	I-T038
of	O
active	B-T017
zone	I-T017
proteins	B-T103
described	O
herein	O
is	O
similar	O
to	O
active	B-T017
zone	I-T017
structures	B-T082
described	O
using	O
electron	B-T058
microscope	I-T058
tomography	I-T058
.	O

Molecular	O
serum	B-T031
signature	B-T201
of	O
treatment	B-T038
resistant	I-T038
depression	I-T038

A	O
substantial	O
number	O
of	O
patients	O
suffering	O
from	O
major	B-T038
depressive	I-T038
disorder	I-T038
(	O
MDD	B-T038
)	O
do	O
not	O
respond	O
to	O
multiple	O
trials	B-T062
of	O
anti	B-T103
-	I-T103
depressants	I-T103
,	O
develop	O
a	O
chronic	O
course	B-T038
of	I-T038
disease	I-T038
and	O
become	O
treatment	B-T058
resistant	B-T038
.	O

Most	O
of	O
the	O
studies	O
investigating	O
molecular	O
changes	O
in	O
treatment	B-T038
-	I-T038
resistant	I-T038
depression	I-T038
(	O
TRD	B-T038
)	O
have	O
only	O
examined	O
a	O
limited	O
number	O
of	O
molecules	O
and	O
genes	B-T017
.	O

Consequently	O
,	O
biomarkers	B-T201
associated	O
with	O
TRD	B-T038
are	O
still	O
lacking	O
.	O

This	O
study	O
aimed	O
to	O
use	O
recently	O
advanced	O
high	B-T091
-	I-T091
throughput	I-T091
proteomic	I-T091
platforms	I-T091
to	O
identify	O
peripheral	B-T082
biomarkers	B-T201
of	O
TRD	B-T038
defined	O
by	O
two	O
staging	B-T170
models	I-T170
,	O
the	O
Thase	B-T170
and	I-T170
Rush	I-T170
staging	I-T170
model	I-T170
(	O
TRM	B-T170
)	O
and	O
the	O
Maudsley	B-T170
Staging	I-T170
Model	I-T170
(	O
MSM	B-T170
)	O
.	O

Serum	B-T031
collected	O
from	O
an	O
inpatient	O
cohort	O
of	O
65	O
individuals	B-T098
suffering	O
from	O
MDD	B-T038
was	O
analysed	O
using	O
two	O
different	O
mass	B-T058
spectrometric	I-T058
-	I-T058
based	I-T058
platforms	I-T058
,	O
label	B-T058
-	I-T058
free	I-T058
liquid	I-T058
chromatography	I-T058
mass	I-T058
spectrometry	I-T058
(	O
LC	B-T058
-	I-T058
MS	I-T058
(	I-T058
E	I-T058
)	I-T058
)	O
and	O
selective	O
reaction	O
monitoring	O
(	O
SRM	O
)	O
,	O
as	O
well	O
as	O
a	O
multiplex	B-T058
bead	I-T058
based	I-T058
assay	I-T058
.	O

In	O
the	O
LC	B-T058
-	I-T058
MS	I-T058
(	I-T058
E	I-T058
)	I-T058
analysis	I-T058
,	O
proteins	B-T103
involved	O
in	O
the	O
acute	B-T038
phase	I-T038
response	I-T038
and	O
complement	B-T038
activation	I-T038
and	O
coagulation	B-T038
were	O
significantly	O
different	O
between	O
the	O
staging	B-T170
groups	I-T170
in	O
both	O
models	B-T170
.	O

In	O
the	O
multiplex	B-T058
bead	I-T058
-	I-T058
based	I-T058
assay	I-T058
analysis	O
TNF	B-T058
-	I-T058
α	I-T058
levels	I-T058
(	O
log	O
(	O
odds	O
)	O
=	O
-	O
4	O
.	O
95	O
,	O
p	O
=	O
0	O
.	O
045	O
)	O
were	O
significantly	O
different	O
in	O
the	O
TRM	B-T170
comparison	O
.	O

Using	O
SRM	O
,	O
significant	O
changes	O
of	O
three	O
apolipoproteins	B-T103
A	I-T103
-	I-T103
I	I-T103
(	O
β	O
=	O
0	O
.	O
029	O
,	O
p	O
=	O
0	O
.	O
035	O
)	O
,	O
M	B-T103
(	O
β	O
=	O
-	O
0	O
.	O
017	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
F	B-T103
(	O
β	O
=	O
-	O
0	O
.	O
031	O
,	O
p	O
=	O
0	O
.	O
024	O
)	O
were	O
associated	O
with	O
the	O
TRM	B-T170
but	O
not	O
the	O
MSM	B-T170
.	O

Overall	O
,	O
our	O
findings	B-T033
suggest	O
that	O
proteins	B-T103
,	O
which	O
are	O
involved	O
in	O
immune	B-T038
and	O
complement	B-T038
activation	I-T038
,	O
may	O
represent	O
potential	O
biomarkers	B-T201
that	O
could	O
be	O
used	O
by	O
clinicians	B-T097
to	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
.	O

Nevertheless	O
,	O
given	O
that	O
the	O
molecular	O
changes	O
between	O
the	O
staging	B-T170
groups	I-T170
were	O
subtle	O
,	O
the	O
results	O
need	O
to	O
be	O
interpreted	O
cautiously	O
.	O

Benchmark	O
study	B-T062
on	O
fine	O
-	O
mode	O
aerosol	O
in	O
a	O
big	O
urban	O
area	O
and	O
relevant	O
doses	O
deposited	O
in	O
the	O
human	B-T204
respiratory	B-T017
tract	I-T017

It	O
is	O
well	O
-	O
known	O
that	O
the	O
health	O
effects	O
of	O
PM	B-T103
increase	O
as	O
particle	O
size	O
decreases	O
:	O
particularly	O
,	O
great	O
concern	O
has	O
risen	O
on	O
the	O
role	O
of	O
UltraFine	B-T103
Particles	I-T103
(	O
UFPs	B-T103
)	O
.	O

Starting	O
from	O
the	O
knowledge	O
that	O
the	O
main	O
fraction	O
of	O
atmospheric	O
aerosol	O
in	O
Rome	B-T082
is	O
characterized	O
by	O
significant	O
levels	O
of	O
PM2	B-T103
.	I-T103
5	I-T103
(	O
almost	O
75	O
%	O
of	O
PM10	B-T103
fraction	O
is	O
PM2	B-T103
.	I-T103
5	I-T103
)	O
,	O
the	O
paper	O
is	O
focused	O
on	O
submicron	B-T103
particles	I-T103
in	O
such	O
great	O
urban	O
area	O
.	O

The	O
daytime	O
/	O
nighttime	O
,	O
work	O
-	O
/	O
weekdays	O
and	O
cold	O
/	O
hot	O
seasonal	O
trends	O
of	O
submicron	B-T103
particles	I-T103
will	O
be	O
investigated	O
and	O
discussed	O
along	O
with	O
NOx	B-T103
and	O
total	O
PAH	B-T103
drifts	O
demonstrating	O
the	O
primary	O
origin	O
of	O
UFPs	B-T103
from	O
combustion	O
processes	O
.	O

Furthermore	O
,	O
moving	O
from	O
these	O
data	O
,	O
the	O
total	O
dose	O
of	O
submicron	B-T103
particles	I-T103
deposited	O
in	O
the	O
respiratory	B-T022
system	I-T022
(	O
i	O
.	O
e	O
.	O
,	O
head	B-T082
,	O
tracheobronchial	B-T017
and	O
alveolar	B-T017
regions	I-T017
in	O
different	O
lung	B-T017
lobes	I-T017
)	O
has	O
been	O
estimated	O
.	O

Dosimeter	B-T074
estimates	O
were	O
performed	O
with	O
the	O
Multiple	B-T170
-	I-T170
Path	I-T170
Particle	I-T170
Dosimetry	I-T170
model	I-T170
(	O
MPPD	B-T170
v	I-T170
.	I-T170
2	I-T170
.	I-T170
1	I-T170
)	O
.	O

The	O
paper	O
discusses	O
the	O
aerosol	O
doses	O
deposited	O
in	O
the	O
respiratory	B-T022
system	I-T022
of	O
individuals	B-T098
exposed	O
in	O
proximity	O
of	O
traffic	O
.	O

During	O
traffic	O
peak	O
hours	O
,	O
about	O
6	O
.	O
6	O
×	O
10	O
(	O
10	O
)	O
particles	B-T103
are	O
deposited	O
into	O
the	O
respiratory	B-T022
system	I-T022
.	O

Such	O
dose	O
is	O
almost	O
entirely	O
made	O
of	O
UFPs	B-T103
.	O

According	O
to	O
the	O
greater	O
dose	O
estimated	O
,	O
right	B-T017
lung	I-T017
lobes	I-T017
are	O
expected	O
to	O
be	O
more	O
susceptible	O
to	O
respiratory	O
pathologies	B-T038
than	O
left	B-T017
lobes	I-T017
.	O

International	B-T170
Liver	I-T170
Transplant	I-T170
Society	I-T170
Practice	I-T170
Guidelines	I-T170
:	O
Diagnosis	B-T033
and	O
Management	B-T058
of	O
Hepatopulmonary	B-T038
Syndrome	I-T038
and	O
Portopulmonary	B-T038
Hypertension	I-T038

Two	O
distinct	O
pulmonary	B-T038
vascular	I-T038
disorders	I-T038
,	O
hepatopulmonary	B-T038
syndrome	I-T038
(	O
HPS	B-T038
)	O
and	O
portopulmonary	B-T038
hypertension	I-T038
(	O
POPH	B-T038
)	O
may	O
occur	O
as	O
a	O
consequence	O
of	O
hepatic	B-T017
parenchymal	I-T017
or	O
vascular	B-T033
abnormalities	I-T033
.	O

HPS	B-T038
and	O
POPH	B-T038
have	O
major	O
clinical	O
implications	B-T033
for	O
liver	B-T058
transplantation	I-T058
.	O

A	O
European	O
Respiratory	O
Society	O
Task	O
Force	O
on	O
Pulmonary	B-T038
-	I-T038
Hepatic	I-T038
Disorders	I-T038
convened	O
in	O
2002	O
to	O
standardize	O
the	O
diagnosis	B-T033
and	O
guide	B-T170
management	I-T170
of	O
these	O
disorders	B-T038
.	O

These	O
International	B-T170
Liver	I-T170
Transplant	I-T170
Society	I-T170
diagnostic	I-T170
and	I-T170
management	I-T170
guidelines	I-T170
are	O
based	O
on	O
that	O
task	O
force	O
consensus	O
and	O
should	O
continue	O
to	O
evolve	O
as	O
clinical	O
experience	O
dictates	O
.	O

Based	O
on	O
a	O
review	O
of	O
over	O
1000	O
published	O
HPS	B-T038
and	O
POPH	B-T038
articles	O
identified	O
via	O
a	O
MEDLINE	B-T170
search	I-T170
(	O
1985	O
-	O
2015	O
)	O
,	O
clinical	B-T170
guidelines	I-T170
were	O
based	O
on	O
,	O
selected	B-T058
single	I-T058
care	I-T058
reports	I-T058
,	O
small	O
series	O
,	O
registries	B-T170
,	O
databases	B-T170
,	O
and	O
expert	O
opinion	O
.	O

The	O
paucity	O
of	O
randomized	B-T062
,	I-T062
controlled	I-T062
trials	I-T062
in	O
either	O
of	O
these	O
disorders	B-T038
was	O
noted	O
.	O

Guidelines	B-T170
are	O
presented	O
in	O
5	O
parts	O
;	O
I	O
.	O

Definitions	O
/	O
Diagnostic	B-T170
criteria	I-T170
;	O
II	O
.	O

Hepatopulmonary	B-T038
syndrome	I-T038
;	O
III	O
.	O

Portopulmonary	B-T038
hypertension	I-T038
;	O
IV	O
.	O

Implications	B-T033
for	O
liver	B-T058
transplantation	I-T058
;	O
and	O
V	O
.	O

Suggestions	O
for	O
future	O
clinical	B-T062
research	I-T062
.	O

Uveitis	B-T038
in	O
children	O

The	O
review	O
provides	O
updates	O
on	O
novel	O
risk	O
markers	O
for	O
the	O
development	O
of	O
pediatric	O
inflammatory	B-T038
uveitis	I-T038
and	O
a	O
severe	B-T038
disease	I-T038
course	I-T038
,	O
on	O
treatment	B-T058
of	O
refractory	B-T033
disease	I-T033
,	O
and	O
on	O
the	O
measurement	O
of	O
visual	O
outcomes	O
.	O

There	O
are	O
several	O
new	O
genetic	B-T038
markers	I-T038
,	O
biomarkers	B-T201
,	O
and	O
clinical	O
factors	O
that	O
may	O
influence	O
a	O
child	O
'	O
s	O
uveitis	B-T038
disease	B-T038
course	I-T038
.	O

It	O
is	O
important	O
to	O
identify	O
children	O
at	O
risk	O
for	O
poor	O
visual	O
outcomes	O
and	O
who	O
are	O
refractory	O
to	O
traditional	B-T058
therapy	I-T058
.	O

Racial	B-T033
disparities	I-T033
have	O
recently	O
been	O
reported	B-T170
.	O

We	O
describe	O
agents	B-T103
of	O
potential	O
benefit	O
.	O

In	O
addition	O
,	O
we	O
discuss	O
the	O
importance	O
of	O
patient	B-T170
reported	I-T170
outcomes	I-T170
in	O
this	O
population	O
.	O

Uveitis	B-T038
can	O
lead	O
to	O
vision	B-T038
-	I-T038
threatening	I-T038
complications	I-T038
.	O

Timely	B-T058
and	I-T058
aggressive	I-T058
treatment	I-T058
of	O
children	O
identified	O
to	O
be	O
at	O
risk	O
for	O
a	O
severe	B-T038
uveitis	I-T038
course	I-T038
may	O
lead	O
to	O
improved	O
outcomes	O
.	O

Utility	O
of	O
a	O
mHealth	B-T170
App	I-T170
for	O
Self	B-T058
-	I-T058
Management	I-T058
and	O
Education	O
of	O
Cardiac	B-T038
Diseases	I-T038
in	O
Spanish	B-T082
Urban	B-T082
and	I-T082
Rural	I-T082
Areas	I-T082

Analyze	B-T062
the	O
utility	O
of	O
a	O
mobile	B-T170
health	I-T170
app	I-T170
named	O
HeartKeeper	B-T170
in	O
several	B-T098
groups	I-T098
of	I-T098
population	I-T098
and	O
obtain	O
conclusions	O
to	O
be	O
applied	O
to	O
other	B-T170
similar	I-T170
apps	I-T170
.	O

A	O
questionnaire	B-T170
has	O
been	O
designed	O
to	O
evaluate	O
the	O
usage	O
and	O
utility	O
of	O
the	O
HeartKeeper	B-T170
app	I-T170
.	O

The	O
questionnaire	B-T170
information	O
was	O
collected	O
by	O
collaborating	O
cardiologists	B-T097
from	O
32	O
patients	O
before	O
and	O
after	O
they	O
used	O
the	O
app	B-T170
.	O

Patients	O
were	O
randomly	B-T062
selected	I-T062
with	O
established	O
quotas	B-T062
within	O
interest	B-T098
groups	I-T098
,	O
so	O
that	O
men	B-T098
and	O
women	B-T098
,	O
patients	O
older	B-T098
or	O
younger	O
than	O
60	O
years	O
old	O
and	O
patients	O
living	O
in	O
urban	B-T082
or	I-T082
rural	I-T082
areas	I-T082
were	O
equally	O
represented	O
.	O

Using	O
the	O
appropriate	O
statistical	B-T062
techniques	I-T062
we	O
see	O
that	O
the	O
HeartKeeper	B-T170
app	I-T170
was	O
useful	O
for	O
patients	O
as	O
they	O
qualify	O
with	O
70	O
points	O
(	O
out	O
of	O
100	O
)	O
the	O
overall	B-T033
opinion	I-T033
of	O
the	O
app	B-T170
,	O
it	O
helps	O
them	O
remember	B-T038
more	O
easily	O
taking	O
their	O
pills	B-T103
with	O
a	O
mean	O
improvement	O
of	O
20	O
.	O
94	O
points	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
they	O
perceive	O
a	O
global	O
improvement	O
of	O
their	O
health	O
(	O
8	O
.	O
28	O
points	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

We	O
also	O
observe	O
that	O
these	O
improvements	O
do	O
not	O
depend	O
,	O
in	O
general	O
,	O
on	O
the	O
area	B-T082
(	I-T082
urban	I-T082
or	I-T082
rural	I-T082
)	I-T082
where	O
the	O
patient	O
comes	O
from	O
or	O
on	O
their	O
sex	O
.	O

Although	O
older	B-T098
patients	I-T098
needed	O
more	O
help	O
to	O
use	O
the	O
app	B-T170
and	O
used	O
it	O
slightly	O
less	O
frequently	O
,	O
the	O
improvements	O
on	O
several	O
measures	O
considered	O
,	O
such	O
as	O
remembering	B-T038
taking	O
pills	B-T103
,	O
breathing	O
problems	O
or	O
trouble	B-T033
developing	I-T033
activities	I-T033
,	O
depend	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
on	O
age	O
with	O
older	B-T098
patients	I-T098
reporting	O
higher	O
improvements	O
than	O
younger	O
ones	O
.	O

The	O
results	O
obtained	O
with	O
the	O
sample	O
of	O
patients	O
considered	O
in	O
this	O
research	B-T062
prove	O
the	O
utility	O
of	O
the	O
HeartKeeper	B-T170
app	I-T170
.	O

This	O
utility	O
is	O
similar	O
in	O
urban	B-T082
and	I-T082
rural	I-T082
areas	I-T082
and	O
for	O
patients	O
of	O
both	O
sexes	O
and	O
,	O
to	O
some	O
extent	O
,	O
depends	O
on	O
the	O
age	O
of	O
the	O
patient	O
with	O
older	B-T098
patients	I-T098
reporting	O
slightly	O
lower	O
frequency	O
of	O
use	O
but	O
higher	O
health	O
improvements	O
than	O
younger	O
ones	O
.	O

A	O
holistic	O
approach	O
to	O
age	O
estimation	B-T038
in	O
refugee	B-T098
children	O

Many	O
refugee	B-T098
children	O
arriving	O
in	O
Australia	B-T082
have	O
an	O
inaccurately	O
documented	B-T058
date	B-T170
of	I-T170
birth	I-T170
(	O
DOB	B-T170
)	O
.	O

A	O
medical	B-T058
assessment	I-T058
of	O
a	O
child	O
'	O
s	O
age	O
is	O
often	O
requested	O
when	O
there	O
is	O
a	O
concern	O
that	O
their	O
documented	B-T058
DOB	B-T170
is	O
incorrect	O
.	O

This	O
study	O
'	O
s	O
aim	O
was	O
to	O
assess	O
the	O
accuracy	O
a	O
holistic	B-T170
age	I-T170
assessment	I-T170
tool	I-T170
(	O
AAT	B-T170
)	O
in	O
estimating	B-T038
the	O
age	O
of	O
refugee	B-T098
children	O
newly	O
settled	O
in	O
Australia	B-T082
.	O

A	O
holistic	B-T170
AAT	I-T170
that	O
combines	O
medical	O
and	O
non	O
-	O
medical	O
approaches	O
was	O
used	O
to	O
estimate	B-T038
the	O
ages	O
of	O
60	O
refugee	B-T098
children	O
with	O
a	O
known	O
DOB	B-T170
.	O

The	O
tool	B-T170
used	O
four	O
components	O
to	O
assess	O
age	O
:	O
an	O
oral	B-T082
narrative	O
,	O
developmental	O
assessment	B-T058
,	O
anthropometric	B-T170
measures	I-T170
and	O
pubertal	B-T033
assessment	B-T058
.	O

Assessors	B-T097
were	O
blinded	B-T062
to	O
the	O
true	O
age	O
of	O
the	O
child	O
.	O

Correlation	O
coefficients	O
for	O
the	O
actual	O
and	O
estimated	B-T038
age	O
were	O
calculated	O
for	O
the	O
tool	B-T170
overall	O
and	O
individual	O
components	O
.	O

The	O
correlation	O
coefficient	O
between	O
the	O
actual	O
and	O
estimated	B-T038
age	O
from	O
the	O
AAT	B-T170
was	O
very	O
strong	O
at	O
0	O
.	O
9802	O
(	O
boys	O
0	O
.	O
9748	O
,	O
girls	O
0	O
.	O
9876	O
)	O
.	O

The	O
oral	B-T082
narrative	O
component	O
of	O
the	O
tool	B-T170
performed	O
best	O
(	O
R	O
=	O
0	O
.	O
9603	O
)	O
.	O

Overall	O
,	O
86	O
.	O
7	O
%	O
of	O
age	O
estimates	B-T038
were	O
within	O
1	O
year	O
of	O
the	O
true	O
age	O
.	O

The	O
range	O
of	O
differences	O
was	O
-	O
1	O
.	O
43	O
to	O
3	O
.	O
92	O
years	O
with	O
a	O
standard	O
deviation	O
of	O
0	O
.	O
77	O
years	O
(	O
9	O
.	O
24	O
months	O
)	O
.	O

The	O
AAT	B-T170
is	O
a	O
holistic	O
,	O
simple	O
and	O
safe	O
instrument	O
that	O
can	O
be	O
used	O
to	O
estimate	B-T038
age	O
in	O
refugee	B-T098
children	O
with	O
results	O
comparable	O
with	O
radiological	B-T091
methods	I-T091
currently	O
used	O
.	O

CAGEd	B-T170
-	I-T170
oPOSSUM	I-T170
:	O
motif	B-T062
enrichment	I-T062
analysis	I-T062
from	O
CAGE	B-T170
-	O
derived	O
TSSs	B-T103

With	O
the	O
emergence	O
of	O
large	B-T170
-	I-T170
scale	I-T170
Cap	I-T170
Analysis	I-T170
of	I-T170
Gene	I-T170
Expression	I-T170
(	I-T170
CAGE	I-T170
)	I-T170
datasets	I-T170
from	O
individual	B-T092
labs	I-T092
and	O
the	O
FANTOM	O
consortium	O
,	O
one	O
can	O
now	O
analyze	O
the	O
cis	B-T103
-	I-T103
regulatory	I-T103
regions	I-T103
associated	O
with	O
gene	B-T038
transcription	I-T038
at	O
an	O
unprecedented	O
level	O
of	O
refinement	O
.	O

By	O
coupling	O
transcription	B-T038
factor	I-T038
binding	I-T038
site	I-T038
(	O
TFBS	B-T038
)	O
enrichment	B-T062
analysis	I-T062
with	O
CAGE	B-T170
-	O
derived	O
genomic	O
regions	O
,	O
CAGEd	B-T170
-	I-T170
oPOSSUM	I-T170
can	O
identify	O
TFs	B-T103
that	O
act	O
as	O
key	O
regulators	O
of	O
genes	B-T017
involved	O
in	O
specific	O
mammalian	B-T017
cell	I-T017
and	O
tissue	B-T017
types	I-T017
.	O

The	O
webtool	B-T170
allows	O
for	O
the	O
analysis	B-T062
of	O
CAGE	B-T170
-	O
derived	O
transcription	B-T103
start	I-T103
sites	I-T103
(	O
TSSs	B-T103
)	O
either	O
provided	O
by	O
the	O
user	B-T098
or	O
selected	O
from	O
∼1300	O
mammalian	B-T204
samples	O
from	O
the	O
FANTOM5	O
project	O
with	O
pre	O
-	O
computed	O
TFBS	B-T038
predicted	O
with	O
JASPAR	B-T170
TF	I-T170
binding	I-T170
profiles	I-T170
.	O

The	O
tool	B-T170
helps	O
power	O
insights	B-T038
into	O
the	O
regulation	B-T038
of	I-T038
genes	I-T038
through	O
the	O
study	B-T062
of	O
the	O
specific	O
usage	O
of	O
TSSs	B-T103
within	O
specific	O
cell	B-T170
types	I-T170
and	O
/	O
or	O
under	O
specific	O
conditions	O
.	O

The	O
CAGEd	B-T170
-	I-T170
oPOSUM	I-T170
web	I-T170
tool	I-T170
is	O
implemented	O
in	O
Perl	B-T170
,	O
MySQL	B-T170
and	O
Apache	B-T170
and	O
is	O
available	O
at	O
http	B-T170
:	I-T170
/	I-T170
/	I-T170
cagedop	I-T170
.	I-T170
cmmt	I-T170
.	I-T170
ubc	I-T170
.	I-T170
ca	I-T170
/	I-T170
CAGEd	I-T170
_	I-T170
oPOSSUM	I-T170
CONTACTS	O
:	O
anthony	B-T170
.	I-T170
mathelier	I-T170
@	I-T170
ncmm	I-T170
.	I-T170
uio	I-T170
.	I-T170
no	I-T170
or	O
wyeth	B-T170
@	I-T170
cmmt	I-T170
.	I-T170
ubc	I-T170
.	I-T170
ca	I-T170
Supplementary	B-T170
information	I-T170
:	O
Supplementary	B-T170
data	I-T170
are	O
available	O
at	O
Bioinformatics	B-T170
online	B-T170
.	O

Self	O
-	O
assembled	O
polymeric	B-T103
vectors	B-T074
mixtures	O
:	O
characterization	O
of	O
the	O
polymorphism	O
and	O
existence	O
of	O
synergistic	O
effects	O
in	O
photodynamic	B-T058
therapy	I-T058

The	O
objective	O
of	O
this	O
work	O
was	O
to	O
assess	O
the	O
relation	O
between	O
the	O
purity	O
of	O
polymeric	B-T103
self	O
-	O
assemblies	O
vectors	B-T074
solution	O
and	O
their	O
photodynamic	B-T058
therapeutic	I-T058
efficiency	O
.	O

For	O
this	O
,	O
several	O
amphiphilic	B-T103
block	B-T103
copolymers	I-T103
of	O
poly	B-T103
(	I-T103
ethyleneoxide	I-T103
-	I-T103
b	I-T103
-	I-T103
ε	I-T103
-	I-T103
caprolactone	I-T103
)	I-T103
have	O
been	O
used	O
to	O
form	O
self	O
-	O
assemblies	O
with	O
different	O
morphologies	O
(	O
micelles	B-T103
,	O
worm	B-T103
-	I-T103
like	I-T103
micelles	I-T103
or	O
vesicles	O
)	O
.	O

In	O
a	O
first	O
step	O
,	O
controlled	O
mixtures	O
of	O
preformed	O
micelles	B-T103
and	O
vesicles	O
have	O
been	O
characterized	O
both	O
by	O
dynamic	B-T058
light	I-T058
scattering	I-T058
and	O
asymmetrical	B-T058
flow	I-T058
field	I-T058
flow	I-T058
fractionation	I-T058
(	O
AsFlFFF	B-T058
)	O
.	O

For	O
this	O
,	O
a	O
custom	O
-	O
made	O
program	B-T170
,	O
STORMS	B-T170
,	O
was	O
developed	O
to	O
analyze	O
DLS	B-T058
data	O
in	O
a	O
thorough	O
manner	O
by	O
providing	O
a	O
large	O
set	O
of	O
fitting	O
parameters	O
.	O

This	O
showed	O
that	O
DLS	B-T058
only	O
sensed	O
the	O
larger	O
vesicles	O
when	O
the	O
micelles	B-T103
/	O
vesicles	O
ratio	O
was	O
80	O
/	O
20	O
w	O
/	O
w	O
.	O

On	O
the	O
other	O
hand	O
,	O
AsFlFFF	B-T058
allowed	O
clear	O
detection	B-T033
of	O
the	O
presence	O
of	O
micelles	B-T103
when	O
this	O
same	O
ratio	O
was	O
as	O
low	O
as	O
10	O
/	O
90	O
.	O

Subsequently	O
,	O
the	O
photodynamic	B-T058
therapy	I-T058
efficiency	O
of	O
various	O
controlled	O
mixtures	O
was	O
assessed	O
using	O
multicellular	O
spheroids	B-T033
when	O
a	O
photosensitizer	B-T103
,	O
pheophorbide	B-T103
a	I-T103
,	O
was	O
encapsulated	O
in	O
the	O
polymer	B-T103
self	O
-	O
assemblies	O
.	O

Some	O
mixtures	O
were	O
shown	O
to	O
be	O
as	O
efficient	O
as	O
monomorphous	B-T033
systems	I-T033
.	O

In	O
some	O
cases	O
,	O
mixtures	O
were	O
found	O
to	O
exhibit	O
a	O
higher	O
PDT	B-T058
efficiency	O
compared	O
to	O
the	O
individual	O
nano	O
-	O
objects	O
,	O
revealing	O
a	O
synergistic	O
effect	O
for	O
the	O
efficient	O
delivery	O
of	O
the	O
photosensitizer	B-T103
.	O

Polymorphous	O
vectors	B-T074
can	O
therefore	O
be	O
superior	O
in	O
therapeutic	O
applications	O
.	O

Fuzheng	B-T103
Qingjie	I-T103
Granules	I-T103
Inhibit	O
Growth	B-T038
of	O
Hepatoma	O
Cells	O
via	O
Inducing	O
Mitochondria	B-T017
-	O
Mediated	O
Apoptosis	B-T038
and	O
Enhancing	O
Immune	B-T038
Function	I-T038

Fuzheng	B-T103
Qingjie	I-T103
(	B-T103
FZQJ	I-T103
)	I-T103
granules	I-T103
,	O
a	O
compound	B-T103
Chinese	O
medicine	O
,	O
have	O
been	O
used	O
as	O
an	O
adjuvant	B-T058
therapy	I-T058
for	O
alimentary	B-T022
tract	I-T022
cancers	B-T038
.	O

However	O
,	O
the	O
underlying	O
anticancer	B-T033
mechanisms	O
are	O
still	O
not	O
well	O
understood	O
.	O

In	O
the	O
present	O
study	B-T062
,	O
HepG2	B-T017
cells	I-T017
were	O
treated	O
with	O
FZQJ	B-T103
-	O
containing	O
serum	B-T031
.	O

Cell	B-T038
proliferation	I-T038
was	O
evaluated	B-T058
using	O
MTT	B-T062
assay	I-T062
.	O

Apoptosis	B-T038
was	O
analyzed	B-T062
using	O
a	O
flow	B-T074
cytometer	I-T074
.	O

Cell	O
ultrastructure	O
was	O
observed	O
under	O
a	O
transmission	B-T074
electron	I-T074
microscope	I-T074
.	O

The	O
mitochondrial	B-T038
membrane	I-T038
potential	I-T038
(	O
Δψ	B-T038
)	O
was	O
examined	B-T033
with	O
JC	B-T103
-	I-T103
1	I-T103
dye	I-T103
.	O

In	O
H22	B-T038
tumor	I-T038
-	I-T038
bearing	I-T038
mice	I-T038
,	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
,	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
,	O
CD3	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
,	O
and	O
natural	B-T017
killer	I-T017
cells	I-T017
(	O
NK	B-T017
)	O
in	O
peripheral	B-T031
blood	I-T031
were	O
evaluated	O
cytometrically	B-T074
.	O

Interleukin	B-T103
(	I-T103
IL	I-T103
)	I-T103
-	I-T103
2	I-T103
and	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
(	B-T103
TNF	I-T103
)	I-T103
-	I-T103
α	I-T103
levels	O
were	O
measured	O
using	O
radioimmunoassay	B-T058
.	O
The	O
mRNA	B-T103
levels	O
of	O
Bax	B-T017
and	O
Bcl	B-T017
-	I-T017
2	I-T017
were	O
examined	B-T033
by	O
reverse	B-T062
transcription	I-T062
-	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
.	O

The	O
protein	B-T103
levels	O
of	O
Bax	B-T103
,	O
Bcl	B-T103
-	I-T103
2	I-T103
,	O
cytochrome	B-T103
C	I-T103
,	O
caspase	B-T103
3	I-T103
and	O
9	B-T103
,	O
PARP	B-T103
,	O
and	O
CD69	B-T103
were	O
examined	B-T033
by	O
Western	B-T058
blotting	I-T058
.	O

The	O
apoptotic	O
cells	B-T017
in	O
tissues	B-T017
were	O
observed	O
using	O
TUNEL	O
method	O
.	O

Alanine	B-T103
transaminase	I-T103
(	O
ALT	B-T103
)	O
,	O
aspartate	B-T103
transaminase	I-T103
(	O
AST	B-T103
)	O
,	O
blood	B-T103
urea	I-T103
nitrogen	I-T103
(	O
BUN	B-T103
)	O
,	O
and	O
creatinine	B-T103
(	O
CRE	B-T103
)	O
were	O
detected	B-T033
by	O
an	O
automatic	O
biochemical	O
analyzer	B-T074
.	O

The	O
results	O
showed	O
that	O
FZQJ	B-T103
-	O
containing	O
serum	B-T031
remarkably	O
inhibited	O
proliferation	B-T038
of	O
HepG2	B-T017
cells	I-T017
in	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
manners	O
,	O
induced	O
HepG2	B-T017
cell	I-T017
apoptosis	B-T038
and	O
caused	O
a	O
decrease	O
of	O
Δψ	B-T038
.	O

Analysis	B-T062
of	O
tumor	B-T017
tissue	I-T017
showed	O
that	O
FZQJ	B-T103
-	O
induced	O
apoptosis	B-T038
was	O
accompanied	O
by	O
downregulation	B-T038
of	O
Bcl	B-T103
-	I-T103
2	I-T103
and	O
upregulation	B-T038
of	O
Bax	B-T103
,	O
release	O
of	O
cytochrome	B-T103
c	I-T103
,	O
activation	B-T038
of	O
caspase	B-T103
3	I-T103
and	O
9	B-T103
,	O
and	O
cleavage	B-T038
of	O
PARP	B-T103
.	O

In	O
addition	O
,	O
FZQJ	B-T103
increased	O
the	O
percentages	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
and	O
NK	B-T017
cells	I-T017
,	O
the	O
ratio	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
/	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
as	O
well	O
as	O
the	O
levels	O
of	O
serum	B-T031
TNF	B-T103
-	I-T103
α	I-T103
.	O

FZQJ	B-T103
also	O
increased	O
CD69	B-T103
expression	B-T038
in	O
tumor	B-T017
tissue	I-T017
.	O

No	B-T033
hepatorenal	I-T033
toxicity	I-T033
was	O
observed	O
in	O
H22	B-T038
tumor	I-T038
-	I-T038
bearing	I-T038
mice	I-T038
.	O

These	O
results	O
indicated	B-T033
that	O
FZQJ	B-T103
could	O
inhibit	O
the	O
growth	B-T038
of	O
hepatoma	O
cells	O
via	O
regulating	O
immune	B-T038
function	I-T038
and	O
inducing	O
mitochondria	B-T017
mediated	O
apoptosis	B-T038
.	O

Professional	B-T170
reinventions	I-T170
:	O
Swedish	B-T098
psychologists	B-T097
,	O
1990	O
-	O
2010	O

Since	O
the	O
early	O
20th	O
century	O
,	O
the	O
Swedish	B-T098
psychology	B-T091
profession	I-T091
has	O
undergone	O
several	O
changes	O
in	O
its	O
essential	O
tasks	O
,	O
epistemological	B-T170
foundations	I-T170
,	O
and	O
social	O
roles	O
.	O

These	O
changes	O
occurred	O
through	O
an	O
ongoing	O
"	O
tuning	O
"	O
with	O
Swedish	B-T098
society	B-T092
,	O
in	O
which	O
the	O
profession	O
strove	O
to	O
appear	O
relevant	O
to	O
society	B-T092
'	I-T092
s	I-T092
concerns	O
and	O
problems	B-T033
as	O
well	O
as	O
enroll	O
others	O
to	O
share	O
the	O
profession	O
'	O
s	O
goals	B-T170
and	O
aims	O
.	O

Studying	O
the	O
history	O
of	O
the	O
profession	O
can	O
thus	O
shed	O
light	O
on	O
the	O
changing	O
definitions	B-T170
and	O
contours	B-T082
of	O
the	O
psychology	B-T091
profession	I-T091
itself	O
as	O
well	O
as	O
on	O
the	O
organization	O
of	O
the	O
society	B-T092
in	O
which	O
it	O
acts	O
.	O

This	O
article	B-T170
examines	O
the	O
history	O
of	O
the	O
Swedish	B-T098
psychology	B-T091
profession	I-T091
from	O
1990	O
to	O
2010	O
,	O
through	O
an	O
analysis	B-T062
of	O
the	O
discussions	O
and	O
debates	O
taking	O
place	O
in	O
the	O
Swedish	B-T098
Psychological	B-T170
Association	I-T170
'	I-T170
s	I-T170
journal	I-T170
.	O

The	O
analytical	O
framework	O
used	O
draws	O
on	O
work	O
done	O
within	O
actor	B-T170
-	I-T170
network	I-T170
theory	I-T170
and	O
science	B-T062
studies	I-T062
.	O

We	O
argue	O
that	O
the	O
profession	O
'	O
s	O
institutional	O
connections	O
,	O
defining	O
tasks	O
,	O
epistemological	B-T170
underpinnings	O
,	O
and	O
social	O
position	O
have	O
changed	O
in	O
major	O
ways	O
during	O
these	O
2	O
decades	O
.	O

Overall	O
,	O
as	O
a	O
result	O
of	O
an	O
increasingly	O
felt	O
insecurity	B-T038
,	O
the	O
profession	O
has	O
turned	O
outward	O
and	O
tried	O
to	O
find	O
new	O
ways	O
to	O
legitimize	O
itself	O
to	O
politicians	O
,	O
the	O
media	B-T170
,	O
patients	O
,	O
and	O
customers	O
through	O
means	O
such	O
as	O
a	O
more	O
economized	O
vocabulary	B-T170
and	O
novel	O
forms	O
of	O
empirical	B-T062
research	I-T062
.	O

These	O
changes	O
have	O
led	O
to	O
a	O
more	O
socialized	O
profession	O
,	O
now	O
more	O
closely	O
tuned	O
to	O
other	O
actors	B-T097
in	O
Swedish	B-T098
society	B-T092
,	O
leading	O
to	O
conflicts	O
within	O
the	O
profession	O
over	O
whether	O
this	O
is	O
an	O
opportunity	O
to	O
better	O
control	O
their	O
own	O
destiny	O
or	O
if	O
it	O
will	O
lead	O
to	O
a	O
loss	O
of	O
autonomy	O
.	O

(	O
PsycINFO	B-T170
Database	I-T170
Record	I-T170

Personally	O
Meaningful	O
Rituals	O
:	O
A	O
Way	O
to	O
Increase	O
Compassion	O
and	O
Decrease	O
Burnout	B-T033
among	O
Hospice	B-T058
Staff	B-T097
and	O
Volunteers	B-T098

Rituals	O
can	O
increase	O
a	O
sense	O
of	O
connectedness	O
,	O
meaning	O
,	O
and	O
support	O
,	O
especially	O
after	O
the	O
death	B-T038
of	O
those	O
for	O
whom	O
we	O
care	O
.	O

Hospice	B-T058
staff	O
may	O
benefit	O
from	O
the	O
use	O
of	O
personal	O
rituals	O
as	O
they	O
cope	O
with	O
the	O
frequent	O
deaths	O
of	O
their	O
patients	O
,	O
ultimately	O
aiming	O
to	O
provide	O
compassionate	O
care	O
while	O
minimizing	O
burnout	B-T033
.	O

This	O
study	O
investigated	O
the	O
role	O
of	O
personally	O
meaningful	O
rituals	O
in	O
increasing	O
compassion	O
and	O
decreasing	O
burnout	B-T033
among	O
hospice	B-T058
staff	O
and	O
volunteers	B-T098
.	O

An	O
online	B-T170
survey	I-T170
was	O
completed	O
by	O
members	O
of	O
the	O
National	O
Hospice	B-T058
and	O
Palliative	O
Care	O
Organization	O
(	O
NHPCO	O
)	O
which	O
inquired	O
about	O
personal	O
ritual	O
practices	O
,	O
and	O
included	O
the	O
Professional	B-T170
Quality	I-T170
of	I-T170
Life	I-T170
(	I-T170
ProQOL	B-T170
)	I-T170
scale	I-T170
to	O
measure	O
current	O
levels	O
of	O
Compassion	O
Satisfaction	B-T038
,	O
Burnout	B-T033
,	O
and	O
Secondary	B-T038
Traumatic	I-T038
Stress	I-T038
.	O

Three	O
hundred	O
ninety	O
hospice	B-T058
staff	O
and	O
volunteers	B-T098
from	O
across	O
38	O
states	B-T082
completed	O
the	O
online	B-T170
survey	I-T170
.	O

The	O
majority	O
of	O
participants	B-T098
were	O
Caucasian	B-T098
and	O
female	O
,	O
with	O
an	O
average	O
of	O
nine	O
years	O
of	O
experience	O
in	O
hospice	B-T058
and	O
palliative	O
care	O
.	O

The	O
majority	O
of	O
hospice	B-T058
staff	O
and	O
volunteers	B-T098
used	O
personally	O
meaningful	O
rituals	O
after	O
the	O
death	B-T038
of	O
their	O
patients	O
to	O
help	O
them	O
cope	O
(	O
71	O
%	O
)	O
.	O

Those	O
who	O
used	O
rituals	O
demonstrated	O
significantly	O
higher	O
Compassion	O
Satisfaction	B-T038
and	O
significantly	O
lower	O
Burnout	B-T033
as	O
measured	O
by	O
the	O
ProQOL	B-T170
,	O
with	O
professional	O
support	O
,	O
social	O
support	O
,	O
and	O
age	O
playing	O
significant	B-T033
roles	I-T033
as	O
well	O
.	O

Rituals	O
may	O
be	O
an	O
important	O
way	O
to	O
increase	O
compassion	O
and	O
decrease	O
burnout	B-T033
among	O
hospice	B-T058
staff	O
and	O
volunteers	B-T098
.	O

Organizations	O
may	O
benefit	O
from	O
providing	O
training	O
and	O
support	O
for	O
personalized	O
rituals	O
among	O
team	O
members	O
,	O
especially	O
new	O
staff	O
who	O
may	O
be	O
at	O
greater	O
risk	O
for	O
burnout	B-T033
.	O

Activation	O
of	O
the	O
orphan	B-T103
receptor	I-T103
GPR55	I-T103
by	O
lysophosphatidylinositol	B-T103
promotes	O
metastasis	B-T038
in	O
triple	B-T038
-	I-T038
negative	I-T038
breast	I-T038
cancer	I-T038

The	O
orphan	B-T103
G	I-T103
protein	I-T103
-	I-T103
coupled	I-T103
receptor	I-T103
GPR55	B-T103
has	O
been	O
directly	O
or	O
indirectly	O
related	O
to	O
basic	O
alterations	O
that	O
drive	O
malignant	O
growth	B-T038
:	O
uncontrolled	O
cancer	O
cell	B-T038
proliferation	I-T038
,	O
sustained	B-T038
angiogenesis	I-T038
,	O
and	O
cancer	O
cell	B-T038
adhesion	I-T038
and	O
migration	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
involvement	O
of	O
this	O
receptor	B-T103
in	O
metastasis	B-T038
.	O

Here	O
,	O
we	O
show	O
that	O
elevated	O
GPR55	O
expression	O
in	O
human	B-T204
tumors	B-T038
is	O
associated	O
with	O
the	O
aggressive	B-T038
basal	I-T038
/	O
triple	B-T038
-	I-T038
negative	I-T038
breast	I-T038
cancer	I-T038
population	B-T098
,	O
higher	O
probability	O
to	O
develop	O
metastases	B-T038
,	O
and	O
therefore	O
poor	O
patient	O
prognosis	B-T058
.	O

Activation	O
of	O
GPR55	B-T103
by	O
its	O
proposed	O
endogenous	O
ligand	B-T103
lysophosphatidylinositol	B-T103
confers	O
pro	O
-	O
invasive	O
features	O
on	O
breast	B-T017
cancer	I-T017
cells	I-T017
both	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

Specifically	O
,	O
this	O
effect	O
is	O
elicited	O
by	O
coupling	O
to	O
Gq	B-T103
/	I-T103
11	I-T103
heterotrimeric	I-T103
proteins	I-T103
and	O
the	O
subsequent	O
activation	O
,	O
through	O
ERK	B-T103
,	O
of	O
the	O
transcription	B-T103
factor	I-T103
ETV4	I-T103
/	O
PEA3	B-T103
.	O

Together	O
,	O
these	O
data	O
show	O
that	O
GPR55	B-T103
promotes	O
breast	B-T038
cancer	I-T038
metastasis	B-T038
,	O
and	O
supports	O
the	O
notion	O
that	O
this	O
orphan	B-T103
receptor	I-T103
may	O
constitute	O
a	O
new	O
therapeutic	O
target	O
and	O
potential	O
biomarker	B-T201
in	O
the	O
highly	O
aggressive	B-T170
triple	I-T170
-	I-T170
negative	I-T170
subtype	I-T170
.	O

Effect	O
of	O
ultrasonic	O
processing	O
on	O
the	O
changes	O
in	O
activity	O
,	O
aggregation	O
and	O
the	O
secondary	B-T082
and	O
tertiary	B-T082
structure	I-T082
of	O
polyphenol	B-T103
oxidase	I-T103
in	O
oriental	B-T082
sweet	B-T168
melon	I-T168
(	O
Cucumis	B-T204
melo	I-T204
var	I-T204
.	I-T204
makuwa	I-T204
Makino	I-T204
)	O

Polyphenol	B-T103
oxidase	I-T103
(	O
PPO	B-T103
)	O
mainly	O
contributes	O
to	O
the	O
browning	O
reaction	O
of	O
fruits	B-T168
and	O
vegetables	B-T168
and	O
causes	O
serious	O
damage	O
to	O
the	O
quality	O
of	O
sweet	B-T168
melon	I-T168
products	O
.	O

However	O
,	O
traditional	O
methods	O
to	O
inactivate	O
browning	O
may	O
induce	O
more	O
unexpected	B-T170
risks	O
than	O
ultrasonic	O
processing	O
.	O

Meanwhile	O
,	O
there	O
are	O
no	O
reports	B-T170
on	O
the	O
effect	O
of	O
ultrasound	O
on	O
PPO	B-T103
directly	O
purified	O
from	O
sweet	B-T168
melon	I-T168
.	O

The	O
PPO	B-T103
in	O
the	O
original	O
juice	B-T168
was	O
less	O
inactivated	O
than	O
the	O
purified	O
form	O
when	O
treated	B-T058
with	I-T058
ultrasound	O
.	O

As	O
for	O
purified	O
PPO	B-T103
,	O
superior	O
to	O
thermal	B-T058
treatment	I-T058
,	O
less	O
heat	O
was	O
needed	O
to	O
inactivate	O
the	O
PPO	B-T103
with	O
ultrasonic	O
treatment	B-T058
.	O

At	O
intensity	O
lower	O
than	O
200	O
W	O
,	O
ultrasound	O
did	O
not	O
significantly	O
affect	O
the	O
structure	B-T082
and	O
activity	O
of	O
PPO	B-T103
(	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
and	O
latent	O
PPO	B-T103
was	O
activated	O
.	O

At	O
intensity	O
higher	O
than	O
200	O
W	O
,	O
ultrasound	O
inactivated	O
PPO	B-T103
,	O
induced	O
aggregation	O
and	O
dissociation	B-T038
of	O
PPO	B-T103
particles	B-T103
and	O
significantly	O
decreased	O
the	O
α	B-T082
-	I-T082
helix	I-T082
structure	I-T082
content	O
.	O

Low	O
-	O
frequency	O
high	B-T170
-	I-T170
intensity	I-T170
ultrasound	O
caused	O
an	O
inactivation	O
effect	O
and	O
conformational	B-T038
changes	I-T038
of	O
purified	O
PPO	B-T103
from	O
oriental	B-T082
sweet	B-T168
melons	I-T168
.	O

Changes	O
in	O
the	O
PPO	B-T103
structure	B-T082
induced	O
by	O
ultrasound	O
eventually	O
inactivated	O
the	O
enzyme	B-T103
.	O

Ultrasound	O
may	O
be	O
a	O
potential	O
method	O
to	O
inactivate	O
PPO	B-T103
in	O
oriental	B-T082
sweet	B-T168
melons	I-T168
.	O

©	O
2016	O
Society	O
of	O
Chemical	O
Industry	O
.	O

Phylogeography	O
of	O
the	O
Spanish	B-T098
Moon	B-T204
Moth	I-T204
Graellsia	B-T204
isabellae	I-T204
(	O
Lepidoptera	B-T204
,	O
Saturniidae	B-T204
)	O

Geographic	O
and	O
demographic	O
factors	O
as	O
well	O
as	O
specialisation	O
to	O
a	O
new	O
host	O
-	O
plant	O
may	O
lead	O
to	O
host	O
-	O
associated	O
differentiation	O
in	O
plant	B-T204
-	O
feeding	O
insects	B-T204
.	O

We	O
explored	O
the	O
phylogeography	O
of	O
a	O
protected	O
moth	B-T204
,	O
Graellsia	B-T204
isabellae	I-T204
,	O
and	O
its	O
two	O
recognised	O
host	O
-	O
plant	O
species	B-T170
(	O
Pinus	B-T204
sylvestris	I-T204
and	O
P	B-T204
.	I-T204

nigra	I-T204
)	O
in	O
order	O
to	O
seek	O
for	O
any	O
concordance	O
useful	O
to	O
disentangle	O
the	O
evolutionary	O
history	O
of	O
this	O
iconic	O
lepidopteran	B-T204
.	O

DNA	B-T103
variation	O
in	O
one	O
mitochondrial	B-T017
marker	B-T082
and	O
nine	O
nuclear	B-T017
microsatellite	B-T017
loci	I-T017
revealed	O
a	O
strong	O
phylogeographic	B-T033
pattern	I-T033
across	O
28	O
populations	O
of	O
G	B-T204
.	I-T204

isabellae	I-T204
studied	O
in	O
Spain	B-T082
and	O
France	B-T082
comprising	O
six	O
groups	O
mostly	O
distributed	O
along	O
different	O
mountain	B-T082
ranges	I-T082
.	O

Reanalysis	B-T062
of	O
a	O
previously	O
published	O
chloroplast	B-T017
microsatellite	B-T170
dataset	I-T170
revealed	O
a	O
three	O
and	O
two	O
-	O
group	O
structure	O
for	O
Spanish	B-T098
P	B-T204
.	I-T204

sylvestris	I-T204
and	O
P	B-T204
.	I-T204

nigra	I-T204
,	O
respectively	O
.	O

Overall	O
,	O
the	O
population	O
groupings	O
of	O
this	O
protected	O
moth	B-T204
did	O
not	O
match	O
the	O
ones	O
of	O
P	B-T204
.	I-T204

sylvestris	I-T204
and	O
P	B-T204
.	I-T204

nigra	I-T204
.	O

There	O
was	O
no	O
evidence	O
of	O
host	O
-	O
associated	O
differentiation	O
between	O
populations	O
using	O
P	B-T204
.	I-T204

sylvestris	I-T204
and	O
the	O
ones	O
inhabiting	O
P	B-T204
.	I-T204

nigra	I-T204
.	O

The	O
two	O
major	O
mitochondrial	B-T017
clades	O
of	O
G	B-T204
.	I-T204

isabellae	I-T204
likely	O
diverged	O
before	O
the	O
Last	O
Glacial	O
Maximum	O
and	O
geographically	B-T082
separated	O
the	O
species	B-T170
into	O
a	O
"	O
southern	B-T082
"	O
(	O
Central	O
and	O
Southern	O
Iberian	O
clusters	O
)	O
and	O
a	O
"	O
northern	B-T082
"	O
lineage	O
(	O
Eastern	O
Iberian	O
,	O
Pyrenean	O
and	O
French	O
Alpine	O
clusters	O
)	O
.	O

The	O
Eastern	O
Iberian	O
System	O
,	O
where	O
this	O
insect	B-T204
uses	O
both	O
host	O
-	O
plants	O
,	O
harboured	O
the	O
highest	O
level	O
of	O
genetic	O
diversity	O
.	O

Such	O
a	O
group	O
independently	O
colonised	B-T033
the	O
West	B-T082
and	O
East	B-T082
parts	I-T082
of	O
the	O
Pyrenees	O
.	O

Our	O
results	O
point	O
to	O
a	O
native	O
origin	O
for	O
the	O
French	O
populations	O
occurring	O
in	O
the	O
Alps	B-T082
,	O
genetically	O
related	O
to	O
the	O
Eastern	O
Iberian	O
and	O
Pyrenean	O
sites	O
.	O

The	O
Central	O
Iberian	O
group	O
derived	O
from	O
Southern	O
Iberian	O
ancestors	O
.	O

Secondary	O
contacts	O
were	O
inferred	O
between	O
the	O
Southern	O
/	O
Central	O
Iberian	O
populations	O
and	O
Eastern	O
Iberian	O
cluster	O
as	O
well	O
as	O
between	O
the	O
two	O
Pyrenean	O
ones	O
.	O

The	O
mito	O
-	O
nuclear	O
discordance	O
observed	O
with	O
regard	O
to	O
the	O
Eastern	O
Iberian	O
cluster	O
is	O
congruent	O
with	O
a	O
secondary	O
contact	O
after	O
the	O
evolution	B-T038
of	O
mito	O
-	O
nuclear	O
incompatibilities	O
in	O
geographically	O
isolated	O
areas	O
.	O

Prevalence	O
of	O
Physical	O
Activity	O
and	O
Sitting	B-T038
Time	O
Among	O
South	B-T098
Korean	I-T098
Adolescents	O
:	O
Results	O
From	O
the	O
Korean	B-T098
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
,	O
2013	O

This	O
study	O
aimed	O
to	O
describe	O
physical	O
activity	O
(	O
PA	O
)	O
and	O
sitting	B-T038
time	O
,	O
and	O
to	O
examine	O
associations	O
between	O
sociodemographic	O
factors	O
,	O
weight	O
status	O
,	O
PA	O
,	O
and	O
sitting	B-T038
time	O
among	O
South	B-T098
Korean	I-T098
adolescents	O
(	O
12	O
-	O
18	O
years	O
)	O
.	O

Findings	O
are	O
based	O
on	O
self	B-T062
-	I-T062
report	I-T062
data	I-T062
from	O
638	O
participants	B-T098
in	O
the	O
2013	O
Korea	B-T082
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
.	O

Only	O
4	O
.	O
9	O
%	O
of	O
adolescents	O
accumulated	O
60	O
minutes	O
of	O
moderate	O
-	O
to	O
-	O
vigorous	O
PA	O
daily	O
.	O

Adolescents	O
spent	O
532	O
.	O
4	O
±	O
9	O
.	O
3	O
mins	O
/	O
d	O
sitting	B-T038
.	O

After	O
controlling	O
for	O
age	O
and	O
sex	O
,	O
individuals	B-T098
in	O
higher	B-T098
income	I-T098
groups	I-T098
compared	O
with	O
the	O
lowest	B-T098
income	I-T098
group	I-T098
,	O
living	O
in	O
nonmetro	O
Seoul	B-T082
compared	O
with	O
metro	O
Seoul	B-T082
,	O
and	O
who	O
were	O
overweight	B-T033
compared	O
with	O
nonoverweight	O
were	O
more	O
likely	O
to	O
meet	O
PA	O
guidelines	B-T170
.	O

Participants	B-T098
in	O
the	O
highest	B-T098
income	I-T098
group	I-T098
compared	O
with	O
lowest	B-T098
income	I-T098
group	I-T098
,	O
and	O
residing	O
in	O
nonmetro	O
Seoul	B-T082
compared	O
with	O
metro	O
Seoul	B-T082
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
high	O
sitting	B-T038
time	O
group	O
(	O
>	O
720	O
min	O
/	O
d	O
)	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Increasing	O
PA	O
and	O
reducing	O
sitting	B-T038
should	O
be	O
a	O
public	B-T170
health	I-T170
priority	O
in	O
South	B-T082
Korea	I-T082
.	O

Graphene	B-T103
/	O
Nafion	B-T103
composite	O
film	O
modified	O
glassy	O
carbon	B-T074
electrode	I-T074
for	O
simultaneous	O
determination	B-T058
of	O
paracetamol	B-T103
,	O
aspirin	B-T103
and	O
caffeine	B-T103
in	O
pharmaceutical	O
formulations	O

A	O
graphene	B-T103
-	O
Nafion	B-T103
composite	O
film	O
was	O
fabricated	O
on	O
the	O
glassy	O
carbon	B-T074
electrode	I-T074
(	O
GR	B-T074
-	I-T074
NF	I-T074
/	I-T074
GCE	I-T074
)	O
,	O
and	O
used	O
for	O
simultaneous	O
determination	B-T058
of	O
paracetamol	B-T103
(	O
PAR	B-T103
)	O
,	O
aspirin	B-T103
(	O
ASA	B-T103
)	O
and	O
caffeine	B-T103
(	O
CAF	B-T103
)	O
.	O

The	O
electrochemical	O
behaviors	O
of	O
PAR	B-T103
,	O
ASA	B-T103
and	O
CAF	B-T103
were	O
investigated	O
by	O
cyclic	O
voltammetry	O
and	O
square	B-T058
-	I-T058
wave	I-T058
adsorptive	I-T058
anodic	I-T058
stripping	I-T058
voltammetry	I-T058
.	O

By	O
using	O
stripping	B-T058
one	O
for	O
simultaneous	O
determination	B-T058
of	O
PAR	B-T103
,	O
ASA	B-T103
and	O
CAF	B-T103
,	O
their	O
electrochemical	O
oxidation	O
peaks	O
appeared	O
at	O
+	O
0	O
.	O
64	O
,	O
1	O
.	O
04	O
and	O
1	O
.	O
44V	O
,	O
and	O
good	O
linear	O
current	O
responses	O
were	O
obtained	O
with	O
the	O
detection	O
limits	O
of	O
18ngmL	O
(	O
-	O
1	O
)	O
(	O
1	O
.	O
2×10	O
(	O
-	O
9	O
)	O
M	O
)	O
,	O
11	O
.	O
7ngmL	O
(	O
-	O
1	O
)	O
(	O
6	O
.	O
5×10	O
(	O
-	O
8	O
)	O
M	O
)	O
and	O
7	O
.	O
3ngmL	O
(	O
-	O
1	O
)	O
(	O
3	O
.	O
8×10	O
(	O
-	O
8	O
)	O
M	O
)	O
,	O
respectively	O
.	O

Finally	O
,	O
the	O
proposed	O
electrochemical	O
sensor	O
was	O
successfully	O
applied	O
for	O
quantifying	O
PAR	B-T103
,	O
ASA	B-T103
and	O
CAF	B-T103
in	O
commercial	B-T170
tablet	O
formulations	O
.	O

Long	O
-	O
term	O
antibiofilm	O
activity	O
of	O
carboxymethyl	B-T103
chitosan	I-T103
on	O
mixed	B-T007
biofilm	I-T007
on	O
silicone	B-T103

Silicone	B-T103
voice	B-T074
prostheses	I-T074
are	O
most	O
frequently	O
used	O
in	O
voice	B-T058
rehabilitation	I-T058
of	O
laryngectomized	B-T058
patients	O
.	O

However	O
,	O
the	O
functional	O
device	O
lifetimes	O
are	O
limited	O
due	O
to	O
formation	O
of	O
mixed	B-T007
biofilms	I-T007
.	O

Existing	O
in	B-T062
vitro	I-T062
models	I-T062
simulating	O
biofilm	B-T038
formation	I-T038
are	O
restricted	O
to	O
only	O
short	O
-	O
term	O
periods	O
.	O

The	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
effect	O
of	O
carboxymethyl	B-T103
chitosan	I-T103
on	O
mixed	B-T038
biofilm	I-T038
formation	I-T038
of	O
fungi	B-T204
and	O
bacteria	B-T007
on	O
silicone	B-T103
over	O
a	O
long	O
-	O
term	O
period	O
.	O

Mixed	O
species	B-T170
biofilms	B-T007
of	O
Candida	B-T204
albicans	I-T204
,	O
Candida	B-T204
tropicalis	I-T204
,	O
Lactobacillus	B-T007
gasseri	I-T007
,	O
Streptococcus	B-T007
salivarius	I-T007
,	O
Rothia	B-T007
dentocariosa	I-T007
,	O
and	O
Staphylococcus	B-T007
epidermidis	I-T007
were	O
cultivated	O
on	O
the	O
surfaces	B-T082
of	O
medical	B-T103
-	I-T103
grade	I-T103
silicone	I-T103
with	O
and	O
without	O
addition	O
of	O
carboxymethyl	B-T103
chitosan	I-T103
.	O

Biofilm	O
kinetics	O
was	O
monitored	O
using	O
specially	O
designed	O
image	O
analysis	O
software	O
to	O
calculate	O
the	O
percentual	O
surface	O
covering	O
of	O
each	O
platelet	B-T017
.	O

Biofilm	O
architecture	O
was	O
investigated	O
by	O
scanning	B-T058
electron	I-T058
microscopy	I-T058
.	O

A	O
cover	O
of	O
living	O
mixed	B-T007
biofilm	I-T007
could	O
be	O
generated	O
over	O
22	O
days	O
on	O
silicone	B-T103
and	O
the	O
maximum	O
of	O
22	O
%	O
biofilm	B-T007
surface	O
covering	O
at	O
day	O
22	O
.	O

However	O
,	O
less	O
than	O
4	O
%	O
surface	O
coverage	O
was	O
observed	O
on	O
the	O
carboxymethyl	B-T103
chitosan	I-T103
-	O
treated	O
plates	O
in	O
the	O
testing	O
period	O
.	O

Scanning	B-T058
electron	I-T058
microscopy	I-T058
confirms	B-T033
that	O
,	O
on	O
surfaces	B-T082
treated	O
by	O
carboxymethyl	B-T103
chitosan	I-T103
,	O
the	O
biofilm	B-T007
was	O
less	O
dense	O
.	O

In	O
addition	O
,	O
there	O
were	O
fewer	O
layers	O
of	O
cells	B-T017
and	O
profuse	B-T033
cellular	I-T033
debris	I-T033
,	O
together	O
with	O
degrading	O
and	O
morphologically	B-T017
altered	I-T017
yeast	B-T017
cells	I-T017
.	O

Carboxymethyl	B-T103
chitosan	I-T103
may	O
serve	O
as	O
a	O
possible	B-T033
antibiofilm	O
agent	O
to	O
limit	O
biofilm	B-T038
formation	I-T038
on	O
voice	B-T074
prostheses	I-T074
.	O

NA	O
Laryngoscope	B-T074
,	O
126	O
:	O
E404	O
-	O
E408	O
,	O
2016	O
.	O

Spectral	B-T058
fingerprints	I-T058
of	O
large	O
-	O
scale	O
cortical	B-T017
dynamics	O
during	O
ambiguous	O
motion	B-T038
perception	I-T038

Ambiguous	O
stimuli	O
have	O
been	O
widely	O
used	O
to	O
study	O
the	O
neuronal	B-T017
correlates	O
of	O
consciousness	B-T038
.	O

Recently	O
,	O
it	O
has	O
been	O
suggested	O
that	O
conscious	B-T038
perception	B-T038
might	O
arise	O
from	O
the	O
dynamic	O
interplay	O
of	O
functionally	O
specialized	O
but	O
widely	O
distributed	O
cortical	B-T017
areas	I-T017
.	O

While	O
previous	O
research	O
mainly	O
focused	O
on	O
phase	B-T038
coupling	I-T038
as	O
a	O
correlate	O
of	O
cortical	B-T017
communication	O
,	O
more	O
recent	O
findings	O
indicated	O
that	O
additional	O
coupling	B-T038
modes	I-T038
might	O
coexist	O
and	O
possibly	O
subserve	O
distinct	O
cortical	B-T038
functions	I-T038
.	O

Here	O
,	O
we	O
studied	O
two	O
coupling	B-T038
modes	I-T038
,	O
namely	O
phase	B-T038
and	I-T038
envelope	I-T038
coupling	I-T038
,	O
which	O
might	O
differ	O
in	O
their	O
origins	O
,	O
putative	O
functions	O
and	O
dynamics	O
.	O

Therefore	O
,	O
we	O
recorded	O
128	O
-	O
channel	O
EEG	B-T058
while	O
participants	B-T098
performed	O
a	O
bistable	B-T058
motion	I-T058
task	I-T058
and	O
utilized	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
source	O
-	O
space	O
connectivity	O
analysis	B-T062
techniques	O
to	O
study	O
the	O
functional	O
relevance	O
of	O
different	O
coupling	B-T038
modes	I-T038
for	O
cortical	B-T017
communication	O
.	O

Our	O
results	O
indicate	O
that	O
gamma	B-T038
-	I-T038
band	I-T038
phase	I-T038
coupling	I-T038
in	O
extrastriate	O
visual	B-T017
cortex	I-T017
might	O
mediate	O
the	O
integration	O
of	O
visual	B-T058
tokens	I-T058
into	O
a	O
moving	B-T038
stimulus	O
during	O
ambiguous	O
visual	B-T058
stimulation	I-T058
.	O

Furthermore	O
,	O
our	O
results	O
suggest	O
that	O
long	O
-	O
range	O
fronto	O
-	O
occipital	O
gamma	O
-	O
band	O
envelope	B-T038
coupling	I-T038
sustains	O
the	O
horizontal	O
percept	O
during	O
ambiguous	O
motion	B-T038
perception	I-T038
.	O

Additionally	O
,	O
our	O
results	O
support	O
the	O
idea	O
that	O
local	B-T017
parieto	I-T017
-	I-T017
occipital	I-T017
alpha	B-T038
-	I-T038
band	I-T038
phase	I-T038
coupling	I-T038
controls	O
the	O
inter	O
-	O
hemispheric	B-T082
information	O
transfer	O
.	O

These	O
findings	O
provide	O
correlative	O
evidence	O
for	O
the	O
notion	O
that	O
synchronized	O
oscillatory	O
brain	B-T038
activity	I-T038
reflects	O
the	O
processing	B-T038
of	I-T038
sensory	I-T038
input	O
as	O
well	O
as	O
the	O
information	B-T038
integration	I-T038
across	O
several	O
spatiotemporal	B-T062
scales	I-T062
.	O

The	O
results	O
indicate	O
that	O
distinct	O
coupling	O
modes	O
are	O
involved	O
in	O
different	O
cortical	B-T017
computations	O
and	O
that	O
the	O
rich	O
spatiotemporal	B-T062
correlation	I-T062
structure	B-T017
of	I-T017
the	I-T017
brain	I-T017
might	O
constitute	O
the	O
functional	O
architecture	O
for	O
cortical	B-T017
processing	O
and	O
specific	O
multi	O
-	O
site	O
communication	O
.	O

Hum	O
Brain	O
Mapp	O
37	O
:	O
4099	O
-	O
4111	O
,	O
2016	O
.	O

©	O
2016	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Beneficial	O
effects	O
of	O
voglibose	B-T103
administration	B-T058
on	O
body	O
weight	O
and	O
lipid	B-T038
metabolism	I-T038
via	O
gastrointestinal	B-T022
bile	B-T103
acid	I-T103
modification	O

This	O
study	B-T062
was	O
designed	O
with	O
the	O
goal	B-T170
of	O
examining	O
the	O
effects	O
of	O
voglibose	B-T103
administration	B-T058
on	O
body	O
weight	O
and	O
lipid	B-T038
metabolism	I-T038
and	O
underlying	O
mechanism	O
high	B-T058
fat	I-T058
diet	I-T058
-	O
induced	O
obese	B-T204
mice	I-T204
.	O

Male	O
C57BL	B-T204
/	I-T204
6	I-T204
mice	I-T204
were	O
randomly	O
assigned	O
to	O
one	O
of	O
four	O
groups	O
:	O
a	O
control	O
diet	O
(	O
CTL	O
)	O
,	O
high	O
-	O
fat	O
diet	O
(	O
HF	O
)	O
,	O
high	O
-	O
fat	O
diet	O
supplemented	O
with	O
voglibose	O
(	O
VO	O
)	O
,	O
and	O
high	O
fat	O
diet	O
pair	O
-	O
fed	O
group	O
(	O
PF	O
)	O
.	O

After	O
12	O
weeks	O
,	O
the	O
following	O
characteristics	O
were	O
investigated	O
:	O
serum	B-T058
lipid	I-T058
and	O
glucose	B-T033
levels	I-T033
,	O
serum	O
polar	O
metabolite	O
profiles	O
,	O
and	O
expression	O
levels	O
of	O
genes	B-T017
involved	O
in	O
lipid	B-T038
and	O
bile	B-T038
acid	I-T038
metabolism	I-T038
.	O

In	O
addition	O
,	O
pyrosequencing	B-T058
was	O
used	O
to	O
analyze	O
the	O
composition	B-T201
of	O
gut	O
microbiota	O
found	O
in	O
feces	B-T031
.	O

Total	B-T033
body	I-T033
weight	I-T033
gain	I-T033
was	O
significantly	O
lower	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
CTL	O
,	O
HF	O
,	O
and	O
PF	O
groups	O
.	O

The	O
VO	O
group	O
exhibited	O
improved	O
metabolic	B-T038
profiles	I-T038
including	O
those	O
of	O
blood	B-T058
glucose	I-T058
,	O
triglyceride	B-T033
,	O
and	O
total	B-T033
cholesterol	I-T033
levels	I-T033
.	O

The	O
12	O
-	O
week	O
voglibose	B-T103
administration	B-T058
decreased	O
the	O
ratio	O
of	O
Firmicutes	B-T007
to	O
Bacteroidetes	B-T007
found	O
in	O
feces	B-T031
.	O

Circulating	O
levels	O
of	O
taurocholic	B-T103
and	O
cholic	B-T103
acid	I-T103
were	O
significantly	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
and	O
CTL	O
groups	O
.	O

Deoxycholic	B-T103
acid	I-T103
levels	O
tended	O
to	O
be	O
higher	O
in	O
the	O
VO	O
group	O
than	O
in	O
the	O
HF	O
group	O
.	O

Voglibose	B-T103
administration	B-T058
downregulated	B-T038
expression	O
levels	O
of	O
CYP8B1	B-T017
and	O
HNF4α	B-T017
genes	I-T017
and	O
upregulated	B-T038
those	O
of	O
PGC1α	B-T017
,	O
whereas	O
FXRα	B-T017
was	O
not	O
affected	O
.	O

Voglibose	B-T103
administration	B-T058
elicits	O
changes	O
in	O
the	O
composition	B-T201
of	O
the	O
intestinal	O
microbiota	O
and	O
circulating	B-T103
metabolites	I-T103
,	O
which	O
ultimately	O
has	O
systemic	O
effects	O
on	O
body	O
weight	O
and	O
lipid	B-T038
metabolism	I-T038
in	O
mice	B-T204
.	O

Supramolecular	O
Recognition	O
of	O
Amino	B-T103
Acids	I-T103
by	O
Twisted	B-T103
Cucurbit	I-T103
[	I-T103
14	I-T103
]	I-T103
uril	I-T103

Binding	B-T038
interactions	O
between	B-T082
twisted	B-T103
cucurbit	I-T103
[	I-T103
14	I-T103
]	I-T103
uril	I-T103
(	B-T103
tQ	I-T103
[	I-T103
14	I-T103
]	I-T103
)	I-T103
and	O
twenty	O
standard	O
amino	B-T103
acids	I-T103
(	B-T103
AAs	I-T103
)	I-T103
have	O
been	O
investigated	O
by	O
NMR	B-T058
spectroscopy	I-T058
and	O
isothermal	B-T058
titration	I-T058
calorimetry	I-T058
(	B-T058
ITC	I-T058
)	I-T058
in	O
aqueous	B-T103
HCl	B-T103
solutions	I-T103
and	O
in	O
DMSO	B-T103
.	O

The	O
results	O
showed	O
that	O
tQ	B-T103
[	I-T103
14	I-T103
]	I-T103
displays	O
clear	O
binding	B-T038
affinity	O
for	O
AAs	B-T103
with	O
a	O
positively	O
charged	O
side	O
chain	O
or	O
containing	O
an	O
aromatic	B-T103
ring	I-T103
,	O
but	O
weaker	O
binding	B-T038
affinity	O
for	O
AAs	B-T103
with	O
hydrophobic	O
or	O
polar	O
side	O
chains	O
,	O
with	O
the	O
binding	B-T038
mode	O
depending	O
on	O
the	O
type	O
of	O
side	O
chain	O
present	O
in	O
the	O
AAs	B-T103
.	O

Comparison	O
of	O
alkaline	B-T038
phosphatase	I-T038
activity	I-T038
of	O
MC3T3	B-T017
-	I-T017
E1	I-T017
cells	I-T017
cultured	O
on	O
different	O
Ti	B-T103
surfaces	B-T082
:	O
modified	O
sandblasted	O
with	O
large	O
grit	B-T103
and	O
acid	O
-	O
etched	O
(	O
MSLA	B-T103
)	O
,	O
laser	O
-	O
treated	O
,	O
and	O
laser	O
and	O
acid	O
-	O
treated	O
Ti	B-T103
surfaces	B-T082

In	O
this	O
study	B-T062
,	O
the	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
effect	O
of	O
implant	O
surface	B-T082
treatment	O
on	O
cell	B-T038
differentiation	I-T038
of	O
osteoblast	B-T017
cells	I-T017
.	O

For	O
this	O
purpose	O
,	O
three	O
surfaces	B-T082
were	O
compared	O
:	O
(	O
1	O
)	O
a	O
modified	O
SLA	O
(	O
MSLA	O
:	O
sand	O
-	O
blasted	O
with	O
large	O
grit	B-T103
,	O
acid	O
-	O
etched	O
,	O
and	O
immersed	O
in	O
0	O
.	O
9	O
%	O
NaCl	B-T103
)	O
,	O
(	O
2	O
)	O
a	O
laser	O
treatment	O
(	O
LT	O
:	O
laser	O
treatment	O
)	O
titanium	B-T103
surface	B-T082
and	O
(	O
3	O
)	O
a	O
laser	O
and	O
acid	O
-	O
treated	O
(	O
LAT	O
:	O
laser	O
treatment	O
,	O
acid	O
-	O
etched	O
)	O
titanium	B-T103
surface	B-T082
.	O

The	O
MSLA	B-T103
surfaces	B-T082
were	O
considered	O
as	O
the	O
control	O
group	O
,	O
and	O
LT	B-T103
and	O
LAT	B-T103
surfaces	B-T082
as	O
test	O
groups	O
.	O

Alkaline	B-T103
phosphatase	I-T103
expression	B-T038
(	O
ALP	B-T103
)	O
was	O
used	O
to	O
quantify	O
osteoblastic	B-T038
differentiation	I-T038
of	O
MC3T3	B-T017
-	I-T017
E1	I-T017
cell	I-T017
.	O

Surface	B-T082
roughness	O
was	O
evaluated	B-T058
by	O
a	O
contact	B-T074
profilometer	I-T074
(	O
URFPAK	O
-	O
SV	O
;	O
Mitutoyo	O
,	O
Kawasaki	O
,	O
Japan	B-T082
)	O
and	O
characterized	O
by	O
two	O
parameters	O
:	O
mean	O
roughness	O
(	O
Ra	O
)	O
and	O
maximum	O
peak	O
-	O
to	O
-	O
valley	O
height	O
(	O
Rt	O
)	O
.	O

Scanning	B-T074
electron	I-T074
microscope	I-T074
revealed	O
that	O
MSLA	O
(	O
control	O
group	O
)	O
surface	B-T082
was	O
not	O
as	O
rough	O
as	O
LT	B-T103
,	O
LAT	B-T103
surface	B-T082
(	O
test	O
groups	O
)	O
.	O

Alkaline	B-T103
phosphatase	I-T103
expression	B-T038
,	O
the	O
measure	O
of	O
osteoblastic	B-T038
differentiation	I-T038
,	O
and	O
total	O
ALP	B-T103
expression	B-T038
by	O
surface	B-T017
-	I-T017
adherent	I-T017
cells	I-T017
were	O
found	O
to	O
be	O
highest	O
at	O
21	O
days	O
for	O
all	O
three	O
surfaces	B-T082
tested	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
ALP	B-T103
expression	B-T038
levels	O
of	O
MSLA	B-T103
and	O
LAT	B-T103
surfaces	B-T082
were	O
significantly	O
higher	O
than	O
expression	B-T038
levels	O
of	O
LT	B-T103
surface	B-T017
-	I-T017
adherent	I-T017
cells	I-T017
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
,	O
respectively	O
(	O
P	O
<	O
.	O
05	O
)	O
.	O

However	O
,	O
ALP	B-T103
expression	B-T038
levels	O
between	O
MSLA	B-T103
and	O
LAT	B-T103
surface	B-T082
were	O
equal	O
at	O
7	O
,	O
14	O
,	O
and	O
21	O
days	O
(	O
P	O
>	O
.	O
05	O
)	O
.	O

This	O
study	B-T062
suggested	O
that	O
MSLA	B-T103
and	O
LAT	B-T103
surfaces	B-T082
exhibited	O
more	O
favorable	O
environment	B-T082
for	O
osteoblast	B-T038
differentiation	I-T038
when	O
compared	O
with	O
LT	B-T103
surface	B-T082
,	O
the	O
results	O
that	O
are	O
important	O
for	O
implant	B-T074
surface	B-T082
modification	O
studies	B-T062
.	O

Overcoming	O
structural	B-T082
inequalities	O
in	O
oral	B-T058
health	I-T058
:	O
the	O
role	O
of	O
dental	B-T058
curricula	B-T170

To	O
date	O
the	O
role	O
of	O
health	B-T092
professional	I-T092
schools	I-T092
in	O
addressing	O
oral	B-T058
health	I-T058
inequalities	O
have	O
been	O
minimal	O
,	O
as	O
attempts	O
have	O
focused	O
principally	O
upon	O
systemic	O
reform	O
and	O
broader	O
societal	O
obligations	O
.	O

Professionalism	O
is	O
a	O
broad	O
competency	O
that	O
is	O
taught	O
throughout	O
dental	B-T092
schools	I-T092
and	O
encompasses	O
a	O
range	O
of	O
attributes	O
.	O

Professionalism	O
as	O
a	O
competency	O
draws	O
some	O
debate	O
and	O
appears	O
to	O
be	O
a	O
shifting	O
phenomenon	O
.	O

We	O
may	O
ask	O
if	O
professionalism	O
in	O
the	O
dental	B-T058
curricula	B-T170
may	O
be	O
better	O
addressed	O
by	O
social	O
accountability	O
?	O
Social	O
accountability	O
directs	O
oral	B-T058
health	I-T058
professional	B-T170
curricula	I-T170
(	O
education	B-T170
,	O
research	B-T062
,	O
and	O
service	O
activities	O
)	O
towards	O
addressing	O
the	O
priority	O
health	O
concerns	O
of	O
the	O
community	O
,	O
in	O
our	O
case	O
oral	B-T058
health	I-T058
inequalities	O
.	O

Although	O
working	O
toward	O
dental	B-T092
schools	I-T092
becoming	O
more	O
socially	O
accountable	O
seems	O
like	O
a	O
sensible	O
way	O
to	O
address	B-T170
oral	B-T058
health	I-T058
inequalities	O
,	O
it	O
might	O
have	O
limitations	O
.	O

We	O
will	O
consider	O
some	O
of	O
the	O
challenges	O
in	O
the	O
dental	B-T058
curricula	B-T170
by	O
considering	O
some	O
of	O
the	O
political	O
,	O
structural	B-T082
,	O
social	O
and	O
ethical	O
factors	O
that	O
influence	O
our	O
institutions	B-T092
and	O
our	O
graduates	B-T098
.	O

Function	O
analysis	B-T062
of	O
Mef2c	B-T017
promoter	B-T103
in	O
muscle	B-T038
differentiation	I-T038

Regeneration	B-T038
of	I-T038
adult	I-T038
skeletal	I-T038
muscle	I-T038
following	O
injury	B-T037
occurs	O
through	O
the	O
activation	B-T038
of	O
satellite	B-T017
cells	I-T017
,	O
that	O
proliferates	B-T038
,	O
differentiates	B-T038
,	O
and	O
fuses	B-T038
with	O
injured	O
myofibers	B-T017
.	O

Myocyte	B-T103
enhancer	I-T103
factor	I-T103
2	I-T103
(	I-T103
MEF2	I-T103
)	I-T103
proteins	I-T103
are	O
reported	O
that	O
they	O
have	O
the	O
potential	O
contributions	O
to	O
adult	O
muscle	B-T033
regeneration	I-T033
.	O

In	O
order	O
to	O
further	O
understand	O
Mef2c	B-T017
gene	I-T017
,	O
the	O
promoter	B-T103
of	O
pig	B-T204
Mef2c	B-T017
gene	I-T017
was	O
analyzed	O
in	O
this	O
paper	O
.	O

Quantitative	B-T062
real	I-T062
-	I-T062
time	I-T062
PCR	I-T062
(	O
qRT	B-T062
-	I-T062
PCR	I-T062
)	O
revealed	O
the	O
expression	B-T038
pattern	O
of	O
Mef2c	B-T017
gene	I-T017
in	O
muscle	B-T017
of	O
eight	O
tissues	B-T017
.	O

The	O
Mef2c	B-T017
promoter	B-T103
had	O
the	O
higher	O
transcriptional	B-T038
activity	I-T038
in	O
differentiated	B-T038
C2C12	B-T017
cells	I-T017
than	O
that	O
in	O
proliferating	B-T038
C2C12	B-T017
cells	I-T017
,	O
which	O
was	O
accompanied	O
by	O
the	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
mRNA	B-T038
expression	I-T038
of	O
Mef2c	B-T017
gene	I-T017
.	O

Function	O
deletion	B-T038
and	O
mutation	B-T038
analyses	B-T062
showed	O
that	O
MyoD	B-T103
and	O
MEF2	B-T103
binding	B-T082
sites	I-T082
within	O
the	O
Mef2c	B-T017
promoter	B-T103
were	O
responsible	O
for	O
the	O
regulation	B-T038
of	O
Mef2c	B-T017
transcription	B-T038
.	O

MEF2C	B-T017
could	O
up	B-T038
-	I-T038
regulate	I-T038
the	I-T038
transcriptional	I-T038
activities	I-T038
of	O
Mef2c	B-T017
promoter	B-T103
constructs	I-T103
which	O
contained	O
a	O
3	B-T082
'	I-T082
-	I-T082
end	I-T082
nucleotide	I-T082
sequence	I-T082
with	O
p300	B-T103
binding	B-T082
site	I-T082
.	O

The	O
Electrophoretic	B-T058
mobility	I-T058
shift	I-T058
assays	I-T058
(	O
EMSA	B-T058
)	O
and	O
chromatin	B-T058
immunoprecipitation	I-T058
(	I-T058
ChIP	I-T058
)	I-T058
assays	I-T058
determined	O
the	O
MyoD	B-T103
binding	B-T082
site	I-T082
in	O
Mef2c	B-T017
promoter	B-T103
.	O

These	O
results	O
advanced	O
our	O
knowledge	O
of	O
the	O
promoter	B-T103
of	O
the	O
pig	B-T204
Mef2c	B-T017
gene	I-T017
.	O

And	O
the	O
study	O
of	O
Mef2c	B-T017
promoter	B-T103
regulator	O
elements	O
helped	O
to	O
elucidating	O
the	O
regulation	B-T038
mechanisms	I-T038
of	O
Mef2c	B-T017
in	O
muscle	B-T038
differentiation	I-T038
or	O
muscle	B-T058
repair	I-T058
and	O
regeneration	B-T033
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Novel	O
insights	O
into	O
development	O
of	O
diabetic	B-T033
bladder	B-T038
disorder	I-T038
provided	O
by	O
metabolomic	B-T091
analysis	I-T091
of	O
the	O
rat	B-T204
nondiabetic	O
and	O
diabetic	B-T033
detrusor	B-T017
and	O
urothelial	B-T017
layer	I-T017

There	O
are	O
at	O
present	O
no	O
published	O
studies	O
providing	O
a	O
global	O
overview	O
of	O
changes	O
in	O
bladder	B-T017
metabolism	B-T038
resulting	O
from	O
diabetes	B-T038
.	O

Such	O
studies	O
have	O
the	O
potential	O
to	O
provide	O
mechanistic	O
insight	O
into	O
the	O
development	O
of	O
diabetic	B-T033
bladder	B-T038
disorder	I-T038
(	I-T038
DBD	I-T038
)	I-T038
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
the	O
metabolome	O
of	O
detrusor	B-T017
and	O
urothelial	B-T017
layer	I-T017
in	O
a	O
1	O
-	O
mo	O
streptozotocin	B-T103
-	O
induced	O
rat	B-T204
model	B-T038
of	O
type	B-T038
1	I-T038
diabetes	I-T038
with	O
nondiabetic	O
controls	O
.	O

Our	O
studies	O
revealed	O
that	O
diabetes	B-T038
caused	O
both	O
common	O
and	O
differential	O
changes	O
in	O
the	O
detrusor	B-T017
and	O
urothelial	B-T017
layer	I-T017
'	I-T017
s	I-T017
metabolome	O
.	O

Diabetes	B-T038
resulted	O
in	O
similar	O
changes	O
in	O
the	O
levels	O
of	O
previously	O
described	O
diabetic	B-T038
markers	B-T201
in	O
both	O
tissues	B-T017
,	O
such	O
as	O
glucose	B-T103
,	O
lactate	B-T103
,	O
2	B-T103
-	I-T103
hydroxybutyrate	I-T103
,	O
branched	B-T103
-	I-T103
chain	I-T103
amino	I-T103
acid	I-T103
degradation	I-T103
products	I-T103
,	O
bile	B-T103
acids	I-T103
,	O
and	O
1	B-T103
,	I-T103
5	I-T103
-	I-T103
anhydroglucitol	I-T103
,	O
as	O
well	O
as	O
markers	B-T201
of	O
oxidative	B-T038
stress	I-T038
.	O

In	O
the	O
detrusor	B-T017
(	O
but	O
not	O
the	O
urothelial	B-T017
layer	I-T017
)	O
,	O
diabetes	B-T038
caused	O
activation	O
of	O
the	O
pentose	B-T103
-	I-T103
phosphate	I-T103
and	O
polyol	B-T103
pathways	B-T038
,	O
concomitant	O
with	O
a	O
reduction	O
in	O
the	O
TCA	B-T038
cycle	I-T038
and	O
β	B-T038
-	I-T038
oxidation	I-T038
.	O

Changes	O
in	O
detrusor	B-T017
energy	B-T038
-	I-T038
generating	I-T038
pathways	I-T038
resulted	O
in	O
an	O
accumulation	O
of	O
sorbitol	B-T103
that	O
,	O
through	O
generation	O
of	O
advanced	B-T103
glycation	I-T103
end	I-T103
products	I-T103
,	O
is	O
likely	O
to	O
play	O
a	O
central	O
role	O
in	O
the	O
development	O
of	O
DBD	B-T038
.	O

In	O
the	O
diabetic	B-T033
urothelial	B-T017
layer	I-T017
there	O
was	O
decreased	O
flux	O
of	O
glucose	B-T103
via	O
glycolysis	B-T038
and	O
changes	O
in	O
lipid	B-T038
metabolism	I-T038
,	O
particularly	O
prostaglandin	B-T103
synthesis	O
,	O
which	O
also	O
potentially	O
contributes	O
to	O
detrusor	B-T017
dysfunction	B-T038
.	O

Proximal	B-T058
Soil	I-T058
Sensing	I-T058
-	O
A	O
Contribution	O
for	O
Species	B-T170
Habitat	B-T082
Distribution	O
Modelling	B-T062
of	O
Earthworms	B-T204
in	O
Agricultural	B-T082
Soils	O
?	O

Earthworms	B-T204
are	O
important	O
for	O
maintaining	O
soil	O
ecosystem	O
functioning	O
and	O
serve	O
as	O
indicators	B-T103
of	O
soil	O
fertility	O
.	O

However	O
,	O
detection	O
of	O
earthworms	B-T204
is	O
time	O
-	O
consuming	O
,	O
which	O
hinders	O
the	O
assessment	O
of	O
earthworm	B-T204
abundances	O
with	O
high	O
sampling	O
density	O
over	O
entire	O
fields	B-T082
.	O

Recent	O
developments	O
of	O
mobile	O
terrestrial	O
sensor	O
platforms	O
for	O
proximal	B-T058
soil	I-T058
sensing	I-T058
(	O
PSS	B-T058
)	O
provided	O
new	O
tools	O
for	O
collecting	O
dense	O
spatial	O
information	O
of	O
soils	O
using	O
various	O
sensing	B-T170
principles	I-T170
.	O

Yet	O
,	O
the	O
potential	O
of	O
PSS	B-T058
for	O
assessing	O
earthworm	B-T204
habitats	B-T082
is	O
largely	O
unexplored	O
.	O

This	O
study	B-T062
investigates	O
whether	O
PSS	B-T058
data	O
contribute	O
to	O
the	O
spatial	O
prediction	O
of	O
earthworm	B-T204
abundances	O
in	O
species	B-T170
distribution	O
models	B-T170
of	O
agricultural	B-T082
soils	O
.	O

Proximal	B-T058
soil	I-T058
sensing	I-T058
data	O
,	O
e	O
.	O
g	O
.	O
,	O
soil	O
electrical	O
conductivity	O
(	O
EC	O
)	O
,	O
pH	O
,	O
and	O
near	B-T058
infrared	I-T058
absorbance	I-T058
(	O
NIR	B-T058
)	O
,	O
were	O
collected	O
in	O
real	O
-	O
time	O
in	O
a	O
field	B-T082
with	O
two	O
management	O
strategies	O
(	O
reduced	O
tillage	O
/	O
conventional	O
tillage	O
)	O
and	O
sandy	O
to	O
loam	O
soils	O
.	O

PSS	B-T058
was	O
related	O
to	O
observations	B-T062
from	O
a	O
long	O
-	O
term	O
(	O
11	O
years	O
)	O
earthworm	B-T204
observation	O
study	O
conducted	O
at	O
42	O
plots	B-T082
.	O

Earthworms	B-T204
were	O
sampled	O
from	O
0	O
.	O
5	O
x	O
0	O
.	O
5	O
x	O
0	O
.	O
2	O
m³	O
soil	O
blocks	O
and	O
identified	O
to	O
species	B-T170
level	O
.	O

Sensor	O
data	O
were	O
highly	O
correlated	O
with	O
earthworm	B-T204
abundances	O
observed	O
in	O
reduced	O
tillage	O
but	O
less	O
correlated	O
with	O
earthworm	B-T204
abundances	O
observed	O
in	O
conventional	O
tillage	O
.	O

This	O
may	O
indicate	O
that	O
management	O
influences	O
the	O
sensor	O
-	O
earthworm	B-T204
relationship	O
.	O

Generalized	O
additive	O
models	B-T170
and	O
state	B-T170
-	I-T170
space	I-T170
models	I-T170
showed	O
that	O
modelling	B-T062
based	O
on	O
data	O
fusion	O
from	O
EC	O
,	O
pH	O
,	O
and	O
NIR	B-T058
sensors	O
produced	O
better	O
results	O
than	O
modelling	B-T062
without	O
sensor	O
data	O
or	O
data	O
from	O
just	O
a	O
single	O
sensor	O
.	O

Regarding	O
the	O
individual	O
earthworm	B-T204
species	B-T170
,	O
particular	O
sensor	O
combinations	O
were	O
more	O
appropriate	O
than	O
others	O
due	O
to	O
the	O
different	O
habitat	B-T082
requirements	O
of	O
the	O
earthworms	B-T204
.	O

Earthworm	B-T204
species	B-T170
with	O
soil	O
-	O
specific	O
habitat	B-T082
preferences	O
were	O
spatially	O
predicted	O
with	O
higher	O
accuracy	O
by	O
PSS	B-T058
than	O
more	O
ubiquitous	O
species	B-T170
.	O

Our	O
findings	B-T033
suggest	O
that	O
PSS	B-T058
contributes	O
to	O
the	O
spatial	O
modelling	B-T062
of	O
earthworm	B-T204
abundances	O
at	O
field	O
scale	O
and	O
that	O
it	O
will	O
support	O
species	B-T170
distribution	O
modelling	B-T062
in	O
the	O
attempt	O
to	O
understand	O
the	O
soil	O
-	O
earthworm	B-T204
relationships	O
in	O
agroecosystems	O
.	O

Size	O
matters	O
to	O
function	O
:	O
Brain	O
volume	O
correlates	O
with	O
intrinsic	B-T082
brain	B-T038
activity	I-T038
across	O
healthy	O
individuals	B-T098

A	O
fundamental	O
issue	O
in	O
neuroscience	B-T091
is	O
to	O
understand	O
the	O
structural	B-T082
substrates	O
of	O
neural	O
activities	O
.	O

Intrinsic	B-T082
brain	B-T038
activity	I-T038
has	O
been	O
increasingly	O
recognized	O
as	O
an	O
important	O
functional	O
activity	O
mode	O
and	O
is	O
tightly	O
linked	O
with	O
various	O
cognitive	B-T038
functions	I-T038
.	O

Structurally	O
,	O
cognitive	B-T038
functions	I-T038
have	O
also	O
shown	O
a	O
relation	O
with	O
brain	O
volume	O
/	O
size	O
.	O

Therefore	O
,	O
an	O
association	O
between	O
intrinsic	B-T082
brain	B-T038
activities	I-T038
and	O
brain	O
volume	O
/	O
size	O
can	O
be	O
hypothesized	O
,	O
and	O
brain	O
volume	O
/	O
size	O
may	O
impact	O
intrinsic	B-T082
brain	B-T038
activity	I-T038
in	O
human	B-T204
brains	B-T017
.	O

The	O
present	O
study	B-T062
aimed	O
to	O
explicitly	O
investigate	O
this	O
brain	B-T017
structure	I-T017
-	O
function	B-T038
relationship	O
using	O
two	O
large	O
independent	O
cohorts	B-T098
of	O
176	O
and	O
236	O
young	O
adults	O
.	O

Structural	B-T082
-	O
MRI	B-T058
was	O
performed	O
to	O
estimate	O
the	O
brain	O
volume	O
,	O
and	O
resting	B-T058
-	I-T058
state	I-T058
functional	I-T058
-	I-T058
MRI	I-T058
was	O
applied	O
to	O
extract	O
the	O
amplitude	O
of	O
low	O
-	O
frequency	O
fluctuations	O
(	O
ALFF	O
)	O
,	O
an	O
imaging	O
measure	O
of	O
intrinsic	B-T082
brain	B-T038
activity	I-T038
.	O

Intriguingly	O
,	O
our	O
results	O
revealed	O
a	O
robust	O
linear	B-T082
correlation	O
between	O
whole	O
-	O
brain	O
size	O
and	O
ALFF	O
.	O

Moreover	O
,	O
specific	O
brain	B-T017
lobes	I-T017
/	O
regions	B-T082
,	O
including	O
the	O
frontal	B-T017
lobe	I-T017
,	O
the	O
left	B-T017
middle	I-T017
frontal	I-T017
gyrus	I-T017
,	O
anterior	B-T017
cingulate	I-T017
gyrus	I-T017
,	O
Rolandic	B-T017
operculum	I-T017
,	O
and	O
insula	B-T017
,	O
also	O
showed	O
a	O
reliable	O
,	O
positive	B-T033
volume	O
-	O
ALFF	O
correlation	O
in	O
the	O
two	O
cohorts	B-T098
.	O

These	O
findings	O
offer	O
direct	O
,	O
empirical	O
evidence	O
of	O
a	O
strong	O
association	O
between	O
brain	O
size	O
/	O
volume	O
and	O
intrinsic	B-T082
brain	B-T038
activity	I-T038
,	O
as	O
well	O
as	O
provide	O
novel	O
insight	O
into	O
the	O
structural	B-T082
substrates	O
of	O
the	O
intrinsic	B-T082
brain	B-T038
activity	I-T038
of	O
the	O
human	B-T204
brain	B-T017
.	O

On	O
the	O
Control	O
of	O
Social	O
Approach	B-T033
-	I-T033
Avoidance	I-T033
Behavior	I-T033
:	O
Neural	O
and	O
Endocrine	O
Mechanisms	O

The	O
ability	O
to	O
control	O
our	O
automatic	O
action	O
tendencies	O
is	O
crucial	O
for	O
adequate	O
social	B-T033
interactions	I-T033
.	O

Emotional	B-T033
events	O
trigger	O
automatic	O
approach	B-T033
and	I-T033
avoidance	I-T033
tendencies	O
.	O

Although	O
these	O
actions	O
may	O
be	O
generally	O
adaptive	O
,	O
the	O
capacity	O
to	O
override	O
these	O
emotional	B-T033
reactions	I-T033
may	O
be	O
key	O
to	O
flexible	O
behavior	O
during	O
social	B-T033
interaction	I-T033
.	O

The	O
present	O
chapter	O
provides	O
a	O
review	O
of	O
the	O
neuroendocrine	B-T022
mechanisms	O
underlying	O
this	O
ability	O
and	O
their	O
relation	O
to	O
social	O
psychopathologies	B-T091
.	O

Aberrant	O
social	O
behavior	O
,	O
such	O
as	O
observed	O
in	O
social	O
anxiety	O
or	O
psychopathy	B-T038
,	O
is	O
marked	O
by	O
abnormalities	B-T033
in	O
approach	B-T033
-	I-T033
avoidance	I-T033
tendencies	O
and	O
the	O
ability	O
to	O
control	O
them	O
.	O

Key	O
neural	O
regions	B-T082
involved	O
in	O
the	O
regulation	B-T038
of	O
approach	B-T033
-	I-T033
avoidance	I-T033
behavior	I-T033
are	O
the	O
amygdala	B-T017
,	O
widely	O
implicated	O
in	O
automatic	O
emotional	B-T033
processing	B-T038
,	O
and	O
the	O
anterior	B-T082
prefrontal	B-T017
cortex	I-T017
,	O
which	O
exerts	B-T038
control	O
over	O
the	O
amygdala	B-T017
.	O

Hormones	B-T103
,	O
especially	O
testosterone	B-T103
and	O
cortisol	B-T103
,	O
have	O
been	O
shown	O
to	O
affect	B-T038
approach	B-T033
-	I-T033
avoidance	I-T033
behavior	I-T033
and	O
the	O
associated	O
neural	O
mechanisms	O
.	O

The	O
present	O
chapter	O
also	O
discusses	O
ways	O
to	O
directly	O
influence	O
social	O
approach	B-T033
and	I-T033
avoidance	I-T033
behavior	I-T033
and	O
will	O
end	O
with	O
a	O
research	B-T062
agenda	O
to	O
further	O
advance	O
this	O
important	O
research	B-T062
field	I-T062
.	O

Control	O
over	O
approach	B-T033
-	I-T033
avoidance	I-T033
tendencies	O
may	O
serve	O
as	O
an	O
exemplar	B-T170
of	O
emotional	B-T033
action	O
regulation	B-T038
and	O
might	O
have	O
a	O
great	O
value	O
in	O
understanding	B-T038
the	O
underlying	O
mechanisms	O
of	O
the	O
development	O
of	O
affective	B-T038
disorders	I-T038
.	O

High	O
Occurrence	O
of	O
Non	B-T038
-	I-T038
Clear	I-T038
Cell	I-T038
Renal	I-T038
Cell	I-T038
Carcinoma	I-T038
in	O
Oman	B-T082

It	O
is	O
conventionally	O
accepted	O
that	O
renal	B-T038
cell	I-T038
carcinoma	I-T038
(	O
RCC	B-T038
)	O
occurs	O
in	O
older	O
patients	O
and	O
the	O
clear	B-T038
cell	I-T038
type	I-T038
is	O
the	O
most	O
common	O
histology	B-T091
.	O

However	O
,	O
ethnic	O
variations	O
exist	O
and	O
this	O
study	B-T062
was	O
carried	O
out	O
to	O
determine	O
the	O
epidemiological	O
pattern	O
of	O
RCC	B-T038
in	O
Oman	B-T082
.	O

Ninety	O
RCC	B-T038
patients	O
who	O
presented	O
to	O
a	O
tertiary	B-T092
care	I-T092
center	I-T092
in	O
the	O
Sultanate	B-T082
of	I-T082
Oman	I-T082
from	O
2010	O
to	O
2014	O
were	O
studied	B-T062
.	O

The	O
main	B-T033
findings	I-T033
were	O
that	O
the	O
median	O
age	O
of	O
presentation	O
was	O
low	O
,	O
more	O
patients	O
presented	O
with	O
localized	B-T082
stage	O
,	O
and	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
non	B-T038
-	I-T038
clear	I-T038
(	O
especially	O
papillary	B-T038
)	O
histology	B-T091
.	O

Data	O
from	O
other	O
Gulf	B-T082
countries	I-T082
and	O
possible	O
reasons	O
for	O
the	O
different	O
profile	O
are	O
discussed	O
.	O

Patient	O
Mobility	O
for	O
Elective	O
Secondary	B-T058
Health	I-T058
Care	I-T058
Services	I-T058
in	O
Response	B-T038
to	O
Patient	B-T170
Choice	I-T170
Policies	I-T170
:	O
A	O
Systematic	B-T170
Review	I-T170

Our	O
review	O
establishes	O
the	O
empirical	O
evidence	O
for	O
patient	O
mobility	O
for	O
elective	B-T058
secondary	I-T058
care	I-T058
services	I-T058
in	O
countries	B-T082
that	O
allow	O
patients	O
to	O
choose	O
their	O
health	O
care	O
provider	O
.	O

PubMed	B-T170
and	O
Embase	B-T170
were	O
searched	O
for	O
relevant	O
articles	B-T170
between	O
1990	O
and	O
2015	O
.	O

Of	O
5	O
,	O
994	O
titles	B-T170
/	O
abstracts	B-T170
reviewed	O
,	O
26	O
studies	B-T062
were	O
included	O
.	O

The	O
studies	B-T062
used	O
three	O
main	O
methodological	O
models	B-T170
to	O
establish	O
mobility	B-T033
.	O

Variation	O
in	O
the	O
extent	O
of	O
patient	O
mobility	O
was	O
observed	O
across	O
the	O
studies	O
.	O

Mobility	B-T033
was	O
positively	O
associated	O
with	O
lower	O
waiting	O
times	O
,	O
indicators	O
of	O
better	B-T058
service	I-T058
quality	I-T058
,	O
and	O
access	O
to	O
advanced	B-T092
technology	I-T092
.	O

It	O
was	O
negatively	O
associated	O
with	O
advanced	B-T098
age	I-T098
or	O
lower	O
socioeconomic	O
backgrounds	O
.	O

From	O
a	O
policy	B-T170
perspective	B-T170
we	O
demonstrate	O
that	O
a	O
significant	O
proportion	O
of	O
patients	O
are	O
prepared	O
to	O
travel	O
beyond	O
their	O
nearest	O
provider	O
for	O
elective	O
services	O
.	O

As	O
a	O
consequence	O
,	O
some	O
providers	O
are	O
likely	O
to	O
be	O
"	O
winners	O
"	O
and	O
others	O
"	O
losers	B-T033
,	O
"	O
which	O
could	O
result	O
in	O
overall	O
decreased	O
provider	O
capacity	O
or	O
inefficient	O
utilization	O
of	O
existing	O
services	B-T058
.	O

Equity	O
also	O
remains	O
a	O
key	O
concern	O
.	O

New	O
Breast	B-T033
Pain	I-T033
Chart	B-T074
for	O
Objective	B-T170
Record	I-T170
of	O
Mastalgia	B-T033

Mastalgia	B-T033
is	O
the	O
commonest	O
affliction	B-T038
of	O
mammary	B-T017
gland	I-T017
among	O
ladies	B-T098
of	O
the	O
reproductive	O
age	O
group	O
.	O

Since	O
etiopathogenesis	O
and	O
therapy	B-T058
are	O
different	O
for	O
cyclical	B-T033
and	O
noncyclical	B-T033
pain	I-T033
,	O
it	O
is	O
imperative	O
to	O
ascertain	O
the	O
exact	O
type	O
correctly	O
.	O

This	O
is	O
usually	O
done	O
in	O
the	O
breast	B-T092
clinics	I-T092
by	O
advising	O
the	O
patient	O
to	O
fill	O
a	O
pain	B-T170
diary	I-T170
over	O
a	O
period	O
of	O
2	O
months	O
over	O
two	O
menstrual	B-T038
cycles	I-T038
.	O

The	O
Cardiff	B-T074
pain	I-T074
chart	I-T074
records	I-T074
the	O
severity	O
of	O
pain	B-T033
in	O
the	O
form	O
of	O
a	O
triangle	O
for	O
mild	O
to	O
moderate	B-T033
pain	I-T033
and	O
a	O
square	B-T082
for	O
severe	B-T033
pain	I-T033
.	O

Moreover	O
,	O
Cardiff	B-T074
pain	I-T074
chart	I-T074
does	O
not	O
allow	O
a	O
patient	O
to	O
record	O
the	O
severity	O
of	O
pain	B-T033
on	O
days	O
of	O
menses	B-T038
,	O
as	O
she	O
has	O
to	O
put	O
the	O
letter	O
"	O
P	O
"	O
in	O
the	O
box	O
.	O

These	O
problems	B-T033
have	O
been	O
resolved	O
in	O
the	O
new	O
breast	B-T033
pain	I-T033
chart	B-T074
.	O

In	O
the	O
new	O
pain	B-T074
chart	I-T074
,	O
the	O
lady	B-T098
records	O
pain	B-T033
severity	O
in	O
the	O
form	O
of	O
visual	B-T201
linear	I-T201
analogue	I-T201
scale	I-T201
score	I-T201
on	O
every	O
day	O
of	O
menstrual	B-T038
cycle	I-T038
.	O

She	O
enters	O
her	O
menstrual	B-T038
experience	B-T038
on	O
a	O
separate	O
part	O
of	O
chart	B-T074
,	O
which	O
allows	O
us	O
to	O
visualize	B-T082
the	O
full	O
month	O
'	O
s	O
pain	B-T033
severity	O
in	O
an	O
uncluttered	O
way	O
.	O

The	O
Demand	O
for	O
Cigarettes	O
in	O
Tanzania	B-T082
and	O
Implications	O
for	O
Tobacco	B-T103
Taxation	O
Policy	O

The	O
study	B-T062
attempts	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	O
in	O
Tanzania	B-T082
and	O
presents	O
simulation	B-T062
results	O
on	O
the	O
effect	O
of	O
the	O
cigarette	O
excise	O
tax	O
on	O
smoking	O
participation	O
,	O
government	O
revenue	O
,	O
and	O
related	O
topics	O
.	O

After	O
briefly	O
summarizing	O
the	O
magnitude	O
and	O
spread	O
of	O
cigarette	B-T033
consumption	I-T033
in	O
the	O
country	B-T082
,	O
the	O
paper	O
reviews	O
some	O
empirical	O
estimates	O
from	O
African	B-T082
and	O
other	O
countries	B-T082
.	O

The	O
2008	O
Tanzanian	B-T082
household	B-T170
budget	I-T170
survey	B-T170
was	O
used	O
to	O
estimate	O
the	O
demand	O
for	O
cigarettes	O
in	O
Tanzania	B-T082
.	O

The	O
descriptive	O
statistics	O
suggest	O
that	O
the	O
smoking	O
prevalence	O
for	O
Tanzania	B-T082
is	O
15	O
.	O
35	O
percent	O
with	O
low	O
variability	O
across	O
expenditure	O
(	O
income	O
)	O
groups	O
.	O

Smoking	O
intensity	O
and	O
per	O
capita	O
consumption	O
were	O
estimated	O
at	O
7	O
.	O
08	O
cigarettes	O
and	O
1	O
.	O
33	O
cigarettes	O
,	O
respectively	O
,	O
a	O
relatively	O
low	O
value	O
.	O

A	O
two	B-T170
-	I-T170
part	I-T170
demand	I-T170
equation	I-T170
model	I-T170
was	O
used	O
to	O
estimate	O
various	O
elasticities	O
.	O

For	O
the	O
overall	O
equation	O
,	O
the	O
price	O
elasticities	O
of	O
smoking	O
participation	O
,	O
smoking	O
intensity	O
,	O
and	O
total	O
elasticity	O
were	O
estimated	O
at	O
-	O
0	O
.	O
879	O
,	O
-	O
0	O
.	O
853	O
,	O
and	O
-	O
1	O
.	O
732	O
,	O
respectively	O
.	O

Compared	O
to	O
similar	O
results	O
in	O
other	O
developing	O
countries	O
,	O
the	O
estimates	O
appear	O
quite	O
high	O
.	O

When	O
estimated	O
by	O
expenditure	O
(	O
income	O
)	O
groups	O
,	O
the	O
magnitude	O
of	O
the	O
elasticity	O
appears	O
higher	O
among	O
high	O
expenditure	O
groups	O
than	O
among	O
low	O
expenditure	O
groups	O
.	O

Two	O
simulation	B-T062
exercises	O
were	O
undertaken	O
.	O

First	O
,	O
the	O
effect	O
of	O
different	O
excise	O
rates	O
on	O
smoking	O
participation	O
rate	O
,	O
cigarette	B-T033
consumption	I-T033
,	O
tax	O
revenue	O
,	O
and	O
related	O
responses	O
was	O
estimated	O
and	O
highlighted	O
.	O

Second	O
,	O
the	O
same	O
exercise	O
was	O
undertaken	O
to	O
determine	O
the	O
effect	O
of	O
a	O
given	O
increase	O
in	O
the	O
cigarette	O
excise	O
tax	O
on	O
various	O
expenditure	O
groups	O
.	O

The	O
overall	O
results	O
suggest	O
that	O
an	O
increase	O
in	O
the	O
excise	O
tax	O
on	O
cigarettes	O
in	O
Tanzania	B-T082
would	O
reduce	O
cigarette	B-T033
consumption	I-T033
and	O
increase	O
government	O
tax	O
revenue	O
.	O

Physicians	B-T097
'	I-T097
knowledge	O
on	O
the	O
work	O
-	O
related	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038

Chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
(	O
COPD	B-T038
)	O
may	O
be	O
induced	O
by	O
the	O
work	B-T082
environment	I-T082
conditions	O
.	O

According	O
to	O
the	O
estimates	O
,	O
10	O
-	O
20	O
%	O
of	O
all	O
COPD	B-T038
cases	O
are	O
associated	O
with	O
occupational	B-T037
exposure	I-T037
to	O
dusts	O
and	O
irritant	B-T103
gases	B-T103
.	O

However	O
,	O
in	O
2014	O
,	O
only	O
11	O
cases	O
of	O
work	O
-	O
related	O
COPD	B-T038
were	O
recognized	O
in	O
Poland	B-T082
.	O

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
analyze	B-T062
the	O
reasons	O
for	O
the	O
low	O
incidence	O
of	O
work	O
-	O
related	O
COPD	B-T038
in	O
the	O
context	O
of	O
pulmonologists	B-T097
'	O
knowledge	O
about	O
occupational	O
risk	B-T033
factors	I-T033
and	O
procedures	O
on	O
reporting	B-T058
suspected	B-T038
occupational	B-T038
diseases	I-T038
.	O

A	O
survey	B-T170
included	O
94	O
pulmonologists	B-T097
randomly	O
selected	O
out	O
of	O
225	O
specialists	O
registered	O
at	O
the	O
Local	B-T092
Physicians	I-T092
Chamber	I-T092
in	O
Łódź	O
.	O

The	O
study	B-T062
was	O
performed	O
anonymously	O
with	O
the	O
use	O
of	O
original	O
questionnaire	B-T170
.	O

More	O
than	O
a	O
half	O
of	O
the	O
surveyed	B-T170
pulmonologists	B-T097
identified	O
environmental	B-T082
risk	B-T033
factors	I-T033
for	O
COPD	B-T038
correctly	O
,	O
while	O
only	O
23	O
.	O
4	O
%	O
properly	O
identified	O
the	O
main	O
occupational	O
risk	B-T033
factors	I-T033
as	O
the	O
cause	O
of	O
COPD	B-T038
.	O

Only	O
58	O
.	O
5	O
%	O
of	O
the	O
pulmonologists	B-T097
always	O
asked	O
their	O
patients	O
suffering	B-T033
from	O
COPD	B-T038
about	O
their	O
job	O
/	O
profession	O
and	O
60	O
.	O
6	O
%	O
of	O
them	O
did	O
not	O
have	O
any	O
knowledge	O
about	O
procedures	O
on	O
reporting	B-T058
suspected	B-T038
occupational	B-T038
diseases	I-T038
.	O

The	O
physicians	B-T097
rarely	O
ask	O
patients	O
suffering	B-T033
from	O
COPD	B-T038
about	O
their	O
job	O
/	O
profession	O
and	O
the	O
relationship	O
between	O
their	O
ailments	B-T033
and	O
occupational	B-T037
exposure	I-T037
.	O

What	O
is	O
more	O
,	O
they	O
do	O
not	O
know	O
legal	O
regulations	O
on	O
proper	O
referral	B-T058
of	I-T058
a	I-T058
patient	I-T058
with	O
a	O
suspected	B-T038
case	O
of	O
occupational	B-T038
disease	I-T038
.	O

The	O
results	O
of	O
the	O
study	B-T062
clearly	O
indicate	O
that	O
there	O
is	O
an	O
urgent	O
need	O
for	O
increasing	O
pulmonologists	B-T097
'	O
knowledge	O
on	O
work	O
-	O
related	O
COPD	B-T038
.	O

Med	O
Pr	O
2016	O
;	O
67	O
(	O
3	O
)	O
:	O
375	O
-	O
384	O
.	O

Case	B-T170
Report	I-T170
of	O
Necrotizing	B-T038
Fasciitis	I-T038
Associated	O
with	O
Streptococcus	B-T007
pneumoniae	I-T007

Necrotizing	B-T038
fasciitis	I-T038
,	O
caused	O
by	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
is	O
an	O
extremely	O
rare	O
and	O
life	B-T033
-	I-T033
threatening	I-T033
bacterial	B-T007
soft	B-T038
tissue	I-T038
infection	I-T038
.	O

We	O
report	B-T058
a	O
case	O
of	O
early	O
necrotizing	B-T038
fasciitis	I-T038
associated	O
with	O
Streptococcus	B-T007
pneumoniae	I-T007
infection	B-T038
in	O
a	O
26	O
-	O
year	O
-	O
old	O
man	B-T098
who	O
was	O
immunocompromised	B-T033
with	O
mixed	B-T038
connective	I-T038
tissue	I-T038
disease	I-T038
.	O

The	O
patient	O
presented	O
with	O
acute	O
,	O
painful	B-T033
,	O
erythematous	O
,	O
and	O
edematous	B-T038
skin	I-T038
lesions	B-T033
of	O
his	O
right	B-T082
lower	I-T082
back	I-T082
,	O
which	O
rapidly	O
progressed	O
to	O
the	O
right	B-T017
knee	I-T017
.	O

The	O
patient	O
underwent	O
surgical	B-T058
exploration	I-T058
,	O
and	O
a	O
diagnosis	B-T033
of	O
necrotizing	B-T038
fasciitis	I-T038
was	O
confirmed	O
by	O
pathological	O
evidence	O
of	O
necrosis	B-T038
of	O
the	O
fascia	B-T017
and	O
neutrophil	B-T038
infiltration	I-T038
in	O
tissue	O
biopsies	O
.	O

Cultures	O
of	O
fascial	B-T082
tissue	O
biopsies	O
and	O
blood	B-T031
samples	I-T031
were	O
positive	B-T033
for	O
Streptococcus	B-T007
pneumoniae	I-T007
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	B-T058
of	O
necrotizing	B-T038
fasciitis	I-T038
resulting	O
from	O
Streptococcus	B-T007
pneumoniae	I-T007
diagnosed	B-T033
at	O
early	O
phase	O
;	O
the	O
patient	O
recovered	O
well	O
without	O
surgical	B-T058
debridement	I-T058
.	O

A	O
Comparative	B-T062
Study	I-T062
of	O
the	O
Efficacy	O
of	O
IV	B-T082
Dexketoprofen	B-T103
,	O
Lornoxicam	B-T103
,	O
and	O
Diclophenac	B-T103
Sodium	I-T103
on	O
Postoperative	B-T058
Analgesia	I-T058
and	O
Tramadol	B-T103
Consumption	O
in	O
Patients	O
Receiving	O
Patient	B-T058
-	I-T058
Controlled	I-T058
Tramadol	B-T103

This	O
study	B-T062
was	O
designed	O
to	O
compare	O
the	O
effects	O
of	O
dexketoprofen	B-T103
,	O
lornoxicam	B-T103
,	O
and	O
diclophenac	B-T103
sodium	I-T103
on	O
postoperative	B-T058
analgesia	I-T058
and	O
tramadol	B-T103
consumption	O
in	O
patients	O
receiving	O
postoperative	O
patient	B-T058
-	I-T058
controlled	I-T058
tramadol	B-T103
after	O
a	O
major	O
abdominal	B-T058
surgery	I-T058
.	O

Eighty	O
patients	O
were	O
randomized	B-T033
to	O
receive	O
one	O
of	O
the	O
four	O
study	B-T062
drugs	B-T103
.	O

Patients	O
in	O
group	O
dexketoprofen	B-T103
(	O
DT	B-T103
)	O
received	O
IV	B-T082
50	O
mg	O
dexketoprofen	B-T103
,	O
group	O
lornoxicam	B-T103
(	O
LR	B-T103
)	O
received	O
IV	B-T082
8	O
mg	O
lornoxicam	B-T103
,	O
group	O
diclophenac	B-T103
sodium	I-T103
(	O
DS	B-T103
)	O
received	O
75	O
mg	O
IV	B-T082
diclophenac	B-T103
sodium	I-T103
and	O
group	O
saline	O
(	O
S	O
)	O
received	O
0	O
.	O
9	O
%	O
saline	O
in	O
2	O
mL	O
syringes	B-T074
,	O
20	O
min	O
before	O
the	O
end	O
of	O
anaesthesia	B-T058
.	O

A	O
standardized	O
(	O
1	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
dose	O
of	O
tramadol	B-T103
was	O
routinely	O
administered	O
to	O
all	O
patients	O
as	O
the	O
loading	O
dose	O
at	O
the	O
end	O
of	O
surgery	B-T058
.	O

Postoperatively	O
,	O
whenever	O
patients	O
requested	O
,	O
they	O
were	O
allowed	O
to	O
use	O
a	O
tramadol	B-T103
patient	B-T033
-	I-T033
controlled	I-T033
analgesia	I-T033
device	I-T033
giving	O
a	O
bolus	B-T058
dose	I-T058
(	O
0	O
.	O
2	O
mg	O
kg	O
(	O
-	O
1	O
)	O
)	O
of	O
tramadol	B-T103
.	O

Pain	B-T033
,	O
discomfort	B-T033
,	O
and	O
sedation	B-T033
scores	O
,	O
cumulative	O
tramadol	B-T103
consumption	O
,	O
supplemental	O
meperidine	B-T103
requirement	O
,	O
and	O
side	B-T038
effects	I-T038
were	O
recorded	O
.	O

Visual	O
rating	O
scale	O
and	O
patient	O
discomfort	B-T033
scores	O
were	O
significantly	O
lower	O
in	O
DT	B-T103
,	O
LR	B-T103
and	O
DS	B-T103
groups	O
compared	O
to	O
those	O
in	O
in	O
group	O
S	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Cumulative	O
tramadol	B-T103
consumption	O
was	O
significantly	O
lower	O
in	O
non	B-T103
-	I-T103
steroidal	I-T103
anti	I-T103
-	I-T103
inflammatory	I-T103
drug	I-T103
(	O
NSAID	B-T103
)	O
-	O
treated	O
groups	O
at	O
each	O
study	B-T062
period	I-T062
after	O
the	O
second	O
postoperative	O
hour	O
than	O
in	O
group	O
S	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Supplemental	O
meperidine	B-T103
requirement	O
was	O
significantly	O
higher	O
in	O
group	O
S	O
at	O
each	O
study	B-T062
period	I-T062
after	O
postoperative	O
30	O
min	O
than	O
in	O
NSAID	B-T103
-	O
treated	O
groups	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

After	O
major	O
abdominal	B-T058
surgery	I-T058
,	O
adding	O
IV	B-T082
diclophenac	B-T103
,	O
lornoxicam	B-T103
or	O
dexketoprofen	B-T103
to	O
patient	B-T058
-	I-T058
controlled	I-T058
tramadol	B-T103
resulted	O
in	O
lower	O
pain	B-T033
scores	O
,	O
smaller	O
tramadol	B-T103
consumption	O
,	O
less	O
rescue	O
supplemental	O
analgesic	B-T103
requirement	O
,	O
and	O
fewer	O
side	B-T038
effects	I-T038
compared	O
with	O
the	O
tramadol	B-T103
alone	O
group	O
.	O

Perioperative	B-T058
Management	I-T058
of	O
Severe	B-T033
Hypertension	I-T033
during	O
Laparoscopic	B-T058
Surgery	I-T058
for	O
Pheochromocytoma	B-T038

Phaeochromocytoma	B-T038
is	O
a	O
catecholamine	B-T038
-	I-T038
secreting	I-T038
vascular	B-T038
tumour	I-T038
that	O
is	O
derived	O
from	O
chromaffin	B-T017
cell	I-T017
.	O

Lethal	B-T033
cardiovascular	B-T038
complications	I-T038
,	O
such	O
as	O
serious	O
hypertension	B-T038
,	O
myocardial	B-T038
infarction	I-T038
and	O
aortic	B-T038
dissection	I-T038
,	O
may	O
occur	O
because	O
of	O
uncontrolled	B-T038
catecholamine	I-T038
release	I-T038
.	O

Each	O
stage	O
of	O
anaesthesia	B-T058
management	I-T058
has	O
vital	O
importance	O
because	O
of	O
this	O
destructive	B-T038
catecholamine	I-T038
secretion	I-T038
that	O
may	O
occur	O
during	O
induction	B-T058
,	O
perioperative	O
stage	O
and	O
surgical	B-T058
manipulation	I-T058
.	O

In	O
this	O
study	O
,	O
we	O
report	O
regarding	O
the	O
preoperative	B-T058
preparation	I-T058
and	O
severe	O
,	O
persistent	O
hypertension	O
attack	O
management	O
with	O
a	O
combination	O
of	O
α	B-T103
-	I-T103
adrenergic	I-T103
blockade	I-T103
,	O
β	B-T103
-	I-T103
adrenergic	I-T103
blockade	I-T103
,	O
sodium	B-T103
nitroprusside	I-T103
and	O
remifentanil	B-T103
in	O
a	O
patient	O
who	O
underwent	O
laparoscopic	B-T058
surgery	I-T058
for	O
phaeochromocytoma	B-T038
.	O

A	O
case	O
based	O
reflection	B-T033
on	O
communicating	O
end	O
of	O
life	O
information	O
in	O
non	O
-	O
English	O
speaking	O
patients	O

Mr	O
X	O
was	O
a	O
56	O
year	O
old	O
Chinese	B-T098
man	B-T098
(	O
non	O
-	O
English	O
speaking	O
)	O
,	O
who	O
presented	O
to	O
the	O
emergency	B-T092
department	I-T092
with	O
a	O
range	O
of	O
non	O
-	O
specific	O
symptoms	B-T033
.	O

On	O
full	O
workup	O
,	O
he	O
was	O
diagnosed	B-T033
with	O
an	O
advanced	B-T038
cancer	I-T038
of	I-T038
the	I-T038
pancreas	I-T038
.	O

It	O
was	O
an	O
aggressive	O
,	O
highly	O
treatment	O
resistant	O
cancer	O
,	O
with	O
an	O
alarmingly	O
poor	B-T033
prognosis	I-T033
.	O

Before	O
the	O
diagnosis	B-T033
had	O
been	O
made	O
,	O
the	O
family	O
had	O
informed	O
our	O
team	B-T058
that	O
we	O
were	O
not	O
to	O
discuss	O
medical	O
issues	B-T033
with	O
Mr	O
X	O
directly	O
,	O
and	O
that	O
upon	O
arriving	O
on	O
a	O
diagnosis	B-T033
we	O
were	O
to	O
come	O
to	O
them	O
first	O
and	O
they	O
would	O
subsequently	O
inform	O
him	O
.	O

They	O
reported	O
that	O
Mr	O
X	O
was	O
in	O
support	O
of	O
this	O
arrangement	O
.	O

Eventually	O
we	O
told	O
the	O
family	O
about	O
Mr	O
X	O
'	O
s	O
diagnosis	B-T033
,	O
and	O
they	O
asserted	O
their	O
collective	O
will	O
to	O
keep	O
this	O
information	O
from	O
him	O
,	O
reaffirming	O
that	O
all	O
medical	O
discussion	B-T058
go	O
through	O
them	O
.	O

However	O
,	O
the	O
doctor	B-T097
in	I-T097
charge	I-T097
explained	O
the	O
diagnosis	B-T033
to	O
Mr	O
X	O
using	O
an	O
interpreter	B-T097
while	O
his	O
family	O
were	O
away	O
from	O
his	O
bed	O
.	O

In	O
this	O
discussion	O
,	O
I	O
consider	O
this	O
case	O
from	O
the	O
perspective	O
of	O
respecting	B-T058
patients	I-T058
'	I-T058
and	I-T058
families	I-T058
'	I-T058
preferences	I-T058
around	O
medical	B-T058
treatment	I-T058
and	I-T058
care	I-T058
.	O

Difference	B-T062
-	I-T062
in	I-T062
-	I-T062
Differences	I-T062
Method	I-T062
in	O
Comparative	B-T062
Effectiveness	I-T062
Research	I-T062
:	O
Utility	O
with	O
Unbalanced	O
Groups	O

Comparative	B-T062
effectiveness	I-T062
research	I-T062
(	O
CER	B-T062
)	O
often	O
includes	O
observational	B-T170
studies	I-T170
utilizing	O
administrative	B-T033
data	I-T033
.	O

Multiple	O
conditioning	O
methods	O
can	O
be	O
used	O
for	O
CER	B-T062
to	O
adjust	O
for	O
group	O
differences	O
,	O
including	O
difference	B-T062
-	I-T062
in	I-T062
-	I-T062
differences	I-T062
(	I-T062
DiD	I-T062
)	I-T062
estimation	I-T062
.	O

This	O
study	O
presents	O
DiD	B-T062
and	O
demonstrates	O
how	O
to	O
apply	O
this	O
conditioning	O
method	B-T170
to	O
estimate	O
treatment	O
outcomes	O
in	O
the	O
CER	B-T062
setting	O
by	O
utilizing	O
the	O
MarketScan®	B-T170
Databases	I-T170
for	O
multiple	B-T038
sclerosis	I-T038
(	O
MS	B-T038
)	O
patients	O
receiving	O
different	O
therapies	B-T058
.	O

The	O
sample	O
included	O
6762	O
patients	O
,	O
with	O
363	O
in	O
the	O
Test	B-T098
Cohort	I-T098
[	O
glatiramer	B-T103
acetate	I-T103
(	O
GA	B-T103
)	O
switched	B-T058
to	O
fingolimod	B-T103
(	O
FTY	B-T103
)	O
]	O
and	O
6399	O
in	O
the	O
Control	O
Cohort	O
(	O
GA	B-T103
only	O
,	O
no	B-T033
switch	I-T033
)	O
from	O
a	O
US	B-T170
administrative	I-T170
claims	I-T170
database	I-T170
.	O

A	O
trend	O
analysis	O
was	O
conducted	O
to	O
rule	O
out	O
concerns	O
regarding	O
regression	B-T170
to	O
the	O
mean	O
and	O
to	O
compare	O
relapse	O
rates	O
among	O
treatment	B-T098
cohorts	I-T098
.	O

DiD	B-T062
analysis	I-T062
was	O
used	O
to	O
enable	O
comparisons	O
among	O
the	O
Test	B-T098
and	O
Control	O
Cohorts	O
.	O

Logistic	B-T062
regression	I-T062
was	O
used	O
to	O
estimate	O
the	O
probability	O
of	O
relapse	O
after	O
switching	B-T058
from	O
GA	B-T103
to	O
FTY	B-T103
,	O
and	O
to	O
compare	O
group	O
differences	O
in	O
the	O
pre	O
-	O
and	O
post	O
-	O
index	O
periods	O
.	O

Crude	O
DiD	B-T062
analysis	I-T062
showed	O
that	O
in	O
the	O
pre	O
-	O
index	O
period	O
more	O
patients	O
in	O
the	O
Test	B-T098
Cohort	I-T098
experienced	O
an	O
MS	B-T038
relapse	O
and	O
had	O
a	O
higher	O
mean	O
number	O
of	O
relapses	O
than	O
in	O
the	O
Control	O
Cohort	O
.	O

During	O
the	O
pre	O
-	O
index	O
period	O
,	O
numeric	O
and	O
relative	O
data	O
for	O
MS	B-T038
relapses	O
in	O
patients	O
in	O
the	O
Test	B-T098
Cohort	I-T098
were	O
significantly	O
higher	O
than	O
in	O
the	O
Control	O
Cohort	O
,	O
while	O
no	B-T033
significant	I-T033
between	O
-	O
group	O
differences	O
emerged	O
during	O
the	O
post	O
-	O
index	O
period	O
.	O

Generalized	O
linear	O
modeling	O
with	O
DiD	B-T062
regression	O
estimation	O
showed	O
that	O
the	O
mean	O
number	O
of	O
MS	B-T038
relapses	O
decreased	O
significantly	O
in	O
the	O
post	O
-	O
index	O
period	O
among	O
patients	O
in	O
the	O
Test	B-T098
Cohort	I-T098
compared	O
with	O
patients	O
in	O
the	O
Control	O
Cohort	O
.	O

In	O
this	O
study	O
,	O
an	O
MS	B-T038
population	B-T098
was	O
utilized	O
to	O
demonstrate	O
how	O
DiD	B-T062
can	O
be	O
applied	O
to	O
estimate	O
treatment	B-T033
effects	I-T033
in	O
a	O
heterogeneous	O
population	B-T098
,	O
where	O
the	O
Test	B-T098
and	O
Control	O
Cohorts	O
varied	O
greatly	O
.	O

The	O
results	O
show	O
that	O
DiD	B-T062
offers	O
a	O
robust	O
method	O
for	O
comparing	O
diverse	O
cohorts	B-T098
when	O
other	O
risk	O
-	O
adjustment	O
methods	O
may	O
not	O
be	O
adequate	O
.	O

Metabolomic	B-T091
analysis	O
of	O
glycerophospholipid	B-T103
signatures	O
of	O
inflammation	B-T038
treated	B-T058
with	I-T058
non	B-T103
-	I-T103
steroidal	I-T103
anti	I-T103
-	I-T103
inflammatory	I-T103
drugs	I-T103
-	O
induced	O
-	O
RAW264	B-T017
.	I-T017
7	I-T017
cells	I-T017
using	O
(	B-T058
1	I-T058
)	I-T058
H	I-T058
NMR	I-T058
and	O
U	B-T058
-	I-T058
HPLC	I-T058
/	O
Q	O
-	O
TOF	O
-	O
MS	O

Non	B-T058
-	I-T058
destructive	I-T058
proton	I-T058
nuclear	I-T058
magnetic	I-T058
resonance	I-T058
(	I-T058
(	I-T058
1	I-T058
)	I-T058
H	I-T058
NMR	I-T058
)	I-T058
spectroscopy	I-T058
and	O
highly	O
sensitive	O
ultra	B-T058
-	I-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
quadrupole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
U	B-T058
-	I-T058
HPLC	I-T058
/	O
Q	O
-	O
TOF	O
-	O
MS	O
)	O
coupled	O
to	O
data	O
processing	O
methods	B-T170
were	O
applied	O
to	O
analyze	O
the	O
metabolic	B-T091
profiling	I-T091
changes	O
of	O
glycerophospholipids	B-T103
(	O
GPLs	B-T103
)	O
in	O
RAW264	B-T017
.	I-T017
7	I-T017
cells	I-T017
from	O
inflammation	B-T038
to	O
prognosis	B-T058
.	O

Analysis	B-T062
of	O
(	B-T058
1	I-T058
)	I-T058
H	I-T058
NMR	I-T058
was	O
shown	O
that	O
the	O
models	B-T170
were	O
grouped	O
successfully	O
,	O
illustrating	O
that	O
all	O
of	O
them	O
had	O
significant	O
differences	O
.	O

Based	O
on	O
the	O
highly	O
simple	O
,	O
accurate	O
,	O
non	O
-	O
targeted	O
and	O
non	O
-	O
destructively	O
advantages	O
of	O
(	B-T058
1	I-T058
)	I-T058
H	I-T058
NMR	I-T058
,	O
it	O
could	O
be	O
used	O
as	O
a	O
new	O
screening	O
tool	O
of	O
anti	B-T103
-	I-T103
inflammatory	I-T103
drugs	I-T103
in	O
the	O
metabolic	B-T091
profiling	I-T091
of	O
GPLs	B-T103
.	O

58	O
GPLs	B-T103
were	O
identified	O
by	O
U	B-T058
-	I-T058
HPLC	I-T058
/	O
Q	O
-	O
TOF	O
-	O
MS	O
,	O
and	O
19	O
components	O
were	O
firstly	O
identified	O
in	O
this	O
study	B-T062
compared	O
with	O
our	O
previous	O
results	O
.	O

In	O
addition	O
,	O
ten	O
potential	O
biomarkers	B-T201
were	O
proved	O
,	O
of	O
which	O
phosphatidylcholine	B-T103
(	O
PC	B-T103
)	O
(	O
16	O
:	O
0	O
/	O
18	O
:	O
1	O
)	O
and	O
(	O
18	O
:	O
0	O
/	O
18	O
:	O
1	O
)	O
changed	O
consistently	O
in	O
three	O
drug	O
-	O
induced	O
groups	O
and	O
might	O
be	O
the	O
important	O
biomarkers	B-T201
.	O

Compared	O
with	O
(	B-T058
1	I-T058
)	I-T058
H	I-T058
NMR	I-T058
,	O
U	B-T058
-	I-T058
HPLC	I-T058
/	O
Q	O
-	O
TOF	O
-	O
MS	O
showed	O
higher	O
sensitivity	O
and	O
specificity	O
and	O
was	O
more	O
suitable	O
for	O
the	O
determination	B-T058
of	O
biomarkers	B-T201
apart	O
from	O
the	O
deficiency	O
of	O
time	O
-	O
consuming	O
sample	B-T058
preparation	I-T058
steps	I-T058
and	O
unambiguous	O
metabolite	B-T103
identification	O
.	O

Therefore	O
,	O
it	O
is	O
feasible	O
to	O
analyze	O
the	O
changes	O
of	O
GPLs	B-T103
during	O
inflammation	B-T038
by	O
combining	O
(	B-T058
1	I-T058
)	I-T058
H	I-T058
NMR	I-T058
spectroscopy	I-T058
with	O
U	B-T058
-	I-T058
HPLC	I-T058
/	O
Q	O
-	O
TOF	O
-	O
MS	O
.	O

The	O
metabolic	B-T091
profiling	I-T091
of	O
GPLs	B-T103
provides	O
valuable	O
evidence	O
for	O
inflammation	B-T038
diagnosis	B-T033
and	O
prognosis	B-T058
,	O
and	O
might	O
unravel	O
the	O
mechanisms	O
involved	O
in	O
inflammation	B-T038
progression	B-T038
.	O

Characterization	O
of	O
novel	O
DeoR	B-T103
-	I-T103
family	I-T103
member	O
from	O
the	O
Streptomyces	B-T007
ahygroscopicus	I-T007
strain	O
CK	O
-	O
15	O
that	O
acts	O
as	O
a	O
repressor	B-T103
of	O
morphological	B-T082
development	O

Wuyiencin	B-T103
is	O
produced	O
by	O
Streptomyces	B-T007
ahygroscopicus	I-T007
var	I-T007
.	I-T007

wuyiensis	I-T007
,	O
which	O
has	O
been	O
widely	O
used	O
in	O
China	B-T082
as	O
an	O
industrially	B-T092
produced	O
biopesticide	B-T103
to	O
control	O
various	O
fungal	B-T038
diseases	I-T038
.	O

Although	O
its	O
mechanism	O
of	O
action	O
,	O
breeding	B-T038
,	O
and	O
fermentation	B-T038
had	O
been	O
extensively	O
characterized	O
,	O
less	O
is	O
known	O
about	O
the	O
regulatory	B-T038
functions	I-T038
that	O
affect	O
its	O
biosynthesis	O
or	O
morphological	B-T082
development	O
.	O

The	O
wysR3	B-T017
gene	I-T017
of	O
S	B-T007
.	I-T007

ahygroscopicus	I-T007
strain	O
CK	O
-	O
15	O
,	O
a	O
novel	O
member	O
of	O
the	O
DeoR	B-T103
family	I-T103
of	O
regulatory	B-T017
genes	I-T017
,	O
was	O
assessed	O
to	O
determine	O
its	O
function	O
by	O
gene	B-T062
knockdown	I-T062
.	O

Herein	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
DeoR	B-T103
family	I-T103
proteins	I-T103
derived	O
from	O
the	O
same	O
source	B-T033
are	O
likely	O
to	O
be	O
a	O
single	O
branch	B-T082
in	O
a	O
phylogenetic	O
tree	O
and	O
show	O
that	O
wysR3	B-T017
acts	O
as	O
a	O
repressor	B-T103
for	O
its	O
morphological	B-T082
development	O
without	O
effecting	O
wuyiencin	B-T103
production	O
.	O

We	O
found	O
that	O
the	O
ΔwysR3	B-T017
strain	O
can	O
grow	O
quickly	O
to	O
reach	O
a	O
plateau	O
stage	O
of	O
maximum	O
biomass	O
at	O
60	O
h	O
,	O
which	O
is	O
~	O
12	O
h	O
faster	O
than	O
the	O
wild	B-T017
-	I-T017
type	I-T017
strain	O
.	O

In	O
the	O
industrial	B-T092
fermentation	B-T038
production	O
process	O
,	O
the	O
ΔwysR3	B-T017
strain	O
can	O
reduce	O
consumption	O
and	O
save	O
both	O
time	O
and	O
money	O
.	O

Targeting	O
the	O
ecology	O
within	O
:	O
The	O
role	O
of	O
the	O
gut	B-T082
-	I-T082
brain	I-T082
axis	I-T082
and	O
human	B-T204
microbiota	O
in	O
drug	B-T038
addiction	I-T038

Despite	O
major	O
advances	O
in	O
our	O
understanding	B-T038
of	O
the	O
brain	B-T017
using	O
traditional	B-T091
neuroscience	I-T091
,	O
reliable	O
and	O
efficacious	O
treatments	B-T058
for	O
drug	B-T038
addiction	I-T038
have	O
remained	B-T033
elusive	I-T033
.	O

Hence	O
,	O
the	O
time	O
has	O
come	O
to	O
utilize	O
novel	O
approaches	B-T082
,	O
particularly	O
those	O
drawing	O
upon	O
contemporary	O
advances	O
in	O
fields	O
outside	O
of	O
established	O
neuroscienc	B-T091
e	O
and	O
psychiatry	B-T091
.	O

Put	O
another	O
way	O
,	O
the	O
time	O
has	O
come	O
for	O
a	O
paradigm	O
shift	O
in	O
the	O
addiction	B-T038
sciences	O
.	O

Apropos	O
,	O
a	O
revolution	O
in	O
the	O
area	B-T082
of	O
human	B-T204
health	O
is	O
underway	O
,	O
which	O
is	O
occurring	O
at	O
the	O
nexus	O
between	O
enteric	B-T082
microbiology	B-T091
and	O
neuroscience	B-T091
.	O

It	O
has	O
become	O
increasingly	O
clear	O
that	O
the	O
human	B-T204
microbiota	O
(	O
the	O
vast	O
ecology	O
of	O
bacteria	B-T007
residing	O
within	O
the	O
human	B-T204
organism	O
)	O
,	O
plays	O
an	O
important	O
role	O
in	O
health	O
and	O
disease	B-T038
.	O

This	O
is	O
not	O
surprising	O
,	O
as	O
it	O
has	O
been	O
estimated	O
that	O
bacteria	B-T007
living	O
in	O
the	O
human	B-T204
body	I-T204
(	O
approximately	O
1kg	O
of	O
mass	O
,	O
roughly	O
equivalent	O
to	O
that	O
of	O
the	O
human	B-T204
brain	B-T017
)	O
outnumber	O
human	B-T033
cells	I-T033
10	O
to	O
1	O
.	O

While	O
advances	O
in	O
the	O
understanding	B-T038
of	O
the	O
role	O
of	O
microbiota	O
in	O
other	O
areas	B-T082
of	O
human	B-T204
health	O
have	O
yielded	O
intriguing	O
results	O
(	O
e	O
.	O
g	O
.	O
,	O
Clostridium	B-T038
difficile	I-T038
,	O
irritable	B-T038
bowel	I-T038
syndrome	I-T038
,	O
autism	B-T038
,	O
etc	O
.	O
)	O
,	O
to	O
date	O
,	O
no	O
systematic	O
programs	O
of	O
research	B-T062
have	O
examined	B-T033
the	O
role	O
of	O
microbiota	O
in	O
drug	B-T038
addiction	I-T038
.	O

The	O
current	O
hypothesis	O
,	O
therefore	O
,	O
is	O
that	O
gut	O
dysbiosis	O
plays	O
a	O
key	O
role	O
in	O
addictive	B-T038
disorders	B-T038
.	O

In	O
the	O
context	O
of	O
this	O
hypothesis	O
,	O
this	O
paper	B-T170
provides	O
a	O
rationale	O
for	O
future	O
research	B-T062
to	O
target	O
the	O
"	O
gut	B-T017
-	O
brain	B-T017
axis	B-T082
"	O
in	O
addiction	B-T038
.	O

A	O
brief	O
background	O
of	O
the	O
gut	B-T017
-	O
brain	B-T017
axis	B-T082
is	O
provided	O
,	O
along	O
with	O
a	O
series	O
of	O
hypothesis	O
-	O
driven	O
ideas	O
outlining	O
potential	O
treatments	B-T058
for	O
addiction	B-T038
via	O
manipulations	B-T033
of	O
the	O
"	O
ecology	O
within	O
.	O
"	O

Homogeneous	O
synthesis	O
of	O
Ag	O
nanoparticles	O
-	O
doped	O
water	B-T103
-	I-T103
soluble	I-T103
cellulose	I-T103
acetate	I-T103
for	O
versatile	O
applications	O

We	O
report	B-T170
a	O
facile	O
and	O
efficient	O
approach	B-T082
for	O
synthesis	O
of	O
well	B-T082
-	I-T082
dispersed	I-T082
and	O
stable	O
silver	O
nanoparticles	O
(	O
Ag	O
NPs	O
)	O
using	O
water	B-T103
-	I-T103
soluble	I-T103
cellulose	I-T103
acetate	I-T103
(	O
CA	B-T103
)	O
as	O
both	O
reductant	B-T103
and	O
stabilizer	O
.	O

Partially	O
substituted	O
CA	B-T103
with	O
highly	O
active	O
hydroxyl	B-T103
groups	I-T103
and	O
excellent	O
water	O
-	O
solubility	O
is	O
able	B-T033
to	O
reduce	O
silver	B-T103
ions	I-T103
in	O
homogeneous	O
aqueous	O
medium	O
effectively	O
.	O

The	O
synthesized	O
Ag	O
NPs	O
were	O
characterized	O
by	O
UV	B-T058
-	I-T058
vis	I-T058
spectroscopy	I-T058
,	O
X	B-T058
-	I-T058
ray	I-T058
diffraction	I-T058
,	O
X	B-T058
-	I-T058
ray	I-T058
photoelectron	I-T058
spectroscopy	I-T058
,	O
transmission	B-T058
electron	I-T058
microscopy	I-T058
and	O
energy	B-T058
dispersive	I-T058
X	I-T058
-	I-T058
ray	I-T058
spectroscope	I-T058
analysis	B-T058
.	O

The	O
as	O
-	O
prepared	B-T033
Ag	O
NPs	O
were	O
well	B-T082
-	I-T082
dispersed	I-T082
,	O
showing	O
a	O
surface	B-T062
plasmon	I-T062
resonance	I-T062
peak	O
at	O
426	O
nm	O
.	O

The	O
resulted	O
Ag	O
NPs	O
@	O
CA	B-T103
nanohybrids	O
exhibit	O
high	O
catalytic	O
activity	O
for	O
the	O
reduction	O
of	O
4	B-T103
-	I-T103
nitrophenol	I-T103
to	O
4	B-T103
-	I-T103
aminophenol	I-T103
in	O
the	O
presence	O
of	O
NaBH4	B-T103
.	O

Meanwhile	O
,	O
the	O
nanohybrids	O
are	O
also	O
effective	O
in	O
inhibiting	O
the	O
growth	B-T038
of	O
bacterial	B-T007
.	O

This	O
environmentally	O
friendly	O
method	O
promotes	O
the	O
use	O
of	O
renewable	O
natural	O
resources	O
to	O
prepare	O
a	O
variety	O
of	O
inorganic	O
-	O
organic	O
materials	O
for	O
catalysis	O
,	O
antibacterial	B-T103
,	O
sensors	O
and	O
other	O
applications	O
.	O

ISX	B-T103
-	I-T103
9	I-T103
can	O
potentiate	O
cell	B-T038
proliferation	I-T038
and	O
neuronal	B-T017
commitment	B-T038
in	O
the	O
rat	B-T204
dentate	B-T017
gyrus	I-T017

Adult	O
hippocampal	B-T017
neurogenesis	B-T038
can	O
be	O
modulated	B-T082
by	O
various	O
physiological	O
and	O
pathological	B-T038
conditions	I-T038
,	O
including	O
stress	B-T033
,	O
affective	B-T038
disorders	I-T038
,	O
and	O
several	O
neurological	O
conditions	O
.	O

Given	O
the	O
proposed	O
role	O
of	O
this	O
form	O
of	O
structural	O
plasticity	O
in	O
the	O
functioning	B-T038
of	O
the	O
hippocampus	B-T017
(	O
namely	O
learning	B-T038
and	O
memory	B-T038
and	O
affective	O
behaviors	O
)	O
,	O
it	O
is	O
believed	O
that	O
alterations	O
in	O
hippocampal	B-T017
neurogenesis	B-T038
might	O
underlie	O
some	O
of	O
the	O
behavioral	O
deficits	O
associated	O
with	O
these	O
psychiatric	O
and	O
neurological	O
conditions	O
.	O

Thus	O
,	O
the	O
search	O
for	O
compounds	B-T103
that	O
can	O
reverse	O
these	O
deficits	O
with	O
minimal	O
side	B-T038
effects	I-T038
has	O
become	O
a	O
recognized	O
priority	O
.	O

In	O
the	O
present	O
study	B-T062
we	O
tested	O
the	O
pro	O
-	O
neurogenic	O
effects	O
of	O
isoxazole	B-T103
9	I-T103
(	O
Isx	B-T103
-	I-T103
9	I-T103
)	O
,	O
a	O
small	O
synthetic	O
molecule	O
that	O
has	O
been	O
recently	O
identified	O
through	O
the	O
screening	B-T058
of	I-T058
chemical	I-T058
libraries	I-T058
in	O
stem	B-T058
cell	I-T058
-	I-T058
based	I-T058
assays	I-T058
.	O

We	O
found	O
that	O
administration	B-T058
of	O
Isx	B-T103
-	I-T103
9	I-T103
for	O
14days	O
was	O
able	O
to	O
potentiate	O
cell	B-T038
proliferation	I-T038
and	O
increase	O
the	O
number	O
of	O
immature	O
neurons	B-T017
in	O
the	O
hippocampal	B-T017
DG	B-T017
of	O
adult	O
rats	B-T204
.	O

In	O
addition	O
,	O
Isx	B-T103
-	I-T103
9	I-T103
treatment	B-T058
was	O
able	O
to	O
completely	O
reverse	O
the	O
marked	O
reduction	O
in	O
these	O
initial	O
stages	O
of	O
the	O
neurogenic	B-T038
process	I-T038
observed	O
in	O
vehicle	B-T103
-	O
treated	O
animals	B-T204
(	O
which	O
were	O
submitted	O
to	O
repeated	O
handling	B-T058
and	O
exposure	O
to	O
daily	O
intraperitoneal	B-T058
injections	I-T058
)	O
.	O

Based	O
on	O
these	O
results	O
,	O
we	O
recommend	O
that	O
future	O
neurogenesis	B-T038
studies	B-T062
that	O
require	O
repeated	O
handling	B-T058
and	O
manipulation	B-T058
of	O
animals	B-T204
should	O
include	O
a	O
naïve	O
(	O
non	O
-	O
manipulated	O
)	O
control	O
to	O
determine	O
the	O
baseline	O
levels	O
of	O
hippocampal	B-T017
cell	B-T038
proliferation	I-T038
and	O
neuronal	B-T017
differentiation	B-T038
.	O

Overall	O
,	O
these	O
findings	B-T033
demonstrate	O
that	O
Isx	B-T103
-	I-T103
9	I-T103
is	O
a	O
promising	O
synthetic	O
compound	B-T103
for	O
the	O
mitigation	O
of	O
stress	B-T033
-	O
induced	O
deficits	O
in	O
adult	O
hippocampal	B-T017
neurogenesis	B-T038
.	O

Future	O
studies	B-T062
are	O
thus	O
warranted	O
to	O
evaluate	B-T058
the	O
pro	O
-	O
neurogenic	O
properties	O
of	O
Isx	B-T103
-	I-T103
9	I-T103
in	O
animal	B-T204
models	I-T204
of	O
affective	B-T038
and	O
neurological	B-T038
disorders	I-T038
associated	O
with	O
impaired	O
hippocampal	B-T017
structural	O
plasticity	O
.	O

Changes	O
in	O
parenting	O
strategies	O
after	O
a	O
young	O
person	B-T098
'	I-T098
s	I-T098
self	B-T037
-	I-T037
harm	I-T037
:	O
a	O
qualitative	B-T062
study	I-T062

When	O
faced	O
with	O
the	O
discovery	O
of	O
their	O
child	O
'	O
s	O
self	B-T037
-	I-T037
harm	I-T037
,	O
mothers	O
and	O
fathers	O
may	O
re	B-T058
-	I-T058
evaluate	I-T058
their	O
parenting	O
strategies	O
.	O

This	O
can	O
include	O
changes	O
to	O
the	O
amount	O
of	O
support	O
they	O
provide	O
their	O
child	O
and	O
changes	O
to	O
the	O
degree	O
to	O
which	O
they	O
control	O
and	O
monitor	O
their	O
child	O
.	O

We	O
conducted	O
an	O
in	B-T062
-	I-T062
depth	I-T062
qualitative	I-T062
study	I-T062
with	O
37	O
parents	O
of	O
young	O
people	B-T098
who	O
had	O
self	B-T037
-	I-T037
harmed	I-T037
in	O
which	O
we	O
explored	O
how	O
and	O
why	O
their	O
parenting	O
changed	O
after	O
the	O
discovery	O
of	O
self	B-T037
-	I-T037
harm	I-T037
.	O

Early	O
on	O
,	O
parents	O
often	O
found	O
themselves	O
"	O
walking	O
on	O
eggshells	O
"	O
so	O
as	O
not	O
to	O
upset	B-T038
their	O
child	O
,	O
but	O
later	O
they	O
felt	O
more	O
able	O
to	O
take	O
some	O
control	O
.	O

Parents	O
'	O
reactions	O
to	O
the	O
self	B-T037
-	I-T037
harm	I-T037
often	O
depended	O
on	O
how	O
they	O
conceptualised	O
it	O
:	O
as	O
part	O
of	O
adolescence	O
,	O
as	O
a	O
mental	O
health	O
issue	O
or	O
as	O
"	O
naughty	O
behaviour	O
"	O
.	O

Parenting	O
of	O
other	O
children	O
in	O
the	O
family	O
could	O
also	O
be	O
affected	O
,	O
with	O
parents	O
worrying	O
about	O
less	O
of	O
their	O
time	O
being	O
available	O
for	O
siblings	O
.	O

Many	O
parents	O
developed	O
specific	O
strategies	O
they	O
felt	O
helped	O
them	O
to	O
be	O
more	O
effective	O
parents	O
,	O
such	O
as	O
learning	B-T038
to	O
avoid	O
blaming	B-T038
themselves	O
or	O
their	O
child	O
for	O
the	O
self	B-T037
-	I-T037
harm	I-T037
and	O
developing	O
new	O
ways	O
to	O
communicate	B-T033
with	O
their	O
child	O
.	O

Parents	O
were	O
generally	O
eager	O
to	O
pass	O
their	O
knowledge	B-T170
on	O
to	O
other	O
people	B-T098
in	O
the	O
same	O
situation	O
.	O

Parents	O
reported	O
changes	O
in	O
their	O
parenting	O
behaviours	O
after	O
the	O
discovery	O
of	O
a	O
child	O
'	O
s	O
self	B-T037
-	I-T037
harm	I-T037
.	O

Professionals	B-T097
involved	O
in	O
the	O
care	O
of	O
young	O
people	B-T098
who	O
self	B-T037
-	I-T037
harm	I-T037
might	O
use	O
this	O
information	O
in	O
supporting	O
and	O
advising	O
parents	O
.	O

Optimizing	O
Survival	O
of	O
Patients	O
With	O
Marginally	O
Operable	O
Stage	B-T038
IIIA	I-T038
Non	I-T038
-	I-T038
Small	I-T038
-	I-T038
Cell	I-T038
Lung	I-T038
Cancer	I-T038
Receiving	O
Chemoradiotherapy	B-T058
With	O
or	O
Without	O
Surgery	O

For	O
marginally	O
operable	O
stage	B-T038
IIIA	I-T038
non	I-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
(	O
NSCLC	B-T038
)	O
,	O
surgery	O
might	O
not	O
be	O
done	O
as	O
planned	O
after	O
neoadjuvant	B-T058
concurrent	B-T058
chemoradiotherapy	I-T058
(	O
CCRT	B-T058
)	O
for	O
reasons	O
(	O
unresectable	B-T201
or	O
medically	O
inoperable	O
conditions	O
,	O
or	O
patient	O
refusal	O
)	O
.	O

This	O
study	B-T062
aims	O
to	O
investigate	O
the	O
outcomes	O
of	O
a	O
phased	B-T058
CCRT	I-T058
protocol	I-T058
established	O
to	O
maximize	O
the	O
operability	O
of	O
marginally	O
operable	O
stage	B-T038
IIIA	I-T038
NSCLC	I-T038
and	O
to	O
care	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
in	O
comparison	O
with	O
continuous	B-T058
-	I-T058
course	I-T058
definitive	I-T058
CCRT	I-T058
.	O

Forty	O
-	O
seven	O
patients	O
with	O
marginally	O
operable	O
stage	B-T038
IIIA	I-T038
NSCLC	I-T038
receiving	O
CCRT	B-T058
were	O
included	O
.	O

Twenty	O
-	O
eight	O
patients	O
were	O
treated	O
with	O
our	O
phased	B-T058
CCRT	I-T058
protocol	I-T058
,	O
including	O
neoadjuvant	B-T058
CCRT	B-T058
followed	O
by	O
surgery	O
(	O
group	O
A	O
,	O
n	O
=	O
16	O
)	O
or	O
,	O
for	O
reassessed	O
inoperable	O
patients	O
,	O
maintenance	B-T033
chemotherapy	I-T033
and	O
split	B-T058
-	I-T058
course	I-T058
CCRT	I-T058
boost	O
(	O
group	O
B	O
,	O
n	O
=	O
12	O
)	O
.	O

The	O
other	O
19	O
were	O
treated	O
with	O
continuous	B-T058
-	I-T058
course	I-T058
definitive	I-T058
CCRT	I-T058
(	O
group	O
C	O
)	O
.	O

Overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
were	O
analyzed	B-T062
.	O

Among	O
all	O
,	O
median	O
OS	O
and	O
PFS	O
were	O
35	O
.	O
6	O
and	O
12	O
.	O
8	O
months	O
,	O
respectively	O
(	O
median	O
follow	B-T058
-	I-T058
up	I-T058
,	O
22	O
.	O
3	O
months	O
)	O
.	O

The	O
median	O
OS	O
of	O
group	O
A	O
(	O
not	O
reached	O
)	O
was	O
better	O
than	O
that	O
of	O
group	O
B	O
(	O
34	O
.	O
4	O
months	O
)	O
and	O
group	O
C	O
(	O
15	O
.	O
2	O
months	O
)	O
(	O
P	O
=	O
.	O
009	O
)	O
.	O

On	O
multivariate	O
analysis	O
,	O
performance	B-T201
status	I-T201
0	O
to	O
1	O
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
0	O
.	O
026	O
;	O
P	O
<	O
.	O
001	O
)	O
,	O
adenocarcinoma	B-T038
(	O
HR	O
,	O
0	O
.	O
156	O
;	O
P	O
=	O
.	O
003	O
)	O
,	O
and	O
group	O
A	O
(	O
HR	O
,	O
0	O
.	O
199	O
;	O
P	O
=	O
.	O
033	O
)	O
were	O
independent	B-T201
prognostic	I-T201
factors	I-T201
.	O

The	O
OS	O
of	O
group	O
B	O
(	O
HR	O
,	O
0	O
.	O
450	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
118	O
-	O
1	O
.	O
717	O
;	O
P	O
=	O
.	O
243	O
)	O
was	O
not	O
statistically	O
different	O
from	O
that	O
of	O
group	O
C	O
.	O

For	O
marginally	O
operable	O
stage	B-T038
IIIA	I-T038
NSCLC	I-T038
,	O
our	O
phased	B-T058
CCRT	I-T058
strategy	I-T058
may	O
optimize	O
survival	O
by	O
maximizing	O
operability	O
and	O
maintain	O
an	O
acceptable	O
survival	O
for	O
reassessed	O
inoperable	O
patients	O
by	O
split	B-T058
-	I-T058
course	I-T058
CCRT	I-T058
boost	O
following	O
maintenance	B-T033
chemotherapy	I-T033
.	O

Evaluation	O
of	O
Three	O
Protein	B-T058
-	I-T058
Extraction	I-T058
Methods	I-T058
for	O
Proteome	B-T103
Analysis	B-T058
of	O
Maize	B-T204
Leaf	B-T204
Midrib	B-T170
,	O
a	O
Compound	B-T017
Tissue	I-T017
Rich	O
in	O
Sclerenchyma	B-T017
Cells	I-T017

Leaf	B-T204
morphology	O
is	O
closely	O
related	O
to	O
the	O
growth	B-T038
and	I-T038
development	I-T038
of	O
maize	B-T204
(	I-T204
Zea	I-T204
mays	I-T204
L	I-T204
.	I-T204
)	I-T204
plants	I-T204
and	O
final	O
kernel	B-T168
production	O
.	O

As	O
an	O
important	O
part	O
of	O
the	O
maize	B-T204
leaf	B-T204
,	O
the	O
midrib	B-T170
holds	O
leaf	B-T204
blades	O
in	O
the	O
aerial	B-T204
position	I-T204
for	O
maximum	O
sunlight	O
capture	O
.	O

Leaf	B-T204
midrib	B-T170
s	O
of	O
adult	O
plants	B-T204
contain	O
substantial	O
sclerenchyma	B-T017
cells	I-T017
with	O
heavily	O
thickened	O
and	O
lignified	B-T103
secondary	B-T017
walls	I-T017
and	O
have	O
a	O
high	O
amount	O
of	O
phenolics	B-T103
,	O
making	O
protein	B-T058
extraction	I-T058
and	O
proteome	B-T103
analysis	B-T058
difficult	O
in	O
leaf	B-T204
midrib	B-T170
tissue	O
.	O

In	O
the	O
present	O
study	O
,	O
three	O
protein	B-T058
-	I-T058
extraction	I-T058
methods	I-T058
that	O
are	O
commonly	O
used	O
in	O
plant	B-T204
proteomics	B-T091
,	O
i	O
.	O
e	O
.	O
,	O
phenol	B-T103
extraction	B-T058
,	O
TCA	B-T103
/	O
acetone	B-T103
extraction	B-T058
,	O
and	O
TCA	B-T103
/	O
acetone	B-T103
/	O
phenol	B-T103
extraction	B-T058
,	O
were	O
qualitatively	O
and	O
quantitatively	O
evaluated	O
based	O
on	O
2DE	O
maps	O
and	O
MS	B-T058
/	I-T058
MS	I-T058
analysis	I-T058
using	O
the	O
midribs	B-T170
of	O
the	O
10th	O
newly	O
expanded	O
leaves	B-T204
of	O
maize	B-T204
plants	I-T204
.	O

Microscopy	B-T058
revealed	O
the	O
existence	O
of	O
substantial	O
amounts	O
of	O
sclerenchyma	B-T017
underneath	O
maize	B-T204
midrib	B-T170
epidermises	B-T204
(	O
particularly	O
abaxial	O
epidermises	B-T204
)	O
.	O

The	O
spot	O
-	O
number	O
order	O
obtained	O
via	O
2DE	B-T058
mapping	I-T058
was	O
as	O
follows	O
:	O
phenol	B-T103
extraction	B-T058
(	O
655	O
)	O
>	O
TCA	B-T103
/	O
acetone	B-T103
extraction	B-T058
(	O
589	O
)	O
>	O
TCA	B-T103
/	O
acetone	B-T103
/	O
phenol	B-T103
extraction	B-T058
(	O
545	O
)	O
.	O

MS	B-T058
/	I-T058
MS	I-T058
analysis	I-T058
identified	O
a	O
total	O
of	O
17	O
spots	O
that	O
exhibited	O
2	O
-	O
fold	O
changes	O
in	O
abundance	O
among	O
the	O
three	O
methods	O
(	O
using	O
phenol	B-T103
extraction	B-T058
as	O
a	O
control	O
)	O
.	O

Sixteen	O
of	O
the	O
proteins	B-T103
identified	O
were	O
hydrophilic	O
,	O
with	O
GRAVY	O
values	O
ranging	O
from	O
-	O
0	O
.	O
026	O
to	O
-	O
0	O
.	O
487	O
.	O

For	O
all	O
three	O
methods	O
,	O
we	O
were	O
able	O
to	O
obtain	O
high	O
-	O
quality	O
protein	B-T103
samples	O
and	O
good	O
2DE	B-T058
maps	I-T058
for	O
the	O
maize	B-T204
leaf	B-T204
midrib	B-T170
.	O

However	O
,	O
phenol	B-T103
extraction	B-T058
produced	O
a	O
better	O
2DE	B-T058
map	I-T058
with	O
greater	O
resolution	O
between	O
spots	O
,	O
and	O
TCA	B-T103
/	O
acetone	B-T103
extraction	B-T058
produced	O
higher	O
protein	B-T103
yields	O
.	O

Thus	O
,	O
this	O
paper	O
includes	O
a	O
discussion	O
regarding	O
the	O
possible	O
reasons	O
for	O
differential	O
protein	B-T058
extraction	I-T058
among	O
the	O
three	O
methods	O
.	O

This	O
study	O
provides	O
useful	O
information	O
that	O
can	O
be	O
used	O
to	O
select	O
suitable	O
protein	B-T058
extraction	I-T058
methods	O
for	O
the	O
proteome	B-T103
analysis	B-T058
of	O
recalcitrant	O
plant	B-T017
tissues	I-T017
that	O
are	O
rich	O
in	O
sclerenchyma	B-T017
cells	I-T017
.	O

Dominant	B-T033
and	O
Non	O
-	O
Dominant	B-T033
Frequency	O
Structure	O
of	O
Evoked	O
Ventricular	B-T038
Fibrillation	I-T038
in	O
Dogs	B-T204
with	O
Myocardial	B-T038
Ischemia	I-T038

The	O
first	O
10	O
min	O
of	O
electrically	B-T058
provoked	I-T058
ventricular	B-T038
fibrillation	I-T038
in	O
dogs	B-T204
with	O
ischemic	B-T038
heart	I-T038
disease	I-T038
were	O
characterized	O
by	O
organized	O
myocardial	O
activity	O
evidenced	O
by	O
the	O
dominant	B-T033
ECG	I-T033
frequency	I-T033
structure	O
.	O

During	O
the	O
first	O
2	O
min	O
of	O
ventricular	B-T038
fibrillation	I-T038
,	O
low	O
-	O
frequency	O
oscillations	O
(	O
4	O
-	O
7	O
Hz	O
)	O
dominated	O
,	O
while	O
on	O
min	O
3	O
to	O
10	O
after	O
the	O
onset	O
of	O
fibrillation	B-T038
,	O
the	O
dominant	B-T033
frequencies	I-T033
were	O
low	O
and	O
medium	O
(	O
4	O
-	O
12	O
Hz	O
)	O
.	O

After	O
10	O
-	O
min	O
fibrillation	B-T038
,	O
the	O
oscillations	O
became	O
non	O
-	O
dominant	B-T033
.	O

Thus	O
,	O
ischemic	B-T033
myocardium	I-T033
maintains	O
the	O
organized	O
structure	O
of	O
ventricular	B-T038
fibrillation	I-T038
for	O
the	O
first	O
10	O
min	O
,	O
which	O
is	O
important	O
for	O
the	O
development	O
of	O
automatic	B-T058
diagnostics	I-T058
of	O
abnormal	O
cardiac	O
activity	O
in	O
humans	B-T204
.	O

Adverse	B-T038
events	I-T038
risk	O
associated	O
with	O
angiogenesis	B-T103
inhibitors	I-T103
addition	O
to	O
therapy	B-T058
in	O
ovarian	B-T038
cancer	I-T038
:	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
randomized	B-T062
controlled	I-T062
trials	I-T062

Inhibition	B-T038
of	I-T038
angiogenesis	I-T038
has	O
been	O
regarded	O
as	O
an	O
attractive	O
treatment	B-T058
strategy	I-T058
for	O
advanced	B-T038
or	O
recurrent	B-T038
ovarian	I-T038
cancer	I-T038
.	O

We	O
conduct	O
this	O
meta	B-T062
-	I-T062
analysis	I-T062
to	O
investigate	O
the	O
risk	O
of	O
adverse	B-T038
events	I-T038
of	O
special	O
interest	O
related	O
to	O
angiogenesis	B-T103
inhibitors	I-T103
(	O
AIs	B-T103
)	O
in	O
ovarian	B-T038
cancer	I-T038
.	O

Databases	B-T170
from	O
PubMed	B-T170
,	O
Web	B-T170
of	I-T170
Science	I-T170
and	O
Cochrane	B-T092
library	I-T092
up	O
to	O
December	O
2015	O
were	O
searched	O
to	O
identify	O
relevant	O
studies	B-T062
.	O

Eligible	O
studies	B-T062
included	O
prospective	B-T062
randomized	I-T062
controlled	I-T062
phase	I-T062
II	I-T062
/	I-T062
III	I-T062
clinical	I-T062
trials	I-T062
evaluating	B-T058
therapy	B-T058
with	O
or	O
without	O
AIs	B-T103
for	O
ovarian	B-T038
cancer	I-T038
.	O

Summary	O
relative	O
risk	O
(	O
RR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
using	O
random	O
-	O
effects	O
or	O
fixed	O
-	O
effects	O
according	O
to	O
the	O
heterogeneity	O
among	O
included	O
trials	B-T062
.	O

A	O
total	O
of	O
7	O
,	O
761	O
patients	O
from	O
ten	O
clinical	B-T062
trials	I-T062
were	O
included	O
in	O
the	O
meta	B-T062
-	I-T062
analysis	I-T062
.	O

Pooled	O
RR	O
showed	O
that	O
the	O
use	O
of	O
AIs	B-T103
was	O
associated	O
with	O
a	O
statistically	O
increased	O
risk	O
in	O
four	O
of	O
the	O
adverse	O
outcomes	O
studied	O
:	O
arterial	B-T038
thromboembolic	I-T038
events	O
(	O
RR	O
=	O
2	O
.	O
0	O
)	O
,	O
gastrointestinal	B-T038
(	I-T038
GI	I-T038
)	I-T038
perforation	I-T038
(	O
RR	O
=	O
3	O
.	O
86	O
)	O
,	O
proteinuria	B-T033
(	O
RR	O
=	O
2	O
.	O
44	O
)	O
,	O
and	O
hypertension	B-T038
(	O
RR	O
=	O
5	O
.	O
39	O
)	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
found	O
for	O
hemorrhagic	B-T038
events	O
(	O
p	O
=	O
0	O
.	O
07	O
)	O
,	O
venous	B-T038
thromboembolic	I-T038
events	O
(	O
p	O
=	O
0	O
.	O
13	O
)	O
,	O
or	O
fatal	O
adverse	B-T038
events	I-T038
(	O
p	O
=	O
0	O
.	O
26	O
)	O
.	O

The	O
addition	O
of	O
AIs	B-T103
to	O
therapy	B-T058
in	O
ovarian	B-T038
cancer	I-T038
did	O
significantly	O
increase	O
the	O
risk	O
of	O
arterial	B-T038
thromboembolic	I-T038
events	O
,	O
GI	B-T038
perforation	I-T038
,	O
proteinuria	B-T033
and	O
hypertension	B-T038
,	O
but	O
not	O
for	O
venous	B-T038
thromboembolic	I-T038
events	O
,	O
hemorrhagic	B-T038
events	O
,	O
or	O
fatal	O
adverse	B-T038
events	I-T038
.	O

Relationship	O
between	O
LRRK2	B-T017
R1628P	B-T082
polymorphism	I-T082
and	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
in	O
Asian	B-T098
populations	I-T098

Although	O
the	O
leucine	B-T017
-	I-T017
rich	I-T017
repeat	I-T017
kinase	I-T017
2	I-T017
(	O
LRRK2	B-T017
)	O
R1628P	B-T082
polymorphism	I-T082
has	O
been	O
associated	O
with	O
the	O
risk	O
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
in	O
Taiwan	B-T082
,	O
China	B-T082
,	O
and	O
Singapore	B-T082
,	O
there	O
are	O
conflicting	O
findings	O
regarding	O
this	O
relationship	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
present	O
meta	B-T062
-	I-T062
analysis	I-T062
was	O
to	O
evaluate	O
the	O
associations	O
between	O
the	O
LRRK2	B-T017
R1628P	B-T082
polymorphism	I-T082
(	O
rs33949390	B-T082
)	O
and	O
PD	B-T038
in	O
Asian	B-T098
populations	I-T098
.	O

A	O
search	O
for	O
eligible	O
studies	B-T062
was	O
performed	O
in	O
PubMed	B-T170
,	O
Embase	B-T170
,	O
SinoMed	B-T170
,	O
and	O
the	O
China	B-T170
Knowledge	I-T170
Resource	I-T170
Integrated	I-T170
Database	I-T170
,	O
and	O
pooled	O
odds	O
ratios	O
and	O
95	O
%	O
confidence	O
intervals	O
were	O
used	O
to	O
evaluate	O
the	O
strength	O
of	O
the	O
association	O
between	O
the	O
R1628P	B-T082
polymorphism	I-T082
and	O
PD	B-T038
.	O

This	O
meta	B-T062
-	I-T062
analysis	I-T062
assessed	O
19	O
studies	B-T062
from	O
14	O
papers	O
that	O
involved	O
a	O
total	O
of	O
9	O
,	O
927	O
PD	B-T038
patients	O
and	O
8	O
,	O
602	O
controls	O
and	O
found	O
that	O
the	O
R1628P	B-T082
polymorphism	I-T082
was	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
PD	B-T038
in	O
Asian	B-T098
populations	I-T098
.	O

Moreover	O
,	O
stratification	B-T062
analyses	I-T062
indicated	O
that	O
the	O
R1628P	B-T082
polymorphism	I-T082
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
PD	B-T038
among	O
Chinese	B-T098
as	O
well	O
as	O
non	B-T098
-	I-T098
Chinese	I-T098
Asian	I-T098
populations	I-T098
and	O
an	O
increased	O
risk	O
of	O
PD	B-T038
in	O
Chinese	O
patients	O
from	O
China	B-T082
,	O
Taiwan	B-T082
,	O
and	O
Singapore	B-T082
.	O

In	O
a	O
stratified	B-T062
analysis	I-T062
conducted	O
according	O
to	O
age	O
,	O
significant	O
associations	O
were	O
found	O
for	O
both	O
late	O
-	O
onset	O
PD	B-T038
and	O
early	O
-	O
onset	O
PD	B-T038
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
R1628P	B-T082
polymorphism	I-T082
of	O
the	O
LRRK2	B-T017
gene	I-T017
contributes	O
to	O
PD	B-T038
susceptibility	B-T201
in	O
Asian	B-T098
,	O
especially	O
Chinese	B-T098
,	O
populations	B-T098
.	O

Efficacy	O
and	O
safety	O
of	O
cisplatin	B-T103
,	O
dexamethasone	B-T103
,	O
gemcitabine	B-T103
and	O
pegaspargase	B-T103
(	O
DDGP	B-T103
)	O
regimen	B-T058
in	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
extranodal	B-T038
natural	I-T038
killer	I-T038
/	I-T038
T	I-T038
-	I-T038
cell	I-T038
lymphoma	I-T038
:	O
interim	O
analysis	B-T062
of	O
a	O
phase	O
4	O
study	B-T062
NCT01501149	O

To	O
explore	O
a	O
more	O
effective	O
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
extranodal	B-T038
natural	I-T038
killer	I-T038
/	I-T038
T	I-T038
-	I-T038
cell	I-T038
lymphoma	I-T038
,	I-T038
nasal	I-T038
type	I-T038
(	O
ENKTL	B-T038
)	O
,	O
we	O
conducted	O
a	O
phase	O
4	O
study	B-T062
of	O
the	O
cisplatin	B-T103
,	O
dexamethasone	B-T103
,	O
gemcitabine	B-T103
,	O
pegaspargase	B-T103
(	O
DDGP	B-T103
)	O
regimen	B-T058
.	O

The	O
primary	O
end	O
point	O
was	O
the	O
2	O
-	O
year	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
after	O
the	O
protocol	B-T058
treatment	I-T058
.	O

Secondary	O
endpoints	O
included	O
response	O
rate	O
(	O
RR	O
)	O
,	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
median	O
survival	O
time	O
(	O
MST	O
)	O
.	O

The	O
interim	O
analysis	B-T062
included	O
data	O
only	O
from	O
March	O
2011	O
to	O
September	O
2013	O
,	O
who	O
received	O
six	O
cycles	O
of	O
DDGP	B-T103
chemotherapy	B-T058
.	O

A	O
total	O
of	O
25	O
eligible	O
patients	O
were	O
enrolled	O
.	O

Seventeen	O
patients	O
(	O
17	O
/	O
24	O
,	O
70	O
.	O
83	O
%	O
)	O
achieved	O
complete	B-T033
response	I-T033
(	O
CR	B-T033
)	O
and	O
four	O
(	O
4	O
/	O
24	O
,	O
16	O
.	O
67	O
%	O
)	O
achieved	O
partial	B-T033
response	I-T033
(	O
PR	B-T033
)	O
,	O
three	O
(	O
3	O
/	O
24	O
,	O
12	O
.	O
50	O
%	O
)	O
had	O
progressive	B-T038
disease	I-T038
(	O
PD	B-T038
)	O
.	O

The	O
RR	O
after	O
treatment	O
was	O
87	O
.	O
50	O
%	O
.	O

After	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
duration	O
of	O
24	O
.	O
67	O
months	O
(	O
range	O
4	O
-	O
48	O
months	O
)	O
.	O

The	O
2	O
-	O
year	O
PFS	O
and	O
OS	O
rate	O
were	O
61	O
.	O
80	O
%	O
(	O
95	O
%	O
CI	O
,	O
42	O
.	O
00	O
%	O
to	O
81	O
.	O
60	O
%	O
)	O
and	O
68	O
.	O
50	O
%	O
(	O
95	O
%	O
CI	O
,	O
48	O
.	O
70	O
%	O
to	O
88	O
.	O
30	O
%	O
)	O
,	O
respectively	O
.	O

The	O
MST	O
was	O
36	O
.	O
55	O
months	O
(	O
95	O
%	O
CI	O
,	O
29	O
.	O
41	O
months	O
to	O
43	O
.	O
70	O
months	O
)	O
.	O

Grade	B-T170
3	O
/	O
4	O
leukopenia	B-T038
occurred	O
in	O
fourteen	O
patients	O
(	O
58	O
.	O
33	O
%	O
)	O
and	O
grade	B-T170
3	O
/	O
4	O
thrombocytopenia	B-T038
occurred	O
in	O
eleven	O
patients	O
(	O
45	O
.	O
83	O
%	O
)	O
.	O

Twelve	O
patients	O
(	O
50	O
.	O
00	O
%	O
)	O
experienced	O
Activated	B-T058
Partial	I-T058
Phromboplastin	I-T058
Ptime	I-T058
(	O
APTT	B-T058
)	O
elongation	B-T033
and	O
fourteen	O
patients	O
(	O
58	O
.	O
33	O
%	O
)	O
experienced	O
hypofibrinogenemia	B-T038
.	O

In	O
conclusion	O
,	O
DDGP	B-T103
regimen	B-T058
is	O
an	O
effective	O
and	O
tolerated	B-T033
treatment	O
for	O
newly	O
diagnosed	O
,	O
advanced	O
-	O
stage	O
ENKTL	B-T038
.	O

This	O
trial	B-T062
was	O
registered	B-T058
at	O
www	B-T170
.	I-T170
ClinicalTrials	I-T170
.	I-T170
gov	I-T170
as	O
#	O
NCT01501149	O
.	O

Effect	O
of	O
Hepatitis	B-T038
C	I-T038
Virus	I-T038
Coinfection	I-T038
on	O
the	O
Content	O
of	O
CD4	O
(	O
+	O
)	O
and	O
CD8	O
(	O
+	O
)	O
T	B-T017
Cell	I-T017
Subpopulations	B-T170
in	O
HIV	B-T005
-	O
Infected	B-T033
Patients	O
Receiving	O
Antiretroviral	B-T058
Therapy	I-T058

We	O
studied	O
the	O
effect	O
of	O
hepatitis	B-T038
C	I-T038
virus	I-T038
coinfection	I-T038
on	O
T	B-T017
cell	I-T017
subpopulations	B-T170
in	O
HIV	B-T005
-	O
infected	B-T033
patients	O
receiving	O
antiretroviral	B-T058
therapy	I-T058
.	O

Coinfection	B-T038
with	O
hepatitis	B-T005
C	I-T005
virus	I-T005
was	O
followed	O
by	O
a	O
decrease	O
in	O
the	O
number	O
of	O
naive	B-T017
CD4	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
and	O
an	O
increase	O
in	O
the	O
count	O
of	O
central	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
memory	I-T017
T	I-T017
cells	I-T017
in	O
these	O
patients	O
.	O

Hepatitis	B-T005
C	I-T005
virus	I-T005
had	O
no	O
effect	O
on	O
the	O
number	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
memory	I-T017
T	I-T017
cells	I-T017
(	O
main	O
target	O
for	O
HIV	B-T005
)	O
.	O

This	O
can	O
explain	O
the	O
absence	O
of	O
strong	O
negative	B-T033
effect	O
of	O
hepatitis	B-T005
C	I-T005
virus	I-T005
on	O
the	O
course	O
of	O
HIV	B-T005
infection	B-T038
.	O

Examining	O
the	O
contribution	O
of	O
motor	O
movement	O
and	O
language	O
dominance	O
to	O
increased	O
left	B-T082
lateralization	B-T038
during	O
sign	O
generation	O
in	O
native	O
signers	B-T098

The	O
neural	B-T022
systems	I-T022
supporting	O
speech	B-T038
and	O
sign	O
processing	B-T038
are	O
very	O
similar	O
,	O
although	O
not	O
identical	O
.	O

In	O
a	O
previous	O
fTCD	B-T062
study	I-T062
of	O
hearing	B-T038
native	O
signers	B-T098
(	O
Gutierrez	O
-	O
Sigut	O
,	O
Daws	O
,	O
et	O
al	O
.	O
,	O
2015	O
)	O
we	O
found	O
stronger	O
left	B-T082
lateralization	B-T038
for	O
sign	O
than	O
speech	B-T038
.	O

Given	O
that	O
this	O
increased	O
lateralization	B-T038
could	O
not	O
be	O
explained	O
by	O
hand	B-T017
movement	B-T038
alone	O
,	O
the	O
contribution	O
of	O
motor	O
movement	O
versus	O
'	O
linguistic	O
'	O
processes	B-T038
to	O
the	O
strength	O
of	O
hemispheric	B-T082
lateralization	B-T038
during	O
sign	O
production	B-T038
remains	O
unclear	O
.	O

Here	O
we	O
directly	O
contrast	O
lateralization	B-T038
strength	O
of	O
covert	O
versus	O
overt	O
signing	O
during	O
phonological	O
and	O
semantic	O
fluency	O
tasks	O
.	O

To	O
address	O
the	O
possibility	O
that	O
hearing	B-T038
native	O
signers	B-T098
'	O
elevated	O
lateralization	O
indices	O
(	O
LIs	O
)	O
were	O
due	O
to	O
performing	O
a	O
task	O
in	O
their	O
less	O
dominant	O
language	O
,	O
here	O
we	O
test	O
deaf	O
native	O
signers	B-T098
,	O
whose	O
dominant	O
language	O
is	O
British	O
Sign	O
Language	O
(	O
BSL	O
)	O
.	O

Signers	B-T098
were	O
more	O
strongly	O
left	B-T082
lateralized	B-T038
for	O
overt	O
than	O
covert	O
sign	O
generation	O
.	O

However	O
,	O
the	O
strength	O
of	O
lateralization	B-T038
was	O
not	O
correlated	O
with	O
the	O
amount	O
of	O
time	O
producing	O
movements	B-T038
of	O
the	O
right	B-T017
hand	I-T017
.	O

Comparisons	O
with	O
previous	O
data	O
from	O
hearing	B-T038
native	O
English	O
speakers	B-T098
suggest	O
stronger	O
laterality	O
indices	O
for	O
sign	O
than	O
speech	B-T038
in	O
both	O
covert	O
and	O
overt	O
tasks	O
.	O

This	O
increased	O
left	B-T082
lateralization	B-T038
may	O
be	O
driven	O
by	O
specific	O
properties	O
of	O
sign	O
production	B-T038
such	O
as	O
the	O
increased	O
use	O
of	O
self	O
-	O
monitoring	O
mechanisms	O
or	O
the	O
nature	O
of	O
phonological	B-T038
encoding	I-T038
of	O
signs	O
.	O

Hard	B-T204
ticks	I-T204
(	O
Acari	B-T204
:	I-T204
Ixodidae	I-T204
)	O
of	O
livestock	B-T204
in	O
Nicaragua	B-T082
,	O
with	O
notes	B-T170
about	O
distribution	O

We	O
document	B-T170
the	O
species	B-T170
of	O
ticks	B-T204
that	O
parasitize	B-T038
livestock	B-T204
in	O
Nicaragua	B-T082
.	O

The	O
study	B-T062
was	O
based	O
on	O
tick	B-T204
collection	O
on	O
cattle	B-T204
and	O
horses	B-T204
from	O
437	O
farms	B-T082
in	O
nine	O
departments	B-T092
.	O

Of	O
4841	O
animals	B-T204
examined	O
(	O
4481	O
cows	B-T204
and	O
360	O
horses	B-T204
)	O
,	O
3299	O
were	O
parasitized	B-T038
,	O
which	O
represent	O
68	O
%	O
of	O
the	O
bovines	B-T204
and	O
67	O
%	O
of	O
the	O
equines	B-T204
in	O
study	B-T062
:	O
59	O
cows	B-T204
and	O
25	O
horses	B-T204
were	O
parasitized	B-T038
by	O
more	O
than	O
one	O
species	B-T170
.	O

In	O
addition	O
,	O
280	O
specimens	O
of	O
the	O
entomological	O
museum	O
in	O
León	B-T082
were	O
examined	O
.	O

The	O
ticks	B-T204
found	O
on	O
cattle	B-T204
were	O
Rhipicephalus	B-T204
microplus	I-T204
(	O
75	O
.	O
2	O
%	O
of	O
the	O
ticks	B-T204
collected	O
)	O
,	O
Amblyomma	B-T204
mixtum	I-T204
(	O
20	O
.	O
8	O
%	O
)	O
,	O
A	B-T204
.	I-T204

parvum	I-T204
(	O
2	O
.	O
6	O
%	O
)	O
,	O
A	B-T204
.	I-T204

tenellum	I-T204
(	O
0	O
.	O
7	O
%	O
)	O
,	O
A	B-T204
.	I-T204

maculatum	I-T204
(	O
0	O
.	O
7	O
%	O
)	O
.	O

While	O
the	O
ticks	B-T204
collected	O
from	O
the	O
horses	B-T204
were	O
:	O
Dermacentor	B-T204
nitens	I-T204
(	O
41	O
.	O
5	O
%	O
)	O
,	O
A	B-T204
.	I-T204

mixtum	I-T204
(	O
31	O
.	O
7	O
%	O
)	O
,	O
R	B-T204
.	I-T204

microplus	I-T204
(	O
13	O
.	O
8	O
%	O
)	O
,	O
A	B-T204
.	I-T204

parvum	I-T204
(	O
6	O
.	O
5	O
%	O
)	O
,	O
A	B-T204
.	I-T204

tenellum	I-T204
(	O
3	O
.	O
3	O
%	O
)	O
,	O
D	B-T204
.	I-T204

dissimilis	I-T204
(	O
2	O
.	O
4	O
%	O
)	O
and	O
A	B-T204
.	I-T204

maculatum	I-T204
(	O
0	O
.	O
8	O
%	O
)	O
.	O

Assessment	B-T058
the	O
Exposure	O
Level	O
of	O
Rare	B-T103
Earth	I-T103
Elements	I-T103
in	O
Workers	B-T098
Producing	O
Cerium	B-T103
,	O
Lanthanum	B-T103
Oxide	I-T103
Ultrafine	B-T103
and	O
Nanoparticles	O

In	O
order	O
to	O
assess	O
occupational	O
exposure	O
level	O
of	O
15	O
rare	B-T103
earth	I-T103
elements	I-T103
(	O
REEs	B-T103
)	O
and	O
identify	O
the	O
associated	O
influence	O
,	O
we	O
used	O
inductively	B-T058
coupled	I-T058
plasma	I-T058
mass	I-T058
spectrometry	I-T058
(	O
ICP	B-T058
-	I-T058
MS	I-T058
)	O
based	O
on	O
closed	O
-	O
vessel	O
microwave	O
-	O
assisted	O
wet	O
digestion	O
procedure	O
to	O
determinate	B-T058
the	O
concentration	O
of	O
Y	B-T103
,	O
La	B-T103
,	O
Ce	B-T103
,	O
Pr	B-T103
,	O
Nd	B-T103
,	O
Sm	B-T103
,	O
Eu	B-T103
,	O
Gd	B-T103
,	O
Tb	B-T103
,	O
Dy	B-T103
,	O
Ho	B-T103
,	O
Er	B-T103
,	O
Tm	B-T103
,	O
Yb	B-T103
and	O
Lu	B-T103
in	O
urinary	B-T031
samples	I-T031
obtained	O
from	O
workers	B-T098
producing	O
ultrafine	B-T103
and	O
nanoparticles	O
containing	O
cerium	B-T103
and	O
lanthanum	B-T103
oxide	I-T103
.	O

The	O
results	O
suggest	O
that	O
La	B-T103
and	O
Ce	B-T103
were	O
the	O
primary	O
component	O
,	O
together	O
accounting	O
for	O
97	O
%	O
of	O
total	O
REEs	B-T103
in	O
workers	B-T098
.	O

The	O
urinary	B-T031
levels	O
of	O
La	B-T103
,	O
and	O
Ce	B-T103
among	O
the	O
workers	B-T098
(	O
6	O
.	O
36	O
,	O
15	O
.	O
32	O
μg	O
.	O
g	O
(	O
-	O
1	O
)	O
creatinine	B-T103
,	O
respectively	O
)	O
were	O
significantly	O
enriched	O
compared	O
to	O
those	O
levels	O
measured	O
in	O
the	O
control	O
subjects	O
(	O
1	O
.	O
52	O
,	O
4	O
.	O
04	O
μg	O
.	O
g	O
(	O
-	O
1	O
)	O
creatinine	B-T103
,	O
respectively	O
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

This	O
study	B-T062
simultaneously	O
identified	O
the	O
associated	O
individual	B-T098
factors	O
,	O
the	O
results	O
indicate	O
that	O
the	O
concentrations	O
in	O
over	O
5	O
years	O
group	O
(	O
11	O
.	O
64	O
±	O
10	O
.	O
93	O
for	O
La	B-T103
,	O
27	O
.	O
83	O
±	O
24	O
.	O
38	O
for	O
Ce	B-T103
)	O
were	O
significantly	O
elevated	O
compared	O
to	O
1	O
-	O
5	O
years	O
group	O
(	O
2	O
.	O
58	O
±	O
1	O
.	O
51	O
for	O
La	B-T103
,	O
6	O
.	O
87	O
±	O
3	O
.	O
90	O
for	O
Ce	B-T103
)	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Compared	O
the	O
urinary	B-T031
levels	O
of	O
La	B-T103
and	O
Ce	B-T103
at	O
the	O
separation	O
and	O
packaging	O
locations	B-T082
(	O
9	O
.	O
10	O
±	O
9	O
.	O
51	O
for	O
La	B-T103
,	O
22	O
.	O
29	O
±	O
21	O
.	O
01	O
for	O
Ce	B-T103
)	O
with	O
the	O
other	O
locations	B-T082
(	O
2	O
.	O
85	O
±	O
0	O
.	O
98	O
for	O
La	B-T103
,	O
6	O
.	O
37	O
±	O
2	O
.	O
12	O
for	O
Ce	B-T103
)	O
,	O
the	O
results	O
show	O
urinary	B-T031
concentrations	O
were	O
significantly	O
higher	O
in	O
workers	B-T098
at	O
separation	O
and	O
packaging	O
locations	B-T082
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Inter	O
-	O
individual	B-T098
variation	O
in	O
levels	O
of	O
La	B-T103
and	O
Ce	B-T103
in	O
urine	B-T031
is	O
the	O
result	O
of	O
multi	O
-	O
factorial	O
comprehensive	O
action	O
.	O

Further	O
researches	B-T097
should	O
focus	O
on	O
the	O
multiple	O
factors	O
contributing	O
to	O
the	O
REEs	B-T103
levels	O
of	O
the	O
occupationally	O
exposed	O
workers	B-T098
.	O

Two	O
known	O
and	O
one	O
new	O
species	B-T170
of	O
Draconematidae	B-T204
and	O
Epsilonematida	B-T204
(	O
Nematoda	B-T204
,	O
Desmodorida	B-T204
)	O
from	O
the	O
White	B-T082
Sea	I-T082
,	O
North	B-T082
Russia	I-T082

Morphological	B-T082
descriptions	B-T170
of	O
three	O
"	O
walking	B-T204
nematode	I-T204
"	O
species	B-T170
found	O
for	O
the	O
first	O
time	O
in	O
the	O
White	B-T082
Sea	I-T082
are	O
presented	O
.	O

Draconema	B-T204
ophicephalum	I-T204
(	O
Claparède	O
,	O
1863	O
)	O
(	O
Draconematidae	B-T204
)	O
and	O
Epsilonema	B-T204
steineri	I-T204
Chitwood	O
,	O
1935	O
(	O
Epsilonematidae	B-T204
)	O
,	O
both	O
known	O
from	O
insufficient	O
material	O
and	O
females	O
only	O
,	O
are	O
re	O
-	O
described	O
and	O
problems	B-T033
of	O
their	O
taxonomic	O
identification	O
as	O
well	O
as	O
species	B-T170
compositions	B-T201
of	O
respective	O
genera	B-T170
are	O
discussed	O
.	O

The	O
new	O
species	B-T170
Prochaetosoma	B-T204
marisalbi	I-T204
sp	I-T204
.	O

n	O
.	O

(	O
Draconematidae	B-T204
)	O
differs	O
from	O
other	O
Prochaetosoma	B-T204
species	I-T204
except	O
P	B-T204
.	I-T204

longicapitatum	I-T204
(	O
Allgén	O
,	O
1935	O
)	O
in	O
that	O
the	O
pharyngeal	B-T017
bulb	B-T017
lumen	B-T082
is	O
not	B-T033
cuticularised	I-T033
,	O
from	O
P	B-T204
.	I-T204

longicapitatum	I-T204
by	O
shape	B-T017
of	I-T017
body	I-T017
and	O
rostrum	B-T017
,	O
greater	O
number	O
of	O
cephalic	B-T082
adhesive	B-T017
tubes	I-T017
,	O
and	O
from	O
P	B-T204
.	I-T204

maertensi	I-T204
Decraemer	O
,	O
1989	O
by	O
having	O
a	O
relatively	O
longer	O
tail	B-T017
,	O
fewer	O
anterior	B-T082
adhesive	B-T017
tubes	I-T017
and	O
longer	O
spicules	O
,	O
besides	O
lacking	O
cuticular	B-T038
thickening	I-T038
in	O
the	O
pharyngeal	B-T017
bulb	B-T017
.	O

Draconema	B-T204
hoonsooi	I-T204
,	O
D	B-T204
.	I-T204

youngeouni	I-T204
,	O
P	B-T204
.	I-T204
rochaetosoma	I-T204
beomseomense	I-T204
,	O
P	B-T204
.	I-T204

brevicaudatum	I-T204
,	O
P	B-T204
.	I-T204

byungilli	I-T204
,	O
P	B-T204
.	I-T204

cracense	I-T204
,	O
P	B-T204
.	I-T204

saheungi	I-T204
,	O
P	B-T204
.	I-T204

sujungi	I-T204
,	O
P	B-T204
.	I-T204

supseomense	I-T204
erected	O
by	O
Rho	O
&	O
Min	O
(	O
2011	O
)	O
are	O
considered	O
as	O
invalid	O
species	B-T170
while	O
Prochaetosoma	B-T204
arcticum	I-T204
,	O
P	B-T204
.	I-T204

lugubre	I-T204
and	O
Epsilonema	B-T204
cygnoides	I-T204
are	O
assumed	O
as	O
species	B-T170
inquirenda	I-T170
.	O

From	O
a	O
phylogenetic	B-T062
tree	I-T062
based	O
on	O
the	O
18S	B-T017
rRNA	I-T017
gene	I-T017
,	O
all	O
three	O
White	B-T082
Sea	I-T082
species	B-T170
adjoin	B-T082
to	O
unidentified	O
species	B-T170
of	O
their	O
respective	O
genera	B-T170
.	O

Differential	O
effects	O
of	O
crude	B-T103
oil	I-T103
on	O
denitrification	O
and	O
anammox	B-T038
,	O
and	O
the	O
impact	O
on	O
N2O	B-T103
production	O

Denitrification	O
and	O
anammox	B-T038
are	O
key	O
processes	O
for	O
reducing	O
the	O
external	B-T082
nitrogen	B-T103
loads	O
delivered	O
to	O
coastal	B-T082
ecosystems	O
,	O
and	O
these	O
processes	O
can	O
be	O
affected	O
by	O
pollutants	B-T103
.	O

In	O
this	O
study	B-T062
,	O
we	O
investigated	O
the	O
effect	O
of	O
crude	B-T103
oil	I-T103
on	O
denitrification	O
and	O
anammox	B-T038
.	O

Controlled	B-T062
laboratory	I-T062
experiments	I-T062
were	O
performed	O
using	O
sediment	O
slurries	O
from	O
the	O
Lima	B-T082
Estuary	O
(	O
NW	O
Portugal	B-T082
)	O
.	O

Anammox	B-T038
and	O
denitrification	O
rates	O
were	O
measured	O
using	O
(	B-T103
15	I-T103
)	I-T103
N	I-T103
-	I-T103
labeled	I-T103
NO3	B-T103
(	I-T103
-	I-T103
)	I-T103
,	O
and	O
the	O
production	O
of	O
(	B-T103
29	I-T103
)	I-T103
N2	I-T103
and	O
(	B-T103
30	I-T103
)	I-T103
N2	I-T103
quantified	O
by	O
membrane	B-T058
inlet	I-T058
mass	I-T058
spectrometry	I-T058
.	O

Results	O
revealed	O
that	O
while	O
denitrification	O
rates	O
were	O
stimulated	O
between	O
10	O
and	O
25	O
000	O
times	O
after	O
crude	B-T103
oil	I-T103
amendment	B-T170
,	O
anammox	B-T038
activity	O
was	O
partially	O
(	O
between	O
2	O
and	O
5	O
times	O
)	O
or	O
completely	O
inhibited	O
by	O
the	O
addition	O
of	O
crude	B-T103
oil	I-T103
when	O
comparing	O
to	O
rates	O
in	O
unamended	O
controls	O
.	O

Similar	O
results	O
were	O
observed	O
across	O
four	O
estuarine	O
sediment	O
types	O
,	O
despite	O
their	O
different	O
physical	O
-	O
chemical	O
characteristics	O
.	O

Moreover	O
,	O
N2O	B-T103
production	O
was	O
reduced	O
by	O
2	O
-	O
36	O
times	O
following	O
crude	B-T103
oil	I-T103
addition	O
.	O

Further	O
work	O
is	O
required	O
to	O
fully	O
understand	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
the	O
observed	O
reduction	O
in	O
N2O	B-T103
production	O
.	O

This	O
study	B-T062
represents	O
one	O
of	O
the	O
first	O
contributions	O
to	O
the	O
understanding	O
of	O
the	O
impact	O
of	O
crude	B-T103
oil	I-T103
pollution	O
on	O
denitrification	O
and	O
anammox	B-T038
,	O
with	O
profound	O
implications	O
for	O
the	O
management	O
of	O
aquatic	O
ecosystems	O
regarding	O
eutrophication	O
(	O
N	O
-	O
removal	O
)	O
.	O

Shining	O
the	O
light	O
on	O
the	O
dark	O
side	O
of	O
medical	O
leadership	O
-	O
a	O
qualitative	B-T062
study	I-T062
in	O
Australia	B-T082

Purpose	O
The	O
paper	O
aims	O
to	O
explore	O
the	O
beliefs	O
of	O
doctors	B-T097
in	O
leadership	O
roles	O
of	O
the	O
concept	O
of	O
"	O
the	O
dark	O
side	O
"	O
,	O
using	O
data	O
collected	O
from	O
interviews	O
carried	O
out	O
with	O
45	O
doctors	B-T097
in	O
medical	O
leadership	O
roles	O
across	O
Australia	B-T082
.	O

The	O
paper	O
looks	O
at	O
the	O
beliefs	O
from	O
the	O
perspectives	O
of	O
doctors	B-T097
who	O
are	O
already	O
in	O
leadership	O
roles	O
themselves	O
;	O
to	O
identify	O
potential	O
barriers	O
they	O
might	O
have	O
encountered	O
and	O
to	O
arrive	O
at	O
better	O
-	O
informed	O
strategies	O
to	O
engage	O
more	O
doctors	B-T097
in	O
the	O
leadership	O
of	O
the	O
Australian	B-T098
health	O
system	O
.	O

The	O
research	B-T062
question	O
is	O
:	O
"	O
What	O
are	O
the	O
beliefs	O
of	O
medical	O
leaders	B-T097
that	O
form	O
the	O
key	O
themes	O
or	O
dimensions	O
of	O
the	O
negative	O
perception	O
of	O
the	O
'	O
dark	O
side	O
'	O
?	O
"	O
.	O

Design	O
/	O
methodology	O
/	O
approach	O
The	O
paper	O
analysed	O
data	O
from	O
two	O
similar	O
qualitative	B-T062
studies	I-T062
examining	O
medical	O
leadership	O
and	O
engagement	O
in	O
Australia	B-T082
by	O
the	O
same	O
author	O
,	O
in	O
collaboration	O
with	O
other	O
researchers	B-T097
,	O
which	O
used	O
in	O
-	O
depth	O
semi	O
-	O
structured	O
interviews	O
with	O
45	O
purposively	O
sampled	O
senior	O
medical	O
leaders	B-T097
in	O
leadership	O
roles	O
across	O
Australia	B-T082
in	O
health	B-T058
services	I-T058
,	O
private	B-T092
and	O
public	B-T092
hospitals	I-T092
,	O
professional	O
associations	O
and	O
health	B-T092
departments	I-T092
.	O

The	O
data	O
were	O
analysed	O
using	O
deductive	O
and	O
inductive	O
approaches	B-T082
through	O
a	O
coding	O
framework	O
based	O
on	O
the	O
interview	O
data	O
and	O
literature	B-T170
review	I-T170
,	O
with	O
all	O
sections	O
of	O
coded	O
data	O
grouped	O
into	O
themes	O
.	O

Findings	O
Medical	O
leaders	B-T097
had	O
four	O
key	O
beliefs	O
about	O
the	O
"	O
dark	O
side	O
"	O
as	O
perceived	O
through	O
the	O
eyes	B-T017
of	O
their	O
own	O
past	O
clinical	O
experience	O
and	O
/	O
or	O
their	O
clinical	O
colleagues	O
.	O

These	O
four	O
beliefs	O
or	O
dimensions	O
of	O
the	O
negative	O
perception	O
colloquially	O
known	O
as	O
"	O
the	O
dark	O
side	O
"	O
are	O
the	O
belief	O
that	O
they	O
lack	O
both	O
managerial	O
and	O
clinical	O
credibility	O
,	O
they	O
have	O
confused	O
identities	O
,	O
they	O
may	O
be	O
in	O
conflict	O
with	O
clinicians	B-T097
,	O
their	O
clinical	O
colleagues	O
lack	O
insight	O
into	O
the	O
complexities	O
of	O
medical	O
leadership	O
and	O
,	O
as	O
a	O
result	O
,	O
doctors	B-T097
are	O
actively	O
discouraged	O
from	O
making	O
the	O
transition	O
from	O
clinical	O
practice	O
to	O
medical	O
leadership	O
roles	O
in	O
the	O
first	O
place	O
.	O

Research	O
limitations	O
/	O
implications	O
This	O
research	B-T062
was	O
conducted	O
within	O
the	O
Western	B-T082
developed	O
-	O
nation	O
setting	O
of	O
Australia	B-T082
and	O
only	O
involved	O
interviews	O
with	O
doctors	B-T097
in	O
medical	O
leadership	O
roles	O
.	O

The	O
findings	O
are	O
therefore	O
limited	O
to	O
the	O
doctors	B-T097
'	O
own	O
perceptions	O
of	O
themselves	O
based	O
on	O
their	O
past	O
experiences	O
and	O
beliefs	O
.	O

Future	O
research	B-T062
involving	O
doctors	B-T097
who	O
have	O
not	O
chosen	O
to	O
transition	O
to	O
leadership	O
roles	O
,	O
or	O
other	O
health	B-T097
practitioners	I-T097
in	O
other	O
settings	O
,	O
may	O
provide	O
a	O
broader	O
perspective	O
.	O

Also	O
,	O
this	O
research	B-T062
was	O
exploratory	O
and	O
descriptive	B-T033
in	O
nature	O
using	O
qualitative	O
methods	O
,	O
and	O
quantitative	O
research	O
can	O
be	O
carried	O
out	O
in	O
the	O
future	O
to	O
extend	O
this	O
research	B-T062
for	O
statistical	O
generalisation	O
.	O

Practical	O
implications	O
The	O
paper	O
includes	O
implications	O
for	O
health	B-T092
organisations	I-T092
,	O
training	O
providers	O
,	O
medical	O
employers	B-T097
and	O
health	B-T092
departments	I-T092
and	O
describes	O
a	O
multi	O
-	O
prong	O
strategy	O
to	O
address	O
this	O
important	O
issue	O
.	O

Originality	O
/	O
value	O
This	O
paper	O
fulfils	O
an	O
identified	O
need	O
to	O
study	B-T062
the	O
concept	O
of	O
"	O
moving	O
to	O
the	O
dark	O
side	O
"	O
as	O
a	O
negative	O
perception	O
of	O
medical	O
leadership	O
and	O
contributes	O
to	O
the	O
evidence	O
in	O
this	O
under	O
-	O
researched	B-T062
area	O
.	O

This	O
paper	O
has	O
used	O
data	O
from	O
two	O
similar	O
studies	B-T062
,	O
combined	O
together	O
for	O
the	O
first	O
time	O
,	O
with	O
new	O
analysis	B-T062
and	O
coding	O
,	O
looking	O
at	O
the	O
concept	O
of	O
the	O
"	O
dark	O
side	O
"	O
to	O
discover	O
new	O
emergent	O
findings	O
.	O

Erlotinib	B-T103
plus	O
gemcitabine	B-T103
versus	O
gemcitabine	B-T103
for	O
pancreatic	B-T038
cancer	I-T038
:	O
real	O
-	O
world	B-T098
analysis	B-T062
of	O
Korean	B-T082
national	B-T092
database	B-T170

A	O
randomized	B-T062
clinical	I-T062
trial	I-T062
has	O
found	O
that	O
the	O
addition	O
of	O
erlotinib	B-T103
to	O
gemcitabine	B-T103
(	O
GEM	B-T103
-	O
E	B-T103
)	O
for	O
pancreatic	B-T038
cancer	I-T038
led	O
to	O
a	O
modest	O
increase	O
in	O
survival	O
.	O

The	O
aim	O
of	O
this	O
national	O
population	B-T098
-	O
based	O
retrospective	B-T062
study	I-T062
was	O
to	O
compare	O
the	O
effectiveness	O
of	O
GEM	B-T103
-	O
E	B-T103
to	O
GEM	B-T103
alone	O
for	O
pancreatic	B-T038
cancer	I-T038
patients	O
in	O
real	O
clinical	O
practice	O
.	O

Patients	O
with	O
pancreatic	B-T038
cancer	I-T038
(	B-T170
ICD	I-T170
-	I-T170
10	I-T170
:	O
C25	O
)	O
with	O
prescription	B-T170
claims	O
of	O
gemcitabine	B-T103
or	O
erlotinib	B-T103
between	O
Jan	O
1	O
,	O
2007	O
and	O
Dec	O
31	O
,	O
2012	O
were	O
retrospectively	O
identified	O
from	O
the	O
Korean	B-T082
Health	B-T058
Insurance	I-T058
claims	O
database	B-T170
.	O

To	O
be	O
included	O
in	O
the	O
study	B-T062
population	B-T098
,	O
patients	O
were	O
required	O
to	O
have	O
had	O
a	O
histological	O
or	O
cytological	B-T033
diagnosis	I-T033
within	O
one	O
year	O
before	O
chemotherapy	B-T058
.	O

Patients	O
treated	B-T033
with	I-T033
prior	O
radiotherapy	B-T058
,	O
surgery	B-T058
,	O
or	O
chemotherapy	B-T058
were	O
excluded	O
to	O
reduce	B-T058
heterogeneity	O
.	O

Overall	O
survival	O
from	O
the	O
initiation	O
of	O
therapy	B-T058
and	O
the	O
medical	O
costs	O
of	O
GEM	B-T103
-	O
E	B-T103
and	O
GEM	B-T103
were	O
compared	O
.	O

A	O
total	O
of	O
4	O
,	O
267	O
patients	O
were	O
included	O
in	O
the	O
analysis	B-T062
.	O

Overall	O
survival	O
was	O
not	O
significantly	O
longer	O
in	O
patients	O
treated	B-T033
with	O
GEM	B-T103
-	O
E	B-T103
(	O
median	O
6	O
.	O
77	O
months	O
for	O
GEM	B-T103
-	O
E	B-T103
vs	O
.	O

6	O
.	O
68	O
months	O
for	O
GEM	B-T103
,	O
p	O
=	O
0	O
.	O
0977	O
)	O
.	O

There	O
was	O
also	O
no	O
significant	O
difference	O
in	O
the	O
respective	O
one	O
-	O
year	O
survival	O
rates	O
(	O
27	O
.	O
0	O
%	O
vs	O
.	O

27	O
.	O
3	O
%	O
;	O
p	O
=	O
0	O
.	O
5988	O
)	O
.	O

Multivariate	O
analysis	O
using	O
age	O
,	O
gender	O
,	O
and	O
comorbidities	O
as	O
covariates	O
did	O
not	O
reveal	O
any	O
significant	O
differences	O
in	O
survival	O
.	O

Based	O
on	O
this	O
relative	O
effectiveness	O
,	O
the	O
incremental	O
cost	O
per	O
life	O
year	O
gained	O
over	O
GEM	B-T103
was	O
estimated	O
at	O
USD	O
70	O
,	O
843	O
.	O
64	O
for	O
GEM	B-T103
-	O
E	B-T103
.	O

GEM	B-T103
-	O
E	B-T103
for	O
pancreatic	B-T038
cancer	I-T038
is	O
not	O
more	O
effective	O
than	O
GEM	B-T103
in	O
a	O
real	O
-	O
world	B-T098
setting	O
,	O
and	O
it	O
does	O
not	O
provide	O
reasonable	B-T033
cost	O
-	O
effectiveness	O
over	O
GEM	B-T103
.	O

Development	O
of	O
a	O
Novel	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
Model	B-T170
to	O
Accurately	O
Predict	O
Pulmonary	B-T038
Absorption	I-T038
and	O
Replace	O
Routine	O
Use	O
of	O
the	O
Isolated	O
Perfused	O
Respiring	B-T038
Rat	B-T017
Lung	I-T017
Model	B-T170

We	O
developed	O
and	O
tested	O
a	O
novel	O
Quantitative	O
Structure	O
-	O
Activity	O
Relationship	O
(	O
QSAR	O
)	O
model	B-T170
to	O
better	O
understand	O
the	O
physicochemical	O
drivers	O
of	O
pulmonary	B-T038
absorption	I-T038
,	O
and	O
to	O
facilitate	O
compound	O
design	O
through	O
improved	O
prediction	O
of	O
absorption	O
.	O

The	O
model	B-T170
was	O
tested	O
using	O
a	O
large	O
array	O
of	O
both	O
existing	O
and	O
newly	O
designed	O
compounds	B-T103
.	O

Pulmonary	B-T038
absorption	I-T038
data	O
was	O
generated	O
using	O
the	O
isolated	O
perfused	O
respiring	B-T038
rat	B-T017
lung	I-T017
(	O
IPRLu	B-T017
)	O
model	B-T170
for	O
82	O
drug	B-T062
discovery	I-T062
compounds	B-T103
and	O
17	O
marketed	B-T103
drugs	I-T103
.	O

This	O
dataset	O
was	O
used	O
to	O
build	O
a	O
novel	O
QSAR	O
model	B-T170
based	O
on	O
calculated	O
physicochemical	O
properties	O
.	O

A	O
further	O
9	O
compounds	B-T103
were	O
used	O
to	O
test	O
the	O
model	B-T170
'	I-T170
s	I-T170
predictive	O
capability	O
.	O

The	O
QSAR	O
model	B-T170
performed	O
well	O
on	O
the	O
9	O
compounds	B-T103
in	O
the	O
"	O
Test	B-T170
set	I-T170
"	O
with	O
a	O
predicted	O
versus	O
observed	O
correlation	O
of	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
85	O
,	O
and	O
>	O
65	O
%	O
of	O
compounds	B-T103
correctly	O
categorised	O
.	O

Calculated	O
descriptors	O
associated	O
with	O
permeability	O
and	O
hydrophobicity	O
positively	O
correlated	O
with	O
pulmonary	B-T038
absorption	I-T038
,	O
whereas	O
those	O
associated	O
with	O
charge	O
,	O
ionisation	O
and	O
size	B-T082
negatively	O
correlated	O
.	O

The	O
novel	O
QSAR	O
model	B-T170
described	O
here	O
can	O
replace	O
routine	O
generation	O
of	O
IPRLu	B-T017
model	B-T170
data	O
for	O
ranking	B-T170
and	O
classifying	B-T170
compounds	B-T103
prior	O
to	O
synthesis	O
.	O

It	O
will	O
also	O
provide	O
scientists	O
working	O
in	O
the	O
field	O
of	O
inhaled	B-T062
drug	I-T062
discovery	I-T062
with	O
a	O
deeper	O
understanding	O
of	O
the	O
physicochemical	O
drivers	O
of	O
pulmonary	B-T038
absorption	I-T038
based	O
on	O
a	O
relevant	O
respiratory	O
compound	B-T103
dataset	B-T170
.	O

The	O
EpiDerm™	B-T170
3D	B-T058
human	I-T058
reconstructed	I-T058
skin	I-T058
micronucleus	I-T058
(	I-T058
RSMN	I-T058
)	I-T058
assay	I-T058
:	O
Historical	B-T062
control	I-T062
data	O
and	O
proof	B-T033
of	O
principle	B-T062
studies	I-T062
for	O
mechanistic	B-T058
assay	I-T058
adaptations	O

The	O
in	B-T058
vitro	I-T058
human	I-T058
reconstructed	I-T058
skin	I-T058
micronucleus	I-T058
(	I-T058
RSMN	I-T058
)	I-T058
assay	I-T058
in	O
EpiDerm™	B-T170
is	O
a	O
promising	O
novel	O
animal	B-T062
alternative	I-T062
for	O
evaluating	O
genotoxicity	O
of	O
topically	O
applied	O
chemicals	B-T103
.	O

It	O
is	O
particularly	O
useful	O
for	O
assessing	O
cosmetic	B-T103
ingredients	I-T103
that	O
can	O
no	O
longer	O
be	O
tested	O
using	O
in	B-T082
vivo	I-T082
assays	B-T058
.	O

To	O
advance	O
the	O
use	O
of	O
this	O
test	B-T170
especially	O
for	O
regulatory	B-T170
decision	B-T038
-	I-T038
making	I-T038
,	O
we	O
have	O
established	O
the	O
RSMN	B-T058
assay	I-T058
in	O
our	O
laboratory	B-T092
according	O
to	O
Good	B-T170
Laboratory	I-T170
Practice	I-T170
and	O
following	O
the	O
principles	O
of	O
the	O
OECD	B-T092
test	B-T170
guideline	I-T170
487	I-T170
in	O
vitro	O
mammalian	B-T017
cell	I-T017
micronucleus	B-T058
test	I-T058
.	O

Proficiency	O
with	O
the	O
assay	B-T058
was	O
established	O
by	O
correctly	O
identifying	O
direct	B-T103
-	I-T103
acting	I-T103
genotoxins	I-T103
and	O
genotoxins	B-T103
requiring	O
metabolism	B-T038
,	O
as	O
well	O
as	O
non	B-T033
-	I-T033
genotoxic	I-T033
/	O
non	B-T033
-	I-T033
carcinogenic	I-T033
chemicals	B-T103
.	O

We	O
also	O
report	B-T170
the	O
analysis	B-T062
of	O
our	O
historical	B-T062
control	I-T062
data	O
that	O
demonstrate	O
vehicle	O
control	O
and	O
positive	O
control	O
values	O
for	O
%	O
micronuclei	B-T017
in	O
binucleated	B-T038
cells	I-T038
are	O
in	O
the	O
ranges	O
reported	O
previously	O
.	O

Technical	O
issues	O
including	O
evaluating	O
various	O
solvents	B-T103
with	O
both	O
48h	O
and	O
72h	O
treatment	B-T058
regimens	I-T058
were	O
investigated	O
.	O

For	O
the	O
first	O
time	O
,	O
mechanistic	B-T170
studies	I-T170
using	O
CREST	B-T062
analysis	I-T062
revealed	O
that	O
the	O
RSMN	B-T058
assay	I-T058
is	O
suitable	O
for	O
distinguishing	O
aneugens	B-T103
and	O
clastogens	B-T103
.	O

Moreover	O
,	O
the	O
assay	B-T058
is	O
also	O
suitable	O
for	O
measuring	O
cytokines	B-T103
as	O
markers	O
for	O
proliferative	B-T038
and	O
toxic	B-T037
effects	I-T037
of	O
chemicals	B-T103
.	O

Wnt	B-T103
-	I-T103
5a	I-T103
/	O
Frizzled9	B-T103
receptor	B-T038
signaling	I-T038
through	O
the	O
Gαo	B-T103
/	O
Gβγ	B-T103
complex	I-T103
regulates	B-T038
dendritic	B-T017
spine	I-T017
formation	B-T038

Wnt	B-T103
ligands	I-T103
play	O
crucial	O
roles	O
in	O
the	O
development	O
and	O
regulation	B-T038
of	I-T038
synapse	I-T038
structure	I-T038
and	I-T038
function	I-T038
.	O

Specifically	O
,	O
Wnt	B-T103
-	I-T103
5a	I-T103
acts	O
as	O
a	O
secreted	B-T103
growth	I-T103
factor	I-T103
that	O
regulates	B-T038
dendritic	B-T017
spine	I-T017
formation	B-T038
in	O
rodent	B-T204
hippocampal	B-T017
neurons	B-T017
,	O
resulting	O
in	O
postsynaptic	B-T017
development	O
that	O
promotes	O
the	O
clustering	B-T038
of	I-T038
the	I-T038
postsynaptic	I-T038
density	I-T038
protein	I-T038
-	I-T038
95	I-T038
(	I-T038
PSD	I-T038
-	I-T038
95	I-T038
)	I-T038
.	O

Here	O
,	O
we	O
focused	O
on	O
the	O
early	O
events	O
occurring	O
after	O
the	O
interaction	B-T038
between	O
Wnt	B-T103
-	I-T103
5a	I-T103
and	O
its	O
Frizzled	B-T103
receptor	I-T103
at	O
the	O
neuronal	B-T017
cell	B-T017
surface	I-T017
.	O

Additionally	O
,	O
we	O
studied	O
the	O
role	O
of	O
heterotrimeric	B-T103
G	I-T103
proteins	I-T103
in	O
Wnt	B-T103
-	I-T103
5a	I-T103
-	O
dependent	O
synaptic	B-T017
development	O
.	O

We	O
report	O
that	O
Frizzled9	B-T103
(	O
FZD9	B-T103
)	O
,	O
a	O
Wnt	B-T103
receptor	B-T103
related	O
to	O
Williams	B-T038
'	I-T038
syndrome	I-T038
,	O
is	O
localized	O
in	O
the	O
postsynaptic	O
region	O
,	O
where	O
it	O
interacts	B-T038
with	O
Wnt	B-T103
-	I-T103
5a	I-T103
.	O

Functionally	O
,	O
FZD9	B-T103
is	O
required	O
for	O
the	O
Wnt	B-T103
-	I-T103
5a	I-T103
-	O
mediated	O
increase	O
in	O
dendritic	B-T017
spine	I-T017
density	I-T017
.	O

FZD9	B-T103
forms	O
a	O
pre	B-T017
-	I-T017
coupled	I-T017
complex	I-T017
with	O
Gαo	B-T103
under	O
basal	O
conditions	O
that	O
dissociates	B-T038
after	O
Wnt	B-T103
-	I-T103
5a	I-T103
stimulation	B-T038
.	O

Accordingly	O
,	O
we	O
found	O
that	O
G	B-T038
-	I-T038
protein	I-T038
inhibition	I-T038
abrogates	I-T038
Wnt	B-T103
-	I-T103
5a	I-T103
-	O
dependent	O
pathway	B-T038
in	O
hippocampal	B-T017
neurons	B-T017
.	O

In	O
particular	O
,	O
the	O
activation	O
of	O
Gαo	B-T103
appears	O
to	O
be	O
a	O
key	O
factor	O
controlling	O
the	O
Wnt	B-T103
-	I-T103
5a	I-T103
-	O
induced	O
dendritic	B-T017
spine	I-T017
density	I-T017
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
Gβγ	B-T103
is	O
required	O
for	O
the	O
Wnt	B-T103
-	I-T103
5a	I-T103
-	O
mediated	O
increase	O
in	O
cytosolic	B-T017
calcium	B-T103
levels	O
and	O
spinogenesis	B-T038
.	O

Our	O
findings	O
reveal	O
that	O
FZD9	B-T103
and	O
heterotrimeric	B-T103
G	I-T103
proteins	I-T103
regulate	B-T038
Wnt	B-T103
-	I-T103
5a	I-T103
signaling	B-T038
and	O
dendritic	B-T017
spines	I-T017
in	O
cultured	B-T017
hippocampal	B-T017
neurons	B-T017
.	O

A	O
Delayed	O
Diagnosis	B-T033
of	O
Chronic	B-T038
Mesenteric	I-T038
Ischaemia	I-T038
:	O
The	O
Role	O
of	O
Clinicians	B-T097
'	O
Cognitive	O
Errors	O

Chronic	O
diarrhoeal	B-T038
illnesses	I-T038
with	O
nausea	B-T033
and	O
weight	B-T033
loss	I-T033
are	O
a	O
common	O
indication	O
for	O
gastroenterology	B-T091
review	O
.	O

While	O
many	O
such	O
cases	O
have	O
intra	B-T082
-	I-T082
luminal	I-T082
aetiologies	O
,	O
such	O
as	O
inflammatory	B-T038
bowel	I-T038
disease	I-T038
,	O
coeliac	B-T038
disease	I-T038
or	O
other	O
malabsorptive	B-T033
conditions	I-T033
,	O
with	O
many	O
other	O
cases	O
due	O
to	O
functional	O
gut	B-T017
disorders	B-T038
or	O
systemic	O
malignancy	B-T038
,	O
clinicians	B-T097
must	O
also	O
keep	O
vascular	B-T038
disorders	I-T038
in	O
mind	O
.	O

Here	O
we	O
report	O
a	O
patient	O
with	O
a	O
delayed	O
diagnosis	B-T033
of	O
chronic	B-T038
mesenteric	I-T038
ischaemia	I-T038
after	O
6	O
months	O
of	O
gastrointestinal	B-T033
symptoms	I-T033
strongly	O
mimicking	O
an	O
alternative	O
diagnosis	B-T033
such	O
as	O
inflammatory	B-T038
bowel	I-T038
disease	I-T038
due	O
an	O
atypical	O
predominance	O
of	O
nausea	B-T033
and	O
diarrhoea	B-T033
rather	O
than	O
pain	B-T033
.	O

We	O
briefly	O
review	O
the	O
literature	B-T170
on	O
treatment	O
of	O
this	O
condition	B-T038
but	O
also	O
discuss	O
with	O
particular	O
attention	O
the	O
sequence	O
of	O
cognitive	O
errors	O
made	O
by	O
clinicians	B-T097
that	O
led	O
to	O
a	O
diagnostic	B-T033
delay	O
,	O
inviting	O
readers	O
to	O
thus	O
reflect	O
on	O
how	O
such	O
errors	O
can	O
be	O
minimised	O
in	O
their	O
practice	O
.	O

Evaluation	B-T058
of	O
Choroidal	B-T017
Thickness	O
in	O
Patients	O
with	O
Pseudoexfoliation	B-T038
Syndrome	I-T038
and	O
Pseudoexfoliation	B-T038
Glaucoma	I-T038

Purpose	O
.	O

To	O
compare	O
the	O
macular	O
and	O
peripapillary	B-T082
choroidal	B-T017
thickness	O
in	O
eyes	B-T017
with	O
pseudoexfoliation	B-T038
(	I-T038
PEX	I-T038
)	I-T038
syndrome	I-T038
and	O
PEX	B-T038
glaucoma	I-T038
with	O
the	O
normal	O
eyes	B-T017
of	O
healthy	O
controls	O
.	O

Materials	O
and	O
Methods	O
.	O

In	O
this	O
prospective	B-T062
study	I-T062
,	O
30	O
eyes	B-T017
of	O
30	O
patients	O
with	O
PEX	B-T038
syndrome	I-T038
,	O
28	O
eyes	B-T017
of	O
28	O
patients	O
with	O
PEX	B-T038
glaucoma	I-T038
,	O
and	O
30	O
eyes	B-T017
of	O
30	O
age	O
-	O
matched	O
healthy	O
subjects	O
were	O
enrolled	O
.	O

Choroidal	B-T017
thicknesses	O
in	O
the	O
macular	O
and	O
peripapillary	B-T082
areas	B-T082
were	O
measured	O
by	O
using	O
spectral	B-T074
domain	I-T074
optical	I-T074
coherence	I-T074
tomography	I-T074
.	O

Results	O
.	O

Gender	O
,	O
age	O
,	O
and	O
axial	O
length	O
did	O
not	B-T033
significantly	I-T033
differ	O
between	O
the	O
groups	O
(	O
all	O
,	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
values	O
of	O
choroidal	B-T017
thickness	O
in	O
the	O
macular	O
and	O
peripapillary	B-T082
areas	B-T082
(	O
except	O
the	O
superior	B-T082
quadrant	B-T082
)	O
in	O
the	O
patients	O
with	O
PEX	B-T038
syndrome	I-T038
and	O
PEX	B-T038
glaucoma	I-T038
were	O
lower	O
compared	O
with	O
controls	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
values	O
of	O
the	O
macular	O
and	O
peripapillary	B-T082
choroidal	B-T017
thickness	O
in	O
the	O
PEX	B-T038
glaucoma	I-T038
group	O
were	O
lower	O
compared	O
with	O
PEX	B-T038
syndrome	I-T038
group	O
;	O
however	O
this	O
difference	O
was	O
not	B-T033
significant	I-T033
.	O

Conclusions	O
.	O

The	O
findings	B-T033
of	O
this	O
study	B-T062
revealed	O
that	O
macular	O
and	O
peripapillary	B-T082
choroidal	B-T017
thicknesses	O
were	O
decreased	O
in	O
PEX	B-T038
syndrome	I-T038
and	O
PEX	B-T038
glaucoma	I-T038
cases	O
.	O

The	O
role	O
of	O
choroid	B-T017
in	O
the	O
development	O
of	O
glaucomatous	B-T038
damage	O
in	O
patients	O
with	O
PEX	B-T038
syndrome	I-T038
remains	O
unclear	O
.	O

Clinical	B-T033
Features	I-T033
and	O
Complications	B-T038
of	O
the	O
HLA	B-T103
-	I-T103
B27	I-T103
-	O
associated	O
Acute	B-T038
Anterior	I-T038
Uveitis	I-T038
:	O
A	O
Metanalysis	B-T062

In	O
this	O
article	B-T170
,	O
we	O
report	O
a	O
literature	B-T170
-	I-T170
based	I-T170
metanalysis	B-T062
we	O
have	O
conducted	O
to	O
outline	O
the	O
clinical	B-T033
features	I-T033
of	O
the	O
HLA	B-T103
-	I-T103
B27	I-T103
Acute	B-T038
Anterior	I-T038
Uveitis	I-T038
(	O
AAU	B-T038
)	O
.	O

The	O
examined	B-T033
material	O
was	O
based	O
on	O
observational	B-T062
studies	I-T062
in	O
which	O
participants	B-T098
were	O
affected	O
by	O
Acute	B-T038
Anterior	I-T038
Uveitis	I-T038
and	O
divided	O
into	O
HLA	O
B27	O
+	O
and	O
HLA	B-T033
B27	I-T033
-	I-T033
.	O

We	O
performed	O
a	O
search	O
on	O
articles	B-T170
with	O
the	O
words	O
"	O
HLA	B-T038
B27	I-T038
uveitis	I-T038
"	O
dated	O
before	O
May	O
2014	O
.	O

Among	O
these	O
,	O
29	O
articles	B-T170
were	O
selected	O
for	O
a	O
second	O
review	O
.	O

After	O
a	O
further	O
evaluation	O
,	O
22	O
articles	B-T170
were	O
analyzed	B-T062
.	O

The	O
clinical	O
characteristics	O
studied	O
in	O
the	O
metanalysis	B-T062
were	O
:	O
(	O
1	O
)	O
systemic	B-T038
disease	I-T038
;	O
(	O
2	O
)	O
sex	O
distribution	O
;	O
(	O
3	O
)	O
laterality	O
;	O
(	O
4	O
)	O
visual	B-T201
acuity	I-T201
;	O
(	O
5	O
)	O
hypopion	B-T038
;	O
(	O
6	O
)	O
anterior	B-T103
chamber	I-T103
'	I-T103
s	I-T103
fibrin	I-T103
;	O
(	O
7	O
)	O
elevated	B-T033
intraocular	I-T033
pressure	I-T033
(	O
IOP	B-T038
)	O
during	O
inflammation	B-T038
;	O
(	O
8	O
)	O
glaucoma	B-T038
;	O
(	O
9	O
)	O
posterior	B-T038
synechiae	I-T038
;	O
(	O
10	O
)	O
cataract	B-T017
;	O
(	O
11	O
)	O
cystoid	B-T038
macular	I-T038
edema	I-T038
;	O
(	O
12	O
)	O
papillitis	B-T038
.	O

We	O
have	O
calculated	O
a	O
relative	O
risk	O
(	O
RR	O
)	O
for	O
each	O
outcome	O
measured	O
.	O

The	O
results	O
obtained	O
remark	O
some	O
of	O
the	O
peculiar	O
features	O
linked	O
to	O
the	O
HLA	B-T103
B27	I-T103
Acute	B-T038
Anterior	I-T038
Uveitis	I-T038
,	O
such	O
as	O
strong	O
association	O
with	O
ankylosing	B-T038
spondylitis	I-T038
(	O
RR	O
=	O
6	O
.	O
80	O
)	O
and	O
systemic	B-T038
diseases	I-T038
(	O
RR	O
=	O
9	O
.	O
9	O
)	O
,	O
male	O
prevalence	O
(	O
RR	O
=	O
1	O
.	O
2	O
)	O
,	O
unilateral	B-T082
(	O
RR	O
=	O
1	O
.	O
1	O
)	O
or	O
alternating	O
bilateral	B-T082
(	O
RR	O
=	O
2	O
.	O
2	O
)	O
involvement	O
,	O
hypopion	B-T038
(	O
RR	O
=	O
5	O
.	O
5	O
)	O
,	O
fibrinous	B-T103
reaction	O
and	O
even	O
papillitis	B-T038
(	O
R	O
=	O
7	O
.	O
7	O
)	O
.	O

Simultaneous	O
bilateral	B-T082
(	O
RR	O
=	O
0	O
.	O
3	O
)	O
AAU	B-T038
is	O
more	O
frequent	O
in	O
HLA	B-T103
-	I-T103
B27	I-T103
negative	B-T033
form	O
.	O

We	O
report	O
higher	O
risk	O
of	O
elevated	B-T033
IOP	I-T033
and	O
glaucoma	B-T038
(	O
RR	O
=	O
0	O
.	O
6	O
)	O
in	O
B27	B-T038
-	I-T038
Acute	I-T038
Anterior	I-T038
Uveitis	I-T038
.	O

No	O
significant	O
difference	O
between	O
HLA	B-T033
B	I-T033
27	I-T033
positive	I-T033
and	O
negative	B-T033
AAU	B-T038
was	O
observed	O
according	O
to	O
final	O
visual	B-T201
acuity	I-T201
and	O
complications	B-T038
such	O
as	O
posterior	B-T038
synechiae	I-T038
,	O
cataract	B-T017
,	O
and	O
maculare	B-T038
edema	I-T038
.	O

We	O
trust	O
that	O
this	O
will	O
inform	O
on	O
the	O
clinical	B-T058
evaluation	I-T058
and	O
therapeutic	O
decision	B-T038
in	O
addressing	O
a	O
still	O
ill	O
-	O
defined	O
ophthalmologic	O
condition	O
.	O

A	O
Case	O
Presenting	O
with	O
Splenic	B-T038
Infarct	I-T038
Diagnosed	B-T033
as	O
Primary	B-T017
Bone	I-T017
Marrow	I-T017
CD5	B-T017
Positive	I-T017
DLBCL	B-T038
:	O
A	O
Clinicopathological	O
Correlation	O

De	O
novo	O
CD5	B-T017
+	I-T017
Diffuse	B-T033
large	I-T033
B	I-T033
cell	I-T033
lymphoma	I-T033
(	O
DLBCL	B-T038
)	O
is	O
a	O
rare	O
and	O
aggressive	B-T033
subtype	I-T033
of	O
DLBCL	B-T038
.	O

It	O
is	O
a	O
distinct	O
clinicopathologic	B-T033
entity	O
with	O
complex	O
molecular	O
profile	O
and	O
poor	B-T033
prognosis	I-T033
.	O

A	O
59	O
year	O
old	O
female	O
presented	B-T033
with	I-T033
pyrexia	B-T033
of	I-T033
unknown	I-T033
origin	I-T033
since	O
1	O
month	O
.	O

On	O
examination	B-T058
,	O
there	O
was	O
severe	B-T033
pallor	I-T033
,	O
hepatosplenomegaly	B-T033
and	O
no	O
palpable	O
lymphadenopathy	B-T038
.	O

Complete	B-T058
blood	I-T058
count	I-T058
revealed	O
bicytopenia	B-T033
with	O
normal	B-T033
total	I-T033
leucocyte	I-T033
count	I-T033
.	O

Liver	B-T058
and	O
renal	B-T058
function	I-T058
tests	I-T058
were	O
normal	O
.	O

Ultrasonography	B-T058
abdomen	I-T058
revealed	O
splenic	B-T033
enlargement	I-T033
with	O
two	B-T033
focal	I-T033
lesions	I-T033
attributed	O
to	O
either	O
splenic	B-T038
abscess	I-T038
or	O
infarcts	B-T038
.	O

Patient	O
was	O
being	O
managed	O
as	O
splenic	B-T038
infarct	I-T038
but	O
continued	O
to	O
have	O
bicytopenia	B-T033
.	O

Further	O
investigation	B-T058
showed	O
elevated	B-T033
serum	I-T033
ferritin	I-T033
,	O
triglycerides	B-T033
and	O
LDH	B-T033
.	O

With	O
a	O
clinical	O
suspicion	B-T038
of	O
infection	B-T038
and	O
haemophagocytic	B-T038
lymphohistiocytosis	I-T038
bone	B-T058
marrow	I-T058
aspiration	I-T058
(	I-T058
BMA	B-T058
)	I-T058
and	I-T058
biopsy	B-T058
(	I-T058
BMBx	I-T058
)	I-T058
was	O
done	O
.	O

BMA	O
showed	O
extensive	O
haemophagocytosis	B-T038
and	O
~	O
7	O
.	O
4	O
%	O
large	B-T038
lymphoma	I-T038
-	I-T038
like	I-T038
cells	I-T038
.	O

On	O
this	O
basis	O
PET	B-T058
-	I-T058
CT	I-T058
was	O
suggested	O
which	O
showed	O
enlarged	B-T033
spleen	I-T033
with	O
diffuse	B-T033
uptake	I-T033
.	O

BMBx	B-T058
showed	O
nodular	B-T017
and	O
intrasinusoidal	B-T082
collection	O
of	O
abnormal	B-T017
lymphoid	I-T017
cells	I-T017
.	O

On	O
immunohistochemistry	B-T058
,	O
these	O
cells	B-T017
were	O
positive	B-T033
for	I-T033
CD20	I-T033
,	O
CD5	B-T103
,	O
MUM1	B-T103
,	O
BCL	O
-	O
2	O
,	O
BCL	O
-	O
6	O
and	O
negative	B-T033
for	O
CD3	B-T103
,	O
CD10	B-T103
and	O
CD23	B-T103
.	O

CD34	B-T103
highlighted	O
focal	B-T082
intrasinusoidal	B-T082
pattern	B-T082
.	O

The	O
complete	O
clinicopathological	O
profile	O
suggested	O
the	O
diagnosis	B-T033
of	O
de	O
novo	O
CD5	B-T017
+	I-T017
DLBCL	B-T038
,	O
with	O
primary	B-T038
hepatosplenic	I-T038
pattern	B-T082
of	O
involvement	O
.	O

CD5	B-T017
+	I-T017
DLBCL	B-T038
presenting	O
as	O
splenic	B-T038
infarct	I-T038
is	O
very	B-T033
rare	I-T033
.	O

This	O
case	O
was	O
unusual	O
as	O
the	O
diagnosis	B-T033
of	O
a	O
primary	B-T038
aggressive	I-T038
lymphoma	I-T038
with	O
haemophagocytosis	B-T038
was	O
established	O
in	O
a	O
patient	O
who	O
presented	O
with	O
fever	B-T033
and	O
splenic	B-T038
infarct	I-T038
without	O
lymphadenopathy	B-T038
.	O

This	O
indicates	O
the	O
importance	O
of	O
good	O
morphological	B-T082
assessment	O
of	O
a	O
bone	B-T031
marrow	I-T031
aspirate	I-T031
and	O
biopsy	B-T058
to	O
make	O
a	O
correct	B-T033
diagnosis	I-T033
.	O

The	O
cost	O
-	O
effectiveness	O
of	O
family	O
/	O
family	B-T058
-	I-T058
based	I-T058
therapy	I-T058
for	O
treatment	O
of	O
externalizing	B-T038
disorders	I-T038
,	O
substance	B-T038
use	I-T038
disorders	I-T038
and	O
delinquency	B-T038
:	O
a	O
systematic	O
review	B-T170

Family	B-T058
therapy	I-T058
and	O
family	O
-	O
based	O
treatment	O
has	O
been	O
commonly	O
applied	O
in	O
children	O
and	O
adolescents	O
in	O
mental	B-T058
health	I-T058
care	I-T058
and	O
has	O
been	O
proven	O
to	O
be	O
effective	O
.	O

There	O
is	O
an	O
increased	O
interest	O
in	O
economic	O
evaluations	O
of	O
these	O
,	O
often	O
expensive	O
,	O
interventions	B-T058
.	O

The	O
aim	O
of	O
this	O
systematic	O
review	B-T170
is	O
to	O
summarize	O
and	O
evaluate	B-T058
the	O
evidence	O
on	O
cost	O
-	O
effectiveness	O
of	O
family	O
/	O
family	B-T058
-	I-T058
based	I-T058
therapy	I-T058
for	O
externalizing	B-T038
disorders	I-T038
,	O
substance	B-T038
use	I-T038
disorders	I-T038
and	O
delinquency	B-T038
.	O

A	O
systematic	O
literature	O
search	O
was	O
performed	O
in	O
PubMed	B-T170
,	O
Education	O
Resource	O
information	O
Centre	O
(	O
ERIC	O
)	O
,	O
Psycinfo	O
and	O
Cochrane	B-T170
reviews	B-T170
including	O
studies	B-T058
conducted	O
after	O
1990	O
and	O
before	O
the	O
first	O
of	O
August	O
of	O
2013	O
.	O

Full	O
economic	O
evaluations	O
investigating	O
family	O
/	O
family	B-T058
-	I-T058
based	I-T058
interventions	I-T058
for	O
adolescents	O
between	O
10	O
and	O
20	O
years	O
treated	O
for	O
substance	B-T038
use	I-T038
disorders	I-T038
,	O
delinquency	B-T038
or	O
externalizing	B-T038
disorders	I-T038
were	O
included	O
.	O

Seven	O
hundred	O
thirty	O
-	O
one	O
articles	B-T170
met	O
the	O
search	O
criteria	O
and	O
51	O
studies	B-T058
were	O
initially	O
selected	O
.	O

The	O
final	O
selection	O
resulted	O
in	O
the	O
inclusion	O
of	O
11	O
studies	B-T058
.	O

The	O
quality	O
of	O
these	O
studies	B-T058
was	O
assessed	O
.	O

Within	O
the	O
identified	O
studies	B-T058
,	O
there	O
was	O
great	O
variation	O
in	O
the	O
specific	O
type	O
of	O
family	O
/	O
family	B-T058
-	I-T058
based	I-T058
interventions	I-T058
and	O
disorders	B-T038
.	O

According	O
to	O
the	O
outcomes	O
of	O
the	O
checklists	O
,	O
the	O
overall	O
quality	O
of	O
the	O
economic	O
evaluations	O
was	O
low	O
.	O

Results	O
varied	O
by	O
study	B-T058
.	O

Due	O
to	O
the	O
variations	O
in	O
setting	O
,	O
design	O
and	O
outcome	O
it	O
was	O
not	O
feasible	O
to	O
pool	O
results	O
using	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
.	O

The	O
quality	O
of	O
the	O
identified	O
economic	O
evaluations	O
of	O
family	O
/	O
family	B-T058
-	I-T058
based	I-T058
therapy	I-T058
for	O
treatment	O
of	O
externalizing	B-T038
disorders	I-T038
,	O
adolescent	O
substance	B-T038
use	I-T038
disorders	I-T038
and	O
delinquency	B-T038
was	O
insufficient	O
to	O
determine	O
the	O
cost	O
-	O
effectiveness	O
.	O

Although	O
commonly	O
applied	O
,	O
family	O
/	O
family	B-T058
-	I-T058
based	I-T058
therapy	I-T058
is	O
costly	O
and	O
more	O
research	O
of	O
higher	O
quality	O
is	O
needed	O
.	O

Regulation	B-T038
of	O
ABCA1	B-T017
and	O
ABCG1	B-T017
gene	B-T038
expression	I-T038
in	O
the	O
intraabdominal	B-T017
adipose	I-T017
tissue	I-T017

Tissue	B-T038
specific	I-T038
expression	I-T038
of	I-T038
genes	I-T038
encoding	O
cholesterol	B-T103
transporters	B-T103
ABCA1	B-T103
and	O
ABCG1	B-T103
as	O
well	O
as	O
genes	B-T017
encoding	O
the	O
most	O
important	O
transcriptional	B-T038
regulators	B-T103
of	O
adipogenesis	B-T038
-	O
LXRa	B-T103
,	O
LXRb	B-T103
,	O
PPARg	B-T103
and	O
RORa	B-T103
has	O
been	O
investigated	O
in	O
intraabdominal	B-T017
adipose	I-T017
tissue	I-T017
(	O
IAT	B-T017
)	O
samples	O
.	O
A	O
direct	O
correlation	O
between	O
the	O
content	O
of	O
ABCA1	B-T103
and	O
ABCG1	B-T103
proteins	I-T103
with	O
RORa	B-T103
protein	I-T103
level	O
(	O
r	O
=	O
0	O
.	O
480	O
,	O
p	O
<	O
0	O
.	O
05	O
;	O
r	O
=	O
0	O
.	O
435	O
,	O
p	O
<	O
0	O
.	O
05	O
,	O
respectively	O
)	O
suggests	O
the	O
role	O
of	O
the	O
transcription	B-T103
factor	I-T103
RORa	B-T103
in	O
the	O
regulation	B-T038
of	O
IAT	B-T017
ABCA1	B-T103
and	O
ABCG1	B-T103
protein	I-T103
levels	O
.	O

ABCA1	B-T017
and	O
ABCG1	B-T017
gene	B-T038
expression	I-T038
positively	O
correlated	O
with	O
obesity	B-T038
indicators	B-T103
such	O
as	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
(	O
r	O
=	O
0	O
.	O
522	O
,	O
p	O
=	O
0	O
.	O
004	O
;	O
r	O
=	O
0	O
.	O
594	O
,	O
p	O
=	O
0	O
.	O
001	O
,	O
respectively	O
)	O
and	O
waist	B-T201
circumference	I-T201
(	O
r	O
=	O
0	O
.	O
403	O
,	O
p	O
=	O
0	O
.	O
033	O
;	O
r	O
=	O
0	O
.	O
474	O
,	O
p	O
=	O
0	O
.	O
013	O
,	O
respectively	O
)	O
.	O

The	O
development	O
of	O
obesity	B-T038
is	O
associated	O
with	O
decreased	O
IAT	B-T017
levels	O
of	O
RORa	B-T017
and	O
LXRb	B-T017
mRNA	B-T103
(	O
p	O
=	O
0	O
.	O
016	O
and	O
p	O
=	O
0	O
.	O
002	O
,	O
respectively	O
)	O
.	O

These	O
data	O
suggest	O
that	O
the	O
nuclear	B-T103
factor	I-T103
RORa	I-T103
can	O
play	O
a	O
significant	O
role	O
in	O
the	O
regulation	B-T038
of	O
cholesterol	B-T038
metabolism	I-T038
and	O
control	O
IAT	B-T017
expression	B-T038
of	O
ABCA1	B-T103
and	O
ABCG1	B-T103
,	O
while	O
the	O
level	O
of	O
IAT	B-T017
LXRb	B-T017
gene	B-T038
expression	I-T038
may	O
be	O
an	O
important	O
factor	O
associated	O
with	O
the	O
development	O
of	O
obesity	B-T038
.	O

Triterpenoids	B-T103
from	O
the	O
stems	B-T204
of	O
Tripterygium	B-T204
regelii	I-T204

Three	O
new	O
triterpenoids	B-T103
,	O
triregelolides	B-T103
A	O
,	O
B	O
(	O
1	O
,	O
2	O
)	O
,	O
and	O
triregeloic	B-T103
acid	I-T103
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
stems	B-T204
of	O
Tripterygium	B-T204
regelii	I-T204
along	O
with	O
twenty	O
known	O
triterpene	B-T103
analogues	B-T103
(	O
4	O
-	O
23	O
)	O
.	O

The	O
structures	O
of	O
three	O
new	O
compounds	B-T103
were	O
identified	O
by	O
analyzing	O
their	O
NMR	B-T058
spectroscopic	I-T058
and	O
HRESIMS	B-T058
data	O
.	O

Compounds	B-T103
4	B-T103
,	O
7	B-T103
,	O
8	B-T103
,	O
10	B-T103
,	O
13	B-T103
,	O
14	B-T103
,	O
17	B-T103
,	O
21	B-T103
-	I-T103
23	I-T103
were	O
isolated	O
from	O
T	B-T204
.	I-T204

regelii	I-T204
for	O
the	O
first	O
time	O
.	O

Compounds	B-T103
3	B-T103
,	O
5	B-T103
,	O
6	B-T103
,	O
8	B-T103
,	O
9	B-T103
,	O
10	B-T103
,	O
14	B-T103
and	O
16	B-T103
showed	O
inhibitory	B-T038
effects	I-T038
on	I-T038
the	I-T038
proliferation	I-T038
of	O
human	B-T017
breast	I-T017
cancer	I-T017
cells	I-T017
MCF	B-T017
-	I-T017
7	I-T017
by	O
24	O
.	O
1	O
%	O
,	O
69	O
.	O
6	O
%	O
,	O
72	O
.	O
8	O
%	O
,	O
21	O
.	O
6	O
%	O
,	O
23	O
.	O
1	O
%	O
,	O
43	O
.	O
3	O
%	O
,	O
25	O
.	O
5	O
%	O
and	O
23	O
.	O
5	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
at	O
a	O
concentration	O
of	O
10μM	O
,	O
respectively	O
.	O

Biochemical	O
evidence	O
for	O
a	O
mitochondrial	B-T017
genetic	O
modifier	B-T017
in	O
the	O
phenotypic	O
manifestation	O
of	O
Leber	B-T038
'	I-T038
s	I-T038
hereditary	I-T038
optic	I-T038
neuropathy	I-T038
-	O
associated	O
mitochondrial	B-T017
DNA	I-T017
mutation	I-T017

Leber	B-T038
'	I-T038
s	I-T038
hereditary	I-T038
optic	I-T038
neuropathy	I-T038
(	O
LHON	B-T038
)	O
is	O
the	O
most	O
common	O
mitochondrial	B-T038
disease	I-T038
.	O

Mitochondrial	B-T017
modifiers	B-T017
are	O
proposed	O
to	O
modify	O
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	B-T038
-	O
associated	O
mitochondrial	B-T103
DNA	I-T103
(	O
mtDNA	B-T103
)	O
mutations	B-T017
.	O

In	O
this	O
study	B-T062
,	O
we	O
demonstrated	O
that	O
the	O
LHON	B-T038
susceptibility	B-T201
allele	B-T017
(	O
m	B-T017
.	I-T017
14502T	I-T017
>	I-T017
C	I-T017
,	O
p	B-T017
.	I-T017

58I	I-T017
>	I-T017
V	I-T017
)	O
in	O
the	O
ND6	B-T017
gene	I-T017
modulated	B-T082
the	O
phenotypic	O
expression	O
of	O
primary	O
LHON	B-T038
-	O
associated	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutation	I-T038
.	O

Twenty	O
-	O
two	O
Han	O
Chinese	O
pedigrees	B-T170
carrying	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
and	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutations	I-T038
exhibited	O
significantly	O
higher	O
penetrance	O
of	O
optic	B-T038
neuropathy	I-T038
than	O
those	O
carrying	O
only	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutation	I-T038
.	O

We	O
performed	O
functional	O
assays	B-T058
using	O
the	O
cybrid	B-T017
cell	I-T017
models	I-T017
,	O
generated	O
by	O
fusing	O
mtDNA	B-T017
-	I-T017
less	I-T017
ρ	I-T017
(	I-T017
o	I-T017
)	I-T017
cells	I-T017
with	O
enucleated	B-T017
cells	I-T017
from	O
LHON	B-T038
patients	O
carrying	O
both	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
and	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
mutations	I-T038
,	O
only	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
or	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutation	I-T038
and	O
a	O
control	O
belonging	O
to	O
the	O
same	O
mtDNA	B-T103
haplogroup	O
.	O

These	O
cybrids	B-T017
cell	I-T017
lines	I-T017
bearing	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
mutation	I-T038
exhibited	O
mild	O
effects	O
on	O
mitochondrial	B-T017
functions	O
compared	O
with	O
those	O
carrying	O
only	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutation	I-T038
.	O

However	O
,	O
more	O
severe	O
mitochondrial	B-T017
dysfunctions	O
were	O
observed	O
in	O
cell	B-T017
lines	I-T017
bearing	O
both	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
and	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutations	I-T038
than	O
those	O
carrying	O
only	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
or	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
mutation	I-T038
.	O

In	O
particular	O
,	O
the	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
mutation	I-T038
altered	O
assemble	O
of	O
complex	B-T103
I	I-T103
,	O
thereby	O
aggravating	O
the	O
respiratory	O
phenotypes	O
associated	O
with	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutation	I-T038
,	O
resulted	O
in	O
a	O
more	O
defective	O
complex	B-T103
I	I-T103
.	O

Furthermore	O
,	O
more	O
reductions	O
in	O
the	O
levels	O
of	O
mitochondrial	B-T017
ATP	B-T103
and	O
increasing	O
production	O
of	O
reactive	B-T103
oxygen	I-T103
species	I-T103
were	O
also	O
observed	O
in	O
mutant	B-T038
cells	B-T017
bearing	O
both	O
m	B-T038
.	I-T038
14502T	I-T038
>	I-T038
C	I-T038
and	O
m	B-T038
.	I-T038
11778G	I-T038
>	I-T038
A	I-T038
mutation	I-T038
than	O
those	O
carrying	O
only	O
11778G	B-T038
>	I-T038
A	I-T038
mutation	I-T038
.	O

Our	O
findings	O
provided	O
new	O
insights	O
into	O
the	O
pathophysiology	O
of	O
LHON	B-T038
that	O
were	O
manifested	O
by	O
interaction	O
between	O
primary	O
and	O
secondary	O
mtDNA	B-T103
mutations	B-T017
.	O

Improving	O
Care	B-T058
Transitions	I-T058
Across	O
Healthcare	B-T058
Settings	O
Through	O
a	O
Human	O
Factors	O
Approach	O

After	O
more	O
than	O
two	O
decades	O
of	O
research	B-T062
focused	O
on	O
care	B-T058
transition	I-T058
improvement	O
and	O
intervention	B-T058
development	O
,	O
unfavorable	B-T033
outcome	I-T033
measures	O
associated	O
with	O
care	B-T058
transitions	I-T058
across	O
healthcare	B-T058
settings	O
persist	O
.	O

Readmissions	O
rates	O
remain	O
an	O
important	O
outcome	O
to	O
target	O
for	O
intervention	B-T058
,	O
adverse	B-T038
events	I-T038
associated	O
with	O
care	B-T058
transitions	I-T058
continue	O
to	O
be	O
an	O
issue	B-T033
,	O
and	O
patients	O
are	O
often	O
dissatisfied	B-T038
with	O
the	O
quality	O
of	O
their	O
care	O
.	O

Currently	O
,	O
interventions	B-T058
to	O
improve	O
care	B-T058
transitions	I-T058
are	O
disease	B-T038
specific	O
,	O
require	O
substantial	O
financial	O
investments	O
in	O
training	O
allied	B-T097
healthcare	I-T097
professionals	I-T097
,	O
or	O
focus	O
primarily	O
on	O
hospital	B-T058
-	I-T058
based	I-T058
discharge	I-T058
planning	I-T058
with	O
mixed	O
results	O
.	O

This	O
complex	O
situation	O
requires	O
a	O
method	B-T062
of	I-T062
evaluation	I-T062
that	O
can	O
provide	O
a	O
comprehensive	O
,	O
in	B-T082
-	I-T082
depth	I-T082
,	O
and	O
context	O
-	O
driven	O
investigation	B-T058
of	O
potential	B-T033
risks	I-T033
to	O
safe	O
care	B-T058
transitions	I-T058
across	O
healthcare	B-T058
settings	O
,	O
which	O
can	O
lead	O
to	O
the	O
creation	O
of	O
effective	O
,	O
usable	O
,	O
and	O
sustainable	O
interventions	B-T058
.	O

A	O
systems	O
'	O
approach	O
known	O
as	O
Human	O
Factors	O
and	O
Ergonomics	O
(	O
HFE	O
)	O
evaluates	O
the	O
factors	O
in	O
a	O
system	O
that	O
affect	O
human	O
performance	O
.	O

This	O
article	B-T170
describes	O
how	O
HFE	O
can	O
complement	O
and	O
further	O
strengthen	O
efforts	O
to	O
improve	O
care	B-T058
transitions	I-T058
.	O

Adenosine	B-T103
and	O
the	O
adenosine	B-T103
A2A	I-T103
receptor	I-T103
agonist	I-T103
,	O
CGS21680	B-T103
,	O
upregulate	B-T038
CD39	B-T103
and	O
CD73	B-T103
expression	O
through	O
E2F	B-T103
-	I-T103
1	I-T103
and	O
CREB	B-T103
in	O
regulatory	B-T017
T	I-T017
cells	I-T017
isolated	O
from	O
septic	O
mice	B-T204

The	O
number	O
of	O
regulatory	B-T017
T	I-T017
cells	I-T017
(	O
Treg	B-T017
cells	I-T017
)	O
and	O
the	O
expression	O
of	O
ectonucleoside	B-T103
triphosphate	I-T103
diphosphohydrolase	I-T103
1	I-T103
(	O
ENTPD1	B-T103
;	O
also	O
known	O
as	O
CD39	B-T103
)	O
and	O
5	B-T103
'	I-T103
-	I-T103
ectonucleotidase	I-T103
(	O
NT5E	B-T103
;	O
also	O
known	O
as	O
CD73	B-T103
)	O
on	O
the	O
Treg	B-T017
cell	I-T017
surface	B-T082
are	O
increased	O
during	O
sepsis	B-T038
.	O

In	O
this	O
study	O
,	O
to	O
determine	O
the	O
factors	B-T103
leading	O
to	O
the	O
high	O
expression	O
of	O
CD39	B-T103
and	O
CD73	B-T103
,	O
and	O
the	O
regulation	B-T038
of	I-T038
the	O
CD39	B-T103
/	O
CD73	B-T103
/	O
adenosine	B-T103
pathway	O
in	O
Treg	B-T017
cells	I-T017
under	O
septic	O
conditions	O
,	O
we	O
constructed	O
a	O
mouse	B-T038
model	I-T038
of	O
sepsis	B-T038
and	O
separated	O
the	O
Treg	B-T017
cells	I-T017
using	O
a	O
flow	B-T074
cytometer	I-T074
.	O

The	O
Treg	B-T017
cells	I-T017
isolated	O
from	O
the	O
peritoneal	B-T058
lavage	I-T058
and	O
splenocytes	B-T017
of	O
the	O
mice	B-T204
were	O
treated	B-T058
with	I-T058
adenosine	B-T103
or	O
the	O
specific	O
adenosine	B-T103
A2A	I-T103
receptor	I-T103
agonist	I-T103
,	O
CGS21680	B-T103
,	O
and	O
were	O
transfected	B-T062
with	O
specific	O
siRNA	B-T103
targeting	O
E2F	B-T103
transcription	I-T103
factor	I-T103
1	I-T103
(	O
E2F	B-T103
-	I-T103
1	I-T103
)	O
or	O
cyclic	B-T103
adenosine	I-T103
monophosphate	I-T103
(	I-T103
cAMP	I-T103
)	I-T103
response	I-T103
element	I-T103
-	I-T103
binding	I-T103
protein	I-T103
(	O
CREB	B-T103
)	O
,	O
which	O
are	O
predicted	O
transcription	B-T103
regulatory	I-T103
factors	I-T103
of	O
CD39	B-T103
or	O
CD73	B-T103
.	O

The	O
regulatory	B-T038
relationships	O
among	O
these	O
factors	B-T103
were	O
then	O
determined	O
by	O
western	B-T058
blot	I-T058
analysis	I-T058
and	O
dual	B-T058
-	I-T058
luciferase	I-T058
reporter	I-T058
assay	I-T058
.	O

In	O
addition	O
,	O
changes	O
in	O
adenosine	B-T038
metabolism	I-T038
were	O
measured	O
in	O
the	O
treated	O
cells	B-T017
.	O

The	O
results	O
revealed	O
that	O
adenosine	B-T103
and	O
CGS21680	B-T103
significantly	O
upregulated	B-T038
CD39	B-T103
and	O
CD73	B-T103
expression	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

E2F	B-T103
-	I-T103
1	I-T103
and	O
CREB	B-T103
induced	O
CD39	B-T103
and	O
CD73	B-T103
expression	O
,	O
and	O
were	O
upregulated	B-T038
by	O
adenosine	B-T103
and	O
CGS21680	B-T103
.	O

Adenosine	B-T038
triphosphate	I-T038
(	I-T038
ATP	I-T038
)	I-T038
hydrolysis	I-T038
and	O
adenosine	B-T103
generation	O
were	O
inhibited	O
by	O
the	O
knockdown	O
of	O
E2F	B-T103
-	I-T103
1	I-T103
or	O
CREB	B-T103
,	O
and	O
were	O
accelerated	O
in	O
the	O
presence	O
of	O
CGS21680	B-T103
.	O

Based	O
on	O
these	O
results	O
,	O
it	O
can	O
be	O
inferred	O
that	O
adenosine	B-T103
,	O
the	O
adenosine	B-T103
A2A	I-T103
receptor	I-T103
agonist	I-T103
,	O
E2F	B-T103
-	I-T103
1	I-T103
and	O
CREB	B-T103
are	O
the	O
possible	O
factors	B-T103
contributing	O
to	O
the	O
high	O
expression	O
of	O
CD39	B-T103
and	O
CD73	B-T103
on	O
the	O
Treg	B-T017
cell	I-T017
surface	B-T082
during	O
sepsis	B-T038
.	O

Adenosine	B-T103
and	O
its	O
A2A	B-T103
receptor	I-T103
agonist	I-T103
served	O
as	O
the	O
signal	B-T038
transducer	I-T038
factors	B-T103
of	O
the	O
CD39	B-T103
/	O
CD73	B-T103
/	O
adenosine	B-T103
pathway	O
,	O
accelerating	O
adenosine	B-T103
generation	O
.	O

Our	O
study	O
may	O
benefit	O
further	O
research	B-T062
on	O
adenosine	B-T038
metabolism	I-T038
for	O
the	O
treatment	B-T058
of	O
sepsis	B-T038
.	O

Exploring	O
Consumer	B-T098
and	O
Patient	O
Knowledge	B-T170
,	O
Behavior	O
,	O
and	O
Attitude	B-T038
Toward	O
Medicinal	B-T103
and	O
Lifestyle	O
Products	O
Purchased	O
From	O
the	O
Internet	O
:	O
A	O
Web	O
-	O
Based	O
Survey	B-T170

In	O
recent	O
years	O
,	O
lifestyle	O
products	O
have	O
emerged	O
to	O
help	O
improve	B-T033
people	B-T098
'	I-T098
s	I-T098
physical	O
and	O
mental	B-T038
performance	O
.	O

The	O
Internet	O
plays	O
a	O
major	O
role	O
in	O
the	O
spread	O
of	O
these	O
products	O
.	O

However	O
,	O
the	O
literature	B-T170
has	O
reported	O
issues	O
regarding	O
the	O
authenticity	O
of	O
medicines	B-T103
purchased	O
from	O
the	O
Internet	O
and	O
the	O
impact	O
of	O
counterfeit	B-T103
medicines	I-T103
on	O
public	B-T092
health	O
.	O

Little	O
or	O
no	O
data	O
are	O
available	O
on	O
the	O
authenticity	O
of	O
lifestyle	O
products	O
and	O
actual	O
toxicity	O
associated	O
with	O
their	O
use	O
and	O
misuse	B-T033
.	O

Our	O
aim	O
was	O
to	O
investigate	O
consumer	O
and	O
patient	O
attitudes	O
toward	O
the	O
purchase	O
of	O
lifestyle	O
products	O
from	O
the	O
Internet	O
,	O
their	O
knowledge	B-T170
of	O
product	O
authenticity	O
and	O
toxicity	O
,	O
and	O
their	O
experiences	B-T038
with	O
counterfeit	O
lifestyle	O
products	O
.	O

A	O
Web	O
-	O
based	O
study	B-T062
was	O
performed	O
between	O
May	O
2014	O
and	O
May	O
2015	O
.	O

Uniform	O
collection	B-T062
of	I-T062
data	I-T062
was	O
performed	O
through	O
an	O
anonymous	O
online	B-T170
questionnaire	B-T170
.	O

Participants	B-T098
were	O
invited	O
worldwide	B-T082
via	O
email	B-T170
,	O
social	B-T170
media	I-T170
,	O
or	O
personal	O
communication	O
to	O
complete	O
the	O
online	B-T170
questionnaire	B-T170
.	O

A	O
total	O
of	O
320	O
participants	B-T098
completed	O
the	O
questionnaire	B-T170
.	O

The	O
results	O
of	O
the	O
questionnaire	B-T170
showed	O
that	O
208	O
(	O
65	O
.	O
0	O
%	O
)	O
participants	B-T098
purchased	O
lifestyle	O
products	O
from	O
the	O
Internet	O
mainly	O
due	O
to	O
convenience	O
and	O
reduced	O
cost	O
.	O

More	O
than	O
half	O
(	O
55	O
.	O
6	O
%	O
,	O
178	O
/	O
320	O
)	O
of	O
participants	B-T098
purchased	O
cosmetic	O
products	O
,	O
whereas	O
only	O
a	O
minority	O
purchased	O
medicinal	B-T103
products	I-T103
.	O

Yet	O
,	O
62	O
.	O
8	O
%	O
(	O
201	O
/	O
320	O
)	O
of	O
participants	B-T098
were	O
aware	B-T038
of	O
the	O
presence	B-T033
of	O
counterfeit	O
lifestyle	O
products	O
from	O
the	O
Internet	O
,	O
and	O
11	O
.	O
9	O
%	O
(	O
38	O
/	O
320	O
)	O
experienced	B-T038
counterfeit	O
products	O
.	O

In	O
only	O
0	O
.	O
9	O
%	O
(	O
3	O
/	O
320	O
)	O
of	O
those	O
cases	O
were	O
counterfeit	O
lifestyle	O
products	O
reported	B-T058
to	O
authorities	B-T092
.	O

Moreover	O
,	O
7	O
.	O
2	O
%	O
(	O
23	O
/	O
320	O
)	O
of	O
the	O
participants	B-T098
experienced	B-T038
adverse	B-T038
effects	I-T038
due	O
to	O
counterfeit	O
lifestyle	O
products	O
.	O

In	O
summary	O
,	O
patients	O
experienced	B-T038
counterfeit	O
lifestyle	O
products	O
that	O
resulted	O
in	O
adverse	B-T038
effects	I-T038
on	O
their	O
health	O
.	O

Although	O
certain	O
adverse	B-T038
effects	I-T038
were	O
reported	B-T058
in	O
this	O
study	B-T062
,	O
counterfeit	O
products	O
were	O
underreported	B-T058
to	O
authorities	B-T092
.	O

Further	O
public	O
awareness	O
campaigns	O
and	O
patient	O
education	O
are	O
needed	O
.	O

It	O
'	O
s	O
not	O
All	O
Doom	O
and	O
Gloom	O
:	O
Prune	B-T038
Belly	I-T038
Syndrome	I-T038
Associated	B-T017
with	I-T017
VACTERL	I-T017

Prune	B-T038
belly	I-T038
syndrome	I-T038
is	O
a	O
rare	O
abnormality	B-T033
;	O
its	O
association	B-T017
with	I-T017
VACTERL	I-T017
is	O
even	O
rarer	O
.	O

This	O
association	B-T017
has	O
been	O
reported	B-T058
in	O
literature	B-T170
a	O
few	O
times	O
since	O
first	O
reported	B-T058
in	O
1993	O
and	O
so	O
far	O
the	O
majority	O
have	O
either	O
been	O
stillbirths	B-T033
or	I-T033
died	I-T033
shortly	I-T033
after	I-T033
birth	I-T033
.	O

We	O
present	O
a	O
case	O
of	O
Prune	B-T038
belly	I-T038
syndrome	I-T038
associated	B-T017
with	I-T017
VACTERL	I-T017
who	O
is	O
now	O
one	O
year	O
old	O
.	O

Changes	O
in	O
Cardiovascular	B-T082
Health	O
Status	O
and	O
the	O
Risk	O
of	O
New	O
-	O
Onset	O
Hypertension	O
in	O
Kailuan	B-T098
Cohort	O
Study	O

American	B-T092
Heart	I-T092
Association	I-T092
cardiovascular	B-T082
health	B-T170
metrics	I-T170
are	O
intimately	O
related	O
to	O
cardiovascular	B-T038
diseases	I-T038
.	O

Acting	O
as	O
a	O
key	O
independent	O
risk	B-T033
factor	I-T033
for	O
high	O
morbidity	O
and	O
mortality	O
of	O
cardiovascular	B-T038
diseases	I-T038
,	O
hypertension	B-T038
and	O
its	O
relationship	O
between	O
health	O
status	O
get	O
urgent	O
attention	B-T038
.	O

While	O
the	O
influence	O
of	O
individual	B-T098
health	O
status	O
changes	O
and	O
the	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
is	O
rarely	O
understood	O
,	O
the	O
present	O
study	O
applied	O
this	O
construct	O
to	O
assess	O
the	O
changes	O
of	O
cardiovascular	B-T082
health	O
status	O
and	O
the	O
morbidity	O
of	O
hypertension	B-T038
in	O
Kailuan	B-T098
cohort	O
study	O
in	O
north	B-T082
China	B-T082
.	O

The	O
Cardiovascular	B-T082
Health	O
Score	O
(	O
CHS	O
)	O
was	O
evaluated	B-T058
by	O
the	O
follow	B-T058
-	I-T058
ups	I-T058
of	O
2006	O
-	O
2007	O
,	O
2008	O
-	O
2009	O
,	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
.	O

The	O
study	B-T098
population	I-T098
(	O
n	O
=	O
19381	O
)	O
was	O
divided	O
into	O
5	O
groups	O
based	O
on	O
the	O
changes	O
in	O
their	O
CHS	O
score	O
between	O
the	O
first	O
two	O
follow	B-T058
-	I-T058
ups	I-T058
(	O
△CHS	O
)	O
of	O
2006	O
-	O
2007	O
and	O
2008	O
-	O
2009	O
(	O
≤	O
-	O
2	O
,	O
-	O
1	O
,	O
0	O
,	O
1	O
,	O
≥2	O
)	O
.	O

The	O
morbidity	O
of	O
hypertension	B-T038
was	O
collected	O
during	O
2010	O
-	O
2011	O
and	O
2012	O
-	O
2013	O
follow	B-T058
-	I-T058
ups	I-T058
.	O

Data	O
analysis	O
showed	O
that	O
during	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
3	O
.	O
79±0	O
.	O
96	O
years	O
,	O
morbidity	O
of	O
hypertension	B-T038
had	O
a	O
graded	O
relationship	O
with	O
△CHS	O
.	O

As	O
△CHS	O
scored	O
from	O
low	O
to	O
high	O
,	O
the	O
standardized	O
morbidity	O
of	O
hypertension	B-T038
for	O
all	O
participants	B-T098
were	O
81	O
.	O
40	O
,	O
75	O
.	O
47	O
,	O
68	O
.	O
37	O
,	O
71	O
.	O
43	O
and	O
83	O
.	O
13	O
per	O
1000	O
person	O
-	O
year	O
,	O
respectively	O
.	O

An	O
increased	O
△CHS	O
score	O
of	O
1	O
was	O
associated	O
with	O
a	O
10	O
%	O
decrease	O
in	O
the	O
future	O
risk	O
of	O
new	O
-	O
onset	O
hypertension	O
(	O
HR	O
:	O
0	O
.	O
90	O
,	O
95	O
%	O
CI	O
:	O
0	O
.	O
88	O
-	O
0	O
.	O
92	O
)	O
.	O

In	O
conclusion	O
,	O
there	O
was	O
a	O
strong	O
inverse	O
relationship	O
between	O
the	O
incidence	O
of	O
new	O
-	O
onset	O
hypertension	O
and	O
elevation	O
of	O
cardiovascular	B-T082
health	B-T170
metrics	I-T170
.	O

Population	B-T098
-	O
wide	O
prevention	O
,	O
especially	O
the	O
promotion	B-T058
of	O
lifestyle	O
improvements	O
,	O
is	O
critical	O
to	O
reducing	O
the	O
morbidity	O
of	O
new	O
-	O
onset	O
hypertension	O
.	O

An	O
HIV	B-T005
-	O
tailored	B-T058
quit	O
-	O
smoking	O
counselling	B-T058
pilot	B-T062
intervention	B-T058
targeting	O
depressive	B-T033
symptoms	I-T033
plus	O
Nicotine	B-T058
Replacement	I-T058
Therapy	I-T058

Cardiovascular	B-T038
disease	I-T038
(	O
CVD	B-T038
)	O
rates	O
among	O
people	B-T098
living	O
with	O
HIV	O
/	O
AIDS	O
(	O
PHAs	O
)	O
are	O
high	O
.	O

Rates	O
of	O
cigarette	O
smoking	O
,	O
a	O
leading	O
contributor	O
to	O
CVD	B-T038
among	O
PHAs	O
,	O
are	O
40	O
-	O
70	O
%	O
(	O
2	O
-	O
3	O
times	O
higher	O
than	O
the	O
general	B-T098
population	I-T098
)	O
.	O

Furthermore	O
,	O
PHAs	O
have	O
high	O
rates	O
of	O
depression	B-T038
(	O
40	O
-	O
60	O
%	O
)	O
,	O
a	O
risk	B-T033
factor	I-T033
for	O
smoking	O
cessation	O
relapse	O
.	O

The	O
current	O
pilot	B-T062
study	I-T062
examined	B-T033
the	O
effectiveness	O
of	O
a	O
specifically	O
tailored	B-T058
5	O
-	O
session	O
smoking	O
cessation	O
counselling	B-T058
programme	I-T058
for	O
PHAs	O
,	O
which	O
addressed	O
depression	B-T038
,	O
in	O
combination	O
with	O
Nicotine	B-T058
Replacement	I-T058
Therapy	I-T058
(	O
NRT	B-T058
)	O
in	O
a	O
cohort	B-T098
of	O
PHA	O
smokers	B-T033
(	O
n	O
=	O
50	O
)	O
.	O

At	O
6	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
,	O
28	O
%	O
of	O
participants	B-T098
demonstrated	O
biochemically	O
verified	O
abstinence	O
from	O
smoking	O
.	O

This	O
result	B-T033
compares	O
favourably	O
to	O
other	O
quit	O
-	O
smoking	O
intervention	B-T058
studies	B-T062
,	O
particularly	O
given	O
the	O
high	O
percentage	O
of	O
HIV	B-T033
+	I-T033
smokers	B-T033
with	O
depression	B-T038
.	O

At	O
study	B-T062
baseline	O
,	O
52	O
%	O
of	O
HIV	B-T033
+	I-T033
smokers	B-T033
scored	O
above	O
the	O
clinical	O
cut	O
-	O
off	O
for	O
depression	B-T038
on	O
the	O
Centre	B-T170
for	I-T170
Epidemiological	I-T170
Studies	I-T170
-	I-T170
Depression	I-T170
(	I-T170
CES	I-T170
-	I-T170
D	I-T170
)	I-T170
scale	I-T170
.	O

HIV	B-T033
+	I-T033
smokers	B-T033
with	O
depression	B-T038
at	O
study	B-T062
baseline	O
demonstrated	O
quantitatively	O
lower	O
depression	B-T038
at	O
6	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
with	O
a	O
large	O
effect	O
size	O
(	O
d	O
=	O
1	O
)	O
,	O
though	O
it	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
p	O
=	O
.	O
058	O
)	O
.	O

Furthermore	O
,	O
those	O
with	O
depression	B-T038
were	O
no	O
more	O
likely	O
to	O
relapse	O
than	O
those	O
without	O
depression	B-T038
(	O
p	O
=	O
.	O
33	O
)	O
,	O
suggesting	O
that	O
our	O
counselling	B-T058
programme	I-T058
adequately	O
addressed	O
this	O
significant	O
barrier	O
to	O
smoking	O
cessation	O
among	O
PHAs	O
.	O

Our	O
pilot	B-T062
study	I-T062
indicates	O
the	O
importance	O
of	O
tailored	B-T058
programmes	I-T058
to	O
help	O
PHAs	O
quit	O
smoking	O
,	O
the	O
significance	O
of	O
addressing	O
depressive	B-T033
symptoms	I-T033
,	O
and	O
the	O
need	O
for	O
tailored	B-T058
counselling	I-T058
programmes	I-T058
to	O
enhance	O
quit	O
rates	O
among	O
PHAs	O
.	O

Effects	O
of	O
complex	O
life	O
cycles	O
on	O
genetic	O
diversity	O
:	O
cyclical	B-T038
parthenogenesis	I-T038

Neutral	O
patterns	O
of	O
population	B-T098
genetic	O
diversity	O
in	O
species	B-T170
with	O
complex	O
life	O
cycles	O
are	O
difficult	O
to	O
anticipate	O
.	O

Cyclical	B-T038
parthenogenesis	I-T038
(	O
CP	B-T038
)	O
,	O
in	O
which	O
organisms	O
undergo	O
several	O
rounds	O
of	O
clonal	B-T017
reproduction	B-T038
followed	O
by	O
a	O
sexual	O
event	O
,	O
is	O
one	O
such	O
life	O
cycle	O
.	O

Many	O
species	B-T170
,	O
including	O
crop	B-T204
pests	O
(	O
aphids	B-T204
)	O
,	O
human	B-T204
parasites	I-T204
(	O
trematodes	B-T204
)	O
or	O
models	B-T170
used	O
in	O
evolutionary	B-T091
science	I-T091
(	O
Daphnia	B-T204
)	O
,	O
are	O
cyclical	O
parthenogens	O
.	O

It	O
is	O
therefore	O
crucial	O
to	O
understand	O
the	O
impact	O
of	O
such	O
a	O
life	O
cycle	O
on	O
neutral	O
genetic	O
diversity	O
.	O

In	O
this	O
paper	O
,	O
we	O
describe	O
distributions	O
of	O
genetic	O
diversity	O
under	O
conditions	O
of	O
CP	B-T038
with	O
various	O
clonal	B-T017
phase	O
lengths	O
.	O

Using	O
a	O
Markov	O
chain	O
model	O
of	O
CP	B-T038
for	O
a	O
single	O
locus	B-T082
and	O
individual	O
-	O
based	O
simulations	B-T062
for	O
two	O
loci	B-T082
,	O
our	O
analysis	O
first	O
demonstrates	O
that	O
strong	O
departures	O
from	O
full	O
sexuality	O
are	O
observed	O
after	O
only	O
a	O
few	O
generations	O
of	O
clonality	O
.	O

The	O
convergence	O
towards	O
predictions	O
made	O
under	O
conditions	O
of	O
full	O
clonality	O
during	O
the	O
clonal	B-T017
phase	O
depends	O
on	O
the	O
balance	O
between	O
mutations	B-T038
and	O
genetic	B-T038
drift	I-T038
.	O

Second	O
,	O
the	O
sexual	O
event	O
of	O
CP	B-T038
usually	O
resets	O
the	O
genetic	O
diversity	O
at	O
a	O
single	O
locus	B-T082
towards	O
predictions	O
made	O
under	O
full	O
sexuality	O
.	O

However	O
,	O
this	O
single	O
recombination	B-T038
event	O
is	O
insufficient	O
to	O
reshuffle	O
gametic	B-T038
phases	I-T038
towards	O
full	O
-	O
sexuality	O
predictions	O
.	O

Finally	O
,	O
for	O
similar	O
levels	O
of	O
clonality	O
,	O
CP	B-T038
and	O
acyclic	O
partial	O
clonality	O
(	O
wherein	O
a	O
fixed	O
proportion	O
of	O
individuals	B-T098
are	O
clonally	O
produced	O
within	O
each	O
generation	O
)	O
differentially	O
affect	O
the	O
distribution	O
of	O
genetic	O
diversity	O
.	O

Overall	O
,	O
this	O
work	O
provides	O
solid	O
predictions	O
of	O
neutral	O
genetic	O
diversity	O
that	O
may	O
serve	O
as	O
a	O
null	B-T170
model	I-T170
in	O
detecting	O
the	O
action	O
of	O
common	O
evolutionary	B-T038
or	O
demographic	O
processes	O
in	O
cyclical	O
parthenogens	O
(	O
for	O
example	O
,	O
selection	O
or	O
bottlenecks	O
)	O
.	O

Recent	O
advances	O
in	O
chitosan	B-T103
-	O
based	O
nanoparticulate	O
pulmonary	B-T017
drug	B-T074
delivery	I-T074

The	O
advent	O
of	O
biodegradable	O
polymer	O
-	O
encapsulated	O
drug	B-T103
nanoparticles	O
has	O
made	O
the	O
pulmonary	B-T017
route	O
of	O
administration	O
an	O
exciting	O
area	O
of	O
drug	B-T074
delivery	I-T074
research	B-T062
.	O

Chitosan	B-T103
,	O
a	O
natural	O
biodegradable	O
and	O
biocompatible	B-T103
polysaccharide	B-T103
has	O
received	O
enormous	O
attention	O
as	O
a	O
carrier	B-T103
for	O
drug	B-T074
delivery	I-T074
.	O

Recently	O
,	O
nanoparticles	O
of	O
chitosan	B-T103
(	O
CS	B-T103
)	O
and	O
its	O
synthetic	B-T103
derivatives	I-T103
have	O
been	O
investigated	O
for	O
the	O
encapsulation	O
and	O
delivery	O
of	O
many	O
drugs	B-T103
with	O
improved	B-T033
targeting	O
and	O
controlled	O
release	O
.	O

Herein	O
,	O
recent	O
advances	O
in	O
the	O
preparation	O
and	O
use	O
of	O
micro	B-T017
-	I-T017
/	O
nanoparticles	O
of	O
chitosan	B-T103
and	O
its	O
derivatives	B-T103
for	O
pulmonary	B-T017
delivery	O
of	O
various	O
therapeutic	O
agents	O
(	O
drugs	B-T103
,	O
genes	B-T017
,	O
vaccines	B-T103
)	O
are	O
reviewed	O
.	O

Although	O
chitosan	B-T103
has	O
wide	O
applications	O
in	O
terms	O
of	O
formulations	B-T062
and	O
routes	O
of	O
drug	O
delivery	O
,	O
this	O
review	B-T170
is	O
focused	O
on	O
pulmonary	B-T017
delivery	B-T058
of	I-T058
drug	I-T058
-	I-T058
encapsulated	I-T058
nanoparticles	I-T058
of	O
chitosan	B-T103
and	O
its	O
derivatives	B-T103
.	O

In	O
addition	O
,	O
the	O
controversial	O
toxicological	B-T037
effects	I-T037
of	O
chitosan	B-T103
nanoparticles	O
for	O
lung	B-T017
delivery	O
will	O
also	O
be	O
discussed	O
.	O

Form	O
and	O
function	O
in	O
gene	B-T038
regulatory	I-T038
networks	I-T038
:	O
the	O
structure	B-T082
of	O
network	O
motifs	O
determines	O
fundamental	O
properties	O
of	O
their	O
dynamical	O
state	O
space	O

Network	O
motifs	O
have	O
been	O
studied	O
extensively	O
over	O
the	O
past	O
decade	O
,	O
and	O
certain	O
motifs	O
,	O
such	O
as	O
the	O
feed	O
-	O
forward	O
loop	O
,	O
play	O
an	O
important	O
role	O
in	O
regulatory	B-T038
networks	I-T038
.	O

Recent	O
studies	B-T062
have	O
used	O
Boolean	B-T170
network	O
motifs	O
to	O
explore	O
the	O
link	O
between	O
form	O
and	O
function	O
in	O
gene	B-T038
regulatory	I-T038
networks	I-T038
and	O
have	O
found	O
that	O
the	O
structure	B-T082
of	O
a	O
motif	O
does	O
not	O
strongly	O
determine	O
its	O
function	O
,	O
if	O
this	O
is	O
defined	O
in	O
terms	O
of	O
the	O
gene	B-T038
expression	I-T038
patterns	B-T082
the	O
motif	O
can	O
produce	O
.	O

Here	O
,	O
we	O
offer	O
a	O
different	O
,	O
higher	O
-	O
level	O
definition	B-T170
of	O
the	O
'	O
function	O
'	O
of	O
a	O
motif	O
,	O
in	O
terms	O
of	O
two	O
fundamental	O
properties	O
of	O
its	O
dynamical	O
state	O
space	O
as	O
a	O
Boolean	B-T170
network	O
.	O

One	O
is	O
the	O
basin	O
entropy	O
,	O
which	O
is	O
a	O
complexity	O
measure	O
of	O
the	O
dynamics	O
of	O
Boolean	B-T170
networks	O
.	O

The	O
other	O
is	O
the	O
diversity	O
of	O
cyclic	O
attractor	O
lengths	O
that	O
a	O
given	O
motif	O
can	O
produce	O
.	O

Using	O
these	O
two	O
measures	O
,	O
we	O
examine	O
all	O
104	O
topologically	O
distinct	O
three	O
-	O
node	O
motifs	O
and	O
show	O
that	O
the	O
structural	B-T082
properties	O
of	O
a	O
motif	O
,	O
such	O
as	O
the	O
presence	O
of	O
feedback	O
loops	O
and	O
feed	O
-	O
forward	O
loops	O
,	O
predict	O
fundamental	O
characteristics	O
of	O
its	O
dynamical	O
state	O
space	O
,	O
which	O
in	O
turn	O
determine	O
aspects	O
of	O
its	O
functional	O
versatility	O
.	O

We	O
also	O
show	O
that	O
these	O
higher	O
-	O
level	O
properties	O
have	O
a	O
direct	O
bearing	O
on	O
real	O
regulatory	B-T038
networks	I-T038
,	O
as	O
both	O
basin	O
entropy	O
and	O
cycle	O
length	O
diversity	O
show	O
a	O
close	O
correspondence	O
with	O
the	O
prevalence	O
,	O
in	O
neural	B-T038
and	O
genetic	B-T038
regulatory	I-T038
networks	I-T038
,	O
of	O
the	O
13	O
connected	O
motifs	O
without	O
self	O
-	O
interactions	O
that	O
have	O
been	O
studied	O
extensively	O
in	O
the	O
literature	B-T170
.	O

Jak1	B-T103
-	O
STAT3	B-T103
Signals	B-T038
Are	O
Essential	O
Effectors	O
of	O
the	O
USP6	B-T103
/	O
TRE17	B-T103
Oncogene	I-T103
in	O
Tumorigenesis	B-T038

Bone	B-T038
and	O
soft	B-T038
tissue	I-T038
tumors	I-T038
(	O
BSTT	B-T038
)	O
are	O
relatively	O
poorly	O
understood	O
,	O
hampering	O
the	O
development	O
of	O
effective	O
therapies	B-T058
.	O

Here	O
we	O
report	B-T170
a	O
role	O
for	O
the	O
ubiquitin	B-T103
-	I-T103
specific	I-T103
protease	I-T103
6	I-T103
(	O
USP6	B-T103
)	O
/	O
TRE17	B-T103
oncogene	I-T103
,	O
which	O
is	O
overexpressed	B-T038
upon	O
chromosome	B-T038
translocation	I-T038
in	O
various	O
human	B-T204
tumors	B-T038
,	O
including	O
aneurysmal	B-T038
bone	I-T038
cyst	I-T038
(	O
ABC	B-T038
)	O
,	O
and	O
the	O
related	O
benign	O
lesion	B-T033
nodular	B-T038
fasciitis	I-T038
.	O

Ectopic	B-T038
expression	I-T038
of	O
USP6	B-T103
is	O
known	O
to	O
drive	O
formation	O
of	O
tumors	B-T038
,	O
which	O
recapitulate	O
key	O
features	O
of	O
ABC	B-T038
and	O
nodular	B-T038
fasciitis	I-T038
;	O
however	O
,	O
the	O
identity	O
of	O
USP6	B-T103
'	I-T103
s	I-T103
relevant	O
substrates	O
has	O
been	O
obscure	O
.	O

Here	O
we	O
report	B-T170
that	O
the	O
Jak1	B-T103
-	O
STAT3	B-T103
signaling	B-T038
pathway	I-T038
serves	O
as	O
an	O
essential	O
effector	O
of	O
USP6	B-T103
in	O
BSTT	B-T038
formation	O
.	O

We	O
found	O
that	O
USP6	B-T103
directly	O
deubiquitinated	B-T038
Jak1	B-T103
,	O
leading	O
to	O
its	O
stabilization	B-T033
and	O
activation	O
of	O
STAT3	B-T103
.	O

The	O
tumorigenic	B-T038
potential	O
of	O
USP6	B-T103
was	O
attenuated	O
significantly	O
by	O
CRISPR	B-T103
-	O
mediated	O
deletion	B-T038
of	O
Jak1	B-T017
or	O
STAT3	B-T017
,	O
or	O
by	O
administration	O
of	O
a	O
Jak	B-T103
family	I-T103
inhibitor	O
.	O

Analysis	B-T062
of	O
primary	O
clinical	O
samples	O
of	O
nodular	B-T038
fasciitis	I-T038
confirmed	B-T033
the	O
activation	O
of	O
a	O
Jak1	B-T103
-	O
STAT3	B-T103
gene	O
signature	O
in	O
vivo	O
Together	O
,	O
our	O
studies	B-T058
highlight	O
Jak1	B-T103
as	O
the	O
first	O
identified	O
substrate	O
for	O
USP6	B-T103
,	O
and	O
they	O
offer	O
a	O
mechanistic	O
rationale	O
for	O
the	O
clinical	B-T058
investigation	I-T058
of	O
Jak	B-T103
and	O
STAT3	B-T103
inhibitors	O
as	O
therapeutics	O
for	O
the	O
treatment	B-T058
of	O
bone	B-T038
and	O
soft	B-T038
tissue	I-T038
tumors	I-T038
along	O
with	O
other	O
neoplasms	B-T038
driven	O
by	O
USP6	B-T103
overexpression	B-T038
.	O

Cancer	O
Res	O
;	O
76	O
(	O
18	O
)	O
;	O
5337	O
-	O
47	O
.	O

©2016	O
AACR	O
.	O

The	O
Evidence	O
Behind	O
Integrating	O
Palliative	B-T091
Care	I-T091
Into	O
Oncology	B-T038
Practice	O

Palliative	B-T092
care	I-T092
services	I-T092
provided	O
alongside	O
traditional	O
oncology	O
care	O
have	O
been	O
shown	O
to	O
be	O
beneficial	O
to	O
patients	O
and	O
families	O
.	O

This	O
article	B-T170
provides	O
a	O
brief	O
history	O
of	O
palliative	B-T091
care	I-T091
,	O
a	O
pathway	O
to	O
implementing	O
these	O
services	O
into	O
currently	O
established	O
oncology	B-T058
programs	I-T058
,	O
and	O
a	O
brief	O
discussion	O
of	O
common	O
barriers	O
.	O

Secondary	B-T017
Ossification	I-T017
Center	I-T017
Appearance	O
and	O
Closure	B-T058
in	I-T058
the	I-T058
Pelvis	I-T058
and	O
Proximal	B-T082
Femur	I-T082

Variable	O
ossification	B-T038
patterns	B-T082
of	O
the	O
pelvis	B-T017
in	O
skeletally	B-T022
immature	O
patients	O
can	O
make	O
the	O
interpretation	O
of	O
pelvic	B-T017
radiographs	B-T058
challenging	O
.	O

Inconsistencies	O
among	O
prior	O
studies	O
and	O
lack	O
of	O
sex	O
comparisons	O
underscore	O
the	O
need	O
for	O
a	O
more	O
comprehensive	O
characterization	O
of	O
the	O
secondary	B-T017
ossification	I-T017
centers	I-T017
.	O

This	O
study	O
evaluates	B-T058
the	O
chronology	B-T170
and	O
sex	O
differences	O
for	O
appearance	O
and	O
closure	B-T058
of	I-T058
pelvic	I-T058
and	O
proximal	B-T082
femoral	I-T082
secondary	B-T017
ossification	I-T017
centers	I-T017
using	O
computed	B-T058
tomography	I-T058
(	O
CT	B-T058
)	O
.	O

Patients	O
who	O
underwent	O
abdominal	B-T058
and	O
pelvic	O
CT	O
scans	O
between	O
January	O
2009	O
and	O
December	O
2014	O
at	O
2	O
tertiary	O
level	O
1	O
trauma	B-T092
centers	I-T092
were	O
retrospectively	O
reviewed	O
.	O

Patients	O
between	O
the	O
ages	O
of	O
2	O
and	O
32	O
years	O
with	O
adequate	O
imaging	B-T058
of	O
the	O
pelvis	B-T017
and	O
proximal	B-T082
femurs	I-T082
were	O
included	O
.	O

Patients	O
with	O
a	O
history	O
of	O
orthopaedic	B-T091
trauma	I-T091
or	O
pathology	B-T091
affecting	O
ossification	B-T038
were	O
excluded	O
.	O

CT	B-T058
scans	I-T058
were	O
assessed	O
for	O
the	O
appearance	O
and	O
closure	B-T058
of	O
the	O
following	O
secondary	B-T017
ossification	I-T017
centers	I-T017
:	O
anterior	B-T017
inferior	I-T017
iliac	I-T017
spine	I-T017
(	O
AIIS	B-T017
)	O
,	O
anterior	B-T017
superior	I-T017
iliac	I-T017
spine	I-T017
(	O
ASIS	B-T017
)	O
,	O
femoral	B-T017
head	I-T017
(	O
FH	B-T017
)	O
,	O
greater	B-T017
trochanter	I-T017
(	O
GT	B-T017
)	O
,	O
iliac	B-T017
crest	I-T017
(	O
IC	B-T017
)	O
,	O
ischial	B-T017
tuberosity	I-T017
(	O
IT	B-T017
)	O
,	O
lesser	B-T017
trochanter	I-T017
(	O
LT	B-T017
)	O
,	O
posterior	B-T017
superior	I-T017
iliac	I-T017
spine	I-T017
(	O
PSIS	B-T017
)	O
,	O
symphysis	B-T082
pubis	I-T082
(	O
SP	B-T082
)	O
,	O
and	O
triradiate	B-T017
cartilage	I-T017
(	O
TRC	B-T017
)	O
.	O

Basic	O
descriptive	O
statistics	O
are	O
reported	O
.	O

A	O
total	O
of	O
496	O
CT	B-T058
scans	I-T058
met	O
inclusion	O
criteria	O
(	O
240	O
males	O
and	O
256	O
females	O
)	O
.	O

The	O
order	O
of	O
appearance	O
of	O
the	O
secondary	B-T017
ossification	I-T017
centers	I-T017
was	O
:	O
(	O
male	O
)	O
GT	B-T017
,	O
LT	B-T017
,	O
AIIS	B-T017
,	O
IT	B-T017
,	O
ASIS	B-T017
,	O
PSIS	B-T017
,	O
IC	B-T017
,	O
and	O
SP	B-T082
;	O
(	O
female	O
)	O
GT	B-T017
,	O
LT	B-T017
,	O
IT	B-T017
,	O
AIIS	B-T017
,	O
PSIS	B-T017
,	O
IC	B-T017
,	O
ASIS	B-T017
,	O
and	O
SP	B-T082
.	O

The	O
order	O
of	O
closure	B-T058
was	O
similar	O
:	O
(	O
male	O
)	O
TRC	B-T017
,	O
LT	B-T017
,	O
FH	B-T017
,	O
AIIS	B-T017
,	O
GT	B-T017
,	O
ASIS	B-T017
,	O
PSIS	B-T017
,	O
IT	B-T017
,	O
IC	B-T017
,	O
and	O
SP	B-T082
;	O
(	O
female	O
)	O
LT	B-T017
,	O
TRC	B-T017
,	O
AIIS	B-T017
,	O
FH	B-T017
,	O
GT	B-T017
,	O
ASIS	B-T017
,	O
PSIS	B-T017
,	O
IT	B-T017
,	O
IC	B-T017
,	O
and	O
SP	B-T082
.	O

Female	O
ossification	B-T017
centers	I-T017
appeared	O
~	O
1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	B-T082
.	O

Female	O
ossification	B-T017
centers	I-T017
closed	O
~	O
1	O
to	O
2	O
years	O
before	O
males	O
in	O
all	O
locations	B-T082
except	O
TRC	B-T017
,	O
IC	B-T017
,	O
and	O
SP	B-T082
.	O

The	O
appearance	O
and	O
closure	B-T058
of	I-T058
the	I-T058
pelvis	I-T058
and	O
proximal	B-T082
femur	I-T082
secondary	B-T017
ossification	I-T017
centers	I-T017
follow	O
a	O
predictable	O
pattern	O
of	O
development	O
,	O
occurring	O
slightly	O
earlier	O
in	O
females	O
than	O
males	O
.	O

Knowledge	O
of	O
more	O
precise	O
ages	O
of	O
developmen	O
t	O
and	O
sex	O
differences	O
better	O
characterize	O
this	O
complex	O
skeletal	B-T038
development	I-T038
.	O

Future	O
studies	O
may	O
use	O
secondary	B-T017
ossification	I-T017
centers	I-T017
to	O
further	O
evaluate	B-T058
skeletal	O
maturity	O
,	O
assess	O
pediatric	B-T091
pathology	B-T091
,	O
and	O
aid	O
surgical	B-T058
management	I-T058
.	O

Level	O
III	O
.	O

Pediatric	O
Orthopaedic	B-T022
Trauma	B-T037
and	O
Associated	B-T037
Injuries	I-T037
of	O
Snowmobile	O
,	O
ATV	O
,	O
and	O
Dirtbike	O
Accidents	O
:	O
A	O
19	O
-	O
Year	O
Experience	O
at	O
a	O
Level	O
1	O
Pediatric	O
Trauma	B-T092
Center	I-T092

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
type	O
and	O
severity	O
of	O
orthopaedic	B-T037
and	O
associated	O
injuries	O
for	O
snowmobile	O
,	O
All	O
-	O
terrain	O
vehicles	O
(	O
ATV	O
)	O
and	O
motorized	O
dirtbike	O
accidents	O
in	O
a	O
pediatric	O
patient	O
population	O
.	O

A	O
total	O
of	O
758	O
patients	O
who	O
presented	O
following	O
either	O
snowmobile	B-T037
(	O
n	O
=	O
87	O
)	O
,	O
ATV	B-T037
-	I-T037
related	I-T037
(	O
n	O
=	O
308	O
)	O
or	O
dirtbike	B-T037
(	I-T037
n	I-T037
=	I-T037
363	I-T037
)	I-T037
-	I-T037
related	I-T037
trauma	I-T037
at	O
our	O
institution	B-T092
between	O
1996	O
and	O
2015	O
were	O
retrospectively	O
reviewed	O
.	O

A	O
total	O
of	O
441	O
axial	B-T037
and	O
appendicular	B-T037
fractures	I-T037
occurred	O
requiring	O
533	O
procedures	O
.	O

Snowmobile	O
and	O
dirtbike	O
accidents	O
were	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
fractures	B-T037
(	O
63	O
%	O
,	O
64	O
%	O
)	O
than	O
the	O
ATV	B-T098
group	I-T098
(	O
50	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
0008	O
)	O
.	O

Snowmobile	O
injuries	O
had	O
the	O
highest	O
rate	O
of	O
spinal	B-T037
(	O
23	O
%	O
)	O
and	O
lower	B-T037
extremity	I-T037
fractures	I-T037
(	O
53	O
%	O
)	O
(	O
P	O
=	O
0	O
.	O
0004	O
)	O
.	O

Snowmobile	B-T098
and	O
dirtbike	B-T098
cohorts	I-T098
had	O
higher	O
rate	O
of	O
femur	B-T037
fractures	I-T037
(	O
22	O
%	O
,	O
17	O
%	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
whereas	O
the	O
ATV	B-T098
cohort	I-T098
had	O
higher	O
rates	O
of	O
upper	B-T017
extremity	I-T017
(	O
18	O
%	O
)	O
,	O
hand	B-T017
(	O
11	O
%	O
)	O
,	O
scapula	B-T017
(	O
4	O
.	O
6	O
%	O
)	O
,	O
and	O
open	B-T037
fractures	I-T037
(	O
28	O
.	O
6	O
%	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Head	B-T037
trauma	I-T037
was	O
the	O
most	O
commonly	O
associated	O
injury	O
in	O
275	O
patients	O
with	O
the	O
highest	O
rate	O
in	O
the	O
ATV	B-T098
group	I-T098
(	O
44	O
%	O
)	O
who	O
also	O
had	O
the	O
highest	O
rate	O
of	O
no	O
helmet	O
use	O
(	O
76	O
%	O
)	O
.	O

Snowmobile	O
and	O
ATV	O
patients	O
had	O
higher	O
Injury	B-T170
Severity	I-T170
Score	I-T170
(	O
11	O
.	O
3	O
,	O
9	O
.	O
6	O
)	O
than	O
dirtbike	O
patients	O
(	O
7	O
.	O
8	O
)	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

ATV	O
patients	O
were	O
found	O
to	O
be	O
younger	O
(	O
11	O
.	O
8	O
y	O
)	O
compared	O
with	O
snowmobile	O
(	O
13	O
.	O
2	O
y	O
)	O
and	O
dirtbike	O
(	O
13	O
.	O
5	O
y	O
)	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Pediatric	O
snowmobile	O
,	O
ATV	O
and	O
dirtbike	O
accidents	O
result	O
in	O
severe	O
orthopaedic	B-T037
and	O
associated	O
injuries	O
with	O
each	O
vehicle	O
demonstrating	O
significantly	O
different	O
injury	B-T037
patterns	B-T082
.	O

Injury	B-T058
prevention	I-T058
should	O
focus	O
on	O
improved	O
safety	B-T058
mechanisms	I-T058
,	O
protective	O
gear	O
,	O
safe	O
areas	O
for	O
off	O
-	O
road	O
vehicle	O
use	O
and	O
strict	B-T170
laws	I-T170
with	O
minimum	O
age	O
requirements	O
LEVEL	O
OF	O
EVIDENCE	O
:	O
:	O
Level	O
IV	O
.	O

Hospitalist	B-T097
Co	O
-	O
management	O
of	O
Pediatric	O
Orthopaedic	B-T058
Surgical	O
Patients	O
at	O
a	O
Community	B-T092
Hospital	I-T092

The	O
benefits	O
of	O
hospitalist	B-T097
co	O
-	O
management	O
of	O
pediatric	O
surgical	O
patients	O
include	O
bettering	O
patient	B-T058
safety	I-T058
,	O
decreasing	B-T033
negative	O
patient	O
outcomes	O
,	O
providing	O
comprehensive	B-T058
medical	I-T058
care	I-T058
,	O
and	O
establishing	O
a	O
dedicated	O
resource	O
to	O
patients	O
for	O
postoperative	B-T058
care	I-T058
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
characterize	O
the	O
nature	O
of	O
patients	O
co	O
-	O
managed	O
by	O
a	O
pediatric	O
hospitalist	B-T097
.	O

The	O
authors	B-T097
hypothesize	O
that	O
hospitalist	B-T097
co	O
-	O
management	O
is	O
safe	B-T033
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	B-T058
surgical	O
patients	O
who	O
are	O
admitted	B-T058
to	O
a	O
community	B-T092
hospital	I-T092
.	O

A	O
retrospective	B-T062
review	I-T062
was	O
performed	O
of	O
all	O
pediatric	O
orthopaedic	B-T058
surgical	O
patients	O
admitted	B-T058
to	O
a	O
community	B-T092
hospital	I-T092
who	O
were	O
co	O
-	O
managed	O
by	O
a	O
pediatric	O
hospitalist	B-T097
.	O

Indications	O
for	O
hospitalization	B-T058
included	O
pain	B-T058
control	I-T058
,	O
antibiotic	B-T058
infusion	I-T058
,	O
and	O
need	O
for	O
neurovascular	B-T058
monitoring	I-T058
.	O

Parameters	O
of	O
postoperative	B-T058
care	I-T058
and	O
co	O
-	O
management	O
were	O
assessed	O
,	O
including	O
presence	B-T033
of	O
complications	O
,	O
medication	B-T058
introduction	I-T058
or	O
adjustment	O
by	O
the	O
hospitalist	B-T097
,	O
follow	B-T058
-	I-T058
up	I-T058
adherence	O
,	O
and	O
readmission	B-T058
/	O
complication	O
rates	O
after	O
discharge	B-T058
.	O

Thirty	O
-	O
two	O
patients	O
were	O
assessed	O
with	O
an	O
average	O
age	O
of	O
8	O
.	O
8	O
years	O
.	O

Twenty	O
-	O
five	O
percent	O
of	O
patients	O
had	O
an	O
associated	O
comorbidity	O
,	O
including	O
asthma	B-T038
,	O
attention	B-T038
deficit	I-T038
disorder	I-T038
,	O
and	O
/	O
or	O
autism	B-T038
.	O

The	O
pediatric	O
hospitalist	B-T097
added	O
pain	O
medication	O
to	O
the	O
original	O
postoperative	B-T058
orders	I-T058
placed	O
by	O
the	O
orthopaedics	B-T097
team	I-T097
in	O
44	O
percent	O
of	O
patients	O
(	O
14	O
of	O
the	O
32	O
)	O
either	O
for	O
breakthrough	B-T033
pain	I-T033
or	O
better	O
long	O
-	O
term	O
coverage	O
.	O

Additionally	O
,	O
25	O
percent	O
of	O
patients	O
had	O
pain	O
medication	O
adjusted	O
from	O
the	O
original	O
dosing	O
and	O
schedule	B-T058
.	O

The	O
hospitalist	B-T097
team	O
contacted	O
the	O
surgeon	B-T097
about	O
the	O
four	O
patients	O
(	O
12	O
.	O
5	O
percent	O
)	O
.	O

In	O
three	O
of	O
the	O
cases	O
,	O
the	O
surgeon	B-T097
was	O
contacted	O
to	O
discuss	O
pain	O
medication	O
,	O
and	O
one	O
patient	O
woke	O
up	O
agitated	O
from	O
anesthesia	B-T058
,	O
necessitating	O
a	O
visit	O
from	O
the	O
surgeon	B-T097
on	O
the	O
pediatrics	O
floor	O
.	O

The	O
length	O
of	O
stay	O
was	O
one	O
day	O
for	O
all	O
patients	O
.	O

The	O
hospitalists	B-T097
rounded	O
on	O
and	O
discharged	B-T058
patients	I-T058
the	O
subsequent	O
morning	O
.	O

All	O
patients	O
were	O
given	O
a	O
follow	O
-	O
up	O
appointment	O
and	O
schedule	O
by	O
the	O
hospitalist	B-T097
team	O
,	O
and	O
every	O
patient	O
followed	B-T058
up	I-T058
accordingly	O
within	O
ten	O
days	O
of	O
discharge	B-T058
.	O

No	O
complications	O
or	O
hospital	B-T058
readmissions	I-T058
occurred	O
within	O
thirty	O
days	O
of	O
discharge	B-T058
.	O

Hospitalist	B-T097
co	O
-	O
management	O
of	O
pediatric	O
orthopaedic	B-T058
surgical	O
patients	O
in	O
a	O
community	B-T092
hospital	I-T092
allows	O
for	O
better	O
medical	O
comorbidity	O
and	O
medication	B-T058
management	I-T058
.	O

Hospitalist	B-T097
s	O
can	O
provide	O
closer	O
observation	O
during	O
the	O
inpatient	O
stay	O
and	O
help	O
streamline	O
communication	O
between	O
providers	B-T097
and	O
patients	O
while	O
allowing	O
the	O
surgeon	B-T097
the	O
ability	O
to	O
be	O
more	O
mobile	O
.	O

Co	O
-	O
management	O
is	O
safe	B-T033
and	O
efficacious	O
in	O
pediatric	O
orthopaedic	B-T058
surgical	O
patients	O
who	O
are	O
admitted	B-T058
to	O
a	O
community	B-T092
hospital	I-T092
.	O

Extra	O
carbohydrate	B-T103
binding	I-T103
module	I-T103
contributes	O
to	O
the	O
processivity	O
and	O
catalytic	B-T038
activity	I-T038
of	O
a	O
non	B-T103
-	I-T103
modular	I-T103
hydrolase	I-T103
family	O
5	B-T103
endoglucanase	I-T103
from	O
Fomitiporia	B-T204
mediterranea	I-T204
MF3	I-T204
/	I-T204
22	I-T204

FmEG	B-T103
from	O
Fomitiporia	B-T204
mediterranea	I-T204
is	O
a	O
non	B-T103
-	I-T103
modular	I-T103
endoglucanase	I-T103
composed	O
of	O
a	O
24	B-T103
-	I-T103
amino	I-T103
acids	I-T103
extension	O
and	O
13	B-T103
-	I-T103
amino	I-T103
acids	I-T103
linker	B-T103
-	I-T103
like	I-T103
peptide	I-T103
at	O
the	O
N	B-T082
-	I-T082
terminus	I-T082
and	O
a	O
312	B-T103
-	I-T103
amino	I-T103
acids	I-T103
GH5	B-T082
catalytic	I-T082
domain	I-T082
(	O
CD	B-T082
)	O
at	O
the	O
C	B-T082
-	I-T082
terminus	I-T082
.	O

In	O
this	O
study	O
,	O
six	O
FmEG	B-T103
derivatives	O
with	O
deletion	O
of	O
N	B-T103
-	I-T103
terminal	I-T103
fragments	I-T103
or	O
fusion	B-T103
with	O
an	O
extra	O
family	B-T103
1	I-T103
carbohydrate	I-T103
-	I-T103
binding	I-T103
module	I-T103
(	O
CBM1	B-T103
)	O
was	O
constructed	O
in	O
order	O
to	O
evaluate	O
the	O
contribution	O
of	O
CBM1	B-T103
to	O
FmEG	B-T103
processivity	O
and	O
catalytic	B-T038
activity	I-T038
.	O

FmEG	B-T103
showed	O
a	O
weak	O
processivity	O
and	O
released	O
cellobiose	B-T103
(	O
G2	B-T103
)	O
and	O
cellotriose	B-T103
(	O
G3	B-T103
)	O
as	O
main	O
end	O
products	O
,	O
and	O
cellotriose	B-T103
(	O
G4	B-T103
)	O
as	O
minor	O
end	O
product	O
from	O
filter	O
paper	O
(	O
FP	O
)	O
,	O
but	O
more	O
amount	O
of	O
G4	B-T103
was	O
released	O
from	O
regenerated	B-T103
amorphous	I-T103
cellulose	I-T103
(	O
RAC	B-T103
)	O
.	O

All	O
derivatives	B-T103
had	O
similar	O
activity	O
on	O
carboxymethylcellulose	B-T103
(	O
CMC	B-T103
)	O
with	O
the	O
same	O
optimal	O
pH	O
(	O
7	O
.	O
0	O
)	O
and	O
temperature	O
(	O
50°C	O
)	O
.	O

However	O
,	O
fusing	O
an	O
extra	O
CBM1	B-T103
to	O
FmEG△24	B-T103
or	O
FmEG△37	B-T103
with	O
flexible	B-T103
peptide	I-T103
significantly	O
improved	O
its	O
processivity	O
and	O
catalytic	O
activity	O
to	O
FP	O
and	O
RAC	B-T103
.	O

Overall	O
,	O
1	O
.	O
79	O
-	O
and	O
1	O
.	O
84	O
-	O
fold	O
increases	O
in	O
the	O
soluble	O
/	O
insoluble	O
product	O
ratio	O
on	O
FP	O
,	O
and	O
1	O
.	O
38	O
-	O
and	O
1	O
.	O
39	O
-	O
fold	O
increases	O
on	O
RAC	B-T103
,	O
compared	O
to	O
FmEG△24	B-T103
,	O
were	O
recorded	O
for	O
CBM1	B-T103
-	O
FmEG△24	B-T103
and	O
CBM1	B-T103
-	O
linker	O
-	O
FmEG△24	B-T103
,	O
respectively	O
.	O

Meanwhile	O
,	O
they	O
displayed	O
2	O
.	O
64	O
-	O
and	O
2	B-T033
.	I-T033
67	I-T033
-	I-T033
fold	I-T033
more	I-T033
activity	I-T033
on	O
RAC	B-T103
,	O
and	O
1	O
.	O
68	O
-	O
and	O
1	O
.	O
77	O
-	O
fold	O
on	O
FP	O
,	O
respectively	O
.	O

Similar	O
improvement	O
was	O
also	O
obtained	O
for	O
CBM1	B-T103
-	O
linker	O
-	O
FmEG△37	B-T103
as	O
compared	O
with	O
FmEG△37	B-T103
.	O

Interestingly	O
,	O
fusion	O
of	O
an	O
extra	O
CBM1	B-T103
with	O
FmEG	B-T103
also	O
caused	O
an	O
alteration	O
of	O
cleavage	O
pattern	O
on	O
insoluble	B-T103
celluloses	I-T103
.	O

Our	O
results	O
suggest	O
that	O
such	O
improvements	O
in	O
processivity	O
and	O
catalytic	O
activity	O
may	O
arise	O
from	O
CBM1	B-T103
binding	B-T038
affinity	I-T038
.	O

The	O
N	B-T103
-	I-T103
terminal	I-T103
24	I-T103
-	I-T103
or	I-T103
37	I-T103
-	I-T103
amino	I-T103
acids	I-T103
may	O
serve	O
as	O
linker	O
for	O
sufficient	O
spatial	O
separation	O
of	O
the	O
two	B-T082
domains	I-T082
required	O
for	O
processivity	O
and	O
catalytic	O
activity	O
.	O

In	O
addition	O
,	O
deletion	O
of	O
the	O
N	B-T103
-	I-T103
terminal	I-T103
24	I-T103
-	I-T103
or	I-T103
37	I-T103
-	I-T103
amino	I-T103
acids	I-T103
led	O
to	O
significant	O
reduction	O
in	O
thermostability	O
but	O
not	O
the	O
enzymatic	B-T038
activity	I-T038
.	O

Overnight	O
switching	B-T058
from	O
oxcarbazepine	B-T103
to	O
eslicarbazepine	B-T103
acetate	I-T103
:	O
an	O
observational	B-T062
study	I-T062

There	O
are	O
clinical	O
situations	O
where	O
it	O
might	O
be	O
appropriate	O
to	O
switch	B-T058
patients	O
from	O
immediate	B-T103
-	I-T103
release	I-T103
oxcarbazepine	B-T103
(	O
OXC	B-T103
)	O
to	O
eslicarbazepine	B-T103
acetate	I-T103
(	O
ESL	B-T103
)	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
transitioning	O
patients	O
overnight	O
from	O
OXC	B-T103
to	O
ESL	B-T103
.	O

A	O
retrospective	B-T062
,	O
single	B-T062
-	I-T062
center	I-T062
study	I-T062
was	O
conducted	O
in	O
which	O
patients	O
with	O
drug	B-T038
-	I-T038
resistant	I-T038
focal	B-T038
epilepsy	I-T038
on	O
a	O
stable	O
dose	O
of	O
immediate	B-T103
-	I-T103
release	I-T103
OXC	B-T103
for	O
at	O
least	O
4	O
weeks	O
were	O
switched	B-T058
overnight	O
to	O
ESL	B-T103
.	O

Patients	O
were	O
switched	B-T058
because	O
they	O
experienced	O
persistent	O
seizures	B-T033
with	O
OXC	B-T103
but	O
were	O
unable	B-T033
to	O
tolerate	O
increased	O
OXC	B-T103
dosing	O
due	O
to	O
adverse	B-T038
events	I-T038
.	O

Tolerability	O
was	O
assessed	O
using	O
the	O
Adverse	B-T170
Events	I-T170
Profile	I-T170
(	O
AEP	B-T170
)	O
,	O
quality	O
of	O
life	O
was	O
assessed	O
using	O
the	O
Quality	B-T170
of	I-T170
Life	I-T170
in	I-T170
Epilepsy	I-T170
Inventory	I-T170
10	I-T170
(	O
QOLIE	B-T170
-	I-T170
10	I-T170
)	O
,	O
and	O
alertness	B-T038
was	O
assessed	O
as	O
reaction	O
time	O
using	O
a	O
subtest	O
of	O
the	O
Test	B-T170
Battery	I-T170
for	I-T170
Attention	I-T170
Performance	I-T170
version	I-T170
2	I-T170
.	I-T170
3	I-T170
.	O

Assessments	B-T058
were	O
performed	O
immediately	O
prior	O
to	O
and	O
5	O
days	O
after	O
switching	B-T058
from	O
OXC	B-T103
to	O
ESL	B-T103
(	O
days	O
0	O
and	O
5	O
,	O
respectively	O
)	O
.	O

The	O
analysis	B-T062
included	O
21	O
patients	O
(	O
12	O
women	B-T098
,	O
9	O
men	B-T098
;	O
mean	B-T033
age	I-T033
36	I-T033
years	I-T033
)	O
.	O

After	O
switching	B-T058
from	O
OXC	B-T103
to	O
ESL	B-T103
,	O
there	O
were	O
significant	O
improvements	O
in	O
mean	O
scores	O
for	O
AEP	B-T170
(	O
P	O
<	O
.	O
001	O
)	O
,	O
QOLIE	B-T170
-	I-T170
10	I-T170
(	O
P	O
=	O
.	O
001	O
)	O
,	O
and	O
alertness	B-T038
(	O
P	O
<	O
.	O
05	O
)	O
.	O

Adverse	B-T170
Events	I-T170
Profile	I-T170
total	O
scores	O
improved	B-T033
for	O
21	O
/	O
21	O
(	O
100	O
.	O
0	O
%	O
)	O
patients	O
,	O
QOLIE	B-T170
-	I-T170
10	I-T170
total	O
scores	O
improved	B-T033
for	O
17	O
/	O
21	O
(	O
81	O
.	O
0	O
%	O
)	O
patients	O
,	O
and	O
alertness	B-T038
scores	O
improved	B-T033
for	O
16	O
/	O
21	O
(	O
76	O
.	O
2	O
%	O
)	O
patients	O
.	O

In	O
this	O
short	O
-	O
term	O
,	O
single	B-T062
-	I-T062
center	I-T062
study	I-T062
,	O
an	O
overnight	O
switch	B-T058
from	O
twice	O
-	O
daily	O
OXC	B-T103
to	O
once	O
-	O
daily	O
ESL	B-T103
in	O
patients	O
with	O
drug	B-T038
-	I-T038
resistant	I-T038
focal	B-T038
epilepsies	I-T038
resulted	B-T033
in	O
improvements	O
in	O
side	B-T038
effects	I-T038
,	O
quality	O
of	O
life	O
,	O
and	O
alertness	B-T038
.	O

Complete	O
Genome	B-T017
Sequences	B-T082
of	O
Three	O
Outbreak	O
-	O
Associated	O
Legionella	B-T007
pneumophila	I-T007
Isolates	B-T103

We	O
report	O
here	O
the	O
complete	O
genome	B-T017
sequences	B-T082
of	O
three	O
Legionella	B-T007
pneumophila	I-T007
isolates	B-T103
that	O
are	O
associated	O
with	O
a	O
Legionnaires	B-T038
'	I-T038
disease	I-T038
outbreak	O
in	O
New	B-T082
York	I-T082
in	O
2012	O
.	O

Two	O
clinical	O
isolates	B-T103
(	O
D7630	B-T007
and	O
D7632	B-T007
)	O
and	O
one	O
environmental	B-T082
isolate	B-T103
(	O
D7631	B-T007
)	O
were	O
recovered	O
from	O
this	O
outbreak	O
.	O

A	O
single	O
isolate	B-T103
-	I-T103
specific	I-T103
virulence	B-T038
gene	B-T017
was	O
found	O
in	O
D7632	B-T007
.	O

These	O
isolates	B-T103
were	O
included	O
in	O
a	O
large	O
study	O
evaluating	B-T058
the	O
genomic	B-T017
resolution	O
of	O
various	O
bioinformatics	B-T091
approaches	O
for	O
L	B-T007
.	I-T007

pneumophila	I-T007
serogroup	B-T170
1	I-T170
isolates	B-T103
.	O

Complete	O
Genome	B-T058
Sequence	I-T058
Analysis	I-T058
of	O
a	O
Naturally	O
Reassorted	O
Infectious	B-T005
Bursal	I-T005
Disease	I-T005
Virus	I-T005
from	O
India	B-T082

The	O
novel	O
infectious	B-T005
bursal	I-T005
disease	I-T005
virus	I-T005
(	O
IBDV	B-T005
)	O
isolate	B-T103
BGE14	B-T005
/	I-T005
ABT1	I-T005
/	I-T005
MVC	I-T005
/	I-T005
India	I-T005
is	O
a	O
very	O
virulent	O
IBDV	B-T005
that	O
was	O
isolated	B-T103
from	O
broiler	B-T204
flocks	I-T204
in	O
southern	O
parts	O
of	O
India	B-T082
during	O
2014	O
.	O

Here	O
,	O
we	O
report	O
,	O
for	O
the	O
first	O
time	O
in	O
India	B-T082
,	O
the	O
complete	O
genome	B-T017
sequence	I-T017
of	O
BGE14	B-T005
/	I-T005
ABT1	I-T005
/	I-T005
MVC	I-T005
/	I-T005
India	I-T005
,	O
a	O
reassortment	O
strain	O
with	O
segments	B-T017
A	I-T017
and	I-T017
B	I-T017
derived	O
from	O
a	O
very	O
virulent	O
IBDV	B-T005
strain	O
and	O
an	O
attenuated	O
IBDV	B-T005
,	O
respectively	O
.	O

The	O
findings	O
from	O
this	O
study	O
provide	O
additional	O
insight	O
into	O
the	O
genetic	B-T038
exchange	I-T038
between	O
attenuated	O
and	O
very	O
virulent	O
strains	O
of	O
IBDV	B-T005
circulating	O
in	B-T082
the	I-T082
field	I-T082
.	O

Patient	O
Satisfaction	O
With	O
Postpartum	O
Teaching	O
Methods	B-T170

Postpartum	O
discharge	B-T170
instructions	I-T170
are	O
a	O
crucial	O
part	O
of	O
a	O
mother	O
'	O
s	O
birth	B-T038
experience	B-T038
.	O

Finding	B-T033
the	O
method	B-T170
to	O
provide	O
those	O
discharge	B-T170
instructions	I-T170
in	O
a	O
manner	O
that	O
increases	O
the	O
mother	O
'	O
s	O
satisfaction	B-T038
with	O
her	O
hospital	B-T092
experience	B-T038
is	O
important	O
.	O

This	O
quasi	B-T062
-	I-T062
experimental	I-T062
study	I-T062
examined	B-T033
the	O
relationship	O
between	O
new	O
mothers	O
'	O
interaction	B-T033
with	O
nurses	B-T097
providing	O
postpartum	O
instructions	B-T170
by	O
the	O
traditional	O
and	O
class	O
methods	B-T170
and	O
their	O
satisfaction	B-T038
with	O
discharge	O
teaching	O
.	O

The	O
results	O
indicated	O
new	O
mothers	O
were	O
satisfied	B-T038
with	O
both	O
methods	B-T170
of	O
discharge	O
teaching	O
;	O
however	O
,	O
they	O
were	O
more	O
likely	O
to	O
report	O
stronger	O
agreement	O
with	O
overall	O
satisfaction	B-T038
with	O
the	O
traditional	O
method	B-T170
of	O
discharge	O
teaching	O
than	O
with	O
attending	O
the	O
discharge	O
class	O
.	O

Splicing	B-T038
variants	O
of	O
ADAR2	B-T103
and	O
ADAR2	B-T103
-	O
mediated	O
RNA	B-T038
editing	I-T038
in	O
glioma	B-T038

The	O
roles	O
of	O
alternative	B-T038
splicing	I-T038
and	O
RNA	B-T038
editing	I-T038
in	O
gene	B-T038
regulation	I-T038
and	O
transcriptome	B-T082
diversity	O
are	O
well	O
documented	O
.	O

Adenosine	B-T103
deaminases	I-T103
acting	O
on	O
RNA	B-T103
(	O
ADARs	B-T103
)	O
are	O
responsible	O
for	O
adenosine	B-T038
-	I-T038
to	I-T038
-	I-T038
inosine	I-T038
(	I-T038
A	I-T038
-	I-T038
to	I-T038
-	I-T038
I	I-T038
)	I-T038
editing	I-T038
and	O
exemplify	O
the	O
complex	O
association	O
between	O
RNA	B-T038
editing	I-T038
and	O
alternative	B-T038
splicing	I-T038
.	O

The	O
self	B-T038
-	I-T038
editing	I-T038
activity	O
of	O
ADAR2	B-T103
,	O
which	O
acts	O
on	O
its	O
own	O
pre	B-T103
-	I-T103
mRNA	I-T103
,	O
leads	O
to	O
its	O
alternative	B-T038
splicing	I-T038
.	O

Alternative	B-T038
splicing	I-T038
occurs	O
independently	O
at	O
nine	O
splicing	B-T038
sites	O
on	O
ADAR2	B-T103
pre	B-T103
-	I-T103
mRNA	I-T103
,	O
generating	O
numerous	O
alternative	B-T038
splicing	I-T038
variants	O
with	O
various	O
catalytic	B-T038
activities	I-T038
.	O

A	B-T038
-	I-T038
to	I-T038
-	I-T038
I	I-T038
RNA	I-T038
editing	I-T038
is	O
important	O
in	O
a	O
range	O
of	O
physiological	B-T038
processes	I-T038
in	O
humans	B-T204
and	O
is	O
associated	O
with	O
several	O
diseases	B-T038
,	O
including	O
amyotrophic	B-T038
lateral	I-T038
sclerosis	I-T038
,	O
mood	B-T038
disorders	I-T038
,	O
epilepsy	B-T038
and	O
glioma	B-T038
.	O

Reduced	O
editing	B-T038
at	O
the	O
glutamine	B-T103
/	O
arginine	B-T103
site	O
of	O
the	O
AMPA	B-T103
receptor	I-T103
subunit	I-T103
GluA2	I-T103
in	O
glioma	B-T038
,	O
without	O
any	O
alteration	O
in	O
ADAR2	B-T103
expression	B-T038
,	O
is	O
a	O
notable	O
phenomenon	O
.	O

Several	O
studies	O
have	O
tried	O
to	O
explain	O
this	O
alteration	O
in	O
the	O
catalytic	B-T038
activity	I-T038
of	O
ADAR2	B-T103
;	O
however	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

The	O
present	O
review	B-T170
summarizes	O
the	O
relevant	O
literature	B-T170
and	O
shares	O
experimental	B-T033
results	I-T033
concerning	O
ADAR2	B-T103
alternative	B-T038
splicing	I-T038
.	O

In	O
particular	O
,	O
the	O
present	O
review	B-T170
demonstrates	O
that	O
shifts	O
in	O
the	O
relative	O
abundance	O
of	O
the	O
active	O
and	O
inactive	O
splicing	B-T038
variants	O
of	O
ADAR2	B-T103
may	O
reduce	O
the	O
ADAR2	B-T103
editing	B-T038
activity	O
in	O
glioma	B-T038
.	O

Dominant	O
expression	B-T038
of	O
ADAR2	B-T103
splicing	B-T038
variant	O
with	O
low	O
enzyme	B-T038
activity	I-T038
causes	O
reduced	O
RNA	B-T038
editing	I-T038
of	O
GluA2	B-T103
subunit	I-T103
at	O
the	O
glutamine	B-T103
/	O
arginine	B-T103
site	O
in	O
glioma	B-T038
.	O

Heat	B-T103
-	I-T103
shock	I-T103
protein	I-T103
60	I-T103
of	O
Porphyromonas	B-T007
gingivalis	I-T007
may	O
induce	O
dysfunction	O
of	O
human	B-T017
umbilical	I-T017
endothelial	I-T017
cells	I-T017
via	O
regulation	B-T038
of	O
endothelial	B-T103
-	I-T103
nitric	I-T103
oxide	I-T103
synthase	I-T103
and	O
vascular	B-T103
endothelial	I-T103
-	I-T103
cadherin	I-T103

Accumulating	O
evidence	O
has	O
established	O
that	O
periodontitis	B-T038
was	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
coronary	B-T038
heart	I-T038
disease	I-T038
(	O
CAD	B-T038
)	O
.	O

Porphyromonus	B-T007
gingivalis	I-T007
(	O
P	B-T007
.	I-T007

gingivalis	I-T007
)	O
,	O
a	O
major	O
periodontal	O
pathogen	O
,	O
has	O
already	O
been	O
shown	O
to	O
have	O
a	O
significant	O
role	O
in	O
the	O
inflammatory	B-T038
response	I-T038
of	O
CAD	B-T038
in	B-T082
vivo	I-T082
.	O

The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
identify	O
whether	O
P	B-T007
.	I-T007

gingivalis	I-T007
heat	B-T103
-	I-T103
shock	I-T103
protein	I-T103
60	I-T103
(	O
HSP60	B-T103
)	O
induced	O
the	O
dysfunction	O
of	O
human	B-T017
umbilical	I-T017
vein	I-T017
endothelial	I-T017
cells	I-T017
(	O
HUVECs	B-T017
)	O
in	O
vitro	O
.	O

HUVECs	B-T017
were	O
stimulated	O
with	O
a	O
range	O
of	O
P	B-T007
.	I-T007

gingivalis	I-T007
HSP60	B-T103
concentrations	O
(	O
1	O
,	O
10	O
and	O
100	O
ng	O
/	O
l	O
)	O
at	O
different	O
time	O
-	O
points	O
.	O

The	O
levels	O
of	O
vascular	B-T103
endothelial	I-T103
(	I-T103
VE	I-T103
)	I-T103
-	I-T103
cadherin	I-T103
,	O
endothelial	B-T103
nitric	I-T103
oxide	I-T103
synthase	I-T103
(	O
eNOS	B-T103
)	O
and	O
cysteinyl	B-T103
aspartate	I-T103
-	I-T103
specific	I-T103
protease	I-T103
-	I-T103
3	I-T103
(	O
caspase	B-T103
-	I-T103
3	I-T103
)	O
were	O
measured	O
using	O
western	B-T058
blot	I-T058
analysis	B-T062
.	O

The	O
apoptotic	B-T038
rate	O
of	O
HUVECs	B-T017
was	O
detected	O
using	O
flow	B-T058
cytometry	I-T058
.	O

P	B-T007
.	I-T007

gingivalis	I-T007
HSP60	B-T103
at	O
a	O
concentration	O
of	O
10	O
ng	O
/	O
l	O
significantly	O
decreased	O
the	O
expression	B-T038
levels	O
of	O
VE	B-T103
-	I-T103
cadherin	I-T103
and	O
eNOS	B-T103
protein	I-T103
at	O
24	O
h	O
stimulation	O
,	O
whereas	O
no	O
difference	O
in	O
these	O
proteins	B-T103
was	O
identified	O
following	O
a	O
low	O
dose	O
of	O
P	B-T007
.	I-T007

gingivalis	I-T007
HSP60	B-T103
(	O
1	O
ng	O
/	O
l	O
)	O
.	O

P	B-T007
.	I-T007

gingivalis	I-T007
HSP60	B-T103
at	O
100	O
ng	O
/	O
l	O
significantly	O
downregulated	B-T038
the	O
expression	B-T038
levels	O
of	O
VE	B-T103
-	I-T103
cadherin	I-T103
and	O
eNOS	B-T103
protein	I-T103
at	O
12	O
h	O
in	O
HUVECs	B-T017
.	O

However	O
,	O
the	O
cleavage	O
of	O
caspase	B-T103
-	I-T103
3	I-T103
showed	O
an	O
opposing	O
change	O
at	O
different	O
concentrations	O
.	O

Consistently	O
,	O
P	B-T007
.	I-T007

gingivalis	I-T007
HSP60	B-T103
induced	O
apoptosis	B-T038
of	O
HUVECs	B-T017
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

These	O
results	O
indicated	O
that	O
P	B-T007
.	I-T007

gingivalis	I-T007
HSP60	B-T103
may	O
induce	O
dysfunction	O
and	O
apoptosis	B-T038
in	O
HUVECs	B-T017
via	O
downregulating	B-T038
the	O
expression	B-T038
levels	O
of	O
VE	B-T103
-	I-T103
cadherin	I-T103
and	O
eNOS	B-T103
,	O
and	O
promoting	O
the	O
cleavage	O
of	O
caspase	B-T103
-	I-T103
3	I-T103
.	O

Estradiol	B-T103
prodrugs	B-T103
(	O
EP	B-T103
)	O
for	O
efficient	O
oral	B-T058
estrogen	O
treatment	O
and	O
abolished	O
effects	O
on	O
estrogen	B-T103
modulated	O
liver	B-T038
functions	I-T038

Oral	B-T058
compared	O
to	O
parenteral	O
estrogen	O
administration	O
is	O
characterized	O
by	O
reduced	O
systemic	O
but	O
prominent	O
hepatic	B-T082
estrogenic	B-T033
effects	I-T033
on	O
lipids	B-T103
,	O
hemostatic	B-T038
factors	I-T038
,	O
GH	B-T103
-	O
/	O
IGF	B-T103
I	I-T103
axis	O
,	O
angiotensinogen	B-T103
.	O

In	O
order	O
to	O
avoid	O
such	O
adverse	O
metabolic	O
effects	O
of	O
oral	B-T058
treatment	I-T058
,	O
estradiol	B-T103
(	O
E2	B-T103
)	O
prodrugs	B-T103
(	O
EP	B-T103
)	O
were	O
designed	O
which	O
bypass	O
the	O
liver	B-T017
tissue	I-T017
as	O
inactive	O
molecules	O
.	O

Carbone17	O
-	O
OH	O
sulfonamide	O
[	O
-	O
O2	O
-	O
NH2	O
]	O
substituted	O
esters	O
of	O
E2	B-T103
(	O
EC508	B-T103
,	O
others	O
)	O
were	O
synthesized	O
and	O
tested	O
for	O
carbonic	B-T103
anhydrase	I-T103
II	I-T103
(	O
CA	B-T103
-	I-T103
II	I-T103
)	O
binding	B-T038
.	O

CA	B-T103
II	I-T103
in	O
erythrocytes	B-T017
is	O
thought	O
to	O
oppose	O
extraction	O
of	O
EP	B-T103
from	O
portal	B-T017
vein	I-T017
blood	I-T017
during	O
liver	B-T017
passage	B-T082
.	O

Ovariectomized	O
(	O
OVX	O
,	O
day	O
minus	O
14	O
)	O
rats	B-T204
were	O
orally	B-T058
treated	I-T058
once	O
daily	O
from	O
day	O
1	O
-	O
3	O
.	O

Sacrifice	O
day	O
4	O
.	O

Uteri	B-T017
were	O
dissected	O
and	O
weighed	B-T058
.	O

Cholesterol	B-T058
fractions	I-T058
and	O
angiotensinogen	B-T058
were	O
determined	O
in	O
plasma	B-T031
.	O

Oral	O
E2	O
and	O
ethinyl	B-T103
estradiol	I-T103
(	O
EE	B-T103
)	O
generated	O
dose	O
related	O
uterine	B-T017
growth	B-T038
and	O
important	O
hepatic	B-T082
estrogenic	B-T033
effects	I-T033
.	O

EP	B-T103
induced	O
uterine	B-T038
growth	I-T038
at	O
about	O
hundred	O
-	O
fold	O
lower	O
doses	O
.	O

This	O
was	O
possible	O
with	O
almost	O
absent	O
effects	O
on	O
plasma	B-T031
cholesterol	B-T103
or	O
angiotensinogen	B-T103
.	O

Preliminary	O
pharmacokinetic	B-T062
studies	I-T062
with	O
EC508	B-T103
used	O
intravenous	B-T082
and	O
oral	B-T058
administration	I-T058
in	O
male	O
rats	B-T204
.	O

Resulting	O
blood	O
levels	O
revealed	O
complete	O
oral	B-T058
bioavailability	O
.	O

Further	O
high	O
blood	B-T031
-	O
but	O
low	O
plasma	B-T031
concentrations	O
indicated	O
erythrocyte	B-T017
binding	O
of	O
EC508	B-T103
in	B-T082
vivo	I-T082
as	O
potential	O
mechanism	O
of	O
low	O
extraction	O
at	O
liver	B-T017
passage	B-T082
.	O

Very	O
high	O
systemic	O
estrogenicity	B-T103
combined	O
with	O
markedly	O
lower	O
or	O
absent	O
adverse	O
hepatic	B-T082
estrogenic	B-T033
effects	I-T033
is	O
evidence	O
for	O
a	O
systemic	O
release	O
of	O
E2	B-T103
from	O
sulfonamide	B-T103
EP	I-T103
.	O

In	O
conclusion	O
,	O
tested	O
oral	B-T058
EP	B-T103
bypass	O
the	O
liver	B-T017
in	O
erythrocytes	B-T017
furnishing	O
systemic	O
estradiol	B-T103
at	O
hydrolysis	O
.	O

This	O
mechanism	O
avoids	O
the	O
hepatic	B-T082
estrogenic	O
impact	O
of	O
conventional	O
oral	B-T058
estrogen	B-T058
therapy	I-T058
.	O

Differences	O
in	O
pain	B-T033
experience	B-T038
and	O
cooperation	O
between	O
consecutive	B-T058
surgeries	I-T058
in	O
patients	O
undergoing	O
phacoemulsification	B-T058

The	O
purpose	O
of	O
this	O
study	B-T062
is	O
to	O
compare	O
pain	B-T033
experience	B-T038
and	O
cooperation	O
between	O
consecutive	B-T058
surgeries	I-T058
in	O
patients	O
undergoing	O
phacoemulsification	B-T058
in	O
both	O
eyes	B-T017
,	O
using	O
sub	B-T058
-	I-T058
Tenon	I-T058
'	I-T058
s	I-T058
local	I-T058
anesthesia	I-T058
without	O
sedation	B-T058
.	O

In	O
this	O
study	B-T062
,	O
268	O
patients	O
with	O
bilateral	O
senile	O
cataracts	O
were	O
recruited	O
.	O

All	O
operations	B-T058
were	O
performed	O
without	O
sedation	B-T058
,	O
using	O
a	O
clear	O
corneal	B-T017
phacoemulsification	B-T058
technique	I-T058
and	O
sub	B-T058
-	I-T058
Tenon	I-T058
'	I-T058
s	I-T058
local	I-T058
anesthesia	I-T058
,	O
by	O
one	O
of	O
four	O
surgeons	B-T097
.	O

The	O
first	O
surgery	B-T058
was	O
performed	O
on	O
the	O
eye	B-T017
with	O
the	O
higher	O
grade	O
cataract	B-T017
.	O

The	O
other	O
eye	B-T017
was	O
operated	O
on	O
within	O
3	O
months	O
by	O
the	O
same	O
surgeon	B-T097
(	O
mean	O
interval	O
1	O
.	O
9	O
±	O
1	O
.	O
1	O
months	O
)	O
.	O

All	O
patients	O
were	O
asked	O
to	O
grade	O
their	O
pain	B-T033
experience	B-T038
during	O
induction	B-T058
and	O
maintenance	O
of	O
anesthesia	B-T058
and	O
also	O
during	O
the	O
phacoemulsification	B-T058
surgery	I-T058
,	O
using	O
a	O
visual	B-T058
analogue	I-T058
scale	I-T058
(	O
VAS	B-T058
)	O
from	O
0	O
(	O
no	B-T033
pain	I-T033
)	O
to	O
10	O
(	O
unbearable	B-T033
pain	I-T033
)	O
administered	O
after	O
the	O
surgery	B-T058
.	O

The	O
cooperation	O
of	O
the	O
patient	O
was	O
graded	O
from	O
0	O
(	O
no	O
event	O
)	O
to	O
3	O
(	O
markedeye	B-T038
and	O
head	B-T038
movement	I-T038
and	O
lid	B-T033
squeezing	I-T033
)	O
by	O
the	O
attending	O
surgeon	B-T097
.	O

The	O
VAS	O
scores	O
and	O
cooperation	O
scores	O
of	O
the	O
patients	O
were	O
the	O
outcome	O
measurements	O
.	O

The	O
mean	B-T033
pain	I-T033
score	I-T033
was	O
2	O
.	O
11	O
±	O
0	O
.	O
79	O
in	O
the	O
first	O
eye	B-T017
and	O
3	O
.	O
33	O
±	O
0	O
.	O
80	O
in	O
the	O
second	O
eye	B-T017
during	O
the	O
administration	B-T058
of	O
sub	B-T058
-	I-T058
Tenon	I-T058
'	I-T058
s	I-T058
anesthesia	I-T058
,	O
and	O
1	O
.	O
50	O
±	O
0	O
.	O
60	O
in	O
the	O
first	O
eye	B-T017
and	O
2	O
.	O
10	O
±	O
0	O
.	O
57	O
in	O
the	O
second	O
eye	B-T017
during	O
the	O
phacoemulsification	B-T058
surgery	I-T058
.	O

The	O
patient	O
cooperation	O
score	O
was	O
1	O
.	O
60	O
±	O
0	O
.	O
75	O
in	O
the	O
first	O
surgery	B-T058
and	O
2	O
.	O
08	O
±	O
0	O
.	O
72	O
in	O
the	O
second	O
surgery	B-T058
.	O

The	O
differences	O
between	O
the	O
first	O
and	O
second	O
surgeries	B-T058
were	O
statistically	O
significant	O
for	O
all	O
outcome	O
measures	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Patients	O
who	O
previously	O
underwent	O
phaco	B-T058
surgery	I-T058
in	O
one	O
eye	B-T017
experienced	O
more	O
pain	B-T033
and	O
showed	O
worse	B-T033
cooperation	O
during	O
the	O
phaco	B-T058
surgery	I-T058
in	O
the	O
second	O
eye	B-T017
,	O
especially	O
if	O
there	O
was	O
a	O
short	O
time	O
between	O
the	O
surgeries	B-T058
,	O
viz	O
.	O
,	O
less	O
than	O
3	O
months	O
.	O

Therefore	O
,	O
if	O
the	O
surgeon	B-T097
has	O
difficulty	O
in	O
the	O
first	O
operation	B-T058
gaining	O
the	O
patient	O
'	O
s	O
cooperation	O
,	O
the	O
surgeon	B-T097
must	O
be	O
careful	O
:	O
if	O
contralateral	B-T058
eye	I-T058
surgery	I-T058
is	O
required	O
,	O
the	O
addition	O
of	O
sedation	B-T058
/	O
analgesia	B-T058
should	O
be	O
considered	O
or	O
the	O
surgery	B-T058
postponed	O
for	O
a	O
while	O
to	O
abolish	O
the	O
influence	O
of	O
recent	B-T038
memory	I-T038
on	O
the	O
patient	O
'	O
s	O
subsequent	O
pain	B-T033
experience	B-T038
.	O

Co	B-T058
-	I-T058
ChIP	I-T058
enables	O
genome	B-T062
-	I-T062
wide	I-T062
mapping	I-T062
of	O
histone	B-T082
mark	I-T082
co	O
-	O
occurrence	O
at	O
single	O
-	O
molecule	O
resolution	O

Histone	B-T038
modifications	I-T038
play	O
an	O
important	O
role	O
in	O
chromatin	B-T038
organization	I-T038
and	O
transcriptional	B-T038
regulation	I-T038
,	O
but	O
despite	O
the	O
large	O
amount	O
of	O
genome	B-T017
-	I-T017
wide	I-T017
histone	B-T038
modification	I-T038
data	O
collected	O
in	O
different	O
cells	B-T017
and	O
tissues	B-T017
,	O
little	O
is	O
known	O
about	O
co	O
-	O
occurrence	O
of	O
modifications	B-T038
on	O
the	O
same	O
nucleosome	B-T103
.	O

Here	O
we	O
present	O
a	O
genome	O
-	O
wide	O
quantitative	O
method	O
for	O
combinatorial	B-T170
indexed	I-T170
chromatin	B-T058
immunoprecipitation	I-T058
(	O
co	B-T058
-	I-T058
ChIP	I-T058
)	O
to	O
characterize	O
co	O
-	O
occurrence	O
of	O
histone	B-T038
modifications	I-T038
on	O
nucleosomes	B-T103
.	O

Using	O
co	B-T058
-	I-T058
ChIP	I-T058
,	O
we	O
study	B-T062
the	O
genome	B-T017
-	I-T017
wide	I-T017
co	O
-	O
occurrence	O
of	O
14	O
chromatin	B-T082
marks	I-T082
(	O
70	O
pairwise	O
combinations	O
)	O
,	O
and	O
find	O
previously	O
undescribed	O
co	O
-	O
occurrence	O
patterns	B-T082
,	O
including	O
the	O
co	O
-	O
occurrence	O
of	O
H3K9me1	B-T017
and	O
H3K27ac	B-T017
in	O
super	B-T082
-	I-T082
enhancers	I-T082
.	O

Finally	O
,	O
we	O
apply	O
co	B-T058
-	I-T058
ChIP	I-T058
to	O
measure	O
the	O
distribution	O
of	O
the	O
bivalent	O
H3K4me3	B-T017
-	O
H3K27me3	B-T017
domains	B-T082
in	O
two	O
distinct	O
mouse	B-T017
embryonic	I-T017
stem	I-T017
cell	I-T017
(	O
mESC	B-T017
)	O
states	O
and	O
in	O
four	O
adult	B-T017
tissues	I-T017
.	O

We	O
observe	O
dynamic	O
changes	O
in	O
5	O
,	O
786	O
regions	O
and	O
discover	O
both	O
loss	O
and	O
de	O
novo	O
gain	O
of	O
bivalency	O
in	O
key	O
tissue	O
-	O
specific	O
regulatory	B-T017
genes	I-T017
,	O
suggesting	O
a	O
functional	O
role	O
for	O
bivalent	O
domains	B-T082
during	O
different	O
stages	O
of	O
development	O
.	O

These	O
results	O
show	O
that	O
co	B-T058
-	I-T058
ChIP	I-T058
can	O
reveal	O
the	O
complex	O
interactions	O
between	O
histone	B-T038
modifications	I-T038
.	O

Hand	B-T058
-	I-T058
Assisted	I-T058
Laparoscopic	I-T058
Versus	O
Standard	B-T058
Laparoscopic	I-T058
Colectomy	I-T058
:	O
Are	O
Outcomes	O
and	O
Operative	O
Time	O
Different	O
?	O

HAL	B-T058
colectomy	B-T058
is	O
a	O
technique	O
perceived	O
to	O
provide	O
the	O
benefits	O
of	O
laparoscopic	B-T058
surgery	I-T058
while	O
improving	O
tactile	O
feedback	O
and	O
operative	O
time	O
.	O

Published	O
data	O
are	O
largely	O
limited	O
to	O
small	O
,	O
single	B-T062
-	I-T062
institution	I-T062
studies	I-T062
.	O

The	O
2012	O
-	O
2013	O
National	B-T170
Surgical	I-T170
Quality	I-T170
Improvement	I-T170
Program	I-T170
Participant	I-T170
Data	I-T170
Use	I-T170
File	I-T170
was	O
queried	O
for	O
patients	O
undergoing	O
elective	O
SL	B-T058
or	O
HAL	B-T058
colectomy	B-T058
.	O

Patients	O
underwent	O
1	O
:	O
1	O
propensity	O
matching	O
and	O
had	O
outcomes	O
compared	O
.	O

An	O
additional	O
subgroup	B-T062
analysis	I-T062
was	O
performed	O
for	O
patients	O
undergoing	O
segmental	B-T082
resections	B-T058
only	O
.	O

13	O
,	O
949	O
patients	O
were	O
identified	O
,	O
of	O
whom	O
6084	O
(	O
43	O
.	O
6	O
%	O
)	O
underwent	O
HAL	B-T058
colectomy	B-T058
.	O

Patients	O
undergoing	O
HAL	B-T058
versus	O
SL	B-T058
colectomy	I-T058
had	O
higher	O
rates	O
of	O
postoperative	B-T038
ileus	I-T038
(	O
8	O
.	O
7	O
vs	O
.	O

6	O
.	O
3	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
wound	B-T037
complication	I-T037
(	O
8	O
.	O
8	O
vs	O
.	O

6	O
.	O
8	O
%	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
,	O
and	O
30	O
-	O
day	O
readmission	B-T058
(	O
7	O
.	O
5	O
vs	O
.	O

6	O
.	O
0	O
%	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
,	O
without	O
any	O
differences	O
in	O
operative	O
time	O
(	O
156	O
vs	O
.	O

157	O
min	O
,	O
p	O
=	O
0	O
.	O
713	O
)	O
.	O

Amongst	O
segmental	B-T082
colectomies	B-T058
,	O
HAL	B-T058
remained	O
associated	O
with	O
higher	O
rates	O
of	O
wound	B-T037
complications	I-T037
(	O
8	O
.	O
6	O
vs	O
.	O

6	O
.	O
5	O
%	O
,	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
postoperative	B-T038
ileus	I-T038
(	O
8	O
.	O
9	O
vs	O
.	O

6	O
.	O
3	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
30	O
-	O
day	O
readmission	B-T058
(	O
7	O
.	O
1	O
vs	O
.	O

5	O
.	O
9	O
%	O
,	O
p	O
=	O
0	O
.	O
041	O
)	O
with	O
no	O
difference	O
in	O
operative	O
time	O
between	O
HAL	B-T058
and	O
SL	O
(	O
145	O
vs	O
.	O

145	O
min	O
,	O
p	O
=	O
0	O
.	O
334	O
)	O
.	O

Use	O
of	O
HAL	B-T058
colectomy	B-T058
is	O
associated	O
with	O
increased	O
risk	B-T058
of	O
wound	B-T037
complications	I-T037
,	O
postoperative	B-T038
ileus	I-T038
,	O
and	O
readmissions	B-T058
.	O

Importantly	O
,	O
this	O
technique	O
is	O
not	O
associated	O
with	O
any	O
decrease	O
in	O
operative	O
time	O
.	O

Safety	O
and	O
immunogenecity	B-T062
of	O
a	O
live	O
attenuated	B-T103
Rift	B-T103
Valley	I-T103
fever	I-T103
vaccine	I-T103
(	O
CL13T	B-T103
)	O
in	O
camels	B-T204

Rift	B-T038
Valley	I-T038
fever	I-T038
is	O
an	O
emerging	O
zoonotic	O
viral	B-T038
disease	I-T038
,	O
enzootic	B-T038
and	O
endemic	B-T038
in	O
Africa	B-T082
and	O
the	O
Arabian	B-T082
Peninsula	I-T082
,	O
which	O
poses	O
a	O
significant	O
threat	O
to	O
both	O
human	B-T204
and	O
animal	B-T204
health	O
.	O

The	O
disease	B-T038
is	O
most	O
severe	O
in	O
ruminants	B-T204
causing	O
abortions	B-T038
in	O
pregnant	B-T038
animals	B-T204
,	O
especially	O
sheep	B-T204
animals	I-T204
and	O
high	O
mortality	O
in	O
young	O
populations	B-T098
.	O

High	O
mortality	O
rates	O
and	O
severe	O
clinical	O
manifestation	O
have	O
also	O
been	O
reported	B-T170
among	O
camel	B-T204
populations	B-T098
in	O
Africa	B-T082
,	O
to	O
attend	O
however	O
none	O
of	O
the	O
currently	O
available	O
live	B-T103
vaccines	I-T103
against	O
RVF	B-T038
have	O
been	O
tested	O
for	O
safety	O
and	O
efficacy	O
in	O
this	O
species	B-T170
.	O

In	O
this	O
study	B-T062
,	O
the	O
safety	O
and	O
efficacy	O
(	O
through	O
a	O
neutralizing	B-T103
antibody	I-T103
response	O
)	O
of	O
the	O
thermostable	B-T103
live	I-T103
attenuated	I-T103
RVF	B-T103
CL13T	I-T103
vaccine	I-T103
were	O
evaluated	B-T058
in	O
camels	B-T204
in	O
two	O
different	O
preliminary	O
experiments	B-T062
involving	O
16	O
camels	B-T204
,	O
(	O
that	O
12	O
camels	B-T204
and	O
4	O
pregnant	B-T038
camels	B-T204
)	O
.	O

The	O
study	B-T062
revealed	O
that	O
the	O
CL13T	B-T103
vaccine	I-T103
was	O
safe	O
to	O
use	O
in	O
camels	B-T204
and	O
no	O
abortions	B-T038
or	O
teratogenic	B-T038
effects	I-T038
were	O
observed	O
.	O

The	O
single	O
dose	O
of	O
the	O
vaccine	B-T103
stimulated	O
a	O
strong	O
and	O
long	O
-	O
lasting	O
neutralizing	B-T103
antibody	I-T103
response	O
for	O
up	O
to	O
12	O
months	O
.	O

The	O
presence	B-T033
of	O
neutralization	B-T103
antibodies	I-T103
is	O
likely	O
to	O
correlate	O
with	O
protection	O
;	O
however	O
protection	O
would	O
need	O
to	O
be	O
confirmed	O
by	O
challenge	O
experiments	B-T062
using	O
the	O
virulent	O
RVF	B-T005
virus	I-T005
.	O

Autoantibodies	B-T103
to	O
MOG	B-T103
in	O
a	O
distinct	O
subgroup	B-T170
of	O
adult	O
multiple	B-T038
sclerosis	I-T038

To	O
evaluate	B-T058
the	O
presence	O
of	O
antibodies	B-T103
to	O
conformation	B-T082
-	O
intact	O
myelin	B-T103
oligodendrocyte	I-T103
glycoprotein	I-T103
(	O
MOG	B-T103
)	O
in	O
a	O
subgroup	B-T170
of	O
adult	O
patients	O
with	O
clinically	O
definite	O
multiple	B-T038
sclerosis	I-T038
(	O
MS	B-T038
)	O
preselected	O
for	O
a	O
specific	O
clinical	O
phenotype	O
including	O
severe	O
spinal	B-T017
cord	I-T017
,	O
optic	B-T017
nerve	I-T017
,	O
and	O
brainstem	B-T017
involvement	O
.	O

Antibodies	B-T103
to	O
MOG	B-T103
were	O
investigated	O
using	O
a	O
cell	B-T058
-	I-T058
based	I-T058
assay	I-T058
in	O
3	O
groups	B-T098
of	O
patients	O
:	O
104	O
preselected	O
patients	O
with	O
MS	B-T038
(	O
group	B-T098
1	I-T098
)	O
,	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
,	O
otherwise	O
unselected	O
patients	O
with	O
MS	B-T038
(	O
group	B-T098
2	I-T098
)	O
,	O
and	O
in	O
22	O
brain	B-T058
-	I-T058
biopsied	I-T058
patients	O
with	O
demyelinating	B-T038
diseases	I-T038
of	O
the	O
CNS	B-T022
(	O
n	O
=	O
19	O
with	O
MS	B-T038
)	O
,	O
4	O
of	O
whom	O
classified	B-T170
as	O
MS	B-T038
type	I-T038
II	I-T038
(	O
group	B-T098
3	I-T098
)	O
.	O

Recognized	O
epitopes	B-T103
were	O
identified	O
with	O
mutated	B-T038
variants	B-T017
of	O
MOG	B-T017
.	O

Antibodies	B-T103
to	O
MOG	B-T103
were	O
found	O
in	O
about	O
5	O
%	O
(	O
5	O
/	O
104	O
)	O
of	O
preselected	O
adult	O
patients	O
with	O
MS	B-T038
.	O

In	O
contrast	O
,	O
in	O
groups	B-T098
2	I-T098
and	O
3	B-T098
,	O
none	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
MOG	B-T103
antibodies	B-T103
.	O

Patients	O
with	O
MS	B-T038
with	O
antibodies	B-T103
to	O
MOG	B-T103
predominantly	O
manifested	O
with	O
concomitant	O
severe	O
brainstem	B-T017
and	O
spinal	B-T017
cord	I-T017
involvement	O
and	O
had	O
a	O
severe	O
disease	B-T038
course	I-T038
with	O
high	O
relapse	O
rates	O
and	O
failure	B-T033
to	O
several	O
disease	B-T058
-	I-T058
modifying	I-T058
therapies	I-T058
.	O

Three	O
of	O
them	O
had	O
been	O
treated	B-T058
with	I-T058
plasma	B-T058
exchange	I-T058
with	O
a	O
favorable	O
response	O
.	O

All	O
anti	B-T103
-	I-T103
MOG	I-T103
-	O
positive	O
patients	O
with	O
MS	B-T038
showed	O
typical	O
MS	B-T038
lesions	B-T033
on	O
brain	B-T058
MRI	I-T058
.	O

Longitudinal	O
analysis	O
up	O
to	O
9	O
years	O
revealed	O
fluctuations	B-T033
and	O
reappearance	O
of	O
anti	B-T038
-	I-T038
MOG	I-T038
reactivity	I-T038
.	O

Epitope	B-T058
mapping	I-T058
indicated	O
interindividual	O
heterogeneity	O
,	O
yet	O
intraindividual	O
stability	O
of	O
the	O
antibody	B-T038
response	I-T038
.	O

Antibodies	B-T103
to	O
MOG	B-T103
can	O
be	O
found	O
in	O
a	O
distinct	O
subgroup	B-T170
of	O
adult	O
MS	B-T038
with	O
a	O
specific	O
clinical	O
phenotype	O
and	O
may	O
indicate	O
disease	B-T038
heterogeneity	O
.	O

Acute	B-T038
Ph	I-T038
-	I-T038
negative	I-T038
lymphoblastic	I-T038
leukemias	I-T038
in	O
adults	O
:	O
Risk	B-T033
factors	I-T033
in	O
the	O
use	O
of	O
the	O
ALL	B-T170
-	I-T170
2009	I-T170
protocol	I-T170

to	O
analyze	O
well	O
-	O
known	O
risk	B-T033
factors	I-T033
(	O
RFs	B-T033
)	O
,	O
such	O
as	O
age	O
,	O
immunophenotype	B-T058
,	O
baseline	O
leukocytosis	B-T038
,	O
enhanced	O
lactate	B-T103
dehydrogenase	I-T103
(	O
LDH	B-T103
)	O
activity	B-T038
,	O
time	O
to	O
achieve	O
complete	O
remission	B-T033
,	O
a	O
risk	O
group	O
,	O
and	O
cytogenetic	B-T038
abnormalities	I-T038
)	O
in	O
patients	O
with	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
(	O
ALL	B-T038
)	O
in	O
the	O
use	O
of	O
the	O
ALL	B-T170
-	I-T170
2009	I-T170
protocol	I-T170
.	O

The	O
protocol	B-T170
covered	O
298	O
patients	O
(	O
137	O
women	B-T098
(	O
including	O
13	O
pregnant	B-T098
women	I-T098
)	O
and	O
161	O
men	B-T098
)	O
aged	O
15	O
to	O
55	O
years	O
(	O
median	O
age	O
28	O
years	O
)	O
with	O
Ph	B-T038
-	I-T038
negative	I-T038
ALL	I-T038
.	O

The	O
phenotype	O
was	O
unknown	O
in	O
6	O
patients	O
.	O

Three	O
(	O
1	O
%	O
)	O
were	O
ascertained	O
to	O
have	O
a	O
biphenotypic	O
variant	O
.	O

182	O
(	O
62	O
.	O
4	O
%	O
)	O
patients	O
were	O
found	O
to	O
have	O
B	B-T038
-	I-T038
cell	I-T038
ALL	I-T038
(	O
early	O
pre	B-T038
-	I-T038
B	I-T038
ALL	I-T038
(	O
n	O
=	O
51	O
)	O
;	O
common	O
ALL	B-T038
(	O
n	O
=	O
92	O
)	O
,	O
and	O
pre	B-T038
-	I-T038
B	I-T038
ALL	I-T038
(	O
n	O
=	O
39	O
)	O
;	O
107	O
(	O
36	O
.	O
6	O
%	O
)	O
patients	O
had	O
T	B-T038
-	I-T038
cell	I-T038
ALL	I-T038
(	O
early	O
T	B-T038
-	I-T038
ALL	I-T038
(	O
n	O
=	O
56	O
)	O
;	O
thymic	B-T017
T	B-T038
-	I-T038
ALL	I-T038
(	O
n	O
=	O
41	O
)	O
,	O
and	O
mature	O
T	B-T038
-	I-T038
ALL	I-T038
(	O
n	O
=	O
10	O
)	O
.	O

According	O
to	O
the	O
baseline	O
clinical	O
and	O
laboratory	B-T092
parameters	B-T033
(	O
leukocytosis	B-T038
of	O
30	O
·	O
109	O
/	O
l	O
and	O
more	O
for	O
B	B-T038
-	I-T038
ALL	I-T038
;	O
and	O
that	O
of	O
100	O
·	O
109	O
/	O
l	O
and	O
more	O
for	O
T	B-T038
-	I-T038
ALL	I-T038
;	O
phenotype	O
В	O
-	O
I	O
for	O
B	B-T038
-	I-T038
ALL	I-T038
,	O
phenotype	O
Т	O
-	O
I	O
-	O
II	O
-	O
IV	O
for	O
T	B-T038
-	I-T038
ALL	I-T038
;	O
LDH	B-T103
activity	B-T038
was	O
more	O
than	O
twice	O
the	O
normal	O
values	O
;	O
the	O
presence	B-T033
of	O
translocation	B-T038
t	I-T038
(	I-T038
4	I-T038
;	I-T038
11	I-T038
)	I-T038
)	O
,	O
the	O
high	O
-	O
risk	O
group	O
included	O
most	O
patients	O
with	O
B	B-T038
-	I-T038
ALL	I-T038
(	O
n	O
=	O
110	O
(	O
72	O
.	O
8	O
%	O
)	O
)	O
and	O
T	B-T038
-	I-T038
ALL	I-T038
(	O
n	O
=	O
76	O
(	O
76	O
%	O
)	O
)	O
.	O

Thirty	O
-	O
five	O
patients	O
with	O
T	B-T038
-	I-T038
ALL	I-T038
underwent	O
autologous	B-T058
bone	I-T058
marrow	I-T058
transplantation	I-T058
(	O
BMT	B-T058
)	O
.	O

Allogeneic	B-T058
BMT	I-T058
was	O
performed	O
in	O
18	O
(	O
7	O
%	O
)	O
of	O
the	O
258	O
patients	O
who	O
had	O
undergone	O
an	O
induction	B-T062
phase	I-T062
.	O

Five	O
-	O
year	O
overall	O
survival	O
for	O
all	O
the	O
patients	O
included	O
in	O
the	O
investigation	B-T058
was	O
59	O
%	O
;	O
relapse	B-T058
-	I-T058
free	I-T058
survival	O
was	O
65	O
%	O
,	O
which	O
was	O
significantly	O
different	O
in	O
the	O
patients	O
with	O
B	B-T038
-	I-T038
ALL	I-T038
and	O
in	O
those	O
with	O
T	B-T038
-	I-T038
ALL	I-T038
:	O
the	O
overall	O
survival	O
rates	O
were	O
53	O
.	O
3	O
and	O
67	O
.	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
1	O
)	O
;	O
the	O
relapse	O
-	O
free	O
survival	O
was	O
56	O
and	O
79	O
%	O
(	O
p	O
=	O
0	O
.	O
005	O
)	O
,	O
respectively	O
.	O

Multivariate	O
analysis	O
including	O
the	O
well	O
-	O
known	O
RFs	B-T033
demonstrated	O
that	O
the	O
latter	O
for	O
T	B-T038
-	I-T038
ALL	I-T038
were	O
of	O
no	O
independent	O
prognostic	O
value	O
and	O
only	O
the	O
patient	O
'	O
s	O
age	O
was	O
identified	O
for	O
B	B-T038
-	I-T038
ALL	I-T038
(	O
p	O
=	O
0	O
.	O
013	O
)	O
.	O

A	O
lower	O
chemotherapeutic	B-T103
load	O
and	O
a	O
small	O
number	O
of	O
allogeneic	B-T058
BMTs	I-T058
did	O
not	O
affect	O
total	O
positive	O
treatment	B-T058
results	B-T033
in	O
adult	O
patients	O
with	O
ALL	B-T038
,	O
by	O
complying	O
with	O
the	O
principle	O
achieving	O
the	O
continuity	O
of	O
cytostatic	B-T103
effects	O
and	O
by	O
preserving	O
the	O
total	O
cytostatic	B-T103
loading	O
dose	O
.	O

The	O
results	B-T033
of	O
the	O
Russian	B-T082
investigation	B-T058
casts	O
some	O
doubt	O
on	O
the	O
necessity	O
of	O
using	O
very	O
intensive	O
consolidation	O
cycles	O
and	O
performing	O
a	O
large	O
number	O
of	O
allogeneic	B-T058
BMTs	I-T058
in	O
adult	O
patients	O
with	O
ALL	B-T038
.	O

Multidetector	B-T058
CT	I-T058
of	O
expected	B-T170
findings	B-T033
and	O
complications	B-T038
after	O
contemporary	O
inguinal	B-T058
hernia	I-T058
repair	I-T058
surgery	B-T058

Inguinal	B-T058
hernia	I-T058
repair	I-T058
(	O
IHR	B-T058
)	O
with	O
prosthetic	B-T074
mesh	B-T074
implantation	B-T058
is	O
the	O
most	O
common	O
procedure	B-T058
in	O
general	B-T058
surgery	I-T058
,	O
and	O
may	O
be	O
performed	O
using	O
either	O
an	O
open	B-T082
or	O
laparoscopic	B-T082
approach	I-T082
.	O

This	O
paper	O
provides	O
an	O
overview	O
of	O
contemporary	O
tension	O
-	O
free	O
IHR	B-T058
techniques	O
and	O
materials	O
,	O
and	O
illustrates	O
the	O
expected	B-T170
postoperative	B-T033
imaging	B-T033
findings	I-T033
and	O
iatrogenic	B-T037
injuries	I-T037
.	O

Emphasis	O
is	O
placed	O
on	O
multidetector	B-T058
CT	I-T058
,	O
which	O
represents	O
the	O
ideal	O
modality	O
to	O
comprehensively	O
visualize	O
the	O
operated	O
groin	B-T082
region	I-T082
and	O
deeper	B-T082
intra	B-T017
-	I-T017
abdominal	I-T017
structures	I-T017
.	O

CT	B-T058
consistently	O
depicts	O
seroma	B-T038
,	O
mesh	B-T038
infections	I-T038
,	O
hemorrhages	B-T038
,	O
bowel	B-T017
complications	B-T038
and	O
urinary	B-T017
bladder	I-T017
injuries	B-T037
,	O
and	O
thus	O
generally	O
provides	O
a	O
consistent	O
basis	O
for	O
therapeutic	O
choice	O
.	O

Since	O
radiologists	B-T097
are	O
increasingly	O
requested	O
to	O
investigate	O
suspected	O
iatrogenic	O
complications	B-T038
,	O
this	O
paper	O
aims	O
to	O
provide	O
an	O
increased	O
familiarity	B-T038
with	O
early	O
CT	B-T058
studies	B-T058
after	O
IHR	B-T058
,	O
including	O
complications	B-T038
and	O
normal	O
postoperative	B-T033
appearances	O
such	O
as	O
focal	B-T082
pseudolesions	B-T038
,	O
in	O
order	O
to	O
avoid	O
misinterpretation	O
and	O
inappropriate	O
management	B-T058
.	O

The	O
transcription	B-T103
factors	I-T103
MS188	B-T103
and	O
AMS	B-T103
form	O
a	O
complex	O
to	O
activate	O
the	O
expression	B-T038
of	O
CYP703A2	B-T103
for	O
sporopollenin	B-T038
biosynthesis	I-T038
in	O
Arabidopsis	B-T204
thaliana	I-T204

The	O
sexine	B-T017
layer	I-T017
of	O
pollen	B-T204
grain	I-T204
is	O
mainly	O
composed	O
of	O
sporopollenins	B-T103
.	O

The	O
sporophytic	B-T017
secretory	I-T017
tapetum	I-T017
is	O
required	O
for	O
the	O
biosynthesis	B-T038
of	I-T038
sporopollenin	I-T038
.	O

Although	O
several	O
enzymes	B-T103
involved	O
in	O
sporopollenin	B-T038
biosynthesis	I-T038
have	O
been	O
reported	O
,	O
the	O
regulatory	B-T038
mechanism	I-T038
of	O
these	O
enzymes	B-T103
in	O
tapetal	B-T017
layer	I-T017
remains	O
elusive	O
.	O

ABORTED	B-T103
MICROSPORES	I-T103
(	O
AMS	B-T103
)	O
and	O
MALE	B-T103
STERILE	I-T103
188	I-T103
/	O
MYB103	B-T103
/	O
MYB80	B-T103
(	O
MS188	B-T103
/	O
MYB103	B-T103
/	O
MYB80	B-T103
)	O
are	O
two	O
tapetal	B-T017
cell	I-T017
-	O
specific	O
transcription	B-T103
factors	I-T103
required	O
for	O
pollen	B-T038
wall	I-T038
formation	I-T038
.	O

AMS	B-T103
functions	O
upstream	B-T082
of	O
MS188	B-T103
.	O

Here	O
we	O
report	O
that	O
AMS	B-T103
and	O
MS188	B-T103
target	O
the	O
CYP703A2	B-T017
gene	I-T017
,	O
which	O
is	O
involved	O
in	O
sporopollenin	B-T038
biosynthesis	I-T038
.	O

We	O
found	O
that	O
AMS	B-T103
and	O
MS188	B-T103
were	O
localized	B-T082
in	O
tapetum	B-T017
while	O
CYP703A2	B-T103
was	O
localized	B-T082
in	O
both	O
tapetum	B-T017
and	O
locule	B-T204
.	O

Chromatin	B-T058
immunoprecipitation	I-T058
(	O
ChIP	B-T058
)	O
showed	O
that	O
MS188	B-T103
directly	O
bound	O
to	O
the	O
promoter	B-T103
of	O
CYP703A2	B-T017
and	O
luciferase	B-T103
-	I-T103
inducible	I-T103
assay	B-T058
showed	O
that	O
MS188	B-T103
activated	O
the	O
expression	B-T038
of	O
CYP703A2	B-T103
.	O

Yeast	B-T062
two	I-T062
-	I-T062
hybrid	I-T062
and	O
electrophoretic	B-T058
mobility	I-T058
shift	I-T058
assays	I-T058
(	O
EMSAs	B-T058
)	O
further	O
demonstrated	O
that	O
MS188	B-T103
complexed	O
with	O
AMS	B-T103
.	O

The	O
expression	B-T038
of	O
CYP703A2	B-T017
could	O
be	O
partially	O
restored	O
by	O
the	O
elevated	O
levels	O
of	O
MS188	B-T103
in	O
the	O
ams	B-T103
mutant	B-T038
.	O

Therefore	O
,	O
our	O
data	O
reveal	O
that	O
MS188	B-T103
coordinates	O
with	O
AMS	B-T103
to	O
activate	O
CYP703A2	B-T103
in	O
sporopollenin	B-T038
biosynthesis	I-T038
of	O
plant	B-T204
tapetum	B-T017
.	O

Activation	O
of	O
ephrinB	O
-	O
EphB	O
receptor	O
signalling	O
in	O
rat	B-T017
spinal	I-T017
cord	I-T017
contributes	O
to	O
maintenance	O
of	O
diabetic	B-T033
neuropathic	B-T033
pain	I-T033

Diabetic	B-T033
neuropathic	B-T033
pain	I-T033
(	O
DNP	B-T033
)	O
is	O
severe	O
and	O
intractable	O
in	O
clinic	B-T092
.	O

The	O
specific	O
cellular	B-T038
and	O
molecular	B-T038
mechanisms	O
underlying	O
DNP	B-T033
remain	O
elusive	O
and	O
its	O
treatment	O
are	O
limited	O
.	O

We	O
investigated	O
roles	O
of	O
EphB1	B-T103
receptor	I-T103
in	O
the	O
development	O
of	O
DNP	B-T033
.	O

Diabetic	B-T033
neuropathic	B-T033
pain	I-T033
was	O
produced	O
in	O
male	O
,	O
adult	O
,	O
Sprague	B-T204
-	I-T204
Dawley	I-T204
rats	I-T204
by	O
a	O
single	O
i	O
.	O
p	O
.	O

streptozotocin	B-T103
(	O
STZ	B-T103
)	O
or	O
alloxan	B-T103
.	O

Western	B-T058
blot	I-T058
analysis	I-T058
and	O
immunohistochemistry	B-T058
were	O
used	O
to	O
analyse	O
expression	B-T038
of	O
EphB1	B-T103
receptor	I-T103
as	O
well	O
as	O
the	O
activation	O
of	O
the	O
glial	B-T017
cells	I-T017
and	O
the	O
pro	B-T103
-	I-T103
inflammatory	I-T103
cytokines	I-T103
in	O
the	O
spinal	B-T017
cord	I-T017
.	O

DNP	B-T033
manifested	O
as	O
mechanical	B-T033
allodynia	I-T033
,	O
which	O
was	O
determined	O
by	O
measuring	O
incidence	O
of	O
foot	B-T017
withdrawal	O
in	O
response	O
to	O
mechanical	B-T082
indentation	I-T082
of	O
the	O
hind	B-T082
paw	B-T017
by	O
an	O
electro	O
von	O
Frey	O
filament	O
.	O

Diabetic	B-T033
neuropathic	B-T033
pain	I-T033
and	O
high	B-T033
blood	I-T033
glucose	I-T033
were	O
exhibited	O
simultaneously	O
in	O
around	O
70	O
%	O
of	O
animals	B-T204
that	O
received	O
i	O
.	O
p	O
.	O

STZ	B-T103
or	O
alloxan	B-T103
.	O

Phosphorylation	B-T038
of	O
EphB1	B-T103
,	O
activation	O
of	O
the	O
astrocytes	B-T017
and	O
microglial	B-T017
cells	I-T017
,	O
and	O
level	O
of	O
tumour	B-T103
necrosis	I-T103
factor	I-T103
(	B-T103
TNF	I-T103
)	I-T103
-	I-T103
α	I-T103
and	O
interleukin	B-T103
(	I-T103
IL	I-T103
)	I-T103
-	I-T103
1β	I-T103
in	O
the	O
spinal	B-T017
cord	I-T017
were	O
significantly	O
increased	O
in	O
rats	B-T204
with	O
DNP	B-T033
.	O

Spinal	B-T082
blocking	O
EphB1	B-T103
receptor	I-T103
activation	O
in	O
the	O
late	O
phase	O
after	O
STZ	B-T103
injection	B-T058
significantly	O
suppressed	O
the	O
established	O
mechanical	B-T033
allodynia	I-T033
as	O
well	O
as	O
activation	O
of	O
the	O
astrocytes	B-T017
and	O
microglial	B-T017
cells	I-T017
and	O
activity	O
of	O
TNF	B-T103
-	I-T103
α	I-T103
and	O
IL	B-T103
-	I-T103
1β	I-T103
.	O

However	O
,	O
spinal	B-T082
treatment	O
of	O
EphB1	B-T103
-	O
Fc	B-T103
in	O
the	O
early	O
phase	O
after	O
STZ	B-T103
injection	B-T058
did	O
not	O
prevent	O
the	O
induction	O
of	O
DNP	B-T033
.	O

EphB1	B-T103
receptor	I-T103
activation	O
in	O
the	O
spinal	B-T017
cord	I-T017
is	O
critical	O
to	O
the	O
maintenance	O
,	O
but	O
not	O
induction	O
of	O
diabetic	B-T033
pain	B-T033
.	O

EphB1	B-T103
receptor	I-T103
may	O
be	O
a	O
potential	O
target	O
for	O
relieving	B-T058
the	O
established	O
diabetic	B-T033
pain	B-T033
.	O

Activation	O
of	O
EphB1	B-T103
receptor	I-T103
in	O
the	O
spinal	B-T017
cord	I-T017
is	O
critical	O
to	O
maintaining	O
the	O
established	O
diabetic	B-T033
neuropathic	B-T033
pain	I-T033
,	O
but	O
not	O
to	O
diabetic	B-T033
pain	B-T033
induction	O
.	O

Spinal	B-T082
blocking	O
EphB1	B-T103
receptor	I-T103
activation	O
suppresses	O
ongoing	O
diabetic	B-T033
neuropathic	B-T033
pain	I-T033
.	O

Conservation	O
of	O
the	O
Red	B-T204
Kite	I-T204
Milvus	B-T204
milvus	I-T204
(	O
Aves	B-T204
:	O
Accipitriformes	O
)	O
Is	O
Not	O
Affected	O
by	O
the	O
Establishment	O
of	O
a	O
Broad	O
Hybrid	O
Zone	B-T082
with	O
the	O
Black	B-T204
Kite	I-T204
Milvus	B-T204
migrans	I-T204
migrans	I-T204
in	O
Central	O
Europe	O

Among	O
Accipitriformes	O
sensu	O
stricto	O
,	O
only	O
a	O
few	O
species	B-T170
have	O
been	O
reported	B-T170
to	O
form	O
hybrid	O
zones	B-T082
;	O
these	O
include	O
the	O
red	B-T204
kite	I-T204
Milvus	B-T204
milvus	I-T204
and	O
black	B-T204
kite	I-T204
Milvus	B-T204
migrans	I-T204
migrans	I-T204
.	O

M	B-T204
.	I-T204

milvus	I-T204
is	O
endemic	O
to	O
the	O
western	O
Palearctic	O
and	O
has	O
an	O
estimated	O
total	O
population	O
of	O
20	O
-	O
24	O
,	O
000	O
breeding	B-T038
pairs	O
.	O

The	O
species	B-T170
was	O
in	O
decline	O
until	O
the	O
1970s	O
due	O
to	O
persecution	O
and	O
has	O
declined	O
again	O
since	O
the	O
1990s	O
due	O
to	O
ingestion	B-T038
of	O
rodenticide	B-T103
-	I-T103
treated	I-T103
baits	I-T103
,	O
illegal	O
poisoning	B-T037
and	O
changes	O
in	O
agricultural	O
practices	O
,	O
particularly	O
in	O
its	O
core	B-T082
range	O
.	O

Whereas	O
F1	O
M	B-T204
.	I-T204

milvus	I-T204
×	O
M	B-T204
.	I-T204

migr	I-T204
.	I-T204

migrans	I-T204
hybrid	O
offspring	O
have	O
been	O
found	O
,	O
F2	O
and	O
F3	O
hybrids	O
have	O
only	O
rarely	O
been	O
reported	B-T170
,	O
with	O
low	O
nesting	O
success	O
rates	O
of	O
F1	O
hybrids	O
and	O
partial	O
hybrid	O
sterility	O
likely	O
playing	O
a	O
role	O
.	O

Here	O
,	O
we	O
analyzed	B-T062
the	O
mitochondrial	B-T017
(	O
CO1	B-T017
and	O
CytB	B-T017
)	O
and	O
nuclear	B-T017
(	O
Myc	B-T017
)	O
DNA	B-T103
loci	B-T082
of	O
184	O
M	B-T204
.	I-T204

milvus	I-T204
,	O
124	O
M	B-T204
.	I-T204

migr	I-T204
.	I-T204

migrans	I-T204
and	O
3	O
F1	O
hybrid	O
individuals	O
collected	O
across	O
central	O
Europe	O
.	O

In	O
agreement	B-T170
with	O
previous	O
studies	B-T062
,	O
we	O
found	O
low	O
heterozygosity	O
in	O
M	B-T204
.	I-T204

milvus	I-T204
regardless	O
of	O
locus	B-T082
.	O

We	O
found	O
that	O
populations	O
of	O
both	O
examined	B-T033
species	B-T170
were	O
characterized	O
by	O
a	O
high	O
gene	B-T038
flow	I-T038
within	O
populations	O
,	O
with	O
all	O
of	O
the	O
major	O
haplotypes	O
distributed	O
across	O
the	O
entire	O
examined	B-T033
area	B-T082
.	O

Few	O
haplotypes	O
displayed	O
statistically	O
significant	O
aggregation	O
in	O
one	O
region	B-T082
over	O
another	O
.	O

We	O
did	O
not	O
find	O
mitochondrial	B-T103
DNA	I-T103
of	O
one	O
species	B-T170
in	O
individuals	O
with	O
the	O
plumage	B-T017
of	O
the	O
other	O
species	B-T170
,	O
except	O
in	O
F1	O
hybrids	O
,	O
which	O
agrees	O
with	O
Haldane´s	B-T170
Rule	I-T170
.	O

It	O
remains	O
to	O
be	O
investigated	O
by	O
genomic	B-T017
methods	O
whether	O
occasional	O
gene	B-T038
flow	I-T038
occurs	O
through	O
the	O
paternal	O
line	O
,	O
as	O
the	O
examined	B-T033
Myc	B-T017
gene	I-T017
displayed	O
only	O
marginal	O
divergence	B-T082
between	O
M	B-T204
.	I-T204

milvus	I-T204
and	O
M	B-T204
.	I-T204

migr	I-T204
.	I-T204

migrans	I-T204
.	O

The	O
central	O
Europe	O
an	O
population	O
of	O
M	B-T204
.	I-T204

milvus	I-T204
is	O
clearly	O
subject	O
to	O
free	O
intraspecific	O
gene	B-T038
flow	I-T038
,	O
which	O
has	O
direct	O
implications	O
when	O
considering	O
the	O
origin	O
of	O
individuals	O
in	O
M	B-T204
.	I-T204

milvus	I-T204
re	O
-	O
introduction	O
programs	O
.	O

Extracellular	B-T017
Potassium	B-T103
and	O
Seizures	B-T033
:	O
Excitation	O
,	O
Inhibition	O
and	O
the	O
Role	O
of	O
Ih	B-T103

Seizure	B-T033
activity	I-T033
leads	O
to	O
increases	O
in	O
extracellular	B-T017
potassium	B-T103
concentration	O
(	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
)	O
,	O
which	O
can	O
result	O
in	O
changes	O
in	O
neuronal	B-T017
passive	O
and	O
active	O
membrane	B-T017
properties	O
as	O
well	O
as	O
in	O
population	B-T098
activities	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
examined	O
how	O
extracellular	B-T017
potassium	B-T103
modulates	O
seizure	B-T033
activities	I-T033
using	O
an	O
acute	O
4	B-T103
-	I-T103
AP	I-T103
induced	O
seizure	B-T033
model	B-T170
in	O
the	O
neocortex	B-T017
,	O
both	O
in	B-T082
vivo	I-T082
and	O
in	O
vitro	O
.	O

Moderately	O
elevated	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
up	O
to	O
9	O
[	O
Formula	O
:	O
see	O
text	O
]	O
mM	O
prolonged	O
seizure	B-T033
durations	O
and	O
shortened	O
interictal	O
intervals	O
as	O
well	O
as	O
depolarized	O
the	O
neuronal	B-T017
resting	B-T038
membrane	I-T038
potential	I-T038
(	O
RMP	B-T038
)	O
.	O

However	O
,	O
when	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
reached	O
higher	O
than	O
9	O
[	O
Formula	O
:	O
see	O
text	O
]	O
mM	O
,	O
seizure	B-T033
like	I-T033
events	I-T033
(	O
SLEs	B-T033
)	O
were	O
blocked	O
and	O
neurons	B-T017
went	O
into	O
a	O
depolarization	O
-	O
blocked	O
state	O
.	O

Spreading	O
depression	B-T038
was	O
never	O
observed	O
as	O
the	O
blockade	O
of	O
ictal	B-T033
events	I-T033
could	O
be	O
reversed	O
within	O
1	O
-	O
2	O
[	O
Formula	O
:	O
see	O
text	O
]	O
min	O
after	O
the	O
raised	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
was	O
changed	O
back	O
to	O
control	O
levels	O
.	O

This	O
concentration	O
-	O
dependent	O
dual	O
effect	O
of	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
was	O
observed	O
using	O
in	B-T082
vivo	I-T082
and	O
in	O
vitro	O
mouse	B-T017
brain	I-T017
preparations	I-T017
as	O
well	O
as	O
in	O
human	B-T204
neocortical	B-T017
tissue	B-T017
resected	O
during	O
epilepsy	B-T038
surgery	B-T058
.	O

Blocking	O
the	O
Ih	O
current	O
,	O
mediated	O
by	O
hyperpolarization	B-T103
-	I-T103
activated	I-T103
cyclic	I-T103
nucleotide	I-T103
-	I-T103
gated	I-T103
(	I-T103
HCN	I-T103
)	I-T103
channels	I-T103
,	O
modulated	O
the	O
elevated	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
influence	O
on	O
SLEs	B-T033
by	O
promoting	O
the	O
high	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
inhibitory	O
actions	O
.	O

These	O
results	O
demonstrate	O
biphasic	O
actions	O
of	O
raised	O
[	O
K	B-T103
[	O
Formula	O
:	O
see	O
text	O
]	O
]	O
o	O
on	O
neuronal	B-T017
excitability	B-T033
and	O
seizure	B-T033
activity	I-T033
.	O

Activation	B-T038
of	O
general	B-T103
control	I-T103
nonderepressible	I-T103
2	I-T103
kinase	I-T103
protects	O
human	B-T204
glomerular	B-T017
endothelial	I-T017
cells	I-T017
from	O
harmful	O
high	B-T033
-	I-T033
glucose	I-T033
-	O
induced	O
molecular	B-T038
pathways	I-T038

Considering	O
the	O
referred	O
beneficial	O
effects	O
of	O
protein	B-T103
restriction	O
on	O
diabetic	B-T038
nephropathy	I-T038
(	O
DN	B-T038
)	O
and	O
the	O
role	O
of	O
renal	B-T017
endothelium	B-T017
in	O
its	O
pathogenesis	B-T038
,	O
we	O
evaluated	B-T058
the	O
effect	O
of	O
general	B-T103
control	I-T103
nonderepressible	I-T103
2	I-T103
(	I-T103
GCN2	I-T103
)	I-T103
kinase	I-T103
activation	B-T038
,	O
a	O
sensor	O
of	O
amino	B-T103
acid	I-T103
deprivation	O
,	O
on	O
known	O
detrimental	O
molecular	B-T038
pathways	I-T038
in	O
primary	O
human	B-T204
glomerular	B-T017
endothelial	I-T017
cells	I-T017
(	O
GEnC	B-T017
)	O
.	O

GEnC	B-T017
were	O
cultured	B-T058
under	O
normal	O
or	O
high	B-T038
-	I-T038
glucose	I-T038
conditions	I-T038
in	O
the	O
presence	O
or	O
not	O
of	O
the	O
GCN2	B-T103
kinase	I-T103
activator	B-T038
,	O
tryptophanol	B-T103
.	O

Glucose	B-T103
transporter	I-T103
1	I-T103
(	O
GLUT1	B-T103
)	O
expression	B-T038
was	O
assessed	O
by	O
western	B-T058
blotting	I-T058
and	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
using	O
a	O
fluorogenic	B-T103
probe	I-T103
.	O

Activities	B-T038
of	O
glyceraldehyde	B-T103
3	I-T103
-	I-T103
phosphate	I-T103
dehydrogenase	I-T103
(	O
GAPDH	B-T103
)	O
and	O
protein	B-T103
kinase	I-T103
C	I-T103
(	O
PKC	B-T103
)	O
were	O
assessed	O
by	O
commercial	B-T058
activity	I-T058
assays	I-T058
,	O
sorbitol	B-T103
colorimetrically	B-T058
,	O
methylglyoxal	B-T103
by	O
ELISA	B-T058
and	O
O	B-T103
-	I-T103
linked	I-T103
β	I-T103
-	I-T103
N	I-T103
-	I-T103
acetyl	I-T103
glucosamine	I-T103
(	I-T103
O	I-T103
-	I-T103
GlcNAc	I-T103
)	I-T103
-	I-T103
modified	I-T103
proteins	I-T103
by	O
western	B-T058
blotting	I-T058
.	O

High	B-T033
glucose	I-T033
induced	O
GLUT1	B-T103
expression	B-T038
,	O
increased	O
ROS	B-T103
and	O
inhibited	O
GAPDH	B-T103
.	O

Also	O
it	O
increased	O
the	O
polyol	B-T103
pathway	B-T038
product	O
sorbitol	B-T103
,	O
PKC	B-T103
activity	B-T038
,	O
the	O
level	O
of	O
the	O
O	B-T103
-	I-T103
GlcNAc	I-T103
-	I-T103
modified	I-T103
proteins	I-T103
that	O
produced	O
by	O
the	O
hexosamine	B-T103
pathway	B-T038
and	O
the	O
advanced	B-T103
glycation	I-T103
endproducts	I-T103
'	I-T103
precursor	O
methylglyoxal	B-T103
.	O

Co	O
-	O
treatment	O
of	O
GEnC	B-T017
with	O
tryptophanol	B-T103
restored	O
the	O
above	O
high	B-T033
-	I-T033
glucose	I-T033
-	O
induced	O
alterations	O
.	O

Activation	B-T038
of	O
GCN2	B-T103
kinase	I-T103
protects	O
GEnC	B-T017
from	O
high	B-T033
-	I-T033
glucose	I-T033
-	O
induced	O
harmful	O
molecular	B-T038
pathways	I-T038
.	O

By	O
inhibiting	O
concurrently	O
many	O
pathways	B-T038
involved	O
in	O
DN	B-T038
pathogenesis	B-T038
,	O
GCN2	B-T103
kinase	I-T103
may	O
serve	O
as	O
a	O
pharmaceutical	B-T091
target	O
for	O
the	O
treatment	B-T058
of	O
DN	B-T038
.	O

Juicer	B-T170
Provides	O
a	O
One	O
-	O
Click	O
System	O
for	O
Analyzing	B-T062
Loop	B-T058
-	I-T058
Resolution	I-T058
Hi	I-T058
-	I-T058
C	I-T058
Experiments	I-T058

Hi	B-T058
-	I-T058
C	I-T058
experiments	I-T058
explore	O
the	O
3D	B-T082
structure	I-T082
of	O
the	O
genome	B-T017
,	O
generating	O
terabases	B-T170
of	I-T170
data	I-T170
to	O
create	O
high	O
-	O
resolution	O
contact	O
maps	O
.	O

Here	O
,	O
we	O
introduce	O
Juicer	B-T170
,	O
an	O
open	B-T170
-	I-T170
source	I-T170
tool	I-T170
for	O
analyzing	O
terabase	O
-	O
scale	O
Hi	B-T170
-	I-T170
C	I-T170
datasets	I-T170
.	O

Juicer	B-T170
allows	O
users	B-T098
without	O
a	O
computational	O
background	O
to	O
transform	B-T062
raw	B-T170
sequence	I-T170
data	I-T170
into	O
normalized	O
contact	O
maps	O
with	O
one	O
click	O
.	O

Juicer	B-T170
produces	O
a	O
hic	B-T170
file	I-T170
containing	O
compressed	O
contact	B-T082
matrices	I-T082
at	O
many	O
resolutions	O
,	O
facilitating	O
visualization	B-T038
and	O
analysis	B-T062
at	O
multiple	O
scales	O
.	O

Structural	B-T082
features	I-T082
,	O
such	O
as	O
loops	B-T017
and	O
domains	O
,	O
are	O
automatically	O
annotated	O
.	O

Juicer	B-T170
is	O
available	O
as	O
open	O
source	O
software	B-T170
at	O
http	O
:	O
/	O
/	O
aidenlab	O
.	O
org	O
/	O
juicer	O
/	O
.	O

BJN	O
Awards	O
2016	O
:	O
IV	B-T058
therapy	I-T058

Claire	O
Rickard	O
Professor	B-T097
of	O
Nursing	B-T097
,	O
National	O
Health	O
and	O
Medical	O
Research	O
Council	O
(	O
NHMRC	O
)	O
Centre	B-T097
of	I-T097
Research	I-T097
Excellence	I-T097
in	O
Nursing	B-T097
,	O
Griffith	O
University	O
,	O
was	O
awarded	O
second	O
place	O
in	O
the	O
BJN	O
Awards	O
2016	O
for	O
IV	B-T058
Therapy	I-T058
Nurse	B-T097
of	O
the	O
Year	O
.	O

Here	O
she	O
talks	O
about	O
the	O
she	O
has	O
done	O
to	O
be	O
recognised	O
in	O
this	O
field	O
.	O

Stressful	O
life	O
events	O
and	O
leucocyte	B-T038
telomere	I-T038
length	I-T038
:	O
Do	O
lifestyle	B-T201
factors	I-T201
,	O
somatic	O
and	O
mental	B-T038
health	I-T038
,	O
or	O
low	B-T038
grade	I-T038
inflammation	I-T038
mediate	O
this	O
relationship	O
?	O
Results	O
from	O
a	O
cohort	B-T098
of	O
Danish	B-T098
men	I-T098
born	B-T038
in	O
1953	O

Exposure	O
to	O
psychosocial	O
stress	B-T033
is	O
associated	O
with	O
increased	O
risk	O
of	O
a	O
number	O
of	O
somatic	O
and	O
mental	B-T038
disorders	I-T038
with	O
relation	O
to	O
immune	B-T022
system	I-T022
functioning	O
.	O

We	O
aimed	O
to	O
explore	O
whether	O
stressful	O
events	O
in	O
early	O
and	O
recent	O
life	O
was	O
associated	O
with	O
leucocyte	B-T038
telomere	I-T038
length	I-T038
(	O
TL	B-T038
)	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
accumulated	B-T033
burden	O
of	O
inflammation	B-T038
and	O
oxidative	B-T038
stress	I-T038
occurring	O
during	O
the	O
life	O
course	O
.	O

We	O
specifically	O
aimed	O
to	O
address	O
whether	O
childhood	O
constitutes	O
a	O
sensitive	O
period	O
and	O
how	O
much	O
of	O
the	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	B-T038
is	O
mediated	O
through	O
somatic	O
and	O
mental	B-T038
health	I-T038
,	O
lifestyle	O
,	O
and	O
markers	B-T201
of	O
low	B-T038
-	I-T038
grade	I-T038
inflammation	I-T038
.	O

A	O
cohort	B-T098
of	O
Danish	B-T098
men	I-T098
born	B-T038
in	O
1953	O
has	O
been	O
followed	O
since	O
birth	B-T038
in	O
the	O
Metropolit	B-T098
Cohort	I-T098
.	O

These	O
men	B-T098
underwent	O
a	O
health	B-T058
examination	I-T058
including	O
blood	B-T058
sampling	I-T058
in	O
2010	O
and	O
a	O
subset	O
of	O
324	O
also	O
had	O
a	O
quantitative	B-T058
PCR	I-T058
-	I-T058
based	I-T058
measurement	I-T058
of	O
TL	B-T038
.	O

The	O
relation	O
between	O
stressful	O
life	O
events	O
and	O
TL	B-T038
was	O
analysed	O
using	O
structural	O
equation	O
modelling	O
,	O
which	O
also	O
provided	O
an	O
estimate	O
of	O
the	O
proportion	O
of	O
the	O
total	O
effect	O
mediated	O
by	O
somatic	O
and	O
mental	B-T038
health	I-T038
(	O
cardiovascular	B-T038
disease	I-T038
,	O
body	O
mass	O
and	O
depressive	B-T033
mood	I-T033
)	O
,	O
lifestyle	B-T201
factors	I-T201
,	O
and	O
low	B-T038
grade	I-T038
inflammation	I-T038
(	O
C	B-T103
-	I-T103
reactive	I-T103
protein	I-T103
(	O
CRP	B-T103
)	O
,	O
interleukin	B-T103
(	I-T103
IL	I-T103
)	I-T103
-	I-T103
6	I-T103
and	O
IL	B-T103
-	I-T103
10	I-T103
)	O
.	O

Total	O
number	O
of	O
stressful	O
events	O
experienced	O
during	O
the	O
life	O
course	O
was	O
not	O
associated	O
with	O
TL	B-T038
.	O

In	O
terms	O
of	O
sensitive	O
periods	O
,	O
we	O
found	O
that	O
number	O
of	O
stressful	O
events	O
in	O
childhood	O
was	O
associated	O
with	O
shorter	B-T038
TL	I-T038
(	O
βper	O
number	O
stressful	O
events	O
in	O
childhood	O
=	O
-	O
0	O
.	O
02	O
(	O
SE	O
=	O
-	O
0	O
.	O
02	O
)	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

This	O
relation	O
was	O
particularly	O
strong	O
for	O
being	O
placed	O
away	O
from	O
home	B-T082
(	O
β	O
=	O
-	O
0	O
.	O
16	O
;	O
P	O
<	O
0	O
.	O
000	O
)	O
.	O

Thirty	O
percent	O
of	O
the	O
total	O
effect	O
of	O
stressful	O
events	O
in	O
childhood	O
on	O
TL	B-T038
was	O
mediated	O
by	O
the	O
included	O
variables	O
,	O
with	O
the	O
largest	O
proportion	O
being	O
mediated	O
through	O
depressive	B-T033
mood	I-T033
(	O
16	O
%	O
)	O
and	O
CRP	B-T103
(	O
9	O
%	O
)	O
.	O

This	O
study	O
suggests	O
that	O
stressful	O
events	O
in	O
childhood	O
are	O
associated	O
with	O
shorter	B-T038
TL	I-T038
in	O
middle	O
-	O
aged	O
men	O
and	O
that	O
part	O
of	O
this	O
relation	O
is	O
explained	O
by	O
depressive	B-T038
mood	I-T038
and	O
low	B-T038
grade	I-T038
inflammation	I-T038
.	O

Description	B-T170
of	O
Ancylomarina	B-T007
subtilis	I-T007
gen	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	O
isolated	O
from	O
coastal	B-T082
sediment	I-T082
,	O
proposal	O
of	O
Marinilabiliales	B-T007
ord	I-T007
.	I-T007
nov	I-T007
.	I-T007
and	O
transfer	O
of	O
Marinilabiliaceae	B-T007
,	O
Prolixibacteraceae	B-T007
and	O
Marinifilaceae	B-T007
to	O
the	O
order	B-T170
Marinilabiliales	B-T007

A	O
Gram	B-T007
-	I-T007
stain	I-T007
-	I-T007
negative	I-T007
,	O
facultatively	B-T007
anaerobic	I-T007
,	O
moderately	O
halophilic	O
,	O
filamentous	O
,	O
non	B-T007
-	I-T007
motile	I-T007
bacterium	I-T007
,	O
designated	O
FA102T	B-T007
,	O
was	O
isolated	O
from	O
marine	O
sediment	O
of	O
the	O
coast	B-T082
of	O
Weihai	B-T082
,	I-T082
China	I-T082
.	O

Phylogenetic	B-T062
analysis	I-T062
based	O
on	O
16S	B-T103
rRNA	I-T103
gene	I-T103
sequences	I-T103
showed	O
that	O
strain	O
FA102T	B-T007
formed	O
a	O
distinct	O
evolutionary	B-T038
lineage	O
within	O
the	O
family	O
Marinifilaceae	B-T007
and	O
its	O
closest	B-T033
relative	I-T033
was	O
Marinifilum	B-T007
fragile	I-T007
JCM	I-T007
15579T	I-T007
(	O
93	O
.	O
2	O
%	O
sequence	O
similarity	O
)	O
.	O

The	O
DNA	B-T103
G	O
+	O
C	O
content	O
of	O
the	O
novel	O
strain	O
was	O
36	O
.	O
5	O
mol	O
%	O
.	O

The	O
predominant	O
cellular	B-T017
fatty	B-T103
acids	I-T103
and	O
respiratory	O
quinone	B-T103
were	O
iso	B-T103
-	I-T103
C15	I-T103
:	I-T103
0	I-T103
and	O
iso	B-T103
-	I-T103
C15	I-T103
:	I-T103
0	I-T103
3	I-T103
-	I-T103
OH	I-T103
,	O
and	O
MK	B-T103
-	I-T103
7	I-T103
,	O
respectively	O
.	O

On	O
the	O
basis	O
of	O
the	O
phylogenetic	O
,	O
phenotypic	O
and	O
physiological	O
data	O
,	O
strain	O
FA102T	B-T007
represents	O
a	O
novel	O
genus	B-T170
and	O
species	B-T170
,	O
for	O
which	O
the	O
name	O
Ancylomarina	B-T007
subtilis	I-T007
gen	I-T007
.	I-T007

nov	I-T007
.	I-T007
,	I-T007
sp	I-T007
.	I-T007

nov	I-T007
.	I-T007

is	O
proposed	O
.	O

The	O
type	O
strain	O
of	O
Ancylomarina	B-T007
subtilis	I-T007
is	O
FA102T	B-T007
(	O
=	O
KCTC	B-T007
42257T	I-T007
=	O
DSM	B-T007
28825T	I-T007
=	O
CICC	B-T007
10902T	I-T007
)	O
.	O

Furthermore	O
,	O
a	O
new	O
order	B-T170
named	O
Marinilabiliales	B-T007
is	O
proposed	O
to	O
accommodate	B-T033
three	O
families	O
previously	O
classified	B-T170
in	O
the	O
order	B-T170
Bacteroidales	B-T007
.	O

Marinilabiliales	B-T007
ord	I-T007
.	I-T007

nov	I-T007
.	I-T007

encompasses	O
the	O
families	O
Marinilabiliaceae	B-T007
,	O
Prolixibacteraceae	B-T007
and	O
Marinifilaceae	B-T007
.	O

Treatment	B-T058
for	O
Rheumatoid	B-T038
Arthritis	I-T038
and	O
Risk	B-T033
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
Disease	I-T038
:	O
A	O
Nested	B-T062
Case	I-T062
-	I-T062
Control	I-T062
Analysis	I-T062

It	O
is	O
increasingly	O
becoming	O
accepted	O
that	O
inflammation	B-T038
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	B-T038
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
,	O
as	O
several	O
immune	B-T022
-	O
related	O
genes	B-T017
have	O
been	O
associated	O
with	O
AD	B-T038
.	O

Among	O
these	O
is	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
(	I-T103
TNF	I-T103
)	I-T103
-	I-T103
α	I-T103
,	O
a	O
proinflammatory	B-T103
cytokine	I-T103
known	O
to	O
play	O
an	O
important	O
role	O
in	O
autoimmune	B-T038
disorders	I-T038
,	O
including	O
rheumatoid	B-T038
arthritis	I-T038
(	O
RA	B-T038
)	O
.	O

Although	O
AD	B-T038
and	O
RA	B-T038
appear	O
to	O
involve	O
similar	O
pathological	B-T038
mechanisms	I-T038
through	O
the	O
production	B-T038
of	O
TNF	B-T103
-	I-T103
α	I-T103
,	I-T103
the	O
relationship	O
between	O
AD	B-T038
and	O
RA	B-T038
remains	O
unknown	O
.	O

To	O
determine	O
the	O
relative	O
risk	O
of	O
AD	B-T038
among	O
RA	B-T038
patients	O
and	O
non	O
-	O
RA	B-T038
patients	O
,	O
and	O
whether	O
anti	B-T058
-	I-T058
TNF	I-T058
therapy	I-T058
for	O
RA	B-T038
was	O
associated	O
with	O
a	O
lower	O
risk	B-T033
of	O
AD	B-T038
in	O
RA	B-T038
patients	O
.	O

We	O
performed	O
a	O
nested	B-T062
case	I-T062
-	I-T062
control	I-T062
study	I-T062
of	O
more	O
than	O
8	O
.	O
5	O
million	O
commercially	O
insured	O
adults	O
(	O
aged	O
≥18	O
years	O
)	O
in	O
all	O
50	O
US	B-T082
states	I-T082
,	O
Puerto	B-T082
Rico	I-T082
,	O
and	O
US	B-T082
Virgin	I-T082
Islands	I-T082
in	O
the	O
Verisk	B-T170
Health	I-T170
claims	I-T170
database	I-T170
.	O

We	O
derived	O
a	O
sub	B-T098
-	I-T098
cohort	I-T098
of	O
subjects	O
with	O
a	O
diagnosis	B-T033
of	O
RA	B-T038
(	O
controls	O
)	O
,	O
or	O
RA	B-T038
and	O
AD	B-T038
(	O
cases	O
)	O
,	O
matching	B-T062
cases	O
and	O
controls	O
based	O
on	O
age	O
,	O
sex	O
,	O
exposure	O
assessment	O
period	O
,	O
and	O
methotrexate	O
treatment	O
.	O

We	O
also	O
assessed	B-T058
relative	I-T058
risk	I-T058
of	O
AD	B-T038
following	O
exposure	O
to	O
standard	O
RA	B-T038
therapies	B-T058
,	O
including	O
anti	B-T103
-	I-T103
TNF	I-T103
agents	I-T103
(	O
infliximab	B-T103
,	O
adalimumab	B-T103
,	O
etanercept	B-T103
)	O
,	O
methotrexate	B-T103
,	O
prednisone	B-T103
,	O
sulfasalazine	B-T103
,	O
and	O
rituximab	B-T103
.	O

Odds	O
ratios	O
were	O
adjusted	O
for	O
comorbidities	O
,	O
including	O
coronary	B-T038
artery	I-T038
disease	I-T038
,	O
diabetes	B-T038
mellitus	I-T038
,	O
and	O
peripheral	B-T038
vascular	I-T038
disease	I-T038
.	O

AD	B-T038
was	O
more	O
prevalent	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
among	O
RA	B-T038
patients	O
(	O
0	O
.	O
79	O
%	O
)	O
than	O
among	O
those	O
without	O
RA	B-T038
(	O
0	O
.	O
11	O
%	O
)	O
.	O

Chronic	B-T033
conditions	I-T033
such	O
as	O
coronary	B-T038
artery	I-T038
disease	I-T038
(	O
odds	O
ratio	O
[	O
OR	O
]	O
1	O
.	O
48	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
1	O
.	O
04	O
-	O
2	O
.	O
05	O
;	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
diabetes	B-T038
(	O
OR	O
1	O
.	O
86	O
;	O
95	O
%	O
CI	O
1	O
.	O
32	O
-	O
2	O
.	O
62	O
;	O
p	O
=	O
0	O
.	O
0004	O
)	O
,	O
and	O
peripheral	B-T038
vascular	I-T038
disease	I-T038
(	O
OR	O
1	O
.	O
61	O
;	O
95	O
%	O
CI	O
1	O
.	O
06	O
-	O
2	O
.	O
43	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
significantly	O
increased	O
the	O
relative	O
risk	O
of	O
AD	B-T038
among	O
RA	B-T038
patients	O
.	O

Exposure	O
to	O
anti	B-T103
-	I-T103
TNF	I-T103
agents	I-T103
as	O
a	O
class	O
,	O
but	O
not	O
other	O
immunosuppressive	B-T103
drugs	I-T103
studied	O
,	O
was	O
associated	O
with	O
lowered	O
risk	B-T033
of	O
AD	B-T038
among	O
RA	B-T038
patients	O
(	O
unadjusted	O
OR	O
0	O
.	O
44	O
;	O
95	O
%	O
CI	O
0	O
.	O
22	O
-	O
0	O
.	O
87	O
;	O
p	O
=	O
0	O
.	O
02	O
;	O
adjusted	O
OR	O
0	O
.	O
45	O
;	O
95	O
%	O
CI	O
0	O
.	O
23	O
-	O
0	O
.	O
90	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

Sub	O
-	O
group	O
analysis	O
demonstrated	O
that	O
of	O
the	O
three	O
anti	B-T103
-	I-T103
TNF	I-T103
agents	I-T103
studied	O
,	O
only	O
etanercept	B-T103
(	O
unadjusted	O
OR	O
,	O
0	O
.	O
33	O
;	O
95	O
%	O
CI	O
0	O
.	O
08	O
-	O
0	O
.	O
94	O
;	O
p	O
=	O
0	O
.	O
03	O
;	O
adjusted	O
OR	O
0	O
.	O
30	O
;	O
95	O
%	O
CI	O
0	O
.	O
08	O
-	O
0	O
.	O
89	O
;	O
p	O
=	O
0	O
.	O
02	O
)	O
was	O
associated	O
with	O
a	O
decreased	O
risk	B-T033
of	O
AD	B-T038
in	O
RA	B-T038
patients	O
.	O

There	O
is	O
an	O
increased	O
risk	B-T033
of	O
AD	B-T038
in	O
the	O
studied	O
RA	B-T038
population	O
.	O

The	O
relative	O
risk	O
of	O
AD	B-T038
among	O
RA	B-T038
subjects	O
was	O
lowered	O
in	O
those	O
exposed	O
to	O
etanercept	B-T103
.	O

Anti	B-T058
-	I-T058
TNF	I-T058
therapy	I-T058
with	O
etanercept	B-T103
shows	O
promise	O
as	O
a	O
potential	O
treatment	B-T058
for	O
AD	B-T038
.	O

Dimerization	O
of	O
EGFR	B-T103
and	O
HER2	B-T103
induces	O
breast	B-T038
cancer	I-T038
cell	B-T038
motility	I-T038
through	O
STAT1	B-T103
-	O
dependent	O
ACTA2	B-T103
induction	O

The	O
dimerization	O
of	O
EGFR	B-T103
and	O
HER2	B-T103
is	O
associated	O
with	O
poor	O
prognosis	B-T058
such	O
as	O
induction	O
of	O
tumor	O
growth	O
and	O
cell	B-T038
invasion	I-T038
compared	O
to	O
when	O
EGFR	B-T103
remains	O
as	O
a	O
homodimer	O
.	O

However	O
,	O
the	O
mechanism	O
for	O
events	O
after	O
dimerization	O
in	O
breast	B-T038
cancer	I-T038
models	O
is	O
not	O
clear	O
.	O

We	O
found	O
that	O
expressions	B-T038
of	O
alpha	B-T103
-	I-T103
smooth	I-T103
muscle	I-T103
actin	I-T103
(	O
ACTA2	B-T103
)	O
and	O
signal	B-T103
transducer	I-T103
and	I-T103
activator	I-T103
of	I-T103
transcription	I-T103
1	I-T103
(	O
STAT1	B-T103
)	O
significantly	O
increased	O
with	O
transient	O
or	O
stable	O
overexpression	B-T038
of	O
HER2	B-T103
in	O
EGFR	B-T103
-	O
positive	B-T033
breast	B-T038
cancer	I-T038
cells	B-T017
.	O

ACTA2	B-T103
and	O
STAT1	B-T103
expression	B-T038
was	O
also	O
increased	O
in	O
HER2	B-T103
-	O
positive	B-T033
breast	B-T038
cancer	I-T038
patients	O
.	O

In	O
contrast	O
,	O
ACTA2	B-T103
expression	B-T038
was	O
decreased	O
by	O
HER2	B-T103
siRNA	I-T103
.	O

Next	O
,	O
we	O
investigated	O
the	O
co	O
-	O
relation	O
between	O
STAT1	B-T103
and	O
ACTA2	B-T103
expression	B-T038
.	O

Basal	O
ACTA2	B-T103
expression	B-T038
was	O
significantly	O
decreased	O
by	O
treatment	B-T058
with	O
the	O
STAT1	B-T103
inhibitor	I-T103
fludarabine	B-T103
or	O
the	O
JAK2	B-T103
inhibitor	I-T103
AG490	B-T103
.	O

In	O
contrast	O
,	O
ACTA2	B-T103
expression	B-T038
was	O
increased	O
by	O
STAT1	B-T103
overexpression	B-T038
.	O

Levels	O
of	O
ACTA2	B-T103
,	O
STAT1	B-T103
,	O
and	O
HER2	B-T103
were	O
increased	O
and	O
relapse	O
free	O
survival	O
was	O
decreased	O
in	O
high	B-T033
-	I-T033
risk	I-T033
breast	B-T038
cancer	I-T038
patients	O
.	O

We	O
also	O
investigated	O
the	O
effect	O
of	O
ACTA2	B-T103
on	O
cell	B-T038
motility	I-T038
,	O
which	O
was	O
suppressed	O
by	O
ACTA2	B-T103
shRNA	I-T103
overexpression	B-T038
in	O
MDA	B-T017
-	I-T017
MB231	I-T017
HER2	B-T103
and	O
4T1	B-T017
mammary	I-T017
carcinoma	I-T017
cells	I-T017
.	O

The	O
number	O
of	O
lung	B-T033
metastatic	I-T033
nodules	I-T033
was	O
significantly	O
decreased	O
in	O
ACTA2	B-T103
knockdown	B-T204
mice	I-T204
.	O

Taken	O
together	O
,	O
these	O
results	O
demonstrated	O
that	O
induction	O
of	O
ACTA2	B-T103
by	O
EGFR	B-T103
and	O
HER2	B-T103
dimerization	O
was	O
regulated	O
through	O
a	O
JAK2	B-T103
/	O
STAT1	B-T103
signaling	B-T038
pathway	I-T038
,	O
and	O
aberrant	O
ACTA2	B-T103
expression	B-T038
accelerated	O
the	O
invasiveness	B-T038
and	O
metastasis	B-T038
of	O
breast	B-T038
cancer	I-T038
cells	B-T017
.	O

Intensive	O
social	O
cognitive	B-T058
treatment	I-T058
(	O
can	O
do	O
treatment	O
)	O
with	O
participation	O
of	O
support	O
partners	B-T098
in	O
persons	B-T098
with	O
relapsing	B-T038
remitting	I-T038
multiple	I-T038
sclerosis	I-T038
:	O
observation	B-T058
of	O
improved	B-T033
self	B-T038
-	I-T038
efficacy	I-T038
,	O
quality	O
of	O
life	O
,	O
anxiety	B-T033
and	O
depression	B-T038
1	O
year	O
later	O

In	O
persons	B-T098
with	O
multiple	B-T038
sclerosis	I-T038
(	O
MS	B-T038
)	O
self	B-T038
-	I-T038
efficacy	I-T038
positively	B-T033
affects	O
health	O
-	O
related	O
quality	O
of	O
life	O
(	O
HRQoL	O
)	O
and	O
physical	O
activity	O
.	O

In	O
a	O
previous	O
study	O
we	O
observed	O
that	O
6	O
months	O
after	O
an	O
intensive	O
3	O
-	O
day	O
social	O
cognitive	B-T058
treatment	I-T058
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	B-T098
,	O
self	B-T038
-	I-T038
efficacy	I-T038
and	O
HRQoL	O
had	O
improved	B-T033
in	O
persons	B-T098
with	O
relapsing	B-T038
remitting	I-T038
MS	I-T038
(	O
RRMS	B-T038
)	O
.	O

Given	O
the	O
chronic	O
nature	O
of	O
the	O
disease	O
,	O
it	O
is	O
important	O
to	O
know	O
whether	O
these	O
beneficial	O
changes	O
may	O
last	O
.	O

Can	O
Do	O
treatment	O
was	O
given	O
to	O
60	O
persons	B-T098
with	O
MS	B-T038
and	O
their	O
support	O
partners	B-T098
.	O

At	O
baseline	O
and	O
12	O
months	O
after	O
treatment	B-T058
self	B-T038
-	I-T038
efficacy	I-T038
control	O
,	O
self	B-T038
-	I-T038
efficacy	I-T038
function	O
,	O
physical	O
and	O
mental	B-T038
HRQoL	O
,	O
anxiety	B-T033
,	O
depression	B-T038
and	O
fatigue	B-T033
were	O
assessed	O
via	O
self	B-T062
-	I-T062
report	I-T062
questionnaires	B-T170
.	O

Differences	O
were	O
tested	O
via	O
a	O
paired	B-T170
t	I-T170
test	I-T170
.	O

Of	O
the	O
57	O
persons	B-T098
with	O
MS	B-T038
that	O
completed	O
the	O
baseline	O
assessment	O
and	O
the	O
3	O
-	O
day	O
treatment	O
,	O
38	O
filled	O
in	O
the	O
12th	O
month	O
questionnaires	B-T170
(	O
response	B-T033
rate	O
66	O
.	O
7	O
%	O
)	O
,	O
22	O
with	O
RRMS	B-T038
and	O
14	O
with	O
progressive	O
MS	B-T038
.	O

In	O
the	O
RR	B-T038
group	O
self	B-T038
-	I-T038
efficacy	I-T038
control	O
had	O
increased	O
by	O
20	O
.	O
2	O
%	O
and	O
physical	O
HRQoL	O
by	O
15	O
.	O
0	O
%	O
,	O
and	O
depression	B-T038
and	O
anxiety	B-T033
had	O
decreased	O
by	O
29	O
.	O
8	O
and	O
25	O
.	O
9	O
%	O
,	O
respectively	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
the	O
changes	O
in	O
mental	B-T038
HRQoL	O
(	O
+	O
17	O
%	O
)	O
and	O
fatigue	B-T033
(	O
-	O
20	O
%	O
)	O
failed	O
to	O
be	O
statistically	O
significant	O
(	O
P	O
=	O
0	O
.	O
087	O
,	O
P	O
=	O
0	O
.	O
080	O
,	O
respectively	O
)	O
.	O

In	O
the	O
progressive	O
group	O
no	O
changes	O
suggestive	O
of	O
improvement	O
were	O
seen	O
.	O

The	O
findings	O
suggest	O
that	O
a	O
3	O
-	O
day	O
intensive	O
social	O
cognitive	B-T058
treatment	I-T058
(	O
Can	O
Do	O
treatment	O
)	O
with	O
the	O
participation	O
of	O
support	O
partners	B-T098
may	O
have	O
long	O
lasting	O
beneficial	O
effects	O
on	O
the	O
self	B-T038
-	I-T038
efficacy	I-T038
and	O
HRQoL	O
in	O
persons	B-T098
with	O
RRMS	B-T038
;	O
and	O
that	O
improvements	O
in	O
anxiety	B-T033
and	O
depression	B-T038
,	O
not	O
seen	O
in	O
the	O
6	O
-	O
month	O
study	O
,	O
may	O
yet	O
develop	O
at	O
12	O
months	O
.	O

Perineal	B-T037
injuries	I-T037
and	O
birth	B-T033
positions	I-T033
among	O
2992	O
women	B-T098
with	O
a	O
low	B-T033
risk	I-T033
pregnancy	I-T033
who	O
opted	O
for	O
a	O
homebirth	B-T033

Whether	O
certain	O
birth	B-T033
positions	I-T033
are	O
associated	O
with	O
perineal	B-T037
injuries	I-T037
and	O
severe	O
perineal	O
trauma	O
(	O
SPT	O
)	O
is	O
still	O
unclear	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
describe	O
the	O
prevalence	O
of	O
perineal	B-T037
injuries	I-T037
of	O
different	O
severity	O
in	O
a	O
low	O
-	O
risk	O
population	B-T098
of	O
women	B-T098
who	O
planned	O
to	O
give	O
birth	B-T033
at	I-T033
home	I-T033
and	O
to	O
compare	O
the	O
prevalence	O
of	O
perineal	B-T037
injuries	I-T037
,	O
SPT	O
and	O
episiotomy	B-T058
in	O
different	O
birth	B-T033
positions	I-T033
in	O
four	O
Nordic	B-T082
countries	I-T082
.	O

A	O
population	B-T098
-	O
based	O
prospective	B-T062
cohort	I-T062
study	I-T062
of	O
planned	O
home	B-T033
births	I-T033
in	O
four	O
Nordic	B-T082
countries	I-T082
.	O

To	O
assess	O
medical	O
outcomes	O
a	O
questionnaire	B-T170
completed	O
after	O
birth	B-T038
by	O
the	O
attending	O
midwife	B-T097
was	O
used	O
.	O

Descriptive	B-T062
statistics	I-T062
,	O
bivariate	O
analysis	O
and	O
logistic	B-T062
regression	I-T062
were	O
used	O
to	O
analyze	O
the	O
data	O
.	O

Two	O
thousand	O
nine	O
hundred	O
ninety	O
-	O
two	O
women	B-T098
with	O
planned	O
home	B-T033
births	I-T033
,	O
who	O
birthed	O
spontaneously	O
at	O
home	B-T082
or	O
after	O
transfer	B-T058
to	I-T058
hospital	I-T058
,	O
between	O
2008	O
and	O
2013	O
were	O
included	O
.	O

The	O
prevalence	O
of	O
SPT	O
was	O
0	O
.	O
7	O
%	O
and	O
the	O
prevalence	O
of	O
episiotomy	B-T058
was	O
1	O
.	O
0	O
%	O
.	O

There	O
were	O
differences	O
between	O
the	O
countries	O
regarding	O
all	O
maternal	B-T033
characteristics	O
.	O

No	O
association	O
between	O
flexible	O
sacrum	B-T082
positions	B-T082
and	O
sutured	O
perineal	B-T037
injuries	I-T037
was	O
found	O
(	O
OR	O
1	O
.	O
02	O
;	O
95	O
%	O
CI	O
0	O
.	O
86	O
-	O
1	O
.	O
21	O
)	O
or	O
SPT	O
(	O
OR	O
0	O
.	O
68	O
;	O
CI	O
95	O
%	O
0	O
.	O
26	O
-	O
1	O
.	O
79	O
)	O
.	O

Flexible	O
sacrum	B-T082
positions	B-T082
were	O
associated	O
with	O
fewer	O
episiotomies	B-T058
(	O
OR	O
0	O
.	O
20	O
;	O
CI	O
95	O
%	O
0	O
.	O
10	O
-	O
0	O
.	O
54	O
)	O
.	O

A	O
low	O
prevalence	O
of	O
SPT	O
and	O
episiotomy	B-T058
was	O
found	O
among	O
women	B-T098
opting	O
for	O
a	O
home	B-T033
birth	I-T033
in	O
four	O
Nordic	B-T082
countries	I-T082
.	O

Women	B-T098
used	O
a	O
variety	O
of	O
birth	B-T033
positions	I-T033
and	O
a	O
majority	O
gave	O
birth	B-T038
in	O
flexible	O
sacrum	B-T082
positions	B-T082
.	O

No	O
associations	O
were	O
found	O
between	O
flexible	O
sacrum	B-T082
positions	B-T082
and	O
SPT	O
.	O

Flexible	O
sacrum	B-T082
positions	B-T082
were	O
associated	O
with	O
fewer	O
episiotomies	B-T058
.	O

Parallel	O
-	O
processing	O
continuous	O
-	O
flow	O
device	O
for	O
optimization	O
-	O
free	O
polymerase	B-T062
chain	I-T062
reaction	I-T062

A	O
parallel	O
-	O
processing	O
four	B-T062
-	I-T062
station	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
PCR	B-T062
)	O
device	O
has	O
been	O
developed	O
,	O
which	O
performs	O
continuous	O
-	O
flow	O
PCR	B-T062
without	O
optimization	O
of	O
the	O
annealing	B-T038
temperature	O
.	O

Since	O
the	O
annealing	B-T038
temperature	O
of	O
each	O
station	O
can	O
be	O
controlled	O
independently	O
,	O
the	O
device	O
covers	O
an	O
annealing	B-T038
temperature	O
range	O
of	O
50	O
-	O
68	O
°C	O
,	O
which	O
is	O
wide	B-T082
enough	O
to	O
perform	O
PCR	B-T062
for	O
any	O
DNA	O
fragment	O
regardless	O
of	O
its	O
optimum	O
annealing	B-T038
condition	O
.	O

This	O
arrangement	O
lets	O
us	O
continuously	O
obtain	O
an	O
amplified	O
amount	O
of	O
a	O
DNA	O
fragment	O
at	O
least	O
from	O
one	O
of	O
the	O
stations	O
.	O

The	O
device	O
consists	O
of	O
four	O
identical	O
cylindrical	B-T082
stations	O
(	O
diameter	O
20	O
mm	O
,	O
height	O
55	O
mm	O
)	O
.	O

A	O
polytetrafluoroethylene	B-T103
capillary	B-T074
reactor	I-T074
(	O
length	O
2	O
m	O
,	O
I	O
.	O
D	O
.	O

100	O
μm	O
,	O
O	O
.	O
D	O
.	O

400	O
μm	O
)	O
is	O
wound	B-T082
helically	I-T082
up	B-T082
around	O
each	O
station	O
.	O

The	O
whole	O
assembly	O
is	O
designed	O
to	O
minimize	O
the	O
number	O
of	O
heating	O
blocks	O
(	O
for	O
providing	O
temperatures	O
of	O
denaturation	B-T038
,	O
annealing	B-T038
,	O
and	O
extension	O
)	O
to	O
be	O
seven	O
and	O
to	O
shape	B-T082
a	O
compact	B-T033
cube	B-T082
(	O
height	O
55	O
mm	O
,	O
base	O
60	O
mm	O
×	O
60	O
mm	O
)	O
.	O

The	O
reproducibility	O
for	O
continuous	O
-	O
flow	O
PCR	B-T062
is	O
reasonably	O
high	O
(	O
run	O
-	O
to	O
-	O
run	O
and	O
station	O
-	O
to	O
-	O
station	O
relative	O
standard	O
deviation	O
of	O
their	O
amplification	B-T038
is	O
lower	O
than	O
6	O
%	O
and	O
about	O
4	O
%	O
,	O
respectively	O
)	O
.	O

Performance	O
on	O
the	O
optimization	O
-	O
free	O
DNA	B-T038
amplification	I-T038
has	O
been	O
evaluated	B-T058
with	O
four	O
DNA	B-T017
samples	I-T017
with	O
different	O
annealing	B-T038
conditions	O
and	O
product	O
sizes	B-T082
(	O
323	O
,	O
608	O
,	O
828	O
,	O
and	O
1101	O
bp	O
)	O
,	O
which	O
has	O
demonstrated	O
that	O
in	O
all	O
cases	O
,	O
PCR	B-T062
is	O
successful	O
at	O
least	O
on	O
one	O
station	O
.	O

In	O
addition	O
,	O
three	O
DNA	O
fragment	O
s	O
with	O
different	O
lengths	O
(	O
323	O
,	O
1101	O
,	O
and	O
2836	O
bp	O
)	O
have	O
been	O
successfully	O
amplified	O
in	O
a	O
segmented	B-T082
-	O
flow	O
mode	O
without	O
the	O
carry	O
-	O
over	O
contamination	O
between	O
segments	B-T082
.	O

This	O
result	O
suggests	O
that	O
this	O
device	O
could	O
serve	O
as	O
the	O
PCR	B-T062
module	O
of	O
a	O
continuous	O
-	O
flow	O
high	O
-	O
throughput	O
on	O
-	O
line	O
total	O
DNA	O
analysis	O
system	O
integrating	O
all	O
necessary	O
modules	O
from	O
cell	B-T017
lysis	B-T038
/	O
DNA	B-T062
extraction	I-T062
to	O
PCR	B-T062
product	O
analysis	B-T062
.	O

Assessing	O
sex	O
-	O
differences	O
and	O
the	O
effect	O
of	O
timing	O
of	O
vaccination	B-T058
on	O
immunogenicity	B-T038
,	O
reactogenicity	B-T033
and	O
efficacy	O
of	O
vaccines	O
in	O
young	O
children	O
:	O
study	B-T170
protocol	I-T170
for	O
an	O
individual	B-T098
participant	B-T098
data	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
randomised	B-T062
controlled	I-T062
trials	I-T062

Disease	B-T038
incidence	O
differs	O
between	O
males	O
and	O
females	O
for	O
some	O
infectious	B-T038
or	O
inflammatory	B-T038
diseases	I-T038
.	O

Sex	O
-	O
differences	O
in	O
immune	B-T038
responses	I-T038
to	O
some	O
vaccines	B-T103
have	O
also	O
been	O
observed	O
,	O
mostly	O
to	O
viral	B-T103
vaccines	I-T103
in	O
adults	O
.	O

Little	O
evidence	O
is	O
available	O
on	O
whether	O
sex	O
-	O
differences	O
occur	O
in	O
response	B-T033
to	O
immunisation	B-T058
in	O
infancy	O
even	O
though	O
this	O
is	O
the	O
age	O
group	O
in	O
which	O
most	O
vaccines	B-T103
are	O
administered	O
.	O

Factors	O
other	O
than	O
sex	O
,	O
such	O
as	O
timing	O
or	O
coadministration	B-T058
of	O
other	O
vaccines	B-T103
,	O
can	O
also	O
influence	O
the	O
immune	B-T038
response	I-T038
to	O
vaccination	B-T058
.	O

Individual	B-T098
participant	B-T098
data	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
randomised	B-T062
controlled	I-T062
trials	I-T062
of	O
vaccines	B-T103
in	O
healthy	O
infants	O
and	O
young	O
children	O
will	O
be	O
conducted	O
.	O

Fully	O
anonymised	O
data	O
from	O
∼170	O
randomised	B-T062
controlled	I-T062
trials	I-T062
of	O
v	O
accines	B-T103
for	O
diphtheria	B-T038
,	O
tetanus	B-T038
,	O
Bordetella	B-T007
pertussis	I-T007
,	O
polio	B-T038
,	O
Haemophilus	B-T007
influenzae	I-T007
type	I-T007
B	I-T007
,	O
hepatitis	B-T038
B	I-T038
,	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
Neisseria	B-T007
meningitidis	I-T007
,	O
measles	B-T038
,	O
mumps	B-T038
,	O
rubella	B-T038
,	O
varicella	B-T038
and	O
rotavirus	B-T005
will	O
be	O
combined	O
for	O
analysis	B-T062
.	O

Outcomes	O
include	O
measures	O
of	O
immunogenicity	B-T038
(	O
immunoglobulins	B-T103
)	O
,	O
reactogenicity	B-T033
,	O
safety	O
and	O
disease	B-T038
-	O
specific	O
clinical	O
efficacy	O
.	O

Data	O
from	O
trials	B-T062
of	O
vaccines	B-T103
containing	O
similar	O
components	O
will	O
be	O
combined	O
in	O
hierarchical	O
models	B-T170
and	O
the	O
effect	O
of	O
sex	O
and	O
timing	O
of	O
vaccinations	B-T058
estimated	O
for	O
each	O
outcome	O
separately	O
.	O

Systematic	B-T170
reviews	I-T170
of	O
published	O
estimates	O
of	O
sex	O
-	O
differences	O
cannot	O
adequately	O
answer	O
questions	O
in	O
this	O
field	O
since	O
such	O
comparisons	O
are	O
never	O
the	O
main	O
purpose	O
of	O
a	O
clinical	B-T062
trial	I-T062
,	O
thus	O
a	O
large	O
degree	O
of	O
reporting	B-T058
bias	O
exists	O
in	O
the	O
published	O
literature	B-T170
.	O

Recent	O
improvements	O
in	O
the	O
widespread	B-T082
availability	O
of	O
individual	B-T098
participant	B-T098
data	O
from	O
randomised	B-T062
controlled	I-T062
trials	I-T062
makes	O
it	O
feasible	O
to	O
conduct	O
extensive	O
individual	B-T098
participant	B-T098
data	O
meta	B-T062
-	I-T062
analyses	I-T062
which	O
were	O
previously	O
impossible	B-T033
,	O
thereby	O
reducing	O
the	O
effect	O
of	O
publication	B-T170
or	O
reporting	B-T058
bias	O
on	O
the	O
understanding	B-T038
of	O
the	O
infant	O
immune	B-T038
response	I-T038
.	O

Preliminary	O
results	O
will	O
be	O
available	O
in	O
2016	O
with	O
final	O
results	O
available	O
in	O
2019	O
.	O

No	O
ethics	O
review	B-T170
is	O
required	O
for	O
secondary	O
analyses	O
of	O
anonymised	O
data	O
.	O

An	O
ultrasensitive	O
electrochemiluminescence	B-T058
sensor	O
based	O
on	O
reduced	B-T103
graphene	I-T103
oxide	I-T103
-	O
copper	B-T103
sulfide	I-T103
composite	O
coupled	O
with	O
capillary	B-T058
electrophoresis	I-T058
for	O
determination	B-T058
of	O
amlodipine	B-T103
besylate	I-T103
in	O
mice	B-T204
plasma	B-T031

A	O
new	O
electrochemiluminescence	B-T058
(	O
ECL	B-T058
)	O
sensor	O
based	O
on	O
reduced	B-T103
graphene	I-T103
oxide	I-T103
-	O
copper	B-T103
sulfide	I-T103
(	O
rGO	B-T103
-	O
CuS	B-T103
)	O
composite	O
coupled	O
with	O
capillary	B-T058
electrophoresis	I-T058
(	O
CE	B-T058
)	O
was	O
constructed	O
for	O
the	O
ultrasensitive	O
detection	B-T058
of	O
amlodipine	B-T103
besylate	I-T103
(	O
AML	B-T103
)	O
for	O
the	O
first	O
time	O
.	O

In	O
this	O
work	O
,	O
rGO	B-T103
-	O
CuS	B-T103
composite	O
was	O
synthesized	O
by	O
one	O
-	O
pot	O
hydrothermal	O
method	O
and	O
used	O
for	O
electrode	B-T074
modification	B-T033
.	O

The	O
electrochemical	B-T058
and	O
ECL	B-T058
behaviors	O
of	O
the	O
sensor	O
were	O
investigated	O
.	O

More	O
than	O
5	O
-	O
fold	O
enhance	O
in	O
ECL	B-T058
intensity	O
was	O
observed	O
after	O
modified	O
with	O
rGO	B-T103
-	O
CuS	B-T103
composite	O
.	O

The	O
results	B-T033
can	O
be	O
ascribed	O
to	O
the	O
presence	O
of	O
rGO	B-T103
-	O
CuS	B-T103
composite	O
on	O
the	O
electrode	B-T074
surface	B-T082
that	O
facilitates	O
the	O
electron	O
transfer	O
rate	O
between	O
the	O
electroactive	O
center	B-T082
of	O
Ru	B-T103
(	I-T103
bpy	I-T103
)	I-T103
3	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
and	O
the	O
electrode	B-T074
.	O

The	O
ECL	B-T058
sensor	O
was	O
coupled	O
with	O
CE	B-T058
to	O
improve	O
the	O
selectivity	O
and	O
the	O
CE	B-T058
-	O
ECL	B-T058
parameters	B-T033
that	O
affect	O
separation	O
and	O
detection	B-T058
were	O
optimized	O
.	O

Under	O
the	O
optimum	O
conditions	O
,	O
the	O
linear	O
ranges	O
for	O
AML	B-T103
was	O
0	O
.	O
008	O
-	O
5	O
.	O
0μg	O
/	O
mL	O
with	O
a	O
detection	O
limit	O
of	O
2	O
.	O
8ng	O
/	O
mL	O
(	O
S	O
/	O
N	O
=	O
3	O
)	O
.	O

The	O
method	B-T058
displayed	O
the	O
advantages	O
of	O
high	O
sensitivity	O
,	O
good	O
selectivity	O
,	O
wide	O
linear	O
range	O
,	O
low	O
detection	O
limit	O
and	O
fine	O
reproducibility	O
,	O
and	O
was	O
used	O
to	O
analyze	O
AML	B-T103
in	O
mice	B-T204
plasma	B-T031
with	O
a	O
satisfactory	O
result	B-T033
,	O
which	O
holds	O
a	O
great	O
potential	O
in	O
the	O
field	O
of	O
pharmaceutical	B-T062
analysis	I-T062
.	O

Estrogen	B-T103
and	O
Progesterone	B-T103
hormone	B-T103
receptor	O
expression	O
in	O
oral	B-T038
cavity	I-T038
cancer	I-T038

Recent	O
studies	O
have	O
shown	O
an	O
increase	O
in	O
the	O
incidence	O
of	O
oral	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
OSCC	B-T038
)	O
in	O
younger	O
patients	O
.	O

The	O
hypothesis	O
that	O
tumors	B-T038
could	O
be	O
hormonally	B-T103
induced	O
during	O
pregnancy	B-T038
or	O
in	O
young	O
female	O
patients	O
without	O
the	O
well	O
-	O
known	O
risk	B-T033
factors	I-T033
alcohol	B-T038
or	O
tobacco	B-T038
abuse	I-T038
seems	O
to	O
be	O
plausible	O
.	O

Estrogen	B-T103
Receptor	I-T103
alpha	I-T103
(	O
ERα	B-T103
)	O
and	O
Progesterone	B-T103
Receptor	I-T103
(	O
PR	B-T103
)	O
expression	O
were	O
analyzed	B-T062
in	O
normal	O
oral	B-T017
mucosa	I-T017
(	O
n	O
=	O
5	O
)	O
,	O
oral	B-T033
precursor	I-T033
lesions	I-T033
(	O
simple	B-T038
hyperplasia	I-T038
,	O
n	O
=	O
11	O
;	O
squamous	B-T038
intraepithelial	I-T038
neoplasia	I-T038
,	O
SIN	B-T038
I	I-T038
-	I-T038
III	I-T038
,	O
n	O
=	O
35	O
)	O
,	O
and	O
OSCC	B-T038
specimen	O
.	O

OSCCs	B-T038
were	O
stratified	O
in	O
a	O
young	O
female	O
(	O
n	O
=	O
7	O
)	O
study	O
cohort	B-T098
and	O
older	O
patients	O
(	O
n	O
=	O
46	O
)	O
.	O

In	O
the	O
young	O
female	O
study	O
cohort	B-T098
three	O
patients	O
(	O
n	O
=	O
3	O
/	O
7	O
)	O
developed	O
OSCC	B-T038
during	O
or	O
shortly	O
after	O
pregnancy	B-T038
.	O

Breast	B-T038
cancer	I-T038
tissues	B-T017
were	O
used	O
as	O
positive	O
control	O
for	O
ERα	B-T103
and	O
PR	B-T103
expression	O
.	O

ERα	B-T103
expression	O
was	O
found	O
in	O
four	O
oral	B-T033
precursor	I-T033
lesions	I-T033
(	O
squamous	B-T038
intraepithelial	I-T038
neoplasia	I-T038
,	O
SIN	B-T038
I	I-T038
-	I-T038
III	I-T038
,	O
n	O
=	O
4	O
/	O
35	O
,	O
11	O
%	O
)	O
and	O
in	O
five	O
OSCC	B-T038
specimen	O
(	O
n	O
=	O
5	O
/	O
46	O
,	O
11	O
%	O
)	O
.	O

The	O
five	O
ERα	B-T103
positive	B-T033
OSCC	B-T038
samples	O
were	O
older	O
male	O
patients	O
.	O

All	O
patients	O
within	O
the	O
young	O
female	O
study	O
cohort	B-T098
were	O
negatively	B-T033
stained	O
for	O
both	O
ERα	B-T103
and	O
PR	B-T103
.	O

ER	B-T103
expression	O
could	O
be	O
regarded	O
as	O
a	O
seldom	O
risk	B-T033
factor	I-T033
for	O
OSCC	B-T038
.	O

PR	B-T103
expression	O
seems	O
to	O
be	O
not	O
relevant	O
for	O
the	O
development	O
of	O
OSCC	B-T038
.	O

Studying	B-T062
neuroprotective	O
effect	O
of	O
Atorvastatin	B-T103
as	O
a	O
small	B-T103
molecule	I-T103
drug	B-T103
on	O
high	B-T033
glucose	I-T033
-	O
induced	O
neurotoxicity	B-T037
in	O
undifferentiated	O
PC12	B-T017
cells	I-T017
:	O
role	O
of	O
NADPH	B-T103
oxidase	I-T103

Overproduction	O
of	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
by	O
NADPH	B-T103
oxidase	I-T103
(	O
NOX	B-T103
)	O
activation	B-T038
has	O
been	O
considered	O
the	O
essential	O
mechanism	O
induced	O
by	O
hyperglycemia	B-T038
in	O
various	O
tissues	B-T017
.	O

However	O
,	O
there	O
is	O
no	O
comprehensive	O
study	B-T062
on	O
the	O
role	O
of	O
NOXs	B-T103
in	O
high	B-T033
glucose	I-T033
(	O
HG	B-T033
)	O
-	O
induced	O
toxic	B-T037
effect	I-T037
in	O
neural	B-T017
tissues	I-T017
.	O

Recently	O
,	O
a	O
therapeutic	O
strategy	O
in	O
oxidative	O
related	O
pathologies	B-T091
has	O
been	O
introduced	O
by	O
blocking	O
the	O
undesirable	O
actions	O
of	O
NOX	B-T103
enzymes	I-T103
by	O
small	B-T103
molecules	I-T103
.	O

The	O
protective	O
roles	O
of	O
Statins	B-T103
in	O
ameliorating	O
oxidative	B-T038
stress	I-T038
by	O
NOX	B-T103
inhibition	B-T038
have	O
been	O
shown	O
in	O
some	O
tissues	B-T017
except	O
neural	B-T017
.	O

We	O
hypothesized	O
then	O
,	O
that	O
different	O
NOXs	B-T103
may	O
have	O
role	O
in	O
HG	B-T033
-	O
induced	O
neural	O
cell	O
injury	O
.	O

Furthermore	O
,	O
we	O
postulate	O
that	O
Atorvastatin	B-T103
as	O
a	O
small	B-T103
molecule	I-T103
may	O
modulate	B-T082
this	O
NOXs	B-T038
activity	I-T038
to	O
protect	O
neural	B-T017
cells	I-T017
.	O

Undifferentiated	O
PC12	B-T017
cells	I-T017
were	O
treated	B-T058
with	I-T058
HG	B-T033
(	O
140	O
mM	O
/	O
24	O
h	O
)	O
in	O
the	O
presence	B-T033
and	O
absence	O
of	O
Atorvastatin	B-T103
(	O
1	O
μM	O
/	O
96	O
h	O
)	O
.	O

The	O
cell	B-T038
viability	I-T038
was	O
measured	O
by	O
MTT	B-T062
assay	I-T062
and	O
the	O
gene	O
and	O
protein	B-T033
expressions	I-T033
profile	I-T033
of	O
NOX	B-T103
(	O
1	O
-	O
4	O
)	O
were	O
determined	O
by	O
RT	B-T062
-	I-T062
PCR	I-T062
and	O
western	B-T058
blotting	I-T058
,	O
respectively	O
.	O

Levels	O
of	O
ROS	B-T103
and	O
malondialdehyde	B-T103
(	O
MDA	B-T103
)	O
were	O
also	O
evaluated	O
.	O

Gene	B-T038
and	O
protein	B-T038
expression	I-T038
levels	O
of	O
NOX	B-T103
(	O
1	O
-	O
4	O
)	O
and	O
consequently	O
ROS	B-T103
and	O
MDA	B-T103
levels	O
were	O
elevated	O
in	O
HG	B-T033
-	O
treated	O
PC12	B-T017
cells	I-T017
.	O

Atorvastatin	B-T103
could	O
significantly	O
decrease	O
HG	B-T033
-	O
induced	O
NOXs	B-T103
,	O
ROS	B-T103
and	O
MDA	B-T103
elevation	B-T082
and	O
improve	B-T033
impaired	O
cell	B-T038
viability	I-T038
.	O

It	O
can	O
be	O
concluded	O
that	O
HG	B-T033
could	O
elevate	O
NOXs	B-T038
activity	I-T038
,	O
ROS	B-T103
and	O
MDA	B-T103
levels	O
in	O
neural	B-T017
tissues	I-T017
and	O
Atorvastatin	B-T103
as	O
a	O
small	B-T103
molecule	I-T103
NOX	B-T103
inhibitor	I-T103
drug	I-T103
may	O
prevent	O
and	O
delay	O
diabetic	B-T038
complications	I-T038
,	O
particularly	O
neuropathy	B-T038
.	O

Intravascular	B-T082
Inflammation	B-T038
Triggers	O
Intracerebral	B-T082
Activated	O
Microglia	B-T017
and	O
Contributes	O
to	O
Secondary	B-T037
Brain	I-T037
Injury	I-T037
After	O
Experimental	O
Subarachnoid	B-T038
Hemorrhage	I-T038
(	O
eSAH	B-T038
)	O

Activation	O
of	O
innate	O
immunity	O
contributes	O
to	O
secondary	B-T037
brain	I-T037
injury	I-T037
after	O
experimental	O
subarachnoid	B-T038
hemorrhage	I-T038
(	O
eSAH	B-T038
)	O
.	O

Microglia	B-T017
accumulation	B-T033
and	O
activation	O
within	O
the	O
brain	B-T017
has	O
recently	O
been	O
shown	O
to	O
induce	O
neuronal	B-T038
cell	I-T038
death	I-T038
after	O
eSAH	B-T038
.	O

In	O
isolated	O
mouse	B-T204
brain	B-T017
capillaries	B-T017
after	O
eSAH	B-T038
,	O
we	O
show	O
a	O
significantly	O
increased	O
gene	B-T038
expression	I-T038
for	O
intercellular	B-T017
adhesion	I-T017
molecule	I-T017
-	I-T017
1	I-T017
(	O
ICAM	B-T017
-	I-T017
1	I-T017
)	O
and	O
P	B-T017
-	I-T017
selectin	I-T017
.	O

Hence	O
,	O
we	O
hypothesized	O
that	O
extracerebral	O
intravascular	B-T082
inflammatory	B-T038
processes	I-T038
might	O
initiate	O
the	O
previously	O
reported	B-T058
microglia	B-T017
accumulation	B-T033
within	O
the	O
brain	B-T017
tissue	I-T017
.	O

We	O
therefore	O
induced	O
eSAH	B-T038
in	O
knockout	B-T204
mice	I-T204
for	O
ICAM	B-T017
-	I-T017
1	I-T017
(	O
ICAM	B-T017
-	I-T017
1	I-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
)	O
and	O
P	B-T017
-	I-T017
selectin	I-T017
glycoprotein	I-T017
ligand	I-T017
-	I-T017
1	I-T017
(	O
PSGL	B-T017
-	I-T017
1	I-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
)	O
to	O
find	O
a	O
significant	O
decrease	O
in	O
neutrophil	B-T017
-	O
endothelial	B-T017
interaction	B-T038
within	O
the	O
first	O
7	O
days	O
after	O
the	O
bleeding	B-T038
in	O
a	O
chronic	O
cranial	B-T082
window	O
model	O
.	O

This	O
inhibition	O
of	O
neutrophil	B-T038
recruitment	I-T038
to	O
the	O
endothelium	B-T017
results	O
in	O
significantly	O
ameliorated	B-T033
microglia	B-T017
accumulation	B-T033
and	O
neuronal	B-T038
cell	I-T038
death	I-T038
in	O
knockout	O
animals	O
in	O
comparison	O
to	O
controls	O
.	O

Our	O
results	O
suggest	O
an	O
outside	O
-	O
in	O
activation	O
of	O
the	O
CNS	B-T022
innate	I-T022
immune	B-T022
system	I-T022
at	O
the	O
vessel	B-T082
/	O
brain	B-T017
interface	O
following	O
eSAH	B-T038
.	O

Microglia	B-T017
cells	B-T017
,	O
as	O
part	O
of	O
the	O
brain	B-T017
'	I-T017
s	I-T017
innate	O
immune	O
system	O
,	O
are	O
triggered	O
by	O
an	O
inflammatory	B-T038
reaction	I-T038
in	O
the	O
microvasculature	B-T038
after	O
eSAH	B-T038
,	O
thus	O
contributing	O
to	O
neuronal	B-T038
cell	I-T038
death	I-T038
.	O

This	O
finding	O
offers	O
a	O
whole	O
range	O
of	O
new	O
research	B-T062
targets	O
,	O
as	O
well	O
as	O
possible	O
therapy	O
options	O
for	O
patients	O
suffering	O
from	O
eSAH	B-T038
.	O

Amphetamine	B-T038
Withdrawal	I-T038
Differentially	O
Increases	O
the	O
Expression	B-T038
of	O
Organic	B-T103
Cation	I-T103
Transporter	I-T103
3	I-T103
and	O
Serotonin	B-T103
Transporter	I-T103
in	O
Limbic	B-T022
Brain	B-T017
Regions	I-T017

Amphetamine	B-T038
withdrawal	I-T038
increases	O
anxiety	B-T033
and	O
stress	B-T033
sensitivity	O
related	O
to	O
blunted	O
ventral	B-T082
hippocampus	B-T017
(	O
vHipp	B-T017
)	O
and	O
enhances	O
the	O
central	B-T017
nucleus	I-T017
of	I-T017
the	I-T017
amygdala	I-T017
(	O
CeA	B-T017
)	O
serotonin	B-T103
responses	O
.	O

Extracellular	B-T017
serotonin	B-T103
levels	O
are	O
regulated	O
by	O
the	O
serotonin	B-T103
transporter	I-T103
(	O
SERT	B-T103
)	O
and	O
organic	B-T103
cation	I-T103
transporter	I-T103
3	I-T103
(	O
OCT3	B-T103
)	O
,	O
and	O
vHipp	B-T017
OCT3	B-T103
expression	B-T038
is	O
enhanced	O
during	O
24	O
hours	O
of	O
amphetamine	B-T038
withdrawal	I-T038
,	O
while	O
SERT	B-T103
expression	B-T038
is	O
unaltered	O
.	O

Here	O
,	O
we	O
tested	O
whether	O
OCT3	B-T103
and	O
SERT	B-T103
expression	B-T038
in	O
the	O
CeA	B-T017
is	O
also	O
affected	O
during	O
acute	O
withdrawal	B-T038
to	O
explain	O
opposing	O
regional	O
alterations	O
in	O
limbic	B-T022
serotonergic	B-T038
neurotransmission	I-T038
and	O
if	O
respective	O
changes	O
continued	O
with	O
two	O
weeks	O
of	O
withdrawal	B-T038
.	O

We	O
also	O
determined	O
whether	O
changes	O
in	O
transporter	B-T103
expression	B-T038
were	O
confined	O
to	O
these	O
regions	O
.	O

Male	O
rats	B-T204
received	O
amphetamine	B-T103
or	O
saline	O
for	O
two	O
weeks	O
followed	O
by	O
24	O
hours	O
or	O
two	O
weeks	O
of	O
withdrawal	B-T038
,	O
with	O
transporter	B-T103
expression	B-T038
measured	O
using	O
Western	B-T058
immunoblot	I-T058
.	O

OCT3	B-T103
and	O
SERT	B-T103
expression	B-T038
increased	O
in	O
the	O
CeA	B-T017
at	O
both	O
withdrawal	B-T038
timepoints	O
.	O

In	O
the	O
vHipp	B-T017
,	O
OCT3	B-T103
expression	B-T038
increased	O
only	O
at	O
24	O
hours	O
of	O
withdrawal	B-T038
,	O
with	O
an	O
equivalent	O
pattern	O
seen	O
in	O
the	O
dorsomedial	B-T017
hypothalamus	I-T017
.	O

No	B-T033
changes	I-T033
were	O
evident	O
in	O
any	O
other	O
regions	B-T082
sampled	O
.	O

These	O
regionally	O
specific	O
changes	O
in	O
limbic	B-T022
OCT3	B-T103
and	O
SERT	B-T103
expression	B-T038
may	O
partially	O
contribute	O
to	O
the	O
serotonergic	B-T103
imbalance	B-T033
and	O
negative	B-T033
affect	I-T033
during	O
amphetamine	B-T038
withdrawal	I-T038
.	O

Nutritional	O
aspects	O
of	O
night	O
eating	B-T038
and	O
its	O
association	O
with	O
weight	O
status	O
among	O
Korean	B-T098
adolescents	O

A	O
growing	O
body	O
of	O
research	B-T062
has	O
indicated	O
that	O
night	O
eating	B-T038
could	O
be	O
associated	O
with	O
poor	B-T033
diet	I-T033
quality	O
and	O
negative	B-T033
health	O
outcomes	O
.	O

This	O
study	B-T170
examined	O
the	O
nutritional	O
aspects	O
of	O
night	O
eating	B-T038
,	O
its	O
related	O
factors	O
,	O
and	O
the	O
association	O
between	O
night	O
eating	B-T038
and	O
body	O
weight	O
among	O
Korean	B-T098
adolescents	O
.	O

This	O
study	B-T170
analysed	O
the	O
data	O
from	O
a	O
one	O
day	O
24	O
-	O
hour	O
dietary	B-T062
recall	I-T062
as	O
well	O
as	O
a	O
demographic	B-T062
survey	I-T062
of	O
1	O
,	O
738	O
Korean	B-T098
adolescents	O
aged	O
12	O
to	O
18	O
-	O
years	O
-	O
old	O
obtained	O
from	O
the	O
2010	O
-	O
2012	O
Korea	B-T082
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
.	O

'	O
Night	O
eating	B-T038
'	O
was	O
defined	O
as	O
consuming	O
25	O
%	O
or	O
more	O
of	O
one	O
'	O
s	O
daily	O
energy	O
intake	O
between	O
21	O
:	O
00	O
and	O
06	O
:	O
00	O
.	O

Subjects	B-T098
complying	O
with	O
the	O
preceding	O
condition	O
were	O
classified	O
as	O
'	O
night	O
eaters	B-T098
'	O
,	O
whereas	O
the	O
rest	O
were	O
considered	O
'	O
non	B-T098
-	I-T098
night	I-T098
eaters	I-T098
'	O
.	O

Logistic	O
regression	O
analysis	O
examined	O
factors	O
related	O
to	O
night	O
eating	B-T038
.	O

Multiple	O
linear	O
regression	O
analyses	O
were	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
night	O
eating	B-T038
and	O
BMI	B-T201
z	O
-	O
scores	O
,	O
whereas	O
multinomial	O
logistic	O
regression	O
analysis	O
was	O
used	O
to	O
examine	O
the	O
relationship	O
between	O
night	O
eating	B-T038
and	O
weight	O
status	O
.	O

About	O
21	O
%	O
of	O
Korean	B-T098
adolescents	O
appeared	O
to	O
be	O
night	O
eaters	B-T098
.	O

Night	O
eaters	B-T098
showed	O
increased	O
breakfast	O
skipping	B-T033
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
higher	O
energy	O
intake	O
from	O
snacks	B-T168
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
greater	O
proportion	O
of	O
energy	O
intake	O
from	O
fat	O
(	O
P	O
=	O
0	O
.	O
029	O
)	O
,	O
and	O
lower	O
Dietary	O
Diversity	O
Scores	O
(	O
P	O
=	O
0	O
.	O
008	O
)	O
than	O
non	B-T098
-	I-T098
night	I-T098
eaters	I-T098
.	O

Male	O
adolescents	O
presented	O
1	O
.	O
9	O
times	O
higher	O
odds	O
of	O
being	O
night	O
eaters	B-T098
than	O
females	O
.	O

Adolescents	O
whose	O
both	O
parents	O
were	O
night	O
eaters	B-T098
were	O
4	O
.	O
4	O
times	O
as	O
likely	O
to	O
be	O
night	O
eaters	B-T098
as	O
those	O
whose	O
neither	O
parents	O
were	O
.	O

Female	O
adolescents	O
showed	O
a	O
significant	O
relationship	O
between	O
night	O
eating	B-T038
and	O
BMI	B-T201
z	O
-	O
scores	O
(	O
β	O
=	O
0	O
.	O
28	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

However	O
,	O
night	O
eating	B-T038
did	O
not	O
increase	O
odds	O
of	O
being	O
overweight	B-T033
or	O
obese	B-T038
in	O
adolescents	O
.	O

Night	O
eating	B-T038
in	O
Korean	B-T098
adolescents	O
was	O
related	O
to	O
undesirable	B-T033
dietary	I-T033
behaviours	I-T033
and	O
low	O
diet	O
quality	O
in	O
general	O
as	O
well	O
as	O
higher	O
BMI	B-T201
z	O
-	O
scores	O
in	O
females	O
.	O

Male	O
gender	O
and	O
parental	O
night	O
eating	B-T038
appeared	O
to	O
be	O
the	O
factors	O
that	O
significantly	O
increased	O
odds	O
of	O
night	O
eating	B-T038
.	O

These	O
results	O
suggest	O
that	O
night	O
eating	B-T038
should	O
be	O
considered	O
when	O
designing	O
nutrition	O
education	O
or	O
intervention	O
programs	O
targeting	O
adolescents	O
.	O

A	O
randomized	B-T062
trial	I-T062
of	O
Plasma	B-T103
-	I-T103
Lyte	I-T103
A	I-T103
and	O
0	O
.	O
9	O
%	O
sodium	O
chloride	O
in	O
acute	B-T038
pediatric	I-T038
gastroenteritis	I-T038

Compare	O
the	O
efficacy	O
and	O
safety	O
of	O
Plasma	B-T103
-	I-T103
Lyte	I-T103
A	I-T103
(	O
PLA	B-T103
)	O
versus	O
0	O
.	O
9	O
%	O
sodium	O
chloride	O
(	O
NaCl	O
)	O
intravenous	B-T058
(	I-T058
IV	I-T058
)	I-T058
fluid	I-T058
replacement	I-T058
in	O
children	O
with	O
moderate	O
to	O
severe	B-T038
dehydration	I-T038
secondary	O
to	O
acute	B-T038
gastroenteritis	I-T038
(	O
AGE	B-T038
)	O
.	O

Prospective	B-T062
,	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
study	I-T062
conducted	O
at	O
eight	O
pediatric	O
emergency	B-T092
departments	I-T092
(	O
EDs	B-T092
)	O
in	O
the	O
US	B-T082
and	O
Canada	B-T082
(	O
NCT	O
#	O
01234883	O
)	O
.	O

The	O
primary	O
outcome	O
measure	O
was	O
serum	B-T033
bicarbonate	I-T033
level	I-T033
at	O
4	O
h	O
.	O

Secondary	O
outcomes	O
included	O
safety	O
and	O
tolerability	B-T062
.	O

The	O
hypothesis	O
was	O
that	O
PLA	B-T103
would	O
be	O
superior	O
to	O
0	O
.	O
9	O
%	O
NaCl	O
in	O
improvement	B-T058
of	I-T058
4	I-T058
-	I-T058
h	I-T058
bicarbonate	I-T058
.	O

Patients	O
(	O
n	O
=	O
100	O
)	O
aged	O
≥6	O
months	O
to	O
<	O
11	O
years	O
with	O
AGE	B-T038
-	O
induced	O
moderate	O
-	O
to	O
-	O
severe	B-T038
dehydration	I-T038
were	O
enrolled	O
.	O

Patients	O
with	O
a	O
baseline	O
bicarbonate	B-T033
level	I-T033
≤22	O
mEq	O
/	O
L	O
formed	O
the	O
modified	O
intent	O
to	O
treat	O
(	O
mITT	O
)	O
group	B-T098
.	O

At	O
baseline	O
,	O
the	O
treatment	B-T058
groups	B-T098
were	O
comparable	O
except	O
that	O
the	O
PLA	B-T103
group	B-T098
was	O
older	O
.	O

At	O
hour	O
4	O
,	O
the	O
PLA	B-T103
group	B-T098
had	O
greater	O
increases	B-T033
in	I-T033
serum	I-T033
bicarbonate	I-T033
from	O
baseline	O
than	O
did	O
the	O
0	O
.	O
9	O
%	O
NaCl	O
group	B-T098
(	O
mean	O
±	O
SD	O
at	O
4	O
h	O
:	O
18	O
±	O
3	O
.	O
74	O
vs	O
18	O
.	O
0	O
±	O
3	O
.	O
67	O
;	O
change	O
from	O
baseline	O
of	O
1	O
.	O
6	O
and	O
0	O
.	O
0	O
,	O
respectively	O
;	O
P	O
=	O
.	O
004	O
)	O
.	O

Both	O
treatment	B-T058
groups	B-T098
received	O
similar	O
fluid	O
volumes	O
.	O

The	O
PLA	B-T103
group	B-T098
had	O
less	O
abdominal	B-T033
pain	I-T033
and	O
better	O
dehydration	B-T038
scores	O
at	O
hour	O
2	O
(	O
both	O
P	O
=	O
.	O
03	O
)	O
but	O
not	O
at	O
hour	O
4	O
(	O
P	O
=	O
0	O
.	O
15	O
and	O
0	O
.	O
08	O
,	O
respectively	O
)	O
.	O

No	O
patient	O
experienced	O
clinically	O
relevant	O
worsening	O
of	O
laboratory	B-T033
findings	I-T033
or	O
physical	B-T058
examination	I-T058
,	O
and	O
hospital	O
admission	O
rates	O
were	O
similar	O
.	O

One	O
patient	O
in	O
each	O
treatment	B-T058
group	B-T098
developed	O
hyponatremia	B-T038
.	O

Four	O
patients	O
developed	O
hyperkalemia	B-T033
(	O
PLA	B-T103
:	O
1	O
,	O
0	O
.	O
9	O
%	O
NaCl	O
:	O
3	O
)	O
.	O

In	O
comparison	O
with	O
0	O
.	O
9	O
%	O
NaCl	O
,	O
PLA	B-T103
for	O
rehydration	B-T058
in	O
children	O
with	O
AGE	B-T038
was	O
well	O
tolerated	O
and	O
led	O
to	O
more	O
rapid	O
improvement	B-T058
in	I-T058
serum	I-T058
bicarbonate	I-T058
and	O
dehydration	B-T038
score	O
.	O

NCT	O
#	O
01234883	O
(	O
Registration	O
Date	O
:	O
November	O
3	O
,	O
2010	O
)	O
.	O

The	O
relationships	O
between	O
symptoms	B-T033
and	O
quality	O
of	O
life	O
over	O
the	O
course	O
of	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
therapy	I-T058
for	O
panic	B-T038
disorder	I-T038
in	O
Japan	B-T082

This	O
study	B-T062
examined	B-T033
the	O
relationships	O
between	O
changes	O
in	O
symptoms	B-T033
and	O
changes	O
in	O
quality	O
of	O
life	O
(	O
QOL	O
)	O
during	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
therapy	I-T058
(	O
CBT	B-T058
)	O
for	O
panic	B-T038
disorder	I-T038
(	O
PD	B-T038
)	O
.	O

We	O
treated	O
198	O
PD	B-T038
patients	O
with	O
group	O
CBT	B-T058
in	O
Japan	B-T082
.	O

Using	O
multiple	B-T170
regression	I-T170
analysis	I-T170
,	O
we	O
examined	B-T033
the	O
associations	O
between	O
changes	O
in	O
QOL	O
and	O
changes	O
in	O
PD	B-T038
symptoms	B-T033
or	O
comorbid	B-T033
psychological	I-T033
symptoms	I-T033
during	O
CBT	B-T058
.	O

Changes	O
in	O
anticipatory	B-T033
anxiety	I-T033
,	O
agoraphobic	B-T038
fear	I-T038
/	O
avoidance	B-T038
,	O
and	O
somatization	B-T038
were	O
significant	O
predictors	O
of	O
changes	O
in	O
some	O
aspects	O
of	O
QOL	O
.	O

It	O
might	O
be	O
useful	O
to	O
decrease	O
somatization	B-T038
,	O
anticipatory	B-T033
anxiety	I-T033
,	O
and	O
agoraphobic	B-T038
fear	I-T038
to	O
improve	O
QOL	O
in	O
CBT	B-T058
for	O
PD	B-T038
.	O

Coupling	O
of	O
TRPV6	B-T103
and	O
TMEM16A	B-T103
in	O
epithelial	B-T017
principal	I-T017
cells	I-T017
of	O
the	O
rat	B-T017
epididymis	I-T017

The	O
epididymis	B-T017
establishes	O
a	O
congenial	O
environment	B-T082
for	O
sperm	B-T038
maturation	I-T038
and	O
protection	O
.	O

Its	O
fluid	B-T031
is	O
acidic	O
,	O
and	O
the	O
calcium	B-T103
concentration	O
is	O
low	O
and	O
declines	O
along	O
the	O
length	O
of	O
the	O
epididymal	B-T017
tubule	I-T017
.	O

However	O
,	O
our	O
knowledge	O
of	O
ionic	B-T038
currents	I-T038
and	O
mechanisms	O
of	O
calcium	B-T038
homeostasis	I-T038
in	O
rat	B-T017
epididymal	I-T017
epithelial	B-T017
cells	I-T017
remains	O
enigmatic	O
.	O

In	O
this	O
study	B-T062
,	O
to	O
better	O
understand	O
calcium	B-T038
regulation	I-T038
in	O
the	O
epididymis	B-T017
,	O
we	O
use	O
the	O
patch	B-T062
-	I-T062
clamp	I-T062
method	I-T062
to	O
record	O
from	O
single	O
rat	B-T204
cauda	B-T017
epididymal	I-T017
principal	B-T017
cells	I-T017
.	O

We	O
detect	B-T033
a	O
constitutively	O
active	O
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
current	B-T038
with	O
characteristics	O
that	O
match	O
the	O
epithelial	B-T017
calcium	B-T103
channel	I-T103
TRPV6	B-T103
.	O

Electrophysiological	O
and	O
pharmacological	B-T058
data	I-T058
also	O
reveal	O
a	O
constitutively	O
active	B-T103
calcium	I-T103
-	I-T103
activated	I-T103
chloride	I-T103
conductance	I-T103
(	O
CaCC	B-T103
)	O
.	O

Removal	O
of	O
extracellular	B-T017
calcium	B-T103
attenuates	O
not	O
only	O
the	O
TRPV6	B-T103
-	O
like	O
conductance	O
,	O
but	O
also	O
the	O
CaCC	B-T103
.	O

Lanthanide	B-T103
block	O
is	O
time	O
dependent	O
such	O
that	O
the	O
TRPV6	B-T103
-	O
like	O
component	O
is	O
inhibited	B-T038
first	O
,	O
followed	O
by	O
the	O
CaCC	B-T103
.	O

The	O
putative	O
CaCC	B-T103
blocker	O
niflumic	B-T103
acid	I-T103
partially	O
inhibits	B-T038
whole	B-T017
-	I-T017
cell	I-T017
currents	B-T038
,	O
whereas	O
La	B-T103
(	I-T103
3	I-T103
+	I-T103
)	I-T103
almost	O
abolishes	O
whole	B-T017
-	I-T017
cell	I-T017
currents	B-T038
in	O
principal	B-T017
cells	I-T017
.	O

Membrane	B-T038
potential	I-T038
measurements	O
reveal	O
an	O
interplay	O
between	O
La	B-T103
(	I-T103
3	I-T103
+	I-T103
)	I-T103
-	O
sensitive	B-T103
ion	I-T103
channels	I-T103
and	O
those	O
that	O
are	O
sensitive	O
to	O
the	O
specific	B-T170
TMEM16A	B-T103
inhibitor	B-T103
tannic	B-T103
acid	I-T103
.	O

In	B-T082
vivo	I-T082
perfusion	B-T058
of	O
the	O
cauda	B-T017
epididymal	I-T017
tubule	I-T017
shows	O
a	O
substantial	O
rate	O
of	O
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
reabsorption	B-T038
from	O
the	O
luminal	B-T082
side	I-T082
,	O
which	O
is	O
dose	O
-	O
dependently	O
suppressed	O
by	O
ruthenium	B-T103
red	I-T103
,	O
a	O
putative	O
blocker	O
of	O
epithelial	B-T017
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
channels	I-T103
and	O
CaCC	B-T103
.	O

Finally	O
,	O
we	O
discover	O
messenger	B-T103
RNA	I-T103
for	O
both	O
TRPV6	B-T103
and	O
TMEM16A	B-T103
in	O
the	O
rat	B-T017
epididymis	I-T017
and	O
show	O
that	O
their	O
proteins	B-T103
colocalize	B-T082
in	O
the	O
apical	O
membrane	O
of	O
principal	B-T017
cells	I-T017
.	O

Collectively	O
,	O
these	O
data	O
provide	O
evidence	O
for	O
a	O
coupling	O
mechanism	O
between	O
TRPV6	B-T103
and	O
TMEM16A	B-T103
in	O
principal	B-T017
cells	I-T017
that	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	B-T038
of	I-T038
calcium	I-T038
homeostasis	I-T038
in	O
the	O
epididymis	B-T017
.	O

Voices	O
:	O
A	O
Conversation	O
with	O
Allen	B-T204
J	I-T204
.	I-T204
Wilcox	I-T204

Allen	B-T204
James	I-T204
Wilcox	I-T204
was	O
born	O
on	O
30	O
September	O
1946	O
in	O
Columbus	B-T082
,	I-T082
OH	I-T082
.	O

He	O
studied	O
medicine	B-T091
at	O
the	O
University	B-T092
of	I-T092
Michigan	I-T092
,	O
graduated	O
in	O
1973	O
,	O
and	O
after	O
a	O
rotating	O
internship	O
,	O
he	O
completed	O
a	O
master	O
'	O
s	O
degree	O
in	O
maternal	O
and	O
child	O
health	O
(	O
1976	O
)	O
and	O
a	O
PhD	B-T170
in	O
epidemiology	B-T091
(	O
1979	O
)	O
at	O
the	O
University	B-T092
of	I-T092
North	I-T092
Carolina	I-T092
in	O
Chapel	B-T082
Hill	I-T082
.	O

After	O
graduation	O
,	O
he	O
went	O
to	O
work	O
at	O
the	O
National	B-T092
Institute	I-T092
of	I-T092
Environmental	I-T092
Health	I-T092
Sciences	I-T092
(	O
NIEHS	B-T092
,	O
one	O
of	O
the	O
US	B-T092
National	I-T092
Institutes	I-T092
of	I-T092
Health	I-T092
)	O
in	O
Durham	B-T082
,	I-T082
NC	I-T082
,	O
where	O
he	O
has	O
spent	O
his	O
career	O
.	O

He	O
developed	O
a	O
research	O
program	O
in	O
reproductive	O
and	O
perinatal	B-T091
epidemiology	I-T091
,	O
a	O
relatively	O
unexplored	O
area	O
at	O
the	O
time	O
.	O

His	O
studies	O
include	O
the	O
early	O
pregnancy	O
study	O
,	O
which	O
documented	B-T058
the	O
extent	O
of	O
subclinical	O
pregnancy	B-T038
loss	I-T038
in	O
humans	B-T204
and	O
established	O
the	O
fertile	O
days	O
of	O
a	O
woman	B-T098
'	I-T098
s	I-T098
menstrual	B-T038
cycle	I-T038
.	O

He	O
served	O
as	O
the	O
Chief	B-T097
of	I-T097
the	O
Epidemiology	B-T091
Branch	B-T097
from	O
1991	O
to	O
2001	O
,	O
and	O
as	O
Editor	B-T097
-	I-T097
in	I-T097
-	I-T097
Chief	I-T097
of	O
the	O
journal	B-T170
EPIDEMIOLOGY	B-T091
from	O
2001	O
to	O
2014	O
.	O

His	O
textbook	B-T170
,	O
Fertility	B-T170
and	I-T170
Pregnancy	I-T170
-	I-T170
An	I-T170
Epidemiologic	I-T170
Perspective	I-T170
,	O
was	O
published	O
by	O
Oxford	B-T170
University	I-T170
Press	I-T170
in	O
2010	O
.	O

He	O
was	O
elected	O
to	O
the	O
American	B-T092
Epidemiological	I-T092
Society	I-T092
in	O
1989	O
,	O
and	O
served	O
as	O
its	O
president	O
in	O
2003	O
.	O

He	O
also	O
served	O
as	O
president	O
of	O
the	O
Society	B-T092
of	I-T092
Pediatric	I-T092
and	I-T092
Perinatal	I-T092
Epidemiological	I-T092
Research	I-T092
(	O
1996	O
)	O
and	O
the	O
president	O
of	O
the	O
Society	B-T092
of	I-T092
Epidemiological	I-T092
Research	I-T092
(	O
1998	O
)	O
.	O

He	O
holds	O
adjunct	O
teaching	O
appointments	O
at	O
the	O
University	B-T092
of	I-T092
North	I-T092
Carolina	I-T092
,	O
Harvard	B-T092
University	I-T092
,	O
and	O
the	O
University	B-T092
of	I-T092
Bergen	I-T092
(	O
Norway	B-T082
)	O
,	O
which	O
awarded	O
him	O
an	O
honorary	O
doctoral	B-T170
degree	I-T170
in	O
2008	O
.	O

Evaluation	B-T058
of	O
Spontaneous	O
Bone	B-T038
Regeneration	I-T038
after	O
Enucleation	B-T058
of	O
Large	O
Cysts	B-T038
of	O
the	O
Jaws	B-T017
using	O
Radiographic	O
Computed	B-T058
Software	B-T170

Spontaneous	O
regeneration	B-T038
of	I-T038
bone	I-T038
is	O
commonly	O
seen	O
in	O
the	O
small	O
surgical	B-T058
defects	O
caused	O
by	O
enucleation	B-T058
of	O
cysts	B-T038
.	O

However	O
,	O
in	O
case	O
of	O
large	O
surgical	B-T058
defects	O
caused	O
by	O
the	O
enucleation	B-T058
,	O
spontaneous	O
regeneration	B-T038
of	I-T038
bone	I-T038
is	O
a	O
rare	O
phenomenon	O
and	O
it	O
depends	O
on	O
factors	O
,	O
such	O
as	O
age	O
of	O
the	O
patient	O
,	O
intact	O
periosteum	B-T017
,	O
and	O
proper	O
stabilization	B-T058
.	O

The	O
study	B-T062
included	O
16	O
patients	O
,	O
who	O
reported	B-T058
to	O
the	O
department	B-T092
of	I-T092
oral	I-T092
and	I-T092
maxillofacial	I-T092
surgery	I-T092
with	O
the	O
complaint	B-T038
of	O
pain	B-T033
and	O
swelling	B-T033
in	O
the	O
jaws	B-T017
diagnosed	B-T033
as	O
cyst	B-T038
.	O

The	O
sample	O
included	O
equal	O
numbers	O
of	O
male	O
and	O
female	O
subjects	O
aged	O
between	O
15	O
and	O
40	O
years	O
.	O

Panoramic	B-T058
radiographs	I-T058
were	O
taken	O
pre	O
-	O
and	O
postoperatively	O
on	O
day	O
2	O
of	O
the	O
enucleation	B-T058
.	O

The	O
dimensions	O
of	O
the	O
cyst	B-T038
were	O
evaluated	B-T058
on	O
the	O
radiograph	B-T058
according	O
to	O
the	O
proforma	O
.	O

Subsequent	O
radiographs	B-T058
were	O
taken	O
at	O
regular	O
intervals	O
of	O
1	O
.	O
5	O
,	O
3	O
,	O
and	O
6	O
months	O
using	O
standard	O
parameters	O
and	O
were	O
analyzed	B-T062
using	O
MCID™	O
analysis	O
software	B-T170
of	O
imaging	B-T058
research	I-T058
.	O

Mean	O
reduction	B-T058
was	O
seen	O
in	O
up	O
to	O
39	O
and	O
60	O
%	O
in	O
the	O
cystic	O
cavity	B-T017
size	B-T082
and	O
increase	O
in	O
the	O
mean	O
density	O
up	O
to	O
59	O
and	O
90	O
.	O
2	O
%	O
at	O
3	O
and	O
6	O
months	O
intervals	O
respectively	O
.	O

Spontaneous	O
bone	B-T038
regeneration	I-T038
was	O
seen	O
even	O
after	O
primary	O
closure	B-T058
of	O
the	O
large	O
cystic	O
defect	O
without	O
the	O
need	O
for	O
placement	B-T058
of	O
foreign	O
substances	O
or	O
grafts	B-T103
and	O
it	O
also	O
eliminated	O
the	O
complications	B-T038
resulting	O
from	O
placement	B-T058
of	O
foreign	O
substance	O
.	O

Further	O
studies	B-T062
are	O
required	O
in	O
a	O
larger	O
sample	O
with	O
longer	O
follow	B-T058
-	I-T058
up	I-T058
durations	O
to	O
confirm	O
the	O
outcome	O
of	O
the	O
present	O
work	O
for	O
the	O
benefit	O
of	O
patients	O
.	O

The	O
present	O
study	B-T062
depicted	O
that	O
spontaneous	O
bone	B-T038
regeneration	I-T038
can	O
occur	O
with	O
accepted	O
results	O
after	O
simple	O
enucleation	B-T058
of	O
jaw	B-T017
cyst	B-T038
without	O
the	O
aid	O
of	O
any	O
graft	B-T103
material	I-T103
.	O

Hence	O
,	O
simple	O
enucleation	B-T058
may	O
be	O
considered	O
as	O
a	O
first	B-T058
line	I-T058
of	I-T058
treatment	I-T058
modality	O
for	O
cystic	O
lesion	B-T033
of	O
the	O
jaws	B-T017
.	O

This	O
simplifies	O
the	O
surgical	B-T058
procedure	I-T058
,	O
decreases	O
the	O
economic	O
and	O
biologic	O
costs	O
,	O
and	O
reduces	B-T058
the	O
risk	O
of	O
postoperative	B-T038
complications	I-T038
.	O

Follow	B-T058
-	I-T058
up	I-T058
is	O
necessary	O
along	O
with	O
patient	O
'	O
s	O
compliance	O
for	O
the	O
success	O
of	O
treatment	O
.	O

Membrane	B-T038
Protein	I-T038
Solubilization	I-T038
and	O
Composition	O
of	O
Protein	B-T103
Detergent	B-T103
Complexes	B-T103

Membrane	B-T103
proteins	I-T103
are	O
typically	B-T038
expressed	I-T038
in	O
heterologous	O
systems	O
with	O
a	O
view	O
to	O
in	O
vitro	O
characterization	O
.	O

A	O
critical	O
step	O
in	O
the	O
preparation	O
of	O
membrane	B-T103
proteins	I-T103
after	O
expression	B-T038
in	O
any	O
system	O
is	O
the	O
solubilization	B-T038
of	I-T038
the	I-T038
protein	I-T038
in	O
aqueous	O
solution	O
,	O
typically	O
using	O
detergents	B-T103
and	O
lipids	B-T103
,	O
to	O
obtain	O
the	O
protein	B-T103
in	O
a	O
form	O
suitable	O
for	O
purification	O
,	O
structural	B-T058
or	O
functional	O
analysis	B-T062
.	O

This	O
process	O
is	O
particularly	O
difficult	O
as	O
the	O
objective	O
is	O
to	O
prepare	O
the	O
protein	B-T103
in	O
an	O
unnatural	O
environment	B-T082
,	O
a	O
protein	B-T103
detergent	B-T103
complex	B-T103
,	O
separating	O
it	O
from	O
its	O
natural	O
lipid	B-T103
partners	O
while	O
causing	O
the	O
minimum	O
destabilization	B-T038
or	O
modification	B-T033
of	O
the	O
structure	B-T082
.	O

Although	O
the	O
process	O
is	O
difficult	O
,	O
and	O
relatively	O
hard	O
to	O
master	O
,	O
an	O
increasing	O
number	O
of	O
membrane	B-T103
proteins	I-T103
have	O
been	O
successfully	O
isolated	O
after	O
expression	B-T038
in	O
a	O
wide	O
variety	O
of	O
systems	O
.	O

In	O
this	O
chapter	O
we	O
give	O
a	O
general	B-T170
protocol	I-T170
for	O
preparing	O
protein	B-T103
detergent	B-T103
complexes	B-T103
that	O
is	O
aimed	O
at	O
guiding	O
the	O
reader	O
through	O
the	O
different	O
critical	O
steps	O
.	O

In	O
the	O
second	O
part	O
of	O
the	O
chapter	O
we	O
illustrate	O
how	O
to	O
analyze	B-T062
the	O
composition	O
of	O
protein	B-T103
detergent	B-T103
complexes	B-T103
;	O
this	O
analysis	B-T062
is	O
important	O
as	O
it	O
has	O
been	O
found	O
that	O
compositional	O
variation	O
often	O
causes	O
irreproducible	O
results	O
.	O

Can	O
We	O
Predict	O
Burnout	B-T038
among	O
Student	B-T097
Nurses	I-T097
?	O
An	O
Exploration	O
of	O
the	O
ICWR	B-T170
-	I-T170
1	I-T170
Model	I-T170
of	O
Individual	B-T098
Psychological	O
Resilience	O

The	O
nature	O
of	O
nursing	B-T091
work	I-T091
is	O
demanding	B-T058
and	O
can	O
be	O
stressful	O
.	O

Previous	O
studies	O
have	O
shown	O
a	O
high	O
rate	O
of	O
burnout	B-T038
among	O
employed	B-T033
nurses	B-T097
.	O

Recently	O
,	O
efforts	O
have	O
been	O
made	O
to	O
understand	O
the	O
role	O
of	O
resilience	O
in	O
determining	O
the	O
psychological	O
adjustment	O
of	O
employed	B-T033
nurses	B-T097
.	O

A	O
theoretical	B-T170
model	I-T170
of	O
resilience	O
was	O
proposed	O
recently	O
that	O
includes	O
several	O
constructs	B-T170
identified	O
in	O
the	O
literature	B-T170
related	O
to	O
resilience	O
and	O
to	O
psychological	B-T038
functioning	I-T038
.	O

As	O
nursing	B-T097
students	I-T097
are	O
the	O
future	O
of	O
the	O
nursing	B-T091
workforce	B-T097
it	O
is	O
important	O
to	O
advance	O
our	O
understanding	O
of	O
the	O
determinants	O
of	O
resilience	O
in	O
this	O
population	B-T098
.	O

Student	B-T097
nurses	I-T097
who	O
had	O
completed	O
their	O
final	O
practicum	O
were	O
invited	O
to	O
participate	O
in	O
an	O
online	B-T170
survey	I-T170
measuring	O
the	O
key	O
constructs	B-T170
of	O
the	O
ICWR	B-T170
-	I-T170
1	I-T170
model	I-T170
.	O

422	O
students	B-T097
from	O
across	O
Australia	B-T082
and	O
Canada	B-T082
completed	O
the	O
survey	B-T170
between	O
July	O
2014	O
and	O
July	O
2015	O
.	O

As	O
well	O
as	O
several	O
key	O
demographics	O
,	O
trait	B-T033
negative	I-T033
affect	I-T033
,	O
mindfulness	B-T038
,	O
self	B-T038
-	I-T038
efficacy	I-T038
,	O
coping	O
,	O
resilience	O
,	O
and	O
burnout	B-T038
were	O
measured	O
.	O

We	O
used	O
structural	O
equation	O
modeling	O
and	O
found	O
support	O
for	O
the	O
major	O
pathways	O
of	O
the	O
model	B-T170
;	O
namely	O
that	O
resilience	O
had	O
a	O
significant	O
influence	O
on	O
the	O
relationship	O
between	O
mindfulness	B-T038
,	O
self	B-T038
-	I-T038
efficacy	I-T038
and	O
coping	O
,	O
and	O
psychological	O
adjustment	O
(	O
burnout	B-T038
scores	O
)	O
.	O

Furthermore	O
,	O
as	O
predicted	O
,	O
Neuroticism	B-T038
moderated	O
the	O
relationship	O
between	O
coping	O
and	O
burnout	B-T038
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
potential	O
approaches	O
to	O
supporting	O
nursing	B-T097
students	I-T097
who	O
may	O
be	O
at	O
risk	O
of	O
burnout	B-T038
.	O

Medication	O
Intervention	O
for	O
Chronic	B-T038
Kidney	I-T038
Disease	I-T038
Patients	O
Transitioning	O
from	O
Hospital	B-T092
to	O
Home	B-T082
:	O
Study	B-T062
Design	I-T062
and	O
Baseline	O
Characteristics	O

The	O
hospital	B-T058
readmission	I-T058
rate	O
in	O
the	O
population	B-T098
with	O
chronic	B-T038
kidney	I-T038
disease	I-T038
(	O
CKD	B-T038
)	O
is	O
high	O
and	O
strategies	O
to	O
reduce	O
this	O
risk	O
are	O
urgently	O
needed	O
.	O

The	O
CKD	B-T038
-	O
Medication	O
Intervention	O
Trial	O
(	O
CKD	B-T038
-	O
MIT	O
;	O
www	B-T170
.	I-T170
clinicaltrials	I-T170
.	I-T170
gov	I-T170
;	I-T170
NCTO1459770	I-T170
)	O
is	O
a	O
single	B-T062
-	I-T062
blind	I-T062
(	O
investigators	B-T097
)	O
,	O
randomized	B-T062
,	O
clinical	B-T062
trial	I-T062
conducted	O
at	O
Providence	B-T058
Health	I-T058
Care	I-T058
in	O
Spokane	B-T082
,	I-T082
Washington	I-T082
.	O

Study	O
participants	O
are	O
hospitalized	O
patients	O
with	O
CKD	B-T038
stages	O
3	O
-	O
5	O
(	O
not	O
treated	B-T058
with	I-T058
kidney	B-T058
replacement	I-T058
therapy	I-T058
)	O
and	O
acute	O
illness	O
.	O

The	O
study	B-T170
intervention	I-T170
is	O
a	O
pharmacist	B-T097
-	I-T097
led	I-T097
,	O
home	B-T058
-	I-T058
based	I-T058
,	O
medication	B-T058
management	I-T058
intervention	B-T058
delivered	O
within	O
7	O
days	O
after	O
hospital	B-T058
discharge	I-T058
.	O

The	O
primary	O
outcome	O
is	O
a	O
composite	O
of	O
hospital	B-T058
readmissions	I-T058
and	O
visits	O
to	O
emergency	B-T092
departments	I-T092
and	O
urgent	B-T092
care	I-T092
centers	I-T092
for	O
90	O
days	O
following	O
hospital	B-T058
discharge	I-T058
.	O

Secondary	O
outcomes	O
are	O
achievements	O
of	O
guideline	B-T170
-	I-T170
based	I-T170
targets	O
for	O
CKD	B-T038
risk	B-T033
factors	I-T033
and	O
complications	B-T038
.	O

Enrollment	B-T058
began	O
in	O
February	O
2012	O
and	O
ended	O
in	O
May	O
2015	O
.	O

At	O
baseline	O
,	O
the	O
age	O
of	O
participants	B-T098
was	O
69	O
±	O
11	O
years	O
(	O
mean	O
±	O
SD	O
)	O
,	O
50	O
%	O
(	O
77	O
of	O
155	O
)	O
were	O
women	B-T098
,	O
83	O
%	O
(	O
117	O
of	O
141	O
)	O
had	O
hypertension	B-T038
and	O
56	O
%	O
(	O
79	O
of	O
141	O
)	O
had	O
diabetes	B-T038
.	O

At	O
baseline	O
,	O
the	O
estimated	B-T058
glomerular	I-T058
filtration	I-T058
rate	O
was	O
41	O
±	O
14	O
ml	O
/	O
min	O
/	O
1	O
.	O
73	O
m2	O
and	O
urine	B-T058
albumin	I-T058
-	I-T058
to	I-T058
-	I-T058
creatinine	I-T058
ratio	I-T058
was	O
43	O
mg	O
/	O
g	O
(	O
interquartile	O
range	O
8	O
-	O
528	O
mg	O
/	O
g	O
)	O
.	O

The	O
most	O
frequent	O
diagnosis	O
category	O
for	O
the	O
index	O
hospital	B-T058
admission	I-T058
was	O
cardiovascular	B-T038
diseases	I-T038
at	O
34	O
%	O
(	O
53	O
of	O
155	O
)	O
,	O
but	O
the	O
most	O
common	O
single	B-T033
diagnosis	I-T033
for	O
admission	B-T058
was	O
community	O
-	O
acquired	O
acute	B-T038
kidney	I-T038
injury	I-T038
at	O
10	O
%	O
(	O
16	O
of	O
155	O
)	O
.	O

Participants	B-T098
in	O
CKD	B-T038
-	O
MIT	O
are	O
typical	O
of	O
acutely	O
ill	O
hospitalized	O
patients	O
with	O
CKD	B-T038
.	O

A	O
medication	B-T058
management	I-T058
intervention	B-T058
after	O
hospital	B-T058
discharge	I-T058
is	O
under	O
study	B-T062
to	O
reduce	O
post	O
-	O
hospitalization	B-T058
acute	B-T058
care	I-T058
utilization	O
and	O
to	O
improve	O
CKD	B-T038
management	B-T058
.	O

Direct	O
Repair	B-T058
of	O
Lumbar	B-T017
Pars	I-T017
Interarticularis	I-T017
Defects	O
by	O
Utilizing	O
Intraoperative	O
O	O
-	O
Arm	O
-	O
Based	O
Navigation	O
and	O
Microendoscopic	B-T058
Techniques	I-T058

A	O
retrospective	B-T062
analysis	I-T062
of	O
the	O
clinical	B-T033
outcomes	I-T033
of	O
eight	O
patients	O
with	O
the	O
lumbar	B-T017
pars	I-T017
interarticulars	I-T017
defects	O
treated	B-T033
by	O
direct	O
repair	B-T058
with	O
the	O
aid	O
of	O
intraoperative	O
O	O
-	O
arm	O
based	O
navigation	O
and	O
microendoscopic	B-T058
techniques	I-T058
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
the	O
efficacy	O
and	O
safety	O
of	O
direct	O
screw	B-T074
repair	B-T058
by	O
using	O
minimally	B-T058
invasive	I-T058
surgery	I-T058
for	O
the	O
lumbar	B-T017
pars	I-T017
interarticulars	I-T017
defects	O
in	O
a	O
pilot	B-T062
study	I-T062
.	O

Direct	O
repair	B-T058
of	O
pars	B-T017
interarticulars	I-T017
defects	O
has	O
been	O
used	O
to	O
treat	B-T058
young	O
adult	O
patients	O
.	O

Reports	B-T170
concerning	O
direct	O
repair	B-T058
by	O
minimally	B-T058
invasive	I-T058
techniques	I-T058
for	O
pars	B-T017
interarticulars	I-T017
defects	O
are	O
quite	O
rare	O
.	O

Review	O
of	O
medical	B-T170
records	I-T170
identified	O
eight	O
consecutive	O
patients	O
treated	B-T033
with	O
intraoperative	O
O	O
-	O
arm	O
based	O
navigation	O
and	O
microendoscopic	B-T058
techniques	I-T058
.	O

Debridement	B-T058
and	O
autograft	B-T058
of	O
pars	B-T017
interarticularis	I-T017
defects	O
was	O
performed	O
under	O
microendoscopic	B-T058
procedure	I-T058
.	O

Then	O
,	O
percutaneous	B-T082
bilateral	B-T082
intralaminar	B-T082
screws	B-T074
were	O
inserted	B-T058
by	O
utilizing	O
intraoperative	O
navigation	O
.	O

The	O
clinical	B-T170
and	O
radiological	B-T091
data	O
were	O
collected	O
and	O
analyzed	B-T062
retrospectively	O
.	O

Eight	O
patients	O
had	O
a	O
mean	O
age	O
of	O
28	O
.	O
4	O
years	O
,	O
and	O
five	O
were	O
30	O
years	O
or	O
younger	O
at	O
the	O
time	O
of	O
treatment	B-T058
.	O

Symptoms	B-T033
included	O
axial	B-T082
back	B-T033
pain	I-T033
in	O
100	O
%	O
of	O
patients	O
without	O
concomitant	O
radiculopathy	B-T038
.	O

Autograft	B-T058
was	O
used	O
in	O
all	O
cases	O
.	O

The	O
average	O
follow	B-T058
-	I-T058
up	I-T058
duration	O
was	O
27	O
.	O
4	O
months	O
with	O
a	O
range	O
of	O
20	O
to	O
33	O
months	O
.	O

Symptoms	B-T033
resolved	B-T033
completely	O
or	O
partially	O
in	O
all	O
patients	O
.	O

Low	B-T033
back	I-T033
pain	I-T033
visual	B-T201
analog	I-T201
scores	I-T201
decrease	O
from	O
preoperative	O
6	O
.	O
8	O
to	O
postoperative	O
1	O
.	O
4	O
of	O
eight	O
cases	O
.	O

Of	O
16	O
pars	B-T017
defects	O
,	O
healing	B-T038
was	O
observed	O
in	O
13	O
(	O
81	O
.	O
3	O
%	O
)	O
at	O
last	O
radiological	B-T091
follow	B-T058
-	I-T058
up	I-T058
.	O

One	O
patient	O
with	O
bilateral	B-T017
fusion	I-T017
failure	I-T017
refused	O
revision	B-T058
surgery	I-T058
because	O
of	O
mild	B-T033
complaint	I-T033
.	O

No	B-T033
complications	I-T033
such	O
as	O
dural	B-T037
tear	I-T037
,	O
nerve	B-T037
root	I-T037
injury	I-T037
,	O
and	O
infection	B-T038
occurred	O
.	O

Minimally	B-T058
invasive	I-T058
direct	O
repair	B-T058
of	O
the	O
pars	B-T017
interarticularis	I-T017
defects	O
with	O
intralaminar	B-T082
screws	B-T074
by	O
using	O
microendoscopic	B-T058
system	I-T058
and	O
navigation	O
procedure	O
can	O
provide	O
safe	O
and	O
effective	O
treatment	B-T058
of	O
spondylolysis	B-T038
with	O
satisfactory	O
clinical	O
and	O
radiological	B-T091
outcomes	O
,	O
which	O
need	O
some	O
special	B-T074
tools	I-T074
with	O
steep	O
learning	B-T038
curve	I-T038
.	O

4	O
.	O

Evidence	O
-	O
Based	O
Review	B-T170
and	O
Survey	B-T170
of	O
Expert	O
Opinion	O
of	O
Reconstruction	B-T058
of	O
Metastatic	B-T038
Spine	I-T038
Tumors	I-T038

Systematic	O
review	B-T170
and	O
consensus	O
expert	O
opinion	O
.	O

To	O
provide	O
surgeons	B-T097
and	O
other	O
health	B-T097
care	I-T097
professionals	I-T097
with	O
guidelines	B-T170
for	O
surgical	B-T058
reconstruction	I-T058
of	O
metastatic	B-T038
spine	B-T038
disease	I-T038
based	O
on	O
evidence	O
and	O
expert	O
opinion	O
.	O

The	O
surgical	B-T058
treatment	I-T058
of	O
spinal	B-T038
metastases	I-T038
is	O
controversial	O
.	O

Specifically	O
two	O
aspects	O
of	O
surgical	B-T058
reconstruction	I-T058
are	O
addressed	O
in	O
this	O
study	O
:	O
(	O
i	O
)	O
choice	O
of	O
bone	B-T058
graft	I-T058
used	O
during	O
surgery	B-T058
for	O
metastatic	B-T038
spine	I-T038
tumors	I-T038
and	O
(	O
ii	O
)	O
the	O
design	O
of	O
reconstruction	B-T058
or	O
construct	B-T103
to	O
stabilize	B-T033
.	O

A	O
systematic	O
review	B-T170
of	O
the	O
available	O
medical	O
literature	B-T170
from	O
1980	O
to	O
2015	O
was	O
conducted	O
,	O
and	O
combined	O
with	O
consensus	O
expert	O
opinion	O
from	O
a	O
recent	O
survey	B-T170
of	O
spine	B-T017
surgeons	B-T097
who	O
treat	B-T058
metastatic	B-T038
spine	I-T038
tumors	I-T038
.	O

There	O
is	O
very	O
little	O
evidence	O
in	O
the	O
literature	B-T170
to	O
provide	O
guidance	B-T058
on	O
the	O
use	O
of	O
bone	B-T058
graft	I-T058
in	O
metastatic	B-T038
tumor	I-T038
reconstruction	B-T058
.	O

There	O
is	O
little	O
evidence	O
in	O
the	O
literature	B-T170
to	O
support	O
the	O
preferential	O
use	O
of	O
one	O
graft	B-T170
type	I-T170
over	O
the	O
other	O
.	O

Approximately	O
,	O
41	O
%	O
of	O
respondents	B-T098
said	O
they	O
used	O
bone	B-T058
graft	I-T058
or	O
bone	B-T058
graft	I-T058
substitutes	B-T103
to	O
accomplish	O
fusion	B-T058
.	O

There	O
were	O
17	O
studies	B-T062
that	O
described	O
the	O
use	O
of	O
a	O
prefabricated	B-T074
prosthetic	I-T074
,	O
10	O
studies	B-T062
describing	O
the	O
use	O
of	O
polymethyl	B-T103
methacrylate	I-T103
(	O
PMMA	B-T103
)	O
bone	B-T103
cement	I-T103
,	O
and	O
only	O
three	O
studies	B-T062
describing	O
the	O
use	O
of	O
bone	B-T058
graft	I-T058
for	O
anterior	B-T082
column	B-T017
reconstruction	B-T058
.	O

The	O
use	O
of	O
structural	O
allograft	O
was	O
most	O
popular	O
among	O
the	O
experts	B-T097
for	O
anterior	B-T082
reconstruction	B-T058
,	O
followed	O
by	O
cage	B-T074
reconstruction	B-T058
,	O
and	O
PMMA	B-T103
bone	B-T103
cement	I-T103
.	O

Achieving	O
bony	B-T082
union	I-T082
may	O
be	O
of	O
importance	O
for	O
the	O
maintenance	O
of	O
spinal	B-T017
stability	O
in	O
the	O
long	O
term	O
after	O
reconstruction	B-T058
.	O

Whether	O
bony	B-T082
union	I-T082
is	O
required	O
for	O
patients	O
with	O
shorter	O
life	O
expectancies	O
is	O
debatable	O
.	O

The	O
literature	B-T170
supports	O
the	O
use	O
of	O
anterior	B-T082
reconstruction	B-T058
with	O
either	O
a	O
prefabricated	B-T074
prosthetic	I-T074
or	O
PMMA	B-T103
bone	B-T103
cement	I-T103
.	O

It	O
also	O
supports	O
the	O
use	O
of	O
an	O
anterior	B-T082
construct	B-T103
reinforced	O
with	O
bilateral	B-T082
posterior	B-T082
instrumentation	O
when	O
performing	B-T058
a	O
three	B-T058
-	I-T058
column	I-T058
reconstruction	I-T058
.	O

N	O
/	O
A	O
.	O

The	O
value	O
of	O
transesophageal	B-T058
echocardiography	I-T058
for	O
embolic	B-T038
strokes	I-T038
of	I-T038
undetermined	I-T038
source	I-T038

Our	O
aim	O
was	O
to	O
evaluate	O
the	O
diagnostic	B-T058
yield	I-T058
of	O
transesophageal	B-T058
echocardiography	I-T058
(	O
TEE	B-T058
)	O
in	O
consecutive	O
patients	O
with	O
ischemic	B-T038
stroke	I-T038
(	O
IS	B-T038
)	O
fulfilling	O
the	O
diagnostic	B-T170
criteria	I-T170
of	O
embolic	B-T038
strokes	I-T038
of	I-T038
undetermined	I-T038
source	I-T038
(	O
ESUS	B-T038
)	O
.	O

We	O
prospectively	O
evaluated	O
consecutive	O
patients	O
with	O
acute	O
IS	B-T038
satisfying	O
ESUS	B-T038
criteria	O
who	O
underwent	O
in	O
-	O
hospital	B-T092
TEE	B-T058
examination	I-T058
in	O
3	O
tertiary	B-T092
care	I-T092
stroke	I-T092
centers	I-T092
during	O
a	O
12	O
-	O
month	O
period	O
.	O

We	O
also	O
performed	O
a	O
systematic	B-T170
review	I-T170
and	O
meta	B-T062
-	I-T062
analysis	I-T062
estimating	I-T062
the	O
cumulative	O
effect	O
of	O
TEE	B-T058
findings	B-T033
on	O
therapeutic	O
management	O
for	O
secondary	B-T058
stroke	I-T058
prevention	I-T058
among	O
different	O
IS	B-T038
subgroups	O
.	O

We	O
identified	O
61	O
patients	O
with	O
ESUS	B-T038
who	O
underwent	B-T058
investigation	I-T058
with	O
TEE	B-T058
(	O
mean	O
age	O
44	O
±	O
12	O
years	O
,	O
49	O
%	O
men	B-T098
,	O
median	O
NIH	O
Stroke	O
Scale	O
score	O
=	O
5	O
points	O
[	O
interquartile	O
range	O
:	O
3	O
-	O
8	O
]	O
)	O
.	O

TEE	B-T058
revealed	O
additional	O
findings	B-T033
in	O
52	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
40	O
%	O
-	O
65	O
%	O
)	O
of	O
the	O
study	B-T098
population	I-T098
.	O

TEE	B-T058
findings	B-T033
changed	O
management	O
(	O
initiation	O
of	O
anticoagulation	B-T058
therapy	I-T058
,	O
administration	B-T058
of	O
IV	B-T058
antibiotic	I-T058
therapy	I-T058
,	O
and	O
patent	B-T058
foramen	I-T058
ovale	I-T058
closure	I-T058
)	O
in	O
10	O
(	O
16	O
%	O
[	O
95	O
%	O
CI	O
:	O
9	O
%	O
-	O
28	O
%	O
]	O
)	O
patients	O
.	O

The	O
pooled	O
rate	O
of	O
reported	O
anticoagulation	B-T058
therapy	I-T058
attributed	O
to	O
abnormal	B-T033
TEE	B-T058
findings	B-T033
among	O
3	O
,	O
562	O
acute	O
IS	B-T038
patients	O
included	O
in	O
the	O
meta	B-T062
-	I-T062
analysis	I-T062
(	O
12	O
studies	O
)	O
was	O
8	O
.	O
7	O
%	O
(	O
95	O
%	O
CI	O
:	O
7	O
.	O
3	O
%	O
-	O
10	O
.	O
4	O
%	O
)	O
.	O

In	O
subgroup	B-T062
analysis	I-T062
,	O
the	O
rates	O
of	O
initiation	O
of	O
anticoagulation	B-T058
therapy	I-T058
on	O
the	O
basis	O
of	O
TEE	B-T058
investigation	O
did	O
not	O
differ	O
(	O
p	O
=	O
0	O
.	O
315	O
)	O
among	O
patients	O
with	O
cryptogenic	O
stroke	O
(	O
6	O
.	O
9	O
%	O
[	O
95	O
%	O
CI	O
:	O
4	O
.	O
9	O
%	O
-	O
9	O
.	O
6	O
%	O
]	O
)	O
,	O
ESUS	B-T038
(	O
8	O
.	O
1	O
%	O
[	O
95	O
%	O
CI	O
:	O
3	O
.	O
4	O
%	O
-	O
18	O
.	O
1	O
%	O
]	O
)	O
,	O
and	O
IS	B-T038
(	O
9	O
.	O
4	O
%	O
[	O
95	O
%	O
CI	O
:	O
7	O
.	O
5	O
%	O
-	O
11	O
.	O
8	O
%	O
]	O
)	O
.	O

Abnormal	O
TEE	B-T058
findings	B-T033
may	O
decisively	O
affect	O
the	O
selection	O
of	O
appropriate	O
therapeutic	B-T058
strategy	I-T058
in	O
approximately	O
1	O
of	O
7	O
patients	O
with	O
ESUS	B-T038
.	O

Simultaneous	O
thrombosis	B-T038
of	O
multiple	B-T017
coronary	I-T017
arteries	I-T017
in	O
a	O
patient	O
with	O
rheumatoid	B-T038
arthritis	I-T038

We	O
present	O
a	O
case	O
of	O
simultaneous	O
coronary	B-T038
thrombosis	I-T038
of	I-T038
the	I-T038
left	I-T038
main	I-T038
,	O
the	O
left	B-T017
anterior	I-T017
descending	I-T017
artery	I-T017
and	O
the	O
right	B-T017
coronary	I-T017
artery	I-T017
in	O
a	O
patient	O
,	O
recently	O
diagnosed	B-T058
with	O
rheumatoid	B-T038
arthritis	I-T038
.	O

Unintentional	B-T037
Injuries	I-T037
in	O
Children	O
Up	O
to	O
Six	O
Years	O
of	O
Age	O
and	O
Related	O
Parental	O
Knowledge	B-T170
,	O
Attitudes	B-T038
,	O
and	O
Behaviors	O
in	O
Italy	B-T082

To	O
describe	O
risk	B-T033
factors	I-T033
associated	O
with	O
unintentional	B-T037
injuries	I-T037
among	O
children	O
aged	O
<	O
6	O
years	O
and	O
to	O
examine	O
parents	O
'	O
level	O
of	O
knowledge	B-T170
,	O
attitudes	B-T038
,	O
and	O
behaviors	O
about	O
pediatric	O
injuries	B-T037
and	O
related	O
preventive	O
measures	O
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
survey	I-T062
was	O
conducted	O
between	O
May	O
and	O
July	O
2015	O
on	O
a	O
random	B-T062
sample	I-T062
of	O
794	O
parents	O
of	O
3	O
-	O
to	O
6	O
-	O
year	O
-	O
old	O
children	O
through	O
a	O
self	O
-	O
administered	O
anonymous	B-T170
questionnaire	I-T170
.	O

A	O
total	O
of	O
409	O
parents	O
participated	O
.	O

Two	O
-	O
thirds	O
of	O
the	O
children	O
had	O
experienced	O
at	O
least	O
1	O
unintentional	B-T037
injury	I-T037
in	O
the	O
previous	O
12	O
months	O
.	O

More	O
than	O
one	O
-	O
half	O
of	O
these	O
children	O
were	O
boys	O
.	O

The	O
leading	B-T033
cause	I-T033
was	O
falls	B-T037
;	O
the	O
injuries	B-T037
occurred	O
mainly	O
at	O
home	B-T082
,	O
and	O
only	O
9	O
.	O
2	O
%	O
were	O
brought	O
for	O
attention	O
to	O
an	O
emergency	B-T092
department	I-T092
.	O

Parents	O
who	O
did	O
not	O
believe	O
that	O
it	O
is	O
possible	O
to	O
prevent	O
unintentional	B-T037
injuries	I-T037
were	O
more	O
likely	O
to	O
have	O
had	O
a	O
child	O
injured	O
.	O

Approximately	O
70	O
%	O
of	O
respondents	B-T098
were	O
aware	B-T038
of	O
security	B-T170
measures	I-T170
to	O
prevent	O
pediatric	O
injuries	B-T037
,	O
and	O
this	O
knowledge	B-T170
was	O
more	O
prevalent	O
in	O
older	O
parents	O
and	O
in	O
those	O
with	O
at	O
least	O
a	O
college	O
level	O
of	O
education	O
compared	O
with	O
those	O
with	O
a	O
middle	O
school	O
education	O
.	O

The	O
perceived	B-T038
utility	O
of	O
education	O
about	O
preventive	O
measures	O
of	O
pediatric	O
injuries	B-T037
had	O
a	O
mean	O
value	O
of	O
8	O
.	O
9	O
on	O
a	O
Likert	B-T170
scale	I-T170
of	O
1	O
-	O
10	O
(	O
1	O
,	O
not	O
useful	O
,	O
to	O
10	O
,	O
very	O
useful	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
mothers	O
.	O

This	O
study	O
highlights	O
a	O
clear	O
need	O
for	O
public	B-T058
health	I-T058
educational	O
programs	O
for	O
parents	O
regarding	O
prevention	O
of	O
unintentional	B-T037
injuries	I-T037
in	O
children	O
as	O
a	O
valuable	O
tool	O
to	O
increase	O
safety	O
and	O
injury	B-T058
prevention	I-T058
and	O
to	O
reduce	O
risks	O
,	O
because	O
the	O
majority	O
of	O
such	O
injuries	B-T037
occur	O
at	O
home	B-T082
.	O

Truncated	B-T204
Bovine	I-T204
Integrin	B-T103
Alpha	I-T103
-	I-T103
v	I-T103
/	I-T103
Beta	I-T103
-	I-T103
6	I-T103
as	O
a	O
Universal	B-T038
Capture	I-T038
Ligand	I-T038
for	O
FMD	B-T038
Diagnosis	B-T033

Foot	B-T038
-	I-T038
and	I-T038
-	I-T038
mouth	I-T038
disease	I-T038
(	O
FMD	B-T038
)	O
is	O
endemic	B-T038
in	O
many	O
regions	B-T082
of	O
the	O
world	B-T098
and	O
is	O
one	O
of	O
the	O
most	O
prevalent	O
epizootic	O
animal	B-T038
diseases	I-T038
.	O

FMD	B-T038
affects	O
livestock	B-T204
,	O
such	O
as	O
cattle	B-T204
,	O
sheep	B-T204
,	O
goats	B-T204
and	O
pigs	B-T204
,	O
and	O
causes	O
enormous	O
economic	O
losses	O
due	O
to	O
reduced	O
productivity	O
and	O
trade	O
restrictions	O
.	O

Preparedness	B-T033
and	O
early	B-T058
diagnosis	I-T058
are	O
essential	O
for	O
effective	B-T058
control	I-T058
of	O
FMD	B-T038
.	O

Many	O
diagnostic	B-T058
assays	I-T058
are	O
dependent	O
on	O
raising	O
high	O
-	O
affinity	O
,	O
anti	B-T005
-	I-T005
FMD	I-T005
virus	I-T005
(	O
FMDV	B-T005
)	O
serotype	B-T103
-	I-T103
specific	I-T103
antibodies	I-T103
in	O
small	O
animals	B-T204
(	O
rabbits	B-T204
and	O
guinea	B-T204
pigs	I-T204
)	O
that	O
give	O
broad	O
virus	B-T005
coverage	O
.	O

Here	O
we	O
show	O
that	O
soluble	O
,	O
truncated	O
forms	O
of	O
bovine	B-T204
αvβ6	B-T103
bind	B-T038
FMDV	B-T005
in	O
an	O
authentic	O
RGD	B-T103
and	O
divalent	B-T038
cation	I-T038
dependent	I-T038
interaction	I-T038
and	O
can	O
be	O
used	O
as	O
the	O
trapping	B-T103
reagent	I-T103
in	O
a	O
FMDV	B-T005
sandwich	B-T058
ELISA	I-T058
.	O

In	O
addition	O
,	O
inclusion	O
of	O
FLAG	B-T103
or	O
His	B-T103
tags	I-T103
facilitates	O
simple	O
purification	B-T058
without	O
the	O
loss	O
of	O
virus	B-T038
binding	I-T038
.	O

We	O
also	O
provide	O
evidence	O
that	O
when	O
combined	O
with	O
a	O
guinea	B-T204
pig	I-T204
polyclonal	B-T031
serum	I-T031
,	O
or	O
serotype	B-T103
-	I-T103
specific	I-T103
monoclonal	I-T103
antibodies	I-T103
,	O
the	O
integrin	B-T103
can	O
be	O
used	O
to	O
detect	B-T033
viruses	B-T005
representative	O
of	O
all	O
FMDV	O
serotypes	O
.	O

We	O
also	O
show	O
that	O
recombinant	O
FMDV	O
empty	B-T017
capsids	I-T017
,	O
with	O
stabilising	O
disulphide	O
bonds	O
,	O
can	O
serve	O
as	O
an	O
antigen	B-T103
in	O
the	O
ELISA	B-T058
and	O
can	O
therefore	O
replace	O
inactivated	B-T103
virus	I-T103
antigen	I-T103
as	O
a	O
positive	O
control	O
for	O
the	O
assay	B-T058
.	O

Our	O
results	B-T033
demonstrate	O
the	O
potential	O
use	O
of	O
bovine	B-T204
αvβ6	B-T103
and	O
FMDV	B-T005
empty	B-T017
capsids	I-T017
in	O
FMD	B-T038
diagnostic	B-T058
assays	I-T058
.	O

Stress	B-T038
and	O
binge	O
drinking	O
:	O
A	O
toxic	B-T037
combination	O
for	O
the	O
teenage	O
brain	B-T017

Young	O
adult	O
university	O
students	O
frequently	O
binge	O
on	O
alcohol	O
and	O
have	O
high	O
stress	B-T033
levels	I-T033
.	O

Based	O
on	O
findings	O
in	O
rodents	B-T204
,	O
we	O
predicted	O
that	O
heavy	O
current	O
alcohol	O
use	O
and	O
elevated	O
stress	B-T038
and	O
depression	O
scores	O
would	O
be	O
associated	O
with	O
deficits	O
on	O
high	O
interference	O
memory	B-T038
tasks	O
,	O
while	O
early	B-T033
onset	I-T033
,	O
prolonged	O
binge	O
patterns	O
would	O
lead	O
to	O
broader	O
cognitive	B-T038
deficits	I-T038
on	O
tests	O
of	O
associative	B-T038
encoding	I-T038
and	O
executive	B-T038
functions	I-T038
.	O

We	O
developed	O
the	O
Concentration	B-T038
Memory	B-T038
Task	O
,	O
a	O
novel	O
computerized	O
version	O
of	O
the	O
Concentration	B-T038
card	O
game	O
with	O
a	O
high	O
degree	O
of	O
interference	O
.	O

We	O
found	O
that	O
young	O
adults	O
with	O
elevated	O
stress	O
,	O
depression	O
,	O
and	O
alcohol	O
consumption	O
scores	O
were	O
impaired	O
in	O
the	O
Concentration	B-T038
Memory	B-T038
Task	O
.	O

We	O
also	O
analyzed	O
data	O
from	O
a	O
previous	O
study	O
,	O
and	O
found	O
that	O
higher	O
alcohol	O
consumption	O
scores	O
were	O
associated	O
with	O
impaired	O
performance	O
on	O
another	O
high	O
interference	O
memory	B-T038
task	O
,	O
based	O
on	O
Kirwan	B-T170
and	I-T170
Stark	I-T170
'	I-T170
s	I-T170
Mnemonic	I-T170
Similarity	I-T170
Test	I-T170
.	O

On	O
the	O
other	O
hand	O
,	O
adolescent	O
onset	O
of	O
binge	O
drinking	O
predicted	O
poorer	O
performance	O
on	O
broader	O
range	O
of	O
memory	B-T038
tests	B-T170
,	O
including	O
a	O
more	O
systematic	B-T170
test	I-T170
of	I-T170
spatial	I-T170
recognition	I-T170
memory	I-T170
,	O
and	O
an	O
associative	B-T038
learning	I-T038
task	O
.	O

Our	O
results	O
are	O
broadly	O
consistent	O
with	O
findings	O
in	O
rodents	B-T204
that	O
acute	O
alcohol	O
and	O
stress	B-T038
exposure	O
suppress	O
neurogenesis	B-T038
in	O
the	O
adult	O
hippocampus	B-T017
,	O
which	O
in	O
turn	O
impairs	O
performance	O
in	O
high	O
interference	O
memory	B-T038
tasks	O
,	O
while	O
adolescent	O
onset	O
binge	O
drinking	O
causes	O
more	O
extensive	O
brain	B-T037
damage	I-T037
and	O
cognitive	B-T038
deficits	I-T038
.	O

Of	O
Kindlins	B-T103
and	O
Cancer	B-T038

Kindlins	B-T103
are	O
4	B-T082
.	I-T082
1	I-T082
-	I-T082
ezrin	I-T082
-	I-T082
ridixin	I-T082
-	I-T082
moesin	I-T082
(	I-T082
FERM	I-T082
)	I-T082
domain	I-T082
containing	O
proteins	B-T103
.	O

There	O
are	O
three	O
kindlins	B-T103
in	O
mammals	B-T204
,	O
which	O
share	O
high	O
sequence	B-T082
identity	O
.	O

Kindlin	B-T103
-	I-T103
1	I-T103
is	O
expressed	B-T038
primarily	O
in	O
epithelial	B-T017
cells	I-T017
,	O
kindlin	B-T103
-	I-T103
2	I-T103
is	O
widely	O
distributed	O
and	O
is	O
particularly	O
abundant	O
in	O
adherent	B-T017
cells	I-T017
,	O
and	O
kindlin	B-T103
-	I-T103
3	I-T103
is	O
expressed	B-T038
primarily	O
in	O
hematopoietic	B-T017
cells	I-T017
.	O

These	O
distributions	O
are	O
not	O
exclusive	O
;	O
some	O
cells	B-T017
express	B-T038
multiple	O
kindlins	B-T103
,	O
and	O
transformed	B-T017
cells	I-T017
often	O
exhibit	O
aberrant	O
expression	B-T038
,	O
both	O
in	O
the	O
isoforms	B-T103
and	O
the	O
levels	O
of	O
kindlins	B-T103
.	O

Great	O
interest	O
in	O
the	O
kindlins	B-T103
has	O
emerged	O
from	O
the	O
recognition	O
that	O
they	O
play	O
major	O
roles	O
in	O
controlling	O
integrin	B-T103
function	B-T038
.	O

In	O
vitro	O
studies	O
,	O
in	O
vivo	O
studies	O
of	O
mice	B-T204
deficient	O
in	O
kindlins	B-T103
,	O
and	O
studies	B-T062
of	O
patients	O
with	O
genetic	O
deficiencies	O
of	O
kindlins	B-T103
have	O
clearly	O
established	O
that	O
they	O
regulate	O
the	O
capacity	O
of	O
integrins	B-T103
to	O
mediate	O
their	O
functions	O
.	O

Kindlins	B-T103
are	O
adaptor	B-T103
proteins	I-T103
;	O
their	O
function	O
emanate	O
from	O
their	O
interaction	O
with	O
binding	B-T038
partners	O
,	O
including	O
the	O
cytoplasmic	B-T017
tails	I-T017
of	O
integrins	B-T103
and	O
components	O
of	O
the	O
actin	B-T017
cytoskeleton	I-T017
.	O

The	O
purpose	O
of	O
this	O
review	B-T170
is	O
to	O
provide	O
a	O
brief	O
overview	O
of	O
kindlin	B-T103
structure	B-T103
and	O
function	B-T038
,	O
a	O
consideration	B-T033
of	O
their	O
binding	B-T038
partners	O
,	O
and	O
then	O
to	O
focus	O
on	O
the	O
relationship	O
of	O
each	O
kindlin	B-T103
family	B-T103
member	O
with	O
cancer	B-T038
.	O

In	O
view	B-T082
of	O
many	O
correlations	O
of	O
kindlin	B-T103
expression	B-T038
levels	O
and	O
neoplasia	B-T038
and	O
the	O
known	O
association	O
of	O
integrins	B-T103
with	O
tumor	B-T038
progression	I-T038
and	O
metastasis	B-T038
,	O
we	O
consider	O
whether	O
regulation	O
of	O
kindlins	B-T103
or	O
their	O
function	O
would	O
be	O
attractive	O
targets	O
for	O
treatment	B-T058
of	I-T058
cancer	I-T058
.	O

Preclinical	O
fibrinolysis	B-T038
in	O
patients	O
with	O
ST	B-T038
-	I-T038
segment	I-T038
elevation	I-T038
myocardial	I-T038
infarction	I-T038
in	O
a	O
rural	O
region	O

In	O
the	O
current	B-T170
guidelines	I-T170
for	O
the	O
treatment	B-T058
of	O
patients	O
with	O
ST	B-T038
-	I-T038
segment	I-T038
elevation	I-T038
myocardial	I-T038
infarction	I-T038
(	O
STEMI	B-T038
)	O
,	O
the	O
European	O
Society	O
of	O
Cardiology	O
(	O
ESC	O
)	O
recommends	O
preclinical	O
fibrinolysis	B-T038
as	O
a	O
reperfusion	B-T058
therapy	I-T058
if	O
,	O
due	O
to	O
long	O
transportation	O
times	O
,	O
no	O
cardiac	B-T058
catheterisation	I-T058
is	O
available	O
within	O
90	O
-	O
120	O
min	O
.	O

However	O
,	O
there	O
is	O
little	O
remaining	O
in	O
-	O
depth	O
expertise	O
in	O
this	O
method	O
because	O
fibrinolysis	B-T038
is	O
presently	O
only	O
rarely	O
indicated	B-T033
.	O

In	O
a	O
rural	O
area	O
in	O
southwestern	B-T082
Germany	B-T082
,	O
where	O
an	O
emergency	B-T058
primary	I-T058
percutaneous	I-T058
coronary	I-T058
intervention	I-T058
was	O
not	O
routinely	O
available	O
within	O
90	O
-	O
120	O
min	O
,	O
156	O
STEMI	B-T038
patients	O
underwent	O
fibrinolysis	B-T038
with	O
the	O
plasminogen	B-T103
activator	I-T103
reteplase	I-T103
,	O
performed	O
by	O
trained	O
emergency	O
physicians	B-T097
.	O

The	O
practicality	O
of	O
the	O
treatment	B-T058
,	O
as	O
well	O
as	O
complications	B-T038
and	O
the	O
mortality	O
of	O
the	O
patients	O
in	O
the	O
preclinical	O
phase	O
until	O
arrival	O
at	O
the	O
hospital	B-T092
,	O
were	O
retrospectively	B-T062
studied	I-T062
.	O

The	O
mean	O
time	O
from	O
onset	O
of	O
the	O
symptoms	B-T033
to	O
first	O
medical	B-T058
contact	I-T058
was	O
114	O
±	O
116	O
min	O
.	O

The	O
mean	O
interval	O
to	O
the	O
start	O
of	O
fibrinolysis	B-T038
of	O
13	O
.	O
5	O
±	O
6	O
.	O
4	O
min	O
was	O
within	O
the	O
30	O
min	O
mandated	B-T170
by	O
the	O
ESC	O
.	O

Patients	O
with	O
inferior	B-T038
STEMI	I-T038
represented	O
the	O
largest	O
subgroup	B-T170
.	O

Occurring	O
in	O
39	O
cases	O
(	O
25	O
%	O
)	O
,	O
complications	B-T038
due	O
to	O
infarction	B-T038
were	O
relatively	O
common	O
during	O
the	O
prehospital	B-T058
phase	O
,	O
including	O
15	O
cases	O
(	O
9	O
.	O
6	O
%	O
)	O
of	O
cardiogenic	B-T038
shock	I-T038
,	O
but	O
in	O
all	O
cases	O
the	O
complications	B-T038
were	O
manageable	B-T033
.	O

No	O
patient	O
died	B-T033
before	O
arrival	O
at	O
the	O
hospital	B-T092
.	O

As	O
lysis	B-T038
-	O
associated	O
adverse	B-T038
effects	I-T038
,	O
merely	O
two	O
uncomplicated	O
mucosal	B-T033
haemorrhages	I-T033
and	O
one	O
case	O
of	O
mild	B-T038
allergic	I-T038
skin	I-T038
reactions	I-T038
were	O
seen	O
.	O

In	O
emergency	O
situations	O
with	O
long	O
transportation	O
times	O
to	O
the	O
nearest	O
suitable	O
cardiac	B-T058
catheterisation	I-T058
laboratory	B-T092
,	O
preclinical	O
fibrinolysis	B-T038
in	O
STEMI	B-T038
still	O
represents	O
a	O
workable	O
method	O
.	O

Success	O
of	O
this	O
strategy	O
requires	O
particularly	O
strong	O
training	O
of	O
the	O
emergency	O
physicians	B-T097
in	O
ECG	B-T058
and	O
lysis	B-T038
therapy	B-T058
,	O
and	O
co	O
-	O
operation	O
with	O
nearby	O
cardiac	B-T092
centres	I-T092
.	O

A	O
method	O
of	O
providing	O
engaging	O
formative	O
feedback	O
to	O
large	O
cohort	B-T098
first	O
-	O
year	O
physiology	B-T091
and	O
anatomy	B-T091
students	B-T098

A	O
growing	O
body	O
of	O
evidence	O
demonstrates	O
a	O
critical	O
role	O
for	O
effective	O
,	O
meaningful	O
feedback	B-T038
to	O
enhance	O
student	B-T098
learning	B-T038
.	O

Effective	O
feedback	B-T038
can	O
become	O
part	B-T082
of	I-T082
the	O
learning	B-T038
cycle	O
that	O
is	O
not	O
only	O
a	O
learning	B-T038
opportunity	O
for	O
the	O
student	B-T098
but	O
can	O
also	O
be	O
used	O
to	O
inform	O
the	O
teacher	B-T097
and	O
ongoing	O
curriculum	O
development	O
.	O

Feedback	B-T038
is	O
considered	O
particularly	O
important	O
during	O
the	O
first	O
year	O
of	O
university	B-T092
and	O
can	O
even	O
be	O
viewed	O
as	O
a	O
retention	O
strategy	O
that	O
can	O
help	O
attenuate	O
student	B-T098
performance	B-T038
anxieties	I-T038
and	O
solidify	O
perceptions	B-T038
of	O
academic	O
support	O
.	O

Unfortunately	O
,	O
the	O
provision	O
of	O
individualized	O
,	O
timely	O
feedback	B-T038
can	O
be	O
particularly	O
challenging	O
in	O
first	O
-	O
year	O
courses	O
as	O
they	O
tend	O
to	O
be	O
large	O
and	O
diverse	O
cohort	B-T098
classes	B-T170
that	O
pose	O
challenges	O
of	O
time	O
and	O
logistics	O
.	O

Various	O
forms	O
of	O
generic	O
feedback	B-T038
can	O
provide	O
rapid	O
and	O
cost	O
-	O
effect	O
feedback	B-T038
to	O
large	O
cohorts	B-T098
but	O
may	O
be	O
of	O
limited	O
benefit	O
to	O
students	B-T098
other	O
than	O
signaling	O
weaknesses	B-T033
in	O
knowledge	B-T170
.	O

The	O
present	B-T033
study	B-T062
describes	O
a	O
method	O
that	O
was	O
used	O
to	O
provide	O
formative	O
task	O
-	O
related	O
feedback	O
to	O
a	O
large	O
cohort	B-T098
of	O
first	O
-	O
year	O
physiology	B-T091
and	O
anatomy	B-T091
students	B-T098
.	O

Based	O
on	O
student	B-T098
evaluations	B-T058
presented	O
in	O
this	O
study	B-T062
,	O
this	O
method	O
provided	O
feedback	B-T038
in	O
a	O
manner	O
that	O
engaged	O
students	B-T098
,	O
uncovered	O
underlying	B-T033
misconceptions	I-T033
,	O
facilitated	O
peer	B-T098
discussion	O
,	O
and	O
provided	O
opportunity	O
for	O
new	O
instruction	O
while	O
allowing	O
the	O
lecturer	O
to	O
recognize	B-T038
common	O
gaps	B-T082
in	O
knowledge	B-T170
and	O
inform	O
ongoing	O
curriculum	O
development	O
.	O

SIRT2	B-T103
Deacetylates	B-T038
and	O
Inhibits	B-T038
the	I-T038
Peroxidase	I-T038
Activity	I-T038
of	O
Peroxiredoxin	B-T103
-	I-T103
1	I-T103
to	O
Sensitize	B-T017
Breast	I-T017
Cancer	I-T017
Cells	I-T017
to	O
Oxidant	B-T038
Stress	I-T038
-	O
Inducing	O
Agents	O

SIRT2	B-T103
is	O
a	O
protein	B-T038
deacetylase	I-T038
with	O
tumor	B-T038
suppressor	I-T038
activity	I-T038
in	O
breast	B-T038
and	O
liver	B-T038
tumors	I-T038
where	O
it	O
is	O
mutated	B-T038
;	O
however	O
,	O
the	O
critical	O
substrates	O
mediating	O
its	O
antitumor	B-T033
activity	I-T033
are	O
not	O
fully	O
defined	O
.	O

Here	O
we	O
demonstrate	O
that	O
SIRT2	B-T103
binds	B-T038
,	O
deacetylates	B-T038
,	O
and	O
inhibits	B-T038
the	I-T038
peroxidase	I-T038
activity	I-T038
of	O
the	O
antioxidant	B-T103
protein	I-T103
peroxiredoxin	I-T103
(	O
Prdx	B-T103
-	I-T103
1	I-T103
)	O
in	O
breast	B-T017
cancer	I-T017
cells	I-T017
.	O

Ectopic	B-T082
overexpression	B-T038
of	O
SIRT2	B-T103
,	O
but	O
not	O
its	O
catalytically	B-T038
dead	I-T038
mutant	I-T038
,	O
increased	O
intracellular	B-T082
levels	I-T082
of	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
induced	B-T103
by	I-T103
hydrogen	I-T103
peroxide	I-T103
,	I-T103
which	O
led	O
to	O
increased	O
levels	O
of	O
an	O
overoxidized	B-T103
and	I-T103
multimeric	I-T103
form	I-T103
of	I-T103
Prdx	I-T103
-	I-T103
1	I-T103
with	O
activity	B-T103
as	I-T103
a	I-T103
molecular	I-T103
chaperone	I-T103
.	O

Elevated	O
levels	O
of	O
SIRT2	B-T017
sensitized	B-T017
breast	I-T017
cancer	I-T017
cells	I-T017
to	O
intracellular	B-T038
DNA	I-T038
damage	I-T038
and	O
cell	B-T038
death	I-T038
induced	I-T038
by	I-T038
oxidative	I-T038
stress	I-T038
,	O
as	O
associated	O
with	O
increased	O
levels	O
of	O
nuclear	B-T103
FOXO3A	I-T103
and	O
the	O
proapoptotic	B-T103
BIM	I-T103
protein	I-T103
.	O

In	O
addition	O
,	O
elevated	O
levels	O
of	O
SIRT2	B-T103
sensitized	B-T017
breast	I-T017
cancer	I-T017
cells	I-T017
to	O
arsenic	B-T103
trioxide	I-T103
,	O
an	O
approved	O
therapeutic	O
agent	O
,	O
along	O
with	O
other	O
intracellular	B-T103
ROS	I-T103
-	O
inducing	B-T103
agents	I-T103
.	O

Conversely	O
,	O
antisense	B-T103
RNA	I-T103
-	O
mediated	O
attenuation	O
of	O
SIRT2	B-T103
reversed	O
ROS	B-T103
-	O
induced	B-T037
toxicity	I-T037
as	O
demonstrated	O
in	O
a	O
zebrafish	B-T204
embryo	B-T017
model	I-T017
system	I-T017
.	O

Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
tumor	B-T038
suppressor	I-T038
activity	I-T038
of	O
SIRT2	B-T103
requires	O
its	O
ability	O
to	O
restrict	O
the	O
antioxidant	B-T038
activity	I-T038
of	O
Prdx	B-T103
-	I-T103
1	I-T103
,	O
thereby	O
sensitizing	B-T017
breast	I-T017
cancer	I-T017
cells	I-T017
to	O
ROS	B-T103
-	O
induced	B-T038
DNA	I-T038
damage	I-T038
and	O
cell	B-T038
cytotoxicity	I-T038
.	O

Cancer	O
Res	O
;	O
76	O
(	O
18	O
)	O
;	O
5467	O
-	O
78	O
.	O

©2016	O
AACR	O
.	O

On	O
the	O
development	O
of	O
conjunctival	B-T038
hyperemia	I-T038
computer	B-T058
-	I-T058
assisted	I-T058
diagnosis	I-T058
tools	I-T058
:	O
Influence	O
of	O
feature	O
selection	O
and	O
class	B-T170
imbalance	I-T170
in	O
automatic	O
gradings	O

The	O
sudden	O
increase	O
of	O
blood	B-T038
flow	I-T038
in	O
the	O
bulbar	B-T017
conjunctiva	I-T017
,	O
known	O
as	O
hyperemia	B-T038
,	O
is	O
associated	O
to	O
a	O
red	O
hue	O
of	O
variable	O
intensity	O
.	O

Experts	O
measure	O
hyperemia	B-T038
using	O
levels	O
in	O
a	O
grading	B-T170
scale	I-T170
,	O
a	O
procedure	O
that	O
is	O
subjective	O
,	O
non	O
-	O
repeatable	O
and	O
time	O
consuming	O
,	O
thus	O
creating	O
a	O
need	O
for	O
its	O
automatisation	O
.	O

However	O
,	O
the	O
task	O
is	O
far	O
from	O
straightforward	O
due	O
to	O
data	O
issues	O
such	O
as	O
class	B-T170
imbalance	I-T170
or	O
correlated	O
features	O
.	O

In	O
this	O
paper	O
,	O
we	O
study	O
the	O
specific	O
features	O
of	O
hyperemia	B-T038
and	O
propose	O
various	O
approaches	O
to	O
address	O
these	O
problems	O
in	O
the	O
context	O
of	O
an	O
automatic	B-T170
framework	I-T170
for	O
hyperemia	B-T038
grading	B-T033
.	O

Oversampling	B-T170
,	O
undersampling	B-T170
and	O
SMOTE	B-T170
approaches	I-T170
were	O
applied	O
in	O
order	O
to	O
tackle	O
the	O
problem	O
of	O
class	B-T170
imbalance	I-T170
.	O

25	O
features	O
were	O
computed	O
for	O
each	O
image	O
and	O
regression	B-T170
methods	I-T170
were	O
then	O
used	O
to	O
transform	O
them	O
into	O
a	O
value	O
on	O
the	O
grading	B-T170
scale	I-T170
.	O

The	O
values	O
and	O
relationships	O
among	O
features	O
and	O
experts	B-T033
'	I-T033
values	I-T033
were	O
analysed	O
,	O
and	O
five	O
feature	O
selection	O
techniques	O
were	O
subsequently	O
studied	O
.	O

The	O
lowest	O
mean	O
square	O
error	O
(	O
MSE	O
)	O
for	O
the	O
regression	B-T170
systems	I-T170
trained	O
with	O
individual	O
features	O
is	O
below	O
0	O
.	O
1	O
for	O
both	O
scales	O
.	O

Multi	B-T170
-	I-T170
layer	I-T170
perceptron	I-T170
(	O
MLP	B-T170
)	O
obtains	O
the	O
best	O
values	O
,	O
but	O
is	O
less	O
consistent	O
than	O
the	O
random	B-T170
forest	I-T170
(	I-T170
RF	I-T170
)	I-T170
method	I-T170
.	O

When	O
all	O
features	O
are	O
combined	O
,	O
the	O
best	O
results	O
for	O
both	O
scales	O
are	O
achieved	O
with	O
MLP	B-T170
.	O

Correlation	B-T170
based	I-T170
feature	I-T170
selection	I-T170
(	O
CFS	B-T170
)	O
and	O
M5	O
provide	O
the	O
best	O
results	O
,	O
MSE	O
=	O
0	O
.	O
108	O
and	O
MSE	O
=	O
0	O
.	O
061	O
respectively	O
.	O

Finally	O
,	O
the	O
class	B-T170
imbalance	I-T170
problem	I-T170
is	O
minimised	O
with	O
the	O
SMOTE	B-T170
approach	I-T170
for	O
both	O
scales	O
(	O
MSE	O
<	O
0	O
.	O
006	O
)	O
.	O

Machine	O
learning	O
methods	O
are	O
able	O
to	O
perform	O
an	O
objective	O
assessment	O
of	O
hyperemia	B-T038
grading	B-T033
,	O
removing	O
both	O
intra	O
-	O
and	O
inter	O
-	O
expert	O
subjectivity	O
while	O
providing	O
a	O
gain	O
in	O
computation	O
time	O
.	O

SMOTE	B-T170
and	O
oversampling	B-T170
approaches	I-T170
minimise	O
the	O
class	B-T170
imbalance	I-T170
problem	I-T170
,	O
while	O
feature	O
selection	O
reduces	O
the	O
number	O
of	O
features	O
from	O
25	O
to	O
3	O
-	O
5	O
without	O
worsening	O
the	O
MSE	O
.	O

As	O
the	O
differences	O
between	O
the	O
system	B-T170
and	O
a	O
human	B-T097
expert	I-T097
are	O
similar	O
to	O
the	O
differences	O
between	O
experts	B-T097
,	O
we	O
can	O
therefore	O
conclude	O
that	O
the	O
system	B-T170
behaves	O
like	O
an	O
expert	B-T097
.	O

Medication	B-T058
,	O
rehabilitation	O
and	O
health	O
care	O
consumption	O
in	O
adults	O
with	O
cerebral	B-T038
palsy	I-T038
:	O
A	O
population	B-T062
based	I-T062
study	I-T062

To	O
evaluate	O
medication	B-T058
,	O
rehabilitation	O
and	O
healthcare	O
consumption	O
in	O
adults	O
with	O
CP	B-T038
as	O
a	O
function	O
of	O
Gross	B-T170
Motor	I-T170
Function	I-T170
Classification	I-T170
System	I-T170
(	O
GMFCS	B-T170
)	O
level	O
.	O

Questionnaire	B-T170
-	O
based	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
.	O

Brittany	B-T082
,	O
a	O
French	B-T082
county	I-T082
.	O

Adults	O
with	O
cerebral	B-T038
palsy	I-T038
.	O

Questionnaires	B-T170
relating	O
to	O
drugs	B-T103
,	O
orthotic	B-T074
devices	I-T074
,	O
mobility	B-T074
aids	I-T074
,	O
rehabilitation	O
and	O
medical	B-T033
input	I-T033
were	O
sent	O
to	O
435	O
members	B-T098
of	O
a	O
unique	O
regional	B-T082
French	I-T082
network	O
dedicated	O
to	O
adults	O
with	O
cerebral	B-T038
palsy	I-T038
.	O

The	O
questionnaire	B-T170
was	O
completed	O
by	O
the	O
participant	B-T098
or	O
a	O
helper	O
if	O
necessary	O
.	O

Of	O
the	O
282	O
responders	B-T033
,	O
7	O
.	O
8	O
%	O
had	O
a	O
GMFCS	B-T170
level	I-T170
of	O
I	O
,	O
14	O
.	O
2	O
%	O
II	O
,	O
17	O
.	O
7	O
%	O
III	O
,	O
29	O
.	O
1	O
%	O
IV	O
and	O
31	O
.	O
2	O
%	O
V	O
.	O

Participants	B-T098
consumed	O
a	O
large	O
amount	O
of	O
healthcare	O
.	O

Almost	O
three	O
-	O
quarters	O
took	O
orally	B-T103
administered	I-T103
drugs	I-T103
,	O
of	O
which	O
antispastic	O
and	O
antiepileptic	B-T103
drugs	I-T103
were	O
among	O
the	O
most	O
frequent	O
.	O

Nearly	O
all	O
patients	O
had	O
at	O
least	O
one	O
type	O
of	O
rehabilitation	O
,	O
87	O
.	O
2	O
%	O
had	O
physiotherapy	B-T058
,	O
78	O
%	O
used	O
at	O
least	O
one	O
mobility	B-T074
aid	I-T074
and	O
69	O
.	O
5	O
%	O
used	O
at	O
least	O
one	O
orthotic	B-T074
device	I-T074
.	O

The	O
frequency	O
of	O
numerous	O
inputs	O
increased	O
with	O
GMFCS	B-T170
level	I-T170
.	O

Specificities	O
were	O
found	B-T033
for	O
each	O
GMFCS	B-T170
level	I-T170
,	O
e	O
.	O
g	O
.	O

participants	B-T098
with	O
GMFCS	B-T170
level	I-T170
IV	O
and	O
V	O
had	O
a	O
high	O
level	O
of	O
medical	B-T033
input	I-T033
and	O
a	O
greater	O
use	O
of	O
trunk	B-T074
-	I-T074
supporting	I-T074
devices	I-T074
,	O
antireflux	B-T058
and	O
laxative	B-T103
.	O

Profiles	O
could	O
be	O
established	O
based	O
on	O
GMFCS	B-T170
levels	I-T170
.	O

Adults	O
with	O
cerebral	B-T038
palsy	I-T038
use	O
a	O
large	O
amount	O
of	O
drugs	B-T103
,	O
mobility	B-T074
aids	I-T074
,	O
orthotic	B-T074
devices	I-T074
,	O
rehabilitation	O
and	O
medical	B-T033
input	I-T033
.	O

Healthcare	B-T058
is	O
targeted	O
at	O
cerebral	B-T033
palsy	I-T033
-	I-T033
related	I-T033
issues	I-T033
.	O

GMFCS	B-T170
is	O
a	O
determinant	O
of	O
healthcare	O
consumption	O
and	O
thus	O
a	O
useful	O
tool	O
for	O
clinical	O
practice	O
to	O
target	O
care	O
appropriately	O
.	O

Transcriptome	B-T058
sequencing	I-T058
and	O
de	O
novo	O
characterization	O
of	O
Korean	B-T082
endemic	O
land	B-T204
snail	I-T204
,	O
Koreanohadra	B-T204
kurodana	I-T204
for	O
functional	O
transcripts	B-T103
and	O
SSR	B-T103
markers	B-T038

The	O
Korean	B-T082
endemic	O
land	B-T204
snail	I-T204
Koreanohadra	B-T204
kurodana	I-T204
(	O
Gastropoda	B-T204
:	O
Bradybaenidae	B-T204
)	O
found	O
in	O
humid	O
areas	O
of	O
broadleaf	O
forests	O
and	O
shrubs	B-T204
have	O
been	O
considered	O
vulnerable	O
as	O
the	O
number	O
of	O
individuals	B-T098
are	O
declining	O
in	O
recent	O
years	O
.	O

The	O
species	B-T204
is	O
poorly	O
characterized	O
at	O
the	O
genomic	B-T017
level	I-T017
that	O
limits	O
the	O
understanding	O
of	O
functions	O
at	O
the	O
molecular	O
and	O
genetics	O
level	O
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
performed	O
de	O
novo	O
transcriptome	B-T058
sequencing	I-T058
to	O
produce	O
a	O
comprehensive	O
transcript	B-T103
dataset	B-T170
of	O
visceral	B-T017
mass	I-T017
tissue	I-T017
of	O
K	B-T204
.	I-T204

kurodana	I-T204
by	O
the	O
Illumina	B-T062
paired	I-T062
-	I-T062
end	I-T062
sequencing	I-T062
technology	I-T062
.	O

Over	O
234	O
million	O
quality	O
reads	O
were	O
assembled	O
to	O
a	O
total	O
of	O
315	O
,	O
924	O
contigs	B-T082
and	O
191	O
,	O
071	O
unigenes	B-T170
,	O
with	O
an	O
average	O
and	O
N50	B-T103
length	O
of	O
585	O
.	O
6	O
and	O
715	O
bp	O
and	O
678	O
and	O
927	O
bp	O
,	O
respectively	O
.	O

Overall	O
,	O
36	O
.	O
32	O
%	O
of	O
the	O
unigenes	B-T170
found	O
matches	O
to	O
known	O
protein	B-T082
/	O
nucleotide	B-T082
sequences	I-T082
in	O
the	O
public	B-T170
databases	I-T170
.	O

The	O
direction	B-T082
of	O
the	O
unigenes	B-T170
to	O
functional	O
categories	O
was	O
determined	O
using	O
COG	B-T170
,	O
GO	B-T170
,	O
KEGG	B-T170
,	O
and	O
InterProScan	B-T170
protein	B-T082
domain	I-T082
search	O
.	O

The	O
GO	B-T170
analysis	B-T062
search	O
resulted	O
in	O
22	O
,	O
967	O
unigenes	B-T170
(	O
12	O
.	O
02	O
%	O
)	O
being	O
categorized	O
into	O
40	O
functional	O
groups	O
.	O

The	O
KEGG	B-T170
annotation	I-T170
revealed	O
that	O
metabolism	O
pathway	O
genes	B-T017
were	O
enriched	O
.	O

The	O
most	O
prominent	O
protein	B-T082
motifs	I-T082
include	O
the	O
zinc	B-T082
finger	I-T082
,	O
ribonuclease	B-T103
H	I-T103
,	O
reverse	B-T103
transcriptase	I-T103
,	O
and	O
ankyrin	B-T038
repeat	I-T038
domains	I-T038
.	O

The	O
simple	B-T103
sequence	I-T103
repeats	I-T103
(	O
SSRs	B-T103
)	O
identified	O
from	O
>	O
1	O
kb	O
length	O
of	O
unigenes	B-T170
show	O
a	O
dominancy	O
of	O
dinucleotide	B-T103
repeat	I-T103
motifs	I-T103
followed	O
with	O
tri	B-T103
-	I-T103
and	O
tetranucleotide	B-T103
motifs	I-T103
.	O

A	O
number	O
of	O
unigenes	B-T170
were	O
putatively	O
assessed	O
to	O
belong	O
to	O
adaptation	B-T038
and	O
defense	B-T038
mechanisms	I-T038
including	O
heat	B-T103
shock	I-T103
proteins	I-T103
70	I-T103
,	O
Toll	B-T103
-	I-T103
like	I-T103
receptor	I-T103
4	I-T103
,	O
AMP	B-T103
-	I-T103
activated	I-T103
protein	I-T103
kinase	I-T103
,	O
aquaporin	B-T103
-	I-T103
2	I-T103
,	O
etc	O
.	O

Our	O
data	O
provide	O
a	O
rich	O
source	O
for	O
the	O
identification	O
and	O
functional	O
characterization	O
of	O
new	O
genes	B-T017
and	O
candidate	O
polymorphic	O
SSR	B-T103
markers	B-T038
in	O
K	B-T204
.	I-T204

kurodana	I-T204
.	O

The	O
availability	O
of	O
transcriptome	B-T082
information	O
(	O
http	B-T170
:	I-T170
/	I-T170
/	I-T170
bioinfo	I-T170
.	I-T170
sch	I-T170
.	I-T170
ac	I-T170
.	I-T170
kr	I-T170
/	I-T170
submission	I-T170
/	I-T170
)	O
would	O
promote	O
the	O
utilization	O
of	O
the	O
resources	O
for	O
phylogenetics	B-T062
study	I-T062
and	O
genetic	O
diversity	O
assessment	O
.	O

Prediction	O
of	O
Estrogenic	B-T103
Bioactivity	O
of	O
Environmental	B-T103
Chemical	I-T103
Metabolites	B-T103

The	O
US	B-T092
Environmental	I-T092
Protection	I-T092
Agency	I-T092
'	I-T092
s	I-T092
(	O
EPA	B-T092
)	O
Endocrine	O
Disruptor	O
Screening	O
Program	O
(	O
EDSP	O
)	O
is	O
using	O
in	O
vitro	O
data	O
generated	O
from	O
ToxCast	B-T170
/	O
Tox21	B-T170
high	B-T058
-	I-T058
throughput	I-T058
screening	I-T058
assays	I-T058
to	O
assess	O
the	O
endocrine	B-T022
activity	O
of	O
environmental	B-T103
chemicals	I-T103
.	O

Considering	O
that	O
in	B-T058
vitro	I-T058
assays	I-T058
may	O
have	O
limited	O
metabolic	O
capacity	O
,	O
inactive	B-T103
chemicals	I-T103
that	O
are	O
biotransformed	B-T038
into	O
metabolites	B-T103
with	O
endocrine	B-T022
bioactivity	O
may	O
be	O
missed	O
for	O
further	O
screening	O
and	O
testing	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
value	O
in	O
developing	O
novel	O
approaches	O
to	O
account	O
for	O
metabolism	B-T038
and	O
endocrine	B-T022
activity	O
of	O
both	O
parent	B-T103
chemicals	I-T103
and	O
their	O
associated	O
metabolites	B-T103
.	O

We	O
used	O
commercially	O
available	O
software	B-T170
to	O
predict	O
metabolites	B-T103
of	O
50	O
parent	B-T103
compounds	I-T103
,	O
out	O
of	O
which	O
38	O
chemicals	B-T103
are	O
known	O
to	O
have	O
estrogenic	B-T103
metabolites	B-T103
,	O
and	O
12	O
compounds	B-T103
and	O
their	O
metabolites	B-T103
are	O
negative	O
for	O
estrogenic	B-T103
activity	O
.	O

Three	O
ER	B-T103
QSAR	O
models	B-T170
were	O
used	O
to	O
determine	O
potential	O
estrogen	B-T103
bioactivity	O
of	O
the	O
parent	B-T103
compounds	I-T103
and	O
predicted	O
metabolites	B-T103
,	O
the	O
outputs	O
of	O
the	O
models	B-T170
were	O
averaged	O
,	O
and	O
the	O
chemicals	B-T103
were	O
then	O
ranked	O
based	O
on	O
the	O
total	O
estrogenicity	O
of	O
the	O
parent	B-T103
chemical	I-T103
and	O
metabolites	B-T103
.	O

The	O
metabolite	B-T170
prediction	I-T170
software	I-T170
correctly	O
identified	O
known	O
estrogenic	B-T103
metabolites	B-T103
for	O
26	O
out	O
of	O
27	O
parent	B-T103
chemicals	I-T103
with	O
associated	O
metabolite	B-T103
data	O
,	O
and	O
39	O
out	O
of	O
46	O
estrogenic	B-T103
metabolites	B-T103
were	O
predicted	O
as	O
potential	O
biotransformation	B-T038
products	B-T103
derived	O
from	O
the	O
parent	B-T103
chemical	I-T103
.	O

The	O
QSAR	O
models	B-T170
estimated	O
stronger	O
estrogenic	B-T103
activity	O
for	O
the	O
majority	O
of	O
the	O
known	O
estrogenic	B-T103
metabolites	B-T103
compared	O
to	O
their	O
parent	B-T103
chemicals	I-T103
.	O

Finally	O
,	O
the	O
three	O
models	B-T170
identified	O
a	O
similar	O
set	O
of	O
parent	B-T103
compounds	I-T103
as	O
top	O
ranked	O
chemicals	B-T103
based	O
on	O
the	O
estrogenicity	O
of	O
putative	O
metabolites	B-T103
.	O

This	O
proposed	O
in	O
silico	O
approach	O
is	O
an	O
inexpensive	O
and	O
rapid	O
strategy	O
for	O
the	O
detection	B-T033
of	O
chemicals	B-T103
with	O
estrogenic	B-T103
metabolites	B-T103
and	O
may	O
reduce	O
potential	O
false	B-T033
negative	I-T033
results	O
from	O
in	B-T058
vitro	I-T058
assays	I-T058
.	O

Effects	O
of	O
Application	O
of	O
Social	O
Marketing	O
Theory	O
and	O
the	O
Health	B-T058
Belief	I-T058
Model	I-T058
in	O
Promoting	O
Cervical	B-T058
Cancer	I-T058
Screening	I-T058
among	O
Targeted	O
Women	B-T098
in	O
Sisaket	B-T082
Province	I-T082
,	O
Thailand	B-T082

Cervical	B-T038
cancer	I-T038
is	O
a	O
major	O
public	B-T033
health	I-T033
problem	I-T033
in	O
Thailand	B-T082
,	O
being	O
ranked	B-T170
second	O
only	O
to	O
breast	B-T038
cancer	I-T038
.	O

Thai	B-T098
women	B-T098
have	O
been	O
reported	B-T058
to	O
have	O
a	O
low	O
rate	O
of	O
cervical	B-T058
cancer	I-T058
screening	I-T058
(	O
27	O
.	O
7	O
%	O
of	O
the	O
80	O
%	O
goal	B-T170
of	O
WHO	B-T092
)	O
.	O

We	O
therefore	O
aimed	O
to	O
apply	O
the	O
social	O
marketing	O
theory	O
and	O
health	B-T058
belief	I-T058
model	I-T058
in	O
promoting	O
cervical	B-T058
cancer	I-T058
screening	I-T058
in	O
Kanthararom	B-T082
District	I-T082
,	O
Sisaket	B-T082
Province	I-T082
.	O

A	O
total	O
of	O
92	O
from	O
974	O
targeted	O
women	B-T098
aged	O
3060	O
years	O
were	O
randomly	B-T062
divided	O
into	O
two	O
groups	O
.	O

The	O
experimental	B-T098
group	I-T098
underwent	O
application	O
of	O
social	O
marketing	O
theory	O
and	O
a	O
health	B-T058
belief	I-T058
model	I-T058
program	O
promoting	O
cervical	B-T058
cancer	I-T058
screening	I-T058
while	O
the	O
control	O
group	O
received	O
normal	O
services	O
.	O

Two	O
research	B-T170
tools	I-T170
were	O
used	O
:	O
(	O
1	O
)	O
application	O
of	O
social	O
marketing	O
theory	O
and	O
health	B-T058
belief	I-T058
model	I-T058
program	O
and	O
(	O
2	O
)	O
questionnaire	B-T170
used	O
to	O
evaluate	O
perceptions	B-T038
of	O
cervical	B-T038
cancer	I-T038
.	O

Descriptive	B-T170
and	O
inferential	O
statistics	O
including	O
paired	O
sample	B-T170
ttest	I-T170
and	O
independent	O
ttest	B-T170
were	O
used	O
to	O
analyze	O
the	O
data	O
.	O

After	O
the	O
program	O
had	O
been	O
used	O
,	O
the	O
mean	O
score	O
of	O
perception	B-T038
of	O
cervical	B-T038
cancer	I-T038
of	O
experimental	B-T098
group	I-T098
was	O
at	O
a	O
higher	O
level	O
(	O
x	O
=	O
4	O
.	O
09	O
;	O
S	O
.	O
D	O
.	O

=	O
0	O
.	O
30	O
)	O
,	O
than	O
in	O
the	O
control	O
group	O
(	O
x	O
=	O
3	O
.	O
82	O
;	O
S	O
.	O
D	O
.	O

=	O
0	O
.	O
20	O
)	O
with	O
statistical	O
significance	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

This	O
research	B-T062
demonstrated	O
an	O
appropriate	O
communication	O
process	O
in	O
behavioral	O
modification	O
to	O
prevent	O
cervical	B-T038
cancer	I-T038
.	O

It	O
can	O
be	O
recommended	O
that	O
this	O
program	O
featuring	O
social	O
marketing	O
and	O
the	O
health	B-T058
belief	I-T058
model	I-T058
be	O
used	O
to	O
promote	O
cervical	B-T058
cancer	I-T058
screening	I-T058
in	O
targeted	O
women	B-T098
and	O
it	O
can	O
be	O
promoted	O
as	O
a	O
guideline	B-T170
for	O
other	O
health	B-T058
services	I-T058
,	O
especially	O
in	O
health	B-T058
promotion	I-T058
and	O
disease	O
prevention	O
.	O

Visualization	B-T058
of	O
the	O
Intimal	B-T017
Flap	I-T017
in	O
Intracranial	B-T017
Arterial	I-T017
Dissection	I-T017
Using	O
High	O
-	O
Resolution	O
3T	B-T058
MRI	I-T058

Presence	B-T033
of	O
an	O
intimal	B-T017
flap	I-T017
is	O
a	O
critical	O
imaging	B-T033
finding	I-T033
in	O
diagnosing	B-T033
intracranial	B-T017
artery	I-T017
dissection	I-T017
(	O
ICAD	B-T017
)	O
.	O

Recent	O
reports	B-T170
showed	O
that	O
high	O
-	O
resolution	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
(	O
MRI	B-T058
)	O
was	O
better	O
at	O
identifying	O
intimal	B-T017
flaps	I-T017
as	O
compared	O
with	O
routine	O
MRI	B-T058
techniques	I-T058
used	O
in	O
clinical	O
settings	O
.	O

However	O
,	O
no	O
current	O
standardized	O
sequence	O
for	O
high	O
-	O
resolution	O
MRI	B-T058
without	O
gadolinium	B-T103
enhancement	O
produces	O
images	O
of	O
satisfactory	O
quality	O
with	O
clinically	O
tolerable	O
scanning	B-T058
times	O
.	O

This	O
study	O
evaluated	B-T058
a	O
nonenhanced	B-T058
high	I-T058
-	I-T058
resolution	I-T058
fast	I-T058
spin	I-T058
echo	I-T058
(	I-T058
HR	I-T058
-	I-T058
FSE	I-T058
)	I-T058
MRI	I-T058
sequence	O
for	O
visualizing	O
intimal	B-T017
flaps	I-T017
in	O
patients	O
with	O
ICAD	B-T017
.	O

Three	O
patients	O
with	O
ICAD	B-T017
underwent	O
plain	O
MRI	B-T058
examination	O
using	O
a	O
2	B-T082
-	I-T082
dimensional	I-T082
T2	B-T058
-	I-T058
weighted	I-T058
FSE	I-T058
imaging	I-T058
sequence	O
optimized	O
for	O
our	O
3T	O
system	O
(	O
in	O
-	O
plane	O
pixel	O
size	O
,	O
.	O
23	O
mm	O
×	O
.	O
23	O
mm	O
;	O
slice	O
thickness	O
3	O
mm	O
with	O
no	O
interslice	O
gap	O
)	O
,	O
as	O
well	O
as	O
scanning	B-T058
with	O
conventional	O
modalities	O
,	O
including	O
CT	B-T058
angiography	I-T058
,	O
magnetic	B-T058
resonance	I-T058
angiography	I-T058
,	O
and	O
digital	B-T058
subtraction	I-T058
angiography	I-T058
.	O

We	O
assessed	O
whether	O
these	O
imaging	O
methods	O
could	O
visualize	O
an	O
intimal	B-T017
flap	I-T017
and	O
/	O
or	O
double	B-T033
lumen	I-T033
sign	I-T033
in	O
the	O
participants	B-T098
and	O
compared	O
the	O
results	O
between	O
HR	B-T058
-	I-T058
FSE	I-T058
and	O
the	O
other	O
modalities	O
.	O

HR	B-T058
-	I-T058
FSE	I-T058
images	O
clearly	O
showed	O
intimal	B-T017
flaps	I-T017
and	O
double	B-T033
lumen	I-T033
signs	I-T033
in	O
all	O
3	O
patients	O
,	O
whereas	O
the	O
conventional	O
modalities	O
identified	O
a	O
double	B-T033
lumen	I-T033
sign	I-T033
in	O
only	O
2	O
of	O
the	O
3	O
patients	O
.	O

The	O
present	O
method	O
of	O
optimized	O
HR	B-T058
-	I-T058
FSE	I-T058
imaging	I-T058
with	O
a	O
3T	O
system	O
improved	B-T033
visualization	B-T058
of	O
intimal	B-T017
flaps	I-T017
and	O
should	O
thus	O
be	O
considered	O
for	O
assessing	O
patients	O
with	O
suspected	O
ICAD	B-T017
that	O
cannot	O
be	O
definitively	O
diagnosed	B-T033
by	O
conventional	O
imaging	O
modalities	O
.	O

Quantification	O
of	O
intact	O
plasma	B-T031
AGT	B-T103
consisting	O
of	O
oxidized	O
and	O
reduced	B-T082
conformations	I-T082
using	O
a	O
modified	O
ELISA	B-T058

The	O
pleiotropic	O
actions	O
of	O
the	O
renin	B-T022
-	I-T022
angiotensin	I-T022
system	I-T022
(	O
RAS	B-T022
)	O
depend	O
on	O
the	O
availability	O
of	O
angiotensinogen	B-T103
(	O
AGT	B-T103
)	O
which	O
generates	O
angiotensin	B-T103
I	I-T103
(	O
ANG	B-T103
I	I-T103
)	O
when	O
cleaved	B-T082
by	O
renin	B-T103
.	O

Thus	O
,	O
quantification	O
of	O
the	O
intact	O
AGT	B-T103
(	O
iAGT	B-T103
)	O
concentrations	O
is	O
important	O
to	O
evaluate	O
the	O
actual	O
renin	B-T103
substrate	I-T103
available	O
.	O

The	O
iAGT	B-T103
conformation	B-T082
exists	O
as	O
oxidized	B-T103
AGT	I-T103
(	O
oxi	B-T103
-	I-T103
AGT	I-T103
)	O
and	O
reduced	B-T103
AGT	I-T103
(	O
red	B-T103
-	I-T103
AGT	I-T103
)	O
in	O
a	O
disulfide	B-T082
bond	I-T082
,	O
and	O
oxi	B-T103
-	I-T103
AGT	I-T103
has	O
a	O
higher	O
affinity	O
for	O
renin	B-T103
,	O
which	O
may	O
exacerbate	O
RAS	B-T022
-	O
associated	B-T038
diseases	I-T038
.	O

Accordingly	O
,	O
we	O
determined	O
iAGT	B-T103
,	O
oxi	B-T103
-	I-T103
AGT	I-T103
,	O
and	O
red	B-T103
-	I-T103
AGT	I-T103
levels	O
in	O
plasma	B-T031
from	O
rats	B-T204
and	O
mice	B-T204
.	O

Blood	B-T031
samples	I-T031
were	O
obtained	O
by	O
cardiac	B-T058
puncture	I-T058
and	O
then	O
immediately	O
mixed	O
with	O
an	O
inhibitor	B-T103
solution	O
containing	O
a	O
renin	B-T103
inhibitor	I-T103
.	O

Total	O
AGT	B-T103
(	O
tAGT	B-T103
)	O
levels	O
were	O
measured	O
by	O
tAGT	B-T103
ELISA	B-T058
which	O
detects	B-T033
both	O
cleaved	B-T082
and	O
iAGT	B-T103
.	O

iAGT	B-T103
levels	O
were	O
determined	O
by	O
iAGT	B-T103
ELISA	B-T058
which	O
was	O
found	O
to	O
only	O
detect	B-T033
red	B-T103
-	I-T103
AGT	I-T103
.	O

Thus	O
,	O
it	O
was	O
necessary	O
to	O
treat	O
samples	B-T031
with	O
dithiothreitol	B-T103
,	O
a	O
reducing	B-T103
agent	I-T103
,	O
to	O
quantify	O
total	O
iAGT	B-T103
concentration	O
.	O

tAGT	B-T103
levels	O
in	O
rat	B-T204
and	O
mouse	B-T204
plasma	B-T031
were	O
1	O
,	O
839	O
±	O
139	O
and	O
1	O
,	O
082	O
±	O
77	O
ng	O
/	O
ml	O
,	O
respectively	O
.	O

iAGT	B-T103
levels	O
were	O
53	O
%	O
of	O
tAGT	B-T103
in	O
rat	B-T204
plasma	B-T031
but	O
only	O
22	O
%	O
in	O
mouse	B-T204
plasma	B-T031
,	O
probably	O
reflecting	O
the	O
greater	O
plasma	B-T031
renin	B-T103
activity	B-T038
in	O
mice	B-T204
.	O

The	O
ratios	O
of	O
oxi	B-T103
-	I-T103
AGT	I-T103
and	O
red	B-T103
-	I-T103
AGT	I-T103
were	O
∼4	O
:	O
1	O
(	O
rat	B-T204
)	O
and	O
16	O
:	O
1	O
(	O
mouse	B-T204
)	O
.	O

Plasma	B-T031
iAGT	B-T103
consists	O
of	O
oxi	B-T103
-	I-T103
AGT	I-T103
and	O
red	B-T103
-	I-T103
AGT	I-T103
,	O
suggesting	O
that	O
oxidative	B-T038
stress	I-T038
can	O
influence	O
ANG	B-T103
I	I-T103
generation	O
by	O
the	O
AGT	B-T103
conformation	B-T082
switch	O
.	O

Furthermore	O
,	O
the	O
lower	O
availability	O
of	O
plasma	B-T031
iAGT	B-T103
in	O
mice	B-T204
suggests	O
that	O
it	O
may	O
serve	O
as	O
a	O
limiting	O
factor	O
in	O
ANG	B-T103
I	I-T103
formation	O
in	O
this	O
species	B-T170
.	O

Carbon	B-T103
Monoxide	I-T103
Improves	B-T033
Efficacy	O
of	O
Mesenchymal	B-T017
Stromal	I-T017
Cells	I-T017
During	O
Sepsis	B-T038
by	O
Production	O
of	O
Specialized	O
Proresolving	B-T033
Lipid	O
Mediators	O

Mesenchymal	B-T017
stromal	I-T017
cells	I-T017
are	O
being	O
investigated	O
as	O
a	O
cell	B-T058
-	I-T058
based	I-T058
therapy	I-T058
for	O
a	O
number	O
of	O
disease	B-T038
processes	I-T038
,	O
with	O
promising	O
results	B-T033
in	O
animal	B-T204
models	I-T204
of	O
systemic	O
inflammation	O
and	O
sepsis	B-T038
.	O

Studies	B-T062
are	O
ongoing	O
to	O
determine	O
ways	O
to	O
further	O
improve	B-T033
the	O
therapeutic	O
potential	O
of	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
.	O

A	O
gas	B-T103
molecule	O
that	O
improves	B-T033
outcome	O
in	O
experimental	O
sepsis	B-T038
is	O
carbon	B-T103
monoxide	I-T103
.	O

We	O
hypothesized	O
that	O
preconditioning	O
of	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
with	O
carbon	B-T103
monoxide	I-T103
ex	O
vivo	O
would	O
promote	O
further	O
therapeutic	O
benefit	O
when	O
cells	B-T017
are	O
administered	O
in	B-T082
vivo	I-T082
after	O
the	O
onset	O
of	O
polymicrobial	B-T038
sepsis	B-T038
in	O
mice	B-T204
.	O

Animal	B-T204
study	I-T204
and	O
primary	B-T058
cell	I-T058
culture	I-T058
.	O

Laboratory	B-T092
investigation	B-T058
.	O

BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
.	O

Polymicrobial	B-T038
sepsis	B-T038
was	O
induced	O
by	O
cecal	B-T017
ligation	B-T058
and	O
puncture	B-T058
.	O

Mesenchymal	B-T017
stromal	I-T017
cells	I-T017
,	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
-	O
conditioned	O
with	O
carbon	B-T103
monoxide	I-T103
,	O
fibroblasts	B-T017
,	O
or	O
fibroblasts	B-T017
-	O
conditioned	O
with	O
carbon	B-T103
monoxide	I-T103
were	O
delivered	O
by	O
tail	B-T017
vein	I-T017
injections	B-T058
to	O
septic	O
mice	B-T204
.	O

The	O
mice	B-T204
were	O
assessed	O
for	O
survival	O
,	O
bacterial	O
clearance	O
,	O
and	O
the	O
inflammatory	B-T038
response	I-T038
during	O
sepsis	B-T038
in	O
each	O
of	O
the	O
groups	O
.	O

Mesenchymal	B-T017
stromal	I-T017
cells	I-T017
were	O
also	O
assessed	O
for	O
their	O
ability	O
to	O
promote	O
bacterial	O
phagocytosis	B-T038
by	O
neutrophils	B-T017
,	O
the	O
production	O
of	O
specialized	O
proresolving	B-T033
lipid	O
mediators	O
,	O
and	O
their	O
importance	O
for	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
function	B-T038
using	O
gene	B-T038
silencing	I-T038
.	O

Ex	O
vivo	O
preconditioning	O
with	O
carbon	B-T103
monoxide	I-T103
allowed	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
to	O
be	O
administered	O
later	O
after	O
the	O
onset	O
of	O
sepsis	B-T038
(	O
6	O
hr	O
)	O
,	O
and	O
yet	O
maintain	O
their	O
therapeutic	B-T201
effect	I-T201
with	O
increased	O
survival	O
.	O

Carbon	B-T103
monoxide	I-T103
preconditioned	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
were	O
also	O
able	O
to	O
alleviate	O
organ	B-T037
injury	I-T037
,	O
improve	B-T033
bacterial	O
clearance	O
,	O
and	O
promote	O
the	O
resolution	B-T038
of	O
inflammation	B-T038
.	O

Mesenchymal	B-T017
stromal	I-T017
cells	I-T017
exposed	O
to	O
carbon	B-T103
monoxide	I-T103
,	O
with	O
docosahexaenoic	B-T103
acid	I-T103
substrate	O
,	O
produced	O
specialized	O
proresolving	B-T033
lipid	O
mediators	O
,	O
particularly	O
D	O
-	O
series	O
resolvins	B-T103
,	O
which	O
promoted	O
survival	O
.	O

Silencing	B-T038
of	O
lipoxygenase	B-T038
pathways	I-T038
(	O
5	B-T038
-	I-T038
lipoxygenase	I-T038
and	O
12	B-T038
/	O
15	B-T038
-	I-T038
lipoxygenase	I-T038
)	O
,	O
which	O
are	O
important	O
enzymes	B-T103
for	O
specialized	O
proresolving	B-T033
lipid	O
mediator	O
biosynthesis	O
,	O
resulted	O
in	O
a	O
loss	O
of	O
therapeutic	O
benefit	O
bestowed	O
on	O
mesenchymal	B-T017
stromal	I-T017
cells	I-T017
by	O
carbon	B-T103
monoxide	I-T103
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
production	O
of	O
specialized	O
proresolving	B-T033
lipid	O
mediators	O
contribute	O
to	O
improved	B-T033
mesenchymal	B-T017
stromal	I-T017
cell	I-T017
efficacy	O
when	O
exposed	O
to	O
carbon	B-T103
monoxide	I-T103
,	O
resulting	O
in	O
an	O
improved	B-T033
therapeutic	B-T201
response	I-T201
during	O
sepsis	B-T038
.	O

Effect	O
of	O
primary	B-T058
health	I-T058
care	I-T058
reforms	O
in	O
Turkey	B-T082
on	O
health	B-T058
service	I-T058
utilization	I-T058
and	O
user	O
satisfaction	O

Strengthening	O
primary	B-T058
health	I-T058
care	I-T058
(	O
PHC	B-T058
)	O
is	O
considered	O
a	O
priority	O
for	O
efficient	O
and	O
responsive	O
health	B-T092
systems	I-T092
,	O
but	O
empirical	O
evidence	O
from	O
low	O
-	O
and	O
middle	O
-	O
income	O
countries	B-T082
is	O
limited	O
.	O

The	O
stepwise	B-T058
introduction	I-T058
of	O
family	B-T091
medicine	I-T091
across	O
all	O
81	O
provinces	B-T082
of	O
Turkey	B-T082
(	O
a	O
middle	O
-	O
income	O
country	B-T082
)	O
between	O
2005	O
and	O
2010	O
,	O
aimed	O
at	O
PHC	B-T058
strengthening	O
,	O
presents	O
a	O
natural	B-T062
experiment	I-T062
for	O
assessing	O
the	O
effect	O
of	O
family	B-T091
medicine	I-T091
on	O
health	B-T058
service	I-T058
utilization	I-T058
and	O
user	O
satisfaction	O
.	O
The	O
effect	O
of	O
health	B-T092
system	I-T092
reforms	O
,	O
that	O
introduced	O
family	B-T091
medicine	I-T091
,	O
on	O
utilization	O
was	O
assessed	O
using	O
longitudinal	B-T062
,	O
province	B-T062
-	I-T062
level	I-T062
data	I-T062
for	O
12	O
years	O
and	O
multivariate	O
regression	O
models	O
adjusting	O
for	O
supply	O
-	O
side	O
variables	O
,	O
demographics	O
,	O
socio	O
-	O
economic	O
development	O
and	O
underlying	O
yearly	O
trends	O
.	O

User	O
satisfaction	O
with	O
primary	B-T058
and	O
secondary	B-T058
care	I-T058
services	B-T058
was	O
explored	O
using	O
data	O
from	O
annual	B-T170
Life	I-T170
Satisfaction	I-T170
Surveys	I-T170
.	O

Trends	O
in	O
preferred	O
first	O
point	O
of	O
contact	O
(	O
primary	B-T058
vs	O
secondary	B-T058
,	O
public	B-T092
vs	O
.	O

private	B-T092
)	O
,	O
reason	O
for	O
choice	O
and	O
health	B-T058
services	I-T058
issues	O
,	O
were	O
described	O
and	O
stratified	O
by	O
patient	O
characteristics	O
,	O
provider	O
type	O
,	O
and	O
rural	B-T082
/	I-T082
urban	I-T082
settings	I-T082
.	O
Between	O
2002	O
and	O
2013	O
,	O
the	O
average	O
number	O
of	O
PHC	B-T058
consultations	B-T058
increased	O
from	O
1	O
.	O
75	O
to	O
2	O
.	O
83	O
per	O
person	B-T098
per	O
year	O
.	O

In	O
multivariate	O
models	O
,	O
family	B-T091
medicine	I-T091
introduction	B-T058
was	O
associated	O
with	O
an	O
increase	O
of	O
0	O
.	O
37	O
PHC	B-T058
consultations	B-T058
per	O
person	B-T098
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
slower	O
annual	O
growth	O
in	O
PHC	B-T058
and	O
secondary	B-T058
care	I-T058
consultations	B-T058
.	O

Following	O
family	B-T091
medicine	I-T091
introduction	B-T058
,	O
the	O
growth	O
of	O
PHC	B-T058
and	O
secondary	B-T058
care	I-T058
consultations	B-T058
per	O
person	B-T098
was	O
0	O
.	O
08	O
and	O
0	O
.	O
30	O
,	O
respectively	O
,	O
a	O
year	O
.	O

PHC	B-T058
increased	O
as	O
preferred	O
provider	O
by	O
9	O
.	O
5	O
%	O
over	O
7	O
years	O
with	O
the	O
reasons	O
of	O
proximity	B-T082
and	O
service	O
satisfaction	O
,	O
which	O
increased	O
by	O
14	O
.	O
9	O
%	O
and	O
11	O
.	O
8	O
%	O
,	O
respectively	O
.	O

Reporting	B-T058
of	O
poor	O
facility	O
hygiene	O
,	O
difficulty	O
getting	O
an	O
appointment	O
,	O
poor	O
physician	B-T097
behaviour	O
and	O
high	O
costs	O
of	O
health	O
care	O
all	O
declined	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
in	O
PHC	B-T058
settings	B-T082
,	O
but	O
remained	O
higher	O
among	O
urban	O
,	O
low	B-T033
-	I-T033
income	I-T033
and	O
working	O
-	O
age	O
populations	B-T098
.	O

Laparoscopic	B-T058
radical	B-T058
lymph	I-T058
node	I-T058
dissection	I-T058
for	O
advanced	B-T038
colon	I-T038
cancer	I-T038
close	O
to	O
the	O
hepatic	B-T082
flexure	I-T082

Complete	B-T058
mesocolic	I-T058
excision	I-T058
is	O
currently	O
recognized	O
as	O
a	O
standard	B-T058
procedure	I-T058
for	O
colon	B-T038
cancer	I-T038
.	O

Gastroepiploic	B-T017
,	O
infrapyloric	B-T017
,	O
and	O
superficial	B-T017
pancreatic	I-T017
head	I-T017
lymph	I-T017
node	I-T017
metastases	B-T038
in	O
the	O
gastrocolic	B-T017
ligament	I-T017
have	O
been	O
reported	O
for	O
colon	B-T038
cancer	I-T038
close	O
to	O
the	O
hepatic	B-T082
flexure	I-T082
.	O

We	O
sought	O
to	O
investigate	O
metastases	B-T038
in	O
the	O
gastrocolic	B-T017
ligament	I-T017
in	O
colon	B-T038
cancer	I-T038
close	O
to	O
the	O
hepatic	B-T082
flexure	I-T082
.	O

This	O
was	O
a	O
single	B-T062
-	I-T062
center	I-T062
retrospective	I-T062
study	I-T062
.	O

All	O
patients	O
with	O
T2	B-T033
or	O
deeper	O
invasive	O
colon	B-T038
cancer	I-T038
in	O
the	O
relevant	O
tumor	B-T082
location	I-T082
who	O
underwent	O
laparoscopic	B-T058
right	I-T058
hemicolectomy	I-T058
or	O
extended	B-T058
right	I-T058
hemicolectomy	I-T058
at	O
our	O
institution	B-T092
between	O
1	O
April	O
2011	O
and	O
31	O
March	O
2015	O
were	O
included	O
.	O

Lymph	B-T058
node	I-T058
dissection	I-T058
in	O
the	O
gastrocolic	B-T017
ligament	I-T017
was	O
performed	O
in	O
35	O
cases	O
.	O

Complications	B-T038
occurred	O
in	O
11	O
patients	O
(	O
31	O
%	O
)	O
and	O
were	O
grades	O
I	O
and	O
II	O
according	O
to	O
the	O
Clavien	B-T170
-	I-T170
Dindo	I-T170
classification	I-T170
.	O

Lymph	B-T038
node	I-T038
metastases	I-T038
in	O
the	O
gastrocolic	B-T017
ligament	I-T017
were	O
found	O
in	O
only	O
three	O
patients	O
(	O
9	O
%	O
)	O
.	O

Each	O
metastasis	B-T038
was	O
larger	O
than	O
9	O
mm	O
.	O

Metastases	B-T038
in	O
the	O
gastrocolic	B-T017
ligament	I-T017
occurred	O
in	O
9	O
%	O
of	O
patients	O
with	O
T2	B-T033
or	O
deeper	O
invasive	O
colon	B-T038
cancer	I-T038
close	O
to	O
the	O
hepatic	B-T082
flexure	I-T082
.	O

Laparoscopy	B-T058
was	O
feasible	O
and	O
useful	O
during	O
gastrocolic	B-T058
ligament	I-T058
resection	I-T058
.	O

This	O
study	B-T062
included	O
a	O
small	O
sample	O
and	O
lacked	O
an	O
extended	B-T082
follow	B-T058
-	I-T058
up	I-T058
.	O

Further	O
studies	B-T062
are	O
needed	O
to	O
determine	O
the	O
clinical	O
relevance	O
of	O
this	O
finding	B-T033
,	O
particularly	O
in	O
terms	O
of	O
recurrence	O
and	O
long	O
-	O
term	O
survival	O
.	O

Smartphone	O
-	O
Based	O
Psychotherapeutic	B-T058
Micro	B-T058
-	I-T058
Interventions	I-T058
to	O
Improve	O
Mood	B-T038
in	O
a	O
Real	O
-	O
World	O
Setting	O

Using	O
mobile	O
communication	O
technology	O
as	O
new	O
personalized	O
approach	B-T082
to	O
treat	B-T058
mental	B-T038
disorders	I-T038
or	O
to	O
more	O
generally	O
improve	O
quality	O
of	O
life	O
is	O
highly	O
promising	O
.	O

Knowledge	B-T170
about	O
intervention	B-T058
components	O
that	O
target	O
key	O
psychopathological	B-T091
processes	O
in	O
terms	O
of	O
transdiagnostic	O
psychotherapy	B-T058
approaches	B-T082
is	O
urgently	O
needed	O
.	O

We	O
explored	O
the	O
use	O
of	O
smartphone	O
-	O
based	O
micro	B-T058
-	I-T058
interventions	I-T058
based	O
on	O
psychotherapeutic	B-T170
techniques	I-T170
,	O
guided	O
by	O
short	O
video	B-T170
-	I-T170
clips	I-T170
,	O
to	O
elicit	O
mood	B-T038
changes	I-T038
.	O

As	O
part	O
of	O
a	O
larger	O
neurofeedback	B-T058
study	B-T062
,	O
all	O
subjects	B-T098
-	O
after	O
being	O
randomly	O
assigned	O
to	O
an	O
experimental	O
or	O
control	O
neurofeedback	B-T058
condition	O
-	O
underwent	O
daily	O
smartphone	O
-	O
based	O
micro	B-T058
-	I-T058
interventions	I-T058
for	O
13	O
consecutive	O
days	O
.	O

They	O
were	O
free	O
to	O
choose	O
out	O
of	O
provided	O
techniques	O
,	O
including	O
viscerosensory	O
attention	B-T038
,	O
emotional	B-T033
imagery	B-T038
,	O
facial	B-T033
expression	I-T033
,	O
and	O
contemplative	O
repetition	O
.	O

Changes	O
in	O
mood	B-T038
were	O
assessed	O
in	O
real	O
world	O
using	O
the	O
Multidimensional	B-T170
Mood	I-T170
State	I-T170
Questionnaire	I-T170
(	O
scales	O
:	O
good	O
-	O
bad	O
,	O
GB	O
;	O
awake	B-T033
-	O
tired	B-T033
,	O
AT	O
;	O
and	O
calm	B-T038
-	O
nervous	B-T033
,	O
CN	O
)	O
.	O

Twenty	O
-	O
seven	O
men	B-T098
participated	O
on	O
at	O
least	O
11	O
days	O
and	O
were	O
thus	O
included	O
in	O
the	O
analyses	B-T062
.	O

Altogether	O
,	O
they	O
underwent	O
335	O
,	O
generally	O
well	O
-	O
tolerated	O
,	O
micro	O
-	O
intervention	O
sessions	O
,	O
with	O
viscerosensory	O
attention	B-T038
(	O
178	O
sessions	O
,	O
53	O
.	O
13	O
%	O
)	O
and	O
contemplative	O
repetition	O
(	O
68	O
sessions	O
,	O
20	O
.	O
30	O
%	O
)	O
being	O
the	O
most	O
frequently	O
applied	O
techniques	O
.	O

Mixed	O
models	B-T170
indicated	O
that	O
subjects	B-T098
showed	O
better	O
mood	B-T038
[	O
GB	O
:	O
b	O
=	O
0	O
.	O
464	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
[	O
0	O
.	O
068	O
,	O
0	O
.	O
860	O
]	O
,	O
t	O
(	O
613	O
.	O
3	O
)	O
=	O
2	O
.	O
298	O
,	O
p	O
=	O
0	O
.	O
022	O
]	O
and	O
became	O
more	O
awake	B-T033
[	O
AT	O
:	O
b	O
=	O
0	O
.	O
514	O
,	O
95	O
%	O
CI	O
[	O
0	O
.	O
103	O
,	O
0	O
.	O
925	O
]	O
,	O
t	O
(	O
612	O
.	O
4	O
)	O
=	O
2	O
.	O
456	O
,	O
p	O
=	O
0	O
.	O
014	O
]	O
and	O
calmer	B-T038
[	O
CN	O
:	O
b	O
=	O
0	O
.	O
685	O
,	O
95	O
%	O
CI	O
[	O
0	O
.	O
360	O
,	O
1	O
.	O
010	O
]	O
,	O
t	O
(	O
612	O
.	O
3	O
)	O
=	O
4	O
.	O
137	O
,	O
p	O
<	O
0	O
.	O
001	O
]	O
from	O
pre	O
-	O
to	O
post	O
-	O
micro	O
-	O
intervention	O
.	O

These	O
mood	B-T038
improvements	O
from	O
pre	O
-	O
to	O
post	O
-	O
micro	O
-	O
intervention	O
were	O
associated	O
with	O
changes	B-T038
in	I-T038
mood	I-T038
from	O
the	O
1st	O
day	O
until	O
the	O
last	O
day	O
with	O
regard	O
to	O
GB	B-T038
mood	I-T038
(	O
r	O
=	O
0	O
.	O
614	O
,	O
95	O
%	O
CI	O
[	O
0	O
.	O
297	O
,	O
0	O
.	O
809	O
]	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
AT	B-T038
mood	I-T038
(	O
r	O
=	O
0	O
.	O
279	O
,	O
95	O
%	O
CI	O
[	O
-	O
0	O
.	O
122	O
,	O
0	O
.	O
602	O
]	O
,	O
p	O
=	O
0	O
.	O
167	O
)	O
and	O
CN	B-T038
mood	I-T038
(	O
r	O
=	O
0	O
.	O
277	O
,	O
95	O
%	O
CI	O
[	O
0	O
.	O
124	O
,	O
0	O
.	O
601	O
]	O
,	O
p	O
=	O
0	O
.	O
170	O
)	O
.	O

Our	O
findings	B-T033
provide	O
evidence	O
for	O
the	O
applicability	O
of	O
smartphone	O
-	O
based	O
micro	B-T058
-	I-T058
interventions	I-T058
eliciting	O
short	O
-	O
term	O
mood	B-T038
changes	I-T038
,	O
based	O
on	O
techniques	O
used	O
in	O
psychotherapeutic	B-T058
approaches	B-T082
,	O
such	O
as	O
mindfulness	B-T038
-	O
based	O
psychotherapy	B-T058
,	O
transcendental	B-T038
meditation	I-T038
,	O
and	O
other	O
contemplative	O
therapies	B-T058
.	O

The	O
results	O
encourage	O
exploring	O
these	O
techniques	O
'	O
capability	O
to	O
improve	O
mood	B-T038
in	O
randomized	O
controlled	B-T062
studies	I-T062
and	O
patients	O
.	O

Smartphone	O
-	O
based	O
micro	B-T058
-	I-T058
interventions	I-T058
are	O
promising	O
to	O
modify	O
mood	B-T038
in	O
real	O
-	O
world	O
settings	O
,	O
complementing	O
other	O
psychotherapeutic	B-T058
interventions	I-T058
,	O
in	O
line	O
with	O
the	O
precision	O
medicine	O
approach	O
.	O

The	O
here	O
presented	O
data	O
were	O
collected	O
within	O
a	O
randomized	B-T062
trial	I-T062
,	O
registered	O
at	O
ClinicalTrials	O
.	O
gov	O
(	O
Identifier	O
:	O
NCT01921088	O
)	O
https	O
:	O
/	O
/	O
clinicaltrials	O
.	O
gov	O
/	O
ct2	O
/	O
show	O
/	O
NCT01921088	O
.	O

Primary	O
pituitary	B-T017
diffuse	B-T038
large	I-T038
B	I-T038
-	I-T038
cell	I-T038
lymphoma	I-T038
with	O
somatotroph	B-T017
hyperplasia	I-T017
and	O
acromegaly	B-T038
:	O
case	B-T170
report	I-T170

Diffuse	B-T038
large	I-T038
B	I-T038
-	I-T038
cell	I-T038
lymphoma	I-T038
(	O
DLBCL	B-T038
)	O
is	O
the	O
most	O
common	O
type	O
of	O
non	B-T038
-	I-T038
Hodgkin	I-T038
lymphoma	I-T038
and	O
comprises	O
approximately	O
30	O
%	O
of	O
all	O
lymphomas	B-T038
.	O

Patients	O
typically	O
present	B-T033
with	O
a	O
nonpainful	O
mass	B-T033
in	O
the	O
neck	B-T082
,	O
groin	B-T082
,	O
or	O
abdomen	B-T082
associated	O
with	O
constitutional	B-T033
symptoms	I-T033
.	O

In	O
this	O
report	B-T170
,	O
however	O
,	O
the	O
authors	B-T097
describe	O
a	O
rare	O
case	O
of	O
a	O
61	O
-	O
year	O
-	O
old	O
woman	B-T098
with	O
hyperprolactinemia	B-T038
,	O
hypothyroidism	B-T038
,	O
and	O
acromegaly	B-T038
(	O
elevation	O
of	O
insulin	B-T103
-	I-T103
like	I-T103
growth	I-T103
factor	I-T103
-	I-T103
1	I-T103
[	O
IGF	B-T103
-	I-T103
1	I-T103
]	O
)	O
with	O
elevated	O
growth	B-T103
hormone	I-T103
-	I-T103
releasing	I-T103
hormone	I-T103
(	O
GHRH	B-T103
)	O
in	O
whom	O
an	O
MRI	B-T058
demonstrated	O
diffuse	B-T033
enlargement	I-T033
of	I-T033
the	I-T033
pituitary	I-T033
gland	I-T033
.	O

Despite	O
medical	B-T058
treatment	I-T058
,	O
the	O
patient	O
had	O
persistent	O
elevation	O
of	O
IGF	B-T103
-	I-T103
1	I-T103
.	O

She	O
underwent	O
a	O
transsphenoidal	B-T058
biopsy	I-T058
,	O
which	O
yielded	O
a	O
diagnosis	B-T033
of	O
DLBCL	B-T038
with	O
an	O
activated	O
B	B-T017
-	I-T017
cell	I-T017
immunophenotype	B-T058
with	O
somatotroph	B-T017
hyperplasia	I-T017
.	O

After	O
stereo	B-T058
-	I-T058
tactic	I-T058
radiation	I-T058
therapy	I-T058
in	O
combination	O
with	O
chemotherapy	B-T058
,	O
she	O
is	O
currently	O
in	O
remission	B-T038
from	O
her	O
lymphoma	B-T038
and	O
has	O
normalized	B-T062
IGF	B-T103
-	I-T103
1	I-T103
levels	O
without	O
medical	B-T058
therapy	I-T058
,	O
8	O
months	O
after	O
her	O
histopathological	O
diagnosis	B-T033
.	O

This	O
is	O
the	O
only	O
reported	B-T170
case	O
of	O
its	O
kind	O
and	O
displays	O
the	O
importance	O
of	O
a	O
broad	O
differential	B-T058
diagnosis	I-T058
,	O
multidisciplinary	B-T058
evaluation	I-T058
,	O
and	O
critical	O
intraoperative	O
decision	B-T038
-	I-T038
making	I-T038
when	O
treating	O
atypical	O
sellar	B-T017
lesions	B-T033
.	O

Doctor	B-T097
Competence	O
and	O
the	O
Demand	B-T058
for	O
Healthcare	B-T058
:	O
Evidence	O
from	O
Rural	B-T082
China	I-T082

The	O
agency	B-T092
problem	B-T033
between	O
patients	O
and	O
doctors	B-T097
has	O
long	O
been	O
emphasised	O
in	O
the	O
health	B-T170
economics	I-T170
literature	I-T170
,	O
but	O
the	O
empirical	O
evidence	O
on	O
whether	O
patients	O
can	O
evaluate	O
and	O
respond	O
to	O
better	O
quality	B-T058
care	I-T058
remains	O
mixed	O
and	O
inconclusive	O
.	O

Using	O
household	O
data	O
linked	O
to	O
an	O
assessment	O
of	O
village	B-T082
doctors	B-T097
'	I-T097
clinical	O
competence	O
in	O
rural	B-T082
China	I-T082
,	O
we	O
show	O
that	O
there	O
is	O
no	O
correlation	O
between	O
doctor	B-T097
competence	O
and	O
patients	O
'	O
healthcare	B-T058
utilisation	O
,	O
with	O
confidence	O
intervals	O
reasonably	O
tight	O
around	O
zero	O
.	O

Household	O
perceptions	B-T038
of	O
quality	O
are	O
an	O
important	O
determinant	O
of	O
care	O
-	O
seeking	O
behaviour	O
,	O
yet	O
patients	O
appear	O
unable	B-T033
to	O
recognise	O
more	O
competent	O
doctors	B-T097
-	O
there	O
is	O
no	O
relationship	O
between	O
doctor	B-T097
competence	O
and	O
perceptions	B-T038
of	O
quality	O
.	O

Copyright	O
©	O
2016	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd	O
.	O

JOURNAL	O
ARTICLE	O

Unintentional	O
insecticide	B-T037
poisoning	I-T037
by	O
age	O
:	O
an	O
analysis	B-T062
of	O
Queensland	O
Poisons	O
Information	O
Centre	O
calls	O

Data	O
from	O
the	O
Queensland	O
Poisons	O
Information	O
Centre	O
(	O
QPIC	O
)	O
was	O
assessed	O
to	O
determine	O
mechanisms	O
of	O
acute	O
insecticide	B-T037
poisoning	I-T037
in	O
young	O
children	O
(	O
<	O
5	O
years	O
)	O
and	O
whether	O
age	O
affects	B-T038
insecticide	B-T037
-	I-T037
poisoning	I-T037
patterns	B-T082
.	O

Records	B-T170
of	O
all	O
insecticide	O
-	O
related	O
calls	O
placed	O
to	O
QPIC	O
in	O
2014	O
were	O
obtained	O
.	O

A	O
stratified	O
analysis	B-T062
of	O
call	O
patterns	B-T082
by	O
age	O
was	O
conducted	O
.	O

Of	O
743	O
insecticide	O
-	O
related	O
calls	O
received	O
by	O
QPIC	O
364	O
(	O
49	O
.	O
0	O
%	O
)	O
were	O
for	O
young	O
children	O
.	O

The	O
number	O
of	O
calls	O
peaked	O
in	O
children	O
aged	O
one	O
.	O

Ant	B-T204
and	O
cockroach	B-T204
baits	O
accounted	O
for	O
39	O
.	O
0	O
%	O
of	O
calls	O
.	O

Sprays	B-T103
,	O
which	O
were	O
found	B-T033
to	O
contain	O
not	O
only	O
pyrethroids	B-T103
,	O
pyrethrins	B-T103
and	O
/	O
or	O
piperonly	B-T103
butoxide	I-T103
but	O
also	O
the	O
organophosphate	B-T103
diazinon	I-T103
,	O
accounted	O
for	O
25	O
.	O
8	O
%	O
of	O
calls	O
.	O

Mouthing	B-T038
or	O
ingesting	B-T038
a	O
pest	B-T103
-	I-T103
control	I-T103
product	I-T103
and	O
consuming	O
an	O
item	O
/	O
insect	O
after	O
treatment	O
were	O
common	O
mechanisms	O
for	O
children	O
under	O
the	O
age	O
of	O
two	O
.	O

Topical	B-T082
exposure	O
to	O
sprays	B-T103
,	O
via	O
direct	O
application	O
,	O
typically	O
by	O
the	O
child	O
or	O
an	O
older	O
sibling	O
,	O
peaked	O
in	O
children	O
aged	O
two	O
.	O

In	O
12	O
.	O
3	O
%	O
of	O
calls	O
medical	B-T058
attention	I-T058
for	O
the	O
child	O
was	O
already	O
sought	O
or	O
advised	B-T058
by	I-T058
QPIC	O
.	O

Normal	O
behaviours	O
associated	O
with	O
child	B-T038
development	I-T038
,	O
particularly	O
mouthing	B-T038
behaviours	O
,	O
explained	O
the	O
peak	O
of	O
exposure	O
in	O
one	O
-	O
year	O
-	O
olds	O
.	O

This	O
finding	B-T033
should	O
guide	O
strategies	O
to	O
minimise	O
poisonings	B-T037
in	O
this	O
vulnerable	B-T098
population	I-T098
.	O

Investigating	O
Synthetic	O
Oligonucleotide	B-T103
Targeting	O
of	O
Mir31	B-T103
in	O
Duchenne	B-T038
Muscular	I-T038
Dystrophy	I-T038

Exon	B-T038
-	I-T038
skipping	I-T038
via	O
synthetic	O
antisense	B-T103
oligonucleotides	I-T103
represents	O
one	O
of	O
the	O
most	O
promising	O
potential	O
therapies	B-T058
for	O
Duchenne	B-T038
muscular	I-T038
dystrophy	I-T038
(	O
DMD	B-T038
)	O
,	O
yet	O
this	O
approach	O
is	O
highly	O
sequence	B-T038
-	I-T038
specific	I-T038
and	O
thus	O
each	O
oligonucleotide	B-T103
is	O
of	O
benefit	O
to	O
only	O
a	O
subset	O
of	O
patients	O
.	O

The	O
discovery	O
that	O
dystrophin	B-T103
mRNA	B-T103
is	O
subject	O
to	O
translational	B-T038
suppression	I-T038
by	O
the	O
microRNA	B-T103
miR31	B-T103
,	O
and	O
that	O
miR31	B-T103
is	O
elevated	O
in	O
the	O
muscle	B-T017
of	O
DMD	B-T038
patients	O
,	O
raises	O
the	O
possibility	O
that	O
the	O
same	O
oligonucleotide	B-T103
chemistries	O
employed	O
for	O
exon	B-T038
skipping	I-T038
could	O
be	O
directed	O
toward	O
relieving	O
this	O
translational	B-T038
block	I-T038
.	O

This	O
approach	O
would	O
act	O
synergistically	O
with	O
exon	B-T038
skipping	I-T038
where	O
possible	O
,	O
but	O
by	O
targeting	O
the	O
3	B-T082
'	I-T082
UTR	I-T082
it	O
would	O
further	O
be	O
of	O
benefit	O
to	O
the	O
many	O
DMD	B-T038
patients	O
who	O
express	O
low	O
levels	O
of	O
in	B-T082
-	I-T082
frame	I-T082
transcript	B-T103
.	O

We	O
here	O
present	O
investigations	B-T058
into	O
the	O
feasibility	O
of	O
combining	O
exon	B-T038
skipping	I-T038
with	O
several	O
different	O
strategies	O
for	O
miR31	B-T103
-	O
modulation	O
,	O
using	O
both	O
in	B-T058
vitro	I-T058
models	O
and	O
the	O
mdx	B-T204
mouse	I-T204
(	O
the	O
classical	O
animal	B-T204
model	I-T204
of	O
DMD	B-T038
)	O
,	O
and	O
monitoring	B-T058
effects	O
on	O
dystrophin	B-T103
at	O
the	O
transcriptional	B-T038
and	O
translational	B-T038
level	O
.	O

We	O
show	O
that	O
despite	O
promising	O
results	O
from	O
our	O
cell	B-T058
culture	I-T058
model	O
,	O
our	O
in	B-T082
vivo	I-T082
data	O
failed	O
to	O
demonstrate	O
similarly	O
reproducible	O
enhancement	O
of	O
dystrophin	B-T103
translation	B-T038
,	O
suggesting	O
that	O
miR31	B-T103
-	O
modulation	O
may	O
not	O
be	O
practical	O
under	O
current	O
oligonucleotide	B-T103
approaches	O
.	O

Possible	O
explanations	O
for	O
this	O
disappointing	O
outcome	O
are	O
discussed	O
,	O
along	O
with	O
suggestions	O
for	O
future	O
investigations	B-T058
.	O

Undisclosed	O
HIV	B-T038
infection	I-T038
and	O
art	B-T058
use	O
in	O
the	O
kenya	B-T170
AIDS	I-T170
indicator	I-T170
survey	I-T170
2012	I-T170
:	O
relevance	O
to	O
targets	O
for	O
HIV	O
diagnosis	O
and	O
treatment	B-T058
in	O
kenya	B-T082

To	O
assess	O
the	O
impact	O
of	O
undisclosed	O
HIV	B-T038
infection	I-T038
and	O
antiretroviral	B-T058
(	I-T058
ARV	I-T058
)	I-T058
therapy	I-T058
(	O
ART	B-T058
)	O
on	O
national	O
estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	B-T058
coverage	O
in	O
Kenya	B-T082
.	O

HIV	O
-	O
positive	O
dried	B-T031
blood	I-T031
spot	I-T031
samples	I-T031
from	O
Kenya	B-T170
'	I-T170
s	I-T170
second	I-T170
AIDS	I-T170
Indicator	I-T170
Survey	I-T170
were	O
tested	O
for	O
an	O
ARV	O
biomarker	B-T201
by	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
.	O

Estimates	O
of	O
diagnosed	O
HIV	O
and	O
ART	B-T058
use	O
based	O
on	O
self	B-T062
-	I-T062
report	I-T062
were	O
compared	O
with	O
those	O
corrected	O
for	O
undisclosed	O
HIV	B-T038
infection	I-T038
and	O
ART	B-T058
use	O
based	O
on	O
ARV	O
testing	O
.	O

Multivariate	O
analysis	O
determined	O
factors	O
associated	O
with	O
undisclosed	O
HIV	B-T038
infection	I-T038
and	O
ART	B-T058
use	O
among	O
persons	B-T098
on	O
ART	B-T058
.	O

Among	O
559	O
HIV	O
-	O
positive	O
samples	B-T031
,	O
the	O
ARV	O
biomarker	B-T201
was	O
detected	B-T033
in	O
42	O
.	O
5	O
%	O
(	O
CI	O
37	O
.	O
4	O
-	O
47	O
.	O
7	O
)	O
.	O

ARV	B-T103
drugs	I-T103
were	O
present	O
in	O
90	O
.	O
7	O
%	O
(	O
CI	O
86	O
.	O
1	O
-	O
95	O
.	O
2	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
and	O
receiving	O
ART	B-T058
,	O
66	O
.	O
7	O
%	O
(	O
CI	O
59	O
.	O
9	O
-	O
73	O
.	O
4	O
)	O
reporting	O
HIV	O
-	O
positive	O
status	O
irrespective	O
of	O
ART	B-T058
use	O
,	O
21	O
.	O
0	O
%	O
(	O
CI	O
13	O
.	O
4	O
-	O
28	O
.	O
6	O
)	O
reporting	B-T058
HIV	B-T033
-	I-T033
negative	I-T033
status	I-T033
,	O
and	O
19	O
.	O
3	O
%	O
(	O
CI	O
9	O
.	O
0	O
-	O
29	O
.	O
5	O
)	O
reporting	B-T058
no	B-T033
previous	O
HIV	B-T058
test	I-T058
.	O

After	O
correcting	O
for	O
undisclosed	O
HIV	B-T038
infection	I-T038
and	O
ART	B-T058
use	O
,	O
diagnosed	O
HIV	O
increased	O
from	O
46	O
.	O
9	O
%	O
to	O
57	O
.	O
2	O
%	O
and	O
ART	B-T058
coverage	O
increased	O
from	O
31	O
.	O
8	O
%	O
to	O
42	O
.	O
8	O
%	O
.	O

Undisclosed	O
HIV	B-T038
infection	I-T038
on	O
ART	B-T058
was	O
associated	O
with	O
being	O
aged	B-T098
25	O
-	O
39	O
years	O
and	O
not	O
visiting	O
a	O
health	B-T097
provider	I-T097
in	O
the	O
past	O
year	O
,	O
while	O
younger	O
age	O
and	O
higher	O
wealth	O
was	O
associated	O
with	O
undisclosed	O
ART	B-T058
use	O
.	O

Substantial	O
levels	O
of	O
undisclosed	O
HIV	B-T038
infection	I-T038
and	O
ART	B-T058
use	O
while	O
on	O
ART	B-T058
were	O
observed	O
,	O
resulting	O
in	O
diagnosed	O
HIV	O
underestimated	O
by	O
112	O
,	O
000	O
persons	B-T098
and	O
ART	B-T058
coverage	O
by	O
131	O
,	O
000	O
persons	B-T098
.	O

Supplementing	O
self	B-T062
-	I-T062
reported	I-T062
ART	B-T058
status	O
with	O
objective	O
measures	O
of	O
ART	B-T058
use	O
in	O
national	O
population	B-T098
-	O
based	O
sero	B-T058
-	I-T058
surveys	I-T058
can	O
improve	B-T033
monitoring	B-T058
of	O
treatment	B-T058
targets	O
in	O
countries	B-T082
.	O

Differential	O
control	O
and	O
function	O
of	O
Arabidopsis	B-T204
ProDH1	B-T017
and	O
ProDH2	B-T017
genes	I-T017
on	O
infection	B-T038
with	O
biotrophic	B-T033
and	O
necrotrophic	B-T033
pathogens	O

Arabidopsis	B-T204
contains	O
two	O
proline	B-T017
dehydrogenase	I-T017
(	I-T017
ProDH	I-T017
)	I-T017
genes	I-T017
,	O
ProDH1	B-T017
and	O
ProDH2	B-T017
,	O
encoding	O
for	O
homologous	B-T103
and	O
functional	O
isoenzymes	B-T103
.	O

Although	O
ProDH1	B-T017
has	O
been	O
studied	O
extensively	O
,	O
especially	O
under	O
abiotic	B-T038
stress	I-T038
,	O
ProDH2	B-T017
has	O
only	O
started	O
to	O
be	O
analysed	O
in	O
recent	O
years	O
.	O

These	O
genes	B-T017
display	O
distinctive	O
expression	B-T038
patterns	B-T082
and	O
show	O
weak	O
transcriptional	B-T038
co	I-T038
-	I-T038
regulation	I-T038
,	O
but	O
are	O
both	O
activated	O
in	O
pathogen	O
-	O
infected	B-T033
tissues	B-T017
.	O

We	O
have	O
demonstrated	O
previously	O
that	O
Arabidopsis	B-T204
plants	I-T204
with	O
silenced	B-T038
ProDH1	B-T017
/	O
2	B-T017
expression	B-T038
fail	O
to	O
trigger	O
defences	B-T038
against	O
the	O
hemibiotrophic	B-T033
bacterial	B-T007
pathogen	O
Pseudomonas	B-T007
syringae	I-T007
pv	I-T007
.	I-T007

tomato	I-T007
AvrRpm1	I-T007
(	O
Pst	B-T007
-	I-T007
AvrRpm1	I-T007
)	O
,	O
and	O
that	O
ProDH1	B-T017
and	O
ProDH2	B-T017
are	O
differentially	O
regulated	O
by	O
salicylic	B-T103
acid	I-T103
(	O
SA	B-T103
)	O
.	O

In	O
the	O
current	O
work	O
,	O
we	O
used	O
prodh1	B-T204
and	O
prodh2	B-T204
single	O
-	O
mutant	B-T038
plants	B-T204
to	O
assess	O
the	O
particular	O
contribution	O
of	O
each	O
gene	B-T017
to	O
resistance	O
against	O
Pst	B-T007
-	I-T007
AvrRpm1	I-T007
and	O
the	O
necrotrophic	B-T033
fungal	O
pathogen	O
Botrytis	B-T204
cinerea	I-T204
.	O

In	O
addition	O
,	O
we	O
studied	O
the	O
sensitivity	O
of	O
ProDH1	B-T017
and	O
ProDH2	B-T017
to	O
the	O
jasmonic	B-T103
acid	I-T103
(	O
JA	B-T103
)	O
defence	B-T038
pathway	B-T038
.	O

We	O
found	O
that	O
ProDH1	B-T103
and	O
ProDH2	B-T103
are	O
both	O
necessary	O
to	O
achieve	O
maximum	O
resistance	O
against	O
Pst	B-T007
-	I-T007
AvrRpm1	I-T007
and	O
B	B-T204
.	I-T204

cinerea	I-T204
.	O

However	O
,	O
ProDH2	B-T103
has	O
a	O
major	O
effect	O
on	O
early	O
restriction	O
of	O
B	B-T204
.	I-T204

cinerea	I-T204
growth	B-T038
.	O

Interestingly	O
,	O
ProDH1	B-T017
is	O
up	B-T038
-	I-T038
regulated	I-T038
by	O
SA	B-T103
and	O
JA	B-T103
,	O
whereas	O
ProDH2	B-T017
is	O
only	O
activated	O
by	O
JA	B-T103
,	O
and	O
both	O
genes	B-T017
display	O
transcriptional	B-T038
inter	I-T038
-	I-T038
regulation	I-T038
at	O
basal	B-T082
and	O
infection	B-T038
conditions	O
.	O

These	O
studies	O
provide	O
the	O
first	O
evidence	O
of	O
the	O
contribution	O
of	O
ProDH2	B-T017
to	O
disease	B-T038
resistance	I-T038
,	O
and	O
describe	O
the	O
differential	O
regulation	O
and	O
non	O
-	O
redundant	O
but	O
complementary	O
function	O
of	O
both	O
enzyme	B-T103
isoforms	I-T103
in	O
infected	B-T033
tissues	B-T017
,	O
providing	O
support	O
for	O
a	O
fundamental	O
role	O
of	O
ProDH	B-T017
in	O
the	O
control	O
of	O
biotrophic	B-T033
and	O
necrotrophic	B-T033
pathogens	O
.	O

Effect	O
of	O
Protein	B-T103
Repetitiveness	O
on	O
Protein	B-T038
-	I-T038
Protein	I-T038
Interaction	I-T038
Prediction	O
Results	O
Using	O
Support	O
Vector	O
Machines	O

There	O
are	O
many	O
computational	B-T062
approaches	I-T062
to	O
predict	O
the	O
protein	B-T038
-	I-T038
protein	I-T038
interactions	I-T038
using	O
support	O
vector	O
machines	O
(	O
SVMs	O
)	O
with	O
high	O
performance	O
.	O

In	O
fact	O
,	O
performance	O
of	O
currently	O
reported	O
methods	B-T170
are	O
significantly	O
over	O
-	O
estimated	O
and	O
affected	O
by	O
the	O
object	O
repetitiveness	O
in	O
the	O
datasets	B-T170
used	O
.	O

To	O
study	B-T062
the	O
effect	O
of	O
object	O
repetitiveness	O
of	O
datasets	B-T170
on	O
predicting	O
results	O
.	O

We	O
present	O
novel	O
methods	B-T170
to	O
construct	O
different	O
positive	B-T033
datasets	B-T170
with	O
or	O
without	O
repeating	O
proteins	B-T103
using	O
graph	B-T170
maximum	O
matching	O
in	O
the	O
protein	B-T038
-	I-T038
protein	I-T038
interaction	I-T038
datasets	B-T170
and	O
corresponding	O
series	O
of	O
negative	B-T033
datasets	B-T170
with	O
different	O
proteins	B-T103
repetitiveness	O
are	O
constructed	O
using	O
graph	B-T170
adjacency	B-T082
matrix	I-T082
.	O

The	O
relationship	O
between	O
the	O
SVM	O
prediction	O
results	O
and	O
the	O
repeated	O
proteins	B-T103
(	O
repeat	O
numbers	O
and	O
repeat	O
rates	O
)	O
and	O
the	O
distributions	O
of	O
repeated	O
proteins	B-T103
in	O
the	O
datasets	B-T170
are	O
analyzed	O
.	O

Protein	B-T103
repetitiveness	O
of	O
positive	B-T033
and	O
negative	B-T033
datasets	B-T170
can	O
affect	O
the	O
prediction	O
result	O
:	O
high	O
protein	B-T103
repetitiveness	O
of	O
positive	B-T033
or	O
negative	B-T033
datasets	B-T170
yield	O
high	O
performance	O
prediction	O
result	O
.	O

This	O
indicate	O
that	O
dealing	O
with	O
object	O
repetitiveness	O
of	O
datasets	B-T170
is	O
a	O
key	O
issue	O
in	O
protein	B-T038
-	I-T038
protein	I-T038
interactions	I-T038
prediction	O
using	O
SVMs	O
since	O
real	O
world	O
data	O
contain	O
certain	O
degrees	O
of	O
repeat	O
proteins	B-T103
.	O

From	O
'	O
sense	O
of	O
number	O
'	O
to	O
'	O
sense	B-T038
of	I-T038
magnitude	O
'	O
-	O
The	O
role	O
of	O
continuous	O
magnitudes	O
in	O
numerical	O
cognition	B-T038

In	O
this	O
review	O
,	O
we	O
are	O
pitting	O
two	O
theories	O
against	O
each	O
other	O
:	O
the	O
more	O
accepted	O
theory	O
-	O
the	O
'	O
number	O
sense	O
'	O
theory	O
-	O
suggesting	O
that	O
a	O
sense	O
of	O
number	O
is	O
innate	O
and	O
non	O
-	O
symbolic	O
numerosity	O
is	O
being	O
processed	O
independently	O
of	O
continuous	O
magnitudes	O
(	O
e	O
.	O
g	O
.	O
,	O
size	B-T082
,	O
area	B-T082
,	O
density	O
)	O
;	O
and	O
the	O
newly	O
emerging	O
theory	O
suggesting	O
that	O
(	O
1	O
)	O
both	O
numerosities	O
and	O
continuous	O
magnitudes	O
are	O
processed	O
holistically	O
when	O
comparing	O
numerosities	O
,	O
and	O
(	O
2	O
)	O
a	O
sense	O
of	O
number	O
might	O
not	O
be	O
innate	O
.	O

In	O
the	O
first	O
part	O
of	O
this	O
review	O
,	O
we	O
discuss	O
the	O
'	O
number	O
sense	O
'	O
theory	O
.	O

Against	O
this	O
background	O
,	O
we	O
demonstrate	O
how	O
the	O
natural	O
correlation	O
between	O
numerosities	O
and	O
continuous	O
magnitudes	O
makes	O
it	O
nearly	O
impossible	O
to	O
study	O
non	O
-	O
symbolic	O
numerosity	O
processing	O
in	O
isolation	O
from	O
continuous	O
magnitudes	O
,	O
and	O
therefore	O
the	O
results	O
of	O
behavioral	B-T062
and	O
imaging	B-T058
studies	I-T058
with	O
infants	O
,	O
adults	O
and	O
animals	B-T204
can	O
be	O
explained	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
relying	O
on	O
continuous	O
magnitudes	O
.	O

In	O
the	O
second	O
part	O
,	O
we	O
explain	O
the	O
'	O
sense	B-T038
of	I-T038
magnitude	O
'	O
theory	O
and	O
review	O
studies	O
that	O
directly	O
demonstrate	O
that	O
continuous	O
magnitudes	O
are	O
more	O
automatic	O
and	O
basic	O
than	O
numerosities	O
.	O

Finally	O
,	O
we	O
present	O
outstanding	O
questions	O
.	O

Our	O
conclusion	O
is	O
that	O
there	O
is	O
not	O
enough	O
convincing	O
evidence	O
to	O
support	O
the	O
number	O
sense	O
theory	O
anymore	O
.	O

Therefore	O
,	O
we	O
encourage	O
researchers	O
not	O
to	O
assume	O
that	O
number	O
sense	O
is	O
simply	O
innate	O
,	O
but	O
to	O
put	O
this	O
hypothesis	O
to	O
the	O
test	O
,	O
and	O
to	O
consider	O
if	O
such	O
an	O
assumption	O
is	O
even	O
testable	O
in	O
light	O
of	O
the	O
correlation	O
of	O
numerosity	O
and	O
continuous	O
magnitudes	O
.	O

How	O
Integrated	B-T058
Management	I-T058
Strategies	I-T058
Promote	O
Protein	B-T103
Quality	O
of	O
Cotton	B-T204
Embryos	I-T204
:	O
High	O
Levels	O
of	O
Soil	O
Available	O
N	B-T103
,	O
N	B-T103
Assimilation	O
and	O
Protein	B-T103
Accumulation	B-T033
Rate	O

Cottonseed	B-T204
is	O
widely	O
used	O
as	O
a	O
source	B-T033
of	O
ruminant	B-T204
feed	B-T168
and	O
for	O
industrial	O
purposes	O
.	O

Therefore	O
,	O
there	O
is	O
a	O
tremendous	O
need	O
to	O
improve	B-T033
the	O
nutritional	O
value	O
of	O
cotton	B-T204
embryos	I-T204
.	O

In	O
this	O
study	B-T062
,	O
a	O
conventional	B-T058
management	I-T058
(	O
CM	B-T058
)	O
and	O
two	O
integrated	O
cotton	B-T204
management	B-T058
strategies	I-T058
(	O
IMS1	B-T058
,	O
IMS2	B-T058
)	O
were	O
performed	O
at	O
two	O
soil	O
fertility	B-T033
levels	O
to	O
study	B-T062
the	O
relationships	O
among	O
soil	O
N	B-T103
,	O
N	B-T103
assimilation	O
,	O
embryonic	B-T204
protein	B-T103
accumulation	B-T033
and	O
protein	B-T103
quality	O
.	O

The	O
levels	B-T058
of	I-T058
proteins	I-T058
,	O
essential	B-T058
amino	I-T058
acids	I-T058
,	O
and	O
semi	B-T058
-	I-T058
essential	I-T058
amino	I-T058
acids	I-T058
,	O
especially	O
those	O
of	O
glutamate	B-T058
,	O
lysine	B-T058
,	O
and	O
methionine	B-T058
,	O
were	O
higher	O
in	O
IMS1	B-T058
and	O
IMS2	B-T058
embryos	B-T204
than	O
in	O
CM	B-T058
embryos	B-T204
.	O

These	O
changes	O
were	O
significantly	O
positively	B-T033
correlated	O
with	O
the	O
soil	O
-	O
available	O
N	B-T058
content	I-T058
,	O
glutamine	B-T038
synthetase	I-T038
activity	I-T038
and	O
peak	O
value	O
of	O
protein	B-T103
accumulation	B-T033
rate	O
and	O
were	O
negatively	B-T033
correlated	O
with	O
the	O
free	O
amino	B-T058
acid	I-T058
level	I-T058
.	O

These	O
results	O
illustrated	O
that	O
integrated	B-T058
management	I-T058
strategies	I-T058
,	O
especially	O
the	O
rates	O
and	O
timing	O
of	O
N	B-T103
application	O
,	O
raise	O
the	O
level	O
of	O
soil	O
available	O
N	B-T103
,	O
which	O
is	O
beneficial	O
for	O
N	B-T103
assimilation	O
in	O
developing	O
cotton	B-T204
embryos	I-T204
.	O

The	O
protein	B-T058
content	I-T058
was	O
limited	O
by	O
the	O
rate	O
of	O
protein	B-T103
accumulation	B-T033
rather	O
than	O
by	O
the	O
free	O
amino	B-T058
acid	I-T058
content	I-T058
.	O

The	O
combination	O
of	O
target	O
yield	O
fertilization	O
,	O
a	O
growth	B-T038
-	O
driven	O
N	B-T103
application	O
schedule	O
,	O
a	O
high	O
plant	B-T204
density	O
and	O
the	O
seedling	B-T204
raising	O
with	O
bio	O
-	O
organic	O
fertilizer	O
can	O
substantially	O
improve	B-T033
protein	B-T103
quality	O
in	O
cotton	B-T204
embryos	I-T204
,	O
especially	O
at	O
a	O
soil	O
with	O
low	O
soil	O
organic	B-T103
matter	I-T103
and	O
total	O
nitrogen	B-T103
.	O

Help	O
end	O
the	O
HIV	B-T005
epidemic	O

After	O
many	O
delays	O
,	O
the	O
public	O
consultation	O
on	O
HIV	O
prevention	O
tool	B-T170
PrEP	B-T058
(	O
pre	B-T058
-	I-T058
exposure	I-T058
prophylaxis	I-T058
)	O
is	O
finally	O
here	O
.	O

Now	O
is	O
the	O
time	O
to	O
mobilise	O
-	O
help	O
end	O
the	O
HIV	B-T005
epidemic	O
by	O
responding	O
to	O
this	O
NHS	O
England	O
consultation	O
before	O
23	O
September	O
.	O

Osseointegration	B-T038
behavior	O
of	O
novel	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
for	O
dental	B-T074
implants	I-T074
:	O
an	O
in	B-T082
vivo	I-T082
study	B-T062

This	O
study	O
aimed	O
to	O
evaluate	B-T058
the	O
effects	O
of	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
implants	B-T074
on	O
mineral	O
apposition	O
rate	O
and	O
new	O
BIC	O
contact	O
in	O
rabbits	B-T204
.	O

Twelve	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
implants	B-T074
were	O
fabricated	O
and	O
placed	B-T058
into	O
the	O
right	B-T082
femur	B-T017
sites	B-T082
in	O
six	O
rabbits	B-T204
,	O
and	O
commercially	O
pure	O
titanium	B-T103
implants	B-T074
were	O
used	O
as	O
controls	O
in	O
the	O
left	B-T082
femur	B-T017
.	O

Tetracycline	B-T103
and	O
alizarin	B-T103
red	I-T103
were	O
administered	O
3	O
weeks	O
and	O
1	O
week	O
before	O
euthanization	B-T058
,	O
respectively	O
.	O

At	O
4	O
weeks	O
and	O
8	O
weeks	O
after	O
implantation	B-T058
,	O
animals	B-T204
were	O
euthanized	O
,	O
respectively	O
.	O

Surface	B-T082
characterization	O
and	O
implant	O
-	O
bone	O
contact	O
surface	B-T082
analysis	B-T062
were	O
performed	O
by	O
using	O
a	O
scanning	B-T074
electron	I-T074
microscope	I-T074
and	O
an	O
energy	B-T074
dispersive	I-T074
X	I-T074
-	I-T074
ray	I-T074
detector	I-T074
.	O

Mineral	O
apposition	O
rate	O
was	O
evaluated	B-T058
using	O
a	O
confocal	B-T058
laser	I-T058
scanning	I-T058
microscope	I-T058
.	O

Toluidine	B-T058
blue	I-T058
staining	I-T058
was	O
performed	O
on	O
undecalcified	B-T033
sections	O
for	O
histology	B-T091
and	O
histomorphology	O
evaluation	O
.	O

Scanning	B-T074
electron	I-T074
microscope	I-T074
and	O
histomorphology	O
observation	O
revealed	O
a	O
direct	O
contact	O
between	O
implants	B-T074
and	O
bone	B-T017
of	O
all	O
groups	O
.	O

After	O
a	O
healing	B-T038
period	O
of	O
4	O
weeks	O
,	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
implants	B-T074
showed	O
significantly	O
higher	O
mineral	O
apposition	O
rate	O
compared	O
to	O
commercially	O
pure	O
titanium	B-T103
implants	B-T074
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
there	O
was	O
no	B-T033
significant	I-T033
difference	O
between	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
implants	B-T074
and	O
commercially	O
pure	O
titanium	B-T103
implants	B-T074
(	O
P	O
>	O
0	O
.	O
05	O
)	O
at	O
8	O
weeks	O
.	O

No	B-T033
significant	I-T033
difference	O
of	O
bone	O
-	O
to	O
-	O
implant	O
contact	O
was	O
observed	O
between	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
implants	B-T074
and	O
commercially	O
pure	O
titanium	B-T103
implants	B-T074
implants	B-T074
after	O
a	O
healing	B-T038
period	O
of	O
4	O
weeks	O
and	O
8	O
weeks	O
.	O

This	O
study	O
showed	O
that	O
Ti	B-T103
-	I-T103
Nb	I-T103
-	I-T103
Zr	I-T103
-	I-T103
Ta	I-T103
-	I-T103
Si	I-T103
alloy	I-T103
implants	B-T074
could	O
establish	O
a	O
close	O
direct	O
contact	O
comparedto	O
commercially	O
pure	O
titanium	B-T103
implants	B-T074
implants	B-T074
,	O
improved	B-T033
mineral	O
matrix	O
apposition	O
rate	O
,	O
and	O
may	O
someday	O
be	O
an	O
alternative	O
as	O
a	O
material	O
for	O
dental	B-T074
implants	I-T074
.	O

Simultaneous	O
edited	O
MRS	B-T058
of	O
GABA	B-T103
and	O
glutathione	B-T103

Edited	O
MRS	B-T058
allows	O
the	O
detection	B-T058
of	O
low	O
-	O
concentration	O
metabolites	B-T103
,	O
whose	O
signals	O
are	O
not	O
resolved	O
in	O
the	O
MR	B-T058
spectrum	I-T058
.	O

Tailored	O
acquisitions	O
can	O
be	O
designed	O
to	O
detect	B-T058
,	O
for	O
example	O
,	O
the	O
inhibitory	O
neurotransmitter	B-T103
γ	B-T103
-	I-T103
aminobutyric	I-T103
acid	I-T103
(	O
GABA	B-T103
)	O
,	O
or	O
the	O
reduction	B-T038
-	I-T038
oxidation	I-T038
(	O
redox	B-T038
)	O
compound	O
glutathione	B-T103
(	O
GSH	B-T103
)	O
,	O
and	O
single	O
-	O
voxel	O
edited	O
experiments	B-T062
are	O
generally	O
acquired	O
at	O
a	O
rate	O
of	O
one	O
metabolite	B-T103
-	O
per	B-T062
-	I-T062
experiment	I-T062
.	O

We	O
demonstrate	O
that	O
simultaneous	O
detection	B-T058
of	O
the	O
overlapping	O
signals	O
of	O
GABA	B-T103
and	O
GSH	B-T103
is	O
possible	O
using	O
Hadamard	B-T058
Encoding	I-T058
and	I-T058
Reconstruction	I-T058
of	I-T058
Mega	I-T058
-	I-T058
Edited	I-T058
Spectroscopy	I-T058
(	O
HERMES	B-T058
)	O
.	O

HERMES	B-T058
applies	O
orthogonal	O
editing	O
encoding	O
(	O
following	O
a	O
Hadamard	B-T170
scheme	I-T170
)	O
,	O
such	O
that	O
GSH	B-T103
-	I-T103
and	O
GABA	B-T103
-	O
edited	O
difference	O
spectra	O
can	O
be	O
reconstructed	O
from	O
a	O
single	B-T062
multiplexed	I-T062
experiment	I-T062
.	O

At	O
a	O
TE	O
of	O
80ms	O
,	O
20	O
-	O
ms	O
editing	O
pulses	O
are	O
applied	O
at	O
4	O
.	O
56ppm	O
(	O
on	O
GSH	B-T103
)	O
,	O
1	O
.	O
9ppm	O
(	O
on	O
GABA	B-T103
)	O
,	O
both	O
offsets	O
(	O
using	O
a	O
dual	O
-	O
lobe	O
cosine	O
-	O
modulated	O
pulse	O
)	O
or	O
neither	O
.	O

Hadamard	B-T170
combinations	I-T170
of	O
the	O
four	O
sub	B-T062
-	I-T062
experiments	I-T062
yield	O
GABA	B-T103
and	O
GSH	B-T103
difference	O
spectra	O
.	O

It	O
is	O
shown	O
that	O
HERMES	B-T058
gives	O
excellent	O
separation	O
of	O
the	O
edited	O
GABA	B-T103
and	O
GSH	B-T103
signals	O
in	O
phantoms	O
,	O
and	O
resulting	O
edited	O
lineshapes	O
agree	B-T033
well	O
with	O
separate	O
Mescher	B-T058
-	I-T058
Garwood	I-T058
Point	I-T058
-	I-T058
resolved	I-T058
Spectroscopy	I-T058
(	O
MEGA	B-T058
-	I-T058
PRESS	I-T058
)	O
acquisitions	O
.	O

In	B-T082
vivo	I-T082
,	O
the	O
quality	O
and	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
SNR	O
)	O
of	O
HERMES	B-T058
spectra	O
are	O
similar	O
to	O
those	O
of	O
sequentially	O
acquired	O
MEGA	B-T058
-	I-T058
PRESS	I-T058
spectra	O
,	O
with	O
the	O
benefit	O
of	O
saving	O
half	O
the	O
acquisition	O
time	O
.	O

Chitosan	B-T103
-	O
functionalised	O
poly	B-T103
(	I-T103
2	I-T103
-	I-T103
hydroxyethyl	I-T103
methacrylate	I-T103
)	I-T103
core	B-T103
-	I-T103
shell	I-T103
microgels	I-T103
as	O
drug	B-T074
delivery	I-T074
carriers	I-T074
:	O
salicylic	B-T103
acid	I-T103
loading	O
and	O
release	O

This	O
work	O
presents	O
the	O
evaluation	O
of	O
chitosan	B-T103
-	O
functionalised	O
poly	B-T103
(	I-T103
2	I-T103
-	I-T103
hydroxyethyl	I-T103
methacrylate	I-T103
)	I-T103
(	O
CS	B-T103
/	O
PHEMA	B-T103
)	O
core	B-T103
-	I-T103
shell	I-T103
microgels	I-T103
as	O
drug	B-T074
delivery	I-T074
carriers	I-T074
.	O

CS	B-T103
/	O
PHEMA	B-T103
microgels	B-T103
were	O
prepared	O
by	O
emulsifier	O
-	O
free	O
emulsion	O
polymerisation	O
with	O
N	B-T103
,	I-T103
N	I-T103
'	I-T103
-	I-T103
methylenebisacrylamide	I-T103
(	O
MBA	B-T103
)	O
as	O
a	O
crosslinker	B-T103
.	O

The	O
study	B-T062
on	I-T062
drug	I-T062
loading	I-T062
,	O
using	O
salicylic	B-T103
acid	I-T103
(	O
SA	B-T103
)	O
as	O
a	O
model	B-T103
drug	I-T103
,	O
was	O
performed	O
.	O

The	O
results	O
showed	O
that	O
the	O
encapsulation	O
efficiency	O
(	O
EE	O
)	O
increased	O
as	O
drug	B-T103
-	O
to	O
-	O
microgel	O
ratio	O
was	O
increased	O
.	O

Higher	O
EE	O
can	O
be	O
achieved	O
with	O
the	O
increase	O
in	O
degree	O
of	O
crosslinking	O
,	O
by	O
increasing	O
the	O
amount	O
of	O
MBA	B-T103
from	O
0	O
.	O
01	O
g	O
to	O
0	O
.	O
03	O
g	O
.	O

In	O
addition	O
,	O
the	O
highest	O
EE	O
(	O
61	O
.	O
1	O
%	O
)	O
was	O
observed	O
at	O
pH	O
3	O
.	O

The	O
highest	O
release	O
of	O
SA	O
(	O
60	O
%	O
)	O
was	O
noticed	O
at	O
pH	O
2	O
.	O
4	O
,	O
while	O
the	O
lowest	O
one	O
(	O
49	O
.	O
4	O
%	O
)	O
was	O
obtained	O
at	O
pH	O
7	O
.	O
4	O
.	O

Moreover	O
,	O
the	O
highest	O
release	O
of	O
SA	O
was	O
enhanced	O
by	O
the	O
presence	O
of	O
0	O
.	O
2	O
M	O
NaCl	B-T103
.	O

The	O
pH	O
-	O
and	O
ionic	O
-	O
sensitivity	O
of	O
CS	B-T103
/	O
PHEMA	B-T103
could	O
be	O
useful	O
as	O
a	O
sustained	B-T103
release	I-T103
delivery	I-T103
device	I-T103
,	O
especially	O
for	O
oral	O
delivery	O
.	O

Breast	B-T058
Augmentation	I-T058
after	O
Conservation	B-T058
Surgery	I-T058
and	O
Radiation	B-T058
Therapy	I-T058

There	O
is	O
a	O
paucity	O
of	O
data	O
regarding	O
outcomes	O
for	O
patients	O
undergoing	O
breast	B-T058
augmentation	I-T058
with	O
implants	B-T074
after	O
breast	B-T058
conservation	I-T058
surgery	I-T058
(	O
BCS	B-T058
)	O
and	O
radiotherapy	B-T058
.	O

This	O
retrospective	B-T062
study	I-T062
examined	O
outcomes	O
for	O
patients	O
with	O
breast	B-T074
implant	I-T074
-	O
only	O
augmentation	B-T058
after	O
BCS	B-T058
and	O
radiotherapy	B-T058
.	O

Between	O
June	O
1998	O
and	O
December	O
2010	O
,	O
671	O
women	B-T098
underwent	O
prosthetic	B-T074
breast	B-T058
reconstruction	I-T058
.	O

Nineteen	O
patients	O
(	O
2	O
.	O
8	O
%	O
)	O
underwent	O
an	O
augmentation	B-T058
after	O
BCS	B-T058
and	O
radiotherapy	B-T058
.	O

The	O
mean	O
age	O
was	O
55	O
.	O
8	O
years	O
(	O
range	O
,	O
40	O
-	O
69	O
years	O
)	O
.	O

Sixteen	O
of	O
these	O
patients	O
underwent	O
one	B-T058
-	I-T058
stage	I-T058
implant	I-T058
-	O
only	O
breast	B-T058
augmentation	I-T058
,	O
whereas	O
3	O
patients	O
underwent	O
two	B-T058
-	I-T058
stage	I-T058
expander	I-T058
and	O
then	O
implant	B-T058
augmentation	I-T058
.	O

All	O
surgeries	B-T058
were	O
successful	O
.	O

The	O
average	O
size	O
of	O
breast	B-T074
implant	I-T074
used	O
was	O
258	O
.	O
7€	O
‰	O
g	O
.	O

Seven	O
patients	O
also	O
received	O
contralateral	O
augmentation	O
with	O
an	O
average	O
implant	O
size	O
of	O
232	O
.	O
2€	O
‰	O
g	O
.	O

One	O
patient	O
received	O
oral	O
antibiotics	O
for	O
minor	O
wound	O
infection	O
.	O

Patients	O
were	O
judged	O
to	O
have	O
an	O
excellent	O
(	O
14	O
/	O
19	O
;	O
73	O
.	O
7	O
%	O
)	O
,	O
good	O
(	O
3	O
/	O
19	O
;	O
15	O
.	O
8	O
%	O
)	O
,	O
or	O
fair	O
(	O
2	O
/	O
19	O
;	O
10	O
.	O
5	O
%	O
)	O
cosmetic	O
result	O
.	O

The	O
breasts	O
of	O
selected	O
patients	O
with	O
breast	O
cancer	O
after	O
BCS	O
and	O
radiotherapy	O
.	O

with	O
asymmetry	O
can	O
be	O
adequately	O
augmented	O
with	O
breast	O
implants	O
alone	O
.	O

Mitochondrial	B-T017
pyruvate	I-T017
dehydrogenase	I-T017
phosphatase	I-T017
1	I-T017
regulates	O
the	O
early	O
differentiation	B-T038
of	I-T038
cardiomyocytes	I-T038
from	O
mouse	B-T017
embryonic	I-T017
stem	I-T017
cells	I-T017

Mitochondria	B-T017
are	O
crucial	O
for	O
maintaining	O
the	O
properties	O
of	O
embryonic	B-T017
stem	I-T017
cells	I-T017
(	O
ESCs	B-T017
)	O
and	O
for	O
regulating	O
their	O
subsequent	O
differentiation	B-T038
into	O
diverse	O
cell	O
lineages	O
,	O
including	O
cardiomyocytes	B-T017
.	O

However	O
,	O
mitochondrial	B-T103
regulators	I-T103
that	O
manage	O
the	O
rate	O
of	O
differentiation	O
or	O
cell	O
fate	O
have	O
been	O
rarely	O
identified	O
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
potential	O
mitochondrial	B-T103
factor	I-T103
that	O
controls	O
the	O
differentiation	B-T038
of	I-T038
ESCs	I-T038
into	O
cardiac	B-T017
myocytes	I-T017
.	O

We	O
induced	O
cardiomyocyte	B-T038
differentiation	I-T038
from	O
mouse	B-T017
ESCs	I-T017
(	O
mESCs	B-T017
)	O
and	O
performed	O
microarray	B-T058
assays	I-T058
to	O
assess	O
messenger	B-T103
RNA	I-T103
(	O
mRNA	B-T103
)	O
expression	B-T038
changes	O
at	O
differentiation	B-T033
day	I-T033
8	I-T033
(	O
D8	B-T033
)	O
compared	O
with	O
undifferentiated	O
mESCs	B-T017
(	O
D0	O
)	O
.	O

Among	O
the	O
differentially	O
expressed	B-T017
genes	I-T017
,	O
Pdp1	B-T017
expression	B-T038
was	O
significantly	O
decreased	O
(	O
27	O
-	O
fold	O
)	O
on	O
D8	B-T033
compared	O
to	O
D0	O
,	O
which	O
was	O
accompanied	O
by	O
suppressed	O
mitochondrial	B-T017
indices	B-T170
,	O
including	O
ATP	B-T103
levels	O
,	O
membrane	B-T038
potential	I-T038
,	O
ROS	B-T038
and	O
mitochondrial	B-T038
Ca	I-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
.	O

Notably	O
,	O
Pdp1	B-T017
overexpression	B-T038
significantly	O
enhanced	O
the	O
mitochondrial	B-T017
indices	B-T170
and	O
pyruvate	B-T038
dehydrogenase	I-T038
activity	I-T038
and	O
reduced	O
the	O
expression	B-T038
of	O
cardiac	B-T038
differentiation	I-T038
marker	O
mRNA	O
and	O
the	O
cardiac	B-T038
differentiation	I-T038
rate	O
compared	O
to	O
a	O
mock	O
control	O
.	O

In	O
confirmation	O
of	O
this	O
,	O
a	O
knockdown	B-T062
of	O
the	O
Pdp1	B-T017
gene	I-T017
promoted	O
the	O
expression	B-T038
of	O
cardiac	B-T038
differentiation	I-T038
marker	O
mRNA	O
and	O
the	O
cardiac	B-T038
differentiation	I-T038
rate	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
suggest	O
that	O
mitochondrial	B-T017
PDP1	I-T017
is	O
a	O
potential	O
regulator	O
that	O
controls	O
cardiac	B-T038
differentiation	I-T038
at	O
an	O
early	O
differentiation	O
stage	O
in	O
ESCs	B-T017
.	O

Thermo	O
-	O
reversible	O
capture	O
and	O
release	O
of	O
DNA	B-T103
by	O
zwitterionic	B-T103
surfactants	I-T103

The	O
thermo	O
-	O
reversible	O
capture	O
and	O
release	O
of	O
DNA	B-T103
were	O
studied	O
by	O
the	O
protonation	O
and	O
deprotonation	O
of	O
alkyldimethylamine	B-T103
oxide	I-T103
(	O
CnDMAO	B-T103
,	O
n	O
=	O
10	O
,	O
12	O
and	O
14	O
)	O
in	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
.	O

DNA	B-T103
/	O
C14DMAO	B-T103
in	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
with	O
pH	O
=	O
7	O
.	O
2	O
is	O
transparent	O
at	O
25	O
°C	O
,	O
indicating	O
that	O
DNA	B-T103
molecules	O
exist	O
mainly	O
in	O
individuals	B-T098
and	O
the	O
binding	B-T038
of	O
C14DMAO	B-T103
is	O
weak	O
.	O

With	O
the	O
increase	O
of	O
temperature	O
,	O
the	O
pH	O
of	O
the	O
buffer	O
solution	O
continuously	O
decreases	O
,	O
which	O
leads	O
to	O
protonation	O
of	O
C14DMAO	B-T103
(	O
C14DMAO	B-T103
+	O
H	B-T103
(	I-T103
+	I-T103
)	I-T103
→	O
C14DMAOH	B-T103
(	I-T103
+	I-T103
)	I-T103
)	O
and	O
an	O
obvious	O
increase	B-T033
of	I-T033
the	I-T033
turbidity	I-T033
of	O
the	O
samples	O
.	O

This	O
indicates	O
a	O
stronger	O
binding	B-T038
of	O
the	O
protonated	O
C14DMAOH	B-T103
(	I-T103
+	I-T103
)	I-T103
to	O
DNA	B-T103
.	O

Further	O
investigations	O
demonstrated	O
the	O
formation	O
of	O
DNA	B-T103
/	O
C14DMAOH	B-T103
(	I-T103
+	I-T103
)	I-T103
complexes	B-T103
,	O
in	O
which	O
the	O
stretched	O
DNA	B-T103
molecules	O
are	O
effectively	O
compacted	B-T033
as	O
evidenced	O
from	O
UV	B-T058
-	I-T058
vis	I-T058
absorptions	I-T058
,	O
circular	B-T058
dichroism	I-T058
(	O
CD	B-T058
)	O
measurements	O
,	O
atomic	B-T058
force	I-T058
microscopy	I-T058
(	O
AFM	B-T058
)	O
observations	B-T062
,	O
dynamic	B-T058
light	I-T058
scattering	I-T058
(	O
DLS	B-T058
)	O
measurements	O
and	O
agarose	B-T058
gel	I-T058
electrophoresis	I-T058
(	O
AGE	B-T058
)	O
.	O

Interestingly	O
,	O
when	O
the	O
temperature	O
is	O
turned	O
back	O
to	O
25	O
°C	O
,	O
the	O
compacted	B-T033
DNA	B-T103
molecules	O
can	O
fully	O
recover	O
to	O
the	O
stretched	O
conformation	O
.	O

This	O
cycle	O
can	O
be	O
repeated	O
several	O
times	O
without	O
obvious	O
loss	O
of	O
efficiency	O
.	O

The	O
effect	O
of	O
the	O
chain	O
length	O
of	O
CnDMAO	B-T103
has	O
also	O
been	O
investigated	O
.	O

When	O
C14DMAO	B-T103
was	O
replaced	O
by	O
C12DMAO	B-T103
,	O
similar	O
phenomena	O
can	O
be	O
observed	O
with	O
a	O
slightly	O
higher	O
critical	O
surfactant	B-T103
concentration	O
for	O
DNA	B-T103
compaction	B-T033
and	O
a	O
slightly	O
lower	O
pH	O
of	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
with	O
pH	O
=	O
6	O
.	O
8	O
.	O

For	O
the	O
DNA	B-T103
/	O
C10DMAO	B-T103
system	O
,	O
however	O
,	O
no	O
DNA	B-T103
compaction	B-T033
was	O
observed	O
even	O
in	O
Tris	O
-	O
HCl	O
buffer	O
solution	O
with	O
a	O
much	O
lower	O
pH	O
and	O
a	O
much	O
higher	O
C10DMAO	B-T103
concentration	O
.	O

The	O
negative	O
charges	O
of	O
DNA	B-T103
molecules	O
can	O
easily	O
be	O
neutralized	O
by	O
positive	O
charges	O
of	O
cationic	B-T103
CnDMAOH	I-T103
(	I-T103
+	I-T103
)	I-T103
(	O
n	O
=	O
12	O
and	O
14	O
)	O
micelles	B-T103
.	O

DNA	B-T103
was	O
compacted	B-T033
and	O
then	O
insoluble	O
DNA	B-T103
/	O
CnDMAOH	B-T103
(	I-T103
+	I-T103
)	I-T103
complexes	B-T103
were	O
formed	O
.	O

Because	O
of	O
the	O
much	O
higher	O
critical	O
micelle	B-T103
concentration	O
(	O
cmc	O
)	O
of	O
the	O
shorter	O
chain	O
length	O
C10DMAOH	B-T103
(	I-T103
+	I-T103
)	I-T103
,	O
cationic	B-T103
C10DMAOH	I-T103
(	I-T103
+	I-T103
)	I-T103
micelles	B-T103
cannot	O
form	O
under	O
the	O
studied	O
condition	O
to	O
compact	B-T033
DNA	B-T103
.	O

The	O
strategy	O
may	O
provide	O
an	O
efficient	O
and	O
alternative	O
approach	O
for	O
stimuli	B-T058
-	I-T058
responsive	I-T058
gene	I-T058
therapy	I-T058
and	O
drug	O
release	O
.	O

Collaborating	O
for	O
Systems	O
Change	O
:	O
A	O
Social	O
Science	O
Framework	O
for	O
Academic	O
Roles	O
in	O
Community	O
Partnerships	O

Environmental	B-T091
health	I-T091
researchers	B-T097
,	O
government	B-T092
agencies	I-T092
,	O
and	O
community	O
groups	O
have	O
endorsed	O
long	O
-	O
term	O
community	O
-	O
academic	O
partnerships	B-T092
as	O
an	O
effective	O
strategy	O
to	O
support	O
science	O
-	O
based	O
improvements	O
in	O
environmental	B-T091
health	I-T091
.	O

Social	O
sciences	O
concepts	O
,	O
approaches	O
,	O
and	O
methods	B-T170
are	O
fundamental	O
to	O
these	O
translational	B-T092
partnerships	I-T092
.	O

However	O
,	O
appropriate	O
roles	O
for	O
academic	O
partners	B-T098
vary	O
throughout	O
the	O
process	O
of	O
changing	O
systems	O
(	O
policies	B-T170
,	O
practices	O
,	O
programs	O
,	O
etc	O
.	O
)	O
.	O

This	O
can	O
complicate	O
planning	B-T170
,	O
evaluating	O
,	O
and	O
sustaining	O
such	O
partnerships	B-T092
.	O

We	O
set	O
forth	O
a	O
conceptual	O
framework	O
for	O
academic	O
partners	B-T098
'	O
roles	O
at	O
different	O
stages	O
of	O
systems	O
change	O
.	O

We	O
apply	O
this	O
framework	O
to	O
three	O
longstanding	O
academic	O
-	O
community	O
partnerships	B-T092
involving	O
National	B-T092
Institute	I-T092
of	I-T092
Environmental	I-T092
Health	I-T092
Sciences	I-T092
Community	B-T097
Outreach	I-T097
and	I-T097
Engagement	I-T097
Cores	I-T097
.	O

We	O
conclude	O
by	O
discussing	O
how	O
the	O
framework	O
can	O
help	O
academic	O
partners	B-T098
tap	O
appropriate	O
expertise	O
,	O
redefine	O
their	O
roles	O
,	O
and	O
evaluate	O
their	O
contributions	O
to	O
community	O
efforts	O
to	O
improve	B-T033
environmental	B-T091
health	I-T091
.	O

A	O
novel	O
mechanical	B-T074
simulator	I-T074
for	O
cannulation	B-T058
and	O
sphincterotomy	O
after	O
Billroth	B-T058
II	I-T058
or	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
reconstruction	I-T058

In	O
patients	O
with	O
Billroth	B-T058
II	I-T058
(	O
B	B-T058
II	I-T058
)	O
or	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
anatomy	B-T017
,	O
endoscopic	B-T058
retrograde	I-T058
cholangiopancreatography	I-T058
(	O
ERCP	B-T058
)	O
is	O
demanding	O
.	O

Here	O
,	O
we	O
describe	O
a	O
novel	O
simulator	B-T074
with	O
simulated	B-T062
fluoroscopy	B-T058
for	O
cannulation	B-T058
and	O
sphincterotomy	O
training	O
in	O
such	O
situations	O
.	O

A	O
custom	O
-	O
made	O
simulation	B-T074
system	I-T074
was	O
built	O
based	O
upon	O
a	O
common	O
chassis	O
of	O
a	O
series	O
of	O
previously	O
described	O
ERCP	B-T058
simulators	B-T074
.	O

The	O
papilla	B-T017
is	O
made	O
out	O
of	O
organic	O
material	O
and	O
can	O
be	O
cut	O
by	O
high	O
frequency	O
current	O
.	O

The	O
advancement	O
of	O
guidewires	O
and	O
other	O
instruments	B-T074
within	O
transparent	O
mock	O
bile	B-T017
ducts	I-T017
can	O
be	O
viewed	O
in	O
the	O
window	O
of	O
the	O
simulator	B-T074
without	O
the	O
need	O
for	O
fluoroscopy	B-T058
.	O

The	O
ERCP	B-T058
B	B-T058
II	I-T058
/	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
simulation	B-T074
system	I-T074
was	O
first	O
evaluated	B-T058
during	O
an	O
ERCP	B-T058
course	O
.	O

There	O
were	O
no	O
technical	O
problems	O
related	O
to	O
the	O
novel	O
simulator	B-T074
during	O
the	O
course	O
.	O

After	O
sphincterotomy	O
,	O
the	O
organic	O
papillae	B-T017
could	O
easily	O
be	O
exchanged	O
within	O
a	O
few	O
seconds	O
.	O

Overall	O
,	O
the	O
novel	O
B	B-T058
II	I-T058
/	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
simulator	B-T074
achieved	O
favorable	O
results	O
by	O
trainees	B-T097
and	O
expert	B-T097
endoscopists	B-T097
in	O
all	O
categories	B-T170
assessed	O
.	O

The	O
new	O
B	B-T058
II	I-T058
/	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
mechanical	B-T074
simulator	I-T074
is	O
simple	O
and	O
practicable	O
.	O

A	O
first	O
evaluation	B-T058
during	O
an	O
ERCP	B-T058
course	O
showed	O
promising	O
results	O
.	O

A	O
thermophilic	O
-	O
like	O
ene	B-T103
-	I-T103
reductase	I-T103
originating	O
from	O
an	O
acidophilic	O
iron	B-T007
oxidizer	I-T007

Ene	B-T103
-	I-T103
reductases	I-T103
originating	O
from	O
extremophiles	O
are	O
gaining	O
importance	O
in	O
the	O
field	O
of	O
biocatalysis	O
due	O
to	O
higher	O
-	O
stability	O
properties	O
.	O

The	O
genome	B-T017
of	O
the	O
acidophilic	O
iron	B-T007
-	I-T007
oxidizing	I-T007
bacterium	I-T007
"	O
Ferrovum	B-T007
"	I-T007
sp	I-T007
.	I-T007

JA12	I-T007
was	O
found	O
to	O
harbor	O
a	O
thermophilic	O
-	O
like	O
ene	B-T103
-	I-T103
reductase	I-T103
(	O
FOYE	B-T103
-	I-T103
1	I-T103
)	O
.	O

The	O
foye	B-T017
-	I-T017
1	I-T017
gene	I-T017
was	O
ligated	O
into	O
a	O
pET16bp	B-T103
expression	B-T038
vector	B-T103
system	I-T103
,	O
and	O
the	O
enzyme	B-T103
was	O
produced	O
in	O
Escherichia	B-T007
coli	I-T007
BL21	B-T017
(	I-T017
DE3	I-T017
;	I-T017
pLysS	I-T017
)	I-T017
cells	I-T017
in	O
yields	O
of	O
10	O
mg	O
L	O
(	O
-	O
1	O
)	O
.	O

FOYE	B-T103
-	I-T103
1	I-T103
showed	O
remarkable	O
activity	B-T038
and	O
rates	O
on	O
N	B-T103
-	I-T103
phenylmaleimide	I-T103
and	O
N	B-T103
-	I-T103
phenyl	I-T103
-	I-T103
2	I-T103
-	I-T103
methylmaleimide	I-T103
(	O
up	O
to	O
89	O
U	O
mg	O
(	O
-	O
1	O
)	O
,	O
>	O
97	O
%	O
conversion	O
,	O
95	O
%	O
(	O
R	O
)	O
-	O
selective	O
)	O
with	O
both	O
nicotinamide	B-T103
cofactors	I-T103
,	O
NADPH	B-T103
and	O
NADH	B-T103
.	O

The	O
catalytic	O
efficiency	O
with	O
NADPH	B-T103
was	O
27	O
times	O
higher	O
compared	O
to	O
NADH	B-T103
.	O

At	O
the	O
temperature	O
maximum	O
(	O
50	O
°C	O
)	O
and	O
pH	O
optimum	O
(	O
6	O
.	O
5	O
)	O
,	O
activity	B-T038
was	O
almost	O
doubled	O
to	O
160	O
U	O
mg	O
(	O
-	O
1	O
)	O
.	O

These	O
findings	B-T033
accomplish	O
FOYE	B-T103
-	I-T103
1	I-T103
for	O
a	O
valuable	O
biocatalyst	O
in	O
the	O
synthesis	O
of	O
succinimides	B-T103
.	O

The	O
appearance	O
of	O
a	O
thermophilic	O
-	O
like	O
ene	B-T103
-	I-T103
reductase	I-T103
in	O
an	O
acidic	B-T082
habitat	I-T082
is	O
discussed	O
with	O
respect	O
to	O
its	O
phylogenetic	O
placement	O
and	O
to	O
the	O
genomic	B-T017
neighborhood	B-T082
of	O
the	O
encoding	O
gene	B-T017
,	O
awarding	O
FOYE	B-T103
-	I-T103
1	I-T103
a	O
putative	O
involvement	O
in	O
a	O
quorum	B-T038
-	I-T038
sensing	I-T038
process	O
.	O

A	O
tanshinone	B-T103
I	I-T103
derivative	O
enhances	O
the	O
activities	B-T038
of	O
antibiotics	B-T103
against	O
Staphylococcus	B-T007
aureus	I-T007
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082

Infections	B-T038
caused	O
by	O
Staphylococcus	B-T007
aureus	I-T007
are	O
prevalent	O
.	O

The	O
dramatically	O
reduced	O
discovery	O
of	O
new	O
antibiotics	B-T103
,	O
as	O
well	O
as	O
the	O
persistent	O
emergence	O
of	O
resistant	B-T007
bacteria	I-T007
,	O
represents	O
a	O
major	O
health	O
problem	B-T033
in	O
both	O
hospital	B-T092
and	O
community	B-T092
settings	I-T092
.	O

Using	O
antibiotic	B-T103
enhancers	O
to	O
rescue	O
existing	O
classes	O
of	O
antibiotics	B-T103
is	O
an	O
attractive	O
strategy	O
.	O

In	O
this	O
study	B-T062
,	O
16	B-T103
-	I-T103
aldehyde	I-T103
tanshinone	I-T103
I	I-T103
(	O
ALT	B-T103
)	O
was	O
synthesized	O
and	O
bacteriostatic	B-T038
activity	I-T038
was	O
explored	O
.	O

In	O
addition	O
,	O
synergistic	O
or	O
additive	O
activity	B-T038
between	O
ALT	B-T103
and	O
aminoglycoside	B-T103
antibiotics	I-T103
or	O
β	B-T103
-	I-T103
lactam	I-T103
antibiotics	I-T103
in	O
vitro	O
was	O
identified	O
.	O

Moreover	O
,	O
ALT	B-T103
was	O
documented	O
to	O
augment	O
clearance	O
of	O
streptomycin	B-T103
(	O
STR	B-T103
)	O
and	O
ampicillin	B-T103
(	O
AMP	B-T103
)	O
against	O
S	B-T007
.	I-T007

aureus	I-T007
in	O
a	O
murine	B-T038
infection	I-T038
model	I-T038
.	O

Primary	O
mechanistic	O
insight	O
indicated	O
that	O
ALT	B-T103
could	O
damage	O
the	O
bacterial	B-T007
cell	B-T017
membrane	I-T017
,	O
leading	O
to	O
accumulation	B-T033
of	O
antibiotics	B-T103
inside	O
bacterial	B-T007
cells	I-T007
.	O

This	O
finding	O
might	O
be	O
useful	O
for	O
treating	O
infections	B-T038
caused	O
by	O
S	B-T007
.	I-T007

aureus	I-T007
and	O
expand	O
the	O
scope	O
of	O
application	O
of	O
tanshinones	B-T103
.	O

Investigation	O
of	O
argyrophilic	B-T017
nucleolar	B-T017
organizing	I-T017
region	I-T017

Ischemia	B-T037
/	I-T037
reperfusion	I-T037
(	I-T037
I	I-T037
/	I-T037
R	I-T037
)	I-T037
injury	I-T037
is	O
a	O
complex	O
event	O
frequently	O
observed	O
in	O
vascular	B-T058
surgery	I-T058
and	O
can	O
cause	O
functional	B-T038
and	O
structural	B-T017
cell	O
damage	O
.	O

Nucleolar	B-T017
-	I-T017
organizing	I-T017
regions	I-T017
(	O
NORs	B-T017
)	O
are	O
sites	B-T082
of	O
the	O
ribosomal	B-T017
genes	I-T017
located	O
on	O
chromosomes	B-T017
and	O
can	O
be	O
stained	B-T058
with	O
silver	B-T103
when	O
they	O
are	O
active	O
.	O

Thus	O
these	O
proteins	B-T103
are	O
named	O
as	O
argyrophilic	B-T103
-	I-T103
NOR	I-T103
(	I-T103
AgNOR	I-T103
)	I-T103
-	I-T103
associated	I-T103
proteins	I-T103
.	O

We	O
aimed	O
to	O
investigate	O
any	O
possible	O
effects	O
of	O
renal	B-T017
I	B-T037
/	I-T037
R	I-T037
injury	I-T037
on	O
the	O
NOR	B-T103
protein	I-T103
synthesis	B-T038
and	O
association	O
between	O
the	O
AgNOR	B-T103
proteins	I-T103
amount	O
and	O
histopathological	B-T033
injuring	I-T033
score	I-T033
.	O

Nine	O
female	O
wistar	B-T204
-	I-T204
albino	I-T204
rats	I-T204
with	O
weight	O
of	O
200	O
-	O
250g	O
were	O
included	O
into	O
the	O
study	O
.	O

The	O
animals	B-T204
were	O
randomly	O
divided	O
in	O
two	O
groups	O
,	O
a	O
Control	O
Group	O
and	O
an	O
I	B-T037
/	I-T037
R	I-T037
Group	O
.	O

In	O
I	B-T037
/	I-T037
R	I-T037
group	O
,	O
rats	B-T204
were	O
subjected	O
to	O
45	O
minutes	O
of	O
renal	B-T017
pedicle	I-T017
occlusion	B-T038
followed	O
by	O
24	O
hours	O
of	O
reperfusion	B-T038
.	O

In	O
the	O
control	O
group	O
no	O
drug	B-T058
injections	I-T058
or	O
ischemia	B-T037
reperfusion	I-T037
were	O
performed	O
in	O
animals	B-T204
.	O

Then	O
histopathological	B-T033
injury	I-T033
score	I-T033
,	O
mean	B-T033
AgNOR	I-T033
number	I-T033
and	O
total	B-T033
AgNOR	I-T033
area	I-T033
/	O
nuclear	B-T033
area	I-T033
(	O
TAA	B-T033
/	O
NA	B-T033
)	O
were	O
detected	B-T033
for	O
each	O
rat	B-T204
.	O

The	O
differences	O
between	O
control	O
and	O
I	B-T037
/	I-T037
R	I-T037
groups	O
were	O
significant	O
for	O
histopathological	B-T033
injury	I-T033
scores	I-T033
(	O
p	O
=	O
0	O
.	O
016	O
)	O
.	O

Also	O
the	O
differences	O
between	O
control	O
group	O
and	O
I	B-T037
/	I-T037
R	I-T037
group	O
were	O
significant	O
for	O
mean	B-T033
AgNOR	I-T033
number	I-T033
(	O
p	O
=	O
0	O
.	O
000	O
)	O
and	O
TAA	O
/	O
NA	O
ratio	O
(	O
p	O
=	O
0	O
.	O
000	O
)	O
.	O

Additionally	O
,	O
there	O
was	O
a	O
positive	O
correlation	O
between	O
TAA	O
/	O
NA	O
ratio	O
and	O
histopathological	B-T033
injury	I-T033
score	I-T033
(	O
r	O
=	O
0	O
.	O
728	O
;	O
p	O
=	O
0	O
.	O
026	O
)	O
and	O
between	O
mean	B-T033
AgNOR	I-T033
number	I-T033
and	O
histopathological	B-T033
injury	I-T033
score	I-T033
(	O
r	O
=	O
0	O
.	O
670	O
;	O
p	O
=	O
0	O
.	O
048	O
)	O
.	O

The	O
detection	B-T058
of	O
AgNOR	B-T103
proteins	I-T103
amount	O
may	O
be	O
used	O
as	O
an	O
indicator	O
to	O
obtain	O
information	O
about	O
the	O
cellular	B-T038
behaviour	I-T038
(	O
self	B-T038
-	I-T038
protective	I-T038
mechanism	O
of	O
tubular	B-T017
epithelial	I-T017
cells	I-T017
)	O
against	O
I	B-T037
/	I-T037
R	I-T037
injury	I-T037
and	O
cellular	O
damage	O
levels	O
(	O
Tab	O
.	O

2	O
,	O
Fig	O
.	O

4	O
,	O
Ref	O
.	O

24	O
)	O
.	O

When	O
emotion	B-T038
and	O
expression	B-T033
diverge	O
:	O
The	O
social	O
costs	O
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038

Patients	O
with	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
are	O
perceived	B-T038
more	O
negatively	B-T033
than	O
their	O
healthy	O
peers	B-T098
,	O
yet	O
it	O
remains	O
unclear	O
what	O
factors	O
contribute	O
to	O
this	O
negative	B-T033
social	B-T038
perception	I-T038
.	O

Based	O
on	O
a	O
cohort	B-T098
of	O
17	O
PD	B-T038
patients	O
and	O
20	O
healthy	O
controls	O
,	O
we	O
assessed	O
how	O
naïve	O
raters	O
judge	O
the	O
emotion	B-T038
and	O
emotional	B-T033
intensity	O
displayed	O
in	O
dynamic	O
facial	B-T033
expressions	I-T033
as	O
adults	O
with	O
and	O
without	O
PD	B-T038
watched	O
emotionally	B-T038
evocative	O
films	B-T170
(	O
Experiment	B-T062
1	O
)	O
,	O
and	O
how	O
age	O
-	O
matched	O
peers	B-T098
naïve	O
to	O
patients	O
'	O
disease	B-T038
status	O
judge	O
their	O
social	O
desirability	O
along	O
various	O
dimensions	O
from	O
audiovisual	B-T170
stimuli	O
(	O
interview	B-T097
excerpts	I-T097
)	O
recorded	O
after	O
certain	O
films	B-T170
(	O
Experiment	B-T062
2	O
)	O
.	O

In	O
Experiment	B-T062
1	O
,	O
participants	B-T098
with	O
PD	B-T038
were	O
rated	O
as	O
significantly	O
more	O
facially	B-T033
expressive	I-T033
than	O
healthy	O
controls	O
;	O
moreover	O
,	O
ratings	O
demonstrated	O
that	O
PD	B-T038
patients	O
were	O
routinely	O
mistaken	O
for	O
experiencing	B-T038
a	O
negative	B-T033
emotion	B-T038
,	O
whereas	O
controls	O
were	O
rated	O
as	O
displaying	O
a	O
more	O
positive	B-T033
emotion	B-T038
than	O
they	O
reported	B-T058
feeling	B-T038
.	O

In	O
Experiment	B-T062
2	O
,	O
results	B-T033
showed	O
that	O
age	B-T098
-	I-T098
peers	I-T098
rated	O
PD	B-T038
patients	O
as	O
significantly	O
less	O
socially	O
desirable	O
than	O
control	O
participants	B-T098
.	O

Specifically	O
,	O
PD	B-T038
patients	O
were	O
rated	O
as	O
less	O
involved	O
,	O
interested	B-T038
,	O
friendly	O
,	O
intelligent	O
,	O
optimistic	B-T033
,	O
attentive	O
,	O
and	O
physically	O
attractive	O
than	O
healthy	O
controls	O
.	O

Taken	O
together	O
,	O
our	O
results	B-T033
point	O
to	O
a	O
disconnect	O
between	O
how	O
PD	B-T038
patients	O
report	B-T058
feeling	B-T038
and	O
attributions	B-T038
that	O
others	O
make	O
about	O
their	O
emotions	B-T038
and	O
social	O
characteristics	O
,	O
underlining	O
significant	O
social	O
challenges	O
of	O
the	O
disease	B-T038
.	O

In	O
particular	O
,	O
changes	O
in	O
the	O
ability	O
to	O
modulate	B-T082
the	O
expression	B-T033
of	O
negative	B-T033
emotions	B-T038
may	O
contribute	O
to	O
the	O
negative	B-T033
social	O
impressions	O
that	O
many	O
PD	B-T038
patients	O
face	O
.	O

Establishing	O
in	O
-	O
hospital	B-T092
geriatrics	B-T092
services	I-T092
in	O
Africa	B-T082
:	O
Insights	O
from	O
the	O
University	B-T092
of	I-T092
Benin	I-T092
Teaching	I-T092
Hospital	I-T092
geriatrics	B-T091
project	O

Unawareness	O
of	O
the	O
peculiar	O
healthcare	B-T058
needs	O
of	O
the	O
elderly	B-T098
and	O
resource	O
constraints	O
may	O
be	O
some	O
reasons	O
why	O
until	O
recently	O
,	O
Nigerian	B-T082
hospitals	B-T092
have	O
not	O
been	O
equipped	O
with	O
the	O
human	O
and	O
infrastructural	O
resources	O
required	O
to	O
meet	O
older	B-T098
adults	I-T098
'	O
special	O
healthcare	B-T058
needs	O
.	O

There	O
is	O
paucity	O
of	O
specialized	O
health	B-T092
services	I-T092
for	O
the	O
elderly	B-T098
in	O
Africa	B-T082
.	O

Nigeria	B-T082
,	O
with	O
a	O
population	B-T098
of	O
over	O
170	O
million	O
,	O
did	O
not	O
have	O
any	O
healthcare	B-T092
facility	I-T092
with	O
dedicated	O
services	B-T058
for	O
the	O
elderly	B-T098
until	O
2012	O
.	O

The	O
University	B-T092
of	I-T092
Benin	I-T092
Teaching	I-T092
Hospital	I-T092
(	O
UBTH	B-T092
)	O
in	O
Nigeria	B-T082
was	O
established	O
in	O
1973	O
and	O
created	O
its	O
geriatrics	B-T091
unit	O
in	O
October	O
2013	O
.	O

A	O
prepared	O
environment	O
and	O
trained	B-T058
interdisciplinary	I-T058
teams	I-T058
are	O
pivotal	O
in	O
providing	O
effective	O
healthcare	B-T092
services	I-T092
for	O
the	O
elderly	B-T098
.	O

The	O
ongoing	O
UBTH	B-T092
geriatrics	B-T091
project	O
aims	O
to	O
provide	O
specialized	O
interdisciplinary	O
health	B-T058
services	I-T058
to	O
older	B-T098
adults	I-T098
and	O
to	O
provide	O
training	O
and	O
continuing	O
professional	O
development	O
in	O
geriatrics	B-T091
for	O
healthcare	B-T097
staff	I-T097
.	O

In	O
developing	O
our	O
inpatient	O
services	B-T058
,	O
we	O
adopted	O
the	O
acute	O
care	O
for	O
elders	O
(	O
ACE	O
)	O
model	O
and	O
worked	O
in	O
tandem	O
with	O
the	O
"	O
ABCs	O
"	O
of	O
implementing	O
ACE	O
units	O
.	O

In	O
the	O
face	O
of	O
limited	O
resources	O
,	O
it	O
was	O
possible	O
to	O
establish	O
a	O
functional	O
geriatrics	B-T091
unit	I-T091
with	O
a	O
trained	O
interdisciplinary	B-T058
team	I-T058
.	O

Family	O
participation	O
is	O
central	O
in	O
our	O
practice	B-T091
.	O

Since	O
October	O
2013	O
,	O
residents	B-T098
and	O
house	B-T097
officers	I-T097
in	O
internal	B-T103
medicine	I-T103
have	O
been	O
undertaking	O
4	O
-	O
and	O
12	O
-	O
weekly	O
rotations	O
,	O
respectively	O
.	O

There	O
is	O
also	O
a	O
robust	O
academic	O
program	O
,	O
which	O
includes	O
once	O
-	O
weekly	O
geriatric	O
pharmacotherapy	B-T058
seminars	O
,	O
once	O
-	O
weekly	O
interdisciplinary	O
seminars	O
,	O
and	O
2	O
-	O
weekly	O
journal	O
club	O
meetings	O
alternating	O
with	O
seminars	O
on	O
geriatric	B-T170
assessment	I-T170
tools	I-T170
.	O

It	O
is	O
possible	O
to	O
establish	O
geriatric	B-T092
services	I-T092
and	O
achieve	O
best	O
practices	B-T091
in	O
resource	O
-	O
limited	O
settings	O
by	O
investing	O
on	O
improving	O
available	O
human	O
resources	O
and	O
infrastructure	B-T170
.	O

We	O
also	O
make	O
recommendations	O
for	O
setting	O
up	O
similar	O
services	B-T092
in	O
other	O
parts	O
of	O
Africa	B-T082
.	O

Engaging	B-T033
adolescent	O
girls	O
in	O
transactional	O
sex	O
through	O
compensated	O
dating	O

Transactional	O
sex	O
through	O
so	O
-	O
called	O
compensated	O
dating	O
in	O
adolescent	O
girls	O
is	O
a	O
problem	B-T033
in	O
need	O
of	O
public	B-T092
concern	O
.	O

Compensated	O
dating	O
typically	O
involves	O
the	O
use	O
of	O
information	B-T170
communication	I-T170
technology	I-T170
to	O
advertise	O
,	O
search	O
,	O
bargain	O
,	O
and	O
eventually	O
arrange	O
for	O
transactional	O
sex	O
.	O

The	O
technology	B-T170
enables	B-T038
the	O
sexual	B-T098
partners	I-T098
to	O
maintain	O
privacy	O
and	O
secrecy	O
in	O
transactional	O
sex	O
.	O

Such	O
secrecy	O
necessitates	O
the	O
girls	B-T098
'	O
disclosure	O
about	O
their	O
life	O
experiences	O
in	O
order	O
to	O
address	O
the	O
concern	O
.	O

The	O
disclosure	O
is	O
the	O
focus	O
of	O
the	O
present	O
qualitative	B-T062
study	I-T062
of	O
27	O
girls	B-T098
practicing	B-T038
the	O
dating	O
in	O
Hong	B-T082
Kong	I-T082
,	O
China	B-T082
.	O

Based	O
on	O
the	O
disclosure	O
,	O
the	O
study	B-T062
presents	O
a	O
grounded	B-T170
theory	I-T170
that	O
epitomizes	O
engagement	B-T033
in	O
compensated	O
dating	O
by	O
referential	O
choice	O
.	O

Such	O
a	O
referential	O
choice	O
theory	O
unravels	O
that	O
choice	O
with	O
reference	O
to	O
the	O
family	O
push	O
and	O
social	O
norms	O
sustains	O
the	O
engagement	B-T033
.	O

Meanwhile	O
,	O
the	O
choice	O
rests	O
on	O
expectancy	O
and	O
reinforcement	O
from	O
experiential	O
learning	O
about	O
compensated	O
dating	O
.	O

The	O
theory	O
thus	O
implies	O
ways	O
to	O
undercut	O
the	O
engagement	B-T033
through	O
diverting	O
the	O
referential	O
choice	O
of	O
the	O
dating	O
.	O

Numerical	B-T062
simulation	I-T062
of	O
emitted	B-T103
particle	I-T103
characteristics	O
and	O
airway	B-T017
deposition	O
distribution	B-T038
of	O
Symbicort	B-T103
(	I-T103
®	I-T103
)	I-T103
Turbuhaler	I-T103
(	I-T103
®	I-T103
)	I-T103
dry	B-T103
powder	I-T103
fixed	O
combination	B-T103
aerosol	B-T103
drug	I-T103

One	O
of	O
the	O
most	O
widespread	O
dry	B-T103
powder	I-T103
fixed	O
combinations	B-T103
used	O
in	O
asthma	B-T038
and	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
(	O
COPD	B-T038
)	O
management	B-T058
is	O
Symbicort	B-T103
(	I-T103
®	I-T103
)	I-T103
Turbuhaler	I-T103
(	I-T103
®	I-T103
)	I-T103
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
simulate	B-T062
the	O
deposition	O
distribution	B-T038
of	O
both	O
components	O
of	O
this	O
drug	B-T103
within	O
the	O
airways	B-T017
based	O
on	O
realistic	O
airflow	O
measurements	O
.	O

Breathing	B-T038
parameters	O
of	O
25	O
healthy	B-T033
adults	I-T033
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	B-T038
through	O
Turbuhaler	B-T074
(	I-T074
®	I-T074
)	I-T074
.	O

Individual	B-T098
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	B-T038
of	O
Symbicort	B-T103
(	I-T103
®	I-T103
)	I-T103
Turbuhaler	I-T103
(	I-T103
®	I-T103
)	I-T103
were	O
determined	O
.	O

A	O
self	O
-	O
developed	O
particle	B-T103
deposition	O
model	B-T170
was	O
adapted	O
and	O
validated	O
to	O
simulate	B-T062
the	O
deposition	O
of	O
budesonide	B-T103
(	O
inhaled	B-T103
corticosteroid	I-T103
;	O
ICS	B-T103
)	O
and	O
formoterol	B-T103
(	O
long	B-T103
acting	I-T103
β2	I-T103
agonist	I-T103
;	O
LABA	B-T103
)	O
in	O
the	O
upper	B-T082
airways	I-T082
and	O
lungs	B-T017
of	O
the	O
healthy	B-T098
volunteers	I-T098
.	O

Based	O
on	O
current	O
simulations	B-T062
the	O
emitted	O
doses	O
varied	O
between	O
50	O
.	O
4	O
%	O
and	O
92	O
.	O
5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	B-T103
,	O
and	O
between	O
38	O
%	O
and	O
96	O
.	O
1	O
%	O
in	O
case	O
of	O
LABA	B-T103
component	O
depending	O
on	O
the	O
individual	B-T098
inhalation	B-T201
flow	I-T201
rate	I-T201
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter	O
-	O
individual	B-T098
spread	O
of	O
the	O
deposited	O
lung	B-T017
doses	O
(	O
mean	O
:	O
33	O
.	O
6	O
%	O
,	O
range	O
:	O
20	O
.	O
4	O
%	O
-	O
48	O
.	O
8	O
%	O
for	O
budesonide	B-T103
and	O
mean	O
:	O
29	O
.	O
8	O
%	O
,	O
range	O
:	O
16	O
.	O
4	O
%	O
-	O
42	O
.	O
9	O
%	O
for	O
formoterol	B-T103
)	O
.	O

Significant	O
inter	O
-	O
gender	O
differences	O
were	O
also	O
observed	O
.	O

Average	O
lung	B-T017
dose	O
of	O
budesonide	B-T103
was	O
29	O
.	O
2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	B-T103
deposited	O
with	O
26	O
.	O
4	O
%	O
efficiency	O
for	O
females	O
and	O
32	O
.	O
5	O
%	O
for	O
males	O
.	O

Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath	B-T033
-	I-T033
holding	I-T033
after	O
inhalation	B-T038
of	O
the	O
drug	B-T103
.	O

About	O
a	O
half	O
of	O
the	O
total	O
lung	B-T017
deposition	O
occurred	O
during	O
breath	B-T033
-	I-T033
hold	I-T033
at	O
9	O
.	O
6s	O
average	O
breath	B-T033
-	I-T033
hold	I-T033
time	O
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	B-T017
deposition	O
of	O
Symbicort	B-T103
(	I-T103
®	I-T103
)	I-T103
Turbuhaler	I-T103
(	I-T103
®	I-T103
)	I-T103
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	B-T058
inhalation	I-T058
technique	I-T058
is	O
advised	O
for	O
persons	B-T098
with	O
low	B-T033
vital	I-T033
capacity	I-T033
.	O

This	O
study	B-T062
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	B-T017
deposition	O
of	O
aerosol	B-T103
drugs	I-T103
by	O
numerical	B-T062
simulations	I-T062
.	O

The	O
methodology	O
developed	O
in	O
this	O
study	B-T062
will	O
be	O
applicable	O
also	O
to	O
other	O
marketed	O
drugs	B-T103
in	O
the	O
future	O
.	O

Nutrient	B-T058
intake	I-T058
of	O
infants	O
and	O
toddlers	O
in	O
the	O
United	B-T082
Arab	I-T082
Emirates	I-T082
:	O
the	O
Feeding	O
Infants	O
and	O
Toddlers	O
Study	O

This	O
descriptive	O
study	O
evaluated	O
the	O
nutrient	O
adequacy	O
of	O
the	O
diet	B-T168
of	O
infants	O
(	O
aged	O
6	O
-	O
11	O
.	O
9	O
months	O
)	O
and	O
toddlers	O
(	O
aged	O
12	O
-	O
24	O
months	O
)	O
in	O
the	O
United	B-T082
Arab	I-T082
Emirates	I-T082
.	O

A	O
random	O
sample	O
of	O
1000	O
infants	O
and	O
toddlers	O
was	O
recruited	O
from	O
2	O
cities	O
(	O
Al	B-T082
Ain	I-T082
and	O
Dubai	B-T082
)	O
from	O
March	O
2011	O
to	O
February	O
2012	O
and	O
their	O
usual	O
nutrient	B-T058
intake	I-T058
was	O
determined	O
using	O
24	O
-	O
hour	O
recall	O
.	O

In	O
all	O
,	O
54	O
.	O
2	O
%	O
of	O
infants	O
and	O
25	O
.	O
2	O
%	O
of	O
toddlers	O
were	O
breastfeeding	B-T038
.	O

Mean	O
energy	O
intake	O
of	O
infant	O
girls	O
in	O
Al	B-T082
Ain	I-T082
and	O
Dubai	B-T082
was	O
747	O
(	O
SD	O
189	O
)	O
kcal	O
and	O
773	O
(	O
SD	O
215	O
)	O
kcal	O
respectively	O
and	O
810	O
.	O
5	O
(	O
SD	O
232	O
.	O
2	O
)	O
kcal	O
and	O
821	O
.	O
9	O
(	O
SD	O
262	O
)	O
kcal	O
for	O
boys	O
.	O

In	O
toddlers	O
,	O
mean	O
energy	O
intake	O
for	O
girls	O
in	O
Al	O
Ain	O
and	O
Dubai	O
was	O
1032	O
.	O
8	O
(	O
SD	O
252	O
)	O
kcal	O
and	O
1013	O
(	O
SD	O
339	O
.	O
1	O
)	O
kcal	O
respectively	O
and	O
1057	O
.	O
2	O
(	O
SD	O
201	O
.	O
8	O
)	O
kcal	O
and	O
1030	O
.	O
3	O
(	O
SD	O
341	O
.	O
7	O
)	O
kcal	O
for	O
boys	O
.	O

Iron	B-T033
intake	I-T033
was	O
low	O
in	O
both	O
groups	O
.	O

Mean	O
body	B-T201
mass	I-T201
index	I-T201
and	O
body	O
weight	O
and	O
height	O
were	O
similar	O
to	O
World	B-T092
Health	I-T092
Organization	I-T092
figures	O
but	O
significant	O
numbers	O
of	O
infants	O
and	O
toddlers	O
of	O
both	O
sexes	O
were	O
over	B-T033
-	O
or	O
underweight	B-T033
.	O

Although	O
mean	O
energy	O
and	O
macronutrient	O
intakes	B-T058
were	O
comparable	O
to	O
the	O
RDA	B-T170
,	O
significant	O
numbers	O
were	O
over	B-T038
-	O
or	O
underfed	B-T038
.	O

Estimation	O
of	O
the	O
HIV	B-T005
-	I-T005
1	I-T005
backward	B-T082
mutation	O
rate	O
from	O
transmitted	B-T038
drug	I-T038
-	I-T038
resistant	I-T038
strains	O

One	O
of	O
the	O
serious	O
threats	O
facing	O
the	O
administration	O
of	O
antiretroviral	B-T058
therapy	I-T058
to	O
human	B-T005
immunodeficiency	I-T005
virus	I-T005
(	O
HIV	B-T005
-	I-T005
1	I-T005
)	O
infected	B-T038
patients	O
is	O
the	O
reported	O
increasing	O
prevalence	O
of	O
transmitted	B-T038
drug	I-T038
resistance	I-T038
.	O

However	O
,	O
given	O
that	O
HIV	B-T005
-	I-T005
1	I-T005
drug	B-T038
-	I-T038
resistant	I-T038
strains	O
are	O
often	O
less	O
fit	O
than	O
the	O
wild	B-T017
-	I-T017
type	I-T017
strains	O
,	O
it	O
is	O
expected	O
that	O
drug	B-T038
-	I-T038
resistant	I-T038
strains	O
that	O
are	O
present	O
during	O
the	O
primary	O
phase	O
of	O
the	O
HIV	B-T038
-	I-T038
1	I-T038
infection	I-T038
are	O
replaced	O
by	O
the	O
fitter	O
wild	B-T017
-	I-T017
type	I-T017
strains	O
.	O

This	O
replacement	O
of	O
HIV	B-T033
-	I-T033
1	I-T033
resistant	I-T033
mutations	B-T038
involves	O
the	O
emergence	O
of	O
wild	B-T017
-	I-T017
type	I-T017
strains	O
by	O
a	O
process	O
of	O
backward	B-T082
mutation	B-T038
.	O

How	O
quickly	O
the	O
replacement	O
happens	O
is	O
dependent	O
on	O
the	O
class	O
of	O
HIV	B-T005
-	I-T005
1	I-T005
mutation	B-T038
group	O
.	O

We	O
estimate	O
the	O
backward	B-T082
mutation	O
rates	O
and	O
relative	O
fitness	O
of	O
various	O
mutational	B-T038
groups	O
known	O
to	O
confer	O
HIV	B-T005
-	I-T005
1	I-T005
drug	B-T038
resistance	I-T038
.	O

We	O
do	O
this	O
by	O
fitting	O
a	O
stochastic	O
model	O
to	O
data	O
for	O
individuals	B-T098
who	O
were	O
originally	O
infected	B-T033
by	O
an	O
HIV	B-T005
-	I-T005
1	I-T005
strain	O
carrying	O
any	O
one	O
of	O
the	O
known	O
drug	B-T038
resistance	I-T038
-	O
conferring	O
mutations	B-T038
and	O
observed	O
over	O
a	O
period	O
of	O
time	O
to	O
see	O
whether	O
the	O
resistant	O
strain	O
is	O
replaced	O
.	O

To	O
do	O
this	O
,	O
we	O
seek	O
a	O
distribution	O
,	O
generated	O
from	O
simulations	B-T062
of	O
the	O
stochastic	O
model	O
,	O
that	O
best	O
describes	O
the	O
observed	O
(	O
clinical	B-T170
data	I-T170
)	O
replacement	O
times	O
of	O
a	O
given	O
mutation	B-T038
.	O

We	O
found	O
that	O
Lamivudine	O
/	O
Emtricitabine	O
-	O
associated	O
mutations	B-T038
have	O
a	O
distinctly	O
higher	O
,	O
backward	B-T082
mutation	O
rate	O
and	O
low	O
relative	O
fitness	O
compared	O
to	O
the	O
other	O
classes	B-T170
(	O
as	O
has	O
been	O
reported	O
before	O
)	O
while	O
protease	B-T103
inhibitors	I-T103
-	O
associated	O
mutations	B-T038
have	O
a	O
slower	O
backward	B-T082
mutation	O
rate	O
and	O
high	O
relative	O
fitness	O
.	O

For	O
the	O
other	O
mutation	B-T038
classes	B-T170
,	O
we	O
found	O
more	O
uncertainty	O
in	O
their	O
estimates	O
.	O

Modeling	B-T062
the	O
hospital	B-T092
safety	O
partnership	O
preferences	O
of	O
patients	O
and	O
their	O
families	O
:	O
a	O
discrete	O
choice	O
conjoint	B-T062
experiment	I-T062

Patients	O
and	O
their	O
families	O
play	O
an	O
important	O
role	O
in	O
efforts	O
to	O
improve	O
health	B-T058
service	I-T058
safety	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
is	O
to	O
understand	O
the	O
safety	O
partnership	O
preferences	O
of	O
patients	O
and	O
their	O
families	O
.	O

We	O
used	O
a	O
discrete	O
choice	O
conjoint	B-T062
experiment	I-T062
to	O
model	O
the	O
safety	O
partnership	O
preferences	O
of	O
1	O
,	O
084	O
patients	O
or	O
those	O
such	O
as	O
parents	O
acting	O
on	O
their	O
behalf	O
.	O

Participants	B-T098
made	O
choices	O
between	O
hypothetical	O
safety	O
partnerships	O
composed	O
by	O
experimentally	O
varying	O
15	O
four	O
-	O
level	O
partnership	O
design	O
attributes	O
.	O

Participants	B-T098
preferred	O
an	O
approach	B-T082
to	O
safety	O
based	O
on	O
partnerships	O
between	O
patients	O
and	O
staff	B-T097
rather	O
than	O
a	O
model	O
delegating	O
responsibility	O
for	O
safety	O
to	O
hospital	B-T097
staff	I-T097
.	O

They	O
valued	O
the	O
opportunity	O
to	O
participate	O
in	O
point	O
of	O
service	O
safety	O
partnerships	O
,	O
such	O
as	O
identity	O
and	O
medication	O
double	O
checks	O
,	O
that	O
might	O
afford	O
an	O
immediate	O
risk	O
reduction	O
.	O

Latent	O
class	O
analysis	B-T062
yielded	O
two	O
segments	O
.	O

Actively	B-T098
engaged	I-T098
participants	I-T098
(	O
73	O
.	O
3	O
%	O
)	O
comprised	O
outpatients	O
with	O
higher	O
education	O
,	O
who	O
anticipated	O
more	O
benefits	O
to	O
safety	O
partnerships	O
,	O
were	O
more	O
confident	O
in	O
their	O
ability	O
to	O
contribute	O
,	O
and	O
were	O
more	O
intent	O
on	O
participating	O
.	O

They	O
were	O
more	O
likely	O
to	O
prefer	O
a	O
personal	O
engagement	B-T058
strategy	O
,	O
valued	O
scientific	O
evidence	O
,	O
preferred	O
a	O
more	O
active	O
approach	B-T082
to	O
safety	O
education	O
,	O
and	O
advocated	O
disclosure	O
of	O
errors	O
.	O

The	O
passively	O
engaged	O
segment	O
(	O
26	O
.	O
7	O
%	O
)	O
anticipated	O
fewer	O
benefits	O
,	O
were	O
less	O
confident	O
in	O
their	O
ability	O
to	O
contribute	O
,	O
and	O
were	O
less	O
intent	O
on	O
participating	O
.	O

They	O
were	O
more	O
likely	O
to	O
prefer	O
an	O
engagement	B-T058
strategy	O
based	O
on	O
signage	O
.	O

They	O
preferred	O
that	O
staff	B-T097
explain	O
why	O
they	O
thought	O
patients	O
should	O
help	O
make	O
care	B-T058
safer	O
and	O
decide	O
whether	O
errors	O
were	O
disclosed	O
.	O

Inpatients	O
,	O
those	O
with	O
immigrant	B-T033
backgrounds	I-T033
,	O
and	O
those	O
with	O
less	B-T033
education	I-T033
were	O
more	O
likely	O
to	O
be	O
in	O
this	O
segment	O
.	O

Health	B-T058
services	I-T058
need	O
to	O
communicate	O
information	O
regarding	O
risks	O
,	O
ask	O
about	O
partnership	O
preferences	O
,	O
create	O
opportunities	O
respecting	O
individual	O
differences	O
,	O
and	O
ensure	O
a	O
positive	B-T033
response	I-T033
when	O
patients	O
raise	O
safety	O
concerns	O
.	O

Influence	O
of	O
ozone	B-T103
and	O
paracetic	B-T103
acid	I-T103
disinfection	B-T058
on	O
adhesion	O
of	O
resilient	B-T103
liners	I-T103
to	O
acrylic	B-T103
resin	I-T103

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
paracetic	B-T103
acid	I-T103
(	O
PAA	B-T103
)	O
and	O
ozone	B-T103
disinfection	B-T058
on	O
the	O
tensile	O
bond	O
strength	O
(	O
TBS	O
)	O
of	O
silicone	B-T103
-	I-T103
based	I-T103
resilient	B-T103
liners	I-T103
to	O
acrylic	B-T103
resins	I-T103
.	O

One	O
hundred	O
and	O
twenty	O
dumbbell	B-T082
shaped	I-T082
heat	O
-	O
polymerized	O
acrylic	B-T103
resins	I-T103
were	O
prepared	O
.	O

From	O
the	O
mid	O
segment	O
of	O
the	O
specimens	O
,	O
3	O
mm	O
of	O
acrylic	B-T103
were	O
grinded	O
off	O
and	O
separated	O
parts	O
were	O
reattached	O
by	O
resilient	B-T103
liners	I-T103
.	O

The	O
specimens	O
were	O
divided	O
into	O
2	O
control	O
(	O
control1	O
,	O
control7	O
)	O
and	O
4	O
test	O
groups	O
of	O
PAA	B-T103
and	O
ozone	B-T103
disinfection	B-T058
(	O
PAA1	B-T103
,	O
PAA7	B-T103
,	O
ozone1	B-T103
and	O
ozone7	B-T103
;	O
n	O
=	O
10	O
)	O
.	O

While	O
control	O
groups	O
were	O
immersed	O
in	O
distilled	B-T103
water	I-T103
for	O
10	O
min	O
(	O
control1	O
)	O
and	O
7	O
days	O
(	O
control7	O
)	O
,	O
test	O
groups	O
were	O
subjected	O
to	O
PAA	B-T103
(	O
16	O
g	O
/	O
L	O
)	O
or	O
ozone	B-T103
rich	O
water	B-T103
(	O
4	O
mg	O
/	O
L	O
)	O
for	O
1	O
cycle	O
(	O
10	O
min	O
for	O
PAA	B-T103
and	O
60	O
min	O
for	O
ozone	B-T103
)	O
per	O
day	O
for	O
7	O
days	O
prior	O
to	O
tensile	O
tests	B-T058
.	O

Measurements	O
of	O
the	O
TBS	O
were	O
analyzed	O
using	O
3	O
-	O
way	O
ANOVA	O
and	O
Tukey	B-T058
'	I-T058
s	I-T058
HSD	I-T058
test	I-T058
.	O

Adhesive	O
strength	O
of	O
Mollosil	B-T103
decreased	O
significantly	O
by	O
application	O
of	O
ozone	B-T103
disinfection	B-T058
.	O

PAA	B-T103
disinfection	B-T058
had	O
no	O
negative	O
effect	O
on	O
the	O
TBS	O
values	O
of	O
Mollosil	B-T103
and	O
Molloplast	B-T103
B	I-T103
to	O
acrylic	B-T103
resin	I-T103
.	O

Single	O
application	O
of	O
ozone	B-T103
disinfection	B-T058
did	O
not	O
have	O
any	O
negative	O
effect	O
on	O
TBS	O
values	O
of	O
Molloplast	B-T103
B	I-T103
,	O
but	O
prolonged	O
exposure	O
to	O
ozone	O
decreased	O
its	O
adhesive	O
strength	O
.	O

The	O
adhesion	O
of	O
resilient	B-T103
liners	I-T103
to	O
acrylic	O
was	O
not	O
adversely	O
affected	O
by	O
PAA	B-T103
disinfection	B-T058
.	O

Immersion	O
in	O
ozonated	O
water	B-T103
significantly	O
decreased	O
TBS	O
of	O
Mollosil	B-T103
.	O

Prolonged	O
exposure	O
to	O
ozone	B-T103
negatively	O
affects	O
adhesion	O
of	O
Molloplast	B-T103
B	I-T103
to	O
denture	O
base	O
materials	O
.	O

The	O
construction	O
of	O
three	B-T082
-	I-T082
dimensional	I-T082
composite	B-T103
fibrous	O
macrostructures	B-T082
with	O
nanotextures	O
for	O
biomedical	B-T091
applications	O

The	O
development	O
of	O
modern	O
biomedical	B-T091
nanotechnology	O
requires	O
three	B-T082
-	I-T082
dimensional	I-T082
macrostructures	B-T082
with	O
nanotextures	O
to	O
meet	O
the	O
requirements	O
for	O
practical	O
applications	O
in	O
intricate	O
biological	B-T022
systems	I-T022
.	O

Additionally	O
,	O
the	O
restoration	O
and	O
regeneration	B-T038
of	O
some	O
specific	O
body	B-T017
tissues	I-T017
and	O
organs	B-T017
rely	O
on	O
the	O
function	O
of	O
conductive	B-T103
polymers	I-T103
,	O
which	O
can	O
provide	O
electrical	O
cues	O
for	O
cells	B-T017
.	O

In	O
this	O
study	O
,	O
we	O
fabricated	O
three	B-T082
-	I-T082
dimensional	I-T082
composite	B-T103
nanofibre	O
macrostructures	B-T082
of	O
polycaprolactone	B-T103
(	O
PCL	B-T103
)	O
with	O
different	O
concentrations	O
of	O
polyaniline	B-T103
(	O
PANi	B-T103
)	O
by	O
employing	O
an	O
improved	O
electrospinning	O
technology	O
with	O
a	O
specially	O
designed	O
collector	O
.	O

The	O
3D	B-T082
structures	B-T082
possessed	O
cap	B-T082
-	I-T082
like	I-T082
macrostructures	I-T082
with	O
centimetre	O
-	O
scale	O
thickness	O
and	O
interconnected	O
pore	O
nanotextures	O
with	O
nanometre	O
-	O
scale	O
nanofibres	O
.	O

To	O
estimate	O
the	O
biocompatibility	O
of	O
the	O
3D	B-T082
PCL	B-T103
/	O
PANi	B-T103
composite	B-T103
nanofibre	O
macrostructures	B-T082
,	O
mouse	B-T204
myoblasts	B-T017
(	O
C2C12	B-T017
cells	I-T017
)	O
were	O
cultured	O
as	O
model	B-T038
cells	B-T017
.	O

The	O
initial	O
responses	O
of	O
C2C12	B-T017
cells	I-T017
to	O
the	O
3D	B-T082
PCL	B-T103
/	O
PANi	B-T103
composite	B-T103
macrostructures	B-T082
were	O
significantly	O
superior	O
to	O
those	O
to	O
pure	O
PCL	B-T103
,	O
that	O
is	O
,	O
the	O
cells	B-T017
exhibited	O
typical	O
myoblast	O
-	O
like	O
morphologies	O
with	O
obvious	O
pseudopodia	B-T017
and	O
the	O
moderate	O
incorporation	O
(	O
less	O
than	O
2	O
.	O
0	O
wt	O
%	O
)	O
of	O
conductive	O
PANi	B-T103
facilitated	O
cell	B-T038
proliferation	I-T038
,	O
which	O
indicated	O
that	O
PANi	B-T103
has	O
appreciable	O
cell	B-T038
affinity	I-T038
.	O

Moreover	O
,	O
the	O
addition	O
of	O
conductive	O
PANi	B-T103
to	O
the	O
3D	B-T082
composite	B-T103
nanofibre	O
macrostructures	B-T082
considerably	O
enhanced	O
myoblast	B-T038
differentiation	I-T038
and	O
myotube	B-T038
maturation	I-T038
.	O

These	O
results	O
suggest	O
that	O
electrospun	O
3D	B-T082
PCL	B-T103
/	O
PANi	B-T103
composite	B-T103
nanofibre	O
macrostructures	B-T082
would	O
have	O
promising	O
applications	O
in	O
tissue	B-T058
engineering	I-T058
.	O

Mechanisms	O
of	O
replacement	O
of	O
circulating	O
viruses	B-T005
by	O
seasonal	B-T038
and	O
pandemic	B-T005
influenza	I-T005
A	I-T005
viruses	I-T005

Seasonal	B-T038
influenza	I-T038
causes	O
annual	O
epidemics	O
by	O
the	O
accumulation	B-T033
of	O
antigenic	B-T038
changes	I-T038
.	O

Pandemic	B-T038
influenza	I-T038
occurs	O
through	O
a	O
major	O
antigenic	B-T038
change	I-T038
of	O
the	O
influenza	B-T005
A	I-T005
virus	I-T005
,	O
which	O
can	O
originate	O
from	O
other	O
hosts	O
.	O

Although	O
new	O
antigenic	B-T038
variants	I-T038
of	O
the	O
influenza	B-T005
A	I-T005
virus	I-T005
replace	O
formerly	O
circulating	O
seasonal	B-T005
and	O
pandemic	B-T005
viruses	I-T005
,	O
replacement	O
mechanisms	O
remain	O
poorly	O
understood	O
.	O

A	O
stochastic	B-T170
individual	I-T170
-	I-T170
based	I-T170
SEIR	I-T170
(	I-T170
susceptible	I-T170
-	I-T170
exposed	I-T170
-	I-T170
infectious	I-T170
-	I-T170
recovered	I-T170
)	I-T170
model	I-T170
with	O
two	O
viral	O
strains	O
(	O
formerly	O
circulating	O
old	O
strain	O
and	O
newly	O
emerged	O
strain	O
)	O
was	O
developed	O
for	O
simulations	B-T062
to	O
elucidate	O
the	O
replacement	O
mechanisms	O
.	O

Factors	O
and	O
conditions	O
of	O
virus	B-T005
and	O
host	O
populations	O
affecting	O
the	O
replacement	O
were	O
identified	O
.	O

Replacement	O
is	O
more	O
likely	O
to	O
occur	O
in	O
tropical	B-T082
regions	I-T082
than	O
temperate	B-T082
regions	I-T082
.	O

The	O
magnitude	O
of	O
the	O
ongoing	O
epidemic	O
by	O
the	O
old	O
strain	O
,	O
herd	B-T038
immunity	I-T038
against	O
the	O
old	O
strain	O
,	O
and	O
timing	O
of	O
appearance	O
of	O
the	O
new	O
strain	O
are	O
not	O
that	O
important	O
for	O
replacement	O
.	O

It	O
is	O
probable	O
that	O
the	O
frequency	O
of	O
replacement	O
by	O
a	O
pandemic	B-T005
virus	I-T005
is	O
higher	O
than	O
a	O
seasonal	B-T005
virus	I-T005
because	O
of	O
the	O
high	O
initial	O
susceptibility	O
and	O
high	O
basic	O
reproductive	B-T038
number	O
of	O
the	O
pandemic	B-T005
virus	I-T005
.	O

The	O
findings	O
of	O
this	O
study	O
on	O
replacement	O
mechanisms	O
could	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
virus	B-T038
transmission	I-T038
dynamics	O
and	O
may	O
possibly	O
be	O
helpful	O
in	O
establishing	O
an	O
effective	O
strategy	O
to	O
mitigate	O
the	O
impact	O
of	O
seasonal	B-T038
and	O
pandemic	B-T038
influenza	I-T038
.	O

Request	O
and	O
fulfillment	O
of	O
postpartum	O
tubal	B-T058
ligation	I-T058
in	O
patients	O
after	O
high	B-T038
-	I-T038
risk	I-T038
pregnancy	I-T038

Female	B-T058
sterilization	I-T058
is	O
one	O
of	O
the	O
most	O
prevalent	O
methods	B-T170
of	O
contraception	B-T058
in	O
the	O
United	B-T082
States	I-T082
.	O

Prior	O
studies	B-T062
have	O
shown	O
that	O
nearly	O
half	O
of	O
postpartum	O
tubal	B-T058
ligation	I-T058
(	O
PPTL	B-T058
)	O
requests	O
go	O
unfulfilled	O
.	O

This	O
study	B-T062
seeks	O
to	O
establish	O
whether	O
obstetric	O
or	O
medical	O
risk	O
status	O
influences	O
patients	O
'	O
request	O
for	O
or	O
subsequent	O
completion	O
of	O
PPTL	B-T058
.	O

This	O
study	B-T062
was	O
a	O
retrospective	B-T062
cohort	I-T062
study	I-T062
of	O
women	B-T098
delivering	B-T038
at	O
a	O
university	B-T092
hospital	I-T092
in	O
2009	O
-	O
2010	O
who	O
received	O
prenatal	B-T058
care	I-T058
in	O
the	O
faculty	B-T097
and	O
resident	B-T092
clinics	I-T092
.	O

High	B-T033
-	I-T033
risk	I-T033
status	O
was	O
defined	O
by	O
Society	B-T170
for	I-T170
Maternal	I-T170
-	I-T170
Fetal	I-T170
Medicine	I-T170
guidelines	I-T170
.	O

Documentation	B-T170
of	O
contraceptive	B-T170
plan	I-T170
and	O
administration	B-T058
of	O
contraceptive	B-T058
methods	I-T058
was	O
abstracted	O
from	O
patient	B-T170
records	I-T170
.	O

Subsequent	O
pregnancies	B-T038
through	O
March	O
1	O
,	O
2013	O
,	O
were	O
abstracted	O
.	O

Of	O
3063	O
participants	B-T098
(	O
2048	O
low	O
risk	O
and	O
1015	O
high	B-T033
risk	I-T033
)	O
,	O
231	O
requested	O
PPTL	B-T058
(	O
7	O
.	O
5	O
%	O
)	O
.	O

This	O
was	O
more	O
likely	O
among	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
than	O
low	O
-	O
risk	O
patients	O
(	O
10	O
.	O
0	O
%	O
vs	O
.	O

6	O
.	O
3	O
%	O
,	O
p	O
<	O
.	O
001	O
)	O
,	O
those	O
with	O
public	O
insurance	O
(	O
13	O
.	O
8	O
%	O
vs	O
.	O

3	O
.	O
2	O
%	O
,	O
p	O
<	O
.	O
001	O
)	O
and	O
those	O
with	O
an	O
unintended	B-T033
index	I-T033
pregnancy	I-T033
(	O
13	O
.	O
8	O
%	O
vs	O
.	O

4	O
.	O
1	O
%	O
,	O
p	O
<	O
.	O
001	O
)	O
.	O

Of	O
the	O
patients	O
requesting	O
PPTL	B-T058
,	O
118	O
(	O
51	O
.	O
1	O
%	O
)	O
underwent	O
the	O
procedure	B-T058
immediately	O
postpartum	O
.	O

Completion	O
was	O
not	O
associated	O
with	O
high	B-T033
-	I-T033
risk	I-T033
status	O
(	O
54	O
.	O
0	O
%	O
)	O
,	O
or	O
with	O
race	B-T098
,	O
insurance	O
status	O
or	O
parity	B-T033
.	O

Among	O
113	O
women	B-T098
with	O
an	O
unfulfilled	O
PPTL	B-T058
request	O
,	O
there	O
were	O
17	O
subsequent	O
pregnancies	B-T038
(	O
15	O
.	O
0	O
%	O
)	O
during	O
the	O
27	O
months	O
of	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Though	O
women	B-T098
with	O
high	B-T038
-	I-T038
risk	I-T038
pregnancies	I-T038
were	O
more	O
likely	O
to	O
request	O
PPTL	B-T058
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	O
the	O
procedure	B-T058
.	O

Over	O
one	O
third	O
of	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
'	O
requests	O
were	O
unfulfilled	O
,	O
indicating	O
that	O
significant	O
barriers	O
may	O
remain	O
.	O

Though	O
women	B-T098
with	O
high	B-T038
-	I-T038
risk	I-T038
pregnancies	I-T038
were	O
more	O
likely	O
to	O
request	O
PPTL	B-T058
,	O
they	O
were	O
not	O
more	O
likely	O
to	O
complete	O
the	O
procedure	B-T058
.	O

Providers	O
should	O
consider	O
these	O
procedures	B-T058
urgent	O
,	O
especially	O
in	O
high	B-T033
-	I-T033
risk	I-T033
women	B-T098
,	O
and	O
advocate	O
for	O
their	O
patients	O
'	O
access	O
to	O
this	O
procedure	B-T058
.	O

Gut	O
microbiota	O
after	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
gastric	I-T058
bypass	I-T058
and	O
sleeve	B-T058
gastrectomy	I-T058
in	O
a	O
diabetic	B-T038
rat	B-T204
model	B-T038
:	O
Increased	O
diversity	O
and	O
associations	O
of	O
discriminant	O
genera	B-T170
with	O
metabolic	B-T038
changes	O

Recent	O
work	O
with	O
gut	O
microbiota	O
after	O
bariatric	B-T058
surgery	I-T058
is	O
limited	O
,	O
and	O
the	O
results	O
have	O
not	O
been	O
in	O
agreement	O
.	O

Given	O
the	O
role	O
of	O
the	O
gut	O
microbiota	O
in	O
regulating	O
host	O
metabolism	B-T038
,	O
we	O
explored	O
the	O
effect	O
of	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
gastric	I-T058
bypass	I-T058
(	O
RYGB	B-T058
)	O
and	O
sleeve	B-T058
gastrectomy	I-T058
(	O
SG	B-T058
)	O
on	O
the	O
modifications	O
of	O
gut	O
microbiota	O
with	O
regard	O
to	O
the	O
potential	O
influence	O
of	O
food	B-T168
intake	O
and	O
/	O
or	O
weight	O
loss	O
and	O
examined	O
their	O
links	O
with	O
host	O
metabolism	B-T038
.	O

Zucker	O
diabetic	B-T038
fatty	B-T204
rats	I-T204
were	O
divided	O
into	O
the	O
following	O
groups	O
:	O
RYGB	B-T058
;	O
sham	B-T058
-	I-T058
operated	I-T058
with	O
pair	O
-	O
fed	O
as	O
RYGB	B-T058
;	O
sham	B-T058
-	I-T058
operated	I-T058
fed	O
ad	O
libitum	O
;	O
and	O
SG	B-T058
.	O

The	O
metabolic	O
effects	O
and	O
gut	O
microbiota	O
profile	O
were	O
analyzed	B-T062
10	O
weeks	O
postoperatively	O
.	O

Associations	O
between	O
discriminating	O
genera	B-T170
and	O
metabolic	B-T103
markers	I-T103
after	O
RYGB	B-T058
were	O
explored	O
.	O

The	O
2	O
procedures	B-T058
induced	O
similar	O
glucose	B-T103
improvement	O
and	O
increased	O
flora	O
diversity	O
after	O
10	O
weeks	O
compared	O
with	O
sham	B-T058
-	I-T058
operated	I-T058
groups	O
.	O

RYGB	B-T058
induced	O
a	O
marked	O
higher	O
relative	O
abundance	O
of	O
Proteobacteria	B-T007
/	O
Gammaproteobacteria	B-T007
and	O
Betaproteobacteria	B-T007
and	O
increased	O
emergence	O
of	O
Fusobacteria	B-T007
and	O
Clostridium	B-T007
,	O
whereas	O
SG	B-T058
resulted	O
in	O
more	O
abundant	O
Actinobacteria	B-T007
compared	O
with	O
other	O
groups	O
.	O

Most	O
of	O
the	O
12	O
discriminant	O
genera	B-T170
correlated	O
with	O
changes	O
in	O
metabolic	B-T038
phenotype	O
,	O
but	O
only	O
28	O
.	O
6	O
%	O
of	O
these	O
correlations	O
were	O
independent	O
of	O
weight	O
,	O
and	O
4	O
discriminant	O
genera	B-T170
still	O
negatively	O
correlated	O
with	O
serum	B-T033
insulin	I-T033
level	I-T033
independent	O
of	O
food	B-T168
intake	O
and	O
weight	O
loss	O
after	O
RYGB	B-T058
.	O

These	O
data	O
demonstrate	O
that	O
RYGB	B-T058
and	O
SG	B-T058
surgery	O
produced	O
similar	O
diversity	O
but	O
different	O
microbiota	O
compositions	O
changes	O
in	O
Zucker	O
diabetic	B-T038
fatty	B-T204
rats	I-T204
.	O

These	O
findings	O
stimulate	O
deeper	O
explorations	O
of	O
functions	B-T038
of	O
the	O
discriminate	O
microbiota	O
and	O
the	O
mechanisms	O
linking	O
postsurgical	O
modulation	B-T082
of	O
gut	O
microbiota	O
and	O
improvements	O
in	O
insulin	B-T038
resistance	I-T038
.	O

Ocular	B-T037
toxicity	I-T037
of	O
AUY922	B-T103
in	O
pigmented	B-T204
and	O
albino	O
rats	O

AUY922	B-T103
,	O
a	O
heat	B-T103
shock	I-T103
protein	I-T103
90	I-T103
inhibitor	O
is	O
associated	O
with	O
ocular	B-T017
adverse	B-T038
events	I-T038
(	O
AEs	B-T038
)	O
.	O

To	O
provide	O
a	O
better	O
understanding	O
of	O
ocular	B-T017
AEs	B-T038
in	O
patients	O
,	O
4	O
investigative	B-T062
studies	I-T062
were	O
performed	O
in	O
a	O
step	B-T082
-	I-T082
wise	I-T082
approach	I-T082
to	O
assess	O
retinal	B-T017
structure	I-T017
and	O
function	O
in	O
pigmented	B-T204
(	O
Brown	B-T204
Norway	I-T204
)	O
and	O
albino	O
(	O
Wistar	B-T204
)	O
rats	O
.	O

In	O
rats	B-T204
administered	O
30mg	O
/	O
kg	O
of	O
AUY922	B-T103
,	O
the	O
AUC	O
0	O
-	O
24	O
h	O
and	O
Cmax	O
are	O
comparable	O
to	O
that	O
in	O
patients	O
at	O
70mg	O
/	O
m	O
(	O
2	O
)	O
.	O

AUY922	B-T103
at	O
≥30mg	O
/	O
kg	O
was	O
poorly	O
tolerated	O
by	O
rats	B-T204
with	O
morbidity	O
or	O
mortality	O
generally	O
after	O
the	O
third	O
weekly	O
treatment	B-T058
.	O

Electroretinography	B-T058
(	O
ERG	B-T058
)	O
changes	O
were	O
observed	O
at	O
doses	O
≥30mg	O
/	O
kg	O
.	O

The	O
ERG	B-T058
changes	O
were	O
dose	O
dependent	O
,	O
consistent	O
with	O
an	O
effect	O
on	O
the	O
photoreceptors	B-T017
,	O
and	O
fully	O
reversible	O
.	O

The	O
ERG	B-T058
effects	O
could	O
not	O
be	O
minimized	O
by	O
decreasing	O
the	O
Cmax	O
while	O
maintaining	O
AUC	O
.	O

Histopathological	O
changes	O
were	O
seen	O
mainly	O
when	O
rats	B-T204
were	O
administered	O
AUY922	B-T103
at	O
100mg	O
/	O
kg	O
.	O

The	O
2	O
-	O
hour	O
infusion	B-T058
of	O
AUY922	B-T103
at	O
100mg	O
/	O
kg	O
caused	O
disorganization	O
of	O
the	O
outer	B-T017
segment	I-T017
photoreceptor	I-T017
morphology	O
in	O
male	O
Brown	B-T204
Norway	I-T204
rats	I-T204
;	O
the	O
severity	O
of	O
the	O
disorganization	O
increased	O
with	O
the	O
number	O
of	O
administrations	B-T058
,	O
but	O
was	O
reversible	O
during	O
a	O
4	O
-	O
week	O
posttreatment	O
period	O
.	O

There	O
was	O
no	O
major	O
difference	O
in	O
ocular	B-T017
response	O
between	O
Brown	B-T204
Norway	I-T204
and	O
Wistar	B-T204
rats	I-T204
.	O

No	O
changes	O
in	O
serum	B-T033
iron	I-T033
levels	I-T033
,	O
and	O
no	O
changes	O
in	O
rhodopsin	B-T103
,	O
PDE6α	B-T103
,	O
β	B-T103
-	I-T103
transducin	I-T103
concentrations	O
,	O
or	O
retinal	B-T103
pigment	I-T103
epithelium	I-T103
-	I-T103
specific	I-T103
protein	I-T103
RPE65	I-T103
expression	B-T038
were	O
observed	O
after	O
single	O
and	O
multiple	O
infusions	B-T058
of	O
AUY922	B-T103
at	O
100mg	O
/	O
kg	O
compared	O
to	O
vehicle	O
-	O
treated	O
controls	O
.	O

AUY922	B-T103
retinal	B-T017
toxicity	I-T017
in	O
rats	B-T204
recapitulates	O
and	O
further	O
characterizes	O
that	O
reported	O
in	O
patients	O
and	O
is	O
shown	O
to	O
be	O
reversible	O
,	O
while	O
a	O
precise	O
molecular	B-T038
mechanism	I-T038
for	O
the	O
effect	O
was	O
not	O
determined	O
.	O

Assessment	B-T058
of	O
cerebral	B-T017
blood	O
perfusion	O
reserve	O
with	O
acetazolamide	B-T103
using	O
3D	B-T058
spiral	I-T058
ASL	I-T058
MRI	I-T058
:	O
Preliminary	O
experience	O
in	O
pediatric	O
patients	O

To	O
demonstrate	O
the	O
clinical	B-T062
feasibility	I-T062
of	O
a	O
new	O
non	B-T058
-	I-T058
Cartesian	I-T058
cylindrically	I-T058
-	I-T058
distributed	I-T058
spiral	I-T058
3D	I-T058
pseudo	I-T058
-	I-T058
continuous	I-T058
arterial	I-T058
spin	I-T058
labeling	I-T058
(	I-T058
pCASL	I-T058
)	I-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
(	I-T058
MRI	I-T058
)	I-T058
pulse	B-T082
sequence	I-T082
in	O
pediatric	O
patients	O
in	O
quantifying	O
cerebral	B-T033
blood	I-T033
flow	I-T033
(	O
CBF	B-T033
)	O
response	O
to	O
an	O
acetazolamide	B-T103
(	I-T103
ACZ	I-T103
)	I-T103
vasodilator	I-T103
challenge	O
.	O

MRI	B-T058
exams	I-T058
were	O
performed	O
on	O
two	O
3	O
Tesla	O
Philips	O
Ingenia	O
systems	O
using	O
32	O
channel	O
head	O
coil	O
arrays	O
.	O

After	O
local	O
institutional	B-T170
review	I-T170
board	I-T170
approval	I-T170
,	O
the	O
3D	B-T058
spiral	I-T058
-	I-T058
based	I-T058
pCASL	I-T058
technique	I-T058
was	O
added	O
to	O
a	O
standard	O
brain	B-T058
MRI	I-T058
exam	I-T058
and	O
evaluated	O
in	O
13	O
pediatric	O
patients	O
(	O
average	O
age	O
:	O
11	O
.	O
7±6	O
.	O
4years	O
,	O
range	O
:	O
1	O
.	O
4	O
-	O
22	O
.	O
2years	O
)	O
.	O

All	O
patients	O
were	O
administered	B-T058
ACZ	B-T103
for	O
clinically	B-T033
indicated	I-T033
reasons	O
.	O

Quantitative	O
whole	B-T058
-	I-T058
brain	I-T058
CBF	I-T058
measurements	I-T058
were	O
computed	O
pre	O
-	O
and	O
post	O
-	O
ACZ	B-T103
to	O
assess	O
cerebrovascular	B-T038
reserve	I-T038
.	O

3D	B-T058
spiral	I-T058
pCASL	I-T058
data	O
were	O
successfully	O
reconstructed	O
in	O
all	O
13	O
cases	B-T062
.	O

In	O
11	O
patients	O
,	O
CBF	B-T033
increased	O
2	O
.	O
8	O
%	O
to	O
93	O
.	O
2	O
%	O
after	O
administration	B-T058
of	I-T058
ACZ	B-T103
.	O

In	O
the	O
two	O
remaining	O
patients	O
,	O
CBF	B-T033
decreased	O
by	O
2	O
.	O
4	O
to	O
6	O
.	O
0	O
%	O
after	O
ACZ	B-T103
.	O

The	O
group	O
average	O
change	O
in	O
CBF	B-T033
due	O
to	O
ACZ	B-T103
was	O
approximately	O
25	O
.	O
0	O
%	O
and	O
individual	O
changes	O
were	O
statistically	O
significant	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
in	O
all	O
patients	O
using	O
a	O
paired	O
t	B-T170
-	I-T170
test	I-T170
analysis	I-T170
.	O

CBF	B-T033
perfusion	O
data	O
were	O
diagnostically	O
useful	O
in	O
supporting	O
conventional	O
MR	B-T058
angiography	I-T058
and	O
clinical	B-T170
findings	I-T170
.	O

3D	B-T058
cylindrically	I-T058
-	I-T058
distributed	I-T058
spiral	I-T058
pCASL	I-T058
MRI	I-T058
provides	O
a	O
robust	O
approach	O
to	O
assess	O
cerebral	B-T033
blood	I-T033
flow	I-T033
and	O
reserve	O
in	O
pediatric	O
patients	O
.	O

Assessing	O
the	O
learning	B-T038
potential	O
of	O
an	O
interactive	O
digital	O
game	O
versus	O
an	O
interactive	O
-	O
style	O
didactic	O
lecture	B-T170
:	O
the	O
continued	O
importance	O
of	O
didactic	O
teaching	O
in	O
medical	B-T097
student	I-T097
education	O

Games	O
with	O
educational	O
intent	O
offer	O
a	O
possible	B-T033
advantage	O
of	O
being	O
more	O
interactive	O
and	O
increasing	O
learner	B-T098
satisfaction	B-T038
.	O

We	O
conducted	O
a	O
two	B-T062
-	I-T062
armed	I-T062
experiment	I-T062
to	O
evaluate	B-T058
student	B-T098
satisfaction	B-T038
and	O
content	O
mastery	O
for	O
an	O
introductory	O
pediatric	B-T091
radiology	I-T091
topic	B-T170
,	O
taught	O
by	O
either	O
an	O
interactive	O
digital	O
game	O
or	O
with	O
a	O
traditional	O
didactic	O
lecture	B-T170
.	O

Medical	B-T097
students	I-T097
participating	O
in	O
a	O
fourth	O
-	O
year	O
radiology	B-T091
elective	O
were	O
invited	O
to	O
participate	O
.	O

Student	B-T098
cohorts	B-T098
were	O
alternatively	O
given	O
a	O
faculty	B-T097
-	O
supervised	O
1h	O
session	O
playing	O
a	O
simple	O
interactive	O
digital	O
Tic	O
-	O
tac	O
-	O
toe	O
quiz	O
module	O
on	O
pediatric	B-T058
gastrointestinal	I-T058
radiology	I-T058
or	O
a	O
1h	O
didactic	O
introductory	O
lecture	B-T170
on	O
the	O
same	O
topic	B-T170
.	O

Survey	B-T170
questions	B-T170
assessed	O
the	O
learners	B-T098
'	I-T098
perceived	B-T038
ability	O
to	O
recall	O
the	O
material	O
as	O
well	O
as	O
their	O
satisfaction	B-T038
with	O
the	O
educational	O
experience	B-T038
.	O

Results	O
of	O
an	O
end	O
-	O
of	O
-	O
rotation	O
exam	O
were	O
reviewed	O
to	O
evaluate	B-T058
a	O
quantitative	O
measure	O
of	O
learning	B-T038
between	O
groups	O
.	O

Survey	B-T170
responses	B-T038
were	O
analyzed	B-T062
with	O
a	O
chi	B-T170
-	I-T170
squared	I-T170
test	I-T170
.	O

Exam	O
results	O
for	O
both	O
groups	O
were	O
analyzed	B-T062
with	O
a	O
paired	O
Student	O
'	O
s	O
t	O
-	O
test	O
.	O

Students	B-T098
in	O
the	O
lecture	B-T170
group	O
had	O
higher	O
test	O
scores	O
compared	O
to	O
students	B-T098
in	O
the	O
game	O
group	O
(	O
4	O
.	O
0	O
/	O
5	O
versus	O
3	O
.	O
6	O
/	O
5	O
,	O
P	O
=	O
0	O
.	O
045	O
)	O
.	O

Students	B-T098
in	O
the	O
lecture	B-T170
group	O
reported	B-T058
greater	O
understanding	B-T038
and	O
recall	B-T038
of	O
the	O
material	O
than	O
students	B-T098
in	O
the	O
game	O
group	O
(	O
P	O
<	O
0	O
.	O
001	O
and	O
P	O
=	O
0	O
.	O
004	O
,	O
respectively	O
)	O
.	O

Students	B-T098
in	O
the	O
lecture	B-T170
group	O
perceived	B-T038
the	O
lecture	B-T170
to	O
be	O
more	O
enjoyable	O
and	O
a	O
better	O
use	O
of	O
their	O
time	O
compared	O
to	O
those	O
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0	O
.	O
04	O
and	O
P	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
between	O
the	O
lecture	B-T170
and	O
game	O
group	O
in	O
ability	O
to	O
maintain	O
interest	O
(	O
P	O
=	O
0	O
.	O
187	O
)	O
.	O

In	O
comparison	O
to	O
pre	O
-	O
survey	O
results	O
,	O
there	O
was	O
a	O
statistically	O
significant	O
decrease	O
in	O
interest	O
for	O
further	O
digital	O
interactive	O
materials	O
reported	B-T058
by	O
students	B-T098
in	O
the	O
game	O
group	O
(	O
P	O
=	O
0	O
.	O
146	O
)	O
.	O

Our	O
experience	B-T038
supported	O
the	O
use	O
of	O
a	O
traditional	O
lecture	B-T170
over	O
a	O
digital	O
game	O
module	O
.	O

While	O
these	O
results	O
might	O
be	O
affected	O
by	O
the	O
specific	O
lecture	B-T170
and	O
digital	O
content	O
in	O
any	O
given	O
comparison	O
,	O
a	O
digital	O
module	O
is	O
not	O
always	O
the	O
superior	O
option	O
.	O

Predictors	O
of	O
30	O
-	O
day	O
mortality	O
in	O
patients	O
with	O
spontaneous	O
primary	O
intracerebral	B-T033
hemorrhage	I-T033

Intracerebral	B-T033
hemorrhage	I-T033
(	O
ICH	B-T033
)	O
is	O
a	O
life	B-T033
threatening	I-T033
entity	O
,	O
and	O
an	O
early	B-T058
outcome	I-T058
assessment	I-T058
is	O
mandatory	O
for	O
optimizing	O
therapeutic	B-T058
efforts	I-T058
.	O

We	O
retrospectively	O
analyzed	B-T062
data	O
from	O
342	O
patients	O
with	O
spontaneous	O
primary	O
ICH	B-T033
to	O
evaluate	O
possible	O
predictors	O
of	O
30	O
-	O
day	O
mortality	O
considering	O
clinical	O
,	O
radiological	O
,	O
and	O
therapeutical	O
parameters	O
.	O

We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-T170
grading	I-T170
scoring	I-T170
systems	I-T170
[	O
(	O
ICH	O
score	O
,	O
FUNC	O
score	O
and	O
intracerebral	B-T170
hemorrhage	I-T170
grading	I-T170
scale	I-T170
(	O
ICH	B-T170
-	I-T170
GS	I-T170
)	O
]	O
on	O
our	O
population	B-T098
to	O
evaluate	O
the	O
correlation	O
of	O
these	O
scores	O
with	O
the	O
30	O
-	O
day	O
mortality	O
in	O
our	O
study	B-T062
.	O

We	O
also	O
applied	O
three	O
widely	O
accepted	O
outcome	B-T170
grading	I-T170
scoring	I-T170
systems	I-T170
[	O
(	O
ICH	O
score	O
,	O
FUNC	O
score	O
and	O
intracerebral	B-T170
hemorrhage	I-T170
grading	I-T170
scale	I-T170
(	O
ICH	B-T170
-	I-T170
GS	I-T170
)	O
]	O
on	O
our	O
population	B-T098
to	O
evaluate	O
the	O
correlation	O
of	O
these	O
scores	O
with	O
the	O
30	O
-	O
day	O
mortality	O
in	O
our	O
study	B-T062
.	O

From	O
342	O
patients	O
(	O
mean	O
age	O
:	O
67	O
years	O
,	O
mean	O
Glasgow	B-T170
Coma	I-T170
Scale	I-T170
[	O
GCS	B-T170
]	O
on	O
admission	B-T058
:	O
9	O
,	O
mean	O
ICH	B-T033
volume	O
:	O
62	O
.	O
19	O
ml	O
,	O
most	O
common	O
hematoma	B-T038
location	B-T082
:	O
basal	B-T017
ganglia	I-T017
[	O
43	O
.	O
9	O
%	O
]	O
)	O
,	O
102	O
received	O
surgical	B-T058
and	O
240	O
conservative	B-T058
treatment	I-T058
.	O

The	O
30	O
-	O
day	O
mortality	O
was	O
25	O
.	O
15	O
%	O
.	O

In	O
a	O
multivariate	O
analysis	O
,	O
GCS	B-T170
(	O
Odds	O
ratio	O
[	O
OR	O
]	O
=	O
0	O
.	O
726	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0	O
.	O
661	O
-	O
0	O
.	O
796	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
bleeding	B-T038
volume	O
(	O
OR	O
=	O
1	O
.	O
012	O
per	O
ml	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
007	O
-	O
1	O
.	O
017	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
infratentorial	B-T082
hematoma	B-T038
location	B-T082
(	O
OR	O
=	O
5	O
.	O
381	O
,	O
95	O
%	O
CI	O
=	O
2	O
.	O
166	O
-	O
13	O
.	O
356	O
,	O
P	O
=	O
0	O
.	O
009	O
)	O
were	O
significant	O
predictors	O
for	O
the	O
30	O
-	O
day	O
mortality	O
.	O

After	O
receiver	O
operating	O
characteristics	O
analysis	B-T062
,	O
we	O
defined	O
a	O
"	O
high	O
-	O
risk	O
group	O
"	O
for	O
an	O
unfavorable	O
short	O
-	O
term	O
outcome	O
with	O
GCS	B-T170
<	O
11	O
and	O
ICH	B-T033
volume	O
>	O
32	O
ml	O
supratentorially	B-T082
or	O
21	O
ml	O
infratentorially	B-T082
.	O

Using	O
Pearson	B-T170
correlation	I-T170
,	O
we	O
found	O
a	O
correlation	O
of	O
0	O
.	O
986	O
between	O
ICH	O
score	O
and	O
30	O
-	O
day	O
mortality	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
0	O
.	O
853	O
between	O
FUNC	O
score	O
and	O
30	O
-	O
day	O
mortality	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
0	O
.	O
924	O
between	O
ICH	B-T170
-	I-T170
GS	I-T170
and	O
30	O
-	O
day	O
mortality	O
(	O
P	O
=	O
0	O
.	O
001	O
)	O
.	O

GCS	B-T170
score	O
on	O
admission	B-T058
together	O
with	O
the	O
baseline	O
volume	O
and	O
localization	O
of	O
the	O
hemorrhage	B-T038
are	O
strong	O
predictors	O
for	O
30	O
-	O
day	O
mortality	O
in	O
patients	O
with	O
spontaneous	O
primary	O
intracerebral	B-T033
hemorrhage	I-T033
,	O
and	O
by	O
relying	O
on	O
them	O
it	O
is	O
possible	O
to	O
identify	O
high	B-T033
-	I-T033
risk	I-T033
patients	O
with	O
poor	O
short	O
-	O
term	O
outcome	O
.	O

The	O
ICH	O
score	O
and	O
the	O
ICH	B-T170
-	I-T170
GS	I-T170
accurately	O
predict	O
the	O
30	O
-	O
day	O
mortality	O
.	O

Gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
inhibits	O
chicken	B-T204
pre	B-T017
-	I-T017
adipocyte	I-T017
proliferation	B-T038
in	O
part	O
by	O
down	B-T038
-	I-T038
regulating	I-T038
Kruppel	B-T017
-	I-T017
like	I-T017
factor	I-T017
5	I-T017

Gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
is	O
abundantly	O
expressed	B-T038
in	O
chicken	B-T204
pre	B-T017
-	I-T017
adipocytes	I-T017
,	O
but	O
its	O
role	O
is	O
unclear	O
.	O

The	O
present	O
study	O
investigated	O
the	O
role	O
of	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
in	O
chicken	B-T204
pre	B-T017
-	I-T017
adipocyte	I-T017
proliferation	B-T038
.	O

Cell	B-T062
proliferation	I-T062
assay	I-T062
and	O
gene	B-T062
expression	I-T062
analysis	I-T062
of	O
proliferating	B-T017
cell	I-T017
nuclear	I-T017
antigen	I-T017
(	O
PCNA	B-T017
)	O
showed	O
that	O
the	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
mimic	O
inhibited	O
pre	B-T017
-	I-T017
adipocyte	I-T017
proliferation	B-T038
.	O

In	O
contrast	O
,	O
the	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
inhibitor	O
enhanced	O
pre	B-T017
-	I-T017
adipocyte	I-T017
proliferation	B-T038
.	O

The	O
subsequent	O
investigation	O
identified	O
Kruppel	B-T017
-	I-T017
like	I-T017
factor	I-T017
5	I-T017
(	O
KLF5	B-T017
)	O
mRNA	B-T103
as	O
a	O
target	O
of	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
.	O

The	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
mimic	O
inhibited	O
KLF5	B-T017
3	B-T082
(	I-T082
'	I-T082
)	I-T082
UTR	I-T082
reporter	B-T017
activity	O
and	O
decreased	O
endogenous	O
KLF5	B-T017
expression	B-T038
in	O
primary	O
pre	B-T017
-	I-T017
adipocytes	I-T017
.	O

KLF5	B-T017
knockdown	B-T062
using	O
RNAi	B-T038
had	O
a	O
similar	O
effect	O
to	O
that	O
of	O
the	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
mimic	O
on	O
cell	B-T038
proliferation	I-T038
.	O

The	O
promoting	O
effect	O
of	O
the	O
gga	B-T103
-	I-T103
miR	I-T103
-	I-T103
21	I-T103
inhibitor	O
on	O
pre	B-T017
-	I-T017
adipocyte	I-T017
proliferation	B-T038
was	O
partially	O
attenuated	O
by	O
KLF5	B-T017
knockdown	B-T062
.	O

Taken	O
together	O
,	O
our	O
results	O
demonstrated	O
that	O
miR	B-T103
-	I-T103
21	I-T103
inhibits	O
chicken	B-T204
pre	B-T017
-	I-T017
adipocyte	I-T017
proliferation	B-T038
,	O
at	O
least	O
in	O
part	O
,	O
by	O
targeting	B-T062
KLF5	B-T017
.	O

The	O
application	O
of	O
heterogeneous	O
cluster	O
grouping	O
to	O
reflective	O
writing	O
for	O
medical	O
humanities	O
literature	B-T062
study	I-T062
to	O
enhance	O
students	B-T098
'	I-T098
empathy	O
,	O
critical	B-T038
thinking	I-T038
,	O
and	O
reflective	O
writing	O

To	O
facilitate	O
interdisciplinary	O
collaboration	O
and	O
to	O
make	O
connections	B-T082
between	O
patients	O
'	O
diseases	B-T038
and	O
their	O
social	O
/	O
cultural	O
contexts	O
,	O
the	O
study	B-T062
examined	B-T033
whether	O
the	O
use	O
of	O
heterogeneous	O
cluster	O
grouping	O
in	O
reflective	O
writing	O
for	O
medical	O
humanities	O
literature	O
acquisition	O
could	O
have	O
positive	O
effects	O
on	O
medical	B-T092
university	I-T092
students	B-T098
in	O
terms	O
of	O
empathy	O
,	O
critical	B-T038
thinking	I-T038
,	O
and	O
reflective	O
writing	O
.	O

A	O
15	O
-	O
week	O
quasi	O
-	O
experimental	O
design	O
was	O
conducted	O
to	O
investigate	O
the	O
learning	O
outcomes	O
.	O

After	O
conducting	O
cluster	B-T170
algorithms	I-T170
,	O
heterogeneous	O
learning	O
clusters	O
(	O
experimental	O
group	O
;	O
n	O
=	O
43	O
)	O
and	O
non	O
-	O
heterogeneous	O
learning	O
clusters	O
(	O
control	O
group	O
;	O
n	O
=	O
43	O
)	O
were	O
derived	O
for	O
a	O
medical	O
humanities	O
literature	B-T062
study	I-T062
.	O

Before	O
and	O
after	O
the	O
intervention	B-T058
,	O
an	O
Empathy	B-T170
Scale	I-T170
in	O
Patient	B-T058
Care	I-T058
(	O
ES	B-T170
-	O
PC	B-T058
)	O
,	O
a	O
critical	B-T058
thinking	I-T058
disposition	I-T058
assessment	I-T058
(	O
CTDA	B-T058
-	I-T058
R	I-T058
)	O
,	O
and	O
a	O
reflective	O
writing	O
test	O
were	O
administered	O
to	O
both	O
groups	O
.	O

The	O
findings	O
showed	O
that	O
on	O
the	O
empathy	B-T170
scale	I-T170
,	O
significant	O
differences	O
in	O
the	O
"	O
behavioral	O
empathy	O
,	O
"	O
"	O
affective	O
empathy	O
,	O
"	O
and	O
overall	O
sections	O
existed	O
between	O
the	O
post	O
-	O
test	O
mean	O
scores	O
of	O
the	O
experimental	O
group	O
and	O
those	O
of	O
the	O
control	O
group	O
,	O
but	O
such	O
differences	O
did	O
not	O
exist	O
in	O
"	O
intelligent	O
empathy	O
.	O
"	O
Regarding	O
critical	B-T038
thinking	I-T038
,	O
there	O
were	O
significant	O
differences	O
in	O
"	O
systematicity	O
and	O
analyticity	B-T062
,	O
"	O
"	O
skepticism	O
and	O
well	O
-	O
informed	O
,	O
"	O
"	O
maturity	O
and	O
skepticism	O
,	O
"	O
and	O
overall	O
sections	O
.	O

As	O
for	O
reflective	O
writing	O
,	O
significant	O
differences	O
existed	O
in	O
"	O
ideas	O
,	O
"	O
"	O
voice	B-T038
and	O
point	O
of	O
view	O
,	O
"	O
"	O
critical	B-T038
thinking	I-T038
and	O
representation	O
,	O
"	O
"	O
depth	B-T038
of	I-T038
reflection	I-T038
on	O
personal	O
growth	O
,	O
"	O
and	O
overall	O
sections	O
,	O
but	O
not	O
in	O
"	O
focus	O
and	O
context	O
structure	O
"	O
and	O
"	O
language	O
and	O
conventions	O
.	O
"	O
This	O
study	B-T062
outlined	O
an	O
alternative	O
for	O
using	O
heterogeneous	O
cluster	O
grouping	O
in	O
reflective	O
writing	O
about	O
medical	O
humanities	O
literature	O
to	O
facilitate	O
interdisciplinary	O
cooperation	O
to	O
provide	O
more	O
humanizing	O
medical	B-T033
care	I-T033
.	O

The	O
Usefulness	O
of	O
Employing	B-T033
an	O
Electronic	B-T074
Traction	I-T074
Table	I-T074
to	O
Determine	O
Flexibility	O
in	O
Adolescent	B-T017
Idiopathic	I-T017
Scoliosis	I-T017

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
develop	O
new	O
equipment	O
for	O
the	O
assessment	B-T058
of	O
the	O
flexibility	O
of	O
the	O
spine	B-T017
with	O
different	O
forces	O
.	O

This	O
new	O
system	O
should	O
provide	O
a	O
different	O
perspective	O
to	O
adolescent	B-T017
idiopathic	I-T017
scoliosis	I-T017
(	O
AIS	B-T017
)	O
for	O
the	O
selection	O
of	O
fusion	O
levels	O
and	O
surgical	B-T058
success	O
.	O

Eighteen	O
patients	O
suffering	O
from	O
AIS	B-T017
who	O
were	O
scheduled	O
to	O
undergo	O
posterior	B-T082
instrumented	B-T058
spinal	I-T058
fusion	I-T058
in	O
our	O
clinic	B-T092
were	O
recruited	O
in	O
this	O
study	B-T062
.	O

The	O
Electronic	B-T074
Traction	I-T074
Table	I-T074
(	O
ETT	B-T074
)	O
that	O
was	O
designed	O
in	O
our	O
clinic	B-T092
was	O
used	O
to	O
evaluate	O
the	O
radiogical	O
and	O
clinical	O
parameters	O
of	O
the	O
spine	B-T017
.	O

The	O
significant	O
prescriptive	O
angle	O
of	O
major	O
Cobb	B-T033
angles	I-T033
between	O
postoperative	O
angles	O
were	O
longitudinal	B-T082
traction	B-T058
and	O
lateral	B-T033
pushing	I-T033
Cobb	I-T033
angles	I-T033
.	O

Longitudinal	B-T082
traction	B-T058
and	O
lateral	B-T033
pushing	I-T033
angles	I-T033
were	O
more	O
correlated	O
with	O
correction	O
ratios	O
.	O

There	O
was	O
a	O
significant	O
difference	O
between	O
longitudinal	B-T082
traction	B-T058
minor	O
Cobb	B-T033
angle	I-T033
,	O
longitudinal	B-T082
traction	B-T058
lateral	B-T033
pushing	I-T033
minor	I-T033
Cobb	I-T033
angle	I-T033
and	O
postoperative	B-T033
minor	I-T033
Cobb	I-T033
angles	I-T033
.	O

The	O
deformity	B-T017
is	O
needed	O
to	O
balance	O
both	O
tractional	B-T058
and	O
rotational	O
forces	O
and	O
useful	O
technique	O
to	O
evaluate	O
curve	O
flexibility	O
before	O
the	O
operation	B-T058
.	O

Electronic	B-T074
traction	I-T074
table	I-T074
is	O
a	O
new	O
device	B-T074
for	O
determining	O
preoperative	O
flexibility	O
with	O
longitudinal	B-T082
traction	B-T058
and	O
lateral	B-T058
pushing	I-T058
radiographs	I-T058
.	O

It	O
can	O
be	O
useful	O
for	O
choosing	O
selective	O
fusion	O
levels	O
at	O
the	O
proximal	B-T082
and	O
distal	B-T082
end	O
of	O
the	O
vertebral	B-T017
column	I-T017
.	O

The	O
MEssaging	O
for	O
Diabetes	O
Intervention	B-T058
Reduced	O
Barriers	O
to	O
Medication	B-T033
Adherence	I-T033
Among	O
Low	B-T033
-	I-T033
Income	I-T033
,	O
Diverse	O
Adults	O
With	O
Type	B-T038
2	I-T038

Nonadherence	B-T033
to	O
diabetes	B-T038
medication	B-T058
is	O
prevalent	O
and	O
costly	O
.	O

MEssaging	O
for	O
Diabetes	O
(	O
MED	O
)	O
,	O
a	O
mobile	B-T058
health	I-T058
(	O
mHealth	B-T058
)	O
intervention	B-T058
,	O
identified	O
and	O
addressed	O
user	B-T098
-	O
specific	O
barriers	O
to	O
medication	B-T033
adherence	I-T033
.	O

We	O
assessed	O
whether	O
MED	O
reduced	O
users	B-T098
'	O
targeted	O
barriers	O
and	O
if	O
barrier	O
reductions	O
were	O
associated	O
with	O
within	B-T098
-	I-T098
participant	I-T098
improvements	O
in	O
adherence	O
or	O
glycemic	O
control	O
(	O
HbA1c	B-T103
)	O
.	O

Adults	O
(	O
N	O
=	O
80	O
)	O
with	O
type	B-T038
2	I-T038
diabetes	I-T038
completed	O
self	O
-	O
report	O
measures	O
identifying	O
barriers	O
to	O
adherence	O
at	O
baseline	O
and	O
monthly	O
for	O
3	O
months	O
.	O

At	O
each	O
assessment	B-T058
,	O
17	O
barriers	O
were	O
assessed	O
and	O
ranked	O
for	O
each	O
user	B-T098
.	O

Each	O
subsequent	O
month	O
,	O
users	B-T098
received	O
daily	O
text	B-T170
messages	I-T170
addressing	O
their	O
3	O
highest	O
ranked	O
barriers	O
.	O

Targeted	O
barriers	O
were	O
different	O
for	O
each	O
participant	B-T098
and	O
could	O
change	O
monthly	O
.	O

Paired	O
t	B-T170
-	I-T170
tests	I-T170
assessed	O
within	B-T098
-	I-T098
participant	I-T098
improvement	O
in	O
targeted	O
barriers	O
each	O
month	O
,	O
and	O
nested	O
regression	B-T170
models	I-T170
assessed	O
if	O
changes	O
in	O
a	O
participant	B-T098
'	I-T098
s	I-T098
barrier	O
scores	O
were	O
associated	O
with	O
improvements	O
in	O
adherence	O
and	O
HbA1c	B-T103
.	O

Participants	B-T098
were	O
69	O
%	O
non	O
-	O
white	O
and	O
82	O
%	O
had	O
incomes	O
<	O
$	O
25K	O
.	O

Average	O
HbA1c	B-T103
was	O
8	O
.	O
2	O
±	O
2	O
.	O
0	O
%	O
.	O

Assessment	O
completion	O
rates	O
were	O
100	O
%	O
at	O
baseline	O
,	O
59	O
%	O
at	O
1	O
month	O
,	O
30	O
%	O
at	O
2	O
months	O
,	O
and	O
65	O
%	O
at	O
3	O
months	O
.	O

The	O
most	O
commonly	O
reported	O
barriers	O
were	O
the	O
cost	O
of	O
medications	B-T058
(	O
76	O
%	O
)	O
,	O
believing	O
medications	B-T058
are	O
harmful	O
(	O
58	O
%	O
)	O
,	O
and	O
lacking	O
information	O
about	O
medications	B-T058
(	O
53	O
%	O
)	O
.	O

Participants	B-T098
'	O
barrier	O
scores	O
improved	O
each	O
month	O
and	O
barrier	O
improvement	O
predicted	O
adherence	O
assessed	O
via	O
nightly	O
adherence	O
assessment	O
text	B-T170
messages	I-T170
(	O
P	O
<	O
.	O
001	O
)	O
.	O

Among	O
participants	B-T098
who	O
completed	O
assessments	O
each	O
month	O
,	O
barrier	O
improvement	O
in	O
months	O
2	O
and	O
3	O
(	O
P	O
<	O
.	O
05	O
)	O
predicted	O
HbA1c	B-T103
improvement	O
.	O

Iterative	O
,	O
individual	O
tailoring	O
may	O
overcome	O
users	B-T098
'	O
barriers	O
to	O
adherence	O
.	O

Attrition	O
is	O
a	O
challenge	O
for	O
mHealth	B-T058
interventions	B-T058
among	O
low	B-T033
-	I-T033
income	I-T033
patients	O
.	O

Macular	O
Ganglion	B-T017
Cell	I-T017
-	O
Inner	B-T017
Plexiform	I-T017
Layer	I-T017
Thickness	O
Is	O
Associated	O
with	O
Clinical	B-T038
Progression	I-T038
in	O
Mild	B-T038
Cognitive	I-T038
Impairment	I-T038
and	O
Alzheimers	B-T038
Disease	I-T038

We	O
investigated	O
the	O
association	O
of	O
the	O
macular	O
ganglion	B-T017
cell	I-T017
-	O
inner	B-T017
plexiform	I-T017
layer	I-T017
(	O
GCIPL	B-T017
)	O
and	O
peripapillary	B-T017
retinal	I-T017
nerve	I-T017
fiber	I-T017
layer	I-T017
(	O
RNFL	B-T017
)	O
thicknesses	O
with	O
disease	B-T038
progression	I-T038
in	O
mild	B-T038
cognitive	I-T038
impairment	I-T038
(	O
MCI	B-T038
)	O
and	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
.	O

We	O
recruited	O
42	O
patients	O
with	O
AD	B-T038
,	O
26	O
with	O
MCI	B-T038
,	O
and	O
66	O
normal	O
elderly	O
controls	O
.	O

The	O
thicknesses	O
of	O
the	O
RNFL	B-T017
and	O
GCIPL	B-T017
were	O
measured	O
via	O
spectral	B-T074
-	I-T074
domain	I-T074
optic	I-T074
coherent	I-T074
tomography	I-T074
in	O
all	O
participants	B-T098
at	O
baseline	O
.	O

The	O
patients	O
with	O
MCI	B-T038
or	O
AD	B-T038
underwent	O
clinical	O
and	O
neuropsychological	B-T058
tests	I-T058
at	O
baseline	O
and	O
once	O
every	O
year	O
thereafter	O
for	O
2	O
years	O
.	O

The	O
Clinical	B-T170
Dementia	I-T170
Rating	I-T170
scale	I-T170
-	I-T170
Sum	I-T170
of	I-T170
Boxes	I-T170
(	O
CDR	B-T170
-	I-T170
SB	I-T170
)	O
score	O
exhibited	O
significant	O
negative	B-T033
relationships	O
with	O
the	O
average	B-T017
GCIPL	I-T017
thickness	O
(	O
β	O
=	O
-	O
0	O
.	O
15	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
the	O
GCIPL	B-T017
thickness	O
in	O
the	O
superotemporal	B-T082
,	O
superonasal	B-T082
,	O
and	O
inferonasal	B-T082
sectors	I-T082
.	O

The	O
composite	O
memory	O
score	O
exhibited	O
significant	O
positive	B-T033
associations	O
with	O
the	O
average	B-T017
GCIPL	I-T017
thickness	O
and	O
the	O
GCIPL	B-T017
thickness	O
in	O
the	O
superotemporal	B-T082
,	O
inferonasal	B-T082
,	O
and	O
inferotemporal	B-T082
sectors	I-T082
.	O

The	O
temporal	B-T017
RNFL	I-T017
thickness	O
,	O
the	O
average	O
and	O
minimum	O
GCIPL	B-T017
thicknesses	O
,	O
and	O
the	O
GCIPL	B-T017
thickness	O
in	O
the	O
inferonasal	B-T082
,	O
inferior	B-T082
,	O
and	O
inferotemporal	B-T082
sectors	I-T082
at	O
baseline	O
were	O
significantly	O
reduced	O
in	O
MCI	B-T038
patients	O
who	O
were	O
converted	O
to	O
AD	B-T038
compared	O
to	O
stable	O
MCI	B-T038
patients	O
.	O

The	O
change	O
of	O
CDR	B-T170
-	I-T170
SB	I-T170
from	O
baseline	O
to	O
2	O
years	O
exhibited	O
significant	O
negative	B-T033
associations	O
with	O
the	O
average	O
(	O
β	O
=	O
-	O
0	O
.	O
150	O
,	O
p	O
=	O
0	O
.	O
006	O
)	O
and	O
minimum	B-T017
GCIPL	I-T017
thicknesses	O
as	O
well	O
as	O
GCIPL	B-T017
thickness	O
in	O
the	O
superotemporal	B-T082
,	O
superior	B-T082
,	O
superonasal	B-T082
,	O
and	O
inferonasal	B-T082
sectors	I-T082
at	O
baseline	O
.	O

Our	O
data	O
suggest	O
that	O
macular	O
GCIPL	B-T017
thickness	O
represents	O
a	O
promising	O
biomarker	B-T201
for	O
monitoring	O
the	O
progression	B-T038
of	O
MCI	B-T038
and	O
AD	B-T038
.	O

Green	O
and	O
rapid	O
synthesis	O
of	O
silver	B-T103
nanoparticles	O
using	O
Borago	B-T204
officinalis	I-T204
leaf	B-T204
extract	B-T103
:	O
anticancer	B-T033
and	O
antibacterial	B-T033
activities	I-T033

This	O
study	O
highlights	O
the	O
facile	O
,	O
reliable	O
,	O
cost	O
effective	O
,	O
and	O
ecofriendly	O
synthesis	O
of	O
silver	B-T103
nanoparticles	O
(	O
AgNPs	O
)	O
using	O
Borago	B-T204
officinalis	I-T204
leaves	B-T204
extract	B-T103
efficiently	O
.	O

The	O
biosynthesis	O
of	O
AgNPs	O
was	O
verified	O
by	O
UV	O
-	O
Vis	O
spectrum	O
which	O
showed	O
the	O
surface	B-T062
plasmon	I-T062
resonance	I-T062
(	O
SPR	B-T062
)	O
band	O
at	O
422	O
nm	O
.	O

Transmission	B-T058
electron	I-T058
microscope	I-T058
(	I-T058
TEM	I-T058
)	I-T058
analysis	I-T058
revealed	O
that	O
the	O
particles	O
were	O
spherical	B-T082
,	O
hexagonal	B-T082
,	O
and	O
irregular	O
in	O
shape	B-T082
and	O
had	O
size	O
ranging	O
from	O
30	O
to	O
80	O
nm	O
.	O

The	O
energy	B-T058
dispersive	I-T058
X	I-T058
-	I-T058
ray	I-T058
spectroscopy	I-T058
(	O
EDX	B-T058
)	O
and	O
elemental	B-T058
mapping	I-T058
have	O
displayed	O
the	O
purity	O
and	O
maximum	O
distribution	O
of	O
silver	B-T103
in	O
the	O
AgNPs	B-T103
.	O

The	O
crystalline	B-T103
nature	O
of	O
AgNPs	B-T103
had	O
been	O
identified	O
using	O
X	B-T058
-	I-T058
ray	I-T058
diffraction	I-T058
(	O
XRD	B-T058
)	O
and	O
selected	B-T058
area	I-T058
diffraction	I-T058
pattern	I-T058
(	O
SAED	O
)	O
.	O

The	O
particle	O
size	O
analysis	O
revealed	O
that	O
the	O
Z	O
-	O
average	O
diameter	O
of	O
the	O
AgNPs	B-T103
was	O
50	O
.	O
86	O
nm	O
with	O
polydispersity	O
index	O
(	O
PDI	O
)	O
0	O
.	O
136	O
.	O

Zeta	O
potential	O
analysis	O
displayed	O
the	O
colloidal	O
stability	O
of	O
AgNPs	B-T103
.	O

This	O
work	O
also	O
showed	O
the	O
efficacy	O
of	O
AgNPs	O
against	O
lung	B-T017
cancer	B-T017
cell	I-T017
lines	I-T017
(	O
A549	B-T017
)	O
and	O
cervical	B-T017
cancer	B-T017
cell	I-T017
line	I-T017
(	O
HeLa	B-T017
)	O
,	O
in	O
vitro	O
.	O

The	O
AgNPs	O
showed	O
cytotoxicity	B-T038
to	O
the	O
A549	B-T017
and	O
HeLa	B-T017
cancer	B-T017
cell	I-T017
line	I-T017
at	O
the	O
concentrations	O
5	O
and	O
2	O
μg	O
/	O
ml	O
.	O

The	O
AgNPs	B-T103
were	O
also	O
explored	O
for	O
the	O
antibacterial	B-T033
activity	I-T033
including	O
biofilm	B-T007
inhibition	O
against	O
pathogenic	B-T033
bacteria	B-T007
.	O

The	O
B	B-T204
.	I-T204

officinalis	I-T204
leaves	B-T204
extract	B-T103
can	O
be	O
used	O
efficiently	O
for	O
green	O
synthesis	O
AgNPs	B-T103
.	O

The	O
biosynthesized	O
AgNPs	B-T103
demonstrated	O
potentials	O
as	O
anticancer	B-T103
and	O
antibacterial	B-T103
agents	I-T103
.	O

This	O
work	O
provides	O
helpful	O
insight	O
into	O
the	O
development	O
of	O
new	O
anticancer	B-T103
and	O
antimicrobial	B-T103
agents	I-T103
.	O

Genotyping	B-T058
of	O
Staphylococcus	B-T007
aureus	I-T007
in	O
bovine	B-T038
mastitis	I-T038
and	O
correlation	O
to	O
phenotypic	O
characteristics	O

Reducing	O
the	O
prevalence	O
of	O
mastitis	B-T038
caused	O
by	O
Staphylococcus	B-T007
aureus	I-T007
(	O
S	B-T007
.	I-T007

aureus	I-T007
)	O
is	O
essential	O
to	O
improve	O
animal	B-T204
health	O
and	O
reduce	O
economic	O
losses	O
for	O
farmers	B-T097
.	O

The	O
clinical	O
outcome	O
of	O
acute	B-T038
mastitis	I-T038
and	O
risk	O
of	O
progression	O
to	O
persistent	O
mastitis	B-T038
can	O
,	O
at	O
least	O
to	O
some	O
extent	O
,	O
be	O
related	O
to	O
genetic	B-T017
variants	I-T017
of	O
the	O
strain	O
causing	O
the	O
infection	B-T038
.	O

In	O
the	O
present	O
study	B-T062
we	O
have	O
used	O
microarrays	O
to	O
investigate	O
the	O
presence	O
of	O
virulence	B-T038
genes	B-T017
in	O
S	B-T007
.	I-T007

aureus	I-T007
isolates	O
from	O
dairy	O
cows	O
with	O
acute	B-T038
clinical	I-T038
mastitis	I-T038
(	O
n	O
=	O
70	O
)	O
and	O
correlated	O
the	O
findings	B-T033
to	O
other	O
genotypic	O
and	O
phenotypic	O
characteristics	O
.	O

Among	O
the	O
most	O
commonly	O
found	O
virulence	B-T103
factors	I-T103
were	O
genes	B-T017
encoding	O
several	O
hemolysin	B-T103
types	O
,	O
leukocidins	B-T103
D	I-T103
and	O
lukM	B-T103
/	O
lukF	B-T103
-	I-T103
P83	I-T103
,	O
clumping	B-T103
factors	I-T103
A	I-T103
and	O
B	B-T103
,	O
fibrinogen	B-T103
binding	I-T103
protein	I-T103
and	O
fibronectin	B-T103
-	I-T103
binding	I-T103
protein	I-T103
A	I-T103
.	O

Some	O
virulence	B-T103
factors	I-T103
e	O
.	O
g	O
.	O

fibronectin	B-T103
-	I-T103
binding	I-T103
protein	I-T103
B	I-T103
and	O
Staphylococcus	B-T007
aureus	I-T007
surface	B-T103
protein	I-T103
G	I-T103
were	O
less	O
common	O
.	O

Genes	B-T017
coding	O
for	O
several	O
staphylococcal	O
enterotoxins	O
and	O
toxic	B-T103
shock	I-T103
syndrome	I-T103
toxin	I-T103
-	I-T103
1	I-T103
(	O
TSST	B-T103
-	I-T103
1	I-T103
)	O
were	O
commonly	O
found	O
,	O
especially	O
in	O
one	O
major	O
pulsotype	O
.	O

No	B-T033
beta	B-T017
-	I-T017
lactamase	I-T017
genes	I-T017
were	O
found	O
in	O
any	O
common	O
pulsotype	O
,	O
while	O
present	O
in	O
some	O
rare	O
pulsotypes	O
,	O
indicated	O
to	O
be	O
of	O
human	O
origin	O
.	O

Production	O
of	O
TSST	B-T103
-	I-T103
1	I-T103
,	O
enterotoxins	B-T103
,	O
hemolysins	B-T103
and	O
beta	B-T103
-	I-T103
lactamase	I-T103
could	O
all	O
be	O
positively	O
correlated	O
to	O
presence	O
of	O
the	O
corresponding	O
genes	B-T017
.	O

This	O
study	B-T062
reveals	O
a	O
number	O
of	O
genotypic	O
differences	O
and	O
similarities	O
among	O
common	O
and	O
rare	O
pulsotypes	O
of	O
S	B-T007
.	I-T007

aureus	I-T007
from	O
cases	O
of	O
mastitis	B-T038
in	O
Sweden	B-T082
.	O

The	O
results	O
could	O
help	O
the	O
design	O
of	O
diagnostic	B-T062
tools	I-T062
to	O
guide	O
on	O
-	O
farm	O
interventions	O
according	O
to	O
the	O
expected	O
impact	O
on	O
udder	B-T017
health	O
from	O
a	O
specific	O
S	B-T007
.	I-T007

aureus	I-T007
genotype	O
.	O

Uveitis	B-T038
in	O
spondyloarthritis	B-T038
patients	O
and	O
its	O
association	O
with	O
HLA	B-T103
-	I-T103
B27	I-T103
histocompatibility	I-T103
antigen	I-T103
:	O
prospective	B-T062
study	I-T062

T	O
o	O
perform	O
a	O
prospective	B-T062
study	I-T062
of	O
clinical	O
presentation	O
and	O
course	O
of	O
uveitis	B-T038
in	O
spondyloarthritis	B-T038
(	O
SpA	B-T038
)	O
patients	O
as	O
well	O
as	O
its	O
association	O
with	O
the	O
HLA	B-T103
-	I-T103
B27	I-T103
histocompatibility	I-T103
antigen	I-T103
.	O

The	O
study	B-T062
included	O
219	O
patients	O
with	O
uveitis	B-T038
,	O
all	O
tested	O
for	O
HLA	B-T103
-	I-T103
B27	I-T103
antigen	I-T103
and	O
various	O
infections	B-T038
(	O
viral	B-T038
,	O
bacterial	B-T038
,	O
and	O
parasitic	B-T038
)	O
as	O
well	O
as	O
examined	B-T033
for	O
locomotive	B-T022
system	I-T022
involvement	O
.	O

The	O
presence	B-T033
of	O
the	O
HLA	B-T103
-	I-T103
B27	I-T103
antigen	I-T103
was	O
determined	O
in	O
142	O
(	O
64	O
.	O
8	O
%	O
)	O
out	O
of	O
219	O
patients	O
,	O
of	O
them	O
87	O
were	O
diagnosed	B-T033
with	O
an	O
entity	O
of	O
the	O
SpA	B-T038
group	O
.	O

The	O
remaining	O
77	O
(	O
35	O
.	O
2	O
%	O
)	O
patients	O
appeared	O
to	O
be	O
HLA	B-T103
-	I-T103
B27	I-T103
-	O
negative	B-T033
,	O
but	O
13	O
were	O
still	O
diagnosed	B-T033
with	O
an	O
entity	O
of	O
the	O
SpA	B-T038
group	O
.	O

There	O
were	O
10	O
(	O
4	O
.	O
6	O
%	O
)	O
patients	O
with	O
2	O
or	O
more	O
diseases	B-T038
from	O
the	O
SpA	B-T038
group	O
(	O
«	O
clinical	O
decussation	O
»	O
)	O
.	O

When	O
comparing	O
the	O
two	O
groups	O
of	O
HLA	O
-	O
B27	O
-	O
positive	O
and	O
negative	B-T033
patients	O
having	O
both	O
SpA	B-T038
and	O
uveitis	B-T038
,	O
no	O
statistically	O
significant	O
difference	O
was	O
found	O
as	O
to	O
the	O
age	O
of	O
onset	O
,	O
site	B-T082
,	O
frequency	O
of	O
attacks	O
,	O
and	O
uni	B-T082
-	O
or	O
bilateral	B-T082
involvement	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

We	O
also	O
performed	O
a	O
comparison	O
of	O
HLA	O
-	O
B27	O
-	O
positive	O
and	O
negative	B-T033
patients	O
with	O
no	O
account	O
to	O
their	O
SpA	B-T038
status	O
and	O
revealed	O
a	O
higher	O
complication	B-T038
rate	O
in	O
those	O
that	O
were	O
«	O
negative	B-T033
»	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
which	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
HLA	B-T103
-	I-T103
B27	I-T103
-	O
negative	B-T033
patients	O
often	O
have	O
autoimmune	B-T038
or	O
infectious	B-T038
uveitis	I-T038
of	O
different	O
origin	O
notable	O
for	O
long	O
attacks	O
and	O
short	O
remissions	B-T033
.	O

Assessing	O
the	O
site	B-T082
and	O
course	O
of	O
uveitis	B-T038
as	O
well	O
as	O
HLA	B-T103
-	I-T103
B27	I-T103
testing	O
of	O
uveitis	B-T038
patients	O
has	O
proved	O
important	O
for	O
etiological	O
diagnosis	B-T033
.	O

Diseases	B-T038
of	O
the	O
SpA	B-T038
group	O
have	O
been	O
shown	O
to	O
be	O
6	O
.	O
7	O
times	O
more	O
common	O
in	O
HLA	O
-	O
B27	O
-	O
positive	O
patients	O
as	O
compared	O
to	O
HLA	B-T103
-	I-T103
B27	I-T103
-	O
negative	B-T033
ones	O
.	O

Clinical	O
presentation	O
of	O
uveitis	B-T038
in	O
the	O
presence	B-T033
of	O
SpA	B-T038
in	O
both	O
HLA	O
-	O
B27	O
-	O
positive	O
and	O
negative	B-T033
patients	O
resembles	O
that	O
of	O
idiopathic	B-T038
uveitis	I-T038
-	O
an	O
independent	O
HLA	B-T103
-	I-T103
B27	I-T103
-	O
associated	O
syndrome	B-T038
(	O
р	O
>	O
0	O
.	O
05	O
)	O
.	O

Cases	O
of	O
«	O
decussation	O
»	O
between	O
entities	O
of	O
the	O
SpA	B-T038
group	O
are	O
usually	O
more	O
severe	O
in	O
terms	O
of	O
clinical	O
presentation	O
and	O
course	O
of	O
uveitis	B-T038
and	O
are	O
associated	O
with	O
a	O
worse	B-T033
prognosis	I-T033
.	O

Complications	B-T038
of	O
uveitis	B-T038
are	O
more	O
likely	O
to	O
be	O
found	O
in	O
non	B-T033
-	I-T033
SpA	I-T033
HLA	B-T103
-	I-T103
B27	I-T103
-	O
negative	B-T033
patients	O
(	O
р	O
<	O
0	O
.	O
0001	O
)	O
.	O

Human	B-T204
brucellosis	B-T038
in	O
South	B-T082
Africa	I-T082
:	O
Public	B-T170
health	I-T170
and	O
diagnostic	O
pitfalls	O

Human	B-T204
brucellosis	B-T038
in	O
South	B-T082
Africa	I-T082
(	O
SA	B-T082
)	O
is	O
under	O
-	O
diagnosed	O
and	O
under	B-T033
-	I-T033
reported	I-T033
.	O

This	O
is	O
because	O
many	O
clinicians	B-T097
have	O
little	O
or	O
no	O
experience	O
in	O
managing	O
affected	O
patients	O
,	O
and	O
in	O
part	O
because	O
of	O
the	O
nonspecific	O
and	O
insidious	O
nature	O
of	O
the	O
disease	O
.	O

A	O
case	O
of	O
human	B-T204
brucellosis	B-T038
caused	O
by	O
Brucella	B-T007
melitensis	I-T007
in	O
a	O
patient	O
from	O
the	O
Western	O
Cape	O
Province	O
of	O
SA	B-T082
is	O
described	O
,	O
and	O
the	O
resulting	O
exposure	O
of	O
staff	O
members	O
at	O
two	O
medical	B-T092
microbiology	I-T092
laboratories	I-T092
,	O
as	O
well	O
as	O
the	O
public	B-T058
health	I-T058
investigation	I-T058
that	O
was	O
conducted	O
,	O
are	O
discussed	O
.	O

This	O
article	B-T170
aims	O
to	O
highlight	O
the	O
need	O
for	O
strengthening	O
integration	O
between	O
public	B-T170
health	I-T170
,	O
medical	B-T058
and	O
veterinary	B-T091
services	O
and	O
exposing	O
deficiencies	O
in	O
public	B-T170
health	I-T170
,	O
veterinary	B-T091
and	O
laboratory	B-T092
practices	O
.	O

Survey	B-T170
of	O
Trichinella	B-T038
infection	I-T038
from	O
domestic	B-T204
pigs	I-T204
in	O
the	O
historical	B-T033
endemic	B-T082
areas	I-T082
of	O
Henan	B-T082
province	I-T082
,	O
central	B-T082
China	I-T082

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
investigate	O
the	O
current	B-T033
situation	I-T033
of	O
Trichinella	B-T038
infection	I-T038
from	O
domestic	B-T204
pigs	I-T204
in	O
the	O
historical	B-T033
endemic	B-T082
areas	I-T082
of	O
Henan	B-T082
province	I-T082
,	O
central	B-T082
China	I-T082
.	O

A	O
total	O
of	O
823	O
diaphragm	O
samples	O
from	O
the	O
indoor	B-T204
-	I-T204
raised	I-T204
pigs	I-T204
were	O
collected	O
in	O
five	O
cities	B-T082
of	O
Henan	B-T082
during	O
2014	O
-	O
2015	O
and	O
examined	B-T033
by	O
artificial	O
digestion	O
method	O
.	O

The	O
overall	O
prevalence	O
of	O
Trichinella	B-T038
infection	I-T038
in	O
pigs	B-T204
was	O
0	O
.	O
61	O
%	O
(	O
5	O
/	O
823	O
)	O
.	O

Trichinella	B-T204
larvae	I-T204
were	O
detected	B-T033
in	O
0	O
.	O
91	O
%	O
(	O
5	O
/	O
550	O
)	O
of	O
pigs	B-T204
from	O
Nanyang	B-T082
city	I-T082
of	O
Henan	B-T082
.	O

The	O
larval	B-T204
burden	O
in	O
infected	O
animals	O
was	O
0	O
.	O
03	O
larvae	B-T204
per	O
gram	O
(	O
lpg	O
)	O
of	O
muscles	B-T017
with	O
a	O
range	O
from	O
0	O
.	O
02	O
to	O
0	O
.	O
05	O
lpg	O
.	O

The	O
larvae	B-T204
were	O
identified	O
as	O
Trichinella	B-T204
spiralis	I-T204
by	O
multiple	B-T062
PCR	I-T062
.	O

Our	O
study	B-T062
confirms	O
the	O
existence	O
of	O
swine	B-T204
trichinellosis	B-T038
in	O
Henan	B-T082
,	O
but	O
the	O
infection	B-T038
level	O
was	O
under	O
the	O
minimum	O
level	O
for	O
defining	O
infectious	O
sources	O
for	O
humans	B-T204
.	O

However	O
,	O
the	O
prevalence	O
of	O
swine	B-T204
Trichinella	B-T038
infection	I-T038
in	O
Henan	B-T082
need	O
to	O
be	O
further	O
evaluated	B-T058
with	O
a	O
large	O
scale	O
of	O
pork	O
samples	O
for	O
ensuring	O
meat	B-T168
food	O
safety	O
.	O

Voriconazole	B-T103
metabolism	B-T038
is	O
influenced	O
by	O
severe	O
inflammation	B-T038
:	O
a	O
prospective	B-T062
study	I-T062

During	O
an	O
infection	B-T038
or	O
inflammation	B-T038
,	O
several	O
drug	B-T103
-	O
metabolizing	B-T038
enzymes	B-T103
in	O
the	O
liver	B-T017
are	O
down	B-T038
-	I-T038
regulated	I-T038
,	O
including	O
cytochrome	B-T103
P450	I-T103
iso	I-T103
-	I-T103
enzymes	I-T103
.	O

Since	O
voriconazole	B-T103
is	O
extensively	O
metabolized	B-T038
by	O
cytochrome	B-T103
P450	I-T103
iso	I-T103
-	I-T103
enzymes	I-T103
,	O
the	O
metabolism	B-T038
of	O
voriconazole	B-T103
can	O
be	O
influenced	O
during	O
inflammation	B-T038
via	O
reduced	O
clearance	B-T038
of	I-T038
the	I-T038
drug	I-T038
,	O
resulting	O
in	O
higher	O
voriconazole	B-T103
trough	O
concentrations	O
.	O

To	O
investigate	O
prospectively	O
the	O
influence	O
of	O
inflammation	B-T038
on	O
voriconazole	B-T103
metabolism	B-T038
and	O
voriconazole	B-T103
trough	O
concent	O
ratio	O
ns	O
.	O

A	O
prospective	B-T062
observational	I-T062
study	I-T062
was	O
performed	O
at	O
the	O
University	B-T092
Medical	I-T092
Center	I-T092
Groningen	B-T082
.	O

Patients	O
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
≥18	O
years	O
old	O
and	O
treated	B-T058
with	I-T058
voriconazole	B-T103
.	O

Voriconazole	B-T103
and	O
voriconazole	O
-	O
N	O
-	O
oxide	O
concentrations	O
were	O
determined	O
in	O
discarded	O
blood	B-T031
samples	I-T031
.	O

To	O
determine	O
the	O
degree	O
of	O
inflammation	B-T038
,	O
C	B-T058
-	I-T058
reactive	I-T058
protein	I-T058
(	I-T058
CRP	I-T058
)	I-T058
concentrations	I-T058
were	O
used	O
.	O

Subsequently	O
,	O
a	O
longitudinal	B-T062
data	I-T062
analysis	I-T062
was	O
performed	O
to	O
assess	O
the	O
effect	O
of	O
inflammation	B-T038
on	O
the	O
metabolic	B-T038
ratio	O
and	O
voriconazole	B-T103
trough	O
concentration	O
.	O

Thirty	O
-	O
four	O
patients	O
were	O
included	O
.	O

In	O
total	O
489	O
voriconazole	B-T103
trough	O
concentrations	O
were	O
included	O
in	O
the	O
longitudinal	B-T062
data	I-T062
analysis	I-T062
.	O

This	O
analysis	B-T062
showed	O
that	O
inflammation	B-T038
,	O
reflected	O
by	O
CRP	B-T058
concentrations	I-T058
,	O
significantly	O
influence	O
d	O
the	O
metabolic	B-T038
ratio	O
,	O
voriconazole	B-T103
trough	O
concentration	O
and	O
voriconazole	O
-	O
N	O
-	O
oxide	O
concentration	O
(	O
all	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
when	O
corrected	O
for	O
other	O
factors	O
that	O
could	O
influence	O
voriconazole	B-T103
metabolism	B-T038
.	O

The	O
metabolic	B-T038
ratio	O
was	O
decreased	O
by	O
0	O
.	O
99229	O
(	O
N	O
)	O
and	O
the	O
voriconazole	O
-	O
N	O
-	O
oxide	O
concentration	O
by	O
0	O
.	O
99775	O
(	O
N	O
)	O
,	O
while	O
the	O
voriconazole	B-T103
trough	O
concentration	O
was	O
increased	O
by	O
1	O
.	O
005321	O
(	O
N	O
)	O
,	O
where	O
N	O
is	O
the	O
difference	O
in	O
CRP	B-T103
units	O
(	O
in	O
mg	O
/	O
L	O
)	O
.	O

This	O
study	O
shows	O
that	O
voriconazole	B-T103
metabolism	B-T038
is	O
decreased	O
during	O
inflammation	B-T038
,	O
resulting	O
in	O
higher	O
voriconazole	B-T103
trough	O
concentration	O
s	O
.	O

Therefore	O
,	O
frequent	O
monitoring	B-T058
of	O
voriconazole	B-T103
serum	O
concentrations	O
is	O
recommended	O
during	O
and	O
following	O
severe	O
inflammation	B-T038
.	O

Neoadjuvant	O
Chemotherapy	O
of	O
Ovarian	B-T038
Cancer	I-T038
Results	O
in	O
Three	O
Patterns	O
of	O
Tumor	B-T017
-	I-T017
Infiltrating	I-T017
Lymphocyte	I-T017
Response	B-T038
with	O
Distinct	O
Implications	O
for	O
Immunotherapy	B-T058

Purpose	O
:	O
Some	O
forms	O
of	O
chemotherapy	B-T058
can	O
enhance	O
antitumor	O
immunity	B-T038
through	O
immunogenic	O
cell	B-T038
death	I-T038
,	O
resulting	O
in	O
increased	O
T	B-T038
-	I-T038
cell	I-T038
activation	I-T038
and	O
tumor	O
infiltration	O
.	O

Such	O
effects	O
could	O
potentially	O
sensitize	O
tumors	B-T038
to	O
immunotherapies	B-T058
,	O
including	O
checkpoint	B-T038
blockade	I-T038
.	O

We	O
investigated	O
whether	O
platinum	B-T103
-	O
and	O
taxane	B-T103
-	O
based	O
chemotherapy	B-T058
for	O
ovarian	B-T038
cancer	I-T038
induces	O
immunologic	O
changes	O
consistent	O
with	O
this	O
possibility	O
.	O

Experimental	B-T062
Design	I-T062
:	O
Matched	O
pre	O
-	O
and	O
post	O
-	O
neoadjuvant	O
chemotherapy	O
tumor	B-T017
samples	I-T017
from	O
26	O
high	B-T038
-	I-T038
grade	I-T038
serous	I-T038
carcinoma	I-T038
(	O
HGSC	B-T038
)	O
patients	O
were	O
analyzed	O
by	O
immunohistochemistry	B-T058
(	O
IHC	B-T058
)	O
for	O
a	O
large	O
panel	O
of	O
immune	B-T017
cells	I-T017
and	O
associated	O
factors	O
.	O

The	O
prognostic	O
significance	O
of	O
post	O
-	O
chemotherapy	B-T058
TIL	B-T017
patterns	O
was	O
assessed	O
in	O
an	O
expanded	O
cohort	B-T098
(	O
n	O
=	O
90	O
)	O
.	O
Results	O
:	O
Neoadjuvant	O
chemotherapy	O
was	O
associated	O
with	O
increased	O
densities	O
of	O
CD3	B-T103
(	O
+	O
)	O
,	O
CD8	B-T103
(	O
+	O
)	O
,	O
CD8	B-T103
(	O
+	O
)	O
TIA	B-T103
-	I-T103
1	I-T103
(	O
+	O
)	O
,	O
PD	B-T103
-	I-T103
1	I-T103
(	O
+	O
)	O
and	O
CD20	B-T103
(	O
+	O
)	O
TIL	B-T017
.	O

Other	O
immune	O
subsets	O
and	O
factors	O
were	O
unchanged	O
,	O
including	O
CD79a	B-T103
(	O
+	O
)	O
CD138	B-T103
(	O
+	O
)	O
plasma	B-T017
cells	I-T017
,	O
CD68	B-T103
(	O
+	O
)	O
macrophages	B-T017
,	O
and	O
MHC	B-T103
class	I-T103
I	I-T103
on	O
tumor	B-T017
cells	I-T017
.	O

Immunosuppressive	B-T038
cell	B-T017
types	O
were	O
also	O
unchanged	O
,	O
including	O
FoxP3	B-T103
(	O
+	O
)	O
PD	B-T103
-	I-T103
1	I-T103
(	O
+	O
)	O
cells	B-T017
(	O
putative	O
regulatory	B-T017
T	I-T017
cells	I-T017
)	O
,	O
IDO	B-T103
-	I-T103
1	I-T103
(	O
+	O
)	O
cells	O
,	O
and	O
PD	O
-	O
L1	O
(	O
+	O
)	O
cells	O
(	O
both	O
macrophages	B-T017
and	O
tumor	B-T017
cells	I-T017
)	O
.	O

Hierarchical	B-T062
clustering	I-T062
revealed	O
three	O
response	O
patterns	O
:	O
(	O
i	O
)	O
TIL	B-T017
(	O
high	O
)	O
tumors	B-T038
showed	O
increases	O
in	O
multiple	O
immune	O
markers	O
after	O
chemotherapy	O
;	O
(	O
ii	O
)	O
TIL	B-T017
(	O
low	O
)	O
tumors	O
underwent	O
similar	O
increases	O
,	O
achieving	O
patterns	O
indistinguishable	O
from	O
the	O
first	O
group	O
;	O
and	O
(	O
iii	O
)	O
TIL	B-T017
(	O
negative	B-T033
)	O
cases	O
generally	O
remained	O
negative	B-T033
.	O

Despite	O
the	O
dramatic	O
increases	O
seen	O
in	O
the	O
first	O
two	O
patterns	O
,	O
post	O
-	O
chemotherapy	B-T058
TIL	B-T017
showed	O
limited	O
prognostic	O
significance	O
.	O
Conclusions	O
:	O
Chemotherapy	O
augments	O
pre	O
-	O
existing	O
TIL	B-T017
responses	B-T038
but	O
fails	O
to	O
relieve	O
major	O
immune	B-T038
-	I-T038
suppressive	I-T038
mechanisms	I-T038
or	O
confer	O
significant	O
prognostic	O
benefit	O
.	O

Our	O
findings	O
provide	O
rationale	O
for	O
multipronged	O
approaches	O
to	O
immunotherapy	B-T058
tailored	O
to	O
the	O
baseline	O
features	O
of	O
the	O
tumor	O
microenvironment	O
.	O

Clin	O
Cancer	O
Res	O
;	O
23	O
(	O
4	O
)	O
;	O
925	O
-	O
34	O
.	O

©2016	O
AACR	O
.	O

The	O
adder	B-T204
(	O
Vipera	B-T204
berus	I-T204
)	O
in	O
Southern	B-T082
Altay	I-T082
Mountains	I-T082
:	O
population	O
characteristics	O
,	O
distribution	B-T082
,	O
morphology	O
and	O
phylogenetic	O
position	O

As	O
the	O
most	O
widely	O
distributed	B-T082
snake	B-T204
in	O
Eurasia	B-T082
,	O
the	O
adder	B-T204
(	O
Vipera	B-T204
berus	I-T204
)	O
has	O
been	O
extensively	O
investigated	O
in	O
Europe	B-T082
but	O
poorly	O
understood	O
in	O
Asia	B-T082
.	O

The	O
Southern	B-T082
Altay	I-T082
Mountains	I-T082
represent	O
the	O
adder	B-T204
'	I-T204
s	I-T204
southern	B-T082
distribution	B-T082
limit	O
in	O
Central	B-T082
Asia	I-T082
,	O
whereas	O
its	O
population	O
status	O
has	O
never	O
been	O
assessed	O
.	O

We	O
conducted	O
,	O
for	O
the	O
first	O
time	O
,	O
field	B-T062
surveys	I-T062
for	O
the	O
adder	B-T204
at	O
two	O
areas	B-T082
of	O
Southern	B-T082
Altay	I-T082
Mountains	I-T082
using	O
a	O
combination	O
of	O
line	B-T062
transects	I-T062
and	O
random	O
searches	O
.	O

We	O
also	O
described	O
the	O
morphological	O
characteristics	O
of	O
the	O
collected	B-T058
specimens	I-T058
and	O
conducted	O
analyses	B-T062
of	O
external	B-T082
morphology	O
and	O
molecular	O
phylogeny	O
.	O

The	O
results	O
showed	O
that	O
the	O
adder	B-T204
distributed	B-T082
in	O
both	O
survey	B-T062
sites	B-T082
and	O
we	O
recorded	B-T170
a	O
total	O
of	O
34	O
sightings	O
.	O

In	O
Kanas	B-T082
river	I-T082
valley	I-T082
,	O
the	O
estimated	O
encounter	O
rate	O
over	O
a	O
total	O
of	O
137	O
km	O
transects	B-T062
was	O
0	O
.	O
15	O
±	O
0	O
.	O
05	O
sightings	O
/	O
km	O
.	O

The	O
occurrence	O
of	O
melanism	B-T038
was	O
only	O
17	O
%	O
.	O

The	O
small	O
size	O
was	O
typical	O
for	O
the	O
adders	B-T204
in	O
Southern	B-T082
Altay	I-T082
Mountains	I-T082
in	O
contrast	O
to	O
other	O
geographic	O
populations	O
of	O
the	O
nominate	O
subspecies	B-T170
.	O

A	O
phylogenetic	O
tree	O
obtained	O
by	O
Bayesian	O
Inference	O
based	O
on	O
DNA	B-T082
sequences	I-T082
of	O
the	O
mitochondrial	B-T103
cytochrome	I-T103
b	I-T103
(	O
1	O
,	O
023	O
bp	O
)	O
grouped	B-T082
them	O
within	O
the	O
Northern	O
clade	O
of	O
the	O
species	B-T170
but	O
failed	O
to	O
separate	O
them	O
from	O
the	O
subspecies	B-T170
V	B-T204
.	I-T204

b	I-T204
.	I-T204

sachalinensis	I-T204
.	O

Our	O
discovery	O
extends	O
the	O
distribution	B-T082
range	O
of	O
V	B-T204
.	I-T204

berus	I-T204
and	O
provides	O
a	O
basis	O
for	O
further	O
researches	B-T062
.	O

We	O
discuss	O
the	O
hypothesis	O
that	O
the	O
adder	B-T204
expands	B-T082
its	O
distribution	B-T082
border	B-T170
to	O
the	O
southwest	B-T082
along	O
the	O
mountains	B-T082
'	O
elevation	B-T082
gradient	O
,	O
but	O
the	O
population	B-T098
abundance	O
declines	O
gradually	O
due	O
to	O
a	O
drying	O
climate	O
.	O

Binding	O
of	O
Pollutants	B-T103
to	O
Biomolecules	B-T103
:	O
A	O
Simulation	B-T062
Study	I-T062

A	O
number	O
of	O
cases	O
around	O
the	O
world	B-T098
have	O
been	O
reported	O
where	O
animals	B-T204
were	O
found	B-T033
dead	I-T033
or	O
dying	B-T038
with	O
symptoms	B-T033
resembling	O
a	O
thiamine	B-T038
(	B-T038
vitamin	I-T038
B	I-T038
)	I-T038
deficiency	I-T038
,	O
and	O
for	O
some	O
of	O
these	O
,	O
a	O
link	O
to	O
pollutants	B-T103
has	O
been	O
suggested	O
.	O

Here	O
,	O
we	O
investigate	B-T058
whether	O
biomolecules	B-T103
involved	O
in	O
thiamin	B-T038
binding	I-T038
and	O
transport	B-T038
could	O
be	O
blocked	O
by	O
a	O
range	O
of	O
different	O
pollutants	B-T103
.	O

We	O
used	O
in	O
silico	O
docking	B-T038
of	O
five	O
compound	B-T103
classes	B-T170
(	O
25	O
compounds	B-T103
in	O
total	O
)	O
to	O
each	O
of	O
five	O
targets	O
(	O
prion	B-T103
protein	I-T103
,	O
ECF	B-T017
-	I-T017
type	I-T017
ABC	I-T017
transporter	I-T017
,	O
thi	B-T103
-	I-T103
box	I-T103
riboswitch	I-T103
receptor	I-T103
,	O
thiamin	B-T103
pyrophosphokinase	I-T103
,	O
and	O
YKoF	B-T103
protein	I-T103
)	O
and	O
subsequently	O
performed	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
to	O
assess	O
the	O
stability	O
of	O
the	O
complexes	B-T103
.	O

The	O
compound	B-T103
classes	B-T170
were	O
thiamin	B-T103
analogues	B-T103
(	O
control	O
)	O
,	O
pesticides	B-T103
,	O
veterinary	O
medicines	B-T103
,	O
polychlorinated	B-T103
biphenyls	I-T103
,	O
and	O
dioxins	B-T103
,	O
all	O
of	O
which	O
are	O
prevalent	O
in	O
the	O
environment	B-T082
to	O
some	O
extent	O
.	O

A	O
few	O
anthropogenic	O
compounds	B-T103
were	O
found	O
to	O
bind	B-T038
the	O
ECF	B-T017
-	I-T017
type	I-T017
ABC	I-T017
transporter	I-T017
,	O
but	O
none	B-T033
binds	I-T033
stably	I-T033
to	O
prion	B-T103
protein	I-T103
.	O

For	O
the	O
riboswitch	B-T103
,	O
most	O
compounds	B-T103
remained	O
in	O
their	O
binding	O
pockets	O
during	O
50	O
ns	O
of	O
MD	O
simulation	O
,	O
indicating	O
that	O
RNA	B-T103
provides	O
a	O
promiscuous	O
binding	B-T103
site	I-T103
.	O

In	O
both	O
YKoF	B-T103
and	O
thiamin	B-T103
pyrophosphokinase	I-T103
(	O
TPK	B-T103
)	O
,	O
most	O
compounds	B-T103
remain	O
tightly	O
bound	O
.	O

However	O
,	O
TPK	B-T103
biomolecules	B-T103
undergo	O
pollutant	B-T103
-	O
induced	O
conformational	B-T038
changes	I-T038
.	O

Although	O
most	O
compounds	B-T103
are	O
found	O
to	O
bind	O
to	O
some	O
of	O
these	O
targets	O
,	O
a	O
larger	O
data	O
set	O
is	O
needed	O
along	O
with	O
more	O
quantitative	O
methods	O
like	O
free	O
energy	O
perturbation	O
calculations	O
before	O
firm	O
conclusions	O
can	O
be	O
drawn	O
.	O

This	O
study	B-T062
is	O
in	O
part	O
a	O
test	O
bed	O
for	O
large	O
-	O
scale	O
quantitative	O
computational	O
screening	O
of	O
interactions	O
between	O
biological	B-T103
entities	I-T103
and	O
pollutant	B-T103
molecules	I-T103
.	O

Characterisation	O
of	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
clinical	O
isolates	B-T103
from	O
animals	B-T204
in	O
New	B-T082
Zealand	I-T082
,	O
2012	O
-	O
2013	O
,	O
and	O
subclinical	O
colonisation	B-T033
in	O
dogs	B-T204
and	O
cats	B-T204
in	O
Auckland	O

To	O
characterise	O
methicillin	B-T007
-	I-T007
resistant	I-T007
Staphylococcus	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
isolates	B-T103
from	O
infection	B-T038
sites	I-T038
in	O
animals	B-T204
in	O
New	B-T082
Zealand	I-T082
and	O
assess	O
the	O
prevalence	O
of	O
subclinical	O
MRSA	B-T033
colonisation	I-T033
in	O
dogs	B-T204
and	O
cats	B-T204
attending	O
veterinary	B-T092
clinics	I-T092
in	O
Auckland	O
.	O

MRSA	B-T007
isolates	B-T103
from	O
clinical	O
specimens	O
obtained	O
by	O
the	O
main	O
New	B-T082
Zealand	I-T082
veterinary	B-T092
diagnostic	I-T092
laboratories	I-T092
between	O
June	O
2012	O
and	O
June	O
2013	O
,	O
were	O
genotypically	O
characterised	O
by	O
DNA	B-T062
microarray	I-T062
hybridisation	I-T062
analysis	I-T062
and	O
spa	B-T103
typing	B-T058
.	O

In	O
addition	O
,	O
nasal	B-T017
or	O
perineal	B-T017
skin	I-T017
swabs	O
collected	O
from	O
a	O
cross	O
-	O
sectional	O
sample	O
of	O
dogs	B-T204
(	O
n	O
=	O
361	O
)	O
and	O
cats	B-T204
(	O
n	O
=	O
225	O
)	O
attending	O
29	O
veterinary	B-T092
clinics	I-T092
in	O
Auckland	O
during	O
the	O
same	O
period	O
were	O
analysed	B-T062
for	O
MRSA	B-T007
by	O
culture	B-T058
.	O

Eight	O
MRSA	B-T007
clinical	O
isolates	B-T103
were	O
submitted	O
for	O
characterisation	O
by	O
the	O
participating	O
laboratories	B-T092
.	O

The	O
isolates	B-T103
originated	O
from	O
five	O
dogs	B-T204
,	O
including	O
two	O
isolates	B-T103
from	O
the	O
same	O
dog	B-T204
,	O
one	O
foal	O
,	O
and	O
one	O
isolate	B-T103
had	O
no	O
identification	O
of	O
the	O
source	B-T033
.	O

The	O
strain	O
-	O
types	O
identified	O
were	O
AK3	B-T007
(	I-T007
ST	I-T007
-	I-T007
5	I-T007
SCCmecIV	I-T007
t045	O
;	O
n	O
=	O
1	O
)	O
,	O
USA500	B-T007
(	I-T007
ST8	I-T007
SCCmecIV	I-T007
t064	O
;	O
n	O
=	O
1	O
)	O
,	O
WSPP	B-T007
(	I-T007
ST30	I-T007
SCCmecIV	I-T007
t019	O
;	O
n	O
=	O
1	O
)	O
,	O
Rhine	B-T007
Hesse	I-T007
(	I-T007
ST5	I-T007
SCCmecII	I-T007
t002	O
;	O
n	O
=	O
2	O
)	O
,	O
and	O
EMRSA	B-T007
-	I-T007
15	I-T007
(	I-T007
ST22	I-T007
SCCmecIV	I-T007
t032	O
;	O
n	O
=	O
3	O
)	O
.	O

No	O
MRSA	B-T007
were	O
isolated	O
from	O
586	O
cultured	O
swabs	O
.	O

Methicillin	B-T007
-	I-T007
susceptible	I-T007
S	I-T007
.	I-T007

aureus	I-T007
were	O
detected	B-T033
in	O
9	O
/	O
257	O
(	O
3	O
.	O
5	O
%	O
)	O
swabs	O
and	O
non	B-T007
-	I-T007
aureus	I-T007
staphylococci	I-T007
in	O
22	O
/	O
257	O
(	O
8	O
.	O
5	O
%	O
)	O
swabs	O
.	O

The	O
estimated	O
true	O
MRSA	B-T007
subclinical	O
colonisation	B-T033
prevalence	O
was	O
0	O
%	O
,	O
with	O
an	O
upper	O
95	O
%	O
CI	O
boundary	O
of	O
1	O
.	O
9	O
%	O
for	O
cats	B-T204
and	O
1	O
.	O
4	O
%	O
for	O
dogs	B-T204
.	O

The	O
modest	O
number	O
of	O
MRSA	B-T007
isolates	B-T103
submitted	O
for	O
this	O
study	B-T170
by	O
the	O
participating	O
laboratories	B-T092
suggests	O
clinical	O
MRSA	B-T038
infection	I-T038
in	O
animals	B-T204
in	O
New	B-T082
Zealand	I-T082
continues	O
to	O
be	O
sporadic	O
.	O

The	O
wide	O
variety	O
of	O
strain	O
-	O
types	O
found	O
mirrored	O
the	O
evolving	O
strain	O
-	O
type	O
diversity	O
observed	O
in	O
humans	B-T204
.	O

We	O
cannot	O
rule	O
out	O
bias	O
due	O
to	O
the	O
non	B-T062
-	I-T062
random	I-T062
sampling	I-T062
of	O
dogs	B-T204
and	O
cats	B-T204
,	O
but	O
the	O
apparent	O
colonisation	B-T033
prevalence	O
of	O
0	O
%	O
was	O
consistent	O
with	O
the	O
low	O
prevalence	O
of	O
subclinical	O
colonisation	B-T033
in	O
humans	B-T204
in	O
New	B-T082
Zealand	I-T082
.	O

These	O
similarities	O
indicate	O
the	O
epidemiology	B-T091
of	O
animal	B-T204
and	O
human	B-T204
MRSA	B-T038
infections	I-T038
are	O
linked	O
.	O

In	O
the	O
last	O
decade	O
,	O
the	O
prevalence	O
of	O
human	B-T204
MRSA	B-T038
infections	I-T038
in	O
New	B-T082
Zealand	I-T082
has	O
steadily	O
increased	O
.	O

This	O
is	O
the	O
second	O
published	O
study	B-T170
of	O
MRSA	B-T007
in	O
animals	B-T204
in	O
New	B-T082
Zealand	I-T082
.	O

The	O
results	O
indicate	O
clinical	O
MRSA	B-T038
infection	I-T038
in	O
animals	B-T204
remains	O
sporadic	O
,	O
but	O
the	O
diversification	O
of	O
the	O
strain	O
-	O
types	O
may	O
pose	O
new	O
therapeutic	O
challenges	O
to	O
veterinarians	B-T097
,	O
due	O
to	O
their	O
diverse	O
resistome	O
.	O

Cloud	B-T170
-	I-T170
based	I-T170
MOTIFSIM	I-T170
:	O
Detecting	B-T033
Similarity	O
in	O
Large	O
DNA	B-T082
Motif	I-T082
Data	B-T170
Sets	I-T170

We	O
developed	O
the	O
cloud	B-T170
-	I-T170
based	I-T170
MOTIFSIM	I-T170
on	O
Amazon	O
Web	O
Services	O
(	O
AWS	O
)	O
cloud	O
.	O

The	O
tool	B-T170
is	O
an	O
extended	O
version	B-T170
from	O
our	O
web	B-T170
-	I-T170
based	I-T170
tool	I-T170
version	I-T170
2	I-T170
.	I-T170
0	I-T170
,	O
which	O
was	O
developed	O
based	O
on	O
a	O
novel	O
algorithm	B-T170
for	O
detecting	B-T033
similarity	O
in	O
multiple	O
DNA	B-T082
motif	I-T082
data	B-T170
sets	I-T170
.	O

This	O
cloud	O
-	O
based	O
version	B-T170
further	O
allows	O
researchers	B-T097
to	O
exploit	O
the	O
computing	O
resources	O
available	O
from	O
AWS	O
to	O
detect	B-T033
similarity	O
in	O
multiple	O
large	O
-	O
scale	O
DNA	B-T082
motif	I-T082
data	B-T170
sets	I-T170
resulting	O
from	O
the	O
next	B-T062
-	I-T062
generation	I-T062
sequencing	I-T062
technology	I-T062
.	O

The	O
tool	B-T170
is	O
highly	O
scalable	O
with	O
expandable	O
AWS	O
.	O

Utilization	O
and	O
Outcomes	B-T062
of	O
Sentinel	B-T058
Lymph	I-T058
Node	I-T058
Biopsy	I-T058
for	O
Vulvar	B-T038
Cancer	I-T038

To	O
examine	O
the	O
use	O
and	O
predictors	O
of	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
in	O
women	B-T098
with	O
vulvar	B-T038
cancer	I-T038
.	O

The	O
Perspective	B-T170
database	I-T170
,	O
an	O
all	B-T170
-	I-T170
payer	I-T170
database	I-T170
that	O
collects	B-T062
data	I-T062
from	O
more	O
than	O
500	O
hospitals	B-T092
,	O
was	O
used	O
to	O
perform	O
a	O
retrospective	B-T062
cohort	I-T062
study	I-T062
of	O
women	B-T098
with	O
vulvar	B-T038
cancer	I-T038
who	O
underwent	O
vulvectomy	B-T058
and	O
lymph	B-T058
node	I-T058
assessment	I-T058
from	O
2006	O
to	O
2015	O
.	O

Multivariable	O
models	O
were	O
used	O
to	O
determine	O
factors	O
associated	O
with	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
.	O

Length	O
of	O
stay	O
and	O
cost	O
were	O
compared	O
between	O
women	B-T098
who	O
underwent	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
and	O
lymphadenectomy	B-T058
.	O

Among	O
2	O
,	O
273	O
women	B-T098
,	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
was	O
utilized	O
in	O
618	O
(	O
27	O
.	O
2	O
%	O
)	O
and	O
1	O
,	O
655	O
(	O
72	O
.	O
8	O
%	O
)	O
underwent	O
inguinofemoral	B-T058
lymphadenectomy	I-T058
.	O

Performance	O
of	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
increased	O
from	O
17	O
.	O
0	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
12	O
.	O
0	O
-	O
22	O
.	O
0	O
%	O
)	O
in	O
2006	O
to	O
39	O
.	O
1	O
%	O
(	O
95	O
%	O
CI	O
27	O
.	O
1	O
-	O
51	O
.	O
0	O
%	O
)	O
in	O
2015	O
.	O

In	O
a	O
multivariable	O
model	O
,	O
women	B-T098
treated	O
more	O
recently	O
were	O
more	O
likely	O
to	O
have	O
undergone	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
,	O
whereas	O
women	B-T098
with	O
more	O
comorbidities	O
and	O
those	O
treated	O
at	O
rural	B-T092
hospitals	I-T092
were	O
less	O
likely	O
to	O
have	O
undergone	O
the	O
procedure	B-T058
.	O

The	O
median	B-T082
length	O
of	O
stay	O
was	O
shorter	O
for	O
those	O
undergoing	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
(	O
median	B-T082
2	O
days	O
,	O
interquartile	O
range	O
1	O
-	O
3	O
)	O
compared	O
with	O
women	B-T098
who	O
underwent	O
inguinofemoral	B-T058
lymphadenectomy	I-T058
(	O
median	O
3	O
days	O
,	O
interquartile	O
range	O
2	O
-	O
4	O
)	O
.	O

The	O
cost	O
of	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
was	O
$	O
7	O
,	O
599	O
(	O
interquartile	O
range	O
$	O
5	O
,	O
739	O
-	O
9	O
,	O
922	O
)	O
compared	O
with	O
$	O
8	O
,	O
095	O
(	O
interquartile	O
range	O
$	O
5	O
,	O
917	O
-	O
11	O
,	O
281	O
)	O
for	O
lymphadenectomy	B-T058
.	O

The	O
use	O
of	O
sentinel	B-T058
node	I-T058
biopsy	I-T058
for	O
vulvar	B-T038
cancer	I-T038
has	O
more	O
than	O
doubled	O
since	O
2006	O
.	O

Sentinel	B-T058
lymph	I-T058
node	I-T058
biopsy	I-T058
is	O
associated	O
with	O
a	O
shorter	O
hospital	O
stay	O
and	O
decreased	O
cost	O
compared	O
with	O
inguinofemoral	B-T058
lymphadenectomy	I-T058
.	O

Condition	O
-	O
dependent	O
co	B-T038
-	I-T038
regulation	I-T038
of	O
genomic	B-T017
clusters	I-T017
of	O
virulence	B-T103
factors	I-T103
in	O
the	O
grapevine	B-T038
trunk	I-T038
pathogen	O
Neofusicoccum	B-T204
parvum	I-T204

The	O
ascomycete	B-T204
Neofusicoccum	B-T204
parvum	I-T204
,	O
one	O
of	O
the	O
causal	B-T033
agents	I-T033
of	O
Botryosphaeria	B-T204
dieback	I-T204
,	O
is	O
a	O
destructive	O
wood	O
-	O
infecting	B-T033
fungus	B-T204
and	O
a	O
serious	O
threat	O
to	O
grape	B-T168
production	O
worldwide	B-T098
.	O

The	O
capability	O
of	O
colonizing	B-T033
woody	B-T017
tissue	I-T017
combined	O
with	O
the	O
secretion	B-T038
of	O
phytotoxic	O
compounds	B-T103
is	O
thought	O
to	O
underlie	O
its	O
pathogenicity	O
and	O
virulence	B-T038
.	O

Here	O
,	O
we	O
describe	O
the	O
repertoire	O
of	O
virulence	B-T103
factors	I-T103
and	O
their	O
transcriptional	B-T038
dynamics	O
as	O
the	O
fungus	B-T204
feeds	B-T168
on	O
different	O
substrates	O
and	O
colonizes	B-T033
the	O
woody	B-T204
stem	I-T204
.	O

We	O
assembled	O
and	O
annotated	O
a	O
highly	O
contiguous	B-T082
genome	B-T017
using	O
single	O
molecule	O
real	O
-	O
time	O
DNA	O
sequencing	O
.	O

Transcriptome	B-T058
profiling	I-T058
by	O
RNA	B-T058
-	I-T058
sequencing	I-T058
determined	O
the	O
genome	B-T017
-	O
wide	O
patterns	B-T082
of	O
expression	B-T038
of	O
virulence	B-T103
factors	I-T103
both	O
in	O
vitro	O
(	O
potato	B-T168
dextrose	B-T103
agar	I-T103
or	O
medium	B-T103
amended	O
with	O
grape	B-T168
wood	O
as	O
substrate	O
)	O
and	O
in	O
planta	B-T204
.	O

Pairwise	B-T170
statistical	I-T170
testing	I-T170
of	O
differential	O
expression	B-T038
followed	O
by	O
co	B-T062
-	I-T062
expression	I-T062
network	I-T062
analysis	I-T062
revealed	O
that	O
physically	O
clustered	B-T017
genes	I-T017
coding	B-T082
for	O
putative	O
virulence	B-T038
functions	O
were	O
induced	O
depending	O
on	O
substrate	O
or	O
stage	O
of	O
plant	B-T204
infection	B-T038
.	O

Co	B-T038
-	I-T038
expressed	I-T038
gene	B-T017
clusters	I-T017
were	O
significantly	O
enriched	O
not	O
only	O
in	O
genes	B-T017
associated	O
with	O
secondary	B-T038
metabolism	I-T038
,	O
but	O
also	O
with	O
cell	B-T038
wall	I-T038
degradation	I-T038
,	O
suggesting	O
that	O
dynamic	O
co	B-T038
-	I-T038
regulation	I-T038
of	O
transcriptional	B-T038
networks	I-T038
contribute	O
to	O
multiple	O
aspects	O
of	O
N	B-T204
.	I-T204

parvum	I-T204
virulence	B-T038
.	O

In	O
most	O
of	O
the	O
co	B-T038
-	I-T038
expressed	I-T038
clusters	B-T017
,	O
all	O
genes	B-T017
shared	O
at	O
least	O
a	O
common	O
motif	O
in	O
their	O
promoter	B-T103
region	I-T103
indicative	O
of	O
co	B-T038
-	I-T038
regulation	I-T038
by	O
the	O
same	O
transcription	B-T103
factor	I-T103
.	O

Co	B-T062
-	I-T062
expression	I-T062
analysis	I-T062
also	O
identified	O
chromatin	B-T103
regulators	O
with	O
correlated	O
expression	B-T038
with	O
inducible	O
clusters	B-T017
of	O
virulence	B-T103
factors	I-T103
,	O
suggesting	O
a	O
complex	O
,	O
multi	O
-	O
layered	O
regulation	B-T038
of	O
the	O
virulence	B-T038
repertoire	O
of	O
N	B-T204
.	I-T204

parvum	I-T204
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Congenital	B-T017
anomalies	I-T017
following	O
use	O
of	O
isotretinoin	B-T103
:	O
Emphasis	O
on	O
its	O
legal	O
aspects	O

We	O
described	O
a	O
neonate	O
with	O
severe	O
and	O
multiple	B-T017
abnormalities	I-T017
following	O
use	O
of	O
isotretinoin	B-T103
,	O
in	O
spite	O
of	O
the	O
mother	O
'	O
s	O
previous	O
knowledge	B-T170
of	O
drug	O
complications	O
.	O

Initial	O
physical	B-T058
examination	I-T058
after	O
delivery	B-T058
showed	O
congenital	B-T017
absence	I-T017
of	O
both	B-T017
eyes	I-T017
and	O
both	O
auricles	B-T017
as	O
well	O
as	O
anal	B-T017
atresia	I-T017
and	O
a	O
cleft	B-T017
palate	I-T017
.	O

Due	O
to	O
severe	O
respiratory	B-T033
distress	I-T033
and	O
atresia	B-T017
of	O
the	O
anus	B-T017
,	O
the	O
neonate	O
was	O
admitted	O
to	O
a	O
neonatal	O
intensive	B-T092
care	I-T092
unit	I-T092
and	O
underwent	O
reconstructive	B-T058
surgery	I-T058
.	O

The	O
drug	B-T103
should	O
not	O
have	O
been	O
used	O
during	O
pregnancy	B-T038
.	O

Using	O
this	O
drug	B-T103
within	O
pregnancy	B-T038
with	O
awareness	O
of	O
its	O
side	B-T038
effects	I-T038
may	O
have	O
legal	O
consequences	O
.	O

Functional	B-T038
adaptation	I-T038
of	O
crustacean	B-T204
exoskeletal	O
elements	B-T103
through	O
structural	B-T082
and	O
compositional	O
diversity	O
:	O
a	O
combined	O
experimental	B-T062
and	O
theoretical	B-T062
study	I-T062

The	O
crustacean	B-T204
cuticle	B-T204
is	O
a	O
composite	O
material	O
that	O
covers	O
the	O
whole	O
animal	B-T204
and	O
forms	O
the	O
continuous	O
exoskeleton	O
.	O

Nano	O
-	O
fibers	O
composed	O
of	O
chitin	B-T103
and	O
protein	B-T103
molecules	I-T103
form	O
most	O
of	O
the	O
organic	O
matrix	B-T103
of	O
the	O
cuticle	B-T204
that	O
,	O
at	O
the	O
macroscale	O
,	O
is	O
organized	O
in	O
up	O
to	O
eight	O
hierarchical	O
levels	O
.	O

At	O
least	O
two	O
of	O
them	O
,	O
the	O
exo	B-T204
-	I-T204
and	O
endocuticle	B-T204
,	O
contain	O
a	O
mineral	B-T103
phase	I-T103
of	O
mainly	O
Mg	B-T103
-	O
calcite	B-T103
,	O
amorphous	O
calcium	B-T103
carbonate	I-T103
and	O
phosphate	B-T103
.	O

The	O
high	O
number	O
of	O
hierarchical	O
levels	O
and	O
the	O
compositional	O
diversity	O
provide	O
a	O
high	O
degree	O
of	O
freedom	O
for	O
varying	O
the	O
physical	B-T201
,	O
in	O
particular	O
mechanical	O
,	O
properties	O
of	O
the	O
material	O
.	O

This	O
makes	O
the	O
cuticle	B-T204
a	O
versatile	O
material	O
ideally	O
suited	O
to	O
form	O
a	O
variety	O
of	O
skeletal	B-T082
elements	B-T103
that	O
are	O
adapted	B-T038
to	O
different	O
functions	O
and	O
the	O
eco	O
-	O
physiological	O
strains	O
of	O
individual	B-T170
species	I-T170
.	O

This	O
review	B-T170
presents	O
our	O
recent	O
analytical	O
,	O
experimental	B-T062
and	O
theoretical	B-T062
studies	I-T062
on	O
the	O
cuticle	B-T204
,	O
summarising	O
at	O
which	O
hierarchical	O
levels	O
structure	B-T082
and	O
composition	O
are	O
modified	O
to	O
achieve	O
the	O
required	O
physical	B-T201
properties	I-T201
.	O

We	O
describe	O
our	O
multi	O
-	O
scale	O
hierarchical	O
modeling	O
approach	O
based	O
on	O
the	O
results	O
from	O
these	O
studies	B-T062
,	O
aiming	O
at	O
systematically	O
predicting	O
the	O
structure	B-T082
-	O
composition	O
-	O
property	O
relations	O
of	O
cuticle	B-T204
composites	O
from	O
the	O
molecular	O
level	O
to	O
the	O
macro	O
-	O
scale	O
.	O

This	O
modeling	O
approach	O
provides	O
a	O
tool	O
to	O
facilitate	O
the	O
development	O
of	O
optimized	O
biomimetic	O
materials	O
within	O
a	O
knowledge	O
-	O
based	O
design	O
approach	O
.	O

Draft	B-T082
Genome	I-T082
Sequences	I-T082
of	O
15	O
Isolates	B-T103
of	O
Listeria	B-T007
monocytogenes	I-T007
Serotype	I-T007
1	I-T007
/	I-T007
2a	I-T007
,	O
Subgroup	B-T170
ST204	O

Listeria	B-T007
monocytogenes	I-T007
sequence	O
type	O
204	O
(	O
ST204	O
)	O
strains	O
have	O
been	O
isolated	O
from	O
a	O
range	B-T168
of	I-T168
food	I-T168
,	O
environmental	B-T082
,	O
and	O
clinical	O
sources	B-T033
in	O
Australia	B-T082
.	O

This	O
study	O
describes	O
the	O
draft	B-T082
genome	I-T082
sequences	I-T082
of	O
15	O
isolates	O
collected	O
from	O
meat	B-T168
and	O
dairy	B-T168
associated	I-T168
sources	I-T168
.	O

High	O
Transferability	O
of	O
Homoeolog	B-T038
-	I-T038
Specific	I-T038
Markers	I-T038
between	O
Bread	B-T168
Wheat	B-T168
and	O
Newly	O
Synthesized	O
Hexaploid	B-T168
Wheat	I-T168
Lines	I-T168

Bread	B-T168
wheat	B-T168
(	O
Triticum	B-T204
aestivum	I-T204
,	O
2n	O
=	O
6x	O
=	O
42	O
,	O
AABBDD	O
)	O
has	O
a	O
complex	O
allohexaploid	B-T017
genome	I-T017
,	O
which	O
makes	O
it	O
difficult	O
to	O
differentiate	O
between	O
the	O
homoeologous	B-T082
sequences	I-T082
and	O
assign	O
them	O
to	O
the	O
chromosome	B-T017
A	I-T017
,	O
B	B-T017
,	O
or	O
D	B-T017
subgenomes	B-T017
.	O

The	O
chromosome	B-T017
-	O
based	O
draft	O
genome	B-T017
sequence	B-T082
of	O
the	O
'	O
Chinese	B-T168
Spring	I-T168
'	O
common	O
wheat	B-T168
cultivar	I-T168
enables	O
the	O
large	O
-	O
scale	O
development	O
of	O
polymerase	B-T062
chain	I-T062
reaction	I-T062
(	O
PCR	B-T062
)	O
-	O
based	O
markers	B-T038
specific	O
for	O
homoeologs	O
.	O

Based	O
on	O
high	O
-	O
confidence	O
'	O
Chinese	B-T168
Spring	I-T168
'	O
genes	B-T017
with	O
known	O
functions	O
,	O
we	O
developed	O
183	O
putative	O
homoeolog	B-T038
-	I-T038
specific	I-T038
markers	I-T038
for	O
chromosomes	B-T017
4B	I-T017
and	O
7B	B-T017
.	O

These	O
markers	B-T038
were	O
used	O
in	O
PCR	B-T062
assays	I-T062
for	O
the	O
4B	B-T017
and	O
7B	B-T017
nullisomes	O
and	O
their	O
euploid	O
synthetic	B-T168
hexaploid	I-T168
wheat	I-T168
(	I-T168
SHW	I-T168
)	I-T168
line	I-T168
that	O
was	O
newly	O
generated	O
from	O
a	O
hybridization	O
between	O
Triticum	B-T204
turgidum	I-T204
(	O
AABB	O
)	O
and	O
the	O
wild	O
diploid	B-T017
species	I-T017
Aegilops	B-T204
tauschii	I-T204
(	O
DD	O
)	O
.	O

Up	O
to	O
64	O
%	O
of	O
the	O
markers	B-T038
for	O
chromosomes	B-T017
4B	I-T017
or	O
7B	B-T017
in	O
the	O
SHW	B-T168
background	O
were	O
confirmed	O
to	O
be	O
homoeolog	O
-	O
specific	O
.	O

Thus	O
,	O
these	O
markers	B-T038
were	O
highly	O
transferable	O
between	O
the	O
'	O
Chinese	B-T168
Spring	I-T168
'	O
bread	B-T168
wheat	B-T168
and	O
SHW	B-T168
lines	I-T168
.	O

Homoeolog	B-T038
-	I-T038
specific	I-T038
markers	I-T038
designed	O
using	O
genes	B-T017
with	O
known	O
functions	O
may	O
be	O
useful	O
for	O
genetic	B-T058
investigations	I-T058
involving	O
homoeologous	O
chromosome	B-T017
tracking	O
and	O
homoeolog	O
expression	B-T038
and	O
interaction	O
analyses	O
.	O

Participation	O
in	O
and	O
adherence	O
to	O
physical	O
exercise	O
after	O
completion	O
of	O
primary	B-T038
cancer	I-T038
treatment	B-T058

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
identify	B-T038
demographic	O
,	O
clinical	O
,	O
psychosocial	O
,	O
physical	O
and	O
environmental	B-T082
factors	O
that	O
are	O
associated	O
with	O
participation	O
in	O
and	O
adherence	O
to	O
a	O
combined	O
resistance	O
and	O
endurance	B-T058
exercise	I-T058
program	O
among	O
cancer	O
survivors	O
,	O
shortly	O
after	O
completion	O
of	O
primary	B-T038
cancer	I-T038
treatment	B-T058
.	O

Data	O
from	O
the	O
randomized	B-T033
controlled	O
Resistance	B-T170
and	I-T170
Endurance	I-T170
exercise	I-T170
After	I-T170
ChemoTherapy	I-T170
(	O
REACT	B-T170
)	O
study	B-T062
were	O
used	O
for	O
this	O
study	B-T062
.	O

The	O
participants	B-T098
of	O
the	O
REACT	B-T170
study	B-T062
were	O
randomly	O
allocated	O
to	O
either	O
a	O
high	B-T170
intensity	I-T170
(	O
HI	B-T170
)	O
or	O
low	O
-	O
to	O
-	O
moderate	B-T170
intensity	I-T170
(	O
LMI	O
)	O
exercise	O
program	O
.	O

Patients	O
'	O
participation	O
rate	O
was	O
defined	O
as	O
the	O
cancer	O
survivors	O
'	O
decision	O
to	O
participate	O
in	O
the	O
REACT	B-T170
study	B-T062
.	O

Exercise	O
adherence	O
reflected	B-T038
participants	B-T098
'	O
attendance	O
to	O
the	O
scheduled	O
exercise	O
sessions	O
and	O
their	O
compliance	O
to	O
the	O
prescribed	O
exercises	O
.	O

High	O
session	O
attendance	O
rates	O
were	O
defined	O
as	O
attending	O
at	O
least	O
80	O
%	O
of	O
the	O
sessions	O
.	O

High	O
compliance	O
rates	O
were	O
defined	O
as	O
performing	O
at	O
least	O
of	O
90	O
%	O
of	O
the	O
prescribed	O
exercise	O
across	O
all	O
sessions	O
.	O

Correlates	O
of	O
exercise	O
adherence	O
were	O
studied	B-T062
separately	O
for	O
HI	B-T170
and	O
LMI	O
exercise	O
.	O

Demographic	O
,	O
clinical	O
,	O
and	O
physical	O
factors	O
were	O
assessed	O
using	O
self	B-T062
-	I-T062
reported	I-T062
questionnaires	B-T170
.	O

Relevant	O
clinical	B-T170
information	I-T170
was	O
extracted	O
from	O
medical	B-T170
records	I-T170
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
were	O
applied	O
to	O
identify	B-T038
correlates	O
that	O
were	O
significantly	O
associated	O
with	O
participation	O
,	O
high	O
session	O
attendance	O
,	O
high	O
compliance	O
with	O
resistance	O
and	O
high	O
compliance	O
with	O
endurance	B-T058
exercises	I-T058
.	O

Participants	B-T098
were	O
more	O
likely	O
to	O
have	O
higher	B-T170
education	I-T170
,	O
be	O
non	B-T033
-	I-T033
smokers	I-T033
,	O
have	O
lower	O
psychological	O
distress	O
,	O
higher	O
outcome	O
expectations	O
,	O
and	O
perceive	B-T038
more	O
exercise	O
barriers	O
than	O
non	B-T098
-	I-T098
participants	I-T098
.	O

In	O
HI	B-T170
exercise	O
,	O
higher	O
self	B-T038
-	I-T038
efficacy	I-T038
was	O
significantly	O
associated	O
with	O
high	O
session	O
attendance	O
and	O
high	O
compliance	O
with	O
endurance	B-T058
exercises	I-T058
,	O
and	O
lower	O
psychological	O
distress	O
was	O
significantly	O
associated	O
with	O
high	O
compliance	O
with	O
resistance	O
exercise	O
s	O
.	O

In	O
LMI	O
exercise	O
,	O
being	O
a	O
non	B-T033
-	I-T033
smoker	I-T033
was	O
significantly	O
associated	O
with	O
high	O
compliance	O
with	O
resistance	O
exercises	O
and	O
higher	O
BMI	B-T201
was	O
significantly	O
associated	O
with	O
high	O
compliance	O
with	O
resistance	O
and	O
endurance	B-T058
exercises	I-T058
.	O

Furthermore	O
,	O
breast	O
cancer	O
survivors	O
were	O
less	O
likely	O
to	O
report	B-T058
high	O
compliance	O
with	O
resistance	O
and	O
endurance	B-T058
exercises	I-T058
in	O
LMI	O
exercise	O
compared	O
to	O
survivors	O
of	O
other	O
types	O
of	O
cancer	B-T038
.	O

The	O
discriminative	B-T038
ability	O
of	O
the	O
multivariable	O
models	B-T170
ranged	O
from	O
0	O
.	O
62	O
to	O
0	O
.	O
75	O
.	O

Several	O
demographic	O
,	O
clinical	O
and	O
psychosocial	O
factors	O
were	O
associated	O
with	O
participation	O
in	O
and	O
adherence	O
to	O
exercise	O
among	O
cancer	O
survivors	O
.	O

Psychosocial	O
factors	O
were	O
more	O
strongly	O
associated	O
with	O
adherence	O
in	O
HI	B-T170
than	O
LMI	O
exercise	O
.	O

This	O
study	B-T062
was	O
registered	B-T170
at	O
the	O
Netherlands	B-T170
Trial	I-T170
Register	I-T170
[	O
NTR2153	B-T170
]	O
on	O
the	O
5	O
(	O
th	O
)	O
of	O
January	O
2010	O
.	O

In	B-T082
situ	I-T082
stabilization	O
of	O
heavy	B-T103
metals	I-T103
in	O
multiple	O
-	O
metal	B-T103
contaminated	O
paddy	B-T204
soil	O
using	O
different	O
steel	B-T103
slag	O
-	O
based	O
silicon	B-T103
fertilizer	B-T103

Steel	B-T103
slag	O
has	O
been	O
widely	O
used	O
as	O
amendment	O
and	O
silicon	B-T103
fertilizer	B-T103
to	O
alleviate	O
the	O
mobility	B-T033
and	O
bioavailability	O
of	O
heavy	B-T103
metals	I-T103
in	O
soil	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
evaluate	B-T058
the	O
influence	O
of	O
particle	O
size	O
,	O
composition	O
,	O
and	O
application	O
rate	O
of	O
slag	O
on	O
metal	B-T103
immobilization	O
in	O
acidic	B-T103
soil	O
,	O
metals	B-T103
uptake	B-T038
by	O
rice	B-T204
and	O
rice	B-T204
growth	B-T038
.	O

The	O
results	O
indicated	O
that	O
application	O
of	O
slag	O
increased	O
soil	O
pH	O
,	O
plant	B-T204
-	O
available	O
silicon	B-T103
concentrations	O
in	O
soil	O
,	O
and	O
decreased	O
the	O
bioavailability	O
of	O
metals	B-T103
compared	O
with	O
control	O
treatment	O
,	O
whereas	O
pulverous	O
slag	O
(	O
S1	O
)	O
was	O
more	O
effective	O
than	O
granular	O
slag	O
(	O
S2	O
and	O
S3	O
)	O
.	O

The	O
acid	B-T103
-	O
extractable	O
fraction	O
of	O
Cd	B-T103
in	O
the	O
spiked	O
soil	O
was	O
significantly	O
decreased	O
with	O
application	O
of	O
S1	O
at	O
rates	O
of	O
1	O
and	O
3	O
%	O
,	O
acid	O
-	O
extractable	O
fractions	O
of	O
Cu	B-T103
and	O
Zn	B-T103
were	O
decreased	O
when	O
treated	O
at	O
3	O
%	O
.	O

Use	O
of	O
S1	O
at	O
both	O
rates	O
resulted	O
in	O
significantly	O
lower	O
Cd	B-T103
,	O
Cu	B-T103
,	O
and	O
Zn	B-T103
concentrations	O
in	O
rice	B-T204
tissues	B-T017
than	O
in	O
controls	O
by	O
82	O
.	O
6	O
-	O
92	O
.	O
9	O
,	O
88	O
.	O
4	O
-	O
95	O
.	O
6	O
,	O
and	O
67	O
.	O
4	O
-	O
81	O
.	O
4	O
%	O
,	O
respectively	O
.	O

However	O
,	O
use	O
of	O
pulverous	O
slag	O
at	O
1	O
%	O
significantly	O
promotes	O
rice	B-T204
growth	B-T038
,	O
restricted	O
rice	B-T204
growth	B-T038
when	O
treated	O
at	O
3	O
%	O
.	O

Thus	O
,	O
the	O
results	O
explained	O
that	O
reduced	O
particle	O
size	O
and	O
suitable	O
application	O
rate	O
of	O
slag	O
could	O
be	O
beneficial	O
to	O
rice	B-T204
growth	B-T038
and	O
metals	B-T103
stabilization	O
.	O

Plasmodium	B-T204
falciparum	I-T204
Choline	B-T103
Kinase	I-T103
Inhibition	O
Leads	O
to	O
a	O
Major	O
Decrease	O
in	O
Phosphatidylethanolamine	B-T103
Causing	O
Parasite	B-T204
Death	B-T038

Malaria	B-T038
is	O
a	O
life	B-T033
-	I-T033
threatening	I-T033
disease	B-T038
caused	O
by	O
different	O
species	B-T170
of	O
the	O
protozoan	B-T204
parasite	I-T204
Plasmodium	B-T204
,	O
with	O
P	B-T204
.	I-T204

falciparum	I-T204
being	O
the	O
deadliest	O
.	O

Increasing	O
parasitic	O
resistance	O
to	O
existing	O
antimalarials	B-T103
makes	O
the	O
necessity	O
of	O
novel	O
avenues	O
to	O
treat	B-T058
this	O
disease	B-T038
an	O
urgent	O
priority	O
.	O

The	O
enzymes	B-T103
responsible	O
for	O
the	O
synthesis	O
of	O
phosphatidylcholine	B-T103
and	O
phosphatidylethanolamine	B-T103
are	O
attractive	O
drug	O
targets	O
to	O
treat	B-T058
malaria	B-T038
as	O
their	O
selective	O
inhibition	O
leads	O
to	O
an	O
arrest	O
of	O
the	O
parasite	B-T204
'	I-T204
s	I-T204
growth	B-T038
and	O
cures	O
malaria	B-T038
in	O
a	O
mouse	B-T038
model	I-T038
.	O

We	O
present	O
here	O
a	O
detailed	O
study	B-T062
that	O
reveals	O
a	O
mode	O
of	O
action	O
for	O
two	O
P	B-T204
.	I-T204

falciparum	I-T204
choline	B-T103
kinase	I-T103
inhibitors	B-T103
both	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

The	O
compounds	O
present	O
distinct	O
binding	B-T038
modes	O
to	O
the	O
choline	B-T103
/	O
ethanolamine	B-T103
-	O
binding	B-T103
site	I-T103
of	O
P	B-T204
.	I-T204

falciparum	I-T204
choline	B-T103
kinase	I-T103
,	O
reflecting	O
different	O
types	O
of	O
inhibition	O
.	O

Strikingly	O
,	O
these	O
compounds	O
primarily	O
inhibit	O
the	O
ethanolamine	B-T038
kinase	I-T038
activity	I-T038
of	O
the	O
P	B-T204
.	I-T204

falciparum	I-T204
choline	B-T103
kinase	I-T103
,	O
leading	O
to	O
a	O
severe	O
decrease	O
in	O
the	O
phosphatidylethanolamine	B-T103
levels	O
within	O
P	B-T204
.	I-T204

falciparum	I-T204
,	O
which	O
explains	O
the	O
resulting	O
growth	O
phenotype	O
and	O
the	O
parasites	B-T204
death	B-T038
.	O

These	O
studies	O
provide	O
an	O
understanding	O
of	O
the	O
mode	O
of	O
action	O
,	O
and	O
act	O
as	O
a	O
springboard	O
for	O
continued	O
antimalarial	B-T038
development	I-T038
efforts	O
selectively	O
targeting	O
P	B-T204
.	I-T204

falciparum	I-T204
choline	B-T103
kinase	I-T103
.	O

Anti	B-T103
-	I-T103
CD45RB	I-T103
and	O
donor	O
-	O
specific	O
spleen	O
cells	O
transfusion	O
inhibition	O
allograft	B-T038
skin	I-T038
rejection	I-T038
mediated	O
by	O
memory	B-T017
T	I-T017
cells	I-T017

Donor	O
-	O
reactive	O
memory	B-T017
T	I-T017
(	I-T017
Tm	I-T017
)	I-T017
cells	I-T017
mediate	O
accelerated	O
rejection	B-T038
,	O
which	O
is	O
known	O
as	O
a	O
barrier	O
to	O
the	O
survival	O
of	O
transplanted	B-T017
organs	I-T017
.	O

Selective	O
interference	O
with	O
the	O
anti	B-T103
-	I-T103
CD45RB	I-T103
monoclonal	I-T103
antibody	I-T103
(	I-T103
α	I-T103
-	I-T103
CD45RB	I-T103
)	I-T103
reliably	O
induces	O
donor	B-T098
-	O
specific	O
tolerance	B-T038
.	O

In	O
this	O
study	B-T062
,	O
pre	O
-	O
sensitization	O
to	O
female	O
C57BL	B-T204
/	I-T204
6	I-T204
mice	I-T204
with	O
the	O
skin	B-T022
of	O
female	O
BLAB	B-T204
/	I-T204
c	I-T204
mice	I-T204
generated	O
a	O
large	O
number	O
of	O
Tm	B-T017
cells	I-T017
and	O
resulted	O
in	O
rapid	O
rejection	B-T038
of	O
the	O
secondly	O
transplanted	O
allografts	B-T103
.	O

α	B-T103
-	I-T103
CD45RB	I-T103
did	O
induce	O
the	O
tolerance	B-T038
to	O
skin	B-T103
allograft	I-T103
primarily	O
transplanted	O
but	O
failed	O
to	O
induce	O
tolerance	B-T038
in	O
the	O
pre	B-T204
-	I-T204
sensitized	I-T204
mice	I-T204
.	O

Donor	O
-	O
specific	O
spleen	O
cell	O
transfusion	O
(	O
DST	O
)	O
alone	O
also	O
failed	O
to	O
induce	O
the	O
tolerance	B-T038
in	O
the	O
pre	O
-	O
sensitized	O
recipients	O
.	O

Interestingly	O
,	O
combination	O
of	O
α	B-T103
-	I-T103
CD45RB	I-T103
with	O
DST	O
inhibited	O
the	O
rejection	B-T038
induced	O
by	O
memory	B-T017
T	I-T017
cells	I-T017
in	O
the	O
pre	B-T204
-	I-T204
sensitized	I-T204
mice	I-T204
.	O

CD25	B-T017
+	I-T017
T	I-T017
-	I-T017
cell	I-T017
depletion	B-T058
in	O
α	B-T103
-	I-T103
CD45RB	I-T103
combined	O
with	O
DST	O
therapy	B-T058
recipients	O
could	O
prevent	O
skin	B-T103
allograft	I-T103
tolerance	B-T038
from	O
establishing	O
.	O

In	O
addition	O
,	O
adoptive	B-T058
transfer	I-T058
of	O
donor	B-T098
-	O
primed	O
memory	B-T017
T	I-T017
cells	I-T017
into	O
the	O
tolerant	B-T038
recipients	O
markedly	O
broke	O
the	O
established	O
tolerance	B-T038
.	O

Our	O
findings	B-T033
indicate	O
that	O
α	B-T103
-	I-T103
CD45RB	I-T103
and	O
DST	O
can	O
synergistically	O
inhibit	O
the	O
accelerated	O
rejection	B-T038
mediated	O
by	O
memory	B-T017
T	I-T017
cells	I-T017
and	O
induce	O
long	O
-	O
term	O
skin	B-T103
allograft	I-T103
acceptance	B-T038
in	O
mice	B-T204
.	O

Recruitment	O
of	O
Minority	B-T098
Adolescents	O
and	O
Young	O
Adults	O
into	O
Randomised	B-T062
Clinical	I-T062
Trials	I-T062
:	O
Testing	O
the	O
Design	O
of	O
the	O
Technology	B-T058
Enhanced	I-T058
Community	I-T058
Health	I-T058
Nursing	I-T058
(	O
TECH	B-T058
-	I-T058
N	I-T058
)	O
Pelvic	B-T038
Inflammatory	I-T038
Disease	I-T038
Trial	O

Pelvic	B-T038
inflammatory	I-T038
disease	I-T038
(	O
PID	B-T038
)	O
disproportionately	O
affects	O
adolescent	O
and	O
young	O
adult	O
(	O
AYA	O
)	O
women	B-T098
and	O
can	O
negatively	O
influence	O
reproductive	B-T091
health	I-T091
trajectories	O
.	O

Few	O
randomized	B-T062
controlled	I-T062
trials	I-T062
(	O
RCTs	B-T062
)	O
have	O
focused	O
on	O
strategies	O
to	O
improve	B-T033
outpatient	O
adherence	O
or	O
to	O
reduce	O
reproductive	B-T038
morbidity	O
in	O
this	O
population	B-T098
.	O

This	O
paper	O
describes	O
the	O
research	B-T062
methods	I-T062
and	O
preliminary	O
effectiveness	O
of	O
recruitment	O
,	O
retention	O
,	O
and	O
intervention	B-T058
strategies	O
employed	O
in	O
a	O
novel	O
RCT	B-T062
designed	O
to	O
test	O
a	O
technology	B-T058
-	I-T058
enhanced	I-T058
community	I-T058
-	I-T058
health	I-T058
nursing	I-T058
(	O
TECH	B-T058
-	I-T058
N	I-T058
)	O
intervention	B-T058
among	O
urban	O
AYA	O
with	O
PID	B-T038
.	O

AYA	O
women	B-T098
aged	O
13	O
-	O
25	O
years	O
were	O
recruited	O
during	O
acute	B-T038
PID	I-T038
visits	B-T058
in	O
outpatient	B-T092
clinics	I-T092
and	O
emergency	B-T092
departments	I-T092
(	O
ED	B-T092
)	O
to	O
participate	B-T058
in	O
this	O
IRB	B-T170
-	I-T170
approved	I-T170
trial	O
.	O

Participants	B-T098
completed	O
an	O
audio	O
-	O
computerized	O
self	O
-	O
interview	O
(	O
ACASI	O
)	O
,	O
provided	O
vaginal	B-T017
specimens	I-T017
,	O
and	O
were	O
randomized	B-T062
to	O
standard	O
treatment	B-T058
or	O
the	O
intervention	B-T058
.	O

Intervention	B-T058
participants	B-T098
received	O
text	O
-	O
messaging	O
support	O
for	O
30	O
days	O
and	O
a	O
community	B-T097
health	I-T097
nurse	I-T097
(	I-T097
CHN	I-T097
)	I-T097
interventionist	I-T097
performed	O
a	O
home	O
visit	O
with	O
clinical	O
assessment	O
within	O
5	O
days	O
after	O
enrollment	B-T058
.	O

All	O
patients	O
received	O
a	O
full	O
course	O
of	O
medications	O
and	O
completed	O
research	O
visits	O
at	O
14	O
-	O
days	O
(	O
adherence	O
)	O
,	O
30	O
days	O
and	O
90	O
days	O
with	O
by	O
an	O
outreach	B-T097
worker	I-T097
.	O

STI	B-T038
testing	O
performed	O
at	O
the	O
30	O
-	O
and	O
90	O
-	O
day	O
visits	B-T058
.	O

Exploratory	B-T062
analyses	I-T062
using	O
descriptive	B-T062
statistics	I-T062
were	O
conducted	O
to	O
examine	O
recruitment	O
,	O
retention	O
,	O
and	O
follow	B-T058
-	I-T058
up	I-T058
data	O
to	O
test	O
the	O
overall	O
design	O
of	O
the	O
intervention	B-T058
.	O

In	O
the	O
first	O
48	O
months	O
,	O
64	O
%	O
of	O
463	O
patients	O
were	O
eligible	O
for	O
the	O
study	O
and	O
81	O
.	O
2	O
%	O
of	O
293	O
eligible	O
patients	O
were	O
recruited	O
for	O
the	O
study	O
(	O
63	O
.	O
3	O
%	O
)	O
;	O
238	O
(	O
81	O
.	O
2	O
%	O
)	O
of	O
eligible	O
patients	O
were	O
enrolled	B-T058
.	O

Most	O
participants	B-T098
were	O
African	B-T098
American	I-T098
(	O
95	O
.	O
6	O
%	O
)	O
with	O
a	O
mean	O
age	O
of	O
18	O
.	O
6	O
(	O
2	O
.	O
3	O
)	O
.	O

Ninety	O
-	O
four	O
percent	O
of	O
individuals	B-T098
assigned	O
to	O
the	O
TECH	B-T058
-	I-T058
N	I-T058
intervention	I-T058
completed	O
the	O
nursing	O
visits	O
.	O

All	O
completed	O
visits	O
have	O
been	O
within	O
the	O
5	O
-	O
day	O
window	O
and	O
over	O
90	O
%	O
of	O
patients	O
in	O
both	O
arms	O
have	O
been	O
retained	O
over	O
the	O
3	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
period	O
.	O

Biological	O
data	O
suggests	O
a	O
shift	O
in	O
the	O
biological	O
milieu	O
with	O
the	O
predominance	O
of	O
Chlamydia	B-T038
trachomatis	I-T038
,	O
Mycoplasma	B-T038
genitalium	I-T038
,	O
and	O
Trichomonas	B-T038
vaginalis	I-T038
infections	I-T038
.	O

Preliminary	O
data	O
from	O
the	O
TECH	B-T058
-	I-T058
N	I-T058
study	O
demonstrated	O
that	O
urban	B-T082
,	O
low	B-T033
-	I-T033
income	I-T033
,	O
minority	B-T098
AYA	O
with	O
PID	B-T038
can	O
effectively	O
be	O
recruited	O
and	O
retained	O
to	O
participate	B-T058
in	O
sexual	O
and	O
reproductive	B-T091
health	I-T091
RCTs	B-T062
with	O
sufficient	O
investment	O
in	O
the	O
design	O
and	O
infrastructure	B-T170
of	I-T170
the	I-T170
study	I-T170
.	O

Community	O
-	O
based	O
sexual	O
health	O
interventions	B-T058
appear	O
to	O
be	O
both	O
feasible	O
and	O
acceptable	O
in	O
this	O
population	B-T098
.	O

Extended	O
use	O
of	O
Prostate	B-T058
Health	I-T058
Index	I-T058
and	O
percentage	O
of	O
[	B-T103
-	I-T103
2	I-T103
]	I-T103
pro	I-T103
-	I-T103
prostate	I-T103
-	I-T103
specific	I-T103
antigen	I-T103
in	O
Chinese	B-T098
men	B-T098
with	O
prostate	B-T103
specific	I-T103
antigen	I-T103
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B-T058
rectal	I-T058
examination	I-T058

We	O
investigated	O
the	O
extended	O
use	O
of	O
Prostate	B-T058
Health	I-T058
Index	I-T058
(	O
PHI	B-T058
)	O
and	O
percentage	O
of	O
[	B-T103
-	I-T103
2	I-T103
]	I-T103
pro	I-T103
-	I-T103
prostate	I-T103
-	I-T103
specific	I-T103
antigen	I-T103
(	O
%	B-T103
p2PSA	I-T103
)	O
in	O
Chinese	B-T098
men	B-T098
with	O
prostate	B-T103
-	I-T103
specific	I-T103
antigen	I-T103
(	O
PSA	B-T103
)	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
digital	B-T058
rectal	I-T058
examination	I-T058
(	O
DRE	B-T058
)	O
.	O

All	O
consecutive	O
Chinese	B-T098
men	B-T098
with	O
PSA	B-T103
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
DRE	B-T058
who	O
agreed	O
for	O
transrectal	B-T058
ultrasound	I-T058
(	O
TRUS	B-T058
)	O
-	O
guided	O
10	O
-	O
core	O
prostate	B-T058
biopsy	I-T058
were	O
recruited	O
.	O

Blood	B-T031
samples	I-T031
were	O
taken	O
immediately	O
before	O
TRUS	B-T058
-	O
guided	O
prostate	B-T058
biopsy	I-T058
.	O

The	O
performances	O
of	O
total	B-T058
PSA	I-T058
(	O
tPSA	B-T058
)	O
,	O
%	O
free	O
-	O
to	O
-	O
total	O
PSA	O
(	O
%	O
fPSA	O
)	O
,	O
%	B-T103
p2PSA	I-T103
,	O
and	O
PHI	B-T058
were	O
compared	O
using	O
logistic	B-T062
regression	I-T062
,	O
receiver	O
operating	O
characteristic	O
,	O
and	O
decision	B-T062
curve	I-T062
analyses	I-T062
(	O
DCA	B-T062
)	O
.	O

From	O
2008	O
to	O
2015	O
,	O
312	O
consecutive	O
Chinese	B-T098
men	B-T098
were	O
included	O
.	O

Among	O
them	O
,	O
53	O
out	O
of	O
312	O
(	O
17	O
.	O
0	O
%	O
)	O
men	B-T098
were	O
diagnosed	B-T033
to	O
have	O
prostate	B-T038
cancer	I-T038
on	O
biopsy	B-T058
.	O

The	O
proportions	O
of	O
men	B-T098
with	O
positive	B-T033
biopsies	B-T058
were	O
6	O
.	O
7	O
%	O
in	O
PHI	B-T058
<	O
35	O
,	O
22	O
.	O
8	O
%	O
in	O
PHI	B-T058
35	O
-	O
55	O
,	O
and	O
54	O
.	O
5	O
%	O
in	O
PHI	B-T058
>	O
55	O
(	O
chi	B-T170
-	I-T170
square	I-T170
test	I-T170
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
area	O
under	O
curves	O
(	O
AUC	O
)	O
of	O
the	O
base	B-T170
model	I-T170
including	O
age	O
,	O
tPSA	B-T058
and	O
status	O
of	O
initial	O
/	O
repeated	O
biopsy	B-T058
was	O
0	O
.	O
64	O
.	O

Adding	O
%	B-T103
p2PSA	I-T103
and	O
PHI	B-T058
to	O
the	O
base	B-T170
model	I-T170
improved	B-T033
the	O
AUC	O
to	O
0	O
.	O
79	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
0	O
.	O
78	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
respectively	O
,	O
and	O
provided	O
net	O
clinical	O
benefit	O
in	O
DCA	B-T062
.	O

The	O
positive	B-T033
biopsy	B-T058
rates	O
of	O
Gleason	B-T170
7	I-T170
or	I-T170
above	I-T170
prostate	B-T038
cancers	I-T038
were	O
2	O
.	O
2	O
%	O
for	O
PHI	B-T058
<	O
35	O
,	O
7	O
.	O
9	O
%	O
for	O
PHI	B-T058
35	O
-	O
55	O
,	O
and	O
36	O
.	O
4	O
%	O
for	O
PHI	B-T058
>	O
55	O
(	O
chi	B-T170
-	I-T170
square	I-T170
test	I-T170
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

By	O
utilizing	O
the	O
PHI	B-T058
cutoff	O
of	O
35	O
to	O
men	B-T098
with	O
PSA	B-T103
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
DRE	B-T058
,	O
57	O
.	O
1	O
%	O
(	O
178	O
of	O
312	O
)	O
biopsies	B-T058
could	O
be	O
avoided	O
.	O

Both	O
PHI	B-T058
and	O
%	B-T103
p2PSA	I-T103
performed	O
well	O
in	O
predicting	O
prostate	B-T038
cancer	I-T038
and	O
high	B-T038
grade	I-T038
prostate	I-T038
cancer	I-T038
.	O

The	O
use	O
of	O
PHI	B-T058
and	O
%	B-T103
p2PSA	I-T103
should	O
be	O
extended	O
to	O
Chinese	B-T098
men	B-T098
with	O
PSA	O
10	O
-	O
20	O
ng	O
/	O
mL	O
and	O
normal	O
DRE	B-T058
.	O

A	O
pilot	B-T062
study	I-T062
exploring	O
the	O
relationship	O
between	O
self	O
-	O
compassion	O
,	O
self	O
-	O
judgement	B-T038
,	O
self	O
-	O
kindness	B-T038
,	O
compassion	O
,	O
professional	O
quality	O
of	O
life	O
and	O
wellbeing	B-T033
among	O
UK	B-T082
community	B-T097
nurses	I-T097

Compassion	B-T038
fatigue	I-T038
and	O
burnout	B-T038
can	O
impact	O
on	O
performance	O
of	O
nurses	B-T097
.	O

This	O
paper	O
explores	O
the	O
relationship	O
between	O
self	O
-	O
compassion	O
,	O
self	O
-	O
judgement	B-T038
,	O
self	O
-	O
kindness	B-T038
,	O
compassion	O
,	O
professional	O
quality	O
of	O
life	O
,	O
and	O
wellbeing	B-T033
among	O
community	B-T097
nurses	I-T097
.	O

To	O
measure	O
associations	O
between	O
self	O
-	O
compassion	O
,	O
compassion	B-T038
fatigue	I-T038
,	O
wellbeing	B-T033
,	O
and	O
burnout	B-T038
in	O
community	B-T097
nurses	I-T097
.	O

Quantitative	O
data	O
were	O
collected	O
using	O
standardised	O
psychometric	B-T170
questionnaires	I-T170
:	O
(	O
1	O
)	O
Professional	B-T170
Quality	I-T170
of	I-T170
Life	I-T170
Scale	I-T170
;	O
(	O
2	O
)	O
Self	O
-	O
Compassion	O
Scale	O
;	O
(	O
3	O
)	O
short	B-T170
Warwick	I-T170
Edinburgh	I-T170
Mental	I-T170
Wellbeing	I-T170
Scale	I-T170
;	O
(	O
4	O
)	O
Compassion	O
For	O
Others	O
Scale	O
,	O
used	O
to	O
measure	O
relationships	O
between	O
self	O
-	O
compassion	O
,	O
compassion	B-T038
fatigue	I-T038
,	O
wellbeing	B-T033
,	O
and	O
burnout	B-T038
.	O

A	O
cross	B-T062
sectional	I-T062
sample	O
of	O
registered	B-T097
community	I-T097
nurses	I-T097
(	O
n	O
=	O
37	O
)	O
studying	O
for	O
a	O
postgraduate	O
diploma	O
at	O
a	O
University	B-T092
in	O
the	O
North	B-T082
of	I-T082
England	I-T082
took	O
part	O
in	O
this	O
study	B-T062
.	O

Results	O
show	O
that	O
community	B-T097
nurses	I-T097
who	O
score	O
high	O
on	O
measures	O
of	O
self	O
-	O
compassion	O
and	O
wellbeing	B-T033
,	O
also	O
report	O
less	O
burnout	B-T038
.	O

Greater	O
compassion	O
satisfaction	B-T038
was	O
also	O
positively	B-T033
associated	O
with	O
compassion	O
for	O
others	O
,	O
and	O
wellbeing	B-T033
,	O
whilst	O
also	O
being	O
negatively	B-T033
correlated	O
with	O
burnout	B-T038
.	O

High	O
levels	O
of	O
self	O
-	O
compassion	O
were	O
linked	O
with	O
lower	O
levels	O
of	O
burnout	B-T038
.	O

Furthermore	O
when	O
community	B-T097
nurses	I-T097
have	O
greater	O
compassion	O
satisfaction	B-T038
they	O
also	O
report	O
more	O
compassion	O
for	O
others	O
,	O
increased	O
wellbeing	B-T033
,	O
and	O
less	O
burnout	B-T038
.	O

The	O
implications	O
of	O
this	O
are	O
discussed	O
alongside	O
suggestions	O
for	O
the	O
promotion	O
of	O
greater	O
compassion	O

CD169	B-T103
identifies	B-T033
an	O
activated	B-T017
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
subset	B-T170
in	O
regional	B-T017
lymph	I-T017
nodes	I-T017
that	O
predicts	O
favorable	O
prognosis	B-T058
in	O
colorectal	B-T038
cancer	I-T038
patients	O

CD169	B-T103
was	O
first	O
identified	O
on	O
macrophages	B-T017
(	O
Mϕ	B-T017
)	O
and	O
linked	O
to	O
antigen	B-T038
presentation	I-T038
.	O

Here	O
,	O
we	O
showed	O
CD169	B-T038
expression	I-T038
on	O
some	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
lymphocytes	I-T017
in	O
regional	B-T017
lymph	I-T017
nodes	I-T017
(	O
LNs	B-T017
)	O
and	O
investigated	O
the	O
function	B-T038
and	O
clinical	B-T033
relevance	I-T033
of	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
in	O
tumor	B-T017
-	I-T017
draining	I-T017
LNs	I-T017
of	O
colorectal	B-T038
cancer	I-T038
(	O
CRC	B-T038
)	O
patients	O
.	O

Fresh	B-T017
tumor	I-T017
-	I-T017
draining	I-T017
LN	I-T017
tissues	I-T017
from	O
39	O
randomly	O
enrolled	O
patients	O
were	O
assessed	O
by	O
flow	B-T058
cytometry	I-T058
for	O
activation	O
and	O
differentiation	B-T038
of	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
and	O
T	B-T038
cell	I-T038
-	I-T038
mediated	I-T038
killing	I-T038
of	I-T038
tumor	I-T038
cells	I-T038
.	O

In	O
total	O
,	O
114	O
tumor	B-T017
-	I-T017
draining	I-T017
LN	I-T017
paraffin	O
sections	O
from	O
CRC	B-T038
patients	O
were	O
analyzed	O
by	O
multiple	B-T058
-	I-T058
color	I-T058
immunofluorescence	I-T058
for	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
distribution	O
and	O
clinical	O
values	O
.	O

The	O
prognostic	B-T170
significance	O
of	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
was	O
evaluated	B-T058
by	O
Kaplan	O
-	O
Meier	O
analysis	O
.	O

A	O
fraction	O
of	O
CD8	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
in	O
regional	B-T017
LNs	I-T017
,	O
but	O
not	O
peripheral	B-T031
blood	I-T031
,	O
tonsils	B-T017
,	O
or	O
tumors	B-T038
,	O
expressed	B-T103
surface	I-T103
CD169	I-T103
.	O

In	B-T082
situ	I-T082
detection	B-T058
of	O
draining	B-T017
LNs	I-T017
revealed	O
preferential	O
localization	O
of	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
to	O
subcapsular	B-T017
sinus	I-T017
and	O
interfollicular	B-T082
regions	I-T082
,	O
closely	O
associated	O
with	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
Mϕ	I-T017
.	O

CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
ratios	O
were	O
significantly	O
lower	O
in	O
peri	O
-	O
tumor	O
LNs	B-T017
than	O
distant	O
-	O
tumor	O
LNs	B-T017
.	O

CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
predominantly	O
expressed	O
activation	B-T201
markers	I-T201
(	O
CD69	B-T103
,	O
HLA	B-T103
-	I-T103
DR	I-T103
,	O
PD	B-T103
-	I-T103
1	I-T103
)	O
with	O
slightly	O
lower	O
CD45RA	B-T103
and	O
CD62L	B-T103
levels	O
.	O

They	O
produced	O
high	O
granzyme	B-T103
B	I-T103
,	O
perforin	B-T103
,	O
TNF	B-T103
-	I-T103
α	I-T103
,	O
and	O
IFNγ	B-T103
levels	O
,	O
and	O
promoted	O
tumor	B-T058
-	I-T058
killing	I-T058
efficiency	I-T058
ex	O
vitro	O
.	O

Moreover	O
,	O
CD169	B-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
infiltrating	B-T038
tumor	B-T017
-	I-T017
draining	I-T017
LNs	I-T017
decreased	O
with	O
disease	B-T038
progression	I-T038
and	O
were	O
strongly	O
associated	O
with	O
CRC	B-T038
patient	O
survival	O
.	O

We	O
identified	O
novel	O
activated	O
/	O
cytolytic	B-T017
CD169	I-T017
(	I-T017
+	I-T017
)	I-T017
CD8	I-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
selectively	O
present	O
in	O
regional	B-T017
LNs	I-T017
,	O
potentially	O
serving	O
as	O
a	O
powerful	O
prognostic	B-T201
factor	I-T201
and	O
indicator	O
for	O
selecting	O
patients	O
for	O
immunotherapy	B-T058
.	O

Appearance	O
Differences	O
Between	O
Lots	B-T170
and	O
Brands	B-T170
of	O
Similar	O
Shade	O
Designations	B-T170
of	O
Dental	B-T103
Composite	I-T103
Resins	I-T103

The	O
purposes	O
of	O
this	O
study	B-T062
were	O
to	O
investigate	O
differences	O
in	O
two	O
inherent	O
appearance	O
characteristics	O
between	O
lots	B-T170
of	O
an	O
enamel	B-T103
dental	I-T103
composite	I-T103
resin	I-T103
of	O
the	O
same	O
shade	O
and	O
brand	B-T170
,	O
and	O
to	O
further	O
compare	O
these	O
differences	O
to	O
those	O
of	O
similar	O
shade	O
designation	B-T170
of	O
a	O
different	O
brand	B-T170
of	O
dental	B-T103
composite	I-T103
resins	I-T103
.	O

Appearance	O
analyses	B-T062
proceeded	O
for	O
three	O
different	O
lots	B-T170
of	O
shades	O
A1	B-T170
,	O
B2	B-T170
,	O
and	O
D3	B-T170
manufactured	O
by	O
one	O
company	B-T092
and	O
for	O
one	O
lot	B-T170
of	O
shade	O
EA1	B-T170
manufactured	O
by	O
another	O
.	O

Samples	O
were	O
measured	O
on	O
black	O
,	O
white	O
,	O
and	O
gray	O
backings	O
using	O
spectroradiometry	B-T058
.	O

Kubelka	O
-	O
Munk	O
theory	O
was	O
used	O
to	O
determine	O
reflectivity	O
of	O
each	O
lot	B-T170
studied	B-T062
.	O

CIELAB	O
values	O
and	O
color	O
differences	O
between	O
shades	O
and	O
lots	B-T170
were	O
analyzed	B-T062
.	O

Translucency	O
indicators	B-T103
were	O
compared	O
between	O
lots	B-T170
over	O
thicknesses	O
from	O
0	O
.	O
5	O
to	O
3	O
.	O
0	O
mm	O
.	O

Differences	O
in	O
inherent	O
color	O
between	O
some	O
lots	B-T170
of	O
same	O
shade	O
designations	B-T170
within	O
a	O
brand	B-T170
were	O
found	O
to	O
be	O
above	O
the	O
acceptability	O
threshold	O
.	O

Color	O
difference	O
between	O
an	O
enamel	B-T103
composite	I-T103
resin	I-T103
of	O
shade	O
A1	B-T170
and	O
a	O
composite	B-T103
resin	I-T103
of	O
shade	O
EA1	B-T170
was	O
also	O
above	O
the	O
acceptability	O
threshold	O
.	O

Statistically	O
significant	O
differences	O
in	O
the	O
translucency	O
were	O
found	O
between	O
some	O
lots	B-T170
of	O
one	O
shade	O
over	O
the	O
entire	O
range	O
of	O
thicknesses	O
studied	B-T062
.	O

Appearance	O
analyses	B-T062
indicate	O
substantial	O
variation	O
between	O
lots	B-T170
of	O
same	O
shade	O
designations	B-T170
as	O
well	O
as	O
between	O
brands	B-T170
of	O
similar	O
shade	O
designations	B-T170
.	O

Optical	O
principles	O
applied	O
to	O
important	O
clinical	O
appearance	O
attributes	O
are	O
described	O
which	O
characterize	O
inherent	O
appearance	O
attributes	O
and	O
provide	O
aid	O
in	O
the	O
appearance	O
matching	O
process	O
for	O
dental	B-T103
composite	I-T103
resins	I-T103
used	O
in	O
restorative	B-T058
and	O
operative	B-T058
dental	I-T058
procedures	I-T058
.	O

(	O
J	O
Esthet	O
Restor	O
Dent	O
29	O
:	O
E6	O
-	O
E14	O
,	O
2017	O
)	O
.	O

Patient	O
Preferences	O
in	O
Treatment	B-T058
Choices	O
for	O
Early	O
-	O
Stage	O
Lung	B-T038
Cancer	I-T038

Decision	B-T038
-	I-T038
making	I-T038
for	O
lung	B-T038
cancer	I-T038
treatment	B-T058
can	O
be	O
complex	O
because	O
it	O
involves	O
both	O
provider	B-T097
recommendations	O
based	O
on	O
the	O
patient	O
'	O
s	O
clinical	O
condition	O
and	O
patient	O
preferences	O
.	O

This	O
study	B-T062
describes	O
the	O
relative	O
importance	O
of	O
several	O
considerations	B-T033
in	O
lung	B-T038
cancer	I-T038
treatment	B-T058
from	O
the	O
patient	O
'	O
s	O
perspective	O
.	O

A	O
conjoint	B-T062
preference	I-T062
experiment	I-T062
began	O
by	O
asking	O
respondents	B-T098
to	O
imagine	O
that	O
they	O
had	O
just	O
been	O
diagnosed	B-T033
with	O
lung	B-T038
cancer	I-T038
.	O

Respondents	B-T098
then	O
chose	O
among	O
procedures	B-T058
that	O
differed	O
regarding	O
treatment	B-T058
modalities	O
,	O
the	O
potential	O
for	O
treatment	B-T058
-	O
related	O
complications	B-T038
,	O
the	O
likelihood	O
of	O
recurrence	O
,	O
provider	B-T097
case	O
volume	O
,	O
and	O
distance	O
needed	O
to	O
travel	O
for	O
treatment	B-T058
.	O

Conjoint	B-T062
analysis	I-T062
derived	O
relative	O
weights	O
for	O
these	O
attributes	O
.	O

A	O
total	O
of	O
225	O
responses	B-T170
were	O
analyzed	B-T062
.	O

Respondents	B-T098
were	O
most	O
willing	O
to	O
accept	O
minimally	O
invasive	B-T058
operations	I-T058
for	O
treatment	B-T058
of	O
their	O
hypothetical	O
lung	B-T038
cancer	I-T038
,	O
followed	O
by	O
stereotactic	B-T058
body	I-T058
radiation	I-T058
therapy	I-T058
(	O
SBRT	B-T058
)	O
;	O
they	O
were	O
least	O
willing	O
to	O
accept	O
thoracotomy	B-T058
.	O

Treatment	B-T058
type	O
and	O
risk	O
of	O
recurrence	O
were	O
the	O
most	O
important	O
attributes	O
from	O
the	O
conjoint	B-T062
experiment	I-T062
(	O
each	O
with	O
a	O
relative	O
weight	O
of	O
0	O
.	O
23	O
)	O
,	O
followed	O
by	O
provider	B-T097
volume	O
(	O
relative	O
weight	O
of	O
0	O
.	O
21	O
)	O
,	O
risk	O
of	O
major	O
complications	B-T038
(	O
relative	O
weight	O
of	O
0	O
.	O
18	O
)	O
,	O
and	O
distance	O
needed	O
to	O
travel	O
for	O
treatment	B-T058
(	O
relative	O
weight	O
of	O
0	O
.	O
15	O
)	O
.	O

Procedural	B-T058
and	O
treatment	B-T058
preferences	O
did	O
not	O
vary	O
with	O
demographics	O
,	O
self	B-T062
-	I-T062
reported	I-T062
health	O
status	O
,	O
or	O
familiarity	B-T038
with	O
the	O
procedures	B-T058
.	O

Survey	B-T170
respondents	B-T098
preferred	O
minimally	O
invasive	B-T058
operations	I-T058
over	O
SBRT	B-T058
or	O
thoracotomy	B-T058
for	O
treatment	B-T058
of	O
early	O
-	O
stage	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
.	O

Treatment	B-T058
modality	O
and	O
risk	O
of	O
cancer	O
recurrence	O
were	O
the	O
most	O
important	O
factors	O
associated	O
with	O
treatment	B-T058
preferences	O
.	O

Provider	B-T097
experience	B-T038
outweighed	O
the	O
potential	O
need	O
to	O
travel	O
for	O
lung	B-T038
cancer	I-T038
treatment	B-T058
.	O

Suppressed	O
translation	B-T038
and	O
ULK1	B-T103
degradation	B-T038
as	O
potential	O
mechanisms	O
of	O
autophagy	B-T038
limitation	O
under	O
prolonged	O
starvation	B-T033

Macroautophagy	B-T038
/	O
autophagy	B-T038
is	O
a	O
well	O
-	O
organized	O
process	O
of	O
intracellular	B-T038
degradation	I-T038
,	O
which	O
is	O
rapidly	O
activated	O
under	O
starvation	B-T033
conditions	O
.	O

Recent	O
data	O
demonstrate	O
a	O
transcriptional	B-T038
upregulation	B-T038
of	O
several	O
autophagy	B-T038
genes	B-T017
as	O
a	O
mechanism	O
that	O
controls	O
autophagy	B-T038
in	O
response	O
to	O
starvation	B-T033
.	O

Here	O
we	O
report	O
that	O
despite	O
the	O
significant	O
upregulation	B-T038
of	O
mRNA	B-T103
of	O
the	O
essential	O
autophagy	B-T038
initiation	B-T017
gene	I-T017
ULK1	B-T017
,	O
its	O
protein	B-T103
level	O
is	O
rapidly	O
reduced	O
under	O
starvation	B-T033
.	O

Although	O
both	O
autophagic	B-T038
and	O
proteasomal	B-T103
systems	I-T103
contribute	O
to	O
the	O
degradation	B-T038
of	O
ULK1	B-T103
,	O
under	O
prolonged	O
nitrogen	B-T103
deprivation	O
,	O
its	O
level	O
was	O
still	O
reduced	O
in	O
ATG7	B-T017
knockout	B-T017
cells	I-T017
,	O
and	O
only	O
initially	O
stabilized	O
in	O
cells	B-T017
treated	O
with	O
the	O
lysosomal	B-T017
or	O
proteasomal	B-T103
inhibitors	I-T103
.	O

We	O
demonstrate	O
that	O
under	O
starvation	B-T033
,	O
protein	B-T038
translation	I-T038
is	O
rapidly	O
diminished	O
and	O
,	O
similar	O
to	O
treatments	B-T058
with	O
the	O
proteosynthesis	B-T103
inhibitors	I-T103
cycloheximide	B-T103
or	O
anisomycin	B-T103
,	O
is	O
associated	O
with	O
a	O
significant	O
reduction	O
of	O
ULK1	B-T103
.	O

Furthermore	O
,	O
it	O
was	O
found	O
that	O
inhibition	O
of	O
the	O
mitochondrial	B-T017
respiratory	B-T017
complexes	I-T017
or	O
the	O
mitochondrial	B-T017
ATP	B-T038
synthase	I-T038
function	I-T038
that	O
could	O
also	O
take	O
place	O
in	O
the	O
absence	O
of	O
substrates	O
,	O
promote	O
upregulation	B-T038
of	O
ULK1	B-T103
mRNA	I-T103
and	O
protein	B-T038
expression	I-T038
in	O
an	O
AMPK	B-T103
-	O
dependent	O
manner	O
in	O
U1810	B-T017
lung	I-T017
cancer	I-T017
cells	I-T017
growing	O
in	O
complete	O
culture	B-T103
medium	I-T103
.	O

These	O
inhibitors	O
could	O
also	O
drastically	O
increase	O
the	O
ULK1	B-T103
protein	I-T103
in	O
U1810	B-T017
cells	I-T017
with	O
knockout	O
of	O
ATG13	B-T017
,	O
where	O
the	O
ULK1	B-T103
expression	B-T038
is	O
significantly	O
diminished	O
.	O

However	O
,	O
such	O
upregulation	B-T038
of	O
ULK1	B-T103
protein	I-T103
is	O
negligible	O
under	O
starvation	B-T033
conditions	O
,	O
further	O
signifying	O
the	O
contribution	O
of	O
translation	B-T038
and	O
suggesting	O
that	O
transcriptional	B-T038
upregulation	B-T038
of	O
ULK1	B-T103
protein	I-T103
will	O
be	O
diminished	O
under	O
such	O
conditions	O
.	O

Thus	O
,	O
we	O
propose	O
a	O
model	O
where	O
inhibition	O
of	O
protein	B-T038
translation	I-T038
,	O
together	O
with	O
the	O
degradation	B-T038
systems	O
,	O
limit	O
autophagy	B-T038
during	O
starvation	B-T033
.	O

Neuroprotective	O
Role	O
of	O
MicroRNA	B-T017
-	I-T017
22	I-T017
in	O
a	O
6	B-T103
-	I-T103
Hydroxydopamine	I-T103
-	O
Induced	O
Cell	B-T017
Model	B-T038
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
Disease	I-T038
via	O
Regulation	B-T038
of	O
Its	O
Target	O
Gene	B-T017
TRPM7	B-T017

Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
,	O
the	O
second	O
most	O
prevalent	B-T082
neurodegenerative	B-T038
disorder	I-T038
with	O
only	O
symptomatic	O
treatment	B-T058
available	O
,	O
is	O
characterized	O
by	O
a	O
progressive	O
loss	O
of	O
dopaminergic	B-T017
neurons	I-T017
in	O
the	O
midbrain	B-T017
.	O

Ample	O
evidence	O
indicated	O
that	O
microRNAs	B-T103
(	O
miRs	B-T103
)	O
could	O
regulate	B-T038
post	I-T038
-	I-T038
transcriptional	I-T038
gene	B-T038
expression	I-T038
and	O
neuronal	B-T038
disease	I-T038
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
have	O
evaluated	O
the	O
effects	O
and	O
mechanism	O
of	O
miR	B-T017
-	I-T017
22	I-T017
in	O
PC12	B-T017
pheochromocytoma	I-T017
cells	I-T017
treated	O
with	O
6	B-T103
-	I-T103
hydroxydopamine	I-T103
(	O
6	B-T103
-	I-T103
OHDA	I-T103
)	O
to	O
mimic	O
PD	B-T038
.	O

RT	B-T062
-	I-T062
PCR	I-T062
results	O
showed	O
that	O
the	O
expression	B-T038
of	O
miR	B-T017
-	I-T017
22	I-T017
is	O
downregulated	B-T038
in	O
6	B-T103
-	I-T103
OHDA	I-T103
-	O
treated	O
PC12	B-T017
cells	I-T017
,	O
and	O
the	O
overexpression	B-T038
of	O
miR	B-T017
-	I-T017
22	I-T017
significantly	O
promoted	O
the	O
survival	B-T038
and	O
proliferation	B-T038
of	O
6	B-T103
-	I-T103
OHDA	I-T103
-	O
induced	O
PC12	B-T017
cells	I-T017
,	O
whereas	O
miR	B-T017
-	I-T017
22	I-T017
inhibitor	O
reversed	O
these	O
effects	O
.	O

In	O
addition	O
,	O
PC12	B-T017
cells	I-T017
were	O
treated	O
with	O
miR	B-T017
-	I-T017
22	I-T017
mimics	I-T017
or	O
inhibitor	O
following	O
6	B-T103
-	I-T103
OHDA	I-T103
administration	B-T058
,	O
which	O
medicated	O
ROS	B-T103
production	B-T038
and	O
upregulation	B-T038
or	O
downregulation	B-T038
of	O
caspase	B-T038
-	I-T038
3	I-T038
activity	I-T038
,	O
respectively	O
.	O

A	O
luciferase	B-T103
reporter	O
assay	B-T058
revealed	O
that	O
transient	B-T017
receptor	I-T017
potential	I-T017
melastatin	I-T017
7	I-T017
(	O
TRPM7	B-T017
)	O
is	O
a	O
direct	O
target	O
gene	B-T017
of	O
miR	B-T017
-	I-T017
22	I-T017
,	O
and	O
miR	B-T017
-	I-T017
22	I-T017
overexpression	B-T038
markedly	O
downregulated	B-T038
the	O
level	O
of	O
TRPM7	B-T017
.	O

Strikingly	O
,	O
further	O
analysis	B-T062
showed	O
that	O
miR	B-T017
-	I-T017
22	I-T017
mediated	O
6	B-T103
-	I-T103
OHDA	I-T103
-	O
induced	O
PC12	B-T017
cell	B-T038
survival	I-T038
and	O
proliferation	B-T038
by	O
targeting	O
TRPM7	B-T017
.	O

Taken	O
together	O
,	O
the	O
present	O
study	B-T062
showed	O
that	O
miR	B-T017
-	I-T017
22	I-T017
overexpression	B-T038
exhibited	O
neuroprotective	O
and	O
reversal	O
effects	O
on	O
the	O
6	B-T103
-	I-T103
OHDA	I-T103
-	O
induced	O
PC12	B-T017
cell	B-T038
growth	I-T038
and	O
apoptosis	B-T038
by	O
targeting	O
TRPM7	B-T017
.	O

Obstacle	O
course	O
runs	O
:	O
review	B-T170
of	O
acquired	O
injuries	B-T037
and	O
illnesses	B-T033
at	O
a	O
series	O
of	O
Canadian	O
events	O
(	O
RACE	O
)	O

The	O
growing	O
popularity	O
of	O
obstacle	O
course	O
runs	O
(	O
OCRs	O
)	O
has	O
led	O
to	O
significant	O
concerns	O
regarding	O
their	O
safety	O
.	O

The	O
influx	O
of	O
injuries	B-T037
and	O
illnesses	B-T033
in	O
rural	O
areas	O
where	O
OCRs	O
are	O
often	O
held	O
can	O
impose	O
a	O
large	O
burden	O
on	O
emergency	B-T058
medical	I-T058
services	I-T058
(	O
EMS	B-T058
)	O
and	O
local	O
EDs	O
.	O

Literature	B-T170
concerning	O
the	O
safety	O
of	O
these	O
events	O
is	O
minimal	O
and	O
mostly	O
consists	O
of	O
media	B-T170
reports	B-T170
.	O

We	O
sought	O
to	O
characterise	O
the	O
injury	B-T037
and	O
illness	B-T033
profile	O
of	O
OCRs	O
and	O
the	O
level	O
of	O
medical	B-T058
care	I-T058
required	O
.	O

This	O
study	B-T062
analysed	B-T062
OCR	O
events	O
occurring	O
in	O
eight	O
locations	O
across	O
Canada	B-T082
from	O
May	O
to	O
August	O
2015	O
(	O
total	O
45	O
285	O
participants	B-T098
)	O
.	O

Data	O
were	O
extracted	O
from	O
event	O
medical	B-T074
charts	I-T074
of	O
patients	O
presenting	O
to	O
the	O
onsite	B-T082
medical	B-T058
team	I-T058
,	O
including	O
injury	B-T037
or	O
illness	B-T033
type	O
,	O
onsite	O
treatment	B-T058
and	O
disposition	O
.	O

There	O
were	O
557	O
race	B-T098
participants	I-T098
treated	O
at	O
eight	O
OCR	O
events	O
(	O
1	O
.	O
2	O
%	O
of	O
all	O
participants	B-T098
)	O
.	O

There	O
were	O
609	O
medical	B-T170
complaints	I-T170
in	O
total	O
.	O

Three	O
quarters	O
of	O
injuries	B-T037
were	O
musculoskeletal	O
in	O
nature	O
.	O

Eighty	O
-	O
nine	O
per	O
cent	O
returned	O
to	O
the	O
event	O
with	O
no	O
need	O
for	O
further	O
medical	B-T058
care	I-T058
.	O

The	O
majority	O
of	O
treatments	B-T058
were	O
completed	O
with	O
first	B-T058
aid	I-T058
and	O
basic	O
medical	B-T074
equipment	I-T074
.	O

Eleven	O
patients	O
(	O
2	O
%	O
of	O
patients	O
)	O
required	O
transfer	O
to	O
hospital	B-T092
by	O
EMS	B-T058
for	O
presentations	O
including	O
fracture	B-T037
,	O
dislocation	B-T037
,	O
head	B-T037
injury	I-T037
,	O
chest	B-T033
pain	I-T033
,	O
fall	O
from	O
height	O
,	O
and	O
abdominal	B-T033
pain	I-T033
.	O

We	O
found	O
that	O
1	O
.	O
2	O
%	O
of	O
race	B-T098
participants	I-T098
presented	O
to	O
onsite	O
medical	B-T058
services	I-T058
.	O

The	O
majority	O
of	O
complaints	O
were	O
minor	B-T037
and	O
musculoskeletal	B-T037
in	O
nature	O
.	O

Only	O
2	O
%	O
of	O
those	O
treated	O
were	O
transferred	O
to	O
hospital	B-T092
through	O
EMS	B-T058
.	O

This	O
is	O
consistent	O
with	O
other	O
types	O
of	O
mass	O
gathering	O
events	O
.	O

Is	O
Modern	O
Medical	B-T058
Management	I-T058
Changing	O
Ultimate	O
Patient	O
Outcomes	O
in	O
Inflammatory	B-T038
Bowel	I-T038
Disease	I-T038
?	O

The	O
impact	O
of	O
modern	O
medical	B-T058
management	I-T058
of	O
inflammatory	B-T038
bowel	I-T038
disease	I-T038
(	O
IBD	B-T038
)	O
on	O
surgical	B-T058
necessity	I-T058
and	O
outcomes	O
remains	O
unclear	O
.	O

We	O
hypothesized	O
that	O
surgery	B-T058
rates	O
have	O
decreased	O
while	O
outcomes	O
have	O
worsened	B-T033
due	O
to	O
operating	B-T058
on	O
"	O
sicker	B-T033
"	O
patients	O
since	O
the	O
introduction	O
of	O
biologic	B-T058
medications	I-T058
.	O

The	O
Nationwide	O
Inpatient	O
Sample	O
and	O
ICD	B-T170
-	I-T170
9	I-T170
-	I-T170
CM	I-T170
codes	I-T170
were	O
used	O
to	O
identify	O
inpatient	O
admissions	B-T058
for	O
Crohn	B-T038
'	I-T038
s	I-T038
disease	I-T038
and	O
ulcerative	B-T038
colitis	I-T038
.	O

Trends	O
in	O
IBD	B-T038
nutrition	B-T033
,	O
surgeries	B-T058
,	O
and	O
postoperative	B-T038
complications	I-T038
were	O
determined	O
.	O

There	O
were	O
191	O
,	O
743	O
admissions	B-T058
for	O
IBD	B-T038
during	O
the	O
study	B-T062
period	O
.	O

Surgery	B-T058
rates	O
were	O
largely	O
unchanged	B-T033
over	O
the	O
study	B-T062
period	O
,	O
ranging	O
from	O
9	O
to	O
12	O
%	O
of	O
admissions	B-T058
in	O
both	O
Crohn	B-T038
'	I-T038
s	I-T038
disease	I-T038
and	O
ulcerative	B-T038
colitis	I-T038
.	O

The	O
rate	O
of	O
poor	B-T038
nutrition	I-T038
increased	O
by	O
67	O
%	O
in	O
ulcerative	B-T038
colitis	I-T038
and	O
by	O
83	O
%	O
in	O
Crohn	B-T038
'	I-T038
s	I-T038
disease	I-T038
.	O

Rates	O
of	O
postoperative	O
anastomotic	B-T038
leak	I-T038
(	O
10	O
.	O
2	O
-	O
13	O
.	O
9	O
%	O
)	O
were	O
unchanged	B-T033
over	O
the	O
years	O
.	O

Postoperative	B-T038
infection	I-T038
rates	O
decreased	O
by	O
17	O
%	O
in	O
Crohn	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
18	O
%	O
in	O
2003	O
to	O
15	O
%	O
in	O
2012	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
but	O
did	O
not	O
show	O
a	O
trend	O
in	O
any	O
direction	O
in	O
ulcerative	B-T038
colitis	I-T038
.	O

Rates	O
of	O
IBD	B-T038
surgery	B-T091
have	O
remained	O
stable	O
while	O
postoperative	B-T038
infectious	I-T038
complications	I-T038
have	O
remained	O
stable	O
or	O
decreased	O
since	O
the	O
implementation	B-T058
of	O
biologic	B-T058
therapies	I-T058
.	O

We	O
identified	O
an	O
increase	O
in	O
poor	B-T038
nutrition	I-T038
in	O
surgical	O
patients	O
.	O

Clinical	O
Experience	O
With	O
the	O
Subcutaneous	O
Implantable	O
Cardioverter	O
-	O
Defibrillator	O
in	O
Adults	O
With	O
Congenital	B-T017
Heart	I-T017
Disease	I-T017

Sudden	B-T038
cardiac	I-T038
death	I-T038
is	O
a	O
major	O
contributor	O
to	O
mortality	O
for	O
adults	O
with	O
congenital	B-T017
heart	I-T017
disease	I-T017
.	O

The	O
subcutaneous	B-T082
implantable	B-T074
cardioverter	I-T074
-	I-T074
defibrillator	I-T074
(	O
ICD	B-T074
)	O
has	O
emerged	O
as	O
a	O
novel	O
tool	O
for	O
prevention	O
of	O
sudden	B-T038
cardiac	I-T038
death	I-T038
,	O
but	O
clinical	B-T033
performance	I-T033
data	O
for	O
adults	O
with	O
congenital	B-T017
heart	I-T017
disease	I-T017
are	O
limited	O
.	O

A	O
retrospective	B-T062
study	I-T062
involving	O
7	O
centers	O
over	O
a	O
5	O
-	O
year	O
period	O
beginning	O
in	O
2011	O
was	O
performed	O
.	O

Twenty	O
-	O
one	O
patients	O
(	O
median	O
33	O
.	O
9	O
years	O
)	O
were	O
identified	O
.	O

The	O
most	O
common	O
diagnosis	B-T033
was	O
single	B-T017
ventricle	I-T017
physiology	B-T038
(	O
52	O
%	O
)	O
,	O
9	O
palliated	B-T058
by	O
Fontan	B-T058
operation	I-T058
and	O
2	O
by	O
aortopulmonary	B-T058
shunts	I-T058
:	O
d	B-T017
-	I-T017
transposition	I-T017
of	I-T017
the	I-T017
great	I-T017
arteries	I-T017
after	O
Mustard	B-T058
/	O
Senning	B-T058
(	O
n	O
=	O
2	O
)	O
,	O
tetralogy	B-T017
of	I-T017
Fallot	I-T017
(	O
n	O
=	O
2	O
)	O
,	O
aortic	B-T038
valve	I-T038
disease	I-T038
(	O
n	O
=	O
2	O
)	O
,	O
and	O
other	O
biventricular	O
surgery	B-T058
(	O
n	O
=	O
4	O
)	O
.	O

A	O
prior	O
cardiac	B-T074
device	I-T074
had	O
been	O
implanted	B-T058
in	O
7	O
(	O
33	O
%	O
)	O
.	O

The	O
ICD	B-T074
indication	O
was	O
primary	B-T058
prevention	I-T058
in	O
67	O
%	O
and	O
secondary	B-T058
in	O
33	O
%	O
patient	O
s	O
.	O

The	O
most	O
common	O
reason	O
for	O
subcutaneous	B-T082
ICD	B-T074
placement	B-T058
was	O
limited	O
transvenous	B-T082
access	I-T082
for	O
ventricular	B-T074
lead	I-T074
placement	B-T058
(	O
n	O
=	O
10	O
)	O
followed	O
by	O
intracardiac	B-T033
right	I-T033
-	I-T033
to	I-T033
-	I-T033
left	I-T033
shunt	I-T033
(	O
n	O
=	O
5	O
)	O
.	O

Ventricular	B-T038
arrhythmia	I-T038
was	O
induced	O
in	O
17	O
(	O
81	O
%	O
)	O
and	O
was	O
converted	O
with	O
≤80	O
Joules	O
in	O
all	O
.	O

There	O
was	O
one	O
implant	B-T038
complication	I-T038
related	I-T038
to	I-T038
infection	I-T038
,	O
not	O
requiring	O
device	B-T058
removal	I-T058
.	O

Over	O
a	O
median	O
follow	B-T058
-	I-T058
up	I-T058
of	O
14	O
months	O
,	O
4	O
patients	O
(	O
21	O
%	O
)	O
received	O
inappropriate	B-T038
and	O
1	O
(	O
5	O
%	O
)	O
patient	O
received	O
appropriate	B-T038
shocks	I-T038
.	O

There	O
was	O
one	O
arrhythmic	O
death	O
related	O
to	O
asystole	B-T038
in	O
a	O
single	B-T017
ventricle	I-T017
patient	O
.	O

Subcutaneous	B-T082
ICD	B-T074
implantation	B-T058
is	O
feasible	O
for	O
adults	O
with	O
congenital	B-T017
heart	I-T017
disease	I-T017
patients	O
.	O

Most	O
candidates	O
have	O
single	B-T017
ventricle	I-T017
heart	B-T038
disease	I-T038
and	O
limited	O
transvenous	B-T082
options	I-T082
for	O
ICD	B-T074
placement	B-T058
.	O

Despite	O
variable	O
anatomy	O
,	O
this	O
study	B-T062
demonstrates	O
successful	O
conversion	O
of	O
induced	O
ventricular	B-T038
arrhythmia	I-T038
and	O
reasonable	B-T033
rhythm	B-T038
discrimination	B-T038
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Interaction	O
of	O
multiple	O
gene	B-T017
variants	I-T017
and	O
their	O
effects	O
on	O
schizophrenia	B-T038
phenotypes	O

Schizophrenia	B-T038
is	O
a	O
clinically	O
heterogeneous	B-T033
disorder	I-T033
and	O
may	O
be	O
explained	O
by	O
its	O
complex	O
genetic	O
architecture	O
.	O

Many	O
schizophrenia	B-T038
susceptibility	B-T201
genes	B-T017
were	O
identified	O
but	O
the	O
picture	O
remains	O
unclear	O
due	O
to	O
inconsistent	O
or	O
contradictory	O
genetic	B-T062
association	I-T062
studies	I-T062
.	O

This	O
confusion	O
may	O
,	O
in	O
part	O
,	O
be	O
because	O
symptoms	B-T033
result	O
from	O
the	O
combined	O
interaction	O
of	O
many	O
genes	B-T017
and	O
these	O
interacting	O
genes	B-T017
are	O
associated	O
with	O
specific	O
sub	O
-	O
phenotypes	O
of	O
schizophrenia	B-T038
rather	O
than	O
schizophrenia	B-T038
as	O
a	O
whole	O
.	O

This	O
study	O
investigates	O
the	O
relationship	O
between	O
schizophrenia	B-T038
susceptibility	B-T201
genes	B-T017
and	O
schizophrenia	B-T038
sub	O
-	O
phenotypes	O
by	O
identifying	O
multiple	O
gene	B-T017
variant	I-T017
interactions	O
.	O

Fifty	O
SNPs	B-T082
from	O
21	O
genes	B-T017
were	O
genotyped	B-T058
in	O
235	O
Australian	B-T098
participants	B-T098
with	O
schizophrenia	B-T038
screened	B-T058
for	O
various	O
phenotypes	O
.	O

Schizophrenia	B-T038
participants	B-T098
were	O
grouped	O
into	O
relevant	O
phenotype	O
clusters	O
using	O
cluster	B-T062
analysis	I-T062
and	O
normalized	B-T062
phenotype	O
cluster	O
scores	O
were	O
calculated	O
for	O
each	O
patient	O
.	O

The	O
relationship	O
between	O
genotypes	O
and	O
normalized	B-T062
phenotype	O
cluster	O
scores	O
were	O
analyzed	O
by	O
linear	B-T170
regression	I-T170
analysis	I-T170
.	O

Three	O
phenotype	O
clusters	O
were	O
identified	O
.	O

There	O
was	O
some	O
overlap	O
in	O
symptoms	B-T033
between	O
phenotype	O
clusters	O
,	O
particularly	O
for	O
depression	B-T038
.	O

However	O
,	O
cluster	O
1	O
appears	O
to	O
be	O
characterized	O
by	O
speech	B-T038
disorder	I-T038
and	O
affective	O
behavior	O
symptoms	O
,	O
cluster	O
2	O
has	O
predominantly	O
hallucination	B-T038
symptoms	B-T033
and	O
cluster	O
3	O
has	O
mainly	O
delusion	B-T038
symptoms	B-T033
.	O

Interaction	O
of	O
five	O
SNPs	B-T082
was	O
found	O
to	O
have	O
an	O
effect	O
on	O
cluster	O
1	O
symptoms	B-T033
;	O
ten	O
SNPs	B-T082
on	O
cluster	O
2	O
symptoms	B-T033
;	O
and	O
eight	O
SNPs	B-T082
on	O
cluster	O
3	O
symptoms	B-T033
.	O

The	O
interaction	O
of	O
specific	O
susceptibility	B-T201
genes	B-T017
is	O
likely	O
to	O
lead	O
to	O
specific	O
clinical	O
sub	O
-	O
phenotypes	O
of	O
schizophrenia	B-T038
.	O

Larger	O
patient	O
cohorts	B-T098
with	O
more	O
extensive	O
clinical	O
data	O
will	O
improve	O
the	O
detection	B-T033
of	O
gene	O
interactions	O
and	O
the	O
resultant	O
schizophrenia	B-T038
clinical	O
phenotypes	O
.	O

Evaluation	O
of	O
DNMT1	B-T017
gene	O
expression	O
profile	O
and	O
methylation	B-T038
of	O
its	O
promoter	B-T103
region	I-T103
in	O
patients	O
with	O
ankylosing	B-T038
spondylitis	I-T038

Ankylosing	B-T038
spondylitis	I-T038
(	O
AS	B-T038
)	O
is	O
an	O
autoimmune	B-T038
disease	I-T038
with	O
a	O
chronic	B-T038
inflammatory	I-T038
arthritis	I-T038
.	O

The	O
critical	O
role	O
of	O
methylation	B-T038
in	O
the	O
biology	B-T091
of	O
immunocytes	B-T017
has	O
increasingly	O
been	O
surveyed	B-T170
to	O
discover	O
disease	B-T038
etiology	O
.	O

DNA	B-T103
methyltransferase	I-T103
1	I-T103
(	O
DNMT1	B-T103
)	O
is	O
an	O
enzyme	B-T103
,	O
which	O
establishes	O
and	O
regulates	B-T038
patterns	B-T082
of	O
methylated	B-T103
cytosine	I-T103
residues	O
.	O

The	O
aim	O
of	O
the	O
current	O
investigation	B-T058
was	O
to	O
unveil	O
if	O
methylation	B-T038
circumstances	O
of	O
CpG	B-T103
sites	B-T082
in	O
DNMT1	B-T017
promoter	B-T103
could	O
affect	O
the	O
mRNA	B-T038
expression	I-T038
level	O
of	O
this	O
gene	B-T017
in	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
(	O
PBMCs	B-T017
)	O
from	O
AS	B-T038
patients	O
.	O

PBMCs	B-T017
were	O
isolated	O
from	O
whole	B-T031
blood	I-T031
of	O
40	O
AS	B-T038
patients	O
and	O
40	O
healthy	O
individuals	B-T098
.	O

Total	O
RNA	B-T103
and	O
DNA	B-T103
contents	O
of	O
leukocytes	B-T017
were	O
extracted	B-T058
.	O

Afterward	O
,	O
quantitative	O
analysis	O
was	O
carried	O
out	O
by	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
using	O
the	O
SYBR	B-T170
Green	I-T170
PCR	I-T170
Master	I-T170
Mix	I-T170
.	O

Finally	O
,	O
to	O
determine	O
the	O
methylation	B-T038
level	O
,	O
PCR	B-T062
products	B-T103
of	O
bisulfite	B-T103
-	I-T103
treated	I-T103
DNA	I-T103
from	O
patients	O
and	O
controls	O
were	O
sequenced	B-T058
.	O

Compared	O
with	O
healthy	O
controls	O
,	O
expression	B-T038
level	I-T038
of	O
DNMT1	B-T017
in	O
AS	B-T038
patients	O
was	O
significantly	O
downregulated	B-T038
.	O

Methylation	B-T038
of	O
DNMT1	B-T017
promoter	B-T103
was	O
significantly	O
higher	O
in	O
AS	B-T038
patients	O
in	O
comparison	O
to	O
controls	O
.	O

While	O
a	O
negative	B-T033
correlation	O
between	O
methylation	B-T038
and	O
expression	B-T038
level	I-T038
of	O
DNMT1	B-T017
was	O
observed	O
in	O
AS	B-T038
patients	O
,	O
both	O
methylation	B-T038
and	O
expression	B-T038
level	I-T038
of	O
DNMT1	B-T017
did	O
not	O
correlate	O
with	O
clinical	O
manifestations	O
.	O

Considering	O
the	O
observation	O
that	O
decreased	O
expression	B-T038
level	I-T038
of	O
DNMT1	B-T017
was	O
associated	O
with	O
hypermethylation	B-T038
of	O
DNMT1	B-T017
promoter	B-T103
in	O
PBMCs	B-T017
from	O
AS	B-T038
patients	O
,	O
this	O
survey	B-T170
suggests	O
that	O
dysregulation	O
of	O
DNMT1	B-T017
expression	B-T038
through	O
altered	O
methylation	B-T038
level	O
of	O
other	O
target	O
genes	B-T017
would	O
probably	O
contribute	O
to	O
AS	B-T038
development	O
.	O

Antibacterial	B-T103
Activity	O
of	O
Polyaniline	B-T103
Coated	O
Silver	B-T103
Nanoparticles	O
Synthesized	O
from	O
Piper	B-T103
Betle	I-T103
Leaves	I-T103
Extract	I-T103

Plants	B-T204
or	O
natural	O
resources	O
have	O
been	O
found	O
to	O
be	O
a	O
good	O
alternative	O
method	O
for	O
nanoparticles	O
synthesis	O
.	O

In	O
this	O
study	B-T062
,	O
polyaniline	B-T103
coated	O
silver	B-T103
nanoparticles	O
(	O
AgNPs	O
)	O
synthesized	O
from	O
Piper	B-T103
betle	I-T103
leaves	I-T103
extract	I-T103
were	O
investigated	O
for	O
their	O
antibacterial	B-T103
activity	O
.	O

Silver	B-T103
nanoparticles	O
were	O
prepared	O
from	O
the	O
reduction	O
of	O
silver	B-T103
nitrate	I-T103
and	O
NaBH4	B-T103
was	O
used	O
as	O
reducing	B-T103
agent	I-T103
.	O

Silver	B-T103
nanoparticles	O
and	O
extracts	B-T103
were	O
mixed	O
thoroughly	O
and	O
then	O
coated	O
by	O
polyaniline	B-T103
.	O

Prepared	O
nanoparticles	O
were	O
characterized	O
by	O
Visual	O
inspection	O
,	O
Ultraviolet	B-T058
-	I-T058
visible	I-T058
spectroscopy	I-T058
(	O
UV	B-T058
)	O
,	O
Fourier	B-T062
transform	I-T062
infrared	I-T062
Spectroscopy	I-T062
(	O
FT	B-T062
-	I-T062
IR	I-T062
)	O
,	O
Transmission	B-T058
Electron	I-T058
Microscopy	I-T058
(	I-T058
TEM	I-T058
)	I-T058
techniques	I-T058
.	O

Antibacterial	B-T103
activities	O
of	O
the	O
synthesized	O
silver	B-T103
nanoparticles	O
were	O
tested	O
against	O
Staphylococcus	B-T007
aureus	I-T007
ATCC	I-T007
25923	I-T007
,	O
Salmonella	B-T007
typhi	I-T007
ATCC	I-T007
14028	I-T007
,	O
Escherichia	B-T007
coli	I-T007
ATCC	I-T007
25922	I-T007
and	O
Pseudomonas	B-T007
aeruginosa	I-T007
ATCC	I-T007
27853	I-T007
.	O

UV	B-T058
-	I-T058
Vis	I-T058
spectrum	I-T058
of	O
reaction	O
mixture	O
showed	O
strong	O
absorption	O
peak	O
with	O
centering	O
at	O
400	O
nm	O
.	O

The	O
FT	B-T062
-	I-T062
IR	I-T062
results	B-T033
imply	O
that	O
Ag	O
-	O
NPs	O
were	O
successfully	O
synthesized	O
and	O
capped	O
with	O
bio	O
-	O
compounds	O
present	O
in	O
P	B-T103
.	I-T103

betle	I-T103
.	O

TEM	B-T058
image	O
showed	O
that	O
Ag	O
-	O
NPs	O
formed	O
were	O
well	O
dispersed	B-T082
with	O
a	O
spherical	B-T082
structures	I-T082
and	O
particle	O
size	O
ranging	O
from	O
10	O
to	O
30	O
nm	O
.	O

The	O
result	O
revealed	O
that	O
Ag	O
-	O
Extract	O
NPs	O
showed	O
32	O
.	O
78±0	O
.	O
64	O
mm	O
zone	O
of	O
inhibition	O
against	O
S	B-T007
.	I-T007

aureus	I-T007
,	O
whereas	O
norfloxacin	B-T103
(	O
positive	O
control	O
)	O
showed	O
maximum	O
32	O
.	O
15±0	O
.	O
40	O
mm	O
zone	O
of	O
inhibition	O
for	O
S	B-T007
.	I-T007

aureus	I-T007
.	O

Again	O
,	O
maximum	B-T082
zone	I-T082
of	O
inhibition	O
29	O
.	O
55±0	O
.	O
45	O
mm	O
was	O
found	O
for	O
S	B-T007
.	I-T007

typhi	I-T007
,	O
27	O
.	O
12±0	O
.	O
38	O
mm	O
for	O
E	B-T007
.	I-T007

coli	I-T007
and	O
21	O
.	O
95±0	O
.	O
45	O
mm	O
for	O
P	B-T007
.	I-T007

aeruginosa	I-T007
.	O

The	O
results	O
obtained	O
by	O
this	O
study	B-T062
can	O
'	O
t	O
be	O
directly	O
extrapolated	O
to	O
human	B-T204
;	O
so	O
further	B-T062
studies	I-T062
should	O
be	O
undertaken	O
to	O
established	O
the	O
strong	O
antimicrobial	B-T103
activity	O
of	O
Ag	O
-	O
Extract	O
NPs	O
for	O
drug	B-T091
development	I-T091
program	I-T091
.	O

Clinical	B-T170
Pearls	I-T170
in	O
Tremor	B-T033
and	O
Other	O
Hyperkinetic	B-T038
Movement	I-T038
Disorders	B-T038

Hyperkinetic	B-T038
movements	I-T038
,	O
such	O
as	O
tremor	B-T033
,	O
myoclonus	B-T033
,	O
chorea	B-T038
,	O
and	O
dystonia	B-T033
,	O
occur	O
in	O
many	O
neurologic	B-T038
and	O
medical	B-T038
conditions	I-T038
.	O

Accurate	O
clinical	B-T058
evaluation	I-T058
is	O
the	O
important	O
first	O
step	O
for	O
the	O
proper	O
diagnosis	B-T062
and	O
treatment	B-T058
of	O
patients	O
with	O
abnormal	B-T038
movements	I-T038
.	O

Tracking	O
children	O
with	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
who	O
abandoned	O
therapy	B-T058
:	O
Experience	B-T038
,	O
challenges	B-T058
,	O
parental	O
perspectives	B-T082
,	O
and	O
impact	O
of	O
treatment	B-T058
subsidies	B-T058
and	O
intensified	B-T058
counseling	I-T058

Refusal	O
for	O
treatment	O
and	O
therapy	B-T058
abandonment	B-T033
are	O
important	O
reasons	O
for	O
unfavorable	O
outcome	O
of	O
childhood	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
(	O
ALL	B-T038
)	O
in	O
resource	O
-	O
poor	O
countries	B-T082
.	O

The	O
present	O
study	B-T062
,	O
conducted	O
on	O
children	O
with	O
ALL	B-T038
whose	O
treatment	B-T058
was	O
abandoned	O
,	O
attempted	O
to	O
track	O
all	O
these	O
children	O
to	O
ascertain	O
the	O
causes	O
and	O
outcome	O
of	O
therapy	B-T058
abandonment	B-T033
/	O
refusal	O
.	O

In	O
order	O
to	O
improve	O
outcome	O
of	O
ALL	B-T038
,	O
measures	O
to	O
prevent	O
abandonment	B-T033
were	O
introduced	O
in	O
the	O
form	O
of	O
treatment	B-T058
subsidies	B-T058
and	O
intensified	B-T058
multistage	I-T058
counseling	I-T058
.	O

Of	O
the	O
77	O
(	O
of	O
418	O
)	O
children	O
abandoning	O
therapy	B-T058
,	O
17	O
(	O
22	O
%	O
)	O
refused	O
upfront	O
,	O
whereas	O
the	O
rest	O
abandoned	O
during	O
various	O
phases	O
of	O
chemotherapy	B-T058
.	O

Only	O
39	O
(	O
50	O
.	O
6	O
%	O
)	O
of	O
these	O
77	O
families	O
could	O
be	O
subsequently	O
contacted	O
.	O

Financial	B-T033
problems	I-T033
,	O
too	O
many	O
dependents	B-T098
at	O
home	B-T082
,	O
and	O
wrong	O
perceptions	B-T038
about	O
cancer	B-T038
led	O
to	O
abandonment	B-T033
in	O
majority	O
.	O

Children	B-T033
abandoning	I-T033
treatment	I-T033
before	O
completion	O
of	O
induction	B-T058
had	O
a	O
significantly	O
shorter	O
survival	O
than	O
who	O
abandoned	O
post	O
induction	O
(	O
P	O
<	O
.	O
0001	O
)	O
.	O

Intensified	B-T058
preabandonment	I-T058
counseling	I-T058
and	O
subsidized	O
treatment	B-T058
led	O
to	O
significant	O
reduction	O
in	O
abandonment	O
rates	O
(	O
P	O
<	O
.	O
0001	O
)	O
.	O

Effect	O
of	O
New	O
-	O
Onset	O
Left	B-T038
Bundle	I-T038
Branch	I-T038
Block	I-T038
After	O
Transcatheter	B-T058
Aortic	I-T058
Valve	I-T058
Implantation	I-T058
(	O
CoreValve	B-T074
)	O
on	O
Mortality	O
,	O
Frequency	O
of	O
Re	B-T058
-	I-T058
Hospitalization	I-T058
,	O
and	O
Need	O
for	O
Pacemaker	B-T074

New	O
-	O
onset	O
conduction	B-T038
disturbances	I-T038
are	O
common	O
after	O
transcatheter	B-T058
aortic	I-T058
valve	I-T058
implantation	I-T058
(	O
TAVI	B-T058
)	O
.	O

The	O
most	O
common	O
complication	B-T038
is	O
left	B-T038
bundle	I-T038
branch	I-T038
block	I-T038
(	O
LBBB	B-T038
)	O
.	O

The	O
clinical	O
impact	O
of	O
new	O
-	O
onset	O
LBBB	B-T038
after	O
TAVI	B-T058
remains	O
controversial	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
impact	O
of	O
new	O
-	O
onset	O
LBBB	B-T038
in	O
terms	O
of	O
mortality	O
and	O
morbidity	O
(	O
need	O
for	O
pacemakers	B-T074
and	O
admissions	B-T058
for	O
heart	B-T038
failure	I-T038
)	O
at	O
long	B-T058
-	I-T058
term	I-T058
follow	I-T058
-	I-T058
up	I-T058
.	O

From	O
April	O
2008	O
to	O
December	O
2014	O
,	O
220	O
patients	O
who	O
had	O
severe	O
aortic	B-T038
stenosis	I-T038
were	O
treated	B-T058
with	I-T058
the	O
implantation	B-T058
of	O
a	O
CoreValve	B-T074
prosthesis	I-T074
.	O

Sixty	O
-	O
seven	O
of	O
these	O
patients	O
were	O
excluded	O
from	O
the	O
analysis	B-T062
,	O
including	O
22	O
patients	O
with	O
pre	O
-	O
existing	O
LBBB	B-T038
and	O
45	O
with	O
a	O
permanent	O
pacemaker	O
,	O
implanted	B-T074
previously	O
or	O
within	O
72	O
hours	O
of	O
implantation	B-T058
.	O

The	O
remaining	O
153	O
patients	O
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
1	O
(	O
n	O
=	O
80	O
)	O
,	O
those	O
with	O
persistent	O
new	O
-	O
onset	O
LBBB	B-T038
,	O
and	O
group	O
2	O
(	O
n	O
=	O
73	O
)	O
,	O
those	O
without	O
conduction	B-T038
disturbances	I-T038
after	O
treatment	B-T058
.	O

Both	O
groups	O
were	O
followed	B-T058
up	I-T058
at	O
1	O
month	O
,	O
6	O
months	O
,	O
12	O
months	O
,	O
and	O
yearly	O
thereafter	O
.	O

Persistent	O
new	O
-	O
onset	O
LBBB	B-T038
occurred	O
in	O
80	O
patients	O
(	O
36	O
%	O
)	O
immediately	O
after	O
TAVI	B-T058
;	O
73	O
patients	O
(	O
33	O
%	O
)	O
did	O
not	O
develop	O
conduction	B-T038
disturbances	I-T038
.	O

The	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
time	O
of	O
both	O
groups	O
was	O
32	O
±	O
22	O
months	O
(	O
range	O
3	O
to	O
82	O
months	O
)	O
,	O
and	O
there	O
were	O
no	O
differences	O
in	O
time	O
between	O
the	O
groups	O
.	O

There	O
were	O
no	O
differences	O
in	O
mortality	O
between	O
the	O
groups	O
(	O
39	O
%	O
vs	O
48	O
%	O
,	O
p	O
=	O
0	O
.	O
58	O
)	O
.	O

No	O
differences	O
were	O
observed	O
between	O
the	O
groups	O
in	O
re	B-T058
-	I-T058
hospitalizations	I-T058
for	O
heart	B-T038
failure	I-T038
(	O
11	O
%	O
vs	O
16	O
%	O
,	O
p	O
=	O
0	O
.	O
55	O
)	O
.	O

Group	O
1	O
did	O
not	O
require	O
pacemaker	B-T058
implantation	I-T058
more	O
often	O
at	O
follow	B-T058
-	I-T058
up	I-T058
(	O
10	O
%	O
vs	O
13	O
%	O
,	O
p	O
=	O
0	O
.	O
38	O
)	O
than	O
group	O
2	O
.	O

In	O
conclusion	O
,	O
new	O
-	O
onset	O
LBBB	B-T038
was	O
not	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
late	O
need	O
for	O
a	O
permanent	O
pacemaker	O
after	O
CoreValve	B-T074
implantation	B-T058
.	O

In	O
addition	O
,	O
it	O
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
late	O
mortality	O
or	O
re	B-T058
-	I-T058
hospitalization	I-T058
.	O

The	O
relationship	O
between	O
polymorphisms	B-T038
of	O
BDNFOS	B-T017
and	O
BDNF	B-T017
genes	I-T017
and	O
heroin	B-T038
addiction	I-T038
in	O
the	O
Han	O
Chinese	O
population	O

The	O
number	O
of	O
heroin	B-T103
addicts	O
is	O
increasing	O
in	O
the	O
world	B-T098
.	O

Both	O
environmental	O
and	O
genetic	O
factors	O
both	O
play	O
critical	O
roles	O
in	O
the	O
process	O
of	O
heroin	B-T038
addiction	I-T038
.	O

We	O
aimed	O
to	O
investigate	O
the	O
associations	O
between	O
single	B-T082
nucleotide	I-T082
polymorphisms	I-T082
(	O
SNPs	B-T082
)	O
in	O
LIN7C	B-T017
,	O
BDNFOS	B-T017
and	O
BDNF	B-T017
genes	I-T017
and	O
drug	B-T038
addiction	I-T038
in	O
the	O
Han	O
Chinese	O
population	O
.	O

We	O
conducted	O
a	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
among	O
692	O
cases	O
and	O
700	O
healthy	O
controls	O
from	O
Xi	O
'	O
an	O
,	O
China	B-T082
.	O

Eight	O
SNPs	B-T082
were	O
selected	O
and	O
genotyped	B-T058
using	O
MassARRAY	B-T170
technology	I-T170
(	O
Sequenom	B-T092
,	O
San	B-T082
Diego	I-T082
,	I-T082
CA	I-T082
,	O
USA	B-T082
)	O
.	O

Odds	O
ratios	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
were	O
calculated	O
by	O
unconditional	B-T062
logistic	I-T062
regression	I-T062
adjusting	O
for	O
age	O
and	O
sex	O
.	O

Using	O
the	O
chi	B-T170
-	I-T170
squared	I-T170
test	I-T170
,	O
we	O
found	O
that	O
rs7481311	B-T017
(	O
OR	O
=	O
1	O
.	O
275	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
087	O
-	O
1	O
.	O
497	O
,	O
p	O
=	O
0	O
.	O
009	O
)	O
and	O
rs11030096	B-T017
(	O
OR	O
=	O
1	O
.	O
227	O
,	O
95	O
%	O
CI	O
=	O
1	O
.	O
049	O
-	O
1	O
.	O
436	O
,	O
p	O
=	O
0	O
.	O
011	O
)	O
in	O
the	O
BNDFOS	B-T017
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
heroin	B-T038
addiction	I-T038
.	O

By	O
contrast	O
,	O
rs988712	B-T017
located	O
in	O
BDNFOS	B-T017
showed	O
a	O
decreased	O
risk	O
of	O
heroin	B-T038
addiction	I-T038
(	O
OR	O
=	O
0	O
.	O
734	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
582	O
-	O
0	O
.	O
925	O
,	O
p	O
=	O
0	O
.	O
003	O
)	O
.	O

By	O
genetic	B-T170
model	I-T170
analysis	B-T062
,	O
we	O
found	O
that	O
the	O
'	B-T017
T	I-T017
'	I-T017
allele	I-T017
of	O
rs988712	B-T017
in	O
BDNFOS	B-T017
had	O
a	O
protective	O
role	O
for	O
heroin	B-T038
addiction	I-T038
in	O
the	O
additive	B-T170
model	I-T170
and	O
dominant	B-T170
model	I-T170
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

By	O
contrast	O
,	O
the	O
allele	B-T017
'	I-T017
T	I-T017
'	I-T017
of	O
rs7481311	B-T017
in	O
BDNFOS	B-T017
significantly	O
elevated	O
the	O
risk	O
of	O
heroin	B-T038
addiction	I-T038
in	O
the	O
additive	B-T170
model	I-T170
,	O
recessive	B-T170
model	I-T170
and	O
dominant	B-T170
model	I-T170
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
also	O
found	O
that	O
allele	B-T017
'	I-T017
C	I-T017
'	O
of	O
rs11030096	B-T017
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
addiction	B-T038
in	O
the	O
dominant	B-T170
model	I-T170
and	O
additive	B-T170
model	I-T170
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Additionally	O
,	O
we	O
found	O
that	O
rs6265	B-T017
,	O
rs11030104	B-T017
and	O
rs10767664	B-T017
in	O
BDNF	B-T017
were	O
associated	O
with	O
a	O
decreased	O
risk	O
of	O
heroin	B-T038
addiction	I-T038
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

However	O
,	O
only	O
rs7481311	B-T017
in	O
BDNFOS	B-T017
remained	O
significant	O
after	O
Bonferroni	O
correction	O
(	O
p	O
<	O
0	O
.	O
00625	O
)	O
.	O

These	O
results	B-T033
suggest	O
that	O
polymorphisms	B-T038
of	O
BDNFOS	B-T017
play	O
an	O
important	O
role	O
in	O
heroin	B-T038
addiction	I-T038
susceptibility	O
in	O
the	O
Chinese	O
Han	O
population	O
.	O

Risk	O
and	O
protective	O
factors	O
associated	O
with	O
adolescent	O
girls	O
'	O
substance	B-T038
use	I-T038
:	O
Data	O
from	O
a	O
nationwide	O
Facebook	B-T170
sample	O

Despite	O
overall	O
reductions	O
in	O
teenage	O
substance	B-T038
use	I-T038
,	O
adolescent	O
girls	O
'	O
rates	O
of	O
substance	B-T038
use	I-T038
remain	O
unacceptably	O
high	O
.	O

This	O
article	B-T170
examines	O
whether	O
girls	B-T098
'	O
substance	B-T038
use	I-T038
is	O
associated	O
with	O
general	O
risk	O
and	O
protective	O
factors	O
(	O
goal	B-T038
setting	I-T038
,	O
problem	B-T038
solving	I-T038
,	O
refusal	O
skills	O
,	O
peer	O
use	O
,	O
and	O
self	B-T038
-	I-T038
efficacy	I-T038
)	O
and	O
gender	O
-	O
specific	O
risk	O
and	O
protective	O
factors	O
(	O
communication	O
style	O
,	O
coping	O
skills	O
,	O
self	B-T038
-	I-T038
esteem	I-T038
,	O
body	B-T038
image	I-T038
,	O
perceived	B-T038
stress	I-T038
,	O
anxiety	B-T038
,	O
and	O
depression	B-T038
)	O
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
data	I-T062
were	O
collected	O
in	O
2013	O
via	O
online	O
surveys	O
from	O
a	O
nationwide	O
sample	O
of	O
adolescent	O
girls	O
(	O
N	O
=	O
788	O
)	O
,	O
aged	O
13	O
and	O
14	O
years	O
,	O
who	O
were	O
recruited	O
through	O
Facebook	B-T170
.	O

In	O
multivariate	O
analyses	O
,	O
controlling	O
for	O
correlates	O
of	O
adolescent	O
substance	B-T038
use	I-T038
,	O
11	O
of	O
the	O
13	O
general	O
and	O
gender	O
-	O
specific	O
risk	O
and	O
protective	O
factors	O
were	O
consistently	O
associated	O
with	O
past	O
-	O
month	O
alcohol	O
,	O
cigarette	O
,	O
and	O
other	O
drug	B-T038
use	I-T038
in	O
the	O
expected	O
direction	O
;	O
past	O
-	O
month	O
marijuana	O
use	O
was	O
associated	O
with	O
8	O
of	O
the	O
13	O
factors	O
.	O

Refusal	O
skill	O
s	O
,	O
peer	O
use	O
,	O
coping	O
,	O
and	O
depressive	B-T033
mood	I-T033
were	O
most	O
consistently	O
and	O
strongly	O
associated	O
with	O
substance	B-T038
use	I-T038
.	O

Substance	B-T058
abuse	I-T058
prevention	I-T058
programs	B-T058
targeting	O
adolescent	O
girls	O
should	O
focus	O
on	O
such	O
general	O
risk	O
and	O
protective	O
factors	O
as	O
problem	B-T038
solving	I-T038
,	O
refusal	O
skill	O
s	O
,	O
peer	O
influences	O
,	O
and	O
self	B-T038
-	I-T038
efficacy	I-T038
,	O
as	O
well	O
as	O
such	O
gender	O
-	O
specific	O
risk	O
and	O
protective	O
factors	O
as	O
communication	O
style	O
,	O
coping	O
,	O
self	B-T038
-	I-T038
esteem	I-T038
,	O
body	B-T038
image	I-T038
,	O
perceived	B-T038
stress	I-T038
,	O
and	O
mood	B-T058
management	I-T058
.	O

Ethics	O
Hype	O
?	O

There	O
has	O
been	O
growing	O
concern	O
about	O
the	O
phenomenon	O
of	O
science	O
hype	O
,	O
the	O
tendency	O
to	O
exaggerate	O
the	O
value	O
or	O
near	O
-	O
future	O
application	O
of	O
research	O
results	O
.	O

Although	O
this	O
is	O
a	O
problem	B-T033
that	O
touches	O
every	O
area	B-T091
of	I-T091
biomedicine	I-T091
,	O
the	O
topic	B-T170
of	O
genetics	B-T091
seems	O
to	O
be	O
particularly	O
prone	O
to	O
enthusiastic	B-T038
predictions	O
.	O

The	O
world	B-T098
has	O
been	O
told	O
for	O
over	O
two	O
decades	O
-	O
by	O
the	O
media	B-T170
,	O
researchers	B-T097
,	O
politicians	O
,	O
and	O
the	O
biotech	B-T091
industry	O
-	O
that	O
a	O
genome	B-T017
-	O
driven	O
health	B-T058
care	I-T058
revolution	O
is	O
just	O
around	O
the	O
corner	O
.	O

And	O
while	O
the	O
revolution	O
never	O
seems	O
to	O
arrive	O
,	O
the	O
hopeful	O
rhetoric	O
continues	O
.	O

It	O
has	O
been	O
suggested	O
that	O
this	O
unrelenting	O
"	O
genohype	O
"	O
is	O
having	O
a	O
range	O
of	O
adverse	B-T033
social	O
consequences	O
,	O
including	O
misleading	O
the	O
public	B-T098
and	O
hurting	B-T033
the	O
long	O
-	O
term	O
legitimacy	B-T170
of	O
the	O
field	O
.	O

While	O
we	O
need	O
more	O
good	O
data	O
on	O
the	O
nature	O
and	O
magnitude	O
of	O
these	O
possible	O
harms	O
,	O
few	O
would	O
argue	O
with	O
the	O
proposition	B-T170
that	O
sustained	O
science	O
hype	O
is	O
a	O
bad	O
thing	O
.	O

We	O
all	O
benefit	O
from	O
robust	O
science	O
and	O
accurate	O
public	B-T098
representations	O
of	O
biomedical	B-T062
research	I-T062
.	O

But	O
,	O
to	O
date	O
,	O
there	O
has	O
been	O
very	O
little	O
consideration	B-T033
of	O
the	O
degree	O
to	O
which	O
the	O
scholarship	O
on	O
the	O
related	O
ethical	O
,	O
legal	B-T170
,	O
and	O
social	O
issues	O
has	O
been	O
hyped	O
.	O

Are	O
the	O
conclusions	O
from	O
ELSI	O
scholarship	O
also	O
exaggerated	O
?	O

Lubiprostone	B-T103
Accelerates	O
Intestinal	B-T038
Transit	I-T038
and	O
Alleviates	O
Small	B-T038
Intestinal	I-T038
Bacterial	I-T038
Overgrowth	I-T038
in	O
Patients	O
With	O
Chronic	B-T033
Constipation	I-T033

Lubiprostone	B-T103
is	O
an	O
effective	O
treatment	O
for	O
chronic	B-T033
constipation	I-T033
(	O
CC	B-T033
)	O
.	O

The	O
mechanism	O
of	O
action	O
of	O
lubiprostone	B-T103
is	O
through	O
increasing	O
fluid	B-T038
secretion	I-T038
and	O
lubrication	O
of	O
the	O
intestinal	B-T082
lumen	I-T082
.	O

The	O
effects	O
of	O
lubiprostone	B-T103
on	O
gastrointestinal	B-T038
transit	I-T038
and	O
small	B-T038
intestinal	I-T038
bacterial	I-T038
overgrowth	I-T038
(	O
SIBO	B-T038
)	O
have	O
not	O
been	O
adequately	O
explored	O
.	O

The	O
current	O
study	B-T062
was	O
designed	O
to	O
investigate	O
whether	O
lubiprostone	B-T103
(	O
1	O
)	O
alters	O
gastrointestinal	B-T038
transit	I-T038
and	O
(	O
2	O
)	O
affects	O
SIBO	B-T038
in	O
patients	O
with	O
constipation	B-T033
.	O

A	O
total	O
of	O
29	O
female	O
patients	O
(	O
mean	O
age	O
=	O
39	O
years	O
;	O
range	O
:	O
19	O
-	O
64	O
)	O
with	O
CC	B-T033
received	O
2	O
weeks	O
of	O
lubiprostone	B-T103
(	O
24mcg	O
b	O
.	O
i	O
.	O
d	O
.	O
,	O
P	O
.	O
O	O
.	O
)	O
.	O

Stool	B-T033
consistency	I-T033
based	O
on	O
Bristol	B-T170
stool	I-T170
scale	I-T170
and	O
the	O
frequency	B-T033
of	I-T033
bowel	I-T033
movements	I-T033
(	O
BMs	B-T038
)	O
were	O
recorded	O
.	O

Gastric	O
emptying	O
time	O
,	O
small	O
bowel	O
transit	O
time	O
,	O
colon	B-T017
transit	O
time	O
(	O
CTT	O
)	O
,	O
combined	O
small	B-T038
and	I-T038
large	I-T038
bowel	I-T038
transit	I-T038
time	I-T038
(	O
SLBTT	B-T038
)	O
and	O
whole	O
gut	B-T017
transit	O
time	O
were	O
measured	O
using	O
wireless	B-T058
motility	I-T058
capsule	I-T058
.	O

The	O
SIBO	B-T038
status	O
was	O
assessed	O
by	O
the	O
lactulose	B-T058
breath	I-T058
test	I-T058
.	O

Data	O
were	O
analyzed	B-T062
using	O
Wilcoxon	O
rank	O
,	O
Mann	O
-	O
Whitney	O
U	O
,	O
Spearman	O
׳	O
s	O
rank	O
correlation	O
and	O
Chi	B-T170
-	I-T170
square	I-T170
tests	I-T170
.	O

Lubiprostone	B-T103
significantly	O
softened	O
the	O
stool	B-T031
and	O
increased	O
the	O
frequency	B-T033
of	I-T033
BM	I-T033
from	O
median	O
of	O
2	O
to	O
4	O
times	O
per	O
week	O
.	O

The	O
CTT	O
and	O
SLBTT	B-T038
were	O
significantly	O
shorter	O
in	O
responders	B-T098
to	O
lubiprostone	B-T103
(	O
i	O
.	O
e	O
.	O
,	O
those	O
with	O
≥	O
2	O
times	O
increase	O
in	O
the	O
number	O
of	O
their	O
weekly	O
BM	B-T038
)	O
compared	O
with	O
nonresponders	B-T098
.	O

The	O
higher	O
frequency	B-T033
of	I-T033
BM	I-T033
after	O
treatment	O
was	O
significantly	O
correlated	O
with	O
the	O
acceleration	O
of	O
CTT	O
,	O
SLBTT	B-T038
and	O
whole	O
gut	B-T017
transit	O
time	O
.	O

In	O
all	O
,	O
17	O
out	O
of	O
25	O
(	O
68	O
%	O
)	O
patients	O
,	O
who	O
were	O
tested	O
for	O
SIBO	B-T038
at	O
baseline	O
,	O
were	O
positive	B-T033
.	O

In	O
addition	O
,	O
7	O
out	O
of	O
17	O
(	O
41	O
%	O
)	O
SIBO	B-T038
-	O
positive	B-T033
patients	O
became	O
SIBO	B-T038
-	O
negative	B-T033
after	O
lubiprostone	B-T103
treatment	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
CC	B-T033
,	O
lubiprostone	B-T103
improves	O
the	O
frequency	B-T033
of	I-T033
BMs	I-T033
,	O
softens	O
the	O
stool	B-T031
,	O
accelerates	O
intestinal	B-T038
transit	I-T038
and	O
decreases	O
accompanying	O
SIBO	B-T038
.	O

The	O
improvement	O
of	O
SIBO	B-T038
could	O
be	O
explained	O
by	O
the	O
cleansing	O
effect	O
of	O
increased	O
intestinal	B-T038
fluid	I-T038
and	O
mucus	B-T031
combined	O
with	O
enhanced	O
intestinal	B-T038
motility	I-T038
with	O
lubiprostone	B-T103
.	O

Minimally	B-T058
invasive	I-T058
treatment	I-T058
of	O
difficult	O
bleeding	B-T038
lesions	B-T033
of	O
the	O
small	B-T017
bowel	I-T017

Bleeding	B-T038
lesions	B-T033
of	O
the	O
small	B-T017
bowel	I-T017
are	O
often	O
difficult	O
to	O
identify	O
due	O
to	O
the	O
obscure	O
symptomatology	B-T033
.	O

Localizing	B-T082
these	O
lesions	B-T033
requires	O
specific	O
techniques	O
.	O

The	O
Double	B-T058
-	I-T058
balloon	I-T058
enteroscopy	I-T058
(	O
DBE	B-T058
)	O
could	O
be	O
used	O
to	O
precisely	O
localize	B-T082
and	O
mark	O
lesions	B-T033
,	O
so	O
that	O
a	O
minimally	B-T058
invasive	I-T058
surgical	I-T058
treatment	I-T058
could	O
be	O
performed	O
.	O

Twenty	O
robot	O
-	O
assisted	O
small	B-T058
bowel	I-T058
procedures	I-T058
are	O
presented	O
using	O
a	O
combination	O
of	O
DBE	B-T058
for	O
localization	B-T082
and	O
robotic	B-T058
resection	I-T058
.	O

There	O
were	O
10	O
jejunal	O
resections	O
and	O
10	O
ileal	O
resections	O
.	O

Mean	O
age	O
was	O
58	O
.	O
7	O
years	O
.	O

Mean	O
operative	O
time	O
was	O
153	O
.	O
4	O
minutes	O
,	O
mean	O
blood	B-T033
loss	I-T033
of	O
46	O
mL	O
.	O

No	O
conversion	B-T058
-	I-T058
to	I-T058
-	I-T058
open	I-T058
and	O
there	O
were	O
4	O
post	O
-	O
operative	O
complications	B-T038
.	O

The	O
90	O
-	O
day	O
mortality	O
was	O
nil	O
and	O
the	O
median	O
length	O
of	O
stay	O
was	O
4	O
.	O
1	O
days	O
.	O

Final	O
pathology	B-T170
was	O
consistent	O
with	O
malignancy	B-T038
in	O
10	O
cases	O
.	O

The	O
combination	O
of	O
double	B-T058
-	I-T058
balloon	I-T058
enteroscopy	I-T058
and	O
robotic	B-T058
technology	I-T058
allows	O
accurate	O
identification	O
and	O
selective	O
treatment	O
of	O
lesions	B-T033
that	O
could	O
be	O
otherwise	O
difficult	O
to	O
treat	O
in	O
a	O
minimally	B-T058
invasive	I-T058
fashion	I-T058
.	O

Kinematic	B-T091
and	O
EMG	B-T058
Responses	O
to	O
Pelvis	B-T017
and	O
Leg	B-T017
Assistance	O
Force	O
during	O
Treadmill	O
Walking	O
in	O
Children	O
with	O
Cerebral	B-T038
Palsy	I-T038

Treadmill	B-T058
training	I-T058
has	O
been	O
used	O
for	O
improving	O
locomotor	B-T038
function	I-T038
in	O
children	O
with	O
cerebral	B-T038
palsy	I-T038
(	O
CP	B-T038
)	O
,	O
but	O
the	O
functional	O
gains	O
are	O
relatively	O
small	O
,	O
suggesting	O
a	O
need	O
to	O
improve	O
current	O
paradigms	O
.	O

The	O
understanding	O
of	O
the	O
kinematic	B-T091
and	O
EMG	B-T058
responses	O
to	O
force	O
s	O
applied	O
to	O
the	O
body	B-T017
of	O
subjects	O
during	O
treadmill	O
walking	O
is	O
crucial	O
for	O
improving	O
current	O
paradigms	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
kinematic	B-T091
s	O
and	O
EMG	B-T058
responses	O
to	O
the	O
pelvis	B-T017
and	O
/	O
or	O
leg	B-T017
assistance	O
force	O
.	O

Ten	O
children	O
with	O
spastic	B-T017
CP	I-T017
were	O
recruited	O
to	O
participate	B-T058
in	O
this	O
study	B-T062
.	O

A	O
controlled	O
assistance	O
force	O
was	O
applied	O
to	O
the	O
pelvis	B-T017
and	O
/	O
or	O
legs	B-T017
during	O
stance	O
and	O
swing	O
phase	O
of	O
gait	O
through	O
a	O
custom	O
designed	O
robotic	O
system	O
during	O
walking	O
.	O

Muscle	B-T017
activities	O
and	O
spatial	O
-	O
temporal	O
gait	B-T033
parameters	I-T033
were	O
measured	O
at	O
different	O
loading	O
conditions	O
during	O
walking	O
.	O

In	O
addition	O
,	O
the	O
spatial	B-T033
-	I-T033
temporal	I-T033
gait	I-T033
parameters	I-T033
during	O
overground	O
walking	O
before	O
and	O
after	O
treadmill	B-T058
training	I-T058
were	O
also	O
collected	O
.	O

Applying	O
pelvis	B-T017
assistance	O
improved	B-T033
step	B-T033
height	I-T033
and	O
applying	O
leg	B-T017
assistance	O
improved	B-T033
step	B-T033
length	I-T033
during	O
walking	O
,	O
but	O
applying	O
leg	B-T017
assistance	O
also	O
reduced	O
muscle	B-T017
activation	O
of	O
ankle	B-T017
flexor	I-T017
during	O
the	O
swing	O
phase	O
of	O
gait	O
.	O

In	O
addition	O
,	O
step	B-T033
length	I-T033
and	O
self	O
-	O
selected	O
walking	O
speed	O
significantly	O
improved	B-T033
after	O
one	O
session	O
of	O
treadmill	B-T058
training	I-T058
with	O
combined	O
pelvis	B-T017
and	O
leg	B-T017
assistance	O
.	O

Outlining	O
a	O
Population	B-T098
"	I-T098
at	I-T098
Risk	I-T098
"	I-T098
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
Disease	I-T038
:	O
Evidence	O
from	O
a	O
Case	B-T062
-	I-T062
Control	I-T062
Study	I-T062

The	O
multifactorial	B-T038
pathogenesis	I-T038
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
Disease	I-T038
(	O
PD	B-T038
)	O
requires	O
a	O
careful	O
identification	O
of	O
populations	B-T098
"	I-T098
at	I-T098
risk	I-T098
"	I-T098
of	O
developing	O
the	O
disease	B-T038
.	O

In	O
this	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
we	O
analyzed	B-T062
a	O
large	O
Italian	B-T082
population	B-T098
,	O
in	O
an	O
attempt	O
to	O
outline	O
general	O
criteria	O
to	O
define	O
a	O
population	B-T098
"	I-T098
at	I-T098
risk	I-T098
"	I-T098
of	O
PD	B-T038
.	O

We	O
enrolled	O
300	O
PD	B-T038
patients	O
and	O
300	O
controls	O
,	O
gender	O
and	O
age	O
matched	O
,	O
from	O
the	O
same	O
urban	O
geographical	O
area	O
.	O

All	O
subjects	B-T098
were	O
interviewed	O
on	O
demographics	O
,	O
family	B-T033
history	I-T033
of	O
PD	B-T038
,	O
occupational	O
and	O
environmental	O
toxicants	O
exposure	O
,	O
smoking	B-T201
status	I-T201
,	O
and	O
alcohol	O
consumption	O
.	O

A	O
sample	O
of	O
65	O
patients	O
and	O
65	O
controls	O
also	O
underwent	O
serum	B-T031
dosing	O
of	O
iron	B-T058
,	O
copper	B-T058
,	O
mercury	B-T058
,	O
and	O
manganese	B-T058
by	O
means	O
of	O
Inductively	B-T058
Coupled	I-T058
-	I-T058
Plasma	I-T058
-	I-T058
Mass	I-T058
-	I-T058
Spectrometry	I-T058
(	O
ICP	B-T058
-	I-T058
MS	I-T058
)	O
.	O

Positive	B-T033
family	B-T033
history	I-T033
,	O
toxicants	B-T033
exposure	I-T033
,	O
non	B-T033
-	I-T033
current	I-T033
-	I-T033
smoker	I-T033
,	O
and	O
alcohol	B-T033
nonconsumer	I-T033
status	I-T033
occurred	O
as	O
significant	O
risk	B-T033
factors	I-T033
in	O
our	O
population	B-T098
.	O

The	O
number	O
of	O
concurring	B-T033
risk	I-T033
factors	I-T033
overlapping	O
in	O
the	O
same	B-T098
subject	I-T098
impressively	O
increased	O
the	O
overall	O
risk	O
.	O

No	O
significant	O
differences	O
were	O
measured	O
in	O
the	O
metal	B-T103
serum	B-T031
levels	O
.	O

Our	O
findings	B-T033
indicate	O
that	O
combination	O
of	O
three	O
to	O
four	O
concurrent	O
PD	B-T038
-	O
risk	B-T033
factors	I-T033
defines	O
a	O
condition	O
"	O
at	O
risk	O
"	O
of	O
PD	B-T038
.	O

A	O
simple	O
stratification	B-T062
,	O
based	O
on	O
these	O
questionnaires	B-T170
,	O
might	O
be	O
of	O
help	O
in	O
identifying	B-T062
subjects	I-T062
suitable	O
for	O
neuroprotective	O
strategies	O
.	O

Work	O
process	O
,	O
performance	B-T033
and	O
professional	B-T097
profile	I-T097
of	O
a	O
Hearing	B-T058
Health	I-T058
Network	I-T058
:	O
reference	B-T170
for	O
satisfaction	B-T038

To	O
analyze	B-T062
the	O
correlation	O
between	O
the	O
satisfaction	B-T038
of	O
professionals	B-T097
from	O
the	O
Hearing	B-T058
Health	I-T058
Care	I-T058
network	I-T058
in	O
two	O
micro	O
-	O
regions	B-T082
of	O
Minas	O
Gerais	O
state	O
and	O
the	O
sociodemographic	O
profile	O
,	O
work	O
process	O
,	O
and	O
work	B-T033
performance	I-T033
in	O
the	O
health	B-T058
service	I-T058
.	O

This	O
is	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
,	O
observational	B-T062
,	O
analytic	O
study	O
with	O
a	O
non	B-T062
-	I-T062
probabilistic	I-T062
sample	I-T062
including	O
34	O
professionals	B-T097
from	O
the	O
Hearing	B-T058
Health	I-T058
Care	I-T058
services	I-T058
.	O

Data	B-T062
collection	I-T062
occurred	O
through	O
individual	B-T098
interviews	O
in	O
the	O
municipality	B-T082
of	O
professional	O
practice	O
.	O

Associations	O
between	O
the	O
Professional	B-T038
Satisfaction	I-T038
variable	O
and	O
the	O
explanatory	B-T170
variables	O
Sociodemographic	O
Data	O
,	O
Work	O
Routine	O
,	O
and	O
Developed	O
Actions	O
were	O
conducted	O
.	O

Professionals	B-T097
with	O
graduate	O
studies	O
were	O
more	O
satisfied	B-T170
with	O
the	O
human	B-T170
resources	I-T170
policy	I-T170
and	O
the	O
activities	O
developed	O
,	O
whereas	O
health	B-T058
civil	B-T097
servants	I-T097
showed	O
more	O
satisfaction	B-T038
with	O
the	O
wage	O
policy	B-T170
and	O
the	O
work	O
schedule	O
.	O

The	O
correlation	B-T062
analysis	I-T062
between	O
work	O
process	O
and	O
satisfaction	B-T038
revealed	O
a	O
moderate	O
positive	B-T033
correlation	O
between	O
items	O
such	O
as	O
Health	B-T058
Promotion	I-T058
Actions	O
,	O
Satisfaction	B-T038
with	O
Diagnostic	B-T074
Equipment	I-T074
,	O
and	O
Satisfaction	B-T038
with	O
Maintenance	O
Equipment	O
.	O

The	O
present	O
study	B-T062
revealed	O
a	O
higher	O
level	O
of	O
satisfaction	B-T038
among	O
professionals	O
with	O
graduate	O
studies	O
(	O
human	B-T170
resources	I-T170
policy	I-T170
and	O
activities	O
developed	O
)	O
and	O
civil	B-T097
servants	I-T097
(	O
wage	O
policy	B-T170
and	O
work	O
schedule	O
)	O
.	O

The	O
relevance	O
of	O
this	O
study	B-T062
lies	O
on	O
the	O
important	O
role	O
that	O
health	B-T097
professionals	I-T097
play	O
on	O
the	O
Health	B-T058
Care	I-T058
Network	I-T058
.	O

Additionally	O
,	O
the	O
study	B-T062
of	O
satisfaction	B-T038
level	O
can	O
provide	O
a	O
search	O
for	O
improvements	O
,	O
considering	O
that	O
satisfied	B-T170
professionals	O
not	O
only	O
improve	B-T033
service	O
quality	O
,	O
but	O
also	O
show	O
greater	O
creativity	O
,	O
commitment	O
,	O
and	O
performance	B-T033
.	O

Application	B-T058
of	O
Laparoscopic	B-T058
Lumbar	B-T058
Discectomy	I-T058
and	O
Artificial	B-T058
Disc	I-T058
Replacement	I-T058
:	O
At	O
Least	O
Two	O
Years	O
of	O
Follow	B-T058
-	I-T058
Up	I-T058

This	O
prospective	B-T062
observational	B-T062
study	I-T062
included	O
22	O
patients	O
who	O
were	O
diagnosed	B-T033
with	O
symptomatic	O
degenerative	B-T038
disc	I-T038
disease	I-T038
treated	O
via	O
artificial	B-T058
disc	I-T058
replacement	I-T058
(	O
ADR	B-T058
)	O
with	O
a	O
laparoscopic	B-T058
technique	O
.	O

The	O
current	O
study	B-T062
aimed	O
to	O
assess	O
the	O
safety	O
and	O
efficacy	O
of	O
ADR	B-T058
using	O
a	O
laparoscopic	B-T058
technique	O
for	O
lumbar	B-T017
disc	I-T017
herniation	I-T017
.	O

Symptomatic	O
degenerative	B-T038
disc	I-T038
disease	I-T038
is	O
the	O
major	O
cause	O
of	O
low	B-T033
back	I-T033
pain	I-T033
with	O
lumbar	B-T082
segmental	B-T082
instability	B-T033
.	O

ADR	B-T058
has	O
increased	O
in	O
popularity	O
as	O
an	O
alternative	O
treatment	O
for	O
lumbar	B-T017
disc	I-T017
herniation	I-T017
.	O

However	O
,	O
the	O
traditional	O
approach	B-T082
to	O
spinal	B-T058
surgery	I-T058
carries	O
the	O
risk	O
of	O
catastrophic	B-T038
bleeding	B-T038
from	O
injury	B-T037
to	O
major	O
vessels	B-T017
,	O
as	O
well	O
as	O
iatrogenic	O
injury	B-T037
to	O
the	O
viscera	B-T017
and	O
associated	B-T017
structures	I-T017
.	O

Therefore	O
,	O
laparoscopic	B-T058
lumbar	B-T058
discectomy	I-T058
and	O
ADR	B-T058
may	O
represent	O
a	O
useful	O
alternative	O
.	O

Twenty	O
-	O
two	O
patients	O
(	O
8	O
males	O
and	O
14	O
females	O
)	O
who	O
were	O
diagnosed	B-T033
with	O
symptomatic	O
degenerative	B-T038
disc	I-T038
disease	I-T038
were	O
included	O
in	O
this	O
study	B-T062
.	O

Seven	O
cases	O
involved	O
the	O
L4	O
/	O
5	O
level	O
,	O
and	O
15	O
cases	O
involved	O
the	O
L5	O
/	O
S1	O
level	O
.	O

All	O
patients	O
were	O
ineffective	O
after	O
at	O
least	O
6	O
months	O
of	O
conservative	B-T058
treatments	I-T058
;	O
all	O
patients	O
were	O
informed	O
of	O
the	O
surgery	B-T058
before	O
the	O
operation	B-T058
and	O
provided	O
consent	O
.	O

Three	B-T082
-	I-T082
dimensional	I-T082
computed	B-T058
tomographic	I-T058
angiography	I-T058
(	O
3D	B-T082
-	O
CTA	B-T058
)	O
of	O
the	O
iliac	B-T017
great	O
blood	B-T017
vessels	I-T017
was	O
completed	O
before	O
the	O
surgery	B-T058
.	O

All	O
surgical	B-T058
procedures	I-T058
were	O
performed	O
under	O
a	O
laparoscope	B-T074
.	O

All	O
patients	O
were	O
followed	B-T058
up	I-T058
.	O

All	O
surgeries	B-T058
were	O
successfully	O
completed	O
.	O

The	O
average	O
operation	B-T058
time	O
was	O
120	O
minutes	O
(	O
range	O
110	O
-	O
150	O
min	O
)	O
,	O
and	O
the	O
average	O
hemorrhage	B-T038
was	O
145	O
mL	O
(	O
range	O
80	O
-	O
360	O
mL	O
)	O
.	O

All	O
cases	O
underwent	O
X	B-T058
-	I-T058
rays	I-T058
at	O
3	O
days	O
,	O
3	O
months	O
,	O
6	O
months	O
,	O
1	O
year	O
,	O
and	O
the	O
final	O
postoperative	B-T058
follow	B-T058
-	I-T058
up	I-T058
.	O

The	O
outcome	O
indicated	O
that	O
there	O
was	O
no	O
mobilization	O
,	O
displacement	O
,	O
or	O
subsidence	O
in	O
all	O
patients	O
with	O
the	O
exception	O
of	O
one	O
case	O
with	O
prosthesis	O
migration	O
.	O

The	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
43	O
.	O
8	O
months	O
(	O
range	O
24	O
-	O
64	O
months	O
)	O
.	O

The	O
mean	O
visual	B-T201
analog	I-T201
scale	I-T201
(	O
VAS	B-T201
)	O
and	O
Oswestry	B-T033
scores	I-T033
were	O
decreased	O
postoperatively	O
.	O

The	O
mean	O
improvement	O
rate	O
of	O
the	O
VAS	B-T201
score	I-T201
was	O
73	O
.	O
5	O
%	O
.	O

Lumbar	B-T082
ADR	B-T058
using	O
a	O
laparoscope	B-T074
represents	O
a	O
novel	O
,	O
minimally	O
invasive	O
treatment	O
for	O
symptomatic	O
degenerative	B-T038
disc	I-T038
disease	I-T038
and	O
severe	O
lumbar	B-T038
discogenic	I-T038
pain	I-T038
.	O

Low	O
literacy	O
and	O
written	B-T170
drug	I-T170
information	I-T170
:	O
information	O
-	O
seeking	O
,	O
leaflet	B-T170
evaluation	O
and	O
preferences	O
,	O
and	O
roles	O
for	O
images	B-T170

Background	O
Low	B-T098
-	I-T098
literate	I-T098
patients	O
are	O
at	O
risk	O
to	O
misinterpret	O
written	B-T170
drug	I-T170
information	I-T170
.	O

For	O
the	O
(	O
co	O
-	O
)	O
design	O
of	O
targeted	O
patient	B-T170
information	I-T170
,	O
it	O
is	O
key	O
to	O
involve	O
this	O
group	B-T098
in	O
determining	O
their	O
communication	O
barriers	O
and	O
information	O
needs	O
.	O

Objective	O
To	O
gain	O
insight	O
into	O
how	O
people	B-T098
with	O
low	O
literacy	O
use	O
and	O
evaluate	O
written	B-T170
drug	I-T170
information	I-T170
,	O
and	O
to	O
identify	O
ways	O
in	O
which	O
they	O
feel	O
the	O
patient	O
leaflet	B-T170
can	O
be	O
improved	O
,	O
and	O
in	O
particular	O
how	O
images	B-T170
could	O
be	O
used	O
.	O

Setting	O
Food	B-T092
banks	I-T092
and	O
an	O
education	B-T092
institution	I-T092
for	O
Dutch	O
language	O
training	O
in	O
the	O
Netherlands	B-T082
.	O

Method	O
Semi	O
-	O
structured	O
focus	O
groups	O
and	O
individual	B-T098
interviews	O
were	O
held	O
with	O
low	B-T098
-	I-T098
literate	I-T098
participants	I-T098
(	O
n	O
=	O
45	O
)	O
.	O

The	O
thematic	O
framework	O
approach	O
was	O
used	O
for	O
analysis	O
to	O
identify	O
themes	O
in	O
the	O
data	O
.	O

Main	O
outcome	O
measure	O
Low	B-T098
-	I-T098
literate	I-T098
people	I-T098
'	I-T098
s	I-T098
experience	O
with	O
patient	B-T170
information	I-T170
leaflets	B-T170
,	O
ideas	O
for	O
improvements	O
,	O
and	O
perceptions	B-T038
on	O
possible	O
uses	O
for	O
visuals	O
.	O

Results	O
Patient	B-T170
information	I-T170
leaflets	B-T170
were	O
considered	O
discouraging	O
to	O
use	O
,	O
and	O
information	O
difficult	O
to	O
find	O
and	O
understand	B-T038
.	O

Many	O
rely	O
on	O
alternative	O
information	B-T033
sources	I-T033
.	O

The	O
leaflet	B-T170
should	O
be	O
shorter	O
,	O
and	O
improved	O
in	O
terms	O
of	O
organisation	O
,	O
legibility	O
and	O
readability	O
.	O

Participants	B-T098
thought	O
images	B-T170
could	O
increase	O
the	O
leaflet	B-T170
'	I-T170
s	I-T170
appeal	O
,	O
help	O
ask	O
questions	B-T170
,	O
provide	O
an	O
overview	O
,	O
help	O
understand	O
textual	B-T170
information	O
,	O
aid	O
recall	B-T038
,	O
reassure	O
,	O
and	O
even	O
lead	O
to	O
increased	O
confidence	B-T038
,	O
empowerment	O
and	O
feeling	O
of	O
safety	O
.	O

Conclusion	O
Already	O
at	O
the	O
stages	O
of	O
paying	O
attention	O
to	O
the	O
leaflet	B-T170
and	O
maintaining	O
interest	O
in	O
the	O
message	O
,	O
low	B-T098
-	I-T098
literate	I-T098
patients	I-T098
experience	B-T038
barriers	O
in	O
the	O
communication	O
process	O
through	O
written	B-T170
drug	I-T170
information	I-T170
.	O

Short	O
,	O
structured	O
,	O
visual	O
/	O
textual	B-T170
explanations	B-T170
can	O
lower	O
the	O
motivational	O
threshold	O
to	O
use	O
the	O
leaflet	B-T170
,	O
improve	B-T033
understanding	B-T038
,	O
and	O
empower	O
the	O
low	B-T098
-	I-T098
literate	I-T098
target	I-T098
group	I-T098
.	O

Establishment	O
and	O
application	O
of	O
a	O
flow	B-T058
cytometry	I-T058
-	O
based	O
method	B-T170
for	O
detecting	B-T033
histone	B-T038
acetylation	I-T038
levels	O

Histone	B-T103
deacetylase	I-T103
inhibitors	I-T103
,	O
which	O
have	O
also	O
received	O
attention	O
in	O
AIDS	B-T038
and	O
other	O
diseases	B-T038
,	O
are	O
a	O
new	O
class	O
of	O
anticancer	B-T103
drugs	I-T103
developed	O
in	O
recent	O
years	O
.	O

However	O
,	O
there	O
is	O
still	O
a	O
lack	O
of	O
a	O
unified	O
and	O
reliable	O
method	B-T170
for	O
detecting	B-T033
histone	B-T038
acetylation	I-T038
levels	O
in	O
basic	B-T062
and	O
clinical	B-T062
research	I-T062
.	O

In	O
this	O
study	B-T062
,	O
we	O
developed	O
a	O
flow	B-T058
cytometry	I-T058
-	O
based	O
method	B-T170
to	O
detect	B-T033
histone	B-T038
acetylation	I-T038
levels	O
by	O
comparing	O
different	O
sample	O
processing	O
temperature	O
(	O
on	O
ice	B-T103
vs	O
.	O

room	B-T033
temperature	I-T033
)	O
,	O
permeabilization	B-T038
method	B-T170
(	O
intracellular	B-T017
vs	O
.	O

nuclear	B-T017
)	O
,	O
antibody	B-T103
dose	O
(	O
antibody	B-T058
titration	I-T058
)	O
and	O
antibody	B-T103
incubation	O
time	O
(	O
time	O
gradient	O
)	O
using	O
whole	B-T031
blood	I-T031
and	O
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
.	O

In	O
addition	O
,	O
we	O
applied	O
this	O
optimized	O
method	B-T170
in	O
in	O
vitro	O
experiment	B-T062
and	O
clinical	B-T062
trial	I-T062
of	O
Chidamide	B-T103
(	O
the	O
only	O
China	B-T082
FDA	B-T170
approved	I-T170
HDACi	I-T170
)	O
,	O
the	O
result	O
of	O
which	O
confirmed	B-T033
that	O
the	O
flow	B-T058
cytometry	I-T058
-	O
based	O
method	B-T170
for	O
detecting	B-T033
histone	B-T038
acetylation	I-T038
levels	O
is	O
a	O
reliable	O
,	O
fast	O
and	O
convenient	O
method	B-T170
which	O
can	O
be	O
used	O
in	O
basic	B-T062
and	O
clinical	B-T062
research	I-T062
.	O

Performance	O
and	O
safety	O
of	O
collagenated	B-T103
xenogeneic	I-T103
bone	I-T103
block	I-T103
for	O
lateral	B-T058
alveolar	I-T058
ridge	I-T058
augmentation	I-T058
and	O
staged	B-T058
implant	I-T058
placement	I-T058
.	O
A	O
monocenter	B-T062
,	I-T062
prospective	I-T062
single	I-T062
-	I-T062
arm	I-T062
clinical	I-T062
study	I-T062

To	O
assess	O
the	O
clinical	O
safety	O
and	O
performance	O
of	O
collagenated	B-T103
xenogeneic	I-T103
bone	I-T103
block	I-T103
(	O
CXBB	B-T103
)	O
for	O
lateral	B-T058
alveolar	I-T058
ridge	I-T058
augmentation	I-T058
and	O
two	O
-	O
stage	O
implant	B-T058
placement	I-T058
.	O

In	O
ten	O
patients	O
exhibiting	O
a	O
single	O
-	O
tooth	B-T017
gap	B-T082
,	O
the	O
surgical	B-T058
procedure	I-T058
included	O
the	O
preparation	O
of	O
mucoperiosteal	B-T017
flaps	I-T017
,	O
a	O
rigid	B-T058
fixation	I-T058
of	O
CXBB	B-T103
(	O
Geistlich	B-T170
Bio	I-T170
-	I-T170
Graft	I-T170
(	I-T170
®	I-T170
)	I-T170
)	O
using	O
an	O
osteosynthesis	B-T074
screw	I-T074
,	O
and	O
contour	B-T082
augmentation	B-T058
.	O

After	O
24	O
weeks	O
of	O
submerged	B-T038
healing	I-T038
,	O
the	O
primary	B-T103
endpoint	I-T103
was	O
defined	O
as	O
the	O
final	O
ridge	B-T082
width	O
sufficient	O
to	O
place	O
an	O
adequately	O
dimensioned	O
titanium	O
implant	O
at	O
the	O
respective	O
sites	B-T082
.	O

Secondary	O
outcomes	O
included	O
,	O
for	O
example	O
,	O
the	O
gain	O
in	O
ridge	B-T082
width	O
(	O
mm	O
)	O
.	O

Clinical	B-T062
parameters	I-T062
(	O
e	O
.	O
g	O
.	O
,	O
bleeding	B-T033
on	I-T033
probing	I-T033
-	O
BOP	B-T033
,	O
probing	O
depth	O
-	O
PD	O
,	O
mucosal	B-T017
recession	I-T017
-	O
MR	B-T017
)	O
were	O
assessed	O
immediately	O
after	O
the	O
cementation	B-T058
of	I-T058
the	I-T058
crown	I-T058
and	O
at	O
the	O
final	B-T058
visit	I-T058
.	O

At	O
24	O
weeks	O
,	O
implant	B-T058
placement	I-T058
could	O
be	O
achieved	O
in	O
8	O
of	O
10	O
patients	O
exhibiting	O
a	O
mean	O
gain	O
in	O
ridge	B-T082
width	O
(	O
mean	O
±	O
SD	O
)	O
of	O
3	O
.	O
88	O
±	O
1	O
.	O
75	O
mm	O
.	O

Histological	O
analysis	B-T062
has	O
pointed	O
to	O
a	O
homogeneous	B-T082
osseous	B-T017
organization	O
of	O
CXBB	B-T103
.	O

The	O
changes	O
of	O
mean	O
BOP	B-T033
,	O
PD	O
,	O
and	O
MR	B-T017
values	O
at	O
the	O
final	B-T058
visit	I-T058
amounted	O
to	O
16	O
.	O
62	O
±	O
32	O
.	O
02	O
%	O
,	O
0	O
.	O
04	O
±	O
0	O
.	O
21	O
mm	O
,	O
and	O
-	O
0	O
.	O
04	O
±	O
0	O
.	O
12	O
mm	O
,	O
respectively	O
.	O

CXBB	B-T103
may	O
be	O
successfully	O
used	O
to	O
support	O
lateral	B-T058
alveolar	I-T058
ridge	I-T058
augmentation	I-T058
and	O
two	O
-	O
stage	O
implant	B-T058
placement	I-T058
.	O

The	O
link	O
between	O
self	B-T038
-	I-T038
perceptions	I-T038
of	O
aging	B-T038
,	O
cancer	B-T038
view	O
and	O
physical	O
and	O
mental	B-T038
health	I-T038
of	O
older	O
people	O
with	O
cancer	B-T038
:	O
A	B-T062
cross	I-T062
-	I-T062
sectional	I-T062
study	I-T062

Older	O
people	O
may	O
suffer	O
from	O
stigmas	B-T038
linked	O
to	O
cancer	B-T038
and	O
aging	B-T038
.	O

Although	O
some	O
studies	B-T062
suggested	O
that	O
a	O
negative	B-T033
view	B-T082
of	O
cancer	B-T038
may	O
increase	O
the	O
level	B-T033
of	I-T033
depression	I-T033
,	O
such	O
an	O
association	O
has	O
never	O
been	O
studied	B-T062
in	O
the	O
elderly	B-T098
population	I-T098
.	O

Similarly	O
,	O
even	O
though	O
it	O
is	O
established	O
that	O
a	O
negative	B-T033
self	B-T038
-	I-T038
perception	I-T038
of	O
aging	B-T038
has	O
deleterious	O
consequences	O
on	O
mental	B-T038
and	O
physical	O
health	O
in	O
normal	O
aging	B-T038
,	O
the	O
influence	O
in	O
pathological	O
contexts	O
,	O
such	O
as	O
oncology	B-T038
,	O
has	O
not	O
been	O
studied	O
.	O

The	O
main	O
aim	O
of	O
this	O
study	O
is	O
thus	O
to	O
analyze	B-T062
the	O
effect	O
of	O
these	O
two	O
stigmas	B-T038
on	O
the	O
health	O
of	O
elderly	B-T098
oncology	B-T038
patients	O
.	O

101	O
patients	O
suffering	O
from	O
a	O
cancer	B-T038
(	O
breast	B-T038
,	O
gynecological	B-T038
,	O
lung	B-T038
or	O
hematological	B-T038
)	O
were	O
seen	O
as	O
soon	O
as	O
possible	O
after	O
their	O
diagnosis	B-T033
.	O

Their	O
self	B-T038
-	I-T038
perception	I-T038
of	O
age	O
,	O
cancer	B-T038
view	O
and	O
health	O
(	O
physical	O
and	O
mental	B-T038
)	O
was	O
assessed	O
.	O

Multiple	O
regressions	B-T038
showed	O
that	O
patients	O
with	O
a	O
more	O
negative	B-T033
self	B-T038
-	I-T038
perception	I-T038
of	O
aging	B-T038
and	O
/	O
or	O
more	O
negative	B-T033
cancer	B-T038
view	O
reported	O
poorer	O
global	B-T091
health	I-T091
.	O

We	O
also	O
observed	O
that	O
negative	B-T033
self	B-T038
-	I-T038
perception	I-T038
of	O
aging	B-T038
was	O
associated	O
with	O
worse	O
physical	O
and	O
mental	B-T038
health	I-T038
,	O
whereas	O
negative	B-T033
cancer	B-T038
views	O
were	O
only	O
linked	O
to	O
worse	O
mental	B-T038
health	I-T038
.	O

No	O
interaction	O
was	O
observed	O
between	O
these	O
two	O
stigmas	B-T038
,	O
suggesting	O
that	O
their	O
action	O
is	O
independent	O
.	O

Older	O
patients	O
with	O
cancer	B-T038
face	O
double	O
stigmatization	O
,	O
due	O
to	O
negative	B-T033
self	B-T038
-	I-T038
perception	I-T038
of	O
aging	B-T038
and	O
cancer	B-T038
,	O
and	O
these	O
stigmas	B-T038
have	O
impacts	O
on	O
global	O
and	O
mental	B-T038
health	I-T038
.	O

Self	B-T038
-	I-T038
perception	I-T038
of	O
aging	B-T038
is	O
also	O
linked	O
to	O
physical	O
health	O
.	O

Longitudinal	B-T062
studies	I-T062
will	O
be	O
necessary	O
to	O
analyze	B-T062
the	O
direction	O
of	O
the	O
association	O
between	O
this	O
double	O
stigmatization	O
and	O
health	O
.	O

The	O
Aortic	B-T082
Root	I-T082
:	O
Natural	O
History	O
After	O
Root	B-T058
-	I-T058
Sparing	I-T058
Ascending	I-T058
Replacement	I-T058
in	O
Nonsyndromic	B-T033
Aneurysmal	O
Patients	O

Leaving	O
native	O
aortic	B-T017
tissue	I-T017
in	B-T082
situ	I-T082
in	O
root	B-T058
-	I-T058
sparing	I-T058
ascending	I-T058
aortic	I-T058
replacement	I-T058
raises	O
concern	O
regarding	O
potential	O
later	O
need	O
for	O
root	B-T082
reoperation	B-T058
or	O
for	O
the	O
potential	O
occurrence	O
of	O
localized	B-T082
dissections	B-T038
or	O
rupture	B-T037
in	O
the	O
residual	O
root	B-T082
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
natural	B-T038
growth	I-T038
of	O
the	O
aortic	B-T082
root	I-T082
after	O
root	B-T058
-	I-T058
sparing	I-T058
aortic	I-T058
replacement	I-T058
.	O

In	O
all	O
,	O
102	O
consecutive	O
patients	O
(	O
mean	O
age	O
61	O
.	O
8	O
±	O
12	O
.	O
5	O
years	O
;	O
60	O
%	O
male	B-T098
)	O
who	O
had	O
undergone	O
root	B-T058
-	I-T058
sparing	I-T058
aortic	I-T058
replacement	I-T058
had	O
sufficient	O
retrievable	O
information	O
regarding	O
their	O
aortic	B-T082
root	I-T082
diameter	O
at	O
postoperative	O
baseline	O
and	O
follow	B-T058
-	I-T058
up	I-T058
imaging	B-T058
by	O
computed	B-T058
tomography	I-T058
or	O
echocardiography	B-T058
.	O

The	O
annual	O
growth	O
rate	O
was	O
evaluated	O
and	O
also	O
compared	O
according	O
to	O
the	O
influence	O
of	O
valve	O
morphology	O
and	O
concomitant	O
aortic	B-T058
valve	I-T058
replacement	I-T058
.	O

Furthermore	O
,	O
the	O
years	O
of	O
natural	O
history	O
that	O
would	O
require	O
for	O
root	B-T082
enlargement	B-T017
to	O
meet	O
a	O
50	O
mm	O
threshold	O
of	O
the	O
root	B-T082
diameter	O
were	O
calculated	O
.	O

The	O
estimated	O
growth	O
rate	O
of	O
the	O
aortic	B-T082
root	I-T082
after	O
root	B-T058
-	I-T058
sparing	I-T058
aortic	I-T058
replacement	I-T058
is	O
between	O
0	O
.	O
27	O
and	O
0	O
.	O
51	O
mm	O
per	O
year	O
(	O
mean	O
0	O
.	O
41	O
mm	O
,	O
varying	O
according	O
to	O
the	O
underlying	O
diameter	O
)	O
and	O
therefore	O
fivefold	O
less	O
than	O
other	O
aortic	B-T082
regions	I-T082
.	O

Accordingly	O
,	O
a	O
root	B-T038
aneurysm	I-T038
indicating	O
reoperation	B-T058
would	O
not	O
be	O
expected	B-T170
for	O
29	O
.	O
1	O
years	O
on	O
average	O
.	O

Only	O
patients	O
with	O
a	O
diameter	O
of	O
45	O
mm	O
or	O
more	O
are	O
at	O
risk	O
for	O
reoperation	B-T058
,	O
and	O
not	O
until	B-T170
at	O
least	O
after	O
10	O
.	O
4	O
years	O
have	B-T033
passed	I-T033
.	O

Neither	O
the	O
valve	O
morphology	O
(	O
p	O
=	O
0	O
.	O
62	O
)	O
nor	O
concomitant	O
aortic	B-T058
valve	I-T058
replacement	I-T058
(	O
p	O
=	O
0	O
.	O
86	O
)	O
influenced	O
rate	O
of	O
root	B-T038
dilation	I-T038
.	O

In	O
nonsyndromic	B-T033
patients	O
,	O
the	O
aortic	B-T082
root	I-T082
is	O
the	O
slowest	O
growing	B-T038
portion	B-T082
of	O
the	O
thoracic	B-T017
aorta	I-T017
.	O

Leaving	O
the	O
native	O
root	B-T082
,	O
as	O
in	O
root	B-T058
-	I-T058
sparing	I-T058
ascending	I-T058
aortic	I-T058
replacement	I-T058
,	O
is	O
a	O
safe	B-T082
approach	I-T082
regarding	O
secondary	B-T082
root	I-T082
intervention	B-T058
for	O
aortic	B-T082
root	I-T082
diameters	O
of	O
45	O
mm	O
or	O
less	O
.	O

Physical	O
Exercise	O
for	O
Late	O
-	O
Life	O
Depression	B-T038
:	O
Effects	O
on	O
Heart	B-T201
Rate	I-T201
Variability	O

Late	O
-	O
life	O
major	B-T038
depression	I-T038
is	O
associated	O
with	O
increased	O
cardiovascular	O
risk	O
and	O
impaired	B-T038
autonomic	I-T038
control	I-T038
of	I-T038
the	I-T038
heart	I-T038
,	O
as	O
evident	O
from	O
reduced	O
heart	B-T201
rate	I-T201
variability	O
(	O
HRV	O
)	O
.	O

Moreover	O
,	O
antidepressant	B-T103
drug	I-T103
therapy	B-T058
also	O
might	O
be	O
associated	O
with	O
further	O
reductions	O
of	O
HRV	O
.	O

In	O
the	O
SEEDS	B-T062
study	I-T062
,	O
we	O
investigated	O
whether	O
sertraline	B-T103
associated	O
with	O
physical	O
exercise	O
protocols	O
led	O
to	O
improvements	O
of	O
HRV	O
,	O
compared	O
with	O
antidepressant	B-T103
drug	I-T103
therapy	B-T058
alone	O
.	O

Single	B-T062
-	I-T062
blind	I-T062
randomized	B-T062
controlled	I-T062
trial	I-T062
.	O

Psychiatric	O
consultation	O
-	O
liaison	O
program	O
for	O
primary	B-T058
care	I-T058
.	O

Patients	O
aged	O
65	O
-	O
85	O
years	O
with	O
major	B-T038
depression	I-T038
,	O
recruited	O
from	O
primary	B-T058
care	I-T058
.	O

Sertraline	B-T103
plus	O
structured	O
,	O
tailored	O
group	O
physical	O
exercise	O
(	O
S	O
+	O
EX	O
)	O
versus	O
sertraline	B-T103
alone	O
(	O
S	O
)	O
for	O
24	O
weeks	O
.	O

HRV	O
indices	B-T170
(	O
RR	O
,	O
percentage	O
of	O
NN	O
intervals	O
greater	O
than	O
50	O
msec	O
[	O
pNN50	O
]	O
,	O
square	O
root	O
of	O
the	O
mean	O
squared	O
differences	O
of	O
successive	O
NN	O
intervals	O
[	O
RMSSD	O
]	O
,	O
standard	O
deviation	O
of	O
heart	B-T201
rate	I-T201
[	O
SDHR	O
]	O
,	O
standard	O
deviation	O
of	O
the	O
NN	O
interval	O
[	O
SDNN	O
]	O
,	O
high	O
-	O
frequency	O
band	O
[	O
HF	O
]	O
,	O
low	O
-	O
frequency	O
band	O
[	O
LF	O
]	O
,	O
and	O
their	O
ratio	O
[	O
LF	O
/	O
HF	O
]	O
)	O
were	O
measured	O
at	O
baseline	O
,	O
week	O
12	O
,	O
and	O
week	O
24	O
.	O

Psychiatric	B-T058
and	O
medical	B-T058
assessments	I-T058
.	O

Participants	B-T098
displayed	O
significant	O
improvements	O
of	O
most	O
HRV	O
indices	B-T170
over	O
time	O
,	O
irrespective	O
of	O
the	O
group	O
assignment	O
(	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
LF	O
,	O
and	O
LF	O
/	O
HF	O
)	O
.	O

Moreover	O
,	O
patients	O
in	O
the	O
S	O
+	O
EX	O
group	O
displayed	O
greater	O
increases	O
of	O
different	O
HRV	O
indices	B-T170
(	O
RR	O
,	O
pNN50	O
,	O
RMSSD	O
,	O
SDHR	O
,	O
SDNN	O
,	O
HF	O
,	O
and	O
LF	O
)	O
compared	O
with	O
those	O
in	O
the	O
S	O
group	O
.	O

The	O
combination	O
of	O
structured	O
physical	O
exercise	O
and	O
sertraline	B-T103
might	O
exert	O
positive	B-T033
effects	O
on	O
the	O
autonomic	B-T038
control	I-T038
of	I-T038
the	I-T038
heart	I-T038
among	O
older	O
patients	O
with	O
major	B-T038
depression	I-T038
.	O

Genome	B-T058
-	I-T058
Wide	I-T058
SNP	I-T058
Linkage	I-T058
Mapping	I-T058
and	O
QTL	B-T017
Analysis	B-T058
for	O
Fiber	B-T204
Quality	O
and	O
Yield	O
Traits	O
in	O
the	O
Upland	B-T204
Cotton	I-T204
Recombinant	B-T204
Inbred	I-T204
Lines	I-T204
Population	O

It	O
is	O
of	O
significance	O
to	O
discover	O
genes	B-T017
related	O
to	O
fiber	B-T204
quality	O
and	O
yield	O
traits	O
and	O
tightly	O
linked	O
markers	B-T038
for	O
marker	B-T062
-	I-T062
assisted	I-T062
selection	I-T062
(	O
MAS	B-T062
)	O
in	O
cotton	B-T204
breeding	B-T038
.	O

In	O
this	O
study	O
,	O
188	B-T204
F8	I-T204
recombinant	B-T204
inbred	I-T204
lines	I-T204
(	O
RILs	B-T204
)	O
,	O
derived	O
from	O
a	O
intraspecific	O
cross	B-T038
between	O
HS46	B-T204
and	O
MARCABUCAG8US	B-T204
-	I-T204
1	I-T204
-	I-T204
88	I-T204
were	O
genotyped	O
by	O
the	O
cotton	B-T204
63K	O
single	B-T058
nucleotide	I-T058
polymorphism	I-T058
(	I-T058
SNP	I-T058
)	I-T058
assay	I-T058
.	O

Field	O
trials	O
were	O
conducted	O
in	O
Sanya	O
,	O
Hainan	O
Province	O
,	O
during	O
the	O
2014	O
-	O
2015	O
cropping	O
seasons	O
under	O
standard	O
conditions	O
.	O

Results	O
revealed	O
significant	O
differences	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
among	O
RILs	B-T204
,	O
environments	B-T082
and	O
replications	O
for	O
fiber	B-T204
quality	O
and	O
yield	O
traits	O
.	O

Broad	O
-	O
sense	O
heritabilities	O
of	O
all	O
traits	O
including	O
fiber	B-T204
length	O
,	O
fiber	B-T204
uniformity	O
,	O
micronaire	O
,	O
fiber	B-T204
elongation	B-T038
,	O
fiber	B-T204
strength	O
,	O
boll	B-T204
weight	O
,	O
and	O
lint	O
percentage	O
ranged	O
from	O
0	O
.	O
26	O
to	O
0	O
.	O
66	O
.	O

A	O
1784	O
.	O
28	O
cM	O
(	O
centimorgans	O
)	O
linkage	B-T058
map	I-T058
,	O
harboring	O
2618	O
polymorphic	O
SNP	B-T082
markers	B-T038
,	O
was	O
constructed	O
,	O
which	O
had	O
0	O
.	O
68	O
cM	O
per	O
marker	B-T038
density	O
.	O

Seventy	O
-	O
one	O
quantitative	B-T017
trait	I-T017
locus	I-T017
(	O
QTLs	B-T017
)	O
for	O
fiber	B-T204
quality	O
and	O
yield	O
traits	O
were	O
detected	O
on	O
21	O
chromosomes	B-T017
,	O
explaining	O
4	O
.	O
70	O
~	O
32	O
.	O
28	O
%	O
phenotypic	O
variance	O
,	O
in	O
which	O
16	O
were	O
identified	O
as	O
stable	O
QTLs	B-T017
across	O
two	O
environments	B-T082
.	O

Meanwhile	O
,	O
12	O
certain	O
regions	B-T017
were	O
investigated	O
to	O
be	O
involved	O
in	O
the	O
control	O
of	O
one	O
(	O
hotspot	B-T082
)	O
or	O
more	O
(	O
cluster	B-T017
)	O
traits	O
,	O
mainly	O
focused	O
on	O
Chr05	B-T017
,	O
Chr09	B-T017
,	O
Chr10	B-T017
,	O
Chr14	B-T017
,	O
Chr19	B-T017
,	O
and	O
Chr20	B-T017
.	O

Nineteen	O
pairs	O
of	O
epistatic	B-T017
QTLs	B-T017
(	O
e	B-T017
-	I-T017
QTLs	I-T017
)	O
were	O
identified	O
,	O
of	O
which	O
two	O
pairs	O
involved	O
in	O
two	O
additive	O
QTLs	B-T017
.	O

These	O
additive	O
QTLs	B-T017
,	O
e	B-T017
-	I-T017
QTLs	I-T017
,	O
and	O
QTL	B-T017
clusters	B-T017
were	O
tightly	O
linked	O
to	O
SNP	B-T082
markers	B-T038
,	O
which	O
may	O
serve	O
as	O
target	O
regions	B-T017
for	O
map	B-T058
-	I-T058
based	I-T058
cloning	I-T058
,	O
gene	B-T062
discovery	I-T062
,	O
and	O
MAS	B-T062
in	O
cotton	B-T204
breeding	B-T038
.	O

Effects	O
of	O
an	O
early	O
intervention	B-T058
using	O
human	B-T204
amniotic	B-T017
epithelial	B-T017
cells	I-T017
in	O
a	O
COPD	B-T038
rat	B-T204
model	O

The	O
study	B-T062
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
an	O
early	O
intervention	B-T058
using	O
human	B-T204
amniotic	B-T017
epithelial	B-T017
cell	I-T017
(	O
hAEC	B-T017
)	O
in	O
a	O
rat	B-T204
model	O
of	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
(	O
COPD	B-T038
)	O
.	O

Twenty	O
-	O
four	O
specific	O
pathogen	O
-	O
free	O
Wistar	B-T204
rats	I-T204
were	O
randomized	B-T062
to	O
the	O
control	O
,	O
COPD	B-T038
,	O
and	O
COPD	B-T038
+	O
hAEC	B-T017
groups	O
.	O

COPD	B-T038
was	O
established	O
by	O
intratracheal	O
LPS	B-T103
injection	O
combined	O
with	O
smoke	B-T103
fumigation	O
over	O
30	O
days	O
.	O

On	O
the	O
first	O
day	O
of	O
model	O
establishment	O
rats	B-T204
in	O
the	O
AEC	B-T017
group	O
also	O
received	O
intratracheal	O
instillation	O
of	O
500	O
,	O
000	O
hAECs	B-T017
isolated	O
from	O
the	O
placenta	B-T017
of	O
healthy	O
donors	B-T098
.	O

The	O
mean	O
linear	O
intercept	O
(	O
MLI	O
)	O
and	O
mean	O
alveolar	O
number	O
(	O
MAN	O
)	O
were	O
used	O
to	O
assess	O
the	O
degree	O
of	O
lung	B-T038
emphysema	I-T038
.	O

IL	B-T103
-	I-T103
8	I-T103
was	O
measured	O
using	O
a	O
radioimmunoassay	B-T058
,	O
surfactant	B-T103
protein	I-T103
D	I-T103
(	O
SP	B-T103
-	I-T103
D	I-T103
)	O
was	O
measured	O
by	O
ELISA	B-T058
,	O
and	O
matrix	B-T103
metalloproteinase	I-T103
(	I-T103
MMP	I-T103
)	I-T103
2	I-T103
and	O
MMP8	B-T103
expression	B-T038
was	O
assessed	O
by	O
PCR	B-T062
.	O

Smoke	B-T103
fumigation	O
combined	O
to	O
LPS	B-T103
injection	O
successfully	O
established	O
a	O
COPD	B-T038
rat	B-T204
model	O
with	O
significant	O
emphysema	B-T038
and	O
airway	B-T038
inflammation	I-T038
,	O
elevated	O
MLI	O
and	O
MAN	O
,	O
elevated	O
systemic	O
and	O
lung	B-T017
tissue	B-T017
levels	O
of	O
IL	B-T103
-	I-T103
8	I-T103
and	O
SP	B-T103
-	I-T103
D	I-T103
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
high	O
expression	B-T038
of	O
MMP2	B-T103
and	O
MMP8	B-T103
.	O

Rats	B-T204
in	O
the	O
COPD	B-T038
+	O
hAEC	B-T017
group	O
exhibited	O
alleviated	O
lung	B-T017
damage	B-T037
,	O
MLI	O
and	O
MAN	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
reduced	O
systemic	O
and	O
lung	B-T017
tissue	B-T017
levels	O
of	O
IL	B-T103
-	I-T103
8	I-T103
and	O
SP	B-T103
-	I-T103
D	I-T103
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
MMP2	B-T103
and	O
MMP8	B-T103
expression	B-T038
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Early	O
intervention	B-T058
using	O
hAECs	B-T017
could	O
delay	O
disease	B-T038
progression	I-T038
in	O
rats	B-T204
with	O
COPD	B-T038
.	O

Systematic	O
Identification	B-T038
of	O
Pharmacological	B-T038
Targets	O
from	O
Small	B-T103
-	I-T103
Molecule	I-T103
Phenotypic	B-T058
Screens	I-T058

Phenotypic	O
drug	B-T062
discovery	I-T062
offers	O
some	O
advantages	O
over	O
target	O
-	O
based	O
methods	B-T170
,	O
mainly	O
because	O
it	O
allows	O
drug	B-T103
leads	I-T103
to	O
be	O
tested	O
in	O
systems	O
that	O
more	O
closely	B-T033
model	O
distinct	O
disease	B-T033
states	I-T033
.	O

However	O
,	O
a	O
potential	O
disadvantage	O
is	O
the	O
difficulty	O
of	O
linking	O
the	O
observed	O
phenotype	O
to	O
a	O
specific	O
cellular	B-T017
target	O
.	O

To	O
address	O
this	O
problem	B-T033
,	O
we	O
developed	O
DePick	B-T170
,	O
a	O
computational	O
target	O
de	O
-	O
convolution	O
tool	O
to	O
determine	B-T058
targets	O
specifically	O
linked	O
to	O
small	B-T103
-	I-T103
molecule	I-T103
phenotypic	B-T058
screens	I-T058
.	O

We	O
applied	O
DePick	B-T170
to	O
eight	O
publicly	B-T092
available	O
screens	O
and	O
predicted	O
59	O
drug	B-T103
target	O
-	O
phenotype	O
associations	O
.	O

In	O
addition	O
to	O
literature	B-T170
-	O
based	O
evidence	O
for	O
our	O
predictions	O
,	O
we	O
provide	O
experimental	O
support	O
for	O
seven	O
predicted	O
associations	O
.	O

Interestingly	B-T038
,	O
our	O
analysis	B-T062
led	O
to	O
the	O
discovery	O
of	O
a	O
previously	O
unrecognized	O
connection	B-T082
between	O
the	O
Wnt	B-T038
signaling	I-T038
pathway	I-T038
and	O
an	O
aromatase	B-T103
,	O
CYP19A1	B-T103
.	O

These	O
results	O
demonstrate	O
that	O
the	O
DePick	B-T170
approach	O
can	O
not	O
only	O
accelerate	O
target	O
de	O
-	O
convolution	O
but	O
also	O
aid	O
in	O
discovery	O
of	O
new	O
functionally	O
relevant	O
biological	O
relationships	O
.	O

'	O
Yarn	B-T058
with	O
me	O
'	O
:	O
applying	O
clinical	B-T058
yarning	I-T058
to	O
improve	O
clinician	B-T097
-	O
patient	O
communication	O
in	O
Aboriginal	O
health	B-T058
care	I-T058

Although	O
successful	O
communication	O
is	O
at	O
the	O
heart	O
of	O
the	O
clinical	B-T058
consultation	I-T058
,	O
communication	O
between	O
Aboriginal	O
patients	O
and	O
practitioners	B-T097
such	O
as	O
doctors	B-T097
,	O
nurses	B-T097
and	O
allied	B-T097
health	I-T097
professionals	I-T097
,	O
continues	O
to	O
be	O
problematic	B-T033
and	O
is	O
arguably	O
the	O
biggest	O
barrier	O
to	O
the	O
delivery	O
of	O
successful	O
health	B-T058
care	I-T058
to	O
Aboriginal	O
people	O
.	O

This	O
paper	O
presents	O
an	O
overarching	B-T170
framework	I-T170
for	O
practitioners	B-T097
to	O
help	O
them	O
reorientate	O
their	O
communication	O
with	O
Aboriginal	O
patients	O
using	O
'	O
clinical	B-T058
yarning	I-T058
'	O
.	O

Clinical	B-T058
yarning	I-T058
is	O
a	O
patient	O
-	O
centred	O
approach	O
that	O
marries	O
Aboriginal	O
cultural	O
communication	O
preferences	O
with	O
biomedical	B-T091
understandings	O
of	O
health	O
and	O
disease	O
.	O

Clinical	B-T058
yarning	I-T058
consists	O
of	O
three	O
interrelated	O
areas	O
:	O
the	O
social	O
yarn	B-T058
,	O
in	O
which	O
the	O
practitioner	B-T097
aims	O
to	O
find	O
common	O
ground	O
and	O
develop	O
the	O
interpersonal	O
relationship	O
;	O
the	O
diagnostic	O
yarn	B-T058
,	O
in	O
which	O
the	O
practitioner	B-T097
facilitates	O
the	O
patient	O
'	O
s	O
health	O
story	O
while	O
interpreting	O
it	O
through	O
a	O
biomedical	B-T091
or	O
scientific	B-T058
lens	I-T058
;	O
and	O
the	O
management	O
yarn	B-T058
,	O
that	O
employs	O
stories	O
and	O
metaphors	O
as	O
tools	O
for	O
patients	O
to	O
help	O
them	O
understand	O
a	O
health	B-T033
issue	I-T033
so	O
a	O
collaborative	O
management	O
approach	O
can	O
be	O
adopted	O
.	O

There	O
is	O
cultural	O
and	O
research	B-T062
evidence	O
that	O
supports	O
this	O
approach	O
.	O

Clinical	B-T058
yarning	I-T058
has	O
the	O
potential	O
to	O
improve	O
outcomes	O
for	O
patients	O
and	O
practitioners	B-T097
.	O

Effect	O
of	O
single	B-T201
-	I-T201
dose	I-T201
carbapenem	B-T103
exposure	B-T033
on	O
transcriptional	B-T038
expression	I-T038
of	O
blaNDM	O
-	O
1	O
and	O
mexA	B-T017
in	O
Pseudomonas	B-T007
aeruginosa	I-T007

The	O
therapeutic	O
option	O
of	O
a	O
carbapenem	B-T103
antibiotic	I-T103
is	O
compromised	O
in	O
Pseudomonas	B-T007
aeruginosa	I-T007
owing	O
both	O
to	O
acquired	B-T038
and	O
intrinsic	O
resistance	O
mechanisms	O
.	O

In	O
recent	O
years	O
,	O
New	B-T103
Delhi	I-T103
metallo	I-T103
-	I-T103
β	I-T103
-	I-T103
lactamase	I-T103
has	O
been	O
the	O
focus	O
as	O
a	O
predominant	O
carbapenem	O
resistance	O
determinant	O
.	O

However	O
,	O
it	O
is	O
unclear	O
which	O
of	O
the	O
mechanisms	O
might	O
be	O
adopted	O
by	O
a	O
P	B-T007
.	I-T007

aeruginosa	I-T007
strain	O
possessing	O
both	O
blaNDM	O
-	O
1	O
and	O
an	O
overexpressed	B-T038
MexAB	B-T017
-	I-T017
OprM	I-T017
system	O
during	O
carbapenem	B-T103
therapy	B-T058
.	O

This	O
study	O
investigated	O
the	O
interplay	O
of	O
both	O
mechanisms	O
in	O
clinical	B-T103
isolates	I-T103
of	O
P	B-T007
.	I-T007

aeruginosa	I-T007
when	O
exposed	O
to	O
meropenem	B-T103
.	O

Five	O
strains	O
were	O
used	O
:	O
(	O
i	O
)	O
strain	B-T038
overexpressing	I-T038
MexAB	B-T017
-	I-T017
OprM	I-T017
but	O
with	O
no	O
blaNDM	O
-	O
1	O
;	O
(	O
ii	O
)	O
strain	O
harbouring	O
blaNDM	O
-	O
1	O
but	O
expressing	B-T038
MexAB	B-T017
-	I-T017
OprM	I-T017
at	O
basal	O
level	O
;	O
(	O
iii	O
)	O
strain	O
possessing	O
blaNDM	O
-	O
1	O
and	O
overexpressing	B-T038
MexAB	B-T017
-	I-T017
OprM	I-T017
;	O
(	O
iv	O
)	O
P	B-T007
.	I-T007

aeruginosa	I-T007
PAO1	I-T007
;	O
and	O
(	O
v	O
)	O
P	B-T007
.	I-T007

aeruginosa	I-T007
K2733	I-T007
-	I-T007
PAO1	I-T007
(	O
ΔMexAB	B-T017
-	I-T017
OprM	I-T017
ΔMexCD	B-T017
-	I-T017
OprJ	I-T017
ΔMexEF	B-T017
-	I-T017
OprN	I-T017
ΔMexXY	B-T017
-	I-T017
OprM	I-T017
)	O
into	O
which	O
blaNDM	O
-	O
1	O
was	O
cloned	B-T058
.	O

Strains	O
were	O
incubated	O
in	O
Luria	B-T103
-	I-T103
Bertani	I-T103
broth	I-T103
with	O
and	O
without	O
1μg	O
/	O
mL	O
meropenem	B-T103
.	O

Total	B-T058
RNA	I-T058
was	O
isolated	O
at	O
45	O
-	O
min	O
intervals	O
and	O
was	O
immediately	O
reverse	B-T038
transcribed	I-T038
to	O
cDNA	B-T103
.	O

This	O
was	O
repeated	O
for	O
6h	O
.	O

Quantitative	B-T062
real	I-T062
-	I-T062
time	I-T062
PCR	I-T062
was	O
performed	O
for	O
both	O
resistance	B-T062
mechanisms	I-T062
.	O

Meropenem	B-T103
exposure	B-T033
did	O
not	O
significantly	O
elevate	B-T038
transcription	I-T038
of	O
either	O
the	O
blaNDM	O
-	O
1	O
or	O
mexA	B-T017
gene	I-T017
.	O

However	O
,	O
an	O
interesting	O
finding	O
was	O
that	O
upon	O
single	B-T201
-	I-T201
dose	I-T201
exposure	B-T033
to	I-T033
carbapenem	I-T033
,	O
the	O
efflux	B-T017
pump	I-T017
system	I-T017
played	O
a	O
major	O
role	O
in	O
bacterial	O
survival	O
compared	O
with	O
NDM	B-T103
-	I-T103
1	I-T103
.	O

This	O
study	O
gives	O
an	O
insight	O
into	O
the	O
bacterial	B-T038
response	I-T038
to	I-T038
carbapenem	I-T038
antibiotic	I-T038
when	O
two	O
different	O
resistance	B-T062
mechanisms	I-T062
coexist	O
.	O

This	O
type	O
of	O
study	O
would	O
be	O
helpful	O
in	O
designing	O
future	O
antimicrobials	B-T103
.	O

Inducible	O
Expression	B-T038
of	O
both	O
ermB	B-T017
and	O
ermT	B-T017
Conferred	O
High	O
Macrolide	B-T033
Resistance	I-T033
in	O
Streptococcus	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007
pasteurianus	I-T007
Isolates	O
in	O
China	B-T082

Streptococcus	B-T007
gallolyticus	I-T007
subsp	I-T007
.	I-T007

pasteurianus	I-T007
is	O
an	O
under	O
-	O
recognized	O
pathogen	O
and	O
zoonotic	B-T007
agent	I-T007
causing	O
opportunistic	B-T038
infections	I-T038
in	O
humans	B-T204
.	O

Despite	O
increasing	O
recognition	O
of	O
this	O
subspecies	B-T007
as	O
a	O
cause	O
for	O
human	B-T204
infectious	B-T038
diseases	I-T038
,	O
limited	O
information	O
is	O
known	O
about	O
its	O
antibiotic	O
resistance	O
mechanism	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
aim	O
to	O
identify	O
the	O
molecular	B-T038
mechanism	I-T038
underlying	O
the	O
high	O
macrolide	B-T033
resistance	I-T033
of	O
six	O
S	B-T007
.	I-T007

gallolyticus	I-T007
subsp	I-T007
.	I-T007

pasteurianus	I-T007
isolates	O
from	O
dead	B-T033
ducklings	B-T204
collected	O
in	O
several	O
natural	O
outbreaks	O
in	O
China	B-T082
during	O
2010	O
-	O
2013	O
.	O

All	O
isolates	O
exhibited	O
multi	O
-	O
drug	O
resistance	O
including	O
high	O
macrolide	B-T033
resistance	I-T033
(	O
MIC	B-T033
≥	O
1024	O
mg	O
/	O
L	O
for	O
erythromycin	B-T103
,	O
and	O
512	O
mg	O
/	O
L	O
for	O
clarithromycin	B-T103
)	O
.	O

Efflux	B-T017
-	I-T017
encoding	I-T017
mefA	I-T017
and	O
mefE	B-T017
genes	I-T017
were	O
not	O
detectable	O
in	O
these	O
isolates	O
.	O

The	O
presence	O
of	O
23S	B-T103
rRNA	I-T103
mutations	B-T038
in	O
specific	O
isolates	O
did	O
not	O
significantly	O
change	O
macrolide	B-T103
MIC	B-T033
s	O
.	O

No	O
nucleotide	B-T103
substitutions	O
were	O
found	O
in	O
genes	B-T017
encoding	O
ribosomal	B-T103
proteins	I-T103
L4	I-T103
or	O
L22	B-T103
.	O

The	O
ermB	B-T017
and	O
ermT	B-T017
genes	I-T017
were	O
found	O
in	O
the	O
genomes	B-T017
of	O
all	O
isolates	O
.	O

These	O
two	O
genes	B-T017
were	O
acquired	O
independently	O
in	O
one	O
highly	O
virulent	O
isolate	O
AL101002	O
,	O
and	O
clustered	O
with	O
Tn916	O
and	O
IS1216	O
,	O
respectively	O
.	O

The	O
expression	B-T038
of	O
both	O
ermB	B-T017
and	O
ermT	B-T017
in	O
all	O
isolates	O
was	O
erythromycin	B-T103
inducible	O
and	O
yielded	O
comparable	O
macrolide	B-T103
MICs	B-T033
in	O
all	O
six	O
isolates	O
.	O

Taken	O
together	O
,	O
inducible	O
expression	B-T038
of	O
both	O
ermB	B-T017
and	O
ermT	B-T017
conferred	O
high	O
macrolide	B-T033
resistance	I-T033
in	O
these	O
S	B-T007
.	I-T007

gallolyticus	I-T007
subsp	I-T007
.	I-T007

pasterianus	I-T007
isolates	O
.	O

Our	O
findings	B-T033
reveal	O
new	O
macrolide	B-T033
resistance	I-T033
features	O
in	O
S	B-T007
.	I-T007

gallolyticus	I-T007
subsp	I-T007
.	I-T007

pasteurianus	I-T007
by	O
both	O
ermB	B-T017
and	O
ermT	B-T017
.	O

Bilateral	B-T082
C1	B-T074
laminar	I-T074
hooks	I-T074
combined	O
with	O
C2	B-T074
pedicle	I-T074
screw	I-T074
fixation	B-T058
in	O
the	O
treatment	B-T058
of	O
atlantoaxial	B-T037
subluxation	I-T037
after	O
Grisel	B-T038
syndrome	I-T038

Many	O
etiologies	O
can	O
lead	O
to	O
atlantoaxial	B-T037
subluxaion	I-T037
.	O

In	O
Grisel	B-T038
syndrome	I-T038
(	O
GS	B-T038
)	O
,	O
this	O
subluxation	B-T037
occurs	O
spontaneously	O
after	O
inflammatory	O
processes	O
of	O
the	O
head	B-T082
and	O
neck	B-T082
.	O

Diagnosis	B-T033
is	O
typically	O
based	O
on	O
clinical	B-T033
history	I-T033
and	O
a	O
strong	O
suspicion	B-T038
of	O
this	O
syndrome	B-T038
.	O

Nonsurgical	B-T058
treatment	I-T058
most	O
often	O
resolves	O
the	O
symptoms	B-T033
;	O
however	O
,	O
in	O
some	O
cases	O
surgical	B-T058
treatment	I-T058
is	O
necessary	O
to	O
repair	B-T058
the	O
subluxation	B-T037
.	O

Various	O
surgical	B-T058
techniques	I-T058
and	O
instrumentation	B-T074
systems	I-T074
have	O
been	O
used	O
to	O
treat	B-T058
atlantoaxial	B-T037
subluxation	I-T037
,	O
although	O
there	O
is	O
no	O
consensus	O
regarding	O
the	O
best	O
treatment	B-T058
method	I-T058
for	O
the	O
pediatric	O
population	B-T098
.	O

To	O
describe	O
a	O
case	O
of	O
atlantoaxial	B-T037
subluxation	I-T037
in	O
a	O
child	O
with	O
GS	B-T038
treated	B-T033
surgically	B-T058
with	O
an	O
alternative	O
construct	B-T074
.	O

This	O
is	O
a	O
case	B-T170
report	I-T170
and	O
literature	B-T170
review	I-T170
.	O

Our	O
case	B-T170
study	I-T170
involves	O
a	O
5	O
-	O
year	O
-	O
old	O
girl	O
with	O
a	O
6	O
-	O
month	O
history	B-T033
of	O
unresolved	O
Fielding	B-T037
type	I-T037
II	I-T037
atlantoaxial	I-T037
subluxation	I-T037
caused	O
by	O
GS	B-T038
.	O

Despite	O
conservative	B-T058
treatment	I-T058
,	O
the	O
patient	O
'	O
s	O
symptoms	B-T033
continued	O
to	O
progress	O
.	O

After	O
two	O
failed	O
closed	B-T058
reduction	I-T058
attempts	O
,	O
open	B-T058
reduction	I-T058
and	O
C1	B-T058
-	I-T058
C2	I-T058
fusion	I-T058
were	O
performed	O
with	O
atlas	B-T074
laminar	I-T074
hook	I-T074
and	O
axis	B-T074
pedicle	I-T074
polyaxial	I-T074
screws	I-T074
.	O

A	O
literature	B-T170
review	I-T170
of	O
the	O
surgical	B-T058
treatment	I-T058
of	O
GS	B-T038
was	O
also	O
performed	O
.	O

After	O
surgery	O
,	O
the	O
patient	O
exhibited	O
full	O
clinical	O
and	O
functional	B-T033
recovery	I-T033
with	O
complete	O
resolution	O
of	O
symptoms	B-T033
.	O

At	O
the	O
36	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
examination	B-T058
,	O
there	O
was	O
continual	O
evidence	O
of	O
satisfactory	B-T033
reduction	B-T058
and	O
fusion	B-T058
.	O

No	O
complications	B-T038
were	O
observed	O
.	O

Upon	O
completion	O
of	O
the	O
literature	B-T170
review	I-T170
,	O
eight	O
GS	B-T038
cases	O
were	O
found	O
to	O
have	O
been	O
treated	O
surgically	B-T058
with	O
the	O
minimum	O
patient	O
age	O
being	O
9	O
years	O
.	O

Conservative	B-T058
management	I-T058
of	O
GS	B-T038
is	O
the	O
most	O
common	O
and	O
effective	O
treatment	B-T058
;	O
however	O
,	O
a	O
few	O
surgical	O
cases	O
have	O
been	O
reported	B-T058
in	O
the	O
literature	B-T170
with	O
good	O
results	O
.	O

Satisfactory	B-T033
clinical	B-T033
results	I-T033
and	O
fusion	B-T058
at	O
36	O
months	O
post	B-T033
surgery	I-T033
were	O
seen	O
in	O
a	O
pediatric	O
patient	O
with	O
atlantoaxial	B-T037
subluxation	I-T037
and	O
instability	B-T033
using	O
atlas	B-T074
laminar	I-T074
hook	I-T074
and	O
axis	B-T074
pedicle	I-T074
polyaxial	I-T074
screws	I-T074
.	O

Caries	B-T038
with	O
Dental	B-T038
Fluorosis	I-T038
and	O
Oral	O
Health	O
Behaviour	O
Among	O
12	O
-	O
Year	O
School	O
Children	O
in	O
Moderate	O
-	O
Fluoride	O
Drinking	O
Water	O
Community	O
in	O
Quetta	B-T082
,	O
Pakistan	B-T082

To	O
determine	O
the	O
prevalence	O
of	O
dental	B-T038
caries	I-T038
and	O
its	O
relationship	O
with	O
dental	B-T038
fluorosis	I-T038
,	O
oral	O
health	O
behaviour	O
and	O
dietary	B-T033
behaviour	I-T033
among	O
12	O
-	O
year	O
school	O
children	O
in	O
moderate	O
-	O
fluoride	O
drinking	O
water	O
community	O
in	O
Quetta	B-T082
,	O
Pakistan	B-T082
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
.	O

Government	B-T092
and	O
private	B-T092
schools	I-T092
of	O
Quetta	B-T082
,	O
from	O
November	O
2012	O
to	O
February	O
2013	O
.	O

Atotal	O
of	O
349	O
children	O
aged	O
12	O
-	O
year	O
from	O
14	O
randomly	O
selected	O
schools	B-T092
were	O
included	O
.	O

The	O
data	B-T062
collection	I-T062
was	O
done	O
on	O
questionnaire	B-T170
designed	O
for	O
children	O
.	O

Dental	B-T038
caries	I-T038
status	O
was	O
examined	B-T033
by	O
using	O
WHO	B-T092
criteria	O
.	O

Dental	B-T038
caries	I-T038
was	O
found	O
in	O
81	O
children	O
(	O
23	O
.	O
2	O
%	O
)	O
with	O
mean	O
DMFT	O
0	O
.	O
61	O
.	O

Boys	O
had	O
1	O
.	O
6	O
times	O
more	O
chance	O
to	O
have	O
dental	B-T038
caries	I-T038
than	O
girls	O
.	O

Dental	B-T038
fluorosis	I-T038
was	O
found	O
in	O
63	O
.	O
6	O
%	O
of	O
children	O
with	O
majority	O
of	O
moderate	O
degree	O
(	O
50	O
.	O
5	O
%	O
)	O
.	O

Dental	B-T038
fluorosis	I-T038
status	O
was	O
found	O
significantly	O
associated	O
with	O
dental	B-T038
caries	I-T038
status	O
in	O
children	O
.	O

The	O
children	O
who	O
had	O
mild	O
,	O
moderate	O
and	O
severe	O
fluorosis	B-T038
,	O
had	O
4	O
times	O
more	O
chances	O
to	O
develop	O
caries	B-T038
than	O
those	O
who	O
did	O
not	O
have	O
fluorosis	B-T038
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
children	O
'	O
s	O
caries	B-T038
status	O
and	O
use	O
of	O
paste	B-T103
,	O
brushing	B-T058
habit	I-T058
,	O
miswak	B-T103
,	O
and	O
visit	O
to	O
the	O
dentist	B-T097
.	O

The	O
use	O
of	O
pastries	B-T168
and	O
juices	B-T168
had	O
a	O
direct	O
relation	O
with	O
the	O
children	O
'	O
s	O
dental	B-T038
caries	I-T038
status	O
.	O

Dental	B-T038
caries	I-T038
in	O
children	O
of	O
Quetta	B-T082
is	O
not	O
so	O
much	O
frequent	O
as	O
compared	O
to	O
the	O
fluoride	B-T103
deficient	O
countries	B-T082
.	O

However	O
,	O
the	O
high	O
prevalence	O
of	O
moderate	O
dental	B-T038
fluorosis	I-T038
and	O
consumption	O
of	O
pastries	B-T168
and	O
juices	B-T168
resulted	O
in	O
dental	B-T038
caries	I-T038
.	O

Proteomics	B-T103
analysis	B-T058
of	O
the	O
endogenous	O
,	O
constitutive	O
,	O
leaf	B-T204
SUMOylome	B-T038

SUMOylation	B-T038
is	O
a	O
post	B-T038
-	I-T038
translational	I-T038
modification	I-T038
which	O
regulates	B-T038
a	O
number	O
of	O
critical	O
biological	B-T038
processes	I-T038
in	O
,	O
for	O
example	O
mammals	B-T204
,	O
yeast	B-T204
and	O
plants	B-T204
.	O

In	O
order	O
to	O
fully	O
understand	B-T038
the	O
functional	O
effects	O
of	O
SUMOylation	B-T038
an	O
essential	O
first	O
step	O
is	O
the	O
identification	B-T038
of	O
endogenous	O
targets	O
for	O
SUMOylation	B-T038
.	O

Here	O
we	O
report	B-T170
the	O
results	O
of	O
using	O
a	O
recently	O
developed	O
proteomic	B-T091
approach	I-T091
based	O
on	O
the	O
use	O
of	O
3D	B-T082
gels	B-T103
to	O
identify	O
the	O
endogenous	O
SUMO	B-T103
targets	O
in	O
leaves	B-T204
of	O
Solanum	B-T204
tuberosum	I-T204
.	O

By	O
using	O
3D	B-T082
gels	B-T103
we	O
avoid	O
the	O
problem	O
of	O
co	O
-	O
migration	O
of	O
proteins	B-T103
,	O
which	O
is	O
a	O
major	O
limitation	O
of	O
2D	B-T082
gels	B-T103
,	O
and	O
we	O
enable	O
the	O
use	O
of	O
the	O
highly	O
sensitive	O
CyDye	B-T103
DIGE	I-T103
fluor	I-T103
saturation	I-T103
dyes	I-T103
.	O

Using	O
this	O
new	O
method	O
we	O
have	O
identified	O
39	O
individual	B-T103
proteins	I-T103
as	O
probable	O
SUMO	B-T103
targets	O
in	O
leaves	B-T204
of	O
Solanum	B-T204
tuberosum	I-T204
.	O

The	O
advantages	O
of	O
this	O
method	B-T058
compared	O
with	O
other	O
approaches	O
are	O
discussed	O
,	O
and	O
possible	B-T033
future	O
developments	O
are	O
outlined	O
.	O

The	O
authors	B-T097
have	O
no	O
conflicts	O
of	O
interest	O
to	O
declare	O
.	O

All	O
authors	B-T097
have	O
approved	O
the	O
manuscript	B-T170
and	O
agree	B-T033
with	O
submission	O
to	O
Journal	B-T170
of	I-T170
Proteomics	I-T170
.	O

Antenatal	O
consultation	B-T058
following	O
limb	B-T017
malformation	I-T017
discovery	O
using	O
ultrasound	B-T058
scan	I-T058

Our	O
unit	B-T092
has	O
been	O
providing	O
antenatal	O
consultations	B-T058
for	O
30	O
years	O
following	O
the	O
discovery	O
of	O
limb	B-T017
malformation	I-T017
with	O
the	O
fetus	B-T017
.	O

Each	O
of	O
these	O
consultations	B-T058
is	O
specific	O
and	O
carried	B-T058
out	I-T058
by	O
a	O
multi	B-T058
-	I-T058
professional	I-T058
team	I-T058
.	O

It	O
requires	O
a	O
physical	O
and	O
rehabilitation	B-T091
doctor	B-T097
,	O
an	O
orthopedic	B-T097
surgeon	I-T097
,	O
an	O
occupational	B-T097
therapist	I-T097
for	O
upper	O
limb	O
malformation	O
,	O
a	O
physiotherapist	B-T097
for	O
lower	O
malformation	O
and	O
a	O
psychologist	B-T097
.	O

This	O
multidisciplinary	O
consultation	B-T058
is	O
unique	O
because	O
of	O
each	O
pregnancy	B-T038
story	O
,	O
because	O
of	O
each	O
patient	O
life	O
story	O
but	O
also	O
because	O
of	O
the	O
words	O
used	O
by	O
the	O
sonologist	B-T097
when	O
announcing	O
the	O
diagnosis	B-T033
.	O

We	O
deal	O
with	O
couples	O
shocked	B-T033
by	O
the	O
prenatal	B-T058
diagnosis	I-T058
.	O

We	O
help	O
them	O
get	O
acceptance	O
of	O
the	O
child	O
to	O
be	O
born	O
and	O
to	O
forget	O
about	O
their	O
imaginary	B-T038
child	O
.	O

Medical	O
information	O
is	O
often	O
perceived	B-T038
as	O
being	O
"	O
a	O
surfeit	O
of	O
information	O
"	O
difficult	O
to	O
handle	O
by	O
the	O
couple	O
stunned	O
by	O
the	O
overwhelming	O
diagnosis	B-T033
.	O

We	O
must	O
stress	O
that	O
it	O
is	O
critical	O
to	O
not	O
only	O
have	O
a	O
good	O
medical	O
description	O
of	O
the	O
malformations	B-T017
and	O
potential	B-T058
treatments	I-T058
but	O
also	O
a	O
good	O
psychological	B-T058
support	I-T058
(	O
parents	O
personal	O
life	O
story	O
,	O
self	B-T038
-	I-T038
defense	I-T038
mechanism	I-T038
,	O
guilt	B-T038
feeling	I-T038
)	O
.	O

The	O
ethical	O
aspect	O
of	O
this	O
consultation	B-T058
is	O
also	O
important	O
.	O

Team	B-T058
members	B-T098
must	O
be	O
as	O
neutral	B-T170
as	O
possible	B-T033
in	O
their	O
assessments	B-T058
in	O
order	O
to	O
let	O
the	O
couple	O
take	O
the	O
final	O
decision	B-T038
:	O
the	O
continuation	O
of	O
the	O
pregnancy	B-T038
or	O
a	O
request	O
of	O
voluntary	O
termination	B-T058
of	I-T058
pregnancy	I-T058
.	O

These	O
prenatal	O
consultations	B-T058
highlight	O
the	O
importance	O
of	O
the	O
multidisciplinary	O
global	O
care	B-T058
.	O

Bending	B-T170
rules	I-T170
:	O
the	O
shape	B-T082
of	O
the	O
perceptual	B-T038
generalisation	B-T038
gradient	O
is	O
sensitive	O
to	O
inference	B-T170
rules	I-T170

Generalising	B-T038
what	O
is	O
learned	B-T038
about	O
one	O
stimulus	O
to	O
other	O
but	O
perceptually	B-T038
related	O
stimuli	O
is	O
a	O
basic	O
behavioural	O
phenomenon	O
.	O

We	O
evaluated	B-T058
whether	O
a	O
rule	B-T170
learning	B-T038
mechanism	O
may	O
serve	O
to	O
explain	O
such	O
generalisation	B-T038
.	O

To	O
this	O
end	O
,	O
we	O
assessed	O
whether	O
inference	B-T170
rules	I-T170
communicated	B-T033
through	O
verbal	O
instructions	O
affect	O
generalisation	B-T038
.	O

Expectancy	O
ratings	O
,	O
but	O
not	O
valence	O
ratings	O
,	O
proved	O
sensitive	O
to	O
this	O
manipulation	O
.	O

In	O
addition	O
to	O
revealing	O
a	O
role	B-T170
for	O
inference	B-T170
rules	I-T170
in	O
generalisation	B-T038
,	O
our	O
study	B-T062
has	O
clinical	O
implications	O
as	O
well	O
.	O

More	O
specifically	O
,	O
we	O
argue	O
that	O
targeting	O
inference	B-T170
rules	I-T170
might	O
prove	O
to	O
be	O
an	O
effective	O
strategy	O
to	O
affect	O
the	O
excessive	O
generalisation	B-T038
that	O
is	O
often	O
observed	O
in	O
psychopathology	B-T091
.	O

Neuroticism	B-T038
and	O
Fatigue	B-T033
3	O
Months	O
After	O
Ischemic	B-T038
Stroke	I-T038
:	O
A	O
Cross	B-T062
-	I-T062
Sectional	I-T062
Study	I-T062

To	O
examine	B-T033
the	O
relation	O
between	O
neuroticism	B-T038
and	O
fatigue	B-T033
in	O
Chinese	B-T082
patients	O
with	O
stroke	B-T038
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
.	O

Acute	O
stroke	B-T092
unit	I-T092
.	O

Survivors	O
of	O
ischemic	B-T038
stroke	I-T038
(	O
N	O
=	O
191	O
)	O
recruited	O
from	O
the	O
acute	O
stroke	B-T092
unit	I-T092
between	O
May	O
1	O
,	O
2010	O
,	O
and	O
September	O
1	O
,	O
2011	O
.	O

Not	O
applicable	O
.	O

The	O
personality	B-T033
trait	I-T033
of	O
neuroticism	B-T038
was	O
measured	O
with	O
the	O
neuroticism	B-T038
subscale	O
of	O
the	O
Chinese	B-T082
version	B-T170
of	O
the	O
NEO	B-T058
Five	I-T058
-	I-T058
Factor	I-T058
Inventory	I-T058
.	O

The	O
level	O
of	O
fatigue	B-T033
was	O
measured	O
with	O
the	O
Fatigue	B-T170
Assessment	I-T170
Scale	I-T170
.	O

The	O
National	B-T170
Institutes	I-T170
of	I-T170
Health	I-T170
Stroke	I-T170
Scale	I-T170
,	O
Geriatric	B-T170
Depression	I-T170
Scale	I-T170
,	O
Barthel	B-T170
Index	I-T170
,	O
and	O
Mini	B-T058
-	I-T058
Mental	I-T058
State	I-T058
Examination	I-T058
were	O
administered	O
to	O
obtain	O
demographic	O
and	O
clinical	B-T170
information	I-T170
.	O

Fatigue	B-T170
severity	I-T170
3	O
months	O
after	O
stroke	B-T038
positively	O
correlated	O
with	O
Geriatric	B-T170
Depression	I-T170
Scale	I-T170
and	O
NEO	B-T058
Five	I-T058
-	I-T058
Factor	I-T058
Inventory	I-T058
neuroticism	B-T038
scores	O
and	O
negatively	B-T033
correlated	O
with	O
the	O
Barthel	O
Index	O
score	O
.	O

Neuroticism	B-T038
,	O
independent	B-T033
of	O
depressive	B-T033
symptoms	I-T033
,	O
is	O
a	O
predictor	O
of	O
fatigue	B-T170
severity	I-T170
3	O
months	O
after	O
stroke	B-T038
.	O

Interventions	O
such	O
as	O
psychological	O
screening	O
programs	O
are	O
warranted	O
for	O
early	O
detection	B-T058
of	O
patients	O
at	O
high	B-T033
risk	I-T033
of	I-T033
poststroke	B-T038
depression	I-T038
.	O

Hematological	B-T033
,	O
biochemical	B-T033
,	O
and	O
toxicopathic	B-T033
effects	I-T033
of	O
subchronic	O
acetamiprid	B-T103
toxicity	B-T037
in	O
Wistar	B-T204
rats	I-T204

Acetamiprid	B-T103
is	O
one	O
of	O
the	O
most	O
widely	O
used	O
neonicotinoids	B-T103
.	O

This	O
study	O
investigates	O
toxic	B-T037
effects	I-T037
of	O
repeated	O
oral	O
administration	O
of	O
three	O
doses	O
of	O
acetamiprid	B-T103
(	O
1	O
/	O
20	O
,	O
1	O
/	O
10	O
,	O
and	O
1	O
/	O
5	O
of	O
LD50	O
)	O
during	O
60	O
days	O
.	O

For	O
this	O
,	O
male	O
Wistar	B-T204
rats	I-T204
were	O
divided	O
into	O
four	O
different	O
groups	O
.	O

Hematological	B-T033
,	O
biochemical	B-T033
,	O
and	O
toxicopathic	B-T033
effects	I-T033
of	O
acetamiprid	B-T103
were	O
evaluated	B-T058
.	O

According	O
to	O
the	O
results	O
,	O
a	O
significant	O
decrease	O
in	O
the	O
body	B-T033
weight	I-T033
gain	I-T033
at	O
the	O
highest	O
dose	O
1	O
/	O
5	O
of	O
LD50	O
of	O
acetamiprid	B-T103
was	O
noticed	O
.	O

An	O
increase	O
in	O
the	O
relative	O
liver	B-T017
weight	O
was	O
also	O
observed	O
at	O
this	O
dose	O
level	O
.	O

The	O
hematological	O
constituents	O
were	O
affected	O
.	O

A	O
significant	O
decrease	O
in	O
RBC	B-T017
,	O
HGB	B-T103
,	O
and	O
HCT	B-T033
in	O
rats	B-T204
treated	O
with	O
higher	O
doses	O
of	O
acetamiprid	B-T103
(	O
1	O
/	O
10	O
and	O
1	O
/	O
5	O
of	O
LD50	O
)	O
was	O
noted	O
.	O

However	O
,	O
a	O
significant	O
increase	O
in	O
WBC	B-T017
and	O
PLT	B-T017
were	O
observed	O
at	O
the	O
same	O
doses	O
.	O

Furthermore	O
,	O
acetamiprid	B-T103
induced	B-T038
liver	I-T038
toxicity	I-T038
measured	O
by	O
the	O
increased	O
activities	B-T038
of	O
aspartate	B-T103
aminotransferase	I-T103
(	O
AST	B-T103
)	O
,	O
alanine	B-T103
aminotransferase	I-T103
(	O
ALT	B-T103
)	O
,	O
alkaline	B-T103
phosphates	I-T103
(	O
ALPs	B-T103
)	O
,	O
and	O
lactate	B-T103
dehydrogenase	I-T103
(	O
LDH	B-T103
)	O
which	O
may	O
be	O
due	O
to	O
the	O
loss	O
of	O
hepatic	B-T017
membrane	I-T017
architecture	I-T017
and	O
hepatocellular	B-T038
damage	I-T038
.	O

In	O
addition	O
,	O
exposure	O
to	O
acetamiprid	B-T103
resulted	O
in	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
superoxide	B-T103
dismutase	I-T103
and	O
catalase	B-T103
activities	B-T038
(	O
p	O
≤	O
0	O
.	O
01	O
)	O
with	O
concomitant	O
increase	O
in	O
lipid	B-T038
peroxidation	I-T038
in	O
rat	B-T204
liver	B-T017
.	O

These	O
findings	B-T033
highlight	O
the	O
subchronic	O
hepatotoxicity	B-T037
of	O
acetamiprid	B-T103
.	O

Sustained	B-T103
delivery	I-T103
of	O
vincristine	B-T103
inside	O
an	O
orthotopic	B-T082
mouse	B-T038
sarcoma	I-T038
model	O
decreases	O
tumor	O
growth	O

Sarcoma	B-T038
accounts	O
for	O
20	O
%	O
of	O
solid	B-T038
tumors	I-T038
in	O
children	O
.	O

Surgery	B-T058
has	O
significant	O
morbidity	O
.	O

We	O
hypothesized	O
that	O
delivering	O
chemotherapy	B-T058
directly	O
into	O
tumors	B-T038
through	O
sustained	B-T103
release	I-T103
silk	B-T103
systems	O
could	O
slow	O
tumor	O
growth	O
.	O

Human	B-T204
Ewing	B-T038
sarcoma	I-T038
cells	B-T017
A673	I-T017
were	O
cultured	B-T058
with	O
vincristine	B-T103
and	O
doxorubicin	B-T103
to	O
determine	O
half	O
maximal	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
.	O

Cells	B-T017
were	O
injected	O
into	O
mouse	B-T204
hind	B-T017
leg	I-T017
to	O
create	O
orthotopic	B-T082
tumors	B-T038
.	O

Tumor	O
volumes	O
were	O
measured	O
using	O
ultrasound	B-T058
.	O

When	O
volume	O
reached	O
>	O
250mm	O
(	O
3	O
,	O
)	O
interventions	B-T058
included	O
:	O
implantation	B-T058
of	O
drug	O
-	O
free	O
silk	B-T103
foam	O
(	O
Control	O
-	O
F	O
)	O
,	O
doxorubicin	B-T103
400μg	O
foam	O
(	B-T103
Dox400	I-T103
-	O
F	O
)	O
,	O
vincristine	B-T103
50μg	O
foam	O
(	O
Vin50	B-T103
-	O
F	O
)	O
,	O
drug	O
-	O
free	O
silk	B-T103
gel	O
(	O
Control	O
-	O
G	O
)	O
,	O
vincristine	B-T103
50μg	O
gel	O
(	O
Vin50	B-T103
-	O
G	O
)	O
,	O
or	O
single	O
dose	O
intravenous	B-T082
vincristine	B-T103
50μg	O
(	O
Vin50	B-T103
-	O
IV	O
)	O
.	O

End	O
-	O
point	O
was	O
volume	O
>	O
1000mm	O
(	O
3	O
)	O
.	O

Kaplan	O
Meier	O
and	O
ANOVA	O
were	O
used	O
.	O

IC50	O
for	O
vincristine	B-T103
and	O
doxorubicin	B-T103
was	O
0	O
.	O
5ng	O
/	O
mL	O
and	O
200ng	O
/	O
mL	O
,	O
respectively	O
.	O

There	O
was	O
no	O
difference	O
between	O
Dox400	B-T103
-	O
F	O
[	O
6±	O
1days	O
to	O
end	O
point	O
(	O
DTEP	O
)	O
]	O
and	O
Control	O
-	O
F	O
(	O
5±1	O
.	O
3	O
DTEP	O
)	O
.	O

Vin50	B-T103
-	O
F	O
(	O
12	O
.	O
4±3	O
.	O
5	O
DTEP	O
)	O
had	O
slower	B-T033
growth	I-T033
compared	O
to	O
Control	O
-	O
F	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
there	O
was	O
no	O
difference	O
between	O
Vin50	B-T103
-	O
F	O
and	O
Vin50	B-T103
-	O
IV	O
(	O
14±0	O
DTEP	O
)	O
.	O

Growth	B-T033
was	I-T033
slowest	I-T033
with	O
Vin50	B-T103
-	O
G	O
,	O
28±10	O
.	O
3	O
DTEP	O
compared	O
to	O
all	O
other	O
treatment	O
groups	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Sustained	B-T103
delivery	I-T103
of	O
vincristine	B-T103
inside	O
the	O
sarcoma	B-T038
tumor	B-T038
with	O
silk	B-T103
gel	O
decreased	O
tumor	O
growth	O
.	O

Applying	O
this	O
intratumoral	B-T058
treatment	I-T058
strategy	O
may	O
potentially	O
decrease	O
the	O
extent	O
of	O
surgical	B-T058
excision	I-T058
.	O

Spinal	B-T017
load	O
in	O
nurses	B-T097
during	O
emergency	O
lifting	O
of	O
obese	B-T038
patients	O
:	O
preliminary	O
results	O

Nurses	B-T097
are	O
exposed	O
to	O
the	O
risk	O
of	O
injury	B-T037
while	O
handling	B-T033
patients	O
.	O

This	O
is	O
particularly	O
true	O
for	O
obese	B-T038
patients	O
.	O

The	O
goal	B-T170
of	O
this	O
paper	O
is	O
to	O
estimate	O
the	O
spinal	B-T017
loads	O
and	O
the	O
related	O
risk	O
of	O
injury	B-T037
to	O
nurses	B-T097
while	O
lifting	O
obese	B-T038
patients	O
from	O
the	O
floor	O
with	O
a	O
bariatric	B-T074
sheet	I-T074
during	O
a	O
hospital	B-T092
emergency	O
.	O

Six	O
male	O
nurses	B-T097
participated	O
in	O
this	O
study	B-T062
.	O

The	O
biomechanical	B-T058
analysis	I-T058
focused	O
on	O
the	O
lifting	O
strategy	O
.	O

Thirty	O
obese	B-T038
in	O
-	O
patients	O
were	O
enrolled	O
to	O
take	O
part	O
in	O
the	O
experimental	B-T062
study	I-T062
and	O
divided	O
into	O
three	O
groups	O
according	O
to	O
their	O
Body	B-T201
Mass	I-T201
Index	I-T201
(	O
BMI	B-T201
)	O
.	O

Three	B-T058
-	I-T058
dimensional	I-T058
motion	I-T058
analysis	I-T058
was	O
conducted	O
using	O
an	O
optoelectronic	B-T074
system	I-T074
.	O

The	O
trunk	B-T082
kinematics	B-T091
and	O
the	O
loading	O
on	O
the	O
spines	B-T017
of	O
the	O
operating	O
nurses	B-T097
were	O
computed	B-T058
.	O

Our	O
data	O
showed	O
that	O
when	O
the	O
nurse	B-T097
was	O
operating	O
from	O
the	O
central	O
handle	O
,	O
his	O
trunk	B-T082
was	O
more	O
flexed	B-T038
at	O
the	O
end	O
of	O
the	O
lift	O
with	O
a	O
reduced	O
range	B-T201
of	I-T201
motion	I-T201
.	O

The	O
values	O
were	O
higher	O
when	O
the	O
nurse	B-T097
lifted	O
patients	O
with	O
higher	O
BMIs	B-T201
.	O

All	O
kinetic	O
parameters	O
and	O
tension	B-T038
in	O
the	O
lumbar	B-T017
muscles	I-T017
at	O
the	O
end	O
of	O
the	O
movement	B-T038
were	O
characterised	O
by	O
lower	O
values	O
for	O
the	O
nurse	B-T097
placed	O
beside	O
the	O
patient	O
'	O
s	O
head	B-T082
or	O
feet	B-T017
if	O
compared	O
to	O
the	O
operator	O
positioned	O
beside	O
the	O
central	O
handle	O
in	O
all	O
patient	O
groups	O
.	O

Our	O
preliminary	O
data	O
suggest	O
that	O
only	O
the	O
reaction	O
load	O
on	O
the	O
spine	B-T017
of	O
the	O
nurse	B-T097
holding	O
the	O
central	O
handle	O
,	O
closest	O
to	O
the	O
patient	O
'	O
s	O
centre	O
of	O
mass	O
,	O
seems	O
to	O
exceed	O
the	O
recommended	O
safety	O
limits	O
.	O

Expectations	O
for	O
the	O
methodology	O
and	O
translation	B-T062
of	O
animal	B-T062
research	I-T062
:	O
a	O
survey	B-T170
of	O
the	O
general	B-T098
public	I-T098
,	O
medical	B-T097
students	I-T097
and	O
animal	B-T204
researchers	B-T097
in	O
North	B-T082
America	I-T082

To	O
determine	O
what	O
are	O
considered	O
acceptable	O
standards	B-T170
for	O
animal	B-T062
research	I-T062
(	O
AR	B-T062
)	O
methodology	O
and	O
translation	O
rate	O
to	O
humans	B-T204
,	O
a	O
validated	O
survey	B-T170
was	O
sent	O
to	O
:	O
a	O
)	O
a	O
sample	O
of	O
the	O
general	B-T098
public	I-T098
,	O
via	O
Sampling	B-T170
Survey	I-T170
International	I-T170
(	O
SSI	B-T170
;	O
Canada	B-T082
)	O
,	O
Amazon	B-T170
Mechanical	I-T170
Turk	I-T170
(	O
AMT	B-T170
;	O
USA	B-T082
)	O
,	O
a	O
Canadian	B-T082
city	I-T082
festival	O
(	O
CF	O
)	O
and	O
a	O
Canadian	B-T082
children	B-T092
'	I-T092
s	I-T092
hospital	I-T092
(	O
CH	B-T092
)	O
;	O
b	O
)	O
a	O
sample	O
of	O
medical	B-T097
students	I-T097
(	O
two	O
first	O
-	O
year	O
classes	O
)	O
;	O
and	O
c	O
)	O
a	O
sample	O
of	O
scientists	B-T097
(	O
corresponding	O
authors	B-T097
and	O
academic	B-T092
paediatricians	B-T097
)	O
.	O

There	O
were	O
1379	O
responses	O
from	O
the	O
general	B-T098
public	I-T098
sample	O
(	O
SSI	B-T170
,	O
n	O
=	O
557	O
;	O
AMT	B-T170
,	O
n	O
=	O
590	O
;	O
CF	O
,	O
n	O
=	O
195	O
;	O
CH	B-T092
,	O
n	O
=	O
102	O
)	O
,	O
205	O
/	O
330	O
(	O
62	O
%	O
)	O
medical	B-T097
student	I-T097
responses	O
,	O
and	O
23	O
/	O
323	O
(	O
7	O
%	O
,	O
too	O
few	O
to	O
report	O
)	O
scientist	B-T097
responses	O
.	O

Asked	O
about	O
methodological	O
quality	O
,	O
most	O
of	O
the	O
general	B-T098
public	I-T098
and	O
medical	B-T097
student	I-T097
respondents	B-T098
expect	O
that	O
:	O
AR	B-T062
is	O
of	O
high	O
quality	O
(	O
e	O
.	O
g	O
.	O

anaesthesia	B-T058
and	O
analgesia	B-T058
are	O
monitored	O
,	O
even	O
overnight	O
,	O
and	O
'	O
humane	O
'	O
euthanasia	B-T058
,	O
optimal	O
statistical	O
design	O
,	O
comprehensive	O
literature	B-T170
review	I-T170
,	O
randomisation	B-T062
and	O
blinding	B-T062
,	O
are	O
performed	O
)	O
,	O
and	O
costs	O
and	O
difficulty	O
are	O
not	O
acceptable	O
justifications	O
for	O
lower	O
quality	O
(	O
e	O
.	O
g	O
.	O

costs	O
of	O
expert	O
consultation	B-T058
,	O
or	O
more	O
laboratory	B-T097
staff	I-T097
)	O
.	O

Asked	O
about	O
their	O
expectations	O
of	O
translation	B-T062
to	O
humans	B-T204
(	O
of	O
toxicity	B-T037
,	O
carcinogenicity	B-T038
,	O
teratogenicity	B-T038
and	O
treatment	O
findings	O
)	O
,	O
most	O
expect	O
translation	B-T062
more	O
than	O
60	O
%	O
of	O
the	O
time	O
.	O

If	O
translation	B-T062
occurred	O
less	O
than	O
20	O
%	O
of	O
the	O
time	O
,	O
a	O
minority	B-T098
disagreed	O
that	O
this	O
would	O
"	O
significantly	O
reduce	O
your	O
support	O
for	O
AR	B-T062
"	O
.	O

Medical	B-T097
students	I-T097
were	O
more	O
supportive	O
of	O
AR	B-T062
,	O
even	O
if	O
translation	B-T062
occurred	O
less	O
than	O
20	O
%	O
of	O
the	O
time	O
.	O

Expectations	O
for	O
AR	B-T062
are	O
much	O
higher	O
than	O
empirical	O
data	O
show	O
to	O
have	O
been	O
achieved	O
.	O

Predicting	O
violence	B-T038
and	O
recidivism	O
in	O
a	O
large	O
sample	O
of	O
males	O
on	O
probation	O
or	O
parole	O

This	O
study	B-T062
evaluated	O
the	O
utility	O
of	O
items	O
and	O
scales	O
from	O
the	O
Iowa	B-T082
Violence	B-T038
and	O
Victimization	O
Instrument	B-T170
in	O
a	O
sample	O
of	O
1961	O
males	O
from	O
the	O
state	O
of	O
Iowa	B-T082
who	O
were	O
on	O
probation	O
or	O
released	B-T033
from	I-T033
prison	I-T033
to	O
parole	O
supervision	O
.	O

This	O
is	O
the	O
first	O
study	B-T062
to	O
examine	O
the	O
potential	O
of	O
the	O
Iowa	B-T082
Violence	B-T038
and	O
Victimization	O
Instrument	B-T170
to	O
predict	O
criminal	O
offenses	O
.	O

The	O
males	O
were	O
followed	O
for	O
30	O
months	O
immediately	O
following	O
their	O
admission	O
to	O
probation	O
or	O
parole	O
.	O

AUC	O
analyses	B-T062
indicated	O
fair	O
to	O
good	O
predictive	O
power	O
for	O
the	O
Iowa	B-T082
Violence	B-T038
and	O
Victimization	O
Instrument	B-T170
for	O
charges	O
of	O
violence	B-T038
and	O
victimization	O
,	O
but	O
chance	O
predictive	O
power	O
for	O
drug	O
offenses	O
.	O

Notably	O
,	O
both	O
scales	O
of	O
the	O
instrument	B-T170
performed	O
equally	O
well	O
at	O
the	O
30	O
-	O
month	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Items	O
on	O
the	O
Iowa	B-T082
Violence	B-T038
and	O
Victimization	O
Instrument	B-T170
not	O
only	O
predicted	O
violence	B-T038
,	O
but	O
are	O
straightforward	O
to	O
score	O
.	O

Violence	B-T038
management	O
strategies	O
are	O
discussed	O
as	O
they	O
relate	O
to	O
the	O
current	O
findings	O
,	O
including	O
the	O
potential	O
to	O
expand	B-T082
the	O
measure	O
to	O
other	O
jurisdictions	B-T170
and	O
populations	B-T098
.	O

Prognostic	B-T201
significance	I-T201
of	O
non	O
-	O
HPV16	O
genotypes	O
in	O
oropharyngeal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038

Recent	O
studies	O
have	O
found	O
that	O
cases	O
with	O
oropharyngeal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
OPSCC	B-T038
)	O
positive	B-T033
for	O
HPV16	B-T103
genotype	I-T103
have	O
better	O
overall	O
survival	O
compared	O
with	O
cases	O
positive	O
for	O
other	O
HPV	O
genotypes	O
.	O

We	O
sought	O
to	O
further	O
replicate	O
these	O
studies	O
and	O
determine	O
if	O
this	O
relationship	O
is	O
modified	O
by	O
expression	B-T038
of	O
p16	B-T103
tumor	I-T103
suppressor	I-T103
protein	I-T103
.	O

We	O
identified	O
238	O
OPSCC	B-T038
cases	O
from	O
the	O
Carolina	B-T062
Head	I-T062
and	I-T062
Neck	I-T062
Cancer	I-T062
Study	I-T062
(	O
CHANCE	B-T062
)	O
study	O
,	O
a	O
population	B-T062
based	I-T062
case	I-T062
-	I-T062
control	I-T062
study	I-T062
.	O

Tumors	B-T038
that	O
tested	O
positive	B-T033
solely	I-T033
for	O
HPV16	B-T103
genotype	I-T103
and	O
no	O
other	O
genotypes	O
with	O
PCR	B-T062
were	O
classified	B-T170
as	O
HPV16	B-T033
-	I-T033
positive	I-T033
.	O

Tumors	B-T038
positive	B-T033
for	I-T033
any	O
other	O
high	B-T033
-	I-T033
risk	I-T033
HPV	B-T103
genotype	I-T103
were	O
classified	B-T170
as	O
non	B-T033
-	I-T033
HPV16	I-T033
-	I-T033
positive	I-T033
.	O

Expression	B-T038
of	O
p16	B-T103
in	O
the	O
tumor	B-T038
was	O
determined	O
with	O
immunohistochemistry	B-T058
.	O

Follow	O
-	O
up	O
time	O
was	O
calculated	O
from	O
the	O
date	O
of	O
diagnosis	O
to	O
date	O
of	O
death	O
or	O
December	O
31	O
,	O
2013	O
.	O

Overall	O
survival	O
was	O
compared	O
with	O
the	O
Kaplan	O
-	O
Meier	O
curves	O
and	O
log	O
-	O
rank	O
test	O
.	O

Hazard	O
ratios	O
(	O
HR	O
)	O
adjusted	O
for	O
smoking	O
,	O
alcohol	O
use	O
,	O
sex	O
,	O
race	B-T098
,	O
and	O
age	O
was	O
calculated	O
with	O
the	O
Cox	B-T170
proportional	I-T170
hazard	I-T170
regression	I-T170
.	O

Cases	O
with	O
HPV16	B-T033
-	I-T033
positive	I-T033
OPSCC	B-T038
had	O
better	O
overall	O
survival	O
than	O
cases	O
with	O
non	B-T033
-	I-T033
HPV16	I-T033
-	I-T033
positive	I-T033
OPSCC	B-T038
(	O
log	O
-	O
rank	O
p	O
-	O
value	O
:	O
0	O
.	O
010	O
)	O
.	O

When	O
restricted	O
to	O
OPSCC	B-T038
cases	O
positive	B-T033
for	O
p16	B-T038
expression	I-T038
,	O
the	O
same	O
trend	O
continued	O
(	O
log	O
-	O
rank	O
p	O
-	O
value	O
:	O
0	O
.	O
002	O
)	O
.	O

In	O
the	O
adjusted	O
model	O
,	O
cases	O
with	O
non	B-T033
-	I-T033
HPV16	I-T033
-	I-T033
positive	I-T033
OPSCC	B-T038
had	O
greater	B-T033
risk	I-T033
of	I-T033
death	B-T033
compared	O
to	O
cases	O
with	O
HPV16	B-T033
-	I-T033
positive	I-T033
tumors	B-T038
(	O
HR	O
:	O
1	O
.	O
92	O
;	O
95	O
%	O
CI	O
:	O
1	O
.	O
03	O
,	O
3	O
.	O
60	O
)	O
.	O

This	O
finding	B-T033
indicates	B-T033
that	O
HPV	B-T005
genotyping	O
carries	O
valuable	B-T201
prognostic	I-T201
significance	I-T201
in	O
addition	O
to	O
p16	B-T103
status	O
and	O
future	O
survival	O
studies	O
of	O
OPSCC	B-T038
should	O
take	O
into	O
account	O
differing	O
HPV	O
genotypes	O
.	O

Randomized	B-T062
Trials	I-T062
of	O
the	O
Teen	O
Outreach	O
Program	O
in	O
Louisiana	B-T082
and	O
Rochester	B-T082
,	O
New	B-T082
York	I-T082

To	O
evaluate	B-T058
the	O
Teen	O
Outreach	O
Program	O
,	O
a	O
pregnancy	O
prevention	O
program	O
,	O
in	O
2	O
community	O
-	O
based	O
settings	O
.	O

We	O
evaluated	B-T058
the	O
Teen	O
Outreach	O
Program	O
,	O
a	O
9	O
-	O
month	O
positive	O
youth	O
development	O
program	O
,	O
in	O
3	O
cohorts	B-T098
of	O
youths	O
from	O
2012	O
to	O
2015	O
in	O
2	O
states	B-T082
.	O

In	O
Louisiana	B-T082
,	O
7	O
agencies	B-T092
participated	O
in	O
an	O
individualized	O
randomized	B-T062
controlled	I-T062
trial	I-T062
,	O
with	O
youths	O
randomly	O
assigned	O
to	O
a	O
treatment	B-T058
or	O
control	O
condition	O
.	O

Fourteen	O
agencies	B-T092
in	O
Rochester	B-T082
,	O
New	B-T082
York	I-T082
,	O
participated	O
in	O
a	O
cluster	O
randomized	B-T062
controlled	I-T062
trial	I-T062
.	O

We	O
found	O
no	O
differences	O
between	O
the	O
intervention	B-T058
and	O
control	O
youths	O
on	O
delay	O
of	O
sexual	O
onset	O
in	O
Louisiana	B-T082
(	O
adjusted	O
odds	O
ratio	O
[	O
AOR	O
]	O
=	O
0	O
.	O
80	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
=	O
0	O
.	O
62	O
,	O
1	O
.	O
03	O
)	O
or	O
in	O
Rochester	B-T082
,	O
New	B-T082
York	I-T082
(	O
AOR	O
=	O
0	O
.	O
89	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
45	O
,	O
1	O
.	O
77	O
)	O
,	O
or	O
for	O
sex	B-T038
with	O
no	O
effective	O
means	O
of	O
birth	B-T103
control	I-T103
(	O
Louisiana	B-T082
,	O
AOR	O
=	O
1	O
.	O
18	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
78	O
,	O
1	O
.	O
78	O
;	O
Rochester	B-T082
,	O
AOR	O
=	O
0	O
.	O
41	O
;	O
95	O
%	O
CI	O
=	O
0	O
.	O
13	O
,	O
1	O
.	O
27	O
)	O
after	O
controlling	O
for	O
relevant	O
covariates	O
.	O

We	O
found	O
no	B-T033
short	O
-	O
term	O
effects	O
for	O
the	O
offer	O
of	O
the	O
intervention	B-T058
.	O

Research	B-T062
might	O
be	O
needed	O
for	O
the	O
long	O
-	O
term	O
and	O
intermediate	O
impacts	O
of	O
youth	O
development	O
programs	O
on	O
these	O
and	O
other	O
adolescent	O
risk	O
behaviors	O
.	O

A	O
single	O
session	O
of	O
exhaustive	O
exercise	O
markedly	O
decreases	O
circulating	O
levels	O
of	O
guanidinoacetic	B-T103
acid	I-T103
in	O
healthy	O
men	B-T098
and	O
women	B-T098

We	O
evaluated	B-T058
the	O
effects	O
of	O
exercise	O
on	O
circulating	O
concentrations	O
of	O
guanidinoacetic	B-T103
acid	I-T103
(	O
GAA	B-T103
)	O
and	O
creatine	B-T103
in	O
23	O
healthy	B-T098
volunteers	I-T098
subjected	O
to	O
running	O
to	O
exhaustion	B-T033
and	O
free	O
-	O
weight	O
bench	O
-	O
press	O
to	O
volitional	O
failure	O
.	O

Blood	B-T031
was	O
taken	O
before	O
and	O
following	O
each	O
exercise	O
session	O
.	O

Running	O
induced	O
a	O
significant	O
decrease	O
in	O
serum	B-T031
GAA	B-T103
by	O
20	O
.	O
1	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
while	O
free	O
-	O
weight	O
exercise	O
reduced	O
GAA	B-T103
by	O
11	O
.	O
7	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
suggesting	O
the	O
possible	O
use	O
of	O
serum	B-T031
GAA	B-T103
as	O
a	O
novel	O
biomarker	B-T201
of	O
exhaustion	B-T033
.	O

Anti	B-T103
-	I-T103
helminthic	I-T103
activity	O
of	O
Momordica	B-T204
charantia	I-T204
L	I-T204
.	O
against	O
Fasciola	B-T204
hepatica	I-T204
eggs	I-T204
after	O
twelve	O
days	O
of	O
incubation	B-T058
in	O
vitro	O

Fasciolosis	B-T038
,	O
a	O
parasitic	B-T038
disease	I-T038
caused	O
by	O
the	O
trematode	B-T204
Fasciola	B-T204
hepatica	I-T204
underreported	O
is	O
expanding	O
both	O
in	O
human	B-T204
and	O
animal	B-T204
population	I-T204
,	O
throughout	O
the	O
world	B-T098
.	O

The	O
constant	O
use	O
of	O
synthetic	B-T103
drugs	I-T103
to	O
treat	B-T058
this	O
condition	B-T038
has	O
led	O
to	O
the	O
natural	O
selection	O
of	O
resistant	O
strains	O
of	O
the	O
parasite	B-T204
.	O

Hence	O
,	O
there	O
is	O
a	O
growing	O
focus	O
on	O
the	O
potential	O
anti	B-T103
-	I-T103
helminthic	I-T103
properties	O
of	O
medicinal	B-T204
plants	I-T204
and	O
phytopharmaceuticals	B-T103
.	O

The	O
current	O
study	B-T062
assessed	O
the	O
potential	O
anti	O
-	O
fasciolicide	O
action	O
of	O
Momordica	B-T204
charantia	I-T204
leaf	B-T204
extracts	B-T103
and	O
fractions	O
on	O
the	O
eggs	B-T204
of	I-T204
F	I-T204
.	I-T204

hepatica	I-T204
parasites	I-T204
.	O

The	O
lyophilized	O
crude	B-T103
extract	I-T103
(	O
CE	B-T103
)	O
of	O
M	B-T204
.	I-T204

charantia	I-T204
leaves	I-T204
and	O
its	O
sub	O
-	O
fractions	O
,	O
obtained	O
from	O
liquid	B-T058
-	I-T058
liquid	I-T058
partitioning	I-T058
with	O
organic	B-T103
solvents	I-T103
,	O
were	O
analysed	B-T062
by	O
High	B-T058
Performance	I-T058
Liquid	I-T058
Chromatography	I-T058
(	O
HPLC	B-T058
)	O
,	O
suspended	O
in	O
1	O
%	O
DMSO	B-T103
and	O
used	O
in	O
in	O
vitro	O
tests	B-T058
.	O

Quadruplicates	O
of	O
50	O
F	B-T204
.	I-T204

hepatica	I-T204
eggs	I-T204
were	O
incubated	B-T058
at	O
23°C	O
with	O
M	B-T204
.	I-T204

charantia	I-T204
leaf	B-T204
CE	B-T103
in	O
different	O
concentrations	O
.	O

After	O
12	O
days	O
no	O
larvae	B-T204
were	O
formed	O
in	O
eggs	B-T204
incubated	B-T058
with	O
CE	B-T103
concentrations	O
above	O
12	O
.	O
5mg	O
/	O
mL	O
.	O

Eggs	B-T204
incubated	B-T058
with	O
CE	B-T103
sub	O
-	O
fractions	O
at	O
concentrations	O
of	O
1000	O
,	O
100	O
,	O
10	O
,	O
1	O
,	O
0	O
.	O
1	O
,	O
0	O
.	O
01μg	O
/	O
mL	O
affected	O
embryonic	B-T038
development	I-T038
,	O
with	O
n	B-T103
-	I-T103
butanol	I-T103
presenting	O
the	O
strongest	O
inhibition	O
of	O
miracidia	B-T204
formation	O
.	O

In	O
contrast	O
,	O
on	O
the	O
12th	O
day	O
,	O
90	O
%	O
of	O
the	O
miracidia	B-T204
hatched	B-T038
in	O
the	O
control	O
experiments	O
using	O
0	O
.	O
03	O
%	O
DMSO	B-T103
whereas	O
embryogenesis	B-T038
was	O
completely	O
abolished	O
with	O
any	O
concentration	O
of	O
albendazole	B-T103
sulphoxide	I-T103
ABZ	B-T103
(	I-T103
SO	I-T103
)	I-T103
.	O

Chemical	B-T058
analysis	I-T058
of	O
the	O
CE	B-T103
and	O
sub	O
-	O
fractions	O
revealed	O
a	O
prominent	O
presence	O
of	O
flavonoids	B-T103
.	O

HPLC	B-T058
-	I-T058
MS	I-T058
confirmed	O
Quercetin	B-T103
to	O
be	O
one	O
of	O
the	O
main	O
flavonoids	B-T103
present	O
in	O
the	O
CE	B-T103
and	O
the	O
n	B-T103
-	I-T103
butanol	I-T103
subfraction	O
.	O

This	O
is	O
the	O
first	O
study	B-T062
to	O
analyse	B-T062
the	O
potential	O
anti	O
-	O
fasciolicide	O
action	O
of	O
M	B-T204
.	I-T204

charantia	I-T204
leaf	B-T204
CE	B-T103
and	O
subfractions	O
.	O

Dabigatran	B-T103
:	O
A	O
new	O
oral	B-T103
anticoagulant	I-T103
.	O
Guidelines	B-T170
to	O
follow	O
in	O
oral	B-T058
surgery	I-T058
procedures	I-T058
.	O
A	O
systematic	O
review	B-T170
of	I-T170
the	I-T170
literature	I-T170

Dabigatran	B-T103
is	O
a	O
newly	O
commercialized	O
drug	B-T103
that	O
is	O
replacing	O
other	O
anticoagulants	B-T103
in	O
the	O
prevention	O
of	O
venous	B-T038
thromboembolism	I-T038
,	O
stroke	B-T038
and	O
systemic	O
arterial	O
valve	O
embolism	O
.	O

It	O
acts	O
directly	O
on	O
thrombin	B-T103
presenting	O
in	O
a	O
dynamic	O
and	O
predictable	O
way	O
,	O
which	O
does	O
not	O
require	O
monitoring	O
these	O
patients	O
.	O

Therefore	O
,	O
we	O
consider	O
the	O
need	O
to	O
assess	O
whether	O
their	O
use	O
increases	O
the	O
risk	O
of	O
bleeding	O
involved	O
before	O
any	O
dental	B-T058
treatment	I-T058
.	O

We	O
performed	O
a	O
systematic	O
review	O
with	O
a	O
bibliographic	O
search	O
in	O
PubMed	B-T170
/	O
Medline	B-T170
along	O
with	O
the	O
Cochrane	B-T092
Library	I-T092
.	O

We	O
excluded	O
articles	O
dealing	O
with	O
all	O
anticoagulants	B-T103
other	O
than	O
dabigatran	B-T103
,	O
and	O
works	O
about	O
surgical	B-T058
treatments	I-T058
in	O
anatomical	B-T082
locations	I-T082
other	O
than	O
the	O
oral	B-T082
cavity	I-T082
.	O

We	O
included	O
a	O
total	O
of	O
13	O
papers	O
of	O
which	O
1	O
was	O
a	O
randomized	B-T062
clinical	I-T062
trial	I-T062
,	O
9	O
narrative	O
literature	O
reviews	O
,	O
1	O
case	B-T062
series	I-T062
,	O
2	O
clinical	O
cases	O
and	O
1	O
expert	O
opinion	O
.	O

Because	O
we	O
did	O
not	O
obtain	O
any	O
properly	O
designed	O
clinical	B-T062
trials	I-T062
,	O
we	O
were	O
unable	O
to	O
conduct	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
.	O

Currently	O
,	O
there	O
is	O
no	O
consensus	O
on	O
the	O
procedure	B-T058
to	O
be	O
followed	O
in	O
patients	O
taking	O
dabigatran	B-T103
.	O

However	O
,	O
all	O
authors	O
agree	O
to	O
treat	O
each	O
case	O
individually	O
in	O
accordance	O
to	O
the	O
risk	O
of	O
embolism	B-T038
,	O
postoperative	B-T038
bleeding	I-T038
and	O
renal	B-T038
function	I-T038
.	O

Also	O
,	O
it	O
is	O
necessary	O
to	O
perform	O
minimally	O
invasive	B-T058
interventions	I-T058
,	O
and	O
take	O
the	O
appropriate	O
local	O
anti	B-T058
-	I-T058
hemolytic	I-T058
measures	I-T058
.	O

Did	O
FIDELIS	B-T170
projects	O
contribute	O
to	O
the	O
detection	B-T033
of	O
new	O
smear	O
-	O
positive	B-T033
pulmonary	B-T038
tuberculosis	I-T038
cases	O
in	O
China	B-T082
?	O

Setting	O
:	O
The	O
first	B-T170
phase	I-T170
of	I-T170
the	I-T170
Fund	I-T170
for	I-T170
Innovative	I-T170
DOTS	I-T170
Expansion	I-T170
through	I-T170
Local	I-T170
Initiatives	I-T170
to	I-T170
Stop	I-T170
TB	I-T170
(	O
FIDELIS	B-T170
)	O
projects	O
in	O
China	B-T082
started	O
in	O
2003	O
.	O

Objective	O
:	O
To	O
determine	O
whether	O
the	O
FIDELIS	B-T170
projects	O
contribute	O
d	O
to	O
the	O
increased	O
case	O
detection	B-T033
rate	O
for	O
new	O
smear	O
-	O
positive	B-T033
pulmonary	B-T038
tuberculosis	I-T038
(	O
PTB	B-T038
)	O
in	O
China	B-T082
.	O

Methods	O
:	O
We	O
compared	O
the	O
case	O
notification	O
rates	O
(	O
CNRs	O
)	O
in	O
the	O
intervention	O
year	O
with	O
those	O
of	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	B-T170
areas	B-T082
,	O
then	O
compared	O
the	O
difference	O
between	O
the	O
CNRs	O
of	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
in	O
the	O
FIDELIS	B-T170
areas	B-T082
with	O
those	O
in	O
the	O
non	B-T033
-	I-T033
FI	I-T033
-	I-T033
DELIS	I-T033
areas	B-T082
within	O
the	O
province	B-T082
.	O

Results	O
:	O
There	O
was	O
an	O
increase	O
in	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
compared	O
with	O
the	O
previous	O
year	O
for	O
all	O
the	O
project	O
sites	O
.	O

The	O
differences	O
between	O
the	O
CNR	O
in	O
the	O
intervention	O
year	O
and	O
the	O
previous	O
year	O
ranged	O
from	O
6	O
.	O
4	O
to	O
31	O
.	O
1	O
per	O
100	O
000	O
population	B-T098
in	O
the	O
FIDELIS	B-T170
areas	B-T082
and	O
from	O
2	O
.	O
9	O
to	O
20	O
.	O
4	O
/	O
100	O
000	O
in	O
the	O
non	B-T033
-	I-T033
FIDELIS	I-T033
areas	B-T082
.	O

Differences	O
-	O
in	O
-	O
differences	O
analysis	B-T062
shows	O
that	O
the	O
differences	O
in	O
the	O
CNRs	O
in	O
the	O
FIDELIS	B-T170
areas	B-T082
were	O
not	O
statistically	O
significantly	O
different	O
from	O
those	O
in	O
the	O
non	O
-	O
FIDELIS	B-T170
areas	B-T082
(	O
P	O
=	O
0	O
.	O
393	O
)	O
.	O

Conclusion	O
:	O
The	O
FIDELIS	B-T170
projects	O
may	O
have	O
contributed	O
to	O
the	O
increase	O
in	O
case	O
detection	B-T033
of	O
new	O
smear	O
-	O
positive	B-T033
PTB	B-T038
in	O
China	B-T082
,	O
but	O
the	O
level	O
of	O
evidence	O
is	O
low	O
.	O

Liver	B-T103
Fatty	I-T103
Acid	I-T103
Binding	I-T103
Protein	I-T103
Deficiency	O
Provokes	O
Oxidative	B-T038
Stress	I-T038
,	O
Inflammation	B-T038
,	O
and	O
Apoptosis	B-T038
-	O
Mediated	O
Hepatotoxicity	B-T037
Induced	O
by	O
Pyrazinamide	B-T103
in	O
Zebrafish	B-T204
Larvae	B-T204

Pyrazinamide	B-T103
(	O
PZA	B-T103
)	O
is	O
an	O
essential	O
antitubercular	B-T103
drug	I-T103
,	O
but	O
little	O
is	O
still	O
known	O
about	O
its	O
hepatotoxicity	B-T037
potential	O
.	O

This	O
study	O
examined	O
the	O
effects	O
of	O
PZA	B-T103
exposure	O
on	O
zebrafish	B-T204
(	O
Danio	B-T204
rerio	I-T204
)	O
larvae	B-T204
and	O
the	O
mechanisms	O
underlying	O
its	O
hepatotoxicity	B-T037
.	O

A	O
transgenic	B-T017
line	I-T017
of	O
zebrafish	B-T204
larvae	B-T204
that	O
expressed	B-T038
enhanced	B-T103
green	I-T103
fluorescent	I-T103
protein	I-T103
(	O
EGFP	B-T103
)	O
in	O
the	O
liver	B-T017
was	O
incubated	B-T058
with	O
1	O
,	O
2	O
.	O
5	O
,	O
and	O
5	O
mM	O
PZA	B-T103
from	O
72	O
h	O
postfertilization	B-T038
(	O
hpf	O
)	O
.	O

Different	O
endpoints	O
such	O
as	O
mortality	O
,	O
morphology	B-T033
changes	O
in	O
the	O
size	O
and	O
shape	B-T082
of	O
the	O
liver	B-T017
,	O
histological	B-T091
changes	O
,	O
transaminase	B-T058
analysis	I-T058
and	O
apoptosis	B-T038
,	O
markers	B-T201
of	O
oxidative	B-T038
and	O
genetic	B-T038
damage	I-T038
,	O
as	O
well	O
as	O
the	O
expression	B-T038
of	O
certain	O
genes	B-T017
were	O
selected	O
to	O
evaluate	B-T058
PZA	B-T103
-	O
induced	O
hepatotoxicity	B-T037
.	O

Our	O
results	O
confirm	B-T033
the	O
manner	O
of	O
PZA	B-T103
dose	O
-	O
dependent	O
hepatotoxicity	B-T037
.	O

PZA	B-T103
was	O
found	O
to	O
induce	O
marked	O
injury	B-T037
in	O
zebrafish	B-T204
larvae	B-T204
,	O
such	O
as	O
liver	B-T038
atrophy	I-T038
,	O
elevations	B-T033
of	I-T033
transaminase	I-T033
levels	I-T033
,	O
oxidative	B-T038
stress	I-T038
,	O
and	O
hepatocyte	B-T038
apoptosis	I-T038
.	O

To	O
further	O
understand	O
the	O
mechanism	O
behind	O
PZA	B-T103
-	O
induced	O
hepatotoxicity	B-T037
,	O
changes	O
in	O
gene	O
expression	O
levels	O
in	O
zebrafish	B-T204
larvae	B-T204
exposed	O
to	O
PZA	B-T103
for	O
72	O
h	O
postexposure	O
(	O
hpe	O
)	O
were	O
determined	O
.	O

The	O
results	O
of	O
this	O
study	O
demonstrated	O
that	O
PZA	B-T103
decreased	O
the	O
expression	O
levels	O
of	O
liver	B-T103
fatty	I-T103
acid	I-T103
binding	I-T103
protein	I-T103
(	O
L	B-T103
-	I-T103
FABP	I-T103
)	O
and	O
its	O
target	B-T017
gene	I-T017
,	O
peroxisome	B-T103
proliferator	I-T103
-	I-T103
activated	I-T103
receptor	I-T103
α	I-T103
(	O
PPAR	B-T103
-	I-T103
α	I-T103
)	O
,	O
and	O
provoked	O
more	O
severe	O
oxidative	B-T038
stress	I-T038
and	O
hepatitis	B-T038
via	O
the	O
upregulation	B-T038
of	O
inflammatory	B-T038
cytokines	I-T038
such	O
as	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
alpha	I-T103
(	O
TNF	B-T103
-	I-T103
α	I-T103
)	O
and	O
transforming	B-T103
growth	I-T103
factor	I-T103
β	I-T103
(	O
TGF	B-T103
-	I-T103
β	I-T103
)	O
.	O

These	O
findings	O
suggest	O
that	O
L	B-T103
-	I-T103
FABP	I-T103
-	O
mediated	O
PPAR	B-T103
-	I-T103
α	I-T103
downregulation	B-T038
appears	O
to	O
be	O
a	O
hepatotoxic	B-T038
response	I-T038
resulting	O
from	O
zebrafish	B-T204
larva	B-T204
liver	B-T017
cell	I-T017
apoptosis	B-T038
,	O
and	O
L	B-T103
-	I-T103
FABP	I-T103
can	O
be	O
used	O
as	O
a	O
biomarker	B-T201
for	O
the	O
early	B-T058
detection	I-T058
of	O
PZA	B-T103
-	O
induced	O
liver	B-T038
damage	I-T038
in	O
zebrafish	B-T204
larvae	B-T204
.	O

Smooth	O
versus	O
Textured	O
Surfaces	B-T082
:	O
Feature	O
-	O
Based	O
Category	B-T170
Selectivity	O
in	O
Human	B-T204
Visual	B-T017
Cortex	I-T017

In	O
fMRI	B-T058
studies	I-T058
,	O
human	B-T204
lateral	B-T017
occipital	I-T017
(	I-T017
LO	I-T017
)	I-T017
cortex	I-T017
is	O
thought	O
to	O
respond	O
selectively	O
to	O
images	B-T170
of	O
objects	O
,	O
compared	O
with	O
nonobjects	O
.	O

However	O
,	O
it	O
remains	O
unresolved	O
whether	O
all	O
objects	O
evoke	O
equivalent	O
levels	O
of	O
activity	O
in	O
LO	B-T017
,	O
and	O
,	O
if	O
not	O
,	O
which	O
image	O
features	O
produce	O
stronger	O
activation	O
.	O

Here	O
,	O
we	O
used	O
an	O
unbiased	B-T170
parametric	I-T170
texture	I-T170
model	I-T170
to	O
predict	O
preferred	O
versus	O
nonpreferred	O
stimuli	O
in	O
LO	B-T017
.	O

Observation	B-T062
and	O
psychophysical	O
results	O
showed	O
that	O
predicted	O
preferred	O
stimuli	O
(	O
both	O
objects	O
and	O
nonobjects	O
)	O
had	O
smooth	O
(	O
rather	O
than	O
textured	O
)	O
surfaces	B-T082
.	O

These	O
predictions	O
were	O
confirmed	O
using	O
fMRI	B-T058
,	O
for	O
objects	O
and	O
nonobjects	O
.	O

Similar	O
preferences	O
were	O
also	O
found	O
in	O
the	O
fusiform	B-T022
face	I-T022
area	I-T022
(	O
FFA	B-T022
)	O
.	O

Consistent	O
with	O
this	O
:	O
(	O
1	O
)	O
FFA	B-T022
and	O
LO	B-T017
responded	O
more	O
strongly	O
to	O
nonfreckled	O
(	O
smooth	O
)	O
faces	B-T082
,	O
compared	O
with	O
otherwise	O
identical	O
freckled	B-T033
(	O
textured	O
)	O
faces	B-T082
;	O
and	O
(	O
2	O
)	O
strong	O
functional	O
connections	B-T082
were	O
found	O
between	O
LO	B-T017
and	O
FFA	B-T022
.	O

Thus	O
,	O
LO	B-T017
and	O
FFA	B-T022
may	O
be	O
part	O
of	O
an	O
information	O
-	O
processing	O
stream	O
distinguished	O
by	O
feature	O
-	O
based	O
category	B-T170
selectivity	O
(	O
smooth	O
>	O
textured	O
)	O
.	O

High	B-T058
-	I-T058
fructose	I-T058
diet	I-T058
is	O
as	O
detrimental	O
as	O
high	B-T058
-	I-T058
fat	I-T058
diet	I-T058
in	O
the	O
induction	B-T058
of	O
insulin	B-T038
resistance	I-T038
and	O
diabetes	B-T038
mediated	O
by	O
hepatic	B-T082
/	O
pancreatic	B-T017
endoplasmic	B-T038
reticulum	I-T038
(	I-T038
ER	I-T038
)	I-T038
stress	I-T038

In	O
the	O
context	O
of	O
high	O
human	B-T204
consumption	O
of	O
fructose	B-T103
diets	B-T168
,	O
there	O
is	O
an	O
imperative	O
need	O
to	O
understand	B-T038
how	O
dietary	O
fructose	B-T033
intake	I-T033
influence	O
cellular	B-T017
and	O
molecular	O
mechanisms	O
and	O
thereby	O
affect	O
β	B-T033
-	I-T033
cell	I-T033
dysfunction	I-T033
and	O
insulin	B-T038
resistance	I-T038
.	O

While	O
evidence	O
exists	O
for	O
a	O
relationship	O
between	O
high	O
-	O
fat	B-T103
-	O
induced	O
insulin	B-T038
resistance	I-T038
and	O
metabolic	B-T038
disorders	I-T038
,	O
there	O
is	O
lack	O
of	O
studies	B-T062
in	O
relation	O
to	O
high	B-T058
-	I-T058
fructose	I-T058
diet	I-T058
.	O

Therefore	O
,	O
we	O
attempted	O
to	O
study	B-T062
the	O
effect	O
of	O
different	O
diets	B-T168
viz	O
.	O
,	O
high	B-T058
-	I-T058
fat	I-T058
diet	I-T058
(	O
HFD	B-T058
)	O
,	O
high	B-T058
-	I-T058
fructose	I-T058
diet	I-T058
(	O
HFS	B-T058
)	O
,	O
and	O
a	O
combination	O
(	O
HFS	B-T058
+	O
HFD	B-T058
)	O
diet	B-T168
on	O
glucose	B-T038
homeostasis	I-T038
and	O
insulin	B-T038
sensitivity	I-T038
in	O
male	O
Wistar	B-T204
rats	I-T204
compared	O
to	O
control	B-T204
animals	I-T204
fed	O
with	O
normal	O
pellet	O
diet	B-T168
.	O

Investigations	O
include	O
oral	B-T058
glucose	I-T058
tolerance	I-T058
test	I-T058
,	O
insulin	B-T058
tolerance	I-T058
test	I-T058
,	O
histopathology	B-T058
by	O
H	B-T058
&	I-T058
E	I-T058
and	O
Masson	B-T058
'	I-T058
s	I-T058
trichrome	I-T058
staining	I-T058
,	O
mRNA	B-T038
expression	I-T038
by	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
,	O
protein	B-T058
expression	I-T058
by	O
Western	B-T058
blot	I-T058
,	O
and	O
caspase	B-T038
-	I-T038
3	I-T038
activity	I-T038
by	O
colorimetry	B-T058
.	O

Rats	B-T204
subjected	O
to	O
high	B-T058
-	I-T058
fat	I-T058
/	O
fructose	B-T058
diets	I-T058
became	O
glucose	B-T103
intolerant	O
,	O
insulin	B-T038
-	I-T038
resistant	I-T038
,	O
and	O
dyslipidemic	B-T033
.	O

Compared	O
to	O
control	B-T204
animals	I-T204
,	O
rats	B-T204
subjected	O
to	O
different	O
combination	O
of	O
fat	B-T058
/	O
fructose	B-T058
diets	I-T058
showed	O
increased	O
mRNA	B-T038
and	O
protein	B-T038
expression	I-T038
of	O
a	O
battery	O
of	O
ER	B-T038
stress	I-T038
markers	O
both	O
in	O
pancreas	B-T017
and	O
liver	B-T017
.	O

Transcription	B-T103
factors	I-T103
of	O
β	B-T038
-	I-T038
cell	I-T038
function	I-T038
(	O
INSIG1	B-T103
,	O
SREBP1c	B-T103
and	O
PDX1	B-T103
)	O
as	O
well	O
as	O
hepatic	B-T082
gluconeogenesis	B-T038
(	O
FOXO1	B-T103
and	O
PEPCK	B-T103
)	O
were	O
adversely	B-T038
affected	I-T038
in	O
diet	B-T168
-	O
induced	O
insulin	B-T038
-	I-T038
resistant	I-T038
rats	B-T204
.	O

The	O
convergence	O
of	O
chronic	O
ER	B-T038
stress	I-T038
towards	O
apoptosis	B-T038
in	O
pancreas	B-T017
/	O
liver	B-T017
was	O
also	O
indicated	B-T033
by	O
increased	O
levels	O
of	O
CHOP	B-T103
mRNA	I-T103
&	O
increased	O
activity	O
of	O
both	O
JNK	B-T038
and	O
Caspase	B-T038
-	I-T038
3	I-T038
in	O
rats	B-T204
subjected	O
to	O
high	B-T058
-	I-T058
fat	I-T058
/	O
fructose	B-T058
diets	I-T058
.	O

Our	O
study	B-T062
exposes	O
the	O
experimental	O
support	O
in	O
that	O
high	B-T058
-	I-T058
fructose	I-T058
diet	I-T058
is	O
equally	O
detrimental	O
in	O
causing	O
metabolic	B-T038
disorders	I-T038
.	O

Immature	O
stages	O
and	O
larval	B-T204
chaetotaxy	O
of	O
Notofairchildia	B-T204
stenygros	I-T204
(	O
Quate	O
&	O
Alexander	O
)	O
(	O
Diptera	B-T204
:	O
Psychodidae	B-T204
:	O
Bruchomyiinae	B-T204
)	O

Some	O
authors	O
have	O
hypothesized	O
that	O
Bruchomyiinae	B-T204
is	O
"	O
the	O
most	O
plesiomorphic	B-T170
subfamily	I-T170
of	O
Psychodidae	B-T204
"	O
and	O
its	O
members	O
"	O
are	O
among	O
the	O
most	O
primitive	O
living	O
Diptera	B-T204
"	O
.	O

Although	O
Bruchomyiinae	B-T204
is	O
of	O
no	B-T033
medical	O
importance	O
,	O
it	O
is	O
of	O
great	O
evolutionary	B-T038
significance	O
,	O
having	O
long	O
been	O
placed	O
as	O
the	O
sister	O
group	O
of	O
Phlebotominae	B-T204
.	O

In	O
general	O
,	O
species	B-T170
of	O
this	O
subfamily	B-T170
are	O
rarely	O
collected	O
in	O
their	O
natural	B-T082
environment	I-T082
;	O
therefore	O
,	O
adults	B-T204
and	O
,	O
even	O
more	O
so	O
,	O
the	O
immature	O
stages	O
of	O
these	O
flies	B-T204
are	O
poorly	O
known	O
.	O

We	O
describe	O
the	O
egg	B-T204
,	O
larvae	B-T204
and	O
pupae	B-T204
of	O
Notofairchildia	B-T204
stenygros	I-T204
and	O
provide	O
nomenclatural	B-T170
notes	I-T170
on	O
larval	B-T204
chaetotaxy	O
based	O
on	O
analyses	O
using	O
scanning	B-T058
electron	I-T058
microscopy	I-T058
(	O
SEM	B-T058
)	O
and	O
optic	O
microscopy	O
.	O

The	O
morphology	O
of	O
immature	O
Nt	B-T204
.	I-T204

stenygros	I-T204
is	O
compared	O
with	O
other	O
Bruchomyiinae	B-T204
and	O
Psychodidae	B-T204
species	B-T170
,	O
especially	O
with	O
species	B-T170
of	O
Phlebotominae	B-T204
that	O
are	O
superficially	O
similar	O
to	O
Bruchomyiinae	B-T204
.	O

Results	O
of	O
this	O
study	B-T062
revealed	O
striking	O
morphological	B-T082
differences	O
between	O
the	O
immature	O
stages	O
of	O
Bruchomyiinae	B-T204
and	O
Phlebotominae	B-T204
;	O
the	O
former	O
are	O
lacking	O
abdominal	B-T082
pseudopods	B-T017
and	O
microtrichia	B-T017
on	O
the	O
cephalic	B-T082
integument	B-T022
,	O
both	O
of	O
which	O
are	O
present	O
in	O
the	O
larvae	B-T204
of	O
Phlebotominae	B-T204
.	O

These	O
morphological	B-T082
differences	O
observed	O
in	O
the	O
immature	O
stages	O
between	O
members	O
of	O
the	O
two	O
subfamilies	B-T170
support	O
the	O
findings	B-T033
of	O
recent	O
molecular	O
studies	O
indicating	O
that	O
Bruchomyiinae	B-T204
and	O
Phlebtominae	B-T204
are	O
evolutionarily	B-T038
not	O
closely	O
related	O
.	O

Notofairchildia	B-T204
stenygros	I-T204
is	O
now	O
the	O
fourth	O
species	B-T170
of	O
Bruchomyiinae	B-T204
for	O
which	O
the	O
immature	O
stages	O
are	O
described	O
.	O

Initial	O
clinical	B-T033
results	I-T033
with	O
the	O
ThermoCool®	O
SmartTouch®	O
Surround	O
Flow	O
catheter	O

The	O
Biosense	O
Webster	O
ThermoCool	O
(	O
®	O
)	O
SmartTouch	O
(	O
®	O
)	O
Surround	O
Flow	O
(	O
STSF	O
)	O
catheter	O
is	O
a	O
recently	O
developed	O
ablation	B-T058
catheter	B-T074
incorporating	O
Surround	B-T038
Flow	I-T038
(	O
SF	B-T038
)	O
technology	O
to	O
ensure	O
efficient	O
cooling	O
and	O
force	O
sensing	O
to	O
quantify	O
tissue	B-T017
contact	O
.	O

In	O
our	O
unit	O
,	O
it	O
superseded	O
the	O
ThermoCool	O
(	O
®	O
)	O
SF	O
catheter	O
from	O
the	O
time	O
of	O
its	O
introduction	O
in	O
May	O
2015	O
.	O

Procedure	B-T058
-	O
related	O
data	O
were	O
collected	O
prospectively	O
for	O
the	O
first	O
100	O
ablation	B-T058
procedures	I-T058
performed	O
in	O
our	O
department	O
using	O
the	O
STSF	O
catheter	O
.	O

From	O
a	O
database	B-T170
of	O
654	O
procedures	B-T058
performed	O
in	O
our	O
unit	O
using	O
the	O
SF	O
catheter	O
,	O
we	O
selected	O
one	O
to	O
match	O
each	O
STSF	B-T058
procedure	I-T058
,	O
matching	O
for	O
procedure	B-T170
type	I-T170
,	O
operator	B-T098
experience	B-T038
,	O
patient	O
age	O
,	O
and	O
gender	O
.	O

The	O
groups	O
were	O
well	O
matched	O
for	O
patient	O
age	O
,	O
gender	O
,	O
and	O
procedure	B-T170
type	I-T170
.	O

Procedure	O
duration	O
was	O
similar	O
in	O
both	O
groups	O
(	O
mean	O
225	O
.	O
5	O
vs	O
.	O

221	O
.	O
4	O
min	O
,	O
IQR	O
106	O
.	O
5	O
vs	O
.	O

91	O
.	O
5	O
,	O
P	O
=	O
0	O
.	O
55	O
)	O
,	O
but	O
fluoroscopy	O
duration	O
was	O
shorter	O
in	O
the	O
STSF	O
group	O
(	O
mean	O
25	O
.	O
8	O
vs	O
.	O

30	O
.	O
0	O
,	O
IQR	O
19	O
.	O
6	O
vs	O
.	O

18	O
.	O
5	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

No	B-T033
complication	I-T033
occurred	O
in	O
the	O
STSF	O
group	O
.	O

Complications	B-T038
occurred	O
in	O
two	O
cases	O
in	O
the	O
SF	O
group	O
(	O
one	O
pericardial	B-T038
effusion	I-T038
requiring	O
drainage	B-T058
and	O
one	O
need	O
for	O
permanent	O
pacing	B-T058
)	O
.	O

Complete	B-T033
procedural	I-T033
success	I-T033
was	O
achieved	O
in	O
98	O
cases	O
in	O
the	O
STSF	O
group	O
and	O
94	O
cases	O
in	O
the	O
SF	O
group	O
(	O
P	O
=	O
0	O
.	O
15	O
)	O
.	O

The	O
composite	O
endpoint	O
of	O
procedure	O
failure	O
or	O
acute	O
complication	B-T038
was	O
less	O
common	O
in	O
the	O
STSF	O
group	O
(	O
2	O
vs	O
.	O

8	O
,	O
P	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
STSF	O
catheter	O
is	O
safe	O
and	O
effective	O
in	O
treating	O
a	O
range	O
of	O
arrhythmias	B-T033
.	O

Compared	O
with	O
the	O
SF	O
catheter	O
,	O
it	O
shows	O
a	O
trend	O
towards	O
improved	O
safety	O
-	O
efficacy	O
balance	O
.	O

Low	B-T033
birth	I-T033
weight	I-T033
and	O
features	O
of	O
neuroticism	B-T038
and	O
mood	B-T038
disorder	I-T038
in	O
83	O
545	O
participants	B-T098
of	O
the	O
UK	B-T082
Biobank	B-T092
cohort	B-T098

Low	B-T033
birth	I-T033
weight	I-T033
has	O
been	O
inconsistently	O
associated	O
with	O
risk	O
of	O
developing	O
affective	B-T038
disorders	I-T038
,	O
including	O
major	B-T038
depressive	I-T038
disorder	I-T038
(	O
MDD	B-T038
)	O
.	O

To	O
date	O
,	O
studies	B-T062
investigating	O
possible	O
associations	O
between	O
birth	O
weight	O
and	O
bipolar	B-T038
disorder	I-T038
(	O
BD	B-T038
)	O
,	O
or	O
personality	B-T033
traits	I-T033
known	O
to	O
predispose	O
to	O
affective	B-T038
disorders	I-T038
such	O
as	O
neuroticism	B-T038
,	O
have	O
not	O
been	O
conducted	O
in	O
large	O
cohorts	B-T098
.	O

To	O
assess	O
whether	O
very	B-T033
low	I-T033
birth	I-T033
weight	I-T033
(	O
<	O
1500	O
g	O
)	O
and	O
low	B-T033
birth	I-T033
weight	I-T033
(	O
1500	O
-	O
2490	O
g	O
)	O
were	O
associated	O
with	O
higher	B-T033
neuroticism	I-T033
scores	O
assessed	O
in	O
middle	O
age	O
,	O
and	O
lifetime	O
history	O
of	O
either	O
MDD	B-T038
or	O
BD	B-T038
.	O

We	O
controlled	O
for	O
possible	O
confounding	O
factors	O
.	O

Retrospective	O
cohort	O
study	O
using	O
baseline	O
data	O
on	O
the	O
83	O
545	O
UK	B-T082
Biobank	B-T092
participants	B-T098
with	O
detailed	O
mental	B-T038
health	I-T038
and	O
birth	O
weight	O
data	O
.	O

Main	O
outcomes	O
were	O
prevalent	O
MDD	B-T038
and	O
BD	B-T038
,	O
and	O
neuroticism	B-T038
assessed	O
using	O
the	O
Eysenck	B-T170
Personality	I-T170
Inventory	I-T170
Neuroticism	I-T170
scale	I-T170
-	I-T170
Revised	I-T170
(	O
EPIN	B-T170
-	I-T170
R	I-T170
)	O
.	O

Referent	O
to	O
normal	B-T033
birth	I-T033
weight	I-T033
,	O
very	B-T033
low	I-T033
/	O
low	B-T033
birth	I-T033
weight	I-T033
were	O
associated	O
with	O
higher	B-T033
neuroticism	I-T033
scores	O
,	O
increased	O
MDD	B-T038
and	O
BD	B-T038
.	O

The	O
associations	O
between	O
birth	O
weight	O
category	B-T170
and	O
MDD	B-T038
were	O
partially	O
mediated	O
by	O
higher	B-T033
neuroticism	I-T033
.	O

These	O
findings	O
suggest	O
that	O
intrauterine	B-T082
programming	B-T038
may	O
play	O
a	O
role	O
in	O
lifetime	O
vulnerability	O
to	O
affective	B-T038
disorders	I-T038
.	O

None	O
.	O

©	O
The	O
Royal	O
College	O
of	O
Psychiatrists	O
2016	O
.	O

This	O
is	O
an	O
open	O
access	O
article	O
distributed	O
under	O
the	O
terms	O
of	O
the	O
Creative	O
Commons	O
Non	O
-	O
Commercial	O
,	O
No	O
Derivatives	O
(	O
CC	O
BY	O
-	O
NC	O
-	O
ND	O
)	O
licence	O
.	O

DNA	B-T038
annealing	I-T038
by	O
Redβ	B-T103
is	O
insufficient	O
for	O
homologous	B-T038
recombination	I-T038
and	O
the	O
additional	O
requirements	O
involve	O
intra	O
-	O
and	O
inter	O
-	O
molecular	O
interactions	O

Single	B-T103
strand	I-T103
annealing	I-T103
proteins	I-T103
(	O
SSAPs	B-T103
)	O
like	O
Redβ	B-T103
initiate	O
homologous	B-T038
recombination	I-T038
by	O
annealing	B-T103
complementary	I-T103
DNA	I-T103
strands	I-T103
.	O

We	O
show	O
that	O
C	B-T038
-	I-T038
terminally	I-T038
truncated	I-T038
Redβ	B-T103
,	O
whilst	O
still	O
able	O
to	O
promote	O
annealing	B-T038
and	O
nucleoprotein	B-T038
filament	I-T038
formation	I-T038
,	O
is	O
unable	O
to	O
mediate	O
homologous	B-T038
recombination	I-T038
.	O

Mutations	B-T038
of	O
the	O
C	B-T082
-	I-T082
terminal	I-T082
domain	I-T082
were	O
evaluated	O
using	O
both	O
single	B-T103
-	O
and	O
double	B-T103
stranded	I-T103
(	O
ss	B-T103
and	O
ds	B-T103
)	O
substrates	O
in	O
recombination	B-T038
assays	B-T058
.	O

Mutations	B-T058
of	O
critical	B-T103
amino	I-T103
acids	I-T103
affected	O
either	O
dsDNA	B-T103
recombination	B-T038
or	O
both	O
ssDNA	B-T103
and	O
dsDNA	B-T038
recombination	I-T038
indicating	O
two	O
separable	O
functions	O
,	O
one	O
of	O
which	O
is	O
critical	O
for	O
dsDNA	B-T038
recombination	I-T038
and	O
the	O
second	O
for	O
recombination	B-T038
per	O
se	O
.	O

As	O
evaluated	O
by	O
co	B-T058
-	I-T058
immunoprecipitation	I-T058
experiments	I-T058
,	O
the	O
dsDNA	B-T038
recombination	I-T038
function	I-T038
relates	O
to	O
the	O
Redα	B-T103
-	O
Redβ	B-T103
protein	B-T038
-	I-T038
protein	I-T038
interaction	I-T038
,	O
which	O
requires	O
not	O
only	O
contacts	O
in	O
the	O
C	B-T082
-	I-T082
terminal	I-T082
domain	I-T082
but	O
also	O
a	O
region	O
near	O
the	O
N	B-T082
-	I-T082
terminus	I-T082
.	O

Because	O
the	O
nucleoprotein	B-T038
filament	I-T038
formed	I-T038
with	O
C	B-T038
-	I-T038
terminally	I-T038
truncated	I-T038
Redβ	B-T103
has	O
altered	O
properties	O
,	O
the	O
second	O
C	B-T038
-	I-T038
terminal	I-T038
function	I-T038
could	O
be	O
due	O
to	O
an	O
interaction	B-T038
required	O
for	O
functional	O
filaments	B-T017
.	O

Alternatively	O
the	O
second	O
C	B-T038
-	I-T038
terminal	I-T038
function	I-T038
could	O
indicate	O
a	O
requirement	O
for	O
a	O
Redβ	B-T103
-	O
host	B-T038
factor	I-T038
interaction	I-T038
.	O

These	O
data	O
further	O
advance	O
the	O
model	O
for	O
Red	B-T038
recombination	I-T038
and	O
the	O
proposition	O
that	O
Redβ	B-T103
and	O
RAD52	B-T103
SSAPs	B-T103
share	O
ancestral	O
and	O
mechanistic	O
roots	O
.	O

Multi	O
-	O
drug	O
-	O
resistant	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
infection	B-T038
outbreak	O
in	O
dogs	B-T204
and	O
cats	B-T204
in	O
a	O
veterinary	B-T092
hospital	I-T092

Members	O
of	O
the	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
cause	O
severe	O
outbreaks	O
in	O
humans	B-T204
,	O
and	O
are	O
increasingly	O
reported	B-T058
in	O
animals	B-T204
.	O

A	O
retrospective	B-T062
study	I-T062
,	O
describing	O
a	O
severe	O
outbreak	O
in	O
dogs	B-T204
and	O
cats	B-T204
caused	O
by	O
a	O
multidrug	B-T007
resistant	I-T007
member	I-T007
of	O
the	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
in	O
a	O
veterinary	B-T092
hospital	I-T092
,	O
between	O
July	O
2010	O
and	O
November	O
2012	O
.	O

The	O
study	B-T062
included	O
19	O
dogs	B-T204
and	O
4	O
cats	B-T204
.	O

Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
bacteria	I-T007
were	O
isolated	O
from	O
urine	B-T031
(	O
9	O
animals	B-T204
)	O
,	O
respiratory	B-T022
tract	I-T022
(	O
11	O
)	O
,	O
tissues	B-T017
(	O
3	O
)	O
and	O
blood	B-T031
(	O
1	O
)	O
.	O

The	O
most	O
common	O
infection	B-T038
-	O
associated	B-T033
findings	I-T033
included	O
fever	B-T033
,	O
purulent	B-T033
discharge	I-T033
from	O
endotracheal	B-T074
tubes	I-T074
,	O
hypotension	B-T033
,	O
and	O
neutropaenia	B-T038
.	O

Infection	B-T038
s	O
led	O
to	O
pneumonia	B-T038
,	O
urinary	B-T038
tract	I-T038
infection	I-T038
,	O
cellulitis	B-T038
and	O
sepsis	B-T038
.	O

Infection	B-T038
was	O
transmitted	B-T038
in	O
the	O
intensive	B-T092
care	I-T092
unit	I-T092
,	O
where	O
22	O
of	O
23	O
animals	B-T204
were	O
initially	O
hospitalised	B-T058
.	O

The	O
mortality	O
rate	O
was	O
70	O
%	O
(	O
16	O
of	O
23	O
animals	B-T204
)	O
,	O
and	O
was	O
higher	O
in	O
cases	O
of	O
respiratory	B-T038
infection	I-T038
compared	O
to	O
other	O
infections	B-T038
.	O

Aggressive	O
environmental	B-T082
cleaning	O
and	O
disinfection	B-T058
,	O
with	O
staff	O
education	O
for	O
personal	O
hygiene	O
and	O
antisepsis	B-T058
,	O
sharply	O
decreased	O
the	O
infection	B-T038
incidence	O
.	O

Health	O
care	O
-	O
associated	O
outbreaks	O
with	O
multidrug	O
resistant	O
Acinetobacter	B-T007
calcoaceticus	I-T007
-	I-T007
Acinetobacter	I-T007
baumannii	I-T007
complex	I-T007
in	O
dogs	B-T204
and	O
cats	B-T204
are	O
potentially	O
highly	O
fatal	O
and	O
difficult	O
to	O
eradicate	O
,	O
warranting	O
monitoring	B-T058
,	O
antiseptic	B-T103
techniques	O
and	O
judicious	O
antibiotic	B-T103
use	O
.	O

Manipulation	O
of	O
an	O
existing	O
crystal	B-T103
form	I-T103
unexpectedly	B-T033
results	I-T033
in	O
interwoven	B-T103
packing	I-T103
networks	I-T103
with	O
pseudo	O
-	O
translational	O
symmetry	O

Nonribosomal	B-T103
peptide	I-T103
synthetases	I-T103
(	O
NRPSs	B-T103
)	O
are	O
multimodular	B-T103
enzymes	I-T103
that	O
synthesize	O
a	O
myriad	O
of	O
diverse	O
molecules	O
.	O

Tailoring	B-T082
domains	I-T082
have	O
been	O
co	O
-	O
opted	O
into	O
NRPSs	B-T103
to	O
introduce	O
further	O
variety	O
into	O
nonribosomal	B-T103
peptide	I-T103
products	I-T103
.	O

Linear	B-T103
gramicidin	I-T103
synthetase	I-T103
contains	O
a	O
unique	O
formylation	B-T038
-	O
tailoring	B-T082
domain	I-T082
in	O
its	O
initiation	O
module	O
(	O
F	B-T038
-	I-T038
A	I-T038
-	O
PCP	B-T082
)	O
.	O

The	O
structure	O
of	O
the	O
F	B-T038
-	I-T038
A	I-T038
di	B-T082
-	I-T082
domain	I-T082
has	O
previously	O
been	O
determined	O
in	O
a	O
crystal	B-T103
form	I-T103
which	O
had	O
large	O
solvent	B-T103
channels	B-T082
and	O
no	O
density	O
for	O
the	O
minor	O
Asub	B-T082
subdomain	I-T082
.	O

An	O
attempt	O
was	O
made	O
to	O
take	O
advantage	O
of	O
this	O
packing	O
by	O
removing	O
the	O
Asub	B-T082
subdomain	I-T082
from	O
the	O
construct	O
(	O
F	B-T038
-	I-T038
A	I-T038
Δ	O
sub	B-T082
)	O
in	O
order	O
to	O
produce	O
a	O
crystal	B-T103
that	O
could	O
accommodate	O
the	O
PCP	B-T082
domain	I-T082
.	O

In	O
the	O
resulting	O
crystal	B-T103
the	O
original	B-T103
packing	I-T103
network	I-T103
was	O
still	O
present	O
,	O
but	O
a	O
second	B-T103
network	I-T103
with	O
the	O
same	O
packing	O
and	O
almost	O
no	O
contact	O
with	O
the	O
original	B-T103
network	I-T103
took	O
the	O
place	O
of	O
the	O
solvent	B-T103
channels	B-T082
and	O
changed	O
the	O
space	B-T103
group	I-T103
of	I-T103
the	I-T103
crystal	I-T103
.	O

Folate	B-T103
-	O
based	O
single	B-T058
cell	I-T058
screening	I-T058
using	O
surface	B-T058
enhanced	I-T058
Raman	I-T058
microimaging	I-T058

Recent	O
progress	O
in	O
nanotechnology	O
and	O
its	O
application	O
to	O
biomedical	B-T062
settings	I-T062
have	O
generated	O
great	O
advantages	O
in	O
dealing	O
with	O
early	B-T058
cancer	I-T058
diagnosis	I-T058
.	O

The	O
identification	O
of	O
the	O
specific	O
properties	O
of	O
cancer	B-T017
cells	I-T017
,	O
such	O
as	O
the	O
expression	O
of	O
particular	O
plasma	B-T017
membrane	I-T017
molecular	B-T091
receptors	I-T091
,	O
has	O
become	O
crucial	O
in	O
revealing	O
the	O
presence	O
and	O
in	O
assessing	O
the	O
stage	O
of	O
development	O
of	O
the	O
disease	O
.	O

Here	O
we	O
report	O
a	O
single	B-T058
cell	I-T058
screening	I-T058
approach	O
based	O
on	O
Surface	B-T058
Enhanced	I-T058
Raman	I-T058
Scattering	I-T058
(	I-T058
SERS	B-T058
)	I-T058
microimaging	I-T058
.	O

We	O
fabricated	O
a	O
SERS	B-T058
-	I-T058
labelled	I-T058
nanovector	O
based	O
on	O
the	O
biofunctionalization	O
of	O
gold	O
nanoparticles	O
with	O
folic	B-T103
acid	I-T103
.	O

After	O
treating	B-T017
the	I-T017
cells	I-T017
with	O
the	O
nanovector	O
,	O
we	O
were	O
able	O
to	O
distinguish	O
three	O
different	O
cell	O
populations	O
from	O
different	B-T017
cell	I-T017
lines	I-T017
(	O
cancer	B-T017
HeLa	I-T017
and	O
PC	B-T038
-	I-T038
3	I-T038
,	O
and	O
normal	B-T017
HaCaT	I-T017
lines	I-T017
)	O
,	O
suitably	O
chosen	O
for	O
their	O
different	O
expressions	O
of	O
folate	B-T103
binding	I-T103
proteins	I-T103
.	O

The	O
nanovector	O
,	O
indeed	O
,	O
binds	O
much	O
more	O
efficiently	O
on	O
cancer	B-T017
cell	I-T017
lines	I-T017
than	O
on	O
normal	O
ones	O
,	O
resulting	O
in	O
a	O
higher	O
SERS	B-T058
signal	O
measured	O
on	O
cancer	B-T017
cells	I-T017
.	O

These	O
results	O
pave	O
the	O
way	O
for	O
applications	O
in	O
single	B-T058
cell	I-T058
diagnostics	I-T058
and	O
,	O
potentially	O
,	O
in	O
theranostics	B-T091
.	O

Self	B-T062
-	I-T062
reported	I-T062
occupational	B-T037
injuries	I-T037
among	O
industrial	O
beef	B-T204
slaughterhouse	O
workers	B-T098
in	O
the	O
Midwestern	B-T082
United	I-T082
States	I-T082

Although	O
workers	B-T098
in	O
meatpacking	B-T092
facilities	I-T092
in	O
the	O
United	B-T082
States	I-T082
experience	O
high	O
rates	O
of	O
occupational	B-T037
injury	I-T037
,	O
their	O
injury	B-T037
experiences	O
have	O
received	O
limited	O
research	B-T062
attention	O
.	O

Prior	O
research	B-T062
indicates	I-T062
underreporting	B-T058
in	O
injury	O
rates	O
in	O
this	O
industry	O
as	O
well	O
significant	O
variation	O
in	O
injury	O
rates	O
among	O
facilities	O
.	O

To	O
add	O
detail	O
to	O
the	O
rates	O
and	O
circumstances	O
surrounding	O
occupational	B-T037
injury	I-T037
among	O
meatpacking	B-T092
workers	B-T098
,	O
we	O
conducted	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
of	O
workers	B-T098
employed	O
at	O
an	O
industrial	B-T092
beefpacking	I-T092
plant	I-T092
in	O
Nebraska	B-T082
,	O
United	B-T082
States	I-T082
(	O
n	O
=	O
137	O
)	O
and	O
interviewed	O
workers	B-T098
about	O
recent	O
injury	B-T037
experiences	O
.	O

We	O
assessed	O
frequency	O
,	O
cause	O
and	O
nature	O
of	O
self	B-T062
-	I-T062
reported	I-T062
injury	B-T037
.	O

We	O
estimated	O
annual	O
incidence	O
rates	O
of	O
self	B-T062
-	I-T062
reported	I-T062
injuries	B-T037
using	O
the	O
OSHA	B-T092
formula	B-T170
and	O
compared	O
these	O
rates	O
to	O
industry	O
-	O
wide	O
data	O
.	O

We	O
also	O
evaluated	O
psychological	O
distress	O
in	O
this	O
workforce	O
as	O
measured	O
by	O
the	O
Kessler	O
-	O
6	O
scale	O
to	O
assess	O
whether	O
distress	B-T033
was	O
associated	O
with	O
recent	O
occupational	B-T037
injury	B-T037
.	O

In	O
this	O
study	O
,	O
15	O
.	O
1	O
%	O
of	O
workers	B-T098
experienced	O
occupational	B-T037
injuries	I-T037
that	O
required	O
time	O
off	O
work	O
,	O
job	O
transfer	O
,	O
or	O
restriction	O
during	O
the	O
past	O
three	O
months	O
.	O

The	O
estimated	O
annual	O
incidence	O
rate	O
was	O
15	O
.	O
2	O
injuries	B-T037
per	O
100	O
full	O
-	O
time	O
workers	B-T098
for	O
these	O
injuries	B-T037
at	O
this	O
plant	O
.	O

Rushing	O
was	O
identified	O
as	O
the	O
cause	O
of	O
nearly	O
50	O
%	O
of	O
injuries	B-T037
,	O
and	O
repetitive	O
work	O
as	O
the	O
cause	O
of	O
an	O
additional	O
20	O
%	O
of	O
injuries	B-T037
.	O

Use	O
of	O
metal	B-T074
mesh	I-T074
sleeves	B-T074
(	O
POR	O
:	O
0	O
.	O
10	O
(	O
p	O
=	O
0	O
.	O
008	O
)	O
)	O
and	O
metal	B-T074
mesh	I-T074
gloves	O
(	O
POR	O
:	O
0	O
.	O
41	O
(	O
p	O
=	O
0	O
.	O
05	O
)	O
were	O
associated	O
with	O
reduced	O
risk	O
of	O
injury	B-T037
.	O

Use	O
of	O
a	O
carbon	B-T103
steel	B-T103
for	O
knife	O
sharpening	O
(	O
POR	O
:	O
5	O
.	O
2	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
)	O
was	O
associated	O
with	O
elevated	O
risk	O
of	O
moderate	O
and	O
severe	O
injury	B-T037
.	O

There	O
were	O
no	O
associations	O
between	O
self	B-T062
-	I-T062
reported	I-T062
occupational	B-T037
injury	I-T037
and	O
overall	O
measures	O
of	O
psychological	O
distress	O
.	O

Self	B-T062
-	I-T062
reported	I-T062
incidence	O
rate	O
of	O
severe	O
injury	B-T037
in	O
this	O
plant	O
was	O
more	O
than	O
twice	O
official	O
industry	O
estimates	O
.	O

Worker	O
self	B-T062
-	I-T062
reports	I-T062
may	O
illustrate	O
key	O
areas	O
for	O
injury	B-T058
prevention	I-T058
.	O

The	O
Effect	O
of	O
l	B-T103
-	I-T103
Arginine	I-T103
on	O
Dural	B-T038
Healing	I-T038
After	O
Experimentally	O
Induced	O
Dural	B-T017
Defect	O
in	O
a	O
Rat	B-T204
Model	O

Incomplete	O
repair	B-T038
of	O
the	O
dura	B-T017
mater	I-T017
may	O
result	O
in	O
numerous	O
complications	B-T038
such	O
as	O
cerebrospinal	B-T038
fluid	I-T038
leakage	I-T038
and	O
meningitis	B-T038
.	O

For	O
this	O
reason	O
,	O
accurate	O
repair	B-T038
of	O
the	O
dura	B-T017
mater	I-T017
is	O
essential	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
systemic	O
and	O
local	B-T082
supplementation	O
of	O
l	B-T103
-	I-T103
arginine	I-T103
on	O
dural	B-T038
healing	I-T038
was	O
evaluated	O
.	O

Thirty	O
male	O
Wistar	B-T204
rats	I-T204
were	O
used	O
and	O
divided	O
into	O
control	O
,	O
local	B-T082
,	O
and	O
systemic	O
l	B-T103
-	I-T103
arginine	I-T103
groups	O
,	O
with	O
10	O
rats	B-T204
in	O
each	O
.	O

In	O
each	O
group	O
,	O
a	O
5	O
-	O
mm	O
experimental	B-T058
incision	I-T058
was	O
made	O
at	O
the	O
lumbar	B-T082
segment	I-T082
of	I-T082
the	I-T082
dura	I-T082
mater	I-T082
and	O
cerebrospinal	B-T038
fluid	I-T038
leakage	I-T038
was	O
induced	O
.	O

Each	O
group	O
was	O
divided	O
into	O
2	O
subgroups	B-T170
and	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	O
,	O
the	O
rats	B-T204
were	O
killed	B-T058
and	O
the	O
damaged	O
segments	B-T082
of	O
the	O
dura	B-T017
were	O
separated	O
,	O
histologically	O
evaluated	O
and	O
the	O
dural	B-T038
healing	I-T038
indicators	O
including	O
cell	B-T017
types	I-T017
,	O
granulation	B-T017
tissue	I-T017
formation	O
,	O
collagen	B-T103
deposit	O
,	O
and	O
vascularization	O
were	O
compared	O
between	O
groups	O
.	O

The	O
systematic	O
supplementation	O
of	O
l	B-T103
-	I-T103
arginine	I-T103
showed	O
a	O
significant	O
effect	O
in	O
dural	B-T038
healing	I-T038
compared	O
with	O
the	O
control	O
group	O
.	O

After	O
the	O
first	O
week	O
,	O
granulation	B-T017
formation	O
increased	O
considerably	O
(	O
P	O
<	O
0	O
.	O
031	O
)	O
,	O
and	O
after	O
6	O
weeks	O
,	O
collagen	B-T103
deposition	O
and	O
neovascularization	B-T038
were	O
significantly	O
different	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
030	O
;	O
P	O
<	O
0	O
.	O
009	O
)	O
.	O

In	O
comparison	O
between	O
different	O
groups	O
at	O
the	O
end	O
of	O
the	O
first	O
and	O
sixth	O
weeks	O
,	O
maximum	O
changes	O
in	O
healing	B-T038
indicators	O
were	O
observed	O
in	O
the	O
systemic	O
group	O
and	O
the	O
least	O
variations	O
were	O
related	O
to	O
the	O
control	O
group	O
.	O

The	O
systemic	O
supplementation	O
of	O
l	B-T103
-	I-T103
arginine	I-T103
may	O
accelerate	O
dural	B-T038
healing	I-T038
by	O
increasing	O
the	O
level	O
of	O
granulation	B-T017
tissue	I-T017
formation	O
,	O
collagen	B-T103
deposition	O
,	O
and	O
vascularization	O
.	O

Birth	O
Preparedness	O
and	O
Complication	O
Readiness	O
Practice	O
and	O
Associated	O
Factors	O
among	O
Pregnant	B-T098
Women	I-T098
,	O
Northwest	B-T082
Ethiopia	I-T082

Background	O
.	O

Little	O
is	O
known	O
about	O
birth	O
preparedness	O
and	O
complication	O
readiness	O
(	O
BPCR	O
)	O
plan	O
in	O
resource	O
limited	O
settings	O
to	O
decrease	O
maternal	O
mortality	O
.	O

Therefore	O
,	O
this	O
study	B-T062
was	O
done	O
to	O
assess	O
the	O
status	O
of	O
BPCR	O
and	O
associated	O
factors	O
among	O
pregnant	B-T098
women	I-T098
in	O
South	B-T082
Wollo	I-T082
,	O
Northwest	B-T082
Ethiopia	I-T082
,	O
by	O
involving	O
819	O
pregnant	B-T098
women	I-T098
from	O
March	O
to	O
April	O
,	O
2014	O
.	O

Data	O
were	O
collected	O
by	O
using	O
pretested	O
interviewer	B-T097
administered	B-T170
questionnaire	I-T170
and	O
analyzed	B-T062
using	O
a	O
computer	B-T170
program	I-T170
of	O
SPSS	B-T170
version	I-T170
20	I-T170
.	I-T170
00	I-T170
.	O

Results	O
.	O

Pregnant	B-T098
women	I-T098
who	O
were	O
prepared	B-T033
for	O
at	O
least	O
three	O
elements	O
of	O
BPCR	O
were	O
24	O
.	O
1	O
%	O
.	O

Pregnant	B-T098
women	I-T098
knowing	O
at	O
least	O
three	O
key	O
danger	B-T033
signs	I-T033
during	O
pregnancy	B-T038
,	O
delivery	B-T038
,	O
and	O
postnatal	O
period	O
were	O
23	O
.	O
2	O
%	O
,	O
22	O
.	O
6	O
%	O
,	O
and	O
9	O
.	O
6	O
%	O
,	O
respectively	O
.	O

Women	B-T098
having	O
secondary	O
education	O
and	O
higher	O
were	O
6	O
.	O
20	O
(	O
95	O
%	O
CI	O
=	O
[	O
1	O
.	O
36	O
,	O
28	O
.	O
120	O
]	O
)	O
times	O
more	O
likely	O
to	O
be	O
prepared	B-T033
than	O
illiterates	B-T033
.	O

Women	B-T098
having	O
a	O
lifetime	O
history	O
of	O
stillbirth	B-T033
[	O
5	O
.	O
80	O
(	O
1	O
.	O
13	O
,	O
29	O
.	O
63	O
)	O
]	O
,	O
attending	O
ANC	B-T058
for	O
last	O
child	O
pregnancy	B-T038
[	O
5	O
.	O
44	O
(	O
2	O
.	O
07	O
,	O
14	O
.	O
27	O
)	O
]	O
,	O
participating	O
in	O
community	O
BPCR	O
group	O
discussion	O
[	O
4	O
.	O
36	O
(	O
1	O
.	O
17	O
,	O
16	O
.	O
26	O
)	O
]	O
,	O
and	O
having	O
their	O
male	O
partner	O
involved	O
in	O
BPCR	O
counseling	B-T058
during	O
ANC	B-T058
follow	B-T058
-	I-T058
up	I-T058
[	O
4	O
.	O
45	O
(	O
1	O
.	O
95	O
,	O
10	O
.	O
16	O
)	O
]	O
were	O
more	O
likely	O
to	O
be	O
prepared	B-T033
.	O

Conclusions	O
.	O

BPCR	O
was	O
very	O
low	O
and	O
should	O
be	O
strengthened	O
through	O
health	B-T058
communication	I-T058
by	O
involving	O
partner	O
in	O
BPCR	O
counseling	B-T058
.	O

Fluoranthene	B-T103
degradation	O
and	O
binding	B-T038
mechanism	O
study	B-T062
based	O
on	O
the	O
active	O
-	O
site	O
structure	B-T082
of	O
ring	B-T103
-	I-T103
hydroxylating	I-T103
dioxygenase	I-T103
in	O
Microbacterium	B-T007
paraoxydans	I-T007
JPM1	I-T007

In	O
this	O
study	B-T062
,	O
a	O
gram	B-T007
-	I-T007
positive	I-T007
fluoranthene	I-T007
-	I-T007
degrading	I-T007
bacterial	I-T007
strain	O
was	O
isolated	O
from	O
crude	B-T103
oil	I-T103
in	O
Dagang	O
Oilfield	O
and	O
identified	O
as	O
Microbacterium	B-T007
paraoxydans	I-T007
JPM1	I-T007
by	O
the	O
analysis	B-T062
of	O
16S	B-T103
rDNA	I-T103
sequence	B-T082
.	O

After	O
25	O
days	O
of	O
incubation	B-T058
,	O
the	O
strain	O
JPM1	B-T007
could	O
degrade	O
91	O
.	O
78	O
%	O
of	O
the	O
initial	O
amount	O
of	O
fluoranthene	B-T103
.	O

Moreover	O
,	O
four	O
metabolites	B-T103
9	B-T103
-	I-T103
fluorenone	I-T103
-	I-T103
1	I-T103
-	I-T103
carboxylic	I-T103
acid	I-T103
,	O
9	B-T103
-	I-T103
fluorenone	I-T103
,	O
phthalic	B-T103
acid	I-T103
,	O
and	O
benzoic	B-T103
acid	I-T103
were	O
detected	O
in	O
the	O
culture	B-T103
solution	I-T103
.	O

The	O
gene	B-T082
sequence	I-T082
encoding	O
the	O
aromatic	B-T103
-	I-T103
ring	I-T103
-	I-T103
hydroxylating	I-T103
dioxygenase	I-T103
was	O
amplified	B-T038
in	O
the	O
strain	O
JPM1	B-T007
by	O
PCR	B-T062
.	O

Based	O
on	O
the	O
translated	O
protein	B-T082
sequence	I-T082
,	O
a	O
homology	B-T062
modeling	I-T062
method	I-T062
was	O
applied	O
to	O
build	O
the	O
crystal	B-T103
structure	I-T103
of	O
dioxygenase	B-T103
.	O

Subsequently	O
,	O
the	O
interaction	O
mechanism	O
between	O
fluoranthene	B-T103
and	O
the	O
active	O
site	O
of	O
dioxygenase	B-T103
was	O
simulated	B-T062
and	O
analyzed	B-T062
by	O
molecular	B-T062
docking	I-T062
.	O

Consequently	O
,	O
a	O
feasible	O
degrading	O
pathway	B-T038
of	O
fluoranthene	B-T103
in	O
the	O
strain	O
JPM1	B-T007
was	O
proposed	O
based	O
on	O
the	O
metabolites	B-T103
and	O
the	O
interaction	O
analyses	O
.	O

Additionally	O
,	O
the	O
thermodynamic	B-T062
analysis	I-T062
showed	O
that	O
the	O
strain	O
JPM1	B-T007
had	O
high	O
tolerance	O
for	O
fluoranthene	B-T103
,	O
and	O
the	O
influence	O
of	O
fluoranthene	B-T103
for	O
the	O
bacterial	B-T007
growth	B-T038
activity	O
was	O
negligible	O
under	O
100	O
to	O
400	O
mg	O
L	O
(	O
-	O
1	O
)	O
concentrations	O
.	O

Taken	O
together	O
,	O
this	O
study	B-T062
indicates	O
that	O
the	O
strain	O
JPM1	B-T007
has	O
high	O
potential	O
for	O
further	O
study	B-T062
in	O
bioremediation	O
of	O
polycyclic	B-T103
aromatic	I-T103
hydrocarbon	I-T103
(	O
PAH	B-T103
)	O
-	O
contaminated	O
sites	B-T082
.	O

Ultrasonography	B-T058
for	O
acute	B-T038
appendicitis	I-T038
-	O
the	O
way	O
it	O
looks	O
today	O

Despite	O
sophisticated	O
physical	B-T058
examination	I-T058
and	O
laboratory	B-T058
support	I-T058
,	O
diagnosis	B-T033
of	O
acute	B-T038
appendicitis	I-T038
remained	O
challenging	O
in	O
clinical	O
practice	O
with	O
a	O
negative	B-T058
appendectomy	I-T058
rate	O
of	O
15	O
-	O
30	O
%	O
.	O

As	O
a	O
remarkable	O
clue	O
and	O
as	O
early	O
as	O
1986	O
,	O
ultrasonography	B-T058
(	O
US	B-T058
)	O
has	O
been	O
proven	O
a	O
reliable	O
diagnostic	B-T058
method	I-T058
that	O
is	O
also	O
explicitly	O
helpful	O
in	O
difficult	O
cases	O
with	O
atypical	O
presentation	O
and	O
enables	O
to	O
rule	O
out	O
many	O
differential	B-T058
diagnoses	I-T058
.	O
Recent	O
publications	B-T170
emphasized	O
the	O
role	O
of	O
multidetector	B-T058
computed	I-T058
tomography	I-T058
(	O
CT	B-T058
)	O
resulting	O
in	O
a	O
significant	O
reduction	O
of	O
false	B-T033
negative	I-T033
findings	I-T033
at	O
operation	B-T058
.	O

Extensive	O
as	O
well	O
as	O
uncritical	B-T058
application	I-T058
of	O
this	O
method	O
even	O
in	O
children	O
inevitably	O
causes	O
substantial	O
radiation	B-T037
exposure	I-T037
,	O
a	O
sequel	O
to	O
either	O
pure	O
ignorance	O
or	O
unqualified	O
/	O
inadequate	O
performance	O
of	O
US	B-T058
in	O
this	O
particular	O
situation	O
,	O
which	O
in	O
turn	O
can	O
be	O
considered	O
sequel	O
to	O
either	O
egocentric	B-T033
or	O
economic	O
preponderance	O
.	O
Recent	O
data	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
US	B-T058
(	O
and	O
CT	B-T058
)	O
in	O
acute	B-T038
appendicitis	I-T038
.	O

Therefore	O
,	O
1	O
generation	O
after	O
US	B-T058
with	I-T058
graded	I-T058
compression	I-T058
was	O
etched	O
in	O
stone	O
as	O
the	O
method	O
of	O
choice	O
for	O
diagnosing	B-T033
acute	B-T038
appendicitis	I-T038
(	O
Puylaert	O
)	O
,	O
a	O
visual	O
arousal	B-T038
fostering	O
its	O
role	O
and	O
performance	O
in	O
clinical	B-T091
medicine	I-T091
appears	O
justified	O
.	O

Mesenchymal	B-T017
stem	I-T017
cells	I-T017
enhance	O
the	O
oncolytic	O
effect	O
of	O
Newcastle	B-T005
disease	I-T005
virus	I-T005
in	O
glioma	B-T038
cells	B-T017
and	O
glioma	B-T038
stem	B-T017
cells	I-T017
via	O
the	O
secretion	B-T038
of	O
TRAIL	B-T103

Newcastle	B-T005
disease	I-T005
virus	I-T005
(	O
NDV	B-T005
)	O
is	O
an	O
avian	B-T005
paramyxovirus	I-T005
,	O
which	O
selectively	O
exerts	B-T038
oncolytic	O
effects	O
in	O
cancer	B-T017
cells	I-T017
.	O

Mesenchymal	B-T017
stem	I-T017
cells	I-T017
(	O
MSCs	B-T017
)	O
have	O
been	O
reported	O
to	O
affect	O
tumor	O
growth	O
and	O
deliver	O
anti	B-T103
-	I-T103
tumor	I-T103
agents	I-T103
to	O
experimental	O
glioblastoma	B-T038
(	O
GBM	B-T038
)	O
.	O

Here	O
,	O
we	O
explored	O
the	O
effects	O
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T017
derived	O
from	O
different	O
sources	B-T033
,	O
on	O
glioma	B-T038
cells	B-T017
and	O
glioma	B-T038
stem	B-T017
cells	I-T017
(	O
GSCs	B-T017
)	O
and	O
the	O
mechanisms	O
involved	O
in	O
their	O
effects	O
.	O

The	O
glioma	B-T038
cell	B-T017
lines	I-T017
(	O
A172	B-T017
and	O
U87	B-T017
)	O
and	O
primary	O
GSCs	B-T017
that	O
were	O
generated	O
from	O
GBM	B-T038
tumors	B-T038
were	O
used	O
in	O
this	O
study	B-T062
.	O

MSCs	B-T017
derived	O
from	O
bone	B-T017
marrow	I-T017
,	O
adipose	B-T017
tissue	I-T017
or	O
umbilical	B-T017
cord	I-T017
were	O
infected	B-T033
with	O
NDV	B-T005
(	O
MTH	B-T058
-	I-T058
68	I-T058
/	I-T058
H	I-T058
)	O
.	O

The	O
ability	O
of	O
these	O
cells	B-T017
to	O
deliver	O
the	O
virus	B-T005
to	O
glioma	B-T038
cell	B-T017
lines	I-T017
and	O
GSCs	B-T017
and	O
the	O
effects	O
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T017
on	O
cell	B-T038
death	I-T038
and	O
on	O
the	O
stemness	O
and	O
self	B-T038
-	I-T038
renewal	I-T038
of	O
GSCs	B-T017
were	O
examined	B-T033
.	O

The	O
mechanisms	O
involved	O
in	O
the	O
cytotoxic	O
effects	O
of	O
the	O
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T017
and	O
their	O
influence	O
on	O
the	O
radiation	O
sensitivity	O
of	O
GSCs	B-T017
were	O
examined	B-T033
as	O
well	O
.	O

NDV	B-T005
induced	O
a	O
dose	O
-	O
dependent	O
cell	B-T038
death	I-T038
in	O
glioma	B-T038
cells	B-T017
and	O
a	O
low	O
level	O
of	O
apoptosis	B-T038
and	O
inhibition	O
of	O
self	B-T038
-	I-T038
renewal	I-T038
in	O
GSCs	B-T017
.	O

MSCs	B-T017
derived	O
from	O
bone	B-T017
marrow	I-T017
,	O
adipose	B-T017
and	O
umbilical	B-T017
cord	I-T017
that	O
were	O
infected	B-T033
with	O
NDV	B-T005
delivered	O
the	O
virus	B-T005
to	O
co	B-T058
-	I-T058
cultured	I-T058
glioma	B-T038
cells	B-T017
and	O
GSCs	B-T017
.	O

Conditioned	B-T103
medium	I-T103
of	O
NDV	B-T005
-	O
infected	B-T033
MSCs	B-T017
induced	O
higher	O
level	O
of	O
apoptosis	B-T038
in	O
the	O
tumor	B-T017
cells	I-T017
compared	O
with	O
the	O
apoptosis	B-T038
induced	O
by	O
their	O
direct	B-T038
infection	I-T038
with	O
similar	O
virus	O
titers	O
.	O

These	O
results	O
suggest	O
that	O
factor	O
(	O
s	O
)	O
secreted	B-T038
by	O
the	O
infected	B-T033
MSCs	B-T017
sensitized	B-T017
the	O
glioma	B-T038
cells	B-T017
to	O
the	O
cytotoxic	O
effects	O
of	O
NDV	B-T005
.	O

We	O
identified	O
TRAIL	B-T103
as	O
a	O
mediator	O
of	O
the	O
cytotoxic	O
effects	O
of	O
the	O
infected	B-T033
MSCs	B-T017
and	O
demonstrated	O
that	O
TRAIL	B-T103
synergized	O
with	O
NDV	B-T005
in	O
the	O
induction	O
of	O
cell	B-T038
death	I-T038
in	O
glioma	B-T038
cells	B-T017
and	O
GSCs	B-T017
.	O

Moreover	O
,	O
conditioned	O
medium	O
of	O
infected	B-T033
MSCs	B-T017
enhanced	O
the	O
sensitivity	O
of	O
GSCs	B-T017
to	O
γ	O
-	O
radiation	O
.	O

NDV	B-T005
-	O
infected	B-T033
umbilical	B-T017
cord	I-T017
-	O
derived	O
MSCs	B-T017
may	O
provide	O
a	O
novel	O
effective	O
therapeutic	O
approach	B-T082
for	O
targeting	O
GSCs	B-T017
and	O
GBM	B-T038
and	O
for	O
sensitizing	O
these	O
tumors	B-T038
to	O
γ	O
-	O
radiation	O
.	O

Importance	O
of	O
Ecological	O
Factors	O
and	O
Colony	O
Handling	B-T033
for	O
Optimizing	O
Health	O
Status	O
of	O
Apiaries	O
in	O
Mediterranean	B-T098
Ecosystems	O

We	O
analyzed	B-T062
six	O
apiaries	O
in	O
several	O
natural	B-T082
environments	I-T082
with	O
a	O
Mediterranean	B-T098
ecosystem	O
in	O
Madrid	B-T082
,	O
central	B-T082
Spain	I-T082
,	O
in	O
order	O
to	O
understand	B-T038
how	O
landscape	B-T082
and	O
management	O
characteristics	O
may	O
influence	O
apiary	O
health	O
and	O
bee	B-T204
production	O
in	O
the	O
long	O
term	O
.	O

We	O
focused	O
on	O
five	O
criteria	O
(	O
habitat	B-T082
quality	O
,	O
landscape	B-T082
heterogeneity	O
,	O
climate	O
,	O
management	O
and	O
health	O
)	O
,	O
as	O
well	O
as	O
30	O
subcriteria	O
,	O
and	O
we	O
used	O
the	O
analytic	B-T062
hierarchy	I-T062
process	I-T062
(	O
AHP	B-T062
)	O
to	O
rank	B-T170
them	O
according	O
to	O
relevance	O
.	O

Habitat	B-T082
quality	O
proved	O
to	O
have	O
the	O
highest	O
relevance	O
,	O
followed	O
by	O
beehive	O
management	O
.	O

Within	O
habitat	B-T082
quality	O
,	O
the	O
following	O
subcriteria	O
proved	O
to	O
be	O
most	O
relevant	O
:	O
orographic	O
diversity	O
,	O
elevation	B-T082
range	O
and	O
important	O
plant	B-T204
species	B-T170
located	B-T082
1	O
.	O
5	O
km	O
from	O
the	O
apiary	O
.	O

The	O
most	O
important	O
subcriteria	O
under	O
beehive	O
management	O
were	O
honey	B-T168
production	O
,	O
movement	O
of	O
the	O
apiary	O
to	O
a	O
location	B-T082
with	O
a	O
higher	O
altitude	O
and	O
wax	B-T103
renewal	O
.	O

Temperature	O
was	O
the	O
most	O
important	O
subcriterion	O
under	O
climate	O
,	O
while	O
pathogen	O
and	O
Varroa	B-T204
loads	B-T033
were	O
the	O
most	O
significant	O
under	O
health	O
.	O

Two	O
of	O
the	O
six	O
apiaries	O
showed	O
the	O
best	O
values	O
in	O
the	O
AHP	B-T062
analysis	B-T062
and	O
showed	O
annual	O
honey	B-T168
production	O
of	O
70	O
and	O
28	O
kg	O
/	O
colony	O
.	O

This	O
high	O
productivity	O
was	O
due	O
primarily	O
to	O
high	O
elevation	B-T082
range	O
and	O
high	O
orographic	O
diversity	O
,	O
which	O
favored	O
high	O
habitat	B-T082
quality	O
.	O

In	O
addition	O
,	O
one	O
of	O
these	O
apiaries	O
showed	O
the	O
best	O
value	O
for	O
beehive	O
management	O
,	O
while	O
the	O
other	O
showed	O
the	O
best	O
value	O
for	O
health	O
,	O
reflected	O
in	O
the	O
low	O
pathogen	O
load	B-T033
and	O
low	O
average	O
number	O
of	O
viruses	B-T005
.	O

These	O
results	O
highlight	O
the	O
importance	O
of	O
environmental	O
factors	O
and	O
good	O
sanitary	O
practices	O
to	O
maximize	O
apiary	O
health	O
and	O
honey	B-T168
productivity	O
.	O

Chordoma	B-T038
dedifferentiation	I-T038
after	O
proton	B-T058
beam	I-T058
therapy	I-T058
:	O
a	O
case	B-T170
report	I-T170
and	O
review	B-T170
of	I-T170
the	I-T170
literature	I-T170

Chordoma	B-T038
is	O
a	O
rare	O
invasive	O
bone	B-T038
tumor	I-T038
that	O
may	O
occur	O
anywhere	O
along	O
the	O
neuraxis	B-T082
.	O

A	O
total	O
of	O
three	O
primary	O
histological	B-T038
varieties	I-T038
have	O
been	O
identified	O
:	O
conventional	B-T038
,	O
chondroid	B-T038
,	O
and	O
dedifferentiated	B-T038
.	O

We	O
report	B-T170
a	O
case	O
of	O
an	O
8	O
-	O
year	O
-	O
old	O
white	B-T098
girl	O
who	O
presented	O
with	O
conventional	B-T038
chordoma	I-T038
,	O
was	O
treated	B-T033
with	O
surgical	B-T058
resection	I-T058
and	O
mixed	O
proton	O
and	O
photon	B-T058
beam	I-T058
therapy	I-T058
,	O
and	O
had	O
a	O
recurrence	O
in	O
the	O
resection	B-T017
cavity	I-T017
2	O
.	O
5	O
years	O
later	O
with	O
dedifferentiated	B-T038
morphology	I-T038
.	O

The	O
recurrent	B-T038
tumor	I-T038
did	O
not	O
express	B-T038
brachyury	B-T103
,	O
a	O
recently	O
identified	O
protein	B-T103
specific	O
to	O
tissue	B-T017
of	O
notochordal	B-T017
origin	O
.	O

The	O
short	O
time	O
period	O
between	O
radiation	B-T058
therapy	I-T058
and	O
dedifferentiation	B-T038
,	O
low	O
dose	O
of	O
photons	O
,	O
and	O
rarity	O
of	O
dedifferentiated	O
skull	O
base	O
chordomas	O
in	O
pediatric	O
patients	O
should	O
alert	O
clinicians	B-T097
to	O
the	O
possibility	B-T033
of	O
chordoma	B-T038
dedifferentiation	I-T038
after	O
proton	B-T058
beam	I-T058
therapy	I-T058
.	O

Volumetric	B-T058
absorptive	I-T058
microsampling	I-T058
at	O
home	B-T082
as	O
an	O
alternative	O
tool	O
for	O
the	O
monitoring	B-T058
of	O
HbA1c	B-T103
in	O
diabetes	B-T038
patients	O

Microsampling	O
techniques	O
have	O
several	O
advantages	O
over	O
traditional	O
blood	B-T058
collection	I-T058
.	O

Dried	B-T058
blood	I-T058
spot	I-T058
(	I-T058
DBS	I-T058
)	I-T058
sampling	I-T058
and	O
blood	B-T058
collection	I-T058
with	O
heparinized	O
capillaries	O
are	O
the	O
standard	O
techniques	B-T058
.	O

Volumetric	B-T058
absorptive	I-T058
microsampling	I-T058
(	O
VAMS	B-T058
)	O
is	O
a	O
novel	O
technique	B-T058
that	O
collects	O
a	O
fixed	O
volume	O
of	O
blood	B-T031
by	O
applying	O
an	O
absorbent	O
tip	O
to	O
a	O
blood	B-T031
drop	I-T031
.	O

In	O
the	O
present	O
study	B-T062
we	O
explored	O
the	O
feasibility	O
of	O
HbA1c	B-T103
monitoring	B-T058
with	O
VAMS	B-T058
sampling	I-T058
at	O
home	B-T082
and	O
analysis	B-T062
in	O
the	O
laboratory	B-T092
.	O

Diabetic	B-T038
patients	O
were	O
enrolled	O
in	O
this	O
study	B-T062
during	O
consultation	B-T058
with	O
the	O
endocrinologist	B-T097
.	O

A	O
venous	B-T031
(	O
adults	O
)	O
or	O
capillary	B-T031
(	I-T031
children	I-T031
)	I-T031
sample	I-T031
was	O
taken	O
for	O
immediate	O
HbA1c	B-T103
analysis	B-T062
.	O

DBS	B-T058
(	O
n	O
=	O
1	O
)	O
and	O
dried	B-T058
VAMS	I-T058
(	O
n	O
=	O
2	O
)	O
were	O
collected	O
at	O
home	B-T082
and	O
sent	O
to	O
the	O
laboratory	B-T092
.	O

For	O
25	O
pediatric	O
patients	O
one	O
VAMS	B-T058
was	O
collected	O
during	O
consultation	B-T058
for	O
immediate	O
analysis	B-T062
(	O
without	O
drying	O
)	O
,	O
referred	O
to	O
as	O
"	O
wet	B-T058
VAMS	I-T058
"	O
.	O

HbA1c	B-T103
analyses	B-T062
were	O
performed	O
on	O
a	O
Tosoh	B-T074
HLC	I-T074
-	I-T074
723	I-T074
G8	I-T074
high	I-T074
-	I-T074
performance	I-T074
liquid	I-T074
chromatography	I-T074
(	I-T074
HPLC	I-T074
)	I-T074
analyzer	I-T074
.	O

The	O
median	O
time	O
between	O
sampling	B-T058
at	O
home	B-T082
and	O
analysis	B-T062
was	O
3	O
days	O
.	O

Results	O
of	O
HbA1c	B-T103
in	O
dried	O
VAMS	B-T058
showed	O
a	O
poor	O
agreement	O
with	O
venous	B-T031
/	O
capillary	B-T031
blood	I-T031
collected	O
in	O
hospital	B-T092
(	O
concordance	O
correlation	O
coefficient	O
CCC	O
=	O
0	O
.	O
72	O
)	O
.	O

Similar	O
observations	O
were	O
found	O
with	O
standard	O
DBS	B-T058
.	O

An	O
excellent	O
agreement	O
was	O
obtained	O
between	O
HbA1c	B-T103
results	O
on	O
wet	B-T058
VAMS	I-T058
(	O
CCC	O
=	O
0	O
.	O
996	O
)	O
and	O
standard	O
blood	B-T031
samples	I-T031
.	O

Patients	O
experienced	O
VAMS	B-T058
and	O
DBS	B-T058
as	O
easy	B-T033
and	O
convenient	O
to	O
use	O
.	O

Utilizing	O
equipment	O
standard	O
available	O
in	O
the	O
clinical	O
laboratory	B-T092
,	O
the	O
use	O
of	O
home	B-T082
-	O
sampled	O
dried	B-T058
VAMS	I-T058
and	O
DBS	B-T058
is	O
not	O
a	O
reliable	O
tool	O
for	O
the	O
monitoring	B-T058
of	O
HbA1c	B-T103
.	O

However	O
,	O
perfect	O
agreement	O
between	O
HbA1c	B-T103
measured	O
on	O
wet	B-T058
VAMS	I-T058
and	O
capillary	B-T031
microsamples	I-T031
was	O
obtained	O
.	O

Are	O
Eyes	B-T017
a	O
Mirror	O
of	O
the	O
Soul	O
?	O
What	O
Eye	B-T017
Wrinkles	B-T017
Reveal	O
about	O
a	O
Horse	B-T204
'	I-T204
s	I-T204
Emotional	B-T038
State	I-T038

Finding	O
valid	O
indicators	O
of	O
emotional	B-T038
states	I-T038
is	O
one	O
of	O
the	O
biggest	O
challenges	O
in	O
animal	O
welfare	O
science	O
.	O

Here	O
,	O
we	O
investigated	O
in	O
horses	B-T204
whether	O
variation	O
in	O
the	O
expression	O
of	O
eye	B-T017
wrinkles	B-T017
caused	O
by	O
contraction	B-T038
of	O
the	O
inner	B-T017
eyebrow	I-T017
raiser	O
reflects	B-T038
emotional	B-T033
valence	I-T033
.	O

By	O
confronting	O
horses	B-T204
with	O
positive	B-T033
and	O
negative	B-T033
conditions	O
,	O
we	O
aimed	O
to	O
induce	O
positive	B-T033
and	O
negative	B-T033
emotional	B-T038
states	I-T038
,	O
hypothesising	O
that	O
positive	B-T033
emotions	B-T038
would	O
reduce	O
whereas	O
negative	B-T033
emotions	B-T038
would	O
increase	O
eye	B-T017
wrinkle	B-T017
expression	O
.	O

Sixteen	O
horses	B-T204
were	O
individually	O
exposed	O
in	O
a	O
balanced	O
order	O
to	O
two	O
positive	B-T033
(	O
grooming	O
,	O
food	O
anticipation	O
)	O
and	O
two	O
negative	B-T033
condition	O
s	O
(	O
food	B-T168
competition	O
,	O
waving	O
a	O
plastic	O
bag	O
)	O
.	O

Each	O
condition	O
lasted	O
for	O
60	O
seconds	O
and	O
was	O
preceded	O
by	O
a	O
60	O
second	O
control	O
phase	O
.	O

Throughout	O
both	O
phases	O
,	O
pictures	O
of	O
the	O
eyes	B-T017
were	O
taken	O
,	O
and	O
for	O
each	O
horse	B-T204
four	O
pictures	O
per	O
condition	O
and	O
phase	O
were	O
randomly	O
selected	O
.	O

Pictures	O
were	O
scored	O
in	O
random	O
order	O
and	O
by	O
two	O
experimenters	O
blind	B-T062
to	O
condition	O
and	O
phase	O
for	O
six	O
outcome	O
measures	O
:	O
qualitative	O
impression	O
,	O
eyelid	B-T017
shape	B-T082
,	O
markedness	O
of	O
the	O
wrinkles	B-T017
,	O
presence	B-T033
of	O
eye	B-T017
white	I-T017
,	O
number	O
of	O
wrinkles	B-T017
,	O
and	O
the	O
angle	B-T082
between	O
the	O
line	O
through	O
the	O
eyeball	B-T017
and	O
the	O
highest	O
wrinkle	B-T017
.	O

The	O
angle	B-T082
decreased	O
during	O
grooming	O
and	O
increased	O
during	O
food	B-T168
competition	O
compared	O
to	O
control	O
phase	O
s	O
,	O
whereas	O
the	O
two	O
phases	O
did	O
not	O
differ	O
during	O
food	O
anticipation	O
and	O
the	O
plastic	O
bag	O
condition	O
.	O

No	O
effects	O
on	O
the	O
other	O
outcome	O
measures	O
were	O
detected	B-T033
.	O

Taken	O
together	O
,	O
we	O
have	O
defined	O
a	O
set	O
of	O
measures	O
to	O
assess	O
eye	B-T017
wrinkle	B-T017
expression	O
reliably	O
,	O
of	O
which	O
one	O
measure	O
was	O
affected	O
by	O
the	O
conditions	O
the	O
horses	B-T204
were	O
exposed	O
to	O
.	O

Variation	O
in	O
eye	B-T017
wrinkle	B-T017
expression	O
might	O
provide	B-T168
valuable	O
information	O
on	O
horse	B-T204
welfare	O
but	O
further	O
validation	B-T062
of	O
specific	O
measures	O
across	O
different	O
conditions	O
is	O
needed	O
.	O

Effective	O
mercury	B-T103
(	I-T103
II	I-T103
)	I-T103
bioremoval	O
from	O
aqueous	O
solution	O
,	O
and	O
its	O
electrochemical	O
determination	O

This	O
work	O
proposed	O
mercury	B-T103
elimination	O
using	O
agricultural	O
waste	O
(	O
Allium	B-T204
Cepa	I-T204
L	I-T204
.	O
)	O
.	O

The	O
biomass	O
removed	O
99	O
.	O
4	O
%	O
of	O
mercury	B-T103
,	O
following	O
a	O
pseudo	O
-	O
second	O
order	O
kinetics	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
9999	O
)	O
.	O

The	O
Langmuir	B-T170
model	I-T170
was	O
adequately	O
fitted	O
to	O
the	O
adsorption	O
isotherm	O
,	O
thereby	O
obtaining	O
the	O
maximum	O
mercury	B-T103
adsorption	B-T058
capacity	O
of	O
111	O
.	O
1	O
±	O
0	O
.	O
3	O
mg	O
g	O
(	O
-	O
1	O
)	O
.	O

The	O
biomass	O
showed	O
high	O
density	O
of	O
strong	O
mercury	B-T103
chelating	B-T103
groups	I-T103
,	O
thus	O
making	O
it	O
economically	O
attractive	O
.	O

Also	O
,	O
the	O
implementation	O
of	O
a	O
mercury	B-T103
-	O
selective	B-T058
electrode	I-T058
for	O
continuous	O
determination	B-T058
in	O
real	O
time	O
is	O
proposed	O
;	O
this	O
electrode	O
replaces	O
techniques	O
like	O
atomic	B-T058
absorption	I-T058
spectroscopy	I-T058
,	O
thus	O
it	O
can	O
be	O
applied	O
to	O
real	O
time	O
studies	B-T062
.	O

This	O
work	O
therefore	O
presents	O
a	O
new	O
perspective	O
for	O
removing	O
mercury	B-T103
(	I-T103
II	I-T103
)	I-T103
from	O
contaminated	O
water	O
for	O
environmental	O
remediation	O
.	O

Modeling	B-T062
nurse	O
-	O
patient	O
assignments	O
considering	O
patient	O
acuity	O
and	O
travel	O
distance	O
metrics	O

Balancing	O
workload	O
among	O
nurses	B-T097
on	O
a	O
hospital	B-T092
unit	I-T092
is	O
important	O
for	O
the	O
satisfaction	B-T038
and	O
safety	O
of	O
nurses	B-T097
and	O
patients	O
.	O

To	O
balance	O
nurse	B-T097
workloads	O
,	O
direct	O
patient	B-T058
care	I-T058
activities	I-T058
,	O
indirect	O
patient	B-T058
care	I-T058
activities	I-T058
,	O
and	O
non	O
-	O
patient	O
care	O
activities	O
that	O
occur	O
throughout	O
a	O
shift	O
must	O
be	O
considered	O
.	O

The	O
layout	O
of	O
a	O
hospital	B-T092
unit	I-T092
and	O
the	O
location	B-T082
of	O
a	O
nurse	B-T097
'	I-T097
s	I-T097
assigned	O
patients	O
relative	O
to	O
other	O
resources	O
on	O
the	O
unit	B-T092
are	O
also	O
important	O
factors	O
in	O
achieving	B-T033
workload	O
balance	O
.	O

In	O
most	O
hospitals	B-T092
,	O
a	O
unit	O
charge	O
nurse	B-T097
is	O
responsible	B-T033
for	O
the	O
shift	O
assignment	O
of	O
patients	O
to	O
nurses	B-T097
based	O
on	O
experience	B-T038
and	O
past	B-T038
practices	I-T038
.	O

The	O
nurse	O
-	O
patient	O
assignment	O
process	O
is	O
also	O
often	O
a	O
manual	O
process	O
in	O
which	O
the	O
charge	O
nurse	B-T097
must	O
sort	O
through	O
multiple	O
decision	O
criteria	O
in	O
a	O
limited	O
amount	O
of	O
time	O
.	O

In	O
this	O
paper	O
,	O
a	O
methodology	O
for	O
the	O
construction	O
of	O
balanced	O
nurse	O
-	O
patient	O
workload	O
assignments	O
is	O
proposed	O
.	O

Through	O
the	O
illustration	O
of	O
this	O
methodology	O
new	O
scoring	O
metrics	O
are	O
developed	O
using	O
measures	O
currently	O
available	O
on	O
,	O
or	O
from	O
,	O
the	O
hospital	B-T092
unit	I-T092
.	O

It	O
was	O
demonstrated	O
that	O
the	O
complex	O
scheduling	O
problem	B-T033
can	O
be	O
captured	O
.	O

While	O
the	O
methodology	O
was	O
illustrated	O
for	O
a	O
scheduling	O
problem	B-T033
commonly	O
encountered	O
on	O
a	O
hospital	B-T092
unit	I-T092
,	O
the	O
approach	B-T082
can	O
be	O
adapted	O
to	O
other	O
workforce	O
scheduling	O
problems	B-T033
in	O
which	O
measures	O
of	O
workload	O
are	O
required	O
and	O
composed	O
of	O
elements	O
imposed	O
by	O
the	O
work	B-T082
environment	I-T082
,	O
variability	O
within	O
the	O
required	O
tasks	O
,	O
and	O
a	O
measurable	O
perception	B-T038
of	O
the	O
relative	O
intensity	O
of	O
the	O
work	O
elements	O
.	O

Effect	O
of	O
alpha	B-T103
lipoic	I-T103
acid	I-T103
on	O
in	O
vitro	O
development	B-T038
of	O
bovine	B-T204
secondary	B-T017
preantral	I-T017
follicles	I-T017

The	O
present	O
study	B-T062
aimed	O
to	O
evaluate	B-T058
the	O
in	O
vitro	O
effect	O
of	O
alpha	B-T103
lipoic	I-T103
acid	I-T103
(	O
ALA	B-T103
)	O
addition	O
to	O
the	O
culture	B-T103
medium	I-T103
on	O
the	O
development	B-T038
of	O
the	O
bovine	B-T204
secondary	B-T017
preantral	I-T017
follicles	I-T017
.	O

Bovine	B-T204
secondary	B-T017
preantral	I-T017
follicles	I-T017
were	O
collected	O
and	O
divided	O
into	O
two	O
groups	O
depending	O
on	O
their	O
size	B-T082
(	O
80	O
-	O
100	O
μm	O
and	O
100	O
-	O
110	O
μm	O
)	O
.	O

They	O
were	O
cultured	O
in	O
vitro	O
for	O
15	O
days	O
(	O
D	O
)	O
using	O
different	O
media	B-T103
including	O
at	O
three	O
different	O
doses	O
of	O
ALA	B-T103
.	O

The	O
genes	B-T038
expression	I-T038
levels	O
of	O
follicle	B-T017
-	I-T017
stimulating	I-T017
hormone	I-T017
beta	I-T017
-	I-T017
subunit	I-T017
(	O
FSHR	B-T017
)	O
,	O
insulin	B-T017
-	I-T017
like	I-T017
growth	I-T017
factor	I-T017
(	O
IGF	B-T017
-	I-T017
1	I-T017
)	O
,	O
Activin	B-T017
,	O
luteinizing	B-T017
hormone	I-T017
/	I-T017
choriogonadotropin	I-T017
receptor	I-T017
,	O
bone	B-T017
morphogenetic	I-T017
protein	I-T017
receptor	I-T017
type	I-T017
IA	I-T017
,	O
transforming	B-T017
growth	I-T017
factor	I-T017
beta	I-T017
receptor	I-T017
1	I-T017
,	O
growth	B-T017
differentiation	I-T017
factor	I-T017
9	I-T017
,	O
BCL2	B-T017
-	I-T017
associated	I-T017
X	I-T017
protein	I-T017
(	O
BAX	B-T017
)	O
,	O
and	O
C	B-T017
-	I-T017
Myc	I-T017
were	O
studied	O
using	O
real	B-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
.	O

The	O
protein	B-T038
expression	I-T038
levels	O
of	O
FSHR	B-T103
,	O
IGF	B-T103
-	I-T103
1	I-T103
,	O
and	O
BAX	B-T103
were	O
measured	O
using	O
Western	B-T058
blot	I-T058
analysis	I-T058
.	O

The	O
results	O
of	O
the	O
present	O
work	O
revealed	O
that	O
in	O
vitro	O
addition	O
of	O
ALA	B-T103
-	O
induced	O
significant	O
increase	B-T038
in	I-T038
the	I-T038
growth	I-T038
and	O
development	B-T038
of	O
secondary	B-T017
preantral	I-T017
follicles	I-T017
throughout	O
the	O
culture	B-T058
period	O
as	O
compared	O
to	O
control	O
.	O

The	O
FSHR	B-T017
,	O
IGF	B-T017
-	I-T017
1	I-T017
,	O
luteinizing	B-T017
hormone	I-T017
/	I-T017
choriogonadotropin	I-T017
receptor	I-T017
,	O
bone	B-T017
morphogenetic	I-T017
protein	I-T017
receptor	I-T017
type	I-T017
IA	I-T017
,	O
transforming	B-T017
growth	I-T017
factor	I-T017
beta	I-T017
receptor	I-T017
1	I-T017
,	O
growth	B-T017
differentiation	I-T017
factor	I-T017
9	I-T017
,	O
and	O
Activin	B-T017
A	I-T017
genes	I-T017
were	O
upregulated	B-T038
in	O
ALA	B-T103
-	O
treated	O
follicles	B-T017
as	O
compared	O
to	O
the	O
control	O
.	O

On	O
contrary	O
,	O
preapoptotic	B-T017
genes	I-T017
BAX	B-T017
and	O
C	B-T017
-	I-T017
Myc	I-T017
were	O
downregulated	B-T038
in	O
treated	O
follicles	B-T017
compared	O
to	O
control	O
ones	O
.	O

The	O
protein	B-T033
levels	I-T033
of	O
FSHR	B-T103
and	O
IGF	B-T103
-	I-T103
1	I-T103
were	O
highly	O
expressed	B-T038
in	O
treated	O
follicles	B-T017
compared	O
to	O
control	O
;	O
however	O
,	O
BAX	B-T103
protein	I-T103
was	O
downregulated	B-T038
in	O
the	O
treated	O
follicles	B-T017
groups	O
.	O

The	O
addition	O
of	O
ALA	B-T103
to	O
the	O
culture	B-T103
medium	I-T103
enhances	O
secondary	B-T017
preantral	I-T017
follicles	I-T017
development	B-T038
and	O
growth	B-T038
.	O

How	O
should	O
proxies	O
of	O
cognitive	B-T038
reserve	I-T038
be	O
evaluated	B-T058
in	O
a	O
population	B-T098
of	O
healthy	O
older	B-T098
adults	I-T098
?	O

While	O
some	O
tools	B-T170
have	O
been	O
developed	O
to	O
estimate	O
an	O
individual	B-T098
'	I-T098
s	I-T098
cognitive	B-T038
reserve	I-T038
(	O
CR	B-T038
)	O
,	O
no	O
study	O
has	O
assessed	O
the	O
adequacy	O
of	O
the	O
method	O
used	O
for	O
assessing	O
these	O
CR	B-T038
proxy	O
indicators	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
determine	O
the	O
most	O
appropriate	O
method	O
to	O
estimate	O
CR	B-T038
by	O
comparing	O
two	O
approaches	O
:	O
(	O
1	O
)	O
the	O
common	O
assessment	B-T058
of	O
CR	B-T038
proxies	O
in	O
the	O
literature	B-T170
(	O
e	O
.	O
g	O
.	O

years	O
of	O
education	O
)	O
and	O
(	O
2	O
)	O
the	O
calculation	O
of	O
a	O
comprehensive	O
index	B-T170
based	O
on	O
most	O
significant	O
parameters	B-T033
used	O
in	O
the	O
estimation	B-T038
of	O
CR	B-T038
.	O

Data	O
on	O
CR	B-T038
proxies	O
(	O
i	O
.	O
e	O
.	O

education	O
,	O
occupation	O
,	O
and	O
leisure	O
activities	O
)	O
were	O
obtained	O
in	O
a	O
sample	O
of	O
204	O
older	B-T098
adults	I-T098
.	O

Regression	B-T170
analyses	I-T170
were	O
used	O
to	O
develop	O
the	O
two	O
indices	B-T170
of	O
CR	B-T038
(	O
i	O
.	O
e	O
.	O

ICR	B-T170
-	I-T170
standard	I-T170
and	O
ICR	B-T170
-	I-T170
detailed	I-T170
)	O
and	O
to	O
determine	O
which	O
index	B-T170
best	O
represented	O
the	O
level	O
of	O
one	O
'	O
s	O
CR	B-T038
.	O

The	O
ICR	B-T170
-	I-T170
standard	I-T170
was	O
calculated	O
using	O
a	O
combination	O
of	O
the	O
three	O
most	O
common	O
measures	O
of	O
reserve	B-T038
in	O
the	O
literature	B-T170
:	O
number	O
of	O
schooling	O
years	O
,	O
complexity	O
of	O
the	O
primary	O
occupation	O
,	O
and	O
amount	O
of	O
current	O
participation	O
in	O
stimulating	O
activities	O
.	O

The	O
ICR	B-T170
-	I-T170
detailed	I-T170
was	O
calculated	O
using	O
the	O
most	O
significant	O
parameters	B-T033
(	O
established	O
in	O
initial	O
analyses	B-T062
)	O
of	O
CR	B-T038
:	O
highest	O
level	O
of	O
education	O
combined	O
with	O
the	O
number	O
of	O
training	O
courses	O
,	O
last	O
occupation	O
,	O
and	O
amount	O
of	O
current	O
participation	O
in	O
social	O
and	O
intellectual	O
activities	O
.	O

The	O
comparison	O
of	O
both	O
indices	B-T170
showed	O
that	O
higher	O
levels	O
of	O
ICR	B-T170
-	I-T170
standard	I-T170
and	O
ICR	B-T170
-	I-T170
detailed	I-T170
were	O
associated	O
with	O
a	O
greater	O
minimization	O
of	O
the	O
effects	O
of	O
age	O
on	O
cognition	B-T038
.	O

However	O
,	O
the	O
ICR	B-T170
-	I-T170
detailed	I-T170
was	O
more	O
strongly	O
associated	O
to	O
this	O
minimization	O
than	O
the	O
ICR	B-T170
-	I-T170
standard	I-T170
,	O
suggesting	O
that	O
the	O
ICR	B-T170
-	I-T170
detailed	I-T170
best	O
reflect	O
one	O
'	O
s	O
CR	B-T038
.	O

This	O
study	O
is	O
the	O
first	O
to	O
show	O
that	O
it	O
is	O
of	O
great	O
importance	O
to	O
question	O
methods	O
measuring	O
CR	B-T038
proxies	O
in	O
order	O
to	O
develop	O
a	O
clinical	B-T170
tool	I-T170
allowing	O
a	O
comprehensive	O
and	O
accurate	O
estimation	B-T038
of	O
CR	B-T038
.	O

Discordance	O
in	O
pathology	B-T170
report	I-T170
after	O
central	B-T058
pathology	I-T058
review	I-T058
:	O
Implications	O
for	O
breast	B-T038
cancer	I-T038
adjuvant	B-T058
treatment	I-T058

Pathological	O
predictive	B-T170
factors	I-T170
are	O
the	O
most	O
important	O
markers	B-T201
when	O
selecting	O
early	O
breast	B-T038
cancer	I-T038
adjuvant	B-T058
therapy	I-T058
.	O

In	O
randomized	B-T062
clinical	I-T062
trials	I-T062
the	O
variability	O
in	O
pathology	B-T170
report	I-T170
after	O
central	B-T058
pathology	I-T058
review	I-T058
is	O
noteworthy	O
.	O

We	O
evaluated	O
the	O
discordance	O
rate	O
(	O
DR	O
)	O
and	O
inter	O
-	O
rater	O
agreement	O
between	O
local	B-T082
and	O
central	B-T082
histopathological	B-T170
report	I-T170
and	O
the	O
clinical	O
implication	O
on	O
treatment	O
decision	O
.	O

A	O
retrospective	B-T062
analysis	I-T062
was	O
conducted	O
in	O
a	O
series	O
of	O
consecutive	O
early	O
breast	B-T038
cancer	I-T038
tumors	I-T038
diagnosed	O
by	O
local	B-T097
pathologists	I-T097
and	O
subsequently	O
reviewed	O
at	O
the	O
Pathology	B-T092
Division	I-T092
of	O
European	B-T092
Institute	I-T092
of	I-T092
Oncology	I-T092
.	O

The	O
inter	O
-	O
rater	O
agreement	O
(	O
k	O
)	O
between	O
local	O
and	O
central	B-T091
pathology	I-T091
was	O
calculated	O
for	O
Ki	B-T103
-	I-T103
67	I-T103
,	O
grading	B-T170
,	O
hormone	B-T103
receptors	I-T103
(	O
ER	B-T103
/	O
PgR	B-T103
)	O
and	O
HER2	B-T201
/	I-T201
neu	I-T201
.	O

The	O
Bland	B-T062
-	I-T062
Altman	I-T062
plots	I-T062
were	O
derived	O
to	O
determine	O
discrepancies	O
in	O
Ki	B-T103
-	I-T103
67	I-T103
,	O
ER	B-T103
and	O
PgR	B-T103
.	O

DR	O
was	O
calculated	O
for	O
ER	B-T103
/	O
PgR	B-T103
and	O
HER2	B-T103
.	O

From	O
2007	O
to	O
2013	O
,	O
187	O
pathology	B-T031
specimens	I-T031
from	O
10	O
Cancer	B-T092
Centers	I-T092
were	O
reviewed	O
.	O

Substantial	O
agreement	O
was	O
observed	O
for	O
ER	B-T103
(	O
k0	O
.	O
612	O
;	O
95	O
%	O
CI	O
,	O
0538	O
-	O
0	O
.	O
686	O
)	O
,	O
PgR	B-T103
(	O
k0	O
.	O
659	O
;	O
95	O
%	O
CI	O
,	O
0580	O
-	O
0	O
.	O
737	O
)	O
,	O
Ki	B-T103
-	I-T103
67	I-T103
(	O
k0	O
.	O
609	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
534	O
-	O
0	O
.	O
684	O
)	O
and	O
grading	B-T170
(	O
k0	O
.	O
669	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
569	O
-	O
0	O
.	O
769	O
)	O
.	O

Moderate	O
agreement	O
was	O
found	O
for	O
HER2	B-T103
(	O
k0	O
.	O
546	O
;	O
95	O
%	O
CI	O
,	O
0444	O
-	O
0	O
.	O
649	O
)	O
.	O

DR	O
was	O
9	O
.	O
5	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
31	O
.	O
7	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
HER2	B-T103
and	O
26	O
.	O
2	O
%	O
(	O
negativity	O
to	O
positivity	O
)	O
and	O
12	O
.	O
5	O
%	O
(	O
positivity	O
to	O
negativity	O
)	O
for	O
ER	B-T103
/	O
PgR	B-T103
.	O

According	O
to	O
changes	O
in	O
Her2	B-T103
and	O
ER	B-T103
/	O
PgR	B-T103
status	O
,	O
23	O
(	O
12	O
.	O
2	O
%	O
)	O
and	O
33	O
(	O
17	O
.	O
6	O
%	O
)	O
systemic	O
prescription	B-T058
were	O
respectively	O
modified	O
.	O

In	O
our	O
retrospective	B-T062
analysis	I-T062
,	O
central	B-T058
pathological	I-T058
review	I-T058
has	O
a	O
significant	O
impact	O
in	O
the	O
decision	O
-	O
making	O
process	O
in	O
early	O
breast	B-T038
cancer	I-T038
,	O
as	O
shown	O
in	O
clinical	B-T062
trials	I-T062
.	O

Further	O
studies	O
are	O
warranted	O
to	O
confirm	O
these	O
provocative	O
results	O
.	O

Implementing	O
Non	O
-	O
Invasive	O
Prenatal	B-T058
Diagnosis	I-T058
(	O
NIPD	B-T058
)	O
in	O
a	O
National	B-T092
Health	I-T092
Service	I-T092
Laboratory	I-T092
;	O
From	O
Dominant	O
to	O
Recessive	O
Disorders	B-T038

Our	O
UK	B-T092
National	I-T092
Health	I-T092
Service	I-T092
regional	I-T092
genetics	I-T092
laboratory	I-T092
offers	O
NIPD	B-T058
for	O
autosomal	B-T038
dominant	I-T038
and	O
de	O
novo	O
conditions	O
(	O
achondroplasia	B-T017
,	O
thanataphoric	B-T017
dysplasia	I-T017
,	O
Apert	B-T017
syndrome	I-T017
)	O
,	O
paternal	O
mutation	B-T038
exclusion	O
for	O
cystic	B-T038
fibrosis	I-T038
and	O
a	O
range	O
of	O
bespoke	O
tests	O
.	O

NIPD	B-T058
avoids	O
the	O
risks	B-T033
associated	O
with	O
invasive	B-T058
testing	I-T058
,	O
making	O
prenatal	B-T058
diagnosis	I-T058
more	O
accessible	O
to	O
families	O
at	O
high	O
genetic	O
risk	O
.	O

However	O
,	O
the	O
challenge	O
remains	O
in	O
offering	O
definitive	O
diagnosis	B-T033
for	O
autosomal	B-T038
recessive	I-T038
diseases	I-T038
,	O
which	O
is	O
complicated	O
by	O
the	O
predominance	O
of	O
the	O
maternal	O
mutant	B-T038
allele	B-T017
in	O
the	O
cell	B-T103
-	I-T103
free	I-T103
DNA	I-T103
sample	O
and	O
thus	O
requires	O
a	O
variety	O
of	O
different	O
approaches	B-T082
.	O

Validation	B-T062
and	O
diagnostic	O
implementation	O
for	O
NIPD	B-T058
of	O
congenital	B-T038
adrenal	I-T038
hyperplasia	I-T038
(	O
CAH	B-T038
)	O
is	O
further	O
complicated	O
by	O
presence	B-T033
of	O
a	O
pseudogene	B-T017
that	O
requires	O
a	O
different	O
approach	B-T082
.	O

We	O
have	O
used	O
an	O
assay	B-T058
targeting	O
approximately	O
6700	O
heterozygous	O
SNPs	B-T082
around	O
the	O
CAH	B-T017
gene	I-T017
(	O
CYP21A2	B-T017
)	O
to	O
construct	O
the	O
high	B-T033
-	I-T033
risk	I-T033
parental	O
haplotypes	O
and	O
tested	O
this	O
approach	B-T082
in	O
five	O
cases	O
,	O
showing	O
that	O
inheritance	O
of	O
the	O
parental	O
alleles	B-T017
can	O
be	O
correctly	O
identified	O
using	O
NIPD	B-T058
.	O

We	O
are	O
evaluating	O
various	O
measures	O
of	O
the	O
fetal	B-T017
fraction	O
to	O
help	O
determine	O
inheritance	O
of	O
parental	O
mutations	B-T038
.	O

We	O
are	O
currently	O
exploring	O
the	O
utility	O
of	O
an	O
NIPD	B-T058
multi	B-T058
-	I-T058
disorder	I-T058
panel	I-T058
for	O
autosomal	B-T038
recessive	I-T038
disease	I-T038
,	O
to	O
make	O
testing	O
more	O
widely	O
applicable	O
to	O
families	O
with	O
a	O
variety	O
of	O
serious	O
genetic	B-T038
conditions	I-T038
.	O

Silk	O
fibroin	O
based	O
carrier	B-T103
system	I-T103
for	O
delivery	O
of	O
fibrinogen	B-T103
and	O
thrombin	B-T103
as	O
coagulant	B-T103
supplements	O

The	O
control	O
of	O
bleeding	B-T038
is	O
one	O
of	O
the	O
most	O
important	O
interventions	B-T058
after	O
a	O
traumatic	B-T037
injury	I-T037
.	O

Hemostatic	B-T103
devices	I-T103
delivering	O
blood	B-T038
clotting	I-T038
accelerating	O
agents	B-T103
such	O
as	O
fibrinogen	B-T103
are	O
increasingly	O
used	O
due	O
to	O
their	O
efficacy	O
and	O
their	O
ease	O
of	O
application	B-T058
.	O

In	O
the	O
present	O
study	O
,	O
we	O
describe	O
a	O
method	B-T170
to	O
incorporate	O
the	O
coagulant	B-T103
supplements	O
fibrinogen	B-T103
and	O
thrombin	B-T103
in	O
silk	O
protein	O
sponges	B-T074
by	O
mixing	O
the	O
coagulants	B-T103
with	O
an	O
aqueous	B-T103
silk	B-T103
solution	O
,	O
followed	O
by	O
molding	B-T058
,	O
freeze	B-T058
-	I-T058
drying	I-T058
and	O
water	B-T058
annealing	I-T058
.	O

In	O
this	O
combination	O
system	O
we	O
demonstrate	O
the	O
delivery	O
of	O
fibrinogen	B-T103
while	O
maintaining	O
its	O
hemostatic	B-T038
potential	I-T038
.	O

Concentration	O
ratios	O
of	O
silk	B-T103
to	O
fibrinogen	B-T103
of	O
1	O
.	O
0	O
%	O
/	O
2	O
.	O
8	O
%	O
,	O
2	O
.	O
3	O
%	O
/	O
1	O
.	O
5	O
%	O
and	O
3	O
.	O
0	O
%	O
/	O
0	O
.	O
8	O
%	O
were	O
used	O
.	O

The	O
thrombin	B-T103
-	O
induced	O
fibrin	B-T103
polymeric	B-T103
network	O
filled	O
the	O
space	O
in	O
and	O
next	O
to	O
the	O
silk	B-T103
spongy	B-T082
structure	I-T082
but	O
also	O
remained	O
interconnected	O
to	O
the	O
silk	B-T103
,	O
providing	O
an	O
intact	O
network	O
.	O

The	O
mechanical	O
characterization	O
of	O
the	O
fibrinogen	O
-	O
releasing	O
silk	B-T103
sponges	B-T074
before	O
and	O
after	O
the	O
induction	O
of	O
the	O
fibrinogen	B-T103
polymerization	O
demonstrated	O
that	O
the	O
fibrin	B-T103
network	O
resulted	O
in	O
reduced	O
permanent	O
deformation	O
from	O
21	O
.	O
1	O
%	O
to	O
6	O
.	O
5	O
%	O
,	O
19	O
.	O
6	O
%	O
to	O
5	O
.	O
7	O
%	O
and	O
12	O
.	O
7	O
%	O
to	O
9	O
.	O
4	O
%	O
for	O
the	O
2	O
.	O
8	O
%	O
,	O
1	O
.	O
5	O
%	O
and	O
0	O
.	O
8	O
%	O
fibrinogen	B-T103
-	O
containing	O
silk	B-T103
sponges	B-T074
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
fibrin	B-T103
formation	O
lead	O
to	O
a	O
more	O
linear	B-T082
elastic	O
behavior	O
over	O
longer	O
strain	O
ranges	O
.	O

In	O
combination	O
,	O
the	O
Calcein	B-T103
-	I-T103
AM	I-T103
/	O
PI	B-T103
stainings	B-T103
and	O
MTT	B-T062
assay	I-T062
results	O
indicate	O
uniform	O
cell	B-T038
adhesion	I-T038
on	O
the	O
surface	B-T082
and	O
cytocompatibility	O
of	O
the	O
silk	B-T103
/	O
fibrin	B-T103
sponges	B-T074
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
co	O
-	O
delivery	O
of	O
thrombin	B-T103
with	O
fibrinogen	B-T103
via	O
silk	B-T103
as	O
carrier	B-T103
material	I-T103
is	O
described	O
,	O
offering	O
a	O
more	O
mechanically	O
robust	O
and	O
durable	O
system	O
while	O
preserving	O
hemostatic	B-T038
features	I-T038
of	O
the	O
coagulant	B-T103
substances	I-T103
for	O
the	O
generation	O
of	O
hemostatic	B-T103
devices	I-T103
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Adoptively	O
transferred	O
natural	B-T017
killer	I-T017
cells	I-T017
maintain	O
long	O
-	O
term	O
antitumor	B-T033
activity	I-T033
by	O
epigenetic	B-T038
imprinting	I-T038
and	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
help	O

Natural	B-T017
killer	I-T017
(	I-T017
NK	I-T017
)	I-T017
cell	I-T017
infusions	B-T058
can	O
induce	O
remissions	O
in	O
subsets	O
of	O
patients	O
with	O
different	O
types	O
of	O
cancer	B-T038
.	O

The	O
optimal	O
strategies	O
for	O
NK	B-T017
cell	I-T017
activation	B-T038
prior	O
to	O
infusion	B-T058
are	O
still	O
under	O
debate	O
.	O

There	O
is	O
recent	O
evidence	O
that	O
NK	B-T017
cells	I-T017
can	O
acquire	O
long	O
-	O
term	O
functional	O
competence	O
by	O
preactivation	O
with	O
the	O
cytokines	B-T103
IL	B-T103
-	I-T103
12	I-T103
/	O
15	B-T103
/	O
18	B-T103
.	O

The	O
mechanisms	O
supporting	O
the	O
maintenance	O
of	O
long	O
-	O
term	O
NK	B-T017
cell	I-T017
antitumor	B-T033
activity	I-T033
are	O
incompletely	O
under	O
-	O
stood	O
.	O

Here	O
,	O
we	O
show	O
that	O
NK	B-T017
cells	I-T017
preactivated	O
in	B-T058
vitro	I-T058
with	O
IL	B-T103
-	I-T103
12	I-T103
/	O
15	B-T103
/	O
18	B-T103
,	O
but	O
not	O
with	O
IL	B-T103
-	I-T103
15	I-T103
alone	O
,	O
maintained	O
high	O
antitumor	B-T033
activity	I-T033
even	O
1	O
mo	O
after	O
transfer	O
into	O
lymphopenic	B-T038
RAG	B-T017
-	I-T017
2	I-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
γc	O
(	O
-	O
/	O
-	O
)	O
mice	B-T204
.	O

The	O
NK	B-T017
cell	I-T017
intrinsic	O
ability	O
for	O
IFNγ	B-T103
production	O
coincided	O
with	O
demethylation	O
of	O
the	O
conserved	O
non	B-T103
-	I-T103
coding	I-T103
sequence	I-T103
(	O
CNS	B-T103
)	O
1	O
in	O
the	O
Ifng	B-T017
locus	B-T082
,	O
previously	O
shown	O
to	O
enhance	O
transcription	B-T038
of	O
Ifng	B-T017
.	O

In	O
a	O
xenograft	B-T038
melanoma	I-T038
mouse	I-T038
model	I-T038
,	O
human	B-T204
IL	B-T103
-	I-T103
12	I-T103
/	O
15	B-T103
/	O
18	B-T103
-	O
preactivated	O
NK	B-T017
cells	I-T017
rejected	O
tumors	B-T038
more	O
efficiently	O
.	O

In	O
RAG	B-T017
-	I-T017
2	I-T017
(	I-T017
-	I-T017
/	I-T017
-	I-T017
)	I-T017
γc	O
(	O
-	O
/	O
-	O
)	O
mice	B-T204
,	O
co	O
-	O
transfer	O
of	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cells	I-T017
further	O
improved	O
the	O
long	O
-	O
term	O
competence	O
of	O
NK	B-T017
cells	I-T017
for	O
IFNγ	B-T103
production	O
that	O
was	O
dependent	O
on	O
IL	B-T103
-	I-T103
2	I-T103
.	O

CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
activation	B-T038
during	O
homeostatic	B-T038
proliferation	I-T038
required	O
macrophages	B-T017
and	O
further	O
promoted	O
the	O
long	O
-	O
term	O
NK	B-T017
cell	I-T017
antitumor	B-T033
activity	I-T033
.	O

Thus	O
,	O
NK	B-T017
cells	I-T017
can	O
"	O
remember	O
"	O
a	O
previous	O
exposure	O
to	O
cytokines	B-T103
by	O
epigenetic	B-T038
imprinting	I-T038
resulting	O
in	O
a	O
remarkable	O
stability	O
of	O
the	O
IFNγ	B-T103
-	O
producing	O
phenotype	O
after	O
adoptive	O
transfer	O
.	O

In	O
addition	O
,	O
our	O
results	O
support	O
combination	O
of	O
cytokine	B-T103
-	O
preactivated	O
NK	B-T017
cells	I-T017
with	O
CD4	B-T017
(	I-T017
+	I-T017
)	I-T017
T	I-T017
cell	I-T017
activation	B-T038
upon	O
lymphopenic	B-T038
conditioning	O
to	O
achieve	O
long	O
-	O
term	O
NK	B-T017
cell	I-T017
effector	O
function	O
for	O
cancer	B-T058
immunotherapy	I-T058
.	O

Survey	B-T062
of	O
Neonatal	B-T092
Intensive	I-T092
Care	I-T092
Unit	I-T092
Nurse	B-T097
Attitudes	B-T038
Toward	O
Therapeutic	B-T058
Hypothermia	I-T058
Treatment	I-T058

The	O
traumatic	O
experiences	O
of	O
parent	O
s	O
of	O
babies	O
treated	B-T058
with	I-T058
therapeutic	B-T058
hypothermia	I-T058
(	O
TH	B-T058
)	O
have	O
been	O
described	O
.	O

No	O
research	B-T062
has	O
assessed	O
neonatal	B-T092
intensive	I-T092
care	I-T092
unit	I-T092
(	O
NICU	B-T092
)	O
nurse	B-T097
experience	O
in	O
providing	O
care	O
to	O
hypothermic	B-T033
babies	O
and	O
emotional	O
support	O
to	O
their	O
parents	O
.	O

To	O
assess	O
NICU	B-T092
nurse	B-T097
attitudes	B-T038
to	O
the	O
provision	O
of	O
TH	B-T058
with	O
respect	O
to	O
perceptions	B-T038
about	O
baby	O
pain	B-T033
/	O
sedation	B-T058
,	O
need	O
for	O
nurse	B-T097
and	O
parent	O
education	O
,	O
decision	B-T038
making	I-T038
about	O
initiation	O
of	O
TH	B-T058
,	O
and	O
barriers	O
to	O
best	O
care	O
.	O

A	O
survey	B-T062
was	O
electronically	O
sent	O
to	O
219	O
nurses	B-T097
at	O
2	O
affiliated	O
academic	O
level	O
III	O
NICUs	B-T092
:	O
1	O
rural	O
and	O
1	O
urban	O
location	O
.	O

There	O
were	O
17	O
questions	O
where	O
responses	B-T170
were	O
selected	O
from	O
a	O
preset	O
list	O
and	O
7	O
opportunities	O
for	O
nurses	B-T097
to	O
provide	O
free	O
text	O
responses	B-T170
.	O

The	O
response	B-T170
rate	O
was	O
38	O
%	O
(	O
N	O
=	O
83	O
)	O
.	O

Overwhelming	O
similarities	O
between	O
the	O
urban	B-T092
and	O
rural	B-T092
institutions	I-T092
were	O
found	O
with	O
NICU	B-T092
nurses	B-T097
expressing	O
understanding	O
of	O
the	O
indications	O
for	O
initiating	O
TH	B-T058
,	O
agreement	O
that	O
TH	B-T058
improves	O
long	O
-	O
term	O
outcomes	O
and	O
that	O
the	O
benefits	O
of	O
TH	B-T058
outweigh	O
the	O
risks	O
.	O

Nurses	B-T097
at	O
the	O
urban	B-T092
institution	I-T092
more	O
frequently	O
expressed	O
concerns	O
surrounding	O
inadequate	O
treatment	B-T058
of	O
baby	O
pain	B-T033
/	O
sedation	B-T058
,	O
and	O
nurses	B-T097
at	O
both	O
institutions	O
strongly	O
emphasized	O
the	O
need	O
for	O
more	O
nurse	B-T097
and	O
parent	O
education	O
about	O
TH	B-T058
and	O
improved	O
timeliness	O
of	O
decision	B-T038
making	I-T038
for	O
initiation	O
of	O
TH	B-T058
.	O

NICU	B-T092
nurses	B-T097
specifically	O
want	O
to	O
learn	O
more	O
about	O
outcomes	O
of	O
babies	O
after	O
treatment	B-T058
with	O
TH	B-T058
and	O
feel	O
that	O
parents	O
need	O
more	O
education	O
about	O
TH	B-T058
.	O

Research	B-T062
is	O
urgently	O
needed	O
to	O
better	O
understand	O
the	O
implications	O
of	O
TH	B-T058
treatment	I-T058
for	O
parent	O
-	O
baby	O
bonding	O
.	O

Pharmacological	B-T058
Venous	I-T058
Thromboembolism	I-T058
Prophylaxis	I-T058
in	O
Meningioma	B-T038
Patients	O
:	O
Should	O
It	O
Be	O
Earlier	O
Than	O
Clinical	O
Practice	O
?	O

We	O
read	O
the	O
report	B-T170
by	O
Çeltikçi	O
et	O
al	O
in	O
the	O
Turkish	B-T092
Neurosurgery	I-T092
with	O
great	O
interest	O
.	O

In	O
this	O
single	O
-	O
center	O
retrospective	B-T062
study	I-T062
,	O
they	O
analysed	O
449	O
intracranial	B-T038
meningioma	I-T038
patients	O
underwent	O
open	B-T058
surgery	I-T058
.	O

They	O
stated	O
that	O
venous	B-T038
thromboembolism	I-T038
(	O
VTE	B-T038
)	O
had	O
been	O
seen	O
in	O
21	O
(	O
4	O
.	O
6	O
%	O
)	O
of	O
their	O
patients	O
.	O

This	O
is	O
an	O
important	O
issue	O
because	O
VTE	B-T038
,	O
including	O
deep	B-T038
vein	I-T038
thrombosis	I-T038
(	O
DVT	B-T038
)	O
and	O
pulmonary	B-T038
embolism	I-T038
(	O
PE	B-T038
)	O
,	O
is	O
the	O
most	O
common	O
overall	O
complication	B-T038
in	O
meningioma	B-T058
surgery	I-T058
and	O
is	O
fatal	O
in	O
up	O
to	O
one	O
third	O
of	O
patients	O
(	O
2	O
)	O
.	O

We	O
suppose	O
that	O
prophylaxis	B-T058
of	O
VTE	B-T038
is	O
most	O
effective	O
when	O
mechanical	O
and	O
pharmacological	B-T058
prophylaxis	I-T058
are	O
combined	O
.	O

We	O
consider	O
that	O
there	O
key	O
some	O
practical	O
questions	O
to	O
be	O
answered	O
for	O
a	O
proper	O
clinical	O
extrapolation	O
.	O

BEST	B-T170
:	O
Next	O
-	O
Generation	O
Biomedical	B-T170
Entity	I-T170
Search	I-T170
Tool	I-T170
for	O
Knowledge	B-T170
Discovery	O
from	O
Biomedical	O
Literature	O

As	O
the	O
volume	O
of	O
publications	B-T170
rapidly	O
increases	O
,	O
searching	O
for	O
relevant	O
information	O
from	O
the	O
literature	B-T170
becomes	O
more	O
challenging	B-T033
.	O

To	O
complement	O
standard	O
search	B-T170
engines	I-T170
such	O
as	O
PubMed	B-T170
,	O
it	O
is	O
desirable	O
to	O
have	O
an	O
advanced	B-T170
search	I-T170
tool	I-T170
that	O
directly	O
returns	O
relevant	O
biomedical	O
entities	O
such	O
as	O
targets	B-T074
,	O
drugs	B-T103
,	O
and	O
mutations	B-T038
rather	O
than	O
a	O
long	O
list	O
of	O
articles	O
.	O

Some	O
existing	B-T033
tools	B-T170
submit	O
a	O
query	B-T170
to	O
PubMed	B-T170
and	O
process	O
retrieved	O
abstracts	B-T170
to	O
extract	O
information	O
at	O
query	B-T170
time	O
,	O
resulting	O
in	O
a	O
slow	O
response	O
time	O
and	O
limited	O
coverage	O
of	O
only	O
a	O
fraction	O
of	O
the	O
PubMed	B-T170
corpus	I-T170
.	O

Other	O
tools	B-T170
preprocess	O
the	O
PubMed	B-T170
corpus	I-T170
to	O
speed	O
up	O
the	O
response	O
time	O
;	O
however	O
,	O
they	O
are	O
not	O
constantly	O
updated	O
,	O
and	O
thus	O
produce	O
outdated	B-T170
results	O
.	O

Further	O
,	O
most	O
existing	O
tools	B-T170
cannot	O
process	O
sophisticated	O
queries	B-T170
such	O
as	O
searches	O
for	O
mutations	B-T038
that	O
co	O
-	O
occur	O
with	O
query	B-T170
terms	O
in	O
the	O
literature	B-T170
.	O

To	O
address	O
these	O
problems	B-T033
,	O
we	O
introduce	O
BEST	B-T170
,	O
a	O
biomedical	B-T170
entity	I-T170
search	I-T170
tool	I-T170
.	O

BEST	B-T170
returns	O
,	O
as	O
a	O
result	O
,	O
a	O
list	O
of	O
10	O
different	O
types	O
of	O
biomedical	O
entities	O
including	O
genes	B-T017
,	O
diseases	B-T038
,	O
drugs	B-T103
,	O
targets	B-T074
,	O
transcription	B-T103
factors	I-T103
,	O
miRNAs	B-T103
,	O
and	O
mutations	B-T038
that	O
are	O
relevant	O
to	O
a	O
user	O
'	O
s	O
query	B-T170
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	B-T170
,	O
BEST	B-T170
is	O
the	O
only	O
system	O
that	O
processes	O
free	O
text	B-T170
queries	B-T170
and	O
returns	O
up	B-T033
-	I-T033
to	I-T033
-	I-T033
date	I-T033
results	O
in	O
real	O
time	O
including	O
mutation	B-T038
information	O
in	O
the	O
results	O
.	O

BEST	B-T170
is	O
freely	O
accessible	O
at	O
http	O
:	O
/	O
/	O
best	O
.	O
korea	O
.	O
ac	O
.	O
kr	O
.	O

Alanine	B-T103
to	O
Serine	B-T103
Variant	O
at	O
Position	O
986	O
of	O
Calcium	B-T103
Sensing	I-T103
Receptor	I-T103
and	O
Colorectal	B-T038
Cancer	I-T038
Risk	O

With	O
regard	O
to	O
the	O
effect	O
of	O
calcium	B-T103
against	O
colorectal	B-T038
cancer	I-T038
(	O
CRC	B-T038
)	O
and	O
considering	O
the	O
key	O
role	O
of	O
calcium	B-T103
sensing	I-T103
receptor	I-T103
(	O
CaSR	B-T103
)	O
in	O
calcium	O
homeostasis	O
,	O
this	O
study	O
investigated	O
whether	O
CaSR	B-T017
gene	I-T017
rs1801725	B-T017
or	O
A986S	B-T017
variant	I-T017
was	O
associated	O
with	O
susceptibility	O
to	O
CRC	B-T038
risk	O
.	O

This	O
study	O
was	O
conducted	O
as	O
a	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
and	O
303	O
cases	O
with	O
CRC	B-T038
and	O
354	O
controls	O
were	O
enrolled	O
.	O

All	O
657	O
subjects	O
were	O
genotyped	O
for	O
CaSR	B-T017
gene	I-T017
A986S	B-T017
variant	I-T017
using	O
PCR	B-T062
-	O
RFLP	B-T058
method	I-T058
.	O

No	B-T033
significant	I-T033
difference	O
was	O
observed	O
for	O
the	O
A986S	B-T017
variant	I-T017
of	O
CaSR	B-T017
gene	I-T017
in	O
either	O
genotype	O
or	O
allele	O
frequencies	O
between	O
the	O
cases	O
and	O
the	O
controls	O
and	O
this	O
lack	O
of	O
difference	O
remained	O
non	O
-	O
significant	O
even	O
after	O
adjustment	O
for	O
age	O
,	O
BMI	B-T201
,	O
sex	O
,	O
smoking	B-T201
status	I-T201
,	O
and	O
family	B-T033
history	I-T033
of	O
CRC	B-T038
.	O

No	O
evidence	O
for	O
the	O
effect	O
modification	B-T033
of	O
the	O
association	O
A986S	B-T017
variant	I-T017
and	O
CRC	B-T038
by	O
BMI	B-T201
,	O
sex	O
,	O
or	O
tumor	B-T082
site	I-T082
was	O
also	O
observed	O
.	O

Furthermore	O
,	O
the	O
risk	O
of	O
obesity	B-T038
in	O
relation	O
to	O
the	O
A986S	B-T017
variant	I-T017
in	O
the	O
controls	O
and	O
the	O
cases	O
was	O
separately	O
analyzed	B-T062
and	O
we	O
observed	O
no	O
significant	O
difference	O
between	O
normal	B-T033
weight	I-T033
(	O
BMI	B-T201
<	O
25kg	O
/	O
m	O
(	O
2	O
)	O
)	O
and	O
overweight	B-T033
/	O
obese	B-T038
(	O
BMI	B-T201
≥	O
25kg	O
/	O
m	O
(	O
2	O
)	O
)	O
subjects	O
.	O

Our	O
findings	B-T033
do	O
not	O
support	O
a	O
role	O
for	O
effect	O
of	O
the	O
CaSR	B-T017
gene	I-T017
A986S	B-T017
variant	I-T017
on	O
CRC	B-T038
risk	O
;	O
nevertheless	O
,	O
this	O
finding	B-T033
requires	O
confirmation	B-T033
and	O
the	O
role	O
of	O
the	O
gene	B-T017
variant	I-T017
in	O
carcinogenesis	B-T038
needs	O
to	O
be	O
further	O
investigated	O
.	O

Treatment	B-T058
of	O
erythematotelangiectatic	B-T038
rosacea	I-T038
with	O
the	O
fractionation	B-T058
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
-	O
nm	O
pulsed	B-T074
dye	I-T074
laser	I-T074

Various	O
lasers	O
have	O
been	O
used	O
for	O
the	O
treatment	B-T058
of	O
erythematotelangiectatic	B-T038
rosacea	I-T038
(	O
ETR	B-T038
)	O
that	O
does	O
not	O
respond	O
to	O
systemic	B-T058
or	O
topical	B-T058
therapy	I-T058
.	O

The	O
pulsed	B-T074
dye	I-T074
lasers	I-T074
(	O
PDLs	B-T074
)	O
are	O
an	O
effective	O
option	O
for	O
ETR	B-T038
,	O
and	O
the	O
purpuragenic	B-T038
fluence	O
proved	O
to	O
be	O
superior	O
until	O
now	O
.	O

Given	O
that	O
purpura	B-T038
and	O
subsequent	O
possible	O
postinflammatory	B-T038
hyperpigmentation	I-T038
(	O
PIH	B-T038
)	O
are	O
occasionally	O
unbearable	O
in	O
some	O
patients	O
,	O
and	O
several	O
studies	O
using	O
the	O
low	O
nonpurpuragenic	B-T033
fluence	O
were	O
reported	O
.	O

To	O
deliver	O
the	O
sufficient	O
high	O
fluence	O
of	O
a	O
PDL	B-T074
without	O
generating	O
purpura	B-T038
,	O
we	O
designed	O
the	O
fractionation	B-T058
of	O
high	O
fluence	O
using	O
five	O
passes	O
and	O
longer	O
pulse	O
duration	O
(	O
6	O
milliseconds	O
)	O
of	O
a	O
PDL	B-T074
in	O
succession	O
.	O

A	O
total	O
of	O
eight	O
patients	O
with	O
ETR	B-T038
were	O
enrolled	O
in	O
this	O
study	O
;	O
all	O
patients	O
were	O
treated	O
with	O
PDL	B-T074
10	O
times	O
at	O
2	O
-	O
week	O
intervals	O
.	O

Erythema	B-T038
and	O
telangiectasia	B-T038
scores	O
,	O
as	O
well	O
as	O
improvement	O
,	O
were	O
assessed	O
by	O
two	O
physicians	B-T097
using	O
the	O
digital	B-T170
photographs	I-T170
.	O

Moderate	O
-	O
to	O
-	O
marked	O
improvement	O
was	O
achieved	O
in	O
most	O
of	O
the	O
patients	O
,	O
and	O
erythema	B-T038
and	O
telangiectasia	B-T038
scores	O
were	O
significantly	O
decreased	O
.	O

Purpura	B-T038
and	O
PIH	B-T038
were	O
not	O
reported	O
in	O
all	O
patients	O
.	O

The	O
fractionation	B-T058
of	O
high	O
-	O
fluence	O
,	O
long	O
-	O
pulsed	O
595	O
nm	O
PDL	B-T074
is	O
a	O
very	O
safe	O
and	O
effective	O
treatment	B-T058
for	O
ETR	B-T038
.	O

Propulsion	O
strategy	O
in	O
the	O
gait	B-T033
of	O
primary	B-T092
school	I-T092
children	O
;	O
the	O
effect	O
of	O
age	O
and	O
speed	O

The	O
strategy	O
used	O
to	O
generate	O
power	O
for	O
forward	O
propulsion	B-T038
in	O
walking	O
and	O
running	O
has	O
recently	O
been	O
highlighted	O
as	O
a	O
marker	B-T201
of	O
gait	B-T033
maturation	B-T038
and	O
elastic	O
energy	O
recycling	O
.	O

This	O
study	B-T062
investigated	B-T058
ankle	B-T082
and	O
hip	B-T017
power	O
generation	O
as	O
a	O
propulsion	O
strategy	O
(	O
PS	O
)	O
during	O
the	O
late	O
stance	O
/	O
early	O
swing	O
phases	O
of	O
walking	O
and	O
running	O
in	O
typically	O
developing	O
(	O
TD	O
)	O
children	O
(	O
15	O
:	O
six	O
to	O
nine	O
years	O
;	O
17	O
:	O
nine	O
to	O
13	O
years	O
)	O
using	O
three	B-T082
-	I-T082
dimensional	I-T082
gait	B-T058
analysis	I-T058
.	O

Peak	O
ankle	B-T082
power	O
generation	O
at	O
push	O
-	O
off	O
(	O
peakA2	O
)	O
,	O
peak	O
hip	B-T017
power	O
generation	O
in	O
early	O
swing	O
(	O
peakH3	O
)	O
and	O
propulsion	O
strategy	O
(	O
PS	O
)	O
[	O
peakA2	O
/	O
(	O
peakA2	O
+	O
peakH3	O
)	O
]	O
were	O
calculated	O
to	O
provide	O
the	O
relative	O
contribution	O
of	O
ankle	B-T082
power	O
to	O
total	O
propulsion	B-T038
.	O

Mean	O
PS	O
values	O
decreased	O
as	O
speed	O
increased	O
for	O
comfortable	O
walking	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
fast	O
walking	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
fast	O
running	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
less	O
consistently	O
during	O
jogging	O
(	O
p	O
=	O
0	O
.	O
054	O
)	O
.	O

PS	O
varied	O
with	O
age	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
only	O
during	O
fast	O
walking	O
.	O

At	O
any	O
speed	O
of	O
fast	O
walking	O
,	O
older	O
children	O
generated	O
more	O
peakA2	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
less	O
peakH3	O
(	O
p	O
=	O
0	O
.	O
001	O
)	O
than	O
younger	O
children	O
.	O

While	O
the	O
kinetics	O
of	O
running	O
propulsion	B-T038
appear	O
to	O
be	O
developed	O
by	O
age	O
six	O
years	O
,	O
the	O
skills	O
of	O
fast	O
walking	O
appeared	O
to	O
require	O
additional	O
neuromuscular	O
maturity	O
.	O

These	O
findings	B-T033
support	O
the	O
concept	O
that	O
running	O
is	O
a	O
skill	O
that	O
matures	B-T038
early	O
for	O
TD	O
children	O
.	O

The	O
relationship	O
between	O
anthropometry	B-T062
and	O
body	O
composition	O
from	O
computed	B-T058
tomography	I-T058
:	O
The	O
Mediators	O
of	O
Atherosclerosis	B-T038
in	O
South	B-T098
Asians	I-T098
Living	O
in	O
America	B-T082
Study	O

Few	O
studies	O
examine	O
the	O
relationships	O
between	O
anthropometry	B-T062
and	O
the	O
body	O
composition	O
measures	O
they	O
approximate	O
,	O
or	O
whether	O
they	O
differ	O
by	O
sex	O
,	O
and	O
no	O
studies	O
have	O
examined	O
these	O
relationships	O
in	O
South	B-T098
Asians	I-T098
living	O
in	O
the	O
US	B-T082
.	O

We	O
conducted	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
of	O
871	O
participants	B-T098
in	O
the	O
Mediators	O
of	O
Atherosclerosis	B-T038
in	O
South	B-T098
Asians	I-T098
Living	O
in	O
America	B-T082
(	B-T062
MASALA	I-T062
)	I-T062
Study	I-T062
who	O
had	O
BMI	B-T201
<	O
40	O
kg	O
/	O
m	O
(	O
2	O
)	O
and	O
underwent	O
abdominal	B-T058
CT	I-T058
scans	I-T058
for	O
measurement	O
of	O
visceral	B-T017
and	O
subcutaneous	B-T017
fat	I-T017
.	O

Linear	O
regression	O
was	O
used	O
to	O
model	B-T170
the	O
associations	O
between	O
anthropometric	B-T170
measures	I-T170
and	O
naturally	O
log	O
-	O
transformed	O
body	O
composition	O
measures	O
.	O

All	O
measures	O
of	O
anthropometry	B-T062
,	O
except	O
height	O
,	O
were	O
significantly	O
associated	O
with	O
visceral	B-T017
fat	I-T017
and	O
had	O
a	O
significant	O
non	O
-	O
linear	O
component	O
(	O
p	O
<	O
.	O
05	O
)	O
.	O

The	O
only	O
associations	O
for	O
visceral	B-T017
fat	I-T017
that	O
exhibited	O
significant	O
heterogeneity	O
by	O
sex	O
were	O
waist	B-T201
circumference	I-T201
(	O
%	O
difference	O
in	O
visceral	B-T017
fat	I-T017
slope	O
:	O
women	B-T098
1	O
.	O
92	O
,	O
men	B-T098
2	O
.	O
74	O
,	O
p	O
=	O
.	O
007	O
for	O
interaction	O
)	O
and	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
(	O
women	B-T098
25	O
.	O
9	O
,	O
men	B-T098
717	O
.	O
4	O
,	O
p	O
<	O
.	O
001	O
)	O
.	O

Except	O
for	O
height	O
,	O
all	O
measures	O
of	O
anthropometry	B-T062
were	O
significantly	O
associated	O
with	O
subcutaneous	B-T017
fat	I-T017
,	O
had	O
a	O
significant	O
quadratic	O
component	O
,	O
and	O
significant	O
heterogeneity	O
by	O
sex	O
(	O
weight	O
(	O
kg	O
)	O
:	O
2	O
.	O
74	O
for	O
women	B-T098
,	O
4	O
.	O
08	O
for	O
men	B-T098
;	O
BMI	B-T201
(	O
kg	O
/	O
m	O
(	O
2	O
)	O
)	O
:	O
10	O
.	O
3	O
,	O
14	O
.	O
0	O
;	O
waist	B-T201
circumference	I-T201
(	O
cm	O
)	O
:	O
1	O
.	O
51	O
,	O
3	O
.	O
36	O
;	O
hip	B-T201
circumference	I-T201
(	O
cm	O
)	O
:	O
2	O
.	O
53	O
,	O
4	O
.	O
50	O
)	O
with	O
p	O
<	O
.	O
001	O
for	O
each	O
.	O

In	O
MASALA	O
participants	B-T098
,	O
the	O
relationships	O
of	O
anthropometric	B-T170
measures	I-T170
with	O
visceral	B-T017
and	O
subcutaneous	B-T017
fat	I-T017
appear	O
similar	O
to	O
other	O
race	B-T098
/	O
ethnic	B-T098
groups	I-T098
,	O
but	O
with	O
weaker	O
non	O
-	O
linearity	O
and	O
heterogeneity	O
by	O
sex	O
.	O

Given	O
these	O
results	O
,	O
researchers	B-T097
should	O
consider	O
separate	O
models	O
by	O
sex	O
for	O
US	O
South	B-T098
Asians	I-T098
when	O
approximating	O
subcutaneous	B-T017
fat	I-T017
or	O
when	O
using	O
waist	B-T201
circumference	I-T201
to	O
approximate	O
visceral	B-T017
fat	I-T017
.	O

Active	O
packaging	O
of	O
chicken	B-T168
meats	I-T168
with	O
modified	O
atmosphere	O
including	O
oxygen	B-T103
scavengers	O

The	O
effects	O
of	O
modified	O
atmosphere	O
packaging	O
(	O
MAP	O
-	O
70	O
%	O
CO2	B-T103
/	O
30	O
%	O
N2	B-T103
)	O
and	O
iron	B-T103
-	O
based	O
oxygen	B-T103
scavengers	O
(	O
OS	O
)	O
with	O
various	O
absorption	O
capacities	O
(	O
Ageless	O
(	O
®	O
)	O
ss100	O
,	O
ss300	O
,	O
and	O
ss500	O
)	O
as	O
an	O
active	O
packaging	O
system	O
on	O
microbiological	B-T170
and	O
oxidative	O
changes	O
in	O
chicken	B-T168
thigh	I-T168
meats	I-T168
were	O
evaluated	O
during	O
refrigerated	O
storage	O
(	O
4°C	O
)	O
for	O
19	O
d	O
at	O
3	O
-	O
day	O
intervals	O
.	O

Total	O
aerobic	O
mesophilic	O
bacteria	O
counts	O
exceeded	O
the	O
acceptability	O
limit	O
at	O
d	O
7	O
in	O
the	O
control	O
group	O
without	O
MAP	O
(	O
AIR	O
)	O
,	O
and	O
at	O
d	O
19	O
in	O
MAP	O
and	O
OS	O
containing	O
samples	O
.	O

OS	O
utilization	O
resulted	O
in	O
around	O
1	O
.	O
5	O
and	O
1	O
.	O
0	O
log	O
unit	O
reductions	O
in	O
Pseudomonas	B-T007
spp	I-T007
.	I-T007

counts	O
at	O
d	O
7	O
and	O
d	O
10	O
of	O
storage	O
,	O
respectively	O
,	O
as	O
compared	O
with	O
AIR	O
and	O
MAP	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

MAP	O
and	O
OS	O
groups	O
had	O
fewer	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
coliform	O
counts	O
than	O
did	O
the	O
AIR	O
group	O
,	O
with	O
an	O
approximately	O
1	O
.	O
0	O
log	O
reduction	O
observed	O
at	O
d	O
10	O
.	O

Although	O
in	O
some	O
cases	O
OS	O
utilization	O
resulted	O
in	O
lower	O
TBARS	B-T103
values	O
and	O
carbonyl	O
and	O
sulphydryl	O
contents	O
,	O
particularly	O
during	O
later	O
stages	O
of	O
refrigerated	O
storage	O
as	O
compared	O
to	O
AIR	O
and	O
MAP	O
groups	O
,	O
in	O
general	O
,	O
these	O
effects	O
were	O
not	O
always	O
apparent	O
.	O

The	O
results	O
of	O
this	O
study	O
suggested	O
that	O
MAP	O
suppressed	O
microbiological	O
growth	O
and	O
retarded	O
lipid	B-T038
and	O
protein	B-T038
oxidation	I-T038
in	O
chicken	B-T168
thigh	I-T168
meats	I-T168
,	O
with	O
a	O
9	O
-	O
day	O
shelf	O
-	O
life	O
extention	O
with	O
insignificant	O
effects	O
of	O
OS	O
.	O

Multidrug	O
Resistance	O
of	O
Acinetobacter	B-T007
Baumannii	I-T007
in	O
Ladoke	B-T092
Akintola	I-T092
University	I-T092
Teaching	I-T092
Hospital	I-T092
,	O
Osogbo	B-T082
,	I-T082
Nigeria	I-T082

Acinetobacter	B-T007
baumannii	I-T007
is	O
a	O
ubiquitous	O
pathogen	O
that	O
has	O
emerged	O
as	O
a	O
major	O
cause	O
of	O
healthcare	B-T038
-	I-T038
associated	I-T038
infections	I-T038
at	O
Ladoke	B-T092
Akintola	I-T092
University	I-T092
Teaching	I-T092
Hospital	I-T092
.	O

Isolates	B-T103
were	O
assayed	B-T058
according	O
to	O
standard	B-T170
protocol	I-T170
.	O

The	O
isolates	B-T103
were	O
subjected	O
to	O
molecular	B-T062
techniques	I-T062
to	O
detect	O
blaOXA	B-T017
,	I-T017
blaTEM	I-T017
,	I-T017
blaCTX	I-T017
-	I-T017
M	I-T017
,	I-T017
and	I-T017
blaSHV	I-T017
genes	I-T017
in	O
strains	B-T007
of	O
the	O
A	B-T007
.	I-T007

baumannii	I-T007
isolates	B-T103
.	O

The	O
prevalence	O
of	O
A	B-T007
.	I-T007

baumannii	I-T007
was	O
8	O
.	O
5	O
%	O
and	O
was	O
most	O
prevalent	O
among	O
patients	O
in	O
the	O
age	O
group	O
51	O
-	O
60	O
(	O
36	O
%	O
)	O
;	O
the	O
male	O
patients	O
(	O
63	O
.	O
6	O
%	O
)	O
were	O
more	O
infected	B-T033
than	O
their	O
female	O
counterparts	O
.	O

Patients	O
(	O
72	O
.	O
7	O
%	O
)	O
in	O
the	O
intensive	B-T092
care	I-T092
unit	I-T092
(	O
ICU	B-T092
)	O
were	O
most	O
infected	B-T033
with	O
this	O
organism	O
.	O

The	O
isolates	B-T103
showed	O
100	O
%	O
resistance	O
to	O
both	O
amikacin	B-T103
and	O
ciprofloxacin	B-T103
and	O
90	O
.	O
9	O
%	O
to	O
both	O
ceftriaxone	B-T103
and	O
ceftazidime	B-T103
,	O
while	O
resistance	O
to	O
the	O
other	O
antibiotics	B-T103
used	O
in	O
this	O
study	B-T062
were	O
:	O
piperacillin	B-T103
(	O
81	O
.	O
8	O
%	O
)	O
,	O
imipenem	B-T103
(	O
72	O
.	O
7	O
%	O
)	O
,	O
gentamycin	B-T103
(	O
72	O
.	O
2	O
%	O
)	O
,	O
and	O
meropenem	B-T103
(	O
63	O
.	O
6	O
%	O
)	O
.	O

None	O
of	O
the	O
isolates	B-T103
was	O
,	O
however	O
,	O
resistant	O
to	O
colistin	B-T103
.	O

PCR	B-T062
results	B-T033
showed	O
that	O
blaOXA	B-T017
,	I-T017
blaTEM	I-T017
,	I-T017
and	I-T017
blaCTX	I-T017
-	I-T017
M	I-T017
genes	I-T017
were	O
positive	B-T033
in	O
some	O
isolates	B-T103
,	O
while	O
blaSHV	B-T017
was	O
not	B-T033
detected	I-T033
in	O
any	O
of	O
the	O
isolates	B-T103
.	O

This	O
study	B-T062
has	O
revealed	O
that	O
the	O
strains	B-T007
of	O
A	B-T007
.	I-T007

baumannii	I-T007
isolated	O
are	O
multiple	O
drug	O
resistant	O
.	O

Regular	O
monitoring	B-T058
,	O
judicious	O
prescription	B-T058
,	O
and	O
early	O
detection	B-T058
of	O
resistance	O
to	O
these	O
antibiotics	B-T103
are	O
,	O
therefore	O
,	O
necessary	O
to	O
check	O
further	O
dissemination	O
of	O
the	O
organism	O
.	O

Dataset	B-T170
of	O
the	O
molecular	O
dynamics	O
simulations	O
of	O
bilayers	O
consisting	O
of	O
short	O
amyloidogenic	B-T103
peptide	I-T103
VDSWNVLVAG	B-T082
from	O
Bgl2p	B-T103
-	I-T103
glucantransferase	I-T103
of	O
S	B-T204
.	I-T204
cerevisiae	I-T204
cell	B-T017
wall	I-T017

The	O
amyloidogenic	B-T103
peptide	I-T103
VDSWNVLVAG	B-T082
from	O
Bgl2p	B-T103
-	I-T103
glucantransferase	I-T103
of	O
Saccharomyces	B-T204
cerevisiae	I-T204
cell	B-T017
wall	I-T017
and	O
its	O
modifying	O
analog	B-T103
VESWNVLVAG	B-T082
were	O
taken	O
for	O
the	O
construction	O
of	O
four	O
types	O
of	O
bilayers	O
which	O
differ	O
by	O
orientation	B-T082
of	O
the	O
peptides	B-T103
in	O
the	O
layers	O
and	O
of	O
the	O
layers	O
relative	O
to	O
each	O
other	O
.	O

These	O
bilayers	O
were	O
used	O
as	O
starting	O
models	B-T170
for	O
the	O
molecular	B-T038
dynamics	I-T038
(	O
MD	B-T038
)	O
at	O
three	O
charge	O
states	O
(	O
neutral	O
,	O
pH3	O
,	O
and	O
pH5	O
)	O
.	O

The	O
changes	O
of	O
the	O
fraction	O
of	O
secondary	B-T082
structure	I-T082
during	O
1	O
ns	O
simulations	B-T062
were	O
received	O
for	O
96	O
MD	O
trajectories	O
.	O

The	O
data	O
article	B-T170
contains	O
the	O
necessary	O
information	O
for	O
the	O
construction	O
of	O
models	B-T170
of	O
β	B-T082
-	I-T082
strands	I-T082
organization	O
in	O
the	O
oligomer	O
structure	B-T082
.	O

These	O
results	O
were	O
used	O
in	O
the	O
associated	O
research	B-T170
article	I-T170
"	O
Structural	O
model	O
of	O
amyloid	B-T103
fibrils	I-T103
for	O
amyloidogenic	B-T103
peptide	I-T103
from	O
Bgl2p	B-T103
-	I-T103
glucantransferase	I-T103
of	O
S	B-T204
.	I-T204

cerevisiae	I-T204
cell	B-T017
wall	I-T017
and	O
its	O
modifying	O
analog	B-T103
.	O

New	O
morphology	O
of	O
amyloid	B-T103
fibrils	I-T103
"	O
(	O
Selivanova	O
et	O
al	O
.	O
,	O
2016	O
)	O
[	O
1	O
]	O
.	O

Straight	B-T017
configuration	I-T017
saphenous	I-T017
vein	I-T017
transposition	B-T058
to	O
popliteal	B-T017
artery	I-T017
for	O
vascular	O
access	O

The	O
saphenous	B-T017
vein	I-T017
is	O
commonly	O
used	O
as	O
a	O
vascular	B-T017
graft	I-T017
in	O
peripheral	O
artery	O
surgery	B-T058
but	O
rarely	O
used	O
for	O
vascular	O
access	O
.	O

The	O
literature	B-T170
on	O
straight	B-T017
configuration	I-T017
saphenous	I-T017
vein	I-T017
transposition	B-T058
to	O
the	O
popliteal	B-T017
artery	I-T017
is	O
scarce	O
.	O

Here	O
we	O
present	O
two	O
cases	O
of	O
straight	B-T017
configuration	I-T017
saphenous	I-T017
vein	I-T017
transposition	B-T058
to	O
the	O
popliteal	B-T017
artery	I-T017
for	O
vascular	O
access	O
,	O
the	O
surgical	B-T058
technique	I-T058
and	O
respective	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Two	O
young	O
men	B-T098
,	O
aged	O
29	O
and	O
36	O
years	O
,	O
were	O
chosen	O
for	O
lower	B-T058
-	I-T058
limb	I-T058
vascular	I-T058
access	I-T058
for	O
hemodialysis	B-T058
.	O

The	O
first	O
patient	O
was	O
paraplegic	B-T038
since	O
birth	O
.	O

He	O
used	O
his	O
arms	O
to	O
move	O
so	O
upper	O
extremity	O
vascular	O
access	O
was	O
avoided	O
.	O

The	O
second	O
patient	O
presented	O
with	O
an	O
infected	B-T033
upper	O
extremity	O
arteriovenous	O
graft	O
(	O
AVG	O
)	O
and	O
after	O
multiple	O
closed	O
AVFs	B-T017
he	O
had	O
no	O
more	O
available	O
arm	B-T017
veins	I-T017
.	O

Both	O
patients	O
received	O
autologous	O
lower	O
extremity	O
straight	B-T017
configuration	I-T017
saphenous	I-T017
vein	I-T017
transpositions	B-T058
to	O
the	O
popliteal	B-T017
artery	I-T017
under	O
spinal	B-T058
anesthesia	I-T058
in	O
May	O
and	O
October	O
2012	O
,	O
respectively	O
.	O

Cannulation	B-T058
of	O
the	O
fistula	B-T017
was	O
allowed	O
after	O
one	O
month	O
.	O

There	O
were	O
no	B-T033
early	I-T033
complications	I-T033
.	O

Slight	B-T033
swelling	I-T033
on	O
the	O
leg	B-T017
appeared	O
in	O
one	O
of	O
the	O
patients	O
.	O

Both	O
fistulas	B-T017
were	O
still	O
functional	O
after	O
36	O
and	O
32	O
months	O
,	O
respectively	O
.	O

The	O
straight	B-T017
configuration	I-T017
saphenous	I-T017
vein	I-T017
transposition	B-T058
to	O
popliteal	B-T017
artery	I-T017
is	O
simple	O
to	O
perform	O
,	O
offers	O
a	O
long	B-T082
and	I-T082
straight	I-T082
segment	I-T082
for	O
cannulation	B-T058
and	O
may	O
be	O
a	O
suitable	O
autologous	O
vascular	O
access	O
in	O
selected	O
patients	O
.	O

Inhibited	O
Temperament	B-T038
and	O
Hippocampal	B-T017
Volume	O
in	O
Offspring	O
of	O
Parents	O
with	O
Bipolar	B-T038
Disorder	I-T038

Prior	O
studies	O
have	O
suggested	O
that	O
inhibited	O
temperament	B-T038
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
developing	O
anxiety	B-T038
or	O
mood	B-T038
disorder	I-T038
,	O
including	O
bipolar	B-T038
disorder	I-T038
.	O

However	O
,	O
the	O
neurobiological	O
basis	O
for	O
this	O
increased	O
risk	O
is	O
unknown	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	B-T033
temperament	B-T038
in	O
symptomatic	O
and	O
asymptomatic	B-T033
child	O
offspring	O
of	O
parents	O
with	O
bipolar	B-T038
disorder	I-T038
(	O
OBD	B-T038
)	O
and	O
to	O
investigate	O
whether	O
inhibited	O
temperament	B-T038
is	O
associated	O
with	O
aberrant	O
hippocampal	B-T017
volumes	O
compared	O
with	O
healthy	O
control	O
(	O
HC	O
)	O
youth	O
.	O

The	O
OBD	B-T038
group	O
consisted	O
of	O
45	O
youth	O
,	O
24	O
of	O
whom	O
had	O
current	O
psychiatric	B-T033
symptoms	I-T033
(	B-T038
OBD	I-T038
(	I-T038
+	I-T038
)	I-T038
s	I-T038
)	I-T038
and	O
21	O
without	O
any	O
psychiatric	B-T033
symptoms	I-T033
(	O
OBD	O
(	O
-	O
)	O
s	O
)	O
,	O
and	O
were	O
compared	O
with	O
24	O
HC	O
youth	O
.	O

Temperament	B-T038
characteristics	O
were	O
measured	O
by	O
using	O
the	O
Revised	B-T058
Dimensions	I-T058
of	I-T058
Temperament	I-T058
Survey	I-T058
.	O

Magnetic	B-T058
resonance	I-T058
imaging	I-T058
was	O
used	O
to	O
measure	O
hippocampal	B-T017
volumes	O
.	O

The	O
association	O
between	O
temperament	B-T038
and	O
hippocampal	B-T017
volumes	O
was	O
tested	O
by	O
using	O
multiple	O
regression	O
analysis	O
.	O

Compared	O
with	O
the	O
OBD	O
(	O
-	O
)	O
s	O
group	O
,	O
the	O
OBD	B-T038
(	I-T038
+	I-T038
)	I-T038
s	I-T038
group	O
had	O
significantly	O
more	O
inhibited	O
temperament	B-T038
traits	O
,	O
less	O
flexibility	O
,	O
more	O
negative	B-T033
mood	B-T038
,	O
and	O
less	O
regular	O
rhythm	B-T033
in	O
their	O
daily	O
routines	O
.	O

In	O
contrast	O
,	O
the	O
OBD	O
(	O
-	O
)	O
s	O
group	O
was	O
more	O
likely	O
to	O
approach	O
novel	O
situations	O
compared	O
with	O
OBD	B-T038
(	I-T038
+	I-T038
)	I-T038
s	I-T038
or	O
HC	O
groups	O
.	O

Within	O
the	O
OBD	B-T038
(	I-T038
+	I-T038
)	I-T038
s	I-T038
group	O
,	O
a	O
more	O
inhibited	O
temperament	B-T038
was	O
associated	O
with	O
smaller	O
right	B-T082
hippocampal	B-T017
volumes	O
.	O

In	O
this	O
study	O
,	O
symptomatic	O
OBD	B-T038
were	O
characterized	O
by	O
an	O
inhibited	O
temperament	B-T038
that	O
was	O
inversely	O
correlated	O
with	O
hippocampal	B-T017
volume	O
.	O

Additional	O
longitudinal	B-T062
studies	I-T062
are	O
needed	O
to	O
determine	O
whether	O
inverse	O
correlations	O
between	O
hippocampal	B-T017
volume	O
and	O
inhibited	O
temperament	B-T038
represent	O
early	O
markers	B-T201
of	O
risk	O
for	O
later	O
developing	O
bipolar	B-T038
disorder	I-T038
.	O

Dynamic	O
disorder	O
can	O
explain	O
non	O
-	O
exponential	O
kinetics	O
of	O
fast	O
protein	B-T038
mechanical	I-T038
unfolding	I-T038

Protein	B-T038
unfolding	I-T038
often	O
does	O
not	O
obey	O
a	O
simple	O
two	O
-	O
state	O
behavior	O
.	O

Previous	O
single	B-T058
molecule	I-T058
force	I-T058
spectroscopy	I-T058
studies	B-T058
demonstrated	O
stretched	O
exponential	O
kinetics	O
of	O
protein	B-T038
unfolding	I-T038
under	O
a	O
constant	O
pulling	O
force	O
,	O
the	O
molecular	O
origin	O
of	O
which	O
remains	O
subject	O
to	O
debate	O
.	O

We	O
here	O
set	O
out	O
to	O
extensively	O
sample	O
the	O
mechanical	B-T038
unfolding	I-T038
of	O
ubiquitin	B-T103
and	O
NuG2	B-T103
by	O
Molecular	O
Dynamics	O
(	O
MD	O
)	O
simulations	O
.	O

Both	O
proteins	B-T103
show	O
kinetics	O
best	O
fit	O
by	O
stretched	O
exponentials	O
,	O
with	O
stretching	O
exponents	O
similar	O
to	O
those	O
found	O
in	O
experiments	B-T062
,	O
even	O
though	O
static	O
disorder	O
is	O
absent	O
in	O
our	O
short	O
MD	O
simulations	O
.	O

Instead	O
,	O
we	O
can	O
ascribe	O
non	O
-	O
exponential	O
kinetics	O
to	O
dynamic	O
disorder	O
,	O
due	O
to	O
conformational	B-T082
fluctuations	O
on	O
the	O
nanosecond	O
timescale	O
.	O

Our	O
study	B-T062
highlights	O
the	O
general	O
role	O
of	O
dynamic	O
disorder	O
in	O
protein	O
kinetics	O
on	O
a	O
broad	O
range	O
of	O
time	O
scales	O
even	O
including	O
those	O
probed	O
in	O
MD	O
simulations	O
.	O

Identification	O
and	O
functional	O
analysis	O
of	O
the	O
GTPV	B-T005
bidirectional	O
promoter	B-T103
region	I-T103

The	O
goat	B-T005
pox	I-T005
chick	I-T005
embryo	I-T005
-	I-T005
attenuated	I-T005
virus	I-T005
(	O
GTPV	B-T005
)	O
has	O
been	O
developed	O
as	O
an	O
effective	O
vaccine	B-T103
that	O
can	O
elicit	O
protective	O
immune	B-T038
responses	I-T038
.	O

It	O
possesses	O
a	O
large	O
genome	B-T017
and	O
a	O
robust	O
ability	O
to	O
express	B-T038
exogenous	O
genes	B-T017
.	O

Thus	O
,	O
this	O
virus	B-T005
is	O
an	O
ideal	O
vector	O
for	O
recombinant	B-T103
live	I-T103
vaccines	I-T103
for	O
infectious	B-T038
diseases	I-T038
in	O
ruminant	B-T204
animals	I-T204
.	O

In	O
this	O
study	O
,	O
we	O
identified	O
a	O
novel	O
bidirectional	O
promoter	B-T103
region	I-T103
of	O
GTPV	B-T005
through	O
screening	O
named	O
PbVV	B-T103
(	I-T103
±	I-T103
)	I-T103
.	O

PbVV	B-T103
(	I-T103
±	I-T103
)	I-T103
is	O
located	O
between	O
ETF	B-T103
-	I-T103
l	I-T103
and	O
VITF	B-T103
-	I-T103
3	I-T103
,	O
which	O
are	O
transcribed	B-T038
in	O
opposite	B-T082
directions	B-T082
.	O

A	O
new	O
recombinant	B-T005
goat	I-T005
pox	I-T005
virus	I-T005
(	O
rGTPV	B-T005
)	O
was	O
constructed	O
,	O
in	O
which	O
duplicate	O
PbVV	B-T103
(	I-T103
+	I-T103
)	I-T103
was	O
used	O
as	O
a	O
promoter	B-T103
element	O
to	O
enhance	O
Brucella	B-T103
OMP31	I-T103
expression	B-T038
,	O
and	O
duplicate	O
PbVV	B-T103
(	O
-	O
)	O
was	O
used	O
as	O
a	O
promoter	B-T103
element	I-T103
to	O
regulate	O
enhanced	B-T103
green	I-T103
fluorescent	I-T103
protein	I-T103
(	O
EGFP	B-T103
)	O
at	O
the	O
same	O
time	O
as	O
the	O
selection	O
marker	O
.	O

PbVV	B-T103
(	I-T103
-	I-T103
)	I-T103
promoter	I-T103
activity	O
was	O
compared	O
to	O
that	O
of	O
the	O
P7	B-T103
.	I-T103
5	I-T103
promoter	I-T103
of	O
vaccinia	B-T005
virus	I-T005
,	O
as	O
measured	O
by	O
EGFP	B-T103
expression	B-T038
;	O
the	O
fluorescence	B-T058
intensity	I-T058
of	O
EGFP	B-T103
expressed	B-T038
in	O
cells	B-T017
was	O
confirmed	O
by	O
fluorescence	B-T058
microscopy	I-T058
and	O
flow	B-T058
cytometry	I-T058
.	O

PbVV	B-T103
(	I-T103
+	I-T103
)	I-T103
promoter	I-T103
activity	O
was	O
measured	O
by	O
Brucella	B-T103
OMP31	I-T103
expression	B-T038
.	O

Interaction	O
with	O
the	O
anti	B-T103
-	I-T103
Brucella	I-T103
-	I-T103
OMP31	I-T103
monoclonal	I-T103
antibody	I-T103
was	O
confirmed	O
by	O
western	B-T058
blotting	I-T058
,	O
and	O
OMP31	B-T103
mRNA	B-T038
expression	I-T038
was	O
assessed	O
by	O
qRT	B-T062
-	I-T062
PCR	I-T062
.	O

The	O
results	O
of	O
this	O
study	O
will	O
be	O
useful	O
for	O
the	O
further	O
study	O
of	O
effective	O
multivalent	B-T103
vaccines	I-T103
based	O
on	O
rGTPV	B-T005
.	O

This	O
study	O
also	O
provides	O
a	O
theoretical	O
basis	O
for	O
overcoming	O
the	O
problem	O
of	O
low	O
expression	B-T038
of	O
exogenous	O
genes	B-T017
.	O

Psychometric	B-T058
analysis	I-T058
of	O
the	O
Patient	B-T170
Health	I-T170
Questionnaire	I-T170
in	O
Danish	B-T082
patients	O
with	O
an	O
implantable	B-T074
cardioverter	I-T074
defibrillator	I-T074
(	O
The	O
DEFIB	B-T062
-	I-T062
WOMEN	I-T062
study	I-T062
)	O

To	O
assess	O
the	O
psychometric	B-T058
properties	I-T058
of	O
the	O
Patient	B-T170
Health	I-T170
Questionnaire	I-T170
(	O
PHQ	B-T170
-	I-T170
9	I-T170
)	O
,	O
a	O
measure	O
of	O
depressive	B-T033
symptoms	I-T033
,	O
in	O
a	O
large	O
Danish	B-T082
national	B-T098
cohort	I-T098
of	O
patients	O
with	O
heart	B-T038
disease	I-T038
,	O
implanted	B-T058
with	O
an	O
implantable	B-T074
cardioverter	I-T074
defibrillator	I-T074
(	O
ICD	B-T074
)	O
,	O
using	O
item	O
response	O
theory	O
.	O

A	O
prospective	B-T098
cohort	I-T098
of	O
patients	O
implanted	B-T058
with	O
an	O
ICD	B-T074
(	O
n	O
=	O
1531	O
;	O
80	O
.	O
4	O
%	O
men	B-T098
)	O
completed	O
the	O
PHQ	B-T170
-	I-T170
9	I-T170
at	O
the	O
time	O
of	O
implant	B-T058
.	O

Data	O
were	O
analyzed	B-T062
using	O
two	O
item	O
response	O
theory	O
models	O
,	O
the	O
partial	B-T170
credit	I-T170
model	I-T170
and	O
the	O
generalized	B-T170
partial	I-T170
credit	I-T170
model	I-T170
.	O

The	O
analysis	B-T062
showed	O
disordered	B-T170
response	I-T170
thresholds	O
in	O
eight	O
of	O
nine	O
items	O
for	O
the	O
partial	B-T170
credit	I-T170
model	I-T170
and	O
five	O
of	O
nine	O
items	O
for	O
the	O
generalized	B-T170
partial	I-T170
credit	I-T170
model	I-T170
,	O
indicating	O
that	O
respondents	B-T098
have	O
difficulty	O
discriminating	B-T038
between	O
response	B-T170
options	O
.	O

When	O
collapsing	O
response	B-T170
options	O
2	O
and	O
3	O
,	O
the	O
rescored	O
PHQ	B-T170
-	I-T170
9	I-T170
had	O
a	O
better	O
fit	O
to	O
both	O
models	B-T170
.	O

The	O
unidimensionality	O
and	O
the	O
precision	O
of	O
the	O
rescored	O
PHQ	B-T170
-	I-T170
9	I-T170
were	O
confirmed	O
.	O

Items	O
did	O
not	O
have	O
any	O
differential	O
functioning	O
(	O
DIF	O
)	O
across	O
educational	B-T033
level	I-T033
,	O
age	O
,	O
indication	O
for	O
ICD	B-T074
implantation	B-T058
,	O
and	O
severity	O
of	O
heart	B-T038
failure	I-T038
that	O
influence	O
depression	B-T038
outcomes	O
in	O
patients	O
with	O
an	O
ICD	B-T074
.	O

One	O
item	O
exhibited	O
DIF	O
by	O
gender	O
.	O

Three	O
items	O
did	O
not	O
fit	O
the	O
partial	B-T170
credit	I-T170
model	I-T170
,	O
but	O
the	O
generalized	B-T170
partial	I-T170
credit	I-T170
model	I-T170
could	O
be	O
fitted	O
to	O
the	O
full	O
item	O
set	O
.	O

The	O
unidimensionality	O
and	O
reliability	O
of	O
the	O
Danish	O
version	O
of	O
the	O
PHQ	B-T170
-	I-T170
9	I-T170
were	O
confirmed	B-T033
.	O

However	O
,	O
the	O
associated	O
consequences	O
of	O
the	O
number	O
of	O
response	B-T170
options	O
(	O
3	O
-	O
point	O
versus	O
4	O
-	O
point	O
Likert	B-T170
scale	I-T170
)	O
need	O
to	O
be	O
further	O
examined	B-T033
for	O
the	O
PHQ	B-T170
-	I-T170
9	I-T170
both	O
as	O
a	O
screening	B-T058
tool	B-T170
and	O
outcome	O
measure	O
.	O

Geographical	O
variations	O
in	O
incidence	O
,	O
management	B-T058
and	O
survival	O
of	O
hepatocellular	B-T038
carcinoma	I-T038
in	O
a	O
Western	B-T082
country	I-T082

Information	O
on	O
the	O
incidence	O
,	O
management	B-T058
,	O
and	O
prognosis	B-T058
of	O
hepatocellular	B-T038
carcinoma	I-T038
(	O
HCC	B-T038
)	O
is	O
derived	O
from	O
population	B-T098
samples	I-T098
,	O
regional	B-T082
data	O
,	O
or	O
registries	B-T170
.	O

Comprehensive	O
national	O
evaluations	B-T058
within	O
a	O
given	O
country	B-T082
are	O
lacking	O
.	O

This	O
study	B-T062
aimed	O
to	O
investigate	O
regional	B-T082
variations	O
in	O
HCC	B-T038
care	O
within	O
France	B-T082
.	O

This	O
observational	B-T062
study	I-T062
analysed	O
data	O
from	O
French	B-T098
administrative	B-T170
databases	I-T170
for	O
more	O
than	O
30	O
,	O
000	O
patients	O
with	O
HCC	B-T038
diagnosed	B-T033
between	O
2009	O
and	O
2012	O
,	O
and	O
followed	O
-	O
up	O
until	O
2013	O
.	O

The	O
incidence	O
of	O
HCC	B-T038
,	O
access	B-T082
to	O
surgery	B-T058
,	O
and	O
survival	O
,	O
at	O
both	O
the	O
national	O
level	O
and	O
two	O
geographical	O
levels	O
(	O
the	O
21	O
French	B-T082
regions	I-T082
and	O
95	O
French	B-T098
departments	B-T092
into	O
which	O
France	B-T082
is	O
divided	B-T092
administratively	I-T092
)	O
,	O
were	O
determined	O
.	O

The	O
influence	O
on	O
outcome	O
of	O
the	O
structure	O
of	O
the	O
hospital	B-T092
where	O
HCC	B-T038
was	O
first	O
managed	O
was	O
assessed	O
.	O

At	O
the	O
national	O
level	O
,	O
the	O
median	O
survival	O
was	O
9	O
.	O
4	O
months	O
and	O
only	O
22	O
.	O
8	O
%	O
of	O
patients	O
had	O
curative	B-T033
treatment	I-T033
.	O

There	O
were	O
marked	O
variations	O
between	O
regions	B-T082
and	O
departments	B-T092
in	O
incidence	O
,	O
access	B-T082
to	O
curative	B-T033
treatment	I-T033
(	O
range	O
1	O
.	O
3	O
-	O
28	O
.	O
8	O
%	O
and	O
8	O
.	O
1	O
-	O
32	O
.	O
3	O
%	O
respectively	O
)	O
,	O
and	O
in	O
median	O
survival	O
(	O
range	O
5	O
.	O
7	O
-	O
12	O
.	O
1	O
and	O
4	O
.	O
3	O
-	O
16	O
.	O
5	O
months	O
respectively	O
)	O
.	O

The	O
administrative	O
type	O
and	O
annual	O
HCC	B-T038
-	O
caseload	O
of	O
the	O
hospital	B-T092
where	O
patients	O
were	O
first	O
admitted	B-T058
also	O
had	O
an	O
independent	O
influence	O
on	O
treatment	B-T058
and	O
survival	O
.	O

Despite	O
full	O
insurance	O
coverage	O
for	O
all	O
citizens	B-T098
,	O
national	O
measures	O
to	O
reduce	O
inequities	O
in	O
the	O
management	B-T058
of	O
cancer	O
patients	O
,	O
standardised	O
recommendations	O
for	O
HCC	B-T038
surveillance	B-T058
and	O
management	B-T058
,	O
the	O
percentage	O
of	O
patients	O
undergoing	O
curative	B-T033
treatment	I-T033
and	O
their	O
survival	O
may	O
vary	O
four	O
-	O
fold	O
depending	O
on	O
their	O
postcode	B-T033
.	O

The	O
hospital	B-T092
in	O
which	O
patients	O
are	O
first	O
managed	O
has	O
a	O
clear	O
influence	O
on	O
accessibility	O
to	O
both	O
good	O
care	O
and	O
survival	O
.	O

Population	B-T062
-	I-T062
based	I-T062
studies	I-T062
have	O
highlighted	O
large	O
and	O
sometimes	O
unexpected	O
differences	O
between	O
countries	B-T082
in	O
the	O
survival	O
of	O
patients	O
with	O
malignancy	B-T038
.	O

As	O
these	O
differences	O
are	O
considered	O
to	O
indicate	O
the	O
overall	O
effectiveness	O
of	O
health	O
systems	O
,	O
in	O
addition	O
to	O
the	O
incidence	O
of	O
the	O
cancer	B-T038
or	O
quality	O
of	O
registration	B-T058
,	O
variations	O
within	O
a	O
given	O
country	B-T082
should	O
be	O
minimal	O
.	O

However	O
,	O
similar	O
to	O
between	O
countries	B-T082
differences	O
,	O
this	O
study	B-T062
shows	O
differences	O
within	O
the	O
same	O
country	B-T082
in	O
the	O
incidence	O
,	O
curative	B-T033
treatment	I-T033
rate	O
,	O
and	O
survival	O
of	O
patients	O
with	O
HCC	B-T038
.	O

Evidence	O
that	O
access	O
to	O
care	O
and	O
survival	O
varies	O
within	O
a	O
country	B-T082
can	O
strengthen	O
the	O
impetus	O
for	O
government	B-T092
and	O
clinicians	B-T097
to	O
address	O
these	O
disparities	O
.	O

Identification	O
of	O
potential	O
predictive	O
markers	O
of	O
dexamethasone	B-T103
resistance	B-T038
in	O
childhood	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038

Response	B-T038
to	O
dexamethasone	B-T103
(	O
DEXA	B-T103
)	O
,	O
as	O
a	O
hallmark	B-T103
drug	I-T103
in	O
the	O
treatment	O
of	O
childhood	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
(	O
ALL	B-T038
)	O
,	O
is	O
one	O
of	O
the	O
pivotal	O
prognostic	B-T201
factors	I-T201
in	O
the	O
prediction	B-T058
of	I-T058
outcome	I-T058
in	O
ALL	B-T038
.	O

Identification	O
of	O
predictive	O
markers	O
of	O
chemoresistance	B-T038
is	O
beneficial	O
to	O
selecting	O
of	O
the	O
best	O
therapeutic	B-T058
protocol	I-T058
with	O
the	O
lowest	O
effect	B-T038
adverse	I-T038
.	O

Hence	O
,	O
we	O
aimed	O
to	O
find	O
drug	B-T074
targets	I-T074
using	O
the	O
2DE	B-T058
/	O
MS	B-T058
proteomics	B-T058
study	I-T058
of	O
a	O
DEXA	B-T103
-	O
resistant	B-T017
cell	I-T017
line	I-T017
(	O
REH	B-T017
)	O
as	O
a	O
model	O
for	O
poor	O
DEXA	B-T103
responding	O
patients	O
before	O
and	O
after	O
drug	B-T058
treatment	I-T058
.	O

Using	O
the	O
proteomic	B-T058
methods	I-T058
,	O
three	O
differentially	O
expressed	B-T038
proteins	B-T103
were	O
detected	B-T033
,	O
including	O
voltage	B-T103
dependent	I-T103
anion	I-T103
channel	I-T103
1	I-T103
(	O
VDAC1	B-T103
)	O
,	O
sorting	B-T103
Nexin	I-T103
3	I-T103
(	O
SNX3	B-T103
)	O
,	O
and	O
prefoldin	B-T103
subunit	I-T103
6	I-T103
(	O
PFDN6	B-T103
)	O
.	O

We	O
observed	O
low	O
expression	B-T038
of	O
three	O
proteins	B-T103
after	O
DEXA	B-T103
treatment	O
in	O
REH	B-T017
cells	I-T017
.	O

We	O
subsequently	O
verified	O
low	O
expression	B-T038
of	O
resulted	O
proteins	B-T103
at	O
the	O
mRNA	B-T103
level	O
using	O
the	O
quantitative	B-T058
PCR	I-T058
method	I-T058
.	O

These	O
proteins	B-T103
are	O
promising	O
proteins	B-T103
because	O
of	O
their	O
important	O
roles	O
in	O
drug	B-T038
resistance	I-T038
and	O
regulation	B-T038
of	I-T038
apoptosis	I-T038
(	O
VDAC1	B-T103
)	O
,	O
protein	B-T038
trafficking	I-T038
(	O
SNX3	B-T103
)	O
,	O
and	O
protein	B-T038
folding	I-T038
(	O
PFDN6	B-T103
)	O
.	O

Additionally	O
,	O
mRNA	B-T103
expression	O
level	O
of	O
these	O
proteins	B-T103
was	O
assessed	O
in	O
17	O
bone	B-T031
marrow	I-T031
samples	I-T031
from	O
children	O
with	O
newly	O
diagnosed	O
ALL	B-T038
and	O
7	O
non	O
-	O
cancerous	O
samples	O
as	O
controls	O
.	O

The	O
results	O
indicated	O
that	O
independent	O
of	O
the	O
molecular	B-T170
subtypes	I-T170
of	O
leukemia	B-T038
,	O
mRNA	B-T103
expression	B-T038
of	O
VDAC1	B-T103
,	O
SNX3	B-T103
,	O
and	O
PFDN6	B-T103
decreased	O
in	O
ALL	B-T038
samples	O
compared	O
with	O
non	O
-	O
cancerous	O
samples	O
particularly	O
in	O
VDAC1	B-T103
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Additionally	O
,	O
mRNA	B-T103
expression	B-T038
of	O
three	O
proteins	B-T103
was	O
also	O
declined	O
in	O
high	B-T033
-	I-T033
risk	I-T033
samples	O
compared	O
with	O
standard	O
risk	O
cases	O
.	O

These	O
results	O
demonstrated	O
diagnostic	O
and	O
prognostic	B-T170
value	O
of	O
these	O
proteins	B-T103
in	O
childhood	O
ALL	B-T038
.	O

Furthermore	O
,	O
investigation	B-T058
of	O
protein	B-T038
-	I-T038
protein	I-T038
interaction	I-T038
using	O
STRING	B-T170
database	B-T170
indicated	O
that	O
these	O
proteins	B-T103
involved	O
in	O
the	O
signaling	B-T038
pathway	I-T038
of	O
NR3C1	B-T103
as	O
dexamethasone	B-T103
target	B-T033
.	O

In	O
conclusion	O
,	O
our	O
proteomic	B-T058
study	I-T058
in	O
DEXA	B-T103
resistant	B-T038
leukemic	B-T017
cells	I-T017
revealed	O
VDAC1	B-T103
,	O
SNX3	B-T103
,	O
and	O
PFDN6	B-T103
are	O
promising	O
proteins	B-T103
that	O
might	O
serve	O
as	O
potential	O
biomarkers	B-T201
of	O
prognosis	B-T058
and	O
chemotherapy	B-T058
in	O
childhood	O
ALL	B-T038
.	O

Benthic	B-T170
injury	I-T170
dose	I-T170
-	I-T170
response	I-T170
models	I-T170
for	O
polychlorinated	B-T103
biphenyl	I-T103
-	O
contaminated	O
sediment	O
using	O
equilibrium	B-T170
partitioning	I-T170

The	O
study	B-T062
goal	O
was	O
to	O
develop	O
a	O
sediment	O
polychlorinated	B-T103
biphenyl	I-T103
(	O
PCB	B-T103
)	O
dose	B-T170
-	I-T170
response	I-T170
model	I-T170
based	O
on	O
benthic	O
invertebrate	O
effects	O
to	O
PCBs	B-T103
.	O

The	O
authors	O
used	O
an	O
equilibrium	B-T170
partitioning	I-T170
(	I-T170
EqP	I-T170
)	I-T170
approach	I-T170
to	O
generate	O
predicted	O
PCB	B-T103
sediment	O
effect	O
concentrations	O
(	O
largely	O
Aroclor	B-T103
1254	I-T103
)	O
associated	O
with	O
a	O
gradient	O
of	O
toxic	B-T037
effects	I-T037
in	O
benthic	O
organisms	O
from	O
effects	O
observed	O
in	O
aquatic	O
toxicity	B-T037
studies	B-T062
.	O

The	O
present	O
study	B-T062
differs	O
from	O
all	O
other	O
EqP	B-T170
collective	O
sediment	O
investigations	O
in	O
that	O
the	O
authors	O
examined	O
a	O
common	O
dose	O
-	O
response	O
gradient	O
of	O
effects	O
for	O
PCBs	B-T103
rather	O
than	O
a	O
single	O
,	O
protective	O
value	O
.	O

The	O
authors	O
reviewed	O
the	O
chronic	O
aquatic	O
toxicity	B-T037
literature	B-T170
to	O
identify	O
measured	O
aqueous	O
PCB	B-T103
concentrations	O
and	O
associated	O
benthic	O
invertebrate	O
effects	O
.	O

The	O
authors	O
control	O
-	O
normalized	O
the	O
aquatic	O
toxic	B-T037
effect	I-T037
data	O
and	O
expressed	O
results	O
from	O
various	O
studies	B-T062
as	O
a	O
common	O
metric	O
,	O
percent	O
injury	O
.	O

Then	O
,	O
they	O
calculated	O
organic	B-T103
carbon	I-T103
-	O
normalized	O
sediment	O
PCB	B-T103
concentrations	O
(	O
mg	O
/	O
kg	O
organic	B-T103
carbon	I-T103
)	O
from	O
the	O
aqueous	O
PCB	B-T103
toxicity	B-T037
data	B-T170
set	I-T170
using	O
EqP	B-T170
theory	O
based	O
on	O
the	O
US	B-T092
Environmental	I-T092
Protection	I-T092
Agency	I-T092
'	I-T092
s	I-T092
(	O
EPIWEB	B-T170
4	I-T170
.	I-T170
1	I-T170
)	O
derivation	O
of	O
the	O
water	O
-	O
organic	O
carbon	O
partition	O
coefficient	O
(	O
KOC	O
)	O
.	O

Lastly	O
,	O
the	O
authors	O
constructed	O
a	O
nonlinear	O
dose	B-T170
-	I-T170
response	I-T170
numerical	I-T170
model	I-T170
for	O
these	O
synoptic	O
sediment	O
PCB	B-T103
concentrations	O
and	O
biological	O
effects	O
:	O
Y	O
=	O
100	O
/	O
1	O
+	O
10	O
(	O
(	O
[	O
logEC50	O
-	O
logX	O
]	O
×	O
[	O
Hill	O
slope	O
]	O
)	O
)	O
(	O
EC50	O
=	O
median	O
effective	O
concentration	O
)	O
.	O

These	O
models	B-T170
were	O
used	O
to	O
generate	O
"	O
look	O
-	O
up	O
"	O
tables	B-T170
reporting	O
percent	O
injury	O
in	O
benthic	O
biota	O
for	O
a	O
range	O
of	O
Aroclor	B-T103
-	O
specific	O
sediment	O
concentrations	O
.	O

For	O
example	O
,	O
the	O
model	B-T170
using	O
the	O
EPIWEB	B-T170
KOC	O
estimate	O
predicts	O
mean	O
benthic	O
injury	O
of	O
23	O
.	O
3	O
%	O
,	O
46	O
.	O
0	O
%	O
,	O
70	O
.	O
6	O
%	O
,	O
87	O
.	O
1	O
%	O
,	O
and	O
95	O
%	O
for	O
hypothetical	O
sediment	O
concentrations	O
of	O
1	O
mg	O
/	O
kg	O
,	O
2	O
mg	O
/	O
kg	O
,	O
4	O
mg	O
/	O
kg	O
,	O
8	O
mg	O
/	O
kg	O
,	O
and	O
16	O
mg	O
/	O
kg	O
dry	O
weight	O
of	O
Aroclor	B-T103
1254	I-T103
,	O
respectively	O
(	O
at	O
1	O
%	O
organic	B-T103
carbon	I-T103
)	O
.	O

The	O
authors	O
recommend	O
the	O
model	B-T170
presented	O
for	O
screening	O
but	O
suggest	O
,	O
when	O
possible	O
,	O
determining	O
a	O
site	B-T082
-	I-T082
specific	I-T082
KOC	O
that	O
,	O
along	O
with	O
the	O
tables	B-T170
and	O
equations	O
,	O
allows	O
users	O
to	O
create	O
their	O
own	O
protective	O
dose	O
-	O
response	O
sediment	O
concentration	O
.	O

Environ	O
Toxicol	O
Chem	O
2017	O
;	O
36	O
:	O
1311	O
-	O
1329	O
.	O

©	O
2016	O
SETAC	O
.	O

Extract	B-T103
of	I-T103
Caulis	B-T204
Spatholobi	I-T204
,	O
a	O
novel	O
blocker	B-T103
targeting	O
tumor	B-T038
cell	I-T038
‑	I-T038
induced	I-T038
platelet	I-T038
aggregation	I-T038
,	O
inhibits	O
breast	B-T038
cancer	I-T038
metastasis	B-T038

Metastasis	B-T038
of	O
breast	B-T038
cancer	I-T038
is	O
the	O
vital	O
step	O
for	O
malignant	B-T038
progression	I-T038
.	O

During	O
such	O
a	O
process	O
,	O
hematogenous	B-T038
metastasis	I-T038
is	O
an	O
indispensable	O
approach	O
for	O
the	O
dissemination	O
of	O
cancer	B-T017
cells	I-T017
.	O

A	O
platelet	B-T017
,	O
contributes	O
to	O
hypercoagulable	B-T038
state	I-T038
,	O
and	O
is	O
also	O
identified	O
the	O
crucial	O
factor	O
in	O
the	O
coagulation	B-T038
system	O
for	O
supporting	O
metastasis	B-T038
.	O

Therefore	O
,	O
the	O
relationship	O
of	O
a	O
platelet	B-T017
and	O
a	O
tumor	B-T017
cell	I-T017
plays	O
a	O
critical	O
role	O
in	O
tumor	B-T017
cell	I-T017
metastasis	B-T038
.	O

Consequently	O
,	O
inhibiting	O
tumor	B-T038
cell	I-T038
‑	I-T038
induced	I-T038
platelet	I-T038
aggregation	I-T038
(	O
TCIPA	B-T038
)	O
is	O
recongnized	O
as	O
a	O
crucial	O
target	O
on	O
suppression	B-T038
of	O
tumor	B-T038
metastasis	I-T038
such	O
as	O
aspirin	B-T103
(	O
ASA	B-T103
)	O
.	O

Under	O
such	O
circumstance	O
,	O
here	O
we	O
report	O
that	O
,	O
through	O
dissociating	O
the	O
tumor	B-T017
‑	I-T017
platelet	I-T017
(	I-T017
T	I-T017
‑	I-T017
P	I-T017
)	I-T017
complex	I-T017
,	I-T017
80	O
%	O
ethanol	B-T103
extracts	B-T103
of	I-T103
Caulis	B-T204
Spatholobi	I-T204
(	O
SET	B-T103
)	O
successfully	O
alleviated	O
the	O
hypercoagulation	B-T038
state	I-T038
,	O
thereby	O
reducing	O
tumor	B-T038
metastasis	I-T038
and	O
improving	O
the	O
prospects	O
of	O
survival	O
in	O
breast	B-T017
cancer	B-T017
cell	I-T017
model	O
.	O

Through	O
MTT	B-T058
and	O
anti	B-T058
‑	I-T058
aggregation	I-T058
assay	I-T058
stimulated	I-T058
by	I-T058
ADP	I-T058
,	O
we	O
detected	O
the	O
optimum	O
treatment	O
time	O
and	O
the	O
optimum	O
dose	O
of	O
SET	B-T103
.	O

By	O
using	O
confocal	B-T058
microscopy	I-T058
,	O
we	O
observed	O
that	O
SET	B-T103
can	O
strongly	O
block	O
the	O
formation	O
of	O
T	B-T017
‑	I-T017
P	I-T017
complex	I-T017
i	O
n	O
vitro	O
.	O

The	O
result	O
was	O
further	O
quantified	O
and	O
confirmed	O
by	O
the	O
FACS	B-T058
analysis	I-T058
.	O

The	O
fluorescent	O
value	O
of	O
T	B-T017
‑	I-T017
P	I-T017
complex	I-T017
was	O
obviously	O
decreased	O
in	O
the	O
drug	O
‑	O
treated	O
groups	O
.	O

In	B-T082
vivo	I-T082
,	O
4T1	B-T017
cells	I-T017
were	O
injected	B-T058
through	O
the	O
mouse	B-T204
tail	B-T017
vein	I-T017
for	O
dynamic	B-T058
visualization	I-T058
by	O
small	O
animal	O
imaging	O
system	O
.	O

The	O
metastatic	O
intensity	O
was	O
quantified	O
and	O
the	O
survival	O
curve	O
was	O
analyzed	B-T062
.	O

Additionally	O
,	O
general	O
observation	O
and	O
hematoxylin	B-T058
and	I-T058
eosin	I-T058
(	I-T058
H	I-T058
&	I-T058
E	I-T058
)	I-T058
staining	I-T058
of	O
lung	B-T017
tissue	B-T017
was	O
performed	O
.	O

SET	B-T103
exerted	O
an	O
obvious	O
effect	O
on	O
the	O
inhibition	O
of	O
metastasis	B-T038
and	O
increasing	O
the	O
survival	O
rate	O
of	O
mice	B-T204
.	O

For	O
the	O
molecular	B-T038
mechanism	I-T038
study	B-T062
of	O
anti	B-T058
‑	I-T058
TCIPA	I-T058
,	O
zymography	B-T062
and	O
R	O
T	B-T062
‑	I-T062
PCR	I-T062
assay	I-T062
preliminarily	O
revealed	O
the	O
molecular	B-T038
mechanism	I-T038
of	O
SET	B-T103
in	O
the	O
regulation	O
of	O
P	O
‑	B-T038
T	I-T038
interaction	I-T038
.	O

Collectively	O
,	O
through	O
drug	O
efficacy	O
identification	O
and	O
pharmacological	O
revealing	O
,	O
we	O
have	O
obtained	O
a	O
promising	O
candidate	O
for	O
the	O
interference	O
of	O
breast	B-T017
metastasis	B-T038
by	O
suppressing	O
TCIPA	B-T038
,	O
which	O
will	O
be	O
beneficial	O
for	O
clinical	O
cancer	B-T058
treatment	I-T058
.	O

Generalized	B-T038
Epilepsy	I-T038
and	O
Myoclonic	B-T038
Seizures	I-T038
in	O
22q11	B-T038
.	I-T038
2	I-T038
Deletion	I-T038
Syndrome	I-T038

Prompted	O
by	O
the	O
observations	O
of	O
juvenile	B-T038
myoclonic	I-T038
epilepsy	I-T038
(	O
JME	B-T038
)	O
in	O
22q11	B-T038
.	I-T038
2	I-T038
deletion	I-T038
syndrome	I-T038
(	O
22q11DS	B-T038
)	O
and	O
recurrent	B-T082
copy	I-T082
number	I-T082
variants	I-T082
in	O
genetic	O
generalized	B-T038
epilepsy	I-T038
(	O
GGE	B-T038
)	O
,	O
we	O
searched	O
for	O
further	O
evidence	O
supporting	O
a	O
possible	O
correlation	O
of	O
22q11DS	B-T038
with	O
GGE	B-T038
and	O
with	O
myoclonic	B-T038
seizures	I-T038
.	O

Through	O
routine	B-T058
diagnostics	I-T058
,	O
we	O
identified	O
3	O
novel	O
individuals	B-T098
with	O
the	O
seemingly	O
uncommon	O
combination	O
of	O
22q11DS	B-T038
and	O
JME	B-T038
.	O

We	O
subsequently	O
screened	B-T058
the	O
literature	B-T170
for	O
reports	B-T170
focussing	O
on	O
the	O
epilepsy	O
phenotype	O
in	O
22q11DS	B-T038
.	O

We	O
additionally	O
screened	B-T058
a	O
database	B-T170
of	O
173	O
22q11DS	B-T038
patients	O
and	O
identified	O
a	O
fourth	O
individual	B-T098
with	O
JME	B-T038
as	O
well	O
as	O
2	O
additional	O
cases	O
with	O
GGE	B-T038
.	O

We	O
describe	O
6	O
novel	O
and	O
22	O
published	O
cases	O
with	O
co	B-T033
-	I-T033
occurrence	I-T033
of	O
22q11DS	B-T038
and	O
GGE	B-T038
.	O

In	O
many	O
patients	O
,	O
GGE	B-T038
was	O
associated	O
with	O
myoclonic	B-T038
seizures	I-T038
allowing	O
for	O
a	O
diagnosis	B-T033
of	O
JME	B-T038
in	O
at	O
least	O
6	O
individuals	B-T098
.	O

Seventeen	O
of	O
the	O
173	O
22q11DS	B-T038
cases	O
(	O
10	O
%	O
)	O
had	O
a	O
diagnosis	B-T033
of	O
either	O
focal	B-T038
or	O
generalized	B-T038
epilepsy	I-T038
.	O

In	O
these	O
cases	O
,	O
focal	B-T038
epilepsy	I-T038
could	O
often	O
be	O
attributed	O
to	O
syndrome	B-T038
-	I-T038
associated	I-T038
hypocalcaemia	I-T038
,	O
cerebral	B-T033
bleeds	I-T033
,	O
or	O
structural	B-T033
brain	I-T033
anomalies	I-T033
.	O

However	O
,	O
the	O
cause	O
of	O
GGE	B-T038
remained	O
unclear	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
describe	O
and	O
review	O
28	O
individuals	B-T098
with	O
22q11DS	B-T038
and	O
GGE	B-T038
(	O
especially	O
JME	B-T038
)	O
,	O
showing	O
that	O
both	O
disorders	B-T038
frequently	B-T033
co	I-T033
-	I-T033
occur	I-T033
.	O

Compared	O
to	O
the	O
reported	O
prevalence	O
of	O
15	O
-	O
21	O
%	O
,	O
in	O
our	O
case	B-T062
series	I-T062
only	O
10	O
%	O
of	O
22q11DS	B-T038
individuals	B-T098
were	O
found	O
to	O
have	O
epilepsy	B-T038
,	O
often	O
GGE	B-T038
.	O

Since	O
22q11	B-T017
.	I-T017
2	I-T017
does	O
not	O
contain	O
convincing	O
GGE	B-T038
candidate	B-T017
genes	I-T017
,	O
we	O
discuss	O
the	O
possibility	O
of	O
an	O
aetiological	O
correlation	O
through	O
a	O
possibly	O
disturbed	O
interaction	O
with	O
the	O
GABAB	B-T103
receptor	I-T103
.	O

Normal	O
Levels	O
of	O
Urinary	B-T031
CC16	B-T103
Protein	I-T103
.	O
Comments	B-T170
on	I-T170
Beamer	I-T170
et	I-T170
al	I-T170
.	I-T170
Association	I-T170
of	O
Children	O
'	O
s	O
Urinary	B-T031
CC16	B-T103
Levels	B-T058
with	O
Arsenic	B-T058
Concentrations	I-T058
in	O
Multiple	O
Environmental	O
Media	O
.	O
Int	O
.	O
J	O
.	O
Environ	O
.	O
Res	O
.	O
Public	O
Health	O
2016	O
,	O
13	O
,	O
521	O

In	O
1937	O
,	O
Max	B-T204
Clara	I-T204
described	O
a	O
new	O
type	O
of	O
cell	B-T017
in	O
the	O
human	B-T204
lung	B-T017
,	O
which	O
was	O
later	O
determined	O
to	O
be	O
an	O
exocrine	B-T017
secretory	I-T017
cell	I-T017
type	I-T017
containing	I-T017
granules	I-T017
composed	O
of	O
proteins	B-T103
[	O
1	O
]	O
.	O
[	O
.	O
.	O
.	O
]	O
.	O

Diverse	O
Colletotrichum	B-T204
species	I-T204
cause	O
anthracnose	B-T038
of	O
tea	B-T204
plants	I-T204
(	O
Camellia	B-T204
sinensis	I-T204
(	I-T204
L	I-T204
.	I-T204
)	I-T204
O	I-T204
.	I-T204
Kuntze	I-T204
)	O
in	O
China	B-T082

Anthracnose	B-T038
caused	O
by	O
Colletotrichum	B-T204
is	O
one	O
of	O
the	O
most	O
severe	O
diseases	B-T038
that	O
can	O
afflict	O
Camellia	B-T204
sinensis	I-T204
.	O

However	O
,	O
research	B-T062
on	O
the	O
diversity	O
and	O
geographical	O
distribution	O
of	O
Colletotrichum	B-T204
in	O
China	B-T082
remain	O
limited	O
.	O

In	O
this	O
study	B-T062
,	O
106	O
Colletotrichum	B-T204
isolates	B-T103
were	O
collected	O
from	O
diseased	B-T038
leaves	B-T204
of	O
Ca	B-T204
.	I-T204

sinensis	I-T204
cultivated	O
in	O
the	O
15	O
main	O
tea	O
production	O
provinces	B-T082
in	O
China	B-T082
.	O

Multi	B-T062
-	I-T062
locus	I-T062
phylogenetic	I-T062
analysis	I-T062
coupled	O
with	O
morphological	B-T058
identification	I-T058
showed	O
that	O
the	O
collected	O
isolates	B-T103
belonged	O
to	O
11	O
species	B-T170
,	O
including	O
6	O
known	O
species	B-T170
(	O
C	B-T204
.	I-T204

camelliae	I-T204
,	O
C	B-T204
.	I-T204

cliviae	I-T204
,	O
C	B-T204
.	I-T204

fioriniae	I-T204
,	O
C	B-T204
.	I-T204

fructicola	I-T204
,	O
C	B-T204
.	I-T204

karstii	I-T204
,	O
and	O
C	B-T204
.	I-T204

siamense	I-T204
)	O
,	O
3	O
new	O
record	B-T170
species	I-T170
(	O
C	B-T204
.	I-T204

aenigma	I-T204
,	O
C	B-T204
.	I-T204

endophytica	I-T204
,	O
and	O
C	B-T204
.	I-T204

truncatum	I-T204
)	O
,	O
1	O
novel	O
species	B-T170
(	O
C	B-T204
.	I-T204

wuxiense	I-T204
)	O
,	O
and	O
1	O
indistinguishable	O
strain	O
,	O
herein	O
described	O
as	O
Colletotrichum	B-T204
sp	I-T204
.	I-T204

Of	O
these	O
species	B-T170
,	O
C	B-T204
.	I-T204

camelliae	I-T204
and	O
C	B-T204
.	I-T204

fructicola	I-T204
were	O
the	O
dominant	O
species	B-T170
causing	O
anthracnose	B-T038
in	O
Ca	B-T204
.	I-T204

sinensis	I-T204
.	O

In	O
addition	O
,	O
our	O
study	B-T062
provided	O
further	O
evidence	O
that	O
phylogenetic	B-T062
analysis	I-T062
using	O
a	O
combination	O
of	O
ApMat	B-T082
and	I-T082
GS	I-T082
sequences	I-T082
can	O
be	O
used	O
to	O
effectively	O
resolve	O
the	O
taxonomic	O
relationships	O
within	O
the	O
C	B-T204
.	I-T204

gloeosporioides	I-T204
species	B-T170
complex	I-T170
.	O

Finally	O
,	O
pathogenicity	O
tests	B-T058
suggested	O
that	O
C	B-T204
.	I-T204

camelliae	I-T204
,	O
C	B-T204
.	I-T204

aenigma	I-T204
,	O
and	O
C	B-T204
.	I-T204

endophytica	I-T204
are	O
more	O
invasive	O
than	O
other	O
species	B-T170
after	O
the	O
inoculation	B-T058
of	O
the	O
leaves	B-T204
of	O
Ca	B-T204
.	I-T204

sinensis	I-T204
.	O

ATP	B-T103
release	O
from	O
bladder	B-T017
urothelium	I-T017
and	O
serosa	B-T017
in	O
a	O
rat	O
model	B-T038
of	O
partial	B-T038
bladder	I-T038
outlet	I-T038
obstruction	I-T038

Overactive	B-T038
bladder	I-T038
is	O
one	O
of	O
the	O
major	O
health	B-T033
problem	I-T033
especially	O
in	O
elderly	B-T098
people	I-T098
.	O

Adenosine	B-T103
triphosphate	I-T103
(	O
ATP	B-T103
)	O
is	O
released	O
from	O
urinary	B-T017
bladder	I-T017
cells	I-T017
and	O
acts	O
as	O
a	O
smooth	B-T038
muscle	I-T038
contraction	I-T038
and	O
sensory	O
signal	O
in	O
micturition	B-T038
but	O
little	O
is	O
known	O
about	O
the	O
role	O
of	O
ATP	B-T103
release	O
in	O
the	O
pathophysiology	B-T038
of	O
overactive	B-T038
bladder	I-T038
.	O

To	O
assess	O
the	O
relationship	O
between	O
ATP	B-T103
and	O
overactive	B-T038
bladder	I-T038
,	O
we	O
used	O
a	O
partial	B-T038
bladder	I-T038
outlet	I-T038
obstruction	I-T038
(	O
pBOO	B-T038
)	O
model	B-T038
in	O
rats	B-T204
.	O

The	O
bladder	B-T017
caused	O
several	O
changes	O
by	O
pBOO	B-T038
:	O
An	O
increase	O
in	O
bladder	B-T017
weight	O
,	O
hypertrophy	B-T038
of	O
sub	B-T017
-	I-T017
urothelium	I-T017
and	O
sub	B-T017
-	I-T017
serosal	I-T017
area	I-T017
,	O
and	O
frequent	O
non	O
-	O
voiding	B-T038
bladder	I-T038
contraction	I-T038
during	O
urine	B-T031
storage	O
.	O

Basal	B-T082
ATP	B-T103
release	O
from	O
urothelium	B-T017
and	O
serosa	B-T017
of	O
pBOO	B-T038
rats	B-T204
was	O
significantly	O
higher	O
than	O
that	O
of	O
normal	O
rats	B-T204
.	O

Distention	B-T033
induced	O
ATP	B-T103
release	O
from	O
urothelium	B-T017
of	O
normal	O
and	O
pBOO	B-T038
rats	B-T204
had	O
no	O
significant	O
change	O
.	O

However	O
,	O
distention	B-T033
-	O
induced	O
ATP	B-T103
release	O
from	O
serosa	B-T017
of	O
pBOO	B-T038
rats	B-T204
was	O
higher	O
than	O
that	O
of	O
normal	O
.	O

These	O
findings	O
may	O
identify	O
ATP	B-T103
especially	O
released	O
from	O
serosa	B-T017
as	O
one	O
of	O
causes	O
of	O
non	O
-	O
voiding	B-T038
contractions	I-T038
and	O
overactive	B-T038
bladder	I-T038
symptoms	B-T033
.	O

Determining	O
putative	B-T204
vectors	I-T204
of	O
the	O
Bogia	B-T038
Coconut	I-T038
Syndrome	I-T038
phytoplasma	B-T007
using	O
loop	B-T058
-	I-T058
mediated	I-T058
isothermal	I-T058
amplification	I-T058
of	O
single	B-T168
-	I-T168
insect	I-T168
feeding	I-T168
media	I-T168

Phytoplasmas	B-T007
are	O
insect	B-T007
vectored	I-T007
mollicutes	I-T007
responsible	O
for	O
disease	B-T038
in	O
many	O
economically	O
important	O
crops	B-T204
.	O

Determining	O
which	O
insect	B-T204
species	I-T204
are	O
vectors	B-T204
of	O
a	O
given	O
phytoplasma	B-T007
is	O
important	O
for	O
managing	O
disease	B-T038
but	O
is	O
methodologically	O
challenging	O
because	O
disease	B-T204
-	I-T204
free	I-T204
plants	I-T204
need	O
to	O
be	O
exposed	O
to	O
large	O
numbers	O
of	O
insects	B-T204
,	O
often	O
over	O
many	O
months	O
.	O

A	O
relatively	O
new	O
method	O
to	O
detect	O
likely	O
transmission	O
involves	O
molecular	B-T058
testing	I-T058
for	O
phytoplasma	B-T007
DNA	B-T103
in	O
sucrose	B-T103
solution	O
that	O
insects	B-T204
have	O
fed	O
upon	O
.	O

In	O
this	O
study	B-T062
we	O
combined	O
this	O
feeding	B-T058
medium	I-T058
method	I-T058
with	O
a	O
loop	B-T058
-	I-T058
mediated	I-T058
isothermal	I-T058
amplification	I-T058
(	I-T058
LAMP	I-T058
)	I-T058
assay	I-T058
to	O
study	O
627	O
insect	B-T204
specimens	O
of	O
11	O
Hemiptera	B-T204
taxa	I-T204
sampled	O
from	O
sites	O
in	O
Papua	B-T082
New	I-T082
Guinea	I-T082
affected	O
by	O
Bogia	B-T038
coconut	I-T038
syndrome	I-T038
(	O
BCS	B-T038
)	O
.	O

The	O
LAMP	B-T058
assay	I-T058
detected	O
phytoplasma	B-T007
DNA	B-T103
from	O
the	O
feeding	B-T168
solution	I-T168
and	O
head	B-T082
tissue	B-T017
of	O
insects	B-T204
from	O
six	O
taxa	O
belonging	O
to	O
four	O
families	O
:	O
Derbidae	B-T204
,	O
Lophopidae	B-T204
,	O
Flatidae	B-T204
and	O
Ricaniidae	B-T204
.	O

Two	O
other	O
taxa	O
yielded	O
positives	O
only	O
from	O
the	O
heads	B-T082
and	O
the	O
remainder	O
tested	O
negative	O
.	O

These	O
results	O
demonstrate	O
the	O
utility	O
of	O
combining	O
single	B-T058
-	I-T058
insect	I-T058
feeding	I-T058
medium	I-T058
tests	I-T058
with	O
LAMP	B-T058
assays	I-T058
to	O
identify	O
putative	B-T204
vectors	I-T204
that	O
can	O
be	O
the	O
subject	O
of	O
transmission	O
tests	O
and	O
to	O
better	O
understand	O
phytoplasma	B-T007
pathosystems	B-T091
.	O

Non	O
-	O
toxigenic	O
environmental	B-T082
Vibrio	B-T007
cholerae	I-T007
O1	I-T007
strain	O
from	O
Haiti	B-T082
provides	O
evidence	O
of	O
pre	O
-	O
pandemic	O
cholera	B-T038
in	O
Hispaniola	B-T082

Vibrio	B-T007
cholerae	I-T007
is	O
ubiquitous	O
in	O
aquatic	O
environments	O
,	O
with	O
environmental	B-T082
toxigenic	B-T170
V	B-T007
.	I-T007

cholerae	I-T007
O1	I-T007
strains	O
serving	O
as	O
a	O
source	B-T033
for	O
recurrent	O
cholera	B-T038
epidemics	I-T038
and	O
pandemic	O
disease	B-T038
.	O

However	O
,	O
a	O
number	O
of	O
questions	O
remain	O
about	O
long	O
-	O
term	O
survival	O
and	O
evolution	O
of	O
V	B-T007
.	I-T007

cholerae	I-T007
strains	O
within	O
these	O
aquatic	O
environmental	O
reservoirs	B-T082
.	O

Through	O
monitoring	O
of	O
the	O
Haitian	B-T082
aquatic	O
environment	O
following	O
the	O
2010	O
cholera	B-T038
epidemic	I-T038
,	O
we	O
isolated	O
two	O
novel	O
non	O
-	O
toxigenic	O
(	O
ctxA	B-T017
/	I-T017
B	I-T017
-	O
negative	B-T033
)	O
Vibrio	B-T007
cholerae	I-T007
O1	I-T007
.	O

These	O
two	O
isolates	B-T103
underwent	O
whole	B-T062
-	I-T062
genome	I-T062
sequencing	I-T062
and	O
were	O
investigated	O
through	O
comparative	O
genomics	B-T091
and	O
Bayesian	O
coalescent	O
analysis	O
.	O

These	O
isolates	B-T103
cluster	O
in	O
the	O
evolutionary	O
tree	B-T204
with	O
strains	O
responsible	O
for	O
clinical	O
cholera	B-T038
,	O
possessing	O
genomic	B-T017
components	I-T017
of	O
6	O
(	O
th	O
)	O
and	O
7	O
(	O
th	O
)	O
pandemic	O
lineages	O
,	O
and	O
diverge	O
from	O
"	O
modern	O
"	O
cholera	B-T038
strains	O
around	O
1548	O
C	O
.	O
E	O
.	O

[	O
95	O
%	O
HPD	O
:	O
1532	O
-	O
1555	O
]	O
.	O

Vibrio	B-T017
Pathogenicity	I-T017
Island	I-T017
(	B-T017
VPI	I-T017
)	I-T017
-	I-T017
1	I-T017
was	O
present	B-T033
;	O
however	O
,	O
SXT	B-T017
/	I-T017
R391	I-T017
-	I-T017
family	I-T017
ICE	I-T017
and	O
VPI	B-T017
-	I-T017
2	I-T017
were	O
absent	O
.	O

Rugose	O
phenotype	O
conversion	O
and	O
vibriophage	B-T005
resistance	O
evidenced	O
adaption	O
for	O
persistence	B-T038
in	O
aquatic	O
environments	O
.	O

The	O
identification	O
of	O
V	B-T007
.	I-T007

cholerae	I-T007
O1	I-T007
strains	O
in	O
the	O
Haitian	B-T082
environment	O
,	O
which	O
predate	O
the	O
first	O
reported	B-T062
cholera	B-T038
pandemic	O
in	O
1817	O
,	O
broadens	O
our	O
understanding	B-T038
of	O
the	O
history	O
of	O
pandemics	O
.	O

It	O
also	O
raises	O
the	O
possibility	O
that	O
these	O
and	O
similar	O
environmental	O
strains	O
could	O
acquire	O
virulence	O
genes	B-T017
from	O
the	O
2010	O
Haitian	B-T082
epidemic	O
clone	B-T017
,	O
including	O
the	O
cholera	B-T103
toxin	I-T103
producing	O
CTXϕ	B-T103
.	O

The	O
Pre	B-T038
-	I-T038
Eclampsia	I-T038
Ontology	O
:	O
A	O
Disease	O
Ontology	O
Representing	O
the	O
Domain	O
Knowledge	O
Specific	O
to	O
Pre	B-T038
-	I-T038
Eclampsia	I-T038

Pre	B-T038
-	I-T038
eclampsia	I-T038
(	O
PE	B-T038
)	O
is	O
a	O
clinical	O
syndrome	O
characterized	O
by	O
new	O
-	O
onset	O
hypertension	O
and	O
proteinuria	B-T033
at	O
≥20	B-T033
weeks	I-T033
of	I-T033
gestation	I-T033
,	O
and	O
is	O
a	O
leading	O
cause	O
of	O
maternal	O
and	O
perinatal	O
morbidity	O
and	O
mortality	O
.	O

Previous	O
studies	O
have	O
gathered	O
abundant	O
data	O
about	O
PE	B-T038
such	O
as	O
risk	B-T033
factors	I-T033
and	O
pathological	O
findings	O
.	O

However	O
,	O
most	O
of	O
these	O
data	O
are	O
not	O
semantically	O
structured	O
.	O

Clinical	B-T170
data	I-T170
on	O
PE	B-T038
patients	O
are	O
often	O
generated	O
with	O
semantic	O
heterogeneity	O
such	O
as	O
using	O
disparate	B-T170
terminology	I-T170
to	O
describe	O
the	O
same	O
phenomena	O
.	O

In	O
clinical	B-T062
studies	I-T062
,	O
interoperability	O
of	O
heterogenic	O
clinical	B-T170
data	I-T170
is	O
required	O
in	O
various	O
situations	O
.	O

In	O
such	O
a	O
situation	O
,	O
it	O
is	O
necessary	O
to	O
develop	O
an	O
interoperable	O
and	O
standardized	O
semantic	O
framework	O
to	O
research	B-T062
the	O
pathology	O
of	O
PE	B-T038
more	O
comprehensively	O
and	O
to	O
achieve	O
interoperability	O
of	O
heterogenic	O
clinical	B-T170
data	I-T170
of	O
PE	B-T038
patients	O
.	O

In	O
this	O
study	O
,	O
we	O
developed	O
an	O
ontology	O
representing	O
clinical	O
features	O
,	O
treatments	B-T058
,	O
genetic	O
factors	O
,	O
environmental	O
factors	O
,	O
and	O
other	O
aspects	O
of	O
the	O
current	O
knowledge	O
in	O
the	O
domain	O
of	O
PE	B-T038
.	O

We	O
call	O
this	O
pre	B-T038
-	I-T038
eclampsia	I-T038
ontology	O
"	O
PEO	O
"	O
.	O

To	O
achieve	O
interoperability	O
with	O
other	O
ontologies	O
,	O
the	O
core	O
structure	O
of	O
PEO	O
was	O
compliant	O
with	O
the	O
hierarchy	O
of	O
the	O
Basic	O
Formal	O
Ontology	O
(	O
BFO	O
)	O
.	O

The	O
PEO	O
incorporates	O
a	O
wide	O
range	O
of	O
key	O
concepts	O
and	O
terms	O
of	O
PE	B-T038
from	O
clinical	B-T062
and	O
biomedical	B-T062
research	I-T062
in	O
structuring	O
the	O
knowledge	O
base	O
that	O
is	O
specific	O
to	O
PE	B-T038
;	O
therefore	O
,	O
PEO	O
is	O
expected	O
to	O
enhance	O
PE	B-T038
-	O
specific	O
information	O
retrieval	O
and	O
knowledge	O
discovery	O
in	O
both	O
clinical	B-T062
and	O
biomedical	B-T062
research	I-T062
fields	O
.	O

Predictors	O
and	O
Moderators	O
of	O
Spontaneous	O
Pretend	O
Play	O
in	O
Children	O
with	O
and	O
without	O
Autism	B-T038
Spectrum	I-T038
Disorder	I-T038

Although	O
pretend	O
play	O
has	O
long	O
been	O
linked	O
to	O
children	O
'	O
s	O
normative	O
cognitive	B-T038
development	I-T038
,	O
inconsistent	O
findings	B-T033
call	O
for	O
greater	O
rigor	O
in	O
examining	O
this	O
relation	O
(	O
Lillard	O
et	O
al	O
.	O
,	O
2013	O
)	O
.	O

Spontaneous	O
pretend	O
play	O
is	O
often	O
impacted	O
in	O
atypical	O
development	B-T038
,	O
notably	O
in	O
autism	B-T038
spectrum	I-T038
disorder	I-T038
(	O
ASD	B-T038
)	O
.	O

Since	O
ASD	B-T038
traits	O
exist	O
along	O
a	O
continuum	B-T082
in	O
the	O
general	B-T098
population	I-T098
,	O
investigating	O
how	O
pretend	O
play	O
varies	O
across	O
the	O
range	O
of	O
ASD	B-T038
symptoms	B-T033
by	O
indexing	O
variations	O
in	O
ASD	B-T038
traits	O
in	O
both	O
typically	O
developing	O
and	O
ASD	B-T038
populations	B-T098
may	O
provide	O
insight	O
into	O
how	O
ASD	B-T038
symptoms	B-T033
may	O
influence	O
the	O
relation	O
between	O
pretend	O
play	O
and	O
associated	O
processes	O
in	O
cognitive	B-T038
development	I-T038
.	O

This	O
study	B-T062
used	O
rigorous	O
observational	O
methods	O
to	O
assess	O
spontaneous	O
pretend	O
play	O
.	O

Specifically	O
,	O
5	O
-	O
min	O
free	O
-	O
play	O
sessions	O
with	O
two	O
discrete	O
toy	O
sets	O
were	O
double	O
-	O
coded	O
by	O
blinded	O
coders	O
(	O
coder	O
assignment	O
counterbalanced	O
)	O
.	O

Key	O
facets	O
of	O
pretense	B-T038
development	I-T038
[	O
attribution	O
of	O
pretend	O
properties	O
(	O
APP	O
)	O
,	O
object	O
substitution	O
(	O
OS	O
)	O
,	O
imaginary	B-T038
objects	I-T038
]	O
were	O
examined	O
.	O

These	O
facets	O
of	O
pretend	O
play	O
production	B-T038
were	O
then	O
analyzed	B-T062
in	O
relation	O
to	O
ASD	B-T038
symptoms	B-T033
,	O
as	O
well	O
as	O
plausible	O
,	O
long	O
-	O
theorized	O
correlates	O
[	O
theory	O
of	O
mind	O
(	O
ToM	O
)	O
,	O
verbal	O
ability	O
,	O
familiarity	B-T038
,	O
and	O
interest	B-T038
in	O
specific	O
toys	O
]	O
.	O

Forty	O
children	O
(	O
Mage	O
=	O
6	O
;	O
5	O
,	O
SDage	O
=	O
1	O
.	O
45	O
;	O
29	O
males	O
)	O
,	O
six	O
of	O
whom	O
met	O
the	O
threshold	O
for	O
ASD	B-T038
diagnosis	B-T033
via	O
parent	O
-	O
reported	O
ASD	B-T038
symptoms	B-T033
,	O
participated	O
in	O
play	O
sessions	O
and	O
completed	O
measures	O
of	O
verbal	O
IQ	O
and	O
ToM	O
.	O

Besides	O
the	O
measure	O
of	O
child	O
ASD	B-T038
symptoms	B-T033
,	O
parents	O
completed	O
a	O
survey	B-T170
of	O
their	O
child	O
'	O
s	O
interest	B-T038
in	O
and	O
familiarity	B-T038
with	O
the	O
play	O
session	O
toys	O
.	O

Overall	O
,	O
greater	O
ToM	O
predicted	O
more	O
APP	O
,	O
and	O
more	O
interest	B-T038
in	O
the	O
toys	O
presented	O
predicted	O
more	O
OS	O
.	O

In	O
terms	O
of	O
overall	O
pretend	O
play	O
production	B-T038
,	O
two	O
results	O
were	O
counterintuitive	O
.	O

First	O
,	O
among	O
children	O
with	O
more	O
ASD	B-T038
symptoms	B-T033
,	O
verbal	O
ability	O
marginally	O
negatively	O
predicted	O
pretend	O
play	O
production	B-T038
.	O

Second	O
,	O
among	O
children	O
with	O
fewer	O
ASD	B-T038
symptoms	B-T033
,	O
ToM	O
negatively	O
predicted	O
pretend	O
play	O
production	B-T038
.	O

Further	O
probing	O
revealed	O
that	O
the	O
negative	O
effect	O
of	O
ASD	B-T038
symptoms	B-T033
on	O
pretend	O
play	O
was	O
simultaneously	O
moderated	O
by	O
both	O
variables	O
:	O
low	O
ToM	O
and	O
high	O
verbal	O
ability	O
both	O
related	O
to	O
less	O
pretend	O
play	O
production	O
among	O
children	O
with	O
more	O
ASD	B-T038
symptoms	B-T033
.	O

Implications	O
for	O
assessment	O
and	O
subsequent	O
treatment	B-T058
for	O
pretend	O
ability	O
among	O
children	O
with	O
varying	O
degrees	O
of	O
ASD	B-T038
symptoms	B-T033
,	O
as	O
well	O
as	O
for	O
future	O
research	O
,	O
are	O
discussed	O
.	O

Allelic	B-T017
diversity	O
in	O
an	O
NLR	B-T017
gene	I-T017
BPH9	B-T017
enables	O
rice	B-T204
to	O
combat	O
planthopper	B-T204
variation	O

Brown	B-T204
planthopper	I-T204
(	O
BPH	B-T204
)	O
,	O
Nilaparvata	B-T204
lugens	I-T204
Stål	I-T204
,	O
is	O
one	O
of	O
the	O
most	O
devastating	O
insect	B-T204
pests	O
of	O
rice	B-T204
(	O
Oryza	B-T204
sativa	I-T204
L	I-T204
.	I-T204
)	O
.	O

Currently	O
,	O
30	O
BPH	B-T204
-	O
resistance	O
genes	O
have	O
been	O
genetically	O
defined	O
,	O
most	O
of	O
which	O
are	O
clustered	O
on	O
specific	O
chromosome	B-T017
regions	I-T017
.	O

Here	O
,	O
we	O
describe	O
molecular	B-T058
cloning	I-T058
and	O
characterization	O
of	O
a	O
BPH	B-T204
-	O
resistance	O
gene	O
,	O
BPH9	B-T017
,	O
mapped	O
on	O
the	O
long	B-T017
arm	I-T017
of	I-T017
rice	I-T017
chromosome	I-T017
12	I-T017
(	O
12L	O
)	O
.	O

BPH9	B-T017
encodes	O
a	O
rare	O
type	O
of	O
nucleotide	B-T038
-	I-T038
binding	I-T038
and	O
leucine	B-T082
-	I-T082
rich	I-T082
repeat	I-T082
(	O
NLR	B-T082
)	O
-	O
containing	O
protein	B-T103
that	O
localizes	O
to	O
the	O
endomembrane	B-T017
system	I-T017
and	O
causes	O
a	O
cell	B-T038
death	I-T038
phenotype	O
.	O

BPH9	B-T017
activates	O
salicylic	B-T103
acid	I-T103
-	O
and	O
jasmonic	B-T103
acid	I-T103
-	O
signaling	B-T038
pathways	I-T038
in	O
rice	B-T204
plants	B-T204
and	O
confers	O
both	O
antixenosis	O
and	O
antibiosis	O
to	O
BPH	B-T204
.	O

We	O
further	O
demonstrated	O
that	O
the	O
eight	O
BPH	B-T204
-	O
resistance	O
genes	O
that	O
are	O
clustered	O
on	O
chromosome	B-T017
12L	I-T017
,	O
including	O
the	O
widely	O
used	O
BPH1	B-T017
,	O
are	O
allelic	O
with	O
each	O
other	O
.	O

To	O
honor	O
the	O
priority	O
in	O
the	O
literature	B-T170
,	O
we	O
thus	O
designated	O
this	O
locus	B-T082
as	O
BPH1	B-T017
/	I-T017
9	I-T017
These	O
eight	O
genes	B-T017
can	O
be	O
classified	O
into	O
four	O
allelotypes	B-T017
,	O
BPH1	B-T017
/	I-T017
9	I-T017
-	I-T017
1	I-T017
,	O
-	B-T017
2	I-T017
,	O
-	B-T017
7	I-T017
,	O
and	O
-	B-T017
9	I-T017
These	O
allelotypes	B-T017
confer	O
varying	O
levels	O
of	O
resistance	B-T038
to	O
different	O
biotypes	B-T170
of	O
BPH	B-T204
.	O

The	O
coding	B-T017
region	I-T017
of	O
BPH1	B-T017
/	I-T017
9	I-T017
shows	O
a	O
high	O
level	O
of	O
diversity	O
in	O
rice	B-T204
germplasm	I-T204
.	O

Homologous	O
fragments	O
of	O
the	O
nucleotide	B-T038
-	I-T038
binding	I-T038
(	O
NB	B-T038
)	O
and	O
leucine	B-T082
-	I-T082
rich	I-T082
repeat	I-T082
(	O
LRR	B-T082
)	O
domains	B-T082
exist	O
,	O
which	O
might	O
have	O
served	O
as	O
a	O
repository	O
for	O
generating	O
allele	B-T017
diversity	O
.	O

Our	O
findings	O
reveal	O
a	O
rice	B-T204
plant	B-T204
strategy	O
for	O
modifying	O
the	O
genetic	O
information	O
to	O
gain	O
the	O
upper	O
hand	O
in	O
the	O
struggle	O
against	O
insect	B-T204
herbivores	B-T204
.	O

Further	O
exploration	O
of	O
natural	O
allelic	O
variation	O
and	O
artificial	B-T062
shuffling	I-T062
within	O
this	O
gene	B-T017
may	O
allow	O
breeding	B-T038
to	O
be	O
tailored	O
to	O
control	O
emerging	O
biotypes	B-T170
of	O
BPH	B-T204
.	O

Nontoxic	O
Formulations	O
of	O
Scintillation	O
Nanocrystals	O
for	O
Use	O
as	O
X	B-T058
-	I-T058
ray	I-T058
Computed	I-T058
Tomography	I-T058
Contrast	B-T103
Agents	I-T103

X	B-T058
-	I-T058
ray	I-T058
computed	I-T058
tomography	I-T058
(	O
CT	B-T058
)	O
is	O
currently	O
one	O
of	O
the	O
most	O
powerful	O
,	O
noninvasive	B-T170
,	O
clinical	O
in	B-T082
vivo	I-T082
imaging	B-T058
techniques	I-T058
,	O
which	O
has	O
resulted	O
from	O
advances	O
in	O
both	O
X	B-T074
-	I-T074
ray	I-T074
device	I-T074
and	O
contrast	O
enhancement	B-T058
technologies	I-T058
.	O

The	O
present	O
study	B-T062
demonstrates	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
metal	B-T103
tungstates	I-T103
(	O
such	O
as	O
CaWO4	B-T103
)	O
are	O
promising	O
contrast	B-T103
agents	I-T103
for	O
X	B-T058
-	I-T058
ray	I-T058
,	O
radiation	O
,	O
and	O
CT	B-T058
imaging	I-T058
,	O
because	O
of	O
the	O
high	O
X	B-T058
-	I-T058
ray	I-T058
mass	O
attenuation	O
of	O
tungsten	B-T103
(	O
W	B-T103
)	O
.	O

We	O
have	O
developed	O
a	O
method	O
of	O
formulation	O
,	O
in	O
which	O
CaWO4	B-T103
(	O
CWO	B-T103
)	O
nanoparticles	O
(	O
NPs	O
)	O
are	O
encapsulated	O
within	O
a	O
biocompatible	O
poly	B-T103
(	I-T103
ethylene	I-T103
glycol	I-T103
-	I-T103
b	I-T103
-	I-T103
d	I-T103
,	I-T103
l	I-T103
-	I-T103
lactic	I-T103
acid	I-T103
)	I-T103
(	I-T103
PEG	I-T103
-	I-T103
PLA	I-T103
)	I-T103
block	I-T103
copolymer	I-T103
(	I-T103
BCP	I-T103
)	I-T103
capsule	I-T103
.	O

We	O
show	O
that	O
these	O
PEG	B-T103
-	I-T103
PLA	I-T103
-	O
encapsulated	O
CWO	O
NPs	O
(	O
170	O
±	O
10	O
nm	O
hydrodynamic	O
diameter	O
)	O
produce	O
a	O
higher	O
CT	B-T058
contrast	O
(	O
by	O
a	O
factor	O
of	O
about	O
2	O
)	O
than	O
commercial	O
iodine	B-T103
-	O
based	O
radiocontrast	B-T103
agents	I-T103
(	O
e	O
.	O
g	O
.	O
,	O
Iohexol	B-T103
)	O
at	O
identical	O
molar	O
concentrations	O
of	O
W	B-T103
or	O
I	B-T103
atoms	B-T103
.	O

PEG	B-T103
-	I-T103
PLA	I-T103
-	O
coated	O
CWO	O
NPs	O
are	O
chemically	O
stable	O
and	O
completely	O
nontoxic	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
of	O
this	O
material	O
in	O
mice	B-T204
is	O
significantly	O
higher	O
(	O
250	O
±	O
50	O
mg	O
per	O
kg	O
body	O
weight	O
following	O
a	O
single	O
intravenous	B-T082
(	I-T082
IV	I-T082
)	I-T082
administration	I-T082
)	O
than	O
,	O
for	O
instance	O
,	O
commercially	O
available	O
dextran	B-T103
-	O
coated	O
iron	B-T103
oxide	I-T103
nanoparticles	O
that	O
are	O
currently	O
used	O
clinically	O
as	O
MRI	B-T058
contrast	B-T103
agents	I-T103
(	O
MTD	O
in	O
mice	B-T204
≈	O
168	O
mg	O
/	O
kg	O
per	O
dose	O
IV	O
)	O
.	O

IV	O
-	O
injected	O
PEG	B-T103
-	I-T103
PLA	I-T103
/	O
CWO	O
NPs	O
caused	O
no	B-T033
histopathologic	B-T091
damage	O
in	O
major	O
excretory	B-T017
organs	I-T017
(	O
heart	B-T017
,	O
liver	B-T017
,	O
lungs	B-T017
,	O
spleen	B-T017
,	O
and	O
kidney	B-T017
)	O
.	O

When	O
an	O
IV	O
dose	O
of	O
100	O
mg	O
/	O
kg	O
was	O
given	O
to	O
mice	B-T204
,	O
the	O
blood	B-T038
circulation	I-T038
half	O
-	O
life	O
was	O
measured	O
to	O
be	O
about	O
4	O
h	O
,	O
and	O
more	O
than	O
90	O
%	O
of	O
the	O
NPs	O
were	O
cleared	O
from	O
the	O
mice	B-T204
within	O
24	O
h	O
via	O
the	O
renal	B-T017
and	O
hepatobiliary	B-T022
systems	I-T022
.	O

When	O
intratumorally	O
administered	O
,	O
PEG	B-T103
-	I-T103
PLA	I-T103
-	O
coated	O
CWO	O
NPs	O
showed	O
complete	O
retention	O
in	O
a	O
tumor	B-T038
-	I-T038
bearing	I-T038
mouse	I-T038
model	I-T038
(	O
measurements	O
were	O
made	O
up	O
to	O
1	O
week	O
)	O
.	O

These	O
results	O
suggest	O
that	O
PEG	B-T103
-	I-T103
PLA	I-T103
-	O
coated	O
CWO	O
NPs	O
are	O
promising	O
materials	O
for	O
use	O
in	O
CT	B-T058
contrast	O
.	O

Albumin	B-T103
-	O
Bioinspired	O
Gd	B-T103
:	O
CuS	B-T103
Nanotheranostic	O
Agent	O
for	O
In	B-T082
Vivo	I-T082
Photoacoustic	B-T058
/	I-T058
Magnetic	B-T058
Resonance	I-T058
Imaging	I-T058
-	I-T058
Guided	I-T058
Tumor	B-T038
-	I-T058
Targeted	I-T058
Photothermal	I-T058
Therapy	I-T058

Photothermal	B-T058
therapy	I-T058
(	O
PTT	B-T058
)	O
is	O
attracting	O
increasing	O
interest	O
and	O
becoming	O
more	O
widely	O
used	O
for	O
skin	B-T058
cancer	I-T058
therapy	I-T058
in	O
the	O
clinic	B-T092
,	O
as	O
a	O
result	O
of	O
its	O
noninvasiveness	O
and	O
low	B-T038
systemic	I-T038
adverse	I-T038
effects	I-T038
.	O

However	O
,	O
there	O
is	O
an	O
urgent	O
need	O
to	O
develop	O
biocompatible	O
PTT	O
agents	O
,	O
which	O
enable	O
accurate	O
imaging	B-T058
,	O
monitoring	B-T058
,	O
and	O
diagnosis	B-T033
.	O

Herein	O
,	O
a	O
biocompatible	O
Gd	B-T103
-	O
integrated	O
CuS	B-T103
nanotheranostic	O
agent	O
(	O
Gd	B-T103
:	O
CuS	B-T103
@	O
BSA	B-T103
)	O
was	O
synthesized	O
via	O
a	O
facile	O
and	O
environmentally	O
friendly	O
biomimetic	O
strategy	O
,	O
using	O
bovine	B-T103
serum	I-T103
albumin	I-T103
(	O
BSA	B-T103
)	O
as	O
a	O
biotemplate	O
at	O
physiological	O
temperature	O
.	O

The	O
as	O
-	O
prepared	O
Gd	B-T103
:	O
CuS	B-T103
@	O
BSA	B-T103
nanoparticles	O
(	O
NPs	O
)	O
with	O
ultrasmall	O
sizes	O
(	O
ca	O
.	O

9	O
nm	O
)	O
exhibited	O
high	O
photothermal	B-T033
conversion	I-T033
efficiency	I-T033
and	O
good	O
photostability	B-T033
under	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
laser	O
irradiation	O
.	O

With	O
doped	B-T103
Gd	I-T103
species	I-T103
and	O
strong	O
tunable	O
NIR	O
absorbance	O
,	O
Gd	B-T103
:	O
CuS	B-T103
@	O
BSA	B-T103
NPs	O
demonstrate	O
prominent	O
tumor	B-T058
-	I-T058
contrasted	I-T058
imaging	I-T058
performance	O
both	O
on	O
the	O
photoacoustic	B-T058
and	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
modalities	O
.	O

The	O
subsequent	O
Gd	B-T058
:	I-T058
CuS	B-T103
@	I-T058
BSA	B-T103
-	I-T058
mediated	I-T058
PTT	I-T058
result	O
shows	O
high	O
therapy	B-T033
efficacy	I-T033
as	O
a	O
result	O
of	O
their	O
potent	O
NIR	B-T033
absorption	I-T033
and	O
high	O
photothermal	B-T033
conversion	I-T033
efficiency	I-T033
.	O

The	O
immune	B-T038
response	I-T038
triggered	O
by	O
Gd	B-T058
:	I-T058
CuS	B-T103
@	I-T058
BSA	B-T103
-	I-T058
mediated	I-T058
PTT	I-T058
is	O
preliminarily	O
explored	O
.	O

In	O
addition	O
,	O
toxicity	B-T058
studies	I-T058
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
verify	O
that	O
Gd	B-T103
:	O
CuS	B-T103
@	O
BSA	B-T103
NPs	O
qualify	O
as	O
biocompatible	O
agents	O
.	O

A	O
biodistribution	B-T062
study	I-T062
demonstrated	O
that	O
the	O
NPs	O
can	O
undergo	O
hepatic	O
clearance	O
from	O
the	O
body	B-T204
.	O

This	O
study	O
highlights	O
the	O
practicality	O
and	O
versatility	O
of	O
albumin	B-T103
-	O
mediated	O
biomimetic	O
mineralization	O
of	O
a	O
nanotheranostic	O
agent	O
and	O
also	O
suggests	O
that	O
bioinspired	O
Gd	B-T103
:	O
CuS	B-T103
@	O
BSA	B-T103
NPs	O
possess	O
promising	O
imaging	B-T058
guidance	I-T058
and	O
effective	O
tumor	B-T058
ablation	I-T058
properties	I-T058
,	O
with	O
high	O
spatial	O
resolution	O
and	O
deep	O
tissue	B-T017
penetration	O
.	O

Family	O
and	O
healthcare	B-T097
professionals	I-T097
'	O
perceptions	B-T038
of	O
a	O
pilot	O
hospice	B-T058
at	O
home	B-T082
programme	O
for	O
children	O
:	O
a	O
qualitative	O
study	B-T062

Parents	O
commonly	O
report	O
a	O
significant	O
improvement	O
in	O
quality	O
of	O
life	O
following	O
the	O
provision	B-T058
of	O
hospice	B-T058
and	O
supportive	B-T058
care	I-T058
and	O
have	O
identified	O
a	O
need	O
for	O
such	O
a	O
service	B-T058
in	O
the	O
home	B-T082
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
understand	O
the	O
experiences	O
of	O
families	O
receiving	O
a	O
nurse	B-T097
led	O
pilot	O
hospice	B-T058
at	O
home	B-T082
programme	O
and	O
the	O
experiences	B-T038
of	O
healthcare	B-T097
professionals	I-T097
delivering	O
and	O
engaging	O
with	O
the	O
programme	O
.	O

An	O
exploratory	O
,	O
qualitative	O
study	B-T062
was	O
conducted	O
,	O
including	O
telephone	B-T062
interviews	I-T062
with	O
parents	O
and	O
focus	O
groups	O
and	O
individual	B-T098
interviews	O
with	O
healthcare	B-T097
professionals	I-T097
.	O

All	O
parents	O
of	O
families	O
who	O
received	O
the	O
programme	O
of	O
care	B-T058
between	O
June	O
2014	O
and	O
September	O
2015	O
and	O
healthcare	B-T097
professionals	I-T097
delivering	O
and	O
engaging	O
with	O
the	O
programme	O
were	O
invited	O
to	O
participate	O
.	O

Seven	O
parents	O
participated	O
in	O
telephone	B-T062
interviews	I-T062
.	O

Four	O
focus	O
groups	O
took	O
place	O
,	O
two	O
with	O
external	B-T098
stakeholders	I-T098
(	O
18	O
participants	B-T098
in	O
total	O
)	O
,	O
one	O
with	O
in	O
-	O
patient	O
hospice	B-T097
staff	I-T097
(	O
13	O
participants	B-T098
)	O
and	O
one	O
with	O
the	O
hospice	B-T058
at	O
home	O
team	O
(	O
8	O
participants	B-T098
)	O
.	O

Two	O
additional	O
interviews	O
took	O
place	O
with	O
individual	B-T098
stakeholders	B-T098
who	O
were	O
unable	O
to	O
attend	O
a	O
scheduled	O
focus	O
group	O
.	O

Themes	O
from	O
interviews	O
with	O
parents	O
focused	O
on	O
the	O
value	O
of	O
having	O
consistent	O
and	O
expert	O
care	B-T058
.	O

The	O
findings	O
from	O
healthcare	B-T097
professionals	I-T097
centred	O
on	O
communication	O
within	O
and	O
across	O
services	B-T058
,	O
education	O
and	O
training	O
and	O
lone	O
working	O
.	O

The	O
pilot	O
hospice	B-T058
at	O
home	B-T082
programme	O
was	O
welcomed	O
by	O
all	O
those	O
who	O
took	O
part	O
in	O
the	O
study	B-T062
.	O

The	O
programme	O
may	O
be	O
improved	O
by	O
enhanced	O
clarification	O
of	O
roles	O
,	O
enhanced	O
access	O
to	O
multi	O
-	O
disciplinary	O
services	B-T058
,	O
greater	O
communication	O
across	O
services	B-T058
and	O
improved	O
information	O
provision	O
to	O
families	O
.	O

Functional	O
1	B-T103
,	I-T103
3a	I-T103
,	I-T103
6a	I-T103
-	I-T103
triazapentalene	I-T103
scaffold	O
:	O
Design	O
of	O
fluorescent	B-T103
probes	I-T103
for	O
kinesin	B-T103
spindle	I-T103
protein	I-T103
(	O
KSP	B-T103
)	O

1	B-T103
,	I-T103
3a	I-T103
,	I-T103
6a	I-T103
-	I-T103
Triazapentalene	I-T103
is	O
a	O
compact	O
fluorescent	B-T103
chromophore	O
.	O

In	O
this	O
study	B-T062
,	O
triazapentalene	B-T103
was	O
used	O
to	O
modify	O
a	O
series	O
of	O
biphenyl	B-T103
-	I-T103
type	I-T103
inhibitors	B-T103
of	O
kinesin	B-T103
spindle	I-T103
protein	I-T103
(	O
KSP	B-T103
)	O
to	O
develop	O
fluorescent	B-T103
probes	I-T103
for	O
the	O
intracellular	B-T082
visualization	O
of	O
this	O
protein	B-T103
.	O

Microscopic	O
studies	B-T062
demonstrated	O
that	O
these	O
novel	O
triazapentalene	B-T103
-	O
labeled	O
compounds	B-T103
exhibited	O
inhibitory	O
activity	O
towards	O
KSP	B-T103
in	O
cultured	B-T017
cells	I-T017
and	O
provided	O
important	O
information	O
concerning	O
the	O
intracellular	B-T082
distribution	O
.	O

C4b	B-T103
binding	I-T103
protein	I-T103
negatively	B-T038
regulates	I-T038
TLR1	B-T103
/	O
2	B-T103
response	O

TLR2	B-T103
associates	O
with	O
TLR1	B-T103
and	O
recognizes	O
microbial	O
lipoproteins	B-T103
.	O

Pam3CSK4	B-T103
,	O
a	O
triacylated	B-T103
lipoprotein	I-T103
,	O
is	O
anchored	B-T038
to	O
the	O
extracellular	B-T082
domain	I-T082
of	O
TLR1	B-T103
and	O
TLR2	B-T103
and	O
induces	O
pro	B-T038
-	I-T038
inflammatory	I-T038
signals	B-T038
.	O

Here	O
we	O
show	O
that	O
C4b	B-T103
binding	I-T103
protein	I-T103
(	O
C4BP	B-T103
)	O
,	O
which	O
is	O
a	O
complement	B-T038
pathway	I-T038
inhibitor	O
,	O
is	O
a	O
TLR2	B-T103
-	O
associated	O
molecule	O
.	O

Immunoprecipitation	B-T058
assay	I-T058
using	O
anti	B-T103
-	I-T103
TLR2	I-T103
mAb	I-T103
shows	O
that	O
C4BP	B-T103
binds	B-T038
to	I-T038
TLR2	B-T103
.	O

In	O
C4BP	B-T017
-	I-T017
deficient	I-T017
mice	B-T204
,	O
Pam3CSK4	B-T103
-	O
induced	O
IL	B-T103
-	I-T103
6	I-T103
levels	O
were	O
increased	O
compared	O
with	O
wild	B-T204
type	I-T204
mice	I-T204
.	O

In	O
C4BP	B-T103
-	O
expressing	B-T038
cells	B-T017
,	O
Pam3CSK4	B-T103
-	O
induced	O
IL	B-T038
-	I-T038
8	I-T038
production	I-T038
was	O
reduced	O
depending	O
on	O
the	O
C4BP	B-T103
expression	O
levels	O
.	O

These	O
results	O
reveal	O
the	O
important	O
role	O
of	O
C4BP	B-T103
in	O
negative	B-T038
regulation	I-T038
of	O
TLR1	B-T103
/	O
2	B-T103
-	O
dependent	B-T103
pro	B-T038
-	I-T038
inflammatory	I-T038
cytokine	B-T038
production	I-T038
.	O

Furthermore	O
,	O
using	O
a	O
fluorescent	B-T103
conjugated	I-T103
Pam3CSK4	B-T103
,	O
we	O
show	O
that	O
C4BP	B-T103
blocks	O
the	O
binding	B-T038
of	I-T038
Pam3CSK4	B-T103
to	O
TLR1	B-T103
/	O
2	B-T103
.	O

Finally	O
,	O
we	O
show	O
that	O
exogenous	O
C4BP	B-T103
also	O
inhibits	O
Pam3CSK4	B-T103
-	O
induced	B-T038
signaling	I-T038
leading	O
to	O
IL	B-T038
-	I-T038
8	I-T038
production	I-T038
.	O

Our	O
results	O
indicate	O
C4BP	B-T103
binding	B-T038
to	I-T038
TLR2	B-T103
and	O
consequent	O
neutralization	O
of	O
its	O
activity	B-T038
otherwise	O
inducing	O
pro	B-T038
-	I-T038
inflammatory	I-T038
cytokine	B-T038
production	I-T038
.	O

C4BP	B-T103
is	O
a	O
negative	B-T038
regulator	I-T038
of	O
TLR1	B-T103
/	O
2	B-T103
activity	B-T038
.	O

Effect	O
of	O
emodin	B-T103
on	O
mobility	B-T038
signal	I-T038
transduction	I-T038
system	I-T038
of	O
gallbladder	B-T017
smooth	B-T017
muscle	I-T017
in	O
Guinea	B-T204
pig	I-T204
with	O
cholelithiasis	B-T038

To	O
study	B-T062
the	O
effect	O
of	O
emodin	B-T103
on	O
protein	B-T038
and	O
gene	B-T038
expressions	I-T038
of	O
the	O
massagers	O
in	O
mobility	B-T038
signal	I-T038
transduction	I-T038
system	I-T038
of	O
cholecyst	B-T017
smooth	B-T017
muscle	I-T017
cells	I-T017
in	O
guinea	B-T204
pig	I-T204
with	O
cholesterol	B-T031
calculus	I-T031
.	O

The	O
guinea	B-T204
pigs	I-T204
were	O
randomly	O
divided	O
into	O
4	O
groups	O
,	O
such	O
as	O
control	O
group	O
,	O
gall	O
-	O
stone	O
(	O
GS	O
)	O
group	O
,	O
emodin	B-T103
group	O
and	O
ursodeoxycholic	B-T103
acid	I-T103
(	O
UA	B-T103
)	O
group	O
.	O

Cholesterol	B-T031
calculus	I-T031
models	O
were	O
induced	O
in	O
guinea	B-T204
pigs	I-T204
of	O
GS	O
,	O
emodin	B-T103
and	O
UA	B-T103
groups	O
by	O
lithogenic	B-T168
diet	I-T168
,	O
while	O
emodin	B-T103
or	O
UA	B-T103
were	O
given	O
to	O
the	O
corresponding	O
group	O
for	O
7	O
weeks	O
.	O

The	O
histomorphological	O
and	O
ultrastructure	O
change	O
of	O
gallbladder	B-T017
were	O
detected	B-T033
by	O
microscope	B-T074
and	O
electron	B-T074
microscope	I-T074
,	O
the	O
content	O
of	O
plasma	B-T031
cholecystokinin	B-T103
(	O
CCK	B-T103
)	O
and	O
[	B-T103
Ca	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
]	I-T103
i	I-T103
were	O
analyzed	B-T062
successively	O
by	O
radioimmunoassay	B-T058
and	O
flow	B-T058
cytometry	I-T058
.	O

The	O
protein	B-T103
and	O
mRNA	B-T103
of	O
Gsα	B-T103
,	O
Giα	B-T103
and	O
Cap	B-T103
in	O
cholecyst	B-T017
cells	B-T017
were	O
determined	O
by	O
western	B-T058
blotting	I-T058
and	O
real	B-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
(	O
RT	B-T062
-	I-T062
PCR	I-T062
)	O
.	O

Emodin	B-T103
or	O
UA	B-T103
can	O
relieve	O
pathogenic	B-T033
changes	O
in	O
epithelial	B-T017
cells	I-T017
and	O
muscle	B-T017
cells	I-T017
in	O
gallbladder	B-T017
of	O
guinea	B-T204
pig	I-T204
with	O
cholesterol	B-T031
calculus	I-T031
by	O
microscope	B-T074
and	O
transmission	B-T074
electron	I-T074
microscope	I-T074
.	O

In	O
the	O
cholecyst	B-T017
cells	B-T017
of	O
GS	O
group	O
,	O
CCK	B-T103
levels	O
in	O
plasma	B-T031
and	O
[	B-T103
Ca	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
]	I-T103
i	I-T103
decreased	O
,	O
the	O
protein	B-T103
and	O
mRNA	B-T103
of	O
GS	O
were	O
down	B-T038
-	I-T038
regulated	I-T038
,	O
the	O
protein	B-T103
and	O
mRNA	B-T103
of	O
Gi	B-T103
and	O
Cap	B-T103
were	O
up	B-T038
-	I-T038
regulated	I-T038
.	O

Emodin	B-T103
significantly	O
decreased	O
the	O
formative	O
rate	O
of	O
gallstone	O
,	O
improved	O
the	O
pathogenic	B-T033
change	O
in	O
epithelial	B-T017
cells	I-T017
and	O
muscle	B-T017
cells	I-T017
,	O
increased	O
CCK	B-T103
levels	O
in	O
plasma	B-T031
and	O
[	B-T103
Ca	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
]	I-T103
i	I-T103
in	O
cholecyst	B-T017
cells	B-T017
,	O
enhanced	O
the	O
protein	B-T103
and	O
mRNA	B-T103
of	O
Gs	B-T103
in	O
cholecyst	B-T017
cells	B-T017
,	O
reduced	O
the	O
protein	B-T103
and	O
mRNA	B-T103
of	O
Gi	B-T103
and	O
Cap	B-T103
in	O
cholecyst	B-T017
cells	B-T017
in	O
guinea	B-T204
pig	I-T204
with	O
cholesterol	B-T031
calculus	I-T031
.	O

The	O
dysfunction	O
of	O
gallbladder	B-T038
contraction	I-T038
gives	O
rise	O
to	O
the	O
disorders	B-T038
of	O
mobility	B-T038
signal	I-T038
transduction	I-T038
system	I-T038
in	O
cholecyst	B-T017
smooth	B-T017
muscle	I-T017
cells	I-T017
,	O
including	O
low	O
content	O
of	O
plasma	B-T031
CCK	B-T103
and	O
[	B-T103
Ca	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
]	I-T103
i	I-T103
in	O
cholecyst	B-T017
cells	B-T017
,	O
abnormal	B-T103
protein	I-T103
and	O
mRNA	B-T103
of	O
Gs	B-T103
,	O
Gi	B-T103
and	O
Cap	B-T103
.	O

Emodin	B-T103
can	O
enhance	O
the	O
contractibility	B-T038
of	I-T038
gallbladder	I-T038
and	O
alleviate	O
cholestasis	B-T038
by	O
regulating	B-T038
plasma	B-T031
CCK	B-T103
levels	O
,	O
[	B-T103
Ca	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
]	I-T103
i	I-T103
in	O
cholecyst	B-T017
cells	B-T017
and	O
the	O
protein	B-T103
and	O
mRNA	B-T103
of	O
Gs	B-T103
,	O
Gi	B-T103
and	O
Cap	B-T103
.	O

Quantification	O
of	O
urinary	O
mono	B-T103
-	I-T103
hydroxylated	I-T103
metabolites	I-T103
of	O
polycyclic	B-T103
aromatic	I-T103
hydrocarbons	I-T103
by	O
on	B-T058
-	I-T058
line	I-T058
solid	I-T058
phase	I-T058
extraction	I-T058
-	O
high	B-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058

Human	B-T204
exposure	O
to	O
polycyclic	B-T103
aromatic	I-T103
hydrocarbons	I-T103
(	O
PAHs	B-T103
)	O
can	O
be	O
assessed	O
through	O
monitoring	B-T058
of	O
urinary	O
mono	B-T103
-	I-T103
hydroxylated	I-T103
PAHs	I-T103
(	O
OH	B-T103
-	I-T103
PAHs	I-T103
)	O
.	O

Gas	B-T058
chromatography	I-T058
(	O
GC	B-T058
)	O
has	O
been	O
widely	O
used	O
to	O
separate	O
OH	B-T103
-	I-T103
PAHs	I-T103
before	O
quantification	O
by	O
mass	B-T058
spectrometry	I-T058
in	O
biomonitoring	O
studies	B-T062
.	O

However	O
,	O
because	O
GC	B-T058
requires	O
derivatization	O
,	O
it	O
can	O
be	O
time	O
consuming	O
.	O

We	O
developed	O
an	O
on	B-T058
-	I-T058
line	I-T058
solid	I-T058
phase	I-T058
extraction	I-T058
coupled	O
to	O
isotope	B-T103
dilution	O
-	O
high	B-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
(	O
on	B-T058
-	I-T058
line	I-T058
-	I-T058
SPE	I-T058
-	O
HPLC	B-T058
-	I-T058
MS	I-T058
/	O
MS	B-T058
)	O
method	B-T170
for	O
the	O
quantification	O
in	O
urine	B-T031
of	O
1	B-T103
-	I-T103
OH	I-T103
-	I-T103
naphthalene	I-T103
,	O
2	B-T103
-	I-T103
OH	I-T103
-	I-T103
naphthalene	I-T103
,	O
2	B-T103
-	I-T103
OH	I-T103
-	I-T103
fluorene	I-T103
,	O
3	B-T103
-	I-T103
OH	I-T103
-	I-T103
fluorene	I-T103
,	O
1	B-T103
-	I-T103
OH	I-T103
-	I-T103
phenanthrene	I-T103
,	O
the	O
sum	O
of	O
2	B-T103
-	I-T103
OH	I-T103
and	O
3	B-T103
-	I-T103
OH	I-T103
-	I-T103
phenanthrene	I-T103
,	O
4	B-T103
-	I-T103
OH	I-T103
-	I-T103
phenanthrene	I-T103
,	O
and	O
1	B-T103
-	I-T103
OH	I-T103
-	I-T103
pyrene	I-T103
.	O

The	O
method	B-T170
,	O
which	O
employed	B-T033
a	O
96	O
-	O
well	B-T082
plate	I-T082
platform	I-T082
and	O
on	B-T058
-	I-T058
line	I-T058
SPE	I-T058
,	O
showed	O
good	O
sensitivity	O
(	O
i	O
.	O
e	O
.	O
,	O
limits	O
of	O
detection	B-T058
ranged	O
from	O
0	O
.	O
007	O
to	O
0	O
.	O
09	O
ng	O
/	O
mL	O
)	O
and	O
used	O
only	O
100	O
μL	O
of	O
urine	B-T031
.	O

Accuracy	O
,	O
calculated	B-T058
from	O
the	O
recovery	O
percentage	O
at	O
three	O
spiking	B-T082
levels	O
,	O
varied	O
from	O
94	O
to	O
113	O
%	O
,	O
depending	O
on	O
the	O
analyte	O
.	O

The	O
inter	O
-	O
and	O
intra	O
-	O
day	O
precision	O
,	O
calculated	B-T058
from	O
20	O
repeated	O
measurements	O
of	O
two	O
quality	O
control	O
materials	O
,	O
varied	O
from	O
5	O
.	O
2	O
to	O
16	O
.	O
7	O
%	O
.	O

Adequate	O
method	B-T170
performance	O
was	O
also	O
confirmed	O
by	O
acceptable	O
recovery	O
(	O
83	O
-	O
102	O
%	O
)	O
of	O
two	O
NIST	B-T092
standard	O
reference	O
materials	O
(	O
3672	O
and	O
3673	O
)	O
.	O

This	O
high	O
-	O
throughput	O
on	B-T058
-	I-T058
line	I-T058
-	I-T058
SPE	I-T058
-	O
HPLC	B-T058
-	I-T058
MS	I-T058
/	O
MS	B-T058
method	B-T170
can	O
be	O
applied	O
in	O
large	O
-	O
scale	O
epidemiological	B-T062
studies	I-T062
.	O

Graphical	O
abstract	O
Example	O
LC	O
-	O
MS	O
chromatogram	O
of	O
urinary	O
mono	B-T103
-	I-T103
hydroxylated	I-T103
PAH	I-T103
metabolites	B-T103
.	O

Utility	O
and	O
applicability	O
of	O
the	O
"	B-T170
Childhood	I-T170
Obesity	I-T170
Risk	I-T170
Evaluation	I-T170
"	I-T170
(	I-T170
CORE	I-T170
)	I-T170
-	I-T170
index	I-T170
in	O
predicting	O
obesity	B-T038
in	O
childhood	O
and	O
adolescence	O
in	O
Greece	B-T082
from	O
early	O
life	O
:	O
the	O
"	O
National	O
Action	O
Plan	O
for	O
Public	O
Health	O
"	O

Early	O
identification	B-T058
of	O
infants	O
being	O
at	O
high	B-T033
risk	I-T033
to	O
become	O
obese	B-T038
at	O
their	O
later	O
childhood	O
or	O
adolescence	O
can	O
be	O
of	O
vital	O
importance	O
in	O
any	O
obesity	B-T038
prevention	O
initiative	B-T033
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
utility	O
and	O
applicability	O
of	O
the	O
"	B-T170
Childhood	I-T170
Obesity	I-T170
Risk	I-T170
Evaluation	I-T170
(	I-T170
CORE	I-T170
)	I-T170
"	I-T170
index	I-T170
as	O
a	O
screening	B-T058
tool	O
for	O
the	O
early	O
prediction	O
of	O
obesity	B-T038
in	O
childhood	O
and	O
adolescence	O
.	O

Anthropometric	O
,	O
socio	O
-	O
demographic	O
data	O
were	O
collected	O
cross	O
-	O
sectionally	O
and	O
retrospectively	O
from	O
a	O
representative	O
sample	O
of	O
5946	O
children	O
,	O
and	O
adolescents	O
and	O
were	O
combined	O
for	O
calculating	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
score	I-T170
.	O

Logistic	O
regression	O
analyses	O
were	O
performed	O
to	O
examine	O
the	O
associations	O
of	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
score	I-T170
with	O
obesity	B-T038
by	O
gender	O
and	O
age	O
group	O
,	O
and	O
cut	B-T062
-	I-T062
off	I-T062
point	I-T062
analysis	I-T062
was	O
also	O
applied	O
to	O
identify	O
the	O
optimal	O
value	O
of	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
score	I-T170
that	O
differentiates	O
obese	B-T038
from	O
non	O
-	O
obese	O
children	O
.	O

Mean	B-T170
CORE	I-T170
-	I-T170
index	I-T170
score	I-T170
in	O
the	O
total	O
sample	O
was	O
3	O
.	O
06	O
(	O
sd	O
1	O
.	O
92	O
)	O
units	O
(	O
range	O
0	O
-	O
11	O
units	O
)	O
.	O

Each	O
unit	O
increase	O
in	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
score	I-T170
was	O
found	O
to	O
be	O
associated	O
with	O
a	O
30	O
%	O
(	O
95	O
%	O
C	O
.	O
I	O
.	O

1	O
.	O
24	O
-	O
1	O
.	O
36	O
)	O
increased	O
likelihood	O
for	O
obesity	B-T038
in	O
childhood	O
or	O
adolescence	O
,	O
while	O
the	O
optimal	O
cut	O
-	O
off	O
value	O
of	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
score	I-T170
that	O
predicted	O
obesity	B-T038
with	O
the	O
highest	O
possible	O
sensitivity	O
and	O
specificity	O
was	O
found	O
to	O
be	O
3	O
.	O
5	O
.	O

The	O
present	O
study	O
supports	O
the	O
utility	O
and	O
applicability	O
of	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
as	O
a	O
screening	B-T058
tool	O
for	O
the	O
early	O
identification	B-T058
of	O
infants	O
that	O
are	O
potentially	O
at	O
a	O
higher	B-T033
risk	I-T033
for	O
becoming	O
obese	B-T038
at	O
their	O
childhood	O
and	O
adolescence	O
.	O

This	O
tool	O
could	O
be	O
routinely	O
used	O
by	O
health	B-T097
professionals	I-T097
to	O
identify	O
infants	O
at	O
high	B-T033
risk	I-T033
and	O
provide	O
appropriate	O
counselling	B-T058
to	O
their	O
parents	O
and	O
caregivers	B-T097
so	O
as	O
to	O
maximize	O
the	O
effectiveness	O
of	O
early	O
obesity	B-T038
prevention	O
initiatives	B-T033
.	O

What	O
is	O
known	O
?	O
•	O
Childhood	O
obesity	B-T038
has	O
reached	O
epidemic	O
proportions	O
worldwide	O
.	O

•	O
Certain	O
perinatal	B-T033
and	O
socio	B-T033
-	I-T033
demographic	I-T033
indices	I-T033
that	O
were	O
previously	O
identified	O
as	O
correlates	O
of	O
childhood	O
obesity	B-T038
in	O
children	O
were	O
combined	O
to	O
develop	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
,	O
a	O
screening	B-T058
tool	O
that	O
estimates	O
obesity	B-T038
risk	O
in	O
9	O
-	O
13	O
year	O
-	O
old	O
children	O
.	O

What	O
is	O
new	O
?	O
•	O
The	O
utility	O
and	O
applicability	O
of	O
the	O
CORE	B-T170
-	I-T170
index	I-T170
as	O
screening	B-T058
tool	O
can	O
be	O
extended	O
to	O
the	O
age	O
range	O
of	O
6	O
-	O
15	O
years	O
.	O

•	O
The	O
CORE	B-T170
-	I-T170
index	I-T170
is	O
a	O
cost	O
-	O
effective	O
screening	B-T058
tool	O
that	O
can	O
assist	O
health	B-T097
professionals	I-T097
in	O
initiating	O
obesity	B-T038
preventive	B-T170
measures	I-T170
from	O
early	O
life	O
.	O

Methodology	O
development	O
on	O
aquatic	O
environmental	O
assessment	B-T058

The	O
Water	B-T170
Framework	I-T170
Directive	I-T170
aims	O
at	O
reaching	O
the	O
good	O
ecological	O
status	O
of	O
the	O
surface	B-T082
and	O
ground	B-T082
water	I-T082
bodies	I-T082
(	O
László	O
et	O
al	O
.	O

Microchem	O
J	O
85	O
(	O
1	O
)	O
:	O
65	O
-	O
71	O
,	O
2007	O
)	O
.	O

The	O
paper	O
deals	O
with	O
quality	O
evaluation	B-T058
of	O
waters	B-T103
with	O
special	O
focus	O
on	O
the	O
water	B-T103
chemistry	O
parameters	O
as	O
defined	O
in	O
the	O
Water	B-T170
Framework	I-T170
Directive	I-T170
and	O
pertaining	O
legal	O
regulations	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
devise	O
a	O
quantitative	O
type	O
of	O
water	B-T103
quality	O
assessment	B-T058
method	B-T170
which	O
could	O
provide	O
rapid	O
,	O
accurate	O
,	O
and	O
reliable	O
information	O
on	O
the	O
quality	O
of	O
the	O
surface	B-T082
waters	B-T103
by	O
using	O
water	B-T103
chemistry	O
parameters	O
.	O

Quality	O
classes	B-T170
have	O
been	O
defined	O
for	O
every	O
water	B-T103
chemistry	O
parameter	O
in	O
light	O
of	O
the	O
legal	B-T170
limit	I-T170
values	I-T170
of	O
the	O
water	B-T103
parameters	O
.	O

In	O
addition	O
to	O
this	O
,	O
weight	O
indices	O
were	O
calculated	B-T058
on	O
the	O
basis	O
of	O
the	O
outcome	O
of	O
the	O
paired	O
comparison	O
of	O
water	B-T103
chemistry	O
parameters	O
and	O
normalized	B-T062
matrix	B-T082
.	O

This	O
was	O
followed	O
by	O
the	O
parametric	O
level	O
analysis	O
of	O
the	O
water	B-T103
chemistry	O
parameters	O
,	O
and	O
finally	O
,	O
the	O
aquatic	B-T170
environment	I-T170
index	I-T170
(	O
AEI	B-T170
)	O
was	O
calculated	B-T058
,	O
which	O
provided	O
general	B-T170
information	I-T170
on	O
the	O
quality	O
of	O
water	B-T103
regarding	O
the	O
water	B-T103
chemistry	O
parameters	O
.	O

The	O
method	B-T170
was	O
illustrated	O
on	O
Lake	B-T082
Balaton	B-T082
,	O
Hungary	B-T082
in	O
which	O
case	O
water	B-T103
samples	O
taken	O
from	O
Balatonfüred	B-T082
City	I-T082
lake	B-T082
area	B-T082
were	O
analyzed	B-T062
and	O
evaluated	B-T058
with	O
the	O
method	B-T170
devised	O
.	O

WDR26	B-T103
promotes	O
mitophagy	B-T038
of	O
cardiomyocytes	B-T017
induced	O
by	O
hypoxia	B-T038
through	O
Parkin	B-T103
translocation	B-T038

Myocardial	B-T038
ischemia	I-T038
is	O
a	O
heart	B-T017
condition	O
caused	O
by	O
reduction	O
of	O
blood	B-T038
flow	I-T038
to	O
the	O
heart	B-T017
,	O
preventing	O
heart	B-T017
from	O
receiving	O
enough	O
oxygen	B-T103
.	O

Myocardial	B-T038
ischemia	I-T038
is	O
the	O
most	O
common	O
cause	B-T033
of	I-T033
death	I-T033
globally	B-T082
.	O

Heart	B-T017
ischemic	B-T058
preconditioning	I-T058
(	O
IPC	B-T058
)	O
has	O
a	O
protective	O
effect	O
against	O
myocardial	B-T017
cell	I-T017
death	B-T038
induced	O
by	O
ischemia	B-T038
and	O
ischemia	B-T037
-	I-T037
reperfusion	I-T037
injury	I-T037
.	O

WDR26	B-T103
has	O
recently	O
been	O
identified	O
as	O
a	O
protein	B-T103
that	O
is	O
increased	O
following	O
rat	B-T204
cardiac	B-T017
IPC	B-T058
.	O

WDR26	B-T103
can	O
promote	O
the	O
proliferation	B-T038
of	O
H9c2	B-T017
cells	I-T017
and	O
protect	O
cardiomyocytes	B-T017
against	O
oxidative	B-T038
stress	I-T038
through	O
inhibiting	O
apoptosis	B-T038
.	O

However	O
,	O
its	O
role	O
in	O
myocardial	B-T038
ischemia	I-T038
is	O
unclear	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
explore	O
the	O
role	O
of	O
WDR26	B-T103
in	O
myocardial	B-T038
ischemia	I-T038
and	O
H9c2	B-T017
cell	I-T017
hypoxia	B-T038
.	O

Our	O
results	O
showed	O
that	O
WDR26	B-T103
is	O
induced	O
by	O
myocardial	B-T038
ischemia	I-T038
and	O
H9c2	B-T017
cell	I-T017
hypoxia	B-T038
.	O

WDR26	B-T103
protects	O
H9c2	B-T017
cells	I-T017
against	O
hypoxia	B-T038
injury	B-T037
through	O
inhibiting	O
LDH	B-T103
release	O
and	O
increasing	O
cell	B-T038
viability	I-T038
.	O

WDR26	B-T103
promotes	O
hypoxia	B-T038
-	O
induced	O
autophagy	B-T038
in	O
hypoxia	B-T038
of	O
H9c2	B-T017
cells	I-T017
.	O

We	O
further	O
demonstrated	O
that	O
in	O
H9c2	B-T017
cell	I-T017
hypoxia	B-T038
,	O
WDR26	B-T103
increases	O
mitochondrial	B-T038
membrane	I-T038
potential	I-T038
,	O
thereby	O
increases	O
Parkin	B-T103
translocation	B-T038
of	O
mitochondria	B-T017
.	O

After	O
Parkin	B-T103
is	O
translocated	B-T038
at	O
mitochondria	B-T017
,	O
WDR26	B-T103
can	O
increase	O
mitochondria	B-T017
l	O
protein	B-T038
ubiquitination	I-T038
in	O
hypoxia	B-T038
of	O
H9c2	B-T017
cells	I-T017
.	O

WDR26	B-T103
is	O
a	O
mediator	O
of	O
response	O
to	O
hypoxia	B-T038
,	O
and	O
WDR26	B-T103
plays	O
an	O
important	O
role	O
in	O
hypoxia	B-T038
-	O
mediated	O
autophagy	B-T038
and	O
mitophagy	B-T038
.	O

This	O
study	B-T062
provides	O
novel	O
insights	O
into	O
the	O
protective	O
role	O
of	O
WDR26	B-T103
in	O
cardiomyocyte	B-T017
injury	B-T037
during	O
hypoxia	B-T038
.	O

WDR26	B-T103
may	O
serve	O
as	O
a	O
potential	O
target	O
for	O
the	O
treatment	B-T058
of	O
myocardial	B-T038
ischemia	I-T038
.	O

Impact	O
of	O
antibiotic	B-T103
de	B-T058
-	I-T058
escalation	I-T058
on	O
clinical	O
outcomes	O
in	O
community	O
-	O
acquired	O
pneumococcal	B-T038
pneumonia	I-T038

Although	O
antibiotic	B-T103
de	B-T058
-	I-T058
escalation	I-T058
is	O
regarded	O
as	O
a	O
measure	O
that	O
reduces	O
selection	O
pressure	O
,	O
adverse	B-T038
drug	I-T038
effects	I-T038
and	O
costs	O
,	O
evidence	O
supporting	O
this	O
practice	O
in	O
community	B-T038
-	I-T038
acquired	I-T038
pneumococcal	I-T038
pneumonia	I-T038
(	O
CAPP	B-T038
)	O
is	O
lacking	O
.	O

We	O
carried	O
out	O
a	O
retrospective	O
analysis	B-T062
of	O
prospectively	O
collected	O
data	O
of	O
a	O
cohort	B-T098
of	O
hospitalized	O
adults	O
with	O
CAPP	B-T038
.	O

Pneumococcal	B-T038
aetiology	O
was	O
established	O
in	O
patients	O
with	O
one	O
or	O
more	O
positive	B-T033
cultures	I-T033
for	O
Streptococcus	B-T007
pneumoniae	I-T007
obtained	O
from	O
blood	B-T031
,	O
sterile	B-T031
fluids	I-T031
or	O
sputum	B-T031
,	O
and	O
/	O
or	O
a	O
positive	B-T033
urinary	B-T058
antigen	I-T058
test	I-T058
.	O

De	B-T058
-	I-T058
escalation	I-T058
therapy	I-T058
was	O
considered	O
when	O
the	O
initial	O
antibiotic	B-T058
therapy	I-T058
was	O
narrowed	O
to	O
penicillin	B-T103
,	O
amoxicillin	B-T103
or	O
amoxicillin	B-T103
/	I-T103
clavulanate	I-T103
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-T058
.	O

The	O
primary	O
outcomes	O
were	O
30	O
day	O
mortality	O
and	O
length	O
of	O
hospital	O
stay	O
(	O
LOS	O
)	O
.	O

Adjustment	O
for	O
confounders	O
was	O
performed	O
with	O
multivariate	O
and	O
propensity	O
score	O
analyses	B-T062
.	O

Of	O
1410	O
episodes	O
of	O
CAPP	B-T038
,	O
antibiotic	B-T103
de	B-T058
-	I-T058
escalation	I-T058
within	O
the	O
first	O
72	O
h	O
after	O
admission	B-T058
was	O
performed	O
in	O
166	O
cases	O
.	O

After	O
adjustment	O
,	O
antibiotic	B-T103
de	B-T058
-	I-T058
escalation	I-T058
was	O
not	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
mortality	O
(	O
OR	O
=	O
0	O
.	O
83	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
24	O
-	O
2	O
.	O
81	O
)	O
,	O
but	O
it	O
was	O
found	O
to	O
be	O
a	O
protective	O
factor	O
for	O
prolonged	O
LOS	O
(	O
above	O
the	O
median	O
)	O
(	O
OR	O
=	O
0	O
.	O
46	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
30	O
-	O
0	O
.	O
70	O
)	O
.	O

Similar	O
results	O
were	O
found	O
in	O
patients	O
classified	O
into	O
high	B-T033
-	I-T033
risk	I-T033
pneumonia	B-T038
severity	O
index	O
classes	O
(	O
IV	O
-	O
V	O
)	O
,	O
those	O
with	O
clinical	B-T033
instability	I-T033
and	O
those	O
with	O
bacteraemia	B-T038
.	O

No	O
significant	O
differences	O
were	O
documented	B-T058
in	O
adverse	B-T038
drug	I-T038
reactions	I-T038
or	O
readmission	B-T058
(	O
<	O
30	O
days	O
)	O
.	O

Antibiotic	B-T103
de	B-T058
-	I-T058
escalation	I-T058
seems	O
to	O
be	O
safe	O
and	O
effective	O
in	O
reducing	O
the	O
duration	O
of	O
LOS	O
,	O
and	O
did	O
not	O
adversely	B-T038
affect	I-T038
outcomes	O
of	O
patients	O
with	O
CAPP	B-T038
,	O
even	O
those	O
with	O
bacteraemia	B-T038
and	O
severe	B-T038
disease	I-T038
,	O
and	O
those	O
who	O
were	O
clinically	B-T033
unstable	I-T033
.	O

Radiation	O
-	O
induced	O
Parotid	B-T038
Gland	I-T038
Atrophy	I-T038
in	O
Patients	O
with	O
Head	B-T038
and	I-T038
Neck	I-T038
Cancer	I-T038
After	O
Carbon	B-T058
-	I-T058
ion	I-T058
Radiotherapy	I-T058

This	O
study	B-T062
aimed	O
to	O
clarify	O
the	O
relationship	O
between	O
dosimetric	B-T058
factors	O
and	O
parotid	B-T038
gland	I-T038
(	I-T038
PG	I-T038
)	I-T038
atrophy	I-T038
after	O
carbon	B-T058
ion	I-T058
radiotherapy	I-T058
(	O
C	B-T058
-	I-T058
ion	I-T058
RT	I-T058
)	O
.	O

Fifty	O
-	O
four	O
patients	O
with	O
head	B-T038
and	I-T038
neck	I-T038
tumours	I-T038
were	O
enrolled	O
and	O
93	O
irradiated	O
PGs	B-T017
were	O
analyzed	O
.	O

Thirty	O
and	O
24	O
patients	O
were	O
treated	B-T058
with	I-T058
total	O
doses	O
[	O
relative	O
biological	O
effectiveness	O
(	O
RBE	O
)	O
]	O
of	O
57	O
.	O
6	O
Gy	O
and	O
64	O
.	O
0	O
Gy	O
,	O
respectively	O
,	O
in	O
16	O
fractions	O
.	O

PG	B-T017
volumes	O
were	O
measured	B-T058
using	O
computed	O
tomographic	O
images	O
obtained	O
before	O
C	B-T058
-	I-T058
ion	I-T058
RT	I-T058
and	O
every	O
3	O
-	O
6	O
months	O
thereafter	O
.	O

The	O
median	O
follow	B-T058
-	I-T058
up	I-T058
period	O
was	O
46	O
.	O
4	O
months	O
(	O
range	O
=	O
24	O
.	O
0	O
-	O
123	O
.	O
0	O
months	O
)	O
.	O

Univariate	O
analysis	O
showed	O
that	O
PG	B-T017
volumes	O
receiving	O
more	O
than	O
5	O
,	O
10	O
,	O
15	O
,	O
and	O
20	O
Gy	O
RBE	O
(	O
V5	O
,	O
V10	O
,	O
V15	O
and	O
V20	O
,	O
respectively	O
)	O
,	O
mean	O
dose	O
,	O
and	O
maximum	O
dose	O
were	O
significantly	O
associated	O
with	O
PG	B-T038
atrophy	I-T038
.	O

Multivariate	O
analysis	O
indicated	O
that	O
only	O
V5	O
was	O
significantly	O
associated	O
with	O
atrophy	B-T038
.	O

Increasing	O
V5	O
was	O
a	O
significant	O
risk	B-T033
factor	I-T033
for	O
PG	B-T038
atrophy	I-T038
after	O
C	B-T058
-	I-T058
ion	I-T058
RT	I-T058
.	O

IL	B-T103
-	I-T103
27	I-T103
Is	O
Essential	O
for	O
Suppression	B-T058
of	O
Experimental	O
Allergic	B-T038
Asthma	I-T038
by	O
the	O
TLR7	B-T103
/	O
8	B-T103
Agonist	B-T103
R848	B-T103
(	O
Resiquimod	B-T103
)	O

Different	O
models	B-T038
of	I-T038
experimental	I-T038
allergic	B-T038
asthma	I-T038
have	O
shown	O
that	O
the	O
TLR7	B-T103
/	O
8	B-T103
agonist	B-T103
resiquimod	B-T103
(	O
R848	B-T103
)	O
is	O
a	O
potential	O
inhibitor	O
of	O
type	B-T017
2	I-T017
helper	I-T017
cell	I-T017
-	O
driven	O
inflammatory	B-T038
responses	I-T038
.	O

However	O
,	O
the	O
mechanisms	O
mediating	O
its	O
therapeutic	B-T201
effects	I-T201
are	O
not	O
fully	O
understood	O
.	O

Using	O
a	O
model	B-T038
of	I-T038
experimental	I-T038
allergic	B-T038
asthma	I-T038
,	O
we	O
show	O
that	O
induction	B-T058
of	O
IL	B-T103
-	I-T103
27	I-T103
by	O
R848	B-T103
is	O
critical	O
for	O
the	O
observed	O
ameliorative	O
effects	O
.	O

R848	B-T103
significantly	O
inhibited	O
all	O
hallmarks	B-T017
of	O
experimental	O
allergic	B-T038
asthma	I-T038
,	O
including	O
airway	B-T038
hyperreactivity	I-T038
,	O
eosinophilic	O
airway	B-T017
inflammation	B-T038
,	O
mucus	B-T038
hypersecretion	I-T038
,	O
and	O
Ag	B-T103
-	O
specific	B-T103
Ig	I-T103
production	B-T038
.	O

Whereas	O
R848	B-T103
significantly	O
reduced	O
IL	B-T103
-	I-T103
5	I-T103
,	O
IL	B-T103
-	I-T103
13	I-T103
,	O
and	O
IL	B-T103
-	I-T103
17	I-T103
,	O
it	O
induced	O
IFN	B-T103
-	I-T103
γ	I-T103
and	O
IL	B-T103
-	I-T103
27	I-T103
.	O

Neutralization	O
of	O
IL	B-T103
-	I-T103
27	I-T103
completely	O
reversed	O
the	O
therapeutic	B-T201
effect	I-T201
of	O
R848	B-T103
in	O
the	O
experimental	O
asthma	B-T038
model	B-T038
,	O
demonstrating	O
dependence	O
of	O
R848	B-T103
-	O
mediated	O
suppression	B-T058
on	O
IL	B-T103
-	I-T103
27	I-T103
.	O

In	O
vitro	O
,	O
R848	B-T103
induced	B-T058
production	O
of	O
IL	B-T103
-	I-T103
27	I-T103
by	O
murine	B-T204
alveolar	B-T017
macrophages	I-T017
and	O
dendritic	B-T017
cells	I-T017
and	O
enhanced	O
expression	B-T038
of	O
programmed	O
death	O
-	O
ligand	O
1	O
,	O
whose	O
expression	B-T038
on	O
monocytes	B-T017
and	O
dendritic	B-T017
cells	I-T017
has	O
been	O
shown	O
to	O
regulate	B-T038
peripheral	B-T038
tolerance	I-T038
in	O
both	O
murine	B-T204
and	O
human	B-T204
studies	O
.	O

Moreover	O
,	O
in	O
vitro	O
IL	B-T103
-	I-T103
27	I-T103
enhanced	O
secretion	B-T038
of	O
IFN	B-T103
-	I-T103
γ	I-T103
whereas	O
it	O
inhibited	O
IL	B-T103
-	I-T103
5	I-T103
and	O
IL	B-T103
-	I-T103
13	I-T103
,	O
demonstrating	O
its	O
direct	O
effect	O
on	O
attenuating	O
Th2	B-T017
responses	O
.	O

Taken	O
together	O
,	O
our	O
study	O
proves	O
that	O
R848	B-T103
-	O
mediated	O
suppression	B-T058
of	O
experimental	O
asthma	B-T038
is	O
dependent	O
on	O
IL	B-T103
-	I-T103
27	I-T103
.	O

These	O
data	O
provide	O
evidence	O
of	O
a	O
central	O
role	O
of	O
IL	B-T103
-	I-T103
27	I-T103
for	O
the	O
control	O
of	O
Th2	B-T017
-	O
mediated	O
allergic	B-T038
diseases	I-T038
.	O

A	O
comparison	O
of	O
functional	O
outcomes	O
in	O
patients	O
undergoing	O
revision	B-T058
arthroscopic	I-T058
repair	I-T058
of	O
massive	O
rotator	B-T038
cuff	I-T038
tears	I-T038
with	O
and	O
without	O
arthroscopic	B-T082
suprascapular	B-T058
nerve	I-T058
release	I-T058

This	O
study	O
was	O
designed	O
to	O
compare	O
functional	O
outcomes	O
in	O
patients	O
undergoing	O
revision	B-T058
repair	I-T058
of	O
massive	O
rotator	B-T038
cuff	I-T038
tears	I-T038
(	O
retracted	O
medial	O
to	O
the	O
glenoid	B-T082
)	O
with	O
Goutallier	B-T038
Grade	I-T038
4	I-T038
atrophy	I-T038
and	O
concomitant	O
release	B-T058
of	I-T058
the	I-T058
suprascapular	I-T058
nerve	I-T058
to	O
a	O
similar	O
group	O
of	O
patients	O
with	O
Grade	B-T038
3	I-T038
atrophy	I-T038
undergoing	O
revision	B-T058
rotator	I-T058
cuff	I-T058
repair	I-T058
(	O
RTCR	B-T058
)	O
without	O
nerve	B-T058
release	I-T058
.	O

We	O
hypothesized	O
that	O
patients	O
undergoing	O
nerve	B-T058
release	I-T058
would	O
have	O
more	O
favorable	O
functional	O
outcomes	O
as	O
measured	O
by	O
the	O
Modified	O
University	B-T092
of	I-T092
California	I-T092
at	O
Los	B-T082
Angeles	I-T082
shoulder	O
rating	O
scale	O
(	O
UCLA	O
)	O
.	O

Twenty	O
-	O
two	O
patients	O
underwent	O
revision	B-T058
repair	I-T058
of	O
massive	O
rotator	B-T038
cuff	I-T038
tears	I-T038
with	O
release	B-T058
of	I-T058
the	I-T058
suprascapular	I-T058
nerve	I-T058
at	O
the	O
suprascapular	B-T082
notch	I-T082
.	O

We	O
compared	O
total	O
preoperative	O
,	O
postoperative	O
,	O
and	O
change	O
in	O
UCLA	O
score	O
in	O
these	O
patients	O
to	O
a	O
similar	O
group	B-T098
of	O
22	O
patients	O
undergoing	O
revision	B-T058
RTCR	I-T058
without	O
suprascapular	B-T058
nerve	I-T058
release	I-T058
.	O

Additionally	O
,	O
UCLA	O
subscores	O
between	O
the	O
two	O
groups	B-T098
were	O
compared	O
preoperatively	O
and	O
at	O
final	O
follow	B-T058
-	I-T058
up	I-T058
.	O

The	O
average	O
preoperative	O
UCLA	O
score	O
in	O
the	O
nerve	B-T098
-	I-T098
release	I-T098
group	I-T098
was	O
7	O
.	O
91	O
,	O
and	O
final	O
follow	B-T058
-	I-T058
up	I-T058
average	O
was	O
27	O
.	O
86	O
;	O
average	O
3	O
.	O
05	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O

In	O
the	O
comparison	O
group	B-T098
,	O
average	O
preoperative	O
UCLA	O
score	O
was	O
11	O
.	O
77	O
,	O
and	O
final	O
follow	B-T058
-	I-T058
up	I-T058
average	O
was	O
29	O
.	O
09	O
;	O
average	O
1	O
.	O
32	O
grades	O
of	O
strength	O
were	O
recovered	O
.	O

The	O
average	O
preoperative	O
UCLA	O
score	O
was	O
significantly	O
worse	O
in	O
the	O
nerve	B-T098
-	I-T098
release	I-T098
group	I-T098
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

The	O
average	O
postoperative	O
UCLA	O
score	O
was	O
not	O
significantly	O
different	O
(	O
P	O
=	O
0	O
.	O
590	O
)	O
between	O
the	O
groups	B-T098
,	O
indicating	O
a	O
better	O
improvement	O
in	O
the	O
nerve	B-T098
-	I-T098
release	I-T098
group	I-T098
with	O
significantly	O
greater	O
improvement	O
in	O
active	O
forward	O
flexion	B-T038
,	O
strength	B-T038
,	O
and	O
pain	B-T058
relief	I-T058
.	O

Patients	O
who	O
underwent	O
concomitant	O
release	B-T058
of	I-T058
the	I-T058
suprascapular	I-T058
nerve	I-T058
during	O
revision	B-T058
RTCR	I-T058
had	O
greater	O
overall	O
improvement	O
as	O
noted	O
in	O
pain	B-T058
relief	I-T058
,	O
active	B-T038
forward	I-T038
flexion	I-T038
,	O
and	O
strength	B-T038
,	O
than	O
a	O
comparable	O
group	B-T098
without	O
nerve	B-T058
release	I-T058
.	O

Fading	O
With	O
Time	O
of	O
PD	O
-	O
L1	O
Immunoreactivity	O
in	O
Non	B-T038
-	I-T038
Small	I-T038
Cells	I-T038
Lung	I-T038
Cancer	I-T038
Tissues	B-T017
:	O
A	O
Methodological	O
Study	O

Blockade	O
of	O
inhibitory	B-T038
immune	I-T038
checkpoints	I-T038
is	O
currently	O
arising	O
as	O
a	O
potential	O
immunologic	O
option	O
for	O
tumor	B-T058
therapy	I-T058
.	O

Inhibition	O
of	O
programmed	B-T103
cell	I-T103
death	I-T103
protein	I-T103
1	I-T103
and	O
/	O
or	O
its	O
specific	O
ligand	B-T103
programmed	O
death	O
-	O
ligand	O
1	O
(	O
PD	O
-	O
L1	O
)	O
was	O
effective	O
in	O
clinical	B-T062
trials	I-T062
in	O
advanced	O
melanoma	B-T038
,	O
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
(	O
NSCLC	B-T038
)	O
bladder	B-T038
and	O
kidney	B-T038
cancer	I-T038
.	O

The	O
predictive	O
role	O
of	O
the	O
immunohistochemical	O
(	O
IHC	O
)	O
expression	B-T038
of	O
PD	O
-	O
L1	O
is	O
highly	O
debated	O
.	O

Different	O
reagents	B-T103
,	O
clones	B-T017
,	O
cutoffs	O
of	O
cell	B-T017
expression	B-T038
and	O
subjective	O
interpretation	B-T033
of	O
PD	O
-	O
L1	O
immunoreactivity	O
in	O
epithelial	B-T017
cells	I-T017
and	O
lymphocytes	B-T017
are	O
the	O
main	O
issue	B-T033
.	O

In	O
this	O
study	O
we	O
selected	O
58	O
consecutive	O
NSCLC	B-T038
surgical	B-T017
specimens	I-T017
that	O
underwent	O
pathologic	B-T058
examination	I-T058
from	O
January	O
2014	O
to	O
July	O
2015	O
.	O

Using	O
a	O
tissue	O
microarray	B-T058
approach	I-T058
we	O
evaluated	O
the	O
IHC	O
expression	O
of	O
PD	O
-	O
L1	O
in	O
tumor	B-T017
-	I-T017
infiltrating	I-T017
lymphocytes	I-T017
and	O
tumor	B-T017
cells	I-T017
(	O
TCs	B-T017
)	O
and	O
compared	O
the	O
ICH	O
staining	O
with	O
tumor	B-T091
histology	I-T091
,	O
grade	B-T170
and	O
the	O
age	O
of	O
the	O
tissue	B-T017
blocks	I-T017
.	O

The	O
main	O
new	O
finding	B-T033
was	O
the	O
fading	O
of	O
PD	O
-	O
L1	O
IHC	O
expression	O
in	O
TCs	B-T017
in	O
tissues	B-T017
processed	O
in	O
2014	O
compared	O
with	O
2015	O
.	O

PD	O
-	O
L1	O
expression	B-T038
in	O
tumor	B-T017
-	I-T017
infiltrating	I-T017
lymphocytes	I-T017
in	O
the	O
2	O
years	O
was	O
similar	O
.	O

We	O
also	O
found	O
a	O
significant	O
higher	O
immunoreactivity	O
of	O
TCs	B-T017
in	O
high	O
grade	O
NSCLC	B-T038
and	O
in	O
the	O
squamous	B-T038
carcinoma	I-T038
histotype	B-T201
compared	O
with	O
low	O
grade	O
tumors	B-T091
and	O
the	O
adenocarcinoma	B-T038
histology	B-T091
(	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

We	O
demonstrated	O
that	O
the	O
IHC	O
evaluation	O
of	O
PD	O
-	O
L1	O
in	O
NSCLC	B-T038
archival	B-T017
tissues	I-T017
is	O
feasible	O
and	O
can	O
be	O
implemented	O
in	O
a	O
routine	O
pathology	B-T091
setting	I-T091
,	O
but	O
it	O
should	O
be	O
carefully	O
assessed	O
in	O
tissue	B-T017
blocks	I-T017
older	O
than	O
1	O
year	O
.	O

Differential	O
transcriptome	B-T082
expression	B-T038
in	O
human	B-T204
nucleus	B-T017
accumbens	I-T017
as	O
a	O
function	O
of	O
loneliness	B-T033

Loneliness	B-T033
is	O
associated	O
with	O
impaired	B-T038
mental	B-T038
and	O
physical	O
health	O
.	O

Studies	O
of	O
lonely	B-T098
individuals	I-T098
reported	O
differential	B-T038
expression	I-T038
of	O
inflammatory	O
genes	B-T017
in	O
peripheral	B-T082
leukocytes	B-T017
and	O
diminished	O
activation	B-T038
in	O
brain	B-T017
reward	B-T082
regions	I-T082
such	O
as	O
nucleus	B-T017
accumbens	I-T017
,	O
but	O
could	O
not	O
address	O
gene	B-T038
expression	I-T038
in	O
the	O
human	B-T204
brain	B-T017
.	O

Here	O
,	O
we	O
examined	O
genome	B-T038
-	I-T038
wide	I-T038
RNA	I-T038
expression	I-T038
in	O
post	B-T058
-	I-T058
mortem	I-T058
nucleus	B-T017
accumbens	I-T017
from	O
donors	B-T098
(	O
N	O
=	O
26	O
)	O
with	O
known	O
loneliness	B-T033
measures	O
.	O

Loneliness	B-T033
was	O
associated	O
with	O
1710	O
differentially	B-T103
expressed	I-T103
transcripts	I-T103
and	O
genes	B-T017
from	O
1599	O
genes	B-T017
(	O
DEGs	B-T017
;	O
false	O
discovery	O
rate	O
P	O
<	O
0	O
.	O
05	O
,	O
fold	O
change	O
⩾	O
|	O
2	O
|	O
,	O
controlling	O
for	O
confounds	O
)	O
previously	O
associated	O
with	O
behavioral	O
processes	O
,	O
neurological	B-T038
disease	I-T038
,	O
psychological	B-T038
disorders	I-T038
,	O
cancer	B-T038
,	O
organismal	O
injury	B-T037
and	O
skeletal	B-T038
and	O
muscular	B-T038
disorders	I-T038
,	O
as	O
well	O
as	O
networks	O
of	O
upstream	B-T082
RNA	B-T017
regulators	I-T017
.	O

Furthermore	O
,	O
a	O
number	O
of	O
DEGs	B-T017
were	O
associated	O
with	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
genes	B-T017
(	O
that	O
was	O
correlated	O
with	O
loneliness	B-T033
in	O
this	O
sample	O
,	O
although	O
gene	B-T062
expression	I-T062
analyses	I-T062
controlled	O
for	O
AD	B-T038
diagnosis	B-T033
)	O
.	O

These	O
results	O
identify	O
novel	O
targets	O
for	O
future	O
mechanistic	B-T062
studies	I-T062
of	O
gene	B-T017
networks	O
in	O
nucleus	B-T017
accumbens	I-T017
and	O
gene	B-T038
regulatory	I-T038
mechanisms	I-T038
across	O
a	O
variety	O
of	O
diseases	B-T038
exacerbated	O
by	O
loneliness	B-T033
.	O

Molecular	B-T170
Psychiatry	I-T170
advance	I-T170
online	I-T170
publication	I-T170
,	O
1	O
November	O
2016	O
;	O
doi	O
:	O
10	O
.	O
1038	O
/	O
mp	O
.	O
2016	O
.	O
186	O
.	O

Overall	O
Quality	O
Properties	O
of	O
Kiwifruit	B-T168
Treated	B-T058
by	I-T058
Cinnamaldehyde	B-T103
and	O
Citral	B-T103
:	O
Microbial	O
,	O
Antioxidant	B-T038
Capacity	I-T038
during	O
Cold	B-T058
Storage	I-T058

This	O
work	O
was	O
undertaken	O
to	O
evaluate	B-T058
the	O
microbiological	B-T170
characteristics	O
and	O
antioxidant	B-T038
and	O
physiological	B-T038
activities	I-T038
in	O
kiwifruits	B-T168
(	O
Actinida	B-T204
deliciosa	I-T204
var	O
.	O

Qinmei	O
)	O
with	O
/	O
without	O
cinnamaldehyde	B-T103
(	O
C1	O
)	O
and	O
citral	B-T103
(	O
C2	O
)	O
fumigation	O
treatments	O
(	O
5	O
μL	O
/	O
L	O
)	O
during	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
d	O
of	O
storage	O
at	O
4	O
°C	O
.	O

Essential	B-T103
oils	I-T103
(	O
EOs	B-T103
)	O
treatment	O
lowered	O
the	O
total	O
viable	O
counts	O
,	O
yeast	B-T204
,	O
and	O
mold	B-T204
to	O
1	O
.	O
54	O
,	O
2	O
.	O
36	O
,	O
and	O
2	O
.	O
05	O
log	O
CFU	O
/	O
g	O
,	O
respectively	O
.	O

Moreover	O
,	O
EOs	B-T103
improved	O
the	O
antioxidant	B-T038
activities	I-T038
of	O
kiwifruit	B-T168
.	O

They	O
enhanced	O
phenolics	B-T103
and	O
flavonoids	B-T103
content	O
in	O
fruit	B-T168
tissue	B-T017
by	O
49	O
.	O
48	O
%	O
at	O
day	O
3	O
and	O
56	O
.	O
93	O
%	O
at	O
day	O
6	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
ascorbic	B-T103
acid	I-T103
in	O
treated	O
groups	O
had	O
the	O
lower	O
losing	O
rate	O
.	O

Similarly	O
,	O
MDA	B-T103
(	O
malondialdehyde	B-T103
)	O
,	O
H2	B-T103
O2	I-T103
(	O
hydrogen	B-T103
peroxide	I-T103
)	O
,	O
and	O
(	O
•	O
)	O
O2	B-T103
(	I-T103
-	I-T103
)	I-T103
(	O
superoxide	B-T103
anion	I-T103
)	O
production	O
were	O
effectively	O
decreased	O
in	O
the	O
range	O
of	O
27	O
.	O
27	O
%	O
to	O
54	O
.	O
38	O
%	O
.	O

Physicochemical	O
characteristics	O
showed	O
that	O
kiwifruits	B-T168
from	O
treated	O
group	O
maintained	O
higher	O
levels	O
of	O
flesh	O
luminosity	O
and	O
firmness	O
.	O

EOs	B-T103
also	O
decreased	O
the	O
levels	O
of	O
reducing	B-T103
sugar	I-T103
by	O
45	O
.	O
97	O
%	O
at	O
day	O
3	O
,	O
and	O
increased	O
the	O
content	O
of	O
soluble	B-T103
protein	I-T103
and	O
hydrolyzed	O
amino	B-T103
acid	I-T103
.	O

Therefore	O
,	O
postharvest	O
EOs	B-T103
treatment	O
has	O
positive	O
effects	O
on	O
delaying	O
senescence	B-T038
and	O
enhancing	O
antioxidant	B-T038
capacities	I-T038
in	O
kiwifruit	B-T168
.	O

Anti	O
-	O
inflammatory	O
effect	O
of	O
Yu	B-T103
-	I-T103
Ping	I-T103
-	I-T103
Feng	I-T103
-	I-T103
San	I-T103
via	O
TGF	B-T103
-	I-T103
β1	I-T103
signaling	B-T038
suppression	I-T038
in	O
rat	B-T204
model	B-T038
of	O
COPD	B-T038

Yu	B-T103
-	I-T103
Ping	I-T103
-	I-T103
Feng	I-T103
-	I-T103
San	I-T103
(	O
YPFS	B-T103
)	O
is	O
a	O
classical	O
traditional	O
Chinese	B-T103
medicine	I-T103
that	O
is	O
widely	O
used	O
for	O
treatment	O
of	O
the	O
diseases	B-T038
in	O
respiratory	B-T022
systems	I-T022
,	O
including	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
(	O
COPD	B-T038
)	O
recognized	O
as	O
chronic	B-T038
inflammatory	I-T038
disease	I-T038
.	O

However	O
,	O
the	O
molecular	B-T038
mechanism	I-T038
remains	O
unclear	O
.	O

Here	O
we	O
detected	O
the	O
factors	O
involved	O
in	O
transforming	B-T103
growth	I-T103
factor	I-T103
beta	I-T103
1	I-T103
(	O
TGF	B-T103
-	I-T103
β1	I-T103
)	O
/	O
Smad2	B-T103
signaling	B-T038
pathway	I-T038
and	O
inflammatory	B-T103
cytokines	I-T103
,	O
to	O
clarify	O
whether	O
YPFS	B-T103
could	O
attenuate	O
inflammatory	B-T038
response	I-T038
dependent	O
on	O
TGF	B-T103
-	I-T103
β1	I-T103
/	O
Smad2	B-T103
signaling	B-T038
in	O
COPD	B-T038
rats	B-T204
or	O
cigarette	B-T103
smoke	I-T103
extract	I-T103
(	O
CSE	B-T103
)	O
-	O
treated	O
human	B-T204
bronchial	B-T017
epithelial	I-T017
(	I-T017
Beas	I-T017
-	I-T017
2B	I-T017
)	I-T017
cells	I-T017
.	O

The	O
COPD	B-T038
rat	B-T204
model	B-T038
was	O
established	O
by	O
exposure	O
to	O
cigarette	B-T103
smoke	I-T103
and	O
intratracheal	O
instillation	O
of	O
lipopolysaccharide	B-T103
,	O
YPFS	B-T103
was	O
administered	O
to	O
the	O
animals	B-T204
.	O

The	O
efficacy	O
of	O
YPFS	B-T103
was	O
evaluated	O
by	O
comparing	O
the	O
severity	O
of	O
pulmonary	B-T038
pathological	I-T038
damage	I-T038
,	O
pro	B-T103
-	I-T103
inflammation	I-T103
cytokines	I-T103
,	O
collagen	B-T017
related	I-T017
genes	I-T017
and	O
the	O
activation	O
of	O
TGF	B-T103
-	I-T103
β1	I-T103
/	O
Smad2	B-T103
signaling	B-T038
pathway	I-T038
.	O

Furthermore	O
,	O
CSE	B-T103
-	O
treated	O
cells	B-T017
were	O
employed	O
to	O
confirm	O
whether	O
the	O
effect	O
of	O
YPFS	B-T103
was	O
dependent	O
on	O
the	O
TGF	B-T103
-	I-T103
β1	I-T103
/	O
Smad2	B-T103
signaling	B-T038
via	O
knockdown	B-T062
Smad2	B-T017
(	O
Si	B-T103
-	I-T103
RNA	I-T103
)	O
,	O
or	O
pretreatment	O
with	O
the	O
inhibitor	O
of	O
TGF	B-T103
-	I-T103
β1	I-T103
.	O

Administration	O
of	O
YPFS	B-T103
effectively	O
alleviated	O
injury	B-T037
of	I-T037
lung	I-T037
,	O
suppressed	O
releasing	O
of	O
pro	B-T103
-	I-T103
inflammatory	I-T103
cytokines	I-T103
and	O
collagen	B-T038
deposition	I-T038
in	O
COPD	B-T038
animals	B-T204
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
whereas	O
exogenous	B-T103
TGF	I-T103
-	I-T103
β1	I-T103
promoted	O
releasing	O
of	O
IL	B-T103
-	I-T103
1β	I-T103
,	O
IL	B-T103
-	I-T103
6	I-T103
,	O
TNFα	B-T103
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Administration	O
YPFS	B-T103
reduced	O
inflammatory	B-T038
response	I-T038
significantly	O
,	O
also	O
down	B-T038
-	I-T038
regulated	I-T038
TGF	B-T103
-	I-T103
β1	I-T103
/	O
Smad2	B-T103
signaling	B-T038
in	B-T082
vivo	I-T082
and	O
in	O
vitro	O
.	O

Unexpectedly	O
,	O
knockdown	B-T062
Smad2	B-T017
or	O
inhibition	O
of	O
TGF	B-T103
-	I-T103
β1	I-T103
abolished	O
anti	O
-	O
inflammatory	O
effect	O
of	O
YPFS	B-T103
in	O
CSE	B-T103
-	O
treated	O
cells	B-T017
.	O

YPFS	B-T103
accomplished	O
anti	O
-	O
inflammatory	O
effects	O
mainly	O
by	O
suppressing	O
phosphorylation	B-T038
of	O
Smad2	B-T103
,	O
TGF	B-T103
-	I-T103
β1	I-T103
/	O
Smad2	B-T103
signaling	B-T038
pathway	I-T038
was	O
required	O
for	O
YPFS	B-T103
-	O
mediated	O
anti	O
-	O
inflammation	O
in	O
COPD	B-T038
rats	B-T204
or	O
CSE	B-T103
-	O
treated	O
Beas	B-T017
-	I-T017
2B	I-T017
cells	I-T017
.	O

The	O
association	O
between	O
maternal	B-T033
hydronephrosis	B-T038
and	O
acute	O
flank	B-T033
pain	I-T033
during	O
pregnancy	B-T038
:	O
a	O
prospective	B-T062
pilot	B-T062
-	I-T062
study	I-T062

Maternal	B-T033
hydronephrosis	B-T038
may	O
cause	O
flank	B-T033
pain	I-T033
during	O
pregnancy	B-T038
.	O

We	O
aimed	O
to	O
investigate	O
the	O
association	O
between	O
maternal	B-T033
hydronephrosis	B-T038
and	O
flank	B-T033
pain	I-T033
intensity	B-T201
.	O

From	O
2014	O
to	O
2015	O
,	O
all	O
consecutive	O
women	B-T098
with	O
singleton	B-T038
pregnancies	I-T038
,	O
who	O
presented	O
at	O
our	O
tertiary	O
center	O
due	O
to	O
acute	O
flank	B-T033
pain	I-T033
,	O
were	O
prospectively	B-T062
evaluated	B-T058
by	O
renal	B-T017
ultrasonography	B-T058
and	O
pain	B-T033
questionnaires	B-T170
.	O

A	O
visual	B-T058
analogue	I-T058
scale	I-T058
was	O
used	O
to	O
assess	O
pain	B-T201
intensity	I-T201
.	O

The	O
study	B-T062
had	O
90	O
%	O
power	O
to	O
detect	O
a	O
significant	O
correlation	O
between	O
hydronephrosis	B-T038
and	O
flank	B-T033
pain	I-T033
(	O
Spearman	B-T170
'	I-T170
s	I-T170
test	I-T170
)	O
.	O

A	O
total	O
of	O
51	O
consecutive	O
women	B-T098
with	O
left	B-T082
-	I-T082
sided	I-T082
(	O
13	O
.	O
7	O
%	O
)	O
,	O
right	B-T082
-	I-T082
sided	I-T082
(	O
64	O
.	O
7	O
%	O
)	O
or	O
bilateral	B-T082
(	O
21	O
.	O
6	O
%	O
)	O
pain	B-T033
were	O
enrolled	O
.	O

The	O
mean	O
gestational	O
age	O
of	O
these	O
women	B-T098
,	O
who	O
presented	O
due	O
to	O
their	O
pain	B-T033
,	O
was	O
27	O
.	O
5	O
±	O
6	O
.	O
8	O
weeks	O
at	O
the	O
time	O
of	O
consultation	B-T058
.	O

The	O
mean	O
VAS	O
score	O
was	O
7	O
.	O
6	O
±	O
2	O
.	O
2	O
.	O

In	O
43	O
/	O
51	O
(	O
84	O
.	O
3	O
%	O
)	O
women	B-T098
,	O
hydronephrosis	B-T038
was	O
found	O
on	O
renal	B-T017
sonograms	O
.	O

No	O
correlation	O
was	O
found	O
between	O
the	O
grade	O
of	O
hydronephrosis	B-T038
and	O
pain	B-T201
intensity	I-T201
(	O
p	O
=	O
0	O
.	O
466	O
;	O
r	O
=	O
-	O
0	O
.	O
28	O
)	O
.	O

Women	B-T098
delivered	O
at	O
a	O
mean	O
gestational	O
age	O
of	O
38	O
.	O
1	O
±	O
2	O
.	O
4	O
weeks	O
and	O
their	O
infants	O
had	O
a	O
mean	O
birthweight	O
of	O
3138	O
±	O
677	O
g	O
.	O

Hydronephrosis	B-T038
is	O
a	O
common	O
finding	B-T033
among	O
pregnant	B-T098
women	I-T098
with	O
acute	O
flank	B-T033
pain	I-T033
.	O

The	O
grade	O
of	O
hydronephrosis	B-T038
does	O
not	O
affect	O
pain	B-T201
intensity	I-T201
.	O

This	O
study	B-T062
suggests	O
normal	B-T033
pregnancy	I-T033
outcomes	B-T033
in	O
these	O
women	B-T098
.	O

Simulating	B-T062
the	O
potential	O
role	O
of	O
media	O
coverage	O
and	O
infected	B-T033
bats	B-T204
in	O
the	O
2014	O
Ebola	B-T038
outbreak	O

Multiple	O
epidemiological	O
models	O
have	O
been	O
developed	O
to	O
model	O
the	O
transmission	O
dynamics	O
of	O
Ebola	B-T038
virus	I-T038
(	I-T038
EBOV	I-T038
)	I-T038
disease	I-T038
in	O
West	B-T082
Africa	I-T082
in	O
2014	O
because	O
the	O
severity	O
of	O
the	O
epidemic	O
is	O
commonly	O
overestimated	O
.	O

A	O
compartmental	B-T170
model	I-T170
that	O
incorporates	O
the	O
media	O
impact	O
and	O
the	O
effect	O
of	O
infected	B-T033
bats	B-T204
was	O
constructed	O
and	O
calibrated	O
using	O
data	O
reported	O
until	O
the	O
end	O
of	O
2014	O
.	O

The	O
final	O
cumulative	O
number	O
of	O
deaths	O
and	O
confirmed	B-T033
cases	O
were	O
estimated	O
to	O
be	O
1	O
.	O
0921×10	O
(	O
4	O
)	O
(	O
95	O
%	O
CI	O
9	O
.	O
7706×10	O
(	O
3	O
)	O
-	O
1	O
.	O
2072×10	O
(	O
4	O
)	O
)	O
and	O
1	O
.	O
5193×10	O
(	O
4	O
)	O
(	O
95	O
%	O
CI	O
1	O
.	O
3593×10	O
(	O
4	O
)	O
-	O
1	O
.	O
6795×10	O
(	O
4	O
)	O
)	O
,	O
respectively	O
.	O

The	O
epidemic	O
was	O
estimated	O
to	O
end	O
on	O
June	O
2015	O
,	O
which	O
was	O
similar	O
to	O
the	O
data	O
reported	B-T058
by	O
the	O
World	B-T092
Health	I-T092
Organization	I-T092
.	O

A	O
sensitivity	B-T062
analysis	I-T062
indicated	B-T033
that	O
an	O
increase	O
of	O
either	O
the	O
media	O
impact	O
or	O
the	O
number	O
of	O
infectious	O
bats	B-T204
that	O
are	O
captured	O
daily	O
can	O
increase	O
the	O
cumulative	O
number	O
of	O
confirmed	B-T033
cases	O
/	O
deaths	O
.	O

Of	O
the	O
considered	O
epidemiological	O
parameters	O
,	O
only	O
the	O
media	O
coverage	O
can	O
significantly	O
reduce	O
both	O
the	O
peak	B-T033
time	I-T033
and	O
the	O
value	O
of	O
the	O
cumulative	O
confirmed	B-T033
cases	O
/	O
deaths	O
.	O

Thus	O
,	O
we	O
propose	O
'	O
the	O
cumulative	O
confirmed	B-T033
cases	O
and	O
deaths	O
'	O
as	O
another	O
media	B-T170
mechanism	O
.	O

In	O
conclusion	O
,	O
the	O
media	O
impact	O
contributed	O
to	O
the	O
control	O
of	O
the	O
2014	O
Ebola	B-T038
outbreak	O
,	O
and	O
infectious	O
bats	B-T204
may	O
be	O
a	O
potential	O
source	B-T033
of	O
the	O
epidemic	O
.	O

Body	B-T204
Diffusion	B-T058
Weighted	I-T058
Imaging	I-T058
Using	O
Non	B-T058
-	I-T058
CPMG	I-T058
Fast	I-T058
Spin	I-T058
Echo	I-T058

SS	B-T058
-	I-T058
FSE	I-T058
is	O
a	O
fast	O
technique	B-T058
that	O
does	O
not	O
suffer	O
from	O
off	B-T033
-	I-T033
resonance	I-T033
distortions	O
to	O
the	O
degree	O
that	O
EPI	B-T058
does	O
.	O

Unlike	O
EPI	B-T058
,	O
SS	B-T058
-	I-T058
FSE	I-T058
is	O
ill	O
-	O
suited	O
to	O
diffusion	B-T058
weighted	I-T058
imaging	I-T058
(	O
DWI	B-T058
)	O
due	O
to	O
the	O
Carr	B-T033
-	I-T033
Purcell	I-T033
-	I-T033
Meiboom	I-T033
-	I-T033
Geill	I-T033
(	I-T033
CPMG	I-T033
)	I-T033
condition	I-T033
.	O

Non	B-T033
-	I-T033
CPMG	I-T033
phase	O
cycling	O
does	O
accommodate	O
SS	B-T058
-	I-T058
FSE	I-T058
and	O
DWI	B-T058
but	O
places	B-T082
constraints	O
on	O
reconstruction	O
,	O
which	O
are	O
resolved	B-T033
here	O
through	O
parallel	B-T058
imaging	I-T058
.	O

Additionally	O
,	O
improved	B-T033
echo	O
stability	O
can	O
be	O
achieved	O
by	O
using	O
short	O
duration	O
and	O
highly	O
selective	O
DIVERSE	O
radiofrequency	O
pulses	O
.	O

Here	O
,	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
(	O
SNR	O
)	O
comparisons	O
between	O
EPI	B-T058
and	O
nCPMG	B-T033
SS	B-T058
-	I-T058
FSE	I-T058
acquisitions	O
and	O
reconstruction	O
techniques	O
give	O
similar	O
values	O
.	O

Diffusion	B-T058
imaging	I-T058
with	O
nCPMG	B-T033
SS	B-T058
-	I-T058
FSE	I-T058
gives	O
similar	O
SNR	O
to	O
an	O
EPI	B-T058
acquisition	O
,	O
though	O
apparent	O
diffusion	O
coefficient	O
values	O
are	O
higher	O
than	O
seen	O
with	O
EPI	B-T058
.	O

In	B-T082
vivo	I-T082
images	B-T170
have	O
good	O
image	O
quality	O
with	O
little	O
distortion	O
.	O

This	O
method	O
has	O
the	O
ability	O
to	O
capture	O
distortion	O
-	O
free	O
DWI	B-T058
images	B-T170
near	O
areas	B-T082
of	O
significant	O
off	B-T033
-	I-T033
resonance	I-T033
as	O
well	O
as	O
preserve	O
adequate	O
SNR	O
.	O

Parallel	B-T058
imaging	I-T058
and	O
DIVERSE	O
refocusing	O
RF	O
pulses	O
allow	O
shorter	O
ETL	O
compared	O
to	O
previous	O
implementations	O
and	O
thus	O
reduces	O
phase	O
encode	O
direction	B-T082
blur	O
and	O
SAR	B-T038
accumulation	B-T033
.	O

Modification	O
of	O
Mechanical	O
Properties	O
,	O
Polymerization	O
Temperature	O
,	O
and	O
Handling	O
Time	O
of	O
Polymethylmethacrylate	B-T103
Cement	B-T103
for	O
Enhancing	O
Applicability	O
in	O
Vertebroplasty	B-T058

Polymethylmethacrylate	B-T103
(	O
PMMA	B-T103
)	O
bone	B-T103
cement	I-T103
is	O
a	O
popular	O
bone	B-T017
void	B-T082
filler	B-T103
for	O
vertebroplasty	B-T058
.	O

However	O
,	O
the	O
use	O
of	O
PMMA	B-T103
has	O
some	O
drawbacks	O
,	O
including	O
the	O
material	B-T103
'	I-T103
s	I-T103
excessive	O
stiffness	O
,	O
exothermic	O
polymerization	O
,	O
and	O
short	O
handling	O
time	O
.	O

This	O
study	B-T062
aimed	O
to	O
create	O
an	O
ideal	O
modified	O
bone	B-T103
cement	I-T103
to	O
solve	O
the	O
above	O
-	O
mentioned	O
problems	B-T033
.	O

Modified	O
bone	B-T103
cements	I-T103
were	O
prepared	O
by	O
combining	O
PMMA	B-T103
with	O
three	O
different	O
volume	O
fractions	O
of	O
castor	B-T103
oil	I-T103
(	O
5	O
%	O
,	O
10	O
%	O
,	O
and	O
15	O
%	O
)	O
.	O

The	O
peak	O
polymerization	O
temperatures	O
,	O
times	O
to	O
achieve	O
the	O
peak	O
polymerization	O
temperature	O
,	O
porosities	O
,	O
densities	O
,	O
modulus	O
and	O
maximum	O
compression	O
strengths	O
of	O
standard	O
(	O
without	O
castor	B-T103
oil	I-T103
)	O
,	O
and	O
modified	O
cements	B-T103
were	O
investigated	O
following	O
storage	O
at	O
ambient	O
temperature	O
(	O
22°C	O
)	O
or	O
under	O
precooling	O
conditions	O
(	O
3°C	O
)	O
.	O

Six	O
specimens	O
were	O
tested	O
in	O
each	O
group	O
of	O
the	O
aforementioned	O
parameters	O
.	O

Increasing	O
castor	B-T103
oil	I-T103
content	O
and	O
precooling	O
treatment	O
effectively	O
decreased	O
the	O
peak	O
polymerization	O
temperatures	O
and	O
increased	O
the	O
duration	O
to	O
achieve	O
the	O
peak	O
polymerization	O
temperature	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
the	O
mechanical	O
properties	O
of	O
the	O
material	B-T103
,	O
including	O
density	O
,	O
modulus	O
,	O
and	O
maximum	O
compression	O
strength	O
,	O
decreased	O
with	O
increasing	O
castor	B-T103
oil	I-T103
content	O
.	O

However	O
,	O
preparation	O
temperature	O
(	O
room	O
temperature	O
versus	O
precooling	O
)	O
had	O
no	O
significant	O
effect	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
on	O
these	O
mechanical	O
properties	O
.	O

In	O
conclusion	O
,	O
the	O
addition	O
of	O
castor	B-T103
oil	I-T103
to	O
PMMA	B-T103
followed	O
by	O
precooling	O
created	O
an	O
ideal	O
modified	O
bone	B-T103
cement	I-T103
with	O
a	O
low	O
modulus	O
,	O
low	O
polymerization	O
temperature	O
,	O
and	O
long	O
handling	O
time	O
,	O
enhancing	O
its	O
applicability	O
and	O
safety	O
for	O
vertebroplasty	B-T058
.	O

A	O
case	O
of	O
retrograde	B-T017
intussusception	I-T017
at	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
anastomosis	I-T058
10	O
years	O
after	O
total	B-T058
gastrectomy	I-T058
:	O
review	B-T170
of	I-T170
the	I-T170
literature	I-T170

A	O
63	O
-	O
year	O
-	O
old	O
man	O
,	O
who	O
had	O
undergone	O
total	B-T058
gastrectomy	I-T058
and	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
reconstruction	I-T058
for	O
gastric	B-T038
cancer	I-T038
10	O
years	O
previously	O
,	O
was	O
admitted	B-T058
to	O
our	O
hospital	B-T092
with	O
complaints	O
of	O
abdominal	B-T033
pain	I-T033
,	O
palpable	O
abdominal	B-T038
tumor	I-T038
,	O
and	O
hematemesis	B-T033
.	O

On	B-T058
admission	I-T058
,	O
the	O
abdominal	B-T033
tenderness	I-T033
was	O
improving	O
and	O
no	O
abdominal	B-T038
tumor	I-T038
was	O
palpable	O
.	O

Mild	B-T038
inflammatory	I-T038
changes	O
and	O
anemia	B-T038
were	O
noted	O
on	O
blood	O
examination	O
.	O

Abdominal	B-T082
computed	B-T058
tomography	I-T058
revealed	O
a	O
tumor	B-T038
with	O
a	O
layered	O
structure	O
in	O
the	O
left	B-T082
abdomen	I-T082
.	O

The	O
patient	O
was	O
diagnosed	B-T033
with	O
intestinal	B-T038
obstruction	I-T038
secondary	O
to	O
intussusception	B-T038
,	O
and	O
surgery	B-T058
was	O
performed	O
.	O

Retrograde	B-T017
intussusception	I-T017
was	O
found	O
at	O
the	O
site	O
of	O
the	O
Y	B-T058
anastomosis	I-T058
.	O

We	O
conducted	O
manual	B-T058
reduction	I-T058
using	O
the	O
Hutchinson	B-T058
procedure	I-T058
.	O

The	O
intestinal	B-T017
color	O
after	O
the	O
reduction	B-T058
was	O
good	O
,	O
and	O
no	O
intestinal	B-T058
resection	I-T058
was	O
required	O
.	O

Postoperative	B-T033
recovery	I-T033
was	O
uneventful	O
,	O
and	O
the	O
patient	O
was	O
discharged	B-T058
12	O
days	O
after	O
surgery	B-T058
.	O

Reports	B-T170
of	O
jejunal	B-T017
intussusception	B-T038
after	O
total	B-T058
gastrectomy	I-T058
with	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
reconstruction	I-T058
are	O
relatively	O
rare	O
.	O

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
jejunal	B-T017
intussusception	B-T038
after	O
total	B-T058
gastrectomy	I-T058
with	O
Roux	B-T058
-	I-T058
en	I-T058
-	I-T058
Y	I-T058
reconstruction	I-T058
.	O

Brassinosteroid	B-T103
-	O
induced	O
changes	O
of	O
lipid	B-T103
composition	O
in	O
leaves	B-T204
of	O
Pisum	B-T204
sativum	I-T204
L	I-T204
.	I-T204
during	O
senescence	B-T038

The	O
effect	O
of	O
steroid	B-T103
phytohormone	B-T103
24	B-T103
-	I-T103
epibrassinolide	I-T103
(	O
EBR	B-T103
)	O
on	O
the	O
composition	O
of	O
some	O
lipid	B-T103
classes	B-T170
(	O
free	B-T103
fatty	I-T103
acids	I-T103
,	O
triacylglycerols	B-T103
and	O
galactolipids	B-T103
)	O
in	O
detached	O
pea	B-T204
leaves	B-T204
was	O
studied	O
for	O
the	O
first	O
time	O
.	O

EBR	B-T103
(	O
0	O
.	O
1μM	O
)	O
promoted	O
senescence	B-T038
and	O
increased	O
the	O
content	O
of	O
14	O
:	O
0	O
,	O
16	O
:	O
0	O
and	O
18	O
:	O
1	O
free	B-T103
fatty	I-T103
acids	I-T103
as	O
well	O
as	O
18	O
:	O
2	O
and	O
18	O
:	O
3	O
bound	O
to	O
triacylglycerols	B-T103
in	O
the	O
detached	O
leaves	B-T204
in	O
contrast	O
to	O
mock	B-T204
-	I-T204
treated	I-T204
leaves	I-T204
.	O

The	O
content	O
of	O
all	O
identified	O
fatty	B-T103
acids	I-T103
bound	O
to	O
galactolipids	B-T103
decreased	O
in	O
the	O
detached	O
leaves	B-T204
treated	O
with	O
EBR	B-T103
compared	O
to	O
that	O
in	O
mock	B-T204
-	I-T204
treated	I-T204
leaves	I-T204
.	O

These	O
findings	O
suggest	O
that	O
free	B-T103
fatty	I-T103
acids	I-T103
are	O
liberated	O
from	O
polar	O
lipids	B-T103
and	O
then	O
undergo	O
esterification	B-T038
to	O
neutral	B-T103
lipids	I-T103
in	O
the	O
detached	O
leaves	B-T204
upon	O
EBR	B-T103
treatment	O
.	O

We	O
propose	O
that	O
steroid	B-T103
phytohormones	B-T103
may	O
be	O
involved	O
into	O
regulation	B-T038
of	O
leaf	B-T204
senescence	B-T038
via	O
alteration	O
of	O
cell	B-T017
lipid	B-T103
composition	O
.	O

Posterior	B-T037
dislocation	I-T037
of	O
the	O
sternoclavicular	B-T082
joint	I-T082
:	O
report	B-T170
of	O
two	O
cases	O

The	O
authors	O
report	B-T170
the	O
cases	O
of	O
two	O
young	O
patients	O
who	O
had	O
suffered	O
a	O
sporting	B-T037
accident	I-T037
with	O
posterior	B-T037
traumatic	I-T037
dislocation	I-T037
of	O
sternoclavicular	B-T082
joint	I-T082
.	O

In	O
one	O
of	O
the	O
patients	O
closed	B-T058
reduction	I-T058
was	O
accomplished	O
by	O
keeping	O
the	O
limb	B-T017
in	O
a	O
sling	B-T074
.	O

The	O
second	O
patient	O
,	O
after	O
reduction	B-T058
was	O
done	O
,	O
presented	O
recurrence	O
of	O
the	O
dislocation	B-T037
,	O
thus	O
requiring	O
surgical	B-T058
treatment	I-T058
.	O

It	O
is	O
important	O
to	O
observe	O
the	O
relevance	O
of	O
computed	B-T058
tomography	I-T058
to	O
help	O
diagnosing	B-T062
,	O
as	O
well	O
as	O
monitoring	O
the	O
reduction	B-T058
procedure	I-T058
.	O

The	O
objective	O
of	O
this	O
study	B-T062
was	O
to	O
demonstrate	O
two	O
different	O
types	O
of	O
treatment	B-T058
in	O
a	O
rare	O
injury	B-T037
such	O
as	O
the	O
posterior	B-T037
dislocation	I-T037
of	O
sternoclavicular	B-T082
joint	I-T082
.	O

Using	O
a	O
graphical	O
risk	O
tool	O
to	O
examine	O
willingness	B-T033
to	I-T033
take	I-T033
migraine	B-T038
prophylactic	B-T058
medications	B-T103

Many	O
migraine	B-T038
sufferers	O
use	O
daily	O
prophylactic	B-T058
therapy	I-T058
to	O
reduce	O
the	O
frequency	O
of	O
their	O
headache	B-T033
attacks	O
.	O

The	O
Food	B-T092
and	I-T092
Drug	I-T092
Administration	I-T092
has	O
approved	O
several	O
different	O
medications	B-T103
for	O
migraine	B-T038
prophylaxis	B-T058
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
sufferers	O
perceive	O
these	O
treatments	B-T058
to	O
provide	O
clinically	O
significant	O
benefits	O
given	O
their	O
side	B-T038
effect	I-T038
profiles	B-T058
.	O

Three	O
hundred	O
headache	B-T033
sufferers	O
were	O
recruited	O
from	O
the	O
community	O
and	O
local	B-T082
headache	B-T033
clinics	B-T092
using	O
print	O
and	O
television	O
advertising	O
.	O

Participants	B-T098
reported	O
experiencing	O
problematic	O
headache	B-T033
attacks	O
with	O
a	O
median	O
(	O
IQR	O
)	O
frequency	O
of	O
7	O
.	O
0	O
(	O
4	O
-	O
13	O
)	O
headache	B-T033
days	O
per	O
month	O
.	O

These	O
sufferers	O
participated	O
in	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
,	I-T062
single	I-T062
-	I-T062
site	I-T062
,	I-T062
study	I-T062
that	O
used	O
a	O
specially	O
designed	O
computer	O
assessment	O
task	O
.	O

Participants	B-T098
were	O
instructed	O
on	O
the	O
probability	O
of	O
experiencing	O
the	O
3	O
most	O
commonly	O
experienced	O
side	B-T038
effects	I-T038
for	O
several	O
blinded	B-T062
medication	B-T103
profiles	B-T058
:	O
divalproex	B-T103
sodium	I-T103
,	O
venlafaxine	B-T103
,	O
gabapentin	B-T103
,	O
propranolol	B-T103
,	O
and	O
topiramate	B-T103
.	O

After	O
learning	O
the	O
likelihood	O
of	O
experiencing	O
side	B-T038
effect	I-T038
profiles	B-T058
of	O
each	O
medication	B-T103
,	O
participants	B-T098
were	O
asked	O
whether	O
they	O
would	O
be	O
willing	B-T033
to	I-T033
take	I-T033
the	O
medication	B-T103
for	O
a	O
given	O
headache	B-T033
reduction	O
level	O
,	O
which	O
ranged	O
from	O
0	O
to	O
7	O
days	O
per	O
month	O
.	O

The	O
side	B-T038
effect	I-T038
profile	B-T058
for	O
divalproex	B-T103
sodium	I-T103
was	O
associated	O
with	O
the	O
smallest	B-T033
willingness	I-T033
to	I-T033
take	I-T033
,	O
with	O
gabapentin	B-T103
,	O
propranolol	B-T103
,	O
and	O
topiramate	B-T103
perceived	O
to	O
be	O
much	O
more	O
agreeable	O
.	O

However	O
,	O
<	O
60	O
%	O
of	O
participants	B-T098
reported	O
willingness	B-T033
to	I-T033
take	I-T033
any	O
of	O
these	O
medications	B-T103
even	O
if	O
they	O
provided	O
a	O
50	O
%	O
reduction	O
in	O
headache	B-T033
frequency	O
.	O

Several	O
general	O
predictors	O
of	O
willingness	B-T033
to	I-T033
take	I-T033
were	O
observed	O
including	O
high	O
headache	B-T033
-	O
related	O
disability	B-T033
,	O
depressive	B-T033
symptoms	I-T033
,	O
and	O
pain	B-T103
medication	I-T103
concerns	O
including	O
fear	B-T038
of	O
tolerance	B-T038
.	O

These	O
findings	B-T033
suggest	O
that	O
if	O
properly	O
informed	O
of	O
the	O
side	B-T038
effect	I-T038
profiles	B-T058
of	O
these	O
medications	B-T103
,	O
many	O
patients	O
might	O
opt	O
for	O
other	O
treatments	B-T058
.	O

Genome	B-T062
-	I-T062
Wide	I-T062
Detection	I-T062
of	O
Selective	B-T038
Signatures	I-T038
in	O
Chicken	B-T204
through	O
High	B-T082
Density	I-T082
SNPs	I-T082

Chicken	B-T204
is	O
recognized	O
as	O
an	O
excellent	O
model	O
for	O
studies	O
of	O
genetic	O
mechanism	O
of	O
phenotypic	O
and	O
genomic	B-T017
evolution	B-T038
,	O
with	O
large	O
effective	O
population	O
size	O
and	O
strong	O
human	B-T204
-	O
driven	O
selection	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
performed	O
Extended	O
Haplotype	O
Homozygosity	O
(	O
EHH	O
)	O
tests	O
to	O
identify	O
significant	O
core	B-T082
regions	I-T082
employing	O
600K	O
SNP	B-T082
Chicken	B-T204
chip	B-T062
in	O
an	O
F2	O
population	O
of	O
1	O
,	O
534	O
hens	B-T204
,	O
which	O
was	O
derived	O
from	O
reciprocal	B-T058
crosses	I-T058
between	O
White	B-T204
Leghorn	I-T204
and	O
Dongxiang	B-T204
chicken	I-T204
.	O

Results	O
indicated	O
that	O
a	O
total	O
of	O
49	O
,	O
151	O
core	B-T082
regions	I-T082
with	O
an	O
average	O
length	O
of	O
9	O
.	O
79	O
Kb	O
were	O
identified	O
,	O
which	O
occupied	O
approximately	O
52	O
.	O
15	O
%	O
of	O
genome	B-T017
across	O
all	O
autosomes	B-T017
,	O
and	O
806	O
significant	O
core	B-T082
regions	I-T082
attracted	O
us	O
mostly	O
.	O

Genes	B-T017
in	O
candidate	B-T082
regions	I-T082
may	O
experience	O
positive	B-T058
selection	I-T058
and	O
were	O
considered	O
to	O
have	O
possible	O
influence	O
on	O
beneficial	O
economic	O
traits	O
.	O

A	O
panel	O
of	O
genes	B-T017
including	O
AASDHPPT	B-T017
,	O
GDPD5	B-T017
,	O
PAR3	B-T017
,	O
SOX6	B-T017
,	O
GPC1	B-T017
and	O
a	O
signal	B-T038
pathway	I-T038
of	O
AKT1	B-T017
were	O
detected	B-T033
with	O
the	O
most	O
extreme	O
P	O
-	O
values	O
.	O

Further	O
enrichment	B-T062
analyses	I-T062
indicated	O
that	O
these	O
genes	B-T017
were	O
associated	O
with	O
immune	B-T038
function	I-T038
,	O
sensory	B-T038
organ	I-T038
development	I-T038
and	O
neurogenesis	B-T038
,	O
and	O
may	O
have	O
experienced	O
positive	B-T058
selection	I-T058
in	O
chicken	B-T204
.	O

Moreover	O
,	O
some	O
of	O
core	B-T082
regions	I-T082
exactly	O
overlapped	O
with	O
genes	B-T017
excavated	O
in	O
our	O
previous	O
GWAS	B-T062
,	O
suggesting	O
that	O
these	O
genes	B-T017
have	O
undergone	O
positive	B-T058
selection	I-T058
may	O
affect	O
egg	B-T168
production	O
.	O

Findings	O
in	O
our	O
study	O
could	O
draw	O
a	O
comparatively	O
integrate	O
genome	B-T062
-	I-T062
wide	I-T062
map	I-T062
of	O
selection	B-T038
signature	I-T038
in	O
the	O
chicken	B-T204
genome	B-T017
,	O
and	O
would	O
be	O
worthy	O
for	O
explicating	O
the	O
genetic	O
mechanisms	O
of	O
phenotypic	O
diversity	O
in	O
poultry	B-T204
breeding	B-T038
.	O

High	O
-	O
Throughput	O
Genotyping	B-T058
with	O
TaqMan	B-T058
Allelic	I-T058
Discrimination	I-T058
and	O
Allele	B-T058
-	I-T058
Specific	I-T058
Genotyping	I-T058
Assays	I-T058

Real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
-	O
based	O
genotyping	B-T058
methods	I-T058
,	O
such	O
as	O
TaqMan	B-T058
allelic	I-T058
discrimination	I-T058
assays	I-T058
and	O
allele	B-T058
-	I-T058
specific	I-T058
genotyping	I-T058
,	O
are	O
particularly	O
useful	O
when	O
screening	B-T058
a	O
handful	O
of	O
single	B-T082
nucleotide	I-T082
polymorphisms	I-T082
in	O
hundreds	O
of	O
samples	O
;	O
either	O
derived	O
from	O
different	O
individuals	B-T098
,	O
tissues	B-T017
,	O
or	O
pre	O
-	O
amplified	B-T038
DNA	I-T038
.	O

Although	O
real	B-T062
-	I-T062
time	I-T062
PCR	I-T062
-	O
based	O
methods	B-T170
such	O
as	O
TaqMan	B-T058
are	O
well	O
-	O
established	O
,	O
alternative	O
methods	B-T170
,	O
like	O
allele	B-T058
-	I-T058
specific	I-T058
genotyping	I-T058
,	O
are	O
powerful	O
alternatives	O
,	O
especially	O
for	O
genotyping	B-T058
short	B-T103
tandem	I-T103
repeat	I-T103
(	B-T103
STR	I-T103
)	I-T103
length	O
polymorphisms	B-T038
.	O

Here	O
,	O
we	O
describe	O
all	O
relevant	O
aspects	O
when	O
developing	O
an	O
assay	B-T058
for	O
a	O
new	O
SNP	B-T082
or	O
STR	B-T103
using	O
either	O
TaqMan	B-T058
or	O
allele	B-T058
-	I-T058
specific	I-T058
genotyping	I-T058
,	O
respectively	O
,	O
such	O
as	O
primer	B-T103
and	O
probe	B-T103
design	O
,	O
optimization	O
of	O
reaction	O
conditions	O
,	O
the	O
experimental	B-T058
procedure	I-T058
for	I-T058
typing	I-T058
hundreds	O
of	O
samples	O
,	O
and	O
finally	O
the	O
data	O
evaluation	B-T058
.	O

Our	O
goal	B-T170
is	O
to	O
provide	O
a	O
guideline	B-T170
for	O
developing	O
genotyping	B-T058
assays	I-T058
using	O
these	O
two	O
approaches	O
that	O
render	O
reliable	O
and	O
reproducible	O
genotype	B-T058
calls	I-T058
involving	O
minimal	O
optimization	O
.	O

The	O
role	O
of	O
P2X7	B-T103
receptors	I-T103
in	O
a	O
rodent	B-T204
PCP	B-T103
-	O
induced	O
schizophrenia	B-T038
model	B-T038

P2X7	B-T103
receptors	I-T103
(	O
P2X7Rs	B-T103
)	O
are	O
ligand	B-T103
-	I-T103
gated	I-T103
ion	I-T103
channels	I-T103
sensitive	O
to	O
extracellular	B-T017
ATP	B-T103
.	O

Here	O
we	O
examined	B-T033
for	O
the	O
first	O
time	O
the	O
role	O
of	O
P2X7R	B-T103
in	O
an	O
animal	B-T204
model	I-T204
of	O
schizophrenia	B-T038
.	O

Using	O
the	O
PCP	B-T103
induced	O
schizophrenia	B-T038
model	B-T038
we	O
show	O
that	O
both	O
genetic	B-T038
deletion	I-T038
and	O
pharmacological	O
inhibition	O
of	O
P2X7Rs	B-T103
alleviate	O
schizophrenia	B-T033
-	I-T033
like	I-T033
behavioral	O
alterations	O
.	O

In	O
P2rx7	B-T017
+	I-T017
/	I-T017
+	I-T017
mice	B-T204
,	O
PCP	B-T103
induced	O
hyperlocomotion	B-T033
,	O
stereotype	B-T038
behavior	I-T038
,	O
ataxia	B-T033
and	O
social	B-T033
withdrawal	I-T033
.	O

In	O
P2X7	B-T017
receptor	I-T017
deficient	O
mice	B-T204
(	O
P2rx7	B-T017
-	I-T017
/	I-T017
-	I-T017
)	O
,	O
the	O
social	B-T033
interactions	I-T033
were	O
increased	O
,	O
whereas	O
the	O
PCP	B-T103
induced	O
hyperlocomotion	B-T033
and	O
stereotype	B-T038
behavior	I-T038
were	O
alleviated	O
.	O

The	O
selective	O
P2X7	B-T103
receptor	I-T103
antagonist	I-T103
JNJ	B-T103
-	I-T103
47965567	I-T103
partly	O
replicated	O
the	O
effect	O
of	O
gene	B-T038
deficiency	I-T038
on	O
PCP	B-T103
-	O
induced	O
behavioral	O
changes	O
and	O
counteracted	O
PCP	B-T103
-	O
induced	O
social	B-T033
withdrawal	I-T033
.	O

We	O
also	O
show	O
that	O
PCP	B-T103
treatment	O
upregulates	B-T038
and	O
increases	O
the	O
functional	O
responsiveness	O
of	O
P2X7Rs	B-T103
in	O
the	O
prefrontal	B-T017
cortex	I-T017
of	O
young	O
adult	O
animals	B-T204
.	O

The	O
amplitude	O
of	O
NMDA	B-T103
evoked	O
currents	O
recorded	O
from	O
layer	B-T017
V	I-T017
pyramidal	I-T017
neurons	I-T017
of	O
cortical	B-T017
slices	O
were	O
slightly	O
decreased	O
by	O
both	O
genetic	B-T038
deletion	I-T038
of	O
P2rx7	B-T017
and	O
by	O
JNJ	B-T103
-	I-T103
47965567	I-T103
.	O

PCP	B-T103
induced	O
alterations	O
in	O
mRNA	B-T038
expression	I-T038
encoding	O
schizophrenia	B-T038
-	I-T038
related	I-T038
genes	B-T017
,	O
such	O
as	O
NR2A	B-T017
,	O
NR2B	B-T017
,	O
neuregulin	B-T103
1	I-T103
,	O
NR1	B-T103
and	O
GABA	B-T103
α1	I-T103
subunit	O
were	O
absent	O
in	O
the	O
PFC	O
of	O
young	O
adult	O
P2rx7	B-T017
-	I-T017
/	I-T017
-	I-T017
animals	B-T038
.	O

Our	O
findings	B-T033
point	O
to	O
P2X7R	B-T103
as	O
a	O
potential	O
therapeutic	O
target	O
in	O
schizophrenia	B-T038
.	O

The	O
flavor	B-T168
and	O
nutritional	O
characteristic	O
of	O
four	O
strawberry	B-T168
varieties	O
cultured	O
in	O
soilless	O
system	O

Strawberry	B-T168
fruits	I-T168
(	O
cv	B-T168
.	I-T168

Benihoppe	I-T168
,	O
Tochiotome	B-T168
,	O
Sachinoka	B-T168
,	O
and	O
Guimeiren	B-T168
)	O
were	O
harvested	O
and	O
evaluated	O
the	O
flavor	B-T168
and	O
nutritional	O
parameters	O
.	O

By	O
principal	O
component	O
analysis	O
and	O
hierarchical	B-T062
clustering	I-T062
analysis	I-T062
,	O
differences	O
were	O
observed	O
based	O
on	O
the	O
volatile	B-T103
compounds	I-T103
composition	O
,	O
sugar	B-T103
and	O
acid	B-T103
concentration	O
,	O
sweetness	O
,	O
and	O
total	B-T103
soluble	I-T103
sugars	I-T103
/	O
total	B-T103
organic	I-T103
acids	I-T103
of	O
the	O
four	O
varieties	O
.	O

A	O
total	O
of	O
37	O
,	O
48	O
,	O
65	O
,	O
and	O
74	O
volatile	B-T103
compounds	I-T103
were	O
identified	O
and	O
determined	O
in	O
cv	B-T168
.	I-T168

Benihoppe	I-T168
,	O
Tochiotome	B-T168
,	O
Sachinoka	B-T168
,	O
and	O
Guimeiren	B-T168
strawberry	I-T168
fruits	I-T168
extracted	B-T058
by	O
head	B-T058
-	I-T058
space	I-T058
solid	I-T058
-	I-T058
phase	I-T058
microextraction	I-T058
(	O
HS	B-T058
-	I-T058
SPME	I-T058
)	O
,	O
respectively	O
.	O

Esters	B-T103
significantly	O
dominated	O
the	O
chemical	O
composition	O
of	O
the	O
four	O
varieties	O
.	O

Furaneol	B-T103
was	O
detected	O
in	O
cultivars	B-T204
of	O
Sachinoka	B-T168
and	O
Guimeiren	B-T168
,	O
but	O
mesifuran	B-T168
was	O
only	O
found	O
in	O
cv	B-T168
.	I-T168

Tochiotome	I-T168
.	O

Tochiotome	B-T168
and	O
Sachinoka	B-T168
showed	O
higher	O
content	O
of	O
linalool	B-T103
and	O
(	B-T103
E	I-T103
)	I-T103
-	I-T103
nerolidol	I-T103
.	O

Sachinoka	B-T168
showed	O
the	O
highest	O
content	O
of	O
total	B-T103
sugars	I-T103
and	O
total	B-T103
acids	I-T103
.	O

Guimeiren	B-T168
showed	O
higher	O
sweetness	O
index	B-T170
than	O
the	O
other	O
three	O
cultivars	B-T204
.	O

Firmness	O
of	O
Tochiotome	B-T168
was	O
highest	O
among	O
all	O
the	O
varieties	O
.	O

The	O
highest	O
total	O
soluble	O
solids	O
TSS	O
value	O
was	O
found	O
in	O
cv	B-T168
.	I-T168

Sachinoka	I-T168
,	O
followed	O
by	O
the	O
Guimeiren	B-T168
and	O
Tochiotome	B-T168
varieties	O
.	O

Sachinoka	B-T168
had	O
the	O
highest	O
titratable	B-T033
acidity	I-T033
TA	I-T033
value	I-T033
.	O

The	O
content	O
of	O
ascorbic	B-T103
acid	I-T103
(	O
AsA	B-T103
)	O
of	O
cv	B-T168
.	I-T168

Tochiotome	I-T168
was	O
higher	O
than	O
the	O
others	O
,	O
but	O
there	O
was	O
no	B-T033
significant	I-T033
difference	O
in	O
cultivars	B-T204
of	O
Benihoppe	B-T168
,	O
Tochiotome	B-T168
,	O
and	O
Sachinoka	B-T168
.	O

Fructose	B-T103
and	O
glucose	B-T103
were	O
the	O
major	O
sugars	B-T103
in	O
all	O
cultivars	B-T204
.	O

Citric	B-T103
acid	I-T103
was	O
the	O
major	O
organic	B-T103
acid	I-T103
in	O
cv	B-T168
.	I-T168

Tochiotome	I-T168
,	O
cv	B-T168
.	I-T168

Sachinoka	I-T168
,	O
and	O
cv	B-T168
.	I-T168

Guimeiren	I-T168
.	O

Tochiotome	B-T168
had	O
higher	O
ratios	O
of	O
TSS	O
/	O
TA	B-T033
and	O
total	B-T103
sugars	I-T103
/	O
total	B-T103
organic	I-T103
acids	I-T103
than	O
others	O
,	O
arising	O
from	O
its	O
lower	O
acid	B-T103
content	O
.	O

The	O
order	O
of	O
the	O
comprehensive	O
evaluation	O
score	O
was	O
Sachinoka	B-T168
>	O
Guimeiren	B-T168
>	O
Tochiotome	B-T168
>	O
Benihoppe	B-T168
.	O

Prognostic	O
value	O
of	O
GLUT	B-T103
-	I-T103
1	I-T103
expression	B-T038
in	O
oral	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
:	O
A	O
prisma	B-T170
-	I-T170
compliant	I-T170
meta	I-T170
-	I-T170
analysis	I-T170

A	O
variety	O
of	O
studies	B-T062
have	O
evaluated	B-T058
the	O
correlation	O
between	O
glucose	B-T103
transporter	I-T103
-	I-T103
1	I-T103
(	O
GLUT	B-T103
-	I-T103
1	I-T103
)	O
expression	B-T038
and	O
prognosis	B-T058
of	O
oral	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
OSCC	B-T038
)	O
;	O
however	O
,	O
the	O
results	O
were	O
inconsistent	O
and	O
inconclusive	O
.	O

A	O
meta	B-T062
-	I-T062
analysis	I-T062
was	O
performed	O
to	O
assess	O
the	O
prognostic	B-T170
significance	O
of	O
GLUT	B-T103
-	I-T103
1	I-T103
in	O
OSCC	B-T038
.	O

Electronic	O
databases	O
of	O
PubMed	B-T170
,	O
Embase	B-T170
,	O
and	O
Web	B-T170
of	I-T170
Science	I-T170
were	O
searched	O
for	O
relevant	B-T062
studies	I-T062
.	O

The	O
last	O
search	O
was	O
updated	O
on	O
July	O
2016	O
.	O

Odds	O
ratio	O
(	O
OR	O
)	O
and	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
were	O
pooled	O
to	O
evaluate	B-T058
the	O
relationship	O
between	O
GLUT	B-T103
-	I-T103
1	I-T103
and	O
clinical	B-T033
features	I-T033
and	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
95	O
%	O
CI	O
were	O
combined	O
to	O
measure	O
the	O
effect	O
of	O
GLUT	B-T103
-	I-T103
1	I-T103
on	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

P	O
value	O
<	O
0	O
.	O
05	O
was	O
considered	O
as	O
statistically	O
significant	O
.	O

A	O
total	O
of	O
13	O
studies	B-T062
with	O
1301	O
subjects	B-T098
were	O
included	O
for	O
meta	B-T062
-	I-T062
analysis	I-T062
.	O

The	O
pooled	O
data	O
showed	O
that	O
high	O
GLUT	B-T103
-	I-T103
1	I-T103
expression	B-T038
was	O
associated	O
with	O
advanced	B-T201
tumor	I-T201
stages	I-T201
(	O
n	O
=	O
7	O
,	O
OR	O
=	O
2	O
.	O
99	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
01	O
-	O
4	O
.	O
46	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
higher	B-T170
tumor	I-T170
grade	I-T170
(	O
n	O
=	O
5	O
,	O
OR	O
=	O
3	O
.	O
34	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
12	O
-	O
9	O
.	O
94	O
,	O
P	O
=	O
0	O
.	O
031	O
)	O
,	O
tumor	B-T082
size	I-T082
(	O
n	O
=	O
5	O
,	O
OR	O
=	O
3	O
.	O
36	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
04	O
-	O
5	O
.	O
51	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
lymph	B-T033
node	I-T033
metastasis	I-T033
(	O
n	O
=	O
5	O
,	O
OR	O
=	O
3	O
.	O
15	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
89	O
-	O
5	O
.	O
25	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
tobacco	O
use	O
(	O
n	O
=	O
3	O
,	O
OR	O
=	O
2	O
.	O
18	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
18	O
-	O
4	O
.	O
01	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
,	O
and	O
distant	B-T201
metastasis	I-T201
(	O
n	O
=	O
2	O
,	O
OR	O
=	O
3	O
.	O
06	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
19	O
-	O
7	O
.	O
9	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Furthermore	O
,	O
increased	O
GLUT	B-T103
-	I-T103
1	I-T103
expression	B-T038
was	O
also	O
correlated	O
with	O
shorter	O
OS	O
(	O
n	O
=	O
8	O
,	O
HR	O
=	O
1	O
.	O
88	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
51	O
-	O
2	O
.	O
33	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

No	O
significant	O
publication	O
bias	O
was	O
detected	B-T033
in	O
this	O
meta	B-T062
-	I-T062
analysis	I-T062
.	O

GLUT	B-T103
-	I-T103
1	I-T103
overexpression	B-T038
was	O
in	O
connection	O
with	O
aggressive	B-T033
clinical	I-T033
features	I-T033
and	O
worse	O
OS	O
in	O
OSCC	B-T038
.	O

However	O
,	O
further	O
studies	B-T062
are	O
still	O
needed	O
to	O
verify	O
whether	O
GLUT	B-T103
-	I-T103
1	I-T103
could	O
serve	O
as	O
a	O
prognostic	B-T170
biomarker	B-T201
for	O
OSCC	B-T038
.	O

Biogeography	O
and	O
Character	O
Evolution	B-T038
of	O
the	O
Ciliate	B-T204
Genus	B-T170
Euplotes	B-T204
(	O
Spirotrichea	B-T204
,	O
Euplotia	B-T204
)	O
,	O
with	O
Description	B-T170
of	O
Euplotes	B-T204
curdsi	I-T204
sp	I-T204
.	I-T204
nov	I-T204

Ciliates	B-T204
comprise	O
a	O
diverse	O
and	O
ecologically	O
important	O
phylum	B-T170
of	O
unicellular	O
protists	O
.	O

One	O
of	O
the	O
most	O
specious	O
and	O
best	O
-	O
defined	O
genera	B-T170
is	O
Euplotes	B-T204
,	O
which	O
constitutes	O
more	O
than	O
70	O
morphospecies	B-T170
,	O
many	O
of	O
which	O
have	O
never	O
been	O
molecularly	O
tested	O
.	O

The	O
increasing	O
number	O
of	O
described	O
Euplotes	B-T204
taxa	O
emphasizes	O
the	O
importance	O
for	O
detailed	O
characterizations	O
of	O
new	O
ones	O
,	O
requiring	O
standardized	O
morphological	B-T082
observations	B-T062
,	O
sequencing	O
of	O
molecular	B-T201
markers	I-T201
and	O
careful	O
comparison	O
with	O
previous	O
literature	B-T170
.	O

Here	O
we	O
describe	O
Euplotes	B-T204
curdsi	I-T204
sp	I-T204
.	I-T204

nov	I-T204
.	O
,	O
distinguishable	O
by	O
the	O
combination	O
of	O
the	O
following	O
features	O
:	O
45	O
-	O
65	O
μm	O
length	O
,	O
oval	O
or	O
elongated	O
shape	O
with	O
both	O
ends	O
rounded	O
,	O
narrow	O
peristome	O
with	O
25	O
-	O
34	O
adoral	O
membranelles	O
,	O
conspicuous	B-T017
paroral	I-T017
membrane	I-T017
,	O
double	O
-	O
eurystomus	O
dorsal	O
argyrome	O
type	O
,	O
6	O
-	O
7	O
dorsolateral	O
kineties	O
and	O
10	O
frontoventral	O
cirri	O
.	O

Three	O
populations	O
of	O
the	O
novel	O
species	B-T170
have	O
been	O
found	O
in	O
brackish	B-T103
and	O
marine	B-T082
samples	I-T082
in	O
the	O
Mediterranean	B-T082
and	O
the	O
White	B-T082
Sea	I-T082
.	O

We	O
provide	O
the	O
SSU	B-T017
rRNA	I-T017
gene	I-T017
sequences	B-T017
of	O
these	O
populations	O
,	O
and	O
an	O
updated	O
phylogeny	O
of	O
the	O
genus	B-T170
Euplotes	B-T204
.	O

Using	O
the	O
molecular	O
phylogenetic	O
tree	O
,	O
we	O
inferred	O
aspects	O
of	O
the	O
biogeographical	O
history	O
of	O
the	O
genus	B-T170
and	O
the	O
evolution	B-T038
of	O
its	O
most	O
important	O
taxonomic	O
characters	O
in	O
order	O
to	O
provide	O
a	O
frame	O
for	O
future	O
descriptions	B-T170
.	O

Ultimately	O
,	O
these	O
data	O
reveal	O
recurrent	O
trends	O
of	O
freshwater	O
invasion	O
and	O
highlight	O
the	O
dynamic	O
,	O
yet	O
convergent	O
,	O
morphological	B-T082
evolution	B-T038
of	O
Euplotes	B-T204
.	O

Comparative	B-T062
Effectiveness	I-T062
of	O
Treatments	B-T058
for	O
Chronic	B-T038
Low	I-T038
Back	I-T038
Pain	I-T038
:	O
A	O
Multiple	B-T062
Treatment	I-T062
Comparison	I-T062
Analysis	I-T062

A	O
systematic	B-T170
review	I-T170
and	O
network	B-T062
meta	I-T062
-	I-T062
analysis	I-T062
.	O

To	O
determine	O
current	B-T058
treatment	I-T058
options	I-T058
of	O
chronic	B-T038
low	I-T038
back	I-T038
pain	I-T038
(	O
LBP	B-T038
)	O
as	O
defined	O
by	O
randomized	B-T062
controlled	I-T062
trials	I-T062
(	O
RCTs	B-T062
)	O
and	O
to	O
compare	O
effectiveness	O
of	O
those	O
treatments	B-T058
using	O
a	O
mixed	B-T062
-	I-T062
treatment	I-T062
comparison	I-T062
(	O
MTC	B-T062
)	O
.	O

It	O
is	O
important	O
to	O
provide	O
an	O
evidence	O
-	O
based	O
assessment	B-T058
of	O
the	O
treatment	B-T058
options	I-T058
that	O
exist	O
for	O
LBP	B-T038
.	O

A	O
systematic	B-T062
search	I-T062
of	O
RCTs	B-T062
was	O
conducted	O
in	O
MEDLINE	B-T170
and	O
the	O
Cochrane	B-T092
Collaboration	I-T092
Library	I-T092
from	O
1990	O
to	O
2014	O
.	O

From	O
the	O
selected	B-T062
studies	I-T062
,	O
we	O
extracted	O
preoperative	O
and	O
postoperative	O
ODI	B-T033
and	O
VAS	O
back	O
pain	O
scores	O
,	O
additional	B-T058
surgeries	I-T058
,	O
and	O
complications	B-T038
.	O

Standard	B-T062
and	I-T062
network	I-T062
meta	I-T062
-	I-T062
analytic	I-T062
techniques	I-T062
were	O
used	O
.	O

Twelve	O
RCTs	B-T062
were	O
included	O
in	O
the	O
analysis	B-T062
:	O
5	O
total	B-T058
disk	I-T058
replacement	I-T058
(	O
TDR	B-T058
)	O
versus	O
fusion	B-T058
;	O
1	O
TDR	B-T058
versus	O
exercise	B-T058
and	O
cognitive	B-T058
behavioral	I-T058
therapy	I-T058
(	O
CBT	B-T058
)	O
;	O
5	O
fusion	B-T058
versus	O
exercise	B-T058
and	O
CBT	B-T058
;	O
and	O
1	O
fusion	B-T058
versus	O
physical	B-T058
therapy	I-T058
(	O
PT	B-T058
)	O
.	O

On	O
the	O
basis	O
of	O
MTC	B-T062
,	O
with	O
respect	O
to	O
ODI	B-T033
change	I-T033
scores	I-T033
,	O
the	O
pooled	O
mean	O
difference	O
favoring	O
fusion	B-T058
over	O
exercise	B-T058
and	O
CBT	B-T058
was	O
2	O
.	O
0	O
points	O
(	O
95	O
%	O
CI	O
,	O
-	O
1	O
.	O
2	O
to	O
4	O
.	O
8	O
)	O
.	O

The	O
pooled	O
mean	O
difference	O
favoring	O
TDR	B-T058
over	O
exercise	B-T058
and	O
CBT	B-T058
was	O
6	O
.	O
4	O
points	O
(	O
95	O
%	O
CI	O
,	O
3	O
.	O
2	O
-	O
9	O
.	O
3	O
)	O
.	O

The	O
pooled	O
mean	O
difference	O
favoring	O
fusion	B-T058
over	O
PT	B-T058
was	O
8	O
.	O
8	O
points	O
(	O
95	O
%	O
CI	O
,	O
4	O
.	O
1	O
-	O
13	O
.	O
6	O
)	O
.	O

The	O
pooled	O
mean	O
differences	O
favoring	O
TDR	B-T058
over	O
fusion	B-T058
was	O
4	O
.	O
4	O
points	O
(	O
95	O
%	O
CI	O
,	O
2	O
.	O
37	O
-	O
6	O
.	O
63	O
)	O
.	O

For	O
PT	B-T058
versus	O
structured	B-T058
exercise	I-T058
with	O
CBT	B-T058
,	O
the	O
pooled	O
mean	O
difference	O
favoring	O
exercise	B-T058
with	O
CBT	B-T058
over	O
PT	B-T058
was	O
6	O
.	O
8	O
points	O
(	O
95	O
%	O
CI	O
,	O
1	O
.	O
5	O
-	O
12	O
.	O
8	O
)	O
.	O

For	O
TDR	B-T058
versus	O
PT	B-T058
,	O
the	O
pooled	O
mean	O
difference	O
favoring	O
TDR	B-T058
over	O
PT	B-T058
was	O
13	O
.	O
2	O
points	O
(	O
95	O
%	O
CI	O
,	O
8	O
.	O
0	O
-	O
18	O
.	O
4	O
)	O
.	O

Additional	O
surgery	O
rates	O
were	O
similar	O
between	O
treatment	B-T058
options	I-T058
.	O

All	O
4	O
treatments	B-T058
provided	O
some	O
benefit	O
to	O
patients	O
with	O
chronic	B-T038
LBP	I-T038
.	O

According	O
to	O
the	O
MTC	B-T062
analysis	I-T062
,	O
TDR	B-T058
may	O
be	O
the	O
most	O
effective	O
treatment	B-T058
and	O
PT	B-T058
the	O
least	O
effective	O
treatment	B-T058
for	O
chronic	B-T038
LBP	I-T038
.	O

This	O
review	B-T170
is	O
based	O
on	O
a	O
limited	O
number	O
of	O
RCT	B-T062
studies	I-T062
and	O
does	O
not	O
support	O
any	O
1	O
treatment	B-T058
modality	O
for	O
all	O
patients	O
.	O

A	O
Novel	O
Selective	O
Inhibitor	B-T103
of	O
Delta	B-T103
-	I-T103
5	I-T103
Desaturase	I-T103
Lowers	O
Insulin	B-T038
Resistance	I-T038
and	O
Reduces	B-T033
Body	I-T033
Weight	I-T033
in	O
Diet	B-T168
-	O
Induced	O
Obese	B-T038
C57BL	B-T204
/	I-T204
6J	I-T204
Mice	I-T204

Obesity	B-T038
is	O
now	O
recognized	O
as	O
a	O
state	O
of	O
chronic	O
low	O
-	O
grade	O
inflammation	B-T038
and	O
is	O
called	O
as	O
metabolic	O
inflammation	B-T038
.	O

Delta	B-T103
-	I-T103
5	I-T103
desaturase	I-T103
(	O
D5D	B-T103
)	O
is	O
an	O
enzyme	B-T103
that	O
metabolizes	O
dihomo	B-T103
-	I-T103
γ	I-T103
-	I-T103
linolenic	I-T103
acid	I-T103
(	O
DGLA	B-T103
)	O
to	O
arachidonic	B-T103
acid	I-T103
(	O
AA	B-T103
)	O
.	O

Thus	O
,	O
D5D	B-T103
inhibition	B-T038
increases	O
DGLA	B-T103
(	O
precursor	O
to	O
anti	O
-	O
inflammatory	O
eicosanoids	B-T103
)	O
while	O
decreasing	O
AA	B-T103
(	O
precursor	O
to	O
pro	O
-	O
inflammatory	O
eicosanoids	B-T103
)	O
,	O
and	O
could	O
result	O
in	O
synergistic	O
improvement	O
in	O
the	O
low	O
-	O
grade	O
inflammatory	O
state	O
.	O

Here	O
,	O
we	O
demonstrate	O
reduced	O
insulin	B-T038
resistance	I-T038
and	O
the	O
anti	B-T103
-	I-T103
obesity	I-T103
effect	O
of	O
a	O
D5D	B-T103
selective	O
inhibitor	O
(	O
compound	B-T103
-	I-T103
326	I-T103
)	O
,	O
an	O
orally	B-T082
active	O
small	B-T103
-	I-T103
molecule	I-T103
,	O
in	O
a	O
high	B-T168
-	I-T168
fat	I-T168
diet	I-T168
-	O
induced	O
obese	B-T204
(	I-T204
DIO	I-T204
)	I-T204
mouse	I-T204
model	B-T038
.	O

In	O
vivo	O
D5D	B-T103
inhibition	B-T038
was	O
confirmed	O
by	O
determining	O
changes	O
in	O
blood	B-T031
AA	B-T103
/	O
DGLA	B-T103
profiles	O
.	O

In	O
DIO	B-T204
mice	I-T204
,	O
chronic	O
treatment	O
with	O
compound	B-T103
-	I-T103
326	I-T103
lowered	O
insulin	B-T038
resistance	I-T038
and	O
caused	O
body	B-T033
weight	I-T033
loss	I-T033
without	O
significant	O
impact	O
on	O
cumulative	O
calorie	O
intake	O
.	O

Decreased	O
macrophage	B-T033
infiltration	I-T033
into	I-T033
adipose	I-T033
tissue	I-T033
was	O
expected	O
from	O
mRNA	B-T058
analysis	I-T058
.	O

Increased	O
daily	O
energy	B-T038
expenditure	I-T038
was	O
also	O
observed	O
following	O
administration	B-T058
of	O
compound	B-T103
-	I-T103
326	I-T103
,	O
in	O
line	O
with	O
sustained	O
body	B-T033
weight	I-T033
loss	I-T033
.	O

These	O
data	O
indicate	O
that	O
the	O
novel	O
D5D	B-T103
selective	O
inhibitor	B-T103
,	O
compound	B-T103
-	I-T103
326	I-T103
,	O
will	O
be	O
a	O
new	O
class	O
of	O
drug	O
for	O
the	O
treatment	O
of	O
obese	B-T038
and	O
diabetic	B-T038
patients	O
.	O

Blood	B-T074
Collection	I-T074
Tubes	I-T074
and	O
Storage	O
Temperature	O
Should	O
Be	O
Evaluated	O
when	O
Using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
for	O
Measuring	B-T058
25	I-T058
-	I-T058
Hydroxyvitamin	I-T058
D	I-T058

A	O
significant	O
bias	O
was	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
for	O
measurement	B-T058
of	I-T058
25	I-T058
-	I-T058
hydroxyvitamin	I-T058
D	I-T058
(	O
25OHD	B-T103
)	O
with	O
VACUETTE®	B-T074
tubes	I-T074
with	I-T074
Serum	I-T074
Clot	I-T074
Activator	I-T074
and	I-T074
Gel	I-T074
.	O

Here	O
,	O
we	O
examined	O
whether	O
other	O
commonly	O
used	O
tubes	B-T074
or	O
temperatures	O
affected	O
25OHD	B-T058
results	I-T058
obtained	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

Serum	B-T031
was	O
collected	O
into	O
five	O
types	O
of	O
vacuum	B-T074
blood	I-T074
collection	I-T074
tubes	I-T074
from	O
three	O
manufacturers	O
,	O
and	O
25OHD	B-T058
was	I-T058
analyzed	I-T058
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
and	O
liquid	B-T058
chromatography	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
(	O
LC	B-T058
-	I-T058
MS	I-T058
/	I-T058
MS	I-T058
)	O
immediately	O
or	O
after	O
storage	O
at	O
4°C	O
or	O
-	O
80°C	O
for	O
48	O
h	O
.	O

Significantly	O
higher	O
25OHD	B-T058
values	I-T058
were	O
found	O
when	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
with	O
VACUETTE®	B-T074
tubes	I-T074
with	I-T074
serum	I-T074
clot	I-T074
activator	I-T074
and	I-T074
gel	I-T074
and	O
VACUETTE®	B-T074
tubes	I-T074
with	I-T074
clot	I-T074
activator	I-T074
but	O
no	O
gel	O
compared	O
with	O
VACUETTE®	B-T074
tubes	I-T074
with	O
no	O
additives	O
.	O

The	O
25OHD	B-T058
values	I-T058
in	O
all	O
of	O
these	O
tubes	O
were	O
not	O
significantly	O
different	O
from	O
those	O
obtained	O
by	O
LC	B-T058
-	I-T058
MS	I-T058
/	I-T058
MS	I-T058
.	O

Moreover	O
,	O
after	O
storage	O
at	O
-	O
80°C	O
for	O
48	O
h	O
,	O
the	O
values	O
obtained	O
in	O
IMPROVEVACUTER®	B-T074
tubes	I-T074
with	I-T074
serum	I-T074
clot	I-T074
activator	I-T074
and	I-T074
ge	I-T074
l	O
significantly	O
increased	O
,	O
with	O
a	O
mean	O
bias	O
of	O
74	O
.	O
6	O
%	O
compared	O
with	O
the	O
values	O
before	O
storage	O
,	O
on	O
analysis	O
with	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

VACUETTE®	B-T074
tubes	I-T074
containing	O
additives	O
significantly	O
affect	O
the	O
accuracy	O
of	O
25OHD	B-T058
results	I-T058
obtained	O
using	O
the	O
Siemens	O
ADVIA	O
Centaur	O
XP	O
system	O
.	O

Additionally	O
,	O
the	O
composition	O
of	O
serum	B-T031
collected	O
in	O
IMPROVEVACUTER®	B-T074
tubes	I-T074
was	O
affected	O
by	O
freezing	O
,	O
resulting	O
in	O
different	O
measurements	O
when	O
using	O
the	O
Siemens	O
25OHD	B-T103
assay	O
platform	O
.	O

Evolution	B-T038
of	O
Fitness	O
Cost	B-T033
-	I-T033
Neutral	I-T033
Mutant	B-T038
PfCRT	B-T103
Conferring	O
P	B-T204
.	I-T204
falciparum	I-T204
4	B-T103
-	I-T103
Aminoquinoline	I-T103
Drug	B-T038
Resistance	I-T038
Is	O
Accompanied	O
by	O
Altered	O
Parasite	B-T204
Metabolism	B-T038
and	O
Digestive	B-T017
Vacuole	I-T017
Physiology	B-T091

Southeast	B-T082
Asia	I-T082
is	O
an	O
epicenter	O
of	O
multidrug	O
-	O
resistant	O
Plasmodium	B-T204
falciparum	I-T204
strains	I-T204
.	O

Selective	O
pressures	O
on	O
the	O
subcontinent	O
have	O
recurrently	O
produced	O
several	O
allelic	B-T017
variants	B-T017
of	O
parasite	B-T204
drug	B-T038
resistance	I-T038
genes	B-T017
,	O
including	O
the	O
P	B-T017
.	I-T017

falciparum	I-T017
chloroquine	I-T017
resistance	I-T017
transporter	I-T017
(	O
pfcrt	B-T017
)	O
.	O

Despite	O
significant	O
reductions	B-T058
in	O
the	O
deployment	O
of	O
the	O
4	B-T103
-	I-T103
aminoquinoline	I-T103
drug	B-T103
chloroquine	B-T103
(	O
CQ	B-T103
)	O
,	O
which	O
selected	O
for	O
the	O
mutant	B-T017
pfcrt	B-T017
alleles	B-T017
that	O
halted	O
CQ	B-T103
efficacy	O
decades	O
ago	O
,	O
the	O
parasite	B-T204
pfcrt	B-T017
locus	B-T082
is	O
continuously	O
evolving	O
.	O

This	O
is	O
highlighted	O
by	O
the	O
presence	O
of	O
a	O
highly	O
mutated	B-T038
allele	B-T017
,	O
Cam734	B-T017
pfcrt	I-T017
,	O
which	O
has	O
acquired	O
the	O
singular	O
ability	O
to	O
confer	O
parasite	B-T204
CQ	B-T103
resistance	B-T038
without	O
an	O
associated	O
fitness	O
cost	O
.	O

Here	O
,	O
we	O
used	O
pfcrt	B-T017
-	O
specific	O
zinc	B-T103
-	I-T103
finger	I-T103
nucleases	I-T103
to	O
genetically	O
dissect	O
this	O
allele	B-T017
in	O
the	O
pathogenic	B-T033
setting	O
of	O
asexual	B-T038
blood	I-T038
-	I-T038
stage	I-T038
infection	I-T038
.	O

Comparative	O
analysis	O
of	O
drug	B-T038
resistance	I-T038
and	O
growth	B-T038
profiles	O
of	O
recombinant	B-T204
parasites	I-T204
that	O
express	B-T038
Cam734	B-T017
or	O
variants	B-T017
thereof	O
,	O
Dd2	B-T017
(	O
the	O
most	O
common	O
Southeast	B-T082
Asian	I-T082
variant	B-T017
)	O
,	O
or	O
wild	B-T017
-	I-T017
type	I-T017
pfcrt	B-T017
,	O
revealed	O
previously	O
unknown	O
roles	O
for	O
PfCRT	B-T103
mutations	B-T038
in	O
modulating	O
parasite	B-T204
susceptibility	O
to	O
multiple	O
antimalarial	B-T103
agents	I-T103
.	O

These	O
results	O
were	O
generated	O
in	O
the	O
GC03	B-T017
strain	O
,	O
used	O
in	O
multiple	O
earlier	O
pfcrt	B-T017
studies	B-T062
,	O
and	O
might	O
differ	O
in	O
natural	O
isolates	O
harboring	O
this	O
allele	B-T017
.	O

Results	O
presented	O
herein	O
show	O
that	O
Cam734	B-T017
-	O
mediated	O
CQ	B-T103
resistance	B-T038
is	O
dependent	O
on	O
the	O
rare	O
A144F	B-T038
mutation	B-T038
that	O
has	O
not	O
been	O
observed	O
beyond	O
Southeast	B-T082
Asia	I-T082
,	O
and	O
reveal	O
distinct	O
impacts	O
of	O
this	O
and	O
other	O
Cam734	B-T017
-	O
specific	O
mutations	B-T038
on	O
CQ	B-T103
resistance	B-T038
and	O
parasite	B-T204
growth	O
rates	O
.	O

Biochemical	B-T058
assays	I-T058
revealed	O
a	O
broad	O
impact	O
of	O
mutant	B-T038
PfCRT	B-T103
isoforms	B-T103
on	O
parasite	B-T204
metabolism	B-T038
,	O
including	O
nucleoside	O
triphosphate	O
levels	O
,	O
hemoglobin	B-T038
catabolism	I-T038
and	O
disposition	O
of	O
heme	B-T103
,	O
as	O
well	O
as	O
digestive	B-T017
vacuole	I-T017
volume	O
and	O
pH	O
.	O

Results	O
from	O
our	O
study	O
provide	O
new	O
insights	O
into	O
the	O
complex	B-T170
molecular	I-T170
basis	I-T170
and	O
physiological	O
impact	O
of	O
PfCRT	B-T103
-	O
mediated	O
antimalarial	B-T103
drug	B-T038
resistance	I-T038
,	O
and	O
inform	O
ongoing	O
efforts	O
to	O
characterize	O
novel	O
pfcrt	B-T017
alleles	B-T017
that	O
can	O
undermine	O
the	O
efficacy	O
of	O
first	O
-	O
line	O
antimalarial	B-T103
drug	I-T103
regimens	B-T058
.	O

Effect	O
of	O
nutritionally	B-T033
induced	I-T033
hyperlipidaemia	B-T038
on	O
in	O
vitro	O
bovine	B-T204
embryo	B-T017
quality	O
depends	O
on	O
the	O
type	O
of	O
major	O
fatty	B-T103
acid	I-T103
in	O
the	O
diet	B-T168

The	O
present	O
study	B-T062
examined	B-T033
whether	O
the	O
effects	O
of	O
dietary	B-T168
-	O
induced	O
hyperlipidaemia	B-T038
on	O
preimplantation	B-T038
embryo	I-T038
development	I-T038
depend	O
on	O
the	O
predominant	O
fatty	B-T103
acid	I-T103
(	O
FA	B-T103
)	O
type	O
in	O
the	O
diet	B-T168
.	O

In	O
a	O
combined	O
in	B-T082
vivo	I-T082
-	O
in	O
vitro	O
bovine	B-T204
model	B-T204
,	O
two	O
groups	O
of	O
cows	B-T204
(	O
n	O
=	O
3	O
in	O
each	O
group	O
)	O
were	O
fed	O
with	O
three	O
diets	B-T168
consecutively	O
(	O
4	O
weeks	O
feeding	O
for	O
each	O
)	O
:	O
(	O
1	O
)	O
a	O
maintenance	B-T168
control	I-T168
diet	I-T168
(	O
CONT	B-T168
)	O
;	O
(	O
2	O
)	O
a	O
high	O
-	O
starch	B-T168
diet	B-T168
rich	O
in	O
saturated	B-T168
fat	I-T168
(	O
SAT	B-T168
)	O
;	O
and	O
(	O
3	O
)	O
a	O
high	O
-	O
starch	B-T168
diet	B-T168
rich	O
in	O
omega	B-T103
-	I-T103
3	I-T103
unsaturated	B-T103
fat	I-T103
(	O
UNSAT	B-T103
)	O
.	O

Two	O
feeding	O
sequences	O
were	O
used	O
to	O
test	O
for	O
carry	O
-	O
over	O
effects	O
:	O
Group	O
A	O
was	O
fed	O
CONT	B-T168
,	O
SAT1	B-T168
and	O
then	O
UNSAT2	B-T103
,	O
whereas	O
Group	O
B	O
was	O
fed	O
CONT	B-T168
,	O
UNSAT1	B-T103
and	O
then	O
SAT2	B-T168
.	O

Serum	B-T031
was	O
collected	O
after	O
each	O
dietary	B-T168
period	O
,	O
analysed	B-T062
and	O
tested	O
in	O
bovine	B-T204
in	O
vitro	O
embryo	B-T058
culture	I-T058
.	O

Introducing	O
SAT	B-T168
and	O
UNSAT	B-T103
diets	B-T168
induced	O
hyperlipidaemia	B-T038
(	O
specifically	O
hypercholesterolaemia	B-T038
and	O
elevated	O
free	B-T103
FAs	I-T103
)	O
and	O
reduced	O
insulin	B-T038
sensitivity	I-T038
.	O

Carry	O
-	O
over	O
effects	O
in	O
serum	B-T031
metabolites	B-T103
and	O
FA	B-T058
profile	I-T058
were	O
dependent	O
on	O
the	O
diet	B-T168
and	O
feeding	O
sequence	O
.	O

SAT1	B-T168
and	O
SAT2	B-T168
serum	B-T031
decreased	O
blastocyst	B-T017
rates	O
and	O
altered	O
blastocyst	B-T017
mRNA	B-T038
expression	I-T038
related	O
to	O
apoptosis	B-T038
and	O
oxidative	B-T038
stress	I-T038
.	O

UNSAT1	B-T103
and	O
UNSAT2	B-T103
serum	B-T031
resulted	O
in	O
normal	O
embryo	B-T017
development	O
and	O
quality	O
.	O

Other	O
in	O
vitro	O
effects	O
depended	O
on	O
the	O
sequence	O
of	O
feeding	O
.	O

In	O
conclusion	O
,	O
substitution	O
of	O
saturated	B-T168
fat	I-T168
with	O
omega	B-T103
-	I-T103
3	I-T103
fat	I-T103
in	O
a	O
high	B-T058
-	I-T058
caloric	I-T058
diet	I-T058
induced	O
hyperlipidaemia	B-T038
with	O
an	O
FA	B-T058
profile	I-T058
yielding	O
similar	O
rates	O
and	O
quality	O
of	O
blastocysts	B-T017
compared	O
with	O
normolipidaemic	O
controls	O
.	O

Draft	B-T082
Genome	I-T082
Sequence	I-T082
of	O
the	O
Soil	O
Isolate	B-T103
Lysinibacillus	B-T007
fusiformis	I-T007
M5	I-T007
,	O
a	O
Potential	O
Hypoxanthine	B-T103
Producer	O

Lysinibacillus	B-T007
fusiformis	I-T007
strain	I-T007
M5	I-T007
is	O
a	O
potential	O
hypoxanthine	B-T103
producer	O
that	O
was	O
isolated	B-T103
from	O
clay	B-T103
soil	O
.	O

Here	O
,	O
we	O
present	O
the	O
draft	B-T082
genome	I-T082
sequence	I-T082
that	O
was	O
annotated	B-T062
in	O
order	O
to	O
facilitate	O
future	O
studies	B-T062
of	O
L	B-T007
.	I-T007

fusiformis	I-T007
M5	I-T007
.	I-T007

Impact	O
of	O
Clinical	B-T062
Trial	I-T062
Results	B-T033
on	O
the	O
Temporal	O
Trends	O
of	O
Carotid	B-T058
Endarterectomy	I-T058
and	O
Stenting	B-T058
From	O
2002	O
to	O
2014	O

Randomized	B-T062
trials	I-T062
provide	O
conflicting	O
data	O
for	O
the	O
efficacy	O
of	O
carotid	B-T058
-	I-T058
artery	I-T058
stenting	I-T058
compared	O
with	O
endarterectomy	B-T058
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
impact	O
of	O
conflicting	O
clinical	B-T170
trial	I-T170
publications	I-T170
on	O
the	O
utilization	O
rates	O
of	O
carotid	B-T058
revascularization	I-T058
procedures	I-T058
.	O

We	O
conducted	O
a	O
population	B-T062
-	I-T062
level	I-T062
time	I-T062
-	I-T062
series	I-T062
analysis	I-T062
of	O
all	O
individuals	B-T098
who	O
underwent	O
carotid	B-T058
endarterectomy	I-T058
and	O
stenting	B-T058
in	O
Ontario	B-T082
,	O
Canada	B-T082
(	O
2002	O
-	O
2014	O
)	O
.	O

The	O
primary	B-T062
analysis	I-T062
examined	O
temporal	O
changes	O
in	O
the	O
rates	O
of	O
carotid	B-T058
revascularization	I-T058
procedures	I-T058
after	O
publications	B-T170
of	O
major	O
randomized	B-T062
trials	I-T062
.	O

Secondary	O
analyses	O
examined	O
changes	O
in	O
overall	O
and	O
age	O
,	O
sex	O
,	O
carotid	B-T033
-	I-T033
artery	I-T033
symptom	I-T033
,	O
and	O
operator	O
specialty	O
-	O
specific	O
procedure	O
rates	O
.	O

A	O
total	O
of	O
16	O
772	O
patients	O
were	O
studied	O
(	O
14	O
394	O
endarterectomy	B-T058
[	O
86	O
%	O
]	O
;	O
2378	O
stenting	B-T058
[	O
14	O
%	O
]	O
)	O
.	O

The	O
overall	O
rate	O
of	O
carotid	B-T058
revascularization	I-T058
decreased	O
from	O
6	O
.	O
0	O
procedures	B-T058
per	O
100	O
000	O
individuals	B-T098
≥40	O
years	O
old	O
in	O
April	O
2002	O
to	O
4	O
.	O
3	O
procedures	B-T058
in	O
the	O
first	O
quarter	O
of	O
2014	O
(	O
29	O
%	O
decrease	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
rate	O
of	O
endarterectomy	B-T058
decreased	O
by	O
36	O
%	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
whereas	O
the	O
rate	O
of	O
carotid	B-T058
-	I-T058
artery	I-T058
stenting	I-T058
increased	O
by	O
72	O
%	O
(	O
P	O
=	O
0	O
.	O
006	O
)	O
.	O

We	O
observed	O
a	O
marked	O
increase	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
in	O
stenting	B-T058
after	O
publication	B-T170
of	O
the	O
SAPPHIRE	B-T062
trial	I-T062
(	O
Stenting	B-T062
and	I-T062
Angioplasty	I-T062
With	I-T062
Protection	I-T062
in	I-T062
Patients	I-T062
at	I-T062
High	I-T062
Risk	I-T062
for	I-T062
Endarterectomy	I-T062
)	O
in	O
2004	O
,	O
whereas	O
stenting	B-T058
remained	O
relatively	O
unchanged	B-T033
after	O
subsequent	O
randomized	B-T062
trials	I-T062
published	O
in	O
2006	O
(	O
P	O
=	O
0	O
.	O
11	O
)	O
and	O
2010	O
(	O
P	O
=	O
0	O
.	O
34	O
)	O
.	O

In	O
contrast	O
,	O
endarterectomy	B-T058
decreased	O
after	O
trials	O
published	O
in	O
2006	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
and	O
2010	O
(	O
P	O
=	O
0	O
.	O
005	O
)	O
.	O

Although	O
the	O
overall	O
rates	O
of	O
carotid	B-T058
revascularization	I-T058
and	O
endarterectomy	B-T058
have	O
fallen	O
since	O
2002	O
,	O
the	O
rate	O
of	O
carotid	B-T058
-	I-T058
artery	I-T058
stenting	I-T058
has	O
risen	O
since	O
the	O
publication	B-T170
of	O
stenting	B-T058
-	O
favorable	O
SAPPHIRE	B-T062
trial	I-T062
.	O

Subsequent	O
conflicting	O
randomized	B-T062
trials	I-T062
were	O
associated	O
with	O
a	O
decreasing	B-T033
rate	I-T033
of	O
carotid	B-T058
endarterectomy	I-T058
.	O

Electronic	O
tongues	O
to	O
assess	O
wine	B-T168
sensory	O
descriptors	B-T170

This	O
work	O
reports	B-T170
the	O
application	O
of	O
an	O
electronic	O
tongue	O
as	O
a	O
tool	O
towards	O
the	O
analysis	B-T062
of	O
wine	B-T168
in	O
tasks	O
such	O
as	O
its	O
discrimination	O
based	O
on	O
the	O
maturing	O
in	O
barrels	O
or	O
the	O
prediction	O
of	O
the	O
global	O
scores	O
assigned	O
by	O
a	O
sensory	B-T097
panel	I-T097
.	O

To	O
this	O
aim	O
,	O
red	B-T168
wine	I-T168
samples	O
were	O
first	O
analysed	B-T062
with	O
the	O
voltammetric	O
sensor	O
array	O
,	O
without	O
performing	O
any	O
sample	O
pretreatment	O
.	O

Afterwards	O
,	O
obtained	O
responses	O
were	O
preprocessed	O
employing	O
fast	B-T170
Fourier	I-T170
transform	I-T170
(	O
FFT	B-T170
)	O
for	O
the	O
compression	O
and	O
reduction	O
of	O
signal	O
complexity	O
,	O
and	O
obtained	O
coefficients	O
were	O
then	O
used	O
as	O
inputs	O
to	O
build	O
the	O
qualitative	O
and	O
quantitative	O
models	O
employing	O
either	O
linear	B-T062
discriminant	I-T062
analysis	I-T062
(	O
LDA	B-T062
)	O
or	O
partial	B-T170
least	I-T170
squares	I-T170
regression	I-T170
(	O
PLS	B-T170
)	O
,	O
respectively	O
.	O

Satisfactory	O
results	O
were	O
obtained	O
overall	O
,	O
with	O
a	O
classification	B-T170
rate	O
of	O
100	O
%	O
in	O
the	O
discrimination	O
of	O
the	O
type	O
of	O
barrel	O
used	O
during	O
wine	B-T168
maturing	O
,	O
a	O
normalized	O
NRMSE	O
of	O
0	O
.	O
077	O
in	O
the	O
estimation	O
of	O
ageing	B-T038
time	O
(	O
months	O
)	O
or	O
0	O
.	O
11	O
in	O
the	O
prediction	O
of	O
the	O
scores	O
(	O
0	O
-	O
10	O
)	O
from	O
a	O
trained	B-T097
sensory	I-T097
panel	I-T097
(	O
all	O
for	O
the	O
external	O
test	O
subset	B-T170
)	O
.	O

Toward	O
optimizing	O
dental	B-T074
implant	I-T074
performance	O
:	O
Surface	B-T082
characterization	O
of	O
Ti	B-T103
and	O
TiZr	B-T103
implant	B-T103
materials	I-T103

Targeting	O
understanding	O
enhanced	O
osseointegration	B-T038
kinetics	O
,	O
the	O
goal	B-T170
of	O
this	O
study	B-T062
was	O
to	O
characterize	O
the	O
surface	B-T082
morphology	O
and	O
composition	B-T201
of	O
Ti	B-T103
and	O
TiZr	B-T103
dental	B-T074
implant	I-T074
substrates	O
subjected	O
to	O
one	O
of	O
two	O
surface	B-T082
treatments	O
developed	O
by	O
Straumann	O
.	O

These	O
two	O
treatments	O
are	O
typically	O
known	O
as	O
SLA	B-T074
and	O
SLActive	B-T074
,	O
with	O
the	O
latter	O
resulting	O
in	O
more	O
rapid	O
osseointegration	B-T038
.	O

A	O
range	O
of	O
techniques	O
was	O
applied	O
to	O
characterize	O
four	O
different	O
substrate	B-T082
/	O
surface	B-T082
treatment	O
combinations	O
(	O
TiSLA	B-T074
,	O
TiSLActive	B-T074
,	O
TiZrSLA	B-T074
,	O
and	O
TiZrSLActive	B-T074
)	O
.	O

Contact	O
angle	B-T082
measurements	O
establish	O
establish	O
their	O
hydrophilic	O
/	O
hydrophobic	O
nature	O
.	O

Surface	B-T082
morphology	O
was	O
probed	O
with	O
scanning	B-T058
electron	I-T058
microscopy	I-T058
.	O

X	B-T058
-	I-T058
ray	I-T058
diffraction	I-T058
,	O
Raman	B-T058
μ	I-T058
-	I-T058
spectroscopy	I-T058
,	O
and	O
X	B-T058
-	I-T058
ray	I-T058
photoelectron	I-T058
spectroscopy	I-T058
were	O
used	O
to	O
elucidate	O
the	O
composition	B-T201
of	O
the	O
near	O
-	O
surface	B-T082
region	O
.	O

Consistent	O
with	O
previous	O
work	O
,	O
surface	B-T082
morphology	O
was	O
found	O
to	O
differ	O
only	O
at	O
the	O
nanoscale	O
,	O
with	O
both	O
SLActive	B-T074
substrates	O
displaying	O
nano	O
-	O
protrusions	B-T017
.	O

Spectroscopic	B-T058
data	O
indicate	O
that	O
all	O
substrates	O
exhibit	O
surface	B-T082
films	O
of	O
titanium	B-T103
oxide	I-T103
displaying	O
near	O
TiO2	B-T103
stoichiometry	O
.	O

Raman	B-T058
μ	I-T058
-	I-T058
spectroscopy	I-T058
reveals	O
that	O
amorphous	O
TiO2	B-T103
is	O
most	O
likely	O
the	O
only	O
phase	O
present	B-T033
on	O
TiSLA	B-T074
,	O
whilst	O
rutile	B-T103
-	O
TiO2	B-T103
is	O
also	O
evidenced	O
on	O
TiSLActive	B-T074
,	O
TiZrSLA	B-T074
,	O
and	O
TiZrSLActive	B-T074
.	O

For	O
TiZr	B-T103
alloy	B-T103
substrates	O
,	O
there	O
is	O
no	O
evidence	O
of	O
discrete	O
phases	O
of	O
oxidized	B-T038
Zr	B-T103
.	O

X	B-T058
-	I-T058
ray	I-T058
photoelectron	I-T058
spectra	I-T058
demonstrate	O
that	O
all	O
samples	O
are	O
terminated	O
by	O
adventitious	O
carbon	B-T103
,	O
with	O
it	O
being	O
somewhat	O
thicker	O
(	O
∼1nm	O
)	O
on	O
TiSLA	B-T074
and	O
TiZrSLA	B-T074
.	O

Given	O
previous	O
in	O
vivo	O
studies	O
,	O
acquired	O
data	O
suggest	O
that	O
both	O
nanoscale	O
protrusions	B-T017
,	O
and	O
a	O
thinner	O
layer	O
of	O
adventitious	O
carbon	B-T103
contribute	O
to	O
the	O
more	O
rapid	O
osseointegration	B-T038
of	O
SLActive	B-T074
dental	B-T074
implants	I-T074
.	O

Composition	B-T201
of	O
the	O
surface	B-T082
oxide	B-T103
layer	O
is	O
apparently	O
less	O
important	O
in	O
determining	O
osseointegration	B-T038
kinetics	O
.	O

Cocaine	B-T103
Use	O
Reverses	O
Striatal	B-T038
Plasticity	I-T038
Produced	O
During	O
Cocaine	B-T103
Seeking	O

Relapse	O
is	O
a	O
two	O
-	O
component	O
process	O
consisting	O
of	O
a	O
highly	O
motivated	B-T038
drug	O
-	O
seeking	O
phase	O
that	O
,	O
if	O
successful	O
,	O
is	O
followed	O
by	O
a	O
drug	B-T038
-	I-T038
using	I-T038
phase	O
resulting	O
in	O
temporary	O
satiation	B-T038
.	O

In	O
rodents	B-T204
,	O
cue	O
-	O
induced	O
drug	O
seeking	O
requires	O
transient	B-T038
synaptic	I-T038
potentiation	I-T038
(	O
t	B-T038
-	I-T038
SP	I-T038
)	O
of	O
cortical	B-T082
glutamatergic	I-T082
synapses	I-T082
on	O
nucleus	B-T017
accumbens	I-T017
core	B-T082
medium	B-T017
spiny	I-T017
neurons	I-T017
,	O
but	O
it	O
is	O
unknown	O
how	O
achieving	O
drug	B-T038
use	I-T038
affects	B-T038
this	O
plasticity	B-T038
.	O

We	O
modeled	O
the	O
two	O
phases	O
of	O
relapse	O
after	O
extinction	B-T038
from	O
cocaine	B-T103
self	B-T058
-	I-T058
administration	I-T058
to	O
assess	O
how	O
cocaine	B-T103
use	O
affects	B-T038
t	B-T038
-	I-T038
SP	I-T038
associated	O
with	O
cue	O
-	O
induced	O
drug	O
seeking	O
.	O

Rats	B-T204
were	O
trained	O
to	O
self	B-T058
-	I-T058
administer	I-T058
cocaine	B-T103
(	O
n	O
=	O
96	O
)	O
or	O
were	O
used	O
as	O
yoked	O
-	O
saline	O
control	B-T204
animals	I-T204
(	O
n	O
=	O
21	O
)	O
.	O

After	O
extinction	B-T038
,	O
reinstatement	O
was	O
initiated	O
by	O
10	O
minutes	O
of	O
cue	O
-	O
induced	O
drug	O
seeking	O
,	O
followed	O
by	O
45	O
minutes	O
with	O
contingent	O
cocaine	B-T103
access	O
,	O
after	O
which	O
cocaine	B-T103
was	O
discontinued	B-T033
and	O
unreinforced	B-T033
lever	I-T033
pressing	I-T033
ensued	I-T033
.	O

Three	O
measures	O
of	O
t	B-T038
-	I-T038
SP	I-T038
were	O
assayed	B-T058
during	O
reinstatement	O
:	O
dendritic	B-T017
spine	I-T017
morphology	O
,	O
alpha	B-T103
-	I-T103
amino	I-T103
-	I-T103
3	I-T103
-	I-T103
hydroxy	I-T103
-	I-T103
5	I-T103
-	I-T103
methyl	I-T103
-	I-T103
4	I-T103
-	I-T103
isoxazole	I-T103
propionic	I-T103
acid	I-T103
(	O
AMPA	B-T103
)	O
to	O
N	B-T103
-	I-T103
methyl	I-T103
-	I-T103
D	I-T103
-	I-T103
aspartate	I-T103
(	O
NMDA	B-T103
)	O
ratios	O
,	O
and	O
matrix	B-T103
metalloproteinase	I-T103
activity	B-T038
.	O

We	O
found	B-T033
that	O
cocaine	B-T103
use	O
for	O
10	O
minutes	O
collapsed	O
all	O
three	O
measures	O
of	O
cue	O
-	O
potentiated	O
t	B-T038
-	I-T038
SP	I-T038
back	O
to	O
baseline	O
.	O

Moreover	O
,	O
when	O
cocaine	B-T103
use	O
was	O
discontinued	B-T033
45	O
minutes	O
later	O
,	O
dendritic	B-T017
spine	I-T017
morphology	O
and	O
AMPA	B-T103
to	O
NMDA	B-T103
ratios	O
were	O
restored	O
as	O
animals	B-T204
became	O
motivated	B-T038
to	O
engage	O
unrewarded	O
lever	B-T033
pressing	I-T033
.	O

Nonreinforced	O
drug	O
seeking	O
was	O
positively	B-T033
correlated	O
with	O
changes	O
in	O
spine	B-T017
morphology	O
,	O
and	O
cocaine	B-T103
access	O
reversed	O
this	O
relationship	O
.	O

Using	O
a	O
novel	O
modification	O
of	O
the	O
reinstatement	O
paradigm	O
,	O
we	O
show	O
that	O
achieving	O
cocaine	B-T103
use	O
reversed	O
the	O
synaptic	O
plasticity	O
underpinning	O
the	O
motivation	B-T038
to	O
seek	O
the	O
drug	B-T103
.	O

Delicaflavone	B-T103
induces	O
autophagic	B-T038
cell	I-T038
death	I-T038
in	O
lung	B-T038
cancer	I-T038
via	O
Akt	B-T038
/	O
mTOR	B-T038
/	O
p70S6K	B-T103
signaling	B-T038
pathway	I-T038

Searching	O
for	O
potential	O
anticancer	B-T103
agents	I-T103
from	O
natural	B-T033
sources	I-T033
is	O
an	O
effective	O
strategy	O
for	O
developing	O
novel	O
chemotherapeutic	B-T103
agents	I-T103
.	O

In	O
this	O
study	B-T062
,	O
data	O
supporting	O
the	O
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
anticancer	B-T033
effects	I-T033
of	O
delicaflavone	B-T103
,	O
a	O
rarely	O
occurring	O
biflavonoid	B-T103
from	O
Selaginella	B-T204
doederleinii	I-T204
,	O
were	O
reported	O
.	O

Delicaflavone	B-T103
exhibited	O
favorable	O
anticancer	B-T033
properties	O
,	O
as	O
shown	O
by	O
the	O
MTT	B-T062
assay	I-T062
and	O
xenograft	B-T038
model	I-T038
of	O
human	B-T204
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
in	O
male	O
BALB	B-T204
/	I-T204
c	I-T204
nude	I-T204
mice	I-T204
without	O
observable	O
adverse	B-T038
effect	I-T038
.	O

By	O
transmission	B-T058
electron	I-T058
microscopy	I-T058
with	O
acridine	B-T103
orange	I-T103
and	O
Cyto	B-T038
-	I-T038
ID®Autophagy	I-T038
detection	O
dyes	B-T103
,	O
Western	B-T058
blot	I-T058
analysis	B-T062
,	O
and	O
RT	B-T062
-	I-T062
PCR	I-T062
assay	I-T062
,	O
we	O
confirmed	O
that	O
delicaflavone	B-T103
induces	O
autophagic	B-T038
cell	I-T038
death	I-T038
by	O
increasing	O
the	O
ratio	O
of	O
LC3	B-T103
-	I-T103
II	I-T103
to	O
LC3	B-T103
-	I-T103
I	I-T103
,	O
which	O
are	O
autophagy	B-T103
-	I-T103
related	I-T103
proteins	I-T103
,	O
and	O
promoting	O
the	O
generation	O
of	O
acidic	B-T017
vesicular	I-T017
organelles	I-T017
and	O
autolysosomes	B-T017
in	O
the	O
cytoplasm	B-T017
of	O
human	O
lung	B-T038
cancer	I-T038
A549	B-T017
and	O
PC	B-T017
-	I-T017
9	I-T017
cells	I-T017
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
.	O

Delicaflavone	B-T103
downregulated	B-T038
the	O
expression	B-T033
of	I-T033
phospho	I-T033
-	I-T033
Akt	I-T033
,	O
phospho	B-T103
-	I-T103
mTOR	I-T103
,	O
and	O
phospho	B-T103
-	I-T103
p70S6K	I-T103
in	O
a	O
time	O
-	O
and	O
dose	O
-	O
dependent	O
manner	O
,	O
suggesting	O
that	O
it	O
induced	O
autophagy	B-T038
by	O
inhibiting	O
the	O
Akt	B-T038
/	O
mTOR	B-T038
/	O
p70S6K	B-T103
pathway	B-T038
in	O
A549	B-T017
and	O
PC	B-T017
-	I-T017
9	I-T017
cells	I-T017
.	O

Delicaflavone	B-T103
is	O
a	O
potential	O
anticancer	B-T103
agent	I-T103
that	O
can	O
induce	O
autophagic	B-T038
cell	I-T038
death	I-T038
in	O
human	B-T204
non	B-T038
-	I-T038
small	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
via	O
the	O
Akt	B-T038
/	O
mTOR	B-T038
/	O
p70S6K	B-T103
signaling	B-T038
pathway	I-T038
.	O

Delicaflavone	B-T103
showed	O
anti	B-T033
-	I-T033
lung	I-T033
cancer	I-T033
effects	I-T033
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

Delicaflavone	B-T103
induced	O
autophagic	B-T038
cell	I-T038
death	I-T038
via	O
Akt	B-T038
/	O
mTOR	B-T038
/	O
p70S6K	B-T103
signaling	B-T038
pathway	I-T038
.	O

Delicaflavone	B-T103
did	O
not	O
show	O
observable	O
side	B-T038
effects	I-T038
in	O
a	O
xenograft	B-T038
mouse	I-T038
model	I-T038
.	O

Delicaflavone	B-T103
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
lung	B-T038
cancer	I-T038
.	O

Delicaflavone	B-T103
showed	O
anti	B-T033
-	I-T033
lung	I-T033
cancer	I-T033
effects	I-T033
in	O
vitro	O
and	O
in	B-T082
vivo	I-T082
.	O

Delicaflavone	B-T103
induced	O
autophagic	B-T038
cell	I-T038
death	I-T038
via	O
Akt	B-T038
/	O
mTOR	B-T038
/	O
p70S6K	B-T103
signaling	B-T038
pathway	I-T038
.	O

Delicaflavone	B-T103
did	O
not	O
show	O
observable	O
side	B-T038
effects	I-T038
in	O
a	O
xenograft	B-T038
mouse	I-T038
model	I-T038
.	O

Delicaflavone	B-T103
may	O
represent	O
a	O
potential	O
therapeutic	O
agent	O
for	O
lung	B-T038
cancer	I-T038
.	O

Determinants	O
of	O
On	O
-	O
Road	O
Driving	O
in	O
Multiple	B-T038
Sclerosis	I-T038

To	O
investigate	O
the	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	B-T033
deficits	I-T033
underlying	O
poor	O
performance	O
on	O
different	O
dimensions	B-T033
of	O
on	O
-	O
road	O
driving	O
in	O
individuals	B-T098
with	O
multiple	B-T038
sclerosis	I-T038
(	O
MS	B-T038
)	O
.	O

Prospective	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
.	O

MS	B-T092
clinic	I-T092
and	O
driving	O
simulator	B-T062
lab	B-T092
.	O

Active	B-T098
drivers	I-T098
(	O
N	O
=	O
102	O
)	O
with	O
various	O
types	O
of	O
MS	B-T038
.	O

Not	O
applicable	O
.	O

Off	O
-	O
road	O
cognitive	O
,	O
visual	O
,	O
and	O
motor	B-T038
functions	I-T038
,	O
as	O
well	O
as	O
13	O
specific	O
driving	O
skills	O
.	O

These	O
skills	O
were	O
categorized	O
into	O
hierarchic	B-T062
clusters	I-T062
of	O
operational	O
,	O
tactical	O
,	O
visuo	O
-	O
integrative	O
,	O
and	O
mixed	O
driving	O
.	O

Stepwise	B-T170
regression	I-T170
analysis	I-T170
was	O
used	O
to	O
determine	O
the	O
off	O
-	O
road	O
functions	O
influencing	O
performance	O
on	O
the	O
on	O
-	O
road	O
test	O
and	O
each	O
cluster	O
.	O

Visuospatial	O
function	O
(	O
P	O
=	O
.	O
002	O
)	O
,	O
inhibition	B-T038
(	O
P	O
=	O
.	O
008	O
)	O
,	O
binocular	B-T033
acuity	I-T033
(	O
P	O
=	O
.	O
04	O
)	O
,	O
vertical	B-T058
visual	I-T058
field	I-T058
(	O
P	O
=	O
.	O
02	O
)	O
,	O
and	O
stereopsis	B-T038
(	O
P	O
=	O
.	O
03	O
)	O
best	O
determined	O
variance	O
in	O
total	O
on	O
-	O
road	O
score	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=	O
.	O
37	O
)	O
.	O

Attentional	B-T033
shift	I-T033
(	O
P	O
=	O
.	O
0004	O
)	O
,	O
stereopsis	B-T038
(	O
P	O
=	O
.	O
007	O
)	O
,	O
glare	B-T058
recovery	I-T058
(	O
P	O
=	O
.	O
047	O
)	O
,	O
and	O
use	O
of	O
assistive	B-T074
devices	I-T074
(	O
P	O
=	O
.	O
03	O
)	O
best	O
predicted	O
the	O
operational	B-T062
cluster	I-T062
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=	O
.	O
28	O
)	O
.	O

Visuospatial	O
function	O
(	O
P	O
=	O
.	O
002	O
)	O
,	O
inhibition	B-T038
(	O
P	O
=	O
.	O
002	O
)	O
,	O
reasoning	B-T038
(	O
P	O
=	O
.	O
003	O
)	O
,	O
binocular	B-T033
acuity	I-T033
(	O
P	O
=	O
.	O
04	O
)	O
,	O
and	O
stereopsis	B-T038
(	O
P	O
=	O
.	O
005	O
)	O
best	O
determined	O
the	O
tactical	B-T062
cluster	I-T062
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=	O
.	O
41	O
)	O
.	O

The	O
visuo	B-T170
-	I-T170
integrative	I-T170
mode	I-T170
l	O
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=	O
.	O
12	O
)	O
comprised	O
binocular	B-T033
acuity	I-T033
(	O
P	O
=	O
.	O
007	O
)	O
and	O
stereopsis	B-T038
(	O
P	O
=	O
.	O
045	O
)	O
.	O

Inhibition	B-T038
(	O
P	O
=	O
.	O
0001	O
)	O
and	O
binocular	B-T033
acuity	I-T033
(	O
P	O
=	O
.	O
001	O
)	O
provided	O
the	O
best	O
model	B-T170
of	O
the	O
mixed	B-T062
cluster	I-T062
(	O
unadjusted	O
R	O
(	O
2	O
)	O
=	O
.	O
25	O
)	O
.	O

Our	O
results	O
provide	O
more	O
insights	O
into	O
the	O
specific	O
impairments	O
that	O
influence	O
different	O
dimensions	O
of	O
on	O
-	O
road	O
driving	O
and	O
may	O
be	O
used	O
as	O
a	O
framework	O
for	O
targeted	O
driving	O
intervention	O
programs	O
in	O
MS	B-T038
.	O

Netarsudil	B-T103
Increases	O
Outflow	B-T058
Facility	I-T058
in	O
Human	B-T204
Eyes	B-T017
Through	O
Multiple	O
Mechanisms	O

Netarsudil	B-T103
is	O
a	O
Rho	B-T103
kinase	I-T103
/	I-T103
norepinephrine	I-T103
transporter	I-T103
inhibitor	I-T103
currently	O
in	O
phase	B-T062
3	I-T062
clinical	I-T062
development	I-T062
for	O
glaucoma	B-T038
treatment	B-T058
.	O

We	O
investigated	O
the	O
effects	O
of	O
its	O
active	O
metabolite	B-T103
,	O
netarsudil	B-T103
-	I-T103
M1	I-T103
,	O
on	O
outflow	B-T058
facility	I-T058
(	O
C	B-T058
)	O
,	O
outflow	O
hydrodynamics	O
,	O
and	O
morphology	O
of	O
the	O
conventional	O
outflow	O
pathway	O
in	O
enucleated	O
human	O
eyes	O
.	O

Paired	O
human	B-T204
eyes	B-T017
(	O
n	O
=	O
5	O
)	O
were	O
perfused	B-T058
with	O
either	O
0	O
.	O
3	O
μM	O
netarsudil	B-T103
-	I-T103
M1	I-T103
or	O
vehicle	B-T103
solution	I-T103
at	O
constant	O
pressure	O
(	O
15	O
mm	O
Hg	O
)	O
.	O

After	O
3	O
hours	O
,	O
fluorescent	B-T074
microspheres	I-T074
were	O
added	O
to	O
perfusion	B-T058
media	B-T103
to	O
trace	O
the	O
outflow	O
patterns	O
before	O
perfusion	B-T058
-	O
fixation	B-T058
.	O

The	O
percentage	O
effective	O
filtration	O
length	O
(	O
PEFL	O
)	O
was	O
calculated	O
from	O
the	O
measured	O
lengths	O
of	O
tracer	B-T103
distribution	O
in	O
the	O
trabecular	B-T017
meshwork	I-T017
(	O
TM	B-T017
)	O
,	O
episcleral	B-T017
veins	I-T017
(	O
ESVs	B-T017
)	O
,	O
and	O
along	O
the	O
inner	O
wall	O
(	O
IW	O
)	O
of	O
Schlemm	B-T082
'	I-T082
s	I-T082
canal	I-T082
after	O
global	O
and	O
confocal	B-T058
imaging	I-T058
.	O

Morphologic	B-T017
changes	I-T017
along	O
the	O
trabecular	B-T017
outflow	O
pathway	O
were	O
investigated	O
by	O
confocal	B-T058
,	O
light	B-T058
,	O
and	O
electron	B-T058
microscopy	I-T058
.	O

Perfusion	B-T058
with	O
netarsudil	B-T103
-	I-T103
M1	I-T103
significantly	O
increased	O
C	B-T058
when	O
compared	O
to	O
baseline	O
(	O
51	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
to	O
paired	O
controls	O
(	O
102	O
%	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
as	O
well	O
as	O
significantly	O
increased	O
PEFL	O
in	O
both	O
IW	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
ESVs	B-T017
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
treated	O
eyes	B-T017
,	O
PEFL	O
was	O
significantly	O
higher	O
in	O
ESVs	B-T017
than	O
in	O
the	O
IW	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
and	O
was	O
associated	O
with	O
increased	O
cross	B-T082
-	I-T082
sectional	I-T082
area	I-T082
of	O
ESVs	B-T017
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Percentage	O
effective	O
filtration	O
length	O
in	O
ESVs	B-T017
positively	O
correlated	O
with	O
the	O
percentage	O
change	O
in	O
C	B-T058
(	O
R2	O
=	O
0	O
.	O
58	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

A	O
significant	O
increase	O
in	O
juxtacanalicular	B-T017
connective	I-T017
tissue	I-T017
(	O
JCT	B-T017
)	O
thickness	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
was	O
found	O
in	O
treated	O
eyes	B-T017
compared	O
to	O
controls	O
.	O

Netarsudil	B-T103
acutely	O
increased	O
C	B-T058
by	O
expansion	O
of	O
the	O
JCT	B-T017
and	O
dilating	O
the	O
ESVs	B-T017
,	O
which	O
led	O
to	O
redistribution	O
of	O
aqueous	O
outflow	O
through	O
a	O
larger	B-T082
area	I-T082
of	O
the	O
IW	O
and	O
ESVs	B-T017
.	O

Geographical	O
Factors	O
Associated	O
With	O
Health	B-T033
Disparities	I-T033
in	O
Prostate	B-T038
Cancer	I-T038

Treatment	B-T058
variation	O
in	O
prostate	B-T038
cancer	I-T038
is	O
common	O
,	O
and	O
it	O
is	O
driven	O
by	O
clinical	O
and	O
clinician	B-T097
factors	O
,	O
patient	O
preferences	O
,	O
availability	O
of	O
resources	O
,	O
and	O
access	B-T082
to	O
physicians	B-T097
and	O
treating	B-T092
facilities	I-T092
.	O

Most	O
research	B-T062
on	O
treatment	B-T058
disparities	O
in	O
men	B-T098
with	O
prostate	B-T038
cancer	I-T038
has	O
focused	O
on	O
race	B-T098
and	O
socioeconomic	O
factors	O
.	O

However	O
,	O
the	O
geography	O
of	O
disparities	O
-	O
capturing	O
racial	O
and	O
socioeconomic	O
differences	O
based	O
on	O
where	O
patients	O
live	O
-	O
can	O
provide	O
insight	O
into	O
barriers	O
to	O
care	B-T058
and	O
help	O
identify	O
outlier	O
areas	O
in	O
which	O
access	B-T082
to	O
care	B-T058
,	O
health	O
resources	O
,	O
or	O
both	O
are	O
more	O
pronounced	O
.	O

Research	B-T062
regarding	O
treatment	B-T058
patterns	B-T082
and	O
disparities	O
in	O
prostate	B-T038
cancer	I-T038
using	O
the	O
Geographical	B-T170
Information	I-T170
System	I-T170
(	O
GIS	B-T170
)	O
was	O
searched	O
.	O

Studies	B-T062
were	O
limited	O
to	O
English	O
-	O
language	O
articles	B-T170
and	O
research	B-T062
focused	O
on	O
US	B-T082
populations	B-T098
.	O

A	O
total	O
of	O
43	O
articles	B-T170
were	O
found	O
;	O
of	O
those	O
,	O
30	O
provided	O
information	O
about	O
or	O
used	O
spatial	B-T082
or	O
geographical	O
analyses	B-T062
to	O
assess	O
and	O
describe	O
differences	O
or	O
disparities	O
in	O
prostate	B-T038
cancer	I-T038
and	O
its	O
treatment	B-T058
.	O

Two	O
additional	O
GIS	B-T170
resources	O
were	O
included	O
.	O

The	O
research	B-T062
on	O
geographical	O
and	O
spatial	O
determinants	O
of	O
prostate	B-T038
cancer	I-T038
disparities	O
was	O
reviewed	O
.	O

We	O
also	O
examined	O
geographical	O
analyses	B-T062
at	O
the	O
state	O
level	O
,	O
focusing	O
on	O
Florida	B-T082
.	O

Overall	O
,	O
we	O
described	O
a	O
geographical	O
framework	O
to	O
disparities	O
that	O
affect	O
men	B-T098
with	O
prostate	B-T038
cancer	I-T038
and	O
reviewed	O
existing	O
published	O
evidence	O
supporting	O
the	O
interplay	O
of	O
geographical	O
factors	O
and	O
disparities	O
in	O
prostate	B-T038
cancer	I-T038
.	O

Disparities	O
in	O
prostate	B-T038
cancer	I-T038
are	O
common	O
and	O
persistent	O
,	O
and	O
notable	O
differences	O
in	O
treatment	B-T058
are	O
observable	O
across	O
racial	O
and	O
socioeconomic	O
strata	O
.	O

Geographical	O
analysis	B-T062
provides	O
additional	O
information	O
about	O
where	O
disparate	O
groups	B-T098
live	O
and	O
also	O
helps	O
to	O
map	O
access	B-T082
to	O
care	B-T058
.	O

This	O
information	O
can	O
be	O
used	O
by	O
public	B-T097
health	I-T097
officials	I-T097
,	O
health	B-T097
-	I-T097
systems	I-T097
administrators	I-T097
,	O
clinicians	B-T097
,	O
and	O
policymakers	B-T097
to	O
better	O
understand	O
and	O
respond	O
to	O
geographical	O
barriers	O
that	O
contribute	O
to	O
disparities	O
in	O
care	O
.	O

The	O
Novel	O
miR	B-T103
-	I-T103
9600	I-T103
Suppresses	O
Tumor	B-T038
Progression	I-T038
and	O
Promotes	O
Paclitaxel	B-T103
Sensitivity	O
in	O
Non	B-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
Lung	I-T038
Cancer	I-T038
Through	O
Altering	O
STAT3	B-T017
Expression	B-T038

MicroRNAs	B-T103
have	O
been	O
identified	O
to	O
be	O
involved	O
in	O
center	B-T201
stage	I-T201
of	O
cancer	B-T091
biology	I-T091
.	O

They	O
accommodate	O
cell	B-T038
proliferation	I-T038
and	O
migration	B-T038
by	O
negatively	B-T033
regulate	B-T038
gene	I-T038
expression	I-T038
either	O
by	O
hampering	O
the	O
translation	O
of	O
targeted	B-T103
mRNAs	I-T103
or	O
by	O
promoting	O
their	O
degradation	O
.	O

We	O
characterized	O
and	O
identified	O
the	O
novel	O
miR	B-T103
-	I-T103
9600	I-T103
and	O
its	O
target	O
in	O
human	B-T204
non	B-T038
-	I-T038
small	I-T038
-	I-T038
cell	I-T038
lung	I-T038
cancer	I-T038
(	O
NSCLC	B-T038
)	O
.	O

Our	O
results	O
demonstrated	O
that	O
the	O
miR	B-T103
-	I-T103
9600	I-T103
were	O
downregulated	B-T038
in	O
NSCLC	B-T038
tissues	B-T017
and	O
cells	B-T017
.	O

It	O
is	O
confirmed	O
that	O
signal	B-T017
transducer	I-T017
and	I-T017
activator	I-T017
of	I-T017
transcription	I-T017
3	I-T017
(	O
STAT3	B-T017
)	O
,	O
a	O
putative	B-T017
target	I-T017
gene	I-T017
,	O
is	O
directly	O
inhibited	O
by	O
miR	B-T103
-	I-T103
9600	I-T103
.	O

The	O
miR	B-T103
-	I-T103
9600	I-T103
markedly	O
suppressed	O
the	O
protein	B-T038
expression	I-T038
of	O
STAT3	B-T017
,	O
but	O
with	O
no	O
significant	O
influence	O
in	O
corresponding	O
mRNA	B-T103
levels	O
,	O
and	O
the	O
direct	O
combination	O
of	O
miR	B-T103
-	I-T103
9600	I-T103
and	O
STAT3	B-T017
was	O
confirmed	O
by	O
a	O
luciferase	O
reporter	O
assay	O
.	O

miR	B-T103
-	I-T103
9600	I-T103
inhibited	O
cell	B-T038
growth	I-T038
,	O
hampered	O
expression	B-T038
of	O
cell	B-T038
cycle	I-T038
-	O
related	O
proteins	B-T103
and	O
inhibited	O
cell	B-T038
migration	I-T038
and	O
invasion	B-T038
in	O
human	B-T204
NSCLC	B-T038
cell	B-T017
lines	I-T017
.	O

Further	O
,	O
miR	B-T103
-	I-T103
9600	I-T103
significantly	O
suppressed	O
tumor	O
growth	O
in	O
nude	B-T204
mice	I-T204
.	O

Similarly	O
,	O
miR	B-T103
-	I-T103
9600	I-T103
impeded	O
tumorigenesis	B-T038
and	O
metastasis	B-T038
through	O
directly	O
targeting	B-T038
STAT3	B-T017
.	O

Furthermore	O
,	O
we	O
identified	O
that	O
miR	B-T103
-	I-T103
9600	I-T103
augmented	O
paclitaxel	B-T103
and	O
cisplatin	B-T103
sensitivity	O
by	O
downregulating	B-T038
STAT3	B-T017
and	O
promoting	O
chemotherapy	B-T058
-	O
induced	O
apoptosis	B-T038
.	O

These	O
data	O
demonstrate	O
that	O
miR	B-T103
-	I-T103
9600	I-T103
might	O
be	O
a	O
useful	O
and	O
novel	O
therapeutic	O
target	O
for	O
NSCLC	B-T038
.	O

Beneficial	O
effects	O
of	O
natural	B-T103
eggshell	I-T103
membrane	I-T103
(	O
NEM	B-T103
)	O
on	O
multiple	O
indices	O
of	O
arthritis	B-T038
in	O
collagen	B-T038
-	I-T038
induced	I-T038
arthritic	I-T038
rats	B-T204

This	O
study	B-T062
was	O
performed	O
to	O
evaluate	B-T058
the	O
potential	O
efficacy	O
of	O
natural	B-T103
eggshell	I-T103
membrane	I-T103
(	O
NEM	B-T103
)	O
in	O
collagen	B-T038
-	I-T038
induced	I-T038
arthritic	I-T038
rats	B-T204
,	O
a	O
well	O
-	O
established	O
rodent	B-T038
model	I-T038
of	I-T038
inflammation	I-T038
and	O
rheumatoid	B-T038
arthritis	I-T038
.	O

Rats	B-T204
with	O
developing	O
type	B-T038
II	I-T038
collagen	I-T038
-	I-T038
induced	I-T038
arthritis	I-T038
(	O
CIA	B-T038
)	O
were	O
treated	O
once	O
daily	O
by	O
oral	O
gavage	O
on	O
study	O
days	O
-	O
14	O
to	O
17	O
with	O
vehicle	B-T103
or	O
NEM	B-T103
(	O
52	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
.	O

Rats	B-T204
were	O
euthanized	B-T062
on	O
study	O
day	O
17	O
.	O

Efficacy	O
was	O
assessed	O
by	O
daily	O
ankle	B-T082
caliper	B-T074
measurements	O
,	O
ankle	B-T082
diameter	O
expressed	O
as	O
area	O
under	O
the	O
curve	O
(	O
AUCd0	O
-	O
17	O
)	O
,	O
and	O
histopathologic	B-T091
evaluation	I-T091
of	O
ankles	B-T082
and	O
knees	B-T017
.	O

Serum	B-T031
biomarkers	B-T201
of	O
cartilage	B-T038
function	I-T038
and	O
inflammation	B-T038
[	O
collagen	B-T058
type	I-T058
II	I-T058
C	I-T058
-	I-T058
telopeptide	I-T058
(	O
CTXII	B-T058
)	O
,	O
cartilage	B-T058
oligomeric	I-T058
matrix	I-T058
protein	I-T058
(	O
COMP	B-T058
)	O
,	O
and	O
alpha	B-T058
-	I-T058
2	I-T058
-	I-T058
macroglobulin	I-T058
(	O
A2M	B-T058
)	O
]	O
were	O
measured	O
by	O
ELISA	B-T058
.	O

Treatment	O
with	O
NEM	B-T103
resulted	O
in	O
significant	O
beneficial	O
effects	O
on	O
the	O
daily	O
ankle	B-T082
diameter	O
measurements	O
and	O
ankle	B-T082
diameter	O
AUC	O
.	O

Ankle	B-T082
and	O
knee	B-T017
histopathology	B-T033
scores	I-T033
were	O
significantly	O
reduced	O
(	O
36	O
%	O
and	O
43	O
%	O
reduction	O
of	O
summed	O
individual	O
histopathology	B-T033
scores	I-T033
for	O
ankle	B-T082
and	O
knee	B-T017
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
toward	O
normal	O
for	O
rats	B-T204
given	O
NEM	B-T103
compared	O
to	O
vehicle	O
controls	O
.	O

The	O
percent	O
reduction	O
of	O
serum	B-T031
CTXII	B-T058
,	O
COMP	B-T058
,	O
and	O
A2M	B-T058
in	O
NEM	B-T103
-	O
treated	O
rats	B-T204
ranged	O
from	O
30	O
%	O
to	O
72	O
%	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

NEM	B-T103
significantly	O
improved	O
multiple	O
aspects	O
of	O
inflammatory	B-T038
arthritis	I-T038
including	O
inflammation	B-T038
,	O
pannus	B-T038
,	O
cartilage	B-T037
damage	I-T037
,	O
bone	B-T038
resorption	I-T038
,	O
and	O
periosteal	B-T038
bone	I-T038
formation	I-T038
.	O

This	O
study	B-T062
provides	O
further	O
support	O
for	O
the	O
use	O
of	O
CTXII	B-T103
,	O
COMP	B-T103
,	O
and	O
A2M	B-T103
as	O
relevant	O
biomarkers	B-T201
that	O
were	O
responsive	O
to	O
NEM	B-T103
.	O

Mimicking	O
the	O
cell	B-T017
membrane	I-T017
:	O
bio	O
-	O
inspired	O
simultaneous	O
functions	O
with	O
monovalent	O
anion	B-T103
selectivity	O
and	O
antifouling	O
properties	O
of	O
anion	B-T103
exchange	O
membrane	B-T074

A	O
new	O
bio	O
-	O
inspired	O
method	O
was	O
applied	O
in	O
this	O
study	O
to	O
simultaneously	O
improve	O
the	O
monovalent	O
anion	B-T103
selectivity	O
and	O
antifouling	O
properties	O
of	O
anion	B-T103
exchange	O
membranes	B-T074
(	O
AEMs	O
)	O
.	O

Three	O
-	O
layer	O
architecture	O
was	O
developed	O
by	O
deposition	O
of	O
polydopamine	B-T103
(	O
PDA	B-T103
)	O
and	O
electro	O
-	O
deposition	O
of	O
N	B-T103
-	I-T103
O	I-T103
-	I-T103
sulfonic	I-T103
acid	I-T103
benzyl	I-T103
chitosan	I-T103
(	O
NSBC	B-T103
)	O
.	O

The	O
innermost	B-T082
and	O
outermost	B-T082
layers	O
were	O
PDA	B-T103
with	O
different	O
deposition	O
time	O
.	O

The	O
middle	B-T082
layer	O
was	O
prepared	O
by	O
NSBC	B-T103
.	O

Fourier	B-T062
transform	I-T062
infrared	I-T062
spectroscopy	I-T062
and	O
scanning	B-T058
electron	I-T058
microscopy	I-T058
confirmed	O
that	O
PDA	B-T103
and	O
NSBC	B-T103
were	O
successfully	O
modified	O
on	O
the	O
surfaces	O
of	O
AEMs	O
.	O

The	O
contact	O
angle	O
of	O
the	O
membranes	B-T074
indicated	O
an	O
improved	O
hydrophilicity	O
of	O
the	O
modified	O
membranes	B-T074
.	O

A	O
series	O
of	O
electrodialysis	O
experiments	O
in	O
which	O
Cl	B-T103
(	I-T103
-	I-T103
)	I-T103
/	O
SO4	B-T103
(	I-T103
2	I-T103
-	I-T103
)	I-T103
separation	O
was	O
studied	O
,	O
demonstrating	O
the	O
monovalent	O
anion	B-T103
selectivity	O
of	O
the	O
samples	O
.	O

The	O
Cl	B-T103
(	I-T103
-	I-T103
)	I-T103
/	O
SO4	B-T103
(	I-T103
2	I-T103
-	I-T103
)	I-T103
permselectivity	O
of	O
the	O
modified	O
membranes	B-T074
can	O
reach	O
up	O
to	O
2	O
.	O
20	O
,	O
higher	O
than	O
that	O
of	O
the	O
commercial	B-T074
membrane	I-T074
(	O
only	O
0	O
.	O
78	O
)	O
during	O
90	O
minutes	O
in	O
electrodialysis	O
(	O
ED	O
)	O
.	O

The	O
increase	O
value	O
of	O
the	O
resistance	O
of	O
the	O
membranes	B-T074
was	O
also	O
measured	O
to	O
evaluate	O
the	O
antifouling	O
properties	O
.	O

Sodium	B-T103
dodecyl	I-T103
benzene	I-T103
sulfonate	I-T103
(	O
SDBS	B-T103
)	O
was	O
used	O
as	O
the	O
fouling	O
material	O
in	O
the	O
ED	O
process	O
and	O
the	O
membrane	B-T074
area	O
resistance	O
of	O
modified	B-T074
membrane	I-T074
increase	O
value	O
of	O
was	O
only	O
0	O
.	O
08	O
Ωcm	O
(	O
2	O
)	O
30	O
minutes	O
later	O
.	O

The	O
Loop	B-T082
2	I-T082
Region	I-T082
of	O
Ribosomal	B-T103
Protein	I-T103
uS5	I-T103
Influences	O
Spectinomycin	B-T103
Sensitivity	B-T033
,	O
Translational	B-T038
Fidelity	I-T038
,	O
and	O
Ribosome	B-T038
Biogenesis	I-T038

Ribosomal	B-T103
protein	I-T103
uS5	I-T103
is	O
an	O
essential	O
component	O
of	O
the	O
small	B-T017
ribosomal	I-T017
subunit	I-T017
that	O
is	O
involved	O
in	O
subunit	B-T038
assembly	I-T038
,	O
maintenance	B-T038
of	I-T038
translational	I-T038
fidelity	I-T038
,	O
and	O
the	O
ribosome	B-T017
'	I-T017
s	I-T017
response	O
to	O
the	O
antibiotic	B-T103
spectinomycin	I-T103
.	O

While	O
many	O
of	O
the	O
characterized	O
uS5	B-T038
mutations	I-T038
that	O
affect	O
decoding	B-T038
map	O
to	O
its	O
interface	B-T038
with	O
uS4	B-T103
,	O
more	O
recent	O
work	O
has	O
shown	O
that	O
residues	O
distant	O
from	O
the	O
uS4	B-T038
-	I-T038
uS5	I-T038
interface	I-T038
can	O
also	O
affect	O
the	O
decoding	O
process	O
.	O

We	O
targeted	O
one	O
such	O
interface	O
-	O
remote	O
area	O
,	O
the	O
loop	B-T082
2	I-T082
region	I-T082
(	O
residues	O
20	O
to	O
31	O
)	O
,	O
for	O
mutagenesis	B-T038
in	O
Escherichia	B-T007
.	I-T007

coli	I-T007
and	O
generated	O
21	O
unique	B-T038
mutants	I-T038
.	O

A	O
majority	O
of	O
the	O
loop	B-T082
2	I-T082
alterations	O
confer	O
resistance	O
to	O
spectinomycin	B-T103
and	O
affect	O
the	O
fidelity	B-T038
of	I-T038
translation	I-T038
.	O

However	O
,	O
only	O
a	O
minority	O
show	O
altered	O
rRNA	B-T103
processing	O
or	O
ribosome	B-T038
biogenesis	I-T038
defects	O
.	O

Multiplex	O
social	O
ecological	B-T082
network	B-T062
analysis	I-T062
reveals	O
how	O
social	O
changes	O
affect	O
community	O
robustness	O
more	O
than	O
resource	O
depletion	O

Network	B-T062
analysis	I-T062
provides	O
a	O
powerful	O
tool	O
to	O
analyze	O
complex	O
influences	O
of	O
social	O
and	O
ecological	B-T082
structures	I-T082
on	O
community	O
and	O
household	O
dynamics	O
.	O

Most	O
network	B-T062
studies	I-T062
of	O
social	O
-	O
ecological	O
systems	O
use	O
simple	O
,	O
undirected	O
,	O
unweighted	O
networks	O
.	O

We	O
analyze	O
multiplex	O
,	O
directed	B-T082
,	O
and	O
weighted	O
networks	O
of	O
subsistence	O
food	B-T168
flows	O
collected	O
in	O
three	O
small	O
indigenous	O
communities	O
in	O
Arctic	B-T082
Alaska	B-T082
potentially	O
facing	O
substantial	O
economic	O
and	O
ecological	B-T082
changes	O
.	O

Our	O
analysis	O
of	O
plausible	O
future	O
scenarios	O
suggests	O
that	O
changes	O
to	O
social	O
relations	O
and	O
key	O
households	O
have	O
greater	O
effects	O
on	O
community	O
robustness	O
than	O
changes	O
to	O
specific	O
wild	O
food	O
resources	O
.	O

Heavy	B-T058
Resistance	I-T058
Training	I-T058
in	O
Hypoxia	B-T038
Enhances	O
1RM	O
Squat	B-T033
Performance	O

Purpose	O
:	O
To	O
determine	O
if	O
heavy	B-T058
resistance	I-T058
training	I-T058
in	O
hypoxia	B-T038
(	O
IHRT	B-T058
)	O
is	O
more	O
effective	O
at	O
improving	O
strength	O
,	O
power	B-T033
,	O
and	O
increasing	O
lean	B-T201
mass	I-T201
than	O
the	O
same	O
training	O
in	O
normoxia	O
.	O

Methods	O
:	O
A	O
pair	O
-	O
matched	O
,	O
placebo	O
-	O
controlled	O
study	O
design	O
included	O
20	O
resistance	B-T058
-	I-T058
trained	I-T058
participants	B-T098
assigned	O
to	O
IHRT	B-T058
(	O
FIO2	B-T058
0	O
.	O
143	O
)	O
or	O
placebo	O
(	O
FIO2	B-T058
0	O
.	O
20	O
)	O
,	O
(	O
n	O
=	O
10	O
per	O
group	O
)	O
.	O

Participants	B-T098
were	O
matched	O
for	O
strength	O
and	O
training	B-T058
.	O

Both	O
groups	O
performed	O
20	O
sessions	O
over	O
7	O
weeks	O
either	O
with	O
IHRT	B-T058
or	O
placebo	O
.	O

All	O
participants	B-T098
were	O
tested	O
for	O
1RM	O
,	O
20	O
-	O
m	O
sprint	B-T058
,	O
body	O
composition	O
,	O
and	O
countermovement	O
jump	O
pre	O
-	O
,	O
mid	O
-	O
,	O
and	O
post	O
-	O
training	B-T058
and	O
compared	O
via	O
magnitude	O
-	O
based	O
inferences	B-T038
.	O

Presentation	O
of	O
Results	O
:	O
Groups	O
were	O
not	O
clearly	O
different	O
for	O
any	O
test	O
at	O
baseline	O
.	O

Training	B-T058
improved	B-T033
both	O
absolute	O
(	O
IHRT	B-T058
:	O
13	O
.	O
1	O
±	O
3	O
.	O
9	O
%	O
,	O
effect	O
size	O
(	O
ES	O
)	O
0	O
.	O
60	O
,	O
placebo	O
9	O
.	O
8	O
±	O
4	O
.	O
7	O
%	O
,	O
ES	O
0	O
.	O
31	O
)	O
and	O
relative	O
1RM	O
(	O
IHRT	B-T058
:	O
13	O
.	O
4	O
±	O
5	O
.	O
1	O
%	O
,	O
ES	O
0	O
.	O
76	O
,	O
placebo	O
9	O
.	O
7	O
±	O
5	O
.	O
3	O
%	O
,	O
ES	O
0	O
.	O
48	O
)	O
at	O
mid	O
.	O

Similarly	O
,	O
at	O
post	O
both	O
groups	O
increased	O
absolute	O
(	O
IHRT	B-T058
:	O
20	O
.	O
7	O
±	O
7	O
.	O
6	O
%	O
,	O
ES	O
0	O
.	O
74	O
,	O
placebo	O
14	O
.	O
1	O
±	O
6	O
.	O
0	O
%	O
,	O
ES	O
0	O
.	O
58	O
)	O
and	O
relative	O
1RM	O
(	O
IHRT	B-T058
:	O
21	O
.	O
6	O
±	O
8	O
.	O
5	O
%	O
,	O
ES	O
1	O
.	O
08	O
,	O
placebo	O
13	O
.	O
2	O
±	O
6	O
.	O
4	O
%	O
,	O
ES	O
0	O
.	O
78	O
)	O
.	O

Importantly	O
,	O
the	O
change	O
in	O
IHRT	B-T058
was	O
greater	O
than	O
placebo	O
at	O
mid	O
for	O
both	O
absolute	O
[	O
4	O
.	O
4	O
%	O
greater	O
change	O
,	O
90	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
1	O
.	O
0	O
:	O
8	O
.	O
0	O
%	O
,	O
ES	O
0	O
.	O
21	O
,	O
and	O
relative	O
strength	O
(	O
5	O
.	O
6	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1	O
.	O
0	O
:	O
9	O
.	O
4	O
%	O
,	O
ES	O
0	O
.	O
31	O
(	O
relative	O
)	O
]	O
.	O

There	O
was	O
also	O
a	O
greater	O
change	O
for	O
IHRT	B-T058
at	O
post	O
for	O
both	O
absolute	O
(	O
7	O
.	O
0	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1	O
.	O
3	O
:	O
13	O
%	O
,	O
ES	O
0	O
.	O
33	O
)	O
,	O
and	O
relative	O
1RM	O
(	O
9	O
.	O
2	O
%	O
greater	O
change	O
,	O
90	O
%	O
CI	O
1	O
.	O
6	O
:	O
14	O
.	O
9	O
%	O
,	O
ES	O
0	O
.	O
49	O
)	O
.	O

Only	O
IHRT	B-T058
increased	O
countermovement	O
jump	O
peak	O
power	B-T033
at	O
Post	O
(	O
4	O
.	O
9	O
%	O
,	O
ES	O
0	O
.	O
35	O
)	O
,	O
however	O
the	O
difference	O
between	O
IHRT	B-T058
and	O
placebo	O
was	O
unclear	O
(	O
2	O
.	O
7	O
,	O
90	O
%	O
CI	O
-	O
2	O
.	O
0	O
:	O
7	O
.	O
6	O
%	O
,	O
ES	O
0	O
.	O
20	O
)	O
with	O
no	O
clear	O
differences	O
in	O
speed	O
or	O
body	O
composition	O
throughout	O
.	O

Conclusion	O
:	O
Heavy	B-T058
resistance	I-T058
training	I-T058
in	O
hypoxia	B-T038
is	O
more	O
effective	O
than	O
placebo	O
for	O
improving	O
absolute	O
and	O
relative	O
strength	O
.	O

Ultrasonography	B-T058
and	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
evaluation	B-T058
of	O
pediatric	O
spinal	B-T017
anomalies	I-T017

Spinal	B-T017
dysraphisms	I-T017
are	O
congenital	B-T017
abnormalities	I-T017
of	O
the	O
spine	B-T017
due	O
to	O
imperfect	O
fusion	O
of	O
midline	B-T082
mesenchymal	O
,	O
bony	O
and	O
neural	O
structures	B-T082
.	O

Imaging	B-T058
plays	O
a	O
vital	O
role	O
in	O
their	O
evaluation	B-T058
as	O
significant	O
portion	O
of	O
patients	O
may	O
present	O
with	O
concurrent	O
anomalies	B-T017
that	O
need	O
to	O
be	O
corrected	O
simultaneously	O
to	O
avoid	O
repeat	B-T058
surgeries	I-T058
.	O

The	O
aims	O
of	O
the	O
study	B-T062
were	O
to	O
evaluate	B-T058
Spinal	B-T017
dysraphisms	I-T017
using	O
USG	B-T058
and	O
MRI	B-T058
and	O
to	O
correlate	O
imaging	B-T058
findings	O
with	O
operative	O
findings	O
in	O
patients	O
undergoing	O
surgery	B-T058
.	O

Hospital	B-T092
based	O
observational	B-T062
study	I-T062
conducted	O
over	O
a	O
period	O
of	O
year	O
.	O

38	O
cases	O
of	O
both	O
sexes	O
and	O
below	O
12	O
years	O
of	O
age	O
with	O
spinal	B-T017
dysraphism	I-T017
were	O
studied	O
.	O

USG	B-T058
was	O
performed	O
in	O
29	O
cases	O
where	O
acoustic	O
window	O
was	O
available	O
for	O
proper	O
evaluation	B-T058
.	O

MRI	B-T058
was	O
performed	O
in	O
all	O
cases	O
.	O

USG	B-T058
findings	O
were	O
compared	O
with	O
MRI	B-T058
findings	O
and	O
operative	O
follow	B-T058
up	I-T058
was	O
taken	O
in	O
23	O
cases	O
who	O
underwent	O
operative	B-T058
management	I-T058
.	O

Results	O
were	O
analysed	B-T062
using	O
percentage	O
and	O
arithmetic	O
mean	O
.	O

39	O
.	O
47	O
%	O
cases	O
were	O
male	O
and	O
60	O
.	O
53	O
%	O
cases	O
were	O
female	O
.	O

Neonatal	O
period	O
was	O
the	O
most	O
common	O
presenting	O
age	O
group	O
.	O

Closed	O
spinal	B-T017
dysraphism	I-T017
(	O
63	O
.	O
16	O
%	O
)	O
was	O
more	O
common	O
than	O
open	B-T082
(	O
36	O
.	O
84	O
%	O
)	O
.	O

79	O
.	O
31	O
%	O
cases	O
showed	O
full	O
agreement	O
between	O
spinal	B-T082
USG	B-T058
and	O
MRI	B-T058
examinations	B-T058
and	O
6	O
out	O
of	O
20	O
.	O
69	O
%	O
showed	O
partial	O
agreement	O
.	O

On	O
operative	O
correlation	O
,	O
USG	B-T058
findings	O
were	O
confirmatory	B-T033
in	O
91	O
.	O
30	O
%	O
cases	O
and	O
MRI	B-T058
findings	O
were	O
confirmatory	B-T033
in	O
100	O
%	O
cases	O
.	O

USG	B-T058
can	O
be	O
used	O
as	O
the	O
initial	O
modality	O
for	O
evaluation	B-T058
of	O
spinal	B-T017
dysraphism	I-T017
as	O
well	O
as	O
for	O
screening	B-T058
of	O
suspected	O
cases	O
.	O

MRI	B-T058
is	O
indicated	O
to	O
confirm	O
abnormal	B-T033
USG	B-T058
findings	O
,	O
which	O
shows	O
all	O
concurrent	O
abnormalities	B-T017
and	O
also	O
provides	O
additional	O
anatomical	O
details	O
relevant	O
to	O
surgical	B-T170
planning	I-T170
.	O

BORA	B-T017
-	O
dependent	O
PLK1	B-T103
regulation	B-T038
:	O
A	O
new	O
weapon	O
for	O
cancer	B-T058
therapy	I-T058
?	O

The	O
mitotic	B-T103
kinase	I-T103
polo	I-T103
like	I-T103
kinase	I-T103
1	I-T103
(	O
PLK1	B-T103
)	O
is	O
overexpressed	B-T038
in	O
many	O
cancers	B-T038
and	I-T038
its	I-T038
inhibition	I-T038
slows	B-T038
down	I-T038
proliferation	I-T038
and	O
increases	B-T038
apoptosis	I-T038
in	O
cancer	B-T017
cell	I-T017
lines	I-T017
.	O

Understanding	O
how	O
PLK1	B-T038
is	I-T038
activated	I-T038
is	O
therefore	O
crucial	O
for	O
the	O
development	O
of	O
novel	O
PLK1	B-T103
inhibitors	I-T103
with	O
anticancer	B-T103
properties	I-T103
.	O

We	O
recently	O
identified	O
a	O
conserved	O
regulatory	O
loop	O
leading	O
to	O
PLK1	B-T038
activation	I-T038
that	O
involves	O
cyclin	B-T103
-	I-T103
dependent	I-T103
kinase	I-T103
1	I-T103
(	O
CDK1	B-T103
)	O
.	O

Activation	B-T038
of	I-T038
transcription	I-T038
enforces	O
the	O
formation	O
of	O
distinct	O
nuclear	B-T017
bodies	I-T017
in	O
zebrafish	B-T204
embryos	B-T017

Nuclear	B-T017
bodies	I-T017
are	O
cellular	B-T082
compartments	I-T082
that	O
lack	O
lipid	B-T017
bilayers	I-T017
and	O
harbor	O
specific	O
RNAs	B-T103
and	O
proteins	B-T103
.	O

Recent	O
proposals	O
that	O
nuclear	B-T017
bodies	I-T017
form	O
through	O
liquid	O
-	O
liquid	O
phase	O
separation	O
leave	O
the	O
question	O
of	O
how	O
different	O
nuclear	B-T017
bodies	I-T017
maintain	O
their	O
distinct	O
identities	O
unanswered	O
.	O

Here	O
we	O
investigate	O
Cajal	B-T017
bodies	I-T017
(	O
CBs	B-T017
)	O
,	O
histone	B-T017
locus	I-T017
bodies	I-T017
(	O
HLBs	B-T017
)	O
and	O
nucleoli	B-T017
-	O
involved	O
in	O
assembly	O
of	O
the	O
splicing	B-T038
machinery	I-T038
,	O
histone	B-T038
mRNA	I-T038
3	I-T038
'	I-T038
end	I-T038
processing	I-T038
,	O
and	O
rRNA	B-T038
processing	I-T038
,	O
respectively	O
-	O
in	O
the	O
embryos	B-T017
of	O
the	O
zebrafish	B-T204
,	O
Danio	B-T204
rerio	I-T204
.	O

We	O
take	O
advantage	O
of	O
the	O
transcriptional	O
silence	O
of	O
the	O
1	O
-	O
cell	O
embryo	B-T017
and	O
follow	O
nuclear	B-T017
body	I-T017
appearance	O
as	O
zygotic	B-T017
transcription	B-T038
becomes	O
activated	O
.	O

CBs	B-T017
are	O
present	O
from	O
fertilization	B-T038
onwards	O
,	O
while	O
HLB	B-T017
and	O
nucleolar	B-T017
components	B-T017
formed	O
foci	B-T082
several	O
hours	O
later	O
when	O
histone	B-T103
genes	B-T017
and	O
rDNA	B-T103
became	O
active	O
.	O

HLB	B-T017
formation	O
was	O
blocked	O
by	O
transcription	B-T038
inhibition	I-T038
,	O
suggesting	O
nascent	B-T103
histone	I-T103
transcripts	I-T103
recruit	O
HLB	B-T017
components	B-T017
like	O
U7	B-T103
snRNP	I-T103
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
U7	O
base	B-T038
-	I-T038
pairing	I-T038
with	O
nascent	B-T103
histone	I-T103
transcripts	I-T103
was	O
not	O
required	O
for	O
localization	B-T038
to	O
HLBs	B-T017
.	O

Rather	O
,	O
the	O
type	O
of	O
Sm	O
ring	O
assembled	O
on	O
U7	O
determined	O
its	O
targeting	O
to	O
HLBs	B-T017
or	O
CBs	B-T017
;	O
the	O
spliceosomal	O
Sm	O
ring	O
targeted	O
snRNAs	B-T103
to	O
CBs	B-T017
while	O
the	O
specialized	O
U7	O
Sm	O
-	O
ring	O
localized	O
to	O
HLBs	B-T017
,	O
demonstrating	O
the	O
contribution	O
of	O
protein	B-T103
constituents	O
to	O
the	O
distinction	O
among	O
nuclear	B-T017
bodies	I-T017
.	O

Thus	O
,	O
nucleolar	B-T017
,	O
HLB	B-T017
,	O
and	O
CB	B-T017
components	B-T017
can	O
mix	O
in	O
early	O
embryogenesis	B-T038
when	O
transcription	B-T038
is	O
naturally	O
or	O
artificially	O
silenced	O
.	O

These	O
data	O
support	O
a	O
model	O
in	O
which	O
transcription	B-T038
of	O
specific	O
gene	B-T082
loci	I-T082
nucleates	O
nuclear	B-T017
body	I-T017
components	B-T017
with	O
high	O
specificity	O
and	O
fidelity	O
to	O
perform	O
distinct	O
regulatory	O
functions	B-T038
.	O

Variation	O
in	O
the	O
age	O
of	O
first	B-T038
reproduction	I-T038
:	O
different	O
strategies	O
or	O
individual	O
quality	O
?	O

Although	O
age	O
at	O
first	B-T038
reproduction	I-T038
is	O
a	O
key	O
demographic	O
parameter	O
that	O
is	O
probably	O
under	O
high	B-T033
selective	I-T033
pressure	I-T033
,	O
it	O
is	O
highly	O
variable	O
and	O
the	O
cause	O
of	O
this	O
variability	O
is	O
not	O
well	O
understood	O
.	O

Two	O
non	O
-	O
exclusive	O
hypotheses	O
may	O
explain	O
such	O
variability	O
.	O

It	O
could	O
be	O
the	O
expression	O
of	O
different	O
individual	O
strategies	O
,	O
i	O
.	O
e	O
.	O
,	O
different	O
allocation	O
strategies	O
in	O
fitness	O
components	O
,	O
or	O
the	O
consequences	O
of	O
individual	O
difference	O
in	O
intrinsic	B-T082
quality	I-T082
,	O
i	O
.	O
e	O
.	O
,	O
some	O
individuals	B-T098
always	O
doing	O
better	O
than	O
others	O
in	O
all	O
fitness	O
components	O
.	O

We	O
tested	O
these	O
hypotheses	O
in	O
the	O
Wandering	B-T204
Albatross	I-T204
investigating	O
relationships	O
between	O
the	O
age	O
at	O
first	B-T038
reproduction	I-T038
and	O
subsequent	O
adult	O
demographic	O
traits	O
.	O

Using	O
finite	B-T062
mixture	I-T062
capture	I-T062
recapture	I-T062
modeling	I-T062
,	O
we	O
demonstrate	O
that	O
the	O
age	O
at	O
first	B-T038
reproduction	I-T038
is	O
negatively	B-T033
related	O
to	O
both	O
reproductive	B-T038
performances	O
and	O
adult	O
survival	O
,	O
suggesting	O
that	O
individual	O
quality	O
was	O
an	O
important	O
factor	O
explaining	O
variation	O
in	O
the	O
age	O
at	O
first	B-T038
reproduction	I-T038
.	O

Our	O
results	O
suggest	O
that	O
age	O
at	O
first	B-T038
breeding	I-T038
is	O
a	O
good	O
predictor	O
of	O
quality	O
in	O
this	O
long	O
-	O
lived	O
seabird	B-T204
species	I-T204
.	O

Heterogeneity	O
of	O
colorectal	B-T038
cancer	I-T038
risk	O
by	O
tumour	B-T038
characteristics	O
:	O
Large	O
prospective	B-T062
study	I-T062
of	O
UK	B-T082
women	B-T098

Associations	O
between	O
behavioural	O
and	O
other	O
personal	O
factors	O
and	O
colorectal	B-T038
cancer	I-T038
risk	O
have	O
been	O
reported	O
to	O
vary	O
by	O
tumour	B-T038
characteristics	O
,	O
but	O
evidence	O
is	O
inconsistent	O
.	O

In	O
a	O
large	O
UK	B-T082
-	O
based	O
prospective	B-T062
study	I-T062
we	O
examined	O
associations	O
of	O
14	O
postulated	O
risk	B-T033
factors	I-T033
with	O
colorectal	B-T038
cancer	I-T038
risk	O
overall	O
,	O
and	O
across	O
three	O
anatomical	B-T082
sites	I-T082
and	O
four	O
morphological	B-T082
subtypes	B-T170
.	O

Among	O
1	O
.	O
3	O
million	O
women	B-T098
,	O
18	O
,	O
518	O
incident	O
colorectal	B-T038
cancers	I-T038
were	O
identified	O
during	O
13	O
.	O
8	O
(	O
SD	O
3	O
.	O
4	O
)	O
years	O
follow	B-T058
-	I-T058
up	I-T058
via	O
record	O
linkage	O
to	O
national	B-T170
cancer	I-T170
registry	I-T170
data	O
.	O

Cox	B-T170
regression	I-T170
yielded	O
adjusted	O
relative	O
risks	O
.	O

Statistical	O
significance	O
was	O
assessed	O
using	O
correction	O
for	O
multiple	O
testing	O
.	O

Overall	O
,	O
colorectal	B-T038
cancer	I-T038
risk	O
was	O
significantly	O
associated	O
with	O
height	O
,	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
,	O
smoking	O
,	O
alcohol	O
intake	O
,	O
physical	O
activity	O
,	O
parity	B-T033
and	O
menopausal	B-T058
hormone	I-T058
therapy	I-T058
use	O
.	O

For	O
smoking	O
there	O
was	O
substantial	O
heterogeneity	O
across	O
morphological	B-T082
types	O
;	O
relative	O
risks	O
around	O
two	O
or	O
greater	O
were	O
seen	O
in	O
current	O
smokers	B-T033
both	O
for	O
signet	B-T017
ring	I-T017
cell	I-T017
and	O
for	O
neuroendocrine	B-T038
tumours	I-T038
.	O

Obese	B-T038
women	B-T098
were	O
also	O
at	O
higher	O
risk	O
for	O
signet	B-T017
ring	I-T017
cell	I-T017
tumours	B-T038
.	O

For	O
adenocarcinomas	B-T038
,	O
the	O
large	O
majority	O
of	O
colorectal	B-T038
cancers	I-T038
in	O
the	O
cohort	B-T098
,	O
all	O
risk	B-T033
factor	I-T033
associations	O
were	O
weak	O
.	O

There	O
was	O
little	O
or	O
no	O
heterogeneity	O
in	O
risk	O
between	O
tumours	B-T038
of	O
the	O
right	B-T017
colon	I-T017
,	O
left	B-T017
colon	I-T017
and	O
rectum	B-T017
for	O
any	O
of	O
the	O
14	O
factors	B-T033
examined	O
.	O

These	O
epidemiological	B-T091
findings	B-T033
complement	O
an	O
emerging	O
picture	O
from	O
molecular	O
studies	O
of	O
possible	O
different	O
developmental	O
pathways	O
for	O
different	O
tumour	B-T038
types	O
.	O

Impact	O
of	O
alcohol	O
use	O
on	O
EEG	B-T058
dynamics	I-T058
of	O
response	B-T038
inhibition	I-T038
:	O
a	O
cotwin	B-T062
control	I-T062
analysis	I-T062

Research	O
indicates	O
that	O
alcohol	O
misuse	O
is	O
associated	O
with	O
behavioral	B-T038
disinhibition	I-T038
,	O
but	O
the	O
neurophysiological	B-T038
mechanisms	I-T038
governing	O
this	O
relationship	O
remain	O
largely	O
unknown	O
.	O

Recent	O
work	O
suggests	O
that	O
successful	O
inhibition	B-T038
and	O
cognitive	B-T038
control	I-T038
involve	O
electrophysiological	O
theta	O
-	O
band	O
dynamics	O
,	O
including	O
medial	B-T017
frontal	I-T017
cortex	I-T017
(	O
MFC	B-T017
)	O
power	O
enhancement	O
and	O
functional	O
connectivity	O
between	O
the	O
MFC	B-T017
and	O
dorsal	B-T017
prefrontal	I-T017
cortex	I-T017
(	O
dPFC	B-T017
)	O
regions	O
,	O
which	O
may	O
be	O
disrupted	O
by	O
alcohol	O
misuse	O
.	O

In	O
addition	O
,	O
research	O
suggests	O
that	O
,	O
compared	O
to	O
men	B-T098
,	O
women	B-T098
are	O
at	O
heightened	O
risk	O
of	O
experiencing	O
the	O
negative	O
physical	O
and	O
neurocognitive	O
correlates	O
of	O
drinking	O
.	O

The	O
present	O
study	B-T062
tested	O
the	O
hypothesis	O
that	O
alcohol	O
misuse	O
has	O
a	O
deleterious	B-T038
effect	I-T038
on	O
theta	B-T058
-	I-T058
band	I-T058
response	B-T038
inhibition	I-T038
EEG	B-T058
dynamics	I-T058
in	O
a	O
sample	B-T098
of	O
300	O
24	O
-	O
year	O
-	O
old	O
same	O
-	O
sex	O
twins	O
.	O

A	O
cotwin	B-T062
control	I-T062
(	I-T062
CTC	I-T062
)	I-T062
design	I-T062
was	O
used	O
to	O
disentangle	O
premorbid	O
risk	O
for	O
alcohol	O
use	O
from	O
the	O
causal	O
effects	O
of	O
alcohol	O
exposure	O
.	O

Drinking	O
was	O
negatively	O
associated	O
with	O
theta	B-T058
-	I-T058
band	I-T058
MFC	O
power	O
and	O
MFC	B-T017
-	O
dPFC	B-T017
connectivity	B-T082
during	O
response	B-T038
inhibition	I-T038
,	O
and	O
this	O
effect	O
was	O
stronger	O
among	O
women	B-T098
.	O

The	O
CTC	B-T062
analysis	I-T062
suggested	O
that	O
,	O
for	O
women	B-T098
,	O
reduced	O
nogo	O
-	O
related	O
theta	B-T058
-	I-T058
band	I-T058
MFC	O
power	O
and	O
MFC	B-T017
-	O
dPFC	B-T017
connectivity	B-T082
were	O
both	O
consistent	O
with	O
the	O
potential	O
deleterious	B-T038
causal	I-T038
effects	I-T038
of	O
alcohol	O
exposure	O
.	O

These	O
findings	O
suggest	O
that	O
diminished	O
theta	B-T058
-	I-T058
band	I-T058
MFC	O
power	O
and	O
MFC	B-T017
-	O
dPFC	B-T017
connectivity	B-T082
may	O
be	O
neurophysiological	B-T038
mechanisms	I-T038
underlying	O
alcohol	B-T038
-	I-T038
related	I-T038
disinhibition	I-T038
.	O

Although	O
preliminary	O
,	O
these	O
results	O
suggest	O
that	O
normative	B-T033
levels	I-T033
of	O
alcohol	O
use	O
during	O
emerging	O
adulthood	O
have	O
potential	O
sex	O
-	O
specific	O
causal	O
effects	O
on	O
response	B-T038
inhibition	I-T038
EEG	B-T058
dynamics	I-T058
,	O
and	O
thus	O
have	O
potentially	O
significant	O
public	O
health	O
implications	O
.	O

Neutrophil	B-T017
and	O
Monocyte	B-T017
Function	B-T038
in	O
Patients	O
with	O
Chronic	B-T038
Hepatitis	I-T038
C	I-T038
Undergoing	O
Antiviral	B-T058
Therapy	I-T058
with	O
Regimens	B-T058
Containing	O
Protease	B-T103
Inhibitors	I-T103
with	O
and	O
without	O
Interferon	B-T103

Real	O
-	O
life	O
data	O
showed	O
an	O
increased	O
incidence	O
of	O
bacterial	B-T038
infections	I-T038
in	O
patients	O
with	O
advanced	O
liver	B-T038
disease	I-T038
receiving	O
a	O
protease	B-T103
inhibitor	I-T103
(	O
PI	B-T103
)	O
-	O
containing	O
antiviral	B-T058
regimen	I-T058
against	O
hepatitis	B-T005
C	I-T005
(	O
HCV	B-T005
)	O
.	O

However	O
,	O
the	O
causes	O
of	O
this	O
event	O
are	O
unknown	O
.	O

We	O
hypothesized	O
that	O
PIs	B-T103
might	O
impair	O
innate	O
immune	O
responses	O
through	O
the	O
inhibition	B-T038
of	I-T038
proteases	I-T038
participating	O
in	O
the	O
anti	B-T038
-	I-T038
bacterial	I-T038
functions	I-T038
of	O
neutrophils	B-T017
and	O
monocytes	B-T017
.	O

The	O
aims	O
of	O
the	O
study	O
were	O
to	O
assess	O
phagocytic	B-T038
and	I-T038
oxidative	I-T038
burst	I-T038
capacity	O
in	O
neutrophils	B-T017
and	O
monocytes	B-T017
obtained	O
from	O
patients	O
receiving	O
a	O
PI	B-T103
containing	O
-	O
antiviral	B-T058
regimen	I-T058
,	O
and	O
to	O
determine	O
cytokine	B-T038
secretion	I-T038
after	O
neutrophil	B-T017
stimulation	B-T038
with	O
flagellin	B-T103
.	O

Forty	O
patients	O
with	O
chronic	B-T038
HCV	I-T038
(	O
80	O
%	O
with	O
cirrhosis	B-T038
)	O
were	O
enrolled	O
in	O
the	O
study	O
,	O
28	O
received	O
triple	B-T058
therapy	I-T058
(	O
Group	B-T170
A	I-T170
)	O
with	O
pegylated	B-T103
-	I-T103
interferon	I-T103
and	O
ribavirin	B-T103
for	O
4	O
weeks	O
followed	O
by	O
the	O
addition	O
of	O
a	O
PI	B-T103
(	O
telaprevir	B-T103
,	O
boceprevir	B-T103
or	O
simeprevir	B-T103
)	O
,	O
and	O
12	O
patients	O
received	O
an	O
interferon	B-T058
-	I-T058
free	I-T058
regimen	I-T058
(	O
Group	B-T170
B	I-T170
)	O
with	O
simeprevir	B-T103
and	O
sofosbuvir	B-T103
.	O

Phagocytosis	B-T038
and	I-T038
oxidative	I-T038
burst	I-T038
capacity	O
were	O
analyzed	O
by	O
flow	B-T058
cytometry	I-T058
at	O
baseline	O
,	O
week	O
4	O
,	O
and	O
week	O
8	O
of	O
therapy	B-T058
.	O

In	O
neutrophils	B-T017
from	O
Group	B-T170
A	I-T170
patients	O
,	O
oxidative	B-T038
burst	I-T038
rate	O
and	O
oxidative	O
enzymatic	B-T038
activity	I-T038
per	I-T038
cell	I-T038
significantly	O
decreased	O
throughout	O
the	O
study	O
period	O
(	O
p	O
=	O
0	O
.	O
014	O
and	O
p	O
=	O
0	O
.	O
010	O
,	O
respectively	O
)	O
.	O

Pairwise	O
comparisons	O
showed	O
a	O
decrease	O
between	O
baseline	O
and	O
week	O
4	O
and	O
8	O
of	O
therapy	B-T058
.	O

No	O
differences	O
were	O
observed	O
after	O
the	O
introduction	B-T058
of	O
the	O
PI	B-T103
.	O

The	O
oxidative	O
enzymatic	B-T038
activity	I-T038
per	I-T038
cell	I-T038
in	O
monocytes	B-T017
significantly	O
decrease	O
during	O
the	O
study	O
period	O
(	O
p	O
=	O
0	O
.	O
042	O
)	O
due	O
to	O
a	O
decrease	O
from	O
baseline	O
to	O
week	O
8	O
of	O
therapy	B-T058
(	O
p	O
=	O
0	O
.	O
037	O
)	O
in	O
patients	O
from	O
Group	B-T170
A	I-T170
.	O

None	O
of	O
these	O
findings	O
were	O
observed	O
in	O
Group	B-T170
B	I-T170
patients	O
.	O

Cytokine	B-T038
secretion	I-T038
did	O
not	O
significantly	O
change	O
during	O
the	O
study	O
in	O
both	O
groups	O
.	O

In	O
conclusion	O
,	O
our	O
data	O
suggest	O
that	O
the	O
use	O
interferon	B-T103
(	O
rather	O
than	O
the	O
PI	B-T103
)	O
has	O
a	O
deleterious	O
effect	O
on	O
neutrophil	B-T017
and	O
monocyte	B-T017
phagocytic	B-T038
and	I-T038
oxidative	I-T038
burst	I-T038
capacity	O
in	O
this	O
cohort	B-T098
of	O
patients	O
with	O
HCV	B-T005
-	O
related	O
advanced	B-T038
liver	I-T038
fibrosis	I-T038
.	O

Child	B-T033
death	I-T033
and	O
maternal	B-T033
psychosis	B-T038
-	I-T038
like	I-T038
experiences	I-T038
in	O
44	O
low	B-T098
-	I-T098
and	O
middle	O
-	O
income	O
countries	B-T082
:	O
The	O
role	O
of	O
depression	B-T038

Studies	O
on	O
the	O
effect	O
of	O
child	B-T033
death	I-T033
on	O
the	O
mental	B-T038
wellbeing	I-T038
of	O
women	B-T098
in	O
low	B-T098
-	I-T098
and	O
middle	O
-	O
income	O
countries	B-T082
(	O
LMICs	B-T082
)	O
are	O
scarce	O
despite	O
the	O
high	O
child	O
mortality	O
rates	O
.	O

Thus	O
,	O
the	O
aim	O
of	O
the	O
current	O
study	O
was	O
to	O
assess	O
the	O
association	O
between	O
child	B-T033
death	I-T033
and	O
psychosis	B-T038
-	I-T038
like	I-T038
experiences	I-T038
(	O
PLEs	B-T038
)	O
,	O
as	O
well	O
as	O
the	O
role	O
of	O
depression	B-T038
in	O
this	O
association	O
.	O

Data	O
from	O
44	O
LMICs	B-T082
which	O
participated	O
in	O
the	O
World	B-T062
Health	I-T062
Survey	I-T062
(	O
WHS	B-T062
)	O
were	O
analyzed	O
.	O

A	O
total	O
of	O
59	O
,	O
444	O
women	B-T098
who	O
ever	O
gave	O
birth	B-T038
,	O
aged	O
18	O
-	O
49	O
years	O
,	O
without	O
a	O
self	B-T062
-	I-T062
reported	I-T062
lifetime	O
psychosis	O
diagnosis	O
,	O
were	O
included	O
in	O
the	O
analysis	O
.	O

The	O
World	O
Mental	O
Health	O
Survey	O
version	O
of	O
the	O
Composite	B-T170
International	I-T170
Diagnostic	I-T170
Interview	I-T170
(	O
CIDI	B-T170
)	O
was	O
used	O
to	O
establish	O
the	O
diagnosis	B-T062
of	O
past	O
12	O
-	O
month	O
DSM	B-T170
-	I-T170
IV	I-T170
depression	B-T038
,	O
and	O
assess	O
four	O
positive	B-T033
psychotic	I-T033
symptoms	I-T033
.	O

Depression	B-T038
was	O
defined	O
as	O
self	B-T062
-	I-T062
reported	I-T062
lifetime	O
depression	O
diagnosis	O
and	O
/	O
or	O
past	O
12	O
-	O
month	O
depression	B-T038
.	O

Multivariable	O
logistic	O
regression	O
analyses	O
were	O
performed	O
.	O

After	O
adjustment	O
for	O
potential	O
confounders	O
,	O
women	B-T098
who	O
experienced	O
child	B-T033
death	I-T033
had	O
higher	O
odds	O
for	O
all	O
types	O
of	O
PLEs	B-T038
(	O
when	O
unadjusted	O
for	O
depression	B-T038
)	O
(	O
OR	O
1	O
.	O
20	O
-	O
1	O
.	O
71	O
;	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
depression	B-T038
(	O
OR	O
=	O
1	O
.	O
64	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
39	O
-	O
1	O
.	O
93	O
)	O
.	O

When	O
adjusted	O
for	O
depression	B-T038
,	O
only	O
delusion	B-T038
of	I-T038
control	I-T038
was	O
strongly	O
associated	O
with	O
child	B-T033
death	I-T033
(	O
OR	O
=	O
1	O
.	O
54	O
;	O
95	O
%	O
CI	O
=	O
1	O
.	O
20	O
-	O
1	O
.	O
97	O
)	O
.	O

Child	B-T033
death	I-T033
may	O
be	O
an	O
important	O
determinant	O
of	O
mental	B-T038
wellbeing	I-T038
among	O
women	B-T098
in	O
LMICs	B-T082
.	O

Given	O
the	O
known	O
adverse	O
health	O
outcomes	O
associated	O
with	O
PLEs	B-T038
and	O
depression	B-T038
,	O
as	O
well	O
as	O
the	O
co	O
-	O
occurrence	O
of	O
these	O
symptoms	B-T033
,	O
mental	B-T058
health	I-T058
care	I-T058
may	O
be	O
particularly	O
important	O
for	O
mothers	O
who	O
have	O
experienced	O
child	O
loss	O
in	O
LMICs	B-T082
.	O

Prednisolone	B-T103
is	O
associated	O
with	O
a	O
worse	B-T033
lipid	I-T033
profile	I-T033
than	O
hydrocortisone	B-T103
in	O
patients	O
with	O
adrenal	B-T038
insufficiency	I-T038

Prednisolone	B-T103
is	O
used	O
as	O
glucocorticoid	B-T103
replacement	B-T058
therapy	I-T058
for	O
adrenal	B-T038
insufficiency	I-T038
(	O
AI	B-T038
)	O
.	O

Recent	O
data	O
indicate	O
that	O
its	O
use	O
in	O
AI	B-T038
is	O
associated	O
with	O
low	O
bone	B-T201
mineral	I-T201
density	I-T201
.	O

Data	O
on	O
risk	B-T033
factors	I-T033
for	O
cardiovascular	B-T038
disease	I-T038
in	O
patients	O
with	O
AI	B-T038
treated	O
with	O
prednisolone	B-T103
are	O
scarce	O
,	O
despite	O
this	O
condition	O
being	O
the	O
predominant	O
cause	B-T033
of	O
excess	O
mortality	O
.	O

We	O
aimed	O
to	O
address	O
this	O
question	O
using	O
real	O
-	O
world	O
data	O
from	O
the	O
European	B-T170
Adrenal	I-T170
Insufficiency	I-T170
Registry	I-T170
(	O
EU	B-T170
-	I-T170
AIR	I-T170
)	O
.	O

EU	B-T170
-	I-T170
AIR	I-T170
,	O
comprising	O
of	O
19	O
centres	B-T092
across	O
Germany	B-T082
,	O
the	O
Netherlands	B-T082
,	O
Sweden	B-T082
and	O
the	O
UK	B-T082
,	O
commenced	O
enrolling	O
patients	O
with	O
AI	B-T038
in	O
August	O
2012	O
.	O

Patients	O
receiving	O
prednisolone	B-T103
(	O
3	O
-	O
6	O
mg	O
/	O
day	O
,	O
n	O
=	O
50	O
)	O
or	O
hydrocortisone	B-T103
(	O
15	O
-	O
30	O
mg	O
/	O
day	O
,	O
n	O
=	O
909	O
)	O
were	O
identified	O
and	O
grouped	B-T082
at	O
a	O
ratio	O
of	O
1	O
:	O
3	O
(	O
prednisolone	B-T103
:	O
hydrocortisone	B-T103
)	O
by	O
matching	O
for	O
gender	O
,	O
age	O
,	O
duration	O
and	O
type	B-T170
of	I-T170
disease	I-T170
.	O

Data	O
from	O
baseline	O
and	O
follow	B-T058
-	I-T058
up	I-T058
visits	B-T058
were	O
analysed	O
.	O

Data	O
from	O
patients	O
with	O
congenital	B-T038
adrenal	I-T038
hyperplasia	I-T038
were	O
excluded	O
.	O

Significantly	O
higher	O
mean	O
±	O
s	O
.	O
d	O
.	O

total	O
(	O
6	O
.	O
3	O
±	O
1	O
.	O
6	O
vs	O
5	O
.	O
4	O
±	O
1	O
.	O
1	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
and	O
low	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
(	I-T103
LDL	B-T103
)	I-T103
cholesterol	I-T103
levels	O
(	O
3	O
.	O
9	O
±	O
1	O
.	O
4	O
vs	O
3	O
.	O
2	O
±	O
1	O
.	O
0	O
mmol	O
/	O
L	O
;	O
P	O
=	O
0	O
.	O
013	O
)	O
were	O
identified	O
in	O
47	O
patients	O
on	O
prednisolone	B-T103
vs	O
141	O
receiving	O
hydrocortisone	B-T103
at	O
baseline	O
and	O
at	O
follow	B-T058
-	I-T058
up	I-T058
(	O
P	O
=	O
0	O
.	O
005	O
and	O
P	O
=	O
0	O
.	O
006	O
,	O
respectively	O
)	O
.	O

HbA1c	B-T103
,	O
high	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
and	O
triglyceride	B-T033
levels	I-T033
,	O
body	B-T201
mass	I-T201
index	I-T201
,	O
systolic	B-T038
and	O
diastolic	B-T038
blood	I-T038
pressure	I-T038
and	O
waist	B-T201
circumference	I-T201
were	O
not	O
significantly	O
different	O
.	O

This	O
is	O
the	O
first	O
matched	O
analysis	B-T062
of	O
its	O
kind	O
.	O

Significantly	O
higher	O
LDL	B-T033
levels	I-T033
in	O
patients	O
receiving	O
prednisolone	B-T103
relative	O
to	O
hydrocortisone	B-T103
could	O
predict	O
a	O
higher	O
relative	O
risk	O
of	O
cardiovascular	B-T038
disease	I-T038
in	O
the	O
former	O
group	O
.	O

Oxytocin	B-T103
Reduces	O
Face	B-T082
Processing	O
Time	O
but	O
Leaves	O
Recognition	B-T038
Accuracy	O
and	O
Eye	B-T017
-	O
Gaze	B-T033
Unaffected	O

Previous	O
studies	B-T062
have	O
found	O
that	O
oxytocin	B-T103
(	O
OXT	B-T103
)	O
can	O
improve	B-T033
the	O
recognition	B-T038
of	O
emotional	B-T033
facial	B-T033
expressions	I-T033
;	O
it	O
has	O
been	O
proposed	O
that	O
this	O
effect	O
is	O
mediated	O
by	O
an	O
increase	O
in	O
attention	B-T038
to	O
the	O
eye	B-T082
-	I-T082
region	I-T082
of	O
faces	B-T082
.	O

Nevertheless	O
,	O
evidence	O
in	O
support	O
of	O
this	O
claim	O
is	O
inconsistent	O
,	O
and	O
few	O
studies	B-T062
have	O
directly	O
tested	O
the	O
effect	O
of	O
oxytocin	B-T103
on	O
emotion	B-T038
recognition	B-T038
via	O
altered	O
eye	B-T017
-	O
gaze	B-T033
Methods	B-T170
:	O
In	O
a	O
double	B-T062
-	I-T062
blind	I-T062
,	O
within	B-T082
-	O
subjects	B-T098
,	O
randomized	B-T062
control	I-T062
experiment	I-T062
,	O
40	O
healthy	O
male	B-T098
participants	I-T098
received	O
24	O
IU	O
intranasal	B-T058
OXT	B-T103
and	O
placebo	B-T103
in	O
two	O
identical	O
experimental	O
sessions	O
separated	O
by	O
a	O
2	O
-	O
week	O
interval	O
.	O

Visual	B-T038
attention	I-T038
to	O
the	O
eye	B-T082
-	I-T082
region	I-T082
was	O
assessed	O
on	O
both	O
occasions	O
while	O
participants	B-T098
completed	O
a	O
static	O
facial	B-T082
emotion	B-T038
recognition	B-T038
task	O
using	O
medium	O
intensity	O
facial	B-T033
expressions	I-T033
.	O

Although	O
OXT	B-T103
had	O
no	O
effect	O
on	O
emotion	B-T038
recognition	B-T038
accuracy	O
,	O
recognition	B-T038
performance	O
was	O
improved	B-T033
because	O
face	B-T082
processing	O
was	O
faster	O
across	O
emotions	B-T038
under	O
the	O
influence	O
of	O
OXT	B-T103
.	O

This	O
effect	O
was	O
marginally	O
significant	O
(	O
p	O
<	O
.	O
06	O
)	O
.	O

Consistent	O
with	O
a	O
previous	O
study	B-T062
using	O
dynamic	O
stimuli	O
,	O
OXT	B-T103
had	O
no	O
effect	O
on	O
eye	B-T017
-	O
gaze	B-T033
patterns	B-T082
when	O
viewing	B-T082
static	O
emotional	B-T033
faces	B-T082
and	O
this	O
was	O
not	O
related	O
to	O
recognition	B-T038
accuracy	O
or	O
face	B-T082
processing	O
time	O
.	O

These	O
findings	B-T033
suggest	O
that	O
OXT	B-T103
-	O
induced	O
enhanced	O
facial	B-T082
emotion	B-T038
recognition	B-T038
is	O
not	O
necessarily	O
mediated	O
by	O
an	O
increase	O
in	O
attention	B-T038
to	O
the	O
eye	B-T082
-	I-T082
region	I-T082
of	O
faces	B-T082
,	O
as	O
previously	O
assumed	O
.	O

We	O
discuss	O
several	O
methodological	O
issues	B-T033
which	O
may	O
explain	O
discrepant	B-T033
findings	I-T033
and	O
suggest	O
the	O
effect	O
of	O
OXT	B-T103
on	O
visual	B-T038
attention	I-T038
may	O
differ	O
depending	O
on	O
task	O
requirements	O
.	O

(	O
JINS	O
,	O
2017	O
,	O
23	O
,	O
23	O
-	O
33	O
)	O
.	O

New	O
directions	O
for	O
psychiatric	B-T058
rehabilitation	I-T058
in	O
the	O
USA	B-T082

American	B-T098
researchers	B-T097
have	O
led	O
the	O
world	B-T098
in	O
developing	O
,	O
evaluating	B-T058
,	O
and	O
disseminating	B-T082
evidence	O
-	O
based	O
psychiatric	B-T058
rehabilitation	I-T058
practices	O
for	O
people	B-T098
with	O
serious	O
mental	B-T038
illness	I-T038
.	O

Paradoxically	O
,	O
however	O
,	O
the	O
USA	B-T082
lags	O
behind	O
most	O
industrialized	O
nations	O
in	O
providing	O
access	O
to	O
high	B-T058
-	I-T058
quality	I-T058
mental	B-T058
health	I-T058
and	O
psychiatric	B-T058
services	I-T058
.	O

This	O
essay	B-T170
examines	O
several	O
evidence	O
-	O
based	O
practices	O
developed	O
in	O
the	O
USA	B-T082
,	O
the	O
spread	O
of	O
these	O
practices	B-T058
,	O
the	O
barriers	O
to	O
ensuring	O
availability	O
to	O
people	B-T098
who	O
could	O
benefit	O
from	O
these	O
services	B-T058
,	O
and	O
some	O
promising	O
directions	O
for	O
overcoming	O
the	O
barriers	O
.	O

Factors	O
influencing	O
the	O
growth	O
and	O
sustainment	O
of	O
effective	O
client	O
-	O
centred	O
practices	B-T058
include	O
the	O
availability	O
of	O
adequate	O
and	O
stable	O
funding	O
,	O
committed	O
leadership	O
,	O
and	O
the	O
influence	O
of	O
vested	O
interests	O
.	O

Two	O
strategies	O
for	O
promoting	O
the	O
spread	O
and	O
sustainment	O
of	O
well	O
-	O
implemented	O
evidence	O
-	O
based	O
practices	O
are	O
the	O
adoption	O
of	O
fidelity	O
scales	O
and	O
learning	B-T038
communities	O
.	O

Modifiable	O
Healthy	O
Lifestyle	O
Behaviors	O
:	O
10	O
-	O
Year	O
Health	O
Outcomes	O
From	O
a	O
Health	B-T058
Promotion	I-T058
Program	I-T058

Previous	O
studies	O
have	O
examined	O
the	O
impact	O
of	O
healthy	O
lifestyle	O
choices	O
on	O
health	O
-	O
related	O
outcomes	O
;	O
however	O
,	O
given	O
their	O
fragmented	O
,	O
often	O
cross	B-T062
-	I-T062
sectional	I-T062
nature	I-T062
,	O
assessing	B-T058
the	I-T058
relative	I-T058
impact	I-T058
of	O
daily	O
modifiable	O
behaviors	O
on	O
overall	O
long	O
-	O
term	O
outcomes	O
,	O
particularly	O
for	O
a	O
diverse	O
working	B-T098
adult	I-T098
population	I-T098
,	O
remains	O
challenging	O
.	O

Relationships	O
between	O
ten	O
self	B-T062
-	I-T062
reported	I-T062
healthy	O
lifestyle	O
behaviors	O
and	O
health	O
outcomes	O
during	O
the	O
subsequent	O
9	O
years	O
in	O
a	O
cohort	B-T098
of	O
10	O
,	O
248	O
participants	B-T098
enrolled	O
during	O
2003	O
in	O
a	O
voluntary	O
workplace	B-T082
wellness	B-T058
program	I-T058
were	O
assessed	O
.	O

Cox	B-T170
proportional	I-T170
-	I-T170
hazards	I-T170
models	I-T170
computed	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
lifestyle	O
characteristics	O
associated	O
with	O
time	O
to	O
one	O
of	O
seven	O
self	B-T062
-	I-T062
reported	I-T062
chronic	B-T038
diseases	I-T038
or	O
death	B-T038
.	O

Data	B-T033
were	I-T033
collected	I-T033
between	O
2003	O
and	O
2012	O
and	O
analyzed	O
between	O
2014	O
and	O
2016	O
.	O

Behaviors	O
that	O
most	O
significantly	O
affected	O
future	O
outcomes	O
were	O
low	B-T058
-	I-T058
fat	I-T058
diet	I-T058
,	O
aerobic	B-T058
exercise	I-T058
,	O
nonsmoking	O
,	O
and	O
adequate	B-T033
sleep	I-T033
.	O

A	O
dose	B-T062
-	I-T062
response	I-T062
effect	I-T062
was	O
seen	O
between	O
dietary	B-T033
fat	I-T033
intake	I-T033
and	O
hypertension	B-T038
,	O
obesity	B-T038
,	O
diabetes	B-T038
,	O
heart	B-T038
disease	I-T038
,	O
and	O
hypercholesterolemia	B-T038
.	O

After	O
dietary	B-T033
fat	I-T033
intake	I-T033
,	O
aerobic	B-T058
exercise	I-T058
was	O
the	O
next	O
most	O
significant	O
behavior	O
associated	O
with	O
development	B-T062
of	I-T062
outcomes	I-T062
.	O

Compared	O
with	O
sedentary	O
participants	B-T098
,	O
those	O
who	O
exercised	O
4	O
days	O
per	O
week	O
were	O
less	O
likely	O
to	O
develop	O
new	O
-	O
onset	O
diabetes	O
(	O
HR	O
=	O
0	O
.	O
31	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
20	O
,	O
0	O
.	O
48	O
)	O
;	O
heart	B-T038
disease	I-T038
(	O
HR	O
=	O
0	O
.	O
46	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
27	O
,	O
0	O
.	O
80	O
)	O
;	O
and	O
hypercholesterolemia	B-T038
(	O
HR	O
=	O
0	O
.	O
61	O
,	O
95	O
%	O
CI	O
=	O
0	O
.	O
50	O
,	O
0	O
.	O
74	O
)	O
.	O

Low	B-T058
-	I-T058
fat	I-T058
diet	I-T058
and	O
adequate	B-T033
sleep	I-T033
were	O
more	O
significant	O
than	O
commonly	O
promoted	O
healthy	O
behaviors	O
,	O
such	O
as	O
eating	O
a	O
daily	O
breakfast	O
.	O

Modifiable	O
lifestyle	O
behaviors	O
targeted	O
in	O
health	B-T058
promotion	I-T058
programs	I-T058
should	O
be	O
prioritized	O
in	O
an	O
evidence	O
-	O
based	O
manner	O
.	O

Top	O
priorities	O
for	O
workplace	B-T082
health	B-T058
promotion	I-T058
should	O
include	O
low	B-T058
-	I-T058
fat	I-T058
diet	I-T058
,	O
aerobic	B-T058
exercise	I-T058
,	O
nonsmoking	O
,	O
and	O
adequate	B-T033
sleep	I-T033
.	O

Diazoxide	B-T103
prevents	O
reactive	B-T103
oxygen	I-T103
species	I-T103
and	O
mitochondrial	B-T038
damage	I-T038
,	O
leading	O
to	O
anti	B-T033
-	I-T033
hypertrophic	I-T033
effects	I-T033

Pathological	O
cardiac	B-T038
hypertrophy	I-T038
is	O
characterized	O
by	O
wall	B-T017
thickening	B-T033
or	O
chamber	B-T017
enlargement	B-T038
of	O
the	O
heart	B-T017
in	O
response	O
to	O
pressure	O
or	O
volume	O
overload	O
,	O
respectively	O
.	O

This	O
condition	O
will	O
,	O
initially	O
,	O
improve	B-T033
the	O
organ	B-T017
contractile	B-T038
function	I-T038
,	O
but	O
if	O
sustained	O
will	O
render	O
dysfunctional	O
mitochondria	B-T017
and	O
oxidative	B-T038
stress	I-T038
.	O

Mitochondrial	B-T103
ATP	I-T103
-	I-T103
sensitive	I-T103
K	I-T103
(	I-T103
+	I-T103
)	I-T103
channels	I-T103
(	O
mitoKATP	B-T103
)	O
modulate	B-T082
the	O
redox	B-T038
status	I-T038
of	O
the	O
cell	B-T017
and	O
protect	O
against	O
several	O
cardiac	B-T017
insults	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
mitoKATP	B-T103
opening	B-T082
(	O
using	O
diazoxide	B-T103
)	O
will	O
avoid	O
isoproterenol	B-T103
-	O
induced	O
cardiac	B-T038
hypertrophy	I-T038
in	B-T082
vivo	I-T082
by	O
decreasing	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	B-T103
ROS	I-T103
)	O
production	O
and	O
mitochondrial	B-T017
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
induced	O
swelling	B-T033
.	O

To	O
induce	O
cardiac	B-T038
hypertrophy	I-T038
,	O
Swiss	B-T204
mice	I-T204
were	O
treated	O
intraperitoneally	B-T082
with	O
isoproterenol	B-T103
(	O
30	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
8	O
days	O
.	O

Diazoxide	B-T103
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
used	O
to	O
open	O
mitoKATP	B-T103
and	O
5	B-T103
-	I-T103
hydroxydecanoate	I-T103
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
administrated	O
as	O
a	O
mitoKATP	B-T103
blocker	O
.	O

Isoproterenol	B-T103
-	O
treated	O
mice	B-T204
had	O
elevated	O
heart	B-T017
weight	O
/	O
tibia	B-T017
length	O
ratios	O
and	O
increased	O
myocyte	B-T017
cross	B-T033
-	I-T033
sectional	I-T033
areas	I-T033
.	O

Additionally	O
,	O
hypertrophic	O
hearts	B-T017
produced	O
higher	O
levels	O
of	O
H2O2	B-T103
and	O
had	O
lower	O
glutathione	B-T038
peroxidase	I-T038
activity	I-T038
.	O

In	O
contrast	O
,	O
mitoKATP	B-T103
opening	B-T082
with	O
diazoxide	B-T103
blocked	O
all	O
isoproterenol	B-T103
effects	O
in	O
a	O
manner	O
reversed	O
by	O
5	B-T103
-	I-T103
hydroxydecanoate	I-T103
.	O

Isolated	O
mitochondria	B-T017
from	O
Isoproterenol	B-T103
-	O
induced	O
hypertrophic	O
hearts	B-T017
had	O
increased	O
susceptibility	O
to	O
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
induced	O
swelling	B-T033
secondary	O
to	O
mitochondrial	B-T103
permeability	I-T103
transition	I-T103
pore	I-T103
opening	B-T082
.	O

MitokATP	B-T103
opening	B-T082
was	O
accompanied	O
by	O
lower	O
Ca	B-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	O
induced	O
mitochondrial	B-T038
swelling	I-T038
,	O
an	O
effect	O
blocked	O
by	O
5	B-T103
-	I-T103
hydroxydecanoate	I-T103
.	O

Our	O
results	O
suggest	O
that	O
mitoKATP	B-T103
opening	B-T082
negatively	B-T033
regulates	B-T038
cardiac	B-T038
hypertrophy	I-T038
by	O
avoiding	O
oxidative	O
impairment	O
and	O
mitochondrial	B-T038
damage	I-T038
.	O

Anticholinergic	B-T103
premedication	B-T058
to	O
prevent	O
bradycardia	B-T038
in	O
combined	O
spinal	B-T058
anesthesia	I-T058
and	O
dexmedetomidine	B-T103
sedation	B-T058
:	O
a	O
randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	O
-	O
controlled	O
study	O

When	O
dexmedetomidine	B-T103
is	O
used	O
in	O
patients	O
undergoing	O
spinal	B-T058
anesthesia	I-T058
,	O
high	O
incidence	O
of	O
bradycardia	B-T038
in	O
response	O
to	O
parasympathetic	B-T022
activation	O
is	O
reported	O
.	O

Therefore	O
,	O
we	O
aimed	O
to	O
evaluate	O
the	O
effectiveness	O
of	O
atropine	B-T103
premedication	B-T058
for	O
preventing	O
the	O
incidence	O
of	O
bradycardia	B-T038
and	O
the	O
hemodynamic	B-T038
effect	I-T038
on	O
patients	O
undergoing	O
spinal	B-T058
anesthesia	I-T058
with	O
sedation	B-T058
by	O
dexmedetomidine	B-T103
.	O

Randomized	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	O
-	O
controlled	O
study	O
.	O

Operating	B-T092
room	I-T092
.	O

One	O
hundred	O
fourteen	O
patients	B-T103
(	O
age	O
range	O
,	O
2	O
-	O
65	O
years	O
;	O
American	B-T092
Society	I-T092
of	I-T092
Anesthesiology	I-T092
class	I-T092
I	I-T092
-	I-T092
II	I-T092
)	O
participated	O
in	O
this	O
study	B-T062
,	O
willing	O
to	O
be	O
sedated	O
and	O
to	O
undergo	O
spinal	B-T058
anesthesia	I-T058
.	O

The	O
patients	B-T103
were	O
divided	O
into	O
2	O
groups	O
:	O
group	O
A	O
and	O
group	O
C	O
.	O

After	O
performing	O
spinal	B-T058
anesthesia	I-T058
,	O
dexmedetomidine	B-T103
was	O
infused	B-T058
at	O
a	O
loading	O
dose	O
of	O
0	O
.	O
6	O
μg	O
/	O
kg	O
for	O
10	O
minutes	O
,	O
followed	O
by	O
an	O
infusion	B-T058
at	O
0	O
.	O
25	O
μg	O
/	O
(	O
kg	O
h	O
)	O
.	O

Simultaneously	O
with	O
the	O
loading	O
dose	O
of	O
dexmedetomidine	B-T103
,	O
patients	B-T103
in	O
group	O
A	O
received	O
an	O
intravenous	O
bolus	O
of	O
0	O
.	O
5	O
mg	O
atropine	B-T103
,	O
whereas	O
patients	B-T103
in	O
group	O
C	O
received	O
an	O
intravenous	O
normal	O
saline	O
bolus	B-T058
.	O

Data	O
on	O
administration	B-T058
of	O
atropine	B-T103
and	O
ephedrine	B-T103
were	O
collected	O
.	O

Hemodynamic	B-T058
data	O
including	O
heart	B-T201
rate	I-T201
,	O
systolic	B-T201
blood	I-T201
pressure	I-T201
,	O
diastolic	B-T201
blood	I-T201
pressure	I-T201
(	O
DBP	B-T201
)	O
,	O
and	O
mean	B-T033
blood	I-T033
pressure	I-T033
(	O
MBP	B-T033
)	O
were	O
also	O
recorded	O
.	O

The	O
incidence	O
of	O
bradycardia	B-T038
requiring	O
atropine	B-T103
treatment	B-T058
was	O
significantly	O
higher	O
in	O
group	O
C	O
than	O
group	O
A	O
(	O
P	O
=	O
.	O
035	O
)	O
.	O

However	O
,	O
the	O
incidence	O
of	O
hypotension	B-T033
needing	O
ephedrine	B-T103
treatment	B-T058
showed	O
no	O
significant	O
difference	O
between	O
the	O
2	O
groups	O
(	O
P	O
=	O
.	O
7	O
)	O
.	O

Systolic	B-T201
blood	I-T201
pressure	I-T201
and	O
heart	B-T201
rate	I-T201
showed	O
no	O
significant	O
differences	O
between	O
the	O
2	O
groups	O
(	O
P	O
=	O
.	O
138	O
and	O
.	O
464	O
,	O
respectively	O
)	O
.	O

However	O
,	O
group	O
A	O
showed	O
significant	O
increases	O
in	O
DBP	B-T201
and	O
MBP	B-T033
,	O
and	O
group	O
C	O
did	O
not	O
(	O
P	O
=	O
.	O
014	O
and	O
.	O
008	O
,	O
respectively	O
)	O
.	O

Prophylactic	B-T058
atropine	B-T103
reduces	O
the	O
incidence	O
of	O
bradycardia	B-T038
in	O
patients	B-T103
undergoing	O
spinal	B-T058
anesthesia	I-T058
with	O
dexmedetomidine	B-T103
sedation	B-T058
.	O

However	O
,	O
DBP	B-T201
and	O
MBP	B-T033
showed	O
significant	O
increases	O
in	O
patients	B-T103
when	O
prophylactic	B-T058
atropine	B-T103
was	O
administrated	B-T058
.	O

Therefore	O
,	O
atropine	B-T103
premedication	B-T058
should	O
be	O
administered	B-T058
cautiously	O
.	O

Downregulation	B-T038
of	O
Endothelial	B-T103
Transient	I-T103
Receptor	I-T103
Potential	I-T103
Vanilloid	I-T103
Type	I-T103
4	I-T103
Channel	I-T103
and	O
Small	B-T103
-	I-T103
Conductance	I-T103
of	I-T103
Ca2	I-T103
+	I-T103
-	I-T103
Activated	I-T103
K	I-T103
+	I-T103
Channels	I-T103
Underpins	O
Impaired	O
Endothelium	B-T103
-	I-T103
Dependent	I-T103
Hyperpolarization	I-T103
in	O
Hypertension	B-T038

Endothelium	B-T103
-	I-T103
dependent	I-T103
hyperpolarization	I-T103
(	O
EDH	B-T103
)	O
-	O
mediated	O
responses	B-T033
are	O
impaired	O
in	O
hypertension	B-T038
,	O
but	O
the	O
underlying	O
mechanisms	O
have	O
not	O
yet	O
been	O
determined	O
.	O

The	O
activation	O
of	O
small	B-T103
-	I-T103
and	O
intermediate	B-T103
-	I-T103
conductance	I-T103
of	I-T103
Ca	I-T103
(	I-T103
2	I-T103
+	I-T103
)	I-T103
-	I-T103
activated	I-T103
K	I-T103
(	I-T103
+	I-T103
)	I-T103
channels	I-T103
(	O
SKCa	B-T103
and	O
IKCa	B-T103
)	O
underpins	O
EDH	B-T103
-	O
mediated	O
responses	B-T033
.	O

It	O
was	O
recently	O
reported	B-T170
that	O
Ca	B-T038
(	I-T038
2	I-T038
+	I-T038
)	I-T038
influx	I-T038
through	O
endothelial	B-T103
transient	I-T103
receptor	I-T103
potential	I-T103
vanilloid	I-T103
type	I-T103
4	I-T103
channel	I-T103
(	O
TRPV4	B-T103
)	O
is	O
a	O
prerequisite	O
for	O
the	O
activation	O
of	O
SKCa	B-T103
/	O
IKCa	B-T103
in	O
endothelial	B-T017
cells	I-T017
in	O
specific	O
beds	O
.	O

Here	O
,	O
we	O
attempted	O
to	O
determine	O
whether	O
the	O
impairment	O
of	O
EDH	B-T103
in	O
hypertension	B-T038
is	O
attributable	O
to	O
the	O
dysfunction	O
of	O
TRPV4	B-T103
and	O
S	B-T103
/	O
IKCa	B-T103
,	O
using	O
isolated	O
superior	B-T017
mesenteric	I-T017
arteries	I-T017
of	O
20	O
-	O
week	O
-	O
old	O
stroke	B-T204
-	I-T204
prone	I-T204
spontaneously	I-T204
hypertensive	I-T204
rats	I-T204
(	O
SHRSP	B-T204
)	O
and	O
age	O
-	O
matched	O
Wistar	B-T204
-	I-T204
Kyoto	I-T204
(	I-T204
WKY	I-T204
)	I-T204
rats	I-T204
.	O

In	O
the	O
WKY	B-T204
arteries	B-T017
,	O
EDH	B-T103
-	O
mediated	O
responses	B-T033
were	O
reduced	O
by	O
a	O
combination	O
of	O
SKCa	B-T103
/	O
IKCa	B-T103
blockers	O
(	O
apamin	B-T103
plus	O
TRAM	B-T103
-	I-T103
34	I-T103
;	O
1	B-T103
-	I-T103
[	I-T103
(	I-T103
2	I-T103
-	I-T103
chlorophenyl	I-T103
)	I-T103
diphenylmethl	I-T103
]	I-T103
-	I-T103
1H	I-T103
-	I-T103
pyrazole	I-T103
)	O
and	O
by	O
the	O
blockade	O
of	O
TRPV4	B-T103
with	O
the	O
selective	O
antagonist	B-T103
RN	B-T103
-	I-T103
1734	I-T103
or	O
HC	B-T103
-	I-T103
067047	I-T103
.	O

In	O
the	O
SHRSP	B-T204
arteries	B-T017
,	O
EDH	B-T103
-	I-T103
mediated	I-T103
hyperpolarization	I-T103
and	O
relaxation	O
were	O
significantly	O
impaired	O
when	O
compared	O
with	O
WKY	B-T204
.	O

GSK1016790A	B-T103
,	O
a	O
selective	O
TRPV4	B-T103
activator	B-T103
,	O
evoked	O
robust	O
hyperpolarization	B-T038
and	O
relaxation	O
in	O
WKY	B-T204
arteries	B-T017
.	O

In	O
contrast	O
,	O
in	O
SHRSP	B-T204
arteries	B-T017
,	O
the	O
GSK1016790A	B-T103
-	O
evoked	O
hyperpolarization	B-T038
was	O
small	O
and	O
relaxation	O
was	O
absent	O
.	O

Hyperpolarization	B-T038
and	O
relaxation	O
to	O
cyclohexyl	B-T103
-	I-T103
[	I-T103
2	I-T103
-	I-T103
(	I-T103
3	I-T103
,	I-T103
5	I-T103
-	I-T103
dimethyl	I-T103
-	I-T103
pyrazol	I-T103
-	I-T103
1	I-T103
-	I-T103
yl	I-T103
)	I-T103
-	I-T103
6	I-T103
-	I-T103
methyl	I-T103
-	I-T103
pyrimidin	I-T103
-	I-T103
4	I-T103
-	I-T103
yl	I-T103
]	I-T103
-	I-T103
amine	I-T103
,	O
a	O
selective	O
SKCa	B-T103
activator	B-T103
,	O
were	O
marginally	O
decreased	O
in	O
SHRSP	B-T204
arteries	B-T017
compared	O
with	O
WKY	B-T204
arteries	B-T017
.	O

The	O
expression	B-T038
of	O
endothelial	B-T103
TRPV4	I-T103
and	O
SKCa	B-T103
protein	O
was	O
significantly	O
decreased	O
in	O
the	O
SHRSP	B-T204
mesenteric	B-T017
arteries	I-T017
compared	O
with	O
those	O
of	O
WKY	B-T204
,	O
whereas	O
function	O
and	O
expression	B-T038
of	O
IKCa	B-T103
were	O
preserved	O
in	O
SHRSP	B-T204
arteries	B-T017
.	O

These	O
findings	B-T033
suggest	O
that	O
EDH	B-T103
-	O
mediated	O
responses	B-T033
are	O
impaired	O
in	O
superior	B-T017
mesenteric	I-T017
arteries	I-T017
of	O
SHRSP	B-T204
because	O
of	O
a	O
reduction	B-T058
in	O
both	O
TRPV4	B-T103
and	O
SKCa	B-T103
input	O
to	O
EDH	B-T103
.	O

Bioavailability	B-T062
and	O
health	O
risk	O
assessment	O
of	O
potentially	O
toxic	B-T103
elements	I-T103
in	O
Thriasio	B-T082
Plain	I-T082
,	I-T082
near	I-T082
Athens	I-T082
,	O
Greece	B-T082

Elevated	O
concentrations	O
of	O
potentially	O
toxic	B-T103
elements	I-T103
(	O
PTEs	B-T103
)	O
are	O
usually	O
found	O
in	O
areas	O
of	O
intense	O
industrial	O
activity	O
.	O

Thriasio	B-T082
Plain	I-T082
is	O
a	O
plain	B-T082
near	I-T082
Athens	I-T082
,	O
Greece	B-T082
,	O
where	O
most	O
of	O
the	O
heavy	O
industry	O
of	O
the	O
country	O
has	O
been	O
situated	O
for	O
decades	O
,	O
but	O
it	O
also	O
is	O
a	O
residential	B-T082
and	O
horticultural	O
area	B-T082
.	O

We	O
aimed	O
at	O
measuring	O
the	O
levels	O
of	O
PTEs	B-T103
in	O
soils	O
and	O
indigenous	O
plant	B-T204
species	I-T204
and	O
assessing	O
the	O
health	O
risk	O
associated	O
with	O
direct	O
soil	O
ingestion	B-T038
.	O

Samples	O
of	O
soils	O
at	O
roadsides	O
and	O
growing	O
plants	B-T204
were	O
collected	O
from	O
31	O
sites	O
of	O
that	O
area	B-T082
.	O

Concentrations	O
of	O
Al	B-T103
,	O
As	B-T103
,	O
Cd	B-T103
,	O
Co	B-T103
,	O
Cr	B-T103
,	O
Cu	B-T103
,	O
Fe	B-T103
,	O
Mn	B-T103
,	O
Mo	B-T103
,	O
Ni	B-T103
,	O
Pb	B-T103
,	O
V	B-T103
and	O
Zn	B-T103
were	O
measured	O
in	O
both	O
soils	O
(	O
as	O
pseudo	O
-	O
total	O
)	O
and	O
aerial	O
plant	B-T017
tissues	I-T017
.	O

We	O
found	O
that	O
As	B-T103
,	O
Cd	B-T103
,	O
Cr	B-T103
,	O
Cu	B-T103
,	O
Ni	B-T103
,	O
Pb	B-T103
and	O
Zn	B-T103
were	O
higher	O
than	O
maximum	O
regulatory	B-T170
limits	O
.	O

Element	B-T103
concentrations	O
in	O
plants	B-T204
were	O
rather	O
lower	O
than	O
expected	O
,	O
probably	O
because	O
indigenous	O
plants	B-T204
have	O
developed	O
excluder	O
behaviour	O
over	O
time	O
.	O

Copper	B-T103
and	O
Zn	B-T103
soil	O
-	O
to	O
-	O
plant	B-T204
coefficients	O
were	O
highest	O
among	O
the	O
other	O
elements	B-T103
;	O
for	O
Cu	B-T103
this	O
was	O
unexpected	O
,	O
and	O
probably	O
associated	O
with	O
recent	O
Cu	B-T103
-	O
releasing	O
industrial	O
activity	O
.	O

Risk	B-T058
assessment	I-T058
analysis	I-T058
indicated	O
that	O
As	B-T103
was	O
the	O
element	B-T103
contributing	O
more	O
than	O
50	O
%	O
of	O
the	O
health	O
risk	O
related	O
to	O
direct	O
soil	O
ingestion	B-T038
,	O
followed	O
by	O
Cr	B-T103
,	O
Pb	B-T103
,	O
and	O
,	O
surprisingly	O
,	O
Mn	B-T103
.	O

We	O
concluded	O
that	O
in	O
a	O
multi	O
-	O
element	B-T103
contamination	O
situation	O
,	O
elevated	O
risk	O
of	O
PTEs	B-T103
(	O
such	O
as	O
As	B-T103
,	O
Cr	B-T103
and	O
Pb	B-T103
)	O
may	O
reduce	O
the	O
tolerance	O
limits	O
of	O
exposure	O
to	O
less	O
-	O
toxic	B-T103
elements	I-T103
(	O
here	O
,	O
Mn	B-T103
)	O
.	O

Nutrients	B-T168
influence	O
the	O
thermal	O
ecophysiology	O
of	O
an	O
intertidal	O
macroalga	B-T204
:	O
multiple	O
stressors	O
or	O
multiple	O
drivers	O
?	O

Urbanization	O
of	O
coastlines	O
is	O
leading	O
to	O
increased	O
introduction	O
of	O
nutrients	B-T168
from	O
the	O
terrestrial	B-T082
environment	I-T082
to	O
nearshore	B-T082
habitats	I-T082
.	O

While	O
such	O
nutrient	B-T168
influxes	O
can	O
be	O
detrimental	O
to	O
coastal	O
marine	O
organisms	O
due	O
to	O
increased	O
eutrophication	O
and	O
subsequent	O
reduced	O
oxygen	B-T103
,	O
they	O
could	O
also	O
have	O
positive	O
effects	O
(	O
i	O
.	O
e	O
.	O
,	O
increased	O
food	B-T168
availability	O
)	O
on	O
species	B-T170
that	O
are	O
nitrogen	B-T103
-	I-T103
limited	I-T103
such	O
as	O
macroalgae	B-T204
.	O

Nutrient	B-T168
enrichment	O
in	O
this	O
environment	B-T082
thus	O
has	O
the	O
potential	O
to	O
counteract	O
some	O
of	O
the	O
negative	O
impacts	O
of	O
increasing	O
temperatures	O
,	O
at	O
least	O
for	O
some	O
species	B-T170
.	O

Characterizing	O
the	O
physiological	O
response	O
of	O
organisms	O
to	O
simultaneous	O
changes	O
in	O
multiple	O
drivers	O
such	O
as	O
these	O
is	O
an	O
important	O
first	O
step	O
in	O
predicting	O
how	O
global	O
climate	O
change	O
may	O
lead	O
to	O
ecological	O
responses	O
at	O
more	O
local	O
levels	O
.	O

We	O
evaluated	O
how	O
nutrient	B-T168
enrichment	O
(	O
i	O
.	O
e	O
.	O
,	O
nitrogen	B-T103
availability	O
)	O
affected	O
the	O
growth	B-T038
of	O
Fucus	B-T204
vesiculosus	I-T204
,	O
a	O
foundational	O
macroalgal	B-T204
species	B-T204
in	O
the	O
North	B-T082
Atlantic	I-T082
rocky	I-T082
intertidal	I-T082
zone	I-T082
,	O
and	O
found	O
that	O
nutrient	B-T168
-	O
enriched	O
algal	B-T170
blades	I-T170
showed	O
a	O
significant	O
increase	O
in	O
tissue	B-T038
growth	I-T038
compared	O
to	O
individuals	O
grown	O
under	O
ambient	O
conditions	O
.	O

We	O
further	O
quantified	O
net	O
photosynthesis	O
by	O
ambient	O
and	O
nutrient	B-T168
-	O
enriched	O
tissues	B-T017
at	O
saturating	O
irradiance	O
over	O
a	O
range	O
of	O
temperature	O
conditions	O
(	O
6	O
-	O
30°C	O
)	O
.	O

Respiration	B-T038
was	O
unaffected	O
by	O
nutrient	B-T168
treatment	O
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
photosynthetic	O
oxygen	B-T103
production	O
for	O
nutrient	B-T168
-	O
enriched	O
tissue	B-T017
compared	O
to	O
ambient	O
,	O
but	O
only	O
at	O
elevated	O
(	O
≥18°C	O
)	O
temperatures	O
.	O

This	O
study	B-T062
contributes	O
to	O
a	O
growing	O
body	O
of	O
literature	B-T170
showing	O
the	O
complexity	O
of	O
responses	O
to	O
changes	O
in	O
multiple	O
drivers	O
,	O
and	O
highlights	O
the	O
importance	O
of	O
studying	B-T062
the	O
impacts	O
of	O
global	O
climate	O
change	O
within	O
the	O
context	O
of	O
more	O
local	O
environmental	B-T082
conditions	O
.	O

A	O
trial	B-T062
to	O
determine	O
whether	O
septic	B-T038
shock	I-T038
-	O
reversal	O
is	O
quicker	O
in	O
pediatric	O
patients	O
randomized	B-T062
to	O
an	O
early	O
goal	B-T058
-	I-T058
directed	I-T058
fluid	I-T058
-	I-T058
sparing	I-T058
strategy	I-T058
versus	O
usual	O
care	O
(	O
SQUEEZE	B-T062
)	O
:	O
study	B-T170
protocol	I-T170
for	O
a	O
pilot	B-T062
randomized	I-T062
controlled	I-T062
trial	I-T062

Current	O
pediatric	O
septic	B-T038
shock	I-T038
resuscitation	B-T058
guidelines	B-T170
from	O
the	O
American	B-T092
College	I-T092
of	I-T092
Critical	I-T092
Care	I-T092
Medicine	I-T092
focus	O
on	O
the	O
early	O
and	O
goal	B-T058
-	I-T058
directed	I-T058
administration	I-T058
of	O
intravascular	B-T082
fluid	B-T031
followed	O
by	O
vasoactive	O
medication	B-T103
infusions	B-T058
for	O
persistent	O
and	O
fluid	B-T038
-	I-T038
refractory	I-T038
shock	I-T038
.	O

However	O
,	O
accumulating	B-T033
adult	O
and	O
pediatric	O
data	O
suggest	O
that	O
excessive	O
fluid	B-T058
administration	I-T058
is	O
associated	O
with	O
worse	B-T033
patient	O
outcomes	O
and	O
even	O
increased	B-T033
risk	I-T033
of	I-T033
death	I-T033
.	O

The	O
optimal	O
amount	O
of	O
intravascular	B-T082
fluid	B-T031
required	O
in	O
early	O
pediatric	O
septic	B-T038
shock	I-T038
resuscitation	B-T058
prior	O
to	O
the	O
initiation	O
of	O
vasoactive	O
support	O
remains	O
unanswered	O
.	O

The	O
SQUEEZE	B-T062
Pilot	I-T062
Trial	I-T062
is	O
a	O
pragmatic	O
,	O
two	B-T062
-	I-T062
arm	I-T062
,	O
parallel	B-T062
-	I-T062
group	I-T062
,	O
open	B-T062
-	I-T062
label	I-T062
,	O
prospective	B-T062
pilot	I-T062
randomized	I-T062
controlled	I-T062
trial	I-T062
.	O

Participants	B-T098
are	O
children	O
aged	O
29	O
days	O
to	O
under	O
18	O
years	O
with	O
suspected	O
or	O
confirmed	B-T033
septic	B-T038
shock	I-T038
and	O
a	O
need	O
for	O
ongoing	O
resuscitation	B-T058
.	O

Eligible	O
participants	B-T098
are	O
enrolled	B-T058
under	O
an	O
exception	O
to	O
consent	O
process	O
and	O
randomly	O
assigned	O
via	O
concealed	O
allocation	O
to	O
either	O
the	O
Usual	O
Care	O
(	O
control	O
)	O
or	O
Fluid	B-T058
Sparing	I-T058
(	I-T058
intervention	I-T058
)	I-T058
resuscitation	I-T058
strategy	I-T058
.	O

The	O
primary	O
objective	B-T170
of	O
this	O
pilot	B-T062
trial	I-T062
is	O
to	O
determine	O
feasibility	B-T062
,	O
based	O
on	O
the	O
ability	O
to	O
enroll	B-T058
participants	B-T098
and	O
to	O
adhere	O
to	O
the	O
study	B-T170
protocol	I-T170
.	O

The	O
primary	O
outcome	O
measure	O
by	O
which	O
success	O
will	O
be	O
determined	O
is	O
participant	B-T098
enrollment	B-T058
rate	O
(	O
"	O
pass	O
"	O
defined	O
as	O
at	O
least	O
two	O
participants	B-T098
/	O
site	B-T082
/	O
month	O
,	O
recognizing	O
that	O
enrollment	B-T058
may	O
be	O
slower	O
during	O
the	O
run	O
-	O
in	O
phase	O
)	O
.	O

Secondary	O
objectives	B-T170
include	O
assessing	O
(	O
1	O
)	O
appropriateness	O
of	O
eligibility	O
criteria	O
,	O
and	O
(	O
2	O
)	O
completeness	O
of	O
clinical	O
outcomes	O
to	O
inform	O
the	O
endpoints	O
for	O
the	O
planned	O
multisite	B-T062
trial	I-T062
.	O

To	O
support	O
the	O
nested	B-T062
translational	I-T062
study	I-T062
,	O
SQUEEZE	B-T062
-	I-T062
D	I-T062
,	O
we	O
will	O
also	O
evaluate	O
the	O
feasibility	B-T062
of	O
describing	O
cell	B-T103
-	I-T103
free	I-T103
DNA	I-T103
(	O
a	O
procoagulant	B-T103
molecule	I-T103
with	O
prognostic	B-T170
utility	I-T170
)	O
in	O
blood	B-T031
samples	I-T031
obtained	O
from	O
children	O
enrolled	B-T058
into	O
the	O
SQUEEZE	B-T062
Pilot	I-T062
Trial	I-T062
at	O
baseline	O
and	O
at	O
24	O
h	O
.	O

The	O
optimal	O
degree	O
of	O
fluid	B-T031
resuscitation	B-T058
and	O
the	O
timing	O
of	O
initiation	O
of	O
vasoactive	O
support	O
in	O
order	O
to	O
achieve	O
recommended	O
therapeutic	O
targets	O
in	O
children	O
with	O
septic	B-T038
shock	I-T038
remains	O
unanswered	O
.	O

No	O
prospective	B-T062
study	I-T062
to	O
date	O
has	O
examined	O
this	O
important	O
question	B-T170
for	O
children	O
in	O
developed	O
countries	O
including	O
Canada	B-T082
.	O

Recruitment	O
for	O
the	O
SQUEEZE	B-T062
Pilot	I-T062
Trial	I-T062
opened	O
on	O
6	O
January	O
2014	O
.	O

Findings	B-T033
will	O
inform	O
the	O
feasibility	B-T062
of	O
the	O
planned	O
multicenter	B-T062
trial	I-T062
to	O
answer	O
our	O
overall	O
research	O
question	O
.	O

ClinicalTrials	O
.	O
gov	O
Identifier	O
NCT01973907	O
,	O
registered	O
on	O
23	O
October	O
2013	O
.	O

Entropy	O
-	O
driven	O
reactions	O
in	O
living	O
cells	B-T017
for	O
assay	B-T058
let	B-T103
-	I-T103
7a	I-T103
microRNA	I-T103

Imaging	B-T058
of	O
microRNA	B-T103
(	O
miRNA	B-T103
)	O
in	O
living	O
cells	B-T017
could	O
facilitate	O
the	O
monitoring	O
of	O
the	O
expression	B-T038
and	O
distribution	O
of	O
miRNA	B-T103
and	O
research	B-T062
on	O
miRNA	B-T103
-	O
related	O
diseases	B-T038
.	O

Given	O
the	O
low	O
expression	O
levels	O
and	O
even	O
down	B-T038
-	I-T038
regulation	I-T038
of	O
cellular	B-T017
miRNA	B-T103
that	O
is	O
associated	O
with	O
some	O
diseases	B-T038
,	O
enzyme	B-T103
-	O
free	O
amplification	B-T062
strategies	I-T062
are	O
imperative	O
for	O
intracellular	B-T082
miRNA	B-T103
assay	B-T058
.	O

In	O
this	O
work	O
,	O
we	O
report	O
an	O
entropy	O
-	O
driven	O
reaction	O
for	O
amplification	B-T062
assay	B-T058
miRNA	B-T103
with	O
a	O
detection	O
limit	O
of	O
0	O
.	O
27	O
pM	O
.	O

The	O
resulting	O
signal	O
amplification	O
provides	O
excellent	O
recognition	O
and	O
signal	O
enhancement	O
of	O
specific	O
miRNA	B-T103
s	O
in	O
living	O
cells	B-T017
.	O

This	O
method	O
supplies	O
accurate	O
information	O
regarding	O
cellular	B-T017
miRNA	B-T103
-	O
related	O
biological	B-T038
events	I-T038
and	O
provides	O
a	O
new	O
tool	O
for	O
highly	O
sensitive	O
and	O
simultaneous	O
imaging	B-T058
of	O
multiple	O
low	O
-	O
level	O
biomarkers	B-T201
,	O
thereby	O
improving	O
the	O
accuracy	O
of	O
early	B-T058
disease	I-T058
diagnosis	I-T058
.	O

Iterative	B-T033
Development	O
and	O
Evaluation	B-T058
of	O
a	O
Pharmacogenomic	B-T091
-	O
Guided	O
Clinical	B-T170
Decision	I-T170
Support	I-T170
System	I-T170
for	O
Warfarin	O
Dosing	O

Pharmacogenomic	B-T091
-	O
guided	O
dosing	O
has	O
the	O
potential	O
to	O
improve	O
patient	O
outcomes	O
but	O
its	O
implementation	O
has	O
been	O
met	O
with	O
clinical	O
challenges	B-T058
.	O

Our	O
objective	O
was	O
to	O
develop	O
and	O
evaluate	B-T058
a	O
clinical	B-T170
decision	I-T170
support	I-T170
system	I-T170
(	O
CDSS	B-T170
)	O
for	O
pharmacogenomic	B-T091
-	O
guided	O
warfarin	O
dosing	O
designed	O
for	O
physicians	B-T097
and	O
pharmacists	B-T097
.	O

Twelve	O
physicians	B-T097
and	O
pharmacists	B-T097
completed	O
6	O
prescribing	O
tasks	O
using	O
simulated	O
patient	O
scenarios	O
in	O
two	O
iterations	B-T033
(	O
development	O
and	O
validation	B-T062
phases	O
)	O
of	O
a	O
newly	O
developed	O
pharmacogenomic	B-T091
-	O
driven	O
CDSS	B-T170
prototype	O
.	O

For	O
each	O
scenario	O
,	O
usability	O
was	O
measured	O
via	O
efficiency	O
,	O
recorded	B-T170
as	O
time	O
to	O
task	O
completion	O
,	O
and	O
participants	B-T098
'	O
perceived	B-T038
satisfaction	B-T038
which	O
were	O
compared	O
using	O
Kruskal	B-T170
-	I-T170
Wallis	I-T170
and	I-T170
Mann	I-T170
Whitney	I-T170
U	I-T170
tests	I-T170
,	O
respectively	O
.	O

Debrief	O
interviews	O
were	O
conducted	O
and	O
qualitatively	B-T058
analyzed	I-T058
.	O

Usability	O
findings	O
from	O
the	O
first	O
(	O
i	O
.	O
e	O
.	O

development	O
)	O
iteration	B-T033
were	O
incorporated	O
into	O
the	O
CDSS	B-T170
design	O
for	O
the	O
second	O
(	O
i	O
.	O
e	O
.	O

validation	B-T062
)	O
iteration	B-T033
.	O

During	O
the	O
CDSS	B-T170
validation	B-T062
iteration	B-T033
,	O
participants	B-T098
took	O
more	O
time	O
to	O
complete	O
tasks	O
with	O
a	O
median	B-T082
(	O
IQR	O
)	O
of	O
183	O
(	O
124	O
-	O
247	O
)	O
seconds	O
versus	O
101	O
(	O
73	O
.	O
5	O
-	O
197	O
)	O
seconds	O
in	O
the	O
development	O
iteration	B-T033
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

This	O
increase	O
in	O
time	O
on	O
task	O
was	O
due	O
to	O
the	O
increase	O
in	O
time	O
spent	O
in	O
the	O
CDSS	B-T170
corresponding	O
to	O
several	O
design	O
changes	O
.	O

Efficiency	O
differences	O
that	O
were	O
observed	O
between	O
pharmacists	B-T097
and	O
physicians	B-T097
in	O
the	O
development	O
iteration	B-T033
were	O
eliminated	O
in	O
the	O
validation	B-T062
iteration	B-T033
.	O

The	O
increased	O
use	O
of	O
the	O
CDSS	B-T170
corresponded	O
to	O
a	O
greater	O
acceptance	O
of	O
CDSS	B-T170
recommended	O
doses	O
in	O
the	O
validation	B-T062
iteration	B-T033
(	O
4	O
%	O
in	O
the	O
first	O
iteration	B-T033
vs	O
.	O

37	O
.	O
5	O
%	O
in	O
the	O
second	O
iteration	B-T033
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Overall	O
satisfaction	B-T038
did	O
not	O
change	O
statistically	O
between	O
the	O
iterations	B-T033
but	O
the	O
qualitative	B-T058
analysis	I-T058
revealed	O
greater	O
trust	O
in	O
the	O
second	O
prototype	O
.	O

A	O
pharmacogenomic	B-T091
-	O
guided	O
CDSS	B-T170
has	O
been	O
developed	O
using	O
warfarin	B-T103
as	O
the	O
test	O
drug	B-T103
.	O

The	O
final	O
CDSS	B-T170
prototype	O
was	O
trusted	O
by	O
prescribers	O
and	O
significantly	O
increased	O
the	O
time	O
using	O
the	O
tool	O
and	O
acceptance	O
of	O
the	O
recommended	O
doses	O
.	O

This	O
study	O
is	O
an	O
important	O
step	O
toward	O
incorporating	O
pharmacogenomics	B-T091
into	O
CDSS	B-T170
design	O
for	O
clinical	B-T062
testing	I-T062
.	O

Pedicle	B-T074
Screw	I-T074
Combined	O
With	O
Lateral	B-T074
Mass	I-T074
Screw	I-T074
Fixation	B-T058
in	O
the	O
Treatment	B-T058
of	O
Basilar	B-T017
Invagination	I-T017
and	O
Congenital	B-T017
C2	I-T017
-	I-T017
C3	I-T017
Fusion	I-T017

Clinical	B-T058
evaluation	I-T058
of	O
a	O
surgical	B-T058
fixation	B-T058
technique	O
featuring	O
combined	O
use	O
of	O
pedicle	B-T074
screw	I-T074
and	O
lateral	B-T074
mass	I-T074
screw	I-T074
(	O
LMS	B-T074
)	O
.	O

Introduction	O
of	O
a	O
novel	O
technique	O
for	O
the	O
treatment	B-T058
of	O
congenital	B-T017
C2	I-T017
-	I-T017
C3	I-T017
fusion	I-T017
and	O
basilar	B-T017
invagination	I-T017
(	O
BI	B-T017
)	O
.	O

Posterior	B-T082
occipitocervical	B-T082
fixation	B-T058
using	O
C2	B-T074
pedicle	I-T074
screw	I-T074
was	O
widely	O
used	O
for	O
BI	B-T017
.	O

However	O
,	O
in	O
cases	O
where	O
BI	B-T017
is	O
concurrent	O
with	O
congenital	B-T017
C2	I-T017
-	I-T017
C3	I-T017
fusion	I-T017
,	O
the	O
C2	B-T017
pedicles	I-T017
tend	O
to	O
be	O
thinner	O
than	O
that	O
in	O
normal	O
population	B-T098
and	O
hence	O
more	O
likely	O
to	O
fail	O
.	O

We	O
prompted	O
to	O
tackle	O
the	O
issue	B-T033
by	O
combining	O
the	O
pedicle	B-T074
screw	I-T074
with	O
the	O
additional	O
use	O
of	O
LMS	B-T074
in	O
attempt	O
to	O
strengthen	O
the	O
fixation	B-T058
.	O

Twenty	O
-	O
five	O
patients	O
who	O
underwent	O
combined	O
pedicle	B-T074
screw	I-T074
with	O
LMS	B-T074
fixation	B-T058
were	O
retrospectively	B-T062
studied	I-T062
.	O

The	O
instrument	B-T074
position	B-T082
,	O
fusion	O
status	O
,	O
and	O
complications	B-T038
were	O
analyzed	B-T062
.	O

None	O
had	O
spinal	B-T037
cord	I-T037
or	O
vertebral	B-T037
artery	I-T037
injury	I-T037
.	O

The	O
average	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
20	O
months	O
.	O

Solid	O
fusion	O
was	O
achieved	O
in	O
23	O
patients	O
(	O
92	O
%	O
)	O
as	O
detected	O
radiologically	B-T058
.	O

Two	O
cases	O
suffered	O
from	O
recurred	O
BI	B-T017
and	O
instrument	B-T074
failure	B-T033
but	O
eventually	O
achieved	O
solid	O
fusion	O
between	O
the	O
occiput	B-T082
and	O
C2	B-T017
was	O
after	O
revision	B-T058
.	O

Among	O
all	O
25	O
patients	O
,	O
4	O
suffered	O
from	O
complications	B-T038
including	O
instrument	B-T074
s	O
failure	B-T033
,	O
cerebrospinal	B-T038
fluid	I-T038
leakage	I-T038
,	O
and	O
intracranial	B-T082
infection	B-T038
.	O

The	O
clinical	O
outcome	O
indicates	O
that	O
the	O
technique	O
is	O
reliable	O
for	O
the	O
treatment	B-T058
of	O
BI	B-T017
with	O
congenital	B-T017
C2	I-T017
-	I-T017
C3	I-T017
fusion	I-T017
.	O

Co	O
-	O
occurrence	O
and	O
clustering	O
of	O
health	O
conditions	O
at	O
age	O
11	O
:	O
cross	B-T062
-	I-T062
sectional	I-T062
findings	O
from	O
the	O
Millennium	O
Cohort	O
Study	O

To	O
identify	O
patterns	O
of	O
co	O
-	O
occurrence	O
and	O
clustering	O
of	O
6	O
common	O
adverse	B-T038
health	O
conditions	O
in	O
11	O
-	O
year	O
-	O
old	O
children	O
and	O
explore	O
differences	O
by	O
sociodemographic	O
factors	O
.	O

Nationally	O
representative	O
prospective	B-T062
cohort	I-T062
study	I-T062
.	O

Children	O
born	O
in	O
the	O
UK	B-T082
between	O
2000	O
and	O
2002	O
.	O

11	O
399	O
11	O
-	O
year	O
-	O
old	O
singleton	O
children	O
for	O
whom	O
data	O
on	O
all	O
6	O
health	O
conditions	O
and	O
sociodemographic	O
information	O
were	O
available	O
(	O
complete	O
cases	O
)	O
.	O

Prevalence	O
,	O
co	O
-	O
occurrence	O
and	O
clustering	O
of	O
6	O
common	O
health	O
conditions	O
:	O
wheeze	B-T033
;	O
eczema	B-T038
;	O
long	B-T033
-	I-T033
standing	I-T033
illness	I-T033
(	O
excluding	O
wheeze	B-T033
and	O
eczema	B-T038
)	O
;	O
injury	B-T037
;	O
socioemotional	B-T038
difficulties	I-T038
(	O
measured	O
using	O
Strengths	B-T170
and	I-T170
Difficulties	I-T170
Questionnaire	I-T170
)	O
and	O
unfavourable	O
weight	O
(	O
thin	B-T033
/	O
overweight	B-T033
/	O
obese	B-T038
vs	O
normal	O
)	O
.	O

42	O
.	O
4	O
%	O
of	O
children	O
had	O
2	O
or	O
more	O
adverse	B-T038
health	O
conditions	O
(	O
co	O
-	O
occurrence	O
)	O
.	O

Co	O
-	O
occurrence	O
was	O
more	O
common	O
in	O
boys	O
and	O
children	O
from	O
lower	O
income	O
households	O
.	O

Latent	B-T062
class	I-T062
analysis	I-T062
identified	O
6	O
classes	B-T170
:	O
'	O
normative	O
'	O
(	O
57	O
.	O
4	O
%	O
)	O
:	O
'	O
atopic	B-T038
burdened	O
'	O
(	O
14	O
.	O
0	O
%	O
)	O
;	O
'	O
socioemotional	B-T038
burdened	I-T038
'	O
(	O
11	O
.	O
0	O
%	O
)	O
;	O
'	O
unfavourable	O
weight	O
/	O
injury	B-T037
'	O
(	O
7	O
.	O
7	O
%	O
)	O
;	O
'	O
eczema	B-T038
/	O
injury	B-T037
'	O
(	O
6	O
.	O
0	O
%	O
)	O
and	O
'	O
eczema	B-T038
/	O
unfavourable	O
weight	O
'	O
(	O
3	O
.	O
9	O
%	O
)	O
.	O

As	O
with	O
co	O
-	O
occurrence	O
,	O
class	B-T170
membership	O
differed	O
by	O
sociodemographic	O
factors	O
:	O
boys	O
,	O
children	O
of	O
mothers	O
with	O
lower	O
educational	B-T033
attainment	I-T033
and	O
children	O
from	O
lower	O
income	O
households	O
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
socioemotional	B-T038
burdened	I-T038
'	O
class	B-T170
.	O

Children	O
of	O
mothers	O
with	O
higher	O
educational	B-T033
attainment	I-T033
were	O
more	O
likely	O
to	O
be	O
in	O
the	O
'	O
normative	O
'	O
and	O
'	O
eczema	B-T038
/	O
unfavourable	O
weight	O
'	O
classes	B-T170
.	O

Co	O
-	O
occurrence	O
of	O
adverse	B-T038
health	O
conditions	O
at	O
age	O
11	O
is	O
common	O
and	O
is	O
associated	O
with	O
adverse	B-T038
socioeconomic	O
circumstances	O
.	O

Holistic	O
,	O
child	O
focused	O
care	O
,	O
particularly	O
in	O
boys	O
and	O
those	O
in	O
lower	O
income	O
groups	O
,	O
may	O
help	O
to	O
prevent	O
and	O
reduce	O
co	O
-	O
occurrence	O
in	O
later	O
childhood	O
and	O
adolescence	O
.	O

Genomic	B-T017
characterization	O
of	O
a	O
wild	B-T204
-	I-T204
bird	I-T204
-	O
origin	B-T033
pigeon	B-T204
paramyxovirus	B-T005
type	I-T005
1	I-T005
(	O
PPMV	B-T005
-	I-T005
1	I-T005
)	O
first	O
isolated	O
in	O
the	O
northwest	B-T082
region	I-T082
of	I-T082
China	I-T082

Pigeon	B-T204
paramyxovirus	B-T005
type	I-T005
-	I-T005
1	I-T005
(	O
PPMV	B-T005
-	I-T005
1	I-T005
)	O
is	O
an	O
enzootic	O
in	O
pigeon	B-T204
flocks	O
and	O
causes	O
severe	O
economic	O
losses	O
in	O
the	O
poultry	B-T204
industry	O
in	O
many	O
countries	B-T082
.	O

A	O
PPMV	B-T005
-	I-T005
1	I-T005
isolate	B-T103
,	O
abbreviated	O
as	O
PPMV	B-T005
-	I-T005
1	I-T005
/	I-T005
QL	I-T005
-	I-T005
01	I-T005
/	I-T005
CH	I-T005
/	I-T005
15	I-T005
,	O
was	O
isolated	O
from	O
a	O
great	O
spotted	O
woodpecker	B-T204
in	O
the	O
northwest	B-T082
region	I-T082
of	I-T082
China	I-T082
in	O
2015	O
.	O

The	O
complete	O
genome	B-T017
was	O
sequenced	B-T058
,	O
and	O
the	O
results	O
showed	O
that	O
the	O
virus	B-T005
genome	B-T017
was	O
15	O
,	O
192	O
nt	O
in	O
length	O
,	O
in	O
the	O
gene	B-T038
arrangement	I-T038
3	I-T038
'	I-T038
-	I-T038
NP	I-T038
-	I-T038
P	I-T038
-	I-T038
M	I-T038
-	I-T038
F	I-T038
-	I-T038
HN	I-T038
-	I-T038
L	I-T038
-	I-T038
5	I-T038
'	I-T038
.	O

Several	O
amino	B-T103
acid	I-T103
mutations	B-T038
were	O
identified	O
in	O
the	O
functional	B-T082
domains	I-T082
of	O
the	O
F	B-T103
and	O
HN	B-T103
proteins	I-T103
.	O

The	O
pathogenicity	O
index	O
of	O
the	O
isolate	B-T103
was	O
evaluated	B-T058
,	O
and	O
the	O
mean	O
death	O
time	O
(	O
MDT	O
)	O
was	O
72	O
h	O
and	O
the	O
intracerebral	O
pathogenicity	O
index	O
(	O
ICPI	O
)	O
was	O
0	O
.	O
925	O
,	O
indicating	O
that	O
this	O
isolate	B-T103
was	O
mesogenic	O
.	O

Sequencing	B-T058
results	O
showed	O
that	O
it	O
had	O
a	O
virulent	O
Newcastle	B-T005
disease	I-T005
virus	I-T005
cleavage	B-T082
motif	I-T082
(	I-T082
112	I-T082
)	I-T082
R	I-T082
-	I-T082
R	I-T082
-	I-T082
Q	I-T082
-	I-T082
K	I-T082
-	I-T082
R	I-T082
-	I-T082
F	I-T082
(	I-T082
117	I-T082
)	I-T082
at	O
the	O
fusion	B-T103
protein	I-T103
cleavage	B-T082
site	I-T082
.	O

Morbidity	O
and	O
mortality	O
were	O
70	O
%	O
and	O
50	O
%	O
,	O
after	O
inoculation	B-T058
of	O
pigeons	B-T204
,	O
whereas	O
this	O
virus	B-T005
was	O
nonpathogenic	B-T033
in	O
chickens	B-T204
.	O

Different	O
immune	B-T038
responses	I-T038
of	O
pigeons	B-T204
and	O
chickens	B-T204
were	O
induced	O
in	B-T082
vivo	I-T082
,	O
which	O
led	O
to	O
different	O
HI	O
serum	O
antibody	O
titers	O
.	O

The	O
results	O
of	O
phylogenetic	B-T062
and	O
evolutionary	B-T062
distance	I-T062
analysis	I-T062
showed	O
that	O
this	O
PPMV	B-T005
-	I-T005
1	I-T005
strain	O
belonged	O
to	O
sub	B-T170
-	I-T170
genotype	I-T170
VIa	I-T170
in	O
class	B-T170
II	I-T170
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
identification	B-T058
and	O
analysis	B-T062
of	O
PPMV	B-T005
-	I-T005
1	I-T005
co	B-T033
-	I-T033
circulation	I-T033
among	O
wild	B-T204
birds	I-T204
and	O
domestic	B-T204
pigeon	I-T204
flocks	O
in	O
China	B-T082
.	O

The	O
data	O
from	O
this	O
study	B-T062
highlight	O
the	O
important	O
role	O
of	O
wild	B-T204
birds	I-T204
in	O
the	O
dissemination	B-T082
of	O
PPMV	B-T005
-	I-T005
1	I-T005
and	O
provide	O
useful	O
references	B-T170
for	O
improving	O
our	O
understanding	O
of	O
the	O
distribution	B-T082
and	O
evolution	B-T038
of	O
PPMV	B-T005
-	I-T005
1	I-T005
in	O
China	B-T082
.	O

Memory	B-T038
consolidation	I-T038
effects	O
on	O
memory	B-T038
stabilization	I-T038
and	O
item	B-T038
integration	I-T038
in	O
older	B-T098
adults	I-T098

This	O
study	B-T062
examined	O
the	O
differential	O
effects	O
of	O
aging	B-T038
on	O
consolidation	B-T038
processes	I-T038
that	O
strengthen	O
newly	O
acquired	O
memory	O
traces	O
in	O
veridical	O
form	O
(	O
memory	B-T038
stabilization	I-T038
)	O
versus	O
consolidation	B-T038
processes	I-T038
that	O
are	O
responsible	O
for	O
integrating	B-T038
these	O
memory	O
traces	O
into	O
an	O
existing	O
body	O
of	O
knowledge	B-T170
(	O
item	B-T038
integration	I-T038
)	O
.	O

Older	B-T098
adults	I-T098
learned	B-T038
13	O
nonwords	B-T170
and	O
were	O
tested	O
on	O
their	O
memory	B-T038
for	O
the	O
nonwords	B-T170
,	O
and	O
on	O
whether	O
these	O
nonwords	B-T170
impacted	O
upon	O
processing	O
of	O
similar	O
-	O
sounding	O
English	O
words	B-T170
immediately	O
and	O
24	O
hours	O
later	O
.	O

Participants	B-T098
accurately	O
recognized	O
the	O
nonwords	B-T170
immediately	O
,	O
but	O
showed	O
significant	O
decreases	O
in	O
delayed	O
recognition	B-T038
and	O
recall	B-T038
.	O

In	O
comparison	O
,	O
the	O
nonwords	B-T170
impacted	O
upon	O
processing	O
of	O
similar	B-T170
-	I-T170
sounding	I-T170
words	I-T170
only	O
in	O
the	O
delayed	B-T170
test	I-T170
.	O

Together	O
,	O
these	O
findings	O
suggest	O
that	O
memory	B-T038
consolidation	I-T038
processes	I-T038
may	O
be	O
more	O
evident	O
in	O
item	B-T038
integration	I-T038
than	O
memory	B-T038
stabilization	I-T038
processes	I-T038
for	O
new	O
declarative	O
memories	B-T038
in	O
older	B-T098
adults	I-T098
.	O

Mucosa	B-T031
-	O
associated	O
biohydrogenating	O
microbes	O
protect	O
the	O
simulated	O
colon	B-T204
microbiome	O
from	O
stress	B-T033
associated	O
with	O
high	O
concentrations	O
of	O
poly	B-T103
-	I-T103
unsaturated	I-T103
fat	I-T103

Polyunsaturated	B-T103
fatty	I-T103
acids	I-T103
(	O
PUFAs	B-T103
)	O
may	O
affect	O
colon	B-T204
microbiome	O
homeostasis	B-T038
by	O
exerting	B-T038
(	O
specific	O
)	O
antimicrobial	B-T103
effects	O
and	O
/	O
or	O
interfering	O
with	O
mucosal	B-T031
biofilm	O
formation	O
at	O
the	O
gut	B-T017
mucosal	I-T017
interface	I-T017
.	O

We	O
used	O
standardized	B-T058
batch	I-T058
incubations	I-T058
and	O
the	O
Mucosal	B-T170
-	I-T170
Simulator	I-T170
of	I-T170
the	I-T170
Human	I-T170
Microbial	I-T170
Intestinal	I-T170
Ecosystem	I-T170
(	O
M	B-T170
-	I-T170
SHIME	I-T170
)	O
to	O
show	O
the	O
in	O
vitro	O
luminal	B-T082
and	O
mucosal	B-T031
effects	O
of	O
the	O
main	O
PUFA	B-T103
in	O
the	O
Western	B-T058
diet	I-T058
,	O
linoleic	B-T103
acid	I-T103
(	O
LA	B-T103
)	O
.	O

High	O
concentrations	O
of	O
LA	B-T103
were	O
found	O
to	O
decrease	O
butyrate	B-T103
production	O
and	O
Faecalibacterium	B-T007
prausnitzii	I-T007
numbers	O
dependent	O
on	O
LA	B-T103
biohydrogenation	O
to	O
vaccenic	B-T103
acid	I-T103
(	O
VA	B-T103
)	O
and	O
stearic	B-T103
acid	I-T103
(	O
SA	B-T103
)	O
.	O

In	O
faecal	B-T031
batch	B-T058
incubations	I-T058
,	O
LA	B-T103
biohydrogenation	O
and	O
butyrate	B-T103
production	O
were	O
positively	O
correlated	O
and	O
SA	B-T103
did	O
not	O
inhibit	O
butyrate	B-T103
production	O
.	O

In	O
the	O
M	B-T170
-	I-T170
SHIME	I-T170
,	O
addition	O
of	O
a	O
mucosal	B-T031
environment	B-T082
stimulated	O
biohydrogenation	O
to	O
SA	B-T103
and	O
protected	O
F	B-T007
.	I-T007

prausnitzii	I-T007
from	O
inhibition	O
by	O
LA	B-T103
.	O

This	O
was	O
probably	O
due	O
to	O
the	O
preference	O
of	O
two	O
biohydrogenating	O
genera	B-T170
Roseburia	B-T007
and	O
Pseudobutyrivibrio	B-T007
for	O
the	O
mucosal	B-T031
niche	O
.	O

Co	B-T058
-	I-T058
culture	I-T058
batch	B-T058
incubations	I-T058
using	O
Roseburia	B-T007
hominis	I-T007
and	O
F	B-T007
.	I-T007

prausnitzii	I-T007
validated	B-T062
these	O
observations	B-T062
.	O

Correlations	O
networks	O
further	O
uncovered	O
the	O
central	O
role	O
of	O
Roseburia	B-T007
and	O
Pseudobutyrivibrio	B-T007
in	O
protecting	O
luminal	B-T082
and	O
mucosal	B-T058
SHIME	I-T058
microbiota	I-T058
from	O
LA	B-T103
-	O
induced	B-T033
stress	I-T033
.	O

Our	O
results	O
confirm	O
how	O
cross	O
-	O
shielding	O
interactions	O
provide	O
resilience	O
to	O
the	O
microbiome	O
and	O
demonstrate	O
the	O
importance	O
of	O
biohydrogenating	O
,	O
mucosal	B-T031
bacteria	B-T007
for	O
recovery	O
from	O
LA	B-T103
stress	B-T033
.	O

Genetic	O
parameters	B-T033
for	O
tick	O
count	O
and	O
udder	B-T017
health	O
in	O
commercial	B-T170
and	O
indigenous	O
ewes	O
in	O
South	B-T082
Africa	I-T082

The	O
genetics	O
of	O
tick	B-T038
infestation	I-T038
in	O
sheep	B-T204
need	O
study	O
,	O
as	O
host	O
resistance	O
often	O
forms	O
part	O
of	O
integrated	O
pest	O
control	O
programs	O
.	O

Repeated	O
udder	B-T017
health	O
scores	O
,	O
site	B-T082
-	I-T082
specific	I-T082
tick	O
count	O
,	O
mating	B-T038
weight	O
and	O
reproduction	B-T038
records	B-T170
(	O
N	O
=	O
879	O
-	O
1204	O
)	O
were	O
recorded	O
annually	O
from	O
2010	O
to	O
2015	O
on	O
ewes	O
of	O
the	O
indigenous	O
Namaqua	B-T204
Afrikaner	I-T204
(	O
NA	B-T204
)	O
fat	B-T170
-	I-T170
tailed	I-T170
breed	I-T170
,	O
as	O
well	O
as	O
the	O
commercial	B-T170
Dorper	B-T204
and	O
SA	B-T204
Mutton	I-T204
Merino	I-T204
(	I-T204
SAMM	I-T204
)	I-T204
breeds	I-T204
.	O

Udder	B-T017
s	O
were	O
scored	O
subjectively	O
on	O
a	O
1	O
-	O
5	O
scale	O
(	O
1	O
-	O
udder	B-T017
intact	O
and	O
5	O
-	O
udder	B-T017
damaged	B-T037
severely	I-T037
)	O
and	O
ticks	B-T038
were	O
counted	O
on	O
three	B-T082
locations	I-T082
.	O

The	O
body	B-T082
sites	I-T082
counted	O
were	O
the	O
head	B-T017
and	I-T017
thoracic	I-T017
limb	I-T017
(	O
HTLTC	B-T017
)	O
,	O
udder	B-T017
-	I-T017
pelvic	I-T017
limb	I-T017
(	O
UPLTC	B-T017
)	O
and	O
perineum	B-T017
-	I-T017
breech	I-T017
-	I-T017
tail	I-T017
(	O
PBTTC	B-T017
)	O
.	O

These	O
counts	O
were	O
also	O
totaled	O
for	O
a	O
total	O
tick	O
count	O
(	O
TTC	O
)	O
.	O

Reproduction	B-T038
traits	O
were	O
number	O
of	O
lambs	B-T204
weaned	B-T033
per	O
ewe	B-T033
lambed	I-T033
and	O
total	O
weight	O
of	O
lamb	B-T033
weaned	I-T033
per	O
ewe	B-T033
lambed	I-T033
.	O

Udder	B-T017
health	O
scores	O
of	O
NA	B-T204
ewes	O
were	O
lower	O
than	O
those	O
of	O
Dorpers	B-T204
,	O
which	O
in	O
turn	O
had	O
lower	O
scores	O
than	O
SAMM	B-T204
ewes	O
.	O

NA	B-T204
ewes	O
had	O
lower	O
values	O
for	O
HTLTC	B-T017
,	O
UPLTC	B-T017
and	O
TTC	O
than	O
the	O
commercial	B-T170
breeds	B-T170
,	O
but	O
higher	O
values	O
for	O
PBTTC	B-T017
than	O
Dorpers	B-T204
.	O

Heritability	O
estimates	O
amounted	O
to	O
0	O
.	O
26±0	O
.	O
04	O
for	O
HTLTC	B-T017
,	O
0	O
.	O
53±0	O
.	O
04	O
for	O
UPLTC	B-T017
,	O
0	O
.	O
07±0	O
.	O
06	O
for	O
PBTTC	B-T017
,	O
0	O
.	O
44±0	O
.	O
06	O
for	O
TTC	O
and	O
0	O
.	O
61±0	O
.	O
03	O
for	O
udder	B-T017
health	O
score	O
.	O

Animal	B-T082
permanent	I-T082
environment	I-T082
also	O
affected	O
PBTTC	B-T017
(	O
0	O
.	O
14±0	O
.	O
07	O
)	O
.	O

Significant	O
genetic	O
correlations	O
were	O
found	O
between	O
the	O
HTLTC	B-T017
and	O
UPLTC	B-T017
(	O
0	O
.	O
47±0	O
.	O
10	O
)	O
,	O
UPLTC	B-T017
and	O
udder	B-T017
health	O
score	O
(	O
0	O
.	O
52±0	O
.	O
07	O
)	O
,	O
HTLTC	B-T017
and	O
UPLTC	B-T017
(	O
0	O
.	O
24±0	O
.	O
11	O
)	O
as	O
well	O
as	O
UPLTC	B-T017
and	O
PBTTC	B-T017
(	O
-	O
0	O
.	O
44±0	O
.	O
11	O
)	O
.	O

Heavier	O
ewes	O
had	O
higher	O
UPLTC	B-T017
(	O
0	O
.	O
38±0	O
.	O
09	O
)	O
,	O
TTC	O
(	O
0	O
.	O
33±0	O
.	O
09	O
)	O
and	O
impaired	O
udder	B-T017
health	O
(	O
0	O
.	O
21±0	O
.	O
08	O
)	O
.	O

Udder	B-T017
health	O
score	O
s	O
and	O
tick	O
counts	O
at	O
all	O
sites	O
were	O
not	O
related	O
to	O
reproduction	B-T038
traits	O
.	O

The	O
indigenous	O
NA	B-T204
breed	B-T170
outperformed	O
the	O
commercial	B-T170
breeds	B-T170
with	O
lower	O
values	O
for	O
HTLTC	B-T017
,	O
UPLTC	B-T017
,	O
TTC	O
and	O
a	O
better	O
udder	B-T017
health	O
score	O
.	O

Mechanisms	O
contributing	O
to	O
the	O
better	O
performance	O
of	O
the	O
NA	B-T204
breed	B-T170
under	O
pastoral	B-T058
conditions	I-T058
and	O
the	O
scope	O
for	O
selection	O
for	O
tick	B-T038
tolerance	O
within	O
breeds	B-T170
should	O
be	O
studied	O
further	O
.	O

Starvation	B-T033
-	O
and	O
antibiotics	B-T103
-	O
induced	O
formation	B-T038
of	O
persister	B-T007
cells	I-T007
in	O
Pseudomonas	B-T007
aeruginosa	I-T007

Planktonic	B-T007
stationary	B-T058
and	I-T058
exponential	I-T058
cultures	I-T058
of	O
Pseudomonas	B-T007
aeruginosa	I-T007
are	O
highly	O
resistant	O
to	O
killing	B-T033
by	O
bactericidal	B-T103
antimicrobials	I-T103
because	O
of	O
the	O
presence	O
of	O
persisters	B-T007
,	O
cells	B-T007
that	O
are	O
multidrug	B-T033
tolerant	I-T033
and	O
play	O
a	O
key	O
role	O
in	O
the	O
recalcitrance	O
of	O
biofilm	B-T007
infections	B-T038
.	O

The	O
aim	O
of	O
this	O
study	B-T170
was	O
to	O
investigate	O
the	O
formation	B-T038
of	O
persister	B-T007
cells	I-T007
in	O
P	B-T007
.	I-T007

aeruginosa	I-T007
stationary	B-T058
vs	O
.	O

exponential	B-T058
cultures	I-T058
using	O
different	O
class	B-T170
antimicrobials	B-T103
.	O

The	O
susceptibilities	O
of	O
P	B-T007
.	I-T007

aeruginosa	I-T007
PAO1	I-T007
wild	I-T007
-	I-T007
type	I-T007
and	O
mutant	O
strains	O
to	O
antimicrobials	B-T103
were	O
determined	O
by	O
standard	B-T058
microtiter	I-T058
broth	I-T058
dilution	I-T058
method	I-T058
.	O

In	O
order	O
to	O
determine	O
persister	B-T007
formation	B-T038
,	O
dose	O
-	O
and	O
time	O
-	O
dependent	O
killing	B-T058
experiments	I-T058
were	O
performed	O
with	O
antibiotics	B-T103
.	O

Ceftazidime	B-T103
(	O
Cephalosporin	B-T103
)	O
showed	O
little	O
efficacy	O
against	O
either	O
culture	B-T058
.	O

Stationary	B-T007
-	I-T007
phase	I-T007
cells	I-T007
were	O
more	O
tolerant	B-T033
to	O
imipenem	B-T103
(	O
Carbapenem	B-T103
)	O
than	O
exponential	B-T007
cells	I-T007
,	O
leaving	O
a	O
small	O
fraction	O
of	O
persisters	B-T007
at	O
high	O
imipenem	B-T103
concentration	O
in	O
both	O
populations	B-T098
.	O

Polymyxin	B-T103
B	I-T103
(	O
Polymyxin	B-T103
)	O
appeared	O
to	O
be	O
ineffective	O
at	O
low	O
concentrations	O
against	O
both	O
cell	B-T098
populations	I-T098
.	O

Very	O
high	O
polymyxin	B-T103
B	I-T103
concentration	O
completely	O
eradicated	O
exponential	B-T007
cells	I-T007
and	O
regrowth	O
was	O
seen	O
in	O
a	O
stationary	B-T098
population	I-T098
.	O

Stationary	B-T007
cells	I-T007
were	O
more	O
tolerant	B-T033
to	O
tobramycin	B-T103
(	O
Aminoglycoside	B-T103
)	O
than	O
exponential	B-T007
cells	I-T007
but	O
a	O
higher	O
concentration	O
of	O
tobramycin	B-T103
completely	O
eliminated	O
survivors	O
.	O

Ciprofloxacin	B-T103
(	O
Fluoroquinolone	B-T103
)	O
at	O
a	O
low	O
concentration	O
resulted	O
in	O
killing	B-T033
of	O
both	O
cultures	B-T058
of	O
P	B-T007
.	I-T007

aeruginosa	I-T007
,	O
producing	O
persisters	B-T007
that	O
were	O
invulnerable	O
to	O
killing	B-T033
.	O

Stationary	B-T007
cells	I-T007
appear	O
to	O
be	O
somewhat	O
more	O
tolerant	B-T033
than	O
exponential	B-T007
cells	I-T007
in	O
all	O
of	O
these	O
assays	B-T058
.	O

We	O
also	O
showed	O
that	O
nutrient	B-T168
deprivation	O
(	O
serine	B-T103
starvation	B-T033
)	O
regulated	O
by	O
stringent	B-T038
and	I-T038
general	I-T038
stress	I-T038
response	I-T038
,	O
contribute	O
to	O
the	O
increased	B-T033
tolerance	I-T033
of	O
P	B-T007
.	I-T007

aeruginosa	I-T007
exponential	B-T007
and	I-T007
stationary	I-T007
planktonic	I-T007
cells	I-T007
via	O
production	B-T038
of	O
persisters	B-T007
.	O

Chaetomium	B-T204
thermophilum	I-T204
formate	B-T103
dehydrogenase	I-T103
has	O
high	O
activity	O
in	O
the	O
reduction	O
of	O
hydrogen	B-T103
carbonate	I-T103
(	O
HCO3	B-T103
-	I-T103
)	O
to	O
formate	B-T103

While	O
formate	B-T103
dehydrogenases	I-T103
(	O
FDHs	B-T103
)	O
have	O
been	O
used	O
for	O
cofactor	B-T103
recycling	O
in	O
chemoenzymatic	B-T038
synthesis	I-T038
,	O
the	O
ability	O
of	O
FDH	B-T103
to	O
reduce	O
CO2	B-T103
could	O
also	O
be	O
utilized	O
in	O
the	O
conversion	O
of	O
CO2	B-T103
to	O
useful	O
products	O
via	O
formate	B-T103
(	O
HCOO	B-T103
(	I-T103
-	I-T103
)	I-T103
)	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
reduction	O
of	O
CO2	B-T103
in	O
the	O
form	O
of	O
hydrogen	B-T103
carbonate	I-T103
(	O
HCO3	B-T103
(	I-T103
-	I-T103
)	I-T103
)	O
to	O
formate	B-T103
by	O
FDHs	B-T103
from	O
Candida	B-T204
methylica	I-T204
(	O
CmFDH	B-T103
)	O
and	O
Chaetomium	B-T204
thermophilum	I-T204
(	O
CtFDH	B-T103
)	O
in	O
a	O
NADH	B-T103
-	O
dependent	O
reaction	O
.	O

The	O
catalytic	B-T038
performance	I-T038
with	O
HCO3	B-T103
(	I-T103
-	I-T103
)	I-T103
as	O
a	O
substrate	O
was	O
evaluated	O
by	O
measuring	O
the	O
kinetic	O
rates	O
and	O
conducting	O
productivity	B-T058
assays	I-T058
.	O

CtFDH	B-T103
showed	O
a	O
higher	O
efficiency	O
in	O
converting	O
HCO3	B-T103
(	I-T103
-	I-T103
)	I-T103
to	O
formate	B-T103
than	O
CmFDH	B-T103
,	O
whereas	O
CmFDH	B-T103
was	O
better	O
in	O
the	O
oxidation	B-T038
of	O
formate	B-T103
.	O

The	O
pH	O
optimum	O
of	O
the	O
reduction	O
was	O
at	O
pH	O
7	O
-	O
8	O
.	O

However	O
,	O
the	O
high	O
concentrations	O
of	O
HCO3	B-T103
(	I-T103
-	I-T103
)	I-T103
reduced	O
the	O
reaction	O
rate	O
.	O

CtFDH	B-T103
was	O
modeled	O
in	O
the	O
presence	O
of	O
HCO3	B-T103
(	I-T103
-	I-T103
)	I-T103
showing	O
that	O
it	O
fits	O
to	O
the	O
active	O
site	O
.	O

The	O
active	O
site	O
setting	O
for	O
hydride	B-T038
transfer	I-T038
in	O
CO2	B-T103
reduction	O
was	O
modeled	O
.	O

The	O
hydride	B-T038
donated	I-T038
by	O
NADH	B-T103
would	O
form	O
a	O
favorable	O
contact	O
to	O
the	O
carbon	B-T103
atom	I-T103
of	O
HCO3	B-T103
(	I-T103
-	I-T103
)	I-T103
,	O
resulting	O
in	O
a	O
surplus	O
of	O
electrons	B-T103
within	O
the	O
molecule	O
.	O

This	O
would	O
cause	O
the	O
complex	O
formed	O
by	O
hydrogen	B-T103
carbonate	I-T103
and	O
the	O
hydride	B-T103
to	O
break	O
into	O
formate	B-T103
and	O
hydroxide	B-T103
ions	I-T103
.	O

Evaluation	B-T170
of	O
an	O
international	O
educational	O
programme	O
for	O
health	B-T097
care	I-T097
professionals	I-T097
on	O
best	O
practice	O
in	O
the	O
management	O
of	O
a	O
perinatal	O
death	B-T038
:	O
IMproving	O
Perinatal	O
mortality	O
Review	O
and	O
Outcomes	O
Via	O
Education	O
(	O
IMPROVE	O
)	O

Stillbirths	B-T033
and	O
neonatal	B-T033
deaths	I-T033
are	O
devastating	O
events	O
for	O
both	O
parents	O
and	O
clinicians	O
and	O
are	O
global	B-T091
public	I-T091
health	I-T091
concerns	O
.	O

Careful	O
clinical	B-T058
management	I-T058
after	O
these	O
deaths	B-T038
is	O
required	O
,	O
including	O
appropriate	O
investigation	B-T058
and	O
assessment	B-T058
to	O
determine	O
cause	O
(	O
s	O
)	O
to	O
prevent	O
future	O
losses	O
,	O
and	O
to	O
improve	O
bereavement	B-T058
care	I-T058
for	O
families	O
.	O

An	O
educational	O
programme	O
for	O
health	B-T097
care	I-T097
professionals	I-T097
working	O
in	O
maternal	B-T033
and	O
child	B-T058
health	I-T058
has	O
been	O
designed	O
to	O
address	O
these	O
needs	O
according	O
to	O
the	O
Perinatal	B-T170
Society	I-T170
of	I-T170
Australia	I-T170
and	I-T170
New	I-T170
Zealand	I-T170
Guideline	I-T170
for	I-T170
Perinatal	I-T170
Mortality	I-T170
:	O
IMproving	O
Perinatal	O
mortality	O
Review	O
and	O
Outcomes	O
Via	O
Education	O
(	O
IMPROVE	O
)	O
.	O

The	O
programme	O
has	O
a	O
major	O
focus	O
on	O
stillbirth	B-T033
and	O
is	O
delivered	O
as	O
six	O
interactive	O
skills	O
-	O
based	O
stations	O
.	O

We	O
aimed	O
to	O
determine	O
participants	B-T098
'	O
pre	O
-	O
and	O
post	O
-	O
programme	O
knowledge	B-T170
of	O
and	O
confidence	B-T038
in	O
the	O
management	O
of	O
perinatal	O
deaths	B-T038
,	O
along	O
with	O
satisfaction	B-T038
with	O
the	O
programme	O
.	O

We	O
also	O
aimed	O
to	O
determine	O
suitability	O
for	O
international	O
use	O
.	O

The	O
IMPROVE	O
programme	O
was	O
delivered	O
to	O
health	B-T097
professionals	I-T097
in	O
maternity	B-T092
hospitals	I-T092
in	O
all	O
seven	O
Australian	B-T082
states	B-T082
and	O
territories	O
and	O
modified	O
for	O
use	O
internationally	O
with	O
piloting	O
in	O
Vietnam	B-T082
,	O
Fiji	B-T082
,	O
and	O
the	O
Netherlands	B-T082
(	O
with	O
the	O
assistance	B-T058
of	O
the	O
International	B-T092
Stillbirth	I-T092
Alliance	I-T092
,	O
ISA	B-T092
)	O
.	O

Modifications	O
were	O
made	O
to	O
programme	B-T170
materials	I-T170
in	O
consultation	B-T058
with	O
local	O
teams	O
and	O
included	O
translation	B-T170
for	O
the	O
Vietnam	O
programme	O
.	O

Participants	B-T098
completed	O
pre	O
-	O
and	O
post	O
-	O
programme	O
evaluation	B-T170
questionnaires	B-T170
on	O
knowledge	B-T170
and	O
confidence	B-T038
on	O
six	O
key	O
components	O
of	O
perinatal	O
death	B-T038
management	O
as	O
well	O
as	O
a	O
satisfaction	B-T170
questionnaire	I-T170
.	O

Over	O
the	O
period	O
May	O
2012	O
to	O
May	O
2015	O
,	O
30	O
IMPROVE	O
workshops	O
were	O
conducted	O
,	O
including	O
26	O
with	O
758	O
participants	B-T098
in	O
Australia	B-T082
and	O
four	O
with	O
136	O
participants	B-T098
internationally	O
.	O

Evaluations	B-T170
showed	O
a	O
significant	O
improvement	O
between	O
pre	O
-	O
and	O
post	O
-	O
programme	O
knowledge	B-T170
and	O
confidence	B-T038
in	O
all	O
six	O
stations	O
and	O
overall	O
,	O
and	O
a	O
high	O
degree	O
of	O
satisfaction	B-T038
in	O
all	O
settings	B-T082
.	O

The	O
IMPROVE	O
programme	O
has	O
been	O
well	O
received	O
in	O
Australia	B-T082
and	O
in	O
three	O
different	O
international	O
settings	B-T082
and	O
is	O
now	O
being	O
made	O
available	O
through	O
ISA	B-T092
.	O

Future	O
research	B-T062
is	O
required	O
to	O
determine	O
whether	O
the	O
immediate	O
improvements	O
in	O
knowledge	B-T170
are	O
sustained	O
with	O
less	O
causes	O
of	O
death	B-T038
being	O
classified	O
as	O
unknown	O
,	O
changes	O
in	O
clinical	O
practice	O
and	O
improvement	O
in	O
parents	O
'	O
experiences	O
with	O
care	O
.	O

The	O
suitability	O
for	O
this	O
programme	O
in	O
low	B-T033
-	I-T033
income	I-T033
countries	B-T082
also	O
needs	O
to	O
be	O
established	O
.	O

Experiences	O
of	O
support	O
in	O
working	O
toward	O
personal	O
recovery	B-T038
goals	B-T170
:	O
a	O
collaborative	O
,	O
qualitative	B-T062
study	I-T062

Recovery	B-T038
can	O
be	O
understood	O
as	O
a	O
subjective	O
process	O
guided	O
by	O
personal	O
expectations	O
,	O
goals	B-T170
and	O
hopes	B-T038
.	O

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
explore	O
how	O
persons	B-T098
using	O
a	O
Community	B-T092
Mental	I-T092
Health	I-T092
Centre	I-T092
(	O
CMHC	B-T092
)	O
experienced	O
that	O
their	O
expectations	O
for	O
treatment	B-T058
,	O
and	O
goals	B-T170
and	O
hopes	B-T038
for	O
recovery	B-T038
were	O
supported	O
by	O
the	O
health	B-T097
professionals	I-T097
during	O
treatment	B-T058
.	O

Employing	O
a	O
hermeneutic	O
-	O
phenomenological	O
approach	O
,	O
eight	O
service	O
users	O
were	O
interviewed	O
about	O
their	O
expectations	O
for	O
treatment	B-T058
and	O
their	O
goals	B-T170
and	O
hopes	B-T038
for	O
recovery	B-T038
at	O
the	O
start	O
of	O
their	O
contact	O
with	O
health	B-T097
professionals	I-T097
at	O
a	O
CMHC	B-T092
.	O

Two	O
years	O
later	O
,	O
they	O
were	O
re	O
-	O
interviewed	O
about	O
their	O
experiences	O
of	O
treatment	B-T058
and	O
support	O
from	O
the	O
health	B-T097
professionals	I-T097
in	O
their	O
work	O
towards	O
these	O
goals	B-T170
and	O
hopes	B-T038
.	O

A	O
collaborative	O
approach	O
was	O
adopted	O
.	O

A	O
co	B-T097
-	I-T097
researcher	I-T097
with	O
lived	O
experience	O
took	O
part	O
in	O
all	O
stages	O
of	O
the	O
study	B-T062
.	O

Data	O
were	O
analysed	O
by	O
means	O
of	O
a	O
data	O
-	O
driven	O
stepwise	O
approach	O
in	O
line	O
with	O
thematic	B-T062
analysis	I-T062
.	O

Five	O
themes	O
reflecting	O
how	O
participants	B-T098
experienced	O
support	O
from	O
health	B-T097
professionals	I-T097
at	O
the	O
CMHC	B-T092
in	O
their	O
work	O
towards	O
their	O
recovery	B-T038
goals	B-T170
were	O
elicited	O
,	O
as	O
follows	O
:	O
developing	O
an	O
understanding	O
of	O
oneself	O
and	O
one	O
'	O
s	O
mental	B-T033
health	I-T033
problems	I-T033
;	O
learning	O
how	O
to	O
change	O
feelings	B-T038
and	O
behaviours	O
;	O
being	B-T033
'	I-T033
pushed	I-T033
'	I-T033
into	I-T033
social	I-T033
arenas	I-T033
;	O
finding	B-T033
helpful	I-T033
medication	I-T033
;	O
and	O
counselling	B-T058
in	O
family	B-T033
,	O
practical	B-T033
and	O
financial	B-T033
issues	I-T033
.	O

The	O
participants	B-T098
'	O
expectations	O
about	O
counselling	B-T058
with	O
regard	O
to	O
longer	O
-	O
term	O
family	B-T033
,	O
practical	B-T033
,	O
and	O
financial	B-T033
challenges	I-T033
were	O
insufficiently	O
met	O
by	O
the	O
CMHC	B-T092
.	O

In	O
the	O
experience	O
of	O
the	O
service	O
users	O
,	O
recovery	B-T038
occurred	O
within	O
the	O
context	O
of	O
their	O
everyday	O
life	O
with	O
or	O
without	O
the	O
support	O
of	O
their	O
professional	B-T097
helpers	B-T097
.	O

To	O
facilitate	O
recovery	B-T038
,	O
health	B-T097
professionals	I-T097
should	O
acknowledge	O
the	O
service	O
user	O
'	O
s	O
personal	O
goals	B-T170
and	O
hopes	B-T038
and	O
take	O
a	O
more	O
comprehensive	O
and	O
longer	O
-	O
term	O
approach	O
to	O
his	O
or	O
her	O
needs	O
and	O
desires	O
.	O

Acknowledging	O
and	O
facilitating	O
recovery	B-T038
goals	B-T170
by	O
offering	O
counselling	B-T058
with	O
regard	O
to	O
family	B-T033
,	O
practical	B-T033
and	O
financial	B-T033
issues	I-T033
seems	O
particularly	O
important	O
.	O

Pathogenesis	B-T038
of	O
COPD	B-T038
and	O
Asthma	B-T038

Asthma	B-T038
and	O
COPD	B-T038
remain	O
two	O
diseases	B-T038
of	I-T038
the	I-T038
respiratory	I-T038
tract	I-T038
with	O
unmet	O
medical	O
needs	O
.	O

This	O
review	B-T170
considers	O
the	O
current	O
state	O
of	O
play	O
with	O
respect	O
to	O
what	O
is	O
known	O
about	O
the	O
underlying	O
pathogenesis	B-T038
of	O
these	O
two	O
chronic	B-T038
inflammatory	I-T038
diseases	I-T038
of	O
the	O
lung	B-T017
.	O

The	O
review	B-T170
highlights	O
why	O
they	O
are	O
different	O
conditions	O
requiring	O
different	O
approaches	O
to	O
treatment	B-T058
and	O
provides	O
a	O
backdrop	O
for	O
the	O
subsequent	O
chapters	O
in	O
this	O
volume	O
discussing	O
recent	O
advances	O
in	O
the	O
pharmacology	B-T091
and	O
treatment	B-T058
of	O
asthma	B-T038
and	O
COPD	B-T038
.	O

Antigen	O
specificity	O
determines	O
anti	B-T103
-	I-T103
red	I-T103
blood	I-T103
cell	I-T103
IgG	I-T103
-	I-T103
Fc	I-T103
alloantibody	I-T103
glycosylation	O
and	O
thereby	O
severity	O
of	O
haemolytic	B-T038
disease	I-T038
of	I-T038
the	I-T038
fetus	I-T038
and	I-T038
newborn	I-T038

Haemolytic	B-T038
disease	I-T038
of	I-T038
the	I-T038
fetus	I-T038
and	I-T038
newborn	I-T038
(	O
HDFN	B-T038
)	O
is	O
a	O
severe	O
disease	B-T038
in	O
which	O
fetal	B-T017
red	B-T017
blood	I-T017
cells	I-T017
(	O
RBC	B-T017
)	O
are	O
destroyed	O
by	O
maternal	B-T103
anti	I-T103
-	I-T103
RBC	I-T103
IgG	I-T103
alloantibodies	I-T103
.	O

HDFN	B-T038
is	O
most	O
often	O
caused	O
by	O
anti	B-T103
-	I-T103
D	I-T103
but	O
may	O
also	O
occur	O
due	O
to	O
anti	B-T103
-	I-T103
K	I-T103
,	O
-	B-T103
c	I-T103
-	O
or	O
-	B-T103
E	I-T103
.	O

We	O
recently	O
found	O
N	B-T038
-	I-T038
linked	I-T038
glycosylation	I-T038
of	O
anti	B-T103
-	I-T103
D	I-T103
to	O
be	O
skewed	O
towards	O
low	O
fucosylation	B-T038
,	O
thereby	O
increasing	O
the	O
affinity	B-T038
to	O
IgG	B-T103
-	I-T103
Fc	I-T103
receptor	I-T103
IIIa	I-T103
and	O
IIIb	B-T103
,	O
which	O
correlated	O
with	O
HDFN	B-T038
disease	B-T038
severity	O
.	O

Here	O
,	O
we	O
analysed	O
230	O
pregnant	B-T098
women	I-T098
with	O
anti	B-T103
-	I-T103
c	I-T103
,	O
-	B-T103
E	I-T103
or	O
-	B-T103
K	I-T103
alloantibodies	B-T103
from	O
a	O
prospective	O
screening	B-T058
cohort	I-T058
and	O
investigated	O
the	O
type	O
of	O
Fc	B-T038
-	I-T038
tail	I-T038
glycosylation	I-T038
of	O
these	O
antibodies	B-T103
in	O
relation	O
to	O
the	O
trigger	O
of	O
immunisation	B-T058
and	O
pregnancy	B-T033
outcome	I-T033
.	O

Anti	B-T103
-	I-T103
c	I-T103
,	O
-	B-T103
E	I-T103
and	O
-	B-T103
K	I-T103
show	O
-	O
independent	O
of	O
the	O
event	O
that	O
had	O
led	O
to	O
immunisation	B-T058
-	O
a	O
different	O
kind	O
of	O
Fc	B-T038
-	I-T038
glycosylation	I-T038
compared	O
to	O
that	O
of	O
the	O
total	O
IgG	B-T103
fraction	I-T103
,	O
but	O
with	O
less	O
pronounced	O
differences	O
compared	O
to	O
anti	B-T103
-	I-T103
D	I-T103
.	O

High	O
Fc	B-T038
-	I-T038
galactosylation	I-T038
and	O
sialylation	B-T038
of	O
anti	B-T103
-	I-T103
c	I-T103
correlated	O
with	O
HDFN	B-T038
disease	B-T038
severity	O
,	O
while	O
low	O
anti	B-T103
-	I-T103
K	I-T103
Fc	B-T038
-	I-T038
fucosylation	I-T038
correlated	O
with	O
severe	O
fetal	B-T038
anaemia	I-T038
.	O

IgG	B-T038
-	I-T038
Fc	I-T038
glycosylation	I-T038
of	O
anti	B-T103
-	I-T103
RBC	I-T103
antibodies	I-T103
is	O
shaped	O
depending	O
on	O
the	O
antigen	B-T103
.	O

These	O
features	O
influence	O
their	O
clinical	O
potency	O
and	O
may	O
therefore	O
be	O
used	O
to	O
predict	O
severity	O
and	O
identify	O
those	O
needing	O
treatment	O
.	O

Shout	O
louder	O
about	O
poor	O
pay	O

It	O
seems	O
increasingly	O
clear	O
to	O
me	O
that	O
the	O
NHS	B-T058
pay	O
campaign	O
is	O
not	O
making	O
waves	O
either	O
in	O
the	O
NHS	B-T058
or	O
with	O
the	O
public	B-T098
.	O

SARS	B-T038
-	O
CoV	B-T005
fusion	O
peptides	B-T103
induce	O
membrane	B-T017
surface	B-T082
ordering	O
and	O
curvature	O

Viral	B-T038
membrane	I-T038
fusion	I-T038
is	O
an	O
orchestrated	O
process	O
triggered	O
by	O
membrane	B-T017
-	I-T017
anchored	I-T017
viral	B-T103
fusion	I-T103
glycoproteins	I-T103
.	O

The	O
S2	B-T103
subunit	B-T103
of	O
the	O
spike	B-T103
glycoprotein	I-T103
from	O
severe	B-T038
acute	I-T038
respiratory	I-T038
syndrome	I-T038
(	O
SARS	B-T038
)	O
coronavirus	B-T005
(	O
CoV	B-T005
)	O
contains	O
internal	B-T082
domains	I-T082
called	O
fusion	B-T103
peptides	I-T103
(	O
FP	B-T103
)	O
that	O
play	O
essential	O
roles	O
in	O
virus	B-T038
entry	I-T038
.	O

Although	O
membrane	B-T038
fusion	I-T038
has	O
been	O
broadly	O
studied	B-T062
,	O
there	O
are	O
still	O
major	O
gaps	O
in	O
the	O
molecular	O
details	O
of	O
lipid	B-T103
rearrangements	O
in	O
the	O
bilayer	B-T017
during	O
fusion	B-T103
peptide	I-T103
-	O
membrane	B-T017
interactions	O
.	O

Here	O
we	O
employed	O
differential	B-T058
scanning	I-T058
calorimetry	I-T058
(	O
DSC	B-T058
)	O
and	O
electron	B-T058
spin	I-T058
resonance	I-T058
(	O
ESR	B-T058
)	O
to	O
gather	O
information	O
on	O
the	O
membrane	B-T038
fusion	I-T038
mechanism	O
promoted	O
by	O
two	O
putative	O
SARS	B-T038
FPs	B-T103
.	O

DSC	B-T058
data	O
showed	O
the	O
peptides	B-T103
strongly	O
perturb	O
the	O
structural	B-T082
integrity	O
of	O
anionic	B-T017
vesicles	I-T017
and	O
support	O
the	O
hypothesis	O
that	O
the	O
peptides	B-T103
generate	O
opposing	O
curvature	O
stresses	O
on	O
phosphatidylethanolamine	B-T103
membranes	B-T017
.	O

ESR	B-T058
showed	O
that	O
both	O
FPs	B-T103
increase	O
lipid	B-T103
packing	O
and	O
head	O
group	O
ordering	O
as	O
well	O
as	O
reduce	O
the	O
intramembrane	B-T017
water	O
content	O
for	O
anionic	B-T017
membranes	I-T017
.	O

Therefore	O
,	O
bending	O
moment	O
in	O
the	O
bilayer	B-T017
could	O
be	O
generated	O
,	O
promoting	O
negative	O
curvature	O
.	O

The	O
significance	O
of	O
the	O
ordering	O
effect	O
,	O
membrane	B-T017
dehydration	B-T033
,	O
changes	O
in	O
the	O
curvature	O
properties	O
and	O
the	O
possible	O
role	O
of	O
negatively	O
charged	O
phospholipids	B-T103
in	O
helping	O
to	O
overcome	O
the	O
high	O
kinetic	O
barrier	O
involved	O
in	O
the	O
different	O
stages	O
of	O
the	O
SARS	B-T038
-	O
CoV	B-T005
-	O
mediated	O
membrane	B-T038
fusion	I-T038
are	O
discussed	O
.	O

Elucidating	O
a	O
chemical	O
defense	B-T038
mechanism	I-T038
of	O
Antarctic	B-T082
sponges	B-T204
:	O
A	O
computational	O
study	O

In	O
2000	O
,	O
a	O
novel	O
secondary	B-T103
metabolite	I-T103
(	O
erebusinone	B-T103
,	O
Ereb	B-T103
)	O
was	O
isolated	O
from	O
the	O
Antarctic	B-T082
sea	B-T204
sponge	I-T204
,	O
Isodictya	B-T204
erinacea	I-T204
.	O

The	O
bioactivity	O
of	O
Ereb	B-T103
was	O
investigated	O
,	O
and	O
it	O
was	O
found	O
to	O
inhibit	O
molting	B-T038
when	O
fed	O
to	O
the	O
arthropod	B-T204
species	I-T204
Orchomene	B-T204
plebs	I-T204
.	O

Xanthurenic	B-T103
acid	I-T103
(	O
XA	B-T103
)	O
is	O
a	O
known	O
endogenous	O
molt	O
regulator	O
present	O
in	O
arthropods	B-T204
.	O

Experimental	O
studies	O
have	O
confirmed	O
that	O
XA	B-T103
inhibits	O
molting	B-T038
by	O
binding	B-T038
to	O
either	O
(	O
or	O
both	O
)	O
of	O
two	O
P450	B-T103
enzymes	I-T103
(	O
CYP315a1	B-T103
or	O
CYP314a1	B-T103
)	O
that	O
are	O
responsible	O
for	O
the	O
final	O
two	O
hydroxylations	O
in	O
the	O
production	O
of	O
the	O
molt	B-T103
-	I-T103
inducing	I-T103
hormone	I-T103
,	O
20	B-T103
-	I-T103
hydroxyecdysone	I-T103
(	O
20E	B-T103
)	O
.	O

The	O
lack	O
of	O
crystal	B-T103
structures	I-T103
and	O
biochemical	B-T058
assays	I-T058
for	O
CYP315a1	B-T103
or	O
CYP314a1	B-T103
,	O
has	O
prevented	O
further	O
experimental	O
exploration	B-T062
of	O
XA	B-T103
and	O
Ereb	B-T103
'	I-T103
s	I-T103
molt	B-T038
inhibition	O
mechanisms	O
.	O

Herein	O
,	O
a	O
wide	O
array	O
of	O
computational	B-T062
techniques	I-T062
-	O
homology	B-T062
modeling	I-T062
,	O
molecular	O
dynamics	O
simulations	O
,	O
binding	B-T038
site	I-T038
bioinformatics	B-T091
,	O
flexible	B-T038
receptor	I-T038
-	I-T038
flexible	I-T038
ligand	I-T038
docking	I-T038
,	O
and	O
molecular	O
mechanics	O
-	O
generalized	O
Born	B-T170
surface	I-T170
area	I-T170
calculations	I-T170
-	O
have	O
been	O
employed	O
to	O
elucidate	O
the	O
structure	O
-	O
function	O
relationships	O
between	O
the	O
aforementioned	O
P450s	B-T103
and	O
the	O
two	O
described	O
small	O
molecule	O
inhibitors	B-T103
(	O
Ereb	B-T103
and	O
XA	B-T103
)	O
.	O

Results	O
indicate	O
that	O
Ereb	B-T103
likely	O
targets	O
CYP315a1	B-T103
by	O
interacting	O
with	O
a	O
network	O
of	O
aromatic	O
residues	O
in	O
the	O
binding	B-T038
site	I-T038
,	O
while	O
XA	B-T103
may	O
inhibit	O
both	O
CYP315a1	B-T103
and	O
CYP314a1	B-T103
because	O
of	O
its	O
aromatic	O
,	O
as	O
well	O
as	O
charged	B-T103
nature	I-T103
.	O

The	O
anatomical	B-T204
mummies	I-T204
of	O
Mombello	O
:	O
detection	B-T033
of	O
cocaine	B-T103
,	O
nicotine	B-T103
,	O
and	O
caffeine	B-T103
in	O
the	O
hair	B-T017
of	O
psychiatric	O
patients	O
of	O
the	O
early	O
20th	O
century	O

The	O
Mombello	B-T092
Psychiatric	I-T092
Hospital	I-T092
in	O
Limbiate	O
,	O
near	O
Milan	O
,	O
replaced	O
the	O
old	O
Senavra	B-T092
Hospital	I-T092
as	O
the	O
Psychiatric	B-T092
Hospital	I-T092
for	O
the	O
Province	O
of	O
Milan	O
in	O
the	O
19th	O
century	O
.	O

During	O
the	O
early	O
20th	O
century	O
,	O
bodies	B-T204
of	O
several	O
Mombello	O
patients	O
were	O
dissected	O
and	O
preserved	B-T058
by	O
Giuseppe	B-T204
Paravicini	I-T204
,	O
an	O
anatomist	B-T097
who	O
operated	O
within	O
the	O
asylum	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
examine	O
and	O
memorialize	O
this	O
important	O
assemblage	B-T062
.	O

To	O
this	O
end	O
,	O
we	O
were	O
allowed	O
to	O
sample	O
the	O
head	B-T017
hair	I-T017
of	O
six	O
such	O
preparations	O
for	O
toxicological	O
analysis	B-T062
.	O

By	O
means	O
of	O
high	B-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
,	O
cocaine	B-T103
and	O
its	O
main	O
metabolite	B-T103
,	O
benzoylecgonine	B-T103
,	O
were	O
detected	B-T033
in	O
two	O
out	O
of	O
six	O
hair	O
samples	O
.	O

The	O
concentrations	O
for	O
cocaine	B-T103
were	O
0	O
.	O
151	O
and	O
0	O
.	O
09ng	O
/	O
mg	O
and	O
for	O
benzoylecgonine	B-T103
0	O
.	O
103	O
and	O
0	O
.	O
147ng	O
/	O
mg	O
,	O
respectively	O
.	O

Given	O
that	O
cocaine	B-T103
was	O
a	O
commonly	O
used	O
medicine	B-T103
,	O
beginning	O
in	O
the	O
mid	O
-	O
19th	O
century	O
and	O
persisting	O
into	O
the	O
20th	O
century	O
,	O
it	O
is	O
not	O
surprising	O
that	O
some	O
patients	B-T092
may	O
have	O
ingested	B-T038
this	O
drug	B-T103
.	O

In	O
addition	O
to	O
the	O
detection	B-T033
of	O
cocaine	B-T103
,	O
these	O
analyses	B-T062
also	O
provided	O
evidence	O
of	O
nicotine	B-T103
and	O
caffeine	B-T103
intake	O
.	O

Terahertz	B-T058
identification	I-T058
and	O
quantification	O
of	O
neurotransmitter	B-T103
and	O
neurotrophy	B-T103
mixture	I-T103

Terahertz	B-T058
spectroscopy	I-T058
has	O
been	O
widely	O
used	O
for	O
investigating	O
the	O
fingerprint	B-T058
spectrum	I-T058
of	O
different	O
substances	O
.	O

For	O
cancerous	B-T038
tissues	B-T017
,	O
the	O
greatest	O
difficulty	O
is	O
the	O
absorption	O
peaks	O
of	O
various	O
substances	O
contained	O
in	O
tissues	B-T017
overlap	O
with	O
each	O
other	O
,	O
which	O
are	O
hard	O
to	O
identify	O
and	O
quantitative	O
analyze	B-T062
.	O

As	O
a	O
result	O
,	O
it	O
is	O
very	O
hard	O
to	O
measure	O
the	O
presence	O
of	O
cancer	B-T017
cell	I-T017
and	O
then	O
to	O
diagnose	B-T033
accurately	O
.	O

In	O
this	O
paper	O
,	O
we	O
select	O
three	O
typical	O
neurotransmitters	B-T103
(	O
γ	B-T103
-	I-T103
aminobutyric	I-T103
acid	I-T103
,	O
L	B-T103
-	I-T103
glutamic	I-T103
acid	I-T103
,	O
dopamine	B-T103
hydrochloride	I-T103
)	O
and	O
two	O
typical	O
metabolites	B-T103
(	O
inositol	B-T103
and	O
creatine	B-T103
)	O
in	O
neurons	B-T017
to	O
measure	O
their	O
terahertz	B-T058
spectra	I-T058
with	O
different	O
mixture	O
ratios	O
.	O

By	O
choosing	O
characteristic	O
absorption	O
peaks	O
,	O
removing	O
baseline	O
and	O
using	O
the	O
least	O
square	O
method	O
,	O
we	O
can	O
identify	O
the	O
components	O
and	O
proportions	O
of	O
each	O
mixture	O
,	O
where	O
the	O
goodness	O
of	O
fit	O
to	O
practical	O
situation	O
is	O
up	O
to	O
94	O
%	O
.	O

These	O
results	O
provide	O
important	O
evidences	O
for	O
identifying	O
nerve	B-T103
substances	I-T103
and	O
obtaining	O
exact	O
quantitative	O
analysis	B-T062
.	O

Comparing	O
the	O
bulking	O
effect	O
of	O
calcium	B-T103
hydroxyapatite	I-T103
and	O
Deflux	B-T103
injection	B-T058
into	O
the	O
bladder	B-T017
neck	I-T017
for	O
improvement	O
of	O
urinary	B-T038
incontinence	I-T038
in	O
bladder	B-T038
exstrophy	I-T038
-	I-T038
epispadias	I-T038
complex	I-T038

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
efficacy	O
of	O
the	O
endoscopic	B-T058
injection	I-T058
of	O
calcium	B-T103
hydroxyapatite	I-T103
(	O
CaHA	B-T103
)	O
into	O
the	O
bladder	B-T017
neck	I-T017
(	O
BN	B-T017
)	O
region	O
of	O
patients	O
with	O
urinary	B-T038
incontinence	I-T038
and	O
bladder	B-T038
exstrophy	I-T038
-	I-T038
epispadias	I-T038
complex	I-T038
(	O
BEEC	B-T038
)	O
.	O

We	O
designed	O
a	O
retrospective	B-T062
cohort	I-T062
study	I-T062
in	O
which	O
we	O
retrospectively	B-T062
studied	I-T062
medical	O
charts	O
of	O
female	O
and	O
male	O
patients	O
of	O
BEEC	B-T038
who	O
had	O
undergone	O
CaHA	B-T103
or	O
Deflux	B-T103
injection	B-T058
for	O
continence	B-T058
improvement	I-T058
between	O
2009	O
and	O
2014	O
.	O

Sixteen	O
incontinent	B-T038
patients	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
8	O
.	O
09	O
±	O
3	O
.	O
5	O
years	O
received	O
an	O
endoscopic	B-T058
submucosal	I-T058
injection	I-T058
of	O
5	O
.	O
4	O
ml	O
of	O
pure	O
CaHA	B-T103
powder	O
with	O
autologous	O
plasma	B-T031
(	O
group	O
A	O
)	O
.	O

Patients	O
in	O
group	O
B	O
(	O
N	O
=	O
21	O
)	O
,	O
control	O
group	O
,	O
with	O
a	O
mean	O
±	O
SD	O
age	O
of	O
7	O
.	O
51	O
±	O
2	O
.	O
8	O
years	O
received	O
Deflux	B-T103
injection	B-T058
(	O
5	O
.	O
1	O
ml	O
)	O
.	O

The	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
after	O
injection	B-T058
was	O
38	O
±	O
5	O
.	O
2	O
and	O
33	O
±	O
4	O
.	O
1	O
months	O
in	O
groups	O
A	O
and	O
B	O
,	O
respectively	O
.	O

No	O
post	B-T038
-	I-T038
injection	I-T038
complication	I-T038
was	O
detected	B-T033
in	O
none	O
of	O
the	O
patients	O
during	O
the	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Eleven	O
patients	O
(	O
68	O
.	O
75	O
%	O
)	O
in	O
group	O
A	O
became	O
socially	O
dry	O
following	O
1	O
-	O
2	O
injections	B-T058
,	O
the	O
degree	O
of	O
incontinence	B-T038
was	O
improved	O
in	O
4	O
patients	O
(	O
25	O
%	O
)	O
,	O
and	O
there	O
was	O
no	B-T033
change	I-T033
in	O
one	O
patient	O
(	O
6	O
.	O
25	O
%	O
)	O
.	O

However	O
,	O
Deflux	B-T103
injection	B-T058
resulted	O
in	O
complete	O
dryness	O
in	O
14	O
(	O
66	O
.	O
66	O
%	O
)	O
,	O
improvement	O
in	O
the	O
degree	O
of	O
incontinence	B-T038
in	O
5	O
(	O
23	O
.	O
81	O
%	O
)	O
and	O
no	B-T033
change	I-T033
in	O
2	O
patients	O
(	O
9	O
.	O
52	O
%	O
)	O
,	O
leading	O
to	O
no	O
significant	O
difference	O
in	O
continence	B-T058
achievement	I-T058
between	O
CaHA	B-T103
and	O
Deflux	B-T103
groups	O
(	O
p	O
=	O
0	O
.	O
9	O
)	O
.	O

The	O
statistical	O
analysis	O
was	O
not	O
significantly	O
different	O
in	O
terms	O
of	O
bladder	B-T033
capacity	I-T033
(	O
p	O
=	O
0	O
.	O
7	O
)	O
or	O
Q	O
max	O
(	O
p	O
=	O
0	O
.	O
8	O
)	O
.	O

The	O
preliminary	O
results	O
of	O
this	O
study	B-T062
revealed	O
that	O
CaHA	B-T103
may	O
be	O
applied	O
as	O
an	O
affordable	O
bulking	B-T103
agent	I-T103
in	O
treatment	B-T058
of	O
urinary	B-T038
incontinence	I-T038
in	O
BEEC	B-T038
.	O

Opportunities	O
for	O
genomic	B-T017
prediction	O
for	O
fertility	B-T038
using	O
endocrine	B-T022
and	O
classical	O
fertility	B-T038
traits	O
in	O
dairy	B-T204
cattle	I-T204

Endocrine	B-T022
fertility	B-T038
traits	O
,	O
defined	O
from	O
progesterone	B-T103
concentration	O
levels	O
in	O
milk	B-T031
,	O
have	O
been	O
suggested	O
as	O
alternative	O
indicators	O
for	O
fertility	B-T038
in	O
dairy	B-T204
cows	I-T204
because	O
they	O
are	O
less	O
biased	O
by	O
farm	B-T082
management	O
decisions	B-T038
and	O
more	O
directly	O
reflect	O
a	O
cow	B-T204
'	O
s	O
reproductive	B-T038
physiology	B-T038
than	O
classical	O
traits	O
derived	O
from	O
insemination	B-T038
and	O
calving	O
data	O
.	O

To	O
determine	O
the	O
potential	O
use	O
of	O
endocrine	B-T022
fertility	B-T038
traits	O
in	O
genomic	B-T017
evaluations	B-T062
,	O
the	O
improvement	O
in	O
accuracy	O
from	O
using	O
endocrine	B-T022
fertility	B-T038
traits	O
concurrent	O
with	O
classical	O
traits	O
in	O
the	O
genomic	B-T017
prediction	O
of	O
fertility	B-T038
was	O
quantified	O
.	O

The	O
impact	O
of	O
recording	O
all	O
traits	O
on	O
all	O
training	O
animals	B-T204
was	O
also	O
investigated	O
.	O

Endocrine	B-T022
and	O
classical	O
fertility	B-T038
records	O
were	O
available	O
on	O
5	O
,	O
339	O
lactations	B-T038
from	O
2	O
,	O
447	O
Holstein	B-T204
cows	I-T204
in	O
Ireland	B-T082
,	O
the	O
Netherlands	B-T082
,	O
Sweden	B-T082
,	O
and	O
the	O
United	B-T082
Kingdom	I-T082
.	O

The	O
endocrine	B-T022
traits	O
were	O
commencement	O
of	O
luteal	O
activity	O
(	O
C	O
-	O
LA	O
)	O
and	O
proportion	O
of	O
samples	O
with	O
luteal	O
activity	O
(	O
PLA	O
)	O
;	O
the	O
classical	O
trait	O
was	O
the	O
interval	O
from	O
calving	O
to	O
first	O
service	O
(	O
CFS	O
)	O
.	O

The	O
interval	O
from	O
C	O
-	O
LA	O
to	O
first	O
service	O
(	O
C	O
-	O
LAFS	O
)	O
,	O
which	O
is	O
a	O
combination	O
of	O
an	O
endocrine	B-T022
trait	O
and	O
a	O
classical	O
trait	O
,	O
was	O
also	O
investigated	O
.	O

The	O
target	O
(	O
breeding	O
goal	O
)	O
trait	O
for	O
fertility	B-T038
was	O
CFS	O
or	O
C	O
-	O
LAFS	O
,	O
whereas	O
C	O
-	O
LA	O
and	O
PLA	O
served	O
as	O
predictor	O
traits	O
.	O

Genomic	B-T017
EBV	I-T017
(	O
GEBV	B-T017
)	O
for	O
fertility	B-T038
were	O
derived	O
using	O
genomic	B-T062
BLUP	I-T062
in	O
bivariate	O
models	O
with	O
85	O
,	O
485	O
SNP	B-T082
.	O

Genomic	O
EBV	O
for	O
the	O
separate	O
fertility	B-T038
traits	O
were	O
also	O
computed	O
,	O
in	O
univariate	O
models	O
.	O

The	O
accuracy	O
of	O
GEBV	B-T017
was	O
evaluated	O
by	O
5	O
-	O
fold	O
cross	B-T062
-	I-T062
validation	I-T062
.	O

The	O
highest	O
accuracy	O
of	O
GEBV	B-T017
was	O
achieved	O
using	O
bivariate	O
predictions	O
,	O
where	O
both	O
an	O
endocrine	B-T022
fertility	B-T038
trait	O
and	O
the	O
classical	O
fertility	B-T038
trait	O
were	O
used	O
.	O

Accuracy	O
of	O
GEBV	B-T017
for	O
predicting	O
adjusted	O
phenotypes	O
for	O
CFS	O
in	O
the	O
univariate	O
model	O
was	O
0	O
.	O
04	O
,	O
but	O
when	O
predicting	O
CFS	O
using	O
a	O
bivariate	O
model	O
with	O
C	O
-	O
LA	O
,	O
the	O
accuracy	O
increased	O
to	O
0	O
.	O
14	O
when	O
all	O
training	B-T204
animals	I-T204
were	O
phenotyped	O
for	O
C	O
-	O
LA	O
and	O
(	O
or	O
not	O
)	O
for	O
CFS	O
.	O

On	O
phenotyping	O
all	O
training	B-T204
animals	I-T204
for	O
both	O
C	O
-	O
LA	O
and	O
CFS	O
,	O
accuracy	O
for	O
CFS	O
increased	O
to	O
0	O
.	O
18	O
;	O
however	O
,	O
when	O
validation	B-T062
animals	B-T204
were	O
also	O
phenotyped	O
for	O
C	O
-	O
LA	O
,	O
there	O
was	O
no	B-T033
substantial	O
increase	O
in	O
accuracy	O
.	O

When	O
predicting	O
CFS	O
in	O
bivariate	O
analysis	O
with	O
PLA	O
,	O
accuracy	O
ranged	O
from	O
0	O
.	O
07	O
to	O
0	O
.	O
14	O
.	O

This	O
first	O
study	B-T062
on	O
genomic	B-T017
predictions	O
for	O
fertility	B-T038
using	O
endocrine	B-T022
traits	O
suggests	O
some	O
improvement	O
in	O
the	O
accuracy	O
of	O
prediction	O
over	O
using	O
only	O
the	O
classical	O
traits	O
.	O

Further	O
studies	B-T062
with	O
larger	O
training	B-T098
populations	I-T098
may	O
show	O
greater	O
improvements	O
.	O

A	O
Microfluidic	O
Platform	O
to	O
design	O
crosslinked	O
Hyaluronic	O
Acid	O
Nanoparticles	O
(	O
cHANPs	O
)	O
for	O
enhanced	B-T058
MRI	I-T058

Recent	O
advancements	O
in	O
imaging	B-T058
diagnostics	I-T058
have	O
focused	O
on	O
the	O
use	O
of	O
nanostructures	O
that	O
entrap	O
Magnetic	B-T058
Resonance	I-T058
Imaging	I-T058
(	O
MRI	B-T058
)	O
Contrast	B-T103
Agents	I-T103
(	O
CAs	B-T103
)	O
,	O
without	O
the	O
need	O
to	O
chemically	B-T103
modify	O
the	O
clinically	O
approved	O
compounds	B-T103
.	O

Nevertheless	O
,	O
the	O
exploitation	O
of	O
microfluidic	O
platforms	O
for	O
their	O
controlled	O
and	O
continuous	O
production	O
is	O
still	O
missing	O
.	O

Here	O
,	O
a	O
microfluidic	O
platform	O
is	O
used	O
to	O
synthesize	O
crosslinked	O
Hyaluronic	O
Acid	O
NanoParticles	O
(	O
cHANPs	O
)	O
in	O
which	O
a	O
clinically	O
relevant	O
MRI	B-T058
-	O
CAs	B-T103
,	O
gadolinium	B-T103
diethylenetriamine	I-T103
penta	I-T103
-	I-T103
acetic	I-T103
acid	I-T103
(	O
Gd	B-T103
-	I-T103
DTPA	I-T103
)	O
,	O
is	O
entrapped	O
.	O

This	O
microfluidic	O
process	O
facilitates	O
a	O
high	O
degree	O
of	O
control	O
over	O
particle	O
synthesis	O
,	O
enabling	O
the	O
production	O
of	O
monodisperse	O
particles	O
as	O
small	O
as	O
35	O
nm	O
.	O

Furthermore	O
,	O
the	O
interference	O
of	O
Gd	B-T103
-	I-T103
DTPA	I-T103
during	O
polymer	B-T103
precipitation	O
is	O
overcome	O
by	O
finely	O
tuning	O
process	O
parameters	O
and	O
leveraging	O
the	O
use	O
of	O
hydrophilic	O
-	O
lipophilic	O
balance	O
(	O
HLB	O
)	O
of	O
surfactants	B-T103
and	O
pH	O
conditions	O
.	O

For	O
both	O
production	O
strategies	O
proposed	O
to	O
design	O
Gd	B-T103
-	O
loaded	O
cHANPs	O
,	O
a	O
boosting	O
of	O
the	O
relaxation	O
rate	O
T1	O
is	O
observed	O
since	O
a	O
T1	O
of	O
1562	O
is	O
achieved	O
with	O
a	O
10	O
μM	O
of	O
Gd	B-T103
-	O
loaded	O
cHANPs	O
while	O
a	O
similar	O
value	O
is	O
reached	O
with	O
100	O
μM	O
of	O
the	O
relevant	O
clinical	O
Gd	B-T103
-	I-T103
DTPA	I-T103
in	O
solution	O
.	O

The	O
advanced	O
microfluidic	O
platform	O
to	O
synthesize	O
intravascularly	B-T082
-	O
injectable	B-T103
and	O
completely	O
biocompatible	B-T103
hydrogel	I-T103
nanoparticles	O
entrapping	O
clinically	O
approved	O
CAs	B-T103
enables	O
the	O
implementation	O
of	O
straightforward	O
and	O
scalable	O
strategies	O
in	O
diagnostics	O
and	O
therapy	B-T058
applications	O
.	O

Arthrobacter	B-T007
ginkgonis	I-T007
sp	I-T007
.	I-T007
nov	I-T007
.	I-T007
,	O
an	O
actinomycete	B-T007
isolated	O
from	O
rhizosphere	O
of	O
Ginkgo	B-T204
biloba	I-T204
L	I-T204

A	O
Gram	B-T033
-	I-T033
stain	I-T033
-	I-T033
positive	I-T033
,	O
aerobic	O
actinobacterial	B-T007
strain	I-T007
(	O
designated	O
SYP	B-T007
-	I-T007
A7299T	I-T007
)	O
,	O
which	O
displayed	O
a	O
rod	B-T007
-	I-T007
coccus	I-T007
growth	I-T007
lifecycle	I-T007
,	O
was	O
isolated	O
from	O
the	O
rhizosphere	O
of	O
Ginkgo	B-T204
biloba	I-T204
L	I-T204
.	O

Phylogenetic	B-T062
analyses	I-T062
based	O
on	O
16S	B-T017
rRNA	I-T017
gene	I-T017
sequences	I-T017
indicated	O
that	O
strain	B-T007
SYP	I-T007
-	I-T007
A7299T	I-T007
belongs	O
to	O
the	O
genus	B-T170
Arthrobacter	B-T007
and	O
is	O
most	O
closely	O
related	O
to	O
Arthrobacter	B-T007
halodurans	I-T007
JSM	I-T007
078085T	I-T007
(	O
97	O
.	O
4	O
%	O
16S	B-T017
rRNA	I-T017
gene	I-T017
sequence	I-T017
similarity	O
)	O
.	O

The	O
DNA	B-T103
-	O
DNA	B-T103
relatedness	O
value	O
between	O
strain	B-T007
SYP	I-T007
-	I-T007
A7299T	I-T007
and	O
A	B-T007
.	I-T007

halodurans	I-T007
JSM	I-T007
078085T	I-T007
was	O
37	O
%	O
±2	O
.	O
9	O
.	O

The	O
cell	B-T017
-	I-T017
wall	I-T017
peptidoglycan	B-T103
was	O
A4α	B-T103
,	O
and	O
glucose	B-T103
and	O
galactose	B-T103
were	O
whole	B-T103
-	I-T103
cell	I-T103
sugars	I-T103
.	O

The	O
polar	B-T103
lipids	I-T103
consisted	O
of	O
diphosphatidylglycerol	B-T103
,	O
phosphatidylglycerol	B-T103
,	O
phosphatidylinositol	B-T103
,	O
two	O
glycolipids	B-T103
and	O
an	O
unknown	O
polar	B-T103
lipid	I-T103
.	O

The	O
major	O
menaquinone	B-T103
were	O
MK	B-T103
-	I-T103
8	I-T103
(	I-T103
H2	I-T103
)	I-T103
(	O
72	O
%	O
)	O
and	O
MK	B-T103
-	I-T103
9	I-T103
(	I-T103
H2	I-T103
)	I-T103
(	O
28	O
%	O
)	O
,	O
and	O
the	O
predominant	O
cellular	B-T103
fatty	I-T103
acids	I-T103
were	O
anteiso	B-T103
-	I-T103
C15	I-T103
:	I-T103
0	I-T103
,	O
iso	B-T103
-	I-T103
C15	I-T103
:	I-T103
0	I-T103
and	O
anteiso	B-T103
-	I-T103
C17	I-T103
:	I-T103
0	I-T103
.	O

The	O
DNA	B-T103
G	O
+	O
C	O
content	O
was	O
68	O
.	O
9	O
mol	O
%	O
.	O

Based	O
on	O
the	O
morphological	B-T082
,	O
physiological	O
,	O
biochemical	O
and	O
chemotaxonomic	O
characters	O
presented	O
in	O
this	O
study	O
,	O
strain	B-T007
SYP	I-T007
-	I-T007
A7299T	I-T007
represents	O
a	O
novel	O
species	B-T170
of	O
the	O
genus	B-T170
Arthrobacter	B-T007
,	O
for	O
which	O
the	O
name	O
Arthrobacter	B-T007
ginkgonis	I-T007
sp	I-T007
.	I-T007

nov	I-T007
.	I-T007

is	O
proposed	O
.	O

The	O
type	O
strain	O
is	O
SYP	B-T007
-	I-T007
A7299T	I-T007
(	O
=	B-T007
DSM	I-T007
100491T	I-T007
=	I-T007
KCTC	I-T007
39	I-T007
592T	I-T007
)	O
.	O

Decoding	O
the	O
Interactions	B-T038
Regulating	O
the	O
Active	O
State	O
Mechanics	O
of	O
Eukaryotic	B-T204
Protein	B-T103
Kinases	I-T103

Eukaryotic	B-T204
protein	B-T103
kinases	I-T103
regulate	O
most	O
cellular	B-T038
functions	I-T038
by	O
phosphorylating	B-T038
targeted	O
protein	B-T103
substrates	O
through	O
a	O
highly	O
conserved	O
catalytic	B-T017
core	I-T017
.	O

In	O
the	O
active	O
state	O
,	O
the	O
catalytic	B-T017
core	I-T017
oscillates	O
between	O
open	B-T082
,	O
intermediate	B-T082
,	O
and	O
closed	B-T082
conformations	B-T082
.	O

Currently	O
,	O
the	O
intramolecular	B-T038
interactions	I-T038
that	O
regulate	O
the	O
active	O
state	O
mechanics	O
are	O
not	O
well	O
understood	O
.	O

Here	O
,	O
using	O
cAMP	B-T103
-	I-T103
dependent	I-T103
protein	I-T103
kinase	I-T103
as	O
a	O
representative	O
model	O
coupled	O
with	O
biochemical	O
,	O
biophysical	B-T038
,	O
and	O
computational	B-T062
techniques	I-T062
,	O
we	O
define	O
a	O
set	O
of	O
highly	O
conserved	O
electrostatic	O
and	O
hydrophobic	B-T038
interactions	I-T038
working	O
harmoniously	O
to	O
regulate	O
these	O
mechanics	O
.	O

These	O
include	O
the	O
previously	O
identified	O
salt	B-T038
bridge	I-T038
between	O
a	O
lysine	B-T103
from	O
the	O
β3	B-T082
-	I-T082
strand	I-T082
and	O
a	O
glutamate	B-T103
from	O
the	O
αC	B-T082
-	I-T082
helix	I-T082
as	O
well	O
as	O
an	O
electrostatic	O
interaction	O
between	O
the	O
phosphorylated	B-T038
activation	O
loop	B-T082
and	O
αC	B-T082
-	I-T082
helix	I-T082
and	O
an	O
ensemble	O
of	O
hydrophobic	O
residues	O
of	O
the	O
Regulatory	O
spine	O
and	O
Shell	O
.	O

Moreover	O
,	O
for	O
over	O
three	O
decades	O
it	O
was	O
thought	O
that	O
the	O
highly	O
conserved	O
β3	B-T103
-	I-T103
lysine	I-T103
was	O
essential	O
for	O
phosphoryl	B-T038
transfer	I-T038
,	O
but	O
our	O
findings	O
show	O
that	O
the	O
β3	B-T103
-	I-T103
lysine	I-T103
is	O
not	O
required	O
for	O
phosphoryl	B-T038
transfer	I-T038
but	O
is	O
essential	O
for	O
the	O
active	O
state	O
mechanics	O
.	O

Acute	O
clinical	O
adverse	B-T037
radiation	I-T037
effects	I-T037
after	O
Gamma	B-T058
Knife	I-T058
surgery	I-T058
for	O
vestibular	B-T038
schwannomas	I-T038

OBJECTIVE	O
Vestibular	B-T038
schwannomas	I-T038
(	O
VSs	B-T038
)	O
represent	O
a	O
common	O
indication	O
of	O
Gamma	B-T058
Knife	I-T058
surgery	I-T058
(	O
GKS	B-T058
)	O
.	O

While	O
most	O
studies	B-T062
focus	O
on	O
the	O
long	O
-	O
term	O
morbidity	O
and	O
adverse	B-T037
radiation	I-T037
effects	I-T037
(	O
AREs	B-T037
)	O
,	O
none	O
describe	O
the	O
acute	O
clinical	O
AREs	B-T037
that	O
might	O
appear	O
on	O
a	O
short	O
-	O
term	O
basis	O
.	O

These	O
types	O
of	O
events	O
are	O
investigated	O
,	O
and	O
their	O
incidence	O
,	O
type	O
,	O
and	O
outcomes	B-T062
are	O
reported	B-T170
in	O
the	O
present	O
paper	O
.	O

METHODS	O
The	O
included	O
patients	O
were	O
treated	O
between	O
July	O
2010	O
and	O
March	O
2016	O
,	O
underwent	O
at	O
least	O
6	O
months	O
of	O
follow	B-T058
-	I-T058
up	I-T058
,	O
and	O
presented	O
with	O
a	O
disabling	O
symptom	B-T033
during	O
the	O
first	O
6	O
months	O
after	O
GKS	B-T058
that	O
affected	O
their	O
quality	O
of	O
life	O
.	O

The	O
timing	O
of	O
appearance	O
,	O
as	O
well	O
as	O
the	O
type	O
of	O
main	O
symptom	B-T033
and	O
outcome	B-T062
,	O
were	O
noted	O
.	O

The	O
prescribed	O
dose	O
was	O
12	O
Gy	O
at	O
the	O
margin	O
.	O

RESULTS	O
Thirty	O
-	O
five	O
(	O
22	O
%	O
)	O
of	O
159	O
patients	O
who	O
fulfilled	O
the	O
inclusion	O
criteria	O
had	O
acute	O
clinical	O
AREs	B-T037
.	O

The	O
mean	O
followup	B-T058
period	O
was	O
30	O
months	O
(	O
range	O
6	O
-	O
49	O
.	O
2	O
months	O
)	O
.	O

The	O
mean	O
time	O
of	O
appearance	O
was	O
37	O
.	O
9	O
days	O
(	O
median	O
31	O
days	O
;	O
range	O
3	O
-	O
110	O
days	O
)	O
.	O

In	O
patients	O
with	O
de	O
novo	O
symptoms	B-T033
,	O
the	O
more	O
frequent	O
symptoms	B-T033
were	O
vertigo	B-T033
(	O
n	O
=	O
4	O
;	O
11	O
.	O
4	O
%	O
)	O
and	O
gait	B-T033
disturbance	I-T033
(	O
n	O
=	O
3	O
;	O
8	O
.	O
6	O
%	O
)	O
.	O

The	O
exacerbation	B-T033
of	O
a	O
preexisting	O
symptom	B-T033
was	O
more	O
frequently	O
related	O
to	O
hearing	B-T033
loss	I-T033
(	O
n	O
=	O
10	O
;	O
28	O
.	O
6	O
%	O
)	O
,	O
followed	O
by	O
gait	B-T033
disturbance	I-T033
(	O
n	O
=	O
7	O
;	O
20	O
%	O
)	O
and	O
vertigo	B-T033
(	O
n	O
=	O
3	O
,	O
8	O
.	O
6	O
%	O
)	O
.	O

In	O
the	O
univariate	O
logistic	O
regression	O
analysis	O
,	O
the	O
following	O
factors	O
were	O
statistically	O
significant	O
:	O
age	O
(	O
p	O
=	O
0	O
.	O
002	O
;	O
odds	O
ratio	O
[	O
OR	O
]	O
0	O
.	O
96	O
)	O
,	O
hearing	O
at	O
baseline	O
by	O
Gardner	B-T170
-	I-T170
Robertson	I-T170
(	O
GR	B-T170
)	O
class	O
(	O
p	O
=	O
0	O
.	O
006	O
;	O
OR	O
0	O
.	O
21	O
)	O
,	O
pure	O
tone	O
average	O
at	O
baseline	O
(	O
p	O
=	O
0	O
.	O
006	O
;	O
OR	O
0	O
.	O
97	O
)	O
,	O
and	O
Koos	B-T170
grade	I-T170
at	O
baseline	O
(	O
with	O
Koos	B-T170
Grade	I-T170
I	I-T170
used	O
as	O
a	O
reference	O
)	O
(	O
for	O
Koos	B-T170
Grade	I-T170
II	I-T170
,	O
OR	O
0	O
.	O
17	O
and	O
p	O
=	O
0	O
.	O
002	O
;	O
for	O
Koos	B-T170
Grade	I-T170
III	I-T170
,	O
OR	O
0	O
.	O
42	O
and	O
p	O
=	O
0	O
.	O
05	O
)	O
.	O

The	O
following	O
were	O
not	O
statistically	O
significant	O
but	O
showed	O
a	O
tendency	O
toward	O
significance	O
:	O
the	O
number	O
of	O
isocenters	B-T082
(	O
p	O
=	O
0	O
.	O
06	O
;	O
OR	O
0	O
.	O
94	O
)	O
and	O
the	O
maximal	O
dose	O
received	O
by	O
the	O
cochlea	B-T038
(	O
p	O
=	O
0	O
.	O
07	O
;	O
OR	O
0	O
.	O
74	O
)	O
.	O

Fractional	B-T170
polynomial	I-T170
regression	I-T170
analysis	I-T170
showed	O
a	O
nonlinear	O
relationship	O
between	O
the	O
outcome	B-T062
and	O
the	O
radiation	O
dose	O
rate	O
(	O
minimum	O
reached	O
at	O
a	O
cutoff	O
of	O
2	O
.	O
5	O
Gy	O
/	O
minute	O
)	O
and	O
the	O
maximal	O
vestibular	B-T082
dose	O
(	O
maximum	O
reached	O
at	O
a	O
cutoff	O
of	O
8	O
Gy	O
)	O
,	O
but	O
the	O
small	O
sample	O
size	O
precludes	O
a	O
detailed	O
analysis	B-T062
of	O
the	O
former	O
.	O

The	O
clinical	O
acute	O
AREs	B-T037
disappeared	O
in	O
32	O
(	O
91	O
.	O
4	O
%	O
)	O
patients	O
during	O
the	O
first	O
6	O
months	O
after	O
appearance	O
.	O

Permanent	O
and	O
somewhat	O
disabling	O
morbidity	O
was	O
found	O
in	O
3	O
cases	O
(	O
1	O
.	O
9	O
%	O
from	O
the	O
whole	O
series	O
)	O
:	O
1	O
each	O
with	O
complete	B-T033
hearing	I-T033
loss	I-T033
(	O
GR	B-T170
Class	I-T170
I	I-T170
before	O
and	O
V	B-T170
after	O
)	O
,	O
hemifacial	B-T033
spasm	I-T033
(	O
persistent	O
but	O
alleviated	O
)	O
,	O
and	O
dysgeusia	B-T033
.	O

CONCLUSIONS	O
Acute	O
effects	O
after	O
radiosurgery	B-T058
for	O
VS	B-T038
are	O
not	O
rare	O
.	O

They	O
concern	O
predominantly	O
de	O
novo	O
vertigo	B-T033
and	O
gait	B-T033
disturbance	I-T033
and	O
the	O
exacerbation	B-T033
of	O
preexistent	O
hearing	B-T033
loss	I-T033
.	O

In	O
de	O
novo	O
vestibular	B-T082
symptom	B-T033
s	O
,	O
a	O
vestibular	B-T082
dose	O
of	O
more	O
than	O
8	O
Gy	O
is	O
thought	O
to	O
play	O
a	O
role	O
.	O

In	O
most	O
cases	O
,	O
none	O
of	O
these	O
effects	O
are	O
permanent	O
,	O
and	O
they	O
will	O
ultimately	O
improve	O
or	O
disappear	O
with	O
steroid	B-T058
therapy	I-T058
.	O

Permanent	O
AREs	B-T037
remain	O
very	O
rare	O
.	O

Long	B-T103
-	I-T103
chain	I-T103
n	I-T103
-	I-T103
3	I-T103
PUFA	I-T103
supplied	O
by	O
the	O
usual	O
diet	B-T168
decrease	O
plasma	B-T103
stearoyl	I-T103
-	I-T103
CoA	I-T103
desaturase	I-T103
index	B-T170
in	O
non	B-T033
-	I-T033
hypertriglyceridemic	I-T033
older	B-T098
adults	I-T098
at	O
high	O
vascular	B-T017
risk	O

The	O
activity	B-T038
of	O
stearoyl	B-T103
-	I-T103
CoA	I-T103
desaturase	I-T103
-	I-T103
1	I-T103
(	O
SCD1	B-T103
)	O
,	O
the	O
central	B-T103
enzyme	I-T103
in	O
the	O
synthesis	O
of	O
monounsaturated	B-T103
fatty	I-T103
acids	I-T103
(	O
MUFA	B-T103
)	O
,	O
has	O
been	O
associated	O
with	O
de	O
novo	O
lipogenesis	B-T038
.	O

In	O
experimental	B-T170
models	I-T170
SCD1	B-T103
is	O
down	B-T038
-	I-T038
regulated	I-T038
by	O
polyunsaturated	B-T103
fatty	I-T103
acids	I-T103
(	O
PUFA	B-T103
)	O
,	O
but	O
clinical	B-T062
studies	I-T062
are	O
scarce	O
.	O

The	O
effect	O
of	O
long	B-T103
-	I-T103
chain	I-T103
n	I-T103
-	I-T103
3	I-T103
PUFA	I-T103
(	O
LCn	B-T103
-	I-T103
3PUFA	I-T103
)	O
supplied	O
by	O
the	O
regular	B-T168
diet	I-T168
,	O
in	O
the	O
absence	O
of	O
fatty	B-T168
fish	I-T168
or	O
fish	B-T168
oil	I-T168
supplementation	B-T168
,	I-T168
remains	O
to	O
be	O
explored	O
.	O

We	O
related	O
1	O
-	O
y	O
changes	O
in	O
plasma	B-T103
SCD1	I-T103
index	B-T170
,	O
as	O
assessed	O
by	O
the	O
C16	B-T103
:	I-T103
1n	I-T103
-	I-T103
7	I-T103
/	O
C16	B-T103
:	I-T103
0	I-T103
ratio	O
,	O
to	O
both	O
adiposity	O
traits	O
and	O
nutrient	B-T033
intake	I-T033
changes	O
in	O
a	O
sub	B-T098
-	I-T098
cohort	I-T098
(	O
n	O
=	O
243	O
)	O
of	O
non	B-T033
-	I-T033
hypertriglyceridemic	I-T033
subjects	B-T098
of	O
the	O
PREDIMED	B-T062
(	I-T062
PREvención	I-T062
con	I-T062
DIeta	I-T062
MEDiterranea	I-T062
)	I-T062
trial	I-T062
.	O

After	O
adjustment	O
for	O
confounders	O
,	O
including	O
changes	O
in	O
fasting	B-T033
triglycerides	B-T103
,	O
plasma	B-T103
SCD1	I-T103
index	B-T170
increased	O
in	O
parallel	O
with	O
body	O
weight	O
(	O
0	O
.	O
221	O
[	O
95	O
%	O
confidence	O
interval	O
,	O
0	O
.	O
021	O
to	O
0	O
.	O
422	O
]	O
,	O
P	O
=	O
0	O
.	O
031	O
)	O
and	O
BMI	B-T201
(	O
0	O
.	O
115	O
[	O
0	O
.	O
027	O
to	O
0	O
.	O
202	O
]	O
,	O
P	O
=	O
0	O
.	O
011	O
)	O
.	O

Additionally	O
,	O
dietary	B-T168
LCn	B-T103
-	I-T103
3PUFA	I-T103
(	O
but	O
not	O
MUFA	B-T103
or	O
plant	B-T103
-	I-T103
derived	I-T103
PUFA	I-T103
)	O
were	O
associated	O
with	O
decreased	O
plasma	B-T103
SCD1	I-T103
index	B-T170
(	O
-	O
0	O
.	O
544	O
[	O
-	O
1	O
.	O
044	O
to	O
-	O
0	O
.	O
043	O
]	O
,	O
P	O
=	O
0	O
.	O
033	O
,	O
for	O
each	O
1	O
g	O
/	O
d	O
-	O
increase	O
in	O
LCn	B-T103
-	I-T103
3PUFA	I-T103
)	O
.	O

No	O
associations	O
were	O
found	O
for	O
other	O
food	B-T168
groups	O
,	O
but	O
there	O
was	O
a	O
trend	O
for	O
fatty	B-T168
fish	I-T168
intake	O
(	O
-	O
0	O
.	O
083	O
[	O
-	O
0	O
.	O
177	O
to	O
0	O
.	O
012	O
]	O
,	O
P	O
=	O
0	O
.	O
085	O
,	O
for	O
each	O
10	O
g	O
/	O
d	O
-	O
increase	O
)	O
.	O

Our	O
data	O
add	O
clinical	O
evidence	O
on	O
the	O
down	B-T038
-	I-T038
regulation	I-T038
of	O
plasma	B-T103
SCD1	I-T103
index	B-T170
by	O
LCn	B-T103
-	I-T103
3PUFA	I-T103
in	O
the	O
context	O
of	O
realistic	O
changes	O
in	O
fish	B-T204
consumption	O
in	O
the	O
customary	O
,	O
non	B-T033
-	I-T033
supplemented	I-T033
diet	B-T168
.	O

http	O
:	O
/	O
/	O
www	O
.	O
Controlled	O
-	O
trials	O
.	O
com	O
/	O
ISRCTN35739639	O
.	O

Distinct	B-T017
cortical	I-T017
and	I-T017
sub	I-T017
-	I-T017
cortical	I-T017
neurogenic	I-T017
domains	I-T017
for	O
GABAergic	B-T038
interneuron	B-T017
precursor	O
transcription	B-T103
factors	I-T103
NKX2	B-T103
.	I-T103
1	I-T103
,	O
OLIG2	B-T103
and	O
COUP	B-T103
-	I-T103
TFII	I-T103
in	O
early	O
fetal	O
human	B-T204
telencephalon	B-T017

The	O
extent	O
of	O
similarities	O
and	O
differences	O
between	O
cortical	B-T038
GABAergic	I-T038
interneuron	I-T038
generation	I-T038
in	O
rodent	B-T204
and	O
primate	B-T204
telencephalon	B-T017
remains	O
contentious	O
.	O

We	O
examined	O
expression	B-T038
of	O
three	O
interneuron	B-T017
precursor	O
transcription	B-T103
factors	I-T103
,	O
alongside	O
other	O
markers	B-T201
,	O
using	O
immunohistochemistry	B-T058
on	O
8	O
-	O
12	O
post	O
-	O
conceptional	O
weeks	O
(	O
PCW	O
)	O
human	B-T204
telencephalon	B-T017
sections	O
.	O

NKX2	B-T103
.	I-T103
1	I-T103
,	O
OLIG2	B-T103
,	O
and	O
COUP	B-T103
-	I-T103
TFII	I-T103
expression	B-T038
occupied	O
distinct	O
(	O
although	O
overlapping	O
)	O
neurogenic	B-T017
domains	I-T017
which	O
extended	O
into	O
the	O
cortex	B-T017
and	O
revealed	O
three	O
CGE	B-T017
compartments	I-T017
:	O
lateral	B-T082
,	O
medial	B-T082
,	O
and	O
ventral	B-T082
.	O

NKX2	B-T103
.	I-T103
1	I-T103
expression	B-T038
was	O
very	O
largely	O
confined	O
to	O
the	O
MGE	B-T017
,	O
medial	B-T082
CGE	B-T017
,	O
and	O
ventral	B-T082
septum	B-T017
confirming	O
that	O
,	O
at	O
this	O
developmental	O
stage	O
,	O
interneuron	B-T017
generation	O
from	O
NKX2	B-T103
.	I-T103
1	I-T103
+	O
precursor	O
s	O
closely	O
resembles	O
the	O
process	O
observed	O
in	O
rodents	B-T204
.	O

OLIG2	B-T103
immunoreactivity	O
was	O
observed	O
in	O
GABAergic	B-T017
cells	I-T017
of	O
the	O
proliferative	B-T038
zones	B-T082
of	O
the	O
MGE	B-T017
and	O
septum	B-T017
,	O
but	O
not	O
necessarily	O
co	O
-	O
expressed	O
with	O
NKX2	B-T103
.	I-T103
1	I-T103
,	O
and	O
OLIG2	B-T103
expression	B-T038
was	O
also	O
extensively	O
seen	O
in	O
the	O
LGE	B-T017
,	O
CGE	B-T017
,	O
and	O
cortex	B-T017
.	O

At	O
8	O
PCW	O
,	O
OLIG2	B-T103
+	O
cells	B-T017
were	O
only	O
present	O
in	O
the	O
medial	B-T082
and	O
anterior	B-T082
cortical	B-T017
wall	I-T017
suggesting	O
a	O
migratory	O
pathway	O
for	O
interneuron	B-T017
precursor	O
s	O
via	O
the	O
septum	B-T017
into	O
the	O
medial	B-T082
cortex	B-T017
.	O

By	O
12	O
PCW	O
,	O
OLIG2	B-T103
+	O
cells	B-T017
were	O
present	O
throughout	O
the	O
cortex	B-T017
and	O
many	O
were	O
actively	O
dividing	O
but	O
without	O
co	O
-	O
expressing	O
cortical	B-T017
progenitor	B-T017
markers	B-T201
.	O

Dividing	O
COUP	B-T103
-	I-T103
TFII	I-T103
+	O
progenitor	B-T017
cells	I-T017
were	O
localized	B-T082
to	O
ventral	B-T082
CGE	B-T017
as	O
previously	O
described	O
but	O
were	O
also	O
numerous	O
in	O
adjacent	O
ventral	B-T082
cortex	B-T017
;	O
in	O
both	O
the	O
cases	O
,	O
COUP	B-T103
-	I-T103
TFII	I-T103
was	O
co	O
-	O
expressed	O
with	O
PAX6	B-T103
in	O
proliferative	B-T038
zones	B-T082
and	O
TBR1	B-T103
or	O
calretinin	B-T103
in	O
post	O
-	O
mitotic	O
cortical	B-T017
neurons	I-T017
.	O

Thus	O
COUP	B-T103
-	I-T103
TFII	I-T103
+	O
progenitors	B-T017
gave	O
rise	O
to	O
pyramidal	B-T017
cells	I-T017
,	O
but	O
also	O
interneurons	B-T017
which	O
not	O
only	O
migrated	O
posteriorly	O
into	O
the	O
cortex	B-T017
from	O
ventral	B-T082
CGE	B-T017
but	O
also	O
anteriorly	B-T082
via	O
the	O
LGE	B-T017
.	O

Primary	B-T038
neuroendocrine	I-T038
carcinoma	I-T038
of	O
the	O
breast	B-T017
A	O
single	B-T038
Center	I-T038
experience	I-T038
and	O
review	B-T170
of	I-T170
the	I-T170
literature	I-T170

Neuroendocrine	B-T038
carcinoma	I-T038
of	O
the	O
breast	B-T017
is	O
an	O
extremely	O
rare	O
tumor	B-T038
.	O

A	O
standard	O
treatment	B-T058
has	O
yet	O
to	O
be	O
established	O
because	O
only	O
a	O
few	O
cases	O
have	O
been	O
reported	O
in	O
literature	B-T170
.	O

The	O
authors	B-T097
report	O
five	O
cases	O
observed	O
from	O
January	O
2007	O
to	O
December	O
2014	O
and	O
a	O
review	B-T170
of	I-T170
literature	I-T170
.	O

Four	O
patients	O
underwent	O
quadrantectomy	B-T058
and	O
in	O
two	O
cases	O
axillary	B-T058
nodal	I-T058
dissection	I-T058
and	O
only	O
one	O
to	O
mastectomy	B-T058
with	O
axillary	B-T058
nodal	I-T058
dissection	I-T058
.	O

Tumor	B-T082
size	I-T082
was	O
from	O
T1	B-T033
to	O
T2	B-T033
with	O
N0	B-T033
to	O
N1	B-T033
,	O
according	O
TNM	B-T170
classification	I-T170
.	O

Pathological	B-T031
specimens	I-T031
were	O
stained	O
with	O
hematoxylin	B-T103
and	O
eosin	B-T103
and	O
an	O
immunohistochemical	O
panel	O
of	O
antibodies	B-T103
(	O
Neuron	B-T103
-	I-T103
specific	I-T103
enolase	I-T103
,	O
Chromogranin	B-T103
,	O
Synaptophysin	B-T103
,	O
Estrogen	O
and	O
Progesterone	O
receptors	O
,	O
c	B-T103
-	I-T103
erb	I-T103
and	O
Ki	B-T103
-	I-T103
67	I-T103
)	O
.	O

All	O
cases	O
showed	O
markers	O
positivity	O
to	O
Neuron	B-T103
-	I-T103
specific	I-T103
enolase	I-T103
,	O
Chromogranin	B-T103
,	O
Synaptophysin	B-T103
and	O
Estrogen	O
and	O
Progesterone	O
receptors	O
were	O
found	O
.	O

Ki	B-T103
-	I-T103
67	I-T103
was	O
higher	O
than	O
40	O
%	O
in	O
four	O
patients	O
.	O

Adjuvant	B-T058
chemotherapy	I-T058
was	O
administrated	B-T058
in	O
patients	O
with	O
Ki	B-T103
-	I-T103
67	I-T103
>	O
10	O
%	O
;	O
every	O
patients	O
were	O
treated	O
with	O
radiotherapy	B-T058
and	O
with	O
hormonal	B-T058
therapy	I-T058
too	O
.	O

Although	O
Neuroendocrine	B-T038
breast	I-T038
tumor	I-T038
is	O
considered	O
a	O
distinct	O
entity	O
,	O
the	O
best	O
treatment	B-T058
seems	O
to	O
be	O
correlate	O
to	O
the	O
size	B-T082
of	I-T082
tumor	I-T082
and	O
to	O
the	O
lymph	B-T017
node	I-T017
status	O
and	O
to	O
Ki	B-T103
-	I-T103
67	I-T103
index	B-T170
like	O
the	O
common	O
breast	B-T038
cancer	I-T038
.	O

Diagnosis	B-T033
,	O
Neuroendocrine	B-T038
breast	I-T038
carcinoma	I-T038
.	O

A	O
new	O
parametric	B-T170
model	I-T170
to	O
assess	O
delay	O
and	O
compression	O
of	O
mortality	O

A	O
decrease	O
in	O
mortality	O
across	O
all	O
ages	O
causes	O
a	O
shift	O
of	O
the	O
age	O
pattern	B-T082
of	O
mortality	O
,	O
or	O
mortality	O
delay	O
,	O
while	O
differences	O
in	O
the	O
rate	O
of	O
decrease	O
across	O
ages	O
cause	O
a	O
change	O
in	O
the	O
shape	B-T082
of	O
the	O
age	B-T033
-	I-T033
at	I-T033
-	I-T033
death	I-T033
distribution	O
,	O
mortality	O
compression	O
or	O
expansion	O
.	O

Evidence	O
exists	O
for	O
both	O
compression	O
and	O
delay	O
of	O
mortality	O
.	O

Existing	O
parametric	B-T170
models	I-T170
to	O
describe	O
the	O
full	O
age	O
pattern	B-T082
of	O
mortality	O
are	O
not	O
able	O
to	O
capture	O
mortality	O
delay	O
versus	O
mortality	O
compression	O
.	O

More	O
recent	O
models	B-T170
that	O
assess	O
delay	O
versus	O
compression	O
mostly	O
focused	O
on	O
the	O
adult	O
or	O
old	B-T098
ages	I-T098
alone	O
and	O
did	O
not	O
distinguish	O
mortality	O
compression	O
below	O
and	O
above	O
the	O
modal	O
age	O
at	O
death	B-T033
,	O
although	O
they	O
represent	O
different	O
mechanisms	O
.	O

This	O
paper	B-T170
presents	O
a	O
new	O
parametric	B-T170
model	I-T170
that	O
describes	O
the	O
full	O
age	O
pattern	B-T082
of	O
mortality	O
and	O
assesses	O
compression	O
-	O
at	O
different	O
stages	O
of	O
life	O
-	O
and	O
delay	O
of	O
mortality	O
:	O
the	O
CoDe	B-T170
model	I-T170
.	O

The	O
model	B-T170
includes	O
10	O
parameters	O
,	O
of	O
which	O
five	O
are	O
constant	O
over	O
time	O
.	O

The	O
five	O
time	O
-	O
varying	O
parameters	O
reflect	O
delay	O
of	O
mortality	O
and	O
compression	O
of	O
mortality	O
in	O
infancy	O
,	O
adolescence	O
,	O
young	O
adulthood	O
,	O
late	O
adulthood	O
,	O
and	O
old	B-T098
age	I-T098
.	O

The	O
model	B-T170
describes	O
infant	O
and	O
background	O
mortality	O
by	O
two	O
simple	O
functions	O
,	O
uses	O
a	O
mixed	B-T170
logistic	I-T170
model	I-T170
with	O
different	O
slopes	O
in	O
adult	O
,	O
middle	O
,	O
and	O
old	B-T098
age	I-T098
,	O
and	O
includes	O
the	O
modal	O
age	O
at	O
death	B-T033
as	O
a	O
parameter	O
to	O
account	O
for	O
the	O
delay	O
in	O
mortality	O
.	O

Applying	O
the	O
CoDe	B-T170
model	I-T170
to	O
age	O
-	O
specific	O
probabilities	O
of	O
death	B-T033
for	O
Japanese	B-T098
,	O
French	B-T098
,	O
American	B-T098
,	O
and	O
Danish	B-T098
men	B-T098
and	O
women	B-T098
between	O
1950	O
and	O
2010	O
showed	O
a	O
very	O
good	O
fit	O
of	O
the	O
full	O
age	O
pattern	B-T082
of	O
mortality	O
.	O

Delay	O
of	O
mortality	O
explained	O
about	O
two	O
-	O
thirds	O
of	O
the	O
increase	O
in	O
life	O
expectancy	O
at	O
birth	B-T038
,	O
whereas	O
compression	O
of	O
mortality	O
due	O
to	O
mortality	O
declines	O
in	O
young	O
age	O
explained	O
about	O
one	O
-	O
third	O
.	O

No	O
strong	O
compression	O
of	O
mortality	O
in	O
late	O
adulthood	O
age	O
was	O
observed	O
.	O

Mortality	O
compression	O
in	O
old	B-T098
age	I-T098
has	O
had	O
a	O
small	O
negative	O
impact	O
on	O
life	O
expectancy	O
.	O

The	O
CoDe	B-T170
model	I-T170
proved	O
a	O
valid	O
instrument	O
for	O
describing	O
the	O
full	O
age	O
pattern	B-T082
of	O
mortality	O
and	O
for	O
disentangling	O
the	O
effects	O
of	O
mortality	O
delay	O
and	O
compression	O
-	O
at	O
different	O
stages	O
of	O
life	O
-	O
on	O
the	O
increase	O
in	O
life	O
expectancy	O
.	O

Prevalence	O
of	O
Hypothyroidism	B-T038
in	O
Andalusia	B-T082
,	I-T082
Spain	I-T082
,	I-T082
Determined	O
by	O
Thyroid	B-T103
Hormone	I-T103
Comsumption	O

Hypothyroidism	B-T038
is	O
the	O
most	O
common	O
condition	O
linked	O
to	O
a	O
hormone	O
deficiency	O
,	O
nevertheless	O
data	O
on	O
its	O
prevalence	O
are	O
scarce	O
in	O
Spain	B-T082
.	O

For	O
that	O
reason	O
,	O
we	O
have	O
estimated	O
its	O
prevalence	O
through	O
the	O
registration	B-T058
of	O
patients	O
who	O
had	O
used	O
thyroid	B-T103
hormones	I-T103
in	O
Andalusia	B-T082
(	I-T082
South	I-T082
Spain	I-T082
)	I-T082
.	O

Data	O
of	O
patients	O
who	O
had	O
withdrawn	O
levothyroxine	B-T103
under	O
the	O
public	O
system	O
during	O
2014	O
from	O
the	O
base	O
of	O
the	O
Andalusian	B-T058
Health	I-T058
Service	I-T058
were	O
considered	O
.	O

Prevalence	O
were	O
calculated	O
with	O
confidence	O
intervals	O
of	O
95	O
%	O
for	O
each	O
management	O
area	O
,	O
stratified	O
by	O
sex	O
and	O
age	O
groups	O
,	O
and	O
differences	O
between	O
them	O
were	O
evaluated	B-T058
.	O

321	O
,	O
368	O
people	B-T098
(	O
98	O
%	O
older	O
than	O
18	O
years	O
and	O
83	O
%	O
female	O
)	O
were	O
identified	O
as	O
levothyroxine	B-T103
users	O
and	O
a	O
prevalence	O
of	O
hypothyroidism	B-T038
of	O
3	O
.	O
95	O
%	O
(	O
95	O
%	O
CI	O
:	O
3	O
.	O
94	O
-	O
3	O
.	O
96	O
)	O
was	O
estimated	O
for	O
the	O
general	O
population	B-T098
.	O

The	O
condition	O
was	O
more	O
common	O
in	O
females	O
,	O
in	O
the	O
older	O
18	O
years	O
7	O
.	O
81	O
%	O
(	O
95	O
%	O
CI	O
:	O
7	O
.	O
80	O
to	O
7	O
.	O
82	O
)	O
compared	O
to	O
males	O
1	O
.	O
75	O
%	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
73	O
-	O
1	O
.	O
77	O
)	O
with	O
a	O
ratio	O
of	O
4	O
.	O
5	O
-	O
fold	O
.	O

It	O
increases	O
in	O
the	O
population	B-T098
of	O
women	B-T098
older	O
than	O
45	O
years	O
,	O
10	O
.	O
32	O
%	O
(	O
95	O
%	O
CI	O
:	O
10	O
.	O
30	O
-	O
0	O
.	O
32	O
)	O
and	O
in	O
the	O
over	O
60	O
years	O
11	O
.	O
37	O
%	O
(	O
95	O
%	O
CI	O
:	O
11	O
.	O
35	O
-	O
11	O
.	O
40	O
)	O
.	O

The	O
prevalence	O
in	O
adult	O
women	B-T098
in	O
the	O
western	B-T082
provinces	I-T082
is	O
7	O
.	O
38	O
%	O
(	O
95	O
%	O
CI	O
:	O
7	O
.	O
36	O
-	O
7	O
.	O
40	O
)	O
,	O
in	O
the	O
eastern	B-T082
provinces	I-T082
8	O
.	O
59	O
%	O
(	O
95	O
%	O
CI	O
:	O
8	O
.	O
57	O
-	O
8	O
.	O
62	O
)	O
and	O
in	O
coastal	B-T082
areas	I-T082
6	O
.	O
70	O
%	O
(	O
95	O
%	O
CI	O
:	O
6	O
.	O
68	O
-	O
6	O
.	O
72	O
)	O
compared	O
to	O
the	O
mountainous	B-T098
ones	I-T098
,	O
which	O
is	O
8	O
.	O
91	O
%	O
(	O
95	O
%	O
CI	O
:	O
8	O
.	O
88	O
-	O
8	O
.	O
94	O
)	O
.	O

The	O
results	O
denote	O
a	O
high	O
prevalence	O
of	O
hypothyroidism	B-T038
in	O
the	O
adult	O
population	B-T098
of	O
Andalusia	B-T082
compared	O
to	O
the	O
nearby	O
countries	B-T082
,	O
with	O
a	O
clear	O
increased	O
associated	O
with	O
females	O
and	O
age	O
.	O

Furthermore	O
,	O
the	O
prevalence	O
of	O
the	O
illness	B-T033
presents	O
also	O
a	O
geographically	O
-	O
related	O
variability	O
.	O

Disease	O
Activity	O
and	O
Increased	B-T033
Risk	I-T033
of	I-T033
Cardiovascular	B-T038
Death	I-T038
among	O
Patients	O
with	O
Psoriatic	B-T038
Arthritis	I-T038

Recent	O
studies	O
indicate	O
increased	O
cardiovascular	B-T038
(	I-T038
CV	I-T038
)	I-T038
morbidity	I-T038
and	O
mortality	B-T038
in	O
patients	O
with	O
psoriatic	B-T038
arthritis	I-T038
(	O
PsA	B-T038
)	O
,	O
but	O
results	O
are	O
inconsistent	O
.	O

This	O
prompted	O
our	O
investigation	O
of	O
the	O
mortality	O
rate	O
,	O
cause	B-T033
of	I-T033
death	I-T033
,	O
and	O
incidence	O
of	O
acute	O
CV	B-T033
events	I-T033
in	O
patients	O
from	O
northern	B-T082
Sweden	B-T082
with	O
PsA	B-T038
.	O

Patients	O
with	O
established	O
PsA	B-T038
(	O
464	O
)	O
were	O
included	O
.	O

To	O
calculate	O
standardized	O
mortality	O
ratio	O
(	O
SMR	O
)	O
and	O
standardized	O
incidence	O
ratio	O
(	O
SIR	O
)	O
for	O
CV	B-T033
events	I-T033
,	O
data	O
were	O
extracted	O
from	O
the	O
National	B-T170
Causes	I-T170
of	I-T170
Death	I-T170
Register	I-T170
and	O
the	O
National	B-T170
Inpatient	I-T170
Care	I-T170
Register	I-T170
in	O
Sweden	B-T082
,	O
and	O
compared	O
with	O
the	O
general	B-T098
population	I-T098
.	O

The	O
study	O
period	O
was	O
1995	O
-	O
2011	O
.	O

To	O
study	O
the	O
effect	O
of	O
inflammatory	O
activity	O
,	O
a	O
composite	O
disease	O
activity	O
index	O
(	O
DAI	O
)	O
was	O
used	O
.	O

The	O
SMR	O
(	O
95	O
%	O
CI	O
)	O
for	O
overall	O
mortality	O
and	O
diseases	B-T038
of	I-T038
the	I-T038
circulatory	I-T038
system	I-T038
(	O
International	B-T170
Classification	I-T170
of	I-T170
Diseases	I-T170
,	O
10th	O
edition	O
;	O
I00	O
-	O
I99	O
)	O
was	O
1	O
.	O
22	O
(	O
0	O
.	O
89	O
-	O
1	O
.	O
63	O
)	O
and	O
1	O
.	O
64	O
(	O
1	O
.	O
02	O
-	O
2	O
.	O
52	O
)	O
,	O
respectively	O
.	O

In	O
regression	B-T170
analysis	I-T170
,	O
DAI	O
was	O
significantly	O
associated	O
with	O
death	B-T033
(	O
OR	O
1	O
.	O
99	O
,	O
95	O
%	O
CI	O
1	O
.	O
41	O
-	O
2	O
.	O
80	O
)	O
when	O
adjusted	O
for	O
age	O
and	O
sex	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
remained	O
significant	O
after	O
stratifying	O
patients	O
into	O
the	O
2	O
major	O
causes	B-T033
of	I-T033
death	I-T033
:	O
diseases	B-T038
of	I-T038
the	I-T038
circulatory	I-T038
system	I-T038
and	O
malignant	B-T038
neoplasms	I-T038
.	O

Peripheral	B-T038
and	O
axial	B-T033
disease	I-T033
was	O
associated	O
with	O
death	B-T033
(	O
OR	O
4	O
.	O
02	O
,	O
95	O
%	O
CI	O
1	O
.	O
84	O
-	O
8	O
.	O
84	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
compared	O
with	O
peripheral	B-T038
disease	I-T038
only	O
.	O

The	O
SIR	O
(	O
95	O
%	O
CI	O
)	O
for	O
a	O
CV	B-T033
event	I-T033
(	O
myocardial	B-T038
infarction	I-T038
or	O
stroke	B-T037
)	O
was	O
0	O
.	O
597	O
(	O
0	O
.	O
40	O
-	O
0	O
.	O
86	O
)	O
;	O
this	O
association	O
was	O
only	O
significant	O
in	O
men	B-T098
.	O

Patients	O
with	O
PsA	B-T038
had	O
a	O
small	O
but	O
significant	O
increase	O
in	O
SMR	O
for	O
death	B-T033
due	O
to	O
diseases	B-T038
of	I-T038
the	I-T038
circulatory	I-T038
system	I-T038
compared	O
with	O
the	O
general	B-T098
population	I-T098
.	O

Among	O
patients	O
,	O
death	B-T033
was	O
associated	O
with	O
DAI	O
,	O
as	O
well	O
as	O
axial	B-T033
involvement	I-T033
in	O
combination	O
with	O
peripheral	B-T038
disease	I-T038
,	O
indicating	O
more	O
aggressive	O
disease	O
phenotypes	O
.	O

Histomorphometric	B-T058
and	O
transcriptome	B-T082
evaluation	B-T058
of	O
early	O
healing	B-T033
bone	I-T033
treated	B-T058
with	I-T058
a	O
novel	O
human	B-T031
particulate	I-T031
dentin	I-T031
powder	B-T103

Human	B-T031
particulate	I-T031
dentin	I-T031
(	O
HPD	B-T031
)	O
shows	O
potential	O
as	O
an	O
alternative	O
bone	B-T058
grafting	I-T058
material	B-T103
.	O

However	O
,	O
the	O
mechanism	O
of	O
bone	B-T033
healing	I-T033
at	O
the	O
molecular	O
level	O
after	O
grafting	B-T058
with	O
HPD	B-T031
is	O
unclear	O
.	O

This	O
study	B-T062
assessed	O
the	O
histological	O
and	O
global	O
gene	B-T038
expression	I-T038
of	O
bone	B-T017
tissues	I-T017
grafted	O
with	O
HPD	B-T031
.	O

The	O
HPD	B-T031
was	O
prepared	B-T033
to	O
250	O
-	O
500	O
µm	O
in	O
size	O
.	O

X	B-T058
-	I-T058
ray	I-T058
diffraction	I-T058
(	O
XRD	B-T058
)	O
and	O
energy	B-T058
dispersive	I-T058
x	I-T058
-	I-T058
ray	I-T058
spectroscopy	I-T058
(	O
EDX	B-T058
)	O
were	O
performed	O
to	O
confirm	O
the	O
crystal	B-T103
structure	I-T103
,	O
organic	B-T103
compound	I-T103
residues	O
,	O
and	O
surface	O
morphology	O
,	O
respectively	O
.	O

Bony	O
defects	O
were	O
created	O
on	O
the	O
heads	B-T082
of	O
24	O
New	B-T204
Zealand	I-T204
White	I-T204
rabbits	I-T204
.	O

Sterilized	O
HPD	B-T031
was	O
used	O
as	O
the	O
grafting	B-T103
material	I-T103
.	O

The	O
quality	O
and	O
quantity	O
of	O
new	B-T038
bone	I-T038
formation	I-T038
was	O
evaluated	B-T058
using	O
micro	B-T058
-	I-T058
CT	I-T058
and	O
histologic	O
analyses	B-T062
during	O
the	O
8	O
week	O
experimental	O
periods	O
.	O

For	O
microarray	B-T058
assay	I-T058
,	O
bone	B-T017
tissue	I-T017
and	O
blood	B-T031
samples	I-T031
were	O
taken	O
at	O
3	O
,	O
5	O
and	O
7	O
d	O
post	O
-	O
implantation	O
.	O

The	O
results	B-T033
of	O
XRD	B-T058
and	O
EDX	B-T058
showed	O
that	O
HPD	B-T031
exhibited	O
physical	O
and	O
chemical	O
properties	O
similar	O
to	O
natural	O
hydroxyapatite	B-T103
.	O

New	B-T038
bone	I-T038
formation	I-T038
was	O
observed	O
after	O
HPD	B-T031
implantation	B-T058
compared	O
to	O
the	O
controls	O
,	O
as	O
shown	O
on	O
hematoxylin	B-T058
and	I-T058
eosin	I-T058
staining	I-T058
and	O
micro	B-T058
-	I-T058
CT	I-T058
.	O

The	O
bone	O
volume	O
of	O
HPD	B-T031
treated	O
animals	B-T204
was	O
higher	O
than	O
that	O
of	O
the	O
control	O
group	O
at	O
all	O
observation	B-T062
times	O
.	O

Microarray	B-T058
analysis	I-T058
showed	O
that	O
vascular	B-T038
development	I-T038
coupled	O
with	O
immune	O
and	O
inflammatory	O
related	O
genes	B-T017
were	O
expressed	B-T038
in	O
the	O
early	O
healing	B-T038
stage	O
.	O

The	O
gene	B-T017
coding	I-T017
for	O
the	O
IL	B-T103
-	I-T103
1	I-T103
antagonist	I-T103
,	O
IL1RN	B-T017
,	O
was	O
expressed	B-T038
to	O
inhibit	B-T038
the	O
inflammatory	B-T038
response	I-T038
,	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
CCL2	B-T017
gene	I-T017
was	O
activated	O
to	O
2	O
.	O
3	O
times	O
the	O
normal	O
level	O
.	O

BMP2	B-T017
,	O
RUNX2	B-T017
,	O
COL1A	B-T017
,	O
and	O
OPN	B-T017
expression	B-T038
were	O
also	O
up	B-T038
-	I-T038
regulated	I-T038
.	O

CCL2	B-T017
predominated	O
in	O
osteoblastogenesis	B-T038
of	O
the	O
HPD	B-T031
-	O
treated	O
bony	O
defect	O
in	O
the	O
early	O
stage	O
of	O
healing	B-T038
.	O

HPD	B-T031
accelerated	O
bone	B-T038
regeneration	I-T038
and	O
augmentation	B-T033
.	O

These	O
results	B-T033
suggested	O
that	O
HPD	B-T031
provided	O
potential	O
as	O
a	O
bone	B-T058
graft	I-T058
resource	O
during	O
the	O
bone	B-T017
healing	B-T038
process	I-T038
.	O

'	O
You	O
can	O
'	O
t	O
be	O
a	O
person	B-T098
and	O
a	O
docto	B-T097
r	O
'	O
:	O
the	O
work	O
-	O
life	O
balance	O
of	O
doctors	B-T097
in	O
training	O
-	O
a	O
qualitative	B-T062
study	I-T062

Investigate	O
the	O
work	O
-	O
life	O
balance	O
of	O
doctors	B-T097
in	O
training	O
in	O
the	O
UK	B-T082
from	O
the	O
perspectives	O
of	O
trainers	O
and	O
trainees	O
.	O

Qualitative	O
semistructured	O
focus	O
groups	O
and	O
interviews	O
with	O
trainees	O
and	O
trainers	O
.	O

Postgraduate	O
medical	O
training	O
in	O
London	B-T082
,	O
Yorkshire	B-T082
and	O
Humber	B-T082
,	O
Kent	B-T082
,	O
Surrey	B-T082
and	O
Sussex	B-T082
,	O
and	O
Wales	B-T082
during	O
the	O
junior	B-T097
doctor	I-T097
contract	B-T170
dispute	O
at	O
the	O
end	O
of	O
2015	O
.	O

Part	O
of	O
a	O
larger	O
General	B-T092
Medical	I-T092
Council	I-T092
study	B-T062
about	O
the	O
fairness	O
of	O
postgraduate	O
medical	O
training	O
.	O

96	O
trainees	O
and	O
41	O
trainers	O
.	O

Trainees	O
comprised	O
UK	B-T082
graduates	B-T098
and	O
International	B-T097
Medical	I-T097
Graduates	I-T097
,	O
across	O
all	O
stages	O
of	O
training	O
in	O
6	O
specialties	B-T091
(	O
General	B-T091
Practice	I-T091
,	O
Medicine	B-T091
,	O
Obstetrics	B-T091
and	I-T091
Gynaecology	I-T091
,	O
Psychiatry	B-T091
,	O
Radiology	B-T091
,	O
Surgery	B-T091
)	O
and	O
Foundation	B-T092
.	O

Postgraduate	O
training	O
was	O
characterised	O
by	O
work	O
-	O
life	O
imbalance	O
.	O

Long	O
hours	O
at	O
work	O
were	O
typically	O
supplemented	O
with	O
revision	O
and	O
completion	O
of	O
the	O
e	O
-	O
portfolio	O
.	O

Trainees	O
regularly	O
moved	O
workplaces	B-T082
which	O
could	O
disrupt	O
their	O
personal	O
lives	O
and	O
sometimes	O
led	O
to	O
separation	O
from	O
friends	B-T098
and	O
family	O
.	O

This	O
made	O
it	O
challenging	O
to	O
cope	O
with	O
personal	O
pressures	O
,	O
the	O
stresses	B-T038
of	O
which	O
could	O
then	O
impinge	O
on	O
learning	B-T038
and	O
training	O
,	O
while	O
also	O
leaving	O
trainees	O
with	O
a	O
lack	O
of	O
social	O
support	O
outside	O
work	O
to	O
buffer	O
against	O
the	O
considerable	O
stresses	B-T038
of	O
training	O
.	O

Low	O
morale	B-T033
and	O
harm	B-T033
to	O
well	O
-	O
being	O
resulted	O
in	O
some	O
trainees	O
feeling	B-T038
dehumanised	O
.	O

Work	O
-	O
life	O
imbalance	O
was	O
particularly	O
severe	O
for	O
those	O
with	O
children	O
and	O
especially	O
women	B-T098
who	O
faced	O
a	O
lack	O
of	O
less	O
-	O
than	O
-	O
full	O
-	O
time	O
positions	O
and	O
discriminatory	B-T038
attitudes	B-T038
.	O

Female	O
trainees	O
frequently	O
talked	O
about	O
having	O
to	O
choose	O
a	O
specialty	B-T091
they	O
felt	O
was	O
more	O
conducive	O
to	O
a	O
work	O
-	O
life	O
balance	O
such	O
as	O
General	B-T091
Practice	I-T091
.	O

The	O
proposed	O
junior	B-T097
doctor	I-T097
contract	B-T170
was	O
felt	O
to	O
exacerbate	B-T033
existing	O
problems	B-T033
.	O

A	O
lack	O
of	O
work	O
-	O
life	O
balance	O
in	O
postgraduate	O
medical	O
training	O
negatively	O
impacted	O
on	O
trainees	O
'	O
learning	B-T038
and	O
well	O
-	O
being	O
.	O

Women	B-T098
with	O
children	O
were	O
particularly	O
affected	O
,	O
suggesting	O
this	O
group	O
would	O
benefit	O
the	O
greatest	O
from	O
changes	O
to	O
improve	B-T033
the	O
work	O
-	O
life	O
balance	O
of	O
trainees	O
.	O

Reappraisal	O
Modulates	O
Attentional	B-T038
Bias	I-T038
to	O
Angry	B-T033
Faces	I-T033

Heightened	O
attentional	B-T038
bias	I-T038
to	O
emotional	B-T033
information	O
is	O
one	O
of	O
the	O
main	O
characteristics	O
of	O
disorders	B-T038
related	O
to	O
emotion	B-T038
dysregulation	B-T038
such	O
as	O
anxiety	B-T038
,	O
depression	B-T038
,	O
and	O
substance	B-T038
abuse	I-T038
.	O

Although	O
reappraisal	O
,	O
an	O
emotion	O
regulation	O
strategy	O
,	O
is	O
known	O
to	O
effectively	O
modulate	O
subjective	B-T038
experience	I-T038
of	O
emotions	B-T038
,	O
it	O
remains	O
unknown	O
whether	O
reappraisal	O
can	O
alter	O
attentional	B-T038
biases	I-T038
to	O
emotional	B-T033
information	O
.	O

In	O
the	O
current	O
research	B-T062
,	O
we	O
investigated	O
the	O
influence	O
of	O
instruction	O
-	O
induced	O
state	O
reappraisal	O
(	O
Study	B-T062
1	I-T062
)	O
and	O
trait	O
reappraisal	O
(	O
Study	B-T062
2	I-T062
)	O
on	O
attentional	B-T038
biases	I-T038
to	O
happy	B-T033
and	O
angry	B-T033
faces	I-T033
.	O

In	O
Study	B-T062
1	I-T062
,	O
healthy	O
young	B-T098
women	I-T098
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
one	O
of	O
the	O
three	O
groups	O
:	O
up	O
-	O
,	O
down	O
-	O
,	O
and	O
no	O
-	O
regulation	O
.	O

Participants	B-T098
were	O
instructed	O
to	O
reappraise	O
their	O
emotions	B-T038
to	O
increase	O
and	O
decrease	O
emotional	B-T033
experience	B-T038
while	O
viewing	O
an	O
emotionally	B-T170
negative	I-T170
film	I-T170
clip	I-T170
.	O

Attentional	B-T038
bias	I-T038
was	O
assessed	O
with	O
a	O
dot	B-T058
-	I-T058
probe	I-T058
task	I-T058
with	O
pictures	O
of	O
angry	B-T038
and	O
happy	B-T038
facial	B-T033
expressions	I-T033
.	O

In	O
Study	B-T062
2	I-T062
,	O
a	O
separate	O
group	O
of	O
healthy	O
young	B-T098
men	I-T098
and	O
women	B-T098
participated	O
.	O

Participants	B-T098
'	O
trait	O
reappraisal	O
and	O
suppression	B-T038
as	O
well	O
as	O
state	B-T038
and	O
trait	B-T033
anxiety	I-T033
were	O
assessed	O
.	O

A	O
dot	B-T058
-	I-T058
probe	I-T058
task	I-T058
was	O
completed	O
by	O
all	O
participants	B-T098
.	O

Statistical	B-T170
tests	I-T170
in	O
Study	B-T062
1	I-T062
revealed	O
that	O
participants	B-T098
who	O
reappraised	O
to	O
decrease	O
negative	B-T038
emotions	I-T038
while	O
viewing	O
an	O
emotionally	B-T170
negative	I-T170
film	I-T170
clip	I-T170
had	O
reduced	O
attentional	B-T038
bias	I-T038
to	O
subsequently	O
presented	O
angry	B-T033
faces	I-T033
compared	O
to	O
participants	B-T098
who	O
reappraised	O
to	O
increase	O
negative	B-T038
emotions	I-T038
.	O

Multiple	B-T170
regression	I-T170
analyses	I-T170
in	O
Study	B-T062
2	I-T062
revealed	O
that	O
trait	O
reappraisal	O
predicted	O
slower	O
orienting	O
toward	O
angry	B-T033
faces	I-T033
,	O
whereas	O
state	B-T038
anxiety	I-T038
predicted	O
slower	O
disengagement	O
from	O
angry	B-T033
faces	I-T033
.	O

Interestingly	O
,	O
trait	B-T038
suppression	I-T038
predicted	O
slower	O
disengagement	O
from	O
happy	B-T033
faces	I-T033
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
both	O
instruction	O
-	O
induced	O
state	O
reappraisal	O
and	O
trait	O
reappraisal	O
are	O
linked	O
to	O
reduced	O
attentional	B-T038
bias	I-T038
to	O
negative	B-T033
information	O
and	O
contribute	O
to	O
better	O
understanding	O
of	O
how	O
everyday	O
emotion	O
regulation	O
styles	O
contribute	O
to	O
attentional	O
processing	O
of	O
emotional	B-T033
information	O
.	O

Graded	B-T170
Structure	I-T170
in	O
Sexual	O
Definitions	B-T170
:	O
Categorizations	B-T170
of	O
Having	O
"	O
Had	B-T033
Sex	I-T033
"	O
and	O
Virginity	O
Loss	O
Among	O
Homosexual	B-T098
and	O
Heterosexual	B-T098
Men	B-T098
and	O
Women	B-T098

Definitions	B-T170
of	O
sexual	O
behavior	O
display	O
a	O
robust	O
hierarchy	O
of	O
agreement	O
regarding	O
whether	O
or	O
not	O
acts	O
should	O
be	O
classed	O
as	O
,	O
for	O
example	O
,	O
sex	B-T038
or	O
virginity	O
loss	O
.	O

The	O
current	O
research	B-T062
offers	O
a	O
theoretical	O
explanation	B-T170
for	O
this	O
hierarchy	O
,	O
proposing	O
that	O
sexual	O
definitions	B-T170
display	O
graded	B-T170
categorical	I-T170
structure	I-T170
,	O
arising	O
from	O
goodness	O
of	O
membership	O
judgments	B-T038
.	O

Moderation	O
of	O
this	O
graded	B-T170
structure	I-T170
is	O
also	O
predicted	O
,	O
with	O
the	O
focus	O
here	O
on	O
how	O
sexual	O
orientation	O
identity	B-T038
affects	O
sexual	O
definitions	B-T170
.	O

A	O
total	O
of	O
300	O
18	O
-	O
to	O
30	O
-	O
year	O
-	O
old	O
participants	B-T098
completed	O
an	O
online	B-T170
survey	I-T170
,	O
rating	O
18	O
behaviors	O
for	O
how	O
far	O
each	O
constitutes	O
having	O
"	O
had	B-T033
sex	I-T033
"	O
and	O
virginity	O
loss	O
.	O

Participants	B-T098
fell	O
into	O
one	O
of	O
four	O
groups	O
:	O
heterosexual	B-T098
male	B-T098
or	O
female	B-T098
,	O
gay	B-T098
male	I-T098
or	O
lesbian	B-T098
.	O

The	O
predicted	O
ratings	O
hierarchy	O
emerged	O
,	O
in	O
which	O
bidirectional	O
genital	O
acts	O
were	O
rated	O
significantly	O
higher	O
than	O
unidirectional	O
or	O
nonpenetrative	B-T033
contact	I-T033
,	O
which	O
was	O
in	O
turn	O
rated	O
significantly	O
higher	O
than	O
acts	O
involving	O
no	B-T033
genital	I-T033
contact	I-T033
.	O

Moderation	O
of	O
graded	B-T170
structure	I-T170
was	O
also	O
in	O
line	O
with	O
predictions	O
.	O

Compared	O
to	O
the	O
other	O
groups	O
,	O
the	O
lesbian	O
group	O
significantly	O
upgraded	O
ratings	O
of	O
genital	O
contact	O
that	O
was	O
either	O
unidirectional	O
or	O
nonpenetrative	B-T033
.	O

There	O
was	O
also	O
evidence	O
of	O
upgrading	O
by	O
the	O
gay	B-T098
male	I-T098
sample	O
of	O
anal	O
intercourse	O
ratings	O
.	O

These	O
effects	O
are	O
theorized	O
to	O
reflect	O
group	O
-	O
level	O
variation	O
in	O
experience	B-T038
,	O
contextual	B-T038
perspective	I-T038
,	O
and	O
identity	B-T038
-	O
management	O
.	O

The	O
implications	O
of	O
the	O
findings	B-T033
in	O
relation	O
to	O
previous	O
research	B-T062
are	O
discussed	O
.	O

It	O
is	O
suggested	O
that	O
a	O
graded	B-T170
structure	I-T170
approach	O
can	O
greatly	O
benefit	O
future	O
research	B-T062
into	O
sexual	O
definitions	B-T170
,	O
by	O
permitting	O
variable	O
definitions	B-T170
to	O
be	O
predicted	O
and	O
explained	O
,	O
rather	O
than	O
merely	O
identified	O
.	O

Effects	O
of	O
soybean	B-T103
isoflavone	I-T103
on	O
intestinal	B-T017
antioxidant	B-T038
capacity	I-T038
and	O
cytokines	B-T103
in	O
young	O
piglets	B-T204
fed	O
oxidized	B-T038
fish	B-T103
oil	I-T103

To	O
investigate	O
the	O
effect	O
of	O
glycitein	B-T103
,	O
a	O
synthetic	O
soybean	B-T103
isoflavone	I-T103
(	O
ISF	B-T103
)	O
,	O
on	O
the	O
intestinal	B-T017
antioxidant	B-T038
capacity	I-T038
,	O
morphology	O
,	O
and	O
cytokine	B-T103
content	O
in	O
young	O
piglets	B-T204
fed	O
oxidized	B-T038
fish	B-T103
oil	I-T103
,	O
72	O
4	O
-	O
d	O
-	O
old	O
male	O
piglets	B-T204
were	O
assigned	O
to	O
three	O
treatments	B-T058
.	O

The	O
control	O
group	O
was	O
fed	O
a	O
basal	B-T168
diet	I-T168
containing	O
fresh	O
fish	B-T103
oil	I-T103
,	O
and	O
the	O
other	O
two	O
groups	O
received	O
the	O
same	O
diet	O
except	O
for	O
the	O
substitution	O
with	O
the	O
same	O
dosage	O
of	O
oxidized	B-T038
fish	B-T103
oil	I-T103
alone	O
or	O
with	O
ISF	B-T103
(	O
oxidized	B-T038
fish	B-T103
oil	I-T103
plus	O
ISF	B-T103
)	O
.	O

After	O
21	O
d	O
of	O
feeding	O
,	O
supplementation	B-T058
of	O
oxidized	B-T038
fish	B-T103
oil	I-T103
increased	O
the	O
levels	O
of	O
malondialdehyde	B-T103
(	O
MDA	B-T103
)	O
,	O
oxidized	B-T103
glutathione	I-T103
(	O
GSSG	B-T103
)	O
,	O
interleukin	B-T103
-	I-T103
1β	I-T103
(	O
IL	B-T103
-	I-T103
1β	I-T103
)	O
,	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
-	I-T103
α	I-T103
(	O
TNF	B-T103
-	I-T103
α	I-T103
)	O
,	O
interleukin	B-T103
-	I-T103
2	I-T103
(	O
IL	B-T103
-	I-T103
2	I-T103
)	O
,	O
nuclear	B-T103
factor	I-T103
κ	I-T103
B	I-T103
(	B-T103
NF	I-T103
-	I-T103
κB	I-T103
)	O
,	O
inducible	B-T103
nitric	I-T103
oxide	I-T103
synthase	I-T103
(	O
iNOS	B-T103
)	O
,	O
NO	B-T103
,	O
and	O
Caspase	B-T103
-	I-T103
3	I-T103
in	O
jejunal	B-T017
mucosa	I-T017
,	O
and	O
decreased	O
the	O
villous	B-T017
height	O
in	O
duodenum	B-T017
and	O
the	O
levels	O
of	O
secretory	B-T103
immunoglobulin	I-T103
A	I-T103
(	B-T103
sIgA	I-T103
)	O
and	O
IL	B-T103
-	I-T103
4	I-T103
in	O
the	O
jejunal	B-T017
mucosa	I-T017
compared	O
with	O
supplementation	B-T058
with	O
fresh	O
oil	B-T103
.	O

The	O
addition	O
of	O
oxidized	B-T038
fish	B-T103
oil	I-T103
plus	O
ISF	B-T103
partially	O
alleviated	O
this	O
negative	O
effect	O
.	O

The	O
addition	O
of	O
oxidized	B-T038
fish	B-T103
oil	I-T103
plus	O
ISF	B-T103
increased	O
the	O
villous	B-T017
height	O
and	O
levels	O
of	O
sIgA	B-T103
and	O
IL	B-T103
-	I-T103
4	I-T103
in	O
jejunal	B-T017
mucosa	I-T017
,	O
but	O
decreased	O
the	O
levels	O
of	O
IL	B-T103
-	I-T103
1β	I-T103
and	O
IL	B-T103
-	I-T103
2	I-T103
in	O
jejunal	B-T017
mucosa	I-T017
(	O
P	O
<	O
0	O
.	O
05	O
)	O
compared	O
with	O
oxidized	B-T038
fish	B-T103
oil	I-T103
.	O

Collectively	O
,	O
these	O
results	O
show	O
that	O
dietary	B-T058
supplementation	I-T058
of	O
ISF	B-T103
could	O
partly	O
alleviate	O
the	O
negative	O
effect	O
of	O
oxidized	B-T038
fish	B-T103
oil	I-T103
by	O
improving	O
the	O
intestinal	B-T017
morphology	I-T017
as	O
well	O
as	O
the	O
antioxidant	B-T038
capacity	I-T038
and	O
immune	B-T038
function	I-T038
in	O
young	O
piglets	B-T204
.	O

Evolution	O
:	O
Enhanced	O
Footing	O
for	O
Snake	B-T204
Limb	B-T038
Development	I-T038

Two	O
groups	O
have	O
studied	O
the	O
loss	O
of	O
limbs	B-T017
in	O
snake	B-T204
evolution	O
by	O
focusing	O
on	O
a	O
long	B-T033
-	I-T033
distance	I-T033
cis	B-T082
-	I-T082
acting	I-T082
enhancer	I-T082
of	O
Sonic	B-T017
Hedgehog	I-T017
.	O

They	O
find	O
a	O
progressive	O
degeneration	O
of	O
binding	B-T082
sites	I-T082
for	O
key	O
transcription	B-T103
factors	I-T103
,	O
mirroring	O
the	O
progressive	O
limblessness	O
occurring	O
in	O
these	O
reptiles	B-T204
.	O

Dynamin	B-T103
-	I-T103
related	I-T103
protein	I-T103
1	I-T103
mediates	O
low	B-T103
glucose	I-T103
-	O
induced	O
endothelial	B-T038
dysfunction	I-T038
in	O
human	B-T204
arterioles	B-T017

Intensive	O
glycemic	B-T038
regulation	I-T038
has	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
hypoglycemia	B-T038
.	O

Hypoglycemic	B-T038
burden	O
correlates	O
with	O
adverse	O
cardiovascular	B-T038
complications	I-T038
and	O
contributes	O
acutely	O
and	O
chronically	O
to	O
endothelial	B-T038
dysfunction	I-T038
.	O

Prior	O
data	O
indicate	O
that	O
mitochondrial	B-T033
dysfunction	I-T033
contributes	O
to	O
hypoglycemia	B-T038
-	O
induced	O
endothelial	B-T038
dysfunction	I-T038
,	O
but	O
the	O
mechanisms	O
behind	O
this	O
linkage	O
remain	O
unknown	O
.	O

We	O
attempt	O
to	O
determine	O
whether	O
clinically	O
relevant	O
low	B-T103
-	I-T103
glucose	I-T103
(	O
LG	B-T103
)	O
exposures	O
acutely	O
induce	O
endothelial	B-T038
dysfunction	I-T038
through	O
activation	O
of	O
the	O
mitochondrial	B-T038
fission	I-T038
process	I-T038
.	O

Characterization	O
of	O
mitochondrial	B-T033
morphology	I-T033
was	O
carried	O
out	O
in	O
cultured	O
endothelial	B-T017
cells	I-T017
by	O
using	O
confocal	B-T058
microscopy	I-T058
.	O

Isolated	O
human	B-T204
arterioles	B-T017
were	O
used	O
to	O
explore	O
the	O
effect	O
LG	B-T103
-	O
induced	O
mitochondrial	B-T038
fission	I-T038
has	O
on	O
the	O
formation	O
of	O
detrimental	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
,	O
bioavailability	O
of	O
nitric	B-T103
oxide	I-T103
(	O
NO	B-T103
)	O
,	O
and	O
endothelial	B-T038
-	I-T038
dependent	I-T038
vascular	I-T038
relaxation	I-T038
.	O

Fluorescence	B-T058
microscopy	I-T058
was	O
employed	O
to	O
visualize	O
changes	O
in	O
mitochondrial	B-T017
ROS	O
and	O
NO	B-T103
levels	O
and	O
videomicroscopy	B-T058
applied	O
to	O
measure	O
vasodilation	B-T038
response	O
.	O

Pharmacological	O
disruption	O
of	O
the	O
profission	B-T103
protein	I-T103
Drp1	B-T103
with	O
Mdivi	B-T103
-	I-T103
1	I-T103
during	O
LG	B-T103
exposure	O
reduced	O
mitochondrial	B-T038
fragmentation	I-T038
among	O
vascular	B-T017
endothelial	I-T017
cells	I-T017
(	O
LG	B-T103
:	O
0	O
.	O
469	O
;	O
LG	B-T103
+	O
Mdivi	B-T103
-	I-T103
1	I-T103
:	O
0	O
.	O
276	O
;	O
P	O
=	O
0	O
.	O
003	O
)	O
,	O
prevented	O
formation	O
of	O
vascular	B-T017
ROS	O
(	O
LG	B-T103
:	O
2	O
.	O
036	O
;	O
LG	B-T103
+	O
Mdivi	B-T103
-	I-T103
1	I-T103
:	O
1	O
.	O
774	O
;	O
P	O
=	O
0	O
.	O
005	O
)	O
,	O
increased	O
the	O
presence	B-T033
of	O
NO	B-T103
(	O
LG	B-T103
:	O
1	O
.	O
352	O
;	O
LG	B-T103
+	O
Mdivi	B-T103
-	I-T103
1	I-T103
:	O
1	O
.	O
502	O
;	O
P	O
=	O
0	O
.	O
048	O
)	O
,	O
and	O
improved	B-T033
vascular	B-T038
dilation	I-T038
response	O
to	O
acetylcholine	B-T103
(	O
LG	B-T103
:	O
31	O
.	O
6	O
%	O
;	O
LG	B-T103
+	O
Mdivi	B-T103
-	I-T103
1	I-T103
;	O
78	O
.	O
5	O
%	O
at	O
maximum	O
dose	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Additionally	O
,	O
decreased	O
expression	B-T038
of	O
Drp1	B-T103
via	O
siRNA	B-T103
knockdown	B-T062
during	O
LG	B-T103
conditions	O
also	O
improved	B-T033
vascular	B-T038
relaxation	I-T038
.	O

Exposure	O
to	O
LG	B-T103
imparts	O
endothelial	B-T038
dysfunction	I-T038
coupled	O
with	O
altered	O
mitochondrial	B-T017
phenotypes	O
among	O
isolated	O
human	B-T204
arterioles	B-T017
.	O

Disruption	O
of	O
Drp1	B-T103
and	O
subsequent	O
mitochondrial	B-T038
fragmentation	I-T038
events	O
prevents	O
impaired	O
vascular	B-T038
dilation	I-T038
,	O
restores	O
mitochondrial	B-T017
phenotype	O
,	O
and	O
implicates	O
mitochondrial	B-T038
fission	I-T038
as	O
a	O
primary	O
mediator	O
of	O
LG	B-T103
-	O
induced	O
endothelial	B-T038
dysfunction	I-T038
.	O
NEW	O
&	O
NOTEWORTHY	O
Acute	O
low	B-T103
-	I-T103
glucose	I-T103
exposure	O
induces	O
mitochondrial	B-T038
fragmentation	I-T038
in	O
endothelial	B-T017
cells	I-T017
via	O
Drp1	B-T103
and	O
is	O
associated	O
with	O
impaired	O
endothelial	B-T017
function	B-T038
in	O
human	B-T204
arterioles	B-T017
.	O

Targeting	B-T038
of	O
Drp1	B-T103
prevents	O
fragmentation	B-T038
,	O
improves	O
vasofunction	O
,	O
and	O
may	O
provide	O
a	O
therapeutic	O
target	O
for	O
improving	O
cardiovascular	B-T038
complications	I-T038
among	O
diabetics	B-T033
.	O
Listen	O
to	O
this	O
article	O
'	O
s	O
corresponding	O
podcast	O
@	O
http	B-T170
:	I-T170
/	I-T170
/	I-T170
ajpheart	I-T170
.	I-T170
podbean	I-T170
.	I-T170
com	I-T170
/	I-T170
e	I-T170
/	I-T170
mitochondrial	I-T170
-	I-T170
dynamics	I-T170
-	I-T170
impact	I-T170
-	I-T170
endothelial	I-T170
-	I-T170
function	I-T170
/	I-T170
.	O

A	O
16	O
Yin	B-T017
Yang	I-T017
gene	B-T038
expression	I-T038
ratio	O
signature	O
for	O
ER	B-T038
+	I-T038
/	O
node	B-T038
-	I-T038
breast	I-T038
cancer	I-T038

Breast	B-T038
cancer	I-T038
is	O
one	O
of	O
the	O
leading	O
causes	O
of	O
cancer	B-T038
death	B-T038
in	O
women	B-T098
.	O

It	O
is	O
a	O
complex	O
and	O
heterogeneous	O
disease	B-T038
with	O
different	O
clinical	O
outcomes	O
.	O

Stratifying	O
patients	O
into	O
subgroups	B-T170
with	O
different	O
outcomes	O
could	O
help	O
guide	O
clinical	B-T058
decision	I-T058
making	I-T058
.	O

In	O
this	O
study	B-T062
,	O
we	O
used	O
two	O
opposing	O
groups	O
of	O
genes	B-T017
,	O
Yin	B-T017
and	I-T017
Yang	I-T017
,	O
to	O
develop	O
a	O
prognostic	B-T201
expression	B-T038
ratio	O
signature	O
.	O

Using	O
the	O
METABRIC	B-T170
cohort	B-T062
we	O
identified	O
a16	O
-	O
gene	O
signature	O
capable	O
of	O
stratifying	O
breast	B-T038
cancer	I-T038
patients	O
into	O
four	O
risk	O
levels	O
with	O
intention	O
that	O
low	O
-	O
risk	O
patients	O
would	O
not	O
undergo	O
adjuvant	O
systemic	B-T058
therapy	I-T058
,	O
intermediate	B-T082
-	O
low	O
-	O
risk	O
patients	O
will	O
be	O
treated	B-T058
with	I-T058
hormonal	B-T058
therapy	I-T058
only	O
,	O
and	O
intermediate	B-T082
-	O
high	O
-	O
and	O
high	O
-	O
risk	O
groups	O
will	O
be	O
treated	B-T058
by	O
chemotherapy	B-T058
in	O
addition	O
to	O
the	O
hormonal	B-T058
therapy	I-T058
.	O

The	O
16	O
-	O
gene	O
signature	O
for	O
four	O
risk	O
level	O
stratifications	B-T170
of	O
breast	B-T038
cancer	I-T038
patients	O
has	O
been	O
validated	B-T062
using	O
14	O
independent	O
datasets	B-T170
.	O

Notably	O
,	O
the	O
low	O
-	O
risk	O
group	B-T098
(	O
n	O
=	O
51	O
)	O
of	O
205	O
estrogen	B-T038
receptor	I-T038
-	I-T038
positive	I-T038
and	O
node	B-T038
negative	I-T038
(	O
ER	B-T038
+	I-T038
/	O
node	B-T038
-	I-T038
)	O
patients	O
from	O
three	O
different	O
datasets	B-T170
who	O
had	O
not	O
had	O
any	O
systemic	O
adjuvant	B-T058
therapy	I-T058
had	O
100	O
%	O
15	O
-	O
year	O
disease	O
-	O
specific	O
survival	O
rate	O
.	O

The	O
Concordance	B-T170
Index	I-T170
of	O
YMR	B-T058
for	O
ER	B-T038
+	I-T038
/	O
node	B-T038
negative	I-T038
patients	O
is	O
close	O
to	O
the	O
commercially	B-T170
available	O
signatures	O
.	O

However	O
,	O
YMR	B-T058
showed	O
more	O
significance	O
(	O
HR	O
=	O
3	O
.	O
7	O
,	O
p	O
=	O
8	O
.	O
7e	O
-	O
12	O
)	O
in	O
stratifying	O
ER	B-T038
+	I-T038
/	O
node	B-T038
-	I-T038
subgroup	B-T170
than	O
OncotypeDx	B-T058
(	O
HR	O
=	O
2	O
.	O
7	O
,	O
p	O
=	O
1	O
.	O
3e	O
-	O
7	O
)	O
,	O
MammaPrint	B-T058
(	O
HR	O
=	O
2	O
.	O
5	O
,	O
p	O
=	O
5	O
.	O
8e	O
-	O
7	O
)	O
,	O
rorS	B-T058
(	O
HR	O
=	O
2	O
.	O
4	O
,	O
p	O
=	O
1	O
.	O
4e	O
-	O
6	O
)	O
,	O
and	O
NPI	B-T058
(	O
HR	O
=	O
2	O
.	O
6	O
,	O
p	O
=	O
1	O
.	O
2e	O
-	O
6	O
)	O
.	O

YMR	B-T058
signature	O
may	O
be	O
developed	O
as	O
a	O
clinical	O
tool	B-T170
to	O
select	O
a	O
subgroup	B-T170
of	O
low	O
-	O
risk	O
ER	B-T038
+	I-T038
/	O
node	B-T038
-	I-T038
patients	O
who	O
do	O
not	O
require	O
any	O
adjuvant	O
hormonal	B-T058
therapy	I-T058
(	O
AHT	B-T058
)	O
.	O

Risk	B-T033
Factors	I-T033
Associated	O
With	O
Repeated	O
HIV	B-T058
Testing	I-T058
Among	O
Internet	O
-	O
Using	O
Men	B-T098
Who	I-T098
Have	I-T098
Sex	I-T098
With	I-T098
Men	I-T098

Men	B-T098
who	I-T098
have	I-T098
sex	I-T098
with	I-T098
men	I-T098
(	O
MSM	B-T098
)	O
represent	O
a	O
disproportionately	O
impacted	O
risk	O
group	O
for	O
HIV	B-T005
incidence	O
among	O
at	O
-	O
risk	O
U	B-T082
.	I-T082
S	I-T082
.	O

Few	O
studies	B-T062
have	O
identified	O
risk	B-T033
factors	I-T033
associated	O
with	O
HIV	B-T058
testing	I-T058
frequency	O
both	O
within	B-T082
and	O
outside	B-T082
of	O
traditional	O
health	B-T058
care	I-T058
settings	I-T058
.	O

MSM	B-T098
enrolled	O
in	O
a	O
prospective	B-T062
cohort	I-T062
were	O
mailed	O
at	B-T074
-	I-T074
home	I-T074
specimen	I-T074
collection	I-T074
kits	I-T074
and	O
followed	O
for	O
a	O
year	O
.	O

Incidence	O
density	O
rate	O
ratios	O
(	O
IDRR	O
)	O
of	O
testing	O
were	O
calculated	O
,	O
and	O
generalized	B-T082
estimating	O
equations	O
were	O
used	O
to	O
analyze	O
the	O
association	O
between	O
HIV	B-T058
testing	I-T058
and	O
behavioral	O
factors	O
.	O

The	O
incidence	O
rate	O
of	O
testing	O
was	O
higher	O
among	O
Black	B-T098
MSM	B-T098
than	O
White	B-T098
MSM	B-T098
(	O
IDRR	O
:	O
1	O
.	O
3	O
,	O
95	O
%	O
confidence	O
interval	O
CI	O
[	O
1	O
.	O
1	O
,	O
1	O
.	O
5	O
]	O
)	O
and	O
higher	O
among	O
MSM	B-T098
who	O
reported	O
3	O
+	O
condomless	B-T098
anal	B-T017
intercourse	I-T098
partners	I-T098
(	O
CAI	B-T098
)	O
than	O
MSM	B-T098
who	O
reported	O
no	B-T033
CAI	B-T098
(	O
IDRR	O
:	O
1	O
.	O
6	O
,	O
95	O
%	O
CI	O
[	O
1	O
.	O
3	O
,	O
2	O
.	O
0	O
]	O
)	O
.	O

Increasing	O
availability	O
of	O
HIV	B-T058
testing	I-T058
outside	B-T082
traditional	O
health	B-T058
care	I-T058
settings	I-T058
,	O
including	O
at	O
-	O
home	O
testing	O
kits	O
,	O
in	O
conjunction	O
with	O
targeted	O
behavioral	O
interventions	O
and	O
biomedical	B-T091
treatment	B-T058
preventions	I-T058
is	O
needed	O
.	O

nursingstandard	B-T170
.	I-T170
com	I-T170

1	O
Nurse	B-T097
Donna	O
Wood	O
has	O
been	O
suspended	O
for	O
2	O
months	O
by	O
the	O
Nursing	B-T092
and	I-T092
Midwifery	I-T092
Council	I-T092
(	O
NMC	B-T092
)	O
for	O
concealing	O
the	O
high	B-T033
temperature	I-T033
of	O
colleague	B-T097
Pauline	O
Cafferkey	O
,	O
who	O
later	O
developed	O
Ebola	B-T038
.	O

Read	O
more	O
:	O
rcni	B-T170
.	I-T170
com	I-T170
/	I-T170
donna	I-T170
-	I-T170
wood	I-T170
.	O

Theory	O
of	O
Mind	O
in	O
Adolescents	O
with	O
Bipolar	B-T038
Disorder	I-T038
in	O
Euthymic	B-T038
Phase	I-T038
:	O
Using	O
the	O
Strange	O
Stories	O
Test	O

Test	I-T170
:	O
This	O
study	O
evaluated	O
the	O
theory	O
of	O
mind	O
(	O
ToM	O
)	O
in	O
adolescents	O
diagnosed	O
with	O
bipolar	O
disorder	O
(	O
BD	O
)	O
during	O
their	O
euthymic	O
period	O
compared	O
to	O
a	O
typically	O
developing	O
(	O
TD	O
)	O
group	O
.	O
Method	O
:	O
The	O
BD	O
group	O
consisted	O
of	O
BD	B-T038
11	O
-	O
18	O
year	O
old	O
inpatients	O
in	O
euthymic	O
phase	O
.	O

The	O
TD	O
group	O
euthymic	B-T038
30	O
age	O
,	O
gender	O
,	O
and	O
IQ	O
matched	O
volunteer	O
students	O
.	O

To	O
assess	O
the	O
diagnosis	O
and	O
comorbid	O
disorders	O
,	O
we	O
performed	O
the	O
semi	O
-	O
structured	O
interview	O
of	O
the	O
Kiddie	O
Schedule	O
for	O
Affective	O
Disorders	O
and	O
Schizophrenia	O
-	O
Present	O
and	O
Lifetime	O
Version	O
(	O
K	O
-	O
SADS	O
-	O
PL	O
)	O
for	O
the	O
BD	O
adolescents	O
.	O

To	O
evaluate	O
the	O
severity	O
of	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
and	O
mania	O
,	O
Conner	O
attention	B-T038
s	O
Parent	O
Rating	O
Scale	O
-	O
Revised	O
version	O
(	O
CPRS	O
-	O
R	O
)	O
,	O
and	O
Young	O
mania	B-T038
Rating	O
Scale	O
(	O
YMRS	O
)	O
were	O
used	O
,	O
respectively	O
.	O

Ravens	O
Progressive	O
Matrices	O
was	O
Rating	I-T170
to	O
evaluate	O
intellectual	O
ability	O
in	O
Ravens	B-T170
both	O
Progressive	I-T170
.	O

Happe	O
Strange	O
Stories	O
test	O
was	O
performed	O
to	O
assess	O
ToM	O
in	O
the	O
participants	O
.	O

Data	O
Happe	B-T170
analyzed	O
using	O
the	O
independent	O
t	O
-	O
test	O
,	O
analysis	O
of	O
covariance	O
,	O
and	O
Pearson	O
Correlation	O
analysis	O
.	O
Results	O
:	O
The	O
two	O
groups	O
did	O
not	O
t	B-T170
any	O
differences	O
in	O
comprehending	O
the	O
stories	O
Correlation	I-T062
however	O
,	O
the	O
BD	O
group	O
'	O
s	O
mentalizing	O
scores	O
were	O
significantly	O
weaker	O
than	O
the	O
TD	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O
Conclusion	O
:	O
The	O
ToM	O
impairments	O
in	O
adolescents	O
with	O
BD	O
may	O
be	O
explained	O
as	O
a	O
trait	O
marker	O
which	O
may	O
lead	O
to	O
continuation	O
of	O
social	O
problems	O
even	O
during	O
remission	O
.	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
the	O
TYW3	B-T103
/	O
Taw3	B-T103
class	O
of	O
SAM	B-T103
-	I-T103
dependent	I-T103
methyltransferases	I-T103

S	B-T103
-	I-T103
adenosylmethionine	I-T103
(	I-T103
SAM	I-T103
)	I-T103
-	I-T103
dependent	I-T103
methyltransferases	I-T103
regulate	B-T038
a	O
wide	O
range	O
of	O
biological	B-T038
processes	I-T038
through	O
the	O
modification	B-T038
of	O
proteins	B-T103
,	O
nucleic	B-T103
acids	I-T103
,	O
polysaccharides	B-T103
,	O
as	O
well	O
as	O
various	O
metabolites	B-T103
.	O

TYW3	B-T103
/	O
Taw3	B-T103
is	O
a	O
SAM	B-T103
-	I-T103
dependent	I-T103
methyltransferase	I-T103
responsible	O
for	O
the	O
formation	O
of	O
a	O
tRNA	B-T038
modification	I-T038
known	O
as	O
wybutosine	B-T103
and	O
its	O
derivatives	O
that	O
are	O
required	O
for	O
accurate	O
decoding	B-T038
in	O
protein	B-T038
synthesis	I-T038
.	O

Here	O
,	O
we	O
report	O
the	O
crystal	B-T017
structure	I-T017
of	O
Taw3	B-T103
,	O
a	O
homolog	O
of	O
TYW3	B-T103
from	O
Sulfolobus	O
solfataricus	O
,	O
which	O
revealed	O
a	O
novel	O
α	B-T038
/	I-T038
β	I-T038
fold	I-T038
.	O

The	O
sequence	O
motif	O
(	O
S	B-T082
/	I-T082
T	I-T082
)	I-T082
xSSCxGR	I-T082
and	O
invariant	O
aspartate	B-T103
and	O
histidine	B-T103
,	O
conserved	O
in	O
TYW3	B-T103
/	O
Taw3	B-T103
,	O
cluster	O
to	O
form	O
the	O
catalytic	O
center	O
.	O

These	O
structural	B-T103
and	O
sequence	B-T082
features	O
indicate	O
that	O
TYW3	B-T103
/	O
Taw3	B-T103
proteins	O
constitute	O
a	O
distinct	O
class	O
of	O
SAM	B-T103
-	I-T103
dependent	I-T103
methyltransferases	I-T103
.	O

Using	O
site	B-T038
-	I-T038
directed	I-T038
mutagenesis	I-T038
along	O
with	O
in	B-T058
vivo	I-T058
complementation	I-T058
assays	I-T058
combined	O
with	O
mass	B-T058
spectrometry	I-T058
as	O
well	O
as	O
ligand	B-T038
docking	I-T038
and	O
cofactor	B-T038
binding	I-T038
assays	B-T058
,	O
we	O
have	O
identified	O
the	O
active	O
site	O
of	O
TYW3	B-T103
and	O
residues	O
essential	O
for	O
cofactor	B-T038
binding	I-T038
and	O
methyltransferase	B-T038
activity	I-T038
.	O

Developmental	O
Profile	B-T058
and	O
Diagnoses	B-T062
in	O
Children	O
Presenting	O
with	O
Motor	B-T033
Stereotypies	I-T033

Motor	B-T033
stereotypies	I-T033
represent	O
a	O
typical	O
example	O
of	O
the	O
difficulty	O
in	O
distinguishing	O
non	O
-	O
clinical	O
behaviors	O
(	O
physiological	B-T038
and	O
transient	O
)	O
from	O
symptoms	B-T033
or	O
among	O
different	O
disorders	B-T038
[	O
"	O
primary	B-T038
stereotypies	I-T038
,	O
"	O
associated	O
with	O
autistic	B-T038
spectrum	I-T038
disorder	I-T038
(	O
ASD	B-T038
)	O
,	O
intellectual	B-T038
disabilities	I-T038
,	O
genetic	B-T038
syndromes	I-T038
,	O
and	O
sensory	O
impairment	O
]	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
obtain	O
an	O
accurate	O
assessment	B-T058
on	O
the	O
relationship	O
between	O
stereotypies	B-T038
and	O
neurodevelopmental	B-T038
disorders	I-T038
.	O

We	O
studied	B-T062
23	O
children	O
(	O
3	O
girls	O
)	O
,	O
aged	O
36	O
-	O
95	O
months	O
,	O
who	O
requested	O
a	O
consultation	B-T058
due	O
to	O
the	O
persistence	O
or	O
increased	O
severity	O
of	O
motor	B-T033
stereotypies	I-T033
.	O

None	O
of	O
the	O
patients	O
had	O
a	O
previous	O
diagnosis	B-T062
of	O
ASD	B-T038
.	O

The	O
assessment	B-T058
included	O
the	O
Motor	B-T170
Severity	I-T170
Stereotypy	I-T170
Scale	I-T170
(	O
MSSS	B-T170
)	O
,	O
the	O
Repetitive	B-T170
Behavior	I-T170
Scale	I-T170
-	I-T170
Revised	I-T170
(	O
RBS	B-T170
-	I-T170
R	I-T170
)	O
,	O
the	O
Raven	B-T033
'	I-T033
s	I-T033
Colored	I-T033
Progressive	I-T033
Matrices	I-T033
,	O
the	O
Child	O
Behavior	O
CheckList	O
for	O
ages	O
1½	O
-	O
5	O
or	O
4	O
-	O
18	O
(	O
CBCL	O
)	O
,	O
the	O
Social	B-T170
Responsiveness	I-T170
Scale	I-T170
(	B-T170
SRS	I-T170
)	I-T170
,	O
and	O
the	O
Autism	B-T170
Diagnostic	I-T170
Observation	I-T170
Schedule	I-T170
-	I-T170
second	I-T170
edition	I-T170
(	O
ADOS	B-T170
2	I-T170
)	O
.	O

All	O
patients	O
were	O
showing	O
motor	B-T033
stereotypies	I-T033
for	O
periods	O
of	O
time	O
varying	O
from	O
6	O
to	O
77	O
months	O
.	O

The	O
MSSS	B-T170
showed	O
that	O
each	O
child	O
had	O
a	O
limited	O
number	O
of	O
stereotypies	B-T038
;	O
their	O
frequency	O
and	O
intensity	O
were	O
mild	O
.	O

The	O
interference	O
of	O
stereotypies	B-T038
was	O
variable	O
;	O
the	O
impairment	O
in	O
daily	O
life	O
was	O
mild	O
.	O

The	O
RBS	B-T170
-	I-T170
R	I-T170
scores	O
were	O
positive	O
for	O
the	O
subscale	O
of	O
"	O
stereotypic	B-T038
behaviors	I-T038
"	O
in	O
all	O
children	O
.	O

Moreover	O
,	O
several	O
children	O
presented	O
other	O
repetitive	B-T033
behaviors	I-T033
,	O
mainly	O
"	O
ritualistic	B-T033
behavior	I-T033
"	O
and	O
"	O
sameness	B-T033
behavior	I-T033
.	O
"	O
All	O
patients	O
showed	O
a	O
normal	B-T033
cognitive	I-T033
level	I-T033
.	O

The	O
CBCL	O
evidenced	O
behavioral	B-T038
problems	I-T038
in	O
22	O
%	O
of	O
the	O
children	O
:	O
internalizing	B-T033
problems	I-T033
,	O
attention	B-T038
,	O
and	O
withdrawn	B-T038
were	O
the	O
main	O
complaints	O
.	O

On	O
the	O
SRS	B-T170
,	O
all	O
but	O
one	O
of	O
the	O
tested	O
patients	O
obtained	O
clinical	O
scores	O
in	O
the	O
clinical	O
range	O
for	O
at	O
least	O
one	O
area	O
.	O

On	O
the	O
ADOS	B-T170
2	I-T170
,	O
4	O
patients	O
obtained	O
scores	O
indicating	O
a	O
moderate	O
level	O
of	O
ASD	B-T038
symptoms	B-T033
,	O
4	O
had	O
a	O
mild	O
level	O
,	O
and	O
15	O
showed	O
no	O
or	O
minimal	O
signs	B-T033
of	O
ASD	B-T038
.	O

Motor	B-T033
stereotypies	I-T033
in	O
children	O
with	O
normal	B-T033
cognitive	I-T033
level	I-T033
represent	O
a	O
challenging	O
diagnostic	O
issue	B-T033
for	O
which	O
a	O
finely	O
tailored	O
assessment	B-T058
is	O
mandatory	O
in	O
order	O
to	O
define	O
a	O
precise	O
developmental	O
profile	O
.	O

Thus	O
,	O
careful	O
and	O
cautious	O
use	O
of	O
standardized	O
tests	O
is	O
warranted	O
to	O
avoid	O
misdiagnosis	B-T033
.	O

Furthermore	O
,	O
it	O
is	O
hard	O
to	O
consider	O
motor	B-T033
stereotypies	I-T033
,	O
even	O
the	O
primary	O
ones	O
,	O
exclusively	O
as	O
a	O
movement	B-T038
disorder	I-T038
.	O

Left	B-T017
ventricular	I-T017
rotational	B-T082
mechanics	O
in	O
infants	O
with	O
hypoxic	B-T038
ischemic	I-T038
encephalopathy	I-T038
and	O
preterm	O
infants	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
:	O
A	O
comparison	O
with	O
healthy	O
term	O
controls	O

There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
left	B-T017
ventricle	I-T017
(	O
LV	B-T017
)	O
rotational	B-T091
physiology	I-T091
in	O
neonates	O
.	O

We	O
aimed	O
to	O
assess	O
rotational	B-T082
mechanics	O
in	O
infants	O
with	O
hypoxic	B-T038
ischemic	I-T038
encephalopathy	I-T038
(	O
HIE	B-T038
)	O
and	O
premature	O
infants	O
(	O
<	O
32	O
weeks	O
)	O
at	O
36	O
weeks	O
postmenstrual	O
age	O
(	O
PMA	O
)	O
(	O
preterm	B-T098
group	I-T098
)	O
and	O
compare	O
them	O
with	O
healthy	O
term	O
controls	O
(	O
term	O
controls	O
)	O
.	O

We	O
also	O
compared	O
the	O
parameters	O
in	O
preterm	O
infants	O
with	O
and	O
without	O
chronic	B-T038
lung	I-T038
disease	I-T038
(	O
CLD	B-T038
)	O
.	O

Echocardiography	B-T058
was	O
performed	O
within	O
48	O
hours	O
of	O
birth	B-T038
or	O
at	O
36	O
weeks	O
PMA	O
.	O

LV	B-T017
basal	B-T082
and	O
apical	O
rotation	O
,	O
twist	B-T082
(	O
and	O
torsion	O
=	O
twist	B-T082
/	O
LV	O
length	O
)	O
,	O
twist	O
rate	O
(	O
LVTR	O
)	O
,	O
and	O
untwist	O
rate	O
(	O
LVUTR	O
)	O
were	O
measured	O
.	O

One	O
-	O
way	O
ANOVA	O
was	O
used	O
to	O
compare	O
values	O
.	O

There	O
was	O
no	O
difference	O
in	O
gestation	B-T038
(	O
40	O
.	O
0	O
[	O
39	O
.	O
1	O
-	O
40	O
.	O
3	O
]	O
vs	O
39	O
.	O
9	O
[	O
39	O
.	O
0	O
-	O
40	O
.	O
9	O
]	O
,	O
P	O
>	O
.	O
05	O
)	O
or	O
birthweight	O
(	O
3	O
.	O
7	O
[	O
3	O
.	O
4	O
-	O
4	O
.	O
1	O
]	O
vs	O
3	O
.	O
5	O
[	O
3	O
.	O
2	O
-	O
3	O
.	O
9	O
]	O
,	O
P	O
>	O
.	O
05	O
)	O
between	O
the	O
HIE	B-T038
group	B-T098
(	O
n	O
=	O
16	O
)	O
and	O
term	O
controls	O
(	O
n	O
=	O
30	O
)	O
.	O

The	O
preterm	B-T098
group	I-T098
(	O
n	O
=	O
35	O
)	O
had	O
a	O
gestation	B-T038
and	O
weight	O
of	O
36	O
.	O
0	O
[	O
34	O
.	O
6	O
-	O
36	O
.	O
3	O
]	O
weeks	O
and	O
2	O
.	O
3	O
[	O
2	O
.	O
0	O
-	O
2	O
.	O
4	O
]	O
kg	O
.	O

The	O
HIE	B-T038
group	O
had	O
lower	O
twist	B-T082
,	O
torsion	O
,	O
LVTR	O
,	O
and	O
LVUTR	O
than	O
the	O
other	O
two	O
groups	O
.	O

The	O
preterm	B-T098
group	I-T098
had	O
a	O
more	O
negative	O
(	O
clockwise	O
)	O
basal	B-T082
rotation	O
while	O
the	O
term	B-T098
group	I-T098
had	O
a	O
more	O
positive	O
(	O
counterclockwise	O
)	O
apical	B-T082
rotation	O
.	O

Preterm	O
infants	O
with	O
CLD	B-T038
had	O
higher	O
apical	B-T082
rotation	O
,	O
twist	B-T082
,	O
and	O
torsion	O
when	O
compared	O
to	O
infants	O
without	O
CLD	B-T038
.	O

Infants	O
with	O
HIE	B-T038
have	O
reduced	O
rotational	B-T082
mechanics	O
.	O

Preterm	O
infants	O
at	O
36	O
weeks	O
PMA	O
have	O
comparable	O
measurements	O
of	O
twist	B-T082
to	O
term	O
infants	O
.	O

This	O
is	O
achieved	O
by	O
predominant	O
basal	B-T082
rather	O
than	O
apical	B-T082
rotation	O
.	O

Infants	O
with	O
CLD	B-T038
have	O
increased	O
apical	B-T082
rotation	O
.	O

Comparing	O
the	O
effects	O
of	O
different	O
dynamic	B-T058
sitting	I-T058
strategies	I-T058
in	O
wheelchair	B-T074
seating	I-T074
on	O
lumbar	B-T082
-	I-T082
pelvic	I-T082
angle	I-T082

Prolonged	O
static	B-T033
sitting	I-T033
in	O
a	O
wheelchair	B-T074
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
lower	B-T033
back	I-T033
pain	I-T033
.	O

The	O
wheelchair	B-T074
seating	I-T074
system	I-T074
is	O
a	O
key	O
factor	O
of	O
this	O
risk	O
because	O
it	O
affects	O
spinal	B-T082
loading	O
in	O
the	O
sitting	B-T033
position	I-T033
.	O

In	O
this	O
study	B-T062
,	O
7	O
dynamic	B-T058
sitting	I-T058
strategies	I-T058
(	O
DSSs	B-T058
)	O
are	O
examined	B-T033
:	O
lumbar	B-T058
prominent	I-T058
dynamic	I-T058
sitting	I-T058
(	O
LPDS	B-T058
)	O
,	O
back	B-T058
reclined	I-T058
dynamic	I-T058
sitting	I-T058
(	O
BRDS	B-T058
)	O
,	O
femur	B-T058
upward	I-T058
dynamic	I-T058
sitting	I-T058
(	O
FUDS	B-T058
)	O
,	O
lumbar	B-T058
prominent	I-T058
with	I-T058
back	I-T058
reclined	I-T058
dynamic	I-T058
sitting	I-T058
(	O
LBDS	B-T058
)	O
,	O
lumbar	B-T058
prominent	I-T058
with	I-T058
femur	I-T058
upward	I-T058
dynamic	I-T058
sitting	I-T058
(	O
LFDS	B-T058
)	O
,	O
back	B-T058
reclined	I-T058
with	I-T058
femur	I-T058
upward	I-T058
dynamic	I-T058
sitting	I-T058
(	O
BFDS	B-T058
)	O
,	O
and	O
lumbar	B-T058
prominent	I-T058
with	I-T058
back	I-T058
reclined	I-T058
with	I-T058
femur	I-T058
upward	I-T058
dynamic	I-T058
sitting	I-T058
(	O
LBFDS	B-T058
)	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
analyze	B-T062
the	O
biomechanical	O
effects	O
of	O
these	O
sitting	B-T058
strategies	I-T058
on	O
lumbar	B-T082
-	I-T082
pelvic	I-T082
angles	I-T082
.	O

Twenty	O
able	B-T033
-	I-T033
bodied	I-T033
participants	B-T098
were	O
recruited	O
for	O
the	O
study	B-T062
.	O

All	O
participants	B-T098
performed	O
LPDS	B-T058
,	O
BRDS	B-T058
,	O
FUDS	B-T058
,	O
LBDS	B-T058
,	O
LFDS	B-T058
,	O
BFDS	B-T058
,	O
and	O
LBFDS	B-T058
in	O
a	O
random	O
order	O
.	O

All	O
lumbar	B-T082
-	I-T082
pelvic	I-T082
angle	I-T082
parameters	O
,	O
including	O
the	O
static	O
lumbar	B-T082
angle	I-T082
,	O
static	O
pelvic	B-T017
angle	I-T017
,	O
lumbar	B-T033
range	I-T033
of	I-T033
motion	I-T033
,	O
and	O
pelvic	B-T033
range	I-T033
of	I-T033
motion	I-T033
were	O
measured	O
and	O
compared	O
.	O

Results	O
show	O
that	O
LBDS	B-T058
and	O
LBFDS	B-T058
enabled	B-T038
the	O
most	O
beneficial	O
lumbar	B-T201
movements	I-T201
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
strategies	O
was	O
nonsignificant	B-T033
.	O

BRDS	B-T058
and	O
BFDS	B-T058
enabled	B-T038
the	O
most	O
beneficial	O
pelvic	B-T058
movements	I-T058
,	O
although	O
the	O
difference	O
between	O
the	O
2	O
strategies	O
was	O
nonsignificant	B-T033
.	O

Among	O
all	O
the	O
upright	O
DSSs	B-T058
,	O
LPDS	B-T058
and	O
LFDS	B-T058
enabled	B-T038
the	O
most	O
beneficial	O
lumbar	B-T201
and	O
pelvic	B-T058
movements	I-T058
,	O
although	O
no	B-T033
significant	I-T033
difference	O
was	O
observed	O
between	O
these	O
2	O
strategies	O
.	O

We	O
identified	O
the	O
effects	O
and	O
differences	O
among	O
7	O
DSSs	B-T058
on	O
lumbar	B-T082
-	I-T082
pelvic	I-T082
angles	I-T082
.	O

Wheelchair	O
users	O
can	O
choose	O
the	O
most	O
suitable	O
DSS	B-T058
that	O
meets	O
their	O
needs	O
.	O

These	O
findings	B-T033
may	O
serve	O
as	O
a	O
reference	O
for	O
practicing	B-T097
physicians	I-T097
or	O
wheelchair	O
users	O
to	O
choose	O
an	O
appropriate	O
dynamic	O
wheelchair	B-T074
seating	I-T074
system	O
.	O

ISRCTN12389808	O
,	O
18th	O
November	O
2016	O
,	O
retrospectively	O
registered	O
.	O

Source	O
apportionment	O
and	O
heavy	B-T103
metal	I-T103
health	O
risk	O
(	O
HMHR	O
)	O
quantification	O
from	O
sources	B-T033
in	O
a	O
southern	B-T082
city	B-T082
in	O
China	B-T082
,	O
using	O
an	O
ME2	B-T170
-	O
HMHR	O
model	O

Heavy	B-T103
metals	I-T103
(	O
Cr	B-T103
,	O
Co	B-T103
,	O
Ni	B-T103
,	O
As	B-T103
,	O
Cd	B-T103
,	O
and	O
Pb	B-T103
)	O
can	O
be	O
bound	O
to	O
PM	O
adversely	B-T038
affecting	I-T038
human	B-T204
health	O
.	O

Quantifying	O
the	O
source	B-T033
impacts	O
on	O
heavy	B-T103
metals	I-T103
can	O
provide	O
source	B-T033
-	O
specific	O
estimates	O
of	O
the	O
heavy	B-T103
metal	I-T103
health	O
risk	O
(	O
HMHR	O
)	O
to	O
guide	O
effective	O
development	O
of	O
strategies	O
to	O
reduce	O
such	O
risks	O
from	O
exposure	O
to	O
heavy	B-T103
metals	I-T103
in	O
PM2	O
.	O
5	O
(	O
particulate	O
matter	O
(	O
PM	O
)	O
with	O
aerodynamic	O
diameter	O
less	O
than	O
or	O
equal	O
to	O
2	O
.	O
5	O
μm	O
)	O
.	O

In	O
this	O
study	O
,	O
a	O
method	O
combining	O
Multilinear	B-T170
Engine	I-T170
2	I-T170
(	O
ME2	B-T170
)	O
and	O
a	O
risk	B-T058
assessment	I-T058
model	O
is	O
developed	O
to	O
more	O
effectively	O
quantify	O
source	B-T033
contributions	O
to	O
HMHR	O
,	O
including	O
heavy	B-T103
metal	I-T103
non	B-T033
-	I-T033
cancer	I-T033
risk	I-T033
(	O
non	B-T033
-	I-T033
HMCR	I-T033
)	O
and	O
cancer	O
risk	O
(	O
HMCR	O
)	O
.	O

The	O
combined	O
model	O
(	O
called	O
ME2	O
-	O
HMHR	O
)	O
has	O
two	O
steps	O
:	O
step1	O
,	O
source	B-T033
contributions	O
to	O
heavy	B-T103
metals	I-T103
are	O
estimated	O
by	O
employing	O
the	O
ME2	B-T170
model	O
;	O
step2	O
,	O
the	O
source	B-T033
contributions	O
in	O
step	O
1	O
are	O
introduced	O
into	O
the	O
risk	B-T058
assessment	I-T058
model	O
to	O
calculate	O
the	O
source	B-T033
contributions	O
to	O
HMHR	O
.	O

The	O
approach	O
was	O
applied	O
to	O
Huzou	B-T082
,	O
China	B-T082
and	O
five	O
significant	O
sources	B-T033
were	O
identified	O
.	O

Soil	O
dust	O
is	O
the	O
largest	O
source	B-T033
of	O
non	B-T033
-	I-T033
HMCR	I-T033
.	O

For	O
HMCR	O
,	O
the	O
source	B-T033
contributions	O
of	O
soil	O
dust	O
,	O
coal	B-T103
combustion	O
,	O
cement	O
dust	O
,	O
vehicle	B-T103
,	O
and	O
secondary	O
sources	B-T033
are	O
1	O
.	O
0	O
×	O
10	O
(	O
-	O
4	O
)	O
,	O
3	O
.	O
7	O
×	O
10	O
(	O
-	O
5	O
)	O
,	O
2	O
.	O
7	O
×	O
10	O
(	O
-	O
6	O
)	O
,	O
1	O
.	O
6	O
×	O
10	O
(	O
-	O
6	O
)	O
and	O
1	O
.	O
9	O
×	O
10	O
(	O
-	O
9	O
)	O
,	O
respectively	O
.	O

The	O
soil	O
dust	O
is	O
the	O
largest	O
contributor	O
to	O
HMCR	O
,	O
being	O
driven	O
by	O
the	O
high	O
impact	O
of	O
soil	O
dust	O
on	O
PM2	O
.	O
5	O
and	O
the	O
abundance	O
of	O
heavy	B-T103
metals	I-T103
in	O
soil	O
dust	O
.	O

Aspirin	B-T103
Suppresses	O
Growth	B-T038
in	O
PI3K	B-T017
-	O
Mutant	B-T017
Breast	B-T038
Cancer	I-T038
by	O
Activating	O
AMPK	B-T103
and	O
Inhibiting	O
mTORC1	B-T103
Signaling	O

Despite	O
the	O
high	O
incidence	O
of	O
oncogenic	B-T017
mutations	B-T038
in	O
PIK3CA	B-T017
,	O
the	O
gene	B-T017
encoding	I-T017
the	O
catalytic	B-T082
subunit	I-T082
of	O
PI3K	B-T103
,	O
PI3K	B-T103
inhibitors	B-T103
have	O
yielded	O
little	O
clinical	B-T033
benefit	I-T033
for	O
breast	B-T038
cancer	I-T038
patients	O
.	O

Recent	O
epidemiologic	B-T062
studies	I-T062
have	O
suggested	O
a	O
therapeutic	O
benefit	O
from	O
aspirin	B-T103
intake	O
in	O
cancers	B-T038
harboring	O
oncogenic	B-T103
PIK3CA	I-T103
Here	O
,	O
we	O
show	O
that	O
mutant	B-T017
PIK3CA	B-T103
-	O
expressing	B-T038
breast	B-T017
cancer	I-T017
cells	I-T017
have	O
greater	O
sensitivity	O
to	O
aspirin	B-T103
-	O
mediated	O
growth	B-T038
suppression	B-T038
than	O
their	O
wild	B-T017
-	I-T017
type	I-T017
counterparts	O
.	O

Aspirin	B-T103
decreased	O
viability	B-T038
and	O
anchorage	B-T058
-	I-T058
independent	I-T058
growth	I-T058
of	O
mutant	B-T017
PIK3CA	B-T103
breast	B-T017
cancer	I-T017
cells	I-T017
independently	B-T033
of	O
its	O
effects	O
on	O
COX	B-T103
-	I-T103
2	I-T103
and	O
NF	B-T103
-	I-T103
κB	I-T103
.	O

We	O
ascribed	O
the	O
effects	O
of	O
aspirin	B-T103
to	O
AMP	B-T103
-	I-T103
activated	I-T103
protein	I-T103
kinase	I-T103
(	O
AMPK	B-T103
)	O
activation	O
,	O
mTORC1	B-T103
inhibition	B-T038
,	O
and	O
autophagy	B-T038
induction	O
.	O

In	O
vivo	O
,	O
oncogenic	B-T017
PIK3CA	B-T103
-	O
driven	O
mouse	B-T204
mammary	B-T038
tumors	I-T038
treated	O
daily	O
with	O
aspirin	B-T103
resulted	O
in	O
decreased	O
tumor	O
growth	O
kinetics	O
,	O
whereas	O
combination	O
therapy	B-T058
of	O
aspirin	B-T103
and	O
a	O
PI3K	B-T103
inhibitor	O
further	O
attenuated	O
tumor	O
growth	O
.	O

Our	O
study	O
supports	O
the	O
evaluation	B-T058
of	O
aspirin	B-T103
and	O
PI3K	B-T103
pathway	O
inhibitors	B-T103
as	O
a	O
combination	O
therapy	B-T058
for	O
targeting	O
breast	B-T038
cancer	I-T038
.	O

Cancer	O
Res	O
;	O
77	O
(	O
3	O
)	O
;	O
790	O
-	O
801	O
.	O

©2016	O
AACR	O
.	O

Prevalence	O
of	O
Psychiatric	O
Disorders	O
among	O
Female	O
Juvenile	B-T098
Offenders	I-T098

Inmates	B-T098
of	O
Juvenile	B-T092
Developmental	I-T092
Centers	I-T092
are	O
the	O
special	O
group	B-T098
of	O
youth	O
population	B-T098
who	O
are	O
in	O
conflict	O
with	O
law	B-T170
.	O

They	O
are	O
vulnerable	O
to	O
psychiatric	O
illness	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
see	O
the	O
prevalence	O
and	O
type	O
of	O
psychiatric	O
disorders	O
in	O
institutionalized	B-T033
female	O
juvenile	B-T098
offenders	I-T098
and	O
non	B-T098
-	I-T098
offenders	I-T098
of	O
same	O
age	O
,	O
sex	O
and	O
socioeconomic	O
group	O
in	O
the	O
community	O
.	O

The	O
association	B-T038
of	O
mental	B-T038
disorders	I-T038
was	O
examined	B-T033
in	O
43	O
female	O
inmates	B-T098
of	O
Juvenile	B-T092
Development	I-T092
Centers	I-T092
and	O
43	O
randomly	O
selected	O
comparison	O
subjects	O
in	O
community	O
.	O

One	O
stage	O
-	O
structured	O
assessment	O
of	O
psychopathology	B-T091
was	O
carried	O
out	O
by	O
using	O
a	O
structured	O
and	O
valid	O
Bangla	O
version	B-T170
of	O
the	O
Development	O
and	O
Well	O
-	O
Being	O
Assessment	O
(	O
DAWBA	O
)	O
.	O

Development	O
and	O
Well	O
-	O
Being	O
Assessment	O
generated	O
psychiatric	O
diagnosis	B-T033
was	O
assigned	O
based	O
on	O
ICD	B-T170
-	I-T170
10	I-T170
diagnostic	B-T170
criteria	I-T170
for	O
research	B-T062
.	O

The	O
result	O
revealed	O
that	O
,	O
of	O
those	O
who	O
were	O
in	O
conflict	O
with	O
law	B-T170
,	O
93	O
%	O
had	O
mental	B-T038
disorder	I-T038
,	O
whereas	O
14	O
%	O
of	O
non	B-T098
-	I-T098
offenders	I-T098
had	O
psychiatric	O
disorder	O
.	O

Among	O
the	O
offenders	B-T098
with	O
psychiatric	O
disorders	O
,	O
most	O
of	O
them	O
(	O
32	O
.	O
6	O
%	O
)	O
suffered	O
from	O
Major	B-T038
Depressive	I-T038
Disorder	I-T038
(	O
MDD	B-T038
)	O
,	O
followed	O
by	O
combined	O
MDD	B-T038
&	O
Post	B-T038
Traumatic	I-T038
Stress	I-T038
Disorder	I-T038
(	O
PTSD	B-T038
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
among	O
the	O
non	B-T098
-	I-T098
offenders	I-T098
with	O
psychiatric	O
disorder	O
9	O
.	O
3	O
%	O
suffered	O
from	O
MDD	B-T038
.	O

It	O
can	O
be	O
concluded	O
that	O
considerable	O
psychiatric	O
disorders	O
are	O
prevalent	O
among	O
the	O
female	O
juvenile	B-T098
offenders	I-T098
with	O
comparison	O
to	O
non	B-T098
-	I-T098
offenders	I-T098
.	O

Broad	B-T082
-	O
based	O
replication	O
study	O
could	O
confirm	O
these	O
findings	B-T033
.	O

Association	O
between	O
neutrophil	B-T017
-	O
to	O
-	O
lymphocyte	B-T017
ratio	O
and	O
differentiated	B-T038
thyroid	I-T038
cancer	I-T038
:	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062

The	O
association	O
between	O
neutrophil	B-T017
-	O
to	O
-	O
lymphocyte	B-T017
ratio	O
(	O
NLR	O
)	O
and	O
differentiated	B-T038
thyroid	I-T038
cancer	I-T038
(	O
DTC	B-T038
)	O
is	O
undecided	O
.	O

To	O
rectify	O
this	O
question	O
,	O
we	O
conducted	O
a	O
systematic	O
meta	B-T062
-	I-T062
analysis	I-T062
based	O
on	O
7	O
prospective	B-T062
cohort	I-T062
studies	I-T062
published	B-T170
between	O
2013	O
and	O
2015	O
,	O
comprising	O
7349	O
patients	O
.	O

Six	O
of	O
these	O
cohorts	B-T098
included	O
pretreatment	O
(	O
baseline	O
)	O
NLR	O
data	O
for	O
patients	O
with	O
thyroid	B-T038
nodules	I-T038
.	O

The	O
meta	B-T062
-	I-T062
analysis	I-T062
of	O
these	O
6	O
cohorts	B-T098
showed	O
that	O
the	O
NLR	O
of	O
patients	O
with	O
DTC	B-T038
(	O
4617	O
cases	O
)	O
was	O
statistically	O
similar	O
to	O
patients	O
with	O
benign	B-T038
nodules	I-T038
only	O
(	O
1666	O
cases	O
)	O
,	O
with	O
a	O
mean	O
difference	O
(	O
MD	O
)	O
of	O
0	O
.	O
19	O
(	O
95	O
%	O
CI	O
:	O
-	O
0	O
.	O
09	O
to	O
0	O
.	O
46	O
;	O
I	O
(	O
2	O
)	O
=	O
93	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

No	O
significant	O
difference	O
in	O
NLR	O
was	O
found	O
between	O
patients	O
with	O
DTC	B-T038
and	O
patients	O
with	O
benign	B-T038
nodules	I-T038
.	O

Two	O
studies	B-T058
addressed	O
an	O
association	O
between	O
NLR	O
and	O
papillary	B-T038
thyroid	I-T038
carcinoma	I-T038
in	O
patients	O
stratified	O
by	O
age	O
<	O
45	O
and	O
≥45	O
years	O
(	O
496	O
and	O
891	O
cases	O
,	O
respectively	O
)	O
;	O
the	O
pooled	O
MD	O
was	O
0	O
.	O
09	O
(	O
95	O
%	O
CI	O
:	O
-	O
0	O
.	O
37	O
to	O
0	O
.	O
55	O
;	O
I	O
(	O
2	O
)	O
=	O
92	O
.	O
2	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

An	O
elevated	O
NLR	O
seems	O
not	O
a	O
reliable	O
indicator	O
of	O
progressing	O
DTC	B-T038
in	O
patients	O
with	O
goiters	B-T038
,	O
and	O
there	O
was	O
no	O
difference	O
in	O
NLR	O
between	O
patients	O
aged	O
<	O
45	O
years	O
and	O
those	O
aged	O
≥45	O
years	O
.	O

Well	O
-	O
designed	O
and	O
large	O
-	O
scale	O
investigations	B-T058
are	O
warranted	O
to	O
understand	O
the	O
value	O
of	O
NLR	O
in	O
the	O
prognosis	B-T033
of	O
DTC	B-T038
.	O

Transcriptomic	B-T082
insights	O
into	O
the	O
allelopathic	O
effects	O
of	O
the	O
garlic	B-T168
allelochemical	B-T103
diallyl	B-T103
disulfide	I-T103
on	O
tomato	B-T168
roots	B-T204

Garlic	B-T168
is	O
an	O
allelopathic	O
crop	B-T204
that	O
can	O
alleviate	O
the	O
obstacles	O
to	O
continuous	O
cropping	O
of	O
vegetable	B-T204
crops	I-T204
.	O

Diallyl	B-T103
disulfide	I-T103
(	O
DADS	B-T103
)	O
,	O
one	O
of	O
the	O
most	O
important	O
allelochemicals	B-T103
in	O
garlic	B-T168
,	O
promotes	O
tomato	B-T168
root	B-T038
growth	I-T038
.	O

Therefore	O
,	O
the	O
global	O
transcriptome	B-T082
profiles	O
of	O
DADS	B-T103
-	O
treated	O
tomato	B-T168
roots	B-T204
over	O
time	O
were	O
investigated	O
to	O
reveal	O
the	O
potential	O
growth	O
-	O
promoting	O
mechanisms	O
.	O

We	O
detected	B-T033
1828	O
,	O
1296	O
and	O
1190	O
differentially	B-T038
expressed	I-T038
genes	B-T017
(	O
DEGs	B-T017
)	O
in	O
the	O
4	O
,	O
24	O
and	O
48	O
h	O
samples	O
,	O
respectively	O
.	O

Most	O
DEGs	B-T017
involved	O
in	O
assimilatory	B-T038
sulfate	I-T038
reduction	I-T038
and	O
glutathione	B-T038
metabolism	I-T038
were	O
up	B-T038
-	I-T038
regulated	I-T038
after	O
short	O
-	O
term	O
(	O
4	O
h	O
)	O
DADS	B-T103
treatment	O
.	O

In	O
addition	O
,	O
increased	B-T033
activity	I-T033
of	I-T033
defensive	I-T033
enzymes	I-T033
and	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
six	O
peroxidase	B-T017
genes	I-T017
were	O
observed	O
,	O
suggesting	O
that	O
DADS	B-T103
could	O
induce	O
tomato	B-T168
resistance	O
.	O

In	O
plant	B-T038
-	I-T038
pathogen	I-T038
interactions	I-T038
,	O
DEGs	B-T017
related	O
to	O
calcium	B-T038
signaling	I-T038
were	O
primarily	O
inhibited	O
,	O
while	O
those	O
encoding	O
pathogenesis	B-T103
-	I-T103
related	I-T103
proteins	I-T103
were	O
primarily	O
up	B-T038
-	I-T038
regulated	I-T038
.	O

Although	O
plant	B-T204
hormone	B-T038
synthesis	I-T038
and	O
signal	B-T038
transduction	I-T038
were	O
both	O
significantly	O
affected	O
by	O
DADS	B-T103
,	O
the	O
expression	B-T038
trends	O
of	O
the	O
genes	B-T017
in	O
these	O
two	O
pathways	B-T038
were	O
conflicting	O
.	O

This	O
research	B-T062
provides	O
comprehensive	O
information	O
concerning	O
the	O
changes	O
in	O
the	O
tomato	B-T168
root	B-T204
transcriptome	B-T082
affected	O
by	O
DADS	B-T103
and	O
may	O
help	O
direct	O
further	O
studies	B-T062
on	O
DADS	B-T103
-	O
responsive	O
genes	B-T017
to	O
enhance	O
the	O
current	O
understanding	O
of	O
the	O
mechanisms	O
by	O
which	O
DADS	B-T103
alleviates	O
the	O
obstacles	O
to	O
continuous	O
cropping	O
.	O

Mitotic	O
phosphotyrosine	B-T103
network	B-T170
analysis	I-T170
reveals	O
that	O
tyrosine	B-T038
phosphorylation	I-T038
regulates	O
Polo	B-T103
-	I-T103
like	I-T103
kinase	I-T103
1	I-T103
(	O
PLK1	B-T103
)	O

Tyrosine	B-T038
phosphorylation	I-T038
is	O
closely	O
associated	O
with	O
cell	B-T038
proliferation	I-T038
.	O

During	O
the	O
cell	B-T038
cycle	I-T038
,	O
serine	B-T038
and	I-T038
threonine	I-T038
phosphorylation	I-T038
plays	O
the	O
leading	O
role	O
,	O
and	O
such	O
phosphorylation	B-T038
events	O
are	O
most	O
dynamic	O
during	O
the	O
mitotic	B-T038
phase	I-T038
of	O
the	O
cell	B-T038
cycle	I-T038
.	O

However	O
,	O
mitotic	O
phosphotyrosine	B-T103
is	O
not	O
well	O
characterized	O
.	O

Although	O
a	O
few	O
functionally	O
-	O
relevant	O
mitotic	O
phosphotyrosine	B-T103
sites	B-T082
have	O
been	O
characterized	O
,	O
evidence	O
suggests	O
that	O
this	O
modification	O
may	O
be	O
more	O
prevalent	O
than	O
previously	O
appreciated	O
.	O

Here	O
,	O
we	O
examined	B-T033
tyrosine	B-T038
phosphorylation	I-T038
in	O
mitotic	B-T017
human	I-T017
cells	I-T017
including	O
those	O
on	O
spindle	B-T103
-	I-T103
associated	I-T103
proteins	I-T103
.	O
?	O
Database	O
mining	O
confirmed	O
~	O
2000	O
mitotic	O
phosphotyrosine	B-T103
sites	B-T082
,	O
and	O
network	B-T170
analysis	I-T170
revealed	O
a	O
number	O
of	O
subnetworks	O
that	O
were	O
enriched	O
in	O
tyrosine	B-T103
-	I-T103
phosphorylated	I-T103
proteins	I-T103
,	O
including	O
components	O
of	O
the	O
kinetochore	B-T017
or	O
spindle	B-T017
and	O
SRC	B-T103
family	I-T103
kinases	I-T103
.	O

We	O
identified	O
Polo	B-T103
-	I-T103
like	I-T103
kinase	I-T103
1	I-T103
(	O
PLK1	B-T103
)	O
,	O
a	O
major	O
signaling	B-T038
hub	O
in	O
the	O
spindle	B-T017
subnetwork	O
,	O
as	O
phosphorylated	B-T103
at	O
the	O
conserved	O
Tyr	B-T103
(	I-T103
217	I-T103
)	I-T103
in	O
the	O
kinase	B-T082
domain	I-T082
.	O

Substitution	B-T038
of	O
Tyr	B-T103
(	I-T103
217	I-T103
)	I-T103
with	O
a	O
phosphomimetic	O
residue	O
eliminated	O
PLK1	B-T103
activity	O
in	O
vitro	O
and	O
in	O
cells	B-T017
.	O

Further	O
analysis	B-T062
showed	O
that	O
Tyr	B-T103
(	I-T103
217	I-T103
)	I-T103
phosphorylation	B-T038
reduced	O
the	O
phosphorylation	B-T038
of	I-T038
Thr	I-T038
(	I-T038
210	I-T038
)	I-T038
in	O
the	O
activation	B-T082
loop	I-T082
,	O
a	O
phosphorylation	B-T038
event	O
necessary	O
for	O
PLK1	B-T103
activity	O
.	O

Our	O
data	O
indicate	O
that	O
mitotic	O
tyrosine	B-T038
phosphorylation	I-T038
regulated	O
a	O
key	O
serine	B-T103
/	I-T103
threonine	I-T103
kinase	I-T103
hub	O
in	O
mitotic	B-T017
cells	I-T017
and	O
suggested	O
that	O
spatially	O
separating	O
tyrosine	B-T038
phosphorylation	I-T038
events	O
can	O
reveal	O
previously	O
unrecognized	O
regulatory	O
events	O
and	O
complexes	O
associated	O
with	O
specific	O
structures	B-T017
of	O
the	O
cell	B-T038
cycle	I-T038
.	O

Divided	O
and	O
Sliding	O
Superficial	B-T017
Temporal	I-T017
Artery	I-T017
Flap	B-T017
for	O
Primary	O
Donor	B-T082
-	I-T082
site	I-T082
Closure	B-T058

Superficial	B-T017
temporal	I-T017
artery	I-T017
(	O
STA	B-T017
)	O
flaps	B-T017
are	O
often	O
used	O
for	O
reconstruction	B-T058
of	O
hair	B-T082
-	I-T082
bearing	I-T082
areas	I-T082
.	O

However	O
,	O
primary	B-T058
closure	I-T058
of	O
the	O
donor	B-T082
site	I-T082
is	O
not	O
easy	O
when	O
the	O
size	B-T082
of	O
the	O
necessary	O
skin	B-T022
island	I-T022
is	O
relatively	O
large	O
.	O

In	O
such	O
cases	O
,	O
skin	B-T017
grafts	I-T017
are	O
needed	O
at	O
the	O
donor	B-T082
site	I-T082
,	O
resulting	O
in	O
baldness	B-T038
.	O

We	O
have	O
solved	O
this	O
issue	O
by	O
applying	O
the	O
divided	O
and	O
sliding	O
flap	B-T017
technique	O
,	O
which	O
was	O
first	O
reported	O
for	O
primary	B-T058
donor	I-T058
-	I-T058
site	I-T058
closure	I-T058
of	O
a	O
latissimus	B-T017
dorsi	I-T017
musculocutaneous	I-T017
flap	B-T017
.	O

We	O
applied	O
this	O
technique	O
to	O
the	O
hair	B-T017
-	I-T017
bearing	I-T017
STA	I-T017
flap	B-T017
,	O
where	O
primary	B-T058
donor	I-T058
-	I-T058
site	I-T058
closure	I-T058
is	O
extremely	O
beneficial	O
for	O
preventing	O
baldness	B-T038
consequent	O
to	O
skin	B-T058
grafting	I-T058
.	O

The	O
STA	B-T017
flap	B-T017
was	O
divided	O
into	O
3	O
,	O
and	O
creation	O
of	O
large	O
flap	B-T017
was	O
possible	O
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
the	O
divided	O
and	O
sliding	O
STA	B-T017
flap	B-T017
could	O
at	O
least	O
partially	O
solve	O
the	O
donor	B-T082
-	I-T082
site	I-T082
problem	B-T033
.	O

Although	O
further	O
investigation	B-T058
is	O
necessary	O
to	O
validate	B-T062
the	O
maximum	O
possible	B-T033
flap	B-T017
size	B-T082
,	O
this	O
technique	O
may	O
be	O
applicable	O
to	O
at	O
least	O
small	O
defects	O
that	O
are	O
common	O
after	O
skin	B-T038
cancer	I-T038
ablation	B-T058
or	O
trauma	B-T037
.	O

Influence	O
of	O
Surface	O
Properties	O
on	O
Adhesion	O
Forces	O
and	O
Attachment	O
of	O
Streptococcus	B-T007
mutans	I-T007
to	O
Zirconia	B-T103
In	O
Vitro	O

Zirconia	B-T103
is	O
becoming	O
a	O
prevalent	O
material	O
in	O
dentistry	B-T091
.	O

However	O
,	O
any	O
foreign	B-T037
bodies	I-T037
inserted	B-T058
may	O
provide	O
new	O
niches	O
for	O
the	O
bacteria	B-T007
in	O
oral	B-T082
cavity	I-T082
.	O

The	O
object	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
effect	O
of	O
surface	O
properties	O
including	O
surface	B-T033
roughness	I-T033
and	O
hydrophobicity	O
on	O
the	O
adhesion	O
and	O
biofilm	B-T038
formation	I-T038
of	O
Streptococcus	B-T007
mutans	I-T007
(	O
S	B-T007
.	I-T007

mutans	I-T007
)	O
to	O
zirconia	B-T103
.	O

Atomic	B-T058
force	I-T058
microscopy	I-T058
was	O
employed	O
to	O
determine	O
the	O
zirconia	B-T103
surface	B-T082
morphology	O
and	O
the	O
adhesion	O
forces	O
between	O
the	O
S	B-T007
.	I-T007

mutans	I-T007
and	O
zirconia	B-T103
.	O

The	O
results	O
showed	O
that	O
the	O
surface	B-T033
roughness	I-T033
was	O
nanoscale	O
and	O
significantly	O
different	O
among	O
tested	O
groups	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
:	O
Coarse	O
(	O
23	O
.	O
94	O
±	O
2	O
.	O
52	O
nm	O
)	O
>	O
Medium	O
(	O
17	O
.	O
00	O
±	O
3	O
.	O
81	O
nm	O
)	O
>	O
Fine	O
(	O
11	O
.	O
89	O
±	O
1	O
.	O
68	O
nm	O
)	O
.	O

The	O
contact	B-T082
angles	I-T082
of	O
the	O
Coarse	O
group	O
were	O
the	O
highest	O
,	O
followed	O
by	O
the	O
Medium	O
and	O
the	O
Fine	O
groups	O
.	O

Increasing	O
the	O
surface	B-T033
roughness	I-T033
and	O
hydrophobicity	O
resulted	O
in	O
an	O
increase	O
of	O
adhesion	O
forces	O
and	O
early	O
attachment	O
(	O
2	O
h	O
and	O
4	O
h	O
)	O
of	O
S	B-T007
.	I-T007

mutans	I-T007
on	O
the	O
zirconia	B-T103
but	O
no	O
influence	O
on	O
the	O
further	O
development	O
of	O
biofilm	B-T007
(	O
6	O
h	O
~	O
24	O
h	O
)	O
.	O

Our	O
findings	O
suggest	O
that	O
the	O
surface	B-T033
roughness	I-T033
in	O
nanoscale	O
and	O
hydrophobicity	O
of	O
zirconia	B-T103
had	O
influence	O
on	O
the	O
S	B-T007
.	I-T007

mutans	I-T007
initial	O
adhesion	O
force	O
and	O
early	O
attachment	O
instead	O
of	O
whole	O
stages	O
of	O
biofilm	B-T038
formation	I-T038
.	O

The	O
relationship	O
between	O
thiamine	B-T103
and	O
two	O
symbioses	O
:	O
Root	B-T204
nodule	I-T204
symbiosis	O
and	O
arbuscular	B-T204
mycorrhiza	I-T204

Lotus	B-T204
japonicus	I-T204
THIC	B-T017
is	O
expressed	B-T038
in	O
all	O
organs	B-T204
,	O
and	O
the	O
encoded	B-T103
protein	I-T103
catalyzes	O
thiamine	B-T038
biosynthesis	I-T038
.	O

Loss	B-T033
of	I-T033
function	I-T033
produces	O
chlorosis	B-T038
,	O
a	O
typical	O
thiamine	B-T103
-	O
deficiency	O
phenotype	O
,	O
and	O
mortality	O
.	O

To	O
investigate	O
thiamine	B-T103
'	I-T103
s	I-T103
role	O
in	O
symbiosis	O
,	O
we	O
focused	O
on	O
THI1	B-T017
,	O
a	O
thiamine	B-T017
-	I-T017
biosynthesis	I-T017
gene	I-T017
expressed	B-T038
in	O
roots	B-T204
,	O
nodules	B-T204
,	O
and	O
seeds	B-T204
.	O

The	O
thi1	B-T017
mutant	I-T017
had	O
green	B-T204
leaves	I-T204
,	O
but	O
formed	O
small	O
nodules	B-T204
and	O
immature	O
seeds	B-T204
.	O

These	O
phenotypes	O
were	O
rescued	O
by	O
THI1	B-T017
complementation	O
and	O
by	O
exogenous	O
thiamine	B-T103
.	O

Thus	O
,	O
THI1	B-T017
is	O
required	O
for	O
nodule	B-T204
enlargement	O
and	O
seed	B-T038
maturation	I-T038
.	O

On	O
the	O
other	O
hand	O
,	O
colonization	B-T033
by	O
arbuscular	B-T204
mycorrhiza	I-T204
(	O
AM	B-T204
)	O
fungus	B-T204
Rhizophagus	B-T204
irregularis	I-T204
was	O
not	O
affected	O
in	O
the	O
thi1	B-T017
mutant	I-T017
or	O
by	O
exogenous	O
thiamine	B-T103
.	O

However	O
,	O
spores	B-T204
of	O
R	B-T204
.	I-T204

irregularis	I-T204
stored	O
more	O
thiamine	B-T103
than	O
the	O
source	O
(	O
host	O
plants	O
)	O
,	O
despite	O
lacking	O
thiamine	B-T017
biosynthesis	I-T017
genes	I-T017
.	O

Therefore	O
,	O
disturbance	O
of	O
the	O
thiamine	B-T103
supply	O
would	O
affect	O
progeny	O
phenotypes	O
such	O
as	O
spore	B-T038
formation	I-T038
and	O
hyphal	B-T038
growth	I-T038
.	O

Further	O
investigation	O
will	O
be	O
required	O
to	O
elucidate	O
thiamine	B-T103
'	I-T103
s	I-T103
effect	O
on	O
AM	B-T204
.	O

Bilateral	B-T082
sternal	B-T017
infusion	B-T058
of	O
ropivacaine	B-T103
and	O
length	O
of	O
stay	O
in	O
ICU	B-T092
after	O
cardiac	B-T058
surgery	I-T058
with	O
increased	O
respiratory	O
risk	O
:	O
A	O
randomised	B-T062
controlled	I-T062
trial	I-T062

The	O
continuous	O
bilateral	B-T082
infusion	B-T058
of	O
a	O
local	B-T103
anaesthetic	I-T103
solution	B-T103
around	O
the	O
sternotomy	B-T058
wound	B-T037
(	O
bilateral	B-T082
sternal	B-T017
)	O
is	O
an	O
innovative	O
technique	O
for	O
reducing	O
pain	B-T033
after	O
sternotomy	B-T058
.	O

To	O
assess	O
the	O
effects	O
of	O
the	O
technique	O
on	O
the	O
need	O
for	O
intensive	B-T058
care	I-T058
in	O
cardiac	O
patients	O
at	O
increased	O
risk	O
of	O
respiratory	B-T038
complications	I-T038
.	O

Randomised	B-T062
,	I-T062
observer	I-T062
-	I-T062
blind	I-T062
controlled	I-T062
trial	I-T062
.	O

Single	O
centre	O
,	O
French	B-T092
University	I-T092
Hospital	I-T092
.	O

In	O
total	O
,	O
120	O
adults	O
scheduled	O
for	O
open	B-T058
-	I-T058
heart	I-T058
surgery	I-T058
,	O
with	O
one	O
of	O
the	O
following	O
conditions	O
:	O
age	O
more	O
than	O
75	O
years	O
,	O
BMI	B-T201
>	O
30	O
kg	O
m	O
,	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
,	O
active	O
smoking	O
habit	O
.	O

Either	O
a	O
bilateral	B-T082
sternal	B-T017
infusion	B-T058
of	O
0	O
.	O
2	O
%	O
ropivacaine	B-T103
(	O
3	O
ml	O
h	O
through	O
each	O
catheter	B-T074
;	O
'	B-T098
intervention	I-T098
'	I-T098
group	I-T098
)	O
,	O
or	O
standardised	O
care	O
only	O
(	O
'	O
control	O
'	O
group	O
)	O
.	O

Analgesia	B-T058
was	O
provided	O
with	O
paracetamol	B-T103
and	O
self	O
-	O
administered	O
intravenous	O
morphine	B-T103
.	O

The	O
length	O
of	O
time	O
to	O
readiness	B-T033
for	O
discharge	B-T058
from	O
ICU	B-T092
,	O
blindly	O
assessed	O
by	O
a	O
committee	O
of	O
experts	B-T097
.	O

No	O
effect	O
was	O
found	O
between	O
groups	O
for	O
the	O
primary	O
outcome	O
(	O
P	O
=	O
0	O
.	O
680	O
,	O
intention	B-T062
to	I-T062
treat	I-T062
)	O
;	O
the	O
median	O
values	O
were	O
42	O
.	O
4	O
and	O
37	O
.	O
7	O
h	O
,	O
respectively	O
for	O
the	O
control	O
and	O
intervention	B-T098
groups	I-T098
(	O
P	O
=	O
0	O
.	O
873	O
)	O
.	O

Similar	O
nonsignificant	O
trends	O
were	O
noted	O
for	O
other	O
postoperative	B-T033
delays	O
.	O

Significant	O
effects	O
favouring	O
the	O
intervention	B-T058
were	O
noted	O
for	O
dynamic	B-T033
pain	I-T033
,	O
patient	O
satisfaction	O
,	O
occurrence	O
of	O
nausea	O
and	O
vomiting	B-T033
,	O
occurrence	O
of	O
delirium	B-T038
or	O
mental	B-T038
confusion	I-T038
and	O
occurrence	O
of	O
pulmonary	B-T038
complications	I-T038
.	O

In	O
12	O
patients	O
,	O
although	O
no	O
symptoms	B-T033
actually	O
occurred	O
,	O
the	O
total	O
ropivacaine	O
plasma	O
level	O
exceeded	O
the	O
lowest	O
value	O
for	O
which	O
neurological	B-T033
symptoms	I-T033
have	O
been	O
observed	O
in	O
healthy	B-T098
volunteers	I-T098
.	O

Because	O
of	O
a	O
small	O
size	O
effect	O
,	O
and	O
despite	O
significant	O
analgesic	B-T033
effects	I-T033
,	O
this	O
strategy	O
failed	O
to	O
reduce	O
the	O
time	O
spent	O
in	O
ICU	B-T092
.	O

EudraCT	O
(	O
N°	O
:	O
2012	O
-	O
005225	O
-	O
69	O
)	O
;	O
ClinicalTrials	B-T170
.	I-T170
gov	I-T170
(	O
NCT01828788	O
)	O
.	O

Pupil	B-T201
Sizes	I-T201
Scale	B-T170
with	O
Attentional	B-T170
Load	I-T170
and	O
Task	O
Experience	B-T038
in	O
a	O
Multiple	O
Object	O
Tracking	B-T082
Task	O

Previous	O
studies	O
have	O
related	O
changes	O
in	O
attentional	B-T170
load	I-T170
to	O
pupil	B-T201
size	I-T201
modulations	B-T082
.	O

However	O
,	O
studies	O
relating	O
changes	O
in	O
attentional	B-T170
load	I-T170
and	O
task	O
experience	B-T038
on	O
a	O
finer	O
scale	B-T170
to	O
pupil	B-T201
size	I-T201
modulations	B-T082
are	O
scarce	O
.	O

Here	O
,	O
we	O
investigated	O
how	O
these	O
changes	O
affect	B-T038
pupil	B-T201
sizes	I-T201
.	O

To	O
manipulate	O
attentional	B-T170
load	I-T170
,	O
participants	B-T098
covertly	O
tracked	B-T082
between	O
zero	O
and	O
five	O
objects	O
among	O
several	O
randomly	O
moving	O
objects	O
on	O
a	O
computer	O
screen	O
.	O

To	O
investigate	O
effects	O
of	O
task	O
experience	B-T038
,	O
the	O
experiment	O
was	O
conducted	O
on	O
three	O
consecutive	O
days	O
.	O

We	O
found	O
that	O
pupil	B-T201
sizes	I-T201
increased	O
with	O
each	O
increment	O
in	O
attentional	B-T170
load	I-T170
.	O

Across	O
days	O
,	O
we	O
found	O
systematic	O
pupil	B-T201
size	I-T201
reductions	O
.	O

We	O
compared	O
the	O
model	O
fit	O
for	O
predicting	O
pupil	B-T201
size	I-T201
modulations	B-T082
using	O
attentional	B-T170
load	I-T170
,	O
task	O
experience	B-T038
,	O
and	O
task	B-T058
performance	I-T058
as	O
predictors	O
.	O

We	O
found	O
that	O
a	O
model	B-T170
which	O
included	O
attentional	B-T170
load	I-T170
and	O
task	O
experience	B-T038
as	O
predictors	O
had	O
the	O
best	O
model	O
fit	O
while	O
adding	O
performance	B-T058
as	O
a	O
predictor	O
to	O
this	O
model	B-T170
reduced	O
the	O
overall	O
model	O
fit	O
.	O

Overall	O
,	O
results	O
suggest	O
that	O
pupillometry	B-T058
provides	O
a	O
viable	O
metric	O
for	O
precisely	O
assessing	O
attentional	B-T170
load	I-T170
and	O
task	O
experience	B-T038
in	O
visuospatial	O
tasks	O
.	O

Back	O
to	O
the	O
Roots	O
:	O
Deep	O
View	O
into	O
the	O
Evolutionary	B-T038
History	O
of	O
ADP	O
-	O
Ribosylation	O
Opened	O
by	O
the	O
DNA	B-T103
-	O
Targeting	O
Toxin	B-T103
-	O
Antitoxin	B-T103
Module	O
DarTG	O

In	O
this	O
issue	O
of	O
Molecular	B-T091
Cell	I-T091
,	O
Jankevicius	O
et	O
al	O
.	O

(	O
2016	O
)	O
characterize	O
the	O
DarTG	O
toxin	B-T103
-	O
antitoxin	B-T103
module	O
in	O
which	O
the	O
DarT	B-T103
toxin	B-T103
ADP	O
-	O
ribosylates	O
single	B-T103
-	I-T103
stranded	I-T103
DNA	I-T103
and	O
the	O
DarG	B-T103
antitoxin	B-T103
counteracts	O
DarT	B-T103
by	O
direct	O
binding	B-T038
and	O
by	O
enzymatic	B-T103
remova	O
l	O
of	O
the	O
ADP	O
-	O
ribosylation	O
.	O

Growth	B-T103
differentiation	I-T103
factor	I-T103
15	I-T103
is	O
a	O
myomitokine	B-T103
governing	B-T038
systemic	I-T038
energy	I-T038
homeostasis	I-T038

Reduced	O
mitochondrial	B-T017
electron	I-T017
transport	I-T017
chain	I-T017
activity	O
promotes	O
longevity	O
and	O
improves	B-T033
energy	B-T038
homeostasis	I-T038
via	O
cell	B-T038
-	I-T038
autonomous	I-T038
and	O
-	O
non	B-T038
-	I-T038
autonomous	I-T038
factors	I-T038
in	O
multiple	O
model	O
systems	O
.	O

This	O
mitohormetic	B-T038
effect	O
is	O
thought	O
to	O
involve	O
the	O
mitochondrial	B-T038
unfolded	I-T038
protein	I-T038
response	I-T038
(	O
UPR	B-T038
(	I-T038
mt	I-T038
)	I-T038
)	O
,	O
an	O
adaptive	B-T038
stress	I-T038
-	I-T038
response	I-T038
pathway	O
activated	O
by	O
mitochondrial	B-T017
proteotoxic	B-T038
stress	I-T038
.	O

Using	O
mice	B-T204
with	O
skeletal	B-T017
muscle	I-T017
-	I-T017
specific	I-T017
deficiency	O
of	O
Crif1	B-T103
(	O
muscle	B-T017
-	I-T017
specific	I-T017
knockout	B-T204
[	O
MKO	B-T204
]	O
)	O
,	O
an	O
integral	B-T103
protein	I-T103
of	O
the	O
large	B-T017
mitoribosomal	I-T017
subunit	I-T017
(	O
39S	B-T017
)	O
,	O
we	O
identified	O
growth	B-T103
differentiation	I-T103
factor	I-T103
15	I-T103
(	O
GDF15	B-T103
)	O
as	O
a	O
UPR	B-T038
(	I-T038
mt	I-T038
)	I-T038
-	O
associated	O
cell	B-T038
-	I-T038
non	I-T038
-	I-T038
autonomous	I-T038
myomitokine	B-T103
that	O
regulates	B-T038
systemic	I-T038
energy	I-T038
homeostasis	I-T038
.	O

MKO	B-T204
mice	I-T204
were	O
protected	O
against	O
obesity	B-T038
and	O
sensitized	B-T038
to	O
insulin	B-T103
,	O
an	O
effect	O
associated	O
with	O
elevated	O
GDF15	B-T103
secretion	B-T038
after	O
UPR	B-T038
(	I-T038
mt	I-T038
)	I-T038
activation	O
.	O

In	O
ob	B-T204
/	I-T204
ob	I-T204
mice	I-T204
,	O
administration	O
of	O
recombinant	B-T103
GDF15	B-T103
decreased	O
body	O
weight	O
and	O
improved	B-T033
insulin	B-T038
sensitivity	I-T038
,	O
which	O
was	O
attributed	O
to	O
elevated	O
oxidative	B-T038
metabolism	I-T038
and	O
lipid	B-T038
mobilization	I-T038
in	O
the	O
liver	B-T017
,	O
muscle	B-T017
,	O
and	O
adipose	B-T017
tissue	I-T017
.	O

Thus	O
,	O
GDF15	B-T103
is	O
a	O
potent	O
mitohormetic	B-T038
signal	B-T038
that	O
safeguards	O
against	O
the	O
onset	B-T033
of	I-T033
obesity	I-T033
and	O
insulin	B-T038
resistance	I-T038
.	O

Synthesis	O
and	O
characterization	O
of	O
acetylated	B-T103
amylose	I-T103
and	O
development	O
of	O
inclusion	O
complexes	O
with	O
rifampicin	B-T103

Amylose	B-T103
(	O
AM	B-T103
)	O
tends	O
to	O
form	O
single	O
helical	O
inclusion	O
complexes	O
with	O
suitable	O
agents	B-T103
.	O

These	O
complexes	B-T103
are	O
considered	O
promising	O
biomaterial	B-T103
carrier	O
since	O
the	O
guest	O
molecules	O
can	O
be	O
released	O
later	O
,	O
leading	O
to	O
many	O
applications	O
,	O
especially	O
in	O
the	O
pharmaceutical	B-T092
industry	I-T092
.	O

Rifampicin	B-T103
(	O
RIF	B-T103
)	O
has	O
long	O
been	O
recognized	O
as	O
an	O
active	O
drug	B-T103
against	O
Mycobacterium	B-T007
tuberculosis	I-T007
,	O
however	O
,	O
the	O
administration	B-T058
of	O
RIF	B-T103
in	O
high	O
dosages	O
can	O
originate	O
unwanted	O
side	O
-	O
effects	O
.	O

Due	O
to	O
the	O
fact	O
that	O
the	O
use	O
of	O
native	O
amylose	B-T103
(	O
AM	B-T103
)	O
in	O
the	O
formation	O
of	O
complexes	B-T103
is	O
limited	O
by	O
their	O
low	O
water	O
solubility	O
,	O
it	O
was	O
acetylated	O
with	O
a	O
medium	O
degree	O
of	O
substitution	O
(	O
DS	O
)	O
,	O
allowing	O
solubilizing	O
(	O
0	O
.	O
5gL	O
(	O
-	O
1	O
)	O
)	O
acetylated	B-T103
amylose	I-T103
(	O
AMA	B-T103
)	O
in	O
water	B-T103
at	O
neutral	O
pH	O
,	O
in	O
opposition	O
to	O
that	O
observed	O
with	O
native	O
amylose	B-T103
(	O
trace	O
solubility	O
)	O
.	O

The	O
resulting	O
acetylated	B-T103
amylose	I-T103
was	O
characterized	O
by	O
means	O
of	O
Fourier	B-T062
Transform	I-T062
Infrared	I-T062
(	I-T062
FT	I-T062
-	I-T062
IR	I-T062
)	I-T062
spectroscopy	I-T062
and	O
Scanning	B-T058
Electron	I-T058
Microscopy	I-T058
(	O
SEM	B-T058
)	O
.	O

FT	B-T062
-	I-T062
IR	I-T062
results	O
indicated	B-T033
that	O
the	O
acetylation	B-T038
of	O
anhydroglucose	B-T103
units	O
of	O
amylose	B-T103
corresponds	O
to	O
a	O
low	O
DS	O
,	O
whereas	O
SEM	B-T058
results	O
suggested	O
that	O
the	O
smooth	B-T082
surfaces	I-T082
of	O
amylose	B-T103
granules	O
were	O
changed	O
into	O
rougher	O
surfaces	B-T082
after	O
acetylation	B-T038
.	O

Ultraviolet	O
absorption	O
spectroscopy	O
(	O
UV	O
-	O
vis	O
)	O
analysis	B-T062
confirmed	O
the	O
formation	O
and	O
allowed	O
the	O
quantification	O
of	O
both	O
native	O
(	O
AM	B-T103
-	O
RIF	B-T103
)	O
and	O
acetylated	O
(	O
AMA	B-T103
-	O
RIF	B-T103
)	O
amylose	B-T103
inclusion	O
complexes	O
.	O

Their	O
characterization	O
in	O
solution	O
was	O
performed	O
by	O
dynamic	B-T058
light	I-T058
scattering	I-T058
(	O
DLS	B-T058
)	O
and	O
zeta	O
potential	O
(	O
ZP	O
)	O
measurements	O
.	O

The	O
average	B-T082
size	I-T082
of	O
inclusion	O
complexes	O
as	O
determined	O
by	O
DLS	B-T058
,	O
ranged	O
between	O
70	O
and	O
100nm	O
.	O

Besides	O
,	O
ZP	O
analysis	B-T062
showed	O
that	O
both	O
complexes	B-T103
are	O
more	O
stable	O
in	O
the	O
presence	B-T033
of	O
RIF	B-T103
.	O

This	O
study	O
may	O
lead	O
to	O
the	O
development	O
of	O
an	O
effective	O
method	O
for	O
the	O
preparation	O
of	O
amylose	B-T103
inclusion	O
complexes	O
,	O
which	O
is	O
beneficial	O
to	O
their	O
further	B-T082
application	O
in	O
drug	B-T074
delivery	I-T074
systems	I-T074
.	O

Selective	O
reaching	B-T038
in	O
macaques	B-T204
:	O
evidence	O
for	O
action	O
-	O
centred	O
attention	B-T038

When	O
a	O
monkey	B-T204
selects	O
a	O
piece	O
of	O
food	B-T168
lying	O
on	O
the	O
ground	O
from	O
among	O
other	O
viable	O
objects	O
in	O
the	O
near	O
vicinity	B-T082
,	O
only	O
the	O
desired	O
item	B-T168
governs	O
the	O
particular	O
pattern	B-T082
and	O
direction	B-T082
of	O
the	O
animal	B-T204
'	I-T204
s	I-T204
reaching	B-T038
action	O
.	O

It	O
would	O
seem	O
then	O
that	O
selection	O
is	O
an	O
important	O
component	O
controlling	O
the	O
animal	B-T204
'	I-T204
s	I-T204
action	O
.	O

But	O
,	O
we	O
may	O
ask	O
,	O
is	O
the	O
selection	O
process	O
in	O
such	O
cases	O
impervious	O
to	O
the	O
presence	O
of	O
other	O
objects	O
that	O
could	O
constitute	O
potential	O
obstacles	O
to	O
or	O
constraints	O
on	O
movement	B-T038
execution	O
?	O
And	O
if	O
it	O
is	O
,	O
in	O
fact	O
,	O
pervious	O
to	O
other	O
objects	O
,	O
do	O
they	O
have	O
a	O
direct	O
influence	O
on	O
the	O
organization	B-T038
of	O
the	O
response	O
?	O
The	O
kinematics	B-T091
of	O
macaques	B-T204
'	O
reaching	B-T038
movements	B-T038
were	O
examined	B-T033
by	O
the	O
current	O
study	B-T062
that	O
analysed	B-T062
some	O
exemplars	O
as	O
they	O
selectively	O
reached	B-T038
to	O
grasp	B-T038
a	O
food	B-T168
item	I-T168
in	O
the	O
absence	O
as	O
well	O
as	O
in	O
the	O
presence	O
of	O
potential	O
obstacles	O
(	O
i	O
.	O
e	O
.	O
,	O
stones	O
)	O
that	O
could	O
affect	B-T038
the	O
arm	B-T082
trajectory	B-T082
.	O

Changes	O
in	O
movement	B-T038
parameterization	O
were	O
noted	O
in	O
temporal	O
measures	O
,	O
such	O
as	O
movement	B-T038
time	O
,	O
as	O
well	O
as	O
in	O
spatial	O
ones	O
,	O
such	O
as	O
paths	O
of	O
trajectory	B-T082
.	O

Generally	O
speaking	O
,	O
the	O
presence	O
of	O
stones	O
in	O
the	O
vicinity	B-T082
of	O
the	O
acting	O
hand	B-T017
stalled	O
the	O
reaching	B-T038
movement	B-T038
and	O
affected	B-T038
the	O
arm	B-T082
trajectory	B-T082
as	O
the	O
hand	B-T017
veered	B-T033
away	I-T033
from	O
the	O
stone	O
even	O
when	O
it	O
was	O
not	O
a	O
physical	O
obstacle	O
.	O

We	O
concluded	O
that	O
nearby	O
objects	O
evoke	O
a	O
motor	B-T201
response	I-T201
in	O
macaques	B-T204
,	O
and	O
the	O
attentional	B-T038
mechanisms	O
that	O
allow	O
for	O
a	O
successful	O
action	O
selection	O
are	O
revealed	O
in	O
the	O
reaching	B-T038
path	B-T082
.	O

The	O
data	O
outlined	O
here	O
concur	O
with	O
human	B-T204
studies	B-T062
indicating	O
that	O
potential	O
obstacles	O
are	O
internally	B-T082
represented	O
,	O
a	O
finding	B-T033
implying	O
basic	O
cognitive	O
operations	O
allowing	O
for	O
action	O
selection	O
in	O
macaques	B-T204
.	O

A	O
novel	O
method	B-T170
for	O
interactive	O
multi	O
-	O
objective	O
dose	B-T058
-	I-T058
guided	I-T058
patient	I-T058
positioning	I-T058

In	O
intensity	B-T058
-	I-T058
modulated	I-T058
radiation	I-T058
therapy	I-T058
(	O
IMRT	B-T058
)	O
,	O
3D	O
in	O
-	O
room	O
imaging	B-T058
data	O
is	O
typically	O
utilized	O
for	O
accurate	O
patient	O
alignment	O
on	O
the	O
basis	O
of	O
anatomical	B-T082
landmarks	I-T082
.	O

In	O
the	O
presence	O
of	O
non	O
-	O
rigid	O
anatomical	O
changes	O
,	O
it	O
is	O
often	O
not	O
obvious	O
which	O
patient	B-T033
position	I-T033
is	O
most	O
suitable	O
.	O

Thus	O
,	O
dose	O
-	O
guided	O
patient	O
alignment	O
is	O
an	O
interesting	O
approach	O
to	O
use	O
available	O
in	O
-	O
room	O
imaging	B-T058
data	O
for	O
up	O
-	O
to	O
-	O
date	O
dose	O
calculation	O
,	O
aimed	O
at	O
finding	B-T033
the	O
position	O
that	O
yields	O
the	O
optimal	O
dose	O
distribution	O
.	O

This	O
contribution	O
presents	O
the	O
first	O
implementation	O
of	O
dose	O
-	O
guided	O
patient	O
alignment	O
as	O
multi	O
-	O
criteria	O
optimization	O
problem	O
.	O

User	O
-	O
defined	O
clinical	O
objectives	B-T170
are	O
employed	O
for	O
setting	O
up	O
a	O
multi	O
-	O
objective	O
problem	O
.	O

Using	O
pre	O
-	O
calculated	O
dose	O
distributions	O
at	O
a	O
limited	O
number	O
of	O
patient	B-T058
shifts	I-T058
and	O
dose	O
interpolation	B-T062
,	O
a	O
continuous	O
space	O
of	O
Pareto	B-T058
-	I-T058
efficient	I-T058
patient	I-T058
shifts	I-T058
becomes	O
accessible	O
.	O

Pareto	O
sliders	O
facilitate	O
interactive	O
browsing	O
of	O
the	O
possible	O
shifts	O
with	O
real	O
-	O
time	O
dose	O
display	O
to	O
the	O
user	O
.	O

Dose	O
interpolation	B-T062
accuracy	O
is	O
validated	O
and	O
the	O
potential	O
of	O
multi	O
-	O
objective	O
dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
demonstrated	O
for	O
three	O
head	B-T038
and	I-T038
neck	I-T038
(	O
H	B-T038
&	I-T038
N	I-T038
)	O
and	O
three	O
prostate	B-T038
cancer	I-T038
patients	O
.	O

Dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
is	O
compared	O
to	O
replanning	O
for	O
all	O
cases	O
.	O

A	O
delineated	O
replanning	O
CT	B-T058
served	O
as	O
surrogate	O
for	O
in	O
-	O
room	O
imaging	B-T058
data	O
.	O

Dose	O
interpolation	B-T062
accuracy	O
was	O
high	O
.	O

Using	O
a	O
[	O
Formula	O
:	O
see	O
text	O
]	O
dose	O
difference	O
criterion	O
,	O
a	O
median	O
pass	O
-	O
rate	O
of	O
95	O
.	O
7	O
%	O
for	O
H	B-T038
&	I-T038
N	I-T038
and	O
99	O
.	O
6	O
%	O
for	O
prostate	B-T038
cases	I-T038
was	O
determined	O
in	O
a	O
comparison	O
to	O
exact	O
dose	O
calculations	O
.	O

For	O
all	O
patients	O
,	O
dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
allowed	O
to	O
find	O
a	O
clinically	O
preferable	O
dose	O
distribution	O
compared	O
to	O
bony	O
anatomy	O
based	O
alignment	O
.	O

For	O
all	O
H	B-T038
&	I-T038
N	I-T038
cases	O
,	O
mean	O
dose	O
to	O
the	O
spared	O
parotid	B-T017
glands	I-T017
was	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
up	O
to	O
[	O
Formula	O
:	O
see	O
text	O
]	O
with	O
bony	O
alignment	O
)	O
and	O
clinical	O
target	O
volume	O
(	O
CTV	O
)	O
[	O
Formula	O
:	O
see	O
text	O
]	O
above	O
99	O
.	O
1	O
%	O
(	O
compared	O
to	O
95	O
.	O
1	O
%	O
)	O
.	O

For	O
all	O
prostate	B-T038
patients	O
,	O
CTV	O
[	O
Formula	O
:	O
see	O
text	O
]	O
was	O
above	O
98	O
.	O
9	O
%	O
(	O
compared	O
to	O
88	O
.	O
5	O
%	O
)	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
to	O
the	O
rectum	O
below	O
[	O
Formula	O
:	O
see	O
text	O
]	O
(	O
compared	O
to	O
56	O
.	O
1	O
%	O
)	O
.	O

Replanning	O
yielded	O
improved	O
results	O
for	O
the	O
H	B-T038
&	I-T038
N	I-T038
cases	O
.	O

For	O
the	O
prostate	B-T038
cases	I-T038
,	O
differences	O
to	O
dose	B-T058
-	I-T058
guided	I-T058
positioning	I-T058
were	O
minor	O
.	O

Clinical	B-T033
and	O
radiological	B-T058
outcome	O
following	O
pneumothorax	B-T038
after	O
endoscopic	B-T058
lung	I-T058
volume	I-T058
reduction	I-T058
with	O
valves	B-T074

Valve	B-T074
implantation	B-T058
has	O
evolved	O
as	O
a	O
therapy	B-T058
for	O
patients	O
with	O
advanced	O
emphysema	B-T038
.	O

Although	O
it	O
is	O
a	O
minimally	B-T058
invasive	I-T058
treatmen	I-T058
t	O
,	O
it	O
is	O
associated	O
with	O
complications	B-T038
,	O
the	O
most	O
common	O
being	O
pneumothorax	B-T038
.	O

Pneumothorax	B-T038
occurs	O
due	O
to	O
the	O
rapid	O
target	O
lobe	B-T017
volume	B-T058
reduction	I-T058
and	O
may	O
be	O
a	O
predictor	O
of	O
clinical	O
benefit	O
despite	O
this	O
complication	B-T038
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
conduct	O
an	O
exploratory	O
data	O
analysis	O
of	O
patients	O
who	O
developed	O
a	O
pneumothorax	B-T038
following	O
endoscopic	B-T058
valve	I-T058
therapy	I-T058
for	O
emphysema	B-T038
.	O

This	O
study	B-T062
performed	O
a	O
retrospective	B-T062
evaluation	I-T062
of	O
pneumothorax	B-T038
management	B-T058
and	O
the	O
impact	O
of	O
pneumothorax	B-T038
on	O
clinical	B-T033
outcomes	I-T033
in	O
70	O
patients	O
following	O
valve	B-T058
therapy	I-T058
in	O
381	O
consecutive	O
patients	O
.	O

Pneumothorax	B-T038
rate	O
following	O
valve	B-T058
therapy	I-T058
was	O
18	O
%	O
.	O

Pneumothorax	B-T038
management	B-T058
consisted	O
of	O
chest	B-T058
tube	I-T058
insertion	I-T058
,	O
valve	B-T074
removal	B-T058
,	O
and	O
surgical	B-T033
intervention	I-T033
in	O
87	O
%	O
(	O
61	O
/	O
70	O
)	O
,	O
44	O
%	O
(	O
31	O
/	O
70	O
)	O
,	O
and	O
19	O
%	O
(	O
13	O
/	O
70	O
)	O
of	O
the	O
patients	O
,	O
respectively	O
.	O

Despite	O
pneumothorax	B-T038
,	O
patients	O
experienced	O
modest	O
but	O
significant	O
improvements	O
in	O
lung	B-T038
function	I-T038
parameters	O
(	O
forced	B-T038
expiratory	I-T038
volume	I-T038
in	O
1	O
second	O
:	O
55±148	O
mL	O
,	O
residual	B-T201
volume	I-T201
:	O
-	O
390±964	O
mL	O
,	O
total	B-T033
lung	I-T033
capacity	I-T033
:	O
-	O
348±876	O
;	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Persistent	O
lobar	B-T038
atelectasis	I-T038
3	O
months	O
after	O
recovering	O
from	O
pneumothorax	B-T038
,	O
which	O
was	O
associated	O
with	O
relevant	O
clinical	O
improvement	O
,	O
was	O
observed	O
in	O
only	O
21	O
%	O
(	O
15	O
/	O
70	O
)	O
of	O
the	O
patients	O
.	O

Pneumothorax	B-T038
is	O
a	O
frequent	O
severe	O
complication	B-T038
following	O
valve	B-T058
therapy	I-T058
that	O
requires	O
further	O
intervention	B-T058
.	O

Nevertheless	O
,	O
the	O
pneumothorax	B-T038
does	O
not	O
impair	O
the	O
clinical	O
status	O
in	O
the	O
majority	O
of	O
patients	O
.	O

Patients	O
with	O
lobar	B-T038
atelectasis	I-T038
benefit	O
after	O
recovering	O
from	O
pneumothorax	B-T038
in	O
terms	O
of	O
lung	B-T038
function	I-T038
parameters	O
.	O

3Mo	O
:	O
A	O
Model	O
for	O
Music	B-T170
-	O
Based	O
Biofeedback	B-T058

In	O
the	O
domain	O
of	O
sports	O
and	O
motor	B-T038
rehabilitation	O
,	O
it	O
is	O
of	O
major	O
importance	O
to	O
regulate	B-T038
and	O
control	O
physiological	B-T038
processes	I-T038
and	O
physical	O
motion	O
in	O
most	O
optimal	O
ways	O
.	O

For	O
that	O
purpose	O
,	O
real	O
-	O
time	O
auditory	O
feedback	O
of	O
physiological	O
and	O
physical	O
information	O
based	O
on	O
sound	O
signals	O
,	O
often	O
termed	O
"	O
sonification	O
,	O
"	O
has	O
been	O
proven	O
particularly	O
useful	O
.	O

However	O
,	O
the	O
use	O
of	O
music	B-T170
in	O
biofeedback	B-T058
systems	O
has	O
been	O
much	O
less	O
explored	B-T058
.	O

In	O
the	O
current	O
article	B-T170
,	O
we	O
assert	O
that	O
the	O
use	O
of	O
music	B-T170
,	O
and	O
musical	B-T170
principles	O
,	O
can	O
have	O
a	O
major	O
added	O
value	B-T170
,	O
on	O
top	O
of	O
mere	O
sound	O
signals	O
,	O
to	O
the	O
benefit	O
of	O
psychological	O
and	O
physical	O
optimization	O
of	O
sports	O
and	O
motor	B-T038
rehabilitation	O
tasks	O
.	O

In	O
this	O
article	B-T170
,	O
we	O
present	O
the	O
3Mo	O
model	O
to	O
describe	O
three	O
main	O
functions	O
of	O
music	B-T170
that	O
contribute	O
to	O
these	O
benefits	O
.	O

These	O
functions	O
relate	O
the	O
power	O
of	O
music	B-T170
to	O
Motivate	B-T038
,	O
and	O
to	O
Monitor	B-T058
and	O
Modify	O
physiological	O
and	O
physical	O
processes	O
.	O

The	O
model	O
brings	O
together	O
concepts	O
and	O
theories	O
related	O
to	O
human	B-T204
sensorimotor	O
interaction	O
with	O
music	B-T170
,	O
and	O
specifies	O
the	O
underlying	O
psychological	O
and	O
physiological	O
principles	O
.	O

This	O
3Mo	O
model	O
is	O
intended	O
to	O
provide	O
a	O
conceptual	O
framework	O
that	O
guides	B-T170
future	O
research	B-T062
on	O
musical	B-T170
biofeedback	B-T058
systems	O
in	O
the	O
domain	O
of	O
sports	O
and	O
motor	B-T038
rehabilitation	O
.	O

Journal	O

Analysis	B-T058
of	O
tilianin	B-T103
and	O
acacetin	B-T103
in	O
Agastache	B-T204
rugosa	I-T204
by	O
high	B-T058
-	I-T058
performance	I-T058
liquid	I-T058
chromatography	I-T058
with	O
ionic	B-T103
liquids	I-T103
-	O
ultrasound	O
based	O
extraction	B-T058

Ionic	B-T103
liquid	I-T103
1	B-T103
-	I-T103
butyl	I-T103
-	I-T103
3	I-T103
-	I-T103
methylimidazolium	I-T103
bromide	I-T103
-	O
methanol	B-T103
-	O
based	O
ultrasonic	O
-	O
assisted	O
extraction	B-T058
(	O
ILUAE	B-T058
)	O
was	O
used	O
to	O
extract	B-T058
tilianin	B-T103
and	O
acacetin	B-T103
from	O
the	O
aerial	B-T204
parts	I-T204
of	O
Agastache	B-T204
rugose	I-T204
(	O
A	B-T204
.	I-T204

rugose	I-T204
)	O
,	O
and	O
simultaneously	O
determined	O
by	O
reversed	B-T058
phase	I-T058
high	I-T058
performance	I-T058
liquid	I-T058
chromatographic	I-T058
(	O
RP	B-T058
-	I-T058
HPLC	I-T058
)	O
method	O
with	O
ultraviolet	B-T170
detection	I-T170
(	O
RP	B-T170
-	I-T170
HPLC	I-T170
-	I-T170
UV	I-T170
)	I-T170
.	O

An	O
InertSustain	O
RP	O
-	O
C18	O
column	O
was	O
used	O
with	O
the	O
mobile	B-T103
phase	I-T103
consisting	O
of	O
methanol	B-T103
and	O
0	O
.	O
2	O
%	O
acetic	B-T103
acid	I-T103
as	O
gradient	O
elution	O
at	O
the	O
detection	O
wavelength	O
of	O
332	O
nm	O
.	O

The	O
flow	O
rate	O
was	O
0	O
.	O
8	O
mL	O
/	O
min	O
,	O
and	O
the	O
column	O
temperature	O
was	O
30	O
°C	O
.	O

Under	O
the	O
optimized	O
conditions	O
,	O
tilianin	B-T103
and	O
acacetin	B-T103
displayed	O
good	O
linearity	O
in	O
the	O
ranges	O
of	O
0	O
.	O
0595	O
-	O
4	O
.	O
76	O
and	O
0	O
.	O
0585	O
-	O
4	O
.	O
68	O
μg	O
/	O
mL	O
,	O
respectively	O
,	O
with	O
the	O
average	O
recoveries	O
being	O
96	O
.	O
93	O
and	O
97	O
.	O
88	O
%	O
,	O
respectively	O
.	O

The	O
method	O
of	O
ILUAE	B-T058
was	O
compared	O
with	O
the	O
traditional	O
methods	O
,	O
it	O
exhibited	O
higher	O
efficiency	O
,	O
higher	O
reproducibility	O
and	O
environmental	B-T082
friendly	I-T082
in	O
analyzing	O
the	O
active	O
compounds	B-T103
in	O
traditional	B-T091
Chinese	I-T091
medicines	I-T091
(	O
TCMs	B-T091
)	O
.	O

Evaluation	B-T058
of	O
MIF	B-T017
-	I-T017
173	I-T017
G	I-T017
/	I-T017
C	I-T017
Polymorphism	O
in	O
Turkish	B-T098
Patients	O
with	O
Ankylosing	B-T038
Spondylitis	I-T038

Ankylosing	B-T038
spondylitis	I-T038
(	O
AS	B-T038
)	O
is	O
a	O
chronic	B-T038
inflammatory	I-T038
disease	I-T038
mainly	O
affecting	O
the	O
spine	B-T017
and	O
sacroiliac	B-T082
joints	I-T082
.	O

Macrophage	B-T103
migration	I-T103
inhibitory	I-T103
(	I-T103
MIF	I-T103
)	I-T103
factor	I-T103
is	O
a	O
regulatory	O
cytokine	B-T103
that	O
inhibits	O
random	O
immune	B-T038
cell	I-T038
migration	I-T038
.	O

MIF	B-T017
gene	I-T017
promoter	B-T017
polymorphisms	O
play	O
a	O
role	O
in	O
the	O
progression	B-T038
of	O
several	O
inflammatory	B-T038
disorders	I-T038
.	O

To	O
investigate	O
the	O
relationship	O
between	O
the	O
MIF	B-T017
gene	I-T017
-	I-T017
173	I-T017
G	I-T017
/	I-T017
C	I-T017
single	B-T082
-	I-T082
nucleotide	I-T082
polymorphism	I-T082
(	O
SNP	B-T082
)	O
and	O
AS	B-T038
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
.	O

In	O
this	O
study	B-T062
,	O
a	O
total	O
of	O
161	O
AS	B-T038
and	O
194	O
normal	O
controls	O
were	O
recruited	O
.	O

The	O
MIF	B-T017
gene	I-T017
-	I-T017
173	I-T017
G	I-T017
/	I-T017
C	I-T017
SNP	B-T082
was	O
analyzed	B-T062
by	O
polymerase	B-T062
chain	I-T062
reaction	I-T062
using	O
the	O
restriction	B-T058
fragment	I-T058
length	I-T058
polymorphism	I-T058
method	I-T058
.	O

There	O
was	O
no	O
significant	O
difference	O
between	O
groups	B-T098
in	O
terms	O
of	O
genotype	O
distribution	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

When	O
wild	B-T017
-	I-T017
type	I-T017
G	O
/	O
G	O
and	O
G	O
/	O
C	O
+	O
C	O
/	O
C	O
genotypes	O
are	O
compared	O
in	O
terms	O
of	O
clinical	O
characteristics	O
,	O
there	O
is	O
a	O
significant	O
difference	O
between	O
the	O
average	O
age	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	B-T038
patients	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

No	O
significant	O
relationship	O
between	O
AS	B-T038
disease	B-T038
and	O
MIF	B-T017
-	I-T017
173	I-T017
G	I-T017
/	I-T017
C	I-T017
polymorphism	O
was	O
found	O
.	O

MIF	B-T017
-	I-T017
173	I-T017
G	I-T017
/	I-T017
C	I-T017
polymorphism	O
(	O
C	B-T017
allele	I-T017
)	O
may	O
affect	O
the	O
time	O
of	O
onset	O
and	O
the	O
duration	O
of	O
disease	O
in	O
AS	B-T038
patients	O
.	O

Mechanisms	O
of	O
Global	O
Cerebral	B-T038
Edema	I-T038
Formation	O
in	O
Aneurysmal	B-T038
Subarachnoid	I-T038
Hemorrhage	I-T038

A	O
growing	O
body	O
of	O
clinical	O
literature	B-T170
emphasizes	O
the	O
impact	O
of	O
cerebral	B-T038
edema	I-T038
in	O
early	B-T037
brain	I-T037
injury	I-T037
following	O
aneurysmal	B-T038
subarachnoid	I-T038
hemorrhage	I-T038
(	O
aSAH	B-T038
)	O
.	O

Aneurysm	B-T038
rupture	I-T038
itself	O
initiates	O
global	O
cerebral	B-T038
edema	I-T038
in	O
up	O
to	O
two	O
thirds	O
of	O
cases	O
.	O

Although	O
cerebral	B-T038
edema	I-T038
is	O
not	O
a	O
universal	O
feature	O
of	O
aSAH	B-T038
,	O
it	O
portends	O
a	O
poor	O
clinical	O
course	O
,	O
with	O
quantitative	O
analysis	O
revealing	O
a	O
direct	O
correlation	O
between	O
cerebral	B-T038
edema	I-T038
and	O
poor	B-T033
outcome	I-T033
,	O
including	O
mortality	O
and	O
cognitive	O
deficits	O
.	O

Mechanistically	O
,	O
global	O
cerebral	B-T038
edema	I-T038
has	O
been	O
linked	O
to	O
global	O
ischemia	B-T038
at	O
the	O
time	O
of	O
aneurysm	B-T038
rupture	I-T038
,	O
dysfunction	O
of	O
autoregulation	B-T038
,	O
blood	B-T038
breakdown	I-T038
products	O
,	O
neuroinflammation	O
,	O
and	O
hyponatremia	B-T038
/	O
endocrine	B-T017
abnormalities	I-T017
.	O

At	O
a	O
molecular	O
level	O
,	O
several	O
culprits	O
have	O
been	O
identified	O
,	O
including	O
aquaporin	B-T103
-	I-T103
4	I-T103
,	O
matrix	B-T103
metalloproteinase	I-T103
-	I-T103
9	I-T103
,	O
SUR1	B-T103
-	O
TRPM4	B-T103
cation	I-T103
channels	I-T103
,	O
vascular	B-T103
endothelial	I-T103
growth	I-T103
factor	I-T103
,	O
bradykinin	B-T103
,	O
and	O
others	O
.	O

Here	O
,	O
we	O
review	O
these	O
cellular	B-T017
and	O
molecular	O
mechanisms	O
of	O
global	O
cerebral	B-T038
edema	I-T038
formation	O
in	O
aSAH	B-T038
.	O

Given	O
the	O
importance	O
of	O
edema	B-T033
to	O
the	O
outcome	O
of	O
patients	O
with	O
aSAH	B-T038
and	O
its	O
status	O
as	O
a	O
highly	O
modifiable	O
pathological	B-T038
process	I-T038
,	O
a	O
better	O
understanding	O
of	O
cerebral	B-T038
edema	I-T038
in	O
aSAH	B-T038
promises	O
to	O
hasten	O
the	O
development	O
of	O
medical	B-T058
therapies	I-T058
to	O
improve	O
outcomes	O
in	O
this	O
frequently	O
devastating	O
disease	B-T038
.	O

Biliary	B-T017
Phospholipids	B-T103
Sustain	O
Enterocyte	B-T017
Proliferation	B-T038
and	O
Intestinal	B-T038
Tumor	I-T038
Progression	B-T038
via	O
Nuclear	B-T103
Receptor	I-T103
Lrh1	B-T103
in	O
mice	B-T204

The	O
proliferative	O
-	O
crypt	O
compartment	O
of	O
the	O
intestinal	B-T017
epithelium	I-T017
is	O
enriched	O
in	O
phospholipids	B-T103
and	O
accumulation	B-T033
of	O
phospholipids	B-T103
has	O
been	O
described	O
in	O
colorectal	B-T038
tumors	I-T038
.	O

Here	O
we	O
hypothesize	O
that	O
biliary	B-T017
phospholipid	B-T103
flow	O
could	O
directly	O
contribute	O
to	O
the	O
proliferative	O
power	O
of	O
normal	B-T017
and	O
dysplastic	B-T017
enterocytes	I-T017
.	O

We	O
used	O
Abcb4	B-T017
(	O
-	O
/	O
-	O
)	O
mice	B-T204
which	O
lack	O
biliary	B-T017
phospholipid	B-T103
secretion	B-T038
.	O

We	O
first	O
show	O
that	O
Abcb4	B-T017
(	O
-	O
/	O
-	O
)	O
mice	B-T204
are	O
protected	O
against	O
intestinal	B-T017
tumorigenesis	B-T038
.	O

At	O
the	O
molecular	O
level	O
,	O
the	O
transcriptional	B-T038
activity	I-T038
of	O
the	O
nuclear	B-T103
receptor	I-T103
Liver	B-T103
Receptor	I-T103
Homolog	I-T103
-	I-T103
1	I-T103
(	O
Lrh1	B-T103
)	O
is	O
reduced	O
in	O
Abcb4	B-T017
(	O
-	O
/	O
-	O
)	O
mice	B-T204
and	O
its	O
re	O
-	O
activation	O
re	O
-	O
establishes	O
a	O
tumor	B-T038
burden	O
comparable	O
to	O
control	O
mice	B-T204
.	O

Feeding	O
Abcb4	B-T017
(	O
-	O
/	O
-	O
)	O
mice	B-T204
a	O
diet	B-T168
supplemented	I-T168
with	O
phospholipids	B-T103
completely	O
overcomes	O
the	O
intestinal	B-T038
tumor	I-T038
protective	O
phenotype	O
,	O
thus	O
corroborating	O
the	O
hypothesis	O
that	O
the	O
absence	O
of	O
biliary	B-T017
phospholipids	B-T103
and	O
not	O
lack	O
of	O
Abcb4	B-T017
gene	I-T017
per	O
se	O
is	O
responsible	O
for	O
the	O
protection	O
.	O

In	O
turn	O
,	O
phospholipids	B-T103
cannot	O
re	O
-	O
establish	O
intestinal	B-T017
tumorigenesis	B-T038
in	O
Abcb4	B-T017
(	O
-	O
/	O
-	O
)	O
mice	B-T204
crossed	O
with	O
mice	B-T204
with	O
intestinal	B-T017
specific	O
ablation	B-T058
of	O
Lrh1	B-T103
,	O
a	O
nuclear	B-T103
hormone	I-T103
receptor	I-T103
that	O
is	O
activates	O
by	O
phospholipids	B-T103
.	O

Our	O
data	O
identify	O
the	O
key	O
role	O
of	O
biliary	B-T017
phospholipids	B-T103
in	O
sustaining	O
intestinal	B-T017
mucosa	I-T017
proliferation	O
and	O
tumor	B-T038
progression	I-T038
through	O
the	O
activation	O
of	O
nuclear	B-T103
receptor	I-T103
Lrh1	B-T103
.	O

Metalloproteinase	B-T103
meprin	B-T103
α	I-T103
regulates	O
migration	B-T038
and	O
invasion	B-T033
of	O
human	B-T204
hepatocarcinoma	B-T038
cells	B-T017
and	O
is	O
a	O
mediator	O
of	O
the	O
oncoprotein	B-T103
Reptin	B-T103

Hepatocellular	B-T038
carcinoma	I-T038
is	O
associated	O
with	O
a	O
high	O
rate	O
of	O
intra	B-T082
-	I-T082
hepatic	I-T082
invasion	B-T033
that	O
carries	O
a	O
poor	B-T033
prognosis	I-T033
.	O

Meprin	B-T103
alpha	I-T103
(	O
Mep1A	B-T103
)	O
is	O
a	O
secreted	B-T038
metalloproteinase	B-T103
with	O
many	O
substrates	O
relevant	O
to	O
cancer	B-T033
invasion	I-T033
.	O

We	O
found	O
that	O
Mep1A	B-T103
was	O
a	O
target	O
of	O
Reptin	B-T103
,	O
a	O
protein	B-T103
that	I-T103
is	I-T103
oncogenic	I-T103
in	O
HCC	B-T038
.	O

We	O
studied	O
Mep1A	B-T103
regulation	B-T038
by	O
Reptin	B-T103
,	O
its	O
role	O
in	O
HCC	B-T038
,	O
and	O
whether	O
it	O
mediates	O
Reptin	B-T103
oncogenic	B-T103
effects	O
.	O

MepA	B-T103
and	O
Reptin	B-T103
expression	B-T038
was	O
measured	O
in	O
human	B-T204
HCC	B-T038
by	O
qRT	B-T062
-	I-T062
PCR	I-T062
and	O
in	O
cultured	B-T017
cells	I-T017
by	O
PCR	B-T062
,	O
western	B-T058
blot	I-T058
and	O
enzymatic	O
activity	O
measurements	O
.	O

Cell	B-T038
growth	I-T038
was	O
assessed	O
by	O
counting	B-T058
and	O
MTS	B-T062
assay	I-T062
.	O

Cell	B-T038
migration	I-T038
was	O
measured	O
in	O
Boyden	B-T074
chambers	I-T074
and	O
wound	B-T038
healing	I-T038
assays	B-T058
,	O
and	O
cell	B-T033
invasion	I-T033
in	O
Boyden	B-T074
chambers	I-T074
.	O

Silencing	B-T038
Reptin	B-T017
decreased	O
Mep1A	B-T103
expression	B-T038
and	O
activity	O
,	O
without	O
affecting	O
meprin	B-T103
β	I-T103
.	O

Mep1A	B-T103
,	O
but	O
not	O
meprin	B-T103
β	I-T103
,	O
was	O
overexpressed	B-T038
in	O
a	O
series	O
of	O
242	O
human	B-T204
HCC	B-T038
(	O
2	O
.	O
04	O
fold	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
,	O
and	O
a	O
high	O
expression	B-T038
correlated	O
with	O
a	O
poor	B-T033
prognosis	I-T033
.	O

Mep1A	B-T103
and	O
Reptin	B-T103
expressions	B-T038
were	O
positively	O
correlated	O
(	O
r	O
=	O
0	O
.	O
39	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

Silencing	B-T038
Mep1A	B-T017
had	O
little	O
effect	O
on	O
cell	B-T038
proliferation	I-T038
,	O
but	O
decreased	O
cell	B-T038
migration	I-T038
and	O
invasion	B-T033
of	O
HuH7	B-T017
and	O
Hep3B	B-T017
cells	I-T017
.	O

Conversely	O
,	O
overexpression	B-T038
of	O
Mep1A	B-T103
or	O
addition	O
of	O
recombinant	O
Mep1A	B-T103
increased	O
migration	B-T038
and	O
invasion	B-T033
.	O

Finally	O
,	O
overexpression	B-T038
of	O
Mep1A	B-T103
restored	O
a	O
normal	O
cell	B-T038
migration	I-T038
in	O
cells	B-T017
where	O
Reptin	B-T103
was	O
depleted	O
.	O

Mep1A	B-T103
is	O
overexpressed	B-T038
in	O
most	O
HCC	B-T038
and	O
induces	O
HCC	B-T038
cell	B-T038
migration	I-T038
and	O
invasion	B-T033
.	O

Mep1A	B-T103
expression	B-T038
is	O
regulated	O
by	O
Reptin	B-T103
,	O
and	O
Mep1A	B-T103
mediates	O
Reptin	B-T103
-	O
induced	O
migration	B-T038
.	O

Overall	O
,	O
we	O
suggest	O
that	O
Mep1A	B-T103
may	O
be	O
a	O
useful	O
target	O
in	O
HCC	B-T038
.	O

Psychosocial	O
impact	O
on	O
families	O
with	O
an	O
infant	O
with	O
a	O
hypoplastic	B-T038
left	I-T038
heart	I-T038
syndrome	I-T038
during	O
and	O
after	O
the	O
interstage	O
monitoring	O
period	O
-	O
a	O
prospective	B-T062
mixed	I-T062
-	I-T062
method	I-T062
study	I-T062

To	O
investigate	O
parents	B-T038
'	I-T038
experiences	I-T038
,	O
coping	O
ability	O
and	O
quality	O
of	O
life	O
while	O
monitoring	B-T058
their	O
sick	O
child	O
with	O
hypoplastic	B-T038
left	I-T038
heart	I-T038
syndrome	I-T038
at	O
home	B-T082
.	O

Interstage	B-T058
home	I-T058
monitoring	I-T058
for	O
children	O
with	O
hypoplastic	B-T038
left	I-T038
heart	I-T038
syndrome	I-T038
reduces	O
interstage	O
mortality	O
between	O
Norwood	B-T058
stages	I-T058
I	I-T058
and	I-T058
II	I-T058
.	O

Little	O
is	O
known	O
about	O
the	O
psychosocial	O
impact	O
of	O
interstage	B-T058
home	I-T058
monitoring	I-T058
.	O

Prospective	B-T062
mixed	I-T062
-	I-T062
method	I-T062
study	I-T062
.	O

This	O
study	O
assessed	O
the	O
psychosocial	O
impact	O
on	O
parents	O
during	O
interstage	B-T058
home	I-T058
monitoring	I-T058
.	O

This	O
contains	O
for	O
quantitative	O
assessment	O
the	O
Short	B-T170
Form	I-T170
Health	I-T170
Survey	I-T170
questionnaire	I-T170
and	O
the	O
Impact	O
of	O
Family	B-T033
Scale	I-T033
administered	I-T033
one	O
and	O
five	O
weeks	O
following	O
discharge	B-T058
before	O
and	O
after	O
stage	O
II	O
.	O

For	O
qualitative	O
assessment	O
,	O
semi	O
-	O
structured	O
interviews	O
focussing	O
on	O
the	O
postdischarge	B-T033
coping	B-T058
strategies	I-T058
were	O
conducted	O
twice	O
,	O
five	O
weeks	O
after	B-T033
hospital	I-T033
discharge	I-T033
before	O
and	O
after	O
stage	O
II	O
.	O

Ten	O
infants	O
(	O
eight	O
males	O
)	O
with	O
hypoplastic	B-T038
left	I-T038
heart	I-T038
syndrome	I-T038
(	O
n	O
=	O
7	O
)	O
or	O
other	O
types	O
of	O
univentricular	B-T017
heart	I-T017
malformations	I-T017
(	O
n	O
=	O
3	O
)	O
,	O
and	O
their	O
parents	O
(	O
nine	O
mother	O
/	O
father	O
two	O
-	O
parent	O
households	O
,	O
one	O
single	O
mother	O
)	O
were	O
included	O
.	O

There	O
were	O
no	B-T033
interstage	I-T033
deaths	I-T033
.	O

Mental	B-T038
Health	I-T038
Composite	O
Summary	O
scores	O
were	O
low	O
in	O
both	O
parents	O
(	O
mothers	O
:	O
40	O
·	O
45	O
±	O
9	O
·	O
07	O
;	O
fathers	O
:	O
40	O
·	O
58	O
±	O
9	O
·	O
69	O
)	O
and	O
lowest	O
for	O
the	O
item	O
'	O
vitality	B-T033
'	O
(	O
mothers	O
:	O
37	O
·	O
0	O
±	O
19	O
·	O
46	O
;	O
fathers	O
:	O
43	O
·	O
12	O
±	O
25	O
·	O
9	O
)	O
before	O
and	O
after	O
stage	O
II	O
.	O

Impact	O
of	O
Family	B-T033
Scale	I-T033
values	I-T033
showed	O
higher	O
daily	O
and	O
social	O
burdens	O
for	O
mothers	O
.	O

'	O
Becoming	O
a	O
family	O
'	O
was	O
the	O
most	O
important	O
task	O
as	O
coping	B-T058
strategy	I-T058
to	O
equilibrate	O
the	O
fragile	B-T038
emotional	I-T038
balance	I-T038
.	O

The	O
parents	O
judged	O
interstage	B-T058
home	I-T058
monitoring	I-T058
as	O
a	O
protective	B-T058
intervention	I-T058
.	O

Although	O
psychosocial	O
burden	O
before	O
and	O
after	O
stage	O
II	O
remains	O
high	O
,	O
becoming	O
a	O
family	O
is	O
an	O
essential	O
experience	O
for	O
parents	O
and	O
confirms	O
their	O
parenthood	O
.	O

Healthcare	B-T097
professionals	I-T097
must	O
be	O
aware	O
of	O
parents	O
'	O
needs	O
during	O
this	O
vulnerable	O
interstage	O
period	O
and	O
to	O
provide	O
psychosocial	O
and	O
nursing	B-T058
support	I-T058
.	O

Rates	O
and	O
predictors	O
of	O
injury	B-T037
in	O
a	O
population	O
-	O
based	O
cohort	B-T098
of	O
people	B-T098
living	O
with	O
HIV	B-T038

Injuries	B-T037
are	O
responsible	O
for	O
10	O
%	O
of	O
the	O
global	O
burden	O
of	O
disease	B-T038
;	O
however	O
,	O
the	O
epidemiology	O
of	O
injury	B-T037
among	O
people	B-T038
living	I-T038
with	I-T038
HIV	I-T038
(	O
PLHIV	B-T038
)	O
has	O
not	O
been	O
well	O
elucidated	O
.	O

This	O
study	B-T062
seeks	O
to	O
characterize	O
rates	O
and	O
predictors	O
of	O
injury	B-T037
among	O
PLHIV	B-T038
compared	O
to	O
the	O
general	B-T098
population	I-T098
in	O
British	B-T082
Columbia	I-T082
(	O
BC	B-T082
)	O
,	O
Canada	B-T082
.	O

A	O
population	O
-	O
based	O
dataset	B-T170
was	O
created	O
via	O
linkage	B-T062
between	B-T082
the	O
BC	B-T092
Centre	I-T092
for	I-T092
Excellence	I-T092
in	I-T092
HIV	I-T092
/	I-T092
AIDS	I-T092
and	O
PopulationDataBC	O
.	O

PLHIV	B-T038
aged	O
20	O
years	O
and	O
older	O
were	O
compared	O
to	O
a	O
random	O
10	O
%	O
sample	O
of	O
the	O
adult	O
general	B-T098
population	I-T098
.	O

The	O
International	O
Classification	B-T170
of	O
Diseases	B-T038
9	O
and	O
10	O
codes	O
were	O
used	O
to	O
classify	B-T170
unintentional	B-T037
and	O
intentional	B-T037
injuries	I-T037
based	O
on	O
the	O
external	O
cause	O
of	O
the	O
injury	B-T037
from	O
1996	O
to	O
2013	O
.	O

Generalized	B-T170
estimating	I-T170
equation	I-T170
(	O
GEE	B-T170
)	O
Poisson	O
regression	O
models	O
were	O
fit	O
to	O
estimate	O
the	O
effect	O
of	O
HIV	B-T038
status	O
on	O
rates	O
of	O
unintentional	B-T037
and	O
intentional	B-T037
injury	I-T037
,	O
and	O
to	O
identify	O
correlates	O
of	O
injury	B-T037
among	O
PLHIV	B-T038
.	O

The	O
crude	O
incidence	O
rate	O
of	O
unintentional	B-T037
injury	I-T037
was	O
18	O
.	O
56	O
/	O
1000	O
person	B-T098
-	O
years	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
17	O
.	O
77	O
-	O
19	O
.	O
39	O
]	O
among	O
PLHIV	B-T038
and	O
8	O
.	O
51	O
/	O
1000	O
person	B-T098
-	O
years	O
(	O
95	O
%	O
CI	O
8	O
.	O
42	O
-	O
8	O
.	O
59	O
)	O
in	O
the	O
general	B-T098
population	I-T098
.	O

Among	O
PLHIV	B-T038
,	O
13	O
.	O
45	O
%	O
of	O
deaths	B-T033
were	O
due	O
to	O
injury	B-T037
,	O
compared	O
to	O
5	O
.	O
52	O
%	O
of	O
deaths	B-T033
in	O
the	O
general	B-T098
population	I-T098
.	O

In	O
adjusted	O
models	B-T170
,	O
PLHIV	B-T038
were	O
more	O
likely	O
to	O
report	B-T058
unintentional	B-T037
(	O
incidence	O
rate	O
ratio	O
1	O
.	O
42	O
,	O
95	O
%	O
CI	O
1	O
.	O
32	O
-	O
1	O
.	O
52	O
)	O
and	O
intentional	B-T037
injury	I-T037
(	O
incidence	O
rate	O
ratio	O
1	O
.	O
93	O
,	O
95	O
%	O
CI	O
1	O
.	O
70	O
-	O
2	O
.	O
18	O
)	O
compared	O
to	O
the	O
general	B-T098
population	I-T098
.	O

We	O
identified	O
elevated	O
rates	O
of	O
intentional	B-T037
and	O
unintentional	B-T037
injury	I-T037
among	O
PLHIV	B-T038
.	O

Injuries	B-T037
are	O
largely	O
preventable	O
;	O
as	O
such	O
,	O
targeted	O
efforts	O
are	O
needed	O
to	O
decrease	O
the	O
burden	O
of	O
injury	B-T037
-	O
related	O
disability	B-T033
and	O
death	B-T033
among	O
PLHIV	B-T038
.	O

TREK	B-T103
-	I-T103
1	I-T103
(	I-T103
K2P2	I-T103
.	I-T103
1	I-T103
)	I-T103
K	I-T103
(	I-T103
+	I-T103
)	I-T103
channels	I-T103
are	O
suppressed	O
in	O
patients	O
with	O
atrial	B-T038
fibrillation	I-T038
and	O
heart	B-T038
failure	I-T038
and	O
provide	O
therapeutic	O
targets	O
for	O
rhythm	O
control	O

Atrial	B-T038
fibrillation	I-T038
(	O
AF	B-T038
)	O
is	O
the	O
most	O
common	O
cardiac	B-T033
arrhythmia	I-T033
.	O

Concomitant	B-T038
heart	I-T038
failure	I-T038
(	O
HF	B-T038
)	O
poses	O
a	O
particular	O
therapeutic	O
challenge	B-T058
and	O
is	O
associated	O
with	O
prolonged	O
atrial	B-T038
electrical	I-T038
refractoriness	I-T038
compared	O
with	O
non	B-T017
-	I-T017
failing	I-T017
hearts	I-T017
.	O

We	O
hypothesized	O
that	O
downregulation	B-T038
of	O
atrial	B-T038
repolarizing	I-T038
TREK	B-T103
-	I-T103
1	I-T103
(	I-T103
K2P2	I-T103
.	I-T103
1	I-T103
)	I-T103
K	I-T103
(	I-T103
+	I-T103
)	I-T103
channels	I-T103
contributes	O
to	O
electrical	B-T038
remodeling	I-T038
during	O
AF	B-T038
with	O
HF	B-T038
,	O
and	O
that	O
TREK	B-T062
-	I-T062
1	I-T062
gene	I-T062
transfer	I-T062
would	O
provide	O
rhythm	O
control	O
via	O
normalization	B-T062
of	O
atrial	B-T033
effective	I-T033
refractory	I-T033
periods	I-T033
in	O
this	O
AF	B-T038
subset	B-T062
.	O

In	O
patients	O
with	O
chronic	B-T038
AF	I-T038
and	O
HF	B-T038
,	O
atrial	B-T103
TREK	I-T103
-	I-T103
1	I-T103
mRNA	B-T103
levels	O
were	O
reduced	O
by	O
82	O
%	O
(	O
left	B-T017
atrium	I-T017
)	O
and	O
81	O
%	O
(	O
right	B-T017
atrium	I-T017
)	O
compared	O
with	O
sinus	B-T033
rhythm	I-T033
(	O
SR	B-T033
)	O
subjects	B-T098
.	O

Human	B-T204
findings	B-T033
were	O
recapitulated	O
in	O
a	O
porcine	O
model	O
of	O
atrial	B-T038
tachypacing	I-T038
-	I-T038
induced	I-T038
AF	I-T038
and	O
reduced	O
left	B-T038
ventricular	I-T038
function	I-T038
.	O

TREK	B-T103
-	I-T103
1	I-T103
mRNA	B-T103
(	O
-	O
66	O
%	O
)	O
and	O
protein	B-T103
(	O
-	O
61	O
%	O
)	O
was	O
suppressed	O
in	O
AF	B-T038
animals	B-T204
at	O
14	O
-	O
day	O
follow	O
-	O
up	O
compared	O
with	O
SR	B-T033
controls	O
.	O

Downregulation	B-T038
of	O
repolarizing	B-T038
TREK	B-T103
-	I-T103
1	I-T103
channels	I-T103
was	O
associated	O
with	O
prolongation	O
of	O
atrial	B-T033
effective	I-T033
refractory	I-T033
periods	I-T033
versus	O
baseline	O
conditions	O
,	O
consistent	O
with	O
prior	O
observations	B-T062
in	O
humans	B-T204
with	O
HF	B-T038
.	O

In	O
a	O
preclinical	O
therapeutic	O
approach	O
,	O
pigs	B-T204
were	O
randomized	B-T062
to	O
either	O
atrial	B-T058
Ad	I-T058
-	I-T058
TREK	I-T058
-	I-T058
1	I-T058
gene	I-T058
therapy	I-T058
or	O
sham	B-T058
treatment	I-T058
.	O

Gene	B-T062
transfer	I-T062
effectively	O
increased	O
TREK	B-T103
-	I-T103
1	I-T103
protein	I-T103
levels	O
and	O
attenuated	O
atrial	B-T033
effective	I-T033
refractory	I-T033
period	I-T033
prolongation	O
in	O
the	O
porcine	O
AF	O
model	O
.	O

Ad	B-T103
-	I-T103
TREK	I-T103
-	I-T103
1	I-T103
increased	O
the	O
SR	B-T033
prevalence	O
to	O
62	O
%	O
during	O
follow	O
-	O
up	O
in	O
AF	B-T038
animals	B-T204
,	O
compared	O
to	O
35	O
%	O
in	O
the	O
untreated	O
AF	B-T038
group	O
.	O

In	O
conclusion	O
,	O
TREK	B-T103
-	I-T103
1	I-T103
downregulation	B-T038
and	O
rhythm	O
control	O
by	O
Ad	B-T062
-	I-T062
TREK	I-T062
-	I-T062
1	I-T062
transfer	I-T062
suggest	O
mechanistic	B-T058
and	I-T058
potential	I-T058
therapeutic	I-T058
significance	O
of	O
TREK	B-T103
-	I-T103
1	I-T103
channels	I-T103
in	O
a	O
subgroup	B-T170
of	O
AF	B-T038
patients	O
with	O
HF	B-T038
and	O
prolonged	O
atrial	B-T033
effective	I-T033
refractory	I-T033
periods	I-T033
.	O

Functional	O
correction	O
of	O
ionic	O
remodeling	O
through	O
TREK	B-T058
-	I-T058
1	I-T058
gene	I-T058
therapy	I-T058
represents	O
a	O
novel	O
paradigm	O
to	O
optimize	O
and	O
specify	O
AF	B-T038
management	O
.	O

A	O
Rasch	O
Rating	O
Scale	O
Analysis	B-T062
of	O
the	O
Presence	B-T033
of	O
Nursing	B-T091
Scale	O
-	O
RN	B-T097

The	O
phenomenon	O
of	O
nursing	B-T091
presence	B-T033
encompasses	O
the	O
emotional	B-T033
connection	B-T082
between	O
nurse	B-T097
and	O
patient	O
,	O
and	O
technical	O
skills	O
performed	O
by	O
the	O
nurse	B-T097
.	O

The	O
Presence	B-T033
of	O
Nursing	B-T091
Scale	O
-	O
RN	B-T097
version	B-T170
(	O
PONS	O
-	O
RN	B-T097
)	O
was	O
developed	O
to	O
measure	O
nurses	B-T097
'	I-T097
perceptions	B-T038
of	O
their	O
ability	O
to	O
be	O
present	B-T033
to	O
their	O
patients	O
.	O

This	O
study	B-T062
summarizes	B-T170
the	O
process	O
of	O
re	O
-	O
evaluation	O
of	O
the	O
psychometric	B-T058
properties	I-T058
of	O
the	O
PONS	O
-	O
RN	B-T097
instrument	O
.	O

A	O
sample	B-T098
of	O
76	O
registered	B-T097
nurses	I-T097
providing	O
direct	O
patient	B-T058
care	I-T058
responded	B-T038
to	O
the	O
31	O
-	O
item	O
questionnaire	B-T170
.	O

The	O
Rasch	O
rating	O
scale	O
model	O
was	O
used	O
for	O
assessing	O
construct	O
validity	O
of	O
PONS	O
-	O
RN	B-T097
data	O
.	O

A	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
of	O
residuals	O
supported	O
appropriateness	O
of	O
the	O
subscales	O
defined	O
by	O
a	O
2	B-T082
-	I-T082
dimensional	I-T082
structure	B-T082
.	O

The	O
results	O
of	O
item	O
and	O
person	B-T098
fit	O
analysis	B-T062
,	O
rating	O
scale	O
functioning	O
analysis	B-T062
and	O
reliability	O
analysis	O
have	O
demonstrated	O
that	O
the	O
thirty	O
-	O
one	O
item	O
Presence	B-T033
of	O
Nursing	B-T091
Scale	O
-	O
RN	B-T097
instrument	O
yielded	O
measures	O
with	O
high	O
validity	O
and	O
reliability	O
as	O
two	O
sub	O
-	O
scales	O
.	O

Jou	O
rn	B-T097

Elastin	B-T103
Is	O
Differentially	B-T038
Regulated	I-T038
by	O
Pressure	B-T058
Therapy	I-T058
in	O
a	O
Porcine	B-T204
Model	B-T204
of	O
Hypertrophic	B-T017
Scar	I-T017

Beneficial	O
effects	O
of	O
pressure	B-T058
therapy	I-T058
for	O
hypertrophic	B-T017
scars	I-T017
have	O
been	O
reported	O
,	O
but	O
the	O
mechanisms	O
of	O
action	O
are	O
not	O
fully	O
understood	O
.	O

This	O
study	B-T062
evaluated	O
elastin	B-T103
and	O
its	O
contribution	O
to	O
scar	B-T017
pliability	O
.	O

The	O
relationship	O
between	O
changes	O
in	O
Vancouver	B-T170
Scar	I-T170
Scale	I-T170
(	O
VSS	B-T170
)	O
scores	O
of	O
pressure	B-T058
-	I-T058
treated	I-T058
scars	B-T017
and	O
differential	O
regulation	O
of	O
elastin	B-T103
was	O
assessed	O
.	O

Hypertrophic	B-T017
scars	I-T017
were	O
created	O
and	O
assessed	O
weekly	O
using	O
VSS	B-T170
and	O
biopsy	B-T058
procurement	B-T033
.	O

Pressure	B-T058
treatment	I-T058
began	O
on	O
day	O
70	O
postinjury	O
.	O

Treated	B-T058
scars	B-T017
were	O
compared	O
with	O
untreated	O
shams	B-T058
.	O

Treatment	B-T058
lasted	O
2	O
weeks	O
,	O
through	O
day	O
84	O
,	O
and	O
scars	B-T017
were	O
assessed	O
weekly	O
through	O
day	O
126	O
.	O

Transcript	B-T103
and	O
protein	B-T033
levels	I-T033
of	O
elastin	B-T103
were	O
quantified	O
.	O

Pressure	B-T058
treatment	I-T058
resulted	O
in	O
lower	O
VSS	B-T170
scores	O
compared	O
with	O
sham	B-T058
-	I-T058
treated	I-T058
scars	B-T017
.	O

Pliability	O
(	O
VSSP	O
)	O
was	O
a	O
key	O
contributor	O
to	O
this	O
difference	O
.	O

At	O
day	O
70	O
pretreatment	O
,	O
VSSP	O
=	O
2	O
.	O

Without	B-T058
treatment	I-T058
,	O
sham	B-T058
-	I-T058
treated	I-T058
scars	B-T017
became	O
less	O
pliable	O
,	O
while	O
pressure	B-T058
-	I-T058
treated	I-T058
scars	B-T017
became	O
more	O
pliable	O
.	O

The	O
percentage	O
of	O
elastin	B-T103
in	O
scars	B-T017
at	O
day	O
70	O
was	O
higher	O
than	O
in	O
uninjured	B-T022
skin	I-T022
.	O

Following	O
treatment	B-T058
,	O
the	O
percentage	O
of	O
elastin	B-T103
increased	O
and	O
continued	O
to	O
increase	O
through	O
day	O
126	O
.	O

Untreated	O
sham	B-T058
scars	B-T017
did	O
not	O
show	O
a	O
similar	O
increase	O
.	O

Quantification	O
of	O
Verhoeff	B-T058
-	I-T058
Van	I-T058
Gieson	I-T058
staining	I-T058
corroborated	O
the	O
findings	B-T033
and	O
immunofluorescence	B-T058
revealed	O
the	O
alignment	O
of	O
elastin	B-T103
fibers	I-T103
.	O

Pressure	B-T058
treatment	I-T058
results	O
in	O
increased	O
protein	B-T038
level	I-T038
expression	I-T038
of	O
elastin	B-T103
compared	O
with	O
sham	B-T058
-	O
untreated	O
scars	B-T017
.	O

These	O
findings	B-T033
further	O
characterize	O
the	O
extracellular	B-T017
matrix	I-T017
'	I-T017
s	I-T017
response	O
to	O
the	O
application	O
of	O
pressure	O
as	O
a	O
scar	B-T017
treatment	B-T058
,	O
which	O
will	O
contribute	O
to	O
the	O
refinement	O
of	O
rehabilitation	O
practices	O
and	O
ultimately	O
improvements	O
in	O
functional	O
and	O
psychosocial	O
outcomes	O
for	O
patients	O
.	O

Epigenome	B-T062
-	I-T062
wide	I-T062
analysis	I-T062
links	O
SMAD3	B-T017
methylation	B-T038
at	O
birth	B-T038
to	O
asthma	B-T038
in	I-T038
children	I-T038
of	O
asthmatic	B-T038
mothers	O

The	O
timing	O
and	O
mechanisms	O
of	O
asthma	B-T038
inception	O
remain	O
imprecisely	O
defined	O
.	O

Although	O
epigenetic	B-T038
mechanisms	O
likely	O
contribute	O
to	O
asthma	B-T038
pathogenesis	B-T038
,	O
little	O
is	O
known	O
about	O
their	O
role	O
in	O
asthma	B-T038
inception	O
.	O

We	O
sought	O
to	O
assess	O
whether	O
the	O
trajectory	O
to	O
asthma	B-T038
begins	O
already	O
at	O
birth	B-T038
and	O
whether	O
epigenetic	B-T038
mechanisms	O
,	O
specifically	O
DNA	B-T038
methylation	I-T038
,	O
contribute	O
to	O
asthma	B-T038
inception	O
.	O

We	O
used	O
the	O
Methylated	B-T058
CpG	I-T058
Island	I-T058
Recovery	I-T058
Assay	I-T058
chip	I-T058
to	O
survey	B-T170
DNA	B-T038
methylation	I-T038
in	O
cord	B-T031
blood	I-T031
mononuclear	O
cells	O
from	O
36	O
children	O
(	O
18	O
nonasthmatic	B-T098
and	O
18	O
asthmatic	B-T038
subjects	B-T098
by	O
age	O
9	O
years	O
)	O
from	O
the	O
Infant	O
Immune	O
Study	B-T062
(	O
IIS	B-T062
)	O
,	O
an	O
unselected	O
birth	B-T038
cohort	B-T098
closely	O
monitored	O
for	O
asthma	B-T038
for	O
a	O
decade	O
.	O

SMAD3	B-T017
methylation	B-T038
in	O
IIS	B-T062
(	O
n	O
=	O
60	O
)	O
and	O
in	O
2	O
replication	B-T038
cohorts	B-T098
(	O
the	O
Manchester	O
Asthma	B-T038
and	O
Allergy	O
Study	O
[	O
n	O
=	O
30	O
]	O
and	O
the	O
Childhood	B-T038
Origins	I-T038
of	I-T038
Asthma	I-T038
Study	B-T062
[	O
n	O
=	O
28	O
]	O
)	O
was	O
analyzed	B-T062
by	O
using	O
bisulfite	B-T062
sequencing	I-T062
or	O
Illumina	B-T058
450K	I-T058
arrays	I-T058
.	O

Cord	B-T031
blood	I-T031
mononuclear	O
cell	O
-	O
derived	O
IL	B-T103
-	I-T103
1β	I-T103
levels	O
were	O
measured	O
by	O
means	O
of	O
ELISA	B-T058
.	O

Neonatal	O
immune	O
cells	B-T017
harbored	O
589	O
differentially	O
methylated	B-T082
regions	I-T082
that	O
distinguished	O
IIS	B-T062
children	B-T098
who	O
did	O
and	O
did	O
not	O
have	O
asthma	B-T038
by	O
age	O
9	O
years	O
.	O

In	O
all	O
3	O
cohorts	B-T098
methylation	B-T038
in	O
SMAD3	B-T017
,	O
the	O
most	O
connected	O
node	O
within	O
the	O
network	O
of	O
asthma	B-T038
-	O
associated	O
,	O
differentially	O
methylated	B-T082
regions	I-T082
,	O
was	O
selectively	O
increased	O
in	O
asthmatic	B-T038
children	O
of	O
asthmatic	B-T038
mothers	O
and	O
was	O
associated	O
with	O
childhood	B-T038
asthma	I-T038
risk	O
.	O

Moreover	O
,	O
SMAD3	B-T017
methylation	B-T038
in	O
IIS	B-T062
neonates	O
with	O
maternal	O
asthma	B-T038
was	O
strongly	O
and	O
positively	O
associated	O
with	O
neonatal	O
production	O
of	O
IL	B-T103
-	I-T103
1β	I-T103
,	O
an	O
innate	B-T103
inflammatory	I-T103
mediator	I-T103
.	O

The	O
trajectory	O
to	O
childhood	B-T038
asthma	I-T038
begins	O
at	O
birth	B-T038
and	O
involves	O
epigenetic	B-T038
modifications	O
in	O
immunoregulatory	B-T038
and	O
proinflammatory	O
pathways	B-T038
.	O

Maternal	O
asthma	B-T038
influences	O
epigenetic	B-T038
mechanisms	O
that	O
contribute	O
to	O
the	O
inception	O
of	O
this	O
trajectory	O
.	O

Clinical	O
correlates	O
of	O
faecal	B-T038
incontinence	I-T038
in	O
systemic	B-T038
sclerosis	I-T038
:	O
identifying	O
therapeutic	O
avenues	O

The	O
aim	O
was	O
to	O
establish	O
the	O
prevalence	O
and	O
severity	O
of	O
faecal	B-T038
incontinence	I-T038
(	O
FI	B-T038
)	O
in	O
SSc	B-T038
,	O
its	O
association	O
with	O
other	O
intestinal	B-T017
manifestations	O
and	O
potential	O
predictors	O
of	O
FI	B-T038
,	O
and	O
its	O
impact	O
on	O
quality	O
of	O
life	O
.	O

A	O
multicentre	O
,	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
of	O
298	O
SSc	B-T038
subjects	O
followed	O
in	O
the	O
Canadian	B-T092
Scleroderma	I-T092
Research	I-T092
Group	I-T092
cohort	B-T098
was	O
performed	O
using	O
validated	O
questionnaires	B-T170
:	O
Jorge	B-T170
-	I-T170
Wexner	I-T170
score	I-T170
(	O
an	O
FI	B-T038
severity	B-T170
scale	I-T170
)	O
,	O
Bristol	B-T170
stool	I-T170
scale	I-T170
(	O
a	O
visual	O
scale	O
of	O
stool	B-T033
consistency	I-T033
)	O
and	O
FI	B-T038
Quality	B-T170
-	I-T170
of	I-T170
-	I-T170
Life	I-T170
scale	I-T170
.	O

Constipation	B-T033
was	O
defined	O
by	O
the	O
Rome	B-T170
III	I-T170
criteria	I-T170
.	O

Associations	O
between	O
the	O
Jorge	B-T170
-	I-T170
Wexner	I-T170
score	I-T170
and	O
other	O
clinical	B-T033
variables	I-T033
were	O
determined	O
using	O
multivariate	B-T170
regression	I-T170
analyses	I-T170
.	O

Eighty	O
-	O
one	O
(	O
27	O
.	O
2	O
%	O
)	O
subjects	O
had	O
FI	B-T038
,	O
which	O
was	O
mild	O
in	O
37	O
(	O
12	O
.	O
4	O
%	O
)	O
and	O
moderate	O
to	O
severe	O
in	O
44	O
(	O
14	O
.	O
8	O
%	O
)	O
.	O

Most	O
patients	O
had	O
well	O
-	O
formed	O
stools	B-T031
,	O
111	O
(	O
38	O
.	O
8	O
%	O
)	O
reported	O
constipation	B-T033
and	O
38	O
(	O
13	O
.	O
4	O
%	O
)	O
had	O
been	O
previously	O
treated	O
for	O
small	B-T038
intestinal	I-T038
bacterial	I-T038
overgrowth	I-T038
(	O
SIBO	B-T038
)	O
.	O

Variables	O
independently	O
associated	O
with	O
FI	B-T038
were	O
:	O
loose	B-T033
vs	O
well	O
-	O
formed	O
stools	B-T031
[	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
7	O
.	O
01	O
,	O
95	O
%	O
CI	O
:	O
2	O
.	O
09	O
,	O
23	O
.	O
51	O
)	O
]	O
,	O
constipation	B-T033
(	O
OR	O
=	O
3	O
.	O
64	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
61	O
,	O
8	O
.	O
27	O
,	O
P	O
=	O
0	O
.	O
002	O
)	O
,	O
history	O
of	O
SIBO	B-T038
(	O
OR	O
=	O
2	O
.	O
97	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
06	O
,	O
8	O
.	O
27	O
)	O
and	O
urinary	B-T038
incontinence	I-T038
(	O
OR	O
=	O
2	O
.	O
45	O
,	O
95	O
%	O
CI	O
:	O
1	O
.	O
14	O
,	O
5	O
.	O
27	O
)	O
.	O

Quality	O
of	O
life	O
measured	O
with	O
the	O
FI	B-T038
Quality	B-T170
-	I-T170
of	I-T170
-	I-T170
Life	I-T170
scale	I-T170
was	O
inversely	O
correlated	O
with	O
FI	B-T038
severity	O
(	O
correlation	O
coefficients	O
between	O
-	O
0	O
.	O
602	O
and	O
-	O
0	O
.	O
702	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

FI	B-T038
was	O
common	O
and	O
often	O
severe	O
in	O
SSc	B-T038
.	O

Loose	B-T033
stools	I-T033
,	O
SIBO	B-T038
,	O
constipation	B-T033
and	O
urinary	B-T038
incontinence	I-T038
were	O
strongly	O
associated	O
with	O
FI	B-T038
.	O

Other	O
than	O
targeting	O
anorectal	O
dysfunction	B-T038
,	O
concomitant	O
treatment	B-T058
of	O
clinical	O
correlates	O
could	O
lead	O
to	O
improvement	O
in	O
FI	B-T038
and	O
quality	O
of	O
life	O
in	O
SSc	B-T038
.	O

From	O
training	O
to	O
practice	O
:	O
the	O
impact	O
of	O
ENGAGE	B-T092
,	O
Ireland	B-T082
'	I-T082
s	I-T082
national	O
men	O
'	O
s	O
health	O
training	O
programme	O

Ireland	B-T082
'	I-T082
s	I-T082
National	B-T170
Men	I-T170
'	I-T170
s	I-T170
Health	I-T170
Policy	I-T170
recommended	O
developing	O
training	O
programmes	O
tailored	B-T058
to	O
the	O
needs	O
of	O
those	O
working	O
in	O
health	B-T097
and	O
allied	B-T097
health	I-T097
professionals	I-T097
and	O
ENGAGE	B-T092
was	O
developed	O
to	O
meet	O
that	O
recommendation	O
.	O

This	O
study	B-T062
evaluated	B-T058
the	O
impact	O
of	O
ENGAGE	B-T092
on	O
frontline	O
service	O
providers	O
'	O
self	B-T033
-	I-T033
reported	I-T033
knowledge	I-T033
,	O
skills	O
,	O
capacity	O
and	O
practice	O
up	O
to	O
5	O
-	O
months	O
post	O
training	O
.	O

Between	O
2012	O
and	O
2015	O
,	O
ENGAGE	B-T092
Trainers	O
(	O
n	O
=	O
57	O
)	O
delivered	O
62	O
1	O
-	O
day	O
training	O
programmes	O
to	O
810	O
participants	B-T098
.	O

This	O
study	B-T062
was	O
conducted	O
on	O
a	O
subset	B-T170
of	O
those	O
training	O
days	O
(	O
n	O
=	O
26	O
)	O
and	O
participants	B-T098
.	O

Quantitative	O
methodologies	B-T062
were	O
used	O
to	O
collect	O
pre	O
(	O
n	O
=	O
295	O
)	O
,	O
post	O
(	O
n	O
=	O
295	O
)	O
and	O
5	O
-	O
month	O
post	O
(	O
n	O
=	O
128	O
)	O
training	O
questionnaire	B-T170
data	O
.	O

Overall	O
,	O
participants	B-T098
were	O
highly	O
satisfied	B-T170
with	O
the	O
training	O
immediately	O
post	O
training	O
(	O
8	O
.	O
60	O
±	O
1	O
.	O
60	O
out	O
of	O
10	O
)	O
and	O
at	O
5	O
-	O
month	O
follow	B-T033
up	I-T033
(	O
8	O
.	O
06	O
±	O
1	O
.	O
43	O
out	O
of	O
10	O
)	O
.	O

Participants	B-T098
'	I-T098
self	B-T033
-	I-T033
reported	I-T033
level	I-T033
of	I-T033
knowledge	I-T033
,	O
skill	O
and	O
capacity	O
in	O
identifying	O
priorities	O
,	O
engaging	O
men	B-T098
and	O
influencing	O
practice	O
beyond	O
their	O
own	O
organisation	O
increased	O
immediately	O
following	O
training	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
,	O
with	O
the	O
exception	O
of	O
improving	O
capacity	O
to	O
engage	O
men	B-T098
and	O
influencing	O
practice	O
beyond	O
their	O
organisation	O
,	O
these	O
improvements	O
were	O
sustained	O
at	O
5	O
-	O
month	O
post	O
training	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
vast	O
majority	O
of	O
service	O
providers	O
(	O
93	O
.	O
4	O
%	O
)	O
reported	B-T058
that	O
ENGAGE	B-T092
had	O
impacted	O
their	O
work	O
practice	O
up	O
to	O
5	O
-	O
month	O
post	O
training	O
.	O

The	O
findings	B-T033
suggest	O
that	O
ENGAGE	B-T092
has	O
succeeded	B-T033
in	O
improving	O
service	O
providers	O
'	O
capacity	O
to	O
engage	O
and	O
work	O
with	O
men	B-T098
;	O
improving	O
gender	O
competency	O
in	O
the	O
delivery	O
of	O
health	O
and	O
health	B-T058
related	I-T058
services	I-T058
may	O
increase	O
the	O
utilisation	B-T058
of	O
such	O
services	B-T058
by	O
men	B-T098
and	O
thereby	O
improve	B-T033
health	O
outcomes	O
for	O
men	B-T098
.	O

Double	B-T038
strand	I-T038
break	I-T038
induction	O
and	O
kinetics	O
indicate	O
preserved	O
hypersensitivity	B-T038
in	O
keratinocytes	B-T017
to	O
subtherapeutic	O
doses	O
for	O
7	O
weeks	O
of	O
radiotherapy	B-T058

Previously	O
we	O
reported	O
that	O
hyper	O
-	O
radiosensitivity	O
(	O
HRS	O
)	O
was	O
evidenced	O
by	O
quantifying	O
DNA	B-T017
double	I-T017
strand	I-T017
break	I-T017
(	I-T017
DSB	I-T017
)	I-T017
foci	I-T017
in	O
epidermis	B-T017
biopsies	B-T058
collected	O
after	O
delivering	O
radiotherapeutic	B-T170
one	O
and	O
five	O
dose	O
fractions	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
whether	O
HRS	O
was	O
preserved	O
throughout	O
a	O
7	O
-	O
week	O
radiotherapy	B-T058
treatment	B-T058
,	O
and	O
also	O
to	O
examine	O
the	O
rate	O
of	O
foci	B-T017
decline	O
and	O
foci	B-T017
persistence	O
between	O
dose	O
fractions	O
.	O

42	O
patients	O
with	O
prostate	B-T038
cancer	I-T038
received	O
7	O
-	O
week	O
fractionated	O
radiotherapy	B-T058
treatment	I-T058
(	O
RT	B-T058
)	O
with	O
daily	O
dose	O
fractions	O
of	O
0	O
.	O
05	O
-	O
1	O
.	O
10Gy	O
to	O
the	O
skin	B-T022
.	O

Before	O
RT	B-T058
,	O
and	O
at	O
several	O
times	O
throughout	O
treatment	B-T058
,	O
skin	B-T058
biopsies	I-T058
(	O
n	O
=	O
452	O
)	O
were	O
collected	O
at	O
30min	O
,	O
and	O
2	O
,	O
3	O
,	O
24	O
,	O
and	O
72h	O
after	O
dose	O
fractions	O
.	O

DSB	B-T017
-	I-T017
foci	I-T017
markers	B-T082
,	O
γH2AX	B-T017
and	O
53BP1	B-T017
,	O
were	O
labelled	O
in	O
epidermal	B-T017
keratinocytes	B-T017
with	O
immunofluorescence	B-T058
and	O
immunohistochemical	O
staining	O
.	O

Foci	O
were	O
counted	O
both	O
with	O
digital	B-T058
image	I-T058
analysis	I-T058
and	O
manually	O
.	O

HRS	O
in	O
keratinocytes	B-T017
was	O
evidenced	O
by	O
the	O
dose	O
-	O
response	O
relationships	O
of	O
DSB	B-T017
foci	I-T017
,	O
observed	O
throughout	O
the	O
treatment	O
course	O
,	O
independent	O
of	O
sampling	B-T058
time	O
and	O
quantification	O
method	B-T170
.	O

Foci	B-T017
observed	O
at	O
24h	O
after	O
dose	O
fractions	O
indicated	O
considerable	O
DSB	B-T038
persistence	O
.	O

Accordingly	O
,	O
foci	B-T017
significantly	O
accumulated	O
after	O
5	O
consecutive	O
dose	O
fractions	O
.	O

For	O
doses	O
below	O
0	O
.	O
3Gy	O
,	O
persistent	O
foci	B-T017
could	O
be	O
observed	O
even	O
at	O
72h	O
after	O
damage	B-T038
induction	O
.	O

A	O
comparison	O
of	O
γH2AX	B-T017
and	O
53BP1	B-T017
quantifications	O
in	O
double	O
-	O
staine	O
d	O
biopsies	B-T058
showed	O
similar	O
HRS	O
dose	O
-	O
response	O
relationships	O
.	O

These	O
results	O
represented	O
the	O
first	O
evidence	O
of	O
preserved	O
HRS	O
,	O
assessed	O
by	O
γH2AX	B-T017
-	O
and	O
53BP1	B-T017
-	O
labelled	O
DSB	B-T017
foci	I-T017
,	O
throughout	O
a	O
7	O
-	O
week	O
treatment	O
course	O
with	O
daily	O
repeated	O
subtherapeutic	O
dose	O
fractions	O
.	O

CT	B-T058
angiography	I-T058
for	O
planning	O
transcatheter	B-T058
aortic	I-T058
valve	I-T058
replacement	I-T058
using	O
automated	O
tube	O
voltage	O
selection	O
:	O
Image	O
quality	O
and	O
radiation	O
exposure	O

To	O
assess	O
image	O
quality	O
and	O
accuracy	O
of	O
CT	B-T058
angiography	I-T058
(	O
CTA	B-T058
)	O
for	O
transcatheter	B-T058
aortic	I-T058
valve	I-T058
replacement	I-T058
(	O
TAVR	B-T058
)	O
planning	O
performed	O
with	O
3rd	B-T058
generation	I-T058
dual	I-T058
-	I-T058
source	I-T058
CT	I-T058
(	O
DSCT	B-T058
)	O
.	O

We	O
evaluated	O
125	O
patients	O
who	O
underwent	O
TAVR	B-T058
-	O
planning	O
CTA	B-T058
on	O
3rd	B-T058
generation	I-T058
DSCT	I-T058
.	O

A	O
two	B-T058
-	I-T058
part	I-T058
protocol	I-T058
was	O
performed	O
including	O
retrospectively	O
ECG	B-T058
-	I-T058
gated	I-T058
coronary	I-T058
CTA	I-T058
(	O
CCTA	B-T058
)	O
and	O
prospectively	O
ECG	B-T058
-	I-T058
triggered	I-T058
aortoiliac	I-T058
CTA	I-T058
using	O
60mL	O
of	O
contrast	B-T103
medium	I-T103
.	O

Automated	O
tube	O
voltage	O
selection	O
and	O
advanced	B-T058
iterative	I-T058
reconstruction	I-T058
were	O
applied	O
.	O

Effective	O
dose	O
(	O
ED	O
)	O
,	O
signal	O
-	O
to	O
-	O
noise	O
(	O
SNR	O
)	O
and	O
contrast	O
-	O
to	O
-	O
noise	O
ratios	O
(	O
CNR	O
)	O
were	O
calculated	O
.	O

Five	B-T170
-	I-T170
point	I-T170
scales	I-T170
were	O
used	O
for	O
subjective	O
image	B-T058
quality	I-T058
analysis	I-T058
.	O

In	O
patients	O
who	O
underwent	O
TAVR	B-T058
,	O
sizing	B-T033
parameters	I-T033
were	O
obtained	O
.	O

Image	O
quality	O
was	O
rated	O
good	O
to	O
excellent	O
in	O
97	O
.	O
6	O
%	O
of	O
CCTA	B-T058
and	O
100	O
%	O
of	O
aortoiliac	B-T058
CTAs	I-T058
.	O

CTA	B-T058
studies	B-T062
at	O
>	O
100kV	O
showed	O
decreased	O
objective	O
image	O
quality	O
compared	O
to	O
70	O
-	O
100kV	O
(	O
SNR	O
,	O
all	O
p≤0	O
.	O
0459	O
;	O
CNR	O
,	O
all	O
p≤0	O
.	O
0462	O
)	O
.	O

Mean	O
ED	O
increased	O
continuously	O
from	O
70	O
to	O
>	O
100kV	O
(	O
CCTA	B-T058
:	O
4	O
.	O
5±1	O
.	O
7mSv	O
-	O
13	O
.	O
6±2	O
.	O
9mSv	O
,	O
all	O
p≤0	O
.	O
0233	O
;	O
aortoiliac	B-T058
CTA	I-T058
:	O
2	O
.	O
4±0	O
.	O
9mSv	O
-	O
6	O
.	O
8±2	O
.	O
7mSv	O
,	O
all	O
p≤0	O
.	O
0414	O
)	O
.	O

In	O
39	O
patients	O
TAVR	B-T058
was	O
performed	O
and	O
annulus	B-T017
diameter	O
was	O
within	O
the	O
recommended	O
range	O
in	O
all	O
patients	O
.	O

No	B-T033
severe	O
cardiac	B-T038
or	O
vascular	B-T038
complications	I-T038
were	O
noted	O
.	O

3rd	B-T058
generation	I-T058
DSCT	I-T058
provides	O
diagnostic	O
image	O
quality	O
in	O
TAVR	B-T058
-	O
planning	O
CTA	B-T058
and	O
facilitates	O
reliable	O
assessment	B-T058
of	O
TAVR	B-T058
device	B-T074
and	O
delivery	O
option	O
while	O
reducing	O
radiation	O
dose	O
.	O

A	O
Giant	B-T017
Aneurysmal	B-T038
Bone	I-T038
Cyst	I-T038
in	O
the	O
Mandibular	B-T017
Condyle	I-T017

Aneurysmal	B-T038
bone	I-T038
cyst	I-T038
(	O
ABC	B-T038
)	O
is	O
a	O
rare	O
,	O
rapidly	O
expanding	B-T082
,	O
locally	B-T082
destructive	O
,	O
and	O
easily	B-T033
misdiagnosed	B-T033
lesion	B-T033
.	O

An	O
ABC	B-T038
of	O
the	O
condyle	B-T017
is	O
rare	O
.	O

This	O
report	O
presents	O
a	O
25	O
-	O
year	O
-	O
old	O
female	O
with	O
a	O
giant	B-T017
ABC	B-T038
in	O
the	O
left	B-T082
mandibular	B-T017
condyle	I-T017
.	O

This	O
patient	O
was	O
treated	B-T058
with	I-T058
surgical	B-T058
resection	I-T058
of	O
the	O
affected	O
bone	B-T017
and	O
immediate	O
mandibular	B-T058
reconstruction	I-T058
using	O
autologous	O
bone	B-T017
.	O

Follow	O
-	O
up	O
to	O
date	O
showed	O
no	O
signs	B-T033
of	O
recurrence	O
.	O

The	O
clinical	O
feature	O
,	O
imaging	B-T033
finding	I-T033
,	O
pathogenesis	B-T038
,	O
and	O
treatment	B-T058
methods	I-T058
of	O
ABCs	B-T038
are	O
discussed	O
.	O

Association	O
between	O
postpartum	B-T038
depression	I-T038
and	O
the	O
practice	B-T038
of	O
exclusive	O
breastfeeding	O
in	O
the	O
first	O
three	O
months	O
of	O
life	O

To	O
investigate	O
the	O
association	O
between	O
postpartum	B-T038
depression	I-T038
and	O
the	O
occurrence	O
of	O
exclusive	O
breastfeeding	O
.	O

This	O
is	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
conducted	O
in	O
the	O
states	B-T082
of	O
the	O
Northeast	B-T082
region	I-T082
,	O
during	O
the	O
vaccination	B-T058
campaign	I-T058
in	O
2010	O
.	O

The	O
sample	O
consisted	O
of	O
2583	O
mother	O
-	O
child	O
pairs	O
,	O
with	O
children	O
aged	O
from	O
15	O
days	O
to	O
3	O
months	O
.	O

The	O
Edinburgh	B-T170
Postnatal	I-T170
Depression	I-T170
Scale	I-T170
was	O
used	O
to	O
screen	B-T058
for	O
postpartum	B-T038
depression	I-T038
.	O

The	O
outcome	O
was	O
lack	O
of	O
exclusive	O
breastfeeding	O
,	O
defined	O
as	O
the	O
occurrence	O
of	O
this	O
practice	O
in	O
the	O
24h	O
preceding	O
the	O
interview	O
.	O

Postpartum	B-T038
depression	I-T038
was	O
the	O
explanatory	O
variable	O
of	O
interest	O
and	O
the	O
covariates	O
were	O
:	O
socioeconomic	O
and	O
demographic	O
conditions	O
;	O
maternal	B-T058
health	I-T058
care	I-T058
;	O
prenatal	B-T058
,	O
delivery	B-T058
,	O
and	O
postnatal	B-T058
care	I-T058
;	O
and	O
the	O
child	O
'	O
s	O
biological	O
factors	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
was	O
conducted	O
to	O
control	O
for	O
possible	O
confounding	O
factors	O
.	O

Exclusive	O
breastfeeding	O
was	O
observed	O
in	O
50	O
.	O
8	O
%	O
of	O
the	O
infants	O
and	O
11	O
.	O
8	O
%	O
of	O
women	B-T098
had	O
symptoms	B-T033
of	O
postpartum	B-T038
depression	I-T038
.	O

In	O
the	O
multivariate	O
logistic	O
regression	O
analysis	O
,	O
a	O
higher	O
chance	O
of	O
exclusive	O
breastfeeding	O
absence	O
was	O
found	O
among	O
mothers	O
with	O
symptoms	B-T033
of	O
postpartum	B-T038
depression	I-T038
(	O
OR	O
=	O
1	O
.	O
67	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
among	O
younger	B-T098
subjects	I-T098
(	O
OR	O
=	O
1	O
.	O
89	O
;	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
those	O
who	O
reported	O
receiving	O
benefits	O
from	O
the	O
Bolsa	O
Família	O
Program	O
(	O
OR	O
=	O
1	O
.	O
25	O
;	O
p	O
=	O
0	O
.	O
016	O
)	O
,	O
and	O
those	O
started	O
antenatal	B-T058
care	I-T058
later	O
during	O
pregnancy	B-T038
(	O
OR	O
=	O
2	O
.	O
14	O
;	O
p	O
=	O
0	O
.	O
032	O
)	O
.	O

Postpartum	B-T038
depression	I-T038
contributed	O
to	O
reducing	O
the	O
practice	O
of	O
exclusive	O
breastfeeding	O
.	O

Therefore	O
,	O
this	O
disorder	B-T038
should	O
be	O
included	O
in	O
the	O
prenatal	B-T058
and	O
early	O
postpartum	O
support	B-T170
guidelines	I-T170
for	O
breastfeeding	B-T038
,	O
especially	O
in	O
low	O
socioeconomic	O
status	O
women	B-T098
.	O

Evidence	O
of	O
toothpick	O
groove	B-T082
formation	O
in	O
Neandertal	B-T204
anterior	B-T082
and	O
posterior	B-T082
teeth	B-T017

During	O
the	O
microscopic	B-T058
examination	I-T058
of	O
the	O
Neandertal	B-T204
dentitions	B-T017
from	O
El	B-T082
Sidrón	I-T082
(	O
Spain	B-T082
)	O
and	O
Hortus	B-T082
(	O
France	B-T082
)	O
,	O
we	O
found	O
unusual	O
fine	O
parallel	O
microstriations	O
on	O
the	O
mesial	B-T082
and	O
distal	B-T082
sides	I-T082
of	O
all	O
tooth	B-T017
types	O
,	O
near	O
the	O
cervix	B-T082
.	O

As	O
its	O
appearance	O
was	O
similar	O
to	O
toothpick	O
grooves	B-T082
described	O
in	O
other	O
Homo	B-T204
species	I-T204
,	O
it	O
could	O
correspond	O
to	O
early	O
stages	O
on	O
its	O
formation	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
developed	O
an	O
experimental	B-T062
replication	I-T062
of	O
a	O
groove	B-T082
using	O
grass	B-T204
stalks	B-T204
.	O

Comparisons	O
between	O
204	O
isolated	O
Neandertal	B-T204
teeth	B-T017
and	O
the	O
two	O
experimental	O
dental	O
specimens	O
corroborate	O
that	O
the	O
marks	B-T033
correspond	O
to	O
initial	O
stages	O
of	O
toothpick	O
groove	B-T082
formation	O
,	O
and	O
we	O
propose	O
a	O
five	B-T170
-	I-T170
grade	I-T170
recording	I-T170
scale	I-T170
that	O
summarized	O
the	O
groove	B-T082
formation	O
process	O
.	O

Using	O
this	O
new	O
recording	O
procedure	O
,	O
we	O
found	O
that	O
Hortus	B-T082
individuals	B-T098
have	O
higher	O
incidence	O
of	O
this	O
trait	O
(	O
eight	O
individuals	B-T098
out	O
of	O
nine	O
)	O
than	O
the	O
El	B-T082
Sidrón	I-T082
individuals	B-T098
(	O
nine	O
out	O
of	O
11	O
)	O
.	O

Toothpick	O
grooves	B-T082
from	O
El	B-T082
Sidrón	I-T082
show	O
the	O
earliest	O
stages	O
of	O
development	O
,	O
whereas	O
the	O
grooves	B-T082
found	O
on	O
Hortus	B-T082
Neandertals	B-T204
were	O
well	O
-	O
developed	O
.	O

Toothpick	O
grooves	B-T082
were	O
also	O
found	O
in	O
21	O
incisors	B-T017
and	O
canines	B-T017
.	O

These	O
differences	O
could	O
be	O
due	O
to	O
the	O
more	O
advanced	O
occlusal	B-T082
dental	B-T037
wear	I-T037
in	O
Hortus	B-T082
individuals	B-T098
,	O
maybe	O
age	O
-	O
related	O
and	O
with	O
a	O
more	O
meat	B-T168
-	O
based	O
diet	B-T168
maybe	O
favoring	O
the	O
inclusion	O
of	O
food	B-T168
debris	O
and	O
thus	O
probing	O
as	O
the	O
cleaning	O
methodology	O
.	O

Our	O
results	O
allow	O
the	O
identification	O
and	O
characterization	O
of	O
incipient	O
toothpick	O
grooves	B-T082
on	O
the	O
human	B-T204
fossil	O
record	B-T170
and	O
contribute	O
to	O
increase	O
our	O
knowledge	B-T170
on	O
Neandertals	B-T204
behavioral	O
and	O
oral	B-T033
care	I-T033
habits	I-T033
.	O

THSD7A	B-T103
expression	B-T038
in	O
human	B-T204
cancer	B-T038

We	O
recently	O
described	O
a	O
case	O
of	O
a	O
Thrombospondin	B-T103
Type	I-T103
-	I-T103
1	I-T103
Domain	I-T103
containing	I-T103
7A	I-T103
(	O
THSD7A	B-T103
)	O
associated	O
membranous	B-T038
nephropathy	I-T038
in	O
a	O
female	O
patient	O
who	O
was	O
synchronously	O
suffering	B-T033
from	O
a	O
THSD7A	B-T103
-	O
positive	B-T033
malignancy	O
.	O

We	O
here	O
investigated	O
the	O
role	O
of	O
THSD7A	B-T103
as	O
a	O
new	O
potential	O
tumor	B-T103
antigen	I-T103
by	O
evaluating	O
over	O
20	O
000	O
tissue	B-T017
spots	I-T017
in	O
more	O
than	O
70	O
different	O
tumor	B-T033
entities	I-T033
by	O
immunohistochemistry	B-T058
using	O
tissue	O
microarrays	O
.	O

THSD7A	B-T103
expression	B-T038
was	O
highly	O
variable	O
in	O
different	B-T038
neoplasias	I-T038
with	O
differing	O
staining	B-T082
patterns	I-T082
.	O

Both	O
gain	B-T033
and	I-T033
loss	I-T033
of	O
THSD7A	B-T103
expression	B-T038
compared	O
to	O
expression	B-T038
status	I-T038
in	O
non	B-T017
-	I-T017
tumor	I-T017
tissue	I-T017
were	O
linked	O
to	O
tumor	B-T103
-	I-T103
specific	I-T103
markers	I-T103
in	O
the	O
different	O
tumor	B-T033
entities	I-T033
and	O
were	O
of	O
prognostic	O
value	O
.	O

The	O
potential	O
role	O
of	O
THSD7A	B-T103
in	O
tumor	B-T033
development	I-T033
and	O
therapy	B-T058
needs	O
further	O
investigation	O
.	O

Civil	O
Society	O
-	O
Driven	O
Drug	O
Policy	O
Reform	O
for	O
Health	O
and	O
Human	B-T092
Welfare	I-T092
-	O
India	B-T082

The	O
lack	O
of	O
adequate	O
access	O
to	O
opioids	B-T103
in	O
India	B-T082
as	O
analgesics	B-T103
and	O
for	O
agonist	B-T103
therapies	B-T058
,	O
forces	O
millions	O
to	O
live	O
with	O
severe	O
unalleviated	B-T033
pain	I-T033
,	O
or	O
languish	O
with	O
suffering	B-T038
associated	O
with	O
drug	B-T038
dependence	I-T038
.	O

Although	O
India	B-T082
is	O
a	O
major	O
opium	B-T103
exporter	B-T097
,	O
the	O
excessively	O
prohibitive	O
1985	O
narcotics	B-T170
law	I-T170
formulated	O
to	O
control	O
harmful	B-T038
use	I-T038
of	I-T038
drugs	I-T038
,	O
impeded	O
the	O
availability	O
and	O
access	B-T082
to	O
opioids	B-T103
for	O
medical	O
and	O
scientific	O
purposes	O
.	O

Amendment	B-T170
of	O
this	O
law	B-T170
in	O
2014	O
established	O
a	O
new	O
national	B-T170
regulatory	I-T170
framework	I-T170
for	O
improved	O
access	B-T082
to	O
essential	O
opioid	B-T103
analgesics	I-T103
.	O

This	O
article	O
reflects	O
on	O
key	O
elements	O
and	O
processes	O
that	O
led	O
to	O
this	O
landmark	O
achievement	O
.	O

Unlike	O
quick	O
timelines	O
associated	O
with	O
effecting	O
policy	O
reforms	O
for	O
law	O
enforcement	O
,	O
realizing	O
the	O
2014	O
drug	O
policy	O
change	O
primarily	O
to	O
mitigate	O
human	B-T038
suffering	I-T038
,	I-T038
was	O
a	O
22	O
-	O
year	O
-	O
long	O
process	O
.	O

The	O
most	O
exacting	O
challenges	O
included	O
recognizing	O
the	O
multilayered	B-T033
complexities	I-T033
of	O
the	O
prior	O
policy	B-T170
framework	I-T170
and	O
understanding	O
their	O
adverse	O
impact	O
on	O
field	O
practices	O
to	O
chart	O
an	O
appropriate	O
and	O
viable	O
path	O
for	O
reform	O
.	O

The	O
evolution	O
of	O
an	O
informal	O
civil	O
society	O
movement	O
involving	O
health	B-T097
care	I-T097
professionals	I-T097
,	O
lawyers	B-T097
,	O
media	B-T097
,	O
policy	O
analysts	O
,	O
government	B-T097
officials	I-T097
,	O
and	O
the	O
public	B-T098
was	O
pivotal	O
in	O
addressing	O
these	O
challenges	B-T058
and	O
garnering	O
momentum	O
for	O
reform	O
.	O

The	O
success	O
of	O
the	O
effort	O
for	O
improving	O
access	O
to	O
opioid	B-T103
medications	B-T058
was	O
underpinned	O
by	O
a	O
three	O
-	O
pronged	O
strategy	O
of	O
1	O
)	O
persuading	O
the	O
executive	B-T097
arm	I-T097
of	I-T097
the	I-T097
government	I-T097
to	O
take	O
interim	O
enabling	O
measures	B-T170
;	O
2	O
)	O
leveraging	O
judicial	O
intervention	O
through	O
public	B-T098
interest	B-T098
litigation	O
;	O
and	O
3	O
)	O
crafting	O
a	O
viable	O
policy	O
document	O
for	O
legislative	O
approval	O
and	O
implementation	O
.	O

We	O
hope	O
our	O
findings	O
are	O
useful	O
for	O
realizing	O
drug	O
policy	O
reforms	O
,	O
given	O
the	O
current	O
transformed	O
global	O
policy	B-T170
mandates	O
emphasizing	O
humanitarian	B-T092
,	O
healthcare	B-T058
,	O
and	O
quality	O
-	O
of	O
-	O
life	O
considerations	B-T033
.	O

Efficacy	O
of	O
Synbiotics	B-T168
for	O
Treatment	B-T058
of	O
Bacillary	B-T038
Dysentery	I-T038
in	O
Children	O
:	O
A	O
Double	B-T062
-	I-T062
Blind	I-T062
,	O
Randomized	B-T062
,	O
Placebo	O
-	O
Controlled	O
Study	O

Bacillary	B-T038
dysentery	I-T038
is	O
a	O
major	O
cause	O
of	O
children	O
'	O
s	O
admission	B-T058
to	I-T058
hospitals	I-T058
.	O

To	O
assess	O
the	O
probiotic	B-T007
and	O
prebiotic	B-T103
(	O
synbiotics	B-T168
)	O
effects	O
in	O
children	O
with	O
dysentery	B-T038
in	O
a	O
randomized	B-T062
clinical	I-T062
trial	I-T062
,	O
200	O
children	O
with	O
dysentery	B-T038
were	O
studied	O
in	O
2	O
groups	O
:	O
the	O
synbiotic	B-T168
group	O
received	O
1	O
tablet	B-T103
/	O
day	O
of	O
synbiotic	B-T168
for	O
3	O
-	O
5	O
days	O
and	O
the	O
placebo	B-T103
group	O
received	O
placebo	B-T103
tablets	B-T103
(	O
identical	O
tablet	B-T103
form	O
like	O
probiotics	B-T007
)	O
.	O

The	O
standard	O
treatment	B-T058
was	O
administered	O
for	O
all	O
patients	O
.	O

Duration	O
of	O
hospitalization	B-T058
,	O
dysentery	B-T038
,	O
fever	B-T033
,	O
and	O
the	O
weight	B-T033
loss	I-T033
were	O
assessed	O
in	O
each	O
group	O
.	O

It	O
was	O
concluded	O
that	O
there	O
was	O
no	O
significant	O
difference	O
in	O
both	O
groups	O
in	O
the	O
baseline	O
characteristics	O
.	O

The	O
mean	O
duration	O
of	O
dysentery	B-T038
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
mean	O
duration	O
of	O
fever	B-T033
has	O
been	O
significantly	O
reduced	O
in	O
the	O
synbiotic	B-T168
group	O
(	O
1	O
.	O
64	O
±	O
0	O
.	O
87	O
days	O
)	O
in	O
comparison	O
to	O
the	O
placebo	B-T103
group	O
(	O
2	O
.	O
13	O
±	O
0	O
.	O
94	O
days	O
)	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

Average	O
amount	O
of	O
weight	B-T033
loss	I-T033
was	O
significantly	O
lower	O
in	O
the	O
synbiotic	B-T168
group	O
in	O
comparison	O
to	O
that	O
in	O
the	O
placebo	B-T103
group	O
(	O
129	O
.	O
5	O
±	O
23	O
.	O
388	O
grams	O
and	O
278	O
±	O
28	O
.	O
385	O
grams	O
,	O
resp	O
.	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
duration	O
of	O
hospitalization	B-T058
in	O
both	O
groups	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
use	O
of	O
synbiotics	B-T168
as	O
an	O
adjuvant	B-T058
therapy	I-T058
to	O
the	O
standard	O
treatment	B-T058
of	O
dysentery	B-T038
significantly	O
reduces	O
the	O
duration	O
of	O
dysentery	B-T038
,	O
fever	B-T033
,	O
and	O
rate	B-T033
of	I-T033
weight	I-T033
losses	I-T033
.	O

The	O
trial	B-T062
is	O
registered	B-T058
with	O
IRCT201109267647N1	O
.	O

Effect	O
of	O
type	B-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
on	O
the	O
pharmacokinetics	O
and	O
transplacental	O
transfer	O
of	O
nifedipine	B-T103
in	O
hypertensive	B-T038
pregnant	B-T098
women	I-T098

Diabetes	B-T038
mellitus	I-T038
can	O
inhibit	O
cytochrome	B-T103
P450	I-T103
3A4	I-T103
,	O
an	O
enzyme	B-T103
responsible	O
for	O
the	O
metabolism	B-T038
of	O
nifedipine	B-T103
,	O
used	O
for	O
the	O
treatment	B-T058
of	O
hypertension	B-T038
in	O
pregnant	B-T098
women	I-T098
.	O

We	O
aimed	O
to	O
assess	O
the	O
effect	O
of	O
type	B-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
(	O
T2DM	B-T038
)	O
on	O
the	O
pharmacokinetics	O
,	O
placental	O
transfer	O
and	O
distribution	O
of	O
nifedipine	B-T103
in	O
amniotic	B-T031
fluid	I-T031
in	O
hypertensive	B-T038
pregnant	B-T098
women	I-T098
.	O

The	O
study	B-T062
was	O
conducted	O
in	O
12	O
hypertensive	B-T038
pregnant	B-T098
women	I-T098
[	O
control	O
group	O
(	O
CG	O
)	O
]	O
and	O
10	O
hypertensive	B-T038
pregnant	B-T098
women	I-T098
with	O
T2DM	B-T038
taking	O
slow	O
-	O
release	O
nifedipine	B-T103
(	O
20	O
mg	O
,	O
12	O
/	O
12	O
h	O
)	O
.	O

On	O
the	O
34th	O
week	O
of	O
gestation	B-T038
,	O
serial	O
blood	B-T031
samples	I-T031
were	O
collected	O
(	O
0	O
-	O
12	O
h	O
)	O
after	O
administration	B-T058
of	O
the	O
medication	B-T103
.	O

At	O
delivery	O
,	O
samples	B-T031
of	O
maternal	O
and	O
fetal	B-T031
blood	I-T031
and	O
amniotic	B-T031
fluid	I-T031
were	O
collected	O
for	O
determination	B-T058
of	O
nifedipine	B-T103
distribution	O
in	O
these	O
compartments	O
.	O

The	O
median	O
pharmacokinetic	O
parameters	O
of	O
CG	O
were	O
:	O
peak	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
26	O
.	O
41	O
ng	O
ml	O
(	O
-	O
1	O
)	O
,	O
time	O
to	O
reach	O
Cmax	O
(	O
tmax	O
)	O
1	O
.	O
79	O
h	O
,	O
area	O
under	O
the	O
plasma	O
concentration	O
vs	O
.	O

time	O
curve	O
from	O
0	O
-	O
12	O
h	O
(	O
AUC	O
0	O
-	O
12	O
)	O
235	O
.	O
99	O
ng	O
.	O
h	O
ml	O
(	O
-	O
1	O
)	O
,	O
half	O
-	O
life	O
(	O
t½	O
)	O
4	O
.	O
34	O
h	O
,	O
volume	O
of	O
distribution	O
divided	O
by	O
bioavailability	O
(	O
Vd	O
/	O
F	O
)	O
560	O
.	O
96	O
l	O
,	O
and	O
ClT	O
/	O
F	O
84	O
.	O
77	O
l	O
h	O
(	O
-	O
1	O
)	O
.	O

The	O
parameters	O
for	O
T2DM	B-T038
group	B-T098
were	O
:	O
Cmax	O
23	O
.	O
52	O
ng	O
ml	O
(	O
-	O
1	O
)	O
,	O
tmax	O
1	O
.	O
48	O
h	O
,	O
AUC	O
0	O
-	O
12	O
202	O
.	O
23	O
ng	O
.	O
h	O
ml	O
(	O
-	O
1	O
)	O
,	O
t½	O
5	O
.	O
00	O
h	O
,	O
Vd	O
/	O
F	O
609	O
.	O
40	O
l	O
,	O
and	O
apparent	O
total	O
clearance	O
(	O
ClT	O
/	O
F	O
)	O
98	O
.	O
94	O
l	O
h	O
(	O
-	O
1	O
)	O
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
of	O
nifedipine	B-T103
in	O
the	O
umbilical	B-T017
vein	I-T017
,	O
intervillous	B-T082
space	I-T082
and	O
amniotic	B-T031
fluid	I-T031
to	O
those	O
in	O
the	O
maternal	O
vein	O
for	O
CG	O
and	O
T2DM	B-T038
were	O
0	O
.	O
53	O
and	O
0	O
.	O
44	O
,	O
0	O
.	O
78	O
and	O
0	O
.	O
87	O
,	O
respectively	O
,	O
with	O
an	O
amniotic	B-T031
fluid	I-T031
/	O
maternal	O
plasma	B-T031
ratio	O
of	O
0	O
.	O
05	O
for	O
both	O
groups	B-T098
.	O

The	O
ratios	O
of	O
plasma	O
concentrations	O
in	O
the	O
umbilical	B-T017
artery	I-T017
to	O
those	O
in	O
the	O
umbilical	B-T017
vein	I-T017
were	O
0	O
.	O
82	O
for	O
CG	O
and	O
0	O
.	O
88	O
for	O
T2DM	B-T038
.	O

There	O
was	O
no	O
influence	O
of	O
T2DM	B-T038
on	O
the	O
pharmacokinetics	O
or	O
placental	O
transfer	O
of	O
nifedipine	B-T103
in	O
hypertensive	B-T038
women	B-T098
with	O
controlled	B-T033
diabetes	B-T038
.	O

Results	O
of	O
an	O
International	B-T062
Postmarketing	I-T062
Surveillance	I-T062
Study	I-T062
of	O
pl	B-T103
-	I-T103
VEGF165	I-T103
Safety	O
and	O
Efficacy	O
in	O
210	O
Patients	O
with	O
Peripheral	B-T038
Arterial	I-T038
Disease	I-T038

The	O
effective	O
treatment	B-T058
of	O
chronic	O
lower	B-T017
limb	I-T017
ischemia	B-T038
is	O
one	O
of	O
the	O
most	O
challenging	O
issues	O
confronting	O
vascular	B-T097
surgeons	I-T097
.	O

Current	O
pharmacological	O
therapies	B-T058
play	O
an	O
auxiliary	O
role	O
and	O
cannot	O
prevent	O
disease	B-T038
progression	I-T038
,	O
and	O
new	O
treatment	B-T058
methods	I-T058
are	O
needed	O
.	O

pl	B-T103
-	I-T103
VEGF165	I-T103
,	O
a	O
gene	B-T058
therapy	I-T058
drug	B-T103
,	O
was	O
approved	O
in	O
Russia	B-T082
for	O
the	O
treatment	B-T058
of	O
atherosclerotic	O
peripheral	B-T038
arterial	I-T038
disease	I-T038
(	O
PAD	B-T038
)	O
after	O
clinical	B-T062
studies	I-T062
in	O
2011	O
.	O

The	O
study	B-T062
drug	B-T103
is	O
an	O
original	O
gene	B-T103
construction	I-T103
in	O
which	O
pl	B-T103
-	I-T103
VEGF165	I-T103
1	O
.	O
2	O
mg	O
is	O
the	O
active	B-T103
substance	I-T103
.	O

This	O
postmarketing	B-T062
surveillance	I-T062
study	I-T062
was	O
undertaken	O
to	O
evaluate	O
the	O
safety	O
(	O
identification	O
of	O
uncommon	O
side	B-T038
effects	I-T038
)	O
and	O
efficacy	O
of	O
gene	B-T058
therapy	I-T058
in	O
patients	O
in	O
routine	O
clinical	O
practice	O
.	O

In	O
total	O
,	O
210	O
patients	O
with	O
stage	O
II	O
-	O
III	O
chronic	O
limb	B-T017
ischemia	B-T038
(	O
according	O
to	O
the	O
Fontaine	B-T170
classification	I-T170
modified	O
by	O
AV	O
Pokrovsky	O
)	O
in	O
33	O
healthcare	B-T092
facilities	I-T092
in	O
Russia	B-T082
and	O
the	O
Ukraine	B-T082
were	O
enrolled	O
in	O
the	O
study	B-T062
.	O

The	O
control	O
group	O
(	O
n	O
=	O
60	O
)	O
received	O
conservative	B-T058
therapy	I-T058
without	O
prostaglandins	B-T103
and	O
prostacyclins	B-T103
,	O
and	O
the	O
treatment	B-T098
group	I-T098
(	O
n	O
=	O
150	O
)	O
received	O
treatment	B-T058
with	O
pl	B-T103
-	I-T103
VEGF165	I-T103
as	O
two	O
intramuscular	O
injections	O
for	O
a	O
total	O
dose	O
of	O
2	O
.	O
4	O
mg	O
.	O

Pain	B-T033
-	I-T033
free	I-T033
walking	I-T033
distance	I-T033
(	O
PWD	B-T033
)	O
(	O
the	O
primary	O
efficacy	O
criterion	O
for	O
Fontaine	B-T170
stages	O
II	O
-	O
III	O
)	O
,	O
blood	B-T033
flow	I-T033
linear	I-T033
velocity	I-T033
(	O
BFLV	B-T033
)	O
,	O
and	O
ankle	B-T201
-	I-T201
brachial	I-T201
index	I-T201
(	O
ABI	B-T201
)	O
were	O
monitored	O
for	O
6	O
months	O
.	O

The	O
safety	O
of	O
pl	B-T103
-	I-T103
VEGF165	I-T103
gene	B-T062
transfer	I-T062
in	O
terms	O
of	O
the	O
trial	B-T062
protocol	I-T062
was	O
initially	O
evaluated	O
6	O
months	O
after	O
the	O
start	O
of	O
the	O
study	O
;	O
adverse	B-T038
events	I-T038
(	O
AEs	B-T038
)	O
and	O
serious	B-T038
adverse	I-T038
events	I-T038
(	O
SAEs	B-T038
)	O
were	O
recorded	O
during	O
both	O
routine	O
visits	B-T058
and	O
unscheduled	O
requests	O
for	O
medical	O
care	O
.	O

Overall	O
,	O
PWD	B-T033
increased	O
by	O
177	O
%	O
,	O
from	O
100	O
.	O
3	O
±	O
6	O
.	O
9	O
to	O
277	O
.	O
1	O
±	O
16	O
.	O
2	O
m	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
,	O
in	O
the	O
treatment	B-T098
group	I-T098
,	O
whereas	O
the	O
mean	O
value	O
was	O
unchanged	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0	O
.	O
218	O
)	O
.	O

Both	O
BFLV	B-T033
and	O
ABI	B-T201
values	I-T201
increased	O
by	O
24	O
%	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
in	O
the	O
treatment	B-T098
group	I-T098
but	O
decreased	O
in	O
the	O
control	O
group	O
.	O

The	O
greatest	O
therapeutic	B-T201
effect	I-T201
was	O
observed	O
for	O
stage	O
III	O
disease	B-T038
:	O
PWD	B-T033
increased	O
by	O
683	O
%	O
(	O
p	O
=	O
0	O
.	O
0001	O
)	O
.	O

No	B-T033
angiogenic	B-T058
therapy	I-T058
-	O
related	O
AEs	B-T038
or	O
side	B-T038
effects	I-T038
were	O
recorded	O
,	O
and	O
target	O
limb	B-T058
salvage	I-T058
was	O
96	O
and	O
97	O
%	O
in	O
the	O
treatment	B-T098
and	O
control	O
groups	O
,	O
respectively	O
.	O

The	O
results	O
obtained	O
in	O
this	O
study	B-T062
are	O
not	O
significantly	O
different	O
from	O
those	O
observed	O
in	O
the	O
phase	B-T062
IIb	I-T062
/	O
III	B-T062
registration	O
clinical	B-T062
study	I-T062
completed	O
in	O
2011	O
.	O

pl	B-T103
-	I-T103
VEGF165	I-T103
intramuscular	B-T082
gene	B-T062
transfer	I-T062
is	O
an	O
effective	O
treatment	B-T058
for	O
moderate	O
to	O
severe	O
claudication	B-T038
due	O
to	O
chronic	O
lower	B-T017
limb	I-T017
ischemia	B-T038
in	O
routine	O
clinical	O
practice	O
.	O

ClinicalTrials	O
.	O
gov	O
identifier	O
:	O
NCT02369809	O
.	O

Psychological	B-T038
factors	I-T038
associated	O
with	O
NAFLD	B-T038
/	O
NASH	B-T038
:	O
a	O
systematic	B-T170
review	I-T170

Nonalcoholic	B-T038
fatty	I-T038
liver	I-T038
disease	I-T038
(	O
NAFLD	B-T038
)	O
represents	O
one	O
of	O
the	O
most	O
common	O
chronic	B-T038
liver	I-T038
diseases	I-T038
worldwide	O
.	O

So	O
far	O
,	O
the	O
pathogenesis	B-T038
of	O
NAFLD	B-T038
and	O
its	O
more	O
severe	O
variant	O
nonalcoholic	B-T038
steatohepatitis	I-T038
(	O
NASH	B-T038
)	O
is	O
yet	O
unclear	O
,	O
with	O
many	O
mechanisms	O
being	O
proposed	O
as	O
possible	O
causes	O
.	O

This	O
article	O
aims	O
to	O
review	O
the	O
psychological	B-T038
factors	I-T038
associated	O
with	O
NAFLD	B-T038
/	O
NASH	B-T038
.	O

Three	O
main	O
categories	O
of	O
factors	O
have	O
been	O
investigated	O
:	O
emotional	B-T033
,	O
cognitive	O
and	O
behavioral	O
.	O

Five	O
electronic	O
databases	O
were	O
searched	O
,	O
limited	O
to	O
studies	O
published	O
in	O
the	O
English	O
language	O
,	O
during	O
the	O
period	O
2005	O
-	O
2015	O
:	O
PubMed	B-T170
,	O
Thomson	B-T170
ISI	I-T170
-	I-T170
Web	I-T170
of	I-T170
Science	I-T170
,	O
Scopus	B-T170
,	O
ProQuest	B-T170
,	O
and	O
ScienceDirect	B-T170
.	O

Results	O
indicated	O
the	O
most	O
relevant	O
emotional	B-T033
factors	O
to	O
be	O
depression	B-T038
and	O
anxiety	B-T033
.	O

The	O
areas	O
of	O
investigation	O
for	O
cognitive	B-T038
functioning	I-T038
concern	O
those	O
contents	O
and	O
processes	O
related	O
to	O
the	O
ability	O
to	O
initiate	O
and	O
maintain	O
lifestyle	O
changes	O
.	O

The	O
most	O
important	O
behavioral	O
factors	O
identified	O
are	O
physical	O
activity	O
,	O
nutrition	B-T038
/	O
food	B-T038
intake	I-T038
and	O
substance	O
consumption	B-T038
:	O
coffee	B-T168
,	O
alcohol	B-T168
,	O
cigarettes	O
.	O

Some	O
of	O
the	O
factors	O
identified	O
act	O
as	O
protective	O
factors	O
,	O
other	O
as	O
vulnerability	B-T033
factors	I-T033
.	O

NAFLD	B-T038
/	O
NASH	B-T038
may	O
be	O
considered	O
a	O
cognitive	B-T038
-	I-T038
behavioral	I-T038
disease	I-T038
,	O
the	O
most	O
effective	O
management	B-T058
being	O
lifestyle	O
changes	O
,	O
with	O
emphasis	O
on	O
diet	B-T168
and	O
exercise	O
.	O

An	O
approach	O
to	O
functionally	O
relevant	O
clustering	O
of	O
the	O
protein	B-T103
universe	I-T103
:	O
Active	O
site	O
profile	O
-	O
based	O
clustering	O
of	O
protein	B-T103
structures	I-T103
and	O
sequences	B-T082

Protein	B-T038
function	I-T038
identification	O
remains	O
a	O
significant	O
problem	O
.	O

Solving	O
this	O
problem	O
at	O
the	O
molecular	O
functional	O
level	O
would	O
allow	O
mechanistic	O
determinant	O
identification	O
-	O
amino	B-T103
acids	I-T103
that	O
distinguish	O
details	O
between	O
functional	O
families	O
within	O
a	O
superfamily	O
.	O

Active	B-T062
site	I-T062
profiling	I-T062
was	O
developed	O
to	O
identify	O
mechanistic	O
determinants	O
.	O

DASP	B-T170
and	O
DASP2	B-T170
were	O
developed	O
as	O
tools	O
to	O
search	O
sequence	B-T170
databases	I-T170
using	O
active	B-T062
site	I-T062
profiling	I-T062
.	O

Here	O
,	O
TuLIP	B-T170
(	O
Two	B-T170
-	I-T170
Level	I-T170
Iterative	I-T170
clustering	I-T170
Process	I-T170
)	O
is	O
introduced	O
as	O
an	O
iterative	O
,	O
divisive	O
clustering	O
process	O
that	O
utilizes	O
active	B-T062
site	I-T062
profiling	I-T062
to	O
separate	O
structurally	O
characterized	O
superfamily	O
members	O
into	O
functionally	O
relevant	O
clusters	O
.	O

Underlying	O
TuLIP	B-T170
is	O
the	O
observation	O
that	O
functionally	O
relevant	O
families	O
(	O
curated	O
by	O
Structure	B-T170
-	I-T170
Function	I-T170
Linkage	I-T170
Database	I-T170
,	O
SFLD	B-T170
)	O
self	O
-	O
identify	O
in	O
DASP2	B-T170
searches	O
;	O
clusters	O
containing	O
multiple	O
functional	O
families	O
do	O
not	O
.	O

Each	O
TuLIP	B-T170
iteration	O
produces	O
candidate	O
clusters	O
,	O
each	O
evaluated	O
to	O
determine	O
if	O
it	O
self	O
-	O
identifies	O
using	O
DASP2	B-T170
.	O

If	O
so	O
,	O
it	O
is	O
deemed	O
a	O
functionally	O
relevant	O
group	O
.	O

Divisive	O
clustering	O
continues	O
until	O
each	O
structure	O
is	O
either	O
a	O
functionally	O
relevant	O
group	O
member	O
or	O
a	O
singlet	O
.	O

TuLIP	B-T170
is	O
validated	O
on	O
enolase	B-T103
and	O
glutathione	B-T103
transferase	I-T103
structures	O
,	O
superfamilies	O
well	O
-	O
curated	O
by	O
SFLD	B-T170
.	O

Correlation	O
is	O
strong	O
;	O
small	O
numbers	O
of	O
structures	B-T082
prevent	O
statistically	O
significant	O
analysis	O
.	O

TuLIP	B-T170
-	O
identified	O
enolase	B-T103
clusters	O
are	O
used	O
in	O
DASP2	B-T170
GenBank	I-T170
searches	O
to	O
identify	O
sequences	B-T082
sharing	O
functional	O
site	O
features	O
.	O

Analysis	O
shows	O
a	O
true	O
positive	O
rate	O
of	O
96	O
%	O
,	O
false	O
negative	O
rate	O
of	O
4	O
%	O
,	O
and	O
maximum	O
false	O
positive	O
rate	O
of	O
4	O
%	O
.	O

F	O
-	O
measure	O
and	O
performance	B-T062
analysis	I-T062
on	O
the	O
enolase	B-T103
search	O
results	O
and	O
comparison	O
to	O
GEMMA	B-T170
and	O
SCI	B-T170
-	I-T170
PHY	I-T170
demonstrate	O
that	O
TuLIP	B-T170
avoids	O
the	O
over	O
-	O
division	O
problem	O
of	O
these	O
methods	O
.	O

Mechanistic	O
determinants	O
for	O
enolase	B-T103
families	I-T103
are	O
evaluated	O
and	O
shown	O
to	O
correlate	O
well	O
with	O
literature	B-T170
results	O
.	O

Early	O
high	O
school	O
engagement	O
in	O
students	B-T098
with	O
attention	B-T038
/	I-T038
deficit	I-T038
hyperactivity	I-T038
disorder	I-T038

Students	B-T098
with	O
attention	B-T038
/	I-T038
deficit	I-T038
hyperactivity	I-T038
disorder	I-T038
(	O
ADHD	B-T038
)	O
continue	O
to	O
languish	O
behind	O
their	O
peers	B-T098
with	O
regard	O
to	O
academic	O
achievement	O
and	O
education	B-T033
attainment	I-T033
.	O

School	O
engagement	O
is	O
potentially	O
modifiable	O
,	O
and	O
targeting	O
engagement	O
may	O
be	O
a	O
means	O
to	O
improve	O
education	O
outcomes	O
.	O

To	O
investigate	O
school	O
engagement	O
for	O
students	B-T098
with	O
ADHD	B-T038
during	O
the	O
crucial	O
high	O
school	O
transition	O
period	O
and	O
to	O
identify	O
factors	O
associated	O
with	O
low	B-T033
school	I-T033
engagement	I-T033
.	O

Participants	B-T098
are	O
adolescents	O
(	O
12	O
-	O
15	O
years	O
)	O
in	O
the	O
first	O
and	O
third	O
year	O
of	O
high	B-T092
school	I-T092
with	O
diagnosed	B-T062
ADHD	B-T038
(	O
n	O
=	O
130	O
)	O
.	O

Participants	B-T098
were	O
recruited	O
from	O
21	O
paediatric	B-T091
practices	O
.	O

Cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
assessing	O
school	O
engagement	O
.	O

Data	O
were	O
collected	O
through	O
direct	O
assessment	B-T058
and	O
child	O
,	O
parent	O
,	O
and	O
teacher	B-T097
surveys	B-T170
.	O

School	O
engagement	O
is	O
measured	O
as	O
student	O
attitudes	O
to	O
school	B-T092
(	O
cognitive	B-T038
and	O
emotional	B-T038
)	O
and	O
suspension	O
rates	O
(	O
behavioural	O
)	O
.	O

Multivariable	B-T170
regression	I-T170
analyses	I-T170
examined	O
student	B-T098
,	O
family	O
,	O
and	O
school	O
factors	O
affecting	O
engagement	O
.	O

In	O
comparison	O
with	O
state	O
data	O
,	O
students	B-T098
with	O
ADHD	B-T038
in	O
the	O
first	O
year	O
of	O
high	B-T092
school	I-T092
were	O
less	O
motivated	O
(	O
p	O
<	O
.	O
01	O
)	O
and	O
less	O
connected	O
to	O
peers	B-T098
(	O
p	O
<	O
.	O
01	O
)	O
.	O

Overall	O
,	O
there	O
was	O
no	O
discordance	O
in	O
third	O
year	O
attitudes	B-T038
.	O

There	O
were	O
high	B-T033
rates	I-T033
of	I-T033
suspension	I-T033
in	O
both	O
years	O
in	O
comparison	O
to	O
state	O
-	O
wide	O
suspensions	O
(	O
21	O
%	O
vs	O
.	O

6	O
%	O
,	O
p	O
<	O
.	O
01	O
)	O
.	O

Explanatory	O
factors	O
for	O
poor	O
attitudes	B-T038
include	O
adolescent	O
depression	B-T038
,	O
poor	O
adolescent	O
supervision	B-T058
,	O
and	O
devaluing	B-T038
education	O
.	O

Conduct	O
problems	O
and	O
increased	O
hyperactivity	B-T038
were	O
related	O
to	O
increased	B-T033
likelihood	I-T033
of	I-T033
being	I-T033
suspended	I-T033
,	O
whilst	O
higher	O
cognitive	B-T038
ability	I-T038
,	O
family	O
socio	O
-	O
economic	O
status	O
,	O
and	O
independent	O
schools	B-T092
reduced	O
risk	O
.	O

Potentially	O
modifiable	O
individual	B-T098
and	O
family	O
factors	O
including	O
adolescent	O
depression	B-T038
,	O
behavioural	B-T038
problems	I-T038
,	O
education	O
values	O
,	O
and	O
family	O
supervision	B-T058
could	O
be	O
targeted	O
to	O
better	O
manage	O
the	O
high	O
school	O
transition	O
for	O
students	B-T098
with	O
ADHD	B-T038
.	O

Proliferation	B-T038
-	O
Related	O
Activity	O
in	O
Endothelial	B-T017
Cells	I-T017
Is	O
Enhanced	O
by	O
Micropower	O
Plasma	B-T103

Nonthermal	B-T058
plasma	I-T058
has	O
received	O
a	O
lot	O
of	O
attention	O
as	O
a	O
medical	O
treatment	O
technique	O
in	O
recent	O
years	O
.	O

It	O
can	O
easily	O
create	O
various	O
reactive	B-T103
chemical	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
and	O
is	O
harmless	O
to	O
living	B-T204
body	I-T204
.	O

Although	O
plasma	B-T103
at	O
gas	B-T103
-	O
liquid	O
interface	O
has	O
a	O
potential	O
for	O
a	O
biomedical	B-T058
application	I-T058
,	O
the	O
interactions	O
between	O
the	O
gas	B-T103
-	O
liquid	O
plasma	B-T103
and	O
living	B-T017
cells	I-T017
remain	O
unclear	O
.	O

Here	O
,	O
we	O
show	O
characteristics	O
of	O
a	O
micropower	O
plasma	B-T103
with	O
0	O
.	O
018	O
W	O
of	O
the	O
power	O
input	O
,	O
generated	O
at	O
gas	B-T103
-	O
liquid	O
interface	O
.	O

We	O
also	O
provide	O
the	O
evidence	O
of	O
plasma	B-T103
-	O
induced	O
enhancement	O
in	O
proliferation	B-T038
activity	O
of	O
endothelial	B-T017
cells	I-T017
.	O

The	O
plasma	B-T103
produced	O
H2O2	B-T103
,	O
HNO2	B-T103
,	O
and	O
HNO3	B-T103
in	O
phosphate	B-T103
buffered	I-T103
saline	O
containing	O
Mg	B-T103
(	I-T103
+	I-T103
+	I-T103
)	I-T103
and	O
Ca	B-T103
(	I-T103
+	I-T103
+	I-T103
)	I-T103
(	O
PBS	B-T103
(	O
+	O
)	O
)	O
,	O
and	O
their	O
concentration	O
increased	O
linearly	O
during	O
600	O
-	O
second	O
discharge	O
.	O

The	O
value	O
of	O
pH	O
in	O
PBS	B-T103
(	O
+	O
)	O
against	O
the	O
plasma	B-T103
discharge	O
time	O
was	O
stable	O
at	O
about	O
7	O
.	O
0	O
.	O

Temperature	O
in	O
PBS	B-T103
(	O
+	O
)	O
rose	O
monotonically	O
,	O
and	O
its	O
rise	O
was	O
up	O
to	O
0	O
.	O
8°C	O
at	O
the	O
bottom	O
of	O
a	O
cell	B-T017
-	I-T017
cultured	I-T017
dish	O
by	O
the	O
plasma	B-T103
discharge	O
for	O
600	O
s	O
.	O

Short	O
-	O
time	O
treatment	O
of	O
the	O
plasma	B-T103
enhanced	O
proliferation	B-T038
activity	O
of	O
endothelial	B-T017
cells	I-T017
.	O

In	O
contrast	O
,	O
the	O
treatment	O
of	O
H2O2	B-T103
does	O
not	O
enhance	O
the	O
cell	B-T038
proliferation	I-T038
.	O

Thus	O
,	O
the	O
ROS	B-T103
production	O
and	O
the	O
nuclear	O
factor	O
-	O
kappa	O
B	O
(	O
NF	O
-	O
κB	O
)	O
activation	O
due	O
to	O
the	O
plasma	B-T103
treatment	O
might	O
be	O
related	O
to	O
enhancement	O
of	O
the	O
cell	B-T038
proliferation	I-T038
.	O

Our	O
results	O
may	O
potentially	O
provide	O
the	O
basis	O
for	O
developing	O
the	O
biomedical	B-T058
applications	I-T058
using	O
the	O
gas	B-T103
-	O
liquid	O
plasma	B-T103
.	O

pH	O
-	O
Dependent	O
Transmembrane	B-T038
Activity	I-T038
of	O
Peptide	B-T103
-	O
Functionalized	O
Gold	B-T103
Nanostars	I-T103
for	O
Computed	B-T058
Tomography	I-T058
/	O
Photoacoustic	B-T058
Imaging	I-T058
and	O
Photothermal	B-T058
Therapy	I-T058

Progress	O
in	O
multifunctional	O
nanomaterials	O
for	O
tumor	B-T058
therapy	I-T058
mostly	O
depends	O
on	O
the	O
development	O
of	O
tumor	B-T038
-	O
targeting	O
delivery	B-T058
strategies	I-T058
.	O

One	O
approach	O
is	O
to	O
explore	O
a	O
pH	O
-	O
responsive	O
strategy	O
to	O
target	O
the	O
slightly	O
acidic	O
solid	O
tumor	O
microenvironment	O
.	O

A	O
novel	O
class	O
of	O
pH	B-T103
(	I-T103
low	I-T103
)	I-T103
insertion	I-T103
peptides	I-T103
(	O
pHLIPs	B-T103
)	O
with	O
pH	O
-	O
dependent	O
transmembrane	B-T038
activity	I-T038
can	O
fold	B-T082
and	O
rapidly	O
insert	O
into	O
the	O
lipid	B-T017
bilayer	I-T017
of	O
tumor	B-T017
cells	I-T017
triggered	O
by	O
acidity	O
,	O
facilitating	O
the	O
cellular	O
internalization	O
of	O
nanomaterials	O
synchronously	O
.	O

Here	O
,	O
we	O
innovatively	O
decorated	O
gold	B-T103
nanostars	I-T103
(	O
GNSs	B-T103
)	O
with	O
pHLIPs	B-T103
(	O
GNS	B-T103
-	O
pHLIP	B-T103
)	O
to	O
improve	O
their	O
targeting	O
ability	O
and	O
photothermal	B-T058
therapeutic	I-T058
(	O
PTT	B-T058
)	O
efficiency	O
.	O

The	O
obtained	O
GNS	B-T103
-	O
pHLIP	B-T103
exhibited	O
the	O
excellent	O
characteristics	O
of	O
uniform	O
size	B-T082
and	O
good	O
biocompatibility	O
.	O

As	O
compared	O
to	O
GNS	B-T103
-	O
mPEG	B-T103
,	O
the	O
cellular	O
internalization	O
of	O
GNS	B-T103
-	O
pHLIP	B-T103
was	O
1	O
-	O
fold	O
higher	O
after	O
a	O
2	O
h	O
incubation	O
with	O
cells	B-T017
in	O
media	O
at	O
pH	O
6	O
.	O
4	O
than	O
at	O
pH	O
7	O
.	O
4	O
.	O

Moreover	O
,	O
the	O
tumor	B-T038
accumulation	B-T033
of	O
the	O
GNS	B-T103
-	O
pHLIP	B-T103
was	O
3	O
-	O
fold	O
higher	O
than	O
that	O
of	O
GNS	B-T103
-	O
mPEG	B-T103
after	O
intravenous	O
injection	O
into	O
MCF	B-T017
-	I-T017
7	I-T017
breast	B-T038
tumor	I-T038
animal	B-T038
models	I-T038
for	O
24	O
h	O
.	O

Furthermore	O
,	O
GNS	B-T103
-	O
pHLIP	B-T103
exhibited	O
stronger	O
signals	O
than	O
the	O
GNS	B-T103
-	O
mPEG	B-T103
through	O
computed	B-T058
tomography	I-T058
(	O
CT	B-T058
)	O
and	O
photoacoustic	B-T058
(	I-T058
PA	I-T058
)	I-T058
imaging	I-T058
.	O

Simultaneously	O
,	O
the	O
desirable	O
targeting	O
efficiency	O
significantly	O
improved	O
the	O
PTT	B-T058
efficacy	O
to	O
tumors	B-T038
,	O
with	O
low	O
side	B-T038
effects	I-T038
on	O
normal	O
tissues	B-T017
.	O

The	O
results	O
clearly	O
demonstrate	O
that	O
the	O
GNS	B-T103
-	O
pHLIP	B-T103
successfully	O
took	O
advantage	O
of	O
the	O
tumor	B-T038
-	O
targeting	O
ability	O
of	O
pHLIPs	B-T103
and	O
the	O
good	O
characteristics	O
of	O
GNS	B-T103
s	I-T103
,	O
which	O
may	O
contribute	O
to	O
the	O
study	O
of	O
tumor	B-T038
imaging	B-T058
and	O
therapy	B-T058
.	O

Stepwise	O
cyclopropanation	B-T038
on	O
the	O
polycyclopropanated	B-T103
polyketide	I-T103
formation	O
in	O
jawsamycin	B-T103
biosynthesis	O

Jawsamycin	B-T103
is	O
a	O
polyketide	B-T103
-	O
nucleoside	B-T103
hybrid	O
with	O
a	O
unique	O
polycyclopropane	B-T103
moiety	O
on	O
a	O
single	O
polyketide	B-T103
chain	I-T103
.	O

The	O
unexpected	O
isolation	O
of	O
cyclopropane	B-T103
deficient	O
jawsamycin	B-T103
analogs	O
allowed	O
us	O
to	O
propose	O
a	O
stepwise	O
cyclopropanation	B-T038
mechanism	O
for	O
the	O
enzymatic	B-T103
synthesis	O
of	O
this	O
polyketide	B-T103
.	O

The	O
concise	O
timing	O
of	O
the	O
cyclopropanation	B-T038
could	O
be	O
regulated	O
by	O
a	O
delicate	O
balance	O
between	O
reaction	O
rates	O
of	O
the	O
condensation	O
and	O
cyclopropanation	B-T038
reactions	I-T038
.	O

Initial	O
experience	O
with	O
laparoscopic	B-T058
radical	I-T058
antegrade	I-T058
modular	I-T058
pancreatosplenectomy	I-T058
for	O
left	B-T038
-	I-T038
sided	I-T038
pancreatic	I-T038
cancer	I-T038
in	O
a	O
single	O
institution	B-T092
:	O
technical	O
aspects	O
and	O
oncological	B-T033
outcomes	I-T033

Laparoscopic	B-T058
surgery	I-T058
has	O
been	O
performed	O
less	O
frequently	O
in	O
the	O
era	O
of	O
pancreatic	B-T038
cancer	I-T038
due	O
to	O
technical	O
difficulties	O
and	O
concerns	O
about	O
oncological	B-T038
safety	O
.	O

Radical	O
antegrade	O
modular	O
pancreatosplenectomy	O
(	O
RAMPS	O
)	O
is	O
expected	O
to	O
be	O
helpful	O
to	O
obtain	O
a	O
negative	B-T033
margin	I-T033
during	O
radical	B-T058
lymph	I-T058
node	I-T058
dissection	I-T058
.	O

We	O
hypothesized	O
that	O
it	O
would	O
also	O
be	O
favorable	O
as	O
a	O
laparoscopic	B-T082
application	I-T082
due	O
to	O
unique	O
features	O
.	O

Fifteen	O
laparoscopic	B-T058
RAMPS	O
for	O
well	O
-	O
selected	O
patients	O
with	O
left	B-T038
-	I-T038
sided	I-T038
pancreatic	I-T038
cancer	I-T038
were	O
performed	O
from	O
July	O
2011	O
to	O
April	O
2016	O
.	O

Five	O
trocars	B-T074
were	O
usually	O
used	O
,	O
and	O
the	O
operative	B-T058
procedures	I-T058
and	O
range	B-T058
of	I-T058
dissection	I-T058
were	O
similar	O
to	O
or	O
the	O
same	O
as	O
those	O
of	O
open	O
RAMPS	O
described	O
by	O
Strasberg	O
.	O

All	O
medical	O
records	O
and	O
follow	B-T170
-	I-T170
up	I-T170
data	I-T170
were	O
reviewed	O
and	O
analyzed	O
.	O

All	O
patients	O
had	O
pancreatic	B-T038
ductal	I-T038
adenocarcinoma	I-T038
.	O

Mean	O
operative	O
time	O
was	O
219	O
.	O
3	O
±	O
53	O
.	O
8	O
min	O
,	O
and	O
estimated	B-T033
blood	I-T033
loss	I-T033
was	O
250	O
±	O
70	O
ml	O
.	O

The	O
length	O
of	O
postoperative	O
hospital	O
stay	O
was	O
6	O
.	O
1	O
±	O
1	O
.	O
2	O
days	O
,	O
and	O
postoperative	B-T038
morbidities	O
developed	O
in	O
two	O
patients	O
(	O
13	O
.	O
3	O
%	O
)	O
with	O
urinary	B-T033
retention	I-T033
.	O

The	O
median	O
number	O
of	O
retrieved	O
lymph	B-T017
nodes	I-T017
was	O
18	O
.	O
1	O
±	O
6	O
.	O
2	O
and	O
all	O
had	O
negative	B-T033
margins	I-T033
.	O

Median	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
46	O
.	O
0	O
months	O
,	O
and	O
the	O
3	O
-	O
year	O
disease	O
free	O
survival	O
and	O
overall	O
survival	O
rates	O
were	O
56	O
.	O
3	O
%	O
and	O
74	O
.	O
1	O
%	O
,	O
respectively	O
.	O

Our	O
early	O
experience	O
with	O
laparoscopic	B-T058
RAMPS	O
achieved	O
feasible	O
perioperative	O
results	O
accompanied	O
by	O
acceptable	O
survival	O
outcomes	O
.	O

Laparoscopic	B-T058
RAMPS	O
could	O
be	O
a	O
safe	O
and	O
oncologically	B-T038
feasible	O
procedure	O
in	O
well	O
-	O
selected	O
patients	O
with	O
left	B-T038
-	I-T038
sided	I-T038
pancreatic	I-T038
cancer	I-T038
.	O

Individual	B-T098
classification	B-T170
of	O
strong	O
risk	O
attitudes	B-T038
:	O
An	O
application	O
across	O
lottery	O
types	O
and	O
age	O
groups	O

Empirical	O
evaluations	O
of	O
risk	O
attitudes	B-T038
often	O
rely	O
on	O
a	O
weak	O
definition	B-T170
of	O
risk	O
that	O
concerns	O
preferences	O
towards	O
risky	O
and	O
riskless	O
options	O
(	O
e	O
.	O
g	O
.	O
,	O
a	O
lottery	O
vs	O
.	O

a	O
sure	O
outcome	O
)	O
.	O

A	O
large	O
body	O
of	O
work	O
has	O
shown	O
that	O
individuals	B-T098
tend	O
to	O
be	O
weak	O
risk	O
averse	O
in	O
choice	O
contexts	O
involving	O
risky	O
and	O
riskless	O
gains	O
but	O
weak	O
risk	O
seeking	O
in	O
contexts	O
involving	O
losses	O
,	O
a	O
phenomenon	O
known	O
as	O
the	O
reflection	O
effect	O
.	O

Recent	O
attempts	O
to	O
evaluate	O
age	O
differences	O
in	O
risk	O
attitudes	B-T038
have	O
relied	O
on	O
this	O
weak	O
definition	B-T170
,	O
testing	O
whether	O
the	O
reflection	O
effect	O
increases	O
or	O
diminishes	O
as	O
we	O
grow	O
older	O
.	O

The	O
present	O
work	O
argues	O
that	O
weak	O
risk	O
attitudes	B-T038
have	O
limited	O
generalizability	O
and	O
proposes	O
the	O
use	O
of	O
a	O
strong	O
definition	B-T170
of	O
risk	O
that	O
is	O
concerned	O
with	O
preferences	O
towards	O
options	O
with	O
the	O
same	O
expected	O
value	O
but	O
different	O
degrees	O
of	O
risk	O
(	O
i	O
.	O
e	O
.	O
,	O
outcome	O
variance	O
)	O
.	O

A	O
reanalysis	B-T062
of	O
previously	O
-	O
published	O
data	O
and	O
the	O
results	O
from	O
a	O
new	O
study	O
show	O
that	O
only	O
a	O
minority	O
of	O
individuals	B-T098
manifests	O
the	O
reflection	O
effect	O
under	O
a	O
strong	O
definition	B-T170
of	O
risk	O
,	O
and	O
that	O
,	O
when	O
facing	O
certain	O
lottery	O
-	O
pair	O
types	O
,	O
older	B-T098
adults	I-T098
appear	O
to	O
be	O
more	O
risk	O
seeking	O
than	O
younger	O
adults	O
.	O

Treating	O
the	O
binge	B-T038
or	O
the	O
(	B-T017
fat	I-T017
)	I-T017
body	I-T017
?	O
Representations	O
of	O
fatness	B-T033
in	O
a	O
gold	O
standard	O
psychological	O
treatment	O
manual	O
for	O
binge	B-T038
eating	I-T038
disorder	I-T038

This	O
article	O
reports	B-T058
the	O
results	B-T033
of	O
a	O
Foucauldian	B-T204
-	O
informed	O
discourse	O
analysis	O
exploring	O
representations	O
of	O
fatness	B-T033
embedded	O
within	O
an	O
empirically	O
based	O
psychological	O
treatment	O
manual	O
for	O
binge	B-T038
eating	I-T038
disorder	I-T038
,	O
a	O
condition	O
characterized	O
by	O
overvaluation	O
of	O
weight	O
and	O
shape	O
.	O

Analyses	B-T062
indicate	B-T033
that	O
the	O
manual	B-T170
prioritizes	O
weight	B-T033
loss	I-T033
with	O
relatively	O
less	O
emphasis	O
placed	O
on	O
treating	O
the	O
diagnostic	O
symptoms	B-T033
and	O
underlying	O
mechanisms	O
of	O
binge	B-T038
eating	I-T038
disorder	I-T038
.	O

We	O
raise	O
critical	O
concerns	O
about	O
these	O
observations	B-T062
and	O
link	O
our	O
findings	B-T033
to	O
mainstream	O
psychology	B-T091
'	I-T091
s	I-T091
adoption	O
of	O
the	O
medical	O
framing	O
of	O
fatness	B-T033
as	O
obesity	B-T038
within	O
the	O
"	O
gold	O
standard	O
"	O
approach	O
to	O
intervention	B-T058
.	O

We	O
recommend	O
that	O
psychology	B-T091
as	O
a	O
discipline	B-T058
abandons	O
the	O
weight	B-T033
loss	I-T033
imperative	O
associated	O
with	O
binge	B-T038
eating	I-T038
disorder	I-T038
and	O
fat	B-T017
bodies	I-T017
.	O

We	O
recommend	O
that	O
practitioners	B-T097
locate	O
the	O
problem	B-T033
of	O
fat	B-T038
shame	I-T038
in	O
society	B-T092
as	O
opposed	O
to	O
the	O
individual	B-T098
person	O
'	O
s	O
body	B-T204
and	O
provide	O
individuals	B-T098
with	O
tools	O
to	O
identify	O
and	O
resist	O
fat	B-T033
stigma	I-T033
and	O
oppression	O
,	O
rather	O
than	O
provide	O
them	O
with	O
tools	O
to	O
reshape	O
their	O
bodies	B-T204
.	O

High	O
Diversity	O
of	O
Planctomycetes	B-T007
in	O
Soils	O
of	O
Two	O
Lichen	B-T204
-	O
Dominated	O
Sub	B-T082
-	I-T082
Arctic	I-T082
Ecosystems	O
of	O
Northwestern	B-T082
Siberia	B-T082

A	O
wide	O
variety	O
of	O
terrestrial	B-T082
ecosystems	O
in	O
tundra	B-T082
have	O
a	O
ground	O
vegetation	O
cover	O
composed	O
of	O
reindeer	O
lichens	B-T204
(	O
genera	B-T170
Cladonia	B-T204
and	O
Cetraria	B-T204
)	O
.	O

The	O
microbial	O
communities	O
of	O
two	O
lichen	B-T204
-	O
dominated	O
ecosystems	O
typical	O
of	O
the	O
sub	B-T082
-	I-T082
arctic	I-T082
zone	I-T082
of	O
northwestern	B-T082
Siberia	B-T082
,	O
that	O
is	O
a	O
forested	O
tundra	B-T082
soil	O
and	O
a	O
shallow	B-T082
acidic	I-T082
peatland	I-T082
,	O
were	O
examined	O
in	O
our	O
study	B-T062
.	O

As	O
revealed	O
by	O
molecular	O
analyses	O
,	O
soil	O
and	O
peat	O
layers	O
just	O
beneath	O
the	O
lichen	B-T204
cover	O
were	O
abundantly	O
colonized	B-T033
by	O
bacteria	B-T007
from	O
the	O
phylum	B-T170
Planctomycetes	B-T007
.	O

Highest	O
abundance	O
of	O
planctomycetes	B-T007
detected	O
by	O
fluorescence	O
in	B-T062
situ	I-T062
hybridization	I-T062
was	O
in	O
the	O
range	O
2	O
.	O
2	O
-	O
2	O
.	O
7	O
×	O
10	O
(	O
7	O
)	O
cells	O
per	O
gram	O
of	O
wet	O
weight	O
.	O

16S	B-T103
rRNA	I-T103
gene	B-T017
fragments	I-T017
from	O
the	O
Planctomycetes	B-T007
comprised	O
8	O
-	O
13	O
%	O
of	O
total	O
16S	B-T103
rRNA	I-T103
gene	B-T017
reads	O
retrieved	O
using	O
Illumina	B-T170
pair	I-T170
-	I-T170
end	I-T170
sequencing	I-T170
from	O
the	O
soil	O
and	O
peat	O
samples	O
.	O

Lichen	B-T204
-	O
associated	O
assemblages	O
of	O
planctomycetes	B-T007
displayed	O
unexpectedly	O
high	O
diversity	O
,	O
with	O
a	O
total	O
of	O
89	O
,	O
662	O
reads	O
representing	O
1723	O
operational	O
taxonomic	O
units	O
determined	O
at	O
97	O
%	O
sequence	O
identity	O
.	O

The	O
soil	O
of	O
forested	O
tundra	B-T082
was	O
dominated	O
by	O
uncultivated	O
members	O
of	O
the	O
family	O
Planctomycetaceae	B-T007
(	O
53	O
-	O
71	O
%	O
of	O
total	O
Planctomycetes	B-T007
-	O
like	O
reads	O
)	O
,	O
while	O
sequences	B-T082
affiliated	O
with	O
the	O
Phycisphaera	B-T007
-	I-T007
related	I-T007
group	I-T007
WD2101	I-T007
(	O
recently	O
assigned	O
to	O
the	O
order	B-T170
Tepidisphaerales	B-T007
)	O
were	O
most	O
abundant	O
in	O
peat	O
(	O
28	O
-	O
51	O
%	O
of	O
total	O
reads	O
)	O
.	O

Representatives	O
of	O
the	O
Isosphaera	B-T007
-	O
Singulisphaera	B-T007
group	I-T007
(	O
14	O
-	O
28	O
%	O
of	O
total	O
reads	O
)	O
and	O
the	O
lineages	O
defined	O
by	O
the	O
genera	B-T170
Gemmata	B-T007
(	O
1	O
-	O
4	O
%	O
)	O
and	O
Planctopirus	B-T007
-	O
Rubinisphaera	B-T007
(	O
1	O
-	O
3	O
%	O
)	O
were	O
present	O
in	O
both	O
habitats	B-T082
.	O

Two	O
strains	O
of	O
Singulisphaera	B-T007
-	I-T007
like	I-T007
bacteria	I-T007
were	O
isolated	O
from	O
studied	O
soil	O
and	O
peat	O
samples	O
.	O

These	O
planctomycetes	B-T007
displayed	O
good	O
tolerance	O
of	O
low	O
temperatures	O
(	O
4	O
-	O
15°C	O
)	O
and	O
were	O
capable	O
of	O
growth	B-T038
on	O
a	O
number	O
of	O
polysaccharides	B-T103
,	O
including	O
lichenan	B-T103
,	O
a	O
characteristic	O
component	O
of	O
lichen	B-T204
-	O
derived	O
phytomass	O
.	O

Relationship	O
between	O
polycythemia	B-T038
and	O
in	O
-	O
hospital	O
mortality	O
in	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
patients	O
with	O
low	O
-	O
risk	O
pulmonary	B-T038
embolism	I-T038

Pulmonary	B-T038
embolism	I-T038
(	O
PE	B-T038
)	O
is	O
frequent	O
in	O
subjects	B-T098
with	O
chronic	B-T038
obstructive	I-T038
pulmonary	I-T038
disease	I-T038
(	O
COPD	B-T038
)	O
and	O
associated	O
with	O
high	O
mortality	O
.	O

This	O
multi	B-T062
-	I-T062
center	I-T062
retrospective	I-T062
study	I-T062
was	O
performed	O
to	O
investigate	O
if	O
secondary	O
polycythemia	B-T038
is	O
associated	O
with	O
in	O
-	O
hospital	O
mortality	O
in	O
COPD	B-T038
patients	O
with	O
low	O
-	O
risk	O
PE	B-T038
.	O

We	O
identified	O
COPD	B-T038
patients	O
with	O
proven	O
PE	B-T038
between	O
October	O
,	O
2005	O
and	O
October	O
,	O
2015	O
.	O

Patients	O
in	O
risk	O
classes	O
III	O
-	O
V	O
on	O
the	O
basis	O
of	O
the	O
PESI	B-T033
score	I-T033
were	O
excluded	O
.	O

We	O
extracted	O
demographic	O
,	O
clinical	O
and	O
laboratory	O
information	O
at	O
the	O
time	O
of	O
admission	O
from	O
medical	B-T170
records	I-T170
.	O

All	O
subjects	B-T098
were	O
followed	O
until	O
hospital	B-T058
discharge	I-T058
to	O
identify	O
all	O
-	O
cause	O
mortality	O
.	O

We	O
enrolled	O
629	O
consecutive	O
patients	O
with	O
COPD	B-T038
and	O
PE	B-T038
at	O
low	O
risk	O
:	O
132	O
of	O
them	O
(	O
21	O
.	O
0	O
%	O
)	O
with	O
and	O
497	O
(	O
79	O
.	O
0	O
%	O
)	O
without	O
secondary	O
polycythemia	B-T038
.	O

Compared	O
with	O
those	O
without	O
polycythemia	B-T038
,	O
the	O
polycythemia	B-T038
group	O
had	O
significantly	O
lower	O
forced	B-T058
expiratory	I-T058
volume	I-T058
in	I-T058
one	I-T058
second	I-T058
(	I-T058
FEV1	I-T058
)	I-T058
level	I-T058
(	O
0	O
.	O
9±0	O
.	O
3	O
vs	O
.	O

1	O
.	O
4±0	O
.	O
5	O
,	O
P	O
=	O
0	O
.	O
000	O
)	O
,	O
lower	B-T033
PaO2	I-T033
and	O
SpO2	B-T038
as	O
well	O
as	O
higher	B-T033
PaCO2	I-T033
(	O
P	O
=	O
0	O
.	O
03	O
,	O
P	O
=	O
0	O
.	O
03	O
and	O
P	O
=	O
0	O
.	O
000	O
,	O
respectively	O
)	O
.	O

COPD	B-T038
patients	O
with	O
polycythemia	B-T038
had	O
a	O
higher	O
proportion	O
of	O
arrhythmia	B-T033
in	O
electrocardiogram	B-T033
(	O
ECG	B-T033
)	O
(	O
49	O
.	O
5	O
%	O
vs	O
.	O

35	O
.	O
7	O
%	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
a	O
longer	O
hospital	O
duration	O
time	O
(	O
15	O
.	O
3±10	O
.	O
1	O
vs	O
.	O

9	O
.	O
7±9	O
.	O
1	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
,	O
a	O
higher	O
mechanical	O
ventilation	O
rate	O
(	O
noninvasive	B-T170
and	O
invasive	O
,	O
51	O
.	O
7	O
%	O
vs	O
.	O

30	O
.	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
04	O
and	O
31	O
.	O
0	O
%	O
vs	O
.	O

7	O
.	O
9	O
%	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
respectively	O
)	O
,	O
and	O
a	O
higher	O
in	O
-	O
hospital	O
mortality	O
(	O
12	O
.	O
1	O
%	O
vs	O
.	O

6	O
.	O
6	O
%	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

Multivariate	O
logistic	O
regression	O
analysis	O
revealed	O
that	O
polycythemia	B-T038
was	O
associated	O
with	O
mortality	O
in	O
COPD	B-T038
patients	O
with	O
low	O
-	O
risk	O
PE	B-T038
(	O
adjusted	O
OR	O
1	O
.	O
11	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
04	O
-	O
1	O
.	O
66	O
)	O
.	O

Polycythemia	B-T038
is	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
all	O
-	O
cause	O
in	O
-	O
hospital	O
mortality	O
in	O
COPD	B-T038
patients	O
with	O
PE	B-T038
at	O
low	O
risk	O
.	O

Masitinib	B-T103
for	O
treatment	B-T058
of	O
severely	O
symptomatic	O
indolent	B-T038
systemic	I-T038
mastocytosis	I-T038
:	O
a	O
randomised	B-T062
,	O
placebo	B-T062
-	I-T062
controlled	I-T062
,	O
phase	B-T062
3	I-T062
study	I-T062

Indolent	B-T038
systemic	I-T038
mastocytosis	I-T038
,	O
including	O
the	O
subvariant	O
of	O
smouldering	B-T038
systemic	I-T038
mastocytosis	I-T038
,	O
is	O
a	O
lifelong	O
condition	O
associated	O
with	O
reduced	B-T033
quality	I-T033
of	I-T033
life	I-T033
.	O

Masitinib	B-T103
inhibits	O
KIT	B-T103
and	O
LYN	B-T103
kinases	I-T103
that	O
are	O
involved	O
in	O
indolent	B-T038
systemic	I-T038
mastocytosis	I-T038
pathogenesis	B-T038
.	O

We	O
aimed	O
to	O
assess	O
safety	B-T062
and	O
efficacy	B-T062
of	O
masitinib	B-T103
versus	O
placebo	B-T103
in	O
severely	B-T033
symptomatic	I-T033
patients	O
who	O
were	O
unresponsive	O
to	O
optimal	O
symptomatic	O
treatments	B-T058
.	O

In	O
this	O
randomised	B-T062
,	O
double	B-T062
-	I-T062
blind	I-T062
,	O
placebo	B-T062
-	I-T062
controlled	I-T062
,	O
phase	B-T062
3	I-T062
study	I-T062
,	O
we	O
enrolled	O
adults	O
(	O
aged	O
18	O
-	O
75	O
years	O
)	O
with	O
indolent	B-T038
or	O
smouldering	B-T038
systemic	I-T038
mastocytosis	I-T038
,	O
according	O
to	O
WHO	B-T092
classification	B-T170
or	O
documented	B-T170
mastocytosis	B-T038
based	O
on	O
histological	B-T201
criteria	I-T201
,	O
at	O
50	O
centres	O
in	O
15	O
countries	B-T082
.	O

We	O
excluded	O
patients	O
with	O
cutaneous	B-T082
or	O
non	O
-	O
severe	O
systemic	B-T038
mastocytosis	I-T038
after	O
a	O
protocol	B-T170
amendment	I-T170
.	O

Patients	O
were	O
centrally	O
randomised	B-T062
(	O
1	O
:	O
1	O
)	O
to	O
receive	O
either	O
oral	O
masitinib	B-T103
(	O
6	O
mg	O
/	O
kg	O
per	O
day	O
over	O
24	O
weeks	O
with	O
possible	O
extension	O
)	O
or	O
matched	O
placebo	B-T103
with	O
minimisation	O
according	O
to	O
severe	B-T033
symptoms	I-T033
.	O

The	O
primary	B-T103
endpoint	I-T103
was	O
cumulative	O
response	B-T201
(	O
≥75	O
%	O
improvement	O
from	O
baseline	O
within	O
weeks	O
8	O
-	O
24	O
)	O
in	O
at	O
least	O
one	O
severe	B-T033
baseline	I-T033
symptom	I-T033
from	O
the	O
following	O
:	O
pruritus	B-T033
score	O
of	O
9	O
or	O
more	O
,	O
eight	O
or	O
more	O
flushes	O
per	O
week	O
,	O
Hamilton	B-T170
Rating	I-T170
Scale	I-T170
for	I-T170
Depression	I-T170
of	O
19	O
or	O
more	O
,	O
or	O
Fatigue	B-T170
Impact	I-T170
Scale	I-T170
of	O
75	O
or	O
more	O
.	O

We	O
assessed	O
treatment	O
effect	O
using	O
repeated	O
measures	O
methodology	B-T062
for	O
rare	B-T038
diseases	I-T038
via	O
the	O
generalised	B-T170
estimating	I-T170
equation	I-T170
model	I-T170
in	O
a	O
modified	O
intention	B-T062
-	I-T062
to	I-T062
-	I-T062
treat	I-T062
population	B-T098
,	O
including	O
all	O
participants	B-T098
assigned	O
to	O
treatment	B-T058
minus	O
those	O
who	O
withdrew	O
due	O
to	O
a	O
non	B-T033
-	I-T033
treatment	I-T033
-	I-T033
related	I-T033
cause	I-T033
.	O

We	O
assessed	O
safety	B-T062
in	O
all	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	B-T062
drug	I-T062
.	O

This	O
trial	B-T062
is	O
registered	O
with	O
ClinicalTrials	B-T062
.	I-T062
gov	I-T062
,	I-T062
number	I-T062
NCT00814073	I-T062
.	O

Between	O
Feb	O
19	O
,	O
2009	O
,	O
and	O
July	O
15	O
,	O
2015	O
,	O
135	O
patients	O
were	O
randomly	O
assigned	O
to	O
masitinib	B-T103
(	O
n	O
=	O
71	O
)	O
or	O
placebo	B-T103
(	O
n	O
=	O
64	O
)	O
.	O

By	O
24	O
weeks	O
,	O
masitinib	B-T103
was	O
associated	O
with	O
a	O
cumulative	O
response	B-T201
of	O
18	O
·	O
7	O
%	O
in	O
the	O
primary	B-T103
endpoint	I-T103
(	O
122	O
·	O
6	O
responses	B-T201
of	O
656	O
·	O
5	O
possible	O
responses	B-T201
[	O
weighted	O
generalised	O
estimating	O
equation	O
]	O
)	O
compared	O
with	O
7	O
·	O
4	O
%	O
for	O
placebo	B-T103
(	O
48	O
·	O
9	O
of	O
656	O
·	O
5	O
;	O
difference	O
11	O
·	O
3	O
%	O
;	O
odds	O
ratio	O
3	O
·	O
6	O
;	O
95	O
%	O
CI	O
1	O
·	O
2	O
-	O
10	O
·	O
8	O
;	O
p	O
=	O
0	O
·	O
0076	O
)	O
.	O

Frequent	O
severe	B-T033
adverse	I-T033
events	I-T033
(	O
>	O
4	O
%	O
difference	O
from	O
placebo	B-T103
)	O
were	O
diarrhoea	B-T033
(	O
eight	O
[	O
11	O
%	O
]	O
of	O
70	O
in	O
the	O
masitinib	B-T103
group	O
vs	O
one	O
[	O
2	O
%	O
]	O
of	O
63	O
in	O
the	O
placebo	B-T103
group	O
)	O
,	O
rash	O
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
asthenia	B-T033
(	O
four	O
[	O
6	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
.	O

The	O
most	O
frequent	O
serious	B-T033
adverse	I-T033
events	I-T033
were	O
diarrhoea	B-T033
(	O
three	O
patients	O
[	O
4	O
%	O
]	O
vs	O
one	O
[	O
2	O
%	O
]	O
)	O
and	O
urticaria	B-T038
(	O
two	O
[	O
3	O
%	O
]	O
vs	O
none	O
)	O
,	O
and	O
no	O
life	B-T033
-	I-T033
threatening	I-T033
toxicities	B-T037
occurred	O
.	O

One	O
patient	O
in	O
the	O
placebo	B-T103
group	O
died	B-T033
(	O
unrelated	O
to	O
study	B-T062
treatment	I-T062
)	O
.	O

These	O
study	O
findings	O
indicate	O
that	O
masitinib	B-T103
is	O
an	O
effective	O
and	O
well	O
tolerated	B-T103
agent	I-T103
for	O
the	O
treatment	B-T058
of	O
severely	B-T033
symptomatic	I-T033
indolent	B-T038
or	O
smouldering	B-T038
systemic	I-T038
mastocytosis	I-T038
.	O

AB	O
Science	O
(	O
Paris	O
,	O
France	O
)	O
.	O

Attributable	O
risk	O
of	O
ambient	O
PM10	O
on	O
daily	O
mortality	O
and	O
years	O
of	O
life	O
lost	O
in	O
Chengdu	O
,	O
China	B-T082

Attributable	O
risk	O
is	O
an	O
important	O
indicator	O
for	O
planning	B-T058
and	O
evaluating	B-T058
public	I-T058
health	I-T058
interventions	I-T058
.	O

However	O
,	O
most	O
current	O
measures	O
of	O
the	O
attributable	O
risk	O
of	O
air	B-T103
pollutants	I-T103
have	O
not	O
considered	O
temporal	O
relationships	O
between	O
exposure	O
and	O
risk	O
.	O

More	O
importantly	O
,	O
limited	O
information	O
is	O
available	O
regarding	O
the	O
attributable	O
risk	O
due	O
to	O
ambient	O
air	B-T103
pollutants	I-T103
in	O
basin	O
regions	O
like	O
the	O
Sichuan	O
Basin	O
,	O
China	B-T082
.	O

To	O
quantify	O
the	O
association	O
between	O
PM10	O
and	O
deaths	B-T033
in	O
the	O
Basin	O
region	O
,	O
we	O
used	O
a	O
measure	O
proposed	O
recently	O
within	O
the	O
framework	O
of	O
the	O
distributed	O
lag	O
non	O
-	O
linear	O
model	O
to	O
estimate	O
the	O
attributable	O
risk	O
in	O
Chengdu	O
,	O
China	B-T082
.	O

Meanwhile	O
,	O
we	O
examined	O
the	O
association	O
between	O
PM10	O
and	O
years	O
of	O
life	O
lost	O
(	O
YLL	O
)	O
.	O

Our	O
analysis	B-T062
showed	O
that	O
population	O
-	O
attributable	O
fractions	O
for	O
non	O
-	O
accidental	O
,	O
respiratory	O
,	O
and	O
cardiovascular	O
mortality	O
were	O
0	O
.	O
569	O
%	O
(	O
95	O
%	O
CI	O
:	O
-	O
3	O
.	O
474	O
%	O
,	O
4	O
.	O
374	O
%	O
)	O
,	O
0	O
.	O
695	O
%	O
(	O
95	O
%	O
CI	O
:	O
-	O
5	O
.	O
260	O
%	O
,	O
6	O
.	O
457	O
%	O
)	O
,	O
and	O
0	O
.	O
631	O
%	O
(	O
95	O
%	O
CI	O
:	O
-	O
6	O
.	O
973	O
%	O
,	O
7	O
.	O
390	O
%	O
)	O
,	O
respectively	O
.	O

On	O
average	O
,	O
a	O
1μg	O
/	O
m	O
(	O
3	O
)	O
increase	O
in	O
PM10	O
was	O
associated	O
with	O
cumulative	O
increases	O
of	O
0	O
.	O
26893	O
,	O
0	O
.	O
30437	O
,	O
and	O
0	O
.	O
21924	O
YLL	O
for	O
non	O
-	O
accidental	O
,	O
respiratory	O
,	O
and	O
cardiovascular	O
mortality	O
,	O
respectively	O
,	O
referring	O
to	O
20μg	O
/	O
m	O
(	O
3	O
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
an	O
inverse	B-T082
U	I-T082
-	I-T082
shaped	I-T082
pattern	I-T082
for	O
the	O
cumulative	O
risk	O
with	O
350μg	O
/	O
m	O
(	O
3	O
)	O
as	O
the	O
reverse	O
point	O
.	O

With	O
a	O
1μg	O
/	O
m	O
(	O
3	O
)	O
increase	O
in	O
PM10	O
,	O
YLL	O
changed	O
more	O
significantly	O
than	O
mortality	O
.	O

Moreover	O
,	O
PM10	O
demonstrated	O
remarkable	O
effects	O
on	O
YLL	O
among	O
men	B-T098
and	O
the	O
elderly	B-T098
.	O

Far	O
-	O
infrared	O
protects	O
vascular	B-T017
endothelial	I-T017
cells	I-T017
from	O
advanced	B-T103
glycation	I-T103
end	I-T103
products	I-T103
-	O
induced	O
injury	B-T037
via	O
PLZF	B-T103
-	O
mediated	O
autophagy	B-T038
in	O
diabetic	B-T204
mice	I-T204

The	O
accumulation	O
of	O
advanced	B-T103
glycation	I-T103
end	I-T103
products	I-T103
(	O
AGEs	B-T103
)	O
in	O
diabetic	B-T038
patients	O
induces	O
vascular	B-T017
endothelial	I-T017
injury	B-T037
.	O

Promyelocytic	B-T103
leukemia	I-T103
zinc	I-T103
finger	I-T103
protein	I-T103
(	O
PLZF	B-T103
)	O
is	O
a	O
transcription	B-T103
factor	I-T103
that	O
can	O
be	O
activated	B-T038
by	O
low	O
-	O
temperature	O
far	O
-	O
infrared	O
(	O
FIR	O
)	O
irradiation	O
to	O
exert	B-T038
beneficial	I-T038
effects	I-T038
on	O
the	O
vascular	B-T017
endothelium	I-T017
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
investigated	O
the	O
influence	O
of	O
FIR	O
-	O
induced	O
PLZF	B-T103
activation	B-T038
on	O
AGE	B-T103
-	O
induced	O
endothelial	B-T017
injury	B-T037
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

FIR	O
irradiation	O
inhibited	O
AGE	B-T103
-	O
induced	O
apoptosis	B-T038
in	O
human	B-T017
umbilical	I-T017
vein	I-T017
endothelial	I-T017
cells	I-T017
(	O
HUVECs	B-T017
)	O
.	O

PLZF	B-T103
activation	B-T038
increased	O
the	O
expression	B-T038
of	O
phosphatidylinositol	B-T103
-	I-T103
3	I-T103
kinases	I-T103
(	O
PI3K	B-T103
)	O
,	O
which	O
are	O
important	O
kinases	B-T103
in	O
the	O
autophagic	B-T038
signaling	B-T038
pathway	I-T038
.	O

FIR	O
-	O
induced	O
PLZF	B-T103
activation	B-T038
led	O
to	O
autophagy	B-T038
in	O
HUVEC	B-T017
,	O
which	O
was	O
mediated	O
through	O
the	O
upregulation	B-T038
of	O
PI3K	B-T103
.	O

Immunofluorescence	B-T058
staining	B-T058
showed	O
that	O
AGEs	B-T103
were	O
engulfed	O
by	O
HUVECs	B-T017
and	O
localized	B-T082
to	O
lysosomes	B-T017
.	O

FIR	O
-	O
induced	O
autophagy	B-T038
promoted	O
AGEs	B-T103
degradation	O
in	O
HUVECs	B-T017
.	O

In	O
nicotinamide	B-T103
/	O
streptozotocin	B-T103
-	O
induced	O
diabetic	B-T204
mice	I-T204
,	O
FIR	O
therapy	B-T058
reduced	O
serum	B-T103
AGEs	I-T103
and	O
AGEs	B-T103
deposition	O
at	O
the	O
vascular	B-T017
endothelium	I-T017
.	O

FIR	O
therapy	B-T058
also	O
reduced	O
diabetes	B-T038
-	O
induced	O
inflammatory	B-T033
markers	I-T033
in	O
the	O
vascular	B-T017
endothelium	I-T017
and	O
improved	B-T033
vascular	B-T017
endothelial	I-T017
function	O
.	O

These	O
protective	B-T038
effects	I-T038
of	O
FIR	O
therapy	B-T058
were	O
not	B-T033
found	I-T033
in	O
PLZF	B-T103
-	O
knockout	B-T204
mice	I-T204
.	O

Our	O
data	O
suggest	O
that	O
FIR	O
-	O
induced	O
PLZF	B-T103
activation	B-T038
in	O
vascular	B-T017
endothelial	I-T017
cells	I-T017
protects	O
the	O
vascular	B-T017
endothelium	I-T017
in	O
diabetic	B-T204
mice	I-T204
from	O
AGE	B-T103
-	O
induced	O
injury	B-T037
.	O

Ultrasonic	B-T058
computed	I-T058
tomography	I-T058
imaging	I-T058
of	O
iron	O
oxide	O
nanoparticles	O

Iron	O
oxide	O
nanoparticles	O
(	O
IONPs	O
)	O
are	O
becoming	O
increasingly	O
used	O
and	O
intensively	O
investigated	O
in	O
the	O
field	O
of	O
medical	B-T058
imaging	I-T058
.	O

They	O
are	O
currently	O
FDA	B-T092
approved	O
for	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
(	O
MRI	B-T058
)	O
,	O
and	O
it	O
would	O
be	O
highly	O
desirable	O
to	O
visualize	O
them	O
by	O
ultrasound	O
as	O
well	O
.	O

Previous	O
reports	B-T170
using	O
the	O
conventional	O
ultrasound	B-T058
B	I-T058
-	I-T058
scan	I-T058
(	I-T058
pulse	I-T058
-	I-T058
echo	I-T058
)	I-T058
imaging	I-T058
technique	I-T058
have	O
shown	O
very	O
limited	O
detectability	B-T201
of	O
these	O
particles	B-T103
.	O

The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
explore	O
the	O
feasibility	O
of	O
imaging	B-T058
IONPs	O
using	O
the	O
through	O
-	O
transmission	O
ultrasound	O
methodology	O
and	O
demonstrate	O
their	O
detectability	O
using	O
ultrasonic	B-T058
computed	I-T058
tomography	I-T058
(	O
UCT	B-T058
)	O
.	O

Commercially	O
available	O
IONPs	O
were	O
acoustically	O
analysed	B-T062
to	O
quantify	O
their	O
effect	O
on	O
the	O
speed	O
of	O
sound	O
(	O
SOS	O
)	O
and	O
acoustic	O
attenuation	O
as	O
a	O
function	O
of	O
concentration	O
.	O

Next	O
,	O
through	B-T058
-	I-T058
transmission	I-T058
projection	I-T058
and	O
UCT	B-T058
imaging	I-T058
were	O
performed	O
on	O
a	O
breast	B-T017
mimicking	O
phantom	O
and	O
on	O
an	O
ex	B-T038
vivo	I-T038
tissue	I-T038
model	I-T038
,	O
to	O
which	O
IONPs	O
were	O
injected	O
.	O

Finally	O
,	O
an	O
MRI	B-T058
scan	I-T058
was	O
performed	O
to	O
verify	O
that	O
the	O
same	O
particles	B-T103
examined	B-T033
in	O
the	O
ultrasound	O
experiment	B-T062
can	O
be	O
imaged	B-T170
by	O
magnetic	O
resonance	O
,	O
using	O
the	O
same	O
clinically	O
relevant	O
concentrations	O
.	O

The	O
results	O
have	O
shown	O
a	O
consistent	O
concentration	O
dependent	O
speed	O
of	O
sound	O
increase	O
(	O
1	O
.	O
86	O
[	O
Formula	O
:	O
see	O
text	O
]	O
rise	O
per	O
100	O
µg	O
·	O
ml	O
(	O
-	O
1	O
)	O
IONPs	O
)	O
.	O

Imaging	B-T058
based	O
on	O
this	O
property	O
has	O
shown	O
a	O
substantial	O
contrast	O
-	O
to	O
-	O
noise	O
ratio	O
improvement	O
(	O
up	O
to	O
5	O
fold	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
SOS	O
-	O
related	O
effect	O
generated	O
a	O
well	O
discernible	O
image	B-T170
contrast	O
and	O
allowed	O
the	O
detection	B-T033
of	O
the	O
particles	B-T103
existence	O
and	O
location	B-T082
,	O
in	O
both	O
raster	B-T058
-	I-T058
scan	I-T058
projection	I-T058
and	O
UCT	B-T058
imaging	I-T058
.	O

Conversely	O
,	O
no	O
significant	O
change	O
in	O
the	O
acoustic	O
attenuation	O
coefficient	O
was	O
noted	O
.	O

Based	O
on	O
these	O
findings	B-T033
,	O
it	O
is	O
concluded	O
that	O
IONPs	O
can	O
be	O
used	O
as	O
an	O
effective	O
SOS	O
-	O
based	O
contrast	B-T103
agent	I-T103
,	O
potentially	O
useful	O
for	O
ultrasonic	O
breast	B-T017
imaging	B-T058
.	O

Furthermore	O
,	O
the	O
particle	B-T103
offers	O
the	O
capacity	O
of	O
significantly	O
enhancing	O
diagnosis	O
accuracy	O
using	O
multimodal	B-T058
MRI	B-T058
-	O
ultrasound	B-T058
imaging	I-T058
capabilities	O
.	O

Genetically	O
encoded	O
calcium	O
indicators	O
for	O
studying	O
long	O
-	O
term	O
calcium	B-T103
dynamics	B-T038
during	O
apoptosis	B-T038

Intracellular	B-T038
calcium	I-T038
release	I-T038
is	O
essential	O
for	O
regulating	B-T038
almost	O
all	O
cellular	B-T038
functions	I-T038
.	O

Specific	O
spatio	B-T062
-	I-T062
temporal	I-T062
patterns	B-T082
of	O
cytosolic	B-T017
calcium	B-T103
elevations	O
are	O
critical	O
determinants	O
of	O
cell	O
fate	O
in	O
response	O
to	O
pro	O
-	O
apoptotic	O
cellular	B-T017
stressors	O
.	O

As	O
the	O
apoptotic	B-T038
program	I-T038
can	O
take	O
hours	O
or	O
days	O
,	O
measurement	O
of	O
long	O
-	O
term	O
calcium	B-T103
dynamics	B-T038
are	O
essential	O
for	O
understanding	B-T038
the	O
mechanistic	O
role	O
of	O
calcium	B-T103
in	O
apoptotic	B-T038
cell	I-T038
death	I-T038
.	O

Due	O
to	O
the	O
technical	O
limitations	O
of	O
using	O
calcium	B-T103
-	O
sensitive	O
dyes	B-T103
to	O
measure	O
cytosolic	B-T017
calcium	B-T103
little	O
is	O
known	O
about	O
long	O
-	O
term	O
calcium	B-T103
dynamics	B-T038
in	O
living	B-T017
cells	I-T017
after	O
treatment	B-T058
with	O
apoptosis	B-T038
-	O
inducing	O
drugs	B-T103
.	O

Genetically	O
encoded	O
calcium	O
indicators	O
could	O
potentially	O
overcome	O
some	O
of	O
the	O
limitations	O
of	O
calcium	B-T103
-	O
sensitive	O
dyes	B-T103
.	O

Here	O
,	O
we	O
compared	O
the	O
performance	O
of	O
the	O
genetically	O
encoded	O
calcium	B-T103
indicators	B-T103
GCaMP6s	O
and	O
GCaMP6f	O
with	O
the	O
ratiometric	B-T103
dye	I-T103
Fura	B-T103
-	I-T103
2	I-T103
.	O

GCaMP6s	O
performed	O
as	O
well	O
or	O
better	O
than	O
Fura	B-T103
-	I-T103
2	I-T103
in	O
detecting	O
agonist	B-T103
-	O
induced	O
calcium	B-T103
transients	O
.	O

We	O
then	O
examined	O
the	O
utility	O
of	O
GCaMP6s	O
for	O
continuously	O
measuring	O
apoptotic	O
calcium	B-T058
release	I-T058
over	O
the	O
course	O
of	O
ten	O
hours	O
after	O
treatment	B-T058
with	O
staurosporine	B-T103
.	O

We	O
found	O
that	O
GCaMP6s	O
was	O
suitable	O
for	O
measuring	O
apoptotic	O
calcium	B-T058
release	I-T058
over	O
long	O
time	O
courses	O
and	O
revealed	O
significant	O
heterogeneity	O
in	O
calcium	B-T058
release	I-T058
dynamics	B-T038
in	O
individual	O
cells	B-T017
challenged	O
with	O
staurosporine	B-T103
.	O

Our	O
results	O
suggest	O
GCaMP6s	O
is	O
an	O
excellent	O
indicator	B-T103
for	O
monitoring	B-T058
long	O
-	O
term	O
changes	O
cytosolic	B-T017
calcium	B-T103
during	O
apoptosis	B-T038
.	O

Staphylococcus	B-T007
pseudintermedius	I-T007
Human	B-T204
Infection	B-T038
Cases	O
in	O
Spain	B-T082
:	O
Dog	B-T204
-	O
to	O
-	O
Human	B-T204
Transmission	B-T038

Staphylococcus	B-T007
pseudintermedius	I-T007
is	O
an	O
opportunistic	O
pathogen	O
that	O
has	O
been	O
identified	O
as	O
infectious	O
agent	O
or	O
colonizer	B-T033
mainly	O
in	O
dogs	B-T204
.	O

S	B-T007
.	I-T007

pseudintermedius	I-T007
has	O
been	O
also	O
detected	B-T033
in	O
humans	B-T204
and	O
more	O
specifically	O
in	O
people	B-T098
in	O
contact	O
with	O
dogs	B-T204
.	O

In	O
this	O
study	B-T062
,	O
the	O
possible	B-T033
S	B-T007
.	I-T007

pseudintermedius	I-T007
pet	B-T204
-	O
to	O
-	O
human	B-T204
transmission	B-T038
was	O
analyzed	B-T062
in	O
four	O
clinical	O
human	B-T204
cases	O
.	O

Two	O
patients	O
were	O
dog	B-T204
owners	B-T098
and	O
S	B-T007
.	I-T007

pseudintermedius	I-T007
was	O
also	O
detected	B-T033
as	O
colonizer	B-T033
in	O
these	O
healthy	O
animals	B-T204
.	O

S	B-T007
.	I-T007

pseudintermedius	I-T007
isolates	B-T103
from	O
patients	O
and	O
dogs	B-T204
of	O
the	O
same	O
household	O
showed	O
identical	O
pulsed	B-T058
-	I-T058
field	I-T058
gel	I-T058
electrophoresis	I-T058
patterns	B-T082
,	O
sequence	B-T033
types	I-T033
(	O
STs	B-T033
)	O
,	O
and	O
antimicrobial	B-T201
resistance	I-T201
phenotypes	O
and	O
genotypes	O
,	O
and	O
were	O
methicillin	O
susceptible	O
.	O

Resistance	O
to	O
erythromycin	B-T103
,	O
clindamycin	B-T103
,	O
tetracycline	B-T103
,	O
trimetoprim	B-T103
-	I-T103
sulfamethoxazole	I-T103
,	O
and	O
/	O
or	O
ciprofloxacin	B-T103
was	O
identified	O
among	O
S	B-T007
.	I-T007

pseudintermedius	I-T007
strains	O
.	O

The	O
lineages	O
ST241	B-T033
and	O
the	O
new	O
ST521	B-T033
were	O
detected	B-T033
in	O
the	O
strains	O
of	O
the	O
two	O
dog	B-T204
-	O
owner	B-T098
patients	O
,	O
respectively	O
.	O

The	O
strains	O
from	O
the	O
other	O
two	O
patients	O
presented	O
two	O
new	O
STs	B-T033
,	O
ST719	B-T033
and	O
ST720	B-T033
.	O

To	O
our	O
knowledge	B-T170
,	O
this	O
is	O
the	O
first	O
description	B-T170
of	O
human	B-T204
infections	B-T038
caused	O
by	O
S	B-T007
.	I-T007

pseudintermedius	I-T007
in	O
Spain	B-T082
.	O

TANGO	B-T170
-	O
a	O
screening	B-T058
tool	I-T058
to	O
identify	O
comorbidities	O
on	O
the	O
causal	B-T170
pathway	I-T170
of	O
nocturia	B-T038

To	O
develop	O
a	O
robust	B-T058
screening	I-T058
metric	I-T058
for	O
use	O
in	O
identifying	O
non	O
-	O
lower	O
urinary	B-T017
tract	I-T017
comorbidities	O
pertinent	O
to	O
the	O
multidisciplinary	B-T058
assessment	I-T058
of	O
patients	O
with	O
nocturia	B-T038
.	O

Variables	O
having	O
a	O
significant	O
risk	O
association	O
with	O
nocturia	B-T038
of	O
greater	O
than	O
once	O
per	O
night	O
were	O
identified	O
.	O

Discriminating	O
items	O
from	O
validated	O
and	O
reliable	O
tools	B-T058
measuring	O
these	O
comorbidities	O
were	O
identified	O
.	O

A	O
self	O
-	O
completed	O
57	O
-	O
item	O
questionnaire	B-T170
was	O
developed	O
and	O
a	O
medical	O
checklist	B-T170
and	O
pertinent	O
clinical	B-T033
measures	I-T033
added	O
.	O

Pre	O
-	O
determined	O
criteria	O
were	O
applied	O
to	O
retain	O
or	O
remove	O
items	O
in	O
the	O
development	O
of	O
the	O
Short	O
-	O
Form	O
(	O
SF	O
)	O
screening	B-T058
tool	I-T058
.	O

The	O
tool	B-T058
was	O
administered	O
to	O
252	O
individuals	B-T098
with	O
nocturia	B-T038
who	O
were	O
attending	O
either	O
a	O
tertiary	O
level	O
Sleep	B-T038
,	O
Continence	B-T058
,	O
Falls	B-T033
or	O
Rehabilitation	B-T058
service	I-T058
for	O
routine	B-T058
care	I-T058
.	O

Data	B-T033
collected	I-T033
were	O
subjected	O
to	O
descriptive	B-T170
analysis	I-T170
;	O
criteria	O
were	O
applied	O
to	O
reduce	O
the	O
number	O
of	O
items	O
.	O

Using	O
pre	O
-	O
determined	O
domains	O
,	O
a	O
nocturia	B-T038
screening	B-T058
metric	I-T058
,	O
entitled	O
TANGO	B-T170
,	O
was	O
generated	O
.	O

The	O
acronym	O
TANGO	B-T170
stands	O
for	O
Targeting	O
the	O
individual	O
'	O
s	O
Aetiology	O
of	O
Nocturia	B-T038
to	O
Guide	O
Outcomes	O
.	O

The	O
demographic	O
characteristics	O
of	O
the	O
sample	O
are	O
described	O
,	O
along	O
with	O
item	O
endorsement	O
levels	O
.	O

The	O
statistical	O
and	O
structural	O
framework	O
to	O
justify	O
deleting	O
or	O
retaining	O
of	O
items	O
from	O
the	O
TANGO	B-T170
Long	O
-	O
Form	O
to	O
the	O
SF	O
is	O
presented	O
.	O

The	O
resultant	O
TANGO	B-T170
-	O
SF	O
patient	O
-	O
completed	O
nocturia	B-T038
screening	B-T058
tool	I-T058
is	O
reported	O
.	O

A	O
novel	O
all	O
-	O
cause	O
diagnostic	O
metric	O
for	O
identifying	O
co	O
-	O
existing	O
morbidities	O
of	O
clinical	O
relevance	O
to	O
nocturia	B-T038
in	O
patients	O
who	O
present	O
across	O
disciplines	B-T058
and	O
medical	B-T091
specialties	I-T091
has	O
been	O
developed	O
.	O

TANGO	B-T170
has	O
the	O
potential	O
to	O
improve	O
practice	O
and	O
smooth	O
inequalities	O
associated	O
with	O
a	O
siloed	O
approach	O
to	O
assessment	B-T058
and	O
subsequent	O
care	O
of	O
patients	O
with	O
nocturia	B-T038
.	O

Probabilistic	O
acute	O
risk	B-T058
assessment	I-T058
of	O
cumulative	O
exposure	O
to	O
organophosphorus	B-T103
and	O
carbamate	B-T103
pesticides	I-T103
from	O
dietary	B-T168
vegetables	I-T168
and	O
fruits	B-T168
in	O
Shanghai	O
populations	B-T098

Organophosphorus	B-T103
pesticides	I-T103
(	O
OPs	B-T103
)	O
and	O
carbamate	B-T103
pesticides	I-T103
(	O
CPs	B-T103
)	O
are	O
among	O
the	O
most	O
widely	O
used	O
pesticides	B-T103
in	O
China	B-T082
,	O
playing	O
a	O
major	O
role	O
in	O
protecting	O
agricultural	B-T204
commodities	I-T204
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
the	O
cumulative	O
acute	O
exposure	O
to	O
OPs	B-T103
and	O
CPs	B-T103
of	O
Shanghai	O
residents	B-T098
from	O
vegetables	B-T168
and	O
fruits	B-T168
(	O
VFs	B-T168
)	O
.	O

The	O
food	O
consumption	O
data	O
were	O
obtained	O
from	O
the	O
Shanghai	B-T170
Food	I-T170
Consumption	I-T170
Survey	I-T170
(	O
SHFCS	B-T170
)	O
of	O
2012	O
-	O
14	O
including	O
a	O
total	O
of	O
1973	O
participants	B-T098
aged	O
2	O
-	O
90	O
years	O
.	O

The	O
pesticide	B-T103
residue	I-T103
data	O
were	O
obtained	O
from	O
the	O
Shanghai	O
monitoring	B-T058
programme	O
during	O
2008	O
-	O
11	O
with	O
34	O
organophosphates	B-T103
and	O
11	O
carbamates	B-T103
analysed	O
in	O
a	O
total	O
of	O
5335	O
samples	O
of	O
VFs	B-T168
.	O

A	O
probabilistic	O
approach	O
was	O
performed	O
as	O
recommended	O
by	O
the	O
EFSA	B-T170
,	O
using	O
the	O
optimistic	B-T170
model	I-T170
with	O
non	O
-	O
detects	O
set	O
as	O
zero	O
and	O
with	O
processing	O
factors	O
(	O
PFs	O
)	O
being	O
used	O
and	O
the	O
pessimistic	B-T170
model	I-T170
with	O
non	O
-	O
detects	O
replaced	O
by	O
limit	O
of	O
detection	O
(	O
LOD	O
)	O
and	O
without	O
PFs	O
.	O

We	O
used	O
the	O
relative	B-T170
potency	I-T170
factor	I-T170
(	I-T170
RPF	I-T170
)	I-T170
method	I-T170
to	O
normalise	O
the	O
various	O
pesticides	B-T103
to	O
the	O
index	B-T103
compound	I-T103
(	O
IC	B-T103
)	O
of	O
methamidophos	B-T103
and	O
chlorpyrifos	B-T103
separately	O
.	O

Only	O
in	O
the	O
pessimistic	B-T170
model	I-T170
using	O
methamidophos	B-T103
as	O
the	O
IC	B-T103
was	O
there	O
was	O
small	O
risk	O
of	O
exposure	O
exceeding	O
the	O
ARfD	O
(	O
3	O
µg	O
kg	O
(	O
-	O
)	O
(	O
1	O
)	O
bw	O
day	O
(	O
-	O
)	O
(	O
1	O
)	O
)	O
in	O
the	O
populations	B-T098
of	O
preschool	O
children	O
(	O
0	O
.	O
029	O
%	O
)	O
,	O
school	O
-	O
age	O
children	O
(	O
0	O
.	O
022	O
%	O
)	O
and	O
adults	O
(	O
0	O
.	O
002	O
%	O
)	O
.	O

There	O
were	O
no	O
risk	O
of	O
exposure	O
exceeding	O
the	O
ARfD	O
of	O
methamidophos	B-T103
in	O
the	O
optimistic	B-T170
model	I-T170
and	O
of	O
chlorpyrifos	B-T103
(	O
100	O
µg	O
kg	O
(	O
-	O
)	O
(	O
1	O
)	O
bw	O
day	O
(	O
-	O
)	O
(	O
1	O
)	O
)	O
in	O
both	O
optimistic	B-T033
and	O
pessimistic	B-T170
models	I-T170
in	O
all	O
three	O
populations	B-T098
.	O

Considering	O
the	O
Chinese	B-T033
habits	I-T033
of	O
overwhelmingly	O
eating	B-T038
processed	B-T168
food	I-T168
(	O
vegetables	B-T168
being	O
cooked	O
,	O
and	O
fruits	B-T168
being	O
washed	O
or	O
peeled	O
)	O
,	O
we	O
conclude	O
that	O
little	O
acute	O
risk	O
was	O
found	O
for	O
the	O
exposure	O
to	O
VF	B-T168
-	O
sourced	B-T033
OPs	B-T103
and	O
CPs	B-T103
in	O
Shanghai	O
.	O

MODEM	O
:	O
A	O
comprehensive	O
approach	B-T082
to	O
modelling	B-T062
outcome	O
and	O
costs	O
impacts	O
of	O
interventions	B-T058
for	O
dementia	B-T038
.	O
Protocol	B-T170
paper	O

The	O
MODEM	O
project	O
(	O
A	O
comprehensive	O
approach	B-T082
to	O
MODelling	B-T062
outcome	O
and	O
costs	O
impacts	O
of	O
interventions	B-T058
for	O
DEMentia	B-T038
)	O
explores	O
how	O
changes	O
in	O
arrangements	O
for	O
the	O
future	O
treatment	B-T058
and	O
care	O
of	O
people	B-T098
living	O
with	O
dementia	B-T038
,	O
and	O
support	B-T058
for	O
family	O
and	O
other	O
unpaid	B-T033
carers	B-T097
,	O
could	O
result	O
in	O
better	O
outcomes	O
and	O
more	O
efficient	O
use	O
of	O
resources	O
.	O

MODEM	O
starts	O
with	O
a	O
systematic	O
mapping	O
of	O
the	O
literature	B-T170
on	O
effective	O
and	O
(	O
potentially	O
)	O
cost	O
-	O
effective	O
interventions	B-T058
in	O
dementia	B-T038
care	O
.	O

Those	O
findings	O
,	O
as	O
well	O
as	O
data	O
from	O
a	O
cohort	B-T098
,	O
will	O
then	O
be	O
used	O
to	O
model	B-T170
the	O
quality	O
of	O
life	O
and	O
cost	O
impacts	O
of	O
making	O
these	O
evidence	O
-	O
based	O
interventions	B-T058
more	O
widely	O
available	O
in	O
England	B-T082
over	O
the	O
period	O
from	O
now	O
to	O
2040	O
.	O

Modelling	B-T062
will	O
use	O
a	O
suite	O
of	O
models	B-T170
,	O
combining	O
microsimulation	O
and	O
macrosimulation	O
methods	O
,	O
modelling	B-T062
the	O
costs	O
and	O
outcomes	O
of	O
care	O
,	O
both	O
for	O
an	O
individual	B-T098
over	O
the	O
life	O
-	O
course	O
from	O
the	O
point	O
of	O
dementia	B-T038
diagnosis	I-T038
,	O
and	O
for	O
individuals	B-T098
and	O
England	B-T082
as	O
a	O
whole	O
in	O
a	O
particular	O
year	O
.	O

Project	O
outputs	O
will	O
include	O
an	O
online	O
Dementia	B-T170
Evidence	I-T170
Toolkit	I-T170
,	O
making	O
evidence	O
summaries	B-T170
and	O
a	O
literature	B-T170
database	B-T170
available	O
free	O
to	O
anyone	O
,	O
papers	O
in	O
academic	B-T170
journals	I-T170
and	O
other	O
written	O
outputs	O
,	O
and	O
a	O
MODEM	B-T170
Legacy	I-T170
Model	I-T170
,	O
which	O
will	O
enable	O
local	B-T097
commissioners	I-T097
of	O
services	O
to	O
apply	O
the	O
model	B-T170
to	O
their	O
own	O
populations	B-T098
.	O

Modelling	B-T062
the	O
effects	O
of	O
evidence	O
-	O
based	O
cost	O
-	O
effective	O
interventions	B-T058
and	O
making	O
this	O
information	O
widely	O
available	O
has	O
the	O
potential	O
to	O
improve	B-T033
the	O
health	O
and	O
quality	O
of	O
life	O
both	O
of	O
people	B-T098
with	O
dementia	B-T038
and	O
their	O
carers	B-T097
,	O
while	O
ensuring	O
that	O
resources	O
are	O
used	O
efficiently	O
.	O

Assessment	B-T062
of	O
neuroanatomical	O
and	O
behavioural	O
effects	O
of	O
in	O
ovo	O
methylmercury	B-T103
exposure	O
in	O
zebra	B-T204
finches	I-T204
(	O
Taeniopygia	B-T204
guttata	I-T204
)	O

Methylmercury	B-T103
(	O
MeHg	B-T103
)	O
readily	O
crosses	O
the	O
blood	B-T017
brain	I-T017
barrier	I-T017
and	O
is	O
a	O
known	O
neuro	O
-	O
toxicant	O
.	O

MeHg	B-T103
accumulation	B-T033
in	O
the	O
brain	B-T017
causes	O
histopathological	O
alterations	O
,	O
neurobehavioral	O
changes	O
,	O
and	O
impairments	O
to	O
cognitive	O
motor	B-T038
functions	I-T038
in	O
mammalian	B-T204
models	B-T038
.	O

However	O
,	O
in	O
birds	B-T204
the	O
neurotoxic	B-T037
effects	I-T037
of	O
MeHg	B-T103
on	O
the	O
developing	O
pre	O
-	O
hatching	B-T038
brain	B-T017
and	O
consequent	O
behavioral	O
alterations	O
in	O
adult	O
birds	B-T204
have	O
not	O
received	O
much	O
attention	B-T038
.	O

Moreover	O
,	O
passerine	B-T204
birds	I-T204
are	O
poorly	O
represented	O
in	O
MeHg	B-T103
neurotoxicology	O
studies	B-T062
in	O
comparison	O
to	O
other	O
avian	B-T204
orders	O
.	O

Hence	O
in	O
this	O
study	B-T062
,	O
we	O
used	O
the	O
egg	B-T168
injection	B-T170
method	I-T170
to	O
investigate	O
the	O
long	O
term	O
effects	O
of	O
in	O
ovo	O
MeHg	B-T103
exposure	O
on	O
brain	B-T017
histopathology	O
and	O
courtship	O
behavior	O
in	O
a	O
model	B-T038
songbird	B-T204
species	B-T170
,	O
the	O
zebra	B-T204
finch	I-T204
(	O
Taeniopygia	B-T204
guttata	I-T204
)	O
.	O

Egg	B-T168
treatment	O
groups	O
included	O
:	O
a	O
low	O
MeHg	B-T103
dose	O
of	O
0	O
.	O
2μg	O
Hg	B-T103
g	O
(	O
-	O
1	O
)	O
egg	B-T168
,	O
a	O
high	O
MeHg	B-T103
dose	O
of	O
3	O
.	O
2μg	O
Hg	B-T103
g	O
(	O
-	O
1	O
)	O
egg	B-T168
,	O
and	O
a	O
vehicle	B-T103
control	I-T103
(	O
water	B-T103
)	O
.	O

No	B-T033
adverse	I-T033
effects	I-T033
of	O
in	O
ovo	O
MeHg	B-T103
treatment	O
were	O
detected	B-T033
on	O
courtship	O
song	O
quality	O
or	O
on	O
mating	B-T038
behavior	I-T038
in	O
experimental	O
males	O
at	O
sexually	B-T033
maturity	I-T033
which	O
would	O
suggest	O
that	O
observable	B-T201
neurobehavioral	O
effects	O
of	O
MeHg	B-T103
exposure	O
may	O
depend	O
on	O
the	O
timing	O
of	O
exposure	O
during	O
offspring	O
development	B-T038
.	O

However	O
,	O
neuroanatomical	O
analysis	B-T062
indicated	B-T033
an	O
increase	O
in	O
telencephalon	B-T017
volume	O
with	O
increased	O
MeHg	B-T103
concentrations	O
which	O
may	O
suggest	O
a	O
prolonged	O
inflammatory	B-T038
response	I-T038
in	O
this	O
region	B-T082
of	I-T082
the	I-T082
brain	I-T082
.	O

Evaluation	B-T058
of	O
the	O
Condom	B-T170
Barriers	I-T170
Scale	I-T170
for	O
Young	O
Black	B-T098
Men	I-T098
Who	I-T098
Have	I-T098
Sex	I-T098
With	I-T098
Men	I-T098
:	O
Reliability	O
and	O
Validity	O
of	O
3	O
Subscales	B-T170

Reliable	O
and	O
valid	O
scale	B-T170
measures	O
of	O
barriers	B-T058
to	O
condom	O
use	O
are	O
not	O
available	O
for	O
young	O
black	B-T098
men	I-T098
who	I-T098
have	I-T098
sex	I-T098
with	I-T098
men	I-T098
(	O
YBMSM	B-T098
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
Condom	B-T170
Barriers	I-T170
Scales	I-T170
for	O
application	O
with	O
YBMSM	B-T098
.	O

A	O
clinic	O
-	O
based	O
sample	O
of	O
600	O
YBMSM	B-T098
completed	O
a	O
computer	O
-	O
assisted	O
self	O
-	O
interview	O
.	O

The	O
primary	O
measure	O
was	O
a	O
14	O
-	O
item	O
abbreviated	B-T170
version	I-T170
of	O
the	O
Condom	B-T170
Barriers	I-T170
Scale	I-T170
.	O

Reliability	O
and	O
criterion	O
validity	O
were	O
assessed	O
.	O

All	O
3	O
subscales	B-T170
were	O
reliable	O
:	O
partner	B-T098
-	O
related	O
barriers	B-T058
(	O
Cronbach	O
α	O
=	O
0	O
.	O
73	O
)	O
,	O
sensation	B-T038
-	O
related	O
barriers	B-T058
(	O
α	O
=	O
0	O
.	O
70	O
)	O
,	O
and	O
motivation	B-T038
-	O
related	O
barriers	B-T058
(	O
α	O
=	O
0	O
.	O
81	O
)	O
.	O

A	O
complete	O
absence	O
of	O
barriers	O
was	O
common	O
:	O
47	O
.	O
0	O
%	O
(	O
partner	B-T098
-	O
related	O
)	O
,	O
30	O
.	O
7	O
%	O
(	O
sensation	B-T038
-	O
related	O
)	O
,	O
and	O
46	O
.	O
5	O
%	O
(	O
motivation	B-T038
-	O
related	O
)	O
.	O

Dichotomized	O
subscales	B-T170
were	O
significantly	O
associated	O
with	O
reporting	O
any	O
condomless	B-T033
insertive	O
anal	O
sex	O
(	O
all	O
Ps	O
<	O
0	O
.	O
001	O
)	O
and	O
any	O
condomless	B-T033
receptive	O
anal	O
sex	O
(	O
all	O
Ps	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
subscales	B-T170
were	O
significantly	O
associated	O
with	O
these	O
measures	O
of	O
condomless	B-T033
sex	B-T038
preserved	O
at	O
a	O
continuous	O
level	O
(	O
all	O
Ps	O
<	O
0	O
.	O
001	O
,	O
except	O
for	O
sensation	B-T038
barriers	B-T058
associated	O
with	O
condomless	B-T033
receptive	O
anal	O
sex	O
=	O
0	O
.	O
03	O
)	O
.	O

Further	O
,	O
the	O
subscales	B-T170
were	O
significantly	O
associated	O
with	O
reporting	O
any	O
condom	O
use	O
problems	O
(	O
all	O
Ps	O
<	O
0	O
.	O
001	O
)	O
and	O
a	O
measure	O
of	O
condomless	B-T033
oral	O
sex	O
(	O
all	O
Ps	O
<	O
0	O
.	O
001	O
,	O
except	O
for	O
partner	B-T098
-	O
related	O
barriers	B-T058
=	O
0	O
.	O
31	O
)	O
.	O

Finally	O
,	O
the	O
sensation	B-T038
-	O
related	O
barriers	B-T058
subscale	B-T170
was	O
significantly	O
associated	O
with	O
testing	O
positive	B-T033
for	O
Chlamydia	B-T007
and	O
/	O
or	O
gonorrhea	B-T038
(	O
P	O
=	O
0	O
.	O
049	O
)	O
.	O

The	O
3	O
identified	O
subscales	B-T170
yielded	O
adequate	O
reliability	O
and	O
strong	O
evidence	O
of	O
validity	O
,	O
thereby	O
suggesting	O
the	O
utility	O
of	O
these	O
brief	O
measures	O
for	O
use	O
in	O
observational	B-T062
and	O
experimental	B-T062
research	I-T062
with	O
YBMSM	B-T098
.	O

Variation	O
in	O
the	O
Intensity	O
of	O
Selection	B-T038
on	O
Codon	B-T082
Bias	O
over	O
Time	O
Causes	O
Contrasting	B-T082
Patterns	I-T082
of	O
Base	O
Composition	O
Evolution	B-T038
in	O
Drosophila	B-T204

Four	O
-	O
fold	O
degenerate	O
coding	B-T017
sites	I-T017
form	O
a	O
major	O
component	O
of	O
the	O
genome	B-T017
,	O
and	O
are	O
often	O
used	O
to	O
make	O
inferences	O
about	O
selection	B-T038
and	O
demography	O
,	O
so	O
that	O
understanding	O
their	O
evolution	B-T038
is	O
important	O
.	O

Despite	O
previous	O
efforts	O
,	O
many	O
questions	O
regarding	O
the	O
causes	O
of	O
base	O
composition	O
changes	O
at	O
these	O
sites	B-T017
in	O
Drosophila	B-T204
remain	O
unanswered	O
.	O

To	O
shed	O
further	O
light	O
on	O
this	O
issue	B-T033
,	O
we	O
obtained	O
a	O
new	O
whole	O
-	O
genome	O
polymorphism	O
data	O
set	O
from	O
D	B-T204
.	I-T204

simulans	I-T204
.	O

We	O
analyzed	B-T062
samples	B-T017
from	O
the	O
putatively	O
ancestral	O
range	O
of	O
D	B-T204
.	I-T204

simulans	I-T204
,	O
as	O
well	O
as	O
an	O
existing	O
polymorphism	O
data	O
set	O
from	O
an	O
African	O
population	O
of	O
D	B-T204
.	I-T204

melanogaster	I-T204
.	O

By	O
using	O
D	B-T204
.	I-T204

yakuba	I-T204
as	O
an	O
outgroup	O
,	O
we	O
found	O
clear	O
evidence	O
for	O
selection	B-T038
on	O
4	O
-	O
fold	O
sites	B-T017
along	O
both	O
lineages	O
over	O
a	O
substantial	O
period	O
,	O
with	O
the	O
intensity	O
of	O
selection	B-T038
increasing	O
with	O
GC	O
content	O
.	O

Based	O
on	O
an	O
explicit	O
model	O
of	O
base	O
composition	O
evolution	B-T038
,	O
we	O
suggest	O
that	O
the	O
observed	O
AT	O
-	O
biased	O
substitution	B-T082
pattern	I-T082
in	O
both	O
lineages	O
is	O
probably	O
due	O
to	O
an	O
ancestral	O
reduction	O
in	O
selection	B-T038
intensity	O
,	O
and	O
is	O
unlikely	O
to	O
be	O
the	O
result	B-T033
of	O
an	O
increase	O
in	O
mutational	B-T038
bias	O
towards	O
AT	O
alone	O
.	O

By	O
using	O
two	O
polymorphism	B-T058
-	I-T058
based	I-T058
methods	I-T058
for	O
estimating	O
selection	B-T038
coefficients	O
over	O
different	O
timescales	O
,	O
we	O
show	O
that	O
the	O
selection	B-T038
intensity	O
on	O
codon	B-T082
usage	O
has	O
been	O
rather	O
stable	O
in	O
D	B-T204
.	I-T204

simulans	I-T204
in	O
the	O
recent	O
past	O
,	O
but	O
the	O
long	O
-	O
term	O
estimates	O
in	O
D	B-T204
.	I-T204

melanogaster	I-T204
are	O
much	O
higher	O
than	O
the	O
short	O
-	O
term	O
ones	O
,	O
indicating	O
a	O
continuing	O
decline	O
in	O
selection	B-T038
intensity	O
,	O
to	O
such	O
an	O
extent	B-T082
that	O
the	O
short	O
-	O
term	O
estimates	O
suggest	O
that	O
selection	B-T038
is	O
only	O
active	O
in	O
the	O
most	O
GC	O
-	O
rich	O
parts	O
of	O
the	O
genome	B-T017
.	O

Finally	O
,	O
we	O
provide	O
evidence	O
for	O
complex	O
evolutionary	B-T082
patterns	I-T082
in	O
the	O
putatively	O
neutral	B-T103
short	I-T103
introns	I-T103
,	O
which	O
cannot	O
be	O
explained	O
by	O
the	O
standard	O
GC	O
-	O
biased	O
gene	B-T038
conversion	I-T038
model	O
.	O

These	O
results	B-T033
reveal	O
a	O
dynamic	O
picture	O
of	O
base	O
composition	O
evolution	B-T038
.	O

A	O
Case	O
of	O
Koch	B-T038
'	I-T038
s	I-T038
Spine	I-T038
Treated	O
with	O
Modified	O
Transpedicular	B-T058
Vertebral	I-T058
Curettage	I-T058
and	O
Posterior	B-T082
Fixation	B-T058
:	O
A	O
Novel	O
Technique	O

Tuberculosis	B-T038
(	O
TB	B-T038
)	O
is	O
a	O
chronic	O
granulomatous	B-T038
infection	I-T038
caused	O
by	O
acid	B-T007
-	I-T007
fast	I-T007
mycobacterium	I-T007
tuberculosis	I-T007
bacilli	I-T007
.	O

Spinal	B-T082
involvement	I-T082
occurs	O
in	O
less	O
than	O
one	O
percent	O
of	O
TB	B-T038
.	O

Spinal	B-T038
TB	I-T038
(	O
Pott	B-T038
'	I-T038
s	I-T038
disease	I-T038
)	O
accounts	O
for	O
50	O
%	O
of	O
skeletal	O
TB	O
.	O

Though	O
it	O
most	O
commonly	O
affects	O
the	O
thoracolumbar	B-T082
junction	I-T082
,	O
it	O
can	O
occur	O
at	O
any	O
level	O
of	O
the	O
spine	B-T017
.	O

Early	O
diagnosis	B-T033
and	O
treatment	B-T058
is	O
mandatory	O
in	O
order	O
to	O
avoid	O
neurological	B-T038
complications	I-T038
and	O
spinal	B-T017
deformity	I-T017
.	O

We	O
report	B-T170
a	O
case	O
of	O
a	O
young	O
female	O
with	O
tuberculosis	B-T038
of	O
D12	B-T082
-	I-T082
L1	I-T082
who	O
was	O
treated	O
with	O
posterior	B-T082
decompression	B-T058
using	O
a	O
modified	O
transpedicular	B-T058
approach	I-T058
and	O
posterior	B-T082
instrumentation	B-T058
with	O
a	O
successful	O
outcome	O
.	O

A	O
comparison	O
of	O
two	O
comorbidity	O
indices	O
for	O
predicting	O
inpatient	O
rehabilitation	B-T058
outcomes	O

Comorbid	B-T033
conditions	I-T033
are	O
important	O
in	O
health	B-T058
care	I-T058
.	O

The	O
best	O
comorbidity	O
index	O
for	O
predicting	O
the	O
impact	O
of	O
comorbidities	O
on	O
rehabilitation	B-T058
outcomes	O
has	O
not	O
been	O
determined	O
.	O

Compare	O
the	O
associations	O
of	O
comorbidity	O
measured	O
using	O
the	O
Charlson	O
Comorbidity	O
Index	O
(	O
CCI	O
)	O
and	O
the	O
Cumulative	O
Index	O
Rating	O
Scale	O
(	O
CIRS	O
)	O
with	O
key	O
rehabilitation	B-T058
outcomes	O
.	O

Aim	O
was	O
to	O
determine	O
whether	O
either	O
of	O
these	O
comorbidity	O
indices	O
helped	O
explain	O
the	O
variation	O
in	O
key	O
rehabilitation	B-T058
outcomes	O
.	O

Prospective	B-T062
open	I-T062
-	I-T062
cohort	I-T062
study	I-T062
.	O

Inpatient	O
rehabilitation	B-T058
ward	B-T092
,	O
Melbourne	B-T082
,	O
Australia	B-T082
.	O

Adults	O
admitted	B-T058
for	O
inpatient	O
rehabilitation	B-T058
(	O
n	O
=	O
280	O
)	O
.	O

The	O
main	O
outcomes	O
were	O
demographic	O
(	O
e	O
.	O
g	O
.	O

age	O
,	O
gender	O
,	O
discharge	B-T058
destination	B-T082
)	O
and	O
clinical	O
outcomes	O
(	O
reason	B-T033
for	O
rehabilitation	B-T058
,	O
length	O
of	O
stay	O
,	O
Functional	B-T170
Independence	I-T170
Measure	I-T170
,	O
CCI	O
and	O
CIRS	O
)	O
.	O

A	O
series	O
of	O
regression	B-T170
analyses	I-T170
were	O
performed	O
to	O
determine	O
the	O
influence	O
of	O
comorbidity	O
on	O
three	O
dependent	O
variables	O
:	O
LOS	O
in	O
rehabilitation	B-T058
;	O
2	O
)	O
the	O
change	O
in	O
Functional	B-T170
Independence	I-T170
Measure	I-T170
-	I-T170
motor	I-T170
score	O
between	O
rehabilitation	B-T058
discharge	B-T058
and	O
admission	B-T058
;	O
and	O
3	O
)	O
the	O
discharge	B-T058
destination	B-T082
(	O
home	B-T082
vs	O
other	O
)	O
.	O

The	O
mean	O
age	O
was	O
57	O
.	O
7	O
years	O
,	O
there	O
were	O
slightly	O
more	O
females	O
(	O
51	O
%	O
)	O
,	O
most	O
(	O
95	O
%	O
)	O
patients	O
previously	O
lived	B-T033
at	I-T033
home	I-T033
with	O
family	O
or	O
other	O
relatives	O
(	O
63	O
%	O
)	O
.	O

The	O
most	O
common	O
reason	B-T033
for	O
rehabilitation	B-T058
was	O
orthopaedic	B-T058
or	O
other	O
conditions	O
(	O
52	O
%	O
)	O
and	O
most	O
(	O
80	O
%	O
)	O
people	B-T098
were	O
discharged	B-T058
home	B-T082
.	O

The	O
median	O
LOS	O
was	O
27	O
days	O
.	O

There	O
were	O
100	O
(	O
35	O
.	O
7	O
%	O
)	O
patients	O
who	O
had	O
no	O
comorbidity	O
recorded	B-T170
using	O
the	O
CCI	O
,	O
112	O
(	O
40	O
.	O
0	O
%	O
)	O
and	O
26	O
(	O
9	O
.	O
3	O
%	O
)	O
who	O
three	O
or	O
more	O
.	O

All	O
patients	O
had	O
at	O
least	O
one	O
comorbidity	O
recorded	B-T170
with	O
the	O
CIRS	O
,	O
and	O
264	O
(	O
94	O
.	O
3	O
%	O
)	O
had	O
3	O
or	O
more	O
comorbidities	O
.	O

There	O
was	O
little	O
or	O
no	O
difference	O
between	O
the	O
CCI	O
or	O
CIRS	O
in	O
terms	O
of	O
their	O
ability	O
to	O
explain	O
the	O
variance	O
in	O
LOS	O
(	O
adjusted	O
R2	O
=	O
0	O
.	O
38	O
with	O
and	O
without	O
comorbidities	O
)	O
,	O
change	O
in	O
disability	B-T033
during	O
rehabilitation	B-T058
(	O
adjusted	O
R2	O
=	O
0	O
.	O
31	O
-	O
0	O
.	O
33	O
with	O
and	O
without	O
comorbidities	O
)	O
or	O
the	O
discharge	B-T058
destination	B-T082
(	O
AUC	O
=	O
0	O
.	O
72	O
without	O
comorbidities	O
;	O
0	O
.	O
73	O
-	O
0	O
.	O
74	O
with	O
comorbidities	O
)	O
beyond	O
that	O
accounted	O
for	O
by	O
demographic	O
and	O
clinical	B-T170
information	I-T170
.	O

Neither	O
the	O
CIRS	O
nor	O
the	O
CCI	O
in	O
our	O
patient	O
sample	O
provide	O
additional	O
information	O
that	O
explains	O
the	O
impact	O
of	O
comorbidities	O
on	O
key	O
rehabilitation	B-T058
outcomes	O
.	O

Further	O
research	B-T062
is	O
needed	O
to	O
determine	O
the	O
most	O
appropriate	O
measure	O
of	O
comorbidity	O
of	O
relevance	O
to	O
inpatient	O
rehabilitation	B-T058
outcomes	O
.	O

Internet	O
Gaming	O
Disorder	B-T038
Explains	O
Unique	O
Variance	O
in	O
Psychological	O
Distress	O
and	O
Disability	B-T033
After	O
Controlling	O
for	O
Comorbid	B-T033
Depression	B-T038
,	O
OCD	B-T038
,	O
ADHD	B-T038
,	O
and	O
Anxiety	B-T033

This	O
study	B-T062
extends	O
knowledge	B-T170
about	O
the	O
relationship	O
of	O
Internet	B-T038
Gaming	I-T038
Disorder	I-T038
(	O
IGD	B-T038
)	O
to	O
other	O
established	O
mental	B-T038
disorders	I-T038
by	O
exploring	O
comorbidities	O
with	O
anxiety	B-T033
,	O
depression	B-T038
,	O
Attention	B-T038
Deficit	I-T038
Hyperactivity	I-T038
Disorder	I-T038
(	O
ADHD	B-T038
)	O
,	O
and	O
obsessive	B-T038
compulsive	I-T038
disorder	I-T038
(	O
OCD	B-T038
)	O
,	O
and	O
assessing	O
whether	O
IGD	B-T038
accounts	O
for	O
unique	O
variance	O
in	O
distress	B-T033
and	O
disability	B-T033
.	O

An	O
online	B-T170
survey	I-T170
was	O
completed	O
by	O
a	O
convenience	B-T062
sample	I-T062
that	O
engages	O
in	O
Internet	O
gaming	O
(	O
N	O
=	O
404	O
)	O
.	O

Participants	B-T098
meeting	O
criteria	O
for	O
IGD	B-T038
based	O
on	O
the	O
Personal	B-T062
Internet	I-T062
Gaming	I-T062
Disorder	I-T062
Evaluation	I-T062
-	I-T062
9	I-T062
(	O
PIE	B-T062
-	I-T062
9	I-T062
)	O
reported	O
higher	O
comorbidity	O
with	O
depression	B-T038
,	O
OCD	B-T038
,	O
ADHD	B-T038
,	O
and	O
anxiety	B-T033
compared	O
with	O
those	O
who	O
did	O
not	O
meet	O
the	O
IGD	B-T038
criteria	O
.	O

IGD	B-T038
explained	O
a	O
small	O
proportion	O
of	O
unique	O
variance	O
in	O
distress	B-T033
(	O
1	O
%	O
)	O
and	O
disability	B-T033
(	O
3	O
%	O
)	O
.	O

IGD	B-T038
accounted	O
for	O
a	O
larger	O
proportion	O
of	O
unique	O
variance	O
in	O
disability	B-T033
than	O
anxiety	B-T033
and	O
ADHD	B-T038
,	O
and	O
a	O
similar	O
proportion	O
to	O
depression	B-T038
.	O

Replications	O
with	O
clinical	B-T098
samples	I-T098
using	O
longitudinal	O
designs	O
and	O
structured	O
diagnostic	O
interviews	O
are	O
required	O
.	O

What	O
Is	O
the	O
Real	O
Impact	O
of	O
Urinary	B-T038
Incontinence	I-T038
on	O
Female	B-T038
Sexual	I-T038
Dysfunction	I-T038
?	O
A	O
Case	B-T062
Control	I-T062
Study	I-T062

Urinary	B-T038
incontinence	I-T038
(	O
UI	B-T038
)	O
has	O
been	O
associated	O
with	O
negative	B-T033
effects	O
on	O
women	B-T098
'	I-T098
s	I-T098
sexuality	O
.	O

Women	B-T098
'	I-T098
s	I-T098
sexuality	O
and	O
sexual	B-T038
function	I-T038
are	O
a	O
complex	O
issue	B-T033
,	O
and	O
the	O
role	O
of	O
UI	B-T038
is	O
not	O
completely	O
clear	O
.	O

To	O
assess	O
the	O
impact	O
of	O
UI	B-T038
on	O
female	B-T038
sexual	I-T038
function	I-T038
by	O
comparing	O
this	O
population	B-T098
with	O
a	O
control	O
group	O
of	O
continent	O
women	B-T098
.	O

We	O
performed	O
a	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
from	O
August	O
2012	O
to	O
September	O
2013	O
.	O

We	O
evaluated	B-T058
continent	O
and	O
incontinent	O
women	B-T098
(	O
age	O
range	O
=	O
30	O
-	O
70	O
years	O
)	O
for	O
their	O
sexuality	O
.	O

All	O
patients	O
were	O
evaluated	B-T058
by	O
anamnesis	B-T038
,	O
physical	B-T058
examination	I-T058
,	O
and	O
self	B-T062
-	I-T062
report	I-T062
quality	B-T170
-	I-T170
of	I-T170
-	I-T170
life	I-T170
questionnaires	I-T170
.	O

In	O
addition	O
,	O
incontinent	O
women	B-T098
underwent	O
a	O
1	O
-	O
hour	O
pad	B-T058
test	I-T058
.	O

Patients	O
without	O
sexual	O
activity	O
were	O
evaluated	B-T058
for	O
the	O
role	O
of	O
UI	B-T038
in	O
their	O
sexual	O
abstinence	O
.	O

Sexual	O
abstinence	O
was	O
defined	O
as	O
the	O
absence	O
of	O
sexual	O
activity	O
for	O
more	O
than	O
6	O
months	O
.	O

All	O
sexually	B-T033
active	I-T033
women	B-T098
completed	O
the	O
self	B-T062
-	I-T062
report	I-T062
Sexuality	O
Quotient	O
-	O
Female	O
Version	B-T170
(	O
SQ	O
-	O
F	O
)	O
questionnaire	B-T170
.	O

A	O
total	O
of	O
356	O
women	B-T098
were	O
included	O
in	O
the	O
study	B-T062
(	O
incontinent	O
,	O
n	O
=	O
243	O
;	O
continent	O
,	O
n	O
=	O
113	O
)	O
.	O

Sexual	O
abstinence	O
was	O
found	O
in	O
162	O
women	B-T098
(	O
45	O
%	O
)	O
.	O

Incontinent	O
women	B-T098
presented	O
a	O
higher	O
prevalence	O
(	O
P	O
<	O
.	O
001	O
)	O
of	O
sexual	O
abstinence	O
than	O
their	O
counterparts	O
(	O
129	O
[	O
53	O
%	O
]	O
and	O
33	O
[	O
29	O
.	O
2	O
%	O
]	O
,	O
respectively	O
)	O
.	O

Age	O
,	O
marital	O
status	O
,	O
and	O
UI	B-T038
were	O
found	O
to	O
be	O
isolated	O
predictive	B-T170
factors	I-T170
for	O
more	O
sexual	O
abstinence	O
in	O
incontinent	O
women	B-T098
.	O

Sexually	B-T033
active	I-T033
women	B-T098
(	O
incontinent	O
,	O
n	O
=	O
114	O
;	O
continent	O
,	O
n	O
=	O
80	O
)	O
presented	O
similar	O
demographic	O
data	O
.	O

Despite	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
,	O
incontinent	O
women	B-T098
had	O
less	O
sexual	O
desire	O
,	O
foreplay	B-T033
,	O
harmony	O
with	O
a	O
partner	B-T098
,	O
sexual	B-T038
comfort	I-T038
,	O
and	O
sexual	B-T038
satisfaction	I-T038
than	O
their	O
counterparts	O
.	O

Women	B-T098
with	O
greater	O
urinary	B-T033
leakage	I-T033
during	O
the	O
1	O
-	O
hour	O
pad	B-T058
test	I-T058
(	O
weight	O
>	O
11	O
g	O
)	O
had	O
the	O
worst	O
sexual	B-T038
function	I-T038
(	O
SQ	O
-	O
F	O
)	O
score	O
.	O

Women	B-T098
with	O
UI	B-T038
were	O
more	O
likely	O
to	O
be	O
sexual	O
abstinent	O
than	O
continent	O
women	B-T098
.	O

Furthermore	O
,	O
women	B-T098
with	O
UI	B-T038
showed	O
less	O
sexual	O
desire	O
,	O
sexual	B-T038
comfort	I-T038
,	O
and	O
sexual	B-T038
satisfaction	I-T038
than	O
their	O
counterparts	O
despite	O
having	O
a	O
similar	O
frequency	O
of	O
sexual	O
activity	O
.	O

Salvianolic	B-T103
Acids	I-T103
for	O
Injection	B-T103
(	O
SAFI	B-T103
)	O
suppresses	O
inflammatory	B-T038
responses	I-T038
in	O
activated	O
microglia	B-T017
to	O
attenuate	O
brain	B-T037
damage	I-T037
in	O
focal	B-T038
cerebral	I-T038
ischemia	I-T038

Inflammatory	B-T038
reactions	I-T038
induced	O
by	O
microglia	B-T017
in	O
the	O
brain	B-T017
play	O
crucial	O
roles	O
in	O
ischemia	B-T038
/	O
reperfusion	B-T037
(	I-T037
I	I-T037
/	I-T037
R	I-T037
)	I-T037
cerebral	I-T037
injuries	I-T037
.	O

Microglia	B-T017
activation	O
has	O
been	O
shown	O
to	O
be	O
closely	O
related	O
to	O
TLR4	B-T038
/	O
NF	B-T038
-	I-T038
κB	I-T038
signal	I-T038
pathways	I-T038
.	O

Salvianolic	B-T103
acids	I-T103
for	O
injection	B-T103
(	O
SAFI	B-T103
)	O
have	O
been	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
ischemic	B-T038
stroke	I-T038
with	O
reported	B-T058
neuroprotective	O
effects	O
;	O
however	O
,	O
the	O
underlying	O
mechanisms	O
are	O
still	O
uncertain	O
.	O

First	O
,	O
we	O
studied	B-T062
the	O
effect	O
of	O
SAFI	B-T103
on	O
inflammatory	B-T038
responses	I-T038
in	O
LPS	B-T103
-	O
stimulated	O
BV	B-T007
-	I-T007
2	I-T007
microglia	B-T017
.	O

Then	O
,	O
to	O
discover	O
whether	O
the	O
beneficial	O
in	O
vitro	O
effects	O
of	O
SAFI	B-T103
lead	O
to	O
in	O
vivo	O
therapeutic	B-T201
effect	I-T201
s	O
,	O
an	O
MCAO	B-T017
(	O
Middle	B-T017
cerebral	I-T017
artery	I-T017
occlusion	I-T017
)	O
rat	B-T204
model	B-T038
was	O
further	O
employed	B-T033
to	O
elucidate	O
the	O
probable	O
mechanism	O
of	O
SAFI	B-T103
in	O
treating	O
ischemic	B-T038
stroke	I-T038
.	O

Rats	B-T204
in	O
the	O
SAFI	B-T103
group	O
were	O
given	O
SAFI	B-T103
(	O
23	O
or	O
46mg	O
/	O
kg	O
)	O
before	O
I	B-T038
/	O
R	B-T037
injury	I-T037
.	O

The	O
results	O
showed	O
that	O
SAFI	B-T103
treatment	O
significantly	O
decreased	O
neuroinflammation	B-T038
and	O
the	O
infarction	B-T038
volume	O
compared	O
with	O
the	O
vehicle	B-T103
group	O
.	O

Activation	O
of	O
microglia	B-T017
cells	I-T017
was	O
reduced	O
,	O
and	O
TLR4	B-T038
/	O
NF	B-T038
-	I-T038
κB	I-T038
signals	I-T038
,	O
which	O
were	O
markedly	O
inhibited	O
by	O
SAFI	B-T103
treatment	O
in	O
ischemic	O
hemisphere	B-T017
,	O
were	O
accompanied	O
by	O
reduced	O
expression	B-T038
and	O
release	B-T058
of	O
cytokines	B-T103
IL	B-T103
-	I-T103
1β	I-T103
and	O
IL	B-T103
-	I-T103
6	I-T103
.	O

This	O
study	B-T062
provides	O
evidence	O
that	O
SAFI	B-T103
effectively	O
protects	O
the	O
brain	B-T017
after	O
cerebral	B-T038
ischemia	I-T038
,	O
which	O
may	O
be	O
caused	O
by	O
attenuating	O
inflammation	B-T038
in	O
microglia	B-T017
.	O

Dynamics	O
of	O
bacterial	O
class	B-T007
Bacilli	I-T007
in	O
the	O
deepest	B-T082
valley	I-T082
lake	I-T082
of	O
Kashmir	O
-	O
the	O
Manasbal	B-T082
Lake	I-T082

In	O
recognition	O
of	O
the	O
importance	O
of	O
bacteria	B-T007
as	O
ecological	B-T103
indicators	I-T103
of	O
the	O
aquatic	O
systems	O
a	O
comprehensive	B-T062
and	I-T062
systematic	I-T062
analysis	I-T062
was	O
carried	O
out	O
on	O
Manasbal	B-T082
Lake	I-T082
,	O
the	O
deepest	B-T082
spring	I-T082
fed	I-T082
valley	I-T082
lake	I-T082
of	O
Kashmir	O
.	O

The	O
main	O
objective	O
envisaged	O
was	O
to	O
analyze	B-T062
bacterial	O
community	O
composition	O
(	O
BCC	O
)	O
and	O
for	O
this	O
purpose	O
systematic	O
and	O
regular	O
sampling	O
of	O
waters	B-T103
from	O
ten	O
different	O
sampling	B-T082
stations	I-T082
,	O
predetermined	O
in	O
the	O
Lake	B-T082
according	O
to	O
differences	O
in	O
degree	O
of	O
human	O
interference	O
and	O
also	O
as	O
zones	B-T082
of	O
special	O
ecological	O
interests	O
were	O
selected	O
.	O

The	O
isolated	O
species	B-T170
were	O
identified	O
according	O
to	O
Bergey	B-T170
'	I-T170
s	I-T170
Manual	I-T170
specification	I-T170
by	O
examining	O
their	O
micro	O
and	O
macro	O
morphological	O
characteristics	O
and	O
biochemical	O
characteristics	O
on	O
different	O
culture	B-T103
media	I-T103
.	O

Further	O
confirmation	B-T033
was	O
done	O
by	O
sequencing	O
the	O
16s	B-T017
rRNA	I-T017
gene	I-T017
by	O
using	O
universal	B-T103
bacterial	I-T103
primers	I-T103
27F	B-T103
and	O
1429R	B-T103
.	O

From	O
all	O
the	O
sampling	B-T082
stations	I-T082
the	O
class	B-T007
Bacilli	I-T007
showed	O
a	O
maximum	O
relative	O
abundance	O
with	O
a	O
contribution	O
of	O
16	O
bacterial	B-T170
species	I-T170
.	O

The	O
whole	O
process	O
resulted	O
in	O
the	O
identification	O
of	O
Bacillus	B-T007
aerius	I-T007
,	O
Bacillus	B-T007
altitudinis	I-T007
,	O
Bacillus	B-T007
anthracis	I-T007
,	O
Bacillus	B-T007
cereus	I-T007
,	O
Bacillus	B-T007
ginsengisoli	I-T007
,	O
Bacillus	B-T007
pumilus	I-T007
,	O
Bacillus	B-T007
safensis	I-T007
,	O
Bacillus	B-T007
stratosphericus	I-T007
,	O
Bacillus	B-T007
subtilis	I-T007
,	O
Bacillus	B-T007
tequilensis	I-T007
,	O
Bacillus	B-T007
thermocopriae	I-T007
,	O
Bacillus	B-T007
thuringiensis	I-T007
,	O
Brevibacillus	B-T007
agri	I-T007
strain	I-T007
,	O
Lysinibacillus	B-T007
boronitolerans	I-T007
,	O
Lysinibacillus	B-T007
pakistanensis	I-T007
and	O
Lysinibacillus	B-T007
sphaericus	I-T007
.	O

A	O
new	O
angle	B-T082
and	O
its	O
relationship	O
with	O
early	O
fixation	B-T038
failure	I-T038
of	O
femoral	B-T037
neck	I-T037
fractures	I-T037
treated	O
with	O
three	O
cannulated	B-T074
compression	I-T074
screws	I-T074

The	O
Pauwels	O
angle	O
has	O
been	O
used	O
widely	O
,	O
however	O
an	O
accurate	O
evaluation	O
of	O
this	O
angle	B-T082
is	O
difficult	O
because	O
of	O
deformity	B-T017
of	O
the	O
affected	O
lower	B-T017
extremity	I-T017
.	O

Therefore	O
we	O
designed	O
a	O
new	O
measurement	O
of	O
the	O
orientation	B-T082
of	O
femoral	B-T037
neck	I-T037
fracture	I-T037
and	O
applied	O
this	O
in	O
a	O
retrospective	B-T062
study	I-T062
to	O
assess	O
:	O
(	O
1	O
)	O
its	O
reproducibility	O
,	O
(	O
2	O
)	O
its	O
advantages	O
compared	O
with	O
the	O
Pauwels	O
angle	O
,	O
(	O
3	O
)	O
its	O
relationship	O
with	O
the	O
short	B-T058
-	I-T058
term	I-T058
prognosis	I-T058
treated	O
with	O
three	O
cannulated	B-T074
compression	I-T074
screws	I-T074
.	O

This	O
new	O
measurement	O
is	O
reproducible	O
and	O
has	O
some	O
reference	O
meaning	O
for	O
the	O
treatment	B-T058
of	O
femoral	B-T037
neck	I-T037
fractures	I-T037
.	O

Two	O
hundred	O
and	O
twenty	O
-	O
eight	O
patients	O
with	O
femoral	B-T037
neck	I-T037
fractures	I-T037
treated	O
with	O
three	O
cannulated	B-T074
compression	I-T074
screws	I-T074
were	O
retrospectively	B-T062
analyzed	I-T062
.	O

The	O
VN	O
angle	O
,	O
which	O
was	O
the	O
angle	B-T082
between	O
the	O
fracture	O
line	O
and	O
the	O
vertical	B-T082
of	O
the	O
neck	B-T082
axis	I-T082
,	O
and	O
the	O
Pauwels	O
angle	O
were	O
measured	O
respectively	O
.	O

The	O
method	O
of	O
ICC	O
was	O
performed	O
to	O
assess	O
the	O
reproducibility	O
of	O
the	O
two	O
angles	B-T082
,	O
and	O
the	O
absolute	O
value	O
of	O
difference	O
in	O
pre	O
-	O
operative	O
and	O
post	O
-	O
operative	O
radiographs	B-T058
was	O
used	O
to	O
evaluate	O
the	O
uniformity	O
of	O
the	O
two	O
angles	B-T082
.	O

These	O
fractures	B-T037
were	O
divided	O
into	O
four	O
groups	O
according	O
to	O
VN	O
angle	O
(	O
VN	O
<	O
0°	O
(	O
n	O
=	O
92	O
)	O
,	O
0°≤VN	O
<	O
10°	O
(	O
n	O
=	O
82	O
)	O
,	O
10°≤VN	O
<	O
15°	O
(	O
n	O
=	O
26	O
)	O
,	O
VN≥15°	O
(	O
n	O
=	O
28	O
)	O
)	O
,	O
and	O
the	O
short	O
-	O
term	O
(	O
within	O
6	O
months	O
)	O
fixation	B-T058
results	O
of	O
radiographs	B-T058
in	O
these	O
fractures	B-T037
were	O
evaluated	O
.	O

The	O
ICC	O
of	O
the	O
VN	O
angle	O
and	O
the	O
Pauwels	O
angle	O
in	O
pre	O
-	O
operative	O
radiographs	B-T058
were	O
0	O
.	O
937	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
0	O
.	O
922	O
-	O
0	O
.	O
950	O
)	O
and	O
0	O
.	O
942	O
respectively	O
(	O
95	O
%	O
CI	O
:	O
0	O
.	O
914	O
-	O
0	O
.	O
970	O
)	O
,	O
indicating	O
both	O
angles	B-T082
had	O
a	O
good	O
inter	O
-	O
rater	O
reproducibility	O
.	O

However	O
,	O
there	O
was	O
a	O
great	O
difference	O
between	O
the	O
Pauwels	O
angle	O
in	O
pre	O
-	O
operative	O
and	O
post	O
-	O
operative	O
radiographs	B-T058
(	O
P	O
=	O
0	O
.	O
037	O
)	O
,	O
the	O
absolute	O
difference	O
was	O
10	O
.	O
66±6	O
.	O
47	O
(	O
range	O
:	O
1	O
.	O
72	O
-	O
38	O
.	O
48	O
)	O
,	O
while	O
no	O
statistical	O
difference	O
for	O
the	O
VN	O
angle	O
(	O
P	O
=	O
0	O
.	O
084	O
)	O
and	O
the	O
absolute	O
difference	O
was	O
2	O
.	O
20±1	O
.	O
63	O
(	O
range	O
:	O
0	O
.	O
05	O
-	O
7	O
.	O
56	O
)	O
.	O

The	O
overall	O
fixation	B-T038
failure	I-T038
rate	O
which	O
was	O
defined	O
as	O
screw	B-T038
loosening	I-T038
,	O
varus	O
collapse	O
,	O
obvious	O
fracture	B-T037
displacement	I-T037
or	O
femoral	B-T017
neck	I-T017
shortening	O
was	O
11	O
.	O
84	O
%	O
,	O
and	O
the	O
mean	O
failure	O
rates	O
according	O
to	O
VN	O
angles	O
were	O
respectively	O
0	O
%	O
,	O
3	O
.	O
24	O
%	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
64	O
-	O
4	O
.	O
84	O
)	O
,	O
22	O
.	O
69	O
%	O
(	O
95	O
%	O
CI	O
:	O
16	O
.	O
43	O
-	O
28	O
.	O
96	O
)	O
,	O
65	O
.	O
45	O
%	O
(	O
95	O
%	O
CI	O
:	O
59	O
.	O
36	O
-	O
71	O
.	O
53	O
)	O
.	O

The	O
mean	O
failure	O
rates	O
of	O
fractures	B-T037
according	O
to	O
post	O
-	O
operative	O
Pauwels	O
angle	O
(	O
<	O
30°	O
,	O
30	O
-	O
50°	O
,	O
>	O
50°	O
)	O
were	O
respectively	O
0	O
%	O
,	O
1	O
.	O
46	O
%	O
(	O
95	O
%	O
CI	O
:	O
1	O
.	O
42	O
-	O
1	O
.	O
50	O
)	O
and	O
36	O
.	O
24	O
%	O
(	O
95	O
%	O
CI	O
:	O
34	O
.	O
93	O
-	O
37	O
.	O
54	O
)	O
.	O

The	O
VN	O
angle	O
has	O
a	O
good	O
inter	O
-	O
rater	O
reproducibility	O
,	O
a	O
higher	O
reliability	O
than	O
the	O
Pauwels	O
angle	O
and	O
is	O
closely	O
related	O
to	O
the	O
short	B-T058
-	I-T058
term	I-T058
prognosis	I-T058
of	O
femoral	B-T037
neck	I-T037
fractures	I-T037
treated	O
with	O
cannulated	B-T074
compression	I-T074
screws	I-T074
.	O

Level	O
IV	O
,	O
retrospective	O
diagnostic	O
study	O
.	O

Retirement	B-T033
crisis	B-T033
warnings	O
becoming	O
a	O
reality	O

The	O
figures	O
are	O
startling	B-T033
:	O
the	O
number	O
of	O
NHS	O
staff	B-T097
applying	O
to	O
retire	B-T033
has	O
surged	O
by	O
a	O
quarter	O
since	O
2012	O
.	O

The	O
potential	O
consequences	O
are	O
alarming	O
;	O
a	O
serious	O
shortage	O
of	O
nurses	B-T097
and	O
other	O
healthcare	B-T097
professionals	I-T097
now	O
seems	O
inevitable	O
.	O

The	O
Burden	O
of	O
Mental	B-T038
Disorders	I-T038
in	O
the	O
Eastern	B-T082
Mediterranean	I-T082
Region	I-T082
,	O
1990	O
-	O
2013	O

The	O
Eastern	B-T082
Mediterranean	I-T082
Region	I-T082
(	O
EMR	B-T082
)	O
is	O
witnessing	O
an	O
increase	O
in	O
chronic	B-T038
disorders	I-T038
,	O
including	O
mental	B-T038
illness	I-T038
.	O

With	O
ongoing	O
unrest	O
,	O
this	O
is	O
expected	O
to	O
rise	O
.	O

This	O
is	O
the	O
first	O
study	B-T062
to	O
quantify	O
the	O
burden	O
of	O
mental	B-T038
disorders	I-T038
in	O
the	O
EMR	B-T082
.	O

We	O
used	O
data	O
from	O
the	O
Global	B-T170
Burden	I-T170
of	I-T170
Disease	I-T170
study	I-T170
(	O
GBD	B-T170
)	O
2013	O
.	O

DALYs	O
(	O
disability	O
-	O
adjusted	O
life	O
years	O
)	O
allow	O
assessment	B-T058
of	O
both	O
premature	B-T033
mortality	I-T033
(	O
years	O
of	O
life	O
lost	O
-	O
YLLs	O
)	O
and	O
nonfatal	O
outcomes	O
(	O
years	O
lived	O
with	O
disability	O
-	O
YLDs	O
)	O
.	O

DALYs	O
are	O
computed	O
by	O
adding	O
YLLs	O
and	O
YLDs	O
for	O
each	O
age	O
-	O
sex	O
-	O
country	O
group	O
.	O

In	O
2013	O
,	O
mental	B-T038
disorders	I-T038
contributed	O
to	O
5	O
.	O
6	O
%	O
of	O
the	O
total	O
disease	O
burden	O
in	O
the	O
EMR	B-T082
(	O
1894	O
DALYS	O
/	O
100	O
,	O
000	O
population	B-T098
)	O
:	O
2519	O
DALYS	O
/	O
100	O
,	O
000	O
(	O
2590	O
/	O
100	O
,	O
000	O
males	O
,	O
2426	O
/	O
100	O
,	O
000	O
females	O
)	O
in	O
high	B-T082
-	I-T082
income	I-T082
countries	I-T082
,	O
1884	O
DALYS	O
/	O
100	O
,	O
000	O
(	O
1618	O
/	O
100	O
,	O
000	O
males	O
,	O
2157	O
/	O
100	O
,	O
000	O
females	O
)	O
in	O
middle	O
-	O
income	O
countries	B-T082
,	O
1607	O
DALYS	O
/	O
100	O
,	O
000	O
(	O
1500	O
/	O
100	O
,	O
000	O
males	O
,	O
1717	O
/	O
100	O
,	O
000	O
females	O
)	O
in	O
low	B-T033
-	I-T033
income	I-T033
countries	B-T082
.	O

Females	O
had	O
a	O
greater	O
proportion	O
of	O
burden	O
due	O
to	O
mental	B-T038
disorders	I-T038
than	O
did	O
males	O
of	O
equivalent	O
ages	O
,	O
except	O
for	O
those	O
under	O
15	O
years	O
of	O
age	O
.	O

The	O
highest	O
proportion	O
of	O
DALYs	O
occurred	O
in	O
the	O
25	O
-	O
49	O
age	O
group	O
,	O
with	O
a	O
peak	O
in	O
the	O
35	O
-	O
39	O
years	O
age	O
group	O
(	O
5344	O
DALYs	O
/	O
100	O
,	O
000	O
)	O
.	O

The	O
burden	O
of	O
mental	B-T038
disorders	I-T038
in	O
EMR	B-T082
increased	O
from	O
1726	O
DALYs	O
/	O
100	O
,	O
000	O
in	O
1990	O
to	O
1912	O
DALYs	O
/	O
100	O
,	O
000	O
in	O
2013	O
(	O
10	O
.	O
8	O
%	O
increase	O
)	O
.	O

Within	O
the	O
mental	B-T098
disorders	I-T098
group	I-T098
in	O
EMR	B-T082
,	O
depressive	B-T038
disorders	I-T038
accounted	O
for	O
most	O
DALYs	O
,	O
followed	O
by	O
anxiety	B-T038
disorders	I-T038
.	O

Among	O
EMR	B-T082
countries	O
,	O
Palestine	O
had	O
the	O
largest	O
burden	O
of	O
mental	B-T038
disorders	I-T038
.	O

Nearly	O
all	O
EMR	B-T082
countries	I-T082
had	O
a	O
higher	O
mental	O
disorder	O
burden	O
compared	O
to	O
the	O
global	O
level	O
.	O

Our	O
findings	O
call	O
for	O
EMR	O
ministries	O
of	O
health	O
to	O
increase	O
provision	O
of	O
mental	B-T058
health	I-T058
services	I-T058
and	O
to	O
address	O
the	O
stigma	O
of	O
mental	O
illness	O
.	O

Moreover	O
,	O
our	O
results	O
showing	O
the	O
accelerating	O
burden	O
of	O
mental	O
health	O
are	O
alarming	O
as	O
the	O
region	O
is	O
seeing	O
an	O
increased	O
level	O
of	O
instability	B-T033
.	O

Indeed	O
,	O
mental	B-T033
health	I-T033
problems	I-T033
,	O
if	O
not	O
properly	O
addressed	O
,	O
will	O
lead	O
to	O
an	O
increased	O
burden	O
of	O
diseases	O
in	O
the	O
region	B-T082
.	O

Like	O
Father	O
,	O
Like	O
Daughter	O
-	O
inherited	O
cutis	B-T017
aplasia	I-T017
occurring	O
in	O
a	O
family	O
with	O
Marfan	B-T038
syndrome	I-T038
:	O
a	O
case	B-T170
report	I-T170

We	O
present	O
the	O
case	O
of	O
a	O
newborn	O
with	O
co	O
-	O
occurrence	O
of	O
Marfan	B-T038
syndrome	I-T038
and	O
aplasia	B-T017
cutis	I-T017
congenita	I-T017
(	O
ACC	B-T017
)	O
and	O
a	O
family	B-T033
history	I-T033
significant	O
for	O
Marfan	B-T038
syndrome	I-T038
and	O
ACC	B-T017
in	O
the	O
father	O
.	O

This	O
case	O
details	O
a	O
previously	O
unreported	O
mutation	B-T038
in	O
Marfan	B-T038
syndrome	I-T038
and	O
describes	O
a	O
novel	O
coinheritance	O
of	O
Marfan	B-T038
syndrome	I-T038
and	O
ACC	B-T017
.	O

Hyperandrogenemia	B-T033
in	O
women	B-T098
with	O
polycystic	B-T038
ovary	I-T038
syndrome	I-T038
:	O
prevalence	O
,	O
characteristics	O
and	O
association	O
with	O
body	B-T201
mass	I-T201
index	I-T201

Hyperandrogenemia	B-T033
is	O
one	O
of	O
the	O
major	O
diagnostic	O
features	O
for	O
the	O
diagnosis	B-T033
of	O
polycystic	B-T038
ovary	I-T038
syndrome	I-T038
(	O
PCOS	B-T038
)	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
prevalence	O
and	O
the	O
characteristics	O
of	O
hyperandrogenemia	B-T033
in	O
women	B-T098
with	O
PCOS	B-T038
and	O
to	O
investigate	O
the	O
association	O
of	O
clinical	O
and	O
biochemical	O
characteristics	O
with	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
according	O
to	O
the	O
presence	B-T033
of	O
hyperandrogenemia	B-T033
.	O

We	O
studied	O
266	O
women	B-T098
diagnosed	B-T033
with	O
PCOS	B-T038
.	O

Hyperandrogenemia	B-T033
was	O
defined	O
by	O
testosterone	B-T103
(	O
T	B-T103
)	O
and	O
/	O
or	O
free	B-T103
testosterone	I-T103
(	O
FT	B-T103
)	O
and	O
/	O
or	O
∆4	B-T103
androstenedione	I-T103
(	O
Δ4	B-T103
-	I-T103
A	I-T103
)	O
higher	O
than	O
75	O
%	O
of	O
the	O
upper	O
limits	O
of	O
each	O
hormone	B-T103
.	O

Patients	O
were	O
stratified	O
in	O
two	O
groups	B-T098
according	O
to	O
a	O
BMI	B-T201
threshold	O
of	O
25	O
kg	O
/	O
m2	O
.	O

Hyperandrogenemia	B-T033
was	O
present	B-T033
in	O
78	O
.	O
2	O
%	O
of	O
the	O
patients	O
.	O

Elevated	O
levels	O
of	O
T	B-T103
were	O
found	O
in	O
58	O
.	O
4	O
%	O
,	O
while	O
elevated	O
levels	O
of	O
FT	B-T103
and	O
Δ4	B-T103
-	I-T103
A	I-T103
were	O
found	O
in	O
42	O
.	O
5	O
%	O
and	O
34	O
.	O
1	O
%	O
of	O
patients	O
.	O

In	O
normal	B-T033
weight	I-T033
women	B-T098
(	O
BMI	B-T201
≤25	O
kg	O
/	O
m2	O
)	O
with	O
hyperandrogenemia	B-T033
lower	O
values	O
of	O
hip	B-T201
circumference	I-T201
and	O
HOMA	B-T058
-	I-T058
IR	I-T058
and	O
increased	O
levels	O
of	O
T	B-T103
,	O
FT	B-T103
,	O
Δ4	B-T103
-	I-T103
A	I-T103
,	O
17	B-T103
-	I-T103
hydroxyprogesterone	I-T103
(	O
17	B-T103
-	I-T103
OHP	I-T103
)	O
,	O
dehydroepiandrosterone	B-T103
sulfate	I-T103
(	O
DHEAS	B-T103
)	O
,	O
white	B-T017
blood	I-T017
cells	I-T017
(	O
WBC	B-T017
)	O
and	O
neutrophils	B-T017
were	O
observed	O
compared	O
to	O
women	B-T098
without	O
hyperandrogenemia	B-T033
.	O

Also	O
,	O
in	O
overweight	B-T033
women	B-T098
higher	O
levels	O
of	O
T	B-T103
,	O
FT	B-T103
,	O
Δ4	B-T103
-	I-T103
A	I-T103
,	O
17	B-T103
-	I-T103
OHP	I-T103
,	O
DHEAS	B-T103
and	O
cortisol	B-T103
were	O
measured	O
,	O
while	O
lower	O
thyroid	B-T058
-	I-T058
stimulating	I-T058
hormone	I-T058
(	I-T058
TSH	I-T058
)	I-T058
levels	I-T058
were	O
comparable	O
to	O
women	B-T098
without	O
hyperandrogenemia	B-T033
.	O

This	O
study	O
showed	O
high	O
prevalence	O
of	O
hyperandrogenemia	B-T033
in	O
PCOS	B-T038
women	B-T098
.	O

Women	B-T098
with	O
BMI	B-T201
≤25	O
kg	O
/	O
m2	O
have	O
significant	O
differences	O
in	O
androgens	B-T103
,	O
WBC	B-T017
,	O
neutrophils	B-T017
and	O
HOMA	B-T058
-	I-T058
IR	I-T058
and	O
women	B-T098
with	O
BMI	B-T201
≥25	O
kg	O
/	O
m2	O
in	O
androgens	B-T103
,	O
TSH	B-T103
and	O
cortisol	B-T103
according	O
to	O
the	O
presence	B-T033
or	O
not	O
of	O
hyperandrogenemia	B-T033
.	O

A	O
Course	O
-	O
Based	O
Approach	B-T082
to	O
the	O
Doctor	B-T097
of	O
Nursing	B-T062
Practice	I-T062
Project	I-T062
:	O
Supporting	O
Student	B-T098
Growth	O
From	O
Concept	O
to	O
Completion	O

We	O
describe	O
a	O
course	O
-	O
based	O
approach	B-T082
to	O
the	O
doctor	B-T097
of	O
nursing	B-T062
practice	I-T062
project	I-T062
in	O
which	O
students	B-T098
work	O
in	O
groups	O
of	O
8	O
to	O
12	O
with	O
a	O
faculty	B-T097
member	I-T097
to	O
complete	O
individual	O
final	O
projects	O
that	O
require	O
a	O
minimum	O
of	O
360	O
practicum	O
hours	O
in	O
3	O
-	O
semester	O
-	O
long	O
courses	O
.	O

Project	O
teams	O
include	O
agency	B-T092
or	O
community	O
-	O
based	O
mentors	B-T098
.	O

Project	B-T033
findings	I-T033
are	O
disseminated	B-T082
through	O
written	B-T170
and	O
oral	B-T170
reports	I-T170
.	O

This	O
approach	B-T082
preserves	O
faculty	B-T097
resources	O
and	O
provides	O
students	B-T098
with	O
mentoring	O
,	O
opportunities	O
for	O
reflection	O
,	O
and	O
time	O
for	O
project	O
development	O
.	O

Clinical	O
and	O
angiographic	B-T058
correlation	O
of	O
high	B-T103
-	I-T103
sensitivity	I-T103
C	I-T103
-	I-T103
reactive	I-T103
protein	I-T103
with	O
acute	B-T038
ST	I-T038
elevation	I-T038
myocardial	I-T038
infarction	I-T038

Vascular	B-T038
inflammation	I-T038
and	O
associated	O
ongoing	O
inflammatory	B-T038
responses	I-T038
are	O
considered	O
as	O
the	O
critical	O
culprits	O
in	O
the	O
pathogenesis	B-T038
of	O
acute	O
atherothrombotic	B-T017
events	O
such	O
as	O
acute	B-T038
coronary	I-T038
syndrome	I-T038
(	O
ACS	B-T038
)	O
and	O
myocardial	B-T038
infarction	I-T038
(	O
MI	B-T038
)	O
.	O

ST	B-T038
segment	I-T038
elevation	I-T038
myocardial	I-T038
infarction	I-T038
(	O
STEMI	B-T038
)	O
is	O
considered	O
as	O
one	O
of	O
the	O
prominent	O
clinical	O
forms	O
of	O
ACS	B-T038
.	O

Moreover	O
,	O
C	B-T103
-	I-T103
reactive	I-T103
protein	I-T103
(	O
CRP	B-T103
)	O
is	O
an	O
important	O
acute	B-T103
phase	I-T103
prsotein	I-T103
,	O
which	O
may	O
be	O
estimated	O
using	O
high	B-T058
-	I-T058
sensitivity	I-T058
methods	I-T058
(	O
hs	B-T058
-	I-T058
CRP	I-T058
)	O
,	O
and	O
its	O
elevated	O
level	B-T033
in	O
body	B-T031
fluids	I-T031
reflects	O
chronic	B-T038
inflammatory	I-T038
status	O
.	O

The	O
circulating	O
hs	B-T058
-	I-T058
CRP	I-T058
level	B-T033
has	O
been	O
proposed	O
as	O
a	O
promising	O
inflammatory	B-T038
marker	B-T201
of	O
coronary	B-T038
artery	I-T038
disease	I-T038
(	O
CAD	B-T038
)	O
.	O

The	O
present	O
study	B-T062
investigated	O
the	O
correlation	O
of	O
hs	B-T058
-	I-T058
CRP	I-T058
level	B-T033
with	O
clinical	O
and	O
angiographic	B-T058
features	O
of	O
STEMI	B-T038
,	O
various	O
other	O
traditional	O
risk	B-T033
factors	I-T033
,	O
complications	B-T038
of	O
myocardial	B-T038
infarction	I-T038
and	O
angiographically	O
significant	O
CAD	B-T038
.	O

Out	O
of	O
190	O
patients	O
with	O
STEMI	B-T038
that	O
were	O
analyzed	B-T062
,	O
the	O
interval	O
between	O
symptom	O
onset	O
and	O
reperfusion	B-T058
therapy	I-T058
(	O
window	O
period	O
)	O
varied	O
from	O
0	O
.	O
5	O
to	O
24	O
h	O
.	O

The	O
hs	B-T058
-	I-T058
CRP	I-T058
value	O
was	O
found	O
to	O
be	O
higher	O
in	O
non	O
-	O
diabetic	O
patients	O
(	O
0	O
.	O
61	O
mg	O
/	O
dl	O
)	O
compared	O
with	O
diabetic	B-T038
patients	O
(	O
0	O
.	O
87	O
mg	O
/	O
dl	O
)	O
.	O

Moreover	O
,	O
a	O
significant	O
correlation	O
between	O
hs	B-T058
-	I-T058
CRP	I-T058
and	O
hs	B-T058
-	I-T058
troponin	I-T058
T	I-T058
was	O
also	O
recorded	O
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
the	O
mean	O
hs	B-T058
-	I-T058
CRP	I-T058
values	O
in	O
patients	O
with	O
or	O
without	O
mortality	O
.	O

It	O
is	O
considered	O
that	O
the	O
present	O
study	B-T062
will	O
increase	O
the	O
understanding	O
of	O
atherosclerosis	B-T038
in	O
general	O
and	O
may	O
also	O
have	O
clinical	O
applications	O
in	O
the	O
targeting	O
of	O
therapy	B-T058
for	O
this	O
harmful	O
disease	B-T038
.	O

Bioelectrochemical	B-T058
anaerobic	O
sewage	O
treatment	O
technology	O
for	O
Arctic	B-T082
communities	O

This	O
study	B-T062
describes	O
a	O
novel	O
wastewater	B-T082
treatment	O
technology	O
suitable	O
for	O
small	O
remote	B-T082
northern	B-T082
communities	O
.	O

The	O
technology	O
is	O
based	O
on	O
an	O
enhanced	O
biodegradation	O
of	O
organic	B-T103
carbon	I-T103
through	O
a	O
combination	O
of	O
anaerobic	O
methanogenic	O
and	O
microbial	O
electrochemical	B-T058
(	O
bioelectrochemical	B-T058
)	O
degradation	O
processes	O
leading	O
to	O
biomethane	B-T103
production	O
.	O

The	O
microbial	O
electrochemical	B-T058
degradation	O
is	O
achieved	O
in	O
a	O
membraneless	B-T033
flow	I-T033
-	O
through	O
bioanode	O
-	O
biocathode	O
setup	O
operating	O
at	O
an	O
applied	O
voltage	O
below	O
the	O
water	B-T103
electrolysis	B-T058
threshold	O
.	O

Laboratory	B-T092
wastewater	B-T082
treatment	O
tests	B-T170
conducted	O
through	O
a	O
broad	B-T082
range	I-T082
of	O
mesophilic	O
and	O
psychrophilic	O
temperatures	O
(	O
5	O
-	O
23	O
°C	O
)	O
using	O
synthetic	O
wastewater	B-T082
showed	O
a	O
biochemical	O
oxygen	O
demand	O
(	O
BOD5	O
)	O
removal	O
efficiency	O
of	O
90	O
-	O
97	O
%	O
and	O
an	O
effluent	O
BOD5	O
concentration	O
as	O
low	O
as	O
7	O
mg	O
L	O
(	O
-	O
1	O
)	O
.	O

An	O
electricity	O
consumption	O
of	O
0	O
.	O
6	O
kWh	O
kg	O
(	O
-	O
1	O
)	O
of	O
chemical	B-T038
oxygen	I-T038
demand	I-T038
(	O
COD	B-T038
)	O
removed	O
was	O
observed	O
.	O

Low	O
energy	O
consumption	O
coupled	O
with	O
enhanced	O
methane	B-T103
production	O
led	O
to	O
a	O
net	O
positive	B-T033
energy	O
balance	O
in	O
the	O
bioelectrochemical	B-T058
treatment	O
system	O
.	O

Impact	O
of	O
femoral	B-T017
artery	I-T017
puncture	B-T058
using	O
digital	B-T058
subtraction	I-T058
angiography	I-T058
and	O
road	O
mapping	O
on	O
vascular	O
and	O
bleeding	B-T038
complications	B-T038
after	O
transfemoral	O
transcatheter	B-T058
aortic	I-T058
valve	I-T058
implantation	I-T058

The	O
use	O
of	O
large	O
-	O
diameter	O
sheaths	O
carries	O
the	O
risk	O
of	O
significant	O
vascular	O
and	O
bleeding	B-T038
complications	B-T038
after	O
transfemoral	O
transcatheter	B-T058
aortic	I-T058
valve	I-T058
implantation	I-T058
(	O
TAVI	B-T058
)	O
.	O

In	O
this	O
analysis	B-T062
,	O
we	O
sought	O
to	O
assess	O
the	O
impact	O
of	O
a	O
modified	O
femoral	B-T017
artery	I-T017
puncture	B-T058
technique	O
using	O
digital	B-T058
subtraction	I-T058
angiography	I-T058
(	O
DSA	B-T058
)	O
and	O
road	O
mapping	O
during	O
transfemoral	O
TAVI	B-T058
on	O
periprocedural	B-T038
vascular	B-T017
and	O
bleeding	B-T038
events	O
.	O

This	O
is	O
a	O
retrospective	O
analysis	B-T062
of	O
transfemoral	O
TAVI	B-T058
patients	O
included	O
in	O
a	O
prospective	B-T170
institutional	I-T170
database	I-T170
.	O

The	O
modified	O
femoral	B-T017
artery	I-T017
puncture	B-T058
technique	O
using	O
DSA	B-T058
-	O
derived	O
road	O
mapping	O
guidance	O
was	O
introduced	O
in	O
October	O
2012	O
.	O

Before	O
the	O
introduction	O
of	O
this	O
technique	O
,	O
vascular	B-T017
puncture	B-T058
was	O
acquired	O
based	O
on	O
an	O
integration	O
of	O
angiographic	B-T058
data	O
,	O
the	O
bony	O
iliofemoral	B-T017
landmarks	B-T082
and	O
a	O
radiopaque	O
object	O
.	O

Consecutive	O
patients	O
who	O
underwent	O
TAVI	B-T058
with	O
the	O
road	O
mapping	O
technique	O
(	O
RM	O
group	O
,	O
n	O
=	O
160	O
)	O
were	O
compared	O
with	O
consecutive	O
patients	O
who	O
underwent	O
TAVI	B-T058
without	O
road	O
mapping	O
(	O
control	O
group	O
,	O
n	O
=	O
160	O
)	O
prior	O
to	O
its	O
introduction	O
.	O

A	O
standardised	O
strategy	O
of	O
periprocedural	B-T058
anticoagulation	I-T058
was	O
adopted	O
in	O
both	O
groups	O
as	O
well	O
as	O
the	O
use	O
of	O
a	O
single	B-T074
suture	I-T074
-	I-T074
based	I-T074
closure	I-T074
device	I-T074
.	O

All	O
endpoints	O
were	O
defined	O
according	O
to	O
the	O
VARC	B-T170
-	I-T170
2	I-T170
criteria	I-T170
for	O
event	O
definition	O
.	O

The	O
mean	O
age	O
in	O
the	O
RM	O
group	O
was	O
80±7	O
.	O
7	O
years	O
compared	O
to	O
81±5	O
.	O
9	O
years	O
in	O
the	O
control	O
group	O
(	O
p	O
=	O
0	O
.	O
19	O
)	O
,	O
and	O
females	O
were	O
equally	O
distributed	O
between	O
both	O
groups	O
(	O
63	O
.	O
1	O
%	O
vs	O
.	O

58	O
.	O
1	O
%	O
,	O
p	O
=	O
0	O
.	O
36	O
)	O
.	O

The	O
baseline	B-T170
logistic	I-T170
EuroSCORE	I-T170
was	O
20	O
.	O
7±14	O
.	O
4	O
%	O
vs	O
.	O

24	O
.	O
9±15	O
.	O
2	O
%	O
in	O
the	O
RM	O
and	O
control	O
group	O
,	O
respectively	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

Notably	O
,	O
sheath	B-T082
size	I-T082
was	O
significantly	O
larger	O
in	O
the	O
RM	O
compared	O
to	O
the	O
control	O
group	O
due	O
to	O
the	O
more	O
frequent	O
use	O
of	O
the	O
20	O
Fr	O
sheath	O
(	O
23	O
.	O
8	O
%	O
vs	O
.	O

1	O
.	O
8	O
%	O
,	O
p	O
<	O
0	O
.	O
001	O
,	O
respectively	O
)	O
associated	O
with	O
the	O
more	O
frequent	O
implantation	B-T058
of	O
the	O
29	O
mm	O
Edwards	O
SAPIEN	O
XT	O
valve	O
in	O
the	O
RM	O
group	O
(	O
43	O
.	O
8	O
%	O
vs	O
.	O

7	O
%	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Despite	O
the	O
latter	O
finding	O
,	O
both	O
major	O
vascular	O
complications	O
and	O
major	O
bleeding	B-T038
at	O
30	O
days	O
were	O
significantly	O
lower	O
in	O
the	O
RM	O
group	O
compared	O
to	O
the	O
control	O
group	O
(	O
4	O
.	O
3	O
%	O
vs	O
.	O

11	O
.	O
8	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
,	O
and	O
14	O
.	O
4	O
%	O
vs	O
.	O

25	O
.	O
6	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
.	O

An	O
analysis	B-T062
limited	O
to	O
access	O
site	O
-	O
related	O
complications	B-T038
also	O
revealed	O
lower	O
events	O
in	O
the	O
road	O
map	O
group	O
but	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
8	O
.	O
1	O
%	O
vs	O
.	O

13	O
.	O
8	O
%	O
,	O
p	O
=	O
0	O
.	O
1	O
)	O
.	O

Other	O
forms	O
of	O
vascular	O
and	O
bleeding	B-T038
complications	B-T038
as	O
well	O
as	O
all	O
-	O
cause	O
mortality	O
were	O
comparable	O
in	O
both	O
groups	O
.	O

A	O
modified	O
femoral	B-T017
artery	I-T017
puncture	B-T058
technique	O
using	O
DSA	B-T058
and	O
road	O
mapping	O
was	O
associated	O
with	O
a	O
reduction	O
in	O
major	O
vascular	O
and	O
bleeding	B-T038
complications	B-T038
after	O
transfemoral	O
TAVI	B-T058
,	O
and	O
provides	O
a	O
simple	O
and	O
effective	O
strategy	O
for	O
potentially	O
improving	O
patient	B-T170
outcomes	I-T170
.	O

Differential	O
Roles	O
of	O
AXIN1	B-T103
and	O
AXIN2	B-T103
in	O
Tankyrase	B-T103
Inhibitor	B-T103
-	I-T103
Induced	I-T103
Formation	O
of	O
Degradasomes	B-T103
and	O
β	B-T103
-	I-T103
Catenin	I-T103
Degradation	O

Inhibition	B-T038
of	O
the	O
tankyrase	B-T103
enzymes	I-T103
(	O
TNKS1	B-T103
and	O
TNKS2	B-T103
)	O
has	O
recently	O
been	O
shown	O
to	O
induce	O
highly	O
dynamic	O
assemblies	O
of	O
β	B-T103
-	I-T103
catenin	I-T103
destruction	B-T103
complex	I-T103
components	B-T103
known	O
as	O
degradasomes	B-T103
,	O
which	O
promote	O
degradation	O
of	O
β	B-T103
-	I-T103
catenin	I-T103
and	O
reduced	O
Wnt	B-T038
signaling	I-T038
activity	O
in	O
colorectal	B-T038
cancer	I-T038
cells	B-T017
.	O

AXIN1	B-T103
and	O
AXIN2	B-T103
/	O
Conductin	B-T103
,	O
the	O
rate	O
-	O
limiting	O
factors	O
for	O
the	O
stability	O
and	O
function	O
of	O
endogenous	O
destruction	B-T103
complexes	I-T103
,	O
are	O
stabilized	B-T033
upon	O
TNKS	B-T103
inhibition	B-T038
due	O
to	O
abrogated	O
degradation	O
of	O
AXIN	B-T103
by	O
the	O
proteasome	B-T103
.	O

Since	O
the	O
role	O
of	O
AXIN1	B-T103
versus	O
AXIN2	B-T103
as	O
scaffolding	B-T103
proteins	I-T103
in	O
the	O
Wnt	B-T038
signaling	I-T038
pathway	I-T038
still	O
remains	O
incompletely	O
understood	B-T038
,	O
we	O
sought	O
to	O
elucidate	O
their	O
relative	O
contribution	O
in	O
the	O
formation	O
of	O
degradasomes	B-T103
,	O
as	O
these	O
protein	B-T103
assemblies	O
most	O
likely	O
represent	O
the	O
morphological	B-T082
and	O
functional	O
correlates	O
of	O
endogenous	O
β	B-T103
-	I-T103
catenin	I-T103
destruction	B-T103
complexes	I-T103
.	O

In	O
SW480	B-T017
colorectal	B-T038
cancer	I-T038
cells	B-T017
treated	O
with	O
the	O
tankyrase	B-T103
inhibitor	I-T103
(	O
TNKSi	B-T103
)	O
G007	B-T103
-	I-T103
LK	I-T103
we	O
found	B-T033
that	O
AXIN1	B-T103
was	O
not	O
required	O
for	O
degradasome	B-T103
formation	O
.	O

In	O
contrast	O
,	O
the	O
formation	O
of	O
degradasomes	B-T103
as	O
well	O
as	O
their	O
capacity	O
to	O
degrade	O
β	B-T103
-	I-T103
catenin	I-T103
were	O
considerably	O
impaired	O
in	O
G007	B-T103
-	I-T103
LK	I-T103
-	I-T103
treated	I-T103
cells	B-T017
depleted	O
of	O
AXIN2	B-T103
.	O

These	O
findings	B-T033
give	O
novel	O
insights	B-T038
into	O
differential	O
functional	O
roles	O
of	O
AXIN1	B-T103
versus	O
AXIN2	B-T103
in	O
the	O
β	B-T103
-	I-T103
catenin	I-T103
destruction	B-T103
complex	I-T103
.	O

MRI	B-T058
-	O
based	O
prostate	B-T038
cancer	I-T038
detection	B-T033
with	O
high	O
-	O
level	O
representation	O
and	O
hierarchical	O
classification	B-T170

Extracting	O
the	O
high	O
-	O
level	O
feature	O
representation	O
by	O
using	O
deep	B-T170
neural	I-T170
networks	I-T170
for	O
detection	B-T033
of	O
prostate	B-T038
cancer	I-T038
,	O
and	O
then	O
based	O
on	O
high	O
-	O
level	O
feature	O
representation	O
constructing	O
hierarchical	O
classification	B-T170
to	O
refine	O
the	O
detection	B-T033
results	O
.	O

High	O
-	O
level	O
feature	O
representation	O
is	O
first	O
learned	O
by	O
a	O
deep	B-T170
learning	I-T170
network	I-T170
,	O
where	O
multiparametric	B-T058
MR	I-T058
images	B-T170
are	O
used	O
as	O
the	O
input	O
data	O
.	O

Then	O
,	O
based	O
on	O
the	O
learned	O
high	O
-	O
level	O
features	O
,	O
a	O
hierarchical	O
classification	B-T170
method	B-T170
is	O
developed	O
,	O
where	O
multiple	B-T170
random	I-T170
forest	I-T170
classifiers	I-T170
are	O
iteratively	O
constructed	O
to	O
refine	O
the	O
detection	B-T033
results	O
of	O
prostate	B-T038
cancer	I-T038
.	O

The	O
experiments	B-T062
were	O
carried	O
on	O
21	O
real	O
patient	O
subjects	O
,	O
and	O
the	O
proposed	O
method	B-T170
achieves	O
an	O
averaged	O
section	B-T058
-	I-T058
based	I-T058
evaluation	I-T058
(	O
SBE	B-T058
)	O
of	O
89	O
.	O
90	O
%	O
,	O
an	O
averaged	O
sensitivity	O
of	O
91	O
.	O
51	O
%	O
,	O
and	O
an	O
averaged	O
specificity	O
of	O
88	O
.	O
47	O
%	O
.	O

The	O
high	O
-	O
level	O
features	O
learned	O
from	O
our	O
proposed	O
method	B-T170
can	O
achieve	O
better	O
performance	O
than	O
the	O
conventional	O
handcrafted	O
features	O
(	O
e	O
.	O
g	O
.	O
,	O
LBP	O
and	O
Haar	O
-	O
like	O
features	O
)	O
in	O
detecting	B-T033
prostate	B-T038
cancer	I-T038
regions	B-T082
,	O
also	O
the	O
context	O
features	O
obtained	O
from	O
the	O
proposed	O
hierarchical	O
classification	B-T170
approach	O
are	O
effective	O
in	O
refining	O
cancer	B-T038
detection	B-T033
result	O
.	O

Quantitative	B-T058
Susceptibility	I-T058
Mapping	I-T058
using	O
Structural	O
Feature	O
based	O
Collaborative	O
Reconstruction	O
(	O
SFCR	O
)	O
in	O
the	O
Human	B-T204
Brain	B-T017

The	O
reconstruction	O
of	O
MR	O
quantitative	B-T058
susceptibility	I-T058
mapping	I-T058
(	O
QSM	B-T058
)	O
from	O
local	O
phase	O
measurements	O
is	O
an	O
ill	O
posed	O
inverse	O
problem	O
and	O
different	O
regularization	O
strategies	O
incorporating	O
a	O
priori	O
information	O
extracted	O
from	O
magnitude	O
and	O
phase	B-T170
images	I-T170
have	O
been	O
proposed	O
.	O

However	O
,	O
the	O
anatomy	B-T017
observed	O
in	O
magnitude	O
and	O
phase	B-T170
images	I-T170
does	O
not	O
always	O
coincide	O
spatially	O
with	O
that	O
in	O
susceptibility	O
maps	O
,	O
which	O
could	O
give	O
erroneous	O
estimation	O
in	O
the	O
reconstructed	O
susceptibility	O
map	O
.	O

In	O
this	O
paper	O
,	O
we	O
develop	O
a	O
structural	O
feature	O
based	O
collaborative	O
reconstruction	O
(	O
SFCR	O
)	O
method	O
for	O
QSM	B-T058
including	O
both	O
magnitude	O
and	O
susceptibility	O
based	O
information	O
.	O

The	O
SFCR	O
algorithm	B-T170
is	O
composed	O
of	O
two	O
consecutive	O
steps	O
corresponding	O
to	O
complementary	O
reconstruction	B-T170
models	I-T170
,	O
each	O
with	O
a	O
structural	B-T082
feature	I-T082
based	O
l1	O
norm	O
constraint	O
and	O
a	O
voxel	O
fidelity	O
based	O
l2	O
norm	O
constraint	O
,	O
which	O
allows	O
both	O
the	O
structure	B-T082
edges	O
and	O
tiny	O
features	O
to	O
be	O
recovered	O
,	O
whereas	O
the	O
noise	O
and	O
artifacts	O
could	O
be	O
reduced	O
.	O

In	O
the	O
M	O
-	O
step	O
,	O
the	O
initial	O
susceptibility	O
map	O
is	O
reconstructed	O
by	O
employing	O
a	O
k	O
-	O
space	O
based	O
compressed	B-T170
sensing	I-T170
model	I-T170
incorporating	O
magnitude	O
prior	O
.	O

In	O
the	O
S	O
-	O
step	O
,	O
the	O
susceptibility	O
map	O
is	O
fitted	O
in	O
spatial	O
domain	O
using	O
weighted	O
constraints	O
derived	O
from	O
the	O
initial	O
susceptibility	O
map	O
from	O
the	O
M	O
-	O
step	O
.	O

Simulations	B-T062
and	O
in	B-T082
vivo	I-T082
human	B-T204
experiments	B-T062
at	O
7T	O
MRI	B-T058
show	O
that	O
the	O
SFCR	O
method	O
provides	O
high	O
quality	O
susceptibility	O
maps	O
with	O
improved	O
RMSE	O
and	O
MSSIM	O
.	O

Finally	O
,	O
the	O
susceptibility	O
values	O
of	O
deep	O
gray	B-T017
matter	I-T017
are	O
analyzed	O
in	O
multiple	B-T082
head	I-T082
positions	I-T082
,	O
with	O
the	O
supine	B-T082
position	I-T082
most	O
approximate	O
to	O
the	O
gold	O
standard	O
COSMOS	O
result	O
.	O

High	O
HbA1c	B-T103
at	O
onset	O
cannot	O
be	O
used	O
as	O
a	O
predictor	O
for	O
future	O
metabolic	B-T038
control	I-T038
for	O
the	O
individual	B-T098
child	O
with	O
type	B-T038
1	I-T038
diabetes	I-T038
mellitus	I-T038

To	O
study	O
how	O
metabolic	B-T038
control	I-T038
at	O
onset	O
of	O
type	B-T038
1	I-T038
diabetes	I-T038
correlates	O
to	O
metabolic	B-T038
control	I-T038
and	O
clinical	O
parameters	B-T033
during	O
childhood	O
until	O
transition	O
from	O
pediatric	B-T058
care	I-T058
to	O
adult	O
diabetes	B-T058
care	I-T058
.	O

Data	O
at	O
onset	O
,	O
three	O
months	O
,	O
one	O
,	O
three	O
,	O
and	O
five	O
years	O
after	O
diagnosis	B-T033
and	O
at	O
transition	O
,	O
on	O
HbA1c	B-T103
and	O
clinical	O
parameters	B-T033
,	O
on	O
8084	O
patients	O
in	O
the	O
Swedish	B-T170
pediatric	I-T170
quality	I-T170
registry	I-T170
,	I-T170
SWEDIABKIDS	I-T170
,	O
were	O
used	O
.	O

Of	O
these	O
patients	O
,	O
26	O
%	O
had	O
been	O
referred	O
to	O
adult	O
diabetes	B-T058
care	I-T058
by	O
2014	O
.	O

Children	O
with	O
HbA1c	B-T103
<	O
72	O
mmol	O
/	O
mol	O
(	O
8	O
.	O
7	O
%	O
)	O
(	O
20	O
%	O
of	O
patients	O
,	O
low	O
group	B-T098
)	O
at	O
diagnosis	B-T033
continued	O
to	O
have	O
good	O
metabolic	B-T038
control	I-T038
during	O
childhood	O
,	O
in	O
contrast	O
to	O
children	O
with	O
HbA1c	B-T103
>	O
114	O
mmol	O
/	O
mol	O
(	O
12	O
.	O
6	O
%	O
)	O
(	O
20	O
%	O
of	O
patients	O
,	O
high	O
group	B-T098
)	O
at	O
diagnosis	B-T033
,	O
who	O
continued	O
to	O
have	O
high	O
HbA1c	B-T103
at	O
follow	B-T058
-	I-T058
up	I-T058
.	O

For	O
the	O
individual	B-T098
,	O
there	O
was	O
no	B-T033
significant	I-T033
correlation	O
between	O
high	O
HbA1c	B-T103
at	O
onset	O
and	O
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O

During	O
follow	B-T058
-	I-T058
up	I-T058
,	O
children	O
in	O
the	O
high	O
group	B-T098
were	O
more	O
often	O
smokers	B-T033
,	O
less	O
physically	B-T033
active	I-T033
,	O
and	O
more	O
often	O
had	O
retinopathy	B-T038
than	O
children	O
in	O
the	O
low	O
group	B-T098
(	O
P	O
<	O
.	O
01	O
,	O
.	O
01	O
,	O
.	O
03	O
respectively	O
)	O
.	O

High	O
HbA1c	B-T103
at	O
onset	O
was	O
associated	O
with	O
high	O
HbA1c	B-T103
during	O
follow	B-T058
-	I-T058
up	I-T058
on	O
a	O
group	B-T098
level	O
,	O
but	O
it	O
cannot	O
be	O
used	O
as	O
a	O
predictor	O
of	O
future	O
metabolic	B-T038
control	I-T038
on	O
an	O
individual	B-T098
level	O
.	O

These	O
results	O
emphasize	O
the	O
important	O
work	O
done	O
by	O
the	O
diabetes	B-T038
team	O
in	O
the	O
first	O
years	O
after	O
diagnosis	B-T033
.	O

It	O
is	O
important	O
to	O
continuously	O
set	O
high	O
goals	B-T170
for	O
the	O
achievement	O
of	O
tight	O
metabolic	B-T038
control	I-T038
,	O
in	O
order	O
to	O
decrease	O
the	O
risk	O
of	O
microvascular	O
complications	O
.	O

Photosensitizer	B-T103
Decorated	O
Red	B-T017
Blood	I-T017
Cells	I-T017
as	O
an	O
Ultra	B-T074
-	I-T074
Sensitive	I-T074
Light	I-T074
-	I-T074
Responsive	I-T074
Drug	I-T074
Delivery	I-T074
System	I-T074

Red	B-T017
blood	I-T017
cells	I-T017
(	O
RBCs	B-T017
)	O
,	O
the	O
most	O
abundant	O
type	O
of	O
cells	B-T017
in	O
our	O
blood	B-T031
,	O
have	O
shown	O
promises	O
as	O
a	O
natural	O
drug	O
delivery	O
system	O
(	O
DDS	O
)	O
with	O
inherent	O
biocompatibility	O
.	O

Herein	O
,	O
we	O
uncover	O
that	O
a	O
photosensitizer	B-T103
,	O
chlorin	B-T103
e6	I-T103
(	O
Ce6	B-T103
)	O
,	O
could	O
be	O
decorated	O
into	O
the	O
membrane	B-T017
of	O
RBCs	B-T017
upon	O
simple	O
mixing	O
,	O
without	O
affecting	O
the	O
membrane	B-T017
integrity	O
and	O
stability	O
in	O
dark	O
.	O

Upon	O
light	O
irradiation	O
with	O
a	O
rather	O
low	O
power	O
density	O
,	O
the	O
generated	O
singlet	B-T103
oxygen	I-T103
by	O
Ce6	B-T103
as	O
the	O
result	O
of	O
photodynamic	O
effect	O
would	O
lead	O
to	O
rather	O
efficient	O
disruption	O
of	O
RBC	B-T017
membrane	B-T017
.	O

With	O
doxorubicin	B-T103
(	O
DOX	B-T103
)	O
,	O
a	O
typical	O
chemotherapy	B-T058
drug	B-T103
,	O
as	O
the	O
model	B-T170
,	O
we	O
engineer	O
a	O
unique	O
type	O
of	O
light	B-T074
-	I-T074
responsive	I-T074
RBC	I-T074
-	I-T074
based	I-T074
DDS	I-T074
by	O
decorating	O
Ce6	B-T103
on	O
the	O
cell	B-T017
membrane	I-T017
and	O
loading	O
DOX	B-T103
inside	O
cells	B-T017
.	O

The	O
light	O
triggered	O
cell	B-T017
membrane	I-T017
break	O
down	O
would	O
thus	O
trigger	O
instant	O
release	O
of	O
DOX	B-T103
,	O
enabling	O
light	B-T058
-	I-T058
controlled	I-T058
chemotherapy	I-T058
with	O
great	O
specificity	O
.	O

Beyond	O
that	O
,	O
our	O
RBC	B-T017
system	O
could	O
also	O
be	O
utilized	O
for	O
loading	O
of	O
larger	O
biomolecules	O
such	O
as	O
enzymes	B-T103
,	O
whose	O
release	O
as	O
well	O
as	O
catalytic	O
function	O
is	O
also	O
controlled	O
by	O
light	O
.	O

Our	O
work	O
thus	O
presents	O
a	O
unique	O
type	O
of	O
biocompatible	B-T074
cell	I-T074
-	I-T074
based	I-T074
DDS	I-T074
that	O
can	O
be	O
precisely	O
controlled	O
by	O
mild	O
external	O
stimuli	O
,	O
promising	O
not	O
only	O
for	O
cancer	B-T058
therapy	I-T058
but	O
also	O
for	O
other	O
potential	O
applications	O
in	O
biotechnologies	B-T091
.	O

Validation	B-T062
of	O
the	O
Neogen®	B-T103
Fentanyl	I-T103
ELISA	B-T058
Kit	O
for	O
Blood	B-T031
and	O
Urine	B-T031

The	O
Neogen®	B-T103
Fentanyl	I-T103
ready	O
-	O
to	O
-	O
use	O
enzyme	B-T058
-	I-T058
linked	I-T058
immunosorbent	I-T058
assay	I-T058
kit	O
was	O
validated	O
following	O
the	O
Scientific	B-T098
Working	I-T098
Group	I-T098
for	O
Forensic	O
Toxicology	O
Standard	B-T091
Practices	I-T091
for	O
Method	O
Validation	B-T062
in	O
Forensic	O
Toxicology	O
Laboratory	B-T170
Guidelines	I-T170
.	I-T170

Two	O
decision	O
points	O
,	O
0	O
.	O
5	O
and	O
1	O
ng	O
/	O
mL	O
,	O
were	O
successfully	O
validated	O
for	O
whole	B-T031
blood	I-T031
.	O

For	O
urine	B-T031
,	O
two	O
decision	O
points	O
,	O
1	O
and	O
5	O
ng	O
/	O
mL	O
,	O
were	O
also	O
successfully	O
validated	O
.	O

The	O
validation	B-T062
included	O
the	O
evaluation	B-T058
of	O
sensitivity	O
,	O
precision	O
,	O
specificity	O
,	O
carryover	O
,	O
plate	O
drift	O
,	O
ruggedness	O
/	O
robustness	O
and	O
a	O
case	O
sample	O
evaluation	B-T058
.	O

The	O
empirically	O
determined	O
limit	O
of	O
detection	O
was	O
0	O
.	O
25	O
ng	O
/	O
mL	O
for	O
blood	B-T031
and	O
0	O
.	O
5	O
ng	O
/	O
mL	O
for	O
urine	B-T031
.	O

Precision	O
was	O
determined	O
at	O
five	O
different	O
concentrations	O
ranging	O
from	O
0	O
.	O
25	O
to	O
1	O
.	O
5	O
ng	O
/	O
mL	O
with	O
15	O
replicates	O
at	O
each	O
level	O
for	O
whole	B-T031
blood	I-T031
and	O
demonstrated	O
a	O
<	O
2	O
.	O
4	O
%	O
coefficient	O
of	O
variation	O
(	O
CV	O
)	O
.	O

In	O
urine	B-T031
,	O
the	O
CV	O
was	O
<	O
5	O
.	O
6	O
%	O
at	O
six	O
different	O
concentrations	O
from	O
0	O
.	O
5	O
to	O
7	O
.	O
5	O
ng	O
/	O
mL	O
with	O
15	O
replicates	O
at	O
each	O
level	O
.	O

Cross	B-T038
-	I-T038
reactivity	I-T038
was	O
evaluated	B-T058
for	O
norfentanyl	B-T103
,	O
acetyl	O
fentanyl	O
,	O
4	B-T103
-	I-T103
anilino	I-T103
-	I-T103
N	I-T103
-	I-T103
phenethylpiperidine	I-T103
,	O
beta	O
-	O
hydroxythiofentanyl	O
,	O
butyryl	B-T103
fentanyl	I-T103
and	O
furanyl	B-T103
fentanyl	I-T103
.	O

Everolimus	B-T103
for	O
Treatment	B-T058
of	O
Pseudomyogenic	B-T038
Hemangioendothelioma	I-T038

Pseudomyogenic	B-T038
hemangioendothelioma	I-T038
(	O
PMH	B-T038
)	O
is	O
a	O
recently	O
described	O
vascular	B-T038
neoplasm	I-T038
that	O
occurs	O
most	O
commonly	O
in	O
the	O
soft	B-T017
tissue	I-T017
of	O
the	O
distal	O
extremities	O
of	O
young	O
adults	O
.	O

Metastatic	O
PMH	B-T038
can	O
be	O
fatal	O
and	O
there	O
are	O
no	O
effective	O
medications	B-T103
.	O

We	O
describe	O
a	O
case	O
of	O
a	O
15	O
-	O
year	O
-	O
old	O
boy	O
with	O
metastatic	O
PMH	B-T038
,	O
who	O
responded	B-T201
to	I-T201
treatment	I-T201
with	O
everolimus	B-T103
,	O
a	O
mammalian	B-T103
target	I-T103
of	I-T103
rapamycin	I-T103
inhibitor	I-T103
.	O

Immunohistochemistry	B-T058
showed	O
that	O
mammalian	B-T103
target	I-T103
of	I-T103
rapamycin	I-T103
was	O
expressed	B-T038
in	O
PMH	B-T038
biopsy	B-T017
specimens	I-T017
,	O
which	O
may	O
explain	O
the	O
reduction	O
in	O
PMH	B-T038
tumor	B-T082
size	I-T082
following	O
treatment	B-T058
.	O

Opposing	O
Roles	O
of	O
Acetylation	B-T038
and	O
Phosphorylation	B-T038
in	O
LIFR	B-T103
-	O
Dependent	O
Self	B-T038
-	I-T038
Renewal	I-T038
Growth	B-T038
Signaling	B-T038
in	O
Mouse	B-T017
Embryonic	I-T017
Stem	I-T017
Cells	I-T017

LIF	B-T103
promotes	O
self	B-T038
-	I-T038
renewal	I-T038
of	O
mouse	B-T017
embryonic	I-T017
stem	I-T017
cells	I-T017
(	O
mESCs	B-T017
)	O
,	O
and	O
in	O
its	O
absence	O
,	O
the	O
cells	B-T017
differentiate	O
.	O

LIF	B-T103
binds	O
to	O
the	O
LIF	B-T103
receptor	I-T103
(	O
LIFR	B-T103
)	O
and	O
activates	O
the	O
JAK	B-T038
-	I-T038
STAT3	I-T038
pathway	I-T038
,	O
but	O
it	O
remains	O
unknown	O
how	O
the	O
receptor	B-T017
complex	I-T017
triggers	O
differentiation	O
or	O
self	B-T038
-	I-T038
renewal	I-T038
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
LIFR	B-T103
cytoplasmic	B-T017
domain	I-T017
contains	O
a	O
self	B-T038
-	I-T038
renewal	I-T038
domain	O
within	O
the	O
juxtamembrane	B-T017
region	I-T017
and	O
a	O
differentiation	O
domain	O
within	O
the	O
C	B-T082
-	I-T082
terminal	I-T082
region	I-T082
.	O

The	O
differentiation	O
domain	O
contains	O
four	O
SPXX	B-T103
repeats	I-T103
that	O
are	O
phosphorylated	B-T038
by	O
MAPK	B-T103
to	O
restrict	O
STAT3	B-T038
activation	I-T038
;	O
the	O
self	B-T038
-	I-T038
renewal	I-T038
domain	O
is	O
characterized	O
by	O
a	O
3K	B-T103
motif	I-T103
that	O
is	O
acetylated	B-T038
by	O
p300	O
.	O

In	O
mESCs	B-T017
,	O
acetyl	O
-	O
LIFR	B-T103
undergoes	O
homodimerization	B-T038
,	O
leading	O
to	O
STAT3	B-T103
hypo	O
-	O
or	O
hyper	O
-	O
activation	O
depending	O
on	O
the	O
presence	B-T033
or	O
absence	O
of	O
gp130	B-T103
.	O

LIFR	B-T103
-	O
activated	O
STAT3	B-T103
restricts	O
differentiation	O
via	O
cytokine	B-T103
induction	O
.	O

Thus	O
,	O
LIFR	B-T103
acetylation	B-T038
and	O
serine	B-T038
phosphorylation	I-T038
differentially	O
promote	O
stem	B-T017
cell	I-T017
self	B-T038
-	I-T038
renewal	I-T038
and	O
differentiation	O
.	O

Interprofessional	O
primary	B-T058
care	I-T058
team	B-T058
meetings	I-T058
:	O
a	O
qualitative	O
approach	B-T082
comparing	O
observations	B-T062
with	O
personal	O
opinions	O

The	O
number	O
of	O
people	B-T098
with	O
multiple	B-T038
chronic	I-T038
conditions	I-T038
requiring	O
primary	B-T058
care	I-T058
services	I-T058
increases	O
.	O

Professionals	B-T097
from	O
different	O
disciplines	O
collaborate	O
and	O
coordinate	O
care	O
to	O
deal	O
with	O
the	O
complex	O
health	B-T058
care	I-T058
needs	I-T058
.	O

There	O
is	O
lack	O
of	O
information	O
on	O
current	O
practices	O
regarding	O
interprofessional	O
team	B-T058
(	I-T058
IPT	I-T058
)	I-T058
meetings	I-T058
.	O

This	O
study	B-T062
aimed	O
to	O
improve	O
our	O
understanding	O
of	O
the	O
process	O
of	O
interprofessional	O
collaboration	O
in	O
primary	B-T058
care	I-T058
team	B-T058
meetings	I-T058
in	O
the	O
Netherlands	B-T082
by	O
observing	O
the	O
current	O
practice	O
and	O
exploring	O
personal	O
opinions	O
.	O

Qualitative	B-T062
study	I-T062
involving	O
observations	B-T062
of	O
team	B-T058
meeting	I-T058
s	O
and	O
interviews	O
with	O
participants	B-T098
.	O

Eight	O
different	O
IPT	B-T058
meetings	I-T058
(	O
n	O
=	O
8	O
)	O
in	O
different	O
primary	B-T058
care	I-T058
practices	I-T058
were	O
observed	O
by	O
means	O
of	O
video	O
recordings	O
.	O

Experiences	B-T038
were	O
explored	O
by	O
conducting	O
individual	O
semi	O
-	O
structured	O
interviews	O
(	O
n	O
=	O
60	O
)	O
with	O
participants	B-T098
(	O
i	O
.	O
e	O
.	O

health	B-T097
care	I-T097
professionals	I-T097
from	O
different	O
disciplines	O
)	O
of	O
the	O
observed	O
team	B-T058
meetings	I-T058
.	O

The	O
data	O
were	O
analysed	B-T062
by	O
means	O
of	O
content	O
analysis	O
.	O

Most	O
participants	B-T098
expressed	O
favourable	O
opinions	O
about	O
their	O
team	B-T058
meetings	I-T058
.	O

However	O
,	O
observations	B-T062
showed	O
that	O
team	B-T058
meetings	I-T058
were	O
more	O
or	O
less	O
hectic	O
,	O
and	O
lacked	O
a	O
clear	O
structure	O
and	O
team	B-T097
coordinator	I-T097
or	O
leader	B-T097
.	O

There	O
appears	O
to	O
be	O
a	O
discrepancy	B-T033
between	O
findings	B-T033
from	O
observations	B-T062
and	O
interviews	O
.	O

From	O
the	O
interviews	O
,	O
four	O
main	O
themes	O
were	O
extracted	O
:	O
(	O
1	O
)	O
Team	B-T098
structure	I-T098
and	I-T098
composition	I-T098
,	O
(	O
2	O
)	O
Patient	B-T058
-	I-T058
centredness	I-T058
,	O
(	O
3	O
)	O
Interaction	O
and	O
(	O
4	O
)	O
Attitude	B-T038
and	O
motivation	B-T038
.	O

IPT	B-T058
meetings	I-T058
could	O
benefit	O
from	O
improvements	O
in	O
structure	O
,	O
patient	B-T058
-	I-T058
centredness	I-T058
and	O
leadership	O
by	O
the	O
chairpersons	B-T097
.	O

Given	O
the	O
discrepancy	B-T033
between	O
observations	B-T062
and	O
interviews	O
,	O
it	O
would	O
appear	O
useful	O
to	O
improve	O
team	O
members	O
'	O
awareness	B-T038
of	O
aspects	O
that	O
could	O
be	O
improved	O
before	O
training	O
them	O
in	O
dealing	O
with	O
specific	O
challenges	B-T058
.	O

Urachal	B-T038
carcinoma	I-T038
:	O
Report	B-T170
of	O
two	O
cases	O
and	O
review	O
of	O
the	O
literature	B-T170

Urachal	B-T038
carcinoma	I-T038
is	O
a	O
rare	O
tumor	B-T038
that	O
most	O
commonly	O
occurs	O
in	O
ovaries	B-T017
and	O
less	O
often	O
in	O
the	O
adnexal	B-T017
region	B-T082
and	O
urinary	B-T022
system	I-T022
.	O

We	O
herein	O
present	O
two	O
cases	O
of	O
urachal	B-T038
carcinoma	I-T038
:	O
One	O
case	O
was	O
a	O
32	O
-	O
year	O
-	O
old	O
male	B-T098
patient	O
who	O
presented	O
with	O
painless	B-T033
hematuria	I-T033
with	O
blood	B-T038
clots	I-T038
for	O
1	O
month	O
,	O
whereas	O
the	O
other	O
case	O
was	O
a	O
50	O
-	O
year	O
-	O
old	O
woman	B-T098
who	O
presented	O
with	O
gross	B-T033
hematuria	I-T033
with	O
mild	O
dysuria	B-T033
,	O
urgency	B-T038
and	I-T038
frequent	I-T038
urination	I-T038
for	O
1	O
year	O
.	O

Following	O
surgical	B-T058
resection	I-T058
,	O
the	O
two	O
patients	O
were	O
diagnosed	B-T033
with	O
urachal	B-T038
adenocarcinoma	I-T038
(	O
mixed	O
type	O
)	O
and	O
urachal	B-T038
mucinous	I-T038
adenocarcinoma	I-T038
,	O
respectively	O
,	O
based	O
on	O
the	O
histopathological	O
examination	B-T058
.	O

A	O
review	O
of	O
previously	O
published	O
cases	O
and	O
relevant	O
literature	B-T170
is	O
also	O
presented	O
.	O

The	O
aim	O
of	O
the	O
present	B-T033
study	B-T062
was	O
to	O
help	O
understand	B-T038
this	O
disease	B-T038
better	O
,	O
in	O
order	O
to	O
reduce	O
the	O
rate	O
of	O
clinical	O
and	O
pathological	O
misdiagnosis	B-T033
.	O

A	O
Recombinant	B-T062
Human	B-T204
Anti	B-T103
-	I-T103
Platelet	I-T103
scFv	B-T103
Antibody	I-T103
Produced	O
in	O
Pichia	B-T204
pastoris	I-T204
for	O
Atheroma	B-T038
Targeting	O

Cells	B-T017
of	O
the	O
innate	O
and	O
adaptive	O
immune	B-T022
system	I-T022
are	O
key	O
factors	O
in	O
the	O
progression	B-T038
of	O
atherosclerotic	B-T031
plaque	I-T031
,	O
leading	O
to	O
plaque	B-T033
instability	B-T033
and	O
rupture	B-T037
,	O
potentially	O
resulting	O
in	O
acute	O
atherothrombotic	B-T017
events	O
such	O
as	O
coronary	B-T038
artery	I-T038
disease	I-T038
,	O
cerebrovascular	B-T038
disease	I-T038
and	O
peripheral	B-T038
arterial	I-T038
disease	I-T038
.	O

Here	O
,	O
we	O
describe	O
the	O
cloning	B-T062
,	O
expression	B-T038
,	O
purification	O
,	O
and	O
immunoreactivity	O
assessment	B-T058
of	O
a	O
recombinant	O
single	B-T103
-	I-T103
chain	I-T103
variable	I-T103
fragment	I-T103
(	O
scFv	B-T103
)	O
derived	O
from	O
a	O
human	B-T204
anti	B-T103
-	I-T103
αIIbβ3	I-T103
antibody	I-T103
(	O
HuAb	B-T103
)	O
selected	O
to	O
target	O
atheromatous	B-T038
lesions	B-T033
for	O
the	O
presence	B-T033
of	O
platelets	B-T017
.	O

Indeed	O
,	O
platelets	B-T017
within	O
atheroma	B-T031
plaques	I-T031
have	O
been	O
shown	O
to	O
play	O
a	O
role	O
in	O
inflammation	B-T038
,	O
in	O
platelet	B-T017
-	O
leucocyte	B-T017
aggregates	O
and	O
in	O
thrombi	B-T038
formation	O
and	O
might	O
thus	O
be	O
considered	O
relevant	O
biomarkers	B-T201
of	O
atherosclerotic	O
progression	B-T038
.	O

The	O
DNA	B-T082
sequence	I-T082
that	O
encodes	O
the	O
anti	B-T103
-	I-T103
αIIbβ3	I-T103
TEG4	I-T103
scFv	I-T103
previously	O
obtained	O
from	O
a	O
phage	B-T062
-	I-T062
display	I-T062
selection	I-T062
on	O
activated	O
platelets	B-T017
,	O
was	O
inserted	B-T038
into	O
the	O
eukaryote	B-T204
vector	B-T103
(	O
pPICZαA	B-T103
)	O
in	O
fusion	O
with	O
a	O
tag	B-T082
sequence	I-T082
encoding	O
2	O
cysteines	B-T103
useable	O
for	O
specific	O
probes	O
grafting	B-T058
experiments	I-T058
.	O

The	O
recombinant	B-T103
protein	I-T103
was	O
expressed	B-T038
at	O
high	O
yields	O
in	O
Pichia	B-T204
pastoris	I-T204
(	O
30	O
mg	O
/	O
L	O
culture	B-T103
)	O
.	O

The	O
advantage	O
of	O
P	B-T204
.	I-T204

pastoris	I-T204
as	O
an	O
expression	B-T038
system	O
is	O
the	O
production	O
and	O
secretion	B-T038
of	O
recombinant	B-T103
proteins	I-T103
in	O
the	O
supernatant	B-T031
,	O
ruling	O
out	O
the	O
difficulties	O
encountered	O
when	O
scFv	B-T103
are	O
produced	O
in	O
the	O
cytoplasm	B-T017
of	O
bacteria	B-T007
(	O
low	O
yield	O
,	O
low	O
solubility	O
and	O
reduced	O
affinity	B-T038
)	O
.	O

The	O
improved	B-T033
conditions	O
allowed	O
for	O
the	O
recovery	O
of	O
highly	O
purified	O
and	O
biologically	B-T103
active	I-T103
scFv	B-T103
fragments	I-T103
ready	O
to	O
be	O
grafted	O
in	O
a	O
site	B-T082
-	O
directed	O
way	O
to	O
nanoparticles	O
for	O
the	O
imaging	B-T058
of	O
atherosclerotic	B-T031
plaques	I-T031
involving	O
inflammatory	O
processes	O
and	O
thus	O
at	O
high	B-T033
risk	I-T033
of	I-T033
instability	B-T033
.	O

Identification	O
of	O
MiR	B-T103
-	I-T103
21	I-T103
-	I-T103
5p	I-T103
as	O
a	O
Functional	B-T017
Regulator	I-T017
of	O
Mesothelin	B-T017
Expression	B-T038
Using	O
MicroRNA	B-T103
Capture	O
Affinity	O
Coupled	O
with	O
Next	B-T062
Generation	I-T062
Sequencing	I-T062

MicroRNAs	B-T103
(	O
miRNAs	B-T103
)	O
are	O
small	B-T103
non	I-T103
-	I-T103
coding	I-T103
RNAs	I-T103
that	O
regulate	B-T038
mRNA	B-T038
expression	I-T038
mainly	O
by	O
silencing	B-T038
target	O
transcripts	B-T103
via	O
binding	B-T038
to	O
miRNA	B-T082
recognition	I-T082
elements	I-T082
(	I-T082
MREs	I-T082
)	I-T082
in	O
the	O
3	B-T082
'	I-T082
untranslated	I-T082
region	I-T082
(	O
3	B-T082
'	I-T082
UTR	I-T082
)	O
.	O

The	O
identification	O
of	O
bona	B-T082
fide	I-T082
targets	O
is	O
challenging	O
for	O
researchers	B-T033
working	I-T033
on	O
the	O
functional	O
aspect	O
of	O
miRNAs	B-T103
.	O

Recently	O
,	O
we	O
developed	O
a	O
method	O
(	O
miR	O
-	O
CATCH	O
)	O
based	O
on	O
biotinylated	B-T038
DNA	B-T103
antisense	B-T103
oligonucleotides	I-T103
that	O
capture	O
the	O
mRNA	B-T103
of	O
interest	O
and	O
facilitates	O
the	O
characterisation	O
of	O
miRNAs	B-T038
:	I-T038
:	I-T038
mRNA	I-T038
interactions	I-T038
in	O
a	O
physiological	B-T038
cellular	I-T038
context	O
.	O

Here	O
,	O
the	O
miR	O
-	O
CATCH	O
technique	O
was	O
applied	O
to	O
the	O
mesothelin	B-T017
(	I-T017
MSLN	I-T017
)	I-T017
gene	I-T017
and	O
coupled	O
with	O
next	B-T062
generation	I-T062
sequencing	I-T062
(	O
NGS	B-T062
)	O
,	O
to	O
identify	O
miRNAs	B-T103
that	O
regulate	B-T038
MSLN	B-T017
mRNA	I-T017
and	O
that	O
may	O
be	O
responsible	O
for	O
its	O
increased	O
protein	B-T033
levels	I-T033
found	O
in	O
malignant	B-T038
pleural	I-T038
mesothelioma	I-T038
(	O
MPM	B-T038
)	O
.	O

Biotinylated	B-T038
MSLN	B-T017
oligos	I-T017
were	O
employed	O
to	O
isolate	O
miRNA	B-T103
:	I-T103
:	I-T103
MSLN	I-T103
mRNA	I-T103
complexes	I-T103
from	O
a	O
normal	O
cell	B-T017
line	I-T017
(	I-T017
Met	I-T017
-	I-T017
5A	I-T017
)	I-T017
which	O
expresses	B-T038
low	O
levels	O
of	O
MSLN	B-T103
.	O

MiRNAs	B-T103
targeting	O
the	O
MSLN	B-T017
mRNA	I-T017
were	O
identified	O
by	O
NGS	B-T062
and	O
miR	B-T103
-	I-T103
21	I-T103
-	I-T103
5p	I-T103
and	O
miR	B-T103
-	I-T103
100	I-T103
-	I-T103
5p	I-T103
were	O
selected	O
for	O
further	O
validation	B-T062
analyses	I-T062
.	O

MiR	B-T103
-	I-T103
21	I-T103
-	I-T103
5p	I-T103
was	O
shown	O
to	O
be	O
able	O
to	O
modulate	B-T082
MSLN	B-T017
expression	B-T038
in	O
miRNA	B-T103
mimic	B-T058
experiments	B-T062
in	O
a	O
panel	O
of	O
malignant	B-T017
and	O
non	O
-	O
malignant	O
cell	B-T017
lines	I-T017
.	O

Further	O
miRNA	B-T103
inhibitor	O
experiments	B-T062
and	O
luciferase	B-T103
assays	B-T058
in	O
Mero	B-T017
-	I-T017
14	I-T017
cells	I-T017
validated	O
miR	B-T103
-	I-T103
21	I-T103
-	I-T103
5p	I-T103
as	O
a	O
true	O
regulator	B-T017
of	O
MSLN	B-T017
.	O

Moreover	O
,	O
in	O
vitro	O
experiments	O
showed	O
that	O
treatment	B-T058
with	O
miR	B-T103
-	I-T103
21	I-T103
-	I-T103
5p	I-T103
mimic	B-T058
reduced	O
proliferation	O
of	O
MPM	B-T038
cell	B-T017
lines	I-T017
.	O

Altogether	O
,	O
this	O
work	O
shows	O
that	O
the	O
miR	O
-	O
CATCH	O
technique	O
,	O
coupled	O
with	O
NGS	B-T062
and	O
in	O
vitro	O
validation	B-T062
,	O
represents	O
a	O
reliable	O
method	O
to	O
identify	O
native	O
miRNA	B-T038
:	I-T038
:	I-T038
mRNA	I-T038
interactions	I-T038
.	O

MiR	B-T103
-	I-T103
21	I-T103
-	I-T103
5p	I-T103
is	O
suggested	O
as	O
novel	O
regulator	B-T017
of	O
MSLN	B-T017
with	O
a	O
possible	O
functional	O
role	O
in	O
cellular	B-T038
growth	I-T038
.	O

Zoonotic	O
and	O
Non	B-T033
-	I-T033
zoonotic	I-T033
Parasites	B-T204
of	O
Wild	B-T170
Rodents	B-T204
in	O
Turkman	B-T082
Sahra	I-T082
,	I-T082
Northeastern	I-T082
Iran	I-T082

This	O
study	B-T062
was	O
conducted	O
to	O
collect	B-T062
informative	I-T062
data	I-T062
on	O
the	O
parasitic	B-T038
infection	I-T038
of	O
wild	B-T170
rodents	B-T204
,	O
emphasizing	O
on	O
finding	B-T033
parasites	B-T204
,	O
which	O
have	O
medical	O
importance	O
to	O
human	B-T204
.	O

During	O
2012	O
-	O
2014	O
,	O
a	O
total	O
number	O
of	O
91	O
wild	B-T170
rodents	B-T204
were	O
captured	O
from	O
rural	O
areas	O
of	O
Turkmen	B-T082
Sahra	I-T082
,	I-T082
Golestan	I-T082
Province	I-T082
,	O
using	O
handmade	O
traps	O
.	O

Animals	B-T204
were	O
anesthetized	B-T033
,	O
surveyed	B-T170
for	O
any	O
ectoparasite	B-T204
and	O
then	O
their	O
carcasses	B-T017
were	O
carefully	O
dissected	O
for	O
examination	B-T033
of	O
endoparsites	B-T204
.	O

Four	O
species	B-T170
of	O
rodents	B-T204
including	O
Mus	B-T204
musculus	I-T204
(	O
52	O
.	O
75	O
%	O
)	O
,	O
Rattus	B-T204
norvegicus	I-T204
(	O
38	O
.	O
46	O
%	O
)	O
,	O
Rhombomys	B-T204
opimus	I-T204
(	O
4	O
.	O
40	O
%	O
)	O
and	O
Meriones	B-T204
libycus	I-T204
(	O
4	O
.	O
40	O
%	O
)	O
were	O
captured	O
.	O

Parasitic	B-T038
infestation	I-T038
was	O
detected	B-T033
in	O
38	O
.	O
5	O
%	O
of	O
sampled	O
rodents	B-T204
.	O

Parasite	B-T038
infestation	I-T038
rates	O
of	O
sampled	O
rodents	B-T204
was	O
Hymenolepis	B-T204
diminuta	I-T204
=	O
7	O
.	O
7	O
%	O
,	O
Cryptosporidium	B-T204
spp	I-T204
=	O
6	O
.	O
6	O
%	O
,	O
Trichuris	B-T204
spp	I-T204
.	O
=	O
5	O
.	O
5	O
%	O
,	O
Cysticercus	B-T204
fasciolaris	I-T204
=	O
2	O
.	O
20	O
%	O
,	O
Angiostrongylus	B-T204
spp	I-T204
.	O
=	O
2	O
.	O
20	O
%	O
,	O
Capillaria	B-T204
sp	I-T204
.	O
=	O
1	O
.	O
09	O
%	O
,	O
Rhipicephalus	B-T204
spp	I-T204
.	O

=	O
8	O
.	O
70	O
%	O
,	O
Nosopsyllus	B-T204
fasciatus	I-T204
=	O
1	O
.	O
09	O
%	O
,	O
and	O
Laelaps	B-T204
nuttalli	I-T204
=	O
3	O
.	O
29	O
%	O
.	O

Among	O
10	O
genera	B-T170
/	O
species	B-T170
of	O
identified	O
parasites	B-T204
,	O
at	O
least	O
8	O
of	O
them	O
were	O
zoonotic	O
with	O
public	B-T170
health	I-T170
importance	O
.	O

L	B-T204
.	I-T204

nuttalli	I-T204
and	O
N	B-T204
.	I-T204

fasciatus	I-T204
were	O
the	O
only	O
two	O
non	B-T033
-	I-T033
zoonotic	I-T033
detected	B-T033
parasites	B-T204
in	O
this	O
survey	B-T170
.	O

Harboring	O
a	O
wide	B-T082
variety	O
of	O
zoonotic	O
parasites	B-T204
in	O
sampled	O
wild	B-T170
rodents	B-T204
particularly	O
when	O
they	O
live	O
nearby	O
villages	B-T082
,	O
represents	O
a	O
potential	O
risk	O
to	O
native	B-T098
inhabitants	I-T098
.	O

Hence	O
,	O
controlling	O
rodents	B-T204
'	O
population	B-T098
in	O
residential	B-T082
regions	I-T082
and	O
improving	B-T033
awareness	B-T038
of	O
local	B-T082
people	B-T098
about	O
the	O
risk	O
of	O
disease	B-T038
transmission	I-T038
through	O
rodents	B-T204
seems	O
to	O
be	O
entirely	O
necessary	O
.	O

Creative	O
approach	O
for	O
successful	O
aging	B-T038
:	O
A	O
pilot	B-T062
study	I-T062
of	O
an	O
intergenerational	O
health	B-T058
promotion	I-T058
program	I-T058

To	O
develop	O
and	O
evaluate	B-T058
the	O
effectiveness	O
of	O
an	O
intergenerational	O
health	B-T058
promotion	I-T058
program	I-T058
.	O

This	O
was	O
an	O
action	O
research	O
project	O
.	O

A	O
total	O
of	O
34	O
participants	B-T098
attended	O
the	O
12	O
-	O
week	O
program	B-T058
and	O
completed	O
the	O
pre	B-T170
-	I-T170
test	I-T170
and	I-T170
post	I-T170
-	I-T170
test	I-T170
.	O

There	O
were	O
16	O
middle	O
-	O
aged	O
and	O
nine	O
older	B-T098
adults	I-T098
recruited	O
from	O
a	O
district	O
of	O
Taipei	B-T082
,	O
and	O
nine	O
young	O
adults	O
recruited	O
from	O
the	O
principal	B-T097
investigator	I-T097
'	I-T097
s	I-T097
university	B-T092
.	O

The	O
"	O
Attitudes	B-T170
toward	I-T170
Aging	I-T170
Scale	I-T170
"	O
and	O
the	O
"	O
Spiritual	B-T170
Health	I-T170
Scale	I-T170
"	O
were	O
two	O
assessment	B-T058
instruments	B-T170
used	O
in	O
the	O
study	B-T062
.	O

The	O
results	O
showed	O
that	O
there	O
were	O
significant	O
improvements	O
in	O
the	O
Attitudes	B-T170
toward	I-T170
Aging	I-T170
Scale	I-T170
for	O
the	O
young	O
adult	O
group	O
(	O
aged	O
18	O
-	O
29	O
years	O
)	O
and	O
in	O
the	O
Spiritual	B-T170
Health	I-T170
Scale	I-T170
for	O
the	O
older	B-T098
adult	I-T098
group	O
(	O
aged	O
65	O
-	O
80	O
years	O
)	O
.	O

The	O
evaluation	B-T058
showed	O
that	O
participants	B-T098
were	O
satisfied	B-T038
with	O
the	O
program	B-T058
.	O

The	O
results	O
of	O
the	O
present	O
study	O
provide	O
future	O
directions	O
for	O
successful	O
aging	B-T038
and	O
intergenerational	O
learning	O
.	O

Geriatr	O
Gerontol	O
Int	O
2017	O
;	O
•	O
•	O
:	O
•	O
•	O
-	O
•	O
•	O
.	O

Signs	B-T033
of	O
dysarthria	B-T038
in	O
adults	O
with	O
22q11	B-T038
.	I-T038
2	I-T038
deletion	I-T038
syndrome	I-T038

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
investigate	O
how	O
adults	O
with	O
22q11	B-T038
.	I-T038
2	I-T038
deletion	I-T038
syndrome	I-T038
(	O
22q11DS	B-T038
)	O
performed	O
on	O
dysarthria	B-T038
and	O
intelligibility	B-T038
tests	O
compared	O
with	O
a	O
control	O
group	O
.	O

Ten	O
participants	B-T098
with	O
confirmed	O
22q11	B-T038
.	I-T038
2	I-T038
deletion	I-T038
,	O
five	O
males	O
and	O
five	O
females	O
with	O
a	O
mean	O
age	O
of	O
31	O
years	O
(	O
range	O
:	O
19	O
-	O
49	O
)	O
,	O
were	O
compared	O
with	O
a	O
control	O
group	O
matched	O
for	O
gender	O
and	O
age	O
(	O
five	O
males	O
and	O
five	O
females	O
,	O
mean	O
age	O
:	O
32	O
years	O
,	O
range	O
:	O
19	O
-	O
49	O
)	O
.	O

Assessment	O
of	O
non	B-T058
-	I-T058
verbal	I-T058
and	I-T058
verbal	I-T058
tasks	I-T058
reflecting	O
respiration	B-T038
,	O
phonation	B-T038
,	O
oral	B-T038
motor	I-T038
function	I-T038
,	O
velopharyngeal	O
function	O
,	O
articulation	B-T038
,	O
and	O
prosody	B-T033
was	O
performed	O
as	O
well	O
as	O
the	O
Swedish	B-T170
Test	I-T170
of	I-T170
Intelligibility	I-T170
(	O
STI	B-T170
)	O
.	O

All	O
assessments	O
were	O
made	O
by	O
two	O
raters	O
;	O
inter	O
-	O
rater	O
and	O
intra	O
-	O
rater	O
reliability	O
was	O
acceptable	O
.	O

The	O
participants	B-T098
with	O
22q11DS	B-T038
had	O
significantly	O
more	O
problems	B-T033
than	O
the	O
control	O
group	O
on	O
all	O
investigated	O
dimensions	O
except	O
the	O
STI	B-T170
.	O

Overall	O
,	O
the	O
severity	O
of	O
their	O
speech	B-T033
deviation	I-T033
was	O
rated	O
as	O
mild	O
to	O
moderate	O
.	O

The	O
largest	O
difficulties	O
were	O
found	O
regarding	O
speech	B-T038
respiration	B-T038
,	O
phonation	B-T038
,	O
oral	B-T038
motor	I-T038
function	I-T038
,	O
and	O
velopharyngeal	O
function	O
.	O

The	O
results	O
of	O
the	O
present	O
study	B-T062
suggest	O
that	O
a	O
neurological	O
etiology	O
could	O
be	O
added	O
to	O
the	O
previously	O
described	O
structural	O
etiology	O
explaining	O
the	O
speech	B-T033
difficulties	I-T033
found	O
in	O
22q11DS	B-T038
.	O

Signs	B-T033
of	O
difficulties	O
in	O
both	O
speech	B-T038
motor	I-T038
planning	I-T038
and	O
speech	B-T038
motor	I-T038
programming	I-T038
were	O
found	O
.	O

Further	O
studies	B-T062
are	O
needed	O
to	O
confirm	O
the	O
results	O
,	O
as	O
are	O
studies	B-T062
of	O
the	O
association	O
between	O
structural	B-T033
brain	I-T033
abnormalities	I-T033
and	O
neurological	B-T033
speech	I-T033
symptoms	I-T033
.	O

For	O
clinical	O
purposes	O
,	O
it	O
is	O
important	O
that	O
clinicians	B-T097
have	O
knowledge	O
about	O
the	O
variable	O
speech	B-T033
symptoms	I-T033
that	O
may	O
occur	O
in	O
individuals	B-T098
with	O
22q11DS	B-T038
and	O
that	O
they	O
be	O
aware	O
of	O
the	O
complexity	O
of	O
the	O
etiology	O
of	O
such	O
speech	B-T033
symptoms	I-T033
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Sulfur	B-T103
and	O
Zinc	B-T103
Availability	O
from	O
Co	O
-	O
granulated	O
Zn	B-T103
-	O
Enriched	O
Elemental	B-T103
Sulfur	I-T103
Fertilizers	B-T103

Acidification	O
by	O
oxidation	B-T038
of	O
elemental	B-T103
sulfur	I-T103
(	O
ES	B-T103
)	O
can	O
solubilize	O
ZnO	B-T103
,	O
providing	O
slow	O
release	O
of	O
both	O
sulfur	B-T103
(	O
S	B-T103
)	O
and	O
zinc	B-T103
(	O
Zn	B-T103
)	O
in	O
soil	O
.	O

For	O
this	O
study	O
,	O
a	O
new	O
granular	O
fertilizer	B-T103
with	O
ES	B-T103
and	O
ZnO	B-T103
was	O
produced	O
and	O
evaluated	O
.	O

The	O
effect	O
of	O
incorporating	O
microorganisms	O
or	O
a	O
carbon	B-T103
source	B-T033
in	O
the	O
granule	O
was	O
also	O
evaluated	O
.	O

Four	O
granulated	O
ES	O
-	O
Zn	O
fertilizers	O
with	O
and	O
without	O
S	O
-	O
oxidizing	O
microorganisms	O
,	O
a	O
commercial	O
ES	O
pastille	O
,	O
ZnSO4	B-T103
,	O
and	O
ZnO	B-T103
were	O
applied	O
to	O
the	O
center	B-T082
of	O
Petri	B-T074
dishes	I-T074
containing	O
two	O
contrasting	O
pH	O
soils	O
.	O

Soil	O
pH	O
,	O
CaCl2	B-T103
-	O
extractable	O
S	B-T103
and	O
Zn	B-T103
,	O
and	O
remaining	O
ES	B-T103
were	O
evaluated	O
at	O
30	O
and	O
60	O
days	O
in	O
two	O
soil	O
sections	O
(	O
0	O
-	O
5	O
and	O
5	O
-	O
9	O
mm	O
from	O
the	O
fertilizer	B-T103
application	B-T082
site	I-T082
)	O
.	O

A	O
visualization	B-T058
test	I-T058
was	O
performed	O
to	O
evaluate	O
Zn	B-T103
diffusion	O
over	O
time	O
.	O

A	O
significant	O
pH	B-T033
decrease	I-T033
was	O
observed	O
in	O
the	O
acidic	B-T103
soil	O
for	O
all	O
ES	O
-	O
Zn	O
fertilizer	O
treatments	O
and	O
in	O
the	O
alkaline	O
soil	O
for	O
the	O
Acidithiobacillus	B-T007
thiooxidans	I-T007
-	O
inoculated	B-T033
treatment	I-T033
only	O
.	O

In	O
agreement	O
with	O
Zn	B-T103
visualization	B-T058
tests	I-T058
,	O
extractable	O
-	O
Zn	B-T103
concentrations	O
were	O
higher	O
from	O
the	O
point	O
of	O
application	O
in	O
the	O
acidic	B-T103
(	O
62	O
.	O
9	O
mg	O
dm	O
(	O
-	O
3	O
)	O
)	O
compared	O
to	O
the	O
alkaline	O
soil	O
(	O
5	O
.	O
5	O
mg	O
dm	O
(	O
-	O
3	O
)	O
)	O
.	O

Elemental	B-T038
S	I-T038
oxidation	I-T038
was	O
greater	O
in	O
the	O
acidic	B-T103
soil	O
(	O
20	O
.	O
9	O
%	O
)	O
than	O
slightly	O
alkaline	O
soil	O
(	O
12	O
%	O
)	O
.	O

The	O
ES	O
-	O
Zn	O
granular	O
fertilizers	O
increased	O
S	B-T103
and	O
Zn	B-T103
concentrations	O
in	O
soil	O
and	O
can	O
provide	O
a	O
strategically	O
slow	O
release	O
of	O
nutrients	B-T168
to	O
the	O
soil	O
.	O

Impact	O
of	O
Blood	B-T058
Transfusions	I-T058
on	O
Survival	O
of	O
Locally	B-T082
Advanced	O
Cervical	B-T038
Cancer	I-T038
Patients	O
Undergoing	O
Neoadjuvant	O
Chemotherapy	O
Plus	O
Radical	B-T058
Surgery	I-T058

Transfusions	B-T058
represent	O
one	O
of	O
the	O
main	O
progresses	O
of	O
modern	O
medicine	O
.	O

However	O
,	O
accumulating	O
evidence	O
supports	O
that	O
transfusions	B-T058
correlate	O
with	O
worse	O
survival	O
outcomes	O
in	O
patients	O
affected	O
by	O
solid	B-T038
cancers	I-T038
.	O

In	O
the	O
present	O
study	B-T062
,	O
we	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
perioperative	O
blood	B-T058
transfusion	I-T058
in	O
locally	B-T082
advanced	O
cervical	B-T038
cancer	I-T038
.	O

Data	O
of	O
consecutive	O
patients	O
affected	O
by	O
locally	B-T082
advanced	O
cervical	B-T038
cancer	I-T038
scheduled	O
to	O
undergo	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	B-T058
surgery	I-T058
were	O
retrospectively	B-T062
searched	O
to	O
test	O
the	O
impact	O
of	O
perioperative	O
transfusions	B-T058
on	O
survival	O
outcomes	O
.	O

Five	O
-	O
year	O
survival	O
outcomes	O
were	O
evaluated	O
using	O
Kaplan	B-T062
-	I-T062
Meier	I-T062
and	O
Cox	B-T170
models	I-T170
.	O

The	O
study	B-T062
included	O
275	O
patients	O
.	O

Overall	O
,	O
170	O
(	O
62	O
%	O
)	O
patients	O
had	O
blood	B-T058
transfusion	I-T058
.	O

Via	O
univariate	O
analysis	O
,	O
we	O
observed	O
that	O
transfusion	B-T058
correlated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
recurrence	B-T038
(	O
hazard	O
ratio	O
[	O
HR	O
]	O
,	O
2	O
.	O
2	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
1	O
.	O
09	O
-	O
4	O
.	O
40	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
.	O

Other	O
factors	O
associated	O
with	O
5	O
-	O
year	O
disease	O
-	O
free	O
survival	O
were	O
noncomplete	B-T033
clinical	B-T033
response	I-T033
after	O
neoadjuvant	O
chemotherapy	O
(	O
HR	O
,	O
2	O
.	O
99	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
92	O
-	O
9	O
.	O
63	O
;	O
P	O
=	O
0	O
.	O
06	O
)	O
and	O
pathological	B-T033
(	O
P	O
=	O
0	O
.	O
03	O
)	O
response	B-T033
at	O
neoadjuvant	O
chemotherapy	O
as	O
well	O
as	O
parametrial	B-T082
(	O
P	O
=	O
0	O
.	O
004	O
)	O
,	O
vaginal	B-T017
(	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
and	O
lymph	B-T017
node	I-T017
(	O
P	O
=	O
0	O
.	O
002	O
)	O
involvements	O
.	O

However	O
,	O
via	O
multivariate	O
analysis	O
,	O
only	O
vaginal	B-T017
(	O
HR	O
,	O
3	O
.	O
07	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
20	O
-	O
7	O
.	O
85	O
;	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
lymph	B-T017
node	I-T017
involvements	O
(	O
HR	O
,	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
00	O
-	O
6	O
.	O
06	O
;	O
P	O
=	O
0	O
.	O
05	O
)	O
correlate	O
with	O
worse	O
disease	O
-	O
free	O
survival	O
.	O

No	O
association	O
with	O
worse	O
outcomes	O
was	O
observed	O
for	O
patients	O
undergoing	O
blood	B-T058
transfusion	I-T058
(	O
HR	O
,	O
2	O
.	O
71	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
91	O
-	O
8	O
.	O
03	O
;	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Looking	O
at	O
factors	O
influencing	O
overall	O
survival	O
,	O
we	O
observed	O
that	O
lymph	B-T017
node	I-T017
status	O
(	O
P	O
=	O
0	O
.	O
01	O
)	O
and	O
vaginal	B-T017
involvement	O
(	O
P	O
=	O
0	O
.	O
06	O
)	O
were	O
independently	O
associated	O
with	O
survival	O
.	O

The	O
role	O
of	O
blood	B-T058
transfusions	I-T058
in	O
increasing	O
the	O
risk	O
of	O
developing	O
recurrence	B-T038
in	O
LAAC	B-T038
patients	O
treated	B-T058
by	O
neoadjuvant	O
chemotherapy	O
plus	O
radical	B-T058
surgery	I-T058
remains	O
unclear	O
;	O
further	O
prospective	B-T062
studies	I-T062
are	O
warranted	O
.	O

Tissue	B-T017
reservoirs	O
of	O
antiviral	B-T033
T	B-T038
cell	I-T038
immunity	I-T038
in	O
persistent	O
human	B-T204
CMV	B-T038
infection	I-T038

T	B-T017
cell	I-T017
responses	B-T038
to	O
viruses	B-T005
are	O
initiated	O
and	O
maintained	O
in	O
tissue	B-T017
sites	O
;	O
however	O
,	O
knowledge	O
of	O
human	B-T204
antiviral	B-T033
T	B-T017
cells	I-T017
is	O
largely	O
derived	O
from	O
blood	B-T031
.	O

Cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
persists	O
in	O
most	O
humans	B-T204
,	O
requires	O
T	B-T038
cell	I-T038
immunity	I-T038
to	O
control	O
,	O
yet	O
tissue	B-T017
immune	B-T038
responses	I-T038
remain	O
undefined	O
.	O

Here	O
,	O
we	O
investigated	O
human	B-T204
CMV	B-T005
-	O
specific	O
T	B-T017
cells	I-T017
,	O
virus	B-T005
persistence	O
and	O
CMV	B-T005
-	O
associated	O
T	B-T017
cell	I-T017
homeostasis	B-T038
in	O
blood	B-T031
,	O
lymphoid	B-T017
,	O
mucosa	B-T017
l	O
and	O
secretory	B-T017
tissues	I-T017
of	O
44	O
CMV	B-T005
seropositive	O
and	O
28	O
seronegative	B-T033
donors	B-T098
.	O

CMV	B-T005
-	O
specific	O
T	B-T017
cells	I-T017
were	O
maintained	O
in	O
distinct	O
distribution	B-T082
patterns	I-T082
,	O
highest	O
in	O
blood	B-T031
,	O
bone	B-T017
marrow	I-T017
(	O
BM	B-T017
)	O
,	O
or	O
lymph	B-T017
nodes	I-T017
(	O
LN	B-T017
)	O
,	O
with	O
the	O
frequency	O
and	O
function	O
in	O
blood	B-T031
distinct	O
from	O
tissues	B-T017
.	O

CMV	B-T005
genomes	B-T017
were	O
detected	B-T033
predominantly	O
in	O
lung	B-T017
and	O
also	O
in	O
spleen	B-T017
,	O
BM	B-T017
,	O
blood	B-T031
and	O
LN	B-T017
.	O

High	O
frequencies	O
of	O
activated	O
CMV	B-T005
-	O
specific	O
T	B-T017
cells	I-T017
were	O
found	O
in	O
blood	B-T031
and	O
BM	B-T017
samples	O
with	O
low	O
virus	B-T038
detection	I-T038
,	O
whereas	O
in	O
lung	B-T017
,	O
CMV	B-T005
-	O
specific	O
T	B-T017
cells	I-T017
were	O
present	O
along	O
with	O
detectable	O
virus	B-T005
.	O

In	O
LNs	B-T017
,	O
CMV	B-T005
-	O
specific	O
T	B-T017
cells	I-T017
exhibited	O
quiescent	O
phenotypes	O
independent	O
of	O
virus	B-T005
.	O

Overall	O
,	O
T	B-T017
cell	I-T017
differentiation	B-T038
was	O
enhanced	O
in	O
sites	O
of	O
viral	O
persistence	O
with	O
age	O
.	O

Together	O
,	O
our	O
results	O
suggest	O
tissue	B-T017
T	B-T017
cell	I-T017
reservoirs	O
for	O
CMV	B-T005
control	B-T058
shaped	O
by	O
both	O
viral	O
and	O
tissue	B-T017
-	O
intrinsic	B-T103
factors	I-T103
,	O
with	O
global	O
effects	O
on	O
homeostasis	B-T038
of	O
tissue	B-T017
T	B-T017
cells	I-T017
over	O
the	O
lifespan	O
.	O

Lipid	B-T058
levels	I-T058
and	O
risk	O
of	O
recurrent	B-T038
venous	I-T038
thrombosis	I-T038
:	O
results	O
from	O
the	O
MEGA	B-T062
follow	I-T062
-	I-T062
up	I-T062
study	I-T062

Essentials	O
The	O
role	O
of	O
lipid	B-T058
levels	I-T058
in	O
the	O
risk	O
of	O
recurrent	B-T038
venous	I-T038
thrombosis	I-T038
is	O
unclear	O
.	O

Lipids	B-T103
were	O
assessed	O
in	O
patients	O
with	O
a	O
first	O
venous	B-T038
thrombosis	I-T038
(	O
n	O
=	O
2106	O
)	O
followed	O
for	O
6	O
.	O
9	O
years	O
.	O

Lipids	B-T103
were	O
not	O
associated	O
with	O
recurrence	O
,	O
overall	O
or	O
in	O
patients	O
with	O
unprovoked	O
first	O
events	O
.	O

Testing	B-T058
lipid	I-T058
levels	I-T058
is	O
not	O
useful	O
to	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

Background	O
Knowledge	O
of	O
risk	B-T033
factors	I-T033
for	O
recurrent	B-T038
venous	I-T038
thrombosis	I-T038
may	O
guide	O
decisions	O
on	O
duration	O
of	O
anticoagulation	B-T058
.	O

The	O
association	O
between	O
lipid	B-T058
levels	I-T058
and	O
first	O
venous	B-T038
thrombosis	I-T038
has	O
been	O
studied	O
extensively	O
.	O

However	O
,	O
data	O
on	O
the	O
role	O
of	O
lipids	B-T103
in	O
the	O
risk	O
of	O
recurrence	O
are	O
scarce	O
.	O

Objective	O
To	O
assess	O
the	O
association	O
between	O
lipid	B-T058
levels	I-T058
and	O
recurrent	B-T038
venous	I-T038
thrombosis	I-T038
.	O

Patients	O
/	O
Methods	O
Patients	O
with	O
a	O
first	O
venous	B-T038
thrombosis	I-T038
from	O
the	O
MEGA	B-T062
study	I-T062
were	O
included	O
.	O

Follow	B-T058
-	I-T058
up	I-T058
started	O
at	O
the	O
date	O
of	O
end	B-T082
of	O
anticoagulant	B-T058
treatment	I-T058
.	O

Percentile	O
categories	B-T170
of	O
total	B-T103
/	O
low	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
/	O
high	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
cholesterol	I-T103
,	O
triglycerides	B-T103
and	O
apolipoproteins	B-T103
B	I-T103
and	O
A1	B-T103
were	O
established	O
(	O
<	O
10th	O
,	O
10th	O
-	O
25th	O
,	O
25th	O
-	O
75th	O
[	O
reference	O
]	O
,	O
75th	O
-	O
90th	O
,	O
>	O
90th	O
percentile	O
)	O
.	O

Lipids	B-T103
were	O
measured	O
at	O
least	O
3	O
months	O
after	O
discontinuing	B-T033
anticoagulation	B-T058
.	O

Results	O
Of	O
2106	O
patients	O
followed	O
for	O
a	O
median	O
of	O
6	O
.	O
9	O
years	O
,	O
326	O
developed	O
recurrence	O
(	O
incidence	O
rate	O
,	O
2	O
.	O
7	O
/	O
100	O
patient	O
-	O
years	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
2	O
.	O
5	O
-	O
3	O
.	O
1	O
)	O
.	O

With	O
hazard	O
ratios	O
ranging	O
from	O
0	O
.	O
88	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
55	O
-	O
1	O
.	O
42	O
)	O
to	O
1	O
.	O
33	O
(	O
95	O
%	O
CI	O
,	O
0	O
.	O
86	O
-	O
2	O
.	O
04	O
)	O
in	O
the	O
highest	O
percentile	O
category	B-T170
vs	O
.	O

the	O
reference	O
,	O
we	O
found	O
no	O
association	O
across	O
percentile	O
categories	B-T170
between	O
recurrence	O
and	O
lipid	B-T058
levels	I-T058
in	O
age	O
-	O
and	O
sex	O
-	O
adjusted	O
models	O
,	O
nor	O
after	O
further	B-T082
adjustments	O
for	O
body	B-T201
mass	I-T201
index	I-T201
,	O
diabetes	B-T038
,	O
estrogen	B-T103
and	O
statin	B-T103
use	O
,	O
and	O
duration	O
of	O
anticoagulation	B-T058
.	O

Subgroup	B-T170
analyses	B-T062
stratified	O
by	O
unprovoked	O
or	O
provoked	O
first	O
events	O
,	O
location	B-T082
(	O
deep	B-T038
vein	I-T038
thrombosis	I-T038
or	O
pulmonary	B-T038
embolism	I-T038
)	O
and	O
sex	O
also	O
did	O
not	O
reveal	O
an	O
association	O
with	O
any	O
of	O
the	O
lipid	B-T058
levels	I-T058
studied	O
.	O

Conclusions	O
Testing	B-T058
lipid	I-T058
levels	I-T058
did	O
not	O
identify	O
patients	O
at	O
an	O
increased	O
risk	O
of	O
recurrent	B-T038
venous	I-T038
thrombosis	I-T038
in	O
this	O
study	B-T062
,	O
including	O
those	O
with	O
unprovoked	O
first	O
events	O
,	O
and	O
these	O
should	O
not	O
influence	O
decisions	O
on	O
duration	O
of	O
anticoagulation	B-T058
.	O

Insecticidal	O
effects	O
of	O
deltamethrin	B-T103
in	O
laboratory	B-T092
and	O
field	O
populations	O
of	O
Culicoides	B-T204
species	I-T204
:	O
how	O
effective	O
are	O
host	O
-	O
contact	O
reduction	O
methods	B-T062
in	O
India	B-T082
?	O

Bluetongue	B-T005
virus	I-T005
(	O
BTV	B-T005
)	O
is	O
transmitted	B-T038
by	O
Culicoides	B-T204
biting	B-T204
midges	I-T204
and	O
causes	O
bluetongue	B-T038
(	O
BT	B-T038
)	O
,	O
a	O
clinical	B-T038
disease	I-T038
observed	O
primarily	O
in	O
sheep	B-T204
.	O

BT	B-T038
has	O
a	O
detrimental	B-T038
effect	I-T038
on	O
subsistence	O
farmers	B-T097
in	O
India	B-T082
,	O
where	O
hyperendemic	B-T038
outbreaks	I-T038
impact	O
on	O
smallholdings	O
in	O
the	O
southern	B-T082
states	I-T082
of	O
the	O
country	B-T082
.	O

In	O
this	O
study	O
,	O
we	O
establish	O
a	O
reliable	O
method	B-T062
for	O
testing	O
the	O
toxic	B-T037
effects	I-T037
of	O
deltamethrin	B-T103
on	O
Culicoides	B-T204
and	O
then	O
compare	O
deltamethrin	B-T103
with	O
traditional	O
control	O
methods	O
used	O
by	O
farmers	B-T097
in	O
India	B-T082
.	O

Effects	O
of	O
deltamethrin	B-T103
were	O
initially	O
tested	O
using	O
a	O
colonised	O
strain	O
of	O
Culicoides	B-T204
nubeculosus	I-T204
Meigen	I-T204
and	O
a	O
modified	O
World	B-T092
Health	I-T092
Organisation	I-T092
exposure	B-T058
assay	I-T058
.	O

This	O
method	B-T062
was	O
then	O
applied	O
to	O
field	O
populations	O
of	O
Culicoides	B-T204
spp	I-T204
.	I-T204

in	O
India	B-T082
.	O

The	O
field	O
population	O
of	O
C	B-T204
.	I-T204

oxystoma	I-T204
in	O
India	B-T082
had	O
a	O
greater	O
LC50	O
(	O
0	O
.	O
012	O
±	O
0	O
.	O
009	O
%	O
)	O
for	O
deltamethrin	B-T103
than	O
laboratory	B-T058
-	I-T058
reared	I-T058
C	B-T204
.	I-T204
nubeculosus	I-T204
(	O
0	O
.	O
0013	O
±	O
0	O
.	O
0002	O
%	O
)	O
.	O

Exposure	O
of	O
C	B-T204
.	I-T204

nubeculosus	I-T204
to	O
deltamethrin	B-T103
at	O
higher	O
ambient	O
temperatures	O
resulted	O
in	O
greater	O
rates	O
of	O
knockdown	O
but	O
a	O
lower	O
mortality	O
rate	O
at	O
24	O
h	O
post	O
-	O
exposure	O
.	O

Behavioural	B-T058
assays	I-T058
with	O
C	B-T204
.	I-T204

nubeculosus	I-T204
in	O
WHO	B-T092
tubes	O
provided	O
evidence	O
for	O
contact	O
irritancy	O
and	O
spatial	O
repellence	O
caused	O
by	O
deltamethrin	B-T103
.	O

The	O
field	O
experiments	B-T062
in	O
India	B-T082
,	O
however	O
,	O
provided	O
no	O
evidence	O
for	O
repellent	O
or	O
toxic	B-T037
effects	I-T037
of	O
deltamethrin	B-T103
.	O

Traditional	B-T062
methods	I-T062
such	O
as	O
the	O
application	O
of	O
neem	B-T103
oil	I-T103
and	O
burning	O
of	O
neem	B-T204
leaves	B-T204
also	O
provided	O
no	B-T033
protection	O
.	O

Our	O
study	O
demonstrates	O
that	O
field	O
-	O
collected	O
Culicoides	B-T204
in	O
India	B-T082
are	O
less	O
susceptible	O
to	O
deltamethrin	B-T103
exposure	O
than	O
laboratory	B-T058
-	I-T058
bred	I-T058
C	B-T204
.	I-T204

nubeculosus	I-T204
and	O
traditional	B-T062
methods	I-T062
of	O
insect	O
control	O
do	O
not	O
provide	O
protection	O
to	O
sheep	B-T204
.	O

These	O
low	O
levels	O
of	O
susceptibility	B-T038
to	O
deltamethrin	B-T103
have	O
not	O
been	O
recorded	O
before	O
in	O
field	O
populations	O
of	O
Culicoides	B-T204
and	O
suggest	O
resistance	O
to	O
synthetic	B-T103
pyrethrioids	I-T103
.	O

Alternative	O
insect	O
control	O
methods	B-T062
,	O
in	O
addition	O
to	O
vaccination	B-T058
,	O
may	O
be	O
needed	O
to	O
protect	O
Indian	B-T082
livestock	B-T204
from	O
BTV	B-T005
transmission	B-T038
.	O

Correlation	O
of	O
the	O
Lipid	B-T103
Profile	B-T058
,	O
BMI	B-T201
and	O
Bone	B-T201
Mineral	I-T201
Density	I-T201
in	O
Postmenopausal	B-T038
Women	B-T098

To	O
the	O
reduction	O
of	O
bone	B-T201
density	I-T201
and	O
osteoporosis	B-T038
in	O
postmenopausal	B-T038
women	B-T098
contribute	O
elevated	O
lipid	B-T103
parameters	B-T033
and	O
Body	B-T201
Mass	I-T201
Index	I-T201
(	O
BMI	B-T201
)	O
.	O

The	O
goal	O
of	O
our	O
study	B-T062
was	O
to	O
determine	O
the	O
correlation	O
between	O
lipid	B-T103
parameters	B-T033
,	O
BMI	B-T201
and	O
osteoporosis	B-T038
in	O
postmenopausal	B-T038
women	B-T098
.	O

The	O
study	B-T062
was	O
carried	O
out	O
by	O
matched	O
type	O
between	O
experimental	O
group	O
and	O
controls	O
.	O

The	O
experimental	O
group	O
consisted	O
of	O
100	O
females	B-T098
at	O
postmenopausal	B-T038
age	O
,	O
in	O
which	O
by	O
the	O
DEXA	B-T058
method	I-T058
was	O
diagnosed	B-T033
osteoporosis	B-T038
at	O
the	O
Department	O
of	O
Endocrinology	O
,	O
Diabetes	O
and	O
Metabolic	O
Diseases	O
,	O
University	B-T092
Medical	I-T092
Center	I-T092
of	I-T092
RS	I-T092
during	O
2015	O
-	O
2016	O
,	O
while	O
the	O
control	O
group	O
consisted	O
of	O
100	O
females	B-T098
in	O
a	O
postmenopausal	B-T038
age	O
but	O
without	O
diagnosed	B-T033
osteoporosis	B-T038
.	O

The	O
groups	O
were	O
matched	O
by	O
age	O
(	O
±	O
2	O
years	O
)	O
.	O

To	O
all	O
participants	B-T098
of	O
the	O
study	B-T062
were	O
carried	O
out	O
biochemical	B-T058
analysis	I-T058
of	I-T058
blood	I-T058
,	O
or	O
the	O
analysis	B-T062
of	O
the	O
lipid	B-T103
profile	B-T058
that	O
included	O
total	B-T103
cholesterol	I-T103
,	O
LDL	B-T103
cholesterol	I-T103
,	O
triglycerides	B-T103
(	O
TG	B-T103
)	O
and	O
HDL	B-T103
cholesterol	I-T103
,	O
and	O
was	O
determined	O
the	O
values	O
of	O
BMI	B-T201
and	O
waist	B-T201
circumference	I-T201
(	O
WC	B-T201
)	O
.	O

Analysis	B-T062
of	O
the	O
data	O
of	O
our	O
research	B-T062
shows	O
that	O
by	O
the	O
univariate	B-T062
logistic	I-T062
regression	I-T062
the	O
values	O
of	O
lipid	B-T103
parameters	B-T033
total	B-T103
cholesterol	I-T103
(	O
p	O
=	O
0	O
.	O
000	O
)	O
,	O
LDL	B-T103
(	O
p	O
=	O
0	O
.	O
005	O
)	O
and	O
TG	B-T103
(	O
p	O
=	O
0	O
.	O
033	O
)	O
were	O
significantly	O
associated	O
with	O
osteoporosis	B-T038
,	O
while	O
in	O
multivariate	B-T170
logistic	I-T170
model	I-T170
only	O
total	B-T103
cholesterol	I-T103
(	O
p	O
=	O
0	O
.	O
018	O
)	O
was	O
found	O
as	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
osteoporosis	B-T038
in	O
postmenopausal	B-T038
women	B-T098
.	O

BMI	B-T201
values	O
were	O
not	B-T033
statistically	O
significantly	O
associated	O
with	O
osteoporosis	B-T038
(	O
p	O
=	O
0	O
.	O
727	O
)	O
.	O

On	O
the	O
decrease	O
in	O
bone	B-T201
mineral	I-T201
density	I-T201
and	O
osteoporosis	B-T038
in	O
postmenopausal	B-T038
women	B-T098
influence	O
many	O
risk	B-T033
factors	I-T033
whose	O
identification	O
has	O
the	O
aim	O
to	O
develop	O
more	O
effective	O
prevention	O
of	O
this	O
disease	B-T038
in	O
the	O
elderly	B-T098
.	O

Heterotopic	B-T038
ossification	I-T038
after	O
the	O
use	O
of	O
recombinant	B-T103
human	I-T103
bone	I-T103
morphogenetic	I-T103
protein	I-T103
-	I-T103
7	I-T103

To	O
present	O
the	O
incidence	O
of	O
heterotopic	B-T038
ossification	I-T038
after	O
the	O
use	O
of	O
recombinant	B-T103
human	I-T103
bone	I-T103
morphogenetic	I-T103
protein	I-T103
-	I-T103
7	I-T103
(	O
rhBMP	B-T103
-	I-T103
7	I-T103
)	O
for	O
the	O
treatment	B-T058
of	O
nonunions	B-T033
.	O

Bone	B-T103
morphogenetic	I-T103
proteins	I-T103
(	O
BMPs	B-T103
)	O
promote	O
bone	B-T038
formation	I-T038
by	O
auto	B-T038
-	I-T038
induction	I-T038
.	O

Recombinant	B-T103
human	I-T103
BMP	I-T103
-	I-T103
7	I-T103
in	O
combination	O
with	O
bone	B-T103
grafts	I-T103
was	O
used	O
in	O
84	O
patients	O
for	O
the	O
treatment	B-T058
of	O
long	B-T033
bone	I-T033
nonunions	I-T033
.	O

All	O
patients	O
were	O
evaluated	B-T058
radiographicaly	O
for	O
the	O
development	O
of	O
heterotopic	B-T038
ossification	I-T038
during	O
the	O
standard	O
assessment	B-T058
for	O
the	O
nonunion	B-T033
healing	B-T038
.	O

In	O
all	O
patients	O
(	O
80	O
.	O
9	O
%	O
)	O
with	O
radiographic	O
signs	B-T033
of	O
heterotopic	B-T038
ossification	I-T038
,	O
a	O
CT	B-T058
scan	I-T058
was	O
performed	O
.	O

Nonunion	B-T033
site	B-T082
palpation	B-T058
and	O
ROM	B-T058
evaluation	I-T058
of	O
the	O
adjacent	B-T082
joints	B-T082
were	O
also	O
carried	O
out	O
.	O

Factors	O
related	O
to	O
the	O
patient	O
(	O
age	O
,	O
gender	O
)	O
,	O
the	O
nonunion	B-T033
(	O
location	B-T082
,	O
size	B-T082
,	O
chronicity	O
,	O
number	O
of	O
previous	O
procedures	O
,	O
infection	B-T038
,	O
surrounding	B-T082
tissues	B-T017
condition	O
)	O
and	O
the	O
surgical	B-T058
procedure	I-T058
(	O
graft	B-T103
and	O
fixation	B-T058
type	O
,	O
amount	O
of	O
rhBMP	B-T103
-	I-T103
7	I-T103
)	O
were	O
correlated	O
with	O
the	O
development	O
of	O
heterotopic	B-T038
ossification	I-T038
and	O
statistical	O
analysis	O
with	O
Pearsons	B-T170
χ	I-T170
(	I-T170
2	I-T170
)	I-T170
test	I-T170
was	O
performed	O
.	O

Eighty	O
point	O
nine	O
percent	O
of	O
the	O
nonunions	B-T033
treated	O
with	O
rhBMP	B-T103
-	I-T103
7	I-T103
,	O
healed	O
with	O
no	O
need	O
for	O
further	O
procedures	O
.	O

Heterotopic	B-T038
bone	I-T038
formation	I-T038
occurred	O
in	O
15	O
of	O
84	O
patients	O
(	O
17	O
.	O
8	O
%	O
)	O
and	O
it	O
was	O
apparent	O
in	O
the	O
routine	O
radiological	B-T058
evaluation	I-T058
of	O
the	O
nonunion	B-T033
site	O
,	O
in	O
a	O
mean	O
time	O
of	O
5	O
.	O
5	O
mo	O
after	O
the	O
rhBMP	B-T103
-	I-T103
7	I-T103
application	O
(	O
range	O
3	O
-	O
12	O
)	O
.	O

The	O
heterotopic	B-T038
ossification	I-T038
was	O
located	O
at	O
the	O
femur	B-T017
in	O
8	O
cases	O
,	O
at	O
the	O
tibia	B-T017
in	O
6	O
,	O
and	O
at	O
the	O
humerus	B-T017
in	O
οne	O
patient	O
.	O

In	O
4	O
patients	O
a	O
palpable	B-T033
mass	I-T033
was	O
present	O
and	O
only	O
in	O
one	O
patient	O
,	O
with	O
a	O
para	B-T033
-	I-T033
articular	I-T033
knee	I-T033
nonunion	I-T033
treated	O
with	O
rhBMP	B-T103
-	I-T103
7	I-T103
,	O
the	O
size	B-T082
of	O
heterotopic	B-T038
ossification	I-T038
affected	O
the	O
knee	B-T033
range	I-T033
of	I-T033
motion	I-T033
.	O

All	O
the	O
patients	O
with	O
heterotopic	B-T038
ossification	I-T038
were	O
male	O
.	O

Statistical	O
analysis	O
proved	O
that	O
patient	O
'	O
s	O
gender	O
was	O
the	O
only	O
important	O
factor	O
for	O
the	O
development	O
of	O
heterotopic	B-T038
ossification	I-T038
(	O
P	O
=	O
0	O
.	O
007	O
)	O
.	O

Heterotopic	B-T038
ossification	I-T038
after	O
the	O
use	O
of	O
rhBMP	B-T103
-	I-T103
7	I-T103
in	O
nonunions	B-T033
was	O
common	O
but	O
it	O
did	O
not	O
compromise	O
the	O
final	O
clinical	O
outcome	O
in	O
most	O
cases	O
,	O
and	O
affected	O
only	O
male	O
patients	O
.	O

Hypocretin	B-T103
/	I-T103
Orexin	I-T103
Peptides	I-T103
Excite	O
Rat	B-T204
Neuroendocrine	B-T022
Dopamine	B-T017
Neurons	I-T017
through	O
Orexin	B-T103
2	I-T103
Receptor	I-T103
-	O
Mediated	O
Activation	O
of	O
a	O
Mixed	O
Cation	B-T103
Current	B-T038

Hypocretin	B-T103
/	I-T103
Orexin	I-T103
(	O
H	B-T103
/	I-T103
O	I-T103
)	O
neurons	B-T017
of	O
the	O
lateral	B-T082
hypothalamus	I-T082
are	O
compelling	O
modulator	B-T098
candidates	I-T098
for	O
the	O
chronobiology	B-T091
of	O
neuroendocrine	B-T022
output	O
and	O
,	O
as	O
a	O
consequence	O
,	O
hormone	O
release	O
from	O
the	O
anterior	B-T017
pituitary	I-T017
.	O

Here	O
we	O
investigate	O
the	O
effects	O
of	O
H	B-T103
/	I-T103
O	I-T103
peptides	I-T103
upon	O
tuberoinfundibular	B-T017
dopamine	I-T017
(	I-T017
TIDA	I-T017
)	I-T017
neurons	I-T017
-	O
cells	B-T017
which	O
control	O
,	O
via	O
inhibition	O
,	O
the	O
pituitary	B-T017
secretion	B-T038
of	I-T038
prolactin	I-T038
.	O

In	O
whole	B-T062
cell	I-T062
recordings	I-T062
performed	O
in	O
male	O
rat	B-T204
hypothalamic	B-T082
slices	I-T082
,	O
application	O
of	O
H	B-T103
/	I-T103
O	I-T103
-	I-T103
A	I-T103
,	O
as	O
well	O
as	O
H	B-T103
/	I-T103
O	I-T103
-	I-T103
B	I-T103
,	O
excited	O
oscillating	O
TIDA	B-T017
neurons	I-T017
,	O
inducing	O
a	O
reversible	O
depolarising	O
switch	O
from	O
phasic	O
to	O
tonic	O
discharge	O
.	O

The	O
H	B-T103
/	I-T103
O	I-T103
-	O
induced	O
inward	B-T082
current	B-T038
underpinning	O
this	O
effect	O
was	O
post	B-T017
-	I-T017
synaptic	I-T017
(	O
as	O
it	O
endured	O
in	O
the	O
presence	B-T033
of	O
tetrodotoxin	B-T103
)	O
,	O
appeared	O
to	O
be	O
carried	O
by	O
a	O
Na	B-T103
(	I-T103
+	I-T103
)	I-T103
-	O
dependent	O
transient	B-T103
receptor	I-T103
potential	I-T103
-	I-T103
like	I-T103
channel	I-T103
(	O
as	O
it	O
was	O
blocked	O
by	O
2	B-T103
-	I-T103
APB	I-T103
and	O
was	O
diminished	O
by	O
removal	O
of	O
extracellular	B-T017
Na	B-T103
(	I-T103
+	I-T103
)	I-T103
)	O
,	O
and	O
was	O
a	O
consequence	O
of	O
OX2R	B-T103
receptor	I-T103
activation	O
(	O
as	O
it	O
was	O
blocked	O
by	O
the	O
OX2R	B-T103
receptor	I-T103
antagonist	B-T103
TCS	B-T103
OX2	I-T103
29	I-T103
,	O
but	O
not	O
the	O
OX1R	B-T103
receptor	I-T103
antagonist	B-T103
SB	B-T103
334867	I-T103
)	O
.	O

Application	B-T058
of	O
the	O
hormone	B-T103
,	O
melatonin	B-T103
,	O
failed	O
to	O
alter	O
TIDA	B-T017
membrane	B-T038
potential	I-T038
or	O
oscillatory	O
activity	O
.	O

This	O
first	O
description	B-T170
of	O
the	O
electrophysiological	O
effects	O
of	O
H	B-T103
/	I-T103
Os	I-T103
upon	O
the	O
TIDA	B-T017
network	I-T017
identifies	O
cellular	B-T038
mechanisms	I-T038
that	O
may	O
contribute	O
to	O
the	O
circadian	B-T038
rhythmicity	I-T038
of	O
prolactin	B-T038
secretion	I-T038
.	O

Improving	O
exchange	O
with	O
consumers	B-T098
within	O
mental	O
health	O
organizations	O
:	O
Recognizing	O
mental	B-T038
ill	I-T038
health	I-T038
experience	O
as	O
a	O
'	O
sneaky	O
,	O
special	O
degree	O
'	O

Stigmatizing	B-T033
views	O
towards	O
consumers	B-T098
may	O
be	O
held	O
even	O
by	O
those	O
working	O
within	O
mental	O
health	O
organizations	O
.	O

Contemporary	O
mental	O
health	O
policies	O
require	O
organizations	O
to	O
work	O
collaboratively	O
with	O
consumers	B-T098
in	O
producing	O
and	O
delivering	B-T058
services	O
.	O

Using	O
social	O
exchange	O
theory	O
,	O
which	O
emphasises	O
mutual	O
exchange	O
to	O
maximise	O
benefits	O
in	O
partnership	O
,	O
the	O
current	O
study	B-T062
explores	O
the	O
perspectives	O
of	O
those	O
working	O
within	O
organizations	O
that	O
have	O
some	O
level	O
of	O
consumer	B-T098
leadership	O
.	O

Interviews	O
were	O
conducted	O
with	O
14	O
participants	B-T098
from	O
a	O
range	O
of	O
mental	O
health	O
organizations	O
.	O

Data	O
were	O
transcribed	O
,	O
and	O
analyzed	B-T062
using	O
thematic	B-T062
analytic	I-T062
and	O
discursive	O
psychological	B-T058
techniques	I-T058
.	O

Findings	B-T033
suggest	O
stigma	B-T033
is	O
still	O
prevalent	O
even	O
in	O
organizations	O
that	O
have	O
consumers	B-T098
in	O
leadership	O
positions	O
,	O
and	O
consumers	B-T098
are	O
often	O
perceived	B-T038
as	O
less	O
able	O
to	O
work	O
in	O
mental	O
health	O
organizations	O
than	O
non	O
-	O
consumers	O
.	O

Several	O
discourses	O
challenged	O
such	O
a	O
view	O
-	O
showing	O
how	O
consumers	B-T098
bring	O
value	O
to	O
mental	O
health	O
organizations	O
through	O
their	O
expertise	O
in	O
the	O
mental	O
health	O
system	O
,	O
and	O
their	O
ability	O
to	O
provide	O
safety	B-T058
and	O
support	O
to	O
other	O
consumers	B-T098
.	O

Through	O
a	O
social	O
exchange	O
theory	O
lens	O
,	O
the	O
authors	B-T097
call	O
for	O
organizations	O
to	O
challenge	O
stigma	B-T033
and	O
promote	O
the	O
value	O
that	O
consumers	B-T098
can	O
bring	O
to	O
maximize	O
mutual	O
benefits	O
.	O

Does	O
sex	O
really	O
matter	O
?	O
Explaining	O
intraspecies	B-T170
variation	O
in	O
ocean	B-T082
acidification	O
responses	O

Ocean	B-T082
acidification	O
(	O
OA	O
)	O
poses	O
a	O
major	O
threat	O
to	O
marine	O
ecosystems	O
globally	O
,	O
having	O
significant	O
ecological	O
and	O
economic	O
importance	O
.	O

The	O
number	O
and	O
complexity	O
of	O
experiments	B-T062
examining	B-T033
the	O
effects	O
of	O
OA	O
has	O
substantially	O
increased	O
over	O
the	O
past	O
decade	O
,	O
in	O
an	O
attempt	O
to	O
address	O
multi	O
-	O
stressor	O
interactions	O
and	O
long	O
-	O
term	O
responses	O
in	O
an	O
increasing	O
range	O
of	O
aquatic	O
organisms	O
.	O

However	O
,	O
differences	O
in	O
the	O
response	O
of	O
males	O
and	O
females	O
to	O
elevated	B-T033
pCO2	I-T033
have	O
been	O
investigated	O
in	O
fewer	O
than	O
4	O
%	O
of	O
studies	O
to	O
date	O
,	O
often	O
being	O
precluded	O
by	O
the	O
difficulty	O
of	O
determining	O
sex	O
non	O
-	O
destructively	O
,	O
particularly	O
in	O
early	O
life	O
stages	O
.	O

Here	O
we	O
highlight	O
that	O
sex	O
can	O
significantly	O
impact	O
organism	O
responses	O
to	O
OA	O
,	O
differentially	O
affecting	O
physiology	B-T038
,	O
reproduction	B-T038
,	O
biochemistry	O
and	O
ultimately	O
survival	O
.	O

What	O
is	O
more	O
,	O
these	O
impacts	O
do	O
not	O
always	O
conform	O
to	O
ecological	O
theory	O
based	O
on	O
differential	O
resource	O
allocation	O
towards	O
reproduction	B-T038
,	O
which	O
would	O
predict	O
females	O
to	O
be	O
more	O
sensitive	O
to	O
OA	O
owing	O
to	O
the	O
higher	O
production	O
cost	O
of	O
eggs	B-T017
compared	O
with	O
sperm	B-T017
.	O

Therefore	O
,	O
non	O
-	O
sex	O
-	O
specific	B-T062
studies	I-T062
may	O
overlook	O
subtle	O
but	O
ecologically	O
significant	O
differences	O
in	O
the	O
responses	O
of	O
males	O
and	O
females	O
to	O
OA	O
,	O
with	O
consequences	O
for	O
forecasting	O
the	O
fate	O
of	O
natural	O
populations	B-T098
in	O
a	O
near	O
-	O
future	O
ocean	B-T082
.	O

Computational	O
analysis	O
of	O
conserved	B-T082
coil	I-T082
functional	O
residues	O
in	O
the	O
mitochondrial	O
genomic	O
sequences	O
of	O
dermatophytes	B-T204

Dermatophyte	B-T204
is	O
a	O
group	O
of	O
closely	O
related	O
fungi	B-T204
that	O
have	O
the	O
capacity	O
to	O
invade	O
keratinized	O
tissue	B-T017
of	O
humans	B-T204
and	O
other	O
animals	B-T204
.	O

The	O
infection	B-T038
known	O
as	O
dermatophytosis	B-T038
,	O
caused	O
by	O
members	O
of	O
the	O
genera	B-T170
Microsporum	B-T204
,	O
Trichophyton	B-T204
,	O
and	O
Epidermophyton	B-T204
includes	O
infection	B-T038
to	O
the	O
groin	B-T082
(	O
tinea	B-T038
cruris	I-T038
)	O
,	O
beard	B-T017
(	O
tinea	B-T038
barbae	I-T038
)	O
,	O
scalp	B-T017
(	O
tinea	B-T038
capitis	I-T038
)	O
,	O
feet	B-T017
(	O
tinea	B-T038
pedis	I-T038
)	O
,	O
glabrous	B-T017
skin	I-T017
(	O
tinea	B-T038
corporis	I-T038
)	O
,	O
nail	B-T017
(	O
tinea	B-T038
unguium	I-T038
)	O
,	O
and	O
hand	B-T017
(	O
tinea	B-T038
manuum	I-T038
)	O
.	O

The	O
identification	O
of	O
evolutionary	B-T038
relationship	O
between	O
these	O
three	B-T170
genera	I-T170
of	O
dermatophyte	B-T204
is	O
epidemiologically	O
important	O
to	O
understand	O
their	O
pathogenicity	O
.	O

Mitochondrial	B-T103
DNA	I-T103
evolves	B-T038
more	O
rapidly	O
than	O
a	O
nuclear	B-T103
DNA	I-T103
due	O
to	O
higher	O
rate	O
of	O
mutation	O
but	O
is	O
very	O
less	O
affected	O
by	O
genetic	B-T038
recombination	I-T038
,	O
making	O
it	O
an	O
important	O
tool	O
for	O
phylogenetic	B-T062
studies	I-T062
.	O

Thus	O
,	O
here	O
we	O
present	O
a	O
novel	O
scheme	O
to	O
identify	O
the	O
conserved	B-T082
coil	I-T082
functional	O
residues	O
of	O
Trichophyton	B-T204
rubrum	I-T204
,	O
Trichophyton	B-T204
mentagrophytes	I-T204
,	O
Epidermophyton	B-T204
floccosum	I-T204
and	O
Microsporum	B-T204
canis	I-T204
.	O

Protein	B-T017
coding	I-T017
sequences	I-T017
of	O
the	O
mitochondrial	B-T017
genome	I-T017
were	O
aligned	O
for	O
their	O
similar	B-T082
sequences	I-T082
and	O
homology	B-T062
modelling	I-T062
was	O
performed	O
for	O
structure	B-T103
and	O
pocket	O
identification	B-T062
.	O

The	O
results	O
obtained	O
from	O
comparative	O
analysis	O
of	O
the	O
protein	B-T082
sequences	I-T082
revealed	O
the	O
presence	O
of	O
functionally	O
active	O
sites	O
in	O
all	O
the	O
species	O
of	O
the	O
genera	B-T170
Trichophyton	B-T204
and	O
Microsporum	B-T204
.	O

However	O
in	O
Epidermophyton	B-T204
floccosum	I-T204
it	O
was	O
observed	O
in	O
three	O
protein	B-T082
sequences	I-T082
of	O
the	O
five	O
studied	O
.	O

The	O
absence	O
of	O
these	O
conserved	B-T082
coil	I-T082
functional	O
residues	O
in	O
E	B-T204
.	I-T204

floccusum	I-T204
may	O
be	O
correlated	O
with	O
lesser	O
infectivity	O
of	O
this	O
organism	O
.	O

The	O
functional	O
residues	O
identified	O
in	O
the	O
present	O
study	O
could	O
be	O
responsible	O
for	O
the	O
disease	B-T038
and	O
thus	O
can	O
act	O
as	O
putative	O
target	O
sites	O
for	O
drug	O
designing	O
.	O

Non	B-T058
-	I-T058
intubated	I-T058
subxiphoid	B-T082
uniportal	B-T058
video	I-T058
-	I-T058
assisted	I-T058
thoracoscopic	I-T058
thymectomy	B-T058
using	O
glasses	B-T033
-	I-T033
free	I-T033
3D	B-T082
vision	B-T038

Trans	B-T058
-	I-T058
sternal	I-T058
thymectomy	I-T058
has	O
long	O
been	O
accepted	O
as	O
the	O
standard	O
surgical	B-T058
procedure	I-T058
for	O
thymic	B-T017
masses	I-T017
.	O

Recently	O
,	O
minimally	O
invasive	O
methods	B-T170
,	O
such	O
as	O
video	B-T058
-	I-T058
assisted	I-T058
thoracoscopic	I-T058
surgery	I-T058
(	B-T058
VATS	I-T058
)	I-T058
and	O
,	O
even	O
more	O
recently	O
,	O
non	B-T058
-	I-T058
intubated	I-T058
anesthesia	B-T058
,	O
have	O
emerged	O
.	O

These	O
methods	B-T170
provide	O
advantages	O
including	O
reductions	O
in	O
surgical	O
trauma	O
,	O
postoperative	B-T033
associated	I-T033
pain	I-T033
,	O
and	O
in	O
regards	O
to	O
VATS	B-T058
,	O
provide	O
certain	O
cosmetic	B-T058
benefits	O
.	O

Considering	O
these	O
advantages	O
,	O
we	O
herein	O
present	O
a	O
case	O
of	O
subxiphoid	B-T082
uniportal	B-T058
VATS	I-T058
for	O
thymic	B-T017
mass	I-T017
using	O
a	O
glasses	B-T033
-	I-T033
free	I-T033
3D	B-T082
thoracoscopic	B-T082
display	O
system	O
.	O

Trends	O
in	O
dietary	B-T038
intake	I-T038
among	O
adults	O
with	O
type	B-T038
2	I-T038
diabetes	I-T038
:	O
NHANES	B-T062
1988	O
-	O
2012	O

Dietary	B-T168
recommendations	O
for	O
adults	O
with	O
diabetes	B-T038
are	O
to	O
follow	O
a	O
healthy	B-T058
diet	I-T058
in	O
appropriate	O
portion	O
sizes	O
.	O

We	O
determined	O
recent	O
trends	O
in	O
energy	O
and	O
nutrient	O
intakes	O
among	O
a	O
nationally	O
representative	O
sample	O
of	O
US	B-T082
adults	O
with	O
and	O
without	O
type	B-T038
2	I-T038
diabetes	I-T038
.	O

Participants	B-T098
were	O
adults	O
aged	O
≥20	O
years	O
from	O
the	O
cross	B-T062
-	I-T062
sectional	I-T062
National	I-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Surveys	I-T062
,	O
1988	O
-	O
2012	O
(	O
N	O
=	O
49	O
770	O
)	O
.	O

Diabetes	B-T038
was	O
determined	O
by	O
self	B-T062
-	I-T062
report	I-T062
of	O
a	O
physician	B-T097
'	I-T097
s	I-T097
diagnosis	B-T033
(	O
n	O
=	O
4885	O
)	O
.	O

Intake	O
of	O
energy	O
and	O
nutrients	B-T168
were	O
determined	O
from	O
a	O
24	O
-	O
h	O
recall	O
by	O
participants	B-T098
of	O
all	O
food	B-T168
consumed	O
.	O

Linear	O
regression	O
was	O
used	O
to	O
test	O
for	O
trends	O
in	O
mean	O
intake	B-T038
over	O
time	O
for	O
all	O
participants	B-T098
and	O
by	O
demographic	O
characteristics	O
.	O

Among	O
adults	O
with	O
diabetes	B-T038
,	O
overall	O
total	O
energy	O
intake	O
increased	O
between	O
1988	O
-	O
1994	O
and	O
2011	O
-	O
2012	O
(	O
1689	O
kcal	O
versus	O
1895	O
kcal	O
;	O
Ptrend	O
<	O
0	O
.	O
001	O
)	O
with	O
evidence	O
of	O
a	O
plateau	O
between	O
2003	O
-	O
2006	O
and	O
2011	O
-	O
2012	O
.	O

In	O
2007	O
-	O
2012	O
,	O
energy	O
intake	O
was	O
greater	O
for	O
younger	O
than	O
older	B-T098
adults	I-T098
,	O
for	O
men	B-T098
than	O
women	B-T098
,	O
and	O
for	O
non	O
-	O
Hispanic	O
whites	O
versus	O
non	B-T098
-	I-T098
Hispanic	I-T098
blacks	I-T098
.	O

There	O
was	O
no	O
change	O
in	O
the	O
percentage	O
of	O
calories	O
from	O
carbohydrate	B-T168
,	O
total	B-T103
fat	I-T103
or	O
protein	B-T168
.	O

Percentage	O
of	O
calories	O
from	O
saturated	O
fat	O
was	O
similar	O
across	O
study	B-T062
periods	O
but	O
remained	O
above	O
recommendations	O
(	O
11	O
.	O
2	O
%	O
in	O
2011	O
-	O
2012	O
)	O
.	O

Fibre	B-T033
intake	I-T033
significantly	O
decreased	O
and	O
remained	O
below	O
recommendations	O
(	O
Ptrend	O
=	O
0	O
.	O
002	O
)	O
.	O

Sodium	B-T168
,	O
cholesterol	B-T103
and	O
calcium	B-T103
intakes	B-T038
increased	O
.	O

There	O
was	O
no	O
change	O
in	O
energy	O
intake	O
among	O
adults	O
without	O
diabetes	B-T038
and	O
dietary	B-T168
trends	O
were	O
similar	O
to	O
those	O
with	O
diabetes	B-T038
.	O

Future	O
data	O
are	O
needed	O
to	O
confirm	O
a	O
plateau	O
in	O
energy	O
intake	O
among	O
adults	O
with	O
diabetes	B-T038
,	O
although	O
the	O
opportunity	O
exists	O
to	O
increase	O
fibre	B-T168
and	O
reduce	O
saturated	O
fat	O
.	O

Clonal	B-T017
and	O
serotype	B-T170
dynamics	O
of	O
serogroup	B-T007
6	I-T007
isolates	B-T103
causing	O
invasive	B-T038
pneumococcal	I-T038
disease	I-T038
in	O
Portugal	B-T082
:	O
1999	O
-	O
2012	O

Although	O
serogroup	B-T007
6	I-T007
was	O
among	O
the	O
first	O
to	O
be	O
recognized	O
among	O
Streptococcus	B-T007
pneumoniae	I-T007
,	O
several	O
new	O
serotypes	B-T170
were	O
identified	O
since	O
the	O
introduction	O
of	O
pneumococcal	B-T103
conjugate	I-T103
vaccines	I-T103
(	O
PCVs	B-T103
)	O
.	O

A	O
decrease	O
of	O
the	O
6B	O
-	O
2	O
variant	O
among	O
invasive	B-T038
pneumococcal	I-T038
disease	I-T038
(	O
IPD	B-T038
)	O
,	O
but	O
not	O
6B	O
-	O
1	O
,	O
was	O
noted	O
post	O
conjugate	B-T103
vaccine	I-T103
introduction	O
,	O
underpinned	O
by	O
a	O
decrease	O
of	O
CC273	B-T103
isolates	I-T103
.	O

Serotype	B-T007
6C	I-T007
was	O
associated	O
with	O
adult	O
IPD	B-T038
and	O
increased	O
in	O
this	O
age	O
group	O
representing	O
two	O
lineages	O
(	O
CC315	O
and	O
CC395	O
)	O
,	O
while	O
the	O
same	O
lineages	O
expressed	B-T038
other	O
serogroup	B-T007
6	I-T007
serotypes	B-T170
in	O
children	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
a	O
potential	O
cross	B-T038
-	I-T038
protection	I-T038
of	O
PCVs	B-T103
against	O
serotype	B-T007
6C	I-T007
IPD	B-T038
among	O
vaccinated	B-T033
children	O
but	O
not	O
among	O
adults	O
.	O

Serotype	B-T007
6A	I-T007
became	O
the	O
most	O
important	O
serogroup	B-T007
6	I-T007
serotype	B-T170
in	O
children	O
but	O
it	O
decreased	O
in	O
adult	O
IPD	B-T038
.	O

No	O
other	O
serogroup	B-T007
6	I-T007
serotypes	B-T170
were	O
detected	B-T033
,	O
so	O
available	O
phenotypic	O
or	O
simple	O
genotypic	O
assays	B-T058
remain	O
adequate	O
for	O
distinguishing	O
serotypes	B-T170
within	O
serogroup	B-T007
6	I-T007
isolates	B-T103
.	O

Minimally	O
invasive	O
percutaneous	B-T058
nephrolithotomy	I-T058
improves	O
stone	O
-	O
free	O
rates	O
for	O
impacted	O
proximal	B-T082
ureteral	B-T038
stones	I-T038
:	O
A	O
systematic	B-T170
review	I-T170
and	O
meta	B-T062
-	I-T062
analysis	I-T062

Urinary	B-T038
stones	I-T038
are	O
common	O
medical	O
disorders	B-T038
and	O
the	O
treatment	O
of	O
impacted	B-T038
proximal	B-T082
ureteral	I-T038
stones	I-T038
(	O
IPUS	B-T038
)	O
is	O
still	O
a	O
challenge	O
for	O
urologists	B-T097
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
compare	B-T062
the	I-T062
efficacy	I-T062
and	O
safety	B-T062
of	O
minimally	O
invasive	O
percutaneous	B-T058
nephrolithotomy	I-T058
(	O
MI	O
-	O
PCNL	B-T058
)	O
and	O
ureteroscopic	B-T058
lithotripsy	I-T058
(	O
URL	B-T058
)	O
in	O
the	O
treatment	O
of	O
IPUS	B-T038
via	O
a	O
meta	B-T062
-	I-T062
analysis	I-T062
.	O

We	O
collected	O
studies	B-T062
using	O
PubMed	B-T170
,	O
Embase	B-T170
,	O
and	O
Cochrane	B-T170
Library	I-T170
from	O
1978	O
to	O
November	O
2016	O
and	O
analyzed	B-T062
them	O
using	O
Stata	B-T170
12	I-T170
.	I-T170
0	I-T170
and	O
RevMan	B-T170
5	I-T170
.	I-T170
3	I-T170
.	O

Odds	O
ratios	O
(	O
OR	O
s	O
)	O
and	O
standard	O
mean	O
difference	O
(	O
SMD	O
)	O
were	O
calculated	O
for	O
binary	O
and	O
continuous	O
variables	O
respectively	O
,	O
accompanied	O
with	O
95	O
%	O
confidence	O
intervals	O
(	O
CIs	O
)	O
.	O

All	O
study	B-T062
procedures	O
followed	O
the	O
PRISMA	B-T170
guidelines	I-T170
.	O

Five	O
prospective	B-T062
studies	I-T062
were	O
included	O
in	O
our	O
meta	B-T062
-	I-T062
analysis	I-T062
,	O
with	O
242	O
MI	O
-	O
PCNL	B-T058
and	O
256	O
URL	B-T058
cases	O
.	O

MI	O
-	O
PCNL	B-T058
was	O
associated	O
with	O
a	O
longer	O
postoperative	O
hospital	O
stay	O
than	O
URL	B-T058
(	O
SMD	O
,	O
3	O
.	O
14	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
27	O
to	O
5	O
.	O
55	O
)	O
.	O

However	O
,	O
no	O
significant	O
difference	O
was	O
observed	O
in	O
operative	O
time	O
(	O
SMD	O
,	O
-	O
0	O
.	O
38	O
;	O
95	O
%	O
CI	O
,	O
-	O
3	O
.	O
15	O
to	O
2	O
.	O
38	O
)	O
.	O

In	O
addition	O
,	O
MI	O
-	O
PCNL	B-T058
had	O
higher	O
initial	O
(	O
OR	O
,	O
11	O
.	O
12	O
;	O
95	O
%	O
CI	O
,	O
5	O
.	O
56	O
to	O
22	O
.	O
24	O
)	O
and	O
overall	O
stone	O
-	O
free	O
rates	O
(	O
OR	O
,	O
8	O
.	O
70	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
23	O
to	O
23	O
.	O
45	O
)	O
than	O
URL	B-T058
,	O
along	O
with	O
lower	O
possibilities	O
of	O
surgical	B-T058
conversion	I-T058
(	O
OR	O
,	O
0	O
.	O
11	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
03	O
to	O
0	O
.	O
49	O
)	O
and	O
postoperative	O
shock	B-T058
wave	I-T058
lithotripsy	I-T058
(	O
OR	O
,	O
0	O
.	O
06	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
02	O
to	O
0	O
.	O
18	O
)	O
.	O

Regarding	O
complications	B-T038
,	O
no	O
significant	O
differences	O
were	O
observed	O
between	B-T082
MI	O
-	O
PCNL	B-T058
and	O
URL	B-T058
(	O
OR	O
,	O
1	O
.	O
39	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
93	O
to	O
2	O
.	O
10	O
)	O
,	O
except	O
for	O
hematuria	B-T038
(	O
OR	O
,	O
4	O
.	O
80	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
45	O
to	O
15	O
.	O
94	O
)	O
.	O

MI	O
-	O
PCNL	B-T058
is	O
optimal	O
and	O
should	O
be	O
considered	O
as	O
the	O
preferred	O
treatment	B-T058
method	I-T058
for	O
IPUS	B-T038
,	O
as	O
it	O
has	O
better	O
efficacy	O
and	O
a	O
safety	B-T062
profile	O
similar	O
to	O
that	O
of	O
URL	B-T058
.	O

However	O
,	O
further	O
high	O
quality	O
studies	O
with	O
larger	O
sample	O
size	O
are	O
required	O
in	O
future	O
.	O

Predictive	B-T170
Factors	I-T170
for	O
Long	O
-	O
term	O
Outcome	O
of	O
Subthalamic	B-T017
Nucleus	I-T017
Deep	B-T058
Brain	I-T058
Stimulation	I-T058
for	O
Parkinson	B-T038
'	I-T038
s	I-T038
Disease	I-T038

Despite	O
the	O
recognition	O
of	O
the	O
usefulness	O
of	O
subthalamic	B-T017
nucleus	I-T017
deep	B-T058
brain	I-T058
stimulation	I-T058
(	O
STN	B-T017
-	O
DBS	B-T058
)	O
for	O
the	O
treatment	O
of	O
Parkinson	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
PD	B-T038
)	O
,	O
preoperative	O
predictive	B-T170
factors	I-T170
for	O
the	O
long	O
-	O
term	O
outcome	O
of	O
STN	B-T017
-	O
DBS	B-T058
are	O
not	O
sufficiently	O
established	O
.	O

We	O
performed	O
this	O
study	B-T062
to	O
determine	O
such	O
predictive	B-T170
factors	I-T170
.	O

The	O
subjects	O
were	O
66	O
patients	O
who	O
were	O
classified	B-T170
into	O
two	O
groups	O
on	O
the	O
basis	O
of	O
their	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
evaluated	O
five	O
years	O
after	O
the	O
STN	B-T017
-	O
DBS	B-T058
surgery	B-T058
:	O
33	O
patients	O
were	O
assigned	O
to	O
the	O
independent	O
ADL	O
group	O
(	O
group	O
I	O
)	O
and	O
the	O
remaining	O
33	O
patients	O
to	O
the	O
dependent	O
ADL	O
group	O
(	O
group	O
D	O
)	O
.	O

Group	O
I	O
patients	O
showed	O
a	O
Schwab	O
and	O
England	O
(	O
S	O
&	O
E	O
)	O
scale	O
score	O
of	O
more	O
than	O
70	O
during	O
the	O
off	O
-	O
period	O
,	O
indicating	O
that	O
these	O
patients	O
can	O
maintain	O
their	O
independent	O
ADL	O
all	O
the	O
time	O
.	O

Group	O
D	O
patients	O
showed	O
a	O
score	O
of	O
70	O
or	O
lower	O
during	O
the	O
off	O
-	O
period	O
,	O
indicating	O
that	O
these	O
patients	O
cannot	O
maintain	O
their	O
independent	O
ADL	O
for	O
an	O
entire	O
day	O
.	O

We	O
studied	B-T062
the	O
differences	O
in	O
the	O
preoperative	B-T033
state	I-T033
between	O
these	O
two	O
groups	O
.	O

Statistically	O
significant	O
differences	O
were	O
noted	O
in	O
PD	B-T038
onset	O
age	O
,	O
age	O
at	O
surgery	B-T058
,	O
preoperative	O
unified	O
Parkinson	O
'	O
s	O
disease	O
rating	O
scale	O
(	O
UPDRS	O
)	O
part	B-T082
I	I-T082
score	O
,	O
part	B-T082
II	I-T082
score	O
,	O
total	O
subscore	O
for	O
axial	B-T033
symptoms	I-T033
in	O
part	B-T082
III	I-T082
,	O
mini	B-T033
-	I-T033
mental	I-T033
state	I-T033
examination	I-T033
(	I-T033
MMSE	I-T033
)	I-T033
score	I-T033
and	O
S	O
&	O
E	O
score	O
.	O

Multiple	O
logistic	O
regression	O
analysis	O
showed	O
that	O
the	O
significant	O
independent	O
variables	O
related	O
to	O
long	O
-	O
term	O
independent	O
ADL	O
were	O
the	O
age	O
at	O
surgery	B-T058
,	O
MMSE	B-T033
score	I-T033
and	O
preoperative	O
S	O
&	O
E	O
scale	O
score	O
during	O
the	O
off	O
-	O
period	O
.	O

The	O
PD	B-T038
onset	O
age	O
,	O
age	O
at	O
surgery	B-T058
,	O
preoperative	O
high	O
-	O
level	O
ADL	O
,	O
cognitive	B-T038
function	I-T038
,	O
and	O
axial	B-T033
symptoms	I-T033
are	O
important	O
predictive	B-T170
factors	I-T170
for	O
the	O
long	O
-	O
term	O
outcome	O
of	O
STN	B-T017
-	O
DBS	B-T058
.	O

Who	O
Persuades	O
Who	O
?	O
An	O
Analysis	B-T062
of	O
Persuasion	O
Choices	O
Related	O
to	O
Antibiotic	B-T103
-	O
Free	O
Food	B-T168

Personal	O
communication	O
,	O
in	O
which	O
one	O
person	B-T098
persuades	O
another	O
to	O
engage	O
in	O
a	O
particular	O
behavior	O
,	O
is	O
one	O
means	O
through	O
which	O
behaviors	O
spread	O
.	O

To	O
better	O
understand	B-T038
how	O
personal	O
communication	O
spreads	O
behavior	O
,	O
we	O
investigated	O
adults	O
'	O
(	O
N	O
=	O
228	O
)	O
likelihood	O
of	O
persuading	O
others	O
in	O
a	O
fictitious	O
social	B-T098
network	I-T098
to	O
buy	O
antibiotic	B-T103
-	O
free	O
food	B-T168
,	O
and	O
who	O
they	O
attempted	O
to	O
persuade	O
,	O
based	O
on	O
behavioral	O
determinants	O
,	O
homophily	O
,	O
and	O
superdiffuser	O
traits	O
.	O

For	O
potential	O
consumers	B-T098
,	O
the	O
findings	B-T033
showed	O
that	O
behavioral	O
determinants	O
,	O
behavioral	O
intentions	B-T038
,	O
and	O
mavenism	O
predicted	O
intentions	B-T038
to	O
persuade	O
others	O
.	O

Homophily	O
,	O
mavenism	O
,	O
and	O
connectivity	O
predicted	O
patterns	B-T082
of	O
interpersonal	O
persuasion	O
.	O

For	O
vegetarians	B-T098
(	O
without	O
homophily	O
in	O
action	O
)	O
,	O
behavioral	O
determinants	O
and	O
mavenism	O
predicted	O
persuasion	O
intentions	B-T038
.	O

Persuasiveness	O
was	O
associated	O
with	O
targeting	O
more	O
network	B-T098
members	B-T098
;	O
mavenism	O
was	O
associated	O
with	O
selecting	O
structurally	B-T082
central	B-T082
members	B-T098
.	O

Modeling	B-T062
the	O
flux	O
of	O
metabolites	B-T103
in	O
the	O
juvenile	B-T103
hormone	I-T103
biosynthesis	B-T038
pathway	B-T038
using	O
generalized	O
additive	O
models	O
and	O
ordinary	B-T170
differential	I-T170
equations	I-T170

Juvenile	B-T103
hormone	I-T103
(	O
JH	B-T103
)	O
regulates	O
development	O
and	O
reproductive	B-T038
maturation	I-T038
in	O
insects	B-T204
.	O

The	O
corpora	B-T017
allata	I-T017
(	O
CA	B-T017
)	O
from	O
female	O
adult	B-T204
mosquitoes	I-T204
synthesize	O
fluctuating	O
levels	O
of	O
JH	B-T103
,	O
which	O
have	O
been	O
linked	O
to	O
the	O
ovarian	B-T038
development	I-T038
and	O
are	O
influenced	O
by	O
nutritional	O
signals	B-T038
.	O

The	O
rate	O
of	O
JH	B-T103
biosynthesis	B-T038
is	O
controlled	O
by	O
the	O
rate	O
of	O
flux	O
of	O
isoprenoids	B-T103
in	O
the	O
pathway	B-T038
,	O
which	O
is	O
the	O
outcome	O
of	O
a	O
complex	O
interplay	O
of	O
changes	O
in	O
precursor	O
pools	O
and	O
enzyme	B-T103
levels	O
.	O

A	O
comprehensive	O
study	B-T062
of	O
the	O
changes	O
in	O
enzymatic	B-T038
activities	I-T038
and	O
precursor	O
pool	O
sizes	O
have	O
been	O
previously	O
reported	O
for	O
the	O
mosquito	B-T204
Aedes	B-T204
aegypti	I-T204
JH	B-T103
biosynthesis	B-T038
pathway	B-T038
.	O

In	O
the	O
present	O
studies	B-T062
,	O
we	O
used	O
two	O
different	O
quantitative	O
approaches	O
to	O
describe	O
and	O
predict	O
how	O
changes	O
in	O
the	O
individual	O
metabolic	O
reactions	O
in	O
the	O
pathway	B-T038
affect	O
JH	B-T103
synthesis	B-T038
.	O

First	O
,	O
we	O
constructed	O
generalized	O
additive	O
models	O
(	O
GAMs	O
)	O
that	O
described	O
the	O
association	O
between	O
changes	O
in	O
specific	O
metabolite	B-T103
concentrations	O
with	O
changes	O
in	O
enzymatic	B-T038
activities	I-T038
and	O
substrate	O
concentrations	O
.	O

Changes	O
in	O
substrate	O
concentrations	O
explained	O
50	O
%	O
or	O
more	O
of	O
the	O
model	O
deviances	O
in	O
7	O
of	O
the	O
13	O
metabolic	O
steps	O
analyzed	B-T062
.	O

Addition	O
of	O
information	O
on	O
enzymatic	B-T038
activities	I-T038
almost	O
always	O
improved	O
the	O
fitness	O
of	O
GAMs	O
built	O
solely	O
based	O
on	O
substrate	O
concentrations	O
.	O

GAMs	O
were	O
validated	O
using	O
experimental	O
data	O
that	O
were	O
not	O
included	O
when	O
the	O
model	O
was	O
built	O
.	O

In	O
addition	O
,	O
a	O
system	O
of	O
ordinary	B-T170
differential	I-T170
equations	I-T170
(	O
ODE	B-T170
)	O
was	O
developed	O
to	O
describe	O
the	O
instantaneous	O
changes	O
in	O
metabolites	B-T103
as	O
a	O
function	O
of	O
the	O
levels	O
of	O
enzymatic	B-T038
catalytic	I-T038
activities	I-T038
.	O

The	O
results	O
demonstrated	O
the	O
ability	O
of	O
the	O
models	O
to	O
predict	O
changes	O
in	O
the	O
flux	O
of	O
metabolites	B-T103
in	O
the	O
JH	B-T103
pathway	B-T038
,	O
and	O
can	O
be	O
used	O
in	O
the	O
future	O
to	O
design	O
and	O
validate	B-T062
experimental	O
manipulations	O
of	O
JH	B-T103
synthesis	B-T038
.	O

Associations	O
between	O
human	O
breast	O
milk	O
hormones	B-T103
and	O
adipocytokines	B-T103
and	O
infant	B-T038
growth	I-T038
and	O
body	O
composition	O
in	O
the	O
first	B-T033
6	I-T033
months	I-T033
of	I-T033
life	I-T033

Much	O
is	O
to	O
be	O
learnt	O
about	O
human	O
breast	O
milk	O
(	O
HBM	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
is	O
to	O
extend	O
our	O
knowledge	O
of	O
HBM	O
by	O
investigating	O
the	O
role	O
of	O
maternal	B-T033
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
,	O
sex	O
and	O
stage	B-T038
of	I-T038
lactation	I-T038
(	O
month	O
1	O
vs	O
.	O

6	O
)	O
on	O
HBM	O
insulin	B-T103
,	O
glucose	B-T103
,	O
leptin	B-T103
,	O
IL	B-T103
-	I-T103
6	I-T103
and	O
TNF	B-T103
-	I-T103
α	I-T103
and	O
their	O
associations	O
with	O
infant	O
body	O
composition	O
.	O

Thirty	O
-	O
seven	O
exclusively	O
breastfeeding	B-T033
infants	I-T033
(	O
n	O
=	O
37	O
;	O
16♀	O
,	O
21♂	O
)	O
,	O
and	O
their	O
mothers	B-T033
(	O
19	O
-	O
47	O
kg	O
m	O
(	O
-	O
2	O
)	O
)	O
were	O
studied	O
at	O
1	O
and	O
6	O
months	O
of	O
lactation	B-T038
.	O

Infants	O
had	O
body	B-T201
composition	I-T201
measured	I-T201
(	O
using	O
dual	B-T058
-	I-T058
energy	I-T058
X	I-T058
-	I-T058
ray	I-T058
absorptiometry	I-T058
)	O
and	O
HBM	O
collected	O
.	O

A	O
significant	O
interaction	O
between	O
maternal	B-T033
BMI	B-T201
and	O
infant	O
sex	O
on	O
insulin	B-T058
levels	I-T058
(	O
p	O
=	O
0	O
.	O
0322	O
)	O
was	O
observed	O
such	O
that	O
insulin	B-T033
was	I-T033
229	I-T033
%	I-T033
higher	I-T033
in	O
obese	B-T038
mothers	O
nursing	O
female	O
infants	O
than	O
in	O
normal	B-T033
weight	I-T033
mothers	O
nursing	B-T038
female	O
infants	O
and	O
179	O
%	O
higher	O
than	O
obese	B-T038
mothers	O
nursing	O
male	O
infants	O
.	O

For	O
leptin	B-T103
,	O
a	O
significant	O
association	O
with	O
BMI	B-T201
category	O
was	O
observed	O
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
such	O
that	O
overweight	B-T033
and	O
obese	B-T038
mothers	O
had	O
96	O
.	O
5	O
%	O
and	O
315	O
.	O
1	O
%	O
higher	B-T033
leptin	I-T033
levels	I-T033
than	O
normal	B-T033
weight	I-T033
mothers	O
,	O
respectively	O
.	O

Leptin	B-T103
was	O
also	O
found	O
to	O
have	O
a	O
significant	O
(	O
p	O
=	O
0	O
.	O
0004	O
)	O
33	O
.	O
7	O
%	O
decrease	O
from	O
months	O
1	O
to	O
6	O
,	O
controlling	O
for	O
BMI	B-T201
category	O
and	O
sex	O
.	O

A	O
significant	O
inverse	O
relationship	O
between	O
month	O
1	O
leptin	B-T103
levels	O
and	O
infant	B-T033
length	I-T033
(	O
p	O
=	O
0	O
.	O
0257	O
)	O
,	O
percent	B-T033
fat	I-T033
(	O
p	O
=	O
0	O
.	O
0223	O
)	O
,	O
total	O
fat	O
mass	O
(	O
p	O
=	O
0	O
.	O
0226	O
)	O
and	O
trunk	O
fat	O
mass	O
(	O
p	O
=	O
0	O
.	O
0111	O
)	O
at	O
month	O
6	O
was	O
also	O
found	O
.	O

No	O
associations	O
or	O
interactions	O
were	O
observed	O
for	O
glucose	B-T103
,	O
TNF	B-T103
-	I-T103
α	I-T103
or	O
IL	B-T103
-	I-T103
6	I-T103
.	O

These	O
data	O
demonstrate	O
that	O
maternal	B-T033
BMI	B-T201
,	O
infant	O
sex	O
and	O
stage	B-T038
of	I-T038
lactation	I-T038
affect	O
the	O
compositional	O
make	O
-	O
up	O
of	O
insulin	B-T103
and	O
leptin	B-T103
.	O

Aryl	B-T017
hydrocarbon	I-T017
receptor	I-T017
(	I-T017
AhR	I-T017
)	I-T017
rs2066853	I-T017
gene	O
polymorphism	O
association	O
with	O
infertile	B-T038
oligoasthenoteratozoospermic	B-T038
men	B-T098
and	O
seminal	B-T201
oxidative	B-T038
stress	I-T038

This	O
study	O
aimed	O
to	O
assess	O
the	O
association	O
between	O
aryl	B-T017
hydrocarbon	I-T017
receptor	I-T017
(	I-T017
AhR	I-T017
)	I-T017
rs2066853	I-T017
gene	O
polymorphism	O
with	O
infertile	B-T038
oligoasthenoteratozoospermic	B-T038
(	O
OAT	B-T038
)	O
men	B-T098
and	O
seminal	B-T201
oxidative	B-T038
stress	I-T038
(	O
OS	B-T038
)	O
.	O

A	O
total	O
of	O
170	O
Egyptian	B-T098
men	I-T098
were	O
allocated	O
according	O
to	O
their	O
semen	B-T058
analysis	I-T058
into	O
fertile	B-T038
normozoospermic	B-T033
controls	I-T033
(	O
n	O
=	O
50	O
)	O
and	O
infertile	B-T038
OAT	B-T038
men	B-T098
(	O
n	O
=	O
120	O
)	O
.	O

They	O
were	O
subjected	O
to	O
history	B-T058
taking	I-T058
,	O
clinical	B-T201
examination	I-T201
,	O
semen	B-T058
analysis	I-T058
,	O
estimation	O
of	O
seminal	B-T201
glutathione	B-T103
peroxidase	I-T103
(	O
GPx	B-T103
)	O
,	O
and	O
malondialdehyde	B-T103
(	O
MDA	B-T103
)	O
.	O

AhR	B-T017
rs2066853	I-T017
gene	O
polymorphism	O
was	O
identified	O
in	O
the	O
blood	B-T031
by	O
PCR	B-T062
-	O
RFLP	B-T038
.	O

Comparing	O
infertile	B-T038
OAT	B-T038
men	B-T098
with	O
fertile	B-T038
controls	O
,	O
AhR	B-T017
rs2066853	I-T017
genotypes	O
showed	O
decreased	O
prevalence	O
for	O
wild	B-T017
homozygous	O
genotype	O
GG	O
(	O
35	O
.	O
8	O
vs	O
56	O
%	O
)	O
and	O
for	O
heterozygous	O
genotype	O
GA	O
(	O
17	O
.	O
5	O
vs	O
30	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
for	O
homozygous	O
genotype	O
AA	O
(	O
46	O
.	O
7	O
vs	O
14	O
%	O
)	O
.	O

Distribution	O
of	O
alleles	B-T017
of	O
AhR	B-T017
rs2066853	I-T017
among	O
OAT	B-T038
men	B-T098
compared	O
with	O
fertile	B-T038
men	B-T098
showed	O
decreased	O
prevalence	O
of	O
G	B-T017
allele	I-T017
(	O
44	O
.	O
6	O
vs	O
71	O
%	O
)	O
and	O
an	O
increased	O
prevalence	O
of	O
A	B-T017
allele	I-T017
(	O
55	O
.	O
4	O
vs	O
29	O
%	O
)	O
.	O

Seminal	B-T201
MDA	B-T103
demonstrated	O
significant	O
increase	O
whereas	O
seminal	B-T201
GPx	B-T103
demonstrated	O
significant	O
decrease	O
in	O
cases	O
with	O
AA	O
and	O
GA	O
/	O
AA	O
genotypes	O
compared	O
to	O
cases	O
with	O
GG	O
genotype	O
.	O

It	O
is	O
concluded	O
that	O
there	O
is	O
a	O
significant	O
association	O
between	O
AhR	B-T017
rs2066853	I-T017
genotype	O
polymorphism	O
with	O
decreased	O
sperm	B-T017
parameters	O
as	O
well	O
as	O
increased	O
seminal	B-T201
oxidative	B-T038
stress	I-T038
in	O
infertile	B-T038
OAT	B-T038
men	B-T098
.	O

Associations	O
of	O
gender	O
and	O
a	O
proxy	O
of	O
female	O
menopausal	B-T201
status	I-T201
with	O
histological	O
features	O
of	O
drug	B-T038
-	I-T038
induced	I-T038
liver	I-T038
injury	I-T038

Gender	O
and	O
menopause	B-T038
may	O
contribute	O
to	O
type	O
and	O
severity	O
of	O
drug	B-T038
-	I-T038
induced	I-T038
liver	I-T038
injury	I-T038
(	O
DILI	B-T038
)	O
by	O
influencing	O
host	O
responses	B-T033
to	O
injury	B-T037
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
assess	O
the	O
associations	O
of	O
gender	O
and	O
female	O
age	O
50	O
[	O
a	O
proxy	O
of	O
menopause	B-T038
]	O
with	O
histological	O
features	O
of	O
liver	B-T037
injury	I-T037
in	O
212	O
adults	O
enrolled	O
in	O
the	O
Drug	B-T038
-	I-T038
Induced	I-T038
Liver	I-T038
Injury	I-T038
Network	O
(	O
DILIN	O
)	O
registry	B-T170
.	O

All	O
participants	B-T098
had	O
a	O
causality	O
score	O
of	O
at	O
least	O
'	O
probable	B-T033
'	O
,	O
a	O
liver	B-T058
biopsy	I-T058
within	O
30	O
days	O
of	O
DILI	B-T038
onset	O
,	O
and	O
no	O
prior	O
chronic	B-T038
liver	I-T038
disease	I-T038
.	O

Biochemical	O
and	O
histological	O
injury	B-T037
types	O
were	O
classified	O
as	O
hepatocellular	B-T038
or	O
cholestatic	B-T038
/	I-T038
mixed	I-T038
injury	I-T038
.	O

The	O
cohort	B-T098
was	O
divided	O
into	O
three	O
gender	O
/	O
age	O
categories	B-T170
:	O
men	B-T098
(	O
41	O
.	O
0	O
%	O
)	O
,	O
women	B-T098
<	O
50	O
years	O
(	O
27	O
.	O
4	O
%	O
)	O
and	O
women	B-T098
≥50	O
years	O
of	O
age	O
(	O
31	O
.	O
6	O
%	O
)	O
.	O

Interaction	O
of	O
gender	O
and	O
age	O
category	B-T170
(	O
≥50	O
or	O
not	O
)	O
was	O
assessed	O
.	O

Hepatocellular	B-T038
injury	I-T038
was	O
more	O
prevalent	O
in	O
women	B-T098
<	O
50	O
years	O
vs	O
.	O

others	O
(	O
P	O
=	O
.	O
002	O
)	O
.	O

After	O
adjusting	O
for	O
biochemical	O
injury	B-T037
types	O
,	O
black	B-T098
race	I-T098
and	O
possible	B-T033
ageing	B-T038
effects	O
,	O
more	O
severe	O
interface	O
hepatitis	B-T038
was	O
noted	O
in	O
biopsies	B-T058
of	O
women	B-T098
<	O
50	O
years	O
compared	O
to	O
those	O
of	O
men	B-T098
and	O
women	B-T098
≥50	O
years	O
(	O
P	O
=	O
.	O
009	O
and	O
P	O
=	O
.	O
055	O
respectively	O
)	O
.	O

Compared	O
to	O
those	O
of	O
men	B-T098
,	O
biopsies	B-T058
of	O
women	B-T098
showed	O
greater	O
plasma	B-T038
cell	I-T038
infiltration	I-T038
,	O
hepatocyte	B-T038
apoptosis	I-T038
,	O
hepatocyte	B-T017
rosettes	B-T033
and	O
lobular	O
disarray	O
but	O
less	O
iron	B-T103
-	O
positive	B-T033
hepatocytes	B-T017
and	O
histological	O
cholestasis	B-T038
(	O
P	O
<	O
.	O
05	O
)	O
.	O

These	O
associations	O
persisted	O
after	O
excluding	O
cases	O
of	O
amoxicillin	B-T103
/	I-T103
clavulanic	I-T103
acid	I-T103
,	O
anabolic	B-T103
steroids	I-T103
or	O
nitrofurantoin	B-T103
DILI	B-T038
which	O
showed	O
gender	O
-	O
specific	O
distributions	O
.	O

Gender	O
and	O
a	O
proxy	O
of	O
menopause	B-T038
were	O
associated	O
with	O
various	O
features	O
of	O
inflammation	B-T038
and	O
injury	B-T037
in	O
DILI	B-T038
.	O

A	O
Novel	O
Potent	O
Anticancer	B-T103
Compound	I-T103
Optimized	O
from	O
a	O
Natural	O
Oridonin	B-T103
Scaffold	O
Induces	O
Apoptosis	B-T038
and	O
Cell	B-T038
Cycle	I-T038
Arrest	I-T038
through	O
the	O
Mitochondrial	B-T038
Pathway	I-T038

The	O
cytotoxicity	B-T038
of	O
the	O
natural	O
ent	B-T103
-	I-T103
kaurene	I-T103
diterpenoid	I-T103
,	O
oridonin	B-T103
,	O
has	O
been	O
extensively	O
studied	O
.	O

However	O
,	O
the	O
application	O
of	O
oridonin	B-T103
for	O
cancer	B-T058
therapy	I-T058
was	O
hampered	O
primarily	O
by	O
its	O
moderate	O
potency	O
.	O

In	O
this	O
study	O
,	O
a	O
series	O
of	O
oridonin	B-T103
A	B-T103
-	I-T103
ring	I-T103
modified	I-T103
analogues	I-T103
,	I-T103
and	I-T103
their	I-T103
derivatives	I-T103
bearing	O
various	O
substituents	O
on	O
14	O
-	O
OH	O
position	O
,	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
evaluated	B-T058
for	O
anticancer	B-T103
efficacy	O
.	O

Some	O
of	O
the	O
derivatives	B-T103
were	O
significantly	O
more	O
potent	O
than	O
oridonin	B-T103
against	O
both	O
drug	B-T103
-	O
sensitive	O
and	O
drug	B-T038
-	I-T038
resistant	I-T038
cancer	B-T017
cells	I-T017
.	O

The	O
most	O
potent	O
compound	B-T103
,	I-T103
13p	I-T103
,	O
was	O
200	O
-	O
fold	O
more	O
efficacious	O
than	O
oridonin	B-T103
in	O
MCF	B-T017
-	I-T017
7	I-T017
cancer	I-T017
cells	I-T017
.	O

Furthermore	O
,	O
13p	B-T103
induced	O
apoptosis	B-T038
and	O
cell	B-T038
cycle	I-T038
arrest	I-T038
at	O
the	O
G2	B-T038
/	I-T038
M	I-T038
phase	I-T038
.	O

A	O
decrease	O
in	O
mitochondrial	B-T038
membrane	I-T038
potential	I-T038
and	O
an	O
increase	O
in	O
Bax	B-T103
/	I-T103
Bcl	I-T103
-	I-T103
2	I-T103
ratio	O
,	O
accompanied	O
by	O
activated	B-T103
caspase	I-T103
-	I-T103
3	I-T103
cleavage	B-T038
,	O
were	O
observed	O
in	O
MCF	B-T017
-	I-T017
7	I-T017
cells	I-T017
after	O
treatment	B-T058
with	O
13p	B-T103
,	O
suggesting	O
that	O
the	O
mitochondrial	B-T038
pathway	I-T038
was	O
involved	O
in	O
the	O
13p	B-T103
-	O
mediated	O
apoptosis	B-T038
.	O

Moreover	O
,	O
13p	B-T103
significantly	O
inhibited	O
tumor	O
growth	O
in	O
mouse	B-T204
xenograft	B-T038
models	I-T038
and	O
had	O
no	B-T033
observable	I-T033
toxic	I-T033
effect	I-T033
.	O

Stromal	B-T033
alterations	I-T033
in	O
ovarian	B-T038
cancers	I-T038
via	O
wavelength	O
dependent	O
Second	B-T058
Harmonic	I-T058
Generation	I-T058
microscopy	I-T058
and	O
optical	O
scattering	O

Ovarian	B-T038
cancer	I-T038
remains	O
the	O
most	O
deadly	O
gynecological	B-T091
cancer	B-T038
with	O
a	O
poor	O
aggregate	O
survival	O
rate	O
;	O
however	O
,	O
the	O
specific	O
rates	O
are	O
highly	O
dependent	O
on	O
the	O
stage	O
of	O
the	O
disease	B-T038
upon	O
diagnosis	B-T033
.	O

Current	O
screening	B-T058
and	O
imaging	B-T074
tools	I-T074
are	O
insufficient	O
to	O
detect	O
early	B-T033
lesions	I-T033
and	O
are	O
not	O
capable	O
of	O
differentiating	O
the	O
subtypes	O
of	O
ovarian	B-T038
cancer	I-T038
that	O
may	O
benefit	O
from	O
specific	O
treatments	B-T058
.	O

As	O
an	O
alternative	O
to	O
current	O
screening	B-T058
and	O
imaging	B-T074
tools	I-T074
,	O
we	O
utilized	O
wavelength	O
dependent	O
collagen	B-T103
-	O
specific	O
Second	B-T058
Harmonic	I-T058
Generation	I-T058
(	I-T058
SHG	I-T058
)	I-T058
imaging	I-T058
microscopy	I-T058
and	O
optical	B-T058
scattering	I-T058
measurements	I-T058
to	O
probe	O
the	O
structural	B-T103
differences	O
in	O
the	O
extracellular	B-T017
matrix	I-T017
(	O
ECM	B-T017
)	O
of	O
normal	O
stroma	B-T017
,	O
benign	B-T038
tumors	I-T038
,	O
endometrioid	B-T038
tumors	I-T038
,	O
and	O
low	B-T038
and	O
high	B-T038
-	I-T038
grade	I-T038
serous	I-T038
tumors	I-T038
.	O

The	O
SHG	B-T058
signatures	O
of	O
the	O
emission	O
directionality	O
and	O
conversion	O
efficiency	O
as	O
well	O
as	O
the	O
optical	O
scattering	O
are	O
related	O
to	O
the	O
organization	O
of	O
collagen	B-T103
on	O
the	O
sub	O
-	O
micron	O
size	B-T170
scale	I-T170
and	O
encode	O
structural	B-T103
information	O
.	O

The	O
wavelength	O
dependence	O
of	O
these	O
readouts	O
adds	O
additional	O
characterization	O
of	O
the	O
size	B-T082
and	O
distribution	O
of	O
collagen	B-T017
fibrils	I-T017
/	O
fibers	B-T017
relative	O
to	O
the	O
interrogating	O
wavelengths	O
.	O

We	O
found	O
a	O
strong	O
wavelength	O
dependence	O
of	O
these	O
metrics	B-T017
that	O
are	O
related	O
to	O
significant	O
structural	B-T103
differences	O
in	O
the	O
collagen	B-T103
organization	O
and	O
are	O
consistent	O
with	O
the	O
dualistic	O
classification	B-T170
of	O
type	B-T038
I	I-T038
and	I-T038
II	I-T038
serous	I-T038
tumors	I-T038
.	O

Moreover	O
,	O
type	B-T038
I	I-T038
endometrioid	I-T038
tumors	I-T038
have	O
strongly	O
differing	O
ECM	B-T017
architecture	O
than	O
the	O
serous	B-T038
malignancies	I-T038
.	O

The	O
SHG	B-T058
metrics	B-T017
and	O
optical	B-T058
scattering	I-T058
measurements	I-T058
were	O
used	O
to	O
form	O
a	O
linear	B-T170
discriminant	I-T170
model	I-T170
to	O
classify	O
the	O
tissues	B-T017
,	O
and	O
we	O
obtained	O
high	O
accuracy	O
(	O
>	O
90	O
%	O
)	O
between	O
high	B-T038
-	I-T038
grade	I-T038
serous	I-T038
tumors	I-T038
from	O
the	O
other	O
tissue	B-T017
types	I-T017
.	O

High	B-T038
-	I-T038
grade	I-T038
serous	I-T038
tumors	I-T038
account	O
for	O
~	O
70	O
%	O
of	O
ovarian	B-T038
cancers	I-T038
,	O
and	O
this	O
delineation	O
has	O
potential	O
clinical	O
applications	O
in	O
terms	O
of	O
supplementing	O
histological	O
analysis	O
,	O
understanding	O
the	O
etiology	O
,	O
as	O
well	O
as	O
development	O
of	O
an	O
in	O
vivo	O
screening	B-T058
tool	I-T058
.	O

SHG	B-T058
and	O
optical	B-T058
scattering	I-T058
measurements	I-T058
provide	O
sub	O
-	O
resolution	O
information	O
and	O
when	O
combined	O
provide	O
superior	B-T058
diagnostic	I-T058
power	I-T058
over	O
clinical	B-T058
imaging	I-T058
modalities	O
.	O

Additionally	O
the	O
measurements	O
are	O
able	O
to	O
delineate	O
the	O
different	O
subtypes	O
of	O
ovarian	B-T038
cancer	I-T038
and	O
may	O
potentially	O
assist	O
in	O
treatment	B-T058
protocols	I-T058
.	O

Understanding	O
the	O
altered	O
collagen	B-T103
assembly	O
can	O
supplement	O
histological	O
analysis	O
and	O
provide	O
new	O
insight	O
into	O
the	O
etiology	O
.	O

These	O
methods	O
could	O
become	O
an	O
in	O
vivo	O
screening	B-T058
tool	I-T058
for	O
earlier	O
detection	O
which	O
is	O
important	O
since	O
ovarian	B-T038
malignancies	I-T038
can	O
metastasize	B-T038
while	O
undetectable	O
by	O
current	O
clinical	B-T058
imaging	I-T058
resolution	O
.	O

The	O
Role	O
of	O
Metal	B-T074
-	I-T074
on	I-T074
-	I-T074
Metal	I-T074
Bearings	I-T074
in	O
Total	B-T058
Hip	I-T058
Arthroplasty	I-T058
and	O
Hip	B-T058
Resurfacing	I-T058
:	O
Review	B-T170
Article	I-T170

The	O
current	O
role	O
of	O
metal	B-T074
-	I-T074
on	I-T074
-	I-T074
metal	I-T074
(	I-T074
MoM	I-T074
)	I-T074
bearings	I-T074
in	O
hip	B-T058
arthroplasty	I-T058
remains	O
controversial	O
.	O

The	O
low	O
wear	O
offered	O
by	O
MoM	B-T074
bearings	I-T074
compared	O
to	O
metal	B-T074
-	I-T074
on	I-T074
-	I-T074
polyethylene	I-T074
and	O
the	O
possibility	O
of	O
a	O
lower	O
risk	O
of	O
dislocation	B-T037
with	O
larger	O
head	O
sizes	O
,	O
encouraged	O
a	O
trend	O
towards	O
the	O
re	B-T058
-	I-T058
introduction	I-T058
of	O
the	O
MoM	B-T074
bearing	I-T074
couple	O
.	O

However	O
,	O
recent	O
evidence	O
has	O
shown	O
that	O
not	O
all	O
designs	O
of	O
the	O
MoM	B-T074
bearing	I-T074
have	O
been	O
successful	O
.	O

The	O
purpose	O
of	O
this	O
paper	O
is	O
to	O
provide	O
an	O
update	O
on	O
the	O
use	O
of	O
MoM	B-T074
bearings	I-T074
and	O
address	O
the	O
following	O
issues	O
:	O
(	O
1	O
)	O
the	O
reintroduction	B-T058
of	O
metal	B-T074
-	I-T074
on	I-T074
-	I-T074
metal	I-T074
bearings	I-T074
in	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
,	O
(	O
2	O
)	O
the	O
failure	O
of	O
metal	B-T074
-	I-T074
on	I-T074
-	I-T074
metal	I-T074
bearings	I-T074
in	O
stemmed	B-T058
total	I-T058
hip	I-T058
arthroplasty	I-T058
,	O
(	O
3	O
)	O
the	O
role	O
of	O
metal	B-T058
-	I-T058
on	I-T058
-	I-T058
metal	I-T058
hip	I-T058
resurfacing	I-T058
in	O
modern	O
orthopaedics	B-T091
and	O
(	O
4	O
)	O
metal	B-T058
-	I-T058
on	I-T058
-	I-T058
metal	I-T058
hip	I-T058
resurfacing	I-T058
versus	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
.	O

A	O
literature	B-T170
search	O
strategy	O
was	O
conducted	O
using	O
various	O
search	O
terms	O
in	O
MEDLINE	B-T170
and	O
Embase	B-T170
.	O

The	O
highest	O
quality	B-T170
articles	I-T170
that	O
met	O
the	O
inclusion	O
criteria	O
and	O
best	O
answered	O
the	O
topics	O
of	O
focus	O
of	O
this	O
review	B-T170
were	O
selected	O
.	O

Key	O
search	O
terms	O
included	O
'	O
metal	B-T074
-	I-T074
on	I-T074
-	I-T074
metal	I-T074
'	O
,	O
'	O
total	B-T058
hip	I-T058
arthroplasty	I-T058
'	O
and	O
'	O
hip	B-T058
resurfacing	I-T058
'	O
.	O

The	O
initial	O
search	O
retrieved	O
1240	O
articles	B-T170
.	O

Twenty	O
-	O
two	O
articles	B-T170
were	O
selected	O
and	O
used	O
in	O
the	O
review	B-T170
.	O

Metal	B-T074
-	I-T074
on	I-T074
-	I-T074
metal	I-T074
hip	I-T074
resurfacing	I-T074
is	O
still	O
a	O
suitable	O
treatment	B-T058
option	O
in	O
specific	O
patient	O
populations	O
with	O
the	O
appropriate	O
implant	B-T058
design	I-T058
and	O
surgical	O
skill	O
,	O
while	O
stemmed	O
metal	B-T074
-	I-T074
on	I-T074
-	I-T074
metal	I-T074
total	I-T074
hip	I-T074
arthroplasty	I-T074
should	O
be	O
avoided	O
in	O
all	O
patient	O
populations	O
.	O

Continued	O
follow	B-T058
-	I-T058
up	I-T058
of	O
patients	O
undergoing	O
metal	B-T058
-	I-T058
on	I-T058
-	I-T058
metal	I-T058
hip	I-T058
resurfacing	I-T058
is	O
critical	O
in	O
order	O
to	O
further	O
understand	O
the	O
long	O
-	O
term	O
outcomes	O
of	O
these	O
patients	O
and	O
why	O
certain	O
complications	B-T038
tend	O
to	O
occur	O
with	O
this	O
procedure	O
.	O

Morphogenetic	B-T038
Alterations	O
of	O
Alternaria	B-T204
alternata	I-T204
Exposed	O
to	O
Dicarboximide	B-T103
Fungicide	I-T103
,	O
Iprodione	B-T103

Fungicide	O
-	O
resistant	O
Alternaria	B-T204
alternata	I-T204
impede	O
the	O
practical	O
control	O
of	O
the	O
Alternaria	B-T038
diseases	I-T038
in	O
crop	B-T204
fields	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
cytological	O
fungicide	B-T103
resistance	B-T038
mechanisms	O
of	O
A	B-T204
.	I-T204

alternata	I-T204
against	O
dicarboximide	B-T103
fungicide	I-T103
iprodione	B-T103
.	O

A	B-T204
.	I-T204

alternata	I-T204
isolated	O
from	O
cactus	B-T204
brown	O
spot	O
was	O
cultured	B-T058
on	O
potato	O
-	O
dextrose	O
agar	O
(	O
PDA	O
)	O
with	O
or	O
without	O
iprodione	B-T103
,	O
and	O
the	O
fungal	B-T058
cultures	I-T058
with	O
different	O
growth	B-T038
characteristics	O
from	O
no	O
,	O
initial	O
and	O
full	O
growth	B-T038
were	O
observed	O
by	O
light	B-T058
and	O
electron	B-T058
microscopy	I-T058
.	O

Mycelia	B-T204
began	O
to	O
grow	B-T038
from	O
one	O
day	O
after	O
incubation	O
(	O
DAI	O
)	O
and	O
continued	O
to	O
be	O
in	O
full	O
growth	B-T038
(	O
control	B-T038
-	I-T038
growth	I-T038
,	O
Con	B-T038
-	I-T038
G	I-T038
)	O
on	O
PDA	O
without	O
fungicide	B-T103
,	O
while	O
on	O
PDA	O
with	O
iprodione	B-T103
,	O
no	O
fungal	O
growth	O
(	O
iprodione	O
-	O
no	O
growth	O
,	O
Ipr	O
-	O
N	O
)	O
occurred	O
for	O
the	O
first	O
3	O
DAI	O
,	O
but	O
once	O
the	O
initial	O
growth	B-T038
(	O
iprodione	B-T038
-	I-T038
initial	I-T038
growth	I-T038
,	O
Ipr	B-T038
-	I-T038
I	I-T038
)	O
began	O
at	O
4	O
-	O
5	O
DAI	O
,	O
the	O
colonies	B-T017
grew	O
and	O
expanded	B-T082
continuously	O
to	O
be	O
in	O
full	O
growth	B-T038
(	O
iprodione	B-T038
-	I-T038
growth	I-T038
,	O
Ipr	B-T038
-	I-T038
G	I-T038
)	O
,	O
suggesting	O
Ipr	B-T038
-	I-T038
I	I-T038
may	O
be	O
a	O
turning	O
moment	O
of	O
the	O
morphogenetic	B-T038
changes	O
resisting	B-T038
fungicidal	B-T038
toxicity	O
.	O

Con	B-T038
-	I-T038
G	I-T038
formed	O
multicellular	B-T204
conidia	I-T204
with	O
cell	O
walls	O
and	O
septa	B-T017
and	O
intact	O
dense	O
cytoplasm	B-T017
.	O

In	O
Ipr	O
-	O
N	O
,	O
fungal	B-T204
sporulation	B-T038
was	O
inhibited	O
by	O
forming	O
mostly	O
undeveloped	B-T033
unicellular	B-T204
conidia	I-T204
with	O
degraded	B-T033
and	O
necrotic	B-T038
cytoplasm	B-T017
.	O

However	O
,	O
in	O
Ipr	B-T038
-	I-T038
I	I-T038
,	O
conspicuous	B-T038
cellular	I-T038
changes	I-T038
occurred	O
during	O
sporulation	B-T038
by	O
forming	O
multicellular	B-T204
conidia	I-T204
with	O
double	B-T033
layered	I-T033
(	O
thickened	B-T033
)	O
cell	O
walls	O
and	O
accumulation	B-T033
of	O
proliferated	O
lipid	B-T017
bodies	I-T017
in	O
the	O
conidial	B-T204
cytoplasm	B-T017
,	O
which	O
may	O
inhibit	O
the	O
penetration	O
of	O
the	O
fungicide	B-T103
into	O
conidial	B-T204
cells	B-T017
,	O
reducing	O
fungicide	B-T103
-	O
associated	O
toxicity	O
,	O
and	O
may	O
be	O
utilized	O
as	O
energy	O
and	O
nutritional	O
sources	B-T033
,	O
respectively	O
,	O
for	O
the	O
further	O
fungal	B-T204
growth	B-T038
to	O
form	O
mature	O
colonies	B-T017
as	O
in	O
Ipr	B-T038
-	I-T038
G	I-T038
that	O
formed	O
multicellular	B-T204
conidia	I-T204
with	O
cell	O
walls	O
and	O
intact	O
cytoplasm	B-T017
with	O
lipid	B-T017
bodies	I-T017
as	O
in	O
Con	B-T038
-	I-T038
G	I-T038
.	O

Limits	O
of	O
the	O
possible	O
:	O
diagnostic	O
image	O
quality	O
in	O
coronary	B-T058
angiography	I-T058
with	O
third	B-T058
-	I-T058
generation	I-T058
dual	I-T058
-	I-T058
source	I-T058
CT	I-T058

The	O
usage	O
of	O
coronary	B-T058
CT	I-T058
angiography	I-T058
(	O
CTA	B-T058
)	O
is	O
appropriate	O
in	O
patients	O
with	O
acute	B-T033
or	O
chronic	B-T033
chest	I-T033
pain	I-T033
;	O
however	O
the	O
diagnostic	O
accuracy	O
may	O
be	O
challenged	O
with	O
increased	O
Agatston	O
score	O
(	O
AS	O
)	O
,	O
increased	O
heart	B-T201
rate	I-T201
,	O
arrhythmia	B-T033
and	O
severe	B-T038
obesity	I-T038
.	O

Thus	O
,	O
we	O
aim	O
to	O
determine	O
the	O
potential	O
of	O
the	O
recently	O
introduced	O
third	B-T058
-	I-T058
generation	I-T058
dual	I-T058
-	I-T058
source	I-T058
CT	I-T058
(	O
DSCT	B-T058
)	O
for	O
CTA	B-T058
in	O
a	O
'	O
real	O
-	O
life	O
'	O
clinical	O
setting	O
.	O

Two	O
hundred	O
and	O
sixty	O
-	O
eight	O
consecutive	O
patients	O
(	O
age	O
:	O
67	O
±	O
10	O
years	O
;	O
BMI	B-T201
:	O
27	O
±	O
5	O
kg	O
/	O
m²	O
;	O
61	O
%	O
male	B-T098
)	O
undergoing	O
clinically	O
indicated	O
CTA	B-T058
with	O
DSCT	B-T058
were	O
included	O
in	O
the	O
retrospective	B-T062
single	I-T062
-	I-T062
center	I-T062
analysis	I-T062
.	O

A	O
contrast	B-T170
-	I-T170
enhanced	I-T170
volume	I-T170
dataset	I-T170
was	O
acquired	O
in	O
sequential	B-T058
(	O
SSM	B-T058
)	O
(	O
n	O
=	O
151	O
)	O
or	O
helical	B-T058
scan	I-T058
mode	I-T058
(	O
HSM	B-T058
)	O
(	O
n	O
=	O
117	O
)	O
.	O

Coronary	B-T017
segments	I-T017
were	O
classified	O
in	O
diagnostic	O
or	O
non	O
-	O
diagnostic	O
image	O
quality	O
.	O

A	O
subset	O
underwent	O
invasive	B-T058
angiography	I-T058
to	O
determine	O
the	O
diagnostic	O
accuracy	O
of	O
CTA	B-T058
.	O

SSM	B-T058
(	O
96	O
.	O
8	O
±	O
6	O
%	O
)	O
and	O
HSM	B-T058
(	O
97	O
.	O
5	O
±	O
8	O
%	O
)	O
provided	O
no	O
significant	O
differences	O
in	O
the	O
overall	O
diagnostic	O
image	O
quality	O
.	O

However	O
,	O
AS	O
had	O
significant	O
influence	O
on	O
diagnostic	O
image	O
quality	O
exclusively	O
in	O
SSM	B-T058
(	O
B	O
=	O
0	O
.	O
003	O
;	O
p	O
=	O
0	O
.	O
0001	O
)	O
,	O
but	O
not	O
in	O
HSM	B-T058
.	O

Diagnostic	O
image	O
quality	O
significantly	O
decreased	O
in	O
SSM	B-T058
in	O
patients	O
with	O
AS	O
≥2	O
,	O
000	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

SSM	B-T058
(	O
sensitivity	O
:	O
93	O
.	O
9	O
%	O
;	O
specificity	O
:	O
96	O
.	O
7	O
%	O
;	O
PPV	O
:	O
88	O
.	O
6	O
%	O
;	O
NPV	O
:	O
98	O
.	O
3	O
%	O
)	O
and	O
HSM	B-T058
(	O
sensitivity	O
:	O
97	O
.	O
4	O
%	O
;	O
specificity	O
:	O
94	O
.	O
3	O
%	O
;	O
PPV	O
:	O
86	O
.	O
0	O
%	O
;	O
NPV	O
:	O
99	O
.	O
0	O
%	O
)	O
provided	O
comparable	O
diagnostic	O
accuracy	O
(	O
p	O
=	O
n	O
.	O
s	O
.	O
)	O
.	O

SSM	B-T058
yielded	O
significantly	O
lower	O
radiation	O
doses	O
as	O
compared	O
to	O
HSM	B-T058
(	O
2	O
.	O
1	O
±	O
2	O
.	O
0	O
vs	O
.	O

5	O
.	O
1	O
±	O
3	O
.	O
3	O
mSv	O
;	O
p	O
=	O
0	O
.	O
0001	O
)	O
in	O
age	B-T098
and	O
BMI	B-T201
-	O
matched	O
cohorts	B-T098
.	O

SSM	B-T058
in	O
third	B-T058
-	I-T058
generation	I-T058
DSCT	I-T058
enables	O
significant	O
dose	O
savings	O
and	O
provides	O
robust	O
diagnostic	O
image	O
quality	O
in	O
patients	O
with	O
AS	O
≤2000	O
independent	O
of	O
heart	B-T201
rate	I-T201
,	O
heart	B-T038
rhythm	I-T038
or	O
obesity	B-T038
.	O

Antagonistic	B-T038
Self	B-T038
-	I-T038
Organizing	I-T038
Patterning	I-T038
Systems	O
Control	O
Maintenance	O
and	O
Regeneration	B-T038
of	O
the	O
Anteroposterior	B-T082
Axis	B-T082
in	O
Planarians	B-T204

Planarian	B-T204
flatworms	B-T204
maintain	O
their	O
body	B-T017
plan	O
in	O
the	O
face	O
of	O
constant	O
internal	O
turnover	O
and	O
can	O
regenerate	O
from	O
arbitrary	O
tissue	B-T017
fragments	B-T031
.	O

Both	O
phenomena	O
require	O
self	O
-	O
maintaining	O
and	O
self	B-T038
-	I-T038
organizing	I-T038
patterning	I-T038
mechanisms	O
,	O
the	O
molecular	O
mechanisms	O
of	O
which	O
remain	O
poorly	O
understood	O
.	O

We	O
show	O
that	O
a	O
morphogenic	B-T038
gradient	O
of	O
canonical	B-T038
Wnt	I-T038
signaling	I-T038
patterns	O
gene	B-T038
expression	I-T038
along	O
the	O
planarian	B-T204
anteroposterior	B-T082
(	O
A	B-T082
/	I-T082
P	I-T082
)	O
axis	B-T082
.	O

Our	O
results	O
demonstrate	O
that	O
gradient	O
formation	O
likely	O
occurs	O
autonomously	O
in	O
the	O
tail	B-T017
and	O
that	O
an	O
autoregulatory	B-T038
module	O
of	O
Wnt	B-T103
-	O
mediated	O
Wnt	B-T017
expression	B-T038
both	O
shapes	O
the	O
gradient	O
at	O
steady	O
state	O
and	O
governs	O
its	O
re	O
-	O
establishment	O
during	O
regeneration	B-T038
.	O

Functional	O
antagonism	B-T038
between	O
the	O
tail	B-T017
Wnt	B-T103
gradient	O
and	O
an	O
unknown	O
head	B-T082
patterning	B-T038
system	O
further	O
determines	O
the	O
spatial	B-T082
proportions	O
of	O
the	O
planarian	B-T204
A	B-T082
/	I-T082
P	I-T082
axis	B-T082
and	O
mediates	O
mutually	O
exclusive	O
molecular	B-T038
fate	I-T038
choices	O
during	O
regeneration	B-T038
.	O

Overall	O
,	O
our	O
results	O
suggest	O
that	O
the	O
planarian	B-T204
A	B-T082
/	I-T082
P	I-T082
axis	B-T082
is	O
patterned	O
by	O
self	B-T038
-	I-T038
organizing	I-T038
patterning	I-T038
systems	O
deployed	O
from	O
either	O
end	O
that	O
are	O
functionally	O
coupled	O
by	O
mutual	O
antagonism	B-T038
.	O

Characterization	O
and	O
Ectopic	B-T038
Expression	I-T038
of	O
CoWRI1	B-T017
,	O
an	O
AP2	B-T017
/	I-T017
EREBP	I-T017
Domain	O
-	O
Containing	O
Transcription	B-T103
Factor	I-T103
from	O
Coconut	B-T204
(	O
Cocos	B-T204
nucifera	I-T204
L	I-T204
.	O
)	O
Endosperm	B-T204
,	O
Changes	O
the	O
Seeds	B-T204
Oil	B-T103
Content	O
in	O
Transgenic	B-T204
Arabidopsis	B-T204
thaliana	I-T204
and	O
Rice	B-T204
(	O
Oryza	B-T204
sativa	I-T204
L	I-T204
.	O
)	O

Coconut	B-T204
(	O
Cocos	B-T204
nucifera	I-T204
L	I-T204
.	I-T204
)	O
is	O
a	O
key	O
tropical	O
crop	B-T204
and	O
a	O
member	O
of	O
the	O
monocotyledonous	O
family	O
Arecaceae	B-T204
(	O
Palmaceae	B-T204
)	O
.	O

Few	O
genes	B-T017
and	O
related	O
metabolic	B-T038
processes	I-T038
involved	O
in	O
coconut	B-T204
endosperm	B-T204
development	O
have	O
been	O
investigated	O
.	O

In	O
this	O
study	B-T062
,	O
a	O
new	O
member	O
of	O
the	O
WRI1	B-T017
gene	B-T017
family	I-T017
was	O
isolated	O
from	O
coconut	B-T204
endosperm	B-T204
and	O
was	O
named	O
CoWRI1	B-T017
.	O

Its	O
transcriptional	B-T038
activities	O
and	O
interactions	O
with	O
the	O
acetyl	B-T103
-	I-T103
CoA	I-T103
carboxylase	I-T103
(	O
BCCP2	B-T103
)	O
promoter	B-T103
of	O
CoWRI1	B-T017
were	O
confirmed	O
by	O
the	O
yeast	B-T062
two	I-T062
-	I-T062
hybrid	I-T062
and	O
yeast	B-T062
one	I-T062
-	I-T062
hybrid	I-T062
approaches	O
,	O
respectively	O
.	O

Functional	O
characterization	O
was	O
carried	O
out	O
through	O
seed	B-T204
-	O
specific	O
expression	B-T038
in	O
Arabidopsis	B-T204
and	O
endosperm	B-T204
-	O
specific	O
expression	B-T038
in	O
rice	B-T204
.	O

In	O
transgenic	B-T204
Arabidopsis	B-T204
,	O
high	O
over	B-T038
-	I-T038
expressions	I-T038
of	O
CoWRI1	B-T017
in	O
seven	O
independent	O
T2	B-T204
lines	B-T204
were	O
detected	O
by	O
quantitative	B-T062
real	I-T062
-	I-T062
time	I-T062
PCR	I-T062
.	O

The	O
relative	O
mRNA	B-T103
accumulation	O
of	O
genes	B-T017
encoding	O
enzymes	B-T103
involved	O
in	O
either	O
fatty	B-T038
acid	I-T038
biosynthesis	I-T038
or	O
triacylglycerols	B-T103
assembly	O
(	O
BCCP2	B-T017
,	O
KASI	B-T017
,	O
MAT	B-T017
,	O
ENR	B-T017
,	O
FATA	B-T017
,	O
and	O
GPDH	B-T017
)	O
were	O
also	O
assayed	B-T058
in	O
mature	O
seeds	B-T204
.	O

Furthermore	O
,	O
lipid	B-T103
and	O
fatty	B-T103
acids	I-T103
C16	B-T103
:	I-T103
0	I-T103
and	O
C18	B-T103
:	I-T103
0	I-T103
significantly	O
increased	O
.	O

In	O
two	O
homozygous	O
T2	B-T204
transgenic	B-T204
rice	B-T204
lines	I-T204
(	O
G5	B-T204
and	O
G2	B-T204
)	O
,	O
different	O
CoWRI1	B-T017
expression	B-T038
levels	O
were	O
detected	O
,	O
but	O
no	O
CoWRI1	B-T017
transcripts	B-T103
were	O
detected	O
in	O
the	O
wild	B-T017
type	I-T017
.	O

Analyses	B-T062
of	O
the	O
seed	B-T204
oil	B-T103
content	O
,	O
starch	B-T103
content	O
,	O
and	O
total	O
protein	B-T103
content	O
indicated	O
that	O
the	O
two	O
T2	B-T204
transgenic	B-T204
lines	I-T204
showed	O
a	O
significant	O
increase	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
seed	B-T204
oil	B-T103
content	O
.	O

The	O
transgenic	B-T204
lines	I-T204
also	O
showed	O
a	O
significant	O
increase	O
in	O
starch	B-T103
content	O
,	O
whereas	O
total	O
protein	B-T103
content	O
decreased	O
significantly	O
.	O

Further	O
analysis	B-T062
of	O
the	O
fatty	B-T103
acid	I-T103
composition	O
revealed	O
that	O
palmitic	B-T103
acid	I-T103
(	O
C16	B-T103
:	I-T103
0	I-T103
)	O
and	O
linolenic	B-T103
acid	I-T103
(	O
C18	B-T103
:	I-T103
3	I-T103
)	O
increased	O
significantly	O
in	O
the	O
seeds	B-T204
of	O
the	O
transgenic	B-T204
rice	B-T204
lines	I-T204
,	O
but	O
oleic	B-T103
acid	I-T103
(	O
C18	B-T103
:	I-T103
1	I-T103
)	O
levels	O
significantly	O
declined	O
.	O

Tooth	B-T033
Discoloration	I-T033
Resulting	O
from	O
a	O
Nano	O
Zinc	B-T103
Oxide	I-T103
-	I-T103
Eugenol	I-T103
Sealer	B-T103

A	O
desirable	O
quality	O
of	O
any	O
endodontic	B-T103
sealer	I-T103
is	O
its	O
ability	O
to	O
be	O
tooth	B-T033
color	I-T033
friendly	O
.	O

Therefore	O
the	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
evaluate	O
the	O
tooth	B-T033
discoloration	I-T033
potential	O
of	O
a	O
nano	O
zinc	B-T103
oxide	I-T103
-	I-T103
eugenol	I-T103
(	O
NZOE	B-T103
)	O
sealer	B-T103
.	O

In	O
order	O
to	O
evaluate	O
tooth	B-T033
discoloration	I-T033
,	O
the	O
pulp	B-T082
chamber	I-T082
of	O
60	O
human	B-T204
maxillary	B-T017
central	I-T017
and	O
lateral	B-T017
incisors	I-T017
were	O
filled	O
with	O
one	O
of	O
the	O
sealers	B-T103
,	O
naming	O
AH	B-T103
-	I-T103
26	I-T103
(	O
resin	B-T103
-	I-T103
based	I-T103
sealer	I-T103
)	O
,	O
Pulpdent	B-T103
sealer	B-T103
(	O
ZOE	B-T103
-	O
based	O
)	O
and	O
a	O
NZOE	B-T103
experimental	O
sealer	B-T103
.	O

Color	O
measurements	O
was	O
assessed	O
at	O
the	O
baseline	O
(	O
before	O
placement	O
of	O
sealers	B-T103
)	O
(	O
T0	O
)	O
,	O
24	O
h	O
(	O
T1	O
)	O
and	O
72	O
h	O
(	O
T2	O
)	O
h	O
,	O
1	O
-	O
week	O
(	O
T3	O
)	O
,	O
and	O
1	O
-	O
month	O
(	O
T4	O
)	O
after	O
the	O
placement	O
of	O
sealers	B-T103
using	O
the	O
Easy	B-T074
Shade	I-T074
spectrophotometer	I-T074
.	O

Data	O
were	O
analyzed	B-T062
in	O
SPSS	B-T170
software	I-T170
using	O
one	O
-	O
way	O
ANOVA	O
,	O
and	O
repeated	O
measured	O
ANOVA	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
when	O
the	O
paired	B-T170
comparison	I-T170
test	I-T170
was	O
performed	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
tested	O
NZOE	B-T103
sealer	B-T103
had	O
similar	O
tooth	B-T033
discoloration	I-T033
potential	O
in	O
comparison	O
with	O
AH	B-T103
-	I-T103
26	I-T103
and	O
ZOE	B-T103
sealer	B-T103
.	O

On	O
the	O
identity	O
of	O
the	O
Palearctic	O
species	B-T170
of	O
the	O
wolf	B-T204
spider	I-T204
genus	B-T170
<	O
i	O
>	O
Trebacosa	B-T204
<	O
/	O
i	O
>	O
(	O
Araneae	B-T204
:	O
Lycosidae	B-T204
)	O

In	O
this	O
paper	B-T170
we	O
propose	O
Trebacosa	B-T204
brunhesi	I-T204
Villepoux	O
,	O
2007	O
as	O
a	O
junior	O
synonym	O
of	O
Trebacosa	B-T204
europaea	I-T204
Szinetár	O
&	O
Kan	O
-	O
csal	O
,	O
2007	O
based	O
on	O
the	O
examination	O
of	O
specimens	O
from	O
all	O
the	O
localities	B-T082
from	O
where	O
those	O
species	B-T170
are	O
known	O
.	O

Illustration	O
of	O
the	O
type	O
species	B-T170
of	O
the	O
genus	B-T170
,	O
Trebacosa	B-T204
marxi	I-T204
(	O
Stone	O
,	O
1890	O
)	O
and	O
specimens	O
from	O
all	O
known	O
localities	B-T082
of	O
T	B-T204
.	I-T204

europaea	I-T204
are	O
given	O
to	O
show	O
both	O
the	O
inter	O
-	O
and	O
the	O
intraspecific	O
differences	O
of	O
the	O
genus	B-T170
.	O

Scanning	B-T058
electron	I-T058
micrographs	I-T058
were	O
used	O
to	O
illustrate	O
the	O
detailed	O
structure	B-T082
of	O
the	O
female	B-T017
'	I-T017
s	I-T017
genitalia	I-T017
.	O

A	O
numerical	O
study	B-T062
on	O
the	O
application	O
of	O
the	O
functionally	O
graded	O
materials	O
in	O
the	O
stent	B-T074
design	O

Undesirable	O
deformation	O
of	O
the	O
stent	B-T074
can	O
induce	O
a	O
significant	B-T037
amount	O
of	O
injure	B-T037
not	O
only	O
to	O
the	O
blood	B-T017
vessel	I-T017
but	O
also	O
to	O
the	O
plaque	B-T033
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
reduce	B-T033
/	I-T033
minimize	I-T033
these	O
undesirable	O
deformations	O
by	O
the	O
application	O
of	O
Functionally	O
Graded	O
Materials	O
(	O
FGM	O
)	O
.	O

To	O
do	O
this	O
,	O
Finite	O
Element	O
(	O
FE	O
)	O
method	O
was	O
employed	B-T033
to	O
simulate	B-T062
the	O
expansion	O
of	O
a	O
stent	B-T074
and	O
the	O
corresponding	O
displacement	O
of	O
the	O
stenosis	B-T038
plaque	B-T033
.	O

Three	O
hyperelastic	O
plaque	B-T033
types	O
as	O
well	O
as	O
five	O
elastoplastic	B-T074
stents	I-T074
were	O
simulated	O
.	O

Dogboning	O
,	O
foreshortening	B-T033
,	O
maximum	O
stress	B-T033
in	O
the	O
plaque	B-T033
,	O
and	O
the	O
pressure	O
which	O
is	O
needed	O
to	O
fully	O
expand	B-T082
the	O
stent	B-T074
for	O
different	O
stent	B-T074
materials	O
,	O
were	O
acquired	O
.	O

While	O
all	O
FGMs	O
had	O
lower	O
dogboning	O
in	O
comparison	O
to	O
the	O
stents	B-T074
made	O
of	O
the	O
uniform	O
materials	O
,	O
the	O
stent	B-T074
with	O
the	O
lowest	O
heterogeneous	B-T170
index	I-T170
displayed	O
the	O
lowest	O
amount	O
of	O
dogboning	O
.	O

Steel	B-T103
stent	B-T074
showed	O
the	O
lowest	O
foreshortening	B-T033
and	O
fully	O
expansion	O
pressure	O
but	O
the	O
difference	O
was	O
much	O
lower	O
than	O
that	O
the	O
one	O
for	O
dogboning	O
.	O

Therefore	O
,	O
the	O
FGM	O
with	O
the	O
heterogeneous	B-T170
index	I-T170
of	O
0	O
.	O
5	O
is	O
expected	O
to	O
exhibit	O
the	O
most	O
suitable	O
results	O
.	O

In	O
addition	O
,	O
the	O
results	O
revealed	O
that	O
the	O
material	O
parameters	O
has	O
crucial	O
effects	O
on	O
the	O
deformation	O
of	O
the	O
stent	B-T074
and	O
,	O
as	O
a	O
result	O
,	O
as	O
a	O
design	O
point	O
of	O
view	O
the	O
FGM	O
parameters	O
can	O
be	O
tailored	O
to	O
achieve	O
the	O
goal	O
of	O
the	O
biomechanical	O
optimization	O
.	O

Women	B-T098
'	I-T098
s	I-T098
perspectives	O
on	O
human	B-T005
papillomavirus	I-T005
self	B-T058
-	I-T058
sampling	I-T058
in	O
the	O
context	O
of	O
the	O
UK	B-T082
cervical	B-T017
screening	O
programme	O

Testing	O
for	O
human	B-T005
papillomavirus	I-T005
(	O
HPV	B-T005
)	O
is	O
being	O
incorporated	O
into	O
the	O
cervical	B-T017
screening	O
programme	O
,	O
with	O
the	O
probable	O
future	O
introduction	O
of	O
HPV	B-T005
as	O
a	O
primary	O
test	O
and	O
a	O
possibility	O
of	O
HPV	B-T005
self	B-T058
-	I-T058
sampling	I-T058
.	O

In	O
anticipation	O
of	O
this	O
development	O
,	O
we	O
sought	O
to	O
inform	O
future	O
policy	B-T170
and	O
practice	B-T038
by	O
identifying	O
potential	O
barriers	O
to	O
HPV	B-T005
self	B-T058
-	I-T058
sampling	I-T058
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
survey	I-T062
of	O
194	O
women	B-T098
aged	O
20	O
-	O
64	O
years	O
was	O
conducted	O
.	O

Logistic	O
regression	O
analysis	O
was	O
used	O
to	O
identify	O
determinants	O
of	O
self	B-T058
-	I-T058
sampling	I-T058
intentions	O
.	O

A	O
purposive	O
subsample	O
of	O
19	O
women	B-T098
who	O
reported	O
low	O
self	B-T058
-	I-T058
sampling	I-T058
intentions	O
were	O
interviewed	O
.	O

Interviews	O
were	O
framework	O
-	O
analysed	O
.	O

Most	O
survey	B-T170
participants	B-T098
(	O
N	O
=	O
133	O
,	O
69	O
.	O
3	O
%	O
)	O
intended	O
to	O
HPV	B-T005
self	O
-	O
sample	O
.	O

Lower	O
intention	B-T038
was	O
associated	O
with	O
lower	O
self	O
-	O
efficacy	O
(	O
OR	O
=	O
24	O
.	O
96	O
,	O
P≤	O
.	O
001	O
)	O
,	O
lower	O
education	O
(	O
OR	O
=	O
6	O
.	O
06	O
,	O
P≤	O
.	O
05	O
)	O
and	O
lower	O
perceived	B-T038
importance	O
of	O
HPV	B-T005
as	O
a	O
cause	O
of	O
cervical	B-T038
cancer	I-T038
(	O
OR	O
=	O
2	O
.	O
33	O
,	O
P≤	O
.	O
05	O
)	O
.	O

Interviews	O
revealed	O
personal	O
and	O
system	O
-	O
related	O
barriers	O
.	O

Personal	O
barriers	O
included	O
a	O
lack	O
of	O
knowledge	B-T170
about	O
HPV	B-T005
self	B-T058
-	I-T058
sampling	I-T058
,	O
women	B-T098
'	I-T098
s	I-T098
low	B-T033
confidence	I-T033
in	O
their	O
ability	O
to	O
self	O
-	O
sample	O
correctly	O
and	O
low	B-T033
confidence	I-T033
in	O
the	O
subsequent	O
results	O
.	O

System	O
-	O
related	O
factors	O
included	O
a	O
lack	B-T033
of	I-T033
confidence	I-T033
in	O
the	O
rationale	O
for	O
modifying	O
the	O
current	O
cervical	B-T017
screening	O
programme	O
,	O
and	O
concerns	O
about	O
sample	O
contamination	O
and	O
identity	O
theft	O
.	O

Insights	O
gained	O
from	O
this	O
research	B-T062
can	O
be	O
used	O
to	O
guide	O
further	O
enquiry	O
into	O
the	O
possibility	O
of	O
HPV	B-T005
self	B-T058
-	I-T058
sampling	I-T058
and	O
to	O
help	O
inform	O
future	O
policy	B-T170
and	O
practice	B-T038
.	O

Personal	O
and	O
system	B-T033
-	I-T033
related	I-T033
barriers	I-T033
including	O
low	B-T033
confidence	I-T033
in	O
the	O
reasons	O
for	O
changing	O
current	O
cervical	B-T017
screening	B-T058
provision	O
need	O
to	O
be	O
addressed	O
,	O
should	O
HPV	B-T005
self	B-T058
-	I-T058
sampling	I-T058
be	O
incorporated	O
into	O
the	O
cervical	B-T017
screening	O
programme	O
.	O

N	B-T082
-	I-T082
Terminal	I-T082
Hypothesis	O
for	O
Alzheimer	B-T038
'	I-T038
s	I-T038
Disease	I-T038

Although	O
the	O
amyloid	B-T103
(	O
abeta	B-T103
peptide	I-T103
,	O
Aβ	B-T103
)	O
hypothesis	O
is	O
25	O
years	O
old	O
,	O
is	O
the	O
dominant	O
model	B-T170
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
pathogenesis	B-T038
,	O
and	O
guides	O
the	O
development	O
of	O
potential	O
treatments	B-T058
,	O
it	O
is	O
still	O
controversial	O
.	O

One	O
possible	O
reason	O
is	O
a	O
lack	O
of	O
a	O
mechanistic	O
path	O
from	O
the	O
cleavage	O
products	O
of	O
the	O
amyloid	B-T103
precursor	I-T103
protein	I-T103
(	O
APP	B-T103
)	O
such	O
as	O
soluble	O
Aβ	O
monomer	O
and	O
soluble	O
molecular	O
fragments	O
to	O
the	O
deleterious	O
effects	O
on	O
synaptic	B-T038
form	I-T038
and	O
function	O
.	O

From	O
a	O
review	O
of	O
the	O
recent	O
literature	B-T170
and	O
our	O
own	O
published	B-T170
work	I-T170
including	O
aggregation	O
kinetics	O
and	O
structural	B-T082
morphology	O
,	O
Aβ	B-T103
clearance	O
,	O
molecular	O
simulations	B-T062
,	O
long	B-T038
-	I-T038
term	I-T038
potentiation	I-T038
measurements	O
with	O
inhibition	B-T038
binding	I-T038
,	O
and	O
the	O
binding	B-T038
of	O
a	O
commercial	O
monoclonal	B-T103
antibody	I-T103
,	O
aducanumab	B-T103
,	O
we	O
hypothesize	O
that	O
the	O
N	B-T082
-	I-T082
terminal	I-T082
domains	I-T082
of	O
neurotoxic	O
Aβ	B-T103
oligomers	I-T103
are	O
implicated	O
in	O
causing	O
the	O
disease	B-T038
.	O

Generation	O
of	O
High	O
-	O
Quality	O
SWATH	B-T170
(	I-T170
®	I-T170
)	I-T170
Acquisition	O
Data	O
for	O
Label	B-T033
-	I-T033
free	I-T033
Quantitative	O
Proteomics	B-T091
Studies	I-T091
Using	O
TripleTOF	B-T074
(	I-T074
®	I-T074
)	I-T074
Mass	I-T074
Spectrometers	I-T074

Data	O
-	O
independent	O
acquisition	O
is	O
a	O
powerful	O
mass	B-T058
spectrometry	I-T058
technique	I-T058
that	O
enables	O
comprehensive	O
MS	B-T058
and	O
MS	B-T062
/	I-T062
MS	I-T062
analysis	B-T062
of	O
all	O
detectable	B-T201
species	O
,	O
providing	O
an	O
information	O
rich	O
data	O
file	O
that	O
can	O
be	O
mined	O
deeply	O
.	O

Here	O
,	O
we	O
describe	O
how	O
to	O
acquire	O
high	O
-	O
quality	O
SWATH	B-T170
(	I-T170
®	I-T170
)	I-T170
Acquisition	O
data	O
to	O
be	O
used	O
for	O
large	O
quantitative	O
proteomic	B-T091
studies	I-T091
.	O

We	O
specifically	O
focus	O
on	O
using	O
variable	O
sized	B-T082
Q1	B-T170
windows	I-T170
for	O
acquisition	O
of	O
MS	B-T062
/	I-T062
MS	I-T062
data	O
for	O
generating	O
higher	O
specificity	O
quantitative	O
data	O
.	O

A	O
new	O
light	O
on	O
Alkaptonuria	B-T038
:	O
A	O
Fourier	O
-	O
transform	O
infrared	O
microscopy	O
(	O
FTIRM	O
)	O
and	O
low	B-T058
energy	I-T058
X	I-T058
-	I-T058
ray	I-T058
fluorescence	I-T058
microscopy	I-T058
(	O
LEXRF	B-T058
)	O
correlative	B-T062
study	I-T062
on	O
a	O
rare	B-T038
disease	I-T038

Alkaptonuria	B-T038
(	O
AKU	B-T038
)	O
is	O
an	O
ultra	B-T038
-	I-T038
rare	I-T038
disease	I-T038
associated	O
to	O
the	O
lack	O
of	O
an	O
enzyme	B-T103
involved	O
in	O
tyrosine	B-T038
catabolism	I-T038
.	O

This	O
deficiency	O
results	O
in	O
the	O
accumulation	B-T033
of	O
homogentisic	B-T103
acid	I-T103
(	O
HGA	B-T103
)	O
in	O
the	O
form	O
of	O
ochronotic	O
pigment	O
in	O
joint	B-T082
cartilage	B-T017
,	O
leading	O
to	O
a	O
severe	O
arthropathy	B-T038
.	O

Secondary	B-T038
amyloidosis	I-T038
has	O
been	O
also	O
unequivocally	O
assessed	O
as	O
a	O
comorbidity	O
of	O
AKU	B-T038
arthropathy	B-T038
.	O

Composition	O
of	O
ochronotic	O
pigment	O
and	O
how	O
it	O
is	O
structurally	B-T082
related	O
to	O
amyloid	B-T103
is	O
still	O
unknown	O
.	O

We	O
exploited	O
Synchrotron	O
Radiation	O
Infrared	O
and	O
X	B-T058
-	I-T058
Ray	I-T058
Fluorescence	I-T058
microscopies	I-T058
in	O
combination	O
with	O
conventional	O
bio	B-T058
-	I-T058
assays	I-T058
and	O
analytical	B-T062
tools	O
to	O
characterize	O
chemical	O
composition	O
and	O
morphology	O
of	O
AKU	B-T038
cartilage	B-T017
.	O

We	O
evinced	O
that	O
AKU	B-T038
cartilage	B-T017
is	O
characterized	O
by	O
proteoglycans	B-T103
depletion	O
,	O
increased	B-T033
Sodium	I-T033
levels	I-T033
,	O
accumulation	B-T033
of	O
lipids	B-T103
in	O
the	O
peri	B-T082
-	I-T082
lacunar	I-T082
regions	I-T082
and	O
amyloid	B-T103
formation	O
.	O

We	O
also	O
highlighted	O
an	O
increase	O
of	O
aromatic	B-T103
compounds	I-T103
and	O
oxygen	B-T103
-	I-T103
containing	I-T103
species	I-T103
,	O
depletion	O
in	O
overall	O
Magnesium	B-T103
content	O
(	O
although	O
localized	B-T082
in	O
the	O
peri	B-T082
-	I-T082
lacunar	I-T082
region	I-T082
)	O
and	O
the	O
presence	B-T033
of	O
calcium	B-T103
carbonate	I-T103
fragments	O
in	O
proximity	B-T082
of	O
cartilage	B-T082
lacunae	I-T082
.	O

We	O
highlighted	O
common	O
features	O
between	O
AKU	B-T038
and	O
arthropathy	B-T038
,	O
but	O
also	O
specific	O
signatures	O
of	O
the	O
disease	B-T038
,	O
like	O
presence	B-T033
of	O
amyloids	B-T103
and	O
peculiar	B-T033
calcifications	B-T038
.	O

Our	O
analyses	B-T062
provide	O
a	O
unified	O
picture	O
of	O
AKU	B-T038
cartilage	B-T017
,	O
shedding	O
a	O
new	O
light	O
on	O
the	O
disease	B-T038
and	O
opening	O
new	O
perspectives	O
.	O

Ochronotic	O
pigment	O
is	O
a	O
hallmark	O
of	O
AKU	B-T038
and	O
responsible	O
of	O
tissue	B-T038
degeneration	I-T038
.	O

Conventional	O
bio	B-T058
-	I-T058
assays	I-T058
have	O
not	O
yet	O
clarified	O
its	O
composition	O
and	O
its	O
structural	B-T082
relationship	O
with	O
amyloids	B-T103
.	O

The	O
present	O
work	B-T062
proposes	O
new	O
strategies	O
for	O
filling	O
the	O
aforementioned	O
gap	O
that	O
encompass	O
the	O
integration	O
of	O
new	O
analytical	B-T062
approaches	O
with	O
standardized	O
analyses	B-T062
.	O

Unbiased	B-T062
estimates	I-T062
of	O
cerebrospinal	B-T031
fluid	I-T031
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
cutoffs	O
in	O
a	O
large	O
memory	B-T092
clinic	I-T092
population	B-T098

We	O
sought	O
to	O
define	O
a	O
cutoff	O
for	O
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
in	O
cerebrospinal	B-T031
fluid	I-T031
(	O
CSF	B-T031
)	O
,	O
a	O
key	O
marker	B-T201
for	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
,	O
with	O
data	O
-	O
driven	O
Gaussian	B-T170
mixture	I-T170
modeling	I-T170
in	O
a	O
memory	B-T092
clinic	I-T092
population	B-T098
.	O

We	O
performed	O
a	O
combined	O
cross	B-T062
-	I-T062
sectional	I-T062
and	O
prospective	B-T062
cohort	I-T062
study	I-T062
.	O

We	O
selected	O
2462	O
subjects	B-T098
with	O
subjective	B-T038
cognitive	I-T038
decline	I-T038
,	O
mild	B-T038
cognitive	I-T038
impairment	I-T038
,	O
AD	B-T038
-	O
type	O
dementia	B-T038
,	O
and	O
dementia	B-T038
other	O
than	O
AD	B-T038
from	O
the	O
Amsterdam	O
Dementia	B-T038
Cohort	B-T098
.	O

We	O
defined	O
CSF	B-T031
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
cutoffs	O
by	O
data	O
-	O
driven	O
Gaussian	B-T170
mixture	I-T170
modeling	I-T170
in	O
the	O
total	O
population	O
and	O
in	O
subgroups	B-T170
based	O
on	O
clinical	B-T058
diagnosis	I-T058
,	O
age	O
,	O
and	O
apolipoprotein	B-T058
E	I-T058
(	I-T058
APOE	I-T058
)	I-T058
genotype	I-T058
.	O

We	O
investigated	O
whether	O
abnormal	B-T033
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
as	O
defined	O
by	O
the	O
data	O
-	O
driven	O
cutoff	O
could	O
better	O
predict	O
progression	O
to	O
AD	B-T038
-	O
type	O
dementia	B-T038
than	O
abnormal	B-T033
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
defined	O
by	O
a	O
clinical	B-T058
diagnosis	I-T058
-	O
based	O
cutoff	O
using	O
Cox	B-T170
proportional	I-T170
hazards	I-T170
regression	I-T170
.	O

In	O
the	O
total	O
group	O
of	O
patients	O
,	O
we	O
found	O
a	O
cutoff	O
for	O
abnormal	B-T033
CSF	B-T031
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
of	O
680	O
pg	O
/	O
ml	O
(	O
95	O
%	O
CI	O
660	O
-	O
705	O
pg	O
/	O
ml	O
)	O
.	O

Similar	O
cutoffs	O
were	O
found	O
within	O
diagnostic	B-T033
and	O
APOE	B-T058
genotype	I-T058
subgroups	B-T170
.	O

The	O
cutoff	O
was	O
higher	O
in	O
elderly	B-T098
subjects	B-T098
than	O
in	O
younger	O
subjects	B-T098
.	O

The	O
data	O
-	O
driven	O
cutoff	O
was	O
higher	O
than	O
our	O
clinical	B-T058
diagnosis	I-T058
-	O
based	O
cutoff	O
and	O
had	O
a	O
better	O
predictive	O
accuracy	O
for	O
progression	O
to	O
AD	B-T038
-	O
type	O
dementia	B-T038
in	O
nondemented	O
subjects	B-T098
(	O
HR	O
7	O
.	O
6	O
versus	O
5	O
.	O
2	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Mixture	B-T170
modeling	I-T170
is	O
a	O
robust	O
method	B-T170
to	O
determine	O
cutoffs	O
for	O
CSF	B-T031
β	B-T103
-	I-T103
amyloid	I-T103
1	I-T103
-	I-T103
42	I-T103
.	O

It	O
might	O
better	O
capture	O
biological	O
changes	O
that	O
are	O
related	O
to	O
AD	B-T038
than	O
cutoffs	O
based	O
on	O
clinical	B-T058
diagnosis	I-T058
.	O

Identification	O
of	O
the	O
anti	B-T103
-	I-T103
mycobacterial	I-T103
functional	O
properties	O
of	O
piperidinol	B-T103
derivatives	I-T103

Tuberculosis	B-T038
(	O
TB	B-T038
)	O
remains	O
a	O
major	O
global	O
health	O
threat	O
and	O
is	O
now	O
the	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
from	O
a	O
single	O
infectious	O
agent	O
worldwide	O
.	O

The	O
current	O
TB	B-T038
drug	B-T103
regimen	B-T058
is	O
inadequate	O
,	O
and	O
new	O
anti	B-T103
-	I-T103
tubercular	I-T103
agents	I-T103
are	O
urgently	O
required	O
to	O
be	O
able	O
to	O
successfully	O
combat	O
the	O
increasing	O
prevalence	O
of	O
drug	B-T038
-	I-T038
resistant	I-T038
TB	I-T038
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
a	O
piperidinol	B-T103
compound	I-T103
derivative	I-T103
that	O
is	O
highly	O
active	O
against	O
the	O
Mycobacterium	B-T007
tuberculosis	I-T007
bacillus	B-T007
.	O

The	O
antibacterial	B-T103
properties	O
of	O
the	O
piperidinol	B-T103
compound	I-T103
and	O
its	O
corresponding	O
bis	B-T103
-	I-T103
Mannich	I-T103
base	I-T103
analogue	B-T103
were	O
evaluated	B-T058
against	O
M	B-T007
.	I-T007

smegmatis	I-T007
and	O
Gram	B-T007
-	I-T007
negative	I-T007
organisms	I-T007
.	O

Cytotoxicity	B-T038
studies	B-T062
were	O
undertaken	O
in	O
order	O
to	O
determine	O
the	O
selectivity	B-T170
index	I-T170
for	O
these	O
compounds	B-T103
.	O

Spontaneous	O
resistant	O
mutants	B-T038
of	O
M	B-T007
.	I-T007

smegmatis	I-T007
were	O
generated	O
against	O
the	O
piperidinol	B-T103
and	O
corresponding	O
bis	B-T103
-	I-T103
Mannich	I-T103
base	I-T103
lead	I-T103
derivatives	I-T103
and	O
whole	O
genome	O
sequencing	O
employed	O
to	O
determine	O
the	O
genetic	B-T062
modifications	I-T062
that	O
lead	O
to	O
selection	O
pressure	O
in	O
the	O
presence	O
of	O
these	O
compounds	B-T103
.	O

The	O
piperidinol	B-T103
and	O
the	O
bis	B-T103
-	I-T103
Mannich	I-T103
base	I-T103
analogue	I-T103
were	O
found	O
to	O
be	O
selective	O
for	O
mycobacteria	B-T007
and	O
rapidly	O
kill	O
this	O
organism	O
with	O
a	O
cytotoxicity	B-T038
selectivity	B-T170
index	I-T170
for	O
mycobacteria	B-T007
of	O
>	O
30	O
-	O
fold	O
.	O

Whole	O
genome	O
sequencing	O
of	O
M	B-T007
.	I-T007

smegmatis	I-T007
strains	O
resistant	O
to	O
the	O
lead	B-T103
compounds	I-T103
led	O
to	O
the	O
identification	O
of	O
a	O
number	O
of	O
single	B-T082
nucleotide	I-T082
polymorphisms	I-T082
indicating	O
multiple	O
targets	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
piperidinol	B-T103
moiety	I-T103
represents	O
an	O
attractive	O
compound	B-T103
class	I-T103
in	O
the	O
pursuit	O
of	O
novel	O
anti	B-T103
-	I-T103
tubercular	I-T103
agents	I-T103
.	O

Metatranscriptomics	B-T058
Reveals	O
the	O
Active	O
Bacterial	B-T007
and	O
Eukaryotic	B-T007
Fibrolytic	I-T007
Communities	I-T007
in	O
the	O
Rumen	B-T017
of	O
Dairy	O
Cow	O
Fed	O
a	O
Mixed	O
Diet	B-T168

Ruminants	B-T204
have	O
a	O
unique	O
ability	O
to	O
derive	O
energy	O
from	O
the	O
degradation	O
of	O
plant	B-T204
polysaccharides	B-T103
through	O
the	O
activity	O
of	O
the	O
rumen	B-T017
microbiota	B-T204
.	O

Although	O
this	O
process	O
is	O
well	O
studied	O
in	O
vitro	O
,	O
knowledge	O
gaps	O
remain	O
regarding	O
the	O
relative	O
contribution	O
of	O
the	O
microbiota	B-T204
members	I-T204
and	O
enzymes	B-T103
in	B-T082
vivo	I-T082
.	O

The	O
present	O
study	O
used	O
RNA	B-T058
-	I-T058
sequencing	I-T058
to	O
reveal	O
both	O
the	O
expression	B-T038
of	O
genes	B-T017
encoding	O
carbohydrate	B-T103
-	I-T103
active	I-T103
enzymes	I-T103
(	O
CAZymes	B-T103
)	O
by	O
the	O
rumen	B-T017
microbiota	B-T204
of	O
a	O
lactating	O
dairy	O
cow	O
and	O
the	O
microorganisms	O
forming	O
the	O
fiber	B-T204
-	O
degrading	O
community	O
.	O

Functional	B-T062
analysis	I-T062
identified	O
12	O
,	O
237	O
CAZymes	B-T103
,	O
accounting	O
for	O
1	O
%	O
of	O
the	O
transcripts	B-T103
.	O

The	O
CAZyme	B-T103
profile	O
was	O
dominated	O
by	O
families	O
GH94	B-T103
(	O
cellobiose	B-T103
-	I-T103
phosphorylase	I-T103
)	O
,	O
GH13	B-T103
(	O
amylase	B-T103
)	O
,	O
GH43	B-T103
and	O
GH10	B-T103
(	O
hemicellulases	B-T103
)	O
,	O
GH9	B-T103
and	O
GH48	B-T103
(	O
cellulases	B-T103
)	O
,	O
PL11	B-T103
(	O
pectinase	B-T103
)	O
as	O
well	O
as	O
GH2	B-T103
and	O
GH3	B-T103
(	O
oligosaccharidases	B-T103
)	O
.	O

Our	O
data	O
support	O
the	O
pivotal	O
role	O
of	O
the	O
most	O
characterized	O
fibrolytic	B-T007
bacteria	I-T007
(	O
Prevotella	B-T007
,	O
Ruminocccus	B-T007
and	O
Fibrobacter	B-T007
)	O
,	O
and	O
highlight	O
a	O
substantial	O
,	O
although	O
most	O
probably	O
underestimated	O
,	O
contribution	O
of	O
fungi	B-T204
and	O
ciliate	B-T204
protozoa	I-T204
to	O
polysaccharide	B-T103
degradation	O
.	O

Particularly	O
these	O
results	O
may	O
motivate	O
further	O
exploration	O
of	O
the	O
role	O
and	O
the	O
functions	O
of	O
protozoa	B-T204
in	O
the	O
rumen	B-T017
.	O

Moreover	O
,	O
an	O
important	O
part	O
of	O
the	O
fibrolytic	B-T007
bacterial	I-T007
community	I-T007
remains	O
to	O
be	O
characterized	O
since	O
one	O
third	O
of	O
the	O
CAZyme	B-T103
transcripts	B-T103
originated	O
from	O
distantly	O
related	O
strains	B-T007
.	O

These	O
findings	O
are	O
used	O
to	O
highlight	O
limitations	O
of	O
current	O
metatranscriptomics	B-T058
approaches	O
to	O
understand	O
the	O
functional	O
rumen	B-T017
microbial	O
community	O
and	O
opportunities	O
to	O
circumvent	O
them	O
.	O

Fine	O
Mapping	O
of	O
Carbon	B-T017
Assimilation	I-T017
Rate	I-T017
8	I-T017
,	O
a	O
Quantitative	B-T017
Trait	I-T017
Locus	I-T017
for	O
Flag	B-T204
Leaf	I-T204
Nitrogen	B-T103
Content	O
,	O
Stomatal	B-T204
Conductance	O
and	O
Photosynthesis	O
in	O
Rice	B-T204

Increasing	O
the	O
rate	O
of	O
leaf	O
photosynthesis	O
is	O
one	O
important	O
approach	O
for	O
increasing	O
grain	O
yield	O
in	O
rice	B-T204
(	O
Oryza	B-T204
sativa	I-T204
)	O
.	O

Exploiting	O
the	O
natural	O
variation	O
in	O
CO2	O
assimilation	O
rate	O
(	O
A	O
)	O
between	O
rice	B-T204
cultivars	I-T204
using	O
quantitative	O
genetics	O
is	O
one	O
promising	O
means	O
to	O
identify	O
genes	B-T017
contributing	O
to	O
higher	O
photosynthesis	O
.	O

In	O
this	O
study	O
,	O
we	O
determined	O
precise	O
location	B-T082
of	O
Carbon	B-T017
Assimilation	I-T017
Rate	I-T017
8	I-T017
(	O
CAR8	B-T017
)	O
by	O
crossing	B-T038
a	O
high	O
-	O
yielding	O
indica	B-T204
cultivar	I-T204
with	O
a	O
Japanese	B-T082
commercial	B-T170
cultivar	B-T204
.	O

Fine	O
mapping	O
suggested	O
that	O
CAR8	B-T017
encodes	O
a	O
putative	B-T103
Heme	I-T103
Activator	I-T103
Protein	I-T103
3	I-T103
(	O
OsHAP3	B-T103
)	O
subunit	O
of	O
a	O
CCAAT	B-T103
-	I-T103
box	I-T103
-	I-T103
binding	I-T103
transcription	I-T103
factor	I-T103
called	O
OsHAP3H	B-T017
.	O

Sequencing	O
analysis	O
revealed	O
that	O
the	O
indica	B-T204
allele	B-T017
of	O
CAR8	B-T017
has	O
a	O
1	B-T038
-	I-T038
bp	I-T038
deletion	I-T038
at	O
322	O
bp	B-T038
from	O
the	O
start	B-T082
codon	I-T082
,	O
resulting	O
in	O
a	O
truncated	B-T103
protein	I-T103
of	O
125	O
amino	B-T103
acids	I-T103
.	O

In	O
addition	O
,	O
CAR8	B-T017
is	O
identical	O
to	O
DTH8	B-T017
/	O
Ghd8	B-T017
/	O
LHD1	B-T017
,	O
which	O
was	O
reported	O
to	O
control	O
rice	B-T204
flowering	B-T038
date	O
.	O

The	O
increase	O
of	O
A	O
is	O
largely	O
due	O
to	O
an	O
increase	O
of	O
RuBP	O
regeneration	O
rate	O
via	O
increased	O
leaf	B-T204
nitrogen	B-T103
content	O
,	O
and	O
partially	O
explained	O
by	O
reduced	O
stomatal	B-T204
limitation	O
via	O
increased	O
stomatal	B-T204
conductance	O
relative	O
to	O
A	O
.	O

This	O
allele	B-T017
also	O
increases	O
hydraulic	O
conductivity	O
,	O
which	O
would	O
promote	O
higher	O
stomatal	B-T204
conductance	O
.	O

This	O
indicates	O
that	O
CAR8	B-T017
affects	O
multiple	O
physiological	B-T038
aspects	I-T038
relating	O
to	O
photosynthesis	O
.	O

The	O
detailed	O
analysis	B-T062
of	O
molecular	B-T038
functions	I-T038
of	O
CAR8	B-T017
would	O
help	O
to	O
understand	O
the	O
association	O
between	O
photosynthesis	O
and	O
flowering	B-T038
and	O
demonstrate	O
specific	O
genetic	O
mechanisms	O
that	O
can	O
be	O
exploited	O
to	O
improve	B-T033
photosynthesis	O
in	O
rice	B-T204
and	O
potentially	O
other	O
crops	O
.	O

Allogeneic	B-T058
stem	I-T058
cell	I-T058
transplantation	I-T058
for	O
adult	O
patients	O
with	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
who	O
had	O
central	B-T033
nervous	I-T033
system	I-T033
involvement	I-T033
:	O
a	O
study	B-T062
from	O
the	O
Adult	O
ALL	B-T038
Working	B-T098
Group	I-T098
of	O
the	O
Japan	B-T082
Society	B-T092
for	O
Hematopoietic	B-T058
Cell	I-T058
Transplantation	I-T058

The	O
prognosis	B-T058
for	O
adult	O
acute	B-T038
lymphoblastic	I-T038
leukemia	I-T038
(	O
ALL	B-T038
)	O
patients	O
with	O
central	B-T033
nervous	I-T033
system	I-T033
(	I-T033
CNS	I-T033
)	I-T033
involvement	I-T033
(	O
CNS	B-T033
+	I-T033
)	O
who	O
received	O
allogeneic	B-T058
hematopoietic	I-T058
stem	I-T058
cell	I-T058
transplantation	I-T058
(	O
allo	B-T058
-	I-T058
SCT	I-T058
)	O
remains	O
unclear	O
.	O

We	O
retrospectively	O
compared	O
the	O
outcomes	O
of	O
allo	B-T058
-	I-T058
SCT	I-T058
for	O
patients	O
with	O
CNS	B-T033
involvement	I-T033
and	O
for	O
patients	O
without	O
CNS	B-T033
involvement	I-T033
(	O
CNS	B-T033
-	I-T033
)	O
using	O
a	O
database	B-T170
in	O
Japan	B-T082
.	O

The	O
eligibility	O
criteria	O
for	O
this	O
study	B-T062
were	O
as	O
follows	O
:	O
diagnosis	B-T062
of	O
ALL	B-T038
,	O
aged	O
more	O
than	O
16	O
years	O
,	O
allo	B-T058
-	I-T058
SCT	I-T058
between	O
2005	O
and	O
2012	O
,	O
and	O
first	O
SCT	B-T058
.	O

Data	O
for	O
2582	O
patients	O
including	O
136	O
CNS	O
+	O
patients	O
and	O
2446	O
CNS	O
-	O
patients	O
were	O
used	O
for	O
analyses	B-T062
.	O

As	O
compared	O
with	O
CNS	O
-	O
patients	O
,	O
CNS	O
+	O
patients	O
were	O
younger	O
,	O
had	O
worse	B-T033
disease	B-T038
status	O
at	O
SCT	B-T058
and	O
had	O
poorer	O
performance	B-T201
status	I-T201
(	O
PS	B-T201
)	O
at	O
SCT	B-T058
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Incidence	O
of	O
relapse	O
was	O
higher	O
in	O
CNS	O
+	O
patients	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
incidence	O
of	O
CNS	B-T022
relapse	O
was	O
also	O
higher	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
probability	O
of	O
3	O
-	O
year	O
overall	O
survival	O
(	O
OS	O
)	O
was	O
better	O
in	O
CNS	O
-	O
patients	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
by	O
univariate	O
analysis	O
.	O

However	O
,	O
in	O
patients	O
who	O
received	O
SCT	B-T058
in	O
CR	B-T033
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
probability	O
of	O
OS	O
between	O
CNS	B-T033
+	I-T033
and	O
CNS	B-T033
-	I-T033
patients	O
(	O
P	O
=	O
0	O
.	O
38	O
)	O
and	O
CNS	B-T033
involvement	I-T033
did	O
not	O
have	O
an	O
unfavorable	O
effect	O
on	O
OS	O
by	O
multivariate	O
analysis	O
.	O

CNS	O
+	O
patients	O
who	O
achieved	O
CR	B-T033
showed	O
OS	O
comparable	O
to	O
that	O
of	O
CNS	O
-	O
patients	O
.	O

Silent	O
strain	O
of	O
caregiving	O
:	O
exploring	O
the	O
best	B-T033
predictors	I-T033
of	O
distress	B-T033
in	O
family	O
carers	O
of	O
geriatric	O
patients	O

The	O
aim	O
of	O
this	O
article	O
was	O
to	O
identify	O
the	O
best	B-T033
predictors	I-T033
of	O
distress	B-T033
suffered	I-T033
by	O
family	O
carers	O
(	O
FCs	O
)	O
of	O
geriatric	O
patients	O
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
of	O
100	O
FC	O
-	O
geriatric	O
patient	O
dyads	O
was	O
conducted	O
.	O

The	O
negative	B-T033
impact	I-T033
of	I-T033
care	I-T033
(	O
NIoC	B-T033
)	O
subscale	O
of	O
the	O
COPE	O
index	O
was	O
dichotomized	O
to	O
identify	O
lower	B-T033
stress	I-T033
(	O
score	O
of	O
≤15	O
on	O
the	O
scale	O
)	O
and	O
higher	B-T033
stress	I-T033
(	O
score	O
of	O
≥16	O
on	O
the	O
scale	O
)	O
exerted	O
on	O
FCs	O
by	O
the	O
process	B-T058
of	I-T058
providing	I-T058
care	I-T058
.	O

The	O
set	O
of	O
explanatory	B-T170
variables	B-T033
comprised	O
a	O
wide	O
range	O
of	O
sociodemographic	O
and	O
care	B-T058
-	I-T058
related	I-T058
attributes	I-T058
,	O
including	O
patient	B-T033
-	I-T033
related	I-T033
results	I-T033
from	O
comprehensive	O
geriatric	B-T058
assessments	I-T058
and	O
disease	B-T038
profiles	O
.	O

The	O
best	O
combination	O
of	O
explanatory	B-T170
variables	B-T033
that	O
provided	O
the	O
highest	O
predictive	O
powe	O
r	O
for	O
distress	B-T033
among	O
FCs	O
in	O
the	O
multiple	O
logistic	O
regression	O
(	O
LR	O
)	O
model	O
was	O
determined	O
according	O
to	O
statistical	O
information	O
criteria	O
.	O

The	O
statistical	O
robustness	O
of	O
the	O
observed	O
relationships	O
and	O
the	O
discriminative	O
power	O
of	O
the	O
model	O
were	O
verified	O
with	O
the	O
cross	B-T062
-	I-T062
validation	I-T062
method	I-T062
.	O

The	O
mean	O
age	O
of	O
FCs	O
was	O
57	O
.	O
2	O
(	O
±10	O
.	O
6	O
)	O
years	O
,	O
whereas	O
that	O
of	O
geriatric	O
patients	O
was	O
81	O
.	O
7	O
(	O
±6	O
.	O
4	O
)	O
years	O
.	O

Despite	O
the	O
broad	O
initial	O
set	O
of	O
potential	O
explanatory	B-T170
variables	B-T033
,	O
only	O
five	O
predictors	B-T033
were	O
jointly	O
selected	O
for	O
the	O
best	O
statistical	B-T170
model	I-T170
.	O

A	O
higher	O
level	O
of	O
distress	B-T033
was	O
independently	O
predicted	O
by	O
lower	B-T058
self	I-T058
-	I-T058
evaluation	I-T058
of	I-T058
health	I-T058
;	O
worse	O
self	B-T038
-	I-T038
appraisal	I-T038
of	O
coping	O
well	O
as	O
a	O
caregiver	O
;	O
lower	O
sense	O
of	O
general	B-T058
support	I-T058
;	O
more	O
hours	O
of	O
care	O
per	O
week	O
;	O
and	O
the	O
motor	B-T033
retardation	I-T033
of	O
the	O
cared	O
-	O
for	O
person	O
measured	O
with	O
the	O
speed	O
of	O
the	O
Timed	B-T058
Up	I-T058
and	I-T058
Go	I-T058
(	I-T058
TUG	I-T058
)	I-T058
test	I-T058
.	O

Worse	O
performance	O
on	O
the	O
TUG	B-T058
test	I-T058
was	O
only	O
the	O
patient	O
-	O
related	O
predictor	B-T033
of	O
distress	B-T033
among	O
the	O
variables	B-T033
examined	O
as	O
contributors	O
to	O
the	O
higher	O
NIoC	B-T033
.	O

Enhancing	O
the	O
mobility	O
of	O
geriatric	O
patients	O
through	O
suitably	O
tailored	O
kinesitherapeutic	B-T058
methods	I-T058
during	O
their	O
hospital	O
stay	O
may	O
mitigate	O
the	O
burden	O
endured	O
by	O
FCs	O
.	O

Microbiological	B-T170
and	O
Clinical	O
Characteristics	O
of	O
Hypermucoviscous	B-T007
Klebsiella	I-T007
pneumoniae	I-T007
Isolates	B-T103
Associated	O
with	O
Invasive	B-T038
Infections	I-T038
in	O
China	B-T082

A	O
distinctive	B-T038
syndrome	I-T038
caused	O
by	O
hypermucoviscous	B-T007
Klebsiella	I-T007
pneumoniae	I-T007
(	O
HMKP	B-T007
)	O
including	O
pyogenic	B-T038
liver	I-T038
abscess	I-T038
(	O
PLA	B-T038
)	O
is	O
now	O
becoming	O
a	O
globally	B-T038
emerging	I-T038
disease	I-T038
.	O

In	O
the	O
present	O
study	B-T062
,	O
22	O
.	O
8	O
%	O
(	O
84	O
/	O
369	O
)	O
of	O
K	B-T007
.	I-T007

pneumoniae	I-T007
clinical	O
isolates	B-T103
associated	O
with	O
various	O
types	O
of	O
invasive	B-T038
infections	I-T038
were	O
identified	O
as	O
HMKP	B-T007
,	O
with	O
45	O
.	O
2	O
%	O
associated	O
with	O
PLA	B-T038
.	O

Multivariate	O
regression	O
analysis	O
showed	O
that	O
male	O
patients	O
with	O
41	O
-	O
50	O
years	O
,	O
PLA	B-T038
,	O
diabetes	B-T038
mellitus	I-T038
,	O
and	O
hypertension	B-T038
were	O
independent	O
risk	B-T033
factors	I-T033
for	O
HMKP	B-T038
infections	I-T038
.	O

K2	B-T170
(	O
42	O
.	O
9	O
%	O
,	O
36	O
/	O
84	O
)	O
was	O
the	O
most	O
common	O
capsular	B-T082
serotype	B-T170
among	O
HMKP	B-T007
isolates	B-T103
,	O
followed	O
by	O
K1	B-T170
(	O
23	O
.	O
8	O
%	O
,	O
20	O
/	O
84	O
)	O
.	O

Seventy	O
-	O
five	O
percentage	O
of	O
K1	B-T170
HMKP	B-T007
isolates	B-T103
were	O
associated	O
with	O
PLA	B-T038
,	O
while	O
K2	B-T170
HMKP	B-T007
isolates	B-T103
accounted	O
for	O
more	O
types	O
of	O
invasive	B-T038
infections	I-T038
.	O

The	O
positive	B-T033
rates	O
of	O
iutA	B-T017
,	O
mrkD	B-T017
,	O
aerobactin	B-T017
,	O
iroN	B-T017
,	O
and	O
rmpA	B-T017
among	O
HMKP	B-T007
isolates	B-T103
were	O
significantly	O
higher	O
than	O
those	O
among	O
non	B-T007
-	I-T007
HMKP	I-T007
isolates	B-T103
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
was	O
a	O
correlation	O
between	O
magA	B-T017
,	O
ybtS	B-T017
,	O
alls	B-T017
,	O
and	O
wcaG	B-T017
and	O
K1	B-T170
isolates	B-T103
.	O

Interestingly	O
,	O
mrkD	B-T017
was	O
exclusively	B-T033
detected	I-T033
among	O
HMKP	B-T007
(	O
32	O
.	O
1	O
%	O
,	O
27	O
/	O
84	O
)	O
and	O
K2	B-T170
isolates	B-T103
(	O
65	O
.	O
9	O
%	O
,	O
27	O
/	O
41	O
)	O
.	O

All	O
K1	B-T170
and	O
K2	B-T170
HMKP	B-T007
and	O
non	B-T007
-	I-T007
HMKP	I-T007
isolates	B-T103
were	O
positive	B-T033
for	O
rmpA	B-T017
.	O

Aerobactin	B-T017
was	O
found	B-T033
among	O
95	O
.	O
0	O
and	O
97	O
.	O
5	O
%	O
of	O
K1	B-T170
and	O
K2	B-T170
isolates	B-T103
.	O

ST23	B-T170
was	O
found	B-T033
to	O
be	O
the	O
most	O
prevalent	O
ST	B-T170
among	O
69	O
HMKP	B-T007
isolates	B-T103
with	O
K1	B-T170
,	O
K2	B-T170
,	O
K5	B-T170
,	O
K20	B-T170
,	O
and	O
K57	B-T170
(	O
27	O
.	O
5	O
%	O
,	O
19	O
/	O
69	O
)	O
and	O
was	O
only	O
found	B-T033
among	O
K1	B-T170
isolates	B-T103
.	O

ST65	B-T170
was	O
the	O
second	O
most	O
prevalent	O
ST	B-T170
(	O
26	O
.	O
1	O
%	O
,	O
18	O
/	O
69	O
)	O
and	O
was	O
also	O
only	O
found	B-T033
among	O
K2	B-T170
isolates	B-T103
.	O

ST23	B-T170
-	I-T170
K1	I-T170
HMKP	B-T007
isolates	B-T103
(	O
84	O
.	O
2	O
%	O
,	O
16	O
/	O
19	O
)	O
were	O
associated	O
with	O
PLA	B-T038
,	O
while	O
ST65	B-T170
-	I-T170
K2	I-T170
isolates	B-T103
were	O
correlated	O
with	O
more	O
types	B-T170
of	I-T170
infections	I-T170
relative	O
to	O
ST23	B-T170
-	I-T170
K1	I-T170
isolates	B-T103
.	O

PFGE	B-T058
results	O
showed	O
that	O
the	O
homology	O
of	O
84	O
HMKP	B-T007
isolates	B-T103
was	O
diverse	O
.	O

Only	O
five	O
PFGE	B-T058
clusters	O
with	O
more	O
than	O
75	O
%	O
similarity	O
accounted	O
for	O
more	O
than	O
three	O
isolates	B-T103
.	O

These	O
five	O
PFGE	B-T058
clusters	O
only	O
accounted	O
for	O
35	O
(	O
41	O
.	O
7	O
%	O
,	O
35	O
/	O
84	O
)	O
isolates	B-T103
.	O

In	O
conclusion	O
,	O
our	O
study	B-T062
first	O
found	B-T033
that	O
hypertension	B-T038
and	O
male	O
patients	O
with	O
41	O
-	O
50	O
years	O
old	O
were	O
independent	O
risk	B-T033
factors	I-T033
.	O

The	O
composition	B-T201
of	O
ST	B-T170
types	I-T170
and	O
PFGE	B-T058
clusters	O
among	O
K	B-T007
.	I-T007

pneumoniae	I-T007
K2	B-T170
isolates	B-T103
was	O
more	O
diverse	O
than	O
K1	B-T170
isolates	B-T103
.	O

K1	B-T170
and	O
K2	B-T170
HMKP	B-T007
isolates	B-T103
had	O
respective	O
specific	O
profiles	O
of	O
virulence	B-T038
-	O
associated	O
genes	B-T017
.	O

Haemoglobinopathies	B-T038
and	O
β	B-T038
-	I-T038
Thalassaemia	I-T038
among	O
the	O
Tribals	B-T098
Working	O
in	O
the	O
Tea	B-T168
Gardens	O
of	O
Assam	O
,	O
India	B-T082

Prevalence	O
of	O
haemoglobinopathies	B-T038
and	O
β	B-T038
-	I-T038
thalassaemia	I-T038
are	O
very	O
high	O
in	O
India	B-T082
but	O
information	O
about	O
its	O
status	O
among	O
the	O
tribals	B-T098
working	O
in	O
the	O
tea	B-T168
gardens	O
of	O
Assam	O
is	O
very	O
less	O
.	O

The	O
present	O
study	B-T062
was	O
carried	O
out	O
to	O
determine	O
the	O
prevalence	O
of	O
haemoglobinopathies	B-T038
and	O
β	B-T038
-	I-T038
thalassaemia	I-T038
among	O
the	O
tribals	B-T098
working	O
in	O
the	O
tea	B-T168
gardens	O
of	O
Assam	O
.	O

A	O
total	O
1204	O
samples	O
from	O
the	O
tribals	B-T098
working	O
in	O
tea	B-T168
gardens	O
of	O
Assam	O
were	O
analysed	B-T062
for	O
both	O
Complete	B-T058
Blood	I-T058
Count	I-T058
(	O
CBC	B-T058
)	O
and	O
High	B-T058
Pressure	I-T058
Liquid	I-T058
Chromatography	I-T058
(	O
HPLC	B-T058
)	O
for	O
detection	B-T058
of	O
haemoglobinopathies	B-T038
and	O
β	B-T038
-	I-T038
thalassaemia	I-T038
.	O

This	O
study	B-T062
showed	O
that	O
the	O
prevalence	O
of	O
sickle	B-T038
cell	I-T038
anaemia	I-T038
and	O
β	B-T038
-	I-T038
thalassaemia	I-T038
were	O
very	O
high	O
among	O
this	O
population	B-T098
.	O

Our	O
results	O
indicated	B-T033
a	O
higher	O
prevalence	O
of	O
β	B-T038
-	I-T038
thalassaemia	I-T038
(	O
3	O
.	O
07	O
%	O
)	O
among	O
the	O
Munda	B-T098
ethnic	I-T098
group	I-T098
and	O
higher	O
prevalence	O
of	O
sickle	B-T038
cell	I-T038
anaemia	I-T038
(	O
4	O
.	O
73	O
%	O
)	O
among	O
the	O
Lohar	B-T098
ethnic	I-T098
group	I-T098
.	O

This	O
was	O
the	O
first	O
study	B-T062
to	O
report	O
the	O
presence	B-T033
of	O
HbE	B-T103
among	O
the	O
tribals	B-T098
working	O
in	O
the	O
tea	B-T168
gardens	O
of	O
Assam	O
.	O

Based	O
on	O
the	O
present	O
findings	B-T033
,	O
sickle	B-T038
cell	I-T038
anaemia	I-T038
and	O
β	B-T038
-	I-T038
thalassaemia	I-T038
were	O
major	O
health	O
problem	B-T033
for	O
the	O
tribals	B-T098
working	O
in	O
the	O
tea	B-T168
gardens	O
of	O
Assam	O
.	O

Proper	O
diagnostic	B-T058
facilities	I-T058
for	O
haemoglobinopathy	B-T038
and	O
thalassaemia	B-T038
should	O
be	O
established	O
in	O
these	O
areas	B-T082
,	O
including	O
establishment	O
of	O
haemoglobinopathy	B-T038
and	O
thalassaemia	B-T038
database	B-T170
collection	O
,	O
haematological	B-T092
analysis	I-T092
laboratories	I-T092
,	O
genetic	B-T092
counselling	I-T092
clinics	I-T092
,	O
prenatal	B-T092
diagnosis	I-T092
centres	I-T092
and	O
neonatal	B-T092
screening	I-T092
centres	I-T092
.	O

Long	O
Term	O
Outcome	O
in	O
Patients	O
with	O
Esophageal	B-T058
Stenting	I-T058
for	O
Cancer	B-T038
Esophagus	I-T038
-	O
Our	O
Experience	O
at	O
a	O
Rural	B-T092
Hospital	I-T092
of	O
Punjab	O
,	O
India	B-T082

Cancer	B-T038
of	I-T038
the	I-T038
esophagus	I-T038
is	O
among	O
the	O
leading	O
cause	O
of	O
cancer	O
deaths	O
in	O
Punjab	O
,	O
India	B-T082
.	O

Patients	O
generally	O
present	B-T033
with	O
dysphagia	B-T038
as	O
their	O
first	O
symptom	B-T033
and	O
more	O
often	O
they	O
have	O
advanced	O
disease	O
at	O
the	O
time	O
of	O
presentation	O
to	O
a	O
tertiary	B-T092
care	I-T092
centre	I-T092
.	O

Palliative	B-T058
procedures	I-T058
have	O
important	O
roles	O
in	O
this	O
setting	O
.	O

Stenting	B-T058
is	O
the	O
best	O
option	O
to	O
palliate	O
the	O
symptoms	B-T033
of	O
dysphagia	B-T038
,	O
from	O
which	O
patient	O
is	O
suffering	B-T033
the	I-T033
most	I-T033
.	O

To	O
know	O
the	O
success	O
rate	O
,	O
early	B-T033
and	O
long	O
term	O
complications	B-T038
and	O
mortality	O
in	O
esophageal	B-T058
stenting	I-T058
,	O
when	O
it	O
was	O
done	O
in	O
malignant	B-T038
esophageal	I-T038
stricture	I-T038
patients	O
.	O

One	O
hundred	O
patients	O
,	O
who	O
had	O
undergone	O
esophageal	B-T058
stenting	I-T058
from	O
January	O
2012	O
to	O
January	O
2015	O
,	O
were	O
included	O
in	O
the	O
study	B-T062
.	O

We	O
retrospectively	B-T062
analysed	I-T062
the	O
data	O
for	O
patient	O
characteristics	O
,	O
causes	O
of	O
non	O
-	O
operability	O
,	O
early	B-T033
and	O
long	O
term	O
complications	B-T038
,	O
re	B-T058
-	I-T058
interventions	I-T058
,	O
efficacy	O
and	O
mortality	O
.	O

Out	O
of	O
100	O
patients	O
,	O
indications	O
for	O
stenting	B-T058
were	O
locally	O
advanced	O
disease	O
not	O
amenable	O
to	O
surgery	B-T058
(	O
52	O
%	O
)	O
,	O
metastatic	B-T038
disease	I-T038
(	O
35	O
%	O
)	O
,	O
CVA	B-T038
(	O
1	O
%	O
)	O
,	O
cardiac	O
and	O
respiratory	B-T033
problem	I-T033
(	O
8	O
%	O
)	O
,	O
un	O
-	O
willing	O
for	O
surgery	B-T058
in	O
5	O
%	O
of	O
patients	O
.	O

Majority	O
of	O
patients	O
(	O
94	O
%	O
)	O
had	O
squamous	B-T038
cell	I-T038
carcinoma	I-T038
,	O
while	O
only	O
6	O
%	O
had	O
adenocarcinoma	B-T038
.	O

84	O
%	O
of	O
patients	O
presented	O
with	O
dysphagia	B-T038
with	O
or	O
without	O
chest	B-T033
pain	I-T033
and	O
recurrent	B-T033
cough	I-T033
while	O
16	O
%	O
had	O
recurrent	B-T033
vomiting	I-T033
.	O

58	O
%	O
had	O
dysphagia	B-T038
to	O
liquids	O
and	O
solids	O
and	O
17	O
%	O
had	O
complete	B-T038
dysphagia	I-T038
.	O

After	O
stenting	B-T058
93	O
%	O
had	O
significant	O
improvement	O
in	O
dysphagia	B-T038
score	O
from	O
median	O
of	O
3	O
to	O
1	O
.	O

Post	O
procedure	O
stay	O
was	O
3	O
.	O
61±1	O
.	O
0	O
days	O
.	O

One	O
patient	O
had	O
procedure	B-T058
related	O
major	O
complication	B-T038
in	O
the	O
form	O
of	O
post	B-T037
procedural	I-T037
bleed	I-T037
(	O
after	O
16	O
days	O
of	O
stenting	B-T058
)	O
leading	O
to	O
death	B-T033
of	O
that	O
patient	O
.	O

Minor	B-T038
complications	B-T038
were	O
present	B-T033
in	O
52	O
patients	O
treated	O
conservatively	O
not	O
affecting	O
the	O
efficacy	O
of	O
procedure	B-T058
.	O

These	O
include	O
pain	B-T033
after	O
stenting	B-T058
(	O
38	O
%	O
)	O
,	O
stent	B-T038
obstruction	I-T038
(	O
23	O
%	O
)	O
and	O
stent	B-T038
migration	I-T038
(	O
6	O
%	O
)	O
.	O

All	O
the	O
minor	B-T038
complications	B-T038
were	O
treated	O
conservatively	O
except	O
in	O
six	O
patients	O
in	O
whom	O
re	B-T058
-	I-T058
stenting	I-T058
was	O
done	O
.	O

Esophageal	B-T058
stenting	I-T058
is	O
relatively	O
safe	O
procedure	B-T058
with	O
short	O
stay	O
of	O
the	O
patient	O
in	O
the	O
hospital	B-T092
.	O

Although	O
,	O
it	O
helps	O
in	O
alleviating	O
patients	O
'	O
morbidity	O
very	O
effectively	O
and	O
reliably	O
,	O
there	O
are	O
many	O
technical	O
glitches	O
,	O
which	O
needs	O
to	O
be	O
kept	O
into	O
account	O
and	O
patient	O
should	O
be	O
properly	O
counseled	B-T058
before	O
the	O
procedure	B-T058
to	O
prevent	O
and	O
manage	O
post	O
procedure	O
complications	B-T038
and	O
medico	O
legal	O
aspects	O
.	O

Treatment	O
of	O
Carcinoma	B-T038
In	I-T038
Situ	I-T038
of	I-T038
the	I-T038
Glans	I-T038
Penis	I-T038
With	O
Topical	O
Imiquimod	O
Followed	O
by	O
Carbon	B-T074
Dioxide	I-T074
Laser	I-T074
Excision	B-T058

Different	O
approaches	O
have	O
been	O
described	O
in	O
published	O
studies	O
for	O
carcinoma	B-T038
in	I-T038
situ	I-T038
(	I-T038
CIS	I-T038
)	I-T038
of	I-T038
the	I-T038
glans	I-T038
penis	I-T038
(	O
erythroplasia	B-T038
of	I-T038
Queyrat	I-T038
)	O
,	O
including	O
topical	B-T058
chemotherapy	I-T058
or	O
immunotherapy	B-T058
and	O
laser	O
or	O
surgical	B-T058
excision	I-T058
.	O

We	O
evaluated	B-T058
the	O
efficacy	O
of	O
topical	O
imiquimod	O
(	O
IQ	O
)	O
followed	O
by	O
carbon	B-T074
dioxide	I-T074
laser	I-T074
ablation	B-T058
of	O
the	O
lesion	B-T033
.	O

From	O
2010	O
to	O
2015	O
,	O
10	O
patients	O
affected	O
by	O
CIS	B-T038
of	O
the	O
glans	O
were	O
treated	B-T058
by	O
IQ	O
,	O
followed	O
by	O
carbon	B-T074
dioxide	I-T074
laser	I-T074
ablation	B-T058
.	O

For	O
every	O
patient	O
,	O
we	O
performed	O
histologic	B-T058
examination	I-T058
before	O
and	O
after	O
IQ	O
.	O

Local	O
toxicity	B-T037
and	O
adverse	B-T038
effects	I-T038
were	O
recorded	O
.	O

After	O
treatment	O
,	O
histologic	B-T058
examination	I-T058
showed	O
no	B-T033
residual	I-T033
tumor	I-T033
in	O
6	O
patients	O
(	O
complete	B-T033
response	I-T033
[	O
CR	B-T033
]	O
)	O
,	O
stable	B-T033
disease	I-T033
in	O
2	O
patients	O
,	O
and	O
progressive	B-T038
disease	I-T038
in	O
2	O
patients	O
.	O

Those	O
with	O
a	O
CR	B-T033
had	O
human	B-T005
papillomavirus	I-T005
-	O
related	O
lesions	B-T033
,	O
and	O
they	O
had	O
no	B-T033
experienced	O
relapses	O
after	O
a	O
mean	O
follow	B-T058
-	I-T058
up	I-T058
of	O
26	O
months	O
.	O

The	O
2	O
patients	O
with	O
progressive	B-T038
disease	I-T038
underwent	O
total	O
penectomy	B-T058
.	O

All	O
patients	O
were	O
alive	B-T033
at	O
the	O
last	O
follow	B-T033
-	I-T033
up	I-T033
examination	I-T033
.	O

All	O
patients	O
experienced	O
a	O
mild	O
local	O
toxicity	B-T037
(	O
burning	B-T033
erythema	I-T033
)	O
but	O
no	B-T033
major	O
adverse	B-T038
effects	I-T038
.	O

Local	O
treatment	O
with	O
IQ	O
for	O
glans	O
CIS	B-T038
is	O
effective	O
mainly	O
for	O
human	B-T005
papillomavirus	I-T005
-	O
related	O
lesions	B-T033
.	O

The	O
present	O
study	O
is	O
the	O
first	O
to	O
record	O
the	O
histologic	B-T058
examination	I-T058
findings	O
before	O
and	O
after	O
IQ	O
treatment	O
.	O

The	O
small	O
number	O
of	O
patients	O
,	O
owing	O
to	O
the	O
rarity	O
of	O
this	O
disease	B-T038
,	O
was	O
the	O
main	O
limitation	O
of	O
the	O
present	O
study	O
.	O

IQ	O
must	O
be	O
used	O
carefully	O
,	O
and	O
a	O
close	O
follow	B-T058
-	I-T058
up	I-T058
protocol	B-T170
is	O
mandatory	O
because	O
of	O
the	O
lack	O
of	O
long	O
-	O
term	O
efficacy	O
data	O
.	O

Progressive	O
subcortical	O
calcifications	B-T038
secondary	O
to	O
venous	B-T038
hypertension	I-T038
in	O
an	O
intracranial	B-T082
dural	B-T017
arteriovenous	I-T017
fistula	I-T017

Intracranial	B-T082
dural	B-T017
arteriovenous	I-T017
fistulas	I-T017
(	O
dAVF	B-T017
)	O
are	O
acquired	B-T033
lesions	I-T033
,	O
with	O
the	O
most	O
commonly	O
reported	B-T058
findings	B-T033
on	O
CT	B-T058
haemorrhage	B-T038
or	O
focal	B-T038
oedema	I-T038
.	O

We	O
describe	O
a	O
case	O
of	O
progressive	O
subcortical	O
calcification	B-T038
on	O
CT	B-T058
secondary	O
to	O
venous	B-T038
hypertension	I-T038
from	O
a	O
high	O
grade	O
dAVF	B-T017
.	O

Effects	O
of	O
Static	B-T058
Cold	I-T058
Storage	I-T058
and	O
Hypothermic	B-T058
Machine	I-T058
Perfusion	I-T058
on	O
Oxidative	B-T058
Stress	I-T058
Factors	I-T058
,	O
Adhesion	B-T103
Molecules	I-T103
,	O
and	O
Zinc	B-T103
Finger	I-T103
Transcription	I-T103
Factor	I-T103
Proteins	I-T103
Before	O
and	O
After	O
Liver	B-T058
Transplantation	I-T058

BACKGROUND	O
This	O
study	O
aimed	O
to	O
investigate	O
the	O
effects	O
of	O
static	B-T058
cold	I-T058
storage	I-T058
(	O
SCS	B-T058
)	O
and	O
hypothermic	B-T058
machine	I-T058
perfusion	I-T058
(	O
HMP	B-T058
)	O
on	O
the	O
oxidative	B-T058
stress	I-T058
factors	I-T058
(	O
OSF	B-T058
)	O
,	O
adhesion	B-T103
molecules	I-T103
(	O
AM	B-T103
)	O
,	O
and	O
zinc	B-T103
finger	I-T103
transcription	I-T103
factor	I-T103
(	O
Snail	B-T103
)	O
before	O
and	O
after	O
liver	B-T058
transplantation	I-T058
.	O

MATERIAL	O
AND	O
METHODS	O
Experimental	O
dogs	B-T204
were	O
randomly	O
divided	O
into	O
donor	O
(	O
group	O
A	O
)	O
,	O
SCS	B-T058
(	O
group	O
B	O
)	O
,	O
and	O
HMP	B-T058
(	O
group	O
C	O
)	O
(	O
n	O
=	O
30	O
)	O
groups	O
.	O

Livers	B-T058
retrieved	I-T058
from	O
group	O
A	O
were	O
transplanted	B-T058
into	O
group	O
B	O
after	O
SCS	B-T058
,	O
and	O
the	O
livers	B-T017
sampled	O
from	O
group	O
B	O
were	O
transplanted	B-T058
into	O
group	O
C	O
after	O
HMP	B-T058
.	O

The	O
dogs	O
in	O
group	O
A	O
were	O
euthanized	O
and	O
discarded	O
,	O
and	O
the	O
livers	B-T017
sampled	O
from	O
group	O
C	O
were	O
used	O
for	O
other	O
experiments	O
.	O

Twenty	O
dogs	B-T204
with	O
successful	O
liver	B-T058
transplants	I-T058
were	O
randomly	O
selected	O
from	O
groups	O
B	O
and	O
C	O
for	O
analysis	O
.	O

RESULTS	O
During	O
the	O
liver	B-T017
sampling	B-T062
process	I-T062
,	O
the	O
levels	O
of	O
OSF	B-T058
,	O
AM	B-T103
,	O
and	O
Snail	O
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
;	O
before	O
the	O
transplantation	B-T058
,	O
the	O
levels	O
of	O
chemokine	B-T103
CXCL14	I-T103
and	O
Snail	B-T103
between	O
the	O
2	O
groups	O
showed	O
no	O
significant	O
differences	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
,	O
and	O
compared	O
with	O
group	O
B	O
,	O
HIF	O
-	O
1α	O
and	O
P	B-T103
-	I-T103
selectin	I-T103
in	O
group	O
C	O
were	O
lower	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
;	O
60	O
min	O
after	O
the	O
transplantation	B-T058
,	O
HIF	B-T103
-	I-T103
1α	I-T103
,	O
chemokine	B-T103
CXCL14	I-T103
,	O
P	B-T103
-	I-T103
selectin	I-T103
,	O
and	O
Snail	B-T103
in	O
group	O
C	O
were	O
lower	O
than	O
that	O
in	O
group	O
B	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

CONCLUSIONS	O
HMP	B-T058
can	O
significantly	O
reduce	O
the	O
levels	O
of	O
OSF	B-T058
and	O
inflammatory	O
factors	O
,	O
which	O
is	O
conducive	B-T033
for	O
liver	B-T058
transplantation	I-T058
.	O

Physiology	B-T038
of	O
respiratory	B-T033
disturbances	I-T033
in	O
muscular	B-T038
dystrophies	I-T038

Muscular	B-T038
dystrophy	I-T038
is	O
a	O
group	O
of	O
inherited	O
myopathies	B-T038
characterised	O
by	O
progressive	O
skeletal	B-T038
muscle	I-T038
wasting	I-T038
,	O
including	O
of	O
the	O
respiratory	B-T017
muscles	I-T017
.	O

Respiratory	B-T038
failure	I-T038
,	O
i	O
.	O
e	O
.	O

when	O
the	O
respiratory	B-T022
system	I-T022
fails	O
in	O
its	O
gas	O
exchange	O
functions	O
,	O
is	O
a	O
common	O
feature	O
in	O
muscular	B-T038
dystrophy	I-T038
,	O
being	O
the	O
main	O
cause	O
of	O
death	B-T033
,	O
and	O
it	O
is	O
a	O
consequence	O
of	O
lung	B-T017
failure	B-T038
,	O
pump	B-T038
failure	I-T038
or	O
a	O
combination	O
of	O
the	O
two	O
.	O

The	O
former	O
is	O
due	O
to	O
recurrent	O
aspiration	B-T038
,	O
the	O
latter	O
to	O
progressive	O
weakness	B-T033
of	I-T033
respiratory	I-T033
muscles	I-T033
and	O
an	O
increase	O
in	O
the	O
load	O
against	O
which	O
they	O
must	O
contract	O
.	O

In	O
fact	O
,	O
both	O
the	O
resistive	O
and	O
elastic	O
components	O
of	O
the	O
work	O
of	O
breathing	B-T038
increase	O
due	O
to	O
airway	B-T038
obstruction	I-T038
and	O
chest	B-T017
wall	I-T017
and	O
lung	B-T017
stiffening	B-T033
,	O
respectively	O
.	O

The	O
respiratory	B-T033
disturbances	I-T033
in	O
muscular	B-T038
dystrophy	I-T038
are	O
restrictive	B-T033
pulmonary	I-T033
function	I-T033
,	O
hypoventilation	B-T038
,	O
altered	O
thoracoabdominal	B-T082
pattern	O
,	O
hypercapnia	B-T033
,	O
dyspnoea	B-T033
,	O
impaired	O
regulation	O
of	O
breathing	O
,	O
inefficient	B-T033
cough	I-T033
and	O
sleep	B-T038
disordered	I-T038
breathing	I-T038
.	O

They	O
can	O
be	O
present	O
at	O
different	O
rates	O
according	O
to	O
the	O
type	O
of	O
muscular	B-T038
dystrophy	I-T038
and	O
its	O
progression	B-T038
,	O
leading	O
to	O
different	O
onset	O
of	O
each	O
symptom	B-T033
,	O
prognosis	B-T058
and	O
degree	B-T033
of	I-T033
respiratory	I-T033
involvement	I-T033
.	O

A	O
common	O
feature	O
of	O
muscular	B-T038
dystrophy	I-T038
is	O
respiratory	B-T038
failure	I-T038
,	O
i	O
.	O
e	O
.	O

the	O
inability	O
of	O
the	O
respiratory	B-T022
system	I-T022
to	O
provide	O
proper	O
oxygenation	O
and	O
carbon	B-T038
dioxide	I-T038
elimination	I-T038
.	O
In	O
the	O
lung	B-T017
,	O
respiratory	B-T038
failure	I-T038
is	O
caused	O
by	O
recurrent	O
aspiration	B-T038
,	O
and	O
leads	O
to	O
hypoxaemia	B-T033
and	O
hypercarbia	B-T033
.	O

Ventilatory	B-T038
failure	I-T038
in	O
muscular	B-T038
dystrophy	I-T038
is	O
caused	O
by	O
increased	O
respiratory	B-T033
load	I-T033
and	O
respiratory	B-T033
muscles	I-T033
weakness	I-T033
.	O

Respiratory	B-T033
load	I-T033
increases	O
in	O
muscular	B-T038
dystrophy	I-T038
because	O
scoliosis	B-T017
makes	O
chest	B-T033
wall	I-T033
compliance	I-T033
decrease	O
,	O
atelectasis	B-T038
and	O
fibrosis	B-T038
make	O
lung	B-T038
compliance	I-T038
decrease	O
,	O
and	O
airway	B-T038
obstruction	I-T038
makes	O
airway	B-T038
resistance	I-T038
increase	O
.	O
The	O
consequences	O
of	O
respiratory	B-T038
pump	I-T038
failure	I-T038
are	O
restrictive	B-T033
pulmonary	I-T033
function	I-T033
,	O
hypoventilation	B-T038
,	O
altered	O
thoracoabdominal	B-T082
pattern	O
,	O
hypercapnia	B-T033
,	O
dyspnoea	B-T033
,	O
impaired	O
regulation	O
of	O
breathing	O
,	O
inefficient	B-T033
cough	I-T033
and	O
sleep	B-T038
disordered	I-T038
breathing	I-T038
.	O

To	O
understand	O
the	O
mechanisms	B-T033
leading	O
to	O
respiratory	B-T033
disturbances	I-T033
in	O
patients	O
with	O
muscular	B-T038
dystrophy	I-T038
.	O
To	O
understand	O
the	O
impact	O
of	O
respiratory	B-T033
disturbances	I-T033
in	O
patients	O
with	O
muscular	B-T038
dystrophy	I-T038
.	O
To	O
provide	O
a	O
brief	O
description	O
of	O
the	O
main	O
forms	O
of	O
muscular	B-T038
dystrophy	I-T038
with	O
their	O
respiratory	B-T033
implications	I-T033
.	O

Significance	O
of	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
in	O
early	B-T170
-	I-T170
stage	I-T170
cervical	B-T038
cancer	I-T038

To	O
examine	O
characteristics	O
and	O
survival	O
outcomes	O
of	O
women	B-T098
with	O
surgically	B-T058
-	I-T058
treated	I-T058
cervical	B-T038
cancer	I-T038
exhibiting	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
.	O

We	O
utilized	O
The	O
Surveillance	B-T092
,	I-T092
Epidemiology	I-T092
,	I-T092
and	I-T092
End	I-T092
Results	I-T092
Program	I-T092
to	O
identify	O
cervical	B-T038
cancer	I-T038
patients	O
who	O
underwent	O
hysterectomy	B-T058
between	O
1973	O
and	O
2003	O
.	O

Logistic	O
regression	O
models	O
were	O
used	O
to	O
identify	O
risk	B-T033
factors	I-T033
for	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
on	O
multivariable	O
analysis	O
.	O

Association	O
of	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
and	O
cause	O
-	O
specific	O
survival	O
(	O
CSS	O
)	O
from	O
cervical	B-T038
cancer	I-T038
was	O
examined	O
with	O
Cox	B-T170
proportional	I-T170
hazard	I-T170
regression	I-T170
models	I-T170
on	O
multivariable	O
analysis	O
.	O

We	O
identified	O
837	O
(	O
4	O
.	O
9	O
%	O
)	O
cases	O
of	O
uterine	B-T038
corpus	I-T038
invasion	B-T033
and	O
16	O
,	O
237	O
(	O
95	O
.	O
1	O
%	O
)	O
cases	O
of	O
non	O
-	O
invasion	O
.	O

Median	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
14	O
.	O
0	O
years	O
.	O

There	O
were	O
1642	O
deaths	B-T038
due	O
to	O
cervical	B-T038
cancer	I-T038
.	O

Uterine	B-T038
corpus	I-T038
invasion	B-T033
was	O
independently	O
associated	O
with	O
older	O
age	O
,	O
non	O
-	O
squamous	O
histology	O
,	O
high	B-T038
-	I-T038
grade	I-T038
tumors	I-T038
,	O
large	B-T082
tumor	I-T082
size	I-T082
,	O
and	O
nodal	B-T082
metastasis	B-T038
on	O
multivariable	O
analysis	O
(	O
all	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

On	O
univariable	O
analysis	O
,	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
was	O
significantly	O
associated	O
with	O
decreased	O
CSS	O
compared	O
to	O
the	O
non	O
-	O
invasion	O
(	O
5	O
-	O
year	O
rates	O
,	O
79	O
.	O
0	O
%	O
versus	O
94	O
.	O
5	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

After	O
controlling	O
for	O
other	O
significant	O
prognostic	B-T201
factors	I-T201
,	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
remained	O
an	O
independent	O
prognostic	B-T201
factor	I-T201
for	O
decreased	O
CSS	O
(	O
adjusted	O
-	O
hazard	O
ratio	O
1	O
.	O
45	O
,	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
21	O
-	O
1	O
.	O
74	O
)	O
.	O

Among	O
stage	B-T170
T1b	I-T170
cases	O
(	O
n	O
=	O
6730	O
)	O
,	O
uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
remained	O
an	O
independent	O
prognostic	B-T201
factor	I-T201
for	O
decreased	O
CSS	O
(	O
adjusted	O
-	O
hazard	O
ratio	O
1	O
.	O
95	O
,	O
95	O
%	O
CI	O
1	O
.	O
47	O
-	O
2	O
.	O
60	O
)	O
.	O

Uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
was	O
significantly	O
associated	O
with	O
decreased	O
CSS	O
in	O
stage	B-T170
T1b1	I-T170
disease	B-T038
(	O
74	O
.	O
5	O
%	O
versus	O
90	O
.	O
7	O
%	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
and	O
in	O
stage	B-T170
T1b2	I-T170
disease	B-T038
(	O
67	O
.	O
0	O
%	O
versus	O
79	O
.	O
5	O
%	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
.	O

Uterine	B-T038
corpus	I-T038
tumor	I-T038
invasion	B-T033
is	O
an	O
independent	O
prognostic	B-T201
factor	I-T201
for	O
decreased	O
survival	O
of	O
women	B-T098
with	O
early	B-T170
-	I-T170
stage	I-T170
cervical	B-T038
cancer	I-T038
.	O

Efficient	O
gene	B-T062
targeting	I-T062
in	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
-	O
deficient	O
Lipomyces	B-T204
starkeyi	I-T204
strains	O

Microbial	O
lipids	B-T103
are	O
sustainable	O
feedstock	O
for	O
the	O
production	O
of	O
oleochemicals	B-T103
and	O
biodiesel	B-T103
.	O

Oleaginous	B-T204
yeasts	I-T204
have	O
recently	O
been	O
proposed	O
as	O
alternative	O
lipid	B-T103
producers	B-T204
to	O
plants	B-T204
and	O
animals	B-T204
to	O
promote	O
sustainability	O
in	O
the	O
chemical	B-T092
and	O
fuel	O
industries	O
.	O

The	O
oleaginous	B-T204
yeast	I-T204
Lipomyces	B-T204
starkeyi	I-T204
has	O
great	O
industrial	O
potential	O
as	O
an	O
excellent	O
lipid	B-T103
producer	B-T204
.	O

However	O
,	O
improvement	O
of	O
its	O
lipid	B-T103
productivity	O
is	O
essential	O
for	O
the	O
cost	O
-	O
effective	O
production	O
of	O
oleochemicals	B-T103
and	O
fuels	O
.	O

Genetic	B-T062
and	O
metabolic	B-T062
engineering	I-T062
of	O
L	B-T204
.	I-T204

starkeyi	I-T204
via	O
gene	O
manipulation	O
techniques	O
may	O
result	O
in	O
improvements	O
in	O
lipid	B-T103
production	O
and	O
our	O
understanding	O
of	O
the	O
mechanisms	O
behind	O
lipid	B-T103
biosynthesis	O
pathways	O
.	O

We	O
previously	O
described	O
an	O
integrative	O
transformation	O
system	O
using	O
a	O
drug	B-T103
-	O
resistant	O
marker	B-T038
for	O
L	B-T204
.	I-T204

starkeyi	I-T204
.	O

However	O
,	O
gene	B-T062
-	I-T062
targeting	I-T062
frequencies	O
were	O
very	O
low	O
because	O
non	B-T038
-	I-T038
homologous	I-T038
recombination	I-T038
is	O
probably	O
predominant	O
in	O
L	B-T204
.	I-T204

starkeyi	I-T204
.	O

Genetic	B-T062
engineering	I-T062
tools	I-T062
for	O
L	B-T204
.	I-T204

starkeyi	I-T204
have	O
not	O
been	O
sufficiently	O
developed	O
.	O

In	O
this	O
study	O
,	O
we	O
describe	O
a	O
new	O
genetic	B-T062
tool	I-T062
and	O
its	O
application	O
in	O
L	B-T204
.	I-T204

starkeyi	I-T204
.	O

To	O
develop	O
a	O
highly	O
efficient	O
gene	B-T062
-	I-T062
targeting	I-T062
system	I-T062
for	O
L	B-T204
.	I-T204

starkeyi	I-T204
,	O
we	O
constructed	O
a	O
series	O
of	O
mutants	B-T017
by	O
disrupting	O
genes	B-T017
for	O
LsKu70p	B-T103
,	O
LsKu80p	B-T103
,	O
and	O
/	O
or	O
LsLig4p	B-T103
,	O
which	O
share	O
homology	O
with	O
other	O
yeasts	B-T204
Ku70p	B-T103
,	O
Ku80p	B-T103
,	O
and	O
Lig4p	B-T103
,	O
respectively	O
,	O
being	O
involved	O
in	O
non	O
-	O
homologous	O
end	O
-	O
joining	O
pathway	O
.	O

Deletion	B-T038
of	O
the	O
LsLIG4	B-T017
gene	I-T017
dramatically	O
improved	O
the	O
homologous	B-T038
recombination	I-T038
efficiency	O
(	O
80	O
.	O
0	O
%	O
)	O
at	O
the	O
LsURA3	B-T017
locus	B-T082
compared	O
with	O
that	O
in	O
the	O
wild	B-T017
-	I-T017
type	I-T017
strain	O
(	O
1	O
.	O
4	O
%	O
)	O
,	O
when	O
2000	B-T082
-	I-T082
bp	I-T082
homologous	I-T082
flanking	I-T082
regions	I-T082
were	O
used	O
.	O

The	O
homologous	B-T038
recombination	I-T038
efficiencies	O
of	O
the	O
double	O
mutant	B-T017
∆l	B-T017
sku70∆lslig4	I-T017
and	O
the	O
triple	O
mutant	B-T017
∆lsku70∆lsku80∆lslig4	B-T017
were	O
also	O
markedly	O
enhanced	O
.	O

Therefore	O
,	O
the	O
L	B-T204
.	I-T204

starkeyi	I-T204
∆lslig4	B-T017
background	O
strains	O
have	O
promise	O
as	O
efficient	O
recipient	O
strains	O
for	O
genetic	B-T062
and	O
metabolic	B-T062
engineering	I-T062
approaches	O
in	O
this	O
yeast	B-T204
.	O

Evaluating	O
clinical	O
,	O
dietary	B-T168
and	O
psychological	O
risk	B-T033
factors	I-T033
for	O
relapse	O
of	O
ulcerative	B-T038
colitis	I-T038
in	O
clinical	O
,	O
endoscopic	B-T082
and	O
histological	O
remission	O

The	O
literature	O
on	O
possible	O
factors	O
that	O
could	O
trigger	O
a	O
relapse	O
in	O
patients	O
with	O
ulcerative	B-T038
colitis	I-T038
(	O
UC	B-T038
)	O
in	O
clinical	O
,	O
endoscopic	B-T082
and	O
histological	O
remission	O
on	O
long	O
term	O
follow	B-T058
up	I-T058
is	O
scarce	O
.	O

To	O
determine	O
the	O
relapse	O
rate	O
in	O
patients	O
with	O
UC	B-T038
in	O
clinical	O
,	O
endoscopic	B-T082
and	O
histological	O
remission	O
and	O
identify	O
factors	O
that	O
may	O
influence	O
the	O
risk	O
of	O
relapse	O
.	O

Patients	O
with	O
UC	B-T038
in	O
clinical	O
,	O
endoscopic	B-T082
and	O
histological	O
remission	O
were	O
enrolled	O
between	O
January	O
-	O
July	O
2010	O
and	O
followed	B-T058
up	I-T058
for	O
1	O
year	O
to	O
determine	O
the	O
effect	O
of	O
clinical	O
,	O
dietary	B-T168
and	O
psychological	O
factors	B-T033
on	O
relapse	O
.	O

Information	O
regarding	O
factors	O
that	O
may	O
affect	O
relapse	O
such	O
as	O
infection	B-T038
,	O
antibiotic	B-T103
or	O
NSAIDs	B-T103
use	O
and	O
any	O
other	O
factor	O
which	O
the	O
patient	O
felt	O
important	O
,	O
and	O
compliance	O
with	O
medications	B-T058
was	O
obtained	O
.	O

97	O
patients	O
(	O
59	O
males	B-T098
,	O
mean	O
age	O
39	O
+	O
11	O
.	O
9	O
years	O
)	O
were	O
followed	B-T058
up	I-T058
for	O
a	O
mean	O
duration	O
of	O
9	O
+	O
2	O
.	O
3	O
months	O
.	O

18	O
(	O
18	O
.	O
6	O
%	O
)	O
relapsed	O
with	O
the	O
median	O
time	O
to	O
relapse	O
being	O
3	O
.	O
5	O
months	O
.	O

On	O
univariate	O
analysis	O
more	O
relapsers	O
had	O
significantly	O
higher	O
NSAIDs	B-T103
use	O
within	O
15	O
days	O
of	O
relapse	O
,	O
respiratory	B-T038
tract	I-T038
infection	I-T038
within	O
4	O
weeks	O
,	O
use	O
of	O
steroids	B-T103
more	O
than	O
once	O
in	O
past	O
,	O
higher	O
consumption	B-T038
of	O
calcium	B-T103
,	O
riboflavin	B-T103
,	O
vitamin	B-T103
A	I-T103
and	O
lower	O
consumption	B-T038
of	O
sugars	B-T103
.	O

On	O
multivariate	O
analysis	O
,	O
NSAIDs	B-T103
use	O
[	O
HR	O
(	O
95	O
%	O
CI	O
)	O
:	O
6	O
.	O
41	O
(	O
1	O
.	O
88	O
-	O
21	O
.	O
9	O
)	O
]	O
and	O
intake	O
of	O
Vitamin	B-T103
A	I-T103
[	O
HR	O
(	O
95	O
%	O
CI	O
)	O
:	O
1	O
.	O
008	O
(	O
1	O
.	O
000	O
-	O
1	O
.	O
016	O
)	O
]	O
were	O
statistically	O
significant	O
predictors	O
of	O
relapse	O
.	O

With	O
a	O
relapse	O
rate	O
of	O
18	O
.	O
6	O
%	O
over	O
a	O
follow	B-T058
up	I-T058
of	O
9	O
months	O
in	O
patients	O
with	O
UC	B-T038
in	O
clinical	O
,	O
endoscopic	B-T082
and	O
histological	O
remission	O
,	O
independent	O
predictors	O
of	O
relapse	O
were	O
history	O
of	O
NSAIDs	B-T103
use	O
within	O
15	O
days	O
of	O
relapse	O
and	O
higher	O
intake	O
of	O
Vitamin	B-T103
A	I-T103
.	O

High	O
Performance	O
Reduction	O
of	O
H2O2	B-T103
with	O
an	O
Electron	B-T038
Transport	I-T038
Decaheme	B-T103
Cytochrome	I-T103
on	O
a	O
Porous	O
ITO	B-T103
Electrode	O

The	O
decaheme	B-T103
cytochrome	I-T103
MtrC	I-T103
from	O
Shewanella	B-T007
oneidensis	I-T007
MR	I-T007
-	I-T007
1	I-T007
immobilized	B-T103
on	O
an	O
ITO	B-T103
electrode	O
displays	O
unprecedented	O
H2O2	B-T103
reduction	O
activity	O
.	O

Although	O
MtrC	B-T103
showed	O
lower	O
peroxidase	B-T038
activity	I-T038
in	O
solution	O
compared	O
to	O
horseradish	B-T103
peroxidase	I-T103
,	O
the	O
ten	O
heme	B-T103
cofactors	B-T103
enable	O
excellent	O
electronic	O
communication	O
and	O
a	O
superior	O
activity	O
on	O
the	O
electrode	O
surface	O
.	O

A	O
hierarchical	O
ITO	B-T103
electrode	O
enabled	O
optimal	O
immobilization	O
of	O
MtrC	B-T103
and	O
a	O
high	O
current	O
density	O
of	O
1	O
mA	O
cm	O
(	O
-	O
2	O
)	O
at	O
0	O
.	O
4	O
V	O
vs	O
SHE	O
could	O
be	O
obtained	O
at	O
pH	O
6	O
.	O
5	O
(	O
Eonset	O
=	O
0	O
.	O
72	O
V	O
)	O
.	O

UV	O
-	O
visible	O
and	O
Resonance	B-T058
Raman	I-T058
spectroelectrochemical	I-T058
studies	I-T058
suggest	O
the	O
formation	O
of	O
a	O
high	O
valent	O
iron	O
-	O
oxo	O
species	O
as	O
the	O
catalytic	O
intermediate	O
.	O

Our	O
findings	O
demonstrate	O
the	O
potential	O
of	O
multiheme	B-T103
cytochromes	I-T103
to	O
catalyze	O
technologically	O
relevant	O
reactions	O
and	O
establish	O
MtrC	B-T103
as	O
a	O
new	O
benchmark	O
in	O
biotechnological	B-T091
H2O2	B-T103
reduction	O
with	O
scope	O
for	O
applications	O
in	O
fuel	O
cells	O
and	O
biosensors	O
.	O

Ophthalmic	B-T033
Manifestations	I-T033
of	O
Facial	B-T082
Dog	B-T037
Bites	I-T037
in	O
Children	O

To	O
characterize	O
ophthalmic	B-T033
manifestations	I-T033
and	O
periocular	B-T037
injuries	I-T037
of	O
pediatric	O
facial	B-T082
dog	B-T037
bites	I-T037
.	O

A	O
retrospective	O
review	B-T170
of	O
all	O
children	O
younger	O
than	O
18	O
years	O
who	O
sought	O
medical	O
attention	B-T038
after	O
a	O
dog	B-T037
bite	I-T037
to	O
the	O
face	B-T082
between	O
January	O
1	O
,	O
2003	O
and	O
May	O
22	O
,	O
2014	O
was	O
performed	O
at	O
a	O
large	O
tertiary	O
pediatric	B-T092
hospital	I-T092
.	O

Data	O
on	O
type	O
and	O
location	B-T033
of	I-T033
injury	I-T033
,	O
surgical	B-T033
intervention	I-T033
,	O
and	O
complications	B-T038
were	O
collected	O
.	O

A	O
total	O
of	O
1	O
,	O
989	O
children	O
aged	O
0	O
.	O
19	O
to	O
17	O
years	O
were	O
identified	O
with	O
dog	B-T037
bite	I-T037
s	I-T037
.	O

Dog	B-T037
bite	I-T037
s	I-T037
to	O
the	O
face	B-T082
occurred	O
in	O
most	O
patients	O
(	O
n	O
=	O
1	O
,	O
414	O
[	O
71	O
%	O
]	O
)	O
.	O

Of	O
those	O
children	O
with	O
facial	B-T082
dog	B-T037
bite	I-T037
injuries	I-T037
,	O
230	O
(	O
16	O
%	O
)	O
suffered	B-T038
ophthalmic	B-T033
manifestations	I-T033
.	O

The	O
average	O
age	O
was	O
4	O
.	O
3	O
years	O
.	O

Eyelid	B-T037
injuries	I-T037
occurred	O
in	O
227	O
(	O
99	O
%	O
)	O
of	O
children	O
,	O
47	O
(	O
20	O
%	O
)	O
sustained	O
canalicular	B-T022
system	I-T022
injuries	B-T037
,	O
3	O
(	O
1	O
.	O
3	O
%	O
)	O
suffered	B-T038
corneal	B-T037
abrasions	I-T037
,	O
and	O
2	O
patients	O
sustained	O
facial	B-T082
nerve	B-T037
injury	I-T037
resulting	O
in	O
lagophthalmos	B-T038
.	O

No	O
patients	O
suffered	B-T038
vision	B-T033
loss	I-T033
.	O

Complications	B-T038
occurred	O
in	O
32	O
patients	O
(	O
14	O
%	O
)	O
,	O
with	O
the	O
most	O
common	O
being	O
epiphora	B-T204
in	O
9	O
patients	O
(	O
28	O
%	O
)	O
,	O
upper	O
eyelid	O
ptosis	O
in	O
8	O
(	O
25	O
%	O
)	O
,	O
and	O
prominent	O
scar	O
formation	O
in	O
4	O
patients	O
(	O
13	O
%	O
)	O
.	O

Thirteen	O
children	O
(	O
5	O
.	O
7	O
%	O
)	O
needed	O
one	O
or	O
more	O
secondary	B-T058
procedure	I-T058
to	O
correct	O
complications	B-T038
.	O

The	O
authors	B-T097
report	B-T170
the	O
clinical	O
features	O
and	O
management	O
on	O
the	O
largest	O
series	O
of	O
ophthalmic	B-T037
and	O
periocular	B-T037
injuries	I-T037
associated	O
with	O
pediatric	O
facial	B-T082
dog	B-T037
bite	I-T037
s	I-T037
.	O

These	O
injuries	B-T037
occur	O
in	O
about	O
1	O
in	O
6	O
dog	B-T037
bite	I-T037
s	I-T037
to	O
the	O
face	B-T082
and	O
primarily	O
involve	O
the	O
ocular	B-T017
adnexa	I-T017
.	O

Despite	O
early	O
and	O
appropriate	O
surgical	B-T058
management	I-T058
,	O
complications	B-T038
and	O
the	O
need	O
for	O
revision	B-T058
surgery	I-T058
are	O
relatively	O
common	O
.	O

Blastocystis	B-T204
subtyping	I-T204
and	O
its	O
association	O
with	O
intestinal	B-T038
parasites	I-T038
in	O
children	O
from	O
different	O
geographical	B-T082
regions	I-T082
of	I-T082
Colombia	I-T082

Blastocystis	B-T204
is	O
a	O
common	O
enteric	B-T033
protist	I-T033
colonizing	I-T033
probably	O
more	O
than	O
1	O
billion	O
people	B-T098
with	O
a	O
large	O
variety	O
of	O
non	O
-	O
human	O
hosts	O
.	O

Remarkable	O
genetic	O
diversity	O
has	O
been	O
observed	O
,	O
leading	O
to	O
the	O
subdivision	B-T170
of	I-T170
the	I-T170
genus	I-T170
into	O
multiple	B-T170
subtypes	I-T170
(	O
ST	B-T170
)	O
,	O
some	O
of	O
which	O
are	O
exclusively	O
found	O
in	O
non	O
-	O
human	O
hosts	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
distribution	O
of	O
Blastocystis	B-T204
STs	I-T204
/	O
18S	B-T017
alleles	I-T017
in	O
symptomatic	O
(	O
abdominal	B-T033
pain	I-T033
,	O
anal	B-T033
pruritus	I-T033
,	O
diarrhea	B-T033
,	O
headache	B-T033
,	O
nauseas	B-T033
and	O
/	O
or	O
vomit	B-T033
)	O
and	O
asymptomatic	B-T033
children	O
from	O
nine	O
geographical	B-T082
regions	I-T082
of	I-T082
Colombia	I-T082
.	O

A	O
total	O
of	O
2026	O
fecal	B-T058
samples	I-T058
were	O
collected	O
as	O
part	O
of	O
a	O
national	O
survey	O
to	O
estimate	O
the	O
frequency	O
of	O
intestinal	B-T038
parasites	I-T038
in	O
children	O
.	O

A	O
set	O
of	O
256	O
samples	O
that	O
were	O
Blastocystis	B-T204
positive	I-T204
was	O
finally	O
selected	O
.	O

The	O
samples	O
were	O
submitted	O
to	O
DNA	B-T062
extraction	I-T062
,	O
Real	B-T062
Time	I-T062
PCR	I-T062
and	O
sequencing	B-T058
using	O
Blastocystis	O
-	O
specific	O
primers	B-T103
targeting	O
the	O
small	B-T017
subunit	I-T017
rRNA	B-T017
gene	I-T017
for	O
ST	B-T058
identification	I-T058
.	O

DNA	B-T103
of	O
Ascaris	B-T204
lumbricoides	I-T204
(	O
16	O
.	O
4	O
%	O
)	O
,	O
Trichuris	B-T204
trichiura	I-T204
(	O
8	O
.	O
2	O
%	O
)	O
,	O
hookworms	B-T204
(	O
Necator	B-T204
americanus	I-T204
/	O
Ancylostoma	B-T204
duodenale	I-T204
)	O
(	O
7	O
.	O
3	O
%	O
)	O
,	O
Giardia	B-T204
duodenalis	I-T204
(	O
23	O
.	O
1	O
%	O
)	O
,	O
Entamoeba	B-T204
complex	I-T204
(	O
82	O
%	O
)	O
,	O
Entamoeba	B-T204
coli	I-T204
(	O
55	O
%	O
)	O
,	O
Hymenolepis	B-T204
nana	I-T204
(	O
0	O
.	O
8	O
%	O
)	O
,	O
Endolimax	B-T204
nana	I-T204
(	O
33	O
.	O
2	O
%	O
)	O
and	O
Neobalantidium	B-T204
coli	I-T204
(	O
2	O
.	O
7	O
%	O
)	O
was	O
detected	O
in	O
the	O
Blastocystis	B-T204
-	O
positive	B-T033
samples	I-T033
.	O

We	O
detected	O
ST1	B-T204
(	O
21	O
.	O
4	O
%	O
)	O
,	O
ST2	B-T204
(	O
19	O
.	O
5	O
%	O
)	O
,	O
ST3	B-T204
(	O
55	O
.	O
5	O
%	O
)	O
,	O
ST4	B-T204
(	O
0	O
.	O
8	O
%	O
)	O
,	O
ST6	B-T204
(	O
2	O
%	O
)	O
and	O
ST7	B-T204
(	O
0	O
.	O
8	O
%	O
)	O
;	O
alleles	B-T017
1	O
,	O
2	O
,	O
4	O
,	O
81	O
,	O
82	O
and	O
83	O
for	O
ST1	B-T204
;	O
alleles	B-T017
9	O
,	O
11	O
,	O
12	O
,	O
15	O
,	O
67	O
,	O
71	O
and	O
73	O
for	O
ST2	B-T204
;	O
alleles	B-T017
34	O
,	O
36	O
,	O
38	O
,	O
45	O
,	O
49	O
,	O
55	O
,	O
134	O
and	O
128	O
for	O
ST3	B-T204
;	O
allele	B-T017
42	O
for	O
ST4	B-T204
;	O
allele	B-T017
122	O
for	O
ST6	B-T204
,	O
and	O
allele	B-T017
142	O
for	O
ST7	B-T204
.	O

Further	O
studies	O
implementing	O
high	O
-	O
resolution	O
molecular	B-T201
markers	I-T201
are	O
necessary	O
to	O
understand	O
the	O
dynamics	O
of	O
Blastocystis	B-T204
transmission	O
and	O
the	O
role	O
of	O
this	O
Stramenopila	B-T204
in	O
health	O
and	O
disease	O
.	O

Did	O
municipal	O
solid	O
waste	O
landfill	B-T082
have	O
obvious	O
influence	O
on	O
polychlorinated	B-T103
dibenzo	I-T103
-	I-T103
p	I-T103
-	I-T103
dioxins	I-T103
and	O
polychlorinated	B-T103
dibenzofurans	I-T103
(	O
PCDD	B-T103
/	O
Fs	B-T103
)	O
in	O
ambient	O
air	O
:	O
A	O
case	B-T170
study	I-T170
in	O
East	B-T082
China	I-T082

Municipal	O
solid	O
waste	O
(	O
MSW	O
)	O
landfill	B-T082
was	O
a	O
main	O
way	O
to	O
disposal	O
of	O
MSW	O
and	O
almost	O
95	O
%	O
of	O
MSW	O
was	O
disposed	O
by	O
landfills	B-T082
in	O
the	O
world	B-T098
.	O

In	O
order	O
to	O
understand	O
the	O
influence	O
of	O
MSW	O
landfill	B-T082
on	O
polychlorinated	B-T103
dibenzo	I-T103
-	I-T103
p	I-T103
-	I-T103
dioxins	I-T103
and	O
polychlorinated	B-T103
dibenzofurans	I-T103
(	O
PCDD	B-T103
/	O
Fs	B-T103
)	O
in	O
surrounding	O
atmosphere	O
,	O
42	O
ambient	O
air	O
samples	O
were	O
collected	O
and	O
analyzed	B-T062
from	O
surrounding	B-T082
sites	I-T082
,	O
background	B-T082
site	I-T082
,	O
upwind	B-T082
site	I-T082
and	O
downwind	B-T082
site	I-T082
of	O
a	O
MSW	O
landfill	B-T082
in	O
East	B-T082
China	I-T082
.	O

The	O
results	O
of	O
present	O
study	B-T062
were	O
summarized	O
as	O
follows	O
.	O

(	O
1	O
)	O
The	O
total	O
concentrations	O
of	O
PCDD	B-T103
/	O
Fs	B-T103
(	O
∑	O
PCDD	B-T103
/	O
Fs	B-T103
)	O
in	O
ambient	O
air	O
from	O
surrounding	B-T082
sites	I-T082
,	O
background	B-T082
site	I-T082
,	O
upwind	B-T082
site	I-T082
and	O
downwind	B-T082
site	I-T082
were	O
2	O
.	O
215±1	O
.	O
004	O
,	O
2	O
.	O
058±0	O
.	O
458	O
,	O
2	O
.	O
617±1	O
.	O
092	O
and	O
1	O
.	O
822±0	O
.	O
566pgNm	O
(	O
-	O
3	O
)	O
,	O
respectively	O
.	O

(	O
2	O
)	O
The	O
toxic	O
equivalent	O
concentrations	O
(	O
TEQ	O
)	O
of	O
PCDD	B-T103
/	O
Fs	B-T103
in	O
ambient	O
air	O
from	O
surrounding	B-T082
sites	I-T082
,	O
background	B-T082
site	I-T082
,	O
upwind	B-T082
site	I-T082
and	O
downwind	B-T082
site	I-T082
were	O
0	O
.	O
103±0	O
.	O
017	O
,	O
0	O
.	O
096±0	O
.	O
015	O
,	O
0	O
.	O
120±0	O
.	O
024	O
and	O
0	O
.	O
108±0	O
.	O
014pg	O
I	O
-	O
TEQNm	O
(	O
-	O
3	O
)	O
,	O
respectively	O
.	O

(	O
3	O
)	O
The	O
congener	B-T058
profiles	I-T058
,	O
∑	O
PCDD	B-T103
/	O
Fs	B-T103
and	O
TEQ	O
between	O
background	O
atmosphere	O
and	O
surrounding	O
atmosphere	O
of	O
landfill	B-T082
did	O
not	O
show	O
statistically	O
significant	O
difference	O
.	O

(	O
4	O
)	O
The	O
∑	O
PCDD	B-T103
/	O
Fs	B-T103
and	O
TEQ	O
in	O
ambient	O
air	O
of	O
downwind	B-T082
site	I-T082
were	O
not	O
higher	O
than	O
that	O
of	O
upwind	B-T082
site	I-T082
,	O
suggesting	O
that	O
studied	O
landfill	B-T082
did	O
not	O
have	O
obvious	O
influence	O
on	O
PCDD	B-T103
/	O
Fs	B-T103
in	O
ambient	O
air	O
from	O
downwind	B-T082
site	I-T082
.	O

(	O
5	O
)	O
The	O
95th	O
percentile	O
carcinogenic	O
risk	O
(	O
CR	O
)	O
of	O
PCDD	B-T103
/	O
Fs	B-T103
in	O
ambient	O
air	O
from	O
s	O
urrounding	B-T082
sites	I-T082
,	O
background	B-T082
site	I-T082
,	O
upwind	B-T082
site	I-T082
and	O
downwind	B-T082
site	I-T082
were	O
8	O
.	O
03×10	O
(	O
-	O
9	O
)	O
,	O
7	O
.	O
57×10	O
(	O
-	O
9	O
)	O
,	O
9	O
.	O
69×10	O
(	O
-	O
9	O
)	O
and	O
8	O
.	O
15×10	O
(	O
-	O
9	O
)	O
,	O
respectively	O
,	O
which	O
were	O
much	O
lower	O
than	O
the	O
threshold	O
value	O
of	O
CR	O
(	O
10	O
(	O
-	O
6	O
)	O
)	O
,	O
suggesting	O
that	O
studied	O
landfill	B-T082
did	O
not	O
influence	O
the	O
CR	O
of	O
PCDD	B-T103
/	O
Fs	B-T103
in	O
surrounding	O
atmosphere	O
and	O
negligible	O
cancer	O
risk	O
occurred	O
.	O

(	O
6	O
)	O
The	O
non	O
-	O
carcinogenic	O
risk	O
(	O
non	O
-	O
CR	O
)	O
analysis	B-T062
indicated	O
that	O
landfill	B-T082
did	O
not	O
have	O
influence	O
on	O
the	O
non	O
-	O
CR	O
of	O
PCDD	B-T103
/	O
Fs	B-T103
in	O
surrounding	O
atmosphere	O
and	O
no	O
obvious	O
non	O
-	O
carcinogenic	O
effects	O
developed	O
.	O

Methodological	O
considerations	O
for	O
designing	O
a	O
community	O
water	O
fluoridation	O
cessation	O
study	B-T062

High	O
-	O
quality	O
,	O
up	O
-	O
to	O
-	O
date	O
research	B-T062
on	O
community	O
water	O
fluoridation	O
(	O
CWF	O
)	O
,	O
and	O
especially	O
on	O
the	O
implications	O
of	O
CWF	O
cessation	O
for	O
dental	B-T058
health	I-T058
,	O
is	O
limited	O
.	O

Although	O
CWF	O
cessation	O
studies	B-T062
have	O
been	O
conducted	O
,	O
they	O
are	O
few	O
in	O
number	O
;	O
one	O
of	O
the	O
major	O
reasons	O
is	O
the	O
methodological	O
complexity	O
of	O
conducting	O
such	O
a	O
study	B-T062
.	O

This	O
article	O
draws	O
on	O
a	O
systematic	B-T170
review	I-T170
of	O
existing	O
cessation	O
studies	B-T062
(	O
n	O
=	O
15	O
)	O
to	O
explore	O
methodological	O
considerations	O
of	O
conducting	O
CWF	O
cessation	O
studies	B-T062
in	O
future	O
.	O

We	O
review	O
nine	O
important	O
methodological	O
aspects	O
(	O
study	B-T062
design	I-T062
,	O
comparison	O
community	O
,	O
target	B-T098
population	I-T098
,	O
time	O
frame	O
,	O
sampling	B-T170
strategy	I-T170
,	O
clinical	O
indicators	O
,	O
assessment	O
criteria	O
,	O
covariates	O
and	O
biomarkers	B-T201
)	O
and	O
provide	O
recommendations	O
for	O
planning	B-T058
future	O
CWF	O
cessation	O
studies	B-T062
that	O
examine	O
effects	O
on	O
dental	B-T038
caries	I-T038
.	O

There	O
is	O
no	O
one	O
ideal	O
study	B-T062
design	I-T062
to	O
answer	O
a	O
research	O
question	O
.	O

However	O
,	O
recommendations	O
proposed	O
regarding	O
methodological	O
aspects	O
to	O
conduct	O
an	O
epidemiological	B-T062
study	I-T062
to	O
observe	O
the	O
effects	O
of	O
CWF	O
cessation	O
on	O
dental	B-T038
caries	I-T038
,	O
coupled	O
with	O
our	O
identification	O
of	O
important	O
methodological	O
gaps	O
,	O
will	O
be	O
useful	O
for	O
researchers	B-T097
who	O
are	O
looking	O
to	O
optimize	O
resources	O
to	O
conduct	O
such	O
a	O
study	B-T062
with	O
standards	O
of	O
rigour	O
.	O

Central	B-T038
Myxoma	I-T038
/	O
Myxofibroma	B-T038
of	O
the	O
Jaws	B-T017
:	O
A	O
Clinico	B-T092
-	O
Epidemiologic	O
Review	B-T170

Myxomas	B-T038
are	O
a	O
group	O
of	O
benign	O
rare	B-T038
tumors	I-T038
of	O
connective	B-T017
-	I-T017
tissue	I-T017
origin	O
that	O
occur	O
in	O
both	O
hard	B-T017
(	I-T017
central	I-T017
)	I-T017
and	O
soft	B-T017
tissues	I-T017
of	O
the	O
body	B-T204
.	O

The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
highlight	O
our	O
experience	O
in	O
the	O
management	O
of	O
central	O
myxoma	O
of	O
the	O
jaw	O
,	O
with	O
emphasis	O
on	O
its	O
clinic	B-T092
-	O
epidemiologic	O
features	O
as	O
seen	O
in	O
our	O
environment	B-T082
.	O

All	O
patients	O
who	O
were	O
managed	O
for	O
central	O
myxoma	O
of	O
the	O
jaw	O
at	O
the	O
Oral	B-T092
and	I-T092
Maxillofacial	I-T092
Surgery	I-T092
department	I-T092
of	O
a	O
regional	B-T092
University	I-T092
Teaching	I-T092
Hospital	I-T092
between	O
September	O
1997	O
and	O
October	O
2015	O
were	O
retrospectively	B-T062
studied	I-T062
.	O

Details	O
sourced	O
included	O
age	O
,	O
sex	O
,	O
site	B-T082
of	I-T082
tumor	I-T082
,	O
duration	O
,	O
signs	B-T033
/	I-T033
symptoms	I-T033
,	O
treatment	B-T033
given	I-T033
,	O
and	O
complications	B-T038
.	O

Data	O
were	O
analyzed	B-T062
using	O
Statistical	B-T170
Package	I-T170
for	I-T170
Social	I-T170
Sciences	I-T170
(	I-T170
SPSS	I-T170
)	I-T170
version	I-T170
16	I-T170
(	O
SPSS	B-T092
Inc	I-T092
.	O
,	O
Chicago	B-T082
,	O
IL	B-T082
,	O
USA	B-T082
)	O
and	O
Microsoft	B-T170
Excel	I-T170
2007	I-T170
(	O
Microsoft	B-T092
,	O
Redmond	B-T082
,	O
WA	B-T082
,	O
USA	B-T082
)	O
.	O

Results	O
from	O
descriptive	O
statistics	O
were	O
represented	O
in	O
the	O
form	O
of	O
tables	B-T170
and	O
charts	B-T170
,	O
with	O
a	O
test	B-T170
for	I-T170
significance	I-T170
(	O
ρ	O
)	O
using	O
Pearson	B-T170
Chi	I-T170
-	I-T170
square	I-T170
(	O
χ	O
(	O
2	O
)	O
)	O
set	O
at	O
0	O
.	O
05	O
.	O

A	O
total	O
of	O
16	O
patients	O
were	O
managed	O
within	O
the	O
period	O
reviewed	O
,	O
consisting	O
of	O
10	O
(	O
62	O
.	O
5	O
%	O
)	O
females	O
and	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
males	O
,	O
giving	O
a	O
male	O
-	O
to	O
-	O
female	O
ratio	O
of	O
1	O
:	O
1	O
.	O
7	O
.	O

The	O
ages	O
of	O
patients	O
ranged	O
from	O
5	O
to	O
70	O
years	O
,	O
with	O
a	O
mean	O
of	O
27	O
.	O
06±15	O
.	O
45	O
years	O
.	O

The	O
mandible	B-T017
accounted	O
for	O
nine	O
(	O
56	O
.	O
3	O
%	O
)	O
cases	O
and	O
the	O
maxilla	B-T017
for	O
six	O
(	O
37	O
.	O
5	O
%	O
)	O
cases	O
,	O
while	O
a	O
combination	O
of	O
the	O
maxilla	B-T017
and	O
the	O
zygoma	B-T017
were	O
involved	O
in	O
one	O
(	O
6	O
.	O
3	O
%	O
)	O
case	O
.	O

Bucco	B-T017
-	I-T017
lingual	I-T017
or	O
bucco	B-T017
-	I-T017
palatal	I-T017
expansion	B-T082
were	O
the	O
most	O
common	O
presentation	O
(	O
six	O
[	O
46	O
.	O
2	O
%	O
]	O
cases	O
each	O
)	O
.	O

Histological	O
assessment	B-T058
of	O
tissue	B-T017
specimens	I-T017
showed	O
that	O
fibromyxoma	B-T038
accounted	O
for	O
seven	O
(	O
43	O
.	O
8	O
%	O
)	O
cases	O
,	O
while	O
the	O
remaining	O
nine	O
(	O
56	O
.	O
3	O
%	O
)	O
cases	O
were	O
diagnosed	B-T033
as	O
myxoma	B-T038
.	O

All	O
patients	O
had	O
jaw	O
resections	O
,	O
and	O
these	O
consisted	O
of	O
mandibulectomies	B-T058
in	O
nine	O
(	O
60	O
.	O
0	O
%	O
)	O
patients	O
and	O
maxillectomies	B-T058
in	O
six	O
(	O
40	O
.	O
0	O
%	O
)	O
patients	O
.	O

The	O
duration	O
of	O
hospital	O
stay	O
ranged	O
from	O
5	O
to	O
29	O
days	O
,	O
with	O
a	O
mean	O
of	O
17	O
.	O
86±7	O
.	O
68	O
days	O
.	O

Complications	B-T038
were	O
noted	O
in	O
three	O
patients	O
,	O
and	O
all	O
were	O
surgical	B-T038
wound	I-T038
infections	I-T038
.	O

Most	O
patients	O
in	O
our	O
environment	B-T082
present	O
late	O
with	O
large	O
tumors	O
and	O
are	O
usually	O
not	O
compliant	O
with	O
follow	B-T058
-	I-T058
up	I-T058
review	O
.	O

Thus	O
,	O
a	O
radical	O
approach	O
is	O
favored	O
in	O
most	O
patients	O
.	O

Pediatric	O
Hypovitaminosis	B-T038
D	I-T038
:	O
Molecular	O
Perspectives	O
and	O
Clinical	O
Implications	O

Vitamin	B-T103
D	I-T103
,	O
a	O
secosteroid	B-T103
,	O
is	O
essential	O
for	O
the	O
development	B-T038
and	O
maintenance	O
of	O
healthy	O
bone	B-T017
in	O
both	O
the	O
adult	O
and	O
pediatric	O
populations	B-T098
.	O

Low	O
level	O
of	O
25	B-T103
-	I-T103
hydroxy	I-T103
vitamin	I-T103
D	I-T103
(	O
25	B-T103
-	I-T103
(	I-T103
OH	I-T103
)	I-T103
-	I-T103
D	I-T103
)	O
is	O
highly	O
prevalent	O
in	O
children	O
worldwide	O
and	O
has	O
been	O
linked	O
to	O
various	O
adverse	B-T038
health	O
outcomes	O
including	O
rickets	B-T038
,	O
osteomalacia	B-T038
,	O
osteomalacic	B-T038
myopathy	I-T038
,	O
sarcopenia	B-T038
,	O
and	O
weakness	B-T033
,	O
growth	B-T038
retardation	I-T038
,	O
hypocalcemia	B-T038
,	O
seizure	B-T033
and	O
tetany	B-T038
,	O
autism	B-T038
,	O
cardiovascular	B-T038
diseases	I-T038
,	O
diabetes	B-T038
mellitus	I-T038
,	O
cancers	B-T038
(	O
prostate	B-T038
,	O
colon	B-T038
,	O
breast	B-T038
)	O
,	O
infectious	B-T038
diseases	I-T038
(	O
viral	B-T038
,	O
tuberculosis	B-T038
)	O
,	O
and	O
autoimmune	B-T038
diseases	I-T038
,	I-T038
such	O
as	O
multiple	B-T038
sclerosis	I-T038
and	O
Hashimoto	B-T038
'	I-T038
s	I-T038
thyroiditis	I-T038
.	O

Risk	B-T033
factors	I-T033
for	O
hypovitaminosis	B-T038
D	I-T038
are	O
people	B-T098
with	O
darker	B-T038
skin	I-T038
pigmentation	I-T038
,	O
use	O
of	O
sunscreen	O
,	O
insufficient	O
ultraviolet	O
B	O
exposure	O
,	O
prematurity	B-T038
,	O
living	B-T082
in	I-T082
northern	I-T082
latitudes	I-T082
,	O
malnutrition	B-T038
,	O
obesity	B-T038
,	O
exclusive	O
breastfeeding	O
,	O
low	B-T033
maternal	I-T033
vitamin	I-T033
D	I-T033
level	I-T033
,	O
certain	O
medications	B-T103
,	O
drinking	B-T038
unfortified	B-T168
cow	I-T168
'	I-T168
s	I-T168
milk	I-T168
,	O
liver	B-T038
failure	I-T038
,	O
chronic	B-T038
renal	I-T038
insufficiency	I-T038
,	O
cystic	B-T038
fibrosis	I-T038
,	O
asthma	B-T038
,	O
and	O
sickle	O
cell	O
hemoglobinopathy	O
.	O

This	O
review	B-T170
highlights	O
and	O
summarizes	O
the	O
molecular	O
perspectives	O
of	O
vitamin	B-T038
D	I-T038
deficiency	I-T038
and	O
its	O
potential	O
adverse	B-T038
health	O
outcomes	O
in	O
pediatric	O
age	O
groups	O
.	O

The	O
recommended	O
treatment	O
regimen	O
is	O
beyond	O
the	O
scope	O
of	O
this	O
review	B-T170
.	O

Causes	O
of	O
ecological	B-T082
gradients	O
in	O
leaf	B-T204
margin	B-T082
entirety	O
:	O
Evaluating	B-T170
the	O
roles	O
of	O
biomechanics	B-T091
,	O
hydraulics	O
,	O
vein	O
geometry	O
,	O
and	O
bud	B-T204
packing	O

A	O
recent	O
commentary	B-T170
by	O
Edwards	O
et	O
al	O
.	O

(	O
Am	O
.	O

J	O
.	O

Bot	O
.	O

103	O
:	O
975	O
-	O
978	O
)	O
proposed	O
that	O
constraints	O
imposed	O
by	O
the	O
packing	O
of	O
young	O
leaves	B-T204
in	O
buds	B-T204
could	O
explain	O
the	O
positive	B-T033
association	O
between	O
non	O
-	O
entire	O
leaf	B-T204
margins	B-T082
and	O
latitude	O
but	O
did	O
not	O
thoroughly	O
consider	O
alternative	O
explanations	B-T170
.	O

We	O
review	O
the	O
logic	O
and	O
evidence	O
underlying	O
six	O
major	O
hypotheses	O
for	O
the	O
functional	O
significance	O
of	O
marginal	B-T082
teeth	B-T204
,	O
involving	O
putative	O
effects	O
on	O
(	O
1	O
)	O
leaf	B-T204
cooling	O
,	O
(	O
2	O
)	O
optimal	O
support	O
and	O
supply	O
of	O
the	O
areas	B-T082
served	O
by	O
major	O
veins	B-T017
,	O
(	O
3	O
)	O
enhanced	O
leaf	B-T204
-	O
margin	B-T082
photosynthesis	O
,	O
(	O
4	O
)	O
hydathodal	B-T038
function	I-T038
,	O
(	O
5	O
)	O
defense	O
against	O
herbivores	B-T204
,	O
and	O
(	O
6	O
)	O
bud	B-T204
packing	O
.	O

Theoretical	O
and	O
empirical	O
problems	B-T033
undermine	O
all	O
hypotheses	O
except	O
the	O
support	O
-	O
supply	O
hypothesis	O
,	O
which	O
implies	O
that	O
thinner	O
leaves	B-T204
should	O
have	O
non	O
-	O
entire	O
margins	B-T082
.	O

Phylogenetically	O
structured	B-T062
analyses	I-T062
across	O
angiosperms	B-T204
,	O
the	O
El	O
Yunque	O
flora	B-T033
,	O
and	O
the	O
genus	B-T170
Viburnum	B-T204
all	O
demonstrate	O
that	O
non	O
-	O
entire	O
margins	B-T082
are	O
indeed	O
more	O
common	O
in	O
thinner	O
leaves	B-T204
.	O

Across	O
angiosperms	B-T204
,	O
the	O
association	O
of	O
leaf	B-T204
thickness	O
with	O
non	O
-	O
entire	O
leaf	B-T204
margins	B-T082
is	O
stronger	O
than	O
that	O
of	O
latitude	O
.	O

We	O
outline	B-T170
a	O
synthetic	B-T170
model	I-T170
showing	O
how	O
biomechanics	B-T091
,	O
hydraulics	O
,	O
vein	B-T017
geometry	O
,	O
rates	O
of	O
leaf	B-T204
expansion	B-T038
,	O
and	O
length	O
of	O
development	O
within	O
resting	B-T033
buds	B-T204
,	O
all	O
tied	O
to	O
leaf	B-T204
thickness	O
,	O
drive	B-T033
patterns	B-T082
in	O
the	O
distribution	B-T082
of	O
entire	O
vs	O
.	O

non	O
-	O
entire	O
leaf	B-T204
margins	B-T082
.	O

Our	O
model	B-T170
accounts	O
for	O
dominance	O
of	O
entire	O
margins	B-T082
in	O
the	O
tropics	O
,	O
Mediterranean	B-T082
scrub	I-T082
,	O
and	O
tundra	B-T082
,	O
non	O
-	O
entire	O
margins	B-T082
in	O
cold	O
temperate	O
deciduous	O
forests	O
and	O
tropical	O
vines	B-T204
and	O
early	B-T204
-	I-T204
successional	I-T204
trees	I-T204
,	O
and	O
entire	O
leaf	B-T204
margins	B-T082
in	O
monocots	B-T204
.	O

Spinose	B-T204
-	I-T204
toothed	I-T204
leaves	I-T204
should	O
be	O
favored	O
in	O
short	B-T033
-	I-T033
statured	I-T033
evergreen	B-T204
trees	I-T204
and	O
shrubs	B-T204
,	O
primarily	O
in	O
Mediterranean	B-T082
scrub	I-T082
and	O
related	O
semiarid	B-T082
habitats	I-T082
.	O

Viral	B-T103
Vector	I-T103
Biosafety	B-T170
in	O
Laboratory	B-T062
Animal	I-T062
Research	I-T062

Viral	B-T103
vector	I-T103
research	B-T062
presents	O
unique	O
occupational	B-T091
health	I-T091
and	O
safety	O
challenges	B-T058
to	O
institutions	B-T092
due	O
to	O
the	O
rapid	O
development	O
ofboth	O
in	B-T082
vivo	I-T082
and	O
in	O
vitro	O
gene	B-T062
-	I-T062
editing	I-T062
technologies	I-T062
.	O

Risks	O
to	O
human	B-T204
and	O
animal	B-T204
health	O
make	O
it	O
incumbent	O
on	O
institutions	B-T092
to	O
appropriately	O
evaluate	B-T058
viral	B-T103
vector	I-T103
usage	O
in	O
research	B-T062
on	O
the	O
basis	O
of	O
available	O
information	O
and	O
governmental	O
regulations	O
and	O
guidelines	B-T170
.	O
Here	O
we	O
review	O
the	O
factors	O
related	O
to	O
risk	B-T058
assessment	I-T058
regarding	O
viral	B-T103
vector	I-T103
usage	O
in	O
animals	B-T204
and	O
the	O
relevant	O
regulatory	B-T170
documents	I-T170
associated	O
with	O
this	O
research	B-T062
,	O
and	O
we	O
highlight	O
the	O
most	O
commonly	O
used	O
viral	B-T103
vectors	I-T103
in	O
research	B-T062
today	O
.	O

This	O
review	O
is	O
particularly	O
focused	O
on	O
the	O
background	O
,	O
use	O
in	O
research	B-T062
and	O
associated	O
health	O
and	O
environmental	O
risks	O
related	O
to	O
adenoviral	B-T005
,	O
adeno	B-T005
-	I-T005
associated	I-T005
viral	I-T005
,	O
lentiviral	B-T005
,	O
and	O
herpesviral	B-T005
vectors	B-T103
.	O

Liver	B-T038
Inflammation	I-T038
Relates	O
to	O
Decreased	O
Canalicular	B-T017
Bile	B-T103
Transporter	I-T103
Expression	B-T038
in	O
Pediatric	O
Onset	O
Intestinal	B-T038
Failure	I-T038

Although	O
liver	B-T038
disease	I-T038
is	O
a	O
major	O
complication	B-T038
of	O
parenteral	B-T058
nutrition	I-T058
(	O
PN	B-T058
)	O
for	O
intestinal	B-T038
failure	I-T038
(	O
IF	B-T038
)	O
,	O
its	O
pathogenesis	B-T038
remains	O
unclear	O
.	O

We	O
investigated	O
potential	O
molecular	O
mechanisms	O
of	O
liver	B-T037
injury	I-T037
in	O
pediatric	O
onset	O
IF	B-T038
.	O

Liver	B-T017
expression	B-T038
of	O
canalicular	B-T017
phospholipid	B-T103
(	O
ABCB4	B-T103
)	O
,	O
bile	B-T103
acid	I-T103
(	O
ABCB11	B-T103
)	O
,	O
and	O
sterol	B-T103
(	O
ABCG5	B-T103
/	I-T103
8	I-T103
)	O
transporters	B-T103
,	O
their	O
upstream	B-T103
regulators	I-T103
LXR	B-T103
and	O
FXR	B-T103
as	O
well	O
as	O
pro	B-T103
-	I-T103
inflammatory	I-T103
cytokines	I-T103
interleukin	B-T103
-	I-T103
6	I-T103
(	O
IL6	B-T103
)	O
and	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
(	O
TNF	B-T103
)	O
were	O
investigated	O
among	O
patients	O
with	O
IF	B-T038
[	O
age	O
median	O
3	O
.	O
8	O
(	O
IQR	O
1	O
.	O
2	O
to	O
11	O
)	O
]	O
in	O
relation	O
to	O
biochemical	O
and	O
histologic	O
liver	B-T037
injury	I-T037
,	O
PN	B-T058
,	O
serum	B-T031
plant	B-T103
sterols	I-T103
,	O
fibroblast	B-T103
growth	I-T103
factor	I-T103
19	I-T103
,	O
and	O
α	B-T103
-	I-T103
tocopherol	I-T103
.	O

Patients	O
receiving	O
PN	B-T058
currently	O
(	O
n	O
=	O
18	O
)	O
showed	O
more	O
advanced	O
liver	B-T037
injury	I-T037
than	O
patients	O
after	O
weaning	B-T033
off	O
PN	B-T058
(	O
n	O
=	O
30	O
)	O
.	O

Histologic	O
portal	B-T033
inflammation	I-T033
strongly	O
segregated	O
PN	B-T058
-	O
dependent	O
(	O
44	O
%	O
)	O
from	O
weaned	B-T033
off	O
patients	O
(	O
3	O
%	O
,	O
P	O
=	O
0	O
.	O
001	O
)	O
and	O
coupled	O
with	O
progression	B-T038
of	O
cholestasis	B-T038
and	O
liver	B-T038
fibrosis	I-T038
.	O

Patients	O
with	O
portal	B-T033
inflammation	I-T033
demonstrated	O
markedly	O
induced	O
liver	B-T017
RNA	B-T038
expression	I-T038
of	O
IL6	B-T017
and	O
TNF	B-T017
,	O
repression	B-T038
of	O
FXR	B-T103
and	O
its	O
canalicular	B-T017
bile	B-T103
transporter	I-T103
target	O
gene	B-T017
RNA	B-T038
expression	I-T038
,	O
including	O
ABCB4	B-T017
and	O
ABCB11	B-T017
as	O
well	O
as	O
decreased	O
protein	B-T038
expression	I-T038
of	O
ABCB11	B-T103
and	O
ABCB4	B-T103
.	O

Furthermore	O
,	O
upregulation	B-T038
of	O
LXR	B-T103
and	O
ABCG5	B-T017
/	I-T017
8	I-T017
RNA	B-T038
expression	I-T038
was	O
suppressed	O
in	O
patients	O
with	O
portal	B-T033
inflammation	I-T033
.	O

Current	O
PN	B-T058
,	O
increased	O
serum	B-T031
levels	O
of	O
plant	B-T103
sterols	I-T103
stigmasterol	B-T103
,	O
avenasterol	B-T103
,	O
and	O
sitosterol	B-T103
along	O
with	O
serum	B-T031
citrulline	B-T103
,	O
a	O
marker	B-T201
of	O
enterocyte	B-T017
mass	I-T017
,	O
predicted	O
portal	B-T033
inflammation	I-T033
.	O

In	O
pediatric	O
onset	O
IF	B-T038
,	O
current	O
PN	B-T058
delivery	O
synergistically	O
with	O
intestinal	B-T017
compromise	O
promote	O
liver	B-T038
inflammation	I-T038
,	O
which	O
associates	O
with	O
progression	B-T038
of	O
biochemical	O
and	O
histologic	O
liver	B-T037
injury	I-T037
,	O
while	O
reducing	O
expression	B-T038
of	O
canalicular	B-T017
bile	B-T103
transporters	I-T103
.	O

Impaired	B-T033
mobility	I-T033
,	O
depressed	B-T033
mood	I-T033
,	O
cognitive	B-T038
impairment	I-T038
and	O
polypharmacy	B-T033
are	O
independently	O
associated	O
with	O
disability	B-T033
in	O
older	O
cancer	B-T038
outpatients	O
:	O
The	O
prospective	O
Physical	B-T033
Frailty	I-T033
in	O
Elderly	B-T098
Cancer	O
patients	O
(	O
PF	B-T033
-	O
EC	O
)	O
cohort	O
study	O

To	O
assess	O
the	O
prevalence	O
of	O
disability	B-T033
and	O
the	O
oncologic	O
factors	O
associated	O
with	O
disability	B-T033
in	O
older	O
outpatients	O
with	O
cancer	B-T038
.	O

The	O
Physical	B-T033
Frailty	I-T033
in	O
Elderly	B-T098
Cancer	O
patients	O
(	O
PF	B-T033
-	O
EC	O
)	O
study	O
(	O
France	B-T082
)	O
is	O
a	O
prospective	B-T062
bicentric	I-T062
observational	I-T062
cohort	I-T062
study	I-T062
.	O

Two	O
hundred	O
and	O
ninety	O
outpatients	O
with	O
cancer	B-T038
were	O
included	O
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
analysis	I-T062
of	O
oncologic	O
factors	O
and	O
geriatric	O
variables	O
associated	O
with	O
disability	B-T033
that	O
were	O
collected	O
using	O
a	O
comprehensive	O
geriatric	B-T058
assessment	I-T058
(	O
CGA	B-T058
)	O
was	O
conducted	O
.	O

Disability	B-T033
was	O
defined	O
as	O
impairment	O
in	O
activities	O
of	O
daily	O
living	O
(	O
ADL	O
)	O
and	O
/	O
or	O
instrumental	B-T033
activities	I-T033
of	I-T033
daily	I-T033
living	I-T033
(	B-T033
IADL	I-T033
)	O
,	O
simplified	O
to	O
four	O
items	O
.	O

Univariate	O
and	O
multivariate	O
logistic	B-T170
models	I-T170
of	O
disabled	O
patients	O
were	O
performed	O
.	O

The	O
three	O
final	O
multivariate	O
models	B-T170
were	O
compared	O
using	O
the	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AUC	O
/	O
ROC	O
)	O
of	O
the	O
logistic	B-T170
model	I-T170
.	O

The	O
mean	O
age	O
was	O
80	O
.	O
6years	O
,	O
and	O
51	O
%	O
of	O
the	O
patients	O
were	O
women	B-T098
with	O
various	O
types	O
of	O
cancer	B-T038
.	O

The	O
prevalence	O
of	O
disability	B-T033
was	O
67	O
.	O
6	O
%	O
.	O

No	O
oncologic	O
factors	O
(	O
cancer	O
site	O
,	O
cancer	B-T038
extension	I-T038
)	O
were	O
associated	O
with	O
disability	B-T033
.	O

Impaired	B-T033
mobility	I-T033
,	O
poor	B-T033
functional	I-T033
status	I-T033
,	O
depressive	B-T033
mood	I-T033
,	O
cognitive	B-T038
impairment	I-T038
and	O
polypharmacy	B-T033
were	O
independently	O
associated	O
with	O
disability	B-T033
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
AUC	O
/	O
ROC	O
of	O
the	O
final	O
models	O
was	O
similar	O
.	O

Disability	B-T033
was	O
highly	O
prevalent	O
in	O
older	O
cancer	B-T038
outpatients	O
before	O
cancer	B-T058
treatment	I-T058
but	O
was	O
not	O
associated	O
with	O
oncologic	O
factors	O
.	O

Impaired	B-T033
mobility	I-T033
,	O
depressed	B-T033
mood	I-T033
,	O
cognitive	B-T038
impairment	I-T038
and	O
polypharmacy	B-T033
were	O
the	O
geriatric	O
variables	O
significantly	O
and	O
independently	O
associated	O
with	O
disability	B-T033
.	O

Identifying	O
these	O
factors	O
prior	O
to	O
cancer	B-T058
treatment	I-T058
could	O
enable	O
the	O
implementation	O
of	O
corrective	O
actions	O
to	O
improve	O
patient	O
autonomy	O
before	O
treatment	B-T058
and	O
during	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Synthesis	O
,	O
SAR	O
and	O
molecular	B-T062
docking	I-T062
study	B-T062
of	O
novel	O
non	B-T103
-	I-T103
β	I-T103
-	I-T103
lactam	I-T103
inhibitors	I-T103
of	O
TEM	B-T103
type	I-T103
β	I-T103
-	I-T103
lactamase	I-T103

The	O
novel	O
classes	O
of	O
acylated	B-T103
phenoxyanilide	I-T103
and	O
thiourea	B-T103
compounds	I-T103
were	O
investigated	O
for	O
their	O
ability	O
to	O
inhibit	B-T038
TEM	B-T103
type	I-T103
β	I-T103
-	I-T103
lactamase	I-T103
enzyme	I-T103
.	O

Two	O
compounds	B-T103
4g	I-T103
and	O
5c	B-T103
reveal	O
the	O
inhibition	B-T038
potency	O
in	O
micromolar	O
range	O
and	O
show	O
their	O
action	O
by	O
non	B-T038
-	I-T038
covalent	I-T038
binding	I-T038
in	O
the	O
vicinity	O
of	O
the	O
TEM	B-T103
-	I-T103
171	I-T103
active	O
site	O
.	O

The	O
structure	O
activity	O
relationship	O
around	O
carbon	O
chain	O
length	O
and	O
different	O
substituents	O
in	O
ortho	O
-	O
and	O
para	O
-	O
positions	O
of	O
acylated	B-T103
phenoxyanilide	I-T103
as	O
well	O
as	O
molecular	B-T062
modelling	I-T062
study	B-T062
has	O
been	O
performed	O
.	O

Metabolic	B-T033
responses	I-T033
of	O
the	O
growing	O
Daphnia	B-T204
similis	I-T204
to	O
chronic	O
AgNPs	O
exposure	O
as	O
revealed	O
by	O
GC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O
and	O
LC	O
-	O
Q	O
-	O
TOF	O
/	O
MS	O

Silver	B-T103
nanoparticles	O
(	O
AgNPs	O
)	O
are	O
one	O
of	O
the	O
most	O
widely	O
used	O
nanomaterials	O
.	O

Their	O
fast	B-T033
-	I-T033
growing	I-T033
utilization	O
has	O
increased	O
the	O
occurrence	O
of	O
AgNPs	O
in	O
the	O
environment	B-T082
,	O
posing	O
potential	O
health	O
and	O
ecological	O
risks	O
.	O

In	O
this	O
study	O
,	O
we	O
conducted	O
chronic	B-T058
toxicity	I-T058
tests	I-T058
and	O
investigated	O
the	O
metabolic	B-T103
changes	O
of	O
the	O
growing	O
Daphna	B-T204
similis	I-T204
with	O
exposure	O
to	O
0	O
,	O
0	O
.	O
02	O
,	O
and	O
1	O
ppb	O
AgNPs	O
,	O
using	O
non	B-T058
-	I-T058
targeted	I-T058
mass	I-T058
spectrometry	I-T058
-	O
based	O
metabolomics	B-T091
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
study	O
is	O
the	O
first	O
to	O
report	O
the	O
baseline	O
metabolite	B-T103
change	O
of	O
a	O
common	O
aquatic	O
organism	O
Daphnia	B-T204
crustacean	I-T204
through	O
its	O
life	O
-	O
cycle	O
.	O

The	O
results	O
show	O
a	O
dynamic	B-T033
kinetic	I-T033
pattern	I-T033
of	O
the	O
growing	O
Daphnia	B-T204
'	I-T204
s	I-T204
metabolome	O
underwent	O
a	O
cycle	O
from	O
day	O
0	O
to	O
day	O
21	O
,	O
with	O
the	O
level	O
of	O
metabolites	B-T103
gradually	O
increasing	O
from	O
day	O
0	O
to	O
day	O
13	O
,	O
before	O
falling	O
back	O
to	O
the	O
baseline	O
level	O
of	O
day	O
0	O
on	O
day	O
21	O
.	O

As	O
for	O
the	O
samples	O
exposed	O
to	O
environmental	O
concentrations	O
of	O
AgNPs	O
,	O
although	O
without	O
morphological	B-T033
or	I-T033
structural	I-T033
changes	I-T033
,	O
numerous	O
metabolite	B-T103
changes	O
occurred	O
abruptly	O
during	O
the	O
first	O
10	O
days	O
,	O
and	O
these	O
changes	O
reached	O
steady	O
state	O
by	O
day	O
13	O
.	O

The	O
significant	O
changes	O
in	O
certain	O
metabolites	B-T103
,	O
such	O
as	O
amino	B-T103
acids	I-T103
(	O
serine	B-T103
,	O
threonine	B-T103
and	O
tyrosine	B-T103
)	O
,	O
sugars	B-T103
(	O
d	B-T103
-	I-T103
allose	I-T103
)	O
and	O
fatty	B-T103
acids	I-T103
(	O
arachidonic	B-T103
acid	I-T103
)	O
revealed	O
new	O
insights	O
into	O
how	O
these	O
metabolites	B-T103
in	O
Daphnia	B-T204
respond	O
to	O
chronic	O
AgNPs	O
stress	O
.	O

These	O
findings	O
highlight	O
the	O
capability	O
of	O
metabolomics	B-T091
to	O
discover	O
early	O
metabolic	B-T033
responses	I-T033
to	O
environmental	B-T082
silver	B-T103
nanoparticles	O
.	O

Evaluating	O
the	O
relative	O
effectiveness	O
of	O
high	B-T170
-	I-T170
intensity	I-T170
and	O
low	O
-	O
intensity	O
models	O
of	O
behaviour	O
change	O
communication	B-T058
interventions	I-T058
for	O
abortion	B-T033
care	O
-	O
seeking	O
in	O
Bihar	O
and	O
Jharkhand	O
,	O
India	B-T082
:	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062

This	O
study	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
a	O
high	B-T170
-	I-T170
intensity	I-T170
model	I-T170
(	O
HIM	B-T170
)	O
and	O
a	O
low	O
-	O
intensity	O
model	O
(	O
LIM	O
)	O
of	O
behaviour	O
change	O
communication	B-T058
interventions	I-T058
in	O
Bihar	O
and	O
Jharkhand	O
states	O
of	O
India	B-T082
designed	O
to	O
improve	O
women	B-T098
'	I-T098
s	I-T098
knowledge	B-T033
and	O
usage	O
of	O
safe	B-T033
abortion	I-T033
services	O
,	O
as	O
well	O
as	O
the	O
dose	O
effect	O
of	O
intervention	B-T058
exposure	O
.	O

We	O
conducted	O
two	O
cross	B-T062
-	I-T062
sectional	I-T062
household	I-T062
surveys	I-T062
among	O
married	B-T033
women	B-T098
aged	O
15	O
-	O
49	O
years	O
in	O
intervention	B-T058
and	O
comparison	O
districts	O
.	O

Difference	O
-	O
in	O
-	O
difference	O
models	O
were	O
used	O
to	O
assess	O
the	O
efficacy	O
of	O
the	O
intervention	B-T058
,	O
adjusting	O
for	O
sociodemographic	B-T033
characteristics	I-T033
.	O

Although	O
both	O
intervention	B-T058
types	O
improved	O
abortion	B-T033
knowledge	B-T170
,	O
the	O
HIM	B-T170
intervention	B-T058
was	O
more	O
effective	O
in	O
improving	O
comprehensive	B-T170
knowledge	I-T170
about	O
abortion	B-T033
.	O

In	O
particular	O
,	O
there	O
were	O
improvements	O
in	O
knowledge	B-T170
on	O
legality	B-T058
of	I-T058
abortion	I-T058
(	O
AOR	O
=	O
2	O
.	O
2	O
;	O
95	O
%	O
CI	O
1	O
.	O
6	O
to	O
2	O
.	O
9	O
)	O
and	O
nearby	O
sources	O
of	O
safe	B-T058
abortion	I-T058
care	I-T058
(	O
AOR	O
=	O
1	O
.	O
7	O
;	O
95	O
%	O
CI	O
1	O
.	O
2	O
to	O
1	O
.	O
3	O
)	O
.	O

Higher	O
level	O
of	O
exposure	O
to	O
abortion	O
-	O
related	O
messages	O
was	O
related	O
to	O
more	O
accurate	O
knowledge	B-T170
about	O
abortion	B-T033
within	O
both	O
intervention	B-T058
groups	O
.	O

Evidence	O
was	O
mixed	O
on	O
changes	O
in	O
abortion	B-T033
care	O
-	O
seeking	O
behaviour	O
.	O

More	O
work	O
is	O
needed	O
to	O
ensure	O
that	O
women	B-T098
seek	O
safe	B-T033
abortion	I-T033
services	O
in	O
lieu	O
of	O
informal	O
services	O
that	O
may	O
be	O
more	O
likely	O
to	O
lead	O
to	O
postabortion	B-T038
complications	I-T038
.	O

Tissue	B-T017
MicroRNA	B-T103
profiles	O
as	O
diagnostic	B-T201
and	O
prognostic	O
biomarkers	O
in	O
patients	O
with	O
resectable	B-T058
pancreatic	B-T038
ductal	I-T038
adenocarcinoma	I-T038
and	O
periampullary	B-T038
cancers	I-T038

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
validate	O
previously	O
described	O
diagnostic	O
and	O
prognostic	B-T170
microRNA	B-T103
expression	O
profiles	O
in	O
tissue	B-T017
samples	O
from	O
patients	O
with	O
pancreatic	B-T038
cancer	I-T038
and	O
other	O
periampullary	B-T038
cancers	I-T038
.	O

Expression	B-T038
of	O
46	O
selected	O
microRNAs	B-T103
was	O
studied	O
in	O
formalin	B-T103
-	O
fixed	O
paraffin	B-T017
-	I-T017
embedded	I-T017
tissue	I-T017
from	O
patients	O
with	O
resected	B-T058
pancreatic	B-T038
ductal	I-T038
adenocarcinoma	I-T038
(	O
n	O
=	O
165	O
)	O
,	O
ampullary	B-T038
cancer	I-T038
(	O
n	O
=	O
59	O
)	O
,	O
duodenal	B-T038
cancer	I-T038
(	O
n	O
=	O
6	O
)	O
,	O
distal	B-T082
common	B-T038
bile	I-T038
duct	I-T038
cancer	I-T038
(	O
n	O
=	O
21	O
)	O
,	O
and	O
gastric	B-T038
cancer	I-T038
(	O
n	O
=	O
20	O
)	O
;	O
chronic	B-T038
pancreatitis	I-T038
(	O
n	O
=	O
39	O
)	O
;	O
and	O
normal	B-T033
pancreas	I-T033
(	O
n	O
=	O
35	O
)	O
.	O

The	O
microRNAs	B-T103
were	O
analyzed	O
by	O
PCR	B-T062
using	O
the	O
Fluidigm	B-T170
platform	I-T170
.	O

Twenty	O
-	O
two	O
microRNAs	B-T103
were	O
significantly	O
differently	O
expressed	B-T038
in	O
patients	O
with	O
pancreatic	B-T038
cancer	I-T038
when	O
compared	O
to	O
healthy	O
controls	O
and	O
chronic	B-T038
pancreatitis	I-T038
patients	O
;	O
17	O
miRNAs	B-T103
were	O
upregulated	B-T038
(	O
miR	B-T017
-	I-T017
21	I-T017
-	I-T017
5p	I-T017
,	O
-	O
23a	B-T017
-	I-T017
3p	I-T017
,	O
-	O
31	B-T017
-	I-T017
5p	I-T017
,	O
-	O
34c	B-T017
-	I-T017
5p	I-T017
,	O
-	O
93	B-T017
-	I-T017
3p	I-T017
,	O
-	O
135b	B-T017
-	I-T017
3p	I-T017
,	O
-	O
155	B-T017
-	I-T017
5p	I-T017
,	O
-	O
186	B-T017
-	I-T017
5p	I-T017
,	O
-	O
196b	B-T017
-	I-T017
5p	I-T017
,	I-T017
-	O
203	B-T017
,	O
-	O
205	B-T103
-	I-T103
5p	I-T103
,	O
-	O
210	B-T017
,	O
-	O
222	B-T017
-	I-T017
3p	I-T017
,	O
-	O
451	B-T017
,	O
-	O
492	B-T017
,	O
-	O
614	B-T017
,	O
and	O
miR	B-T017
-	I-T017
622	I-T017
)	O
and	O
5	O
were	O
downregulated	B-T038
(	O
miR	B-T017
-	I-T017
122	I-T017
-	I-T017
5p	I-T017
,	O
-	O
130b	B-T017
-	I-T017
3p	I-T017
,	O
-	O
216b	B-T017
,	O
-	O
217	B-T017
,	O
and	O
miR	B-T017
-	I-T017
375	I-T017
)	O
.	O

MicroRNAs	B-T103
were	O
grouped	O
into	O
diagnostic	O
indices	O
of	O
varying	O
complexity	O
.	O

Ten	O
microRNAs	B-T103
associated	O
with	O
prognosis	B-T058
were	O
identified	O
(	O
let	B-T103
-	I-T103
7	I-T103
g	I-T103
,	O
miR	B-T017
-	I-T017
29a	I-T017
-	I-T017
5p	I-T017
,	O
-	O
34a	B-T017
-	I-T017
5p	I-T017
,	O
-	O
125a	B-T017
-	I-T017
3p	I-T017
,	O
-	O
146a	B-T017
-	I-T017
5p	I-T017
,	O
-	O
187	B-T017
,	O
-	O
205	B-T103
-	I-T103
5p	I-T103
,	O
-	O
212	B-T017
-	I-T017
3p	I-T017
,	O
-	O
222	B-T017
-	I-T017
5p	I-T017
,	O
and	O
miR	B-T017
-	I-T017
450b	I-T017
-	I-T017
5p	I-T017
)	O
.	O

Prognostic	O
indices	O
based	O
on	O
differences	O
in	O
expression	B-T038
of	O
2	O
different	O
microRNAs	B-T103
were	O
constructed	O
for	O
pancreatic	B-T038
and	O
ampullary	B-T038
cancer	I-T038
combined	O
and	O
separately	O
(	O
30	O
,	O
5	O
,	O
and	O
21	O
indices	O
)	O
.	O

The	O
study	B-T062
confirms	O
that	O
pancreatic	B-T038
cancer	I-T038
tissue	B-T017
has	O
a	O
microRNA	B-T103
expression	O
profile	O
that	O
is	O
different	O
from	O
that	O
of	O
other	O
periampullary	B-T038
cancers	I-T038
,	O
chronic	B-T038
pancreatitis	I-T038
,	O
and	O
normal	B-T033
pancreas	I-T033
.	O

We	O
identified	O
prognostic	B-T170
microRNAs	B-T103
and	O
microRNA	B-T103
indices	O
that	O
were	O
associated	O
with	O
shorter	O
overall	O
survival	O
in	O
patients	O
with	O
radically	O
resected	B-T058
pancreatic	B-T038
cancer	I-T038
.	O

Effectiveness	O
of	O
workers	B-T098
'	O
general	B-T058
health	I-T058
examination	I-T058
in	O
Korea	B-T082
by	O
health	O
examination	O
period	O
and	O
compliance	B-T033
:	O
retrospective	B-T062
cohort	I-T062
study	I-T062
using	O
nationwide	O
data	O

Our	O
study	O
evaluated	B-T058
the	O
effectiveness	O
of	O
the	O
Workers	B-T098
'	O
General	B-T058
Health	I-T058
Examination	I-T058
by	O
health	O
examination	O
period	O
and	O
compliance	B-T033
.	O

A	O
retrospective	B-T062
cohort	I-T062
of	O
the	O
health	O
examination	O
participants	B-T098
in	O
2006	O
(	O
baseline	O
year	O
:	O
N€	O
‰	O
=	O
€	O
‰	O
6	O
,	O
527	O
,	O
045	O
)	O
was	O
used	O
.	O

We	O
identified	O
newly	O
occurring	O
cardio	O
-	O
cerebrovascular	O
disease	O
over	O
7	O
years	O
(	O
from	O
2007	O
to	O
2013	O
)	O
.	O

After	O
stratification	O
by	O
age	O
,	O
sex	O
,	O
and	O
national	O
health	O
insurance	O
type	O
type	I-T058
we	O
identified	O
7	O
years	O
'	O
cumulative	O
incidence	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
by	O
health	O
examination	O
compliance	O
and	O
estimated	O
its	O
relative	O
risk	O
by	O
health	O
examination	O
period	O
and	O
compliance	O
.	O

The	O
compliant	O
group	O
presented	O
a	O
lower	O
cumulative	O
incidence	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
than	O
the	O
non	O
-	O
non	B-T098
group	O
;	O
this	O
result	O
was	O
consistent	O
across	O
sex	O
,	O
working	O
age	O
(	O
40s	O
and	O
50s	O
)	O
,	O
and	O
workplace	O
policyholder	O
.	O

Relative	O
risk	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
by	O
health	O
examination	O
period	O
(	O
1	O
and	O
2	O
years	O
)	O
showed	O
statistically	O
significant	O
results	O
in	O
ischemic	O
heart	O
disease	O
for	O
male	O
participants	O
.	O

Of	O
men	O
men	B-T098
their	O
40s	O
,	O
office	O
workers	O
(	O
over	O
a	O
2	O
-	O
year	O
period	O
)	O
presented	O
statistically	O
higher	O
relative	O
risk	O
of	O
ischemic	O
heart	O
disease	O
than	O
non	O
-	O
non	B-T098
workers	O
(	O
over	O
a	O
1	O
-	O
year	O
period	O
:	O
1	O
.	O
03	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
02	O
-	O
1	O
.	O
03	O
)	O
.	O

However	O
,	O
there	O
were	O
no	O
consistent	O
results	O
in	O
ischemic	O
cerebrovascular	O
disease	O
and	O
hemorrhagic	O
cerebrovascular	O
disease	O
for	O
men	O
men	B-T098
cardio	O
-	O
cerebrovascular	O
disease	O
for	O
women	O
.	O

A	O
1	O
-	O
year	O
period	O
of	O
Workers	O
'	O
General	O
Health	O
Examinations	O
in	O
non	O
-	O
non	B-T098
workers	O
had	O
a	O
more	O
significant	O
prevention	O
effect	O
on	O
ischemic	O
heart	O
disease	O
than	O
a	O
2	O
-	O
year	O
period	O
in	O
office	O
workers	O
among	O
working	O
age	O
(	O
40s	O
-	O
50s	O
)	O
men	O
.	O

It	O
is	O
,	O
however	O
,	O
necessary	O
to	O
consider	O
that	O
prevention	O
of	O
cardio	O
-	O
cerebrovascular	O
disease	O
can	O
be	O
partially	O
explained	O
by	O
their	O
occupational	O
characteristics	O
rather	O
than	O
by	O
health	O
examination	O
period	O
.	O

Calibration	O
of	O
Self	B-T062
-	I-T062
Report	I-T062
Measures	O
of	O
Physical	O
Activity	O
and	O
Sedentary	O
Behavior	O

Calibration	O
equations	O
offer	O
potential	O
to	O
improve	O
the	O
accuracy	O
and	O
utility	O
of	O
self	B-T062
-	I-T062
report	I-T062
measures	O
of	O
physical	O
activity	O
(	O
PA	O
)	O
and	O
sedentary	O
behavior	O
(	O
SB	O
)	O
by	O
re	O
-	O
scaling	O
potentially	O
biased	O
estimates	O
.	O

The	O
present	O
study	O
evaluates	O
calibration	O
models	B-T170
designed	O
to	O
estimate	O
PA	O
and	O
SB	O
in	O
a	O
representative	O
sample	O
of	O
adults	O
from	O
the	O
Physical	O
Activity	O
Measurement	B-T062
Survey	I-T062
(	O
PAMS	B-T062
)	O
.	O

Participants	B-T098
in	O
the	O
PAMS	B-T062
project	O
completed	O
replicate	O
single	O
day	O
trials	O
that	O
involved	O
wearing	O
a	O
Sensewear	O
armband	O
(	O
SWA	O
)	O
monitor	B-T074
for	O
24	O
hours	O
followed	O
by	O
a	O
telephone	B-T062
administered	O
24	O
-	O
hour	O
physical	O
activity	O
recall	O
(	O
PAR	O
)	O
.	O

Comprehensive	O
statistical	B-T170
model	I-T170
selection	O
and	O
validation	O
procedures	O
were	O
used	O
to	O
develop	O
and	O
test	O
separate	O
calibration	O
models	B-T170
designed	O
to	O
predict	O
objectively	O
-	O
measured	O
SB	O
and	O
moderate	O
to	O
vigorous	O
PA	O
(	O
MVPA	O
from	O
self	B-T062
-	I-T062
reported	I-T062
PAR	O
data	O
.	O

Equivalence	O
testing	O
was	O
used	O
to	O
evaluate	O
the	O
equivalence	O
of	O
the	O
model	O
-	O
predicted	O
values	O
with	O
the	O
objective	O
measures	O
in	O
a	O
separate	O
holdout	O
sample	O
.	O

The	O
final	O
prediction	O
model	O
for	O
both	O
SB	O
and	O
MVPA	O
included	O
reported	O
time	O
spent	O
in	O
SB	O
and	O
MVPA	O
,	O
as	O
well	O
as	O
terms	O
capturing	O
sex	O
,	O
age	O
,	O
education	B-T033
,	O
and	O
BMI	B-T201
.	O

Cross	B-T062
-	I-T062
validation	I-T062
analyses	O
on	O
an	O
independent	O
sample	O
exhibited	O
high	O
correlations	O
with	O
observed	O
SB	O
(	O
r	O
=	O
0	O
.	O
72	O
)	O
and	O
MVPA	O
(	O
r	O
=	O
0	O
.	O
75	O
)	O
.	O

Equivalence	O
testing	O
demonstrated	O
that	O
the	O
model	O
-	O
predicted	O
values	O
were	O
statistically	O
equivalent	O
to	O
the	O
corresponding	O
objective	O
values	O
for	O
both	O
SB	O
and	O
MVPA	O
.	O

The	O
results	O
demonstrate	O
that	O
simple	O
regression	B-T170
models	B-T170
can	O
be	O
used	O
to	O
statistically	O
adjust	O
for	O
over	O
or	O
underestimation	O
in	O
self	B-T062
-	I-T062
report	I-T062
measures	O
among	O
different	O
segments	O
of	O
the	O
population	B-T098
.	O

The	O
models	B-T170
produced	O
group	O
estimates	O
from	O
the	O
PAR	O
that	O
were	O
statistically	O
equivalent	O
to	O
the	O
observed	O
time	O
spent	O
in	O
SB	O
and	O
MVPA	O
obtained	O
from	O
the	O
objective	O
SWA	O
monitor	B-T074
;	O
however	O
additional	O
work	O
is	O
needed	O
to	O
correct	O
for	O
estimates	O
of	O
individual	O
behavior	O
.	O

Human	B-T204
amnion	B-T017
epithelial	B-T017
cells	I-T017
rescue	O
cell	B-T038
death	I-T038
via	O
immunomodulation	B-T058
of	O
microglia	B-T017
in	O
a	O
mouse	B-T038
model	I-T038
of	O
perinatal	B-T037
brain	I-T037
injury	I-T037

Human	B-T204
amnion	B-T017
epithelial	B-T017
cells	I-T017
(	O
hAECs	B-T017
)	O
are	O
clonogenic	O
and	O
have	O
been	O
proposed	O
to	O
reduce	O
inflammatory	B-T038
-	O
induced	O
tissue	B-T037
injury	I-T037
.	O

Perturbation	O
of	O
the	O
immune	B-T038
response	I-T038
is	O
implicated	O
in	O
the	O
pathogenesis	B-T038
of	O
perinatal	B-T037
brain	I-T037
injury	I-T037
;	O
modulating	B-T082
this	O
response	B-T038
could	O
thus	O
be	O
a	O
novel	O
therapy	B-T058
for	O
treating	O
or	O
preventing	O
such	O
injury	B-T037
.	O

The	O
immunomodulatory	B-T058
properties	O
of	O
hAECs	B-T017
have	O
been	O
shown	O
in	O
other	O
animal	B-T204
models	I-T204
,	O
but	O
a	O
detailed	O
investigation	B-T058
of	O
the	O
effects	O
on	O
brain	B-T017
immune	O
cells	B-T017
following	O
injury	B-T037
has	O
not	O
been	O
undertaken	O
.	O

Here	O
,	O
we	O
investigate	B-T058
the	O
effects	O
of	O
hAECs	B-T017
on	O
microglia	B-T017
,	O
the	O
first	O
immune	B-T038
responders	I-T038
to	O
injury	B-T037
within	O
the	O
brain	B-T017
.	O

We	O
generated	O
a	O
mouse	B-T038
model	I-T038
combining	O
neonatal	O
inflammation	B-T038
and	O
perinatal	O
hyperoxia	B-T033
,	O
both	O
of	O
which	O
are	O
risk	B-T033
factors	I-T033
associated	O
with	O
perinatal	B-T037
brain	I-T037
injury	I-T037
.	O

On	O
embryonic	B-T038
day	O
16	O
we	O
administered	B-T058
lipopolysaccharide	B-T103
(	O
LPS	B-T103
)	O
,	O
or	O
saline	O
(	O
control	O
)	O
,	O
intra	O
-	O
amniotically	O
to	O
C57Bl	B-T204
/	I-T204
6	I-T204
J	I-T204
mouse	I-T204
pups	I-T204
.	O

On	O
postnatal	O
day	O
(	O
P	O
)	O
0	O
,	O
LPS	B-T103
pups	B-T204
were	O
placed	O
in	O
hyperoxia	B-T033
(	O
65	O
%	O
oxygen	B-T103
)	O
and	O
control	O
pups	O
in	O
normoxia	O
for	O
14	O
days	O
.	O

Pups	B-T204
were	O
given	O
either	O
hAECs	B-T017
or	O
saline	O
intravenously	B-T058
on	O
P4	O
.	O

At	O
P14	O
,	O
relative	O
to	O
controls	O
,	O
LPS	B-T103
and	O
hyperoxia	B-T033
pups	B-T204
had	O
reduced	O
body	O
weight	O
,	O
increased	O
density	O
of	O
apoptotic	O
cells	B-T017
(	O
TUNEL	B-T062
)	O
in	O
the	O
cortex	B-T017
,	O
striatum	B-T017
and	O
white	B-T017
matter	I-T017
,	O
astrocytes	B-T017
(	O
GFAP	B-T103
)	O
in	O
the	O
white	B-T017
matter	I-T017
and	O
activated	O
microglia	B-T017
(	O
CD68	B-T103
)	O
in	O
the	O
cortex	B-T017
and	O
striatum	B-T017
,	O
but	O
no	O
change	O
in	O
total	O
microglia	B-T017
density	O
(	O
Iba1	B-T103
)	O
.	O

hAEC	B-T017
administration	B-T058
rescued	O
the	O
decreased	O
body	O
weight	O
and	O
reduced	O
apoptosis	B-T038
and	O
astrocyte	B-T017
areal	O
coverage	O
in	O
the	O
white	B-T017
matter	I-T017
,	O
but	O
increased	O
the	O
density	O
of	O
total	O
and	O
activated	O
microglia	B-T017
.	O

We	O
then	O
stimulated	O
primary	O
microglia	B-T017
(	O
CD45	B-T103
(	O
low	O
)	O
CD11b	B-T103
(	O
+	O
)	O
)	O
with	O
LPS	B-T103
for	O
24	O
h	O
,	O
followed	O
by	O
co	B-T058
-	I-T058
culture	I-T058
with	O
hAEC	B-T017
conditioned	B-T103
medium	I-T103
for	O
48	O
h	O
.	O

hAEC	B-T017
conditioned	B-T103
medium	I-T103
increased	O
microglial	B-T017
phagocytic	B-T038
activity	I-T038
,	O
decreased	O
microglia	B-T017
apoptosis	B-T038
and	O
decreased	O
M1	B-T038
activation	I-T038
markers	I-T038
(	O
CD86	B-T103
)	O
.	O

Stimulating	O
hAECs	B-T017
for	O
24	O
h	O
with	O
LPS	B-T103
did	O
not	O
alter	O
release	B-T058
of	O
cytokines	B-T103
known	O
to	O
modulate	B-T082
microglia	B-T017
activity	O
.	O

These	O
data	O
demonstrate	O
that	O
hAECs	B-T017
can	O
directly	O
immunomodulate	B-T058
brain	B-T017
microglia	B-T017
,	O
probably	O
via	O
release	B-T058
of	O
trophic	B-T103
factors	I-T103
.	O

This	O
observation	B-T062
offers	O
promise	O
that	O
hAECs	B-T017
may	O
afford	O
therapeutic	B-T058
utility	I-T058
in	O
the	O
management	B-T058
of	O
perinatal	B-T037
brain	I-T037
injury	I-T037
.	O

Identification	O
of	O
Predictive	O
DNA	B-T038
Methylation	I-T038
Biomarkers	B-T103
for	O
Chemotherapy	B-T058
Response	B-T201
in	O
Colorectal	B-T038
Cancer	I-T038

Resistance	B-T038
to	O
5	B-T103
-	I-T103
Fluorouracil	I-T103
(	O
5	B-T103
-	I-T103
FU	I-T103
)	O
is	O
a	O
major	O
obstacle	O
to	O
the	O
successful	O
treatment	O
of	O
colorectal	B-T038
cancer	I-T038
(	O
CRC	B-T038
)	O
and	O
posed	O
an	O
increased	O
risk	O
of	O
recurrence	O
.	O

DNA	B-T038
methylation	I-T038
has	O
been	O
suggested	O
as	O
one	O
of	O
the	O
underlying	O
mechanisms	O
for	O
recurrent	B-T038
disease	I-T038
and	O
its	O
contribution	O
to	O
the	O
development	O
of	O
drug	B-T038
resistance	I-T038
remains	O
to	O
be	O
clarified	O
.	O

This	O
study	B-T062
aimed	O
to	O
determine	O
the	O
methylation	B-T038
phenotype	O
in	O
CRC	B-T038
for	O
identification	O
of	O
predictive	O
markers	B-T103
for	O
chemotherapy	B-T058
response	B-T201
.	O

We	O
performed	O
DNA	B-T038
methylation	I-T038
profiling	O
on	O
43	O
non	O
-	O
recurrent	O
and	O
five	O
recurrent	O
CRC	B-T038
patients	O
using	O
the	O
Illumina	B-T062
Infinium	I-T062
HumanMethylation450	I-T062
Beadchip	I-T062
assay	I-T062
.	O

In	O
addition	O
,	O
CRC	B-T038
cells	B-T017
with	O
different	O
genetic	O
backgrounds	O
,	O
response	B-T201
to	O
5	B-T103
-	I-T103
FU	I-T103
and	O
global	B-T038
methylation	I-T038
levels	O
(	O
HT29	B-T017
and	O
SW48	B-T017
)	O
were	O
treated	O
with	O
5	B-T103
-	I-T103
FU	I-T103
and	O
DNA	B-T038
methylation	I-T038
inhibitor	O
5	B-T103
-	I-T103
aza	I-T103
-	I-T103
2	I-T103
'	I-T103
-	I-T103
deoxycytidine	I-T103
(	O
5	B-T103
-	I-T103
azadC	I-T103
)	O
.	O

The	O
singular	O
and	O
combined	O
effects	O
of	O
these	O
two	O
drug	B-T103
classes	B-T170
on	O
cell	B-T038
viability	I-T038
and	O
global	B-T038
methylation	I-T038
profiles	B-T058
were	O
investigated	O
.	O

Our	O
genome	B-T062
-	I-T062
wide	I-T062
methylation	I-T062
study	I-T062
on	O
the	O
clinical	O
specimens	O
showed	O
that	O
recurrent	O
CRCs	B-T038
exhibited	O
higher	O
methylation	B-T038
levels	O
compared	O
to	O
non	O
-	O
recurrent	O
CRCs	B-T038
.	O

We	O
identified	O
4787	O
significantly	O
differentially	O
methylated	B-T017
genes	I-T017
(	O
P	O
<	O
0	O
.	O
05	O
)	O
;	O
3112	O
genes	B-T017
were	O
hyper	B-T033
-	O
while	O
1675	O
genes	B-T017
were	O
hypomethylated	B-T033
in	O
the	O
recurrent	O
group	O
compared	O
to	O
the	O
non	O
-	O
recurrent	O
.	O

Fifty	O
eight	O
and	O
47	O
of	O
the	O
significantly	O
hypermethylated	B-T017
and	I-T017
hypomethylated	I-T017
genes	I-T017
have	O
an	O
absolute	O
recurrent	O
/	O
non	O
-	O
recurrent	O
methylation	B-T038
difference	O
of	O
≥20	O
%	O
.	O

Most	O
of	O
the	O
hypermethylated	B-T017
genes	I-T017
were	O
involved	O
in	O
the	O
MAPK	B-T038
signaling	I-T038
pathway	I-T038
which	O
is	O
a	O
key	O
regulator	O
for	O
apoptosis	B-T038
while	O
the	O
hypomethylated	B-T017
genes	I-T017
were	O
involved	O
in	O
the	O
PI3K	B-T038
-	I-T038
AKT	I-T038
signaling	I-T038
pathway	I-T038
and	O
proliferation	O
process	O
.	O

We	O
also	O
demonstrate	O
that	O
5	B-T103
-	I-T103
azadC	I-T103
treatment	O
enhanced	O
response	B-T201
to	O
5	B-T103
-	I-T103
FU	I-T103
which	O
resulted	O
in	O
significant	O
growth	B-T038
inhibition	I-T038
compared	O
to	O
5	B-T103
-	I-T103
FU	I-T103
alone	O
in	O
hypermethylated	B-T017
cell	I-T017
lines	I-T017
SW48	I-T017
.	O

In	O
conclusion	O
,	O
we	O
found	O
the	O
evidence	O
of	O
five	O
potentially	O
biologically	O
important	O
genes	B-T017
in	O
recurrent	O
CRCs	B-T038
that	O
could	O
possibly	O
serve	O
as	O
a	O
new	O
potential	O
therapeutic	B-T058
targets	O
for	O
patients	O
with	O
chemoresistance	B-T038
.	O

We	O
postulate	O
that	O
aberrant	O
methylation	B-T038
of	O
CCNEI	B-T017
,	O
CCNDBP1	B-T017
,	O
PON3	B-T017
,	O
DDX43	B-T017
,	O
and	O
CHL1	B-T017
in	O
CRC	B-T038
might	O
be	O
associated	O
with	O
the	O
recurrence	O
of	O
CRC	B-T038
and	O
5	B-T103
-	I-T103
azadC	I-T103
-	O
mediated	O
restoration	O
of	O
5	B-T103
-	I-T103
FU	I-T103
sensitivity	O
is	O
mediated	O
at	O
least	O
in	O
part	O
by	O
MAPK	B-T038
signaling	I-T038
pathway	I-T038
.	O

Effect	O
of	O
Successive	B-T058
Administration	I-T058
of	O
Vancomycin	B-T103
and	O
Amikacin	B-T103
on	O
Auditory	B-T038
Function	I-T038
of	O
Immature	O
Animals	O

Effect	O
of	O
successive	B-T058
administration	I-T058
vancomycin	B-T103
and	O
amikacin	B-T103
in	O
therapeutic	O
doses	O
on	O
immature	O
auditory	B-T022
organ	I-T022
was	O
compared	O
to	O
single	O
administration	B-T058
of	O
the	O
same	O
drugs	B-T103
in	O
chronic	O
experiments	B-T062
on	O
immature	O
rabbits	B-T204
by	O
recording	O
of	O
short	O
-	O
latency	O
auditory	B-T201
brainstem	I-T201
response	I-T201
(	O
ABR	B-T201
)	O
and	O
distortion	B-T058
product	I-T058
otoacoustic	I-T058
emission	I-T058
(	O
DPOAE	B-T058
)	O
.	O

Drug	B-T058
administration	I-T058
always	O
increased	O
significantly	O
the	O
ABR	B-T201
peak	O
I	O
threshold	O
.	O

Ototoxic	B-T037
antibiotics	B-T103
did	O
not	O
change	O
DPOAE	B-T058
,	O
but	O
selectively	O
affected	O
activity	B-T033
of	O
outer	B-T017
hair	I-T017
cells	I-T017
.	O

No	B-T033
enhancement	O
of	O
the	O
ototoxic	B-T037
effects	I-T037
was	O
observed	O
after	O
successive	B-T058
administration	I-T058
of	O
the	O
two	O
antibiotics	B-T103
.	O

Water	B-T103
safety	O
in	O
healthcare	B-T092
facilities	I-T092
.	O
The	O
Vieste	B-T170
Charter	I-T170

The	O
Study	B-T097
Group	I-T097
on	O
Hospital	B-T092
Hygiene	B-T091
of	O
the	O
Italian	B-T092
Society	I-T092
of	I-T092
Hygiene	I-T092
,	I-T092
Preventive	I-T092
Medicine	I-T092
and	I-T092
Public	I-T092
Health	I-T092
(	O
GISIO	B-T092
-	I-T092
SItI	I-T092
)	O
and	O
the	O
Local	B-T092
Health	I-T092
Authority	I-T092
of	O
Foggia	B-T082
,	O
Apulia	B-T082
,	O
Italy	B-T082
,	O
after	O
the	O
National	O
Convention	O
"	O
Safe	O
water	B-T103
in	O
healthcare	B-T092
facilities	I-T092
"	O
held	O
in	O
Vieste	B-T082
-	I-T082
Pugnochiuso	I-T082
on	O
27	O
-	O
28	O
May	O
2016	O
,	O
present	O
the	O
"	O
Vieste	B-T170
Charter	I-T170
"	O
,	O
drawn	O
up	O
in	O
collaboration	O
with	O
experts	B-T097
from	O
the	O
National	O
Institute	O
of	O
Health	O
and	O
the	O
Ministry	O
of	O
Health	O
.	O

This	O
paper	O
considers	O
the	O
risk	B-T033
factors	I-T033
that	O
may	O
affect	B-T058
the	O
water	B-T103
safety	O
in	O
healthcare	B-T092
facilities	I-T092
and	O
reports	O
the	O
current	O
regulatory	B-T170
frameworks	I-T170
governing	O
the	O
management	O
of	O
installations	O
and	O
the	O
quality	O
of	O
the	O
water	B-T103
.	O

The	O
Authors	O
promote	O
a	O
careful	O
analysis	O
of	O
the	O
risks	O
that	O
characterize	O
the	O
health	B-T092
facilities	I-T092
,	O
for	O
the	O
control	O
of	O
which	O
specific	O
actions	O
are	O
recommended	O
in	O
various	O
areas	O
,	O
including	O
water	O
safety	O
plans	O
;	O
approval	O
of	O
treatments	O
;	O
healthcare	B-T092
facilities	I-T092
responsibility	O
,	O
installation	O
and	O
maintenance	O
of	O
facilities	B-T092
;	O
multidisciplinary	B-T082
approach	I-T082
;	O
education	O
and	O
research	B-T062
;	O
regional	O
and	O
national	O
coordination	O
;	O
communication	O
.	O

In	B-T082
Vivo	I-T082
Three	B-T082
-	I-T082
Dimensional	I-T082
Patellar	B-T017
Mechanics	O
:	O
Normal	O
Knees	B-T017
Compared	O
with	O
Domed	B-T082
and	O
Anatomic	O
Patellar	B-T017
Components	O

Patellofemoral	B-T082
complications	O
are	O
a	O
major	O
cause	O
of	O
revision	B-T058
surgery	I-T058
following	O
total	B-T058
knee	I-T058
arthroplasty	I-T058
(	O
TKA	B-T058
)	O
.	O

High	O
forces	O
occurring	O
at	O
the	O
patellofemoral	B-T082
articulation	I-T082
coupled	O
with	O
a	O
small	O
patellofemoral	B-T082
contact	B-T082
area	I-T082
pose	O
substantial	O
design	O
challenges	O
.	O

In	O
this	O
study	B-T062
,	O
the	O
three	B-T082
-	I-T082
dimensional	I-T082
(	O
3D	B-T082
)	O
in	B-T082
vivo	I-T082
mechanics	O
of	O
domed	B-T082
and	O
anatomically	O
shaped	B-T082
patellar	B-T017
components	O
were	O
compared	O
with	O
those	O
of	O
native	O
patellae	B-T017
.	O

Ten	O
normal	O
knees	B-T017
,	O
10	O
treated	B-T058
with	I-T058
an	O
LCS	B-T058
-	I-T058
PS	I-T058
(	I-T058
low	I-T058
contact	I-T058
stress	I-T058
-	I-T058
posterior	I-T058
stabilized	I-T058
)	I-T058
TKA	I-T058
(	O
anatomically	O
shaped	B-T082
patellar	B-T017
component	O
)	O
,	O
and	O
10	O
treated	B-T058
with	I-T058
a	O
PFC	B-T058
Sigma	I-T058
RP	I-T058
-	I-T058
PS	I-T058
(	I-T058
press	I-T058
-	I-T058
fit	I-T058
condylar	I-T058
Sigma	I-T058
rotating	I-T058
platform	I-T058
-	I-T058
posterior	I-T058
stabilized	I-T058
)	I-T058
TKA	I-T058
(	O
domed	B-T082
patellar	B-T017
component	O
)	O
were	O
analyzed	B-T062
under	O
fluoroscopic	B-T058
surveillance	O
while	O
the	O
patient	O
performed	O
a	O
weight	B-T033
-	I-T033
bearing	I-T033
deep	B-T082
knee	B-T033
bend	I-T033
from	O
full	O
knee	O
extension	O
to	O
maximum	O
knee	B-T033
flexion	I-T033
.	O

Relevant	O
bone	O
geometries	O
were	O
segmented	B-T082
out	O
from	O
computed	B-T058
tomography	I-T058
(	O
CT	B-T058
)	O
scans	B-T058
,	O
and	O
computer	O
-	O
assisted	O
-	O
design	O
(	O
CAD	O
)	O
models	B-T170
of	O
the	O
implanted	B-T074
components	O
were	O
obtained	O
from	O
the	O
manufacturer	O
.	O

Three	B-T082
-	I-T082
dimensional	I-T082
patellofemoral	B-T082
kinematics	B-T091
were	O
obtained	O
using	O
a	O
3D	B-T082
-	O
to	O
-	O
2D	B-T082
registration	O
process	O
.	O

Contact	O
mechanics	O
were	O
calculated	O
using	O
a	O
distance	O
map	O
between	O
the	O
articulating	B-T017
patellar	I-T017
and	O
femoral	B-T082
surfaces	I-T082
.	O

Both	O
patellar	B-T017
component	O
designs	O
exhibited	O
good	O
rotational	B-T091
kinematics	I-T091
and	O
tracked	O
well	O
within	O
the	O
femoral	B-T017
trochlea	I-T017
when	O
compared	O
with	O
the	O
normal	O
patella	B-T017
.	O

The	O
contact	B-T082
areas	I-T082
in	O
the	O
TKA	B-T058
groups	O
peaked	O
at	O
60°	O
of	O
knee	B-T033
flexion	I-T033
(	O
mean	O
and	O
standard	O
deviation	O
,	O
201	O
±	O
63	O
.	O
4	O
mm	O
for	O
the	O
LCS	O
-	O
PS	O
group	O
and	O
218	O
±	O
95	O
.	O
4	O
mm	O
for	O
the	O
Sigma	O
RP	O
-	O
PS	O
group	O
)	O
,	O
and	O
the	O
areas	B-T082
were	O
substantially	O
smaller	O
than	O
those	O
previously	O
reported	B-T170
for	O
the	O
normal	O
patella	B-T017
.	O

Contact	B-T082
points	I-T082
in	O
the	O
TKA	B-T058
groups	O
stayed	O
close	O
to	O
the	O
center	B-T082
of	O
the	O
patellar	B-T017
components	O
.	O

Both	O
designs	O
performed	O
satisfactorily	O
,	O
although	O
patellofemoral	B-T082
contact	B-T082
areas	I-T082
were	O
reduced	O
in	O
comparison	O
with	O
those	O
in	O
the	O
native	O
patella	B-T017
.	O

Therapeutic	O
Level	O
III	O
.	O

See	O
Instructions	O
for	O
Authors	O
for	O
a	O
complete	O
description	O
of	O
levels	O
of	O
evidence	O
.	O

Assessment	O
of	O
the	O
Extravascular	B-T074
Implantable	I-T074
Defibrillator	I-T074
:	O
Feasibility	O
of	O
Substernal	B-T058
Ventricular	I-T058
Pacing	I-T058

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
assess	O
feasibility	O
of	O
ventricular	B-T058
pacing	I-T058
and	O
thresholds	O
from	O
within	B-T082
the	O
substernal	B-T082
space	I-T082
to	O
examine	O
a	O
new	O
extravascular	B-T074
ICD	I-T074
configuration	B-T082
with	O
pacing	B-T058
capabilities	O
.	O

In	O
patients	O
undergoing	O
midline	B-T058
sternotomy	I-T058
,	O
a	O
duodecapolar	B-T074
diagnostic	I-T074
pacing	I-T074
catheter	I-T074
was	O
positioned	B-T082
in	O
the	O
substernal	B-T082
space	I-T082
anterior	B-T082
to	O
the	O
pericardium	B-T017
,	O
and	O
a	O
cutaneous	B-T033
patch	I-T033
in	O
left	B-T082
lateral	I-T082
position	I-T082
.	O

Different	O
unipolar	B-T082
and	O
bipolar	B-T082
pacing	B-T058
configurations	B-T082
were	O
assessed	O
.	O

Strength	B-T058
-	I-T058
duration	I-T058
curves	I-T058
were	O
performed	O
to	O
identify	O
the	O
optimal	O
output	B-T058
,	O
starting	O
at	O
25	O
mA	O
with	O
a	O
pulse	O
width	O
of	O
10	O
milliseconds	O
.	O

Eight	O
patients	O
with	O
mean	O
age	O
69	O
±	O
9	O
years	O
were	O
included	O
.	O

In	O
5	O
,	O
ventricular	B-T082
capture	O
was	O
achieved	O
in	O
≥1	O
configuration	B-T082
.	O

The	O
mean	O
bipolar	B-T082
pacing	B-T058
thresholds	O
at	O
PW	O
10	O
,	O
5	O
,	O
3	O
,	O
1	O
milliseconds	O
were	O
12	O
.	O
4	O
±	O
3	O
.	O
7	O
mA	O
(	O
5	O
patients	O
)	O
,	O
13	O
.	O
3	O
±	O
5	O
.	O
8	O
mA	O
(	O
3	O
patients	O
)	O
,	O
18	O
.	O
3	O
±	O
5	O
.	O
7	O
mA	O
(	O
3	O
patients	O
)	O
,	O
and	O
25	O
±	O
0	O
mA	O
(	O
2	O
patients	O
)	O
,	O
respectively	O
.	O

The	O
60	O
-	O
mm	O
electrode	B-T074
spacing	O
was	O
the	O
most	O
successful	O
bipolar	B-T082
configuration	B-T082
.	O

Unipolar	B-T082
pacing	B-T058
was	O
successful	O
in	O
3	O
out	O
of	O
4	O
patients	O
with	O
mean	O
thresholds	O
of	O
10	O
±	O
0	O
mA	O
at	O
10	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
15	O
±	O
0	O
mA	O
at	O
5	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
16	O
.	O
7	O
±	O
2	O
.	O
9	O
mA	O
at	O
3	O
milliseconds	O
(	O
3	O
patients	O
)	O
,	O
and	O
20	O
±	O
7	O
.	O
1	O
mA	O
at	O
1	O
milliseconds	O
(	O
2	O
patients	O
)	O
.	O

Ventricular	B-T058
pacing	B-T058
from	O
the	O
substernal	B-T082
space	I-T082
in	O
patients	O
with	O
midline	B-T058
sternotomy	I-T058
is	O
feasible	O
.	O

Closed	O
sternum	B-T017
studies	B-T062
are	O
needed	O
to	O
determine	O
pacing	B-T058
thresholds	O
more	O
accurately	O
.	O

Effects	O
of	O
a	O
specific	O
blend	O
of	O
essential	B-T103
oils	I-T103
on	O
apparent	O
nutrient	B-T168
digestion	B-T038
,	O
rumen	B-T017
fermentation	B-T038
and	O
rumen	B-T017
microbial	O
populations	O
in	O
sheep	B-T204
fed	O
a	O
50	O
:	O
50	O
alfalfa	B-T204
hay	I-T204
:	O
concentrate	B-T168
diet	I-T168

An	O
experiment	B-T062
was	O
conducted	O
to	O
investigate	O
the	O
effects	O
of	O
a	O
specific	O
mixture	O
of	O
essential	B-T103
oils	I-T103
(	O
MEO	B-T103
)	O
,	O
containing	O
thyme	B-T103
,	O
clove	B-T103
and	O
cinnamon	B-T103
EO	I-T103
,	O
on	O
rumen	B-T017
microbial	B-T038
fermentation	I-T038
,	O
nutrient	B-T168
apparent	O
digestibility	B-T033
and	O
blood	B-T031
metabolites	B-T103
in	O
fistulated	B-T204
sheep	I-T204
.	O

Six	O
sheep	B-T204
fitted	O
with	O
ruminal	B-T017
fistulas	I-T017
were	O
used	O
in	O
a	O
repeated	B-T170
measurement	I-T170
design	I-T170
with	O
two	O
24	O
-	O
d	O
periods	O
to	O
investigate	O
the	O
effect	O
of	O
adding	O
MEO	B-T103
at	O
0	O
(	O
control	O
)	O
,	O
0	O
.	O
8	O
,	O
and	O
1	O
.	O
6	O
mL	O
/	O
d	O
on	O
apparent	O
nutrient	B-T168
digestibility	B-T033
,	O
rumen	B-T017
fermentation	B-T038
characteristics	O
,	O
rumen	B-T017
microbial	O
population	O
and	O
blood	B-T031
chemical	B-T103
metabolites	I-T103
.	O

Animals	B-T204
were	O
fed	O
with	O
a	O
50	O
:	O
50	O
alfalfa	B-T204
hay	I-T204
:	O
concentrate	B-T168
diet	I-T168
.	O

Ruminal	O
pH	O
,	O
total	O
volatile	B-T103
fatty	I-T103
acids	I-T103
(	O
VFA	B-T103
)	O
concentration	O
,	O
molar	O
proportion	O
of	O
individual	O
VFA	B-T103
,	O
acetate	O
:	O
propionate	O
ratio	O
and	O
methane	B-T038
production	I-T038
were	O
not	O
affected	O
with	O
MEO	B-T103
.	O

Relative	O
to	O
the	O
control	O
,	O
Small	B-T103
peptides	I-T103
plus	O
amino	O
acid	O
nitrogen	O
and	O
large	B-T103
peptides	I-T103
nitrogen	O
concentration	O
in	O
rumen	B-T031
fluid	I-T031
were	O
not	O
affected	O
with	O
MEO	B-T103
supplementation	B-T058
;	O
while	O
,	O
rumen	B-T031
fluid	I-T031
ammonia	B-T103
nitrogen	O
concentration	O
at	O
0	O
and	O
6	O
h	O
after	O
morning	O
feeding	O
in	O
sheep	B-T204
fed	O
with	O
1	O
.	O
6	O
mL	O
/	O
d	O
of	O
MEO	B-T103
was	O
lower	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
compared	O
to	O
the	O
control	O
and	O
0	O
.	O
8	O
mL	O
/	O
d	O
of	O
MEO	B-T103
.	O

At	O
0	O
h	O
after	O
morning	O
feeding	O
,	O
ammonia	B-T103
nitrogen	O
concentration	O
was	O
higher	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
sheep	B-T204
fed	O
0	O
.	O
8	O
mL	O
/	O
d	O
of	O
MEO	B-T103
relative	O
to	O
1	O
.	O
6	O
mL	O
/	O
d	O
and	O
control	O
diet	B-T168
.	O

Ruminal	B-T204
protozoa	I-T204
and	O
hyper	B-T007
ammonia	I-T007
producing	I-T007
(	I-T007
HAP	I-T007
)	I-T007
bacteria	I-T007
counts	B-T058
were	O
not	O
affected	O
by	O
addition	O
of	O
MEO	B-T103
in	O
the	O
diet	B-T168
.	O

Relative	O
to	O
the	O
control	O
,	O
no	O
changes	O
were	O
observed	O
in	O
the	O
red	B-T058
and	O
white	B-T033
blood	I-T033
cells	I-T033
,	O
hemoglobin	B-T058
,	O
hematocrit	B-T033
,	O
glucose	B-T058
,	O
beta	B-T103
-	I-T103
hydroxybutyric	I-T103
acid	I-T103
,	O
cholesterol	B-T058
,	O
total	B-T058
protein	I-T058
,	O
albumin	B-T058
,	O
blood	B-T058
urea	I-T058
nitrogen	I-T058
and	O
aspartate	B-T058
aminotransferase	I-T058
and	O
alanine	B-T058
aminotransferase	I-T058
concentration	O
.	O

Apparent	O
total	B-T033
tract	I-T033
digestibility	I-T033
of	O
dry	O
matter	O
,	O
crude	B-T103
proten	I-T103
,	O
organic	O
matter	O
,	O
and	O
neutral	O
detergent	O
fiber	O
were	O
not	O
influenced	O
by	O
MEO	B-T103
supplementation	B-T058
.	O

The	O
results	O
of	O
the	O
present	O
study	O
suggested	O
that	O
supplementation	B-T058
of	O
MEO	B-T103
may	O
have	O
limited	O
effects	O
on	O
apparent	O
nutrient	B-T168
digestibility	B-T033
,	O
ruminal	B-T038
fermentation	I-T038
and	O
protozoa	B-T204
and	O
HAP	B-T007
bacteria	I-T007
count	B-T058
,	O
blood	B-T017
cells	I-T017
and	O
metabolites	B-T103
.	O

High	O
throughput	O
selection	O
of	O
antibiotic	O
-	O
resistant	O
transgenic	B-T204
Arabidopsis	B-T204
plants	I-T204

Kanamycin	B-T103
resistance	O
is	O
the	O
most	O
frequently	O
used	O
antibiotic	O
-	O
resistance	O
marker	B-T201
for	O
Arabidopsis	B-T204
transformations	B-T038
,	O
however	O
,	O
this	O
method	B-T170
frequently	O
causes	O
escape	O
of	O
untransformed	B-T204
plants	I-T204
,	O
particularly	O
at	O
the	O
high	O
seedling	B-T204
density	O
during	O
the	O
selection	O
.	O

Here	O
we	O
developed	O
a	O
robust	O
high	O
-	O
density	O
selection	O
method	B-T170
using	O
top	B-T082
agar	B-T103
for	O
Arabidopsis	B-T204
thaliana	I-T204
.	O

Top	B-T082
agar	B-T103
effectively	O
suppressed	O
growth	B-T038
of	O
untransformed	B-T204
wild	I-T204
-	I-T204
type	I-T204
plants	I-T204
on	O
selection	O
media	B-T103
at	O
high	O
density	O
.	O

Survival	O
of	O
the	O
transformed	B-T038
plants	B-T204
during	O
the	O
selection	O
were	O
confirmed	B-T033
by	O
production	O
of	O
green	O
true	O
leaves	B-T204
and	O
expression	B-T038
of	O
a	O
firefly	B-T103
luciferase	I-T103
reporter	B-T017
gene	I-T017
.	O

Top	B-T082
agar	B-T103
method	B-T170
allowed	O
selection	O
using	O
a	O
large	O
amount	O
of	O
seeds	B-T204
in	O
Arabidopsis	B-T204
transformation	B-T038
.	O

Limb	B-T017
remote	B-T058
ischaemic	I-T058
postconditioning	I-T058
-	O
induced	O
elevation	O
of	O
fibulin	B-T103
-	I-T103
5	I-T103
confers	O
neuroprotection	B-T038
to	O
rats	B-T204
with	O
cerebral	B-T038
ischaemia	I-T038
/	O
reperfusion	B-T037
injury	I-T037
:	O
Activation	O
of	O
the	O
AKT	B-T038
pathway	I-T038

Limb	B-T017
remote	B-T058
ischaemic	I-T058
postconditioning	I-T058
(	O
RIPostC	B-T058
)	O
is	O
an	O
effective	O
and	O
well	O
-	O
acknowledged	O
treatment	B-T058
for	O
brain	O
ischaemia	O
injury	O
.	O

The	O
present	O
study	B-T062
aimed	O
to	O
evaluate	O
the	O
role	O
of	O
fibulin	B-T103
-	I-T103
5	I-T103
in	O
the	O
neuroprotection	B-T038
of	O
RIPostC	B-T058
against	O
cerebral	B-T038
ischaemia	I-T038
/	O
reperfusion	B-T037
(	I-T037
I	I-T037
/	I-T037
R	I-T037
)	I-T037
injury	I-T037
in	O
rats	B-T204
.	O

The	O
middle	B-T017
cerebral	I-T017
artery	I-T017
occlusion	I-T017
(	O
MCAO	B-T017
)	O
model	O
was	O
established	O
in	O
rats	B-T204
and	O
then	O
RIPostC	B-T058
was	O
carried	O
out	O
by	O
three	O
cycles	O
of	O
10	O
minutes	O
occlusion	B-T017
/	O
10	O
minutes	O
release	O
of	O
the	O
bilateral	B-T082
femoral	B-T017
artery	I-T017
at	O
the	O
beginning	O
of	O
the	O
reperfusion	B-T058
.	O

To	O
downregulate	B-T038
the	O
fibulin	B-T103
-	I-T103
5	I-T103
level	O
,	O
fibulin	B-T103
-	I-T103
5	I-T103
siRNA	I-T103
was	O
injected	B-T058
into	O
the	O
lateral	B-T082
ventricle	I-T082
24	O
hours	O
before	O
MCAO	B-T017
.	O

According	O
to	O
our	O
present	O
study	B-T062
,	O
RIPostC	B-T058
attenuated	O
cerebral	B-T038
I	I-T038
/	O
R	B-T037
injury	I-T037
by	O
decreasing	B-T033
infarct	B-T038
volume	O
,	O
improving	O
neurobehavioral	O
score	O
and	O
suppressing	O
blood	B-T017
brain	I-T017
barrier	I-T017
(	O
BBB	B-T017
)	O
leakage	B-T038
.	O

Moreover	O
,	O
the	O
mRNA	B-T103
and	O
protein	B-T033
levels	I-T033
of	O
fibulin	B-T103
-	I-T103
5	I-T103
were	O
upregulated	B-T038
by	O
RIPostC	B-T058
at	O
24	O
hours	O
and	O
72	O
hours	O
after	O
reperfusion	B-T058
.	O

Downregulation	B-T038
of	O
fibulin	B-T103
-	I-T103
5	I-T103
attenuated	O
the	O
neuroprotection	B-T038
of	O
RIPostC	B-T058
.	O

Finally	O
,	O
the	O
result	O
showed	O
that	O
fibulin	B-T103
-	I-T103
5	I-T103
was	O
upregulated	B-T038
by	O
RIPostC	B-T058
via	O
activation	O
of	O
the	O
PI3K	B-T038
/	I-T038
AKT	I-T038
pathway	I-T038
.	O

Taken	O
together	O
,	O
these	O
results	O
provide	O
evidence	O
that	O
upregulation	B-T038
of	O
fibulin	B-T103
-	I-T103
5	I-T103
is	O
involved	O
in	O
the	O
beneficial	O
effect	O
of	O
RIPostC	B-T058
against	O
cerebral	B-T038
I	I-T038
/	O
R	B-T037
injury	I-T037
.	O

Optomechanical	O
Control	O
of	O
Quantum	O
Yield	O
in	O
Trans	O
-	O
Cis	O
Ultrafast	O
Photoisomerization	O
of	O
a	O
Retinal	B-T103
Chromophore	O
Model	O

The	O
quantum	O
yield	O
of	O
a	O
photochemical	O
reaction	O
is	O
one	O
of	O
the	O
most	O
fundamental	O
quantities	O
in	O
photochemistry	O
,	O
as	O
it	O
measures	O
the	O
efficiency	O
of	O
the	O
transduction	B-T038
of	I-T038
light	I-T038
energy	I-T038
into	I-T038
chemical	I-T038
energy	I-T038
.	O

Nature	O
has	O
evolved	O
photoreceptors	B-T017
in	O
which	O
the	O
reactivity	O
of	O
a	O
chromophore	O
is	O
enhanced	O
by	O
its	O
molecular	B-T082
environment	I-T082
to	O
achieve	O
high	O
quantum	O
yields	O
.	O

The	O
retinal	B-T103
chromophore	O
sterically	O
constrained	O
inside	O
rhodopsin	B-T103
proteins	I-T103
represents	O
an	O
outstanding	O
example	O
of	O
such	O
a	O
control	O
.	O

In	O
a	O
more	O
general	O
framework	O
,	O
mechanical	O
forces	O
acting	O
on	O
a	O
molecular	O
system	O
can	O
strongly	O
modify	O
its	O
reactivity	O
.	O

Herein	O
,	O
we	O
show	O
that	O
the	O
exertion	O
of	O
tensile	O
forces	O
on	O
a	O
simplified	O
retinal	B-T103
chromophore	O
model	O
provokes	O
a	O
substantial	O
and	O
regular	O
increase	O
in	O
the	O
trans	O
-	O
to	O
-	O
cis	O
photoisomerization	O
quantum	O
yield	O
in	O
a	O
counterintuitive	O
way	O
,	O
as	O
these	O
extension	O
forces	O
facilitate	O
the	O
formation	O
of	O
the	O
more	O
compressed	O
cis	O
photoisomer	O
.	O

A	O
rationale	O
for	O
the	O
mechanochemical	O
effect	O
on	O
this	O
photoisomerization	O
mechanism	O
is	O
also	O
proposed	O
.	O

Quality	O
of	O
nursing	B-T170
intensity	I-T170
data	I-T170
:	O
inter	O
-	O
rater	O
reliability	O
of	O
the	O
patient	O
classification	B-T170
after	O
two	O
decades	O
in	O
clinical	O
use	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
measure	O
the	O
inter	O
-	O
rater	O
reliability	O
of	O
the	O
Oulu	B-T170
Patient	I-T170
Classification	I-T170
and	O
to	O
discuss	O
existing	O
methods	O
of	O
reliability	O
testing	O
.	O

The	O
Oulu	B-T170
Patient	I-T170
Classification	I-T170
,	O
part	O
of	O
the	O
RAFAELA	B-T170
(	I-T170
®	I-T170
)	I-T170
System	I-T170
,	O
has	O
been	O
developed	O
to	O
assist	O
nursing	B-T097
managers	I-T097
with	O
the	O
proper	O
allocation	O
of	O
nursing	B-T058
resources	O
.	O

Due	O
to	O
the	O
increased	O
intensity	O
of	O
inpatient	B-T058
care	I-T058
during	O
recent	O
years	O
,	O
there	O
is	O
a	O
need	O
for	O
the	O
reliability	O
testing	O
of	O
the	O
classification	B-T170
,	O
which	O
has	O
been	O
in	O
clinical	O
use	O
for	O
20	O
years	O
.	O

Retrospective	O
statistical	B-T170
study	I-T170
.	O

To	O
test	O
inter	O
-	O
rater	O
reliability	O
,	O
a	O
pair	O
of	O
nurses	B-T097
classified	B-T170
the	O
same	O
patients	O
,	O
without	O
knowledge	O
of	O
each	O
other	O
'	O
s	O
ratings	O
,	O
as	O
a	O
part	O
of	O
annually	O
conducted	O
standardization	B-T062
.	O

Data	O
on	O
the	O
parallel	B-T170
classifications	I-T170
(	O
n	O
=	O
19	O
,	O
997	O
)	O
was	O
obtained	O
from	O
inpatient	O
units	O
(	O
n	O
=	O
32	O
)	O
with	O
different	O
specialties	B-T091
at	O
a	O
university	B-T092
hospital	I-T092
in	O
Finland	B-T082
during	O
2010	O
-	O
2015	O
.	O

Parallel	B-T170
classification	I-T170
practices	O
were	O
also	O
analysed	O
.	O

The	O
reliability	O
of	O
the	O
overall	O
classification	B-T170
and	O
its	O
subareas	O
were	O
calculated	O
using	O
suitable	O
statistical	O
coefficients	O
.	O

Inter	O
-	O
rater	O
reliability	O
coefficients	O
were	O
a	O
reliable	O
or	O
almost	O
perfect	O
means	O
of	O
considering	O
the	O
nursing	B-T058
intensity	O
category	B-T170
and	O
various	O
practices	O
,	O
but	O
there	O
were	O
detectable	B-T033
differences	O
between	O
subareas	O
.	O

The	O
lowest	O
agreement	O
levels	O
occurred	O
in	O
the	O
subareas	O
'	O
Planning	O
and	O
Coordination	O
of	O
Nursing	O
Care	O
'	O
and	O
'	O
Guiding	O
of	O
Care	O
/	O
Continued	B-T058
Care	I-T058
and	O
Emotional	B-T058
Support	I-T058
'	O
.	O

There	O
is	O
a	O
need	O
to	O
develop	O
the	O
descriptions	B-T170
of	O
subareas	O
and	O
to	O
clarify	O
the	O
related	O
concepts	O
.	O

Precise	O
nursing	B-T058
documentation	I-T058
can	O
promote	O
a	O
high	O
level	O
of	O
agreement	O
and	O
reliable	O
results	O
.	O

The	O
traditional	O
overall	O
proportion	O
of	O
agreement	O
does	O
not	O
provide	O
an	O
adequate	O
picture	O
of	O
reliability	O
-	O
weighted	O
kappa	O
coefficients	O
should	O
be	O
used	O
instead	O
.	O

Water	O
pipe	O
(	O
Shisha	O
,	O
Hookah	O
,	O
Arghile	O
)	O
Smoking	O
and	O
Secondhand	B-T037
Tobacco	I-T037
Smoke	I-T037
Effects	O
on	O
CYP1A2	B-T103
and	O
CYP2A6	B-T103
Phenotypes	O
as	O
Measured	O
by	O
Caffeine	B-T058
Urine	I-T058
Test	I-T058

Public	B-T097
policies	I-T097
to	O
stop	O
or	O
reduce	O
cigarette	O
smoking	O
and	O
exposure	O
to	O
secondhand	B-T037
smoke	I-T037
and	O
associated	B-T038
diseases	I-T038
have	O
yielded	O
successful	O
results	O
over	O
the	O
past	O
decade	O
.	O

Yet	O
,	O
the	O
growing	O
worldwide	O
popularity	O
of	O
another	O
form	O
of	O
tobacco	O
consumption	O
,	O
water	O
pipe	O
smoking	O
,	O
has	O
received	O
relatively	O
less	O
attention	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
study	O
to	O
date	O
has	O
evaluated	O
the	O
effects	O
of	O
water	O
pipe	O
smoking	O
on	O
cytochrome	B-T038
P450	I-T038
(	I-T038
CYP450	I-T038
)	I-T038
activities	I-T038
and	O
drug	B-T038
interaction	I-T038
potential	O
in	O
humans	B-T204
,	O
whereas	O
only	O
limited	O
information	O
is	O
available	O
on	O
the	O
impact	O
of	O
secondhand	B-T037
smoke	I-T037
on	O
drug	B-T038
metabolism	I-T038
.	O

In	O
a	O
sample	O
of	O
99	O
healthy	B-T098
volunteers	I-T098
(	O
28	O
water	O
pipe	O
smokers	O
,	O
30	O
secondhand	B-T037
tobacco	I-T037
smoke	I-T037
exposed	O
persons	B-T098
,	O
and	O
41	O
controls	O
)	O
,	O
we	O
systematically	O
compared	O
CYP1A2	B-T103
and	O
CYP2A6	B-T103
enzyme	B-T038
activities	I-T038
in	B-T082
vivo	I-T082
using	O
caffeine	B-T058
urine	I-T058
test	I-T058
.	O

The	O
median	O
self	B-T062
-	I-T062
reported	I-T062
duration	O
of	O
water	O
pipe	O
smoking	O
was	O
7	O
.	O
5	O
h	O
/	O
week	O
and	O
3	O
years	O
of	O
exposure	O
in	O
total	O
.	O

The	O
secondhand	B-T037
smoke	I-T037
group	B-T098
had	O
a	O
median	O
of	O
14	O
h	O
of	O
self	B-T062
-	I-T062
reported	I-T062
weekly	O
exposure	O
to	O
tobacco	B-T103
smoke	I-T103
indoor	O
where	O
a	O
minimum	O
of	O
five	O
cigarettes	O
were	O
smoked	B-T103
/	O
hour	O
for	O
a	O
total	O
of	O
3	O
.	O
5	O
years	O
(	O
median	O
)	O
.	O

Analysis	B-T062
of	O
variance	O
did	O
not	O
find	O
a	O
significant	O
difference	O
in	O
CYP1A2	B-T103
and	O
CYP2A6	B-T103
activities	B-T038
among	O
the	O
three	O
study	B-T062
groups	B-T098
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Nor	O
was	O
there	O
a	O
significant	O
association	O
between	O
the	O
extent	O
of	O
water	O
pipe	O
or	O
secondhand	B-T037
smoke	I-T037
exposure	O
and	O
the	O
CYP1A2	B-T103
and	O
CYP2A6	B-T103
activities	B-T038
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Further	O
analysis	B-T062
in	O
a	O
subsample	O
with	O
smoke	O
exposure	O
more	O
than	O
the	O
median	O
values	O
also	O
did	O
not	O
reveal	O
a	O
significant	O
difference	O
from	O
the	O
controls	O
.	O

Although	O
we	O
do	O
not	O
rule	O
out	O
an	O
appreciable	O
possible	O
impact	O
of	O
water	O
pipe	O
smoke	O
and	O
secondhand	B-T037
smoke	I-T037
on	O
in	B-T082
vivo	I-T082
activities	B-T038
of	O
these	O
two	O
drug	B-T038
metabolism	I-T038
pathways	B-T038
,	O
variability	O
in	O
smoke	O
constituents	O
from	O
different	O
tobacco	O
consumption	O
methods	O
(	O
e	O
.	O
g	O
.	O
,	O
water	O
pipe	O
)	O
might	O
affect	O
drug	B-T038
metabolism	I-T038
in	O
ways	O
that	O
might	O
differ	O
from	O
that	O
of	O
cigarette	B-T103
smoke	I-T103
.	O

Further	O
studies	B-T062
in	O
larger	O
prospective	O
samples	O
are	O
recommended	O
to	O
evaluate	O
water	O
pipe	O
and	O
secondhand	B-T037
tobacco	I-T037
smoke	I-T037
effects	O
on	O
CYP450	B-T103
function	O
,	O
particularly	O
at	O
higher	O
smoke	B-T103
exposure	O
conditions	O
.	O

How	O
do	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	B-T033
degree	I-T033
affect	O
the	O
biological	B-T033
response	I-T033
of	O
biomaterials	B-T103
?	O

It	O
is	O
well	O
known	O
that	O
composition	O
,	O
electric	O
charge	O
,	O
wettability	O
and	O
roughness	O
of	O
implant	B-T074
surfaces	B-T082
have	O
great	O
influence	O
on	O
their	O
interaction	O
with	O
the	O
biological	B-T031
fluids	I-T031
and	O
tissues	B-T017
,	O
but	O
systematic	B-T062
studies	I-T062
of	O
different	O
materials	O
in	O
the	O
same	O
experimental	O
conditions	O
are	O
still	O
lacking	O
in	O
the	O
scientific	B-T170
literature	I-T170
.	O

The	O
aim	O
of	O
this	O
research	B-T062
is	O
to	O
investigate	O
the	O
correlations	O
between	O
some	O
surface	O
characteristics	O
(	O
wettability	O
,	O
zeta	O
potential	O
and	O
hydroxylation	B-T033
degree	I-T033
)	O
and	O
the	O
biological	B-T033
response	I-T033
(	O
protein	B-T033
adsorption	I-T033
,	O
blood	B-T031
wettability	O
,	O
cell	B-T038
and	O
bacterial	B-T038
adhesion	I-T038
)	O
to	O
some	O
model	O
biomaterials	B-T103
.	O

The	O
resulting	O
knowledge	O
can	O
be	O
applied	O
for	O
the	O
development	O
of	O
future	O
innovative	O
surfaces	B-T082
for	O
implantable	B-T103
biomaterials	I-T103
.	O

Roughness	O
was	O
not	O
considered	O
as	O
a	O
variable	O
because	O
it	O
is	O
a	O
widely	O
explored	O
feature	O
:	O
smooth	B-T082
surfaces	I-T082
prepared	O
by	O
a	O
controlled	B-T170
protocol	I-T170
were	O
compared	O
in	O
order	O
to	O
have	O
no	O
roughness	O
effects	O
.	O

Three	O
oxides	B-T103
(	O
ZrO2	B-T103
,	O
Al2O3	B-T103
,	O
SiO2	B-T103
)	O
,	O
three	O
metals	B-T103
(	O
316LSS	B-T103
steel	I-T103
,	O
Ti	B-T103
,	O
Nb	B-T103
)	O
and	O
two	O
polymers	B-T103
(	O
corona	B-T103
treated	I-T103
polystyrene	I-T103
for	O
cell	O
culture	O
and	O
untreated	B-T103
polystyrene	I-T103
for	O
bacteria	B-T058
culture	I-T058
)	O
,	O
widely	O
used	O
for	O
biomedical	O
applications	O
,	O
were	O
considered	O
.	O

The	O
surfaces	B-T082
were	O
characterized	O
by	O
contact	B-T062
profilometry	I-T062
,	O
SEM	B-T058
-	O
EDS	B-T058
,	O
XPS	B-T058
,	O
FTIR	B-T062
,	O
zeta	O
potential	O
and	O
wettability	O
with	O
different	O
fluids	O
.	O

Protein	B-T033
adsorption	I-T033
,	O
blood	B-T031
wettability	O
,	O
bacterial	B-T038
and	O
cell	B-T038
adhesion	I-T038
were	O
evaluated	O
in	O
order	O
to	O
investigate	O
the	O
correlations	O
between	O
the	O
surface	O
physiochemical	O
properties	O
and	O
biological	B-T033
responses	I-T033
.	O

From	O
a	O
methodological	O
standpoint	O
,	O
XPS	B-T058
and	O
electrokinetic	O
measurements	O
emerged	O
as	O
the	O
more	O
suitable	O
techniques	O
respectively	O
for	O
the	O
evaluation	O
of	O
hydroxylation	B-T033
degree	I-T033
and	O
surface	O
charge	O
/	O
isoelectric	O
point	O
.	O

Moreover	O
,	O
determination	O
of	O
wettability	O
by	O
blood	B-T031
appeared	O
a	O
specific	O
and	O
crucial	O
test	B-T170
,	O
the	O
results	O
of	O
which	O
are	O
not	O
easily	O
predictable	O
by	O
using	O
other	O
type	O
of	O
tests	B-T170
.	O

Hydroxylation	B-T033
degree	I-T033
resulted	O
correlated	O
to	O
the	O
wettability	O
by	O
water	B-T103
,	O
but	O
not	O
directly	O
to	O
surface	O
charge	O
.	O

Wetting	B-T062
tests	I-T062
with	O
different	O
media	O
showed	O
the	O
possibility	O
to	O
highlight	O
some	O
differences	O
among	O
look	O
-	O
alike	O
materials	O
.	O

A	O
dependence	O
of	O
protein	B-T033
absorption	I-T033
on	O
hydroxylation	B-T033
degree	I-T033
,	O
charge	O
and	O
wettability	O
was	O
evidenced	O
and	O
its	O
maximum	O
was	O
registered	O
for	O
surfaces	B-T082
with	O
low	O
wettability	O
in	O
both	O
water	B-T103
based	O
and	O
protein	B-T103
containing	O
media	O
and	O
a	O
moderate	O
surface	O
charge	O
.	O

As	O
far	O
as	O
bacterial	B-T038
adhesion	I-T038
is	O
concerned	O
,	O
no	O
effect	O
of	O
surface	O
charge	O
or	O
protein	B-T033
adsorption	I-T033
was	O
evidenced	O
,	O
while	O
the	O
presence	O
of	O
a	O
high	O
acid	O
component	O
of	O
the	O
surface	O
energy	O
appeared	O
significant	O
.	O

Finally	O
,	O
the	O
combination	O
of	O
hydroxylation	B-T033
degree	I-T033
,	O
wettability	O
,	O
surface	O
charge	O
and	O
energy	O
(	O
polar	O
component	O
)	O
emerged	O
as	O
a	O
key	O
parameter	O
for	O
cell	B-T038
adhesion	I-T038
and	O
viability	B-T038
.	O

Persistent	O
effects	O
of	O
pre	O
-	O
Columbian	O
plant	B-T204
domestication	O
on	O
Amazonian	O
forest	O
composition	B-T201

The	O
extent	O
to	O
which	O
pre	O
-	O
Columbian	O
societies	B-T092
altered	O
Amazonian	O
landscapes	B-T082
is	O
hotly	O
debated	O
.	O

We	O
performed	O
a	O
basin	B-T062
-	I-T062
wide	I-T062
analysis	I-T062
of	O
pre	O
-	O
Columbian	O
impacts	O
on	O
Amazonian	O
forests	O
by	O
overlaying	O
known	O
archaeological	B-T082
sites	I-T082
in	O
Amazonia	O
with	O
the	O
distributions	O
and	O
abundances	O
of	O
85	O
woody	B-T204
species	B-T170
domesticated	O
by	O
pre	O
-	O
Columbian	O
peoples	B-T098
.	O

Domesticated	O
species	B-T170
are	O
five	O
times	O
more	O
likely	O
than	O
nondomesticated	B-T170
species	I-T170
to	O
be	O
hyperdominant	O
.	O

Across	O
the	O
basin	O
,	O
the	O
relative	O
abundance	O
and	O
richness	O
of	O
domesticated	O
species	B-T170
increase	O
in	O
forests	O
on	O
and	O
around	O
archaeological	B-T082
sites	I-T082
.	O

In	O
southwestern	O
and	O
eastern	O
Amazonia	O
,	O
distance	O
to	O
archaeological	B-T082
sites	I-T082
strongly	O
influences	O
the	O
relative	O
abundance	O
and	O
richness	O
of	O
domesticated	O
species	B-T170
.	O

Our	O
analyses	B-T062
indicate	O
that	O
modern	O
tree	B-T204
communities	O
in	O
Amazonia	O
are	O
structured	O
to	O
an	O
important	O
extent	O
by	O
a	O
long	O
history	O
of	O
plant	B-T204
domestication	O
by	O
Amazonian	O
peoples	B-T098
.	O

Halogenated	B-T103
phenolic	I-T103
compounds	I-T103
in	O
wild	B-T204
fish	I-T204
from	O
Canadian	B-T082
Areas	I-T082
of	O
Concern	O

Concentrations	O
of	O
halogenated	B-T103
phenolic	I-T103
compounds	I-T103
were	O
measured	O
in	O
the	O
plasma	B-T031
of	O
brown	B-T204
bullhead	I-T204
(	O
Ameiurus	B-T204
nebulosus	I-T204
)	O
from	O
4	O
Canadian	B-T082
Areas	I-T082
of	O
Concern	O
(	O
AOCs	B-T082
)	O
,	O
to	O
assess	O
exposure	O
to	O
suspected	O
thyroid	B-T017
-	O
disrupting	B-T103
chemicals	I-T103
.	O

Hydroxylated	B-T103
polychlorinated	I-T103
biphenyls	I-T103
(	O
OH	B-T103
-	I-T103
PCBs	I-T103
)	O
were	O
detected	O
in	O
every	O
sample	O
collected	O
in	O
3	O
of	O
the	O
AOCs	B-T082
;	O
the	O
detection	B-T058
frequency	O
was	O
lower	O
in	O
samples	O
from	O
the	O
Detroit	O
River	O
AOC	B-T082
.	O

The	O
OH	B-T103
-	I-T103
PCBs	I-T103
most	O
frequently	O
detected	O
were	O
pentachloro	O
,	O
hexachloro	O
,	O
and	O
heptachloro	O
congeners	O
,	O
which	O
are	O
structurally	O
similar	O
to	O
thyroid	B-T103
hormones	I-T103
.	O

Pentachlorophenol	B-T103
(	O
PCP	B-T103
)	O
was	O
detected	O
at	O
highest	O
concentrations	O
(	O
1	O
.	O
8	O
ng	O
/	O
g	O
)	O
in	O
fish	B-T204
from	O
Prince	B-T082
Edward	I-T082
Bay	I-T082
,	O
the	O
Bay	B-T082
of	I-T082
Quinte	I-T082
Lake	I-T082
reference	I-T082
site	I-T082
,	O
and	O
Hillman	O
Marsh	O
(	O
the	O
Wheatley	O
Harbour	O
reference	O
site	O
)	O
,	O
suggesting	O
local	O
sources	O
of	O
contamination	O
.	O

Elevated	B-T058
PCP	I-T058
concentrations	I-T058
were	O
also	O
detected	O
in	O
the	O
plasma	B-T031
of	O
brown	B-T204
bullhead	I-T204
from	O
exposed	O
sites	O
in	O
the	O
Toronto	B-T082
and	I-T082
Region	I-T082
AOC	I-T082
(	O
0	O
.	O
4	O
-	O
0	O
.	O
6	O
ng	O
/	O
g	O
)	O
.	O

Triclosan	B-T103
was	O
consistently	O
detected	O
in	O
the	O
Toronto	B-T082
and	I-T082
Region	I-T082
AOC	I-T082
(	O
0	O
.	O
05	O
-	O
0	O
.	O
9	O
ng	O
/	O
g	O
)	O
,	O
consistent	O
with	O
wastewater	B-T082
emission	O
.	O

Greater	O
concentrations	O
were	O
occasionally	O
detected	O
in	O
the	O
plasma	B-T031
of	O
brown	B-T204
bullhead	I-T204
from	O
the	O
Bay	B-T082
of	I-T082
Quinte	I-T082
AOC	B-T082
.	O

Concentrations	O
of	O
polybrominated	B-T103
diphenyl	I-T103
ethers	I-T103
were	O
highest	O
in	O
the	O
Toronto	B-T082
and	I-T082
Region	I-T082
AOC	I-T082
,	O
and	O
at	O
2	O
of	O
the	O
Bay	B-T082
of	I-T082
Quinte	I-T082
AOC	B-T082
exposed	O
sites	O
near	O
Trenton	B-T082
and	I-T082
Belleville	I-T082
.	O

Distribution	B-T082
patterns	I-T082
reflected	O
the	O
properties	O
and	O
usage	O
of	O
the	O
compounds	O
under	O
investigation	O
and	O
the	O
characteristics	O
of	O
each	O
AOC	B-T082
.	O

Environ	O
Toxicol	O
Chem	O
2017	O
;	O
9999	O
:	O
1	O
-	O
8	O
.	O

©	O
2017	O
SETAC	O
.	O

The	O
genetic	O
basis	O
for	O
variation	O
in	O
resistance	B-T038
to	O
infection	B-T038
in	O
the	O
Drosophila	B-T204
melanogaster	I-T204
genetic	I-T204
reference	I-T204
panel	I-T204

Individuals	B-T098
vary	O
extensively	O
in	O
the	O
way	O
they	O
respond	O
to	O
disease	B-T038
but	O
the	O
genetic	O
basis	O
of	O
this	O
variation	O
is	O
not	O
fully	O
understood	O
.	O

We	O
found	O
substantial	O
individual	B-T098
variation	O
in	O
resistance	B-T038
and	O
tolerance	O
to	O
the	O
fungal	B-T204
pathogen	I-T204
Metarhizium	I-T204
anisopliae	I-T204
Ma549	I-T204
using	O
the	O
Drosophila	B-T204
melanogaster	I-T204
Genetic	I-T204
Reference	I-T204
Panel	I-T204
(	O
DGRP	B-T204
)	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
host	B-T038
defense	I-T038
to	O
Ma549	B-T204
was	O
correlated	O
with	O
defense	O
to	O
the	O
bacterium	B-T007
Pseudomonas	B-T007
aeruginosa	I-T007
Pa14	I-T007
,	O
and	O
several	O
previously	O
published	O
DGRP	B-T204
phenotypes	O
including	O
oxidative	B-T038
stress	I-T038
sensitivity	O
,	O
starvation	B-T033
stress	O
resistance	O
,	O
hemolymph	B-T031
glucose	B-T058
levels	I-T058
,	O
and	O
sleep	B-T038
indices	B-T170
.	O

We	O
identified	O
polymorphisms	B-T038
associated	O
with	O
differences	O
between	O
lines	O
in	O
both	O
their	O
mean	O
survival	O
times	O
and	O
microenvironmental	O
plasticity	O
,	O
suggesting	O
that	O
lines	O
differ	O
in	O
their	O
ability	O
to	O
adapt	B-T038
to	O
variable	O
pathogen	O
exposures	O
.	O

The	O
majority	O
of	O
polymorphisms	B-T038
increasing	O
resistance	B-T038
to	O
Ma549	B-T204
were	O
sex	O
biased	O
,	O
located	O
in	O
non	B-T103
-	I-T103
coding	I-T103
regions	I-T103
,	O
had	O
moderately	O
large	O
effect	O
and	O
were	O
rare	O
,	O
suggesting	O
that	O
there	O
is	O
a	O
general	O
cost	O
to	O
defense	O
.	O

Nevertheless	O
,	O
host	B-T038
defense	I-T038
was	O
not	O
negatively	O
correlated	O
with	O
overall	O
longevity	O
and	O
fecundity	B-T038
.	O

In	O
contrast	O
to	O
Ma549	B-T204
,	O
minor	B-T017
alleles	I-T017
were	O
concentrated	O
in	O
the	O
most	O
Pa14	B-T007
-	O
susceptible	O
as	O
well	O
as	O
the	O
most	O
Pa14	B-T007
-	O
resistant	B-T038
lines	O
.	O

A	O
pathway	O
based	O
analysis	B-T062
revealed	O
a	O
network	O
of	O
Pa14	B-T007
and	O
Ma549	B-T204
-	O
resistance	B-T038
genes	B-T017
that	O
are	O
functionally	O
connected	O
through	O
processes	O
that	O
encompass	O
phagocytosis	B-T038
and	O
engulfment	B-T038
,	O
cell	B-T038
mobility	I-T038
,	O
intermediary	B-T038
metabolism	I-T038
,	O
protein	B-T038
phosphorylation	I-T038
,	O
axon	B-T038
guidance	I-T038
,	O
response	B-T038
to	I-T038
DNA	I-T038
damage	I-T038
,	O
and	O
drug	B-T038
metabolism	I-T038
.	O

Functional	O
testing	O
with	O
insertional	B-T038
mutagenesis	I-T038
lines	O
indicates	O
that	O
12	O
/	O
13	O
candidate	B-T017
genes	I-T017
tested	O
influence	O
susceptibility	O
to	O
Ma549	B-T204
.	O

Many	O
candidate	B-T017
genes	I-T017
have	O
homologs	B-T082
identified	O
in	O
studies	B-T062
of	O
human	B-T204
disease	B-T038
,	O
suggesting	O
that	O
genes	B-T017
affecting	O
variation	O
in	O
susceptibility	O
are	O
conserved	O
across	O
species	B-T170
.	O

Surrogate	O
inaccuracy	O
in	O
predicting	O
older	B-T098
adults	I-T098
'	I-T098
desire	O
for	O
life	O
-	O
sustaining	O
interventions	O
in	O
the	O
event	O
of	O
decisional	B-T038
incapacity	O
:	O
is	O
it	O
due	O
in	O
part	O
to	O
erroneous	O
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
life	I-T058
assessments	I-T058
?	O

Family	O
members	O
are	O
often	O
called	O
upon	O
to	O
make	O
decisions	B-T038
for	O
an	O
incapacitated	O
relative	O
.	O

Yet	O
they	O
have	O
difficulty	O
predicting	O
a	O
loved	O
one	O
'	O
s	O
desire	O
to	O
receive	O
treatments	B-T058
in	O
hypothetical	O
situations	O
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
this	O
difficulty	O
could	O
in	O
part	O
be	O
explained	O
by	O
discrepant	O
quality	B-T058
-	I-T058
of	I-T058
-	I-T058
life	I-T058
assessments	I-T058
.	O

The	O
data	O
come	O
from	O
235	O
community	O
-	O
dwelling	O
adults	O
aged	O
70	O
years	O
and	O
over	O
who	O
rated	O
their	O
quality	O
of	O
life	O
and	O
desire	O
for	O
specified	O
interventions	B-T058
in	O
four	O
health	O
states	O
(	O
current	O
state	O
,	O
mild	O
to	O
moderate	O
stroke	B-T038
,	O
incurable	O
brain	B-T038
cancer	I-T038
,	O
and	O
severe	O
dementia	B-T038
)	O
.	O

All	O
ratings	O
were	O
made	O
on	O
Likert	B-T170
-	I-T170
type	I-T170
scales	I-T170
.	O

Using	O
identical	O
rating	O
scales	O
,	O
a	O
surrogate	O
chosen	O
by	O
the	O
older	B-T098
adult	I-T098
was	O
asked	O
to	O
predict	O
the	O
latter	O
'	O
s	O
responses	O
.	O

Linear	O
mixed	O
models	O
were	O
fitted	O
to	O
determine	O
whether	O
differences	O
in	O
quality	O
-	O
of	O
-	O
life	O
ratings	O
between	O
the	O
older	B-T098
adult	I-T098
and	O
surrogate	O
were	O
associated	O
with	O
surrogates	O
'	O
inaccuracy	O
in	O
predicting	O
desire	O
for	O
treatment	B-T058
.	O

The	O
difference	O
in	O
quality	O
-	O
of	O
-	O
life	O
ratings	O
was	O
a	O
significant	O
predictor	O
of	O
prediction	O
inaccuracy	O
for	O
the	O
three	O
hypothetical	O
health	O
states	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
nearly	O
significant	O
for	O
the	O
current	O
health	O
state	O
(	O
p	O
=	O
0	O
.	O
077	O
)	O
.	O

All	O
regression	O
coefficients	O
were	O
negative	B-T033
,	O
implying	O
that	O
the	O
more	O
the	O
surrogate	O
overestimated	O
quality	O
of	O
life	O
compared	O
to	O
the	O
older	B-T098
adult	I-T098
,	O
the	O
more	O
he	O
or	O
she	O
overestimated	O
the	O
older	B-T098
adult	I-T098
'	O
s	O
desire	O
to	O
be	O
treated	O
.	O

Discrepant	O
quality	O
-	O
of	O
-	O
life	O
ratings	O
are	O
associated	O
with	O
surrogates	O
'	O
difficulty	O
in	O
predicting	O
desire	O
for	O
life	O
-	O
sustaining	O
interventions	O
in	O
hypothetical	O
situations	O
.	O

This	O
finding	O
underscores	O
the	O
importance	O
of	O
discussing	O
anticipated	O
quality	O
of	O
life	O
in	O
states	O
of	O
cognitive	B-T038
decline	I-T038
,	O
to	O
better	O
prepare	O
family	O
members	O
for	O
making	O
difficult	O
decisions	B-T038
for	O
their	O
loved	O
ones	O
.	O

ISRCTN89993391	O
.	O

Gain	B-T038
-	I-T038
of	I-T038
-	I-T038
function	I-T038
mutation	I-T038
in	O
SCN5A	B-T017
causes	O
ventricular	B-T038
arrhythmias	I-T038
and	O
early	B-T033
onset	I-T033
atrial	B-T038
fibrillation	I-T038

Mutations	B-T038
in	O
SCN5A	B-T017
,	O
the	O
gene	B-T017
encoding	O
the	O
α	O
-	O
subunit	O
of	O
the	O
cardiac	B-T017
sodium	B-T103
channel	I-T103
(	I-T103
NaV1	I-T103
.	I-T103
5	I-T103
)	I-T103
,	O
are	O
associated	O
with	O
a	O
broad	O
spectrum	O
of	O
inherited	O
cardiac	B-T033
arrhythmia	I-T033
disorders	I-T033
.	O

The	O
purpose	O
of	O
this	O
study	B-T062
was	O
to	O
identify	O
the	O
genetic	O
and	O
functional	O
determinants	O
underlying	O
a	O
Dutch	B-T098
family	O
that	O
presented	O
with	O
a	O
combined	O
phenotype	O
of	O
ventricular	B-T038
arrhythmias	I-T038
with	O
a	O
likely	O
adrenergic	O
component	O
,	O
either	O
in	O
isolation	O
or	O
in	O
combination	O
with	O
a	O
mildly	O
decreased	O
heart	B-T038
function	I-T038
and	O
early	B-T033
onset	I-T033
(	O
<	O
55	O
years	O
)	O
atrial	B-T038
fibrillation	I-T038
.	O

We	O
performed	O
next	O
generation	O
sequencing	B-T082
in	O
the	O
proband	O
of	O
a	O
two	O
-	O
generation	O
Dutch	B-T098
family	O
and	O
demonstrated	O
a	O
novel	O
missense	B-T038
mutation	I-T038
in	O
SCN5A	B-T017
-	I-T017
(	I-T017
p	I-T017
.	I-T017
M1851V	I-T017
)	I-T017
which	O
co	O
-	O
segregated	O
with	O
the	O
clinical	O
phenotype	O
in	O
the	O
family	O
.	O

We	O
functionally	O
evaluated	O
the	O
putative	O
genetic	O
defect	O
by	O
patch	O
clamp	O
electrophysiological	O
studies	O
in	O
human	O
embryonic	O
kidney	B-T017
cells	I-T017
transfected	B-T062
with	O
mutant	B-T038
or	O
wild	B-T017
-	I-T017
type	I-T017
Nav1	I-T017
.	I-T017
5	I-T017
.	O

The	O
current	O
inactivation	O
was	O
slower	O
and	O
recovery	O
from	O
inactivation	O
was	O
faster	O
in	O
SCN5A	B-T103
-	I-T103
M1851V	I-T103
channels	I-T103
.	O

The	O
voltage	O
dependence	O
of	O
inactivation	O
was	O
shifted	O
towards	O
more	O
positive	B-T033
potentials	O
and	O
consequently	O
,	O
a	O
larger	O
TTX	B-T103
-	O
sensitive	O
window	O
current	O
was	O
observed	O
in	O
SCN5A	B-T103
-	I-T103
M1851V	I-T103
channels	I-T103
.	O

Furthermore	O
,	O
a	O
higher	O
upstroke	O
velocity	O
was	O
observed	O
for	O
the	O
SCN5A	B-T103
-	I-T103
M1851V	I-T103
channels	I-T103
,	O
while	O
the	O
depolarization	O
voltage	O
was	O
more	O
negative	B-T033
,	O
both	O
indicating	O
increased	O
excitability	O
.	O

This	O
mutation	B-T038
leads	O
to	O
a	O
gain	O
-	O
of	O
-	O
function	O
mechanism	O
based	O
on	O
increased	O
channel	B-T103
availability	O
and	O
increased	O
window	O
current	O
,	O
fitting	O
the	O
observed	O
clinical	O
phenotype	O
of	O
(	O
likely	O
adrenergic	O
-	O
induced	O
)	O
ventricular	B-T038
arrhythmias	I-T038
and	O
atrial	B-T038
fibrillation	I-T038
.	O

These	O
findings	B-T033
further	O
expand	O
the	O
range	O
of	O
cardiac	B-T033
arrhythmias	I-T033
associated	O
with	O
mutations	B-T038
in	O
SCN5A	B-T017
.	O

The	O
cancer	B-T038
Warburg	B-T038
effect	I-T038
may	O
be	O
a	O
testable	O
example	O
of	O
the	O
minimum	O
entropy	O
production	O
rate	O
principle	O

Cancer	B-T017
cells	I-T017
consume	O
more	O
glucose	B-T103
by	O
glycolytic	B-T038
fermentation	I-T038
to	O
lactate	B-T103
than	O
by	O
respiration	B-T038
,	O
a	O
characteristic	O
known	O
as	O
the	O
Warburg	B-T038
effect	I-T038
.	O

In	O
contrast	O
with	O
the	O
34	O
moles	O
of	O
ATP	B-T103
produced	O
by	O
respiration	B-T038
,	O
fermentation	B-T038
produces	O
two	O
moles	O
of	O
ATP	B-T103
per	O
mole	O
of	O
glucose	B-T103
consumed	O
,	O
which	O
poses	O
a	O
puzzle	O
on	O
the	O
function	O
of	O
the	O
Warburg	B-T038
effect	I-T038
.	O

Productions	O
of	O
free	O
energy	O
(	O
ΔG	O
)	O
,	O
enthalpy	O
(	O
ΔH	O
)	O
and	O
entropy	O
(	O
ΔS	O
)	O
per	O
mole	O
linearly	B-T082
vary	O
with	O
the	O
fraction	O
(	O
x	O
)	O
of	O
glucose	B-T103
consumed	O
by	O
fermentation	B-T038
that	O
is	O
frequently	O
estimated	O
around	O
0	O
.	O
9	O
.	O

Hence	O
,	O
calculation	O
shows	O
that	O
,	O
in	O
respect	O
to	O
pure	O
respiration	B-T038
,	O
the	O
predominant	O
fermentative	B-T038
metabolism	B-T038
decreases	O
around	O
10	O
%	O
the	O
production	O
of	O
entropy	O
per	O
mole	O
of	O
glucose	B-T103
consumed	O
in	O
cancer	B-T017
cells	I-T017
.	O

We	O
hypothesize	O
that	O
increased	O
fermentation	B-T038
could	O
allow	O
cancer	B-T017
cells	I-T017
to	O
accomplish	O
the	O
Prigogine	B-T170
theorem	I-T170
of	O
the	O
trend	O
to	O
minimize	O
the	O
rate	O
of	O
production	O
of	O
entropy	O
.	O

According	O
the	O
theorem	B-T170
,	O
open	B-T017
cellular	I-T017
systems	I-T017
near	O
the	O
steady	O
state	O
could	O
evolve	O
to	O
minimize	O
the	O
rates	O
of	O
entropy	O
production	O
that	O
may	O
be	O
reached	O
by	O
modified	B-T033
replicating	O
cells	B-T017
producing	O
entropy	O
at	O
low	O
rate	O
.	O

Remarkably	O
,	O
at	O
CO2	B-T103
concentrations	O
above	O
930	O
ppm	O
,	O
glucose	B-T103
respiration	B-T038
produces	O
less	O
entropy	O
than	O
fermentation	B-T038
,	O
which	O
suggests	O
experimental	O
tests	B-T058
to	O
validate	O
the	O
hypothesis	O
of	O
minimization	O
of	O
the	O
rate	O
of	O
entropy	O
production	O
through	O
the	O
Warburg	B-T038
effect	I-T038
.	O

Potential	O
drug	B-T038
-	I-T038
drug	I-T038
interactions	I-T038
among	O
prescriptions	B-T058
for	O
elderly	B-T098
patients	O
in	O
primary	B-T058
health	I-T058
care	I-T058

Elderly	B-T098
patients	O
are	O
at	O
high	B-T033
risk	I-T033
from	O
drug	B-T038
-	I-T038
drug	I-T038
interactions	I-T038
(	O
DDIs	B-T038
)	O
.	O

This	O
study	B-T062
evaluates	B-T058
the	O
potential	O
DDIs	B-T038
in	O
Turkish	O
elderly	B-T098
patients	O
at	O
a	O
primary	B-T058
health	I-T058
care	I-T058
outpatient	B-T092
clinic	I-T092
.	O

Online	B-T170
database	I-T170
systems	I-T170
were	O
used	O
to	O
examine	O
DDIs	B-T038
on	O
the	O
prescriptions	B-T058
of	O
patients	O
(	O
n	O
=	O
1206	O
)	O
.	O

The	O
clinical	B-T033
severity	I-T033
of	O
DDIs	B-T038
was	O
classified	O
by	O
the	O
Lexi	B-T170
-	I-T170
Interact	I-T170
Online	I-T170
database	I-T170
.	O

Of	O
the	O
5059	O
prescriptions	B-T058
,	O
33	O
%	O
were	O
found	O
to	O
have	O
DDIs	B-T038
.	O

We	O
detected	B-T033
29	O
(	O
0	O
.	O
9	O
%	O
)	O
A	O
,	O
380	O
(	O
11	O
.	O
8	O
%	O
)	O
B	O
,	O
2494	O
(	O
77	O
.	O
7	O
%	O
)	O
C	O
,	O
289	O
(	O
9	O
%	O
)	O
D	O
,	O
and	O
18	O
(	O
0	O
.	O
6	O
%	O
)	O
X	O
risk	O
rating	O
category	O
DDIs	B-T038
among	O
the	O
prescriptions	B-T058
.	O

Prescriptions	B-T058
of	O
female	O
patients	O
and	O
patients	O
aged	O
between	O
65	O
and	O
72	O
years	O
showed	O
significantly	O
higher	O
number	O
of	O
DDIs	B-T038
.	O

The	O
frequency	O
of	O
DDIs	B-T038
increased	O
both	O
with	O
the	O
number	O
of	O
drugs	B-T103
and	O
combined	O
preparations	O
per	O
prescription	B-T058
.	O

Acetylsalicylic	B-T103
acid	I-T103
and	O
salbutamol	B-T103
were	O
the	O
most	O
frequently	O
prescribed	O
drugs	B-T103
contributing	O
to	O
clinically	B-T033
important	I-T033
DDIs	B-T038
.	O

Additionally	O
,	O
acetylsalicylic	B-T103
acid	I-T103
and	O
escitalopram	B-T103
,	O
which	O
interact	O
with	O
each	O
other	O
,	O
were	O
found	O
on	O
the	O
list	O
of	O
Beers	O
criteria	O
.	O

The	O
most	O
predicted	B-T033
clinical	I-T033
outcomes	I-T033
of	O
DDIs	B-T038
were	O
increase	O
in	O
therapeutic	O
efficacy	O
and	O
adverse	B-T038
/	O
toxic	B-T033
reactions	I-T033
.	O

Conclusions	O
:	O
Prediction	O
of	O
DDIs	B-T038
in	O
elderly	B-T098
patients	O
will	O
provide	O
better	O
prescribing	B-T058
and	O
drug	O
safety	O
.	O

Use	O
of	O
nonsteroidal	B-T103
anti	I-T103
-	I-T103
inflammatory	I-T103
agents	I-T103
,	O
selective	B-T103
serotonin	I-T103
reuptake	I-T103
inhibitors	I-T103
,	O
and	O
beta	B-T103
-	I-T103
2	I-T103
adrenergic	I-T103
receptor	I-T103
agonists	I-T103
should	O
be	O
closely	O
monitored	O
.	O

Discontinued	B-T033
Splenogonadal	B-T017
Fusion	I-T017
and	O
Bilateral	B-T017
Empty	I-T017
Scrotum	I-T017
in	O
an	O
18	O
-	O
Month	O
-	O
Old	O
Boy	O

Splenogonadal	B-T017
fusion	I-T017
is	O
a	O
rare	O
benign	O
congenital	B-T017
anomaly	I-T017
defined	O
as	O
the	O
presence	O
of	O
splenic	B-T017
tissue	I-T017
adherent	O
to	O
gonads	B-T017
.	O

It	O
was	O
first	O
described	O
in	O
1883	O
by	O
Bostroem	B-T204
,	O
a	O
German	B-T098
pathologist	B-T097
.	O

We	O
present	O
a	O
case	O
of	O
an	O
18	O
-	O
month	O
-	O
old	O
boy	O
who	O
was	O
referred	O
as	O
a	O
case	O
of	O
bilateral	B-T017
empty	I-T017
scrotum	I-T017
since	O
birth	O
.	O

During	O
routine	O
laparoscopic	B-T058
exploration	B-T058
,	O
right	B-T017
vas	I-T017
deferens	I-T017
and	O
testicular	O
vessels	O
were	O
entering	O
the	O
right	B-T017
internal	I-T017
inguinal	I-T017
ring	I-T017
so	O
right	B-T082
inguinal	I-T082
exploration	B-T058
was	O
done	O
,	O
which	O
revealed	O
blind	B-T033
ending	I-T033
vas	B-T017
deferens	I-T017
and	O
testicular	O
vessels	O
and	O
the	O
left	B-T017
testis	I-T017
was	O
found	O
intra	B-T082
-	I-T082
abdominally	I-T082
near	O
the	O
left	O
internal	B-T082
ring	I-T082
with	O
a	O
mass	B-T033
on	O
its	O
upper	B-T017
pole	I-T017
.	O

Wedge	B-T058
biopsy	I-T058
was	O
taken	O
from	O
the	O
upper	B-T017
pole	I-T017
of	I-T017
the	I-T017
testicle	I-T017
(	O
site	B-T082
of	O
the	O
mass	B-T033
)	O
for	O
tissue	O
diagnosis	O
followed	O
by	O
orchidopexy	B-T058
.	O

Histology	B-T058
showed	O
splenic	B-T017
tissue	I-T017
.	O

Although	O
splenogonadal	B-T017
fusion	I-T017
is	O
a	O
rare	O
condition	B-T038
,	O
surgeons	B-T097
should	O
be	O
aware	O
of	O
this	O
rare	B-T038
disease	I-T038
entity	O
to	O
avoid	O
unnecessary	B-T058
aggressive	O
interventions	B-T058
such	O
as	O
orchiectomy	B-T058
.	O

Real	O
-	O
world	O
impact	O
of	O
non	B-T033
-	I-T033
breast	I-T033
cancer	I-T033
-	I-T033
specific	I-T033
death	I-T033
on	O
overall	O
survival	O
in	O
resectable	O
breast	B-T038
cancer	I-T038

The	O
real	O
-	O
world	O
occurrence	O
rate	O
of	O
non	B-T033
-	I-T033
breast	I-T033
cancer	I-T033
-	I-T033
specific	I-T033
death	I-T033
(	O
non	B-T033
-	I-T033
BCSD	I-T033
)	O
and	O
its	O
impact	O
on	O
patients	O
with	O
breast	B-T038
cancer	I-T038
are	O
poorly	O
recognized	O
.	O

Women	B-T098
with	O
resectable	O
breast	B-T038
cancer	I-T038
from	O
1990	O
to	O
2007	O
in	O
the	O
Surveillance	B-T092
,	I-T092
Epidemiology	I-T092
,	I-T092
and	I-T092
End	I-T092
Results	I-T092
database	I-T092
(	O
n	O
=	O
199	O
,	O
963	O
)	O
were	O
analyzed	B-T062
.	O

The	O
outcome	O
events	O
of	O
breast	B-T038
cancer	I-T038
were	O
classified	O
as	O
breast	O
cancer	O
-	O
specific	O
death	O
(	O
BCSD	O
)	O
,	O
non	B-T033
-	I-T033
BCSD	I-T033
,	O
or	O
survival	O
.	O

Binary	B-T062
logistics	I-T062
was	O
used	O
to	O
estimate	O
the	O
occurrence	O
rates	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
and	O
BCSD	O
with	O
different	O
clinicopathological	O
factors	O
.	O

The	O
Gray	B-T170
method	I-T170
was	O
used	O
to	O
measure	O
the	O
cumulative	O
incidence	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
and	O
BCSD	O
.	O

The	O
ratio	O
of	O
non	B-T033
-	I-T033
BCSDs	I-T033
to	O
all	O
causes	B-T033
of	I-T033
death	I-T033
and	O
stacked	B-T082
cumulative	O
incidence	O
function	B-T170
plots	I-T170
were	O
used	O
to	O
present	O
the	O
impact	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
on	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

Models	B-T170
of	I-T170
Cox	I-T170
proportional	I-T170
hazards	I-T170
regression	I-T170
and	O
competing	B-T170
risk	I-T170
regression	I-T170
were	O
compared	O
to	O
highlight	O
the	O
suitable	B-T170
model	I-T170
.	O

There	O
were	O
12	O
,	O
879	O
non	B-T033
-	I-T033
BCSDs	I-T033
(	O
6	O
.	O
44	O
%	O
)	O
and	O
28	O
,	O
784	O
BCSDs	O
(	O
14	O
.	O
39	O
%	O
)	O
.	O

The	O
oldest	O
age	O
group	O
(	O
>	O
62	O
years	O
)	O
,	O
black	B-T098
race	I-T098
,	O
and	O
a	O
single	O
or	O
divorced	O
marital	O
status	O
were	O
associated	O
with	O
more	O
non	B-T033
-	I-T033
BCSDs	I-T033
.	O

With	O
adjustments	O
for	O
age	O
,	O
a	O
hormone	B-T038
receptor	I-T038
-	I-T038
positive	I-T038
(	I-T038
HoR	I-T038
+	I-T038
)	I-T038
status	I-T038
was	O
no	O
longer	O
related	O
to	O
increased	O
non	B-T033
-	I-T033
BCSD	I-T033
s	O
.	O

In	O
patients	O
with	O
grade	B-T038
1	I-T038
,	I-T038
stage	I-T038
I	I-T038
disease	I-T038
and	O
an	O
HoR	B-T038
+	I-T038
status	I-T038
as	O
well	O
as	O
the	O
oldest	O
subgroup	O
,	O
a	O
great	O
dilution	O
of	O
non	B-T033
-	I-T033
BCSD	I-T033
on	O
all	O
causes	B-T033
of	I-T033
death	I-T033
could	O
be	O
observed	O
,	O
and	O
this	O
led	O
to	O
incorrect	O
interpretations	O
.	O

The	O
inaccuracy	O
,	O
caused	O
by	O
the	O
commonly	O
used	O
Cox	B-T170
proportional	I-T170
hazards	I-T170
model	I-T170
,	O
could	O
be	O
corrected	O
by	O
a	O
competing	B-T170
risk	I-T170
model	I-T170
.	O

OS	O
was	O
largely	O
impaired	O
by	O
non	B-T033
-	I-T033
BCSD	I-T033
during	O
early	O
breast	B-T038
cancer	I-T038
.	O

For	O
some	O
future	O
clinical	B-T062
trial	I-T062
planning	O
,	O
especially	O
for	O
the	O
oldest	O
patients	O
and	O
those	O
with	O
HoR	B-T038
+	I-T038
breast	B-T038
cancer	I-T038
,	O
non	B-T033
-	I-T033
BCSD	I-T033
should	O
be	O
considered	O
a	O
competing	O
risk	O
event	O
.	O

Cancer	O
2017	O
.	O

©	O
2017	O
American	B-T092
Cancer	I-T092
Society	I-T092
.	O

Hip	B-T017
segmentation	O
from	O
MRI	B-T058
volumes	O
in	O
infants	O
for	O
DDH	B-T017
diagnosis	B-T033
and	O
treatment	B-T170
planning	I-T170

Diagnosis	B-T033
and	O
surgical	B-T058
management	I-T058
of	O
Developmental	B-T017
Dysplasia	I-T017
of	I-T017
the	I-T017
Hip	I-T017
(	O
DDH	B-T017
)	O
relies	O
on	O
physical	B-T058
examination	I-T058
and	O
2D	O
ultrasound	B-T058
scanning	I-T058
.	O

Magnetic	B-T058
Resonance	I-T058
Imaging	I-T058
(	O
MRI	B-T058
)	O
can	O
be	O
used	O
to	O
complement	O
existing	O
techniques	O
and	O
could	O
be	O
advantageous	O
in	O
treatment	B-T170
planning	I-T170
due	O
to	O
its	O
larger	O
field	O
of	O
view	O
.	O

In	O
this	O
paper	O
we	O
propose	O
a	O
semi	O
-	O
automatic	O
method	B-T170
to	O
segment	B-T170
surface	I-T170
models	I-T170
of	O
the	O
acetabulum	B-T017
from	O
MRI	B-T058
images	O
.	O

The	O
method	B-T170
incorporates	O
clinical	O
knowledge	B-T170
in	O
the	O
form	O
of	O
intensity	B-T170
priors	I-T170
which	O
are	O
integrated	O
into	O
a	O
Random	B-T170
Walker	I-T170
(	I-T170
RW	I-T170
)	I-T170
formulation	I-T170
.	O

We	O
use	O
a	O
modified	O
RW	B-T170
framework	O
which	O
compensates	O
for	O
incomplete	O
or	O
blurred	O
boundaries	B-T170
in	O
the	O
image	O
by	O
using	O
information	O
from	O
neighboring	O
slices	O
in	O
the	O
sequence	O
incorporated	O
as	O
node	O
weights	O
.	O

We	O
conducted	O
a	O
pilot	B-T062
study	I-T062
to	O
evaluate	B-T058
the	O
segmentation	O
on	O
a	O
set	O
of	O
10	O
infant	O
hip	B-T017
MRI	B-T058
sequences	O
using	O
a	O
1	O
.	O
5	O
Tesla	O
MR	B-T074
scanner	I-T074
.	O

Contours	B-T082
obtained	O
from	O
the	O
semi	O
-	O
automated	O
segmentation	O
were	O
compared	O
against	O
manually	O
segmented	O
hip	B-T017
contours	B-T082
using	O
Dice	O
Ratio	O
(	O
DR	O
)	O
,	O
Hausdorff	O
Distance	O
(	O
HD	O
)	O
and	O
Root	O
Mean	O
Square	O
(	O
RMS	O
)	O
distance	O
.	O

The	O
proposed	O
method	B-T170
gave	O
values	O
of	O
(	O
DR	O
=	O
0	O
.	O
84	O
±	O
0	O
.	O
5	O
,	O
HD	O
=	O
3	O
.	O
0	O
±	O
0	O
.	O
7	O
,	O
RMS	O
=	O
1	O
.	O
9	O
±	O
0	O
.	O
3	O
)	O
and	O
(	O
DR	O
=	O
0	O
.	O
86	O
±	O
0	O
.	O
2	O
,	O
HD	O
=	O
3	O
.	O
0	O
±	O
0	O
.	O
1	O
,	O
RMS	O
=	O
2	O
.	O
0	O
±	O
0	O
.	O
6	O
)	O
for	O
right	B-T082
and	O
left	B-T082
acetabular	I-T082
contours	I-T082
respectively	O
which	O
was	O
higher	O
than	O
the	O
corresponding	O
values	O
obtained	O
from	O
conventional	O
RW	B-T170
segmentation	O
.	O

The	O
execution	O
time	O
of	O
the	O
segmentation	O
algorithm	B-T170
was	O
less	O
than	O
~	O
4	O
seconds	O
on	O
a	O
3	O
.	O
5	O
GHz	O
CPU	O
.	O

Automated	O
basal	B-T038
cell	I-T038
carcinoma	I-T038
detection	O
in	O
high	B-T058
-	I-T058
definition	I-T058
optical	I-T058
coherence	I-T058
tomography	I-T058

Basal	B-T038
cell	I-T038
carcinoma	I-T038
(	O
BCC	B-T038
)	O
is	O
the	O
most	O
common	O
non	B-T038
-	I-T038
melanoma	I-T038
skin	I-T038
cancer	I-T038
.	O

Conventional	O
diagnosis	O
of	O
BCC	B-T038
requires	O
invasive	O
biopsies	B-T058
.	O

Recently	O
,	O
a	O
high	B-T058
-	I-T058
definition	I-T058
optical	I-T058
coherence	I-T058
tomography	I-T058
(	O
HD	B-T058
-	I-T058
OCT	I-T058
)	O
technique	O
has	O
been	O
developed	O
,	O
which	O
provides	O
a	O
non	O
-	O
invasive	O
in	B-T058
vivo	I-T058
imaging	I-T058
method	I-T058
of	O
skin	B-T022
.	O

Good	O
agreements	O
of	O
BCC	B-T038
features	O
between	O
HD	B-T058
-	I-T058
OCT	I-T058
images	O
and	O
histopathological	O
architecture	O
have	O
been	O
found	O
.	O

Therefore	O
it	O
is	O
possible	O
to	O
automatically	O
detect	O
BCC	B-T038
using	O
HD	B-T058
-	I-T058
OCT	I-T058
.	O

This	O
paper	O
presents	O
a	O
novel	O
BCC	B-T038
detection	B-T058
method	I-T058
that	O
consists	O
of	O
four	O
steps	O
:	O
graph	O
based	O
skin	B-T082
surface	I-T082
segmentation	B-T058
,	O
surface	O
flattening	O
,	O
deep	O
feature	O
extraction	O
and	O
the	O
BCC	B-T038
classification	O
.	O

The	O
effectiveness	O
of	O
the	O
proposed	O
method	O
is	O
well	O
demonstrated	O
on	O
a	O
dataset	O
of	O
5	O
,	O
040	O
images	O
.	O

It	O
can	O
therefore	O
serve	O
as	O
an	O
automatic	O
tool	O
for	O
screening	O
BCC	B-T038
.	O

Fall	B-T033
risk	B-T033
factors	I-T033
analysis	B-T062
based	O
on	O
sample	O
entropy	O
of	O
plantar	B-T082
kinematic	O
signal	O
during	O
stance	O
phase	O

Falls	B-T033
are	O
a	O
multi	O
-	O
causal	O
phenomenon	O
with	O
a	O
complex	O
interaction	O
.	O

The	O
aim	O
of	O
our	O
research	B-T062
is	O
to	O
study	B-T062
the	O
effect	O
of	O
multiple	O
variables	O
for	O
potential	O
risk	B-T033
of	I-T033
falls	I-T033
and	O
construct	B-T170
an	O
elderly	B-T170
fall	I-T170
risk	I-T170
assessment	I-T170
model	I-T170
based	O
on	O
demographics	O
data	O
and	O
gait	O
characteristics	O
.	O

A	O
total	O
of	O
101	O
subjects	B-T098
,	O
whom	O
belong	O
to	O
Malianwa	O
Street	O
,	O
aged	O
above	O
50	O
years	O
old	O
and	O
participated	O
in	O
questionnaire	B-T170
survey	B-T170
.	O

Participants	B-T098
were	O
classified	O
into	O
three	O
groups	O
(	O
high	O
,	O
medium	B-T098
and	O
low	O
risk	O
group	O
)	O
according	O
to	O
the	O
score	O
of	O
elderly	B-T170
fall	I-T170
risk	I-T170
assessment	I-T170
scale	I-T170
.	O

In	O
addition	O
,	O
the	O
data	O
of	O
ground	O
reaction	O
force	O
(	O
GRF	O
)	O
and	O
ground	O
reaction	O
moment	O
(	O
GRM	O
)	O
was	O
record	O
when	O
they	O
performed	O
walking	O
at	O
comfortable	O
state	O
.	O

The	O
demographic	O
variables	O
,	O
sample	O
entropy	O
of	O
GRF	O
and	O
GRM	O
,	O
and	O
impulse	O
difference	O
of	O
bilateral	O
foot	O
were	O
considered	O
as	O
potential	O
explanatory	B-T170
variables	O
of	O
risk	B-T058
assessment	I-T058
model	B-T170
.	O

Firstly	O
,	O
we	O
investigated	O
whether	O
different	O
groups	O
could	O
present	O
difference	O
in	O
every	O
variable	O
.	O

Statistical	O
differences	O
were	O
found	B-T033
for	O
the	O
following	O
variables	O
:	O
age	O
(	O
p	O
=	O
2	O
.	O
28e	O
-	O
05	O
)	O
;	O
impulse	O
difference	O
(	O
p	O
=	O
0	O
.	O
02036	O
)	O
;	O
sample	O
entropy	O
of	O
GRF	O
in	O
vertical	B-T082
direction	B-T082
(	O
p	O
=	O
0	O
.	O
0144	O
)	O
;	O
sample	O
entropy	O
of	O
GRM	O
in	O
anterior	B-T082
-	I-T082
posterior	I-T082
direction	B-T082
(	O
p	O
=	O
0	O
.	O
0387	O
)	O
.	O

Finally	O
,	O
the	O
multiple	O
regression	B-T170
analysis	I-T170
results	O
indicated	B-T033
that	O
age	O
,	O
impulse	O
difference	O
and	O
sample	O
entropy	O
of	O
resultant	O
GRM	O
could	O
identify	O
individuals	B-T098
who	O
had	O
different	O
levels	B-T058
of	I-T058
fall	I-T058
risk	I-T058
.	O

Therefore	O
,	O
those	O
results	O
could	O
potentially	O
be	O
useful	O
in	O
the	O
fall	B-T058
risk	I-T058
assessment	I-T058
and	O
monitor	B-T058
the	O
state	O
of	O
physical	B-T033
function	I-T033
in	O
elderly	B-T098
population	I-T098
.	O

Endurance	B-T033
based	O
personalized	B-T170
fitness	I-T170
planner	I-T170

Endurance	B-T033
is	O
an	O
important	O
factor	O
of	O
cardiovascular	B-T038
fitness	I-T038
indicating	O
the	O
capacity	O
of	O
an	O
individual	B-T098
to	O
perform	O
exercise	O
for	O
a	O
longer	O
duration	O
with	O
increased	O
intensity	O
.	O

Various	O
subject	O
specific	O
and	O
exercise	O
related	O
parameters	O
affect	O
endurance	B-T033
of	O
an	O
individual	B-T098
.	O

In	O
this	O
work	O
,	O
we	O
propose	O
a	O
statistical	B-T062
technique	I-T062
to	O
model	B-T170
endurance	B-T033
as	O
a	O
function	O
of	O
these	O
factors	O
incorporating	O
the	O
serial	O
dependence	O
of	O
observations	B-T062
generated	O
by	O
individuals	B-T098
over	O
time	O
.	O

The	O
proposed	O
model	B-T170
provides	O
a	O
device	B-T074
to	O
predict	O
future	O
endurance	B-T033
of	O
a	O
test	O
subject	O
following	O
particular	O
exercise	B-T058
regime	I-T058
.	O

This	O
facilitates	O
a	O
test	O
user	O
with	O
a	O
fitness	B-T170
planner	I-T170
with	O
the	O
provision	O
to	O
fix	O
exercise	B-T058
regimes	I-T058
to	O
reach	O
a	O
set	O
fitness	O
goal	B-T170
.	O

Heart	B-T201
rate	I-T201
variability	O
as	O
a	O
biomarker	B-T201
for	O
sedation	B-T033
depth	I-T033
estimation	O
in	O
ICU	B-T092
patients	O

An	O
automated	O
patient	O
-	O
specific	O
system	O
to	O
classify	O
the	O
level	O
of	O
sedation	O
in	O
ICU	B-T092
patients	O
using	O
heart	B-T201
rate	I-T201
variability	O
signal	O
is	O
presented	O
in	O
this	O
paper	B-T170
.	O

ECG	B-T033
from	O
70	O
mechanically	B-T058
ventilated	I-T058
adult	O
patients	O
with	O
administered	O
sedatives	B-T103
in	O
an	O
ICU	B-T092
setting	I-T092
were	O
used	O
to	O
develop	O
a	O
support	O
vector	O
machine	O
based	O
system	O
for	O
sedation	B-T033
depth	I-T033
monitoring	B-T058
using	O
several	O
heart	B-T201
rate	I-T201
variability	O
measures	O
.	O

A	O
leave	B-T062
-	I-T062
one	I-T062
-	I-T062
subject	I-T062
-	I-T062
out	I-T062
cross	I-T062
validation	I-T062
was	O
used	O
for	O
classifier	O
training	O
and	O
performance	O
evaluations	B-T058
.	O

The	O
proposed	O
patient	O
-	O
specific	O
system	O
provided	O
a	O
sensitivity	O
,	O
specificity	O
and	O
an	O
AUC	O
of	O
64	O
%	O
,	O
84	O
.	O
8	O
%	O
and	O
0	O
.	O
72	O
,	O
respectively	O
.	O

It	O
is	O
hoped	O
that	O
with	O
the	O
help	O
of	O
additional	O
physiological	O
signals	O
the	O
proposed	O
patient	O
-	O
specific	O
sedation	O
level	O
prediction	O
system	O
could	O
lead	O
to	O
a	O
fully	O
automated	O
multimodal	O
system	O
to	O
assist	O
clinical	O
staff	B-T097
in	O
ICUs	B-T092
to	O
interpret	O
the	O
sedation	O
level	O
of	O
the	O
patient	O
.	O

RELIABILITY	O
AND	O
VALIDITY	O
OF	O
THE	O
DIABETES	B-T058
EATING	I-T058
PROBLEM	I-T058
SURVEY	I-T058
-	I-T058
REVISED	I-T058
ON	O
TURKISH	B-T098
CHILDREN	O
AND	O
ADOLESCENTS	O
WITH	O
TYPE	B-T038
1	I-T038
DIABETES	I-T038
MELLITUS	I-T038

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
examine	O
the	O
reliability	O
and	O
validity	O
of	O
Turkish	B-T098
version	B-T170
of	O
Diabetes	B-T058
Eating	I-T058
Problem	I-T058
Survey	I-T058
-	I-T058
Revised	I-T058
(	O
DEPS	B-T058
-	I-T058
R	I-T058
)	O
for	O
children	O
and	O
adolescent	O
with	O
Type	B-T038
1	I-T038
Diabetes	I-T038
Mellitus	I-T038
.	O

A	O
total	O
of	O
200	O
children	O
and	O
adolescents	O
with	O
type	B-T038
1	I-T038
diabetes	I-T038
,	O
ages	O
9	O
-	O
18	O
years	O
,	O
completed	O
the	O
DEPS	B-T058
-	I-T058
R	I-T058
Turkish	B-T098
version	B-T170
.	O

In	O
addition	O
to	O
tests	O
of	O
validity	O
,	O
confirmatory	O
factor	O
analysis	O
was	O
conducted	O
to	O
investigate	O
the	O
factor	O
structure	O
of	O
the	O
16	O
-	O
item	O
Turkish	B-T098
version	B-T170
of	O
DEPS	B-T058
-	I-T058
R	I-T058
.	O

The	O
Turkish	B-T098
version	B-T170
of	O
DEPS	B-T058
-	I-T058
R	I-T058
demonstrated	O
satisfactory	O
Cronbach	O
'	O
s	O
∝	O
(	O
0	O
.	O
847	O
)	O
and	O
was	O
significantly	O
correlated	O
with	O
ag	O
e	O
(	O
r	O
=	O
0	O
.	O
194	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
hemoglobin	B-T033
A1c	I-T033
levels	I-T033
(	O
r	O
=	O
0	O
.	O
303	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
BMI	B-T201
-	O
SDS	O
(	O
r	O
=	O
0	O
.	O
412	O
;	O
p	O
<	O
0	O
.	O
01	O
)	O
indicating	O
criterion	O
validity	O
.	O

Median	O
DEPS	B-T058
-	I-T058
R	I-T058
scores	O
of	O
Turkish	B-T098
version	B-T170
for	O
the	O
total	O
samples	B-T098
,	O
females	O
and	O
males	O
were	O
as	O
follows	O
:	O
11	O
.	O
0	O
,	O
11	O
.	O
5	O
and	O
10	O
.	O
5	O
respectively	O
.	O

Disturbed	O
eating	O
behaviors	O
and	O
insulin	B-T103
restriction	O
were	O
associated	O
with	O
poor	O
metabolic	B-T038
control	I-T038
.	O

A	O
short	O
,	O
self	O
-	O
administered	O
diabetes	B-T038
specific	O
screening	B-T058
tool	O
for	O
disordered	O
eating	O
behavior	O
can	O
be	O
used	O
routinely	O
in	O
the	O
clinical	O
care	B-T058
of	O
adolescents	O
with	O
type	B-T038
1	I-T038
diabetes	I-T038
.	O

The	O
Turkish	B-T098
version	B-T170
of	O
DEPS	B-T058
-	I-T058
R	I-T058
is	O
a	O
valid	O
screening	B-T058
tool	O
for	O
disordered	O
eating	O
behaviors	O
in	O
type	B-T038
1	I-T038
diabetes	I-T038
and	O
it	O
is	O
potentially	O
important	O
to	O
early	O
detect	O
disordered	O
eating	O
behaviors	O
.	O

A	O
comparison	O
of	O
the	O
localization	O
of	O
rectal	B-T038
carcinomas	I-T038
according	O
to	O
the	O
general	B-T082
rules	B-T170
of	O
the	O
Japanese	B-T170
classification	I-T170
of	I-T170
colorectal	I-T170
carcinoma	I-T170
(	O
JCCRC	B-T170
)	O
and	O
Western	B-T082
guidelines	B-T170

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
localization	O
of	O
rectal	B-T038
cancers	I-T038
as	O
classified	B-T170
according	O
to	O
the	O
general	B-T082
rules	B-T170
of	O
the	O
Japanese	B-T170
classification	I-T170
of	I-T170
colorectal	I-T170
carcinoma	I-T170
(	O
JCCRC	B-T170
)	O
and	O
also	O
according	O
to	O
the	O
European	B-T092
Society	I-T092
for	I-T092
Medical	I-T092
Oncology	I-T092
(	O
ESMO	B-T092
)	O
and	O
the	O
National	B-T092
Comprehensive	I-T092
Cancer	I-T092
Network	I-T092
(	O
NCCN	B-T092
)	O
guidelines	B-T170
,	O
which	O
are	O
based	O
on	O
rigid	B-T058
endoscopic	I-T058
measurements	O
.	O

The	O
medical	B-T170
records	I-T170
of	O
patients	O
scheduled	O
to	O
receive	O
curative	B-T058
surgery	I-T058
for	O
histologically	O
proven	O
rectal	B-T038
adenocarcinoma	I-T038
during	O
2009	O
-	O
2015	O
were	O
investigated	O
(	O
n	O
=	O
230	O
)	O
.	O

Rigid	B-T058
proctoscopy	I-T058
was	O
performed	O
in	O
patients	O
with	O
rectal	B-T038
cancer	I-T038
located	B-T082
in	I-T082
the	O
upper	B-T082
(	O
Ra	B-T082
)	O
or	O
lower	B-T082
(	O
Rb	B-T082
)	O
division	B-T058
using	O
double	B-T058
-	I-T058
contrast	I-T058
barium	I-T058
enema	I-T058
.	O

The	O
median	O
values	O
of	O
height	O
from	O
the	O
anal	B-T017
verge	I-T017
were	O
7	O
.	O
5	O
cm	O
(	O
range	O
2	O
-	O
12	O
)	O
and	O
3	O
cm	O
(	O
0	O
-	O
9	O
.	O
5	O
)	O
on	O
rigid	B-T058
proctoscopy	I-T058
for	O
cancers	B-T038
assigned	O
as	O
Ra	B-T082
and	O
Rb	B-T082
,	O
respectively	O
.	O

All	O
159	O
cancers	B-T038
at	O
Ra	B-T082
or	O
Rb	B-T082
were	O
located	B-T082
within	B-T082
12	O
cm	O
from	O
the	O
anal	B-T017
verge	I-T017
by	O
rigid	B-T058
proctoscopy	I-T058
,	O
while	O
only	O
79	O
.	O
7	O
%	O
of	O
Ra	B-T082
or	O
82	O
.	O
1	O
%	O
of	O
Rb	B-T082
cancers	B-T038
were	O
located	B-T082
in	I-T082
the	O
mid	B-T082
(	O
5	O
.	O
1	O
-	O
10	O
cm	O
)	O
or	O
low	O
(	O
≤5	O
cm	O
)	O
rectum	B-T017
,	O
respectively	O
.	O

Ra	B-T082
and	O
Rb	B-T082
cancers	B-T038
are	O
deemed	O
to	O
be	O
rectal	B-T038
cancers	I-T038
according	O
to	O
NCCN	B-T092
guidelines	B-T170
,	O
but	O
these	O
classifications	B-T170
are	O
not	O
interchangeable	O
with	O
mid	B-T082
-	I-T082
and	O
low	O
-	O
rectal	B-T038
cancers	I-T038
,	O
respectively	O
,	O
according	O
to	O
the	O
ESMO	B-T092
guidelines	B-T170
.	O

Natural	B-T058
orifice	I-T058
transluminal	I-T058
endoscopic	I-T058
surgery	I-T058
with	O
a	O
snake	O
-	O
mechanism	O
using	O
a	O
movable	B-T074
pulley	I-T074

Natural	B-T058
orifice	I-T058
transluminal	I-T058
endoscopic	I-T058
surgery	I-T058
is	O
an	O
emerging	O
technique	O
.	O

We	O
aimed	O
to	O
develop	O
an	O
advanced	O
surgical	O
robot	O
mechanism	O
for	O
natural	B-T058
orifice	I-T058
surgery	I-T058
.	O

We	O
propose	O
the	O
active	O
-	O
controlled	O
overtube	O
-	O
type	O
platform	O
with	O
multiple	O
channels	B-T082
for	O
an	O
endoscopic	B-T074
camera	I-T074
and	O
surgical	B-T058
tools	O
.	O

To	O
make	O
such	O
a	O
platform	O
,	O
we	O
suggest	O
an	O
advanced	O
snake	O
mechanism	O
comprising	O
movable	B-T074
pulleys	I-T074
to	O
make	O
a	O
snake	O
mechanism	O
with	O
multiple	O
degrees	O
of	O
freedom	O
and	O
high	O
operating	O
force	O
.	O

The	O
stiffness	O
and	O
maneuverability	O
of	O
the	O
active	O
-	O
controlled	O
platform	O
appeared	O
satisfactory	O
.	O

Using	O
prototypes	B-T170
and	O
ex	O
vivo	O
experiments	B-T062
,	O
we	O
confirmed	O
that	O
the	O
mechanism	O
was	O
suitable	O
for	O
a	O
snake	O
-	O
like	O
robotic	O
platform	O
for	O
natural	B-T058
orifice	I-T058
surgery	I-T058
.	O

The	O
suggested	O
snake	O
mechanism	O
using	O
movable	B-T074
pulleys	I-T074
has	O
the	O
advantages	O
of	O
stiffness	O
and	O
maneuverability	O
.	O

This	O
new	O
mechanism	O
can	O
be	O
an	O
alternative	O
platform	O
for	O
natural	B-T058
orifice	I-T058
surgery	I-T058
.	O

Real	O
role	O
of	O
β	B-T103
-	I-T103
blockers	I-T103
in	O
regression	O
of	O
left	B-T033
ventricular	I-T033
mass	I-T033
in	O
hypertension	B-T038
patients	O
:	O
Bayesian	B-T170
network	I-T170
meta	B-T062
-	I-T062
analysis	I-T062

Left	B-T038
ventricular	I-T038
hypertrophy	I-T038
(	O
LVH	B-T038
)	O
is	O
commonly	O
present	O
in	O
patients	O
with	O
hypertension	B-T038
(	O
HT	B-T038
)	O
.	O

According	O
to	O
the	O
expert	B-T170
consensus	I-T170
document	I-T170
from	O
American	B-T098
,	O
angiotensin	B-T103
-	I-T103
converting	I-T103
enzyme	I-T103
inhibitor	I-T103
(	O
ACEI	B-T103
)	O
and	O
angiotensin	B-T103
receptor	I-T103
blockers	I-T103
(	O
ARBs	B-T103
)	O
were	O
recommended	O
as	O
1st	O
-	O
line	O
therapeutic	B-T103
drugs	I-T103
.	O

However	O
,	O
none	O
noticed	O
the	O
different	O
efficacy	O
between	O
fat	B-T103
-	I-T103
soluble	I-T103
and	I-T103
selective	I-T103
β1	I-T103
-	I-T103
receptor	I-T103
blockers	I-T103
(	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
)	O
and	O
other	O
β	B-T103
-	I-T103
blockers	I-T103
on	O
regression	O
of	O
LVH	B-T038
before	O
.	O

The	O
aim	O
of	O
this	O
analysis	B-T062
was	O
to	O
compare	O
the	O
efficacy	O
of	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
with	O
the	O
other	O
4	O
different	O
classes	O
of	O
antihypertensive	B-T103
drugs	I-T103
(	O
ACEI	B-T103
,	O
ARBs	B-T103
,	O
calcium	B-T103
channel	I-T103
blockers	I-T103
[	O
CCBs	B-T103
]	O
,	O
and	O
diuretics	B-T103
)	O
on	O
regression	O
of	O
LVH	B-T038
.	O

Relative	O
trials	B-T062
were	O
identified	O
in	O
the	O
PubMed	B-T170
,	O
Web	B-T170
of	I-T170
Science	I-T170
,	O
OVID	B-T170
EBM	I-T170
Reviews	I-T170
and	O
Cochrane	B-T170
databases	I-T170
,	O
and	O
the	O
relevant	O
papers	B-T170
were	O
examined	O
.	O

We	O
performed	O
both	O
traditional	O
and	O
Bayesian	B-T170
meta	B-T062
-	I-T062
analysis	I-T062
of	O
randomized	B-T062
controlled	I-T062
trials	I-T062
(	O
RCTs	B-T062
)	O
about	O
the	O
regression	O
of	O
LVH	B-T038
.	O

Sensitivity	B-T062
analysis	I-T062
and	O
regression	B-T170
analysis	I-T170
were	O
performed	O
to	O
explore	O
possible	O
sources	O
of	O
heterogeneity	O
.	O

Inconsistency	B-T062
analysis	I-T062
was	O
performed	O
to	O
check	O
whether	O
the	O
analysis	B-T062
of	O
the	O
trials	B-T062
in	O
the	O
network	B-T170
was	O
indeed	O
consistent	O
.	O

A	O
total	O
of	O
41	O
RCTs	B-T062
involving	O
2566	O
patients	O
with	O
HT	B-T038
and	O
LVH	B-T038
were	O
included	O
in	O
this	O
analysis	B-T062
.	O

Bayesian	B-T170
network	I-T170
meta	B-T062
-	I-T062
analysis	I-T062
indicated	O
no	O
statistically	O
significant	O
differences	O
between	O
these	O
groups	O
:	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
and	O
ACEI	B-T103
(	O
MD	O
,	O
-	O
7	O
.	O
09	O
;	O
95	O
%	O
CI	O
,	O
-	O
14	O
.	O
99	O
,	O
1	O
.	O
27	O
)	O
;	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
and	O
ARB	B-T103
(	O
MD	O
,	O
-	O
2	O
.	O
66	O
;	O
95	O
%	O
Cl	O
,	O
-	O
12	O
.	O
02	O
,	O
6	O
.	O
31	O
)	O
.	O

Although	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
showed	O
greater	O
efficacy	O
when	O
compared	O
with	O
diuretic	B-T103
(	O
MD	O
,	O
13	O
.	O
04	O
;	O
95	O
%	O
CI	O
,	O
3	O
.	O
38	O
,	O
22	O
.	O
59	O
)	O
or	O
CCB	B-T103
(	O
MD	O
,	O
10	O
.	O
90	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
98	O
,	O
19	O
.	O
49	O
)	O
.	O

The	O
probabilities	O
of	O
being	O
among	O
the	O
most	O
efficacious	O
treatments	B-T058
were	O
:	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
(	O
72	O
%	O
)	O
,	O
ARB	B-T103
(	O
27	O
%	O
)	O
,	O
ACEI	B-T103
(	O
0	O
.	O
01	O
%	O
)	O
,	O
CCB	B-T103
(	O
0	O
.	O
00	O
%	O
)	O
,	O
and	O
diuretic	B-T103
(	O
0	O
.	O
00	O
%	O
)	O
.	O

Evidence	O
from	O
our	O
analysis	B-T062
reveals	O
that	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
have	O
potential	O
to	O
become	O
1st	O
-	O
line	O
therapeutic	B-T103
drugs	I-T103
in	O
HT	B-T038
and	O
LVH	B-T038
patients	O
.	O

However	O
,	O
the	O
real	O
efficacy	O
of	O
FS	B-T103
-	I-T103
β	I-T103
-	I-T103
B	I-T103
on	O
regression	O
of	O
LVH	B-T038
should	O
be	O
confirmed	O
by	O
further	O
large	O
,	O
high	O
quality	O
trials	B-T062
considering	O
the	O
limitation	O
of	O
the	O
study	O
number	O
.	O

Improved	B-T033
risk	O
stratification	B-T062
for	O
patients	O
with	O
high	O
-	O
grade	O
urothelial	B-T038
carcinoma	I-T038
following	O
application	O
of	O
the	O
Paris	B-T082
System	O
for	O
Reporting	B-T058
Urinary	B-T058
Cytology	I-T058

The	O
Paris	B-T082
System	O
for	O
Reporting	B-T058
Urinary	B-T058
Cytology	I-T058
(	O
TPS	B-T058
)	O
requires	O
4	O
cytomorphologic	B-T017
criteria	O
for	O
a	O
definitive	O
diagnosis	B-T033
of	O
high	B-T038
-	I-T038
grade	I-T038
urothelial	I-T038
carcinoma	I-T038
(	O
HGUC	B-T038
)	O
in	O
urinary	B-T058
tract	I-T058
cytology	I-T058
(	O
UTC	B-T058
)	O
specimens	O
:	O
an	O
elevated	O
nuclear	B-T038
-	I-T038
to	I-T038
-	I-T038
cytoplasmic	I-T038
(	I-T038
N	I-T038
/	I-T038
C	I-T038
)	I-T038
ratio	I-T038
(	O
at	O
or	O
above	O
0	O
.	O
7	O
)	O
,	O
markedly	O
atypical	O
nuclear	B-T017
borders	B-T082
,	O
moderate	O
to	O
severe	O
hyperchromasia	B-T033
,	O
and	O
coarse	B-T033
chromatin	I-T033
.	O

However	O
,	O
malignant	O
UTC	B-T058
specimens	O
often	O
contain	O
degenerative	O
changes	O
,	O
and	O
this	O
limits	O
the	O
number	O
of	O
malignant	B-T017
cells	I-T017
meeting	O
all	O
4	O
TPS	B-T058
cytomorphologic	B-T017
criteria	O
.	O

One	O
hundred	O
twelve	O
UTC	B-T058
specimens	O
from	O
patients	O
with	O
a	O
subsequent	O
diagnosis	B-T033
of	O
HGUC	B-T038
were	O
reviewed	O
and	O
reclassified	O
according	O
to	O
TPS	B-T058
criteria	O
.	O

The	O
presence	B-T033
of	O
TPS	B-T058
cytomorphologic	B-T017
criteria	O
for	O
HGUC	B-T038
in	O
each	O
specimen	O
was	O
recorded	O
,	O
as	O
was	O
the	O
proportion	O
of	O
atypical	O
cells	B-T017
meeting	O
all	O
4	O
criteria	O
.	O

The	O
number	O
of	O
specimens	O
definitively	O
diagnosed	B-T033
as	O
HGUC	B-T038
did	O
not	O
significantly	O
change	O
upon	O
reclassification	B-T170
.	O

However	O
,	O
approximately	O
40	O
%	O
of	O
indeterminate	O
specimens	O
(	O
21	O
of	O
51	O
)	O
were	O
reclassified	O
into	O
a	O
higher	O
risk	O
category	B-T170
.	O

The	O
most	O
restrictive	O
cytomorphologic	B-T017
criterion	O
was	O
an	O
N	B-T038
/	I-T038
C	I-T038
ratio	I-T038
of	O
0	O
.	O
7	O
or	O
higher	O
(	O
seen	O
in	O
78	O
%	O
of	O
specimens	O
)	O
,	O
and	O
approximately	O
half	O
of	O
specimens	O
containing	O
all	O
4	O
cytomorphologic	B-T017
criteria	O
did	O
not	O
meet	O
TPS	B-T058
'	O
s	O
numerical	O
criterion	O
for	O
HGUC	B-T038
(	O
at	O
least	O
5	O
malignant	B-T017
cells	I-T017
)	O
.	O

In	O
the	O
majority	O
of	O
specimens	O
qualifying	O
for	O
HGUC	B-T038
by	O
TPS	B-T058
standards	O
,	O
only	O
a	O
small	O
fraction	O
of	O
atypical	O
cells	B-T017
(	O
10	O
%	O
-	O
20	O
%	O
)	O
met	O
all	O
the	O
criteria	O
.	O

When	O
applied	O
to	O
malignant	O
UTC	B-T058
specimens	O
,	O
TPS	B-T058
criteria	O
improved	B-T033
specimen	O
risk	O
stratification	B-T062
by	O
upgrading	O
approximately	O
40	O
%	O
of	O
indeterminate	O
specimens	O
into	O
higher	O
risk	O
categories	B-T170
while	O
not	O
significantly	O
changing	O
the	O
frequency	O
of	O
HGUC	B-T038
diagnoses	B-T033
.	O

Cancer	B-T038
Cytopathol	O
2017	O
.	O

©	O
2017	O
American	B-T092
Cancer	I-T092
Society	I-T092
.	O

Questionable	O
diagnostic	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
bee	B-T103
venom	I-T103
components	O

For	O
many	O
years	O
,	O
only	O
the	O
major	O
allergen	B-T103
rApi	B-T103
m	I-T103
1	I-T103
has	O
been	O
available	O
on	O
the	O
ImmunoCAP	B-T170
system	I-T170
for	O
routine	O
diagnosis	B-T033
of	O
bee	B-T038
venom	I-T038
(	I-T038
BV	I-T038
)	I-T038
allergy	I-T038
.	O

Now	O
,	O
there	O
are	O
five	O
components	O
available	O
,	O
and	O
we	O
aimed	O
to	O
detect	O
the	O
sensitivity	O
and	O
specificity	O
of	O
rApi	B-T103
m	I-T103
1	I-T103
,	O
2	B-T103
,	O
3	B-T103
,	O
5	B-T103
,	O
and	O
10	B-T103
in	O
BV	B-T038
-	I-T038
allergic	I-T038
patients	O
.	O

We	O
further	O
evaluated	O
the	O
sensitivity	O
of	O
rApi	B-T103
m	I-T103
1	I-T103
and	O
2	B-T103
of	O
an	O
alternative	O
platform	O
and	O
investigated	O
possible	O
differences	O
in	O
the	O
sensitization	B-T038
profile	O
between	O
monosensitization	B-T038
and	O
clinically	O
relevant	O
double	B-T038
sensitization	I-T038
.	O

Analysis	B-T062
of	O
the	O
whole	O
panel	O
of	O
BV	B-T103
allergens	B-T103
of	O
the	O
CAP	B-T170
system	I-T170
still	O
resulted	O
in	O
a	O
lower	O
sensitivity	O
than	O
analysis	B-T062
of	O
the	O
combination	O
of	O
rApi	B-T103
m	I-T103
1	I-T103
and	O
2	B-T103
of	O
the	O
Immulite	O
(	O
71	O
.	O
6	O
%	O
vs	O
85	O
.	O
8	O
%	O
)	O
.	O

Sensitization	B-T038
rate	O
of	O
rApi	B-T103
m	I-T103
5	I-T103
was	O
more	O
than	O
doubled	O
in	O
double	B-T038
-	I-T038
sensitized	I-T038
patients	O
,	O
while	O
there	O
was	O
no	O
difference	O
for	O
rApi	B-T103
m	I-T103
2	I-T103
.	O

The	O
benefit	O
of	O
the	O
commercially	O
available	O
panel	O
of	O
BV	B-T103
components	O
is	O
questionable	O
,	O
due	O
to	O
the	O
insufficient	O
sensitivity	O
and	O
still	O
unavailable	O
important	O
cross	B-T038
-	I-T038
reacting	I-T038
allergens	B-T103
.	O

Orai1	B-T103
-	O
Mediated	O
Antimicrobial	B-T103
Secretion	B-T031
from	O
Pancreatic	B-T017
Acini	I-T017
Shapes	O
the	O
Gut	O
Microbiome	O
and	O
Regulates	B-T038
Gut	B-T017
Innate	O
Immunity	O

The	O
gut	O
microbiome	O
participates	O
in	O
numerous	O
physiologic	O
functions	O
and	O
communicates	B-T033
intimately	O
with	O
the	O
host	O
immune	B-T022
system	I-T022
.	O

Antimicrobial	B-T103
peptides	I-T103
are	O
critica	O
l	O
components	B-T103
of	O
intestinal	B-T017
innate	O
immunity	O
.	O

We	O
report	O
a	O
prominent	O
role	O
for	O
antimicrobials	B-T038
secreted	I-T038
by	O
pancreatic	B-T017
acini	I-T017
in	O
shaping	O
the	O
gut	O
microbiome	O
that	O
is	O
essential	O
for	O
intestinal	B-T017
innate	O
immunity	O
,	O
barrier	O
function	O
,	O
and	O
survival	O
.	O

Deletion	O
of	O
the	O
Ca	B-T017
(	I-T017
2	I-T017
+	I-T017
)	I-T017
channel	I-T017
Orai1	I-T017
in	O
pancreatic	B-T017
acini	I-T017
of	O
adult	O
mice	B-T204
resulted	O
in	O
60	O
%	O
-	O
70	O
%	O
mortality	O
within	O
3	O
weeks	O
.	O

Despite	O
robust	O
activation	B-T038
of	I-T038
the	I-T038
intestinal	I-T038
innate	I-T038
immune	I-T038
response	I-T038
,	O
mice	B-T204
lacking	O
acinar	B-T082
Orai1	B-T017
exhibited	O
intestinal	B-T017
bacterial	O
outgrowth	B-T038
and	O
dysbiosis	O
,	O
ultimately	O
causing	O
systemic	O
translocation	B-T038
,	O
inflammation	B-T038
,	O
and	O
death	B-T038
.	O

While	O
digestive	B-T103
enzyme	I-T103
supplementation	B-T058
was	O
ineffective	O
,	O
treatments	B-T058
constraining	O
bacterial	O
outgrowth	B-T038
(	O
purified	O
liquid	B-T058
diet	I-T058
,	O
broad	B-T103
-	I-T103
spectrum	I-T103
antibiotics	I-T103
)	O
rescued	O
survival	O
,	O
feeding	O
,	O
and	O
weight	B-T033
gain	I-T033
.	O

Pancreatic	B-T033
levels	I-T033
of	O
cathelicidin	B-T103
-	O
related	O
antimicrobial	B-T103
peptide	I-T103
(	O
CRAMP	B-T103
)	O
were	O
reduced	O
,	O
and	O
supplement	O
of	O
synthetic	O
CRAMP	B-T103
prevented	O
intestinal	B-T038
disease	I-T038
.	O

These	O
findings	B-T033
reveal	O
a	O
critical	O
role	O
for	O
antimicrobial	B-T103
pancreatic	B-T038
secretion	I-T038
in	O
gut	B-T017
innate	O
immunity	O
.	O

Palliative	B-T091
Care	I-T091
with	O
Attachment	O
Hybrid	O
Removable	O
Prosthesis	O

Abutment	B-T017
injury	B-T037
,	O
unsatisfactory	O
aesthetics	O
and	O
lesser	O
retention	B-T058
exist	O
with	O
the	O
cast	O
partial	O
denture	O
.	O

Though	O
these	O
constraints	O
exist	O
in	O
the	O
Removable	B-T074
Partial	I-T074
Denture	I-T074
(	O
RPD	B-T074
)	O
it	O
is	O
still	O
widely	O
used	O
because	O
of	O
the	O
simplicity	O
in	O
design	B-T058
,	O
fabrication	O
,	O
economics	O
and	O
patient	B-T058
comfort	I-T058
.	O

This	O
clinical	B-T170
report	I-T170
describes	O
a	O
hybrid	O
RPD	B-T074
technique	O
which	O
uses	O
extra	O
coronal	B-T082
attachment	O
that	O
reduces	O
the	O
limitations	O
and	O
provides	O
better	O
comfort	B-T038
for	O
the	O
patient	O
.	O

CXCL5	B-T103
Plays	O
a	O
Promoting	O
Role	O
in	O
Osteosarcoma	B-T038
Cell	B-T038
Migration	I-T038
and	I-T038
Invasion	I-T038
in	O
Autocrine	B-T038
-	O
and	O
Paracrine	O
-	O
Dependent	O
Manners	O

CXCL5	B-T103
,	O
a	O
CXC	B-T103
-	I-T103
type	I-T103
chemokine	I-T103
,	O
is	O
an	O
important	O
attractant	O
for	O
granulocytic	B-T017
immune	I-T017
cells	I-T017
by	O
binding	B-T038
to	I-T038
its	I-T038
receptor	I-T038
CXCR2	I-T038
.	O

Recently	O
,	O
CXCL5	B-T103
/	O
CXCR2	B-T103
has	O
been	O
found	O
to	O
play	O
an	O
oncogenic	B-T103
role	O
in	O
many	O
human	B-T204
cancers	B-T038
.	O

However	O
,	O
the	O
exact	O
role	O
of	O
CXCL5	B-T103
in	O
osteosarcoma	B-T038
cell	B-T038
migration	I-T038
and	I-T038
invasion	I-T038
has	O
not	O
been	O
revealed	O
.	O

Here	O
we	O
found	O
that	O
the	O
protein	B-T038
expression	I-T038
of	O
CXCL5	B-T103
was	O
significantly	O
increased	O
in	O
osteosarcoma	B-T038
tissues	B-T017
compared	O
with	O
that	O
in	O
matched	B-T017
adjacent	I-T017
nontumor	I-T017
tissues	I-T017
.	O

Moreover	O
,	O
the	O
expression	B-T038
of	O
CXCL5	B-T103
was	O
significantly	O
associated	O
with	O
advanced	O
clinical	O
stage	O
and	O
metastasis	B-T038
.	O

Further	O
investigation	O
showed	O
that	O
the	O
CXCL5	B-T103
expression	O
levels	O
were	O
also	O
significantly	O
increased	O
in	O
osteosarcoma	B-T038
cell	B-T017
lines	I-T017
,	O
including	O
Saos	B-T017
-	I-T017
2	I-T017
,	O
MG63	B-T017
,	O
U2OS	B-T017
,	O
and	O
SW1353	B-T017
,	O
when	O
compared	O
with	O
those	O
in	O
normal	B-T017
osteoblast	I-T017
hFoB1	B-T017
.	I-T017
19	I-T017
cells	I-T017
.	O

U2OS	B-T017
cells	I-T017
were	O
further	O
transfected	B-T038
with	O
CXCL5	B-T017
-	O
specific	B-T103
siRNA	I-T103
or	O
overexpression	B-T038
plasmid	B-T103
.	O

Knockdown	B-T062
of	O
CXCL5	B-T017
significantly	O
suppressed	O
U2OS	B-T017
cell	B-T038
migration	I-T038
and	I-T038
invasion	I-T038
.	O

On	O
the	O
contrary	O
,	O
overexpression	B-T038
of	O
CXLC5	B-T103
remarkably	O
promoted	O
the	O
migration	B-T038
and	I-T038
invasion	I-T038
of	O
U2OS	B-T017
cells	I-T017
.	O

Interestingly	O
,	O
both	O
exogenous	O
CXCL5	B-T103
treatment	O
and	O
the	O
conditioned	O
medium	O
of	O
CXCL5	B-T103
-	O
overexpressing	B-T038
hFoB1	B-T017
.	I-T017
19	I-T017
cells	I-T017
could	O
also	O
enhance	O
the	O
migration	B-T038
and	I-T038
invasion	I-T038
of	O
U2OS	B-T017
cells	I-T017
,	O
suggesting	O
that	O
the	O
promoting	O
role	O
of	O
CXCL5	B-T103
in	O
U2OS	B-T017
cell	B-T038
migration	I-T038
and	I-T038
invasion	I-T038
is	O
also	O
in	O
a	O
paracrine	O
-	O
dependent	O
manner	O
.	O

According	O
to	O
these	O
data	O
,	O
our	O
study	O
demonstrates	O
that	O
CXCL5	B-T103
is	O
upregulated	O
in	O
osteosarcoma	B-T038
and	O
may	O
play	O
an	O
oncogenic	B-T103
role	O
in	O
osteosarcoma	B-T038
metastasis	B-T038
.	O

Therefore	O
,	O
CXCL5	B-T103
may	O
become	O
a	O
potential	O
therapeutic	O
target	O
for	O
osteosarcoma	B-T038
treatment	O
.	O

Integrating	O
molecular	O
QTL	B-T017
data	O
into	O
genome	B-T062
-	I-T062
wide	I-T062
genetic	I-T062
association	I-T062
analysis	I-T062
:	O
Probabilistic	O
assessment	O
of	O
enrichment	O
and	O
colocalization	O

We	O
propose	O
a	O
novel	O
statistical	B-T170
framework	I-T170
for	O
integrating	O
the	O
result	O
from	O
molecular	O
quantitative	B-T017
trait	I-T017
loci	I-T017
(	O
QTL	B-T017
)	O
mapping	O
into	O
genome	B-T062
-	I-T062
wide	I-T062
genetic	I-T062
association	I-T062
analysis	I-T062
of	O
complex	O
traits	O
,	O
with	O
the	O
primary	O
objectives	O
of	O
quantitatively	O
assessing	O
the	O
enrichment	O
of	O
the	O
molecular	O
QTLs	B-T017
in	O
complex	O
trait	O
-	O
associated	O
genetic	B-T017
variants	I-T017
and	O
the	O
colocalizations	O
of	O
the	O
two	O
types	O
of	O
association	O
signals	O
.	O

We	O
introduce	O
a	O
natural	O
Bayesian	O
hierarchical	O
model	O
that	O
treats	O
the	O
latent	O
association	O
status	O
of	O
molecular	O
QTLs	B-T017
as	O
SNP	B-T082
-	O
level	O
annotations	O
for	O
candidate	O
SNPs	B-T082
of	O
complex	O
traits	O
.	O

We	O
detail	O
a	O
computational	O
procedure	O
to	O
seamlessly	O
perform	O
enrichment	O
,	O
fine	O
-	O
mapping	O
and	O
colocalization	O
analyses	B-T062
,	O
which	O
is	O
a	O
distinct	O
feature	O
compared	O
to	O
the	O
existing	O
colocalization	O
analysis	B-T062
procedures	O
in	O
the	O
literature	B-T170
.	O

The	O
proposed	O
approach	B-T082
is	O
computationally	O
efficient	O
and	O
requires	O
only	O
summary	B-T170
-	O
level	O
statistics	O
.	O

We	O
evaluate	O
and	O
demonstrate	O
the	O
proposed	O
computational	O
approach	B-T082
through	O
extensive	O
simulation	O
studies	B-T062
and	O
analyses	B-T062
of	O
blood	O
lipid	O
data	O
and	O
the	O
whole	B-T031
blood	I-T031
eQTL	B-T017
data	O
from	O
the	O
GTEx	B-T062
project	I-T062
.	O

In	O
addition	O
,	O
a	O
useful	O
utility	B-T170
from	O
our	O
proposed	O
method	B-T170
enables	O
the	O
computation	O
of	O
expected	O
colocalization	O
signals	O
using	O
simple	O
characteristics	O
of	O
the	O
association	O
data	O
.	O

Using	O
this	O
utility	B-T170
,	O
we	O
further	O
illustrate	O
the	O
importance	O
of	O
enrichment	O
analysis	B-T062
on	O
the	O
ability	O
to	O
discover	O
colocalized	O
signals	O
and	O
the	O
potential	O
limitations	O
of	O
currently	O
available	O
molecular	O
QTL	B-T017
data	O
.	O

The	O
software	B-T170
pipeline	O
that	O
implements	O
the	O
proposed	O
computation	O
procedures	O
,	O
enloc	B-T170
,	O
is	O
freely	O
available	O
at	O
https	B-T170
:	I-T170
/	I-T170
/	I-T170
github	I-T170
.	I-T170
com	I-T170
/	I-T170
xqwen	I-T170
/	I-T170
integrative	I-T170
.	O

Engineering	B-T062
the	O
ribosomal	B-T103
DNA	I-T103
in	O
a	O
megabase	O
synthetic	O
chromosome	O

We	O
designed	O
and	O
synthesized	O
a	O
976	O
,	O
067	O
-	O
base	O
pair	O
linear	O
chromosome	O
,	O
synXII	O
,	O
based	O
on	O
native	O
chromosome	B-T017
XII	I-T017
in	O
Saccharomyces	B-T204
cerevisiae	I-T204
SynXII	O
was	O
assembled	O
using	O
a	O
two	O
-	O
step	O
method	O
,	O
specified	O
by	O
successive	O
megachunk	B-T062
integration	I-T062
and	O
meiotic	B-T062
recombination	I-T062
-	I-T062
mediated	I-T062
assembly	I-T062
,	O
producing	O
a	O
functional	O
chromosome	B-T017
in	O
S	B-T204
.	I-T204

cerevisiae	I-T204
.	O

Minor	O
growth	O
defect	O
"	O
bugs	O
"	O
detected	B-T033
in	O
synXII	O
,	O
caused	O
by	O
deletion	B-T038
of	O
tRNA	B-T103
genes	B-T017
,	O
were	O
rescued	O
by	O
introducing	O
an	O
ectopic	B-T017
copy	I-T017
of	O
a	O
single	B-T103
tRNA	I-T103
gene	B-T017
.	O

The	O
ribosomal	B-T017
gene	I-T017
cluster	I-T017
(	O
rDNA	B-T017
)	O
on	O
synXII	O
was	O
left	O
intact	O
during	O
the	O
assembly	B-T062
process	I-T062
and	O
subsequently	O
replaced	O
by	O
a	O
modified	O
rDNA	B-T017
unit	O
used	O
to	O
regenerate	O
rDNA	B-T017
at	O
three	O
distinct	O
chromosomal	B-T017
locations	I-T017
.	O

The	O
signature	O
sequences	B-T082
within	O
rDNA	B-T017
,	O
which	O
can	O
be	O
used	O
to	O
determine	O
species	B-T170
identity	B-T033
,	O
were	O
swapped	O
to	O
generate	O
a	O
Saccharomyces	B-T204
synXII	O
strain	O
that	O
would	O
be	O
identified	O
as	O
Saccharomyces	B-T204
bayanus	I-T204
by	O
standard	O
DNA	O
barcoding	O
procedures	O
.	O

Reversible	O
Humidity	O
Sensitive	O
Clothing	O
for	O
Personal	B-T058
Thermoregulation	I-T058

Two	O
kinds	O
of	O
humidity	O
-	O
induced	O
,	O
bendable	O
smart	O
clothing	O
have	O
been	O
designed	B-T062
to	I-T062
reversibly	I-T062
adapt	I-T062
their	O
thermal	O
insulation	O
functionality	O
.	O

The	O
first	O
design	O
mimics	O
the	O
pores	B-T017
in	O
human	B-T022
skin	I-T022
,	O
in	O
which	O
pre	O
-	O
cut	O
flaps	O
open	O
to	O
produce	O
pores	B-T017
in	O
Nafion	B-T103
sheets	O
when	O
humidity	O
increases	O
,	O
as	O
might	O
occur	O
during	O
human	B-T033
sweating	I-T033
thus	O
permitting	O
air	O
flow	O
and	O
reducing	O
both	O
the	O
humidity	O
level	O
and	O
the	O
apparent	O
temperature	O
.	O

Like	O
the	O
smart	O
human	B-T017
sweating	I-T017
pores	I-T017
,	O
the	O
flaps	O
can	O
close	O
automatically	O
after	O
the	O
perspiration	B-T033
to	O
keep	O
the	O
wearer	O
warm	O
.	O

The	O
second	O
design	O
involves	O
thickness	O
adjustable	O
clothes	O
by	O
inserting	O
the	O
bent	O
polymer	O
sheets	O
between	O
two	O
fabrics	O
.	O

As	O
the	O
humidity	O
increases	O
,	O
the	O
sheets	O
become	O
thinner	O
,	O
thus	O
reducing	O
the	O
gap	O
between	O
the	O
two	O
fabrics	O
to	O
reduce	O
the	O
thermal	O
insulation	O
.	O

The	O
insulation	O
layer	O
can	O
recover	O
its	O
original	O
thickness	O
upon	O
humidity	O
reduction	O
to	O
restore	O
its	O
warmth	B-T038
-	I-T038
preservation	I-T038
function	O
.	O

Such	O
humidity	O
sensitive	O
smart	O
polymer	O
materials	O
can	O
be	O
utilized	O
to	O
adjust	O
personal	B-T038
comfort	I-T038
,	O
and	O
be	O
effective	O
in	O
reducing	B-T033
energy	I-T033
consumption	I-T033
for	O
building	O
heating	O
or	O
cooling	O
with	O
numerous	O
smart	O
design	O
.	O

Development	B-T038
of	O
an	O
automaton	O
model	O
of	O
rotational	O
activity	O
driving	O
atrial	B-T038
fibrillation	I-T038

Atrial	B-T038
fibrillation	I-T038
(	O
AF	B-T038
)	O
is	O
difficult	O
to	O
treat	B-T058
effectively	O
,	O
owing	O
to	O
uncertainty	B-T033
in	O
where	O
to	O
best	O
ablate	B-T058
to	O
eliminate	O
arrhythmogenic	B-T038
substrate	O
.	O

A	O
model	O
providing	O
insight	O
into	O
the	O
electrical	O
activation	O
events	O
would	O
be	O
useful	O
to	O
guide	O
catheter	B-T058
ablation	I-T058
strategy	I-T058
.	O

Method	O
A	O
two	B-T082
-	I-T082
dimensional	I-T082
,	O
576×576	O
node	O
automaton	O
was	O
developed	O
to	O
simulate	O
atrial	B-T017
electrical	O
activity	O
.	O

The	O
substrate	O
field	O
was	O
altered	O
by	O
the	O
presence	O
of	O
differing	O
refractory	O
period	O
at	O
varying	O
locations	B-T082
.	O

Fibrosis	B-T038
was	O
added	O
in	O
the	O
form	O
of	O
short	O
,	O
randomly	O
positioned	O
lines	O
of	O
conduction	B-T038
block	B-T038
.	O

Larger	O
areas	B-T082
of	O
block	B-T038
were	O
used	O
to	O
simulate	O
ablation	B-T033
lesions	I-T033
.	O

Anisotropy	O
was	O
imposed	O
in	O
a	O
2	O
:	O
1	O
ratio	O
.	O

A	O
premature	O
electrical	B-T038
impulse	I-T038
from	O
one	O
of	O
four	O
grid	O
corners	O
was	O
utilized	O
to	O
initiate	O
activation	O
.	O

Rotational	O
activity	O
was	O
uninducible	O
when	O
refractory	O
patch	O
dimensions	O
were	O
less	O
than	O
20×20mm	O
.	O

For	O
larger	O
refractory	O
regions	O
,	O
a	O
single	O
premature	O
stimulus	O
was	O
capable	O
of	O
inducing	O
an	O
average	O
of	O
1	O
.	O
19±1	O
.	O
10	O
rotors	B-T074
,	O
which	O
often	O
formed	O
near	O
the	O
patch	O
edges	O
.	O

A	O
maximum	O
of	O
5	O
rotors	B-T074
formed	O
when	O
refractory	O
patch	O
dimensions	O
approached	O
the	O
size	B-T082
of	O
the	O
entire	O
left	B-T017
atrial	I-T017
virtual	O
field	O
.	O

Rotors	B-T074
formed	O
along	O
a	O
refractory	O
patch	O
edge	O
,	O
after	O
wavefront	B-T033
arrival	I-T033
was	I-T033
delayed	I-T033
at	O
turning	O
points	O
or	O
due	O
to	O
the	O
presence	O
of	O
a	O
fiber	B-T017
cluster	O
of	O
sufficient	O
size	B-T082
.	O

However	O
,	O
rotational	O
activity	O
could	O
also	O
occur	O
around	O
a	O
large	O
fiber	B-T017
cluster	O
without	O
the	O
need	O
of	O
spatially	O
variable	O
refractoriness	O
.	O

When	O
obstacles	O
to	O
conduction	B-T038
were	O
lacking	O
in	O
size	B-T082
,	O
nascent	B-T074
rotors	I-T074
drifted	O
and	O
either	O
extinguished	O
,	O
or	O
stabilized	B-T033
upon	O
anchoring	B-T038
at	O
a	O
sufficiently	O
large	O
fiber	B-T017
cluster	O
elsewhere	O
in	O
the	O
field	O
.	O

Transient	O
rotors	B-T074
terminated	O
when	O
traversing	O
a	O
region	B-T082
with	O
differing	O
refractory	O
periods	O
,	O
if	O
no	O
obstacle	O
to	O
conduction	B-T038
was	O
present	O
to	O
sufficiently	O
delay	B-T033
wavefront	I-T033
arrival	I-T033
beyond	O
the	O
longest	O
refractory	O
period	O
.	O

Other	O
rotors	B-T074
were	O
annihilated	O
when	O
a	O
nearby	O
rotor	B-T074
with	O
faster	O
spin	O
rate	O
gradually	O
interrupted	O
the	O
activation	B-T038
pathway	I-T038
.	O

Elimination	O
of	O
anchors	B-T058
by	O
removal	B-T058
,	O
or	O
by	O
simulated	O
ablation	B-T058
over	O
a	O
sufficient	O
region	B-T082
,	O
prevented	O
rotor	B-T074
onset	O
at	O
a	O
particular	O
location	B-T082
where	O
it	O
would	O
otherwise	O
form	O
.	O

The	O
presence	O
of	O
obstacles	O
to	O
conduction	B-T038
and	O
spatial	B-T033
differences	I-T033
in	O
refractory	O
period	O
are	O
important	O
parameters	O
for	O
initiating	O
and	O
maintaining	O
rotational	O
activity	O
in	O
this	O
simulation	B-T062
of	O
an	O
atrial	B-T017
substrate	O
.	O

Multimodal	B-T058
brain	I-T058
imaging	I-T058
with	O
magnetoencephalography	B-T058
:	O
A	O
method	B-T058
for	O
measuring	O
blood	B-T038
pressure	I-T038
and	O
cardiorespiratory	B-T038
oscillations	I-T038

Studies	B-T062
with	O
magnetoencephalography	B-T058
(	O
MEG	B-T058
)	O
are	O
still	O
quite	O
rarely	O
combined	O
simultaneously	O
with	O
methods	B-T058
that	O
can	O
provide	O
a	O
metabolic	O
dimension	O
to	O
MEG	B-T058
investigation	B-T058
s	O
.	O

In	O
addition	O
,	O
continuous	O
blood	B-T058
pressure	I-T058
measurements	I-T058
which	O
comply	O
with	O
MEG	B-T058
compatibility	O
requirements	O
are	O
lacking	O
.	O

For	O
instance	O
,	O
by	O
combining	O
methods	B-T058
reflecting	O
neurovascular	B-T058
status	I-T058
one	O
could	O
obtain	O
more	O
information	O
on	O
low	O
frequency	O
fluctuations	B-T033
that	O
have	O
recently	O
gained	O
increasing	O
interest	O
as	O
a	O
mediator	O
of	O
functional	O
connectivity	O
within	O
brain	B-T017
networks	I-T017
.	O

This	O
paper	O
presents	O
a	O
multimodal	B-T058
brain	I-T058
imaging	I-T058
setup	O
,	O
capable	O
to	O
non	O
-	O
invasively	O
and	O
continuously	O
measure	O
cerebral	B-T017
hemodynamic	B-T038
,	O
cardiorespiratory	O
and	O
blood	B-T038
pressure	I-T038
oscillations	B-T038
simultaneously	O
with	O
MEG	B-T058
.	O

In	O
the	O
setup	O
,	O
all	O
methods	B-T058
apart	O
from	O
MEG	B-T058
rely	O
on	O
the	O
use	O
of	O
fibre	O
optics	O
.	O

In	O
particular	O
,	O
we	O
present	O
a	O
method	B-T058
for	O
measuring	O
of	O
blood	B-T038
pressure	I-T038
and	O
cardiorespiratory	B-T038
oscillations	I-T038
continuously	O
with	O
MEG	B-T058
.	O

The	O
potential	O
of	O
this	O
type	O
of	O
multimodal	B-T058
setup	O
for	O
brain	B-T062
research	I-T062
is	O
demonstrated	O
by	O
our	O
preliminary	O
studies	O
on	O
human	B-T204
,	O
showing	O
effects	O
of	O
mild	B-T033
hypercapnia	I-T033
,	O
gathered	O
simultaneously	O
with	O
the	O
presented	O
modalities	O
.	O

Effect	O
of	O
peritoneal	B-T058
lavage	I-T058
solution	O
temperature	O
on	O
body	O
temperature	O
in	O
anaesthetised	B-T033
cats	B-T204
and	O
small	O
dogs	B-T204

A	O
prospective	B-T062
,	O
randomised	B-T062
,	O
non	B-T062
-	I-T062
blinded	I-T062
,	O
clinical	B-T062
study	I-T062
to	O
assess	O
the	O
effect	O
of	O
peritoneal	B-T058
lavage	I-T058
using	O
warmed	O
fluid	O
on	O
body	O
temperature	O
in	O
anesthetised	B-T033
cats	B-T204
and	O
dogs	B-T204
of	O
less	O
than	O
10	O
kg	O
body	O
mass	O
undergoing	O
coeliotomy	B-T058
.	O

A	O
standardised	B-T170
anaesthetic	I-T170
protocol	I-T170
was	O
used	O
.	O

Oesophageal	B-T058
and	O
rectal	B-T033
temperatures	I-T033
were	O
measured	O
at	O
various	O
time	O
points	O
.	O

At	O
the	O
end	O
of	O
surgery	B-T058
,	O
group	O
1	O
patients	O
(	O
n	O
=	O
10	O
)	O
were	O
lavaged	B-T058
with	O
200	O
ml	O
/	O
kg	O
sterile	O
isotonic	B-T103
saline	I-T103
at	O
34±1°C	O
and	O
group	O
2	O
(	O
n	O
=	O
10	O
)	O
at	O
40±1°C	O
.	O

Groups	O
were	O
similar	O
with	O
respect	O
to	O
age	O
,	O
mass	O
,	O
body	O
condition	O
and	O
surgical	B-T058
incision	I-T058
length	O
.	O

Duration	O
of	O
anaesthesia	B-T058
,	O
surgical	B-T058
procedures	I-T058
and	O
peritoneal	B-T058
lavage	I-T058
was	O
similar	O
between	O
groups	O
.	O

Linear	O
regression	O
showed	O
no	B-T033
significant	I-T033
change	I-T033
in	O
oesophageal	B-T058
temperature	I-T058
during	O
the	O
lavage	B-T058
period	O
for	O
group	O
1	O
(	O
P	O
=	O
0	O
.	O
64	O
)	O
,	O
but	O
a	O
significant	O
increase	O
for	O
group	O
2	O
patients	O
(	O
P	O
<	O
0	O
.	O
0001	O
)	O
,	O
with	O
mean	O
temperature	O
changes	O
of	O
-	O
0	O
.	O
5°C	O
(	O
from	O
(	O
36	O
.	O
3°C	O
to	O
35	O
.	O
9°C	O
)	O
and	O
+	O
0	O
.	O
9°C	O
(	O
from	O
35	O
.	O
4°C	O
to	O
36	O
.	O
3°C	O
)	O
,	O
respectively	O
.	O

Similar	O
results	B-T033
were	O
found	O
for	O
rectal	B-T033
temperature	I-T033
,	O
with	O
mean	O
changes	O
of	O
-	O
0	O
.	O
5°C	O
and	O
+	O
0	O
.	O
8°C	O
(	O
P	O
=	O
0	O
.	O
922	O
and	O
0	O
.	O
045	O
)	O
,	O
respectively	O
.	O

The	O
use	O
of	O
isotonic	B-T103
crystalloid	B-T103
solution	I-T103
for	O
peritoneal	B-T058
lavage	I-T058
at	O
a	O
temperature	O
of	O
40±1°C	O
significantly	O
warms	O
small	O
animal	O
patients	O
,	O
when	O
applied	O
in	O
a	O
clinical	O
setting	O
,	O
compared	O
with	O
lavage	B-T058
solution	O
at	O
34±1°C	O
.	O

Bioengineered	O
3D	B-T082
Models	O
for	O
Studying	B-T062
Human	B-T204
Cell	B-T017
-	O
Tuberculosis	B-T007
Interactions	O

In	B-T082
vivo	I-T082
animal	B-T204
models	I-T204
have	O
intrinsic	O
limitations	O
for	O
studying	B-T062
relationships	O
between	O
tuberculosis	B-T007
and	O
its	O
host	O
and	O
there	O
is	O
a	O
need	O
for	O
alternative	O
,	O
in	O
vitro	O
cellular	O
models	O
.	O

A	O
microsphere	B-T074
-	O
based	O
3D	B-T082
in	O
vitro	O
culture	B-T062
system	I-T062
of	O
Mycobacterium	B-T007
tuberculosis	I-T007
-	O
infected	O
human	B-T204
blood	B-T031
mononuclear	O
cells	O
was	O
reported	O
to	O
address	O
specific	O
aspects	O
of	O
host	O
-	O
pathogen	O
interactions	O
.	O

Perspectives	O
on	O
cardiovascular	B-T022
effects	O
of	O
incretin	B-T103
-	O
based	O
drugs	B-T103
:	O
From	O
bedside	O
to	O
bench	O
,	O
return	O
trip	O

Recently	O
,	O
cardiovascular	B-T022
outcome	O
trials	B-T062
with	O
glucose	B-T103
-	O
lowering	O
drugs	B-T103
used	O
in	O
type	B-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
,	O
namely	O
glucagon	B-T103
-	I-T103
like	I-T103
peptide	I-T103
-	I-T103
1	I-T103
receptor	I-T103
agonists	B-T103
(	O
GLP	B-T103
-	I-T103
1RA	I-T103
)	O
,	O
liraglutide	B-T103
and	O
semaglutide	B-T103
,	O
showed	O
a	O
reduction	O
in	O
cardiovascular	B-T033
events	I-T033
,	O
which	O
had	O
not	O
been	O
observed	O
in	O
trials	B-T062
with	O
other	O
incretin	B-T103
-	O
based	O
drugs	B-T103
,	O
such	O
as	O
lixisenatide	B-T103
or	O
with	O
dipeptidyl	B-T103
peptidase	I-T103
-	I-T103
4	I-T103
inhibitors	I-T103
(	O
DPP4i	B-T103
)	O
.	O

Mechanisms	O
underlying	O
the	O
observed	O
cardiovascular	B-T022
differences	O
between	O
DPP4i	B-T103
and	O
GLP1	B-T103
-	I-T103
RA	I-T103
,	O
and	O
across	O
individual	O
GLP1	B-T103
-	I-T103
RA	I-T103
are	O
poorly	O
understood	O
.	O

This	O
review	B-T170
is	O
aimed	O
at	O
collecting	O
and	O
summarizing	O
available	O
evidence	O
from	O
experimental	B-T062
and	O
mechanistic	B-T062
studies	I-T062
on	O
the	O
action	O
of	O
GLP1	B-T103
-	I-T103
RA	I-T103
and	O
DPP4i	B-T103
on	O
the	O
cardiovascular	B-T022
system	I-T022
,	O
both	O
deriving	O
from	O
clinical	O
and	O
pre	O
-	O
clinical	O
sources	O
.	O

The	O
results	O
of	O
cardiovascular	B-T022
outcome	O
trials	B-T062
are	O
interpreted	O
on	O
the	O
basis	O
of	O
the	O
experimental	B-T062
preclinical	B-T170
data	I-T170
available	O
,	O
paying	O
particular	O
attention	O
to	O
the	O
heart	B-T038
failure	I-T038
results	O
,	O
and	O
suggesting	O
some	O
novel	O
intriguing	O
hypotheses	O
to	O
explain	O
some	O
of	O
the	O
unexpected	O
findings	O
of	O
cardioprotection	O
of	O
incretin	B-T103
-	O
based	O
drugs	B-T103
.	O

In	O
particular	O
,	O
we	O
discuss	O
the	O
possible	O
contribution	O
to	O
the	O
incretin	B-T103
cardiovascular	B-T022
effects	O
of	O
a	O
direct	O
cardiac	B-T017
action	O
of	O
GLP	B-T103
-	I-T103
1	I-T103
metabolites	B-T103
through	O
GLP	B-T103
-	I-T103
1	I-T103
receptor	I-T103
-	O
independent	O
pathways	B-T038
,	O
and	O
of	O
DPP4	B-T103
substrates	O
other	O
than	O
GLP	B-T103
-	I-T103
1	I-T103
.	O

Role	O
of	O
breast	B-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
in	O
predicting	O
residual	O
lobular	B-T038
carcinoma	I-T038
in	I-T038
situ	I-T038
after	O
initial	O
excision	B-T058

Breast	B-T058
magnetic	I-T058
resonance	I-T058
(	I-T058
MR	I-T058
)	I-T058
imaging	I-T058
is	O
a	O
useful	O
screening	B-T058
modality	O
in	O
detecting	B-T058
suspicious	B-T033
lesions	B-T033
in	O
patients	O
with	O
a	O
history	B-T033
of	O
lobular	B-T038
carcinoma	I-T038
in	I-T038
situ	I-T038
(	O
LCIS	B-T038
)	O
.	O

This	O
study	B-T062
aimed	O
to	O
evaluate	B-T058
the	O
effectiveness	O
of	O
breast	B-T058
MR	I-T058
imaging	I-T058
in	O
detecting	B-T058
remnant	B-T017
LCIS	B-T038
lesions	B-T033
after	O
initial	O
excision	B-T058
.	O

Between	O
2011	O
and	O
2015	O
,	O
29	O
patients	O
with	O
LCIS	B-T038
who	O
underwent	B-T033
initial	O
excision	B-T058
were	O
enrolled	O
.	O

Breast	B-T058
ultrasonography	I-T058
and	O
breast	B-T058
MR	I-T058
imaging	I-T058
was	O
conducted	O
after	O
initial	O
excision	B-T058
.	O

Imaging	B-T033
findings	I-T033
were	O
compared	O
with	O
pathologic	B-T038
results	O
.	O

There	O
were	O
nine	O
(	O
31	O
.	O
0	O
%	O
)	O
cases	O
with	O
positive	B-T033
margins	I-T033
after	O
initial	O
excision	B-T058
;	O
they	O
were	O
LCIS	B-T038
(	O
n	O
=	O
8	O
)	O
and	O
atypical	B-T038
lobular	I-T038
hyperplasia	I-T038
(	O
n	O
=	O
1	O
)	O
.	O

Residual	O
lesions	B-T033
were	O
identified	O
in	O
12	O
cases	O
;	O
they	O
were	O
invasive	B-T038
lobular	I-T038
carcinoma	I-T038
(	O
n	O
=	O
1	O
;	O
3	O
.	O
4	O
%	O
)	O
,	O
LCIS	B-T038
(	O
n	O
=	O
9	O
;	O
31	O
.	O
0	O
%	O
)	O
,	O
atypical	B-T038
lobular	I-T038
hyperplasia	I-T038
(	O
n	O
=	O
1	O
;	O
3	O
.	O
4	O
%	O
)	O
,	O
and	O
papillary	B-T038
carcinoma	I-T038
in	I-T038
situ	I-T038
(	O
n	O
=	O
1	O
;	O
3	O
.	O
4	O
%	O
)	O
.	O

Prior	O
to	O
the	O
second	O
operation	B-T058
,	O
these	O
lesions	B-T033
could	O
be	O
detected	O
in	O
seven	O
cases	O
using	O
ultrasonography	B-T058
(	O
sensitivity	O
,	O
53	O
.	O
3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
and	O
in	O
10	O
cases	O
using	O
breast	B-T058
MR	I-T058
imaging	I-T058
(	O
sensitivity	O
,	O
83	O
.	O
3	O
%	O
;	O
specificity	O
,	O
100	O
%	O
)	O
.	O

Breast	B-T058
MR	I-T058
imaging	I-T058
showed	O
higher	O
sensitivity	O
than	O
breast	B-T058
ultrasonography	I-T058
in	O
detecting	B-T058
remnant	B-T017
LCIS	B-T038
lesions	B-T033
.	O

If	O
a	O
suspicious	B-T033
lesion	B-T033
was	O
found	O
using	O
breast	B-T058
MR	I-T058
imaging	I-T058
,	O
a	O
second	O
operation	B-T058
should	O
be	O
considered	O
because	O
of	O
the	O
possibility	B-T033
of	O
multifocality	B-T033
,	O
even	O
if	O
LCIS	B-T038
was	O
confirmed	B-T033
at	O
the	O
initial	O
operation	B-T058
.	O

Construction	O
of	O
Fused	O
Polyheterocycles	O
through	O
Sequential	O
[	O
4	O
+	O
2	O
]	O
and	O
[	O
3	O
+	O
2	O
]	O
Cycloadditions	O

A	O
method	O
for	O
Pd	B-T103
-	O
catalyzed	O
aerobic	O
oxidative	B-T038
reaction	I-T038
of	O
quinazolinones	B-T103
and	O
alkynes	B-T103
has	O
been	O
developed	O
for	O
sequential	O
[	O
4	O
+	O
2	O
]	O
and	O
[	O
3	O
+	O
2	O
]	O
cycloadditions	O
to	O
assemble	O
a	O
novel	O
fused	O
-	O
polycyclic	O
system	O
containing	O
tetrahydropyridine	B-T103
and	O
dihydrofuran	B-T103
rings	I-T103
.	O

The	O
reaction	O
process	O
involves	O
C	O
-	O
H	O
and	O
N	O
-	O
H	O
bond	O
functionalization	O
for	O
the	O
formation	O
of	O
tetrahydropyridine	B-T103
and	O
an	O
oxygen	B-T103
radical	I-T103
cyclization	O
for	O
the	O
dihydrofuran	B-T103
ring	I-T103
.	O

This	O
atom	B-T103
-	O
and	O
step	O
-	O
economical	O
synthesis	O
is	O
highly	O
efficient	O
and	O
has	O
good	O
substrate	O
tolerance	O
,	O
which	O
provides	O
a	O
new	O
approach	O
for	O
the	O
construction	O
of	O
polycyclic	O
molecules	O
with	O
potential	O
pharmaceutical	B-T091
interest	I-T091
.	I-T091

Biological	O
basis	B-T103
of	O
radiation	B-T058
protection	I-T058
needs	O
rejuvenation	B-T058

Human	B-T204
beings	I-T204
encounter	O
radiation	O
in	O
many	O
different	O
situations	O
-	O
from	O
proximity	B-T082
to	O
radioactive	B-T103
waste	I-T103
sites	B-T082
to	O
participation	O
in	O
medical	B-T058
procedures	I-T058
using	O
X	O
-	O
rays	O
etc	O
.	O

Limits	O
for	O
radiation	B-T037
exposures	I-T037
are	O
legally	O
regulated	O
;	O
however	O
,	O
current	O
radiation	B-T058
protection	I-T058
policy	B-T170
does	O
not	O
explicitly	O
acknowledge	O
that	O
biological	O
,	O
cellular	B-T058
and	O
molecular	O
effects	O
of	O
low	O
doses	O
and	O
low	O
dose	O
rates	O
of	O
radiation	O
differ	O
from	O
effects	O
induced	O
by	O
medium	O
and	O
high	O
dose	O
radiation	B-T037
exposures	I-T037
.	O

Recent	O
technical	O
developments	O
in	O
biology	B-T091
and	O
medicine	B-T091
,	O
from	O
single	B-T058
cell	I-T058
techniques	I-T058
to	O
big	O
data	O
computational	O
research	O
,	O
have	O
enabled	O
new	O
approaches	O
for	O
study	B-T062
of	O
biology	B-T091
of	O
low	O
doses	O
of	O
radiation	O
.	O

Results	O
of	O
the	O
work	O
done	O
so	O
far	O
support	O
the	O
idea	O
that	O
low	O
doses	O
of	O
radiation	O
have	O
effects	O
that	O
differ	O
from	O
those	O
associated	O
with	O
high	O
dose	O
exposures	B-T037
;	O
this	O
work	O
,	O
however	O
,	O
is	O
far	O
from	O
sufficient	O
for	O
the	O
development	O
of	O
a	O
new	O
theoretical	B-T170
framework	I-T170
needed	O
for	O
the	O
understanding	O
of	O
low	O
dose	O
radiation	B-T037
exposures	I-T037
.	O

Mechanistic	O
understanding	O
of	O
radiation	O
effects	O
at	O
low	O
doses	O
is	O
necessary	O
in	O
order	O
to	O
develop	O
better	O
radiation	B-T058
protection	I-T058
policy	B-T170
.	O

Gleason	B-T170
grade	I-T170
grouping	I-T170
of	O
prostate	B-T038
cancer	I-T038
is	O
of	O
prognostic	B-T201
value	I-T201
in	O
Asian	B-T098
men	B-T098

The	O
International	B-T092
Society	I-T092
of	I-T092
Urological	I-T092
Pathology	I-T092
made	O
recommendations	O
for	O
the	O
use	O
of	O
Grade	B-T170
Groups	I-T170
(	O
GG	B-T170
)	O
originally	O
described	O
by	O
Epstein	B-T170
and	O
colleagues	O
over	O
Gleason	B-T033
score	I-T033
(	O
GS	B-T033
)	O
alone	O
in	O
2014	O
,	O
which	O
was	O
subsequently	O
adopted	B-T033
by	O
the	O
WHO	O
classification	O
in	O
2016	O
.	O

The	O
majority	O
of	O
studies	B-T062
validating	O
this	O
revision	O
have	O
been	O
in	O
Caucasian	B-T098
populations	I-T098
.	O

We	O
therefore	O
asked	O
whether	O
the	O
new	O
GG	B-T170
system	I-T170
was	O
retrospectively	O
associated	O
with	O
biochemical	O
disease	O
-	O
free	O
survival	O
in	O
a	O
mixed	B-T098
-	I-T098
ethnicity	I-T098
cohort	B-T098
of	O
Asian	B-T098
men	B-T098
.	O

A	O
total	O
of	O
680	O
radical	B-T058
prostatectomies	I-T058
(	O
RPs	B-T058
)	O
from	O
2005	O
to	O
2014	O
were	O
included	O
.	O

GS	B-T033
from	O
initial	O
biopsy	B-T058
and	O
RP	B-T058
were	O
compared	O
and	O
used	O
to	O
allocate	O
cases	O
to	O
GG	B-T170
,	O
defined	O
as	O
:	O
1	O
(	O
GS	B-T033
≤6	O
)	O
;	O
2	O
(	O
GS	B-T033
3	O
+	O
4	O
=	O
7	O
)	O
;	O
3	O
(	O
GS	B-T033
4	O
+	O
3	O
=	O
7	O
)	O
;	O
4	O
(	O
GS	B-T033
4	O
+	O
4	O
=	O
8	O
/	O
5	O
+	O
3	O
=	O
8	O
/	O
3	O
+	O
5	O
=	O
8	O
)	O
and	O
5	O
(	O
GS	B-T033
9	O
-	O
10	O
)	O
.	O

Biochemical	B-T033
recurrence	I-T033
was	O
defined	O
as	O
two	O
consecutive	O
post	O
-	O
RP	B-T058
prostate	B-T103
-	I-T103
specific	I-T103
antigen	I-T103
(	O
PSA	B-T103
)	O
levels	O
of	O
>	O
0	O
.	O
2	O
ng	O
/	O
mL	O
after	O
post	O
-	O
RP	B-T058
PSA	B-T103
reaching	O
the	O
nadir	O
of	O
<	O
0	O
.	O
1	O
ng	O
/	O
mL	O
.	O

Our	O
data	O
showed	O
that	O
Kaplan	O
-	O
Meier	O
analysis	O
revealed	O
significant	O
differences	O
in	O
biochemical	B-T033
recurrence	I-T033
within	O
Gleason	B-T170
GG	I-T170
based	O
on	O
either	O
biopsy	B-T058
or	O
prostatectomy	B-T058
scoring	O
.	O

Multivariate	O
analysis	O
further	O
confirmed	O
that	O
a	O
higher	O
GG	B-T170
was	O
significantly	O
associated	O
with	O
risk	O
of	O
biochemical	B-T033
recurrence	I-T033
.	O

This	O
GG	B-T170
system	I-T170
had	O
a	O
higher	O
prognostic	O
discrimination	O
for	O
both	O
initial	O
biopsy	B-T058
and	O
RP	B-T058
than	O
GS	B-T033
.	O

Our	O
study	B-T062
validates	B-T062
the	O
use	O
of	O
the	O
revised	O
and	O
updated	O
GG	B-T170
system	I-T170
in	O
a	O
mixed	B-T098
-	I-T098
ethnicity	I-T098
population	I-T098
of	O
Asian	B-T098
men	B-T098
.	O

Higher	O
GG	B-T170
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
biochemical	B-T033
recurrence	I-T033
.	O

We	O
therefore	O
recommend	O
its	O
use	O
to	O
inform	O
clinical	B-T058
management	I-T058
for	O
patients	O
with	O
prostate	B-T038
cancer	I-T038
.	O

Membrane	B-T017
nanoclusters	O
of	O
FcγRI	B-T103
segregate	O
from	O
inhibitory	O
SIRPα	B-T103
upon	O
activation	B-T038
of	I-T038
human	I-T038
macrophages	I-T038

Signal	B-T038
integration	I-T038
between	O
activating	O
Fc	B-T103
receptors	I-T103
and	O
inhibitory	O
signal	B-T103
regulatory	I-T103
protein	I-T103
α	I-T103
(	O
SIRPα	B-T103
)	O
controls	O
macrophage	B-T017
phagocytosis	B-T038
.	O

Here	O
,	O
using	O
dual	B-T058
-	I-T058
color	I-T058
direct	I-T058
stochastic	I-T058
optical	I-T058
reconstruction	I-T058
microscopy	I-T058
,	O
we	O
report	O
that	O
Fcγ	B-T103
receptor	I-T103
I	I-T103
(	O
FcγRI	B-T103
)	O
,	O
FcγRII	B-T103
,	O
and	O
SIRPα	B-T103
are	O
not	O
homogeneously	O
distributed	O
at	O
macrophage	B-T017
surfaces	B-T017
but	O
are	O
organized	O
in	O
discrete	O
nanoclusters	O
,	O
with	O
a	O
mean	O
radius	O
of	O
71	O
±	O
11	O
nm	O
,	O
60	O
±	O
6	O
nm	O
,	O
and	O
48	O
±	O
3	O
nm	O
,	O
respectively	O
.	O

Nanoclusters	O
of	O
FcγRI	B-T103
,	O
but	O
not	O
FcγRII	B-T103
,	O
are	O
constitutively	O
associated	O
with	O
nanoclusters	O
of	O
SIRPα	B-T103
,	O
within	O
62	O
±	O
5	O
nm	O
,	O
mediated	O
by	O
the	O
actin	B-T017
cytoskeleton	I-T017
.	O

Upon	O
Fc	B-T103
receptor	I-T103
activation	B-T038
,	O
Src	B-T103
-	I-T103
family	I-T103
kinase	I-T103
signaling	B-T038
leads	O
to	O
segregation	O
of	O
FcγRI	B-T103
and	O
SIRPα	B-T103
nanoclusters	O
to	O
be	O
197	O
±	O
3	O
nm	O
apart	O
.	O

Co	B-T038
-	I-T038
ligation	I-T038
of	O
SIRPα	B-T103
with	O
CD47	B-T103
abrogates	O
nanocluster	O
segregation	O
.	O

If	O
the	O
balance	O
of	O
signals	B-T038
favors	O
activation	O
,	O
FcγRI	B-T103
nanoclusters	O
reorganize	O
into	O
periodically	O
spaced	O
concentric	O
rings	O
.	O

Thus	O
,	O
a	O
nanometer	O
-	O
and	O
micron	O
-	O
scale	O
reorganization	O
of	O
activating	O
and	O
inhibitory	O
receptors	B-T103
occurs	O
at	O
the	O
surface	O
of	O
human	B-T017
macrophages	I-T017
concurrent	O
with	O
signal	B-T038
integration	I-T038
.	O

Firecracker	O
eye	B-T033
exposure	I-T033
:	O
experimental	B-T062
study	I-T062
and	O
simulation	B-T062

Understanding	O
the	O
mechanisms	O
of	O
traumatic	O
ocular	B-T037
injury	I-T037
is	O
helpful	O
to	O
make	O
accurate	O
diagnoses	B-T033
before	O
the	O
symptoms	B-T033
emerge	O
and	O
to	O
develop	O
specific	O
eye	O
protection	O
.	O

The	O
comprehension	B-T038
of	O
the	O
dynamics	O
of	O
primary	O
blast	B-T037
injury	I-T037
mechanisms	O
is	O
a	O
challenging	O
issue	B-T033
.	O

The	O
question	O
is	O
whether	O
the	O
pressure	O
wave	O
propagation	O
and	O
reflection	O
alone	O
could	O
cause	O
ocular	O
damage	O
.	O

To	O
date	O
,	O
there	O
are	O
dissenting	O
opinions	O
and	O
no	O
conclusive	O
evidence	O
thereupon	O
.	O

A	O
previous	O
numerical	B-T058
investigation	I-T058
of	O
blast	O
trauma	B-T037
highlighted	O
the	O
dynamic	O
effect	O
of	O
pressure	O
propagation	O
and	O
its	O
amplification	O
by	O
the	O
geometry	O
of	O
the	O
bony	B-T017
orbit	I-T017
,	O
inducing	O
a	O
resonance	O
cavity	B-T082
effect	O
and	O
a	O
standing	O
wave	O
hazardous	O
for	O
eye	B-T017
tissues	B-T017
.	O

The	O
objective	O
of	O
the	O
current	O
work	O
is	O
to	O
find	O
experimental	O
evidence	O
of	O
the	O
numerically	O
identified	O
phenomenon	O
.	O

Therefore	O
,	O
tests	B-T170
aimed	O
at	O
evaluating	B-T058
the	O
response	O
of	O
porcine	B-T204
eyes	B-T017
to	O
blast	O
overpressure	O
generated	O
by	O
firecrackers	O
explosion	O
were	O
performed	O
.	O

The	O
orbital	B-T082
cavity	I-T082
effect	O
was	O
considered	O
mounting	O
the	O
enucleated	O
eyes	O
inside	O
a	O
dummy	O
orbit	B-T082
.	O

The	O
experimental	O
measurements	O
obtained	O
during	O
the	O
explosion	O
tests	B-T170
presented	O
in	O
this	O
paper	B-T170
corroborate	O
the	O
numerical	O
evidence	O
of	O
a	O
high	O
-	O
frequency	O
pressure	O
amplification	O
,	O
enhancing	O
the	O
loading	O
on	O
the	O
ocular	B-T017
tissues	B-T017
,	O
attributable	B-T038
to	O
the	O
orbital	B-T082
bony	I-T082
walls	I-T082
surrounding	O
the	O
eye	B-T017
.	O

The	O
platelet	B-T103
-	I-T103
activating	I-T103
receptor	I-T103
C	B-T103
-	I-T103
type	I-T103
lectin	I-T103
receptor	I-T103
-	I-T103
2	I-T103
plays	O
an	O
essential	O
role	O
in	O
liver	B-T038
regeneration	I-T038
after	O
partial	B-T058
hepatectomy	I-T058
in	O
mice	B-T204

Essentials	O
Regeneration	B-T038
role	O
of	O
C	B-T103
-	I-T103
type	I-T103
lectin	I-T103
receptor	I-T103
-	I-T103
2	I-T103
(	O
CLEC	B-T103
-	I-T103
2	I-T103
)	O
after	O
70	B-T058
%	I-T058
hepatectomy	I-T058
(	O
HPx	B-T058
)	O
was	O
investigated	O
.	O

Wild	B-T017
-	I-T017
type	I-T017
or	O
CLEC	B-T017
-	I-T017
2	I-T017
deleted	B-T038
from	O
platelets	B-T017
of	O
chimeric	B-T204
mice	I-T204
(	O
flKO	B-T204
)	O
underwent	O
HPx	B-T058
.	O

The	O
liver	O
/	O
body	O
weight	O
ratio	O
was	O
significantly	O
lower	O
in	O
the	O
flKO	B-T204
than	O
in	O
the	O
wild	B-T204
-	I-T204
type	I-T204
.	O

CLEC	B-T103
-	I-T103
2	I-T103
plays	O
an	O
essential	O
role	O
in	O
liver	B-T038
regeneration	I-T038
after	O
HPx	B-T058
.	O

Background	O
and	O
aim	O
The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
role	O
of	O
C	B-T103
-	I-T103
type	I-T103
lectin	I-T103
receptor	I-T103
(	I-T103
CLEC	I-T103
)	I-T103
-	I-T103
2	I-T103
in	O
liver	B-T038
regeneration	I-T038
following	O
partial	B-T058
liver	I-T058
resection	I-T058
in	O
mice	B-T204
.	O

Materials	O
and	O
methods	O
Irradiated	O
chimeric	B-T204
mice	I-T204
transplanted	O
with	O
fetal	O
liver	B-T017
cells	I-T017
from	O
wild	B-T204
-	I-T204
type	I-T204
(	I-T204
WT	I-T204
)	I-T204
mice	I-T204
,	O
CLEC	B-T017
-	I-T017
2	I-T017
-	O
deleted	B-T038
(	O
KO	O
)	O
mice	B-T204
or	O
mice	B-T204
with	O
CLEC	B-T017
-	I-T017
2	I-T017
deleted	B-T038
specifically	O
from	O
platelets	B-T017
(	O
flKO	O
)	O
were	O
generated	O
.	O

Mice	B-T204
underwent	O
70	B-T058
%	I-T058
partial	I-T058
hepatectomy	I-T058
(	O
PH	B-T058
)	O
.	O

Immunohistochemical	B-T058
staining	I-T058
was	O
performed	O
to	O
investigate	O
the	O
expression	B-T038
of	O
the	O
endogenous	O
ligand	B-T103
for	O
CLEC	B-T103
-	I-T103
2	I-T103
,	O
podoplanin	B-T103
.	O

The	O
accumulation	B-T038
of	O
platelets	B-T017
in	O
the	O
liver	B-T017
was	O
also	O
quantified	O
.	O

The	O
hepatic	B-T082
expression	B-T038
of	O
the	O
IL	B-T103
-	I-T103
6	I-T103
/	O
gp130	B-T103
and	O
STAT3	B-T103
,	O
Akt	B-T103
and	O
ERK1	B-T103
/	I-T103
2	I-T103
was	O
also	O
examined	O
.	O

Results	O
The	O
liver	O
/	O
body	O
weight	O
ratio	O
and	O
expression	B-T038
of	O
all	O
cell	B-T038
proliferation	I-T038
markers	B-T058
were	O
significantly	O
lower	O
in	O
the	O
flKO	B-T204
group	I-T204
than	O
in	O
the	O
WT	B-T204
group	I-T204
.	O

The	O
expression	B-T038
of	O
phosphorylated	B-T103
(	I-T103
p	I-T103
)	I-T103
Akt	I-T103
and	O
pERK1	B-T103
/	O
2	O
was	O
similar	O
in	O
the	O
WT	B-T204
and	O
flKO	B-T204
groups	I-T204
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
expression	B-T038
of	O
pSTAT3	B-T103
and	O
IL	B-T103
-	I-T103
6	I-T103
was	O
significantly	O
stronger	O
in	O
the	O
WT	B-T204
group	I-T204
than	O
in	O
the	O
flKO	B-T204
group	I-T204
.	O

The	O
expression	B-T038
of	O
podoplanin	B-T103
was	O
detected	O
in	O
the	O
hepatic	B-T017
sinusoids	I-T017
of	O
both	O
groups	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
platelets	B-T017
accumulated	O
in	O
hepatic	B-T017
sinusoids	I-T017
was	O
significantly	O
less	O
in	O
the	O
flKO	B-T204
group	I-T204
than	O
in	O
the	O
WT	B-T204
group	I-T204
.	O

Conclusion	O
CLEC	B-T103
-	I-T103
2	I-T103
was	O
involved	O
in	O
hepatic	B-T038
regeneration	I-T038
after	O
liver	B-T058
resection	I-T058
and	O
CLEC	B-T103
-	I-T103
2	I-T103
-	O
related	O
liver	B-T038
regeneration	I-T038
was	O
attributed	O
to	O
the	O
interaction	O
between	O
platelets	B-T017
and	O
sinusoidal	B-T082
endothelial	B-T017
cells	I-T017
.	O

Temporal	O
Stability	O
of	O
Heavy	B-T033
Drinking	I-T033
Days	O
and	O
Drinking	O
Reductions	B-T058
Among	O
Heavy	O
Drinkers	O
in	O
the	O
COMBINE	B-T062
Study	I-T062

Recently	O
,	O
the	O
Food	B-T092
and	I-T092
Drug	I-T092
Administration	I-T092
(	O
FDA	B-T092
)	O
proposed	O
to	O
expand	B-T082
the	O
options	O
for	O
primary	O
end	O
points	O
in	O
the	O
development	O
of	O
medications	B-T058
for	O
alcohol	O
use	O
disorder	O
to	O
include	O
either	O
abstinence	O
from	O
alcohol	B-T168
or	O
a	O
nonabstinent	B-T033
outcome	O
:	O
no	O
heavy	B-T033
drinking	I-T033
days	O
(	O
with	O
a	O
heavy	B-T033
drinking	I-T033
day	O
defined	B-T170
as	O
more	O
than	O
3	O
drinks	B-T168
per	O
day	O
for	O
women	B-T098
and	O
more	O
than	O
4	O
drinks	B-T168
per	O
day	O
for	O
men	B-T098
[	O
>	O
3	O
/	O
>	O
4	O
cutoff	O
]	O
)	O
.	O

The	O
FDA	B-T092
also	O
suggested	O
that	O
6	O
months	O
would	O
be	O
the	O
most	O
appropriate	O
length	B-T062
for	I-T062
a	I-T062
clinical	I-T062
trial	I-T062
to	O
demonstrate	O
the	O
stability	O
of	O
this	O
nonabstinent	B-T033
drinking	O
outcome	O
.	O

However	O
,	O
few	O
alcohol	O
clinical	B-T062
trials	I-T062
have	O
examined	B-T033
the	O
stability	O
of	O
nonheavy	B-T033
drinking	I-T033
during	O
and	O
after	B-T058
treatment	I-T058
.	O

In	O
a	O
secondary	O
analysis	O
of	O
the	O
COMBINE	B-T062
study	I-T062
data	O
(	O
n	O
=	O
1	O
,	O
383	O
)	O
,	O
we	O
examined	B-T033
transitions	O
in	O
heavy	B-T033
drinking	I-T033
days	O
during	O
the	O
course	O
of	O
treatment	O
(	O
months	O
1	O
through	O
4	O
)	O
,	O
during	O
the	O
transition	O
out	O
of	O
treatment	B-T058
(	O
months	O
4	O
through	O
7	O
)	O
,	O
and	O
up	O
to	O
12	O
months	O
afterward	O
(	O
months	O
13	O
through	O
16	O
)	O
using	O
latent	O
variable	O
mixture	O
models	O
.	O

Heavy	B-T033
drinking	I-T033
and	O
nonheavy	B-T033
drinking	I-T033
were	O
relatively	O
stable	O
in	O
consecutive	O
months	O
(	O
minimum	O
agreement	O
[	O
kappa	O
]	O
=	O
0	O
.	O
64	O
for	O
months	O
1	O
to	O
2	O
)	O
.	O

Most	O
individuals	B-T098
were	O
stable	O
low	O
-	O
risk	O
drinkers	B-T033
/	O
abstainers	O
or	O
heavy	O
drinkers	O
by	O
the	O
end	O
of	O
treatment	B-T058
,	O
as	O
characterized	O
by	O
a	O
10	O
%	O
probability	O
(	O
or	O
less	O
)	O
of	O
transitioning	O
out	O
of	O
either	O
a	O
no	O
heavy	B-T033
drinking	I-T033
state	O
or	O
a	O
heavy	B-T033
drinking	I-T033
state	O
.	O

More	O
than	O
two	O
-	O
thirds	O
of	O
the	O
heavy	O
drinkers	O
who	O
exceeded	O
the	O
heavy	B-T033
drinking	I-T033
threshold	O
during	O
treatment	O
reported	B-T058
,	O
on	O
average	O
,	O
a	O
64	O
%	O
reduction	B-T058
in	O
drinking	B-T033
frequency	I-T033
and	O
a	O
38	O
%	O
reduction	B-T058
in	O
drinking	O
intensity	O
from	O
pretreatment	O
drinking	O
levels	O
.	O

The	O
results	B-T033
show	O
stability	O
of	O
no	O
heavy	B-T033
drinking	I-T033
as	O
an	O
outcome	O
within	O
the	O
first	O
4	O
months	O
of	O
treatment	B-T058
and	O
that	O
the	O
>	O
3	O
/	O
>	O
4	O
drink	B-T168
cutoff	O
may	O
mask	O
substantial	O
reductions	B-T058
in	O
alcohol	O
consumption	O
among	O
some	O
patients	O
.	O

Future	O
studies	B-T062
should	O
explore	O
the	O
clinical	O
utility	O
of	O
reduction	B-T058
end	O
points	O
.	O

Oral	B-T058
health	I-T058
in	O
transition	O
:	O
The	O
Hadza	B-T098
foragers	I-T098
of	O
Tanzania	B-T082

Conventional	O
wisdom	O
holds	O
that	O
a	O
decline	O
in	O
oral	B-T058
health	I-T058
accompanies	O
the	O
transition	O
from	O
hunting	O
and	O
gathering	O
to	O
agriculture	O
,	O
given	O
increased	O
consumption	B-T038
of	O
carbohydrates	B-T103
.	O

This	O
widely	O
touted	O
example	O
of	O
the	O
mismatch	O
between	O
our	O
biology	B-T091
and	O
modern	O
lifestyle	O
has	O
been	O
intuited	O
largely	O
from	O
the	O
bioarchaeological	B-T170
record	I-T170
of	O
the	O
Neolithic	B-T103
Revolution	I-T103
in	O
the	O
New	B-T098
World	I-T098
.	O

Recent	O
studies	B-T062
of	O
other	O
populations	O
have	O
,	O
however	O
,	O
challenged	O
the	O
universality	O
of	O
this	O
assertion	O
.	O

Here	O
,	O
we	O
present	O
the	O
first	O
comprehensive	O
study	B-T062
of	O
oral	B-T058
health	I-T058
among	O
a	O
living	B-T098
population	I-T098
in	O
transition	O
from	O
the	O
bush	B-T204
to	O
village	O
life	O
,	O
the	O
Hadza	B-T098
hunter	O
-	O
gatherers	B-T098
of	O
Tanzania	B-T082
,	O
to	O
test	O
the	O
hypothesis	O
that	O
the	O
shift	O
from	O
foraging	O
to	O
farming	O
,	O
or	O
agricultural	O
intensification	O
,	O
inevitably	O
leads	O
to	O
increased	O
periodontal	B-T038
disease	I-T038
,	O
caries	B-T038
,	O
and	O
orthodontic	O
disorders	B-T038
.	O

Our	O
results	O
showed	O
that	O
women	B-T098
living	O
in	O
villages	B-T082
consuming	B-T038
a	O
mostly	O
agricultural	B-T204
diet	B-T168
exhibited	O
more	O
caries	B-T038
and	O
periodontal	B-T038
disease	I-T038
than	O
those	O
living	O
in	O
the	O
bush	B-T204
consuming	B-T038
a	O
mostly	O
wild	B-T168
-	I-T168
food	I-T168
diet	I-T168
.	O

Furthermore	O
,	O
men	B-T098
living	O
in	O
the	O
bush	B-T204
consuming	B-T038
mostly	O
a	O
wild	B-T168
-	I-T168
food	I-T168
diet	I-T168
had	O
more	O
than	O
those	O
living	O
in	O
the	O
village	B-T082
consuming	B-T038
a	O
mostly	O
agricultural	B-T204
diet	B-T168
.	O

These	O
findings	B-T033
are	O
explained	O
by	O
the	O
high	O
incidence	O
of	O
maize	B-T168
consumption	B-T038
in	O
village	B-T082
settings	O
,	O
along	O
with	O
previously	O
recognized	O
variation	O
in	O
rate	O
of	O
caries	B-T038
between	O
men	B-T098
and	O
women	B-T098
.	O

The	O
unexpected	O
discovery	O
of	O
high	O
caries	B-T038
incidences	O
for	O
men	B-T098
in	O
the	O
bush	B-T204
is	O
likely	O
explained	O
by	O
heavy	O
reliance	O
on	O
honey	B-T168
,	O
and	O
perhaps	O
differential	O
access	O
to	O
tobacco	O
and	O
marijuana	B-T103
.	I-T103

These	O
data	O
support	O
the	O
notions	O
that	O
mechanisms	O
of	O
cariogenesis	B-T038
are	O
multifactorial	B-T033
and	O
that	O
the	O
relationships	O
between	O
oral	B-T058
health	I-T058
and	O
the	O
shift	O
from	O
a	O
predominantly	O
wild	B-T168
-	I-T168
food	I-T168
diet	I-T168
to	O
one	O
dominated	O
by	O
cultigens	B-T204
are	O
nuanced	O
.	O

The	O
R2R3MYB	B-T103
VvMYBPA1	B-T103
from	O
grape	B-T204
reprograms	O
the	O
phenylpropanoid	B-T038
pathway	I-T038
in	O
tobacco	B-T204
flowers	B-T204

This	O
work	O
shows	O
that	O
,	O
in	O
tobacco	B-T204
,	O
the	O
ectopic	B-T038
expression	I-T038
of	O
VvMYBPA1	B-T103
,	O
a	O
grape	B-T204
regulator	O
of	O
proanthocyanidin	B-T103
biosynthesis	O
,	O
up	B-T038
-	I-T038
or	I-T038
down	I-T038
-	I-T038
regulates	I-T038
different	O
branches	O
of	O
the	O
phenylproanoid	B-T038
pathway	I-T038
,	O
in	O
a	O
structure	O
-	O
specific	O
fashion	O
.	O

Proanthocyanidins	B-T103
are	O
flavonoids	B-T103
of	O
paramount	O
importance	O
for	O
animal	B-T168
and	O
human	B-T168
diet	I-T168
.	O

Research	B-T062
interest	O
increasingly	O
tilts	O
towards	O
generating	O
crops	B-T204
enriched	O
with	O
these	O
health	O
-	O
promoting	O
compounds	O
.	O

Flavonoids	B-T103
synthesis	O
is	O
regulated	O
by	O
the	O
MBW	B-T017
transcriptional	B-T017
complex	I-T017
,	O
made	O
of	O
R2R3MYB	B-T103
,	O
bHLH	B-T103
and	O
WD40	B-T103
proteins	I-T103
,	O
with	O
the	O
MYB	B-T103
components	O
liable	O
for	O
channeling	B-T082
the	O
complex	B-T103
towards	O
specific	O
branches	O
of	O
the	O
pathway	B-T038
.	O

Hence	O
,	O
using	O
tobacco	B-T204
as	O
a	O
model	O
,	O
here	O
,	O
we	O
tested	O
if	O
the	O
ectopic	B-T038
expression	I-T038
of	O
the	O
proanthocyanidin	B-T103
regulator	O
VvMYBPA1	B-T103
from	O
grape	B-T204
induces	O
the	O
biosynthesis	O
of	O
these	O
compounds	O
in	O
not	O
-	O
naturally	O
committed	B-T017
cells	I-T017
.	O

Here	O
,	O
we	O
show	O
,	O
via	O
targeted	O
transcriptomic	B-T038
and	O
metabolic	O
analyses	B-T062
of	O
primary	O
transgenic	B-T204
lines	I-T204
and	O
their	O
progeny	O
,	O
that	O
VvMYBPA1	B-T103
alters	O
the	O
phenylpropanoid	B-T038
pathway	I-T038
in	O
tobacco	B-T204
floral	B-T204
organs	I-T204
,	O
in	O
a	O
structure	O
-	O
specific	O
fashion	O
.	O

We	O
also	O
report	O
that	O
a	O
modest	O
VvMYBPA1	B-T103
expression	B-T038
is	O
sufficient	O
to	O
induce	O
the	O
expression	B-T038
of	O
both	O
proanthocyanidin	B-T103
-	O
specific	O
and	O
early	B-T017
genes	I-T017
of	O
the	O
phenylpropanoid	B-T038
pathway	I-T038
.	O

Consequently	O
,	O
proanthocyanidins	B-T103
and	O
chlorogenic	B-T103
acids	I-T103
are	O
induced	O
or	O
de	O
novo	O
synthetised	O
in	O
floral	B-T204
limbs	I-T204
,	I-T204
tubes	I-T204
and	O
stamens	B-T204
.	O

Other	O
phenylpropanoid	B-T038
branches	I-T038
are	O
conversely	O
induced	O
or	O
depleted	O
according	O
to	O
the	O
floral	B-T204
structure	I-T204
.	O

Our	O
study	O
documents	O
a	O
novel	O
and	O
distinct	O
function	O
of	O
VvMYBPA1	B-T103
with	O
respect	O
to	O
other	O
MYBs	B-T103
regulating	O
proanthocyanidins	B-T103
.	O

Present	O
findings	O
may	O
have	O
major	O
implications	O
in	O
designing	O
strategies	O
for	O
enriching	O
crops	B-T204
with	O
health	O
-	O
promoting	O
compounds	O
.	O

Genome	B-T062
-	I-T062
wide	I-T062
association	I-T062
mapping	I-T062
in	O
winter	B-T204
barley	I-T204
for	O
grain	B-T204
yield	O
and	O
culm	B-T204
cell	B-T017
wall	I-T017
polymer	O
content	O
using	O
the	O
high	O
-	O
throughput	O
CoMPP	B-T058
technique	I-T058

A	O
collection	O
of	O
112	O
winter	B-T204
barley	I-T204
varieties	I-T204
(	O
Hordeum	B-T204
vulgare	I-T204
L	I-T204
.	I-T204
)	O
was	O
grown	B-T038
in	O
the	O
field	O
for	O
two	O
years	O
(	O
2008	O
/	O
09	O
and	O
2009	O
/	O
10	O
)	O
in	O
northern	B-T082
Italy	B-T082
and	O
grain	B-T204
and	O
straw	B-T103
yields	O
recorded	O
.	O

In	O
the	O
first	O
year	O
of	O
the	O
trial	O
,	O
a	O
severe	O
attack	O
of	O
barley	B-T005
yellow	I-T005
mosaic	I-T005
virus	I-T005
(	O
BaYMV	B-T005
)	O
strongly	O
influenced	O
final	O
performances	O
with	O
an	O
average	O
reduction	O
of	O
~	O
50	O
%	O
for	O
grain	B-T204
and	O
straw	B-T103
harvested	O
in	O
comparison	O
to	O
the	O
second	O
year	O
.	O

The	O
genetic	B-T058
determination	I-T058
(	O
GD	B-T058
)	O
for	O
grain	B-T204
yield	O
was	O
0	O
.	O
49	O
and	O
0	O
.	O
70	O
,	O
for	O
the	O
two	O
years	O
respectively	O
,	O
and	O
for	O
straw	B-T103
yield	O
GD	B-T058
was	O
low	O
in	O
2009	O
(	O
0	O
.	O
09	O
)	O
and	O
higher	O
in	O
2010	O
(	O
0	O
.	O
29	O
)	O
.	O

Cell	B-T017
wall	I-T017
polymers	O
in	O
culms	B-T204
were	O
quantified	O
by	O
means	O
of	O
the	O
monoclonal	B-T103
antibodies	I-T103
LM6	B-T103
,	O
LM11	B-T103
,	O
JIM13	B-T103
and	O
BS	B-T103
-	I-T103
400	I-T103
-	I-T103
3	I-T103
and	O
the	O
carbohydrate	B-T103
-	I-T103
binding	I-T103
module	I-T103
CBM3a	I-T103
using	O
the	O
high	O
-	O
throughput	O
CoMPP	B-T058
technique	I-T058
.	O

Of	O
these	O
,	O
LM6	B-T103
,	O
which	O
detects	B-T033
arabinan	B-T103
components	O
,	O
showed	O
a	O
relatively	O
high	O
GD	B-T058
in	O
both	O
years	O
and	O
a	O
significantly	O
negative	B-T033
correlation	O
with	O
grain	B-T204
yield	O
(	O
GYLD	O
)	O
.	O

Overall	O
,	O
heritability	O
(	O
H2	O
)	O
was	O
calculated	O
for	O
GYLD	O
,	O
LM6	B-T103
and	O
JIM	B-T103
and	O
resulted	O
to	O
be	O
0	O
.	O
42	O
,	O
0	O
.	O
32	O
and	O
0	O
.	O
20	O
,	O
respectively	O
.	O

A	O
total	O
of	O
4	O
,	O
976	O
SNPs	B-T082
from	O
the	O
9K	O
iSelect	O
array	O
were	O
used	O
in	O
the	O
study	B-T062
for	O
the	O
analysis	O
of	O
population	O
structure	O
,	O
linkage	O
disequilibrium	O
(	O
LD	O
)	O
and	O
genome	B-T062
-	I-T062
wide	I-T062
association	I-T062
study	I-T062
(	O
GWAS	B-T062
)	O
.	O

Marker	O
-	O
trait	O
associations	O
(	O
MTA	O
)	O
were	O
analyzed	O
for	O
grain	B-T204
yield	O
and	O
cell	B-T017
wall	I-T017
determination	O
by	O
LM6	B-T103
and	O
JIM13	B-T103
as	O
these	O
were	O
the	O
traits	O
showing	O
significant	O
correlations	O
between	O
the	O
years	O
.	O

A	O
single	B-T017
QTL	I-T017
for	O
GYLD	O
containing	O
three	O
MTAs	O
was	O
found	O
on	O
chromosome	B-T017
3H	I-T017
located	O
close	O
to	O
the	O
Hv	B-T017
-	I-T017
eIF4E	I-T017
gene	I-T017
,	O
which	O
is	O
known	O
to	O
regulate	O
resistance	O
to	O
BaYMV	B-T005
.	O

Subsequently	O
the	O
QTL	B-T017
was	O
shown	O
to	O
be	O
tightly	O
linked	O
to	O
rym4	B-T017
,	O
a	O
locus	B-T082
for	O
resistance	O
to	O
the	O
virus	B-T005
.	O

GWAs	B-T062
on	O
arabinans	B-T103
quantified	O
by	O
LM6	B-T103
resulted	O
in	O
the	O
identification	O
of	O
major	O
QTLs	B-T017
closely	O
located	O
on	O
3H	B-T017
and	O
hypotheses	O
regarding	O
putative	B-T017
candidate	I-T017
genes	I-T017
were	O
formulated	O
through	O
the	O
study	B-T062
of	O
gene	B-T038
expression	I-T038
levels	O
based	O
on	O
bioinformatics	B-T091
tools	O
.	O

The	O
Prevalence	O
and	O
Clinical	O
Relevance	O
of	O
ASA	B-T103
Nonresponse	B-T033
After	O
Cardiac	B-T058
Surgery	I-T058

We	O
aimed	O
to	O
identify	O
the	O
prevalence	O
of	O
acetylsalicylic	B-T103
acid	I-T103
(	O
ASA	B-T103
)	O
nonresponse	B-T033
in	O
patients	O
after	O
coronary	B-T058
artery	I-T058
bypass	I-T058
graft	I-T058
(	I-T058
CABG	I-T058
)	I-T058
surgery	I-T058
and	O
the	O
possible	O
consequences	O
for	O
the	O
rate	O
of	O
major	O
cardiovascular	B-T033
events	I-T033
.	O

This	O
prospective	B-T062
,	O
observational	B-T062
,	O
bicentric	O
cohort	O
study	O
was	O
conducted	O
in	O
two	O
German	B-T092
University	I-T092
hospitals	I-T092
.	O

A	O
total	O
of	O
400	O
patients	O
(	O
200	O
in	O
each	O
study	O
center	O
)	O
undergoing	O
elective	B-T058
CABG	B-T058
surgery	I-T058
were	O
enrolled	O
after	O
written	O
informed	O
consent	O
.	O

Platelet	B-T038
function	I-T038
was	O
analyzed	O
on	O
day	O
3	O
(	O
d3	O
)	O
and	O
day	O
5	O
(	O
d5	O
)	O
postoperatively	O
following	O
stimulation	O
with	O
arachidonic	B-T103
acid	I-T103
(	O
ASPItest	B-T058
)	O
and	O
with	O
thrombin	B-T103
receptor	I-T103
-	I-T103
activating	I-T103
peptide	I-T103
6	I-T103
(	O
TRAPtest	B-T058
)	O
using	O
multiple	B-T058
electrode	I-T058
aggregometry	I-T058
(	O
Multiplate	B-T058
)	O
.	O

Individuals	O
with	O
an	O
ASPItest	B-T058
≥40	O
AU	O
·	O
min	O
were	O
categorized	O
as	O
ASA	B-T103
nonresponders	B-T033
.	O

A	O
1	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
recorded	O
the	O
combined	O
end	O
point	O
of	O
cardiovascular	B-T033
events	I-T033
,	O
hospital	B-T058
admissions	I-T058
,	O
or	O
deaths	B-T033
related	O
to	O
cardiovascular	B-T038
disease	I-T038
.	O

The	O
prevalence	O
of	O
ASA	B-T103
nonresponse	B-T033
was	O
51	O
.	O
5	O
%	O
on	O
d3	O
,	O
and	O
it	O
significantly	O
increased	O
to	O
71	O
.	O
3	O
%	O
on	O
d5	O
(	O
P	O
=	O
.	O
0049	O
)	O
.	O

The	O
area	O
under	O
the	O
aggregation	B-T058
curve	I-T058
in	O
the	O
TRAPtest	B-T058
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
the	O
platelet	B-T058
count	I-T058
on	O
d5	O
(	O
P	O
=	O
.	O
009	O
)	O
,	O
and	O
the	O
cardiopulmonary	B-T033
bypass	I-T033
time	I-T033
(	O
P	O
=	O
.	O
01	O
)	O
were	O
identified	O
as	O
independent	O
predictors	O
of	O
an	O
ASA	B-T103
nonresponse	B-T033
.	O

A	O
1	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
recorded	O
54	O
events	O
fulfilling	O
criteria	O
for	O
the	O
combined	O
end	O
point	O
with	O
no	O
difference	O
between	O
ASA	B-T103
responders	B-T033
and	O
nonresponders	B-T033
.	O

This	O
study	B-T062
indicates	O
a	O
high	O
incidence	O
of	O
perioperative	O
ASA	B-T103
nonresponse	B-T033
in	O
patients	O
following	O
CABG	B-T058
.	O

No	O
effect	O
on	O
the	O
incidence	O
of	O
cardiovascular	B-T033
events	I-T033
was	O
recorded	O
in	O
the	O
1	O
-	O
year	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Therefore	O
,	O
a	O
randomized	B-T062
dosage	I-T062
adjustment	I-T062
trial	I-T062
should	O
elucidate	O
whether	O
a	O
tailored	O
ASA	B-T103
treatment	B-T058
after	O
CABG	B-T058
surgery	I-T058
represents	O
a	O
useful	O
concept	O
.	O

Genome	B-T082
Sequences	I-T082
of	O
Mycobacteriophages	B-T005
Jane	I-T005
and	I-T005
Sneeze	I-T005
,	O
New	O
Members	O
of	O
Cluster	O
G	O

Jane	O
and	O
Sneeze	O
are	O
newly	O
isolated	O
phages	B-T005
of	O
Mycobacterium	B-T007
smegmatis	I-T007
mc	I-T007
(	I-T007
2	I-T007
)	I-T007
155	I-T007
from	O
Hillsborough	B-T082
,	O
NJ	B-T082
,	O
and	O
Palo	B-T082
Verde	I-T082
,	O
Costa	B-T082
Rica	I-T082
,	O
respectively	O
.	O

Both	O
are	O
cluster	O
G	O
,	O
subcluster	O
G1	O
mycobacteriophages	B-T005
.	O

Notable	O
nucleotide	B-T103
differences	O
exist	O
between	O
genomes	B-T017
in	O
the	O
right	O
half	O
,	O
including	O
the	O
presence	O
of	O
mycobacteriophage	B-T005
mobile	B-T103
element	I-T103
1	I-T103
(	O
MPME1	O
)	O
in	O
Jane	O
.	O

Effect	O
of	O
Punica	B-T204
granatum	I-T204
fruit	B-T168
peel	I-T168
on	O
glucose	B-T103
-	I-T103
6	I-T103
-	I-T103
phosphate	I-T103
dehydrogenase	I-T103
and	O
malate	B-T103
dehydrogenase	I-T103
in	O
amphistome	B-T204
Gastrothylax	B-T204
indicus	I-T204

Increasing	O
anthelmintic	B-T103
resistance	B-T038
and	O
the	O
impact	O
of	O
conventional	O
anthelmintics	B-T103
on	O
the	O
environment	B-T082
,	O
it	O
is	O
important	O
to	O
look	O
for	O
alternative	O
strategies	O
against	O
helminth	B-T204
parasite	I-T204
in	O
sheep	B-T204
.	O

Important	O
lipogenic	B-T103
enzymes	I-T103
like	O
glucose	B-T103
-	I-T103
6	I-T103
-	I-T103
phosphate	I-T103
dehydrogenase	I-T103
(	O
G	B-T103
-	I-T103
6	I-T103
-	I-T103
PDH	I-T103
)	O
and	O
malate	B-T103
dehydrogenase	I-T103
(	O
MDH	B-T103
)	O
show	O
subcellular	B-T017
distribution	B-T082
pattern	I-T082
.	O

Activity	B-T038
of	O
G	B-T103
-	I-T103
6	I-T103
-	I-T103
PDH	I-T103
was	O
largely	O
restricted	O
to	O
cytosolic	B-T017
fraction	I-T017
while	O
MDH	B-T103
was	O
found	O
in	O
both	O
cytosolic	B-T017
and	O
mitochondrial	B-T017
fraction	I-T017
in	O
Gastrothylax	B-T204
indicus	I-T204
.	O

Following	O
in	O
vitro	O
treatment	O
with	O
ethanolic	B-T103
and	O
aqueous	O
extracts	O
of	O
Punica	B-T204
granatum	I-T204
fruit	B-T168
peel	I-T168
and	O
commercial	O
anthelmintic	B-T103
,	O
albendazole	B-T103
G	B-T103
-	I-T103
6	I-T103
-	I-T103
PDH	I-T103
activity	B-T038
was	O
decreased	O
by	O
19	O
-	O
32	O
%	O
,	O
whereas	O
MDH	B-T103
was	O
suppressed	O
by	O
24	O
-	O
41	O
%	O
,	O
compared	O
to	O
the	O
respective	O
control	O
.	O

Albendazole	B-T103
was	O
quite	O
effective	O
when	O
compared	O
with	O
negative	O
control	O
and	O
both	O
the	O
extracts	O
.	O

The	O
results	O
indicate	O
that	O
phytochemicals	B-T103
of	O
plant	B-T204
may	O
act	O
as	O
potential	O
vermifuge	B-T103
or	O
vermicide	O
.	O

Remitting	B-T038
Seronegative	I-T038
Symmetrical	I-T038
Synovitis	I-T038
With	I-T038
Pitting	I-T038
Edema	I-T038
:	O
Appearance	O
on	O
FDG	O
PET	O
/	O
CT	O

Remitting	B-T038
seronegative	I-T038
symmetrical	I-T038
synovitis	I-T038
with	I-T038
pitting	I-T038
edema	I-T038
(	O
RS3PE	B-T038
)	O
is	O
a	O
rare	B-T038
condition	I-T038
in	O
the	O
elderly	B-T098
and	O
can	O
appear	O
as	O
a	O
first	O
presentation	O
of	O
various	O
types	O
of	O
rheumatic	B-T038
and	O
malignant	B-T038
diseases	I-T038
.	O

We	O
presented	O
a	O
62	O
-	O
year	O
-	O
old	O
man	B-T098
with	O
the	O
diagnosis	B-T033
of	O
RS3PE	B-T038
based	O
on	O
the	O
clinical	B-T033
sign	I-T033
and	O
laboratory	O
data	O
.	O

Because	O
of	O
the	O
possibility	O
of	O
associated	O
malignancies	B-T038
in	O
RS3PE	B-T038
,	O
FDG	O
PET	O
/	O
CT	O
was	O
performed	O
to	O
exclude	O
occult	B-T038
tumors	I-T038
.	O

The	O
images	B-T170
showed	O
multiple	O
,	O
symmetrically	B-T033
,	O
diffusely	B-T082
increased	O
F	B-T103
-	I-T103
FDG	I-T103
uptake	B-T038
in	O
the	O
soft	B-T017
tissue	I-T017
around	O
joints	B-T082
and	O
bones	B-T017
in	O
the	O
shoulders	B-T082
,	O
hips	B-T017
,	O
knees	B-T017
,	O
and	O
ankles	B-T082
.	O

Parks	O
as	O
Social	O
and	O
Cultural	O
Spaces	B-T082
Among	O
U	B-T082
.	I-T082
S	I-T082
.	O
-	O
and	O
Foreign	O
-	O
Born	B-T038
Latinas	B-T098

Parks	O
provide	O
opportunities	O
for	O
people	B-T098
to	O
engage	O
in	O
activities	O
that	O
can	O
promote	O
physical	O
and	O
emotional	B-T033
well	O
-	O
being	O
.	O

Using	O
focus	O
groups	O
and	O
personal	O
interviews	O
conducted	O
in	O
selected	O
neighborhoods	O
of	O
a	O
Northeastern	B-T082
city	B-T082
with	O
a	O
high	O
rate	O
of	O
obesity	B-T038
,	O
we	O
examined	B-T033
perceptions	B-T038
of	O
barriers	O
and	O
facilitators	O
regarding	O
the	O
use	O
of	O
parks	O
and	O
park	O
features	O
that	O
would	O
promote	O
physical	O
activity	O
among	O
Latina	B-T098
women	B-T098
(	O
N	O
=	O
39	O
)	O
.	O

Foreign	O
-	O
born	B-T038
Latinas	B-T098
emphasized	O
the	O
environmental	B-T082
characteristics	O
of	O
parks	O
and	O
the	O
types	O
of	O
amenities	O
that	O
can	O
support	O
preferred	O
cultural	O
and	O
social	O
activities	O
,	O
while	O
U	B-T082
.	I-T082
S	I-T082
.	I-T082

-	O
born	B-T038
Latinas	B-T098
emphasized	O
the	O
use	O
of	O
parks	O
for	O
physical	O
activity	O
and	O
weight	O
management	O
.	O

Most	O
striking	O
were	O
the	O
different	O
ways	O
in	O
which	O
foreign	O
-	O
born	B-T038
participants	B-T098
conceptualized	B-T038
parks	O
as	O
sociocultural	O
family	O
centers	O
,	O
extending	O
more	O
common	O
conceptualizations	B-T038
centered	O
on	O
exercise	O
or	O
individual	B-T098
health	O
gain	O
.	O

These	O
findings	O
suggest	O
the	O
need	O
for	O
new	O
policies	B-T170
that	O
incorporate	O
culturally	O
specific	O
park	O
programming	O
to	O
promote	O
national	O
goals	B-T170
of	O
increasing	O
levels	O
of	O
physical	O
activity	O
for	O
health	O
.	O

The	O
impact	O
of	O
childhood	B-T038
maltreatment	I-T038
on	O
the	O
differential	O
efficacy	O
of	O
CBASP	B-T058
versus	O
escitalopram	B-T103
in	O
patients	O
with	O
chronic	B-T038
depression	I-T038
:	O
A	O
secondary	O
analysis	O

Childhood	B-T038
maltreatment	I-T038
(	O
CM	B-T038
)	O
has	O
been	O
indicated	B-T033
as	O
a	O
predictor	O
of	O
a	O
differential	O
response	O
to	O
antidepressant	B-T058
treatment	I-T058
with	O
psychotherapy	B-T058
compared	O
to	O
medication	B-T103
.	O

In	O
this	O
secondary	O
analysis	O
,	O
we	O
investigated	O
whether	O
the	O
presence	O
of	O
CM	B-T038
results	O
in	O
a	O
differential	O
indication	O
for	O
the	O
Cognitive	B-T058
Behavioral	I-T058
Analysis	I-T058
System	I-T058
of	I-T058
Psychotherapy	I-T058
(	O
CBASP	B-T058
)	O
or	O
escitalopram	B-T103
plus	O
clinical	B-T058
management	I-T058
(	O
ESC	B-T103
)	O
.	O

Sixty	O
patients	O
with	O
chronic	B-T038
depression	I-T038
were	O
randomized	B-T062
to	O
either	O
22	O
sessions	O
of	O
CBASP	B-T058
or	O
ESC	B-T103
over	O
the	O
course	O
of	O
8	O
weeks	O
of	O
acute	O
and	O
20	O
weeks	O
of	O
extended	O
treatment	B-T058
at	O
2	O
German	B-T082
treatment	B-T082
sites	I-T082
.	O

CM	B-T038
was	O
assessed	O
using	O
the	O
Childhood	O
Trauma	O
Questionnaire	B-T170
and	O
the	O
clinician	B-T097
rated	O
Early	B-T170
Trauma	I-T170
Inventory	I-T170
.	O

Intention	B-T062
-	I-T062
to	I-T062
-	I-T062
treat	I-T062
analyses	I-T062
were	O
used	O
to	O
examine	O
the	O
impact	O
of	O
CM	B-T038
on	O
depression	B-T038
,	O
global	O
functioning	O
,	O
and	O
quality	O
of	O
life	O
.	O

The	O
presence	O
of	O
CM	B-T038
did	O
not	O
result	O
in	O
significant	O
differences	O
in	O
treatment	B-T201
response	I-T201
to	O
CBASP	B-T058
or	O
ESC	B-T103
on	O
any	O
outcome	O
measure	O
after	O
28	O
weeks	O
of	O
treatment	B-T058
independent	O
of	O
the	O
type	O
of	O
CM	B-T038
assessment	B-T058
.	O

After	O
8	O
weeks	O
,	O
a	O
significant	O
CM	B-T038
×	O
treatment	B-T058
interaction	O
was	O
found	B-T033
for	O
scores	O
on	O
the	O
Montgomery	B-T170
-	I-T170
Asberg	I-T170
Depression	I-T170
Rating	I-T170
Scale	I-T170
.	O

Patients	O
with	O
a	O
history	B-T033
of	O
CM	B-T038
receiving	O
CBASP	B-T058
had	O
a	O
significantly	O
lower	O
response	O
rate	O
compared	O
to	O
patients	O
without	O
CM	B-T038
and	O
to	O
those	O
receiving	O
ESC	B-T103
after	O
8	O
weeks	O
.	O

Conclusively	O
,	O
CBASP	B-T058
and	O
ESC	B-T103
are	O
equally	O
effective	O
treatment	B-T058
options	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	B-T170
of	O
patients	O
with	O
chronic	B-T038
depression	I-T038
and	O
a	O
history	B-T033
of	O
CM	B-T038
.	O

CM	B-T038
may	O
be	O
a	O
predictor	O
of	O
a	O
longer	O
latency	O
of	O
treatment	B-T201
response	I-T201
in	O
the	O
case	O
of	O
psychotherapy	B-T058
.	O

CBASP	B-T058
and	O
escitalopram	B-T103
are	O
equally	O
effective	O
treatment	B-T058
options	O
for	O
chronic	B-T038
depression	I-T038
.	O

Both	O
treatments	B-T058
are	O
also	O
equally	O
effective	O
for	O
the	O
difficult	O
to	O
treat	O
subgroup	B-T170
of	O
patients	O
with	O
chronic	B-T038
depression	I-T038
and	O
a	O
history	B-T033
of	O
childhood	B-T038
maltreatment	I-T038
.	O

Childhood	B-T038
maltreatment	I-T038
may	O
result	O
in	O
a	O
longer	O
latency	O
of	O
treatment	B-T201
response	I-T201
in	O
the	O
case	O
of	O
psychotherapy	B-T058
.	O

A	O
role	O
for	O
the	O
locus	B-T017
coeruleus	I-T017
in	O
the	O
analgesic	B-T033
efficacy	I-T033
of	O
N	B-T103
-	I-T103
acetylaspartylglutamate	I-T103
peptidase	I-T103
(	O
GCPII	B-T103
)	O
inhibitors	B-T103
ZJ43	B-T103
and	O
2	B-T103
-	I-T103
PMPA	I-T103

N	B-T103
-	I-T103
acetylaspartylglutamate	I-T103
(	O
NAAG	B-T103
)	O
is	O
the	O
third	O
most	O
prevalent	O
and	O
widely	O
distributed	O
neurotransmitter	B-T103
in	O
the	O
mammalian	B-T204
nervous	B-T022
system	I-T022
.	O

NAAG	B-T103
activates	O
a	O
group	B-T103
II	I-T103
metabotropic	I-T103
glutamate	I-T103
receptor	I-T103
(	O
mGluR3	B-T103
)	O
and	O
is	O
inactivated	O
by	O
an	O
extracellular	B-T103
enzyme	I-T103
,	I-T103
glutamate	I-T103
carboxypeptidase	I-T103
II	I-T103
(	O
GCPII	B-T103
)	O
in	B-T082
vivo	I-T082
.	O

Inhibitors	B-T103
of	I-T103
this	I-T103
enzyme	I-T103
are	O
analgesic	B-T103
in	O
animal	B-T204
models	I-T204
of	O
inflammatory	B-T033
,	O
neuropathic	B-T033
and	O
bone	B-T038
cancer	I-T038
pain	B-T033
.	O

NAAG	B-T103
and	O
GCPII	B-T103
are	O
present	O
in	O
the	O
locus	B-T017
coeruleus	I-T017
,	O
a	O
center	O
for	O
the	O
descending	O
noradrenergic	O
inhibitory	O
pain	O
system	O
.	O

In	O
the	O
formalin	B-T103
footpad	B-T017
model	B-T038
,	O
systemic	O
treatment	O
with	O
GCPII	B-T103
inhibitors	I-T103
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-T033
pain	I-T033
response	O
and	O
increases	O
release	O
of	O
spinal	B-T082
noradrenaline	B-T103
.	O

This	O
analgesic	B-T033
efficacy	I-T033
is	O
blocked	O
by	O
systemic	O
injection	B-T058
of	O
a	O
group	B-T103
II	I-T103
mGluR	I-T103
antagonist	B-T103
,	O
by	O
intrathecal	B-T058
(	I-T058
spinal	I-T058
)	I-T058
injection	I-T058
of	O
an	O
alpha	B-T103
2	I-T103
adrenergic	I-T103
receptor	I-T103
antagonist	I-T103
and	O
by	O
microinjection	B-T058
of	O
an	O
α	B-T103
-	I-T103
amino	I-T103
-	I-T103
3	I-T103
-	I-T103
hydroxy	I-T103
-	I-T103
5	I-T103
-	I-T103
methylisoxazole	I-T103
-	I-T103
4	I-T103
-	I-T103
propionic	I-T103
acid	I-T103
(	I-T103
AMPA	I-T103
)	I-T103
receptor	I-T103
antagonist	I-T103
directly	O
into	O
the	O
contralateral	B-T082
locus	B-T017
coeruleus	I-T017
.	O

Footpad	B-T017
inflammation	B-T038
increases	O
release	O
of	O
glutamate	B-T103
in	O
the	O
contralateral	B-T082
locus	B-T017
coeruleu	I-T017
s	O
and	O
systemic	O
treatment	O
with	O
a	O
GCPII	B-T103
inhibitor	I-T103
blocks	O
this	O
increase	O
.	O

Direct	O
injection	B-T058
of	O
GCPII	B-T103
inhibitors	I-T103
into	O
the	O
contralateral	B-T082
or	O
ipsilatera	B-T082
l	O
locus	B-T017
coeruleus	I-T017
reduces	O
both	O
phases	O
of	O
the	O
inflammatory	B-T033
pain	I-T033
response	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
the	O
contralateral	B-T082
effect	O
also	O
is	O
blocked	O
by	O
intrathecal	B-T058
injection	I-T058
of	O
an	O
alpha	B-T103
2	I-T103
adrenergic	I-T103
receptor	I-T103
antagonist	I-T103
.	O

These	O
data	O
support	O
the	O
hypothesis	O
that	O
the	O
analgesic	B-T033
efficacy	I-T033
of	O
systemically	O
administered	O
GCPII	B-T103
inhibitors	I-T103
is	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
the	O
contralatera	B-T082
l	O
locus	B-T017
coeruleus	I-T017
via	O
group	B-T103
II	I-T103
mGluR	I-T103
,	O
AMPA	B-T103
and	O
alpha	B-T103
2	I-T103
adrenergic	I-T103
receptors	I-T103
.	O

Association	O
of	O
physical	O
activity	O
on	O
body	O
composition	O
,	O
cardiometabolic	B-T033
risk	I-T033
factors	I-T033
,	O
and	O
prevalence	O
of	O
cardiovascular	B-T038
disease	I-T038
in	O
the	O
Korean	B-T098
population	I-T098
(	O
from	O
the	O
fifth	O
Korea	B-T082
national	B-T062
health	I-T062
and	I-T062
nutrition	I-T062
examination	I-T062
survey	I-T062
,	O
2008	O
-	O
2011	O
)	O

Data	O
regarding	O
associations	O
among	O
physical	O
activity	O
(	O
PA	O
)	O
level	O
,	O
body	O
composition	O
,	O
and	O
prevalence	O
of	O
cardiovascular	B-T038
diseases	I-T038
in	O
Asian	O
populations	O
are	O
rare	O
.	O

The	O
International	B-T170
Physical	I-T170
Activity	I-T170
Questionnaire	I-T170
(	O
IPAQ	B-T170
)	O
was	O
utilized	O
to	O
estimate	O
PA	O
levels	O
and	O
analyze	B-T062
the	O
association	O
of	O
PA	O
level	O
with	O
various	O
body	O
composition	O
parameters	O
and	O
the	O
prevalence	O
of	O
cardiovascular	B-T038
diseases	I-T038
by	O
using	O
data	O
from	O
the	O
Korean	B-T082
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
from	O
2008	O
to	O
2011	O
.	O

Moderate	O
and	O
high	O
PA	O
levels	O
were	O
associated	O
with	O
lower	O
prevalence	O
of	O
hypertension	B-T038
and	O
diabetes	B-T038
mellitus	I-T038
,	O
and	O
lower	O
concentrations	O
of	O
serum	B-T033
ferritin	I-T033
,	O
parathyroid	B-T033
hormone	I-T033
,	O
and	O
alkaline	B-T033
phosphatase	I-T033
.	O

Sarcopenia	B-T038
(	O
low	O
vs	O
.	O

moderate	O
vs	O
.	O

high	O
PA	O
group	O
:	O
14	O
.	O
3	O
%	O
vs	O
.	O

10	O
.	O
5	O
%	O
vs	O
.	O

7	O
.	O
3	O
%	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
underweight	B-T033
(	O
5	O
.	O
7	O
%	O
vs	O
.	O

4	O
.	O
9	O
%	O
vs	O
.	O

3	O
.	O
5	O
%	O
,	O
p	O
=	O
0	O
.	O
001	O
)	O
,	O
and	O
central	B-T033
obesity	I-T033
(	O
7	O
.	O
8	O
%	O
vs	O
.	O

6	O
.	O
9	O
%	O
vs	O
.	O

6	O
.	O
3	O
%	O
,	O
p	O
=	O
0	O
.	O
002	O
)	O
were	O
more	O
often	O
observed	O
in	O
the	O
low	O
PA	O
group	O
.	O

The	O
prevalence	O
rates	O
of	O
cardiovascular	B-T038
diseases	I-T038
were	O
lower	O
in	O
the	O
moderate	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0	O
.	O
822	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
,	O
0	O
.	O
737	O
-	O
0	O
.	O
916	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
and	O
high	O
activity	O
groups	O
(	O
OR	O
,	O
0	O
.	O
663	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
589	O
-	O
0	O
.	O
748	O
;	O
p	O
=	O
0	O
.	O
001	O
)	O
than	O
in	O
the	O
low	O
activity	O
group	O
,	O
even	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
smoking	O
,	O
underlying	B-T038
disease	I-T038
,	O
and	O
general	B-T038
or	O
abdominal	B-T033
obesity	I-T033
and	O
muscle	B-T033
mass	I-T033
.	O

Regular	O
physical	O
activity	O
was	O
associated	O
with	O
a	O
low	O
prevalence	O
of	O
cardiovascular	B-T038
diseases	I-T038
(	O
stroke	B-T037
,	O
myocardial	B-T038
infarction	I-T038
,	O
stable	B-T038
angina	I-T038
,	O
and	O
chronic	B-T038
renal	I-T038
disease	I-T038
)	O
,	O
which	O
was	O
independent	O
of	O
body	O
composition	O
and	O
conventional	O
risk	B-T033
factors	I-T033
in	O
the	O
Korean	B-T098
population	I-T098
,	O
with	O
a	O
positive	B-T033
dose	O
-	O
response	O
relationship	O
.	O

Treated	B-T058
Prevalence	O
of	O
Attention	B-T038
-	I-T038
Deficit	I-T038
/	I-T038
Hyperactivity	I-T038
Disorder	I-T038
Increased	O
from	O
2009	O
to	O
2015	O
Among	O
School	O
-	O
Aged	O
Children	O
and	O
Adolescents	O
in	O
the	O
United	B-T082
States	I-T082

The	O
purpose	O
of	O
this	O
brief	O
is	O
to	O
describe	O
changes	O
in	O
the	O
treated	B-T058
prevalence	O
of	O
medically	O
managed	O
attention	B-T038
-	I-T038
deficit	I-T038
/	I-T038
hyperactivity	I-T038
disorder	I-T038
(	O
ADHD	B-T038
)	O
among	O
insured	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
in	O
the	O
United	B-T082
States	I-T082
from	O
2009	O
to	O
2015	O
.	O

We	O
examine	B-T033
the	O
differences	O
between	O
those	O
with	O
employer	O
-	O
sponsored	O
insurance	O
(	O
ESI	O
)	O
and	O
with	O
Medicaid	B-T058
insurance	I-T058
.	O

We	O
utilized	O
two	O
large	O
longitudinal	B-T082
administrative	B-T170
datasets	I-T170
containing	O
medical	O
and	O
drug	B-T103
claims	O
data	O
on	O
individuals	B-T098
with	O
ESI	O
and	O
Medicaid	B-T058
insurance	I-T058
from	O
Truven	B-T170
Health	I-T170
MarketScan	I-T170
(	I-T170
®	I-T170
)	I-T170
Administrative	I-T170
Claims	I-T170
Databases	I-T170
.	O

Treated	B-T058
prevalence	O
was	O
measured	O
as	O
the	O
percentage	O
of	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
enrolled	O
in	O
a	O
calendar	O
year	O
who	O
met	O
the	O
criteria	O
for	O
medically	O
managed	O
ADHD	B-T038
in	O
the	O
same	O
calendar	O
year	O
.	O

Subjects	B-T098
were	O
eligible	O
for	O
inclusion	O
if	O
they	O
were	O
aged	O
6	O
-	O
17	O
years	O
and	O
were	O
continuously	O
enrolled	O
during	O
a	O
calendar	O
year	O
.	O

The	O
annual	O
prevalence	O
of	O
treated	B-T058
ADHD	B-T038
among	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
with	O
ESI	O
increased	O
from	O
4	O
.	O
5	O
%	O
in	O
2009	O
to	O
6	O
.	O
7	O
%	O
in	O
2015	O
.	O

Among	O
those	O
with	O
Medicaid	B-T058
it	O
increased	O
from	O
11	O
.	O
3	O
%	O
in	O
2009	O
to	O
13	O
.	O
3	O
%	O
in	O
2012	O
,	O
and	O
fell	O
after	O
2012	O
,	O
remaining	O
steady	O
from	O
2013	O
through	O
2015	O
.	O

Treated	B-T058
prevalence	O
of	O
ADHD	B-T038
increased	O
continuously	O
over	O
time	O
among	O
school	O
-	O
aged	O
children	O
and	O
adolescents	O
with	O
ESI	O
,	O
but	O
declined	O
slightly	O
after	O
2012	O
among	O
those	O
in	O
the	O
Medicaid	B-T058
sample	I-T058
.	O

Acute	O
macular	B-T038
edema	I-T038
and	O
peripapillary	B-T082
soft	O
exudate	B-T031
after	O
pancreas	B-T058
transplantation	I-T058
with	O
accelerated	O
progression	B-T038
of	O
diabetic	B-T038
retinopathy	I-T038

The	O
effect	O
of	O
pancreas	B-T058
transplantation	I-T058
on	O
diabetic	B-T038
retinopathy	I-T038
remains	O
inconclusive	O
.	O

Herein	O
,	O
we	O
report	O
six	O
patients	O
with	O
type	B-T038
1	I-T038
diabetes	I-T038
mellitus	I-T038
(	O
DM	B-T038
)	O
who	O
underwent	O
pancreas	B-T058
transplantation	I-T058
and	O
developed	O
acute	O
macular	B-T038
edema	I-T038
and	O
peripapillary	B-T082
soft	O
exudate	B-T031
with	O
rapid	O
progression	B-T038
to	O
proliferative	B-T038
diabetic	I-T038
retinopathy	I-T038
.	O

In	O
this	O
retrospective	B-T062
observational	I-T062
study	I-T062
,	O
diabetic	B-T038
patients	O
who	O
underwent	O
pancreas	B-T058
transplantation	I-T058
in	O
a	O
single	O
medical	B-T092
center	I-T092
and	O
developed	O
symptomatic	O
acute	O
macular	B-T038
edema	I-T038
and	O
peripapillary	B-T082
soft	O
exudate	B-T031
within	B-T082
3	O
months	O
after	O
the	O
operation	B-T058
were	O
enrolled	O
.	O

The	O
complete	O
ophthalmic	O
course	O
and	O
medical	B-T170
records	I-T170
of	O
the	O
patients	O
were	O
retrospectively	O
reviewed	O
.	O

Diabetic	B-T038
retinopathy	I-T038
and	O
progression	B-T038
following	O
treatment	B-T058
after	O
pancreas	B-T058
transplantation	I-T058
were	O
measured	O
.	O

Six	O
Chinese	B-T098
women	B-T098
with	O
type	B-T038
1	I-T038
DM	I-T038
were	O
enrolled	O
in	O
this	O
study	B-T062
.	O

Mean	O
hemoglobin	B-T103
(	I-T103
Hb	I-T103
)	I-T103
A1c	I-T103
was	O
13	O
.	O
4	O
%	O
prior	O
to	O
transplantation	B-T058
and	O
decreased	O
rapidly	O
to	O
6	O
.	O
5	O
%	O
within	B-T082
2	O
months	O
postsurgery	O
.	O

The	O
patients	O
had	O
no	O
or	O
mild	O
pretransplant	O
diabetic	B-T038
retinopathy	I-T038
and	O
developed	O
acute	O
symptomatic	O
macular	B-T038
edema	I-T038
and	O
peripapillary	B-T082
soft	O
exudate	B-T031
in	O
both	B-T017
eyes	I-T017
after	O
pancreas	B-T058
transplantation	I-T058
.	O

All	O
macular	B-T038
edema	I-T038
resolved	B-T033
either	O
with	O
or	O
without	O
treatment	B-T058
.	O

Five	O
cases	O
progressed	B-T038
to	O
proliferative	B-T038
diabetic	I-T038
retinopathy	I-T038
and	O
received	O
panretinal	B-T058
photocoagulation	I-T058
.	O

Diabetic	B-T038
retinopathy	I-T038
remained	O
stable	O
in	O
all	O
eyes	B-T017
after	O
treatment	B-T058
,	O
and	O
the	O
visual	O
prognosis	B-T033
was	I-T033
good	I-T033
,	O
except	O
in	O
one	O
eye	B-T017
that	O
had	O
macular	O
branch	B-T038
retinal	I-T038
artery	I-T038
occlusion	I-T038
with	O
foveal	B-T017
involvement	O
.	O

Acute	O
macular	B-T038
edema	I-T038
after	O
pancreas	B-T058
transplantation	I-T058
has	O
a	O
favorable	O
treatment	O
outcome	O
despite	O
rapid	O
progression	B-T038
to	O
proliferative	B-T038
diabetic	I-T038
retinopathy	I-T038
.	O

High	O
pretransplant	O
HbA1c	B-T103
and	O
abrupt	O
blood	B-T103
sugar	I-T103
normalization	O
may	O
be	O
related	O
to	O
the	O
disease	B-T038
course	I-T038
.	O

Anger	B-T038
and	O
aggression	O
in	O
borderline	B-T038
personality	I-T038
disorder	I-T038
and	O
attention	B-T038
deficit	I-T038
hyperactivity	I-T038
disorder	I-T038
-	O
does	O
stress	B-T033
matter	O
?	O

The	O
impact	O
of	O
stress	B-T033
on	O
anger	B-T038
and	O
aggression	O
in	O
Borderline	B-T038
Personality	I-T038
Disorder	I-T038
(	O
BPD	B-T038
)	O
and	O
Attention	B-T038
Deficit	I-T038
Hyperactivity	I-T038
Disorder	I-T038
(	O
ADHD	B-T038
)	O
has	O
not	O
been	O
thoroughly	O
investigated	O
.	O

The	O
goal	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
different	O
aspects	O
of	O
anger	B-T038
and	O
aggression	O
in	O
patients	O
with	O
these	O
disorders	B-T038
.	O

Twenty	O
-	O
nine	O
unmedicated	B-T033
female	O
BPD	B-T038
patients	O
,	O
28	O
ADHD	B-T038
patients	O
and	O
30	O
healthy	O
controls	O
(	O
HC	O
)	O
completed	O
self	B-T062
-	I-T062
reports	I-T062
measuring	O
trait	O
anger	B-T038
,	O
aggression	O
and	O
emotion	O
regulation	O
capacities	O
.	O

A	O
modified	O
version	O
of	O
the	O
Point	O
Subtraction	O
Aggression	O
Paradigm	O
and	O
a	O
state	B-T062
anger	I-T062
measurement	I-T062
were	O
applied	O
under	O
resting	O
and	O
stress	O
conditions	O
.	O

Stress	B-T033
was	O
induced	O
by	O
the	O
Mannheim	B-T058
Multicomponent	I-T058
Stress	I-T058
Test	I-T058
(	O
MMST	B-T058
)	O
.	O

Both	O
patient	O
groups	O
scored	O
significantly	O
higher	O
on	O
all	O
self	B-T062
-	I-T062
report	I-T062
measures	O
compared	O
to	O
HCs	O
.	O

Compared	O
to	O
ADHD	B-T038
patients	O
,	O
BPD	B-T038
patients	O
reported	O
higher	O
trait	O
aggression	O
and	O
hostility	B-T038
,	O
a	O
stronger	O
tendency	O
to	O
express	O
anger	B-T038
when	O
provoked	O
and	O
to	O
direct	O
anger	B-T038
inwardly	O
.	O

Furthermore	O
,	O
BPD	B-T038
patients	O
exhibited	O
higher	O
state	O
anger	B-T038
than	O
HCs	O
and	O
ADHD	B-T038
patients	O
under	O
both	O
conditions	O
and	O
showed	O
a	O
stress	O
-	O
dependent	O
anger	B-T038
increase	O
.	O

At	O
the	O
behavioral	O
level	O
,	O
no	O
significant	O
effects	O
were	O
found	O
.	O

In	O
BPD	B-T038
patients	O
,	O
aggression	O
and	O
anger	B-T038
were	O
positively	O
correlated	O
with	O
emotion	O
regulation	O
deficits	O
.	O

Our	O
findings	B-T033
suggest	O
a	O
significant	O
impact	O
of	O
stress	B-T033
on	O
self	O
-	O
perceived	O
state	O
anger	B-T038
in	O
BPD	B-T038
patients	O
but	O
not	O
on	O
aggressive	O
behavior	O
towards	O
others	O
in	O
females	O
with	O
BPD	B-T038
or	O
ADHD	B-T038
.	O

However	O
,	O
it	O
appears	O
to	O
be	O
pronounced	O
inwardly	O
directed	O
anger	B-T038
which	O
is	O
of	O
clinical	O
importance	O
in	O
BPD	B-T038
patients	O
.	O

Interferon	B-T017
gamma	I-T017
and	O
interleukin	B-T017
10	I-T017
polymorphisms	O
in	O
Chinese	B-T098
children	O
with	O
hemophagocytic	B-T038
lymphohistiocytosis	I-T038

The	O
aim	O
of	O
the	O
study	B-T062
is	O
to	O
investigate	O
the	O
association	O
of	O
interferon	B-T017
gamma	I-T017
(	O
IFN	B-T017
-	I-T017
γ	I-T017
)	O
and	O
interleukin	B-T017
-	I-T017
10	I-T017
(	O
IL	B-T017
-	I-T017
10	I-T017
)	O
gene	B-T017
single	B-T082
nucleotide	I-T082
polymorphisms	I-T082
with	O
the	O
susceptibility	B-T201
of	O
hemophagocytic	B-T038
lymphohistiocytosis	I-T038
(	O
HLH	B-T038
)	O
in	O
Chinese	B-T098
children	O
without	B-T033
known	I-T033
family	I-T033
history	I-T033
of	I-T033
HLH	B-T038
.	O

Forty	O
children	O
with	O
HLH	B-T038
and	O
160	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
from	O
Xuzhou	B-T092
Children	I-T092
'	I-T092
s	I-T092
Hospital	I-T092
were	O
enrolled	O
in	O
the	O
study	B-T062
.	O

Serum	B-T031
IFN	B-T103
-	I-T103
γ	I-T103
and	O
IL	B-T103
-	I-T103
10	I-T103
levels	O
were	O
measured	O
by	O
enzyme	B-T058
linked	I-T058
-	I-T058
immunosorbent	I-T058
assay	I-T058
.	O

Polymorphisms	O
of	O
the	O
IFN	B-T017
-	I-T017
γ	I-T017
gene	I-T017
at	O
position	O
+	O
874	O
and	O
+	O
2109	O
,	O
and	O
IL	B-T017
-	I-T017
10	I-T017
at	O
position	O
-	O
1082	O
were	O
analyzed	B-T033
by	O
allele	B-T017
-	O
specific	O
PCR	B-T062
.	O

Median	B-T031
serum	I-T031
concentrations	O
of	O
IFN	B-T103
-	I-T103
γ	I-T103
and	O
IL	B-T103
-	I-T103
10	I-T103
were	O
significantly	O
higher	O
in	O
children	O
with	O
HLH	B-T038
compared	O
to	O
healthy	O
controls	O
.	O

The	O
frequencies	O
of	O
IFN	B-T017
-	I-T017
γ	I-T017
+	O
874	O
T	O
/	O
A	O
and	O
T	O
/	O
T	O
genotypes	O
,	O
as	O
well	O
as	O
T	B-T017
allele	I-T017
,	O
were	O
significantly	O
higher	O
in	O
the	O
HLH	B-T038
group	O
compared	O
with	O
those	O
in	O
the	O
control	O
group	O
.	O

The	O
frequencies	O
of	O
IL	B-T017
-	I-T017
10	I-T017
-	O
1082	O
G	O
/	O
A	O
genotype	O
and	O
G	B-T017
allele	I-T017
were	O
significantly	O
increased	O
in	O
HLH	B-T038
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

No	B-T033
significant	I-T033
difference	O
was	O
found	O
in	O
the	O
distribution	O
of	O
IFN	B-T017
-	I-T017
γ	I-T017
+	O
2109	O
G	O
/	O
A	O
genotypes	O
between	O
children	O
with	O
HLH	B-T038
and	O
controls	O
.	O

This	O
study	B-T062
presents	B-T033
preliminary	O
evidence	O
for	O
the	O
association	O
between	O
IFN	B-T017
+	O
874	O
T	O
/	O
A	O
,	O
T	O
/	O
T	O
,	O
IL	B-T017
-	I-T017
10	I-T017
-	O
1082	O
A	O
/	O
G	O
genotypes	O
,	O
and	O
HLH	B-T038
susceptibility	B-T201
in	O
Chinese	B-T098
children	O
with	O
HLH	B-T038
.	O

Data	O
-	O
Driven	O
Implementation	O
of	O
Alarm	B-T074
Reduction	O
Interventions	B-T058
in	O
a	O
Cardiovascular	B-T092
Surgical	I-T092
ICU	I-T092

Alarm	O
fatigue	O
in	O
the	O
ICU	B-T092
setting	O
has	O
been	O
well	O
documented	B-T058
in	O
the	O
literature	B-T170
.	O

The	O
ICU	B-T092
'	I-T092
s	I-T092
high	B-T170
-	I-T170
intensity	I-T170
environment	B-T082
requires	O
staff	B-T097
'	I-T097
s	I-T097
vigilant	B-T038
attention	B-T038
,	O
and	O
distraction	O
from	O
false	O
and	O
non	O
-	O
actionable	O
alarms	B-T074
pulls	O
staff	B-T097
away	O
from	O
important	O
tasks	O
,	O
creates	O
dissatisfaction	B-T038
,	O
and	O
is	O
a	O
potential	O
patient	B-T058
safety	I-T058
risk	O
if	O
alarms	B-T074
are	O
missed	O
or	O
ignored	O
.	O

This	O
project	O
was	O
intended	O
to	O
improve	O
patient	B-T058
safety	I-T058
by	O
optimizing	O
alarm	B-T074
systems	O
in	O
a	O
cardiovascular	B-T092
surgical	I-T092
intensive	I-T092
care	I-T092
unit	I-T092
(	O
CVSICU	B-T092
)	O
.	O

Specific	O
aims	O
were	O
to	O
examine	B-T033
nurses	B-T097
'	O
attitudes	B-T038
toward	O
clinical	O
alarm	B-T074
signals	O
,	O
assess	O
nurses	B-T097
'	O
ability	O
to	O
discriminate	O
audible	O
alarm	O
signals	O
,	O
and	O
implement	O
a	O
bundled	O
set	O
of	O
best	O
practices	O
for	O
monitor	O
alarm	O
reduction	O
without	O
undermining	O
patient	B-T058
safety	I-T058
.	O

CVSICU	B-T092
nurses	B-T097
completed	O
an	O
alarm	B-T074
perception	B-T170
survey	I-T170
and	O
participated	O
in	O
alarm	B-T074
discriminability	O
testing	O
.	O

Nurse	B-T170
survey	I-T170
data	I-T170
and	O
baseline	O
monitor	O
alarm	B-T074
data	O
were	O
used	O
to	O
select	O
targeted	O
alarm	B-T074
reduction	O
interventions	B-T058
,	O
which	O
were	O
progressively	O
phased	O
in	O
.	O

Monitor	O
alarm	B-T074
data	O
and	O
cardiorespiratory	B-T033
event	I-T033
data	O
were	O
trended	O
over	O
one	O
year	O
.	O

Five	O
of	O
the	O
most	O
frequent	O
CVSICU	B-T092
monitor	O
alarm	O
types	O
-	O
pulse	B-T058
oximetry	I-T058
,	O
heart	B-T201
rate	I-T201
,	O
systolic	B-T033
and	O
diastolic	B-T038
blood	I-T038
pressure	I-T038
,	O
pulse	B-T058
oximetry	I-T058
sensor	O
,	O
and	O
ventricular	B-T038
tachycardia	I-T038
>	O
2	O
-	O
were	O
targeted	O
.	O

After	O
implementation	O
,	O
there	O
was	O
a	O
61	O
%	O
reduction	O
in	O
average	O
alarms	B-T074
per	O
monitored	O
bed	O
and	O
a	O
downward	O
trend	O
in	O
cardiorespiratory	B-T033
events	I-T033
.	O

To	O
reduce	O
alarm	O
fatigue	O
it	O
is	O
important	O
to	O
decrease	O
alarm	B-T074
burden	O
through	O
targeted	O
interventions	B-T058
.	O

Methods	O
to	O
reduce	O
non	O
-	O
actionable	O
alarms	B-T074
include	O
adding	O
short	O
delays	O
to	O
allow	O
alarm	B-T074
self	O
-	O
correction	O
,	O
adjusting	O
default	O
alarm	B-T074
threshold	O
limits	O
,	O
providing	O
alarm	B-T074
notification	B-T058
through	O
a	O
secondary	B-T074
device	I-T074
,	O
and	O
teaching	O
staff	B-T097
to	O
optimize	O
alarm	B-T074
settings	O
for	O
individual	B-T098
patients	O
.	O

The	O
NCAM1	B-T017
gene	I-T017
set	I-T017
is	O
linked	O
to	O
depressive	B-T033
symptoms	I-T033
and	O
their	O
brain	B-T017
structural	I-T017
correlates	O
in	O
healthy	B-T098
individuals	I-T098

Depressive	B-T033
symptoms	I-T033
exist	O
on	O
a	O
continuum	O
,	O
the	O
far	O
end	O
of	O
which	O
is	O
found	O
in	O
depressive	B-T038
disorders	I-T038
.	O

Utilizing	O
the	O
continuous	B-T058
spectrum	I-T058
of	O
depressive	B-T033
symptoms	I-T033
may	O
therefore	O
contribute	O
to	O
the	O
understanding	O
of	O
the	O
biological	B-T033
underpinnings	I-T033
of	O
depression	B-T038
.	O

Gene	B-T058
set	I-T058
enrichment	I-T058
analysis	I-T058
(	O
GSEA	B-T058
)	O
is	O
an	O
important	O
tool	O
for	O
the	O
identification	O
of	O
gene	B-T017
groups	I-T017
linked	O
to	O
complex	O
traits	O
,	O
and	O
was	O
applied	O
in	O
the	O
present	O
study	O
on	O
genome	B-T062
-	I-T062
wide	I-T062
association	I-T062
study	I-T062
(	O
GWAS	B-T062
)	O
data	O
of	O
depression	O
scores	O
and	O
their	O
brain	B-T017
-	I-T017
level	I-T017
structural	I-T017
correlates	O
in	O
healthy	B-T098
young	I-T098
individuals	I-T098
.	O

On	O
symptom	B-T033
level	I-T033
(	O
i	O
.	O
e	O
.	O

depression	O
scores	O
)	O
,	O
robust	O
enrichment	O
was	O
identified	O
for	O
two	O
gene	B-T017
sets	I-T017
:	O
NCAM1	B-T017
Interactions	O
and	O
Collagen	B-T038
Formation	I-T038
.	O

Depression	O
scores	O
were	O
also	O
associated	O
with	O
decreased	O
fractional	O
anisotropy	O
(	O
FA	O
)	O
-	O
a	O
brain	B-T017
white	I-T017
matter	I-T017
property	I-T017
-	O
within	B-T017
the	I-T017
forceps	I-T017
minor	I-T017
and	O
the	O
left	B-T017
superior	I-T017
temporal	I-T017
longitudinal	I-T017
fasciculus	I-T017
.	O

Within	O
each	O
of	O
these	O
tracts	O
,	O
mean	O
FA	O
value	O
of	O
depression	O
score	O
-	O
associated	O
voxels	O
was	O
used	O
as	O
a	O
phenotype	O
in	O
a	O
subsequent	O
GSEA	B-T058
.	O

The	O
NCAM1	B-T017
Interactions	O
gene	B-T017
set	I-T017
was	O
significantly	O
enriched	O
in	O
these	O
tracts	O
.	O

By	O
linking	O
the	O
NCAM1	B-T017
Interactions	O
gene	B-T017
set	I-T017
to	O
depression	O
scores	O
and	O
their	O
structural	B-T017
brain	I-T017
correlates	O
in	O
healthy	B-T098
participants	I-T098
,	O
the	O
current	O
study	O
contributes	O
to	O
the	O
understanding	O
of	O
the	O
molecular	B-T033
underpinnings	I-T033
of	O
depressive	B-T033
symptomatology	I-T033
.	O

The	O
burden	O
of	O
HPV	B-T005
-	O
related	O
diseases	B-T038
in	O
Italy	B-T082
,	O
2001	O
-	O
12	O

Human	B-T038
papillomavirus	I-T038
(	I-T038
HPV	I-T038
)	I-T038
infection	I-T038
is	O
the	O
main	O
cause	O
of	O
cervical	B-T038
cancer	I-T038
and	O
plays	O
a	O
relevant	O
role	O
in	O
the	O
development	O
of	O
genital	O
warts	O
and	O
of	O
the	O
cancer	B-T038
of	O
penis	B-T017
and	O
anus	B-T017
,	O
head	B-T082
/	O
neck	B-T082
,	O
oropharynx	B-T082
and	O
genitourinary	B-T022
system	I-T022
.	O

The	O
aim	O
of	O
this	O
study	B-T062
is	O
the	O
evaluation	O
of	O
hospitalizations	B-T058
due	O
to	O
HPV	B-T038
-	I-T038
related	I-T038
pathologies	I-T038
in	O
2001	O
-	O
12	O
in	O
Italy	B-T082
.	O

The	O
national	B-T058
hospital	I-T058
discharge	I-T058
forms	O
were	O
provided	O
by	O
the	O
Ministry	B-T092
of	I-T092
Health	I-T092
.	O

The	O
HPV	B-T005
-	O
related	O
hospitalizations	B-T058
were	O
identified	O
using	O
specific	O
diagnostic	O
codes	B-T170
,	O
accordingly	O
to	O
the	O
ICD	B-T170
-	I-T170
9	I-T170
-	I-T170
CM	I-T170
coding	B-T170
system	I-T170
.	O

The	O
proportion	O
of	O
hospitalizations	B-T058
of	O
potentially	O
HPV	B-T038
-	I-T038
related	I-T038
pathologies	I-T038
,	O
obtained	O
from	O
the	O
literature	B-T170
,	O
was	O
evaluated	O
as	O
well	O
as	O
the	O
hospitalization	O
rates	O
(	O
hr	O
)	O
and	O
their	O
trend	O
over	O
time	O
.	O

Uterine	B-T038
cervical	I-T038
cancer	I-T038
and	O
CIN	B-T038
III	I-T038
accounted	O
for	O
40	O
%	O
of	O
hospitalizations	B-T058
(	O
hr	O
:	O
15	O
.	O
6	O
/	O
100	O
000	O
and	O
17	O
.	O
6	O
/	O
100	O
000	O
,	O
respectively	O
)	O
.	O

Head	B-T082
/	O
neck	B-T082
and	O
oropharynx	B-T082
pathologies	O
accounted	O
for	O
24	O
.	O
5	O
%	O
of	O
cases	O
(	O
hr	O
:	O
16	O
/	O
100	O
000	O
and	O
3	O
.	O
9	O
/	O
100	O
000	O
,	O
in	O
males	O
and	O
females	O
,	O
respectively	O
)	O
,	O
followed	O
by	O
genital	O
warts	O
(	O
17	O
.	O
3	O
%	O
of	O
hospitalizations	B-T058
;	O
hr	O
:	O
7	O
.	O
5	O
/	O
100	O
000	O
in	O
males	O
and	O
8	O
.	O
52	O
/	O
100	O
000	O
in	O
females	O
)	O
,	O
anal	B-T038
(	O
8	O
.	O
1	O
%	O
of	O
hospitalizations	B-T058
)	O
,	O
genitourinary	B-T038
(	O
7	O
.	O
7	O
%	O
)	O
and	O
penis	B-T038
cancers	I-T038
(	O
2	O
.	O
2	O
%	O
)	O
.	O

The	O
study	B-T062
,	O
even	O
if	O
limited	O
to	O
the	O
evaluation	O
of	O
hospitalizations	B-T058
,	O
points	O
out	O
how	O
HPV	B-T038
-	I-T038
related	I-T038
pathologies	I-T038
continue	O
to	O
be	O
a	O
relevant	O
public	O
health	O
issue	B-T033
in	O
Italy	B-T082
with	O
a	O
high	O
impact	O
on	O
population	B-T098
.	O

The	O
discovery	O
of	O
potent	O
and	O
selective	O
kynurenine	B-T103
3	I-T103
-	I-T103
monooxygenase	I-T103
inhibitors	B-T103
for	O
the	O
treatment	B-T058
of	O
acute	B-T038
pancreatitis	I-T038

A	O
series	O
of	O
potent	O
,	O
competitive	O
and	O
highly	O
selective	O
kynurenine	B-T103
monooxygenase	I-T103
inhibitors	B-T103
have	O
been	O
discovered	O
via	O
a	O
substrate	O
-	O
based	O
approach	B-T082
for	O
the	O
treatment	B-T058
of	O
acute	B-T038
pancreatitis	I-T038
.	O

The	O
lead	O
compound	B-T103
demonstrated	O
good	O
cellular	B-T017
potency	O
and	O
clear	O
pharmacodynamic	B-T038
activity	O
in	B-T082
vivo	I-T082
.	O

Draft	B-T017
Genome	I-T017
Sequence	B-T082
of	O
Providencia	B-T007
stuartii	I-T007
PS71	I-T007
,	O
a	O
Multidrug	O
-	O
Resistant	O
Strain	O
Associated	O
with	O
Nosocomial	B-T038
Infections	I-T038
in	O
Greece	B-T082

Providencia	B-T007
stuartii	I-T007
is	O
frequently	O
associated	O
with	O
nosocomial	B-T038
outbreaks	I-T038
and	O
displays	O
intrinsic	B-T082
resistance	O
to	O
many	O
commonly	O
used	O
antimicrobials	B-T103
.	O

We	O
report	O
here	O
the	O
draft	B-T017
genome	I-T017
sequence	B-T082
of	O
a	O
P	B-T007
.	I-T007

stuartii	I-T007
strain	I-T007
carrying	O
acquired	O
resistance	O
genes	O
conferring	O
panresistance	O
to	O
cephalosporins	B-T103
(	O
blaSHV	B-T017
-	I-T017
5	I-T017
and	O
blaVEB	B-T017
-	I-T017
1	I-T017
)	O
,	O
carbapenems	B-T103
(	O
blaVIM	B-T017
-	I-T017
1	I-T017
)	O
,	O
and	O
aminoglycosides	B-T103
(	O
rmtB	B-T017
)	O
involved	O
in	O
an	O
outbreak	O
in	O
Greek	B-T082
hospitals	B-T092
.	O

Impact	O
of	O
diabetic	B-T038
ketoacidosis	I-T038
management	B-T058
in	O
the	O
medical	B-T092
intensive	I-T092
care	I-T092
unit	I-T092
after	O
order	B-T170
set	I-T170
implementation	O

To	O
determine	O
the	O
rate	O
of	O
compliance	B-T058
to	O
the	O
2006	O
and	O
2009	O
ADA	B-T170
DKA	I-T170
guidelines	I-T170
in	O
the	O
medical	B-T092
intensive	I-T092
care	I-T092
unit	I-T092
(	O
MICU	B-T092
)	O
at	O
a	O
large	O
academic	B-T092
medical	I-T092
centre	I-T092
after	O
the	O
implementation	O
of	O
a	O
computerised	B-T170
DKA	I-T170
order	I-T170
set	I-T170
and	O
protocol	B-T058
.	O

Retrospective	O
chart	B-T170
review	I-T170
of	O
adult	O
patients	O
with	O
DKA	B-T038
admitted	B-T058
to	O
the	O
MICU	B-T092
.	O

Results	O
of	O
pre	B-T170
-	I-T170
order	I-T170
set	I-T170
(	O
PRE	B-T170
)	O
were	O
compared	O
to	O
those	O
of	O
data	O
post	B-T170
-	I-T170
order	I-T170
set	I-T170
(	O
POST	B-T170
)	O
.	O

The	O
primary	O
outcome	O
was	O
a	O
composite	O
administration	B-T058
of	O
intravenous	B-T058
fluid	I-T058
resuscitation	I-T058
in	O
the	O
first	O
24	O
h	O
,	O
insulin	B-T103
bolus	B-T058
and	O
initial	O
insulin	B-T103
infusion	O
rate	O
.	O

Twelve	O
of	O
60	O
patients	O
(	O
20	O
%	O
)	O
in	O
the	O
PRE	O
group	O
received	O
treatment	B-T058
compliant	O
with	O
the	O
2006	O
guidelines	B-T170
versus	O
14	O
of	O
55	O
patients	O
(	O
25	O
.	O
5	O
%	O
)	O
in	O
the	O
POST	O
group	O
(	O
OR	O
1	O
.	O
22	O
95	O
%	O
CI	O
0	O
.	O
44	O
to	O
3	O
.	O
4	O
,	O
P	O
=	O
0	O
.	O
51	O
)	O
.	O

Compliance	B-T058
to	O
the	O
2009	O
guidelines	B-T170
was	O
significantly	O
higher	O
in	O
the	O
POST	O
group	O
(	O
31	O
.	O
7	O
%	O
versus	O
65	O
.	O
5	O
%	O
,	O
OR	O
4	O
.	O
44	O
95	O
%	O
CI	O
1	O
.	O
8	O
to	O
10	O
.	O
92	O
,	O
P	O
=	O
0	O
.	O
0004	O
)	O
.	O

Compliance	B-T058
for	O
individual	O
components	O
was	O
26	O
.	O
7	O
%	O
versus	O
70	O
.	O
9	O
%	O
for	O
fluid	B-T058
resuscitation	I-T058
(	O
P	O
=	O
0	O
.	O
0001	O
)	O
,	O
55	O
%	O
versus	O
49	O
.	O
1	O
%	O
for	O
insulin	B-T103
bolus	B-T058
(	O
P	O
=	O
0	O
.	O
58	O
)	O
and	O
60	O
%	O
versus	O
81	O
.	O
3	O
%	O
for	O
initial	O
insulin	B-T103
infusion	O
rate	O
(	O
P	O
=	O
0	O
.	O
014	O
)	O
,	O
respectively	O
.	O

Time	O
to	O
DKA	B-T038
resolution	O
was	O
decreased	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
,	O
and	O
hypoglycaemia	B-T038
was	O
increased	O
(	O
P	O
=	O
0	O
.	O
0022	O
)	O
.	O

Implementation	O
of	O
a	O
computerised	B-T170
DKA	I-T170
order	I-T170
set	I-T170
and	O
protocol	B-T058
was	O
associated	O
with	O
improved	B-T033
compliance	B-T058
to	O
the	O
2009	O
ADA	B-T170
DKA	I-T170
guidelines	I-T170
,	O
24	O
-	O
h	O
fluid	B-T058
resuscitation	I-T058
,	O
initial	O
insulin	B-T103
infusion	O
rate	O
,	O
time	O
to	O
DKA	B-T038
resolution	O
and	O
appropriate	O
transition	O
to	O
subcutaneous	B-T082
insulin	B-T103
.	O

However	O
,	O
patients	O
in	O
the	O
POST	O
implementation	O
group	O
were	O
more	O
likely	O
to	O
exhibit	O
hypoglycaemia	B-T038
.	O

Future	O
assessment	O
is	O
warranted	O
.	O

Construction	O
of	O
an	O
Acetylcholinesterase	B-T103
Sensor	O
Based	O
on	O
Synthesized	B-T103
Paramagnetic	I-T103
Nanoparticles	I-T103
,	O
a	O
Simple	O
Tool	O
for	O
Neurotoxic	O
Compounds	O
Assay	B-T058

Magnetic	B-T103
particles	I-T103
(	O
MPs	B-T103
)	O
have	O
been	O
widely	O
used	O
in	O
biological	O
applications	O
in	O
recent	O
years	O
as	O
a	O
carrier	O
for	O
various	O
molecules	O
.	O

Their	O
big	O
advantage	O
is	O
in	O
repeated	O
use	O
of	O
immobilized	O
molecules	O
including	O
enzymes	B-T103
.	O

Acetylcholinesterase	B-T103
(	O
AChE	B-T103
)	O
is	O
an	O
enzyme	B-T103
playing	O
crucial	O
role	O
in	O
neurotransmission	B-T038
and	O
the	O
enzyme	B-T103
is	O
targeted	O
by	O
various	O
molecules	O
like	O
Alzheimer	B-T038
'	I-T038
s	I-T038
drugs	B-T103
,	O
pesticides	B-T103
and	O
warfare	B-T103
agents	I-T103
.	O

In	O
this	O
work	O
,	O
an	O
electrochemical	O
biosensor	O
having	O
AChE	B-T103
immobilized	B-T103
onto	O
MPs	B-T103
and	O
stabilized	B-T033
through	O
glutaraldehyde	B-T103
(	I-T103
GA	I-T103
)	I-T103
molecule	I-T103
was	O
proposed	O
for	O
assay	B-T058
of	O
the	O
neurotoxic	O
compounds	O
.	O

The	O
prepared	O
nanoparticles	O
were	O
modified	O
by	O
pure	B-T103
AChE	I-T103
and	O
they	O
were	O
used	O
for	O
the	O
measurement	O
anti	B-T033
-	I-T033
Alzheimer	I-T033
'	I-T033
s	I-T033
drug	B-T103
galantamine	B-T103
and	O
carbamate	B-T103
pesticide	I-T103
carbofuran	B-T103
with	O
limit	O
of	O
detection	B-T033
1	O
.	O
5	O
µM	O
and	O
20	O
nM	O
,	O
respectively	O
.	O

All	O
measurements	O
were	O
carried	O
out	O
using	O
screen	O
-	O
printed	O
sensor	O
with	O
carbon	B-T103
working	B-T074
,	O
silver	B-T103
reference	O
,	O
and	O
carbon	B-T103
auxiliary	B-T074
electrode	I-T074
.	O

Standard	B-T058
Ellman	I-T058
'	I-T058
s	I-T058
assay	I-T058
was	O
used	O
for	O
validation	B-T062
measurement	O
of	O
both	O
inhibitors	B-T103
.	O

Part	O
of	O
this	O
work	O
was	O
the	O
elimination	O
of	O
reversible	O
inhibitors	B-T103
represented	O
by	O
galantamine	B-T103
from	O
the	O
active	O
site	O
of	O
AChE	B-T103
.	O

For	O
this	O
purpose	O
,	O
we	O
used	O
a	O
lower	O
pH	O
to	O
get	O
the	O
original	O
activity	O
of	O
AChE	B-T103
after	O
inhibition	O
by	O
galantamine	B-T103
.	O

We	O
also	O
observed	O
decarbamylation	O
of	O
the	O
AChE	B-T103
-	O
carbofuran	B-T103
adduct	O
.	O

Influence	O
of	O
organic	B-T103
solvents	I-T103
to	O
AChE	B-T103
as	O
well	O
as	O
repeatability	O
of	O
measurement	O
with	O
MPs	B-T103
with	O
AChE	B-T103
was	O
also	O
established	O
.	O

Alanine	B-T103
Aminotransferase	I-T103
Is	O
a	O
Marker	B-T201
of	O
Lipotoxicity	B-T038
Consequences	O
and	O
Hyperandrogenemia	B-T033
in	O
Women	B-T098
with	O
Polycystic	B-T038
Ovary	I-T038
Syndrome	I-T038

Several	O
studies	B-T062
have	O
reported	O
higher	O
levels	O
of	O
Alanine	B-T103
aminotransferase	I-T103
(	O
ALT	B-T103
)	O
in	O
women	B-T098
with	O
polycystic	B-T038
ovary	I-T038
syndrome	I-T038
(	O
PCOS	B-T038
)	O
compared	O
with	O
control	O
subjects	O
.	O

Plasma	B-T058
ALT	I-T058
levels	I-T058
are	O
considered	O
a	O
marker	B-T201
of	O
hepatic	B-T082
lipotoxicity	B-T038
because	O
of	O
their	O
significant	O
associations	O
with	O
different	O
hepatic	B-T082
metabolic	O
dysfunctions	O
,	O
such	O
as	O
hepatic	B-T038
steatosis	I-T038
and	O
hepatic	B-T082
insulin	B-T038
resistance	I-T038
.	O

Retrospective	B-T170
chart	I-T170
review	O
aiming	O
to	O
assess	O
,	O
in	O
PCOS	B-T038
women	B-T098
,	O
the	O
relationship	O
between	O
ALT	B-T058
levels	I-T058
and	O
measures	O
of	O
lipotoxicity	B-T038
consequences	O
that	O
are	O
available	O
clinically	O
,	O
both	O
during	O
fasting	B-T058
and	O
using	O
the	O
oral	B-T058
glucose	I-T058
tolerance	I-T058
test	I-T058
.	O

Women	B-T098
(	O
n	O
=	O
132	O
)	O
with	O
PCOS	B-T038
,	O
were	O
in	O
average	O
27	O
.	O
9	O
years	O
of	O
age	O
,	O
with	O
a	O
mean	O
body	B-T201
mass	I-T201
index	I-T201
of	O
34	O
.	O
1	O
kg	O
/	O
m	O
(	O
2	O
)	O
and	O
49	O
%	O
had	O
a	O
metabolic	B-T038
syndrome	I-T038
(	O
MetS	B-T038
)	O
.	O

ALT	B-T058
levels	I-T058
were	O
significantly	O
correlated	O
with	O
homeostatic	B-T058
model	I-T058
assessment	I-T058
for	I-T058
insulin	I-T058
resistance	I-T058
(	O
r	O
=	O
0	O
.	O
42	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
HDL	B-T103
-	I-T103
C	I-T103
(	O
r	O
=	O
-	O
0	O
.	O
31	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
Matsuda	B-T170
index	I-T170
(	O
-	O
0	O
.	O
45	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
insulin	B-T058
secretion	I-T058
-	I-T058
sensitivity	I-T058
index	I-T058
-	I-T058
2	I-T058
(	O
-	O
0	O
.	O
26	O
,	O
P	O
=	O
0	O
.	O
043	O
)	O
,	O
and	O
free	B-T103
testosterone	I-T103
(	O
0	O
.	O
38	O
,	O
P	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
not	O
with	O
fasting	B-T033
glucose	I-T033
and	O
triglyceride	B-T033
levels	I-T033
.	O

ALT	B-T103
cutoff	O
≥24	O
IU	O
/	O
L	O
was	O
associated	O
with	O
all	O
these	O
parameters	O
,	O
including	O
fasting	B-T033
glucose	I-T033
(	O
P	O
=	O
0	O
.	O
021	O
)	O
and	O
triglyceride	B-T033
levels	I-T033
(	O
P	O
=	O
0	O
.	O
041	O
)	O
,	O
and	O
detected	O
more	O
women	B-T098
with	O
the	O
MetS	B-T038
(	O
59	O
.	O
2	O
%	O
vs	O
.	O

36	O
.	O
1	O
%	O
,	O
P	O
=	O
0	O
.	O
008	O
)	O
and	O
whole	B-T038
-	I-T038
body	I-T038
insulin	I-T038
resistance	I-T038
(	O
Matsuda	B-T170
index	I-T170
<	O
12	O
.	O
3	O
L	O
(	O
2	O
)	O
·	O
10	O
/	O
mmol	O
(	O
2	O
)	O
,	O
85	O
.	O
3	O
%	O
vs	O
.	O

51	O
.	O
9	O
%	O
,	O
P	O
=	O
0	O
.	O
004	O
)	O
.	O

Plasma	B-T058
ALT	I-T058
levels	I-T058
seem	O
to	O
be	O
a	O
strong	O
predictor	O
not	O
only	O
of	O
liver	B-T017
lipotoxicity	B-T038
but	O
also	O
of	O
systemic	B-T038
lipotoxic	I-T038
consequences	O
and	O
hyperandrogenemia	B-T033
in	O
women	B-T098
with	O
PCOS	B-T038
.	O

Although	O
it	O
requires	O
validation	B-T062
in	O
another	O
study	B-T062
,	O
an	O
ALT	B-T103
cutoff	O
of	O
≥24	O
IU	O
/	O
L	O
may	O
help	O
clinicians	B-T097
identify	O
women	B-T098
with	O
increased	O
metabolic	O
risks	O
.	O

Opioid	B-T103
Use	O
in	O
Chronic	B-T033
Pain	I-T033
Patients	O
with	O
Chronic	B-T038
Kidney	I-T038
Disease	I-T038
:	O
A	O
Systematic	B-T170
Review	I-T170

To	O
investigate	O
the	O
prevalence	O
of	O
chronic	B-T033
pain	I-T033
and	O
opioid	B-T103
management	B-T058
among	O
patients	O
with	O
chronic	B-T038
kidney	I-T038
disease	I-T038
(	O
CKD	B-T038
)	O
.	O

Systematic	B-T170
review	I-T170
.	O

A	O
systematic	O
search	O
was	O
performed	O
,	O
including	O
citations	O
from	O
1960	O
to	O
May	O
2015	O
.	O

The	O
review	O
highlights	O
methodological	O
quality	O
assessment	O
of	O
the	O
selected	O
studies	B-T170
;	O
prevalence	O
of	O
pain	B-T033
;	O
type	O
,	O
dose	O
,	O
and	O
reason	O
for	O
opioid	B-T103
use	O
;	O
effectiveness	O
of	O
pain	B-T058
control	I-T058
and	O
associated	O
adverse	B-T038
effects	I-T038
of	O
opioids	B-T103
in	O
CKD	B-T038
patients	O
.	O

Twelve	O
of	O
131	O
articles	O
met	O
inclusion	O
criteria	O
.	O

There	O
were	O
no	O
randomized	B-T062
controlled	I-T062
trials	I-T062
(	O
RCT	B-T062
)	O
evaluable	O
,	O
and	O
12	O
were	O
observational	B-T170
studies	I-T170
.	O

Out	O
of	O
12	O
studies	B-T170
,	O
four	O
were	O
of	O
high	O
quality	O
,	O
six	O
were	O
of	O
moderate	O
quality	O
,	O
and	O
the	O
remaining	O
two	O
were	O
low	O
-	O
quality	O
studies	B-T170
.	O

The	O
studies	B-T170
were	O
from	O
different	O
countries	B-T082
with	O
sample	O
size	O
ranging	O
from	O
10	O
to	O
12	O
,	O
782	O
.	O

Several	O
studies	B-T170
showed	O
a	O
high	O
prevalence	O
of	O
chronic	O
uncontrolled	B-T033
pain	I-T033
.	O

The	O
effectiveness	O
of	O
different	O
categories	O
of	O
opioids	B-T103
,	O
dose	O
,	O
duration	O
,	O
and	O
commonly	O
prescribed	O
opioids	B-T103
varied	O
across	O
studies	B-T170
.	O

Based	O
on	O
a	O
systematic	B-T170
review	I-T170
of	O
the	O
current	O
literature	O
,	O
there	O
is	O
fair	O
evidence	O
for	O
the	O
high	O
prevalence	O
of	O
chronic	B-T033
pain	I-T033
among	O
patients	O
with	O
CKD	B-T038
,	O
which	O
is	O
not	O
being	O
effectively	O
managed	O
,	O
probably	O
due	O
to	O
underprescription	O
of	O
analgesics	B-T103
or	O
opioids	B-T103
in	O
the	O
CKD	B-T038
population	O
.	O

Clinicians	B-T097
are	O
in	O
need	O
of	O
additional	O
and	O
well	O
-	O
designed	O
randomized	B-T062
control	I-T062
trials	I-T062
that	O
focus	O
on	O
the	O
indications	O
for	O
opioid	B-T103
therapy	B-T058
,	O
appropriate	O
opioid	B-T103
doses	O
and	O
dosing	O
intervals	O
,	O
outcomes	O
with	O
adequacy	O
of	O
symptom	B-T058
control	I-T058
,	O
and	O
reporting	O
on	O
the	O
incidence	O
of	O
adverse	B-T038
side	I-T038
effects	I-T038
.	O

Cognitive	B-T038
impairment	I-T038
in	O
first	O
-	O
episode	O
drug	O
-	O
naïve	O
patients	O
with	O
schizophrenia	B-T038
:	O
Relationships	O
with	O
serum	O
concentrations	O
of	O
brain	B-T103
-	I-T103
derived	I-T103
neurotrophic	I-T103
factor	I-T103
and	O
glial	B-T103
cell	I-T103
line	I-T103
-	I-T103
derived	I-T103
neurotrophic	I-T103
factor	I-T103

Evidence	O
suggests	O
that	O
brain	B-T103
-	I-T103
derived	I-T103
neurotrophic	I-T103
factor	I-T103
(	O
BDNF	B-T103
)	O
and	O
glial	B-T103
cell	I-T103
line	I-T103
-	I-T103
derived	I-T103
neurotrophic	I-T103
factor	I-T103
(	O
GDNF	B-T103
)	O
are	O
important	O
in	O
the	O
regulation	B-T038
of	I-T038
synaptic	I-T038
plasticity	I-T038
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
the	O
cognitive	O
processes	O
in	O
psychiatric	B-T038
disorders	I-T038
.	O

Our	O
work	O
aimed	O
at	O
exploring	O
the	O
associations	O
between	O
serum	B-T031
BDNF	B-T103
and	O
GDNF	B-T103
levels	O
and	O
cognitive	B-T038
functions	I-T038
in	O
first	O
-	O
episode	O
drug	O
-	O
naïve	O
(	O
FEDN	O
)	O
patients	O
with	O
schizophrenia	B-T038
.	O

The	O
BDNF	B-T103
and	O
GDNF	B-T103
levels	O
of	O
58	O
FEDN	O
patients	O
and	O
55	O
age	O
-	O
and	O
sex	O
-	O
matched	O
healthy	O
controls	O
were	O
measured	O
and	O
test	O
subjects	O
were	O
examined	O
using	O
several	O
neurocognitive	O
tests	O
including	O
the	O
verbal	B-T058
fluency	I-T058
test	I-T058
(	O
VFT	B-T058
)	O
,	O
the	O
trail	B-T170
making	I-T170
test	I-T170
(	O
TMT	B-T170
)	O
,	O
the	O
digit	B-T170
span	I-T170
test	I-T170
(	O
DST	B-T170
)	O
,	O
and	O
the	O
Stroop	B-T058
test	I-T058
.	O

Patients	O
performed	O
significantly	O
worse	O
than	O
controls	O
in	O
nearly	O
all	O
neurocognitive	O
performances	O
except	O
the	O
forward	O
subscale	O
part	O
of	O
the	O
DST	B-T170
.	O

BDNF	B-T103
levels	O
were	O
inversely	O
correlated	O
to	O
TMT	O
-	O
part	O
B	O
scores	O
and	O
positively	O
correlated	O
to	O
VFT	B-T058
-	I-T058
action	I-T058
in	O
the	O
FEDN	O
group	O
.	O

GDNF	B-T103
levels	O
showed	O
a	O
positive	O
correlation	O
with	O
VFT	O
-	O
action	O
scores	O
and	O
a	O
negative	O
correlation	O
with	O
TMT	O
-	O
part	O
B	O
scores	O
of	O
these	O
patients	O
.	O

Current	O
data	O
suggests	O
that	O
cognitive	B-T038
dysfunction	I-T038
widely	O
exists	O
in	O
the	O
early	O
stages	O
of	O
schizophrenia	B-T038
.	O

BDNF	B-T103
and	O
GDNF	B-T103
may	O
be	O
jointly	O
contributed	O
to	O
the	O
pathological	O
mechanisms	O
involved	O
in	O
cognitive	B-T038
impairment	I-T038
in	O
FEDN	O
patients	O
with	O
schizophrenia	B-T038
.	O

Comprehensive	O
functional	B-T062
analysis	I-T062
of	O
large	O
lists	O
of	O
genes	B-T017
and	O
proteins	B-T103

The	O
interpretation	B-T170
of	O
high	B-T170
dimensional	I-T170
datasets	I-T170
resulting	O
from	O
genomic	B-T062
and	O
proteomic	B-T062
experiments	I-T062
in	O
a	O
timely	O
and	O
efficient	O
manner	O
is	O
challenging	O
.	O

ClueGO	B-T170
software	I-T170
is	O
a	O
Cytoscape	B-T170
App	I-T170
that	O
extracts	O
representative	O
functional	O
biological	O
information	O
for	O
large	O
lists	O
of	O
genes	B-T017
or	O
proteins	B-T103
.	O

The	O
functional	B-T062
enrichment	I-T062
analysis	I-T062
is	O
based	O
on	O
the	O
latest	O
publicly	O
available	O
data	O
from	O
multiple	O
annotation	B-T170
and	O
ontology	O
resources	O
that	O
can	O
be	O
automatically	O
accessed	B-T082
through	O
ClueGO	B-T170
.	O

Predefined	B-T170
settings	I-T170
for	O
the	O
selection	O
of	O
the	O
terms	O
are	O
provided	O
to	O
facilitate	O
the	O
analysis	B-T062
.	O

Results	O
are	O
visualized	O
as	O
networks	O
in	O
which	O
Gene	B-T170
Ontology	I-T170
(	O
GO	B-T170
)	O
terms	O
and	O
pathways	O
are	O
grouped	O
based	O
on	O
their	O
biological	O
role	O
.	O

Many	O
species	B-T170
are	O
now	O
supported	O
by	O
ClueGO	B-T170
and	O
additional	O
organisms	O
are	O
added	O
on	O
demand	O
.	O

ClueGO	B-T170
can	O
be	O
used	O
together	O
with	O
the	O
CluePedia	B-T170
App	I-T170
to	O
enable	O
the	O
visualization	O
of	O
protein	B-T038
-	I-T038
protein	I-T038
interactions	I-T038
within	O
or	O
between	O
pathways	O
.	O

Management	B-T058
of	O
precipitated	B-T038
opiate	I-T038
withdrawal	I-T038
syndrome	I-T038
induced	O
by	O
nalmefene	B-T103
mistakenly	O
prescribed	O
in	O
opiate	B-T103
-	O
dependent	O
patients	O
:	O
a	O
review	B-T170
for	O
clinicians	B-T097

Nalmefene	B-T103
,	O
a	O
long	B-T103
-	I-T103
acting	I-T103
µ	I-T103
-	I-T103
opioid	I-T103
antagonist	I-T103
approved	O
to	O
treat	O
alcohol	O
use	O
disorder	O
,	O
is	O
occasionally	O
mistakenly	O
prescribed	O
to	O
opiate	B-T103
-	O
dependent	O
or	O
opioid	B-T103
-	O
treated	O
patients	O
.	O

We	O
review	O
recent	O
literature	B-T170
on	O
drug	B-T038
-	I-T038
drug	I-T038
interactions	I-T038
between	O
nalmefene	B-T103
and	O
opioids	B-T103
that	O
lead	O
to	O
precipitated	B-T038
opioid	I-T038
withdrawal	I-T038
,	O
and	O
focus	O
on	O
its	O
management	B-T058
and	O
planning	O
for	O
care	B-T058
at	O
discharge	B-T058
.	O

Areas	O
covered	O
:	O
This	O
article	O
provides	O
a	O
brief	O
and	O
comprehensive	B-T058
review	I-T058
of	O
management	O
of	O
precipitated	B-T038
opioid	I-T038
withdrawal	I-T038
syndrome	I-T038
when	O
nalmefene	B-T103
is	O
associated	O
with	O
an	O
opioid	B-T103
,	O
whether	O
misused	B-T033
or	O
legally	O
prescribed	O
.	O

Expert	O
opinion	O
:	O
When	O
treating	O
an	O
opiate	B-T103
-	O
dependent	O
patient	O
with	O
co	O
-	O
occurring	O
alcohol	O
use	O
disorder	O
,	O
both	O
conditions	O
need	O
to	O
be	O
a	O
focus	O
of	O
clinical	O
attention	O
.	O

New	O
drugs	B-T103
for	O
alcohol	O
use	O
disorder	O
have	O
been	O
approved	O
,	O
but	O
must	O
be	O
given	O
cautiously	O
and	O
with	O
a	O
full	O
understanding	O
of	O
their	O
potential	O
drug	B-T038
-	I-T038
drug	I-T038
interactions	I-T038
with	O
opioid	B-T103
medications	B-T170
.	O

Opiate	B-T103
-	O
dependent	O
patients	O
should	O
be	O
intensively	O
monitored	O
for	O
risk	B-T033
factors	I-T033
of	O
alcohol	O
use	O
disorder	O
and	O
should	O
be	O
continuously	O
motivated	O
for	O
treatment	O
maintenance	O
.	O

When	O
nalmefene	B-T103
is	O
administered	B-T058
to	O
opiate	B-T103
-	O
dependent	O
patients	O
,	O
acute	O
opioid	B-T038
withdrawal	I-T038
syndrome	I-T038
may	O
occur	O
.	O

Management	B-T058
of	O
precipitated	O
acute	O
opioid	B-T038
withdrawal	I-T038
may	O
include	O
short	O
or	O
long	B-T038
-	I-T038
acting	I-T038
µ	I-T038
-	I-T038
opioid	I-T038
agonists	I-T038
during	O
hospitalization	B-T058
,	O
in	O
addition	O
to	O
supportive	B-T058
treatment	I-T058
.	O

The	O
best	O
management	B-T058
of	O
polydrug	B-T033
abusers	I-T033
is	O
based	O
on	O
a	O
multidisciplinary	B-T058
approach	I-T058
,	O
which	O
should	O
be	O
pursued	O
and	O
improved	B-T033
through	O
continuing	O
medical	O
education	O
.	O

Discovering	O
key	O
residues	O
of	O
dengue	B-T005
virus	I-T005
NS2b	B-T103
-	I-T103
NS3	I-T103
-	I-T103
protease	I-T103
:	O
New	O
binding	B-T103
sites	I-T103
for	O
antiviral	O
inhibitors	O
design	O

The	O
NS2B	B-T103
-	I-T103
NS3	I-T103
protease	I-T103
is	O
essential	O
for	O
the	O
Dengue	B-T005
Virus	I-T005
(	O
DENV	B-T005
)	O
replication	B-T038
process	I-T038
.	O

This	O
complex	B-T017
constitutes	O
a	O
target	O
for	O
efficient	O
antiviral	B-T103
discovery	O
because	O
a	O
drug	B-T103
could	O
inhibit	O
the	O
viral	B-T038
polyprotein	I-T038
processing	I-T038
.	O

Furthermore	O
,	O
since	O
the	O
protease	B-T103
is	O
highly	O
conserved	B-T082
between	O
the	O
four	O
Dengue	B-T005
virus	I-T005
serotypes	B-T170
,	O
it	O
is	O
probable	O
that	O
a	O
drug	B-T103
would	O
be	O
equally	O
effective	O
against	O
all	O
of	O
them	O
.	O

In	O
this	O
article	O
,	O
a	O
strategy	O
is	O
reported	O
that	O
allowed	O
us	O
to	O
identify	O
influential	O
residues	O
on	O
the	O
function	O
of	O
the	O
Dengue	B-T005
NS2b	B-T103
-	I-T103
NS3	I-T103
Protease	I-T103
.	O

Moreover	O
,	O
this	O
is	O
a	O
strategy	O
that	O
could	O
be	O
applied	O
to	O
virtually	O
any	O
protein	B-T103
for	O
the	O
search	O
of	O
alternative	O
influential	O
residues	O
,	O
and	O
for	O
non	O
-	O
competitive	O
inhibitor	O
development	O
.	O

First	O
,	O
we	O
incorporated	O
several	O
features	O
derived	O
from	O
computational	B-T091
alanine	B-T103
scanning	B-T062
mutagenesis	I-T062
,	O
sequence	B-T082
,	O
structure	B-T082
conservation	I-T082
,	O
and	O
other	O
structure	B-T082
-	O
based	O
characteristics	O
.	O

Second	O
,	O
these	O
features	O
were	O
used	O
as	O
variables	O
to	O
obtain	O
a	O
multilayer	B-T170
perceptron	I-T170
model	I-T170
to	O
identify	O
defined	O
groups	O
(	O
clusters	O
)	O
of	O
key	O
residues	O
as	O
possible	O
candidate	O
pockets	O
for	O
binding	B-T103
sites	I-T103
of	O
new	O
leads	O
on	O
the	O
DENV	B-T005
protease	B-T103
.	O

The	O
identified	O
residues	O
included	O
:	O
i	O
)	O
amino	B-T103
acids	I-T103
close	O
to	O
the	O
beta	B-T082
sheet	I-T082
-	O
loop	O
-	O
beta	B-T082
sheet	I-T082
known	O
to	O
be	O
important	O
in	O
its	O
closed	B-T082
conformation	I-T082
for	O
NS2b	B-T103
ii	O
)	O
residues	O
close	O
to	O
the	O
active	O
site	O
,	O
iii	O
)	O
several	O
residues	O
evenly	O
spread	O
on	O
the	O
NS2b	B-T103
-	I-T103
NS3	I-T103
contact	O
surface	O
,	O
and	O
iv	O
)	O
some	O
inner	O
residues	O
most	O
likely	O
related	O
to	O
the	O
overall	O
stability	O
of	O
the	O
protease	B-T103
.	O

In	O
addition	O
,	O
we	O
found	O
concordance	O
on	O
our	O
list	O
of	O
residues	O
with	O
previously	O
identified	O
amino	B-T103
acids	I-T103
part	O
of	O
a	O
highly	O
conserved	O
peptide	B-T103
studied	O
for	O
vaccine	B-T062
development	I-T062
.	O

Association	O
of	O
Toll	B-T103
-	I-T103
Like	I-T103
Receptor	I-T103
4	I-T103
on	O
Human	B-T204
Monocyte	B-T017
Subsets	B-T170
and	O
Vulnerability	O
Characteristics	O
of	O
Coronary	B-T017
Plaque	B-T033
as	O
Assessed	O
by	O
64	B-T058
-	I-T058
Slice	I-T058
Multidetector	I-T058
Computed	I-T058
Tomography	I-T058

Although	O
Toll	B-T103
-	I-T103
like	I-T103
receptor	I-T103
4	I-T103
(	O
TLR	B-T103
-	I-T103
4	I-T103
)	O
is	O
involved	O
in	O
monocyte	B-T038
activation	I-T038
in	O
patients	O
with	O
accelerated	O
forms	O
of	O
atherosclerosis	B-T038
,	O
the	O
relationship	O
between	O
the	O
expression	O
of	O
TLR	B-T103
-	I-T103
4	I-T103
on	O
circulating	O
monocyte	B-T017
s	O
and	O
coronary	B-T017
plaque	B-T033
vulnerability	O
has	O
not	O
previously	O
been	O
evaluated	B-T058
.	O

We	O
investigated	O
this	O
relationship	O
using	O
64	B-T058
-	I-T058
slice	I-T058
multidetector	I-T058
computed	I-T058
tomography	I-T058
(	O
MDCT	B-T058
)	O
in	O
patients	O
with	O
stable	B-T038
angina	I-T038
pectoris	I-T038
(	O
SAP	B-T038
)	O
.	O
Methods	O
and	O
Results	O
:	O
We	O
enrolled	O
65	O
patients	O
with	O
SAP	B-T038
who	O
underwent	O
MDCT	B-T058
.	O

Three	O
monocyte	B-T017
subsets	B-T170
(	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
-	I-T017
)	I-T017
,	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
,	O
and	O
CD14	B-T017
(	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
)	O
and	O
expression	O
of	O
TLR	B-T103
-	I-T103
4	I-T103
were	O
measured	O
by	O
flow	B-T058
cytometry	I-T058
.	O

Intracoronary	B-T017
plaques	B-T033
were	O
assessed	O
by	O
64	B-T058
-	I-T058
slice	I-T058
MDCT	I-T058
.	O

We	O
defined	O
vulnerability	O
of	O
intracoronary	B-T017
plaques	B-T033
according	O
to	O
the	O
presence	O
of	O
positive	B-T038
remodeling	I-T038
(	O
remodeling	B-T033
index	I-T033
>	O
1	O
.	O
05	O
)	O
and	O
/	O
or	O
low	O
CT	B-T058
attenuation	O
(	O
<	O
35	O
HU	O
)	O
.	O

The	O
circulating	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
monocytes	I-T017
more	O
frequently	O
expressed	O
TLR	B-T103
-	I-T103
4	I-T103
than	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
-	I-T017
)	I-T017
and	O
CD14	B-T017
(	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
monocytes	I-T017
(	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

The	O
relative	O
proportion	O
of	O
the	O
expression	O
of	O
TLR	B-T103
-	I-T103
4	I-T103
on	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
monocytes	I-T017
was	O
significantly	O
greater	O
in	O
patients	O
with	O
vulnerable	B-T033
plaque	I-T033
compared	O
with	O
those	O
without	O
(	O
10	O
.	O
4	O
[	O
4	O
.	O
1	O
-	O
14	O
.	O
5	O
]	O
%	O
vs	O
.	O

4	O
.	O
5	O
[	O
2	O
.	O
8	O
-	O
7	O
.	O
8	O
]	O
%	O
,	O
P	O
=	O
0	O
.	O
012	O
)	O
.	O

In	O
addition	O
,	O
the	O
relative	O
proportion	O
of	O
TLR	B-T103
-	I-T103
4	I-T103
expression	O
on	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
monocytes	I-T017
positively	O
correlated	O
with	O
the	O
remodeling	B-T033
index	I-T033
(	O
r	O
=	O
0	O
.	O
28	O
,	O
P	O
=	O
0	O
.	O
025	O
)	O
and	O
negatively	O
correlated	O
with	O
CT	B-T058
attenuation	O
value	O
(	O
r	O
=	O
-	O
0	O
.	O
31	O
,	O
P	O
=	O
0	O
.	O
013	O
)	O
.	O

Upregulation	B-T038
of	O
TLR	B-T103
-	I-T103
4	I-T103
on	O
CD14	B-T017
(	I-T017
+	I-T017
+	I-T017
)	I-T017
CD16	I-T017
(	I-T017
+	I-T017
)	I-T017
monocytes	I-T017
might	O
be	O
associated	O
with	O
coronary	B-T017
plaque	B-T033
vulnerability	O
in	O
patients	O
with	O
SAP	B-T038
.	O

Delta	B-T033
-	I-T033
frequency	I-T033
stimulation	O
of	O
cerebellar	B-T017
projections	B-T082
can	O
compensate	O
for	O
schizophrenia	B-T038
-	O
related	O
medial	O
frontal	O
dysfunction	O

Schizophrenia	B-T038
involves	O
abnormalities	B-T033
in	O
the	O
medial	B-T017
frontal	I-T017
cortex	I-T017
that	O
lead	O
to	O
cognitive	B-T038
deficits	I-T038
.	O

Here	O
we	O
investigate	O
a	O
novel	O
strategy	O
to	O
normalize	B-T062
medial	B-T017
frontal	I-T017
brain	I-T017
activity	B-T038
by	O
stimulating	O
cerebellar	B-T017
projections	B-T082
.	O

We	O
used	O
an	O
interval	O
timing	O
task	O
to	O
study	B-T062
elementary	O
cognitive	B-T038
processing	I-T038
that	O
requires	O
both	O
frontal	B-T017
and	O
cerebellar	B-T017
networks	I-T017
that	O
are	O
disrupted	O
in	O
patients	O
with	O
schizophrenia	B-T038
.	O

We	O
report	O
three	O
novel	O
findings	B-T033
.	O

First	O
,	O
patients	O
with	O
schizophrenia	B-T038
had	O
dysfunctional	O
delta	B-T038
rhythms	I-T038
between	O
1	O
-	O
4	O
Hz	O
in	O
the	O
medial	B-T017
frontal	I-T017
cortex	I-T017
.	O

We	O
explored	O
cerebellar	B-T017
-	O
frontal	B-T017
interactions	O
in	O
animal	B-T204
models	I-T204
and	O
found	O
that	O
both	O
frontal	B-T017
and	O
cerebellar	B-T017
neurons	I-T017
were	O
modulated	B-T082
during	O
interval	O
timing	O
and	O
had	O
delta	B-T033
-	I-T033
frequency	I-T033
interactions	O
.	O

Finally	O
,	O
delta	B-T033
-	I-T033
frequency	I-T033
optogenetic	B-T062
stimulation	O
of	O
thalamic	B-T017
synaptic	B-T017
terminals	I-T017
of	O
lateral	B-T082
cerebellar	B-T017
projection	B-T082
neurons	B-T017
rescued	O
timing	O
performance	O
as	O
well	O
as	O
medial	B-T017
frontal	I-T017
activity	B-T038
in	O
a	O
rodent	B-T038
model	I-T038
of	O
schizophrenia	B-T038
-	I-T038
related	I-T038
frontal	O
dysfunction	O
.	O

These	O
data	O
provide	O
insight	O
into	O
how	O
the	O
cerebellum	B-T017
influences	O
medial	B-T082
frontal	I-T082
networks	I-T082
and	O
the	O
role	O
of	O
the	O
cerebellum	B-T017
in	O
cognitive	B-T038
processing	I-T038
.	O

Variables	O
associated	O
with	O
unplanned	O
general	O
adult	O
ICU	B-T058
admission	I-T058
in	O
hospitalised	O
patients	O
:	O
protocol	B-T170
for	O
a	O
systematic	O
review	O

Failure	O
to	O
promptly	O
identify	O
deterioration	O
in	O
hospitalised	O
patients	O
is	O
associated	O
with	O
delayed	O
admission	B-T058
to	I-T058
intensive	I-T058
care	I-T058
units	I-T058
(	O
ICUs	B-T092
)	O
and	O
poor	O
outcomes	O
.	O

Existing	O
vital	B-T201
sign	I-T201
-	O
based	O
Early	O
Warning	O
Score	O
(	O
EWS	O
)	O
algorithms	B-T170
do	O
not	O
have	O
a	O
sufficiently	O
high	O
positive	O
predictive	O
value	O
to	O
be	O
used	O
for	O
automated	O
activation	O
of	O
an	O
ICU	B-T092
outreach	B-T097
team	I-T097
.	O

Incorporating	O
additional	O
patient	O
data	O
might	O
improve	B-T033
the	O
predictive	O
power	O
of	O
EWS	O
algorithms	B-T170
;	O
however	O
,	O
it	O
is	O
currently	O
not	O
known	O
which	O
patient	O
data	O
(	O
or	O
variables	O
)	O
are	O
most	O
predictive	O
of	O
ICU	B-T058
admission	I-T058
.	O

We	O
describe	O
the	O
protocol	B-T170
for	O
a	O
systematic	O
review	O
of	O
variables	O
associated	O
with	O
ICU	B-T058
admission	I-T058
.	O

MEDLINE	B-T170
,	O
EMBASE	B-T170
,	O
CINAHL	B-T170
and	O
the	O
Cochrane	B-T170
Library	I-T170
,	O
including	O
Cochrane	B-T170
Database	I-T170
of	I-T170
Systematic	I-T170
Reviews	I-T170
and	O
the	O
Cochrane	B-T170
Central	I-T170
Register	I-T170
of	I-T170
Controlled	I-T170
Trials	I-T170
(	B-T170
CENTRAL	I-T170
)	I-T170
will	O
be	O
searched	O
for	O
studies	B-T062
that	O
assess	O
the	O
association	O
of	O
routinely	O
recorded	B-T170
variables	O
associated	O
with	O
subsequent	O
unplanned	O
ICU	B-T058
admission	I-T058
.	O

Only	O
studies	B-T062
involving	O
adult	O
patients	O
admitted	B-T058
to	I-T058
general	B-T082
ICUs	B-T092
will	O
be	O
included	O
.	O

We	O
will	O
extract	O
data	O
relating	O
to	O
the	O
statistical	B-T062
association	I-T062
between	O
ICU	B-T058
admission	I-T058
and	O
predictor	O
variables	O
,	O
the	O
quality	O
of	O
the	O
studies	B-T062
and	O
the	O
generalisability	B-T082
of	O
the	O
findings	B-T033
.	O

The	O
results	O
of	O
this	O
review	O
will	O
aid	O
the	O
development	O
of	O
future	O
models	B-T170
which	O
predict	O
the	O
risk	O
of	O
unplanned	O
ICU	B-T058
admission	I-T058
.	O

PROSPERO	O
:	O
CRD42015029617	O
.	O

Diagnosis	B-T033
of	O
retinal	B-T017
health	O
in	O
digital	B-T058
fundus	I-T058
images	I-T058
using	O
continuous	B-T062
wavelet	I-T062
transform	I-T062
(	O
CWT	B-T062
)	O
and	O
entropies	O

Vision	B-T038
is	O
paramount	O
to	O
humans	B-T204
to	O
lead	O
an	O
active	O
personal	O
and	O
professional	O
life	O
.	O

The	O
prevalence	O
of	O
ocular	B-T038
diseases	I-T038
is	O
rising	O
,	O
and	O
diseases	B-T038
such	O
as	O
glaucoma	B-T038
,	O
Diabetic	B-T038
Retinopathy	I-T038
(	O
DR	B-T038
)	O
and	O
Age	B-T038
-	I-T038
related	I-T038
Macular	I-T038
Degeneration	I-T038
(	O
AMD	B-T038
)	O
are	O
the	O
leading	O
causes	O
of	O
blindness	B-T033
in	O
developed	O
countries	O
.	O

Identifying	O
these	O
diseases	B-T038
in	O
mass	B-T058
screening	I-T058
programmes	I-T058
is	O
time	O
-	O
consuming	O
,	O
labor	O
-	O
intensive	O
and	O
the	O
diagnosis	B-T033
can	O
be	O
subjective	O
.	O

The	O
use	O
of	O
an	O
automated	B-T058
computer	I-T058
aided	I-T058
diagnosis	I-T058
system	I-T058
will	O
reduce	O
the	O
time	O
taken	O
for	O
analysis	B-T062
and	O
will	O
also	O
reduce	O
the	O
inter	O
-	O
observer	O
subjective	O
variabilities	O
in	O
image	B-T058
interpretation	I-T058
.	O

In	O
this	O
work	O
,	O
we	O
propose	O
one	O
such	O
system	O
for	O
the	O
automatic	O
classification	B-T170
of	O
normal	O
from	O
abnormal	B-T033
(	O
DR	B-T038
,	O
AMD	B-T038
,	O
glaucoma	B-T038
)	O
images	O
.	O

We	O
had	O
a	O
total	O
of	O
404	O
normal	O
and	O
1082	O
abnormal	B-T033
fundus	B-T058
images	I-T058
in	O
our	O
database	B-T170
.	O

As	O
the	O
first	O
step	O
,	O
2D	B-T062
-	I-T062
Continuous	I-T062
Wavelet	I-T062
Transform	I-T062
(	O
CWT	B-T062
)	O
decomposition	O
on	O
the	O
fundus	B-T058
images	I-T058
of	O
two	O
classes	O
was	O
performed	O
.	O

Subsequently	O
,	O
energy	O
features	O
and	O
various	O
entropies	O
namely	O
Yager	O
,	O
Renyi	O
,	O
Kapoor	O
,	O
Shannon	O
,	O
and	O
Fuzzy	O
were	O
extracted	O
from	O
the	O
decomposed	O
images	O
.	O

Then	O
,	O
adaptive	O
synthetic	O
sampling	B-T170
approach	I-T170
was	O
applied	O
to	O
balance	O
the	O
normal	O
and	O
abnormal	B-T033
datasets	B-T170
.	O

Next	O
,	O
the	O
extracted	O
features	O
were	O
ranked	O
according	O
to	O
the	O
significances	O
using	O
Particle	B-T170
Swarm	I-T170
Optimization	I-T170
(	O
PSO	B-T170
)	O
.	O

Thereupon	O
,	O
the	O
ranked	O
and	O
selected	O
features	O
were	O
used	O
to	O
train	O
the	O
random	O
forest	O
classifier	O
using	O
stratified	O
10	O
-	O
fold	O
cross	B-T062
validation	I-T062
.	O

Overall	O
,	O
the	O
proposed	O
system	O
presented	O
a	O
performance	O
rate	O
of	O
92	O
.	O
48	O
%	O
,	O
and	O
a	O
sensitivity	O
and	O
specificity	O
of	O
89	O
.	O
37	O
%	O
and	O
95	O
.	O
58	O
%	O
respectively	O
using	O
15	O
features	O
.	O

This	O
novel	O
system	O
shows	O
promise	O
in	O
detecting	O
abnormal	B-T033
fundus	B-T058
images	I-T058
,	O
and	O
hence	O
,	O
could	O
be	O
a	O
valuable	O
adjunct	O
eye	B-T017
health	O
screening	B-T058
tool	I-T058
that	O
could	O
be	O
employed	O
in	O
polyclinics	B-T092
,	O
and	O
thereby	O
reduce	O
the	O
workload	O
of	O
specialists	B-T097
at	O
hospitals	B-T092
.	O

The	O
epigenetic	B-T038
landscape	I-T038
of	O
age	O
-	O
related	O
diseases	B-T038
:	O
the	O
geroscience	O
perspective	O

In	O
this	O
review	B-T170
,	O
we	O
summarize	O
current	O
knowledge	O
regarding	O
the	O
epigenetics	B-T038
of	O
age	O
-	O
related	O
diseases	B-T038
,	O
focusing	O
on	O
those	O
studies	B-T062
that	O
have	O
described	O
DNA	B-T038
methylation	I-T038
landscape	I-T038
in	O
cardio	B-T038
-	I-T038
vascular	I-T038
diseases	I-T038
,	O
musculoskeletal	B-T038
function	I-T038
and	O
frailty	B-T033
.	O

We	O
stress	O
the	O
importance	O
of	O
adopting	O
the	O
conceptual	O
framework	O
of	O
"	O
geroscience	O
"	O
,	O
which	O
starts	O
from	O
the	O
observation	O
that	O
advanced	B-T098
age	O
is	O
the	O
major	O
risk	B-T033
factor	I-T033
for	O
several	O
of	O
these	O
pathologies	O
and	O
aims	O
at	O
identifying	O
the	O
mechanistic	O
links	O
between	O
aging	B-T038
and	O
age	O
-	O
related	O
diseases	B-T038
.	O

DNA	B-T038
methylation	I-T038
undergoes	O
a	O
profound	O
remodeling	O
during	O
aging	B-T038
,	O
which	O
includes	O
global	B-T038
hypomethylation	I-T038
of	O
the	O
genome	B-T017
,	O
hypermethylation	B-T038
at	O
specific	O
loci	B-T017
and	O
an	O
increase	O
in	O
inter	O
-	O
individual	O
variation	O
and	O
in	O
stochastic	O
changes	O
of	O
DNA	B-T038
methylation	I-T038
values	O
.	O

These	O
epigenetic	B-T038
modifications	B-T033
can	O
be	O
an	O
important	O
contributor	O
to	O
the	O
development	O
of	O
age	O
-	O
related	O
diseases	B-T038
,	O
but	O
our	O
understanding	O
on	O
the	O
complex	O
relationship	O
between	O
the	O
epigenetic	B-T038
signatures	I-T038
of	O
aging	B-T038
and	O
age	O
-	O
related	O
disease	B-T038
is	O
still	O
poor	O
.	O

The	O
most	O
relevant	O
results	B-T033
in	O
this	O
field	O
come	O
from	O
the	O
use	O
of	O
the	O
so	O
called	O
"	O
epigenetics	B-T038
clocks	I-T038
"	O
in	O
cohorts	B-T098
of	O
subjects	B-T098
affected	O
by	O
age	O
-	O
related	O
diseases	B-T038
.	O

We	O
report	O
these	O
studies	B-T062
in	O
final	O
section	O
of	O
this	O
review	B-T170
.	O

Beneficial	O
Effects	O
of	O
Phyllanthus	B-T204
amarus	I-T204
Against	O
High	B-T168
Fructose	I-T168
Diet	I-T168
Induced	O
Insulin	B-T038
Resistance	I-T038
and	O
Hepatic	B-T038
Oxidative	I-T038
Stress	I-T038
in	O
Male	O
Wistar	B-T204
Rats	I-T204

Insulin	B-T038
resistance	I-T038
(	O
IR	B-T038
)	O
is	O
a	O
characteristic	O
feature	O
of	O
obesity	B-T038
,	O
type	B-T038
2	I-T038
diabetes	I-T038
mellitus	I-T038
,	O
and	O
cardiovascular	B-T038
diseases	I-T038
.	O

Emerging	O
evidence	O
suggests	O
that	O
the	O
high	B-T103
-	I-T103
fructose	I-T103
consumption	B-T038
is	O
a	O
potential	O
and	O
important	O
factor	O
responsible	O
for	O
the	O
rising	O
incidence	O
of	O
IR	B-T038
.	O

The	O
present	O
study	B-T062
investigates	O
the	O
beneficial	O
effects	O
of	O
aqueous	O
extract	O
of	O
Phyllanthus	B-T204
amaru	I-T204
s	O
(	O
PAAE	O
)	O
on	O
IR	B-T038
and	O
oxidative	B-T038
stress	I-T038
in	O
high	B-T103
-	I-T103
fructose	I-T103
(	O
HF	B-T103
)	O
fed	O
male	O
Wistar	B-T204
rats	I-T204
.	O

HF	B-T168
diet	I-T168
(	O
66	O
%	O
of	O
fructose	O
)	O
and	O
PAAE	O
(	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
)	O
were	O
given	O
concurrently	O
to	O
the	O
rats	B-T204
for	O
a	O
period	O
of	O
60	O
days	O
.	O

Fructose	O
-	O
fed	O
rats	B-T204
showed	O
weight	B-T033
gain	I-T033
,	O
hyperglycemia	B-T038
,	O
hyperinsulinemia	B-T038
,	O
impaired	B-T038
glucose	I-T038
tolerance	I-T038
,	O
impaired	B-T038
insulin	I-T038
sensitivity	I-T038
,	O
dyslipidemia	B-T038
,	O
hyperleptinemia	B-T038
,	O
and	O
hypoadiponectinemia	B-T038
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
60	O
days	O
.	O

Co	B-T058
-	I-T058
administration	I-T058
of	O
PAAE	O
along	O
with	O
HF	B-T168
diet	I-T168
significantly	O
ameliorated	O
all	O
these	O
alterations	O
.	O

Regarding	O
hepatic	B-T082
antioxidant	B-T038
status	I-T038
,	O
higher	O
lipid	B-T038
peroxidation	I-T038
and	O
protein	B-T038
oxidation	I-T038
,	O
lower	O
reduced	B-T033
glutathione	I-T033
levels	O
and	O
lower	B-T038
activities	I-T038
of	O
enzymatic	B-T103
antioxidants	I-T103
,	O
and	O
the	O
histopathological	O
changes	O
like	O
mild	O
to	O
severe	O
distortion	O
of	O
the	O
normal	O
architecture	O
as	O
well	O
as	O
the	O
prominence	O
and	O
widening	O
of	O
the	O
liver	B-T017
sinusoids	I-T017
observed	O
in	O
the	O
HF	B-T168
diet	I-T168
-	O
fed	O
rats	B-T204
were	O
significantly	O
prevented	O
by	O
PAAE	O
treatment	B-T058
.	O

These	O
findings	O
indicate	O
that	O
PAAE	O
is	O
beneficial	O
in	O
improving	O
insulin	B-T038
sensitivity	I-T038
and	O
attenuating	O
metabolic	B-T038
syndrome	I-T038
and	O
hepatic	B-T038
oxidative	I-T038
stress	I-T038
in	O
fructose	O
-	O
fed	O
rats	B-T204
.	O

Environmental	O
factors	O
and	O
hypertension	B-T038

Environmental	O
factors	O
are	O
a	O
major	O
cause	O
of	O
poor	O
health	O
worldwide	B-T098
.	O

The	O
most	O
solid	O
evidence	O
is	O
for	O
air	O
pollution	O
,	O
leading	O
to	O
increased	O
disability	O
-	O
adjusted	O
life	O
years	O
.	O

Outdoor	O
temperature	O
and	O
other	O
seasonal	O
climate	O
changes	O
may	O
also	O
influence	O
cardiovascular	B-T082
health	O
,	O
according	O
to	O
their	O
direct	O
modulation	O
of	O
air	O
pollution	O
.	O

Moreover	O
,	O
an	O
increasing	O
body	O
of	O
evidence	O
associates	O
environmental	B-T037
exposure	I-T037
to	O
noise	O
with	O
poor	B-T033
cardiovascular	I-T033
outcome	I-T033
,	O
and	O
in	O
particular	O
with	O
hypertension	B-T038
.	O

This	O
review	O
is	O
aimed	O
at	O
reviewing	O
current	O
evidence	O
about	O
the	O
role	O
of	O
these	O
environmental	O
factors	O
in	O
cardiovascular	B-T038
disease	I-T038
and	O
specifically	O
hypertension	B-T038
.	O

In	O
particular	O
,	O
the	O
impact	O
of	O
air	O
pollution	O
,	O
with	O
its	O
short	O
-	O
term	O
and	O
long	O
-	O
term	O
effects	O
,	O
the	O
outdoor	O
temperature	O
and	O
noise	O
pollution	O
will	O
be	O
investigated	O
.	O

People	B-T098
belonging	O
to	O
low	O
social	O
classes	O
,	O
as	O
well	O
as	O
children	O
,	O
women	B-T098
,	O
older	O
people	O
and	O
those	O
with	O
established	O
cardiovascular	B-T038
diseases	I-T038
,	O
seem	O
to	O
have	O
a	O
greater	O
susceptibility	O
to	O
the	O
effects	O
of	O
environmental	O
stressors	O
,	O
recalling	O
the	O
concept	O
of	O
"	O
environmental	O
justice	O
"	O
.	O

The	O
accumulating	O
strong	O
scientific	O
evidence	O
may	O
thus	O
support	O
public	O
health	O
policies	O
aimed	O
at	O
reducing	O
social	O
inequalities	O
in	O
cardiovascular	B-T082
health	O
.	O

The	O
effects	O
of	O
probiotic	B-T007
and	O
synbiotic	B-T168
supplementation	B-T058
on	O
metabolic	B-T038
syndrome	I-T038
indices	O
in	O
adults	O
at	O
risk	O
of	O
type	B-T038
2	I-T038
diabetes	I-T038
:	O
study	B-T170
protocol	I-T170
for	O
a	O
randomized	B-T062
controlled	I-T062
trial	I-T062

The	O
incidence	O
of	O
type	B-T038
2	I-T038
diabetes	I-T038
,	O
cardiovascular	B-T038
diseases	I-T038
,	O
and	O
obesity	B-T038
has	O
been	O
rising	O
dramatically	O
;	O
however	O
,	O
their	O
pathogenesis	B-T038
is	O
particularly	O
intriguing	B-T038
.	O

Recently	O
,	O
dysbiosis	B-T038
of	O
the	O
intestinal	O
microbiota	O
has	O
emerged	O
as	O
a	O
new	O
candidate	O
that	O
may	O
be	O
linked	O
to	O
metabolic	B-T038
diseases	I-T038
.	O

We	O
hypothesize	O
that	O
selective	O
modulation	O
of	O
the	O
intestinal	O
microbiota	O
by	O
probiotic	B-T007
or	O
synbiotic	B-T168
supplementation	B-T058
may	O
improve	O
metabolic	B-T038
dysfunction	I-T038
and	O
prevent	O
diabetes	B-T038
in	O
prediabetics	B-T038
.	O

In	O
this	O
study	B-T062
,	O
a	O
synthesis	O
and	O
study	B-T062
of	O
synbiotics	B-T168
will	O
be	O
carried	O
out	O
for	O
the	O
first	O
time	O
in	O
Iran	B-T082
.	O

In	O
a	O
randomized	B-T062
triple	I-T062
-	I-T062
blind	I-T062
controlled	I-T062
clinical	I-T062
trial	I-T062
,	O
120	O
adults	O
with	O
impaired	B-T038
glucose	I-T038
tolerance	I-T038
based	O
on	O
the	O
inclusion	O
criteria	O
will	O
be	O
selected	O
by	O
a	O
simple	O
random	O
sampling	B-T170
method	I-T170
and	O
will	O
be	O
randomly	O
allocated	O
to	O
6	O
months	O
of	O
6	O
g	O
/	O
d	O
probiotic	B-T007
,	O
synbiotic	B-T168
or	O
placebo	B-T103
.	O

The	O
fecal	B-T031
abundance	O
of	O
bacteria	B-T007
,	O
blood	B-T038
pressure	I-T038
,	O
height	O
,	O
weight	O
,	O
and	O
waist	B-T201
and	O
hip	B-T201
circumferences	I-T201
will	O
be	O
measured	O
at	O
baseline	O
and	O
following	O
treatment	B-T058
.	O

Also	O
,	O
plasma	O
lipid	O
profiles	O
,	O
HbA1C	B-T103
,	O
fasting	B-T058
plasma	I-T058
glucose	I-T058
,	O
and	O
insulin	B-T103
levels	O
,	O
will	O
be	O
measured	O
and	O
insulin	B-T058
resistance	I-T058
(	O
HOMA	B-T058
-	I-T058
IR	I-T058
)	O
and	O
beta	B-T058
-	I-T058
cell	I-T058
function	I-T058
(	O
HOMA	B-T058
-	I-T058
B	I-T058
)	O
will	O
be	O
calculated	O
at	O
baseline	O
and	O
will	O
be	O
repeated	O
at	O
months	O
3	O
,	O
6	O
,	O
12	O
,	O
and	O
18	O
.	O

The	O
data	O
will	O
be	O
compared	O
within	O
and	O
between	O
groups	O
using	O
statistical	B-T062
methods	I-T062
.	O

The	O
results	O
of	O
this	O
trial	B-T062
could	O
contribute	O
to	O
the	O
evidence	B-T170
-	I-T170
based	I-T170
clinical	I-T170
guidelines	I-T170
that	O
address	O
gut	O
microbiota	O
manipulation	B-T058
to	O
maximize	O
health	O
benefits	O
in	O
prevention	B-T058
and	O
management	B-T058
of	O
metabolic	B-T038
syndrome	I-T038
in	O
prediabetes	B-T038
.	O

Iranian	B-T170
Registry	I-T170
of	O
Clinical	B-T062
Trials	I-T062
:	O
IRCT201511032321N2	B-T170
.	O

Registered	O
on	O
27	O
February	O
2016	O
.	O

Evaluation	O
of	O
the	O
relationship	O
between	O
the	O
static	O
measurement	O
of	O
transverse	B-T082
arch	I-T082
flexibility	O
of	O
the	O
forefoot	B-T017
and	O
gait	B-T033
parameters	O
in	O
healthy	B-T098
subjects	I-T098

[	O
Purpose	O
]	O
To	O
investigate	O
the	O
relationship	O
between	O
the	O
static	O
measurement	O
of	O
the	O
transverse	B-T082
arch	I-T082
of	O
the	O
forefoot	B-T017
,	O
using	O
a	O
3	B-T082
-	I-T082
dimensional	I-T082
(	O
3D	B-T082
)	O
foot	O
scanner	O
,	O
and	O
kinetics	O
and	O
kinematics	B-T091
of	O
gait	B-T033
parameters	O
in	O
the	O
sagittal	B-T082
plane	I-T082
.	O

[	O
Subjects	B-T098
and	O
Methods	B-T170
]	O
Twenty	O
healthy	B-T098
subjects	I-T098
participated	O
in	O
this	O
study	B-T062
.	O

The	O
transverse	B-T082
arch	I-T082
of	O
the	O
forefoot	B-T017
was	O
measured	O
under	O
three	O
conditions	O
as	O
follows	O
:	O
condition	O
1	O
,	O
sitting	B-T033
;	O
condition	O
2	O
,	O
standing	B-T082
;	O
and	O
condition	O
3	O
,	O
foot	B-T017
forward	B-T082
and	O
lower	B-T017
leg	I-T017
tilting	O
anteriorly	B-T082
to	O
the	O
maximum	O
position	B-T082
with	O
heel	B-T082
contact	O
.	O

Gait	B-T033
parameters	O
were	O
recorded	O
using	O
a	O
3D	O
motion	O
analysis	O
system	O
and	O
force	O
plate	O
.	O

Correlation	O
coefficients	O
between	O
TAF	O
for	O
each	O
comparison	O
of	O
conditions	O
and	O
gait	B-T033
parameters	O
were	O
calculated	O
using	O
the	O
Spearman	B-T062
correlation	I-T062
analysis	I-T062
.	O

[	O
Results	O
]	O
Rates	O
of	O
the	O
transverse	B-T082
arch	I-T082
of	O
the	O
forefoot	B-T017
width	O
and	O
height	O
between	O
condition	O
2	O
and	O
condition	O
3	O
were	O
significantly	O
correlated	O
with	O
the	O
anterior	B-T082
and	O
posterior	B-T082
component	O
of	O
ground	O
reaction	O
forces	O
,	O
the	O
hip	B-T082
joint	I-T082
extension	O
angle	B-T082
,	O
and	O
the	O
ankle	B-T082
plantar	B-T038
flexion	I-T038
moment	I-T038
.	O

[	O
Conclusion	O
]	O
Our	O
study	B-T062
'	I-T062
s	I-T062
findings	B-T033
indicated	B-T033
that	O
increased	O
stiffness	B-T033
of	O
the	O
transverse	B-T082
arch	I-T082
of	O
the	O
forefoot	B-T017
was	O
related	O
to	O
the	O
increase	O
in	O
ankle	B-T082
plantar	B-T038
moment	I-T038
,	O
and	O
decreased	O
stiffness	B-T033
of	O
the	O
transverse	B-T082
arch	I-T082
of	O
the	O
forefoot	B-T017
was	O
related	O
to	O
the	O
increase	O
in	O
hip	B-T082
joint	I-T082
extension	O
angle	B-T082
during	O
gait	B-T033
.	O

Management	B-T058
and	O
Case	B-T062
Outcome	I-T062
of	O
Gastric	O
Impaction	O
in	O
Four	O
Raptors	B-T204
:	O
A	O
Case	B-T062
Series	I-T062

Four	O
captive	O
raptors	B-T204
,	O
an	O
American	B-T204
kestrel	I-T204
(	O
Falco	B-T204
sparverius	I-T204
)	O
,	O
peregrine	B-T204
falcon	I-T204
(	O
Falco	B-T204
peregrinus	I-T204
)	O
,	O
golden	B-T204
eagle	I-T204
(	O
Aquila	B-T204
chrysaetos	I-T204
)	O
,	O
and	O
barn	B-T204
owl	I-T204
(	O
Tyto	B-T204
alba	I-T204
)	O
,	O
were	O
diagnosed	B-T033
with	O
ventricular	B-T017
and	O
/	O
or	O
proventricular	B-T017
foreign	B-T037
material	I-T037
impactions	B-T038
consisting	O
of	O
artificial	O
turf	O
substrate	O
,	O
paper	O
and	O
plastic	O
substrate	O
,	O
grass	B-T204
,	O
and	O
newspaper	B-T170
.	O

Partial	B-T038
or	I-T038
total	I-T038
anorexia	I-T038
was	O
reported	O
in	O
all	O
birds	B-T204
and	O
decreased	O
casting	B-T058
in	O
2	O
birds	B-T204
.	O

Survey	B-T170
radiographs	B-T058
confirmed	O
presence	O
of	O
gastric	B-T017
enlargement	B-T058
in	O
all	O
4	O
birds	B-T204
.	O

The	O
kestrel	B-T204
and	O
eagle	B-T204
were	O
treated	O
unsuccessfully	O
with	O
gastroscopy	B-T058
and	O
gastric	B-T058
lavage	I-T058
,	O
respectively	O
,	O
followed	O
by	O
surgical	B-T033
intervention	I-T033
to	O
remove	O
the	O
ventricular	B-T017
impactions	B-T038
.	O

Both	O
birds	B-T204
died	B-T033
of	I-T033
undetermined	I-T033
causes	I-T033
after	O
surgery	O
.	O

The	O
peregrine	B-T204
falcon	I-T204
died	B-T033
before	B-T058
medical	I-T058
or	O
surgical	B-T033
intervention	I-T033
was	O
started	O
,	O
and	O
the	O
owl	B-T204
was	O
managed	O
successfully	O
with	O
oral	O
mineral	O
oil	O
and	O
liquid	B-T058
diet	I-T058
to	O
facilitate	B-T037
egestion	I-T037
of	I-T037
the	I-T037
foreign	I-T037
material	I-T037
as	O
a	O
pellet	O
.	O

Lead	B-T037
poisoning	I-T037
was	O
suspected	O
as	O
the	O
predisposing	O
cause	O
for	O
foreign	B-T037
body	I-T037
ingestion	I-T037
in	O
the	O
eagle	B-T204
,	O
but	O
underlying	O
causes	O
for	O
pica	B-T038
in	O
the	O
other	O
birds	B-T204
were	O
not	O
determined	O
.	O

Radiographs	B-T058
can	O
provide	O
useful	O
diagnostic	O
information	O
in	O
sick	B-T033
raptors	B-T204
that	O
exhibit	B-T033
vomiting	I-T033
or	O
changes	B-T033
in	I-T033
appetite	I-T033
or	O
casting	B-T058
frequency	I-T058
,	O
and	O
may	O
help	O
guide	O
treatment	B-T058
decisions	I-T058
of	O
impacted	O
birds	B-T204
.	O

Careful	O
consideration	B-T033
of	O
substrate	O
,	O
enrichment	O
items	O
,	O
and	O
access	O
to	O
potential	O
foreign	B-T037
material	I-T037
that	I-T037
could	I-T037
be	I-T037
ingested	I-T037
may	O
be	O
the	O
best	O
pre	O
-	O
emptive	O
management	B-T058
strategy	I-T058
in	O
captive	O
raptors	B-T204
.	O

Anti	B-T033
-	I-T033
inflammatory	I-T033
activity	O
of	O
Elaeagnus	B-T204
angustifolia	I-T204
fruit	B-T103
extract	I-T103
on	O
rat	B-T204
paw	B-T017
edema	B-T033

The	O
Elaeagnus	B-T204
angustifolia	I-T204
fruit	B-T168
has	O
been	O
traditionally	O
used	O
in	O
Iranian	B-T082
herbal	B-T103
medicine	I-T103
to	O
treat	O
diarrhea	B-T033
and	O
rheumatoid	B-T038
arthritis	I-T038
.	O

In	O
the	O
present	O
study	O
,	O
the	O
effects	O
of	O
E	B-T204
.	I-T204

angustifolia	I-T204
fruit	B-T103
extract	I-T103
on	O
the	O
acute	O
and	O
chronic	O
phases	O
of	O
formalin	B-T103
-	O
induced	O
rat	B-T204
paw	B-T017
edema	B-T033
were	O
examined	B-T033
.	O

The	O
acute	O
and	O
chronic	O
anti	B-T033
-	I-T033
inflammatory	I-T033
effects	I-T033
of	O
E	B-T204
.	I-T204

angustifolia	I-T204
fruit	B-T103
extract	I-T103
were	O
investigated	O
through	O
the	O
subcutaneous	O
injection	O
of	O
100	O
μL	O
of	O
formalin	B-T103
(	O
2	O
.	O
5	O
%	O
)	O
into	O
a	O
rat	B-T204
'	I-T204
s	I-T204
hind	O
paw	B-T017
.	O

Thirty	O
minutes	O
before	O
the	O
procedure	O
,	O
the	O
experimental	O
groups	O
were	O
treated	O
intraperitoneally	B-T082
with	O
hydroalcoholic	B-T103
fruit	I-T103
extracts	I-T103
of	O
E	B-T204
.	I-T204

angustifolia	I-T204
(	O
concentrations	O
of	O
100	O
,	O
300	O
,	O
700	O
,	O
and	O
1000	O
mg	O
/	O
kg	O
)	O
;	O
sodium	B-T103
salicylate	I-T103
(	O
SS	B-T103
,	O
400	O
mg	O
/	O
kg	O
)	O
and	O
distilled	B-T103
water	I-T103
were	O
used	O
as	O
positive	B-T033
and	O
negative	B-T033
control	O
groups	O
,	O
respectively	O
.	O

Treatment	O
with	O
SS	B-T103
and	O
the	O
fruit	B-T103
extracts	I-T103
were	O
performed	O
daily	O
for	O
8	O
days	O
,	O
and	O
the	O
degree	O
of	O
edema	B-T033
was	O
measured	O
by	O
using	O
mercury	B-T074
plethysmometer	I-T074
and	O
digital	B-T074
caliper	I-T074
.	O

In	O
the	O
acute	O
anti	B-T033
-	I-T033
inflammatory	I-T033
study	B-T062
,	O
the	O
extract	O
showed	O
a	O
significant	O
anti	O
-	O
inflammatory	O
effect	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
of	O
1000	O
mg	O
/	O
kg	O
of	O
the	O
extract	O
was	O
significantly	O
different	O
compared	O
with	O
the	O
negative	B-T033
control	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
was	O
comparable	O
to	O
sodium	B-T103
salicylate	I-T103
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Results	O
from	O
the	O
chronic	O
study	B-T062
suggested	O
that	O
E	B-T204
.	I-T204

angustifolia	I-T204
extract	O
significantly	O
reduced	O
paw	B-T017
edema	B-T033
and	O
inflammation	B-T038
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
results	O
also	O
showed	O
that	O
the	O
measurement	O
by	O
digital	B-T074
caliper	I-T074
and	O
mercury	B-T074
plethysmometer	I-T074
were	O
both	O
reliable	O
and	O
might	O
be	O
applied	O
interchangeably	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

Phytochemical	B-T058
tests	I-T058
indicated	O
that	O
the	O
hydroalcoholic	B-T103
fruit	I-T103
extract	I-T103
of	O
E	B-T204
.	I-T204

angustifolia	I-T204
was	O
positive	B-T033
for	O
cardiac	B-T103
glycosides	I-T103
,	O
flavonoids	B-T103
,	O
terpenoids	B-T103
,	O
and	O
saponins	B-T103
.	O

Based	O
on	O
our	O
findings	B-T033
,	O
the	O
E	B-T204
.	I-T204

angustifolia	I-T204
fruit	B-T103
extract	I-T103
probably	O
has	O
acute	O
and	O
chronic	O
anti	B-T033
-	I-T033
inflammatory	I-T033
activities	O
to	O
support	O
its	O
applications	O
in	O
folk	B-T058
medicine	I-T058
.	O

Increased	O
cerebral	O
blood	O
volume	O
pulsatility	O
during	O
head	B-T082
-	I-T082
down	I-T082
tilt	I-T082
with	O
elevated	B-T033
carbon	I-T033
dioxide	I-T033
:	O
The	O
SPACECOT	B-T062
Study	I-T062

Astronauts	B-T097
aboard	O
the	O
International	O
Space	O
Station	O
(	O
ISS	O
)	O
have	O
exhibited	O
hyperopic	B-T038
shifts	I-T038
,	O
posterior	B-T082
eye	B-T017
globe	I-T017
flattening	O
,	O
dilated	B-T033
optic	B-T017
nerve	I-T017
sheaths	I-T017
,	O
and	O
even	O
optic	B-T038
disc	I-T038
swelling	I-T038
from	O
spaceflight	O
.	O

Elevated	B-T038
intracranial	I-T038
pressure	I-T038
(	O
ICP	B-T038
)	O
consequent	O
to	O
cephalad	B-T082
fluid	B-T038
shifts	I-T038
is	O
commonly	O
hypothesized	O
as	O
contributing	O
to	O
these	O
ocular	B-T033
changes	I-T033
.	O

Head	B-T082
-	I-T082
down	I-T082
tilt	I-T082
(	O
HDT	B-T082
)	O
is	O
frequently	O
utilized	O
as	O
an	O
Earth	B-T082
-	O
based	O
analog	O
to	O
study	O
similar	O
fluid	B-T038
shifts	I-T038
.	O

Sealed	B-T082
environments	I-T082
like	O
the	O
ISS	O
also	O
exhibit	O
elevated	O
carbon	B-T103
dioxide	I-T103
(	O
CO2	B-T103
)	O
,	O
a	O
potent	O
arteriolar	B-T103
vasodilator	I-T103
that	O
could	O
further	O
affect	O
cerebral	O
blood	O
volume	O
and	O
flow	B-T033
,	O
intracranial	B-T082
compliance	B-T033
,	O
and	O
ICP	B-T038
.	O

A	O
collaborative	B-T062
pilot	I-T062
study	I-T062
between	O
the	O
National	B-T092
Space	I-T092
Biomedical	I-T092
Research	I-T092
Institute	I-T092
and	O
the	O
German	B-T092
Aerospace	I-T092
Center	I-T092
tested	O
the	O
hypotheses	O
that	O
:	O
(	O
1	O
)	O
HDT	B-T082
and	O
elevated	O
CO2	B-T103
physiologically	O
interact	O
,	O
and	O
(	O
2	O
)	O
cerebrovascular	O
pulsatility	O
is	O
related	O
to	O
HDT	B-T082
and	O
/	O
or	O
elevated	O
CO2	B-T103
In	O
a	O
double	B-T062
-	I-T062
blind	I-T062
crossover	B-T062
study	I-T062
(	O
n	O
=	O
6	O
)	O
,	O
we	O
measured	O
cerebral	O
blood	O
volume	O
(	O
CBV	O
)	O
pulsatility	O
via	O
near	B-T058
-	I-T058
infrared	I-T058
spectroscopy	I-T058
,	O
alongside	O
non	O
-	O
invasive	O
ICP	B-T038
and	O
intraocular	B-T038
pressure	I-T038
(	O
IOP	B-T038
)	O
during	O
28	O
-	O
hr	O
-	O
12°	O
HDT	B-T082
at	O
both	O
nominal	O
(	O
0	O
.	O
04	O
%	O
)	O
and	O
elevated	O
(	O
0	O
.	O
5	O
%	O
)	O
ambient	O
CO2	B-T103
In	O
our	O
cohort	B-T098
,	O
CBV	O
pulsatility	O
increased	O
significantly	O
over	O
time	O
at	O
cardiac	B-T082
frequencies	O
(	O
0	O
.	O
031±0	O
.	O
009	O
μM	O
/	O
hr	O
increase	O
in	O
[	O
HbT	O
]	O
pulsatility	O
amplitude	B-T082
)	O
and	O
Mayer	O
wave	O
frequencies	O
(	O
0	O
.	O
019±0	O
.	O
005	O
μM	O
/	O
hr	O
increase	O
)	O
.	O

The	O
HDT	B-T082
-	O
CO2	B-T103
interaction	O
on	O
pulsatility	O
was	O
not	O
robust	O
,	O
but	O
rather	O
driven	O
by	O
an	O
individual	B-T098
.	O

Significant	O
differences	O
between	O
atmospheres	O
were	O
not	B-T033
detected	I-T033
in	O
ICP	B-T038
or	O
IOP	B-T038
.	O

Further	O
work	O
is	O
needed	O
to	O
reproduce	O
these	O
findings	O
in	O
a	O
larger	O
cohort	B-T098
,	O
to	O
determine	O
whether	O
a	O
"	B-T033
water	I-T033
hammer	I-T033
"	I-T033
effect	I-T033
in	O
cerebral	B-T017
pulsatility	O
is	O
also	O
present	O
during	O
spaceflight	O
,	O
and	O
whether	O
it	O
is	O
associated	O
with	O
ocular	B-T033
changes	I-T033
in	O
astronauts	B-T097
.	O

Shift	O
Work	O
Is	O
Associated	O
with	O
Metabolic	B-T038
Syndrome	I-T038
in	O
Young	O
Female	O
Korean	B-T098
Workers	O

Shift	O
work	O
is	O
associated	O
with	O
health	O
problems	O
,	O
including	O
metabolic	B-T038
syndrome	I-T038
.	O

This	O
study	B-T062
investigated	O
the	O
association	O
between	O
shift	O
work	O
and	O
metabolic	B-T038
syndrome	I-T038
in	O
young	O
workers	O
.	O

A	O
total	O
of	O
3	O
,	O
317	O
subjects	B-T098
aged	O
20	O
-	O
40	O
years	O
enrolled	O
in	O
the	O
2011	O
-	O
2012	O
Korean	B-T098
National	B-T062
Health	I-T062
and	I-T062
Nutrition	I-T062
Examination	I-T062
Survey	I-T062
were	O
divided	O
into	O
shift	B-T033
and	O
day	B-T033
workers	I-T033
.	O

We	O
conducted	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
and	O
calculated	O
odds	O
ratios	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
in	O
order	O
to	O
examine	B-T033
the	O
association	O
between	O
shift	O
work	O
and	O
metabolic	B-T038
syndrome	I-T038
.	O

The	O
prevalence	O
of	O
metabolic	B-T038
syndrome	I-T038
was	O
14	O
.	O
3	O
%	O
and	O
7	O
.	O
1	O
%	O
among	O
male	O
and	O
female	O
shift	B-T033
workers	I-T033
,	O
respectively	O
.	O

After	O
adjusting	O
for	O
confounding	O
factors	O
,	O
shift	O
work	O
was	O
associated	O
with	O
metabolic	B-T038
syndrome	I-T038
in	O
female	O
workers	O
(	O
odds	O
ratio	O
,	O
2	O
.	O
53	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1	O
.	O
12	O
to	O
5	O
.	O
70	O
)	O
.	O

Shift	O
work	O
was	O
associated	O
with	O
metabolic	B-T038
syndrome	I-T038
in	O
young	O
women	B-T098
.	O

Timely	O
efforts	O
are	O
necessary	O
to	O
manage	O
metabolic	B-T038
syndrome	I-T038
in	O
the	O
workplace	B-T082
.	O

In	O
Vitro	O
Differentiation	B-T038
of	O
Human	B-T204
Pluripotent	B-T017
Stem	I-T017
Cells	I-T017
into	O
Trophoblastic	B-T017
Cells	I-T017

The	O
placenta	B-T017
is	O
the	O
first	O
organ	B-T017
to	O
develop	O
during	O
embryogenesis	B-T038
and	O
is	O
required	O
for	O
the	O
survival	O
of	O
the	O
developing	O
embryo	B-T017
.	O

The	O
placenta	B-T017
is	O
comprised	O
of	O
various	O
trophoblastic	B-T017
cells	I-T017
that	O
differentiate	B-T038
from	O
the	O
extra	B-T038
-	I-T038
embryonic	I-T038
trophectoderm	I-T038
cells	I-T038
of	O
the	O
preimplantation	B-T038
blastocyst	B-T017
.	O

As	O
such	O
,	O
our	O
understanding	O
of	O
the	O
early	O
differentiation	B-T038
events	I-T038
of	O
the	O
human	B-T204
placenta	B-T017
is	O
limited	O
because	O
of	O
ethical	O
and	O
legal	O
restrictions	O
on	O
the	O
isolation	B-T058
and	O
manipulation	B-T058
of	O
human	B-T204
embryogenesis	B-T038
.	O

Human	B-T017
pluripotent	I-T017
stem	I-T017
cells	I-T017
(	O
hPSCs	B-T017
)	O
are	O
a	O
robust	O
model	B-T170
system	I-T170
for	O
investigating	O
human	B-T038
development	I-T038
and	O
can	O
also	O
be	O
differentiated	B-T038
in	O
vitro	O
into	O
trophoblastic	B-T017
cells	I-T017
that	O
express	O
markers	O
of	O
the	O
various	O
trophoblast	B-T017
cell	B-T017
types	I-T017
.	O

Here	O
,	O
we	O
present	O
a	O
detailed	O
protocol	O
for	O
differentiating	B-T038
hPSCs	B-T017
into	O
trophoblastic	B-T017
cells	I-T017
using	O
bone	B-T103
morphogenic	I-T103
protein	I-T103
4	I-T103
and	O
inhibitors	O
of	O
the	O
Activin	B-T103
/	O
Nodal	B-T038
signaling	I-T038
pathways	I-T038
.	O

This	O
protocol	O
generates	O
various	O
trophoblast	B-T017
cell	B-T017
types	I-T017
that	O
can	O
be	O
transfected	B-T062
with	O
siRNAs	B-T103
for	O
investigating	O
loss	O
-	O
of	O
-	O
function	O
phenotypes	O
or	O
can	O
be	O
infected	B-T033
with	O
pathogens	O
.	O

Additionally	O
,	O
hPSCs	B-T017
can	O
be	O
genetically	O
modified	O
and	O
then	O
differentiated	B-T038
into	O
trophoblast	B-T017
progenitors	B-T017
for	O
gain	O
-	O
of	O
-	O
function	O
analyses	O
.	O

This	O
in	O
vitro	O
differentiation	B-T038
method	I-T038
for	O
generating	O
human	B-T204
trophoblasts	B-T017
starting	O
from	O
hPSCs	B-T017
overcomes	O
the	O
ethical	O
and	O
legal	O
restrictions	O
of	O
working	O
with	O
early	O
human	B-T204
embryos	B-T017
,	O
and	O
this	O
system	O
can	O
be	O
used	O
for	O
a	O
variety	O
of	O
applications	O
,	O
including	O
drug	B-T062
discovery	I-T062
and	O
stem	B-T062
cell	I-T062
research	I-T062
.	O

Metabolomics	B-T103
analysis	B-T062
of	O
anaphylactoid	B-T038
reaction	I-T038
reveals	O
its	O
mechanism	O
in	O
a	O
rat	B-T204
model	B-T204

Anaphylactoid	B-T038
reactions	I-T038
,	O
accounting	O
for	O
more	O
than	O
77	O
%	O
of	O
all	O
immune	B-T038
-	I-T038
mediated	I-T038
immediate	I-T038
hypersensitivity	I-T038
reactions	I-T038
,	O
have	O
become	O
a	O
serious	O
threat	O
to	O
public	B-T058
health	I-T058
,	O
but	O
their	O
effect	O
mechanism	O
is	O
not	O
clear	O
and	O
diagnostic	B-T058
tests	I-T058
are	O
limited	O
.	O

Comprehensive	O
metabolite	B-T103
analysis	B-T062
may	O
reveal	O
the	O
anaphylactoid	O
effect	O
mechanism	O
systematically	O
and	O
provide	O
reference	O
for	O
future	O
diagnostic	O
purposes	O
.	O

Plasma	B-T031
from	O
Brown	B-T204
Norway	I-T204
rats	I-T204
given	O
intravenous	O
injection	O
of	O
saline	O
,	O
compound	B-T103
48	I-T103
/	I-T103
80	I-T103
(	O
2	O
.	O
5	O
mL	O
/	O
kg	O
)	O
or	O
ovalbumin	B-T103
(	O
20	O
mL	O
/	O
kg	O
)	O
in	O
20	O
s	O
for	O
the	O
first	O
time	O
was	O
used	O
to	O
study	B-T062
the	O
effect	O
mechanism	O
of	O
anaphylactoid	B-T038
reactions	I-T038
through	O
metabolomics	B-T103
(	O
UPLC	B-T062
-	I-T062
qTOF	I-T062
-	I-T062
MS	I-T062
/	I-T062
MS	I-T062
)	O
.	O

Metabolomics	B-T103
integrated	O
with	O
proteomics	B-T170
data	I-T170
were	O
used	O
to	O
analyze	B-T062
the	O
anaphylactoid	O
pathways	B-T038
by	O
MetaboAnalyst	B-T170
followed	O
by	O
integrated	O
pathway	B-T170
analysis	I-T170
.	O

Thirty	O
metabolites	B-T103
were	O
identified	O
through	O
the	O
METLIN	B-T170
database	I-T170
by	O
MS	B-T062
/	I-T062
MS	I-T062
and	O
18	O
of	O
them	O
were	O
confirmed	O
by	O
authentic	O
standards	O
.	O

The	O
results	O
showed	O
that	O
adenosine	B-T103
,	O
histamine	B-T103
,	O
N	B-T103
-	I-T103
acetylhistamine	I-T103
,	O
N	B-T103
(	I-T103
α	I-T103
)	I-T103
-	I-T103
γ	I-T103
-	I-T103
glutamylhistamine	I-T103
,	O
malate	B-T103
and	O
xanthine	B-T103
are	O
important	O
indices	O
for	O
anaphylactoid	B-T038
reactions	I-T038
.	O

It	O
could	O
be	O
concluded	O
that	O
the	O
effect	O
mechanism	O
is	O
mainly	O
composed	O
of	O
histidine	B-T038
metabolism	I-T038
,	O
arachidonic	B-T038
acid	I-T038
metabolism	I-T038
,	O
energy	B-T038
metabolism	I-T038
,	O
purine	O
metabolism	O
and	O
other	O
small	O
molecules	O
through	O
30	O
metabolites	B-T103
.	O

Multiple	O
linear	O
regression	O
analysis	O
indicated	B-T033
that	O
not	O
only	O
histamine	B-T103
but	O
also	O
N	B-T103
(	I-T103
α	I-T103
)	I-T103
-	I-T103
γ	I-T103
-	I-T103
glutamylhistamine	I-T103
and	O
arachidonic	B-T103
acid	I-T103
could	O
be	O
used	O
to	O
evaluate	O
anaphylactoid	O
symptoms	B-T033
of	O
animals	B-T204
.	O

Furthermore	O
,	O
the	O
citrate	B-T038
cycle	I-T038
,	O
histidine	B-T038
metabolism	I-T038
and	O
arachidonic	B-T038
acid	I-T038
metabolism	I-T038
could	O
be	O
the	O
main	O
pathways	B-T038
of	O
anaphylactoid	B-T038
reactions	I-T038
as	O
determined	O
by	O
MetaboAnalyst	B-T170
.	O

The	O
results	O
may	O
provide	O
a	O
reference	B-T170
to	O
improve	B-T033
diagnostic	O
accuracy	O
and	O
predict	O
and	O
monitor	O
treatment	O
efficacy	O
in	O
anaphylactoid	B-T038
reactions	I-T038
in	O
the	O
clinical	O
setting	O
.	O

The	O
Prevalence	O
of	O
Sleep	B-T038
Apnea	I-T038
in	O
Type	B-T017
B	I-T017
Aortic	I-T017
Dissection	I-T017
:	O
Implications	O
for	O
False	O
Lumen	B-T082
Thrombosis	B-T038

Obstructive	B-T038
sleep	I-T038
apnea	I-T038
(	O
OSA	B-T038
)	O
has	O
been	O
implicated	O
in	O
aortic	B-T038
dissection	I-T038
.	O

Thrombosis	B-T038
of	O
the	O
false	O
lumen	B-T082
is	O
associated	O
with	O
a	O
prognosis	B-T058
of	O
type	B-T017
B	I-T017
aortic	I-T017
dissection	I-T017
(	O
AoD	B-T017
)	O
,	O
and	O
partial	B-T017
thrombosis	I-T017
has	O
been	O
reported	O
to	O
be	O
an	O
independent	O
predictor	B-T170
of	O
mortality	O
.	O

This	O
study	B-T062
sought	O
to	O
explore	O
whether	O
the	O
severity	O
of	O
OSA	B-T038
is	O
associated	O
with	O
false	O
lumen	B-T082
thrombosis	B-T038
.	O

In	O
this	O
observational	B-T062
study	I-T062
,	O
151	O
type	B-T017
B	I-T017
AoD	I-T017
patients	O
were	O
recruited	O
consecutively	O
from	O
2013	O
to	O
2015	O
.	O

The	O
status	O
of	O
the	O
false	O
lumen	B-T082
was	O
classified	O
as	O
patent	O
,	O
partially	O
thrombosed	B-T038
,	O
or	O
completely	O
thrombosed	B-T038
based	O
on	O
a	O
computer	B-T058
tomography	I-T058
angiography	I-T058
image	O
.	O

Patients	O
were	O
divided	O
into	O
non	O
-	O
OSA	O
group	O
(	O
apnea	B-T170
-	I-T170
hypopnea	I-T170
index	I-T170
[	O
AHI	B-T170
]	O
<	O
5	O
)	O
,	O
and	O
mild	O
(	O
5	O
≤	O
AHI	B-T170
≤	O
15	O
)	O
,	O
moderate	O
(	O
15	O
<	O
AHI	B-T170
≤	O
30	O
)	O
,	O
and	O
severe	O
OSA	O
groups	O
(	O
AHI	B-T170
>	O
30	O
)	O
using	O
the	O
AHI	B-T170
.	O

The	O
prevalence	O
of	O
OSA	B-T038
in	O
type	B-T017
B	I-T017
dissection	I-T017
was	O
66	O
.	O
2	O
%	O
.	O

Among	O
151	O
cases	O
,	O
51	O
patients	O
(	O
33	O
.	O
8	O
%	O
)	O
were	O
in	O
the	O
non	O
-	O
OSA	O
group	O
,	O
56	O
(	O
37	O
.	O
1	O
%	O
)	O
were	O
in	O
the	O
mild	O
group	O
,	O
21	O
(	O
13	O
.	O
9	O
%	O
)	O
were	O
in	O
the	O
moderate	O
group	O
,	O
and	O
23	O
(	O
15	O
.	O
2	O
%	O
)	O
were	O
in	O
the	O
severe	O
group	O
.	O

Additionally	O
,	O
a	O
partially	O
thrombosed	B-T038
false	O
lumen	B-T082
was	O
observed	O
in	O
88	O
patients	O
(	O
58	O
.	O
3	O
%	O
)	O
.	O

Multivariable	O
analysis	O
revealed	O
that	O
OSA	B-T038
severity	O
was	O
positively	B-T033
associated	O
with	O
partial	O
thrombosis	B-T038
(	O
odds	O
ratio	O
,	O
1	O
.	O
784	O
,	O
95	O
%	O
confidence	O
interval	O
:	O
1	O
.	O
182	O
-	O
2	O
.	O
691	O
,	O
P	O
=	O
.	O
006	O
)	O
after	O
adjusting	O
for	O
other	O
confounding	O
factors	O
.	O

OSA	B-T038
was	O
present	O
in	O
two	O
-	O
thirds	O
of	O
patients	O
with	O
type	B-T017
B	I-T017
AoD	I-T017
.	O

The	O
severity	O
of	O
OSA	B-T038
was	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
partial	O
false	O
lumen	B-T082
thrombosis	B-T038
.	O

OSA	B-T038
may	O
therefore	O
be	O
implicated	O
in	O
both	O
the	O
etiology	O
and	O
prognosis	B-T058
of	O
AoD	B-T017
.	O

Contextual	B-T038
Factors	I-T038
for	O
Stunting	B-T038
Among	O
Children	O
of	O
Age	O
6	O
to	O
24	O
Months	O
in	O
an	O
Under	O
-	O
Privileged	O
Community	O
of	O
Dhaka	B-T082
,	O
Bangladesh	B-T082

To	O
determine	O
factors	O
associated	O
with	O
stunting	B-T038
among	O
children	O
aged	O
6	O
to	O
24	O
months	O
in	O
a	O
slum	O
of	O
Dhaka	B-T082
,	O
Bangladesh	B-T082
.	O

We	O
conducted	O
this	O
case	B-T062
control	I-T062
study	I-T062
during	O
November	O
2009	O
to	O
December	O
2012	O
.	O

Children	O
were	O
classified	O
as	O
case	O
if	O
length	O
-	O
for	O
-	O
age	O
Z	O
-	O
score	O
(	O
LAZ	O
)	O
was	O
<	O
-	O
2	O
and	O
as	O
control	O
if	O
LAZ	O
was	O
>	O
-	O
1	O
SD	O
.	O

The	O
logistic	O
regression	O
model	O
was	O
used	O
to	O
find	O
the	O
factors	O
associated	O
with	O
stunting	B-T038
.	O

The	O
significant	O
risk	B-T033
factors	I-T033
for	O
stunting	B-T038
were	O
:	O
child	O
'	O
s	O
age	O
>	O
12	O
months	O
,	O
maternal	O
undernutrition	B-T038
,	O
mother	B-T033
'	I-T033
s	I-T033
education	I-T033
<	O
5	O
years	O
,	O
consumption	B-T038
of	O
untreated	O
drinking	O
water	O
and	O
monthly	O
family	O
income	O
<	O
100	O
USD	O
.	O

The	O
findings	B-T033
of	O
this	O
study	B-T062
reiterated	O
the	O
role	O
of	O
maternal	O
undernutrition	B-T038
and	O
less	B-T033
education	I-T033
,	O
consumption	B-T038
of	O
untreated	O
drinking	O
water	O
and	O
poor	O
family	O
income	O
as	O
important	O
associated	O
factors	O
of	O
childhood	O
stunting	B-T038
in	O
resource	O
-	O
poor	O
setting	O
.	O

Most	O
Americans	B-T098
Have	O
Good	O
Health	O
,	O
Little	O
Unmet	O
Need	O
,	O
And	O
Few	O
Health	O
Care	O
Expenses	O

The	O
distribution	O
of	O
health	O
care	O
expenditures	O
remains	O
highly	O
concentrated	O
,	O
but	O
most	O
Americans	B-T098
use	O
few	O
health	O
care	O
resources	O
and	O
have	O
low	O
out	O
-	O
of	O
-	O
pocket	O
spending	O
.	O

More	O
than	O
93	O
percent	O
of	O
"	O
low	B-T098
spenders	I-T098
"	O
(	O
those	O
in	O
the	O
bottom	O
half	O
of	O
the	O
population	B-T098
)	O
believe	O
they	O
have	O
received	O
all	O
needed	O
care	B-T058
in	O
a	O
timely	O
manner	O
.	O

The	O
low	O
spending	O
by	O
the	O
majority	O
of	O
the	O
population	B-T098
has	O
remained	O
almost	O
unchanged	O
during	O
the	O
thirty	O
-	O
seven	O
-	O
year	O
period	O
examined	B-T033
.	O

Penile	B-T017
Erosion	I-T017
in	O
a	O
Paraplegic	B-T038
Man	B-T098
With	O
Indwelling	B-T074
Urinary	I-T074
Catheter	I-T074
and	O
Scrotal	B-T033
Edema	I-T033

The	O
chronic	O
use	O
of	O
urinary	B-T074
indwelling	I-T074
catheters	I-T074
is	O
a	O
common	O
practice	O
in	O
the	O
setting	O
of	O
long	O
-	O
term	O
patient	B-T058
care	I-T058
and	O
is	O
associated	O
with	O
numerous	O
complications	B-T038
.	O

More	O
awareness	B-T038
about	O
urogenital	B-T022
trauma	B-T037
from	O
urinary	B-T058
catheterization	I-T058
is	O
needed	O
,	O
as	O
it	O
is	O
as	O
common	O
as	O
symptomatic	O
urinary	B-T038
tract	I-T038
infections	I-T038
.	O

There	O
are	O
a	O
number	O
of	O
preventable	O
measures	O
that	O
can	O
be	O
taken	O
to	O
decrease	O
the	O
risk	O
of	O
mechanical	B-T037
trauma	I-T037
to	O
the	O
urethra	B-T017
and	O
glans	B-T017
penis	I-T017
caused	O
by	O
chronic	O
catheterization	B-T058
.	O

We	O
present	O
a	O
case	O
of	O
a	O
27	O
-	O
year	O
old	O
paraplegic	B-T038
male	O
needing	O
a	O
chronic	O
indwelling	B-T074
catheter	I-T074
that	O
acquired	O
ventral	B-T082
penile	B-T017
erosion	I-T017
while	O
being	O
cared	O
for	O
in	O
the	O
ICU	B-T092
setting	I-T092
.	O

Modified	O
anastomotic	B-T058
technique	I-T058
for	O
thoracolaparoscopic	B-T058
Ivor	I-T058
-	I-T058
Lewis	I-T058
esophagectomy	I-T058
:	O
early	O
outcomes	O
and	O
technical	O
details	O

Thoracoscopic	B-T058
intrathoracic	I-T058
esophagogastrostomy	I-T058
is	O
a	O
technically	O
demanding	O
operation	O
;	O
these	O
technical	O
requirements	O
restrict	O
the	O
extensive	O
application	O
of	O
minimally	O
invasive	O
Ivor	B-T058
-	I-T058
Lewis	I-T058
esophagectomy	I-T058
.	O

In	O
an	O
attempt	O
to	O
reduce	O
the	O
difficulty	O
of	O
this	O
surgical	B-T058
procedure	I-T058
,	O
this	O
study	O
developed	O
a	O
modified	O
anastomotic	B-T058
technique	I-T058
for	O
thoracolaparoscopic	B-T058
Ivor	I-T058
-	I-T058
Lewis	I-T058
esophagectomy	I-T058
.	O

During	O
the	O
entirety	O
of	O
this	O
modified	O
approach	O
,	O
neither	O
technically	O
challenging	O
operations	B-T058
such	O
as	O
intrathoracic	B-T058
suturing	I-T058
or	O
knotting	B-T058
,	O
nor	O
special	O
instruments	B-T074
such	O
as	O
an	O
OrVil	B-T074
system	I-T074
or	O
a	O
reverse	B-T074
-	I-T074
puncture	I-T074
head	I-T074
are	O
required	O
.	O

Between	O
October	O
2015	O
and	O
January	O
2016	O
,	O
15	O
consecutive	O
patients	O
with	O
cancer	B-T038
in	O
the	O
distal	B-T082
third	I-T082
of	I-T082
the	I-T082
esophagus	I-T082
or	O
the	O
gastric	B-T082
cardia	I-T082
underwent	O
this	O
modified	O
surgical	B-T058
procedure	I-T058
.	O

The	O
good	O
short	O
-	O
term	O
outcomes	O
that	O
were	O
achieved	O
suggest	O
that	O
the	O
modified	O
anastomotic	B-T058
technique	I-T058
is	O
safe	O
and	O
feasible	O
for	O
thoracolaparoscopic	B-T058
Ivor	I-T058
-	I-T058
Lewis	I-T058
esophagectomy	I-T058
.	O

Quantitative	O
analysis	O
of	O
cell	B-T038
proliferation	I-T038
by	O
a	O
dye	B-T058
dilution	I-T058
assay	I-T058
:	O
Application	O
to	O
cell	B-T017
lines	I-T017
and	O
cocultures	B-T058

Cell	B-T038
proliferation	I-T038
represents	O
one	O
of	O
the	O
most	O
fundamental	O
processes	B-T038
in	I-T038
biological	I-T038
systems	I-T038
,	O
thus	O
the	O
quantitative	O
analysis	O
of	O
cell	B-T038
proliferation	I-T038
is	O
important	O
in	O
many	O
biological	B-T091
applications	O
such	O
as	O
drug	B-T058
screening	I-T058
,	O
production	O
of	O
biologics	B-T103
,	O
and	O
assessment	B-T058
of	O
cytotoxicity	B-T038
.	O

Conventional	O
proliferation	B-T062
assays	I-T062
mainly	O
quantify	O
cell	B-T058
number	I-T058
based	O
on	O
a	O
calibration	O
curve	O
of	O
a	O
homogeneous	O
cell	B-T017
population	I-T017
,	O
and	O
therefore	O
are	O
not	O
applicable	O
for	O
the	O
analysis	B-T062
of	O
cocultured	B-T017
cells	I-T017
.	O

Moreover	O
,	O
these	O
assays	B-T058
measure	O
cell	B-T038
proliferation	I-T038
indirectly	O
,	O
based	O
on	O
cellular	B-T038
metabolic	I-T038
activity	I-T038
or	O
DNA	O
content	O
.	O

To	O
overcome	O
these	O
shortcomings	O
,	O
a	O
dye	B-T058
dilution	I-T058
assay	I-T058
employing	O
fluorescent	B-T103
cell	I-T103
tracking	I-T103
dyes	I-T103
that	O
are	O
retained	O
within	O
cells	B-T017
was	O
applied	O
and	O
was	O
diluted	O
proportionally	O
by	O
subsequent	O
cell	B-T038
divisions	I-T038
.	O

Here	O
,	O
it	O
was	O
demonstrated	O
that	O
this	O
assay	B-T058
could	O
be	O
implemented	O
to	O
quantitatively	O
analyze	O
the	O
cell	B-T038
proliferation	I-T038
of	O
different	O
types	O
of	O
cell	B-T017
lines	I-T017
,	O
and	O
to	O
concurrently	O
analyze	B-T062
the	O
proliferation	O
of	O
two	O
types	O
of	O
cell	B-T017
lines	I-T017
in	O
coculture	B-T058
by	O
utilizing	O
cell	B-T062
tracking	I-T062
dyes	B-T103
with	O
different	O
spectral	O
characteristics	O
.	O

The	O
mean	O
division	O
time	O
estimated	O
by	O
the	O
dye	B-T058
dilution	I-T058
assay	I-T058
is	O
compared	O
with	O
the	O
population	O
doubling	O
time	O
obtained	O
from	O
conventional	O
methods	B-T170
and	O
values	O
from	O
literature	B-T170
.	O

Additionally	O
,	O
dye	B-T103
transfer	O
between	O
cocultured	B-T017
cells	I-T017
was	O
investigated	O
and	O
it	O
was	O
found	O
that	O
it	O
is	O
a	O
characteristic	O
of	O
the	O
cells	B-T017
rather	O
than	O
a	O
characteristic	O
of	O
the	O
dye	B-T103
.	O

It	O
was	O
suggested	O
that	O
this	O
method	O
can	O
be	O
easily	O
combined	O
with	O
other	O
flow	B-T058
cytometric	I-T058
analyses	I-T058
of	O
cellular	B-T017
properties	O
,	O
providing	O
valuable	O
information	O
on	O
cell	O
status	O
under	O
diverse	O
conditions	O
.	O

©	O
2017	O
International	O
Society	O
for	O
Advancement	O
of	O
Cytometry	O
.	O

Engineering	B-T062
and	O
In	B-T082
Vivo	I-T082
Applications	O
of	O
Riboswitches	B-T103

Riboswitches	B-T103
are	O
common	O
gene	B-T017
regulatory	I-T017
units	I-T017
mostly	O
found	O
in	O
bacteria	B-T007
that	O
are	O
capable	O
of	O
altering	O
gene	B-T038
expression	I-T038
in	O
response	O
to	O
a	O
small	B-T103
molecule	I-T103
.	O

These	O
structured	B-T103
RNA	I-T103
elements	I-T103
consist	O
of	O
two	O
modular	O
subunits	O
:	O
an	O
aptamer	B-T103
domain	I-T103
that	O
binds	B-T038
with	O
high	O
specificity	O
and	O
affinity	O
to	O
a	O
target	O
ligand	B-T103
and	O
an	O
expression	B-T038
platform	O
that	O
transduces	B-T038
ligand	B-T038
binding	I-T038
to	O
a	O
gene	B-T038
expression	I-T038
output	O
.	O

Significant	O
progress	O
has	O
been	O
made	O
in	O
engineering	B-T062
novel	O
aptamer	B-T103
domains	I-T103
for	O
new	O
small	B-T103
molecule	I-T103
inducers	O
of	O
gene	B-T038
expression	I-T038
.	O

Modified	O
expression	B-T038
platforms	O
have	O
also	O
been	O
optimized	O
to	O
function	O
when	O
fused	O
with	O
both	O
natural	O
and	O
synthetic	O
aptamer	B-T103
domains	I-T103
.	O

As	O
this	O
field	O
expands	O
,	O
the	O
use	O
of	O
these	O
privileged	O
scaffolds	O
has	O
permitted	O
the	O
development	O
of	O
tools	O
such	O
as	O
RNA	B-T103
-	O
based	O
fluorescent	O
biosensors	O
.	O

In	O
this	O
review	B-T170
,	O
we	O
summarize	B-T170
the	O
methods	B-T170
that	O
have	O
been	O
developed	O
to	O
engineer	O
new	O
riboswitches	B-T103
and	O
highlight	O
applications	O
of	O
natural	O
and	O
synthetic	O
riboswitches	B-T103
in	O
enzyme	B-T058
and	O
strain	B-T091
engineering	I-T091
,	O
in	O
controlling	O
gene	B-T038
expression	I-T038
and	O
cellular	B-T038
physiology	I-T038
,	O
and	O
in	O
real	B-T058
-	I-T058
time	I-T058
imaging	I-T058
of	O
cellular	B-T103
metabolites	I-T103
and	O
signals	B-T038
.	O

Expected	O
final	O
online	O
publication	O
date	O
for	O
the	O
Annual	O
Review	O
of	O
Biochemistry	O
Volume	O
86	O
is	O
June	O
20	O
,	O
2017	O
.	O

Please	O
see	O
http	O
:	O
/	O
/	O
www	O
.	O
annualreviews	O
.	O
org	O
/	O
page	O
/	O
journal	O
/	O
pubdates	O
for	O
revised	O
estimates	O
.	O

A	O
novel	O
assay	B-T058
to	O
measure	O
tertiary	O
and	O
quaternary	B-T103
amines	I-T103
in	O
wastewater	O
:	O
An	O
indicator	O
for	O
NDMA	B-T103
wastewater	O
precursors	O

This	O
study	B-T058
examined	B-T033
the	O
potential	O
of	O
using	O
a	O
novel	O
bulk	B-T058
amine	I-T058
assay	I-T058
as	O
an	O
approximation	O
for	O
the	O
tertiary	O
and	O
quaternary	B-T103
amine	I-T103
load	O
in	O
wastewaters	O
and	O
surface	B-T082
water	B-T103
samples	I-T103
,	O
and	O
this	O
approximation	O
was	O
compared	O
to	O
N	B-T103
-	I-T103
nitrosodimethylamine	I-T103
(	O
NDMA	B-T103
)	O
formation	O
potential	O
using	O
chloramines	B-T103
.	O

An	O
existing	O
colorimetric	B-T058
method	I-T058
was	O
examined	B-T033
and	O
optimized	O
for	O
the	O
detection	B-T033
of	O
amines	B-T103
in	O
environmental	B-T082
water	B-T103
samples	I-T103
.	O

The	O
method	B-T058
consists	O
of	O
liquid	B-T058
-	I-T058
liquid	I-T058
extraction	I-T058
followed	O
by	O
a	O
catalyzed	O
reaction	O
to	O
form	O
a	O
yet	O
-	O
undefined	O
product	O
that	O
is	O
known	O
to	O
be	O
both	O
a	O
strong	O
chromophore	O
and	O
fluorophore	O
.	O

Previous	O
work	O
verified	O
that	O
this	O
reaction	O
was	O
effectively	O
catalyzed	O
by	O
a	O
number	O
of	O
compounds	O
containing	O
tertiary	O
and	O
quaternary	B-T103
amine	I-T103
moieties	O
.	O

Many	O
tertiary	O
and	O
quaternary	B-T103
compounds	I-T103
are	O
also	O
efficient	O
producers	O
of	O
NDMA	B-T103
under	O
chloramination	O
conditions	O
,	O
and	O
a	O
linear	O
correlation	O
was	O
consequently	O
derived	O
from	O
the	O
bulk	O
amine	O
signals	O
vs	O
.	O

NDMA	B-T103
formation	O
potential	O
in	O
various	O
wastewater	O
samples	O
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
74	O
;	O
n	O
=	O
24	O
;	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
results	O
provide	O
evidence	O
that	O
approximately	O
2	O
%	O
of	O
the	O
tertiary	O
and	O
quaternary	O
amines	O
measured	O
can	O
form	O
NDMA	B-T103
and	O
an	O
estimated	O
0	O
.	O
01	O
-	O
1	O
.	O
3	O
%	O
of	O
nitrogen	B-T103
in	O
dissolved	B-T103
organic	I-T103
nitrogen	I-T103
originates	I-T103
from	O
these	O
bulk	B-T103
amines	I-T103
.	O

The	O
normalization	B-T062
of	O
NDMA	B-T103
concentration	O
by	O
the	O
amine	B-T103
measurement	O
revealed	O
that	O
ozone	B-T103
effectively	O
destroyed	O
those	O
tertiary	O
and	O
quaternary	B-T103
amine	I-T103
structures	B-T082
more	O
likely	O
to	O
form	O
NDMA	B-T103
in	O
treated	O
wastewater	O
samples	O
.	O

This	O
bulk	B-T058
amine	I-T058
assay	I-T058
illustrates	O
that	O
proxy	O
measurements	O
of	O
tertiary	O
and	O
quaternary	B-T103
amines	I-T103
can	O
be	O
linked	O
to	O
the	O
NDMA	B-T103
formation	O
potential	O
of	O
a	O
given	O
sample	O
,	O
and	O
this	O
approach	O
may	O
prove	O
useful	O
as	O
a	O
characterizing	O
tool	O
for	O
NDMA	B-T103
precursors	O
in	O
wastewater	O
.	O

Chlamydia	B-T007
pneumoniae	I-T007
infection	B-T038
promotes	O
vascular	B-T017
endothelial	I-T017
cell	I-T017
angiogenesis	B-T038
through	O
an	O
IQGAP1	B-T103
-	O
related	O
signaling	B-T038
pathway	I-T038

Chlamydia	B-T007
pneumoniae	I-T007
(	O
C	B-T007
.	I-T007

pneumoniae	I-T007
)	O
infection	B-T038
plays	O
a	O
potential	O
role	O
in	O
angiogenesis	B-T038
.	O

However	O
,	O
it	O
is	O
still	O
an	O
enigma	O
how	O
C	B-T007
.	I-T007

pneumoniae	I-T007
is	O
involved	O
in	O
this	O
process	O
.	O

Therefore	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
on	O
angiogenesis	B-T038
,	O
and	O
then	O
explored	O
the	O
roles	O
of	O
IQGAP1	B-T103
-	O
related	O
signaling	B-T038
in	O
C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
-	O
induced	O
angiogenesis	B-T038
.	O

C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
significantly	O
enhanced	O
angiogenesis	B-T038
as	O
assessed	O
by	O
the	O
tube	B-T058
formation	I-T058
assay	I-T058
possibly	B-T033
by	O
inducing	O
vascular	B-T017
endothelial	I-T017
cell	I-T017
(	O
VEC	B-T017
)	O
migration	O
in	O
the	O
wound	B-T038
healing	I-T038
and	O
Transwell	B-T058
migration	I-T058
assays	I-T058
.	O

Subsequently	O
,	O
immunoprecipitation	B-T058
,	O
Western	B-T058
blot	I-T058
and	O
tube	B-T058
formation	I-T058
assay	I-T058
results	O
showed	O
that	O
the	O
phosphorylation	B-T038
of	O
both	O
IQGAP1	B-T103
and	O
N	B-T103
-	I-T103
WASP	I-T103
was	O
required	O
for	O
the	O
angiogenesis	B-T038
induced	O
by	O
C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
.	O

Our	O
co	B-T058
-	I-T058
immunoprecipitation	I-T058
study	B-T058
revealed	O
that	O
IQGAP1	B-T103
physically	O
associated	O
with	O
N	B-T103
-	I-T103
WASP	I-T103
after	O
C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
of	O
VECs	B-T017
.	O

Actin	B-T038
polymerization	I-T038
assay	B-T058
further	O
showed	O
that	O
in	O
C	B-T007
.	I-T007

pneumoniae	I-T007
-	O
infected	B-T033
VECs	B-T017
,	O
both	O
IQGAP1	B-T103
and	O
N	B-T103
-	I-T103
WASP	I-T103
were	O
recruited	O
to	O
filamentous	B-T103
actin	I-T103
,	O
and	O
shared	O
some	O
common	O
compartments	O
localized	B-T082
at	O
the	O
leading	B-T017
edge	I-T017
of	O
lamellipodia	B-T017
,	O
which	O
was	O
impaired	O
after	O
the	O
depletion	O
of	O
IQGAP1	B-T103
by	O
using	O
the	O
small	B-T103
interference	I-T103
RNA	I-T103
.	O

Moreover	O
,	O
the	O
knockdown	B-T062
of	O
IQGAP1	B-T017
also	O
significantly	O
decreased	O
N	B-T103
-	I-T103
WASP	I-T103
phosphorylation	B-T038
at	O
Tyr256	B-T103
induced	O
by	O
C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
.	O

We	O
conclude	O
that	O
C	B-T007
.	I-T007

pneumoniae	I-T007
infection	B-T038
promotes	O
VEC	B-T017
migration	O
and	O
angiogenesis	B-T038
presumably	O
through	O
the	O
IQGAP1	B-T103
-	O
related	O
signaling	B-T038
pathway	I-T038
.	O

Four	B-T082
-	I-T082
Dimensional	I-T082
Graded	B-T170
Consciousness	B-T038

Both	O
the	O
multidimensional	B-T082
phenomenon	O
and	O
the	O
polysemous	O
notion	O
of	O
consciousness	B-T038
continue	O
to	O
prove	O
resistant	O
to	O
consistent	O
measurement	O
and	O
unambiguous	B-T170
definition	I-T170
.	O

This	O
is	O
hardly	O
surprising	O
,	O
given	O
that	O
there	O
is	O
no	B-T033
agreement	I-T033
even	O
as	O
regards	O
the	O
most	O
fundamental	O
issues	B-T033
they	O
involve	O
.	O

One	O
of	O
the	O
basic	O
disagreements	O
present	O
in	O
the	O
continuing	O
debate	O
about	O
consciousness	B-T038
pertains	O
to	O
its	O
gradational	B-T170
nature	O
.	O

The	O
general	O
aim	O
of	O
this	O
article	B-T170
is	O
to	O
show	O
how	O
consciousness	B-T038
might	O
be	O
graded	B-T170
and	O
multidimensional	B-T082
at	O
the	O
same	O
time	O
.	O

We	O
therefore	O
focus	O
on	O
the	O
question	B-T170
of	O
what	O
it	O
is	O
,	O
exactly	O
,	O
that	O
is	O
or	O
could	O
be	O
graded	B-T170
in	O
cases	O
of	O
consciousness	B-T038
,	O
and	O
how	O
we	O
can	O
measure	O
it	O
.	O

Ultimately	O
,	O
four	O
different	O
gradable	B-T170
aspects	O
of	O
consciousness	B-T038
will	O
be	O
described	O
:	O
quality	O
,	O
abstractness	O
,	O
complexity	B-T038
and	O
usefulness	O
,	O
which	O
belong	O
to	O
four	O
different	O
dimensions	O
,	O
these	O
being	O
understood	O
,	O
respectively	O
,	O
as	O
phenomenal	O
,	O
semantic	O
,	O
physiological	O
,	O
and	O
functional	O
.	O

Consequently	O
,	O
consciousness	B-T038
may	O
be	O
said	O
to	O
vary	O
with	O
respect	O
to	O
phenomenal	O
quality	O
,	O
semantic	O
abstraction	O
,	O
physiological	O
complexity	B-T038
,	O
and	O
functional	O
usefulness	O
.	O

It	O
is	O
hoped	O
that	O
such	O
a	O
four	B-T082
-	I-T082
dimensional	I-T082
approach	O
will	O
help	O
to	O
clarify	O
and	O
justify	O
claims	O
about	O
the	O
hierarchical	O
nature	O
of	O
consciousness	B-T038
.	O

The	O
approach	B-T082
also	O
proves	O
explanatorily	O
advantageous	O
,	O
as	O
it	O
enables	O
us	O
not	O
only	O
to	O
draw	O
attention	B-T038
to	O
certain	O
new	O
and	O
important	O
differences	O
in	O
respect	O
of	O
subjective	O
measures	O
of	O
awareness	B-T038
and	O
to	O
justify	O
how	O
a	O
given	O
creature	B-T204
may	O
be	O
ranked	B-T170
higher	O
in	O
one	O
dimension	O
of	O
consciousness	B-T038
and	O
lower	O
in	O
terms	O
of	O
another	O
,	O
but	O
also	O
allows	O
for	O
innovative	B-T170
explanations	I-T170
of	O
a	O
variety	O
of	O
well	O
-	O
known	O
phenomena	O
(	O
amongst	O
these	O
,	O
the	O
interpretations	B-T170
of	O
blindsight	O
and	O
locked	B-T038
-	I-T038
in	I-T038
syndrome	I-T038
will	O
be	O
briefly	O
outlined	O
here	O
)	O
.	O

Moreover	O
,	O
a	O
4D	B-T082
framework	O
makes	O
possible	O
many	O
predictions	O
and	O
hypotheses	O
that	O
may	O
be	O
experimentally	B-T062
tested	O
(	O
We	O
point	O
out	O
a	O
few	O
such	O
possibilities	O
pertaining	O
to	O
interdimensional	O
dependencies	O
)	O
.	O

Synthesis	O
of	O
Some	O
Unique	O
Carbamate	B-T103
Derivatives	B-T103
bearing	O
2	B-T103
-	I-T103
Furoyl	I-T103
-	I-T103
1	I-T103
-	I-T103
piperazine	I-T103
as	O
a	O
Valuable	O
Therapeutic	B-T103
Agents	I-T103

The	O
aim	O
of	O
the	O
research	B-T062
work	I-T062
was	O
to	O
synthesize	O
different	O
biologically	B-T103
active	I-T103
carbamate	B-T103
derivatives	B-T103
bearing	O
2	B-T103
-	I-T103
furoyl	I-T103
-	I-T103
1	I-T103
-	I-T103
piperazine	I-T103
and	O
having	O
modest	O
toxicity	B-T037
.	O

The	O
synthesis	O
was	O
completed	O
as	O
a	O
multiple	O
sequence	O
.	O

The	O
structural	B-T082
confirmation	B-T033
of	O
all	O
the	O
synthesized	O
compounds	O
was	O
obtained	O
by	O
EI	B-T058
-	I-T058
MS	I-T058
,	O
IR	B-T058
and	O
1H	B-T058
-	I-T058
NMR	I-T058
spectral	O
data	O
.	O

The	O
enzyme	B-T038
inhibition	I-T038
and	O
antibacterial	B-T033
potential	I-T033
of	O
the	O
synthesized	B-T103
compounds	I-T103
was	O
evaluated	B-T058
.	O

To	O
find	O
the	O
utility	O
of	O
the	O
prepared	O
compounds	B-T103
as	O
possible	O
therapeutic	B-T103
agents	I-T103
their	O
cytotoxicity	B-T038
was	O
also	O
checked	O
.	O

All	O
the	O
compounds	B-T103
were	O
active	O
against	O
acetylcholinesterase	B-T103
enzyme	I-T103
,	O
especially	O
12	B-T103
and	O
14	B-T103
showed	O
very	O
good	O
inhibitory	B-T038
potential	I-T038
relative	O
to	O
Eserine	B-T103
,	O
a	O
reference	O
standard	O
.	O

Almost	O
all	O
the	O
compounds	B-T103
showed	O
good	O
activities	O
against	O
both	O
Gram	B-T007
-	I-T007
positive	I-T007
and	O
Gram	B-T007
-	I-T007
negative	I-T007
bacterial	I-T007
strains	I-T007
.	O

Epidemiology	B-T091
and	O
outcomes	O
of	O
injuries	B-T037
in	O
Kenya	B-T082
:	O
A	O
multisite	O
surveillance	O
study	O

Injury	B-T037
is	O
a	O
leading	O
cause	O
of	O
disability	B-T033
and	O
death	B-T033
worldwide	O
,	O
accounting	O
for	O
over	O
5	O
million	O
deaths	B-T033
each	O
year	O
.	O

The	O
injury	B-T037
burden	O
is	O
higher	O
in	O
low	B-T082
-	I-T082
and	I-T082
middle	I-T082
-	I-T082
income	I-T082
countries	I-T082
where	O
more	O
than	O
90	O
%	O
of	O
injury	B-T033
-	I-T033
related	I-T033
deaths	I-T033
occur	O
.	O

Despite	O
this	O
burden	O
,	O
the	O
use	O
of	O
prospective	O
trauma	B-T037
registries	O
to	O
describe	O
injury	B-T037
epidemiology	B-T091
and	O
outcomes	O
is	O
limited	O
in	O
low	B-T082
-	I-T082
and	I-T082
middle	I-T082
-	I-T082
income	I-T082
countries	I-T082
.	O

Kenya	B-T082
lacks	O
robust	O
data	O
to	O
describe	O
injury	B-T037
epidemiology	B-T091
and	O
care	O
.	O

The	O
objective	B-T170
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
the	O
epidemiology	B-T091
and	O
outcomes	O
of	O
injuries	B-T037
at	O
4	O
referral	B-T092
hospitals	I-T092
in	O
Kenya	B-T082
using	O
hospital	B-T092
-	O
based	O
trauma	B-T037
registries	O
.	O

From	O
January	O
2014	O
to	O
May	O
2015	O
,	O
all	O
injured	O
patients	O
presenting	O
to	O
the	O
casualty	B-T092
departments	I-T092
of	O
Kenyatta	B-T092
National	I-T092
,	O
Thika	B-T092
Level	I-T092
5	I-T092
,	O
Machakos	B-T092
Level	I-T092
5	I-T092
,	O
and	O
Meru	B-T092
Level	I-T092
5	I-T092
Hospitals	I-T092
were	O
enrolled	O
prospectively	O
.	O

Data	B-T062
collected	I-T062
included	O
demographic	O
characteristics	O
,	O
type	O
of	O
prehospital	B-T058
care	I-T058
received	O
,	O
prehospital	O
time	O
,	O
injury	B-T037
pattern	I-T037
,	O
and	O
outcomes	O
.	O

A	O
total	O
of	O
14	O
,	O
237	O
patients	O
were	O
enrolled	O
in	O
our	O
study	O
.	O

Patients	O
were	O
predominantly	O
male	O
(	O
76	O
.	O
1	O
%	O
)	O
and	O
young	O
(	O
mean	O
age	O
28	O
years	O
)	O
.	O

The	O
most	O
common	O
mechanisms	O
of	O
injury	O
were	O
road	O
traffic	B-T037
injuries	I-T037
(	O
36	O
.	O
8	O
%	O
)	O
,	O
falls	B-T037
(	O
26	O
.	O
4	O
%	O
)	O
,	O
and	O
being	O
struck	O
/	O
hit	O
by	O
a	O
person	B-T098
or	O
object	O
(	O
20	O
.	O
1	O
%	O
)	O
.	O

Burn	B-T037
was	O
the	O
most	O
common	O
mechanism	O
of	O
injury	O
in	O
the	O
age	O
category	B-T170
under	O
5	O
years	O
.	O

Body	B-T082
regions	I-T082
commonly	O
injured	O
were	O
lower	B-T017
extremity	I-T017
(	O
35	O
.	O
1	O
%	O
)	O
,	O
upper	B-T017
extremity	I-T017
(	O
33	O
.	O
4	O
%	O
)	O
,	O
and	O
head	B-T082
(	O
26	O
.	O
0	O
%	O
)	O
.	O

The	O
overall	O
mortality	O
rate	O
was	O
2	O
.	O
4	O
%	O
.	O

Significant	O
predictors	O
of	O
mortality	O
from	O
multivariate	O
analysis	O
were	O
Glasgow	B-T033
Coma	I-T033
Scale	I-T033
≤12	I-T033
,	O
estimated	O
injury	B-T170
severity	I-T170
score	I-T170
≥9	O
,	O
burns	B-T037
,	O
and	O
gunshot	B-T037
injuries	I-T037
.	O

Hospital	B-T092
-	O
based	O
trauma	B-T037
registries	O
can	O
be	O
important	O
sources	O
of	O
data	O
to	O
study	B-T062
the	I-T062
epidemiology	I-T062
of	O
injuries	B-T037
in	O
low	B-T082
-	I-T082
and	I-T082
middle	I-T082
-	I-T082
income	I-T082
countries	I-T082
.	O

Data	O
from	O
such	O
trauma	B-T037
registries	O
can	O
highlight	O
key	O
needs	O
and	O
be	O
used	O
to	O
design	O
public	B-T092
health	O
interventions	B-T058
and	O
quality	O
-	O
of	O
-	O
care	O
improvement	O
programs	O
.	O

A	O
child	O
with	O
phenylketonuria	B-T038
and	O
focal	B-T038
segmental	I-T038
glomerulosclerosis	I-T038
,	O
the	O
bright	O
side	O
of	O
proteinuria	B-T033

Phenylketonuria	B-T038
(	O
PKU	B-T038
)	O
is	O
the	O
most	O
common	O
inborn	B-T038
error	I-T038
of	I-T038
amino	I-T038
acid	I-T038
metabolism	I-T038
.	O

Phenylalanine	B-T103
hydroxylase	I-T103
is	O
the	O
underlying	O
deficient	O
enzyme	B-T103
.	O

If	O
left	O
untreated	B-T033
,	O
growth	B-T038
failure	I-T038
,	O
microcephaly	B-T017
,	O
global	B-T038
developmental	I-T038
delay	I-T038
,	O
seizures	B-T033
and	O
severe	O
intellectual	O
impairment	O
would	O
characterize	O
the	O
clinical	O
picture	O
of	O
PKU	B-T038
.	O

On	O
the	O
other	O
side	O
of	O
protein	B-T103
homeostasis	B-T038
lies	O
nephrotic	B-T038
syndrome	I-T038
.	O

It	O
is	O
a	O
well	O
-	O
known	O
quantitative	O
defect	O
due	O
to	O
significant	O
proteinuria	B-T033
.	O

Focal	B-T038
segmental	I-T038
glomerulosclerosis	I-T038
(	O
FSGS	B-T038
)	O
is	O
a	O
special	O
congenital	O
variant	O
affecting	O
children	O
and	O
adults	O
.	O

Hereby	O
,	O
we	O
describe	O
a	O
three	O
-	O
year	O
old	O
male	O
child	O
who	O
presented	B-T033
with	O
generalized	B-T033
edema	I-T033
and	O
global	B-T038
developmental	I-T038
delay	I-T038
.	O

Investigations	B-T058
revealed	O
PKU	B-T038
along	O
with	O
FSGS	B-T038
.	O

We	O
assume	O
that	O
congenital	B-T038
nephrosis	I-T038
ameliorated	B-T033
the	O
picture	O
of	O
PKU	B-T038
,	O
and	O
had	O
a	O
salutary	O
effect	O
on	O
the	O
growth	B-T038
and	I-T038
development	I-T038
.	O

Such	O
coexistence	O
between	O
PKU	B-T038
and	O
FSGS	B-T038
hasn	O
'	O
t	O
been	O
described	O
before	O
.	O

Gastrointestinal	B-T038
disorders	I-T038
in	O
Curry	B-T038
-	I-T038
Jones	I-T038
syndrome	I-T038
:	O
Clinical	O
and	O
molecular	O
insights	B-T038
from	O
an	O
affected	O
newborn	O

Curry	B-T038
-	I-T038
Jones	I-T038
syndrome	I-T038
(	O
CJS	B-T038
)	O
is	O
a	O
pattern	B-T082
of	O
malformation	B-T017
that	O
includes	O
craniosynostosis	B-T038
,	O
pre	B-T033
-	I-T033
axial	I-T033
polysyndactyly	I-T033
,	O
agenesis	B-T017
of	I-T017
the	I-T017
corpus	I-T017
callosum	I-T017
,	O
cutaneous	B-T033
and	O
gastrointestinal	B-T082
abnormalities	O
.	O

A	O
recurrent	O
,	O
mosaic	B-T038
mutation	I-T038
of	O
SMO	B-T038
(	I-T038
c	I-T038
.	I-T038
1234	I-T038
C	I-T038
>	I-T038
T	I-T038
;	I-T038
p	I-T038
.	I-T038
Leu412Phe	I-T038
)	I-T038
causes	O
CJS	B-T038
.	O

This	O
report	B-T170
describes	O
the	O
gastrointestinal	B-T082
and	O
surgical	B-T033
findings	I-T033
in	O
a	O
baby	O
with	O
CJS	B-T038
who	O
presented	O
with	O
abdominal	O
obstruction	O
and	O
reviews	O
the	O
spectrum	B-T033
of	I-T033
gastrointestinal	B-T082
malformations	I-T033
in	O
this	O
rare	B-T038
disorder	I-T038
.	O

A	O
41	O
-	O
week	O
,	O
4	O
,	O
165	O
g	O
,	O
female	O
presented	O
with	O
craniosynostosis	B-T038
,	O
pre	B-T033
-	I-T033
axial	I-T033
polysyndactyly	I-T033
,	O
and	O
cutaneous	B-T033
findings	I-T033
consistent	O
with	O
a	O
clinical	B-T058
diagnosis	I-T058
of	O
CJS	B-T038
.	O

The	O
infant	O
developed	O
abdominal	B-T033
distension	I-T033
beginning	O
on	O
the	O
second	O
day	O
of	O
life	O
.	O

Surgical	B-T058
exploration	I-T058
revealed	O
an	O
intestinal	B-T017
malrotation	I-T017
for	O
which	O
she	O
underwent	O
a	O
Ladd	B-T058
procedure	I-T058
.	O

Multiple	B-T033
small	I-T033
nodules	I-T033
were	O
found	B-T033
on	O
the	O
surface	B-T082
of	I-T082
the	I-T082
small	I-T082
and	I-T082
large	I-T082
bowel	I-T082
in	O
addition	O
to	O
an	O
apparent	O
intestinal	B-T017
duplication	I-T017
that	O
seemed	O
to	O
originate	O
posterior	B-T082
to	O
the	O
pancreas	B-T017
.	O

Histopathology	O
of	O
serosal	O
nodules	B-T017
revealed	O
bundles	B-T017
of	I-T017
smooth	I-T017
muscle	I-T017
with	O
associated	O
ganglion	B-T017
cells	I-T017
.	O

Molecular	B-T062
analysis	I-T062
demonstrated	O
the	O
SMO	B-T038
c	I-T038
.	I-T038
1234	I-T038
C	I-T038
>	I-T038
T	I-T038
mutation	I-T038
in	O
varying	O
amounts	O
in	O
affected	O
skin	B-T022
(	O
up	O
to	O
35	O
%	O
)	O
and	O
intestinal	B-T038
hamartoma	I-T038
(	O
26	O
%	O
)	O
.	O

Gastrointestinal	B-T082
features	B-T033
including	O
structural	B-T033
malformations	B-T017
,	O
motility	B-T038
disorders	I-T038
,	O
and	O
upper	B-T038
GI	I-T038
bleeding	I-T038
are	O
major	O
causes	O
of	O
morbidity	O
in	O
CJS	B-T038
.	O

Smooth	B-T038
muscle	I-T038
hamartomas	I-T038
are	O
a	O
recognized	B-T033
feature	I-T033
of	O
children	O
with	O
CJS	B-T038
typically	O
presenting	O
with	O
abdominal	O
obstruction	O
requiring	B-T033
surgical	I-T033
intervention	I-T033
.	O

A	O
somatic	B-T038
mutation	I-T038
in	O
SMO	B-T017
likely	O
accounts	O
for	O
the	O
structural	B-T033
malformations	B-T017
and	O
predisposition	O
to	O
form	O
bowel	B-T038
hamartomas	I-T038
and	O
myofibromas	B-T038
.	O

The	O
mutation	B-T038
burden	O
in	O
the	O
involved	O
tissues	B-T017
likely	O
accounts	O
for	O
the	O
variable	B-T033
manifestations	I-T033
.	O

Sella	B-T017
turcica	I-T017
bridging	I-T017
and	O
dental	B-T033
anomalies	I-T033
:	O
is	O
there	O
an	O
association	O
?	O

Sella	B-T017
turcica	I-T017
bridging	I-T017
(	O
STB	B-T017
)	O
,	O
or	O
calcification	B-T038
of	O
the	O
interclinoid	B-T017
ligament	I-T017
of	O
sella	B-T017
turcica	I-T017
,	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
some	O
dental	B-T033
anomalies	I-T033
(	O
palatal	B-T033
canine	I-T033
impaction	B-T017
and	O
transposition	B-T017
)	O
.	O

The	O
aim	O
of	O
the	O
study	B-T062
was	O
to	O
find	O
any	O
association	O
between	O
canine	B-T033
impaction	B-T017
,	O
hyperdontia	B-T033
or	O
hypodontia	B-T017
and	O
sellar	B-T017
dimensions	O
or	O
bridging	B-T017
.	O

Lateral	B-T082
cephalometric	B-T058
radiographs	B-T058
from	O
78	O
patients	O
with	O
impacted	B-T017
canines	B-T033
,	O
68	O
with	O
dental	B-T017
agenesis	I-T017
and	O
17	O
with	O
hyperdontia	B-T033
were	O
collected	O
.	O

Linear	B-T082
dimensions	O
of	O
sella	B-T017
turcica	I-T017
were	O
calculated	O
and	O
compared	O
to	O
those	O
of	O
a	O
control	O
group	O
(	O
47	O
individuals	B-T098
)	O
.	O

A	O
standardize	B-T170
scoring	I-T170
scale	I-T170
was	O
used	O
to	O
quantify	O
the	O
extent	O
of	O
STB	B-T017
from	O
each	O
radiographs	B-T058
.	O

The	O
frequency	O
of	O
partial	O
and	O
complete	O
calcifications	B-T038
of	O
sella	B-T017
in	O
patients	O
with	O
dental	B-T033
anomalies	I-T033
is	O
increased	O
when	O
compared	O
to	O
controls	O
.	O

STB	B-T017
can	O
influence	O
the	O
interclinoid	O
distance	O
but	O
does	O
not	O
affect	O
other	O
linear	B-T082
dimensions	O
of	O
sella	B-T017
.	O

No	O
statistically	O
significant	O
difference	O
has	O
been	O
found	O
in	O
sellar	B-T017
dimensions	O
and	O
STB	B-T017
expression	O
when	O
evaluating	O
radiographs	B-T058
at	O
different	O
ages	O
.	O

STB	B-T017
is	O
frequently	O
found	O
in	O
patients	O
with	O
dental	B-T033
abnormalities	I-T033
.	O

Coxiella	B-T007
burnetii	I-T007
isolates	B-T103
originating	O
from	O
infected	B-T204
cattle	I-T204
induce	O
a	O
more	O
pronounced	O
proinflammatory	B-T038
cytokine	I-T038
response	I-T038
compared	O
to	O
isolates	B-T103
from	O
infected	B-T204
goats	I-T204
and	O
sheep	B-T204

Coxiella	B-T007
burnetii	I-T007
is	O
the	O
causative	B-T033
agent	I-T033
of	O
Q	B-T038
fever	I-T038
.	O

Although	O
the	O
prevalence	O
of	O
C	B-T007
.	I-T007

burnetii	I-T007
in	O
cattle	B-T204
is	O
much	O
higher	O
than	O
in	O
goats	B-T204
and	O
sheep	B-T204
,	O
infected	B-T204
cattle	I-T204
are	O
rarely	O
associated	O
with	O
human	B-T204
outbreaks	O
.	O

We	O
investigated	O
whether	O
the	O
immune	B-T038
response	I-T038
of	O
humans	B-T204
differs	O
after	O
contact	O
with	O
C	B-T007
.	I-T007

burnetii	I-T007
isolates	B-T103
from	O
different	O
host	O
origins	O
or	O
with	O
different	O
multilocus	B-T058
variable	I-T058
number	I-T058
of	I-T058
tandem	I-T058
repeat	I-T058
analysis	I-T058
(	O
MLVA	B-T058
)	O
genotypes	O
.	O

Cytokine	B-T038
responses	I-T038
were	O
measured	O
in	O
human	B-T204
peripheral	B-T017
blood	I-T017
mononuclear	I-T017
cells	I-T017
(	O
PBMCs	B-T017
)	O
stimulated	O
with	O
16	O
C	B-T007
.	I-T007

burnetii	I-T007
isolates	B-T103
with	O
known	O
MLVA	B-T058
genotype	O
from	O
goats	B-T204
,	O
sheep	B-T204
,	O
cattle	B-T204
,	O
acute	B-T038
and	O
chronic	B-T038
Q	I-T038
fever	I-T038
patients	O
.	O

Coxiella	B-T007
burnetii	I-T007
isolates	B-T103
originating	O
from	O
cattle	B-T204
induce	O
significantly	O
more	O
IL	B-T103
-	I-T103
1β	I-T103
,	O
TNF	B-T103
-	I-T103
α	I-T103
and	O
IL	B-T103
-	I-T103
22	I-T103
than	O
the	O
isolates	B-T103
from	O
goats	B-T204
,	O
sheep	B-T204
or	O
chronic	B-T038
Q	I-T038
fever	I-T038
patients	O
.	O

Comparing	O
the	O
cytokine	B-T103
induction	O
of	O
the	O
isolates	B-T103
based	O
on	O
their	O
MVLA	B-T058
genotype	O
did	O
not	O
reveal	O
differences	O
in	O
response	B-T038
between	O
the	O
MLVA	B-T058
genotypes	O
.	O

The	O
proinflammatory	B-T038
cytokine	I-T038
response	I-T038
induced	O
in	O
human	B-T204
PBMCs	B-T017
by	O
C	B-T007
.	I-T007

burnetii	I-T007
isolates	B-T103
from	O
cattle	B-T204
may	O
explain	O
the	O
low	O
incidence	O
of	O
human	B-T204
Q	B-T038
fever	I-T038
outbreaks	O
caused	O
by	O
cattle	B-T204
.	O

The	O
cytokine	B-T103
profile	O
of	O
PBMCs	B-T017
stimulated	O
with	O
C	B-T007
.	I-T007

burnetii	I-T007
isolates	B-T103
from	O
chronic	B-T038
Q	I-T038
fever	I-T038
patients	O
resembles	O
isolates	B-T103
from	O
goats	B-T204
.	O

Furthermore	O
,	O
cytokine	B-T038
responses	I-T038
seem	O
to	O
be	O
depending	O
on	O
host	O
origin	O
than	O
on	O
MLVA	B-T058
genotype	O
.	O

A	O
Novel	O
BRCA1	B-T103
-	I-T103
Associated	I-T103
Protein	I-T103
-	I-T103
1	I-T103
Isoform	B-T103
Affects	O
Response	O
of	O
Mesothelioma	B-T038
Cells	I-T038
to	O
Drugs	B-T103
Impairing	O
BRCA1	B-T103
-	O
Mediated	O
DNA	B-T038
Repair	I-T038

BRCA1	B-T103
associated	I-T103
protein1	I-T103
(	O
BAP1	B-T103
)	O
is	O
a	O
tumor	B-T103
suppressor	I-T103
involved	O
in	O
multiple	O
cellular	B-T038
processes	I-T038
such	O
as	O
transcriptional	B-T038
regulation	I-T038
,	O
chromatin	B-T038
modification	I-T038
by	O
deubiquitinating	B-T038
histone	B-T103
2A	I-T103
,	O
and	O
DNA	B-T038
repair	I-T038
.	O

BAP1	B-T103
mutations	B-T038
are	O
frequent	O
in	O
malignant	B-T038
pleural	I-T038
mesothelioma	I-T038
(	O
MPM	B-T038
)	O
.	O

Our	O
aim	O
was	O
to	O
functionally	O
characterize	O
a	O
newly	O
identified	O
isoform	B-T103
of	B-T103
BAP1	I-T103
and	O
investigate	O
the	O
effects	O
of	O
its	O
expression	B-T038
on	O
drug	O
sensitivity	O
in	O
MPM	B-T038
.	O

Expression	B-T038
of	O
BAP1	B-T103
isoforms	O
was	O
detected	B-T033
by	O
quantitative	B-T058
polymerase	I-T058
chain	I-T058
reaction	I-T058
in	O
MPM	B-T038
and	O
normal	O
mesothelium	B-T017
cell	B-T017
lines	I-T017
and	O
tumor	B-T017
and	O
nontumor	B-T017
samples	I-T017
.	O

Histone	B-T103
H2A	I-T103
ubiquitination	B-T038
levels	O
were	O
analyzed	B-T062
by	O
Western	B-T058
blot	I-T058
after	O
acidic	B-T058
extraction	I-T058
of	O
core	B-T103
histones	I-T103
.	O

Subcellular	B-T017
localization	O
of	O
BAP1	B-T103
isoforms	B-T103
was	O
examined	B-T033
by	O
immunofluorescence	B-T058
.	O

MPM	B-T038
cell	B-T038
survival	I-T038
in	O
response	O
to	O
poly	B-T103
(	I-T103
adenosine	I-T103
diphosphate	I-T103
-	I-T103
ribose	I-T103
)	I-T103
polymerase	I-T103
(	O
PARP	B-T103
)	O
and	O
dual	O
phosphoinositide	B-T103
3	I-T103
-	I-T103
kinase	I-T103
(	O
PI3K	B-T103
)	O
-	O
mammalian	B-T103
target	I-T103
of	I-T103
rapamycin	I-T103
(	O
mTOR	B-T103
)	O
inhibitors	B-T103
was	O
analyzed	B-T062
by	O
in	B-T062
vitro	I-T062
assays	I-T062
.	O

We	O
have	O
identified	O
a	O
novel	O
alternative	B-T103
splice	I-T103
isoform	I-T103
of	O
BAP1	B-T103
(	O
BAP1Δ	B-T017
)	O
that	O
misses	O
part	O
of	O
the	O
catalytic	B-T082
domain	I-T082
.	O

Cells	B-T017
transfected	B-T062
with	O
BAP1Δ	B-T017
showed	O
reduced	O
deubiquitinating	B-T038
activity	I-T038
compared	O
with	O
full	O
-	O
length	O
BAP1	B-T103
.	O

The	O
expression	B-T038
of	O
BAP1Δ	B-T017
transcript	B-T103
is	O
more	O
abundant	O
in	O
nontumor	B-T017
than	O
in	O
tumor	O
samples	O
.	O

MPM	B-T038
cell	B-T017
lines	I-T017
expressing	B-T038
more	O
than	O
20	O
%	O
of	O
BAP1Δ	B-T017
are	O
more	O
sensitive	O
to	O
olaparib	B-T103
(	O
a	O
PARP1	B-T103
inhibitor	B-T103
)	O
cytotoxicity	B-T038
,	O
and	O
this	O
sensitivity	O
is	O
enhanced	O
when	O
olaparib	B-T103
treatment	B-T058
is	O
combined	O
with	O
GDC0980	B-T103
(	O
a	O
dual	O
PI3K	B-T103
-	O
mTOR	B-T103
inhibitor	B-T103
)	O
,	O
which	O
induces	O
downregulation	B-T038
of	O
BRCA1	B-T103
.	O

These	O
observations	B-T062
suggest	O
that	O
BAP1Δ	B-T017
does	O
regulate	B-T038
DNA	I-T038
damage	I-T038
response	I-T038
and	O
influences	O
drug	O
sensitivity	O
.	O

It	O
might	O
therefore	O
be	O
relevant	O
to	O
investigate	O
whether	O
patients	O
with	O
high	O
expression	B-T038
of	O
BAP1Δ	B-T017
may	O
be	O
responsive	B-T201
to	O
PARP	B-T103
/	O
PI3K	B-T103
-	O
mTOR	B-T103
inhibitors	B-T103
.	O

Cucurbitacin	B-T103
B	I-T103
Protects	O
Against	O
Pressure	O
Overload	O
Induced	O
Cardiac	B-T038
Hypertrophy	I-T038

Lack	O
of	O
effective	O
anti	B-T103
-	I-T103
cardiac	I-T103
hypertrophy	I-T103
drugs	I-T103
creates	O
a	O
major	O
cause	O
for	O
the	O
increasing	O
prevalence	O
of	O
heart	B-T038
failure	I-T038
.	O

In	O
the	O
present	O
study	O
,	O
we	O
determined	O
the	O
anti	B-T033
-	I-T033
hypertrophy	I-T033
and	O
anti	B-T033
-	I-T033
fibrosis	I-T033
potential	O
of	O
a	O
natural	B-T204
plant	I-T204
triterpenoid	B-T103
,	O
Cucurbitacin	B-T103
B	I-T103
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Aortic	B-T058
banding	I-T058
(	O
AB	B-T058
)	O
was	O
performed	O
to	O
induce	O
cardiac	B-T038
hypertrophy	I-T038
.	O

After	O
1	O
week	O
of	O
surgery	B-T058
,	O
mice	B-T204
were	O
receive	O
cucurbitacin	B-T103
B	I-T103
treatment	B-T058
(	O
Gavage	O
,	O
0	O
.	O
2	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
2	O
day	O
)	O
.	O

After	O
4	O
weeks	O
of	O
AB	B-T058
,	O
cucurbitacin	B-T103
B	I-T103
demonstrated	O
a	O
strong	O
anti	B-T033
-	I-T033
hypertrophy	I-T033
and	O
-	B-T033
fibrosis	I-T033
ability	O
as	O
evidenced	O
by	O
decreased	O
of	O
heart	B-T017
weight	O
,	O
myocardial	B-T017
cell	I-T017
cross	O
-	O
sectional	O
area	O
and	O
interstitial	B-T038
fibrosis	I-T038
,	O
ameliorated	O
of	O
systolic	O
and	O
diastolic	B-T201
abnormalities	B-T033
,	O
normalized	O
in	O
gene	B-T038
expression	I-T038
of	O
hypertrophic	B-T038
and	O
fibrotic	O
markers	B-T201
,	O
reserved	O
microvascular	O
density	O
in	O
pressure	O
overload	O
induced	O
hypertrophic	B-T038
mice	B-T204
.	O

Cucurbitacin	B-T103
B	I-T103
also	O
showed	O
significant	O
hypertrophy	B-T038
inhibitory	B-T033
effect	I-T033
in	O
phenylephrine	B-T103
stimulated	O
cardiomyocytes	B-T017
.	O

The	O
Cucurbitacin	B-T103
B	I-T103
-	O
mediated	O
mitigated	O
cardiac	B-T038
hypertrophy	I-T038
was	O
attributable	O
to	O
the	O
increasing	O
level	O
of	O
autophagy	B-T038
,	O
which	O
was	O
associated	O
with	O
the	O
blockade	O
of	O
Akt	B-T103
/	O
mTOR	B-T103
/	O
FoxO3a	B-T103
signal	B-T038
pathway	I-T038
,	O
validated	O
by	O
SC79	B-T103
,	O
MK2206	B-T103
,	O
and	O
3	B-T103
-	I-T103
MA	I-T103
,	O
the	O
Akt	B-T103
agonist	B-T103
,	O
inhibitor	B-T103
and	O
autophagy	B-T038
inhibitor	B-T103
in	O
vitro	O
.	O

The	O
overexpression	B-T038
of	O
constitutively	O
active	O
Akt	B-T103
completely	O
abolished	O
the	O
Cucurbitacin	B-T103
B	I-T103
-	O
mediated	O
protection	O
of	O
cardiac	B-T038
hypertrophy	I-T038
in	O
human	B-T204
cardiomyocytes	B-T017
AC16	I-T017
.	O

Collectively	O
,	O
our	O
findings	O
suggest	O
that	O
cucurbitacin	B-T103
B	I-T103
protects	O
against	O
cardiac	B-T038
hypertrophy	I-T038
through	O
increasing	O
the	O
autophagy	B-T038
level	O
in	O
cardiomyocytes	B-T017
,	O
which	O
is	O
associated	O
with	O
the	O
inhibition	B-T038
of	O
Akt	B-T103
/	O
mTOR	B-T103
/	O
FoxO3a	B-T103
signal	B-T038
axis	I-T038
.	O

J	O
.	O

Cell	O
.	O

Biochem	O
.	O

9999	O
:	O
1	O
-	O
12	O
,	O
2017	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Inflammatory	O
and	O
Oxidative	B-T038
Stress	I-T038
Markers	B-T201
in	O
Experimental	O
Allergic	B-T038
Asthma	I-T038

Ovalbumin	B-T103
-	O
induced	O
allergic	B-T038
lung	I-T038
inflammation	I-T038
(	O
ALI	B-T038
)	O
is	O
a	O
condition	O
believed	O
to	O
be	O
mediated	O
by	O
cytokines	B-T103
,	O
extracellular	B-T017
matrix	I-T017
remodeling	B-T038
,	O
and	O
redox	B-T038
imbalance	B-T033
.	O

In	O
this	O
study	B-T062
,	O
we	O
evaluated	B-T058
pulmonary	B-T038
function	I-T038
together	O
with	O
inflammatory	O
markers	B-T201
as	O
interleukin	B-T103
-	I-T103
4	I-T103
(	O
IL	B-T103
-	I-T103
4	I-T103
)	O
,	O
myeloperoxidase	B-T103
(	O
MPO	B-T103
)	O
,	O
eosinophil	B-T017
cells	I-T017
,	O
and	O
redox	B-T038
markers	B-T201
in	O
the	O
lungs	B-T017
of	O
BALB	B-T204
/	I-T204
c	I-T204
mice	I-T204
after	O
ovalbumin	B-T103
(	O
OVA	B-T103
)	O
sensitization	B-T038
and	O
challenge	B-T058
.	O

Our	O
results	O
showed	O
an	O
increase	O
in	O
bronchial	B-T038
hyperresponsiveness	I-T038
stimulated	O
by	O
methacholine	B-T103
(	O
Mch	B-T103
)	O
,	O
inflammatory	O
cell	B-T038
influx	I-T038
,	O
especially	O
eosinophils	B-T017
together	O
with	O
an	O
increase	O
of	O
high	B-T103
mobility	I-T103
group	I-T103
box	I-T103
1	I-T103
(	O
HMGB1	B-T103
)	O
and	O
altered	O
lipid	B-T038
peroxidation	I-T038
(	O
LP	B-T038
)	O
and	O
antioxidant	B-T103
defenses	O
in	O
the	O
OVA	B-T103
group	O
compared	O
to	O
the	O
control	O
group	O
(	O
p	O
≤	O
0	O
.	O
5	O
)	O
.	O

Thus	O
,	O
we	O
demonstrated	O
that	O
OVA	B-T103
-	O
induced	O
ALI	B-T038
altered	O
redox	B-T038
status	O
concomitantly	O
with	O
impaired	O
lung	B-T038
function	I-T038
,	O
which	O
was	O
associated	O
with	O
HMGB1	B-T103
expression	B-T038
and	O
proteolytic	B-T038
remodeling	B-T038
.	O

Taken	O
together	O
all	O
results	O
found	O
here	O
,	O
we	O
may	O
suggest	O
HMGB1	B-T103
is	O
an	O
important	O
therapeutic	O
target	O
for	O
asthma	B-T038
,	O
once	O
orchestrates	O
the	O
redox	B-T038
signaling	B-T038
,	O
inflammation	B-T038
,	O
and	O
remodeling	B-T038
that	O
contribute	O
to	O
the	O
disease	B-T038
development	O
.	O

Association	O
among	O
prematurity	B-T038
(	O
<	O
30	O
weeks	O
'	O
gestational	O
age	O
)	O
,	O
blood	B-T038
pressure	I-T038
,	O
urinary	O
albumin	B-T103
,	O
calcium	B-T103
,	O
and	O
phosphate	B-T103
in	O
early	O
childhood	O

There	O
is	O
a	O
paucity	O
of	O
data	O
on	O
blood	B-T038
pressures	I-T038
(	O
BP	B-T038
)	O
,	O
urinary	O
albumin	B-T103
,	O
and	O
mineral	B-T103
excretion	B-T038
in	O
early	O
childhood	O
in	O
contemporary	O
cohorts	B-T098
of	O
extremely	O
low	O
gestational	O
age	O
(	O
GA	O
)	O
neonates	O
.	O

Our	O
aim	O
was	O
to	O
compare	O
BPs	B-T038
and	O
the	O
urinary	O
excretion	B-T038
of	O
albumin	B-T103
,	O
calcium	B-T103
,	O
and	O
phosphate	B-T103
in	O
preterm	O
and	O
term	B-T038
-	I-T038
born	I-T038
cohorts	B-T098
in	O
early	O
childhood	O
.	O

This	O
was	O
a	O
prospective	B-T062
observational	I-T062
study	I-T062
conducted	O
at	O
a	O
single	O
center	B-T092
,	O
involving	O
children	O
<	O
5	O
years	O
age	O
,	O
born	B-T033
preterm	I-T033
(	O
GA	B-T033
<	I-T033
30	I-T033
weeks	I-T033
)	O
or	O
at	B-T038
term	I-T038
(	O
≥37	B-T033
weeks	I-T033
'	I-T033
GA	I-T033
)	O
.	O

Urinary	B-T033
albumin	I-T033
(	O
mg	O
/	O
L	O
)	O
,	O
calcium	B-T033
and	O
phosphate	B-T033
levels	I-T033
indexed	B-T170
to	O
creatinine	B-T103
(	O
mg	O
/	O
dL	O
)	O
,	O
and	O
BP	B-T038
were	O
measured	O
.	O

The	O
median	B-T082
(	O
IQR	O
)	O
follow	B-T058
-	I-T058
up	I-T058
age	O
of	O
our	O
cohort	B-T098
(	O
n	O
=	O
106	O
)	O
was	O
30	O
(	O
16	O
-	O
48	O
)	O
months	O
.	O

Preterm	O
-	O
born	O
children	O
(	O
n	O
=	O
55	O
)	O
had	O
a	O
significantly	O
lower	O
mean	O
GA	O
and	O
birth	O
weight	O
and	O
higher	O
mean	O
systolic	B-T201
,	O
diastolic	B-T201
,	O
and	O
mean	B-T033
BPs	I-T033
,	O
compared	O
with	O
term	B-T038
(	O
n	O
=	O
51	O
)	O
controls	O
.	O

A	O
significantly	O
higher	O
proportion	O
of	O
preterm	O
-	O
born	O
children	O
weighed	O
<	B-T033
10th	I-T033
centile	I-T033
and	O
had	O
systolic	B-T201
BP	I-T201
>	B-T033
95th	I-T033
centile	I-T033
at	O
follow	B-T058
-	I-T058
up	I-T058
.	O

Albumin	B-T103
and	O
calcium	B-T103
excretion	B-T038
did	O
not	O
differ	O
between	O
the	O
groups	O
;	O
median	O
urine	O
-	O
phosphate	O
creatinine	O
ratios	O
were	O
higher	O
in	O
the	O
preterm	O
group	O
.	O

On	O
logistic	B-T062
regression	I-T062
,	O
lower	O
GA	O
and	O
younger	O
age	O
at	O
follow	B-T058
-	I-T058
up	I-T058
were	O
significantly	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
systolic	B-T201
and	O
diastolic	B-T201
BP	I-T201
above	O
the	O
95th	B-T033
centile	I-T033
;	O
male	O
gender	O
was	O
associated	O
with	O
decreased	O
risk	O
of	O
diastolic	B-T038
hypertension	I-T038
.	O

Even	O
in	O
early	O
childhood	O
,	O
children	O
born	O
preterm	O
had	O
significantly	O
elevated	O
BP	B-T038
,	O
compared	O
with	O
their	O
term	B-T038
-	I-T038
born	I-T038
counterparts	O
.	O

Closer	O
monitoring	B-T058
of	O
BPs	B-T038
in	O
this	O
population	B-T098
may	O
be	O
warranted	O
.	O

Recombinant	B-T103
protein	B-T082
transduction	I-T082
domain	I-T082
-	O
Cu	B-T103
/	I-T103
Zn	I-T103
superoxide	I-T103
dismutase	I-T103
alleviates	O
bone	B-T038
cancer	I-T038
pain	B-T033
via	O
peroxiredoxin	B-T103
4	I-T103
modulation	B-T038
and	O
antioxidation	B-T038

Bone	B-T038
cancer	I-T038
pain	B-T033
(	O
BCP	B-T033
)	O
is	O
a	O
serious	O
chronic	O
clinical	O
condition	O
and	O
reactive	B-T103
oxygen	I-T103
species	I-T103
(	O
ROS	B-T103
)	O
were	O
considered	O
to	O
be	O
involved	O
in	O
its	O
development	O
and	O
persistency	O
.	O

Normally	O
,	O
superoxide	B-T103
dismutase	I-T103
(	O
SOD	B-T103
)	O
converts	O
superoxide	B-T103
anions	I-T103
to	O
hydrogen	B-T103
peroxide	I-T103
(	O
H2O2	B-T103
)	O
and	O
H2O2	B-T103
is	O
then	O
naturalized	O
to	O
be	O
water	B-T103
by	O
peroxiredoxin	B-T103
4	I-T103
.	O

We	O
reported	B-T170
previously	O
that	O
recombinant	B-T103
protein	B-T082
transduction	I-T082
domain	I-T082
(	O
PTD	B-T082
)	O
-	O
Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
effectively	O
scavenged	B-T038
excessive	O
ROS	B-T103
and	O
prevented	O
cardiomyocytes	B-T017
from	O
hypoxia	O
-	O
reoxygenation	O
damage	O
.	O

However	O
,	O
whether	O
PTD	B-T082
-	O
Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
would	O
prevent	O
BCP	B-T033
development	O
is	O
unknown	O
.	O

In	O
the	O
current	O
study	B-T062
,	O
we	O
found	B-T033
that	O
an	O
implanted	B-T074
carcinoma	B-T038
in	O
the	O
rat	B-T204
tibia	B-T017
induced	O
remarkable	O
hyperalgesia	B-T033
,	O
increased	O
H2O2	B-T103
levels	O
and	O
decreased	O
SOD	B-T103
and	O
peroxiredoxin	B-T103
4	I-T103
levels	O
.	O

After	O
administration	O
of	O
recombinant	B-T103
PTD	B-T082
-	O
Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
to	O
these	O
tumor	O
-	O
burden	O
rats	B-T204
,	O
their	O
hyperalgesia	B-T033
was	O
significantly	O
attenuated	O
and	O
peroxiredoxin	B-T103
4	I-T103
expression	B-T038
was	O
significantly	O
increased	O
.	O

In	O
addition	O
,	O
an	O
increased	O
expression	O
of	O
N	B-T103
-	I-T103
methyl	I-T103
-	I-T103
d	I-T103
-	I-T103
aspartic	I-T103
acid	I-T103
(	I-T103
NMDA	I-T103
)	I-T103
receptors	I-T103
and	O
a	O
decreased	O
expression	O
of	O
γ	B-T103
-	I-T103
aminobutyric	I-T103
acid	I-T103
(	I-T103
GABA	I-T103
)	I-T103
receptors	I-T103
in	O
this	O
cancer	B-T033
pain	I-T033
were	O
prevented	O
by	O
PTD	B-T082
-	O
Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
administration	O
or	O
peroxiredoxin	B-T103
4	I-T103
overexpression	B-T038
.	O

Our	O
data	O
suggested	O
that	O
reactive	B-T103
oxygen	I-T103
species	I-T103
,	O
at	O
least	O
in	O
part	O
,	O
play	O
a	O
role	O
in	O
cancer	B-T038
metastatic	I-T038
pain	B-T033
development	O
and	O
persistency	O
which	O
can	O
be	O
attenuated	O
by	O
the	O
adminstration	O
of	O
recombinant	B-T103
PTD	I-T103
-	O
Cu	B-T103
/	I-T103
Zn	I-T103
SOD	I-T103
via	O
the	O
peroxiredoxin	B-T103
4	I-T103
modulation	B-T038
from	O
oxidative	B-T038
stress	I-T038
.	O

Immune	B-T033
dysregulation	I-T033
in	O
offspring	O
of	O
a	O
bipolar	B-T038
parent	O
.	O
Altered	O
serum	B-T031
levels	O
of	O
immune	O
growth	B-T103
factors	I-T103
at	O
adolescent	O
age	O

Immune	B-T033
dysregulation	I-T033
plays	O
a	O
role	O
in	O
the	O
vulnerability	O
for	O
mood	B-T038
disorders	I-T038
.	O

Immune	O
growth	B-T103
factors	I-T103
,	O
such	O
as	O
Stem	B-T103
Cell	I-T103
Factor	I-T103
(	O
SCF	B-T103
)	O
,	O
Insulin	B-T103
-	I-T103
like	I-T103
Growth	I-T103
Factor	I-T103
-	I-T103
Binding	I-T103
Protein	I-T103
-	I-T103
2	I-T103
(	O
IGF	B-T103
-	I-T103
BP2	I-T103
)	O
,	O
Epidermal	B-T103
Growth	I-T103
Factor	I-T103
(	O
EGF	B-T103
)	O
,	O
IL	B-T103
-	I-T103
7	I-T103
and	O
sCD25	B-T103
have	O
repeatedly	O
been	O
reported	O
altered	O
in	O
patients	O
with	O
mood	B-T038
disorders	I-T038
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
investigate	O
levels	O
of	O
these	O
factors	B-T103
in	O
serum	B-T031
of	O
adolescent	O
bipolar	B-T038
offspring	O
,	O
who	O
have	O
a	O
heightened	O
risk	O
for	O
mood	B-T038
disorder	I-T038
development	O
and	O
to	O
also	O
analyze	B-T062
the	O
data	O
combined	O
with	O
previously	O
published	B-T170
data	I-T170
.	O

Growth	B-T103
factors	I-T103
were	O
assessed	O
by	O
CBA	B-T058
/	O
ELISA	B-T058
in	O
adolescent	O
bipolar	B-T038
offspring	O
(	O
n	O
=	O
96	O
,	O
mean	O
age	O
=	O
16	O
years	O
)	O
and	O
in	O
age	O
-	O
and	O
gender	O
-	O
matched	O
healthy	O
controls	O
(	O
n	O
=	O
50	O
)	O
.	O

EGF	B-T103
belonged	O
to	O
a	O
mutually	O
correlating	O
cluster	O
of	O
mainly	O
neurotrophic	B-T103
compounds	I-T103
including	O
S100B	B-T103
and	O
BDNF	B-T103
,	O
which	O
were	O
in	O
general	O
decreased	O
in	O
serum	B-T031
.	O

IL	B-T103
-	I-T103
7	I-T103
,	O
SCF	B-T103
,	O
IGF	B-T103
-	I-T103
BP2	I-T103
and	O
sCD25	B-T103
,	O
belonged	O
to	O
a	O
different	O
mutually	O
correlating	O
cluster	O
of	O
immune	O
growth	B-T103
factors	I-T103
,	O
which	O
were	O
in	O
general	O
increased	O
:	O
IGF	B-T103
-	I-T103
BP2	I-T103
significantly	O
in	O
serum	B-T031
of	O
offspring	O
without	O
a	O
mood	B-T038
disorder	I-T038
,	O
IL	B-T103
-	I-T103
7	I-T103
and	O
SCF	B-T103
in	O
serum	B-T031
of	O
offspring	O
who	O
had	O
expirienced	B-T038
a	O
mood	B-T038
episode	I-T038
.	O

This	O
pattern	B-T082
of	O
de	O
-	O
and	O
increases	O
was	O
not	O
different	O
between	O
bipolar	B-T038
offspring	O
that	O
developed	O
or	O
did	O
not	O
develop	O
a	O
mood	B-T038
disorder	I-T038
over	O
time	O
,	O
apart	O
from	O
the	O
IGF	B-T103
-	I-T103
BP2	I-T103
level	O
,	O
which	O
was	O
near	O
significantly	O
higher	O
in	O
offspring	O
later	O
developing	O
a	O
mood	B-T038
disorder	I-T038
.	O

Correlations	O
with	O
the	O
previously	O
published	B-T170
immune	B-T017
-	I-T017
cellular	I-T017
abnormalities	I-T017
were	O
not	O
found	O
.	O

In	O
conclusion	O
non	O
-	O
affected	O
adolescents	O
at	O
familial	O
mood	B-T038
disorder	I-T038
development	O
risk	O
were	O
characterized	O
by	O
a	O
distinct	O
pattern	B-T082
of	O
a	O
series	O
of	O
compounds	B-T103
operating	O
in	O
a	O
network	O
of	O
hematopoiesis	B-T038
,	O
neurogenesis	B-T038
and	O
inflammation	B-T038
.	O

eNOS	B-T103
S	B-T038
-	I-T038
nitrosylates	I-T038
β	B-T103
-	I-T103
actin	I-T103
on	O
Cys374	B-T103
and	O
regulates	B-T038
PKC	B-T103
-	I-T103
θ	I-T103
at	O
the	O
immune	B-T017
synapse	I-T017
by	O
impairing	O
actin	B-T038
binding	I-T038
to	O
profilin	B-T103
-	I-T103
1	I-T103

The	O
actin	B-T038
cytoskeleton	I-T038
coordinates	I-T038
the	I-T038
organization	I-T038
of	O
signaling	B-T103
microclusters	I-T103
at	O
the	O
immune	B-T017
synapse	I-T017
(	O
IS	B-T017
)	O
;	O
however	O
,	O
the	O
mechanisms	B-T038
involved	O
remain	O
poorly	O
understood	O
.	O

We	O
show	O
here	O
that	O
nitric	B-T103
oxide	I-T103
(	O
NO	B-T103
)	O
generated	O
by	O
endothelial	B-T103
nitric	I-T103
oxide	I-T103
synthase	I-T103
(	O
eNOS	B-T103
)	O
controls	O
the	O
coalescence	O
of	O
protein	B-T103
kinase	I-T103
C	I-T103
-	I-T103
θ	I-T103
(	O
PKC	B-T103
-	I-T103
θ	I-T103
)	O
at	O
the	O
central	B-T017
supramolecular	I-T017
activation	I-T017
cluster	I-T017
(	O
c	B-T017
-	I-T017
SMAC	I-T017
)	O
of	O
the	O
IS	B-T017
.	O

eNOS	B-T103
translocated	B-T038
with	O
the	O
Golgi	B-T017
to	O
the	O
IS	B-T017
and	O
partially	O
colocalized	B-T082
with	O
F	B-T103
-	I-T103
actin	I-T103
around	O
the	O
c	B-T017
-	I-T017
SMAC	I-T017
.	O

This	O
resulted	O
in	O
reduced	O
actin	B-T038
polymerization	I-T038
and	O
centripetal	O
retrograde	O
flow	O
of	O
β	B-T103
-	I-T103
actin	I-T103
and	O
PKC	B-T103
-	I-T103
θ	I-T103
from	O
the	O
lamellipodium	B-T017
-	I-T017
like	I-T017
distal	B-T082
(	B-T017
d	I-T017
)	I-T017
-	I-T017
SMAC	I-T017
,	O
promoting	O
PKC	B-T103
-	I-T103
θ	I-T103
activation	B-T038
.	O

Furthermore	O
,	O
eNOS	B-T103
-	O
derived	O
NO	B-T103
S	B-T038
-	I-T038
nitrosylated	I-T038
β	B-T103
-	I-T103
actin	I-T103
on	O
Cys374	B-T103
and	O
impaired	O
actin	B-T038
binding	I-T038
to	O
profilin	B-T103
-	I-T103
1	I-T103
(	O
PFN1	B-T103
)	O
,	O
as	O
confirmed	O
with	O
the	O
transnitrosylating	B-T038
agent	O
S	B-T103
-	I-T103
nitroso	I-T103
-	I-T103
L	I-T103
-	I-T103
cysteine	I-T103
(	O
Cys	B-T103
-	I-T103
NO	I-T103
)	O
.	O

The	O
importance	O
of	O
NO	B-T103
and	O
the	O
formation	O
of	O
PFN1	B-T103
-	I-T103
actin	I-T103
complexes	I-T103
on	O
the	O
regulation	B-T038
of	O
PKC	B-T103
-	I-T103
θ	I-T103
was	O
corroborated	O
by	O
overexpression	B-T038
of	O
PFN1	B-T017
-	O
and	O
actin	B-T038
-	I-T038
binding	I-T038
defective	O
mutants	B-T038
of	O
β	B-T017
-	I-T017
actin	I-T017
(	I-T017
C374S	I-T017
)	I-T017
and	O
PFN1	B-T017
(	I-T017
H119E	I-T017
)	I-T017
,	O
respectively	O
,	O
which	O
reduced	O
the	O
coalescence	O
of	O
PKC	B-T103
-	I-T103
θ	I-T103
at	O
the	O
c	B-T017
-	I-T017
SMAC	I-T017
.	O

These	O
findings	O
unveil	O
a	O
novel	O
NO	B-T103
-	O
dependent	O
mechanism	B-T038
by	O
which	O
the	O
actin	B-T038
cytoskeleton	I-T038
controls	I-T038
the	I-T038
organization	I-T038
and	O
activation	O
of	O
signaling	B-T103
microclusters	I-T103
at	O
the	O
IS	B-T017
.	O

Dobutamine	B-T058
Stress	I-T058
Echocardiography	I-T058
:	O
Impact	O
of	O
Abnormal	B-T033
Blood	B-T033
Potassium	I-T033
Levels	I-T033
on	O
Cardiac	B-T033
Arrhythmias	I-T033

Guidelines	B-T170
suggest	O
that	O
an	O
abnormal	B-T033
blood	B-T033
potassium	I-T033
level	I-T033
is	O
a	O
relative	O
contraindication	O
to	O
performing	O
dobutamine	B-T058
stress	I-T058
echocardiography	I-T058
(	O
DSE	B-T058
)	O
.	O

However	O
,	O
this	O
has	O
not	O
been	O
previously	O
studied	O
.	O

We	O
reviewed	O
a	O
consecutive	B-T062
series	I-T062
of	I-T062
patients	I-T062
who	O
had	O
potassium	B-T103
testing	O
within	O
48	O
hours	O
of	O
undergoing	O
DSE	B-T058
for	O
the	O
evaluation	B-T058
of	O
myocardial	B-T038
ischemia	I-T038
over	O
a	O
10	O
-	O
year	O
period	O
(	O
N	O
=	O
13	O
,	O
198	O
)	O
.	O

Normal	O
potassium	B-T103
range	O
in	O
our	O
laboratory	B-T092
is	O
3	O
.	O
6	O
-	O
5	O
.	O
2	O
mmol	O
/	O
L	O
.	O

Hemolyzed	B-T033
samples	I-T033
were	O
not	O
included	O
.	O

The	O
association	O
of	O
potassium	B-T033
levels	I-T033
with	O
the	O
development	O
of	O
supraventricular	B-T038
and	O
ventricular	B-T038
arrhythmias	I-T038
was	O
assessed	O
.	O

The	O
incidence	O
of	O
clinically	O
significant	O
arrhythmias	B-T033
was	O
very	O
low	O
(	O
supraventricular	B-T038
tachycardia	I-T038
/	O
atrial	B-T038
fibrillation	I-T038
,	O
4	O
.	O
9	O
%	O
;	O
nonsustained	B-T038
ventricular	I-T038
tachycardia	I-T038
,	O
2	O
.	O
9	O
%	O
;	O
sustained	B-T038
ventricular	I-T038
tachycardia	I-T038
or	O
ventricular	B-T038
fibrillation	I-T038
,	O
0	O
.	O
1	O
%	O
)	O
,	O
confirming	O
the	O
overall	O
safety	O
of	O
DSE	B-T058
.	O

Most	O
arrhythmias	B-T033
(	O
88	O
%	O
)	O
occurred	O
in	O
patients	O
with	O
normal	O
potassium	B-T033
levels	I-T033
,	O
and	O
arrhythmia	B-T033
rates	O
remained	O
low	O
in	O
patients	O
with	O
potassium	B-T103
abnormalities	B-T033
.	O

Patients	O
with	O
hyperkalemia	B-T033
had	O
a	O
lower	O
risk	O
of	O
developing	O
mild	O
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
0	O
.	O
39	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
22	O
-	O
0	O
.	O
71	O
)	O
and	O
severe	O
(	O
OR	O
,	O
0	O
.	O
13	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
01	O
-	O
0	O
.	O
68	O
)	O
supraventricular	B-T038
arrhythmias	I-T038
as	O
well	O
as	O
mild	O
ventricular	B-T038
arrhythmias	I-T038
(	O
OR	O
,	O
0	O
.	O
58	O
;	O
95	O
%	O
CI	O
,	O
0	O
.	O
40	O
-	O
0	O
.	O
83	O
)	O
.	O

Even	O
though	O
events	O
were	O
rare	O
,	O
patients	O
with	O
severe	O
hypokalemia	B-T033
(	O
potassium	B-T033
levels	I-T033
≤	O
3	O
.	O
1	O
mmol	O
/	O
L	O
)	O
had	O
an	O
increased	O
risk	O
of	O
supraventricular	B-T038
arrhythmia	I-T038
and	O
ventricular	B-T038
ectopy	I-T038
.	O

DSE	B-T058
is	O
safe	O
even	O
in	O
the	O
setting	O
of	O
abnormalities	B-T033
in	O
blood	B-T033
potassium	I-T033
concentrations	I-T033
,	O
and	O
hence	O
cancellation	O
of	O
DSE	B-T058
in	O
patients	O
with	O
potassium	B-T103
abnormalities	B-T033
does	O
not	O
appear	O
warranted	O
.	O

Elevated	O
potassium	B-T033
levels	I-T033
are	O
associated	O
with	O
lower	O
rates	O
of	O
clinically	O
significant	O
supraventricular	B-T038
and	O
ventricular	B-T038
arrhythmias	I-T038
.	O

While	O
remaining	O
at	O
relatively	O
low	O
risk	O
,	O
patients	O
with	O
very	O
low	O
potassium	B-T033
levels	I-T033
(	O
≤3	O
.	O
1	O
mmol	O
/	O
L	O
)	O
at	O
the	O
time	O
of	O
DSE	B-T058
have	O
a	O
modestly	O
increased	O
risk	O
of	O
arrhythmia	B-T033
.	O

Consideration	O
could	O
be	O
given	O
to	O
correcting	O
severe	O
hypokalemia	B-T033
prior	O
to	O
DSE	B-T058
.	O

Anatomical	O
subgroup	B-T170
analysis	B-T062
of	O
the	O
MERIDIAN	O
cohort	B-T098
:	O
Posterior	B-T033
fossa	I-T033
abnormalities	I-T033

To	O
assess	O
the	O
diagnostic	O
and	O
clinical	O
contribution	O
of	O
in	B-T058
utero	I-T058
magnetic	I-T058
resonance	I-T058
(	I-T058
iuMR	I-T058
)	I-T058
imaging	I-T058
in	O
fetuses	B-T017
diagnosed	B-T033
with	O
abnormalities	B-T033
of	I-T033
the	I-T033
posterior	I-T033
fossa	I-T033
as	O
the	O
only	O
intracranial	B-T033
abnormality	I-T033
recognised	O
on	O
antenatal	B-T058
ultrasonography	I-T058
(	O
USS	B-T058
)	O
.	O

We	O
report	B-T170
a	O
sub	B-T170
-	I-T170
group	I-T170
analysis	B-T062
of	O
fetuses	B-T017
with	O
abnormalities	B-T033
of	I-T033
the	I-T033
posterior	I-T033
fossa	I-T033
diagnosed	B-T033
on	O
antenatal	B-T058
USS	I-T058
(	O
with	O
or	O
without	O
ventriculomegaly	O
)	O
from	O
the	O
MERIDIAN	O
cohort	B-T098
who	O
had	O
iuMR	B-T058
imaging	I-T058
within	O
2	O
weeks	O
of	O
USS	B-T058
and	O
outcome	O
reference	O
data	O
were	O
available	O
.	O

The	O
diagnostic	O
accuracy	O
of	O
USS	B-T058
and	O
iuMR	B-T058
are	O
reported	B-T170
as	O
well	O
as	O
indicators	B-T103
of	O
diagnostic	O
confidence	O
and	O
effects	O
on	O
prognosis	B-T058
and	O
clinical	B-T058
management	I-T058
.	O

Abnormalities	B-T033
confined	I-T033
to	I-T033
the	I-T033
posterior	I-T033
fossa	I-T033
according	O
to	O
USS	B-T058
were	O
found	O
in	O
81	O
fetuses	B-T017
(	O
67	O
with	O
parenchymal	B-T017
and	O
14	O
with	O
CSF	B-T031
-	O
containing	O
lesions	B-T033
)	O
.	O

The	O
overall	O
diagnostic	O
accuracy	O
for	O
detecting	B-T033
an	O
isolated	O
posterior	B-T033
fossa	I-T033
abnormality	I-T033
was	O
65	O
%	O
for	O
USS	B-T058
and	O
88	O
%	O
for	O
iuMR	B-T058
(	O
difference	O
=	O
22	O
%	O
,	O
95	O
%	O
CI	O
:	O
14	O
.	O
0	O
to	O
30	O
.	O
5	O
%	O
,	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

There	O
was	O
an	O
improvement	O
in	O
'	O
appropriate	O
'	O
diagnostic	O
confidence	O
as	O
assessed	O
by	O
a	O
score	O
-	O
based	O
weighted	O
average	O
'	O
method	B-T170
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
and	O
a	O
three	O
-	O
fold	O
reduction	B-T058
in	O
'	O
high	O
confidence	O
but	O
incorrect	O
diagnoses	B-T033
'	O
was	O
achieved	O
by	O
using	O
iuMR	B-T058
imaging	I-T058
.	O

The	O
prognostic	B-T058
information	I-T058
given	O
to	O
the	O
women	B-T098
after	O
iuMR	B-T058
imaging	I-T058
changed	O
in	O
44	O
%	O
of	O
cases	O
and	O
the	O
overall	O
effect	O
of	O
iuMR	B-T058
on	O
clinical	B-T058
management	I-T058
was	O
considered	O
to	O
be	O
'	O
significant	O
'	O
,	O
'	O
major	O
'	O
or	O
'	O
decisive	B-T033
'	O
in	O
35	O
%	O
of	O
cases	O
.	O

Our	O
data	O
suggests	O
that	O
any	O
woman	B-T098
whose	O
fetus	B-T017
has	O
a	O
posterior	B-T033
fossa	I-T033
abnormality	I-T033
as	O
the	O
only	O
intracranial	B-T033
finding	I-T033
on	O
USS	B-T058
should	O
have	O
iuMR	B-T058
imaging	I-T058
for	O
further	O
evaluation	B-T058
.	O

This	O
is	O
on	O
the	O
basis	O
of	O
improved	B-T033
diagnostic	O
accuracy	O
and	O
confidence	O
which	O
has	O
substantial	O
effects	O
on	O
the	O
prognostic	B-T058
information	I-T058
given	O
to	O
women	B-T098
and	O
changes	O
in	O
clinical	B-T058
management	I-T058
.	O

Design	O
,	O
synthesis	O
,	O
and	O
evaluation	B-T058
of	O
curcumin	B-T103
derivatives	B-T103
as	O
Nrf2	B-T103
activators	O
and	O
cytoprotectors	B-T038
against	O
oxidative	B-T038
death	I-T038

Activation	O
of	O
nuclear	B-T103
factor	I-T103
erythroid	I-T103
-	I-T103
2	I-T103
-	I-T103
related	I-T103
factor	I-T103
2	I-T103
(	O
Nrf2	B-T103
)	O
has	O
been	O
proven	O
to	O
be	O
an	O
effective	O
means	O
to	O
prevent	O
the	O
development	O
of	O
cancer	B-T038
,	O
and	O
natural	O
curcumin	B-T103
stands	O
out	O
as	O
a	O
potent	O
Nrf2	B-T103
activator	O
and	O
cancer	B-T038
chemopreventive	B-T103
agent	I-T103
.	O

In	O
this	O
study	B-T062
,	O
we	O
synthesized	O
a	O
series	O
of	O
curcumin	B-T103
analogs	B-T103
by	O
introducing	O
the	O
geminal	O
dimethyl	O
substituents	O
on	O
the	O
active	O
methylene	O
group	O
to	O
find	O
more	O
potent	O
Nrf2	B-T103
activators	O
and	O
cytoprotectors	B-T038
against	O
oxidative	B-T038
death	I-T038
.	O

The	O
geminally	O
dimethylated	O
and	O
catechol	B-T103
-	O
type	O
curcumin	B-T103
analog	B-T103
(	O
compound	B-T103
3	I-T103
)	O
was	O
identified	O
as	O
a	O
promising	O
lead	B-T103
molecule	I-T103
in	O
terms	O
of	O
its	O
increased	O
stability	B-T038
and	O
cytoprotective	B-T038
activity	O
against	O
the	O
tert	B-T103
-	I-T103
butyl	I-T103
hydroperoxide	I-T103
(	O
t	B-T103
-	I-T103
BHP	I-T103
)	O
-	O
induced	O
death	B-T038
of	O
HepG2	B-T017
cells	I-T017
.	O

Mechanism	O
studies	B-T062
indicate	O
that	O
its	O
cytoprotective	B-T038
effects	O
are	O
mediated	O
by	O
activating	O
the	O
Nrf2	B-T103
signaling	B-T038
pathway	I-T038
in	O
the	O
Michael	B-T103
acceptor	I-T103
-	O
and	O
catechol	B-T103
-	O
dependent	O
manners	O
.	O

Additionally	O
,	O
we	O
verified	O
by	O
using	O
copper	B-T103
and	O
iron	B-T103
ion	B-T103
chelators	B-T103
that	O
the	O
two	O
metal	B-T103
ion	B-T103
-	O
mediated	O
oxidations	B-T038
of	O
compound	B-T103
3	I-T103
to	O
its	O
corresponding	O
electrophilic	O
o	B-T103
-	I-T103
quinone	I-T103
,	O
contribute	O
significantly	O
to	O
its	O
Nrf2	B-T103
-	O
dependent	O
cytoprotection	B-T038
.	O

This	O
work	O
provides	O
an	O
example	O
of	O
successfully	O
designing	O
natural	O
curcumin	B-T103
-	O
directed	O
Nrf2	B-T103
activators	O
by	O
a	O
stability	B-T038
-	O
increasing	O
and	O
proelectrophilic	O
strategy	O
.	O

Safe	O
with	O
Self	B-T037
-	I-T037
Injury	I-T037
:	O
A	O
Practical	B-T170
Guide	I-T170
to	O
Understanding	B-T038
,	O
Responding	O
and	O
Harm	B-T058
-	I-T058
reduction	I-T058
Inckle	O
Kay	O
Safe	O
with	O
Self	B-T037
-	I-T037
Injury	I-T037
:	O
A	O
Practical	B-T170
Guide	I-T170
to	O
Understanding	B-T038
,	O
Responding	O
and	O
Harm	B-T058
-	I-T058
reduction	I-T058
274pp	O
£23	O
.	O
99	O
PCCS	O
Books	O
9781910919163	O
1910919160	O
[	O
Formula	O
:	O
see	O
text	O

The	O
author	B-T097
begins	O
her	O
book	B-T170
with	O
a	O
concise	O
exploration	O
of	O
the	O
stereotypes	B-T038
and	O
truths	O
of	O
self	B-T037
-	I-T037
harm	I-T037
.	O

In	O
the	O
following	O
seven	O
chapters	B-T170
,	O
she	O
sets	O
out	O
a	O
grounded	B-T170
and	O
often	O
challenging	B-T082
view	I-T082
of	O
how	O
self	B-T037
-	I-T037
harm	I-T037
is	O
understood	B-T038
from	O
differing	O
perspectives	B-T038
.	O

Pre	O
-	O
hospital	O
policies	B-T170
for	O
the	O
care	B-T058
of	I-T058
patients	I-T058
with	O
acute	B-T038
coronary	I-T038
syndromes	I-T038
in	O
India	B-T082
:	O
A	O
policy	B-T170
document	B-T170
analysis	B-T062

Ischemic	B-T033
heart	I-T033
disease	I-T033
is	O
the	O
leading	O
cause	B-T033
of	I-T033
death	I-T033
in	O
India	B-T082
.	O

In	O
high	B-T033
-	I-T033
income	I-T033
countries	B-T082
,	O
pre	B-T058
-	I-T058
hospital	I-T058
systems	I-T058
of	I-T058
care	I-T058
have	O
been	O
developed	O
to	O
manage	O
acute	O
manifestations	O
of	O
ischemic	B-T033
heart	I-T033
disease	I-T033
,	O
such	O
as	O
acute	B-T038
coronary	I-T038
syndrome	I-T038
(	O
ACS	B-T038
)	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
guidelines	B-T170
,	O
policies	B-T170
,	O
regulations	O
,	O
or	O
laws	B-T170
exist	O
to	O
guide	O
pre	O
-	O
hospital	O
ACS	B-T038
care	B-T058
in	O
India	B-T082
.	O

We	O
undertook	O
a	O
nation	O
-	O
wide	O
document	B-T170
analysis	B-T062
to	O
address	O
this	O
gap	O
in	O
knowledge	B-T170
.	O

From	O
November	O
2014	O
to	O
May	O
2016	O
,	O
we	O
searched	O
for	O
publicly	O
available	O
emergency	B-T058
care	I-T058
guidelines	B-T170
and	O
legislation	B-T170
addressing	O
pre	O
-	O
hospital	O
ACS	B-T038
care	B-T058
in	O
all	O
29	O
Indian	B-T082
states	B-T082
and	O
7	O
Union	B-T082
Territories	I-T082
via	O
Internet	O
search	O
and	O
direct	O
correspondence	B-T170
.	O

We	O
found	B-T033
two	O
documents	B-T170
addressing	O
pre	O
-	O
hospital	O
ACS	B-T038
care	B-T058
.	O

Though	O
India	B-T082
has	O
legislation	O
mandating	O
acute	B-T058
care	I-T058
for	O
emergencies	O
such	O
as	O
trauma	B-T037
,	O
regulations	O
or	O
laws	B-T170
to	O
guide	O
pre	O
-	O
hospital	O
ACS	B-T038
care	B-T058
are	O
largely	O
absent	O
.	O

Policy	B-T097
makers	I-T097
urgently	O
need	O
to	O
develop	O
comprehensive	O
,	O
multi	O
-	O
stakeholder	O
policies	B-T170
for	O
pre	O
-	O
hospital	O
emergency	O
cardiovascular	B-T058
care	I-T058
in	O
India	B-T082
.	O

Lack	O
of	O
antimicrobial	B-T033
efficacy	O
of	O
mecetronium	B-T103
etilsulfate	I-T103
in	O
propanol	B-T103
-	O
based	O
hand	B-T103
rubs	I-T103
for	O
surgical	B-T058
hand	B-T058
disinfection	I-T058

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
determine	O
if	O
mecetronium	B-T103
etilsulfate	I-T103
(	O
MES	B-T103
)	O
contributes	O
to	O
overall	O
efficacy	O
in	O
surgical	B-T058
hand	B-T058
disinfection	I-T058
.	O

Three	O
blinded	O
hand	B-T103
rubs	I-T103
(	O
45	O
%	O
iso	B-T103
-	I-T103
propanol	I-T103
,	O
30	O
%	O
n	B-T103
-	I-T103
propanol	I-T103
)	O
were	O
applied	O
for	O
1	O
.	O
5	O
min	O
and	O
compared	O
with	O
the	O
EN	B-T103
12791	I-T103
reference	O
procedure	O
(	O
crossover	B-T062
design	I-T062
)	O
.	O

One	O
commercial	B-T170
hand	B-T103
rub	I-T103
contained	O
0	O
.	O
2	O
%	O
MES	B-T103
,	O
and	O
the	O
two	O
other	O
hand	B-T103
rubs	I-T103
were	O
identical	O
apart	O
from	O
0	O
.	O
2	O
%	O
MES	B-T103
.	O

None	O
of	O
the	O
formulations	O
had	O
a	O
log10	O
reduction	O
after	O
3	O
h	O
that	O
was	O
significantly	O
better	O
compared	O
with	O
the	O
reference	O
procedure	O
[	O
mean	O
1	O
.	O
72	O
(	O
standard	O
deviation	O
1	O
.	O
15	O
)	O
]	O
.	O

The	O
antimicrobial	B-T033
contribution	O
of	O
MES	B-T103
in	O
hand	B-T103
rubs	I-T103
is	O
questionable	O
.	O

Skin	O
Conductance	O
Responses	O
and	O
Neural	O
Activations	O
During	O
Fear	B-T038
Conditioning	B-T038
and	O
Extinction	B-T038
Recall	B-T038
Across	O
Anxiety	B-T038
Disorders	I-T038

The	O
fear	B-T038
conditioning	B-T038
and	O
extinction	B-T038
neurocircuitry	O
has	O
been	O
extensively	O
studied	B-T062
in	O
healthy	O
and	O
clinical	O
populations	B-T098
,	O
with	O
a	O
particular	B-T082
focus	I-T082
on	O
posttraumatic	B-T038
stress	I-T038
disorder	I-T038
.	O

Despite	O
significant	O
overlap	O
of	O
symptoms	B-T033
between	O
posttraumatic	B-T038
stress	I-T038
disorder	I-T038
and	O
anxiety	B-T038
disorders	I-T038
,	O
the	O
latter	O
has	O
received	O
less	O
attention	B-T038
.	O

Given	O
that	O
dysregulated	O
fear	B-T038
levels	O
characterize	O
anxiety	B-T038
disorders	I-T038
,	O
examining	B-T058
the	O
neural	O
correlates	O
of	O
fear	B-T038
and	O
extinction	B-T038
learning	B-T038
may	O
shed	O
light	O
on	O
the	O
pathogenesis	B-T038
of	O
underlying	O
anxiety	B-T038
disorders	I-T038
.	O

To	O
investigate	O
the	O
psychophysiological	B-T038
and	O
neural	O
correlates	O
of	O
fear	B-T038
conditioning	B-T038
and	O
extinction	B-T038
recall	B-T038
in	O
anxiety	B-T038
disorders	I-T038
and	O
to	O
document	B-T170
how	O
these	O
features	O
differ	O
as	O
a	O
function	O
of	O
multiple	O
diagnoses	B-T033
or	O
anxiety	B-T033
severity	O
.	O

This	O
investigation	B-T058
was	O
a	O
cross	B-T062
-	I-T062
sectional	I-T062
,	O
case	B-T058
-	I-T058
control	I-T058
,	O
functional	B-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
study	B-T062
at	O
an	O
academic	B-T092
medical	I-T092
center	I-T092
.	O

Participants	B-T098
were	O
healthy	O
controls	O
and	O
individuals	B-T098
with	O
at	O
least	O
1	O
of	O
the	O
following	O
anxiety	B-T038
disorders	I-T038
:	O
generalized	B-T038
anxiety	I-T038
disorder	I-T038
,	O
social	O
anxiety	O
disorder	O
,	O
specific	B-T038
phobia	I-T038
,	O
and	O
panic	B-T038
disorder	I-T038
.	O

The	O
study	B-T062
dates	O
were	O
between	O
March	O
2013	O
and	O
May	O
2015	O
.	O

Two	O
-	O
day	O
fear	B-T038
conditioning	B-T038
and	O
extinction	B-T038
paradigm	O
.	O

Skin	O
conductance	O
responses	O
,	O
blood	B-T038
oxygenation	I-T038
level	I-T038
-	I-T038
dependent	I-T038
responses	O
,	O
trait	O
anxiety	O
scores	O
from	O
the	O
State	B-T058
Trait	I-T058
Anxiety	I-T058
Inventory	I-T058
-	O
Trait	O
Form	O
,	O
and	O
functiona	O
l	O
connectivity	O
.	O

This	O
study	B-T062
included	O
21	O
healthy	O
controls	O
(	O
10	O
women	B-T098
)	O
and	O
61	O
individuals	B-T098
with	O
anxiety	B-T038
disorders	I-T038
(	O
36	O
women	B-T098
)	O
.	O

P	O
values	O
reported	B-T058
for	O
the	O
neuroimaging	B-T058
results	B-T033
are	O
all	O
familywise	O
error	O
corrected	O
.	O

Skin	O
conductance	O
responses	O
during	O
extinction	B-T038
recall	B-T038
did	O
not	O
differ	O
between	O
individuals	B-T098
with	O
anxiety	B-T038
disorders	I-T038
and	O
healthy	O
controls	O
(	O
ηp2	O
=	O
0	O
.	O
001	O
,	O
P	O
=	O
.	O
79	O
)	O
,	O
where	O
ηp2	O
is	O
partial	O
eta	O
squared	O
.	O

The	O
anxiety	B-T033
group	B-T098
had	O
lower	O
activation	O
of	O
the	O
ventromedial	B-T017
prefrontal	I-T017
cortex	I-T017
(	O
vmPFC	B-T017
)	O
during	O
extinction	B-T038
recall	B-T038
(	O
ηp2	O
=	O
0	O
.	O
178	O
,	O
P	O
=	O
.	O
02	O
)	O
.	O

A	O
similar	O
hypoactive	B-T033
pattern	B-T082
was	O
found	O
during	O
early	O
conditioning	B-T038
(	O
ηp2	O
=	O
0	O
.	O
106	O
,	O
P	O
=	O
.	O
009	O
)	O
.	O

The	O
vmPFC	B-T017
hypoactivation	O
was	O
associated	O
with	O
anxiety	B-T033
symptom	I-T033
severity	O
(	O
r	O
=	O
-	O
0	O
.	O
420	O
,	O
P	O
=	O
.	O
01	O
for	O
conditioning	B-T038
and	O
r	O
=	O
-	O
0	O
.	O
464	O
,	O
P	O
=	O
.	O
004	O
for	O
extinction	B-T038
recall	B-T038
)	O
and	O
the	O
number	O
of	O
co	O
-	O
occuring	O
anxiety	B-T038
disorders	I-T038
diagnosed	B-T033
(	O
ηp2	O
=	O
0	O
.	O
137	O
,	O
P	O
=	O
.	O
009	O
for	O
conditioning	B-T038
and	O
ηp2	O
=	O
0	O
.	O
227	O
,	O
P	O
=	O
.	O
004	O
for	O
extinction	B-T038
recall	B-T038
)	O
.	O

Psychophysiological	B-T038
interaction	O
analyses	O
revealed	O
that	O
the	O
fear	B-T038
network	B-T038
connectivity	I-T038
differed	O
between	O
healthy	O
controls	O
and	O
the	O
anxiety	B-T033
group	B-T098
during	O
fear	B-T038
learning	B-T038
(	O
ηp2	O
range	O
between	O
0	O
.	O
088	O
and	O
0	O
.	O
176	O
and	O
P	O
range	O
between	O
0	O
.	O
02	O
and	O
0	O
.	O
003	O
)	O
and	O
extinction	B-T038
recall	B-T038
(	O
ηp2	O
range	O
between	O
0	O
.	O
111	O
and	O
0	O
.	O
235	O
and	O
P	O
range	O
between	O
0	O
.	O
02	O
and	O
0	O
.	O
002	O
)	O
.	O

Despite	O
no	O
skin	O
conductance	O
response	O
group	B-T098
differences	O
during	O
extinction	B-T038
recall	B-T038
,	O
brain	B-T017
activation	O
patterns	B-T082
between	O
anxious	O
and	O
healthy	O
individuals	B-T098
differed	O
.	O

These	O
findings	B-T033
encourage	O
future	O
studies	B-T062
to	O
examine	B-T058
the	O
conditions	O
longitudinally	B-T062
and	O
in	O
the	O
context	O
of	O
treatment	B-T062
trials	I-T062
to	O
improve	B-T033
and	O
guide	B-T058
therapeutics	I-T058
via	O
advanced	O
neurobiological	B-T091
understanding	B-T038
of	O
each	O
disorder	B-T038
.	O

Extracellular	B-T017
vesicles	I-T017
from	O
bone	B-T017
marrow	I-T017
derived	O
mesenchymal	B-T017
stem	I-T017
cells	I-T017
protect	O
against	O
murine	B-T204
hepatic	B-T037
ischemia	I-T037
-	I-T037
reperfusion	B-T037
injury	I-T037

Hepatic	B-T037
ischemia	I-T037
-	I-T037
reperfusion	I-T037
injury	I-T037
(	O
IRI	B-T037
)	O
and	O
associated	B-T038
inflammation	I-T038
contributes	O
to	O
liver	B-T038
dysfunction	I-T038
and	O
complications	B-T038
after	O
liver	B-T058
surgery	I-T058
and	O
transplantation	B-T058
.	O

Mesenchymal	B-T017
stem	I-T017
cells	I-T017
(	O
MSC	B-T017
)	O
have	O
been	O
reported	O
to	O
reduce	O
hepatic	B-T037
IRI	I-T037
because	O
of	O
their	O
reparative	O
immunomodulatory	B-T103
effects	O
in	O
injured	O
tissues	B-T017
.	O

Recent	O
studies	O
have	O
highlighted	O
beneficial	O
effects	O
of	O
extracellular	B-T017
vesicles	I-T017
from	O
MSCs	B-T017
(	O
MSC	B-T017
-	O
EV	B-T017
)	O
on	O
tissue	O
injury	O
.	O

The	O
effects	O
of	O
systemically	O
administered	O
mouse	B-T017
bone	I-T017
marrow	I-T017
derived	O
MSC	B-T017
-	O
EV	B-T017
were	O
evaluated	O
in	O
an	O
experimental	B-T204
murine	I-T204
model	I-T204
of	O
hepatic	B-T037
IRI	I-T037
induced	O
by	O
cross	O
clamping	O
the	O
hepatic	B-T017
artery	I-T017
and	O
portal	B-T017
vein	I-T017
for	O
90	O
minutes	O
followed	O
by	O
reperfusion	B-T058
for	O
periods	O
of	O
upto	O
6	O
hours	O
.	O

Compared	O
with	O
controls	B-T082
,	I-T082
intravenous	I-T082
administration	I-T082
of	O
MSC	B-T017
-	O
EV	B-T017
30	O
minutes	O
prior	O
to	O
IRI	B-T037
dramatically	O
reduced	O
the	O
extent	O
of	O
tissue	B-T038
necrosis	I-T038
,	O
decreased	O
caspase	B-T103
-	I-T103
3	I-T103
positive	I-T103
and	O
apoptotic	B-T017
cells	I-T017
,	O
and	O
reduced	O
serum	O
aminotransferase	B-T103
levels	O
.	O

MSC	B-T017
-	O
EV	B-T017
increased	O
hepatic	B-T082
mRNA	B-T038
expression	I-T038
of	O
NACHT	B-T017
,	I-T017
LRR	I-T017
and	I-T017
PYD	I-T017
domains	I-T017
-	I-T017
containing	I-T017
protein	I-T017
12	I-T017
(	O
Nlrp12	B-T017
)	O
,	O
and	O
the	O
chemokine	B-T017
(	I-T017
C	I-T017
-	I-T017
X	I-T017
-	I-T017
C	I-T017
motif	I-T017
)	I-T017
ligand	I-T017
1	I-T017
(	O
CXCL1	B-T017
)	O
,	O
and	O
reduced	O
mRNA	B-T038
expression	I-T038
of	O
several	O
inflammatory	O
cytokines	B-T103
such	O
as	O
IL	B-T103
-	I-T103
6	I-T103
during	O
IRI	B-T037
.	O

MSC	B-T017
-	O
EV	B-T017
increased	O
cell	B-T038
viability	I-T038
and	O
suppressed	O
both	O
oxidative	O
injury	O
and	O
NF	B-T103
-	I-T103
κB	I-T103
activity	O
in	O
AML12	B-T017
murine	I-T017
hepatocytes	I-T017
in	O
vitro	O
.	O

In	O
conclusion	O
,	O
the	O
administration	B-T058
of	O
EV	B-T017
derived	O
from	O
bone	B-T017
marrow	I-T017
derived	O
MSCs	B-T017
may	O
ameliorate	B-T033
hepatic	B-T037
IRI	I-T037
by	O
reducing	O
hepatic	B-T037
injury	I-T037
through	O
modulation	B-T082
of	O
the	O
inflammatory	B-T038
response	I-T038
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Nucleic	B-T058
acid	I-T058
detection	I-T058
with	O
CRISPR	B-T103
-	O
Cas13a	O
/	O
C2c2	O

Rapid	O
,	O
inexpensive	O
,	O
and	O
sensitive	O
nucleic	B-T058
acid	I-T058
detection	I-T058
may	O
aid	O
point	O
-	O
of	O
-	O
care	O
pathogen	O
detection	B-T058
,	O
genotyping	B-T058
,	O
and	O
disease	B-T038
monitoring	B-T058
.	O

The	O
RNA	B-T103
-	O
guided	O
,	O
RNA	B-T103
-	O
targeting	O
clustered	B-T103
regularly	I-T103
interspaced	I-T103
short	I-T103
palindromic	I-T103
repeats	I-T103
(	O
CRISPR	B-T103
)	O
effector	O
Cas13a	O
(	O
previously	O
known	O
as	O
C2c2	O
)	O
exhibits	O
a	O
"	O
collateral	B-T082
effect	O
"	O
of	O
promiscuous	O
ribonuclease	B-T038
activity	I-T038
upon	O
target	O
recognition	O
.	O

We	O
combine	O
the	O
collateral	B-T082
effect	O
of	O
Cas13a	O
with	O
isothermal	B-T058
amplification	I-T058
to	O
establish	O
a	O
CRISPR	B-T103
-	O
based	O
diagnostic	O
(	O
CRISPR	B-T103
-	O
Dx	O
)	O
,	O
providing	O
rapid	O
DNA	B-T103
or	O
RNA	B-T103
detection	B-T058
with	O
attomolar	O
sensitivity	O
and	O
single	B-T103
-	I-T103
base	I-T103
mismatch	O
specificity	O
.	O

We	O
use	O
this	O
Cas13a	O
-	O
based	O
molecular	O
detection	B-T058
platform	O
,	O
termed	O
Specific	O
High	O
-	O
Sensitivity	O
Enzymatic	O
Reporter	O
UnLOCKing	O
(	O
SHERLOCK	O
)	O
,	O
to	O
detect	B-T033
specific	O
strains	O
of	O
Zika	B-T005
and	O
Dengue	B-T005
virus	I-T005
,	O
distinguish	O
pathogenic	O
bacteria	B-T007
,	O
genotype	O
human	B-T204
DNA	B-T103
,	O
and	O
identify	O
mutations	B-T038
in	O
cell	B-T017
-	I-T017
free	I-T017
tumor	B-T103
DNA	I-T103
.	O

Furthermore	O
,	O
SHERLOCK	O
reaction	O
reagents	B-T103
can	O
be	O
lyophilized	B-T058
for	O
cold	O
-	O
chain	O
independence	O
and	O
long	O
-	O
term	O
storage	O
and	O
be	O
readily	O
reconstituted	O
on	O
paper	O
for	O
field	O
applications	O
.	O

A	O
plea	O
for	O
thoracoscopic	B-T058
resection	B-T058
of	O
solitary	B-T038
pulmonary	I-T038
nodule	I-T038
in	O
cancer	B-T038
patients	O

Solitary	B-T038
pulmonary	I-T038
nodules	I-T038
(	O
SPN	B-T038
)	O
are	O
frequently	O
detected	B-T033
in	O
cancer	B-T038
patients	O
.	O

These	O
lesions	B-T033
are	O
often	O
considered	O
as	O
pulmonary	B-T038
metastases	I-T038
and	O
increasingly	O
treated	O
by	O
non	B-T058
-	I-T058
surgical	I-T058
techniques	I-T058
without	O
histological	O
confirmation	B-T033
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
histological	O
nature	O
of	O
SPN	B-T038
resected	O
by	O
thoracoscopy	B-T058
and	O
to	O
identify	O
risk	B-T033
factors	I-T033
of	O
malignancy	B-T038
.	O

Single	B-T062
-	I-T062
institution	I-T062
retrospective	I-T062
analysis	I-T062
of	O
all	O
consecutive	O
patients	O
with	O
previously	O
known	O
malignancies	B-T038
who	O
underwent	O
thoracoscopic	B-T058
resection	B-T058
of	O
SPN	B-T038
with	O
unknown	O
diagnosis	B-T033
between	O
2001	O
and	O
2014	O
.	O

One	O
hundred	O
and	O
forty	O
cancer	B-T038
patients	O
underwent	O
thoracoscopic	B-T058
resection	B-T058
of	O
a	O
SPN	B-T038
.	O

The	O
resected	O
SPN	B-T038
was	O
benign	O
in	O
34	O
patients	O
(	O
24	O
.	O
3	O
%	O
)	O
and	O
malignant	O
in	O
106	O
patients	O
.	O

The	O
latter	O
were	O
metastasis	B-T038
in	O
70	O
patients	O
(	O
50	O
%	O
)	O
and	O
a	O
primary	O
lung	B-T038
cancer	I-T038
in	O
36	O
patients	O
(	O
25	O
.	O
7	O
%	O
)	O
.	O

Upon	O
univariate	O
analysis	O
,	O
malignancy	B-T038
was	O
significantly	O
associated	O
with	O
age	O
>	O
60	O
years	O
,	O
disease	B-T038
-	O
free	O
interval	O
≥24	O
months	O
,	O
SPN	B-T038
size	B-T082
>	O
8	O
mm	O
,	O
upper	B-T017
lobe	I-T017
localization	O
and	O
SUVmax	O
>	O
2	O
.	O
5	O
on	O
PET	B-T058
-	I-T058
CT	I-T058
.	O

Upon	O
multivariate	O
analysis	O
,	O
upper	B-T017
lobe	I-T017
localization	O
and	O
SUVmax	O
>	O
2	O
.	O
5	O
were	O
associated	O
with	O
malignancy	B-T038
.	O

Smoking	O
was	O
significantly	O
associated	O
with	O
SPN	B-T038
containing	O
primary	O
lung	B-T038
cancer	I-T038
.	O

In	O
this	O
series	O
,	O
only	O
50	O
%	O
of	O
SPN	B-T038
in	O
patients	O
with	O
known	O
malignant	B-T038
disease	I-T038
were	O
pulmonary	B-T038
metastases	I-T038
and	O
25	O
%	O
had	O
a	O
newly	O
diagnosed	O
NSCLC	B-T038
.	O

Smoking	O
was	O
associated	O
with	O
primary	O
lung	B-T038
cancer	I-T038
but	O
no	B-T033
other	O
predictor	O
was	O
found	O
to	O
allow	O
the	O
distinction	O
between	O
pulmonary	B-T038
metastasis	I-T038
and	O
lung	B-T038
cancer	I-T038
.	O

These	O
results	O
endorse	O
the	O
need	O
of	O
histological	O
confirmation	B-T033
of	O
SPN	B-T038
in	O
patients	O
with	O
previous	O
malignancies	B-T038
to	O
avoid	O
diagnostic	O
uncertainty	B-T033
and	O
suboptimal	O
treatments	B-T058
.	O

Reliability	O
of	O
Fear	B-T058
Assessment	I-T058
in	O
Growing	O
Pigs	B-T204
Exposed	O
to	O
a	O
Novel	O
Object	O
Test	O
in	O
Commercial	B-T170
Conditions	O

The	O
objective	B-T170
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
reliability	O
and	O
feasibility	B-T062
of	O
a	O
novel	O
object	O
test	O
assessing	O
fear	O
in	O
pigs	B-T204
in	O
commercial	B-T170
conditions	O
.	O

A	O
total	O
of	O
18	O
commercial	B-T170
farms	B-T082
were	O
visited	O
,	O
and	O
321	O
pens	O
housing	O
4	O
,	O
220	O
growing	O
pigs	B-T204
were	O
assessed	O
.	O

Three	O
balloons	O
were	O
used	O
as	O
a	O
novel	B-T204
stimulus	O
.	O

Measures	O
were	O
(	O
a	O
)	O
the	O
time	O
it	O
took	O
for	O
the	O
first	O
pig	B-T204
to	O
contact	O
1	O
of	O
the	O
balloons	O
,	O
(	O
b	O
)	O
percentage	O
of	O
nonhuman	B-T204
animals	B-T204
watching	O
the	O
balloons	O
each	O
for	O
10	O
s	O
,	O
and	O
(	O
c	O
)	O
percentage	O
of	O
animals	B-T204
touching	O
the	O
balloons	O
during	O
periods	O
of	O
5	O
s	O
.	O

The	O
time	O
of	O
the	O
first	O
pig	B-T204
to	O
contact	O
1	O
of	O
the	O
balloons	O
ranged	O
from	O
0	O
s	O
to	O
362	O
s	O
.	O

An	O
effect	O
of	O
the	O
farm	B-T082
was	O
found	O
(	O
p	O
<	O
.	O
0001	O
)	O
for	O
contact	O
latency	O
,	O
ranging	O
from	O
6	O
.	O
8	O
s	O
to	O
73	O
.	O
3	O
s	O
,	O
but	O
little	O
difference	O
was	O
found	O
in	O
terms	O
of	O
intrafarm	B-T082
variability	O
.	O

Interobserver	O
repeatability	O
was	O
also	O
high	O
in	O
this	O
measure	O
,	O
ranging	O
from	O
r	O
=	O
.	O
74	O
to	O
r	O
=	O
.	O
96	O
.	O

As	O
a	O
result	O
,	O
it	O
is	O
concluded	O
that	O
contact	O
latency	O
could	O
be	O
a	O
good	O
measure	O
to	O
assess	O
fear	B-T038
of	O
a	O
novel	O
stimulus	O
in	O
commercial	B-T170
farms	B-T082
.	O

Precise	O
prediction	O
of	O
activators	B-T103
for	O
the	O
human	B-T204
constitutive	B-T103
androstane	I-T103
receptor	I-T103
using	O
structure	B-T082
-	O
based	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
methods	B-T170

The	O
constitutive	B-T103
androstane	I-T103
receptor	I-T103
(	O
CAR	B-T103
,	O
NR1I3	B-T103
)	I-T103
regulates	B-T038
the	I-T038
expression	I-T038
of	O
numerous	O
drug	B-T038
-	I-T038
metabolizing	I-T038
enzymes	B-T103
and	O
transporters	B-T103
.	O

The	O
upregulation	B-T038
of	O
various	O
enzymes	B-T103
,	O
including	O
CYP2B6	B-T103
,	O
by	O
CAR	B-T103
activators	B-T103
is	O
a	O
critical	O
problem	O
leading	O
to	O
clinically	O
severe	O
drug	B-T038
-	I-T038
drug	I-T038
interactions	I-T038
(	O
DDIs	B-T038
)	O
.	O

To	O
date	O
,	O
however	O
,	O
few	O
effective	O
computational	B-T062
approaches	I-T062
for	O
identifying	O
CAR	B-T103
activators	O
exist	O
.	O

In	O
this	O
study	O
,	O
we	O
aimed	O
to	O
develop	O
three	O
-	O
dimensional	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
3D	O
-	O
QSAR	O
)	O
models	B-T170
to	O
predict	O
the	O
CAR	B-T103
activating	B-T038
potency	O
of	O
compounds	B-T103
emerging	O
in	O
the	O
drug	B-T062
-	I-T062
discovery	I-T062
process	O
.	O

Models	B-T170
were	O
constructed	O
using	O
comparative	B-T062
molecular	I-T062
field	I-T062
analysis	I-T062
(	O
CoMFA	B-T062
)	O
based	O
on	O
the	O
molecular	O
alignments	O
of	O
ligands	B-T038
binding	I-T038
to	O
CAR	B-T103
,	O
which	O
were	O
obtained	O
from	O
ensemble	O
ligand	B-T038
-	I-T038
docking	I-T038
using	O
28	B-T103
compounds	I-T103
as	O
a	O
training	O
set	O
.	O

The	O
CoMFA	B-T062
model	B-T170
,	O
modified	O
by	O
adding	O
a	O
lipophilic	O
parameter	O
with	O
calculated	O
logD7	O
.	O
4	O
(	O
S	O
+	O
logD7	O
.	O
4	O
)	O
,	O
demonstrated	O
statistically	O
good	O
predictive	O
ability	O
(	O
r	O
(	O
2	O
)	O
=	O
0	O
.	O
99	O
,	O
q	O
(	O
2	O
)	O
=	O
0	O
.	O
74	O
)	O
.	O

We	O
also	O
confirmed	O
the	O
excellent	O
predictability	O
of	O
the	O
3D	O
-	O
QSAR	O
model	B-T170
for	O
CAR	B-T103
activation	B-T038
(	O
r	O
(	O
2	O
)	O
pred	O
=	O
0	O
.	O
71	O
)	O
using	O
seven	O
compounds	B-T103
as	O
a	O
test	O
set	O
for	O
external	B-T062
validation	I-T062
.	O

Collectively	O
,	O
our	O
results	O
indicate	O
that	O
the	O
3D	O
-	O
QSAR	O
model	B-T170
developed	O
in	O
this	O
study	O
provides	O
precise	O
prediction	O
of	O
CAR	B-T103
activating	B-T038
potency	O
and	O
,	O
thus	O
,	O
should	O
be	O
useful	O
for	O
selecting	O
drug	B-T103
candidates	I-T103
with	O
minimized	O
DDI	B-T038
risk	O
related	O
to	O
enzyme	B-T038
-	I-T038
induction	I-T038
in	O
the	O
early	O
drug	B-T062
-	I-T062
discovery	I-T062
stage	O
.	O

Effects	O
of	O
siRNA	B-T103
-	O
mediated	O
suppression	B-T038
of	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
expression	B-T038
on	O
the	O
proliferation	B-T038
and	O
apoptosis	B-T038
of	O
vaginal	O
epithelial	O
cells	O

The	O
aim	O
of	O
the	O
present	O
study	B-T062
was	O
to	O
investigate	O
the	O
effects	O
of	O
human	B-T038
papillomavirus	I-T038
(	I-T038
HPV	I-T038
)	I-T038
infection	I-T038
on	O
the	O
gynecological	O
disease	O
of	O
vaginitis	B-T038
and	O
to	O
demonstrate	O
how	O
the	O
small	B-T103
interfering	I-T103
RNA	I-T103
(	O
siRNA	B-T103
)	O
method	O
may	O
be	O
used	O
for	O
HPV	B-T005
prevention	B-T058
in	O
the	O
clinic	B-T092
.	O

Human	B-T204
vaginal	O
epithelial	O
cells	O
were	O
transfected	B-T062
with	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
expression	O
vector	O
and	O
siRNA	B-T103
-	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
vectors	B-T103
and	O
a	O
control	O
group	O
was	O
transfected	B-T062
with	O
scrambled	O
siRNA	B-T103
.	O

Cell	B-T038
proliferation	I-T038
in	O
each	O
group	O
was	O
analyzed	O
using	O
the	O
MTT	B-T058
assay	I-T058
and	O
the	O
expression	B-T038
of	O
apoptosis	B-T038
-	O
associated	O
proteins	B-T103
was	O
measured	O
by	O
western	B-T058
blot	I-T058
analysis	I-T058
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
mRNA	B-T103
and	O
protein	B-T033
levels	I-T033
were	O
significantly	O
increased	O
following	O
transfection	B-T062
with	O
the	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
expression	O
vector	O
in	O
cells	B-T017
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
this	O
result	O
was	O
significantly	O
reversed	O
by	O
silencing	B-T038
of	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
addition	O
,	O
cell	B-T038
proliferation	I-T038
in	O
the	O
HPV	O
-	O
11	O
group	O
was	O
lower	O
than	O
that	O
in	O
the	O
control	O
group	O
;	O
however	O
,	O
cell	B-T038
proliferation	I-T038
was	O
significantly	O
increased	O
in	O
cells	B-T017
transfected	B-T062
with	O
silenced	B-T038
L1	B-T017
compared	O
with	O
that	O
in	O
the	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
silencing	B-T038
of	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
significantly	O
decreased	O
caspase	B-T017
-	I-T017
3	I-T017
and	O
caspase	B-T017
-	I-T017
9	I-T017
expressions	B-T038
in	O
cells	B-T017
,	O
whereas	O
the	O
expression	B-T038
was	O
increased	O
in	O
the	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
group	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
present	O
study	B-T062
suggested	O
that	O
siRNA	B-T103
-	O
mediated	O
silencing	B-T038
of	O
HPV	B-T017
-	I-T017
11	I-T017
L1	I-T017
may	O
have	O
potential	O
therapeutic	B-T058
applications	I-T058
for	O
treating	O
gynecological	O
diseases	O
associated	O
with	O
HPV	B-T005
-	I-T005
11	I-T005
infection	B-T038
.	O

An	O
evaluation	B-T058
of	O
neuroendocrine	B-T022
dysfunction	O
following	O
acute	O
aneurysmal	B-T038
subarachnoid	I-T038
hemorrhage	I-T038
:	O
A	O
prospective	B-T062
study	I-T062

The	O
aim	O
was	O
to	O
investigate	O
the	O
incidence	O
and	O
pattern	B-T082
of	O
neuroendocrine	B-T022
changes	O
in	O
cases	O
of	O
acute	O
aneurysmal	B-T038
subarachnoid	I-T038
hemorrhage	I-T038
(	O
SAH	B-T038
)	O
.	O

Endocrine	B-T022
assessment	B-T058
was	O
performed	O
in	O
100	O
consecutive	O
cases	O
of	O
acute	O
aneurysmal	B-T038
SAH	I-T038
presenting	O
within	O
7	O
days	O
of	O
ictus	B-T038
.	O

The	O
gonadotropic	B-T103
,	O
somatotrophic	B-T103
,	O
thyrotropic	B-T103
,	O
and	O
corticotrophic	B-T103
axes	O
were	O
evaluated	B-T058
for	O
their	O
possible	O
dysfunction	O
.	O

A	O
total	O
of	O
100	O
cases	O
(	O
38	O
males	O
,	O
62	O
females	O
;	O
age	O
range	O
-	O
17	O
-	O
76	O
years	O
;	O
mean	O
age	O
-	O
43	O
.	O
6	O
years	O
)	O
of	O
acute	O
SAH	B-T038
were	O
studied	B-T062
.	O

The	O
aneurysms	B-T038
were	O
located	O
in	O
the	O
anterior	B-T038
circulation	I-T038
(	O
n	O
=	O
95	O
)	O
and	O
posterior	B-T038
circulation	I-T038
(	O
n	O
=	O
5	O
)	O
.	O

The	O
most	O
common	O
hormone	O
deficiency	O
was	O
of	O
growth	B-T103
hormone	I-T103
(	O
n	O
=	O
67	O
)	O
,	O
followed	O
by	O
gonadotrophin	B-T103
(	O
n	O
=	O
50	O
)	O
,	O
corticotrophin	B-T103
(	O
n	O
=	O
49	O
)	O
and	O
thyrotrophin	B-T103
(	O
n	O
=	O
35	O
)	O
.	O

Hyperprolactinemia	B-T038
was	O
noted	O
in	O
10	O
cases	O
.	O

One	B-T033
-	I-T033
pituitary	I-T033
hormone	I-T033
axis	I-T033
deficiency	I-T033
was	O
noted	O
in	O
26	O
cases	O
while	O
67	O
cases	O
had	O
two	O
or	O
more	O
pituitary	B-T103
hormone	I-T103
axes	O
dysfunction	O
.	O

A	O
total	O
of	O
93	O
cases	O
had	O
hormonal	B-T103
dysfunction	O
in	O
one	O
or	O
more	O
pituitary	B-T103
hormone	I-T103
axes	I-T103
,	O
and	O
seven	O
cases	O
had	O
no	O
hormonal	B-T103
dysfunction	O
.	O

Endocrine	O
dysfunction	O
occurs	O
in	O
93	O
%	O
cases	O
of	O
acute	O
SAH	B-T038
and	O
multiple	O
pituitary	B-T103
hormone	I-T103
axes	I-T103
dysfunction	O
occurs	O
in	O
67	O
%	O
cases	O
.	O

It	O
is	O
suggested	O
that	O
hormonal	B-T103
evaluation	B-T058
should	O
be	O
considered	O
as	O
part	O
of	O
management	O
of	O
acute	O
SAH	B-T038
.	O

Validity	O
and	O
reliability	O
of	O
fluoroscopy	B-T058
for	O
digital	B-T058
radiography	I-T058
:	O
a	O
new	O
way	O
to	O
evaluate	B-T058
diaphragmatic	B-T017
mobility	O

Fluoroscopy	B-T058
is	O
considered	O
the	O
most	O
accurate	O
method	B-T062
to	O
evaluate	B-T058
the	O
diaphragm	B-T017
,	O
yet	O
most	O
existing	O
methods	B-T062
for	O
measuring	O
diaphragmatic	B-T017
mobility	O
using	O
fluoroscopy	B-T058
are	O
complex	O
.	O

To	O
assess	O
the	O
validity	O
and	O
reliability	O
of	O
a	O
new	O
evaluation	B-T062
method	I-T062
of	O
diaphragmatic	B-T017
motion	O
using	O
fluoroscopy	B-T058
by	O
digital	B-T058
radiography	I-T058
of	O
healthy	O
adults	O
.	O

Twenty	O
-	O
six	O
adults	O
were	O
evaluated	B-T058
,	O
according	O
to	O
the	O
parameters	O
:	O
anthropometry	B-T062
and	O
pulmonary	B-T058
function	I-T058
test	I-T058
.	O

The	O
evaluation	B-T058
of	O
diaphragm	B-T017
mobility	O
by	O
means	O
of	O
fluoroscopy	B-T058
by	O
digital	B-T058
radiography	I-T058
method	B-T062
was	O
randomly	O
conducted	O
by	O
two	O
raters	O
(	O
A	O
and	O
B	O
)	O
.	O

The	O
Pearson	O
correlation	O
coefficient	O
and	O
the	O
intraclass	O
correlation	O
coefficient	O
(	O
ICC	O
)	O
were	O
used	O
to	O
assess	O
the	O
concurrent	O
validity	O
.	O

The	O
inter	O
-	O
rater	O
and	O
intra	O
-	O
rater	O
reliability	O
of	O
the	O
measurement	O
of	O
diaphragmatic	B-T017
motion	O
was	O
determined	O
using	O
ICC	O
and	O
a	O
confidence	O
interval	O
of	O
95	O
%	O
.	O

There	O
was	O
a	O
relationship	O
in	O
the	O
assessment	B-T058
of	O
the	O
concurrent	O
validity	O
.	O

There	O
was	O
good	O
inter	O
-	O
rater	O
reliability	O
for	O
right	O
hemidiaphragm	B-T017
mobility	O
and	O
moderate	O
reliability	O
for	O
left	B-T017
hemidiaphragm	I-T017
in	O
the	O
first	O
assessment	B-T058
.	O

In	O
the	O
second	O
assessment	B-T058
,	O
there	O
was	O
good	O
reliability	O
for	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	B-T017
.	O

There	O
was	O
good	O
intra	O
-	O
rater	O
reliability	O
in	O
the	O
mobility	O
of	O
both	O
hemidiaphragms	B-T017
for	O
raters	O
A	O
and	O
B	O
.	O

The	O
evaluation	B-T058
of	O
diaphragmatic	B-T017
motion	O
using	O
fluoroscopy	B-T058
by	O
digital	B-T058
radiography	I-T058
proved	O
to	O
be	O
a	O
valid	O
and	O
reliable	O
method	B-T062
of	O
healthy	O
adults	O
.	O

Loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
in	O
rats	B-T204
depends	O
on	O
individual	B-T098
vulnerability	O
and	O
duration	O
of	O
alcohol	O
consumption	O
experience	O

Alcohol	O
use	O
disorder	O
(	O
AUD	O
)	O
is	O
characterized	O
by	O
excessive	B-T033
alcohol	I-T033
use	I-T033
and	O
persistent	O
alcohol	O
seeking	O
despite	O
knowledge	O
of	O
its	O
negative	O
consequences	O
.	O

Importantly	O
,	O
AUD	O
typically	O
develops	O
after	O
chronic	O
excessive	B-T033
alcohol	I-T033
use	I-T033
in	O
a	O
subgroup	B-T170
of	O
individuals	B-T098
who	O
drink	O
alcohol	O
,	O
suggesting	O
that	O
AUD	O
results	O
from	O
an	O
interaction	O
between	O
individual	B-T098
vulnerability	O
and	O
prolonged	O
alcohol	O
exposure	O
.	O

The	O
present	O
study	B-T062
assessed	O
the	O
contribution	O
of	O
prolonged	O
exposure	O
to	O
alcohol	O
and	O
individual	O
levels	O
of	O
alcohol	O
intake	O
to	O
the	O
development	O
of	O
loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
in	O
a	O
conditioned	B-T170
suppression	I-T170
model	I-T170
.	O

To	O
investigate	O
the	O
impact	O
of	O
prolonged	O
alcohol	O
exposure	O
,	O
conditioned	O
suppression	O
of	O
alcohol	O
seeking	O
was	O
assessed	O
after	O
2	O
and	O
4	O
months	O
of	O
intermittent	O
alcohol	O
access	O
(	O
IAA	O
)	O
in	O
a	O
subgroup	B-T170
of	O
rats	B-T204
drinking	O
moderate	O
amounts	O
of	O
alcohol	O
.	O

We	O
observed	O
that	O
suppression	O
of	O
alcohol	O
seeking	O
was	O
reduced	O
after	O
4	O
months	O
compared	O
with	O
2	O
months	O
of	O
IAA	O
.	O

The	O
influence	O
of	O
individual	O
levels	O
of	O
alcohol	O
intake	O
on	O
loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
was	O
subsequently	O
determined	O
by	O
assessing	O
conditioned	O
suppression	O
in	O
subgroups	B-T170
of	O
low	O
and	O
high	O
alcohol	O
drinking	O
rats	B-T204
.	O

Unlike	O
the	O
low	O
alcohol	O
drinking	O
rats	B-T204
,	O
the	O
high	O
alcohol	O
drinking	O
rats	B-T204
showed	O
aversion	O
-	O
resistant	O
alcohol	O
seeking	O
after	O
2	O
months	O
of	O
IAA	O
,	O
although	O
both	O
groups	O
showed	O
comparable	O
levels	O
of	O
conditioned	O
freezing	O
.	O

These	O
findings	O
show	O
that	O
the	O
development	O
of	O
loss	O
of	O
control	O
over	O
alcohol	O
seeking	O
,	O
a	O
key	O
characteristic	O
of	O
AUD	O
in	O
humans	B-T204
,	O
is	O
dependent	O
on	O
both	O
the	O
extent	O
of	O
alcohol	O
exposure	O
and	O
the	O
individual	B-T098
'	I-T098
s	I-T098
propensity	O
to	O
consume	O
alcohol	O
.	O

Neural	O
correlates	O
of	O
experimental	O
trauma	B-T037
memory	O
retrieval	O

Traumatic	O
memories	B-T038
such	O
as	O
intrusions	B-T170
and	O
flashbacks	O
play	O
a	O
major	O
role	O
in	O
the	O
development	O
and	O
maintenance	O
of	O
post	B-T038
-	I-T038
traumatic	I-T038
stress	I-T038
disorder	I-T038
(	O
PTSD	B-T038
)	O
.	O

A	O
thorough	O
understanding	O
of	O
the	O
neural	O
mechanisms	O
underlying	O
traumatic	O
memories	B-T038
is	O
indispensable	O
for	O
precise	O
diagnosis	B-T033
,	O
for	O
personalized	O
treatment	B-T058
and	O
prevention	B-T058
.	O

In	O
particular	O
,	O
the	O
identification	O
of	O
early	O
neural	O
predictor	B-T170
variables	I-T170
for	O
intrusion	B-T170
development	O
shortly	O
after	O
trauma	B-T037
exposure	O
requires	O
detailed	O
investigation	B-T058
.	O

Here	O
,	O
we	O
examined	B-T033
the	O
neural	O
correlates	O
of	O
early	O
experimental	O
trauma	B-T037
memory	O
retrieval	O
in	O
a	O
traumatic	O
film	O
paradigm	O
in	O
42	O
young	O
healthy	O
females	O
,	O
using	O
both	O
implicit	B-T033
and	O
explicit	B-T038
retrieval	O
tasks	O
.	O

We	O
show	O
that	O
implicit	B-T033
experimental	O
trauma	B-T037
retrieval	O
specifically	O
involved	O
the	O
retrosplenial	B-T017
cortex	I-T017
and	O
the	O
anterior	B-T017
cingulate	I-T017
cortex	I-T017
(	O
ACC	B-T017
)	O
,	O
while	O
both	O
retrieval	O
tasks	O
resulted	O
in	O
trauma	B-T033
-	I-T033
related	I-T033
activity	O
in	O
the	O
posterior	B-T017
cingulate	I-T017
cortex	I-T017
(	O
PCC	B-T017
)	O
and	O
the	O
precuneus	B-T017
.	O

Importantly	O
,	O
neural	O
activity	O
early	O
after	O
experimental	O
trauma	B-T037
exposure	O
predicted	O
later	O
intrusion	B-T170
development	O
,	O
with	O
independent	O
contributions	O
from	O
activity	O
in	O
the	O
retrosplenial	B-T017
cortex	I-T017
(	O
implicit	B-T033
retrieval	O
)	O
and	O
the	O
PCC	B-T017
(	O
explicit	B-T038
retrieval	O
)	O
.	O

Additional	O
analyses	B-T062
revealed	O
a	O
stronger	O
connectivity	O
between	O
the	O
bilateral	B-T017
amygdala	I-T017
and	O
the	O
supplementary	B-T082
motor	I-T082
area	I-T082
,	O
precentral	B-T017
and	O
paracentral	B-T017
lobule	I-T017
for	O
the	O
control	O
group	O
compared	O
to	O
the	O
experimental	O
trauma	B-T037
group	O
.	O

Our	O
study	B-T062
gives	O
new	O
insights	O
in	O
the	O
neural	O
correlates	O
of	O
experimental	O
trauma	B-T037
memory	O
retrieval	O
and	O
their	O
predictive	O
value	O
for	O
subsequent	O
symptom	B-T033
development	O
.	O

Our	O
results	O
could	O
provide	O
the	O
basis	O
for	O
personalized	O
early	O
treatment	O
and	O
prevention	O
of	O
PTSD	B-T038
.	O

Hum	O
Brain	O
Mapp	O
,	O
2017	O
.	O

©	O
2017	O
Wiley	O
Periodicals	O
,	O
Inc	O
.	O

Targeting	B-T038
the	O
Nrf2	B-T103
/	O
Amyloid	B-T038
-	I-T038
Beta	I-T038
Liaison	I-T038
in	O
Alzheimer	B-T038
'	I-T038
s	I-T038
Disease	I-T038
:	O
A	O
Rational	O
Approach	O

Amyloid	B-T103
is	O
a	O
prominent	O
feature	O
of	O
Alzheimer	B-T038
'	I-T038
s	I-T038
disease	I-T038
(	O
AD	B-T038
)	O
.	O

Yet	O
,	O
a	O
linear	B-T082
linkage	O
between	O
amyloid	B-T103
-	I-T103
β	I-T103
peptide	I-T103
(	O
Aβ	B-T103
)	O
and	O
the	O
disease	O
onset	O
and	O
progression	B-T038
has	O
recently	O
been	O
questioned	O
.	O

In	O
this	O
context	O
,	O
the	O
crucial	O
partnership	O
between	O
Aβ	B-T038
and	O
Nrf2	B-T038
pathways	I-T038
is	O
acquiring	O
paramount	O
importance	O
,	O
offering	O
prospects	O
for	O
deciphering	O
the	O
Aβ	B-T103
-	O
centered	O
disease	B-T038
network	O
.	O

Here	O
,	O
we	O
report	O
on	O
a	O
new	O
class	O
of	O
antiaggregating	B-T103
agents	I-T103
rationally	O
designed	O
to	O
simultaneously	O
activate	B-T038
transcription	I-T038
-	O
based	O
antioxidant	B-T103
responses	B-T038
,	O
whose	O
lead	B-T103
1	I-T103
showed	O
interesting	O
properties	O
in	O
a	O
preliminary	O
investigation	O
.	O

Relying	O
on	O
the	O
requirements	B-T033
of	O
Aβ	B-T103
recognition	O
,	O
we	O
identified	O
the	O
catechol	B-T103
derivative	I-T103
12	I-T103
.	O

In	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
,	O
12	B-T103
combined	O
remarkable	O
free	B-T103
radical	I-T103
scavenger	I-T103
properties	O
to	O
the	O
ability	O
to	O
trigger	O
the	O
Nrf2	B-T038
pathway	I-T038
and	O
induce	B-T038
the	O
Nrf2	B-T103
-	O
dependent	O
defensive	B-T033
gene	B-T017
NQO1	I-T017
by	O
means	O
of	O
electrophilic	O
activation	O
of	O
the	O
transcriptional	B-T038
response	I-T038
.	O

Moreover	O
,	O
12	O
prevented	O
the	O
formation	O
of	O
cytotoxic	O
stable	O
oligomeric	B-T103
intermediates	I-T103
,	O
being	O
significantly	O
more	O
effective	O
,	O
and	O
per	O
se	O
less	B-T037
toxic	I-T037
,	O
than	O
prototype	B-T103
1	I-T103
.	O

More	O
importantly	O
,	O
as	O
different	O
chemical	O
features	O
were	O
exploited	O
to	O
regulate	B-T038
Nrf2	I-T038
and	O
Aβ	B-T103
activities	B-T038
,	O
the	O
two	O
pathways	B-T038
could	O
be	O
tuned	O
independently	O
.	O

These	O
findings	O
point	O
to	O
compound	B-T103
12	I-T103
and	O
its	O
derivatives	B-T103
as	O
promising	O
tools	O
for	O
investigating	O
the	O
therapeutic	O
potential	O
of	O
the	O
Nrf2	B-T103
/	O
Aβ	B-T103
cellular	B-T017
network	O
,	O
laying	O
foundation	O
for	O
generating	O
new	O
drug	B-T103
leads	I-T103
to	O
confront	O
AD	B-T038
.	O

Young	O
people	B-T098
,	O
mental	B-T038
health	I-T038
practitioners	B-T097
and	O
researchers	B-T097
co	O
-	O
produce	O
a	O
Transition	B-T170
Preparation	I-T170
Programme	I-T170
to	O
improve	O
outcomes	O
and	O
experience	B-T038
for	O
young	O
people	B-T098
leaving	O
Child	B-T058
and	I-T058
Adolescent	I-T058
Mental	I-T058
Health	I-T058
Services	I-T058
(	O
CAMHS	B-T058
)	O

In	O
the	O
UK	B-T082
young	O
people	B-T098
attending	O
child	B-T058
and	I-T058
adolescent	I-T058
mental	I-T058
health	I-T058
services	I-T058
(	O
CAMHS	B-T058
)	O
are	O
required	O
to	O
move	O
on	O
,	O
either	O
through	O
discharge	O
or	O
referral	B-T058
to	I-T058
an	O
adult	B-T058
service	I-T058
,	O
at	O
age	O
17	O
/	O
18	O
,	O
a	O
period	O
of	O
increased	O
risk	O
for	O
onset	O
of	O
mental	B-T033
health	I-T033
problems	I-T033
and	O
other	O
complex	O
psychosocial	O
and	O
physical	O
changes	O
.	O

CAMHS	B-T058
transitions	O
are	O
often	O
poorly	O
managed	O
with	O
negative	B-T033
outcomes	O
for	O
young	O
people	B-T098
.	O

Better	O
preparation	O
may	O
improve	O
outcomes	O
and	O
experience	B-T038
.	O

This	O
study	B-T062
aimed	O
to	O
co	O
-	O
produce	O
,	O
with	O
young	O
people	B-T098
who	O
had	O
transitioned	O
or	O
were	O
facing	O
transition	O
from	O
CAMHS	B-T058
,	O
a	O
CAMHS	B-T058
Transition	B-T170
Preparation	I-T170
Programme	I-T170
(	O
TPP	B-T170
)	O
,	O
deliverable	O
in	O
routine	O
NHS	B-T058
settings	O
.	O

Eighteen	O
young	O
people	B-T098
,	O
aged	O
17	O
-	O
22	O
,	O
from	O
three	O
UK	B-T082
National	B-T058
Health	I-T058
Service	I-T058
(	O
NHS	B-T058
)	O
mental	O
health	O
foundation	O
trusts	O
participated	O
in	O
creative	O
,	O
participatory	O
research	O
workshops	O
.	O

Seven	O
parents	O
completed	O
short	O
questionnaires	B-T170
.	O

Thirty	O
clinical	B-T097
staff	I-T097
from	O
two	O
trusts	O
took	O
part	O
in	O
workshops	O
to	O
ensure	O
deliverability	O
of	O
young	O
people	B-T098
'	I-T098
s	I-T098
ideas	O
.	O

Young	O
people	B-T098
were	O
offered	O
co	O
-	O
research	O
opportunities	O
.	O

Most	O
young	O
people	B-T098
felt	O
anxious	B-T033
,	O
fearful	B-T038
and	O
uncertain	O
on	O
leaving	O
CAMHS	B-T058
and	O
perceived	B-T038
mental	B-T058
health	I-T058
services	I-T058
as	O
uncaring	O
.	O

Participants	B-T098
outlined	O
transition	O
procedures	O
and	O
drafted	O
a	O
range	O
of	O
preparation	O
activities	O
,	O
centred	O
around	O
dedicated	O
Transition	O
Peer	O
Support	O
and	O
a	O
transition	O
booklet	B-T170
,	O
which	O
should	O
be	O
offered	O
to	O
all	O
CAMHS	B-T058
leavers	B-T098
,	O
irrespective	O
of	O
discharge	O
or	O
transfer	O
to	O
an	O
adult	B-T058
service	I-T058
.	O

Preparation	O
should	O
aim	O
to	O
build	O
confidence	B-T038
to	O
help	O
young	O
people	B-T098
take	O
responsibility	O
for	O
themselves	O
and	O
flourish	O
in	O
the	O
adult	O
world	B-T098
:	O
coping	O
or	O
getting	O
through	O
it	O
was	O
not	O
enough	O
.	O

Some	O
clinicians	B-T097
also	O
felt	O
anxious	B-T033
at	O
transition	O
and	O
recognised	O
the	O
potential	O
impact	O
on	O
young	O
people	B-T098
of	O
poor	O
communication	O
and	O
lack	O
of	O
understanding	O
between	O
services	B-T058
.	O

Parents	O
would	O
appreciate	O
help	O
to	O
support	O
their	O
offspring	O
during	O
the	O
transition	O
period	O
.	O

Clinicians	B-T097
cited	O
lack	O
of	O
funding	O
and	O
inflexible	O
NHS	B-T058
procedures	O
and	O
policies	B-T170
as	O
potential	O
barriers	O
to	O
the	O
implementation	O
of	O
young	O
people	B-T098
'	I-T098
s	I-T098
ideas	O
.	O

Nine	O
young	O
people	B-T098
took	O
up	O
co	O
-	O
research	O
opportunities	O
.	O

Mental	B-T058
health	I-T058
services	I-T058
underestimate	O
the	O
anxiety	B-T033
of	O
CAMHS	B-T058
leavers	B-T098
.	O

Young	O
people	B-T098
have	O
clear	O
ideas	O
about	O
the	O
preparation	O
they	O
require	O
to	O
leave	O
CAMHS	B-T058
with	O
the	O
confidence	B-T038
to	O
take	O
responsibility	O
for	O
their	O
own	O
health	B-T058
care	I-T058
.	O

Close	O
collaboration	O
of	O
NHS	B-T058
staff	B-T097
and	O
researchers	B-T097
facilitates	O
the	O
implementation	O
of	O
research	B-T062
findings	O
.	O

The	O
Histone	B-T103
Acetyltransferase	I-T103
Gcn5	I-T103
Positively	B-T038
Regulates	I-T038
T	I-T038
Cell	I-T038
Activation	I-T038

Histone	B-T103
acetyltransferases	I-T103
(	O
HATs	B-T103
)	O
regulate	B-T038
inducible	I-T038
transcription	I-T038
in	O
multiple	O
cellular	B-T038
processes	I-T038
and	O
during	O
inflammatory	B-T038
and	O
immune	B-T038
response	I-T038
.	O

However	O
,	O
the	O
functions	B-T038
of	O
general	B-T103
control	I-T103
nonrepressed	I-T103
-	I-T103
protein	I-T103
5	I-T103
(	O
Gcn5	B-T103
)	O
,	O
an	O
evolutionarily	O
conserved	O
HAT	B-T103
from	O
yeast	B-T204
to	O
human	B-T204
,	O
in	O
immune	B-T038
regulation	I-T038
remain	O
unappreciated	O
.	O

In	O
this	O
study	B-T062
,	O
we	O
conditionally	O
deleted	B-T038
Gcn5	B-T103
(	O
encoded	O
by	O
the	O
Kat2a	B-T017
gene	I-T017
)	O
specifically	O
in	O
T	B-T017
lymphocytes	I-T017
by	O
crossing	B-T038
floxed	B-T017
Gcn5	I-T017
and	O
Lck	B-T017
-	I-T017
Cre	I-T017
mice	B-T204
,	O
and	O
demonstrated	O
that	O
Gcn5	B-T103
plays	O
important	O
roles	O
in	O
multiple	O
stages	O
of	O
T	B-T038
cell	I-T038
functions	I-T038
including	O
development	B-T038
,	O
clonal	B-T038
expansion	I-T038
,	O
and	O
differentiation	B-T038
.	O

Loss	B-T033
of	I-T033
Gcn5	B-T103
functions	O
impaired	B-T038
T	I-T038
cell	I-T038
proliferation	I-T038
,	O
IL	B-T038
-	I-T038
2	I-T038
production	I-T038
,	O
and	O
Th1	B-T017
/	O
Th17	B-T017
,	O
but	O
not	O
Th2	B-T017
and	O
regulatory	B-T038
T	I-T038
cell	I-T038
differentiation	I-T038
.	O

Gcn5	B-T103
is	O
recruited	O
onto	O
the	O
il	B-T017
-	I-T017
2	I-T017
promoter	B-T103
by	O
interacting	O
with	O
the	O
NFAT	B-T103
in	O
T	B-T017
cells	I-T017
upon	O
TCR	B-T038
stimulation	I-T038
.	O

Interestingly	O
,	O
instead	O
of	O
directly	O
acetylating	B-T038
NFAT	B-T103
,	O
Gcn5	B-T103
catalyzes	O
histone	B-T038
H3	I-T038
lysine	I-T038
H9	I-T038
acetylation	I-T038
to	O
promote	O
IL	B-T038
-	I-T038
2	I-T038
production	I-T038
.	O

T	B-T017
cell	I-T017
-	O
specific	O
suppression	O
of	O
Gcn5	B-T103
partially	O
protected	O
mice	B-T204
from	O
myelin	B-T103
oligodendrocyte	I-T103
glycoprotein	I-T103
-	O
induced	O
experimental	B-T038
autoimmune	I-T038
encephalomyelitis	I-T038
,	O
an	O
experimental	B-T170
model	I-T170
for	O
human	B-T204
multiple	B-T038
sclerosis	I-T038
.	O

Our	O
study	O
reveals	O
previously	O
unknown	O
physiological	O
functions	O
for	O
Gcn5	B-T103
and	O
a	O
molecular	B-T038
mechanism	I-T038
underlying	O
these	O
functions	B-T038
in	O
regulating	B-T038
T	I-T038
cell	I-T038
immunity	I-T038
.	O

Hence	O
Gcn5	B-T103
may	O
be	O
an	O
important	O
new	O
target	O
for	O
autoimmune	B-T038
disease	I-T038
therapy	B-T058
.	O

Minor	B-T017
physical	I-T017
anomalies	I-T017
and	O
dermatoglyphic	B-T082
signs	O
in	O
affective	B-T038
disorders	I-T038
:	O
A	O
systematic	B-T170
review	I-T170

The	O
increased	O
prevalence	O
of	O
minor	B-T017
physical	I-T017
anomalies	I-T017
(	O
MPAs	B-T017
)	O
and	O
the	O
abnormalities	B-T017
of	I-T017
dermatoglyphic	I-T017
patterns	I-T017
may	O
be	O
physical	O
manifestations	O
of	O
neurodevelopmental	O
disruption	O
in	O
affective	B-T038
disorders	I-T038
.	O

This	O
paper	O
aims	O
to	O
review	B-T170
the	O
current	O
state	O
of	O
knowledge	O
on	O
the	O
frequency	O
of	O
MPAs	B-T017
and	O
dermatoglyphic	B-T017
abnormalities	I-T017
in	O
mood	B-T038
disorders	I-T038
.	O

A	O
MEDLINE	B-T170
,	O
PsychInfo	B-T170
and	O
Web	B-T170
of	I-T170
Science	I-T170
search	I-T170
was	O
carried	O
out	O
to	O
collect	O
all	O
publications	B-T170
on	O
the	O
frequency	O
of	O
MPAs	B-T017
and	O
on	O
dermatoglyphic	B-T017
traits	I-T017
in	O
bipolar	B-T038
disorder	I-T038
and	O
unipolar	B-T038
depression	I-T038
.	O

24	O
studies	B-T062
on	O
MPAs	B-T017
,	O
19	O
on	O
dermatoglyphics	B-T058
,	O
and	O
5	O
dealing	O
with	O
both	O
were	O
found	O
with	O
discrepant	B-T033
findings	O
.	O

The	O
relative	O
contribution	O
of	O
neurodevelopmental	O
retardation	O
to	O
the	O
aetiology	O
of	O
affective	B-T038
disorders	I-T038
remains	O
undetermined	O
,	O
the	O
field	O
is	O
open	O
for	O
further	O
research	B-T062
.	O

Increased	O
recognition	B-T038
of	O
neurodevelopmental	O
processes	O
in	O
the	O
origin	O
of	O
affective	B-T038
disorders	I-T038
may	O
allow	O
for	O
earlier	O
and	O
more	O
effective	O
intervention	B-T058
and	O
prevention	B-T058
.	O

Novel	B-T062
Strategy	I-T062
to	O
Expand	O
Super	B-T017
-	I-T017
Charged	I-T017
NK	I-T017
Cells	I-T017
with	O
Significant	O
Potential	O
to	O
Lyse	B-T038
and	O
Differentiate	O
Cancer	B-T017
Stem	I-T017
Cells	I-T017
:	O
Differences	O
in	O
NK	B-T038
Expansion	I-T038
and	O
Function	O
between	O
Healthy	B-T098
and	O
Cancer	O
Patients	O

Natural	B-T017
killer	I-T017
(	I-T017
NK	I-T017
)	I-T017
cells	I-T017
are	O
known	O
to	O
target	O
cancer	B-T017
stem	I-T017
cells	I-T017
and	O
undifferentiated	B-T038
tumors	I-T038
.	O

In	O
this	O
paper	O
,	O
we	O
provide	O
a	O
novel	B-T062
strategy	I-T062
for	O
expanding	O
large	O
numbers	O
of	O
super	B-T017
-	I-T017
charged	I-T017
NK	I-T017
cells	I-T017
with	O
significant	O
potential	O
to	O
lyse	B-T038
and	O
differentiate	O
cancer	B-T017
stem	I-T017
cells	I-T017
and	O
demonstrate	O
the	O
differences	O
in	O
the	O
dynamics	O
of	O
NK	B-T017
cell	I-T017
expansion	B-T038
between	O
healthy	B-T098
donors	I-T098
and	O
cancer	O
patients	O
.	O

Decline	B-T033
in	I-T033
cytotoxicity	I-T033
and	O
lower	B-T082
interferon	B-T038
(	I-T038
IFN	I-T038
)	I-T038
-	I-T038
γ	I-T038
secretion	I-T038
by	O
osteoclast	B-T017
(	O
OC	B-T017
)	O
-	O
expanded	O
NK	B-T017
cells	I-T017
from	O
cancer	O
patients	O
correlates	O
with	O
faster	O
expansion	B-T038
of	O
residual	O
contaminating	O
T	B-T017
cells	I-T017
within	O
purified	O
NK	B-T017
cells	I-T017
,	O
whereas	O
healthy	B-T098
donors	I-T098
'	O
OCs	B-T017
continue	O
expanding	O
super	B-T017
-	I-T017
charged	I-T017
NK	I-T017
cells	I-T017
while	O
limiting	O
T	B-T017
cell	I-T017
expansion	B-T038
for	O
up	O
to	O
60	O
days	O
.	O

Similar	O
to	O
patient	O
NK	B-T017
cells	I-T017
,	O
NK	B-T017
cells	I-T017
from	O
tumor	B-T038
-	O
bearing	O
BLT	B-T038
-	I-T038
humanized	I-T038
mice	I-T038
promote	O
faster	O
expansion	B-T038
of	O
residual	O
T	B-T033
cells	I-T033
resulting	I-T033
in	I-T033
decreased	I-T033
numbers	I-T033
and	O
function	O
of	O
NK	B-T017
cells	I-T017
,	O
whereas	O
NK	B-T017
cells	I-T017
from	O
mice	B-T204
with	O
no	B-T033
tumor	B-T038
continue	O
expanding	B-T038
NK	B-T017
cells	I-T017
and	O
retain	O
their	O
cytotoxicity	B-T038
.	O

In	O
addition	O
,	O
dendritic	B-T017
cells	I-T017
(	O
DCs	B-T017
)	O
in	O
contrast	O
to	O
OCs	B-T017
are	O
found	O
to	O
promote	O
faster	O
expansion	B-T038
of	O
residual	O
T	B-T017
cells	I-T017
within	O
purified	O
NK	B-T017
cells	I-T017
resulting	O
in	O
the	O
decline	B-T033
in	I-T033
NK	I-T033
cell	I-T033
numbers	I-T033
from	O
healthy	B-T098
individuals	I-T098
.	O

Addition	O
of	O
anti	B-T103
-	I-T103
CD3	I-T103
mAb	I-T103
inhibits	O
T	B-T038
cell	I-T038
proliferation	I-T038
while	O
enhancing	O
NK	B-T017
cell	I-T017
expansion	B-T038
;	O
however	O
,	O
expanding	B-T038
NK	B-T017
cells	I-T017
have	O
lower	B-T082
cytotoxicity	B-T038
but	O
higher	O
secretion	B-T038
of	I-T038
IFN	I-T038
-	I-T038
γ	I-T038
.	O

Expansion	B-T038
and	O
functional	O
activation	O
of	O
super	B-T017
-	I-T017
charged	I-T017
NK	I-T017
cells	I-T017
by	O
OCs	B-T017
is	O
dependent	O
on	O
interleukin	B-T103
(	I-T103
IL	I-T103
)	I-T103
-	I-T103
12	I-T103
and	O
IL	B-T103
-	I-T103
15	I-T103
.	O

Thus	O
,	O
in	O
this	O
report	O
,	O
we	O
not	O
only	O
provide	O
a	O
novel	B-T062
strategy	I-T062
to	O
expand	B-T038
super	B-T017
-	I-T017
charged	I-T017
NK	I-T017
cells	I-T017
,	O
but	O
also	O
demonstrate	O
that	O
rapid	B-T038
and	I-T038
sustained	I-T038
expansion	I-T038
of	O
residual	O
T	B-T017
cells	I-T017
within	O
the	O
purified	O
NK	B-T017
cells	I-T017
during	O
expansion	B-T038
with	O
DCs	B-T017
or	O
OCs	B-T017
could	O
be	O
a	O
potential	O
mechanism	O
by	O
which	O
the	O
numbers	O
and	O
function	O
of	O
NK	B-T033
cells	I-T033
decline	I-T033
in	O
cancer	O
patients	O
and	O
in	O
BLT	B-T038
-	I-T038
humanized	I-T038
mice	I-T038
.	O

Extremely	O
Giant	B-T038
Liver	I-T038
Hemangioma	I-T038
(	O
50	O
cm	O
)	O
with	O
Kasabach	B-T038
-	I-T038
Merritt	I-T038
Syndrome	I-T038

A	O
33	O
-	O
year	O
-	O
old	O
male	O
has	O
been	O
found	B-T033
with	O
a	O
giant	B-T038
liver	I-T038
hemangioma	I-T038
of	O
initial	O
size	B-T082
29	O
cm	O
for	O
5	O
years	O
.	O

He	O
received	O
arterial	B-T058
embolization	I-T058
twice	O
in	O
order	O
to	O
shrink	B-T082
the	O
tumor	B-T038
;	O
however	O
,	O
no	O
effect	O
was	O
obtained	O
.	O

The	O
tumor	B-T038
had	O
rapidly	O
grown	O
to	O
50	O
cm	O
and	O
caused	O
abnormalities	B-T033
in	O
the	O
hematological	B-T022
and	O
coagulative	B-T038
systems	O
.	O

Preoperative	O
computed	B-T058
tomography	I-T058
revealed	O
that	O
the	O
right	B-T082
hepatic	B-T017
vein	I-T017
,	O
right	B-T082
hepatic	B-T017
artery	I-T017
,	O
and	O
right	B-T082
portal	B-T017
vein	I-T017
were	O
not	O
involved	O
by	O
the	O
hemangioma	B-T038
.	O

Resection	B-T058
of	O
the	O
giant	B-T038
liver	I-T038
hemangioma	I-T038
was	O
successfully	O
performed	O
after	O
intraoperative	O
intentional	O
bloodletting	B-T058
with	O
concurrent	O
blood	B-T058
salvage	I-T058
.	O

All	O
hematological	B-T022
and	O
coagulative	B-T038
abnormalities	B-T033
had	O
returned	O
to	O
normal	O
after	O
the	O
procedure	B-T058
.	O

Role	O
of	O
cysteine	B-T103
residues	O
in	O
regulation	O
of	O
peptidyl	B-T038
-	I-T038
prolyl	I-T038
cis	I-T038
-	I-T038
trans	I-T038
isomerase	I-T038
activity	I-T038
of	O
wheat	B-T168
cyclophilin	B-T103
TaCYPA	B-T017
-	I-T017
1	I-T017

Oxidative	O
conditions	O
result	O
in	O
inhibition	O
of	O
peptidyl	B-T038
-	I-T038
prolyl	I-T038
cis	I-T038
-	I-T038
trans	I-T038
isomerase	I-T038
(	I-T038
PPIase	I-T038
)	I-T038
activity	I-T038
of	O
several	O
cyclophilins	B-T103
.	O

Thiol	B-T103
groups	O
have	O
been	O
implicated	O
in	O
redox	B-T038
regulation	O
of	O
these	O
proteins	B-T103
.	O

In	O
our	O
previous	O
study	O
,	O
we	O
proposed	O
that	O
activity	B-T038
of	O
wheat	B-T168
cyclophilin	B-T103
,	O
TaCYPA	B-T017
-	I-T017
1	I-T017
,	O
may	O
be	O
modulated	B-T082
through	O
a	O
novel	O
dual	O
mechanism	O
of	O
redox	B-T038
regulation	O
.	O

To	O
further	O
understand	O
the	O
regulation	O
of	O
PPIase	B-T038
activity	I-T038
of	O
TaCYPA	B-T017
-	I-T017
1	I-T017
,	O
we	O
generated	O
mutants	B-T038
of	O
TaCYPA	B-T017
-	I-T017
1	I-T017
by	O
substituting	O
cysteine	B-T103
residues	O
at	O
positions	B-T082
-	O
40	O
and	O
-	O
122	O
with	O
serine	B-T103
,	O
and	O
at	O
-	O
126	O
with	O
proline	B-T103
.	O

Comparative	O
analysis	O
of	O
their	O
PPIase	B-T038
activity	I-T038
revealed	O
that	O
catalytic	O
efficiencies	O
(	O
Kcat	O
/	O
Km	O
)	O
of	O
TaCYPA	B-T103
-	I-T103
1C40S	I-T103
(	O
0	O
.	O
37	O
X	O
106	O
M	O
-	O
1	O
s	O
-	O
1	O
)	O
and	O
TaCYPA	B-T103
-	I-T103
1C122S	I-T103
(	O
0	O
.	O
31	O
X	O
106	O
M	O
-	O
1	O
s	O
-	O
1	O
)	O
were	O
significantly	O
lower	O
as	O
compared	O
to	O
the	O
native	O
TaCYPA	B-T103
-	I-T103
1	I-T103
(	O
1	O
.	O
33	O
X	O
106	O
M	O
-	O
1	O
s	O
-	O
1	O
)	O
,	O
whereas	O
Kcat	O
/	O
Km	O
of	O
the	O
double	O
mutant	B-T038
TaCYPA	B-T103
-	I-T103
1C40S	I-T103
/	I-T103
C122S	I-T103
was	O
significantly	O
higher	O
(	O
2	O
.	O
36	O
X	O
106	O
M	O
-	O
1	O
s	O
-	O
1	O
)	O
.	O

Compared	O
to	O
wild	B-T017
-	I-T017
type	I-T017
TaCYPA	B-T017
-	I-T017
1	I-T017
,	O
the	O
different	O
mutants	B-T038
also	O
showed	O
differential	O
sensitivity	O
to	O
Cu2	B-T103
+	I-T103
.	O

Furthermore	O
,	O
the	O
results	O
of	O
this	O
study	B-T062
also	O
revealed	O
that	O
despite	O
lacking	O
PPIase	B-T038
activity	I-T038
,	O
the	O
mutant	B-T038
TaCYPA	B-T017
-	I-T017
1C126P	I-T017
was	O
able	O
to	O
confer	O
partial	O
protection	O
against	O
heat	B-T038
stress	I-T038
.	O

These	O
observations	B-T062
suggest	O
that	O
the	O
mechanism	O
of	O
TaCYPA	B-T017
-	I-T017
1	I-T017
-	O
induced	O
thermotolerance	B-T038
may	O
also	O
involve	O
other	O
activities	O
besides	O
cis	O
to	O
trans	O
isomerisation	O
,	O
which	O
needs	O
to	O
be	O
identified	O
further	O
.	O

Association	O
of	O
Exclusive	O
Breastfeeding	O
Duration	O
With	O
Systemic	O
Inflammation	O
Markers	B-T201
in	O
Adolescents	O
:	O
A	O
Cross	B-T062
-	I-T062
Sectional	I-T062
Study	I-T062

Breastfeeding	O
duration	O
has	O
been	O
associated	O
with	O
less	O
low	O
-	O
grade	O
inflammation	B-T038
in	O
healthy	O
adolescents	O
,	O
but	O
there	O
is	O
scarce	O
information	O
regarding	O
obese	B-T038
subjects	O
.	O

This	O
study	O
aimed	O
to	O
evaluate	O
whether	O
exclusive	O
breastfeeding	O
is	O
related	O
to	O
serum	O
concentrations	O
of	O
inflammatory	O
markers	B-T201
in	O
a	O
population	B-T098
of	O
Spanish	B-T098
adolescents	O
.	O

A	O
cross	B-T062
-	I-T062
sectional	I-T062
study	I-T062
was	O
performed	O
on	O
1	O
,	O
001	O
adolescents	O
(	O
13	O
.	O
2	O
±	O
1	O
.	O
2	O
years	O
)	O
randomly	O
recruited	O
from	O
schools	B-T092
in	O
southeast	B-T082
Spain	B-T082
.	O

Data	O
on	O
breastfeeding	O
duration	O
were	O
collected	O
via	O
a	O
parental	B-T170
questionnaire	I-T170
.	O

Interleukin	B-T103
-	I-T103
6	I-T103
(	O
IL	B-T103
-	I-T103
6	I-T103
)	O
and	O
tumor	B-T103
necrosis	I-T103
factor	I-T103
-	I-T103
alpha	I-T103
(	O
TNF	B-T103
-	I-T103
α	I-T103
)	O
were	O
determined	O
by	O
enzyme	B-T058
-	I-T058
linked	I-T058
immunosorbent	I-T058
assay	I-T058
.	O

C	B-T103
-	I-T103
reactive	I-T103
protein	I-T103
(	O
CRP	B-T103
)	O
was	O
determined	O
by	O
solid	B-T058
-	I-T058
phase	I-T058
chemiluminescent	I-T058
immunometric	I-T058
assay	I-T058
.	O

Nonadjusted	O
and	O
adjusted	O
multivariate	O
correlation	B-T062
analyses	I-T062
confirmed	O
a	O
strong	O
association	O
(	O
p	O
<	O
.	O
001	O
,	O
95	O
%	O
confidence	O
interval	O
)	O
between	O
the	O
three	O
markers	B-T201
of	O
inflammation	B-T038
and	O
exclusive	O
breastfeeding	O
duration	O
.	O

No	B-T033
significant	I-T033
differences	O
were	O
observed	O
for	O
IL	B-T103
-	I-T103
6	I-T103
,	O
TNF	B-T103
-	I-T103
α	I-T103
,	O
and	O
CRP	B-T103
serum	O
concentrations	O
among	O
normal	B-T201
weight	I-T201
,	O
overweight	B-T033
,	O
and	O
obese	B-T038
adolescents	O
,	O
except	O
for	O
IL	B-T103
-	I-T103
6	I-T103
between	O
normal	B-T201
weight	I-T201
and	O
obese	B-T038
subjects	O
.	O

Likewise	O
,	O
no	B-T033
significant	I-T033
association	O
was	O
found	B-T033
between	O
these	O
markers	B-T201
of	O
inflammation	B-T038
and	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
z	O
-	O
score	O
.	O

We	O
found	B-T033
a	O
possible	B-T033
association	O
between	O
inflammatory	O
markers	B-T201
and	O
exclusive	O
breastfeeding	O
duration	O
in	O
adolescents	O
,	O
regardless	O
of	O
their	O
BMI	B-T201
.	O

This	O
finding	B-T033
suggests	O
that	O
increased	O
body	O
weight	O
or	O
obesity	B-T038
might	O
not	O
mediate	O
the	O
association	O
between	O
breastfeeding	B-T038
and	O
inflammation	B-T038
.	O

These	O
results	O
contribute	O
to	O
the	O
understanding	B-T038
of	O
the	O
relationship	O
between	O
breastfeeding	B-T038
and	O
inflammatory	O
markers	B-T201
in	O
adolescents	O
.	O

Effect	O
of	O
ultrasound	O
and	O
enzymatic	B-T103
pre	O
-	O
treatment	O
on	O
yield	O
and	O
properties	O
of	O
banana	B-T168
juice	B-T168

Effect	O
of	O
ultrasound	O
and	O
enzymatic	B-T103
pre	O
-	O
treatments	O
with	O
cellulase	B-T103
and	O
pectinase	B-T103
on	O
yield	O
and	O
properties	O
of	O
banana	B-T168
juice	B-T168
were	O
investigated	O
.	O

A	O
two	O
-	O
level	O
full	O
factorial	O
design	O
was	O
employed	O
.	O

The	O
factors	O
selected	O
were	O
ultrasonication	O
time	O
(	O
0	O
and	O
30	O
min	O
)	O
,	O
cellulase	B-T103
concentration	O
(	O
0	O
and	O
0	O
.	O
2	O
%	O
)	O
and	O
pectinase	B-T103
concentration	O
(	O
0	O
and	O
0	O
.	O
2	O
%	O
)	O
.	O

The	O
responses	O
studied	O
were	O
yield	O
,	O
viscosity	O
,	O
clarity	B-T058
,	O
total	O
soluble	O
solids	O
(	O
TSS	O
)	O
and	O
pH	O
.	O

It	O
was	O
observed	O
that	O
pectinase	B-T103
was	O
more	O
effective	O
in	O
increasing	O
the	O
yield	O
of	O
juice	B-T168
compared	O
to	O
cellulase	B-T103
.	O

Ultrasonic	O
pre	O
-	O
treatment	O
alone	O
did	O
not	B-T033
significantly	O
increase	O
the	O
yield	O
of	O
juice	B-T168
.	O

When	O
ultrasound	O
was	O
combined	O
with	O
pre	O
-	O
treatment	O
with	O
both	O
the	O
enzymes	B-T103
maximum	O
yield	O
of	O
89	O
.	O
40	O
%	O
was	O
obtained	O
compared	O
to	O
47	O
.	O
30	O
%	O
in	O
the	O
control	O
.	O

The	O
viscosity	O
of	O
the	O
juice	B-T168
decreased	O
with	O
addition	O
of	O
enzymes	B-T103
and	O
with	O
application	O
of	O
ultrasound	O
.	O

The	O
clarity	O
of	O
the	O
juice	B-T168
was	O
not	O
affected	O
by	O
cellulase	B-T103
treatment	O
,	O
but	O
improved	B-T033
with	O
pectinase	B-T103
treatment	O
.	O

Ultrasonication	O
alone	O
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
pectinase	B-T103
or	O
cellulase	B-T103
treatment	O
in	O
improving	O
the	O
clarity	B-T201
of	O
the	O
juice	B-T168
.	O

The	O
TSS	O
increased	O
with	O
enzymatic	B-T103
treatment	O
,	O
ultrasonication	O
and	O
their	O
combination	O
.	O

pH	O
was	O
not	O
affected	O
by	O
treatment	O
type	O
,	O
but	O
was	O
found	O
to	O
be	O
lower	O
for	O
the	O
treated	O
juices	B-T168
.	O

Significant	O
correlations	O
were	O
observed	O
between	O
the	O
various	O
responses	O
.	O

Electrocardiographic	B-T033
appearance	I-T033
of	O
aortic	B-T038
stenosis	I-T038
before	O
and	O
after	O
aortic	B-T058
valve	I-T058
replacement	I-T058

So	O
far	O
,	O
the	O
specific	O
appearance	O
of	O
QRS	B-T033
complex	I-T033
,	O
ST	B-T033
-	I-T033
segment	I-T033
,	O
and	O
T	B-T033
wave	I-T033
was	O
observed	O
in	O
aortic	B-T038
stenosis	I-T038
(	O
AS	B-T038
)	O
.	O

S	B-T033
-	I-T033
wave	I-T033
dynamic	O
change	O
in	O
leads	B-T082
V1	I-T082
-	O
V3	B-T082
was	O
not	O
reported	O
in	O
AS	B-T038
.	O

In	O
a	O
single	O
-	O
center	O
,	O
prospective	B-T062
study	I-T062
,	O
we	O
included	O
a	O
total	O
number	O
of	O
1	O
.	O
175	O
patients	O
who	O
underwent	O
surgical	B-T058
aortic	B-T058
valve	I-T058
replacement	I-T058
(	O
AVR	B-T058
)	O
.	O

We	O
conducted	O
3	O
-	O
year	O
gathering	O
of	O
patients	O
with	O
symptomatic	O
and	O
asymptomatic	B-T033
severe	O
AS	B-T038
,	O
and	O
separated	O
them	O
by	O
hemodynamic	O
stability	O
into	O
groups	O
A	O
and	O
B	O
,	O
through	O
EFLV	B-T201
(	O
of	O
more	O
or	O
less	O
than	O
50	O
%	O
)	O
,	O
AVA	O
(	O
of	O
more	O
or	O
less	O
than	O
0	O
.	O
9	O
cm	O
(	O
2	O
)	O
)	O
,	O
PG	B-T201
(	O
between	O
55	O
and	O
75	O
mm	O
Hg	O
or	O
over	O
75	O
mm	O
Hg	O
)	O
,	O
and	O
end	O
-	O
diastolic	O
LV	O
dimension	O
(	O
of	O
more	O
or	O
less	O
than	O
56	O
mm	O
)	O
.	O

We	O
evaluated	B-T058
the	O
impact	O
of	O
S	B-T033
-	I-T033
wave	I-T033
magnitude	O
in	O
right	O
precordial	O
leads	O
before	O
and	O
after	O
AVR	B-T058
in	O
all	O
patients	O
.	O

We	O
followed	O
S	B-T033
-	I-T033
wave	I-T033
changes	O
in	O
electrocardiogram	B-T033
altogether	O
with	O
hemodynamic	B-T058
measurements	I-T058
derived	O
from	O
echocardiography	B-T058
.	O

Analysis	B-T062
of	O
echocardiographic	B-T058
parameters	B-T033
,	O
measured	O
in	O
patients	O
before	O
surgery	B-T058
,	O
did	O
not	O
show	O
statistical	O
significance	O
between	O
asymptomatic	B-T033
and	O
symptomatic	O
group	O
.	O

The	O
statistical	O
significance	O
was	O
observed	O
in	O
the	O
change	O
in	O
S	B-T033
-	I-T033
wave	I-T033
magnitude	O
in	O
the	O
right	O
precordial	O
leads	O
in	O
both	O
subsets	O
of	O
patients	O
before	O
AVR	B-T058
.	O

We	O
found	O
statistically	O
significant	O
predictive	O
value	O
of	O
S	B-T033
-	I-T033
wave	I-T033
magnitude	O
in	O
leads	B-T082
V2	I-T082
-	O
V3	B-T082
for	O
dependent	O
variables	O
PG	B-T201
and	O
end	O
-	O
diastolic	O
LV	O
dimension	O
.	O

S	B-T033
-	I-T033
wave	I-T033
changes	O
in	O
right	O
precordial	O
leads	O
can	O
predict	O
increase	O
in	O
PG	B-T201
and	O
critical	O
narrowing	O
of	O
AVA	O
,	O
suggestive	O
of	O
timely	O
referral	B-T058
for	I-T058
AVR	B-T058
.	O

Anemia	B-T038
complicating	O
type	B-T038
2	I-T038
diabetes	I-T038
:	O
Prevalence	O
,	O
risk	B-T033
factors	I-T033
and	O
prognosis	B-T058

To	O
determine	O
the	O
prevalence	O
,	O
risk	B-T033
factors	I-T033
and	O
prognosis	B-T058
of	O
anemia	B-T038
in	O
representative	B-T097
community	O
-	O
based	O
patients	O
with	O
type	B-T038
2	I-T038
diabetes	I-T038
.	O

Data	O
from	O
the	O
Fremantle	B-T062
Diabetes	I-T062
Study	I-T062
Phase	I-T062
II	I-T062
(	O
FDS2	B-T062
;	O
n	O
=	O
1551	O
,	O
mean	O
age	O
65	O
.	O
7years	O
,	O
51	O
.	O
9	O
%	O
males	O
)	O
and	O
Busselton	B-T062
Diabetes	I-T062
Study	I-T062
(	O
BDS	B-T062
;	O
n	O
=	O
186	O
,	O
mean	O
age	O
70	O
.	O
2years	O
,	O
50	O
.	O
0	O
%	O
males	O
)	O
cohorts	B-T098
,	O
and	O
from	O
186	O
matched	O
BDS	B-T062
participants	B-T098
without	O
diabetes	B-T038
,	O
were	O
analyzed	B-T062
.	O

The	O
prevalence	O
of	O
anemia	B-T038
(	O
hemoglobin	B-T103
≤130g	O
/	O
L	O
males	O
,	O
≤120g	O
/	O
L	O
females	O
)	O
was	O
determined	O
in	O
each	O
sample	B-T031
.	O

In	O
FDS2	B-T062
,	O
associates	O
of	O
anemia	B-T038
were	O
assessed	O
using	O
multiple	O
logistic	B-T062
regression	I-T062
and	O
Cox	B-T170
proportional	I-T170
hazards	I-T170
modeling	I-T170
identified	O
predictors	B-T033
of	O
death	B-T038
during	O
4	O
.	O
3±1	O
.	O
2years	O
post	O
-	O
recruitment	O
.	O

The	O
prevalence	O
of	O
anemia	B-T038
at	O
baseline	O
was	O
11	O
.	O
5	O
%	O
in	O
FDS2	B-T062
participants	B-T098
,	O
17	O
.	O
8	O
%	O
in	O
BDS	B-T062
type	O
2	O
patients	O
and	O
5	O
.	O
4	O
%	O
in	O
BDS	B-T062
participants	B-T098
without	O
diabetes	B-T038
.	O

In	O
FDS2	B-T062
,	O
163	O
of	O
178	O
patients	O
with	O
anemia	B-T038
(	O
91	O
.	O
6	O
%	O
)	O
had	O
at	O
least	O
one	O
other	O
risk	B-T033
factor	I-T033
(	O
serum	B-T058
vitamin	I-T058
B12	I-T058
<	O
140pmol	O
/	O
L	O
,	O
serum	B-T033
ferritin	I-T033
<	O
30μg	O
/	O
L	O
and	O
/	O
or	O
transferrin	B-T058
saturation	I-T058
<	O
20	O
%	O
,	O
serum	B-T058
testosterone	I-T058
<	O
10nmol	O
/	O
L	O
(	O
males	O
)	O
,	O
glitazone	B-T103
therapy	B-T058
,	O
estimated	B-T058
glomerular	I-T058
filtration	I-T058
rate	I-T058
(	O
eGFR	B-T058
)	O
<	O
60mL	O
/	O
min	O
1	O
.	O
73m	O
(	O
2	O
)	O
,	O
malignancy	B-T038
,	O
hemoglobinopathy	B-T038
)	O
.	O

More	O
anemic	B-T033
than	O
non	B-T033
-	I-T033
anemic	I-T033
FDS2	B-T062
patients	O
died	O
(	O
28	O
.	O
7	O
%	O
versus	O
8	O
.	O
0	O
%	O
;	O
P	O
<	O
0	O
.	O
001	O
)	O
.	O

After	O
adjustment	O
for	O
other	O
independent	O
predictors	B-T033
(	O
age	O
as	O
time	O
-	O
scale	O
,	O
male	O
sex	O
,	O
Aboriginality	B-T033
,	O
marital	O
status	O
,	O
smoking	O
,	O
eGFR	B-T058
)	O
,	O
anemia	B-T038
was	O
associated	O
with	O
a	O
57	O
%	O
increase	O
in	O
mortality	O
(	O
P	O
=	O
0	O
.	O
015	O
)	O
.	O

Type	B-T038
2	I-T038
diabetes	I-T038
at	O
least	O
doubles	O
the	O
risk	O
of	O
anemia	B-T038
but	O
other	O
mostly	O
modifiable	O
risk	B-T033
factors	I-T033
are	O
usually	O
present	B-T033
.	O

Anemia	B-T038
is	O
associated	O
with	O
an	O
increased	B-T033
risk	I-T033
of	I-T033
death	I-T033
after	O
adjustment	O
for	O
other	O
predictors	B-T033
.	O

Succinic	B-T103
acid	I-T103
production	O
by	O
immobilized	B-T017
cultures	B-T058
using	O
spent	O
sulphite	O
liquor	O
as	O
fermentation	B-T038
medium	O

Spent	B-T103
sulphite	I-T103
liquor	I-T103
(	O
SSL	B-T103
)	O
was	O
used	O
as	O
carbon	B-T103
source	B-T033
for	O
the	O
production	O
of	O
succinic	B-T103
acid	I-T103
using	O
immobilized	B-T017
cultures	B-T058
of	O
Actinobacillus	B-T007
succinogenes	I-T007
and	O
Basfia	B-T007
succiniciproducens	I-T007
on	O
two	O
different	O
supports	O
,	O
delignified	O
cellulosic	O
material	O
(	O
DCM	O
)	O
and	O
alginate	B-T103
beads	O
.	O

Fed	B-T058
-	I-T058
batch	I-T058
immobilized	I-T058
cultures	I-T058
with	O
A	B-T007
.	I-T007

succinogenes	I-T007
in	O
alginates	B-T103
resulted	O
in	O
higher	O
sugar	B-T103
to	O
succinic	B-T103
acid	I-T103
conversion	O
yield	O
(	O
0	O
.	O
81g	O
/	O
g	O
)	O
than	O
the	O
respective	O
yield	O
achieved	O
(	O
0	O
.	O
65g	O
/	O
g	O
)	O
when	O
DCM	O
immobilized	B-T017
cultures	B-T058
were	O
used	O
.	O

The	O
final	O
succinic	B-T103
acid	I-T103
concentration	O
and	O
yield	O
achieved	O
in	O
fed	B-T058
-	I-T058
batch	I-T058
with	O
immobilized	B-T017
cultures	B-T058
of	O
B	B-T007
.	I-T007

succiniciproducens	I-T007
in	O
alginates	B-T103
(	O
45g	O
/	O
L	O
and	O
0	O
.	O
66g	O
/	O
g	O
)	O
were	O
higher	O
than	O
A	B-T007
.	I-T007

succinogenes	I-T007
immobilized	B-T017
cultures	B-T058
(	O
35	O
.	O
4g	O
/	O
L	O
and	O
0	O
.	O
61g	O
/	O
g	O
)	O
using	O
nano	O
-	O
filtrated	O
SSL	O
as	O
fermentation	B-T038
medium	O
.	O

Immobilized	B-T017
cultures	B-T058
of	O
B	B-T007
.	I-T007

succiniciproducens	I-T007
in	O
alginate	B-T103
beads	O
were	O
reused	O
in	O
four	O
sequential	B-T058
fed	I-T058
-	I-T058
batch	I-T058
fermentations	B-T038
of	O
nano	O
-	O
filtrated	B-T103
SSL	I-T103
leading	O
to	O
the	O
production	O
of	O
64	O
.	O
7g	O
of	O
succinic	B-T103
acid	I-T103
with	O
a	O
yield	O
range	O
of	O
0	O
.	O
42	O
-	O
0	O
.	O
67g	O
/	O
g	O
and	O
productivity	O
range	O
of	O
0	O
.	O
29	O
-	O
0	O
.	O
65g	O
/	O
L	O
/	O
h	O
.	O

The	O
immobilized	B-T017
cultures	B-T058
improved	O
the	O
efficiency	O
of	O
succinic	B-T103
acid	I-T103
production	O
as	O
compared	O
to	O
free	B-T058
cell	I-T058
cultures	I-T058
.	O

Interventions	B-T058
to	O
Improve	B-T033
Grandparent	O
Caregivers	O
'	O
Mental	B-T038
and	O
Physical	B-T033
Health	I-T033
:	O
An	O
Integrative	B-T170
Review	I-T170

The	O
aim	O
of	O
this	O
integrative	B-T170
review	I-T170
is	O
to	O
appraise	O
grandparent	O
caregiver	O
interventions	B-T058
that	O
are	O
designed	O
to	O
improve	B-T033
their	O
physical	B-T033
and	O
mental	B-T038
health	I-T038
.	O

A	O
database	B-T170
search	O
was	O
performed	O
to	O
identify	O
relevant	O
studies	B-T062
published	O
between	O
January	O
1	O
,	O
1980	O
,	O
and	O
December	O
31	O
,	O
2014	O
.	O

Thirteen	O
publications	B-T170
,	O
including	O
11	O
studies	B-T062
,	O
met	O
all	O
inclusion	O
and	O
exclusion	O
criteria	O
.	O

All	O
studies	B-T062
included	O
grandparent	O
mental	B-T038
health	I-T038
outcomes	O
with	O
fewer	O
focusing	O
on	O
physical	B-T033
health	I-T033
and	O
social	B-T098
relations	I-T098
.	O

Improvements	O
were	O
found	O
in	O
all	O
three	O
areas	B-T082
with	O
fewer	O
improvements	O
seen	O
in	O
physical	B-T033
health	I-T033
.	O

However	O
,	O
small	O
effect	O
sizes	O
were	O
seen	O
with	O
most	O
measures	O
of	O
these	O
outcomes	O
.	O

Although	O
the	O
interventions	B-T058
led	O
to	O
positive	O
grandparent	O
caregiver	O
outcomes	O
,	O
the	O
studies	B-T062
were	O
limited	O
by	O
their	O
design	O
,	O
only	O
one	O
of	O
which	O
was	O
a	O
randomized	B-T062
controlled	I-T062
trial	I-T062
.	O

Also	O
,	O
interventions	B-T058
did	O
not	O
consider	O
variations	O
in	O
the	O
grandchild	O
'	O
s	O
or	O
parent	O
'	O
s	O
ages	O
or	O
if	O
the	O
grandparent	O
provided	O
primary	O
or	O
shared	O
care	O
.	O

These	O
gaps	O
should	O
be	O
addressed	O
in	O
future	O
research	B-T062
.	O

An	O
attenuated	O
Mycobacterium	B-T007
tuberculosis	I-T007
clinical	O
strain	O
with	O
a	O
defect	O
in	O
ESX	B-T103
-	I-T103
1	I-T103
secretion	B-T038
induces	O
minimal	O
host	O
immune	B-T038
responses	I-T038
and	O
pathology	B-T091

Although	O
Mycobacterium	B-T007
tuberculosis	I-T007
(	I-T007
M	I-T007
.	I-T007
tb	I-T007
)	I-T007
DK9897	I-T007
is	O
an	O
attenuated	O
strain	O
,	O
it	O
was	O
isolated	O
from	O
a	O
patient	O
with	O
extrapulmonary	B-T038
tuberculosis	I-T038
and	O
vaccination	B-T058
with	O
a	O
subunit	B-T103
vaccine	I-T103
(	O
H56	B-T103
)	O
induced	O
poor	O
protection	O
against	O
it	O
.	O

Both	O
attenuation	O
and	O
lack	O
of	O
protection	O
are	O
because	O
M	B-T007
.	I-T007
tb	I-T007
DK9897	I-T007
cannot	O
secrete	B-T038
the	O
EsxA	B-T103
virulence	B-T103
factor	I-T103
nor	O
induce	O
a	O
host	B-T038
response	I-T038
against	O
it	O
.	O

Genome	O
sequencing	O
identified	O
a	O
frameshift	B-T038
mutation	I-T038
in	O
the	O
eccCa1	B-T017
gene	I-T017
.	O

Since	O
the	O
encoded	O
EccCa1	B-T103
protein	I-T103
provides	O
energy	O
for	O
ESX	B-T103
-	I-T103
1	I-T103
secretion	B-T038
,	O
it	O
suggested	O
a	O
defect	O
in	O
the	O
ESX	B-T103
-	I-T103
1	I-T103
type	B-T038
VII	I-T038
secretion	I-T038
system	I-T038
.	O

Genetic	O
complementation	O
with	O
a	O
plasmid	B-T103
carrying	O
the	O
M	B-T007
.	I-T007
tb	I-T007
H37Rv	I-T007
sequence	O
of	O
eccCa1	B-T103
-	I-T103
eccCb1	I-T103
-	I-T103
pe35	I-T103
re	O
-	O
established	O
EsxA	B-T103
secretion	B-T038
,	O
host	O
specific	O
EsxA	B-T103
T	B-T017
-	I-T017
cell	I-T017
responses	B-T038
,	O
and	O
increased	O
strain	O
virulence	B-T038
.	O

The	O
ESX	B-T103
-	I-T103
1	I-T103
secretion	B-T038
defect	O
prevents	O
several	O
virulence	B-T103
factors	I-T103
from	O
being	O
functional	O
during	O
infection	B-T038
and	O
therefore	O
attenuates	O
M	B-T007
.	I-T007
tb	I-T007
.	O

It	O
precludes	O
specific	O
T	B-T017
-	I-T017
cell	I-T017
responses	B-T038
against	O
strong	O
antigens	B-T103
and	O
we	O
found	O
very	O
little	O
in	B-T082
vivo	I-T082
cytokine	B-T038
production	I-T038
,	O
gross	B-T033
pathology	I-T033
or	O
granuloma	B-T038
formation	I-T038
in	O
lungs	B-T017
from	O
M	B-T007
.	I-T007
tb	I-T007
DK9897	I-T007
infected	O
animals	O
.	O

This	O
coincides	O
with	O
M	B-T007
.	I-T007
tb	I-T007
DK9897	I-T007
being	O
unable	O
to	O
disrupt	O
the	O
phagosome	B-T017
membrane	I-T017
and	O
make	O
contact	O
to	O
the	O
cytosol	B-T017
.	O

Results	O
for	O
patients	O
with	O
sarcoma	B-T038
not	O
otherwise	O
specified	O
and	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T038
sarcoma	I-T038
treated	B-T033
according	O
to	O
the	O
Euro	B-T062
-	I-T062
EWING	I-T062
99	I-T062
trial	I-T062

Euro	B-T062
-	I-T062
EWING	I-T062
99	I-T062
trial	I-T062
of	O
the	O
European	B-T098
Ewing	B-T038
tumor	I-T038
Working	O
Initiative	B-T033
of	O
National	B-T092
Groups	O
(	O
EE99	B-T170
)	O
was	O
an	O
international	O
phase	B-T062
III	I-T062
study	I-T062
in	O
patients	O
with	O
Ewing	B-T038
sarcoma	I-T038
.	O

The	O
German	B-T092
Society	I-T092
of	I-T092
Pediatric	I-T092
Oncology	I-T092
and	I-T092
Hematology	I-T092
(	I-T092
GPOH	I-T092
)	I-T092
data	I-T092
center	I-T092
registered	B-T058
and	O
followed	O
patients	O
with	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T038
sarcoma	I-T038
who	O
were	O
treated	B-T033
according	O
to	O
the	O
EE99	B-T170
protocol	I-T170
in	O
an	O
additional	O
non	B-T170
-	I-T170
Ewing	I-T170
database	I-T170
.	O

Data	O
of	O
27	O
patients	O
with	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T038
sarcoma	I-T038
treated	B-T033
according	O
to	O
the	O
EE99	B-T170
protocol	I-T170
were	O
analyzed	B-T062
.	O

Patients	O
had	O
miscellaneous	O
histologic	O
diagnoses	B-T033
,	O
the	O
majority	O
were	O
diagnosed	B-T033
with	O
sarcoma	B-T038
not	O
otherwise	O
specified	O
(	O
NOS	O
)	O
arising	O
in	O
bone	B-T017
and	O
soft	B-T017
tissue	I-T017
(	O
63	O
%	O
)	O
.	O

The	O
median	O
age	O
at	O
diagnosis	B-T033
was	O
16	O
.	O
9	O
years	O
(	O
range	O
4	O
.	O
5	O
-	O
41	O
.	O
4	O
)	O
.	O

Localized	B-T038
disease	I-T038
was	O
diagnosed	B-T033
in	O
61	O
.	O
5	O
%	O
of	O
the	O
patients	O
and	O
38	O
.	O
5	O
%	O
had	O
distant	B-T038
metastases	I-T038
at	O
time	O
of	O
primary	O
diagnosis	B-T033
.	O

The	O
median	O
follow	B-T058
-	I-T058
up	I-T058
time	O
was	O
3	O
.	O
7	O
years	O
(	O
range	O
0	O
.	O
5	O
-	O
9	O
.	O
5	O
)	O
.	O

Patients	O
with	O
localized	B-T038
disease	I-T038
showed	O
a	O
3	O
-	O
year	O
event	O
-	O
free	O
survival	O
(	O
EFS	O
)	O
of	O
68	O
%	O
,	O
compared	O
to	O
3	O
-	O
year	O
EFS	O
of	O
20	O
%	O
in	O
patients	O
with	O
metastases	B-T038
(	O
P	O
=	O
0	O
.	O
042	O
)	O
.	O

Three	O
-	O
year	O
EFS	O
for	O
patients	O
with	O
sarcoma	B-T038
NOS	O
was	O
52	O
%	O
,	O
patients	O
with	O
localized	B-T038
and	O
metastatic	B-T038
disease	I-T038
showed	O
3	O
-	O
year	O
EFS	O
of	O
66	O
and	O
20	O
%	O
,	O
respectively	O
.	O

EFS	O
in	O
patients	O
with	O
other	O
diagnoses	B-T033
than	O
Ewing	B-T038
sarcoma	I-T038
treated	B-T033
according	O
to	O
EE99	B-T170
was	O
significantly	O
higher	O
in	O
patients	O
with	O
localized	B-T038
than	O
metastatic	B-T038
disease	I-T038
.	O

Sarcomas	B-T038
of	O
soft	B-T017
tissue	I-T017
and	O
bone	B-T017
that	O
cannot	O
be	O
classified	B-T170
to	O
current	O
diagnostic	O
categories	O
constitute	O
a	O
therapeutic	O
challenge	B-T058
.	O

Capsular	B-T103
Polysaccharide	I-T103
Types	O
and	O
Virulence	B-T038
-	I-T038
Related	I-T038
Traits	O
of	O
Epidemic	O
KPC	B-T038
-	O
Producing	O
Klebsiella	B-T007
pneumoniae	I-T007
Isolates	B-T103
in	O
a	O
Chinese	B-T082
University	B-T092
Hospital	I-T092

Klebsiella	B-T007
pneumoniae	I-T007
is	O
an	O
important	O
human	B-T204
pathogen	O
associated	O
with	O
a	O
variety	O
of	O
diseases	B-T038
and	O
the	O
prevalence	O
of	O
blaKPC	B-T017
carrying	O
K	B-T007
.	I-T007

pneumoniae	I-T007
(	O
KPC	B-T007
-	I-T007
Kp	I-T007
)	O
is	O
rapidly	O
increasing	O
.	O

Capsule	B-T103
is	O
an	O
important	O
virulence	B-T103
factor	I-T103
in	O
K	B-T007
.	I-T007

pneumoniae	I-T007
.	O

In	O
this	O
study	B-T062
,	O
we	O
determined	O
to	O
first	O
systematically	O
characterize	O
capsular	B-T103
polysaccharide	I-T103
(	O
CPS	B-T103
)	O
and	O
virulence	B-T038
traits	O
in	O
KPC	B-T007
-	I-T007
Kp	I-T007
strains	O
.	O

A	O
total	O
of	O
56	O
KPC	B-T007
-	I-T007
Kp	I-T007
isolates	B-T103
were	O
recovered	O
from	O
clinical	O
samples	O
in	O
a	O
Chinese	B-T092
hospital	I-T092
,	O
which	O
were	O
assigned	O
to	O
clonal	O
lineages	O
by	O
multilocus	B-T062
sequence	I-T062
typing	I-T062
(	O
MLST	B-T062
)	O
.	O

Capsule	B-T103
typing	B-T058
(	O
wzi	B-T058
sequencing	I-T058
and	O
wzc	B-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
[	O
PCR	B-T062
]	O
)	O
and	O
virulence	B-T038
genes	B-T017
were	O
characterized	O
by	O
molecular	B-T058
approaches	I-T058
.	O

The	O
virulence	B-T038
of	O
these	O
strains	O
was	O
determined	O
by	O
biofilm	B-T038
formation	I-T038
,	O
serum	B-T031
killing	B-T038
resistance	O
,	O
phagocytosis	B-T038
,	O
and	O
infection	B-T038
models	B-T170
.	O

Six	O
different	O
STs	B-T033
were	O
found	B-T033
among	O
56	O
KPC	B-T007
-	I-T007
Kp	I-T007
isolates	B-T103
:	O
76	O
.	O
8	O
%	O
(	O
43	O
of	O
56	O
isolates	B-T103
)	O
belonged	O
to	O
ST11	B-T033
,	O
6	B-T033
isolates	B-T103
belonged	O
to	O
ST147	B-T033
,	O
4	O
isolates	B-T103
belonged	O
to	O
ST15	B-T033
,	O
1	O
isolate	O
belonged	O
to	O
ST1456	B-T033
,	O
1	O
isolate	O
belonged	O
to	O
ST65	B-T033
,	O
and	O
1	O
isolate	O
was	O
ST23	B-T033
.	O

Based	O
on	O
the	O
wzi	B-T058
gene	I-T058
DNA	I-T058
sequences	I-T058
and	O
wzc	B-T062
PCR	I-T062
,	O
these	O
56	O
strains	O
were	O
classified	O
as	O
capsular	B-T103
type	O
wzi47	B-T103
-	I-T103
K47	I-T103
(	O
n	O
=	O
37	O
)	O
,	O
wzi64	B-T103
-	I-T103
K64	I-T103
(	O
n	O
=	O
8	O
)	O
,	O
wzi8	B-T103
-	I-T103
K8	I-T103
(	O
n	O
=	O
4	O
)	O
,	O
wzi37	B-T103
-	I-T103
K37	I-T103
(	O
n	O
=	O
4	O
)	O
,	O
wzi53	B-T103
-	I-T103
K53	I-T103
(	O
n	O
=	O
1	O
)	O
,	O
wzi125	B-T103
-	I-T103
K2	I-T103
(	O
n	O
=	O
1	O
)	O
,	O
and	O
wzi1	B-T103
-	I-T103
K1	I-T103
(	O
n	O
=	O
1	O
)	O
.	O

Heterogeneity	O
was	O
detected	B-T033
in	O
biofilm	B-T038
formation	I-T038
and	O
phagocytosis	B-T038
among	O
different	O
CPS	B-T103
types	O
.	O

ST11	B-T033
strains	O
were	O
less	O
virulent	O
than	O
other	O
ST	B-T033
strains	O
.	O

KPC	B-T007
-	I-T007
Kp	I-T007
strains	O
exhibit	O
variability	O
of	O
virulence	B-T038
-	I-T038
associated	I-T038
traits	O
.	O

Differences	O
were	O
associated	O
with	O
the	O
ST	B-T033
types	O
and	O
CPS	B-T103
.	O

Interaction	O
-	O
driven	O
distinctive	O
electronic	B-T082
states	I-T082
of	O
artificial	B-T103
atoms	I-T103
at	O
the	O
ZnO	B-T103
interface	O

We	O
have	O
investigated	O
the	O
electronic	B-T082
states	I-T082
of	O
planar	O
quantum	O
dots	O
at	O
the	O
ZnO	B-T103
interface	O
containing	O
a	O
few	O
interacting	O
electrons	B-T103
in	O
an	O
externally	O
applied	O
magnetic	O
field	O
.	O

The	O
electron	B-T103
-	I-T103
electron	I-T103
interaction	O
effects	O
are	O
expected	O
to	O
be	O
much	O
stronger	O
in	O
this	O
case	O
than	O
in	O
traditional	O
semiconductor	O
quantum	O
systems	O
,	O
such	O
as	O
in	O
GaAs	B-T103
or	O
InAs	B-T103
quantum	O
dots	O
.	O

In	O
order	O
to	O
highlight	O
that	O
stronger	O
Coulomb	O
effects	O
in	O
the	O
ZnO	B-T103
quantum	O
dots	O
,	O
we	O
have	O
compared	O
the	O
energy	O
spectra	O
and	O
the	O
magnetization	O
in	O
this	O
system	O
to	O
those	O
of	O
the	O
InAs	B-T103
quantum	O
dots	O
.	O

We	O
have	O
found	O
that	O
in	O
the	O
ZnO	B-T103
quantum	O
dots	O
the	O
signatures	O
of	O
stronger	O
Coulomb	O
interaction	O
manifests	O
in	O
an	O
unique	O
ground	B-T082
state	I-T082
that	O
has	O
very	O
different	O
properties	O
than	O
the	O
corresponding	O
ones	O
in	O
the	O
InAs	B-T103
dot	O
.	O

Our	O
results	O
for	O
the	O
magnetization	O
also	O
exhibits	O
behaviors	O
never	O
before	O
observed	O
in	O
a	O
quantum	O
dot	O
for	O
a	O
realistic	O
set	O
of	O
parameters	O
.	O

We	O
have	O
found	O
a	O
stronger	O
temperature	O
dependence	O
and	O
other	O
unexpected	O
features	O
,	O
such	O
as	O
paramagnetic	O
-	O
like	O
behavior	O
at	O
high	O
temperatures	O
for	O
a	O
quantum	O
-	O
dot	O
helium	B-T103
.	O

Evaluation	B-T058
of	O
Tobacco	O
Control	O
Policies	O
in	O
San	B-T082
Francisco	I-T082
Homeless	B-T098
Housing	O
Programs	O

The	O
2014	O
Surgeon	B-T170
General	I-T170
'	I-T170
s	I-T170
Report	I-T170
noted	O
that	O
high	O
smoking	O
rates	O
in	O
vulnerable	B-T098
populations	I-T098
such	O
as	O
the	O
homeless	B-T098
have	O
been	O
a	O
persistent	O
public	B-T092
health	O
problem	O
;	O
smoking	O
prevalence	O
among	O
individuals	B-T098
experiencing	O
homelessness	B-T033
exceeds	O
70	O
%	O
.	O

Historically	O
,	O
service	O
providers	O
for	O
the	O
homeless	B-T098
have	O
not	O
enacted	O
comprehensive	O
tobacco	O
control	O
policies	O
.	O

We	O
conducted	O
a	O
qualitative	B-T062
study	I-T062
of	O
homeless	B-T098
housing	O
programs	O
in	O
San	B-T082
Francisco	I-T082
.	O

Administrators	B-T097
representing	O
9	O
of	O
the	O
city	O
'	O
s	O
11	O
homeless	B-T092
service	I-T092
agencies	I-T092
were	O
interviewed	O
to	O
assess	O
institutional	O
smoking	O
-	O
related	O
policies	B-T170
and	O
cessation	O
programs	O
and	O
perceived	B-T038
barriers	O
and	O
receptivity	O
to	O
instituting	O
tobacco	B-T103
control	O
interventions	B-T058
.	O

Respondents	B-T098
indicated	B-T033
that	O
although	O
most	O
programs	O
had	O
adopted	O
smoke	B-T103
-	O
free	O
grounds	O
and	O
some	O
had	O
eliminated	O
evidence	O
of	O
staff	B-T097
smoking	O
,	O
the	O
smoking	O
status	O
of	O
clients	O
was	O
assessed	O
only	O
when	O
required	O
by	O
funders	O
.	O

None	O
of	O
the	O
programs	O
offered	B-T033
smoking	O
cessation	O
interventions	B-T058
.	O

Most	O
administrators	B-T097
were	O
receptive	O
to	O
adopting	O
policies	B-T170
that	O
would	O
promote	O
a	O
tobacco	B-T103
-	O
free	O
culture	B-T092
;	O
however	O
,	O
they	O
noted	O
that	O
their	O
clients	O
had	O
unique	O
challenges	B-T058
that	O
made	O
traditional	O
smoking	O
cessation	O
programs	O
unfeasible	O
.	O

Homeless	B-T098
housing	O
programs	O
in	O
San	B-T082
Francisco	I-T082
have	O
not	O
yet	O
adopted	O
a	O
tobacco	B-T103
-	O
free	O
culture	B-T092
.	O

Existing	O
policies	B-T170
were	O
created	O
in	O
response	O
to	O
external	B-T082
mandates	B-T170
,	O
and	O
smoking	O
cessation	O
programs	O
may	O
need	O
to	O
be	O
modified	O
in	O
order	O
to	O
effectively	O
reach	O
clients	O
.	O

Identification	O
of	O
low	O
micromolar	O
dual	O
inhibitors	B-T103
for	O
aldose	B-T103
reductase	I-T103
(	O
ALR2	B-T103
)	O
and	O
poly	B-T103
(	I-T103
ADP	I-T103
-	I-T103
ribose	I-T103
)	I-T103
polymerase	I-T103
(	O
PARP	B-T103
-	I-T103
1	I-T103
)	O
using	O
structure	B-T082
based	O
design	O
approach	O

Clinical	B-T062
studies	I-T062
have	O
revealed	O
that	O
diabetic	B-T038
retinopathy	I-T038
is	O
a	O
multifactorial	O
disorder	B-T038
.	O

Moreover	O
,	O
studies	O
also	O
suggest	O
that	O
ALR2	B-T103
and	O
PARP	B-T103
-	I-T103
1	I-T103
co	O
-	O
occur	O
in	O
retinal	B-T017
cells	B-T017
,	O
making	O
them	O
appropriate	O
targets	O
for	O
the	O
treatment	B-T058
of	O
diabetic	B-T038
retinopathy	I-T038
.	O

To	O
find	O
the	O
dual	O
inhibitors	B-T103
of	O
ALR2	B-T103
and	O
PARP	B-T103
-	I-T103
1	I-T103
,	O
the	O
structure	B-T082
based	O
design	O
was	O
carried	O
out	O
in	O
parallel	O
for	O
both	O
the	O
target	O
proteins	B-T103
.	O

A	O
series	O
of	O
novel	O
thiazolidine	B-T103
-	I-T103
2	I-T103
,	I-T103
4	I-T103
-	I-T103
dione	I-T103
(	O
TZD	B-T103
)	O
derivatives	O
were	O
therefore	O
rationally	O
designed	O
,	O
synthesized	O
and	O
their	O
in	O
vitro	O
inhibitory	B-T038
activities	I-T038
against	O
ALR2	B-T103
and	O
PARP	B-T103
-	I-T103
1	I-T103
were	O
evaluated	O
.	O

The	O
experimental	B-T033
results	I-T033
showed	O
that	O
compounds	B-T103
5b	I-T103
and	O
5f	B-T103
,	O
with	O
2	O
-	O
chloro	O
and	O
4	O
-	O
fluoro	O
substitutions	O
,	O
showed	O
biochemical	O
activities	O
in	O
micromolar	O
and	O
submicromolar	O
range	O
(	O
IC50	O
1	O
.	O
34	O
-	O
5	O
.	O
03μM	O
)	O
against	O
both	O
the	O
targeted	O
enzymes	B-T103
.	O

The	O
structure	O
-	O
activity	O
relationship	O
elucidated	O
for	O
these	O
novel	O
inhibitors	B-T103
against	O
both	O
the	O
enzymes	B-T103
provide	O
new	O
insight	O
into	O
the	O
binding	B-T038
mode	O
of	O
the	O
inhibitors	B-T103
to	O
the	O
active	O
sites	O
of	O
enzymes	B-T103
.	O

The	O
positive	B-T033
results	O
of	O
the	O
biochemical	O
assay	B-T058
suggest	O
that	O
these	O
compounds	B-T103
may	O
be	O
further	O
optimized	O
and	O
utilized	O
for	O
the	O
treatment	B-T058
of	O
diabetic	B-T038
retinopathy	I-T038
.	O

Microbiology	B-T058
of	O
the	O
Upper	B-T082
and	O
Lower	B-T038
Airways	I-T038
in	O
Pediatric	O
Cystic	B-T038
Fibrosis	I-T038
Patients	O

Objective	O
To	O
evaluate	O
the	O
microbiology	O
of	O
the	O
upper	O
and	O
lower	O
airways	O
in	O
pediatric	O
cystic	B-T038
fibrosis	I-T038
(	O
CF	B-T038
)	O
patients	O
who	O
underwent	O
sinus	B-T058
surgery	I-T058
.	O

Study	O
Design	O
Retrospective	B-T062
case	O
series	O
with	O
chart	O
review	O
.	O

Setting	O
Tertiary	B-T092
care	I-T092
children	B-T092
'	I-T092
s	I-T092
hospital	I-T092
.	O

Subjects	O
and	O
Methods	O
A	O
total	O
of	O
201	O
paired	O
sinus	O
and	O
pulmonary	O
cultures	O
from	O
105	O
CF	B-T038
patients	O
were	O
identified	O
between	O
1996	O
and	O
2014	O
.	O

Demographics	B-T062
and	O
culture	B-T058
results	O
were	O
analyzed	O
.	O

Results	O
The	O
mean	O
age	O
of	O
patients	O
was	O
11	O
.	O
2	O
±	O
5	O
.	O
4	O
years	O
(	O
range	O
,	O
1	O
-	O
27	O
years	O
)	O
,	O
and	O
approximately	O
one	O
-	O
half	O
were	O
female	B-T098
.	O

Methicillin	B-T103
-	O
sensitive	O
Staphylococcus	B-T007
aureus	I-T007
was	O
the	O
most	O
common	O
pathogen	O
overall	O
.	O

A	O
significantly	O
higher	O
prevalence	O
of	O
Pseudomonas	B-T007
aeruginosa	I-T007
(	O
32	O
%	O
for	O
pulmonary	O
and	O
37	O
%	O
for	O
sinus	O
cultures	O
)	O
was	O
observed	O
in	O
older	B-T098
patients	O
versus	O
younger	O
patients	O
(	O
P	O
<	O
.	O
001	O
)	O
.	O

There	O
was	O
low	O
to	O
moderate	O
agreement	O
between	O
sinus	O
and	O
pulmonary	O
cultures	O
(	O
Kappa	B-T170
statistic	O
range	O
,	O
0	O
.	O
03	O
-	O
0	O
.	O
56	O
)	O
.	O

The	O
prevalence	O
of	O
methicillin	B-T007
-	I-T007
resistant	I-T007
S	I-T007
aureus	I-T007
(	O
MRSA	B-T007
)	O
increased	O
significantly	O
for	O
lower	O
respiratory	O
tract	O
culture	O
(	O
from	O
5	O
%	O
to	O
16	O
%	O
)	O
and	O
sinus	O
culture	O
(	O
from	O
5	O
%	O
to	O
27	O
%	O
)	O
between	O
1996	O
-	O
2004	O
and	O
2010	O
-	O
2014	O
(	O
P	O
=	O
.	O
016	O
and	O
P	O
<	O
.	O
001	O
,	O
respectively	O
)	O
.	O

The	O
prevalence	O
of	O
positive	B-T033
sinus	O
cultures	O
increased	O
from	O
40	O
%	O
to	O
85	O
%	O
between	O
1996	O
-	O
2004	O
and	O
2010	O
-	O
2014	O
(	O
P	O
=	O
.	O
018	O
)	O
.	O

Patients	O
with	O
pulmonary	O
MRSA	B-T007
were	O
more	O
likely	O
to	O
be	O
coinfected	B-T038
with	O
pulmonary	O
P	B-T007
aeruginosa	I-T007
(	O
risk	O
ratio	O
,	O
2	O
.	O
4	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
4	O
.	O
8	O
;	O
P	O
=	O
.	O
015	O
)	O
or	O
Aspergillus	B-T204
fumigatus	I-T204
(	O
risk	O
ratio	O
,	O
2	O
.	O
2	O
;	O
95	O
%	O
CI	O
,	O
1	O
.	O
2	O
-	O
4	O
.	O
8	O
;	O
P	O
=	O
.	O
035	O
)	O
.	O

Conclusions	O
There	O
is	O
low	O
to	O
moderate	O
correlation	O
between	O
pulmonary	O
and	O
sinus	B-T082
pathogens	O
in	O
CF	B-T038
patients	O
.	O

This	O
is	O
important	O
to	O
consider	O
when	O
treating	B-T058
infections	B-T038
.	O

The	O
prevalence	O
of	O
MRSA	B-T007
in	O
sinus	O
cultures	O
has	O
increased	O
over	O
time	O
and	O
warrants	O
further	O
investigation	B-T058
.	O

The	O
role	O
of	O
miR	B-T103
-	I-T103
451	I-T103
in	O
the	O
switching	O
between	O
proliferation	O
and	O
migration	B-T038
in	O
malignant	B-T038
glioma	I-T038
cells	B-T017
:	O
AMPK	B-T103
signaling	B-T038
,	O
mTOR	B-T103
modulation	B-T082
and	O
Rac1	B-T103
activation	O
required	O

Glioblastoma	B-T038
multiforme	I-T038
(	O
GBM	B-T038
)	O
,	O
WHO	B-T038
grade	I-T038
IV	I-T038
astrocytoma	I-T038
,	O
is	O
the	O
most	O
common	O
primary	B-T038
neoplasm	I-T038
of	O
the	O
central	B-T022
nervous	I-T022
system	I-T022
(	O
CNS	B-T022
)	O
and	O
has	O
the	O
highest	O
malignancy	B-T038
and	O
mortality	O
rates	O
.	O

The	O
invasive	O
nature	O
of	O
GBM	B-T038
complicates	O
surgical	B-T058
resection	I-T058
and	O
restricts	O
chemotherapeutic	O
access	O
,	O
contributing	O
to	O
poor	O
patient	O
prognosis	B-T058
.	O

The	O
migration	B-T038
of	O
tumor	B-T017
cells	I-T017
is	O
closely	O
related	O
to	O
the	O
tumor	B-T017
cell	I-T017
proliferation	O
.	O

The	O
acquisition	O
of	O
migratory	O
capability	O
,	O
in	O
addition	O
to	O
intracellular	B-T082
factors	O
,	O
is	O
proposed	O
to	O
be	O
a	O
crucial	O
mechanism	O
during	O
the	O
progression	O
of	O
invasion	B-T033
.	O

Using	O
qRT	B-T062
-	I-T062
PCR	I-T062
analysis	B-T062
,	O
we	O
determined	O
that	O
the	O
expression	B-T038
of	O
miR	B-T017
-	I-T017
451	I-T017
in	O
glioma	B-T038
tissue	B-T017
was	O
lower	O
than	O
in	O
control	B-T017
brain	I-T017
tissue	I-T017
,	O
especially	O
in	O
the	O
central	B-T082
portions	B-T082
of	O
the	O
tumor	B-T038
.	O

In	O
glioma	B-T038
cell	B-T017
lines	I-T017
,	O
we	O
found	O
that	O
decreased	O
miR	B-T017
-	I-T017
451	I-T017
expression	B-T038
suppressed	O
tumor	B-T017
cell	I-T017
proliferation	O
but	O
enhanced	O
migration	B-T038
with	O
a	O
concomitant	O
low	O
level	O
of	O
CAB39	B-T103
/	O
AMPK	B-T103
/	O
mTOR	B-T103
pathway	O
activation	O
and	O
high	O
level	O
of	O
Rac1	B-T103
/	O
cofilin	O
pathway	O
activation	O
,	O
respectively	O
.	O

Notably	O
,	O
the	O
effect	O
of	O
miR	B-T103
-	I-T103
451	I-T103
on	O
cytological	O
behavior	O
and	O
on	O
the	O
activation	O
of	O
mTOR	B-T103
and	O
Rac1	B-T103
was	O
limited	O
when	O
AMPKα1	B-T103
expression	B-T038
was	O
knocked	O
-	O
down	O
with	O
a	O
synthetic	O
shRNA	B-T103
.	O

We	O
suggest	O
that	O
the	O
glioma	B-T038
microenvironment	O
results	O
in	O
heterogeneity	O
of	O
miR	B-T017
-	I-T017
451	I-T017
expression	B-T038
.	O

Our	O
data	O
indicated	O
that	O
miR	B-T103
-	I-T103
451	I-T103
relays	O
environmental	O
signals	O
by	O
upregulating	B-T038
the	O
activity	O
of	O
AMPK	B-T103
signaling	B-T038
,	O
thereby	O
modulating	B-T082
the	O
activation	O
of	O
mTOR	B-T103
and	O
Rac1	B-T103
/	O
cofilin	O
which	O
,	O
in	O
turn	O
,	O
play	O
key	O
roles	O
in	O
glioma	B-T038
cell	O
proliferation	O
and	O
migration	B-T038
,	O
respectively	O
.	O

Our	O
results	O
highlight	O
the	O
need	O
to	O
consider	O
opposing	O
roles	O
of	O
a	O
therapeutic	O
target	O
which	O
,	O
while	O
suppressing	O
tumor	B-T017
cell	I-T017
proliferation	O
,	O
could	O
also	O
promote	O
cell	B-T017
infiltration	B-T038
.	O

Comparison	O
of	O
Gasoline	O
Direct	O
-	O
Injection	O
(	O
GDI	O
)	O
and	O
Port	O
Fuel	O
Injection	O
(	O
PFI	O
)	O
Vehicle	B-T103
Emissions	I-T103
:	O
Emission	B-T103
Certification	O
Standards	B-T170
,	O
Cold	B-T033
-	I-T033
Start	I-T033
,	O
Secondary	O
Organic	O
Aerosol	O
Formation	O
Potential	O
,	O
and	O
Potential	O
Climate	O
Impacts	O

Recent	O
increases	O
in	O
the	O
Corporate	O
Average	O
Fuel	O
Economy	O
standards	B-T170
have	O
led	O
to	O
widespread	B-T082
adoption	O
of	O
vehicles	O
equipped	O
with	O
gasoline	O
direct	O
-	O
injection	O
(	O
GDI	O
)	O
engines	O
.	O

Changes	O
in	O
engine	O
technologies	O
can	O
alter	O
emissions	B-T103
.	O

To	O
quantify	O
these	O
effects	O
,	O
we	O
measured	O
gas	B-T103
-	I-T103
and	O
particle	O
-	O
phase	O
emissions	B-T103
from	O
82	O
light	O
-	O
duty	O
gasoline	O
vehicles	O
recruited	O
from	O
the	O
California	B-T082
in	O
-	O
use	O
fleet	O
tested	B-T170
on	O
a	O
chassis	O
dynamometer	O
using	O
the	O
cold	B-T033
-	I-T033
start	I-T033
unified	O
cycle	O
.	O

The	O
fleet	O
included	O
15	O
GDI	O
vehicles	O
,	O
including	O
8	O
GDIs	O
certified	O
to	O
the	O
most	O
-	O
stringent	O
emissions	B-T103
standard	B-T170
,	O
superultra	B-T170
-	I-T170
low	I-T170
-	I-T170
emission	I-T170
vehicles	I-T170
(	O
SULEV	B-T170
)	O
.	O

We	O
quantified	O
the	O
effects	O
of	O
engine	O
technology	O
,	O
emission	B-T103
certification	O
standards	B-T170
,	O
and	O
cold	B-T033
-	I-T033
start	I-T033
on	O
emissions	B-T103
.	O

For	O
vehicles	O
certified	O
to	O
the	O
same	O
emissions	B-T103
standard	B-T170
,	O
there	O
is	O
no	O
statistical	O
difference	O
of	O
regulated	O
gas	O
-	O
phase	O
pollutant	B-T103
emissions	B-T103
between	O
PFIs	O
and	O
GDIs	O
.	O

However	O
,	O
GDIs	O
had	O
,	O
on	O
average	O
,	O
a	O
factor	O
of	O
2	O
higher	O
particulate	O
matter	O
(	O
PM	O
)	O
mass	O
emissions	B-T103
than	O
PFIs	O
due	O
to	O
higher	O
elemental	B-T103
carbon	I-T103
(	O
EC	B-T103
)	O
emissions	B-T103
.	O

SULEV	B-T170
certified	O
GDIs	O
have	O
a	O
factor	O
of	O
2	O
lower	O
PM	O
mass	O
emissions	B-T103
than	O
GDIs	O
certified	O
as	O
ultralow	B-T170
-	I-T170
emission	I-T170
vehicles	I-T170
(	O
3	O
.	O
0	O
±	O
1	O
.	O
1	O
versus	O
6	O
.	O
3	O
±	O
1	O
.	O
1	O
mg	O
/	O
mi	O
)	O
,	O
suggesting	O
improvements	O
in	O
engine	O
design	O
and	O
calibration	O
.	O

Comprehensive	O
organic	O
speciation	O
revealed	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
composition	O
of	O
the	O
volatile	O
organic	B-T103
compounds	I-T103
emissions	B-T103
between	O
PFI	O
and	O
GDIs	O
,	O
including	O
benzene	B-T103
,	O
toluene	B-T103
,	O
ethylbenzene	B-T103
,	O
and	O
xylenes	B-T103
(	O
BTEX	B-T103
)	O
.	O

Therefore	O
,	O
the	O
secondary	O
organic	O
aerosol	O
and	O
ozone	B-T103
formation	O
potential	O
of	O
the	O
exhaust	O
does	O
not	O
depend	O
on	O
engine	O
technology	O
.	O

Cold	B-T033
-	I-T033
start	I-T033
contributes	O
a	O
larger	O
fraction	O
of	O
the	O
total	O
unified	O
cycle	O
emissions	B-T103
for	O
vehicles	O
meeting	O
more	O
-	O
stringent	O
emission	B-T103
standards	B-T170
.	O

Organic	O
gas	B-T103
emissions	B-T103
were	O
the	O
most	O
sensitive	O
to	O
cold	B-T033
-	I-T033
start	I-T033
compared	O
to	O
the	O
other	O
pollutants	B-T103
tested	B-T170
here	O
.	O

There	O
were	O
no	O
statistically	O
significant	O
differences	O
in	O
the	O
effects	O
of	O
cold	B-T033
-	I-T033
start	I-T033
on	O
GDIs	O
and	O
PFIs	O
.	O

For	O
our	O
test	O
fleet	O
,	O
the	O
measured	O
14	O
.	O
5	O
%	O
decrease	O
in	O
CO2	B-T103
emissions	B-T103
from	O
GDIs	O
was	O
much	O
greater	O
than	O
the	O
potential	O
climate	O
forcing	O
associated	O
with	O
higher	O
black	B-T103
carbon	I-T103
emissions	B-T103
.	O

Thus	O
,	O
switching	O
from	O
PFI	O
to	O
GDI	O
vehicles	O
will	O
likely	O
lead	O
to	O
a	O
reduction	O
in	O
net	O
global	O
warming	O
.	O

TRIB3	B-T103
downregulation	B-T038
enhances	O
doxorubicin	B-T103
-	O
induced	O
cytotoxicity	B-T038
in	O
gastric	B-T038
cancer	I-T038
cells	B-T017

TRIB3	B-T103
,	O
which	O
is	O
a	O
pseudokinase	B-T103
known	O
to	O
regulate	B-T038
multiple	I-T038
pro	I-T038
-	I-T038
survival	I-T038
pathways	I-T038
,	O
appears	O
to	O
be	O
a	O
potential	O
therapeutic	B-T058
target	O
for	O
the	O
treatment	B-T058
of	O
human	B-T204
tumors	B-T038
.	O

However	O
,	O
its	O
precise	O
role	O
in	O
cancer	B-T038
is	O
controversial	O
,	O
as	O
TRIB3	B-T103
protein	B-T033
levels	I-T033
have	O
been	O
associated	O
with	O
both	O
good	B-T033
and	O
poor	B-T033
prognosis	I-T033
in	O
cancer	O
patients	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
significance	O
of	O
TRIB3	B-T103
expression	B-T038
in	O
the	O
survival	B-T038
of	O
gastric	B-T038
cancer	I-T038
cells	B-T017
exposed	O
to	O
anticancer	B-T103
drugs	I-T103
.	O

We	O
found	O
that	O
the	O
tested	O
anticancer	B-T103
drug	I-T103
,	O
doxorubicin	B-T103
,	O
induced	O
cytotoxicity	B-T038
by	O
decreasing	O
TRIB3	B-T017
transcription	B-T038
,	O
which	O
was	O
followed	O
by	O
apoptotic	B-T038
cell	I-T038
death	I-T038
.	O

Moreover	O
,	O
TRIB3	B-T103
siRNA	I-T103
knockdown	B-T062
appeared	O
to	O
enhance	O
doxorubicin	B-T103
-	O
induced	O
apoptosis	B-T038
in	O
gastric	B-T038
cancer	I-T038
cells	B-T017
,	O
concurrently	O
with	O
altering	O
the	O
expression	B-T038
of	O
downstream	B-T082
apoptotic	B-T103
factors	I-T103
.	O

Conversely	O
,	O
overexpression	B-T038
of	O
TRIB3	B-T103
significantly	O
protected	B-T017
cells	I-T017
against	O
doxorubicin	B-T103
-	O
induced	O
apoptosis	B-T038
.	O

Our	O
results	O
indicate	O
that	O
downregulation	B-T038
of	O
TRIB3	B-T103
appears	O
to	O
promote	O
cell	B-T038
death	I-T038
and	O
enhance	O
doxorubicin	B-T103
-	O
induced	O
apoptosis	B-T038
,	O
supporting	O
the	O
anti	B-T103
-	I-T103
apoptotic	I-T103
role	O
of	O
TRIB3	B-T103
.	O

The	O
inductions	B-T038
of	O
three	O
classes	O
of	O
MAPKs	B-T103
failed	O
to	O
affect	O
doxorubicin	B-T103
-	O
mediated	O
TRIB3	B-T103
downregulation	B-T038
,	O
while	O
TRIB3	B-T103
overexpression	B-T038
did	O
not	O
affect	O
doxorubicin	B-T103
-	O
induced	O
MAPK	B-T038
activation	I-T038
.	O

In	O
sum	O
,	O
our	O
findings	B-T033
indicate	O
that	O
TRIB3	B-T103
plays	O
an	O
anti	B-T103
-	I-T103
apoptotic	I-T103
role	O
in	O
doxorubicin	B-T103
-	O
treated	O
gastric	B-T038
cancer	I-T038
cell	B-T017
lines	I-T017
,	O
perhaps	O
indicating	O
that	O
the	O
status	O
of	O
TRIB3	B-T103
expression	B-T038
in	O
response	O
to	O
anticancer	B-T103
drugs	I-T103
,	O
such	O
as	O
doxorubicin	B-T103
,	O
irinotecan	B-T103
or	O
oxaliplatin	B-T103
,	O
may	O
reflect	O
the	O
efficiency	O
for	O
cancer	B-T058
therapy	I-T058
.	O

Digital	B-T017
Myopericytoma	B-T038
:	O
A	O
Case	B-T170
Report	I-T170
and	O
Systematic	B-T170
Literature	I-T170
Review	I-T170

A	O
myopericytoma	B-T038
(	O
MP	B-T038
)	O
is	O
an	O
exceedingly	O
rare	O
perivascular	B-T038
tumor	I-T038
of	O
unknown	O
etiology	O
.	O

Given	O
their	O
potential	O
for	O
mimicry	B-T038
and	O
malignancy	B-T038
,	O
MP	B-T038
tumors	I-T038
pose	O
a	O
unique	O
challenge	O
for	O
surgeons	B-T097
and	O
may	O
be	O
overlooked	O
on	O
differential	B-T058
diagnosis	I-T058
.	O

We	O
present	O
a	O
case	B-T170
report	I-T170
of	O
an	O
otherwise	O
healthy	O
33	O
-	O
year	O
-	O
old	O
right	O
-	O
hand	O
dominant	O
male	B-T098
who	O
presented	O
to	O
our	O
outpatient	B-T092
clinic	I-T092
with	O
a	O
2	O
-	O
month	O
history	O
of	O
painless	O
swelling	B-T033
and	O
erythema	O
of	O
the	O
pulp	O
of	O
his	O
left	O
index	O
finger	O
.	O

Subsequent	O
plain	B-T058
film	I-T058
X	I-T058
-	I-T058
ray	I-T058
showed	O
near	O
-	O
complete	O
bony	B-T033
destruction	I-T033
of	O
his	O
distal	B-T017
phalanx	I-T017
.	O

Pathological	B-T038
evaluation	B-T058
of	O
an	O
incisional	B-T058
biopsy	I-T058
showed	O
a	O
benign	B-T038
variant	I-T038
of	O
MP	B-T038
.	O

The	O
lesion	B-T033
was	O
treated	O
by	O
excision	B-T058
with	O
tumor	B-T038
shelling	B-T058
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
recurrence	O
81	O
days	O
postoperatively	O
.	O

A	O
systematic	O
literature	O
review	O
of	O
the	O
management	B-T058
and	O
outcome	O
of	O
all	O
known	O
cases	B-T170
of	O
hand	O
and	O
wrist	O
MP	B-T038
is	O
presented	O
.	O

Gene	B-T038
expression	I-T038
reveals	O
evidence	O
for	O
EGFR	B-T103
-	O
dependent	O
proximal	B-T017
-	I-T017
distal	I-T017
limb	I-T017
patterning	B-T038
in	O
a	O
myriapod	B-T204

Evolution	B-T038
of	O
segmented	B-T017
limbs	I-T017
is	O
one	O
of	O
the	O
key	O
innovations	O
of	O
Arthropoda	B-T204
,	O
allowing	O
development	O
of	O
functionally	O
specific	O
specialized	O
head	B-T082
and	O
trunk	B-T082
appendages	B-T017
,	O
a	O
major	O
factor	O
behind	O
their	O
unmatched	O
evolutionary	O
success	O
.	O

Proximodistal	B-T017
limb	I-T017
patterning	B-T038
is	O
controlled	O
by	O
two	O
regulatory	B-T038
networks	I-T038
in	O
the	O
vinegar	O
fly	O
Drosophila	B-T204
melanogaster	I-T204
,	O
and	O
other	O
insects	B-T204
.	O

The	O
first	O
is	O
represented	O
by	O
the	O
function	O
of	O
the	O
morphogens	B-T103
Wingless	B-T103
(	O
Wg	B-T103
)	O
and	O
Decapentaplegic	B-T103
(	O
Dpp	B-T103
)	O
;	O
the	O
second	O
by	O
the	O
EGFR	B-T038
-	I-T038
signaling	I-T038
cascade	I-T038
.	O

While	O
the	O
role	O
of	O
Wg	B-T103
and	O
Dpp	B-T103
has	O
been	O
studied	B-T062
in	O
a	O
wide	O
range	O
of	O
arthropods	B-T204
representing	O
all	O
main	O
branches	O
,	O
that	O
is	O
,	O
Pancrustacea	B-T204
(	O
=	O
Hexapoda	B-T204
+	O
Crustacea	B-T204
)	O
,	O
Myriapoda	B-T204
and	O
Chelicerata	B-T204
,	O
investigation	O
of	O
the	O
potential	O
role	O
of	O
EGFR	B-T038
-	I-T038
signaling	I-T038
is	O
restricted	O
to	O
insects	B-T204
(	O
Hexapoda	B-T204
)	O
.	O

Gene	B-T062
expression	I-T062
analysis	I-T062
of	O
Egfr	B-T103
,	O
its	O
potential	O
ligands	B-T103
,	O
and	O
putative	B-T103
downstream	I-T103
factors	I-T103
in	O
the	O
pill	B-T204
millipede	I-T204
Glomeris	B-T204
marginata	I-T204
(	O
Myriapoda	B-T204
:	O
Diplopoda	B-T204
)	O
,	O
reveals	O
that	O
-	O
in	O
at	O
least	O
mandibulate	B-T204
arthropods	B-T204
-	O
EGFR	B-T038
-	I-T038
signaling	I-T038
is	O
likely	O
a	O
conserved	O
regulatory	B-T033
mechanism	I-T033
in	O
proximodistal	B-T017
limb	I-T017
patterning	B-T038
.	O

Pirfenidone	B-T103
normalizes	O
the	O
tumor	O
microenvironment	O
to	O
improve	O
chemotherapy	B-T058

Normalization	B-T058
of	O
the	O
tumor	O
microenvironment	O
by	O
selectively	O
targeting	O
components	B-T017
of	O
the	O
tumor	B-T038
extracellular	B-T017
matrix	I-T017
has	O
been	O
recently	O
proposed	O
to	O
have	O
the	O
potential	O
to	O
decompress	O
tumor	B-T038
blood	B-T017
vessels	I-T017
,	O
increase	O
vessel	B-T017
perfusion	O
and	O
thus	O
,	O
improve	O
drug	B-T058
delivery	I-T058
and	O
the	O
efficacy	O
of	O
cancer	B-T058
therapy	I-T058
.	O

Therefore	O
,	O
we	O
now	O
need	O
to	O
identify	O
safe	O
and	O
well	O
tolerated	B-T033
pharmaceutical	B-T103
agents	I-T103
that	O
are	O
able	O
to	O
remodel	O
the	O
microenvironment	O
of	O
solid	B-T038
tumors	I-T038
and	O
enhance	O
chemotherapy	B-T058
.	O

In	O
this	O
study	B-T062
,	O
we	O
repurposed	O
Pirfenidone	B-T103
,	O
a	O
clinically	O
approved	O
anti	O
-	O
fibrotic	O
drug	O
for	O
the	O
treatment	B-T058
of	O
idiopathic	B-T038
pulmonary	I-T038
fibrosis	I-T038
,	O
to	O
investigate	O
its	O
possible	O
role	O
on	O
tumor	O
microenvironment	O
normalization	B-T058
.	O

Using	O
two	O
orthotopic	B-T082
mammary	B-T017
tumor	B-T170
models	I-T170
we	O
demonstrate	O
that	O
Pirfenidone	B-T103
reduces	O
collagen	B-T103
and	O
hyaluronan	B-T103
levels	O
and	O
,	O
as	O
a	O
result	O
,	O
significantly	O
increases	O
blood	B-T017
vessel	I-T017
functionality	O
and	O
perfusion	O
and	O
improves	O
the	O
anti	O
-	O
tumor	O
efficacy	O
of	O
doxorubicin	B-T103
.	O

Reduction	O
of	O
extracellular	B-T017
matrix	I-T017
components	I-T017
were	O
mediated	O
via	O
TGFβ	O
signaling	O
pathway	O
inhibition	O
due	O
to	O
downregulation	B-T038
of	O
TGFβ1	B-T017
,	O
COL1A1	B-T017
,	O
COL3A1	B-T017
,	O
HAS2	B-T017
,	O
HAS3	B-T017
expression	B-T038
levels	O
.	O

Our	O
findings	B-T033
provide	O
evidence	O
that	O
repurposing	O
Pirfenidone	B-T103
could	O
be	O
used	O
as	O
a	O
promising	O
strategy	B-T062
to	O
enhance	O
drug	B-T058
delivery	I-T058
to	O
solid	B-T038
tumors	I-T038
by	O
normalizing	B-T058
the	O
tumor	O
microenvironment	O
.	O

Serum	B-T031
vascular	B-T103
endothelial	I-T103
growth	I-T103
factor	I-T103
receptor	I-T103
-	I-T103
3	I-T103
levels	O
in	O
patients	O
with	O
esophageal	B-T038
squamous	I-T038
cell	I-T038
cancer	I-T038

Esophageal	B-T038
cancer	I-T038
is	O
one	O
of	O
the	O
most	O
aggressive	O
tumors	B-T038
of	I-T038
the	I-T038
gastrointestinal	I-T038
tract	I-T038
.	O

In	O
this	O
study	O
,	O
we	O
quantified	O
the	O
serum	B-T031
vascular	B-T103
endothelial	I-T103
growth	I-T103
factor	I-T103
-	I-T103
3	I-T103
(	O
VEGFR	B-T103
-	I-T103
3	I-T103
)	O
expression	B-T038
in	O
patients	O
with	O
esophageal	B-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
(	O
ESCC	B-T038
)	O
to	O
evaluate	O
the	O
role	O
of	O
VEGFR	B-T103
-	I-T103
3	I-T103
in	O
ESCC	B-T038
.	O

Ninety	O
five	O
patients	O
with	O
ESCC	B-T038
were	O
studied	O
.	O

Pre	O
-	O
therapy	O
and	O
preoperative	O
samples	B-T031
were	O
stored	O
and	O
ELISA	B-T058
was	O
used	O
to	O
designate	O
the	O
concentrations	O
of	O
VEGFR	B-T103
-	I-T103
3	I-T103
.	O

The	O
serum	O
values	O
of	O
VEGFR	B-T103
-	I-T103
3	I-T103
were	O
significantly	O
higher	O
in	O
patients	O
with	O
ESCC	B-T038
than	O
in	O
healthy	O
donors	B-T098
(	O
p	O
<	O
0	O
.	O
0001	O
)	O
.	O

The	O
results	O
imply	O
a	O
very	O
good	O
sensitivity	O
of	O
VEGFR	B-T103
-	I-T103
3	I-T103
in	O
ESCC	B-T038
.	O

VEGFR	B-T103
-	I-T103
3	I-T103
may	O
be	O
a	O
good	O
diagnostic	O
biomarker	B-T201
for	O
ESCC	B-T038
.	O

Biomarker	B-T201
,	O
ESCC	B-T038
,	O
VEGFR	B-T103
-	I-T103
3	I-T103
.	O

Zinc	B-T103
and	O
Wound	B-T038
Healing	I-T038
:	O
A	O
Review	O
of	O
Zinc	B-T103
Physiology	B-T038
and	O
Clinical	O
Applications	O

Our	O
understanding	B-T038
of	O
the	O
role	O
of	O
zinc	B-T103
in	O
normal	O
human	B-T204
physiology	B-T038
is	O
constantly	O
expanding	O
,	O
yet	O
there	O
are	O
major	O
gaps	B-T082
in	O
our	O
knowledge	O
with	O
regard	O
to	O
the	O
function	O
of	O
zinc	B-T103
in	O
wound	B-T038
healing	I-T038
.	O

This	O
review	B-T170
aims	O
to	O
provide	O
the	O
clinician	B-T097
with	O
sufficient	O
understanding	O
of	O
zinc	B-T103
biology	B-T091
and	O
an	O
up	O
-	O
to	O
-	O
date	O
perspective	O
on	O
the	O
role	O
of	O
zinc	B-T103
in	O
wound	B-T038
healing	I-T038
.	O

Zinc	B-T103
is	O
an	O
essential	O
ion	B-T103
that	O
is	O
crucial	O
for	O
maintenance	O
of	O
normal	O
physiology	B-T038
,	O
and	O
zinc	B-T038
deficiency	I-T038
has	O
many	O
manifestations	O
ranging	O
from	O
delayed	O
wound	B-T038
healing	I-T038
to	O
immune	B-T038
dysfunction	I-T038
and	O
impairment	O
of	O
multiple	O
sensory	O
systems	O
.	O

While	O
consensus	O
has	O
been	O
reached	O
regarding	O
the	O
detrimental	O
effects	O
of	O
zinc	B-T038
deficiency	I-T038
on	O
wound	B-T038
healing	I-T038
,	O
there	O
is	O
considerable	O
discord	O
in	O
the	O
literature	B-T170
on	O
the	O
optimal	B-T170
methods	I-T170
and	O
true	O
benefits	O
of	O
zinc	B-T103
supplementation	O
.	O

Receipt	O
of	O
thyroid	B-T038
hormone	I-T038
deficiency	I-T038
treatment	B-T058
and	O
risk	O
of	O
herpes	B-T038
zoster	I-T038

Thyroid	B-T103
hormone	I-T103
(	O
TH	B-T103
)	O
has	O
been	O
suggested	O
to	O
control	O
herpes	B-T005
virus	I-T005
gene	B-T038
expression	I-T038
and	O
replication	B-T038
in	O
neurons	B-T017
via	O
epigenetics	B-T038
through	O
its	O
nuclear	B-T103
receptors	I-T103
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
patients	O
with	O
hypothyroidism	B-T038
are	O
predisposed	O
to	O
herpes	B-T038
zoster	I-T038
(	O
HZ	B-T038
)	O
,	O
suggesting	O
that	O
the	O
TH	B-T038
deficiency	I-T038
may	O
be	O
a	O
risk	B-T033
factor	I-T033
for	O
varicella	B-T005
zoster	I-T005
virus	I-T005
(	O
VZV	B-T005
)	O
reactivation	O
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
test	O
the	O
hypothesis	O
that	O
TH	B-T058
treatment	I-T058
will	O
ameliorate	O
the	O
complication	B-T038
of	O
HZ	B-T038
.	O

This	O
study	B-T062
investigated	O
the	O
hypothesis	O
by	O
enquiring	O
into	O
a	O
comprehensive	B-T170
medical	I-T170
database	I-T170
at	O
Kaiser	B-T092
Permanente	I-T092
Southern	I-T092
California	I-T092
(	O
KPSC	B-T092
)	O
to	O
verify	O
whether	O
patients	O
taking	O
TH	B-T103
medication	B-T058
experience	O
a	O
reduction	O
in	O
HZ	B-T038
occurrence	O
.	O

It	O
was	O
shown	O
by	O
Kaplan	O
-	O
Meier	O
analysis	O
that	O
hypothyroidism	B-T038
patients	O
taking	O
TH	B-T103
medicines	B-T103
had	O
a	O
lower	O
risk	O
of	O
HZ	B-T038
.	O

The	O
fully	O
adjusted	O
analysis	B-T062
indicated	O
that	O
patients	O
receiving	O
medication	B-T058
for	O
the	O
treatment	B-T058
of	O
TH	B-T038
deficiency	I-T038
exhibited	O
a	O
reduced	O
risk	O
of	O
HZ	B-T038
(	O
hazard	O
ratio	O
0	O
.	O
60	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
51	O
-	O
0	O
.	O
71	O
)	O
.	O

This	O
lower	O
risk	O
of	O
HZ	B-T038
was	O
significant	O
in	O
all	O
age	O
groups	O
except	O
the	O
18	O
-	O
39	O
years	O
cohort	B-T098
.	O

In	O
addition	O
,	O
female	O
patients	O
taking	O
TH	B-T058
treatment	I-T058
exhibited	O
a	O
lower	O
risk	O
than	O
their	O
male	O
counterparts	O
.	O

Together	O
these	O
findings	B-T033
support	O
the	O
hypothesis	O
that	O
a	O
constant	O
level	O
of	O
TH	B-T103
will	O
provide	O
a	O
degree	O
of	O
protection	O
from	O
contracting	O
HZ	B-T038
.	O

More	O
studies	B-T062
are	O
underway	O
to	O
evaluate	B-T058
the	I-T058
laboratory	I-T058
data	I-T058
for	O
an	O
analysis	B-T062
of	O
hormonal	O
effects	O
on	O
individuals	B-T098
.	O

Peer	B-T098
Exclusion	O
During	O
the	O
Pubertal	B-T033
Transition	O
:	O
The	O
Role	O
of	O
Social	O
Competence	O

For	O
some	O
youth	O
,	O
early	B-T038
puberty	I-T038
is	O
accompanied	O
by	O
peer	B-T098
exclusion	O
.	O

Yet	O
early	O
developers	B-T098
may	O
experience	B-T038
less	O
peer	B-T098
exclusion	O
if	O
they	O
have	O
social	O
competence	O
,	O
which	O
would	O
bolster	O
their	O
ability	O
to	O
develop	O
and	O
maintain	O
positive	B-T033
relationships	O
with	O
their	O
peers	B-T098
.	O

Accordingly	O
,	O
the	O
present	B-T033
study	B-T062
tests	O
whether	O
pubertal	B-T033
timing	O
and	O
tempo	O
predicts	O
decrements	O
in	O
children	O
'	O
s	O
social	O
competence	O
and	O
whether	O
decrements	O
in	O
social	O
competence	O
account	O
for	O
associations	O
between	O
puberty	B-T038
(	O
timing	O
and	O
tempo	O
)	O
and	O
peer	B-T098
exclusion	O
over	O
time	O
.	O

Longitudinal	B-T062
data	O
were	O
drawn	O
from	O
1364	O
families	O
(	O
48	O
%	O
female	B-T098
;	O
76	O
%	O
White	B-T098
;	O
M	O
=	O
9	O
.	O
32	O
years	O
,	O
SD	O
=	O
.	O
48	O
,	O
at	O
Wave	O
3	O
)	O
who	O
participated	O
in	O
Waves	O
3	O
-	O
5	O
(	O
i	O
.	O
e	O
.	O
,	O
grades	O
4	O
-	O
6	O
)	O
of	O
Phase	B-T062
III	I-T062
of	O
the	O
NICHD	B-T092
-	O
SECCYD	B-T062
.	O

The	O
results	O
from	O
latent	O
growth	O
curve	O
models	O
indicated	O
that	O
earlier	O
pubertal	B-T033
timing	O
and	O
more	O
rapid	O
pubertal	B-T033
tempo	O
among	O
girls	O
were	O
associated	O
with	O
high	O
initial	O
levels	O
of	O
peer	B-T098
exclusion	O
.	O

Moreover	O
,	O
mediation	O
analyses	O
revealed	O
that	O
early	O
developers	B-T098
'	I-T098
susceptibility	O
to	O
peer	B-T098
exclusion	O
was	O
associated	O
with	O
their	O
initial	O
level	O
of	O
social	O
competence	O
.	O

In	O
boys	O
,	O
pubertal	B-T033
timing	O
and	O
tempo	O
were	O
not	O
directly	O
associated	O
with	O
peer	B-T098
exclusion	O
;	O
instead	O
,	O
indirect	O
effects	O
of	O
pubertal	B-T033
timing	O
on	O
peer	B-T098
exclusion	O
(	O
intercept	O
,	O
slope	O
)	O
occurred	O
through	O
initial	O
levels	O
of	O
social	O
competence	O
.	O

On	O
average	O
,	O
early	O
developers	B-T098
'	I-T098
who	O
had	O
low	O
levels	O
of	O
social	O
competence	O
also	O
had	O
high	O
initial	O
levels	O
of	O
peer	B-T098
exclusion	O
but	O
experienced	B-T038
decrements	O
in	O
peer	B-T098
exclusion	O
over	O
time	O
.	O

The	O
association	O
between	O
the	O
intercepts	O
for	O
puberty	B-T038
and	O
peer	B-T098
exclusion	O
and	O
the	O
slopes	O
for	O
social	O
competence	O
and	O
peer	B-T098
exclusion	O
were	O
stronger	O
for	O
boys	O
than	O
girls	O
.	O

Overall	O
,	O
our	O
findings	B-T033
suggest	O
that	O
early	O
developers	B-T098
'	I-T098
susceptibility	O
to	O
and	O
experiences	B-T038
of	O
peer	B-T098
exclusion	O
are	O
associated	O
with	O
their	O
development	O
of	O
social	O
competence	O
.	O

Air	O
pollution	O
characteristics	O
and	O
health	O
risks	O
in	O
Henan	B-T082
Province	I-T082
,	O
China	B-T082

Events	O
of	O
severe	O
air	O
pollution	O
occurred	O
frequently	O
in	O
China	B-T082
recently	O
,	O
thus	O
understanding	O
of	O
the	O
air	O
pollution	O
characteristics	O
and	O
its	O
health	O
risks	O
is	O
very	O
important	O
.	O

In	O
this	O
work	O
,	O
we	O
analyzed	O
a	O
two	O
-	O
year	O
dataset	B-T170
(	O
March	O
2014	O
-	O
February	O
2016	O
)	O
including	O
daily	O
concentrations	O
of	O
six	O
criteria	O
pollutants	B-T103
(	O
PM2	O
.	O
5	O
,	O
PM10	O
,	O
CO	B-T103
,	O
SO2	B-T103
,	O
NO2	B-T103
,	O
and	O
O3	B-T103
)	O
from	O
18	O
cities	O
in	O
Henan	B-T082
province	I-T082
.	O

Results	O
reveal	O
the	O
serious	O
air	O
pollution	O
status	O
in	O
Henan	B-T082
province	I-T082
,	O
especially	O
the	O
northern	B-T082
part	I-T082
,	O
and	O
Zhengzhou	B-T082
is	O
the	O
city	B-T082
with	O
the	O
worst	O
air	O
quality	O
.	O

Annual	O
average	O
PM2	O
.	O
5	O
concentrations	O
exceed	O
the	O
second	O
grade	O
of	O
Chinese	O
Ambient	O
Air	O
Quality	O
Standard	O
(	O
75μg	O
/	O
m	O
(	O
3	O
)	O
)	O
at	O
both	O
2014	O
and	O
2015	O
.	O

PM2	O
.	O
5	O
is	O
typically	O
the	O
major	O
pollutant	B-T103
,	O
but	O
ozone	B-T103
pollution	O
can	O
be	O
significant	O
during	O
summer	O
.	O

Furthermore	O
,	O
as	O
the	O
commonly	O
used	O
air	B-T170
quality	I-T170
index	I-T170
(	O
AQI	B-T170
)	O
neglects	O
the	O
mutual	O
health	O
effects	O
from	O
multiple	O
pollutants	B-T103
,	O
we	O
introduced	O
the	O
aggregate	B-T170
air	I-T170
quality	I-T170
index	I-T170
(	O
AAQI	B-T170
)	O
and	O
health	B-T170
-	I-T170
risk	I-T170
based	I-T170
air	I-T170
quality	I-T170
index	I-T170
(	O
HAQI	B-T170
)	O
to	O
evaluate	O
the	O
health	O
risks	O
.	O

Results	O
show	O
that	O
based	O
on	O
HAQI	B-T170
,	O
the	O
current	O
AQI	B-T170
system	O
likely	O
significantly	O
underestimate	O
the	O
health	O
risks	O
of	O
air	O
pollution	O
,	O
highlighting	O
that	O
the	O
general	B-T098
public	I-T098
may	O
need	O
stricter	O
health	O
protection	O
measures	O
.	O

The	O
population	O
-	O
weighted	O
two	O
-	O
year	O
average	O
HAQI	B-T170
data	O
further	O
demonstrates	O
that	O
all	O
population	O
in	O
the	O
studied	O
cities	B-T082
in	O
Henan	B-T082
province	I-T082
live	O
with	O
polluted	O
air	O
-	O
72	O
%	O
of	O
the	O
population	O
is	O
exposed	O
to	O
air	O
that	O
is	O
unhealthy	B-T033
for	O
sensitive	O
people	B-T098
,	O
while	O
28	O
%	O
of	O
people	B-T098
is	O
exposed	O
to	O
air	O
that	O
can	O
be	O
harmful	O
to	O
healthy	O
people	B-T098
;	O
and	O
the	O
health	O
risks	O
are	O
much	O
greater	O
during	O
winter	O
than	O
during	O
other	O
seasons	O
.	O

Future	O
works	O
should	O
further	O
improve	O
the	O
HAQI	B-T170
algorithm	B-T170
,	O
and	O
validate	O
the	O
links	O
between	O
the	O
clinical	B-T170
/	O
epidemiologic	O
data	B-T170
and	O
the	O
HAQI	B-T170
values	O
.	O

Increased	O
risk	O
of	O
PTLD	B-T038
in	O
lung	B-T033
transplant	I-T033
recipients	I-T033
with	O
cystic	B-T038
fibrosis	I-T038

Post	B-T038
-	I-T038
transplant	I-T038
lymphoproliferative	I-T038
disease	I-T038
(	O
PTLD	B-T038
)	O
is	O
an	O
important	O
cause	O
of	O
morbidity	O
and	O
mortality	O
following	O
lung	B-T058
transplantation	I-T058
.	O

Recipients	O
with	O
cystic	B-T038
fibrosis	I-T038
(	O
CF	B-T038
)	O
may	O
have	O
an	O
increased	O
risk	O
of	O
PTLD	B-T038
although	O
the	O
literature	B-T170
is	O
limited	O
to	O
single	B-T098
center	I-T098
cohorts	I-T098
.	O

Our	O
primary	O
aim	O
is	O
to	O
examine	O
PTLD	B-T038
in	O
an	O
adult	O
lung	B-T058
transplant	I-T058
population	B-T098
by	O
utilizing	O
the	O
International	B-T170
Society	I-T170
for	I-T170
Heart	I-T170
and	I-T170
Lung	I-T170
Transplantation	I-T170
Registry	I-T170
.	O

We	O
studied	B-T062
30	O
,	O
598	O
adult	O
recipients	B-T098
of	O
lung	B-T058
transplants	I-T058
performed	O
between	O
1999	O
and	O
2011	O
.	O

The	O
primary	O
outcome	O
was	O
development	O
of	O
and	O
time	O
to	O
PTLD	B-T038
.	O

In	O
addition	O
to	O
indication	O
for	O
transplant	B-T058
,	O
other	O
predictors	O
examined	O
included	O
Epstein	B-T005
-	I-T005
Barr	I-T005
virus	I-T005
(	O
EBV	B-T005
)	O
and	O
cytomegalovirus	B-T005
(	O
CMV	B-T005
)	O
serostatus	B-T201
,	O
gender	O
,	O
and	O
age	O
.	O

Outcomes	O
were	O
assessed	O
with	O
univariable	O
and	O
multivariable	B-T170
Cox	I-T170
proportional	I-T170
hazard	I-T170
models	I-T170
to	O
obtain	O
hazard	O
ratios	O
(	O
HR	O
)	O
.	O

17	O
%	O
of	O
the	O
cohort	B-T098
had	O
a	O
diagnosis	B-T033
of	O
CF	B-T038
.	O

PTLD	B-T038
developed	O
in	O
2	O
%	O
of	O
CF	B-T038
recipients	O
compared	O
to	O
1	O
%	O
for	O
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
(	O
p	O
<	O
0	O
.	O
001	O
)	O
.	O

Compared	O
to	O
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
,	O
CF	B-T038
recipients	O
had	O
higher	O
prevalence	O
of	O
EBV	B-T005
and	O
CMV	B-T033
seronegativity	I-T033
and	O
higher	O
prevalences	O
of	O
high	O
risk	O
EBV	B-T005
and	O
CMV	B-T005
mismatch	O
(	O
D	O
+	O
/	O
R	O
-	O
)	O
.	O

There	O
is	O
a	O
significant	O
association	O
between	O
CF	B-T038
and	O
the	O
development	O
of	O
PTLD	B-T038
[	O
HR	O
1	O
.	O
66	O
(	O
95	O
%	O
CI	O
1	O
.	O
30	O
-	O
2	O
.	O
12	O
)	O
]	O
.	O

Stratified	O
multivariable	O
analysis	O
controlling	O
for	O
age	O
revealed	O
EBV	B-T005
negative	B-T033
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
have	O
an	O
almost	O
2	O
fold	O
increased	O
risk	O
of	O
developing	O
PTLD	B-T038
,	O
whereas	O
EBV	B-T005
negative	O
CF	B-T038
recipients	O
had	O
an	O
almost	O
6	O
.	O
5	O
fold	O
increased	O
risk	O
.	O

CF	B-T038
recipients	O
have	O
a	O
higher	O
risk	O
for	O
PTLD	B-T038
compared	O
to	O
non	B-T033
-	I-T033
CF	I-T033
recipients	I-T033
.	O

Further	O
studies	B-T062
are	O
needed	O
to	O
account	O
for	O
additional	O
risk	B-T033
factors	I-T033
and	O
management	B-T058
in	O
this	O
population	B-T033
post	I-T033
-	I-T033
transplant	I-T033
.	O

Methods	B-T170
,	O
tools	O
and	O
current	O
perspectives	O
in	O
proteogenomics	B-T091

With	O
combined	O
technological	O
advancements	O
in	O
high	B-T062
-	I-T062
throughput	I-T062
next	I-T062
-	I-T062
generation	I-T062
sequencing	I-T062
and	O
deep	B-T058
mass	I-T058
spectrometry	I-T058
-	O
based	O
proteomics	B-T091
,	O
proteogenomics	B-T091
,	O
i	O
.	O
e	O
.	O
,	O
the	O
integrative	B-T062
analysis	I-T062
of	O
proteomic	O
and	O
genomic	O
data	O
,	O
has	O
emerged	O
as	O
a	O
new	O
research	O
field	O
.	O

Early	O
efforts	O
in	O
the	O
field	O
were	O
focused	O
on	O
improving	O
protein	B-T103
identification	O
using	O
sample	B-T170
-	I-T170
specific	I-T170
genomic	I-T170
and	O
transcriptomic	B-T170
sequencing	I-T170
data	I-T170
.	O

More	O
recently	O
,	O
integrative	B-T062
analysis	I-T062
of	O
quantitative	O
measurements	O
from	O
genomic	B-T062
and	I-T062
proteomic	I-T062
studies	I-T062
have	O
identified	O
novel	O
insights	O
into	O
gene	B-T038
expression	I-T038
regulation	I-T038
,	O
cell	B-T038
signaling	I-T038
,	O
and	O
disease	B-T038
.	O

Many	O
methods	B-T170
and	O
tools	O
have	O
been	O
developed	O
or	O
adapted	O
to	O
enable	O
an	O
array	B-T082
of	O
integrative	O
proteogenomic	O
approaches	O
and	O
in	O
this	O
article	B-T170
,	O
we	O
systematically	O
classify	B-T170
published	O
methods	B-T170
and	O
tools	O
into	O
four	O
major	O
categories	O
,	O
(	O
1	O
)	O
Sequence	B-T091
-	I-T091
centric	I-T091
proteogenomics	I-T091
;	O
(	O
2	O
)	O
Analysis	B-T062
of	O
proteogenomic	O
relationships	O
;	O
(	O
3	O
)	O
Integrative	B-T062
modeling	I-T062
of	O
proteogenomic	O
data	O
;	O
and	O
(	O
4	O
)	O
Data	O
sharing	O
and	O
visualization	B-T038
.	O

We	O
provide	O
a	O
comprehensive	O
review	O
of	O
methods	B-T170
and	O
available	O
tools	O
in	O
each	O
category	B-T170
and	O
highlight	O
their	O
typical	O
applications	O
.	O

Plasma	B-T031
DNA	B-T103
and	O
RNA	B-T103
differentially	O
impact	O
coagulation	B-T038
during	O
abdominal	B-T038
sepsis	I-T038
-	O
an	O
explorative	B-T062
study	I-T062

Cell	B-T103
-	I-T103
free	I-T103
DNA	I-T103
(	O
cfDNA	B-T103
)	O
and	O
extracellular	B-T017
RNA	B-T103
(	O
exRNA	B-T103
)	O
are	O
both	O
suspected	O
to	O
activate	O
coagulation	B-T038
cascades	I-T038
in	O
sepsis	B-T038
.	O

Therefore	O
,	O
our	O
study	B-T062
investigated	O
the	O
influence	O
of	O
plasmatic	B-T031
nucleic	B-T103
acids	I-T103
on	O
coagulation	B-T038
in	O
septic	O
patients	O
in	O
comparison	O
to	O
patients	O
after	O
major	O
abdominal	B-T058
surgery	I-T058
.	O

A	O
total	O
of	O
15	O
patients	O
with	O
sepsis	B-T038
,	O
10	O
postoperative	O
patients	O
,	O
and	O
10	O
healthy	B-T098
volunteers	I-T098
were	O
included	O
in	O
this	O
longitudinal	B-T062
study	I-T062
.	O

Blood	B-T031
was	O
collected	O
at	O
sepsis	B-T038
onset	O
and	O
after	O
surgery	B-T058
respectively	O
,	O
as	O
well	O
as	O
after	O
24	O
,	O
72	O
and	O
168	O
h	O
.	O

Levels	O
of	O
cfDNA	B-T103
and	O
exRNA	B-T103
were	O
measured	O
by	O
quantitative	O
probe	B-T074
-	I-T074
based	I-T074
polymerase	B-T062
chain	I-T062
reaction	I-T062
.	O

In	O
addition	O
,	O
thromboelastography	B-T058
for	O
coagulation	B-T038
as	O
well	O
as	O
thromboaggregometry	B-T058
for	O
platelet	B-T038
function	I-T038
was	O
conducted	O
.	O

Both	O
cfDNA	B-T103
and	O
exRNA	B-T103
were	O
elevated	O
in	O
patients	O
with	O
sepsis	B-T038
compared	O
with	O
postoperative	O
patients	O
and	O
healthy	B-T098
volunteers	I-T098
.	O

While	O
higher	O
exRNA	B-T103
levels	O
correlated	O
with	O
a	O
faster	B-T033
clotting	I-T033
time	I-T033
and	O
more	O
stable	B-T038
clots	I-T038
,	O
cfDNA	B-T103
correlated	O
with	O
a	O
shorter	B-T033
clotting	I-T033
time	I-T033
but	O
also	O
less	O
fibrinolysis	B-T038
.	O

In	O
addition	O
,	O
higher	O
cfDNA	B-T103
seems	O
to	O
be	O
associated	O
with	O
kidney	B-T038
dysfunction	I-T038
as	O
well	O
as	O
with	O
general	O
markers	B-T201
of	O
cell	O
damage	O
(	O
lactate	B-T103
dehydrogenase	I-T103
and	O
lactate	B-T103
)	O
.	O

Both	O
nucleic	B-T103
acid	I-T103
species	O
might	O
be	O
associated	O
with	O
different	O
effects	O
on	O
coagulation	B-T038
during	O
sepsis	B-T038
,	O
with	O
an	O
overall	O
procoagulatory	B-T038
influence	O
.	O

For	O
this	O
reason	O
,	O
individualized	O
therapeutic	B-T058
approaches	I-T058
in	O
patients	O
suffering	B-T033
from	O
coagulation	B-T038
-	O
associated	B-T033
organ	B-T038
dysfunction	I-T038
might	O
be	O
feasible	O
.	O

Association	O
of	O
Fat	O
Mass	O
and	O
Obesity	B-T038
-	O
associated	O
Gene	B-T017
Variant	I-T017
with	O
Lifestyle	O
Factors	O
and	O
Body	B-T201
Fat	I-T201
in	O
Indian	B-T098
Children	O

Common	O
intronic	B-T017
variants	I-T017
of	O
the	O
fat	O
mass	O
and	O
obesity	B-T038
-	O
associated	O
(	B-T017
FTO	I-T017
)	I-T017
gene	I-T017
have	O
been	O
associated	O
with	O
obesity	B-T038
-	O
related	O
traits	O
in	O
humans	B-T204
.	O

(	O
1	O
)	O
The	O
aim	O
of	O
this	O
study	B-T062
is	O
to	O
study	B-T062
the	O
distribution	O
of	O
FTO	B-T017
gene	I-T017
variants	B-T017
across	O
different	O
body	B-T201
mass	I-T201
index	I-T201
(	O
BMI	B-T201
)	O
categories	O
and	O
(	O
2	O
)	O
to	O
explore	O
the	O
association	O
between	O
FTO	B-T017
gene	I-T017
variants	B-T017
and	O
lifestyle	O
factors	O
in	O
obese	B-T038
and	O
normal	B-T033
weight	I-T033
Indian	B-T098
children	O
.	O

Fifty	O
-	O
six	O
children	O
(	O
26	O
boys	O
,	O
mean	O
age	O
10	O
.	O
3	O
±	O
2	O
.	O
2	O
years	O
)	O
were	O
studied	B-T062
.	O

Height	O
,	O
weight	O
,	O
and	O
waist	B-T201
and	O
hip	B-T201
circumference	I-T201
were	O
measured	O
.	O

Physical	O
activity	O
(	O
questionnaire	O
)	O
and	O
food	B-T168
intake	O
(	O
food	B-T170
frequency	I-T170
questionnaire	I-T170
)	O
were	O
assessed	O
.	O

Body	O
fat	O
percentage	O
(	O
%	O
BF	O
)	O
was	O
measured	O
by	O
dual	B-T058
-	I-T058
energy	I-T058
X	I-T058
-	I-T058
ray	I-T058
absorptiometry	I-T058
.	O

FTO	B-T017
allelic	I-T017
variants	I-T017
at	O
rs9939609	B-T082
site	I-T082
were	O
detected	O
by	O
SYBR	B-T062
Green	I-T062
Amplification	I-T062
Refractory	I-T062
Mutation	I-T062
System	I-T062
real	I-T062
-	I-T062
time	I-T062
polymerase	I-T062
chain	I-T062
reaction	I-T062
using	O
allele	B-T017
-	O
specific	O
primers	B-T103
.	O

Generalized	O
linear	O
model	O
was	O
used	O
to	O
investigate	O
the	O
simultaneous	O
influence	O
of	O
genetic	O
and	O
lifestyle	O
factors	O
on	O
%	O
BF	O
.	O

Mean	O
height	O
,	O
weight	O
,	O
and	O
BMI	B-T201
of	O
normal	O
and	O
obese	B-T038
children	O
were	O
130	O
.	O
6	O
±	O
7	O
.	O
1	O
versus	O
143	O
.	O
2	O
±	O
15	O
.	O
6	O
,	O
24	O
.	O
0	O
±	O
5	O
.	O
2	O
versus	O
53	O
.	O
1	O
±	O
15	O
.	O
8	O
,	O
and	O
13	O
.	O
9	O
±	O
2	O
.	O
1	O
versus	O
25	O
.	O
3	O
±	O
3	O
.	O
2	O
,	O
respectively	O
.	O

The	O
frequency	O
of	O
AA	B-T017
allele	I-T017
was	O
57	O
%	O
among	O
obese	B-T038
children	O
and	O
35	O
%	O
in	O
normal	B-T033
weight	I-T033
children	O
.	O

Children	O
with	O
the	O
AA	B-T017
allele	I-T017
who	O
were	O
obese	B-T038
had	O
least	O
physical	O
activity	O
,	O
whereas	O
children	O
with	O
AT	B-T017
allele	I-T017
and	O
obesity	B-T038
had	O
the	O
highest	O
intake	O
of	O
calories	O
when	O
compared	O
to	O
children	O
who	O
had	O
AT	B-T017
allele	I-T017
and	O
were	O
normal	O
.	O

%	O
BF	O
was	O
positively	O
associated	O
with	O
AA	B-T017
alleles	I-T017
and	O
junk	O
food	O
intake	O
and	O
negatively	O
with	O
healthy	O
food	B-T168
intake	O
and	O
moderate	O
physical	O
activity	O
.	O

Healthy	O
lifestyle	O
with	O
high	O
physical	O
activity	O
and	O
diet	B-T168
low	O
in	O
calories	O
and	O
fat	B-T103
may	O
help	O
in	O
modifying	O
the	O
risk	O
imposed	O
by	O
FTO	B-T017
variants	I-T017
in	O
children	O
.	O

Museum	O
specimen	O
data	O
reveal	O
emergence	O
of	O
a	O
plant	B-T038
disease	I-T038
may	O
be	O
linked	O
to	O
increases	O
in	O
the	O
insect	B-T098
vector	I-T098
population	I-T098

The	O
emergence	O
rate	O
of	O
new	O
plant	B-T038
diseases	I-T038
is	O
increasing	O
due	O
to	O
novel	O
introductions	O
,	O
climate	O
change	O
,	O
and	O
changes	O
in	O
vector	B-T098
populations	I-T098
,	O
posing	O
risks	O
to	O
agricultural	O
sustainability	O
.	O

Assessing	O
and	O
managing	O
future	O
disease	B-T038
risks	O
depends	O
on	O
understanding	O
the	O
causes	O
of	O
contemporary	O
and	O
historical	O
emergence	O
events	O
.	O

Since	O
the	O
mid	O
-	O
1990s	O
,	O
potato	B-T097
growers	I-T097
in	O
the	O
western	B-T082
United	I-T082
States	I-T082
,	O
Mexico	B-T082
,	O
and	O
Central	B-T082
America	I-T082
have	O
experienced	O
severe	O
yield	O
loss	O
from	O
Zebra	B-T038
Chip	I-T038
disease	I-T038
and	O
have	O
responded	O
by	O
increasing	O
insecticide	B-T103
use	O
to	O
suppress	O
populations	B-T098
of	O
the	O
insect	B-T204
vector	I-T204
,	O
the	O
potato	B-T204
psyllid	I-T204
,	O
Bactericera	B-T204
cockerelli	I-T204
(	O
Hemiptera	B-T204
:	O
Triozidae	B-T204
)	O
.	O

Despite	O
the	O
severe	O
nature	O
of	O
Zebra	B-T038
Chip	I-T038
outbreaks	O
,	O
the	O
causes	O
of	O
emergence	O
remain	O
unknown	O
.	O

We	O
tested	O
the	O
hypotheses	O
that	O
1	O
)	O
B	B-T204
.	I-T204

cockerelli	I-T204
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	O
in	O
California	B-T082
and	O
2	O
)	O
such	O
increases	O
are	O
related	O
to	O
climate	O
change	O
,	O
specifically	O
warmer	O
winters	O
.	O

We	O
compiled	O
a	O
dataset	B-T170
of	O
87	O
,	O
000	O
museum	O
specimen	O
occurrence	O
records	B-T170
across	O
the	O
order	O
Hemiptera	B-T204
collected	O
between	O
1900	O
and	O
2014	O
.	O

We	O
then	O
analyzed	B-T062
changes	O
in	O
B	B-T204
.	I-T204

cockerelli	I-T204
distribution	O
using	O
a	O
hierarchical	B-T170
occupancy	I-T170
model	I-T170
using	O
changes	O
in	O
background	O
species	B-T170
lists	I-T170
to	O
correct	O
for	O
collecting	O
effort	O
.	O

We	O
found	O
evidence	O
that	O
B	B-T204
.	I-T204

cockerelli	I-T204
occupancy	O
has	O
increased	O
over	O
the	O
last	O
century	O
.	O

However	O
,	O
these	O
changes	O
appear	O
to	O
be	O
unrelated	O
to	O
climate	O
changes	O
,	O
at	O
least	O
at	O
the	O
scale	O
of	O
our	O
analysis	B-T062
.	O

To	O
the	O
extent	O
that	O
species	B-T170
occupancy	O
is	O
related	O
to	O
abundance	O
,	O
our	O
analysis	B-T062
provides	O
the	O
first	O
quantitative	O
support	O
for	O
the	O
hypothesis	O
that	O
B	B-T204
.	I-T204

cockerelli	I-T204
population	B-T098
abundance	O
has	O
increased	O
,	O
but	O
further	O
work	O
is	O
needed	O
to	O
link	O
B	B-T204
.	I-T204

cockerelli	I-T204
population	B-T098
dynamics	O
to	O
Zebra	B-T038
Chip	I-T038
epidemics	I-T038
.	O

Finally	O
,	O
we	O
demonstrate	O
how	O
this	O
historical	B-T082
macro	I-T082
-	I-T082
ecological	I-T082
approach	I-T082
provides	O
a	O
general	O
framework	O
for	O
comparative	B-T058
risk	I-T058
assessment	I-T058
of	O
future	O
pest	B-T204
and	O
insect	B-T204
vector	I-T204
outbreaks	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Effect	O
of	O
halotolerant	B-T007
rhizobacteria	I-T007
isolated	O
from	O
halophytes	B-T204
on	O
the	O
growth	B-T038
of	O
sugar	B-T204
beet	I-T204
(	O
Beta	B-T204
vulgaris	I-T204
L	I-T204
.	O
)	O
under	O
salt	B-T038
stress	I-T038

Utilization	O
of	O
rhizobacteria	B-T007
that	O
have	O
associated	O
with	O
plant	B-T204
roots	I-T204
in	O
harsh	O
environments	B-T082
could	O
be	O
a	O
feasible	B-T062
strategy	I-T062
to	O
deal	O
with	O
limits	O
to	O
agricultural	O
production	O
caused	O
by	O
soil	O
salinity	B-T033
.	O

Halophytes	B-T204
occur	O
naturally	O
in	O
high	O
-	O
salt	O
environments	O
,	O
and	O
their	O
roots	B-T204
may	O
be	O
associated	O
with	O
promising	O
microbial	O
candidates	O
for	O
promoting	O
growth	B-T038
and	O
salt	B-T038
tolerance	I-T038
in	O
crops	B-T204
.	O

This	O
study	B-T062
aimed	O
to	O
isolate	O
efficient	O
halotolerant	B-T204
plant	I-T204
-	O
growth	B-T038
-	O
promoting	O
rhizobacterial	O
strains	O
from	O
halophytes	B-T204
and	O
evaluate	O
their	O
activity	O
and	O
effects	O
on	O
sugar	B-T204
beet	I-T204
(	O
Beta	B-T204
vulgaris	I-T204
L	I-T204
.	O
)	O
growth	B-T038
under	O
salinity	B-T038
stress	I-T038
.	O

A	O
total	O
of	O
23	O
isolates	B-T103
were	O
initially	O
screened	O
for	O
their	O
ability	O
to	O
secrete	O
1	B-T103
-	I-T103
aminocyclopropane	I-T103
-	I-T103
1	I-T103
-	I-T103
carboxylate	I-T103
deaminase	I-T103
(	O
ACD	B-T103
)	O
as	O
well	O
as	O
other	O
plant	B-T038
-	I-T038
growth	I-T038
-	O
promoting	O
characteristics	O
and	O
subsequently	O
identified	O
by	O
sequencing	O
the	O
16S	B-T103
rRNA	I-T103
gene	B-T017
.	O

Three	O
isolates	B-T103
,	O
identified	O
as	O
Micrococcus	B-T007
yunnanensis	I-T007
,	O
Planococcus	B-T007
rifietoensis	I-T007
and	O
Variovorax	B-T007
paradoxus	I-T007
,	O
enhanced	O
salt	B-T038
stress	I-T038
tolerance	O
remarkably	O
in	O
sugar	B-T204
beet	I-T204
,	O
resulting	O
in	O
greater	O
seed	B-T038
germination	I-T038
and	O
plant	B-T204
biomass	O
,	O
higher	O
photosynthetic	O
capacity	O
and	O
lower	O
stress	B-T033
-	O
induced	O
ethylene	B-T103
production	O
at	O
different	O
NaCl	B-T103
concentrations	O
(	O
50	O
-	O
125	O
mM	O
)	O
.	O

These	O
results	O
demonstrate	O
that	O
salinity	B-T033
-	O
adapted	B-T038
,	O
ACD	B-T103
-	O
producing	O
bacteria	B-T007
isolated	O
from	O
halophytes	B-T204
could	O
promote	O
sugar	B-T204
beet	I-T204
growth	B-T038
under	O
saline	B-T038
stress	I-T038
conditions	I-T038
.	O

Potential	O
Sunitinib	B-T103
-	O
Induced	O
Coronary	B-T017
Artery	I-T017
and	O
Aortic	B-T038
Dissections	I-T038

Small	B-T058
-	I-T058
molecule	I-T058
multitargeted	I-T058
tyrosine	I-T058
kinase	I-T058
inhibitor	I-T058
(	I-T058
TKI	I-T058
)	I-T058
therapy	I-T058
is	O
used	O
in	O
different	O
types	O
of	O
cancer	B-T038
.	O

These	O
drugs	B-T103
have	O
been	O
associated	O
with	O
cardiovascular	B-T037
toxicity	I-T037
,	O
including	O
aortic	B-T038
dissection	I-T038
.	O

To	O
our	O
knowledge	B-T170
,	O
this	O
is	O
the	O
first	O
time	O
that	O
a	O
coronary	B-T038
dissection	I-T038
potentially	O
associated	O
with	O
a	O
TKI	B-T058
treatment	I-T058
has	O
been	O
described	O
.	O

Recovery	O
of	O
orthographic	O
processing	B-T038
after	O
stroke	B-T038
:	O
A	O
longitudinal	B-T062
fMRI	B-T058
study	O

An	O
intact	O
orthographic	O
processing	B-T038
system	O
is	O
critical	O
for	O
normal	O
reading	O
and	O
spelling	O
.	O

Here	O
we	O
investigate	O
the	O
neural	O
changes	O
associated	O
with	O
impairment	O
and	O
subsequent	O
recovery	O
of	O
the	O
orthographic	O
lexical	O
processing	O
system	O
in	O
an	O
individual	O
with	O
an	O
ischemic	B-T038
left	O
posterior	O
cerebral	O
artery	O
(	O
PCA	O
)	O
stroke	O
.	O

This	O
work	O
describes	O
a	O
longitudinal	B-T062
case	I-T062
study	I-T062
of	O
a	O
patient	O
,	O
whose	O
initials	O
are	O
MMY	B-T204
,	O
with	O
impairments	O
in	O
orthographic	O
lexical	O
processing	O
for	O
reading	O
and	O
spelling	O
at	O
stroke	B-T038
onset	O
,	O
and	O
who	O
recovered	O
these	O
skills	O
within	O
1	O
year	O
post	O
stroke	B-T038
.	O

We	O
tested	O
the	O
hypothesis	O
that	O
this	O
acute	O
impairment	O
to	O
reading	O
and	O
spelling	O
would	O
be	O
associated	O
with	O
a	O
selective	O
loss	O
of	O
neural	O
activation	O
in	O
the	O
left	B-T017
fusiform	I-T017
gyrus	I-T017
(	O
FG	B-T017
)	O
,	O
and	O
that	O
subsequent	O
recovery	O
would	O
be	O
associated	O
with	O
a	O
gain	O
of	O
neural	O
activation	O
in	O
this	O
region	O
.	O

MMY	B-T204
'	I-T204
s	I-T204
case	O
provided	O
a	O
unique	O
opportunity	O
to	O
assess	O
the	O
selectivity	O
of	O
neural	O
changes	O
because	O
she	O
demonstrated	O
a	O
behavioral	O
recovery	B-T038
of	I-T038
naming	I-T038
as	I-T038
well	I-T038
;	O
i	O
.	O
e	O
.	O
,	O
if	O
there	O
is	O
neural	O
recovery	O
for	O
reading	O
and	O
spelling	O
,	O
but	O
not	O
naming	O
,	O
then	O
these	O
neural	O
changes	O
are	O
selective	O
to	O
the	O
recovery	O
of	O
orthographic	O
processing	B-T038
.	O

To	O
test	O
our	O
hypothesis	O
,	O
we	O
examined	O
longitudinal	B-T062
behavioral	I-T062
and	O
functional	B-T058
magnetic	I-T058
resonance	I-T058
imaging	I-T058
(	O
fMRI	B-T058
)	O
data	O
of	O
reading	B-T038
,	O
spelling	O
,	O
and	O
visual	B-T170
object	I-T170
naming	I-T170
acquired	O
acutely	O
,	O
3	O
weeks	O
,	O
5	O
months	O
,	O
and	O
one	O
year	O
post	O
stroke	B-T038
.	O

In	O
confirmation	O
of	O
our	O
hypothesis	O
,	O
the	O
loss	O
and	O
subsequent	O
gain	O
of	O
orthographic	O
lexical	O
processing	O
was	O
associated	O
with	O
up	B-T038
-	I-T038
regulation	I-T038
of	O
neural	O
activation	O
in	O
areas	O
previously	O
associated	O
with	O
orthographic	O
lexical	O
processing	O
:	O
i	O
.	O
e	O
.	O
,	O
the	O
left	B-T082
mid	I-T082
-	I-T082
FG	I-T082
and	O
inferior	B-T017
frontal	I-T017
junction	I-T017
(	O
IFJ	B-T017
)	O
.	O

Furthermore	O
,	O
these	O
neural	O
changes	O
were	O
found	O
to	O
be	O
selective	O
to	O
orthographic	O
processing	B-T038
,	O
as	O
they	O
were	O
observed	O
for	O
reading	B-T038
and	O
spelling	O
,	O
but	O
not	O
for	O
visual	B-T170
object	I-T170
naming	I-T170
within	O
the	O
left	B-T082
mid	I-T082
-	I-T082
FG	I-T082
.	O

This	O
work	O
shows	O
that	O
left	O
PCA	O
stroke	O
can	O
temporarily	O
and	O
selectively	O
disrupt	O
the	O
orthographic	O
lexical	O
processing	O
system	O
,	O
not	O
only	O
in	O
the	O
posterior	O
region	O
adjacent	B-T082
to	O
the	O
stroke	B-T038
,	O
but	O
also	O
in	O
relatively	O
distant	O
frontal	O
orthographic	O
processing	B-T038
regions	O
.	O

Nodal	B-T082
skip	B-T033
metastasis	B-T038
in	O
thoracic	B-T038
esophageal	I-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
:	O
a	O
cohort	O
study	O

Nodal	B-T082
skip	B-T033
metastasis	B-T038
is	O
a	O
prognostic	B-T201
factor	I-T201
in	O
some	O
sites	O
of	O
malignancies	B-T038
,	O
but	O
its	O
role	O
in	O
esophageal	B-T038
cancer	I-T038
is	O
still	O
unclear	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
occurrence	O
and	O
effect	O
of	O
nodal	B-T082
skip	B-T033
metastases	O
in	O
thoracic	B-T038
esophageal	I-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
.	O

All	O
578	O
patients	O
undergoing	O
esophagectomy	B-T058
for	O
thoracic	B-T038
esophageal	I-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
at	O
the	O
Center	B-T092
for	I-T092
Esophageal	I-T092
Diseases	I-T092
located	O
in	O
Padova	O
between	O
January	O
1992	O
and	O
December	O
2010	O
were	O
retrospectively	B-T062
evaluated	I-T062
.	O

Selection	O
criteria	O
were	O
R0	B-T033
resection	I-T033
,	O
pathological	O
M0	B-T033
stage	I-T033
and	O
pathological	O
lymph	B-T033
node	I-T033
involvement	I-T033
.	O

Patients	O
receiving	O
neoadjuvant	B-T058
therapy	I-T058
were	O
excluded	O
.	O

The	O
selection	O
identified	O
88	O
patients	O
with	O
lymph	B-T033
node	I-T033
involvement	I-T033
confirmed	O
by	O
pathological	O
evaluation	B-T058
.	O

Sixteen	O
patients	O
(	O
18	O
.	O
2	O
%	O
)	O
had	O
nodal	B-T082
skip	B-T033
metastasis	B-T038
.	O

Adjusting	O
for	O
the	O
number	O
of	O
lymph	B-T038
node	I-T038
metastases	I-T038
,	O
patient	O
with	O
nodal	B-T082
skip	B-T033
metastasis	B-T038
had	O
similar	O
5	O
-	O
year	O
overall	O
survival	O
(	O
14	O
%	O
vs	O
.	O

13	O
%	O
,	O
p	O
=	O
0	O
.	O
93	O
)	O
and	O
5	O
-	O
year	O
disease	O
free	O
survival	O
(	O
14	O
%	O
vs	O
.	O

9	O
%	O
,	O
p	O
=	O
0	O
.	O
48	O
)	O
compared	O
to	O
patients	O
with	O
both	O
peritumoral	B-T082
and	O
distant	B-T082
lymph	B-T038
node	I-T038
metastases	I-T038
.	O

The	O
risk	O
difference	O
of	O
nodal	B-T082
skip	B-T033
metastasis	B-T038
was	O
:	O
-	O
24	O
.	O
1	O
%	O
(	O
95	O
%	O
C	O
.	O
I	O
.	O

-	O
43	O
.	O
1	O
%	O
to	O
-	O
5	O
.	O
2	O
%	O
)	O
in	O
patients	O
with	O
more	O
than	O
one	O
lymph	B-T038
node	I-T038
metastasis	I-T038
compared	O
to	O
those	O
with	O
one	O
lymph	B-T038
node	I-T038
metastasis	I-T038
;	O
-	O
2	O
.	O
3	O
%	O
(	O
95	O
%	O
C	O
.	O
I	O
.	O

-	O
29	O
.	O
8	O
%	O
to	O
25	O
.	O
2	O
%	O
)	O
in	O
middle	B-T082
thoracic	B-T017
esophagus	I-T017
and	O
-	O
23	O
.	O
0	O
%	O
(	O
95	O
%	O
C	O
.	O
I	O
.	O

-	O
47	O
.	O
8	O
%	O
to	O
1	O
.	O
8	O
%	O
)	O
in	O
lower	B-T082
thoracic	B-T017
esophagus	I-T017
compared	O
to	O
upper	B-T082
thoracic	B-T017
esophagus	I-T017
;	O
18	O
.	O
1	O
%	O
(	O
95	O
%	O
C	O
.	O
I	O
.	O

3	O
.	O
2	O
%	O
to	O
33	O
.	O
0	O
%	O
)	O
in	O
clinical	O
N0	B-T033
stage	I-T033
vs	O
.	O

clinical	O
N	B-T033
+	I-T033
stage	I-T033
.	O

Nodal	B-T082
skip	B-T033
metastasis	B-T038
is	O
a	O
common	O
pattern	O
of	O
metastatic	B-T033
lymph	I-T033
involvement	I-T033
in	O
thoracic	B-T038
esophageal	I-T038
squamous	I-T038
cell	I-T038
carcinoma	I-T038
.	O

However	O
,	O
neither	O
overall	O
survival	O
nor	O
disease	O
free	O
survival	O
are	O
associated	O
with	O
nodal	B-T082
skip	B-T033
metastasis	B-T038
occurrence	O
.	O

Association	O
of	O
leukemia	B-T017
inhibitory	I-T017
factor	I-T017
gene	I-T017
polymorphism	O
and	O
in	O
vitro	O
fertilization	B-T038
outcome	O
in	O
a	O
population	B-T098
in	O
northern	B-T082
Iran	I-T082

Several	O
studies	B-T062
have	O
been	O
demonstrated	O
that	O
endometrial	B-T082
leukemia	B-T103
inhibitory	I-T103
factor	I-T103
(	O
LIF	B-T103
)	O
is	O
important	O
in	O
embryo	B-T038
implantation	I-T038
.	O

LIF	B-T103
is	O
a	O
secreted	O
glycoprotein	B-T103
with	O
a	O
variety	O
of	O
biological	B-T038
functions	I-T038
including	O
stimulation	O
of	O
cell	B-T038
proliferation	I-T038
,	O
differentiation	B-T038
and	O
survival	B-T038
that	O
are	O
all	O
essential	O
for	O
blastocyete	B-T017
development	O
and	O
implantation	B-T038
.	O

The	O
LIF	B-T103
receptor	I-T103
activates	O
several	O
signaling	B-T038
pathways	I-T038
in	O
diverse	B-T170
cell	I-T170
types	I-T170
,	O
including	O
Jak	O
/	O
STAT	O
,	O
MAPK	B-T103
and	O
PI3	B-T103
-	I-T103
kinase	I-T103
pathways	B-T038
in	O
the	O
endometrium	B-T017
of	O
fertile	B-T038
woman	B-T098
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
initial	O
lower	O
expression	B-T038
of	O
LIF	B-T103
in	O
proliferative	B-T038
phase	O
may	O
be	O
one	O
of	O
the	O
causes	O
for	O
multiple	O
failure	O
of	O
implantation	B-T058
.	O

The	O
aim	O
of	O
this	O
study	B-T062
was	O
to	O
evaluate	O
the	O
association	O
between	O
maternal	B-T033
genotype	O
of	O
SNP	B-T082
3951C	I-T082
/	I-T082
T	I-T082
LIF	B-T103
and	O
in	B-T058
vitro	I-T058
fertilization	I-T058
and	O
embryo	B-T058
transfer	I-T058
(	O
IVF	B-T058
-	O
ET	B-T058
)	O
outcome	O
in	O
infertile	B-T038
women	B-T098
.	O

This	O
case	B-T062
-	I-T062
control	I-T062
study	I-T062
was	O
comprised	O
of	O
infertile	B-T038
patients	O
(	O
n	O
=	O
70	O
)	O
and	O
women	B-T098
having	O
one	O
healthy	B-T033
child	I-T033
as	O
controls	O
(	O
n	O
=	O
73	O
)	O
.	O

Genotyping	B-T058
for	O
SNP	B-T082
-	I-T082
3951C	I-T082
/	I-T082
T	I-T082
was	O
performed	O
by	O
PCR	B-T058
/	I-T058
RFLP	I-T058
.	O

Allele	B-T017
and	O
genotype	O
distribution	O
did	O
not	O
differ	O
significantly	O
between	O
patients	O
and	O
controls	O
(	O
P	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
LIF	B-T103
genotype	O
frequencies	O
amongst	O
the	O
70	O
cases	O
were	O
C	B-T082
/	I-T082
C	I-T082
=	O
40	O
%	O
,	O
C	B-T082
/	I-T082
T	I-T082
=	O
52	O
.	O
8	O
%	O
and	O
T	B-T082
/	I-T082
T	I-T082
=	O
7	O
.	O
2	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	B-T017
frequencies	O
were	O
66	O
%	O
and	O
34	O
%	O
,	O
respectively	O
.	O

The	O
LIF	B-T103
genotype	O
frequencies	O
amongst	O
the	O
73	O
controls	O
were	O
C	B-T082
/	I-T082
C	I-T082
=	O
45	O
.	O
20	O
%	O
,	O
C	B-T082
/	I-T082
T	I-T082
=	O
50	O
.	O
70	O
%	O
and	O
T	B-T082
/	I-T082
T	I-T082
=	O
4	O
.	O
1	O
%	O
;	O
the	O
C	O
and	O
T	O
allele	B-T017
frequencies	O
were	O
70	O
%	O
and	O
30	O
%	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
the	O
results	O
of	O
this	O
study	O
indicate	O
that	O
SNP	B-T082
3951C	I-T082
/	I-T082
T	I-T082
of	O
LIF	B-T103
may	O
not	O
be	O
associated	O
with	O
IVF	B-T058
-	O
ET	B-T058
outcome	O
in	O
this	O
population	B-T098
.	O

Although	O
more	O
studies	B-T062
should	O
be	O
considered	O
with	O
larger	O
number	O
of	O
patients	O
and	O
control	O
subjects	O
to	O
confirm	O
our	O
results	O
.	O

ANTI	B-T033
ANGIOGENIC	I-T033
EFFECT	I-T033
OF	O
CHEBULAGIC	B-T103
ACID	I-T103
INVOLVES	O
INHIBITION	O
OF	O
VEGFR2	B-T038
AND	O
GSK3β	B-T038
DEPENDENT	I-T038
SIGNALING	I-T038
PATHWAYS	I-T038

Inhibition	O
of	O
angiogenesis	B-T038
is	O
a	O
useful	O
strategy	O
to	O
prevent	O
cancer	B-T038
growth	I-T038
,	O
which	O
targets	O
new	O
vessels	B-T017
that	O
grow	O
to	O
nourish	O
actively	O
proliferating	O
tumor	B-T017
cells	I-T017
.	O

Endothelial	B-T017
cells	I-T017
can	O
use	O
a	O
number	O
of	O
different	O
pathways	B-T038
to	O
cause	O
angiogenesis	B-T038
and	O
each	O
step	O
in	O
these	O
pathways	B-T038
can	O
be	O
targeted	O
.	O

The	O
use	O
of	O
multi	B-T103
targeted	I-T103
drugs	I-T103
is	O
gaining	O
much	O
importance	O
in	O
this	O
scenario	O
.	O

Our	O
previous	O
results	O
have	O
shown	O
the	O
anti	B-T033
angiogenic	I-T033
effect	I-T033
of	O
Chebulagic	B-T103
acid	I-T103
-	O
a	O
benzopyran	B-T103
tannin	B-T103
present	O
in	O
the	O
fruits	B-T168
of	O
Terminalia	B-T204
chebula	I-T204
.	O

The	O
present	O
study	O
was	O
designed	O
to	O
examine	O
the	O
molecular	B-T038
mechanism	I-T038
of	O
the	O
anti	B-T033
angiogenic	I-T033
effect	I-T033
of	O
chebulagic	B-T103
acid	I-T103
.	O

Results	O
of	O
our	O
investigations	O
using	O
molecular	B-T170
docking	I-T170
studies	I-T170
and	O
HUVECs	B-T017
in	O
culture	B-T058
suggested	O
that	O
Chebulagic	B-T103
acid	I-T103
inhibited	O
GSK	B-T103
-	I-T103
3β	I-T103
dependent	O
β	B-T103
-	I-T103
catenin	I-T103
phosphorylation	B-T038
,	O
an	O
important	O
mediator	O
of	O
VE	B-T103
-	I-T103
cadherin	I-T103
/	O
β	B-T103
-	I-T103
catenin	I-T103
signaling	B-T038
and	O
VEGFR2	B-T103
phosphorylation	B-T038
which	O
is	O
an	O
important	O
step	O
involved	O
in	O
VEGF	B-T038
signaling	I-T038
.	O

Chebulagic	B-T103
acid	I-T103
inhibits	O
angiogenesis	B-T038
by	O
blocking	O
both	O
VEGF	B-T103
/	O
VEGFR2	B-T103
and	O
cell	B-T038
-	I-T038
cell	I-T038
contact	I-T038
dependent	I-T038
downstream	I-T038
signaling	I-T038
pathway	I-T038
.	O

Identification	O
of	O
protective	O
B	B-T103
-	I-T103
cell	I-T103
epitopes	I-T103
within	O
the	O
novel	O
malaria	B-T103
vaccine	I-T103
candidate	O
P	B-T103
.	I-T103
falciparum	I-T103
Schizont	I-T103
Egress	I-T103
Antigen	I-T103
-	I-T103
1	I-T103

Naturally	O
-	O
acquired	O
antibodies	B-T103
to	O
PfSEA	B-T103
-	I-T103
1A	I-T103
are	O
associated	O
with	O
protection	O
against	O
severe	O
malaria	B-T038
in	O
children	O
.	O

Vaccination	B-T058
of	O
mice	B-T204
with	O
PbSEA	B-T103
-	I-T103
1A	I-T103
decreases	O
parasitemia	B-T038
and	O
prolongs	O
survival	O
following	O
Plasmodium	B-T204
berghei	I-T204
ANKA	I-T204
challenge	O
.	O

To	O
enhance	O
the	O
immunogenicity	B-T038
of	O
PfSEA	B-T103
-	I-T103
1A	I-T103
,	O
we	O
identified	O
five	O
linear	O
,	O
B	B-T103
-	I-T103
cell	I-T103
epitopes	I-T103
using	O
peptide	B-T103
microarrays	O
probed	O
with	O
anti	B-T103
-	I-T103
sera	I-T103
from	O
rPfSEA	B-T103
-	I-T103
1A	I-T103
-	O
vaccinated	B-T033
non	O
-	O
human	O
primates	B-T204
.	O

We	O
evaluated	B-T058
the	O
relationship	O
between	O
epitope	B-T103
-	O
specific	O
antibody	B-T103
levels	O
and	O
protection	O
from	O
parasitemia	B-T038
in	O
a	O
longitudinal	O
treatment	B-T058
-	O
reinfection	O
cohort	B-T098
in	O
Western	B-T082
Kenya	I-T082
.	O

Antibodies	B-T103
to	O
three	O
epitopes	B-T103
were	O
associated	O
with	O
16	O
-	O
17	O
%	O
decreased	O
parasitemia	B-T038
over	O
an	O
18	O
-	O
week	O
high	O
transmission	O
season	O
.	O

We	O
are	O
currently	O
designing	O
immunogens	B-T103
to	O
enhance	O
antibody	B-T038
responses	I-T038
to	O
these	O
three	O
epitopes	B-T103
.	O

Estrogen	B-T103
deficiency	O
accelerates	O
lumbar	B-T082
facet	I-T082
joints	I-T082
arthritis	B-T038

Dramatic	O
increase	O
in	O
the	O
prevalence	O
of	O
lumbar	B-T082
facet	I-T082
joint	I-T082
(	O
LFJ	B-T082
)	O
arthritis	B-T038
in	O
women	B-T098
around	O
the	O
age	O
of	O
menopause	B-T038
indicates	O
a	O
protective	O
role	O
for	O
estrogen	B-T103
in	O
LFJ	B-T082
arthritis	B-T038
.	O

To	O
date	O
,	O
there	O
is	O
no	O
evidence	O
for	O
this	O
indication	O
and	O
the	O
mechanism	O
of	O
such	O
an	O
effect	O
remains	O
poorly	O
understood	O
.	O

In	O
this	O
study	B-T062
,	O
ovariectomized	B-T204
(	I-T204
OVX	I-T204
)	I-T204
mice	I-T204
were	O
used	O
to	O
mimic	O
the	O
estrogen	B-T103
-	O
deficient	O
status	O
of	O
post	B-T038
-	I-T038
menopausal	I-T038
women	B-T098
.	O

Micro	B-T058
-	I-T058
CT	I-T058
and	O
immunohistochemistry	B-T058
was	O
employed	O
to	O
assess	O
the	O
morphological	B-T082
and	O
molecular	O
changes	O
in	O
ovariectomy	B-T058
-	O
induced	O
LFJ	B-T082
arthritis	B-T038
.	O

The	O
results	O
show	O
that	O
the	O
LFJ	B-T082
subchondral	B-T201
bone	I-T201
mass	I-T201
was	O
significantly	O
decreased	O
in	O
OVX	B-T204
mice	I-T204
,	O
with	O
increased	O
cavities	B-T082
on	O
the	O
interface	O
of	O
the	O
subchondral	B-T017
bone	I-T017
.	O

Severe	O
cartilage	B-T017
degradation	O
was	O
observed	O
in	O
ovariectomy	B-T058
-	O
induced	O
LFJ	B-T082
arthritis	B-T038
.	O

Increased	O
blood	B-T017
vessels	I-T017
and	O
innervations	O
were	O
also	O
found	O
in	O
degenerated	B-T038
LFJ	B-T082
,	O
particularly	O
in	O
the	O
subchondral	B-T017
bone	I-T017
area	B-T082
.	O

17β	B-T103
-	I-T103
Estradiol	I-T103
treatment	B-T058
efficiently	O
suppressed	O
LFJ	B-T082
subchondral	B-T033
bone	I-T033
turnover	I-T033
,	O
markedly	O
inhibited	O
cartilage	B-T017
degradation	O
,	O
and	O
increased	O
blood	B-T017
vessel	I-T017
and	O
nerve	B-T017
ending	I-T017
growth	B-T038
in	O
degenerated	B-T038
LFJ	B-T082
in	O
OVX	B-T204
mice	I-T204
.	O

Our	O
study	B-T062
reveals	O
that	O
estrogen	B-T103
is	O
a	O
key	O
factor	O
in	O
regulating	O
LFJ	O
metabolism	O
.	O

Severe	O
LFJ	B-T082
degeneration	B-T038
occurs	O
when	O
estrogen	B-T103
is	O
absent	O
in	B-T082
vivo	I-T082
.	O

Collapsed	O
subchondral	B-T017
bone	I-T017
may	O
be	O
the	O
initiation	O
of	O
this	O
process	O
,	O
and	O
estrogen	B-T058
replacement	I-T058
therapy	I-T058
can	O
effectively	O
prevent	O
degeneration	B-T038
of	O
LFJ	B-T082
under	O
estrogen	B-T103
-	O
deficient	O
conditions	O
.	O

Dexmedetomidine	B-T103
Effect	O
on	O
Emergence	B-T038
Agitation	I-T038
and	O
Delirium	B-T038
in	O
Children	O
Undergoing	O
Laparoscopic	B-T058
Hernia	I-T058
Repair	I-T058
:	O
a	O
Preliminary	O
Study	B-T062

Objective	O
To	O
evaluate	O
the	O
safety	O
and	O
efficacy	O
of	O
dexmedetomidine	B-T103
(	O
Dex	B-T103
)	O
to	O
prevent	O
emergence	B-T038
agitation	I-T038
(	O
EA	B-T038
)	O
and	O
delirium	B-T038
(	O
ED	B-T038
)	O
in	O
children	O
undergoing	O
laparoscopic	B-T058
hernia	I-T058
repair	I-T058
under	O
general	B-T058
anesthesia	I-T058
.	O

Methods	O
100	O
children	O
(	O
1	O
-	O
5	O
years	O
,	O
10	O
-	O
25	O
kg	O
)	O
were	O
randomized	B-T062
into	O
four	O
groups	O
:	O
controls	O
(	O
saline	O
)	O
and	O
intravenous	B-T082
Dex	B-T103
at	O
0	O
.	O
25	O
,	O
0	O
.	O
5	O
,	O
and	O
1	O
.	O
0	O
µg	O
/	O
kg	O
(	O
D1	O
,	O
D2	O
,	O
D3	O
,	O
respectively	O
)	O
.	O

Dex	B-T103
/	O
saline	O
infusion	B-T058
was	O
started	O
following	O
anesthesia	B-T103
.	O

EA	B-T038
and	O
ED	B-T038
were	O
evaluated	O
on	O
a	O
5	B-T170
-	I-T170
point	I-T170
scale	I-T170
.	O

Results	O
For	O
the	O
C	O
,	O
D1	O
,	O
D2	O
,	O
and	O
D3	O
groups	O
,	O
respectively	O
,	O
EA	B-T038
frequencies	O
were	O
45	O
.	O
8	O
%	O
,	O
30	O
.	O
4	O
%	O
,	O
12	O
%	O
,	O
4	O
%	O
;	O
ED	B-T038
frequencies	O
29	O
.	O
1	O
%	O
,	O
13	O
%	O
,	O
4	O
%	O
,	O
4	O
%	O
;	O
CHIPPS	B-T170
scores	O
8	O
,	O
6	O
,	O
3	O
,	O
3	O
;	O
sevoflurane	B-T103
doses	O
from	O
13	O
.	O
2	O
±	O
3	O
.	O
4	O
(	O
controls	O
)	O
to	O
9	O
.	O
4	O
±	O
3	O
.	O
5	O
ml	O
(	O
D3	O
)	O
.	O

Intervals	O
until	O
mask	B-T074
removal	O
/	O
spontaneous	B-T082
eye	I-T082
opening	I-T082
were	O
significantly	O
longer	O
for	O
D2	O
and	O
D3	O
than	O
controls	O
.	O

PACU	B-T092
stay	O
was	O
longer	O
for	O
D3	O
.	O

Conclusions	O
There	O
was	O
significantly	O
less	O
postoperative	O
EA	B-T038
and	O
pain	B-T033
,	O
with	O
less	O
sevoflurane	B-T103
required	O
,	O
using	O
Dex	B-T103
.	O

Farnesylthiosalicylic	B-T103
acid	I-T103
-	O
loaded	O
lipid	B-T103
-	I-T103
polyethylene	I-T103
glycol	I-T103
-	I-T103
polymer	I-T103
hybrid	I-T103
nanoparticles	I-T103
for	O
treatment	B-T058
of	O
glioblastoma	B-T038

We	O
aimed	O
to	O
develop	O
lipid	B-T103
-	I-T103
polyethylene	I-T103
glycol	I-T103
(	I-T103
PEG	I-T103
)	I-T103
-	I-T103
polymer	I-T103
hybrid	I-T103
nanoparticles	I-T103
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	B-T017
tissue	I-T017
with	O
active	B-T103
ingredient	I-T103
,	O
a	O
new	O
generation	O
antineoplastic	B-T103
drug	I-T103
,	O
farnesylthiosalicylic	B-T103
acid	I-T103
(	O
FTA	B-T103
)	O
for	O
treatment	B-T058
of	O
glioblastoma	B-T038
.	O

Farnesylthiosalicylic	B-T103
acid	I-T103
-	O
loaded	O
poly	B-T103
(	I-T103
lactic	I-T103
-	I-T103
co	I-T103
-	I-T103
glycolic	I-T103
acid	I-T103
)	I-T103
-	I-T103
1	I-T103
,	I-T103
2	I-T103
distearoyl	I-T103
-	I-T103
glycerol	I-T103
-	I-T103
3	I-T103
-	I-T103
phospho	I-T103
-	I-T103
ethanolamine	I-T103
-	I-T103
N	I-T103
[	I-T103
methoxy	I-T103
(	I-T103
PEG	I-T103
)	I-T103
-	I-T103
2000	I-T103
]	I-T103
ammonium	I-T103
salt	I-T103
(	O
PLGA	B-T103
-	I-T103
DSPE	I-T103
-	I-T103
PEG	I-T103
)	O
with	O
or	O
without	O
1	B-T103
,	I-T103
2	I-T103
-	I-T103
dioleoyl	I-T103
-	I-T103
3	I-T103
-	I-T103
trimethylammonium	I-T103
-	I-T103
propane	I-T103
(	I-T103
DOTAP	I-T103
)	I-T103
hybrid	I-T103
nanoparticles	I-T103
has	O
been	O
prepared	B-T033
and	O
evaluated	B-T058
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Cytotoxicity	B-T038
of	O
FTA	B-T103
-	I-T103
loaded	I-T103
nanoparticles	I-T103
along	O
with	O
its	O
efficacy	O
on	O
rat	B-T017
glioma	I-T017
-	I-T017
2	I-T017
(	I-T017
RG2	I-T017
)	I-T017
cells	I-T017
was	O
also	O
evaluated	B-T058
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non	B-T017
-	I-T017
malignant	I-T017
cell	I-T017
line	I-T017
,	I-T017
L929	I-T017
)	O
and	O
in	O
vivo	O
.	O

Scanning	B-T058
electron	I-T058
microscopy	I-T058
studies	I-T058
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	B-T201
surface	I-T201
and	O
spherical	B-T082
in	I-T082
shape	I-T082
.	O

FTA	B-T103
and	O
FTA	B-T103
-	I-T103
loaded	I-T103
nanoparticles	I-T103
have	O
cytotoxic	B-T038
activity	I-T038
against	O
RG2	B-T017
glioma	I-T017
cell	I-T017
lines	I-T017
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
DOTAP	B-T103
.	O

Magnetic	B-T058
resonance	I-T058
imaging	I-T058
and	O
histopathologic	B-T091
evaluation	B-T058
on	O
RG2	B-T017
tumour	I-T017
cells	I-T017
in	O
rat	B-T038
glioma	I-T038
model	I-T038
(	O
49	O
female	O
Wistar	B-T204
rats	I-T204
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	B-T103
have	O
been	O
performed	O
and	O
FTA	B-T103
-	I-T103
loaded	I-T103
nanoparticles	I-T103
reduced	O
tumour	B-T082
size	I-T082
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Farnesylthiosalicylic	B-T103
acid	I-T103
-	O
loaded	O
PLGA	B-T103
-	I-T103
DSPE	I-T103
-	I-T103
PEG	I-T103
-	I-T103
DOTAP	I-T103
hybrid	I-T103
nanoparticles	I-T103
are	O
proven	O
to	O
be	O
effective	O
against	O
glioblastoma	B-T038
in	O
both	O
in	O
-	O
vitro	O
and	O
in	O
-	O
vivo	O
experiments	O
.	O

Map	B-T038
learning	I-T038
and	O
working	B-T038
memory	I-T038
:	O
Multimodal	O
learning	O
strategies	O

The	O
current	O
research	B-T062
investigated	O
whether	O
learning	B-T038
spatial	I-T038
information	O
from	O
a	O
map	O
involves	O
different	O
modalities	O
,	O
which	O
are	O
managed	O
by	O
discrete	O
components	O
in	O
working	B-T038
memory	I-T038
.	O

In	O
four	O
experiments	O
,	O
participants	B-T098
studied	O
a	O
map	O
either	O
while	O
performing	O
a	O
simultaneous	O
interference	B-T038
task	I-T038
(	O
high	O
cognitive	O
load	O
)	O
or	O
without	B-T038
interference	I-T038
(	O
low	O
cognitive	O
load	O
)	O
.	O

The	O
modality	O
of	O
interference	B-T038
varied	O
between	O
experiments	O
.	O

Experiment	O
1	O
used	O
a	O
tapping	B-T038
task	I-T038
(	O
visuospatial	O
)	O
,	O
Experiment	O
2	O
a	O
backwards	B-T038
counting	I-T038
task	I-T038
(	O
verbal	O
)	O
,	O
Experiment	O
3	O
an	O
articulatory	B-T038
suppression	B-T058
task	I-T058
(	O
verbal	O
)	O
and	O
Experiment	O
4	O
an	O
n	B-T038
-	I-T038
back	I-T038
task	I-T038
(	O
central	B-T038
executive	I-T038
)	O
.	O

Spatial	B-T033
recall	I-T033
was	O
assessed	O
in	O
two	O
tests	O
,	O
directional	B-T038
judgements	I-T038
and	O
map	O
drawing	O
.	O

Cognitive	O
load	O
was	O
found	O
to	O
affect	O
spatial	B-T033
recall	I-T033
detrimentally	O
regardless	O
of	O
interference	B-T038
modality	O
.	O

The	O
findings	O
suggest	O
that	O
when	O
learning	B-T038
maps	I-T038
people	O
use	O
a	O
multimodal	O
learning	O
strategy	O
,	O
utilising	O
resources	O
from	O
all	O
components	O
of	O
working	B-T038
memory	I-T038
.	O

4	B-T103
-	I-T103
Anilino	I-T103
-	I-T103
2	I-T103
-	I-T103
pyridylquinazolines	I-T103
and	O
-	O
pyrimidines	B-T103
as	O
Highly	O
Potent	O
and	O
Nontoxic	O
Inhibitors	B-T103
of	O
Breast	B-T103
Cancer	I-T103
Resistance	I-T103
Protein	I-T103
(	O
ABCG2	B-T103
)	O

Multidrug	O
resistance	O
(	O
MDR	O
)	O
mediated	O
by	O
ATP	B-T103
-	I-T103
binding	I-T103
cassette	I-T103
(	I-T103
ABC	I-T103
)	I-T103
transport	I-T103
proteins	I-T103
remains	O
a	O
major	O
problem	O
in	O
the	O
chemotherapeutic	B-T058
treatment	I-T058
of	O
cancer	B-T038
and	O
might	O
be	O
overcome	O
by	O
inhibition	O
of	O
the	O
transporter	B-T103
.	O

Because	O
of	O
the	O
lack	O
of	O
understanding	O
,	O
the	O
complex	O
mechanisms	O
involved	O
in	O
the	O
transport	B-T038
process	I-T038
,	O
in	O
particular	O
for	O
breast	B-T103
cancer	I-T103
resistance	I-T103
protein	I-T103
(	O
BCRP	B-T103
/	O
ABCG2	B-T103
)	O
,	O
there	O
is	O
a	O
persistent	O
need	O
for	O
studies	O
of	O
inhibitors	B-T103
of	O
ABCG2	B-T103
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
a	O
systematic	O
series	O
of	O
4	B-T103
-	I-T103
substituted	I-T103
-	I-T103
2	I-T103
-	I-T103
pyridylquinazolines	I-T103
in	O
terms	O
of	O
their	O
inhibitory	O
potency	O
as	O
well	O
as	O
selectivity	O
toward	O
ABCG2	B-T103
.	O

For	O
comparison	O
,	O
the	O
quinazoline	B-T103
scaffold	I-T103
was	O
reduced	O
to	O
the	O
significantly	O
smaller	O
4	B-T103
-	I-T103
methylpyrimidine	I-T103
basic	O
structure	O
.	O

Furthermore	O
,	O
the	O
cytotoxicity	B-T038
and	O
the	O
ability	O
to	O
reverse	O
MDR	O
was	O
tested	O
with	O
the	O
chemotherapeutic	B-T103
agents	I-T103
SN	B-T103
-	I-T103
38	I-T103
and	O
mitoxantrone	B-T103
(	O
MX	B-T103
)	O
.	O

Interaction	O
of	O
the	O
compounds	B-T103
with	O
ABCG2	B-T103
was	O
investigated	O
by	O
a	O
colorimetric	B-T058
ATPase	B-T103
assay	B-T058
.	O

Enzyme	O
kinetic	O
studies	O
were	O
carried	O
out	O
with	O
Hoechst	B-T103
33342	I-T103
as	O
fluorescent	B-T103
dye	I-T103
and	O
substrate	O
of	O
ABCG2	B-T103
to	O
elucidate	O
the	O
compounds	B-T103
binding	O
modes	O
.	O

The	O
Value	O
of	O
Biosamples	O
in	O
Smoking	O
Cessation	O
Trials	B-T062
:	O
A	O
Review	O
of	O
Genetic	B-T033
,	O
Metabolomic	B-T091
,	O
and	O
Epigenetic	B-T038
Findings	B-T033

Evidence	O
is	O
emerging	O
that	O
certain	O
genotypes	O
and	O
biomarkers	B-T201
are	O
associated	O
with	O
smoking	O
cessation	O
success	O
and	O
efficacy	O
of	O
smoking	B-T058
cessation	I-T058
treatments	I-T058
.	O

We	O
review	O
key	O
findings	O
that	O
open	O
potential	O
avenues	O
for	O
personalizing	O
smoking	B-T058
cessation	I-T058
treatment	I-T058
according	O
to	O
an	O
individual	B-T098
'	I-T098
s	I-T098
genetic	B-T058
or	O
metabolic	B-T038
profile	I-T038
.	O

These	O
results	O
provide	O
important	O
incentive	O
for	O
smoking	O
cessation	O
researchers	O
to	O
collect	O
biosamples	O
and	O
perform	O
genotyping	B-T058
in	O
research	B-T062
studies	I-T062
and	O
clinical	B-T062
trials	I-T062
.	O

ACR	B-T092
Appropriateness	O
Criteria	O
(	O
®	O
)	O
Radiologic	O
Management	B-T058
of	O
Mesenteric	B-T038
Ischemia	I-T038

Mesenteric	B-T038
vascular	I-T038
insufficiency	I-T038
is	O
a	O
serious	O
medical	O
condition	O
that	O
may	O
lead	O
to	O
bowel	B-T038
infarction	I-T038
,	O
morbidity	O
,	O
and	O
mortality	O
that	O
may	O
approach	B-T082
50	O
%	O
.	O

Recommended	O
therapy	B-T058
for	O
acute	B-T038
mesenteric	I-T038
ischemia	I-T038
includes	O
aspiration	B-T058
embolectomy	B-T058
,	O
transcatheter	B-T058
thrombolysis	B-T058
,	O
and	O
angioplasty	B-T058
with	O
or	O
without	O
stenting	B-T058
for	O
the	O
treatment	B-T058
of	O
underlying	O
arterial	B-T017
stenosis	I-T017
.	O

Nonocclusive	B-T038
mesenteric	I-T038
ischemia	I-T038
may	O
respond	O
to	O
transarterial	B-T058
infusion	I-T058
of	O
vasodilators	B-T103
such	O
as	O
nitroglycerin	B-T103
,	O
papaverine	B-T103
,	O
glucagon	B-T103
,	O
and	O
prostaglandin	B-T103
E1	I-T103
.	O

Recommended	O
therapy	B-T058
for	O
chronic	B-T038
mesenteric	I-T038
ischemia	I-T038
includes	O
angioplasty	B-T058
with	O
or	O
without	O
stent	B-T058
placement	I-T058
and	O
,	O
if	O
an	O
endovascular	B-T058
approach	I-T058
is	O
not	O
possible	O
,	O
surgical	B-T058
bypass	I-T058
or	O
endarterectomy	B-T058
.	O

The	O
diagnosis	B-T033
of	O
median	B-T038
arcuate	I-T038
ligament	I-T038
syndrome	I-T038
is	O
controversial	O
,	O
but	O
surgical	B-T058
release	O
may	O
be	O
appropriate	O
depending	O
on	O
the	O
clinical	O
situation	O
.	O

Venous	B-T082
mesenteric	B-T038
ischemia	I-T038
may	O
respond	O
to	O
systemic	O
anticoagulation	B-T058
alone	O
.	O

Transhepatic	B-T082
or	O
transjugular	O
superior	B-T017
mesenteric	I-T017
vein	I-T017
catheterization	O
and	O
thrombolytic	O
infusion	O
can	O
be	O
offered	O
depending	O
on	O
the	O
severity	O
of	O
symptoms	B-T033
,	O
condition	B-T033
of	I-T033
the	I-T033
patient	I-T033
,	O
and	O
response	O
to	O
systemic	O
anticoagulation	B-T058
.	O

Adjunct	O
transjugular	B-T058
intrahepatic	I-T058
portosystemic	I-T058
shunt	I-T058
creation	I-T058
can	O
be	O
considered	O
for	O
outflow	O
improvement	O
.	O

The	O
American	B-T092
College	I-T092
of	I-T092
Radiology	I-T092
Appropriateness	O
Criteria	O
are	O
evidence	O
-	O
based	O
guidelines	B-T170
for	O
specific	O
clinical	B-T033
conditions	I-T033
that	O
are	O
reviewed	O
annually	O
by	O
a	O
multidisciplinary	B-T097
expert	I-T097
panel	I-T097
.	O

The	O
guideline	B-T170
development	O
and	O
revision	O
include	O
an	O
extensive	B-T062
analysis	I-T062
of	O
current	O
medical	O
literature	O
from	O
peer	B-T170
-	I-T170
reviewed	I-T170
journals	I-T170
and	O
the	O
application	O
of	O
well	O
-	O
established	O
methodologies	B-T062
(	O
RAND	B-T170
/	O
UCLA	O
Appropriateness	O
Method	O
and	O
Grading	B-T170
of	I-T170
Recommendations	I-T170
Assessment	I-T170
,	I-T170
Development	I-T170
,	I-T170
and	I-T170
Evaluation	I-T170
or	O
GRADE	B-T170
)	O
to	O
rate	O
the	O
appropriateness	O
of	O
imaging	B-T058
and	O
treatment	B-T058
procedures	I-T058
for	O
specific	O
clinical	O
scenarios	O
.	O

In	O
those	O
instances	O
where	O
evidence	O
is	O
lacking	O
or	O
equivocal	O
,	O
expert	O
opinion	O
may	O
supplement	O
the	O
available	O
evidence	O
to	O
recommend	O
imaging	B-T058
or	O
treatment	B-T058
.	O

Blur	O
perception	B-T038
throughout	O
the	O
visual	B-T082
field	I-T082
in	O
myopia	B-T038
and	O
emmetropia	B-T033

We	O
evaluated	B-T058
the	O
ability	O
of	O
emmetropic	B-T033
and	O
myopic	B-T038
observers	O
to	O
detect	B-T033
and	O
discriminate	O
blur	O
across	O
the	O
retina	B-T017
under	O
monocular	B-T038
or	O
binocular	B-T038
viewing	I-T038
conditions	O
.	O

We	O
recruited	O
39	O
young	O
(	O
23	O
-	O
30	O
years	O
)	O
healthy	B-T033
adults	I-T033
(	O
n	O
=	O
19	O
myopes	B-T038
)	O
with	O
best	O
-	O
corrected	O
visual	B-T201
acuity	I-T201
0	O
.	O
0	O
LogMAR	B-T074
(	I-T074
20	I-T074
/	I-T074
20	I-T074
)	I-T074
or	O
better	O
in	O
each	O
eye	B-T017
and	O
no	B-T033
binocular	I-T033
or	O
accommodative	B-T033
dysfunction	I-T033
.	O

Monocular	B-T038
and	O
binocular	B-T038
blur	O
discrimination	O
thresholds	O
were	O
measured	O
as	O
a	O
function	B-T170
of	O
pedestal	O
blur	O
using	O
naturalistic	O
stimuli	O
with	O
an	O
adaptive	B-T058
4AFC	I-T058
procedure	I-T058
.	O

Stimuli	O
were	O
presented	O
in	O
a	O
46°	O
diameter	O
window	O
at	O
40	O
cm	O
.	O

Gaussian	O
blur	O
pedestals	O
were	O
confined	O
to	O
an	O
annulus	O
at	O
either	O
0°	O
,	O
4°	O
,	O
8°	O
,	O
or	O
12°	O
eccentricity	O
,	O
with	O
a	O
blur	O
increment	O
applied	O
to	O
only	O
one	B-T082
quadrant	I-T082
of	O
the	O
image	B-T170
.	O

The	O
adaptive	B-T058
procedure	I-T058
efficiently	O
estimated	O
a	O
dipper	B-T033
shaped	I-T033
blur	O
discrimination	O
threshold	O
function	B-T170
with	O
two	O
parameters	O
:	O
intrinsic	B-T082
blur	O
and	O
blur	O
sensitivity	O
.	O

The	O
amount	O
of	O
intrinsic	B-T082
blur	O
increased	O
for	O
retinal	O
eccentricities	O
beyond	O
4°	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
was	O
lower	O
in	O
binocular	B-T038
than	O
monocular	B-T038
conditions	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
,	O
but	O
was	O
similar	O
across	O
refractive	O
groups	O
(	O
p	O
=	O
0	O
.	O
47	O
)	O
.	O

Blur	O
sensitivity	O
decreased	O
with	O
retinal	O
eccentricity	O
(	O
p	O
<	O
0	O
.	O
001	O
)	O
and	O
was	O
highest	O
for	O
binocular	B-T038
viewing	O
,	O
but	O
only	O
for	O
central	O
vision	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Myopes	B-T038
showed	O
worse	B-T033
blur	O
sensitivity	O
than	O
emmetropes	B-T033
monocularly	B-T038
(	O
p	O
<	O
0	O
.	O
05	O
)	O
but	O
not	O
binocularly	B-T038
(	O
p	O
=	O
0	O
.	O
66	O
)	O
.	O

As	O
expected	O
,	O
blur	O
perception	B-T038
worsens	B-T033
in	O
the	O
visual	B-T038
periphery	I-T038
and	O
binocular	B-T038
summation	B-T038
is	O
most	O
evident	O
in	O
central	O
vision	O
.	O

Furthermore	O
,	O
myopes	B-T038
exhibit	O
a	O
monocular	B-T038
impairment	O
in	O
blur	O
sensitivity	O
that	O
improves	B-T033
under	O
binocular	B-T038
conditions	O
.	O

Implications	B-T038
for	O
the	O
development	O
of	O
myopia	B-T038
are	O
discussed	O
.	O

Risk	B-T033
Factors	I-T033
of	O
Neurological	B-T033
Deterioration	I-T033
in	O
Patients	O
with	O
Cerebral	B-T038
Infarction	I-T038
due	O
to	O
Large	B-T038
-	I-T038
Artery	I-T038
Atherosclerosis	I-T038

In	O
some	O
patients	O
with	O
acute	O
ischemic	B-T038
stroke	I-T038
,	O
neurological	B-T033
deterioration	I-T033
(	O
ND	B-T033
)	O
is	O
observed	O
,	O
and	O
it	O
is	O
difficult	O
to	O
predict	O
at	O
the	O
time	O
of	O
admission	O
.	O

Especially	O
in	O
some	O
patients	O
with	O
large	B-T038
-	I-T038
artery	I-T038
atherosclerosis	I-T038
(	O
LAA	B-T038
)	O
,	O
aggressive	O
medical	B-T058
treatments	I-T058
and	O
surgical	O
interventions	O
might	O
be	O
helpful	O
to	O
prevent	O
ND	B-T033
.	O

Therefore	O
,	O
we	O
investigated	O
factors	O
associated	O
with	O
ND	B-T033
in	O
patients	O
with	O
LAA	B-T038
.	O

We	O
studied	B-T062
patients	O
with	O
LAA	B-T038
who	O
were	O
admitted	B-T058
to	I-T058
our	I-T058
hospital	I-T058
.	O

We	O
divided	O
them	O
into	O
2	O
groups	O
with	O
(	O
group	O
1	O
)	O
and	O
without	O
deterioration	B-T038
(	O
group	O
2	O
)	O
,	O
and	O
evaluated	B-T058
their	O
medical	B-T170
records	I-T170
,	O
risk	B-T033
factors	I-T033
,	O
and	O
radiological	O
findings	B-T033
,	O
such	O
as	O
number	O
of	O
diffusion	O
-	O
positive	B-T033
lesion	B-T033
and	O
degree	O
of	O
stenosis	O
.	O

Our	O
study	B-T098
population	I-T098
consisted	O
of	O
171	O
patients	O
;	O
71	O
(	O
41	O
.	O
5	O
%	O
)	O
did	O
and	O
100	O
(	O
58	O
.	O
5	O
%	O
)	O
did	O
not	O
suffer	B-T038
deterioration	B-T038
.	O

By	O
univariate	O
analysis	O
,	O
blood	B-T038
pressure	I-T038
(	O
BP	B-T038
)	O
,	O
heart	B-T201
rate	I-T201
,	O
National	B-T033
Institutes	I-T033
of	I-T033
Health	I-T033
Stroke	I-T033
Scale	I-T033
(	I-T033
NIHSS	I-T033
)	I-T033
score	I-T033
,	O
number	O
of	O
diffusion	O
-	O
positive	B-T033
lesion	B-T033
,	O
count	B-T058
of	I-T058
red	I-T058
blood	I-T058
cell	I-T058
,	O
high	B-T103
-	I-T103
density	I-T103
lipoprotein	I-T103
,	O
and	O
degree	O
of	O
stenosis	O
differed	O
significantly	O
between	O
the	O
2	O
groups	O
.	O

By	O
multivariate	O
analysis	O
,	O
systolic	B-T201
BP	I-T201
(	O
≥170	O
mm	O
Hg	O
,	O
odds	O
ratio	O
:	O
7	O
.	O
20	O
,	O
P	O
<	O
.	O
001	O
)	O
was	O
associated	O
with	O
ND	B-T033
.	O

Furthermore	O
,	O
number	O
of	O
diffusion	B-T058
-	I-T058
weighted	I-T058
image	I-T058
(	O
DWI	B-T058
)	O
-	O
positive	B-T033
lesion	B-T033
(	O
≥8	O
)	O
,	O
degree	O
of	O
stenosis	O
(	O
>	O
80	O
.	O
0	O
%	O
)	O
,	O
and	O
NIHSS	B-T033
score	I-T033
(	O
≥4	O
)	O
were	O
also	O
independent	O
factors	O
associated	O
with	O
ND	B-T033
.	O

High	B-T038
BP	I-T038
,	O
severity	O
of	O
neurological	B-T033
deficit	I-T033
at	O
the	O
time	O
of	O
admission	O
,	O
and	O
radiological	O
findings	B-T033
,	O
such	O
as	O
degree	O
of	O
stenosis	O
and	O
number	O
of	O
DWI	B-T058
-	O
positive	B-T033
lesion	B-T033
,	O
are	O
independently	B-T033
associated	O
with	O
ND	B-T033
in	O
patients	O
with	O
LAA	B-T038
.	O

Development	O
and	O
validation	B-T062
of	O
an	O
easy	O
-	O
to	O
-	O
use	O
risk	B-T058
assessment	I-T058
tool	I-T058
for	O
cumulative	O
low	B-T017
back	I-T017
loading	O
:	O
The	O
Lifting	B-T103
Fatigue	I-T103
Failure	I-T103
Tool	I-T103
(	O
LiFFT	B-T103
)	O

Recent	O
evidence	O
suggests	O
that	O
musculoskeletal	B-T038
disorders	I-T038
(	O
MSDs	B-T038
)	O
may	O
be	O
the	O
result	O
of	O
a	O
fatigue	B-T033
failure	O
process	O
in	O
affected	O
tissues	B-T017
.	O

This	O
paper	O
describes	O
a	O
new	O
low	O
back	O
exposure	O
assessment	B-T103
tool	I-T103
(	O
the	O
Lifting	B-T103
Fatigue	I-T103
Failure	I-T103
Tool	I-T103
[	O
LiFFT	B-T103
]	O
)	O
,	O
which	O
estimates	O
a	O
"	O
daily	O
dose	O
"	O
of	O
cumulative	O
loading	O
on	O
the	O
low	B-T017
back	I-T017
using	O
fatigue	B-T033
failure	O
principles	O
.	O

Only	O
three	O
variables	O
are	O
necessary	O
to	O
derive	O
the	O
cumulative	O
load	O
associated	O
with	O
a	O
lifting	O
task	O
:	O
the	O
weight	O
of	O
the	O
load	O
,	O
the	O
maximum	O
horizontal	O
distance	O
from	O
the	O
spine	B-T017
to	O
the	O
load	O
,	O
and	O
the	O
number	O
of	O
repetitions	O
for	O
tasks	B-T058
performed	I-T058
during	O
the	O
workday	O
.	O

The	O
new	B-T103
tool	I-T103
was	O
validated	B-T062
using	O
two	O
existing	O
epidemiological	O
databases	B-T170
:	O
the	O
Lumbar	B-T033
Motion	I-T033
Monitor	I-T033
(	O
LMM	B-T033
)	O
database	B-T170
,	O
and	O
a	O
database	B-T170
from	O
a	O
U	B-T082
.	I-T082
S	I-T082
.	O

automotive	O
manufacturer	O
.	O

The	O
LiFFT	B-T103
cumulative	B-T058
damage	I-T058
metric	I-T058
explained	O
92	O
%	O
of	O
the	O
deviance	O
in	O
low	B-T033
back	I-T033
disorders	I-T033
(	O
LBDs	B-T033
)	O
in	O
the	O
LMM	O
database	O
and	O
72	O
-	O
95	O
%	O
of	O
the	O
deviance	O
in	O
low	O
back	O
outcomes	O
in	O
the	O
automotive	O
database	O
(	O
depending	O
on	O
the	O
outcome	O
measure	O
)	O
.	O

Thus	O
,	O
LiFFT	B-T103
is	O
practitioner	O
friendly	O
and	O
its	O
cumulative	O
damage	B-T058
metric	I-T058
highly	O
related	O
to	O
low	O
back	O
outcomes	O
.	O

Genetic	O
Diversity	O
in	O
Various	O
Accessions	B-T170
of	O
Pineapple	B-T204
[	O
Ananas	B-T204
comosus	I-T204
(	I-T204
L	I-T204
.	I-T204
)	I-T204
Merr	I-T204
.	I-T204
]	O
Using	O
ISSR	B-T103
and	O
SSR	B-T103
Markers	B-T082

Inter	B-T103
simple	I-T103
sequence	I-T103
repeat	I-T103
(	O
ISSR	B-T103
)	O
and	O
simple	B-T103
sequence	I-T103
repeat	I-T103
(	O
SSR	B-T103
)	O
markers	B-T082
were	O
used	O
to	O
assess	O
the	O
genetic	O
diversity	O
of	O
36	O
pineapple	B-T204
accessions	B-T170
that	O
were	O
introduced	O
from	O
10	O
countries	B-T082
/	O
regions	B-T082
.	O

Thirteen	O
ISSR	B-T103
primers	B-T103
amplified	O
96	O
bands	O
,	O
of	O
which	O
91	O
(	O
93	O
.	O
65	O
%	O
)	O
were	O
polymorphic	O
,	O
whereas	O
20	O
SSR	B-T103
primers	B-T103
amplified	O
73	O
bands	O
,	O
of	O
which	O
70	O
(	O
96	O
.	O
50	O
%	O
)	O
were	O
polymorphic	O
.	O

Nei	B-T170
'	I-T170
s	I-T170
gene	I-T170
diversity	I-T170
(	O
h	B-T170
=	O
0	O
.	O
28	O
)	O
,	O
Shannon	B-T170
'	I-T170
s	I-T170
information	I-T170
index	I-T170
(	O
I	B-T170
=	O
0	O
.	O
43	O
)	O
,	O
and	O
polymorphism	B-T170
information	I-T170
content	I-T170
(	O
PIC	B-T170
=	O
0	O
.	O
29	O
)	O
generated	O
using	O
the	O
SSR	B-T103
primers	B-T103
were	O
higher	O
than	O
that	O
with	O
ISSR	B-T103
primers	B-T103
(	O
h	B-T170
=	O
0	O
.	O
23	O
,	O
I	B-T170
=	O
0	O
.	O
37	O
,	O
PIC	B-T170
=	O
0	O
.	O
24	O
)	O
,	O
thereby	O
suggesting	O
that	O
the	O
SSR	B-T103
system	I-T103
is	O
more	O
efficient	O
than	O
the	O
ISSR	B-T103
system	I-T103
in	O
assessing	O
genetic	O
diversity	O
in	O
various	O
pineapple	B-T204
accessions	B-T170
.	O

Mean	O
genetic	O
similarities	O
were	O
0	O
.	O
74	O
,	O
0	O
.	O
61	O
,	O
and	O
0	O
.	O
69	O
,	O
as	O
determined	O
using	O
ISSR	B-T103
,	O
SSR	B-T103
,	O
and	O
combined	O
ISSR	B-T103
/	O
SSR	B-T103
,	O
respectively	O
.	O

These	O
results	O
suggest	O
that	O
the	O
genetic	O
diversity	O
among	O
pineapple	B-T204
accessions	B-T170
is	O
very	O
high	O
.	O

We	O
clustered	B-T062
the	O
36	O
pineapple	B-T204
accessions	B-T170
into	O
three	O
or	O
five	O
groups	O
on	O
the	O
basis	O
of	O
the	O
phylogenetic	O
trees	O
constructed	O
based	O
on	O
the	O
results	O
of	O
ISSR	B-T103
,	O
SSR	B-T103
,	O
and	O
combined	O
ISSR	B-T103
/	O
SSR	B-T103
analyses	B-T062
using	O
the	O
unweighted	B-T170
pair	I-T170
-	I-T170
group	I-T170
with	I-T170
arithmetic	I-T170
averaging	I-T170
(	I-T170
UPGMA	I-T170
)	I-T170
method	I-T170
.	O

The	O
results	O
of	O
principal	O
components	O
analysis	O
(	O
PCA	O
)	O
also	O
supported	O
the	O
UPGMA	B-T170
clustering	B-T062
.	O

These	O
results	O
will	O
be	O
useful	O
not	O
only	O
for	O
the	O
scientific	O
conservation	O
and	O
management	O
of	O
pineapple	B-T204
germplasm	B-T204
but	O
also	O
for	O
the	O
improvement	O
of	O
the	O
current	O
pineapple	B-T204
breeding	B-T038
strategies	I-T038
.	O

Advanced	B-T098
age	I-T098
is	O
not	O
a	O
barrier	O
to	O
creating	O
a	O
functional	O
arteriovenous	B-T017
fistula	I-T017
:	O
a	O
retrospective	B-T062
study	I-T062

Arteriovenous	B-T017
fistulas	I-T017
(	O
AVFs	B-T017
)	O
are	O
the	O
recommended	O
form	O
of	O
vascular	O
access	O
for	O
hemodialysis	B-T058
.	O

However	O
,	O
controversy	O
exists	O
regarding	O
whether	O
AVFs	B-T017
are	O
suitable	O
for	O
elderly	B-T098
patients	O
.	O

Single	B-T062
-	I-T062
center	I-T062
retrospective	I-T062
review	I-T062
to	O
investigate	O
the	O
impact	O
of	O
age	O
on	O
AVF	B-T017
outcomes	O
.	O

Five	O
hundred	O
and	O
twenty	O
-	O
five	O
patients	O
with	O
AVF	B-T017
creation	O
were	O
stratified	O
based	O
on	O
age	O
<	O
65	O
,	O
65	O
-	O
75	O
,	O
and	O
>	O
75	O
years	O
.	O

AVF	B-T017
outcomes	O
including	O
primary	O
failure	O
,	O
AVF	B-T017
patency	B-T038
(	O
primary	O
,	O
secondary	O
,	O
and	O
functional	O
)	O
,	O
and	O
AVF	B-T017
complications	B-T038
were	O
studied	O
for	O
3	O
years	O
following	O
AVF	B-T017
creation	O
.	O

The	O
cohort	B-T098
was	O
63	O
%	O
male	B-T098
,	O
44	O
%	O
Caucasian	B-T098
,	O
and	O
55	O
%	O
had	O
diabetes	B-T038
or	O
cardiovascular	B-T038
disease	I-T038
.	O

39	O
%	O
were	O
aged	O
<	O
65	O
years	O
,	O
33	O
%	O
65	O
-	O
75	O
years	O
,	O
and	O
28	O
%	O
were	O
aged	O
>	O
75	O
years	O
.	O

No	O
differences	O
in	O
rates	O
of	O
primary	O
failure	O
,	O
loss	O
of	O
primary	O
patency	B-T038
,	O
complications	B-T038
,	O
or	O
need	O
for	O
intervention	B-T058
were	O
observed	O
between	O
age	O
groups	O
.	O

There	O
was	O
a	O
significant	O
association	O
of	O
age	O
with	O
secondary	O
patency	B-T038
and	O
functional	O
patency	B-T038
,	O
with	O
age	O
>	O
75	O
being	O
an	O
independent	O
risk	B-T033
factor	I-T033
for	O
shortened	O
lifespan	O
of	O
the	O
fistula	O
.	O

For	O
patients	O
aged	O
>	O
75	O
years	O
,	O
secondary	O
patency	B-T038
at	O
3	O
years	O
was	O
64	O
%	O
compared	O
to	O
75	O
%	O
-	O
78	O
%	O
for	O
younger	O
patients	O
.	O

Functional	O
patency	B-T038
at	O
2	O
years	O
was	O
69	O
%	O
for	O
those	O
aged	O
>	O
75	O
years	O
compared	O
to	O
78	O
%	O
-	O
81	O
%	O
for	O
younger	O
patients	O
.	O

We	O
found	O
no	O
difference	O
in	O
AVF	B-T017
maturation	B-T038
,	O
primary	O
patency	B-T038
,	O
complications	B-T038
,	O
or	O
interventions	B-T058
in	O
those	O
over	O
the	O
age	O
of	O
75	O
compared	O
to	O
younger	O
counterparts	O
.	O

While	O
secondary	O
and	O
functional	O
patency	B-T038
rates	O
were	O
significantly	O
lower	O
in	O
those	O
aged	O
>	O
75	O
years	O
,	O
the	O
magnitude	O
of	O
difference	O
is	O
likely	O
not	O
clinically	O
relevant	O
.	O

Therefore	O
,	O
we	O
recommend	O
that	O
advanced	B-T098
age	I-T098
alone	O
should	O
not	O
preclude	O
patients	O
from	O
AVF	B-T017
creation	O
.	O

A	O
modified	O
ESBL	B-T058
Nordmann	I-T058
/	I-T058
Dortet	I-T058
/	I-T058
Poirel	I-T058
-	I-T058
based	I-T058
protocol	I-T058
to	O
optimize	O
early	O
sepsis	B-T038
management	B-T058

We	O
evaluated	O
a	O
modification	O
of	O
a	O
colorimetric	B-T058
test	I-T058
recently	O
described	O
by	O
Dortet	O
et	O
al	O
.	O

(	O
2015	O
)	O
for	O
the	O
rapid	O
detection	B-T058
of	O
ESBL	B-T103
-	O
producing	O
Enterobacteriaceae	B-T007
directly	O
from	O
positive	B-T033
blood	B-T058
cultures	I-T058
that	O
requires	O
less	O
manipulation	B-T058
,	O
materials	O
and	O
hands	O
-	O
on	O
time	O
.	O

The	O
simplified	O
protocol	B-T058
showed	O
a	O
sensitivity	O
and	O
specificity	O
of	O
100	O
%	O
and	O
95	O
.	O
7	O
%	O
respectively	O
.	O

The	O
use	O
of	O
informativity	O
in	O
the	O
development	O
of	O
robust	B-T017
viromics	I-T017
-	O
based	O
examinations	B-T062

Metagenomics	O
-	O
based	O
studies	O
have	O
provided	O
insight	O
into	O
many	O
of	O
the	O
complex	O
microbial	O
communities	O
responsible	O
for	O
maintaining	B-T058
life	I-T058
on	I-T058
this	I-T058
planet	I-T058
.	O

Sequencing	B-T062
efforts	O
often	O
uncover	O
novel	O
genetic	B-T017
content	I-T017
;	O
this	O
is	O
most	O
evident	O
for	O
phage	B-T005
communities	I-T005
,	O
in	O
which	O
upwards	O
of	O
90	O
%	O
of	O
all	O
sequences	B-T058
exhibit	O
no	O
similarity	O
to	O
any	O
sequence	B-T058
in	O
current	O
data	O
repositories	O
.	O

For	O
the	O
small	O
fraction	O
that	O
can	O
be	O
identified	O
,	O
the	O
top	O
BLAST	B-T170
hit	O
is	O
generally	O
posited	O
as	O
being	O
representative	O
of	O
a	O
viral	O
taxon	O
present	O
in	O
the	O
sample	O
of	O
origin	O
.	O

Homology	O
-	O
based	O
classification	B-T170
,	O
however	O
,	O
can	O
be	O
misleading	O
as	O
sequence	B-T170
repositories	I-T170
capture	O
but	O
a	O
small	O
fraction	O
of	O
phage	B-T005
diversity	I-T005
.	O

Furthermore	O
,	O
lateral	B-T082
gene	B-T062
transfer	I-T062
is	O
pervasive	B-T082
within	O
phage	B-T005
communities	I-T005
.	O

As	O
such	O
,	O
the	O
presence	O
of	O
a	O
particular	B-T017
gene	I-T017
may	O
not	O
be	O
indicative	O
of	O
the	O
presence	O
of	O
a	O
particular	B-T005
viral	I-T005
species	I-T005
.	O

Rather	O
,	O
it	O
is	O
just	O
that	O
:	O
an	O
indication	O
of	O
the	O
presence	O
of	O
a	O
specific	B-T017
gene	I-T017
.	O

To	O
circumvent	O
this	O
limitation	O
,	O
we	O
have	O
developed	O
a	O
new	O
method	O
for	O
the	O
analysis	B-T058
of	I-T058
viral	I-T058
metagenomic	I-T058
datasets	I-T058
.	O

BLAST	B-T170
hits	O
are	O
weighted	O
,	O
integrating	O
the	O
sequence	O
identity	O
and	O
length	B-T062
of	I-T062
alignments	I-T062
as	O
well	O
as	O
a	O
taxonomic	O
signal	O
,	O
such	O
that	O
each	B-T017
gene	I-T017
is	O
evaluated	O
with	O
respect	O
to	O
its	O
information	O
content	O
.	O

Through	O
this	O
quantifiable	O
metric	O
,	O
predictions	O
of	O
viral	O
community	O
structure	O
can	O
be	O
made	O
with	O
confidence	O
.	O

As	O
a	O
proof	O
-	O
of	O
-	O
concept	O
,	O
the	O
approach	O
presented	O
here	O
was	O
implemented	O
and	O
applied	O
to	O
seven	O
freshwater	B-T017
viral	I-T017
metagenomes	I-T017
.	O

While	O
providing	O
a	O
robust	O
method	O
for	O
evaluating	O
viral	O
metagenomic	O
data	O
,	O
the	O
tool	B-T170
is	O
versatile	O
and	O
can	O
easily	O
be	O
customized	O
to	O
investigations	B-T058
of	O
any	O
environment	B-T082
or	O
biome	O
.	O

PRESENCE	B-T033
OF	I-T033
CITRININ	B-T103
IN	O
GRAINS	B-T168
AND	O
ITS	O
POSSIBLE	B-T033
HEALTH	O
EFFECTS	O

Citrinin	B-T103
is	O
a	O
mycotoxin	B-T103
produced	O
by	O
several	O
species	B-T170
of	O
the	O
genera	B-T204
Aspergillus	I-T204
,	O
Penicillium	B-T204
and	O
Monascus	B-T204
and	O
it	O
occurs	O
mainly	O
in	O
stored	B-T168
grain	I-T168
.	O

Citrinin	B-T103
is	O
generally	O
formed	O
after	O
harvest	O
and	O
occurs	O
mainly	O
in	O
stored	B-T168
grains	I-T168
,	O
it	O
also	O
occurs	O
in	O
other	O
plant	O
products	O
.	O

Often	O
,	O
the	O
co	O
-	O
occurrence	O
with	O
other	O
mycotoxins	B-T103
is	O
observed	O
,	O
especially	O
ochratoxin	B-T103
A	I-T103
,	O
which	O
is	O
usually	O
associated	O
with	O
endemic	B-T038
nephropathy	I-T038
.	O

At	O
the	O
European	B-T092
Union	I-T092
level	O
,	O
systematic	O
monitoring	B-T058
of	O
Citrinin	B-T103
in	O
grains	B-T168
began	O
with	O
the	O
aim	O
of	O
determining	O
its	O
highest	O
permissible	O
amount	O
in	O
food	B-T168
.	O

Thus	O
,	O
far	O
the	O
systematic	O
monitoring	B-T058
of	O
the	O
above	B-T103
mentioned	I-T103
mycotoxin	I-T103
in	O
Croatia	B-T082
is	O
yet	O
to	O
begin	O
.	O

The	O
main	B-T170
goal	I-T170
of	O
this	O
study	B-T062
was	O
to	O
determine	O
the	O
presence	B-T033
of	I-T033
Citrinin	B-T103
in	O
grains	B-T168
sampled	O
in	O
the	O
area	B-T082
of	O
Međimurje	B-T082
,	O
Osijek	B-T082
-	I-T082
Baranja	I-T082
,	O
Vukovar	B-T082
-	I-T082
Srijem	I-T082
and	O
Brod	B-T082
-	I-T082
Posavina	I-T082
County	I-T082
.	O

For	O
the	O
purpose	O
of	O
identification	O
and	O
quantification	O
of	O
citrinin	B-T103
,	O
high	B-T058
performance	I-T058
liquid	I-T058
chromatograph	I-T058
(	I-T058
HPLC	I-T058
)	I-T058
with	I-T058
fluorescence	I-T058
was	O
used	B-T033
(	O
Calibration	O
curve	O
k	O
>	O
0	O
.	O
999	O
;	O
Intra	O
assay	O
CV	O
=	O
2	O
.	O
1	O
%	O
;	O
Inter	O
assay	O
CV	O
=	O
4	O
.	O
3	O
%	O
;	O
LOQ	O
<	O
1	O
μg	O
/	O
kg	O
)	O
.	O

From	O
the	O
area	B-T082
of	O
Međimurje	B-T082
County	I-T082
,	O
10	O
samples	O
of	O
corn	B-T168
and	O
10	O
samples	O
of	O
wheat	B-T168
were	O
analyzed	B-T062
.	O

None	O
of	O
the	O
samples	O
contained	O
Citrinin	B-T103
(	O
<	O
1	O
μg	O
/	O
kg	O
)	O
.	O

From	O
the	O
area	B-T082
of	O
Osijek	B-T082
-	I-T082
Baranja	I-T082
and	O
Vukovar	B-T082
-	I-T082
Srijem	I-T082
County	I-T082
,	O
15	O
samples	O
from	O
each	O
County	B-T082
were	O
analyzed	B-T062
.	O

The	O
mean	O
value	O
for	O
the	O
samples	O
of	O
Osijek	B-T082
-	I-T082
Baranja	I-T082
County	I-T082
was	O
19	O
.	O
63	O
μg	O
/	O
kg	O
(	O
median	O
=	O
15	O
.	O
8	O
μg	O
/	O
kg	O
)	O
,	O
while	O
for	O
Vukovar	B-T082
-	I-T082
Srijem	I-T082
County	I-T082
the	O
mean	O
value	O
of	O
citrinin	B-T103
was	O
14	O
,	O
6	O
μg	O
/	O
kg	O
(	O
median	O
=	O
1	O
.	O
23	O
μg	O
/	O
kg	O
)	O
.	O

From	O
5	O
analyzed	B-T062
samples	O
from	O
Brod	B-T082
-	I-T082
Posavina	I-T082
County	I-T082
,	O
one	O
of	O
the	O
samples	O
contained	O
citrinin	B-T103
in	O
the	O
amount	O
of	O
23	O
.	O
8	O
μg	O
/	O
kg	O
,	O
while	O
the	O
registered	B-T058
amount	O
s	O
in	O
the	O
other	O
samples	O
were	O
<	O
1	O
μg	O
/	O
kg	O
.	O

The	O
results	O
show	O
that	O
grains	B-T168
from	O
several	O
Counties	B-T082
contain	O
certain	O
amounts	O
of	O
Citrinin	B-T103
possibly	O
indicating	B-T033
a	O
significant	O
intake	O
of	O
citrinin	B-T103
in	O
humans	B-T204
.	O

It	O
must	O
be	O
stated	O
that	O
grains	B-T168
and	O
grain	B-T168
-	I-T168
based	I-T168
products	I-T168
are	O
the	O
basis	O
of	O
everyday	O
diet	B-T168
of	O
all	O
age	O
groups	O
,	O
especially	O
small	O
children	O
,	O
where	O
higher	O
intake	O
of	O
citrinin	B-T103
can	O
occur	O
.	O

Consequently	O
,	O
we	O
emphasize	O
the	O
need	O
for	O
systematic	O
analysis	B-T062
of	O
larger	O
amount	O
of	O
samples	O
,	O
from	O
both	O
large	B-T168
grains	I-T168
and	O
small	B-T168
grains	I-T168
,	O
especially	O
in	O
the	O
area	B-T082
of	O
Brod	B-T082
-	I-T082
Posavina	I-T082
County	I-T082
,	O
in	O
order	O
to	O
obtain	O
more	O
realistic	O
notion	O
of	O
citrinin	B-T103
contamination	O
of	O
grains	B-T168
and	O
to	O
asses	O
the	O
health	O
risk	O
in	O
humans	B-T204
.	O

Recurrent	B-T038
noncoding	I-T038
regulatory	I-T038
mutations	I-T038
in	O
pancreatic	B-T038
ductal	I-T038
adenocarcinoma	I-T038

The	O
contributions	O
of	O
coding	B-T038
mutations	I-T038
to	O
tumorigenesis	B-T038
are	O
relatively	O
well	O
known	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
somatic	B-T038
alterations	I-T038
in	O
noncoding	B-T103
DNA	I-T103
.	O

Here	O
we	O
describe	O
GECCO	O
(	O
Genomic	O
Enrichment	O
Computational	O
Clustering	O
Operation	O
)	O
to	O
analyze	O
somatic	B-T038
noncoding	I-T038
alterations	I-T038
in	O
308	O
pancreatic	B-T038
ductal	I-T038
adenocarcinomas	I-T038
(	O
PDAs	B-T038
)	O
and	O
identify	O
commonly	O
mutated	B-T082
regulatory	I-T082
regions	I-T082
.	O

We	O
find	O
recurrent	B-T038
noncoding	I-T038
mutations	I-T038
to	O
be	O
enriched	O
in	O
PDA	B-T038
pathways	B-T038
,	O
including	O
axon	B-T038
guidance	I-T038
and	O
cell	B-T038
adhesion	I-T038
,	O
and	O
newly	O
identified	O
processes	O
,	O
including	O
transcription	B-T038
and	O
homeobox	B-T017
genes	I-T017
.	O

We	O
identified	O
mutations	B-T038
in	O
protein	B-T082
binding	I-T082
sites	I-T082
correlating	O
with	O
differential	O
expression	B-T038
of	O
proximal	B-T082
genes	B-T017
and	O
experimentally	O
validated	O
effects	O
of	O
mutations	B-T038
on	O
expression	B-T038
.	O

We	O
developed	O
an	O
expression	O
modulation	O
score	O
that	O
quantifies	O
the	O
strength	O
of	O
gene	B-T038
regulation	I-T038
imposed	O
by	O
each	O
class	O
of	O
regulatory	B-T017
elements	I-T017
,	O
and	O
found	O
the	O
strongest	O
elements	B-T017
were	O
most	O
frequently	O
mutated	O
,	O
suggesting	O
a	O
selective	O
advantage	O
.	O

Our	O
detailed	O
single	B-T058
-	I-T058
cancer	I-T058
analysis	I-T058
of	O
noncoding	B-T038
alterations	I-T038
identifies	O
regulatory	B-T038
mutations	I-T038
as	O
candidates	O
for	O
diagnostic	B-T201
and	O
prognostic	O
markers	O
,	O
and	O
suggests	O
new	O
mechanisms	O
for	O
tumor	B-T038
evolution	I-T038
.	O

Distal	B-T082
posterior	B-T017
cerebral	I-T017
artery	I-T017
revascularization	B-T058
for	O
a	O
fusiform	O
PCA	B-T017
aneurysm	B-T038
:	O
A	O
lesson	O
learned	O

The	O
need	O
for	O
revascularization	B-T058
with	O
proximal	B-T082
posterior	B-T017
cerebral	I-T017
artery	I-T017
occlusion	B-T017
in	O
the	O
treatment	O
of	O
giant	B-T038
and	O
fusiform	B-T017
aneurysms	I-T017
is	O
unclear	O
.	O

While	O
early	O
series	O
demonstrated	O
only	O
about	O
a	O
10	O
%	O
chance	O
of	O
infarction	B-T038
following	O
posterior	B-T017
cerebral	I-T017
artery	I-T017
occlusion	B-T017
,	O
recently	O
several	O
authors	B-T097
have	O
advocated	O
a	O
bypass	B-T058
prior	O
to	O
parent	O
vessel	B-T017
sacrifice	O
in	O
all	O
cases	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
adult	O
man	O
with	O
a	O
fusiform	B-T017
aneurysm	I-T017
of	O
the	O
right	O
posterior	B-T017
cerebral	I-T017
artery	I-T017
at	O
the	O
P2	O
-	O
P3	O
junction	O
.	O

He	O
clinically	B-T033
failed	I-T033
a	O
balloon	B-T058
test	I-T058
occlusion	I-T058
preoperatively	O
and	O
therefore	O
underwent	O
an	O
occipital	B-T017
artery	I-T017
to	O
distal	B-T082
posterior	B-T017
cerebral	I-T017
artery	I-T017
bypass	B-T058
with	O
subsequent	O
endovascular	O
occlusion	O
of	O
the	O
parent	O
vessel	O
and	O
aneurysm	B-T038
.	O

Despite	O
the	O
fact	O
that	O
the	O
immediate	O
and	O
6	O
month	O
follow	B-T058
up	I-T058
cerebral	B-T058
angiography	I-T058
confirmed	O
a	O
patent	O
bypass	B-T058
,	O
the	O
patient	O
still	O
developed	O
a	O
posterior	B-T017
cerebral	I-T017
artery	I-T017
territory	B-T038
stroke	I-T038
.	O

We	O
believe	O
this	O
case	O
demonstrates	O
that	O
successful	O
distal	B-T082
revascularization	B-T058
in	O
the	O
setting	O
of	O
proximal	B-T082
posterior	B-T017
cerebral	I-T017
artery	I-T017
occlusion	B-T017
does	O
not	O
guarantee	O
against	O
cerebral	B-T038
ischemia	I-T038
and	O
infarction	B-T038
even	O
in	O
those	O
patients	O
that	O
fail	O
a	O
test	B-T058
occlusion	I-T058
.	O

When	O
Is	O
a	O
Test	O
Score	O
Fair	O
for	O
the	O
Individual	B-T098
Who	O
Is	O
Being	O
Tested	B-T170
?	O
Effects	O
of	O
Different	O
Scoring	B-T062
Procedures	I-T062
across	O
Multiple	O
Attempts	O
When	O
Testing	O
a	O
Motor	B-T038
Skill	I-T038
Task	O

Tests	B-T170
or	O
test	B-T170
batteries	I-T170
used	O
for	O
assessing	O
motor	B-T038
skills	I-T038
,	O
either	O
in	O
research	B-T062
studies	I-T062
or	O
in	O
clinical	B-T062
settings	I-T062
,	O
apply	O
a	O
variety	O
of	O
procedures	O
for	O
scoring	B-T062
performances	O
,	O
including	O
everything	O
from	O
one	O
to	O
ten	O
attempts	O
,	O
of	O
which	O
the	O
best	O
is	O
scored	O
or	O
an	O
average	O
is	O
computed	B-T058
.	O

The	O
rationale	O
behind	O
scoring	B-T062
procedures	O
is	O
rarely	O
stated	O
,	O
and	O
it	O
seems	O
that	O
the	O
number	O
of	O
attempts	O
allowed	O
is	O
decided	O
without	O
much	O
qualification	O
from	O
research	B-T062
.	O

It	O
is	O
uncertain	O
whether	O
procedures	O
fairly	O
capture	O
an	O
individual	B-T098
'	I-T098
s	I-T098
skill	B-T038
level	O
.	O

Thus	O
,	O
the	O
validity	O
of	O
the	O
tests	B-T170
may	O
be	O
compromised	O
.	O

The	O
present	O
study	B-T062
tested	B-T170
24	O
young	O
female	B-T098
soccer	O
players	B-T097
on	O
the	O
juggling	O
of	O
a	O
soccer	O
ball	O
.	O

They	O
were	O
given	O
10	O
attempts	O
,	O
and	O
trials	O
were	O
scored	O
according	O
to	O
nine	O
different	O
procedures	O
including	O
the	O
'	O
best	O
of	O
'	O
or	O
'	O
mean	O
of	O
'	O
either	O
one	O
,	O
two	O
,	O
three	O
,	O
five	O
,	O
or	O
ten	O
attempts	O
.	O

Individual	B-T098
raw	O
scores	O
differed	O
widely	O
across	O
trials	O
,	O
but	O
no	O
general	O
effect	O
of	O
trials	O
was	O
found	O
.	O

The	O
mean	O
(	O
SD	O
)	O
percentage	O
difference	O
between	O
the	O
lowest	O
and	O
highest	O
scores	O
was	O
27	O
.	O
7	O
(	O
9	O
.	O
9	O
)	O
%	O
,	O
with	O
17	O
players	B-T097
(	O
71	O
%	O
)	O
demonstrating	O
a	O
significant	O
change	O
from	O
lowest	O
to	O
highest	O
score	O
.	O

Correlations	O
between	O
raw	O
scores	O
were	O
low	O
across	O
trials	O
,	O
while	O
they	O
were	O
generally	O
higher	O
across	O
scoring	B-T062
procedures	O
.	O

The	O
first	O
trial	O
was	O
significantly	O
different	O
from	O
the	O
remaining	O
both	O
as	O
a	O
raw	O
score	O
and	O
as	O
scoring	B-T062
procedure	O
.	O

The	O
mean	O
percentage	O
difference	O
between	O
best	O
-	O
of	O
-	O
two	O
and	O
best	O
-	O
of	O
-	O
ten	O
scores	O
was	O
95	O
%	O
,	O
with	O
50	O
%	O
of	O
the	O
players	B-T097
demonstrating	O
a	O
significant	O
difference	O
between	O
the	O
two	O
scoring	B-T062
procedures	O
.	O

No	O
significant	O
differences	O
were	O
found	O
across	O
mean	O
-	O
of	O
-	O
rule	O
scorings	O
.	O

Best	O
-	O
of	O
-	O
rule	O
and	O
mean	O
-	O
of	O
-	O
rule	O
scorings	O
were	O
significantly	O
different	O
except	O
for	O
the	O
best	O
-	O
of	O
-	O
two	O
vs	O
.	O

mean	O
-	O
of	O
-	O
two	O
.	O

The	O
mean	O
difference	O
between	O
highest	O
and	O
lowest	O
rank	B-T170
across	O
players	B-T097
was	O
6	O
.	O
7	O
(	O
3	O
.	O
6	O
)	O
,	O
with	O
individual	B-T098
rankings	B-T170
within	O
the	O
group	B-T098
varying	O
33	O
%	O
on	O
average	O
across	O
procedures	O
.	O

One	O
player	O
moved	O
from	O
3rd	O
to	O
23rd	O
place	O
because	O
of	O
procedural	O
differences	O
.	O

Therefore	O
,	O
it	O
is	O
concluded	O
that	O
scoring	B-T062
procedures	O
affect	O
results	B-T033
and	O
may	O
have	O
an	O
impact	O
on	O
test	B-T033
outcomes	I-T033
.	O

This	O
may	O
present	O
consequences	O
for	O
decision	O
-	O
making	O
from	O
test	B-T033
results	I-T033
,	O
such	O
as	O
diagnosing	B-T033
and	O
selection	O
of	O
intervention	B-T058
groups	O
.	O

We	O
hope	O
that	O
our	O
results	O
would	O
inspire	O
further	O
research	B-T062
into	O
the	O
scoring	B-T062
procedures	O
of	O
the	O
vast	O
amount	O
of	O
tests	B-T170
and	O
tasks	O
in	O
common	O
use	O
.	O

A	O
Fast	B-T170
Peak	I-T170
-	I-T170
Searching	I-T170
Algorithm	I-T170
for	O
Ultrasonic	B-T058
Elastography	I-T058

Tissue	B-T058
axial	I-T058
strain	I-T058
estimation	I-T058
with	I-T058
ultrasound	I-T058
elastography	I-T058
has	O
become	O
a	O
hot	O
field	O
in	O
recent	O
years	O
.	O

However	O
,	O
for	O
keypoints	O
tracking	B-T170
-	I-T170
based	I-T170
elastography	I-T170
algorithms	I-T170
,	O
locating	B-T033
extrema	O
in	O
multimodal	O
ultrasonic	O
radiofrequency	O
signals	O
is	O
still	O
a	O
challenging	O
problem	B-T033
.	O

In	O
this	O
paper	O
,	O
a	O
new	O
method	O
is	O
proposed	O
to	O
locate	B-T033
the	O
local	O
maxima	O
and	O
minima	O
of	O
the	O
RF	O
signals	O
directly	O
without	O
derivation	O
operation	O
.	O

This	O
algorithm	B-T170
can	O
accurately	O
locate	B-T033
extrema	O
even	O
if	O
disturbed	O
peaks	O
resulting	O
from	O
different	O
noise	O
exist	O
.	O

Furthermore	O
,	O
the	O
new	O
algorithm	B-T170
can	O
speed	O
up	O
approximately	O
79	O
%	O
of	O
the	O
implementation	O
process	O
as	O
compared	O
with	O
the	O
standard	B-T062
cross	I-T062
-	I-T062
correlation	I-T062
method	I-T062
on	O
the	O
same	O
computing	O
platform	O
.	O

In	O
addition	O
,	O
the	O
elastographic	O
signal	O
-	O
to	O
-	O
noise	O
ratio	O
and	O
the	O
contrast	O
-	O
to	O
-	O
noise	O
ratio	O
are	O
also	O
significantly	O
improved	O
with	O
this	O
new	O
method	O
.	O

Audiovisual	O
integration	B-T038
supports	O
face	B-T082
-	O
name	B-T170
associative	O
memory	B-T038
formation	I-T038

Prior	O
multisensory	O
experience	B-T038
influences	O
how	O
we	O
perceive	O
our	O
environment	B-T082
,	O
and	O
hence	O
how	O
memories	B-T038
are	O
encoded	O
for	O
subsequent	O
retrieval	O
.	O

This	O
study	B-T062
investigated	O
if	O
audiovisual	O
(	O
AV	O
)	O
integration	B-T038
and	O
associative	O
memory	B-T038
formation	I-T038
rely	O
on	O
overlapping	O
or	O
distinct	O
processes	O
.	O

Our	O
functional	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
results	O
demonstrate	O
that	O
the	O
neural	B-T017
mechanisms	O
underlying	O
AV	O
integration	B-T038
and	O
associative	O
memory	B-T038
overlap	O
substantially	O
.	O

In	O
particular	O
,	O
activity	O
in	O
anterior	O
superior	O
temporal	O
sulcus	O
(	O
STS	B-T082
)	O
is	O
increased	O
during	O
AV	O
integration	B-T038
and	O
also	O
determines	O
the	O
success	O
of	O
novel	O
AV	O
face	B-T082
-	O
name	B-T170
association	O
formation	O
.	O

Dynamic	O
causal	O
modeling	O
results	O
further	O
demonstrate	O
how	O
the	O
anterior	O
STS	O
interacts	O
with	O
the	O
associative	O
memory	B-T038
system	I-T038
to	O
facilitate	O
successful	O
memory	B-T038
formation	I-T038
for	O
AV	O
face	B-T082
-	O
name	B-T170
associations	O
.	O

Specifically	O
,	O
the	O
connection	O
of	O
fusiform	B-T017
gyrus	I-T017
to	O
anterior	O
STS	O
is	O
enhanced	O
while	O
the	O
reverse	O
connection	O
is	O
reduced	O
when	O
participants	B-T098
subsequently	O
remembered	B-T038
both	O
face	B-T082
and	O
name	B-T170
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
how	O
multisensory	O
associative	O
memories	B-T038
can	O
be	O
formed	O
for	O
subsequent	O
retrieval	O
.	O

Liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
quantification	O
of	O
acetamiprid	B-T103
and	O
thiacloprid	B-T103
residues	O
in	O
butterbur	B-T204
grown	O
under	O
regulated	B-T082
conditions	I-T082

An	O
analytical	O
method	O
was	O
developed	O
to	O
quantify	O
the	O
residual	O
levels	O
of	O
the	O
neonicotinoid	B-T103
insecticides	I-T103
,	O
acetamiprid	B-T103
and	O
thiacloprid	B-T103
,	O
in	O
field	O
-	O
incurred	O
butterbur	B-T204
samples	O
using	O
liquid	B-T058
chromatography	I-T058
-	I-T058
tandem	I-T058
mass	I-T058
spectrometry	I-T058
(	O
LC	B-T058
-	I-T058
MS	I-T058
/	I-T058
MS	I-T058
)	O
.	O

Samples	O
were	O
extracted	B-T058
with	O
acetonitrile	B-T103
and	O
partitioned	O
with	O
dichloromethane	B-T103
.	O

After	O
partitioning	O
,	O
purification	O
was	O
conducted	O
using	O
a	O
Florisil	O
(	O
®	O
)	O
cartridge	O
.	O

Linearity	B-T082
of	O
a	O
matrix	O
-	O
matched	O
calibration	O
curve	O
of	O
the	O
two	O
compounds	O
over	O
a	O
concentration	O
range	O
of	O
0	O
.	O
004	O
-	O
0	O
.	O
4μg	O
/	O
g	O
was	O
excellent	O
,	O
with	O
determination	O
coefficients	O
(	O
R	O
(	O
2	O
)	O
)	O
≥0	O
.	O
9998	O
.	O

The	O
limits	O
of	O
detection	O
(	O
LOD	O
)	O
and	O
quantitation	O
(	O
LOQ	O
)	O
for	O
both	O
acetamiprid	B-T103
and	O
thiacloprid	B-T103
were	O
0	O
.	O
0006	O
and	O
0	O
.	O
002mg	O
/	O
kg	O
,	O
respectively	O
.	O

The	O
average	O
recoveries	O
for	O
acetamiprid	B-T103
and	O
thiacloprid	B-T103
at	O
two	O
spiking	O
levels	O
(	O
0	O
.	O
02	O
and	O
0	O
.	O
1mg	O
/	O
kg	O
,	O
i	O
.	O
e	O
.	O
,	O
10×	O
LOQ	O
and	O
50×	O
LOQ	O
)	O
were	O
between	O
78	O
.	O
23	O
to	O
82	O
.	O
17	O
%	O
,	O
with	O
relative	O
standard	O
deviations	O
(	O
RSDs	O
)	O
≤7	O
.	O
22	O
%	O
.	O

The	O
method	O
was	O
successfully	O
applied	O
to	O
field	O
-	O
incurred	O
samples	O
treated	O
with	O
a	O
commercial	B-T170
pesticide	B-T103
product	I-T103
,	O
either	O
once	O
(	O
zero	O
or	O
7	O
days	O
before	O
harvest	O
)	O
or	O
twice	O
(	O
0	O
and	O
7	O
,	O
7	O
and	O
14	O
,	O
or	O
14	O
and	O
21	O
days	O
before	O
harvest	O
)	O
.	O

The	O
highest	O
and	O
lowest	O
residues	O
were	O
obtained	O
for	O
the	O
7	O
and	O
0	O
days	O
'	O
treatment	O
and	O
the	O
21	O
and	O
14	O
days	O
'	O
treatment	O
,	O
respectively	O
.	O

The	O
developed	O
method	O
is	O
simple	O
and	O
accurate	O
and	O
can	O
be	O
extrapolated	O
to	O
other	O
leafy	B-T168
vegetables	I-T168
.	O

Percentile	O
categorization	B-T170
of	O
QT	B-T033
interval	I-T033
as	O
an	O
approach	B-T082
for	O
identifying	B-T058
adult	O
patients	O
at	O
risk	O
for	O
cardiovascular	B-T201
death	I-T201

The	O
results	O
from	O
studies	O
of	O
the	O
association	O
of	O
QT	B-T033
prolongation	I-T033
with	O
cardiovascular	B-T201
death	I-T201
(	O
CVD	B-T201
)	O
have	O
been	O
inconsistent	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
compare	O
the	O
major	O
correction	O
formulas	O
to	O
percentile	O
values	O
of	O
QT	O
for	O
heart	B-T201
rate	I-T201
ranges	O
as	O
to	O
their	O
ability	O
to	O
remove	O
the	O
relationship	O
of	O
QT	O
to	O
heart	B-T201
rate	I-T201
and	O
to	O
predict	O
CVD	B-T201
.	O

Participants	B-T098
were	O
16	O
,	O
531	O
veterans	B-T098
who	O
had	O
an	O
initial	O
ECG	B-T033
at	O
the	O
Veterans	B-T170
Affairs	I-T170
Medical	I-T170
Center	I-T170
,	O
Palo	B-T082
Alto	I-T082
,	O
between	O
March	O
31	O
,	O
1987	O
,	O
and	O
December	O
20	O
,	O
1999	O
,	O
and	O
were	O
followed	O
for	O
CVD	B-T201
.	O

The	O
4	O
major	O
correction	O
formulas	O
(	O
Bazett	O
,	O
Fridericia	O
,	O
Framingham	O
,	O
and	O
Hodges	O
)	O
were	O
used	O
to	O
correct	O
QT	B-T033
interval	I-T033
.	O

In	O
addition	O
,	O
the	O
percentiles	O
for	O
heart	B-T201
rate	I-T201
ranges	O
as	O
proposed	O
by	O
Schwartz	B-T204
were	O
calculated	O
.	O

During	O
median	B-T082
follow	O
-	O
up	O
of	O
17	O
.	O
8	O
years	O
,	O
455	O
CVD	B-T201
events	O
occurred	O
.	O

When	O
compared	O
to	O
the	O
other	O
equations	O
,	O
QTc	O
Bazett	O
had	O
the	O
greatest	O
dependence	O
on	O
heart	B-T201
rate	I-T201
(	O
R	O
(	O
2	O
)	O
=	O
0	O
.	O
18	O
)	O
.	O

The	O
hazard	O
ratio	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
for	O
CVD	B-T201
was	O
2	O
.	O
08	O
(	O
1	O
.	O
28	O
-	O
3	O
.	O
9	O
)	O
for	O
the	O
98th	O
percentile	O
of	O
QT	B-T033
interval	I-T033
by	O
heart	B-T201
rate	I-T201
ranges	O
,	O
2	O
.	O
05	O
(	O
1	O
.	O
27	O
-	O
3	O
.	O
33	O
)	O
for	O
QTc	O
Bazett	O
,	O
1	O
.	O
39	O
(	O
0	O
.	O
44	O
-	O
4	O
.	O
34	O
)	O
for	O
QTc	O
Fridericia	O
,	O
1	O
.	O
05	O
(	O
0	O
.	O
26	O
-	O
4	O
.	O
24	O
)	O
for	O
QTc	O
Hodges	O
,	O
and	O
1	O
.	O
12	O
(	O
0	O
.	O
28	O
-	O
4	O
.	O
52	O
)	O
for	O
QTc	O
Framingham	O
.	O

The	O
hazard	O
ratio	O
of	O
QTc	O
Bazett	O
was	O
significantly	O
higher	O
than	O
the	O
other	O
formulas	B-T170
except	O
for	O
the	O
98th	O
percentile	O
method	O
.	O

The	O
Framingham	O
,	O
Hodges	O
,	O
and	O
Fridericia	O
equations	O
remove	O
the	O
effect	O
of	O
heart	B-T201
rate	I-T201
on	O
QT	B-T033
interval	I-T033
significantly	O
better	O
than	O
the	O
Bazett	O
equation	O
.	O

Using	O
QT	B-T033
-	I-T033
interval	I-T033
percentiles	O
based	O
on	O
heart	B-T201
rate	I-T201
provides	O
a	O
consistent	O
approach	B-T082
both	O
for	O
identifying	O
those	O
whose	O
QT	B-T033
intervals	I-T033
prolong	O
due	O
to	O
drugs	B-T058
or	O
other	O
stressors	O
and	O
for	O
assessing	O
CVD	B-T201
risk	O
.	O

How	O
Should	O
I	O
Study	O
for	O
the	O
Exam	O
?	O
Self	O
-	O
Regulated	O
Learning	O
Strategies	O
and	O
Achievement	B-T170
in	O
Introductory	B-T091
Biology	I-T091

In	O
college	O
introductory	O
science	O
courses	O
,	O
students	B-T098
are	O
challenged	O
with	O
mastering	O
large	O
amounts	O
of	O
disciplinary	O
content	O
while	O
developing	O
as	O
autonomous	O
and	O
effective	O
learners	B-T098
.	O

Self	O
-	O
regulated	O
learning	O
(	O
SRL	O
)	O
is	O
the	O
process	O
of	O
setting	O
learning	O
goals	O
,	O
monitoring	O
progress	O
toward	O
them	O
,	O
and	O
applying	O
appropriate	O
study	O
strategies	O
.	O

SRL	O
characterizes	O
successful	O
,	O
"	O
expert	O
"	O
learners	B-T098
,	O
and	O
develops	O
with	O
time	O
and	O
practice	O
.	O

In	O
a	O
large	O
,	O
undergraduate	O
introductory	B-T091
biology	I-T091
course	O
,	O
we	O
investigated	O
:	O
1	O
)	O
what	O
SRL	O
strategies	O
students	B-T098
reported	O
using	O
the	O
most	O
when	O
studying	O
for	O
exams	O
,	O
2	O
)	O
which	O
strategies	O
were	O
associated	O
with	O
higher	O
achievement	O
and	O
with	O
grade	B-T170
improvement	B-T033
on	O
exams	O
,	O
and	O
3	O
)	O
what	O
study	O
approaches	O
students	B-T098
proposed	O
to	O
use	O
for	O
future	O
exams	O
.	O

Higher	O
-	O
achieving	O
students	B-T098
,	O
and	O
students	B-T098
whose	O
exam	O
grades	B-T170
improved	B-T033
in	O
the	O
first	O
half	O
of	O
the	O
semester	O
,	O
reported	O
using	O
specific	O
cognitive	B-T038
and	O
metacognitive	B-T038
strategies	I-T038
significantly	O
more	O
frequently	O
than	O
their	O
lower	O
-	O
achieving	O
peers	B-T098
.	O

Lower	O
-	O
achieving	O
students	B-T098
more	O
frequently	O
reported	O
that	O
they	O
did	O
not	O
implement	O
their	O
planned	O
strategies	O
or	O
,	O
if	O
they	O
did	O
,	O
still	O
did	O
not	O
improve	O
their	O
outcomes	O
.	O

These	O
results	O
suggest	O
that	O
many	O
students	B-T098
entering	O
introductory	B-T091
biology	I-T091
have	O
limited	O
knowledge	O
of	O
SRL	O
strategies	O
and	O
/	O
or	O
limited	O
ability	O
to	O
implement	O
them	O
,	O
which	O
can	O
impact	O
their	O
achievement	B-T170
.	O

Course	O
-	O
specific	O
interventions	B-T058
that	O
promote	O
SRL	O
development	O
should	O
be	O
considered	O
as	O
integral	O
pedagogical	O
tools	O
,	O
aimed	O
at	O
fostering	O
development	O
of	O
students	B-T098
'	O
lifelong	O
learning	O
skills	O
.	O

Characterising	O
bias	O
in	O
regulatory	O
risk	O
and	O
decision	O
analysis	O
:	O
An	O
analysis	B-T062
of	O
heuristics	B-T170
applied	O
in	O
health	B-T058
technology	I-T058
appraisal	O
,	O
chemicals	B-T103
regulation	O
,	O
and	O
climate	O
change	O
governance	O

In	O
many	O
environmental	O
and	O
public	B-T170
health	I-T170
domains	I-T170
,	O
heuristic	B-T170
methods	I-T170
of	O
risk	O
and	O
decision	O
analysis	O
must	O
be	O
relied	O
upon	O
,	O
either	O
because	O
problem	B-T033
structures	I-T033
are	O
ambiguous	O
,	O
reliable	O
data	O
is	O
lacking	O
,	O
or	O
decisions	B-T038
are	O
urgent	O
.	O

This	O
introduces	O
an	O
additional	O
source	B-T033
of	O
uncertainty	B-T033
beyond	O
model	B-T170
and	O
measurement	O
error	O
-	O
uncertainty	B-T033
stemming	O
from	O
relying	O
on	O
inexact	O
inference	B-T170
rules	I-T170
.	O

Here	O
we	O
identify	O
and	O
analyse	O
heuristics	B-T170
used	O
to	O
prioritise	O
risk	O
objects	O
,	O
to	O
discriminate	O
between	O
signal	O
and	O
noise	O
,	O
to	O
weight	O
evidence	O
,	O
to	O
construct	O
models	B-T170
,	O
to	O
extrapolate	O
beyond	O
datasets	B-T170
,	O
and	O
to	O
make	O
policy	B-T170
.	O

Some	O
of	O
these	O
heuristics	B-T170
are	O
based	O
on	O
causal	O
generalisations	O
,	O
yet	O
can	O
misfire	O
when	O
these	O
relationships	O
are	O
presumed	O
rather	O
than	O
tested	O
(	O
e	O
.	O
g	O
.	O

surrogates	O
in	O
clinical	B-T062
trials	I-T062
)	O
.	O

Others	O
are	O
conventions	O
designed	O
to	O
confer	O
stability	O
to	O
decision	O
analysis	O
,	O
yet	O
which	O
may	O
introduce	O
serious	O
error	O
when	O
applied	O
ritualistically	O
(	O
e	O
.	O
g	O
.	O

significance	O
testing	O
)	O
.	O

Some	O
heuristics	B-T170
can	O
be	O
traced	O
back	O
to	O
formal	O
justifications	O
,	O
but	O
only	O
subject	O
to	O
strong	O
assumptions	O
that	O
are	O
often	O
violated	O
in	O
practical	O
applications	O
.	O

Heuristic	B-T170
decision	B-T170
rules	I-T170
(	O
e	O
.	O
g	O
.	O

feasibility	B-T170
rules	I-T170
)	O
in	O
principle	O
act	O
as	O
surrogates	O
for	O
utility	O
maximisation	O
or	O
distributional	O
concerns	O
,	O
yet	O
in	O
practice	O
may	O
neglect	O
costs	O
and	O
benefits	O
,	O
be	O
based	O
on	O
arbitrary	O
thresholds	O
,	O
and	O
be	O
prone	O
to	O
gaming	O
.	O

We	O
highlight	O
the	O
problem	B-T033
of	O
rule	O
-	O
entrenchment	O
,	O
where	O
analytical	O
choices	O
that	O
are	O
in	O
principle	O
contestable	O
are	O
arbitrarily	O
fixed	O
in	O
practice	O
,	O
masking	O
uncertainty	B-T033
and	O
potentially	O
introducing	O
bias	O
.	O

Strategies	O
for	O
making	O
risk	O
and	O
decision	O
analysis	O
more	O
rigorous	O
include	O
:	O
formalising	O
the	O
assumptions	O
and	O
scope	O
conditions	O
under	O
which	O
heuristics	B-T170
should	O
be	O
applied	O
;	O
testing	O
rather	O
than	O
presuming	O
their	O
underlying	O
empirical	O
or	O
theoretical	O
justifications	O
;	O
using	O
sensitivity	O
analysis	B-T062
,	O
simulations	B-T062
,	O
multiple	B-T062
bias	I-T062
analysis	I-T062
,	O
and	O
deductive	B-T170
systems	I-T170
of	I-T170
inference	I-T170
(	O
e	O
.	O
g	O
.	O

directed	B-T170
acyclic	I-T170
graphs	I-T170
)	O
to	O
characterise	O
rule	B-T170
uncertainty	B-T033
and	O
refine	O
heuristics	B-T170
;	O
adopting	O
"	O
recovery	B-T170
schemes	I-T170
"	O
to	O
correct	O
for	O
known	O
biases	O
;	O
and	O
basing	O
decision	B-T170
rules	I-T170
on	O
clearly	O
articulated	O
values	O
and	O
evidence	O
,	O
rather	O
than	O
convention	O
.	O

Multicentric	B-T038
Castleman	I-T038
disease	I-T038
of	O
hyaline	B-T031
vascular	B-T017
variant	O
presenting	O
with	O
unusual	O
systemic	O
manifestations	O
:	O
a	O
case	B-T170
report	I-T170

Castleman	B-T038
disease	I-T038
is	O
a	O
rare	O
lymphoproliferative	B-T038
disorder	I-T038
presenting	O
with	O
localized	B-T082
or	O
disseminated	B-T082
lymphadenopathy	B-T038
and	O
systemic	O
manifestations	O
.	O

It	O
can	O
be	O
categorized	B-T170
in	O
numerous	O
ways	O
,	O
such	O
as	O
unicentric	B-T038
versus	O
multicentric	B-T038
,	O
histopathological	O
variants	O
(	O
hyaline	B-T031
-	O
vascular	B-T017
,	O
plasma	B-T017
cell	I-T017
,	O
and	O
mixed	O
)	O
,	O
or	O
subtypes	O
based	O
on	O
causative	B-T033
viral	B-T038
infections	I-T038
(	O
human	B-T005
immunodeficiency	I-T005
virus	I-T005
,	O
human	B-T005
herpesvirus	I-T005
-	I-T005
8	I-T005
,	O
or	O
Kaposi	B-T005
sarcoma	I-T005
herpesvirus	I-T005
)	O
.	O

Presentation	O
ranges	O
from	O
asymptomatic	B-T033
to	O
symptoms	B-T033
involving	O
multiple	O
organs	B-T017
.	O

Even	O
though	O
the	O
exact	O
mechanism	O
of	O
pathogenesis	B-T038
is	O
unknown	O
,	O
treatment	O
is	O
directed	O
toward	O
possible	O
etiologies	O
such	O
as	O
interleukin	B-T103
-	I-T103
6	I-T103
,	O
cluster	B-T103
of	I-T103
differentiation	I-T103
20	I-T103
,	O
and	O
viral	O
agents	O
.	O

A	O
36	O
-	O
year	O
-	O
old	O
Sri	B-T098
Lankan	I-T098
woman	B-T098
presented	O
with	O
generalized	O
body	B-T033
swelling	I-T033
and	O
foamy	O
urine	O
of	O
2	O
weeks	O
'	O
duration	O
.	O

Examination	B-T058
revealed	O
pallor	B-T033
;	O
generalized	B-T033
edema	I-T033
;	O
axillary	B-T082
,	O
cervical	B-T082
,	O
and	O
inguinal	B-T038
lymphadenopathy	I-T038
;	O
hypertension	B-T038
;	O
and	O
hepatomegaly	B-T033
.	O

Investigations	B-T058
showed	O
bicytopenia	B-T033
,	O
nephrotic	B-T033
range	I-T033
proteinuria	I-T033
with	O
hypoalbuminemia	B-T038
,	O
hypogammaglobulinemia	B-T038
,	O
and	O
features	O
of	O
hyaline	B-T031
-	O
vascular	B-T017
type	O
Castleman	B-T038
disease	I-T038
in	O
a	O
lymph	B-T058
node	I-T058
biopsy	I-T058
.	O

She	O
was	O
managed	B-T058
with	O
rituximab	B-T103
and	O
had	O
good	O
clinical	O
improvement	O
.	O

Castleman	B-T038
disease	I-T038
has	O
a	O
broad	B-T082
spectrum	O
of	O
clinical	O
manifestations	O
,	O
disease	B-T038
pathogeneses	B-T038
,	O
and	O
associations	O
and	O
/	O
or	O
complications	B-T038
.	O

Medical	O
professionals	B-T097
need	O
to	O
be	O
familiar	O
with	O
this	O
spectrum	O
because	O
timely	O
diagnosis	B-T033
and	O
aggressive	B-T058
targeted	I-T058
therapy	I-T058
are	O
the	O
cornerstones	O
of	O
managing	O
these	O
patients	O
.	O

The	O
AGES	B-T170
-	I-T170
Reykjavik	I-T170
study	I-T170
atlases	I-T170
:	O
Non	O
-	O
linear	O
multi	O
-	O
spectral	O
template	O
and	O
atlases	B-T170
for	O
studies	B-T062
of	O
the	O
ageing	B-T038
brain	B-T017

Quantitative	O
analyses	O
of	O
brain	B-T017
structures	B-T082
from	O
Magnetic	B-T058
Resonance	I-T058
(	O
MR	B-T058
)	O
image	B-T058
data	O
are	O
often	O
performed	O
using	O
automatic	O
segmentation	O
algorithms	B-T170
.	O

Many	O
of	O
these	O
algorithms	B-T170
rely	O
on	O
templates	O
and	O
atlases	B-T170
in	O
a	O
common	O
coordinate	B-T170
space	I-T170
.	O

Most	O
freely	O
available	O
brain	B-T017
atlases	B-T170
are	O
generated	O
from	O
relatively	O
young	O
individuals	B-T098
and	O
not	O
always	O
derived	O
from	O
well	O
-	O
defined	O
cohort	O
studies	O
.	O

In	O
this	O
paper	O
,	O
we	O
introduce	O
a	O
publicly	B-T092
available	O
multi	O
-	O
spectral	O
template	O
with	O
corresponding	O
tissue	B-T017
probability	O
atlases	B-T170
and	O
regional	B-T082
atlases	B-T170
,	O
optimised	O
to	O
use	O
in	O
studies	B-T062
of	O
ageing	B-T038
cohorts	B-T098
(	O
mean	O
age	O
75	O
±	O
5	O
years	O
)	O
.	O

Furthermore	O
,	O
we	O
provide	O
validation	B-T062
data	O
from	O
a	O
regional	B-T082
segmentation	O
pipeline	O
to	O
assure	O
the	O
integrity	O
of	O
the	O
dataset	B-T170
.	O

Comparative	O
and	O
evolutionary	B-T062
analysis	I-T062
of	O
an	O
adapter	B-T017
molecule	I-T017
MyD88	I-T017
in	O
invertebrate	B-T204
metazoans	B-T204

The	O
myeloid	B-T017
differentiation	I-T017
factor	I-T017
88	I-T017
(	O
MyD88	B-T017
)	O
is	O
an	O
essential	O
adapter	O
in	O
Toll	B-T103
-	I-T103
like	I-T103
receptor	I-T103
(	O
TLR	B-T103
)	O
signalling	B-T038
pathways	I-T038
,	O
with	O
TLR	B-T103
the	O
first	O
pattern	B-T103
-	I-T103
recognition	I-T103
receptor	I-T103
(	O
PRR	B-T103
)	O
that	O
was	O
discovered	O
in	O
Drosophila	B-T204
.	O

In	O
the	O
present	O
study	B-T062
,	O
a	O
MyD88	B-T017
gene	I-T017
was	O
identified	O
and	O
characterized	O
from	O
a	O
commercially	O
important	O
shellfish	B-T204
,	O
Scapharca	B-T204
subcrenata	I-T204
,	O
including	O
a	O
DEATH	B-T082
domain	I-T082
and	O
TIR	B-T082
domain	I-T082
conserved	O
within	O
other	O
molluscs	B-T204
.	O

Furthermore	O
,	O
comparative	B-T062
genomic	I-T062
evidence	I-T062
revealed	O
that	O
MyD88	B-T017
was	O
of	O
different	O
lengths	O
and	O
contained	O
quantitative	O
exon	B-T103
and	O
intron	B-T103
regions	I-T103
,	O
which	O
might	O
be	O
involved	O
in	O
specific	O
mechanisms	O
.	O

To	O
further	O
explore	O
the	O
phylogenetic	B-T062
relationships	I-T062
of	O
invertebrate	B-T204
metazoan	B-T204
MyD88	B-T017
,	O
we	O
applied	O
MrBayes	B-T170
and	I-T170
PhyML	I-T170
software	I-T170
to	O
construct	B-T170
phylogenetic	O
trees	O
using	O
Bayesian	O
and	O
maximum	B-T170
likelihood	I-T170
approaches	I-T170
,	O
respectively	O
,	O
which	O
suggested	O
that	O
the	O
MyD88	B-T017
of	O
Arthropoda	B-T204
was	O
closely	O
related	O
to	O
lower	O
invertebrates	B-T204
,	O
in	O
contrast	O
to	O
morphological	B-T082
taxonomy	O
.	O

Finally	O
,	O
we	O
investigated	O
the	O
evolutionary	B-T038
patterns	I-T038
and	O
location	O
of	O
positive	B-T017
selection	I-T017
sites	I-T017
(	O
PSSs	B-T017
)	O
in	O
the	O
MyD88	B-T017
gene	I-T017
from	O
Arthropoda	B-T204
,	O
Mollusca	B-T204
and	O
Insecta	B-T204
using	O
PAML	B-T170
software	I-T170
with	O
the	O
maximum	B-T170
likelihood	I-T170
method	I-T170
.	O

The	O
data	O
showed	O
that	O
positive	B-T017
selection	I-T017
sites	I-T017
were	O
detected	B-T033
in	O
these	O
groups	B-T098
,	O
and	O
partial	B-T082
sites	I-T082
were	O
located	O
in	O
the	O
TIR	B-T082
domain	I-T082
but	O
were	O
not	B-T033
found	I-T033
in	O
the	O
DEATH	B-T082
domain	I-T082
.	O

To	O
summarize	O
,	O
in	O
this	O
study	B-T062
,	O
we	O
report	O
on	O
the	O
diversification	O
of	O
MyD88	B-T017
in	O
invertebrate	B-T204
metazoans	B-T204
,	O
the	O
specific	O
evolutionary	B-T038
position	I-T038
of	O
Arthropoda	B-T204
MyD88	B-T017
,	O
and	O
the	O
positive	B-T033
selection	B-T038
pressures	I-T038
on	O
MyD88	B-T017
of	O
Arthropoda	B-T204
,	O
Mollusca	B-T204
and	O
Insecta	B-T204
.	O

These	O
results	O
are	O
a	O
valuable	O
contribution	O
to	O
understand	O
and	O
clarify	O
the	O
evolutionary	B-T038
pattern	I-T038
of	O
TLR	B-T103
/	O
MyD88	B-T017
signalling	B-T038
pathways	I-T038
in	O
invertebrate	B-T204
and	O
vertebrate	B-T204
taxa	I-T204
.	O

Rubinstein	B-T038
-	I-T038
Taybi	I-T038
Syndrome	I-T038
Associated	O
with	O
Pituitary	B-T038
Macroadenoma	I-T038
:	O
A	O
Case	B-T170
Report	I-T170

Rubinstein	B-T038
-	I-T038
Taybi	I-T038
Syndrome	I-T038
(	O
RSTS	B-T038
)	O
is	O
an	O
autosomal	B-T038
dominant	I-T038
disorder	I-T038
that	O
is	O
classically	O
characterized	O
by	O
prenatal	O
and	O
postnatal	O
growth	B-T038
restriction	I-T038
,	O
microcephaly	B-T017
,	O
dysmorphic	B-T017
craniofacial	I-T017
features	I-T017
,	O
broad	B-T033
thumbs	I-T033
and	O
toes	B-T033
,	O
and	O
intellectual	B-T038
disability	I-T038
.	O

We	O
describe	O
the	O
first	O
reported	O
case	O
of	O
a	O
pituitary	B-T038
macroadenoma	I-T038
associated	O
with	O
RSTS	B-T038
.	O

A	O
39	O
-	O
year	O
-	O
old	O
Caucasian	B-T098
female	B-T098
with	O
a	O
past	B-T033
medical	I-T033
history	I-T033
of	O
RSTS	B-T038
diagnosed	B-T033
at	O
age	O
two	O
was	O
found	O
to	O
have	O
a	O
gadolinium	B-T103
-	O
enhancing	O
pituitary	B-T017
mass	I-T017
on	O
magnetic	B-T058
resonance	I-T058
imaging	I-T058
(	O
MRI	B-T058
)	O
of	O
the	O
brain	B-T017
three	O
years	O
ago	O
during	O
workup	O
for	O
migraine	B-T033
-	I-T033
like	I-T033
headaches	I-T033
.	O

Subsequent	O
serial	O
imaging	B-T058
showed	O
radiographic	O
evidence	O
of	O
growth	B-T038
up	O
to	O
11	O
.	O
5	O
x	O
14	O
.	O
0	O
x	O
10	O
.	O
0	O
mm	O
in	O
size	B-T082
.	O

The	O
pituitary	B-T017
sellar	B-T033
lesion	I-T033
was	O
resected	B-T058
through	O
an	O
endoscopic	B-T082
transnasal	B-T082
transsphenoidal	B-T082
approach	I-T082
and	O
was	O
found	O
to	O
be	O
a	O
thyrotroph	B-T038
adenoma	I-T038
.	O

RSTS	B-T038
is	O
a	O
rare	O
,	O
neurodevelopmental	B-T038
genetic	B-T038
disease	I-T038
where	O
most	O
patients	O
with	O
disabilities	O
survive	O
into	O
adulthood	O
.	O

The	O
disorder	B-T038
is	O
associated	O
with	O
an	O
increased	O
predisposition	O
for	O
development	O
of	O
nervous	B-T038
system	I-T038
tumors	I-T038
,	O
including	O
pituitary	B-T038
adenomas	I-T038
.	O

The	O
clinico	O
-	O
radiological	B-T091
paradox	B-T033
of	O
cognitive	B-T038
function	I-T038
and	O
MRI	B-T058
burden	O
of	O
white	B-T017
matter	I-T017
lesions	B-T033
in	O
people	B-T098
with	O
multiple	B-T038
sclerosis	I-T038
:	O
A	O
systematic	B-T170
review	I-T170
and	O
meta	B-T170
-	I-T170
analysis	I-T170

Moderate	O
correlation	O
exists	O
between	O
the	O
imaging	O
quantification	O
of	O
brain	B-T017
white	B-T017
matter	I-T017
lesions	B-T033
and	O
cognitive	O
performance	O
in	O
people	B-T098
with	O
multiple	B-T038
sclerosis	I-T038
(	O
MS	B-T038
)	O
.	O

This	O
may	O
reflect	O
the	O
greater	O
importance	O
of	O
other	O
features	O
,	O
including	O
subvisible	O
pathology	B-T091
,	O
or	O
methodological	O
limitations	O
of	O
the	O
primary	O
literature	B-T170
.	O

To	O
summarise	O
the	O
cognitive	O
clinico	O
-	O
radiological	B-T091
paradox	B-T033
and	O
explore	O
the	O
potential	O
methodological	O
factors	O
that	O
could	O
influence	O
the	O
assessment	O
of	O
this	O
relationship	O
.	O

Systematic	B-T170
review	I-T170
and	O
meta	B-T170
-	I-T170
analysis	I-T170
of	O
primary	O
research	B-T062
relating	O
cognitive	B-T038
function	I-T038
to	O
white	B-T017
matter	I-T017
lesion	B-T033
burden	O
.	O

Fifty	O
papers	O
met	O
eligibility	O
criteria	O
for	O
review	B-T170
,	O
and	O
meta	B-T170
-	I-T170
analysis	I-T170
of	O
overall	O
results	O
was	O
possible	O
in	O
thirty	O
-	O
two	O
(	O
2050	O
participants	B-T098
)	O
.	O

Aggregate	O
correlation	O
between	O
cognition	B-T038
and	O
T2	B-T033
lesion	B-T033
burden	O
was	O
r	O
=	O
-	O
0	O
.	O
30	O
(	O
95	O
%	O
confidence	O
interval	O
:	O
-	O
0	O
.	O
34	O
,	O
-	O
0	O
.	O
26	O
)	O
.	O

Wide	O
methodological	O
variability	O
was	O
seen	O
,	O
particularly	O
related	O
to	O
key	O
factors	O
in	O
the	O
cognitive	O
data	O
capture	O
and	O
image	B-T058
analysis	I-T058
techniques	I-T058
.	O

Resolving	O
the	O
persistent	O
clinico	O
-	O
radiological	B-T091
paradox	B-T033
will	O
likely	O
require	O
simultaneous	O
evaluation	B-T058
of	O
multiple	O
components	O
of	O
the	O
complex	O
pathology	B-T091
using	O
optimum	O
measurement	O
techniques	O
for	O
both	O
cognitive	O
and	O
MRI	B-T058
feature	O
quantification	O
.	O

We	O
recommend	O
a	O
consensus	O
initiative	O
to	O
support	O
common	O
standards	O
for	O
image	B-T058
analysis	I-T058
in	O
MS	B-T038
,	O
enabling	O
benchmarking	O
while	O
also	O
supporting	O
ongoing	O
innovation	B-T170
.	O

Long	B-T103
Non	I-T103
-	I-T103
Coding	I-T103
RNA	I-T103
SNHG6	B-T017
as	O
a	O
Potential	O
Biomarker	B-T103
for	O
Hepatocellular	B-T038
Carcinoma	I-T038

Long	B-T103
Non	I-T103
-	I-T103
coding	I-T103
RNAs	I-T103
(	O
lncRNAs	B-T103
)	O
refer	O
to	O
all	O
non	B-T103
-	I-T103
protein	I-T103
coding	I-T103
transcripts	B-T103
longer	O
than	O
200	O
nucleotides	B-T103
.	O

Their	O
critical	O
roles	O
in	O
different	O
biological	O
pathways	O
have	O
been	O
already	O
well	O
established	O
.	O

Altered	O
expression	B-T038
of	O
lncRNAs	B-T103
can	O
be	O
involved	O
in	O
the	O
cancer	B-T038
initiation	I-T038
and	O
/	O
or	O
progression	B-T038
.	O

Since	O
patients	O
with	O
hepatocellular	B-T038
carcinoma	I-T038
(	O
HCC	B-T038
)	O
are	O
usually	O
diagnosed	B-T033
in	O
late	O
stages	O
,	O
developing	O
diagnostic	B-T058
methods	I-T058
seems	O
to	O
be	O
essential	O
.	O

In	O
this	O
study	B-T062
,	O
the	O
expression	B-T038
levels	O
of	O
different	O
lncRNAs	B-T103
were	O
systematically	O
analysed	B-T062
in	O
different	O
genomic	B-T170
and	O
transcriptome	B-T170
datasets	I-T170
.	O

The	O
analyses	B-T062
showed	O
that	O
SNHG6	B-T017
is	O
among	O
the	O
lncRNAs	B-T103
with	O
distinctive	O
dysregulation	B-T038
of	O
expression	B-T038
and	O
copy	O
number	O
variation	O
in	O
HCC	B-T038
tumors	I-T038
compared	O
with	O
normal	B-T017
tissues	I-T017
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
dysregulation	B-T038
of	O
SNHG6	B-T017
is	O
highly	O
cancer	B-T038
type	O
specific	O
.	O

Through	O
co	O
-	O
occurrence	O
analyses	B-T062
,	O
we	O
found	O
that	O
SNHG6	B-T017
and	O
its	O
related	O
co	B-T038
-	I-T038
expressed	I-T038
genes	B-T017
on	O
8q	B-T082
are	O
involved	O
in	O
the	O
structural	B-T082
integrity	O
of	O
ribosome	B-T017
and	O
translation	B-T038
.	O

This	O
comprehensive	O
in	O
silico	O
analysis	B-T062
,	O
provides	O
a	O
resource	O
for	O
investigating	O
SNHG6	B-T017
in	O
hepatocellular	B-T038
carcinoma	I-T038
and	O
lays	O
the	O
groundwork	O
for	O
design	O
of	O
next	O
researches	B-T062
.	O

Expressional	B-T038
divergence	B-T082
of	O
insect	B-T204
GOX	B-T017
genes	I-T017
:	O
From	O
specialist	O
to	O
generalist	O
glucose	B-T103
oxidase	I-T103

Insect	B-T204
herbivores	I-T204
often	O
secrete	B-T038
glucose	B-T103
oxidase	I-T103
(	O
GOX	B-T103
)	O
onto	O
plants	B-T204
to	O
counteract	O
plant	B-T204
defenses	O
and	O
potential	O
pathogens	O
.	O

Whether	O
generalist	O
herbivores	B-T204
always	O
have	O
significantly	O
higher	O
GOX	B-T103
activities	O
than	O
their	O
specialist	O
counterparts	O
at	O
any	O
comparable	O
stage	O
or	O
conditions	O
and	O
how	O
this	O
is	O
realized	O
remain	O
unknown	O
.	O

To	O
address	O
these	O
two	O
general	O
questions	O
,	O
we	O
subjected	O
larvae	B-T204
of	O
a	O
pair	O
of	O
sister	O
species	B-T170
differed	O
mainly	O
in	O
host	O
range	O
,	O
the	O
generalist	O
Helicoverpa	B-T204
armigera	I-T204
and	O
its	O
specialist	O
counterpart	O
Helicoverpa	B-T204
assulta	I-T204
,	O
to	O
the	O
same	O
sets	O
of	O
stage	O
,	O
protein	B-T103
to	O
digestible	B-T038
carbohydrate	B-T168
(	O
P	O
:	O
C	O
)	O
ratio	O
,	O
allelochemical	B-T103
or	O
host	O
plant	O
treatments	O
for	O
simultaneous	O
analyses	O
of	O
GOX	B-T017
transcripts	B-T103
and	O
activities	O
in	O
their	O
labial	B-T017
glands	I-T017
.	O

GOX	B-T017
activity	O
and	O
transcripts	B-T103
are	O
upregulated	B-T038
concurrently	O
with	O
food	B-T168
ingestion	B-T038
and	O
body	B-T038
growth	I-T038
,	O
downregulated	B-T038
with	O
stopping	O
ingestion	B-T038
and	O
wandering	O
for	O
pupation	B-T038
in	O
both	O
species	B-T170
.	O

The	O
three	O
tested	O
host	O
plants	O
upregulated	B-T038
GOX	B-T017
transcripts	B-T103
,	O
and	O
to	O
a	O
lesser	O
extent	O
,	O
GOX	B-T017
activity	O
in	O
both	O
species	B-T170
.	O

There	O
were	O
significant	O
differences	O
in	O
both	O
GOX	B-T017
transcripts	B-T103
and	O
activity	O
elicited	O
by	O
allelochemicals	B-T103
,	O
but	O
only	O
in	O
GOX	B-T017
transcripts	B-T103
by	O
P	O
:	O
C	O
ratios	O
in	O
both	O
species	B-T170
.	O

GOX	B-T103
activities	O
were	O
higher	O
in	O
H	B-T204
.	I-T204

armigera	I-T204
than	O
H	B-T204
.	I-T204

assulta	I-T204
in	O
all	O
the	O
comparable	O
treatments	O
,	O
but	O
GOX	B-T017
transcripts	B-T103
were	O
significantly	O
higher	O
either	O
in	O
generalists	O
or	O
in	O
specialists	O
,	O
depending	O
on	O
the	O
developmental	O
stages	O
,	O
host	O
plants	O
,	O
P	O
:	O
C	O
ratio	O
and	O
allelochemicals	B-T103
they	O
encounter	O
.	O

These	O
data	O
indicate	O
that	O
the	O
greater	O
GOX	B-T103
activity	O
in	O
generalist	O
herbivores	B-T204
is	O
not	O
achieved	O
by	O
greater	O
transcription	B-T038
rate	O
,	O
but	O
by	O
greater	O
transcript	B-T103
stability	O
,	O
greater	O
translation	B-T038
rate	O
,	O
better	B-T038
enzyme	I-T038
stability	I-T038
and	O
/	O
or	O
their	O
combination	O
.	O

Propranolol	B-T103
Effects	O
on	O
Decompression	B-T038
Sickness	I-T038
in	O
a	O
Simulated	O
DISSUB	O
Rescue	O
in	O
Swine	B-T204

Disabled	O
submarine	O
(	O
DISSUB	O
)	O
survivors	O
may	O
face	O
elevated	B-T033
CO2	I-T033
levels	I-T033
and	O
inert	O
gas	O
saturation	O
,	O
putting	O
them	O
at	O
risk	O
for	O
CO2	B-T103
toxicity	O
and	O
decompression	B-T038
sickness	I-T038
(	O
DCS	B-T038
)	O
.	O

Propranolol	B-T103
was	O
shown	O
to	O
reduce	B-T058
CO2	I-T058
production	I-T058
in	O
an	O
experimental	O
DISSUB	O
model	O
in	O
humans	B-T204
but	O
its	O
effects	O
on	O
DCS	B-T038
in	O
a	O
DISSUB	O
rescue	O
scenario	O
are	O
unknown	O
.	O

A	O
100	O
%	O
oxygen	B-T038
prebreathe	I-T038
(	O
OPB	B-T038
)	O
reduces	O
DCS	B-T038
incidence	O
and	O
severity	O
and	O
is	O
incorporated	O
into	O
some	O
DISSUB	O
rescue	O
protocols	O
.	O

We	O
used	O
a	O
swine	B-T204
model	I-T204
of	O
DISSUB	O
rescue	O
to	O
study	O
the	O
effect	O
of	O
propranolol	B-T103
on	O
DCS	B-T038
incidence	O
and	O
mortality	O
with	O
and	O
without	O
an	O
OPB	B-T038
.	O

In	O
Experiment	O
1	O
,	O
male	O
Yorkshire	B-T204
Swine	I-T204
(	O
70	O
kg	O
)	O
were	O
pressurized	O
to	O
2	O
.	O
8	O
ATA	O
for	O
22	O
h	O
.	O

Propranolol	B-T103
1	O
.	O
0	O
mg	O
·	O
kg	O
-	O
1	O
(	O
IV	O
)	O
was	O
administered	O
at	O
21	O
.	O
25	O
h	O
.	O

At	O
22	O
h	O
,	O
the	O
animal	B-T204
was	O
rapidly	O
decompressed	O
and	O
observed	O
for	O
DCS	B-T038
type	O
,	O
onset	O
time	O
,	O
and	O
mortality	O
.	O

Experimental	O
animals	B-T204
(	O
N	O
=	O
21	O
;	O
69	O
±	O
4	O
.	O
1	O
kg	O
)	O
,	O
PROP1	B-T103
.	I-T103
0	I-T103
,	O
were	O
compared	O
to	O
PROP1	B-T103
.	I-T103
0	I-T103
-	O
OPB45	B-T038
(	O
N	O
=	O
8	O
;	O
69	O
±	O
2	O
.	O
8	O
kg	O
)	O
with	O
the	O
same	O
dive	O
profile	O
,	O
except	O
for	O
a	O
45	O
min	O
OPB	B-T038
prior	O
to	O
decompression	O
.	O

In	O
Experiment	O
2	O
,	O
the	O
same	O
methodology	O
was	O
used	O
with	O
the	O
following	O
changes	O
:	O
swine	B-T204
pressurized	O
to	O
2	O
.	O
8	O
ATA	O
for	O
28	O
h	O
;	O
experimental	O
group	O
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3	O
.	O
3	O
kg	O
)	O
,	O
PROP0	B-T103
.	I-T103
5	I-T103
bis	O
,	O
propranolol	B-T103
0	O
.	O
5	O
mg	O
·	O
kg	O
-	O
1	O
bis	O
(	O
twice	O
)	O
(	O
IV	O
)	O
was	O
administered	O
at	O
22	O
h	O
and	O
26	O
h	O
.	O

Control	B-T204
animals	I-T204
(	O
N	O
=	O
25	O
;	O
67	O
±	O
3	O
.	O
9	O
kg	O
)	O
received	O
normal	B-T103
saline	I-T103
.	O

OPB	B-T038
reduced	O
mortality	O
in	O
PROP1	B-T103
.	I-T103
0	I-T103
-	O
OBP45	B-T038
compared	O
to	O
PROP1	B-T103
.	I-T103
0	I-T103
(	O
0	O
%	O
vs	O
.	O

71	O
%	O
)	O
.	O

PROP0	B-T103
.	I-T103
5	I-T103
bis	O
had	O
increased	O
mortality	O
compared	O
to	O
CONTROL	O
(	O
60	O
-	O
%	O
vs	O
.	O

4	O
%	O
)	O
.	O

Administration	O
of	O
beta	B-T103
blockers	I-T103
prior	O
to	O
saturation	O
decompression	O
appears	O
to	O
increase	O
DCS	B-T038
and	O
worsen	O
mortality	O
in	O
a	O
swine	B-T204
model	O
;	O
however	O
,	O
their	O
effects	O
in	O
bounce	O
diving	O
remain	O
unknown	O
.	O
Forbes	O
AS	O
,	O
Regis	O
DP	O
,	O
HallAA	O
,	O
Mahon	O
RT	O
,	O
Cronin	O
WA	O
.	O

Propranolol	O
effects	O
on	O
decompression	O
sickness	O
in	O
a	O
simulated	O
DISSUB	O
rescue	O
in	O
swine	O
.	O

Aerosp	O
Med	O
Hum	O
Perform	O
.	O

2017	O
;	O
88	O
(	O
4	O
)	O
:	O
385	O
-	O
391	O
.	O

Gut	O
microbiota	O
-	O
mediated	O
protection	O
against	O
diarrheal	B-T033
infections	B-T038

The	O
mammalian	B-T204
gut	O
microbiota	O
is	O
a	O
highly	O
abundant	O
and	O
diverse	O
microbial	O
community	O
that	O
resides	O
in	O
the	O
gastrointestinal	B-T022
tract	I-T022
.	O

One	O
major	O
benefit	O
that	O
the	O
gut	O
microbiota	O
provides	O
to	O
its	O
host	O
is	O
colonization	B-T033
resistance	O
-	O
the	O
ability	O
to	O
prevent	O
colonization	B-T033
by	O
foreign	O
microbes	O
,	O
including	O
diarrheal	B-T033
pathogens	O
such	O
as	O
Clostridium	B-T007
difficile	I-T007
,	O
Salmonella	B-T007
enterica	I-T007
serovar	I-T007
Typhimurium	I-T007
and	O
diarrheagenic	B-T007
Escherichia	I-T007
coli	I-T007
.	O

We	O
conducted	O
a	O
literature	B-T170
review	I-T170
of	O
the	O
effects	O
of	O
the	O
gut	O
microbiota	O
on	O
infection	B-T038
by	O
diarrheal	B-T033
pathogens	O
.	O

We	O
used	O
PubMed	B-T170
to	O
search	O
for	O
relevant	O
articles	B-T170
published	O
before	O
July	O
2016	O
,	O
as	O
well	O
as	O
incorporated	O
data	O
from	O
our	O
laboratory	B-T092
.	O

The	O
gut	O
microbiota	O
provides	O
protection	O
from	O
diarrheal	B-T033
infections	B-T038
both	O
by	O
direct	O
inhibition	O
of	O
pathogens	O
and	O
by	O
indirect	O
effects	O
on	O
host	O
functions	O
.	O

Direct	O
effects	O
of	O
the	O
microbiota	O
on	O
diarrheal	B-T033
pathogens	O
include	O
competing	O
for	O
nutrients	B-T168
and	O
producing	O
metabolites	B-T103
that	O
inhibit	O
pathogen	O
growth	B-T038
or	O
virulence	B-T038
.	O

Indirect	O
effects	O
of	O
the	O
gut	O
microbiota	O
include	O
promoting	O
maintenance	O
of	O
the	O
gut	B-T038
mucosal	I-T038
barrier	I-T038
and	O
stimulating	O
innate	O
and	O
adaptive	B-T038
immunity	I-T038
.	O

Human	B-T204
epidemiological	B-T062
studies	I-T062
and	O
experimental	O
infections	B-T038
of	O
laboratory	B-T204
animals	I-T204
both	O
demonstrate	O
that	O
antibiotic	B-T058
treatment	I-T058
can	O
alter	O
the	O
gut	O
microbial	O
community	O
and	O
thereby	O
reduce	O
colonization	B-T033
resistance	O
against	O
diarrheal	B-T033
pathogens	O
.	O

Further	O
research	B-T062
might	O
lead	O
to	O
the	O
development	O
of	O
next	B-T007
-	I-T007
generation	I-T007
probiotics	I-T007
that	O
could	O
be	O
used	O
to	O
bolster	O
colonization	B-T033
resistance	O
and	O
thus	O
prevent	O
travellers	B-T038
'	I-T038
diarrheal	I-T038
.	O

Ecotoxicity	B-T037
testing	O
and	O
environmental	B-T058
risk	I-T058
assessment	I-T058
of	O
iron	B-T103
nanomaterials	O
for	O
sub	O
-	O
surface	O
remediation	O
-	O
Recommendations	O
from	O
the	O
FP7	O
project	O
NanoRem	O

Nanoremediation	O
with	O
iron	B-T103
(	O
Fe	B-T103
)	O
nanomaterials	O
opens	O
new	O
doors	O
for	O
treating	O
contaminated	O
soil	O
and	O
groundwater	B-T103
,	O
but	O
is	O
also	O
accompanied	O
by	O
new	O
potential	O
risks	O
as	O
large	O
quantities	O
of	O
engineered	O
nanomaterials	O
are	O
introduced	O
into	O
the	O
environment	B-T082
.	O

In	O
this	O
study	B-T062
,	O
we	O
have	O
assessed	O
the	O
ecotoxicity	B-T037
of	O
four	O
engineered	O
Fe	B-T103
nanomaterials	O
,	O
specifically	O
,	O
Nano	B-T103
-	I-T103
Goethite	I-T103
,	O
Trap	B-T103
-	I-T103
Ox	I-T103
Fe	I-T103
-	I-T103
zeolites	I-T103
,	O
Carbo	B-T103
-	I-T103
Iron	I-T103
(	O
®	O
)	O
and	O
FerMEG12	B-T103
,	O
developed	O
within	O
the	O
European	O
FP7	O
project	O
NanoRem	O
for	O
sub	O
-	O
surface	O
remediation	O
towards	O
a	O
test	B-T058
battery	I-T058
consisting	O
of	O
eight	O
ecotoxicity	B-T037
tests	B-T058
on	O
bacteria	B-T007
(	O
V	B-T007
.	I-T007

fisheri	I-T007
,	O
E	B-T007
.	I-T007

coli	I-T007
)	O
,	O
algae	B-T204
(	O
P	B-T204
.	I-T204

subcapitata	I-T204
,	O
Chlamydomonas	B-T204
sp	I-T204
.	I-T204
)	O
,	O
crustaceans	B-T204
(	O
D	B-T204
.	I-T204

magna	I-T204
)	O
,	O
worms	B-T204
(	O
E	B-T204
.	I-T204

fetida	I-T204
,	O
L	B-T204
.	I-T204

variegatus	I-T204
)	O
and	O
plants	B-T204
(	O
R	B-T204
.	I-T204

sativus	I-T204
,	O
L	B-T204
.	I-T204

multiflorum	I-T204
)	O
.	O

The	O
tested	O
materials	O
are	O
commercially	O
available	O
and	O
include	O
Fe	B-T103
oxide	I-T103
and	O
nanoscale	B-T103
zero	I-T103
valent	I-T103
iron	I-T103
(	O
nZVI	B-T103
)	O
,	O
but	O
also	O
hybrid	O
products	O
with	O
Fe	B-T103
loaded	O
into	O
a	O
matrix	B-T082
.	O

All	O
but	O
one	O
material	O
,	O
a	O
ball	B-T103
milled	I-T103
nZVI	I-T103
(	O
FerMEG12	B-T103
)	O
,	O
showed	O
no	B-T033
toxicity	I-T033
in	O
the	O
test	B-T058
battery	I-T058
when	O
tested	O
in	O
concentrations	O
up	O
to	O
100	O
mg	O
/	O
L	O
,	O
which	O
is	O
the	O
cutoff	O
for	O
hazard	O
labeling	O
in	O
chemicals	O
regulation	O
in	O
Europe	B-T082
.	O

However	O
it	O
should	O
be	O
noted	O
that	O
Fe	B-T103
nanomaterials	O
proved	O
challenging	O
to	O
test	O
adequately	O
due	O
to	O
their	O
turbidity	O
,	O
aggregation	O
and	O
sedimentation	O
behavior	O
in	O
aqueous	O
media	O
.	O

This	O
paper	O
provides	O
a	O
number	O
of	O
recommendations	O
concerning	O
future	O
testing	O
of	O
Fe	B-T103
nanomaterials	O
and	O
discusses	O
environmental	B-T058
risk	I-T058
assessment	I-T058
considerations	O
related	O
to	O
these	O
.	O

Grade	B-T170
Group	I-T170
Underestimation	B-T033
in	O
Prostate	B-T058
Biopsy	I-T058
:	O
Predictive	B-T170
Factors	I-T170
and	O
Outcomes	B-T033
in	O
Candidates	B-T098
for	O
Active	B-T058
Surveillance	I-T058

We	O
intended	O
to	O
analyze	O
the	O
outcomes	B-T033
and	O
predictive	B-T170
factors	I-T170
for	O
underestimating	O
the	O
prostate	B-T038
cancer	I-T038
(	O
PCa	B-T038
)	O
grade	B-T170
group	I-T170
(	O
GG	B-T170
)	O
from	O
prostate	B-T058
biopsies	I-T058
in	O
a	O
large	O
monocentric	B-T098
cohort	I-T098
of	O
patients	O
treated	O
by	O
minimally	B-T058
invasive	I-T058
radical	I-T058
prostatectomy	I-T058
(	O
RP	B-T058
)	O
.	O

Using	O
a	O
monocentric	B-T170
prospectively	I-T170
maintained	I-T170
database	I-T170
,	O
we	O
included	O
3062	O
patients	O
who	O
underwent	O
minimally	B-T058
invasive	I-T058
RP	I-T058
between	O
2006	O
and	O
2013	O
.	O

We	O
explored	O
clinicopathologic	O
features	O
and	O
outcomes	B-T033
associated	O
with	O
a	O
GG	B-T170
upgrade	O
from	O
biopsy	B-T058
to	O
RP	B-T058
.	O

Multivariate	B-T062
logistic	I-T062
regression	I-T062
was	O
used	O
to	O
develop	O
and	O
validate	O
a	O
nomogram	B-T170
to	O
predict	O
upgrading	O
for	O
GG1	B-T170
.	O

Biopsy	B-T058
GG	B-T170
was	O
upgraded	O
after	O
RP	B-T058
in	O
51	O
.	O
5	O
%	O
of	O
cases	O
.	O

Patients	O
upgraded	O
from	O
GG1	B-T170
to	O
GG2	B-T170
or	O
GG3	B-T170
after	O
RP	B-T058
had	O
a	O
longer	O
time	O
to	O
biochemical	B-T033
recurrence	I-T033
than	O
those	O
with	O
GG2	B-T170
or	O
GG3	B-T170
respectively	O
,	O
on	O
both	O
biopsy	B-T058
and	O
RP	B-T058
,	O
but	O
a	O
shorter	O
time	O
to	O
biochemical	B-T033
recurrence	I-T033
than	O
those	O
who	O
remained	O
GG1	B-T170
after	O
RP	O
(	O
P	O
<	O
.	O
0001	O
)	O
.	O

In	O
multivariate	O
analyses	O
,	O
variables	O
predicting	O
upgrading	O
for	O
GG1	B-T170
PCa	B-T038
were	O
age	O
(	O
P	O
=	O
.	O
0014	O
)	O
,	O
abnormal	B-T058
digital	I-T058
rectal	I-T058
examination	I-T058
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
prostate	B-T033
-	I-T033
specific	I-T033
antigen	I-T033
density	I-T033
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
percentage	B-T033
of	I-T033
positive	I-T033
cores	I-T033
(	O
P	O
<	O
.	O
0001	O
)	O
,	O
and	O
body	B-T170
mass	I-T170
index	I-T170
(	O
P	O
=	O
.	O
037	O
)	O
.	O

A	O
nomogram	B-T170
was	O
generated	O
and	O
validated	O
internally	O
.	O

Biopsy	B-T058
grading	B-T058
system	I-T058
is	O
misleading	O
in	O
approximately	O
50	O
%	O
of	O
cases	O
.	O

Upgrading	O
GG	B-T170
from	O
biopsy	B-T058
to	O
RP	B-T058
may	O
have	O
consequences	O
on	O
clinical	B-T033
outcomes	I-T033
.	O

A	O
nomogram	B-T170
using	O
clinicopathologic	O
features	O
could	O
aid	O
the	O
probability	O
of	O
needing	O
to	O
upgrade	O
GG1	B-T170
patients	O
at	O
their	O
initial	O
evaluation	B-T058
.	O

Characterization	O
of	O
electrocorticogram	B-T058
high	O
-	O
gamma	O
signal	O
in	O
response	O
to	O
varying	O
upper	B-T017
extremity	I-T017
movement	B-T038
velocity	O

The	O
mechanism	O
by	O
which	O
the	O
human	B-T204
primary	B-T082
motor	I-T082
cortex	I-T082
(	O
M1	B-T082
)	O
encodes	O
upper	B-T017
extremity	I-T017
movement	B-T038
kinematics	B-T091
is	O
not	O
fully	O
understood	O
.	O

For	O
example	O
,	O
human	B-T204
electrocorticogram	B-T058
(	O
ECoG	B-T058
)	O
signals	O
have	O
been	O
shown	O
to	O
modulate	B-T082
with	O
upper	B-T017
extremity	I-T017
movement	B-T038
s	O
;	O
however	O
,	O
this	O
relationship	O
has	O
not	O
been	O
explicitly	O
characterized	O
.	O

To	O
address	O
this	O
issue	B-T033
,	O
we	O
recorded	O
high	O
-	O
density	O
ECoG	B-T058
signals	O
from	O
patients	O
undergoing	O
epilepsy	B-T038
surgery	B-T058
evaluation	B-T058
as	O
they	O
performed	O
elementary	O
upper	B-T017
extremity	I-T017
movements	B-T038
while	O
systematically	O
varying	O
movement	B-T038
speed	O
and	O
duration	O
.	O

Specifically	O
,	O
subjects	O
performed	O
intermittent	O
pincer	B-T033
grasp	I-T033
/	O
release	O
,	O
elbow	O
flexion	O
/	O
extension	O
,	O
and	O
shoulder	B-T033
flexion	I-T033
/	O
extension	O
at	O
slow	O
,	O
moderate	O
,	O
and	O
fast	O
speeds	O
.	O

In	O
all	O
movements	B-T038
,	O
bursts	O
of	O
power	O
in	O
the	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
band	O
(	O
80	O
-	O
160	O
Hz	O
)	O
were	O
observed	O
in	O
M1	B-T082
.	O

In	O
addition	O
,	O
the	O
amplitude	B-T082
of	O
these	O
power	O
bursts	O
and	O
the	O
area	B-T082
of	O
M1	B-T082
with	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
were	O
directly	O
proportional	O
to	O
the	O
movement	B-T038
speed	O
.	O

Likewise	O
,	O
the	O
duration	O
of	O
elevated	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
increased	O
with	O
movement	B-T038
duration	O
.	O

Based	O
on	O
linear	O
regression	O
,	O
M1	B-T082
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
power	O
amplitude	B-T082
and	O
duration	O
covaried	O
with	O
movement	B-T038
speed	O
and	O
duration	O
,	O
respectively	O
,	O
with	O
an	O
average	O
[	O
Formula	O
:	O
see	O
text	O
]	O
of	O
[	O
Formula	O
:	O
see	O
text	O
]	O
and	O
[	O
Formula	O
:	O
see	O
text	O
]	O
.	O

These	O
findings	B-T033
indicate	O
that	O
the	O
encoding	O
of	O
upper	B-T017
extremity	I-T017
movement	B-T038
speed	O
by	O
M1	B-T082
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
is	O
primarily	O
linear	B-T082
.	O

Also	O
,	O
the	O
fact	O
that	O
this	O
activity	O
remained	O
elevated	O
throughout	O
a	O
movement	B-T038
suggests	O
that	O
M1	B-T082
does	O
not	O
merely	O
generate	O
transient	O
instructions	B-T170
for	O
a	O
specific	O
movement	B-T038
duration	O
,	O
but	O
instead	O
is	O
responsible	O
for	O
the	O
entirety	O
of	O
the	O
movement	B-T038
.	O

Finally	O
,	O
the	O
spatial	B-T082
distribution	I-T082
of	O
high	O
-	O
[	O
Formula	O
:	O
see	O
text	O
]	O
activity	O
suggests	O
the	O
presence	B-T033
of	O
a	O
recruitment	O
phenomenon	O
in	O
which	O
higher	O
speeds	O
or	O
increased	O
muscle	B-T017
activity	O
involve	O
activation	O
of	O
larger	O
M1	B-T082
area	B-T082
s	O
.	O

Fatty	B-T103
Acids	I-T103
Have	O
Different	O
Adipogenic	B-T038
Differentiation	I-T038
Potentials	O
in	O
Stromal	B-T017
Vascular	I-T017
Cells	I-T017
Isolated	O
from	O
Abdominal	B-T017
Fat	I-T017
in	O
Laying	B-T038
Hens	B-T204

This	O
study	B-T062
was	O
conducted	O
to	O
examine	O
the	O
effects	O
of	O
fatty	B-T103
acids	I-T103
(	O
FA	B-T103
)	O
with	O
/	O
without	O
chicken	O
serum	O
(	O
CS	O
)	O
on	O
the	O
expression	B-T038
of	O
adipogenic	B-T038
transcripts	B-T103
and	O
adipogenesis	B-T038
in	O
chicken	B-T204
stromal	B-T017
vascular	I-T017
cells	I-T017
(	O
SVC	B-T017
)	O
.	O

In	O
experiment	O
1	O
,	O
SVC	B-T017
were	O
grown	O
in	O
DMEM	B-T103
containing	O
10	O
%	O
FBS	B-T103
(	O
Control	O
)	O
and	O
treated	O
with	O
300	O
µM	O
oleic	B-T103
acid	I-T103
(	O
OLA	B-T103
)	O
+	O
FBS	B-T103
,	O
linoleic	B-T103
acid	I-T103
(	O
LNA	B-T103
)	O
+	O
FBS	B-T103
,	O
palmitic	B-T103
acid	I-T103
(	O
PAM	B-T103
)	O
+	O
FBS	B-T103
,	O
or	O
stearic	B-T103
acid	I-T103
(	O
STA	B-T103
)	O
+	O
FBS	B-T103
for	O
48	O
h	O
.	O

In	O
experiment	O
2	O
,	O
cells	B-T017
were	O
grown	O
in	O
DMEM	B-T103
containing	O
5	O
%	O
CS	O
and	O
treated	O
with	O
300	O
µM	O
OLA	B-T103
(	O
CS	O
+	O
OLA	B-T103
)	O
,	O
PAM	B-T103
(	O
CS	O
+	O
PAM	B-T103
)	O
,	O
STA	B-T103
(	O
CS	O
+	O
STA	B-T103
)	O
or	O
200	O
µM	O
LNA	B-T103
(	O
CS	O
+	O
LNA	B-T103
)	O
for	O
48	O
h	O
.	O

Adipogenesis	B-T038
was	O
determined	O
using	O
Oil	B-T058
Red	I-T058
O	I-T058
staining	I-T058
and	O
glycerol	B-T038
-	I-T038
3	I-T038
-	I-T038
phosphate	I-T038
dehydrogenase	I-T038
(	I-T038
GPDH	I-T038
)	I-T038
activity	I-T038
.	O

The	O
proportion	O
of	O
OLA	B-T103
,	O
PAM	B-T103
,	O
or	O
STA	B-T103
was	O
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
SVC	B-T017
grown	O
in	O
either	O
FBS	B-T103
or	O
CS	O
with	O
OLA	B-T103
,	O
PAM	B-T103
or	O
STA	B-T103
.	O

Adipogenesis	B-T038
was	O
induced	O
in	O
FBS	B-T103
+	O
OLA	B-T103
,	O
FBS	B-T103
+	O
LNA	B-T103
,	O
FBS	B-T103
+	O
PAM	B-T103
,	O
FBS	B-T103
+	O
STA	B-T103
,	O
CS	O
+	O
OLA	B-T103
,	O
CS	O
+	O
LNA	B-T103
,	O
CS	O
+	O
PAM	B-T103
,	O
or	O
CS	O
+	O
STA	B-T103
compared	O
to	O
FBS	B-T103
.	O

GPDH	B-T038
activity	I-T038
was	O
significantly	O
higher	O
in	O
FBS	B-T103
+	O
OLA	B-T103
and	O
FBS	B-T103
+	O
LNA	B-T103
than	O
one	O
in	O
FBS	B-T103
.	O

Compared	O
to	O
FBS	B-T103
,	O
the	O
expression	B-T038
of	O
FABP4	B-T017
mRNA	B-T103
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
FBS	B-T103
+	O
OLA	B-T103
,	O
FBS	B-T103
+	O
LNA	B-T103
,	O
or	O
FBS	B-T103
+	O
PAM	B-T103
,	O
whereas	O
that	O
of	O
C	B-T017
/	I-T017
EBPα	I-T017
,	O
C	B-T017
/	I-T017
EBPβ	I-T017
,	O
and	O
ATGL	B-T017
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
FBS	B-T103
+	O
OLA	B-T103
or	O
FBS	B-T103
+	O
LNA	B-T103
cells	B-T017
.	O

Expression	B-T038
of	O
FABP4	B-T017
and	O
C	B-T017
/	I-T017
EBPβ	I-T017
mRNA	B-T103
was	O
higher	O
in	O
CS	O
,	O
CS	O
+	O
OLA	B-T103
,	O
CS	O
+	O
LNA	B-T103
,	O
CS	O
+	O
PAM	B-T103
,	O
or	O
CS	O
+	O
STA	B-T103
compared	O
with	O
(	O
FBS	B-T103
,	O
whereas	O
the	O
expression	B-T038
of	O
ATGL	B-T017
and	O
C	B-T017
/	I-T017
EBPα	I-T017
was	O
higher	O
in	O
CS	O
,	O
CS	O
+	O
OLA	B-T103
,	O
or	O
CS	O
+	O
LNA	B-T103
than	O
FBS	B-T103
cells	B-T017
.	O

In	O
conclusion	O
,	O
these	O
results	B-T033
showed	O
that	O
FA	B-T103
have	O
different	O
potentials	O
to	O
induce	O
adipogenesis	B-T038
,	O
LNA	B-T103
is	O
the	O
most	O
potent	O
among	O
the	O
tested	O
FA	B-T103
,	O
and	O
these	O
potentials	O
can	O
be	O
improved	O
in	O
the	O
presence	B-T033
of	O
CS	O
.	O

A	O
novel	O
rapid	O
analysis	B-T062
using	O
mass	B-T058
spectrometry	I-T058
to	O
evaluate	O
downstream	B-T082
refolding	B-T038
of	O
recombinant	B-T103
human	I-T103
insulin	I-T103
-	I-T103
like	I-T103
growth	I-T103
factor	I-T103
-	I-T103
1	I-T103
(	O
mecasermin	B-T103
)	O

Mecasermin	B-T103
is	O
used	O
to	O
treat	O
elevated	B-T038
blood	I-T038
sugar	I-T038
as	O
well	O
as	O
growth	B-T103
hormone	I-T103
-	O
resistant	O
Laron	B-T038
-	I-T038
type	I-T038
dwarfism	I-T038
.	O

Mecasermin	B-T103
isolated	O
from	O
inclusion	B-T017
bodies	I-T017
in	O
extracts	O
of	O
E	B-T007
.	I-T007
coli	I-T007
must	O
be	O
refolded	O
to	O
acquire	O
sufficient	O
activity	O
.	O

However	O
,	O
there	O
is	O
no	O
rapid	O
analytical	O
method	O
for	O
monitoring	O
refolding	B-T038
during	O
the	O
purification	B-T058
process	O
.	O

We	O
prepared	O
mecasermin	B-T103
drug	B-T103
product	I-T103
,	O
in	O
-	O
process	O
samples	O
during	O
the	O
oxidation	B-T038
of	O
mecasermin	B-T103
,	O
forced	O
-	O
reduced	O
mecasermin	B-T103
,	O
and	O
aerially	O
oxidized	O
mecasermin	B-T103
after	O
forced	O
reduction	O
.	O

Desalted	O
mecasermin	B-T103
samples	O
were	O
analyzed	O
using	O
MALDI	B-T058
-	I-T058
ISD	I-T058
.	O

The	O
peak	O
intensity	O
ratio	O
of	O
product	O
to	O
precursor	O
ion	O
was	O
determined	O
.	O

The	O
charge	O
state	O
distribution	O
(	O
CSD	O
)	O
of	O
mecasermin	B-T103
ions	O
was	O
evaluated	O
using	O
ESI	B-T058
-	I-T058
MS	I-T058
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-T058
.	O

The	O
drift	O
time	O
and	O
collision	O
cross	O
-	O
sectional	O
areas	O
(	O
CCS	O
)	O
of	O
mecasermin	B-T103
ions	O
were	O
evaluated	O
using	O
ESI	B-T058
-	I-T058
IMS	I-T058
-	I-T058
MS	I-T058
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-T058
.	O

MALDI	B-T058
-	I-T058
ISD	I-T058
data	O
,	O
CSD	O
values	O
determined	O
using	O
ESI	B-T058
-	I-T058
MS	I-T058
,	O
and	O
the	O
CCS	O
acquired	O
using	O
ESI	B-T058
-	I-T058
IMS	I-T058
-	I-T058
MS	I-T058
revealed	O
the	O
relationship	O
between	O
the	O
folded	B-T082
and	O
unfolded	O
proteoforms	B-T103
of	O
forced	O
-	O
reduced	O
mecasermin	B-T103
and	O
aerially	O
oxidized	O
mecasermin	B-T103
with	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	B-T103
drug	B-T103
product	I-T103
.	O

The	O
collision	O
cross	O
-	O
sectional	O
area	O
,	O
which	O
is	O
determined	O
using	O
ESI	B-T058
-	I-T058
IMS	I-T058
-	I-T058
MS	I-T058
,	O
provided	O
proteoform	B-T103
information	O
through	O
rapid	O
monitoring	O
(	O
<	O
2	O
min	O
)	O
of	O
in	O
-	O
process	O
samples	O
during	O
the	O
manufacture	O
of	O
mecasermin	B-T103
.	O

ESI	B-T058
-	I-T058
IMS	I-T058
-	I-T058
MS	I-T058
coupled	O
with	O
SEC	O
-	O
mode	O
HPLC	B-T058
is	O
a	O
rapid	O
and	O
robust	O
method	O
for	O
analyzing	O
the	O
free	O
-	O
SH	O
:	O
protein	O
ratio	O
of	O
mecasermin	B-T103
that	O
allows	O
evaluating	O
and	O
monitoring	O
proteoform	B-T103
changes	O
during	O
the	O
oxidation	B-T038
of	O
mecasermin	B-T103
.	O

ESI	B-T058
-	I-T058
IMS	I-T058
-	I-T058
MS	I-T058
is	O
applicable	O
as	O
a	O
process	O
analytical	O
technology	O
tool	O
for	O
identifying	O
the	O
"	O
critical	O
quality	O
attributes	O
"	O
and	O
implementing	O
"	O
quality	O
by	O
design	O
"	O
for	O
manufacturing	O
mecasermin	B-T103
.	O

Regulated	B-T038
Intron	B-T103
Removal	O
Integrates	O
Motivational	O
State	O
and	O
Experience	B-T038

Myriad	O
experiences	B-T038
produce	O
transient	B-T038
memory	I-T038
,	O
yet	O
,	O
contingent	O
on	O
the	O
internal	B-T038
state	I-T038
of	O
the	O
organism	O
and	O
the	O
saliency	O
of	O
the	O
experience	B-T038
,	O
only	O
some	O
memories	B-T038
persist	O
over	O
time	O
.	O

How	O
experience	B-T038
and	O
internal	B-T038
state	I-T038
influence	O
the	O
duration	O
of	O
memory	B-T038
at	O
the	O
molecular	O
level	O
remains	O
unknown	O
.	O

A	O
self	O
-	O
assembled	O
aggregated	O
state	O
of	O
Drosophila	B-T103
Orb2A	I-T103
protein	I-T103
is	O
required	O
specifically	O
for	O
long	B-T038
-	I-T038
lasting	I-T038
memory	I-T038
.	O

We	O
report	O
that	O
in	O
the	O
adult	O
fly	O
brain	B-T017
the	O
mRNA	B-T103
encoding	O
Orb2A	B-T103
protein	I-T103
exists	O
in	O
an	O
unspliced	B-T103
non	I-T103
-	I-T103
protein	I-T103
-	I-T103
coding	I-T103
form	I-T103
.	O

The	O
convergence	O
of	O
experience	B-T038
and	O
internal	B-T038
drive	I-T038
transiently	O
increases	O
the	O
spliced	B-T103
protein	I-T103
-	I-T103
coding	I-T103
Orb2A	I-T103
mRNA	I-T103
.	O

A	O
screen	O
identified	O
pasilla	B-T103
,	O
the	O
fly	O
ortholog	O
of	O
mammalian	B-T204
Nova	B-T103
-	I-T103
1	I-T103
/	O
2	B-T103
,	O
as	O
a	O
mediator	B-T103
of	O
Orb2A	B-T103
mRNA	I-T103
processing	B-T038
.	O

A	O
single	B-T103
-	I-T103
nucleotide	I-T103
substitution	O
in	O
the	O
intronic	B-T103
region	O
that	O
reduces	O
Pasilla	B-T103
binding	B-T038
and	O
intron	B-T103
removal	O
selectively	O
impairs	O
long	B-T038
-	I-T038
term	I-T038
memory	I-T038
.	O

We	O
posit	O
that	O
pasilla	B-T103
-	O
mediated	O
processing	B-T038
of	O
unspliced	B-T103
Orb2A	I-T103
mRNA	I-T103
integrates	O
experience	B-T038
and	O
internal	B-T038
state	I-T038
to	O
control	O
Orb2A	B-T103
protein	I-T103
abundance	O
and	O
long	B-T038
-	I-T038
term	I-T038
memory	I-T038
formation	O
.	O

The	O
FLASHE	B-T170
Study	I-T170
:	O
Survey	B-T170
Development	O
,	O
Dyadic	O
Perspectives	O
,	O
and	O
Participant	B-T098
Characteristics	O

The	O
National	B-T092
Cancer	I-T092
Institute	I-T092
developed	O
the	O
Family	O
Life	O
,	O
Activity	O
,	O
Sun	O
,	O
Health	O
,	O
and	O
Eating	B-T038
(	O
FLASHE	B-T170
)	O
Study	B-T170
to	O
examine	O
multiple	O
cancer	B-T058
preventive	I-T058
behaviors	O
within	O
parent	O
-	O
adolescent	O
dyads	O
.	O

The	O
purpose	O
of	O
creating	O
FLASHE	B-T170
was	O
to	O
enable	O
the	O
examination	O
of	O
physical	O
activity	O
,	O
diet	B-T168
,	O
and	O
other	O
cancer	B-T058
preventive	I-T058
behaviors	I-T058
and	O
potential	O
correlates	O
among	O
parent	O
-	O
adolescent	O
dyads	O
.	O

FLASHE	B-T170
surveys	I-T170
were	O
developed	O
from	O
a	O
process	O
involving	O
literature	B-T170
reviews	I-T170
,	O
scientific	O
input	O
from	O
experts	B-T097
in	O
the	O
field	O
,	O
cognitive	B-T058
testing	I-T058
,	O
and	O
usability	O
testing	O
.	O

This	O
cross	B-T062
-	I-T062
sectional	I-T062
,	O
web	B-T062
-	I-T062
based	I-T062
study	I-T062
of	O
parents	O
and	O
their	O
adolescent	O
children	O
(	O
aged	O
12	O
-	O
17	O
years	O
)	O
was	O
administered	O
between	O
April	O
and	O
October	O
2014	O
.	O

The	O
nationwide	O
sample	O
consisted	O
of	O
1	O
,	O
573	O
parent	O
-	O
adolescent	O
dyads	O
(	O
1	O
,	O
699	O
parents	O
and	O
1	O
,	O
581	O
adolescents	O
)	O
who	O
returned	O
all	O
FLASHE	B-T170
surveys	I-T170
.	O

FLASHE	B-T170
assessed	O
parent	O
and	O
adolescent	O
reports	O
of	O
several	O
intrapersonal	O
and	O
interpersonal	O
domains	O
(	O
including	O
psychosocial	O
variables	O
,	O
parenting	O
,	O
and	O
the	O
community	O
and	O
home	B-T082
environments	I-T082
)	O
.	O

On	O
a	O
subset	O
of	O
example	O
FLASHE	B-T170
items	O
across	O
these	O
domains	O
,	O
responses	O
of	O
parents	O
and	O
adolescents	O
within	O
the	O
same	O
dyads	O
were	O
positively	O
and	O
significantly	O
correlated	O
(	O
r	O
=	O
0	O
.	O
32	O
-	O
0	O
.	O
63	O
)	O
.	O

Analyses	O
were	O
run	O
in	O
2015	O
-	O
2016	O
.	O

FLASHE	B-T170
data	O
present	O
multiple	O
opportunities	O
for	O
studying	O
research	O
questions	O
among	O
individuals	B-T098
or	O
dyads	O
,	O
including	O
the	O
ability	O
to	O
examine	O
similarity	O
between	O
parents	O
and	O
adolescents	O
on	O
many	O
constructs	O
relevant	O
to	O
cancer	B-T058
preventive	I-T058
behaviors	I-T058
.	O

FLASHE	B-T170
data	O
are	O
publicly	O
available	O
for	O
researchers	B-T097
and	O
practitioners	B-T097
to	O
help	O
advance	O
research	B-T062
on	O
cancer	B-T058
preventive	I-T058
health	O
behaviors	O
.	O

Sex	O
differences	O
in	O
the	O
effect	O
of	O
chronic	O
mild	O
stress	O
on	O
mouse	B-T204
prefrontal	B-T017
cortical	I-T017
BDNF	B-T103
levels	O
:	O
A	O
role	O
of	O
major	O
ovarian	B-T103
hormones	I-T103

Depression	B-T038
induced	O
by	O
stress	B-T033
is	O
affected	O
by	O
sex	O
,	O
age	O
and	O
hormonal	O
status	O
of	O
the	O
animal	B-T204
and	O
also	O
by	O
duration	O
and	O
type	O
of	O
the	O
stressors	O
.	O

Moreover	O
,	O
higher	O
prevalence	O
of	O
depression	B-T038
and	O
comorbidities	O
in	O
women	B-T098
than	O
men	B-T098
implies	O
the	O
need	O
to	O
include	O
the	O
sex	O
variable	O
in	O
studies	O
on	O
animal	B-T204
models	I-T204
of	O
depression	B-T038
.	O

The	O
present	O
study	O
was	O
therefore	O
initiated	O
to	O
evaluate	O
the	O
effect	O
of	O
sex	O
and	O
ovarian	B-T103
hormones	I-T103
on	O
depression	B-T038
-	O
like	O
phenotypes	O
in	O
mice	B-T204
exposed	O
to	O
a	O
21	O
-	O
day	O
Chronic	O
Variable	O
Mild	O
Stress	O
(	O
CVMS	O
)	O
paradigm	B-T062
.	O

Adult	O
male	O
,	O
intact	O
female	O
and	O
,	O
ovariectomized	O
(	O
OVX	O
)	O
female	O
mice	B-T204
exposed	O
to	O
CVMS	O
displayed	O
despair	O
behavior	O
,	O
a	O
depression	B-T038
-	O
like	O
phenotype	O
,	O
in	O
all	O
the	O
groups	O
.	O

However	O
,	O
intact	O
females	O
alone	O
,	O
but	O
not	O
males	O
and	O
OVX	O
females	O
,	O
showed	O
anhedonia	B-T038
,	O
another	O
depression	B-T038
-	O
like	O
phenotype	O
.	O

At	O
the	O
molecular	O
level	O
,	O
the	O
expression	B-T038
of	O
Brain	B-T103
-	I-T103
Derived	I-T103
Neurotrophic	I-T103
Factor	I-T103
(	O
BDNF	B-T103
)	O
,	O
a	O
neuropeptide	B-T103
associated	O
with	O
depression	B-T038
,	O
and	O
few	O
other	O
stress	B-T033
-	O
specific	O
genes	B-T017
CRH	B-T017
,	O
NR3C1	B-T017
,	O
CART	B-T017
,	O
and	O
NPY	B-T017
were	O
measured	O
in	O
the	O
Prefrontal	B-T017
Cortex	I-T017
(	O
PFC	B-T017
)	O
region	O
of	O
the	O
reward	O
circuitry	O
.	O

There	O
was	O
a	O
significant	O
decrease	O
in	O
the	O
BDNF	B-T103
protein	B-T038
expression	I-T038
along	O
with	O
an	O
increase	O
in	O
the	O
mRNA	B-T038
expression	I-T038
of	O
CRH	B-T017
,	O
NR3C1	B-T017
,	O
CART	B-T017
,	O
and	O
NPY	B-T017
in	O
intact	O
females	O
,	O
but	O
not	O
in	O
the	O
other	O
two	O
groups	O
of	O
mice	B-T204
.	O

OVX	O
females	O
resembled	O
males	O
in	O
behavioral	B-T033
and	O
molecular	B-T033
responses	I-T033
to	O
CVMS	O
.	O

17β	B-T103
-	I-T103
Estradiol	I-T103
(	O
E2	B-T103
)	O
administration	B-T058
,	O
not	O
Progesterone	B-T103
(	O
P4	B-T103
)	O
,	O
to	O
OVX	O
female	O
stress	B-T033
mice	B-T204
,	O
mitigated	O
despair	O
and	O
enhanced	O
hedonic	O
capacity	O
with	O
an	O
increased	O
expression	B-T038
of	O
BDNF	B-T103
in	O
PFC	B-T017
.	O

This	O
study	O
strengthens	O
the	O
evidence	O
for	O
the	O
beneficial	O
effects	O
of	O
E2	B-T103
administration	B-T058
in	O
stress	B-T033
condition	O
.	O

Development	O
and	O
Evaluation	B-T062
of	O
the	O
ADHD	B-T170
Cognitions	I-T170
Scale	I-T170
for	O
Adults	O

The	O
clinical	B-T170
literature	I-T170
on	O
ADHD	B-T038
in	O
adults	O
suggests	O
that	O
"	O
overly	B-T038
positive	I-T038
"	O
or	O
optimistic	B-T038
cognitions	I-T038
may	O
contribute	O
to	O
impairment	O
and	O
failure	O
to	O
use	O
self	O
-	O
regulation	O
skills	O
in	O
this	O
population	B-T098
,	O
yet	O
the	O
research	B-T062
literature	B-T170
on	O
this	O
topic	O
is	O
limited	O
.	O

We	O
developed	O
the	O
ADHD	B-T170
Cognitions	I-T170
Scale	I-T170
(	O
ACS	B-T170
)	O
,	O
a	O
brief	O
self	B-T062
-	I-T062
report	I-T062
measure	O
of	O
ADHD	B-T038
-	O
related	O
thoughts	B-T038
,	O
and	O
evaluated	O
its	O
psychometric	O
properties	O
.	O

We	O
collected	O
self	B-T062
-	I-T062
report	I-T062
measures	O
,	O
inculding	O
the	O
ACS	B-T170
,	O
from	O
two	O
large	O
community	O
samples	O
(	O
Ns	O
=	O
262	O
,	O
304	O
)	O
.	O

The	O
measure	O
demonstrated	O
a	O
one	O
-	O
factor	O
solution	O
that	O
replicated	O
in	O
the	O
second	O
sample	O
.	O

Evidence	O
of	O
good	O
internal	O
consistency	O
and	O
also	O
convergent	O
and	O
divergent	O
validity	O
was	O
obtained	O
for	O
both	O
samples	O
.	O

Scores	O
on	O
the	O
ACS	B-T170
correlated	O
with	O
functional	O
impairment	O
,	O
time	B-T033
management	I-T033
problems	I-T033
,	O
and	O
avoidant	B-T033
coping	I-T033
strategies	O
.	O

With	O
additional	O
study	B-T062
,	O
the	O
ACS	B-T170
may	O
be	O
useful	O
to	O
identify	O
and	O
track	O
maladaptive	B-T033
ADHD	B-T038
-	O
related	O
cognitions	B-T038
during	O
cognitive	B-T058
-	I-T058
behavioral	I-T058
treatment	I-T058
,	O
and	O
to	O
further	O
study	B-T062
the	O
role	O
of	O
these	O
thoughts	B-T038
in	O
ADHD	B-T038
-	O
related	O
impairment	O
.	O

Visual	O
Confidence	B-T038

Visual	O
confidence	B-T038
refers	O
to	O
an	O
observer	O
'	O
s	O
ability	O
to	O
judge	B-T038
the	O
accuracy	O
of	O
her	O
perceptual	B-T038
decisions	I-T038
.	O

Even	O
though	O
confidence	B-T038
judgments	B-T038
have	O
been	O
recorded	O
since	O
the	O
early	O
days	O
of	O
psychophysics	B-T091
,	O
only	O
recently	O
have	O
they	O
been	O
recognized	O
as	O
essential	O
for	O
a	O
deeper	O
understanding	O
of	O
visual	B-T038
perception	I-T038
.	O

The	O
reluctance	O
to	O
study	O
visual	O
confidence	B-T038
may	O
have	O
come	O
in	O
part	O
from	O
obtaining	O
convincing	O
experimental	O
evidence	O
in	O
favor	O
of	O
metacognitive	B-T038
abilities	I-T038
rather	O
than	O
just	O
perceptual	B-T038
sensitivity	I-T038
.	O

Some	O
effort	O
has	O
thus	O
been	O
dedicated	O
to	O
offer	O
different	O
experimental	O
paradigms	O
to	O
study	B-T062
visual	O
confidence	B-T038
in	O
humans	B-T204
and	O
nonhuman	B-T204
animals	I-T204
.	O

To	O
understand	O
the	O
origins	O
of	O
confidence	B-T038
judgments	B-T038
,	O
investigators	B-T097
have	O
developed	O
two	O
competing	O
frameworks	O
.	O

The	O
approach	O
based	O
on	O
signal	B-T170
decision	I-T170
theory	I-T170
is	O
popular	O
but	O
fails	O
to	O
account	O
for	O
response	O
times	O
.	O

In	O
contrast	O
,	O
the	O
approach	O
based	O
on	O
accumulation	O
of	O
evidence	O
models	B-T170
naturally	O
includes	O
the	O
dynamics	O
of	O
perceptual	B-T038
decisions	I-T038
.	O

These	O
models	B-T170
can	O
explain	O
a	O
range	O
of	O
results	O
,	O
including	O
the	O
apparently	O
paradoxical	O
dissociation	B-T038
between	O
performance	O
and	O
confidence	B-T038
that	O
is	O
sometimes	O
observed	O
.	O

Grapevine	B-T204
Subtilase	B-T103
Family	I-T103
:	O
Update	O
on	O
New	O
Sequences	B-T082
and	O
Nomenclature	B-T170
Proposal	I-T170

In	O
grapevine	B-T204
,	O
serine	B-T103
peptidases	I-T103
from	O
the	O
subtilase	B-T103
family	I-T103
were	O
recently	O
associated	O
to	O
Plasmopara	B-T204
viticola	I-T204
resistance	O
.	O

This	O
family	O
in	O
grapevine	B-T204
,	O
first	O
characterized	O
in	O
2014	O
,	O
was	O
re	B-T062
-	I-T062
analyzed	I-T062
last	O
year	O
and	O
82	O
subtilase	B-T103
genes	B-T017
were	O
identified	O
.	O

However	O
,	O
in	O
November	O
of	O
2016	O
,	O
the	O
National	B-T092
Center	I-T092
for	I-T092
Biotechnology	I-T092
Information	I-T092
database	B-T170
(	O
NCBI	B-T092
)	O
made	O
a	O
new	O
public	O
release	O
of	O
the	O
grapevine	B-T204
genome	B-T062
annotation	I-T062
based	O
on	O
new	O
sequencing	B-T170
data	I-T170
and	O
better	O
prediction	O
algorithms	B-T170
.	O

As	O
a	O
consequence	O
,	O
some	O
gene	B-T062
annotations	I-T062
and	O
lengths	O
changed	O
.	O

Here	O
we	O
present	O
an	O
update	O
to	O
the	O
grapevine	B-T204
subtilase	B-T103
gene	B-T017
family	I-T017
sequences	B-T082
(	O
SBT	B-T103
)	O
,	O
namely	O
sequence	B-T170
identifiers	I-T170
,	O
bioinformatic	B-T091
predictions	O
and	O
recommend	O
a	O
nomenclature	B-T170
for	O
the	O
grapevine	B-T204
SBT	B-T103
genes	B-T017
.	O

Our	O
results	B-T033
show	O
that	O
grapevine	B-T204
subtilase	B-T103
gene	B-T017
family	I-T017
is	O
now	O
constituted	O
by	O
87	O
subtilase	B-T103
genes	B-T017
encoding	O
for	O
109	O
subtilase	B-T103
proteins	I-T103
and	O
,	O
despite	O
the	O
reported	O
alterations	B-T038
,	O
expression	B-T038
data	O
on	O
subtilases	B-T103
associated	O
to	O
grapevine	B-T204
resistance	O
to	O
P	B-T204
.	I-T204

viticola	I-T204
pathosystem	O
did	O
not	O
suffer	O
any	O
alteration	B-T038
.	O

Shared	B-T038
Decision	I-T038
Making	I-T038
and	O
the	O
promise	O
of	O
a	O
respectful	O
and	O
equitable	O
healthcare	B-T092
system	I-T092
in	O
Peru	B-T082

Peru	B-T082
has	O
achieved	O
sustained	O
development	O
in	O
the	O
last	O
two	O
decades	O
.	O

However	O
,	O
despite	O
this	O
achievement	O
,	O
it	O
has	O
not	O
been	O
matched	O
with	O
improvements	O
in	O
the	O
quality	O
of	O
education	O
and	O
health	B-T058
;	O
investment	O
in	O
both	O
sectors	O
is	O
among	O
the	O
lowest	O
in	O
the	O
region	B-T082
.	O

This	O
situation	O
perpetuates	O
huge	O
gaps	B-T033
in	O
infrastructure	O
and	O
also	O
conditions	O
a	O
poor	O
literacy	O
level	O
of	O
the	O
population	B-T098
specifically	O
in	O
health	O
.	O

Currently	O
,	O
there	O
is	O
a	O
fragmented	O
model	B-T170
of	O
patient	B-T058
care	I-T058
,	O
in	O
which	O
the	O
systems	B-T092
are	O
exclusive	O
of	O
each	O
other	O
.	O

They	O
do	O
not	O
cooperate	O
or	O
communicate	O
with	O
each	O
other	O
;	O
and	O
if	O
there	O
is	O
no	O
vertical	O
communication	O
within	O
the	O
system	B-T092
,	O
preventing	O
referral	B-T058
of	I-T058
patients	I-T058
directly	O
from	O
the	O
basic	B-T033
level	I-T033
to	O
the	O
complex	B-T033
level	I-T033
of	O
care	B-T058
when	O
needed	O
.	O

In	O
addition	O
,	O
there	O
has	O
been	O
no	O
progress	O
in	O
the	O
development	O
of	O
an	O
empathetic	O
,	O
respectful	O
or	O
person	O
-	O
centered	O
clinical	O
practice	O
;	O
instead	O
,	O
economic	O
,	O
social	O
and	O
educational	O
differences	O
perpetuate	O
a	O
paternalistic	O
clinical	O
practice	O
.	O

The	O
task	O
of	O
orienting	O
medical	O
training	O
towards	O
the	O
development	O
of	O
humanism	O
is	O
pending	O
.	O

The	O
patient	O
is	O
the	O
center	O
of	O
the	O
medical	B-T062
act	I-T062
and	O
the	O
main	O
objective	O
of	O
doctors	B-T097
'	I-T097
actions	O
.	O

A	O
humanistic	O
care	O
approach	O
will	O
not	O
only	O
empower	O
the	O
person	B-T098
in	O
the	O
clinical	O
encounter	O
-	O
to	O
participate	O
and	O
make	O
decisions	O
related	O
to	O
his	O
/	O
her	O
health	B-T058
care	I-T058
-	O
but	O
it	O
will	O
allow	O
us	O
to	O
move	O
towards	O
an	O
empathetic	O
,	O
caring	O
,	O
respectful	O
and	O
kind	O
model	B-T170
of	O
clinical	O
practice	O
.	O

Identification	O
of	O
markers	B-T201
for	O
quiescent	O
pancreatic	B-T017
stellate	I-T017
cells	I-T017
in	O
the	O
normal	O
human	B-T204
pancreas	B-T017

Pancreatic	B-T017
stellate	I-T017
cells	I-T017
(	O
PSCs	B-T017
)	O
play	O
a	O
central	O
role	O
as	O
source	O
of	O
fibrogenic	B-T017
cells	I-T017
in	O
pancreatic	B-T038
cancer	I-T038
and	O
chronic	B-T038
pancreatitis	I-T038
.	O

In	O
contrast	O
to	O
quiescent	O
hepatic	B-T017
stellate	I-T017
cells	I-T017
(	O
qHSCs	B-T017
)	O
,	O
a	O
specific	O
marker	B-T201
for	O
quiescent	O
PSCs	B-T017
(	O
qPSCs	B-T017
)	O
that	O
can	O
be	O
used	O
in	O
formalin	B-T017
-	I-T017
fixed	I-T017
and	I-T017
paraffin	I-T017
embedded	I-T017
(	I-T017
FFPE	I-T017
)	I-T017
normal	I-T017
human	I-T017
pancreatic	I-T017
tissue	I-T017
has	O
not	O
been	O
identified	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
a	O
marker	O
enabling	O
the	O
identification	O
of	O
qPSCs	B-T017
in	O
normal	O
human	B-T204
FFPE	B-T017
pancreatic	I-T017
tissue	I-T017
.	O

Immunohistochemical	O
(	O
IHC	O
)	O
,	O
double	O
-	O
IHC	O
,	O
immunofluorescence	B-T058
(	O
IF	B-T058
)	O
and	O
double	B-T058
-	I-T058
IF	I-T058
analyses	I-T058
were	O
carried	O
out	O
using	O
a	O
tissue	O
microarray	O
consisting	O
of	O
cores	O
with	O
normal	O
human	B-T204
pancreatic	B-T017
tissue	I-T017
.	O

Cores	O
with	O
normal	O
human	B-T204
liver	B-T017
served	O
as	O
control	O
.	O

Antibodies	B-T103
directed	O
against	O
adipophilin	B-T103
,	O
α	B-T103
-	I-T103
SMA	I-T103
,	O
CD146	B-T103
,	O
CRBP	B-T103
-	I-T103
1	I-T103
,	O
cytoglobin	B-T103
,	O
desmin	B-T103
,	O
GFAP	B-T103
,	O
nestin	B-T103
,	O
S100A4	B-T103
and	O
vinculin	B-T103
were	O
examined	O
,	O
with	O
special	O
emphasis	O
on	O
their	O
expression	O
in	O
periacinar	B-T082
cells	B-T017
in	O
the	O
normal	O
human	B-T204
pancreas	B-T017
and	O
perisinusoidal	B-T017
cells	I-T017
in	O
the	O
normal	O
human	B-T204
liver	B-T017
.	O

The	O
immunolabelling	B-T058
capacity	O
was	O
evaluated	O
according	O
to	O
a	O
semiquantitative	O
scoring	O
system	O
.	O

Double	B-T058
-	I-T058
IF	I-T058
of	O
the	O
markers	B-T201
of	O
interest	O
together	O
with	O
markers	B-T201
for	O
other	O
periacinar	B-T082
cells	B-T017
was	O
performed	O
.	O

Moreover	O
,	O
the	O
utility	O
of	O
histochemical	O
stains	O
for	O
the	O
identification	O
of	O
human	B-T204
qPSCs	B-T017
was	O
examined	O
,	O
and	O
their	O
ultrastructure	O
was	O
revisited	O
by	O
electron	B-T058
microscopy	I-T058
.	O

Adipophilin	B-T103
,	O
CRBP	B-T103
-	I-T103
1	I-T103
,	O
cytoglobin	B-T103
and	O
vinculin	B-T103
were	O
expressed	O
in	O
qHSCs	B-T017
in	O
the	O
liver	B-T017
,	O
whereas	O
cytoglobin	B-T103
and	O
adipophilin	B-T103
were	O
expressed	O
in	O
qPSCs	B-T017
in	O
the	O
pancreas	B-T017
.	O

Adipophilin	B-T103
immunohistochemistry	B-T058
was	O
highly	O
dependent	O
on	O
the	O
preanalytical	O
time	O
interval	O
(	O
PATI	O
)	O
from	O
removal	O
of	O
the	O
tissue	B-T017
to	O
formalin	B-T058
fixation	I-T058
.	O

Cytoglobin	B-T103
,	O
S100A4	B-T103
and	O
vinculin	B-T103
were	O
expressed	O
in	O
periacinar	B-T082
fibroblasts	B-T017
(	O
FBs	B-T017
)	O
.	O

The	O
other	O
examined	O
markers	B-T201
were	O
negative	O
in	O
human	B-T204
qPSCs	B-T017
.	O

Our	O
data	O
indicate	O
that	O
cytoglobin	B-T103
and	O
adipophilin	B-T103
are	O
markers	B-T201
of	O
qPSCs	B-T017
in	O
the	O
normal	O
human	B-T204
pancreas	B-T017
.	O

However	O
,	O
the	O
use	O
of	O
adipophilin	B-T103
as	O
a	O
qPSC	B-T017
marker	O
may	O
be	O
limited	O
due	O
to	O
its	O
high	O
dependence	O
on	O
optimal	O
PATI	O
.	O

Cytoglobin	B-T103
,	O
on	O
the	O
other	O
hand	O
,	O
is	O
a	O
sensitive	O
marker	B-T201
for	O
qPSCs	B-T017
but	O
is	O
expressed	O
in	O
FBs	B-T017
as	O
well	O
.	O

Biomagnetic	O
monitoring	O
of	O
atmospheric	O
pollution	O
:	O
a	O
review	O
of	O
magnetic	O
signatures	O
from	O
biological	O
sensors	O

Biomagnetic	O
monitoring	O
of	O
atmospheric	O
pollution	O
is	O
a	O
growing	O
application	O
in	O
the	O
field	O
of	O
environmental	B-T082
magnetism	O
.	O

Particulate	O
matter	O
(	O
PM	O
)	O
in	O
atmospheric	O
pollution	O
contains	O
readily	O
-	O
measurable	O
concentrations	O
of	O
magnetic	B-T103
minerals	I-T103
.	O

Biological	O
surfaces	B-T082
,	O
exposed	O
to	O
atmospheric	O
pollution	O
,	O
accumulate	O
magnetic	O
particles	B-T103
over	O
time	O
,	O
providing	O
a	O
record	O
of	O
location	B-T082
-	O
specific	O
,	O
time	B-T033
-	I-T033
integrated	I-T033
air	O
quality	O
information	O
.	O

This	O
review	B-T170
summarizes	O
current	O
knowledge	O
of	O
biological	O
material	O
(	O
'	O
sensors	O
'	O
)	O
used	O
for	O
biomagnetic	O
monitoring	O
purposes	O
.	O

Our	O
work	O
addresses	O
:	O
the	O
range	O
of	O
magnetic	O
properties	O
reported	O
for	O
lichens	B-T204
,	O
mosses	B-T204
,	O
leaves	B-T204
,	O
bark	B-T204
,	O
trunk	B-T204
wood	I-T204
,	O
insects	B-T204
,	O
crustaceans	B-T204
,	O
mammal	B-T204
and	O
human	B-T017
tissues	I-T017
;	O
their	O
associations	O
with	O
atmospheric	B-T103
pollutant	I-T103
species	I-T103
(	O
PM	O
,	O
NOx	B-T103
,	O
trace	B-T103
elements	I-T103
,	O
PAHs	B-T103
)	O
;	O
the	O
pros	B-T033
and	I-T033
cons	I-T033
of	O
biomagnetic	O
monitoring	O
of	O
atmospheric	O
pollution	O
;	O
current	O
challenges	O
for	O
large	O
-	O
scale	O
implementation	O
of	O
biomagnetic	O
monitoring	O
;	O
and	O
future	O
perspectives	O
.	O

A	O
summary	O
table	O
is	O
presented	O
,	O
with	O
the	O
aim	O
of	O
aiding	O
researchers	B-T097
and	O
policy	B-T097
makers	I-T097
in	O
selecting	O
the	O
most	O
suitable	O
biological	O
sensor	O
for	O
their	O
intended	O
biomagnetic	O
monitoring	O
purpose	O
.	O

Role	O
of	O
infrared	B-T058
spectroscopy	I-T058
and	O
imaging	B-T058
in	O
cancer	B-T038
diagnosis	B-T033

FTIR	B-T062
imaging	B-T058
has	O
been	O
used	O
to	O
diagnose	B-T033
and	O
differentiate	O
the	O
molecular	O
differences	O
between	O
normal	B-T017
and	O
diseased	B-T038
tissues	B-T017
.	O

The	O
differences	O
correspond	O
to	O
the	O
distribution	O
and	O
structure	B-T082
of	O
lipids	B-T103
,	O
proteins	B-T103
,	O
nucleic	B-T103
acids	I-T103
as	O
well	O
as	O
other	O
metabolites	B-T103
.	O

These	O
differences	O
depended	O
on	O
the	O
type	O
and	O
the	O
grade	O
of	O
cancer	B-T038
.	O

The	O
sensitivity	O
of	O
chemotherapy	B-T058
drugs	B-T103
on	O
individual	B-T098
specific	O
was	O
also	O
discussed	O
.	O

Here	O
,	O
we	O
emphasize	O
that	O
FTIR	B-T062
spectroscopy	I-T062
and	O
imaging	B-T058
can	O
be	O
considered	O
as	O
a	O
promising	O
technique	O
and	O
will	O
find	O
its	O
place	O
on	O
the	O
detection	B-T058
of	O
this	O
dreadful	B-T038
disease	I-T038
because	O
of	O
high	O
sensitivity	O
,	O
accuracy	O
and	O
inexpensive	O
technique	O
.	O

Now	O
the	O
medical	B-T092
community	I-T092
started	O
using	O
and	O
accepting	O
this	O
technique	O
for	O
early	O
stage	O
cancer	B-T038
detection	B-T058
.	O

But	O
,	O
this	O
technique	O
endures	O
several	O
challenges	B-T058
on	O
its	O
application	O
into	O
the	O
diagnosis	B-T033
of	O
cancer	B-T038
in	O
regards	O
of	O
sample	O
preparations	O
,	O
data	B-T058
interpretation	I-T058
,	O
and	O
data	O
analysis	O
.	O

In	O
general	O
,	O
more	O
research	B-T062
is	O
needed	O
in	O
this	O
field	O
and	O
it	O
is	O
necessary	O
to	O
understand	O
the	O
morphology	O
and	O
biology	B-T091
of	O
the	O
sample	O
before	O
using	O
the	O
spectroscopy	B-T062
and	O
imaging	B-T058
because	O
invaluable	O
information	O
to	O
be	O
figured	O
out	O
.	O

The	O
CLASP2	B-T103
Protein	O
Interaction	O
Network	O
in	O
Adipocytes	B-T017
Links	O
CLIP2	B-T103
to	O
AGAP3	B-T103
,	O
CLASP2	B-T103
to	O
G2L1	B-T103
,	O
MARK2	B-T103
,	O
and	O
SOGA1	B-T103
,	O
and	O
Identifies	O
SOGA1	B-T103
as	O
a	O
Microtubule	B-T103
-	I-T103
Associated	I-T103
Protein	I-T103

CLASP2	B-T103
is	O
a	O
microtubule	B-T103
-	I-T103
associated	I-T103
protein	I-T103
that	O
undergoes	O
insulin	B-T103
-	O
stimulated	O
phosphorylation	B-T038
and	O
co	O
-	O
localization	O
with	O
reorganized	O
actin	B-T103
and	O
GLUT4	B-T103
at	O
the	O
plasma	B-T017
membrane	I-T017
.	O

To	O
gain	O
insight	B-T038
to	O
the	O
role	O
of	O
CLASP2	B-T103
in	O
this	O
system	O
,	O
we	O
developed	O
and	O
successfully	O
executed	O
a	O
streamlined	O
interactome	B-T038
approach	B-T082
and	O
built	O
a	O
CLASP2	B-T103
protein	O
network	O
in	O
3T3	B-T017
-	I-T017
L1	I-T017
adipocytes	I-T017
.	O

Using	O
two	O
different	O
commercially	B-T170
available	O
antibodies	B-T103
for	O
CLASP2	B-T103
and	O
an	O
antibody	B-T103
for	O
epitope	B-T103
-	O
tagged	O
,	O
overexpressed	B-T038
CLASP2	B-T103
,	O
we	O
performed	O
multiple	O
affinity	B-T058
purification	I-T058
coupled	O
with	O
mass	B-T058
spectrometry	I-T058
(	O
AP	B-T058
-	O
MS	B-T058
)	O
experiments	B-T062
in	O
combination	O
with	O
label	B-T033
-	I-T033
free	I-T033
quantitative	O
proteomics	B-T091
and	O
analyzed	B-T062
the	O
data	O
with	O
the	O
bioinformatics	B-T091
tool	B-T170
Significance	O
Analysis	O
of	O
Interactome	O
(	O
SAINT	O
)	O
.	O

We	O
discovered	O
that	O
CLASP2	B-T103
co	B-T103
-	I-T103
immunoprecipitates	I-T103
(	O
co	B-T103
-	I-T103
IPs	I-T103
)	O
the	O
novel	O
protein	B-T103
SOGA1	B-T103
,	O
the	O
microtubule	B-T103
-	I-T103
associated	I-T103
protein	I-T103
kinase	I-T103
MARK2	B-T103
,	O
and	O
the	O
microtubule	B-T017
/	O
actin	B-T103
-	O
regulating	B-T038
protein	B-T103
G2L1	B-T103
.	O

The	O
GTPase	B-T103
-	I-T103
activating	I-T103
proteins	I-T103
AGAP1	B-T103
and	O
AGAP3	B-T103
were	O
also	O
enriched	O
in	O
the	O
CLASP2	B-T103
interactome	B-T038
,	O
although	O
subsequent	O
AGAP3	B-T103
and	O
CLIP2	B-T103
interactome	B-T038
analysis	B-T062
suggests	O
a	O
preference	O
of	O
AGAP3	B-T103
for	O
CLIP2	B-T103
.	O

Follow	O
-	O
up	O
MARK2	B-T103
interactome	B-T038
analysis	B-T062
confirmed	B-T033
reciprocal	O
co	B-T103
-	I-T103
IP	I-T103
of	O
CLASP2	B-T103
and	O
also	O
revealed	O
MARK2	B-T103
can	O
co	B-T103
-	I-T103
IP	I-T103
SOGA1	B-T103
,	O
glycogen	B-T103
synthase	I-T103
,	O
and	O
glycogenin	B-T103
.	O

Investigating	O
the	O
SOGA1	B-T103
interactome	B-T038
confirmed	B-T033
SOGA1	B-T103
can	O
reciprocal	O
co	B-T103
-	I-T103
IP	I-T103
both	O
CLASP2	B-T103
and	O
MARK2	B-T103
as	O
well	O
as	O
glycogen	B-T103
synthase	I-T103
and	O
glycogenin	B-T103
.	O

SOGA1	B-T103
was	O
confirmed	B-T033
to	O
colocalize	B-T082
with	O
CLASP2	B-T103
and	O
also	O
with	O
tubulin	B-T103
,	O
which	O
identifies	O
SOGA1	B-T103
as	O
a	O
new	O
microtubule	B-T103
-	I-T103
associated	I-T103
protein	I-T103
.	O

These	O
results	O
introduce	O
the	O
metabolic	B-T038
function	I-T038
of	O
these	O
proposed	O
novel	O
protein	O
networks	O
and	O
their	O
relationship	O
with	O
microtubules	B-T017
as	O
new	O
fields	O
of	O
cytoskeleton	B-T017
-	O
associated	O
protein	B-T091
biology	I-T091
.	O

